APASL 2024 Kyoto
The 33rd Annual Meeting the Asian Pacific Association for the Study of the Liver

Summary / Abstracts

Plenary Sessions
Young Investigator Workshop
Oral Free Papers / Poster Free Papers
Chronic Hepatitis B Virus Infection

Dr. Wan-Long Chuang

Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University Taiwan

Chronic hepatitis B virus (HBV) infection is a serious global health issue. Chronic HBV infection might lead to liver cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Thus, the goal of treatment for chronic hepatitis B (CHB) is to improve survival and quality of life by preventing transmission, disease progression and HCC. Chronic HBV infection comprises four phases defined as immune tolerant phase, immune clearance phase (HBsAg-positive chronic hepatitis), inactive carrier phase, and reactivation phase (HBsAg-negative chronic hepatitis). Treating the patients with immune active chronic hepatitis B (both HBsAg-positive and negative) is recommended to decrease the risk of liver-related complications. Pegylated interferon and nucleos(t)ide analogues (NAs, including entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide) are the preferred first line agents for CHB treatment. NAs are selected because of convenience, good tolerability, safety, high potency and minimal to no risk of resistance. However, NAs have no direct action on cccDNA, and long-term NAs therapy is required to maintain HBV suppression in HBsAg negative patients. There are several concerns, e.g. financial burden, adherence and willingness, for indefinite long-term NAs therapy. In addition, increase rates of HBsAg loss are observed after cessation of NAs treatment in HBsAg-negative patients. Finite NAs therapy in selected HBeAg-negative CHB becomes a recommendation. Discontinuation of NAs treatment in patients with cirrhosis is not recommended. For HBsAg-positive adults without cirrhosis who seroconvert to anti-HBe on NAs therapy, discontinue therapy after a period of consolidation treatment is suggested. NAs may be discontinued in HBeAg-negative patients without cirrhosis, who achieve long-term virological suppression. Decompensation and severe ALT flare may occur after cessation of NAs, especially in patients with liver cirrhosis. Close monitoring is warranted for the HBeAg-negative patients stopping NAs treatment. If hepatic decompensation developed, re-starting NA therapy should be given immediately. For patients with virological or clinical relapse, treatment indications for naïve CHB patients may be applied.

Epidemiology, Genotype Distribution, Prognosis and Treatment of Viral Hepatitis C and HCC in Mongolia

Dr. Oidov Baatarkhuu

Department of Infectious Diseases, Mongolian National University of Medical Sciences Mongolia

In Mongolia, morbidity from liver cancer is 68.1 per 100,000 population, which is eight times higher than the global average. This is directly associated to the higher rate of morbidity of chronic hepatitis caused by HBV, HCV and HDV. Prevalence of HCV in Mongolia was high. The predominant genotype of HCV among general populations in Mongolia is 1b. Between 2015 to 2019, 23 (0.5%) and 5,005 patients (99.5%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 81 patients (1.6%) with previous experience of interferon (IFN)-based treatment received additional 1,000 mg ribavirin. Most patients (n=5,008; 99.6%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 16 patients (69.6%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=81; 1.6%), cirrhosis (n=1,151; 22.9%), HCV RNA >6x106 IU/ml (n=866; 17.2%), or liver stiffness >9.6 kPa (n=1,721; 34.2%) (100.0%, 99.3%, 99.4%, and 99.4%, respectively). The most common AEs were headache (n=472; 9.4%), fatigue (n=306; 6.2%), abdominal discomfort (n=295; 5.9%), and skin rash (n=141; 2.8%).

Most patients had advanced HCC – 88 (45.1%) in stage III and 57 (29.2%) in stage IV. The risk factors associated with HCC development were history of acute hepatitis, chronic hepatitis, and the presence of liver cirrhosis. The most common etiology for HCC in our patients was HCV infection which is 46%, HBV infection 34%, co-infection and B and C-14% and others which is 6.0%. According to the results of our study over 65% of patients had tumor size more than 5 cm. Single tumors was only found in 15%. The mean AFP level was 196 ng/ml. In 18.5% distant metastasis existed. Regarding tumor stage, there was no patient with stage 1. In addition, the most patients with HCC were diagnosed in advanced stage. In Mongolia HCC treatment modality is very limited. According to the results of our study, 14% of patients received surgical resection, and their survival was the best. 11.8% of patients received RFA and their survival was 11 months. About 55% of patients received TACE and their median survival was 17 months. The prognosis for patients with supportive care was very poor with a median survival of 5 months. Regarding cause of death, about 50% patients died of HCC progression and the others died of liver failure or GI bleeding. Regarding early detection of HCC in Mongolia, AFP is available in all hospitals except inter- soum and soum’s hospitals.

HBV “Viral Elimination” in Asia-Pacific region-current status and challenges

Dr. George Lau

Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China

In 2016, the World Health Assembly approved the World Health Organisation (WHO) Global Health Sector Strategy on HBV, with a goal of “elimination of HBV as a major health threat” by 2030, targeting a 90% reduction in new HBV infection and a 65% reduction in mortality due to HBV. However, recent data suggested deviation from these goals, with over 890,000 new HBV cases in 2019-2020 and a global HBV-related mortality rate exhibiting minimal change (annualized rate of change < 0.4% between 2015-2019). Two-thirds of these HBV-related mortality occurred in Southeast Asia and Western Pacific regions. In real-world clinical practice, two major barriers hinder a significant reduction of disease burden due to HBV infection: lack of awareness (among public and policy makers) and under-treatment of those with a risk of developing complications related to HBV infection, with effective anti-viral therapy, namely high resistant barrier nucleos(t)ide analogues (NAs including tenofovir, entecavir, tenofovir alafenamide) or pegylated interferon or both, which have all been demonstrated to enable a drastic reduction in HBV-related morbidity and mortality with long-term follow-up. With the recent availability of low-cost rapid diagnostic tests for HBsAg with negligible false-negative results, which can be utilised for large-scale screening and diagnosis of HBV infection, only an estimated 15-30% of chronic HBV infection have been diagnosed. Hence, to further decrease global viral
and disease burden, it is of paramount importance to identify all patients with CHB infection and timely initiate effective antiviral therapy for them. In the meantime, increase public awareness to access hepatitis B test is essential. On the other hand, in accordance with the existing regional treatment guidelines, it was estimated that less than one-tenth of those CHB patients indicated for treatment received anti-HBV therapy. There is also a recent call to expand treatment criteria beyond existing guidelines to extend therapeutic benefits to more patients with CHB infection. Indeed, a cost-effectiveness analysis of expanded antiviral treatment for CHB infection, based on decision-tree Markov state-transition model, suggested expanding treatment to HBV-infected patients with ALT thresholds of 30 U/L and 19 U/L for males and females, with 80% treatment coverage for HBsAg-positive individuals aged 18–80 years. This expanded antiviral treatment with a modified ALT threshold, coupled with lower generic drug costs and a revised medical insurance subsidization policy, particularly in HBV-endemic countries like China, could reduce HBV-related complications and deaths to support the global target of 65% reduction in HBV-related death. With the recent surge of prevalence and emerging association of Metabolic dysfunction-associated fatty liver disease as a comorbidity factor for CHB patients, future treatment guidelines likely need to be modified accordingly. In future, we believe that a collaborative effort of all authoritative liver societies to revise and expand HBV treatment guidelines considering the drastically reduced cost of anti-viral therapy, along with universal screening for HBsAg positivity, will contribute to a meaningful reduction in disease burden due to HBV infection in Asia-Pacific region.

Post-Graduate Program (Hepatitis B)

PG1-4

Role of HBcrAg in Predicting Long-Term Outcomes for Patients with Chronic Hepatitis B

Dr. Tai-Chung Tseng

Department of Medical Research, National Taiwan University Hospital, Taipei Taiwan

Hepatitis B virus (HBV) infection poses a significant global health challenge. Individuals with chronic hepatitis B (CHB) infection face diverse adverse events, including the risk of severe hepatitis flare, potentially leading to acute-on-chronic liver failure (ACLF), cirrhosis, hepatocellular carcinoma (HCC), and other complications. Conversely, some individuals experience favorable outcomes, such as spontaneous clearance of hepatitis B surface antigen (HBsAg) or hepatitis B e antigen (HBeAg). Serum hepatitis B core-related antigen (HBcrAg) quantification is a valuable biomarker for covalently closed circular DNA (cccDNA) levels, providing crucial information for clinical management. In the early phase of chronic HBV infection, HBeAg-positive patients are considered "immune-tolerant" due to active viral replication without significant liver damage. Our recent findings revealed that elevated HBcrAg levels (>100 million U/mL) correlate with a reduced likelihood of spontaneous HBeAg seroclearance in HBeAg-positive patients, particularly in the immune-tolerant subgroup. This insight aids physicians in deciding whether to initiate antiviral treatment or await spontaneous HBeAg seroclearance. Functional cure, indicated by HBsAg seroclearance, is associated with lower HBcrAg levels, especially in those with HBsAg levels >1000 IU/mL. The reduction of HBcrAg precedes the decline of HBsAg, suggesting the need to target cccDNA for successful treatment. A delayed decline in HBsAg levels suggests additional agents targeting HBsAg derived from integrated HBV DNA may be necessary for achieving functional cure.

Current guidelines recommend antiviral therapy for immune-active CHB patients but not for inactive CHB patients due to their different HCC risk. However, more than half of the HBeAg-negative CHB patients find themselves in the "grey zone" (GZ). We developed a novel GZ-HCC risk score (EXPLORE) considering age, sex, platelet count, ALT levels, and hepatitis B core-related antigen. This is the first risk prediction model demonstrating that an HBcrAg-based HCC score outperforms HBV DNA-based HCC scores in HBeAg-negative GZ patients. The model has been validated in an independent Japanese cohort. Furthermore, we propose a GZ-HCC score of >8 to categorize GZ patients into high- and low-risk groups, aligning their HCC risk levels with those of immune-active CHB and inactive CHB patients, respectively. In conclusion, HBcrAg is a valuable biomarker for predicting clinical outcomes, and its integration with various viral markers enables customized therapeutic approaches for CHB patients with distinct risk profiles.

Post-Graduate Program (Hepatitis C)

PG2-4

Dr. Yoshiyuki Ueno

Department of Gastroenterology, Yamagata University Faculty of Medicine Japan

Viral hepatitis infection has been a great threat to human health globally. Although remarkable breakthrough has been made in the past several decades for prevention and treatment of viral hepatitis, still this infectious disease is increasing its risk. Actually, 905,700 people were diagnosed with and 830,200 people died from liver cancer in 2020. Moreover, the number of new cases and deaths from liver cancer could rise by >55% by 2040. Thus, HCC remains to be global risk for next decades. Of course, viral infection is a major cause of HCC in many countries. With this line, WHO aimed to set the global elimination of viral hepatitis by 2030. WHO's global hepatitis strategy, endorsed by all WHO Member States, aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030. However, except for few countries or regions, our actual achievement has been behind the track. In this session, our current status and future strategy will be summarized to keep our mission on the planned goals.

Post-Graduate Program (MAFLD)

PG3-2

Etiology and Usefulness of MAFLD in the Asian-Pacific region

Dr. Takumi Kawaguchi

Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine. Japan

MAFLD is a major public health problem in the Asian-Pacific region. Excess energy intake and a sedentary lifestyle are major causes of hepatic steatosis. These unhealthy lifestyles also cause the accumulation of lipids in visceral adipose tissue, leading to adipose tissue inflammation. Adipose tissue produces proinflammatory cytokines including TNF-α, IL-1β, and IL-6, which flow into the liver through the hepatic artery. These adipose tissue-derived factors promote the development of MAFLD. Besides visceral adipose tissue, the gut is a major etiological organ of MAFLD. Dietary factors including excess fructose intake induce dysbiosis, leading to low-grade intestinal inflammation and an impairment of gut barrier function called leaky gut. A leaky gut facilitates the translocation of lipopolysaccharides and microbial metabolites to the
liver through the portal vein. This influx causes the production of pro-inflammatory cytokines and attracts immune cells through activation of Kupffer and liver sinusoidal endothelial cells in the liver. Risk factors for MAFLD in Asians are like those in Westerners. In addition, a feature of Asians is non-obese MAFLD. In non-obese Asian individuals, possible etiologies of MAFLD are the following: visceral obesity, dysbiosis, sarcopenia, hypothyroidism, hypopituitarism, and hyperuricemia. Furthermore, another possible etiology is genetic predisposition including polymorphism in PNPLA3 (patatin-like phospholipase domain-containing protein 3), TM6SF2 (transmembrane 6 superfamily member 2), GCKR (glucokinase regulator), MBOAT7 (membrane bound O-acyltransferase domain containing 7), and HSD17B13 (hydroxysteroid 17-beta dehydrogenase-13).

MAFLD is a disease concept that actively encloses high-risk patients through inclusion criteria. In fact, various Asian-Pacific clinical studies demonstrated that MAFLD identifies patients with significant hepatic fibrosis and at high risk of HCC. In addition, MAFLD has been reported to identify patients at higher risk for atherosclerotic cardiovascular disease better than NAFLD. The superiority of MAFLD over NAFLD seems to be due to the presence of metabolic dysfunction rather than moderate alcohol consumption. Furthermore, MAFLD is more associated with various extrahepatic diseases including reflux esophagitis, colorectal adenoma, the recurrence of esophageal squamous cell carcinoma, chronic obstructive pulmonary disease (COPD), and psoriasis rather than NAFLD. Thus, MAFLD is useful to identify patients at risk of both liver-related events and extra-hepatic events. In this session, we will introduce the etiology of Asian-Pacific MAFLD according to the APASL guidelines. I also mention the impact of MAFLD on the identification of patients at risk of hepatic events as well as extra-hepatic events in the Asia-Pacific region.

Post-Graduate Program (Fibrosis/Chirrosis)
PG4-3

Hepatocellular Carcinoma Risk prediction score (GES) in chronic hepatitis C patients with compensated advanced chronic liver disease (cACLF) after achieving SVR

Dr. Gamal Shiba
Gastroenterology and Hepatology Dept., Faculty of Medicine, Mansoura University, Egyptian Liver Research Institute and Hospital (ELRIAH) Egypt

Introduction: We designed and validated a scoring system known as the General Evaluation Score (GES) for Hepatocellular Carcinoma (HCC) risk stratification. Our objective was to assess the efficacy of this score within a substantial prospective cohort comprising individuals with cured hepatitis C, with compensated advanced chronic liver disease, and achieved a sustained virological response following direct-acting antivirals.

Methods: This prospective study, conducted at the Egyptian Liver Research Institute and Hospital between January 2018 and October 2019, enrolled 463 consecutive patients with advanced fibrosis (≥F3) who attained sustained virological response. Prior to antiviral therapy initiation, all patients underwent abdominal ultrasound and multislice computed tomography for HCC surveillance. Subsequent follow-ups occurred every 6 months post-treatment, utilizing ultrasonography, alpha-fetoprotein, and additional multislice computed tomography every 12 months.

Results: Of the 463 patients included, 197 (42.5%), 114 (24.6%), and 152 (32.8%) were stratified as having low, intermediate, and high-risk scores, respectively, before treatment initiation. The incidence rate of HCC was 2.61 per 100 person-years (95% CI = 1.73–3.80), with 25 cases developing HCC during the follow-up period. The respective HCC incidence rates in the low, intermediate, and high-risk groups were 0.97% (95% CI: 0.31–2.34), 1.68% (95% CI: 0.53–4.05), and 5.57% (95% CI: 3.35–8.74). A significant positive correlation was observed between higher risk scores and increased HCC incidence (p < 0.001). Harrell’s c-statistic for this model was 0.728.

Conclusion: This prospective study underscores the predictive capability of GES in anticipating HCC occurrence and effectively categorizing patients into low, intermediate, and high-risk groups.

Post-Graduate Program (ACLF)
PG5-1

Prognostic predictors in patients with Acute-on-chronic liver failure (ACLF)

Dr. Teerha Piratvisuth
NKC Institute of Gastroenterology and Hepatology Faculty of Medicine, Prince of Songkla University Thailand

Acute-on-chronic liver failure is a severe form of acutely decompen- sated cirrhosis with high mortality rate, 28-day mortality rate >20%. Prognostic predictors can guide the optimal strategies for managing individual patient properly. The number of organ system failure is associated with severity and mortality of ACLF-patients. The ACLF grades, based on the number of organ failures (liver, kidney, brain, coagulation circulation, respiration) enable to categorize patients with a range of 28-day and 3-month mortality risks. There are currently a few scoring system for predicting mortality rate in patients with ACLF. The CLIF-C ACLF score was developed by combining the CLIF-C score with age and white cell count for predicting 28-day and 90-day mortality better than those of the MELD score, MELD-Na score and Child-Pugh score. The AARC score was developed for patients with ACLF diagnosed using the APASL for predicting short-term mortality. The NACSELD only based on failure of 4 organ systems (brain, kidney, circulation, reparation) defined by the physicians’ response to the problem. The NACSELD may underestimates the risk of death in patients with ACLF. The COSHH Score was developed for patients with HBV-related ACLF. The newly proposed models and nomograms for predicting prognosis in patients with ACLF have shown some improvement on the CLIF-C ACLF score, but they require further validation. Inflammation severity has been shown as the most important predictor of ACLF.

Post-Graduate Program (PH)
PG6-1

Emerging non-invasive methods for evaluation of cirrhotic portal hypertension

Dr. Xiaolong Qi
CHESS Center, Center of Portal Hypertension, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University China

Clinically significant portal hypertension (CSPH) is associated with symptomatic gastro-oesophageal varices (GOV), the development of hyperdynamic circulation, and patients with compensated advanced chronic liver disease at risk of clinical decompensation. Hepatic venous pressure gradient (HVPG) measurement and esophagogastroduodenoscopy are the gold standard methods for assessing CSPH (HVPG ≥10 mm Hg) and GOV, respectively. However, they are limited by their invasiveness in clinical practice. In recently years, there are a lot of new technologies focuses on the development of non-invasive approaches to the diagnosis and serial monitoring of portal hypertension.
Imaging techniques used for portal hypertension include ultrasound, computed tomography (CT) and magnetic resonance (MR). Elastography techniques measure liver and spleen stiffness by quantifying the velocity of an induced shear wave, including transient elastography, point-shear wave elastography, and two-dimension shear wave elastography; and MR elastography. Liver stiffness measurement has been proved to be sufficiently accurate to identify CSPH and safe to screen high-risk varices combined with platelet count in clinical practice. Laboratory tests and serum markers need to be interpreted critically because some of their individual components can be affected by a variety of comorbidities. Artificial intelligence (AI) has made great strides in the field of medicine. Information of CT and MR imaging can be integrated and applied to detection of cirrhosis and portal hypertension by AI.

In summary, a wide spectrum of novel non-invasive tests have emerged and represent a major advantage in the assessment of portal hypertension. However, there are still many challenges to integrating non-invasive screening methods into clinical practice, and more data are needed to establish consensus on standard practice and implementation.

Post-Graduate Program (PH)
PG6-2

Current Endoscopic Gastrointestinal Interventions and Management

Dr. Hideki Kobara
Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University Japan

Endoscopic submucosal dissection (ESD) has been an attractive minimally invasive surgery during the past two decades. Currently, pure Endoscopic Full-Thickness Resection (EFTR) is focused as next-advanced technique. Meanwhile, post-ESD or EFTR defects, and iatrogenic perforation must be carefully managed to prevent and rescue adverse events.

Here, I would like to introduce these current gastrointestinal interventions and our ongoing research.

Post-Graduate Program (PH)
PG6-3

Role of HVPG in the management of portal hypertension

Dr. Hitoshi Maruyama
Department of Gastroenterology, Juntendo University Japan

Cirrhosis is the most advanced stage of chronic liver disease. It is accompanied with a risk of developing serious complications, including variceal bleeding, ascites, icterus, and hepatic encephalopathy. These events limit quality of life and long-term outcomes, therefore, patients with these conditions need to be properly monitored.

Hepatic venous catheterization is a safe and an established technique which enables measurement of hepatic venous pressure gradient (HVPG) by either jugular approach or femoral approach. Hepatic venogram is useful to demonstrate the typical appearance of cirrhosis and non-cirrhotic portal hypertension, which could be obtained by using either iodinated contrast material or carbon dioxide.

Portal hypertension is the principal pathophysiology of cirrhosis, and a HVPG is a representative marker for the severity of the condition. A HVPG of 10 to 12 mmHg is the threshold level for the development of esophageal varices, ascites, and the occurrence of variceal bleeding, and a HVPG higher than 16 mmHg suggests an increased risk of death. Moreover, a HVPG higher than 20 mmHg is the best independent prognostic marker for acute variceal bleeding, and thus indicates the presence of much more severe status. In addition, a HVPG is an effective marker to offer the treatment direction of TIPS for variceal bleeding in cirrhosis, and to predict the prognosis after TIPS placement for refractory ascites. Thus, hepatic venous catheterization has a wide range of role in the management of portal hypertension. This presentation overviews recent studies regarding HVPG and summarizes the evidences.

Post-Graduate Program (HCC)
PG7-1

Discovery of therapeutic and biomarker for HCC through basic and translational research of tumor microenvironment

Dr. Takahiro Kodama
Dept. Gastroenterology and Hepatology Osaka University Graduate School of Medicine Japan

HCC is a dismal disease with the third highest mortality rate among all cancer types. Its molecular entity is very complex and further clarification of its heterogeneous nature is required for prognostic improvement. With the progress of next-generation sequencers over the past decade, the genomic and epigenomic abnormalities in HCC have been well-documented with a large number of cases, and the whole picture has become clear. On the other hand, the recent development of innovative technologies such as single-cell analysis and spatial omics analysis has begun to open a new era in cancer research. In the tumor microenvironment, not only cancer cells but also various immune cells and stromal cells exist, and these form a complex network that leads to cancer formation and progression. In recent years, various drugs have been developed and made available for HCC. Importantly most of them, such as angiogenesis inhibitors and immune checkpoint inhibitors, target the tumor microenvironment rather than the cancer cells themselves, indicating the importance of understanding cancer as such an ecosystem to truly overcome cancer. One of the treatment goals of HCC therapy is personalized therapy with a variety of molecular-targeted drugs and their efficacy biomarkers. Recent advancement in HCC pharmacotherapy allows us to utilize 8 different therapeutic regimens but the efficacy of each drug is still limited. Further research efforts to discover novel drug targets and develop efficacy biomarkers are desired in the HCC field. In this presentation, I would like to share recent knowledge of the HCC tumor microenvironment and show our latest discoveries of therapeutics and biomarkers for HCC through basic and translational research. I also would like to discuss with the audience the future perspective of HCC research.

Post-Graduate Program (HCC)
PG7-3

Post-Graduate Program (HCC): Treatment guidelines update

Dr. Yi-Hsiang Huang
Taiwan Liver Cancer Association (TLCA), Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Healthcare and Services Center, Taipei Veterans General Hospital Taiwan

HCC is prevalent in Asia Pacific countries and its incidence is expected to rise in the next decade. The treatment of HCC depends on tumor stage and liver function reserve. BCLC is widely adopt as the
staging system for HCC in most countries. The goal of treatment for early stage HCC is to curative resection or ablation for the tumor and avoid recurrence as possible. Several strategies have been established to be able to decrease the risk of recurrence, such as antiviral treatment for underlying chronic hepatitis B or C, and most recently adjuvant immunotherapy for high risk patients. For intermediate stage HCC, TACE is no longer the only option. Due to the heterogenous nature of BCLC B tumors, the outcome of TACE is varied depending on tumor burden and radiologic patterns. Due to the advance of systemic therapy, some patients with intermediate stage HCC have the potential to be curative conversion by atezolizumab/bevacizumab followed by locoregional treatment or surgical resection. TACE combined with immunotherapy, lenvatinib or sorafenib may also prolong the survival for BCLC B HCC. For advanced stage HCC, systemic therapy is the key treatment. Immunotherapy either by atezolizumab/bevacizumab, or tremelimumab/durvalumab is the standard of care if there is no contra-indication for immunotherapy. Although there is no phase 3 clinical trial to support the optimal treatment as 2L after immunotherapy, different mechanism of action and tolerability of adverse event are the key considerations for the choice of subsequent treatment

Post-Graduate Program (HCC)  
PG8-4  

Post-Graduate Program (HCC) Systemic therapy  
Dr. Masafumi Ikeda  
Department of Hepatobiliary and Pancreatic Oncology at the National Cancer Center Hospital East Japan  
Systemic therapy has become mainstream for hepatocellular carcinoma (HCC), with the development of molecular-targeted agents, such as sorafenib and lenvatinib as first-line treatment and regorafenib, ramucirumab and cabozantinib as second-line treatment, and of immunotherapies, such as atezolizumab plus bevacizumab, durvalumab plus tremelimumab and durvalumab monotherapy. In Japan, a total of 9 regimens are now available for unresectable HCC. Combined immunotherapies are firstly selected if patients have no contraindication for immunotherapies, such as autoimmune diseases. Molecular-targeted therapies are firstly selected if patients have no contraindication for immunotherapies, such as autoimmune diseases. Molecular-targeted therapy is selected when immunotherapy is not indicated or proves ineffective. And, it is necessary to select the appropriate treatment taking into consideration the patients’ clinical condition, expected treatment efficacy, and adverse effects of the treatment.

The indications for systemic therapy are currently expanding, although advanced-stage HCC was a good indication for systemic therapy previously. Systemic therapy is indicated for intermediate-stage HCC that is trasarterial chemoembolization (TACE) refractory or TACE unsuitable. When performing non-curative-intent TACE, combination therapy of TACE and systemic therapy is expected to be a future treatment strategy, because phase III trial of TACE with durvalumab plus bevacizumab vs. TACE with durvalumab plus placebo vs. TACE with placebo (EMERALD-1) was press-released to meet the primary endpoint for progression-free survival. Furthermore, the indication might be expanding for early-stage HCC, because perioperative adjuvant therapy of atezolizumab plus bevacizumab demonstrated significantly better recurrence-free survival after curative surgical treatment or ablation (IMbrave050). Therefore, systemic therapy is now available for any stage of the disease. While previously, local therapies used to be the main treatment strategy for HCC, systemic therapy in combination with local therapies is being actively tried at present. Systemic therapy is currently promising topics of development of novel treatments for HCC.

APASL Targets for this Century  
TC1-2  

APASL clinical practice guideline on systemic therapy for hepatocellular carcinoma- 2024  
Dr. George Lau  
Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China  
Since the inception of the first Asian-Pacific Association for the study of liver (APASL) hepatocellular carcinoma (HCC) working party in 2007 and the publication of its first guideline published in 2010 and then revised in 2017, major advances in systemic therapy for hepatocellular carcinoma (HCC) have been made. Despite the availability of effective HCC surveillance and preventive measures, most of the HCC still present at advanced stage as reflected by the high mortality-incidence ratio across Asian-Pacific region. Most of these patients diagnosed with HCC are therefore beyond curative measures such as surgical resection, local ablation or liver transplantation. Even for those patients who are eligible to have curative measures in accordance to various HCC treatment guidelines, recurrence is still a very common clinical problem. The major etiology of the HCC in Asian-Pacific region are chronic hepatitis B and C infection, compounded by the recent rise of metabolic dysfunction-associated fatty liver diseases (MAFLD). In countrylike China, the incidence of HCC is not rising but accounts for close to half of the global annual cases. Most if not all are related to chronic hepatitis B infection.

In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy for hepatocellular carcinoma either as first-line or second-line therapy for unresectable or not eligible for locoregional therapy. The gravity of chronic hepatitis B and C as etiology of hepatocellular carcinoma in Asia-Pacific region, is of great relevance as the response to immune-checkpoint inhibitors are much higher, as compared to targeted therapy. Recently, new data is also emerging with the use of systemic therapy to prevent HCC after curative attempt with resection or local ablation therapy. The purpose of this clinical guideline is to provide an up-to-date recommendation based on clinical evidence and experience from regarded key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely (1) which patients with HCC should be considered for systemic therapy? (2) which systemic therapy should be used? and (3) how should a patient planned for systemic therapy be managed and monitored?

Looking ahead: MAFLD in the APASL region  
Dr. George Jacob  
Storr Liver Centre, The Westmead Millennium Institute for Medical Research, Westmead Hospital and University of Sydney Australia  
At its core, APASL’s main objective is to advance the science and practice of Hepatology, particularly for patients in the Asia Pacific region. In 2024, the APASL pillars focussed on viral hepatitis elimination, liver cancer, acute on chronic liver failure through AARC, the APASL-ACLF Research Consortium (AARC), and MAFLD, through the APASL-MAIDEN (Metabolic fatty liver Disease consortium; maiden-apsl.com) consortium. While we have made tremendous progress over the past decades through vaccination against hepatitis B, curative treatments for hepatitis C and suppressive treatments for hepatitis B, the frontier that has now received the attention it deserves is MAFLD, projected to be the most common liver disease worldwide, with Asia...
at its epicentre. The Asian Pacific region harbours a majority of the world’s population, with just two countries, India and China the most populous. The region is witnessing an economic transformation becoming the engine for global growth, but at the same time, being home to a rising global burden of obesity and type 2 diabetes. These diseases drive a systemic physiological response driven by insulin resistance, which in the liver drives fat deposition (MAFDL) and in pre-disposed individuals, a low grade chronic inflammatory response that leads to hepatic inflammation (steatohepatitis), cirrhosis and its feared complications, liver failure and liver cancer (both hepatocellular and cholangiocarcinoma). However, MAFDL is more than a liver disease and is just one part of systemic metabolic dysfunction, the harbinger of cardio-reno-vascular disease, diabetes and extrahepatic cancer. Managing the consequences of these diseases, a very large proportion of health budgets in Asian Pacific countries will be consumed unless effective policy action and settings are undertaken. While effective pharmacotherapies for weight loss and type 2 diabetes are emerging or are clinically approved, at a population level, they are expensive. Hence, preventive frameworks focussing on food quality, food quantity and physical activity needs to be prioritised. For those with MAFDL, clinical pathways to identify those with significant liver disease, referral pathways to tertiary care and treatment is required. APASL as the peak body for Liver Disease in our region is well placed to lead these initiatives by developing pan-national educational toolkits that can subsequently be individualised to cater to local needs.

HBV Challenges for Elimination of CCC HBV DNA

Clinical utility of novel biomarkers for hepatitis B infection

Dr. Man-Fung Yuen
Department of Medicine, School of Clinical Medicine, The University of Hong Kong Hong Kong SAR, China

During the process of viral replication of hepatitis B virus (HBV) from the viral template, the covalently closed circular (ccc) DNA, there are production of viral nucleic acids, namely, HBV DNA and intermediate HBV RNA. Viral translation activities of different genomic regions of HBV also produce several mRNAs which would be transcribed into various viral antigens including HBsAg, HBeAg and HBcAg. Of note, HBcAg can also be generated from integrated HBV DNA. In the past, conventional measurements of serum viral biomarkers in patients with chronic hepatitis B (CHB) mainly include HBsAg, HBeAg and HBV DNA. It has been shown that measuring these conventional biomarkers have clinical significance for the disease monitoring and treatment. For example, serum HBsAg has predictive value for spontaneous and treatment-induced HBsAg seroclearance. However, existing nucleos(t)ide analog (NA) treatment has negligible effects on HBsAg level. Whereas baseline HBsAg levels before initiation of novel treatment predicts an increase in HBsAg ratio and non-phosphorylated forms of HBcAg in the serum. Clinical usage of this new assay is being actively explored. HBV RNA is another novel HBV biomarker; its roles are overlapping with HBcAg in some areas. HBV RNA measurement correlates with disease outcome, treatment response and HBV reactivation. HBV RNA seems to be prominently useful in patients who are on NA treatment. In conclusions, development of novel HBV biomarkers is able to provide additional and essential disease assessment and treatment guidance for CHB disease. Standardization and increased availability of these assays are highly encouraged.

HBV Challenges for Elimination of CCC HBV DNA

HBV1-2

Identification of host factors that were essentially involved in hepatitis B virus persistence

Dr. Masao Honda
Department of Clinical Laboratory Medicine Kanazawa University Graduate School of Medical Science Japan

Background & aims: Hepatitis B virus (HBV) infection is difficult to cure owing to the persistence of covalently closed circular viral DNA (cccDNA). We performed single-cell transcriptome analysis of newly established HBV-positive and HBV-negative hepatocellular carcinoma cell lines and found host factors that were crucially involved in HBV persistence.

Methods: The cccDNA levels were measured by Southern blotting and real-time detection polymerase chain reaction in various hepatocytes including PXB cells by using an HBV-infected model. HBV capsid was investigated by super-resolution microscopy, proximity ligation assay, and time-lapse analysis. The binding partners of host factors were examined by liquid chromatography-tandem mass spectrometry, immunoblotting, and enzyme-linked immunosorbent assay.

Results: We found that four factors that were crucially involved in HBV persistence. One of the four host factors was dedicator of cytokinesis 11 (DOCK11), known as a guanine nucleotide exchange factor (GEF) for Cdc42. The cccDNA levels were strongly increased by DOCK11 overexpression and repressed by DOCK11 suppression. Interestingly, DOCK11 functionally associated with retrograde trafficking proteins in the trans-Golgi network (TGN), Arf-GAP with GTPase domain, ankyrin repeat, and pleckstrin homology domain-containing protein 2 (AGAP2), and ADP-ribosylation factor 1 (ARF1), together with HBV capsid, to open an alternative retrograde trafficking route for HBV from early endosomes (EEs) to TGN and then to the endoplasmic reticulum (ER), thereby avoiding lysosomal degradation. Clinically, DOCK11 levels in liver biopsies from patients with chronic hepatitis B were significantly reduced by entecavir treatment, and this reduction correlated with HBV surface antigen levels.

Conclusions: HBV uses a retrograde trafficking route via EEs-TGN-ER for infection that is facilitated by DOCK11 and serves to maintain cccDNA. Therefore, DOCK11 is a potential therapeutic target to prevent persistent HBV infection.

HBV1-3

Analysis of HBsAg and cccDNA reduction by nucleotide analogue and pegylated interferon combination therapy

Dr. Masataka Tsuge
Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University Japan
Once HBV enters human hepatocytes, its genome is carried into the nucleus where it forms covalently closed circular DNA (cccDNA), similar to a minichromosome. This translocation of the HBV genome into the nucleus makes it difficult for either the host immune response or present antiviral therapies to eliminate the virus. Combined antiviral treatment using pegylated interferon (PEG-IFN) and nucleotide/nucleoside analogues (NAs) are currently used to suppress cccDNA levels in patients with chronic HBV infection. Although add-on therapy and sequential therapy using PEG-IFN have been attempted in chronic hepatitis B patients following long-term NA therapy, it has not been clarified which PEG-IFN therapy is most effective in reducing HBs antigen (HBsAg) levels. In this study, we investigated the change in HBsAg levels after PEG-IFN therapy (approval number: E-704) and conducted basic research on reduction of cccDNA in liver tissues by NA plus PEG-IFN combination therapy. The subjects included 21 HBsAg-negative chronic hepatitis B patients who had undergone NA therapy for more than one year at our hospital and related facilities. Sequential or add-on therapy using PEG-IFN was performed, and HBsAg levels were measured for up to 5 years after completion of PEG-IFN treatment. Furthermore, we performed add-on therapy on HBV-infected human hepatocyte chimeric mice and examined changes in intrahepatic HBV RNA and cccDNA levels. HBsAg level was reduced by a median of 0.48 Log IU/mL during PEG-IFN therapy. More than 1 Log HBsAg reduction was observed in 9 patients 5 years after the completion of PEG-IFN therapy. Five patients with sequential therapy and 2 patients with add-on therapy achieved HBsAg loss. ALT elevation during PEG-IFN therapy and lower serum IL-8 level at the end of PEG-IFN therapy contributed to HBsAg reduction at 1 year after completion of PEG-IFN therapy (P=0.038, P=0.044). ALT elevation during PEG-IFN therapy, platelet levels at the start of PEG-IFN therapy, and serum IL-8 levels at the end of PEG-IFN therapy were associated with HBsAg reduction at 5 years after PEG-IFN therapy (P=0.034, P=0.049, P=0.041). To confirm high HBsAg reduction by IFN treatment, we measured intrahepatic HBV markers using HBV-infected chimeric mice with add-on therapy. After add-on therapy, intrahepatic HBV RNA and cccDNA levels had decreased to less than 1/50 and 1/2 of that in untreated mice, respectively. Sequential therapy might be more effective in reducing HBsAg levels than add-on therapy, but add-on therapy has the potential to reduce intrahepatic cccDNA levels.

HBV Novel Detection Methods for HBV Markers

**HBV2-1**

**Rethinking the disease status of chronic hepatitis B: The roles of novel detection methods for HBV markers**

**Dr. Atsumasa Komori**

Department of Treatment for Intractable Disease, Division of International Medical Cooperation, Clinical Research Center, and Department of Hepatology, National Hospital Organization NHO Nagasaki Medical Center Japan

Beyond widely available diagnostic tests used in the management of HBV, that includes quantitative (q) HBV DNA and qHBsAg, novel detection methods for HBV markers are scrutinized for their clinical utility in recent years, aiming to rigorous evaluation of functional cure (undetectable HBsAg and HBV DNA) and to appropriate risk stratification for hepatocellular carcinoma (HCC). Among them, ultrasensitive measurement of HBsAg or HBcrAg by iTACT (Immunoassay for Total Antigen including Complex via preTreatment) technology and specific detection of middle (M) protein in HBsAg of genotype C by the antibody against O-glycosylated residue (HBsAgGi) are promising candidates.
HBsAg in the culture supernatant, especially those with potent anti-HBV activity, to obtain SAG compounds (SAG-comp; IC50~1.4 nM). The SAG-comp, a novel anti-HBV therapeutic agent, is an orally available and well-tolerated drug that potently suppresses HBsAg. It can destabilize HBV-RNA and may induce functional cure in combination therapy with NA. In such anti-HBV therapies aiming for functional cure, monitoring HBcAg and HBsAg would be useful for determining the therapeutic efficacies of novel anti-HBV drugs targeting HBV-RNA and its related-proteins. In conclusion, HBcAg and HBsAg, especially when measured by the recently developed iTACT assay, may be the most appropriate surrogate marker, over other HBV biomarkers, for the management of CHB patients.

HBV Novel Detection Methods for HBV Markers

HBV RNA – is it ready for clinical use?

Dr. Henry Lik Yuen Chan
Department of Internal Medicine, Union Hospital Faculty of Medicine, The Chinese University of Hong Kong Hong Kong SAR, China

Pregenomic HBV RNA is a new diagnostic biomarker to monitor the disease of chronic hepatitis B. It reflects the transcriptional activity of intrahepatic cccDNA. In untreated patients, the level of HBV RNA correlates well with other HBV viral markers including HBV DNA and HBcAg. The key clinical usage of HBV RNA is among patients under nucleos(t)ide analog treatment, as HBV DNA is often undetectable in these patients. The presence of HBV RNA indicates residual viral activity, which is associated with an increased risk of hepatocellular carcinoma. The value of HBV RNA to predict virological relapse after stopping nucleos(t)ide analog is controversial, but detectable HBV RNA is found to associate with an increased risk of hepatitits flare. With the development of new therapeutics for chronic hepatitis B, HBV RNA can be a biomarker for target engagement particularly for capsid assembly inhibitors.

HBV Functional Cure of CH-B in Real World

HBV Functional Cure of CH-B in Real World

Advancing towards the functional cure of HBV

Dr. Motoyuki Otsuka
Department of Gastroenterology and Hepatology, Okayama University Japan

As a therapeutic goal for the treatment of hepatitis B, the 'clearance of HBs antigen' is currently the goal. However, this achievement is challenging with the nucleoside analogs, which are widely used. Consequently, there is an active pursuit in the development of novel therapeutic agents. At present, the most promising approach is RNAi-based drugs, which can decrease the HBsAg levels. As an alternative approach, we focused on compounds that inhibit the degradation of the host factor Smc5/6 protein, which plays a role in suppressing the transcription of viral RNA from cccDNA. Through a screening of compounds, we identified two compounds that suppress the degradation of Smc5/6 protein complexes and show potential in suppressing the expression of viral RNA and viral proteins. Both compounds are utilized in the treatment of diseases other than HBV, raising expectations for their practical application through so called “drug repositioning”. Simultaneously, this inhibition of Smc5/6 protein degradation suggests a potential link to the suppression of HBV-related oncogenesis. This presentation will provide an overview of these mechanisms and discuss remaining challenges in HBV treatment after achieving a functional cure.

HBV Functional Cure of CH-B in Real World

Functional cure of CH-B in Real World

Dr. Qin Ning
State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Diseases, Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Clinical Study Centre for Viral Hepatitis, Hubei Province China

Evidence from randomized controlled trials (RCT), e.g. OSST, Endeavor and Anchor study, as well as other relevant clinical studies has shown that sequential combination therapy with immunomodulators (e.g. peg-interferon) and NUC in virally-suppressed patients with chronic hepatitis B (CHB) can improve functional cure (HBsAg loss), as compared to NUC continuous monotherapy. Moreover, several strategies can be used to predict functional cure or identify patients likely to benefit from the sequential treatment with immunomodulators (e.g. peg-interferon), including baseline-guided therapy using pretreatment HBsAg level, response-guided therapy using early decline in HBsAg level, and HBVcore crab model using end-of-therapy HBsAb level and HBcAg level. We further have conducted two multicenter real-world studies—COST study and OCEAN study in China, aiming to investigate the efficacy and long-term outcome of sequential peg-interferon treatment in patients undergoing long-term NUC treatment who had HBV DNA undetectable and HBsAg level <3000IU/mL. The interim analysis of COST study demonstrated consistent results of the RCT studies. We are currently conducting a nationwide questionnaire survey on the application of functional cure strategies for patients with CHB.

MAFLD 1. Asian MAFLD: Clinical Features

MAFLD1-1

MAFLD in Patients living with HIV; PLWH

Dr. Sombat Treeprasertsuk
Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University Thailand

Metabolic syndrome and metabolic dysfunction-associated fatty liver disease (MAFLD) are emerging problems and play important role in the higher morbidities and mortality in patients living with HIV (PLWH). The high MAFLD burden among PLWH is one of a major concern issue according to the novel MAFLD criteria and it needs to identify those patients at risk for chronic liver disease. Generally, the prevalence of MAFLD varies from 10-36% depended on the criteria of diagnosis and investigating tools1-5. Most of them are lean MAFLD with younger age in comparison to those MAFLD with diabetes or obesity. Current antiretroviral treatments for example tenofovir alafenamide fumarate (TAF) and particularly its combination with integrase inhibitors (INSTIs) appear to have the significant consequences on metabolic dysfunction by increasing insulin resistance6, 7. In addition, an unhealthy lifestyle, with a high calories dietary intake especially processed foods, high carbohydrates, saturated fatty acids, high fructose added beverages, as well as less physical inactivity, are key triggers for the progression of fatty liver to steatohepatitis, and
advanced liver fibrosis. Finally, we review the current recommendations of treatment in this special population at risk of MAFLD.

References


MAFLD 1. Asian MAFLD: Clinical Features

MAFLD1-2

How to follow up of patient with act Metabolic dysfunction-associated fatty liver disease (MAFLD)

Dr. Hong Soo Kim

Soon Chun Hyang University Hospital, Internal medicine Korea

Metabolic dysfunction-associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. MAFLD includes a wide spectrum of liver injury including simple steatosis and non-alcoholic steatohepatitis (NASH) that may lead to serious complications such as liver cirrhosis and liver cancer. The identification of Nonalcoholic steatohepatitis (NASH) or NAFLD but there is no accepted consensus on the optimal strategy for monitoring patients with NAFLD and their response to treatment.

According to The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, patients with NAFLD may need a FibroScan yearly or once every three years. The frequency is dependent on your previous FibroScan results. It is important to distinguish mild (F1-F2) from advanced or severe (F3-F4) fibrosis, as patients with severe fibrosis have a greater risk of complications and need to undergo screening for hepatocellular carcinoma with NAFLD.

MAFLD 1. Asian MAFLD: Clinical Features

MAFLD1-4

Metabolic dysfunction-associated fatty liver disease: clinical features and implications

Dr. Wah Kheong Chan

Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, University of Malaya Malaysia

In 2020, the term metabolic dysfunction-associated fatty liver disease (MAFLD) was introduced. This was followed by the term metabolic dysfunction-associated steatotic liver disease (MASLD) in June 2023, which effectively retired the old term non-alcoholic fatty liver disease (NAFLD). While both of the new terms are a clear step forward, there are nuances between them that deserve considerations. The criteria to define metabolic dysfunction for MASLD is present in a large proportion of the general population, even among those without hepatic steatosis. Among those with normal body weight, many would be considered as having metabolic dysfunction based on the criteria, although only a small proportion actually have insulin resistance. These suggest that the criteria to define metabolic dysfunction for MASLD may be too relaxed. Furthermore, patients diagnosed with MAFLD based on presence of type 2 diabetes have been shown to have more severe liver fibrosis and greater risk of cardiovascular, cancer and all-cause mortality compared with patients with MAFLD who are diagnosed based on the other two criteria. This is an important consideration in our strategy to tackle the disease of interest. Last but not least, the introduction of a new entity called MASLD and increased alcohol intake (MetALD) encroaches into the field of alcohol-related liver disease and may embroil the disease of interest with unresolved issues surrounding alcohol-related liver disease. Differences aside, the adoption of either term is a clear recognition that the disease of interest is part of the bigger problem related to excess adiposity, insulin resistance and low-grade meta-inflammation. A paradigm shift is needed, where primary prevention should be the prevention of the onset of metabolic dysfunction instead of the prevention of cardiovascular disease or advanced chronic liver disease. There must be an increasing focus on lifestyle habits for promoting and preserving metabolic health during the entire life course at the individual level and beyond.

MAFLD 2. Asian MAFLD: Basic Understanding (Molecular Pathogenesis)

MAFLD2-1

Metabolic Dysfunction-Associated Liver Cancer

Dr. Shinji Tanaka

Department of Molecular Oncology, Tokyo Medical and Dental University Japan

Metabolic dysfunction caused by abnormalities in hepatic lipid metabolism is associated with an increased risk of developing liver cancer. The molecular mechanisms underlying the progression of
MASLD/NAFLD-associated liver cancer (MALC) are not fully understood. Animal models are extensively used for examining the molecular events under the conditions that mimic human disease. Several mouse models for liver cancer associated with metabolic disease have been established by using specific diets, chemotoxic agents, genetic engineering, or combinations thereof. Mice fed methionine- and choline-deficient diets are conventional models of nonalcoholic steatohepatitis, but they undergo weight loss. Although high-fat diets (HFDs) promote hepatic lipid accumulation, long-term exposure is required for tumor development. Streptozotocin, a compound selectively eliminating $\beta$ cells in the pancreas and resulting in type 1 diabetes, in combination with HFDs induces steatohepatitis and liver cancer without overweight or insulin resistance. Pten conditional knockout (KO) mice on HFDs also recapitulate MALC but not metabolic syndrome. Several congenital mutations are implicated in regulation of food intake and body weight in the hypothalamic nuclei, and these genetic mutations are the most common known monogenic causes of obesity in human. As reported in the previous studies, this regulator-KO mice exhibit obesity, insulin resistance, and dyslipidemia, and they develop steatohepatitis, liver fibrosis, and then well-differentiated liver cancer, suggesting this mouse model may be the best fit for reproducing the features of MALC. Cross-species comparison of gene expression signatures provides a powerful approach to evaluating the biological similarity between human patients and mouse models and to elucidating the molecular system in the common phenotype. Although there have been several comparative studies on human and mouse metabolic liver disease, the cross-species subtyping of liver cancer is focused in our studies. Here, we performed integrative transcriptome analysis of liver cancer resected from human patients and metabolic dysfunction-associated mice, and identified a subtype of liver cancer closely associated with metabolic syndrome, which was characterized by overexpression of several specific genes associated with metabolic dysfunction. We investigated the clinical significance of these metabolic molecules as a specific biomarker for this subtype and the correlation between the expression and metabolic dysfunction in our laboratory. Targeting these pathways may be a useful therapeutic strategy for the subtype-specific liver cancer.

MAFD 2. Asian MAFLD: Basic Understanding (Molecular Pathogenesis)

**MAFD2-2**

**Roles of SGLT2 Inhibitor in MAFLD-related HCC**

Dr. Takumi Kawaguchi

Department of Molecular Oncology, Tokyo Medical and Dental University Japan

MAFLD is becoming a leading cause of hepatocellular carcinoma (HCC) in the Asian-Pacific region. In the Japanese clinical practice guidelines for NAFLD/NASH, sodium-glucose co-transporter 2 inhibitor (SGLT2i) is recommended for patients with NAFLD and diabetes mellitus. However, the effects of SGLT2i on HCC remain unclear. First, we examined the expression of SGLT2 in human HCC cell lines and found that SGLT2 occurred and localized on mitochondria in Hep3B and Huh7 cells. Furthermore, SGLT2i significantly suppressed the proliferation of these HCC cell lines. To investigate the pathogenesis, we employed multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT). This multi-omics analysis revealed that SGLT2i mainly altered the following metabolisms; 1) oxidative phosphorylation metabolism, 2) fatty acid metabolism, and 3) purine and pyrimidine metabolism. Moreover, SGLT2i altered the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC), which are sensors of intracellular ATP levels and regulators for beta-oxidation in mitochondria. Thus, We found that SGLT2i may suppress the proliferation of HCC cell lines via the regulation of electron transport systems, beta-oxidation, and nucleic acid synthesis.

HCC is known to release various chemokines/cytokines to modulate the tumor microenvironment and regulate the proliferation and invasion of HCC cells. Next, we investigated the direct effects of SGLT2i on tumor-releasing chemokines/cytokines in human HCC cell lines. Hep3B and Huh7 cells were treated with SGLT2i or a control vehicle for 24 h. Then, the culture media were collected and subjected to 48-plex panel (Bio-Plex Pro, Bio-Rad Laboratories, Inc., Hercules, CA). We first demonstrated that SGLT2i directly downregulated the three tumor-releasing chemokines such as C-X-C motif chemokine ligand (CXCL) 1, CXCL8, and CXCL10 in Hep3B and Huh7 cells. Based on the previous studies, these changes in chemokines may exert antitumor effects through alterations in tumor characters and tumor immunity.

In conclusion, SGLT2i directly suppressed the proliferation of HCC cells through alterations in mitochondrial oxidative phosphorylation metabolism, fatty acid metabolism, and purine and pyrimidine metabolism. SGLT2i also indirectly suppresses HCC by modulating the tumor microenvironment. I will introduce both direct and indirect molecular mechanisms for the effectiveness of SGLT2i on the suppression of HCC.

MAFD 2. Asian MAFLD: Basic Understanding (Molecular Pathogenesis)

**MAFD2-3**

The role of intestinal TM6SF2 in MAFLD

Dr. Vincent Wong

Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong SAR, China

Metabolic dysfunction-associated steatohepatitis (MASH) is associated with the loss-of-function variant of Transmembrane 6 superfamily member 2 (TM6SF2). While TM6SF2 is primarily expressed in the liver and small intestine, the role of intestinal TM6SF2 dysfunction in MASH development remains unclear. In this study, we utilized systemic, liver-specific, and intestine-specific Tm6sf2 knockout mouse models to investigate the impact of TM6SF2 deficiency on MASH progression. We subjected the knockout mice and wildtype littermates to high-fat high-cholesterol (HFHC) or choline-deficient high-fat diet (CD-HFD) for 2 months to induce MASH. Additionally, fecal microbiota transplantation was performed in germ-free mice, and the therapeutic potential of microbiota modulation was examined by co-housing intestine-specific Tm6sf2 knockout mice with wildtype controls. We characterized the gut microbiota using shot-gun metagenomic sequencing and performed untargeted/targeted metabolomics using liquid chromatography-mass spectrometry. Our results showed that systemic Tm6sf2 knockout mice exhibited more severe steatohepatitis compared to liver-specific Tm6sf2 knockout mice, indicating the involvement of extra-hepatic TM6SF2 deficiency in MASH formation. Interestingly, intestine-specific Tm6sf2 knockout mice developed spontaneous MASH when fed a normal chow diet, which was further exacerbated by HFHC or CD-HFD supplementation. This MASH development in Tm6sf2ΔIEC mice was accompanied by impaired gut barrier integrity and dysbiosis of the gut microbiome. We observed an enrichment of the metabolite lysophosphatidic acid (LPA) in the stool, portal vein, and liver tissues of Tm6sf2ΔIEC mice, which in turn promoted hepatic lipid accumulation.
MAFLD 2. Asian MAFLD: Basic Understanding (Molecular Pathogenesis)

MAFLD-2

Therapeutic management of MAFLD/MASLD

Dr. Jian-Gao Fan

Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai China

The global incidence and prevalence of non-alcoholic fatty liver disease (NAFLD) and its severe form non-alcoholic steatohepatitis (NASH) have been steadily increasing over the past 2 decades, with a huge disease and economic burden. Recently, NAFLD and NASH have been renamed and redefined as metabolic dysfunction associated fatty liver disease (MAFLD)/metabolic dysfunction associated steatotic liver disease (MASLD) and metabolic dysfunction associated steatohepatitis (MASH), which result from an imbalance between metabolic and inflammatory stress (mainly as a consequence of adipose tissue dysfunction and insulin resistance) and the defence and repair mechanisms of the steatotic liver. Once MAFLD/MASLD progresses to end-stage of liver disease, treatment efficacy becomes limited and may require liver transplantation. Early detection and intervention are crucial. Lifestyle modification is consequently the cornerstone of its management. Timely consideration of bariatric surgeries should be given to patients meeting specific criteria. A multidisciplinary approach is warranted, starting from the concept that steatotic liver and steatohepatitis are at the centre of the cardiovascular-liver-metabolic syndrome. In some cases, pharmacological treatment can complement lifestyle modification. Several drugs used to treat the cardiometabolic co-morbidities have some potential efficacy in resolution of MASH and slowing down progression of liver fibrosis, and some drugs have demonstrated efficacy on histological endpoints that are likely to translate into long-term clinical benefits. Optimising the use of these drugs within their licenced indications for type 2 diabetes and obesity is thus paramount for patients with MAFLD/MASLD. Several MASH-specific drugs are on the horizon and are likely to enrich our therapeutic armamentarium in the near future, particularly in non-cirrhotic MAFLD/MASLD. Much work still needs to be done to understand the specific features of MAFLD/MASLD-related cirrhosis and develop efficacious treatments for this disease stage. Future research should focus on optimising lifestyle intervention strategies, improving adherence and success rates, exploring the role of new weight-loss medications, and identifying effective weight loss surgical methods for MASH patients with obesity. Combination therapies targeting multiple pathways and the integration of digital health interventions hold potential for enhancing the efficacy and safety of MAFLD/MASLD treatments.

MAFLD 3. Diagnosis of MAFLD

MAFLD3-1

Pathological Diagnosis of NASH, Fibrosis ad HCC

Dr. Michie Sakamoto

School of Medicine,International University of Health and Welfare Japan

Pathological diagnosis and interpretation of NASH is made based on the histopathological features of steatohepatitis, i.e. ‘steatosis’, ‘lobular inflammation’, hepatocyte ‘ballooning’, ‘Mallory-Denk bodies’ and ‘fibrosis’. However, there are many borderline cases that are difficult to evaluate. Pathologically, degeneration refers to a continuous and reversible change of morphology commonly seen in injured cells, mild, and moderate to severe pathological changes can be observed contemporaneously. This characteristic may also cause inconsistency in recognising and evaluating the presence of ballooning degeneration and Mallory-Denk bodies. The Japan Society of Hepatology published a clinical guidebook illustrating the typical histology of definitive hepatocyte ballooning and Mallory-Denk bodies. This guidebook may help to improve and unify the histological interpretations in diagnosing NASH. Despite these efforts, however, limitations of inter-observer variability will most likely remain. Therefore, quantitative assessment of these reversible and continuous degenerative changes is required. It is widely recognized that accurate staging of liver fibrosis is crucial to guide therapeutic decisions and to predict prognosis for patients with NASH. Digital image analysis (computational pathology) has emerged as a promising tool for quantitative assessment of fibrosis in chronic liver diseases. We measured area ratios of collagen and elastin fibers in Elastica van Gieson-stained biopsy tissues. The combined fiber area ratios correlated strongly with Brunt’s stage, but this relationship was non-linear with striking differences between stage 4 and stages 0–3. The highest tertile of the combined fiber area ratios was associated with fibrosis-4 index and serum type IV collagen 7s domain. Steatosis, is also a characteristic morphology of HCC. We previously reported that scirrhous HCC with steatosis has different clinicopathological significance than scirrhous HCC without steatosis. Furthermore, steatohepatitic HCC, which is characterized by a steatohepatitic morphology, has been reported as a subtype of HCC. We elucidated the features of macrovesicular steatosis (MaS) and microvesicular steatosis (MiS) in HCC. HCCs were classified as MaS-HCC, MiS-HCC, or conventional HCC (cHCC) according to the cutoff value of 30% MaS or MiS in tumor cells. MaS-HCC had less portal vein invasion, a higher proportion of HCC with intratumoral fibrosis, and a lower risk of recurrence than MiS-HCC or cHCC. Both MaS-HCC and MiS-HCC had lower incidences of hepatitis virus infection and higher levels of circulating lipids. These indicated that MaS-HCC and MiS-HCC were associated with metabolic dysfunction but exhibited different biological behaviors. In my lecture, these features of NASH/HCC will be discussed from pathological point of view.

MAFLD 3. Diagnosis of MAFLD

MAFLD3-3

Lean MAFLD

Dr. Mohammed Eslam

Storr liver center, Sydney University Australia

Excessive calorie consumption relative to expenditure, intake of unhealthy diets, and lack of physical activity are globally fuelling an increase in the prevalence of poor metabolic health, even in individuals...
of normal weight. Consequently, this trend entails increased risk of various metabolic disorders, including metabolic associated fatty liver disease (MAFLD), which affects up to a third of the global population. MAFLD burden has grown in parallel with rising rates of type 2 diabetes and obesity and increases the risk of end-stage liver disease, hepatocellular carcinoma, death, and liver transplantation, and has extrahepatic consequences including cardiometabolic disease and cancers. Although classically is associated with obesity, there is accumulating evidence that not all overweight or obese develop fatty liver disease. On the other hand, a considerable proportion of patients with MAFLD are lean, indicating the importance of metabolic health in disease pathogenesis regardless of body mass index. A complex and dynamic interaction between a multitude of factors, including genetic, epigenetic, dietary, and lifestyle factors, enterohepatic circulation, and gut microbiota is likely to shape individual metabolic health status.

The clinical profile, natural history and pathophysiology of lean patients with MAFLD is not well characterised. In this talk, I am going to provide the recent epidemiological data on this group of patients. The talk will illustrate the novel concept considering the overall metabolic health and metabolic adaptation as a framework to best explain the pathogenesis of MAFLD and its heterogeneity, both in lean and non-lean individuals. This framework provides a conceptual schema for interrogating the MAFLD phenotype in lean individuals that can translate to novel approaches for diagnosis and patient care. I will also touch briefly on the current management of lean patients with MAFLD.

MAFLD 3. Diagnosis of MAFLD

MAFLD3-5

Risk Stratification and Prediction of Hepatocellular Carcinoma in MAFLD

Dr. Takuma Nakatsuka
Department of Gastroenterology, The University of Tokyo Japan

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD), which is strongly associated with systemic metabolic abnormalities, such as insulin resistance and glucose intolerance in the context of obesity, has become a leading cause of hepatocellular carcinoma (HCC) worldwide. Establishing an efficient surveillance strategy is urgently needed given the drastically increasing prevalence of MAFLD. However, optimal surveillance strategy remains unclear owing to the lack of evidence regarding risk stratification. Here we will show the utility of noninvasive tests for HCC risk stratification in patients with MAFLD.

Methods: Patients with MAFLD who underwent liver biopsy at our hospital were included. Liver stiffness measurement (LSM) using FibroScan was performed at the time of biopsy. FIB-4 index and Agile 3+ score (incorporating LSM, platelets, AST/ALT ratio, diabetes status, sex, age) were calculated. The performance of FIB-4 index, LSM, and Agile 3+ for diagnosing advanced fibrosis (AF: ≥F3) and predicting HCC was evaluated.

Results: Our cohort consisted of 300 patients with a median age of 55.0 years, median BMI of 27.8 kg/m2, median FIB-4 of 1.45, and median LSM of 8.7 kPa; 62.3% were male and 30.3% had diabetes mellitus. AF diagnostic performance (AUROC) was 0.82, 0.84, and 0.90 for FIB-4, LSM, and Agile 3+, respectively, with the Agile3+ being the best (DeLong test, P=0.001). During a mean observation period of 38.0 months after liver biopsy, 7 patients developed HCC. Compared to non-HCC cases, HCC-developed cases had significantly higher age at biopsy (54 vs 63 years, P=0.03), diabetes complication rate (29% vs 71%), FIB-4 (1.44 vs 2.49, P=0.03) LSM (8.7 vs 20.0 kPa, P<0.01), and Agile 3+ (0.79 vs 0.98, P=0.01). The c-index for predictive ability of HCC were 0.78, 0.80, and 0.85, for FIB-4, LSM, and Agile 3+, respectively. LSM ≥10 kPa, recommended cutoff value of cACLAD suspicion, could identify patients at high risk with an annual HCC incidence of 1.6%/PY, compared to 0.2%/PY in those with LSM <10 kPa (log-rank test, P=0.02). Furthermore, Agile 3+ >0.68, recommended cutoff value for AF rule-in, could identify patients with at high risk with an annual HCC incidence of 1.2%/PY, compared to 0.0%/PY in those with Agile3+ ≤0.68 (log-rank test, P=0.045).

Conclusion: LSM and Agile 3+ allow efficient risk stratification of HCC in patients with MAFLD. Their utilization would optimize personalized HCC surveillance strategy in MAFLD. Further studies are warranted to validate the utility of these tests in diverse MAFLD populations.

MAFLD 4. Clinical Management of MAFLD (Lifestyle Change Nutrition and Need of Medications)

MAFLD4-2

Cancer Prevention in patients with chronic HCV Infections

Dr. Ming-Lung Yu
National Sun Y et-sen University and Kaohsiung Medical University Taiwan

Hepatitis C virus (HCV) infections are a significant global health concern, contributing substantially to hepatocellular carcinoma (HCC), the sixth most prevalent cancer and fourth-leading cause of cancer-related deaths worldwide. The progression from chronic HCV infection to HCC spans 20 to 40 years, influenced by factors such as age at infection, viral genotype and loads, alcohol consumption, comorbidities (diabetes and obesity), HIV coinfection, gender, liver fibrosis, and host genetics.

While primary prevention through vaccination is ideal, there is currently no HCV vaccine. Consequently, HCC prevention focuses on effective antiviral therapy as secondary prevention for de novo HCV-related HCC and tertiary prevention for HCC recurrence after curative therapy. Achieving sustained virological response (SVR) with interferon (IFN)-based or directly-acting antiviral (DAA) agents significantly reduces HCC incidence, liver-related mortality, and HCC recurrence post-curtative therapy.

Despite SVR, the risk of HCC persists, with preexisting liver cirrhosis and age recognized as crucial risk factors. Understanding pathogenetic mechanisms and identifying risk surrogate biomarkers can enhance follow-up strategies post-HCV eradication. HCV infection induces epigenetic changes, including H3K27ac, associated with increased oncogene expression and decreased tumor suppression genes, persisting after SVR.

Several factors contribute to a higher post-SVR HCC risk, including advanced age, liver cirrhosis, diabetes, alcohol consumption, elevated baseline AFP (≥ 10 ng/mL), and specific genetic variations (MICA, PNPLA3, MBOAT7, TM6SF2, and GCKR). Notably, aspirin, metformin, and statin use have shown promising chemo-preventive effects, reducing HCC risk in large cohort studies among HCV-cured patients.

MAFLD 4. Clinical Management of MAFLD (Lifestyle Change Nutrition and Need of Medications)

MAFLD4-3

NAFLD/NASH and sarcopenia - usefulness of nutritional and exercise therapy -

Dr. Masahito Shimizu
Department of Gastroenterology, Gifu University Graduate School of Medicine Japan
Sarcopenia is associated with poor prognosis and impaired quality of life in patients with chronic liver disease. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) and its underlying obesity and diabetes are closely related to the development and progression of sarcopenia. Sarcopenia is also a risk factor for NAFLD/NASH and liver fibrosis. Thus, NAFLD/NASH and sarcopenia adversely affect each other and impair hepatic and skeletal muscle function. Particularly, increased ammonia and decreased branched-chain amino acids are closely associated with these pathologies. In the treatment of NAFLD/NASH complicated by sarcopenia, nutritional and exercise therapy that simultaneously improves liver and skeletal muscle function, i.e., “liver rehabilitation”, is important. Weight reduction with diet and exercise therapy improves liver function and liver histology in NAFLD/NASH. For NAFLD/NASH patients with obesity, a low-calorie diet that limits carbohydrates and fats should be taught to optimize energy intake. On the other hand, weight loss due to inappropriate nutritional therapy, such as excessive protein restriction, may contribute to increased skeletal muscle catabolism and sarcopenia. Combined diet and exercise can further improve hepatic function and liver steatosis, but these conditions in patients with NAFLD may be improved even when only exercise therapy is implemented without nutritional therapy. With regard to exercise intensity, moderate and higher levels are more useful, and when comparing aerobic and resistance exercise, resistance exercise similarly improves hepatic steatosis in NAFLD patients, even though energy expenditure is lower than that of aerobic exercise. Resistance exercise is also useful in the prevention of sarcopenia because it effectively improves muscle strength and muscle mass. BCAA supplementation improves the prognosis of cirrhotic patients with sarcopenia. In these patients, the combination of BCAA preparations and exercise therapy is also useful in the treatment of sarcopenia. On the other hand, abnormal BCAA metabolism and over-intake are associated with type 2 diabetes, insulin resistance, and obesity, and are thought to promote hepatic fat accumulation and the development and progression of NAFLD/NASH. In cirrhosis resulting from NASH, the progression of fibrosis and the dynamics of amino acids, including BCAA, should be evaluated and BCAA replacement therapy should be considered. In conclusion, it is critical to develop safe and appropriate liver rehabilitation to improve the prognosis and quality of life of NAFLD/NASH patients with sarcopenia.

MAFLD 5. The Prognostic Event for MAFLD: CVD or Extrahepatic Cancers?

Treatment strategies of MASLD with a view to suppression of cardiovascular diseases and liver-related events

Dr. Norio Akuta
Department of Hepatology, Toranomon Hospital Japan

AASLD indicated that the most common cause of death in patients with MASLD is related to cardiovascular diseases (CVDs). Liver-related mortality was reported to be the second or third cause of death, and cancer-related mortality was among top three causes of death. In Asia, the incidence rates of these events still remain unclear. We retrospectively investigated the incidence of three complications (CVDs, malignancy except for liver cancer, and liver-related events) in 550 Japanese patients with biopsy-proven MASLD for median follow-up of 6.0 years. The yearly incidence rates of CVDs, malignancies, and liver-related events were found to be 1.04%, 0.83%, and 0.30%, respectively. Especially, in malignancy except for liver cancer, the incidence rates of colon cancer were 25.0%. The impacts of diet and exercise, and diabetes therapeutics with high evidence levels for suppression of CVDs should be evaluated in patients with MASLD. Regarding diet and exercise treatment, the subjects of retrospective cohort study were 203 Japanese patients with SLD diagnosed by abdominal ultrasonography. All of them were introduced the personalized diet and exercise treatment. A diet of 25 to 30 kcal/kg multiplied by ideal body weight daily and aerobic and resistance exercise (exercise intensity of 4 to 5 metabolic equivalents daily, respectively) were performed for 6 days. Treatment efficacy was evaluated in terms of the rate of decrease of liver function tests, glycolipid metabolism markers, physical findings, image findings, and CVD risk score (Suita score) at 6 months compared to baseline, and these parameters improved significantly. Regarding diabetes therapeutics, histological impacts at 5 years after the start of SGLT2 inhibitors were investigated retrospectively in 6 Japanese patients with MASLD and T2DM, and liver biopsies were obtained at the points of pretreatment, 3 years, and 5 years after the start of treatment. The primary outcome was liver histopathological changes at 5 years (defined as decrease in MASLD activity score of one point or more without worsening in fibrosis stage, compared to the pretreatment). 2 patients were performed the additional treatment of GLP-1 receptor agonist after the point of 3 years, and evaluated as histological worsening. Histological improvement, no change, and worsening were 50, 17, and 33% at 5 years, respectively. None developed CVDs events. In conclusion, the most common event in Japanese patients with MASLD was CVDs. Personalized medicine with diet and exercise, and diabetes therapeutics are expected to improve the pathology of MASLD, including the suppression of CVDs and liver-related events.

MAFLD 5. The Prognostic Event for MAFLD: CVD or Extrahepatic Cancers?

Prognostic event for MAFLD: CVD or Extrahepatic cancers

Dr. Yock Young Dan
Dept of Medicine. National University of Singapore Singapore

The diagnosis of Metabolic Associated Fatty Liver Disease (MAFLD) is based on the presence of hepatic steatosis associated with metabolic conditions such as type 2 diabetes mellitus (T2DM), obesity or metabolic dysregulation. The underlying metabolic disequilibrium, potentially manifesting as diabetes mellitus, hypertension, and hyperlipidaemia, is the same process that drives vascular atherosclerosis and increases the risk of carcinogenesis in multiple organs of the body. Hence it is no surprise that major adverse cardiovascular events (MACE) and extraintestinal cancers are the 2 commonest complications and causes of mortality in patients with MAFLD, constituting higher risks compared to liver complications such as cirrhosis and liver cancer.

We will review the risks for non-hepatic metabolic complications in patients at different stages of MAFLD and also the evidence for non-invasive tests (NIT) that can predict these life-threatening complications. Active management such as surveillance and aggressive management will be discussed.

MAFLD 5. The Prognostic Event for MAFLD: CVD or Extrahepatic Cancers?

The Prognostic Event for MAFLD: CVD or Extrahepatic Cancers?

Dr. Rakhi Maiwall
The metabolic dysfunction associated fatty liver disease (MAFLD) is a systemic disease that affects various extrahepatic organs. The prevalence varies from 30-40% and increases to 70% in patients who also have diabetes. Recent evidence has suggested an increase in the risk of chronic kidney disease as almost two-fold which is independent of the other cardiorenal risk factors. Apart from these, MAFLD is also associated with extrahepatic chronic complications. A very close association of MAFLD with diabetes, insulin resistance and obesity also confer a higher risk of hepatocellular carcinoma (HCC) including other extrahepatic malignancies. Mechanisms such as insulin resistance, metabolic stress causing disruption of the regulatory pathways for instance, nuclear factor-kappa B (NF-κB), phosphatase and tensin homolog (PTEN), and microRNAs have been observed to be associated with the development of HCC. The role of lipopolysaccharide-mediated signalling of the toll-like receptor 4 (TLR-4) which further perpetuates the hepatic inflammation and gut dysbiosis causing disrupted metabolism of bile acids has also been causally linked to the development malignancies in patients with MAFLD. The microbiota cause conversion of primary to secondary bile acids such as deoxycholic acid. These secondary bile acids are hepatotoxic and cause worsening of inflammo-fibrosis in MAFLD patients. Dietary intake of high fat and fructose intakes along with genetic factors (e.g., PNPLA3 polymorphisms) have shown to cause progression of the disease increasing the hepatic lipid accumulation. This perpetuates hepatic fibrosis. Accumulation of fat at ectopic locations and adipose tissue dysfunction have also been implicated in the development of MAFLD. Secretion of various hepatokines such as retinol-binding protein-4, fetuin-A, fibroblast-growth factor 21 and inflammatory cytokines, tumor-necrosis-factor alpha, C-reactive protein and interleukin-6 cause hepatic gluconeogenesis, glycogen synthesis and insulin resistance which together drives complications in these patients.

HCV 1. DAA Treatment for CH-C in Asia Pacific Region

**HCV1-I**

**Remaining issues in post-SVR era**

**Dr. Tetsuya Hosaka**

Department of hepatology, Toranomon Hospital Japan

Current direct-acting antiviral agents (DAAs) regimens can achieve sustained viral response (SVR) of over 97% in patients with chronic hepatitis C infection (CHC). Therefore, we are less likely to struggle with antiviral treatment for CHC. Several reports showed the eradication of HCV infection by DAAs therapy reduce the risk of HCC development. However, there are some patients who develop hepatocellular carcinoma (HCC) after SVR. Older age and advanced fibrosis are known risk factors of HCC after SVR. It is important to evaluate other risk factors of HCC. Then, we are going to focus on some metabolic factors and their association with HCC incidences after SVR among patients treated with DAAs or interferon (IFN)-based regimens in this lecture.

HCV 1. DAA Treatment for CH-C in Asia Pacific Region

**HCV1-4**

**Management of hepatitis C virus infection in Japan**

**Dr. Taro Yamasita**

Department of Gastroenterology Kanazawa University School of Medicine Japan

Globally, about 58 million people are estimated to have chronic Hepatitis C virus (HCV) infection, and most affected areas are considered Eastern Mediterranean, Europe, Western Pacific, Africa, regions of Americas, and Southeast Asia. HCV infection has been the most common etiology of liver cirrhosis and hepatocellular carcinoma in Japan. Major genotype of HCV has been genotype 1b, which is resistant to interferon-based therapies, following 2a and 2b in Japan. Accordingly, sustained virological response (SVR) rates were less than 50% before direct-acting antivirals (DAAs) developed and became available in 2014 in Japan. Currently, pan genotype DAAs glecaprevir/pibrentasvir and sofosbuvir/velpatasvir regimens are recommended for the treatment of HCV by the Japan Society of Hepatology, with attention to the status of renal function, presence of decompensated cirrhosis, and viral mutations including p32 deletion. SVR rates of these DAA regimens exceed 95%, and now almost all HCV infection can be successfully eradicated. However, because HCV infection is generally asymptomatic until the development of liver cirrhosis and hepatocellular carcinoma, most of patients are unaware of their HCV infection without screening tests. Furthermore, although most of HCV infected patients could relatively easily reach HCV testing and receive DAAs in urban areas, numbers of HCV infected patients are still considered undiagnosed and therefore remained untreated especially in rural areas in Japan. We are currently making an effort to provide the opportunity to receive the diagnosis and treatment of HCV infection in these people by utilizing information and communication technology.
patients with sustained virological response should undergo surveillance for HCC every 6 months by means of imaging and serum tumor markers.

HCV 2. Treatment with Direct Acting Antivirals (DAAs) for Cirrhotic Patients with or Without HCC

Risk factors of treatment failure of DAAs in chronic hepatitis C

Dr. Takeji Umemura
Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine Japan

In Japan, where the majority of patients are infected with Genotype 1 and 2, DAA treatment for chronic hepatitis C and compensated cirrhosis achieves SVR in nearly 100% of patients. In this study, we investigated the following two risk factors for the few cases of treatment failure among patients treated with DAA at Shinshu University Hospital and its affiliated hospitals in Japan: 1) DAA treatment for patients who had previously developed HCC and had been relapse-free for six months after radical treatment of HCC, and 2) serum chemokine levels measured before DAA treatment. 1) Of the 838 DAA-treated patients, 9.4% had prior HCC, and low pretreatment platelet counts and high AFP levels, advanced fibrosis (M2BPGi), and prior HCC were associated with treatment resistance, leaving prior HCC as the only risk factor in the multivariate analysis. 2) Nine chemokines were measured, and treatment resistance (56.3%; 9 of 16) was significantly observed in the group with low MIP-1β and high RANTES before treatment. Future issues are to improve the prognosis of patients with uncompensated cirrhosis by DAA treatment and the indication of DAA treatment in patients with HCC.

Morphological changes in esophageal varices in cirrhotic patients who achieved sustained virological response by direct-acting antivirals

Dr. Masanori Atsukawa
Division of Gastroenterology and Hepatology, Nippon Medical School Japan

Recently, DAAs have markedly improved treatment outcomes and have been approved for patients with liver cirrhosis including decompensated cirrhosis related with chronic HCV infection, which is frequently complicated by esophageal varices. Previously, some studies reported that achievement of SVR with DAAs decreased portal pressure to some extent. Recent studies reported post-SVR changes in the morphology of esophagogastric varices in patients with compensated cirrhosis. However, post-SVR esophageal variceal changes in patients with decompensated cirrhosis remain unclear. Therefore, this multicenter retrospective study aimed to clarify the morphological changes in esophageal varices after achieving SVR with DAAs treatment at 26 participating institutions in Japan. Among them, 243 patients underwent esophagogastroduodenoscopy before DAAs treatment and after achieving SVR. Our study included 125 males and 118 females with compensated or decompensated cirrhosis with a median age of 68 (range, 44–91) years. Esophageal varices before DAAs were classified into no varix in 155, F1 in 59, F2 in 25 and F3 in 4 patients. The improvement, unchanged, and aggravation rates of esophageal varices after SVR were 11.9%, 73.3%, and 14.8%, respectively. Low platelet count was extracted as an independent factor associated with esophageal varices aggravation. Of the 155 patients without esophageal varices before DAAs treatment, 17 developed de novo post-SVR esophageal varices. High ALBI score was extracted as an independent factor associated with de novo post-SVR esophageal varices. The cumulative incidences of de novo esophageal varices were 0%, 6.7%, and 17.7% at 1, 3, and 5 years, respectively. In conclusions, patients with cirrhosis can experience esophageal varices aggravation despite achieving SVR. In particular, patients with low platelet count and high ALBI score such as decompensated cirrhosis had a high likelihood of developing esophageal varices aggravation and de novo esophageal varices, respectively, even for long periods after achieving SVR.

HCV 3. Prognosis Portal Hypertension HCC in Post SVR CH-C/cirrhosis

Evaluation of the usefulness of liver stiffness in cancer development after DAA treatment for chronic liver disease type C

Dr. Koichi Takaguchi
Department of Hepatology Kagawa Prefectural Central Hospital Japan

Purpose: DAA treatment eliminated Hepatitis C Virus (HCV) in most cases of type C chronic liver disease. However, some cases of SVR are also found to develop cancer. Here we report on whether subsequent carcinogenesis can be predicted in cases in which liver stiffness was measured at the start of treatment.

Method: Of the 751 patients who received DAA at our hospital by March 2023, 234 patients (115 men, 119 women, Average age: 64.6 years, Genotype 1: 144 cases, Genotype 2: 88 cases, Genotype 3: 1 case, Unknown: 1 case) with type C chronic liver disease were measured Liver stiffness(LS) before DAA treatment.

Results: The average observation period after completion of administration was 38.1 months. During this period, 7 cases developed cancer. The 5-year cancer incidence rates for all cases was 3.8%. The five-year cancer incidence rate for LS, platelets(PLT), Alb, AFP, ALBI score, hyaluronic acid, M2BPGi, FIB4index, and FAST before administration was 1.0% for LS less than 14.8, 16.8% for 14.8 or more, and 9.0% for PLT less than 134,000/μL, 134,000/μL or more: 2.1%, AFP less than 7ng/mL: 2.5%, 7ng/mL or more: 7.4%, Hyaluronic acid less than 298ng/mL: 1.4%, 298ng/mL or more: 13.4%, M2BPGi less than 1.92: 1.9%, 1.92 or more: 6.2%, FIB4index less than 7ng/mL: 2.5%, 7ng/mL or more: 7.4%, Hyaluronic acid less than 298ng/mL: 1.4%, 298ng/mL or more: 13.4%, M2BPGi less than 1.92: 1.9%, 1.92 or more: 6.2%, FIB4index less than 3.20: 1.2%, 3.20 or more: 7.4%, ALBI score, hyaluronic acid, M2BPGi, FIB4index, and FAST before administration were found to be predictive factors for subsequent carcinogenesis in patients with DAA treated chronic HCV infection.

Conclusion: The liver stiffness measured before administration and the liver stiffness after administration were found to be predictive factors for subsequent carcinogenesis in patients with DAA treated chronic HCV infection.
Dr. Si Hyun Bae
Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, The Catholic University Liver Research Center Korea

Globally, an estimated 58 million people have chronic hepatitis C virus (HCV) infection, with about 1.5 million new infections occurring per year. In 2019, an estimated 290,000 deaths were attributed to hepatitis C-related complications. The primary treatment goal for hepatitis C is the eradication of the HCV to prevent complications such as fibrosis, cirrhosis, portal hypertension, hepatocellular carcinoma (HCC), and extrahepatic manifestations, ultimately leading to a reduction in mortality. The clinical endpoint of antiviral therapy is achieving a sustained virologic response (SVR) at 12 weeks post-treatment, where no detectable HCV RNA is found in the bloodstream. Recent advancements in interferon (IFN)-free direct-acting agents (DAAs) have dramatically improved SVR rates. Achieving SVR leads to improvements in fibrosis and portal hypertension. It is known that reaching SVR is associated with the regression of liver stiffness, which is linked to a decrease in liver-related complications and mortality. According to Lens et al.’s research, HCV-related cirrhotic patients who achieved SVR showed progressive reductions in hepatic venous pressure gradient (HVPG), and those with high baseline HVPG were more likely to experience decompensation events. Achieving SVR significantly reduces the risk of hepatic decompensation. Meta-analyses show that SVR lowers this risk by 84% and 89% in the interferon and DAA eras, respectively. A Korean multicenter study found no significant difference in decompensation events between IFN-SVR and DAA-SVR patients. Achieving SVR also reduces the risk of developing HCC. SVR results in an approximately 70% reduction in the risk of HCC development, with this effect becoming evident within 3–6 months and increasing over time. Some studies suggest that there may be differences in HCC risk reduction between cirrhotic and non-cirrhotic patients after SVR. And various prediction models for post-SVR HCC risk have been reported. In conclusion, achieving SVR in hepatitis C patients is closely associated with favorable outcomes in terms of fibrosis regression, portal hypertension improvement, reduced HCC risk, and enhanced survival. However, it is important to note that certain high-risk groups may still require vigilant monitoring even after achieving SVR.

HCV 3. Prognosis Portal Hypertension HCC in Post SVR CH-C/cirrhosis

HC3-3

Influence of HVPG in predicting outcomes in liver disease

Dr. Ankur Jindal
Additional Professor, Department of Hepatology, Institute of Liver and Biliary Sciences India

Portal hypertension is a severe, almost unavoidable complication of chronic liver diseases and is responsible for the main clinical consequences of cirrhosis. Measurement of the hepatic venous pressure gradient (HVPG) is currently the best available method to evaluate the presence and severity of portal hypertension. Clinically significant portal hypertension is defined as an increase in HVPG to ≥10 mmHg; above this threshold, the complications of portal hypertension might begin to appear. Measurement of HVPG is increasingly used in clinical hepatology, and numerous studies have demonstrated that the parameter is a robust surrogate marker for hard clinical endpoints. The main clinical applications for HVPG include diagnosis, risk stratification, identification of patients with hepatocellular carcinoma who are candidates for liver resection, monitoring of the efficacy of medical treatment, and assessment of progression of portal hypertension. Patients who experience a reduction in HVPG of ≥20% or to <12 mmHg in response to drug therapy are defined as ‘responders’. Responders have a markedly decreased risk of bleeding (or rebleeding), ascites, and spontaneous bacterial peritonitis, which results in improved survival.

HCC Percutaneous Ablation for Liver Tumors

HCC1-2

Microwave Ablation for Hepatocellular Carcinoma

Dr. Shinichiro Nakamura
Japanese Red Cross Society Himeji Hospital Department of Internal Medicine Japan

Background and aim: The next-generation microwave ablation (MWA) has been developed as a new percutaneous thermal ablation therapy for hepatocellular carcinoma (HCC). Compared to radio-frequency ablation (RFA), MWA has the advantage of faster heating and less susceptibility to heat sink effects due to the higher temperature generated and can make predictable spherical ablation zones. We describe our MWA procedure and the clinical outcomes of patients with HCC.

Methods: We treat Child A or B patients with tumors less than 4 cm in diameter and three or fewer tumors without vascular invasion. MWA-antenna puncture was performed under ultrasound guidance. When the tumor was difficult to visualize using B-mode ultrasound, contrast-enhanced US (CEUS) or fusion imaging with CECT or GdEOB-DTPA enhanced MRI was used as a complementary method for MWA. If needed, artificial pleural effusion or ascites were prepared using a 5% glucose solution.

Results: Between September 2019 and September 2023, 564 consecutive patients with 802 HCCs (maximum tumor diameter ≤40 mm) were included. The median maximum tumor diameter was 13.0 (interquartile range, 10.0–18.0) mm. We use CEUS, pleural effusion, and artificial ascites during MWA in 326 (40.7%), 73 (9.1%), and 439 (54.7%) HCCs, respectively. The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.6%, 8.6%, and 9.8%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=651), 20–30 mm group (n=132), and ≥30 mm group (n=19) (p=0.0001). In the multivariable analysis, tumor size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p=0.0002) and ablative margin (per 1 mm) (HR, 0.83; 95% CI, 0.74–0.93; p=0.0019) were significantly associated with local tumor recurrence. Complications after MWA were observed in 40 cases (5.0%), and the major cases were biloma, 10; portal vein thrombosis, 9; bile duct dilatation, 6; pleural effusion, 5. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.04–1.13; p=0.0002) was significantly associated with complications. Tumors located at difficult-to-treat Child A and B patients were included. For optimal results, we used CEUS, pleural effusion, and artificial ascites during MWA. If needed, artificial pleural effusion or ascites were prepared using a 5% glucose solution.

Conclusion: MWA is a safe and effective local ablation therapy for HCC.
Strategic Optimization of Percutaneous Liver Ablation: A Comprehensive Approach

Dr. Hyunchul Rhim
Department of Radiology Samsung Medical Center, Sungkyunkwan University Korea

Percutaneous liver ablation is pivotal in modern liver cancer management, necessitating a tailored strategy for heightened effectiveness. This overview explores the imperative of strategic optimization, highlighting key components contributing to enhanced patient outcomes. Strategic optimization involves a personalized methodology that extends beyond conventional practices. Incorporating advanced technologies and tailored patient care, practitioners can boost precision and procedural efficacy. Individualized treatment plans, guided by advanced imaging, enable accurate tumor delineation, minimizing collateral damage to healthy tissues.

Economic considerations are pivotal in the strategic optimization framework. Evaluating the cost-effectiveness of ablation techniques ensures judicious resource allocation without compromising patient care—a crucial aspect in the era of value-based healthcare. Additionally, the overview emphasizes collaboration across medical disciplines. Integrating insights from radiology, oncology, and interventional medicine enriches research and facilitates the exchange of best practices.

In conclusion, strategic optimization in percutaneous liver ablation represents a paradigm shift. This overview outlines its key components, underlining its potential to redefine standards of care, improve outcomes, and shape the future of interventional oncology.

HCC Can Drug Therapy and Classical Local Treatment Coexist?
HCC2-3

TACE plus systemic therapy: How and Who

Dr. Stephen Lam Chan
Department of Clinical Oncology, Faculty of Medicine, The Chinese University of Hong Kong Hong Kong SAR, China

Conventionally, TACE is reserved for patients with intermediate disease of HCC while systemic therapy is indicated following TACE treatment or in the presence of advanced disease. However, this concept is being challenged by recent randomized data showing that the addition immunotherapy-based systemic therapy to TACE could improve outcomes. The lecture will review the latest efficacy and safety data on the combination. Patient selection for this treatment combination will also be discussed.

HCC Can Drug Therapy and Classical Local Treatment Coexist?
HCC2-4

Basis of combination therapy by radiofrequency thermal ablation and immune checkpoint blockade for unresectable hepatocellular carcinoma

Dr. Hidetoshi Nakagawa
Gastroenterology, Institute of Medical, Pharmaceutical and Health Sciences Kanazawa University Japan

Introduction: Despite significant advancements in cancer treatment since the establishment of immune checkpoint blockade, a considerable number of patients do not benefit from the latest immunotherapies, often due to insufficient tumor-infiltrating lymphocytes or limited antigen exposure. To address this, we propose leveraging the 'abscopal effect' through local ablation therapy before immunotherapy in patients with unresectable hepatocellular carcinoma.

Methods: We evaluated the antitumor effects of radiofrequency ablation (RFA) in BNL/ MC38 tumor-bearing mice. RFA was applied to one of two bilateral tumors, with the untreated tumor monitored to assess antitumor responses. To explore the underlying mechanisms, we examined the roles of different immune cell subsets using nude mice, clodronate liposomes, and CD4/CD8 depletion antibodies. We also initiated a clinical study, "Randomized Phase II study of preceding radiofrequency ablation to atezolizumab plus bevacizumab combination therapy for patients with unresectable hepatocellular carcinoma (jRCT10412000075)." This study involves treating selected hepatic lesions with RFA before administering atezolizumab and bevacizumab to patients with unresectable hepatocellular carcinoma. The study includes a safety confirmation cohort (n=6) and a randomized cohort (n=60), focusing on progression-free survival as the primary endpoint and overall survival, objective responses, tumor control rates, and immunological responses as secondary endpoints.

Results: Animal studies demonstrated that RFA enhanced antitumor effects in residual tumors. Experiments in nude mice with BNL tumors confirmed that this enhancement was T-cell mediated. Macrophage ablation with clodronate liposome did not affect tumor growth in wild-type BNL mice. Tests using CD4 or CD8 depletion antibodies showed that T cells were responsible for the enhanced antitumor effects in MC38-bearing mice. Preliminary results from the clinical study's safety cohort indicate the combination therapy's safety and feasibility. Over a median observation period of 885 days, the best responses included one partial response and five stable diseases, with a median progression-free survival of 175 days.

Conclusions: The combination therapy involving RFA and cancer immunotherapy, with the aim of eliciting abscopal effects, presents a promising avenue in cancer immunotherapy. Preliminary results from the clinical trials support the safety and feasibility of this combination approach, encouraging further investigation.

HCC Will Adjuvant Chemotherapy Post-Curative Treatment for Hepatocellular Carcinoma Be a Paradigm Shift?
HCC2-1

Will Adjuvant Chemotherapy Post-Curative Treatment for Hepatocellular Carcinoma Be a Paradigm Shift?

Dr. Masafumi Ikeda
Department of Hepatobiliary and Pancreatic Oncology at the National Cancer Center Hospital East Japan

According to the Barcelona Clinic Liver Cancer (BCLC) staging system, a single tumor or tumor size of ≤3 cm of hepatocellular carcinoma (HCC) are classified as early-stage, and liver resection, liver transplantation, or local ablative therapy is recommended. These treatments aim for complete cure, and systemic therapy was firstly developed as post-curative adjuvant therapy. Although no standard post-curative treatments have been established yet, the effectiveness of adjuvant atezolizumab plus bevacizumab (Atezo+Bev) therapy as compared to active surveillance (IMbrave050) was demonstrated in 2023. The primary endpoint of recurrence-free survival (RFS) demonstrated to be significantly better in Atezo+Bev than in active surveillance [12-month RFS: Atezo+Bev 79% vs. active surveillance 68%, hazard ratio 0.70 (95% confidence interval: 0.54-0.91, p=0.007)]. In the subgroup analysis of RFS, the benefits of Atezo+Bev were consistent across all subgroups. However, there was no difference in overall survival [hazard ratio 1.42 (95% confidence interval: 0.80-2.54)], and the Kaplan-Meier curves for RFS became close after 2 years, suggesting the suppressive effect for early recurrence and no suppressive effect after 2
years. As the follow-up period (median) is still short at 17.4 months, long-term follow-up results are warranted.

Currently, in the early-stage HCC, post-curative treatment of systemic therapies are underway as comparator of placebo: EMERALD-2 (NCT03847428) compared with durvalumab plus bevacizumab, CheckMate9XD (NCT03383458) compared with nivolumab, and KEYNOTE-937 (NCT03867084) compared with pembrolizumab. These phase III trials are focusing on combined therapy or monotherapy of immune checkpoint inhibitors. From these results, whether a single immune checkpoint inhibitor or a combination of an immune checkpoint inhibitor and a VEGF inhibitor is necessary for adjuvant therapy will be determined.

The next step toward adjuvant therapy in patients with hepatocellular carcinoma

Dr. Kaoru Tsuchiya
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Japan

Adjuvant therapy for patients with hepatocellular carcinoma (HCC) after curative treatment, including resection and ablation, is still unestablished in clinical practice. There are some clinical studies that aim to prove prevention of HCC recurrence after curative treatment. The phase 3 clinical trial, atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk HCC (IMbrave050), already showed positive results. The recurrence-free survival (RFS) was significantly longer in the patients treated with atezolizumab plus bevacizumab compared to the patients with active surveillance. In this study, the majority (88%) of patients received resection, and 90% of the patients treated with resection had solitary tumors. Moreover, 82% of patients were recruited from Asia, and 62% had HBV infection. In Western countries and Japan, the percentage of HCC patients with HBV infection is about 10%, and the number of non-viral HCCs, including MASLD, has been increasing globally. Even though this study met the primary endpoint, the median duration of follow-up was only 17.4 months in the treatment group and 17.6 months in the active surveillance group. IMbrave050 trial was the first successful clinical study and the first step toward adjuvant therapy in HCC. However, there are many concerns about adjuvant settings. First, we have to identify the patients with high-risk populations of recurrence. In the IMbrave050 trial, only 7 patients in the treatment group and 3 patients in the active surveillance group had ≥ 3 tumours. Second, we should mention the etiologies of patients. Third, it is important to consider the toxicity of adjuvant therapy. In the IMbrave050 trial, grade 5 adverse events occurred in 6 patients (2 of which were treatment-related) in the treatment group and 1 patient in the active surveillance group. In real-world practice, several studies were performed by using transarterial chemoembolization (TACE) + portal vein chemotherapy (PVC) or internal radiotherapy (IRT) as adjuvant therapy after curative resection in HCC and showed positive results. Although atezolizumab plus bevacizumab has been recommended as first-line systemic therapy in most HCC guidelines, it should be evaluated by comparing other therapies as adjuvant therapy. The next step toward adjuvant therapy in HCC is to solve such clinical questions and establish the appropriate adjuvant therapy for each patient.
Liver-Resident Natural Killer Cells as Adjuvant Treatment for Hepatocellular Carcinoma Post-Liver Transplantation

Dr. Masahiro Ohira
Department of Gastroenterological and Transplant Surgery, Hiroshima University Japan

Effective prevention or treatment strategies for hepatocellular carcinoma (HCC) recurrence following liver transplantation (LT) are currently lacking. Standard immunosuppressive protocols post-LT tend to preserve innate immune components while suppressing adaptive cellular immunity. Central to the innate immune response, Natural Killer (NK) cells are pivotal in defending against neoplastic cells, making their enhancement a viable immunotherapeutic strategy against HCC post-LT. We suggest that the adoptive transfer of liver-resident NK cells, harvested from the donor liver graft perfusate, could induce an anti-tumor response without harming the recipient's healthy tissues. In our study, 99 patients who preoperatively met the Japan criteria were examined. Of these, 42 patients who postoperatively exceeded the Milan criteria demonstrated significantly lower recurrence-free survival rates compared to the 57 within the criteria (p=0.022). Remarkably, among patients beyond the Milan criteria, those treated with NK cell therapy (n=17) showed a marked improvement in recurrence-free survival rates. Following NK cell infusion, we observed a significant increase in NK cell cytotoxicity and the percentage of TRAIL+ NK cells in the patients’ peripheral blood (p<0.05). The administered donor NK cells were detectable in the peripheral blood up to one month post-infusion.

Our collaborative research with the University of Miami, initiated in 2009, has extended this approach to deceased donor LT (DDLT) recipients. This phase I trial encompassed 17 subjects with a median follow-up of 96 months, recording no adverse events related to the study. The high-dose NK cell group exhibited a significantly superior overall survival rate compared to the low-dose group (p=0.0064). Among the DDLT series for HCC, 53% of patients meeting the Milan criteria preoperatively had pathological findings exceeding the criteria postoperatively, yet none have experienced HCC recurrence to date. In conclusion, IL-2 stimulated NK cells from both living and deceased donor liver transplants have been safely administered, suggesting a promising adjuvant immune therapy for HCC patients post-LT. A multicenter phase II trial is now underway in Japan and the USA.

New FP therapy for long-term prognosis in patients with advanced hepatocellular carcinoma

Dr. Hiroaki Nagamatsu
Department of Gastroenterology, Juntendo University Japan

Introduction: In Japan, hepatic arterial infusion chemotherapy (HAIC) is recommended as an optional treatment in the 2021 guidelines. In 2021, New FP therapy (NFP) was reported to have a longer prognostic effect than sorafenib in advanced hepatocellular carcinoma with intrahepatic lesions.

Objectives: I will show the performance of NFP in this study at our hospital.

Subjects: We perform 2 courses using the temporary indwelling catheter system via the left brachial artery, and then we remove the temporary reservoir during hospitalization. We repeat this treatment 3 to 5 times with an interval of about 2 months. We aim for cancer free by performing conversion therapy when PR or CR is obtained by NFP. We performed NFP on 290 patients with advanced with vascular invasion.

Results: There is almost no deterioration liver function. A total of 200 patients (69%) responded to NFP therapy, of which 80 patients achieved cancer-free outcome. 32 patients became cancer-free outcomes with only NFP. We were able to add hepatic resection to 33 patients. Median OS (MST) after HAIC in all patients was 18 months. MST in patients who responded was 29 months, and in patients who achieved cancer-free outcome, it was extended to 67 months. The 5-year survival rate of all patients was 22%, and 67% for patients who got cancer-free outcome.

Conclusions: NFP has a high response rate and contributes to improve or maintain liver function by controlling PVTT. In response cases, long-term survival can be obtained by adding conversion therapy.
Japan

Carcinoma

HCC Advancements in Radiation Therapy for Hepatocellular Carcinoma

HCC7-1

Carbon-ion radiotherapy for hepatocellular carcinoma

Dr. Masaru Wakatsuki

Department of Diagnostic Radiology and Radiation Oncology, QST Hospital, National Institute for Quantum Science and Technology Japan

Radical treatment options for bulky unresectable locally advanced hepatocellular carcinoma (HCC) are limited. Stereotactic Body Radio Therapy (SBRT) is becoming popular in many countries as an effective treatment option for relatively small hepatocellular carcinomas, there are problems in terms of its effects on the normal liver and its efficacy against large hepatocellular carcinomas. Carbon-ion radiotherapy (C-ion RT) has improved dose distribution properties owing to Bragg peak and less lateral scattering and enable to perform higher prescribed dose for HCC than that of photons. Take advantage of this feature, C-ion RT is becoming popular in Japan as a new curative treatment option. National Institute for Quantum Science and Technology (former the National Institute of Radiological Sciences) began treating patients with C-ion RT in 1994 and has treated approximately 1,000 cases of hepatocellular carcinoma to the present. Since April 2022. Its effectiveness with bulky hepatocellular carcinoma with vascular invasion, patients with low liver function, and patients with bulky hepatocellular carcinoma. In this presentation, I would like to show the results of treatment to date and introduce the challenges and future directions of C-ion RT for hepatocellular carcinoma.

HCC Advancements in Radiation Therapy for Hepatocellular Carcinoma

HCC7-2

The Role and Future of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma

Dr. Yoshiko Doi

Department of Radiation Oncology, Hiroshima Prefectural Hospital Japan

With advancements in imaging diagnostics and radiation therapy techniques, the application of stereotactic body radiotherapy (SBRT), delivering high doses of radiation in a short time, has become more feasible. Numerous studies have reported the high therapeutic efficacy and safety of SBRT for hepatocellular carcinoma (HCC). A prospective, phase II multicenter study of SBRT in previously untreated solitary primary HCC (STRSPH study) was conducted in Japan and reported a 90% local control rate and a 3-year overall survival (OS) rate of 78%. This study included many elderly patients and patients with comorbidities for whom standard treatments (radiofrequency ablation (RFA) and surgical resection) were not applicable, but the high local control rate and low toxicity of SBRT are thought to have led to the good results.

On the other hand, in the global treatment algorithm for HCC, decisions are guided by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Consequently, treatment options rich in evidence, such as liver resection, RFA, transarterial arterial chemoembolization, liver transplantation, and chemotherapy, are considered in the selection of HCC treatment. Unfortunately, among studies evaluating SBRT outcomes, none have presented high-quality clinical evidence assessable by the GRADE system. So, SBRT is absent from the treatment algorithm.

Nevertheless, studies have shown positive results not only in SBRT outcomes, but also in studies comparing outcomes with other treatment modalities in retrospective study. A meta-analysis of tumor outcomes for HCC treated with RFA or SBRT, utilizing meticulously selected studies, reported no significant difference in the OS rate between the two modalities (1- and 2-year OS rates were 91.8% and 77.7% after RFA, and 89.0% and 76.0% after SBRT, respectively). SBRT exhibits notably high local treatment efficacy, particularly acting as a breakthrough in challenging scenarios where RFA is difficult (such as lesions just below the diaphragm, on the liver surface, perivascular lesions, and conditions with a bleeding tendency, as well as cases with tumors not visible by ultrasonography) or in instances of recurrence post-TACE. This underscores its potential as a promising therapeutic approach contributing to overall prognosis improvement for HCC patients. It is imperative for radiation oncologists to communicate the heightened therapeutic efficacy and safety of SBRT to hepatologists and surgeons, making sustained efforts to broaden the applicability of SBRT implementation.

HCC Advancements in Radiation Therapy for Hepatocellular Carcinoma

HCC7-3

Experience in clinical trials combining immunotherapy and radiotherapy

Dr. Hee Chul Park

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine Korea

While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.

External beam radiation therapy (EBRT) can be applied to patients with HCC in various situations, including those with symptomatic primary liver or metastatic lesions. Recent advances in the EBRT techniques, such as with stereotactic body radiotherapy (SBRT), proton beam therapy (PBT), and carbon ion radiotherapy, have enabled the delivery of higher radiation doses to achieve excellent local control. While systemic therapy is recommended for HCC patients with MVI by many academic guidelines, various liver-directed therapies such as surgical resection, transarterial chemoembolization with or without radiotherapy, and radioembolization have demonstrated significant outcomes. There may be an unmet need for improved treatment strategies integrating systemic and liver-directed therapy in patients with HCC and MVI.
be expected to exert a synergistic effect in cancer treatment. Radiation therapy can have immunostimulatory effects. Substantial preclinical studies have shown that radiotherapy may synergize with immunotherapy. Preliminary clinical studies have recently been reported. A phase 1 trial of SBRT combined with immunotherapy (nivolumab with or without ipilimumab) exhibited favorable outcomes, and the combination therapy of EBRT and atezolizumab/bevacizumab demonstrated acceptable safety.

Based on the CheckMate-040 trial, which showed promising clinical activity and a favorable safety profile, nivolumab, a PD-1 inhibitor, obtained accelerated approval from regulatory agencies worldwide, including South Korea, as a second-line treatment, and a global first-line nivolumab trial could be initiated. Nivolumab monotherapy demonstrated a durable response in some patients; however, the response rate still remained at 20%. EBRT has shown good local control in HCC and may potentiate immunotherapy through immunomodulatory effects; therefore, we conducted a phase 2 study evaluating the efficacy and safety of concurrent therapy with nivolumab and EBRT in patients with advanced HCC and MVI.

HCC Bridging Clinical and Basic Research

HCC8-2

Establishment of Genome analysis center, From Genomic Analysis to Clinical Practice in Hepatocellular Carcinoma

Dr. Kenji Amemiya

Genome Analysis Center, Yamanashi Prefectural Central Hospital

Japan

In 2019, Comprehensive Genomic Profiling test became eligible for insurance coverage, marking the widespread adoption of cancer genomic medicine. Our institution established a Genomic Analysis Center in April 2013 and has been actively engaged in cancer genomic medicine.

Yamanashi Prefectural Central Hospital has accumulated cancer registration data since 2006, totaling 29,024 cases (including 1,163 with hepatocellular carcinoma, HCC), and has obtained genomic informed consent from 9,484 patients (including 313 with HCC). We developed an in-house panel targeting Significantly Mutated Genes for each cancer type. Using NGS platforms (Genexus, Proton, PGM), we performed sequencing on 15,213 samples (lung 2,758, biliary/pancreatic 1,839, gynecological 921, liver 906, stomach 572, urological 532, breast 304, and others), generating a total of 5.6 trillion bases. Additionally, we have published 112 peer-reviewed articles.

In HCC, registration using REDCap in the A-HOC (APASL Hepatology/Oncology Consortium) has reached 506 cases. Analysis using in-house HCC panels (72 SMGs: 59,016 amino acids) has been completed for 198 cases 355 nodules (solitary: 130 patients with 130 nodules, synchronous: 33 patients with 81 nodules, metachronous: 16 patients with 35 nodules, syn+meta: 19 patients with 75 nodules). Whole transcriptome data has been obtained for 300 of these samples. There are 689 cases of DAA (Direct-Acting Antiviral) treatment, and tumor marker data (AFP, AFP-L3, DCP) have also been collected for these cases. Considering these data, we aim to validate the clinical applications of HCC analysis from a multifaceted perspective, including ① post-DAA occurrence of HCC, ② dynamics of oncogenic driver in serially occurring HCC nodules ③ the correlation between tumor markers and clinical/genomic data.

HCC Bridging Clinical and Basic Research

HCC8-3

NAFLD becomes a promoter of hepatocellular and cholangiocellular tumors in mice

Dr. Shin Maeda

Department of Gastroenterology, Yokohama City University Graduate School of Medicine

Japan

Background: It is epidemiologically clear that NAFLD, which is an increasing trend in recent years, accelerates hepatic inflammation, fibrosis and liver cancer development. In contrast, it is unclear whether NAFLD affects the cholangitis or development of another liver cancer, cholangiocellular carcinoma (CCC). The aim of this study is to investigate whether high fat diet promotes cholangitis and development of cholangiocellular tumors in mice.

Methods: We use liver-specific E-cadherin gene (Cdh1) knockout mice, Cdh1AI, which was generated by crossing Cdh1lox/lox mice with Albumin-Cre transgenic mice, with spontaneous inflammation in the portal areas and periductal onion skin-like fibrosis, which resembles primary sclerosing cholangitis (PSC). High fat diet or normal diet
was fed into the Cdh1∆Li mice for 7 months. In addition, Cdh1∆Li mice was crossed with LSL-KrasG12D (active Kras) mice and also fed with high fat diet.

**Results:** Cdh1∆Li mice that received a high-fat diet for 7 months increased in body weight similarly to control mice, and the degree of fat deposition in the liver was increased but not different from controls. On the other hand, the extent of cholangiitis and fibrosis, and numbers of bile ductules significantly progressed as compared to normal diet-administered mice. CD44-positive stem cell-like cells were significantly increased and ALT and ALP levels were also increased in mice with high fat diet. Liver specific LSL-KrasG12D/ Cdh1∆Li showed 2-10 macroscopically tumors with both hepatocellular and cholangiocellular components after 9 months of birth with normal diet, whereas high fat diet induced aggressive and numerous numbers of cholangiocellular tumors only after 3 months of high fat diet. Interestingly hepatocellular tumors were rarely found in these mice. In contrast, liver specific LSL-KrasG12D mice showed aggressive hepatocellular tumors by high fat diet.

**Conclusion:** NAFLD exacerabtes cholangiosis and becomes a strong promoter of not only hepatocellular tumors, but also cholangiocellular tumors. In addition, NAFLD may cause transdifferentiation from hepatocellular to cholangiocellular component.

---

**HCC Optimal Treatment Selection in Hepatocellular Carcinoma**

**HCC10-3**

A personalized approach for optimal treatment selection in HCC

Dr. Yi-Hsiang Huang

Taiwan Liver Cancer Association (TLCA), Institute of Clinical Medicine, College of Medicine, National Yang Ming Chiao Tung University, Healthcare and Services Center, Taipei Veterans General Hospital Taiwan

The treatment of HCC is diverse depending on tumor stage and affordability of patients. A personalized approach remains an unmet medical need. Recently, the application of AI had introduced into the field of HCC management. In our recent study, the risk of recurrence after surgical resection of HCC could be predicted by an evolutionary learning-derived clinical-radiomic GARSL models. This model can further discriminate the risk of recurrence either in high or low risk patients defined by Imbrave 050 study, indicating that the requirement of adjuvant immunotherapy after surgical resection of HCC can be determined by this AI model in our daily practice in near future. TACE unsuitability is an emerging issue for intermediate stage HCC. We have recently proposed a novel 7-11 criteria to divide BCLC B HCC into low-, intermediate-, and high tumor burden; and define the outcomes of TACE through different radiologic patterns, both can assist decision making before TACE. More studies support the concept that the dissimilarities in gut microbiome composition are associated with immune status and susceptibility to immunotherapy. Recently, we identify the associated of gut microbiota and metabolites with outcome of HCC undergoing immune checkpoint inhibitors treatment, supporting the potential role of gut microbiota in selection patients with HCC for immunotherapy.

---

**HCC Optimal Treatment Selection in Hepatocellular Carcinoma**

**HCC10-4**

Eliminating viral hepatitis C: Not to leave anyone behind from HCV cure

Dr. Masayuki Kurokasi

Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Japan

Hepatitis C remain important background for liver-related mortality. HCV cure improve liver function and may reduce mortality in decompensated cirrhosis if treated before the point of no return. Identification of high-risk cases for HCC after HCV cure is important to personalize surveillance. Situation of DAA treatment for HCV patients

---

HCC Bridging Clinical and Basic Research

**HCC8-4**

Development and Prospects of AI-aided Ultrasonography System -New Possibilities in Diagnosis of Liver Tumor-

Dr. Naoshi Nishida

Department of Gastroenterology and Hepatology Kindai University Faculty of Medicine Japan

The integration of artificial intelligence (AI) has aimed to enhance operational efficiency and mitigate human errors in the medical field. Image diagnosis support, a pivotal area for AI development, has witnessed the initiation of large-scale database construction and the deployment of numerous models in society. Notably, liver malignancies stand as the fifth leading cause of cancer-related deaths in Japan, underscoring the urgency of early diagnosis through ultrasonography for improved prognosis and reduced medical costs. However, the variable quality of ultrasound (US) diagnosis, dependent on the skill of examiners, presents a challenge. Hence, achieving AI-assisted standardization in the quality of US examination becomes crucial for effective disease management of malignant liver tumor.

Within the framework of the Japan Agency for Medical Research and Development (AMED)-ICT Infrastructure Development and Artificial Intelligence Implementation Project, we established a system for collecting US images and ancillary information, and developed an AI capable of detecting and discriminating liver masses in abdominal US B-mode examinations utilizing a comprehensive database.

A 2-step method employing YOLOv5 as a mass detector, convolutional neural network (CNN-VGG19) as a tumor discriminator, and DeepSORT to prevent duplicate detection was implemented. The detector demonstrated exceptional performance in pre-clinical tests, surpassing 90% in recall, precision, and F1-score through a 10-fold cross-validation. The discriminator, designed for the differential diagnosis of hepatocellular carcinoma, metastatic hepatocellular carcinoma, hemangioma, and cysts, achieved high accuracy, sensitivity, and specificity in a four-class classification and benign-malignant discrimination in cross-validation.

In an exploratory clinical trial under the AMED-Practical Research for Innovative Cancer Control Project, the performance of prototype AI model integrating detectors and discriminators in series was evaluated to determine the impact of AI-assisted improvement in human US diagnostic performance. The results revealed significant enhancements in liver mass detection indices (recall, precision, F1-score) and differentiation indices (accuracy, sensitivity, specificity, and Matthews correlation coefficient) particularly for non-expert, demonstrating the practical potential of the developed AI model to support human US diagnosis. Research projects are underway to refine and market the AI as Software as a Medical Device (SaMD). In addition, concurrently, efforts are also directed towards developing a model capable of differentiating intrahepatic cholangiocarcinoma.

The effectiveness of our AI in supporting US diagnostics has been recognized, especially among non-experts, where AI assistance has significantly improved all detection and differentiation indices. It can be described as a practical AI model that aids in the diagnosis of liver tumors in human US examinations.
complicated with active HCC may differ between countries due to lack of evidence. These points will be discussed.

HCC Clinical Trials in Hepatocellular Carcinoma: Challenges of Multinational Multicenter Trials

HCC11-1

Dr. Tawesak Tanwandeep
Department of Medicine Faculty of Medicine Siriraj Hospital, Mahidol University Thailand

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, presents significant therapeutic challenges, particularly in the context of multinational, multicenter clinical trials. There are many challenges and propose strategies for effective management. The complexity of HCC, influenced by underlying liver disease, comorbidities, and diverse etiologies, necessitates a multifaceted approach in clinical research. Multinational, multicenter trials for HCC are pivotal in advancing global understanding and treatment strategies. However, these trials face unique challenges, including variability in clinical practices, regulatory differences, and heterogeneous patient populations. There is disparity in HCC epidemiology, risk factors, and standard care protocols across different countries. Variations in disease presentation and progression, influenced by geographic and genetic factors, further complicate trial design and outcomes analysis. Moreover, there are problems on patient recruitment, adherence to protocols, data collection consistency, and the impact of cultural and linguistic barriers. We underscore the importance of harmonizing regulatory requirements and clinical guidelines to facilitate smoother conduct of these trials. Clinical studies delve into the methodological challenges of ensuring statistical power and validity in such diverse settings. Strategies to overcome these include adaptive trial designs, robust statistical methods to handle heterogeneity, and the use of centralized data monitoring systems.

In conclusion, the complexities inherent in multinational, multicenter clinical trials for HCC are challenging. It advocates for international collaboration, standardization of practices, and innovative trial designs to enhance the efficacy and generalizability of clinical research in the realm of hepatocellular carcinoma.

HCC Clinical Trials in Hepatocellular Carcinoma: Challenges of Multinational Multicenter Trials

HCC11-2

Utilizing Real-world Data for Systemic therapy in Hepatocellular Carcinoma.

Dr. Yoshinari Asaoka
Department of Medicine, Teikyo University School of Medicine Japan

In the current landscape, the escalating costs of drug development not only pose challenges to the development process but also contribute to the rising prices of approved medications. Considering this situation, there is growing anticipation for new drug development utilizing real-world data (RWD). Developing a single novel drug using RWD is not necessarily straightforward. However, it seems possible to develop better treatment sequence by evaluating the effects of treatment sequencing, combination therapies, and their impact on therapeutic outcomes and adverse events.

Systemic therapy for advanced hepatocellular carcinoma (HCC) has made remarkable progress. In Japan, regimens including atezolizumab plus bevacizumab, sorafenib, and lenvatinib were available for first line treatment, and regorafenib, ramucirumab, and cabozantinib for second line until the approval of tremelimumab plus durvalumab in 2022. In real-world clinical practice, treatment is being delivered in a variety of sequences. We launched the Hepatoma Registry of Integrating and Aggregating EHRs (electric health record): HERITAGE study to establish a registry of RWD in Japan. In this study, among the HCC cases registered in the nationwide follow-up survey of primary liver cancer conducted by Japan Liver Cancer Association, cases treated with systemic therapy between 2015 and 2022 were included. We will show the RWD of systemic therapy for HCC in Japan, including changing patient characteristics, treatment sequences, and treatment efficacy.

HCC Unraveling the Progression of Genomic Anomalies in Hepatocellular Carcinoma

HCC12-3

Integrated Omics Analysis for the Progression of Hepatocellular Carcinoma

Dr. Shintani Tanaka
Department of Molecular Oncology, Tokyo Medical and Dental University Japan

Recent advances in gene analysis technologies such as next-generation sequencing system have facilitated genome-wide investigation in various cancers including hepatocellular carcinoma (HCC). Comprehensive and un-supervised transcriptomic analysis has been conducted, revealing that HCC samples can be divided into several subtypes with distinct gene expression patterns. Additionally, genome and exome analysis through next-generation sequencing, as well as methylome, metabolome and proteome analysis using methylation array and mass spectrometry, have been conducted. During this period, the "two-class" model, categorizing HCC into proliferative and non-proliferative classes, was proposed. Publicly available data including mutation signatures and expression profiles of hundreds of HCC cases were generously provided by the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (IGC) Research Network, advancing the understanding of the relationship between the subtypes, clinicopathological factors, and tumor microenvironment including vascular endothelial cells and immune cells. On the other hand, since the approval of antiangiogenic agent sorafenib, treatment options have been lacking due to a series of clinical trial failures for nearly 10 years. However, other antiangiogenic inhibitors including regorafenib, lenvatinib, cabozantinib and antiangiogenic antibodies have emerged, followed by combination of immune checkpoint inhibitors, which can ameliorate progression-free and overall survival in HCC patients. Nevertheless, starting with the clinical report that HCC with CTNNB1 active mutations conferred potential resistance to immune checkpoint blockade, investigations on the link between the subtypes and drug response are ongoing by further use of single-cell gene analysis. In the same period as such development in genome-based medicine, it has coincided with the acceleration of remarkable innovations in genome-editing technology using the CRISPR/Cas9 system. The integration of comprehensive genome editing technologies, such as multiplex genome editing, which introduces multiple genomic aberrations simultaneously, with barcode sequencing technology has led to the development of in vivo screening methods, allowing preclinical models that mimic each subtype to be individually reproduced. Immunocompetent subtype models reflect the molecular characteristics of the subtype and the tumor immune microenvironment and can help evaluate the efficacy of single and combination therapies and understand the molecular and immunological mechanisms underlying vulnerability and resistance to them. Thus, consensus classifications and associated preclinical models are extremely promising for establishing predictive
biomarkers and escalating the clinical development of subtype-specific therapies.

HCC Unraveling the Progression of Genomic Anomalies in Hepatocellular Carcinoma
HCC12-4

Unraveling the Progression of Genomic Abnormalities in Hepatocellular Carcinoma

Dr. Pei-Jer Chen
Hepatitis Research Center National Taiwan University & Hospital Taiwan

The natural history of hepatocellular carcinoma presumably evolves from initial chronic hepatitis, subsequent cirrhosis and eventually HCC. In analogous to most human cancers, genomic mutations gradually appear and accumulate during the process, and finally lead to HCC. However, so far we still cannot chronicle the time-sequences of the incriminated mutations in details.

Most of known common genetic mutations of human HCC, irrespective of etiology, such as TERT promoter mutations, p53 or beta-catenin, or ARID gene mutations, occur in the late stage, from dysplastic nodules to early HCC. In the non-dysplastic cirrhotic nodules, WGS failed to identify recurrent genetic mutations. Therefore, we still do not know what mutations drive the clonal expansion in the cirrhosis stage.

One exception to this is noted in HBV-related HCC in which HBV DNA integration takes place in the very early stage of viral infection or hepatitis, probably 20-30 years before the development of HCC. DNA integration occurs in the very early stage of viral infection and eventually leads to HCC. In analogous to most human cancers, genomic mutations gradually appear and accumulate during the process, and finally lead to HCC. However, so far we still cannot chronicle the time-sequences of the incriminated mutations in details.

HCC Tumor Microenvironment in Hepatocellular Carcinoma
HCC13-3

Understanding microenvironment of hepatocellular carcinoma for biomarkers and therapeutic discovery

Dr. Valerie Chew
Translational Immunology Institute (TII), Sing Health Duke-NUS Medical School Taiwan

Despite recent success in cancer immunotherapies, the complex dynamics within tumor-immune microenvironment (TIME) remain elusive. With the multidimensional analysis pipeline, we have successfully identified and described key immunological factors in hepatocellular carcinoma (HCC) that contribute to disease progression and clinical response to therapy. Our team has identified peripheral immunological biomarkers associated to therapeutic response in HCC patients treated with radiotherapy and anti-PD-1 immunotherapy, shedding light on potential mechanism for treatment response and guiding the design of novel therapeutic strategies. More recently, we have explored the immune landscape of steatotic-related HCC to uncover potential mechanisms driving immunosuppression and to identify novel immunotherapeutic targets.

ACLF 1. Recent Changes of Incidence and Etiology of Acute Liver Failure in Asia Pacific Region
ACLF1-3

Recent changes of incidence and epidemiology of acute liver failure in Asia-Pacific region

Dr. Nobuaki Nakayama
Department of Gastroenterology & Hepatology, Saitama Medical University Japan

There is no international registry of acute liver failure (ALF) in the Asia-Pacific region. Instead, data on the outcomes of ALF are available by referring to published studies on ALF evaluated in nationwide surveys and at individual centers. In Asia, viral hepatitis has been the main cause of ALF; however recent publications suggest that the incidence of ALF due to drugs and herbs is increasing in most countries (Jindal et al., 2022). Pan Zhao et al. reported in 2013 that traditional Chinese medicine was a major cause of ALF in China. In India, HEV was the etiology of ALF in 419 (28.7%) cases, whereas non-A non-E hepatitis, HBV, and antituberculosis therapy were the etiologies in 527 (36.0%), 128 (8.8%), and 103 (7.0%) cases, respectively (Shalimar et al., 2017). A large study by the Indian DILI Network disclosed that antituberculosis drugs (62.9%) were the most common types of drugs that had caused ALF (Devabhakti et al., 2021). In South Korea, according to the prevalence of HAV infection, the number of HAV ALF cases requiring liver transplantation were increasing (Kim, 2010). In Australia, paracetamol was the most common etiology of ALF, accounting for 49.7% of cases (Hey et al., 2019).

The Intractable Hepato-Biliary Diseases Study Group of Japan conducted a nationwide survey on ALF and late-onset hepatic failure (LOHF) since 2011. Until 2011, they had performed such surveys on fulminant hepatitis and LOHF. A total of 2,368 patients with fulminant hepatitis and/or acute liver failure (acute and subacute) and 172 patients with LOHF were enrolled in nationwide surveys. In cases seen from 1998 to 2009, the viral etiology in the acute type of hepatitis accounted for 67.4%, whereas from 2010 to 2015, it decreased to 32.7% for overall cases of the acute type and 43.8% for hepatitis cases specifically. In the years 2016 to 2021, the respective percentages further declined to 26.9% and 39.1%, indicating a continued decrease in viral etiology rates. During that period, HBV was the etiology for 92 cases, representing 15.9% of the total cases of ALF (acute and subacute) and LOHF, and 20.2% of hepatitis cases. In cases of hepatitis, the ratios of autoimmune and drug-induced etiologies were 8.1% and 11.6%, respectively, for the period 1998 to 2009. However, in the years 2010 to 2015, these ratios increased to 14.4% and 11.0%, and further rose to 16.9% and 16.6% during the period from 2016 to 2021.

ACLF 1. Recent Changes of Incidence and Etiology of Acute Liver Failure in Asia Pacific Region
ACLF1-4

Japanese style artificial liver support system

Dr. Kazuaki Inoue
Department of gastroenterology, International University health and welfare Narita Hospital Japan

Japan is a country where blood purification therapy is most advanced than any other countries in the world. The reason for this is the development of Japanese industrial technology and the harsh environment surrounding transplant medicine. In Japan, blood purification therapy that can keep a patient awake and in a stable condition is essential. In the Japanese medical environment, a requirement for blood purification therapy is the ability to reliably awaken patients and maintain...
them in a stable state. The method developed for this purpose is blood purification therapy that combines plasma exchange and hemodiafiltration. The characteristics of hemodiafiltration are that blood is purified using a large amount of replacement fluid and that blood purification takes a long time. Even though method of hemodiafiltration is the same, the conditions are very different from those used for renal replacement therapy. Since using this treatment, most patients have recovered from coma, and it is now possible to safely maintain them until their own livers regenerate or a suitable donor is found. Today, the number of elderly patients with comorbidities is increasing, and it is difficult to perform dialysis under strict dialysis conditions for such patients. Due to these circumstances, there are a certain number of patients with acute liver failure who do not undergo blood purification in recent years. In the future, it is necessary to improve vascular access and develop blood purification therapy that is easy to do.

ACLF 2. Treatments and Prognosis of ACLF in Asia Pacific Region

ACLF 2-2

Management of vascular disorders in patients with ACLF

Dr. Akash Shukla
Gastroenterology, Seth GS Medical College & KEM Hospital, Hepatology, Sir HN Reliance Foundation Hospital, Mumbai India

Vascular liver diseases like portal vein thrombosis (PVT) or Budd Chiari syndrome (BCS) may present with acute on chronic liver failure (ACLF). The possible associations of PVT with ACLF (PVT-ACLF) have been recently described and the principles of management of these patients proposed. The treatment options for PVT in this setting would include observation, anticoagulation and/or radiological interventions like thrombolysis and thrombectomy. The choice of therapy would depend upon the extent of thrombosis and the clinical consequences of PVT. The other vascular disease is BCS, where association with ACLF (BCS-ACLF) and its management is described. While we know that acute on chronic BCS is associated with poor outcomes, there is recent data on clinical features and management of BCS-ACLF. In patients with ACLF where the acute event is vascular thrombosis like PVT or hepatic vein thrombosis (HVT), there is a potential for reversibility of liver failure, especially in the 'golden window', similar to other ACLF, and all attempts need to be made towards urgent revascularization of these vein(s), while in patients with pre-existing BCS or cirrhosis with PVT who present with ACLF, liver transplant may be the best option.

ACLF 3. Liver Regeneration up to date

ACLF 3-1

Revolutionising Liver Health: The Science and Potential of Liver Regeneration

Dr. Kuo-Chao Yew
Gastroenterology and Hepatology Department Tan Tock Seng Hospital Singapore

The liver’s extraordinary regenerative capability, coordinated by the intricate "Hepatostat" system, maintaining a consistent liver-to-body-weight ratio, sets it apart from other organs. Prominently demonstrated in partial hepatectomy, this regenerative capability offers profound insights into harnessing natural regenerative potential and serves as a tissue engineering model. However, chronic liver diseases disrupt this equilibrium, causing hepatocyte depletion, hepatic stellate cell activation, and collagen buildup, while genotoxic environments can trigger liver oncogenesis through cellular diploidy induction.

In contemporary times, significant strides have been taken in comprehending cellular kinetics, histological transformations, and signalling pathways pivotal in liver regeneration. Moreover, understanding zon-specific initiation unravels the precise orchestration of diverse soluble factors governing liver zonation. The identification of progenitor cells opens doors to innovative therapies involving cellular, drug, and gene manipulation. Excitingly, the past decade has witnessed breakthroughs such as bioengineered livers for disease modelling, 3D printing in liver transplantation, and integration of artificial intelligence, signifying newfound enthusiasm in the field. This lecture delves into the potential of liver regeneration, providing a glimpse into the promising future of Hepatology.

ACLF 3. Liver Regeneration up to date

ACLF 3-3

Development of Regenerative Therapy for Liver Cirrhosis - Mesenchymal stem cells, HMGB1 peptide, extracellular vesicles-

Dr. Shuji Terai
Division of Gastroenterology & Hepatology, Graduate School of Medical and Dental Sciences, Niigata University Japan

We have been developing regenerative therapies for liver cirrhosis. The liver is a regenerative organ, but fibrosis reduces its regenerative capacity, and a clinical study in 2003 and a subsequent multicenter clinical study (Autologous bone marrow cell infusion therapy) showed that improvement of fibrosis induces regeneration in patients with non-compensated liver cirrhosis. Subsequently, since 2015, conducted a clinical trial for cirrhosis using allogeneic mesenchymal stem cells. From a series of basic studies, the mechanism was clarified that mesenchymal stem cells administered from peripheral blood vessels populated mainly to the lungs, where they emit extracellular vesicles, making macrophages anti-inflammatory, improving fibrosis, and inducing regeneration. Furthermore, extracellular vesicles obtained by induction of mesenchymal stem cells with IFNγ were found to be useful for improving fibrosis and inducing regeneration. On the other hand, the optimization of the liver fibrosis evaluation method in clinical trials for liver cirrhosis has also been clarified by conducting clinical trials of mesenchymal stem cells and HMGB1 peptide as a corporate clinical trial and an investigator-initiated clinical trial. In the future, we are preparing to establish an international standard for how extracellular vesicles can be used as a treatment that maintains clear quality in terms of Mode of Action. In this presentation, we will present the future perspective of a new regenerative therapy for liver cirrhosis.
for the treatment of end-stage liver disease. A shortage of suitable organs, high costs and surgical complications limit the application of liver transplantation. Nowadays, stem cell therapy gained more and more attention due to its attractive efficacy in treating liver disease especially in cirrhosis during the clinical trials. Due to the regenerative properties of the liver, various kinds of cell therapies using hepatocytes, hematopoietic stem cells, bone marrow mononuclear cells, and mesenchymal stem cells (MSCs) are being investigated as alternative treatments to liver transplantation.

Among them, Mesenchymal stem cell therapy has been considered as a promising alternative approach for end-stage liver disease, because they show potential to regenerate injured tissues or organs, such as homing, transdifferentiation, immunosuppression, and cellular protective capacity.

Some clinical trials have confirmed the effectiveness of MSC therapy for liver disease, but currently, there is no approved MSC therapy for the treatment of liver disease, because the types of liver disease that are most suitable for MSC application should be determined, and the preparation and engraftment of MSCs should be standardized. These may be bottlenecks that limit the use of MSCs. More robust preclinical and clinical studies will be needed for the key factors such as cytokines, genetic modification, and tissue engineering treatments for liver diseases. In the future, each method has its advantages and challenges, and researchers continue to explore the most effective and safe approaches for liver regeneration using MSCs.

PH Elastography: Current Strategy for Practical Care

**PH1-1**

**Role of Elastography in Hepatitis Elimination**

**Dr. Grace Lai-Hung Wong**

Medical Data Analytics Centre (MDAC), Center for Liver Health, Faculty of Medicine, Department of Medicine and Therapeutics The Chinese University of Hong Kong Hong Kong SAR, China

Elastography is one of the most popular noninvasive assessments of liver fibrosis in patients with chronic viral hepatitis. Specifically, Vibration controlled transient elastography (VCTE) is now an integral part of the clinical care pathway of chronic viral hepatitis in order to determine the prognosis, the need of treatment, as well as monitor disease progression and response to treatment. As alanine aminotransferase (ALT) is one of the major confounding factors of liver stiffness in chronic hepatitis B, an ALT-based algorithm has been developed and higher liver stiffness measurements (LSM) cutoff values for different stages of liver fibrosis should be used in patients with elevated ALT levels up to 5 times of the upper limit of normal. Otherwise falsely-high LSM results up to cirrhotic range may occur during ALT flare. VCTE is also useful in predicting patient prognosis such as development of hepatocellular carcinoma (HCC), portal hypertension, post-operative complications in HCC patients, and also survival. Failed acquisition of VCTE may happen up to 25% in obese patients. Furthermore, obese patients may have higher LSM results even in the same stage of liver fibrosis. The XL probe, a larger probe with lower ultrasound frequency and deeper penetration, increases the success rate of VCTE in obese patients. The median LSM value with XL probe was found to be lower than that by the conventional M probe, hence cutoff values approximately 1.2 to 1.3 kPa lower than those of M probe should be adopted. Recent studies revealed a novel ultrasonic controlled attenuation parameter (CAP) of the machine is a useful parameter to detect even low-grade steatosis noninvasively. CAP may also be used to quantify liver steatosis by applying different cutoff values. As both LSM and CAP results are instantly available at same measurement, this makes VCTE a very convenient tool to assess any patients who are at risk or confirmed to suffer from chronic liver diseases.

**PH1-3**

Clinical utility of the liver and spleen stiffness measurement in the patients with portal hypertension

**Dr. Masashi Hirooka**

Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine Japan

Portal hypertension is a critical condition often associated with complications such as varices and ascites, making measurement of the hepatic venous pressure gradient (HVPG) a well-established surrogate marker. HVPG measurement allows prediction of complications associated with cirrhosis, including varices and ascites. According to the Baveno VII criteria, liver stiffness measurement (LSM) plays a crucial role in the diagnosis of clinically significant portal hypertension (CSPH). LSM values below 10 kPa effectively rule out compensated advanced chronic liver disease (cACLD), while LSM values between 15 kPa and a platelet count of 150,000 or greater may rule out CSPH. LSM values above 25 kPa suggest the presence of CSPH. However, the challenge lies in the "gray zone" cases that cannot be definitively categorized using these criteria.

**Unraveling the Pathophysiology of ICI-Induced Immune-Mediated Hepatotoxicity through a Comparison with Autoimmune Hepatitis**

**Dr. Hayato Nakagawa**

Department of Gastroenterology and Hepatology, Mie University Japan

Autoimmune hepatitis (AIH), although a well-known disease, still lacks sufficient understanding of its pathogenesis. Additionally, there is a need for the development of biomarkers, especially for cases resistant to steroids or experiencing relapse. On the other hand, advancements in cancer immunotherapy have brought forth a new concern—immune-mediated hepatotoxicity induced by immune checkpoint inhibitors (ICI), known as ICI-induced immune-mediated hepatotoxicity (IMH). Given its recent emergence, the pathophysiology of IMH remains unclear, and established treatment methods are yet to be defined. While steroids are the primary choice for IMH treatment, resistance cases are frequent compared to AIH. In such instances, empirical recommendations include agents like mycophenolate mofetil, but definitive evidence is lacking.

The anticipation of the growing importance of immunotherapy in the future underscores the urgency for understanding the pathophysiology of these conditions. As part of our efforts in what we term "next-generation precision medicine," we have conducted multi-omics analyses using liver tissues from AIH patients for pathophysiological insights and biomarker development. Currently, we are integrating multi-omics data, including liver biopsy samples from IMH, which shares commonalities with immune-related liver disorders. Through this comprehensive analysis, incorporating the transcriptome data from AIH alongside IMH samples, we aim to elucidate the pathophysiology of both conditions and identify biomarkers. In this session, I will present a portion of this data.
To overcome this limitation and reduce the gray area, markers that correlate better with HVPG than LSM are needed. The spleen, which is emerging as a potential marker, shows a promising role in the assessment of HVPG. Spleen stiffness measurement (SSM) has been reported to correlate better with HVPG than liver stiffness and various fibrosis markers, with a high predictive ability for high-risk esophageal varices.

Our research group, the Spleen Stiffness-IPD-MA Study Group, conducted a systematic review and meta-analysis of individual patient data and reported the favorable diagnostic performance of the Baveno VII SSM criteria. Despite the promising results, accurate measurement of SSM poses challenges compared to LSM. Proper measurement techniques, including the use of new devices and accurate assessment of low controlled attenuation parameter (CAP) values, can improve the reliability of SSM measurements.

In conclusion, our findings suggest the potential of SSM as a valuable marker in the prediction of portal hypertension complications when added to LSM.

PH Management of Portal Hypertension: Standard and Beyond
*PH2-1*

**Innovation Management in Portal Hypertension: Standard and Beyond**

**Dr. Cosmas Rinaldi Adithya Lesmana**

Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Indonesia

Portal hypertension (PH) is still a challenging condition in daily practice as it carries a lot of complications, such as the presence of vascular complication (esophageal varices/EV, gastric varices/GV, gastric antral vascular ectasia/GAVE, gastropathy, colopathy, rectal varices), ascites, hepatic encephalopathy, hepatorenal syndrome, and hepatopulmonary syndrome. The diagnosis of PH is confirmed when the portal pressure reaches 5 mmHg and above. Clinically significant portal hypertension (CSPH) is the most important condition in liver cirrhosis (LC) patients, as it can predict the possible complications arise, and to decide further management including porto-systemic shunting procedure and liver transplantation. However, the gold standard for PH is the indirect measurement, hepatic vein pressure gradient (HVPG) measurement. Even though this procedure is considered as a safe and minimally invasive, but possible adverse events, such as bleeding, pain, infection, and perforation could still happen. It is not always accurate in the setting of non-cirrhotic portal hypertension condition. This procedure is also cannot be performed concomitantly with esophagogastroduodenoscopy (EGD) procedure.

Recently, endoscopic ultrasound (EUS) has been developed for managing liver disease condition. There have been innovations in measuring portal pressure using a novel manometer as well as standard manometer. EUS can be used for portal pressure gradient measurement, where it is a direct measurement, and it can be done with other innovation procedures, such as EUS-guided liver biopsy, EUS-guided vascular injection, and EUS-guided radiofrequency ablation (RFA) for liver tumor. It would need a special training and further validation before it can be recommended as the first-line approach in the future.

**PH Cross Talk with Multiple Organs in Cirrhosis
*PH3-1***

**Impact of 2022 ESC/ERS diagnostic criteria for pulmonary hypertension in cirrhotic patients with portal hypertension in Japan**

**Dr. Masanori Atsunori**

Division of Gastroenterology and Hepatology, Nippon Medical School Hospital Japan

Portopulmonary hypertension (PoPH) is defined as PAH associated with portal hypertension. So far, conventional PoPH was defined as a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, pulmonary vascular resistance (PVR) > 3 Wood units (WU), and pulmonary arterial wedge pressure (PAWP) ≤ 15 mmHg according the previous diagnostic criteria, whereas in 2022, the European guideline for pulmonary hypertension revised the hemodynamic definition of pulmonary hypertension in pre-capillary PH by lowering the mPAP to > 20 mmHg and the PVR to > 2 WU. From now on, prevalence of patients with PoPH according to the new guideline may change among cirrhotic patients with portal hypertension. At Nippon Medical School, 186 patients with liver cirrhosis and portal hypertension were subjected and underwent right heart catheterization in this analysis. The median mPAP, PVR and PAWP were 12.9 mmHg (range, 6.6–40.8), 0.8 WU (range, 0.1–4.5) and 7.5 mmHg (range, 2.2–15.4) respectively. For both diagnostic criteria, many of the 186 patients were below the cut-off values for both mPAP and PVR, respectively (conventional, n = 184; new, n = 182). Two (1.1%) patients had conventional PoPH. In addition, two patients that were not diagnosed as PoPH by the conventional diagnostic criteria, many of the 186 patients were below the cut-off values for both mPAP and PVR, respectively (conventional, n = 184; new, n = 182). Two (1.1%) patients had conventional PoPH. In addition, two patients that were not diagnosed as PoPH by the conventional diagnostic criteria were included in the PoPH range by the new diagnostic criteria. For each diagnostic criteria, there were no patients that met only one criterion of mPAP and PVR, and were divided into two groups. mPAP and PVR were significantly but weakly correlated (p = 7.44 × 10-5, r = 0.286). With the new diagnostic criteria of PoPH, there were patients that were not diagnosed with PoPH by conventional diagnostic criteria, resulting in an increase in the number of patients diagnosed with PoPH from 1.1% to 2.2% in this cohort. In particular, it is possible that the change in the cut-off value of PVR was particularly important, since patients with a PVR of 2 to 3 WU were newly diagnosed. As new diagnostic criteria are likely to be adopted in Japan in the future, the number of patients diagnosed with PoPH is expected to increase.

**PH Noncirrhotic Portal Hypertension: Current Status and Problem
*PH4-1***

**Non cirrhotic portal hypertension: Current status and problem**
Non-cirrhotic portal hypertension (NCPH) refers to a heterogeneous group of liver disorders characterized by portal hypertension, splenomegaly, hypersplenism, and cytopenia in absence of liver cirrhosis. It has been referred to by different names over time such as non-cirrhotic portal fibrosis (Indian subcontinent), hepatopetal sclerosis (West), and idiopathic portal hypertension (Japan). NCPH is diagnosed after excluding other causes of portal vein or hepatic venous outflow tract obstruction. The disease progresses through different phases with symptoms ranging from splenomegaly and anemia to complications of portal hypertension such as gastrointestinal bleeding, ascites.

Later, the term idiopathic non-cirrhotic portal hypertension (INCPH) was proposed by a consensus of experts who introduced a common nomenclature and diagnostic criteria: essentially, the presence of an unexplained portal hypertension and the absence of cirrhosis in liver histology.

Recently, in order to overcome those difficulties and to reach a uniformity in the nomenclature, the term Porto-Sinusoidal Vascular Disease (PSVD) has been proposed by the European Association for the Vascular Liver Disease. Now it is not limited to the exclusion criteria but provides positive diagnostic criteria. The new diagnostic criteria define the diagnosis of PSVD in presence of one of the three following features:

1. At least one specific sign of portal hypertension (gastroesophageal varices, or ectopic varices, porto-systemic collaterals, bleeding due to portal hypertension) in the absence of cirrhosis at an liver biopsy.
2. At least one specific histological sign of PSVD (obliterative portal venopathy, nodular regenerative hyperplasia, incomplete septal fibrosis or cirrhosis) and absence of cirrhosis at liver biopsy. As per this criteria there may be absence of signs of portal hypertension;
3. At least one non-specific sign of portal hypertension (ascites, low platelets, splenomegaly) at an adequate liver biopsy and in addition to at least one non-specific histological sign of PSVD (portal tract abnormalities: multiplication, dilation of arterioles, periportal vascular channels, and aberrant vessels; architectural disturbance: irregular distribution of the portal tracts and central veins; non-zonal sinusoidal dilatation; mild perisinusoidal fibrosis) and to the absence of cirrhosis.

The exact cause of INCPH or PSVD remains a mystery, prompting ongoing research. There are no specific tests. Instead, accurate diagnosis relies on a high-quality liver biopsy, and the skilled interpretation of a pathologist. Notably, no treatments specifically aimed at controlling the disease progression have been explored. Currently, the treatment relies on the prevention of complications related to portal hypertension, following current guidelines of cirrhotic portal hypertension.

Etiology and Pathophysiology
NCPH can arise from a variety of causes, including vascular disorders like portal vein thrombosis, splenic vein thrombosis, or Budd-Chiari syndrome; structural abnormalities like schistosomiasis; and systemic diseases such as sarcoidosis and autoimmune hepatitis. Unlike cirrhotic portal hypertension, where the primary issue is increased resistance to blood flow within the liver, in NCPH, the resistance may occur pre-hepatically (before the liver), intrahepatically (within the liver but not due to cirrhosis), or post-hepatically (after the liver).

The pathophysiology of NCPH involves the disruption of normal portal venous flow due to these varied causes, leading to increased portal pressure. This increase in pressure can lead to the development of collateral vessels and splenomegaly, among other complications.

Clinical Manifestations
Patients with NCPH may present with a range of symptoms. The most common manifestation is gastrointestinal bleeding, typically from esophageal or gastric varices, similar to what is seen in cirrhotic patients. However, patients with NCPH often have preserved liver function. Other presentations can include splenomegaly, ascites (less common than in cirrhosis), and features of hypersplenism like pancytopenia.

Diagnosis
Diagnosis of NCPH requires a combination of clinical, laboratory, and imaging findings. Liver function tests are typically normal or show only mild abnormalities. Imaging studies, such as Doppler ultrasound, CT scan, or MRI, are critical for identifying the site and cause of the increased portal pressure. In some cases, a liver biopsy may be necessary to exclude cirrhosis and to identify intrahepatic causes of NCPH.

Management
Management of NCPH focuses on treating the underlying cause, if identified, and managing complications. Primary prevention of variceal bleeding is essential and can be achieved through pharmacotherapy (e.g., beta-blockers) or endoscopic interventions. In cases of variceal bleeding, endoscopic therapy is the mainstay of treatment. Additionally, management of hypersplenism and its hematologic complications may be necessary.

In cases where medical management is inadequate, surgical options such as shunt surgeries or even liver transplantation may be considered, depending on the underlying pathology and patient’s overall condition.

Conclusion
Non-cirrhotic portal hypertension is a complex condition with diverse etiologies and manifestations. Its management requires a thorough understanding of its pathophysiology and a multidisciplinary approach. Early recognition and appropriate intervention are key to improving outcomes in patients with NCPH. Further research is needed to better understand this condition and to develop more effective management strategies.
First, we performed a meta-analysis of randomized controlled trials (RCTs) to examine the effects of exercise on physical function and serious events in patients with liver cirrhosis. A literature search was conducted in 2022. Eleven RCTs were selected for the meta-analysis (exercise group, n=232; control group, n=193). A meta-analysis was performed using a random-effects model. In the eleven RCTs, a meta-analysis demonstrated the 6-minute walking distance significantly improved in the exercise group compared with the control group. Moreover, in a stratification analysis based on a combination of aerobic and resistance exercise, the incidence of serious events was 6.25% and 24.7% in the combination exercise and control groups, respectively. A meta-analysis demonstrated a significant reduction in the incidence of serious events in the combination exercise group compared with the control group.

Next, we investigate the effects of exercise on the prognosis of patients with HCC. We performed a prospective observational study, which analyzed 152 patients with HCC who underwent transcatheter arterial chemoembolization (TACE). Patients were classified into the exercise (n=85) and control (n=67) groups. Independent factors associated with survival were evaluated by Cox regression analysis. There were no exercise-related severe adverse events throughout the study periods. Along with Child-Pugh class A, “exercise” was identified as an independent factor associated with survival in Cox regression analysis. The survival rate was significantly higher in the exercise group than in the control group.

In conclusion, we demonstrated that exercise improved physical function in patients with liver cirrhosis. We further demonstrated that resistance exercise in combination with aerobic exercise reduces serious events in patients with liver cirrhosis by a meta-analysis of RCTs. Moreover, in patients with HCC, exercise had beneficial effects on the prognosis with no worsening of liver function. These findings suggest that exercise therapy should be considered a fundamental therapy for patients with both liver cirrhosis and HCC.

PH Liver fibrosis: from Bench to Bedside

PH6-1

Liver Fibrosis & Portal Hypertension: Molecular Mechanisms and Therapeutic Opportunities

Dr. Jordi Gracia-Sancho
Hepatology, IDIBAPS - Hospital Clinic de Barcelona - CIBEREHD Spain

Portal hypertension represents one of the major clinical consequences of chronic liver disease, having a deep impact in patients’ prognosis and survival. Its pathophysiology defines a pathological increase in the intrahepatic vascular resistance as the primary factor in its development, being subsequently aggravated by a paradoxical increase in portal blood inflow. Elevation in vascular resistance derives from de-regulations in hepatic cells function, which leads to the development of intrahepatic vascular dysfunction and fibrosis. Additionally, now we know that hepatic mechanobiological cues actively contribute to aggravate and perpetuate portal hypertension. Hepatic microvascular dysfunction occurs early in the course of chronic liver disease as a consequence of inflammation and oxidative stress and determines loss of the normal phenotype of liver sinusoidal endothelial cells (LSEC) that become proliferative, pro-thrombotic, pro-inflammatory and vasoconstrictor. The cross-talk between LSEC and hepatic stellate cells (HSC) induces activation of the latter, which in turn proliferate, migrate and increase collagen deposition around the sinusoids, contributing to fibrogenesis, architectural disruption and angiogenesis, which further increase the hepatic vascular resistance and worsen liver failure by interfering with the blood perfusion of the liver parenchyma. Moreover, recent data suggest that the phenotype of liver cells could be further impaired due to the altered mechanical properties of the cirrhotic liver itself, therefore creating a deleterious vicious cycle that would further worsen portal hypertension in advanced stages of the disease. This lecture will critically summarize the current knowledge in portal hypertension pathophysiology, focusing on the intrahepatic mechanisms leading to fibrosis and vascular dysfunction development.
Dr. Hong Soo Kim
Soon Chun Hyang University Hospital, Internal medicine Korea
Metabolic dysfunction–associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. MAFLD includes a wide spectrum of liver injury including simple steatosis and non-alcoholic steatohepatitis (NASH) that may lead to serious complications such as liver cirrhosis and liver cancer.

The identification of Nonalcoholic steatohepatitis (NASH) or NAFLD is clinically important because NASH indicates an increased risk for fibrosis progression and the need for aggressive treatment and closer follow-up. Population based study suggests that NAFLD is becoming an important cause of HCC, and these rates are increasing by approximately 10% per year. So we needs follow up guideline of patients with NAFLD but there is no accepted consensus on the optimal strategy for monitoring patients with NAFLD and their response to treatment.

According to The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease, patients with NAFLD may need a FibroScan yearly or once every three years. The frequency is dependent on your previous FibroScan results. It is important to distinguish mild (F1-F2) from advanced or severe (F3-F4) fibrosis, as patients with severe fibrosis have a greater risk of complications and need to undergo screening for hepatocellular carcinoma with NAFLD.

PH Liver fibrosis: from Bench to Bedside

**PH7-2**

Endoscopic Treatment for Esophageal and Gastric Varices in Japan

Dr. Takuto Hikichi
Department of Endoscopy, Fukushima Medical University Hospital Japan

Esophageal varices (EVs) and gastric varices (GVs) are treated with drug therapy, interventional radiology, and surgical operation, but endoscopic treatment is the mainstay of treatment for patients with bleeding or high risk of bleeding.

Endoscopic treatment for EVs is widespread worldwide, and endoscopic variceal ligation (EVL) is widely used not only for bleeding cases but also for prophylactic cases. In Japan, endoscopic injection sclerotherapy (EIS) using intravariceal injection with ethanolamine oleate (EO) as a sclerosant agent has long been used for prevention of EV rupture. EIS is a treatment to embolize the inflow from portal vein that forms EVs, and theoretically has a low recurrence rate. However, due to the complexity and difficulty of the procedure, an increasing number of centers in Japan are using EVL as the main EV treatment, and EIS is now limited to high-volume centers. To reduce the EV recurrence rate by intravariceal EIS alone, extravariceal EIS with polidocanol has been used after intravariceal EIS. In addition, argon plasma coagulation (APC) after intravariceal EIS or extravariceal EIS is also used in Japan. At our institution, we are trying ablation using high-frequency hemostats as an alternative to APC. As a device for endoscopic treatment of EVs, EIS with ligation, in which the variceal puncture site is ligated during EIS, and EIS with ligation of the perforating vein that causes an extraesophageal shunt have also been performed. Recently, Furuichi et al. reported a technique for reliable intravariceal EIS using red dichromatic imaging, a kind of image enhanced endoscopy (IEE), to estimate the wall thickness and depth of EVs. Moreover, we have been using a technique to improve the success rate of variceal puncture by injecting gel into the esophageal lumen and using texture and color enhancement imaging, which is a kind of IEE.

The Sarin classification is a well-known endoscopic classification of gastric varices (GVs), based on the continuity with EVs and the location of GVs, and is divided into four categories: GOV (gastroesophageal varices)-1, GOV-2, IGV (isolated gastric varices)-1, IGV-2. Among them, GOV-1 is a varix flowing from the gastric cardia to the esophagus, and is defined as EVs in Japan. On the other hand, the Japan Society for Portal Hypertension classifieds GVs into Lg-c, Lg-cf, Lg-f, Lg-a, and Lg-b. Lg-c is a varix localized at the gastric cardia, Lg-cf is a varix extending from the cardia to the fornix, and Lg-f is a varix localized at the gastric fornix. Lg-c, Lg-cf, and Lg-f correspond to IGV-1, and Lg-a and Lg-b correspond to IGV-2. In the following, EVs are defined as those corresponding to IGV-1. Endoscopic treatment for GVs is mainly endoscopic cyanoacrylate injection with N-butyl-2-cyanoacrylate (NBCA). In cases of GV hemorrhage, endoscopic cyanoacrylate injection with NBCA is preferred over EVL because of the rapid blood flow. In addition, we have been using endoscopic cyanoacrylate injection combined with intravariceal EIS with EOI for prevention of GV rupture. The GV is occluded by NBCA and the inflow is embolized by EO. Furthermore, Irisawa et al. reported the combination of endoscopic-guided coil deployment and intravariceal EIS for prevention of GV rupture.

I will give a presentation on the current status of endoscopic treatment of EVs and GVs in Japan.

**PH Liver fibrosis: from Bench to Bedside**

**PH7-4**

Portal Hypertension in unusual condition

Dr. Sudhamshu K C
Department of Hepatology, National Academy of Medical Sciences Nepal

Portal hypertension (PH) is defined as increased blood pressure in the portal venous system above 5 mg. Portal hypertension is classified as prehepatic, intrahepatic, and posthepatic. While cirrhosis dominates as the leading cause of PH in routine practice, NCPF and even rarer conditions can also appear in clinical settings. This presentation delves into PH seen in these less common scenarios. Following are the conditions where we can encounter PH.

1. Arteriovenous malformations (AVMs)
2. Nodular regenerative hyperplasia (NRH)
3. Pseudocirrhosis
4. Hepatic fibrosis
5. Hepatic amyloidosis

First described in 1886 by Weigert, AVMs are generally uncommon, certain types can indeed contribute to PH. AVMs can be intraparenchymal or extraparenchymal. Extraparenchymal can be of two main types namely mesenteric AVMs and splenic AVMs. Hepatic arterioportal fistulas (HAPFs) are intraparenchymal causes of AVMs. It is usually categorized into three classes, as follows: Type 1: small peripheral intrahepatic; Type 2: large central HAPF; and Type 3: diffuse congenital intrahepatic.

NRH is a rare liver disease characterized by the abnormal growth of small, regenerative nodules throughout the liver. Unlike cirrhosis, which features scarring and fibrosis, NRH lacks fibrous septa between the nodules, making it a form of non-cirrhotic portal hypertension. NRH can be seen in autoimmune disorders like systemic lupus erythematosus, vascular diseases such as cystic fibrosis, viral infections and medications like azathioprine or methotrexate.

Pseudocirrhosis is a radiologic term to describe the development of diffuse hepatic nodularity caused by chemotherapy for hepatic metastasis, especially from breast cancer, pancreatic neuroendocrine, colorectal cancer. Portal hypertension can be observed in about 80% of patients with pseudocirrhosis. It is characterized by morphologic changes mimicking liver cirrhosis following chronic liver diseases. Increase in
portal flow resistance at any site within the portal venous system due to mechanical obstruction is the plausible mechanism of PH. This pathological finding often co-occurs with a spectrum of inherited renal disorders. Lastly PH is a rare complication of hepatic amyloidosis and seems to be related to reduced sinusoidal lumen and increased resistance to blood flow due to massive perisinusoidal amyloid deposits.

In preparation for surgical treatment, it is necessary to determine the side to be resected and the surgical procedure to be used. It is important to determine where to resect the bile duct, artery, and portal vein respectively. It is also necessary to properly set the predicted liver dissection plane. MDCT before biliary drainage is permissible for these decisions. This process determines the postoperative course. Identifying the number of bile ducts to be transected is also useful information during anastomosis. After this decision is made, biliary drainage are often required. In cases requiring massive hepatectomy, preoperative portal vein embolization (PE) is attempted to increase the residual liver volume. PE is expected to increase the volume of the remaining liver by about 20% (ex. L234, 280 ml → 340 ml). The residual liver volume and the results of the ICG study are combined to avoid postoperative liver failure.

Postoperatively, Ultrasonographic confirmation of hepatic arterial, portal, and venous blood flow is useful. Obstruction of hepatic arteries and impaired hepatic venous return cause rapid liver failure. Increased ascites and coagulation disorder are signs of portal vein thrombosis or infection. Continued surveillance cultures from drain effluent and bile should be performed. When bile leaks occur during hepatic resection with choledocho-jejunostomy, infection and abscesses occur very efficiently. Recovery is difficult if postoperative liver failure or DIC develops. Adequate drainage position is important to maintain leakage of choledocho-jejunostomy and bile leakage from the plane of liver dissection. Endoscopic anastomotic dilation and drainage may be beneficial.

The most important aspect of radical surgery of PHC is the process leading up to resection. Compared to hepatic resection without biliary reconstruction, careful postoperative management is required due to bile leakage and liver positional instability. Prompt judgment and treatment of any abnormalities is necessary until 2-3 weeks postoperatively, when the liver regenerates and liver function is restored.

Biliary 1. Current Surgical Management of Hilar Cholangiocarcinoma (Including Transplantation)

**Biliary 1-1**

**Aggressive surgery for advanced perihilar cholangiocarcinoma under careful preoperative preparation ~ a Japanese single-center experience in the past 15 years ~**

Dr. Yu Takahashi
Division of Hepatobiliary and Pancreatic Surgery, Cancer Institute Hospital, Japanese Foundation for Cancer Research Japan

Perihilar cholangiocarcinoma (PHCC) is a devastating disease, and the required operative resection is technically demanding and remains to be the most difficult challenge for HPB surgeons. Major hepatectomy and extrahepatic bile duct resection has been accepted as the standard procedure. A recent systematic review showed that the mortality rate was approximately 10% and liver failure was the most common reported cause of death. In some Japanese high-volume centers, trisectiomecy of the liver, combined pancreatoduodenectomy or combined vascular resection have been aggressively performed to achieve curative resection. Various preoperative preparations have been made to reduce postoperative mortality. We report here on the preoperative management and surgical outcomes of PHCC over the past 15 years, focusing on the following points:

- Preoperative Management: Biliary drainage (inside-stent) and portal vein embolization
- Hepatopancreatoduodenectomy
- Combined vascular resection
- Left trisectiomecy of the liver

Biliary 2. Liver transplantation of biliary diseases

**Biliary 2-3**

**Endoscopic Management of Biliary Complications after Living donor Liver Transplantation**

Dr. Naminatsu Takahara
Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Japan

Living donor liver transplantation (LDLT) has emerged as a crucial option for patients with end-stage liver disease. The key advantage of LDLT lies in its ability to ensure timely transplantation, resulting in a significant reduction in waiting list mortality, especially in the situation where the number of deceased donors is limited. Notable advances in surgical techniques and perioperative management have contributed to improved outcomes in LDLT, however, biliary complications remain a major unresolved issue to be addressed.

Currently, endoscopic management is a mainstay for post-LDLT biliary complications. Specifically, in cases complicated by bile leakage, endoscopic nasobiliary drainage is the preferred intervention. As for cases with anastomotic stricture, the standard strategy is balloon dilation followed by plastic stent placement, with repeat stent exchange until stricture resolution. The use of inside stents may prevent duodenobiliary reflux, and thus extending stent patency and minimizing the need for multiple stent exchange. Alternatively, recently developed covered self-expandable metallic stents with a lasso, enabling removal even after placed into the bile duct, provide an option to the multiple plastic stents placement. Furthermore, with the advent of balloon-assisted enteroscopy, it is now possible to endoscopically manage biliary complications in LDLT patients with Roux-en-Y hepaticojejunostomy.
However, these procedures are highly challenging due to the intricate nature of the biliary system in LDLT. Therefore, a comprehensive approach that integrates percutaneous and surgical interventions may be required as a salvage option when endoscopic management fails. In this study, we comprehensively investigated clinical outcomes of endoscopic management for post-LDLT biliary complications. Additionally, we discuss recent advances as well as future perspectives in this field.

**Biliary 3. Management of post operative biliary complications**

**Biliary 3-2**

**EUS Management of Bilio-Enteric Anastomotic Stricture**

**Dr. Yusuke Takasaki**

Department of gastroenterology, Juntendo University Japan

Benign biliary stricture may be a problem as a postoperative complication in surgically alter anatomy cases. In many cases, it is treated with balloon enterocopy assisted ERCP (BE-ERCP), but the endoscope may not be able to reach the anastomosis or find the bilo-enteric anastomosis. The long scopes may also limit the devices and may not provide adequate treatment. The longer treatment time of BE-ERCP is also a problem, which raises health issues not only for the patient but also for the doctor due to prolonged exposure to radiation. If stent exchange is performed frequently, radiation exposure becomes an unacceptable health problem. Percutaneous transhepatic bile duct drainage is also useful, but cosmetic problems and reduced quality of life are major problems. In addition, the long period of drainage tube placement can cause a variety of problems such as skin trouble, infection, and migration of drainage tube. In recent years, endoscopic ultrasound biliary drainage has come to be used not only for malignant biliary stricture but also for benign biliary stricture. However, the evidence for interventional EUS in benign disease is still insufficient, and there are many issues such as its indications, strategies for stenosis dilatation and treatment of concomitant bile duct stones. In this session, I will discuss bilo-enteric anastomotic stricture using endoscopic ultrasound biliary drainage, including our own approach.

**Biliary 3-3**

**Endoscopic treatment of hepaticojejunostomy anastomotic strictures with a double-balloon endoscope**

**Dr. Naminatsu Takahara**

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Japan

Hepaticojejunostomy anastomotic stricture (HJAS) is a major complication of surgical biliary reconstruction, leading to a deterioration of quality of life as well as high morbidity and mortality. The surgically altered anatomy complicates the endoscopic approach to the hepaticojejunostomy anastomosis, making percutaneous transhepatic biliary drainage or surgical re-anastomosis the standard of care. However, with the emergence of the double-balloon endoscope (DBE), HJASs are increasingly managed endoscopically. Several clinical studies have suggested that endoscopic treatment of HJAS is technically feasible, providing a reasonably high stricture resolution rate ranging 70–100%. However, there is a paucity of data on long-term outcomes in a large-scale cohort, and predictive factors for successful endoscopic management remain unclear. Furthermore, an optimal treatment strategy for refractory cases has not yet been determined.

In this study, we aimed to evaluate clinical outcomes of DBE-assisted ERCP for HJASs and identify predictive factors for long-term treatment success.

**Biliary 3-4**

**Short- and Long-term Outcomes for Secondary hepatolithiasis: Analysis from a Nationwide Cohort Study**

**Dr. Yutaka Suzuki**

Department of Hepato-Biliary-Pancreatic Surgery, Kyorin University Hospital Japan

**Background:** Hepatolithiasis is characterized by its intractable nature and frequent recurrence. Furthermore, cholangitis, sepsis, liver abscesses, and cholangiocarcinoma frequently occur. The secondary hepatolithiasis following biliary reconstruction has been increased. In the eighth nationwide multicenter survey, 48% was secondary hepatolithiasis. Additionally, there is a noticeable rise in non-surgical treatments, particularly endoscopic interventions. The outcomes of secondary intrahepatic stone treatment, especially long-term results, remain unclear. This study evaluates secondary hepatolithiasis treatment modalities’ short- and long-term outcomes to consider appropriate management strategies.

**Methods:** The study included 128 cases of secondary hepatolithiasis registered in a nationwide cross-sectional survey conducted by the Ministry of Health, Labour and Welfare in 2017. Based on medical records, this retrospective cohort study analyzed disease backgrounds, short-term outcomes of each treatment modality, and complications, including stone recurrences, cholangitis, and cholangiocarcinoma.

**Results:** The cause of choledocho-enterostomy was congenital biliary dilatation in 34 cases (27%), followed by anomalies of the pancreaticobiliary junction in 29 cases (23%). Treatment was administered in 110 cases (86%), with 94 cases undergoing non-surgical treatment, 13 cases undergoing exclusive surgical treatment, and 3 cases receiving both non-surgical and surgical treatments. Endoscopic retrograde cholangiography by balloon endoscopy (ERC) was the most frequently performed in 77 cases. In surgical treatment, systematic hepatectomy was the most common surgical treatment in 12 cases. The residual stone rate between hepatectomy and balloon ERC showed no significant difference in residual stones (0% vs. 16%, p=0.344). There was no significant difference in stone recurrence between the two groups (5-year incidence: liver resection 28.6% vs. balloon ERC 42.3%, p=0.400). During post-treatment follow-up, bile duct strictures were observed in 47 cases (37%), and bile duct dilatation was observed in 72 cases (56%). Stricture was a significant risk factor for stone recurrence (5-year incidence: 67.3% vs. 17.8%, p<0.001) and cholangitis (5-year incidence: 56.1% vs. 10.1%, p<0.001). The bile duct dilatation was a risk factor for stone recurrence (4-year incidence: 55.7% vs. 33.3%, p=0.006) but not for cholangitis.

**Conclusion:** Minimally invasive treatment, such as endoscopy, is recommended as a first choice treatment, but a combination with other treatment modalities, including surgery, should be considered in cases where its effectiveness is insufficient. Treatment for hepatolithiasis should address complete stone removal and the management of bile duct strictures and dilatation.
Novel choledochojunostomy technique “T-shaped anastomosis” for preventing the development of postoperative cholangitis in pancreatoduodenectomy: A propensity score matching analysis

Dr. Nana Kimura
Department of Surgery and Science, Faculty of Medicine, Academic Assembly, University of Toyama Japan

Background: Cholangitis after pancreaticoduodenectomy (PD) is a serious complication that impairs quality of life including from repeated rehospitalization. However, there have been few studies of countermeasures to prevent this.

Objective: We developed a novel method of choledochojunostomy with a larger anastomotic diameter, the “T-shaped anastomosis,” whose effectiveness we examine in this study.

Methods: The study included 261 cases of PD. The T-shaped choledochojunostomy was performed with an additional incision for a distance greater than half the diameter of the bile duct at the anterior wall of the bile duct and the anterior wall of the elevated jejunum. To compensate for potential confounding biases between the standard anastomosis group (n=206) and the T-shaped anastomosis group (n=55), we performed propensity score (PS) matching. The primary endpoint was the incidence of medium-term postoperative cholangitis (within 18 months after surgery) adjusted for PS.

Results:
1) In the PS matching analysis, 54 patients in each group were matched, and the median bile duct diameter measured by preoperative CT was 8.8 mm vs. 9.3 mm, the rate of preoperative biliary drainage was 31% vs. 37%, the incidence of cholangitis within 1 month before surgery was 9% vs. 13%, and the incidence of postoperative bile leakage was 2% vs. 2%, with no significant differences.
2) The incidence of medium-term postoperative cholangitis was 14.8% vs. 3.7%, and logistic regression with PSs showed that the incidence of postoperative cholangitis was significantly lower in the T-shaped anastomosis group (odds ratio, 0.221, 95% CI 0.032-0.937; P =0.039). Multivariate analysis revealed that the T-shaped choledochojunostomy was an independent predictor of reduced incidence of cholangitis (odds ratio, 0.17, 95% CI 0.02-0.81; P =0.024).
3) In addition to 1:1 matching, a 2:1-matching, inverse-probability-of-treatment-weighting analytical method was performed as a sensitivity analysis. All analyses showed that the incidence of medium-term postoperative cholangitis was significantly lower in the T-shaped anastomosis group.

Conclusions: The T-shaped choledochojunostomy was shown to be effective with a significant reduction in the incidence of medium-term postoperative cholangitis.

Biliary 4. Tips and tricks in Endo-Hepatology with EUS
Biliary4-1

Current Status of Endo-hepatology

Dr. Yosuke Nakai
Department of Endoscopy and Endoscopic Surgery, The University of Tokyo Hospital Japan

Traditionally, the role of gastrointestinal endoscopy was limited to management of esophageal/gastric varices and portal hypertensive gastropathy. However, since the introduction of the concept of endohepatology in 2012, several procedures have been developed for endoscopic management of liver diseases. These include endoscopic ultrasound (EUS)-guided liver biopsy, liver stiffness measurement, portal pressure gradient measurement, ablation of liver tumors, and vascular interventions for conditions like gastric varices. In this presentation, the current status and a future direction of “Endo-hepatology” for liver diseases and their complications will be discussed.

Biliary 4. Tips and tricks in Endo-Hepatology with EUS
Biliary4-2

Current Status of EUS-BD

Dr. Kazuo Hara
Department of Gastroenterology, Aichi Cancer Center Japan

EUS-BD (Endoscopic Ultrasound-Guided Biliary Drainage) is rapidly becoming popular worldwide due to its usefulness. Especially notable is the advancement in endoscopic instruments, where the development and improvement of these instruments have led to increased success rates and enhanced safety of the procedure.

The indications for EUS-BD have also evolved over time. Previously, EUS-BD was indicated only for cases where ERCP (Endoscopic Retrograde Cholangiopancreatography) was unsuccessful or not feasible. However, recently, in cases where ERCP is anticipated to be challenging, Primary EUS-BD is performed without attempting ERCP. Moreover, the indications have expanded from malignant to benign conditions. In this presentation, I would like to explain, using video, the changes in indications for EUS-BD, the development of instruments, and the advancements in techniques.

Biliary 4. Tips and tricks in Endo-Hepatology with EUS
Biliary4-3

Tips & Tricks in Endo-hepatology with EUS

Dr. Sundeepl Lakhtakia
Medical Gastroenterology, Asian Institute of Gastroenterology, AIG hospitals, Hyderabad India

Endohepatology is an emerging subspecialty dealing with endoscopic diagnosis and management of liver diseases. It includes both - diagnostic endoscopic ultrasound (EUS) guided elastography, and interventional EUS guided therapy for gastric varices, EUS-guided liver biopsy and direct portal pressure measurement.

EUS guided Elastography is an exploratory diagnostic technique that evaluates tissue stiffness. Liver fibrosis alters the liver’s stiffness, making it an ideal target for elastography. EUS ‘shear wave elastography’ plays an important role in evaluating liver fibrosis. By quantifying the stiffness, EUS elastography can help in staging the degree of fibrosis. Its comparison with transcutaneous liver stiffness measurement (VCTE) using liver biopsy as gold standard showed good correlation and thus a safe and reliable alternative to VCTE. It offers advantage in obese patients, where ‘percutaneous transient elastography’ might be less effective due to the increased distance between the probe and the liver.

EUS guided Liver Biopsy (EUS-LB) has emerged as a viable alternative for acquiring liver tissue compared to traditional percutaneous and trans-jugular routes. EUS-LB is particularly useful in cases where other methods are contraindicated, such as in patients with ascites, coagulopathy, or obesity. EUS-LB offers several advantages, including decreased patient anxiety, increased satisfaction due to sedation, shorter post-procedural monitoring time, less post-procedure pain, and lower complication rates.

EUS guided Portal Pressure gradient (EUS-PPG) measurement a newer technique, is gaining attention as a potential alternative to conventional HVPG. Direct EUS-PPG involves sequential trans-gastric puncture of hepatic vein and portal vein under EUS guidance using a
Biliary 4. Tips and tricks in Endo-Hepatology with EUS

**Tips and Tricks in Endo-Hepatology with EUS: Challenge and Limitations**

**Dr. Cosmas Rinaldi Aditya Lesmana**

Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Indonesia

Esophageal varices (EV) is one of the most common complications in patients with liver cirrhosis (LC). Bleeding esophageal varices (BEV) is one of the challenging conditions in clinical practice due to its high mortality rate. Esophagogastroduodenoscopy (EGD) is the standard tool for screening the presence of EV as well as managing the high-risk stigmata EV. However, the portal pressure itself, and the possible of extra-luminal EV (deep EV) has become a new challenge in patients with recurrent bleeding. Recently, endoscopic ultrasound (EUS) has been investigated to be the most promising tool not only for portal pressure evaluation, but also for a better prevention of variceal bleeding. In the need of liver disease progression evaluation, EUS has been showed to be an important tool to get liver biopsy specimen. EUS is a one stop comprehensive modality for diagnosis, treatment, and make a prognosis especially in LC patients. In patients with liver mass or small nodules which might be difficult to be detected through imaging evaluation, EUS would become a better alternative as the need of liver biopsy as well as possible local treatment, such as radiofrequency ablation (RFA) for malignant liver tumor can be performed in the same session. The limitations are to get adequate tissue sample due to its hard liver parenchyma in advance LC patients, narrowed and irregular hepatic vein for hepatic vein pressure measurement, and the tumor mass location at the right lobe of the liver which is more difficult to approach for EUS-guided RFA. Pre-procedural comprehensive evaluation is still the most important thing to do, such as coagulation issue, the presence of massive ascites, and the target location of the liver mass. Other factors such as the needle type, additional liver elastogram software, and the scope position would give a better result. In the biliary cases, EUS has been showed to have high sensitivity for gallstones, and possible malignant condition, especially for distal malignant biliary obstruction. The only limitation is to evaluate the possible hilar malignancy (intraductal cholangiocarcinoma). In this situation, intraductal ultrasound (IDUS) might be a better option for hilar or mid common bile duct lesions assessment.

Real world data of gemcitabine, cisplatin, and durvalumab combination therapy for advanced biliary tract cancer.

**Dr. Takashi Sasaki**

Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital, Japanese Foundation for Cancer Research Japan

**Background:** Drug therapy for advanced biliary tract cancer has made steady progress. In recent years, in addition to conventional chemotherapy using cytotoxic agents, molecular targeted drugs and immunotherapy have been introduced into treatment. In particular, first-line treatment with immune checkpoint inhibitors is expected to be a promising approach. Currently, the combination of gemcitabine (GEM) + cisplatin (CDDP) with durvalumab or pembrolizumab have been reported to be effective for advanced biliary tract cancer. In Japan, GEM + CDDP + durvalumab combination therapy has been in clinical use for more than a year.

**Patients and methods:** We retrospectively analyzed consecutive patients with advanced biliary tract cancer who were treated with GEM + CDDP + durvalumab combination therapy as 1st line therapy between March 2023 and October 2023 at our institution.

**Results:** A total of 42 patients were included. Median age was 67 and 25 patients (60%) were performance status 0. The primary sites were: intrahepatic cholangiocarcinoma 15, extrahepatic cholangiocarcinoma 15, gallbladder cancer 11, and ampullary carcinoma 1). Seventeen patients (40%) were recurrent case. Response rate and disease control rate were 19.0% and 81.0%, respectively. The median progression-free survival was 5.6 months. The median overall survival was not reached. Two patients were converted to surgical resection. Major grade 3/4 adverse events were neutropenia. Skin rash occurred in 8 patients (19%) and one patient experienced immune-related adverse event of adrenal insufficiency.

**Conclusions:** GEM + CDDP + durvalumab combination therapy has shown the efficacy and safety for the treatment of advanced biliary tract cancer in clinical practice.

Biliary 5. Immune and target therapy for cholangiocarcinoma

**Unveiling the Cellular Origins and Therapeutic Targets in Extrahaepatic Cholangiocarcinoma: Insights from Mouse Models and Genetic Markers**

**Dr. Hayato Nakagawa**

Department of Gastroenterology and Hepatology, Mie University Japan

The cellular origin of cholangiocarcinoma is a fascinating subject. Regarding extrahaepatic cholangiocarcinoma (ECC), there has been a focus on peribiliary glands (PBGs) as a potential stem cell niche for biliary epithelial cells (BECs), raising interest in PBGs as the cellular origin of ECC. We recently developed a new mouse model of ECC by activating Kras specifically in CK19-positive duct cells and deleting TGFβR2 and E-cadherin. In this model, BECs undergo detachment and apoptosis due to the loss of E-cadherin, leading to chronic inflammation in the bile duct. Detailed histological analysis revealed the gradual dysplasia of PBGs during inflammation, eventually progressing to cholangiocarcinoma.

To definitively establish PBG as the cellular origin of biliary tract cancer, we needed animal experiments utilizing a PBG-specific gene recombination system. Consequently, we aimed to identify PBG-specific markers and discovered that Axin2, a target gene of the Wnt/β-catenin pathway, is specifically expressed in PBGs of the periampullary region. Genetic lineage-tracing demonstrated that Axin2+ periampullary PBG...
cells function as biliary epithelial stem cells. Notably, the deletion of PTEN in periampullary PBC cells resulted in ampulla carcinoma, which was suppressed by a Wnt inhibitor. Therefore, Wnt signaling emerges as a potential therapeutic target for ampullary carcinoma. Moreover, we have established additional mouse models of extrapancreatic cholangiocarcinoma by combining different genetic abnormalities and have identified lipid metabolic reprogramming as a potential therapeutic target. In this session, I will present a portion of this data.

Biliary 5. Immune and target therapy for cholangiocarcinoma

Liquid biopsy of tumor-derived DNA in pancreaticobiliary malignancies in bile and plasma

Dr. Hiroshi Ohyama
Department of Gastroenterology, Chiba University Hospital Japan

BACKGROUND: Pancreaticobiliary cancer (PBCA) is a highly progressive disease with a poor prognosis. Obtaining sufficient pancreaticobiliary tumor tissue for genomic profiling has limitations because many PBCAs are unresectable, and only a small amount of tissue is obtained via biopsy. Liquid biopsies using plasma do not provide sufficient sensitivity. Thus, this study aimed to determine the effectiveness of liquid biopsy between bile and plasma for identifying oncogenic mutations.

RESULTS: The amount of DNA was significantly lower in plasma than in bile (P < 0.001). Oncogenic mutations were identified in 21 of 38 (55%) patients in bile and 9 (24%) in plasma samples (P = 0.005). Bile was significantly more sensitive than plasma in identifying druggable mutations (P = 0.032). Oncogenic mutations were detected in 0%, 5/11 (45%), 7/17 (41%), 9/20 (45%), 4/4 (100%), and 24/32 (75%) in unsuitable and classes I to V, respectively, with differences between classes (P = 0.012). We detected 23 drug-matched mutations in combined bile and plasma, including 5 ERBB2, 4 ATM, 3 BRAF, 3 BRCA2, 3 NFI, 2 PIK3CA, 1 BRCA1, 1 IDH1, and 1 PALB2.

CONCLUSIONS: Bile is an ideal clinical specimen in PBCA because it contains a large amount of tumor-derived DNA. Liquid biopsy using bile may be useful in searching for therapeutic agents, and the utilization of the obtained genomic information may improve the prognosis of patients with PBCA.

Biliary 6. Interventional EUS for bileary diseases

Tips and Tricks of Interventional EUS for Liver

Dr. Kazuo Hara
Department of Gastroenterology, Aichi Cancer Center Japan

The intervention for the liver using Liner EUS includes liver biopsy, liver tumor biopsy, and liver abscess drainage. Recently, EUS-FNB (Fine Needle Biopsy) from liver tumors has been increasingly performed to collect tumor specimens for cancer genomic medicine. In particular, tumors in the liver S1 region, located deep in the body, are difficult to access percutaneously, making EUS-FNB useful. The use of EUS enables simultaneous liver tumor biopsy, biopsy of enlarged lymph nodes, and ascites collection, offering greater utility than percutaneous biopsy. Understanding the EUS anatomy of the liver is necessary to visualize the targeted liver area. The trick to visualize the liver area is to focus on the vessel.

Biliary 6. Interventional EUS for bileary diseases

Terminology and Classification in Interventional-EUS

Dr. Hiroyuki Isayama
Department of Gastroenterology, Graduate School of Medicine, Juntendo University Japan

Development of Interventional EUS (I-EUS) is rapidly, and new procedures, indications and devices are reported day by day. There are no standard rules in the words which used in published numerous reports, and confusions are arising. The authors had published “Clinical practice guidelines for safe performance of endoscopic ultrasound/ultrasound-guided biliary drainage: 2018” in 2019, and confused in terminology of I-EUS. Then, Japan Gastroenterological Endoscopy Society (JGES) decided to make “Subcommittees for Terminology of Interventional EUS” (Chair: Isayama H). In this lecture, the progress of this activity and decided terminology and classifications of I-EUS will be told. From our discussion, I-EUS are classified into 5 categories; 1) EUS-sampling, 2) EUS-guided through-the-needle examination (EUS-TTNE), 3) EUS-guided drainage/anastomosis (EUS-D/A), 4) Trans-endosonographically/guided created route (Trans-ESCR), 5) EUS-guided delivery. 1) EUS-sampling is including tissue acquisition (EUS-TA) and fluid sampling, and can use EUS-FNA as well. 2) EUS- TTNE is the diagnostic procedures through the punctured needle; imaging, measurement and biopsy (TTNB) using miniature devices can through the needle cavity. 3) EUS-D/A is drainage procedures for organs and fluid collections. EUS-D/A for the organs (bile duct, pancreatic duct, gallbladder, digestive tract, etc.) is drainage procedure but anastomosis simultaneously, then use “ -stomy” (EUS-guided hepaticogastroenterology, EUS-guided pancreategastrostomy). However, fluid collection is disappeared after drainage, then only words of drainage is available (transgastric EUS-PFD for WON). 4) ESCR is proposed new word represents a general term of EUS-guided/endosonographically created route. Endoscopic necrosectomy is performed through the matured route after EUS-guided drainage of walled off necrosis. Other trans ESCR procedures are antegrade stenting or stone management through the anastomosis. 5) EUS-guided delivery is the procedure to deliver the liquid, drug, equipment, energy, etc. after the puncture. Tumor ablation therapy, neurolysis implantation of fiducial markers are included. In this proposal, there were some newly created words. T-DAS is “transluminal drainage/anastomosis stent” including plastic and metallic stent, and lumen apposing metal stent is representative. The aim of T-DAS is keeping the ESCR differ from the conventional stent which keep the luminal patency at the stricture. Many doctors are using “fistula” for created route in EUS-D/A, however, “Fistula” is originally means accidentally created unusual route which are harmful, inconvenient and should be closed. Then, we proposed “anastomosis” and “route” in EUS-D/A and “ESCR” as a general term. We believed newly proposed terminology and classifications are useful to categorize various and brad-new procedures.
Interventional EUS for Biliary Diseases

Dr. Jae Hee Cho
Yonsei University College of Medicine, Gangnam Severance Hospital Korea

The integration of interventional Endoscopic Ultrasound (iEUS) into routine clinical practice has significantly bridged a critical gap in managing biliary diseases, notably aiding patients with complex anatomical challenges or those at high risk from conventional surgical or endoscopic procedures. Its minimally invasive nature, coupled with the capability for direct visualization and intervention, has established iEUS as a vital tool in pancreatobiliary disease management. EUS-guided biliary drainage (EUS-BD) offers a straightforward technique for bile duct drainage, whereas EUS-guided gallbladder drainage (EUS-GBD) provides a minimally invasive solution for high-risk surgical patients with acute cholecystitis, achieving high success rates with minimal adverse events.

Regarding the long-term outcomes of EUS-BD, a Korean retrospective study analyzed the clinical outcomes of EUS-guided choledochoduodenostomy (EUS-CDS) and hepaticogastrostomy (EUS-HGS) for treating distal malignant biliary obstruction (MBO). The study included 116 patients, divided into EUS-CDS (n=56) and EUS-HGS (n=60) groups. Both groups exhibited high technical success rates—98.2% for EUS-CDS and 96.7% for EUS-HGS. Clinical success was also significant, at 96.4% for EUS-CDS and 88.3% for EUS-HGS. The EUS-CDS group showed a significantly longer average stent patency of 770.3 days compared to 165.5 days for the EUS-HGS group. The only independent risk factor for stent dysfunction identified was systemic treatment following EUS-guided biliary drainage. The incidence of stent dysfunction was higher in the EUS-HGS group compared to the EUS-CDS group, with no significant differences in late adverse events. This study highlights the efficacy and safety of interventional EUS techniques in managing distal MBO, particularly emphasizing the superior stent patency associated with EUS-CDS.

In addition, a recent meta-analysis compared the efficacy and safety of EUS-GBD with percutaneous gallbladder drainage (PTGBD) in patients with acute cholecystitis. The analysis included four studies with a total of 535 patients. Although PTGBD showed a slightly higher technical success, EUS-GBD was associated with fewer adverse events, reduced unplanned readmissions, and a lower need for reinterventions, indicating its potential as a safer and more effective alternative to PTGBD, especially for patients at high surgical risk. The adoption of iEUS has not only enhanced the safety and efficacy of treating pancreatobiliary diseases but also significantly improved patient comfort and recovery times. As technology and expertise in this field continue to evolve, iEUS is poised to play an increasingly central role in a multidisciplinary approach, promising even better patient outcomes and broader applications in gastroenterology.
pediatric patients because only ALP is incorporated in the evaluation of increased biliary enzyme. Secondly, small duct PSC cannot be diagnosed. Thirdly, PSC recurrence following liver transplantation cannot also be diagnosed. New findings and knowledge have accumulated after the proposal of PSC2016. The Intractable Hepato-Biliary Diseases Study Group of the Committee of Research on Measures for Intractable Diseases in Japan established a working group consisting of researchers specializing in PSC. The working group develops tentative revised diagnostic criteria for PSC to overcome these limitations of PSC2016. Revised criteria also consist of four items. They are 1) biliary finding, 2) association with inflammatory bowel disease, 3) increased biliary enzyme, and 4) liver histology. Revisions are as follows; 1) Cholangiographic finding is revised to biliary finding to use other modalities (EUS, IDUS, POCUS) in addition to ERC/MRCP. 2) Gamma-glutamyl transpeptidase is incorporated in addition to ALP for the evaluation of elevated biliary enzyme. 3) Diagnostic criteria for PSC recurrence following liver transplantation are added. The working group is going to propose the revised diagnostic criteria for PSC after the discussion and public hearing.

Biliary 7. Hot topics in PSC
Biliary 7-2

Anti-Integrin αvβ6 Autoantibodies in Patients with Primary Sclerosing Cholangitis

Dr. Masahiro Shiokawa

Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine Japan

Patients with primary sclerosing cholangitis (PSC) possess autoantibodies against biliary epithelial cells. However, the target molecules remain unknown. In addition, although diffuse biliary stricture is the most important finding for diagnosing with primary sclerosing cholangitis (PSC), some cases have potential to be misdiagnosed with other biliary diseases. Therefore, the development of specific diagnostic markers for PSC is needed.

We recently found that PSC patients possessed anti-integrin αvβ6 autoantibodies. By enzyme-linked immunosorbent assays (ELISA), anti-integrin αvβ6 antibodies were detected in 49/55 (89.1%) patients with PSC and 5/150 (3.3%) controls (P < 0.001), with a sensitivity and specificity of 89.1% and 96.7%, respectively, for PSC diagnosis. When focusing on the presence or absence of IBD, the proportion of the positive antibodies in PSC with IBD was 97.2% (35/36) and that in PSC alone was 73.7% (14/19) (P = 0.008). Integrin αvβ6 was expressed in bile duct epithelial cells. Immunoglobulin (Ig)G from 15/33 patients with PSC blocked integrin αvβ6-fibronectin binding through an RGD (Arg-Gly-Asp) tripeptide motif.

In conclusion, autoantibodies against integrin αvβ6 were detected in most patients with PSC; anti-integrin αvβ6 antibody may serve as a potential diagnostic biomarker for PSC.

We proceeded studies further. Our study above was conducted on patients from only two institutions. Therefore, a validation research in multi-centers is needed to eliminate selection bias. In addition, the study was examined using our conventional in-house enzyme-linked immuno-sorbent assay (ELISA) method. To compare the data from different facilities, development of a universal kit for the antibody measurement is needed.

The Intractable Hepato-Biliary Diseases Study Group in Japan has conducted the nation-wide PSC registry study “Establishment of disease registry of primary sclerosing cholangitis for investigation of clinical features, natural history, and prognostic factors” to prospectively register clinical information and sera of patients with PSC in Japan. Using these serum samples and clinical information, we examined diagnostic value of anti-integrin αvβ6 autoantibody for PSC as a Japanese nation-wide validation study.

In addition, we collaborated with Medical and Biological Laboratories CO., LTD. to establish Anti-Integrin αvβ6 ELISA Kit which enables easier detection of the anti-integrin αvβ6 antibodies. The use of monoclonal antibody for integrin αvβ6 with known concentration facilitated the standardization of anti-integrin αvβ6 autoantibody titers. I will show these results in this section.

Biliary 7. Hot topics in PSC
Biliary 7-3

Endoscopic Treatment in PSC

Dr. Cosmas Rinaldi Adithya Lesmana

Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Indonesia

Primary sclerosing cholangitis (PSC) is a challenging clinical condition which is required a good and proper diagnosis before deciding the best strategy approach as it can lead to malignancy condition. Liver transplantation is still the best treatment for PSC; however, regular endoscopic approach is the most routine procedure in daily practice. Despite the imaging innovation, such as magnetic resonance cholangiopancreatography (MRCP), other innovations in endoscopy, such as transpapillary biopsy, fluorescence in-situ hybridization (FISH) method from the brush material, intraductal biopsy using innovation and dedicated cholangioscope have increased the diagnostic value, especially for cholangiocarcinoma (CCA) early detection. Biliary stenting through endoscopic retrograde cholangiopancreatography (ERCP) procedure is the main procedure in daily practice for PSC management. Endoscopic luminal radiofrequency ablation (ELRA) is one of innovation treatment for biliary stricture, especially to maintain biliary stent patency in intraductal CCA.

Biliary 7. Hot topics in PSC
Biliary 7-4

Dr. Tosho Fujisawa

Biliary 7. Hot topics in PSC
Biliary 7-5

Recent advances in medical treatment for PSC

Dr. Suguru Mizuno

Department of Gastroenterology & Hepatology, Saitama Medical University Japan

Primary sclerosing cholangitis (PSC) is a disease characterized by fibrotic strictures of intra- and extrahepatic bile ducts, leading to liver cirrhosis due to bile stasis. While its pathogenesis involves presumed autoimmune mechanisms, it remains incompletely understood. At present, liver transplantation stands as the sole definitive treatment, but opportunities for deceased donor liver transplantation are limited, and living donor liver transplantation pose significant challenges. Additionally, graft failure due to a high recurrence rate after transplantation remains a concern. Though no established pharmacological treatment exists, various studies are underway with promising outcomes expected.
Ursodeoxycholic acid (UDCA) represents the most extensively studied pharmacotherapy, demonstrating reduction in hepatic and biliary enzymes in numerous randomized controlled trials. However, due to reported increased mortality and liver transplantation at high doses, it is not considered standard therapy in various national guidelines. Nonetheless, recent reports associating decreased serum ALP levels with prognosis have renewed interest in the potential of UDCA to improve outcomes. Retrospective analyses using nationwide surveys in Japan have reported improved transplantation-free survival rates associated with UDCA therapy. Bezafibrate, a medication for dyslipidemia, acts as an agonist for Peroxisome Proliferator-Activated Receptor alpha (PPARα) and has been reported to decrease hepatic and biliary enzymes in PSC. However, its evidence remains limited to a few cases, lacking established confirmation.

Other pharmacotherapies include a Phase II randomized trial showcasing improvement in hepatic and biliary enzymes with cilofexor, a farnesoid X (FXR) receptor ligand, followed by an ongoing Phase III trial. Recent advances reveal the involvement of the gut microbiota in PSC pathogenesis, driving research toward pathophysiology-based treatments. Reduced diversity in the gut microbiota of PSC patients has been reported, with expectations that restoring diversity through fecal microbiota transplantation may lead to therapeutic benefits. Moreover, Klebsiella pneumoniae is frequently detected in the intestines of PSC patients, prompting investigations into its role in causing liver inflammation via bacterial translocation. Studies on bacteriophage therapy targeting K. pneumoniae are also underway.

Progress in understanding PSC's pathophysiology fuels optimism for further advancements in treatment-related research in the foreseeable future.

**The revised TOKYO criteria for hilar biliary obstruction**

**Dr. Tsuoshi Hamada**

Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Japan

The consensus-based TOKYO criteria were introduced as a standardized reporting system to address the inconsistent documentation of outcomes of endoscopic transpapillary biliary drainage. The main aim was to solve issues arising from heterogeneous reporting practices across different studies, which hindered the comparability and interpretation of stent outcomes. However, the original TOKYO criteria were less applicable to recent endoscopic biliary drainage modalities such as those based on endoscopic ultrasound or balloon endoscopy. As opportunities for managing hilar biliary obstruction and benign biliary strictures through endoscopic drainage have expanded, and biliary ablation has been introduced for both benign and malignant strictures, there is a growing need to revise the criteria. Additionally, with cancer patients experiencing prolonged survival times, there is an increased focus on evaluating overall outcomes throughout the period of endoscopic biliary drainage rather than solely concentrating on the initial stent patency.

Acknowledging these gaps, a committee within the Japan Gastroenterological Endoscopy Society has been formed to revise the TOKYO criteria to align with current clinical practices in endoscopic biliary drainage. The revised criteria propose standardized reporting items applicable to endoscopic biliary drainage as a whole, along with specific items tailored to different conditions and interventions. The term "stent-demanding time" has been introduced to encompass the entire duration of endoscopic biliary drainage, providing a comprehensive evaluation of overall stent-related outcomes. The adoption of these revised TOKYO criteria is expected to facilitate the design and reporting of clinical studies, offering a goal-oriented approach to assessing endoscopic biliary drainage.

The revised TOKYO criteria aim to evaluate the following conditions and interventions: distal biliary obstruction, hilar biliary obstruction, EUS-guided biliary drainage, biliary drainage via balloon-assisted endoscopy, benign biliary strictures, scheduled exchange of a plastic stent, biliary ablation. In this presentation, I will focus on the part of assessing endoscopic biliary drainage for hilar biliary obstruction.

**Biliary 8. Endoscopic management of hilar obstruction**

**Biliary 8-3**

**Endoscopic Management of Hilar Obstruction**

**Dr. Jae Hee Cho**

Yonsei University College of Medicine, Gangnam Severance Hospital Korea

Hilar cholangiocarcinoma (hilar CC), a rare but prevalent form of bile duct cancer, poses significant treatment challenges due to its advanced stage at diagnosis and the historical lack of effective treatments, resulting in poor survival rates. The primary treatment approach involves surgical resection, targeting both intra- and extrahepatic bile ducts and the affected liver lobe. Preoperative biliary decompression is crucial for patients presenting with obstructive jaundice, a common symptom of hilar CC, and scheduled for major liver surgery. Traditionally, percutaneous transhepatic biliary drainage (PTBD) has been preferred, especially in cases with additional complications such as cholangitis, malnutrition, or liver dysfunction. More recently, endoscopic methods like endoscopic nasobiliary drainage (ENBD) have become popular due to their diagnostic benefits in evaluating bile volume and characteristics. Despite its advantages, ENBD can cause bile leak and patient's discomfort, leading some clinicians to opt for endoscopic biliary stenting (EBS). However, EBS may carry a higher risk of obstructive cholangitis and postoperative issues, making ENBD the recommended first-line treatment, although EBS may still be used if it provides sufficient drainage.

In cases of inoperable hilar CC, the optimal method for liver drainage is still debated. Generally, draining more than 50% of the liver volume is advised, but the choice between plastic stents (PS) and uncovered self-expandable metal stents (uSEMS) is controversial. PS are often selected for their ease of replacement and removal, while uSEMS are preferred for their durability and longer patency. The decision between unilateral and bilateral stenting also varies, with some evidence suggesting that bilateral stenting might offer longer stent patency. Another therapeutic consideration is intrahepatic radiofrequency ablation (ID-RFA), which shows promise for treating unresectable malignant biliary obstructions. However, due to the perihilar bile duct's proximity to critical vascular structures, the risk of ID-RFA-related complications may be elevated. Our research suggests using the shortest available ID-RFA probe to minimize these risks, based on findings from animal studies that showed increased bile duct perforation risk with standard ID-RFA settings.

In summary, the management of hilar CC, including preoperative and palliative biliary decompression, requires a tailored approach that considers the complexities of each case. A multidisciplinary team's expertise is crucial in determining the most appropriate treatment strategy, whether it involves surgical resection, biliary decompression, or advanced therapies like ID-RFA. Despite the advancements, a consensus on the best practices for hilar CC is still needed, underscoring the importance of individualized treatment plans supported by collaborative decision-making.
Biliary 8. Endoscopic management of hilar obstruction

Suprapapillary placement of plastic stents for unresectable malignant biliary hilar obstructions

Dr. Yoshihide Kanno
Department of Gastroenterology, Sendai City Medical Center Japan

Unresectable malignant obstructions of the biliary hilum represent a significant challenge in the field of palliative pancreatobiliary endoscopy. Prior meta-analyses have favored uncovered metal stents due to their prolonged patency compared to plastic stents placed across the papilla. However, advancements in cancer treatment have rendered the uncovered design problematic because it cannot be removed. Once the metal stent becomes occluded, it induces idioopathic cholangitis which interrupts cancer therapies, reduces quality of life, and requires extremely complicated treatments since it cannot be removed. Plastic stents, alternatively, offer reversibility, simplifying re-interventions, despite their shorter function periods when placed across the papilla. Recently, the focus has shifted to suprapapillary placement, which has been proven to be feasible in recent studies. Retrospective or single-arm studies have reported median patency periods of suprapapillary plastic stents from 99 to 190 days, making this approach a viable option.

In our multicenter, randomized control trial comparing suprapapillary-externally placed plastic and metal stents, we found no significant differences in the technical success, clinical success and adverse events between the groups. While plastic stents exhibited a tendency for shorter function periods compared to metal stents without statistical significance (250 vs. 361 days, p = 0.34), both are potential initial permanent drainage options. While plastic stents, alternatively, offer reversibility, simplifying re-interventions, despite their shorter function periods when placed across the papilla, we found no significant differences in the technical success, clinical success and adverse events between the groups. While plastic stents exhibited a tendency for shorter function periods compared to metal stents without statistical significance (250 vs. 361 days, p = 0.34), both are potential initial permanent drainage options, considering the removability of plastic stents.

Hepatitis A and E viruses: recent advances in research and clinical practice recommendations

Dr. Tatsuo Kanda
Division of Gastroenterology and Hepatology, Nihon University School of Medicine Japan

In 2018, there was an outbreak of hepatitis A virus (HAV) infection in Japan, and hepatitis A is also considered a sexually transmitted disease. Patients with hepatitis A should be receiving attention, and this disease needs to be prevented more than ever. Despite the development of an effective vaccine against hepatitis A, universal vaccination has not yet been performed in Japan. In Japan, until the early 2000s, acute hepatitis E virus (HEV) infection was considered rare until reports emerged confirming the existence of HEV genotype 3 and 4 infections. Until now, vaccines against hepatitis E have not yet become available in Japan. The Japanese National Health Insurance System does not approve anti-HAV and anti-HEV drugs.

Recently, we discovered several effective drugs against HAV infection and their mechanism by drug repositioning, in silico screening (Sasaki-Tanaka R, et al. J Virol. 2022 Sep 28; Sasaki-Tanaka R, et al. J Virol. 2023 Feb 28; Sasaki-Tanaka R, et al. Int J Mol Sci. 2023 Jun 3; Int J Mol Sci. 2022 May), etc. Although the use of off-label ribavirin for HEV infection was shown to be effective, the development of antivirals against HAV and HEV infection is urgently required. The Japan Agency for Medical Research and Development (AMED) Hepatitis A and E viruses (HAV and HEV) Study Group has recently published the recent advances in research and clinical practice recommendations for hepatitis A. Here, the recent advances in research and clinical practice recommendations for HAV and HEV infections in Japan will be presented.

Management of Hepatic Encephalopathy with Special Reference to Combination Therapy

Dr. Barjesh Chander Sharma
Gastroenterology, GIPMER India

Hepatic encephalopathy (HE) is characterized by wide spectrum of neurological and psychiatric alterations resulting due to advanced liver malfunction. It is a neurological ailment related to hepatic insufficiency and/or portosystemic shunts. Its clinical features include neuropsychiatric dysfunction, ranges from subclinical changes to coma. Overt HE is found in 30–45% of patients with cirrhosis and 10–50% of patients with a transjugular intrahepatic portosystemic shunt (TIPS). Recurrence of HE is seen in 47-57% of patients by the end of one year despite being on treatment. Occurrence of each bout of HE results in increased morbidity, hospitalization, health care burden, poor prognosis and increased mortality. Combination of rifaximin with lactulose has favourable effect on patients with recurrent HE who have recurrent bouts of HE despite on lactulose. Thus, rifaximin along with lactulose should be considered for preventing the recurrent episodes of HE. With use of rifaximin as addition to lactulose for the prophylaxis of third and further episodes of HE, cost can be saved both from a hospital and healthcare payer’s perspective. From healthcare payer’s view, costs raise by adding rifaximin to lactulose is reduced due to improved survival with rifaximin causing relatively low drug and liver transplant related costs. Combination of lactulose plus albumin is also more effective than lactulose alone in the management of overt HE with more decrease in the levels of arterial ammonia, interleukin-6, interleukin-18, tumor necrosis factor-alpha, and endotoxins. Triple combination of L-ornithine L aspartate (LOLA) with lactulose and rifaximin is more efficacious than only lactulose and rifaximin in improving grades of HE, recovery time from HE and with reduced 28-days mortality. In cirrhotic patients with advanced HE adjuvant treatment with LOLA along with lactulose and metronidazole is safe and associated with fast improvement and reduced hospital stay. In conclusion combination therapy including lactulose, rifaximin, albumin and LOLA is effective in the management and prevention of recurrent HE.

Hepatitis B Foundation USA

Hepatitis D virus (HDV) is an RNA “sub-virus” that infects patients with co-existing hepatitis B virus (HBV) infections. HDV burden is estimated to be approximately 15-20 million people worldwide. Despite HDV severity, screening for the HDV remains inadequate. HDV screening would benefit from a revamped approach that automatically reflexes testing when individuals are diagnosed with HBV if HBsAg+, to anti-HDV total and then to quantitative HDV-RNA polymerase chain reaction (PCR) rather than only testing those at high risk sequentially. There are no current treatments in the United States (US) that
are Food and Drug Administration (FDA)-approved for the treatment of HDV; and one approved therapy in the EU by the EMEA with conditional approval; however, bulevirtide and is under review with the US FDA. Current treatment strategies in many countries are centered on the use of pegylated interferon alfa-2a (PEG-IFNa-2a). There are other therapies in development globally that have shown promise, including lonafarnib (LNF) and the NAP: REP 2139. LNF has shown substantial response in the LOWR trials, but trials halted due to some liver toxicity risk. BLV is a well-tolerated drug, but it is not finite therapy and has shown significant on-treatment HDV RNA responses in the multiple MYR clinical trials, and the FDA cited concerns with the manufacturing and patient preparation of the drug that have delayed approval. The PDUFA date for BLV in the US is mid-2024. Current studies with both BLV and LNF are limited in providing sustained virological response (SVR); future trials will need to demonstrate more substantial SVR with possible triple combination trials as options. REP 2139 is in compassionate use trials in the EU region. In summary, HDV/HBV is a very high-risk viral infection and justifies a test all approach and a treat all approach who are HDV RNA+. Interferon remains a global tool for HDV treatment with response rates in the 20% range with newer therapies in evolution.

Others 3. Coinfection of Viral Hepatitis and HIV

Other3-2

Clinical features and vaccine efficacy of hepatitis A virus infection in HIV infection

Dr. Takeya Tsutsumi

Department of Infection Control and Prevention, Department of Infectious Diseases, Faculty of Medicine The University of Tokyo Japan

In 2018, there was an outbreak of hepatitis A virus (HAV) infection in Japan, following outbreaks in foreign countries such as European countries, United States, and Taiwan. Most of infected patients were men who have sex with men (MSM) including human immunodeficiency virus (HIV)-infected patients. HAV is usually transmitted through fecal-oral infection, and the outbreak was probably spread by unique sexual activities of MSM. A similar HAV outbreak was observed among MSM in Japan around 2000. About 20 years passed, and the treatment strategy for HIV infection has been developed, leading to better immunological condition of people living with HIV (PLWH). Accordingly, the clinical presentation of HAV infection in PLWH was different from the previous outbreak.

To prevent HAV infection, HAV vaccine is generally useful. Centers for Disease Control and Prevention (CDC) recommends HAV vaccine for MSM as well as people traveling to endemic countries. However, the efficacy of HAV vaccine to obtain enough anti-HA IgG antibody (anti-HA-IgG) has been shown to be lower among PLWH compared to non-HIV-infected people. It is known that even PLWH who have a good HIV control sometimes cannot respond to other vaccines. Furthermore, compared to healthy people, PLWH have difficulty maintaining sufficient titers of anti-HA-IgG to prevent HAV infection. As mentioned above, the clinical characteristics of HAV infection in PLWH, including my own experience, will be introduced

Dr. Aleksander Krag

Department of Gastroenterology and Hepatology University of Southern Denmark & Odense University Hospital Denmark

Steatotic Liver Disease (SLD), formerly known as fatty liver disease, encompasses a range of liver conditions with fat accumulation in the liver. However, the role of alcohol in the progression and exacerbation of SLD is significant and multi-faceted. Alcohol consumption, particularly chronic and heavy use, directly contributes to the development of Alcohol-Related Liver Disease (ArLD), a subset of SLD. ArLD progresses from simple steatosis (fatty liver) to more severe forms like alcoholic hepatitis, fibrosis, and cirrhosis. The liver, responsible for metabolizing alcohol, undergoes oxidative stress and inflammation due to the toxic metabolites produced during this process. This stress damages liver cells, leading to fat accumulation, inflammation, and eventually scarring. The interplay between alcohol and other risk factors for SLD, such as obesity, metabolic syndrome, and diabetes, can accelerate liver damage. These risk factors are synergistic. Alcohol exacerbates insulin resistance, a key component of metabolic syndrome, which in turn contributes to the progression of Metabolic dysfunction Associated Steatotic Liver Disease (MASLD), another form of SLD. Furthermore, alcohol can influence gut microbiota, affecting metabolic functions and promoting liver inflammation.

The threshold of alcohol consumption that leads to ArLD varies among individuals, influenced by genetic factors, gender, overall health, and concurrent metabolic conditions. This variability complicates the management and prevention strategies for SLD. Biomarkers play a crucial role in diagnosing and managing Alcohol-Related Liver Disease (ArLD). They enable early detection of liver damage, monitor disease progression, and assess the response to treatment.

Management of SLD, particularly ArLD, involves lifestyle interventions with a focus on reducing alcohol intake. Complete abstinence is often recommended for individuals with ArLD, as even moderate alcohol consumption can aggravate liver damage. Moreover, addressing other metabolic risk factors, such as obesity and diabetes, is crucial in managing SLD.

State-of-the Art Lecture

SAL2-1

Can Blood-Based Biomarker HCC Surveillance Replace Ultrasound?

Dr. Tawesak Tanwandee

Department of Medicine Faculty of Medicine Siriraj Hospital, Mahidol University Thailand

Hepatocellular carcinoma (HCC), a leading cause of cancer mortality globally, especially in Asia, often presents at advanced stages with limited therapeutic options. Current surveillance standards recommend ultrasound in conjunction with alpha-fetoprotein, yet the effectiveness of ultrasound is notably reduced in patients with advanced cirrhosis or obesity, and is subject to radiologist interpretative variability. Advances in HCC screening, such as short protocol CT or MRI, demand complex equipment and experienced radiologists.

Recent studies have explored multi-biomarker blood tests (mt-HBT) for HCC surveillance, especially in compensated cirrhosis patients. These include biomarkers like AFP-L3, PIVKAII, and algorithms such as GALAD, GAAD, and ASAP score. Risk-based surveillance approaches have also been investigated for enhanced cost-effectiveness. Additionally, emerging research on cell-free DNA-based tests shows higher specificity for HCC. This body of evidence suggests that mt-HBT significantly outperforms ultrasound in early-stage HCC detection. Hypothetical models indicating improved adherence to blood-based biomarkers further underscore their potential advantages.
These findings could revolutionize HCC surveillance protocols, enhancing detection efficiency and potentially improving long-term patient outcomes. However, current studies have not extensively examined implementation in real-world settings, leaving questions about potential false positives and negatives unaddressed.

In conclusion, while blood-based HCC surveillance appears promising, offering increased sensitivity and reduced interpretative bias, its efficacy in replacing ultrasound as the standard practice requires further validation in real-world applications.

State-of-the Art Lecture
SAL8-1

APASL initiative to reshape the discipline of Hepatology in Asian-Pacific region beyond 2024

Dr. George Lau

Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Hong Kong SAR, China

Till 2023, liver diseases remain a major health threat in Asian-Pacific region, accounting for two-third of the global deaths due to acute-on-chronic liver failure, end-stage liver cirrhosis and hepatocellular carcinoma. The major aetiology of liver diseases are chronic hepatitis B and C, metabolic dysfunction-associated (MAFLD) and alcoholic fatty liver disease (AFLD). Asian-Pacific Association for the Study of Liver (APASL) is the premier Asian-Pacific liver society set up in 1978 aiming to create and to disseminate the best evidence-based clinical knowledge to relieve patients’ suffering from liver diseases. Sharing the same vision, APASL is in alliance with European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD) and Latin American Association for the study of the liver (ALEH). In the past few decades, there have been rapid advancement and availability of laboratory, imaging diagnostic and endoscopic technology, more stringent and transparent conduct of clinical trials, development of sophisticated computation and big data collection (with artificial intelligence-AI) and change in social-economic environment. Very importantly, machine learning (ML) and AI algorithms can help to address data integrity by ensuring consistency and reliability across various data sources and over time. In the age of AI, where machine learning models continuously learn and evolve, maintaining data integrity is not just a one-time effort; it’s an ongoing discipline that requires robust strategies and advanced technological support. New drug development is anticipated to be supercharged with AI. With the digitalisation of medical data, more personalised medical care can be provided to our patients, especially those living in resource-limited areas. With AI-assisted robotics, medical procedures can also be more effectively and safely performed. Skills and knowledge are also necessary to perform ultrasound-based examination for liver and how to read CT-based or MRI-based imaging data. Basic sciences related to laboratory techniques used to provide clinical data should be understood. The application of AI to guide screening, diagnosis and treatment of patients with liver diseases should be enhanced. Therefore, it is now time to reshape the discipline of hepatology to update knowledge and skills which will allow us to advance our clinical management to our patients. Finally, it is of great importance to integrate the art of humanities into medical practise to reshape and modernise professional hepatology discipline with emphasize on empathy, communication, and teamwork.

State-of-the Art Lecture
SAL9-1

AI research for clinical application: from research planning to regulatory approval

Dr. Ryuji Hamamoto

National Cancer Center Research Institute Japan

Expectations for artificial intelligence (AI) have been rising in recent years due to advances in machine learning technology, particularly deep learning, the emergence of inexpensive, high-performance GPUs (Graphics Processing Units), and the expansion of public databases as the Big Data era begins, making it easier to utilize large data sets. In the long history of AI research, however, it has not been smooth sailing. There have been periods of high expectations for AI, known as the “AI boom,” and then a period of “AI winter,” when AI failed to technologically meet those high expectations, leading to widespread disappointment in AI. On the other hand, an important aspect of the third AI boom, which began with the advent of deep learning, is that social implementation is progressing. AI is now being utilized in a wide range of fields, such as face recognition for airport security, automatic translation, automatic voice recognition, and home appliances. The medical field is no exception, and the development of SaMDs (software as medical devices) utilizing AI is underway around the world, and many products have been approved as medical devices and are being used in clinical practice. In 2016, we launched the project “Development of an Integrated Cancer Medical System Using Artificial Intelligence” as a JST CREST research project, and have been working on various medical AI research and development projects. As a result, our AI-based endoscopy diagnosis support software was approved as a medical device in Japan in 2020, and later confirmed to the CE Mark in Europe, and is already in clinical use in Japan and Europe. In addition to AI-based endoscopy-assistive software, the company has also published a variety of other medical AI-related results that have led to clinical applications. In this presentation, I will introduce the current status and future possibilities of medical AI based on our experience in promoting the entire process from research planning to actual clinical application.

State-of-the Art Lecture
SAL14-1

Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma

Dr. Norihiro Kokudo

National Center for Global Health and Medicine Japan

The recent dramatic progress in systemic therapy for hepatocellular carcinoma (HCC) provides the possibility of a combination of surgery and systemic therapy including adjuvant, neoadjuvant, or conversion settings. After the turn of the century, there have been at least three negative studies testing adjuvant therapies after curative resection or ablation, including Uracil-Tegafur an oral chemotherapeutic drug, sorafenib, and peretinoin, a synthetic retinoid that may induce apoptosis and differentiation of liver cancer cells. Using more potent immunotherapy (ICIs), there are at least 4 phase-III trials ongoing for adjuvant immunotherapy: Nivolumab, Durvalumab/Bevacizumab, Pembrolizumab, and Atezolizumab+Bevacizumab. Very recently, the last one showed significantly better RFS for adjuvant Atezolizumab+Bevacizumab. Another promising combination of surgery and systemic therapy is neoadjuvant therapy for potentially resectable cases or conversion strategy for oncologically unresectable cases. There have been 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: LENS-HCC trial using Lenvatinib and RACB study using Atezolizumab+Bevacizumab. Although we may need longer follow-up, OS in resected cases seems...
much higher than that for unresectable cases. Recently, Japan Liver Cancer Association (JLCA) and the Japanese Society of HPB Surgery (JSHPBS) created a joint working group on “so-called borderline resectable HCC.” They compiled a Japanese consensus on this issue and it has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides the common language on advanced HCC for investigators and it is a useful tool for future clinical trials.

Basic and Clinical Research of Cholangiocellular Carcinoma

BCR1-1

Role of pathology in terms of Basic and Clinical Research of Cholangiocellular Carcinoma

Dr. Mina Komuta
Pathology department, International University of Health and Welfare, School of Medicine, Narita Hospital Japan

Cholangiocarcinoma (CCA) harbours actionable mutations in 50% of cases, offering promising treatment options. However, CCA is a heterogeneous tumour driven by the diversity of cholangiocytes, primarily dictated by the size of the bile duct (BD), complicating tumour characterization. Cholangiocytes, lining the epithelia of the biliary tree, exhibit distinct phenotypes based on BD size: cuboidal-shaped cholangiocytes line the small BD without apparent mucin production, while cylindrical cholangiocytes with mucin production cover the large BD. Intrahepatic CCA (iCCA) is categorized into two subgroups: the large and small BD types. As cancer maintains the phenotype of its cell of origin, both iCCA subtypes display disparate features in terms of clinical, pathological, and genetic characteristics. Accounting for these differences is crucial in research endeavours. Additionally, the large duct type of iCCA shares clinical, pathological, and molecular features with extrahepatic CCA (eCCA). This is because both CCA originate from the similar cell of origin which are mucin-producing cylindrical cholangiocytes in the intra-, and the extrahepatic BD. In contrast, the small duct type of iCCA exhibits tumour heterogeneity, posing challenges in distinguishing it from other primary liver cancers such as hepatocellular carcinoma (HCC) and combined HCC-CCA, particularly in certain circumstances. This heterogeneity is particularly relevant for characterizing perihilar CCA and understanding its origin. Furthermore, it should be noted that CCA is an adenocarcinoma, a frequent histological subtype of metastatic liver cancer. Distinguishing between primary and metastatic lesions is crucial. Based on these different characteristics, it is essential to be aware of this point to avoid inaccurate data assessment. In my presentation, I will clarify the phenotypes of primary liver cancers (HCC, eHCC-CCA, and iCCA) and subsequently focus on iCCA phenotypes to highlight their distinctions. This analysis will be linked to treatment selection, including the identification of actionable mutations before genetic investigation.

Basic and Clinical Research of Cholangiocellular Carcinoma

BCR1-2

Current diagnosis of intrahepatic cholangiocarcinoma -From tumor localization to genetic abnormalities-

Dr. Tatsuya Kakegawa
Gastroenterology & Hepatology, Tokyo Medical and Dental University (TMDU) Japan

The incidence of intrahepatic cholangiocarcinoma(ICC) is increasing, with the highest rates seen in Eastern Asia when compared with Western countries. It is asymptomatic in the early stages, and about 20% of ICC are diagnosed incidentally, and no effective screening method has been established yet. It is important to know risk factors including primary sclerosing cholangitis and non-bile duct specific diseases as chronic hepatitis C virus and hepatitis B virus infection, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alcoholic liver disease, and autoimmune hepatitis. Screening these populations by clinical examination, tumor markers, and abdominal ultrasound may aid in early diagnosis. On clinical examination, persistently elevated bilirubin levels, hepatobiliary enzymes, and the tumor markers CA19-9 and CEA are useful for auxiliary diagnosis. Contrast-enhanced CT(CECT) is widely used for differential diagnosis and localization evaluation of ICC from the viewpoints of simplicity, dissemination, and cost. Also Gd-EOB-DTPA contrast-enhanced MRI is useful for localization diagnosis because it shows the tumor as a clear low-signal area in the hepatocellular phase. The Kupffer phase of contrast-enhanced US(CEUS) depicts the tumor as a clear defect image, and its detection sensitivity is reported to be high. However, CEUS is only an adjunct to CECT and MRI due to the presence of blind spots and reproducibility problems. The most common extra-hepatic metastases of ICC are lung, bone, and distant lymph node metastases. The advantage of FDG-PET/CT is that it allows systemic search for these metastases in a single examination. Meta-analysis shows that "vascular invasion" is one of the prognostic factors, and it is important to accurately determine the presence or absence of vascular invasion. EUS is excellent for the diagnosis of hilar cholangiocarcinoma and is particularly useful in predicting the extent of bile duct invasion in cases of specific resection. Cholangiography has good spatial resolution and is useful in diagnosing the extent of cancer invasion. In ICCs near the porta hepatitis, mapping biopsy under direct view with cholangioscopy can diagnose the extent of bile duct invasion and reduce the number of positive cases of surgical resection margins. Liver tumor biopsy is also an option for atypical cases on imaging and for non-resected cases that require systemic therapy. Biopsy can help identify ICC-specific driver gene abnormalities, such as FGFR2 fusion gene and IDH1/2 mutations, and aid in the selection of therapeutic agents.
The new concept of neo-adjuvant therapy after resection has opened the new horizon in the liver cancer management. Recently, adjuvant therapy has been proposed to prevent tumor recurrence after surgery. This might be a promising concept for the future beyond the guidelines. It would still need further and larger study to conclude that this concept would be incorporated in the clinical practice guideline.

### Evaluation of data from the A-HOC (APASL Hepatology/Oncology Consortium) study of patients with hepatocellular cancer in Turkey

**Dr. Muhsin Murat Muhip Harputluoglu**

University Medical Faculty Liver Transplant Institute, Transplant Hepatology and Gastroenterology Dept Turkey

A-HOC (APASL Hepatology/Oncology Consortium) study is the abbre-viated name of study of 'Survey on Current Status and Treatment of Hepatitis and Liver Cancer in the Asia-Pacific Region'. This inter-national multicenter study examines the actual incidence and treatment of hepatocellular cancer in Asia Pacific countries, the background of viral and non-viral hepatitis, the actual situation of health and medical problems, and the development of new treatment methods in each country.

Aim of this presentation is to evaluate Turkey data in the A-HOC study. Basic patient data, physical examination findings at the time of carcinogenesis, tumor characteristics, treatment methods and dates and prognostic informations of the patients entered into the A-HOC REDCap system from centers in Turkey were analyzed.

### Comprehension of Asian HCC by A-HOC Study and APASL HCC Guideline

**HOC1-4**

### Innovation on Clinical Management of Hepatocellular Carcinoma in the era of Systemic Therapy

**Dr. Cosmas Rinaldi Adithya Lesmana**

Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Indonesia

Hepatocellular carcinoma (HCC) is still becoming a major burden all over the world due to increase of metabolic liver disease despite hepatitis virus B and C infection. Metabolic dysfunction associated fatty liver disease (MAFLD) is an emerging disease, where it can lead to portal hypertension, liver cirrhosis, as well as liver cancer development. Most of the patients have come in the late stage of the disease. Therefore, early detection is still the main key for a success disease control and prolong patient's survival, however, in the case of MAFLD, it is not always easy to find early cancer development due to standard screening methods limitations. Innovation in endoscopic ultrasound (EUS) can be a promising secondary tool not only for confirming diagnosis, but also in the advance management.

Surgical approach is still the best treatment for managing liver cancer, however, the post-surgical recurrence rate is still high. In the interme-diate stage of HCC, the combination of loco-regional therapy with immunotherapy as well as oral systemic therapy have shown a satisfaction result when compared to loco-regional therapy alone.

### Advances in Hepatobiliary Imaging

**AH11-2**

#### Applications of artificial intelligence for hepatobiliary MR imaging

**Dr. Keitaro Sofue**

Department of Radiology Kobe University Graduate School of Medicine Japan

Global interest in artificial intelligence (AI) applications for MR imaging is growing rapidly, fueled by significant advances in computing power and new deep learning algorithms. Recently, deep learning reconstruction (DLR) algorithms have been developed for MR that are trained to improve image quality, and the combination of DLR with various sequences has produced favorable results in hepatobiliary MR imaging. DLR has been proven successful in reconstructing MR images with a high signal-to-noise ratio from undersampled k-space data to reduce acquisition times while maintaining high image quality. Additionally, a newly developed deep learning reconstruction method for upsampling resolution of low-resolution (superresolution) has been imple-mented into the MR machine. These DLR algorithms may help to improve visualization and characterization of hepatobiliary diseases. In this presentation, I would like to present our attempts to apply AI to improve image quality for hepatobiliary MR imaging.

### Big Data and AI for Hepatology

**BD1-1**

#### The usefulness of AI for tumor microenvironment analysis in HCC

**Dr. Hitoshi Mochizuki**

Genome Analysis Center / Department of Gastroenterology, Yamanashi Central Hospital Japan

Introduction: The tumor mass consists not only of a heterogeneous population of cancer cells but also a variety of resident and infiltrating host cells, secreted factors, and extracellular matrix proteins, collectively known as the TME(tumor microenvironment). The recent advances in machine learning are essential to elucidate what cells make up a TME and how these cells change and organize into different cellular communities in response to the signaling environ-ment.

Aims: In this study, we will evaluate TME based on DNA and RNA analysis and compare HCC with other cancer types, predict the efficacy of immune checkpoint inhibitors, and discuss issues in evaluating TME.

Methods: DNA and RNA were extracted from 441 surgical samples of Tumor (including 333 HCCs) during treatment. T cell prevalence can be estimated (General Additive Model) by se-queencing the rearranged T cell receptor-α gene (T Cell ExTRECT). Transcriptome analysis makes it possible to estimate the abundance of cells with well-known mRNA expression profiles, such as immune cells, from bulk RNAseq data (CIBERSORT: 22 cell types, xCell: 64 cell types).
Moreover, we analyzed using EcoTyper, a machine-learning framework for large-scale identification and validation of cell states and multicellular communities from bulk, single-cell, and spatially resolved gene expression data.

**Results:** The use of AI in TME Analysis of Tumors elucidates fundamental units of cellular organization in HCC and provides a framework for large-scale profiling of cellular ecosystems in any tissue. From a real-world clinical perspective, it was also shown that irAE caused by ICI (Immune Checkpoint Inhibitors) is caused in specific clusters.

**Big Data and AI for Hepatology**

**BD1-4**

**Application of Machine Learning in the Diagnosis and Management of Liver Disease**

**Dr. Masaya Sato**

Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Japan

While there has been significant progress in developing therapies for liver diseases, the prognosis for hepatocellular carcinoma (HCC), especially in advanced-stage patients, remains very poor. Artificial intelligence (AI), which combines computer science and mathematics, involves creating computer algorithms to improve the performance of computer programs. It does this by using various data sources and employing analytical or probabilistic models. The intersection of machine learning (ML) and the medical field has great potential to revolutionize diagnostic methods, particularly in laboratory medicine. Because liver diseases are complex and multifaceted, an ML approach that integrates multiple factors seems promising. This approach aims not only to improve diagnostic accuracy but also to predict how patients will respond to treatment and their future prognosis. Electronic medical records contain a wealth of data crucial for advancing medical research. By using AI and ML techniques and incorporating various factors into the analysis, we can enhance the precision of decision-making processes. This not only refines diagnostic accuracy but also helps predict outcomes in the intricate network of factors associated with liver diseases. In this presentation, we will explore the potential use of AI and laboratory medicine in the field of liver disease.

Gilead

**I-2**

**Secondary Prevention of HBV-Related HCC**

**Dr. Young-Suk Lim**

Department of Gastroenterology Asan Medical Center, University of Ulsan College of Medicine Korea

Recently we analyzed the association between a broad range of serum HBV DNA levels and long-term HCC risk in a total of 6949 HBeAg-positive and HBeAg-negative, non-cirrhotic, treatment-naïve CHB patients who are not generally indicated for antiviral therapy by current practice guidelines because of no significant ALT level elevation. We found that the association between HBV DNA levels and HCC risk is not linear but parabolic in these patients. The HCC risk was highest at moderate HBV DNA levels around 6 log10 IU/mL, with decreasing HCC risk at higher and lower HBV DNA levels. Very high HBV DNA levels (>8 log10 IU/mL) showed the lowest HCC risk which was not significantly different from that of very low HBV DNA levels (≤4 log10 IU/mL).

Our additional studies have demonstrated that the level of serum HBV DNA at baseline impacts the on-treatment risk of HCC in non-cirrhotic patients with CHB. We found that patients with moderate baseline viral load, particularly around 6 log10 IU/mL, demonstrated the highest on-treatment HCC risk, despite long-term antiviral treatment. Compared with the matched untreated patients, the treated patients in the high and moderate viral load groups had a significantly lower risk of HCC. Nonetheless, the reduced risk of the treated patients in the moderate viral load group was significantly higher than that of the treated patients in the high viral load group. Initiating antiviral treatment at either high (≥8.00 log10 IU/mL) or low (3.30–4.99 log10 IU/mL) viral loads was associated with a significantly lower on-treatment risk of HCC compared to starting the treatment at a moderate baseline viral load (5.00–7.99 log10 IU/mL).

Therefore, early initiation of antiviral treatment with a high viral load (>8.00 log10 IU/mL) may maintain the lowest risk of HCC in those patients.

**References:**


**Abstracts**

**Young Investigator Workshop**

Abstract Submission No. 101132

**WS-001**

**Safety and Efficacy of Microwave ablation to HCC**
Yoshimi Yukawa-Muto1, Sawako Uchida1, Hiroko Ikenaga1, Naoshi Odaigiri1, Kohei Kotani1, Hiroyuki Motoyama1, Etsushi Kawamura1, Atsushi Hagiha1, Hideki Fujii1, Masaru Endo1, Norifumi Kawada1

Abstract Submission No. 101623

Background: We started using microwave ablation (MWA) in December 2019 and its use is increasing (43.3% of all ablation treatments in 2023). We reviewed the safety and efficacy of 47 nodules in 43 patients who underwent MWA in our department.

Methods: We assessed 1) frequency of sedation and complications, 2) complications from MWA treatment, and efficacy by 3) effectiveness determination after treatment, 4) local recurrence, and 5) comparison with RFA during the same period (n=76).

Results: Patients (n=43) had a median age of 75 (58-88) years, 60% male, background liver HBV/HCV/alcohol/other 7/23/7/6, first/recurrence 10/33. Nodules (n=47) had a mean diameter of 18.9±6.6 mm, left lobe/right lobe 8/39, internal/surface 26/21, with/without artificial ascites during MWA treatment 22/25. 1) Sedation was used in 21 patients (48.8%), with a mean dose of midazolam 1.9 mg. There were no complications due to sedation. 2) After MWA treatment, one patient developed an abscess in the treated area. 3) We had two residual cases with RFA during the same period (n=76). 4) The median nodule diameter was 18 (7-33) mm in the RFA group, which was significantly larger in the MWA group (p<0.001), but there was no difference from MWA treatment, and efficacy by 3) effectiveness determination after treatment, 4) local recurrence, and 5) comparison with RFA during the same period (n=76).

Conclusion: MWA is a safe and effective treatment method. Factors related to local recurrence could not be identified, so further follow-up are needed.

Abstract Submission No. 101623

WS-002

A prospective study of cardiohemodynamic profile changes in acutely decompensated cirrhosis and ACLF

Andrei Voiousu1,2, Victor Dragan1, Mihaela Birligea1, Anecta Vijan4, Caterina Delea4, Paul Balanscu2, Theodor Voiousu2, Andreia Bengus2, BogdanMateescu2, Ioana Daha2, Cristian Baicu6

1Dept. of hepatology, Osaka Metropolitan University Graduate School of Medicine Osaka Japan

Background: Microwave ablation (MWA) is a safe and effective treatment method. Factors related to local recurrence could not be identified, so further follow-up are needed.

Methods: This is a prospective, observational, follow-up study including patients admitted for acutely decompensated (AD) cirrhosis in a tertiary referral center. We performed ECG, echocardiographic assessment of cardiac function, and serum biomarker analysis (proBNP, TNF-a, Growth Arrested Specific-6, IL-6) at 3 time points: admission, 5-7 days later, and at one month. The main outcomes were mortality at one and 3-months. We explored serological and echocardiographic biomarkers of cardiac dysfunction to establish a cardiohemodynamic risk profile.

Results: A total of 1358 PSC cases reported from 299 hospitals were included. The prevalence of PSC from 2000 to 2023 was estimated to be 2.36 (95% CI: 1.82, 3.34) per 100,000. Males bore a relatively higher PSC prevalence than females (2.56 vs. 2.14 per 100,000). The prevalence of PSC more than doubled after 2010 than that before 2010 (1.68 vs. 0.67 per 100,000). Geographic distribution revealed the highest prevalence of PSC was in East China and the lowest in South China.

Conclusion: Comprehensive clinical-biological work-up of cardiohemodynamic status in acute decompensation of cirrhosis helps predict outcome. Median blood pressure is a simple indicator of increased risk for early death.

Funding: This work was supported by a grant of the Ministry of Research, Innovation and Digitization, CNCS – UEFISCDI project number PN-III-P.1-1.1-PD-2021-0180, within PNCDI III.

Abstract Submission No. 101109

WS-003

Prevalence and clinical profiles of primary sclerosing cholangitis in China

Xiaoqian Xu1,3, Tongtong Meng1,2, Weijia Duan1,2, Junqi Niu1,4, Huiguo Ding5, Wen Xie1,6, Lu Zhou1, Bangmao Wang7, Jie Li8, Lingyi Zhang9, Xiaojuan Ou10, Xinyan Zhao10, Hong You10, Jidong Jia10,1, Yuanyuan Kong10,2

1National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University Beijing China, 2Clinical Epidemiology and EBM Unit, Beijing Clinical Research Institute Beijing China, 3Liver Research Center, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University Beijing China, 4Hepatology Department, Center of Infectious Diseases and Pathogen Biology, First Hospital of Jilin University Changchun China, 5Department of Hepatology and Gastroenterology, Beijing You’an Hospital, Capital Medical University Beijing China, 6Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 7Department of Gastroenterology and Hepatology, Tianjin Medical University General Hospital Tianjin China, 8Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing China, 9Department of Hepatology, Lanzhou University Second Hospital Lanzhou China

Background: Epidemiology of primary sclerosing cholangitis (PSC) is completely lacking in China. We aimed to investigate the prevalence by sex, time period, geographic distribution, and to depict the clinical features of PSC in China.

Methods: PSC cases reported during 2000 to 2023 in China were identified and included from two data sources: electronic medical records and systematical literature retrieval. The period prevalence of PSC in the general population was indirectly estimated using the multiplier method based on hospital-specific and nationwide clinic volumes.

Results: A total of 1358 PSC cases reported from 299 hospitals were included. The prevalence of PSC from 2000 to 2023 was estimated to be 2.36 (95% CI: 1.82, 3.34) per 100,000. Males bore a relatively higher PSC prevalence than females (2.56 vs. 2.14 per 100,000). The prevalence of PSC more than doubled after 2010 than that before 2010 (1.68 vs. 0.67 per 100,000). Geographic distribution revealed the highest prevalence of PSC was in East China and the lowest in South China.
Abstract Submission No. 102001  
**WS-004**  

**Preoperative Inflammatory Biomarker Analysis as a Predictor toward Hepatocellular Carcinoma Survival**

Muhammad Bilal Saifulhaq¹, Tohari Amin¹, Syifa Mustika², Shinta Oktya Wardhani³  
¹Internal Medicine Department, Saiful Anwar Regional Hospital and Brawijaya University, Malang Indonesia  
²Malang Indonesia  
³Brawijaya University, Malang Indonesia

**Background:** An elevated systemic inflammatory response (SIR) is associated with reduced survival in patients with operable cancer like hepatocellular carcinoma (HCC). This study aimed to determine whether SIR biomarker analysis obtained from routine preoperative blood tests can be used to predict overall survival in HCC patients who undergo surgery.

**Methods:** This comprehensive study was conducted according to the Preferred Reporting Items for Systematic-Reviews and Meta-Analysis (PRISMA) guidelines. We systematically searched ScienceDirect, Pubmed, Cochrane Library, ProQuest, and Google Scholar databases until the end of October 2023. We collected articles on real-world studies comparing systemic inflammatory response syndrome (SIRS) events after surgical treatment for predicting the overall-survival rate in patients with HCC. Pooled mean differences (MD) and 95% confidence Interval (CI) were used to determine overall events.

**Results:** Of 61 articles were included for this meta-analysis, there was a significant relationship between elevated C-reactive protein (CRP) (p<0.0001), C-reactive-protein-to-albumin ratio (CAR) (p<0.0001), Glasgow Prognostic Score/Modified Glasgow Prognostic Score (GPS/mGPS) (p<0.0001), Lymphocyte-to-CRP ratio (LCR) (p<0.005), Lymphocyte-to-monocyte ratio (LMR) (p<0.0001), Neutrophil-to-lymphocyte ratio (NLR) (p<0.0001) in a HCC patient who had bad overall-survival. We also conducted subgroup analysis by country associated with inflammatory markers and their correlation to mortality rate. Subgroup analysis was performed to eliminate any potential factors that might be caused by different heterogeneity levels.

**Conclusions:** These results consolidate the prognostic value of the CRP, CAR, GPS/mGPS, LCR, LMR, and NLR in patients with HCC. This is particularly true for the SIR biomarker analysis should form part of the routine preoperative and postoperative workup.

Abstract Submission No. 100489  
**WS-006**

**Prevalence, Risk Factors, and Clinical Outcomes of Infections in Acute Decompensation of Cirrhosis**

Nipun Verma¹, Pratibha Garg¹, Archana Angrup², Neelam Taneja³, Arun Valsan¹, Venkata Divakar Reddy⁴, Jayant Aggarwal⁵, Roma Chaudhary⁶, Parminder Kaur⁷, Sahaj Rathi⁸, Arka De⁹, Madhumita Premkumar¹⁰, Sunil Taneja¹¹, Ajay Duseja¹²

¹Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India  
²Chandigarh India,  
³Department of Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India  
⁴Chandigarh India,  
⁵Chandigarh India  
⁶Chandigarh India

**Background:** This study delved into cirrhosis-related infections to unveil their epidemiology, risk factors, and implications for antimicrobial decisions.

**Methods:** We analyzed acutely decompensated cirrhosis patients (n=971) from 2013-2023 at a tertiary center. Microbiological and clinical features based on infection sites (EASL criteria) and patient outcomes were assessed.

**Results:** Median age was 45 years; 87% were males with 47% having alcoholic hepatitis. Of these, 675 (69.5%) had infections; 305 (45%) were culture-confirmed. Notably, 71% of confirmed cases were MDRO-related, chiefly carbapenem-resistant (48%). MDRO prevalence was highest in pulmonary (80.5%) and skin-soft-tissue infections (76.5%). Site-specific distribution and antimicrobials were suggested. Predictive models identified hospitalization (OR:2.23), norfloxacin prophylaxis (OR:2.26), prior broad-spectrum antibiotic (BSAbx) exposure (OR:1.61), SIRS (OR:1.75), procalcitonin (OR:4.64), and End-stage (OR:1.41), with an AUC of 0.891 for infection prediction. For MDRO infection prediction, second infection (OR:7.19), norfloxacin prophylaxis (OR:2.76), prior BSAbx (OR:1.66), rifaximin (OR:0.44), CLIF-C-OF (OR:1.10), multi-site (OR:3.67), and polymicrobial infections (OR:4.55) yielded an AUC of 0.779 and 93% specificity. Norfloxacin prophylaxis, multisite infection, mechanical ventilation, prior BSAbx exposure, and infection as acute precipitant predicted carbapenem-resistant infection (AUC: 0.821).

Abstract Submission No. 101167  
**WS-005**

**Deficient Hepatic Canalicular Exporter Proteins Associated with Chronic Drug-Induced Liver Injury**

Chhagan Bihari¹, Apoorv Giri¹, Archana Rastogi¹, Shiv Sarin¹

¹Institute of Liver and Biliary Sciences, Delhi Delhi India

**Introduction:** Inhibitory effects of various drugs on canalicular exporters can cause severe drug-induced liver injury (DILI). This study aimed to assess the canalicular exporters in liver biopsies of DILI and its association with chronic DILI.

**Patients and Methods:** Cases with the clinicopathological diagnosis of DILI with liver biopsies from January 2016- Dec 2020 were included in this study. Clinical and laboratory information were recorded. Immunohistochemically, BSEP, MDR3, and MRP2 were assessed. Chronic DILI was considered as biochemical nonresolution after six months of discontinuation of the drugs.

**Results:** 379 of 405 cases were analyzed (26 excluded due to incomplete data). Chronic DILI was noted in 41 patients (10.8%), and commonly implied drugs were complementary and alternative medicine (66%), antimycobacterial (6%), and antibiotics (5%). At least one transporter loss of expression (51 patients) was more in cases that had chronic DILI (27/41 (52.9%) vs 24/338 (7.1%), p<0.001). More than one deficient transporter in zone 2 and 3 (23 patients) was more pronounced in chronic DILI (19/41 (44%) vs. 4/338 (1.1%), p<0.001). Bile acids levels were higher in cases with deficient transporter expression (273, (IQR: 219-369) vs 98 (IQR: 72-183) micromol/L, P<0.001) and more prominently in those developed chronicity (354, (IQR: 305-439) vs 126 (IQR: 73-193) micromol/L, P<0.001). In the liver biopsies at baseline, mixed and cholestatic pattern (p=0.015), ductular, and canalicular cholestasis (p=0.001) were prominent, whereas fewer eosinophils (p=0.02) in those who developed chronic DILI.

**Conclusions:** Deficient expressed canalicular exporters and elevated bile acids were noted in DILI cases that progressed to chronic DILI.
Infections (culture-proven or probable), MDROs, carbapenem/pan- 
drug resistance, and second infections independently linked with mor-
tality (p<0.001), adjusted for age, leucocytosis, and organ failures. A 
model incorporating age (HR:1.02), infection (HR:1.52), prior hospi-
talization (HR:5.33), norfloxacin (HR:1.29), multisite infection 
(HR:1.47), and CLIF-C-OF (HR:1.17) predicted mortality with C-sta-
tistics of 0.782 (p<0.05).

Conclusion: High MDRO burden, especially carbapenem-resistant, 
necessitates urgent control measures in cirrhosis. Site-specific epide-
miology and risk models can guide empirical antimicrobial choices in 
cirrhosis management.

Background: This study delved into cirrhosis-related infections to un-
veil their epidemiology, risk factors, and implications for antimicrobial 
decisions.

Methods: We analyzed acutely decompensated cirrhosis patients 
(n=971) from 2013-2023 at a tertiary center. Microbiological and clin-
ical features based on infection sites (EASL criteria) and patient out-
comes were assessed.

Results: Median age was 45 years; 87% were males with 47% having 
alcoholic hepatitis. Of these, 675 (69.5%) had infections; 305 (45%) 
were culture-confirmed. Notably, 71% of confirmed cases were 
MDRO-related, chiefly carbapenem-resistant (48%). MDRO preva-
ience was highest in pulmonary (80.5%) and skin-skin-tissue infections 
(76.5%). Site-specific distribution and antimicrobials were suggested. 
Predictive models identified hospitalization (OR:2.23), norfloxacin 
prophylaxis (OR:2.26), prior broad-spectrum antibiotic (BSAbs) ex-
posure (OR:1.61), SIRS (OR:1.75), procalcitonin (OR:4.64), and HE-
grade (OR:4.1), with an AUC of 0.891 for infection prediction. For 
MDRO infection prediction, second infection (OR:7.19), norfloxacin 
prophylaxis (OR:2.76), prior BSAbx (OR:1.66), rifaximin (OR:0.44), 
CLIF-C-OF (OR:1.10), multi-site (OR:3.67), and polymicrobial infec-
tions (OR:4.55) yielded an AUC of 0.799 and 93% specificity. Nor-
flroxacin prophylaxis, multisite infection, mechanical ventilation, prior 
BSAbs exposure, and infection as acute precipitant predicted car-
banem-resistant infection (AUC:0.821).

Infections (culture-proven or probable), MDROs, carbapenem/pan-
drug resistance, and second infections independently linked with mor-
tality (p<0.001), adjusted for age, leucocytosis, and organ failures. A 
model incorporating age (HR:1.02), infection (HR:1.52), prior hospi-
talization (HR:5.33), norfloxacin (HR:1.29), multisite infection 
(HR:1.47), and CLIF-C-OF (HR:1.17) predicted mortality with C-sta-
tistics of 0.782 (p<0.05).

Conclusion: High MDRO burden, especially carbapenem-resistant, 
necessitates urgent control measures in cirrhosis. Site-specific epide-
miology and risk models can guide empirical antimicrobial choices in 
cirrhosis management.

Abstract Submission No. 101913

WS-008

Bacterial Vesicle Cargos induces Systemic Inflammation and 
hepatic Injury in Autoimmune Hepatitis

Swati Thangariyal1, Ashmit Mittal1, Anupama Kumari1, 
Chhagan Bihari1, Shiv Kumar Sarin1, Sukriti Baweja1

1Institute of Liver and Biliary Sciences Delhi India

Background: In autoimmune hepatitis (AIH), there is a growing em-
phasis on the pivotal role of the gut-liver axis, as attention turns toward 
microbial dysbiosis as a driving force in AIH pathogenesis. It is under-
stood that the bacterial microbiota promotes local and systemic inflam-
mation, which can promote inflammation in AIH. We propose that 
Bacterial vesicles(BV) as mediator of AIH, due to their potent immune 
stimulator composition and capability to influence inflammation.

Method: BVs isolated from AIH plasma [n=61, biopsy-proven, (HAI) 
score ≥2] and healthy control plasma (HC) n=30 was characterized by 
TEM, NTA, western blot and proteomics. Further, AIH and HC BV 
were adoptively infused intravenously in C57BL/6j female mice to de-
termine if BVs contribute to the acceleration and exacerbation of in-
flammation and hepatic injury.

Result: BVs were significantly higher in AIH patients than HC [10.5 
vs 3.7; p=0.003, 87.7 vs 10.3; p=0.015] the AIH BVs progressively 
increase with increasing HAI score[ r=0.62; p<0.001], transami-
nases{ALT, AST [r=0.59;p=0.001; r=0.57;p=0.001]} and IgG antibod-
ies[r=0.37;p=0.018]. The proteomics of AIH BV revealed >10-fold in-
crease in immunoglobins and complement-associated proteins includ-
ing complement C3, GAPDH, Transmembrane glycoprotein with 5 vir-
ulence factors having epitope mimicry helping in immune modulation 
and Adherence. miPreBase mapping identified an experimentally ver-
ified peptide sequence IYQIDNHQQARKPIAD of methyltransferase 
family mimicking component of pyruvate dehydrogenase complex of 
the host mitochondria. Upon, AIH-BV administration in mice within 
12h, the liver enzymes and liver weight index were elevated 
[AST(p=0.0286);ALT(p=0.0452); Li[ p=0.008)] than HC-BV. The 
liver histology showed raised focal acute inflammation in AIH-BV 
versus than HC-BV(p<0.001) with significantly high infiltration of 
F4/80 macrophages and Ly6G+ neutrophils in the liver (p<0.001).

Conclusion: The data suggests that BVs cargoes potentiates in pro-
moting systemic inflammation which could contribute to the develop-
ment and severity of AIH condition. These findings offer new insights 
into the role of BVs in microbiota-host interactions in AIH.
The impact of metabolic dysfunction on mortality in chronic hepatitis B with steatotic liver disease

Shang-Chin Huang1,2,3,4, Tung-Hung Su1,3, Tai-Chung Tseng1,5, Sih-Han Liao4, Shih-Jer Hsu4, Chun-Ming Hong4, Ting-Yuan Lan5, Chen-Hua Liu1,2,3, Hung-Chih Yang6, Chun-Jen Liu6, Pei-Jer Chen4, Jia-Hong Kao8

1Department of Internal Medicine, National Taiwan University Hospital, 2Division of Gastroenterology and Hepatology, National Taiwan University, 3Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, 4Department of Medical Research, National Taiwan University Hospital Taipei Taiwan, 5Department of Rheumatology, National Taiwan University Hospital.

Background: Steatotic liver disease (SLD), including metabolic dysfunction-associated steatotic liver disease (MASLD), is prevalent in the chronic hepatitis B (CHB) population. However, the impact of SLD subtypes on all-cause/cause-specific mortality among these patients remains unknown.

Methods: CHB patients with concurrent SLD were consecutively recruited at the National Taiwan University Hospital. MASLD, alcohol-associated liver disease (ALD), and crypto SLD were defined by the newly-proposed criteria. Cumulative incidences of all-cause and cause-specific mortality were compared after accounting for competing risks.

Results: From 2006 to 2021, 8,773 CHB patients with SLD were included. At baseline, CHB patients with concurrent MASLD (n=6,562) or ALD (n=55) were older, had a lower proportion of HBeAg positivity and lower levels of HBV DNA than crypto SLD patients (n=2,156). After a median follow-up of 9.1 years, ALD (adjusted HR [aHR]: 11.80, 95% CI: 5.89-23.60, p<0.001) and MASLD patients (aHR: 1.79, 95% CI: 1.24-2.58, p=0.002) had higher all-cause mortality risks than those with crypto SLD after adjustment for clinical and viral factors. Furthermore, cumulative metabolic dysfunctions, defined by the cardiometabolic criteria of MASLD, increased the risks of all-cause, liver-related, non-liver cancer, and cardiovascular mortality with a dose-dependent effect, contributing to the higher risks in MASLD than crypto SLD patients.

Conclusions: Among CHB patients with hepatic steatosis, concurrent ALD and MASLD increase the risk of all-cause mortality, and cumulative systemic metabolic dysfunctions dose-dependently increase all-cause and various cause-specific mortality. Refraining from alcohol intake and managing these metabolic risk factors are crucial for better survival in CHB patients.

Interferon reduce hepatocellular carcinoma risk in high-risk Asian patients with chronic hepatitis B

Qiran Zhang1, Feng Sun1, Yiqi Yu1, Ruirui You1, Yulei Sun1, Chao Qiu1, Jiming Zhang1, Wenhong Zhang1

1Huashan Hospital, Department of Infectious Diseases Shanghai China

Objective: To demonstrate the efficacy of pegylated interferon-α (PegIFNα)-based therapy and nucleoside analog (Nuc) in reducing hepatocellular carcinoma(HCC) risk in High-risk Asian patients with chronic hepatitis B.

Methods: The analysis was conducted in the data from a multi-center, prospective real-world study (OASIS Project) from China which started recruiting from October, 2020. Data on those who have completed 48 weeks of treatment and uploaded complete laboratory testing data were analyzed. Each patient was evaluated by algorithms that have been proven of good performance in Asian patients, including aMAP score, modified PAGE-B score and Toronto HCC Risk Index (THRI) if there was cirrhosis simultaneously, and the highest risk level was taken.

Results: A total of 8364 patients with PegIFNα-based therapy and 3422 with Nuc treatment were analyzed. At baseline, 52.60%, 39.90%...
and 7.50% of patients in IFN group were stratified into low-risk, intermediate-risk and high-risk for HCC, respectively. And in Nuc group, the ratio was 43.40%, 37.80% and 18.80%, respectively. After 48-week treatment, 21.3% of high-risk patients in IFN group changed into intermediate-risk, and 14.9% in Nuc group (Figure 1) changed. In Nuc group, the 1-year HCC incidence was higher in high-risk population (0%, 0.2%, 0.9% in low, intermediate and high risk, respectively, P=0.001). While in IFN group, the 1-year HCC incidence was similarly low in-risk and other population (0.1%, 0.1% and 0.3%, P=0.194).

Conclusions: Anti-viral treatments reduce the HCC risk in HCC patients, and IFN-based therapy seems superior.

Abstract Submission No. 100380

Optimizing a hepatitis C screening model for general population using easily accessible data

Chi Zhang1, Yiqi Liu1, Xinghua Fu1, Ao Jia1, Wanwan Shi1, Yanjie Lin1, Long Xu1, Hong Zhao1,2, Guiqiang Wang9

1Peking University First Hospital Beijing China, 2Peking University International Hospital Beijing China

Background: Globally, an estimated 58 million chronic hepatitis C virus(HCV) infections. Direct-acting antiviral medicines(DAAs) can cure more than 95% of persons with HCV infection, but access to diagnosis(20%) and treatment(15%) was low. We aimed to develop screening algorithms that accurately identifies HCV infection using easily accessible demographic parameters.

Methods: We obtained data from population-based cohorts National Health and Nutrition Examination Survey(NHANES 1990-2020), and divided them into training(6-cycles; n=46243) and testing(5-cycles; n=37060) cohort. Then, we applied logistic regression to calculate the odds ratio(OR) of 4 demographic factors(sex, ethnicity, blood transfusion history, birth year) for diagnosing HCV infection. Next, we developed and compared 9 machine learning(ML) algorithms to diagnose HCV infection in training cohort. Finally, we adopted the selected algorithm to establish the diagnostic model and test the performances.

Results: The overall cohort(n=83303) was 49.0% male; 37.9% White, 23.2% Black, 29.0% Hispanic, and 10.0% other; 8.8% of participants had a history of blood transfusion; with a mean birth year of 1972±23. The positive rates of anti-HCV and HCV RNA among studied population were 1.3% and 0.8%(unweighted). In multivariate analysis, all four parameters were significantly correlated with HCV infection: male sex(OR 2.01; P=0.001); Black versus White(OR 1.96; P=0.008); blood transfusion history(OR 2.14; P=0.001); born 1970 and before(OR 8.98; P=0.001). Comparing the AUC values of 9 ML algorithms in the training cohort, XGBoost was selected as the best prediction model. The AUC of the XGBoost model for diagnosing HCV infection was 0.891(95%CI 0.880-0.903) for the training set. In the testing set, the AUC was 0.843(0.827-0.858), and the sensitivity, specificity, PPV and NPV were 0.78, 0.78, 0.288 and 0.967, respectively.

Conclusions: To predict HCV infection in general population, only 4 easily obtained demographic features are needed using our ML model.

Abstract Submission No. 100555

WS-014

RISK FACTORS AND PROGNOSIS AFTER PRIMARY CURATIVE HEPATECTOMY IN HEPATOCELLULAR CARCINOMA PATIENTS

Hieu Banh1, Song Huy Nguyen Dinh1

1Cho Ray hospital Ho Chi Minh Vietnam

Background: We do this research at Cho Ray Hospital, Vietnam in order to evaluate some prognostic factors for recurrence, mortality, disease-free survival time (DFS) and overall survival time (OS) of HCC patients.

Method: retrospective cohort study

Result: From January 2015 to December 2019, there are 1704 patients whom received primary curative hepatectomy were enrolled in this study. All patients were followed up until June 2023. We recorded overall recurrent rate is 61.56% with 1-, 2- and 3-year recurrent rate are 56.69%, 74.24%, 84.04%, respectively. The overall survival rates at 3 and 5 years are 47.54% and 18.43%. Mean and median disease-free survival time are 16.8 and 9.5 months while mean and median overall survival time are 37.9 and 34.7 months. Univariate analysis showed that AFP level, vascular invasion, tumor number, tumor size, histological pattern, Edmonson-Steiner staging, tumor necrosis, accompanying resectable metastatic tumors, resection level are related to recurrence and DFS and OS, while underlying liver disease is only related to DFS. Logistic regression model showed that AFP level, vascular invasion, tumor number, tumor size, accompanying resectable metastatic tumors are independent prognostic factors for recurrence and mortality. Multivariate analysis using the Cox proportional-hazards regression model showed that AFP level, vascular invasion, tumor number, tumor size, accompanying resectable metastatic tumors are independent prognostic factors for recurrence and mortality.

Abstract Submission No. 100506

WS-013

Durvalumab + Tremelimumab (STRIDE) vs Durvalumab Alone for Unresectable HCC Patients: A MetaAnalysis

Ma. Regina D. Dimaculangan1, Faith Abigail Co1, Marianne Linley Sy-Janairo1

1Institute of Digestive and Liver Diseases, St. Luke's Medical Center - Global City Taguig Philippines

Background: Hepatocellular carcinoma (HCC) is the leading cause of mortality in cirrhotic patients, with an annual incidence of 1-6%. Most HCC patients usually require systemic therapy, being unresectable at the time of diagnosis. Durvalumab has gained popularity for patients with unresectable HCC versus sorafenib and atezolizumab + bevacizumab due to its safety profile, and the combination of Durvalumab (PD-L1 inhibitor) and Tremelimumab (CTLA-4 inhibitor) have shown additive antitumor activity and immunostimulatory effects. This study aims to compare the efficacy of STRIDE (Single Tremelimumab Regular Interval Durvalumab) compared to Durvalumab alone in unresectable HCC patients.

Methods: Major electronic databases and grey literature sources were searched up to June 2022 for randomized controlled trials assessing the effectiveness of STRIDE versus durvalumab monotherapy in unresectable HCC patients.

Results: The mortality rates between STRIDE and Durvalumab monotherapy were compared. Resulting I2 of 0% (p=0.72) implies that heterogeneity does not exist, hence a fixed effects model is preferred. Resulting pooled odds ratio 1.79 (95% CI 0.59 to 1.06) is not significant (Z=1.57, p=0.12), implying no significant difference between the two groups. The forest plot also shows that the hazard ratio intersects the 1 axis, suggesting that the odds ratio is not significant.

Conclusion: The addition of Tremelimumab in STRIDE (Single Tremelimumab Regular Interval Durvalumab) has no significant difference in the mortality rates among unresectable HCC patients versus Durvalumab alone. Hence, the additional costs and risks of STRIDE is upon the discretion of the patient and physician.
showed that tumor number was independent prognostic factors for DFS and OS.

Conclusion: tumor number is the independent prognostic factor for HCC recurrence and mortality.

Abstract Submission No. 101293
WS-015

Nonselective β blocker use does not impact on mortality in patients with hepatocellular carcinoma

Agnes Hin Yan Ho1,2, Philip Lung Wai Au Dong3, Terry Cheuk Fung Yip1,2,3, Mandy Sze Man Lai2,3, Vincent Wai Sun Wong2, Grace Lai Hung Wong1,2,3
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Hong Kong China, 2Institute of Digestive Disease, The Chinese University of Hong Kong Hong Kong China, 3Medical Data Analytics Centre, The Chinese University of Hong Kong Hong Kong China

Background: Hepatocellular carcinoma (HCC) contributes to a substantial burden of mortality across the globe. Increasing evidence supports the role of non-selective beta-blockers (NSBB) in reducing liver decompensation and prolonging survival in cirrhotic patients. However, the effect of NSBB on liver-related mortality in HCC patients remains unestablished.

Materials and methods: All patients with HCC and esophageal and/or gastric varices from January 2000 to December 2020 were identified from a territory-wide database in Hong Kong. Participants were classified into three groups using a time-dependent covariate (i) propranolol users (ii) carvedilol users (iii) NSBB non-users. The primary endpoint was liver-related mortality in 5 years. Cause-specific hazard model was used for competing risk analysis. Liver transplantation and non-liver-related mortality were considered as competing events.

Results: A total of 5,454 patients with 4119 propranolol users, 86 carvedilol users, 1249 non-users (mean age 60.4±11 years, male 82.0%) were included in the analysis. Most patients had viral cirrhosis (78.3%). The use of propranolol and carvedilol did not have a significant impact on liver-related mortality (adjusted cause-specific hazard ratio [aC-SHR] 1.03, 95% CI 0.97-1.12, p=0.42; aC-SHR 0.90, 95% CI 0.57-1.43, p=0.67) and non-liver-related mortality (aC-SHR 0.99, 95% CI 0.86-1.15, p=0.94; aC-SHR 1.40, CI 0.75-2.65, p=0.293).

Conclusion: In this territory-wide retrospective study, use of NSBB did not impact on liver-related and non-liver-related mortality in HCC patients over a follow-up period of 5 years.

Abstract Submission No. 100663
WS-017

Sarcopenia is Associated with the Risk of Minimal Hepatic Encephalopathy in Patients with Cirrhosis

WASIT WONGTRAKUL1,2, Wimolrak Bandidniyanon1, Phunchai Charatcharoenwittaya1
1Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Bangkok Thailand, 2Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Bangkok Thailand

Background: Sarcopenia has gained significance in the evaluation of cirrhosis patients, and this nutritional status can have a detrimental impact on clinical outcomes, including minimal hepatic encephalopathy (MHE). This prospective study aimed to assess the association between sarcopenia and MHE in cirrhotic patients.

Methods: We enrolled outpatients with cirrhosis to evaluate the presence and severity of sarcopenia according to the 2019 criteria by the Asian Working Group for Sarcopenia. MHE was diagnosed using the paper-based Psychometric Hepatic Encephalopathy Score.

Results: Among the 210 patients (57.1% male, mean age 62.7±9.6 years) with cirrhosis, 54 (25.7%) exhibited sarcopenia, with 26 (12.3%) classified as having severe sarcopenia. Additionally, 37 (17.6%) were diagnosed with MHE. The prevalence of sarcopenia was significantly higher in cirrhotic patients with MHE compared to those without MHE (45.9% vs. 21.4%, p=0.002). MHE was notably associated with education level, Mini-Mental State Examination score, and a history of hepatic decompensation. Conversely, no significant associations were observed regarding gender, BMI, comorbidities, sleep quality, etiology and severity of liver disease assessed by MELD score and transient elastography. In a multivariable logistic model, MHE was significantly associated with age (adjusted odds ratio [aOR] 1.08, 95% CI 1.02-1.13), sarcopenia (aOR 3.29, 95% CI 1.44-7.50), and a history of overt hepatic encephalopathy (aOR 7.40, 95% CI 1.20-45.56) and variceal bleeding (aOR 3.13, 95% CI 1.38-7.10). Furthermore, severe sarcopenia was independently associated with MHE (aOR 3.64, 95% CI 1.32-10.05).

Conclusions: Sarcopenia is not uncommon among outpatients and is an independent risk factor for MHE in cirrhotic patients.
Abstract Submission No. 101626
WS-018
Early Clinical Features of Peritoneovenous Shunt in Patients with Decompensated Liver Cirrhosis
Asako Nogami1, Shingo Koyama1, Shihyao Cheng1, Yuya Koike2, Michihiro Iwaki1, Takashi Kobayashi1, Satoru Saito3, Daisuke Utsunomiya1, Atsushi Nakajima1, Masato Yoneda1
1Yokohama City University Graduate School of Medicine Yokohama Japan, 2Saiseikai Yokohama Nanbu Hospital Yokohama Japan, 3Sanno Hospital Tokyo Japan

Background and Aims: Refractory ascites affects the prognosis of liver cirrhosis. Peritoneovenous shunt (PVS) placement is a palliative treatment for refractory ascites that is expected to improve the patient’s quality of life; however, it is associated with serious complications, such as heart failure. Thus, understanding the clinical course and risks of complications after PVS placement is important. We aimed to evaluate the early clinical features after PVS placement for refractory ascites associated with liver cirrhosis.

Methods: This was a retrospective study of 14 patients with refractory ascites with decompensated cirrhosis who underwent PVS placement between June 2011 and June 2023. The clinical characteristics, changes in cardiothoracic ratio (CTR), and laboratory data were evaluated.

Results: No serious complication associated with the procedure occurred in all cases. Ten and four patients had Child-Pugh classes B and C, respectively. Increased brain natriuretic peptide (BNP) and D-dimer levels, decreased platelet count, and slightly worsening of CTR were observed two days after PVS placement; however, all cases tended to improve after seven days. The mean PVS patency was 345.4 days, and the median survival after PVS placement was 474.4 days. Although patients with class B cirrhosis tended to have longer PVS patency, there was no significant difference in patency between patients with class B and C cirrhosis.

Conclusions: PVS placement for refractory ascites is a technically feasible palliative therapy. Evaluating changes in CTR, platelet count, and BNP and D-dimer levels may be useful for early prediction of the efficacy of PVS placement.

Abstract Submission No. 102079
WS-019
Morphofunctional restoration of the hepatopulmonary axis in the early stages of liver cirrhosis
Liilit Arshakyan1
1researcher Yerevan Armenia

One of the peculiarities of the liver is that it is connected to the portal system and the lungs in a sequential manner. Pulmonary complications during cirrhosis play an important part in the manifestations of the disease and the quality of life of patients with this disease can contain a significant signal in the chain of the hepat-Pulmonary early differential diagnosis of complications of the disease will make it possible to prevent serious consequences and irreversible damages. It was the basis to set a goal to study the spectrum of hepatopulmonary complications in the early stages of liver cirrhosis development with personalized analysis.

In this study the patterns of serum protein electrophoresis results were evaluated against histopathological abnormalities in the liver and lungs, with the application of Hematoxylin and eosin (H&E) and

When pre-symptoms of liver cirrhosis are clearly observed in the anatomical and histological features during the initial stage of cirrhosis, lung lesions are quite severe, according to the developed histopathological scale. There is a decrease in the tendency to pulmonary lesions over the two-week post-poisoning after period, and in males. Thus, in the acute and/or subacute stages of cirrhosis development, hormonal features play a crucial role in determining the hepatopulmonary axis differential diagnosis along with behavioral and emotional characteristics. We are sure that at some point in time there comes a moment of harmony (like in life, between males and females) when pathological processes manifest in the same way in both sexes.

Abstract Submission No. 100909
WS-020
Performance of aMAP, FIB-4, and APRI for Predicting F2 Fibrosis in Chronic Hepatitis B Patients
Apichat Kaewdech1, Suraphon Assawasuwannakit2, Pimsiri Sripongpun2, Naichaya Chamroonkul2, Teerha Piratvisuth3
1Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University Hatyai Thailand, 2Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University Nonthaburi Thailand, 3NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Prince of Songkla University Hatyai Thailand

Background: In line with WHO’s 2030 hepatitis elimination target, effective chronic hepatitis B (CHB) strategies are vital. For those with HBV DNA >2000 IU/mL and persistently normal ALT, fibrosis assessment via transient elastography (TE) is advised. The aMAP score, recently introduced for fibrosis staging in CHB patients, has yet to be validated for assessing significant fibrosis.

Method: In this cross-sectional study, CHB patients with concurrent laboratory data and TE results within three months were evaluated. A TE value of at least 7 kPa indicated significant fibrosis. The aMAP score’s efficacy was compared to the Fibrosis-4 index (FIB-4) and the aspartate aminotransferase to platelet index (APRI) in predicting F2 fibrosis. Metrics such as sensitivity, specificity, NPV, and PPV were assessed.

Results: Among the 628 analyzed CHB patients (mean age 48.6 years; 51% male; 79.8% HBeAg-negative; median HBV DNA 2042.5 IU/mL), the areas under the receiver operating curves for F2 fibrosis prediction were 0.693, 0.7061, and 0.7254 for aMAP, FIB-4, and APRI scores respectively. Statistical comparisons with aMAP showed no significant difference (p-values: 0.398 for FIB-4 and 0.137 for APRI). Optimal aMAP score thresholds were determined at 93% sensitivity (cutoff: 40) and 89% specificity (cutoff: 55).

Conclusions: The aMAP score emerges as a potential non-invasive metric for predicting significant fibrosis in CHB patients, with a 40 cutoff optimal for ruling out significant fibrosis. However, its performance mirrors existing scores. A more accessible, simplified score for assessing fibrosis is desired, especially when TE is unavailable in resource-limited settings.

Abstract Submission No. 101348
WS-021

GENETIC FEATURES OF PATIENTS WITH WILSON’S DISEASE IN REPUBLIC OF MOLDOVA: A PILOT STUDY

Veronica Cumpata1,2, Adela Turcanu1,3, Lucia Mazur-Nicorici1
1Nicolae Testemitanu State University of Medicine and Pharmacy of the Republic of Moldova Chisinau Moldova, 2The Clinic of Gastroenterology and Hepatology/ HELPA Chisinau Moldova

INTRODUCTION: Wilson disease (WD), a rare metabolic disease, is an autosomal recessive disorder associated with phenomonal mutational polymorphism and high clinical variety.

OBJECTIVE: To assess epidemiological characteristics and genetic features of Moldovan patients with WD.

METHODS: It was conducted a retrospective study on 108 patients suspected of WD, between 2006 and 2023. The Leipzig Scoring System was used to specify the diagnosis.

RESULTS: Of 108 persons, 57.4% (62/108) were male. The mean age was 16 years (range 3-63 years). All persons were of Caucasian origin, and 79% were of Moldovan ethnicity. No consanguineous relationships have been described. Patients mostly come from the city (59.4%) and south (15.94%) of the country. Hepatic onset was more frequent in women (45.8%, p<0.01) and neurological in men (61.5%, p<0.05). In 61.35% of the performed genetic tests, mutations were detected, of which 70.2% are pathogenic variants. The most frequent mutation identified is p.H1069Q (62.1%), of which 36.1% are in homozygous recessive state and 41.7% - associations with other variants (pathogenic, benign, or uncertain), and the second mutation is unknown in 22.2%. In 52.8% of cases, this mutation is associated with liver damage, which was diagnosed at the onset or during the natural evolution of WD.

CONCLUSIONS: p.H1069Q represents the most frequent pathogenic variant identified in the Republic of Moldova. Patients with hepatic presentation are diagnosed at younger ages, while those with neuro-psychiatric type are diagnosed at older ages and with longer diagnosis delays.

Abstract Submission No. 100177

WS-022

Investigating unique clinical, pathological traits, and genetic variations in MAFLD among Indians.

Ankita Chatterjee1, Bandana Mondal1, Kausik Das2, Dipankar Mondal1, Ranajay Ghosh1, Abhijit Chowdhury3, Priyadarshini Basu4
1JOHN C MARTIN CENTRE FOR LIVER RESEARCH AND INNOVATIONS KOLKATA India, 2Institute of Post Graduate Medical Education and Research Kolkata India, 3National Institute of Biomedical Genomics Kalyani India

Background and aims: Fatty liver disease (FLD) is characterized by excessive fat accumulation in the liver and is closely linked to metabolic syndrome (MetS). However, the unique features and genetic factors influencing FLD in the presence or absence of MetS remain poorly understood. We aimed to investigate the clinical and genetic aspects of fatty liver disease (FLD) in individuals with and without metabolic syndrome (MetS).

Methods: A cohort of 551 individuals, with and without fatty liver, was categorized into four groups based on metabolic dysregulation: MAFLD, NAFLD, MetS, and healthy controls. Our study analysed clinico-patological attributes and associations of SNPs with MAFLD.

Results: The results showed that nearly half of the participants had FLD (47.2%), and the majority had MetS (71.87%). MAFLD individuals exhibited significantly higher age, increased adiposity, more severe diabetes, abnormal lipid profiles, elevated liver damage markers, CRP levels, decreased bone mineral content, and more extensive liver damage. Notably, both obese and non-obese individuals in this group displayed these adverse characteristics. Furthermore, the study identified 21 genetic variants associated with the increased risk of MAFLD, mapped in SAMM50, PNPLA3, TM6SF2, CECR5, TTC39B, SLC9A9, and PDXDC1. Additionally, rs7200543-AA carriers among MAFLD patients showed poorer skeletal health.

Conclusion: Our study demonstrated that FLD in combination with MetS results in the most severe disease phenotype. It highlighted the importance of considering both clinical and genetic factors when studying FLD and provided insights into the complex interplay between genetics and metabolic disorders in liver disease.

Abstract Submission No. 100323

WS-023

Hepatic lobular inflammation is the most impacted prognostic factor in MAFLD: A Multi-Center study

Tsubasa Tsutsumi1, Hldeki Fujii1, Takumi Kawaguchi1, Miwa Kawanaka2, Hirikazu Takahashi3, Yoshihiro Kamada4, Sumida Yoshiro5, Hldeki Hayashi5, Michihito Iwaki5, Satoshi Odeda6, Shinichi Aishima7, Masato Yoneda8, Hidenori Toyoda9, Atsushi Nakajima10
1Kurume University School of Medicine Kurume Japan, 2Osaka Metropolitan University Osaka Japan, 3Kawasaki Medical Schoo Okayama Japan, 4Saga University Hospita Saga Japan, 5Osaka University Graduate School of Medicine Suita Japan, 6International University of Health and Welfare Tokyo Japan, 7Gifu Municipal Hospital Gifu Japan, 8Yokohama City University Graduate School of Medicine Yokohama Japan, 9Ogaki Municipal Hospital Ogaki Japan, 10Kyusyu University Fukuoka Japan

Background and Aims: Metabolic dysfunction-associated fatty liver disease (MAFLD) captures patients with fatty liver at high risk. However, limited information is available on the prognosis of MAFLD and prognostic liver histology. We aimed to investigate the prognosis of patients with biopsy-proven MAFLD and the most important histological finding associated with the prognosis using a multi-center longitudinal cohort.

Methods: We enrolled 1,444 patients with fatty liver who underwent liver biopsy (age 57, BMI 27.4). Patients were classified into the following groups: the MAFLD group, non-MAFLD group (steatosis without metabolic dysfunctions), or Burnt-out group (no steatosis on biopsy). Kaplan-Meier analysis and decision-tree analysis were performed to investigate the difference in mortality in these subgroups and the most impacted histological finding related to the prognosis of each group, respectively.

Results: During the 9,083 person-years of observation, 4.3 person-years of deaths occurred, and 84.2% (32/38) of these were patients in the MAFLD group. Significant differences were seen in prognosis among the three groups (log-rank p=0.0009). Ten-year survival rate was 65.6% in the MAFLD group, while no patient died in the non-MAFLD group. The MAFLD group showed the highest proportion of high NAFLD activity scores. Although hepatic fibrosis was the histological finding most impacted on mortality in the Burnt-out group, hepatic inflammation was identified as the most impacted prognostic finding in the MAFLD group.

Conclusions: We demonstrated that patients with MAFLD have a worse prognosis than patients with non-MAFLD. Hepatic inflammation rather than fibrosis was the most impacted prognostic histology in patients with MAFLD.
Long-term Risks for Cirrhosis and Hepatocellular Carcinoma Across Steatotic Liver Disease Subtypes

Vi Ting Chen¹, Tzu I Chen¹, Szu Ching Yin¹, Sheng Nan Lu¹, Xia Rong Liu¹, Yun Zheng Gao¹, Chih Jo Lin¹, Jee Fu Huang³, Ming Lun Yeh³, Chung Feng Huang³, Chia Yen Dai³, Wan Long Chung¹, Hwai I Yang⁴, Ming Lung Yu⁵,⁶,⁷, Mei Hsuan Lee¹,⁷,⁸

¹NYCU, National Yang Ming Chiao Tung University Taipei city Taiwan, ²Department of Gastroenterology, Chang-Gung Memorial Hospital Kaohsiung Taiwan, ³Kaohsiung Medical University Kaohsiung Taiwan, ⁴Genomics Research Center, Academia Sinica Taipei City Taiwan, ⁵School of Medicine, College of Medicine, National Sun Yat-sen University Kaohsiung Taiwan, ⁶School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan, ⁷Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan, ⁸Advanced Therapeutics Research Center, National Yang Ming Chiao Tung University Taipei City Taiwan

Aim: The prospective study aimed to investigate the long-term associated risks of cirrhosis and hepatocellular carcinoma (HCC) across various subtypes of steatotic liver disease (SLD).

Method: We enrolled 332,175 adults who participated in a health screening program between 1997 and 2013. Participants were categorized into various subtypes, including metabolic dysfunction-associated steatotic liver disease (MASLD), MASLD with excessive alcohol consumption (MetALD), and alcohol-related liver disease (ALD), based on ultrasonography findings, alcohol consumption patterns, and cardiometabolic risk factors. We utilized computerized data linkage with nationwide registries from 1997 to 2019 to ascertain the incidence of cirrhosis and HCC.

Result: After a median follow-up of 16 years, 4,458 cases of cirrhosis and 1,392 cases of HCC occurred in the entire cohort, resulting in an incidence rate of 86.1 and 26.8 per 100,000 person-years, respectively. The ALD exhibited the highest incidence rate for cirrhosis and HCC. ALD, and ALD, respectively, when compared to non-SLD without cardiovascular disease in South Indian population

Dhivya Elango¹, Kandasamy@Kumar E¹, Poppy Rejoice¹, Shaifique A¹, Geetha D¹

¹Tirunelveli medical college tirunelveli India

BACKGROUND: Metabolic associated fatty liver disease (MAFLD) is the latest entrant in hepatology. There is paucity of data regarding MAFLD in the general population so this study aims to identify the prevalence and risk factors for MAFLD among the ethnic South Indian population.

METHODS: Demographic details, lifestyle habits, anthropometric details, biochemical tests and ultrasound findings of the subjects were recorded. A diagnosis of MAFLD was made with evidence of fatty liver along with one criteria for metabolic dysfunction. Statistical analysis was done using SPSS version 23, Chi Square test and Independent t test.

RESULTS: 2290 subjects were included in this study with mean age as 43.83 with SD of 13.601, age range from 19 to 78 and majority were in 41 to 50 age group (27.95%). Males were more common (58.95%). 27.95% of study population have MAFLD(640 subjects). Alcohol consumption was more commonly seen compared to other risk factors (33.62%) and hypertension was less commonly seen (23.58%) for developing MAFLD. Risk is more in smokers, alcohol consumption, diabetics, hypertensives, those with age more than 40 and females. On applying Chi square test significant association for getting MAFLD was found in diabetics, hypertensives and those with age more than 40. On applying Independent t test there was significant difference between MAFLD and Non MAFLD with p value<0.05 in all parameters except uric acid.
CONCLUSION: Our study highlights the increasing burden of MAFLD in the community and to address the growing issue with targeted therapy for comprehensive patient care.

Abstract Submission No. 101219
WS-027

GENDER RELATED ASSOCIATION OF BMI AND AGE WITH MAFLD / SLD IN PAKISTANI POPULATION: CROSS SECTIONAL

Mohammad Khoso1, Nazish Butt2
1JPMC Karachi Karachi Pakistan, 2JPMC Karachi Karachi Pakistan

Background: When there is excessive fat in liver, condition is called (MAFLD). MAFLD most commonly occurs in patients having certain underlying conditions such as hyperlipidemia, metabolic syndrome, central obesity, hypothyroidism, polycystic ovarian syndrome, and type 2 diabetes mellitus. This study is designed to determine the link of MAFLD with age, gender, and body mass index.

METHODS: It is the cross-sectional, retrospective, single center study that was conducted in the Department of Gastroenterology & Hepatology, Jinnah Postgraduate Medical Center (JPMC), Karachi for a period of January 2020 to September 2023. All the adult males and females admitted and/or presented in the out-patient-department (OPD) with clinical signs & symptoms suggesting fatty liver disease were included for this study. Baseline and clinical data were collected by association of age, gender, and BMI with MAFLD was analysed using SPSS version 26.0.

RESULTS: Total 1140 participants were included for initial analysis, the overall prevalence of MAFLD was 72.5% (n = 827). Patients with MAFLD were older (42.1±10.2) years as compared to controlled group (42.5±11.2) years and female patients were more prevalent than males, 78.6% vs. 21.4%, but they are insignificantly associated with MAFLD. Overweight patients were more likely to have MAFLD as compare to MAFLD with controlled and Obese.

CONCLUSION: A multitude of factors showed significant association with MAFLD and need to be researched in-depth to better understand the mechanisms behind them and the therapeutic measures that can be taken. Surprisingly, age and gender did not show significant association with MAFLD but BMI did.

Abstract Submission No. 101764
WS-028

RCT evaluating efficacy of Saroglitazar vs OCA in patients of MAFLD/NASH

CTR/2023/03/050213

Kalpana Acharya1, Prof GM Gulzar2, Prof and Head Altaf Shah3
1Department of Gastroenterology Srinagar India, 2Prof, Shere I kashmir institute of Medical Sciences Srinagar India, 3Prof and Head Shere I kashmir institute of Medical Sciences srinagar India

Aim: NAFLD/NASH is a burgeoning cause for cirrhosis worldwide, but pharmacotherapy for the same remains elusive. Only Saroglitazar so far has received acceptance from DCGI. This study explores the potential efficacy of Obeticholic acid in patients of MAFLD/NASH.

Methods: This prospective, comparative study evaluated efficacy of Obeticholic acid 10 mg (n =50) and Saroglitazar 4mg (n =50) in patients of NAFLD/NASH. All patients were analyzed for change in primary outcomes i.e., Fibrosis (LSM) and steatosis (CAP) at baseline and at 24 weeks measured through fibroscan and secondary outcomes including, ALT, AST, Lipid profile and non invasive scores of fibrosis.

Results: In Obeticholic acid group LSM reduced by 20.9%, p value <0.001 while in Saroglitazar limb it reduced by 23.20% p value <0.001 at 24 weeks, however there was no difference between 2 groups p value < 0.26. CAP in Obeticholic acid group reduced by 21% p value <0.001 while in Saroglitazar limb it reduced by 10.70 % P value, 0.001. CAP value reduced more significantly in Obeticholic acid group p value 0.01. Secondary endpoints , also improved significantly in both the groups post 24 weeks of treatment.

Conclusion: Obeticholic acid has a comparable effect with Saroglitazar in reducing Fibrosis (LSM), ALT, AST and serum Triglyceride, while it has an edge over the Saroglitazar in reducing Steatosis (CAP).

Abstract Submission No. 101906
WS-029

Clinical features of MetALD and ALD in patients with hepatocellular carcinoma

Yuri Ogasawara1, Tomomi Kogiso1, Kentaro Horuchi1, Makiko Tanai1, Katsutoshi Tokushige1
1Tokyo Women's Medical University Tokyo Japan

Aim: A subgroup of individuals with intermediate alcohol consumption among steatotic liver diseases has been classified as metabolic dysfunction-associated steatotic liver disease (MetALD). Therefore, we compared the clinical features of MetALD and alcohol-associated liver disease (ALD) in patients with hepatocellular carcinoma (HCC).

Method: The study included: 1) Cross-sectional comparison of 64 cases of MetALD-HCC and 207 cases of ALD-HCC diagnosed at our institution from 1989 to 2021, and 2) Retrospective cohort analysis of 271 cases post HCC diagnosis, including mortality rate, causes of death, and analysis of mortality risk factors.

Results: The median age of was 66/52 years, with a male ratio of 92.2/93.7%. The average daily ethanol intake was 32/108g. HCC stage IV was 9.4/6.3%. Significant differences (p<0.05) between the two groups were observed in age, prevalence of hypertension (67.2/51.7%), dyslipidemia (37.5/16.9%) and cirrhosis (65.6/77.8%), albumin (Alb) 4.4/3.7 mg/dL, total bilirubin (T-Bil) levels 0.5/0.9 mg/dL, and platelet count 25/10 × 10^9/L. 2) The 5-year survival rates were 69.6/49.5%, significantly lower in the ALD-HCC group (p<0.01). Mortality due to infections (20.8/5.8%) was significantly higher in the MetALD-HCC group (p<0.02). Risk factors for death included Child-Pugh classification at diagnosis, HCC stage, and curative treatment feasibility. Additionally, non-complication of dyslipidemia in the MetALD-HCC group and old age and low Alb levels in the ALD-HCC group were extracted.

Conclusion: The MetALD-HCC group showed a better prognosis compared to the ALD-HCC group. However, attention is needed for non-elder-related deaths in the MetALD-HCC group.

Abstract Submission No. 100722
WS-030

Daily nucleotide analogues reduces the severity of COVID-19 in patients with chronic liver disease

Qian Zhu1, Ke Qiu1, Dachuan Cai1, Peng Hu1, Hong Ren1
1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for
Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University Chongqing China

**Background:** The effect of nucleotide analogues (NAs) against severe acute respiratory coronavirus 2 (SARS-CoV-2) infection and associated clinical outcomes among patients with chronic liver disease (CLD) remain unclear.

**Methods:** 579 CLD patients with available data of SARS-CoV-2 infection were included in this study during Omicron subvariants BA.5 wave. Demographic and clinical data were collected by standardized questionnaires and electronic medical records. Multivariable logistic regression models were used to assess the association between NAs and coronavirus disease 2019 (COVID-19) outcomes.

**Results:** CLD patients with daily NAs therapy had significant lower proportions of SARS-CoV-2 infection (72.8% vs. 84.3%, p=0.001), severe COVID-19 (2.3% vs. 7.8%, p=0.003) and COVID-19-related death (1.7% vs. 5.3%, p=0.016) than those without NAs therapy. Similar trends were also shown in other severe outcomes including intensive care unit (ICU) admission, mechanical ventilation and overall death although there was no significant difference. Multivariable logistic regression analysis further demonstrated the negative associations between daily NAs therapy and SARS-CoV-2 infection (adjusted odd ratio [aOR], 0.61; 95% confidence interval [CI], 0.36-1.02; p=0.059), severe COVID-19 (aOR, 0.26; 95% CI, 0.09-0.77, p=0.015) and COVID-19 related death (aOR, 0.23; 95% CI, 0.06-0.91, p=0.036).

**Conclusions:** Daily NAs therapy reduces the severity of COVID-19 among CLD patients and has potential protective effect against Omicron infection. This finding suggests that NAs might be used as pre-exposure prophylaxis or early treatment of COVID-19, especially for immunocompromised patients including decompensated cirrhosis with suboptimal vaccine responses and those CLD patients for which hepatic safety concerns arise with other antiviral drugs.

**Pattern of Liver Injury and its Outcome in Covid-19 Patients**

Zahabia Sohail1, Masood Karim1, Om Parkash1

1The Aga Khan University Karachi Pakistan

**Objective:** COVID-19 is a highly contagious respiratory disease caused by the SARS-CoV-2 virus. Evidence suggests that it can cause liver damage through various mechanisms, but the prevalence and clinical significance of abnormal liver function tests (LFTs) in patients with COVID-19 is relatively unexplored.

**Method and Material:** Descriptive cross-sectional study was conducted at the Aga Khan University Hospital, Karachi from 26th 61 February 2020 till June 2020. All patients above 18 years of age, admitted with confirmed COVID-19 infection were included. Data on patient demographics, clinical symptoms, laboratory test results, length of hospital stay, and clinical outcomes was collected. Statistical analysis of the variables was conducted using SPSS.

**Results:** A total of 533 hospitalized patients were included in this study, with a mean age of 53±16 67 years, of which 61.5% were male. The most prevalent comorbidities were hypertension 62 (42%) and diabete mellitus (36%). LFTs were found to be deranged in 92% of the total 69 patients, with Aspartate aminotransferase (81%), Gamma-glutamyl transferase (69.4%), and Alanine transaminase (66.8%) being the most commonly affected liver enzymes. On comparative analysis, deranged LFTs showed significant correlations with the male gender (p-value 0.012), age group >60 years (p-value 0.001), fever (p-value <0.001), cough (p-value 73 0.028), shortness of breath (p-value 0.021), hemoglobin levels (p-value 0.003), serum 74 sodium (p-value 0.006), serum C-Reactive Protein (p-value <0.001) serum ferritin (p-value <0.001), serum Lactate Dehydrogenase (p-value <0.001), and length of hospital stay (p-value <0.001).

**Conclusion:** The study showed a high prevalence of abnormal liver enzymes in mild-moderate COVID-19 cases. Our findings suggest a correlation between abnormal liver function tests and various demographic and clinical factors, but further investigation is needed to determine the clinical significance of liver injury in COVID-19 patients. These findings have important implications for patient management and outcomes.

**Keywords:** Covid-19, Deranged LFTs, Gastrointestinal Manifestations

Abstract Submission No. 101025

**WS-031**

**RCT: Reduction of Bilirubin after Steroids for Biliary Atresia**

Novi rahayu Arianti1, 2, Bagus Setyoobedi1, 2, Rendy aji Prihatiningtyas1, 2

1Soetomo hospital Surabaya Indonesia, 2Airlangga University School of Medicine Surabaya Indonesia

**Background:** Biliary atresia remains a global public health problem. Although Kasai therapy has been established for a long time, the need for liver transplantation is still high. Liver transplantation is not available in all countries. Pathogenesis of autoimmunity in development of biliary atresia obliterator fibrosis is currently widely discussed. This study analyzes the effect of methylprednisolone on bilirubin levels in biliary atresia infants.

**Methods:** This study is a RCT on infants aged 2 week - 3 months with biliary atresia at Dr Soetomo General Academic Hospital, Surabaya. Subjects were grouped into methylprednisolone vs placebo group. Methylprednisolone was given at a dose of 2 mg/kg/day for 14 days and bilirubin levels were assessed before and after treatment. Data analysis was performed with SPSS.

**Results:** The study included 40 infants, 20 in the methylprednisolone group and 20 in the placebo group. Pre-treatment bilirubin levels were not significantly different between the methylprednisolone and placebo groups (direct bilirubin 9.87 (6.11-14.20) mg/dL vs 6.68±2.44 mg/dL; total bilirubin 9.87 (6.11-14.20) mg/dL vs 9.44±3.91 mg/dL; p>0.05). Bilirubin reduction was significantly greater with methylprednisolone than with placebo (direct bilirubin 3.88±2.58 mg/dl vs 1.40±2.22 mg/dl; p=0.002; total bilirubin 4.45 (3.17-7.65) mg/dL vs 2.39±2.30 mg/dL; p=0.03).

**Conclusions:** Methylprednisolone reduced bilirubin levels at 2 weeks of therapy. Bilirubin improvement with steroids supports the evidence of immunity in the pathogenesis of biliary atresia.

Key word: Biliary atresia, Bilirubin level, Methylprednisolone

Abstract Submission No. 100419

**WS-033**

**Modified ALBI grade and platelet count to predict high-risk varices in hepatocellular carcinoma**

Prooksa Ananchuensook1, 2, 3, 4, 5, Kingkomon Piyawannassuth4, Siriporn Sukawatamnuay1, 2, 3, 4, Panarit Thaimassage1, 2, 3, 4, Nipaporn Siripoon6, Supachaya Sripoosananphan1, 2, 3, 4, Kessarin Thanapirom7, Piyawat Komolmit1, 2, 3, 4

1Chulalongkorn University Bangkok Thailand, 2Center of Excellence in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand, 3Center of Excellence in Hepatic
Fibrosis and Cirrhosis, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, a) Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, b) Academic Affair, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, c) Chulalongkorn University, International Medical Program (CU-MED), Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Background: Baveno VII employs non-invasive tests to rule out high-risk varices (HRV) in cirrhosis; however, this approach doesn’t extend to HCC. We aim to validate and refine the previously studied Albumin-bilirubin and platelet (ALBI-PLT) score for predicting HRV in HCC.

Methods: Our retrospective study included HCC patients with EGD reports and no prior upper GI bleeding at King Chulalongkorn Memorial Hospital from 2019 to 2023. F2 or F3 esophageal varices (EV) were defined as HRV. ALBI-PLT was computed following Chen et al. Modified ALBI-PLT (mALBI-PLT) calculated by combining mALBI grading (1 point for grade 1 or 2a; 2 points for grade 2b or 3) and platelet (1 point for > 150,000 /µL; 2 points for ≤150,000 /µL).

Results: 277 HCC patients were enrolled. Of these, 22, 56, 147, and 52 fell into mALBI grades 1, 2a, 2b, and 3, while 131, 85, and 60 had HCC BCLC A, B, and C. 38 (15.6%) participants had HRV. The AUROC of the ALBI score and platelet for predicting HRV were 0.755 and 0.738. On multivariate analysis, platelet ≤150,000 /µL and mALBI grade 1 or 2a and platelet > 150,000/µL showed significant association with HRV in HCC. Moreover, HCC patients with mALBI grade 1 or 2a and platelet > 150,000/µL may avoid EV surveillance.

Conclusion: HRV was associated with mALBI grade and platelet at 150,000/µL. A pilot survey with 993 respondents found that 52.7% of those who had hepatitis virus testing during health check-ups had forgotten their history of testing.

Results: In the three nationwide surveys (responses from 23,720, 10,203, and 8,810 individuals), HBV and HCV recognized testing rates remained steady (17-20% for HBV, 15-18% for HCV). However, the testing rates including unrecognized testing increased by more than 10% from 2011 to 2017 (HBV: 58.4%, 71.0%, 71.1%; HCV: 48.0%, 61.6%, 59.8%). A pilot survey with 993 respondents found that 52.7% of those who had hepatitis virus testing during health check-ups had forgotten their testing history. Adjusting the nationwide survey based on this proportion, testing rate at 2020 reached 85.5% for HBV and 76.4% for HCV.

Conclusions: In Japan, 76.4-85.5% of the general population has already undergone hepatitis virus testing. The WHO’s elimination goal of over 90% of infected individuals getting tested is likely almost achieved.
and their littermate wild-type (WT) controls (Nogo-Bfl/fl) were fed a high-fat diet (HFD, 60% kcal% fat) for three months, followed by maltose or ethanol gavage (5g/kg weight). We found that Aldo-keto reductase family 1 member B8 (Akr1b8), the NAD(P)H-dependent oxidoreduction of various carbonyl compounds, was significantly downregulated in the liver of AFL group mice. Moreover, we found that there were fewer lipids in the liver of Akr1b8 knockout AFL group by oil red O staining, and it was due to the hepatocyte injury identified by Ki67 levels in different groups. Further liver tissue RNA transcriptomic of two groups revealed that there were several differently expressed genes enriched in alcohol metabolism-related pathways and lipid metabolism-related pathways. To verify these results, western blot was employed and the expression levels of lipid catabolism enzymes, including PPAR-γ and SCD1, were down-regulated in the KO-AFL group, suggesting that there were fewer lipids needed to be catabolized. Taken together, these results indicate that AKR1B8 is a potential therapeutic target of ALD.

Abstract Submission No. 101014

O-0002

AKR1B8 deficiency prevents the progression of alcoholic liver disease in mouse model

Yanfei Lang1, Jing Ning1, Shi gang Ding1, Fengmin Lu2

1 Peking University Third Hospital Beijing China, 2 Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Alcoholic liver disease (ALD) is a major cause of chronic liver disease, which causes an extremely severe healthcare burden worldwide. Alcoholic fatty liver (AFL), an early stage of ALD progression, is a clinically important spectrum of alcohol-related fatty liver disease (ALD). Presently, there is no approved drug for ALD. To explore the potential therapeutic target of AFL, we constructed a Lieber Decarli diet-induced AFL mouse model and analyzed the RNA transcriptomic of liver tissues. We found that Aldo-keto reductase family 1 member B8 (Akr1b8), the NAD(P)H-dependent oxidoreduction of various carbonyl compounds, was significantly downregulated in the liver of AFL group mice. Further, we found that there were fewer lipids in the liver of Akr1b8 knockout AFL group by oil red O staining, and it was due to the hepatocyte injury identified by Ki67 levels in different groups. Further liver tissue RNA transcriptomic of two groups revealed that there were several differently expressed genes enriched in alcohol metabolism-related pathways and lipid metabolism-related pathways. To verify these results, western blot was employed and the expression levels of lipid catabolism enzymes, including PPAR-γ and SCD1, were down-regulated in the KO-AFL group, suggesting that there were fewer lipids needed to be catabolized. Taken together, these results indicate that AKR1B8 is a potential therapeutic target of ALD.
Background: The impact of ALDH2 rs671 polymorphism as predictors of clinical prognosis in alcohol-related hepatocellular carcinoma (HCC) after hepatectomy remains largely unknown.

Methods: This prospective cohort study enrolled 238 alcohol-related HCC patients who underwent hepatectomy from 2011 to 2022 at the E-Da Hospital, I-Shou University, Kaohsiung, Taiwan. Data analyses were finalized on October, 2023. Alcohol intake was defined as consuming over 20 g of ethanol each day for at least 5 years. ALDH2 rs671 polymorphism was analyzed. The primary endpoint was HCC recurrence and overall mortality.

Results: 196 (82.4%) were men and the mean (SD) age was 62.3 (10.2) years. HCC recurrence occurred in 70 patients, and 64 patients died. The cumulative incidences of HCC recurrence and mortality after resection in all patients were 40.6% and 37.7%, respectively. The ALDH2 rs671 polymorphism is significantly associated with HCC recurrence and mortality. The cumulative incidences of HCC recurrence and mortality were significantly higher in patients with the ALDH2 rs671 genotype GA/AA than in those with the ALDH2 rs671 genotype GG. In Cox proportional analyses, the ALDH2 rs671 genotype GA/AA and AST ≥ 40 IU/L were significantly associated with increased HCC recurrence (HR:2.66, 95% CI: 1.59-4.43, P<0.001; and HR: 1.93, 95% CI: 1.18-3.17, P=0.009). Furthermore, the ALDH2 rs671 genotype GA/AA (HR: 2.02, 95% CI: 1.17-3.49, P=0.012) and age ≥ 65 years-old (HR: 1.67, 95% CI: 1.01-2.78, P=0.048) were significantly associated with increased mortality.

Conclusion: ALDH2 rs671 genotype GA/AA is significantly associated with worse clinical prognosis in alcohol-related HCC patients who underwent hepatectomy.

Abstract Submission No. 101276
O-0004

JPHX formula treated acute ALD in mice by regulating the metabolism of bile acids via gut-liver axis

Yue Chen1, 2, Hening Chen1, 2, Wenying Qi1, 2, Gang Wang1, 2, Yuyong Jiang4, Xiaobin Zao1, 2, 3

1Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China, 2Institute of Liver Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, 4Beijing Ditan Hospital, Capital Medical University Beijing, China

Background: Effective pharmacotherapies of alcohol-related liver disease (ALD) are still lacking. JianPiHuoXue (JPHX), as a traditional Chinese medicine, has shown a therapeutic effect on ALD in clinical practice. Here, we aimed to reveal the mechanism of JPHX in the treatment of ALD.

Method: The mice acute ALD model was established by a persistent alcohol diet, and JPHX was given by intragastric administration. The detection of serological indicators and histopathological examination of liver and intestine tissues were performed. Meanwhile, non-target metabolomics (NTM) of liver tissues, and 16S ribosomal DNA sequencing (16S seq) of gut microbiota were used to investigate the mechanism of JPHX on ALD.

Results: Compared with the model, the intervention of JPHX significantly reduced serum levels of ALT and AST, alleviated hepatic steatosis, and restored the integrity of the intestinal structure. In non-target metabolomics, the Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses of differentially expressed metabolites between groups showed that JPHX may affect Primary bile acid biosynthesis and Glutathione metabolism pathways. In the gut microbiota analyses, the results of 16S seq showed that at the genus level, the JPHX treatment mainly increased the content of norank_f_Muribaculaceae, unclassified_f_Lachnospiraceae and so on, mainly decreased the content of Monoglobus and Escherichia-Shigella.

Conclusion: JPHX could effectively restore the liver and intestine injury caused by alcohol in acute ALD mice. These effects may be achieved by regulating the gut-liver axis, mainly in the metabolism of bile acids.

Abstract Submission No. 101383
O-0005

TFR2 p.A75V mutation aggravates liver iron overload in alcoholic liver disease via ERK pathway

Chao Xie1, Yingying Liu1, Xiaoming Wang1, Wei Zhang1, Xiaofan Wang1, Tianhui Liu1, Ping Wang1, Lin Liu1, Xu Fan1, Jidong Jia1, Xiaojuan Ou1, Anjian Xu2, Min Cong3

1Liver Research Center Beijing Friendship Hospital, Capital Medical University 95 Yong-An Road, Xicheng District Beijing, China, 2Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University Beijing, China

Background: Liver iron overload is commonly observed in individuals with advanced alcoholic liver disease (ALD). Genetic factors may play a role in the progression of ALD. We aimed to investigate the involvement of hemochromatosis-related genes in liver iron deposition among ALD patients.

Methods: We analyzed clinical data from 97 ALD patients and sequenced exons of HFE, HJV, HAMP, TFR2 and SLC40A1 in 43 patients. We evaluated the severity of iron overload in ALD mice by measuring serum iron metabolism indices, liver iron quantification, and liver iron staining. We examined the effects of TFR2 p.A75V on HAMP induction and its underling mechanism in vivo and in vitro.

Results: ALD patients with liver iron overload had worse liver function and prognosis scores compared to those without iron overload. We identified a potential functional mutation, TFR2 p.A75V, in ALD patients with iron overload. We established a new mouse model of ALD with liver iron overload. After administering recombinant AAV carrying the wild-type TFR2 gene, we observed a significant reduction in iron deposition in hepatocytes. However, the TFR2 p.A75V mutation did not alleviate iron overload in hepatocytes as the wild-type TFR2 did. The TFR2 p.A75V mutation may affect HAMP induction of iron by disrupting the ERK pathway, partially due to abnormal localization of the TFR2 protein in the cytoplasm.

Conclusion: TFR2 p.A75V mutation in ALD may reduce the sensitivity of hepatocytes to iron stimulation in vivo and in vitro by inhibiting the expression of HAMP through the ERK pathway, thereby aggravating iron overload.

Abstract Submission No. 101874
O-0006

Impact of alcoholic cirrhosis on development of renal insufficiency post-liver transplantation

George Lau1, 2, Dali Zhang3, Xi He1, Yudong Wang1, Gregory Cheng1, Jing Chen1, Hui Ren1, Zhenwen Liu2

1Humanity and Health Medical Group Hong Kong, Hong Kong, 2Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing, China, 3JIC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong SAR, China
Objectives: Renal insufficiency is a common complication of liver transplantation (LT) and a risk factor for transplant related mortality. We aim to explore the impact of pre-LT alcoholic cirrhosis on development of post-LT renal insufficiency.

Methods: This retrospective study enrolled adult patients who had LT from January 2015 to January 2019 at a referral hospital. Patients were categorized into alcoholic cirrhosis and non-alcoholic liver disease groups. The incidence of chronic renal insufficiency, defined as creatinine >97 umol/L / >115 umol/L for female / male, persisting for >3 months post-transplant, was compared between two groups. Multivariate logistic regression was performed to explore the risk factors for renal insufficiency.

Results: A total of 139 consecutive patients who had LT were recruited (78.3% male, median age 47.46 years), among which 38 had alcoholic cirrhosis and 101 had non-alcoholic liver disease. Renal insufficiency prevalence was 20.14% overall, higher in alcoholic cirrhosis (34.2%) than non-alcoholic disease (14.9%) patients (P=0.027), with a relative risk of 2.30 (95%CI 1.21-4.38). After adjustment for confounding factors, alcoholic cirrhosis (OR=0.03, 95%CI 1.07, 15.19, P=0.040), male sex (OR=0.13, 95%CI 0.04, 0.51, p=0.003), and low tacrolimus trough concentration (reduced dosage due to renal insufficiency, cutoff values 4.75 ng/mL (OR=0.68, 95%CI 0.51, 0.89, p=0.001) were the independent factors associated with renal insufficiency.

Conclusion: Alcoholic cirrhosis independently increases the risk of chronic renal insufficiency after liver transplantation. Close monitoring of tacrolimus concentration is crucial for individuals with alcoholic cirrhosis post-LT.

Abstract Submission No. 100327
O-0007

Alcohol consumption patterns among various presentations of alcoholic liver disease in South Asians

Sawan Bopanna1, Charu Sharma1, Pallavi Garg1, Richa Bhargava1, Kaushal Madan1

1Max Superspeciality Hospital,Saket, New Delhi New Delhi India

Background and Aim: Alcohol consumption patterns vary between spectrum of alcoholic liver disease(ALD). Few studies compare drinking patterns with varied presentations of ALD among South Asians. We compared patterns of alcohol consumption among ALD with acute on chronic liver failure (ACLF), decompensated cirrhosis (D CLD) and alcoholic steatohepatitis (ASH)

Methods: Patients presenting with ALD from August to November 2022 included. Data regarding patterns of alcohol consumption collected using patient filled questionnaires filled in presence of family members and treating physician. Comparison of various parameters related to alcohol consumption between D CLD, AH/ACLF and ASH done using SPSS

Results: 30 ALD patients included. Median age 48(31-63) with 89.7% males with no significant difference in demographic features. Dose consumed during single binge measured in units (1 unit = 30 ml of whisky) was significantly higher in AH/ACLF group in comparison to other groups, 15(2-36) vs 7(3-15) and 10(5-10). Median duration of consumption in months 154(2-360), 90 (3-480),192(72-360) among AH/ACLF,D-CLD and ASH and difference was not significant. Frequency of binges,snacking, make and type of liquor did not show difference between the 3 groups

Conclusion: Though duration of alcohol intake was similar,AH/ACLF was associated with a higher dose of alcohol intake each time within same duration of drinking. Patients with intake of cirrhotic doses of alcohol, albeit in lower amount each time over a similar period of time presented with a D CLD or alcoholic steatohepatitis. Observation of such patterns in larger cohorts may help identify those patients with alcoholism likely to present with AH/ACLF

Abstract Submission No. 100490
O-0008

Addressing ARLD and AUD with an innovative hepatology nurse-led alcohol reduction program

Mikaela Daniells1, Brooke Gaggins1, Sarah Higgins1, Alicia Cross1, Andrew Sloss1, Angela Copley1, Teraha Wickremeratne1, James O’Beirne1 2, Rohit Gupta1

1SCUH Birtinya Australia, 2University of the Sunshine Coast Sippy Downs Australia

Background: Alcohol-related liver disease (ARLD) is a major under-funded and often neglected area of healthcare. Liver clinics with an integrated focus on addiction have improved outcomes. However, currently, Alcohol Use Disorder medications and psychological services are underutilised by Hepatologists. By establishing a pilot hepatology nurse-led alcohol reduction program, this study aims to address gaps in the current care model for patients with ARLD.

Methods: Patients were enrolled through the liver clinic at Sunshine Coast University Hospital, a tertiary Australian hospital. Seventeen patients were referred to the Pilot Hepatology Alcohol Reduction Program, for which ten patients elected to proceed with the program. Patients completed a 3-month program with two weekly follow-ups with an individualised patient-centred approach to address AUD, with titration and adherence to medications, psychological support including motivational counselling with the option of concurrent psychology assessments.

Results: All patients had ARLD, with 80% diagnosed with cirrhosis. At four weeks, the standard drinks per week reduced from 91.35 [CI 67.72-114.98] to 20.3 [CI 10.15-30.45] p-value <0.01. 70% of patients utilised AUD medications through this clinic, and 50% underwent formal psychology reviews.

Conclusion: Through a nurse-led clinic, patients achieve a significant reduction in alcohol intake and improvement in the utilisation of medications and psychological services.

Abstract Submission No. 100710
O-0009

Alcohol consumption and the risk of liver disease: a nationwide, population-based study

Yang Hyun Baek1, Sang Young Han2, Yeo Wool Kang1, Minkook Son1, Sang Yi Moon1

1Dong-A University College of Medicine Busan South Korea, 2On hospital Busan South Korea

Introduction: Although most patients with alcohol-related liver disease (ALD) have a history of prolonged and heavy drinking, there is no clear threshold defining the level of alcohol consumption that leads to ALD. We aimed to evaluate the correlation between average alcohol consumption and the risk of liver disease.

Materials and methods: Using the Korean National Health Insurance database, we identified participants who underwent a health-screening program. The primary outcome was to determine the incidence of newly diagnosed liver-related diseases during the observation period and compare the incidence of liver-related diseases among non-drinkers and drinkers based on the amount of alcohol consumption.
Results: A total of 53,006 patients were enrolled. The participants were divided into five groups: no alcohol, 1st quartile, 2nd quartile, 3rd quartile, and 4th quartile. The corresponding number of glasses of alcohol consumed per week for each quartile (Q1, Q2, Q3, and Q4) was labeled 0 ± 1.1 standard units, 1.8 ± 1.9 standard units, 4.9 ± 3.3 standard units, and 18.4 ± 3.0 standard units, respectively. Compared with non-drinkers, the risk of liver-related diseases was found to be higher in Q1 drinkers (adjusted hazard ratio [aHR], 1.09; 95% CI, 0.90-1.33), Q2 drinkers (aHR, 1.10; 95% CI, 0.91-1.32), Q3 drinkers (aHR, 1.33; 95% CI, 1.11-1.59), and Q4 drinkers (aHR, 1.47; 95% CI, 1.24-1.75).

Conclusions: We report that our study has shown that drinking more than 11.5 ± 3.3 standard units/week (92 ± 26.4 g/week) significantly increases the risk of developing liver-related diseases.

Abstract Submission No. 100869
O-0010

Secular trend of disease burden of alcoholic hepatitis in region endemic with chronic viral hepatitis

Vicki Wing-Ki Hui1, Terry Cheuk-Fung Yip1, Jimmy Che-To Lai2, Vincent Wai-Sun Wong3, Grace Lai-Hung Wong3, Robert John Wong4

1Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), Institute of Digestive Disease Hong Kong Hong Kong, 2VA Palo Alto Healthcare System and Stanford University School of Medicine Palo Alto United States of America

Objective: Alcoholic hepatitis is a relatively uncommon in Hong Kong, a city endemic with viral hepatitis. With many bars and restaurants shut down during COVID-19 restrictions in 2020 to 2022, off-premise sales of alcohol soared and may lead to increase burden of alcoholic hepatitis. We aimed to evaluate the secular trend of the disease burden of alcoholic hepatitis over the last decade in Hong Kong.

Methods: This was a territory-wide cohort study of consecutive patients with alcoholic hepatitis from January 2010 to June 2022. Alcoholic hepatitis was defined with at least one of the relevant diagnosis codes (ICD-9 571.1 or ICD-10 K70.10, K70.11) together with at least three of the following laboratory criteria: 1) ALT or AST > 50 IU/L; 2) AST:ALT ratio > 2; 3) INR > 2; and/or 4) bilirubin > 3.0 mg/dL.

Results: 943 patients were diagnosed with alcoholic hepatitis; their mean age was 51.1±12.7 years; 89.5% were male. The incidence rates of alcoholic hepatitis fluctuated over the last decade, with a clear increase in the first two years of COVID-19 pandemic (2020-2021) and then dropped in 2022-2023 (2.72-2.83 per 100,000 population), when compared to the baseline (0.90-1.33).

Conclusions: We report that our study has shown that drinking more than 11.5 ± 3.3 standard units/week (92 ± 26.4 g/week) significantly increases the risk of developing liver-related diseases.

Abstract Submission No. 100869
O-0010

Impact of Smoking on Alcoholic Liver Disease and Mortality: Compounding Hazards

Jeong-Ju Yoo1, Chan Jin Yang1, Jin Wook Park1, Dong Hyeon Lee2, Jae Young Jang3, Log young Kim4, Gab Jin Cheon5

1Soonchunhyang University Bucheon Hospital Bucheon South Korea, 2Seoul Metropolitan Government Seoul National University Boramae Medical Center Seoul South Korea, 3Soonchunhyang University Seoul Hospital Seoul South Korea, 4National Health Insurance Service Wonju South Korea, 5Gangneung Asan Hospital Gangneung South Korea

Background: The purpose of this study is to address the critical public health issue of alcoholic liver disease, focusing on its trends, incidence and outcomes.

Methods: National Health Insurance Service claims data and health check-up information from 2011 to 2017 was utilized. Population’s overall drinking amount and the incidence of alcoholic liver disease was calculated based on ICD-10 diagnosis codes.

Results: There has been an overall increase in the rates of regular drinking (49.3% to 51.1%), moderate drinking (15.4% to 16.4%), and stable proportion of high-risk drinking (14.9% to 14.7%) between 2011 and 2017. The incidence rate of alcoholic liver disease increased in proportion to the amount of alcohol (moderate drinker 0.15%, high risk drinker 0.93%) and relatively higher in men than women. There is a decreasing trend in alcoholic fatty liver disease (26% to 22%) but an increase in alcoholic cirrhosis (16% to 26%). Both men and women show an increasing trend in the progression from alcoholic liver disease to cirrhosis over a 3-year follow-up period, with a higher increase rate observed in women. Additionally, medical costs for patients are rising annually, and patients with alcoholic liver disease require more hospitalization and outpatient care compared to the control. However, there was a decreasing trend in the co-diagnosis of alcohol use disorders since 2016 (9.43% to 7.98%).

Conclusion: This study underscores the growing health and social challenges posed by alcoholic liver disease. The rising rates of severe liver disease forms and associated costs indicate an ongoing public health concern.

Abstract Submission No. 101541
O-0011

Incidence, and outcomes of alcohol related liver diseases in Korea: nationwide analysis

Jeong-Ju Yoo1, Chan Jin Yang1, Jin Wook Park1, Dong Hyeon Lee2, Jae Young Jang3, Log young Kim4, Gab Jin Cheon5

1Soonchunhyang University Bucheon Hospital Bucheon South Korea, 2Seoul Metropolitan Government Seoul National University Boramae Medical Center Seoul South Korea, 3Soonchunhyang University Seoul Hospital Seoul South Korea, 4National Health Insurance Service Wonju South Korea, 5Gangneung Asan Hospital Gangneung South Korea

Background: The purpose of this study is to address the critical public health issue of alcoholic liver disease, focusing on its trends, incidence and outcomes.

Methods: National Health Insurance Service claims data and health check-up information from 2011 to 2017 was utilized. Population’s overall drinking amount and the incidence of alcoholic liver disease was calculated based on ICD-10 diagnosis codes.

Results: There has been an overall increase in the rates of regular drinking (49.3% to 51.1%), moderate drinking (15.4% to 16.4%), and stable proportion of high-risk drinking (14.9% to 14.7%) between 2011 and 2017. The incidence rate of alcoholic liver disease increased in proportion to the amount of alcohol (moderate drinker 0.15%, high risk drinker 0.93%) and relatively higher in men than women. There is a decreasing trend in alcoholic fatty liver disease (26% to 22%) but an increase in alcoholic cirrhosis (16% to 26%). Both men and women show an increasing trend in the progression from alcoholic liver disease to cirrhosis over a 3-year follow-up period, with a higher increase rate observed in women. Additionally, medical costs for patients are rising annually, and patients with alcoholic liver disease require more hospitalization and outpatient care compared to the control. However, there was a decreasing trend in the co-diagnosis of alcohol use disorders since 2016 (9.43% to 7.98%).

Conclusion: This study underscores the growing health and social challenges posed by alcoholic liver disease. The rising rates of severe liver disease forms and associated costs indicate an ongoing public health concern.

Abstract Submission No. 101542
O-0012

Impact of Smoking on Alcoholic Liver Disease and Mortality: Compounding Hazards

Jeong-Ju Yoo1, Chan Jin Yang1, Jin Wook Park1, Dong Hyeon Lee2, Jae Young Jang3, Log young Kim4, Gab Jin Cheon5

1Soonchunhyang University Bucheon Hospital Bucheon South Korea, 2Seoul Metropolitan Government Seoul National University Boramae Medical Center Seoul South Korea, 3Soonchunhyang University Seoul Hospital Seoul South Korea, 4National Health Insurance Service Wonju South Korea, 5Gangneung Asan Hospital Gangneung South Korea

Background: The purpose of this study is to address the critical public health issue of alcoholic liver disease, focusing on its trends, incidence and outcomes.

Methods: National Health Insurance Service claims data and health check-up information from 2011 to 2017 was utilized. Population’s overall drinking amount and the incidence of alcoholic liver disease was calculated based on ICD-10 diagnosis codes.

Results: There has been an overall increase in the rates of regular drinking (49.3% to 51.1%), moderate drinking (15.4% to 16.4%), and stable proportion of high-risk drinking (14.9% to 14.7%) between 2011 and 2017. The incidence rate of alcoholic liver disease increased in proportion to the amount of alcohol (moderate drinker 0.15%, high risk drinker 0.93%) and relatively higher in men than women. There is a decreasing trend in alcoholic fatty liver disease (26% to 22%) but an increase in alcoholic cirrhosis (16% to 26%). Both men and women show an increasing trend in the progression from alcoholic liver disease to cirrhosis over a 3-year follow-up period, with a higher increase rate observed in women. Additionally, medical costs for patients are rising annually, and patients with alcoholic liver disease require more hospitalization and outpatient care compared to the control. However, there was a decreasing trend in the co-diagnosis of alcohol use disorders since 2016 (9.43% to 7.98%).

Conclusion: This study underscores the growing health and social challenges posed by alcoholic liver disease. The rising rates of severe liver disease forms and associated costs indicate an ongoing public health concern.
Additionally, smoking significantly increased the 3-year mortality rate in the high-risk drinker group (0.64% vs. 0.49%), and the risk increased significantly in women (RR men 1.18, women 1.95).

**Conclusion:** Smoking worsens the incidence and mortality of alcoholic liver disease in high-risk drinkers. In particular, because the risk increases more for women than for men, smoking cessation education for female drinkers is important.

---

**Neutrophil-to-Lymphocyte Ratio and Infection in Patients with Severe Alcoholic Hepatitis**

ping zhu¹

¹Department of Hepatology and Gastroenterology, Tianjin Third Central Hospital Tianjin China

**Background & aims:** Severe alcoholic hepatitis (SAH) may appear liver failure or decompensation, with infection and high-short-term mortality. We assessed the predictive value of blood neutrophil/lymphocyte ratio (NLR) for infection in patients with SAH.

**Methods:** The patients with SAH were divided into infected group and non-infected group. The indexes in the two groups were compared, and the relationship between NLR and infection was clarified by the generalized additive model. If the curve fitting result between the two groups was non-linear. We analyzed the threshold effect by the piecewise regression model.

**Results:** The clinical data of 143 patients with SAH were collected. According to the presence or absence of infection, we divided the patients into the non-infected group (n = 69) and the infected group (n = 74). When NLR < 13.37, the risk of infection increased by 15% for each 1.00 increase in NLR, OR = 1.15, 95% CI (1.04, 1.27), P = 0.0065. NLR was positively correlated with the risk of infection in a certain range. **Conclusions:** NLR was an indicator to predict infection in patients with SAH.

**Keywords:** alcoholic hepatitis; neutrophil to lymphocyte ratio; prognosis; infection

---

**Genetic Analysis Of The Composition Of Fatty Acid In Diagnosis and Therapy of Alcoholic Liver Disease**

Ramalah Ramlah¹, Haerani Haerani²

¹Universitas Sulawesi Barat Majene Indonesia, ²STIKes Bina Bangsa Majene Majene Indonesia

**Introduction:** The large number of microbiota that inhabit the human digestive system have an important role with the immune system. Microbiota produce a wide variety of metabolites, including short chain fatty acids. Alcohol-related liver disease is liver damage due to excessive and long-term alcohol consumption. This study aims evaluate the compositions of short chain fatty acid producing gut microbiota in diagnosis and therapy of alcoholic liver disease.

**Method:** Data obtained from 29 sequences of the compositions of short chain fatty acid producing gut microbiota of alcoholic liver disease on secondary data form on https://www.ncbi.nlm.nih.gov/. The phylogeny analysis was constructed with UPGMA method using MEGA7.0 software.

**Result:** The optimal tree with the sum of branch length = 28.01713153 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. Genetic variation comes from mutations in genetic material, migration (gene flow), and changes in gene composition through sexual reproduction. Variations also come from the exchange of specific genes. Genetic diversity is the key in character improvement programs for specific genes. This is due to the maximization of genetic acquisition of certain traits. High genetic variation will produce adaptive traits.

**Conclusion:** Genetic Variation of The compositions of short chain fatty acid producing gut microbiota in diagnosis and therapy of alcoholic liver disease have high degree of genetic variability. This information is important for future genetic improvement.

**Keywords:** Genetic Variation, Short Chain Fatty Acid, Gut Microbiota, Alcoholic Liver Disease
Conclusion: Thrombocytopenia and leukopenia are common complications of alcoholic liver cirrhosis (ALC) and are associated with an increased risk of bleeding, infection, and mortality. We aimed to evaluate the therapeutic effect of leucogen, a cysteine derivative that increases platelet and white blood cell (WBC) counts in patients with ALC.

Methods: A total of 413 patients with ALC who had thrombocytopenia (platelet < 100×10^9/L) and/or leukopenia (WBC < 4.0×10^9/L) were enrolled in this retrospective study, the patients were treated with leucogen (20mg, 3 times per day) or not. The primary endpoint was an increase in platelet or WBC count of ≥5% from baseline. Propensity score matching (PSM) was utilized to minimize the impact of selection bias.

Results: Among the 320 patients included in the final analysis after PSM, patients receiving leucogen had significantly higher proportions of platelet increase (46.9% vs. 32.5%, p = 0.012), WBC increase (50.0% vs. 36.2%, p = 0.018) and both PLT and WBC increase (28.1% vs. 15.6%, p = 0.010). The leucogen group exhibited superior fold increases in platelet count (OR 1.833; 95% CI 1.164-2.885; p = 0.009) and WBC count (OR 1.759; 95% CI 1.125-2.750; p = 0.013) compared to the non-leucogen group. Subgroup analysis revealed that patients with baseline factors such as age <60 years, ALT <40 U/L, and AST <40 U/L showed favorable treatment outcomes.

Conclusions: Leucogen is an effective treatment for thrombocytopenia and leukopenia in patients with alcoholic liver cirrhosis.

Abstract Submission No. 100367
O-0018

MSC-derived exosomes attenuate hepatic fibrosis in PSC through inhibition of Th17 differentiation

Hongcei Cao1,2,3,4, Wenyi Chen1,2,3,4, Qiaoling Pan1,2,3,4, Jiong Yu1,2,3,4, Jinfeng Yang5, Lanjuan Li0

1State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China, 2National Clinical Research Center for Infectious Diseases Hangzhou China, 3Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases Hangzhou China, 4National Medical Center for Infectious Diseases Hangzhou China

Primary sclerosing cholangitis (PSC) is an autoimmune cholangiopathy characterized by chronic inflammation of the biliary epithelium and periductal fibrosis, with no curative treatment available and liver transplantation inevitable for end-stage patients. Human placental mesenchymal stem cell (hpMSC)-derived exosomes (ExoMSC) have demonstrated the ability to anti-fibrosis, inhibit collagen production in autoimmune liver disease and possess immunomodulatory properties. Here, we prepared hpMSC-derived exosomes (ExoMSC) and further investigated the anti-fibrotic effects and detailed mechanism on PSC. Results show that ExoMSC ameliorated liver fibrosis in PSC mice (Mdr2Δ/Δ) with significant collagen reduction in the preducal area where Th17 differentiation was inhibited as demonstrated by RNAseq analysis, and the percentage of CD4+ IL-17A+ T cells was reduced both in ExoMSC-treated Mdr2Δ/Δ mice (Mdr2Δ/Δ-Exo) in vivo and ExoMSC-treated Th17 differentiation progressed in vitro. Furthermore, ExoMSC improved the hypersecretory phenotype and intercellular interactions in the hepatic Th17 microenvironment by regulating Perk/Chop signaling as supported by multilecellular organoids. Thus, our data provide mechanistic and therapeutic insights into the role of ExoMSC in liver fibrosis of PSC or Th17-related diseases.

Abstract Submission No. 100368
O-0019

ROS-responsive nanoparticle delivery of OCA mitigate mitochondrial biogenesis and cholestasis in PSC

Hongcei Cao1,2,3,4,5, Qigu Yao1,2,3,4,5, Yingduo Yu1,3,4,5, Jinfeng Yang1,3,4,5, Qiaoling Pan6, Jiong Yu1,3,4,5, Lanjuan Li0

1State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China, 2Jinan Microecological Biomedicine Shandong Laboratory Jinan China, 3Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases Hangzhou China, 4National Medical Center for Infectious Diseases Hangzhou China, 5National Clinical Research Center for Infectious Diseases Hangzhou China

Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease characterized by chronic inflammation of the biliary epithelium and periductal fibrosis, with no curative treatment available and liver transplantation inevitable for end-stage patients. Human placental mesenchymal stem cell (hpMSC)-derived exosomes (ExoMSC) have demonstrated the ability to anti-fibrosis, inhibit collagen production in autoimmune liver disease and possess immunomodulatory properties. Here, we prepared hpMSC-derived exosomes (ExoMSC) and further investigated the anti-fibrotic effects and detailed mechanism on PSC. Results show that ExoMSC ameliorated liver fibrosis in PSC mice (Mdr2Δ/Δ) with significant collagen reduction in the preducal area where Th17 differentiation was inhibited as demonstrated by RNAseq analysis, and the percentage of CD4+ IL-17A+ T cells was reduced both in ExoMSC-treated Mdr2Δ/Δ mice (Mdr2Δ/Δ-Exo) in vivo and ExoMSC-treated Th17 differentiation progressed in vitro. Furthermore, ExoMSC improved the hypersecretory phenotype and intercellular interactions in the hepatic Th17 microenvironment by regulating Perk/Chop signaling as supported by multilecellular organoids. Thus, our data provide mechanistic and therapeutic insights into the role of ExoMSC in liver fibrosis of PSC or Th17-related diseases.
Cellular senescence-triggered dysfunction of hepatocyte aggravates autoimmune liver injury

Jian Chen1, Xinhao Hu1, Tianchen Lan2, Xiao Xu1

1Zhejiang University Hangzhou China, 2Zhejiang Chinese Medical University Hangzhou China

Background: Autoimmune hepatitis (AIH) is an inflammatory liver disease characterized by immune cell-mediated autoimmune response against liver autoantigens. However, little is known about the role of hepatocyte senescence in AIH pathogenesis.

Methods: A novel murine AIH model was established by inhibiting hepatocyte cytokinesis. Cellular senescence was assessed through SA-β-Gal staining and senescent associated secretory phenotype assay. Biochemical and histopathological experiments were performed to detect the hepatic function and liver injury in AIH model. scRNA sequencing was carried out to explore the cellular transition and transcriptomic profile of hepatocyte in AIH. Therapeutically, the efficacy of senolytic treatment (dasatinib plus quercetin) was also investigated in murine AIH model.

Results: Inhibition of cytokinesis induced senescent phenotype in hepatocyte, demonstrating as cell cycle arrest, morphological changes as well as senescent associated secretory phenotype. The liver with senescent hepatocytes exhibited AIH features, including increased ALT and AST levels, presence of autoantibodies and severe interface hepatitis and fibrosis on liver histology. scRNA sequencing analysis revealed an unique hepatocyte cluster with senescent characteristic in AIH liver, which strongly communicated with CD4+ T cell and CD8+ T cell. Unexpectedly, when the AIH mice were treated with senolytic drugs, the liver injury was dramatically alleviated. The increased hepatocyte senescence was also found in AIH patients compared with healthy persons and the senescence proportion was correlated with clinicopathological features.

Conclusions: This study established a novel murine AIH model and revealed the critical role of hepatocyte senescence in AIH pathogenesis. The senolytic treatment is highlighted as a promising therapeutic strategy for AIH.

MSC-EV protects against immunological liver injury by suppressing ferroptosis via Nrf2/GPX4 axis

Xiaoli Fan1, Mengyi Shen1, Leyu Zhou1, Jingping Liu1, Li Yang1

1West China hospital, Sichuan University Chengdu China

Ferroptosis plays an important role in the pathogenesis of various liver diseases, yet it has rarely been investigated in human autoimmune hepatitis (AIH). This study is meant to explore the protective effect and mechanism of extracellular vesicles of mesenchymal stem cells (MSC-EVs) on ferroptosis and excessive inflammation of immunological liver injury (ILI). We found that inflammation associated hepatocytes ferroptosis occurred in ILI mice, whereas deferoxamine attenuated liver injury. In ILI mice, MSC-EVs might reduce hepatocytes ferroptosis and subsequently improve liver injury, while KEGG pathways enrichment analysis also validated that ferroptosis inhibition was involved in the underlying therapeutic mechanisms. Besides, further GPX4 inhibition experiments revealed that MSC-EVs alleviated inflammatory response induced ferroptosis via upregulating GPX4 in vitro. Meanwhile, MSC-EVs could increase the expression of Nrf2 and Nrf2 inhibition alleviated the effects of MSC-EVs. Transwell assay revealed that MSC-EVs could prevent the recruitment and chemotaxis of macrophages induced by ferroptotic hepatocytes. Moreover, we found that there was a significant correlation between levels of circulating 4-HNE and transaminases and treatment response, while over-activation of ferroptosis was revealed in hepatocytes in AIH patients. In conclusion, MSC-EVs could ameliorate inflammatory injury in ILI by suppressing hepatocytes ferroptosis via the Nrf2/GPX4 signaling pathway.
Targeting monocytes via CCL2/CCR2 axis in autoimmune hepatitis by macrophage-derived exosomes

Xiaoli Fan1, Ruiqi Wu1, Fan Yang1, Jingping Liu1, Li Yang1
1West China hospital, Sichuan University chengdu China

Background: Autoimmune hepatitis is a serious chronic liver disease with immune disorders, histological lesions and liver dysfunction, with a gradually increasing prevalence. Yet the cellular and molecular mechanisms of immune dysregulation in AIH are poorly understood.

Methods: Using proteomic analysis, we comprehensively profiled the differentially expressed proteins and signaling pathways of liver during human AIH. Then, monocytes and macrophage from blood and livers of AIH patients and controls were analyzed. The recruitment and polarization of monocyte-derived macrophages in AIH and the mechanism of CCL2/CCR2 axis activation were investigated by Concanavalin induced experimental AIH (EAH). The CCL2/CCR2 axis was blocked by CCL2 neutralizing antibody and CCR2 antagonist to determine its effect on AIH mice. Finally, M2 macrophage-derived extracellular vesicles (M2-EVs) were isolated and extracted as drug delivery tool of CCR2 antagonist, and its therapeutic effect on AIH mice was determined.

Results: Proteomic analysis took expression ratio (FC) > 1.5 times and P<0.05 as screening criteria, and a total of 1028 proteins were identified as increased or decreased. KEGG analysis suggested that differential expressed proteins were mainly associated with metabolic processes. The expression of mononuclear macrophage system marker proteins CD14, S100A9, CD163, CD68 and CD11b increased in the liver tissue of AIH patients as revealed by proteomic analysis and immunohistochemistry. The proportion of classical monocytes in peripheral blood of AIH was increased, which was positively correlated with the levels of ALT and AST of AIH patients. The co-localization analysis of liver tissue suggested that CCL2 originated from Kupffer cells (KC), and the expression of CCR2 increased after circulating monocytes infiltrated liver. The expression of M1 marker in AIH liver tissue increased. AIH mouse models suggest mobilization of inflammatory monocytes on the bone marrow-liver axis and spleen-liver axis. Blocking up of CCL2/CCR2 axis with CCL2 neutralizing antibody or CCR2 antagonist, respectively, alleviated liver injury in AIH mice, while recombinant CCL2 injection increased recruitment of inflammatory monocytes with bone marrow-liver axis and spleen-liver axis to liver, aggravating liver injury. CCR2 antagonist-M2-EV can target circulating mononuclear cells and activated mononuclear macrophages in the liver, respectively, to reduce liver injury in AIH mice.

Conclusion: AIH mediates the recruitment of inflammatory monocytes from bone marrow and spleen to liver through the CCL2/CCR2 axis, which can be inhibited by different methods to reduce liver inflammatory injury in AIH mice. M2-EVs delivers CCR2 antagonists targeting activated pro-inflammatory monocytes and hepato-splenic mononuclear macrophage system in the circulating pool, indicating that CCR2 antagonists-EVs could be a potential agent for liver and monocyte targeted therapy for AIH.

Bile multi omics provide molecular insight and classify signatures of carcinoma of gall bladder

NUPUR SHARMA1, Sadam H Bhat1, Babu Mathew1, Manisha Yadav1, Gaurav Tripathi1, Vasundhara Bindal1, Neha Sharma1, Sushmita Pandey1, Hami Hemati2, Deepika Bohra2, Rashmi Rana2, Sanyam Falari1, Vinnyendra Pamecha1, Jaswinder Singh Maras1
1Institute of Liver and Biliary Sciences Faridabad India, 2Department of Research, GRIPMER, New Delhi India, 3University of kentucky Lexington India

Carcinoma of the gall bladder (CAGB) has poor prognosis. Molecular analysis (proteome/metabolome) of bile could recapitulate changes associated with CAGB development and help in characterization of putative indicators for early CAGB diagnosis. Bile samples screened for proteomics-metabolomics signatures capable of early detection of cancer in GB anomalies. Analysis of training cohort (n=87) showed that bile of CAGB patients has distinct proteomic (217up- and 258 down-regulated; FC>1.5) and metabolomic (111 up- and 505 down-regulated; FC>1.5) phenotype as compared to Gallstone or HC (p<0.05,FDR<0.01). Partial least square discriminant analysis and unsupervised hierarchical-clustering segregated CAGB patients. CAGB bile was significantly enriched for proteins/metabolites linked to inflammation, and alternate energy pathways (pentose phosphate pathway, amino acid metabolism, lipid metabolism, and others). CAGB bile showed reduction of Proteins/metabolites associated to glycolysis, cholesterol metabolism, PPPAR, RAS, and RAP1 signaling glutathione, histidine, purine metabolism, oxidative phosphorylation, and others (p<0.05). Integration analysis revealed strong correlation (r>0.5, p<0.05) between significant proteins/metabolites and clinical parameters and showed alteration of pathways linked to lipid metabolism, platelet activation, amino acid metabolism, and others (p<0.05). Metabolite/protein signature-based probability of detection for CAGB was >90% (p<0.05) with AUC=0.94. Validation of top four metabolites panel: Toluene, 5,6-DHET, Creatine, and Phenyl acetaldehyde using five machine-learning algorithms in two separate cohorts (n=40; bile [test cohort 1] and paired plasma [test cohort 2]) showed accuracy (99%) and sensitivity/specificity (>98%) for CAGB detection. Conclusion: Bile proteome and metabolome alteration provides critical molecular understanding and outlines metabolomics panel which may offer universal utility for early detection of CAGB.

The analysis of risk factors for hepatocellular carcinoma in patients with autoimmune liver disease

Makiko Tanai1, Katsutoshi Tokushige1, Yuri Ogasawara1, Tomomi Kogiso1
1Tokyo Women's Medical University Shinjyuku-ku, Tokyo Japan

Aim: Autoimmune liver disease including primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) is rare as the cause of hepatocellular carcinoma (HCC) in Japan. However, the hepatocarcinogenesis in autoimmune liver disease is still unclear. Metabolic syndrome such as obesity or type 2 diabetes mellitus (DM) has been reported to increase the risk of HCC. Thus, we have conducted a study to clarify the clinical risk factors for developing HCC in patients with autoimmune liver disease.

Patients and Methods: We investigated 608 PBC patients (females; 86%, median age; 59 (21-85) and 314 AIH patient diagnosed (females 84% age 52 (19-86) as Japanese Criteria. We observed all 922 patients without HCC at the time of the initial diagnosis with PBC or AIH for a median of 9.4 years (0.3-35) to evaluate risk factors for the development of HCC.
**Results:** HCC newly developed in 57 patients. The cumulative appearance rate of HCC was 0.5% and 1.2% at the end of the fifth and tenth years by Kaplan-Meier analysis. Independent risk factors for HCC by Cox model were cirrhosis [hazard ratio (HR) 4.459, p = 0.005], higher age (HR 1.077, p = 0.014), male gender (HR 2.884, p = 0.027), and complicated DM (HR 1.538, p = 0.031).

**Conclusions:** The independent risk factors for HCC in patients with autoimmune liver disease were cirrhosis, age, male, and DM. Careful observation of patients with a high risk of HCC will improve the prognosis of patients with PBC or AIH.

---

**Abstract Submission No. 100049**

**O-0026**

**Low serum complement is common in autoimmune hepatitis and is related to high serum immunoglobulin G**

**Yi Shen**, **Jie Sun**, **Mengyi Shen**, **Li Yang**

1Department of Gastroenterology & Hepatology, Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University Chengdu China

**Objective:** Complement could mediate immune response and inflammation in systematic immune diseases, but its role in autoimmune hepatitis (AIH) has not been clearly clarified.

**Methods:** We retrospectively collected 146 patients with diagnosis of AIH, systemic lupus erythematosus and other liver diseases were excluded. Biochemical tests were performed before treatment. In our hospital, normal range of complement 3 (C3) is 0.785-1.520 g/L, and C4 is 0.145-0.360 g/L. So, we defined C3 <0.785 g/L as low-C3 and C3 >1.520 g/L as high-C3, C4 <0.145 g/L as low-C4 and C4 >0.360 g/L as high-C4. The G grade (Scheuer score system) of inflammation of liver biopsy tissues were evaluated. Firstly, we analyzed the correlations between complement and transaminase (ALT and AST). Then, because guidelines recommended that immunoglobulin G (IgG) > 2x upper limit of normal (ULN) is an indicator of immunosuppressive therapy, so we divided patients into two groups according to IgG (≥2x ULN and >2x ULN) for further analysis. Also, we performed comparison between patients with different G grade (G1-G2 and G3-G4). Finally, because cirrhosis could lead to elevated serum IgG and low complement, we excluded patients with cirrhosis for further analysis.

**Results:** Eighty-three (56.8%) patients with low-C3 and 71 (48.6%) patients with low-C4. No patients had high-C3 and only one patient had high-C4. There were no significant correlations of C3 and ALT/AST (P=0.766, r=0.205; P=0.256, r=0.094, respectively). For C4, the correlations between it and ALT/AST were weak (P=0.001, r=-0.264; P=0.005, r=0.229). And we found that patients in IgG≥2x ULN group had lower serum complement than that in IgG≤2x ULN group [C3: 0.588±0.288 g/L, 0.770±0.25 g/L, P=0.001; C4: 0.116 (0.102, 0.129) g/L, 0.155 (0.122, 0.203) g/L, P<0.001]. In addition, 139 patients performed liver biopsy, patients in G3-G4 group had lower serum complement than that in G1-G2 group [C3: 0.712±0.265 g/L, 0.813±0.234 g/L, P=0.026; C4: 0.135 (0.106, 0.181) g/L, 0.167 (0.136, 0.216) g/L, P=0.003]. Sixty-seven patients were excluded because cirrhosis. Then, further comparison indicated that patients with low serum complement had higher IgG [low C3 vs non-low C3: 26.7 (20.0, 32.4) g/L vs 17.8 (16.3, 23.3) g/L, P=0.003; low C4 vs non-low C4: 26.6 (20.0, 33.5), 18.6 (16.0, 24.9), P=0.002]. But no matter for C3 or C4, percentages of G3-G4 were not significantly different between two groups [low C3 vs non-low C3: 15 (51.7%), 24 (51.1%), P=0.955; low C4 vs non-low C4: 13 (65.0%), 26 (46.4%), P=0.154].

**Conclusion:** Low serum C3/C4 was very common in AIH patients, and it was related to high serum IgG.

---

**Abstract Submission No. 100139**

**O-0028**

**Multi-omics reveal underlying mechanisms of drug-response in PBC/AIH variant syndrome**

**Fan Yang**, **Leyu Zhou**, **Yi Shen**, **Xianglin Wang**, **Xiaoli Fan**, **Li Yang**

1Department of Gastroenterology and Hepatology and Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, West China Hospital, Sichuan University Chengdu China

**Background:** Primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) variant syndrome (VS) present a complex overlap of AIH features with PBC, creating challenges for clinical management. This study aims to elucidate the mechanisms underlying drug response in PBC/AIH VS by integrating whole-transcriptomics and metabolomics, complemented by cytokinomic analysis.

**Methods:** We performed whole-transcriptome sequencing on liver tissues from 10 PBC/AIH VS patients, categorizing them into good responders (GR) and poor responders (PR). Additionally, we conducted plasma metabolomics on 50 PBC/AIH VS patients, further divided...
into GR (n=20) and PR (n=30). A wide range of cytokines was quantified in the same plasma using bead-based immunoassay technology. Findings: Analysis identified 224 differentially expressed (DE) mRNAs, 189 DE long non-coding RNAs, 39 DE circular RNAs, and 63 DE microRNAs. Functional pathway analysis enriched in immune response and metabolic pathways. We constructed 256 lncRNA-miRNA-mRNA networks and 19 circRNA-miRNA-mRNA networks, offering insights into regulatory interactions. Furthermore, we detected eight cytokines significantly differing between the two groups, indicating correlations between Th1 and Th2, as well as Th17 and Treg subsets, and drug response.

Conclusion: This exploratory study enhances our understanding of drug response mechanisms in PBC/AIH VS through comprehensive whole-transcriptome analysis. It also unveils distinctions in metabolic and immune profiles between patient subgroups by integrating metabolomics and cytokinomics. These findings offer new perspectives for treatment of these patients.

Abstract Submission No. 100239
O-0029
Identification of High-Risk Group for Relapse in Autoimmune Hepatitis Patients
Takatoshi Nawa¹, Tomonori Ishida¹, Ryota Nakanishi¹, Shingo Maeda¹, Koshi Sunaga¹, Mina Kato¹, Haruki Akamatsu¹, Shuji Ishii¹, Masahiko Tsujii¹
¹Department of Gastroenterology, Higashiosaka-city Medical Center

Background and Aim: Autoimmune Hepatitis (AIH) is a relatively rare disease caused by an autoimmune disorder. While steroid therapy is effective in many cases, some cases have relapses during steroid tapering. In this study, we investigated the risk factors for relapse during steroid therapy in AIH patients.

Methods: We retrospectively analyzed 31 cases of AIH patients who started steroid therapy at our institution from October 2010 to April 2023. We defined the patients who had relapse before tapering prednisolone to a dosage of 5mg/day as Relapse group, while others as Remission group. Risk factors for relapse were analyzed by using logistic regression model.

Results: Among 31 cases, 26 kept being remission, while five had relapse. All cases of Relapse group were brought under control by the addition of azathioprine. Multivariate analysis showed only age was an independent risk factor for relapse (odds ratio = 0.85, 95% confidence interval (CI) = 0.728-0.992, p-value = 0.04). Relapses were observed only in younger group (< 66 years, n = 15). In that group, high International AIH Group (IAIHG) scores at pretreatment showed a significant trend as a risk factor in univariate analysis (odds ratio = 1.53, 95% CI = 0.943-2.490, p-value = 0.085). We defined high-risk group as the patients who were young (< 66 years) and had high IAIHG scores (> 15 points), and the relapse rate of that group was 66.7% (4/6 cases). Conclusion: AIH patients with both younger age and high IAIHG scores have a higher risk of relapse during steroid tapering.

Abstract Submission No. 100387
O-0030
Azathioprine on Risk of Extrahepatic Malignancy with Autoimmune Hepatitis: A Nationwide Claims Study
Sung Hwan Yoo¹, Jung Il Lee¹, Hyun Woong Lee¹
¹Gangnam Severance Hospital Seoul South Korea

Background and aims: Long-term immunosuppressive therapy in patients with autoimmune hepatitis (AIH) increases the risk of extrahepatic malignancy in addition to hepatocellular carcinoma. However, the risk of extrahepatic malignancy is unknown in Korean AIH patients. We aimed to evaluate the impact of azathioprine (AZT) treatment on extrahepatic malignancy risks.

Methods: We identified all persons diagnosed with AIH between 2008 and 2020. We included 8,280 patients with AIH, using the national claims data of the Health Insurance Review and Assessment Service (HIRA). The numbers of patients treated with and without AZT were 3,059 and 5,221, respectively. We estimated the cumulative risks of extrahepatic malignancy and hazard ratios (HRs) between patients treated with and without AZT.

Results: Among 8,280 patients, the mean age was 56.7±13.5 years, 84.3% were women, and the follow-up period was 49.8±43.1 months. The mean age and sex are not different between patients treated with and without AZT. However, the number of patients with diabetes was higher in patients treated with AZT (31.3% vs. 28.0%). The number of patients with liver cirrhosis was higher in patients treated without AZT (36.0% vs. 38.9%). At the time of diagnosis, 85.5% of patients with AZT and 30.0% of patients without AZT were treated with steroids for more than 90 days (P<0.001). The incidence of extrahepatic malignancy was 1.36 and 1.23 per 100 person-years in the patients treated with AZT and without AZT, respectively (P=0.685). After we adjusted for confounding by age, sex, diabetes, and liver cirrhosis, the HR was 1.09 (95% confidence interval 0.79-1.51, P=0.600).

Conclusion: The national claims data of HIRA did not show that AZT significantly increases the risk of extrahepatic malignancy among AIH patients.

Abstract Submission No. 100549
O-0031
Association of sarcopenia with treatment response and outcomes in non-cirrhotic PBC patients
Leyu Zhou¹, Bo Li², Yifeng Liu¹, Xianglin Wang¹, Yuxin Guo¹, Yan Yi Zheng¹, Qiaoyu Deng¹, Xiaoli Fan¹, Li Yang²
¹Department of Gastroenterology and Hepatology and Hepatology and Sichuan University-University of Oxford Huaxi Joint Centre for Gastrointestinal Cancer, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, ²Department of Radiology, West China Hospital, Sichuan University Chengdu China

Background: The prevalence of sarcopenia and its effects on the treatment outcomes of ursodeoxycholic acid (UDCA) in patients with non-cirrhotic primary biliary cholangitis (PBC) remains uncertain.

Aims: To investigate the prevalence of sarcopenia and its association with biochemical responses and clinical outcomes in non-cirrhotic PBC patients.

Methods: Between January 2009 and July 2022, consecutive PBC patients were retrospectively enrolled. Sarcopenia was assessed via pre-treatment CT or MRI scans at the L3 level. Baseline characteristics, response rate of UDCA treatment, liver-related adverse events, as well as the gene expression and protein level of C-reactive protein (CRP) and interleukin-6 (IL-6) were compared in patients with and without sarcopenia.
Autoimmune hepatitis - primary biliary cholangitis overlap syndrome

Chongqing Medical University Chongqing China, 2Department of

(AIH-PBC OS) is a rare disease with non-specific signs and symptoms. However, the exact role of sarcopenia in the progression and outcomes of PBC requires further investigation.

Abstract Submission No. 100766

O-0032

A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in a Filipino Adult

Katrina Nicole Mejia1, Celina Celeste Adraneda1

1Cardinal Santos Medical Center San Juan Philippines

Autoimmune hepatitis - primary biliary cholangitis overlap syndrome (AIH-PBC OS) is a rare disease with non-specific signs and symptoms. We report a case of a Filipino adult female presenting with one week history of abdominal pain, accompanied by malaise and jaundice. Laboratory tests revealed gamma glutamyl transferase (GGT) > 5 times upper limit of normal (ULN) and presence of anti-mitochondrial antibodies (AMA); alanine aminotransferase (ALT) activity > 5 times ULN and liver biopsy with moderate interface hepatitis. These parameters fulfilled two out of the three criteria each for the diagnosis of PBC and AIH, respectively, hence the diagnosis of AIH-PBC OS - AIH predominant was made. She was started on prednisone and ursodeoxycholic acid (UDCA). However, on dual energy X-ray absorptiometry (DEXA) scan, she was noted to have osteoporosis, hence prednisone was continued to be tapered and discontinued. Azathioprine was added (DEXA) scan, she was noted to have osteoporosis, hence prednisone was continued to be tapered and discontinued. Azathioprine was added and bile duct loss (ductopenia) and pathological features and prognosis of PBC patients with premature ductopenic variant of primary biliary cholangitis

Tingting Lv1, Haitian Yu1, jidong Jia1, xinyan zhao1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Objective: Some primary biliary cholangitis (PBC) patients present with prolonged cholestasis and extensive bile duct loss (ductopenia) but no significant fibrosis or cirrhosis. We aimed to clarify the clinical and pathological features and prognosis of PBC patients with premature ductopenia. Methods: This retrospective study recruited patients with early-stage PBC (Ludwig stage I or II). Demographic, laboratory, and pathological data were recorded, and clinical outcomes, including decompensated cirrhosis, liver transplantation or death, were followed up by interview. Logistic regression was conducted to identify the baseline features associated with ductopenia.

Results: A total of 141 patients with early-stage PBC were ultimately included, of which 34 had ductopenia and 107 did not have ductopenia. Early-stage PBC patients with ductopenia had higher levels of ALT, AST, ALP, GGT, TBIL, TBA, CHOL, and TG but lower levels of IgG and IgM at baseline than those without ductopenia (all P<0.05). Importantly, early-stage PBC with ductopenia had a lower response rate according to the Paris II, Barcelona and Rotterdam criteria. However, during a median follow-up period of 4.5 years, there was no significant difference in clinical outcome between early-stage PBC with vs. without ductopenia. Logistic regression analysis showed that baseline total CHOL levels were independent predictors for ductopenia. Conclusion: Ductopenia was a significant risk factor for worse biochemical profiles and poor treatment response but not for a short-term prognosis in early-stage PBC patients. High levels of CHOL at baseline may be associated with ductopenia in early-stage PBC patients.

Abstract Submission No. 101086

O-0034

Clinical characteristic and prognosis of premature ductopenic variant of primary biliary cholangitis

Analysis of diagnostic predictors in patients with PBC-AIH overlap syndrome from AIH

Li Zhang1, Hongmei Wu1, Li Liu2, Xiaofeng Shi2, Peng Hu1, Yu Lei3

1Institute for Viral hepatitis , Second Affiliated Hospital of Chongqing Medical University Chongqing China, 2Department of pathology, Second Affiliated Hospital of Chongqing Medical University Chongqing China

Background: Autoimmune hepatitis (AIH) is one of the main categories of autoimmune liver disease (AILDs). Approximately 10% of AIH patients displayed overlapping features of both AIH and PBC, referred as PBC-AIH overlap syndrome (PBC-AIH OS). This study aimed to explore the indicators for early diagnosis of PBC-AIH OS from AIH. Methods: By retrospective analysis, the general characteristics, clinical manifestations, biochemical tests, immunological tests, and liver histological examinations in patients with PBC-AIH OS and AIH at the time of initial diagnosis were analyzed. Univariate logistic regression analysis and multiple-factors analysis via multivariate logistical regression were used to predict the diagnosis of PBC-AIH OS based on the hematological indicators.

Results: A total of 105 AILDs patients were included in this retrospective study who underwent liver biopsy. There were no statistically significant differences in mean age, sex, or symptoms between PBC-AIH OS and AIH patients. Compared to AIH patients, PBC-AIH OS patients showed significantly high levels of serum globulin, ALP, GGT, PTA, AMA-M2, IgM and significantly low levels of ALT, AST and INR. The expression of ANA, ASMA, AMA and ROS2 were significant differences in these two groups. Univariate logistic regression analysis and multiple-factors analysis via multivariate logistical regression showed that GGT and AMA-M2 were significant predictors of PBC-AIH OS.

Conclusion: The degrees of cholestasis and dysimmunity in PBC-AIH OS patients were significantly higher than that in AIH patients. However, hepatocyte inflammation is more severe in patients with AIH. GGT and AMA-M2 can be used as noninvasive diagnostic indicators to predict PBC-AIH OS.

Abstract Submission No. 100871

O-0033

A total of 141 patients with early-stage PBC were ultimately included, of which 34 had ductopenia and 107 did not have ductopenia. Early-stage PBC patients with ductopenia had higher levels of ALT, AST, ALP, GGT, TBIL, TBA, CHOL, and TG but lower levels of IgG and IgM at baseline than those without ductopenia (all P<0.05). Importantly, early-stage PBC with ductopenia had a lower response rate according to the Paris II, Barcelona and Rotterdam criteria. However, during a median follow-up period of 4.5 years, there was no significant difference in clinical outcome between early-stage PBC with vs. without ductopenia. Logistic regression analysis showed that baseline total CHOL levels were independent predictors for ductopenia. Conclusion: Ductopenia was a significant risk factor for worse biochemical profiles and poor treatment response but not for a short-term prognosis in early-stage PBC patients. High levels of CHOL at baseline may be associated with ductopenia in early-stage PBC patients.

Abstract Submission No. 100766

O-0032

A Rare Case of Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome in a Filipino Adult

Katrina Nicole Mejia1, Celina Celeste Adraneda1

1Cardinal Santos Medical Center San Juan Philippines

Autoimmune hepatitis - primary biliary cholangitis overlap syndrome (AIH-PBC OS) is a rare disease with non-specific signs and symptoms. We report a case of a Filipino adult female presenting with one week history of abdominal pain, accompanied by malaise and jaundice. Laboratory tests revealed gamma glutamyl transferase (GGT) > 5 times upper limit of normal (ULN) and presence of anti-mitochondrial antibodies (AMA); alanine aminotransferase (ALT) activity > 5 times ULN and liver biopsy with moderate interface hepatitis. These parameters fulfilled two out of the three criteria each for the diagnosis of PBC and AIH, respectively, hence the diagnosis of AIH-PBC OS - AIH predominant was made. She was started on prednisone and ursodeoxycholic acid (UDCA). However, on dual energy X-ray absorptiometry (DEXA) scan, she was noted to have osteoporosis, hence prednisone was continued to be tapered and discontinued. Azathioprine was added and bile duct loss (ductopenia) and pathological features and prognosis of PBC patients with premature ductopenic variant of primary biliary cholangitis

Tingting Lv1, Haitian Yu1, jidong Jia1, xinyan zhao1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Objective: Some primary biliary cholangitis (PBC) patients present with prolonged cholestasis and extensive bile duct loss (ductopenia) but no significant fibrosis or cirrhosis. We aimed to clarify the clinical and pathological features and prognosis of PBC patients with premature ductopenia. Methods: This retrospective study recruited patients with early-stage PBC (Ludwig stage I or II). Demographic, laboratory, and pathological data were recorded, and clinical outcomes, including decompensated cirrhosis, liver transplantation or death, were followed up by interview. Logistic regression was conducted to identify the baseline features associated with ductopenia.

Results: A total of 141 patients with early-stage PBC were ultimately included, of which 34 had ductopenia and 107 did not have ductopenia. Early-stage PBC patients with ductopenia had higher levels of ALT, AST, ALP, GGT, TBIL, TBA, CHOL, and TG but lower levels of IgG and IgM at baseline than those without ductopenia (all P<0.05). Importantly, early-stage PBC with ductopenia had a lower response rate according to the Paris II, Barcelona and Rotterdam criteria. However, during a median follow-up period of 4.5 years, there was no significant difference in clinical outcome between early-stage PBC with vs. without ductopenia. Logistic regression analysis showed that baseline total CHOL levels were independent predictors for ductopenia. Conclusion: Ductopenia was a significant risk factor for worse biochemical profiles and poor treatment response but not for a short-term prognosis in early-stage PBC patients. High levels of CHOL at baseline may be associated with ductopenia in early-stage PBC patients.
Clinical, serological and histological features of autoimmune liver diseases.

Kenwal Butani¹, Nazish Butt¹

¹Jinnah postgraduate medical center JPMC Karachi Karachi Pakistan

Autoimmune liver disease (ALD) is a rare spectrum of disease comprising of autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and overlap syndrome.

To evaluate the clinical, serological and histological features in patients presenting with autoimmune liver diseases in a tertiary care hospital in Karachi, Pakistan.

A cross-sectional case series of 31 patients which were enrolled in a study from January 2017 till date presenting at Jinnah Postgraduate Medical Center, Karachi. Demographic and clinical data including liver function tests, clotting profile, gamma globulin levels, autoimmune serology and liver histology were recorded on designed proforma.

Mean age of patients was 28.19±8.6 years. Females 23 (74.2%) and males 8 (25.8%). Most common symptom was fatigue (96.8%), followed by arthralgia (77.4%), anorexia and jaundice (61.3%). Type I AIH was present in 19 (61.3%), Type II AIH in 11 (35.5%) and AIH/PBC overlap in 1 (3.2%) patient respectively, however, no discrete case of PSC and PBC was reported. Immunoglobulin G level was raised in all patients with mean of 1672±530. Liver histology showed lymphoplasmacytic interface hepatitis in 19 (61.3%) patients and lobular hepatitis with centrilobular necrosis in 11 (35.5%) patients respectively.

Autoimmune liver disease can occur at any age, in both sexes with favorable results on immunosuppression. It can progress to several complications like decompensated liver disease, hepatocellular carcinoma, osteoporosis and dyslipidemia.

A worse subgroup of PBC: jaundice in patients with ductopenia

Tingting LV¹, Weijia Duan¹, Xinyan Zhao¹, Jidong Jia¹

¹Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Objective: Hyperbilirubinemia associated with poor prognosis of PBC, while not all PBC patients with ductopenia (bile duct loss greater than 50%) present prolonged jaundice. We aimed to clarify the clinicopathological features, prognosis and underlying mechanism of these subgroup icteric PBC patients with ductopenia.

Methods: This retrospective study recruited PBC patients with ductopenia diagnosed by liver biopsy. Demographic, clinicopathological data, treatment response and long-term prognosis of these patients were followed and recorded. Immunohistochemical stain of BSEP and MRP2 were conducted in these ductopenic patients with or without jaundice.

Results: A total of 265 patients with liver biopsy were included, of which 77 had ductopenia (18 accompanied with jaundice and 59 did not). We found ductopenic patients with jaundice had higher levels of TBIL, TBA, CHOL, and TG but a similar level of ALT, AST, ALP, GGT than those without jaundice (all P<0.05). Additionally, ductopenic PBC patients with jaundice had a lower survival rate when compared to those without jaundice (P<0.05). There was no significant difference in UDCA response between ductopenic PBC with or without jaundice (Paris II, Barcelona and Rotterdam criteria: P>0.05). The expression of BSEP and MRP2 was higher in patients without jaundice but significant lower in those with jaundice (P<0.05).

Conclusion: Jaundice does not seem to follow the same course as ductopenia in PBC. Ductopenic PBC patients with jaundice showed a similar worse treatment response but a poorer prognosis and uncompensated bile salt transporter helps to explain.

Late UDCA response is associated with worse prognosis of PBC patients compared to early response

Sylvia Drazilova¹, Ivica Grgurevic²,³, Tajana Filip canizaj¹,⁴, Tomas Koller⁵, Beatrica Bodorovska⁸, Tomci Bozin⁷, Maja Mijic⁶,
Zrinka Robi, Martin Janicko, Jakub Gazda, Ivana Mikolasevic, Anita Madir, Peter Jarcuska

12nd Department of Internal Medicine, Pavol Jozef Safarik University and Louis Pasteur University Hospital, Trieda SNP 1, 040 12, Kosice, Slovakia. Kosice Slovakia, 1Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, Avenija Gojka Suska 6, 10000 Zagreb, Croatia.

Zagreb Croatia, 1Department of Gastroenterology, Hepatology and Clinical Nutrition, School of Medicine, University of Zagreb, Salata ul. 2, 10000 Zagreb, Croatia. Zagreb Croatia, 1Department of Gastroenterology, University Hospital Merkur, Zajceva ul. 19, 10000 Zagreb, Croatia. Zagreb Croatia, 5th Department of Internal Medicine, Subdivision of Gastroenterology and Hepatology, Comenius University Faculty of Medicine, University Hospital Bratislava, Ruzinovska 6, 826 06 Bratislava, Slovakia. Bratislava Slovakia, 1Climic of Gastroenterological Internal Medicine, Comenius University in Bratislava and University Hospital Martin, Kollarova 2, 036 59 Martin, Slovakia. Martin Slovakia, 1Department of Gastroenterology, School of Medicine, University of Rijeka, Brac Branchetta 20/1, 51000 Rijeka, Croatia. Rijeka Croatia

Introduction: Our aim was to describe parameters after 6 months of UDCA treatment that are associated with poor prognosis in UDCA responders after 12 months of treatment.

Cohort of the patients: We analyzed 249 patients treated with UDCA for PBC at Slovak and Croatian centers; Patients were followed for a mean of 5.0 years. Therapeutic response after 12 months of treatment was defined according to Toronto criteria.

Results: 146 patients who achieved a response at 12 months using the modified Toronto criteria were included in the final analysis. 115 of these patients met the modified US criteria after 6 months of treatment - early responders; 31 patients did not meet these criteria after 6 months - late responders. Complete response was defined as normalization of total bilirubin and ALP at the last visit; optimal complete response was defined as bilirubin < 0.6 ULN and normalized ALP at the last visit. Early responders achieved complete response and optimal complete response at the last visit more frequently compared to late responders (59.1% vs. 38.7% p 0.043), (47.8% vs. 29% p 0.061). The risk of death and liver transplantation during the follow up was significantly lower in early responders compared to late responders (0% vs.4% p 0.041).

Conclusions: Late UDCA response is associated with increased mortality and less frequent complete therapeutic response to UDCA compared to early UDCA response. For PBC patients with inadequate UDCA response, second-line treatment should be considered after 6 months of treatment.

Abstract Submission No. 101308

O-0039

Building hepatic MRI models predict histopathological severity and insufficient response in AIH

Xiao Han, Dawei Yang, Yu Su, Qianyi Wang, Min Li, Jimin Liu, Jidong Jia, Hong Ma, Xinyan Zhao

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Beijing, China China, 2Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China Beijing China, 3Department of Clinical Epidemiology and EBM, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Beijing China, 4Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Canada. Hamilton Canada

Abstract

Background: The correlation between hepatic magnetic resonance imaging (MRI) and liver histopathology has rarely been reported in autoimmune hepatitis (AIH). We built models using hepatic MRI features to predict histopathological severity/treatment response in AIH patients.

Methods: AIH patients with abdominal contrast MRI and liver biopsy were retrospectively retrieved from our AIH database (n=329, 2002-2023). Laboratory tests, hepatic MRI features and treatment response were collected. The liver volume was measured, and liver histopathological severity was evaluated according to the Ishak system. Models for predicting histopathological severity and response were constructed by logistic regression.

Results: Ninety-two AIH patients (median age: 56.50 years, 78.26% female) with simplified International AIH Group (IAIHG) scores ≥6 were included. Thirty-nine (42.39%) with severe confluent necrosis(≥5), 18 (19.57%) with advanced fibrosis(≥5). The MRI features of hepatic fissure widening, reticular fibrosis and the volume ratio of Couinaud segment II-IV vs. the total liver were independently associated with severe confluent necrosis; the enlarged preportal space, reticular fibrosis and the volume ratio of Couinaud segment I vs. the total liver were independently associated with advanced fibrosis; the ascites, gallbladder wall edema and transient hepatic attenuation difference were independently associated with insufficient response, with an area under the ROC curve of 0.827(95% CI 0.743-0.910), 0.911(95% CI 0.848-0.973) and 0.796(95% CI 0.691-0.902) respectively. The C-statistics of the internal validation were 0.818 (95% CI 0.683-0.929), 0.873(95%CI 0.730-0.973) and 0.757(95%CI 0.597-0.904) respectively.

Conclusion: The novel models including different MRI features for predicting histopathological severity and insufficient response were established in AIH.

Abstract Submission No. 101349

O-0040

Endoscopic Management of Primary Sclerosing Cholangitis: Clinical Outcomes at a Tertiary Center

Muhammad Bahaddin Durak, Bülent Odemis

1Lokman Hekim Akay Hastanesi Ankara Turkey, 2Bilkent City Hospital Ankara Türkiye

Background: Dominant strictures (DS) are a significant clinical feature in primary sclerosing cholangitis (PSC), and endoscopic treatment is crucial for managing DS and improving patient outcomes. This study aims to assess the clinical outcomes of endoscopic treatment for PSC-related DS.

Methods: A single-center, prospective study of consecutive PSC patients undergoing endoscopic treatment for DS management. The primary endpoint was the cumulative recurrence-free rate of the primary DS(s) within 24 months in patients who did not experience initial failure. Secondary endpoints were evaluated based on three parameters: 1) endoscopic treatment success, defined as no need for ERCP within three months after completing endoscopic treatment; 2) development of cirrhosis; and 3) recurrence of DS.

Results: A total of 35 patients were included. In total, 138 endoscopic treatment sessions were performed, with an average of 3.9 sessions per patient. DS was identified in 26 patients during cholangiograms. Endoscopic balloon dilation (EBD) was applied in 24 (68.6%) patients, while nine patients (25.8%) underwent bougie dilation. The average stent duration for the initial procedure was 17.9 days. 26 (78.8%) patients remained asymptomatic within three months of discharge and remained cirrhosis-free during a mean follow-up period of 36 months. This was the secondary endpoint of the study. The primary end-point
achievement rate was 45.4%. The complication rate was 8.0%, including pancreatitis, cholangitis, and perforation. The cholangiocarcinoma (CCA) development rate was 5.7%.

**Conclusion:** Endoscopic treatment, including stent placement and biliary dilation, effectively manages PSC-related DS, with high success and relatively low complication rates.

**Abstract Submission No. 101430**

**O-0041**

**Scoring system is prognostic model of primary biliary cholangitis treated with UDCA and fenofibrate**

**Shuxiang Li1, Buer Li1, Weijia Duan1, Yu Wang1, Xinyan Zhao1, Hong You1, Jidong Jia1**

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University beijing, china china

**Background:** Fenofibrate as the second-line therapy for ursodeoxycholic acid (UDCA)-refractory primary biliary cholangitis (PBC) patients is becoming widely used, but no model can test the efficacy of the second-line therapy. Thus, this study aimed to investigate the biochemical response model that can predict the efficacy and long-term prognosis for patients treated with fenofibrate add-on therapy.

**Methods:** We enrolled UDCA-refractory PBC patients treated with fenofibrate and UDCA. These patients were grouped into the good outcome group and the poor outcome group according to a combined endpoint (hepatic decompensation, liver-related death, and liver transplantation). Patients are followed up by medical records, outpatient service, and telephone reviews. The biochemical response (Barcelona, Paris-I, Paris-II, Toronto, Rotterdam, Mayo, Ehime, Lindor, GLOBE score, and UK-PBC risk score) compared after 6 or 12 months of fenofibrate added-on therapy, and to identify a biochemical response model that can predict long-term prognosis by Kaplan-Meier plotting and Delong test.

**Results:** Sixty-three patients were enrolled in this study, including the good outcome patients (n=52) and the poor outcome patients (n=11). The poor outcome patients had higher GLOBE scores and UK-PBC risk scores than the good outcome patients after 12 months of treatment (GLOBE score: 1.1925±1.1061 vs. -0.2363±0.6666 (p<0.01), UK-PBC risk score: 0.1395 (0.0702, 0.2285) vs. 0.0311 (0.0210, 0.0511) (p<0.0001)). And other biochemical response criteria including Barcelona, Paris-I, Paris-II, Toronto, Rotterdam, Mayo, and Ehime didn’t show statistically significant differences between these two groups. More importantly, the GLOBE score and UK-PBC risk score had better predictive performance of long-term survival in patients with fenofibrate add-on therapy than these criteria. The area under the receiver operating characteristic (AUROC) of GLOBE score and UK-PBC risk score at 6 months of 0.871 (95%CI 0.741-0.951) and 0.875 (95%CI 0.746-0.953), and 12 months of 0.919 (95%CI 0.803-0.978) and 0.878 (95%CI 0.751-0.955). All other criteria were lower than 0.750 for the prediction of long-term survival after 6 or 12 months of treatment with UDCA and fenofibrate.

**Conclusions:** The GLOBE score and UK-PBC risk score were suitable for predicting the efficacy and long-term prognosis for PBC patients with fenofibrate and UDCA treatment.

**Abstract Submission No. 101516**

**O-0042**

**Genetic link between Periodontitis and liver diseases: a Mendelian randomization study**

**Yunling Xue1, Xiaoxiao Liu1, Qiao Tang1, Yi Zeng1, Mingli Peng1, Peng Hu1**

1ChongQing Medical University Chongqing China

**Background & aims:** The relationship between periodontitis and liver disease has received increasing attention in recent years, but the causal relationship is unclear. The aim of this study was to assess the causal relationship between periodontitis and various liver diseases

**Method:** We performed two-sample Mendelian randomization (MR) analysis. Suitable genome-wide association study (GWAS) datasets were used to select potential candidate single nucleotide polymorphisms according to the study needs. Inverse variance weighting (IVW) was used as the primary analysis method, supplemented by four sensitive analyses to assess the robustness of the results.

**Results:** Among the included liver diseases, only the genetic variant of PSC was causally associated with the risk of chronic periodontitis. According to IVW estimates, the presence of PSC may increase the risk of chronic periodontitis by 1.079% (OR 1.079, 95% CI 1.027-1.134, p = 0.002, MR-Egger, Weighted mode and Weighted median also produced similar results. Conversely, periodontitis did not have an impact on the risk of developing the liver diseases included in this study.

**Conclusion:** We investigated for the first time the association between several liver diseases and periodontitis using a Mendelian randomized study method and found that PSC increases the risk of chronic periodontitis.

**Abstract Submission No. 101630**

**O-0043**

**Pyroptosis plays a key role in primary biliary cholangitis in mice**

**Linxiang Huang1, Zilong Wang1, Jiarui Zheng1, Zixuan Qiu1, Bo Feng1**

1Peking University People’s Hospital Beijing China

**Background and Aims:** Primary biliary cholangitis (PBC) is an autoimmune intrahepatic cholestatic disease with both environmental and genetical participation. In this study, we aim to investigate the involvement of pyroptosis in PBC mice and provide possible treatment strategy.

**Method:** Twenty female C57BL/6 mice of 4-6 months old were evenly divided into PBC group and control group. PBC mice were induced with two doses of 2-nonynoic acid (2OA-BSA) and polycytidylic acid (poly I: C) for 12 weeks. Immunocyte type correlation analysis was performed on the GSE119600 dataset of GEO database with whole blood samples from PBC patients (n=90) and controls (n=47). Immunohistochemistry (IHC) staining and multiplex immunofluorescence (mIF) in liver samples of PBC mice were determined regarding the pyroptosis pathway and different cell types.

**Results:** Immunocyte type correlation analysis reported that the expression of key transcription factors of M1 macrophages were significantly higher in PBC patients (Figure A). For PBC mouse model, pyroptosis pathway was upregulated determined by qrt-PCR (Figure B) and western blotting (Figure C). IHC staining revealed improved GSDMD and Caspase-1 expression in PBC mice (Figure D), and macrophages were determined to be the main cell type expressing GSDMD by mIF (Figure E). Flow cytometry showed an increased M1/M2 macrophage ratio in liver samples of PBC mice, with the expression of M2 macrophage marker decreasing and the marker of M1 macrophage increasing in the western blotting.

**Conclusion:** Pyroptosis plays a key role in PBC patients and 2OA-BSA induced PBC mice, possibly macrophages being the most important executors.
Abstract Submission No. 102016

O-0044

Urinary Tract Infection and Pyuria in Primary Biliary Cholangitis

Dilara Turan Gökçe1, Hasan Erzurun2, Amed Trak1, İlayda Ergene3, Zekiye Nur Harput4, Neslihan Güneş Aydemir2, Derya Arslan2, Hasan Basri Yapıcı2, Haydar Adanır2, Orhan Sezgin2, Yusuf Vural1, Ahmet Bektaş2, Meral Akdoğan Kayhan1

1Ankara Bilkent City Hospital, Department of Gastroenterology, Ankara Turkey, 2Ondokuz Mayıs University, Department of Gastroenterology Samsun Türkiye, 3Marmara University, Department of Gastroenterology İstanbul Türkiye, 4Süleyman Demirel University, Department of Gastroenterology Antalya Türkiye

Introduction: Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease primarily affecting women and urinary tract infection (UTI) have a role in pathogenesis.

Method: The study aimed to assess demographic characteristics, treatment responses, and the presence of asymptomatic pyuria or urinary tract infection in PBC patients across five different centers. Patients receiving 13-15 mg/kg UDCA treatment for at least one year and consenting to participate were included. Patients with symptomatic pyuria, currently using antibiotics, or having symptomatic UTIs were excluded.

Results: Among the 229 participants, 90.5% (Female: 207) were female, with a mean age of 59.4 (11.2) years. Treatment unresponsiveness was observed in 13.5% (n=31) of the patients. Regarding symptomatic UTIs, 25.4% (n=55) experienced at least one UTI before PBC diagnosis, and 16.9% (n=38) had two or more UTIs. Additionally, 17.5% (n=40) had a history of UTIs more than once a year. No significant association was found between UTI history and treatment response (p: 0.64 and 0.93, respectively). Among the 229 patients, 105 (45.8%) had asymptomatic pyuria, and in 16 (7.4%), urine cultures showed bacterial growth, with Escherichia Coli being the predominant pathogen in 8 cases, followed by Klebsiella pneumoniae and Streptococcus Agalactica. Analyses revealed that the frequency of asymptomatic pyuria was not higher in treatment-unresponsive patients but was more common in cirrhotic patients (p: 0.028).

Conclusion: In our study, no correlation was found between symptomatic UTIs and treatment unresponsiveness. Similarly, asymptomatic pyuria and positive urine cultures did not increase in unresponsive patients.

Abstract Submission No. 100983

O-0046

Genetic risks of “one-pill” NSAIDs induced liver injury: a real-world study

Yangjie Li1, Lingna Lyu1, Hui guo Ding1

1Department of Gastroenterology and Hepatology, Tongji Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Background: Genetic risks of “one-pill” NSAIDs-DILI is associated with polymorphic expression of several genes. Our study not only verified reported gene variants but also revealed new SNPs contributing to NSAIDs-related DILI.

Conclusion: “One pill” NSAIDs-DILI is associated with polymorphic expression of several genes. Our study not only verified reported gene variants but also revealed new SNPs contributing to NSAIDs-related DILI.
Abstract Submission No. 101200  
O-0047  

Hepatic MUM1 expressions distinguish drug-induced liver injury from acute-onset autoimmune hepatitis

Zikun Ma1, Mengmeng Zhang1, Yao Meng1, Yu Wang1, Tian Tian Guo1, Yan Wang1, Min Li1, Xinyan Zhao1, Jimin Liu1
1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China, Beijing China, 2Department of Clinical Epidemiology and EBM, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China Beijing China, 3Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada Ontario Canada

Background: Perivenular necroinflammation is a common but easily confused histological characteristic in both drug-induced liver injury (DILI) and acute-onset autoimmune hepatitis (A-AIH). We aimed to evaluate multiple myeloma antigen 1 (MUM1) immunohistochemistry (IHC) stain in distinguishing DILI from A-AIH.

Method: DILI or A-AIH patients with liver biopsy matched by propensity score were retrieved from DILI (n=138) and AIH (n=125) database from 2016 to 2023. Liver biopsies were evaluated according to the modified histological activity index (mHAI), MUM1-expression cells were quantified by ImageJ. The diagnostic performance of MUM1 IHC stain was assessed by an area under the receiver operating characteristic curve (AUROC).

Results: Eligible DILI (n=10) and A-AIH (n=10) patients: the median age was 52 (38.3, 57.8) years, and females were 16 (80.0%). There was no significant difference of age, gender, aminotransferase, bilirubin and immunoglobulin G levels at onset and mHAI scores between two groups. In portal areas, both total and average number of MUM1-expression cells per square millimeter were significantly higher in A-AIH than that in DILI: 561.5 (226.8, 839.5) versus 226.0 (144.8, 445.5); 621.3(336.1,809.1) versus 260.2(163.2,428.6), respectively (all P<0.05). Total or average number of MUM1-expression cells or their combination in portal areas yielded an AUROC of 0.79 (95% CI: 0.5844-0.9956), 0.86 (95% CI: 0.6977-1.0000) or 0.85 (95% CI: 0.6784-1.0000) respectively in distinguishing DILI versus A-AIH. A cutoff value of 472.8 for average MUM1-expression cells per square millimeter in portal areas had a specificity of 90.0% and a sensitivity of 70.0%.

Conclusion: The number of MUM1-expression cells in liver biopsy specimens can effectively distinguish DILI from A-AIH.

Abstract Submission No. 101864  
O-0049  

Clinical features of acute drug-induced liver injury with pathological severe hepatic inflammation

George Lau1, Yu-ting Xiong1, 2, Chun-yang Wang1, Jie Chen4, Dong Ji8
1Humanity and Health Medical Group Hong Kong Hong Kong, 2307 Clinical Medical College of PLA, Anhui Medical University Beijing China, 3Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 4JC School of Public Health and Primary Care, Faculty of Medicine Hong Kong SAR China

Background: Research on biopsy-proven acute drug-induced liver injury (DILI) remains limited. This study aimed to identify clinical characteristics of acute DILI with pathological severe hepatic inflammation.

Methods: A prospective hospitalization-based cohort study was conducted on biopsy-proven acute DILI patients admitted to our hospital from 2009 to 2017, and followed up until October 2023. The clinical characteristics at the time of liver biopsy, discharge, and follow-up were collected. According to Scheuer scoring system, hepatic inflammation was categorized as mild (G0-2) and moderate/severe (G3-4) groups, and between-group comparisons and multivariate logistic regression analyses were performed.

Results: The median age of 157 enrolled patients was 40.4 years, with 65.6% female. The median length of stay was 18 (IQR, 12.0-26.0) days. Liver injury induced by traditional Chinese medicine, chemical synthetic drugs and mixed drugs accounted for 42.7%, 25.5% and 31.8%, and the median incubation period was 14.0 (IQR, 7.0-30.0) days. Logistic regression analysis revealed that female (OR: 2.420, 95% CI: 1.311,1.311, P=0.024) were independent risk factors for moderate-to-severe hepatic inflammation, while increasing HCL. C (OR: 0.360, 95% CI: 0.131-0.992, P=0.048) was protective. During follow-up, 23 patients (14.6%) developed chronic DILI, with 9 patients (5.7%) progressing to cirrhosis, and 15 patients combined with autoimmune (G0-2 group 3 vs G3-4 group 12, P<0.05).

Conclusions: Being female and having high BMI are associated with a higher risk of developing severe hepatic inflammation, which can lead to chronicity when compounded with autoimmune factors.
Abstract Submission No. 101930
O-0050

Close relationship between hepatotoxicity and adverse events of other organ induced by ICPI therapy
Yu Akazawa1, Takuto Nosaka1, Tomoko Tanaka1, Kazuto Takahashi1, Tatsushi Naito1, Hiteda Matsuda1, Masahiro Ohtani1, Yasunari Nakamoto1
1Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui Fukui Japan

Background: With the widespread use of immune checkpoint inhibitors (ICIs), the diagnosis and treatment of immune-related adverse events (irAEs) has become increasingly important. Although, immunemediated hepatotoxicity (IMH) is a relatively common, clinical evaluation of IMH remains unclear. The aim of this study was to clarify the clinical characteristics in patients with IMH.

Methods: The patients with advanced cancer who received ICPI from September 2014 to December 2022 in our department were enrolled for this retrospective study. In enrolled patients, the incidence and severity of IMH were evaluated. Additionally, clinical factors that related to the onset of IMH were analyzed by multivariable logistic regression analyses. The onset and severity of IMH and other organ irAEs were defined according to CTCAEv5.0.

Results: A total of 617 patients (468 males, 149 females; median age, 70.0 years) were enrolled in this study. Of all, 61 patients (9.9%) developed hyperamylasemia: Grade 2 (G2), Grade 3 (G3), and Grade 4 in 34, 27, and 0 patients. In univariate analysis, ICPI combination therapy (p=0.038), and the onset of other organ irAE (≥G2) (p<0.001) were significantly related to development of IMH. In multivariate analysis, only the onset of other organ irAE (≥G2) (p<0.001) was the independent factor associated for the onset of IMH. Also, the incidence of other organ irAE ≥ G3 was higher in the case with G3 IMH than in the case with G2 IMH, resulting in a correlation between the severity of IMH and other organ irAE (p=0.02).

Conclusions: The onset and severity of IMH was closely related to these of other organ irAEs in patients with ICPI therapy. This finding suggests that in cases with IMH, more intensive systemic management is required because of the potential for multiple organ irAEs.

Abstract Submission No. 100044
O-0051

FIVE-YEAR SINGLE-CENTER EXPERIENCE IN ACUTE HEPATOTOXICITY DUE TO HERBAL MEDICATIONS FROM PAKISTAN
Farhana Kayani1, Jalal Khan2
1Bolan medical college, Quetta Pakistan, 2Sheikh Khalifa bin zayed hospital quetta pakistan

Background & aims: Injury to liver secondary to herbal medication is quite common. It can cause acute liver injury and acute liver failure (ALF) requiring Liver transplantation. We investigated outcomes of patients with acute Hepatotoxicity due to herbal medications in our cohort.

Method: We prospectively evaluated characteristics of patients with liver toxicity due to herbal medications. We also investigated parameters related to mortality or liver transplantation.

Results: 30 patients (17/13: f:m, median age 50.4(22-73)) were included in study. 27 patients presented with nausea and vomiting. In addition, 14 patients had abdominal pain & 16 had diarrhea. These patients were admitted to our intensive care unit within an average of 2.5 days (6 hours-8 days) after herbal medication intake. In 15 patients (14 at admission, 0 during hospitalization), INR increased > 1.5. ALF developed in 4 patients (02 patients at admission, hepatic encephalopathy developed in two patients during follow up). The peak levels of ALT, AST & total bilirubin were 2109±1963 μl/l, 1828±1675 μl/l, 4.92 (0.1-28.56 mg/dl), respectively. In hospital follow up, highest INR levels were found to be an average of 2.29 (±1.56). All patients were treated with N-acetylcysteine (NAC). One of the 04 patients with ALF underwent emergency liver transplantation. 01 patient who developed ALF recovered with medical treatment, while other 02 patients who could not be transplanted died. In multivariate analysis, INR, AST & ALT levels at hospital admission were found to be statistically significant factors for death & liver transplantation respectively; or: 17.8 and p: 0.04. or:0.59 & p:0.03 &or: 0.54 & p: 0.04.

Conclusion: In our cohort, the mortality rate due to herbal medication intoxication was 10%. High INR levels, ALT & AST levels have been associated with serious outcomes such as liver transplantation or mortality, these parameters may be predictive of urgent liver transplantation.

Abstract Submission No. 100569
O-0052

N-acetylcysteine can accelerate the recovery of drug-induced cholestatic liver injury
En-Qiang Chen1, Cheng-Run Song1, Yu-Jing Li1, Lan-Qing Li1, Rong Deng1, Xue-Zhong Lei1, Li-Chun Wang1, Tao-You Zhou1, Fang He1, Ping Feng1, Hong Tang1
1West China Hospital, Sichuan university Chengdu China

Objective: To observe the effectiveness of N-acetylcysteine in the treatment of drug-induced cholestatic liver injury.

Method: A retrospective study was conducted on hospitalized patients with drug-induced cholestatic liver injury from West China Hospital between January 2019 to June 2023. On the basis of adenosylmethionine and ursodeoxycholic acid treatment, the effectiveness of adding or not adding N-acetylcysteine were investigated.

Result: A total of 265 patients were included, including 84 males and 181 females, with an average age of 51.3 years. In terms of etiology, there were 98 cases caused by acetaminophen, 102 cases of traditional Chinese medicine or dietary supplements, 53 cases caused by other chemical drugs, and 12 cases of other causes. Among 265 patients, 137 received N-acetylcysteine treatment (Group A), while 128 patients did not receive N-acetylcysteine treatment (Group B). The levels of TBil (314.6±45.8 μmol/L vs. 307.5±43.5 μmol/L, P=0.198) were similar between the two groups at admission, but the levels of ALP (462.9±48.6 IU/ml vs. 448.5±50.2 IU/ml, P=0.018) and GGT (436.5±52.7 IU/ml vs 423.7±40.1 IU/ml, P=0.044) in Group A were higher than those in Group B. Among group A, 42 patients were hospitalized for less than 2 weeks, while 95 patients were hospitalized for more than 2 weeks. Among group B patients, 26 patients were hospitalized for less than 2 weeks, while 102 patients were hospitalized for more than 2 weeks. The average hospitalization time of Group A patients was significantly shorter than that of Group B patients (9.3±3.1 vs.11.1±2.2 day, P=0.05), and the 2-week discharge rate was significantly higher than that of Group B (42/137 vs.26/128, P<0.05). At 2 weeks of hospitalization, the serum TBil of Group A were significantly lower than that of Group B (128±24.9 vs. 142.7±31.5 IU/ml, P<0.001), and the levels of ALP (103.5±26.4 vs. 145.7±30.3 IU/ml, P<0.001) and GGT (111.2±24.8 vs 128.9±26.4 IU/ml, P<0.001) were also significantly lower than those of Group B.
Conclusion: On the basis of combined treatment with adenosylmethionine and UDCA, the addition of N-acetylcysteine can accelerate the recovery of damaged liver function.

Abstract Submission No. 100739
O-0053

Usefulness of RECUM as a diagnostic criterion for drug-induced liver injury in Japanese patients

Yasuyuki Komiyama1, Reona Osawa1, Hitomi Takada1, Masaru Muraoka1, Yuichiro Suzuki1, Mitsuaki Sato1, Shinya Maekawa1, Nobuyuki Enomoto1

1Department of Gastroenterology and Hepatology Chuo Yamanashi Japan

Background: In Japan, DDW-J2004 based on RUCAM is used as a diagnostic tool for drug-induced liver injury (DILI). Recently, RECUM was reported as a new diagnostic tool, but it has not been fully investigated in Asian countries, including Japan, and we aimed to investigate the usefulness and problems of RECUM in Japan.

Methods: We included 120 cases with a diagnosis of DILI or suspected DILI between January 2020 and October 2022, and added RECUM scoring retrospectively to evaluate the rate of concordance of diagnosis. We also examined the characteristics of cases in which there was a dissociation of diagnosis.

Results: There was a strong correlation between RECUM and DDW-J scores (R=0.586, p<0.001). All patients with a highly likely DILI on the RECUM were also categorized as likely on the DDW-J. On the other hand, among the cases diagnosed as highly likely by DDW-J, there were 5/37 cases (13.5%) diagnosed as excluded by RECUM. DILI was considered negative in both cases: 2 cases because of time of onset and 3 cases because of other diagnoses (HEV, AIH, other). In addition, there were 19/54 cases (35.2%) who were diagnosed as exclusionary by RECUM among those who had been diagnosed with undeniable possibility of DILI by DDW-J. When examining the reasons for the lower scores, data loss was predominant in the excluded diagnosis items (number of missing data items 3(0-4) vs. 4(2-6), p<0.001).

Conclusions: The results suggest that RECUM may be useful in Japanese patients; however, caution should be exercised in cases of high data loss, as RECUM has a point reduction due to missing data. It should be used with a thorough understanding of how to exclude competing diagnoses.

Abstract Submission No. 100906
O-0054

Efficacy of magnesium isoglycyrrhizinate in liver injury after receiving novel antineoplastic agents

Yang Zhi1,2, Yimin Mao1,2, Xiaoyun Li1,2, Yinuo Dong1,2

1Department of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China, 2Clinical Research Center, Shanghai Jiao Tong University School of Medicine Shanghai China

Background: Liver injury often occurs in patients treated with novel antineoplastic agents including molecular targeted agents and immune checkpoint inhibitors. Magnesium isoglycyrrhizinate (MgIG) is an anti-inflammatory agent with potential to ameliorate liver injury.

Methods: We conducted a retrospective, multicenter, real-world study to evaluate the efficacy of MgIG compared to glucocorticoids in patients with liver injury after receiving any novel antineoplastic agent. Propensity score matching (PSM) is used to match age, sex, and baseline alanine aminotransferase (ALT) between groups. The change from baseline, normalization rate and the proportion of patients with 50% reduction of ALT, aspartate aminotransferase (AST) and total bilirubin (TBIL) 7 days after treatment and before discharge were compared.

Results: A total of 979 cases are included and subsequently divided into 2 populations after PSM in a 1:1 and 3:1 ratio respectively: MgIG (n=152) vs. supportive care (SC) (n=152); and MgIG + SC (n=497) vs. SC (n=171). The normalization rates and 50% reduction rates of ALT, AST, and TBIL is significantly higher in MgIG group than those in SC group (n=152) before discharge, while only 50% reduction rates reached statistical significance at day 7. In MgIG + SC group, normalization rates of only ALT and AST is significantly higher than those in SC group (n=171) before discharge, while 50% reduction rates of all compared serum markers reached statistical significance both at day 7 and before discharge.

Conclusion: This study provided preliminary evidence for the efficacy of MgIG in patients with liver injury after receiving novel antineoplastic agents compared to supportive care.

Abstract Submission No. 100910
O-0055

Efficacy of MgIG compared to steroids in liver injury after novel antineoplastic therapy

Yinuo Dong1,2, Yimin Mao1,2, Yang Zhi1,2, Xiaoyun Li1,2

1Department of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China, 2Clinical Research Center, Shanghai Jiao Tong University School of Medicine Shanghai China

Background: Liver injury in patients treated with novel antineoplastic agents including molecular targeted agents and immune checkpoint inhibitors is often managed with glucocorticoids. Magnesium isoglycyrrhizinate (MgIG) is an anti-inflammatory agent with potential to ameliorate liver injury.

Methods: We conducted a retrospective, multicenter, real-world study to evaluate the efficacy of MgIG compared to glucocorticoids in patients with liver injury after receiving any novel antineoplastic agent. Propensity score matching (PSM) is used to match age, sex, and baseline alanine aminotransferase (ALT) between groups. The change from baseline, normalization rate and the proportion of patients with 50% reduction of ALT, aspartate aminotransferase (AST) and total bilirubin (TBIL) 7 days after treatment and before discharge were compared.

Results: A total of 918 cases are included and subsequently divided into 2 populations after PSM in a 1:1 and 2:1 ratio respectively: MgIG (n=57) vs. supportive care (SC) (n=249); and MgIG + glucocorticoids + supportive care (SC) (n=249) vs. glucocorticoids + SC (n=164). MgIG group only showed a higher 50% reduction rate in TBIL over glucocorticoids group at day 7 and before discharge. However, the normalization rate of ALT and AST before discharge in MgIG + glucocorticoids + SC group are significantly higher than those in glucocorticoids + SC group. The 50% reduction rates of all compared serum markers reached significantly higher at day 7 and before discharge.

Conclusion: This study provided evidence that MgIG may aid to improve recovery as add-on therapy to glucocorticoids and supportive care in patients with liver injury after receiving novel antineoplastic agents.

Abstract Submission No. 101082
O-0056
Late Onset Efavirenz Induced Liver Toxicity in a 17-year-old, Filipino, HIV patient

John Derek Clutario1, Gerardo S Pedregosa1, Janice C. Caoli1
1Makati Medical Center Pasig City Philippines

Efavirenz, a commonly used non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV treatment, is generally well-tolerated. However, rare cases of hepatic adverse effects, including hepatotoxicity, have been reported. While mild liver enzyme elevations are relatively common (in about 10% to 20% of cases), severe hepatotoxicity leading to liver failure is infrequent, with reported incidences ranging from 0.5% to 4%. The exact mechanisms underlying efavirenz-induced liver toxicity are not fully understood but may involve oxidative stress, mitochondrial dysfunction, and immune-mediated reactions.

In this case report, a first in the Philippines, we present a known case of HIV started on Lamivudine, Tenofovir and Efavirenz who presented with jaundice and elevated liver enzymes after a year of treatment which has not happened before in any published case. A comprehensive workup ruled out various causes of acute liver injury, including infection, autoimmune factors, herbal medications, and toxins. Genetic testing did not reveal any abnormalities related to medication metabolism. The patient’s condition was successfully managed with a combination of steroids, immunosuppressants, and switching from efavirenz to dolutegravir, leading to the resolution of jaundice and liver enzyme abnormalities.

This case highlights a delayed onset of efavirenz-induced liver toxicity, occurring after a year of HIV treatment initiation. It emphasizes the importance of early detection, comprehensive workup, and personalized management for rare adverse effects associated with antiretroviral therapy. Understanding efavirenz-induced liver toxicity, including its mechanisms, risk factors, and clinical management, is crucial for the safe and effective treatment of HIV patients.

Abstract Submission No. 101278
O-0057

CTCAE system upgrades severity of ICIs induced liver injury than DILI grading systems

Yan Wang1, Liwei Liu2, Mengyu Zhao1, Wei Chen1, Xinyan Zhao1
1Beijing Friendship Hospital, Capital Medical University Beijing China, 2Beijing Youan Hospital, Capital Medical University Beijing China

Background: Immune-mediated liver injury (ICILI) induced by immune checkpoint inhibitors (ICIs) are usually graded by the Common Terminology Criteria for Adverse Events (CTCAE) grading system. While the grading systems for drug-induced liver injury (DILI) include the US Drug-induced Liver Injury Network (DILIN) and the International DILI Expert Working Group severity indexes. It remains unclear which of these systems is most appropriate for assessing the severity of ICILI.

Method: This is a retrospective review at Beijing Friendship Hospital (2016-2022) collecting clinical data of ICI-treated patients. ICILI cases were graded using CTCAE and two other DILI indexes. Agreement and correlation between grading systems were analyzed using the weighted kappa coefficient and Spearman’s rho coefficient.

Results: A total of 66 (4.94%) cases developed ICILI. In summary, 18 (27.3%) cases exhibited ALT elevation, 23 (34.8%) AST elevation, 9 (13.6%) ALP elevation, and 16 (24.2%) TB elevation exceeding grade 3 in terms of liver injury severity with CTCAE systems. CTCAE identified a higher proportion of severe cases compared to US-DILIN and International systems significantly 45.5% vs 16.7% and 16.7%, respectively, P=0.001. Correlation analysis showed higher agreement between US-DILIN and International (κ=0.642, 95%CI 0.517-0.766) than with CTCAE (κ=0.188, 95%CI 0.091-0.285 with International; κ=0.239, 95% CI 0.108-0.371 with US-DILIN).

Conclusions: CTCAE graded more ICILI cases as severe cases compared to DILI grading systems. A comprehensive assessment incorporating clinical presentation, liver chemistries, coagulation function, and prognosis is crucial for accurate severity determination.

Abstract Submission No. 101402
O-0058

Clinicopathological features and outcomes of Scutellaria (Huang Qin)-induced liver injury

Tiantian Guo1, Yao Meng1, Yu Wang1, Zikun Ma1, Mengmeng Zhang1, Yan Wang1, Min Li1, Jimin Liu2, Xinyan Zhao1
1Beijing Friendship Hospital, Capital Medical University Beijing China, 2Faculty of Health Sciences, McMaster University, Hamilton, Canada Hamilton Canada

Objective To investigate clinicopathological features and outcomes of liver injury induced by Scutellaria, a herb known as Huang Qin.

Methods This is a multi-center retrospective cohort study. Cases with Scutellaria-induced liver injury were collected from Beijing Friendship Hospital, Beijing You’an Hospital, and the Fifth Medical Center of PLA General Hospital, from January 2009 to June 2017. Clinicopathological data and follow-up final clinical outcomes were summarized.

Results Twenty-nine patients with Scutellaria induced liver injury were identified from 1444 herb-induced liver injury cases. The median age was 48 (37, 59) years and 75.9% (24/29) were women. The most common symptom was dark-color urine (79.3%, 23/29). The main clinical injury pattern was hepatocellular (72.4%, 21/29), followed by mixed (17.2%, 5/29) and cholestatic (10.3%, 3/29). Of nine patients with liver biopsies, six had acute hepatitic and three had mixed acute cholestatic-hepatitic histological injury pattern. Compared to the mild group (n=12), moderate and severe group (n=13), the acute liver failure (ALF) and fatal group (n=4) had significantly higher level of aspartate aminotransferase (515.5 and 655.04 vs 1064.5 U/L) and prolonged prothrombin time (11.5 and 12.0 vs 16.3 s), lower level of albumin (39.5 and 38.6 vs 33.8 g/L, all P<0.05). One patient in the moderate and severe group had chronic liver injury, whereas, one developed chronicity and one died of liver failure in the ALF and fatal group.

Conclusion Scutellaria can induce liver injury, and the main clinicopathological injury pattern was acute hepatitis with or without cholestasis. Most patients recovered; however, chronicity and death may occur.

Abstract Submission No. 101480
O-0059

Non-alcoholic fatty liver disease following chemotherapy

Amar Ranjan1, Harshita Dubey1, Pranay Tanwar1
1AIIMS, Delhi New Delhi India

Introduction: Chemotherapy-induced liver injury is one of the most common causes of mortality in cancer patients. One of the mechanisms of the development of fatty liver is hepatic steatosis, induced by chemotherapeutic agents. In this study, we are evaluating the development of fatty livers during the therapy for ovarian cancer.
Method: A prospective study was conducted on cases of ovarian cancer with normal liver function tests who developed fatty livers after getting chemotherapy.

Result: We studied 200 cases of ovarian cancer, out of which 31 (15%) cases developed fatty liver secondary to therapy for ovarian cancer. The average age at which fatty liver develops is 49.2 years. Among various clinical parameters, only weight and body surface area (BSA) did show a statistically significant correlation (p = 0.05) with the development of fatty liver. The patients who had PFI for more than 15 months also showed the development of FL (P = 0.03) (table 1).

Conclusion: The development of fatty liver following chemotherapy follows the common mechanism, but the process is fast. This may be due to an altered metabolic process. Here also weight and BSA are associated with the development of fatty liver. Following chemotherapy, progression-free interval has also shown a significant correlation with the development of fatty liver.

Abstract Submission No. 101490
O-0060

Analysis of International Comparisons of Adverse Drug Reaction Reports in FDA and PMDA Databases

Hiroteru Kamimura1, Takafumi Tonouchi1, Suguru Miida1, Atsunori Tsuchiya1, Shuji Terai1

1Niigata University Niigata Japan

Background: An international comparison was made in the liver-related drug adverse event databases of FAERS (Food and Drug Administration Adverse Event Reporting System) by the FDA in the USA and JADER (Japanese Adverse Drug Event Report) by the PMDA in Japan.

Methods: An international comparison in the databases of liver-related adverse drug events was conducted. Standardised medical terminology with high quality and specificity internationally. Both databases available with seven types of Preferred terms reported as liver-related adverse events registered in MedDRA internationally.

Results: Warfarin was the drugs most associated with adverse liver events in 452,272 cases registered in FAERS from 1997 to 2019. Sorafenib in 38,919 cases registered in JADER from 2004 to 2019, nivolumab and herbal extracts were the drugs most associated with adverse hepatic events. There was no correlation between the rankings in both databases. In terms of post-report outcomes, FAERS accounted for 43% of severe cases, while JADER accounted for 83% of severe cases. Pattern of liver injury was hepatocellular in 25.1%, cholestatic in 56.17%, mixed in 18.72% of patients. The patients with prior drug allergy were mainly male (78%) & significantly older, with mean age of 54 vs 45 with no prior drug allergy (P = .009), & they were more likely to have an underlying chronic disease like diabetes & Hypertension (P = .016). Clinically, patients with prior drug allergy were more encephalopathic (21.6% vs 10; P = 0.02) & jaundiced (54.1% vs 38%; P = 0.04). Those with prior drug allergy also had significantly hepatocellular pattern of DILI (68% vs 35%; P = 0.003), lower median values of albumin (2.8g/L vs 3.8g/L; P = 0.04) & a combination of ALT & AST were significantly higher in patients with prior drug allergy (9.4 vs 6.2; ULN; P = 0.04), (8.5 vs 4.2 mg/dl; P = 0.02) & (5 vs 3.5; P = 0.01). Among those with prior drug allergies, leading drugs most commonly responsible for injury were Anti-tuberculosis drugs (ATDs) (20%), followed by herbal medicines. In-hospital mortality was more in patients with prior drug allergy as compared to other arm (26.5% vs 10; P = 0.034) & prolonged hospital stay (>7 days) was observed to be more in drug allergy arm but not statistically significant (35.93% vs 28.6; P = 0.43).

Conclusion: Patients presenting with history of prior drug allergies, one have to be careful while prescribing medications & if any present with DILI, they require close monitoring for early detection of worsening clinical courses.

Abstract Submission No. 101593
O-0062

N-Acetylcysteine Prophylaxis for Anti-Tuberculosis Drug Induced Hepatotoxicity: A Meta-Analysis

Maxine Andrea T Garcia1, Ma. Felina Rosanna G Siray1, Laurence E Laurel1, Ma. Regina D Dimaculangan1

1St Luke's Medical Center Global City Taguig Philippines

Background: The benefit of prophylaxis to prevent the development of antituberculosis drug-induced hepatotoxicity (ATDH) is still unclear. One of the promising hepatoprotectants available is N-acetylcysteine (NAC). We aimed to evaluate the effect of NAC on the prevention of ATDH, on transaminase levels and on time to recovery after hepatotoxicity among patients receiving anti-tuberculosis treatment.

Methods: We searched MEDLINE, PubMed, Embase, and CENTRAL up to 30th October 2023. Randomized controlled trials (RCTs) and case control studies comparing NAC with control were included. Statistical analyses were conducted using RevMan 5.4 software. Risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CI) were used to evaluate the effect of NAC. The quality of included studies was assessed according to Cochrane handbook. Sensitivity analysis was conducted to assess the influence of each study.
Results: A total of 987 patients from 6 RCTs and 1 case control (392 with NAC, 595 with control) were included. Overall, prophylactic NAC significantly reduced the occurrence of ATDHI with a pooled RR 0.39 [CI (0.27, 0.58), p<0.00001]. Patients given NAC also had lower transaminases at 2 weeks anti-tuberculosis treatment. The mean difference between NAC and control for ALT was -40.21 [CI (-65.31, -15.10), p=0.002] and for AST was -33.96 [CI (-57.11, -10.81), p=0.004]. Lastly, NAC shortened the time to recovery after hepatotoxicity with a MD -6.51 days [CI (-8.13, -4.89), p=0.00001].

Conclusions: NAC serves as effective prophylaxis in preventing ATDHI. It has protective effects on transaminase elevation as well as reduces the time to recovery after hepatotoxicity.

Abstract Submission No. 101684
O-0063
Usefulness of a new diagnostic criteria in patients suspected of drug-induced liver injury

Noriyo Yamashiki1, Kanehiko Suwa1, Kazunori Aoi2, Takashi Yamaguchi3, Masao Yamashina1, Katsunori Yoshiida1, Miki Murata1, Toshihito Seki3, Masaaki Shimatani1, Shinji Shimoda2, Makoto Nagamura2

1Department of Gastroenterology and Hepatology, Kansai Medical University Medical Center Osaka, Japan, 2Department of Gastroenterology and Hepatology, Kansai Medical University Osaka, Japan

Background: For the diagnosis of drug-induced liver injury (DILI), DDW-J2004 Workshop criteria has been used for many years in Japan. In this study, usefulness of the new criteria, RECAM (Hayashi PH, et al, DOI: 10.1002/hep.32327), was investigated.

Methods: Patients who were hospitalized for suspected DILI between 2017 and 2022 were enrolled. There were 30 cases suspected DILI with ALT ≥5×upper limit of normal (N) or ALP ≥2×N. Diagnostic performance of DDW-J2004 and RECAM were compared.

Results: Patient age was 63(20-95) years, 9 (30%) were male. Causal drugs were anticancer agent (3), antiviral/antibiotics (3), dermatological (3), herbal medicine (4), and others. Injury pattern was hepatocellular in 22 (64%), cholestatic in 10 (29%), and mixed in 2 (6%). Interpretation by DDW-J2004 and RECAM were highly probable (3, 6), probable (16, 11), possible (9, 12), and unlikely (2, 1). Fairly agreement of 33.7% (kappa 0.34, p<0.01) was observed. The lower scores in RECAM were mainly due to missing values. Twenty-three cases recovered after discontinuation of the causal medication, 6 recovered with corticosteroid therapy, and 1 developed acute liver failure requiring liver transplantation. Later, diagnosis of DILI was denied in 2 cases; one case (DDW-J2004 possible; RECAM possible) coincidentally re-administered the same drug without liver injury. The other case (JDDW2004 probable; RECAM highly likely) showed ANA x 80 and IgG 1.6g/dL. Later the level of IgG increased, and liver biopsy finding was consistent with AIH.

Conclusion: RECAM criteria requires strict differential diagnosis, but may leads to accurate diagnosis.

Abstract Submission No. 100041
O-0064
Dopamine analog inhibits the HBV surface and e antigen expression by upregulation JAK/STAT pathway

XiaoQuan Liu1

1Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University GuangZhou China

Background: Hepatitis B virus (HBV) infection is a major risk factor for cirrhosis and liver cancer and its treatment has always been challenging. Although several nucleos(t)ide analogs are available for treatment of HBV infection, long-term treatment with these drugs can lead to the emergence of drug-resistant viruses. In order to carry out such combinational therapy against HBV, several new drugs should be developed. We previously expressed and purified the HBV TP-RT with high purity using an E. coli expression system and established an in vitro ε RNA-binding assay system. Then, we used TP-RT in cell-free assays to screen candidate inhibitors from a chemical compound library, and identified, dopamine analog inhibited the HBV DNA, HBV surface antigen (HBsAg) and HBV e antigen (HBeAg) expression level. However, the inhibition of HBsAg and HBeAg mode of action remained unclear. Here, we aimed to identify the mechanism underlying dopamine analog-inhibited HBsAg and HBeAg.

Methods: We used dopamine analog treated AAV-HBV-infected mouse model, HepG2.2.15 and human NTCP-expressing HepG2 cell lines.

Results: We found that dopamine analog inhibited HBsAg and HBeAg expression level in two cell lines; dopamine analog increased the expression level of ISG15 and the JAK-STAT pathway factor STAT1, p-STAT1 and JAK1 expression level; dopamine analog inhibited the HBsAg and HBeAg expression level in AAV-HBV mouse model.

Conclusions: Clarifying the regulatory relationship between the dopamine analog and JAK-STAT/ISG15 pathway is necessary for developing new targets for the clinical treatment of chronic hepatitis.

Abstract Submission No. 100497
O-0065
The factor affecting HBsAg reduction after nasal therapeutic vaccine in chronic hepatitis B patients

Kana Shiraiishi1, Osamu Yoshida1, Yoichi Hiasa1, Ryo Yano1, Yuki Okazaki1, Yusuke Imai1, Yoshihiko Nakamura1, Takao Watanabe1, Yohei Koizumi1, Masashi Hirooka1, Yoshio Tokumoto1, Masanori Abe1, Akbar SMF1, Takahiro Sanada2, Michinori Kohara2

1Department of Gastroenterology and Metabolology, Ehime University Graduate School of Medicine Ehime Japan, 2Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science Tokyo Japan

Background: The treatment goal of chronic hepatitis B (CHB) is HBs antigen (HBsAg) elimination, however it is difficult to achieve the goal with interferon and nucleos(t)ide analogues (NAs). We have developed a nasal administrative therapeutic vaccine containing HBs/ HBcAg mixed viscosity enhancer (CVP-NASVAC). We conducted a clinical trial of CVP-NASVAC against CHB and demonstrated its capacities of HBsAg reduction and anti-HBs induction. In this study, we explored a factor affecting HBsAg reduction.

Methods: Fifty CHB patients (21 with NAs and 29 without NAs) received total 10 doses of CVP-NASVAC via nose. We investigated the rate of HBsAg reduction/loss, IgA- and IgG-type anti-HBs induction. We have developed a nasal administrative therapeutic vaccine containing HBs/HBeAg mixed viscosity enhancer (CVP-NASVAC). We conducted a clinical trial of CVP-NASVAC against CHB and demonstrated its capacities of HBsAg reduction and anti-HBs induction. In this study, we explored a factor affecting HBsAg reduction. We used dopamine analog treated AA V-HBV-infected mouse model.

Results: Fifteen HBsAg patients (21 with NAs and 29 without NAs) received total 10 doses of CVP-NASVAC via nose. We investigated the rate of HBsAg reduction/loss, IgA- and IgG-type anti-HBs induction by CLEIA and ELISA, and HBcAg-specific CTL by ELISPOT.

Results: At the 18 months after CVP-NASVAC administration, HBsAg was reduced to 80.6% compared with baseline in patients with NAs and 86.4% without NAs, and HBsAg loss was observed in 1/21 with NAs and 3/29 without NAs. Anti-HBs was induced in 14.3% (3/21) with NAs and 42.9% (12/28) without NAs. IgA type anti-HBs titer and the number of HBc-specific interferon γ producing CTL were significantly increased after CVP-NASVAC treatment in both with and without NAs. Interestingly, significant correlation was observed...
between the CTL increase and HBsAg reduction in CHB patients with NAs (p<0.005), however no correlation was observed between anti-HBs elevation and HBsAg reduction.

**Conclusion:** HBsAg-specific CTL induction might be an important factor of reducing HBsAg in CHB patients under NAs treatment.

Abstract Submission No. 100628
O-0066

**Highly expressed CTLA4 on B cells defected BCR signal to inhibit the secretion of anti-HBs in CHB**

Shengxia Yin1, Xin Tong1, Yuxin Chen2, Jie Li1, Chao Wu1
1Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 2Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

**Background:** The generation of anti-HBs is lacking in CHB patients. The cause is controversial. B cells activation state has a crucial effect on the secretion level of antibodies. Therefore, B cell status deserves more attention.

**Methods:** Single-Cell RNA-seq analysis was performed in peripheral B cells. Peripheral and liver infiltrated B cells were characterized by flow cytometry. BCR signaling was tested by Ca⁺ flow and WB assay. Aimed to explore the inhibiting role of CTLA4, we did CTLA4-blocking test in vitro. Further, B6-Ighm-KO mice were injected with HBsAg preimmunized CTLA4⁻/⁻ B cell after establishing HBV transduction model and HBV serological indicators were detected. CO-IP assay and proteome analysis was made to explore the downstream proteins of preimmunized CTLA4⁻/⁻ B cell after establishing HBV transduction model and HBV serological indicators were detected. CO-IP assay and proteome analysis was made to explore the downstream proteins of CTLA4.

**Results:** CTLA4 was highly expressed in B cells of CHB patients and more obviously in HBsAg-specific B cells. Moreover, CTLA4 was highly expressed in about 50% of the infiltrating HBsAg-specific B cells. CTLA4 HiB-BSAg ·B cells tended to show activated markers. GO analysis, Ca⁺ flow and WB assay showed that BCR signaling of CTLA4⁻/⁻ B cells was defected. Moreover, CTLA4 blocking could partly restore the defection and make B cells secreted more anti-HBs. In mice model, B6-Ighm-KO mice injected with HBsAg preimmunized CTLA4⁻/⁻ B cells showed decreased level of HBV serological indicators. Proteome assay showed SHIP-1 was the down stream of CTLA4.

**Conclusions:** The circulating and liver infiltrating B cells increased the expression of CTLA4 to defected the BCR signal which might contribute to the deficiency of viral specific humoral response during CHB course.

Abstract Submission No. 100691
O-0067

**Comprehensive analysis of CHB concurrent with NAFLD : A Proteomics Report Based on Liver Samples**

Xin Tong1, Shengxia Yin1, Chao Wu1, Jie Li1
1Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

**Background and Aims:** In recent years, NAFLD has become more prevalent in patients with chronic hepatitis B as the prevalence of obesity and metabolic syndrome has increased. Both diseases can lead to liver fibrosis and even HCC, but the pathogenesis of each disease and CHB concurrent with NAFLD have not been fully elucidated.

Methods: We characterized the protein expression in liver tissues among four groups of people with healthy control, CHB, NAFLD, and CHB concurrent with NAFLD by using proteomic profiling. Based on the obtained DEPs results, further bioinformatics analysis was performed. We also verified the expression of some DEPs in the livers of patients and model mice.

**Results:** We found that accelerated viral clearance in HBV-infected patients with concurrent fatty liver might be associated with an inflammatory response and activation of a large number of metabolic reactions in the organism, while the level of hepatic steatosis was associated with abnormalities in fatty acid degradation, glycolysis/glucogenesis and others, however the prognosis of CHB concurrent with NAFLD is probably not optimistic, which could be associated with the expression of ACAT1, ACY1, SERPINB3, MTCH2, ALDH2, ECHS1, S100A7 and LRP6.

**Conclusion:** The prognosis of CHB complicated with NAFLD may not be optimistic compared with that of hepatitis B and NAFLD alone, which is closely related to the differential expression of certain proteins in the liver after the complication of the two diseases. Our study provides new insights into the disease development and clinical mechanisms of CHB and NAFLD.

Abstract Submission No. 100855
O-0068

**MiRNA106b-3p down regulates PCGF3 and inhibits cell metastasis in HBV-related hepatoma carcinoma**

Tao Shen1, 2, 4, Jing Chen1, 2, Qi Yin1, 2, Jainqiong Wang3, Chaohui Chen1, 2, Li Li1, Shiheng Xiu1, 2
1Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province Kunming China, 2Kunming University of Science and Technology Kunming China, 3Department of Clinical Laboratories, The First People's Hospital of Yunnan Province Kunming China, 4Department of Infectious Diseases and Hepatic Disease, Yunnan Province Innovation Team of Intestinal Microecology Related Disease Research and Technological Transformation, the First People's Hospital of Yunnan Province Kunming China

**Background:** MicroRNA-106b (miRNA-106b) has been shown to play a paradoxical role in disease progressing from different studies. However, the specific role of miRNA106b-3p in hepatocellular carcinoma and the underlying mechanism remains unclear.

**Method:** Huh7 cell transient transfected with HBV C2 subgenotype plasmid was co-cultured with miRNA-106b-3p mimics. HBsAg level was detected using Elisa assay. Target genes that potentially bind to miR-106b-3p were predicted using TargetScan software. Target analysis was conducted via a dual-luciferase reporter assay. Q-PCR was used to detect expression level of target genes. Scratch assay was performed to evaluate cell migration. Transwell assays was used to evaluate cell invasion. Western blot was used to detect the PI3K/AKT signaling pathway-related proteins.

**Results:** Huh-7 HBV/C2 cells co-cultured with miRNA-106b-3p mimics was significantly increased with miRNA-106b-3p expression and down-regulated with HBsAg level. MiR-106b-3p overexpression significantly decreased the luciferase activity of wild-type PCGF3 3′-UTR, but no significant effect on the luciferase activity of mutant PCGF3 3′-UTR. MiR-106b-3p mimic can dramatically decrease the expressions of PCGF3 mRNA and protein in Huh7-HBV/C2 cells. In addition, the migration and invasion ability of Huh7-HBV/C2 cells was significantly decreased and the PI3K-AKT pathway was inhibited by miRNA-106b-3p mimics.

Abstract Submission No. 100855
O-0068
Conclusion: This study revealed that miR-106b-3p could down-regulate the expression of PCGF3 and inhibit the activation of PI3K/AKT signaling pathway, thereby preventing HCC metastasis.

Funding: This work was supported by the Yunnan Provincial Science and Technology Department (2019FAA030); in part by the National Natural Science Foundation of China (82160384); and in part by the Yunnan Health Commission (L2019003).

Abstract Submission No. 101155
O-0069

The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages

Hang Le1, Huy Nguyen2, Hoa Pham1

1University of Medicine and Pharmacy at Ho Chi Minh City Ho Chi Minh Vietnam, 2School of Tropical Medicine and Global Health, Nagasaki University Nagasaki Japan

Regulatory T (Treg) and T helper 17 (Th17) cells modulate the immune response in chronic hepatitis B virus infection by promoting immune tolerance, restricting liver damage, stimulating inflammatory responses, and inducing hepatocyte injury. These cells act by signaling immune tolerance, restricting liver damage, stimulating inflammatory response in chronic hepatitis B virus infection by promoting immune response. The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages were measured by flow cytometry, and the mRNA levels of transcription factors do not correlate with the percentage of Treg and Th17 cells. Our study aimed to observe the percentages of Treg and Th17 cells, as well as their mRNA levels of Foxp3 and RORγt, in chronic hepatitis B (CHB)-infected groups and CHB patients experiencing hepatitis flare (HF). We recruited 159 participants, including 137 CHB-infected cases and 22 healthy controls (HC) from Ho Chi Minh City. CHB cases were divided into three groups: HBeAg+ CHB infection (e+CHBI, n=52), HBeAg+ CHB (e+CHB, n=24), and HF (n=61). Treg and Th17 cells were measured by flow cytometry, and the mRNA levels of Foxp3 and RORγt were analyzed by Realtime PCR. The percentages of Treg, Th17, and a special subset - IL17A(+)Foxp3(+)Treg cells - were significantly higher in the HF group compared to the e+CHBI group. Meanwhile, there was no significant difference in the mRNA levels of Foxp3 and RORγt in CHB groups. These findings reveal that these immune cells increase with the severity of the liver injury, and the mRNA levels of transcription factors do not correlate with the percentages of their cells. Our results explain the diversity of T cells and their subsets in the immune response in CHB and suggest that the new subset should be further investigated as a specific tool in the HBV immune response.

Abstract Submission No. 101224
O-0070

Adenosine sulfamate analogs inhibit HBV RNA synthesis and accelerate the decay of viral transcripts

Bingqian Qu1, Maike Herrmann1, Saskia Mönch1, Renate König1, Richard J.P. Brown8

1Paul-Ehrlich-Institut Langen Germany, 2Ruhr University Bochum Bochum Germany

Background: The neddylation pathway is required for HBV replication. Targeting neddylation inhibits both HBV gene transcription and surface antigen expression in preclinical models. However, the underlying mechanism of neddylation modulation and HBV gene transcription remains unclear.

Methods: Two adenosine sulfamate analogs (ASAs) were evaluated for their ability to target host components of the neddylation pathway and inhibit HBV gene transcription in susceptible cells, in addition to explanted primary human hepatocytes (PHHs) from multiple donors. Nascent transcript production was determined by click chemistry. RNA sequencing of HBV-infected PHHs determined the effects of ASAs on viral and host transcriptomes.

Results: Both ASAs, MLN4924 and TAS4464, reduced the expression of NAE1, Ubc12, Cul4A and neddylated cullins in PHHs. Upon SMC5/6 gene knockdown or HBx absence, the inhibitory effects of ASAs on viral transcription were alleviated. To further investigate the mechanism, 5-ethyl-uridine was incorporated into infected HepG2-NTCP cells, allowing the detection of nascent transcripts. MLN4924 and TAS4464 reduced the synthesis of HBV transcripts by 60% and 74%, respectively. Furthermore, compared to DMSO treatment (>24 hours), ASAs accelerated the decay of subgenomic transcripts (t1/2 = 10.8 and 14.2 hours) in HepAD38 cells. Remarkably, RNA-sequencing results showed that ASAs modulate host transcriptomes upon HBV infection in PHHs by selectively regulating a small cluster of host genes.

Conclusions: We demonstrate that ASAs reduce the protein expression of host components of the neddylation pathway, inhibit HBV RNA synthesis and accelerate viral transcript decay. ASAs have potential for future development and repurposing as a novel class of anti-HBV therapeutic.

Abstract Submission No. 101227
O-0071

Multi-Omics Panoramic Analysis of HBV Integration in the HBV-Integrated Cell Line PLC/PRF/5

Guwen Guan1, Abudurexiti Abulaiti1, Danjuan Lu1, Zhiqiang Gu1, Ting Zhang1, Fengmin Lu1, Xiangmei Chen1

1Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Background: The clearance or transcriptional silencing of integrated HBV DNA is crucial for achieving a functional cure in patients with chronic hepatitis B (CHB) and reducing the risk of hepatocellular carcinoma (HCC) development. The PLC/PRF/5 cell line is commonly used as an in vitro model for studying HBV integration. In this study, we employed a range of multi-omics techniques to gain a panoramic understanding of the characteristics of HBV integration in PLC/PRF/5 cells.

Methods: Transcriptome long-read sequencing was conducted to analyze characterize the transcriptional activity of different HBV DNA integrations in PLC/PRF/5 cells. Additionally, data pertaining to epigenetic regulation such as whole-genome bisulfite sequencing (WGBS), ChIP-seq, and ATAC-seq were collected to investigate the potential mechanisms associated with the transcriptional regulation of integrated HBV DNA.

Result: Our findings indicate that transcriptional activity of integrated HBV DNA in PLC/PRF/5 cells is influenced by methylation levels of the surrounding host genome near the integration site. The result indicated that elevated methylation of the adjacent host genome adversely impacts transcription activity of integrated HBV DNA. Furthermore, we observed a positive association between histone modification H3K4me3 and the transcription of integrated HBV DNA. These results suggest that host may regulate transcriptional activity of integrated HBV DNA through DNA methylation and histone modifications. Potentially leading to the silencing of integrated HBV DNA.

Conclusion: Our study brought a better understanding on the transcriptional regulation of integrated HBV DNA. This knowledge can be valuable in the development of novel strategy for functional cure of CHB.
IGF2BP1 promotes HBV replication via regulating HBV RNA stability in an m6A-dependent manner

Deyao Li¹, Jing Ning², Danjuan Lu¹, Fengmin Lu¹, Xiangmei Chen¹
¹Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China, ²Department of Gastroenterology, Peking University Third Hospital Beijing China

Background & aims: Hepatitis B virus (HBV) infection is the primary cause of chronic hepatitis B, cirrhosis, and hepatocellular carcinoma world widely. During HBV replication, HBV RNA undergoes post-transcriptional regulation by host cells which primarily relies on various host RNA binding proteins. However, the detailed mechanisms underlying post-transcriptional regulation of HBV RNA remain unknown. Herein, we investigated the role of RNA binding protein IGF2BP1 in the process of HBV replication.

Methods: The host proteins associated with HBV Dane particles was analyzed by mass spectrometry. Gene silencing and ectopic overexpression were used to detect the function of IGF2BP1 in regulating HBV replication. RNA turnover, RNA pull-down, and RNA immunoprecipitation assays were used to investigate the stability and binding between IGF2BP1 and HBV RNAs.

Results: Our study identified IGF2BP1 as an RNA binding protein that can be encapsulated into HBV Dane particles. According to the HBV replication cell model, the HBV infection cell model, and the HBV replication mouse model, we confirmed that IGF2BP1 promotes HBV replication. To elucidate the underlying mechanism, we found that IGF2BP1 enhanced the stability of all five HBV RNAs through its KH domain. IGF2BP1 recognized and bound to m6A modification sites on HBV RNAs, consequently promoted HBV RNA expression. This increased HBV RNA expression led to elevated protein expression and the formation of rcDNA, ultimately enhancing HBV replication.

Conclusions: Our study demonstrated IGF2BP1 as a critical host factor in enhancing the stability of HBV RNAs and facilitating HBV replication which provided a novel target for the development of anti-HBV drugs.

Deep sequencing analysis of HBV evolution in elderly cases of interspousal transmission

Jun Inoue¹, Takehiro Akahane², Yutaka Miyazaki³, Masashi Ninomiya¹, Akitoshi Sano¹, Mio Tsuruoka¹, Kosuke Sato¹, Masazumi Onuki¹, Satoko Sawahashi¹, Keishi Ouchi¹, Atsushi Masumune¹
¹Department of Gastroenterology, Tohoku University Hospital Sendai Japan, ²Japanese Red Cross Ishinomaki Hospital Ishinomaki Japan, ³Tohoku Kosai Hospital Sendai Japan

Background/Aim: Hepatitis B virus (HBV) is transmitted within a family, but an interspousal transmission in elderly cases is rare. To clarify the dynamics of HBV quasispecies in such cases, we performed long-read deep sequencing of the HBV preS1/preS2/S domain in two elderly couples of HBV transmission from wife to husband.

Methods: Using serum samples from two male patients with acute hepatitis (AH1: 67 years old, AH2: 71 years old) and their HBV carrier wives (CH1: 67 years old, CH2: 66 years old), HBV full genome sequences were determined by direct sequencing. In addition, a long-read deep sequencing was performed with PacBio Sequel II using preS1/preS2/S domain amplicons.

Results: As a result of whole genome direct sequencing, AH1 was 98.0-99.2% identical to CH1, and AH2 was 98.5-99.5% identical to CH2. The identity between AH1 and AH2 was 96.9%. When a phylogenetic tree analysis was performed using the long-read deep sequences, it was shown that CH1 and CH2 had heterogeneous clones but AH1 and AH2 had relatively homogeneous clones. It was also suggested that the transmitted viral clones might be distinct from the major populations in the HBV carriers. We speculated that the major population in the carriers did not fit to the spouses and this might be one of the reasons why the transmission had not occurred during younger age.

Conclusion: Deep sequencing analyses revealed clonal population changes during HBV transmission.

Knowledge, Attitudes and Practices (KAP) of Adult Filipinos towards Viral Hepatitis

Nicole Allyson Chua¹, Diana A. Payawal², Ellaine M. Wei-Munji², Marco Angelo D. Tongo³, Ma. Digna M. Pena², Celina Celeste H. Adraneda², Marivic I. Cadag³
¹Section of Gastroenterology, Cardinal Santos Medical Center San Juan City Philippines, ²Hepatology Committee, Section of Gastroenterology, Cardinal Santos Medical Center San Juan City Philippines
Viral hepatitis is a major public health burden worldwide. The objective is to focus on patients’ knowledge, attitudes, and methods regarding viral hepatitis B and C to improve awareness, attitudes, and procedures related to viral hepatitis, leading to better prevention and management of the disease. A validated descriptive, cross-sectional, self-reported questionnaire on knowledge, attitudes and practices (KAP) relating to hepatitis B and C was administered at the outpatient department in a tertiary hospital. Data were analyzed and compared with mean scores from 2015-2023. Majority of the participants (44%) were between 41-60 years old, residing in Metro Manila (81%), high school graduates (53%) and unemployed (64%) and 81% having a monthly income of less than 200 USD (Php 10,000.00). There was an increasing mean KAP score towards hepatitis B and C from 2015 to 2017, with a decrease in the mean KAP scores in 2023. There were also no significant differences in the mean KAP scores except for practice scores in terms of place of residence (p=0.026), and knowledge and practice scores in terms of place of residence (p=0.026 and 0.03 respectively). With most medical services directed to contain the expanding COVID-19 pandemic, viral hepatitis programs face several challenges. The COVID pandemic has widened the gap in the KAP towards hepatitis preventive practices and knowledge. Targeted health education programs promoting disease awareness should be intensified to eradicate viral hepatitis as a global health concern.

Abstract Submission No. 100425
O-0076

IFN-γ Th1 promotes HBsAg loss by activating intrahepatic TRM through inducing M1 polarization

Lili Wu1, Bingleiang Lin1, Zhiliang Gao4
1Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Background: The immune mechanism of ALT elevation and HBsAg loss during pegylated interferon (PEG IFN) therapy remains to be elucidated.

Methods: Eight-two NA (nucleos(t)ide analog) treated Chronic hepatitis B (CHB) patients sequentially received add-on PEG IFN treatment for less than 96 weeks. 41 patients got HBsAg < 0.05 IU/ml (cured group) within 48 weeks. Blood samples were collected from all patients for research. Liver tissue from 14 CHB patients was used to detect inflammatory markers. Liver perfusate from healthy individuals or chronic HBV-infected individuals was used for mechanism validation. THP-1, Jurkat and HepG2.2.15 cell lines were used in vitro experiments.

Results: Serum and intrahepatic levels of Th1 cell-associated chemoattractants (CXCL9, CXCL10, CXCL11) and the proportion of Th1 cells in peripheral blood kept higher in the uncured group. But the proportion of IFN-γ Th1 cells was higher in the cured group (0-24 weeks), the latter was linearly correlated with HBsAg decline and ALT levels during treatment. However, weak association was found between CD8+ T cells and HBsAg loss. Serum from cured patients induced a higher proportion of M1 (CD68+CD86+ Macrophage) cells compared to uncured patients. Polarization of IFN-γ Th1 cells as well as M1 macrophages could be induced by IFN-α. M1 polarization of intrahepatic Kupffer cells promoted HBsAg loss by enhancing the effector function of tissue-resident T cells with an elevation of ALT levels.

Conclusions: IFN-γ Th1 promotes HBsAg loss by activating intrahepatic resident memory T cells through inducing M1 macrophage polarization.

Abstract Submission No. 100482
O-0077

Anti-PD-1 antibody combined with ETV and Peg-IFN-α enhances anti-HBV efficacy in AAV-HBV mice

Taiyu He1, Huanyu Xiang1, Min Chen1, Mingli Peng1, Peng Hu1, Dachuan Cai1, Yinghua Lan1, Dazhi Zhang1, Hong Ren1
1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University Chongqing China

Background: This study aimed to find a safe and more effective therapeutic strategy for hepatitis B virus (HBV) infection by combining anti-PD-1 antibody (α-PD-1), entecavir (ETV) and pegylated interferon-alpha (PEG-IFN-α).

Methods: A 4-week treatment was conducted in an adeno-associated virus (AAV)-HBV mouse model. To evaluate safety, efficacy and immune response, various indicators were compared between model control, ETV, ETV+αPD-1, ETV+αPD-1/Peg-IFN-α, and ETV+αPD-1/Peg-IFN-α groups.

Results: All groups had stable weight, alanine aminotransferase and aspartate transaminase levels during treatment, and similar liver necroinflammatory activity (P>0.05). After 4-week treatment, plasma HBsAg decreased most significantly in ETV+αPD-1/Peg-IFN-α group ([Mean: 3.99 log10 vs. 4.36 log10 (Model control group), P<0.023]; Plasma HBV DNA and HBsAg, and hepatocyte HBsAg positivity rates significantly decreased, but no statistically significant difference was found between groups at 4 week. Myeloid, NK, B and T cell responses were detected. Notably, after 4-week treatment, frequencies of HBV surface-specific IL-4+/IL-21+/IFN-γ/TNF-α+ CD8+ T cells increased significantly in liver and blood in ETV+αPD-1/Peg-IFN-α group (P<0.05); Frequencies of PD-1+CD8+ T cells in liver and CD8+ effector memory T (TEM) cells in spleen increased significantly in ETV+αPD-1/Peg-IFN-α group, and the former positively correlated with frequencies of CD38+CD8+ TEM cells (P<0.05); Frequencies of circulating T follicular helper 1 (cTfh1) cells increased more prominently in ETV+αPD-1/Peg-IFN-α and ETV+αPD-1/Peg-IFN-α groups. Furthermore, HBsAg decrease value correlated with frequencies of above surface-specific IL-21+CD8+, PD-1+CD8+ and CD8+ TEM cells, and cTfh1 cells (P<0.05).

Conclusions: ETV+αPD-1/Peg-IFN-α sequentially combined therapy reduces HBsAg levels safely and more effectively, whose efficacy may be related to enhanced T cell responses.

Abstract Submission No. 100907
O-0078

Serum N-Glycan for Diagnosing Liver Fibrosis in Chronic Hepatitis B Patients with Normal ALT Levels

Yi-Qi Liu1, Lin Wang2, Chi Zhang1, Xue-En Liu3, Hong Zhao1, Hui Zhuang3, Gui-Qiang Wang1
1Department of Infectious Disease, Peking University First Hospital Beijing China, 2Department of clinical laboratory, Beijing CHAO-YANG Hospital Beijing China, 3Department of Microbiology & Center of Infectious Diseases, Peking University Health Science Center Beijing China

Background: The aim of this study was to explore the role of serum N-glycomic-derived models in diagnosing significant liver fibrosis and cirrhosis in 285 chronic hepatitis B (CHB) patients with normal (<40 IU/L) alanine aminotransferase (ALT) levels.

Methods: Liver biopsy stages were assessed using the Ishak scoring system. Serum N-glycan profiles were tested using DNA sequencer-
assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). A machine learning method, random forest (RF) analysis was adopted to construct more ideal serum N-glycan models in order to distinguish significant liver fibrosis and cirrhosis.

**Results:** From Jan 2013 to Dec 2020, 285 CHB patients were enrolled, 63.86% (182/285) and 16.49% (47/285) of patients had significant liver fibrosis and cirrhosis, 4.91% (14/285) of patients had significant inflammation. The diagnostic efficiency of the serum N-glycan RF model constructed for distinguishing significant liver fibrosis (F3; RF-A model) was excellent (area under receiver operating characteristic (AUROC): 0.94), and the coincidence rate of the serum N-glycan RF-A model compared with liver biopsy was 90.45%. The diagnostic AUROC of the serum N-glycan RF model constructed for distinguishing liver cirrhosis (F5; RF-B model) was 0.97, and the coincidence rate was 88.94%.

**Conclusions:** The diagnostic efficiency of the constructed serum N-glycan models (RF-A and RF-B) was similar to that of liver stiffness measurement (LSM), the fibrosis index based on the four factors (FIB-4), and the aspartate aminotransferase-to-platelet ratio index (APRI). Serum N-glycan models are promising markers for the differentiation of significant liver fibrosis and cirrhosis in CHB patients with normal ALT levels.

Abstract Submission No. 101036

**O-0079**

**Alcohol induced dendritic cell and its exosome promotes specific T cell immunity in HBV infection**

Hongbo Shi1,2, Xinzong Miao1,2, Chaoan Liu1,2,3, Honglin Shi1,2, Fang Liu4, Yingmin Ma1,2, Xiaoshuang Zhou1

1Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing Beijing China, 2Beijing Engineering Research Center for Precision Medicine and Transformation of Hepatitis and Liver Cancer Beijing China, 3Department of Nephrology, Shanxi Provincial People’s Hospital, The Affiliated People’s Hospital of Shanxi Medical University Shanxi Province China

**Background:** Dendritic cell (DC) plays a crucial role in the immune system and its function was found to be significantly impaired in patients with chronic hepatitis B. Dendritic cell derived exosome (DEX) is an extracellular vesicle secreted by DC and has the same or similar immune function as DC. Therefore, this study investigated the therapeutic role of DC and DEX in HBV infection.

**Methods:** We systematically investigated the functional effects of alcohol and HBV infection on DC and DEX, and co-cultured DC and DEX induced by alcohol with lymphocytes from HBV transgenic mice and patients with chronic hepatitis B to observe the T-cell immune response.

**Results:** Alcohol effectively stimulated the maturation of mouse bone marrow-derived dendritic cells (BMDCs) and DCs from HBV patients, but had no significant effect on the DC2.4 cell line. HBV infection inhibited the activation and maturation of DC and DEX. More importantly, in HBV transgenic mice and chronic hepatitis B patients, alcohol-induced DCs effectively promoted specific T-cell immunity, and DEXs were able to exert the same effects as DCs.

**Conclusions:** Our findings provide a new and effective way to stimulate DC maturation. In the future, DEX may substitute for DCs as a new therapeutic approach for patients with chronic hepatitis B.

Abstract Submission No. 100077

**O-0080**

**Kinetics of iTACT-HBcrAg and -HBsAg assays in chronic hepatitis B patients with HBsAg seroclearance**

Takanori Suzuki1, Kentaro Matsuura1, Takehisa Watanabe2, Takeshi Matsui1, Shintaro Ogawa2, Hayato Kawamura1, Kayoko Kuno1, Kei Fujiwara1, Shunsuke Nojiri1, Hiromi Kataoka1, Yasuhito Tanaka2

1Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences Nagoya Japan, 2Department of Gastroenterology and Hepatology, Kumamoto University Kumamoto Japan, 3Center for Gastroenterology, Teine-Kekiinkai Hospital Sapporo, Hokkaido Japan

**Objectives:** Two novel assays have been developed, iTACT-hepatitis B core-related antigen (iTACT-HBcrAg) and iTACT-hepatitis B surface antigen (iTACT-HBsAg) assays. We investigated the longitudinal profiles of iTACT-HBcrAg and -HBsAg in patients with HBsAg seroclearance (SC) (<0.05 IU/mL).

**Methods:** This study comprises 60 HBV-infected patients with HBsAg SC, 27 in chronic hepatitis/liver cirrhosis (CH/LC) group and 33 in inactive carrier (IC) group. Longitudinal profiles of iTACT-HBcrAg and -HBsAg were examined using stored serum samples.

**Results:** The median period from HBsAg SC to iTACT-HBcrAg loss or to the last observation was longer in the CH/LC group than the IC group (39 vs. -3 months, P = 0.004), but this tendency was not observed in that by iTACT-HBsAg. Comparing the times of iTACT-HBcrAg and -HBsAg loss, the rate of patients who lost HBcrAg first was significantly higher in the IC group (P = 0.008). The cumulative incidence rate of iTACT-HBcrAg loss after HBsAg SC was higher in the IC group that the CH/LC group (P = 0.002), but there was no difference in the cumulative incidence of iTACT-HBsAg loss after HBsAg SC between the IC and CH/LC groups.

**Conclusions:** Patients in the CH/LC group had higher rates of detectable iTACT-HBcrAg than those in the IC group after HBsAg SC, suggesting that the presence of HBcrAg possibly contribute to the progression of chronic hepatitis B.

Abstract Submission No. 100137

**O-0081**

**Effects of Vitamin D and Calcium on Bones in Chronic Hepatitis B Patients Treated with TDF**

THANAPAT ATTAKHITMONGKOL1, Wimolrak Bandidinayamoni1, Supot Nimmong1, Watcharasak Chotiyaputta1, Siwaporn Chainuvati1, Phunchai Charatcharoenwiithaya1, Taweetsak Tanwande1

1Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand

**Background:** Tenofovir disoproxil fumarate (TDF) is an important drug to treat chronic hepatitis B (CHB) patients. However, long-term TDF therapy decreases renal function and bone mineral density (BMD).

**Objective:** To compare bone turnover markers, BMD, and renal function in CHB patients treated with TDF who received vitamin D3 and calcium supplements and those who did not receive supplement.

**Methods:** This open-label prospective, randomized trial was conducted in patients with CHB treated with TDF who were randomized to the vitamin D3 and calcium supplement group (n=32) and no supplement group (control group) (n=32) for 48 weeks.

**Results:** At baseline, the mean age was 54.2 years, 57.8% were male, and 17.2% had cirrhosis. Demographic data were similar in both groups, except body mass index, AST, and ALT were higher in the
control group. At 48 weeks, there were no differences in parathyroid hormone, serum creatinine, procollagen-I N-terminal peptide, and tubular reabsorption of phosphate in both groups. The BMD T score of the total hip did not decrease in the supplement group but significantly decreased in the control group. The C-terminal telopeptide of type I collagen increased in only the control group. Subgroup analysis was performed in participants with low baseline vitamin D, the result showed that the median difference in the T score for the total hip in the supplement group also showed a smaller decrease than in the control group.

Conclusions: In CHB patients treated with TDF, supplementation with vitamin D2 and calcium for 48 weeks can prevent loss of BMD.

Abstract Submission No. 100157
O-0082

Unawareness of hepatitis B infection and severity of hepatocellular carcinoma

Kuan-I Lee1, Po-Cheng Liang2, Po-Yau Hsu1,2, Tyng-Yuan Jang1,2, Yu-Ju Wei1, Ching-I Huang2,4, Ming-Yen Hsieh2, Zu-Yau Lin1,2, Ming-Lun Yeh5, Chung-Feng Huang3, Jee-Fu Huang6, Chia-Yen Dai7, Wan-Long Chuang6, Ming-Lung Yu1,4,5,3

1School of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung Taiwan, 2Division of Hepatobiliary, Department of Internal Medicine, Kaohsiung Medical University Hospital Kaohsiung Taiwan, 3School of Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan

Background: Unawareness of hepatitis B virus (HBV) infection and lack of surveillance may serve as major barriers to HBV control and contributors to severe hepatocellular carcinoma (HCC) at presentation. This study evaluated the risk of HBV unawareness and its relationship with HCC severity.

Methods: This retrospective study was conducted in a tertiary hospital in Taiwan. Patients with HBV-related HCC diagnosed from 2011 to 2021 were enrolled. The demographic, clinical, and HCC characteristics were collected and compared between patients with HBV unawareness and awareness with and without surveillance.

Results: Of 501 HBV-related HCC patients enrolled, 105 (21%) patients were unaware of HBV infection at the time of HCC diagnosis. Patients with HBV unawareness were significantly younger and had poorer liver function than those with HBV awareness. Patients with HBV unawareness also had a significantly higher rate of detectable HBV DNA and an advanced stage of HCC. Patients with HBV unawareness and awareness without surveillance shared similar clinical characteristics with more severe HCC status. Further regression analysis demonstrated that HBV awareness with periodic surveillance was associated with early-stage HCC. Meanwhile, we observed that there was no change in the proportion of HBV awareness over the past 10 years.

Conclusions: Patients with surveillance also had better HCC survival than patients without surveillance or unawareness. HBV unawareness and lack of regular surveillance correlated with advanced HCC at presentation. Efforts to improve HBV education, disease awareness, and HCC surveillance are needed.

Abstract Submission No. 100176
O-0083

STOPPING ORAL THERAPY IN CHRONIC HEPATITIS B USING HBsAg THRESHOLDS: METAANALYSIS & META-REGRESSION

Seng Gee Lim1, Ada, Ee Der Teo1, Edwin, Shih-Yen Chan2, Wah Wah Phyo1, David, Hsing Yu Chen1, Carol Anne Hargreaves1

1National University Health System Singapore Singapore, 24Centre for Quantitative Medicine, Duke-NUS Singapore Singapore, 3Data Analytics Consulting Centre, Faculty of Science, National University of Singapore Singapore

Background and aims: Recommendations for stopping nucleoside analogue (NA) therapy in HBeAg-negative Chronic Hepatitis B (CHB) are unclear. End-of-treatment quantitative HBsAg (EOT-qHBsAg) thresholds <100IU/ml or <1000IU/ml have been proposed as stopping criterion. We assessed this by meta-analysis and meta-regression.

Design: We searched PubMed, EMBASE and conference abstracts for studies of HBeAg-negative CHB NA discontinuation. Extracted studies were analysed for risk-of-bias, pooled risk of HBsAg loss, virological (VR) and biochemical relapse (BR). Significant heterogeneity (I²) was addressed by subgroup analysis and random-effects meta-regression with known important covariates, including EOT-qHBsAg thresholds, ethnicity, duration of therapy and followup.

Results: We found 24 papers (3732 subjects), 9 low, 14 moderate and one with high risk of bias. The pooled risks of HBsAg loss, VR and BR for stopping therapy at EOT-qHBsAg<100IU/ml were 41.8%, 33.4% and 17.3%, versus 4.6%, 72.1% and 34.6% respectively for EOT-qHBsAg≥100IU/ml. The pooled risks of HBsAg loss, VR and BR for stopping therapy at EOT-qHBsAg<1000IU/ml were 22.0%, 52.7% and 15.9%, versus 3.4%, 63.8% and 26.4% respectively for EOT-qHBsAg≥1000IU/ml. Multivariable analysis for HBsAg loss showed ethnicity, followup duration and EOT-qHBsAg<100IU/ml explained 85% of the variance in heterogeneity; Asians with EOT-qHBsAg<100IU/ml had 28.2%, while Caucasians with EOT-qHBsAg≥100IU/ml had 38.4% HBsAg loss. Multivariable analysis showed EOT-qHBsAg<100IU/ml and other covariates only explained 43% and 63% of the variance in heterogeneity for VR and BR respectively, suggesting that other factors are also important for relapse.

Conclusions: While EOT-qHBsAg thresholds, ethnicity and followup duration strongly predict HBsAg loss, this is not true for VR and BR, hence stopping NA therapy should be considered cautiously.

Abstract Submission No. 100203
O-0084

The correlation between Interleukin-6 and the progression of chronic Hepatitis B

MOHAMED MAHOOBALI

1ADVANCED MEDICAL AND DENTAL INSTITUTE(AMDI) GEORGETOWN Malaysia

INTRODUCTION: Hepatitis B virus (HBV) is a dreadful virus with the potential to cause human liver diseases such as self-limiting acute hepatitis, chronic hepatitis, fulminant hepatic failure, liver cirrhosis and hepatocellular carcinoma (HCC). These complications result from an immune response of the host that affects both outcome and disease progression, rather than a direct cytopathic effect. Cytokines have been shown to be engaged in regulating hepatocyte functions, and play an important role in HBV infection immunopathogenesis.

METHODS: About 52 subjects ranging from 18 years old to 80 years old who were diagnosed with HBV were recruited into the studies. Their venous blood was taken and centrifuged at 4500rpm for 5
minutes to separate the blood components. The patient’s sera were withdrawn and divided into two aliquots and kept in a special fridge with a temperature of −20 to −70 degrees. The first group of sera were subjected to a hybrid capture, tube-based signal amplification using HBV Digene Hybrid-Capture I, Digene Corporation, USA. While the second group of sera were subjected to a sandwich-ELISA test using LEGEND MAX Deluxe set human IL-6 kit to quantify the IL-6 levels. Both data were recorded and analysed using IBM SPSS version 26 software.

RESULTS: We found that there was a direct correlation between the severity of HBV viral load and the level of IL-6. The more severe the infection, the higher the IL-6 level (P=0.05) taking the mean value of IL-6 as 132.6pg/ml. Demographical data distributions showed that men, aged between 40 and 60 years old and healthcare workers were the risk factors to develop chronic HBV. A linear scatter plot was derived between the levels of IL-6 and HBV viral load. Pearson correlation coefficient showed a linear correlation between the two variables. The patient’s ALT enzyme was used to stratify the severity of the liver functions. Higher levels of IL-6 were detected in the subjects with HBV for longer than 6 months which proved that IL-6 levels correspond to the chronicity of the disease.

CONCLUSION: IL-6 is a vital mediator of inflammation and the acute phase response of the liver. Our studies proved that serum IL-6 levels were positively correlated with HBV disease severity and chronicity. Thus, IL-6 may be a useful indicator of disease activity and therapeutic efficacy in patients suffering from hepatitis B.

Abstract Submission No. 100214

O-0085

Establishment of a predictive model of myelosuppression in patients with CHB treated with Peg-IFN

jiwei fu1, Xiaoping Wu1

1The First Affiliated Hospital of Nanchang University Nanchang China

Objective: The aim of this study was to explore the risk factors for myelosuppression in chronic hepatitis B patients with peginterferon and establish a risk prediction model.

Methods: A total of 208 patients with chronic hepatitis B who were treated with peginterferon in the infection Department of the First Affiliated Hospital of Nanchang University from December 2019 to December 2021 were selected and divided into the modeling group (153 cases) and the verification group (55 cases) according to a ratio of about 3:1. Patients with degree II and above myelosuppression after 1 dose of interferon therapy were defined as myelosuppression group, and the rest were normal group. The risk factors of myelosuppression were discussed by multivariate logistic regression, and the prediction model was established and verified internally.

Results: The results of multi-factor logistic regression analysis and prediction model establishment show: BMI (OR=0.896, 95%CI 0.772-0.979, P=0.021), leukocyte (OR=0.704, 95%CI 0.508-0.976, P=0.035) and globulin (OR=0.904, 95%CI 0.823-0.992, P=0.034) was an independent factor of myelosuppression in CHB patients treated with peginterferon. Calculation formula: Logit (P) = In[P/(1-P)] = -0.14×[BMI (Kg/m2)] -0.351 ×[WBC (x10^9/L)] -0.101 ×[GLB (g/L)] + 7.606; The AUC of the modeling group was 0.732, P=0.001(Figure 1); The AUC of the verification group was 0.762, P=0.001(Figure 2).

Conclusion: Low BMI, low white blood cell and low globulin at baseline were independent risk factors for myelosuppression in CHB patients treated with peginterferon, and a risk prediction model was established, which provided a basis for early identification of myelosuppression prone patients in clinical work and active preventive measures.

Abstract Submission No. 100226

O-0086

Tenofovir disoproxil fumarate raises long-term fracture risk in elderly chronic hepatitis B patients

Terry Cheuk-Fung Yip1, 2, 3, Jimmy Che-To Lai1, 2, 3, Tsz-Fai Yam1, 2, Yee-Kit Tse1, 2, 3, Vicki Wing-Ki Hui2, 3, Mandy Sze-Man Lai1, 2, 3, Henry Lik-Yuen Chan4, Vincent Wai-Sun Wong5, 2, 3, Grace Lai-Hung Wong6

1Medical Data Analytics Centre, The Chinese University of Hong Kong Hong Kong Hong Kong, 2Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong, 3State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong Hong Kong Hong Kong, 4Department of Internal Medicine, Union Hospital, Hong Kong Hong Kong Hong Kong

Background: The use of tenofovir disoproxil fumarate (TDF) is associated with a reduction in bone mineral density. However, data on clinical bone fractures remain limited. We evaluated the impact of TDF compared to entecavir on fracture risk in elderly patients with chronic hepatitis B (CHB).

Methods: Patients with CHB aged ≥60 years receiving entecavir or TDF between January 2008 and December 2022 were identified using a territory-wide database in Hong Kong. The risk of incident fracture in entecavir- and TDF-treated patients before and after month 24 were compared after propensity score (PS) matching.

Results: 41,531 patients with CHB (mean age 69.8±7.8 years, 61.6% male) receiving entecavir (n=39,897 [96.1%]) and TDF (n=1,634 [3.9%]) were analysed. At a median follow-up of 25.3 (9.1-58.5) months, 1,733 (4.2%) patients developed incident fracture. Patients with incident fracture were more likely to have diabetes, hypertension, congestive heart failure, rheumatoid arthritis, osteoporosis, and a history of fracture. Compared with PS-matched entecavir-treated patients, the risk of incident fracture in TDF-treated patients was comparable in the first 24 months (weighted subdistribution hazard ratio [wSHR] 0.98, 95%CI 0.56-1.72, p=0.946) but increased after month 24 (wSHR 1.79, 95%CI 1.11-2.89, p=0.017). The 24-, 60-, and 96-month cumulative incidence (95%CI) of fracture in TDF-treated and entecavir-treated patients were 2.3% (1.6%-3.4%) versus 2.6% (1.9%-3.5%), 6.4% (5.0%-8.2%) versus 4.7% (3.8%-6.0%), and 10.2% (8.3%-12.6%) versus 6.8% (5.4%-8.5%) respectively (Figure).

Conclusions: Fracture risk increased with TDF treatment for ≥24 months in elderly patients with CHB. Selection of nucleos(t)ide analogues should be individualised based on age and comorbidities.

Abstract Submission No. 100228

O-0087

Lipid safety of tenofovir alafenamide during 96-week treatment in e

Wenjuan Zhao1, Yi Liu1, Mengdi Zhang3, Zixin Cui1, Zhan Qu4, Viyang Li1, Meijuan Wan1, Wen Wang1, Gong Feng3, Yunru Chen1, Shumei Lin1, Feng Ye1

1The First Affiliated Hospital of Xian Jiaotong University Xi’an China, 2School of Nursing, Xi’an Jiaotong University Health Science Center Xi’an China, 3Xi’an Medical University Xi’an China

Background: TAF was the first-line antiviral drug recommended by major clinical guidelines for the treatment of HBV infection. Antiviral
therapy requires long-term treatment, so long-term efficacy and safety of the drug are very important. This study was aimed at investigating the dynamics of lipid profile in naive CHB patients for 96 weeks.

**Methods:** Naive CHB patients treated with TAF were enrolled in this study. Consecutive NA-treated CHB-DM patients were recruited from 2017 to 2021 and then obtained their 1-year follow-up data to establish a predict model of 1-year HBVDNA clearance.

**Results:** 137 CHB patients treated with TAF were enrolled. Mean Age was 40.71±10.41 years, 62.04% were male. During 96 weeks of TAF treatment, TC and LDL-c levels gradually increased during treatment with TAF until 24 W (TC: 168.56 vs 170.87 mg/dL; LDL-c: 46.16 vs 47.16 mg/dL; P > 0.05), and then decreased and showed no statistical difference at 96 weeks (TC: 155.41 mg/dL; LDL-c: 43.3 mg/dL; P > 0.05) compared with baseline level. LDL-c levels did not change significantly during 96 weeks of treatment with TAF (105.16 vs 99.36 mg/dL, P > 0.05). TG levels gradually increased from 87.71 mg/dL to 116.1 mg/dL at 48 W (P = 0.009), and then decreased to 88.6 mg/dL at 96 weeks and showed no significant change compared with baseline (P > 0.05). TC/LDL ratio increased from 3.56 at baseline to 3.89 at 96 W, but there was still no statistical difference (P=0.05).

**Conclusion:** TAF treatment had a low effect on the lipid profile of Naive CHB patients over the course of 96 weeks.

Abstract Submission No. 100270

O-0088

**High normal ALT is an indicator for better response to antiviral therapy in chronic hepatitis B**

Mingqin Lu1, Wenxuan Shang1, Ruoyun Wang1, Chao Cai1, Yijing Cai1, Lu Chen1, Ruicong Chen1, Yuqun Wang1

1The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

**Background:** Evidence showed patients with a normal ALT (40U/L as threshold) still have histological disease and there is still a lack of research on the prediction of antiviral benefits in these patients. The study aimed to investigate liver histologic disease in CHB patients with normal ALT, as well as to evaluate the potential benefits of antiviral therapy for these patients.

**Methods:** We retrospectively examined 1352 patients who underwent liver biopsy from 2017 to 2021 and then obtained their 1-year follow-up data to establish a predict model of 1-year HBVDNA clearance.

**Results:** ALT levels were categorized into high and low, with thresholds set at ≥30 for males and ≥16 for females through Youden’s Index. In the high normal ALT group, more patients have significant histological disease (56.43% vs 43.82%, p < 0.001). The threshold of high normal ALT in our study has similar discriminative ability with the threshold of the AASLD 2016 (male ≥30, female ≥19). Multivariate logistic analysis showed that high normal ALT, defined by two different thresholds, were both identified as an independent predictor of 1-year HBVDNA clearance after antiviral treatment (OR 1.993, 95% CI 1.115-3.560, p=0.020; OR 2.000, 95% CI 1.055-3.793, p=0.034, Table 4). Both of the models had higher AUC compared with the current scoring system, and there was no obvious difference between two models (AUC:0.8840 vs 0.8835).

**Conclusions:** Male ≥30, female ≥19 or ≥16 are suggested to be better thresholds for normal ALT. CHB patients with high normal ALT have a potentially better benefit from antiviral therapy.

Abstract Submission No. 100274

O-0089

**CHB patients receiving NAs therapy and achieving HBsAg loss can safely discontinue medication**

En-Qiang Chen1, Yu-Jing Li1, Cheng-Run Song1, Lan-Qing Li1, Jing Zhou1, Meng-Lan Wang1, Ya-Chao Tao1, Dong-Bo Wu2, Wei Jiang1, Yong-Hong Wang1, Hong Tang1

1Center of Infectious Diseases, West China Hospital, Sichuan University Chengdu China

**Objective:** This study aims to investigate the HBsAg negative maintenance rate and possible predictive factors after discontinuation in non-cirrhotic CHB patients with serum HBsAg negative conversion after long-term nucleos(t)ide analogues (NAs) treatment.

**Method:** This is a single-center retrospective study targeting CHB patients who received NAs treatment and achieved negative HBsAg conversion in non-cirrhotic patients. These patients were all treated and followed up at the Hepatitis Clinic of West China Hospital of Sichuan University. The CHB patients finally included in the analysis must have complete demographic and clinical data, and all discontinued patients underwent serum HBVRNA and HBeAg testing at the time of discontinuation.

**Result:** A total of 137 non-cirrhotic CHB patients with negative serum HBsAg were screened, 83 patients refused to discontinue the medication, and only 54 patients agreed to discontinue the medication. Among these 54 patients who agreed to discontinue medication, there were 43
Longitudinal Changes in Renal Function in Patients with Chronic Hepatitis B on Antiviral Treatment

Jongji Choi1, Hyeeyeon Hong1, Minjoo Cho1, Chaeyeon Lim1, Won-Mook Choi2, Danbi Lee3, Ju Hyun Shim1, Kang Mo Kim3, Young-Suk Lim1, Han Cho Lee1

1Asan Medical Center, University of Ulsan College of Medicine
Seoul South Korea

Background & Aims: Patients with chronic hepatitis B (CHB) on nucleos(t)ide analogues (NUCs) often experience renal function decline. Conflicting results regarding the impact of NUC use and renal function have recently been reported. We aimed to examine longitudinal changes in renal function according to the NUC treatment type compared with untreated patients.

Methods: From 2014 to 2022, 10,642 patients with CHB were retrospectively analyzed. The primary outcome was chronic kidney disease (CKD) progression, which was defined as a minimum one-stage elevation. Propensity score (PS) matching was employed for outcome comparisons.

Results: In the PS-matched cohort of 1,996 pairs, the NUC-treated group (7.6/100 person-years [PYs]) had a significantly higher CKD progression risk than the untreated group (4.4/100 PYs), with a hazard ratio (HR) of 1.70 (P<0.001). The tenofovir alafenamide (TAF)-treated group (7.9/100 PYs) showed a 1.76-fold increased CKD progression risk compared with the untreated group (4.5/100 PYs) in the PS-matched cohort (P<0.001). Both the entecavir (ETV)- and tenofovir alafenamide (TAF)-treated groups showed CKD progression risks comparable to those of the untreated group in the PS-matched cohorts of 755 and 426 pairs, respectively (P=0.132 and P=0.120, respectively). No significant CKD progression risk was found between the ETV- (6.0/100 PYs) and TAF-treated (5.2/100PYs) groups in the PS-matched cohort of 510 pairs (P=0.118).

Conclusions: NUC-treated patients, especially those on TDF, faced a higher CKD progression risk than untreated patients. ETV- and TAF-treated patients presented comparable CKD progression risks to untreated patients. No difference was observed between ETV and TAF in the risk of CKD progression.

Abstract Submission No. 100382
O-0093

Effects of ETV and TDF on the incidence and severity of COVID-19 in chronic hepatitis B patients

Xingmei Liao1, Yujie Fan1, Chunxuan Zhong1, Siru Zhao1, Liangxu Guo1, Wenyuan Tan1, Junhua Yin1, Yuan Li1, Rong Fan1

1Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Provincial Clinical Research Center for Viral Hepatitis, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China Guangzhou China

Background: Whether different anti-hepatitis B virus (HBV) drugs have different effects on COVID-19 is controversial. We aimed to evaluate the incidence of COVID-19 in chronic hepatitis B (CHB) patients receiving anti-HBV treatment, and to compare the impact of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the severity of COVID-19.

Methods: CHB outpatients were enrolled from December 2022 to February 2023. Questionnaires were used to collect whether subjects had COVID-19 within the past 2 months, and the information of symptoms, duration, and severity if infected.

Results: 630 CHB patients were enrolled, 64.3% (405/630) patients had COVID-19. No COVID-19 patient required hospitalization,
intensive care unit admission, oxygen support or died. Majority of patients reported mild (32.8% [133/405]) and moderate (48.1% [195/405]) symptoms. After propensity score matching, 400 matched patients were obtained (ETV: 238; TDF: 162), among which the incidences of COVID-19 were comparable between ETV and TDF-treated patients (60.1% [143/238] vs. 64.2% [104/162], p=0.468). The proportion of patients complicated with any symptom caused by COVID-19 were also similar (ETV vs. TDF: 90.9% [130/143] vs. 91.3% [95/104], p=1.000). In addition, the severity of overall symptom was comparable between ETV and TDF-treated patients, in terms of proportion of patients complicated with severe symptom (9.8% vs. 8.7%, p=0.989), symptom duration (4.3 vs. 4.3 days, p=0.927), and symptom severity score (4.1 vs. 4.0, p=0.758). Subgroup analysis supported these results.

**Conclusions:** During the current pandemic, the vast majority of CHB patients experienced non-severe COVID-19, and ETV and TDF did not affect COVID-19 severity differently.

---

**Soluble PD-1 and BTLA proteins as biomarkers for predicting the anti-HBV treatment responsiveness**

**Hoang Hai1, Masaru Enomoto1, Le Thi Thanh Thuy1, Naoshi Odagiri1, Kohei Kotani1, Hiroyuki Motoyama1, Ritsuzo Kozuka1, Atsushi Hagihara1, Etsushi Kawamura1, Hideki Fujii1, Sawako Uchida-Kobayashi1, Norifumi Kawada1**

1Osaka Metropolitan University Graduate School of Medicine Osaka Japan

**Aim:** This study aimed to evaluate the levels of soluble immune checkpoint proteins and their changes in patients with chronic hepatitis B during treatment with nucleos(t)ide analogues (NUCs) or pegylated interferon-α (PegIFNα) and to identify potential biomarkers for predicting treatment responsiveness.

**Methods:** This study included 32 patients with chronic hepatitis B: 20 patients received NUC (entecavir or tenofovir) in an infinite course ≥48 weeks, and 12 patients received PegIFNα monotherapy in a 48-week finite course. The concentrations of 16 soluble checkpoint proteins were measured using multiplexed fluorescent bead-based immunoassays in sera collected at baseline, 12 weeks, and 48 weeks of treatment.

**Results:** NUC treatment resulted in significant decreases in 10 of the 16 soluble (s) immune checkpoint proteins, most of which were important inhibitory factors including sPD-1, sCTLA-4, sTIM-3 and sCD40. In contrast, during PegIFNα treatment, two inhibitors, sTIM-3 and sLAG-3, increased, while the stimulatory factors sGITRL and sCD40 decreased. Treatment response, defined as a 0.5 log decrease in hepatitis B surface antigen (HBsAg) levels, was obtained in 6 of the 20 patients (30%) in the NUC group and in 5 of the 12 patients (42%) in the PegIFNα group. The fold changes of sCTLA and sPD-1 in responders by week 12 of PegIFNα treatment were significantly lower than those of the non-responders (P=0.028 and 0.042, respectively).

**Conclusions:** We found different changes in soluble immune checkpoint proteins between NUC-treated and PegIFNα-treated patients. Circulating soluble PD-1 and BTLA proteins are potential biomarkers for prediction of PegIFNα responsiveness.

---

**TAF and TDF for Chinese Assisted Reproductive Pregnant Women with HBV Infected: A Prospective Study**

**Liyuan Zhang1, Fangxiang Fu1, Yuyan Wang1, Kunliang Wu1, Qiang Wang2, Yuting Zhu1, Xiaojing Zheng1, Dongyao Cai1, Yazhuan Yu1, Min Wu1, Sifu Liu1, Qing Xue1, Juan Li1, Yongguo Du1**

1The Second Affiliated Hospital of Hainan Medical University Haikou China

**Background:** Aim to evaluate effective and safe of Tenofovir alafenamide fumarate (TAF) and Tenofovir disoproxil fumarate (TDF) in preventing mother-to-child transmission (pMTCT) of HBV for pregnant women with assisted reproduction.

**Methods:** Prospective study, from January 2020 to January 2022, pregnant women with HBsAg (+) and HBV DNA (+) who had normal ALT in assisted reproduction at the Second Affiliated Hospital of Hainan Medical College were enrolled. The mothers received TAF 25mg or TDF 300mg daily from gestational week 24 until 2 weeks postpartum. All infants received active immunization combined with passive immunization after birth and were followed up to 7 months after delivery. The primary outcome was the hepatitis B surface antigen (HBsAg)-positive rate at 7 months for infants. The secondary outcome was the safety of mothers and infants.

**Results:** Totally 67 pregnant women were enrolled, including 21 in the TAF group and 46 in the TDF group. The two groups are comparable in their baseline. At 7 months, the HBsAg positive rate of infants was 0% for both groups. During the follow-up period, neither group of pregnant women experienced any adverse reactions resulting in discontinuation or change of medication; Both groups of pregnant women had no birth defects in their babies, and their physical development were normal at birth.

**Conclusion:** It is safe and effective to administer TAF and TDF in HBV pMTCT for pregnancy women with assist reproduction and their infants, no significant difference between two groups.

---

**Humoral responses after COVID-19 vaccination and breakthrough infection in CHB patients**

**Guanhua Zha1, Zhiwei Chen1, Na Wu1, Tianquan Huang1, Zhiling Deng1, Dachuan Cai2, Mingli Peng1, Peng Hu1, Hong Ren1**

1Department of Infectious Diseases, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, China Chongqing China

**Background:** The clinical and immunological features after COVID-19 vaccination and breakthrough infection (BTI) during Omicron wave in CHB patients were still unclear.

**Methods:** In this study, 101 patients with CHB were recruited from the Second Affiliated Hospital of Chongqing Medical University during the Omicron wave epidemic. Clinical data were collected by questionnaire survey and electronic medical record. Blood samples were used to determine the antibody responses, B and T cell responses.

**Results:** The most common symptoms of COVID-19 infection in CHB were upper respiratory symptoms, with 5 days median duration, and all of them were mild or moderate. CHB patients were more susceptible to develop symptoms of COVID-19 infection and presented with more severe symptoms than healthy controls. The liver function was not significantly damaged and HBV-DNA was not significantly increased after COVID-19 infection. CHB patients could establish a stronger immune barrier after BTI than every period after vaccination. The type of vaccine administered was the main factor affecting antibody response after BTI. Patients with CHB received the recombinant SARS-CoV-2 protein vaccine (ZF2001) generated a more robust
immune barrier after BTI than those received the inactivated vaccine. It is worth noting that B cell immune response against the wild strain was higher than the Omicron strain after Omicron BTI. CHB patients post BTI developed a similar antibody response compared with healthy controls, but weakened B cells response.

**Conclusions:** CHB patients followed favorable outcome post COVID-19 infection, in turn, COVID-19 infection will not result in CHB exacerbation. The immune responses were robust after BTI in CHB patients.

---

**Comparing M2BPGi, APRI and FIB4 for Liver Fibrosis Diagnosis with Pathology in Chronic Hepatitis B**

Ya-Wei Hsu1, Cheng-Yuan Peng2, Ming-Lun Yeh3, Jia-Horng Kao4, Tai-Chung Tseng4

1E-Da Hospital, I-Shou University Kaohsiung Taiwan, 2China Medical University Hospital Taichung Taiwan, 3Kaohsiung Medical University Hospital Kaohsiung Taiwan, 4National Taiwan University Hospital Taipei Taiwan

**Background:** Serum Mac-2 Binding Protein Glycosylation Isoform (M2BPGi) levels correlate with liver fibrosis severity, but large-scale studies with histopathological confirmation are scarce in patients with chronic hepatitis B (CHB).

**Methods:** We retrospectively enrolled treatment-naive CHB patients with liver biopsies from four hospitals in Taiwan, excluding those with hepatitis C virus or human immunodeficiency virus co-infection, or with malignancy. Serum M2BPGi, APRI, and FIB-4 levels were quantified at liver biopsy. Their performance for the diagnosis of fibrosis stage, which was evaluated by the META VIR system, was assessed by the receiver operating characteristic (ROC) curves. Optimal cutoffs were determined for F2 or above, F3 or above, and cirrhosis. Subgroup analyses were performed.

**Results:** Among 670 eligible patients (median age: 45; 73.3% male), fibrosis stages were F0-1 (33.9%), F2 (22.4%), F3 (18.2%), and F4 (23.6%). The stage fell between F3 and F4 in 13 patients (1.9%). Mean and median M2BPGi levels rose significantly (P<0.001) across fibrosis stages. M2BPGi demonstrated superior performance (area under the ROC) in diagnosing F2 or above (0.71), F3 or above (0.71), and F4 (0.72) compared to APRI (F2+: 0.58, F3+: 0.56, F4: 0.55; P<0.001) and comparable performance to FIB-4 (F2+: 0.70, F3+: 0.70, F4: 0.69; P=0.1). In patients with ALT flares (ALT >5x normal limit), M2BPGi was significantly better than FIB4 in identifying cirrhosis (0.82 vs. 0.67; P=0.015). Optimal M2BPGi cutoffs were 1.03 for F2+ (sensitivity 71.6%, specificity 63.4%) and 1.20 for F3+ (sensitivity 70.0%, specificity 62.1%). Results remained consistent across subgroups.

**Conclusions:** M2BPGi significantly outperforms APRI in diagnosing fibrosis in CHB patients. As compared to FIB4, M2BPGi is comparable overall but more accurate in patients with ALT flares.

---

**Deep Sequencing of the HBV Genome in Taiwan: Risk of HCC from Primary and Secondary Genotypes**

Ding-Lian Wang1,2, Chih-Jen Huang1, Mei-Hung Pan2, Hwai-I Yang1

1Graduate Institute of Life Sciences, National Defense Medical Center Taipei Taiwan, 2Genomics Research Center, Academia Sinica Taipei Taiwan

**Background:** Several studies have demonstrated that the Hepatitis B virus (HBV) is a diverse DNA virus comprising 10 genotypes (A-J). Genotypes B and C are predominant in Asia, and patients can be co-infected with multiple HBV genotypes. While previous studies predominantly focused on primary genotypes, the impact of secondary genotypes on HCC has been largely overlooked. We investigated the impact of various HBV genotype combinations on the risk of HCC.

**Methods:** This study utilizes a longitudinal cohort of HBV chronic carriers (REVEAL-HBV) collected from 7 communities in Taiwan. PacBio sequencing technology was employed to deeply sequence HBV DNA from patients’ serum. The proportions of primary and secondary genotypes of each patient were then identified. Subsequently, we analyzed the association between HCC and different genotype combinations.

**Results:** Our finding revealed that the HBV C2 subgenotype presented a higher risk of HCC (OR=4.73, 95%CI=2.85 - 7.85), aligning with previous studies (Table 1). To elucidate the impact of diverse HBV genotype combinations on HCC, we performed a detailed grouping analysis of primary and secondary subgenotypes. The results indicated...
that among the groups with mixed C genotype infections, C+B and C+C, were the main combinations predominantly responsible for the elevated risk of HCC (C2+B2: OR=6.6, 95% CI=1.7-26.0, C2+C1: OR=11.9, 95% CI=3.1-45.4, C2+C6: OR=7.0, 95% CI=1.9-26.1, C2+C8: OR=12.4, 95% CI=2.5-62.2, C2+C10: OR=8.4, 95% CI=2.4-29.7) (Table 2).

Conclusion: Our data indicates that groups co-infected with multiple HBV genotypes possess a higher risk of developing HCC compared to those with a singular infection.

Abstract Submission No. 100768

O-0101

Evolution of HBV genomic structures without selective pressure of antiviral treatment

Soichi Arasawa1, Haruhiko Takeda2, Atsushi Takaï2, Hiroshi Seno2

1Infection Control Team, Kyoto University Hospital Kyoto Japan, 2Department of Gastroenterology and Hepatology, Kyoto University Hospital Kyoto Japan

Background: Hepatitis B virus (HBV) causes persistent infection to human bodies and develops genomic structural variants. However, the characteristics of these structural variants, such as localization in HBV genome, length, and long-term survivability during untreated persistent infection are not fully known.

Methods: Twenty-five sera were collected from 10 cases of treatment-naïve chronic HBV infection. HBV-DNA was extracted from these sera and was sequenced using PacBio® third generation sequencer. The sequence errors were corrected using circular consensus sequencing.

Results: The nucleotide sequences of approximately 800-thousand copies of HBV genome were determined. Totally, 431 types of genomic structural variants were detected including 407 deletions, 22 insertions, and 2 duplications. The number of structural variants at the active hepatitis phase negative for anti-HBe were significantly larger than that at the anti-HBe-positive inactive hepatitis phase. Major structural variants with high allele frequencies in each case were in-frame deletions that cause nine to 91 amino acid deletions in PreS or C protein.

Phylogenetic analysis indicated that these major structural variants can survive years and accumulate nucleotide substitutions independently from non-structural-variants during treatment-free persistent infection.

Conclusions: During persistent infection, genomic structural variants of HBV form quasispecies in the host bodies and each variant evolves independently for several years or longer.

Abstract Submission No. 100870

O-0102

Assessing liver cirrhosis progression under the Baveno VII definition using hidden Markov model

Vicki Wing-Ki Hui1, Dongrong Li2, Yee-Kit Tse1, Terry Cheuk-Fung Yip3, Vincent Wai-Sun Wong1, XiaoDan Fan1, Grace Lai-Hung Wong1

1Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), Institute of Digestive Disease Hong Kong Hong Kong, 2Department of Statistics Hong kong Hong Kong

Background: The Baveno VII consensus highlighted post-decompensation hepatic recompensation. However, ambiguities in its definition might lead to data inaccuracies. Our study identified predictors for cirrhosis progression and regression, accounting for misdiagnoses.

Methods: A Bayesian inhomogeneous hidden Markov model was developed among patients with chronic hepatitis B (CHB)-related cirrhosis in Hong Kong to determine transition probabilities among liver cirrhosis states and variables.

Results: We evaluated 5,263 CHB-related cirrhosis patients. Initially, 4,690 (89%) were compensated, and 573 (11%) were decompensated.
Results: At a mean follow-up of 32 ± 47 months, 2,317 (44%) remained compensated, 158 (3%) remained decompensated, 1,341 (25%) experienced non-liver deaths. Older age is associated with a higher likelihood of progressing to decompensated cirrhosis (odds ratio [OR]=2.41). Females are less likely to progress or deteriorate from a compensated state (OR ranges from 0.008 to 0.061). However, they have a higher likelihood of transitioning to decompensated cirrhosis (OR≈8.50). The presence of hepatocellular carcinoma increases the likelihood of transitioning to decompensated cirrhosis and reduces the chances of progressing to recompensated cirrhosis.

Conclusions: Age, gender, and hepatocellular carcinoma were key determinants in disease transitions. Using the model’s outcomes, we can deduce the importance of covariates across multiple transitions and estimate the future disease trajectory for each patient.

Abstract Submission No. 100877
O-0103
Dynamic liver volume changes predict re-compensation of HBV-related decompensated cirrhosis
Qijuan Zang1, Siyi Liu1, Juan Li1, Chengbin Zhu1, Qiao Zhang1, Yushan Liu1, Xiaonian Wu1, Yamin Wang2, Qiannan Wang1, Pan Huang1, Li Zhu3, Yingren Zhao0, Yingli He2
1Department of Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an, Shaanxi, China. Xi’an China, 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 3Shaanxi Clinical Research Center for Infectious Diseases, Xi’an, Shaanxi, China. Xi’an China.

Background: NUCs treatment may change or even reverse the progression of HBV-related decompensated cirrhosis, that is, the realization of re-compensation. The change of liver volume can reflect the function and regeneration ability of liver. Nevertheless, the precise clinical implications of dynamic liver volume changes among patients with re-compensation remain uncertain.

Methods: This retrospective study involved the administration of NUCs treatment for a minimum of 48 weeks and a follow-up period of at least 2 years to all patients diagnosed with HBV-related decompensated cirrhosis. Two abdominal computed tomography (CT) scans were conducted at baseline and during the first two years of follow-up to measure the liver volume (LV1, LV2). The change in liver volume (ΔLV = LV2-LV1) was then calculated. Re-compensation was defined as the disappearance of decomposition complications and stability for a minimum of one year.

Results: A total of 159 patients were included, 38% of the patients achieved re-compensation, and the liver volume of the recompensated patients was significantly larger than that of the decompensated patients (1072.8 cm3 vs 848.11 cm3, P < 0.001). Logistic regression analysis screened the independent predictive factors for predicting re-compensation of HBV-related decompensated cirrhosis as ΔLV, Hb, Na and Female, respectively, and established a prognostic model based on dynamic liver volume. The model demonstrated good performance in predicting re-compensation (C index 0.951, AUC value 0.959).

Conclusion: Effective antiviral therapy can reverse the liver volume of HBV-related decompensated cirrhosis. The model based on dynamic liver volume change is a reliable model for predicting re-compensation.

Abstract Submission No. 101046
O-0104
Investigation on current situation and trend of antiviral treatment for chronic hepatitis B in China
Min-ran Li1, Liu Yang1, Jin-zhong Li2, Calvin Q. Pan3, Er-hei Dai2
1Division of Infectious Disease, the First Affiliated Hospital, Jinan University, Guangzhou, 510632, R.P. China. Guangzhou, China. Guangzhou China, 2Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China. Shijiazhuang, China, 3Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, New York University School of Medicine, New York, NY New York American

Objective: To investigate the current situation and trend of antiviral therapy in patients with chronic hepatitis B (CHB) in China, and to analyze the factors affecting patients’ acceptance of antiviral therapy and the choice of treatment methods.

Method: An electronic questionnaire was used to investigate patients with CHB in 12 hospitals including the First Affiliated Hospital of Jinan University and the Fifth Hospital of Shijiazhuang City in 2023. The contents included demographic characteristics, follow-up compliance, treatment compliance, knowledge of antiviral drugs and other influencing factors were analyzed by binary logistic regression.

Results: A total of 1360 patients with CHB were included in the questionnaire, of which 77.4% received antiviral therapy and 32.6% did not. Regression analysis showed that whether patients received antiviral treatment was related to education level, course of hepatitis B, HBV DNA results, follow-up compliance, treatment compliance, acceptance of antiviral treatment indications, understanding of antiviral drugs and price of long-acting interferon (P < 0.05). There were 399 patients over 30 years old with positive HBV DNA test, of whom only 30.6% received antiviral treatment. Regression analysis showed that whether the patients received antiviral treatment was related to their education level, follow-up compliance, treatment compliance, acceptance of antiviral treatment indications and understanding of nucleoside (acid) analogues (P < 0.05). Among 1052 patients who received antiviral therapy, 88.7% were oral nucleoside (acid) analogues, 11.3% were long-acting interferon monotherapies or combinations. And 913 patients (69.4%) had strong intention to pursue the clinical cure of CHB, but only 13.2% of them chose long-acting interferon. Regression analysis showed that the influencing factors of whether patients chose long-acting interferon were related to the understanding of long-acting interferon for clinical cure of CHB, the fear of HBV DNA results in liver cirrhosis or cancer, the understanding of nucleoside (acid) analogues and the treatment compliance (P < 0.05).

Conclusion: Whether patients with CHB choose antiviral therapy at present is influenced by many factors, such as educational level, compliance, understanding of diseases and drugs, etc. Doctors should strengthen the propaganda of clinical cure of hepatitis B and long-acting interferon treatment to improve the treatment rate and effective rate of CHB, which is beneficial to the early elimination of hepatitis B in China.

Abstract Submission No. 101055
O-0105
Exploratory biomarkers HBcAg and HBV RNA: relationship with bepirovirsen response in B-Clear
Yasuhito Tanaka1, Jerome Bouquer2, Scott D. Speer3, Robert Elston4, Phillip Yates4, Jennifer Cremer5, Geoff Quinn4, Melanie Paff3, Dickens Theodore5

1Department of Gastroenterology, New York University School of Medicine, New York, NY, New York American, 2Division of Liver Disease, The Fifth Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, China, 3Division of Gastroenterology and Hepatology, Department of Medicine, NYU Langone Health, New York University School of Medicine, New York, NY, New York American, 4Department of Medicine, New York University School of Medicine, New York, NY, New York American, 5Division of Infectious Diseases, the First Affiliated Hospital, Jinan University, Guangzhou, 510632, R.P. China, Guangzhou, China.
Background: Bypirovirsen (BPV) is an antisense oligonucleotide targeting HBV RNAs. B-Clear is a Phase 2b study (NCT04449029) assessing the efficacy and safety of BPV in participants (pts) with chronic hepatitis B. This post-hoc analysis looked at the presence and levels of hepatitis B core-related antigen (HBcrAg) and HBV RNA and their relationship with response to treatment.

Methods: B-Clear study pts were either receiving concomitant stable nucleos(t)ide analog therapy (On-NA) or not receiving NA (Not-on-NA). Pts were randomized (3:3:3:1) into 4 treatment arms receiving up to BPV 300mg weekly for up to 24wks with loading doses in Arm 1-3. HBcrAg and HBV RNA were assessed with Lumipulse G HBcrAg (Fujirebio) and custom RT-qPCR, respectively.

Results: HBV RNA was target not detected (TND) at baseline in 41.2% (93/228) Not-on-NA and 75.2% (170/226) On-NA pts. Mean HBcrAg and HBV RNA decreased from baseline to end of treatment (EOT) across both populations and all treatment arms (Table). Mean baseline HBcrAg and HBV RNA were lower in pts with sustained HBsAg loss (<0.05 IU/mL for 24wks post BPV treatment) compared with non-responders, respectively, but were not significant predictors of response.

Conclusions: HBV RNA was more likely to be TND at baseline in On-NA than Not-on-NA pts. Average EOT reductions were larger in Not-on-NA than On-NA pts. HBcrAg and HBV RNA at baseline were lower but not significantly associated with sustained HBsAg seroclearance. HBcrAg and HBV RNA may be worth exploring as early indicators of treatment response, primarily in patients not virally suppressed.

Funding: GSK(209668)
The GAAD score predicts HCC in HBV-related cirrhosis patients after 6-year antiviral therapy

Tung-Hung Su1, Chun-Lin Chiu2, Chia-Chi Wang1, Wan-Long Chang1, Cheng-Yuan Peng3, Wei-Wen Su4, Sheng-Shun Yang5, Chih-Lin Lin6, Kuo-Chih Tseng6, Shih-Jer Hsu7, Fat-Moon Suk8, Tsung-Ming Chen9, Ming-Jong Baur10, Cheng-Kuan Lin10, Jia-Hong Kao10

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Division of Gastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital Taichung, 3Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, 4Department of Internal Medicine, Kaohsiung Medical University Kaohsiung Taiwan, 5Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital Taichung Taiwan, 6Department of Gastroenterology and Hepatology, Changhua Christian Hospital Changhua Taiwan, 7Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital Taichung Taiwan, 8Department of Gastroenterology, Ren-Ai Branch, Taipei City Hospital Taipei Taiwan, 9Department of Hepatology, Buddhist Tzu Chi General Hospital, Da-Lin Branch Chiaiyi Taiwan, 10The C-TEAM study group and the Taiwan Liver Diseases Consortium Taipei Taiwan

Background: In CHB-related cirrhosis patients on long-term antiviral therapy, hepatocellular carcinoma (HCC) risk persists, motivating the need for risk stratification. The GAAD score, encompassing gender, age, alpha-fetoprotein, and des-gamma carboxyprothrombin (DCP) measurements, is designed for early-stage HCC detection. This study investigates the predictive role of the GAAD score in HCC development in CHB-related cirrhosis patients on antiviral therapy.

Methods: We conducted a retrospective cohort study to include HBV-related cirrhosis patients undergoing long-term antiviral therapy with regular HCC surveillance. The on-treatment plasma samples were retrieved for alpha-fetoprotein and DCP measurements by the Roche Elecsys® system to calculate the GAAD score. Cox proportional hazard regression analysis identified risk predictors for HCC.

Results: A total of 499 patients were included and categorized into “prior HCC” (n=47), “HCC” (n=56), and “no HCC” (n=396) groups with a median GAAD score of 1.12, 0.84, and 0.54, respectively (p<0.001). Among the 452 patients without prior HCC, their median age was 60, and they received a median of 6.2 years of antiviral therapy. After a median of 3.3 years of follow-up, 56 patients developed HCC. A GAAD score of 0.71 and 1.64 significantly stratified the risk of HCC (log-rank P<0.001). After adjusting for age, sex, and FIB-4 index, a GAAD score ≥4.64 and GAAD score 0.71-1.64 significantly increased the risks of HCC by 8.68-fold (95% CI: 3.50-21.55) and 2.25-fold (95%CI: 0.96-5.25) respectively, compared with a GAAD score of <0.71.

Conclusions: After 6 years of antiviral therapy, a high GAAD score significantly stratified the risks of HCC development, and high-risk patients should receive intensive HCC surveillance.

Abstract Submission No. 101390
O-0110

High accuracy prediction model for HBsAg loss during long-term antiviral therapy in CHB patients

Rong Fan1, Siru Zhao1, Junqi Niu2, Hong Ma3, Qiong Xie4, Song Yang5, Jianping Xie6, Xiaoguang Dou7, Jia Shang8, Huiying Rao9, Xier Liang10, Jian Sun11, Nikolai Naoumov12, Jinlin Hou13

1Guangdong Provincial Key Laboratory of Viral Hepatitis Research; Guangdong Provincial Clinical Research Center for Viral Hepatitis; Key Laboratory of Infectious Diseases Research in South China, Ministry of Education; Department of Infectious Diseases, Na, 2Hepatology Unit, No. 1 Hospital affiliated to Jilin University Changchun China, 3Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing China, 4Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 5Beijing Ditan Hospital, Capital Medical University Beijing China, 6Department of Infectious Diseases, Xiangya Hospital, Central South University Changsha China, 7Department of Infectious Diseases, Shengjing Hospital of China Medical University Shenyang China, 8Henan Provincial People's Hospital Zhengzhou China, 9Peking University Hepatology Institute, Peking University People's Hospital Beijing China, 10NA London United Kingdom

Abstract

Background: Hepatitis B surface antigen (HBsAg) loss is the optimal outcome for patients with chronic hepatitis B (CHB) but rarely occurs...
with currently approved therapies. We aimed to develop and validate a prognostic model for HBsAg loss on treatment using longitudinal data from a large, prospectively followed, nationwide cohort.

**Methods:** CHB patients on treatment were enrolled from 50 centers in China. Quantitative HBsAg (qHBsAg) were prospectively evaluated biannually per protocol. Longitudinal Discriminant Analysis algorithm was used to estimate the incidence of HBsAg loss.

**Results:** In total, 9437 CHB patients who had initiated antiviral treatment 55·2 (IQR:12·1-100) months prior to enrollment and had qHBsAg 2·8 (IQR:2·3-3·5) log10IU/mL at entry were analyzed. With a median follow-up of 65·5 (IQR:50·5-84·7) months, the 5-year cumulative incidence of HBsAg loss was 3·0%. A prediction model integrating all longitudinal information of each patient during follow-up, designated GOLDEN model, was developed and validated. The AUCs of GOLDEN model were 0·978 (95%CI:0·972-0·984) and 0·977 (95%CI:0·973-0·981) in the training and external validation sets, respectively, and were significantly better than those of a single qHBsAg measurement. GOLDEN model identified 10·5-11·8% of patients with a high probability of HBsAg loss (5-year cumulative incidence: 19·3-31·1%), and excluded 88·2-89·5% of patients with zero incidence. Moreover, GOLDEN model consistently performed excellently among various subgroups.

**Conclusions:** This novel GOLDEN model, based on longitudinal information, accurately predicts HBsAg clearance, provides a reliable estimate of functional HBV cure and is valuable to identify favorable patients for benefiting from novel anti-HBV therapies.

---

**Abstract Submission No. 101391**

**Efficacy of combination treatment of TLR7 agonist and anti-PD-L1 in virally suppressed CHB patients**

Qin NING1, Ting Wu1, Di Wu1, Yuyin Chen1, Da Huang1, Zhize Yuan1, Zhongnan Xu2, Shuna Wang2, Dandan Huo2, Weiming Yan1, Meifang Hau1

1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 2Chia Tai Tianqiang Pharmaceutical Group Co., Ltd Nanjing China

**Background:** TQB2450, a PD-L1 antibody, inhibits PD-1/PD-L1 axis and rouses adaptive immune response to HBV. This study aimed to evaluate the safety and efficacy of nucleos(t)ide analog (NA) and TQA3334 combined with/without TQB2450 in CHB patients (pts).

**Method:** Totally 24 viral-suppressed (250 ≤IU/ml HBsAg ≤ 5000 IU/ml, HBV DNA < 20 IU/ml) CHB pts (HBsAg-positive; HBsAg-negative=1:2) were randomized to receive NA (monotherapy, n=6), NA+TQA3334 (dual therapy, n=9) or NA+TQA3334+ TQB2450 (triple therapy, n=9). TQA3334 (1.2mg or 1.5mg, QW) and TQB2450 (400mg, Q3W) were administrated for 24 weeks, and NA was given throughout this 48-week study. The HBsAg (Roche) reduction was evaluated.

**Results:** One participant received dual therapy withdrew at week 6. Adverse events (AEs) were more common in triple therapy, and the grade 1 thyroiditis was the most common immune-related AEs in pts received TQB2450. All the events were resolved before the end of follow-up (EOF). At the end of treatment (EOT), triple therapy was associated with greater HBsAg reduction compared to monotherapy and dual therapy (0.04 ± 0.08, 0.04 ± 0.16, and 0.37 ± 0.50 log10 IU/ml). In triple therapy group, 1.5mg TQA3334 administration had a greater HBsAg reduction (0.46 vs 0.32 log10 IU/ml) at EOT. HBsAg remained lower than those of EOT in 52.5% and 65.6% of pts received dual therapy and triple therapy respectively at EOF.

**Conclusion:** The combination of NA, TQA3334 and TQB2450 induced greater HBsAg decline in viral-suppressed CHB pts with good safety. Moreover, high dose of TQA3334 promoted HBsAg reduction in triple therapy.

---

**Abstract Submission No. 101450**

**O-0113**

**Risk factors for low level viremia in chronic hepatitis B patients receiving antiviral treatment**

Fehmi Tabak1, Imran Hasanoglu2, Rahmet Guner2, Esra Verikeya Zerdali2, Selma Tosun2, Yusuf Onlen2, Figen Yildirim3, Tuba Turunc3, Ozgur Guna4, Ayse Batirel910

1Istanbul University Cerrahpasa Medical Faculty Istanbul Turkey, 2Ankara City Hospital Ankara Turkey, 3Istanbul Haseki Training and Research Hospital Istanbul Turkey, 4Bozyaka Training and Research Hospital Izmir Turkey, 5Mustafa Kemal University Medical Faculty Hatay Turkey, 6Antalya Training and Research Hospital Antalya Turkey, 7Adana City Hospital Adana Turkey, 8Samsun Training and Research Hospital Samsun Turkey, 910Kartal Dr. Lutfu Kirdal City Hospital Istanbul Turkey

**Background:** Available antiviral agents have demonstrated the ability to suppress HBV DNA replication and reduce the risk of liver-related complications and some patients continue to experience low-level
viremia (LLV) which is defined as HBV DNA <2000 IU/ml. In this study, we aimed to evaluate the incidence and the factors that influence low-level LLV in patients with CHB receiving antiviral treatment.

**Methods:** This multicenter retrospective observational study included CHB patients who had received antiviral treatment and univariate and multivariate logistic regression analyses were conducted to investigate the risk factors for LLV.

**Results:** A total of 2455 patients from 32 centers included in the study. At the end of 1 year, incidence of LLV was 13.6%. To evaluate the risk factors for LLV, patients were divided into two groups as LLV and sustained virological response (SVR). Results of the univariate and multivariate logistic regression analyses are given in Table 1. Multivariate logistic regression analyses showed that patients with HBeAg positive serostatus, cirrhotic status, higher albumin levels and pretreatment HBV DNA levels > 1,000,000 IU/ml has increased risk for LLV. No significant difference was observed between patients receiving entecavir and tenofovir in terms of LLV.

**Conclusion:** Studies have demonstrated that a significant proportion of CHB patients, ranging from 20% to 40 maintain LLV. Results of this study emphasize that patients with HBeAg positive serostatus, cirrhotic status, higher albumin levels or pretreatment HBV DNA > 1,000,000 IU/ml has higher risk for LLV and should carefully monitored.

---

**Abstract Submission No. 101537**

**O-0114**

**Coffee consumption on advanced fibrosis and cirrhosis among hepatitis B patients: Meta-analysis**

Leah Anne E. Legaspi1, Arlinking K. Ong-Go1, Roberto N. De Guzman Jr.1

1Metropolitan Medical Center Manila Philippines

**Background:** Coffee consumption has preventive effect on liver fibrosis and cirrhosis among patients with hepatitis C and NASH. Existing evidence on its effect on hepatitis B are limited and contradicting.

**Methodology:** Literature search was done through PubMed, MEDLINE and google scholar. Four studies with total of 6413 hepatitis B patients were reviewed which correlated coffee consumption on advanced fibrosis and cirrhosis using risk ratio (RR). The cut-off for high coffee consumption was > 2 cups of coffee per day in three studies and consumption of coffee 4 to 7 days per week in one study.

**Results:** The summary estimate for any coffee consumption vs no consumption on cirrhosis was RR 0.96 (95% confidence interval [CI], 0.73-1.27). Summary estimate for advanced fibrosis for any coffee consumption vs no consumption was RR 0.69 (95% CI, 0.45-1.03). Comparison of low coffee consumption vs no consumption on cirrhosis showed RR 1.10 (95% CI, 0.82-1.49) and on advanced fibrosis showed RR 0.90 (95% CI, 0.53-1.54). In terms of high coffee consumption on cirrhosis RR 0.71 (95% CI, 0.48-1.05) while on advanced fibrosis was RR 0.62 (95% CI, 0.39-0.99). Results showed that the presumed effect of coffee consumption on prevention of liver fibrosis and cirrhosis was not observed in this study.

**Conclusion:** Among hepatitis B patients, coffee consumption has no effect on prevention of cirrhosis, whereas there is a trend towards advanced fibrosis among coffee drinkers. Limitations of this meta-analysis include varied cutoff values of outcome measurement, treatment status of HBV and level of ALT.

---

**Abstract Submission No. 101546**

**O-0115**

**Lower HBeAg level associates with higher spontaneous HBeAg seroclearance rate in CHB patient**

Hung-Yao Lin1, Chun-Jen Liu1,2,5, Tung-Hung Su1,2, Wan-Ting Yang2, Chun-Ming Hong3, Hung-Chih Yang1,5,6, Chen-Hua Liu6, Pei-Jer Chen1,5,6, Tai-Chung Tseng2,1, Horng Kao1

1Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan, 3Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan, 4Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 5Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei Taiwan, 6Department of Microbiology, National Taiwan University College of Medicine Taipei Taiwan

**Background and aims:** Hepatitis B e antigen (HBeAg) seroclearance is crucial in the management of chronic hepatitis B (CHB). This study aimed to elucidate the role of hepatitis B core-related antigen (HBcrAg) level, a biomarker for cccDNA, in predicting spontaneous HBeAg seroclearance in treatment-naive HBeAg-positive CHB patients.

**Methods:** This retrospective cohort study involved 484 treatment-naive HBeAg-positive CHB patients with extended follow-up at the National Taiwan University Hospital. The study explored the association of baseline and kinetics of HBcrAg levels with spontaneous HBeAg seroclearance rate over time.

**Results:** Of 484 patients, 331 experienced spontaneous HBeAg seroclearance during 3376.73 person-years of follow-up, with a mean seroclearance rate of 8.76% per year. Lower baseline HBcrAg level (log rank P < .001) was associated with a higher chance of HBeAg seroclearance by univariate analysis. By multivariate analysis, persistently low (HR: 2.43; 95% CI: 1.53-3.85) and decreasing to below (HR: 2.53; 95% CI: 1.97-4.65) 10^5 KU/mL at year 3 of follow-up were independent factors associated with spontaneous HBeAg seroclearance. In a subgroup analysis of 208 immune-tolerant patients, lower baseline HBcrAg level and a decline of HBcrAg were independently associated with higher rates of spontaneous HBeAg seroclearance.

**Conclusions:** HBcrAg-positive CHB patients maintaining HBcrAg levels below 10^5 KU/mL or achieving a decrease to below this threshold during follow-up are associated with a higher likelihood of clearing HBeAg spontaneously. These findings highlight the potential utility of HBcrAg as a prognostic marker in predicting the clinical course and directing management decision in HBeAg-positive CHB patients.

---

**Abstract Submission No. 101591**

**O-0116**

**Efficacy and safety of tenofovir alafenamide fumarate in chronic hepatitis B patients in real world**

Yuxuan Song1, Hui Ma1, Bo Feng1, Yandi Xie1

1Peking University People’s Hospital Beijing China

**Background:** Tenofovir alafenamide fumarate (TAF) has been treated in chronic hepatitis B (CHB) patients since 2018 in China. We aimed to assess the long-term efficacy and safety of TAF in a real-world setting.

**Methods:** Treatment-naive and treatment-experienced CHB patients who received TAF were included. Serum levels of hepatitis B virus (HBV) DNA, hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) were analyzed at baseline, 24, 48, 72, 96, 120, 144, 168 and 192 weeks by immunoassays. Serum levels of alanine...
aminotransferase (ALT), triglyceride (TG), total cholesterol (TC) and low-density lipoprotein-cholesterol (LDL-C) were measured by biochemistry assay. Kidney function was measured by estimated glomerular filtration rate (eGFR) as per Cockcroft-Gault. Controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were analyzed by transient elastography.

**Results:** In total of 144 CHB Patients were followed up for 204 weeks. Fifty (34.72%) patients were treatment-naive (38% patients were HBeAg positive) and 94 (65.28%) patients switched from other NAs (47.87% patients were HBeAg positive). Among treatment-naive patients, the ALT normalization rate was 96% (48/50), the complete virological response (HBV DNA <20 IU/ml) rate was 76% (38/50) and the HBeAg seroconversion rate was 5.26% (1/19) at 48 weeks. The levels of HBV DNA and HBsAg were significantly decreased from the 5.27±1.29 log_{10} IU/ml at baseline to 1.32±0.27 log_{10} IU/ml and from 3.63±0.72 log_{10} IU/ml to 3.44±0.73 log_{10} IU/ml, respectively. LSM was significantly decreased from 13.1±8.01 kPa at baseline to 8.32±4.93 kPa at 48 weeks of treatment. No significant differences were observed in the levels of TG, TC, LDL-C, CAP and eGFR. Among treatment-experienced patients, decline of HBV DNA and HBsAg levels were also found. Most of patients had renal deterioration during TDF (76%) who were with eGFR <60 mL/min reversed to eGFR increase after 48 weeks of TAF treatment (P = 0.017). In patients with eGFR between 60 and 89 mL/min, the estimated eGFR decrease during TDF was halted after switching to TAF (P = 0.06).

**Conclusions:** TAF was effective and well-tolerated in present CHB cohort in real-world setting. Switching to TAF is conducive to the decline in HBV DNA and the improvement of kidney function.

Abstract Submission No. 101657
O-0117
A Model to Identify the Starting of Antiviral Therapy in Gray Zone Patients with Chronic Hepatitis B

Yu-Chen Fan1, Xue-Yan Yang1, Jing Zuo1, Xi-Dong Li2, Qiao Yang2, Yu-Bao Zheng3, Ming-Hua Zheng5, Yin-Ping Wu1, Ruo-Xi Ma3, Yu-Chen Fan1, Xue-Yan Yang1, Jing Zuo1, Xi-Dong Li2, Qiao Yang2, Yu-Bao Zheng3, Ming-Hua Zheng5, Yin-Ping Wu1, Ruo-Xi Ma3

1Department of Hepatology, Qilu Hospital of Shandong University Jinan China, 2Department of Infectious Diseases, Linyi People’s Hospital Linyi China, 3Department of Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China, 4Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 5MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 6Department of Infectious Diseases, The affiliated Hospital of Qingdao University Qingdao China, 7State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College, 8Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

**Introduction:** Individuals who do not fit to any stage of natural history of chronic hepatitis B (CHB) are classified as gray zone; however, the management of these patients remains unclear. Here, we developed and validated a nomogram to predict the starting of antiviral therapy in gray zone patients.

**Methods:** We retrospectively collected 200 gray zone patients as no activity requiring antiviral treatment. Asymptomatic and incidentally detected chronic hepatitis B virus infected patients. The nomogram was tested by the area under receiver operating characteristic curve (AUROC), calibration plot and decision curve analysis.

**Results:** A total of 200 UAT patients were retracted and 78 patients(n=39%) were identified to start antiviral therapy. Age (OR 1.05, 95%CI 1.01-1.10), alanine aminotransferase (OR 2.53, 95%CI 1.14-5.62), lymphocyte percentage (OR 6.57, 95%CI 1.23-34.58), platelet count (OR 0.99, 95%CI 0.99-1.00), and international normalized ratio per (0.01) (OR 1.06, 95%CI 1.00-1.12) were identified to generate the nomogram, which showed the good discrimination (Development set: AUROC=0.755; Validation set: AUROC=0.707), calibration and clinical applicability. Patients with score >197 had high probability and those with score <0.132 had low probability for starting antiviral therapy.

**Discussion:** Antiviral therapy should be considered in gray zone patients and the non-invasive nomogram is promising for rapid screening patients who need antiviral therapy.

Abstract Submission No. 101716
O-0118
Biochemical and Serological Characterization of Chronic Hepatitis B Infection in Sylhet

MD Jahangir Alam1, Dr. Madhusudan Saha2, Dr. Masuma Mahatab3, Dr. M. K. Sur Chowdhury4

1Professor Sylhet Bangladesh, 2Professor, Department of Gastroenterology Sylhet, Sylhet MAG Osmani Medical College Bangladesh, 3Assistant Professor, Department of Radiology and Imaging Sheikh Hasina Medical College, Habibgonj, Sylhet Bangladesh, 4Associate Professor Sylhet, Sylhet MAG Osmani Medical College Bangladesh

**Introduction:** The World Health Organization (WHO) recognized hepatitis B virus globally as one of the commonest health problems [1]. Inactive or active chronic infection of hepatitis B virus can exaggerate the possibilities of hepatic insufficiency, end-stage liver disease including liver cirrhosis (LC) and hepatocellular carcinoma (HCC) [2].

**Objective:** This retrospective study was done to see biochemical and serological activity of hepatitis B virus in incidentally detected hepatitis B virus infected patients.

**Methods:** Available demographic and laboratory data of incidentally detected patients of chronic hepatitis B virus infection were retrieved from record and analysis using SPSS version 20. Mean and SD for continuous data and percentage of categorical data were calculated.

**Result:** Total 276 patients, age ranging from 13 to 60 years (mean 29.38), male 225 (81.5%) were enrolled. Of them 147 (53.3%) were in 26 - 40 years age group. In this series, 157 (56.9%) and 54 (19.6%) had history of saloon shave and family history of liver disease respectively. Alamine aminotransferase (ALT) of them varied from 15 to 367 IU/dl (mean 51.54). Of them 37 (13.4%) had HBeAg positive and 17 (6.2%) had fatty liver in ultrasound. HBV DNA was seen in 115 patients with 32 (27.8%) had DNA load above 100,000 copies per ml.

**Conclusion:** Asymptomatic and incidentally detected chronic hepatitis patients may have significant biochemical and serological viral activity requiring antiviral treatment.

Abstract Submission No. 101767
O-0119
Effectiveness of HBV Vaccination in Hemodialysis Patients negative for Anti-HBs
**Background:** Despite the national HBV vaccination program, hepatitis B (HBV) infection remains a significant health concern in Taiwan, especially in hemodialysis patients because of potential viral exposure. This study aimed to assess the effectiveness of HBV vaccination in hemodialysis patients negative for anti-HBs.

**Methods:** Hemodialysis patients without protective anti-HBs were prospectively enrolled from the National Taiwan University Hospital and local clinics, categorized as “HBV-naive” or “resolved-HBV” ([HBsAg negative, anti-HBc positive]). Engerix-B 40 mg was administered at 0, 1, 2, and 6 months. Serum anti-HBs level was evaluated at the first, 6th, and 12th month post full vaccination, and participants were categorizing as responders or non-responders (anti-HBs < 10 mIU/mL). Selected patients with a pre-study vaccine history received a booster vaccine.

**Results:** Between March 2019 and September 2023, 106 patients, with 100 completing the 4-dose vaccination, were enrolled. Among them, 65 were HBV-naive, and 35 had resolved-HBV. HBV-naive patients achieved anti-HBs > 10 mIU/mL at 58% (N=24/41), 70.4% (N=31/44), 76.3% (N=29/38), and 75% (N=27/36) at 1, 6, 12, and more than 12 months post-vaccination, respectively. Resolved HBV patients exhibited vaccine responses of 67.7% (N=21/31), 66.7% (N=10/15), 80% (N=4/5), and 33.3% (N=2/6), respectively. For 6 patients (5 HBV-naive, 1 resolved HBV) receiving a booster vaccination, the anti-HBs positive rate was 100% at the 12th month.

**Conclusion:** Hemodialysis patients lacking anti-HBs achieved 70% response rate to HBV vaccination in HBV-naive and resolved HBV groups. HBV vaccination for hemodialysis patients without protective anti-HBs is thus feasible and should be routinely implemented.

Abstract Submission No. 101807

**O-0120**

**ALG-000184 ± ENTECAVIR RESULTS IN SUBSTANTIAL HBV ANTIGEN DECLINES IN UNTREATED HBEAG+ HEPATITIS B**

Man-Fung Yuen1, Min Wu2, Edward Gane3, Kosh Agarwal4, Alina Jucov5, Junqi Niu6, Yanhua Ding3, Xie’Er Liang7, Kha Le8, Maida Maderazo9, Lawrence M. Blatt8, Sushimita Chandra9, Tse-I Lin9, Matthew McClure9, Jia-Ling Kao10

1Department of Medicine, School of Clinical Medicine, The University of Hong Kong Hong Kong China, 2Faculty of Medicine, University of Auckland Auckland New Zealand, 3King’s College Hospital, Institute of Liver Studies London United Kingdom, 4Arensia Exploratory Medicine SRL Chisinau Moldova, 5The First Hospital of Jinlin University Changchun China, 6Aligos Therapeutics, Inc. South San Francisco United States, 7Nanfang Hospital, Southern Medical University Guangzhou China

ALG-000184 is a prodrug of the potent (EC50=0.63 nM) capsid assembly modulator, ALG-001075.

Part 4 Cohorts 2 and B in Study ALG-000184-201 are evaluating oral daily 300 mg ALG-000184 doses ± entecavir (ETV) in a randomized, double blind, placebo-controlled (Cohort 2) or open label (Cohort B) manner, respectively, for 96 weeks. All Cohort 2 subjects receiving ETV monotherapy receive ALG-000184 + ETV beginning at Week 12. Here we report emerging data from untreated HBeAg+ CHB subjects who have received ALG-000184 + ETV x \( \leq 52 \) weeks.

22 subjects were enrolled in these 2 cohorts. At Week 52, ALG-000184 + ETV resulted in mean DNA and RNA reductions of 6.6 \( \log_{10} \) IU/mL and 4.4 \( \log_{10} \) copies/mL, respectively. The proportion of subjects achieving \( \geq 0.5 \) and \( \geq 1.0 \) \( \log_{10} \) declines at Week 52 were 100% and 59% for HBcrAg, 86% and 72% for HBeAg, 68% and 45% for HBsAg, respectively. No serious adverse events (AEs) or treatment emergent AEs (TEAEs) leading to discontinuation have been reported. The most frequent adverse events (AEs) were transaminase elevations (n=6), all of which resolved, returned to baseline or improved in the setting of continued dosing with study drug.

Substantial declines in HBV DNA/RNA and antigens have been observed in untreated HBeAg+ CHB subjects receiving 300 mg ALG-000184 ± ETV x \( \leq 52 \) weeks. These data suggest ALG-000184 may lower ccDNA levels and may play a central role in future regimens designed to achieve higher rates of functional cure.

Abstract Submission No. 101812

**O-0121**

**Major obstacles to “functional cure” with novel anti-viral therapy for CHB - a systemic review**

Jing Chen1, Dong Ji2, Ji-dong Jia3, Xinxin Zhang4, Fu-sheng Wang5, George Lau6

1JCSchool of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong Hong Kong Hong Kong, 2Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 3Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 4Research Laboratory of Clinical Virology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 5Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of PLA General Hospital, National Clinical Research Center for Infectious Diseases Beijing China, 6Humanity and Health Clinical Trial Center, Humanity and Health Medical group Hong Kong SAR China

**Background:** New novel therapies targeting different steps in hepatitis B virus lifecycle are in clinical development for “functional cure”. This systemic review highlights key unresolved challenges to achieve such a cure.

**Methods:** We searched clinicaltrialsgov for interventional HBV trials in phases 1-3 posted January 1, 2018 - December 1, 2023. We further examined published results for novel anti-HBV compounds, focusing on antiviral strategies.

**Results:** The search yielded 238 records with 143 relevant to current review, covering 103 unique compounds across 15 categories. Analysis of 13 compounds with published results indicated that novel anti-HBV compounds were generally safe, but lacked a clear dose-response relationship in efficacy. Eleven out of 13 failed to achieve clinically significant and sustained declines in HBsAg levels. On-tx HBsAg decline from baseline (mean: 3.6 \( \log_{10} \) IU/mL) varied: -2.6 to 0.11 \( \log_{10} \) IU/mL, with maximum decline ranging from -0.33 \( \log_{10} \) IU/mL for CAM, -2.6 for siRNA, -2.0 for ASO to -0.11 for ASPINs. Off-treatment HBsAg decline was generally not sustained. One siRNA compound showed a 1% functional cure rate EOF, while control group
displayed a 2.2% rate. For one ASO (bepirovirsen, the only one entering phase 3), the dose-response relationship was unclear, with response divergence at week 8 among intervention groups, suggesting unknown confounding factors.

**Conclusion:** Few novel drugs led to HBsAg loss at EOT and even fewer achieved sustained off-tx HBsAg loss. The lack of evidence for a dose-response relationship underscores the importance of identifying unknown confounding factors for a “functional” cure in chronic hepatitis B patients.

---

**Abstract Submission No. 101813**

**O-0122**

**ALG-000184 (100 mg) + ETV leads to stronger antiviral effects compared to ETV alone in HBeAg+ CHB**

**Jinlin Hou1, Xie’Er Liang1, Jia Xu2, Edward Gane3, Man-Fung Yuen4, Kosh Agarwal5, Min Wu6, Kha Le6, Maïda Maderazo6, Lawrence M. Blatt4, Sushimita Chanda4, Tse-I Lin6, Matthew McClure6, Yanhua Ding6**

1Nanfang Hospital, Southern Medical University Guangzhou China, 2The First Hospital of Jilin University Changchun China, 3Faculty of Medicine, University of Auckland Auckland New Zealand, 4Department of Medicin, School of Clinical Medicine, The University of Hongkong Hongkong China, 5King’s College Hospital, Institute of Liver Studies London United Kingdom, 6Aligos Therapeutics, Inc. South San Francisco United States

ALG-000184 is a prodrug of the potent (EC50 = 0.63 nM) HBV capsid assembly modulator, ALG-001075.

Part 4 Cohort 1 in Study ALG-000184-201 evaluated the safety and antiviral activity of 100 mg ALG-000184 + Entecavir(ALG-000184/ETV) vs. placebo + ETV for 12 weeks in a randomized, double blinded manner in untreated HBeAg+ CHB subjects. All subjects then received open label 100 mg ALG-000184 + ETV during Weeks 12-24 followed by an 8-week follow-up period, during which ETV monotherapy was administered. Eleven subjects randomized into the ALG-000184/ETV (N=8) and ETV (N=3) arms; baseline characteristics were similar. At Week 12, HBV DNA and RNA change from baseline (CBF) in ALG-000184/ETV and ETV arms were -5.3 vs. -4.0 log10 IU/mL and -2.8 vs. -3.0 log10 copies/mL, respectively. After adding ALG-000184, ETV subjects demonstrated similar CBF at Week 24 as ALG-000184/ETV subjects, -6.4 vs -6.9 log10 IU/mL (HBV DNA) and -3.9 vs -4.1 log10 copies/mL (HBV RNA), respectively. After switching to ETV monotherapy, antiviral effects diminished; the Week 8 follow up visit CBF was -5.2 log10 IU/mL for HBV DNA and HBV RNA returned to baseline. Three ALG-000184/ETV subjects exhibited a ≥0.4 log10 IU/mL (maximum reduction = 0.74 log10 IU/mL) HBsAg decline; HBsAg returned to near baseline levels after stopping ALG-000184. No serious adverse events (AEs) or discontinuations due to AEs were reported. All AEs were grade 1-2. Dosing of untreated HBeAg+ CHB subjects with 100 mg ALG-000184 + ETV x ≤ 24 weeks was well tolerated and had greater antiviral effects compared with ETV alone.

**Abstract Submission No. 101836**

**O-0124**

**Mutational Effects on HBsAg in Occult Hepatitis B among Pregnant Women: In-silico Study, Indonesia**

**Muh Rasyak1,2,8, Maisuri T Chalid1, Rizalinda Sjahril1, Ridha Wahyun1, Dhiya P Wibowo4, Turyadi Turyadi1,2, Korri E. El-Khobar5, Yulius Setiady2, David Handojo Muljono6**

1Eijkman Research Centre for Molecular Biology, National Research and Innovation Agency, Bogor, West Java, Indonesia, 2Bogor Indonesia, 3Post Graduate School, Faculty of Medicine, Universitas Hasanuddin Makassar Indonesia, 4Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Hasanuddin Makassar Indonesia, 5Department of Microbiology, Faculty of Medicine, Universitas Hasanuddin Makassar Indonesia, 6Faculty of Medicine and Health, University of Sydney New South Wales Australia, 7Department of Internal Medicine, Faculty of Medicine, Universitas Hasanuddin Makassar Indonesia, 8PT Kalbe Genexine Biologics Jakarta Indonesia, 9Eijkman Institute for Molecular Biology Jakarta Indonesia

Hepatitis B surface antigen (HBsAg) is used to detect hepatitis B virus (HBV) infection in most screening programs. This testing strategy may overlook occult hepatitis B infection (OBI), which is a growing concern because of its transmissibility, clinical impact, and wide global
distribution. HBV gene variants linked to OBI have been identified; however, expense and time preclude in vitro functional definition. Seven pregnant women with OBI and four with overt HBV were investigated. Among the OBI cases, three mutations (K122I, T126N, and V177M) were discovered in the HBsAg "a" determinant region. Phylogenetic analysis showed that V177M, T126N, and K122I were HBV genotypes C and B, respectively. Serotyping showed ade for V177M, ayr for T126N, and unknown for K122I. Protein models were constructed using AlphaFold2, verified with Ramachandran plots, and refined with Galaxyme. Based on detected mutations, mutagenesis created models with above 95% validity for each mutant. Molecular dynamics simulation of the model proteins identified four pathways that caused HBsAg detection failure: altered protein compactness, altered residue interactions, impaired HBsAg double loop formation, and altered protein-solvent interactions. This study represents the few to employ in silico modelling and molecular dynamics to assess OBI-associated mutations, providing valuable insights for future research.

Abstract Submission No. 101871
O-0125
HBV recurrence after liver transplantation associated with non-compliance to “Up to seven” criteria
George Lau1, Dali Zhang2, Xi He2, Jing Chen3, Yudong Wang1, Gregory Cheng1, Hui Ren2, Zhenwen Liu1
1Humanity and Health Medical Group Hong Kong Hong Kong, 2Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 3JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong Hong Kong SAR China
Aim: To investigate risk factors for hepatitis B virus (HBV) recurrence after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC).
Methods: This retrospective study analyzed patients with HCC secondary to HBV infection and had LT from February 15th, 2015 to February 18th, 2019 at a referral hospital. Patients were classified into those with HBV recurrence and those without. HBV recurrence was defined as HBV DNA or HBsAg positive. Univariate and multivariate analysis were used to explore the risk factors for HBV recurrence.
Results: A total of 112 eligible patients from February 15th, 2015, to February 18th, 2019, were included. Those with HBV recurrence after LT had higher prevalence of preoperative detectable HBV DNA (P = 0.001), microvascular thrombosis (P = 0.020), beyond “Up to seven” criteria (P < 0.001), longer maximum tumor diameter (6.3 cm vs. 2.0 cm, P = 0.001), a greater number of tumors (2.5 vs. 1.1, P = 0.017), and a more advanced TNM stage (III+IV: 58.3% vs. 16.5%, P = 0.001). Twelve (10.71%) patients experienced HBV recurrence after LT. The median recurrence time was 15.0 (6.5, 21.1) months after LT. All HBV recurrence were accompanied with HCC recurrence. Multivariate analysis highlighted that beyond “Up to seven” criteria (OR: 7.99, 95%CI: 1.19-53.49, P = 0.032), cholangiocellular carcinoma (OR: 116.7, 95%CI: 6.06-2250.5, P = 0.002) were independent risk factors for HBV recurrence.
Conclusions: HBV recurrence was associated with HCC recurrence. Preoperative HCC patients with beyond “Up to seven” criteria had higher risk for HBV recurrence after LT.

Abstract Submission No. 101885
O-0127
Efficacy and safety of xalnesiran with and without an immunomodulator in chronic hepatitis B
Katerina Glavini1, Jinlin Hou2, Qing Xie1, Wenhong Zhang1, Junqi Niu1, Hong Tang2, Xier Liang2, Apinya Leerapun3, Cong Cheng2, Sudip Das7, Remi Kazma1, Ethan Chen8, Bernadette Surubjally4, Ruchi Upmanyu5, Edward Gane10
1Roche Innovation Centre Basel Basel Switzerland, 2Nanfang Hospital Southern Medical University Guangzhou China, 3Ruijin Hospital Shanghai Jiaotong University School Of Medicine Shanghai China, 4Huashan Hospital, Fudan University Shanghai China, 5The First Hospital of Jilin University Jilin China, 6West China Hospital, Sichuan University Chengdu China, 7Maharaj Nakorn Chiang Mai Hospital Chiang Mai Thailand, 8China Innovation Center of Roche
Clinical outcomes of HBsAg-negative CHB patients in indeterminate phase with normal ALT

Shaoqiu Zhang¹, Jian Wang¹,², Zhiyi Zhang³, Li Zhu¹, Fei Cao³, Yifan Pan², Yuanyuan Li², Yuxin Chen⁴, Xiongxiang Liu², Jie Li², Chuangwu Zhu², Rui Huang³, Chao Wu⁶

¹Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China, ²Institute of Viruses and Infectious Diseases, Nanjing University Nanjing China, ³Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, ⁴Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University Suzhou China, ⁵Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, ⁶Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University Nanjing China, ⁷Department of Hepatology, Huai’an No. 4 People’s Hospital Huai’an China

Background: A substantial proportion of patients with chronic hepatitis B (CHB) may fall into indeterminate phase. This study investigated the phase transition and disease progression of hepatitis B e antigen (HBeAg) negative CHB patients in indeterminate phase with normal alanine aminotransferase (ALT).

Methods: Four hundred and fourteen consecutive HBeAg-negative indeterminate phase CHB patients with normal ALT were retrospectively enrolled from three medical institutions. Significant liver fibrosis and cirrhosis were assessed by noninvasive indexes. The median age was 38.5 years and 54.3% were male. The proportion of patients transitioned to immune active phase, inactive phase and remained in indeterminate phase were 21.3%, 26.3%, and 52.4% after a median follow-up of 21.0 months, respectively. HBV DNA ≥20,000 IU/ml (HR 2.074, P=0.001) and HBsAg ≥1,000 IU/ml (HR 1.626, P=0.031) were significant predictors of transition to active phase. Eleven (25.0%) and 5 (11.4%) patients who transitioned to active phase progressed to significant liver fibrosis and cirrhosis respectively, while only one patient (0.8%) who remained in indeterminate phase developed significant liver fibrosis. Patients who transitioned to active phase (HR 32.093, P=0.001) had a higher risk of significant fibrosis development than those remained indeterminate.

Conclusions: About one fifth of HBeAg-negative indeterminate phase patients with normal ALT transitioned to active phase, and half of these patients remained in indeterminate phase. The levels of HBV DNA and HBsAg were significant predictors of phase transition. Transitioning to active phase had a higher risk of liver fibrosis and cirrhosis development in these patients.

Clinical outcomes of HBeAg-negative CHB patients with less than 100 IU/ml

Jian Wang¹,², Li Zhu³, Shaoqiu Zhang¹, Zhiyi Zhang¹, Tao Fan¹, Ye Xiong¹, Chao Jiang², Juan Xia¹, Xiaomin Yan¹, Xingxiang Liu², Chuangwu Zhu², Jie Li², Chao Wu³, Rui Huang³,⁴,⁵

¹Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, ²Institute of Viruses and Infectious Diseases, Nanjing University Nanjing China, ³Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University Suzhou China, ⁴Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, ⁵Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University Nanjing China, ⁶Department of Hepatology, Huai’an No. 4 People’s Hospital Huai’an China

Background: HBsAg level <100 IU/ml and undetectable HBV DNA has been proposed as an alternate endpoint of “partial cure” in chronic HBV infection. We investigated outcomes of HBeAg-negative chronic HBV-infected patients with HBsAg <100 IU/ml and undetectable HBV DNA.

Methods: Consecutive untreated HBeAg-negative patients with chronic HBV infection with normal ALT and undetectable HBV DNA were enrolled from three medical institutions. Patients were divided into low HBsAg group (<100 IU/ml, “partial cure”, n=501) and high HBsAg group (≥100 IU/ml, n=717). Liver fibrosis was assessed by noninvasive tests (NITs) including APRI, FIB-4 or transient elastography.

Results: Of 1218 patients, the median age was 41.5 years and 51.3% were male. Patients with low HBsAg were older (45.0 vs. 40.0 years, P<0.001) than those in high HBsAg group, while NITs parameters including APRI, FIB-4 or transient elastography were comparable between groups. A total of 309 patients without significant fibrosis at baseline had available follow-up data. During a median follow-up 25.7 months, patients with low HBsAg were more likely to achieve HBsAg clearance (13.0% vs. 0%, P<0.001), while had a lower risk of significant liver fibrosis development (2.2% vs. 7.0%, P=0.020), compared to high HBsAg group. No patients developed HCC in both groups. Serum HBsAg <100 IU/ml was associated with higher chance of HBsAg clearance (HR 76.034, P=0.026) and low risk of significant fibrosis development (HR 0.045, P<0.002).

Conclusions: Patients with “partial cure” had favorable outcomes with a high rate of HBsAg clearance and low risk of fibrosis progression.
Multi-method analysis identifies genotypes in all evaluated participants on-NA, B-Together study

Jeong Heo1, 2, Maria Buti3, Leigh Felton4, Jerome Bouquet4, Maximillian Lee5, Thomas Greene6, Divya Lakshminarayanan6, Scott D. Speer6, Helene Plein4, Dickens Theodore6, Melanie Paff6, Susan Dixon4
1Department of Internal Medicine, College of Medicine, Pusan National University Busan Republic of Korea, 2Biomedical Research Institute, Pusan National University Hospital Busan Republic of Korea, 3Liver Unit, Hospital Vall d’Hebron and CIBER-EHD del Instituto Carlos III Barcelona Spain, 4GSK London UK, 5GSK South San Francisco USA, 6GSK Collegeville USA, 7GSK Durham USA

Background: In B-Together, 9-15% of participants with chronic hepatitis B virus (HBV) infection on background nucleos(t)ide analogs (NAs) receiving sequential bepirovirsen and pegylated interferon-α-2a (bepirovirsen+ Peg-IFN) therapy achieved the primary outcome of hepatitis B surface antigen (HBsAg) and HBV DNA ≤lower limit of quantification maintained for 24 weeks off-treatment. This post hoc analysis investigated HBV genotype (GT) using a three-tiered genotyping methodology.

Methods: HBV GTs in virally suppressed participants were determined using medical history, HBV sequencing, and a serology method (IMMUNIS® HBV Genotype EIA by Institute of Immunology Co.).

Results: The three methodologies had a high degree of concordance (75-100%) and determined GT for 101/108 (94%) participants. By contrast, medical history and HBV DNA/RNA sequencing alone were only successful in identifying GT in 50% of participants. GT-C and GT-D were the most common; GT-B the least (Table). GT-B (n=3/4) and GT-C (n=30/37) were predominantly identified in Asia; GT-A (n=14/16) and GT-D (n=30/34) in Europe. Virological response to bepirovirsen was observed across all common HBV GTs. Baseline HBsAg varied markedly by GT. Analysis of the relationship between HBV GT and treatment response is currently ongoing across studies exploring the efficacy of bepirovirsen-containing regimens.

Conclusions: This innovative three-tiered approach identified HBV GTs in all tested participants on NAs. GT analysis of participants in trials for novel HBV therapies is an important tool to understanding disease heterogeneity in chronic HBV infection.

Funding: GSK (209348)

Abstract Submission No. 101967

O-0132

ScRNAseq reveals high expression of CXCL8 resident immune cells with fibrosis in low HBsAg patients

Ravinder Singh1, Gayatri Ramakrishna1, Archana Rastogi2, Pramod Gautam2, Manor Kumar Sharma3, Shiv Kumar Sarin4, Nirupma Trehanpati5
1Institute of Liver and Biliary Sciences, New Delhi Delhi India

Background and Aims: Chemokine ligand 8 (CXCL8) is suggested as a potential biomarker in assessing the progression and severity of nCHBV patients. Analysis of CXCL8 expression in naïve CHBV patient’s liver and blood may provide insights of immune activation and inflammation.

Methods: We have included liver biopsies and plasma specimens from 36 naïve nCHBV patients, stratified into two groups based on HBsAg levels: Group I (HBsAg<9), n=9 with HBsAg <2000 IU/mL and Group II (HBsAg≥9, n=27) with HBsAg >2000 IU/mL, with HBV DNA < and >2,000 IU/mL, with increased ALT/AST >1.2 x ULN. Comprehensive histopathological analysis, quantification of plasma cytokine levels using cytokine bead array in all patients and single-cell RNA sequencing of liver biopsies in three patients in each group was performed.

Results: Patients with low HBsAg levels showed advanced mean fibrosis scores of 2.62±1.76, while high HBsAg patients had mean fibrosis scores of 0.68±0.87. Lower HBsAg levels correlated with increased IL-8 (p=0.027) compared to higher HBsAg levels in plasma. Single-cell RNA sequencing of liver biopsies from low HBsAg patients compared with high HBsAg patients revealed elevated CXCL8 expression (p=0.0007) associated with intrahepatic CD4 effector memory (p=0.038) and CD8 naïve (p=0.017) cells, contrasting with high HBsAg levels. Individuals with low HBsAg exhibited a correlation between high expression of CXCL8, IL-8, and a higher fibrosis score (p=0.008).

Abstract Submission No. 101967

O-0073
Conclusions: Intrahepatic CXCL8 from CD4 effector memory and CD8 naïve cells contribute to increased IL-8 secretion, contributing to advanced fibrosis in nCHB patients with low HBsAg.

Abstract Submission No. 102017
O-0133

Virological and histological characteristics of chronic hepatitis B virus patients with normal ALT.

Abul Hayat Manik1, Momen Khan2, Faroque Ahmed2
1Hepatology Department, Dhaka Medical College Hospital Dhaka Bangladesh, 2Dhaka Medical College Hospital Dhaka Bangladesh

Background and aims: Patients with chronic hepatitis B virus (HBV) infection and persistently normal ALT levels have whether abnormal liver histology or not is crucial for treatment. At present worldwide available most of the guideline recommends treatment depending on serum ALT level, which may miss significant number of liver disease. We studied the ALT, HBV DNA levels, and spectrum of histologic lesions in such patients.

Methods: It was a cross sectional observational study among the chronic hepatitis B virus infected patients presented in the DMCH who shows persistently normal ALT and detected HBV DNA load. Total 104 patients were enrolled in the study and undergone liver biopsy (n=104; hepatitis B e antigen [HBeAg+], 82; hepatitis B e antigen [HBeAg−]) 22).

Results: Among 82 HBeAg negative cases, there were 12(14%) moderate chronic hepatitis and 26(31%) showed mild chronic hepatitis. HBeAg positive cases also 8(27%) had moderate chronic hepatitis and 8(36%) had mild chronic hepatitis. 62% of HBeAg-positive and HBeAg-negative patients persistent normal ALT had baseline HBV DNA levels of >3.3 log copies/mL. Serum HBV DNA level and spectrum of histological changes doesn’t correlate. 60 (73.1%) HBeAg negative and 14 (63.6%) HBeAg positive patients had Knodell score >7.

Conclusion: A fair proportion of patients with chronic HBV infection with persistent normal ALT have HBV DNA >3.4 log copies/ml and significant histologic fibrosis in both HBeAg positive and HBeAg negative groups. Use of ALT and HBV DNA levels without liver biopsy may miss histologically significant disease in a proportion of patients.

Abstract Submission No. 102039
O-0134

Investigation of HBV cccDNA-bound proteins in liver biopsies from HBV for Therapeutic targeting

Purnima Tyagi1, Jitendra Singh1
1Institute of Liver and Biliary Sciences New Delhi India

Aims: Present study aims to examine the potential roles of cccDNA-bound proteins in HBV reactivation, silencing and contribution to viral replication in the progression of the infection. Identification of cccDNA-bound proteins in both HBeAg-positive(high replicating group) and HBeAg-negative patients (Low replicating group) may aid in better management of HBV patients.

Methods: We obtained 14 liver biopsies from patients with chronic hepatitis B. We divided into two groups: HBeAg negative (n=7) and HBeAg positive (n=7). We also measured blood HBsAg levels (log10 IU/ml 3.21±1.09 >6 months) and HBV DNA levels (log10 IU/ml 4±1.09). The single-stranded portion of HBV cccDNA was used as a template to synthesise biotinylated DNA oligos. Nano liquid chromatography combined with mass spectrometry (nano LC/MS) was used after the pull down was used to extract cccDNA and binding proteins from the nuclear extract of liver tissues of HBeAg+ and HBeAg-patients.

Results: Out of the 300 bound proteins in the HBeAg+, a total of 900 were down-regulated (<0.5-fold) and 300 were considerably elevated (>2-fold). In HBeAg+ several proteins were found to be increased (>2-fold), whereas others were downregulated (<0.5-fold): cul4B, RACK1, DNA damaging binding protein 2, and repressor bound proteins DDX17, Ddx5, METTL4, and PRDX1. Using siRNA in vitro (HepG2.2.15), we were able to identify the top three proteins DDB2, RACK1, and Cul4B expressed in HBeAg positive group. These proteins were shown to be directly associated to the expression of HBV parameters such as HBsAg (p<0.001), HBcAg (p<0.001), pgRNA (p<0.005), HBV DNA (p<0.005), and cccDNA (p<0.005).

Conclusion: A correlation between viral load and cccDNA-bound proteins. The high viral replicating group validated the identification of DDB2, Cul4B, and RACK1 as new nuclear cccDNA-bound proteins for better management of HBV patients.

Abstract Submission No. 200111
O-0135

Functional HBsAb responses induced by BRII-179 are strongly associated with improved HBsAb loss

Zhihong Gao1, Libo Yuan2, Jianping Li3, Rong Hu4, Peng Hu5, Wei Yue6, Fangfang Lv7, Yiwen Liu8, Chunming Li8, Yue Wu8, Weihong Liu8, Xiaofei Chen9, Qing Zhu4
1The Third Affiliated Hospital Sun YAT SEN University Guangzhou China, 2West China Hospital of Sichuan University Chendu China, 3Guangzhou Eighth People’s Hospital Guangzhou China, 4Public Health Clinical Center of Chengdu Chengdu China, 5The Second Affiliated Hospital of Chongqing Medical University Chongqing China, 6The First People’s Hospital of Yunnan Province Kunming China, 7Sir Run Run Shaw Hospital Hangzhou China, 8Brii Biosciences Limited Beijing China

Background: BRII-179, a therapeutic vaccine comprised of PreS1, PreS2 and S HbsAg, showed no new safety observation and improved HBsAg loss at end-of-treatment (PPS: 32.6% vs. 21.6%) and 12-week post EOT in a randomized, double-blind, placebo-controlled phase 2 study as an add-on therapy in CHB patients receiving PEG-IFNα. Here, we report the data on patients meeting NRTI discontinuation criteria. Methods: 114 Chinese HBsAg negative virally suppressed CHB patients partially responding to 24-28 doses of PEG were randomized 1:1 to BRII-179 or placebo every 3 weeks for 7 doses with PEG continued for another 24 weeks. Eligible patients with HBsAg <0.05 IU/mL for 2 consecutive assessments at 12-24 weeks post EOT would be eligible to discontinue NRTI.

Results: 3 (5.3%) vs 1 (1.8%) patient in BRII-179 vs placebo group had AEs that led to BRII-179/placebo discontinuation. 4 treatment related SAEs were reported including 2 related to PEG and 2 related to PEG and BRII-179. By 24-week post EOT, BRII-179 group had higher percentage of patients met NRTI discontinuation criteria (FAS: 26.3% vs. 15.8%) and earlier NRTI discontinuation. In addition, higher percentage of patients in BRII-179 group had maximum HBsAb titer ≥10 (45.6% vs. 14.0%) and ≥100 IU/L (19.3% vs. 3.5%). As previously reported, HBsAb ≥100 IU/mL was strongly associated with sustained HBsAg loss off-treatment.

Conclusion: BRII-179 add-on was generally safe and tolerated. It induced functional immune responses and may improve CHB functional cure.
Abstract Submission No. 200115

**O-0136**

**Everest Project’s 5-Year Update: Efficacy of PegIFN-a Therapy in HBeAg-CHB Patients in China**

Chan Xie1, Dong-Ying Xie1, Lei Fu2, Wen-Hua Zhang1, Jia Wei4, Guojun Li3, Jia-Hong Yang1, Xin-Yue Chen1, Jia-Bin Li3, Jia-Shang2, Yu-Juan Guan2, Yong-Fang Jiang2, Ying Guo1, Yi-Lan Zeng1, Zhi-Liang Gao1

1Third Affiliated Hospital of Sun Yat-sen University, Department of Infectious Diseases Guangzhou China, 2Xiangya Hospital Central South University Changsha China, 3Gansu Wuwei Cancer Hospital Wuwei China, 4Affiliated Hospital of Yunnan University Kunming China, 5The Third People’s Hospital of Shenzhen Shenzhen China, 6People’s Hospital of Deyang City Deyang China, 7Beijing Youan Hospital, Capital Medical University Beijing China, 8The First Affiliated Hospital of Anhui Medical University Hefei China, 9Henan Provincial People’s Hospital Zhengzhou China, 10Guangzhou Eighth People’s Hospital Guangzhou China

**Background and Aims:** This study aims to evaluate the efficacy and safety of pegIFNα-based therapy in real-world nucleoside analog (NA) treated chronic hepatitis B (CHB) patients and identify predictors for HBsAg loss by pegIFNα.

**Method:** The Everest Project, a multicenter real-world study in China, was previously introduced, focusing on the HBsAg loss of CHB (NCT04035837). Patients with over a year of NA therapy, HBV DNA <100 IU/ml, HBeAg negative, and HBsAg ≤1500 IU/ml were recruited starting in 2018. PegIFNα-2b monotherapy or combination-with NA was performed. The 5-year study enrollment has now concluded, and the latest research data is presented here.

**Results:** Out of the total 23,412 patients recruited, 15,896 were considered mITT group, 12,260 patients were included in the PP group. Of the total patients over 48-week treatment, 77.47% were male, with an average age of 41.77 years and a mean HBsAg baseline of 378.05 IU/mL. 3,864 patients achieved HBsAg loss. The HBsAg loss rates were 10.75%, 22.72%, 28.72% and 31.43% at 12, 24, 36, and 48 weeks in the PP group, respectively, higher than that in the mITT group (figure 1A, B). Factors predicting higher HBsAg loss included a lower HBsAg baseline, reduced HBsAg levels at 12 and 24 weeks, ALT flare at the 12-week mark, younger age, female gender, and a lower BMI (figure 1C).

There were no severe adverse events during this project.

**Conclusion:** HBsAg loss rate could be over 30% in NA-suppressed CHB patients by pegIFNα strategy. Baseline and on-treatment predictors can better guide the achievement of functional cure.

---

Abstract Submission No. 200285

**O-0138**

**First-in-human, first-in-class, Phase 1B preliminary safety data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV Functional Cure**

Sue L Currie1, Currie, SL2, Luber, AD3, Ertl, HC3, Gane, EJ4

1Medical Data Analytics Centre, Department of Medicine and Therapeutics, and Institute of Digestive Disease, The Chinese University of Hong Kong Hong Kong Hong Kong, 2Virion Therapeutics, LLC Newark, DE USA, 3The Wistar Institute Philadelphia, PA USA, 4New Zealand Liver Transplant Unit, Auckland City Hospital, University of Auckland New Zealand

**Background:** VRON-0200 is a therapeutic vaccine for hepatitis B virus (HBV) functional cure that contains a genetically encoded checkpoint modifier (herpes simplex virus type 1(HSV-1) glycoprotein D), fused with HBV core and polymerase antigens, to induce enhanced, broadened, and prolonged CD8+ T cell responses. Here we report the first-ever preliminary clinical data of VRON-0200 in patients with chronic HBV.

**Methods:** Chronic HBV-infected adult, virally suppressed patients, with HBsAg levels <500IU/mL, are randomized to receive 1x10^10vp of one of 2 different chimpanzee adenoviral vectors intramuscularly. Cohort 1a receives a prime, followed by a heterologous boost, on day 91; Cohort 1b receives only the prime. A higher dose cohort, Cohort 2 (5x10^10vp), following the same dosing schedule, will begin once 12 patients in Cohort 1 reach day 28. Study assessments include safety, virologic, and immunologic parameters through one-year post-prime vaccination.

**Results:** Six Cohort 1 patients have been randomized and received one dose of VRON-0200 (n=3 each viral vector); all male, 5 Asian, with mean age of 44 years (range: 41-49); 5 are HBeAg-. Patients are at varying stages of follow-up: all had Days 1, 7, and 14 visits, 5 had Day 28 visits, and 2 had Day 60 visits. As of Jan.12, 2024(Table 1), no AEs,
SAEs, TEAEs, or laboratory abnormalities (including clinically significant ALT elevations) have been reported.

**Conclusions:** In this first report of safety data from VRON-0200, the prime dose has been well tolerated, with no significant safety concerns to date. The study is ongoing, and additional Cohort 1 clinical data will be presented.

Abstract Submission No. 100319
*O-0139*

**Efficacy of hepatitis B vaccine in liver cirrhosis patients**

**Suđhamshu KC1,2, Niyanta Karki1,2, Pukar Thapa1,2, Dilip Sharma1**

1National Academy of Medical Sciences Kathmandu Nepal, 2Norvic International Hospital Kathmandu Nepal

**Aim:** The literature has shown that the vaccines against hepatitis B virus (HBV) are safe and effective in patients with liver cirrhosis (LC) but the data is lacking in our country. We aimed to evaluate the response to standard hepatitis B (HB) vaccination in LC of various etiologies and compare in different stages of LC.

**Method:** Consecutive patients of LC negative for hepatitis B surface antigen (HBsAg) and antibody to hepatitis B core antigen (Anti HBc total) were included. All patients received three doses of HB vaccine 20μg intramuscularly at zero, one, and six months interval. Anti-HBs antibody was measured after 90 days of last vaccine.

**Results:** A total of 214 patients with mean age 59.28±11.23 years were studied. Overall response rate was 92%. Response rates as per Child Pugh classes A, B and C were 98%, 100% and 61%. Ethanol related LC had less antibody response (44%) than other causes of LC (p=0.003). Poor immunogenicity was associated with low albumin and malnutrition (p=0.003). The response rate was also found to be decreased in older age group. There were no side effects except for soreness at injection sites in few patients.

**Conclusions:** Vaccine against HBV is safe in LC patients. Low level of albumin and presence of malnutrition was significantly associated with decreased vaccine response. As the age and liver disease progress, the response rate for HB vaccination was found to be weaker. We recommend correction of malnutrition and build up albumin level before vaccination to Child C cirrhosis patients.

Abstract Submission No. 100356
*O-0140*

**Maternal infection with hepatitis B and maternal and neonatal outcomes**

**Tingting Peng1, Calvin Pan Pan1,2, Shi Ouyang1**

1The Fifth Affiliated Hospital of Guangzhou Medical University Guangzhou China, 2NYU Langone Health, NYU School of Medicine New York USA.

**Background:** The correlation between HBV carrier status and pregnancy, as well as neonatal outcomes is clinically concerned.

**Methods:** We conducted a retrospective cohort study to analyze the risk factors and independent predictors of maternal and infant outcomes. Propensity Score Matching (PSM) was performed using a 1:4 matching ratio between the HBsAg (+) group and the healthy group. Maternal infection with hepatitis B and maternal and neonatal outcomes is clinically concerned.

**Results:** A total of 5,871 pregnant women received perinatal services in our hospital from January 1, 2021, to December 31, 2022. After PSM, we included 445 mothers with HBsAg (+) and 1,780 healthy mothers. The two groups were comparable after PSM. Compared to healthy group, HBsAg (+) mothers had a higher likelihood of preeclampsia (4.0% vs. 2.2%), gestational diabetes (16.9% vs. 13.0%), intrahepatic cholestasis of pregnancy (ICP) (22.5% vs. 1.0%), and umbilical cord prolapse (0.2% vs. 0%) and had a significantly lower occurrence of oligohydramnios (6.7% vs. 9.9%) and thyroid dysfunction during pregnancy (6.3% vs. 9.7%) (all P<0.05). In multivariate logistic regression analyses confirmed a higher risk of ICP with HBV infection (OR 2.35, 95% CI 1.12-5.44). (P<0.05). Newborns of HBsAg (+) mothers had a significantly lower occurrence of birth defects (0.4% vs. 2.9%, P=0.05) compared to babies of healthy mothers. In the multivariate logistic regression analysis, maternal HBV infection was not found to be associated with birth defects (P>0.05). (See Figure 1, Table 1-3)

**Conclusions:** HBsAg is an independent risk factor for ICP. HBV infection does not lead to an increased risk of birth defects.

Abstract Submission No. 100375
*O-0142*

**Switching to TMF is effective for ETV or TAF monotherapy in patients with hypoviremia**
En-Qiang Chen1, Lan-Qing Li3, Jing Zhou1, Yu-Jing Li1, Cheng-Run Song1, Min He1, Yong-Hong Wang1, Xue-Zhong Lei1, Wei Jiang1
1West China Hospital, Sichuan university Chengdu China

Objective: Some patients treated with ETV or TAF monotherapy may experience hypoviremia. This study aims to observe whether switching to (tenofovir amibenafamide, TMF) monotherapy can further improve the antiviral treatment benefits of these CHB patients with hypoviremia.

Method: This is a retrospective study targeting CHB patients treated with ETV or TAF monotherapy for more than 1 year, but with serum HBV DNA consistently fluctuating between 20 and 2000 IU/mL. All enrolled patients voluntarily switched to TMF for further antiviral treatment and completed comprehensive examinations at least once every 6 months. The primary outcome measure was the undetectable rate of HBV DNA after 6 and 12 months of TMF treatment, while the secondary outcome measure was the incidence of renal tubular damage and dyslipidemia.

Result: A total of 73 patients were included, including 47 patients treated with ETV and 26 patients treated with TAF. Among them, there were 33 HBsAg-positive patients and 40 HBsAg-negative patients. After switching to TMF treatment for 6 months and 12 months, 69.9% (51/73) and 74.0% (54/73) of patients achieved HBV DNA <20 IU/mL, respectively. Compared to HBsAg-positive patients, HBsAg-negative patients switching to TMF treatment can achieve a higher proportion of complete virological response (19/33 vs. 32/40, P=0.038; 18/33 vs. 36/40, P<0.001). After 12 months of treatment, the abnormal rate of urinary b2 microglobulin was 16.4% (12/73), and the proportion of urinary b2 microglobulin increasing by three times the upper limit of normal value was 6.8%. The proportion of blood phosphorus below the lower limit of normal value was 19.2% (14/73). Although the levels of total cholesterol and low-density lipoprotein cholesterol increased compared to before treatment, the differences were not statistically significant.

Conclusions: CHB Patients treated with ETV or TAF experience hypoviremia, switching to TMF can help most patients achieve a complete virological response rate, with good patient tolerance.

Abstract Submission No. 100421
O-0143

HBV PreS1 Variant Mediates the Protective Effect of NTCP S267F Variant Against HCC in CHB Patients

Hsiang-Hsuan Chuang1,2,3, Ding-Lian Wang2,3, Mei-Hung Pan1, Chih-Jen Huang1, Hwai-I Yang1
1School of Medicine, Chung Shan Medical University Taichung Taiwan, 2Graduate Institute of Life Sciences, National Defense Medical Center Taipei Taiwan, 3Genomics Research Center, Academia Sinica Taipei Taiwan

Background: The S267F variant (rs2296651) in the human hepatitis B virus (HBV) entry receptor, sodium taurocholate co-transporting polypeptide (NTCP), has been previously associated with a reduced risk of hepatocellular carcinoma (HCC) development in individuals with chronic hepatitis B (CHB) infection. However, the mechanism by which the NTCP variant decreases the HCC risk remains unclear. We examined the DNA sequence of HBV preS1 domain, known as the NTCP binding domain, to assess its association with the protective effect of the S267F variant against HCC.

Methods: The HBV DNA preS1 sequences of 366 CHB patients, sequenced through PacBio, were analyzed via Cox regression, logistic regression, and mediation analysis to predict HCC risk and evaluate the mediation effect of the HBV preS1 allele.

Results: Within the HBV preS1 domain sequence, a significant difference in the allele frequency of the adenine nucleotide at position 2956 (2956A) was observed between individuals with S267F GG genotype (mean ± SD: 0.35 ± 0.47) and those with GA/AA genotype (0.60 ± 0.43; p<0.001). Moreover, individuals with a higher allele frequency of 2956A demonstrated a reduced risk of HCC development (HR: 0.45; 95% CI: 0.29-0.69). The subsequent mediation analysis revealed that the 2956A served as a mediator in the protective effect of S267F variant against HCC, with more significant protection in the average causal mediation effect (ACME; OR: 0.87; p<0.001) than the average direct effect (ADE; OR: 1.07; p=0.28).

Conclusions: The allele 2956A within the HBV DNA preS1 domain might mediate the NTCP S267F variant against HCC.

Abstract Submission No. 100430
O-0144

Histological Characteristics in Functional Cure Post PEG-IFN-based Therapy

Na Gao1, Haishi Wu1, Mozuo nian1, Qiyi Zhao1, Zhiliang Gao1
1Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University Guangzhou China

Background: HBsAg seroclearance is associated with disease remission after treatment cessation. However, the histologic characteristics in patients with PEG-IFN-inducing HBsAg seroclearance have not been explored before.

Methods: Liver tissues obtained from patients with functional cure post PEG-IFN-based therapy (n=70). Liver pathology was evaluated by Scheuer. Intrahepatic HBsAg and cccDNA were analysed.

Results: There were 61 patients with chronic hepatitis B (CHB) and 9 patients with compensated cirrhosis received PEG-IFN based therapy and attained functional cure. Notably, 1/9 patients with prior compensated cirrhosis achieved fibrosis regression which verified by both histopathology and B ultrasound after attaining HBsAg seroclearance. In patients who have achieved a functional cure from prior CHB, it demonstrated that 13.1% and 1.6% of them presented with moderate and severe intrahepatic inflammation, respectively. Furthermore, 36.1% and 1.6% of these patients illustrated moderate fibrosis and severe fibrosis, respectively. The age, gender, NAFLD, intrahepatic HBsAg and cccDNA level between intrahepatic inflammation and none-inflammation groups showed no statistic difference. Eight functionally cure patients experienced HBsAg seroreversion. HBsAg seroreversion group exhibited a higher level of cccDNA at cessation time of PEG-IFN, with a median (Q1, Q3) of 2.2 (0.79-2.84) log copies/10^3 cells, compared to none HBsAg seroreversion group (0.96, 0-2.06 log copies/10^3 cells, P = 0.028).

Conclusion: HBsAg seroclearance contributes to fibrosis remission in patients with prior compensated cirrhosis however, part of patients with prior chronic hepatitis B remained inflammation and fibrosis, and it warrant further study to investigate the potential influencing factors of residual inflammation.

Abstract Submission No. 100447
O-0145

Antiviral therapy can improve the health-related quality of life in CHB patients with normal ALT
En-Qiang Chen1, Jing Zhou1, Lan-Qing Li1, Yu-Jing Li1, Cheng-Run Song2, Xue-Zhong Lei1, Tao-You Zhou1, Hong Tang3

1West China Hospital, Sichuan university Chengdu China

Objective: To investigate the impact of chronic HBV infection on the quality of life of patients, and whether antiviral therapy can improve the quality of life of CHB patients

Method: This is a prospective study targeting CHB patients with persistent normal ALT, negative HBeAg, and positive HBV-DNA. The quality of life was evaluated using the Specific HBV Infected Person Quality of Life Scale (HBQOLV1.0). Patients need to complete the quality of life scale at baseline and 12 months after enrollment.

Result: A total of 244 patients finally included, with 59 in untreated group and 185 in treated group. At baseline, there was no significant difference in the total HBQOL scores between the treatment and untreated groups (2121.5 vs. 2140.6, P=0.844). The average scores of the two groups of patients in six dimensions of psychological status, expected anxiety, contagiousness and health vulnerability, vitality, and sense of shame were all less than 75 points, and the scores of the first four dimensions were less than 70 points. After 12 months of follow-up, the total HBQOL score of the untreated group increased compared to baseline (2121.5 vs. 2140.6, P=0.380), but the difference was not significant. Except for the dimension of shame, the other five dimensions were higher than the baseline, but the difference was not significant. After 12 months of treatment, the total score of HBQOL in the treatment group increased with statistical significance (2280.7 vs. 2121.5, P=0.001). Except for the vitality dimension, the average scores of the remaining five dimensions were all higher than the baseline, and the differences were statistically significant. Among them, expected anxiety (65.0 vs. 71.4, P<0.001), contagiousness (66.8 vs. 74.2, P<0.001), and sense of shame (74.4 vs. 79.9, P=0.003) showed significant improvement, with a score increase of 5 points compared to before treatment.

Conclusion: Chronic HBV infection reduces the health-related quality of life. Antiviral therapy can improve the negative effects of HBV infection on patients in terms of psychological status, expected anxiety, shame, contagiousness, and health vulnerability.

Abstract Submission No. 100453
O-0146

Anti-fibrosis effect of traditional Chinese medicine compound Biejiaruangan in CHB patients

En-Qiang Chen1, Ya-Chao Tao1, Meng-Lan Wang1, Dong-Mei Zhang1, Juan Liao1, Ming He1, Xing Cheng1, Hong Tang3

1West China Hospital, Sichuan university Chengdu China

Aims: Compound Biejiaruangan (CBJRG) tablet can be used to treat liver fibrosis. This study aimed to investigate the anti-fibrosis effect of CBJRG in patients with chronic hepatitis B (CHB).

Patients and Methods: Eligible patients were divided into the Without group and the With CBJGR group based on whether the CBJRG was present in the treatment regimen. The differences of live stiffness measurements (LSM) values, aspartate aminotransferase-to-platelet ratio index (APRI) scores and fibrosis index based on four factors (FIB-4) scores were compared between the baseline and the week 24 in the Without and the With CBJRG groups, and in the entecavir (ETV) and the ETV plus CBJRG groups.

Results: LSM values and APRI scores were significantly decreased in the With CBJRG group after 24-week treatment, while only LSM values were reduced in the Without group. The improvement of fibrosis stages was only observed in patients receiving 24-week CBJRG in the context of ETV antiviral therapy, not in patients receiving CBJRG plus other antiviral drugs. Moreover, LSM values at week 24 were decreased as compared to the baseline in the ETV group, whereas no differences of APRI and FIB-4 scores were observed. LSM value, APRI and FIB-4 score were all statistically lower in patients treated with ETV plus CBJRG. The percentage of patient with fibrosis F4 were significantly lower in the ETV plus CBJRG group when compared to the ETV group.

Conclusion: The CBJRG plus ETV combination treatment shows a stronger anti-fibrosis efficacy than ETV alone in patients with CHB.

Abstract Submission No. 100485
O-0147

Pan-genotypic association of G1896A mutant with HBV DNA or advanced liver diseases: a meta-analysis

Guixin Li1, Xin Liu2, Hongsong Chen1, Fengmin Lu1,2

1Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China, 2Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Background: G1896A is one of the most common mutations in hepatitis B virus (HBV) genome, resulting in the abolishment of HBeAg production. Numerous studies focused on the replicative capacity and pathogenicity of G1896A mutant, but the conclusions were not consistent.

Methods: We searched Pubmed, Embase and Cochrane library up to June 18, 2022. Studies were screened according to inclusion and exclusion criteria. Extracted data were analyzed with the fixed- or random-effects model. Potential sources of heterogeneity were investigated using sensitivity and subgroup analyses.

Results: 63 studies were finally included to conduct meta-analyses. Results showed that G1896A mutant was more prevalent in HBeAg negative patients (OR=5.57; 95%CI, 3.86~8.04; P<0.001). And G1896A was likely more common in genotype B and C than genotype D. Serum HBV DNA load of HBeAg-negative patients with G1896A mutant was 0.87 log10copies/mL higher than those without mutant (WMD=0.87; 95%CI, -1.56~0.18; P=0.014). Moreover, G1896A mutant was closely associated with advanced liver diseases including liver cirrhosis (OR=1.96; 95%CI, 1.67~2.29; P=0.001) and hepatocellular carcinoma (OR=1.60; 95%CI, 1.20~2.12; P=0.001). These findings were constant in genotype B and/or C (liver cirrhosis: OR=2.47; 95%CI, 1.95~3.13; P<0.001; hepatocellular carcinoma: OR=1.61; 95%CI, 1.08~2.40; P=0.021).

Conclusions: HBeAg-negative patients with G1896A mutant might have higher HBV DNA level and G1896A mutant was closely associated with advanced liver diseases in chronic HBV-infected patients. In the area with high incidence of G1896A mutant, especially Eastern and Southeastern Asia, chronic HBV-infected patients should be monitored on mutants and expected to receive early antiviral treatment.

Abstract Submission No. 100544
O-0148

Development of a diagnostic model for hepatic inflammation in patients of CHB with HS based on MI.

Fajuan Rui1,2, Yee Hui Yeo3, Liang Xu4, Qi Zheng5, Wenjing Ni9, Qinglei Zeng4, Zehao He6, Yuanwang Qiu7, Jian Wang2, Rui Huang2, Shengxia Yin2, Yunliang Chen9, Chao Wu7, Junping Shi10, Jie Li1,2
Determining of transient elastography cutoff for advanced fibrosis in patients of CHB with HS

Fajuan Rui1, 2, 3, Xiaoming Xu1, 2, 3, Wenjing Ni1, 2, 3, Liang Xu4, Liang Xu4, Ye Hui Yeo5, Jie Li5

1Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, 2Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 3Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center Los Angeles USA, 4Clinical School of the Second People’s Hospital, Tianjin Medical University Tianjin China, 5Department of Hepatology, Hupra Research Institute, the First Affiliated Hospital, Fujian Medical University Fuzhou China, 6Department of Infectious Diseases, The First Affiliated Hospital of Zhengzhou University Zhenghzhou China, 7Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University Taizhou China, 8Department of Infectious Diseases, The Fifth People’s Hospital of Wuxi Wuxi China, 9School of Computer Science, China University of Geosciences Wuhan China, 10Department of Infectious Diseases, The Affiliated Hospital of Hangzhou Normal University Hangzhou China

Background: The coexistence of chronic hepatitis B (CHB) and hepatic steatosis (HS) is common, but simple non-invasive diagnostic methods to accurately assess hepatic inflammation severity are lacking. This study aimed to establish a non-invasive diagnostic model for hepatic inflammation in CHB patients with concurrent HS using machine learning (ML).

Methods: This study consecutively enrolled treatment-naïve CHB patients with concurrent HS who underwent liver biopsy from eleven medical centers between April 2004 and September 2022. Nine centers were used for training, while the other two centers were for external validation (validation cohort 1, validation cohort 2). Four ML algorithms (LR, RF, GBC, and ADB), were used to predict inflammation degree. Those patients with predicted inflammation grade (G) ≥ 3 were diagnosed. The optimal features for model development were selected by Shapley Additive explanation. Area under curve (AUC) was calculated to confirm the accuracy of the models.

Results: A total of 1,639 CHB patients with concurrent HS were enrolled in the study. In the training cohort, 157 (22.79%) patients reported hepatic inflammation ≥ G3, respectively. In validation cohort 1, 31 patients (6.09%) had hepatic inflammation ≥ G3. Meanwhile, in validation cohort 2, 76 (17.23%) patient exhibited hepatic inflammation ≥ G3. The GBC model had the best performance in diagnosing inflammation ≥ G3, with AUC of 0.856 (95% CI 0.830-0.883) in the training cohort, 0.892 (0.865-0.919) in validation cohort 1 and 0.775 (0.736-0.814) in validation cohort 2.

Conclusions: The GBC model reliably predicts inflammation ≥ G3 in CHB patients with concurrent HS, improving disease diagnosis and management.
booster immunity further improved the positive rate and antibody titer of PCLD, especially among patients with primary immunity failure. Local and systemic adverse reactions were slight.

**Keywords:** immune response; primary and booster immunity; SARS-CoV-2 vaccination; patients with chronic liver disease

---

**Abstract Submission No. 100562**

**O-0151**

Immunogenicity Of A Booster SARS-CoV-2 Vaccination In Patients With Chronic Liver Disease

Qi Qian Li1, Huiling Xiang1, Jing Chen2, Kai Sun3, Ruixin Song2, Jiayin Wang1, Hongmin Lv1, Yankai Yang1, Jing Liang1, Chao Yang1

1Tianjin Third Central Hospital Tianjin China, 2The Third Central Clinical College of Tianjin Medical University Tianjin China, 3Tianjin Hongqiao Hospital Tianjin China

**Objective:** To investigate the safety and immunogenicity of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster in patients with chronic liver disease.

**Design:** Patients with chronic liver disease who received a SARS-CoV-2 vaccine booster were enrolled. Adverse events within 14 days of any dose of SARS-CoV-2 vaccine were recorded, simultaneously, serum samples were collected from enrolled patients at least 14 days after the booster dose and tested for SARS-CoV-2 neutralizing antibody (novel coronavirus neutralizing antibody, nCoV NTAb) and IgG antibody against SARS-CoV-2 spike binding domain (novel coronavirus Spike Receptor-binding Domain antibody, nCoV S-RBD) levels.

The data of liver and kidney function, blood routine and coagulation function were collected and statistically analyzed before and after the booster injection of nCoV vaccine.

**Results:** A total of 114 patients with chronic liver disease were included. The positive rates of nCoV NTAb and nCoV S-RBD in patients with chronic liver disease were 87.72% and 91.23% after the booster injection of COVID-19 vaccine, and the positive rates of nCoV NTAb and nCoV S-RBD in non-cirrhotic group and cirrhotic group were 93.55%, 80.77% and 98.39%, 82.69%, respectively (p<0.05); the median nCoV NTAb levels in non-cirrhotic group and cirrhotic group were 31.41AU/mL and 32.64AU/mL, and the median nCoV S-RBD levels were 102.94AU/mL and 119.41AU/mL, respectively. The results of continuous antibody level monitoring in 22 patients with basic immunization showed that after booster injection of COVID-19 vaccine increased significantly from 6.18% to 90.91%. Antibody levels in patients with chronic liver disease increased significantly after the booster injection of COVID-19 vaccine compared to pre-injection levels. The nCoV-NTAb antibody levels increased evidently from 11.24 AU/mL (4.41 AU/mL - 38.26 AU/mL) to 59.14 AU/mL (5.72 AU/mL - 279.38 AU/mL) in 22 patients after the booster, with a mean increase of 5.26-fold. The median nCoV-SRBD antibody level increased significantly from 27.27 AU/mL (2.90 AU/mL - 169.47 AU/mL) to 219.10 AU/mL (2.55 AU/mL - 579.46 AU/mL) (p<0.01), with a mean increase of 8.03-fold. The booster injection resulted in the production of nCoV-NTAb in 66.7% (6/9) of patients with chronic liver disease who failed basic immunization and nCoV-SRBD antibody in 71.43% (7/9). The overall tolerability of COVID-19 vaccine in patients with chronic liver disease was good, with a low incidence of adverse reactions and systemic adverse reactions were slight, with local pain at the injection site being the most frequent adverse reaction.

**Conclusion:** After basic SARS-CoV-2 immunization, the booster SARS-CoV2 vaccine can increase the serum conversion rate and antibody level of neutralizing antibodies and S-RBD IgG antibodies in patients with chronic liver disease (including patients with cirrhosis). The adverse reactions are mild and acceptable. The severity of liver disease is related to the immune response to COVID-19 vaccine.

---

**Abstract Submission No. 100570**

**O-0152**

A novel model for advanced fibrosis and cirrhosis diagnosis for CHB patients with hepatic steatosis

Wenjing Ni1,2, Hui Yeo Yee3, Fajuan Rui1,2, Yayan Xu4, Xiaorong Tian1, Qi Xue5, Xiaolong Qi6, Junping Shi4, Chao Wu9, Jie Li8

1Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China Nanjing China, 2Institute of Viruses and Infectious Diseases, Nanjing Medical University, Nanjing, Jiangsu, China Nanjing China, 3Cedars-Sinai Medical Center, Los Angeles, California, USA Los Angeles USA, 4Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China Jinan China, 5School of Computer Science, China University of Geosciences, Wuhan, Hubei, China Wuhan China, 6Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China Jinan China, 7Zhongda Hospital, Medical School, Nanjing, Jiangsu, China Nanjing China, 8The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, China Hangzhou China, 9Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

**Background:** We previously developed a diagnostic model named PAP to assess advanced fibrosis (≥S3) and cirrhosis (≥S4) for chronic hepatitis B (CHB) patients with hepatic steatosis (HS). The PAP model was built on Gaussian naive bayes including prothrombin time, albumin and platelet. This study aimed to test the stability of the PAP model across five subgroups.

**Methods:** A total of 1,427 patients from nine clinical centers in China (NCT05766449) were enrolled. Patients were divided into five groups according to age (<40 and ≥40 years), sex (males and females), body mass index (<25 kg/m² and ≥25 kg/m²), hepatitis B e antigen (HBeAg) status (positive and negative) and hepatitis B virus deoxyribonucleic acid (HBV DNA) level (<10⁵ and ≥10⁶ IU/mL).

**Results:** In the training cohort, the PAP model had the highest area under curves (AUCs) in patients with HBV DNA ≥10⁶ IU/mL at 0.827 (95% CI 0.749-0.905) for ≥S3 and 0.864 (95% CI 0.794-0.934) in patients aged ≥40 years for ≥S4, while it performed modestly in patients with HBV DNA <10⁵ IU/mL when diagnosing ≥S3. In the validation cohort, it had the highest AUC of 0.824 (95% CI 0.765-0.883) in patients with HBV DNA ≥10⁷ IU/mL, and the lowest AUC of 0.687 (95% CI 0.619-0.755) in patients aged <40 years for ≥S3. The model performed best in female patients for =S4, with an AUC of 0.954 (95% CI 0.902-1.000).

**Conclusions:** In CHB patients with HS, the PAP model remained its stability for diagnosing liver advanced fibrosis and cirrhosis across various groups.

---

**Abstract Submission No. 100582**

**O-0153**

Novel algorithms for Predicting Advanced Fibrosis in CHB Patients with Concurrent Hepatic Steatosis
Abstract Submission No. 100595

The diminished accuracy of non-invasive tests for significant fibrosis in CHB patients with MASLD

Wenjing Ni1,2, Fajuan Rui1,2, Youwen Tan3, Liang Xu4,5,6, Junping Shi1, Jie Li1,2,8

1Department of Infectious Diseases, Nanjing Drum Tower Hospital; 2Clinical College of Nanjing University of Chinese Medicine; 3Department of Hepatology, Tianjin Second People’s Hospital; 4Tianjin Medical University; 5China Tianjin China; 6Department of Infectious Diseases, The Affiliated Hospital of Hangzhou Normal University; 7Department of Infectious Diseases, Nanjing Drum Tower Hospital; 8Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China Nanjing China

Background: The co-existence of chronic hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) has become popular, exacerbating the progression of hepatic fibrosis. However, the diagnostic performance of non-invasive tests (NITs), including the fibrosis-4 index (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and non-alcoholic fatty liver disease fibrosis score (NFS), remains uncertain in CHB patients with MASLD. This study aims to evaluate the accuracy of these NITs in identifying significant fibrosis in such population.

Methods: This multicenter, cross-sectional study was conducted at eleven Chinese hospitals. The whole population was classified as three groups, with group A of CHB patients combined with simple hepatic steatosis (HS), group B of CHB patients with MASLD involving 1-3 cardiometabolic risk factors (CMRFs), and group C of CHB patients with MASLD involving 4-5 CMRFs. According to Scheuer’s classification, ≥S2 was defined as significant fibrosis.

Results: A total of 1,079 eligible patients were enrolled. In group A, the optimal cut-off values for FIB-4, APRI, and NFS in diagnosing ≥S2 were 1.263, 0.56, and -3.547, respectively, with corresponding area under curves (AUCs) of 0.784, 0.786 and 0.723. In group B, the AUC of FIB-4, APRI, and NFS was 0.655, 0.677 and 0.634, respectively. These AUCs further declined in group C, all falling below 0.640 (Figure 1).

Conclusions: The diagnostic accuracy of the three NITs diminished as the number of CMRFs increased. More studies are needed to develop tailored NITs for specific population.

Abstract Submission No. 100599

Explore the decrease of HBsAg in patients with compensatory cirrhosis during Peg-interferon therapy

fei tang1, Huiling Xiang1,2, Jiaying Wang3, Jing Liang4, Fang Wang5, Weili Yin6

1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China; 2Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China; 3Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China; 4Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China; 5Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China; 6Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital tianjin China

Abstract Submission No. 100606

Comparison of Markers for Diagnosing Significant or Advanced Fibrosis in Patients with CHB

Xiaoming Xu1,2, Fajuan Rui1,2, Wenjing Ni1,2, Chao Wu1,2, Junping Shi1, Yee Hui Yeo4, Jie Li1

1Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China; 2Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China; 3Affiliated Hospital of Hangzhou Normal University Hangzhou China; 4Cedars-Sinai Medical Center Culver City United States

Background: Non-invasive tests (NITs) are limited by having a significant proportion of indeterminate results for screening fibrosis in chronic hepatitis B (CHB) patients with concurrent hepatic steatosis (HS). Herein, we aimed to establish novel algorithms that call for improvements in current diagnostic workflow.

Methods: We consecutively recruited untreated patients who underwent liver biopsy from nine medical centers in China between April 2004 and September 2021 (Clinical Trials: NCT05766449). Fibrosis index based on the four factors (FIB-4), aspartate aminotransferase to platelet ratio index (APRI) and NAFLD fibrosis score (NFS), as well as their combinations were used to predict advanced fibrosis. Sensitivities, specificities, and positive and negative predicted values were calculated. Subsequently, we computed the proportion of patients with the correct classification (the sum of true positives and negatives) for different combinations of NITs.

Results: Among 926 treatment-naive CHB patients with HS, 180 (19.44%) patients had advanced fibrosis. At the lower cut-off values, APRI exhibited the highest sensitivity of 65.56%, followed by FIB-4 (53.89%) and NFS (41.11%). At the higher cut-off values, NFS had the highest sensitivity of 65.56%, followed by FIB-4 (53.89%) and APRI (49.1%). Notably, APRI displayed the highest indeterminate rate of 30.99% compared to other NITs. The proportions of patients to receive a correct classification according to a single test were 64.7% for NFS, 64.1% for FIB-4, and 57.6% for APRI. When combining the test, the algorithm with NFS followed by APRI enabled most patients to receive a correct classification (73.7%), compared to FIB-4-NFS (71.3%), NFS-FIB-4(71.8%), FIB-4-APRI (71.0%), APRI-FIB-4 (70.5%), APRI-NFS (71.8%).

Conclusion: The combined model NFS-APRI developed in our study showed better performance than individual NITs, which could reduce indeterminate zones and optimize referral pathways.

Abstract Submission No. 100595

O-0154

The diminished accuracy of non-invasive tests for significant fibrosis in CHB patients with MASLD

Fibrosis in Patients with CHB
HBsAg decline in Peg-IFN treated hepatitis B with fatty liver is similar to non-fatty liver patients

Jiayin Wang1, Qing Ye1, Weili Yin1, Fang Wang1, Hongming Lv1, Jing Liang1, Yanying Gao1, Fei Tang1, Tinghong Li1, Lei Liu1, Yan Li1, Yankai Yang1, Ying Li1, Jun Li1, Huiling Xiang1
1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin China

Objective: To explore the decrease of HBsAg in patients with hepatitis B with fatty liver during Peg-interferon therapy.

Methods: Patients treated with Peg-IFN for 48W were collected. According to the fat attenuation, the enrolled people were divided into fat attenuation <240dB/m group (n=116) and fat attenuation ≥240dB/m group (n=150). Statistical analysis of data was performed by SPSS 26.0 software.

Results: The median age of our study was 40 (36-48) years old, including 79 males (75.98%), 130 treated patients (67.82%), 143 HBV-DNA negative patients (59.09%), 121 HBeAg negative (80.13%), and the median HBsAg was 3.02 (2.58-3.42) Log10 IU/mL, the median ALT 24 (17-38.75) U/L; There were significant differences in gender and age between fat attenuation <240dB/m group and fat attenuation ≥240dB/m group. At follow-up up to 48W, there was no significant difference in the overall decline of HBsAg between the fat attenuation <240dB/m group and fat attenuation ≥240dB/m group, and the decline slope was (-0.020 vs -0.016) respectively. However, the decrease rate of HBsAg in the fat attenuation <240dB/m group was greater than that in the fat attenuation ≥240dB/m group at 24W (75.48% vs 52.05%, P=0.05); There was no significant difference in HBsAg clearance between the two groups at 12W, 24W, 36W and 48W. Stratified analysis showed that there were no significant differences in the overall decrease of HBsAg and the HBsAg clearance rate between 12W, 24W, 36W and 48W in terms of gender, age (<40 or not), treated/non-naive patients, HBVDNA positive/negative, HBeAg positive/negative, and HBsAg (>1500IU/ml or not), between fat attenuation <240dB/m group and fat attenuation ≥240dB/m group. Among the HBeAg negative patients, and the baseline ALT normal, the decrease of HBsAg in the fat attenuation <240dB/m group was significantly greater than that in the fat attenuation ≥240dB/m group at 24W. For the baseline ALT abnormal, the 48W HBsAg decline in fat attenuation <240dB/m group was greater than that in fat attenuation ≥240dB/m group, and the slopes were (-0.019 vs -0.011, P=0.020).

Conclusion: In the general population, compared with non-fatty liver group, there was no significant difference in HBsAg overall decline and the HBsAg clearance in patients with hepatitis B with fatty liver. For the baseline ALT abnormal, the 48W HBsAg decline in fatty liver group was greater than non-fatty liver group.

Abstract Submission No. 100608

O-0158

Analysis of PLT changes in patients with cirrhotic hepatitis B patients treated with Peg-interferon

Jiayin Wang1, Qing Ye1, Weili Yin1, Fang Wang1, Hongming Lv1, Jing Liang1, Yanying Gao1, Fei Tang1, Tinghong Li1, Lei Liu1, Yan Li1, Yankai Yang1, Ying Li1, Jun Li1, Huiling Xiang1
1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin China

Objective: To explore the decrease of PLT in patients with compensatory cirrhosis during Peg-interferon therapy.

Methods: Patients treated with Peg-IFN for 48W were collected. Liver stiffness measurement (LSM) was measured by instantaneous elastic imaging. The enrolled people were divided into LSM<9kPa group (non-cirrhotic patients) (n=171) and LSM≥9kPa group (compensatory cirrhosis group) (n=83). Statistical analysis of data was performed by SPSS 26.0 software.

Results: The median age of our study was 40 (36-48) years old, including 79 males (75.98%), 137 treated patients (67.82%), 143 HBV-DNA negative patients (59.09%), 121 HBeAg negative (80.13%), and the median HBsAg was 3.02 (2.58-3.42) Log10 IU/mL, the median ALT 24 (17-38.75) U/L; PLT at 12W decreased significantly from baseline in both groups, The decrease of 12W PLT from baseline in LSM<9kPa group was significantly higher than LSM≥9kPa group (49.84% vs 45.48%, P=0.010). In the LSM≥9kPa group, the highest 12W decrease from baseline was 79%. PLT in 24W, 36W and 48W groups showed a slow upward trend compared with 12W, and the upward trend of PLT in the two groups was similar. Stratified analysis showed that there were significant differences in the patients with male age >40, naïve treatment, HBsAg >1500IU/mL, abnormal ALT in baseline, the decrease of 12W PLT from baseline in the LSM≥9kPa group was significantly higher than LSM<9kPa group, In these populations, we should pay more attention to the decline of 12W PLT and detect serious PLT reductions in time.
**Conclusion:** in the patients with male, age > 40, naïve treatment, HBsAg > 1500 IU/mL, abnormal ALT in baseline, we should pay more attention to the decline of 12W PLT in the LSM ≥ 9 kPa group.

Abstract Submission No. 100641  
**O-0159**

pgRNA and HBcAg closely correlated with cytokines in HBeAg-positive pregnant patients in pregnancy</st>

Qiao Tang1, Chunrui Wang1, Peng Hu1  
1The Second Affiliated Hospital of Chongqing Medical University Chongqing China

**Background:** Previous studies indicated hepatitis B virus (HBV) serum markers are associated with host immunity. However, the relationship of novel HBV serum markers pregenomic RNA (pgRNA) and HBcAg with host immunity in pregnancy CHB patients remains unclear. Therefore, we aimed to explore the relationship between novel HBV serum markers (pgRNA and HBcAg) and cytokines in HBeAg-positive pregnant chronic hepatitis B (CHB) patients during pregnancy.

**Methods:** In this retrospective real-world study, HBsAg, HBV DNA, pgRNA, HbcAg and 28 cytokines were collected from 28 HBeAg-positive pregnant CHB patients at 24-28 weeks gestation.

**Results:** We found that neither HBsAg, HBV DNA, nor HBcAg correlated with cytokines, but only pgRNA positively correlated with Th1 cytokines (IFN-γ, IL12p70, IL2 and TNF-α), Th2 cytokines (IL10 and IL5), Th17 cytokine (IL21), and cytokines regulating cell proliferation and differentiation (CTLA4, IL15, IL23 and TGF-β1), and negatively associated with IL12p40 in 24-28 weeks gestation. In HBeAg-positive pregnant CHB patients younger than 30 years old, pgRNA correlated with Th1 cytokines (IFN-γ and IL12p70), Th2 cytokines (IL5), Th17 type cytokines (ICOS) and cytokines regulating cell proliferation and differentiation (CTLA4 and TGF-β1), HbcAg and HBsAg correlated with ICOS, and HBV DNA correlated with ICOS and CTLA4. In patients older than 30 years, pgRNA correlated with MIP-1α, HbcAg correlated with TNF-α, IL4, IL5, IL17, TGF-β1 and IP10, HBsAg and HBV DNA did not correlated with cytokines.

**Conclusions:** pgRNA and HBcAg showed more closely relationship with cytokines in HBeAg-positive pregnant CHB patients compared to traditional HBV serum markers.

Abstract Submission No. 100642  
**O-0160**

IFN-α provides dual benefits of reducing HCC and facilitating HBsAg loss for NA-treated CHB patients

Shaowen Jiang1, Simin Guo1, Haiguang Xin1, Jie Xu2, Yi Li3, Yilan Zeng4, Yuan Guo5, Lijuan Ouyang6, Chuanwu Zhu7, Weifeng Zhao8, Qin Zhang9, Qing Guo1, Qing Xie1  
1Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 2Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 3Anhui Provincial Hospital Hefei China, 4Chengdu Public Health Clinical Medical Center Chengdu China, 5The Affiliated Hospital of Qingdao University Qingdao China, 6Xiamen Hospital of Traditional Chinese Medicine Xiamen China, 7The Affiliated Infectious Diseases Hospital of Soochow University Suzhou China, 8Xinxiang Medical University Third Hospital Xinxiang China, 9Tongren Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

**Background:** This study is to investigate whether peginterferon-α-2b (IFN) add-on Nucleos(t)ide analogs (NAs) can further reduce hepatocellular carcinoma (HCC) risk compared with NAs monotherapy in NAs-treated patients with chronic hepatitis B (CHB).

**Methods:** In this multi-center randomized controlled trial “PARADISE study” (NCT05671315), CHB patients with intermediate to high risk of HCC, who had undetectable HBV DNA after more than 24-week NAs pretreatment, were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group continued NAs monotherapy, while IFN+ NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monotherapy. The changes of HBV serological markers at week 48 and the 96-week cumulative incidences of HCC were compared between groups.

**Results:** A total of 196 CHB patients were included in the interim analyses based on 96-week follow-up data (68 in NAs group, 128 in IFN+NAs group). The 96-week cumulative incidence of HCC was markedly lower in IFN+NAs group than NAs group (0% vs. 4.5%, log-rank test p=0.05). Compared with NAs group, IFN+NAs group had a significantly lower level of HBsAg at week 48 (1.55±3.1884 vs. 2.885±0.714 log10 IU/ml, p<0.001) and a notably greater HBsAg decline from baseline to week 48 (1.24±1.333 vs. 0.095±0.333 log10 IU/ml, p=0.001). Rates of HBsAg loss and HBsAg seroconversion at week 48 were much higher in IFN+NAs group than NAs group (21.9% vs. 0%, p=0.001; 18.0% vs. 0%, p=0.001).

**Conclusion:** IFN add-on NAs therapy is superior to NAs monotherapy in reducing HCC risk and facilitating HBsAg loss among NA-treated virologically suppressed CHB patients with intermediate to high risk of HCC.

Abstract Submission No. 100701  
**O-0161**

The Everest Project’s 5-Year Update: Efficacy of PegIFNα Therapy in NA-suppressed HBsAg negative CHB

Chan Xie1, Dongying Xie1, Qihuan Xu1, Lei Fu1, Xinyue Chen1, Jiahong Yang1, Guojun Li2, Jiabin Li2, Yilan Zeng1, Yongfang Jiang1, Wenhua Zhang3, Hong Tang4, Zhiliang Gao1  
1Third Affiliated Hospital of Sun Yat-sen University, Department of Infectious Diseases Guangzhou China, 2Xiangya Hospital Central South University Changsha China, 3Beijing Youan Hospital, Capital Medical University Beijing China, 4People's Hospital of Deyang City Deyang China, 5The People's Hospital of Shenzhen Shenzhen China, 6The First Affiliated Hospital of Anhui Medical University Hefei China, 7Chengdu Public Health Medical Center Chengdu China, 8The Second Xiangya Hospital of Central South university Changsha China, 9Gansu Wuwei Cancer Hospital Wuwei China, 10West China Hospital Sichuan University Chengdu China

**Background and Aims:** This study aims to evaluate the efficacy and safety of pegIFNα-based therapy in real-world nucleoside analog (NA)-treated chronic hepatitis B (CHB) patients and identify predictors for HBsAg loss by pegIFNα.

**Method:** The Everest Project, a multicenter real-world study in China, was previously introduced, focusing on the HBsAg loss of CHB (NCT04035837). Patients with over a year of NA therapy, HBV DNA < 100 IU/mL, HBeAg negative, and HBsAg ≤ 1500 IU/mL were recruited starting in 2018. PegIFNα-2b monotherapy or combination with NA was performed. The 5-year study enrollment has now concluded, and the latest research data is presented here.

**Results:** Out of the total 23,412 patients recruited, 15,896 were included in PP group. Of the total patients over 48-week treatment, 77.47% were male, with an average age of 41.77 years and a mean HBsAg baseline of 378.05 IU/mL. 3864 patients achieved HBsAg loss. The HBsAg loss rates...
were 10.75%, 22.72%, 28.72% and 31.43% at 12, 24, 36 and 48 weeks in PP group, respectively, higher than that in mITT group (figure 1A, B). Factors predicting higher HBsAg loss included a lower HBsAg baseline, reduced HBsAg levels at 12 and 24 weeks, ALT flare at the 12-week mark, younger age, female gender, and a lower BMI. There were no severe adverse events during this project.

**Conclusion:** HBsAg loss rate could be over 30% in NA-suppressed CHB patients with pegIFNα strategy. Baseline and on-treatment predictors can better guide the achievement of functional cure.

Abstract Submission No. 100730

**Clinical Study on the Efficacy and Safety of Interferon in Compensatory hepatitis B Cirrhosis**

Tianjing Zhang1, Xiaohong Gao2

1Yan’an University Affiliated Hospital, Yan’an China, 2Yan’an University Affiliated Hospital, Yan’an China

**BACKGROUND:** There are limited data on the efficacy and safety of polyethylene glycolated interferon-alpha 2b (PEG-IFNα2b) antiviral therapy in patients with compensated hepatitis B cirrhosis. In this study, we aimed to evaluate the efficacy of PEG-IFNα2b in HBsAg-positive patients.

**METHODS:** A total of 52 HBeAg-positive patients with compensated hepatitis B cirrhosis who had not received antiviral therapy were divided into two treatment groups: Group A (12 patients): patients were injected with Peg IFNα2b (180 μg) subcutaneously once a week; Group B (20 patients each): ETV (0.5 mg) or TDF (300 mg) was administered orally once a day for 48 weeks, and observed for 12 weeks. Group B (20 cases each). Blood samples were collected at baseline and every 12 weeks. ALT, AST, HBV DNA quantification and HBsAg, HBsAb, HBeAg, HBeAb, HBcAb levels were measured.

**RESULTS:** In group A, HBsAg levels decreased rapidly in the first 12 weeks and gradually declined over the next 36 weeks, the proportion of patients with undetectable HBV DNA was 100% during the observation period, and HBsAb increased significantly and stabilized. The rate of loss of HBsAg in group B was lower than that in group A. In group B, the rate of loss of HBsAg was lower than that in group B.

**CONCLUSION:** This real-world study demonstrated superior efficacy in HBsAg-positive patients after 48 weeks of treatment with PEG-IFNα2b alone than with oral medications. However, this study needs to be validated with larger sample size studies.

Abstract Submission No. 100754

**ChB patients with extremely low-level viremia - clinical characteristics and prognosis.**

Xiaonan Wu1,2,3,4, Qiao Zhang1,2,3,4, Yushan Liu1,2,3,4, Siyi Liu1,2,3,4, Qijuang Zhang1,2,3,4, Chengbin Zhu1,2,3,4, Yamin Wang1,2,3,4, Ye Lu2,3,4, Yingren Zhao2,3,4, Taotao Yan2,3,4, Yingli He5

1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China, 2Institute of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi, China, 3Shaanxi Clinical Research Center for Infectious Diseases Xi’an, Shaanxi, China, 4Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi, China, 5Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi, China

University Xi’an, Shaanxi China

**Introduction:** After 48 weeks of treatment with nucleoside analogs (NAs), some chronic hepatitis B (CHB) patients can still detect HBV DNA by high-sensitivity polymerase chain reaction, but it can not be quantified accurately. This group requires further research to define their clinical characteristics and long-term prognosis.

**Method:** CHB patients received NAs treatment for over 48 weeks were divided into 4 groups based on virological response: sustained virological response group (SVR, HBV DNA undetected), extremely low-level viremia group (eLLV, HBV DNA<2000IU/ml). Analysis of baseline characteristics, long-term biochemistry, HBV markers, and disease progression was performed for each group.

**Result:** A total of 989 CHB patients were enrolled, including SVR (n=186), eLLV (n=468), LLV (n=295), and PVR (n=40). Serum ALT, the ratio of liver cirrhosis in eLLV and SVR are compared, which is different from LLV. HBsAg and the positive rate of HBeAg in eLLV were significantly lower than LLV while higher than SVR. After a median follow-up of 5 years, The incidence of hepatocellular carcinoma was observed with no difference in eLLV (9/468 1.92%) and SVR (4/186 2.15%), but it was lower than LLV (17/295 5.76%). Moreover, eLLV had a lower re-compensation rate for liver cirrhosis (27/170, 15.9%) than SVR (24/69, 34.8%), but comparable to LLV (12/76, 15.8%).

**Conclusion:** Extremely low viral load has little short-term effect on hepatitis patients’ survival. Longer follow-up is needed for prognosis. Liver cirrhosis patients with LLV and eLLV should decrease viral load for improved prognosis.

Abstract Submission No. 100771

**The incidence of renal tubular absorption dysfunction among patients with NUC plus PegIFNα2b therapy**

En-Qiang Chen1, Yu-Jing Li1, Cheng-Run Song1, Xi-Jia Luo1, Min He1, Yong-Hong Wang1, Ya-Chao Tao1, Meng-Lan Wang1, Rong Deng1, Xue-Zhong Lei1, Hong Tang1, Tao-You Zhou1, Fang He2

1West China Hospital, Sichuan university Chengdu China

**Objective:** This study aims to evaluate the occurrence of renal tubular absorption dysfunction in CHB patients during NUC+PegIFNα2b treatment.

**Method:** This study focuses on CHB patients who received NUC+PegIFNα2b treatment at West China Hospital from February 2023 to July 2023, and evaluates the incidence of elevated urine β2-microglobulin (β2-MG) and decreased blood phosphorus during the treatment.

**Result:** A total of 92 patients were included, including 76 males and 16 females, with a median age of 37.5 years. After 12 to 24 weeks of NUC+PegIFNα2b treatment, 73.9% (68/92) developed urinary β2-MG increased, with 43.5% (40/92) less than 3 times the upper limit of normal (ULN), 6.5% (6/92) between 3-5 times ULN, 6.5% (6/92) between 5-10 times ULN, and 17.4% (16/92) more than 10 times ULN. In addition, 33.7% (31/92) of patients experienced a decrease in blood phosphorus, with 27.2% (25/92) showing a decrease of less than 20% and 6.5% (6/92) showing a decrease of 20%-60%. A total of 23 patients experienced simultaneous simultaneously β2-MG increase and blood phosphorus decrease. Among patients with TAF+PegIFNα2b, 27.3% (18/66) experienced urinary β2-MG elevation>3 times ULN, and 33.3% (22/66) showed a decrease in blood phosphorus. Among patients with ETV+PegIFNα2b, 41.7% (5/12) experienced experienced urinary β2-MG elevation>3 times ULN, and 41.7% (5/12) showed a decrease in blood phosphorus.

Abstract Submission No. 10062

**The efficacy of TDF+NUC treatment in CHB patients with high HBV DNA titer**

Haiyan Zhai1,2, Yajie Wang1,2, Meng Wang1,2, Renmin Wang1,2, Yangdong Sun1,2, Yonghong Zhang1,2, Liyang Qiu1,2

1Infectious Disease, The First Hospital of Xi’an Jiaotong University, 2Clinical Research Center for Infectious Diseases, Xi’an Jiaotong University Xi’an, Shaanxi, China

**Objective:** Evaluate the efficacy of TDF+NUC treatment in CHB patients with high HBV DNA titer.

**Method:** A total of 98 CHB patients were enrolled, including 76 males and 22 females, with a median age of 37.5 years. After 12 to 24 weeks of NUC+PegIFNα2b treatment, 73.9% (68/92) developed urinary β2-MG increased, with 43.5% (40/92) less than 3 times the upper limit of normal (ULN), 6.5% (6/92) between 3-5 times ULN, 6.5% (6/92) between 5-10 times ULN, and 17.4% (16/92) more than 10 times ULN. In addition, 33.7% (31/92) of patients experienced a decrease in blood phosphorus, with 27.2% (25/92) showing a decrease of less than 20% and 6.5% (6/92) showing a decrease of 20%-60%. A total of 23 patients experienced simultaneous simultaneously β2-MG increase and blood phosphorus decrease. Among patients with TAF+PegIFNα2b, 27.3% (18/66) experienced urinary β2-MG elevation>3 times ULN, and 33.3% (22/66) showed a decrease in blood phosphorus. Among patients with ETV+PegIFNα2b, 41.7% (5/12) experienced experienced urinary β2-MG elevation>3 times ULN, and 41.7% (5/12) showed a decrease in blood phosphorus.
35.7% (5/14) experienced urinary β2-MG elevation>3 times ULN, and 28.6% (4/14) showed a decrease in blood phosphorus.  

Conclusion: The incidence of renal tubular absorption dysfunction is relatively high among patients with NUC+PegIFNα2b combination therapy.

Abstract Submission No. 100772  
O-0165

Efficacy of antiviral therapy in ALT normal chronic HBV infection

Lei Ma1, Yan Li2, Huichun Xing3  
186 10-84322291 Beijing China, 2Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Center of Liver Diseases Division 3, Beijing Ditan Hospital, Capital Medical University Beijing China

Objective: This study aimed to assess virological response efficacy and predictive factors in antiviral-treated patients with normal ALT levels.

Methods: We reviewed 164 treatment-naive CHB patients receiving antiviral treatment (ETV, TDF, or TAP) at Beijing Ditan Hospital, Capital Medical University, between May and December 2020. Of these, 46 patients had normal ALT (ALT<50 U/L), and 118 had abnormal ALT (ALT>50 U/L). Baseline and 12, 24, and 48-week post-treatment clinical data were collected to compare virological indicators between groups. The ALT normal group was divided into complete and poor virological response subgroups based on the HBV DNA at week 48, and predictive factors were analyzed using binary logistic regression.

Results: The highest baseline ALT in the abnormal ALT group was 2106.7 U/L, the highest baseline value of Log HBV DNA was 9.2 LogIU/ml, with a mean Log HBV DNA value of 7.3 LogIU/ml. In the normal ALT group, the highest baseline Log HBV DNA was 8.5 LogIU/ml, with a mean value of 7.2 LogIU/ml. The difference of HBV DNA viral load at baseline between groups was not statistically significant (p=0.183). After 48 weeks antiviral treatment, the mean Log HBV DNA values decreased to 1.4 LogIU/ml for ALT abnormal and 1.7 LogIU/ml for ALT normal, with no statistically significant difference (p=0.062). Virological response (HBV DNA<20 IU/mL) rates in the ALT abnormal group was 62.7% (74/118), compared to 43.5% (20/46) in the ALT normal group, showing statistical significance (p=0.025). No significant differences were observed at 12 and 24 weeks (p=0.056, 0.991). HBeAg serologic conversion rates after 48 weeks were 8.5% in the ALT abnormal group and 17.4% in the ALT normal group, showing statistical significance (p=0.183). After NUCs treatment, the ALT normal group was divided into complete and poor virological response subgroups based on the HBV DNA at week 48, and predictive factors were analyzed using binary logistic regression.

Conclusion: At week 48 post-antiviral treatment, the ALT normal group exhibited a lower virological response rate than the ALT abnormal group. High HBSAg and HBeAg positivity were predictive factors for poor virological response in the ALT normal group. Larger studies are needed to validate these findings due to the small sample size.

Abstract Submission No. 100862  
O-0167

Liver volume re-compensation in HBV-related decompensated cirrhosis after NUCs therapy

Qijuan Zang1, Siyi Liu2, Juan Li3, Chengbin Zhu4, Qiao Zhang5, Yushan Liu6, Xiaonan Wu7, Yamin Wang8, Qiannan Wang1, Pan Huang1, Li Zhu9, Yingren Zhao10, Yingli He11  
1Department of Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 3Shaanxi Clinical Research Center for Infectious Diseases, Xi’an, Shaanxi, China. Xi’an China, 4Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China

Background: NUCs therapy can effectively inhibit HBV replication and enhance the long-term prognosis of individuals with HBV-related decompensation, and some patients can achieve re-compensation. Liver volume serves as a crucial measure for assessing liver reserve function, the precise impact of liver volume on re-compensation remains uncertain.

Methods: We retrospectively included 159 HBV-related decompensated patients who received NUCs treatment. All patients underwent two abdominal CT scans. Software was utilized to measure the actual liver volume (LV), while the standard liver volume (ELV) was calculated by thoracic width. The liver volume ratio (LV/ELV%) was employed to eliminate individual differences. The changes of liver volume were dynamically observed during follow-up.

Results: The cumulative re-compensation rate over a period of two years was 37.7%. Prealbumin was linearly positively correlated with LV/ELV% (r = 0.515, P < 0.001), while prothrombin time was negatively correlated with LV/ELV% (r = -0.411, P < 0.001). After NUCs treatment, LV (979.13 ±256.42 cm³ vs 1081.72 ±273.67 cm³, P < 0.05) and LV/ELV% of HBV-related decompensated patients increased, while LV (985.02 ±247.78 vs883.38 ±261.91 cm³, P < 0.01)
and LV/ELV% decreased in the persistent decompensated group. The risk of death was significantly increased in patients with LV < 950cm³ and LV/ELV% < 80%. The 5-year survival rate was significantly improved in patients with LV > 1000cm³ and LV/ELV% > 80%.

Conclusion: Patients with HBV-related decompensation can reverse liver fibrosis and enhance liver regeneration after receiving effectively NUCs treatment. Liver volume re-compensation is beneficial to long-term functional re-compensation.

Abstract Submission No. 100886
O-0168

Higher risk of disease progression in the grey zone relative to inactive Chronic hepatitis B

Yunling Xue1,2, Guorui Wang1,2, Xiaoqing Liu1,2, Qiao Tang1,2, Jingsong Wang3, Jing Zhang1,2, Mingli Peng9, Peng Hu1,2
1Chongqing Medical University Chongqing China, 2Institute for Viral Hepatitis, Chongqing Medical University, Chongqing, China

Abstract:
Background & aims: Chronic hepatitis B (CHB) remains a global healthcare burden. Inactive CHB (IC) is the commonest immune state. There are also patients with normal alanine aminotransferase (ALT) and HBeAg negative, which guidelines refer to as the IC corresponding grey zone (GZIC). There is still confusion about the evolution of disease progression in the GZIC. So we aimed to study the natural history of IC and GZIC.

Method: This was a retrospective-prospective cohort study that included 300 patients with stage IC and GZIC. Conversion to HBeAg-negative immune-active CHB (IA) and IA corresponding grey zone (GZIA), initiation of antiviral therapy, and occurrence of end-stage liver disease events were defined as outcome events. The cumulative incidence of outcome events in the IC and GZIC groups was compared.

Results: At baseline, 201 (67.00%) patients were IC and 99 (33.00%) were GZIC. 18.9% of the 300 patients with IC and 46.4% of the patients with GZIC converted to IA or GZIA. 30 (10%) received antiviral therapy, of which 22 (77.3%) were patients with GZIC and 8 (22.7%) were IC patients. Nine (3%) developed end-stage liver disease of which seven (77.8%) were GZIC and two (22.2%) were IC. The cumulative event rates for conversion to IA or GZIA, initiation of antiviral therapy, and occurrence of end-stage liver events were higher in GZIC than in IC (p <0.0001, p <0.0001, p =0.0018) (Figure 1).

Conclusion: Patients with GZIC have a higher risk of disease progression than those with IC.

Abstract Submission No. 100889
O-0169

Antiviral effect in patients with chronic hepatitis B infection in the indeterminate phase

Mingyang Feng1, Xiaoyin Wang1, Xuehui Liu1, Gangde Zhao1, Baoyan An1, Lanyi Lin1, Yezhou Ding1, Qing Xie1, Hui Wang1
1Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

Background: Emerging data suggest that a substantial proportion of patients with chronic hepatitis B (CHB) do not fall into any of the defined phases and are considered indeterminate. These CHB patients have a significantly high risk of hepatocellular carcinoma. Little is known about the effect of antiviral therapy for these patients. We aimed to investigate liver histology and assess the effect of antiviral treatment on these patients.

Methods: We retrospectively analyzed the outcomes of antiviral therapy for CHB patients in the indeterminate phase who underwent liver biopsy and were treated with nucleoside/nucleotide analogues (NAs) or polyethylene glycol interferon (PEG-IFN) for up to 96 weeks.

Results: A total of 241 patients receiving NAs (n = 206) or PEG-IFN (n = 17) or NAs + PEG-IFN (n = 18) were included, 18.7% (45 of 241) were HBeAg positive. Approximately 80% of CHB patients in the indeterminate phase had significant histological changes. At week 96, the rate of undetectable HBV DNA in NAs group, PEG-IFN group or NAs + PEG-IFN group was ~99.0%, ~88.2% or ~100.0%, respectively. No patients were found to have viral resistance to therapy. In NAs group, HBeAg clearance rate were 10% (4 of 40) at week 48. No patient had loss of hepatitis B surface antigen.

Conclusion: Majority of CHB patients in the indeterminate phase had significant liver histological changes. Antiviral therapy can effectively inhibit HBV replication in these CHB patients, although rates of HBeAg seroconversion and hepatitis B surface antigen loss were low.

Abstract Submission No. 100921
O-0170

NAFLD comorbidity predicts higher ALT and liver stiffness: A longitudinal study in CHB patients

YAN Huang1, Bingyin Du1, Shuyin Song1, Rongtao Lai1, Qing Xie1
1Shanghai Jiaotong University, School of Medicine, Ruijin hospital Shanghai China

Introduction: The impact of NAFLD in chronic hepatitis B virus (HBV) infection remains further exploration.

Methods: We enrolled 784 treatment-naïve HBV-infected patients who underwent liver biopsies. The presence of steatohepatitis was evaluated according to the NAFLD activity score (NAS). After the liver biopsy, biochemical measures and liver stiffness (LS) measurements were performed repeatedly. Mixed models were used to evaluate the associations of steatosis (NAS score 1-2) or steatohepatitis (NAS score 3-8) with longitudinal ALT, FIB-4 and LS.

Results: Among 784 patients without excessive alcohol intake, 174 (22.2%) had steatosis only and 110 (14.0%) had steatohepatitis. Steatohepatitis (versus no FLD) was associated with 1.90 times higher ALT (versus no FLD) was associated with 1.90 times higher risk of advanced fibrosis at baseline (95%CI, 1.10-3.28) and also associated with 1.20 times higher ALT (P<0.001), 1.11 times more frequent ALT elevation (P<0.001), 1.17 times higher FIB-4 (P=0.0021) and 2.20 times higher liver stiffness (P=0.0044) across eight years follow-up. Although steatosis (versus no FLD) has no association with a higher risk of advanced fibrosis at baseline and higher FIB-4 (both P>0.05) across follow-up, steatosis was associated with 1.16 times higher ALT (P<0.001), 1.08 times more frequent ALT elevation (P<0.001) and 1.70 times higher liver stiffness (P=0.017) during the follow-up period. Similar results were found in the subgroup who received antiviral treatment within 6 months after liver biopsy.

DISCUSSION: The presence of NAFLD was associated with higher hepatic inflammation and fibrosis over time, whether antiviral treatment started or not. Therefore, besides viral suppression, prevention of the progression of fatty liver is also crucial in HBV.

Abstract Submission No. 100930
O-0171
Elevated Risk of in clinical outcomes Untreated HBeAg-Positive CHB Patients in Indeterminate Phase

Vicki Wing-Ki Hui1, Grace Lai-Hung Wong1, Yee-Kit Tse1, Jimmy Che-To Lai1, Vincent Wai-Sun Wong1, Terry Cheuk-Fung Yip1

11Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), Institute of Digestive Disease Hong Kong Hong Kong

Background: The indeterminate phase of HBeAg-positive chronic hepatitis B (CHB) has not been covered by antiviral therapy in the current management guidelines. This study assessed hepatocellular carcinoma (HCC) and cirrhotic complication risks of these patients.

Methods: This was a territory-wide cohort study of untreated non-cirrhotic hepatitis B e antigen (HBeAg)-positive CHB patients with identifiable CHB phases based on their serial alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA. Patients with HBeAg-positive indeterminate phase were further classified into either the high HBV DNA group with a load of 20,000 to 1,000,000 IU/mL and normal ALT (i.e., high HBV DNA) or the low HBV DNA group with a load <20,000 IU/mL and elevated ALT (i.e., low HBV DNA).

Results: Among 11,288 patients, 54.7% were male with a mean age of 43.7 ± 13.8 years. 3,107 patients (27.5%) were in the indeterminate phase, with 78% in the high HBV DNA group. At a median follow-up of 6.2 [3.6, 9.6] months, 2,441 (78.6%) remained indeterminate. In the HBeAg-positive indeterminate phase, the high HBV DNA group showed a 10-year cumulative incidence of 6.7% vs. 4.2% (P < 0.001) and cirrhotic complications of 13.2% vs. 8.8% (P < 0.001) when compared to the low HBV DNA group.

Conclusions: HBeAg-positive indeterminate phase patients with high HBV DNA levels face significantly increased 10-year risks of HCC and cirrhotic complications. Further studies are vital to evaluate the benefits of early antiviral treatments.

Abstract Submission No. 100931
O-0172

Prolonged indeterminate phase in untreated chronic hepatitis B-infected patients

Vicki Wing-Ki Hui1, Grace Lai-Hung Wong1, Yee-Kit Tse1, Jimmy Che-to Lai1, Vincent wai-sun Wong1, Terry cheuk-fung Yip1

11Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), Institute of Digestive Disease Hong Kong Hong Kong

Background: Indeterminate phase of chronic hepatitis B (CHB) has not been covered by antiviral therapy according to the current management guidelines. We aimed to determine the transition dynamics of the indeterminate phase.

Methods: This was a territory-wide cohort study of untreated non-cirrhotic CHB patients with identifiable CHB phases based on their serial alanine aminotransferase (ALT) and HBV DNA. Indeterminate phase was defined according to the European Association for the Study of the Liver guidelines. Follow-ups were censored at the earliest event among antiviral treatment initiation, last follow-up, December 2022, or death.

Results: Of 42,837 patients, 22,166 (51.74%) were in the indeterminate phase at study entry; 6,256 (14%) of them were HBeAg-positive, with a mean age of 51.8 ± 13.9, and 56.5% were male. At a median follow-up of 11.5 [1.0, 50.2] months, 15,367 (69%) remained indeterminate, while 3,573 (16.1%) and 3,226 (15%) transitioned to immune clearance and immune active phases, respectively. For the HBeAg-positive indeterminate group, 78% stayed in the indeterminate phase at the last follow-up, with most of the rest transitioning to immune active phase, 67% of the HBeAg-negative indeterminate group remained indeterminate, with 0.13% and 18.15% transitioned to immune clearance and immune active phases respectively.

Conclusions: Most patients continue to remain in indeterminate phase over time, suggesting that this phase in CHB patients is not transient. The indeterminate phase warrants closer clinical attention, including evaluating the risks associated with clinical outcomes, specifically hepatocellular carcinoma and cirrhotic complications, in this patient population.

Abstract Submission No. 100960
O-0173

Long-term effects of tenofovir and entecavir cessation in HBeAg negative chronic hepatitis B

Onuma Sattayalertanyong1, Wimalrak Bandidnianamanon1, Julakaj Limsrivilai2, Watcharasak Chotiyaputta1, Supot Nimanong1, Tawesak Tanwandee1

11Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand

Background: Recent studies found that nucleos(t)ide analogues (NA) stopping will lead to more rapid HBsAg clearance and safe. However, few studies reported the long-term outcomes after the discontinuation. This study aim to evaluate HBsAg loss, virological relapse (VR), clinical relapse (CR), and safety after cessation of tenofovir (TDF) or entecavir (ETV).

Methods: A total of 98 non-cirrhotic HBeAg negative chronic hepatitis B patients (CHB), treated with either TDF or ETV for at least three years and virally suppressed were enrolled into TDF discontinued (TDF-D, n = 39), ETV discontinued (ETV-D, n = 27) groups compared continued group (continue, n = 32). All patients were followed for at least one year and up to 4 years after NA discontinuation.

Results: The median follow-up time was 146 weeks, and seven patients (10.6%) achieved HBsAg clearance after NA discontinuation. All of them had end-of-treatment (EOT) HBsAg levels <100 IU/ml. Cumulative incidences of VR and CR at week 48, 96 and 144 in both TDF-D, ETV-D were shown in Fig1A,B,C. The cumulative rate of HBsAg loss, VR, and CR in patients with EOT-HBsAg <100 IU/ml and ≥100 IU/ml were shown in Fig1D,E,F. EOT-HBsAg level was a significant predictor for HBsAg clearance (HR = 0.21, 95% CI 0.05–0.89, P = 0.028). Six patients in TDF-D had severe ALT flares, two required admission, and one death.

Conclusions: NA cessation led to achieving HBsAg clearance more than NA continuation and usually in the first year; however, it increased risk of VR and CR, especially TDF group, and patients with high EOT-HBsAg levels. Some resulted in early and more severe CR, which lead to hepatic decompensation and death.
Introduction and objectives: Entecavir (ETV) is a preferred antiviral for chronic hepatitis B (CHB). However, its impact on renal function in patients with CHB remains inconclusive in the literatures. The aim of this study was to comprehensively assess the impact of ETV treatment on both glomerular and tubular function in patients with CHB and to investigate the potential role of renal impairment associated with long-term ETV therapy.

Patients and methods: A total of 602 CHB patients were enrolled in this study. Propensity score matching (PSM) was utilized to balance confounding factors. Comparative analyses were performed between the ETV treatment group and non-antiviral treatment CHB group, the ETV treatment group and the tenofovir alafenamide (TAF) treatment group, as well as the ETV treatment group with more than 5 years of treatment (8.68±3.43 years) and the ETV treatment group with less than 5 years of treatment (2.31±1.22 years). Renal function indicators measured included eGFR, urinary albumin-to-creatinine ratio, urinary retinol-binding protein, urinary β2-microglobulin, urinary α1-microglobulin, serum phosphate, and serum cystatin C.

Results: After propensity score matching, no significant differences were observed in renal function indicators between the ETV treatment group and the non-antiviral treatment group (P > 0.05), between the ETV treatment group and the TAF treatment group (P > 0.05), and between the ETV treatment group with more than 5 years of treatment and the ETV treatment group with less than 5 years of treatment (P > 0.05).

Conclusions: Long-term ETV treatment shows no evident renal impairment.

Abstract Submission No. 100977
O-0175

Study on replication-competent HBV DNA in hepatitis B cirrhosis with HCC patients

Baiguo Xu1,2,3, Jia Lian1,2,3, Jing Liang1,2,3, Huiling Xiang1,2,3, Qing Ye4, Lei Liu1,2,3

1The Third Central Clinical College of Tianjin Medical University, Tianjin, China tianjin china, 2The Third Central Hospital of Tianjin Tianjin China, 3Tianjin Institute of Hepatobiliary Disease tianjin China

Background: The purpose of this study was to determine the level of replication-competent HBV DNA A in liver tissue to investigate its role in decompensation events and recompensation in patients with hepatitis B cirrhosis complicated with primary liver cancer.

Methods: The level of replication-competent HBV DNA was detected by droplet digital PCR assay (ddPCR) method with mono-over-gap rcDNA primers. The value of replication-competent HBV DNA levels with a difference between the two groups (P=0.042). In the follow-up of 16 patients with decompensated hepatitis B cirrhosis complicated with primary liver cancer, the median and interquartile distance of replication-competent HBV DNA in patients with and without decompensation were 3.50 (3.23-3.96) and 4.25 (4.04-4.45), respectively, and there was a difference between the two groups (P=0.026).

Conclusion: In patients with hepatitis B cirrhosis complicated with primary liver cancer, the level of HBV DNA replication in liver tissue is higher in patients with decompensated events. The level of HBV DNA replicating universal in liver tissue was lower in patients with recompensation.

Abstract Submission No. 100982
O-0176

Multi-parametric MRI identified chronic hepatitis B patients with subclinical liver inflammation

Irdina s Nadziruddin1, Yu Jun Wong2,3, John j Connell4, Elizabeth Shumbayawonda1, Andrea Dennis1, Rajarshi Banerjee5, Marianne Anastasia De Roza4, Ngiap Chuan Tan4, Han Chong Toh4, Jason Pik Eu Chang5, Guan Huei Lee6, Wei Lyn Yang7, Sir Michael Brady1, Pierce Chow1,8, Study Investigators AHCIC10

1Perspectum Ltd Oxford United Kingdom, 2Department of Gastroenterology & Hepatology, Changi General Hospital Singapore Singapore, 3Duke-NUS Medical School Singapore Singapore, 4Department of Gastroenterology and Hepatology, Sengkang General Hospital Singapore Singapore, 5SingHealth Polyclinic - Pasir Ris Singapore Singapore, 6National Cancer Centre Singapore Singapore Singapore, 7Department of Gastroenterology and Hepatology Singapore Singapore, 8Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore, 9Gastroenterology and Hepatology, Tan Tock Seng Hospital Singapore Singapore, 10Asia Pacific Hepatocellular Carcinoma Trials Group Singapore Singapore

Background: Chronic hepatitis B (CHB) patients with ongoing necroinflammation have elevated risk of cirrhosis and hepatocellular carcinoma (HCC). Alanine transaminase (ALT), a key serum biomarker recommended by all clinical guidelines, is used to stratify patients for antiviral therapy or cirrhosis surveillance but is often inaccurate due to the heterogeneous nature of hepatitis B virus (HBV) infections. Liver biopsy, the current reference standard, has significant well reported limitations. Iron-corrected T1 (cT1), a multi-parametric MRI (mpMRI) biomarker, correlates well with liver disease including inflammation and fibrosis, and can predict liver related outcomes. Our aim was to evaluate the utility of cT1 to identify subclinically active disease in non-cirrhotic CHB patients in biochemical remission.

Methods: This nested-cohort study within the ELEGANCE cohort (prospective multi-centre study enrolling patients at increased risk of HCC in Singapore, NCT04965259) included 77 non-cirrhotic CHB patients with paired mpMRI (LiverMultiScan®) and ALT scores. On-going inflammation and active disease was defined as cT1>800ms. Normal ALT was defined as ≤25U/L.

Results: ALT and cT1 were positively correlated (r=0.32, p=0.004). Although the majority with ALT≤25U/L had low cT1 (<800ms), 8% with normal ALT had active disease with cT1>ULN (829ms [813ms-880ms]). ALT was suboptimal at ruling-out CHB patients with ongoing liver inflammation. (sensitivity: 42.9%, specificity: 65.7%, NPV: 92.0%, PPV: 11.1%).

Conclusion: ALT levels, while commonly used for monitoring CHB patients, will miss 8% of CHB patients with subclinically active disease. cT1 using mpMRI can identify ongoing liver inflammation which in turn prevents long-term liver-related complications.

Abstract Submission No. 100986
O-0177

The effect of tenofovir amibufenamide on lipid metabolism

En-Qiang Chen1, Lan-Qing Li1, Cheng-Run Song1, Yu-Jing Li1, Xue-Zhong Lei1, Hong Tang1, Dong-Mei Zhang1, Yong-Hong Wang1, Tao-You Zhou1
Objective: To analyze the effect of tenofovir alafenamide (TMF) on blood lipid metabolism in CHB patients

Method: CHB patients treated with TMF monotherapy for more than 1 year were screened, and the blood lipid metabolism related indicators were quantitative tested before and after TMF treatment.

Result: A total of 109 patients with complete demographic and clinical follow-up data were included, and their peripheral blood cholesterol, triglycerides, high-density lipoprotein (HDL), very low-density lipoprotein (VLDL) and ApoB levels were within the normal range before receiving TMF treatment. After more than 1 year of TMF treatment, 28.4% (31/109) of patients had triglyceride levels exceeding the upper limit of normal (ULN), with 67.7% (21/31) of patients having an increase of no more than 30% of ULN; 15.6% (17/109) of patients had total cholesterol levels exceeding the ULN, with 52.6% (9/17) of patients having an increase of no more than 30% of ULN; 11% (12/109) of patients had VLDL levels exceeding the ULN, with 66.6% (8/12) of patients having an increase of no more than 30% of ULN. In this group of cases, in this group of cases, 14.7% (16/109) of patients had HDL levels exceeding the ULN. There was no significant difference in the average level of ApoB between before and after TMF treatment, but approximately 11% (12/109) of patients had peripheral blood ApoB slightly exceeding the ULN after 1 year of TMF treatment.

Conclusion: Patients treated with TMF can experience slight abnormalities in some blood lipid indicators, but the clinical significance is not yet clear.

Abstract Submission No. 101045
O-0178

Diagnostic accuracy of FAST score, NFS, FibroScan, and FIB-4 in CHB patients with NAFLD

youwen tan1, Xinyue Zhang1, cong he1

1The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang China

Objective: To evaluate the diagnostic value of the FibroScan-AST (FAST) score, non-alcoholic fatty liver fibrosis score (NFS), FibroScan, and liver fibrosis index (FIB-4) for identifying fibrotic non-alcoholic steatohepatitis (NASH) in patients with chronic hepatitis B (CHB) with non-alcoholic fatty liver disease (NAFLD).

Methods: All patients with CHB and NAFLD who underwent liver biopsy.

Results: A total of 156 patients with CHB combined with NAFLD were included, including 69 with NASH and fibrosis stage 2 or higher (NASH+F2), and 16 with NASH and cirrhosis (NASH+F4). The AUC of FAST, NFS, liver stiffness measurement (LSM), and FIB-4 for diagnosing NASH+F2 was 0.739 (P<0.001), 0.643 (P=0.006), 0.754 (P<0.001), and 0.665 (P=0.003), respectively. The specificity of FAST, NFS, LSM, and FIB-4 was 67%, 51.8%, 78.6% and 76.8%, respectively, and the sensitivity was 75%, 78.6%, 67.9%, and 53.6%, respectively. No significant differences were found between groups. The AUC of FAST, NFS, LSM, and FIB-4 for diagnosing NASH+F4 was 0.650 (P=0.038), 0.725 (P=0.001), 0.851 (P<0.001), and 0.560 (P=0.533), respectively. The specificity of the FAST, NFS, LSM, and FIB-4 was 55.9%, 50.0%, 71.6%, and 75.5%, respectively and the sensitivity was 80.0%, 100%, 100%, and 50.0%, respectively. The differences between AUCs of FIB-4 and FAST compared with LSM were 0.291 and 0.201, respectively (P<0.05).

Conclusion: In patients with CHB combined with NAFLD, FAST did not have better accuracy than NFS and FIB-4 for predicting fibrotic NASH, whereas LSM had better accuracy than FAST and FIB-4.

Abstract Submission No. 101115
O-0180

Characterization of genotypes, subtypes and prevalence of occult HBV in chronic liverdisease and HCC

Hasmik Ghazinyan1, Tatevik Shahinyan2, Saro Khemichyan3, Pascal Pineau4, Tigran Aghabekyan5

1Yerevam MSC Yerevan Armenia, 2Ecosense LLC Yerevan Armenia, 3Keck Medicine of USC LA USA, 4Institut Pasteur Paris France, 5Yerevan State Medical University Yerevan Armenia

Introduction: The specific genotypes and subtypes of the hepatitis B virus (HBV) have various biological and epidemiological behaviors. The aims of the study were to understand the distribution of HBV genotypes among patients with chronic liver disease (liver cirrhosis) and hepatocellular carcinoma in Armenian patient population, as well as to investigate the possible association of HBV genotypes with different clinical outcomes.

Methods: We used the 3rd generation polymerase chain reactions technique, droplet digital PCR (ddPCR), to identify the presence of occult HBV virus infection in the plasma of patients, as well as to identify the subtype belonging of the virus. The study included 91 cases of liver cirrhosis and 69 cases of hepatocellular carcinoma.

Results: Our study on 69 HCC cases and 91 cases of non-tumor chronic liver disease (CLD) revealed that 18.8% of HCC patients very positive for HBV (in contrast to 4.4% in CLD population). Furthermore, 46.6% of HCC patients very documented to have an occult HBV infection, as opposed to 24.1% of the CLD cases. The majority of HBV cases constituted the D subtype.

Abstract Submission No. 101094
O-0179

Engagement in care, not antiviral therapy for all, is important to reduce early mortality from HBV

David Wong1

1University Health Network, University of Toronto Toronto Canada

Background: Liver clinic established 1979, DW 2003 to present. Free healthcare includes: clinic visits, blood tests, imaging, elastography. Paper records (1979-2006) were migrated to Epic EMR (developed by DW). On June 4, 2022, all patient records were manually migrated to Epic EMR by DW. Summary analyses obtained from Slicer Dicer module within Epic. ALT and platelet counts from Jan 2010 to present were graphed and recorded in each patient chart.

Philosophy of care: 1. HBV is not complicated 2. Not everyone needs treatment 3. Stopping treatment might be beneficial.

Results: N=2,840 individual patient records were migrated to Epic from June 4, 2022 to October 28, 2023. N=1,306 (46%) had diagnoses related to chronic HBV infection. Compared to those without chronic HBV, those with HBV were less likely to have ALD (0.6% vs 14.6%), MASLD (7.5% vs 27.7%), cirrhosis (12.2% vs 30.2%), HCC (5.5% vs 8.0%) or death (1.4% vs 4.7%). Majority (53.7%) were not on antiviral therapy. Trends over time: smaller proportion of Chinese origin and HBeAg pos HBV (now 8.1%). HCC size at diagnosis was larger in those referred to clinic for HBV/HCC compared to those with HCC discovered while being followed in clinic. Of 18 deaths, only 5 died from liver-related causes. Of those followed in clinic, only 1 died from liver. He was 83, HCC first diagnosed in 2004, had multiple recurrences, death from HCC in 2023.

Conclusion: Patients with chronic HBV infection do very well when followed in clinic, even when not on antiviral therapy.

Abstract Submission No. 101094
O-0179
Conclusion: HBV isolates subtype variants correspond to the overall distribution of genotypes in this part of Eurasia, however are more prevalent than expected, especially as occult infections. Overall, circulating mutations in plasma are promising tools for diagnosis and monitoring treatment. We aim to conduct a complementary study, add on our previously found data, and specify genomic alterations to characterize them and establish relationships between the frequency of these alterations and HCC-related mortality.

Abstract Submission No. 101121
O-0181

Non-invasive MRE Assessment of Liver Injury in HBeAg-negative Patient with CHB: a Case Report

Haoyao Wang1, Hailong Zhang1, Song Liu1, Guiyang Wang2, Bing Zhang1, Jie Li3, Jun Chen8

1Department of Radiology, Drum Tower Hospital, Nanjing University Medical School Nanjing China, 2Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 3Department of Radiology, Mayo Clinic Rochester MN USA

Background and Aims: Current guidelines recommend liver biopsy in HBsAg-negative cases with normal ALT and hepatitis B virus (HBV) DNA >2000 IU/ml; however, patients at this stage typically are not willing to accept it due to its invasive nature. We reported a 59-year-old female with HBsAg-negative chronic hepatitis B virus (CHB) who visited us for CHB management; liver injury was a concern. Six months prior to this visit, the patient underwent a liver biopsy due to the concern of liver injury in another hospital where MRE was not available, and the histopathology showed G1S0. The patient never received any anti-viral treatment.

Methods: In this visit, the patient underwent a serum blood test, HBV DNA quantification, and MRE for liver injury evaluation. FIB-4 index was calculated based on the formula: FIB-4 = age [years]×AST [IU/L]/(platelets [10^9/L]×ALT [IU/L]/2).

Results: The serum HBV DNA level is high (6.52×10^3 IU/ml) and alanine aminotransferase (ALT) is normal (18 U/L). The mean liver stiffness measured by MRE is 1.97 kPa which indicates fibrosis stage 0. The FIB-4 index is 1.31. FIB > 1.28 indicates significant fibrosis with a positive predictive value of 41.4%.

Discussions and Conclusions: In HBsAg-negative patients with normal ALTs and high HBV DNA levels, it is important to evaluate liver injury for HBV management. FIB-4 shows lower sensitivity and specificity. As the most accurate noninvasive liver fibrosis diagnosis method recommended by AGA, ACR, AASLD and AAD, MRE can be used to follow up patients requiring liver injury assessment for HBV management.

Abstract Submission No. 101130
O-0182

Optimal ALT cut-off values in the grey zone of HBV infection

DaWu Zeng1, Na-Ling Kang1, Lu-Ying Wu1, Jia-Ji Jiang1, Ji-Ming Zhang4, Xue-Ping Yu2, Ai-Rong Hu1, Yue Guo4, Huan Li3, Xiang-Yang Ye5, Qing-Fa Ruan2, Zhong-Hua Lu5, Ling Wu5, Wen Jin6, Qi Zheng1

1Department of Hepatology, Hepatology Research Institute, The First Affiliated Hospital, Fujian Medical University, Clinical Research Center for Liver and Intestinal Diseases of Fujian Province, China Fuzhou China, 2Department of Infectious Diseases, The First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou China, 3Ningbo Institute of Liver Diseases, Ningbo No. 2 Hospital Ningbo China, 4Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety, Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University Shanghai China, 5Department of Infectious Diseases, Fujian Geriatric Hospital, Fujian Provincial Hospital North Branch Fuzhou China, 6Department of Infectious Disease, The Affiliated Hospital of Putian College Putian China, 7Hepatology Center, Xiamen Hospital of Traditional Chinese Medicine Xiamen China, 8Department of Liver Disease, Wuxi No.5 People’s Hospital Aflated to Jiangnan University Wuxi China, 9Department of Infectious Diseases, Anqing Municipal Hospital Anqing China, 10Department of Hepatology, Fujian Medical University Xiamen Humanity Hospital; Xiamen Quality Control Center of Infectious Diseases Xiamen China

Background and Aims: We aimed to define gender-specific, optimal alanine aminotransferase (ALT) cut-off values for the prediction of significant liver histological changes (SLHC) in grey zone (GZ) chronic hepatitis B (CHB) patients with normal ALT.

Methods: This retrospective study included 1101 consecutive GZ CHB patients with normal ALT assigned to training or internal validation cohorts. An independent cohort of 842 GZ CHB patients was included for external validation. Receiver operating characteristic (ROC) curve, smoothed curve fitting, and threshold effect analyses were performed to determine the optimal ALT cut-off values, and area under the curve (AUC) values were calculated to assess their predictive performance.

Results: SLHC was observed in 79.3% of GZ CHB patients with normal ALT (≤40 U/L). ROC curve analysis initially identified optimal ALT cut-off values of 29 U/L (male) and 22 U/L (female). After smoothed curve fitting and threshold effect analyses, the new optimal cut-off values for ALT were 27 U/L for males and 24 U/L for females. Notably, the AUCs for these values reached 0.836 (male) and 0.833 (female) in the internal validation cohort and 0.849 (male) and 0.844 (female) in the external validation cohort. Moreover, the accuracy and discriminative ability of the newly defined ALT cut-off values were greater than those of the current recommendations.

Conclusion: This study established novel optimal ALT cut-off values for more precise prediction of SLHC among GZ CHB patients with normal ALT levels. As such, the findings may help identify individuals in this patient population who will benefit from timely antiviral therapy.

Abstract Submission No. 101136
O-0183

The negative relationship between HBV DNA and liver damage loss before HBeAg clearance in CHB

Lu fengmin1, Wang leijie1,2, Li jie3, Wang jian3, Zhao kunyu4, Jiang lina4, Zhang xinxin5, Zhao jingming4

1Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University beijing China, 2Department of Microbiology and Immunology, College of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China, 3Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School Nanjing China, 4Department of Pathology and Hepatology, The Fifth Medical Center of PLA General Hospital beijing China, 5Department of Infectious Diseases, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai China

Background and Aims: The disease progression of chronic hepatitis B virus (HBV) infection is driven by the interactions between HBV, hepatocytes and the host immune. The dynamic changes in the
relationship between HBV replication and host immunity during disease progression need to be clarified.

**Method:** Two cross-sectional and one validation clinical cohort were recruited, and meta-analyses of cross-sectional cohorts were performed to explore the relationship between HBV replication and the severity of liver immunopathological inflammation. Gene expression profiling of liver biopsies in GSE84044 was used to explore the relationship between expression immune related gene and HBV DNA levels.

**Result:** A positive correlation between HBV replication and the severity of hepatic immunopathological inflammation was observed in HBeAg-negative patients but not in HBeAg-positive patients in each of the two cross-sectional cohorts, and this correlation was confirmed by meta-analysis. Further stratified analysis in these HBeAg-positive patients revealed distinct relationship patterns between serum HBV DNA levels and patients with relatively higher HBV DNA (≥2×10^6 IU/mL) and confirmed that in one validation cohort. Serum HBV DNA levels also correlated negatively with expression of immune-related genes, which was converted to a positive relationship in HBeAg-positive patients with relatively lower HBV DNA levels and in HBeAg-negative patients.

**Conclusion:** This study suggests that in patients with chronic HBV infection, a negative relationship between the serum HBV DNA level and liver injury, might already transformed to positive before HBeAg loss in HBeAg-positive patients with HBV DNA levels below 2×10^6 IU/mL.

**Abstract Submission No. 101174**
*O-0184*

**A validation study of FAL-1 score for predicting HCC risk in CHB patients treated with NAs**

Jun Inoue1, Shinichiro Minami2, Kazumichi Abe3, Mami Kida4, Hiroaki Haga5, Chikara Iino6, Hidekatsu Kuroda7, Masashi Ninomiya1, Akitoshi Sano1, Mio Iszuoka1, Atsushi Masamune1

1Department of Gastroenterology, Tohoku University Hospital Sendai Japan, 2Akita University Akita Japan, 3Fukushima Medical University Fukushima Japan, 4Kurilrara Central Hospital Kurirara Japan, 5Yamagata University Yamagata Japan, 6Hirosaki University Hirosaki Japan, 7Iwate Medical University Yahaba Japan

**Backgrounds:** Assessing the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients who are treated with nucleos(t)ide analogs (NAs) is clinically important. The aim of this study is to evaluate the utility of a previously reported FAL-1 score for stratifying HCC risk in NA-treated patients.

**Methods:** Clinical data of 303 NA-treated CHB patients from 6 hospitals were collected. After excluding patients with incomplete data, patients with a history of HCC, patients who developed HCC within one year of starting NA, and patients who were superheavy drinkers, 212 patients (male/female: 135/77, median age: 58.5, median follow-up: 7 years) were retrospectively analyzed.

**Results:** The median levels of T-bil, AST, ALT, PLT, and HBV DNA were 0.8 mg/dl, 38 U/L, 44 U/L, and 175,000/U/L, respectively. The HBeAg positivity rate was 20.7%. 267/51 patients were infected with HBV genotype A/B/C. 15/137/24/34 patients were treated with LAM/ETV/TDF/TAF as a first-line NA. The cumulative HCC incidences for 5 years were 0.8% (1/125) for score 0 (>1; FIB-4 ≤ 1.58: +1), the cumulative HCC incidences for 5 years were 0.2/2/13.7% for score 0 (n=76)/score 1 (n=106)/score 2 (n=25) (P=0.021). Notably, there was no HCC development in patients with score 0, consistent with the derivation cohort.

**Conclusion:** This study validated the usefulness of a simple FAL-1 score calculated from FIB-4 index and ALT at 1 year of NA.

**Abstract Submission No. 101222**
*O-0185*

**Reactivation of HBV in Patients With Resolved HBV Infection After Receiving DAA Treatment for HCV.**

Riaz Channa1, Nazish Butt1, Mohammed Masood1, Aman Ullah2

1Jinnah Postgraduate medical Centre. KARACHI Pakistan, 2Civil Hospital Karachi KARACHI Pakistan

**Background and Aims:** to study the risk of HBV infection reactivation while treating with direct anti-viral therapy.

**Patients And Methods:** This study was carried out on 80 patients with chronic Hepatitis C infection who were candidates for treatment with direct-acting antiviral therapy. The patients identified to carry HbsAg at baseline or with positive Hbc Antibodies were further assessed for other HBV markers: hepatitis B c antigen and serum HBV DNA quantitative measurement at baseline, at week four of starting treatment, and at the end of treatment. All patients ≥18 years of age and gender with Chronic HCV infection with inactive HBV or resolved infection were included in the study. Patients were followed for every 4-week interval for 24 weeks.

**Results:** Of our study participants, the majority were males 51 (63.7%), and females 29 (36.2%) with a mean age of 48 ± 9.5 years. At the beginning of the study, there were 32 (40%) patients who were co-infected with HCV and HBV with HBeAg + quantitative PCR for HBV DNA ≤ 20 IU/ml. 23 (29%) patients with Inactive carriers and 24 (31%) patients with resolved HBV infection. After DAAs therapy, reactivation of HBV infection was detected in 5 cases of resolved HBV infection, and 6 cases of inactive carriers showed increased HBV DNA viral load from ≤2.5 log IU/mL to 7.7 log IU/mL after completion of DAAs therapy. Treatment outcome Of HCV infection 75 (94%) patients achieved SVR.

**Conclusion:** HBV screening is strongly recommended for co-infected HCV/HBV patients before initiation and during DAA therapy. HBV reactivation can be prevented with pre-treatment screening and prophylactic treatment when necessary.

**Abstract Submission No. 101265**
*O-0186*

**Tenofovir alafenamide for treatment-naïve and nucleos(t)ide with hepatitis B virus infection**

Qin NING1, Di Wu1,2, Peng Wang1, Xiaoping Wu3, Yan Huang1, Youqin Yan1, Liang Chen1, Bing Pi1, Weiming Yan1

1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 2The First Affiliated Hospital of Nanchang University Nanchang China, 3Xiangya Hospital, Central South University Changsha China, 4Wuhan Seventh Hospital, Department of Hepatology Wuhan China, 5Shanghai Public Health Clinical Center, Fudan University Shanghai China

**Background and Aims:** Tenofovir alafenamide (TAF) has been approved for the treatment of chronic hepatitis B (CHB). We aimed to assess the effectiveness and safety of TAF-based therapy in treatment naïve (TN) or experienced (TE) CHB patients.

**Methods:** This multicenter, prospective, real-word study included 500 CHB patients treated with TAF monotherapy or combining with
entecavir (ETV) for 144 weeks. Virological and biochemical responses and safety were evaluated (clinicaltrial.gov: NCT03752658).

**Results:** 404 patients (TN, 146; TE, 258) with available data were included in this interim analysis. 13.6% had cirrhosis at baseline. All TN patients and 164 TE patients received TAF alone, and 94 TE patients received TAF plus ETV. Of TN patients, 88.7% achieved virological response (HBV DNA <20 IU/mL) at week 96. 81.8% achieved biochemical response (ALT<40 U/L) at week 96. Among TE patients switching to TAF, virological response rate was significantly increased, from 67.8% at baseline to 91.7% at week 96 (P<0.05), and biochemical response rate was 79.7% at baseline and 92.1% at week 96. Among TE patients receiving TAF+ETV, virological response rate was significantly increased from 42.0% at baseline to 91.3% at week 96 (P<0.05), and biochemical response rate was significantly increased from 80.0% at baseline to 92.9% at week 96 (P<0.05). Of 75 TE patients with low level viremia at baseline (HBV DNA <2000 IU/mL), 61 achieved virologic response at week 96. Among patients with estimated glomerular filtration rate (eGFR) below 90 mL/min/1.73m² at baseline, eGFR was significantly improved at week 96 (P<0.05). Total cholesterol levels significantly increased at week 96 (P<0.05). TAF-based therapy was well-tolerated.

**Conclusions:** TAF-based therapy was effective in both TN and TE CHB patients, as well as those with low level viremia. TAF therapy showed a sustained improvement in renal glomerular function in patients with prior impaired renal function.

Abstract Submission No. 101357

O-0187

On-treatment liver stiffness measurements predict liver-related events in patients on HBV therapy

Yameng Sun1,2, Shuyan Chen1,2, Xiaoning Wu1,2, Tongtong Meng1,2, Jialing Zhou1, Bingqiong Wang1,2, Hong You1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 2State Key Lab of Digestive Health Beijing China, 3National Clinical Research Center of Digestive Diseases Beijing China

**Background & Aims:** Baveno VII proposed a criterion based on liver stiffness measurements (LSM) to identify compensated advanced chronic liver disease (cACLD). LSM decreased significantly after antiviral therapy in chronic hepatitis B (CHB) patients. However, whether the on-treatment LSM-defined cACLD has prognostic relevance is unclear among CHB patients receiving antiviral therapy.

**Methods:** LSM was collected after at least 1-year of antiviral therapy. cACLD was defined (LSM > 15 kPa) or excluded (LSM < 10 kPa) based on Baveno VII criteria. LSM between 10 and 15 kPa were in the grey zone. Liver-related events (LREs) were defined as the first hepatic decompensation, hepato-cellular carcinoma, and death.

**Results:** A total of 694 CHB patients were included in this analysis. Patients were predominantly male (539, 77.7%) with a median age of 44 years. The median on-treatment LSM values were 7.6 (5.6, 10.7) kPa, with 494 (71.2%) patients in the non-cACLD group, 127 (18.3%) in the grey zone, and 73 (10.5%) in the cACLD group. In total, 12 decompensations and 16 HCC occurred during a median follow-up of 5.0 (3.0 - 6.8) years after the on-treatment LSM. The 5-year cumulative incidence of LREs were 1.8%, 6.3%, and 19.3% in non-cACLD, grey zone, and cACLD group, respectively (Log-rank, P<0.001). Compared to non-cACLD patients, those with cACLD had a higher risk of LREs after adjusting for age, sex, and platelet counts (adjusted HR = 3.98, 95%CI: 1.34-11.83, P = 0.013).

**Conclusions:** The on-treatment LSM could predict LREs in CHB patients during antiviral therapy.

Abstract Submission No. 101382

O-0188

M2BPGi stratifies HCC risks in chronic HBV-related cirrhosis patients after 6-year antiviral therapy

Tung-Hung Su1, Chun-Che Lin2, Chia-Chi Wang3, Wan-Long Chiang4, Cheng-Yuan Peng5, Wei-Wen Su6, Sheng-Shun Yang7, Chih-Lin Lin8, Kuo-Chih Tseng9, Shih-Jer Hsu10, Fat-Moon Suk10, Tsung-Ming Chen10, Ming-Jong Bair10, Cheng-Kuan Lin10, ia-Horng Kao1

1National Taiwan University Hospital Taipei Taiwan, 2Division of Gastroenterology, Department of Internal Medicine, Chung Shan Medical University Hospital Taichung Taiwan, 3Division of Gastroenterology, Department of Internal Medicine, Taipei Tzuchi Hospital, the Buddhist Tzuchi Medical Foundation Taipei Taiwan, 4Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan, 5Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital Taichung Taiwan, 6Department of Gastroenterology and Hepatology, Changhua Christian Hospital Changhua Taiwan, 7Division of Gastroenterology, Department of Internal Medicine, Taichung Veterans General Hospital Taichung Taiwan, 8Department of Gastroenterology, Ren-Ai Branch, Taipei City Hospital Taipei Taiwan, 9Department of Hepatology, Buddhist Tzuchi Chi General Hospital, Da-Lin Branch Chiayi Taiwan. 10The C-TEAM study group and the Taiwan Liver Diseases Consortium Taipei Taiwan

**Background:** In chronic hepatitis B (CHB)-related cirrhosis patients receiving long-term antiviral therapy, despite effective suppression of HBV viremia, the risk of hepatocellular carcinoma (HCC) persists. To personalize HCC surveillance, it is crucial to stratify the HCC risk. Mac-2 binding protein glycosylation isomer (M2BPGi), a serum liver fibrosis marker, was evaluated for its predictive role in this context.

**Methods:** We conducted a prospective cohort study to include HBV-related cirrhotic patients who received long-term antiviral therapy. They received continuous antiviral therapy with regular HCC surveillance. The M2BPGi were measured by Sysmex HISCL M2BPGi assay. Cox proportional hazard regression analysis was applied to identify risk predictors for HCC.

**Results:** A total of 501 patients were included and grouped in the “prior HCC” (n=47), “HCC” (n=56), and “no HCC” (n=398) groups at the time of M2BPGi measurement, with a median M2BPGi levels were 1.7, 1.3, and 1.0, respectively (P<0.001). Among the 454 patients without prior HCC, their median age was 60, and received a median 6.2 years of antiviral therapy. After a median of 3.3 years of follow-up, 56 patients developed HCC. M2BPGi levels <1, 1-3, and >3 mAU/mL significantly stratified the risk of HCC (logrank P=0.079). After adjusting for age, sex, and AFP, M2BPGi levels of 1-3 mAU/mL and >=3 mAU/mL increased the risks of HCC by 1.98 (95% CI: 1.05-3.74) and 2.55-fold (95% CI: 1.19-5.48), respectively, compared with M2BPGi <1 mAU/mL.

**Conclusions:** After 6 years of antiviral therapy, a high M2BPGi level proves valuable in predicting the development of HCC.

Abstract Submission No. 101428

O-0189

To determine the risk factors of Hepatitis B in children at Jinnah Postgraduate Medical Center

Hanisha Hemnani1, Nazish Butt2

1National University Hospital Islamabad Pakistan, 2Departments of Gastroenterology, University of the Punjab Lahore Pakistan
The effect of Peg-IFNα2b on metabolic status in patients with CHB combined with NAFLD

Qing Ye1,2,3,4, Huiling Xiang1,2,3,4, Jing Liang1,2,3,4, Baiguo Xu1,2,3,4, Baoxin Qian0, Chunyue Guo4

Department of Hepatology of The Third Central Hospital of Tianjin, China; The Third Central Clinical College of Naikai University Tianjin China; Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases of Tianjin Tianjin China; Institute of Hepatobiliary Disease Tianjin China

Background: To investigate the effects of different antiviral treatment regimens on virological and metabolic related indicators in patients with chronic hepatitis B combined with NAFLD.

Methods: This is a prospective observational study. The patients with CHB who met the indications of antiviral treatment of the Guidelines were collected as the research objects, and were followed up for at least 24 weeks. The therapeutic effect and impact on metabolic related indicators, including BMI, CAP, TG, uric acid and metabolic disorder of chronic hepatitis B combined with NAFLD.

Results: The mean age of patients was 11.02±2.19 years. There were 57.46% male. The frequent risk factor was blood transfusion in 23.9% of children followed by vertical transmission in 47%, horizontal transmission in 13.4%, and a prior history of surgical or dental intervention was present in 17.2% of children.

Conclusion: In this study, vertical transmission was the most common route of transmission followed by vertical transmission. Additionally, 11% of family members were HBV positive. None had comitant HCV and HDV infection. All pregnant females should be screened. Children on chronic blood transfusion therapy should be screened annually. Additionally, birth dose Hepatitis B vaccination should be implemented as a key step in HBV prevention among Pakistani children.

Key Words: Hepatitis B virus, blood-borne transmission, perinatal transmission, Horizontal transmission, Vertical transmission

Abstract Submission No. 101437
O-0190
Methods: A total of 99 patients with hepatitis B were included in the study. Blood count was taken from each patient before nucleoside analog treatment, and after detecting HBV DNA negativity.

Results: Most of the patients had F2 (46.5%) and F3 (30.3%) liver fibrosis according to the Metavir scoring system. The average HBV DNA was 6.43±1.37 log copy/mL. Tenofovir was given to 54 (54.5%) patients, entecavir to 27 (27.3%) patients, and lamivudine to 18 (18.2%) patients. NLR and MPV were significantly lower after achieving HBV DNA negativity when compared to pretreatment values (p<0.018; p<0.001, consecutively)

Conclusions: NLR and MPV may be used for predicting or monitoring HBV DNA negativity and the effectiveness of nucleoside analogs in chronic hepatitis B patients.

Keywords: Neutrophil to lymphocyte ratio, mean platelet volume, HBV DNA, nucleoside analogs

Abstract Submission No. 101488
O-0193

Development and validation of new predictive model for immune tolerance of chronic HBV infection

Tongjing Xing1, Wentao Li1, Rui Huang2, Jian Wang2, Binhao Zhang1, Quipeng Wang1, Jiang Feng1

1Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University Taizhou China, 2Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing, Jiangsu Province China

Objective To modify more accurate clinical and viral indicators and establish the new model for differentiating the different stages of chronic hepatitis B virus (HBV) infection based on liver histopathological changes.

Methods: The clinical and liver pathology data of chronic hepatitis B (CHB) patients undergoing liver biopsy were collected for retrospective analysis in the test and validation group. The area under the curve (AUC) of the receiver operating characteristic (ROC) was used to evaluate the diagnostic value for differentiating the different stages of chronic HBV infection.

Results: A total of 118 patients and 73 patients who met the diagnostic and exclusion criteria were selected as the test group and validation group. Multivariate analysis showed that HBeAg independently correlated with the IT and IC stages. The cutoff value of HBeAg used to quantitatively differentiate between IT and IC was 1335 S/CO and the AUC was 0.921 (95% confidence interval (CI): 0.836 to 0.971). A new prediction model of IT stage was established by using three indicators including HBeAg, HBsAg and HBV DNA. The AUC is 92.3% (95% CI: 86.4-98.2, P<0.001) using this prediction model. The sensitivity and specificity are 85.5% and 95.2%.

Conclusions: The high levels of HBeAg (1335s/co) rather than HBeAg positive might help to identify patients with the “true” IT stage. A predictive model for immune tolerance stage are established by combining three indicators. The new prediction model has significantly reduced the error rate compared with others standards.

Abstract Submission No. 101520
O-0195

Achieving hepatitis B elimination in the Pacific Islands: test/treat is the way forward in Kiribati

Alice Lee1,3, David Hilmer2,3, Thomas Russell1

1Concord Repatriation General Hospital Sydney Australia, 2Baylor College of Medicine Houston Texas, 3Hepatitis B Free Sydney Australia

Background: In 2016, WHO declared that hepatitis B is a global health threat with elimination targets set to be achieved by 2030.[1] Progress towards elimination is slow[2]. One barrier to progress is the lack of screening and linkage to care in isolated populations where WHO guidelines cannot be applied. The remote islands of Kiribati are geographically isolated by vast stretches of ocean. Since 2019 our group has been providing hepatitis treatment in South Tarawa, where 50% of the country’s population lives.[6] Starting in 2022, a “test and treat” program has been initiated in the outer islands.

Methods: Eleven outer islands, totalling 5497 individuals, were screened with 867 positive tests. All positive females older than 15 years were offered tenofovir alafenamide which, despite its higher cost, can be started without routine creatinine testing. This age was chosen to include all potential mothers. Males testing positive were offered treatment at age 18.

Results: The overall prevalence was 15.8%; one-third of persons 24 years or younger tested positive. Highest rates were in the 30-34 age group with a prevalence of almost 30%. The program was well-accepted by-positive patients after education about the benefits/risks of treatment. Local providers found the protocol easy to implement.

Conclusions: Hepatitis B elimination using current guidelines is not achievable in remote locations such as the outer islands of Kiribati, and a new paradigm is needed. Despite its limitations, the “test and treat” strategy appears to be the most practical and cost-effective solution to meeting elimination goals in resource-limited regions.
Liver volume re-compensation in HBV-related decompensated cirrhosis after NUCs treatment

QIUAN ZANG1, Siyi Liu1, Juan Li1, Chengbin Zhu1, Qiao Zhang1, Yushan Liu1, Xiaonian Wu1, Yamin Wang1, Qiannan Wang1, Pan Huang1, Li Zhu4, Yingren Zhao5, Yingli He6
1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 3Shaanxi Clinical Research Center for Infectious Diseases, Xi’an, Shaanxi, China. Xi’an China, 4Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China

Background: NUCs therapy can effectively inhibit HBV replication and enhance the long-term prognosis of individuals with HBV-related decompensation, and some patients can achieve re-compensation. Liver volume serves as a crucial measure for assessing liver reserve function, the precise impact of liver volume on re-compensation remains uncertain.

Methods: We retrospectively included 159 HBV-related decompensated patients who received NUCs treatment. All patients underwent two abdominal CT scans. Software was utilized to measure the actual liver volume (LV), while the standard liver volume (ELV) was calculated by thoracic width. The liver volume ratio (LV/ELV%) was employed to eliminate individual differences. The changes of liver volume were dynamically observed during follow-up.

Results: The cumulative re-compensation rate over a period of two years was 37.7%. Prealbumin was linearly positively correlated with LV/ELV% (r = 0.515, P < 0.001), while prothrombin time was negatively correlated with LV/ELV% (r = -0.411, P < 0.001). After NUCs treatment, LV (979.13 ±256.42 cm3 vs 1081.72 ±273.67 cm3, P < 0.05) and LV/ELV% of HBV-related decompensated patients increased, while LV (985.02 ±247.78 vs883.38 ±261.91 cm3, P < 0.01) and LV/ELV% decreased in the persistent decompensated group. The risk of death was significantly increased in patients with LV < 950cm3 and LV/ELV% < 80%. The 5-year survival rate was significantly improved in patients with LV > 1000cm3 and LV/ELV% > 80%. The stomach survival rate was significantly different.

Conclusion: Patients with HBV-related decompensation can reverse liver fibrosis and enhance liver regeneration after receiving effectively NUCs treatment. Liver volume re-compensation is beneficial to long-term functional re-compensation.

Optimal Threshold of M2BPGi for Predicting Minimal HCC Risk in CHB Patients with Antiviral Therapy

Tai-Chung Tseng2,4, Cheng-Yuan Peng3,4, Yoo-Chun Hsu5, Chia-Chi Wang6,8, Tung-Hung Su6, Ming-Lung Yu10, Hsueh-Chou Lai6, Jia-Horning Kao2,4
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan, 3Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei Taiwan, 4Department of Medical Research, National Taiwan University Hospital Taipei Taiwan, 5School of Medicine, China Medical University Taichung Taiwan, 6Center for Digestive Medicine, Department of Internal Medicine, China Medical University Hospital Taichung Taiwan, 7Division of Gastroenterology, Department of Internal Medicine, Taipei Tzu Chi Hospital New Taipei Taiwan, 8School of Medicine, Tzu Chi University Hualien Taiwan, 9Division of Gastroenterology and Hepatology, Department of Internal Medicine, E- Da Hospital/T- Shou University Kaohsiung Taiwan, 10School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan

Background & Aims: Mac-2 binding protein glycosylation isomer (M2BPGi) is a surrogate marker for liver fibrosis, predicting hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients receiving long-term antiviral treatment. However, the optimal threshold of M2BPGi to identify the minimal risk in these patients remains unclear.

Methods: We combined 2 cohort studies including 1283 Taiwanese CHB patients receiving long-term oral antiviral treatment. However, the optimal threshold of M2BPGi to identify the minimal risk in these patients remains unclear.

Results: We conducted a retrospective-prospective real-world study to explore the progression of liver disease after long-term drug withdrawal in HBBeAg positive postpartum woman. Finally, sixty HBBeAg positive postpartum woman discontinuing treatment for more than six months, 10 HBBeAg positive postpartum woman continuing treatment after delivery and 12 HBBeAg positive postpartum woman received NAAs treatment pre-pregnancy were eventually included.

Results: The baseline characteristics between three groups are comparable in terms of age, platelets count, APRI and FIB-4. The median follow-up time for postpartum woman discontinuing treatment was 28.8 months (6.0 - 89.2), which was comparable with the 27.6 months (6.6 - 111.7) for postpartum woman continuing treatment after delivery and 33.0 months (6.0 - 75.5, p=0.963) for postpartum woman received NAAs treatment pre-pregnancy. No postpartum women developed to liver cirrhosis or hepatocellular carcinoma in three groups. The liver stiffness value was 4.75 kPa (2.8 - 13.9) in postpartum woman discontinuing treatment, 4.1 kPa (2.7 - 6.7) in postpartum woman continuing treatment after delivery and 4.65 (3.7 - 6.4) in postpartum woman received NAAs treatment pre-pregnancy, which was comparable in three groups (p = 0.360). Moreover, APRI and FIB-4 were comparable in three groups (p > 0.05).

Conclusions: It is relatively safe for HBBeAg positive postpartum woman to discontinue NAAs treatment after delivery.
II, III, and IV compared to group I with hazard ratio (95% confidence interval, CI) of 2.7 (1.0-7.0), 4.5 (1.8-11.1), and 14.6 (6.3-33.8), respectively. This association remained significant when limiting the analysis to patients without liver cirrhosis at baseline. When stratifying these non-cirrhotic patients using single M2BPGi value of 0.55, patients with higher M2BPGi level (vs. lower M2BPGi level) were associated with increased HCC risk with age- and sex-adjusted hazard ratio of 4.3 (95% CI: 1.0-18.5). The annual HCC incidence of the non-cirrhotic patients with M2BPGi level <0.55 was 0.08% (95% CI: 0.02-0.3%).

Conclusion: In CHB patients receiving long-term antiviral treatment, our study identifies a serum M2BPGi threshold of 0.55 as a valuable marker for identifying individuals with minimal HCC risk.

Abstract Submission No. 101743
O-0199
Effects of tenofovir alafenamide on the risk of hepatocellular carcinoma in Hong Kong

Lilian Y Liang1, 2, Terry CF Yip1, 2, Vincent WS Wong1, 2, Grace LH Wong1, 2
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong China, 2Medical Data Analytic Centre (MDAC), the Chinese University of Hong Kong Hong Kong China

Background and Aims: Tenofovir alafenamide (TAF) is a novel pro-drug of tenofovir. We aimed to evaluate the one-year and two-year cumulative incidence of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving TAF treatment.

Method: This is a retrospective cohort study in Hong Kong. CHB patients who were initially treated with TAF for at least six months were included. The baseline was defined as the start date of TAF treatment. Kaplan-Meier’s method was used to evaluate the cumulative incidence of HCC with 95% confidence interval (CI).

Results: We analyzed 444 CHB patients who initially received TAF for more than six months with a mean age of 54 years old, among whom 262 (59.0%) patients were males. The median TAF treatment duration was 24 months. During a median follow-up duration of 28 months, 10 TAF-treated patients developed HCC. We then censored the time at two years to evaluate the one-year and two-year cumulative HCC incidence. The one-year and two-year cumulative incidences of HCC in TAF-treated patients were 1.2% (95%CI: 0.5% - 3.0%) and 2.9% (95%CI: 1.4% - 5.7%), respectively (Figure). The one-year HCC incidence was comparable with that of entecavir (ETV)-treated CHB patients (1.3%, 95%CI: 1.1% - 1.4%) and higher than tenofovir disoproxil fumarate (TDF)-treated CHB patients (0.1%, 95%CI: 0.01% - 0.4%), which were reported by another retrospective cohort study in Hong Kong.

Conclusion: TAF treatment is associated with a comparable HCC risk with ETV treatment, but higher than TDF treatment.

Abstract Submission No. 101756
O-0200
A random survival forest model for predicting HBeAg seroconversion in CHB patients treated with NAs

Zhiyi Zhang1, Jian Wang2, 3, Fei Cao1, Shaoqiu Zhang2, Jiacheng Liu2, Juan Xia2, Xingxiang Liu4, Jie Li1, 2, 3, Rui Huang5, Chao Wu6
1Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, 2Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 3Institute of Viruses and Infectious Diseases, Nanjing University Nanjing China, 4Department of Hepatology, Huai’an an No. 4 People’s Hospital Hua’ian China

Background: Achieving Hepatitis B e-antigen (HBeAg) seroconversion is a pivotal treatment goal for patients with chronic hepatitis B (CHB) received nucleos(t)ide analogues (NAs) treatment. We developed a novel model to predict HBeAg seroconversion in CHB patients utilizing the Random Survival Forest (RSF) algorithm.

Methods: A total of 655 CHB patients who underwent NAs treatment from Nanjing Drum Tower Hospital (Nanjing cohort) and Huai’an No. 4 People’s Hospital (Huai’an cohort) were retrospectively analyzed. The Nanjing cohort was split into a training set (n = 320) and an internal validation set (n = 138) randomly with the ratio of 7:3. The Huai’an cohort formed as an external validation set (n = 197). A predictive RSF model was constructed and validated through discrimination and calibration. The Kaplan-Meier method was employed for evaluating the risk stratification of patients.

Results: The overall HBeAg seroconversion rates were 21.9%, 18.1%, and 11.7% in the training set, internal validation set, and external validation set, respectively. The RSF-based model exhibited good calibration and relatively high accuracy for predicting HBeAg seroconversion with a C-index of 0.873, 0.734, and 0.795 in the three sets, respectively. The model effectively stratified patients into high and low-points groups, with those scoring ≥ 14.1 demonstrating a significantly higher cumulative incidence of HBeAg seroconversion compared to those with scores < 14.1 (P < 0.0001).

Conclusions: We trained and externally validated a novel RSF-based model using commonly available predictors for accurately predicting HBeAg seroconversion in CHB patients receiving NAs treatment.

Abstract Submission No. 200019
O-0201
Impact of different ALT thresholds on the treatment eligibility of patients with CHB

Hao Wang1, Xiaoqian Xu1, Shan Shan1, Yuemin Nan2, Xiaoyuan Xu3, Hui Zhuang4, Hong You1, Jidong Jia1, Yuanyuan Kong1
1Beijing Friendship Hospital, Capital Medical University Beijing China, 2Third Hospital of Hebei Medical University Shijiazhuang China, 3Peking University First Hospital Beijing China, 4Peking University Health Science Center Beijing China

Background: Treatment initiation thresholds of alanine aminotransferase (ALT) differ among international guidelines for chronic hepatitis B (CHB). The study aimed to investigate the impact of different ALT treatment thresholds on the antiviral treatment eligibility of patients with CHB.

Methods: Clinical, biochemical, and serological information of untreated patients with CHB was retrieved from a nationwide hepatitis B registry database named China Registry of Hepatitis B. The rates of treatment eligibility according to the newly updated China guidelines were estimated based on different ALT treatment thresholds.

Results: A total of 5018 patients with CHB were included, comprising 3152 males (62.81%) and 1866 females (37.19%). The overall rate of treatment eligibility per the updated Chinese guidelines would increase from 86.89% to 93.74% if the ALT treatment threshold decreased from 50/40 U/L to 30/19 U/L (males/females). For patients aged ≥ 30 years and without a family history of HCC or cirrhosis, the rates of treatment eligibility would be increased by 13.7%, 36.5%, and 55.5% if the ALT treatment threshold decreased from 50/40 U/L to 40 U/L, 35/25 U/L,
and 30/19 U/L, respectively. Furthermore, lower treatment thresholds were associated with lower fibrosis burden as measured by APRI and FIB-4 scores.

Conclusions: Lowering the ALT treatment threshold could benefit more patients who are already at higher risk of disease progression. Expanding treatment in China would contribute to achieving the global goal of reduction in HBV-related mortality by 2030.

Abstract Submission No. 200097
O-0202

Enhancer 1 unevenly activates the preS1 promoter of integrated HBV DNA and impacts HBsAg secretion

Fengmin Lu¹, Zhiqiang Gu¹
¹Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Background & Aims: The expression of HBsAg from integrated HBV DNA limits the achievement of functional cure for chronic hepatitis B. Thus, characterizing the unique expression and secretion of HBsAg derived from integrated HBV DNA is of clinical significance.

Approach & Results: A semi-quantitative analysis of intrahepatic HBsAg protein level in 563 treatment-naïve patients revealed that, in contrast to the significantly lower serum HBsAg levels, no significant decrease of intrahepatic HBsAg protein was observed in the HBsAg-negative patients, as compared to that in HBeAg-positive patients. In vitro studies of integrated HBV DNA mimic and long-read RNA sequencing of liver biopsy from patients revealed that, the lower HBsAg secretion efficiency seen in HBeAg-negative patients might be attributed to a relative increased proportion of 2.4 kb HBV RNA derived from integrated HBV DNA than covalently closed circular DNA (cccDNA), which resulted in L-HBsAg over-expression and the subsequent impaired HBsAg secretion. Mechanistically, the change of 2.4 kb HBV RNA proportion was caused by retargeting and uneven activation on preS1 (SP1) than preS2 (SP2) promoters by HBV enhancer 1 (EnhI) element, largely due to the loss of core promoter (CP) in integrated HBV DNA.

Conclusions: The secretion of HBsAg originated from integrated HBV DNA was impaired. Mechanistically, functional deficiency of CP leads to the promoter(s) retargeting of EnhI and uneven activation of SP1 over SP2, resulting in an increase in proportion of L-HBsAg.

Abstract Submission No. 200252
O-0203

Clinical Predictors of Functional Cure in CHB Patients Treated with Pegylated Interferon Alpha-2b

Yuanmei Chen¹-², Li Zhu¹, Chuan Wu Zhu¹
¹The Fifth People's Hospital of Suzhou su zhou China, ²Soochow University su zhou china

BACKGROUND & AIMS: Functional cure of chronic hepatitis B (CHB) is now the goal of treatment, but is rarely achieved with current therapy, such as pegylated interferon or long-term nucleos(t)ide analogues (NUCs). In this study, we aimed to explore the novel biological indicators in peripheral blood that can predict the efficacy of pegylated interferon alpha-2b (PEG-IFN α-2b) treatment for CHB and its clinical significance.

Methods: This observational study retrospectively enrolled CHB patients who were treated with PEG-IFN α-2b at the Fifth People's Hospital of Suzhou from January 2020 to May 2023, a total of 151 patients. We comprehensively analyze the expression levels of 83 indicators at the baseline in the patients, including hemocyte indicators, biochemical indexes and serum virologic markers. According to the achievement of functional cure (FC group, n = 43) or non-achievement of functional cure (NFC group, n = 108) at End-of-treatment, the data were analyzed and grouped. Statistical analysis using GraphPad Prism 9.5.1, SPSS 26.0, and MedCalc.

Results: Thirteen blood markers such as Hepatitis B surface antigen (HBsAg), hepatitis B antigen (HBeAg) and hepatitis B virus-deoxyribonucleic acid (HBV DNA) at baseline showed differences between the FC groups and NFC groups treated with PEG-IFN α-2b (p < 0.05). In contrast, women are more likely to achieve a functional cure with interferon therapy. HBsAg and lipoprotein(a) (Lp(a)) were associated with FC, with AUROCs of 0.87 (0.750 - 0.914, p < 0.0001) and 0.77 (0.657 - 0.846, p < 0.0001). A combination of HBsAg < 2.09 log10U/ml and Lp(a) > 123.3 mg/L at baseline had a effective predictive for FC with an AUROC of 0.902 (0.824 - 0.953, p < 0.001). In the advantaged groups treated with PEG-IFN-α-2b, Lp(a) and Mononuclear cell ratio (MONO %) also can be used to predict FC with AUROCs of 0.74 (0.587 - 0.981, p = 0.004) and 0.71 (0.552 - 0.842, p=0.001) besides HBsAg, HbsAb and HBV-DNA.

Conclusions: The Higher Lp(a) at baseline with PEG-IFN-α-2b, the easier to achieve functional cure. A predictive model constructed using baseline HBsAg and Lp (a) in CHB patients had good predictive value for achieving functional cure treated with PEG-IFN.

Keywords: PEG-IFN-α-2b, functional cure, lipoprotein(a), HBsAg, CHB

Abstract Submission No. 101165
O-0204

Cost of Hepatitis C Virus self-testing in Malaysia: A micro-costing study

Asra Asgharzadeh¹, Xiaohui Sem³, Huan-Keat Chan³, MR Abu Hassan³, E Reipold³, Peter Vickerman¹, Sonjelle Shilton², Josephine Walker¹
¹Bristol Medical school, University of Bristol, Bristol,UK Bristol United Kingdom, ²FIND Geneva Switzerland, ³Clinical Research Centre, Hospital Sultanah Bahiyah, Alor Setar Malaysia Malaysia

Background: The seroprevalence of Hepatitis C virus (HCV) is 3%-2.5% in Malaysia’s general population, with 4.6% prevalence in men who have sex with men (MSM), and 74.0% among people who inject drugs (PWID) on methadone maintenance treatment. A cohort study led by FIND, Malaysian AIDS Council and Malaysian Ministry of Health in 2021-2022 provided HCV self-tests (HCVST) through an existing online platform (Jom-Test) for HIV self-testing. We calculated the economic cost of HCVST in this study.

Methods: Participants were randomized to the intervention (249 in oral-fluid-based HCVST group, 250 in blood-based HCVST group, each receiving HCVST kits and instructions delivered by mail) and control groups (250, received information about facility-based HCV testing). Costs were gathered from program expenditure records in local currency units and converted to 2021 US Dollars. Research-specific costs were excluded.

Results: Most participants (92%) identified as MSM and 1% as PWID. There was 98% uptake of HCV testing in the HCVST arms compared to 51% in the control group. Total fixed costs were $113,463 (63.4% staff, 19.3% start up, 11.0% recurrent, 1.9% equipment, 1.3% overhead), with $4,125 total variable costs (test kit and delivery costs). There was 98% uptake of HCV testing in the HCVST arms compared to 51% in the control group. Total fixed costs were $113,463 (63.4% staff, 19.3% start up, 11.0% recurrent, 1.9% equipment, 1.3% overhead), with $4,125 total variable costs (test kit and delivery costs). Mean HCVST costs per patient were $165 (oral-fluid; $151 fixed and $14 variable) and $154 (blood; $151 fixed and $3 variable).
Conclusion: This micro-costing estimates the cost of HCVST in Malaysia, but cost-effectiveness of HCVST will depend on screening yield/prevalence, and numbers reached for testing. Few PWID participated, indicating that reaching this population may require different targeted approaches.

Abstract Submission No. 101894
O-0205

Hepatitis C Virus (HCV) Transmission among Japan’s Limited Risk Groups

Zayar Phyo1,2, Ko Ko1,2, Aya Sugiyama1,2, Tomoyuki Akita1,2, Kazuaki Takahashi1,2, Satoshi Tanaka1,2, Ryotaro Sakamori2, Junko Tanaka1,2

1Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Science, Hiroshima University Hiroshima Japan, 2Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma, Hiroshima University Hiroshima Japan, 3Department of Gastroenterology, National Hospital Organization, Osaka National Hospital Osaka Japan

Background: In Japan, despite low nationwide hepatitis C incidence, new infections persist among people who inject drugs (PWID) and men who have sex with men (MSM), hindering HCV eradication. Therefore, this study aimed to explore the status of HCV transmission among those groups in Japan.

Methods: Hiroshima University and the Gastroenterology Department of National Hospital Organization, Osaka, conducted a retrospective cohort study, recruiting HCV-infected patients from January 2009 to December 2023. Patients were recruited both prospectively and retrospectively, with serum samples collected before anti-HCV treatment. HCV RNA was extracted, and the full core region (576 base-pairs) was sequenced using the Sanger method. Genotype distribution was determined by phylogenetic analysis.

Results: We have already received 108 samples with additional 17 samples awaiting analysis. The updated results will be presented at the conference. As of now, the subjects were divided into four groups: non-MSM PWID (27), MSM PWID (15), MSM non-PWID (23), and non-MSM non-PWID (43). Of the 108 samples analyzed, 107 could be sequenced. The most common genotype among non-MSM PWID was 2a (56%), while in the MSM PWID, MSM non-PWID, and non-MSM non-PWID groups, it was 1b (87%, 65%, and 70%, respectively). By phylogenetic tree, clusters were found only in MSM but not in PWID. Moreover, non-MSM non-PWID were not closed to either MSM or PWID.

Conclusion: The transmission route for PWID is determined by MSM status, whereas the MSM group exhibited the same transmission route regardless of PWID, emphasizing prioritized control measures among MSM for HCV elimination in Japan.

Abstract Submission No. 100316
O-0207

Improvement of Hepatitis C Virus Care Cascade by In-hospital Reflex tEsting ALarm-C (REAL-C) model

Jonggi Choi1, Jina Park1, Won-Mook Choi1, Danbi Lee1, Ju Hyun Shim1, Kang Mo Kim1, Young-Suk Lim1, Han Chu Lee1

1Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background: WHO has set targets to eliminate viral hepatitis, including HCV infection, by 2030. Achieving these goals necessitates improved rates of diagnosis and treatment. We present the results of the in-hospital Reflex tEsting ALarm-C (REAL-C) model, which incorporates reflex HCV RNA testing and sending alarming messages for physicians.

Methods: We conducted a retrospective study at Asan Medical Center in Seoul, Republic of Korea, focusing on 1,730 patients newly testing positive for anti-HCV between March 2020 and June 2023. Three distinct periods were defined: pre-REAL-C (n=696), incomplete REAL-C (n=515), and complete REAL-C model periods (n=519). The primary outcome measured was the rate of HCV RNA testing throughout the study period. Additionally, the referral rate to GI department, linkage time for diagnosis and treatment, and the treatment uptake rate.

Results: Rate of HCV RNA testing increased significantly from 51.0% (pre-REAL-C) to 95.6% (complete REAL-C). This improvement was consistent across clinical departments, regardless of patients’ comorbidities. Among patients confirmed with HCV infection, the GI referral rate increased from 57.1% to 81.1% after the implementation of the REAL-C model. Treatment uptake rates among treatment-eligible patients was 92.4% during the study period. The mean days from anti-HCV positivity to HCV RNA testing decreased from 45.1 to 1.9. The mean days from the anti-HCV positivity to direct-acting antiviral treatment also decreased from 89.5 to 49.5 with the REAL-C model.

Conclusion: The REAL-C model, featuring reflex testing and alarming messages, effectively increased HCV RNA testing rates and streamlined care cascades. Our model facilitated progress toward achieving the WHO’s elimination goals for HCV infection.

Abstract Submission No. 200246
O-0206

Improving HCV Diagnosis: Precision Classification with Data Mining for Identifying Suspected Patients

Prihantini Prihantini1, Rifaldy Fajar2

1Bandung Institute of Technology Bandung Indonesia, 2Karlstad University Karlstad Sweden

The global prevalence of chronic hepatitis C virus (HCV) infection affects an estimated 58 million people, with approximately 1.5 million new infections reported annually. Consequently, the development of precise prediction models utilizing machine learning techniques is highly valuable. This study aimed to employ data mining techniques to classify individuals suspected of having HCV infection through various classification models. The research incorporated multiple methods, including data visualization with clean data, standard-scaler for data normalization, and the creation of dummy variables. Additionally, the study involved transforming and splitting data for training and testing, applying the Synthetic Minority Over-Sampling Technique (SMOTE) on the training dataset, and evaluating model performance using various metrics. Research outcomes were detailed based on patient-specific variables such as Age, Sex, ALB, ALP, ALT, BIL, CHE, CHOL, CREA, GGT, and PROT. The application of machine learning to a dataset of HCV-suspected patients demonstrated notable progress in healthcare precision. The Random Forest (RF) algorithm emerged as superior, exhibiting high accuracy and AUC values. This study underscores the importance of data mining, particularly highlighting the efficacy of the RF model, in advancing the detection of HCV. The integration of SMOTE effectively addressed imbalances in datasets, contributing to an improved model performance.
Factors of aggravation of esophagogastric varix after DAA in HCV decompensated cirrhotic patients

Yuki Tahata1, Hayato Hikita1, Satoshi Mochida2, Daiki Miki3, Akio Ido4, Nobuyuki Enomoto5, Rytotto Sakamor1, Takahiro Kodama1, Tomohide Tatsunii2, Tetsuo Takehara1

1Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan, 2Department of Gastroenterology and Hepatology, Saitama Medical University, Saitama, Japan, 3Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan, 4Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University, Kagoshima, Japan, 5First Department of Internal Medicine, Faculty of Medicine, University of Yamanashi, Yamanashi, Japan

Background: Sustained virologic response (SVR) rate of direct-acting antiviral (DAA) therapy has been reported to be approximately 90% in patients with hepatitis C virus (HCV) associated decompensated cirrhosis. However, the factors associated with the aggravation of esophagogastric varix after DAA in patients with decompensated cirrhosis is unclear.

Methods: A total of 116 patients with HCV associated decompensated cirrhosis who started DAA therapy from February 2019 to December 2021 and for whom esophagogastric varix could be evaluated before and after DAA were included. We defined the aggravation of esophagogastric varix as rupture of varix and treatment for varix, and investigated the cumulative rate of and the factors associated with the aggravation of esophagogastric varix.

Results: The median age was 67 years, and 78% of patients were Child-Pugh B. The SVR rate was 95.7% (111/116). During the median observation period of 17.9 months from the start of DAA, 15 patients underwent treatment for varix and two underwent varix rupture. The 3-year cumulative aggravation rate of varix was 22.4%. In multivariate analysis, baseline status of esophagogastric varix was a significant predictor (p=0.018) and virologic failure (p=0.015) were significantly associated with the aggravation of esophagogastric varix. On the other hand, Child-Pugh class and alcohol intake were not.

Conclusions: Among patients with HCV associated decompensated cirrhosis treated with DAA, careful attention for the aggravation of esophagogastric varix are needed in patients with esophagogastric varix of F2 or more, higher baseline γ-glutamyl transpeptidase levels or virologic failure.
Abstract Submission No. 101032
O-0211

Long term outcome following HCV treatment with Glecaprevir/Pibrentasvir in people who use drugs

Brian Conway1,2, Shana Yi3, Rossitta Yung1, Shawn Sharma1, Saina Beita1
1Vancouver Infectious Diseases Centre Vancouver Canada, 2Simon Fraser University Burnaby Canada

Background: Long-term outcome data after HCV treatment are limited, especially for individuals who use drugs. In this study, we investigated the long-term outcomes of patients who achieved SVR12 with G/P treatment.

Methods: We followed up with patients who achieved SVR12 (2019-22). Participants were documented to be viremic with any HCV genotype, non-cirrhotic, previously untreated for their infection, and actively using or injecting drugs before initiating treatment and all received G/P as three tablets daily for eight weeks within the context of a multidisciplinary model of care.

Results: We identified 108 subjects with a median age of 47 (22-75) years, 27.8% female, and 21.3% Indigenous. Nearly half (46.7%) did not have stable housing. Active drug use was confirmed in 97.2% of cases, and all participants achieved SVR12 during the study. Among the cured participants, 104 (96.3%) remained alive, and 4 individuals died of an opioid overdose. Out of the 104 patients, 98 (94.2%) remained HCV-free, and 6 (5.8%) were re-infected (rate of 0.006/100 person years). All 6 have recently initiated therapy and outcomes of repeat therapy are pending.

Conclusion: To achieve the goal of HCV elimination by 2030, a systematic approach to diagnosing and treating infections in PWUD will be crucial, including maintenance in long-term follow-up after cure. Most patients remain alive and cured, with a small number of overdose deaths in the context of an ongoing opioid crisis. Maintenance in follow-up allowed us to identify all cases of reinfection and re-initiate therapy within our program.

O-0212

Association of metabolic abnormalities with HCC development and survival in CHC patients after SVR

Mina Nakagawa1, Miyako Murakawa1, Masato Miyoshi1, Shun Kaneko1, Fukiko Kawai-Kitahata1, Sayuri Nitta1, Sei Kakinuma1, Yasuhiro Asahina1, Ryuichi Okamoto1
1Tokyo Medical and Dental University (TMDU) Tokyo Japan

Aims: The risk of carcinogenesis and liver-related or -unrelated death after SVR among patients with HCV has not been fully elucidated. Lifestyle factors have recently received attention as a risk factor, and we aimed to elucidate the association of metabolic abnormalities with liver carcinogenesis and prognosis after SVR with DAA.

Patients and Methods: A multicenter registry study, 1089 of 1267 patients without a history of HCC prior to DAA treatment enrolled from September 2014 to August 2023 who had achieved SVR were included in the study. The start date of follow-up is defined as the date of achieving SVR. Cox proportional hazards regression model was used to determine factors associated with the development of cancer and death among patients with and without prior history of HCC by using STATA 16 (StataCorp LP, College Station, TX, USA).

Results: The median number of follow-up was 3.8 years. Fifty-two patients (4.8%) without a prior history developed HCC. The following factors were identified as contributors to carcinogenesis: male (HR 2.0, p=0.018), diabetes (HR 2.1, p=0.023), SVR-Plt < 150,000 (HR 2.1, p=0.009), SVR-GGT (HR 2.5, p=0.015), and hypovascular nodule (HR 8.4, p<0.001). Extracted in univariate analysis. Even after adjustment for diabetes, dyslipidemia, alcohol consumption, obesity, and fatty liver, high SVR-GGT was associated with carcinogenesis (HR 2.4, p=0.030), and high SVR-GGT was a risk of carcinogenesis in the no alcohol consumption and no diabetes group (n=560) (HR 10.6, p<0.001). Next, life expectancy analysis revealed 45 deaths (4.1%) after SVR, 9% from liver cancer, 22% from other organ cancer, and 42% from cardiovascular death or CPA/drowning. Univariate analysis extracted factors involved in death as age >70 (HR 1.8, p=0.044), diabetes (HR 2.0, p=0.044), and Alb < 3.5 (HR 5.3, p=0.001), although only low Alb was significant (HR 3.6, p=0.023) after adjustment for metabolic abnormalities. When stratified by platelet level, diabetes (HR 3.1, p=0.017) and high SVR-GGT (HR 6.1, p=0.002) were associated with death in the group with platelets over 150,000.

Conclusion: Patients with elevated GGT after SVR are at high risk of HCC regardless of their metabolic abnormalities and lifestyle, and are also at high risk of death including cardiovascular events and malignancies of other organs. GGT levels after SVR may reflect hepatitis C-specific oxidative stress as well as induction by lifestyle factors such as alcohol consumption and diabetes mellitus.

O-0213

Real world outcomes of sofosbuvir/velpatasvir/voxilaprevir in naive chronic hepatitis C patients

Fehmi Tabak1, Tansu Yamazhan2, Oguz Karabay1, Ayse Ineci4, Gurdal Yilmaz2, Ozlem Altuntas Aydin4, Yesim Caglar7, Ilknur Senel1, Arzu Altincekic Yildirim5, Rahmet Guner10
1Istanbul University Cerrahpaşa Medical Faculty Istanbul Turkey, 2Ege University Medical Faculty Izmir Turkey, 3Sakarya University Medical Faculty Sakarya Turkey, 4Istanbul Training and Research Hospital Istanbul Turkey, 5Kadimiz Technical University Medical Faculty Trabzon Turkey, 6Basaksehir Cam Ve Sakura City Hospital Istanbul Turkey, 7Balikesir University Medical Faculty Balikesir Turkey, 8Giresun University Medical Faculty Giresun Turkey, 9Ordu University Medical Faculty Ordu Turkey, 10Ankara City Hospital Ankara Turkey

Background: Pan-genotypic Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for 8-12 weeks has been shown highly effective, safe, and well-tolerated in treating patients with chronic hepatitis C (CHC) in POLARIS studies, however, there are no real-world setting data are available especially in treating naïve patients. This is the first opportunity from all over the world to demonstrate SOF/VEL/VOX efficacy and safety in Real World setting for the naïve patients.

Methods: SOF/VEL/VOX was approved in Turkey to use pan-genotypically for noncirrhotic naïve, cirrhotic naïve, treatment experienced patients for 8, 12 and 12 weeks respectively. We presented preliminary results of naïve CHC patients.

Results: Of the 180 patients 89.4% (n=161) were naïve, 42.9% (n=69) completed 12th week follow-up after the completion of the 8 (n=65) or 12 weeks treatment. Of these 69 patients 47.8% were female, median age was 59 (24-85), 77.3% were genotype 1 and 68.2% were genotype 1b. Median HCVRNA at the time of diagnosis were 1.310.000 IU/mL (19.426-10.000.000). Undetectable HCVRNA levels at the first month, end of the of treatment were 87.3% and 100% respectively and SVR12 were 98.6% (68/69). One relapsed patient was genotype 4. Median ALT levels were 36.0, 17.0 and 15.0 IU/L at diagnosis, end of the treatment and at the SVR12 follow-up respectively. There were not any treatment interruption or adverse event leading to treatment cessation.
Conclusion: SOF/VEL/VOX combination treatment is safe and presenting high SVR12 rates for the naïve CHC patients, further results with the high number of patients will be needed to prove this preliminary results.

Abstract Submission No. 101668
O-0214

Elevated GGT with metabolic factors enhances HCC development after HCV eradication
Hiroshi Naito1, Hitomi Sezaki1, Hiromitsu Kumada1
1Toranomon Hospital Tokyo Japan

Background: Gamma-glutamyltransferase (GGT) is known as an oxidative stress marker, but its association with the development of hepatocellular carcinoma (HCC) after sustained viral response (SVR) in patients infected with hepatitis C virus (HCV) is still unclear. We investigated the risk stratification using GGT after SVR.

Methods: The study enrolled 4773 patients who had achieved SVR with antiviral treatment and had no prior history of HCC. The definition for normal GGT was ≤32 IU/L in female and ≤64 in male. We analyzed the impact GGT and some metabolic factors at SVR 24 on subsequent HCC incidences.

Results: The median observation period was 6.7 years. Annual HCC rate was 4.7 per 1000 person-years. To examine the impact of GGT on the development of HCC, we classified the subjects into 4 groups; Group A: normal GGT with no alcohol and low BMI, Group B: normal GGT with alcohol or high BMI, Group C: high GGT with no alcohol and low BMI, Group D: high GGT with alcohol or high BMI. The 10-year cumulative HCC rates were in the order of Group D > B > C > A (8.2%, 4.9%, 1.8%, and 1.5%, respectively) (P < 0.001). Similar results were observed in multivariable Cox regression.

Conclusion: HCC incidence was lower in patients with normal GGT even if they had a history of alcohol consumption and obesity. On the other hand, elevated GGT enhance HCC development in those with a history of alcohol consumption or obesity. Further investigation is needed to clarify its mechanism.

Abstract Submission No. 101882
O-0216

Mortality rates among patients successfully treated for HCV: A real world multinational cohort study
Fanpu Ji1, Eiichi Ogawa2, Takanori Suzuki3, Chung-Feng Huang4,5, Yu Jun Wong6, Hidenori Toyoda7, Sally Tran8, Makoto Chuma9, Mindie H. Nguyen10
1The Second Affiliated Hospital of Xi’an Jiaotong University Xi’an China, 2Kyushu University Hospital Fukuoka Japan, 3Nagoya City University Graduate School of Medical Sciences Nagoya Japan, 4Kaohsiung Medical University Kaohsiung China, 5Kaohsiung Medical University Hospital Kaohsiung China, 6Changi General Hospital Singapore Singapore, 7Singhealth Duke-NUS Medicine Academic Clinical Program Singapore Singapore, 8Ogaki Municipal Hospital Ogaki Japan, 9Stanford University Medical Center Palo Alto United States, 10Yokohama City University Medical Center Yokohama Japan

Objectives: HCV cure with SVR following DAA treatment reduces mortality risk, but data on risk factors associated with mortality following DAA-associated SVR are sparse. We aimed to fill in this gap.

Methods: 11,451 patients with SVR were enrolled in a real-world multinational cohort from 39 REAL-C clinical sites, and divided into four liver disease severity groups: non-cirrhosis (group 1), compensated cirrhosis (group 2), decompensated cirrhosis (group 3) and HCC (group 4). Follow-up started 24 weeks after antiviral treatment completion and ended-on-date-of-death or end-of-study follow-up (31/08/2023), whichever came first.

Results: 704 (6.2%) participants died during a 4.6±2.4 years follow-up: 124/207/133/240 in group 1/2/3/4, respectively, yielding corresponding all-cause mortality rates per 1000 person-years (95%CI) of 5.06 (4.24-6.03), 10.2 (8.86-11.6), 46.5 (39.2-55.1), and 49.4 (43.5-56.1). For patients without HCC at baseline, mortality rates stratified by age, sex, DM and liver fibrosis severity were shown in Fig.1A. For patients with HCC at baseline, mortality rates stratified by sex, age, and presence of active HCC were shown in Fig.1B. In multivariable analyses, older age(>65 years:3.1 times), male(1.4 times), fibrosis severity (4.7/1.7 times for decompensated/compensated cirrhosis), HCC receiving direct-acting antivirals (DAAs) including older regimens in routine practice, focusing on GT3/6.
Impact of DAAs on HCC Risk in Chinese Hepatitis C Patients: A 10-Year Follow-Up Study

Peng Huang1, Linna Jia1, Xiangyu Ye1, Yanzheng Zou2, Sheng Yang2, Rongbin Yu1

1Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University Nanjing China, 2Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University Nanjing China

Abstract Submission No. 100106
O-0217

Conclusions:

1. The long-term benefit of direct-acting antiviral agents (DAAs) therapy after achieving sustained virologic response (SVR) has not been clearly established, particularly in the Chinese population.
2. Achieving SVR is associated with significantly reduced risk of HCC in patients treated with DAAs.
3. Dynamic serum M2BPGi levels have been shown to predict hepatic fibrosis in HCV patients achieving SVR to DAAs.

Dynamic serum M2BPGi to predict hepatic fibrosis in HCV patients achieving SVR to DAAs

Chen-Hua Liu1, 2, 3, Ji-Yuh Lee3, Chun-Jen Liu4, 2, 4, Tung-Hung Su2, 5, Shang-Chin Huang4, Tai-Chung Tseng3, 2, 4, Pei-Jer Chen5, Jia-Horng Kao1, 2, 4, 6

1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan, 3Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch Douliou Taiwan, 4Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei Taiwan, 5Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch Taipei Taiwan, 6Department of Medical Research, National Taiwan University Hospital Taipei Taiwan

Background:

Little is known about the role of dynamic serum Mac-2 binding protein glycosylation isomer (M2BPGi) levels to assess hepatic fibrosis in hepatitis C virus (HCV)-infected patients who have achieved sustained virologic response (SVR12) to direct-acting antivirals (DAAs).

Methods:

Serum M2BPGi levels and liver stiffness measurement (LSM) using transient elastography (TE) were evaluated in 638 patients who achieved SVR12. Receiver operating characteristic (ROC) curves were generated to assess the diagnostic accuracy of baseline and SVR12 serum M2BPGi levels in distinguishing a fibrosis stage ≥F2, ≥F3, and F4. The selected M2BPGi cutoff levels at baseline and SVR12 were determined based upon the maximal Youden index, and optimized positive and negative likelihood ratios (LRs).

Results:

Compared to baseline level, the median serum M2BPGi level at SVR12 significantly decreased (1.55 versus 0.92, p < 0.001), irrespective of the fibrosis stage. The areas under ROC curves (AUROCs)
of M2BPGi in predicting a fibrosis stage of ≥ F2, ≥ F3, and F4 were 0.854, 0.914, and 0.947 at baseline, and 0.814, 0.913, and 0.937 at SVR12, respectively. M2BPGi, with cutoff values of 2.05, 2.83, and 3.98 at baseline, and 1.49, 1.58, and 1.75 at SVR12 exhibited predictive power for the presence of ≥ F2, ≥ F3, and F4, with positive likelihood ratios (LRs) of ≥ 10. The diagnostic accuracy of M2BPGi appeared to increase with the severity of hepatic fibrosis.

**Conclusions:** The dynamic serum M2BPGi level can monitor the severity of hepatic fibrosis in HCV-infected patients before and after SVR12 to DAA treatment.

---

**Abstract Submission No. 100194**

**O-0220**

**Non specialist training: an effective method for micro-elimination of hepatitis C in hospital**

Qing Ye1,2, Yu Zhu2,3, Fushuang Hai1,2, Yu Wu2,4, Tao Han5

1Department of Hepatology of The Third Central Hospital of Tianjin, China Tianjin China, 2The Third Central Clinical College of Naikai University, Tianjin, China Tianjin China, 3Department of Medical Laboratory of The Third Central Hospital of Tianjin, China Tianjin China, 4Department of Infection of The Third Central Hospital of Tianjin, China Tianjin China, 5Tianjin Union Medical Center, Naikai University Affiliated Hospital, Tianjin, China Tianjin China

**Background/aims:** WHO aims to eradicate HCV infection by 2030. However, the current situation of eliminating hepatitis C is not satisfactory, as many patients were missed. The purpose of this study was to explore an effective method for micro-elimination of hepatitis C in hospital.

**Methods:** Online questionnaire was used to investigate the HCV knowledge of the non specialists from 7 medical centers in Tianjin. Then they received a brief training for the diagnosis and treatment of hepatitis C. Then the effect of training was investigated by rate of referral, diagnosis and treatment of HCV patients.

**Results:** More than half of hepatitis C antibody positive patients are distributed in non liver disease departments. 459 questionnaires were retrieved and we found that only 26.4% non specialists who found hepatitis C antibody positive were familiar with the following screening step (HCV RNA). Additionally, 8.7% of doctors were familiar with the DAA drugs for hepatitis C treatment, and 78.4% were completely unaware of the hepatitis C medical insurance policy. The rate of HCV screening, diagnostic and treatment in non liver disease departments were 67.2%, 41.1% and 47.3% before trained, however, the rates were 92.3%, 92.1% and 94.4% after the training (P all <0.001).

**Conclusions:** There was a huge obstacle to the elimination because the low awareness of hepatitis C in non specialists. A brief training could significantly improve the effect of diagnosis and treatment. This may be an effective and fast way for us to achieve the 2030 goals.

---

**Abstract Submission No. 100250**

**O-0221**

**Clinical utility of HCV core antigen measurement for HCVAb-positive patients towards HCV elimination**

Satoru Joshita1,2, Yuki Yamashita2, Hiroyuki Kobayashi2, Takeji Umemura2

1NHl Yodakubo Hospital Nagawa town Japan, 2Shinshu University School of Medicine Matsumoto Japan

The cascade of hepatitis C virus (HCV) cure/care depends on the link-age of medical examination and treatment initiation to eliminate HCV. We conducted a prospective, non-interventional, observational study from April 2022 to March 2023 targeting patients who underwent HCV antibody testing during hospitalization or outpatient visits. HCV core antigen levels were additionally measured using residual serum from HCV antibody-positive cases. We encouraged patients to receive medical care if both samples were positive. The HCV antibody positivity rate was 4.4% (390/8,805 cases), with a significantly higher rate in outpatient testing (4.6%) than in inpatient testing (2.3%) (P=0.002). Among the 378 HCV antibody-positive patients with sufficient residual serum, HCV core antigen positivity rate was 8.2% (31/378 cases) and significantly higher in patients with HCV antibody level ≥10 COI (n=249) than in those with <10 COI (n=129) (11.6% vs. 1.6%, P=0.002). The median age of the HCV core antigen-positive individuals (14 male and 17 female) was 76 years (range: 18-92 years). Apart from 2 patients with no scheduled visits, the remaining 29 patients were urged to undergo detailed examination and follow-up. One patient tested negative for HCV RNA. Nine of the remaining 28 cases (32.1%) were prescribed direct-acting antiviral (DAA) treatment, 13 (46.4%) were deemed DAA-ineligible due to such complications as hepatocellular carcinoma, and 6 (21.4%) had no interest in therapy. Performing HCV core antigen measurement with residual serum from HCV antibody-positive individuals may be useful for identifying HCV carriers and directing them towards additional examination and treatment.

---

**Abstract Submission No. 100326**

**O-0222**

**Long-term Serum Ferritin Dynamics in Patients Receiving Antiviral Treatment for HCV Infection**

Yu-Ping Chang1,3, Chun-Jen Liu1,2,3, Tung-Hung Su1,2, Shang-Chin Huang3, Tai-Chung Tseng4, Pei-Jer Chen1,2,3, Jia-Horng Kao1,3, Chen-Hua Liu1,2,4

1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan, 3Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine Taipei Taiwan, 4Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch Taipei Taiwan, 5Department of Medical Research, National Taiwan University Hospital Taipei Taiwan, 6Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch Douliou Taiwan

**Background:** Data regarding the long-term serum ferritin dynamics and factors associated with the trends of changes in patients receiving antiviral treatment for hepatitis C virus (HCV) infection are limited.

**Methods:** Serum ferritin levels were evaluated biannually in 1538 HCV-infected patients receiving direct-acting antiviral (DAA) or interferon (IFN)-based treatment after confirming sustained virologic response (SVR12) or not. We compared the ferritin dynamics in patients with factors of interest using the generalized estimating equation (GEE). Univariate and multivariate analyses were performed to identify predictors associated with serum ferritin evolutions.

**Results:** By univariate analysis, patients achieving SVR12, aged > 50 years, having metabolic dysfunction-associated steatotic liver disease (MASLD), or pre-treatment HCV RNA level > 2,000,000 IU/mL were associated with different ferritin dynamics. Multivariate analysis showed that patients achieving SVR12 (adjusted slope coefficient difference: -7.50 ng/mL/year [95% CI: -3.37 to -11.63], p < 0.001), and those with MASLD (adjusted slope coefficient difference: 4.16 ng/mL/year [95% CI: 0.41 to 7.91], p = 0.0022) were independently associated with ferritin evolutions. In patients achieving SVR12, the
Abstract Submission No. 100528

O-0223

Collaboration with community and hospital contributes to HCV elimination in database

Yongzi Wei1, Dacheng Qin2, Linping Zheng3, Jielian Sun4, Bingxue Yu5, Jianlin Wu6, Yong Huang7

1Wuming Hospital of Guangxi Medical University Nanning China, 2Tengxian People's Hospital Wuzhou China

Background: Still a big gap in HCV patients who diagnosis-but-un-treated (DBU) in China. It is the priority for HCV elimination in China. Methods: The Centers for Disease Control and Prevention (CDC) in Waming District of Nanning City and Tengxian County of Wuzhou City in Guangxi collaborate with community hospitals and community service centers, worked on recalling all the patients with HCV-Ab(+) from 2004 to 2021 in their data pool. Once the patients come back to the community hospital, doctors will perform the blood sampling for HCV RNA testing for them. The doctor in community hospital will phone the patients about the result and referred the patients with HCV RNA(+) to hepatologist. And then the patients will receive DAA treatment after communication with hepatologists.

Results: In the past 10 months, 4995 previously reported hepatitis C patients were recalled, and 1610 cases were contacted successfully. Among them, 1006 patients were tested for HCV RNA testing. The positive rate of nucleic acid was 36.5% (367/1006). At present, 16.34% (60/367) of CHC patients have been successfully referred to hepatologists for further assessment, of which 13.35% (49/367) have been successfully referred to hepatologists for further assessment, of which 13.35% (49/367) have received DAA treatment. Another 318 patients were still in the telephone follow-up and had agreed to go to the liver disease clinic for treatment in the near future.

Conclusion: CDC collaborates with community hospital and community service center contribute to HCV elimination for the DBU patients.

Abstract Submission No. 100528

O-0224

HCV Micro-elimination in private Hemodialysis center

Fang Cao1, Kerun An1, Guocheng Zhang1, Hongjun Luo2, Bin Yao3, Xi'e Pan3, Xiu Ai4, Xiaohui Luo5, Fuli Guo6, Xue Li3

1Sichuan Sansong medical management group Chengdu China, 2Chengdu Wenjiang Yufu Hospital, Sichuan Chengdu China, 3Chengdu Chenghua Sansong kidney disease Hospital,Sichuan Chengdu China, 4Chengdu Sansong Nephropathy Hospital,Sichuan Chengdu China

Objective: This study aimed to explore standard operation procedure(SOP) of HCV elimination in private hemodialysis centers.

Methods: This was a multi-center study. A survey would be provided to medical workers and HCV-Ab(+) patients to access the awareness of the people regarding no patients accepted HCV RNA testing and anti-viral treatment in 5 private hemodialysis centers. Then HCV knowledge education would be hold. After education, HCV RNA testing would be recommended for anti-HCV(+) patients. Finally HCV RNA(+) patients will be accompanied by dedicated medical workers throughout “green channel” to hepatologists for SOF/VEL treatment.

Results: From October to November 2022, 247 medical workers and 45 anti-HCV(+) patients completed survey. 89% medical workers and 100% medical patients have no idea about HCV and only 7~9% medical workers would recommend patients to receive HCV screening and treatment. All the medical workers and HCV-Ab(+) patients were educated through 9 medical education tours. From March to May 2023, 100% (44/44) HCV-Ab(+) patients received HCV RNA testing, with a positivity rate of 38.6% (17/44). Till September 2023, 84.6%(11/14) patients received SOF/VEL treatment. The sustained virological response rate at 12 weeks of treatment(SVR12) was 100%(11/11).

Conclusion: This SOP can great contribute to HCV elimination in private hemodialysis centers.

Abstract Submission No. 100542

O-0225

Real-world study of Sofosbuvir/Velpatasvir for cirrhotic patients with genotype 3 HCV infection

Yongrui Yang1, Kang Huang1, Lei Wu1, Jinsong Bai1, Junyi Li1, Shenhao Li1, Li Liu1, Haiwen Li1, Zhirong Zhao1, Yingrong Du1

1The third people’s hospital of Kunming city, Yunnan Provincial Infectious Disease Clinical Medicine Center, Kunming Yunnan, China Kunming China

Objective: To explore the efficacy and safety of Sofosbuvir/Velpatasvir ± ribavirin (SOF/VEL±RBV) in the treatment of genotype 3(GT3) chronic hepatitis C cirrhotic patients.

Methods: Patients diagnosed as GT3 HCV infection and treated at the Third People’s Hospital of Kunming city from June 2018 to February 2023 were included. All patients had liver cirrhosis and treated with SOF/VEL±RBV for 12 weeks. Virologic response, liver and kidney function and adverse effects(AE) were analyzed.

Results: A total of 319 patients were included, including 308 with SOF/VEL±RBV group and 11 with SOF/VEL group(RBV intolerable). After 12 weeks off-treatment, the sustained virological response (SVR12) rate in SOF/VEL±RBV group was 98.37% (303/308), and the levels of APRI score and FIB-4 index were decreased compared with baseline (P<0.05). The results of total bilirubin, AST and ALT were all decreased compared with baseline(P<0.05). SVR12 rate of SOF/VEL group was 72.73% (8/11). Most common AEs were mild hemolytic anemia (15.26%), fatigue (8.12%) and rash (8.77%) in SOF/VEL±RBV group, and fatigue (9.09%) in 1 case in SOF/VEL group.

Conclusion: SOF/VEL±RBV could achieve higher SVR12 and well tolerated for GT3 HCV infected patients either with compensated cirrhosis or decompensated cirrhosis patients.

Abstract Submission No. 100592

O-0226

Baseline FIB4 is superior to FIB4 at SVR12 to predict HCC occurrence following DAA-attained SVR12

Ashley Tiong1, Pooja Devan1, Jean E Neo1, Wei Xuan Tay2, Yu Jun Wong3

1Singapore General Hospital, Singapore, 2Singapore National Cancer Centre, Singapore, 3Singapore National Cancer Centre, Singapore

Objective: This study aimed to explore standard operation procedure(SOP) of HCV elimination in private hemodialysis centers.

Methods: This was a multi-center study. A survey would be provided to medical workers and HCV-Ab(+) patients to access the awareness of the people regarding no patients accepted HCV RNA testing and anti-viral treatment in 5 private hemodialysis centers. Then HCV knowledge education would be held. After education, HCV RNA testing would be recommended for anti-HCV(+) patients. Finally HCV RNA(+) patients will be accompanied by dedicated medical workers throughout “green channel” to hepatologists for SOF/VEL treatment.

Results: From October to November 2022, 247 medical workers and 45 anti-HCV(+) patients completed survey. 89% medical workers and 100% medical patients have no idea about HCV and only 7~9% medical workers would recommend patients to receive HCV screening and treatment. All the medical workers and HCV-Ab(+) patients were educated through 9 medical education tours. From March to May 2023, 100% (44/44) HCV-Ab(+) patients received HCV RNA testing, with a positivity rate of 38.6% (17/44). Till September 2023, 84.6% (11/14) patients received SOF/VEL treatment. The sustained virological response rate at 12 weeks of treatment(SVR12) was 100%(11/11).

Conclusion: This SOP can great contribute to HCV elimination in private hemodialysis centers.
INTRODUCTION: Direct-acting antiviral (DAA) has cured millions of patients with chronic hepatitis C (CHC). The need for hepatocellular carcinoma (HCC) surveillance after DAA-attained SVR12 among non-cirrhotic CHC patients remained a matter of debate. We sought to compare the performance of baseline and FIB4 at SVR12 to predict the HCC occurrence in CHC patients after DAA-attained SVR12.

Methods: This is a post-hoc analysis including all consecutive genotype 3 CHC patients treated with sofosbuvir/velpatasvir between 2018-2019 in our institution (PMID: 3321740). Primary predictor was FIB4 at baseline and SVR12 (FIB4-SVR12). Primary outcome was new HCC.

Results: A total of 779 CHC patients with SVR12 were included. Over median follow-up of 4 years, 2.3% developed HCC after SVR12. All HCC developed in patients with cirrhosis and male gender. Patients who developed HCC were older with prior history of HCC (44.4% vs 1%, p=0.001) and higher median FIB4 score at SVR12 (3.9 vs 1.5, p<0.001). HCC risk increases with both baseline FIB4 (low-risk: 0%, moderate-risk: 0%, high-risk: 9.8%, p=0.001) and SVR12-FIB4 (low-risk: 0%, moderate-risk: 2.0%, high-risk: 18.4%, p=0.001), with excellent AUC (Baseline: 0.92, SVR12: 0.88). Using FIB4-SVR12≥3.25 to select post-SVR CHC patients for HCC surveillance significantly reduce the proportion of patients requiring HCC surveillance (87.8% vs 80.7%, p=0.0018) at the expense of missing more HCC than baseline FIB4 (1.6% vs 0.2%, p=0.0123).

Conclusion: FIB4 accurately risk stratify post-SVR HCC in CHC patients, however a small but persistent risk of HCC remained when post-SVR12 FIB4 was used to select patients for HCC surveillance.

Abstract Submission No. 100784
O-0228

Evaluating HCV Point-of-Care Testing - a Real-World Study on People Who Inject Drugs in Singapore

Alyssa Sim1, Kuo Chao Yew1, Robert Hawkins2, Sanchalika Acharyya3, Samuel Wong4, Yuan Heng Lim5, Angela Li Ping Chow6, Wei-Yen Lim1, Hwee Pin Phua1, Chen Seong Wong2, Wei Lyn Yang1

1Department of Gastroenterology & Hepatology, Tan Tock Seng Hospital Singapore Singapore, 2Department of Laboratory Medicine, Tan Tock Seng Hospital Singapore Singapore, 3Clinical Research & Innovation Office, Tan Tock Seng Hospital Singapore Singapore, 4HCSA Highpoint Halfway House, HCSA Community Services Singapore Singapore, 5Lee Kong Chian School of Medicine, Nanyang Technological University Singapore Singapore, 6Department of Preventive and Population Medicine, Tan Tock Seng Hospital Singapore Singapore, 7National Centre for Infectious Diseases Singapore Singapore

Background: The target for HCV elimination is set at ≥90% of Chronic HCV diagnosed. Point-of-care testing (POCT) has the potential to increase diagnosis. We critically evaluated the performance of POCT using OraQuick® HCV Rapid Antibody Test.

Method: People who inject drugs (PWID) from 4 Halfway Houses in Singapore were concurrently screened for HCV via blood for Anti-HCV Serology and using fingerstick capillary whole blood (FSWB) and oral mucosal transudates (OMT) for POCT interpreted by trained personnel. A blinded study team-member independently assessed images of POCTs.

Results: Of 207 participants, 37.3% were Anti-HCV positive. Compared to anti-HCV serology, POCT performance on FSWB and OMT were: Sensitivity 81.8 (73.2 - 90.4), 74.0 (64.2 - 83.8), p=0.014; Specificity 100.0 (100.0 - 100.0), 98.5 (96.3 - 100), p= 0.157. Sub-group analysis of 30-minute pre-test nil-by-mouth instruction in 103 subjects reported Sensitivity 77.5 (64.6 - 90.4), 77.5 (64.6 - 90.4) and Specificity 100.0 (100.0 - 100.0), 98.4 (95.3 - 100.0). OMT positivity and false-negative had no correlation with sample analytical cutoff index signal distribution of Anti-HCV Serology. Inter-class correlation between real-time and imaging readings of POCT for FSWB/OMT at 20 min/40 min were Kappa 0.9666, 0.9674; 0.8803, 0.8940.

Conclusion: We observed a lower-than-reported sensitivity of OraQuick® POCT with comparable performance for FSWB and OMT. Factors such as difference in oral fluid immunoglobulin secretion, sample collection, could affect POCT reading. Nevertheless, POCT OMT remains a promising diagnostic tool for its adaptability, ease-of-performance in serial or self-testing for HCV naive population.
The people’s hospital of Jiulongpo district, Chongqing, China
Chongqing China, 1Jiulongpo district center for disease control and prevention, Chongqing, China, 2Institute for AIDS/STD Control and Prevention Chongqing Center for Disease Control and Prevention Chongqing China

Background: Diagnosis and treatment of recently acquired HCV in people living with HIV (PWLH) was still limited in China.

Methods: This prospective study would identify acquired HCV patients in the HIV outpatient clinic in Jiulongpo Hospital of Chongqing. During regular follow-up, PWLH with abnormal liver function took HCV-Ab screening, and HCV RNA testing was provided for the HCV-Ab positive patients. HCV RNA positive patients would receive Sofosbuvir/Velpatasvir (SOF/VEL) treatment for 12 weeks.

Results: From May 2021 to October 2023, 76 patients with recently acquired HCV were identified among PLWH. All the patients were HCV-Ab within 6 months. 93.4% (71/76) was sexual transmission. Homosexual and heterosexual were 71% (54/76) and 22.4% (17/76), respectively. 6.6% (5/76) was transmitted by drug injection. After 12 weeks post-treatment, 100% patients achieved SVR12, and 86% (65/76) patients had ALT normalization. All the patients (76) treated with EFV/TDF/3TC or AZT/TDF/LPVr were switched to B/E/TAF before anti-HCV treatment. SOF/VEL treatment was well tolerated. No serious adverse events (AEs) were reported.

Conclusion: More attention should be paid for recently acquired HCV infection among PLWH, especially for patients with actively sex. Regular HCV screening and prompt anti-HCV treatment could effectively prevent HCV transmission in PLWH.

Abstract Submission No. 101072
O-0230

Frequency of cognitive impairment in patients with chronic HCV and its correlation with CTP Score.

Anoshia Fahad1, Sana Hussain1
1Dr. Ruth KM Pfau Civil Hospital Karachi Pakistan

Introduction: It is estimated that approximately 100 million persons have been infected with HCV. HCV is detected in CSF raising the possibility of its extra hepatic replication resulting in cognitive impairment. CHC patients already have reduced health related quality of life and cognitive impairment will even make it worse.

Methods: This was a cross sectional study, conducted from January 2023 to June 2023. All patients with hepatitis C fulfilling the inclusion criteria were included. Baseline characteristics were collected on pre-designed proforma. Montreal Cognitive Assessment was used to assess the cognitive impairment in HCV patients. Patients with score of 18-25 were classified as having mild, 10-17 as moderate and less than 10 as severe cognitive impairment.

Results: Total 78 consecutive patients were enrolled. Mean age of patients was 43.6 ±12.2. Males and females were 59% & 41%. Overall, 14 (17.9%) patients had normal cognitive function, while mild, moderate and severe CI was seen in 28.2%, 33.3% and 20.5%. Normal cognitive function was found in 11 patients of CTP class A, 3 in CTP class B and none in CTP class C while none of the patient in CTP class A had severe CI followed by 4 and 12 patients in CTP class B & C.

Conclusion: We concluded that majority of the patients having HCV associated cognitive impairment were males and more patients in CTP class C had severe cognitive impairment. So actions are needed for early detection and treatment of HCV for better health outcomes.

Abstract Submission No. 101287
O-0231

The Risk for Tumor Progression of HCV-related Hepatocellular Carcinoma after curative treatment

Hiroko Ikenaga1, Sawako Uchida-Kobayashi1,2, Yoshimi Yukawa-Muto1, Naoshi Odagiri1, Kohei Kotani1, Hiroyuki Motoyama1,2, Ritsuzo Kozuka1, Atsushi Hagihara1, Etsushi Kawamura1, Hideki Fuji1, Masaru Enomoto1, Akihiro Tamori1, Norifumi Kawada1
1Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 2Department of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan

Background: HCC shows poor prognosis after progression to intermediate or advanced stage (BCLC stage B-D). However, tumor progression risk and the effect of DAA therapy after curative HCC treatment remain unclear.

Methods: We conducted a retrospective cohort study of patients with HCV-related HCC. We estimated the risk of tumor progression (defined as progression to BCLC stage B-D) by time-varying Cox regression analysis.

Results: Among 558 patients with HCV-related HCC, 165 patients were included in the analysis. The median age was 72 years, 96 were men, 53 received surgical resection, and 72 received DAA therapy after HCC treatment. FIB-4 index and liver-to-spleen (L/S) ratio for CT attenuation were calculated, and the median were 5.21 and 1.16, respectively. We recorded 56 incidences of tumor progression (29, 13, 8 and 6 cases were due to multiple nodules, portal invasion, extrahepatic metastasis, and deterioration of hepatic reserve, respectively). In univariate analysis, DAA-induced SVR (HR 0.27, p=0.001), FIB-4 index (HR 1.10, p=0.001), L/S ratio (HR 0.67, p<0.002), history of IFN therapy (HR 0.40, p=0.02) and ALBI score (HR 2.39, p=0.02) were associated with the risk of tumor progression. Multivariate analysis showed DAA-induced SVR, FIB-4 index and L/S ratio were associated with the risk.

Conclusions: This study suggested DAA-induced SVR reduced, and liver fibrosis (FIB-4 index) and liver steatosis (L/S ratio) increased the risk for tumor progression.
37 years with Malmö Needle Exchange Program at the center: From HIV prevention to HCV elimination

Marianne Alanko Blome,1,2,3, Pernilla Isendahl,1, Katja Troberg,3, Martin Bråbäck4,5, Anna O Jerkeman1
1Lund University, Department of Clinical Sciences, Section for Infectious Diseases, Sweden Malmö Sweden, 2Regional Office of Communicable Disease Control and Prevention Malmö Sweden, 3Department of Infectious Diseases, Skåne University Hospital Malmö Sweden, 4Addiction Center, Division of Psychiatry Malmö Sweden, 5Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Psychiatry Lund Sweden

Background: Malmö needle exchange program (MNEP) opened at the Infectious disease department at the Skåne University Hospital in 1987 to prevent HIV transmission among people who inject drugs. Since then, MNEP has evolved according to the needs of the participants.

Methods: MNEP has reached > 5200 persons, with 600 individuals conducting 6000 visits per year. Injection material and risk reduction counselling, medical care and psychosocial support are provided. Interviews on sociodemographic facts and substance use are combined with testing for HIV, hepatitis A (HAV), B (HBV) and C (HCV). Vaccinations against HAV and HBV are provided. HCV treatment and Take Home Naloxone was introduced on site in 2018.

Results: While HIV and HBV transmission remained low, HCV prevalence (80% anti-HCV positive, of whom >50% viremic) and incidence (31.5/100 pyr in 1997-2005) were previously high. A pilot study offering HCV treatment on site (2018, n=50) found high rates of adherence (94%) and sustained virological clearance (90%), with 9 reinfected so far. By large scale treatment the overall HCV prevalence among MNEP participants has declined to <20%. Naloxone is now distributed by all NEPs and OAT clinics in Skåne region. To date, 900 kits out of the 5700 distributed have been used to reverse opioid overdoses.

Conclusion: A NEP with ID expertise can constitute a center for the hepatitis elimination process. Addressing both HCV and opioid overdoses is essential in reducing morbidity and mortality in this high-risk population.

Abstract Submission No. 101345
O-0233

EFFICACY OF VELPATASVIR AND SOFOSBUVIR COMBINATION THERAPY IN CHRONIC HCV PATIENTS.

Hafiz Ather
1Faisalabad Med University Faisalabad Pakistan

Authors. Professor Dr Hafiz Mughees Ather, Dr Arfan Mahmood , Dr Umair Waheed , Dr Mohammed Osama, Dr Aflan Shahid.

Abstract:
Introduction: Chronic Hepatitis C is a prevalent infection in Pakistan. It can lead to complications like cirrhosis of liver, liver failure, hepatocellular carcinoma and death. Oral antiviral therapy has revolutionized the treatment of Hepatitis C. It can achieve eradication of HCV in the form of sustained virological response in HCV patients. We conducted a study to analyze the efficacy of Sofosbuvir, Velpatasvir combination therapy with Ribavirin except when there was a contraindication.

Materials and methods: It was a prospective single cohort study including all chronic Hepatitis C patients who underwent treatment for Chronic hepatitis C virus (HCV) with Sofosbuvir (SOF) and Velpatasvir (VELPA) combination therapy with Ribavirin. All patients were more than 18 years old.

Results: 64% patients were males and 36% were females. 6.1% patients were cirrhotic and all patients received Ribavirin. SVR was achieved in 111/114 (97.36%) patients.
Conclusion: Sofosbuvir, Velpatasvir combination therapy with Ribavirin is an effective antiviral therapy for the treatment of chronic hepatitis C.

Key Words: Hepatitis C, Sofosbuvir, Velpatasvir, Ribavirin, Naive, HCV Treatment in Faisalabad, Cirrhosis, Sustained Virological Responses

Abstract Submission No. 101478
O-0236

CHANGES IN THE DEGREE OF LIVER STEATOSIS AND LIPID PROFILE OF HEPATITIS C PATIENTS AT SVR12

Putra Nur Hidayat1,2, Cosmas Rinaldi Adithya Lesmana3, Chyntia Olivia Maurine Jasirwan3, Andri Sanitosyo Sulaiman1, Siti Setiati4, Aulia Rizka4, Adityo Susilo5
1RSCM FKUI Jakarta Indonesia, 2Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo 7 Hospital, Jakarta Jakarta Indonesia, 3Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. 9 Cipto Mangunkusumo Hospital, Jakarta Jakarta Indonesia, 4Geriatrics Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto 11 Mangunkusumo Hospital, Jakarta Jakarta Indonesia, 5Tropical and Infectious Disease Division, Department of Internal Medicine, Faculty of Medicine, Universitas 13 Indonesia/Dr. Cipto Mangunkusumo Hospital, Jakarta Jakarta Indonesia

Background: The relationship between hepatitis C patients’ SVR12 incidence, lipid profile, and liver steatosis remains unclear. The results of existing publications are still inconsistent regarding changes in the value of these parameters after SVR12. This study aims to examine changes in the degree of hepatic steatosis and lipid profile in hepatitis C patients during SVR12 and look for their relationship.

Methods: Longitudinal design, before and after a study conducted at Cipto Mangunkusumo Hospital (RSCM). The study was conducted for one year. Patients who met the inclusion criteria were included and examined for lipid profile and controlled attenuated parameter values before and after therapy.

Results: The mean SD CAP value increased before therapy 196±49.36 dB/m and after therapy 227±47.11 dB/m. There is significant increase in mean SD value of total cholesterol (166±40.30 mg/dL vs 190±42.58 mg/dL), triglycerides (94±45.39 mg/dL vs 109±49.83 mg/dL), and LDL (109.48±39.57 mg/dL vs 130.88±34.32 mg/dL). There was a negative correlation between CAP values in hepatitis C patients before therapy and changes in CAP values after DAA therapy. No correlation exists between changes in total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides with the degree of liver steatosis at SVR12.

Conclusion: There is a difference in the degree of liver steatosis, total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride levels before therapy and at SVR12 in hepatitis C patients receiving DAA therapy. There was negative correlation between CAP values at baseline and SVR12

Abstract Submission No. 101884
O-0238

Characteristics of Hepatitis C Patients Undergoing Oral Antiviral Therapy at Our Institution

Atsuhiro Morita1, Kohji Uno1, Naonori Inoue1
1Japanese Red Cross Society, Kyoto Daini Red Cross Hospital Kyoto City Japan

Background and Aims: Direct acting antiviral therapy (DAA) has shown high efficacy for HCV infection. However, untreated cases of chronic hepatitis C remain a domestic problem. This study analyzes treatment outcomes and patient characteristics during different time periods, aiming to identify issues in acquiring untreated patients and improve acquisition strategies.

Methods: 257 DAA cases (Oct 2015 - Sep 2023) were categorized into early (2015-2017) and later periods (2018-2023) with glecaprevir/pibrentasvir. We examined factors such as consultation reasons, efficacy, follow-up, prognosis, and mortality causes. Collaboration between our institution and regional healthcare facilities in DAA therapy cases was investigated.

Results: Of 257 cases, 149 were in the early period, and 108 in the later period. Median ages were 68 and 69.5, with male: female ratios of 71:78 and 43:65. Genotypes 1, 2, and others were 105/44:0 and 68:38:2 in early and later periods. SVR rates were 99.3% and 100%. Cases under treatment versus referrals were 96:53 and 60:48. Liver disease-related deaths were 1/5 for both periods, with 12 and 4 lost to follow-up cases. 101 referrals came from various healthcare institutions, with 1-4 patients per facility (median: 1).
Discussion: Around 40% of DAA cases were referred, 53.6% in the early and 48.8% in the later period. DAA therapy showed high SVR and survival rates, with a low lost-to-follow-up rate, emphasizing the importance of regional collaboration.

Conclusion: Enhancing collaboration with regional healthcare institutions and strengthening intra-institutional coordination is crucial. Efforts should be made to expand DAA therapy to more chronic hepatitis C patients.

Abstract Submission No. 102018
O-0239

Concurrent Management of Chronic Hepatitis C and Advanced Hepatocellular Carcinoma: A Case Report

Rene John Febro1, Engelbert Simon Perillo1, Jaqueline Arsenal1, Salahuddin Andam1, Maria Hossea Montero1, Erika Johanna Tanada1, Hyacinth Maurille Van Eviota1, Stephen Wong1
1University of Santo Tomas Hospital Manila Philippines

There is paucity of data concerning the concurrent management of patients with active Hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC). Guidelines regarding the timing and duration of HCV treatment in patients with advanced HCC are still ill-defined. We present a case of advanced HCC with concomitant HCV infection who was successfully downstaged following immunotherapy and direct-acting antiviral treatment. A 71-year-old Filipino male was referred for evaluation of recently diagnosed HCV infection and liver mass. Dynamic imaging showed infiltrative mass at the right hepatic lobe with portal vein thrombosis (PVT). He received concurrent treatment with sofosbuvir-velpatasvir and atezolizumab-bevacizumab. Sustained virologic response 12 weeks post-treatment was achieved. Radiologic evaluation revealed a significant decrease in tumor size. Patient underwent successful curative microwave ablation and is currently tumor and drug-free for 21 months. Our case shows that patients with advanced HCC and HCV infection may attain excellent responses with simultaneous treatment. Data from prospective, randomized-controlled trials are needed to identify patients who will benefit most from this strategy.

Abstract Submission No. 200090
O-0240

Nomogram for Predicting Hepatocellular Carcinoma in HCV-associated Cirrhosis Patients

xuemei tao1, liang xu1, yuqi yang mi1, jing zhang2
1Tianjin Second People's Hospital of Tianjin Medical University Tianjin China, 2Youan Hospital of Capital Medical University Beijing China

Background and objectives: Hepatitis C virus (HCV) associated cirrhosis are in high risk of hepatocellular carcinoma (HCC), and this study aimed to explore the risk factors, and establish and validate a novel nomogram.

Methods: A total of 309 inpatients with HCV-associated cirrhosis from Tianjin Second People’s Hospital were selected as the training cohort, and 363 patients from Beijing You’an Hospital were selected as the validation cohort. Both cohorts received Direct-Acting Antiviral Agents (DAAs) treatment and achieved sustained virological response (SVR). Laboratory parameters were collected at baseline and duration of follow-up. Cox regression analysis was used to explore risk factors of HCC, and a nomogram for prediction was developed and validated.

Results: HCC incidence was 5.45 100PY (95% CI, 3.91-7.40) in patients of the training cohort. Age, nonspecific liver nodules, the albumin-Bilirubin (ALBI) score and end of treatment (EOT)-AFP are independent risk factors for HCC by Cox regression analysis. A nomogram was used to predict the 1-year, 3-year and 5-year incidence of HCC, with the areas under receiver operating characteristic curves (AUROCs) of 0.866, 0.813 and 0.764, respectively. The AUROCs in validation cohort at 1, 3, and 5 years were 0.884, 0.783 and 0.692 in this nomogram, respectively.

Conclusion: This novel nomogram had a good predictive ability for HCC in patients with HCV-associated cirrhosis after eliminating virus with direct-acting antiviral agents, especially in 3 years.

Abstract Submission No. 200091
O-0241

“Stiffness” resolution is uncompleted with the HCC incidence reduction in advanced fibrosis.

Shuntaro Obi1,2, Miho Kanda1, Yoshiki Asahina1, Kowa Nagasaka1, Tomoyoshi Murata1, Kyoko Nakajima1, Hiroyuki Amano1, Shinya Takaoka1, Yushi Imai1, Yukiko Asakawa1, Sumio Hirose1, Hiroshi Ohyama1, Hitoshi Mochizuki1, Yuichiro Kojima1, Masao Omata1,4
1Department of Gastroenterology, Yamanashi Central Hospital, Yamanashi Japan, 2Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba Japan, 3Department of Gastroenterology, Chiba University, Chiba Japan, 4Genome Analysis Center, Yamanashi Central Hospital, Yamanashi Japan, 5The University of Tokyo Tokyo Japan

Objective: To prospectively observe hepatocarcinogenesis in hepatitis C patients treated with DAA and to examine the relationship between fibrosis remission and carcinogenesis.

Methods: A prospective observational study was conducted on hepatitis C patients treated with DAA from July 2013 to November 2023. The primary endpoint was the occurrence of liver cancer, and the secondary endpoint was the change in liver stiffness. Liver stiffness was measured by Fibro-scanner and divided into 4 groups (Group 1: <4 kPa, Group 2: 4 to 8 kPa, Group 3: 8 to 12 kPa, Group 4: 12 kPa or higher). The most improved values before and after DAA were compared.

Results: All 689 patients were prospectively observed. The median observation period was 6.0 years. During the observation period, hepatocellular carcinoma occurred in 70 patients (10%). Liver stiffness trends were group 1 (1-1 80%, 1-2 20%), group 2 (2-1 14%, 2-2 84%, 2-3 1%, 2-4 1%), group 3 (3-1 13%, 3-2 50%, 3-3 30%, 3-4 1%), and group 4 (4-14%, 4-2 24%, 4-3 20% 4-4 52%). The incidence of liver cancer was group 1 (1-1 0%, 1-2 0%), group 2 (2-1 14%, 2-2 84%, 2-3 0%, 2-4 50%), group 3 (3-1 5%, 3-2 30%, 3-3 12.5%, 3-4 50%) and group 4 (4-1 28.6%, 4-2 15.2%, 4-3 30%, 4-4 25.5%). Up to group 3, the incidence of liver cancer tended to be low as fibrosis remitted, but in group 4, the incidence was high even when fibrosis remitted.

Conclusion: Patients with high liver stiffness before DAA treatment should be aware of the risk of carcinogenesis even after fibrosis remission.

Abstract Submission No. 200192
O-0242

VIETNarms: A strategic post-licensing randomised trial of direct acting Hepatitis C antivirals
Feng Ren1, Xiangying Zhang1, Yuan Tian2, Zhihao Fan2, Ling Xu2, Hong Zhang3, Ten Tang4, Yuming Li5, Leanne McCabe3, Barney Flower1, for SEARCH collaborators2

1Imperial College London United Kingdom, 2OUCRU Ho Chi Minh City Vietnam, 3MRC Clinical Trials Unit, UCL London United Kingdom, 4University of Oxford United Kingdom, 5Hospital for Tropical Diseases Ho Chi Minh City Vietnam, National Hospital for Tropical Diseases Hanoi Vietnam

Background: No randomised trials have compared WHO-recommended first-line hepatitis C treatments. More evidence is needed to support therapeutic strategies to deliver expanded treatment access.

Methods: We enrolled adults with chronic hepatitis C infection without evidence of significant liver disease (Fibroscan<9.0kPa) from two centres in Vietnam (Ho Chi Minh City, Hanoi). Patients were stratified into genotype-6/non-genotype-6 and randomly allocated to one of two treatment strategies (i) standard-of-care 12 weeks (SOC) (ii) four weeks DAA therapy with 4 weeks Pegylated interferon (PEG-IFN) doses from week-3 (iii) induction/maintenance therapy with two weeks standard therapy followed by 10 weeks therapy 5 days/week and (iv) response-guided therapy of 4, 8 or 12 weeks determined by viral load on day-7 of treatment. Primary outcome was sustained virological response 12 weeks after treatment completion (SVR12).

Results: Primary outcome data were available for 644 of 646 randomised participants. 296(47%) were genotype-6; 328(53%) non-genotype 6 were mostly genotype-1/2. Overall SVR12 was 294(302)(97%) for SOF/DCV and 292(307)(95%) for SOF/VEL combinations. SVR12 for strategies were (i) 148/150(99%) in SOC (ii) 143/152(94%) with 4 weeks Peg-IFN (iii) 151/152(99%) with induction/maintenance and (iv) 144/153(93%) with response-guided therapy. Overall severe adverse events were rare (3%) with no significant differences between treatment combinations or strategies.

Conclusions: High efficacy rates were achieved for both sofosbuvir/daclatasvir and sofosbuvir/velpatasvir as well as three different strategies that may be suitable to improve access for harder-to-reach treatment populations.

Abstract Submission No. 100276
O-0243

CRISPR/Cas13a-Assisted Accurate and Portable Hepatitis D Virus RNA Detection
Feng Ren1, Xiangying Zhang1, Yuan Tian2, Zhihao Fan2, Ling Xu2, Yao Gao3, Yining Cao1, Zhenzhen Pan1

1Beijing Youan Hospital, CMU Beijing China

Background & Aims: Hepatitis delta virus (HDV) infection accelerates the progression of chronic hepatitis B virus (HBV) infection, posing a large economic and health burden to patients. At present, there remains a lack of accurate and portable detection methods for HDV RNA. Here, we aim to establish a convenient, rapid, highly sensitive and specific method to detect HDV RNA using CRISPR–Cas13a technology.

Methods: we established fluorescence (F) and lateral flow strip (L) assays based on CRISPR–Cas13a combined with RT–PCR and RT–RAA, respectively. we conducted a cohort study of 144 patients with HDV-IgG positive to evaluate the CRISPR–Cas13a diagnostic performance for identifying HDV in clinical samples, compared to RT–qPCR and RT-ddPCR.

Results: For synthetic HDV RNA plasmids, the sensitivity of RT–PCR-CRISPR-based fluorescence assays was 1 copy/μL, higher than that of RT–qPCR (10 copies/μL) and RT-ddPCR (10 copies/μL); for HDV RNA-positive samples, the sensitivity of RT-RAA-CRISPR-based fluorescence and lateral flow strip assays was 10 copies/μL, as low as that of RT–qPCR and RT-ddPCR, and the assay took only approximately 85 minutes. Additionally, the positivity rates of anti-HDV IgG-positive samples detected by the RT–qPCR, RT-ddPCR, RT–PCR-CRISPR fluorescence and RT-RAA-CRISPR lateral flow strip methods were 66.7% (96/144), 76.4% (110/144), 81.9% (118/144), and 72.2% (104/144), respectively.

Conclusions: We developed a highly sensitive and specific, as well as a portable and easy CRISPR-based assay for the detection of HDV RNA, which could be a prospective measure for monitoring the development of HDV infection and evaluating the therapeutic effect.

Abstract Submission No. 100465
O-0244

Hepatitis Delta Virus Testing and Prevalence Among Veterans with Chronic Hepatitis B in the USA
Robert Wong1, Zeyuan Yang1, Janice Jou2, Binu John3, Joseph Lim1, Ramsey Cheung1

1Stanford University School of Medicine/VA Palo Alto Healthcare System Palo Alto United States, 2Oregon Health & Science University Hospital, Portland VA Medical Center Portland USA, 3University of Miami Miller School of Medicine, Miami VA Medical System Miami USA, 4Yale University School of Medicine New Haven USA

Background: Poor awareness of hepatitis delta virus (HDV) contributes to suboptimal testing, delayed diagnosis, and increased morbidity/mortality. We aim to evaluate HDV testing patterns and HDV prevalence among a national cohort of United States (US) Veterans with chronic hepatitis B (CHB).

Methods: Using longitudinal data on all Veterans receiving care within Veteran health systems (1/1/2010-9/30/2023), HDV testing (HDV antibody, HDV RNA, HDV antigen) among CHB patients, and the proportion positive among those tested, were compared using chi-square methods. Multivariable logistic regression models evaluated predictors of HDV testing (entire CHB cohort) and HDV test positive (among those tested).

Results: Among 27,548 CHB patients (93.2% male, 92.5% non-Asian, 2.8% HIV, 22.3% HCV, 32.8% drug use, 10.5% cirrhosis), 16.1% completed HDV testing and 3.25% were positive. HDV testing was higher among Asians vs. non-Hispanic white (29.0% vs. 14.9%, aOR 1.94, 95%CI 1.32-1.68), men vs. women (16.2% vs. 14.5%, aOR 1.24, 95%CI 1.07-1.43), and HIV positive vs. negative (17.8% vs. 16.1%, aOR 1.32, 95%CI 1.07-1.64), p<0.01 for all. Among those tested, HDV positive was higher in HCV-positive vs. HCV-negative (8.45% vs. 2.35%, aOR 3.24, 95%CI 1.94-5.42), cirrhosis vs. non-cirrhosis (7.71% vs. 2.80%, aOR 2.27, 95%CI 1.47-3.53), and drug use vs. non-drug use (5.30% vs. 2.49%, aOR 2.04, 95%CI 1.14-3.63), p<0.01 for all.

Conclusion: Among US Veterans with CHB, HDV testing is alarmingly low, particularly among patients with HDV risk factors. HDV test positive was highest in patients with cirrhosis, HCV, and drug use. Greater HDV awareness is needed to improve timely diagnosis and treatment.

Abstract Submission No. 100802
O-0245
Bulevirtide improves virologic & biochemical response in non or partial responders with CHD

Pietro Lampertico1, Heiner Wedemeyer2, Maurizia R. Brunetto1, Mark Bourlière4, Dmitry Manuilov5, Qi An1, Audrey H. Lau3, Ben L. Da5, Renee-Claude Mercier3, Stefan Zeuzem6, Markus Cornberg2, Dominique Roulot2, Fabien Zoulim7, Soo Aleman8, Tarik Asselah9

1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy, 2Medizinische Hochschule Hannover Hannover Germany, 3Hepatology Unit, University Hospital of Pisa Pisa Italy, 4Hôpital Saint Joseph Marseille France, 5Gilead Sciences, Inc. Foster City, CA United States, 6Frankfurt University Hospital Frankfurt am Main Germany, 7Université Sorbonne Paris Nord Bobigny France, 8Hôpital de la Croix-Rousse Lyon France, 9Karolinska University Hospital/Karolinska Institutet Stockholm Sweden, 10Hôpital Beaujon, Université de Paris Cléchy France

Background: Bulevirtide (BLV) is approved in Europe for chronic hepatitis delta (CHD). It’s unclear whether BLV monotherapy benefits patients with early virologic nonresponse (NR) or partial response (PR) after 24 weeks (Wks).

Methods: Patients completed 96-Wk BLV monotherapy. Virologic response (VR) was defined as undetectable hepatitis delta virus (HDV) RNA or ≥2 log10 IU/mL decline from baseline (BL); NR and PR were defined as HDV RNA declines of <1 log10 IU/mL and ≥1 but <2 log10 IU/mL, respectively. Biochemical responses (alanine aminotransferase [ALT] within normal limits [WNL]) were compared.

Results: At Wk24, 92/141 patients had VR (ALT WNL, 53), 34/141 had PR (ALT WNL, 19), and 15/141 had NR (ALT WNL, 2) (Table). Of the 34 PR patients at Wk24, 25/35 PR patients had VR and 24 had ALT WNL by Wk96. Of the 15 NR patients at Wk24, 7 had VR and 3 had PR by Wk96. More NR at Wk24 achieved VR at Wk96 with BLV 10mg [4/5] vs BLV 2mg [3/10]. Median BL ALT was higher in patients with NR and PR at Wk96. The mean (SD) log10 IU/mL HDV RNA change at Wk96 among VR/PR/NR was −3.6 (1.1), −1.4 (0.3), and −0.2 (0.7) for VR, PR, and NR at Wk96. Median (Q1, Q3)ALT (U/L) change at Wk96 among VR/PR/NR was −48 (−73, −12), −42 (−83, −6), and −67 (−102, −33). Among NR at Wk96, ALT declined >50% from BL in 7/11 patients.

Conclusion: Results support continued BLV monotherapy despite early suboptimal virologic responses.

Abstract Submission No. 100812
O-0246

Efficacy & safety of bulevirtide in combination with pegylated interferon α-2a in patients with CHD

Tarik Asselah1, Pietro Lampertico2, Heiner Wedemeyer3, Adrian Streinu-Cercel4, Victor Pantea5, Stefan Lazar4, Gheorghe Placinta2, Vladimir Chulanov2, Dmitry Manuilov3, Renée-Claude Mercier3, Lei Ye6, Audrey H. Lau3, Stanislas Pol7, Fabien Zoulim8

1Hôpital Beaujon, Université de Paris Cléchy France, 2Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy, 3Medizinische Hochschule Hannover Hannover Germany, 4Matei Balșy National Institute of Infectious Diseases Bucharest Romania, 5Infectious Clinical Hospital “T. Ciorbă” Chișinău Moldova, 6Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital Bucharest Romania, 7National Medical Research Center for Phthisiopulmonology and Infectious Diseases Moscow Russian Federation, 8Gilead Sciences Inc. Foster City, CA United States, 9Hôpital Cochin Paris France, 10Hôpital de la Croix-Rousse Lyon France

Background: Bulevirtide (BLV) is approved for chronic hepatitis delta (CHD). Phase 2 MYR204 evaluated the safety and efficacy of BLV (2 and 10mg) with/without pegylated interferon α-2a (pegIFN) in patients with CHD and compensated cirrhosis (CC).

Methods: Based on CC status, 174 patients were randomized (1:2:2:2) to receive (A) pegIFN for 48 weeks (Wks); (B) BLV 2mg + pegIFN; (C) BLV 10mg + pegIFN for 48 Wks, then BLV 2 or 10mg monotherapy for 48 Wks; or (D) BLV 10mg for 96 Wks. The primary endpoint was sustained virologic response (SVR) at Wk24 (SVR24) after EOT (end of treatment) defined as undetectable hepatitis delta virus (HDV) RNA with comparison between Arms C and D.

Results: Overall, 35% had CC, mean liver stiffness was 13.1 (7.2) kPa, mean HDV RNA was 5.3 (1.2) log10 IU/mL, mean alanine aminotransferase (ALT) was 114.0 (94.8) U/L, 28% were on nucleos(t)ide analogue therapy, and 48% were IFN experienced. SVR24 was achieved by 17% (Arm A), 30% (Arm B), 46% (Arm C), and 12% (Arm D) (P = 0.0003; Arm C vs D) (Table). ALT normalization and composite endpoint at Wk24 after EOT were superior with BLV 10mg + pegIFN vs monotherapy. Hepatitis B surface antigen loss was observed in the combination groups. Adverse events (AEs) observed for the BLV + pegIFN arms were similar to pegIFN monotherapy. Six patients (3%) discontinued treatment (unrelated to BLV).

Conclusions: Combination therapy was effective and well tolerated. Longer-term data will help define durability of BLV + pegIFN for CHD.

Abstract Submission No. 100970
O-0247

BULEVIRTIDE IN PATIENTS WITH CHRONIC HEPATITIS D - REAL WORLD EXPERIENCE

Pavel Bogomolov1, Alexey Bueverov2, Natalia Barsukova3, Ekaterina Isaeva4, Nadezhda Shub5, Mikhail Kalashnikov6, Saniyat Magomedova7, Elena Arbuleivia8, Dzhamal Abdurakhmanov9, Irina Alieva10

1Department of Hepatology of the M.F.Vladimirsky Moscow Regional Research Clinical Institute Moscow Russia, 2Department of Hepatology of the M.F.Vladimirsky Moscow Regional Research Clinical Institute Moscow Russia, 3Department of Hepatology of the M.F.Vladimirsky Moscow Regional Research Clinical Institute Moscow Russia, 4Department of Hepatology of the M.F.Vladimirsky Moscow Regional Research Clinical Institute Moscow Russia, 5LCL “Center for targeted therapy” Moscow Russia, 6Department of Hepatology of the M.F.Vladimirsky Moscow Regional Research Clinical Institute Moscow Russia, 7Dagestan State Medical University Makhachkala Russia, 8Department of Infectious Diseases of the Dagestan State Medical University Makhachkala Russia, 9Department of Internal, Occupational diseases and Rheumatology of the I.M.Sechenov First Moscow State Medical University Sechenov University Moscow Russia, 10Department of Viral hepatitis of the A.M.Magomedov Republican Center for Infectious Diseases, Prevention and Control of AIDS Makhachkala Russia

M.F. Vladimirsky Moscow Regional Research and Clinical Institute; I.M.Sechenov First Moscow State Medical University; A.I.Yevdokimov Moscow State University of Medicine and Dentistry; “Center for targeted therapy”, Moscow, Russia, “Department of Viral hepatitis of the A.M.Magomedov Republican Center for Infectious Diseases, Prevention and Control of AIDS Makhachkala Russia

We analyzed retrospective data from 61 chronic hepatitis D (CHD) patients, including 27 with compensated cirrhosis, treated with bulevirtide, HBV and HDV entry inhibitor, 2 mg/day sc as
monotherapy or dual therapy (combined with peginterferon) up to 144 weeks in Moscow region and Dagestan centers. A 48-week treatment resulted in a significant decrease in HDV RNA levels from 6.9 log to undetectable (p<0.001), median reduction in HDV RNA levels from baseline -5.0 log, monotherapy -4.0 log, dual therapy -5.7 log, alanine aminotransferase (ALT) levels - from 68.0 to 31.0 U/l (p<0.001), high virological response rate (95%), monotherapy 93%, dual therapy 96%, full virological response (aviremia) 58%, ALT normalization (69% vs 20% at baseline). Virolological efficacy improved over the course of treatment. In patients with compensated cirrhosis similar virological response dynamics were observed compared to the overall group. The treatment was well tolerated, without serious adverse events, cases of treatment withdrawal. CHD treatment with bulevirtide in real-world practice demonstrated high efficacy, safety and good tolerability, including patients with compensated cirrhosis. Further development of an optimal treatment algorithm is needed.

Abstract Submission No. 100990
O-0248

Compassionate use of REP 2139-Mg in HBV/HDV infection with advanced liver disease
Andrew Vaillant1
1Replicor Inc. Montreal Canada

Background: In fibrotic patients, REP 2139-based combination therapy achieves high rates of functional cure of HBV and HDV. An ongoing compassionate use program (NCT05683548) provides REP 2139-Mg therapy for cirrhotic HBV / HDV co-infection with viral nonresponse or rebound with pegIFN and or bulevirtide therapy.

Methods: Add-on therapy with 250mg REP 2139-Mg qW SC and 90ug pegIFN (with compensated cirrhosis) was scheduled for 48 weeks. Safety and biochemical response were monitored weekly and virologic response every 4 weeks using standard assays for quantitative HBsAg and anti-HBs, HBV DNA, HDV RNA, HIV RNA and HBeAg.

Results: Currently 27/32 patients have completed > 24 weeks of REP 2139-Mg therapy. Transient grade 1 injection site reactions occur in a majority of patients. Four ALT flares > 5 U/L occurred accompanied pegIFN; 3 self-resolving and one resolved after removal of pegIFN. ALT has normalized in 12/32 patients.

HDV RNA has declined > 2 log, from baseline (22/32) and HDV RNA loss (15/32) is accompanied by HBsAg decline > 2 log (12/32), HBeAg loss (6/32) and anti-HBs seroconversion (6/32). HDV clearance was observed in 1 liver explant after 10 weeks of therapy. Functional cure of HBV with HDV cure (n=1) and persistent HBsAg and HDV RNA loss on TDF monotherapy (n=2) have occurred after removal of REP 2139-Mg.

Conclusions: REP 2139-Mg is safe and effective against HBV/HDV infection in advanced liver disease. REP 2139-Mg can clear HDV RNA from the blood and liver and can establish HBV functional cure and HDV cure in advanced liver disease.

Abstract Submission No. 100610
O-0249

High prevalence of Hepatitis D by double reflex testing of HBsAg positive individuals in Pakistan
Minaam Abbas1, Zaigham Abbas2
1Department of Medicine, University of Cambridge1 West Suffolk Hospital Cambridge United Kingdom, 2Dr. Ziauddin University Hospital, Clifton Karachi Pakistan

Background: Hepatitis D caused by the hepatitis delta virus (HDV) is a serious health problem in many regions of the world. We aimed to determine the prevalence of HDV infection by double reflex testing on HBsAg-positive visitors of screening camps in Usta Muhammad and Dera Allah Yar, two high-prevalence neighbouring towns in the eastern part of Baluchistan province of Pakistan.

Methods: 1643 people were examined for HBsAg and anti-HCV antibodies using ICT methods. HBsAg-positive individuals were further tested for antibodies to HDV (anti-HDV) using enzyme immunoassay (EIA). Samples with detectable anti-HDV were further examined for HDV RNA using real-time PCR.

Results: Of the 1643 individuals examined, HBsAg was reactive in 277 (16.9%) individuals. The reflex test for anti-HDV antibodies of these HBsAg positives was positive in 186 (67.1%); 133 were men and 53 were women. The mean age (years) was 32.2±11.3. HDV RNA was detectable in 108 (58.1%) of the anti-HDV-reactive patients. Log10 HDV RNA levels (IU/ml) were 6.69±1.34. Anti-HCV was detected in 227 (13.8%) of all examined individuals. Of these, four anti-HCV-positive individuals were also positive for HBsAg and one was positive for anti-HCV, HBsAg, and anti-HDV but negative for HDV RNA.

Conclusions: Reflex testing of HBsAg-positive individuals for HDV in an endemic area revealed that 67% of HBsAg-positive individuals had HDV exposure and 58.1% of anti-HDV-positive individuals had HDV viremia. Our study highlights the need for double-reflex testing in HBsAg-positive individuals for anti-HDV antibodies and HDV RNA in anti-HDV-positive individuals.

Abstract Submission No. 101229
O-0250

Development of a network for hepatitis D registration and study in Taiwan: TADR - An update in 2023
Tsung-Hui Hu1, Chun-Jen Liu1, Shiu-Feng Huang2, Ming-Lung Yu1, Chi-Yi Chen1, Chao-Wei Hsu1, Cheng-Yuan Peng1, Pin-Nan Cheng1, Yi-Hsiang Huang3, Chih-Lin Lin1, Chia-Chi Wang1, Teng-Yu Lee1, Hsing-Tao Kuo1, Yao-Chun Hsu1, Pei-Jer Chen1,3
1Taiwan Association for the Study of the Liver (TASL) Taipei Taiwan, 2National Institute of Cancer Research, National Health Research Institutes Miaoli Taiwan, 3Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan

Backgrounds: HBV and hepatitis delta (HDV) dual infections lead to more severe liver disease, with increased rates of cirrhosis and hepatic decompensation, and hepatocellular carcinoma (HCC). We aim to establish a nationwide epidemiological study of HDV in Taiwan.

Methods: We follow the successful launching of TACR (TASL Hepatitis C Registration) in Taiwan and invite the corresponding medical centers to join TADR (TASL Hepatitis D registration). TADR use this existing platform and to set up and manage the platform and blood samples of HDV patients (hospital cohort). A community cohort and special population (HIV/HBV co-infection) cohort will be also included for comparison. TADR already kicked off in February 2022, and includes 14 medical centers so far.

Results: At the end of OCT 2023, there have been 318 HDV cases registered. The prevalence of HDV in hospital cohort is approximately 1.2%. In a subgroup analysis of HBV related cirrhotic patients undergoing nucleos(t)ide therapy (NCT), the prevalence of HDV infection is 1.79% (14/780). There is no significant association between HDV and baseline clinical characteristics of patients (except age), as well as
the development of HCC and survival during follow up. Furthermore, a HDV surveillance in HBV related HCC patients was conducted from Taiwan Liver Cancer Network (TLCN). Among the 4217 patients, the prevalence of HDV is 2.75% (116/4217). HBV-HDV dual infected patients displayed worse 5-year survival than that of HBV mono-infection.

Conclusions: The changing HDV landscape in Taiwan will be refined. A case-controlled study might be mandatory in the future.

Abstract Submission No. 101302
O-0251

Efficacy of Pegylated Interferon-Alpha-2a in HDV: Experience from the Tertiary Care Hospital.

Riaz Hussain1, Nazish Butt1, Mohammad Masood1, Aman Ullah2
1Jinnah Postgraduate Medical Centre, Karachi, Pakistan, 2Civil Hospital Karachi KARACHI Pakistan

Objective: To evaluate the efficacy of Pegylated Interferon-Alpha-2a in chronic hepatitis D (CHD) infected patients presenting at a tertiary care hospital, in Karachi.

Methods: We have enrolled a total of 165 (CHD) patients at the Gastroenterology section of medical unit IV, Jinnah Postgraduate Medical Centre, Karachi, Pakistan, from July 2017-Oct 2023 who were treated for 48 weeks with Pegylated Interferon-Alphander A. Evaluation of HDV infection through Polymerase chain reaction (PCR) was done at 24 weeks, and 48 weeks interval. All laboratory values were repeated at regular intervals to assess the efficacy and side effects of therapy. Baseline and clinical data were recorded in a pre-structured questionnaire and analyzed using a statistical package for the social sciences (SPSS) version 21.0.

Results: A total of 148 patients were enrolled in the study, and final analysis was performed on 148 patients, among all, more than n = 76 (50.66%) of the patients had treatment failure response. While around n = 42 (28%) of the patients had partial treatment response and only n = 32 (21.33%) had treatment success rate. There was an insignificant difference observed when treatment response was compared among patients who received treatment at 24 weeks and 48 weeks (p<0.05). Alanine aminotransferase and total bilirubin levels were significantly improved in patients who achieved partial and end treatment with a mean difference of 7.69±2.5 and 0.33±0.24, (p<0.05), respectively.

Conclusion: Pegylated Interferon-Alpha-2a therapy in patients with CHD shows a sub-optimal outcome of (21.33%). Patients with treatment failure or null response required effective alternate therapy.

Abstract Submission No. 101770
O-0252

Clinical profile of patients with chronic HDV infection by the nationwide Italian PITER-cohort

Loreta A Kondili1, PITER Collaborating Investigators (www.progettopiter.it)1, Giuseppina Brancaccio1, Maria Elena Tosti1, Barbara Coco1, Maria Giovanna Quaranta1, Vincenzo Messina2, Alessia Ciancio3, Filomena Morisco4, Valerio Rosato1, Marianna Ciarello1, Irene Cacciola1, Maurizia Rossana Brunetto2, Giovanni Battista Gaeta2
1Center for Global Health, Istituto Superiore di Sanità Rome Italy, 2Infectious Disease Unit, University L. Vanvitelli Naples Italy, 3Department of Molecular Medicine, Infectious Diseases, University of Padua Padua Italy, 4University Hospital of Pisa Pisa Italy

Background and Aims: We aimed to comprehensively characterize patients with chronic hepatitis D (CHD) and explore treatment eligibility and prioritization criteria.

Methods: In this multicenter, cross-sectional cohort study, hepatitis B surface antigen (HBsAg)-positive patients were enrolled from 59 centers across Italy from November 2019 to February 2023. Multivariate logistic regression models explored the association between the considered variables with hepatitis D virus (HDV)-ribonucleic acid (RNA) positivity or liver cirrhosis.

Results: Of 4,152 enrolled patients, 422 (10.16%) were anti-HDV positive. Patients with anti-HDV were younger, more frequently non-Italian native, with a history of injection drug use, elevated ALT, and the presence of cirrhosis or hepatocellular carcinoma (HCC). Non-Italians were younger (42% aged <42 vs. 21%; p<0.001) and more frequently female (68.6% vs. 43.0%; p<0.001). Cirrhosis and HCC were more frequent among Italian patients. HDV-RNA was detected in 63% of tested patients who were likelier to have elevated ALT or gamma GT values, cirrhosis, and HCC. Body mass index (BMI)>25 was more frequent among HDV-RNA-negative patients. In the multivariable Cox model, only ALT was associated with HDV-RNA presence (OR 12.9, CI 95%: 6.3-26.3). Comorbidities were diagnosed in 47% of anti-HDV-positive patients; comorbidities were independently associated with cirrhosis, together with age and male gender. Based on absolute or relative contraindications, 22% of patients were eligible for IFN-based therapies.

Conclusions: CHD affects young foreign-born patients and older Italians, of whom two-thirds had cirrhosis or HCC. Comorbidities were associated with cirrhosis, and their role in liver disease progression should be further explored.

Abstract Submission No. 101793
O-0253

HCC risk is similar in HDV patients with viral response to treatment compared to HBV patients

Cihan Yurdaydn1-2, Onur Keskin3, Muge Ozari3, Genco Gençdal1, Ramazan İldim1, Mujdat Zeybel1, MURat Akyıldız1
1Kȯtetep University Ankara Turkey, 2Hacettepe University Ankara Turkey, 3Ankara University Ankara Turkey

Meta-analyses reported increased HCC risk in chronic hepatitis D (CHD) vs. chronic hepatitis B (CHB) (Alfawi et al, 2020, Kamal et al, 2021). Aim of this study was to compare effect of treatment on HCC development in CHD vs CHB.

Methods: 124 CHD patients (88male; mean age: 40.3±10.3, 28 [23%] cirrhotic at baseline) received a median 2 years (6 to 126 months) of interferon. 242 CHB patients (166M; mean age: 48.5±12.7, 65 [27%] cirrhotic) treated with entecavir or tenofovir were included. >95% of CHB. and 32% (40/124) of CHD patients had viral response (VR).

Results: Two groups were similar for baseline characteristics except for age (48.5±12.7 vs 40.3±10.3; p<0.01), HBeAg positivity (32.6% vs 16.9% p<0.01), platelets (188.5±76.7 vs 162±55.6; p<0.01) and ALT (80.2±113.4 vs 103.7±101.7; p=0.05) for CHB and CHD, respectively. HCC developed in 23 (9.5%) of CHB and in 21 (16.9%) of CHD patients during median 8 years of follow-up (FU). Cumulative HCC
Lonafarnib-based regimens associated with long-term apparent cures in chronic hepatitis delta

Cihan Yurdaydın1,2, Muge Ozari3, Onur Keskin4,5, Genco Gençdal5, Ramazan Idilman2, Mithat A Bozdaly2, Jeffrey S Glenn6

1Ko_OPERATION from Istanbul Turkey, 2Ankara University Ankara Turkey, 3Hacettepe University Ankara Turkey, 4Stanford University Stanford, CA USA, 5Veterans Administration Palo Alto, CA USA

The farnesyl transferase inhibitor lonafarnib is in advanced clinical development for chronic hepatitis delta virus (HDV) infection, having been studied in multiple phase 2 and 3 studies. Several patients who participated in these studies have now been followed for over eight years following clearance of HDV RNA and ALT. Here we report on four patients who following a single, or one brief retreatment, course of LNF-based therapy of 3 to 12 months duration demonstrated off-treatment virologic and biochemical responses lasting beyond 5 years of treatment discontinuation. In 3 of the 4 patients, long-term off-treatment efficacy was induced after a post-treatment beneficial enzymatic flare leading to regression of liver fibrosis while in one patient HDV RNA negativity was achieved on-treatment. One patient also cleared HBsAg. In 2 additional patients quantitative HBsAg levels at last visit were below 100 IU/mL. In conclusion, lonafarnib-based treatment appears to be an option for finite treatment in CHD where post-treatment virologic and biochemical responses lasting beyond 5 years following clearance of HDV RNA and ALT. Here we report on four patients who participated in these studies have now been followed for over eight years following clearance of HDV RNA and ALT. One patient also cleared HBsAg. In 2 additional patients quantitative HBsAg levels at last visit were below 100 IU/mL. In conclusion, lonafarnib-based treatment appears to be an option for finite treatment in CHD where post-treatment viral response may be at least as important as end of treatment rates in CHB and CHD patients with VR.

Pegylated Interferon α for patients with chronic hepatitis D in Mongolia

Sainzaya Batmunkh1, Sarantuya Gidaagaya1, Munkhbat Batmunkh2,3, Bira Namdag4

1Mongolia Japan hospital, Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2Department of Medical Law and Education, Graduate school, MNUMS, Mongolia Ulaanbaatar Mongolia, 3Department of Public Health, School of Medicine, IUIW, Japan Tokyo Japan

Introduction: Mongolia faces a high prevalence of chronic viral hepatitis, contributing to severe liver diseases like cirrhosis and hepatocellular carcinoma. This retrospective study analyzes the response rate of chronic hepatitis delta (CHD) patients treated with pegylated Interferon alpha (peg-IFNα).

Materials and Methods: Thirty-six CHD patients (mean age 37.4; male: 63.9%) receiving at least 24 weeks of peg-IFNα (between 2014-2019 in Intermed hospital) were analyzed. Virological response was assessed at the end of treatment and during follow-up at 24 and more than 48 weeks post-therapy.

Results: At the end of treatment, biochemical and virological responses were observed in 19.4% (n=7) and 27.8% (n=10) of patients, respectively. At 24 weeks follow-up, 50% (n=18) and 22.2% (n=8) of patients showed biochemical and virological responses. Sustained virological responses were observed in 22.2% (n=8) at 48 weeks, with HDV RNA reappearance in 4 patients. HBsAg-positive patient exhibited seroconversion. Antiviral treatment for over 48 weeks resulted in responses in 11.1% (n=4), including two with HBsAg loss.

Conclusions: Our study reveals sustained HDV clearance in approximately one-ninth of CHD patients. Reduced HBsAg levels, not only during treatment but also in the follow-up period, emerged as a primary predictor for long-term treatment response. These findings underscore the importance of monitoring HBsAg levels for effective CHD management.
Background: Ectopic lipid accumulation in kidney leads to lipotoxicity and contributes to development of diabetic nephropathy (DN). Recently, Apolipoprotein J (ApoJ) is recognized as a hepatokine and participates in lipid and glucose homeostasis. Herein, we reported that accumulation of ApoJ in renal tubule promotes renal injury and facilitates DN progression.

Methods: The pathways involved in ApoJ-associated pathogenesis were identified by Omics analysis and validated using in vitro gain- or loss-of-function assays and in vivo tissue-specific ApoJ knockout mice. A co-immunoprecipitation assay was applied to verify the interactions between ApoJ, mammalian target of rapamycin (mTOR), and transcription factor EB (TFEB). The autophagy-lysosome pathway was dynamically addressed by live image analysis and autophagic flux assay. The efficacy of ApoJ antagonist peptide on DN was evaluated in mouse models of obesity and diabetes.

Results: Elevating in ApoJ levels were found in serum and renal tubules and exerted positive correlations with renal tubular injuries in mouse models of DN. Functionally, ApoJ facilitated mTOR-TFEB interaction, leading to disturb lipid homeostasis and promote epithelial-mesenchymal transition of proximal tubular cells. Coordinated with endogenous ApoJ, accumulation of hepatocyte-derived ApoJ in renal tubule was found to accelerate DN progression. Moreover, targeting ApoJ reactivated TFEB, restored autophagy, and prevented accumulation of lipid and reactive oxygen species. Finally, a peptide antagonizing ApoJ chaperone activity reversed lipid deposition and fibrosis in mouse models of DN.

Conclusion: ApoJ promotes renal injury by inducing lipid and ROS accumulation through mTOR-TFEB-autophagy axis and proposed ApoJ antagonist peptide as a novel therapeutic strategy against DN.

Abstract Submission No. 100890

O-0258

All pediatric fatty liver diseases are not non-alcoholic fatty liver disease (NAFLD)

Alankrita Madhur1, Priti Vijay2, Dilip Ramrakhiani1

1Senior Resident, Department of Pathology, SMS Medical College & Attached Group of Hospitals Jaipur India, 2Assistant Professor, Department of Pediatric Medicine, Sir Padampat Institute of Neonatal and Pediatric Health, SMS Medical College Jaipur India, 3Senior Professor, Department of Pathology, SMS Medical College & Attached Group of Hospitals Jaipur India

Background and objectives: Fatty liver is the most common cause of chronic liver disease in adults due to obesity, whereas pediatric fatty liver disease has wide spectrum of etiology apart from obesity. In this study we aimed to identify all causes of fatty liver in children.

Methods: From June 2021 to June 2023 all liver biopsies done under follow up.

Results: Out of 25 liver biopsies, 15 were of infants. Median age at the time of biopsy was 7 years (Range 1 month-15 years) and 10 were females. Median weight and BMI (Median, IQR) were 38(20-48) & 26 (16-32) respectively. Median Platelet count, AST, ALT, Total Bilirubin was (Median, IQR) 202 (180-250), 165(100-236), 178(97-267), 6 (2-8) respectively. Etiologies of fatty liver were metabolic syndrome and obesity in 4, Wilson’s disease in 4, Glycogen storage disorders in 4, tyrosinemia in 2, celiac disease in 2, malnutrition in 2, Lysosomal acid lipase deficiency in 1, hereditary fructose intolerance in 1, Zellweger syndrome in 1, Cystic fibrosis in 1, steroid toxicity in child with nephrotic syndrome in 1, methotrexate toxicity in child with leukemia in 1, congenital generalized lipodystrophy in 1. All children were managed according to standard practice guidelines. Except Zellweger, congenital lipodystrophy and tyrosinemia all showed clinical improvement on follow up.

Conclusion: All pediatric fatty liver diseases are not due to metabolic syndrome & obesity. All efforts should be made to identify clear etiology to improve outcome.
Moinak Sen Sarma1, Nitu Kumari1, Srinivas Srinidhi Vadlapudi1, Anshu Srivastava1, Ujjal Poddar1, Surender Kumar Yachha1, Arghya Samanta1

1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

Background: Galactosemia constitutes 2% of all neonatal cholestasis. Despite early diagnosis and dietary exclusion, there may be adverse liver and neuro-opthalmic outcomes. We analysed the risk factors of outcome in galactosemia patients.

Methods: Diagnosis was based on galactose-1-phosphatase uridyl transferase (GAL-1-PUT) enzyme <10 U/gHb or mutation of GALT gene. Risk factors of death or neuro-opthalmic morbidity (poor neuro-recognition, learning disability persistent cataract or ambylopia despite cataract surgery) were analysed from a prospectively maintained database.

Results: Fifty-one galactosemia patients presented as infantile cholestasis. Their median age of symptom onset and diagnosis were 10(1-90) and 45(7-450) days respectively. Figure 1 shows the natural history on lactose-free diet. Among the 43 survivors, 28 had follow-up with >6 months were analysed for long term outcome. All had normalisation in liver functions. Ten(36%) had adverse neuro-opthalmic outcome. Eighteen patients are currently asymptomatic in follow up till now. Multivariate analysis of non-survivors(n=8) versus survivors(n=28) identified risk factors: refractory ascites (88% vs.18%, p=0.012), persistent coagulopathy at 4 weeks (88% vs.25%; p=0.02), and culture-positive sepsis (63% vs 43%; p=0.04). In addition, pediatric end-stage liver disease (PELD) score <21 (sensitivity 78%; specificity 50%, p=0.02) and Child score <7.5 (sensitivity 89%; specificity 61%, p=0.01) predicted survival. PELD score correlated with culture-positive sepsis (p=0.05). In the 10 patients with poor neuro-opthalmic morbidity, no risk factors could be identified.

Conclusion: Refractory ascites, uncorrectable coagulopathy at 4 weeks of diagnosis and sepsis were associated with poor liver outcome. PELD and Child score predict survival. Long term neuro-opthalmic morbidity is not associated with disease severity at onset.

Abstract Submission No. 101486
O-0261

Serum iron overload activates SMAD pathway and hepcidin expression of hepatocytes via SMURF1

Pengyao Yang1, Ning Zhang1, Yanmeng Li1, Qin Ouyang1, Fei Hou1, Guixin Zhu1, Bei Zhang1, Jian Huang1, Jidong Jia1, Anjian Xu1

1Capital Medical University, Beijing Friendship Hospital Beijing China

Background: Liver iron overload can induce hepatic expression of bone morphogenic protein (BMP)6 and activate the BMP-SMAD pathway. However, serum iron overload also can activate SMAD while does not induce BMP6 expression. Therefore, the mechanisms whereby serum iron overload activates the BMP-SMAD pathway remain unclear. The aim of this study is to clarify the role of SMURF1 in serum iron overload and BMP-SMAD pathway.

Methods: Cell model of serum iron overload was established by hepatocytes treated with 2 mg/mL Holo-transferrin (Holo-Tf). Serum iron overload mice model and liver iron overload mice model were established by intraperitoneal injection of C57BL/6 mice with 10 mg Holo-Tf and by administration of high iron diet for 1 week followed by a low iron diet for 2 days, respectively. Western blot and Real-time PCR were performed to evaluate the activation of BMP-SMAD pathway and the expression of hepcidin.

Results: Holo-Tf could augment the sensitivity and responsiveness of hepatocytes to BMP6. E3 ubiquitin-protein ligase SMURF1 mediated the Holo-Tf-induced SMAD1/5 activation and hepcidin expression specifically. SMURF1 dramatically decreased when serum iron was overloaded. Additionally, the substrates of SMURF1, important molecules that transduce BMP-SMAD signaling, were significantly upregulated. Furthermore, in vivo analyses confirmed SMURF1 specifically regulates the BMP-SMAD pathway in serum iron overload.

Conclusions: SMURF1 can specifically regulates the BMP-SMAD pathway by augmenting the responsiveness of hepatocytes to BMPs in serum iron overload.

Abstract Submission No. 101653
O-0262

Hepcidin-inducer Laennec® can sorely improve congenital iron and copper metabolism disorder

YUKI HAMADA1, Eiichi HIRANO2, Keizo HANADA3, Taichi KAKU3

1HAMADA Clinic of Gastroenterology sapporo Japan, 2Japan Bio Products Co. Ltd. Kurume Research Center KURUME Japan, 3Japan Bio Products Co. Ltd. TOKYO Japan

Aims: Recent studies indicate that hepcidin deficiency underlies most known forms of hereditary hemochromatosis (H.H.). The high affinity of hepcidin for copper also suggests that hepcidin could bind copper in vivo. Thus Laennec® which can induce hepcidin may be effective not only for H.H. but for Wilson’s disease by regulating iron and copper metabolism through the action of hepcidin.

Case1 H.H.: 55-years-old male patient that developed type2 diabetes mellitus had elevated serum ferritin level (10,191ng/ml). Liver biopsies revealed remarkable iron deposition. Chromosomal analysis revealed the presence of TIR2 mutations. As the substitute for the repeated phlebotomy, the infusion with Laennec® (672mg/d,3times/w) has been done for 11 years. Recent serum ferritin levels were constantly below 550ng/ml. HbA1c also improved with the same dose of insulin (8.86.8%). Liver biopsy revealed the improvement of liver fibrosis (F3àF1).

Case2 Wilson’s disease: 45-years-old male patient with compensated liver cirrhosis presented neuropsychiatric signs. Liver biopsy revealed the presence of the deposition of copper and iron. The infusion with Laennec® has been done for these10 years. Liver biopsies revealed the remarkable improvement of both in fibrosis (F3àF1) and metal deposition.

Conclusion: The discovery of hepcidin and its role in heavy metal metabolism could lead to the development of novel therapies for H.H. and Wilson’s disease. The placenta-derived Laennec®, which can induce hepcidin solely improved iron overload of H.H. patient, and the impaired copper metabolism through chelating excessive copper in Wilson’s disease. The results suggest that Laennec® can take the place of venesecion for H.H. and other hepcidin-deficient diseases.

Abstract Submission No. 101990
O-0263

Evaluation of genetic markers contributing to disease predisposition in patients with MAFLD/NAFLD

Pramod Gautam1, Pooja Rao1, Nisha Choudhary1, Kuldeep Chaudhary1, Vipin Singh1, Rosmy Babu2, Chhagan Bihari2, Shiv Kumar Sarin3

Abstract Submission No. 101652
O-0264

Hepcidin-inducer Laennec® can sorely improve congenital iron and copper metabolism disorder

YUKI HAMADA1, Eiichi HIRANO2, Keizo HANADA3, Taichi KAKU3

1HAMADA Clinic of Gastroenterology sapporo Japan, 2Japan Bio Products Co. Ltd. Kurume Research Center KURUME Japan, 3Japan Bio Products Co. Ltd. TOKYO Japan

Aims: Recent studies indicate that hepcidin deficiency underlies most known forms of hereditary hemochromatosis (H.H.). The high affinity of hepcidin for copper also suggests that hepcidin could bind copper in vivo. Thus Laennec® which can induce hepcidin may be effective not only for H.H. but for Wilson’s disease by regulating iron and copper metabolism through the action of hepcidin.

Case1 H.H.: 55-years-old male patient that developed type2 diabetes mellitus had elevated serum ferritin level (10,191ng/ml). Liver biopsies revealed remarkable iron deposition. Chromosomal analysis revealed the presence of TIR2 mutations. As the substitute for the repeated phlebotomy, the infusion with Laennec® (672mg/d,3times/w) has been done for 11 years. Recent serum ferritin levels were constantly below 550ng/ml. HbA1c also improved with the same dose of insulin (8.86.8%). Liver biopsy revealed the improvement of liver fibrosis (F3àF1).

Case2 Wilson’s disease: 45-years-old male patient with compensated liver cirrhosis presented neuropsychiatric signs. Liver biopsy revealed the presence of the deposition of copper and iron. The infusion with Laennec® has been done for these10 years. Liver biopsies revealed the remarkable improvement of both in fibrosis (F3àF1) and metal deposition.

Conclusion: The discovery of hepcidin and its role in heavy metal metabolism could lead to the development of novel therapies for H.H. and Wilson’s disease. The placenta-derived Laennec®, which can induce hepcidin solely improved iron overload of H.H. patient, and the impaired copper metabolism through chelating excessive copper in Wilson’s disease. The results suggest that Laennec® can take the place of venesecion for H.H. and other hepcidin-deficient diseases.

Abstract Submission No. 101990
O-0263

Evaluation of genetic markers contributing to disease predisposition in patients with MAFLD/NAFLD

Pramod Gautam1, Pooja Rao1, Nisha Choudhary1, Kuldeep Chaudhary1, Vipin Singh1, Rosmy Babu2, Chhagan Bihari2, Shiv Kumar Sarin3
Conclusion: The rising incidence of mortality and morbidity due to metabolic associated fatty liver disease (MAFLD) indicates towards genetic markers and their interplay with lifestyle factors to modulate the disease progression. Generally, 4 or 7 gene signatures are studied for the development and progression of MAFLD/NAFLD. The present study assesses the 68 MAFLD/NAFLD related genes in patients with different disease severity.

Methods: We sequenced 68 genes related to MAFLD/NAFLD phenotypes in 124 patients. The raw data after standard QC were mapped to GRCh38 and variants were called and annotated. The clinical impact of selected mutations was assessed by HGMD Professional and public databases for pathogenicity scores. Few of the genes included, APOB, APOE, FTO, PCSK9, PNPLA3, SAMM50 and TM6SF2.

Results: Out of 124 patients, 42 (34%) had clinical diagnosis of cirrhosis (NAFLD), 43 (35%) had NASH, 11 (8%) had MAFLD and 2 (2%) genetic cirrhosis with miscellaneous in 7 (6%) cases. Total of 168 variations were detected in the 118 patients which were relevant to the clinical phenotype with 6 cases reported no associated polymorphisms. The genes PNPLA3, PCSK9, GCKR and APOB together accounted for 88% of the observed genetic variations (n=148). Other genes included SAMM50, GPAM, TM6SF2 etc. (n=23, 12%). The major mutations included PNPLA3: Lys434Glu (n=43), PCSK9: Glu670Gly (n=25), GCKR: Pro446Leu (n=30) and APOB: Pro2739Leu (n=15).

Conclusion: Although PNPLA3 was most mutated gene, the mutations in GCKR, APOB and PCSK9 may also play a crucial role in MAFLD/NAFLD development and progression in Indian population.

Diagnostic genetic markers implicated in prothrombotic phenotypes in liver disease patients

Pramod Gautam1, Pooja Rao1, Nisha Choudhary1, Kuldeep Chaudhary1, Vinip Singh1, Rosmy Babu2, Chhagan Bihari2, Shiv Kumar Sarin2

1Senior Fellow, Genome Sequencing Lab, ILBS Delhi India, 2Dept of Pathology, ILBS Delhi India, 3Dept of Hepatology, ILBS Delhi India

Introduction: There could be risk of thrombosis in chronic liver disease both at inflow and outflow vessels. Previous reports from India have shown a very low frequency of inherited prothrombotic disorders in patients with vascular diseases. A thorough evaluation of predisposing prothrombotic genetic markers via sequencing is warranted in these patients.

Methods: We sequenced 44 genes related to thrombosis regulation in 88 patients (from Feb-Sep,23) with diagnosed vascular liver disorders. The genes included MTHFR, F5, F9, ADAMTS13 and VWF etc. Following standard QC measures, the clinical impact of selected mutations was assessed by HGMD Professional and public databases for pathogenicity/functional effects.

Results: Out of all, 70 cases had liver cirrhosis with partial/complete/chronic thrombosis of the portal vein, five patients had Chronic Budd-Chiari syndrome (BCH), and 12 patients had extra-hepatic portal vein obstruction (EHPVO). Upon analysis, 58% (n=51, Table) of the cases showed polymorphism associated with vascular thrombosis. In the thrombosis group, most mutations were in GCKR, GP6 and F13B (55%) e.g. GCKR: Pro446Leu, GP6: Ser219Pro and F13B: His115Arg. Similarly in the EHPVO group, F5 and FGA were most mutated (43%) e.g. FGA: Thr331Ala and F5: Arg534Gln. In BCH, CPB2: Thr347Ile, F13B: His115Arg, GP6: Ser219Pro and MTHFR: Ala222Val were observed.

Conclusion: The data presented here might prove useful in elucidation of molecular mechanism altering the regulation of coagulation factors, leading to risk of thrombosis.

Abstract Submission No. 101993

O-0264

Hepatomegaly from Poorly Controlled Type 1 Diabetes: A Rare Case of Mauriac Syndrome

Jan Bendric Borbe1, Jean Darlene Semilla2, Anatole Vallejos2, John Añonuevo2

1Division of Gastroenterology, Department of Medicine, University of the Philippines- Philippine General Hospital Manila Philippines, 2Department of Medicine, University of the Philippines- Philippine General Hospital Manila Philippines

Glycogenic hepatopathy is an underrecognized complication poorly controlled Type 1 Diabetes. Excessive glycogen accumulation in the hepatocytes may lead to massive liver enlargement. When hepatomegaly is accompanied by growth failure, a cushingoid appearance, and dyslipidemia, it is referred to as Mauriac syndrome. We describe a case of a 21-year-old female who was diagnosed with type 1 diabetes mellitus at the age of 8 and was maintained on insulin with poor compliance. She had recurrent hospitalizations for diabetic ketoacidosis since diagnosis. The patient also developed chronic kidney disease from diabetic nephropathy and has been on maintenance hemodialysis for 2 years. On examination, the patient was noticeably shorter compared to her parents with a height of 149cm and had visible abdominal enlargement with cushingoid facial features. The initial consideration for the abdominal enlargement was volume overload
from under dialyzed state. However, imaging revealed hepatomegaly (liver span 20cm) with no free fluid. She had regular follow-up at the outpatient clinic but had difficulty achieving adequate glycemic control from inconsistent insulin administration due to financial constraints. The patient eventually succumbed to complications of catheter-related bloodstream infection.

Strict glycemic control is the mainstay of treatment for hepatic glycogenosis. Complete reversal of hepatomegaly may be possible with improved control. Our case highlights the importance of recognizing the clinical features that comprise this rare syndrome to initiate timely management for this reversible condition.

Abstract Submission No. 101508
O-0267

The role of Vitamin E in the treatment of nonalcoholic steatohepatitis(NASH)

MOHAMED MAHBOOB ALI1

1ADVANCED MEDICAL AND DENTAL INSTITUTE(AMDI) GEORGETOWN Malaysia

Oxidative stress plays a vital role in the transition from simple steatosis to nonalcoholic steatohepatitis (NASH). An effective therapeutic strategy is to target the reduction of oxidative stress in these patients. Vitamins with antioxidant properties have the ability to act through multiple mechanisms to decrease the levels of reactive oxygen species in the body and prevent oxidative damage in the cell that can lead to cellular senescence and apoptosis. These properties may halt the progression of liver injury and facilitate the reversal of hepatic fibrosis in patients with NAFLD who are at risk for developing NASH. Thus, the aim of this study is to explore the functions of vitamin E in the treatment and recovery of patients suffering from NASH.

Abstract Submission No. 101783
O-0268

HEPATIC AMYLOIDOSIS: UNRAVELING THE MYSTERY !!!

Amit Soni1, Akhil Jindal1, Prashant Sarda1, Vivek Ruhela1

1SGRJIM&Hs Dehradun India

INTRODUCTION: Budd chiari syndrome (BCS) is considered as a disorder which mimics other disorders like constrictive pericarditis. We came across a case which was diagnosed and treated as BCS for 2 months, but it actually turn out to be a case of hepatic amyloidosis. CASE REPORT: We present a case of 35-year-old female with complaints of right upper quadrant pain for 1 year and insidious onset abdominal distension for 2 months. On examination patient was pale, had tachycardia, bilateral pedal edema and facial puffiness. Per abdominal examination revealed distended abdomen, shifting dullness and hepatomegaly. She was diagnosed as BCS based on her Triple phase CT abdomen findings and was being treated for same. However patient did not respond to the treatment. Patient was re-evaluated in our institute and her CT images were reviewed which showed thinned out hepatic veins, hepatomegaly and ascites however features like comma shape collaterals, regenerative nodules were not present. To confirm the diagnosis of BCS patient was taken up for hepatic venography which surprisingly revealed, no obstruction in hepatic veins. It was concluded that the false appearance of thinned out hepatic vein is likely due to extrinsic compression due to massive hepatomegaly. A liver biopsy was performed which confirmed the diagnosis of Amyloidosis.

CONCLUSION: This case is difficult and rare as triple phase CT abdomen was diagnostic of BCS but hepatic venography refuted the diagnosis and liver biopsy was performed which clinched the diagnosis of hepatic amyloidosis.

Abstract Submission No. 200039
O-0269

Wilson disease: Our observations over the past five years

Abu Saleh Md Sadequ Islam1, Mamun al Mahtab2, Salimur Rahman3

1SHAHEED ZIAUR RAHMAN MEDICAL COLLEGE BOGURA Bangladesh, 2BSMMU Dhaka Bangladesh, 3BSMMU Dhaka Bangladesh

Background: Wilson disease (WD) occurs worldwide with an average prevalence of ~ 30 affected individuals per million population. WD is due to mutations of the ATP7B gene on chromosome 13, which encodes a copper-transporting P-type ATPase (ATP7B) and responsible for decrease excretion of copper into bile and reduce synthesis of functional ceruloplasmin resulting accumulation of copper in affected tissues. Clinical presentation varies widely commonly liver, brain, eyes, and blood.

Objectives: To evaluate clinical and laboratory presentation over the past five years.

Methods: This is a hospital based observational study carried out in the Department of Hepatology, Shaheed Ziaur Rahman Medical College Hospital (SZMCH), Bogura over a period of five years, from January 2017 to December 2021. Twenty-four index patients of Wilson disease were enrolled in the study. We followed Leipzig Score for Wilson’s disease diagnosis. Total score 4 or more, diagnosis established as WD.

Results: Among 24, 46 % were female (n=11) and mean age was 16.4 year with range from 07 to 34. Liver presentation were Isolated spleenomegaly 8.3% (n=2), Persistently elevated serum aminotransferase activity (AST, ALT) 8.3% (n=2), Fatty liver 20.8% (n=5), Cirrhosis: compensated 8.3% (n=2) or decompensated 20.8 (n=5), Acute liver failure 29.2% (n=7). Hospital mortality of acute liver failure were 70.2 (n=5) without liver transplantation. Among them Neurological and Psychiatric manifestation were 16.6 % (n=04) and 45.8 % (n=11) respectively.

Conclusions: The spectrum of liver disease in WD are highly variable. If unexplained hepatic, neurologic or psychiatric Symptoms present we should carefully look for WD.

Abstract Submission No. 100088
O-0270

Lipid-Associated Macrophages Fuel NAFLD Fibrosis via CD36-Mediated Lipid Uptake & OPN Release

Zhe Dai1, Yinjin Wang1

1Southern University of Science and Technology, School of Medicine, Shenzhen China

Background and Aims: In the context of non-alcoholic fatty liver disease (NAFLD), a progressive transition occurs, replacing resident Kupffer cells (KCs) with distinct lipid-associated macrophages (LAMs) characterized by CD36 upregulation. However, the precise roles and mechanisms of CD36-expressing LAMs in NAFLD pathogenesis remain elusive.
Methods: We investigated LAM traits through single-cell RNA sequencing (scRNA-seq). Oleic acid (OA)-treated THLE-2 cells were co-cultured with THP1 macrophages to mimic LAMs and explore their in vitro functions. We also used high-fat diet (HFD) and methionine-choline-deficient (MCD) NASH mouse models.

Results: ScRNA-seq and in vitro data showed elevated CD36 expression in LAMs, linked to an immunosuppressive profile. By utilizing a co-culture system, we were able to confirm that the increased expression of CD36 in LAMs facilitated a more efficient uptake of lipids from hepatocytes with steatosis, subsequently triggering osteopontin (OPN) release via peroxisome proliferator-activated receptor gamma (PPARγ) pathway. ChIP-seq data and ChIP-qRNA experiments confirmed PPARγ regulation of SPP1, encoding OPN. OPN-stimulated hepatic stellate cells (HSCs) exhibited elevated alpha-smooth muscle actin (α-SMA) and collagen type 1 alpha 1 (COL1A1), driving liver fibrosis. CD36 silencing or inhibition in LAMs reduced lipid uptake and OPN release, mitigating fibrosis, observed in vitro and in mice. Combining a CD36 inhibitor with pioglitazone synergistically curbed fibrosis in murine models.

Conclusion: CD36 aids lipid transfer from hepatic cells to macrophages, activating hepatic stellate cells, and promoting liver fibrosis. Identifying CD36 as a potential therapeutic target holds promise for treating advanced NAFLD-associated fibrosis.

Abstract Submission No. 100307
O-0271

GLP-1RAs regulate lipid metabolism and induce autophagy through AMPK/SIRT1 pathway to improve NAFLD

Chun-Yan Niu1, Qiang Zhang2

1Department of Gastroenterology, Lishui District People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University Nanjing, China, 2Yancheng Third People’s Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University) Yancheng, Jiangsu Province, China China

Background: Non-alcoholic fatty liver disease (NAFLD) is a leading cause of cirrhosis and a major risk factor for hepatocellular carcinoma and liver-related death. Diabetes medications have been studied as potential treatments for NAFLD. Glucagon-like peptide-1 agonists (GLP-1RAs) have been rarely reported in the treatment of NAFLD alone as an anti-diabetic drug, and its specific mechanism of action is unknown. We investigated whether the therapeutic effect of liraglutide (LRG, a representative drug of GLP-1RAs) on hepatic steatosis is related to regulating lipid metabolism and enhancing autophagy in the hepatocytes.

Methods: We examined the effect of LRG on fat accumulation in fatty hepatocytes, and discussed its effects on enzymes related to lipid metabolism and autophagy. Meanwhile, knockdown of SIRT1 in free fatty acids (FFA)-treated cells was used to detected the influence of LRG on lipid metabolism and autophagy by regulating of AMPK/SIRT1 signaling.

Results: Our findings showed that free fatty acids (FFA) induced hepatocyte steatosis, which was significantly reversed by LRG. Meanwhile, LRG significantly regulated the expression of hepatocyte lipogenesis and cytosolic lipolysis-related proteins (FAS, ACC1, ATGL, HSL, LAL). Furthermore, LRG enhanced FFA-induced suppression of autophagy and SIRT1 expression, reducing intracellular lipid accumulation. It is evident that LRG regulates lipid metabolism and induces autophagy in an (AMPK)-dependent manner. Moreover, SIRT1 knockdown inhibited the autophagy-inducing and lipid-lowering effects of LRG.

Conclusion: GLP-1RAs may improve hepatic steatosis by regulating lipid metabolism and enhancing autophagy in an AMPK/SIRT1-dependent manner, which providing a new target for the treatment of NAFLD.

Abstract Submission No. 100313
O-0272

Amitriptyline inhibits NLRP3 inflammasomes activation via suppressing the ASM/CE pathway in NAFLD

Chun-Yan Niu1, Qin Liu2

1Department of Gastroenterology, Lishui District People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University Nanjing, China, 2Shengli Clinical Medical College of Fujian Medical University Fuzhou China

Background: Both Acid sphingomyelinase (ASM)/ceramide (CE) and NLRP3 inflammasome pathway are involved in the occurrence and development of NAFLD. However, it has not been reported whether ASM / CE pathway promote the occurrence of NAFLD by acting on the NLRP3 inflammasome pathway in vitro. Therefore, we conducted relevant cytopathological research.

Methods: NAFLD model cells were divided into 5 groups. The changes of intracellular lipid droplets and cell viability was detected, the biochemical metabolism indexes were determined. Western blot was used to measure ASM, NLRP3, caspase-1 protein expression; ELISA was used to detect the level of CE and ASM; the mRNA expression of ASM and IL-1β was tested by RT-PCR; the apoptotic rate of cells was evaluated by flow cytometry (FCM).

Results: ASM and CE levels in the NAFLD model group were significantly increased, along with the increase of the expressions of NLRP3, Caspase-1, IL-1β, and TG, TC, ALT, AST and MDA. These indicators further increased in the TNF-α group. Amitriptyline suppressed ASM and CE, decreased the levels of all the above biochemical and inflammatory biomarker, and reduced lipid droplets accumulation and improved apoptosis. MCC950 down-regulated the expressions of NLRP3, caspase-1 and IL-1β, improved lipid deposition and apoptosis in the cell of NAFLD.

Conclusions: ASM/CE-NLRP3 inflammasome pathway is a pivotal mechanism of hepatocyte steatosis, inflammation, and cell damage in NAFLD. Amitriptyline can inhibit this pathway from the source and exert the anti-lipid deposition and anti-inflammatory effects, suggesting that ASM/CE-NLRP3 pathway is a key target in the treatment of NAFLD.

Abstract Submission No. 100512
O-0273

Elucidating the role of complement C3 in metabolic-associated fatty liver disease

Van Dien Nguyen1, 2, Timothy R. Hughes1, 2, Biron Zhang1, 2, B. Paul Morgan1, 2, You Zhou

1Division of Infection and Immunity, School of Medicine, Cardiff University Cardiff United Kingdom, 2Systems Immunity Research Institute, School of Medicine, Cardiff University Cardiff United Kingdom

Background: Metabolic-associated fatty liver disease (MAFLD) affects 30% of adults and is the leading cause of liver transplantation. Despite the growing threat, no approved treatment exists. Accumulating evidence suggests an important role of the complement system in causation of MAFLD. As the axial component of the complement
system, C3 is predominantly produced in the liver, the metabolic ‘engine’ of the body; however, its metabolic role remains little known.

**Methods:** This study comprehensively characterized C3 expression in normal and MAFLD livers using single nuclei RNA sequencing and bulk RNA sequencing. Data were validated in free fatty acid-induced steatotic human hepatocytes, and a mouse model.

**Results:** C3 exhibited zonal expression, abundant in perportal hepatocytes. Celluar deconvolution showed that MAFLD disrupted hepatic zonal structure, depleting pericentral hepatocytes while expanding cytoplasms. Cellular deconvolution showed that MAFLD disrupted hepatic interactions between liver donors and recipients on PTDM outcomes. We demonstrate the impact of lipid accumulation on C3 expression in hepatocytes and show that C3 knockout impacts hepatic lipid handling. Overall, our study provides new insights into the role of C3 in MAFLD pathogenesis and suggests its potential as a therapeutic target for the treatment of MAFLD.

**Conclusion:** We demonstrate the impact of lipid accumulation on C3 expression in hepatocytes and show that C3 knockout impacts hepatic lipid handling. Overall, our study provides new insights into the role of C3 in MAFLD pathogenesis and suggests its potential as a therapeutic target for the treatment of MAFLD.

**Abstract Submission No. 100849**

**O-0274**

**Donor and recipient genetic interactions: improving post-transplant diabetes outcomes**

**abraham shaded, oren akedsh, bao-li chang, kim olthoff, rajender reddy**

1university of Pennsylvania philadelphia United States, 2university of pennsylvania philadelphia united states, 3university of pennsylvania philadelphia united states, 4university of pennsylvania philadelphia United States, 5university of Pennsylvania philadelphia United States, 6university of Pennsylvania philadelphia united states

Post-transplant diabetes mellitus (PTDM) is a prevalent complication after liver transplantation and is linked to the emergence of cardiometabolic complications. We studied the consequences of the genetic interactions between liver donors and recipients on PTDM outcomes. Liver transplant recipients without pre-transplant diagnosis of type 2 diabetes mellitus (T2D) and their paired donors underwent genome-wide genotyping. Polygenic risk scores (PRS) for T2D, insulin secretion, and insulin sensitivity were calculated using observations available from independent large-scale genome-wide association studies.

**Results:** 1115 recipient-donor pairs were included. For recipients who had the lowest T2D genetic risk, donor livers with the highest T2D-PRS contributed to the development of PTDM (OR (95% CI) = 3.79 (1.10 - 13.1), p=0.035). Recipient risk was linked to factors associated with insulin secretion and β-cell function (OR (95% CI) = 0.85 (0.74-0.98), p=0.02), while the donor liver contributed to PTDM via gene pathways involved in insulin sensitivity (OR (95% CI) = 0.86 (0.75-0.99), p=0.03).

**Conclusion:** Recipient and donor PRS independently and collectively serve as predictors for the onset of PTDM. The genetically influenced biological pathways in recipients primarily pertain to insulin secretion, while the genetic makeup of donors exerts an influence on insulin sensitivity. Knowledge of recipient and donor T2D-PRS could potentially enhance metabolic genetic matching, particularly in the context of living donor liver transplantation.

**Abstract Submission No. 100963**

**O-0276**

**New AI-digital pathology indices predict adverse clinical outcomes in patients with MASLD**

**Kutbuddin Akbary, Timothy Kendall, Dean Tai, Gideon Ho, Ren Yuan, Elaine Chng, Jonathan Fallowfield**

1Histolindex Pte Ltd Singapore Singapore, 2Centre for Inflammation Research, Institute for Regeneration and Repair, University of Edinburgh Edinburgh UK
Background: Single-Harmonic-Generation/Two-Photon-Excitation (SHG/TPE) imaging reduces observer-related variability in histological assessment of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD). Other digital pathology methods provide ordinal scores, and clinical outcomes are strongly correlated with fibrosis stage. We applied SHG/TPE imaging to cases in the SteatoSITE multimodal MASLD dataset (www.nature.com/articles/s41591-023-02602-2) to generate new indices predicting clinical outcomes, without fibrosis stage as a surrogate, using collagen morphological features unapparent to human observers.

Methods: n=452 biopsies (training n=300, validation n=152) were imaged by SHG/TPE. Following sequential feature selection, 10, 10, and 5 of 184 fibrosis parameters were chosen and linear regression used to aged by SHG/TPE. Following sequential feature selection, 10, 10, and 5 of 184 fibrosis parameters were chosen and linear regression used to predict the risk indices were compared with NASH-CRN fibrosis stage (F0/1/2 vs. F3/4) and SHG/TPE imaging-derived qFibrosis stage (qF0/1/2 vs. qF3/4).

Results: Figure 1 shows that the newly-defined “All-cause Mortality Index” had greater predictive power for all-cause mortality risk (HR=4.49) than NASH-CRN (HR=3.65) or qFibrosis stage (HR=3.59), and the “ Decompensation Index” had greater predictive power for de-compensation events (HR=5.96) than NASH-CRN (HR=3.65) or qFibrosis stage (HR=3.59).

Conclusion: We used a training and internal validation set of clinically-annotated MASLD biopsies to develop novel SHG/TPE imaging-based tissue-to-outcome risk indices that accurately predicted all-cause mortality and hepatic decompensation events. If externally validated, these indices could be leveraged to enhance patient stratification in clinical care pathways or MASLD drug trials.

Abstract Submission No. 100976

O-0277

Liver fibrosis is associated with burden of cardiovascular disease in non-alcoholic steatohepatitis

Kathleen E. Corey1, Anurag Mehta2, Kamal Kant Mangla3, Abhishek Shankar Chandramouli4, Margarida Augusto5, Ahsan Shoaib Patel6, Sharat Varma7, Niels Moeetzuma Krarup8, Katrine Grau9, Elisabetta Bugianesi9

1MGH Fatty Liver Program Massachusetts General Hospital Boston, MA USA, 2VCU Health Pauley Heart Center Richmond, VA USA, 3Novo Nordisk A/S Søborg Denmark, 4Novo Nordisk Service Center India Pvt Ltd Bangalore India, 5Department of Medical Sciences, University of Turin Turin Italy

Background: This study assessed the burden of cardiovascular (CV) disease (CVD) in patients with non-alcoholic steatohepatitis (NASH), using real-world US healthcare data (TriNetX).

Methods: Patients were identified using the International Classification of Diseases code (ICD-10-CM) for NASH (index date) and required the following: ≥1 fibrosis-4 index (FIB-4) measurement(s); ≥12 months of data prior to index date; and no history of CV events or cirrhosis at baseline. CV events were analyzed with FIB-4 continuous baseline FIB-4 measurements, a significantly increased risk of any and individual CV events was observed as FIB-4 increased (Figure). The risk of any CV event increased by 1.3% (HR 1.013; 95% confidence interval [CI] 1.006, 1.02; p=0.0003) and 14% (HR 1.14; 95% CI 1.06, 1.22; p=0.0003) for each 0.1- and 1-unit increase in FIB-4, respectively. For high and intermediate vs low FIB-4, adjusted HRs (95% CI) for any CV event were 2.05 (1.23, 3.41); p=0.006 and 0.87 (0.55, 1.37); p=0.5405.

Conclusions: Fibrosis assessed by baseline FIB-4 scores is associated with increasing clinical burden due to CVD, in terms of risk for CV events.

Funding: Novo Nordisk A/S

Abstract Submission No. 101057

O-0278

Ferroptosis is a cell death at an early stage of MASLD in a mouse model

Kouichi Miura1, Oyunjargar Bat-erdene1, Hiroshi Maeda2, Naoki Morimoto3, Hironori Yamamoto4

1Jichi Medical University Shimotsuke Japan

Background: Ferroptosis is a new form of cell death, characterized by the iron-dependent accumulation of lipid hydroperoxides to lethal levels. However, little information is available on the association between ferroptosis and MASLD.

Methods: Male hepatocyte-specific PTEN KO (PTEN KO) mice were used as a MASLD model. Huh7 was used in vitro experiment. Ferrostatin-1, a ferroptosis inhibitor, and apomorphine, a drug for Parkinson’s disease that has anti-ferroptotic function were used.

Results: PTEN KO mice at 10-week-old showed a moderate grade of steatosis but few hepatocyte ballooning, a hallmark for necrosis. In addition, PTEN KO mice showed increased oxidative stress markers, elevated serum transaminases, and increased proinflammatory and profibrogenic genes in the liver. There were few apoptotic cells and a certain number of hepatocytes positive for lipid peroxide accumulations (PI), a marker for necrosis. Treatment of ferrostatin-1 and apomorphine for 2 weeks ameliorated the features of MAFLD. There were no significant changes in hepatic iron contents in mice treated with ferrostatin-1 or apomorphine. Although necrosis inhibitor did not decrease the number of PI-positive hepatocytes, both ferrostatin-1 and apomorphine decreased the number of PI-positive hepatocytes. In vitro experiments, ferroptosis inducer RSL-3 induced cell death. This cell death was inhibited by ferrostatin-1 and apomorphine but not by necrosis inhibitor. In addition, cell death induced by RSL-3 were positive for PI, which were suppressed by ferrostatin-1 and apomorphine but not a necrosis inhibitor.

Conclusions: Ferroptosis contributes to cell death in an early stage of MASLD. Inhibition of ferroptosis is a potential treatment for MASLD.

Abstract Submission No. 101263

O-0279

NPC1 deficiency mediates autophagy impairment in NAFLD and serves as a target for NAFLD treatment

Qin NING1, Qiang Gao1, Suping Hai1, Xinliang Li2, Wenhui Wu1, Erliang Xie1, Binghui Yu1, Junjian Hu1, Xiaojing Wang1

1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Background: One important pathogenesis of NAFLD attribute to the imbalance of lipid metabolism, autophagy serves as a critical lipid metabolism pathway, but it impaired in NAFLD. We found Niemann-Pick...
C1 (NPC1), a transmembrane protein related to autophagy function, decreased dramatically in NAFLD, we aimed to investigate the role of NPC1 in NAFLD pathogenesis.

Methods: NAFLD mice model was established by feeding with high fat diet (HFD), pharmacological interventions were administrated by intraperitoneal injection. Palmitic acid (PA) was used to stimulate cells to establish NAFLD cell model, agents to regulate autophagy were added in the beginning of PA treatment. Lipid metabolism and autophagy function were tested.

Results: Autophagy flux was impaired in downstream in NAFLD which indicated by the increase of LC3II and P62. A dramatic decrease of NPC1 was detected, by using HP-b-CD, DOPG or Thioperaamide to compensate NPC1 function, we observed increased autophagy flux in vitro. Furthermore, Thioperaamide increased the level of NPC1 in vivo. but only when coupled with upstream activator RAPA, the lipid deposition could be eliminated. So, we sought for a strategy to stimulate autophagy both in upstream and downstream, and found the TFEB activator could improve autophagy flux and eliminate lipid deposition in NAFLD by stimulate autophagosome formation and NPC1 expression.

Conclusions: NPC1 deficiency serves as a critical role in downstream autophagy impairment in NAFLD. Stimulating both upstream and downstream autophagy is a feasible strategy to reverse the progression of NAFLD in vivo. TFEB activator seems to be an ideal approach to reverse NAFLD.

Abstract Submission No. 101275

**O-0280**

Mesenchymal stem cells restore NASH by ameliorating ER stress in the local environment of the liver.

Akihiro Seki1, Norihiko Ogawa1, Alessandro Nasti2, Yoshio Sakai2,1, Taro Yamashita2, Tuyen Ho Thuy Bich2

1Gastroenterology, Kanazawa University Hospital Kanazawa Japan, 2Information-Based Medicine Development Kanazawa Japan

Background: Mesenchymal stromal cells (MSCs) are expected to be the next novel therapy for liver diseases. Endoplasmic reticulum (ER) stress progresses NASH by cellular dysfunction and apoptosis of hepatocytes. In this study, we investigated the modulatory effect of MSCs on ER stress in a NASH mouse model.

Methods: MSCs, isolated from inguinal adipose tissue of C57Bl/6J mice, were injected into the splenic sub-capuscle of NASH mice established by high-fat atherogenic (HF-AT) diet feeding. Liver tissues were collected for gene and protein expression analysis and immunohistochemistry. In vitro, murine immortalized hepatocytes (H2.35) were cultured with conditioned media of IMS/N alone or IMS/N-MSC co-culture. Cell viability of H2.35 was assessed, and RNA or proteins were isolated from H2.35 or IMS/N.

Results: In response to HF-AT diet feeding, expression of Perk-related genes were upregulated in the NASH liver, and MSC treatment ameliorated the Perk-related genes compared to control. In addition, MSC treatment decreased the apoptotic cells and alpha SMA-positive activated stellate cells in the liver of NASH mice. In vitro, IMS/N-culture media induced expression of the Perk molecule. The IMS/N-culture media enhanced the Perk expression of H2.35, meanwhile, the media of IMS/N co-cultured with MSCs did not. Alpha SMA staining showed the de-activation of IMS/N co-cultured with MSCs. DNA microarray analysis revealed that IMS/N co-culture with MSCs attenuated the expression of 1182 genes related to CCL2, IL17, IL1, and HMGBl/RAGE signaling.

Conclusion: Adipose tissue-derived MSCs novel treatment ameliorated the NASH condition by alleviating the ER stress induced by hepatic stellate cells in hepatocytes.

Abstract Submission No. 101850

**O-0282**

Edaravone promotes the AMP-activated protein kinase to relieve nonalcoholic steatohepatitis in mice

Xiaoning Chen1, 2, Yanying You1, 2, Hanxin Xue1, 2, Lisha Wu1, 2, Danyi Zeng0, Qingqing Xing1, 2, Minxia Wu1, Jiaofeng Huang1, 2, Su Lin0, Jinshui Pan0, Yueyong Zhu0

1The First Affiliated Hospital, Fujian Medical University Fuzhou China, 2Fujian Clinical Research Center for Liver and Intestinal Diseases Fuzhou China

Objective: The global burden of nonalcoholic steatohepatitis (NASH) is increasing. Edaravone (EDA) has various biological and pharmacological activities, including anti-inflammatory and anti-oxidant activities. However, the effects of EDA on NASH remain unclear.
Methods: Steatosis cells were induced by palmitate/oleic acid (PO) in vitro. To establish the NASH animal model, C57BL/6j mice were fed a high-fat/high-cholesterol (HFHC) diet for 24 weeks. Furthermore, EDA were administered by intragastric gavage every day for 16 weeks. Glucose and insulin tolerance tests were used to investigate insulin sensitivity. Serum enzymes and lipids were assayed by a biochemistry analyzer. Histological analysis of the liver included HE, Oil red, and Sirius red staining. RNA-sequencing, real-time qPCR, and western blotting were used to investigate the expression of genes associated with lipid metabolism, inflammation, and fibrosis

Results: EDA alleviated lipid accumulation and inflammation in both HepG2 and AML12 cells after PO stimulation. In addition, EDA prevented HFHC-induced insulin resistance, lipid accumulation, liver inflammation, and liver fibrosis in NASH mice. Mechanistically, RNA-sequencing and western blotting suggested that EDA could promote AMPK-signaling pathway activation in vitro and in vivo, and this finding was further verified by determining the phosphorylation levels of AMPKα at the site of T172. Furthermore, the protective effects of EDA on lipid accumulation and inflammation in hepatocytes and livers induced by PO or HFHC disappeared under the effects of the AMPK inhibitor.

Conclusions: EDA protects against metabolic-stress-induced NASH progression through activation of AMPK signaling, indicating that EDA had the potential to be a promising drug for NASH therapy.

Abstract Submission No. 102054

O-0283

iNKT cells are key players in the progression of murine steatohepatitis caused by Western diet

Kazuyoshi Kon1, Akira Uchiyama1, Hiroo Fukada1, Shunhei Yamashina1, Kenichi Ikemijama2

1Juntendo University School of Medicine Tokyo Japan

Aim: We investigated the role of type 1 (iNKT cells) and type II NKT cells in age-related exacerbation of metabolic dysfunction-associated steatotic liver disease (MASLD).

Method: C57BL/6 mice, iNKT cells KO mice (Vα14KO), and all NKT cells KO mice (CD1dKO) aged 8 w.o (young) and 55 w.o (elder) mice were fed a high-fat/high-cholesterol diet (HFHC) or a control diet for 8 weeks.

Results: Whereas HFHC-fed wild young mice developed trivial hepatic steatosis with slight elevation of serum ALT levels to 54±11 IU/L, HFHC-fed wild elder mice showed severe macrovesicular steatohepatitis with marked elevation of serum ALT levels to 406±46 IU/L. Serum ALT levels significantly decreased to 268 ± 45 IU/L in Vα14KO elder mice, and further decreased to 159 ± 23 IU/L in CD1dKO elder mice. HFHC increased hepatic TNFα and TLR4 mRNA twice as much in elder mice as in young mice. HFHC-induced upregulation of TNFα and TLR4 in elder mice was equally significantly suppressed in both Vα14KO/CD1dKO mice. Sirius-Red staining showed pericentral fibrosis in elder mice fed an HFHC, while fibrosis was not observed in HFHC-fed Vα14KO/CD1dKO. Expression of TGFβ mRNA was enhanced only in HFHC-fed elder mice and was equally significantly suppressed in both HFHC-fed Vα14KO/CD1dKO mice.

Conclusion: These findings indicated that iNKT cells are more deeply involved in the induction of inflammatory cytokines and fibrogenesis although both iNKT cells and type II NKT cells are prominently involved in steatohepatitis in aged mice. It was concluded that iNKT cells play an important role in age-related exacerbation of MASLD.

Abstract Submission No. 200265

O-0285

Spatio-temporal immune landscape of tertiary lymphoid structures in non-alcoholic steatohepatitis

Jie Ma1,2,3, Shiming Gong1,2,3, Qiang Xia1,2,3, ZhenZhen Zhan1,2,3

1Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China, 2Shanghai Institute of Transplantation Shanghai China, 3Shanghai Engineering Research Center of Transplantation and Immunology Shanghai China

Background: The global epidemic of non-alcoholic fatty liver disease (NAFLD) and its more severe form, non-alcoholic steatohepatitis (NASH), represents a significant health and economic burden with no approved pharmacotherapy. Therapeutic promotion of sustained suppression of inflammation holds great promise for NASH, while the adaptive immunological mechanisms controlling hepatocyte injury in NASH remain largely unknown.

Methods: In this study, we horizontally investigated the immune landscape of NASH in both clinical samples and preclinical models by comprehensive multi-omic profiling, including spatial transcriptomics (ST), single-cell RNA sequencing (scRNA-seq), bulk RNA
sequencing, tandem mass tagging (TMT)-based proteomics, multiplex immunohistochemical (miHC) staining and H&E staining. C57BL/6J wild-type (WT), B-cell-deficient and transgenic mice were fed different NASH-inducing diets, after which NASH and fibrosis were assessed and analysed.

**Results:** We profiled the spatially resolved transcriptomic architecture of the NASH microenvironment and identified the presence of tertiary lymphoid structures (TLSs) with characteristic spatial patterns and involving genes associated with immune metabolism, cytokine and chemokine signalling, and extracellular matrix remodelling. These TLSs formed a functional hub and contributed to an active in situ process of B cell maturation towards plasma cell (PC) formation, autoantibody accumulation and the initiation of IgG-dependent hepatocyte apoptosis. Meanwhile, robust preclinical evidences demonstrated that B-cell depletion, BTK deficiency and acalabrutinib were effective in blocking B-cell activation, reducing IgG levels and ameliorating NASH phenotypes.

**Conclusions:** Our comprehensive immune profiling confirms the dark side of B-cell-rich TLS in both clinical NASH patients and highly translatable preclinical NASH models, highlighting the need for clinical evaluation of BTK inhibitors in NASH.

**Abstract Submission No. 100063**

**O-0286**

**Mechanistic study of tyrosine kinase inhibitors against metabolic-associated fatty liver disease**

**Han Kiat Ho1, Bhave Sayali Shrivardhan1**

1National University of Singapore Singapore Singapore

The pre-eminence of metabolic-associated fatty liver disease (MAFLD) in the general population calls for more targeted efforts to address this growing problem. While some tyrosine kinases (e.g. EGFR and MET) have been linked to the regulation of lipid homeostasis within the liver, their strategic advantage as pharmacological target has not been evaluated comparatively across the different sub-types of receptor tyrosine kinases. Hence, our lab addressed this research question head-on by using classical inhibitors for different receptor tyrosine kinases and apply them on both drug-induced and diet-induced models of lipid accumulation in liver cell lines. We evaluated their pharmacological potential by measuring the reduction in lipid accumulation as our phenotype-based assay. Thereafter, we explored the mechanism of action by investigating specific biochemical processes relevant to the disposition of lipids: fatty acid uptake, de novo lipogenesis, fatty acid oxidation, VLDL secretion and lipophagy. From this effort, two distinct tyrosine kinases were found to be pivotal in the regulation of lipid accumulation, namely EGFR and AXL. They play significant roles in modulating de novo lipogenesis and fatty acid oxidation, but they differ in the utilization of cell signaling pathways to achieve this. Critically, they present opposing effects on lipophagy which raises questions on the criticality of this process in the overall regulation of lipid homeostasis. Subsequent study using mice on MCD diet ascertained the manifestation of overall lipid reduction in the liver, as well as an attenuation of liver injury. These findings support further work to evaluate the feasibility of this therapeutic strategy.

**Abstract Submission No. 100078**

**O-0287**

**CD18 deficiency ameliorates NASH by inhibiting lipid synthesis and downregulating Th1 cells in mice**

Bayasi Guleng1, Xian-Ling Zhao1

1Department of Gastroenterology, Zhongshan Hospital of Xiamen University; School of Medicine, Xiamen University Xiamen China

**Background & Aims:** Nonalcoholic steatohepatitis (NASH) is the progressive stage of nonalcoholic fatty liver disease, which has a higher chance of progressing to end-stage liver disease, and there is an urgent need to find new molecular mechanisms and therapeutic targets. Contemporary studies have indicated the potential involvement of CD18 in governing cellular metabolic pathways. We aimed to explore the function and mechanisms of CD18 in NASH.

**Methods:** The investigation of the expression levels of CD18 in the liver tissue of NASH patients applied the GEO database. Then WT mice and CD18−/− mice were given a normal chow diet or a western diet (WD) for 16w to produce NASH model. A series of experimental methods were used to assess the expression of CD18 in NASH mice and its effect on NASH-related phenotypes. Flow cytometry and RT-qPCR were used to explore the possible regulatory mechanisms of CD18.

**Results:** Both NASH patients and mice showed remarkably elevated levels of CD18. In WT mice, the western diet causes obesity, steatosis, insulin resistance, fibrosis, and inflammation. CD18 deficiency significantly reduces these effects. Compared with WT WD mice, CD18−/− WD mice had decreased expression of lipid synthesis genes, increased expression of lipid oxidative catabolic genes, and lower numbers of Th1 cells in liver tissue.

**Conclusions:** The expression of CD18 was significantly increased in NASH patients and mouse models. Through the inhibition of lipid synthesis and a decrease in Th1 cell infiltration in liver tissue, CD18 deficiency reduces obesity, steatosis, insulin resistance, and inflammation in NASH mice.

**Abstract Submission No. 100182**

**O-0288**

**MicroRNA 29a ameliorates NAFLD by attenuating the MAVS pathway and mitigating liver steatofibrosis.**

Ying-Hsien Huang1, Ya-Ling Yang1

1Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan

**Aim:** Non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease, consists of fat deposited (steatosis) in the liver due to causes other than excessive alcohol use. NAFLD is a also hepatic manifestation of the metabolic syndrome.

**Methods and Materials:** We utilized miR-29a transgenic mice (miR-29a) and wild-type (WT) mice, subjecting them to a 36-week high-fat Western diet (WD) regimen to induce the NAFLD model. Hepatocellular steatosis was assessed through histopathological analysis, and dsRNA was detected via immunofluorescence staining, and other biochemistry assays.

**Key Findings:** The findings indicated that overexpression of miR-29a significantly curtails weight gain, lowers elevated AST/ALT levels, and reduces steatofibrosis in WD diet-treated mice. Moreover, miR-29a overexpression inhibits GSK3β expression, enhancing HSP60 levels and decreasing dsRNA in WD mice. Additionally, miR-29a over-expression diminishes the mitochondrial antiviral-signaling (MAVS) pathway in WD mice. This suppression of MAVS expression occurs through direct binding to its 3' UTR. In the HepG2 cell line, miR-29a mimics directly inhibits MAVS expression.

In conclusion: Our results support that miR-29a improves NAFLD by dampening the mitochondrial antiviral-signaling (MAVS) pathway and alleviating liver steatofibrosis.
Abstract Submission No. 100289

O-0289

**GSK-3β inhibition for stimulation of liver regeneration in partially hepatectomized rats**

**Vaibhav Sapra**, Onkar Bedi

1Chitkara College of Pharmacy, Chitkara University, Punjab, India, 2Chitkara College of Pharmacy, Chitkara University, Punjab, India

**Background:** The primary treatment for Chronic Liver Disease (CLD) involves dietary and non-dietary interventions. However, when CLD progresses to end-stage liver disease, liver transplantation becomes the only viable option, despite challenges such as donor shortages, transplant rejection, immunosuppressive drug complications, and high costs. To address the urgent need for post-transplantation liver regeneration, the growing focus is emphasized on stimulation of liver regeneration by pharmacological intervention, even in non-transplanted individuals or those with early liver complications.

**Method:** Present study aimed to stimulate the Wnt/β-catenin signaling pathway by inhibiting GSK-3β to promote hepatocyte replenishment and liver regeneration. A partial hepatectomy was performed on 44 rats, with the animals divided into six groups and assessed from postoperative days one to eight. The effects of the GSK-3β inhibitor CHIR99021 (6.25mg/kg/b.w.) on hepatic regeneration and hepatoprotection were evaluated using biochemical, histopathological methods, and docking studies.

**Results:** It was indicated that both single and repeated doses of CHIR99021 significantly improved lipid profiles, liver function, and reduced oxidative stress in partial hepatectomized rats on the 3rd and 7th day as compared to those without drug treatment. Histopathological assessments confirmed substantial hepatocyte regeneration after CHIR99021 treatment, supported by docking studies that showed significant binding interactions with essential amino acids of the protein. Mitotic cell phase determination also validated the histopathological findings in different rodent groups (Fig 1).

**Conclusion:** In conclusion, pharmacological stimulation of the Wnt/β-catenin pathway through GSK-3β inhibition with CHIR99021 demonstrated promising results in promoting hepatocyte regeneration, potentially offering a new treatment strategy for liver regeneration.

Abstract Submission No. 100283

**O-0290**

**Transcriptome analysis revealed FABP5 as a serum marker of metabolic associated fatty liver disease**

**Zhiyu Yang**, Junru Zhou, Binfyong Zhang, Xiuling Li

1Department of gastroenterology, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan Province, China, 2Zhengzhou University, Zhengzhou University, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, China

**Abstract:**

**Objective:** The pathogenesis of metabolic (dysfunction) associated fatty liver disease (MAFLD) is very complex, which has not been fully revealed as so far. In our study, the third-generation ONT (Oxford nanopore technologies) sequencing platform was used to explore the key differentially expressed genes involved in the pathogenesis of MAFLD.

**Methods:** In the present study, we firstly fed male C57/BL6N mice with high fat and high fructose (HFHF) diet for 19 weeks to induce MAFLD model while setting up a normal diet control group (Chow).

Secondly, we collected the liver tissues of the two groups and used the ONT technology to perform transcriptome analysis. Finally, we verified the sequencing results by quantitative polymerase chain reaction (qPCR) and measured the serum concentrations of fatty acid-binding protein 5 (FABP5) in mice and patients with MAFLD by Enzyme linked immunosorbent assay (ELISA).

**Results:** By transcriptome analysis, we found that there were 400 differentially expressed genes between the two groups, 12 of which participated in lipid transport and metabolism. Furthermore, we discovered that the serum level of FABP5 decreased significantly in patients with MAFLD, compared with healthy controls.

**Conclusion:** Involved in lipid transport and metabolism, FABP5 could be used as a serum marker of MAFLD.

Abstract Submission No. 100288

**O-0291**

**Pharmacological exploration of FAS inhibitors for managing diabetic & non diabetic-liver injury**

**Onkar Bedi**, Niharika Srivastava, Davinder Parsad, Pawan Krishna

1Chitkara College of Pharmacy, Chitkara University, Punjab Rajpura India, 2Department of Dermatology, Venereology and leprosy, PGIMER Chandigarh India, 3Department of Dermatology, Venereology and leprosy, PGIMER Chandigarh India, 4Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab India

**Objective:** The onset and development of liver damage is considered to be influenced by drugs and bad dietary habits.

**Methods:** The current study also aims to investigate the relation between paracetamol and high fructose + high fat produced diabetic and non-diabetic liver damage in context of innovative pharmacological therapies (Pterostilbene, Arbutin and Purpurin) with respect to their anti-adiopogenic and hepatoprotective effect (Figure 1). The various biochemical, oxidative stress and qRT-PCR parameters were considered for the evaluation of selected interventions.

**Results:** High fat and fructose diet intake for 28 weeks markedly (P<0.05) upsurge the level of glucose as compared to control diet treated experimental rodents. The scenario was reversed in the case of paracetamol treated rodents there was no significant (P<0.05) increase in the level of glucose which depicted the difference of diabetic and non-diabetic liver injury models. The lipid, liver, inflammatory (IL-6) level, oxidative stress and serum free fatty acid parameters were shown to possess significant (P<0.05) improvement in PTS, ARB and PUR treated groups as compared to the disease treated rodent groups.

**Conclusion:** It is hypothesized that reducing free fatty acid levels by Fatty Acid Synthase inhibition will improve insulin resistance and attenuate diabetic and non-diabetic Liver Injury.

Abstract Submission No. 100402

**O-0292**

**Oxidative-cellular bioenergetics governs the telomerase inhibition-induced senescence in hepatocytes**

**Pavitra Kumar**, Mohsin Hassan, Frank Tacke, Cornelius Engelmann

1Charité - Universitätsmedizin Berlin Berlin Germany, 2Charité - Universitätsmedizin Berlin Berlin Germany

**Objective:** The pathogenesis of metabolic (dysfunction) associated fatty liver disease (MAFLD) is very complex, which has not been fully revealed as so far. In our study, the third-generation ONT (Oxford nanopore technologies) sequencing platform was used to explore the key differentially expressed genes involved in the pathogenesis of MAFLD.

**Methods:** In the present study, we firstly fed male C57/BL6N mice with high fat and high fructose (HFHF) diet for 19 weeks to induce MAFLD model while setting up a normal diet control group (Chow).
Background: Cellular senescence is a state where cells resist growth signals and apoptosis, ceasing proliferation. This leads to a prolonged ‘zombie-like’ state, impacting regenerative tissues like the liver. Senescent cells undergo metabolic shifts, affecting liver function. Heterogeneity among the senescence characteristics makes targeting senescent cells difficult. This study focuses on the link between telomerase inhibition-induced senescence and liver cell metabolism.

Methods: Primary hepatocytes or hepatocyte-derived organoids were cultured in vitro. Both were treated with 20 μM BIBR-1532 (telomerase inhibitor) for 12-72 hours. Senescence was assessed through SA-β-galactosidase, immunofluorescence, immunoblotting (p53, p21, γH2AX), and senescence-associated secretory phenotype (SASP) markers. Cellular bioenergetics were measured using the XF eSea-horse analyzer.

Results: BIBR-1532 increased phosphorylation of histone (γH2AX), a DNA damage marker, by 10-fold (p<0.001), and SA β-galactosidase activity by 11-fold (p<0.001) (Figure 1A). Arrested proliferation is an important feature of senescence cells and the primary hepatocytes have limited proliferation in 2D culture. To overcome this limitation, we validated the results in hepatocyte-derived organoids and observed similar findings (Figure 1A). Coincided with DNA damage, BIBR1532 stabilized p53, increased p21 levels, and SASP expression. In contrast to the studies in immortalized cell lines, telomerase inhibition initially (up to 24 hours of treatment) increased oxidative phosphorylation capacity, however, in the later senescence phase, the cellular bioenergetics became predominantly glycolytic (Figure 1B).

Conclusion: BIBR-1532 (telomerase inhibitor) induces senescence phenotype in mouse primary hepatocytes. Cellular bioenergetic capacity transitions from oxidative phosphorylation to glycolysis in BIBR-1532 treated hepatocytes, which may affect the hepatocytes’ response to toxins and inflammation.

Abstract Submission No. 100503 O-0293

PAK1 protects against nonalcoholic fatty liver disease via suppression of PPARγ

Hanzhi Xu1,2, Xun Qiu1,2, Yawen Tan1,2, Zhoucheng Wang1,2, Xiao Xu1, Kai Wang1,2

1Institute of Organ Transplantation, Zhejiang University Hangzhou China, 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine Hangzhou China

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide characterised by an increase in hepatic accumulation of triglycerides. The p21 activated kinase 1 (PAK1) participates in the regulation of many cellular processes such as cell growth, survival and migration. However, the role of PAK1 in NAFLD remains unclear. This study aims to identify the function and mechanism of PAK1 in NAFLD.

Methods: The mice fed high fat or methionine and choline deficient L-amino acid diet and mouse hepatic cells treated with oleic acid were used to detect the change of PAK1 in the progression of NAFLD/NASH. Lentivirus, siRNA and small molecular chemicals were used to overexpress or suppress targeted genes in mouse hepatic cells. Triglyceride content was detected by oil red O staining. The gene expression was measured by western blotting and RT-qPCR. In vivo investigations have shown that inhibiting FTO’s enzymatic

Abstract Submission No. 100543 O-0294

Antioxidative Activity of Orange Water Kefir to Improve Liver Tissue in The Hyperlipidemic Rat Model

Rafik Prabowo1,2, Saosanti Mariana3

1Region General Hospital of Rokan Hulu Riau Indonesia, 2Faculty of Medicine, Universitas Islam Indonesia Special Region of Yogyakarta Indonesia, 3Faculty of Industrial Technology, Universitas Islam Indonesia Special Region of Yogyakarta Indonesia

Background: This research aims to know the antioxidative activity of orange water kefir drink to improve oxidative stress of liver tissue and lipid profile level in the hyperlipidemic rat model.

Material and Methods: This research used 30 rats divided into 3 groups (K+, K-, B). Group of K+ and B were given quail egg yolk for the first 4 weeks to make hyperlipidemia condition. For the next 4 weeks, K+ and K- groups were only fed ad libitum. Group B was given an orange water kefir drink with a dose of 5 ml/200grBW. Orange water kefir drink was made by good manufacturing product (GMP) standards and the procedure for making water kefir. All of this intervention was administered to rats with the sonde method. Blood sampling was taken to measure lipid profile (Total Cholesterol/TC and High-Density Lipoprotein/HDL) and the animal model was terminated to get liver organs to measure the Malondialdehyde (MDA level) and Superoxide Dismutase (SOD activity). Data will be expressed as mean ± SD and significant differences when the P value < 0.05.

Results: The Mean of TC (mg/dL) was 203.50±0.96 (K+), 77.80±1.52 (K-), and 131.32±2.38 (B). Mean of HDL (mg/dL) was 25.98±0.58 (K+), 82.31±0.88 (K-), and 51.50±1.24 (B). MDA level (nmol/g) was 11.80±0.17 (K+), 2.5±0.12 (K-), and 4.56±0.12 (B). The mean of SOD activity (%) was 21.43±2.52 (K+), 71.43 ± 3.91 (K-), and 71.42 ± 2.70 (B). The results showed significant differences between all groups after the intervention with orange water kefir drink (P<0.001).

Conclusion: The antioxidative activity of orange water kefir drink has been proven to improve oxidative stress of liver tissue and lipid profile levels in the hyperlipidemic rat model.

Abstract Submission No. 100552 O-0295

Entacapone Abrogate Steatotic Liver Disease Progression by Modulating FTO Gene Expression

Sunita Giri1, Vijay Kumar1

1Institute of liver and biliary sciences Delhi India

Background: Steatotic Liver Disease (SLD) is a metabolic dysfunction-associated liver disease that arises in the context of obesity and metabolic disorders, and poses a substantial health burden. The fat mass- and obesity-associated (FTO) gene, initially identified through genome-wide association studies, is positively correlated with obesity and metabolism in both humans and mice. However, the metabolic regulation of FTO in SLD remains unclear. Furthermore, in silico and in vitro investigations have shown that inhibiting FTO’s enzymatic
activity of FTO leads to the dysregulation of genes involved in energy metabolism. In this study, we used entacapone, a drug for Parkinson’s disease treatment and known as an FTO inhibitor, to alleviate SLD in a murine obesity model.

Methods A murine obesity model was established by feeding C57BL/6J male mice a high-fat, high-calorie (HFHC) diet for 13 weeks, with some mice receiving intraperitoneal entacapone injections of varying doses and durations. Key metabolic parameters, including glucose and insulin tolerance, liver histology, serum biochemistry, adiponectin and leptin levels, and hepatic FTO expression, were meticulously assessed using microscopy, ELISA, RT-qPCR, immunohistochemistry, and western blotting.

Results: Compared with their entacapone-treated counterparts, HFHC-fed mice exhibited impaired glucose regulation, increased body weight, heightened liver index score (p<0.0001), and periportal fibrosis. Disease severity, reflected by SLD activity scores (p<0.0001), emphasized exacerbated liver pathology in the HFHC-fed group. Elevated serum biochemical markers, such as alanine transaminase, aspartate transaminase, triglycerides, and total cholesterol, were evident in HFHC-fed mice. In contrast, the entacapone-treated group displayed more favorable metabolic profiles (p<0.01).

Additionally, entacapone-treated mice demonstrated elevated serum adiponectin levels and reduced serum FTO expression (p<0.0001). In contrast, higher levels of serum leptin and FTO were observed in HFHC-fed mice. RT-qPCR, immunohistochemical analysis, and western blot validation confirmed increased FTO expression (p<0.0001) in the livers of HFHC-fed mice compared to that in the treatment groups.

Conclusion: These findings suggest that entacapone has the potential as a therapeutic agent for the management of obesity and SLD by interfering with the progression of MASLD. This study introduced entacapone as a repurposing drug to address metabolic liver disorders associated with obesity, thereby offering novel therapeutic avenues in this demanding medical domain.

Abstract Submission No. 100744

O-0296

METTL14 Promotes Liver Glucose Production and Liver Steatosis in Obesity by RNA m6A modification

Xiao Zhong1, 2, 6, Qiantao Zheng2, 3, Qianqian Kang2, 3, Zhiguo Zhang2, 3, Decheng Ren1, Liangyou Rui1, 2, 5

1Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University Changsha China, 2Department of Molecular & Integrative Physiology, University of Michigan Medical School Ann Arbor USA, 3Elizabeth Weiser Caswell Diabetes Institute, University of Michigan Michigan USA, 4Department of Medicine, University of Chicago Chicago USA, 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical School Ann Arbor USA, 6National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University Changsha China

Hepatic glucose production (HGP), a pivotal process mediated by glycolysis and gluconeogenesis, maintains energy metabolism during fasting and exercise. However, an excessive amount of HGP can lead to diabetes. Glucose-6-phosphatase (G6pase) is a key enzyme that regulates HGP through both glycolysis and gluconeogenesis. N6-methyladenosine (m6A) modification controls RNA processing, trafficking, decay, and translation. Mettl14 binds to Mettl3 and forms a m6A transferase complex to modify RNA. Recent studies have shown that the Mettl3/Mettl14/m6A pathway plays a crucial role in health and disease, but its function in HGP remains unknown. Here, we identify Mettl14 as m6A writer for G6pase transcripts. Obesogenic factors increase expression of Mettl14 and Mettl3 in hepatocytes, thereby increasing RNA m6A modification in the liver. Deletion of hepatic Mettl14 decreases hepatic gluconeogenesis, liver glucagon response, and blood glucose in mice with HFD-induced obesity while not altering HFD-induced obesity. Mettl14 overexpression has the opposite effect. Moreover, Mettl14-deficient male mice are resistant to HFD-induced liver steatosis, and Mettl14 deficiency does not alter liver insulin and glucagon signaling. Notably, HFD feeding increases liver G6pase transcript m6A content and G6pase levels. Overexpression of Mettl14 increases, whereas ablation of Mettl14 decreases G6pase transcript m6A content in hepatocytes. Deletion of Mettl14 decreases G6pase transcript stability and translation, thereby lowering G6Pase levels, gluconeogenesis, and glycogenolysis. These data unravel a hepatic Mettl14/m6A/G6pase/gluconeogenesis and glycogenolysis axis contributes to increased hepatic glucose production and diabetes progression in obesity.

Abstract Submission No. 100780

O-0297

Role of Serum Ferritin Level in The Diagnosis of Non-Alcoholic Fatty Liver Disease

Mohammad AZAM1, A Arbab Chowdhury1, M Anisur Rahman1

1BIRDEM ACADEMY Dhaka Bangladesh

Background: Non-alcoholic fatty liver disease (NAFLD) is characterized by excessive liver fat accumulation and is a major cause of progressive liver disease. Serum ferritin is a biochemical parameter which is elevated in several clinical conditions including both acute and chronic liver diseases. It may indicate hepatic inflammation, necrosis and fibrosis progression in NAFLD due to its association with iron buildup and inflammation.

Aims: To assess the role of serum ferritin as an effective marker in the diagnosis of NAFLD.

Materials and Methods: This cross sectional study was conducted at Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic disorders (BIRDEM) General Hospital, Dhaka on patients attending department of Gastrointestinal, Hepatobiliary and Pancreatic Disorders (GHPD). Purposive sampling technique was applied to enroll the subjects according to selection criteria. Statistical significance were set at 0.05 level and confidence interval at 95% level.

Result: This study included 206 patients. They were divided into two groups on the basis of ultrasonogram of abdomen. Among them 136 patients had NAFLD (Group-A) and 70 patients had normal liver (Group-B). Serum ferritin level was measured in all patients. The mean±SD of serum ferritin was significantly higher among Group-A (326.88±203.94) than Group-B (57.23±14.55) (p<0.001). ROC analysis for serum ferritin level yielded an AUC of 0.993. Sensitivity, specificity, PPV, NPV and accuracy at cut off value 77 ng/ml were 94%, 97%, 94%, 97%, 96%; at 78.5 ng/ml were 95%, 97%, 94%, 95%, 96%; at 81.5 ng/ml were 98%, 95%, 92%, 99%, 97%; at 82.6 ng/ml were 94%, 98%, 99%, 89%, 95% and at 86 ng/ml were 92%, 98%, 90%, 92% and 90% respectively. The cut-off value of serum ferritin ≥81.50 ng/ml showed the highest accuracy.

Conclusion: The findings of this study suggest serum ferritin is an important biochemical test of NAFLD.

Abstract Submission No. 100818

O-0298
INFODEMIOLOGY STUDY

FATTY LIVER DISEASE: A RETROSPECTIVE INFODEMIOLOGY STUDY

Aaron Lemuel Ong1, Janus Po Ong2, Eric David B. Ornos3
1Philippine General Hospital Cebu Philippines, 2Philippine General Hospital Manila Philippines, 3University of the Philippines Manila Philippines

Background: Non-alcoholic fatty liver disease (NAFLD) is a prevalent and growing health concern globally, coinciding with the rise of metabolic disorders. Understanding the search patterns related to NAFLD can provide insights into public interest for this condition. This research aims to analyze global online interest using Google Trends.

Methods: Google Trends data for search terms related to fatty liver over a period of five years was downloaded and analyzed. Spearman’s rank-order correlation correlated NAFLD, diabetes and obesity prevalence data, GDP per capita and internet penetration rate with search volume index.

Results: There was a significant reduction in online search interest during the COVID-19 pandemic (2020) however, there was an increase of approximately 30% in search terms related to fatty liver post-pandemic. The Latin American countries had the highest search volume when using the search term “fatty liver disease” while predominantly North American and Middle Eastern countries used “NAFLD” as a search term. The NAFLD search volume index was positively correlated with obesity prevalence and GDP per capita while searches for fatty liver disease correlated with the NAFLD prevalence in these respective countries. Countries with high liver cirrhosis-related mortality also searched “fatty liver” the most. Although majority of countries had above average internet penetration rate, this did not approach statistical significance.

Conclusions: The study found that the global online interest in fatty liver disease is increasing especially in regions where NAFLD prevalence is high and the use of Google Trends can be utilized as an infodemiologic tool.

Abstract Submission No. 100820
O-0299

A COMPARISON OF THE KNOWLEDGE AND PRACTICES ON NON-ALCOHOLIC FATTY LIVER DISEASE AMONG PHYSICIANS

Aaron Lemuel Ong1, Janus Po Ong2
1Philippine General Hospital Manila Philippines, 2Philippine General Hospital Manila Philippines

Background: NAFLD affects 25% of the population worldwide and poses a significant economic burden. It is important that physicians are aware of the burden of NAFLD and its appropriate management. This study aims to assess the knowledge, attitude, and practices of physicians towards NAFLD in a tertiary hospital.

Methods: A cross-sectional study was done using an online questionnaire distributed to all specialists, fellows and residents in Internal and Family Medicine in Philippine General Hospital.

Results: A total of 97 physicians participated in this online survey. Most of the respondents were from family medicine followed by internal medicine. In terms of knowledge, only half of participants correctly identified the true prevalence of NAFLD and just 20% were aware of the available tools to stage fibrosis in NAFLD. On multiple regression, only number of NAFLD patients seen per year seemed to correlate with knowledge but this did not reach statistical significance.

Despite most physicians agreeing that NAFLD may lead to cirrhosis, a third are not concerned about cirrhosis as a consequence of NAFLD and only half routinely screen for NAFLD in at-risk patients. Fibrosis risk assessment using predictive tools is almost never practiced and referral to specialists is only done occasionally. Majority however, routinely prescribe individualized diet and exercise regimens.

Conclusion: Despite the increasing burden of NAFLD, there is still a significant gap in the knowledge and practices among physicians. Reinforcement of guidelines should be shared to all physicians in order to improve diagnosis and management of this disease.

Abstract Submission No. 100830
O-0300

Lessons on Drug Development: A Literature Review of Challenges Faced in MASLD Clinical Trials

Joel Yeh Siang Chen1, Damien Chua1, Nguan Soon Tan1
1Lee Kong Chian School of Medicine Singapore Singapore

Background: Metabolic-dysfunction associated Steatotic Liver Disease (MASLD) is a leading liver disorder worldwide, resulting in both hepatic and systemic complications, notably cardiovascular diseases. Notwithstanding its profound impact on healthcare, current therapeutic strategies for MASLD primarily hinge on weight management — a task often challenging for patients — with no pharmaceutical solutions approved by the FDA to date.

Methods: We conducted a review of MASLD-focused clinical trials for 22 drugs (Phase 2 and beyond) listed on ClinicalTrials.gov as of 24th August 2022. Data collected encompassed trial identifiers, titles/ acronyms, duration, patient counts and diagnoses, trial outcomes, and associated side effects. Subsequently, drugs were grouped into five analytical categories: Hypoglycemic, Lipid-lowering, Bile-pathway, Anti-inflammatory, and a diverse set which included nutraceuticals.

Results: Challenges hampering progress in the MASLD drug landscape included limited data, challenging trial design and outcomes, and debilitating adverse events. These findings shed light on several key areas for improvement, including repurposing existing drugs, exploring drug combinations, adopting non-invasive outcome measures, advocating for standardization, addressing adverse reactions, and prioritizing precision medicine that duly accounts for the intricate heterogeneity of MASLD in clinical trials.

Conclusion: While every advancement in drug discovery invariably presents unique challenges, this study underscores the importance of drawing lessons from past experiences. Proposing strategic improvements based on prevailing data allow us to advance clinical trials towards uncovering effective therapeutic drugs for MASLD management.

Abstract Submission No. 100866
O-0301

OMENTIN-1: IMPLICATIONS ON ITS ROLE IN DIABETES AND METABOLIC-ASSOCIATED FATTY LIVER DISEASE

Noel Salvoza1,2,3, Pablo Giraudi4, Silvia Gazzin2, Maria Melissa Milito2,3, Deborah Bonazza2, Silvia Palmisano4, Nicolet de Manzi2, Fabrizio Zanconati2, Alan Raseni2, Francesca Sirianni2, Claudio Tiribelli2, Natalia Rosso5
1Philippine Council for Health Research and Development - Department of Science and Technology Philippines Taguig Philippines, 2Fondazione Italiana Fegato - ONLUS Trieste Italy, 3Lee Kong Chian School of Medicine Singapore Singapore, 4Azienda Ospedaliero Universitaria di Trieste Italy, 5Department of Science and Technology Philippines Taguig Philippines

Background: Omentin-1 is an adipocytokine which is expressed in human omentum lipocytes and adipose tissue in vivo and in vitro. Omentin-1 is a 38 kDa protein which is a member of the fibrinogen-like family of proteins. Omentin-1 is known to be involved in the regulation of glucose, lipid and insulin metabolism. Omentin-1 has also been associated with obesity and type 2 diabetes in the past years.

Methods: A comprehensive literature review was conducted to analyze the role of Omentin-1 in diabetes and metabolic-associated fatty liver disease (MAF-LD). The databases PubMed, Scopus, and Web of Science were searched for relevant articles. The search terms included “omentin-1”, “diabetes”, “metabolic syndrome”, “fatty liver disease”, “liver cirrhosis”, and “non-alcoholic fatty liver disease.”

Results: The search resulted in 100 articles, of which 50 were relevant to the study. The majority of the studies found a significant association between Omentin-1 and metabolic diseases, including diabetes, obesity, and metabolic syndrome. Several studies also reported an association between Omentin-1 and non-alcoholic fatty liver disease (NAFLD) and liver cirrhosis.

Conclusion: Omentin-1 is a potential biomarker for metabolic diseases, including diabetes and fatty liver disease. Further studies are needed to clarify the role of Omentin-1 in the development and progression of these diseases.
Objectives: Obesity and diabetes are tightly linked to metabolic-associated fatty liver disease (MAFLD). Here, we explore the potential role of visceral adipose tissue (VAT) omentin-1, identified through in silico analysis, in the context of obesity-related MAFLD and diabetes.

Methods: Omentin-1 levels were measured in obese patients with biopsy-proven MAFLD and mice fed with high-fat diet (HFD). In vitro and/or ex vivo studies were conducted to investigate the effects of omentin-1 on MAFLD-related pathogenesis, including steatosis, inflammation, ER stress, oxidative stress, and glucose-insulin modulation. We also analyzed the levels of omentin-1 in diabetic patients before and after 1 year of bariatric surgery.

Results: VAT and plasma omentin-1 levels exhibit a significant stepwise reduction in MAFLD patients, depending on disease severity but independent of fibrosis status. Likewise, HFD-fed mice with histological signs of MASH exhibited significantly reduced omentin-1 levels compared to their control diet counterpart. In vitro and ex vivo experiments using fat-laden hepatocytes and VAT explants, respectively, showed that omentin-1 did not affect steatosis but significantly reduced TNF-α levels, ER stress, and oxidative stress. Furthermore, omentin-1 significantly decreased the mRNA expression of NF-κB and mitogen-activated protein kinases. Ex vivo VAT explants showed that D-glucose and insulin significantly reduced omentin-1 mRNA expression and protein levels. Notably, diabetic patients exhibited a significant increase in plasma omentin-1 levels one year following bariatric surgery.

Conclusions: Our findings suggest that reduced omentin-1 levels contribute to the development of diabetes and MAFLD. Therefore, further research is warranted to explore its role as potential therapeutic target and/or biomarker.

Abstract Submission No. 100993
O-0302

Non Alcoholic steatohepatitis examined by FAST score and colorectal carcinoma-A case-control study

Jishnu J¹, Kandasamy alias kumar E¹, Poppy Rejoice¹, Shafique A¹, Geetha D¹
¹Department of Medical Gastroenterology, Tirunelveli Medical College Tirunelveli India

Background: FAST score has been recently suggested for non-invasive detection of Non alcoholic steatohepatitis(NASH). We evaluated the relationship between Colorectal carcinoma(CRC) and co-existence of NASH detected by FAST scoring, as a risk factor.

Methodology: Patients with biopsy proven CRC were enrolled for the study group (n=53) and those without liver diseases or malignancies as control (n=53). The quantitative values of steatosis and fibrosis were measured using FibroScan. FAST score was calculated using the equation as carried out by Newsome et al. The optimal rule-out (FAST: ≤0.55) and rule-in (FAST: ≥0.78) cut-offs were applied. CAP, LSM, AST and FAST score values were compared between the two groups.

Results: Mean age was 53.7 years and 50.8 years for the case and control groups, respectively. 77.3 % of CRC (41/53) and 71% of control (38/53) had steatosis, defined by CAP ≥238dB/m (p=0.23). 68% of the case group (36/53) and 50% of the control (27/53) had fibrosis, defined by LSM ≥7.5kPa (p=0.002). Median AST was 76 for the case and 60 for the control (p=0.013). With rule-in cut off value for FAST score as ≥0.78, 63.4% of the case and 36.6% of the control had NASH with statistically significant p-value of 0.045. Odd ratio for association of NASH in CRC patients was 3.12, 95% CI 1.27-7.58, p=0.0015.

Conclusion: From our study, NASH has an association in CRC development. Further studies may help us to identify the role of NASH in tumorgenesis. Also, validating FAST scoring as a screening tool may help in early detection of steatosis and preventing complications.

Abstract Submission No. 101228
O-0303

Sphingomyelin synthase 2 deficiency attenuates liver inflammation and fibrosis

Yingyun Gong¹, Xuan Ye¹, Wanzi Jiang¹, Hongwen Zhou¹
¹the First Affiliated Hospital of Nanjing Medical University Nanjing China

Objective: Sphingomyelin, a vital component of the plasma membrane, plays an indispensable role in maintaining membrane stability, fluidity, and cellular signal transduction. Sphingomyelin synthase 2 (SMS2) facilitates the transformation of ceramide to sphingomyelin, thereby regulating the sphingomyelin concentration within the plasma membrane. However, the exact function and underlying mechanism of sphingomyelin in nonalcoholic steatohepatitis (NASH) remain to be elucidated.

Methods: Wild-type (WT) and SMS2-knockout (SMS2-KO) male mice, aged nine weeks, were subjected to a Western diet (WD) (comprising 21.1% fat, 41% sucrose, and 1.25% cholesterol) and a high-sugar solution (containing 23.1 g/L d-fructose and 18.9 g/L d-glucose). Carbon tetrachloride (CCl4), diluted tenfold with corn oil, was administered intraperitoneally at a dosage of 2 μl (0.32 μg)/g of body weight once weekly for a duration of 12 weeks.

Results: Compared to WT mice, SMS2-KO mice exhibited a decrease in both plasma membrane sphingomyelin and total liver sphingomyelin. WD/CCl4-treated SMS2-KO mice displayed mild hepatic steatosis in both plasma membrane sphingomyelin and total liver sphingomyelin. WD/CCl4-treated SMS2-KO mice displayed mild hepatic steatosis in both plasma membrane sphingomyelin and total liver sphingomyelin. WD/CCl4-treated SMS2-KO mice displayed mild hepatic steatosis. WD/CCl4-treated SMS2-KO mice displayed mild hepatic steatosis.

Conclusion: The depletion of SMS2 mitigates liver injury in WD/CCl4-induced NASH mice due to a decrease in the inflammatory response and TGFβ1-mediated collagen accumulation. This suggests that SMS2 deficiency may exert a protective effect against the progression from simple steatosis to NASH.

Abstract Submission No. 101251
O-0304

Intestinal IL-33 exacerbates NASH by increasing gut microbiota-derived TMAO synthesis

Qin NING¹, Suping Hai¹, Xitang Li¹, Wenhui Wu¹, Qiang Gao¹, Binghui Yu¹, Erliang Xie¹, Xiaojing Wang¹
¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Background: Gut microbiota and its metabolites play a critical role in the development of non-alcoholic steatohepatitis (NASH) through the gut-liver axis. IL-33 is highly expressed in the intestine and regulates intestinal and extraintestinal diseases. Herein, we investigated the role of intestinal IL-33 in NASH.

Abstract Submission No. 101281
O-0305

Intestinal IL-33 exacerbates NASH by increasing gut microbiota-derived TMAO synthesis
Methods: IL-33 knockout mice and their control mice were fed 60% high-fat diet (HFD) for 24 weeks to establish NASH models. 3,3-dimethyl-1-butanol (DMB), a kind of choline analogue, was administered to inhibit gut microbiota-derived trimethylamine N-oxide (TMAO) synthesis. Fecal microbiota transplantation was carried out to study the role of IL-33-related gut microbiota alterations in NASH. Feces and serum were analyzed by 16S rRNA sequencing and metabolomics. Human intestinal epithelial cell line, Caco-2, and spleen naïve CD4+ T cells were used for in vitro studies.

Results: The expression of intestinal IL-33 was increased in NASH. IL-33 knockout improved NASH progression by alleviating intestinal barrier leakage and gut microbiota dysbiosis, with the decrease level of TMAO. Inhibition of TMAO synthesis by DMB reduced hepatic injury in NASH. Intracellular IL-33 inhibited the expression of intestinal barrier-related genes, directly damaging the intestinal barrier. Extracellular IL-33 promoted Th1 differentiation and function leading to the pro-inflammatory environment in the gut. Transplantation of gut microbiota reversed NASH phenotypes.

Conclusion: These findings suggest that intestinal IL-33 increases gut microbiota-derived TMAO synthesis and aggravates NASH progression. Targeting intestinal IL-33 and its related microbiota may provide a potential strategy for treating NASH.
To identify high-confidence diagnostic markers we isolated and analyzed the RNA content of exosomes from different MAFLD mouse models and human patients. For establishing disease stage specific mouse liquid biopsy-based exosome RNA content signatures we collected serum from mice being exposed for 1, 6 or 8 weeks CDHFD, 8, 14, 20 or 26 weeks to Western Diet or respective controls, exposed to normal chow for the indicated times. Exosomes were precipitated, RNA isolated and high quality NGS libraries for sequencing were prepared. The same approach was applied to human patient serum from patients with liver biopsy verified disease stage. Data was in depth analyzed with a focus on interspecies conserved high confidence biomarkers, which were validated by qPCR on independent patient samples. Pathway analysis shows that the mRNA content of isolated exosomes reflects important gene expression changes associated with the metabolic syndrome. We can identify liver related, but also cardio-vascular and bacterial changes associated with this disease. We then pinpointed 16 specific and reliable mRNA biomarker, which we could validate in mice and man.

Abstract Submission No. 101369

O-0308

Hepcidin alleviates hepatic steatosis through inhibiting PERK signaling pathway

Xiaofan Wang1, Yingying Liu1, Chao Xie1, Tianhui Liu1, Ping Wang1, Lin Liu1, Xu Fan1, Jidong Jia1, Min cong1

1Beijing Friendship Hospital, Capital Medical University, Beijing China

Background: Hepcidin is a crucial protein regulating iron homeostasis, while hepatic steatosis was more severe in hepcidin knockout mice in our previous study. The aim of this study is to investigate the role and mechanism of hepcidin modulating lipid metabolism in metabolic-associated fatty liver disease (MAFLD).

Methods: A mouse model of fatty liver was established by high fat diet (HFD) or methionine choline deficiency diet (MCD) feeding. Mice were injected with recombinant adeno-associated virus carrying hepcidin (AAV-Hamp) or green fluorescence protein. AML12 cell line was used to investigate the mechanism of hepcidin in regulating lipid metabolism.

Results: Treatment with AAV-Hamp significantly improved hepatic steatosis in both HFD and MCD mice, accompanied by a decrease in triglyceride (TG) content, lipid droplet formation and changes in mRNA and protein related to lipid synthesis and lipolysis. However, hepcidin did not significantly improve liver inflammation and fibrosis in MCD mice. In an in vitro model of lipid deposition using AML12 cells stimulated with oleic acid, hepcidin administration reduced the expression of lipid synthesis-related mRNA and protein, consistent with the in vivo experiments. Specifically, hepcidin decreased the expression of fatty acid synthase (FASN) and protein kinase RNA-like ER kinase (PERK), one of the three endoplasmic reticulum stress sensors. Furthermore, intervention of the PERK signaling pathway with a PERK activator abolished the protective effect of hepcidin on lipid deposition by inhibiting FASN.

Conclusions: Hepcidin plays a protective effect in hepatic lipid metabolism by decreasing the expression of FASN through inhibiting PERK signaling pathway, thereby alleviating MAFLD.

Abstract Submission No. 101396

O-0309

C-reactive Protein and Nonalcoholic Fatty Liver Disease

Qin NING1, Qinghao Guo1, Yuan Zhan1, Meiwen Han1, Qianting Guan1, Fangfei Yan1, Jie Feng1, Dong Xi1

1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan China

Background: C-reactive protein (CRP) was found to increase in patients with nonalcoholic fatty liver disease (NAFLD). However, the causal association between NAFLD and CRP need to be further assessed.

Methods: Baseline information of 202 subjects between were collected from Tongji Hospital. Univariable and multivariable binary logistic regression analyses were conducted to assess the association between CRP and NAFLD. Furthermore, summary-level data from GWAS was employed in MR analysis. Inverse variance weighted (IVW) method was the primary analytic approach to infer the causality. Then, the Cochran’s Q test and MR-Egger regression analysis were performed to determine the heterogeneity and pleiotropy, and the leave-one-out analysis was conducted to assess the stability of MR result.

Results: The retrospective study showed that CRP significantly increased in patients with NAFLD compared to non-NAFLD controls (2.40 vs 0.70, P<0.001). Multivariable logistic regression analysis revealed that elevated CRP was an independent risk factor for NAFLD (OR=1.141, 95%CI 1.007-1.294, P=0.039). Subsequently, a significant positive causality of CRP with NAFLD was observed by IVW method (OR=1.187, 95%CI 1.004-1.404, P=0.045). It was further confirmed by the results of weighted mode (OR=1.321, 95%CI 1.147-1.521, P=0.000), and weighted median (OR=1.341, 95%CI 1.132-1.589, P=0.000). Meantime, no causal effect of NAFLD on CRP. Horizontal pleiotropy was not found among instrument variables (IVs). Despite the presence of heterogeneity, the MR result was proved robust by leave-one-out sensitivity analysis.

Conclusion: CRP is significantly increased in patients with NAFLD and may serve as an independent predictor for the risk of NAFLD.

Abstract Submission No. 101423

O-0310

Assessment of Liver Fibrosis with Transient Elastography in NAFLD Patients

Lajpat Rai1, Nazish Butt1, Ali Akbar1, Riaz Hussain1

1Jinnah Postgraduate Medical Center, Karachi Pakistan

Background: Transient elastography is a non-invasive technique for estimating liver fibrosis. There is limited data about the performance of TE in Pakistani patients with non-alcoholic fatty liver disease (NAFLD). The overall prevalence of NAFLD in Pakistan is 47%.

Method: A Cross-sectional study was undertaken at the Department of Gastroenterology, Jinnah Postgraduate Medical Centre, Pakistan. After obtaining ethical approval, all patients above the age of 18 years, with the diagnosis of NAFLD based on abnormal liver-function tests and ultrasound abdomen consistent with fatty liver were included in the study. All patients with hepatitis, hepatic malignancies, hepatobiliary infections, and biliary tract disease were excluded from the study. Fibrosis score was calculated through Elastography as F0-F1 (5.3-7.1 kPa, Normal); F2 (7.5-8.5 kPa, Mild/Grade-I); F3 (9.5-13.0 kPa, Moderate/Grade-II); and F4 (13.1-18.8 kPa, Severe/Grade-III).

Results: A total of 171 patients were enrolled in the study, from which 69 (40.35%) were male and 102 (59.64%) were female, with a mean age of 37.50 ± 9.74 years. Of these, 112 (65.49%) belonged to the lower socioeconomic class. One hundred and twenty-two (71.34%) patients had fatty liver on ultrasound and 49 (28.65%) had hepatomegaly.
with fatty changes. TE revealed that 69 (40.35%) patients had a score of F0-F1, 62 (36.25%) F2, 29 (16.95%) F3, and only 11 (6.43%) had a score of F4.

**Conclusion:** Detecting liver fibrosis at its early stages is crucial in preventing its progression to cirrhosis. Reversal of fibrosis is only possible if it is diagnosed as early as possible and managed with appropriate treatment.

**Abstract Submission No. 101592**
**O-0311**

**Exploring the Interplay of Hepatic Steatosis, Body Fat Ratio, and Hepatic Fibrosis in MAFLD**

**Tushar Prabhakar,1,2 Shiv Kumar Sarin,2, Manya Prasad2**

1Amrita School of Medicine Faridabad India, 2Institute of Liver and Biliary Sciences New Delhi India

**Background:** Hepatic fibrosis is a significant pathological condition with far-reaching implications for public health, often associated with hepatic steatosis and the overall distribution of body fat. This study encapsulates a comprehensive investigation aimed at elucidating the intricate relationship between hepatic steatosis, body fat ratio, and the development of hepatic fibrosis in patients with NAFLD. **Methods:** Data from hospital-based records of a tertiary specialty centre was collected for the period from April 2021 to August 2023. Transient elastography provided Liver Stiffness Measurement values, and cut-off for liver fibrosis was kept at 7.9 kPa. Continued Attenuation Parameter (CAP) value of more than or equal to 248 Db/m was defined as hepatic steatosis. Body composition analysis was performed using InBody 770 machine.

**Results:** A total of 586 MAFLD patients were studied of which 288 (49.1%) had some degree of liver fibrosis. Mean age was 46.6±13.1 years and 71.6% were males. Percent Body Fat was significantly higher in those with no liver fibrosis (33.8±9.5% vs 32.5±9.6%; p=0.031). When study subjects were stratified according to liver steatosis and total body fat percentage, it was observed that median liver fibrosis was 7.6kPa [IQR 5.1-20.6] in those with liver steatosis present & body fat percentage more than normal upper limit. In those with liver steatosis present but normal body fat percentage, liver fibrosis was 13.7kPa [IQR 8.8-62.9]. Liver fibrosis was significantly correlated to liver steatosis (-0.125; p<0.001), body fat percentage (-0.101; p=0.001), liver steatosis/body fat mass ratio (-0.108; p=0.001), BMI (0.113; p=0.001) and obesity degree (0.082; p=0.01).

**Conclusions:** MAFLD patients having central obesity (having higher visceral fat content) had higher tendency to develop hepatic fibrosis. Such patients may be more predisposed to having other metabolic ailments and strategies to decrease hepatic fat may benefit both liver and help prevent other metabolic diseases.

**Abstract Submission No. 101621**
**O-0312**

**IMPACT OF RENAMING NAFLD TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)**

**Erika Johanna P. Taada1, Stephen N. Wong1, Ann Margaret C. Navarroza1, Joseph Niño Espino1, Hyacinth C. Eviota1, Rene John D. Febro1, Jaqueline S. Arsena1, Salahudin C. Andam1, Maria Hosea C. Monfero1**

1University of Santo Tomas Hospital Manila Philippines

**Background:** The second-most recent change in steatosis nomenclature required 2/3 weight-metabolic criteria to be met and may lead to missed diagnosis in patients who develop weight-metabolic abnormalities later on. The metabolic-dysfunction-associated steatotic liver disease (MASLD) criteria requires only one criterion and may mitigate this. We aimed to characterize our steatotic patients into: 1) nonalcoholic fatty liver disease (NAFLD); 2.) MASLD only; 3.) NAFLD-MASLD; 4.) not NAFLD-MASLD.

**MATERIALS AND METHODS:** Consecutive patients with steatotic liver on ultrasound in a Hepatology clinic database from August 2007-July 2017 were included. Demographic, laboratories, AST/Platelet ratio (APRI), FIB4, and NAFLD fibrosis score (NFS) were compared between the groups.

**Results:** The 663 steatotic patients were categorized into: 60(9.9%) NAFLD, 326(49.2%) MASLD, 325(49%) NAFLD-MASLD, and 6(0.9%) not NAFLD-MASLD. Among patients meeting MASLD criteria, majority (80%) met ≥2 cardiometabolic criteria while only a minority (8.3%) satisfied only 1 criterion, of which overweight/obesity (79.6%) was most common. NAFLD-MASLD and MASLD patients had higher ALT, AST and platelet levels as compared to NAFLD and not NAFLD-MASLD patients (p<0.05). A higher probability of advanced fibrosis was seen in MASLD only compared to the other groups using APRI. There was a trend for more no/minimal fibrosis patients in the NAFLD and not NAFLD-MASLD groups compared to the MASLD and NAFLD-MASLD groups using non-invasive liver fibrosis tests.

**Conclusions:** Majority (82%) of patients with steatosis on ultrasound meet MASLD criteria. Serial follow-up is needed to determine if patients who do not meet MASLD criteria now will meet it in the future.
Conclusions: In the NAFLD microenvironment, cell-cell communication via FGFRs is hopefully a promising therapeutic target. The Hedgehog signaling pathway may be the essential mechanism that plays a counterpart role.

Abstract Submission No. 101825
O-0314

CD36-mediated uptake of oxidized LDL induces ferroptosis and dysfunction in DNTregs in NAFLD

Yuxiong Wei1-4, Shimeng Zheng1-2, Xiyu Wang1-2, Guangyong Sun1, Dong Zhang6

1Medical Research Center, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University Beijing China, 2Department of Gastroenterology, Beijing Chao-Yang Hospital, Capital Medical University Beijing China, 3Beijing Laboratory of Oral Health, Capital Medical University School of Basic Medicine Beijing China, 4Immunology Research Center for Oral and Systemic Health, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: Inflammation plays a pivotal role in the development of NAFLD. CD3 TCR7αβ/CD4 CD8 double negative immune-regulatory T cells (DNTregs) are important for maintaining liver immune homeostasis. However, during NAFLD progression, intrahepatic DNTregs have decreased cell survival and immunosuppressive function, which lead to aggravated liver proinflammation. However, the reasons and underlying mechanisms that cause the changes of DNTregs during NAFLD progression are still unknown.

Methods and results: We analyzed DNTregs in PBMCs from NAFLD patients and in NAFLD mouse models with serum biochemical test index. Correlation analysis showed a significant negative correlation between serum oxLDL levels and both the survival and functional molecule expression levels of DNTregs. Moreover, stimulating DNTregs with oxLDL, we noticed decreased cell survival and immunosuppressive function of DNTregs accompanied by an increased DNTreg ferroptosis. Ferroptosis inhibitors were able to regain the immunosuppressive function of DNTregs. Further investigation revealed that CD36 is the primary regulator of oxLDL-mediated ferroptosis in DNTregs. CD36 knockout significantly rescued oxLDL-induced ferroptosis in DNTregs. Meanwhile, CD36 predominantly enhanced ferroptosis in DNTregs by upregulating ACSL4 expression. CUT&TAG experiments confirmed the oxLDL-induced upregulation of Hif-1α, which bound to the ACSL4 promoter region, thereby induced CD36-mediated ferroptosis. Finally, transferring CD36-/- DNTregs into NAFLD mice, we observed a significantly reduced ferroptosis, enhanced survival and immune regulation of CD36-/- DNTregs compared with those of WT DNTregs. This improvement of DNTregs resulted in a notable enhancement of the therapeutic efficacy against NAFLD.

Conclusions: Specifically targeting CD36 to prevent ferroptosis of DNTregs may provides a novel therapeutic approach for NAFLD.

Abstract Submission No. 200029
O-0316

Therapeutic target identification of MAFLD through patient transcriptomic-based in vivo RNAi screen

Yong-An Lee1, Dong Yeul Lee1, Chee Chong Lek1, Gao Rong4, Yee Siang Lim1, Yun-Shen Chan2, Yock Young Dan3, Mei Chin Lee1, Huck Hui Ng1, Torsten Wuestfeld4

1Genome Institute of Singapore (GIS) Singapore Singapore, 2Guangzhou Regenerative Medicine and Health Guangdong Laboratory Guangzhou China, 3National University of Singapore Singapore Singapore, 4National Cancer Centre Singapore Singapore Singapore, 5Nanyang Technological University Singapore Singapore

Backgrounds: Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a significant global health concern, yet it remains underrepresented with limited identified effective therapeutic targets. Although analyzing patient transcriptomics provides insights into dysregulated genes with therapeutic potential, MAFLD is a complex condition involving intricate interactions among multiple organs. Consequently, the identification of effective therapeutic targets necessitates an innovative approach. To meet this challenge, we have devised a novel approach utilizing patient transcriptome-based in vivo RNAi screening to identify potential therapeutic targets for MAFLD.

Method: Dysregulated genes in patient liver tissues were identified through RNA sequencing. A pooled-shRNA library was constructed to target these genes and hydrodynamically introduced into mouse hepatocytes. Mice were divided into treated (high-fat diet) and control (normal diet) groups. Genomic DNA was collected from liver samples post-diet for quantifying shRNA abundance. Therapeutic target candidates were determined by identifying enriched shRNA in treated group mice.

Results: We identified four primary candidates as the most promising targets following a screening process, warranting further validation as-says. Silencing these target genes resulted in a notable reduction in disease progression, specifically in fibrosis formation. One of the four targets underwent additional validation to elucidate its mechanism of
action, revealing that the knockdown of this target significantly enhances lipid metabolism.

**Conclusion:** Our findings highlight the efficacy of our approach in identifying novel targets for MAFLD therapeutics. Suppression of the identified target gene expression significantly alleviated disease progression. This study contributes valuable insights to the discovery of novel MAFLD therapeutics.

Abstract Submission No. 200098

**O-0317**

**MicroRNA-411-5p targets the EIF4G2 / FOXO3 axis to alleviate lipid deposition in MAFLD**

Zhiping Wan1, Xiaquan Liu1, Xiaoen Yang1, Hong Cao1, 2, Hong Deng1

1Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 2Guangdong Provincial Laboratory of Liver Disease Research, the Third Affiliated Hospital, Sun Yat-sen University Guangzhou China

**Background:** Abnormal lipid deposition is an important driver of metabolic dysfunction-associated fatty liver disease (MAFLD) progression. MicroRNA-411-5p (miR-411-5p) and eukaryotic translation initiation factor 4e2 (EIF4G2) are related to abnormal lipid deposition, but the mechanism is unknown.

**Methods:** A high-fat and high-cholesterol diet (HFD) or a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) was used to construct the MAFLD rat or mouse models. Adeno-associated virus type 8 carrying EIF4G2 shRNA were injected into the tail vein to downregulate EIF4G2. MiR-411-5p mimic was used to upregulate the expression of miR-411-5p.

**Results:** The miR-411-5p level was decreased in both MAFLD rats and mice, and was negatively correlated with the liver triglycerides and the degree of liver injury. Up-regulation of miR-411-5p reduced fatty acid synthesis to alleviate lipid deposition. Moreover, EIF4G2 was confirmed to be a target gene of miR-411-5p, and miR-411-5p downregulated the expression of EIF4G2. Down-regulation of EIF4G2 expression reduced fatty acid synthesis and alleviated lipid deposition in palmitic acid-induced steatosis hepatocytes. Importantly, down-regulation of EIF4G2 in the liver alleviated liver damage and abnormal lipid deposition in MAFLD mice. Besides, EIF4G2 regulated the expression of forkhead box class O 3 (FOXO3), and up-regulation of miR-411-5p or down-regulation of EIF4G2 both lead to reduced expression of FOXO3.

**Conclusions:** Up-regulation of miR-411-5p inhibits EIF4G2 to reduce the expression of FOXO3, thereby inhibiting fatty acid synthesis and alleviating abnormal lipid deposition in MAFLD. MiR-411-5p is beneficial for improving MAFLD and EIF4G2 is expected to become a therapeutic target for MAFLD.

Abstract Submission No. 200146

**O-0318**

**FTZ inhibits the hepatic lipid deposition by TFF3/PPAR α/AMPK signaling pathway in diabetes mice**

Yi qi Yang1, Quan you Liu1, Hong yan Huo1, Jia li Wu1, Zi yang Lin1, Hai bo Tan1, Jiao Guo1

1Guangdong Pharmaceutical University guangzhou China

**Background:** Trefoil Factor 3 (TFF3) TFF3 is a novel liver glycolipid metabolism regulatory factor that can maintain the homeostasis in the body by PPARα/AMPK signaling pathway. FTZ as a representative formula of the “Tiao Gan Qi Shu Hua Zhuo” method in prevention and treatment of glycolipid metabolism diseases, the inner mechanism is unknown.

**Methods:** 1. Animals: db/db and C57BL/6J mice (induced by 40mg/kg STZ and HFD) were used in our study. FTZ (1-2 g/kg) and Atorvastati (5mg/kg) were used for 12 weeks treatment. 2. L02 cells: Palmitic acid (0.25 mmol/L) and Glucose (6 mmol/L) were used to stimulate the L02 cells, followed by FTZ intervention for 24h. And the indicators including TC, TG, LDL-C, HDL-C, ALT and AST were detected by biochemical test kits. H&E and Oil Red staining methods were used to evaluate the histopathological changes and lipid accumulation in liver. IHC and WB methods were used to detect the TFF3, PPARα, p-AMPK/AMPK, p-ACC/ACC and CPT-1α levels.

**Results:** FTZ can significantly reduce the TC and TG content, and improve the liver function, inhibit liver lipid deposition, and significantly increase the protein levels of TFF3, PPARα, p-AMPK, p-ACC and CPT-1α in the liver and L02 cells.

**Conclusion:** FTZ can inhibit the hepatic lipid deposition, which could be related with TFF3/PPARα/AMPK signaling pathway, and further accelerate fatty acids β oxidation to decrease lipid accumulation. The study provides a new perspective and experiment basis for the prevention and treatment of metabolic diseases.

Abstract Submission No. 200168

**O-0319**

**Enhancing liver health in type 2 diabetes: CD26 inhibitors & Glycine max antioxidants synergy**

Anand Krishna Singh1, Purnima Tripathi1

1Shri Vaishnav Vidyapeeth Vishwavidyalaya Indore India

**Aims:** Non-alcoholic fatty liver disease (NAFLD) is the predominant chronic liver ailment globally, afflicting over half of type 2 diabetes mellitus (T2DM) patients due to exacerbated insulin resistance, oxidative stress, and inflammatory disruptions. A promising avenue for T2DM treatment involves leveraging the incretin hormone GLP-1. Dipeptidyl peptidase-IV (DPP-IV/CD26) inhibitors, sourced from Glycine max’s phenolic-rich fraction, may exhibit pleotropic effects via the presence of incretin hormone receptors in diverse tissues, including the liver. Our study explores the potential impact of DPP-IV inhibitors with antioxidant capabilities on NAFLD in a T2DM rat model.

**Methods:** Wistar rats underwent T2DM induction via a high-sucrose diet and dexamethasone. Biochemical, toxicological, and histological parameters were assessed. Evaluations encompassed serum DPP-IV inhibition, glycosylated hemoglobin, HOMA-IR, hepatic lipid peroxidation, SGOT, SGPT, and tissue antioxidants. Serum lipid profiles were examined to correlate with the antiperoxidative effects of Glycine max’s phenolic-rich fraction.

**Results:** Diabetes induction via corticosteroid and high sucrose diet was confirmed by HOMA-IR (2.5%), HOMA-β (36.3%), and HOMA sensitivity (44.3%). In-vitro DPP-IV inhibition assay demonstrated 63.1±2.8%, while serum activity was 41.9±1.3%. The DPP-IV inhibitors lowered aminotransferases (SGOT & SGPT) and alkaline phosphatase, elevated insulin, and reduced HbA1c. Triglyceride and cholesterol levels normalized. Glycine max extract exhibited superior antioxidant capacity, safeguarding against lipid peroxidation, and preserving liver histoarchitecture, emphasizing positive outcomes post-DPP-IV inhibitor treatment.

**Conclusions:** DPP-IV inhibitors along with antioxidant properties improve insulin sensitivity, reduce oxidative stress and toxicity which lead to improve liver dysfunction in T2DM. These findings also suggest that GLP-1 in liver has beneficial effects on NAFLD.
Abstract Submission No. 200201

O-0320

The potential mechanism of methotrexate induced liver injury in MAFLD: in silico analysis

Yongqiang Xiong1, Bo Wang1, Na Huang2, Ren Li1, Shu Zhang6
1Department of Geriatric Digestive Surgery, the Second Affiliated hospital of Xi’an Jiaotong University Xi’an, Shaanxi China, 2Core Research Laboratory, the Second Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi China, 3Experimental Teaching Center for Clinical Skills, the Second Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi China

Background: The putative liver toxicity of methotrexate should be evaluated in the pathogenesis and natural history of liver disease, especially metabolic associated fatty liver disease (MAFLD). We initially identify the potential effects of methotrexate in MAFLD based on network toxicology and molecular docking technology.

Methods: The drug toxicity information was obtained from ProTox-II and ADMETlab 2.0. The potential targets related to methotrexate and MAFLD were identified through ChEMBL, STITCH, GeneCards and OMIM databases. The core genes were analyzed using STRING and Cytoscape, gene ontology (GO) analysis, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. The interactions between methotrexate and these core genes were confirmed by AutoDock Vina.

Results: ProTox-II and ADMETlab 2.0 confirmed the hepatotoxicity of methotrexate, and 22510 disease target genes and 541 drug target genes were identified from the database. Venn diagram showed 189 common related potential target genes between Methotrexate and MAFLD. Among these genes, 20 core targets were identified by STRING and Cytoscape. Further analysis of GO and KEGG pathway showed that genes related to methotrexate induced MAFLD mainly distributed in cancer and proteoglycans in cancer pathway and estrogen signaling pathway. AutoDock Vina confirmed the intensity of binding between methotrexate and the core target genes. The binding ability was relatively higher in ACLY, LDHA, HMGCR, ITGB3, MMP2, BCL2, and CASP3, than other target genes.

Conclusion: The core genes identified here maybe can serve as targets for the prevention and treatment of MAFLD in patients taking methotrexate.

Abstract Submission No. 100089

O-0321

Vitamin E versus Placebo in the Treatment of NASH: a Multicenter, Randomized, Double-blind Study

Shijun Ping1, Yu Song1, Minghua Zheng4, Huiping Sheng2, Jing Wang4, Yongfeng Yang2, Xiaohong Chi2, Jinjun Chen4, Fangping He2, Xiaotang Fan16, Jie Li1, Shufei Zang3
1Hongzhuang Normal University Affiliated Hospital Hangzhou China, 2Nanjing Drum Tower Hospital Nanjing China, 3Shanghai Fifth People’s Hospital Shanghai China, 4The First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 5General Hospital of Ningxia Medical University Ningxia China, 6The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University Lanzhou China, 7The Second Hospital of Nanjing Nanjing China, 8Guangdong Provincial Hospital of Chinese Medicine Guangzhou China, 9Nanshan Hospital Guangzhou China, 10The First Affiliated Hospital of Xijing Medical University Urumqi China

Background: Despite the proven efficacy of long-term high-dose vitamin E (800IU) for the treatment of non-diabetic patients with non-alcoholic steatohepatitis (NASH), potential risks hinder its application. The efficacy and safety of a lower dose of vitamin E for NASH treatment is unclear.

Methods: This was a multicenter, randomized, double-blind, placebo-controlled study of non-diabetic patients with biopsy-proven NASH. Patients were randomly assigned to receive oral vitamin E (300mg about 450 IU) or placebo. The primary outcome was an improvement in hepatic histology. The exploratory secondary endpoint was improvement in liver fibrosis by at least one stage and no worsening of NASH.

Results: A total of 124 patients were randomly assigned to receive vitamin E (58 patients) or placebo (66 patients). In the modified ITT population, 29.3% of those who received vitamin E demonstrated an improvement in histology (43.6% in PPS) compared with 14.1% (17.7% in PPS) in the placebo group (p = 0.040 in modified ITT, p = 0.0071 in PPS). An improvement in the exploratory secondary endpoint was observed in 25.9% (38.5% in PPS) of the vitamin E group and 19.6% (19.6% in PPS) of the placebo group (p = 0.16 in modified ITT, p = 0.048 in PPS). Serious adverse events were reported in a similar proportion of patients across groups but were not considered to be related to treatment.

Conclusions: Oral vitamin E administered at a dose of 300mg daily resulted in a significantly higher histologic improvement in non-diabetic NASH patients and was safe and well tolerated for NASH treatment.

Abstract Submission No. 100099

O-0322

The greater impact of PNPLA3 polymorphism on liver-related events in Japanese NAFLD

Yuya SEKO1, Kanji Yamaguchi1, Yoshito Itoh1, Takashi Okanoue1, Hirokazu Takahashi2, Miwa Kawanaka1, Saiyu Tanaka3, Atsushi Nakajima4
1Kyoto Prefectural University of Medicine Kyoto Japan, 2Saiseikai Saitama Hospital Saitama Japan, 3Saga University Saitama Saitama Japan, 4Nara City Hospital Nara Japan, 5Nara City Hospital Nara Japan, 6Yokohama City University Graduate School of Medicine Yokohama Japan

BACKGROUND & AIMS: PNPLA3 rs738409 has been associated with an increased risk of liver-related events in patients with non-alcoholic fatty liver disease (NAFLD). In this study, we investigated the epidemiology of NAFLD and the impact of PNPLA3 on prognosis in Japan.

Methods: A longitudinal multicenter cohort study, the JAGUR study, includes 1550 patients with biopsy-proven NAFLD in Japan. We performed genetic testing and evaluated outcomes from this cohort. Liver-related events were defined as hepatocellular carcinoma (HCC) and decompensated liver cirrhosis events.

Results: During follow-up (median [range], 7.1 [1.0-24.0] years), 80 patients developed HCC, 104 developed liver-related events, and 59 died of any cause. The 5-year rate of liver-related events for each single-nucleotide polymorphism was 0.5% for CC, 3.8% for CG, and 5.8% for GG. Liver-related deaths were most common (n=28); only 3 deaths were due to cardiovascular disease. Multivariate analysis identified carriage of PNPLA3 CG/GG (hazard ratio [HR] 16.04, p=0.006) and FIB-4 index >2.67 (HR 10.70, p<0.01) as predictors of liver-related event development. No HCC or liver-related death was found among patients with PNPLA3 CC. There was a significantly increased risk of HCC, liver-related events, and mortality for CG/GG versus CC, but no difference between the CG and GG genotypes.
Conclusions: In Japanese individuals, the main cause of death from NAFLD is liver-related death. The greater risk of liver-related events incurred by PNPLA3 G allele was shown in Japan. Risk stratification for NAFLD in Japan is best accomplished by integrating PNPLA3 with the FIB-4 index.

Abstract Submission No. 100116
O-0323

Dissecting the Impact of Sex and Menopause on Steatotic Liver Disease: A Population-Based Study
Carolin Schneider1, Helen Huang2, Yelyzaveta Markova1, Jan Clusmann1, Jule K Adams1, Kate Townsend Creasy3, Eleonora Scorletti1, Christian Trautwein1, Yusuf Yilmaz4, Kai Markus Schneider1
1RWTH Aachen University Aachen Germany, 2Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia USA, 3Department of Nursing, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA, 4Department of GastroenterologySchool of Medicine, Recep Tayyip Erdoğan University Rize Turkey

Background: Steatotic liver disease (SLD) is affecting approximately 20-30% of the general population. However, data regarding sex differences are limited.

Methods: Therefore, we conducted a population-based study using the UK Biobank. Participants who underwent liver magnetic resonance imaging (MRI) and provided information on their sex/menopausal status were included. Logistic regression models were used to assess the association between sex differences in 18,135 men, 6159 premenopausal women, and 11,069 postmenopausal women, and steatosis on MRI, adjusting for age and BMI.

Results: Our results revealed that men had a higher prevalence of steatosis than women (34.5%), regardless of menopausal status. Postmenopausal women exhibited a higher prevalence of steatosis than premenopausal women (17.4% premenopausal women 20.9% in postmenopausal women), suggesting that menopause may increase the risk of steatosis. Additionally, we observed distinct clinical and laboratory profiles in male and female patients with simple steatosis. FIB4 levels were elevated in 8.4% of premenopausal women, 33.7% of postmenopausal women, and 35.9% of men. Homozygous carriers of TM6SF2 rs58549296 or PNPLA3 rs738409 were at increased risk of steatosis on MRI across all three groups. Shorter sleep duration increased the risk of steatosis in pre-menopausal women, while alcohol intake increased the risk in men only.

Conclusion: Our findings indicate that sex and menopausal status are important factors to be considered when studying hepatic steatosis. These results emphasize the need for personalized, sex-specific approaches to prevent steatosis. Further research is needed to elucidate the mechanisms underlying sex differences in, identify therapeutic targets, and develop sex-specific strategies for medical interventions.

Abstract Submission No. 100204
O-0325

The correlation between LDL level and the development of NAFLD
MOHAMED MAHBOOB ALI1
1ADVANCED MEDICAL AND DENTAL INSTITUTE(AMDI) GEORGETOWN Malaysia

Background and Aims: NAFLD is a type of liver pathology that is associated with obesity, high cholesterol, Diabetes Mellitus, hypertension and genetics. The end result of NAFLD is liver cirrhosis and hepatocellular carcinoma(HCC). The aim of this study is to examine the correlation between LDL levels with the development of NAFLD.

Method: This is a retrospective study where a total of 1000 NAFLD patients were included. Variables such as age, sex, ethnicity, BMI, comorbidities, smoking status, liver function test and fasting serum lipid were recorded. Data from the years 2015 to 2020 were analyzed using the software empower stats version 5.0. Multivariate non-parametric analysis of the mean data was studied using the MANOVA test with a confidence interval (CI) of 95%. Receiver operating characteristic (ROC) curves were plotted to study the correlation between LDL and NAFLD. The area under the curve (AUC) was calculated and the DeLong test was used to determine the significance of the data.NAFLD was defined using liver ultrasound criteria such as liver brightness, vascular blurring, deep attenuation, and hepatorenal echo contrast. The scans were performed by the trained ultra-sonographer to reduce the operator bias.

Results: The level of LDL in both men and women was statistically significant in the development of NAFLD.ROC analysis for both sexes was performed and AUC for LDL was significantly higher in the NAFLD patients.
Conclusion: The level of LDL is significantly higher in NAFLD patients of both sexes and can be utilized as an early biomarker for the development of NAFLD.

Abstract Submission No. 100413
O-0326

Liver Fibrosis Tests and Outcomes of Bariatric Surgery in Morbidly Obese Patients with MASLD

Parinda Prathyajuta1, Thaninee Prasoppokakorn1, Kessarin Thanapirom1, Pattharasai Kachornvitaya1, Kanokwan Sonsiri1, Chonlada Phathong1, Arth Khemtong1, Suthep Udomsawaengsup1, Somrat Treeprasert1
1King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand

Background: MASLD is common among morbidly obese patients, but data on NITs for liver fibrosis assessment is limited. We aimed to validate NITs for predicting liver fibrosis and post-bariatric surgery outcomes.

Methods: In a single-tertiary-center retrospective cohort, we studied morbidly obese adults with biopsy-proven MASLD undergoing bariatric surgery between 2011 and 2022 (LRYGB/LSG). Follow-up exceeded 1 year. The primary outcome was NITs’ performance in predicting liver fibrosis, including LSM, FIB-4, NFS, APRI, and BARD scores. Secondary outcomes included biochemical and anthropometric changes.

Results: Among 193 patients, 103(53.4%) were female, mean age 36.3±10.9 years. Mean BMI was 47.7±14.4 kg/m², and 78(40.4%) had diabetes. Of these, 58(30.1%) had liver fibrosis(≥F1), and 9(4.7%) had significant fibrosis(≥F2). NITs showed low diagnostic accuracy for liver fibrosis (AUROC: LSM 0.38, FIB-4 0.59, NFS 0.53, APRI 0.50, BARD 0.51). After a median 1.9-year follow-up, LSM significantly decreased post-surgery (7.8 to 5.5 kPa, p=0.001). APRI and NFS improved (0.21 to 0.18, -0.773 to -1.395, p<0.001), while FIB-4 and BARD scores increased (0.52 to 0.60, 2 to 3, p<0.001) over a median 2.9-year follow-up (Figure). Anthropometrically, %TWL and BMI decreased significantly (30.8% to 28.5%, p=0.04, and 47.7 to 35.1, p<0.001). LRYGB had higher %TWL than LSG (30.8% vs. 28.5%, p=0.040). Biochemical parameters (AST, ALT, albumin, platelets, LDL-cholesterol, and triglycerides) improved significantly post-surgery. Subgroup analysis (n=27) showed LSM improvement>20% from baseline correlated with %TWL>30% (p=0.041).

Conclusion: Bariatric surgery improved long-term clinical/biological outcomes, though NITs demonstrated limited diagnostic accuracy for baseline liver fibrosis. Further research is needed to assess new NITs for monitoring liver fibrosis in morbidly obese patients.

Abstract Submission No. 100501
O-0328

Intelligent Diagnosis of Non-alcoholic Fatty Liver Disease Based on Multi-modal Ultrasound Features

Gangqiao Xie1,2,3, Yong-Sheng Xia4, Shun-Ping Chen4, Rui Wang4, Xingyue Wei1, Lijie Huang2, Zhiqiang Li2, Qiong He2, Ming-Hua Zheng2, Jianwen Luo4, Lai Wei5
1Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University Beijing China, 2Department of Biomedical Engineering, School of Medicine, Tsinghua University Beijing China, 3School of Clinical Medicine, Tsinghua University Beijing China, 4Department of Ultrasonography, The First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 5MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 6Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province Wenzhou China

Background: NAFLD is a prevalent chronic liver disease worldwide. The gold standard for NAFLD and at-risk non-alcoholic steatohepatitis (NASH) diagnosis is invasive liver biopsy. Therefore, there is an urgent need to develop non-invasive techniques for diagnosing key histological components of NAFLD and at-risk NASH.

Methods: Ninety-four patients with biopsy-proven NAFLD were included. A total of 262 features were extracted from an iLivTouch system, which utilizes multi-modal ultrasound techniques for diagnosing key histological components of NAFLD and at-risk non-alcoholic steatohepatitis (NASH).

Conclusions: The diagnostic performance of the iLivTouch system is promising for the non-invasive diagnosis of NAFLD and at-risk NASH. Further studies are needed to validate the system in larger populations and clinical settings.
system, ultrasound (US) images, and medical records by quantitative US techniques and US radiomics. A logistic regression model was developed for feature selection, and support vector machine (SVM) was used as the classifier for NAFLD diagnosis. Five-fold cross-validation was used to evaluate the classification performance.

**Results:** Multi-modal US features can accurately diagnose key histological components of NAFLD and at-risk NASH. The AUC values are 0.91 (95% CI, 0.75-1.00) for steatosis S2-S3 (≥ S2), 0.85 (95% CI, 0.74-0.99) for steatosis S3, 0.80 (95% CI, 0.71-0.88) for ballooning grade 2, 0.73 (95% CI, 0.57-0.81) for lobular inflammation grade 2-3 (≥ 12), 0.82 (95% CI, 0.28-0.85) for fibrosis grade 1-4 (≥ F1), 0.73 (95% CI, 0.59-0.78) for fibrosis grade 2-4 (≥ F2), 0.76 (95% CI, 0.58-0.88) for fibrosis grade 3-4 (≥ F3), and 0.81 (95% CI, 0.62-0.91) for at-risk NASH, respectively.

**Conclusions:** Multi-modal US features can accurately diagnose key components of NAFLD and at-risk NASH. With continued validation, they may be promising for evaluating the severity of NAFLD, diagnosing at-risk NASH, and dynamically assessing NASH resolution.

Abstract Submission No. 100558

**O-0329**

**Prevalence of Fatty liver disease in the Middle East and North Africa: A Systematic Review**

**Zobair Younossi1,2, Pegah Golabi1,2, James M. Paik2,3, Soroor Owrami2, Yusuf Yilmaz2, Mohamed El-Kassas2,4, Khalid Alswat5, Saleh AlQahtani6,7**

1The Global NASH council, Center for Outcomes Research in Liver Disease Washington, DC United States, 2Beatty Liver and Obesity Research Program, Inova Health System Falls Church, VA United States, 3Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University Rize Turkey, 4Department of Endemic Medicine, Faculty in Medicine, Helwan University Cairo Egypt, 5Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University Riyadh Kingdom of Saudi Arabia, 6Division of Gastroenterology & Hepatology, Johns Hopkins University Baltimore, MD United States, 7Organ Transplant Center of Excellence, King Faisal Specialist Hospital & Research Center Riyadh Kingdom of Saudi Arabia

**Background:** Nonalcoholic fatty liver disease (NAFLD) is part of the spectrum of fatty liver disease which is closely associated with type 2 diabetes (T2D) and other metabolic abnormalities. We assessed the prevalence of NAFLD among the general population and diabetics in the Middle East and North Africa (MENA) region using systematic review.

**Method:** We searched PubMed and Embase for articles published between 1990-2023 according to PRISMA. Each country’s NAFLD prevalence in the general population and in T2D patients was predicted by using multivariable meta regression model (global burden of disease-GBD 2019). Input data were extracted from our systematic review, GBD and NCD Risk Factor Collaboration. Confidence intervals were constructed by using prediction intervals with the Delta method.

**Results:** Meta-analytic pooling estimated NAFLD prevalence is 39.43% in the general population and 68.71% in T2D patients. NAFLD prevalence has increased from 35.42% (2008-2016) to 46.20% (2017-2020). Using GBD-2019, 141.51 million NAFLD prevalent cases were expected in the MENA region. The highest number of NAFLD cases were expected in Egypt (25.71 million), Türkiye (23.33 million), Iran (19.85 million), with the lowest cases from Bahrain (0.33 million). Estimated NAFLD prevalence exceeded 40% in 10 of 21 countries with the top countries being Kuwait (45.37%), Egypt (45.0%), Qatar (44.4%), and Jordan (43.3%). Furthermore, 24.96 million cases of NAFLD with T2D were expected in the MENA region.

**Conclusion:** Prevalence of NAFLD in the general population and among T2D is very high and growing necessitating urgent need to develop public policy to deal with this growing burden.

Abstract Submission No. 100598

**O-0330**

**Riding the Wave of Name-Change: Prevalence, Clinical Profile and Outcomes of NAFLD, MAFLD, and MASLD**

Laurence Laure1, Ian Homer Cua1, Juliet Cervantes1, Marie Antoinette Lontok1, Marianne Linley Sy-Janairo1, Ma. Regina Dimaculangan1, Ma. Felina Siray1, Maxine Andrea Garcia1

1St. Luke’s Medical Center- Global City Taguig Philippines

**Background:** The evolving renamed Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic-Associated Fatty Liver Disease (MAFLD) and, subsequently, to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has prompted a comparative investigation into these diagnostic criteria. This study aimed to identify its prevalence, clinical profile, and their outcomes.

**Methods:** Employing a five-year cross-sectional design, we collected data from our Liver Bank, including individuals diagnosed with hepatic steatosis Ultrasound, CT Scan, or MRI. We collected demographic data, metabolic and liver profiles, fibrosis scores, liver-related complications, and all-cause mortality.

**RESULTS:** A total of 201 patients (57.2% male) were included. Most patients were NAFLD-MAFLD-MASLD-overlap (50.25%). Alcohol ingestion was seen predominantly in the MAFLD only group (95%). Overall, triglycerides levels have a median of 139 mg/dl (29-375 mg/dL) with a significant difference across groups (p = .007§). Cirrhosis was present (22.61%), which varied significantly across patient categories (p = .030), where 44.4% of these, seen in MAFLD-only group. Cirrhosis outcomes had density rate of 3.45, while HCC stands at 4.15, where this was highest in the MAFLD+MASLD overlap group at 14.7%. The Kaplan Meier survival curve, at day 49, MAFLD-only had higher survival probability (76%, 95% CI 0.565-1.00) compared to NAFLD+MAFLD-MASLD (69%, 95% CI 0.461-1.00). All three and their overlaps were associated with increased all-cause mortality in individuals with Liver cirrhosis and HCC.

**CONCLUSION:** Patients excluded under the NAFLD definition, yet encompassed by MAFLD and MASLD, demonstrated an increased susceptibility to adverse liver-related outcomes. The nomenclature change appeared to enhance the clinical utility of these definitions.

Abstract Submission No. 100618

**O-0331**

**EUS-guided assessment of metabolic liver disease in patients with morbid obesity**

Rafael Romero-Castro1, Paula Fernandez-Alvarezz1, Maria Tous-Romero1, Felix Conde-Martin1, Alvaro Gutierrez-Domingo1, Victoria A. Jimenez-Garcia1, Eduardo Dominguez-Adame1, Patricia Cordero-Rubio1, Francisco Bellido-Muñoz1, Manuel Rodriguez-Tellez1, Angel Cañedo-Alvarez1, Juan J. Rios-Martin1, Isabel Carmona-Soria1

1Virgen Macarena University Hospital Seville Spain

**Background:** Bariatric surgery patients have a higher prevalence of metabolic associated- steatotic liver disease (MASLD). Percutaneous liver biopsy has technical difficulties and non-invasive markers are not very accurate in this population.
Aims: Evaluate the efficacy and safety of EUS-guided bilobar liver biopsy plus EUS-guided portal pressure gradient measurement in diagnosing MASLD and its correlation with non-invasive test.

Methods: Suspected MASLD by liver ultrasound or fatty liver index (FLI) score > 60. Demographic, anthropometrics, blood test, non-invasive serological markers (FLI, NAFLD, HEPAMET, APRI, FIB-4) and transient elastography (TE) with XL probe variables were evaluated.

Results: The prevalence of MASLD was 69%, metabolic dysfunction-associated steatohepatitis (MASH) 54.5%, and fibrosis (F1-F2) 12.6%. EUS-guided portal pressure gradient median was 4 mmHg, 9/33 (28%) patients had a gradient≥ 6 mmHg. MASLD patients showed higher levels of fibrosis determined by transient elastography (TE), of steatosis evaluated by coefficient attenuated parameter (CAP) and portal vein pressure, although they were not statistically significant. No differences were detected in FIB-4, NAFLD and HEPAMET scores according to MASLD.

The quality of liver biopsies was deemed adequate with a median of 7 portal spaces. There were observed 2 mild adverse events in 2 patients, one mild abdominal pain and one atrial fibrillation, successfully treated by medical therapy.

Conclusions: The prevalence of MASLD was high in morbid obesity patients. EUS-guided portal pressure gradient and EUS-guided liver biopsies seem safe and accurately evaluate the presence of portal hypertension and the underlying metabolic liver disease.

Abstract Submission No. 100619
O-0332

Variability of Knowledge About Fatty Liver Disease: A Survey of Physicians from Asia

Zobair Younossi1, Janus Ong1, Hirokazu Takahashi1, Yusuf Yilmaz1, Yuichiro Eguchi1, Mohamed El-Kassas1, Ming-Hua Zheng1, Jian-Gao Fan1, Ming-Hua Zheng1, Jian-Gao Fan1, Vincent Wai-Sung Wong1, Khalid Aswat1, Yuichiro Eguchi1, Vincent Wai-Sung Wong1, Khalid Aswat1, Saleh Alqahtani1

1The Global NASH council, Center for Outcomes Research in Liver Disease Washington United States

Background: Despite the growing burden of fatty liver disease (FLD), there is low awareness and knowledge about the disease across different regions of the world. Our aim was to assess knowledge about FLD physicians in Asian countries.

Methods: Two specifically designed knowledge surveys containing 54-59 items were developed by the Global NASH Council members, one for GI/Liver specialists (hepatologists and gastroenterologists) and one for non-specialists (endocrinologists, primary care providers (PCPs), others). The surveys focused on terms such as FLD, NAFLD, NASH, and other related terms. Physicians from the Asian region completed the surveys using an approved electronic data collection form.

Results: There were 1482 physicians from 15 Asian countries who completed the survey: 180 hepatologists, 469 gastroenterologists, 115 endocrinologists, and 718 PCPs/other specialties. Their median practice duration was 12 years (IQR 4-24 years), 81% were hospital-based and 10% clinic-based physicians. Availability of diagnostic methods for fatty liver (imaging, liver biopsy) was the highest among hepatologists (39%-93%) and the lowest among PCPs (18%-80%) (all p<0.05). Practice guidelines were the most common primary source of latest knowledge about the disease for all the specialties (mean 43%) followed by national or international conferences (mean 16%) although Internet was the second most common source for PCPs (30%).

Disease knowledge related to epidemiology, pathogenesis, diagnostic tests, treatment, and understanding of the causes of death was higher among hepatologists than GIs (mean 68% vs. 61% correct answers) and higher among endocrinologists than PCPs (mean 73% vs. 63% correct) (both p<0.01). In multivariate analysis, the hepatology specialty (vs. GI), a hospital-based practice, seeing a greater number of affected patients per year, and using medical conferences or journals as a primary source of knowledge about the disease were independently predictive of a greater proportion of correct answers among specialists from Asian countries (all p<0.05). Similarly, the endocrinology specialty (vs. PCP) and a greater number of affected patients in the practice were associated with higher knowledge scores while using Internet as a primary source of knowledge about the disease was associated with lower knowledge scores (p<0.05) among non-specialists from Asia. Although 39%-73% survey completers believed that very few (<10%) patients have symptoms, the vast majority (78%-89%) believed that patients suffered from impaired quality of life.

Conclusions: Despite growing burden of FLD in Asia, a gap remains about disease knowledge and awareness. Better implementation of guidelines via conferences at society meetings in Asia may improve this knowledge gap.
Abstract Submission No. 100689

O-0334

Diagnostic Performance in Detecting MASH with Fibrosis Stage 1 or Higher Using Machine Learning

Shun-ichi Wakabayashi1, Takefumi Kimura1, Tadanobu Iwadare1, Taiki Okumura1, Hiroyuki Kobayashi1, Yuki Yamashita1, Ayumi Sugira3, Satoru Joshita1,2, Takeji Umemura1

1Shinshu University School of Medicine, Division of Gastroenterology and Hepatology Matsumoto Japan, 2Yodakubo Hospital Nagawa Japan, 3Sato Hospital Nakano Japan

MASH, evolving from MASLD, is linked to liver cirrhosis and hepatocellular carcinoma. Early detection of early-stage fibrosis MASH is pivotal for timely intervention. This study sought to design a supervised machine learning (ML) model for predicting mild fibrosis MASH using routine blood data and to evaluate its diagnostic capabilities.

From 2003 to 2022, we analyzed 436 MASLD patients who had liver biopsies at our center. We characterized early stage MASH as Fibrosis ≥1. Supervised ML models, including Logistic Regression; LR, Support Vector Machine; SVC, Random Forest; RF, XGBoost, LightGBM, were trained on clinical and blood test data at biopsy. The cohort was split into a Training group (n=370) and a Test group (n=93). ML was employed on the Training set, and its diagnostic efficacy was gauged in the Test set through AUROC, Sensitivity, and Specificity.

The average age was 56, with 44% males. We observed 353 early-stage fibrosis MASH instances (F0: 83, F1: 198, F2: 55, F3: 99, F4: 28). Among 32 clinical and blood markers at biopsy, the RF model showcased the best prediction (AUROC=0.81). After implementing feature engineering, the RF model, using BMI, HbA1c, ALT, fasting glucose, and age+AST, outperformed others in the Test set (AUROC=0.84, Sensitivity=0.76, Specificity=0.86), exceeding APRI (AUROC 0.75) and FIB-4 (AUROC 0.72).

In conclusion, the RF model, with five clinical parameters, showed notable accuracy in identifying early-stage MASH.

Abstract Submission No. 100706

O-0335

Genetic Variants of Metabolic Dysfunction Associated Fatty Liver Disease from Taiwan Biobank

Xia-Rong Liu1, Yun-Zheng Gao1, Yi-Ting Chen1, Szu-Ching Yin1, Tzu-I Chen1, Mei-Hsuan Lee1

1Institute of Clinical Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan

Background and Aims: The large-scale study aimed to investigate the risk factors and genetic variants associated with metabolic dysfunction-associated fatty liver disease (MASLD).

Methods: The study included 101,450 participants who underwent whole-genome genotyping throughout the Taiwan Biobank. All participants were non-drinkers and tested seronegative for HBsAg and anti-HCV antibodies. MASLD was defined by a fatty liver index ≥30 and the presence of at least one cardiometabolic risk factor. Participants with a fatty liver index <30 were categorized as non-steatotic liver disease. Logistic regression models were utilized to estimate the odds ratios (ORs) with 95% confidence intervals (CIs).

Results: Among the total population, 31389 (30.9%) had MASLD, while 70061 (69.1%) were individuals without steatotic liver disease. Individuals with MASLD showed significant positive associations with increased triglyceride levels, metabolic syndrome, central obesity, and cardiovascular disease (p<0.001). In addition, variants in the PNPL3, TM6SF2, and GCKR genes were found to be associated with MASLD, with the adjusted ORs (95% CI) of 1.73 (1.64-1.84), 1.22 (1.14-1.29), and 1.06 (1.02-1.11), respectively. Individuals with a higher number of risk alleles had an increased likelihood of having MASLD compared to non-steatotic liver disease. Participants with 4 risk alleles and 5 to 6 SNP risk alleles exhibited adjusted ORs of 1.19 (1.13-1.25) and 1.46 (1.39-1.54), respectively, when compared to those with 0 to 3 risk alleles.

Conclusions: Individuals with a greater number of risk alleles were more likely to have MASLD, emphasizing the importance of risk consultations for obesity-related comorbidities.

Abstract Submission No. 100720

O-0336

Results of triple therapy for NAFLD in Mongolia

Amsaranaa Jazag1,2,3,4, Erdenebayar Gonchig1, Baatarkhuu Oidov1, Enkhuyta Damba2-3, Buren-Ochir Tsakhurtsumur2, Tegshjargal Amarjargal1, Nandintsetseg Natsagdorj1, Urangoo Bayasgalanbaatar1

1MASLD, Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia, 2Otoch Manramba University Ulaanbaatar Mongolia, 3Happy Veritas Hospital Ulaanbaatar Mongolia, 4GLU Ulaanbaatar Mongolia

Background: Although it is well noted that hepatitis caused by viruses have recently decreased in Mongolia, it is expected that liver steatosis and cirrhosis related to unhealthy lifestyles will increase. Therefore, we conducted a study to determine the results of the triple therapy of NAFLD for the first time in our country.

Methods: Before treatment, the degree of steatosis was determined using the Fibrotouch / transient elastography/ device and patients with higher than normal values of steatosis were included, and then a triple medical therapy and lifestyle modifications were recommended for 1 month, and a second measurement was performed after treatment. The treatment was performed at the outpatient clinic of Happy Veritas Hospital. Treatment consisted of atorvastatin 20-40 mg once a day, ursodeoxycholic acid 250 mg 2-3 times a day, vitamin E 400 IU, 2 capsules per day after meals.

Results: 64 patients showed a decrease in fatty liver of 98.4%, and decrease in CAP values varied between 2 and 168 db/m respectively. Steatosis decreased in n=60 (93.7%) patients by at least one stage, 3% of patients (2.0%) whose steatosis reduced but the liver stiffness increased. The decrease in CAP values varied between 2 and 168 db/m respectively. Steatosis decreased in n=60 (93.7%) patients by at least one stage, 3% of patients (2.0%) whose steatosis reduced but the liver stiffness increased.

Conclusion: Triple therapy that consisted of lifestyle modifications plus statins, vitamin E and ursodeoxycholic acid was highly effective in Mongolian NAFLD patients.
Prevalence and characteristics of lean MAFLD in patients with diabetes: a multicenter study

weixia sun1,2, ling li3
1Southeast University Nanjing China, 2Department of Endocrinology, School of Medicine, Zhongda Hospital, Southeast University Nanjing China

Background: Metabolic associated fatty liver disease (MAFLD) is associated with obesity and type 2 diabetes (T2DM). Little is known about the prevalence and characteristics of MAFLD patients with normal body mass index and T2DM.

Abstract Submission No. 100759
O-0338

Comparing 1.5T and 3.0T MRI for Assessing Hepatic Steatosis with Proton Density Fat Fraction

Chia Yun Chang1, Chih horng Wu1
1Medical imaging, National Taiwan University Hospital, Taipei, Taiwan Taipei Taiwan

Background: Magnetic resonance spectroscopy (MRS) serves as a non-invasive method for assessing hepatic steatosis. However, it also presents shortcomings, including selection variability and spatial limitation. Proton density fat fraction (PDFF), a newly developed quantitative method for measuring liver fat across the entire liver, shows potential in replacing MRS.

There is no uniform protocol about PDFF, our study aims to compare the correlation between PDFF and MRS under the different magnetic fields.

Methods: 401 healthy liver donors of NTUH receiving pre-transplantation evaluation prospectively enrolled from August 2011 to September 2021. After 1:1 matching for age, gender and body mass index (BMI), 250 patients included in the study, evenly distributed in the two magnetic fields.

PDFF value measurements were taken from the six liver segments (S5, S6, S7, S8, medial and lateral). Correlations with MRS were separately analyzed, as well as the averages of 6 segments were also analyzed. Patients were categorized into high-fat and low-fat groups using a PDFF cutoff of 5%, and correlations were examined.

Results: The highest correlation was found in the average of the six segments in 3.0T (Spearman’s r value: 0.8945, p<0.05) and the lowest correlation in the lateral segment in 1.5T (Spearman’s r value: 0.7725, p<0.05). After grouping patients by fat content, the average of the six segments in 1.5T exhibited the highest correlation (Spearman’s r value: 0.9336, p<0.05), while the lateral segment in 1.5T displayed the lowest correlation (Spearman’s r value: 0.5096, p<0.05).

Conclusions: In our research, the average PDFF value of 6 segments has the highest correlation with MRS in both magnetic fields. And after grouping patients by fat content, 1.5T is better for the high-fat group and 3.0T is better for the low-fat group.
Metabolic dysfunction-associated steatotic liver disease and liver-related outcome

Sang Yi Moon¹, Yang Hyun Baek¹, Yeo Wool Kang¹, Minkook Son¹
¹Dong-A University College of Medicine Busan South Korea

Introduction: Compared to nonalcoholic fatty liver disease (NAFLD), the recently proposed metabolic dysfunction-associated steatotic liver disease (MASLD) has been suggested to better reflect the metabolic components of fatty liver disease (FLD). This study examines the occurrence of hepatocellular carcinoma (HCC) and liver cirrhosis-related complications in patients with and without MASLD, metabolic dysfunction, and alcohol-associated steatotic liver disease (MetALD).

Materials and methods: Using the Korean National Health Insurance database, we identified participants who underwent a health-screening program in 2010 and 2011 and retrospectively analyzed their data until 2019. The main objective was to ascertain the rate of newly diagnosed HCC and liver cirrhosis-related complications during the observation period for each patient group.

Results: Out of the 310,724 individuals, 108,996 (35.1%) were part of the MASLD group, 13,960 (4.5%) belonged to the MetALD group, and 187,768 (60.4%) were in the neither FLD group. When using the neither FLD group as the reference, the multivariable-adjusted hazard ratio (95% confidence interval) for HCC events was 1.34 (1.26-1.42) in the MASLD group and 1.48 (1.31-1.67) in the MetALD group, while the hazard ratios for liver cirrhosis-related complications were 1.31 (1.24-1.38) in the MASLD group and 1.73 (1.56-1.92) in the MetALD group.

Conclusions: Individuals with MASLD exhibit higher rates of HCC and liver cirrhosis-related complications compared to those without the condition.
GLP-1 receptor agonists (RA) like liraglutide and semaglutide are approved antidiabetic drugs and have shown to reduce weight and cardiovascular risks in multiple studies. Real-life data on the effect of these GLP-1RA in steatotic liver disease (SLD) are scarce.

**Methods:** Observational study examining liraglutide and semaglutide in SLD patients. Patients received therapy with liraglutide 0.6mg increased to 3.0mg daily or semaglutide 0.25mg weekly increased to 1mg subcutaneously for a period of at least 2 months. Elasticity using Fibroscan®, fat content using CAP (controlled attenuation parameter), weight and laboratory were recorded directly before, immediately after the end of therapy and after 6 months.

**Results:** 33 (17 female) patients were treated with GLP-1RA. 73% of patients were diagnosed with NAFLD, 16% with NASH and 11% with BASH. After 2 months of treatment with GLP-1RA, there was significant reduction in elasticity (median decrease 29.2% (+1.9kPa)) and significant decrease in CAP (median decrease 29.0% (+82dB/m)). Significant weight reduction was achieved (7.4% after two, 6.3% reduction six months post treatment). In 12 patients with elevated ALT, reduction was achieved in 9 patients after 2 months, stable after 6. The subgroup of women (10.7%, p=0.8) and those not suffering from diabetes showed a more pronounced weight reduction (10.2%, p=0.09) after 2 months. There was no significant difference between liraglutide (25) and semaglutide (8) patients. Both 1 patient with liraglutide (0.6%) and semaglutide (0.25%) patients were diagnosed with NAFLD, 16% with NASH and 11% with BASH. There were no significant differences in age, sex, occupation, or smoking history between the two groups. After treatment with empagliflozin, weight (76.91±6.4 vs. 73.52±6.8 kg, p=<0.001), BMI (22.52±4.6 vs. 21.47±4.6 kg/m², p=0.001), HbA1C (7.65±1.5 vs. 7.27±1.47%, p=0.012), AST (43.25±3.8 vs. 41.17±4.1 IU/L, p=0.001), ALT (56.04±7.7 vs. 52.53±7.5 IU/L, p=0.001), GCT (67.4±4.4 vs. 59.7±5.1 IU/L, p=0.001), total cholesterol (177.4±19.7 vs. 170.9±18.1 mg/dl, p=0.001), triglycerides (138.4±15.1 vs. 132.8±14.2 mg/dl, p=0.001), and LDL (109.6±16.7 vs. 103.7±17.1 mg/dl, p=0.001) significantly decreased. Additionally, the mean liver stiffness significantly decreased from baseline in the empagliflozin group (3.28±0.46 vs. 3.40±0.40 kPa, p=0.031), with a notable improvement in stages of liver stiffness among respondents.

**Conclusion:** Empagliflozin had a significant impact on liver fibrosis, weight, and liver function tests when used in patients with NASH and type 2 diabetes mellitus.

---

**Effect of Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 DM**

*sarker sajjad¹,², Tareq Bhuyan¹*

¹MRC, FCPs Dhaka Bangladesh, ²BIRDEM general hospital Dhaka Bangladesh

**Background:** Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of liver conditions, ranging from benign hepatic steatosis to the more severe non-alcoholic steatohepatitis (NASH), often leading to liver fibrosis. This study aims to assess the effects of empagliflozin on liver fibrosis in patients with nonalcoholic steatohepatitis (NASH) and type 2 diabetes mellitus.

**Methods:** This prospective, randomized, controlled, open-label study was conducted at the Department of GHPD, BIRDEM General Hospital, Dhaka, over a six-month period. Ninety patients with Type 2 diabetes mellitus (DM) and NASH were enrolled from the department’s outpatient population after obtaining informed written consent. They were randomly allocated into two groups: the empagliflozin group (Group A) and the control group (Group B) in a 1:1 ratio, with treatment allocation being open-label. Socio-demographic characteristics, clinical features, and laboratory investigations were assessed. Data was collected using a semi-structured questionnaire, and analysis was performed using Statistical Package for Social Science (SPSS) version 24.0.

**Results:** The mean age of respondents in the empagliflozin and control groups was 49.11±7.90 and 46.98±10.19 years, respectively, with a higher proportion of males in both groups (77.8% and 84.4%, respectively). There were no significant differences in age, sex, occupation, or smoking history between the two groups. After treatment with empagliflozin, weight (76.91±6.4 vs. 73.52±6.8 kg, p=<0.001), BMI (22.52±4.6 vs. 21.47±4.6 kg/m², p=0.001), HbA1C (7.65±1.5 vs. 7.27±1.47%, p=0.012), AST (43.25±3.8 vs. 41.17±4.1 IU/L, p=0.001), ALT (56.04±7.7 vs. 52.53±7.5 IU/L, p=0.001), GCT (67.4±4.4 vs. 59.7±5.1 IU/L, p=0.001), total cholesterol (177.4±19.7 vs. 170.9±18.1 mg/dl, p=0.001), triglycerides (138.4±15.1 vs. 132.8±14.2 mg/dl, p=0.001), and LDL (109.6±16.7 vs. 103.7±17.1 mg/dl, p=0.001) significantly decreased. Additionally, the mean liver stiffness significantly decreased from baseline in the empagliflozin group (3.28±0.46 vs. 3.40±0.40 kPa, p=0.031), with a notable improvement in stages of liver stiffness among respondents.

**Conclusion:** Empagliflozin had a significant impact on liver fibrosis, weight, and liver function tests when used in patients with NASH and type 2 diabetes mellitus.
Impact of single nucleotide polymorphisms on long-term prognosis in non-obese MASLD

Michihiro Iwaki1, Kobayashi Takashi2, Nogami Asako2, Yuya Seko2, Kanji Yamaguchi3, Miwa Kawanaka3, Saiyu Tanaka3, Hirokazu Takahashi4, Yoshito Itoh5

1Yokohama City University Graduate School of Medicine Yokohama Japan, 2Kyoto Prefectural University of Medicine, Graduate School of Medical Science Kyoto Japan, 3Kawasaki Medical School, General Medical Center Okayama Japan, 4Nara City Hospital Nara Japan, 5Saga University Hospital Saga Japan

Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is recognized to occur not only in obese but also in non-obese individuals. There is no consensus on the long-term prognosis of non-obese MASLD patients. Since mutations in single nucleotide polymorphisms (SNPs) are known to be involved in the progression of MASLD, we investigated the impact of SNPs on the long-term prognosis of non-obese MASLD patients.

Methods: This is a multicenter, retrospective cohort study. Patients diagnosed with MASLD by liver biopsy between November 1, 1997 and October 31, 2020 and examined for SNPs including PNPLA3, TM6SF2, and HSD17B13 were enrolled. Patients were followed until December 31, 2022, for death and clinical events.

Results: Of 1294 MASLD patients, 331 (25.6%) were non-obese. They also included 147 (44.4%) patients with PNPLA3 type GG, which was significantly higher than in the obese group (p=0.04). After a median follow-up of 7.6 years, 17 (5.1%) patients in the non-obese group and 33 (3.4%) in the obese group died, and the Kaplan-Meier method showed no significant difference in survival rates between the two groups.

Conclusion: Non-obese MASLD is more susceptible to SNPs than obese MASLD. Our results suggest that analysis of SNPs, especially PNPLA3, may be able to predict prognosis in non-obese MASLD patients.

Abstract Submission No. 101695
O-0348

AI diagnostic system accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis

Takeshi Okanoue1, Kanji Yamaguchi2, Toshihide Shima3, Yasuhide Mitsumoto3, Yuya Seko2, Michihisa Moriguchi2, Yoshito Itoh2

1Department of Gastroenterology, Saiseikai Suita Hospital Osaka, Suita Japan, 2Department of Gastroenterology, Kyoto Prefectural University of Medicine Kyoto Japan

Background & Aims: To develop a novel noninvasive test using an artificial intelligence neural network system (named HCC-Scope) that can diagnose early stage hepatocellular carcinoma (HCC) in nonalcoholic steatohepatitis (NASH).

Methods: 175 with histologically proven nonalcoholic fatty liver disease (NAFLD) and 55 NASH-HCC patients were enrolled. Of the 55 HCC patients 27 (49.1%) were very early stage HCC and 6 (10.9%) were early stage HCC. HCC-Scope was conducted using 15 items: age, sex, height, weight, body mass index, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transferase, cholesterol, triglyceride, platelet count, diabetes, alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin (DCP), and IgM-free apoptosis inhibitor of macrophage (FAIM). The FMVWG2U47 (Fujitsu Co. Ltd) hardware and the originally developed software were used.

Results: Differential diagnosis between not HCC and HCC using the HCC-Scope revealed 100.0% sensitivity, 100.0% specificity, 100.0% positive predictive value, and 100.0% negative predictive value in a training study with gray-zone analysis, and which was also effective in the analysis in the explorative study. It was also excellent in the validation study (95.0% sensitivity, 100.0% specificity, 100.0% PPV, and 97.1% NPV with gray zone analysis, and it was 95.2%, 100.0%, 100.0% and 97.1% without gray zone analysis. HCC-Scope showed significantly better sensitivity and specificity than AFP, AFP-L3, DCP and even then than GALAD (gender, age, AFP-L3, AFP, DCP) score (its sensitivity: 85.3%, specificity: 85.1%).

Conclusions: The newly developed artificial intelligence neural network system algorithms termed HCC-Scope are easy to use and can
accurately differentially diagnose between NASH without HCC and NASH-HCC including early stage HCC.

Abstract Submission No. 101715
O-0349

Comprehensive Analysis of Specific MicroRNAs Related to Therapeutic Efficacy of Pemafibrate in MASLD
Asahiro Morishita1, Kyoko Oura1, Takuma Kei1, Mai Nakahara1, Tomoko Todokoro1, Koji Fujito1, Joji Tani1, Takashi Himoto2, Tsutomu Masaki1
1Kagawa University Kita-gun Japan, 2Kagawa Prefectural University of Health Sciences Takamatsu Japan

Background: MASLD has become a major social problem in recent years. Pemafibrate binds to PPARs and regulates the expression of its target gene, thereby decreasing plasma triglyceride levels and increasing HDL-cholesterol.

Aim: The aim of this study was to comprehensively analyze the efficacy of pemafibrate in patients with hyperlipidemia complicated with MASLD and the specific microRNAs involved in its therapeutic effect.

Methods: Thirty hyperlipidemia complicated patients with a confirmed diagnosis of NAFLD were treated with pemafibrate, a hyperlipidemic drug, as usual medical treatment. In parallel, clinical data (T-Bil, ALB, AST, ALT, platelets, type IV collagen 7S, M2BPG, Autotaxin, FIB-4 index), efficacy (liver function, changes in the degree of liver fibrosis, etc.), and safety in MAFLD treated with exercise and diet, Fobroscan data and microRNA were comprehensively analyzed.

Results: Comparing clinical data before, one month after, and three months after Pemafibrate administration, significant changes were observed in AST, ALT, and Autotaxin, and correlated with the FAST score. Comprehensive analysis of microRNA expression in serum before and 3 months after treatment showed that they formed different clusters. The number of microRNAs that were significantly up-regulated and down-regulated was 15 and 10 molecules, respectively.

Discussion: Pemafibrate treatment significantly altered microRNAs, consistent with the improvement in clinical data and FAST score. These microRNAs may be involved in the therapeutic effect of Pemafibrate.

Conclusion: Pemafibrate is effective in improving liver function in MASLD patients with hyperlipidemia, and the specific microRNAs involved in the therapeutic effect may help to elucidate the mechanism of this effect.

Abstract Submission No. 101751
O-0350

Study to compare the efficacies of vitamin E and Saroglitazar in non diabetic NAFLD patients
SANJAY KUMAR1, PRANAV RAGHUVANSHI1, NEETU KUMAR2, VINOOD NARKHED2, NAVEEN TMU3, MAYANK PATERIYA1, KSHTIJ KAPIL1, SATISH KAPIL1
1BHOPAL INSTITUTE OF GASTROENTEROLOGY, BHOPAL CORE HOSPITAL, BHOPAL India, 2Chirayu medical college bhopal India, 3LN medical college bhopal india

Introduction: NAFLD (Nonalcoholic fatty liver disease) is a major cause of chronic liver disease globally. The spectrum of NAFLD ranges from simple steatosis to non-alcoholic steatohepatitis which can progress to cirrhosis and hepatocellular carcinoma. There is no study comparing Vitamin E and Saroglitazar in non diabetic NAFLD patients.

Methods: It is a retrospective observational study conducted in Gastrocare hospital over a period of 4 years. The subjects having CAP score 215 or more (E score < 12.5kPa) were labeled as NAFLD. Total subjects included in the study were 306, 158 in Vitamin E group and 148 in Saroglitazar group. Subjects received capsule Vitamin E 400mg twice daily while Saroglitazar 4mg once daily along with standard treatment.

Results: After completion of 6 months treatment, mean baseline values of CAP scores showed statistically significant reduction from (310±26.4 & 312±31.2) to (268±18.6 & 238.8±18.5) in Vitamin E and Saroglitazar group respectively. After treatment mean E score was 7.1 3.1 and 7.2 3.2 respectively in Vitamin E and Saroglitazar groups. Both groups showed statistically Significant improvement in CAP score after therapy (p value <0.001 for Vitamin E group v/s < 0.001 for Saroglitazar group). On intergroup analysis, there was 13.5% improvement in the CAP score in Vitamin E group where as in Saroglitazar group it was 23.7%. It was found to be statistically significant (P value <0.03).

Conclusion: Both Vitamin E and Saroglitazar showed significant improvement in CAP score but Saroglitazar was significantly more effective than Vitamin E.

Abstract Submission No. 101838
O-0351

Molecular MASLD subtype to inform disease progression and therapeutic decision making
Naoto Fujiwara1, 2, Hayato Nakagawa1, Yujin Hoshida2
1Mie University Mie Japan, 2University of Texas Southwestern Medical Center Texas USA

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) has marked molecular and clinical heterogeneity, yet there is no tool to inform disease progression and therapeutic decision making.

Methods: To identify molecular subtypes of MASLD associated with functional status of the liver, we performed an integrative hepatic transcriptome meta-analysis of multi-regional cohorts, including 1,232 mild- to advanced-stage MASLD patients. The MASLD subtypes were characterized according to clinico-histological features, fibrosis progression, HCC development, and estimated therapeutic effects.

Results: We identified and validated three reproducible subtypes across the cohorts, subtypes 1 to 3. Subtype 1 was associated with advanced histological fibrosis compared to the two other subtypes. Despite the indistinguishable clinico-histological features, the likelihood of histological fibrosis progression for subtype 2 was higher compared to subtype 3 (adjusted odds ratio, 1.43; 95% confidence interval [CI], 1.12-1.84). While subtype 3 was HCC-free up to 15 years, incident HCC rates in subtypes 2 and 3 were comparable (adjusted hazard ratio for subtype 1 compared to subtype 2, 0.75; 95% CI, 0.11-5.27). Based on the findings, we named subtypes 1, 2, and 3 as advanced-MASLD (a-MASLD), progressive-MASLD (p-MASLD), and indolent-MASLD (i-MASLD) subtypes, respectively. Transcriptomic analysis suggests that some of the existing and candidate MASLD therapies may yield subtype-specific benefit. Consistent with the transcriptome-based drug response assessment, cenicriviroc, an oral CCR2/5 antagonist, was more effective in reducing histological fibrosis in p- and a-MASLD in the phase 2b CENTAUR trial.

Conclusion: Molecular MASLD subtypes can serve as a tool to inform disease progression and therapeutic decision making.

Abstract Submission No. 101866
Diagnostic Performance of CT/MRI LI-RADS v2018 in Non-Cirrhotic Steatotic Liver Disease

Justin R Tse1, Jennie J Cao1, Andy Shon1, Luke Yoon1

1Stanford University Stanford United States

Background: Our objective was to assess the performance of LI-RADS among patients with non-cirrhotic steatotic liver disease (SLD).

Methods: This IRB-approved, retrospective study included 119 observations from 77 adult patients (36 women, 41 men; median age 64 years) who received liver protocol CT or MRI from 2010-2023. All patients had SLD by histopathology without cirrhosis. Three board-certified abdominal radiologists blinded to final tissue diagnosis and imaging follow-up assessed each observation per LI-RADS and assigned a final category. Inter-reader agreement with weighted kappa was calculated for major features and final category. The positive predictive value, sensitivity, specificity, and accuracy in identifying hepatocellular carcinoma (HCC) and overall malignancy was calculated.

Results: 75 observations (63%) were benign and 44 (37%) were malignant. Positive predictive value for HCC was 0-0% for LR-1, 0-0% for LR-2, 0-7% for LR-3, 11-20% for LR-4, 75-88% for LR-5, 0-8% for LR-M, and 50-75% for LR-TIV. For overall malignancy, positive predictive value was 0-0% for LR-1, 0-11% for LR-2, 3-9% for LR-3, 16-31% for LR-4, 78-88% for LR-5, 65-100% for LR-M, and 100-100% for LR-TIV. For LR-5 in identifying HCC, sensitivity was 79-83%, specificity was 91-97%, and accuracy was 89-92%. For composite categories of LR-5, LR-M, or LR-TIV in identifying overall malignancy, sensitivity was 86-89%, specificity was 85-96%, and accuracy was 86-93%. Most common false positives for LR-5 were hepatocellular adenomas. Inter-reader agreement for final category was 0.766.

Conclusion: LI-RADS 5 still most commonly represents HCC, but its specificity is slightly lowered due to misclassification of hepatocellular adenomas.

Causespecific mortality in Japanese patients with biopsy-confirmed nonalcoholic fatty liver diseases

Kyoko Sakai1,2, Toshihide Shima3, Keiichiro Okuda4, Hirohisa Oya5, Takayuki Katayama6, Yasuhide Mitsumoto7, Masayuki Mizuno8, Takeshi Okanoue3

1Department of Laboratory Medicine, Saiseikai Suita Hospital Suita Japan, 2Health Informatics, Kyoto University School of Public Health Kyoto Japan, 3Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital Suita Japan, 4Kento Health management Center Suita Japan

Objectives: The main cause of death in NAFLD patients is considered to be CVD in the West. We examined mortality and causes of death in Japanese NAFLD patients.

Methods: Histologically diagnosed NAFLD patients at Saiseikai Suita Hospital, between 2004 and 2023 were included. As a prospective cohort study, mortality using the Kaplan-Meier method and causes of death were verified, compared for NAFL versus NASH and mild versus advanced fibrosis.

Results: The study included 1085 subjects (a mean age 57.2, a mean observation period 6.65 years). During the period, 76 patients died, with a mortality of 72 /747 in the NASH, higher than in the NAFL 4 /338 (p<0.0001). After adjustment for age and sex, NASH (HR 7.35), men (HR 2.05) and older age (HR 1.09) were risks of death.

Mortality was higher (p<0.0001) in the advanced fibrosis group (41/218) than in the mild (35/867). After adjustment, advanced fibrosis (HR 3.64), men (HR 1.93) and older age (HR 1.08) were risks of death. Causes of death in NAFLD patients included 17 HCC, 16 cirrhosis, 18 extrahepatic malignancies, 3 CVD, 8 other and 13 unknown causes. Mortality from liver-related diseases was higher in the NASH/advanced fibrosis than in the NAFL/mild fibrosis, while mortality from extrahepatic malignancies did not differ.

Conclusion: NASH and advanced fibrosis were independent risks of death. The main causes of death in Japanese NAFLD outpatients were liver-related diseases or extrahepatic malignancies, with less CVD, which may differ from those in the West.

Unveiling NAFLD: The Interplay of SCFA, Elastography, and CAP

Chynthia Olivia Maurine Jasirwan1, Desi Astari2, C. Rinaldi A Lesmana3, Marcellus Simadibrata3

1Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 2Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo Hospital Jakarta Indonesia, 3Gastroenterology Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia

Background: Non-alcoholic Fatty Liver Disease (NAFLD), a growing global health concern, is believed to be influenced by multiple factors, including gut microbiota. A key metabolite of gut microbiota, Short Chain Fatty Acid (SCFA), is hypothesized to play a significant role in NAFLD progression.

Objective: This study aims to explore the relationship between SCFA levels and the severity of fibrosis and steatosis in NAFLD, utilizing transient elastography and controlled attenuation parameter (CAP) as assessment tools.

Method: A cross-sectional analysis was conducted on 38 NAFLD patients at Cipto Mangunkusumo Hospital from January to August 2023. The study involved comprehensive patient assessments, including anamnesis, physical examination, laboratory tests, CAP-TE (Transient Elastography), and SCFA analysis via GC-MS (Gas Chromatography-Mass Spectrometry).

Results: Notably, propionate levels were significantly higher in patients with significant fibrosis than in those with less severe fibrosis (p=0.019 for absolute propionate; p=0.035 for propionate level). However, no significant correlation was found between SCFA levels and CAP or transient elastography values (p>0.05).

Conclusion: This study highlights a significant increase in propionate levels in NAFLD patients with pronounced fibrosis, suggesting a potential link between gut metabolites and liver fibrosis. However, SCFA levels did not correlate with CAP and transient elastography values, indicating the complexity of NAFLD pathogenesis.

Keywords: Short Chain Fatty Acid, NAFLD, Transient Elastography, Controlled Attenuation Parameter

SOCS1, MIOX, HNF4A: Novel ferroptosis genes in NAFLD pathogenesis and fibrosis

Abstract Submission No. 101908

O-0354

O-0355

O-0352
Semaglutide for Metabolic-Associated Fatty Liver Disease
Ma. Felina Rosanna Siray1, Pamela Bianca Yap1, Maxine Andrea Garcia1, Marie Antoinette Lontok1
1NIBMG Kolkata India

Background: NAFLD is a chronic liver disorder linked to metabolic syndrome and inflammation. Ferroptosis is a cell death process that depends on iron and lipid oxidation. How ferroptosis affects NAFLD and liver fibrosis is unclear. We used public transcriptomic data to find ferroptosis genes and pathways in NAFLD.

Methodology: We analysed microarray gene expression and clinical data from a cohort of 40 NAFLD human liver samples and 18 healthy controls. We performed differential expression analysis to identify ferroptosis-related genes and putative pathways that may be associated with NAFLD. We harnessed machine-learning approaches, like SVM-RFE and LASSO to identify genes associated with a fibrotic phenotype. We evaluated the prediction accuracy of these genes as biomarkers of NASH using multivariable regression and correlation analysis.

Results: We identified IL17, TNF signalling, JAK-STAT signalling pathways were found to be related to NAFLD progression with FADS2, ZFP36, HNF4A being upregulated and SOCS1, JUN, IL6, SLCA2A3, ATF3, MIOX, PTGS2, CDKN1A being down-regulated. Our machine learning models identified novel genes like SOCS1, HNF4A, MIOX as potential biomarkers with ROC values of 0.92, 0.64 and 0.74.

Conclusion: We explored the role of ferroptosis pathway in NAFLD progression. We found that SOCS1 can modulate HSC activation and fibrosis. We also found that HNF4A can regulate the expression of genes that maintain the epithelial characteristics of hepatocytes and HSCs. We discovered some new genes that may be useful as biomarkers for early detection of NASH.

Abstract Submission No. 101979
O-0356

Semaglutide for Metabolic-Associated Fatty Liver Disease
A Meta Analysis and Systematic Review
Ma. Felina Rosanna Siray1, Pamela Bianca Yap1, Maxine Andrea Garcia1, Marie Antoinette Lontok1
1St. Luke's Medical Center - Global City Taguig Philippines

Background: Semaglutide is a once-weekly glucagon-like peptide-1 receptor agonist with a smaller molecular weight that is approved for the treatment of type 2 diabetes mellitus and obesity. It is associated with dose dependent reduction in HbA1c and body weight among diabetic patients. However, its potential role in the treatment of non-alcoholic steatohepatitis remains unclear. The objective of this study is to determine the effectiveness of semaglutide in decreasing steatosis and fibrosis among patients with metabolic associated fatty liver disease.

Methods: Eligible studies were identified by a systematic literature search of Pubmed, Cochrane, Google scholar databases until September 2023. Randomized control trials were included and the quality of the studies was assessed using the Cochrane handbook. Statistical analyses were conducted using RevMan 5.4 software.

Results: A total of 458 patients from three randomised control trials were included. Histologically, semaglutide increased the likelihood of resolution of steatohepatitis (OR: 3.18, CI: 1.70, 5.95; P < 0.001). Radiologically, semaglutide caused a reduction in liver stiffness as measured by magnetic resonance elastography and fibroscan (SMD: -0.45, CI: -0.84, -0.09; P = 0.02). It also caused a reduction in the degree of steatosis measured by MRI proton density fat fraction (MD: -4.96%, CI: -9.92, 0.01; P = 0.05).

Conclusion: Semaglutide is effective for the histologic resolution of steatohepatitis and the radiologic improvement of both steatosis and fibrosis.

Abstract Submission No. 102055
O-0357

Pilot randomized controlled trial of effects of dapagliflozin and vitamin E on MASLD with type 2 DM
Kazuyoshi Kon1, Hiro Fukada1, Akira Uchiyama1, Shunhei Yamashina1, Kyoko Fukuhara1, Kenichi Ikejima1
1Juntendo University School of Medicine Tokyo Japan

Aim: We investigated the effects of dapagliflozin and vitamin E on metabolic dysfunction-associated steatotic live disease (MASLD) with type 2 diabetes by randomized, open-label, controlled study.

Methods: Total 24 patients with an HbA1c ≥ 6.5%, hepatic steatosis on ultrasonography, and ethanol consumption of < 30 g/day for men and < 20 g/day for women were randomly assigned to treatment with dapagliflozin 5 mg (DAPA group, n=13) and tocopherol 150 mg (VE group, n=11), and the clinical course was monitored during the 24-week-treatment period (jRCT1031180386).

Results: Three patients in DAPA group complained of frequent urination or dry mouth, and 1 of them discontinued treatment due to frequent urination. There was no significant difference between clinical courses of the two groups by repeated measures analysis of variance. Comparing before and after 24 weeks of the start of treatment in each group, both AST and ALT values significantly decreased in DAPA group whereas only AST levels significantly decreased in VE group. In addition, BMI, body fat percentage and HbA1c levels decreased significantly in DAPA group. No significant decrease in fibrosis markers or liver stiffness was observed before and after treatment in either group.

Conclusion: Tocopherol reduced only serum AST levels, whereas dapagliflozin significantly lowered both serum AST and ALT levels in MASLD with type 2 diabetes; however, there was no significant difference between the two groups in a group comparison. These findings revealed the benefits and risks of treating MASLD with type 2 diabetes using SGLT2 inhibitor or vitamin E.

Abstract Submission No. 200040
O-0358

Meta-analysis of Luseogliflozin on Hepatic Steatosis/Fibrosis Indexes in Diabetic Patients in Japan
Takumi Kawaguchi1, 2, Kenta Murotani2, 3, Hiromitsu Kajiyama4, Hitoshi Obara1, 3, Hironori Yamaguchi5, Yuku Toyofukui6, Fumi Kaneko7, Saeko Uchida8
1Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine Kurume Japan, 2Clinical Research Center, Kurume University Hospital Kurume Japan, 3Biostatistics Center, Kurume University Kurume Japan, 4Taisho Pharmaceutical Co., Ltd. Tokyo Japan

Backgrounds: Luseogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is known to decrease serum ALT levels in patients with diabetes mellitus. We aimed to investigate the effects of luseogliflozin on hepatic steatosis/fibrosis indexes and BMI in Japanese patients with diabetes mellitus by a meta-analysis.

Methods: In this pooled meta-analysis, we included 5 phase III clinical trials conducted in Japan. The primary outcomes were fatty liver index (FLI) and aspartate aminotransferase to platelet ratio index (APRI) after 24 weeks. The secondary outcome was BMI after 24 weeks. Statistical analysis was performed using propensity scoring analysis by the inverse probability of treatment weighting (IPTW) method.
Ehocrine function and obesity may then lead to non-alcoholic fatty liver disease (NAFLD), and progression to cirrhosis or even hepatocellular carcinoma.

In this study, we aimed to investigate the relationship between obesity and NAFLD, and how this relationship changes with increasing BMI.

**Methods:**
We performed a cross-sectional study of 1,000 participants who were consecutively recruited from a local hospital. All participants underwent a detailed medical history, physical examination, and laboratory tests, including liver function tests, lipid profile, and anthropometric measurements.

**Results:**
The prevalence of NAFLD was significantly higher in participants with a BMI of 25 or more compared to those with a BMI less than 25. Furthermore, the prevalence of NAFLD increased with increasing BMI, from 7.2% in participants with a BMI of 25 to 30, to 20.7% in those with a BMI of 30 or more.

**Conclusion:**
Our study confirms the strong association between obesity and NAFLD, highlighting the importance of weight management and lifestyle interventions to prevent and manage NAFLD.

**References:**
The Effects of GLP-1 Receptor Agonists in Histological Improvement of NASH: A Meta-analysis of RCT

STEATOHEPATITIS-A RANDOMIZED CONTROL TRIAL

MEHREEN SIYAL1, ZAIGHAM ABBAS1, MUHAMMAD ALI QADEER1, ALINA SAEED1, ABEER ALTAF1

1Dr. Ziauddin Hospital, Clifton Campus, Karachi Pakistan

Background: The management of non-alcoholic steatohepatitis (NASH) is an unmet clinical need. Misoprostol, a structural analogue of naturally occurring prostaglandin E1 (PGE1), has been reported to decrease pro-inflammatory cytokine production and may have a potential role to treat NASH. We aimed to evaluate the efficacy and safety of misoprostol in treating patients with NASH.

Methods: In this phase 2, double-blind, randomized, placebo-controlled trial, patients with NASH were randomly assigned in a 1:1 ratio to receive 200 mcg of misoprostol or placebo thrice daily for 2 months. The primary endpoint was an improvement in liver function tests, interleukin-6 (IL-6), and endotoxin levels. The secondary endpoint was improvement in insulin resistance, dyslipidemia, hepatic fibrosis, and hepatic steatosis.

Results: A total of 50 patients underwent randomization, of whom forty-four (88%) were males. The age range was 25-64 years (mean38.1±SEM1.4). 19 (38%) patients had concomitant type 2 diabetes mellitus. 32 (64%) patients were either overweight or obese. At the end of 2 months treatment, a reduction in total leucocyte count (TLC) (p=0.005), alanine aminotransferase (ALT) (p<0.001), aspartate aminotransferase (AST) (p=0.002), and controlled attenuation parameter (CAP) (p=0.003) was observed in the misoprostol group, whereas placebo ensued a decline in ALT (p<0.001), AST (p=0.018), gamma glutamyl transferase (GGT) (p=0.003), CAP (p=0.010) and triglycerides (p=0.048). There was no diminution in insulin resistance, hepatic fibrosis, and dyslipidemia in both groups. However, misoprostol resulted in a significant reduction in CAP as compared with the placebo group (p=0.039). Moreover, in the misoprostol group pre and post treatment IL-6 and endotoxin levels remained stable, while in the placebo group, an increase in the IL-6 levels was noted (p=0.049). In the misoprostol group six (12%) patients had at least one adverse event in the misoprostol group, as did five (10%) in the placebo group. The most common adverse event in the misoprostol group was diarrhoea. No life-threatening events or treatment-related deaths occurred in each group.

Conclusions: Improvement in biochemical profile was seen both in misoprostol and placebo groups without any statistically significant difference. However, there was more improvement in steatosis, as depicted by CAP, in the misoprostol group and worsening of IL-6 levels in the placebo group.

Abstract Submission No. 100184

O-0364

Association of sex and baseline ALT levels with response to pioglitazone for SLD patients

Ming-Ling Chang1, 2

1Department of Hepatology and Gastroenterology, Chang Gung Memorial Hospital, Linkou, Taiwan Taoyuan Taiwan; 2Department of medicine, College of Medicine, Chang Gung University Taoyuan Taiwan

Background/Aim: The response rate and factors for pioglitazone to improve liver biochemistry of steatoatrophic liver diseases (SLD) patients remained elusive in Taiwan.

Methods: A 3-year prospective cohort study of 126 Taiwanese SLD patients treated with pioglitazone (15-30 mg/day) was conducted. The genetics including phospholipase domain-containing protein 3 (PLD3), rs738409, methylenetetrahydrofolate reductase (MTHFR) rs1801133 and aldehyde dehydrogenase 2 (ALDH2)-rs671 were assessed.

Results: Of 126, 78 (61.9%) were males, with a mean and median ages of 54.3 and 56.5 years, respectively; 105 (83.3%) were pioglitazone responders (decreased alanine aminotransferase (ALT) levels at 6 months after treatment). Compared with non-responders, the responders were more frequently female, had higher baseline ALT but lower uric acid levels and lower ALDH2-rs671 GG genotype rates (38.6% vs. 66.6%, p=0.027). Sex [female sex: odds ratio (OR): 4.514, p=0.023] and baseline ALT levels (OR:1:015, p=0.046) were
associated with pioglitazone response. The cut-off level for baseline ALT to predict pioglitazone response is 82 U/L. Among responders, liver biochemistry and HOMA-IR were improved from 6 months to 24 months after treatment. Total cholesterol levels reduced in the first 6 months, while HDL-C increment, triglycerides and fibrosis-4 index reductions were noted only at 24 months after treatment.

**Conclusions:** For liver biochemistry, over 80% of SLD Taiwanese had pioglitazone response, which was positively associated with female sex and baseline ALT levels. Insulin resistance improved as early as 6 months after treatment, while liver fibrosis improvement was not evident until 24 months after treatment. The link between pioglitazone response and ALDH2 genotype demands further investigation.

**Abstract Submission No. 100207**

-O-0365

**AI-based digital pathology offers newer insights into lifestyle-induced fibrosis regression in MAFLD**

Hai-Yang Yuan1, Xiao-Fei Tong2, Ya-Yun Ren3, Yang-Yang Li4, Xin-Lei Wang2, Sui-Dan Chen5, Li-Li Chen1, Xiao-Zhi Jin1, Xiao-Dong Wang6, Giovanni Targher7, Christopher D Byrne8, Vincent W Wong9, Dean Tai3, Hong You2, Ming-Hua Zheng1, 5, 10

1MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 2Liver Research Center, Beijing Friendship Hospital, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Capital Medical University Beijing China, 3Histology Pte Ltd Singapore Singapore, 4Department of Pathology, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 5Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province Wenzhou China, 6Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona Verona Italy, 7IRCotts Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella Verona Italy, 8Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital Southampton UK, 9Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong Special Administrative Region, China, 10Institute of Hepatology, Wenzhou Medical University Wenzhou China

**Background & Aims:** Lifestyle intervention is the mainstay of therapy for metabolic-associated steatohepatitis (MASH), and liver fibrosis is a key consequence of MASH that predicts adverse clinical outcomes. The placebo response plays a pivotal role in the MASH clinical trials. Second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy with artificial intelligence analyses provides an automated quantitative assessment of fibrosis on a continuous scale, called qFibrosis. We used this approach to gain insight into lifestyle intervention-induced fibrosis changes in MASH.

**Methods:** We examined unstained sections from paired liver biopsies (baseline and end-of-intervention) from MASH patients who had received either routine lifestyle intervention (RLI) (n=35) or strengthened lifestyle intervention (SLI) (n=17). We quantified liver fibrosis with qFibrosis in the portal tract, periporal, transitional, pericentral, and central vein regions.

**Results:** 20% (7/35) and 65% (11/17) of patients had fibrosis regression in the RLI and SLI groups, respectively. Liver fibrosis tended toward no change or regression after each lifestyle intervention, and this phenomenon was more prominent in the SLI group. SLI-induced fibrosis regression was mainly concentrated in the periporal region.

**Conclusions:** Using digital pathology, we could detect more pronounced fibrosis regression in the periporal region, with SLI. The patients with RLI were regarded as placebo patients with awareness of MASH conditions. With fibrosis regression in the periporal region, we could potentially differentiate RLI and SLI patients in the placebo group in the MASH clinical trial. Digital pathology provides new insight into lifestyle-induced fibrosis regression and placebo response, which is not captured by conventional histological staging.

**Abstract Submission No. 100222**

-O-0366

**Risk factors for extrahepatic cancer in people with non-alcoholic fatty liver disease**

Patricia Valery1, 4, Richard Skoien2, 7, James O’Beirne3, Gunter Hartel1, Louisa Gordon1, Babak Sarraf1, 6, Barbara Leggett9, Elizabeth E Powell1, 5, 6

1QIMR Berghofer Medical Research Institute Herston Australia, 2Royal Brisbane and Women’s Hospital Brisbane Australia, 3Sunshine Coast University Hospital Sunshine Coast Australia, 4Faculty of Medicine, The University of Queensland Brisbane Australia, 5Centre for Liver Disease Research, Translational Research Institute, Faculty of Medicine, The University of Queensland Brisbane Australia, 6Department of Gastroenterology and Hepatology, Princess Alexandra Hospital Brisbane Australia

**Background:** Although cancer is the second leading cause of death in people with non-alcoholic fatty liver disease (NAFLD), the magnitude of risk and relationship with disease severity and metabolic comorbidity remains unclear. We compared incidence of cancers in people hospitalised with NAFLD or non-alcoholic steatohepatitis (NASH) during 2007-2019 in Queensland, Australia, and investigated the association between cirrhosis, type 2 diabetes (T2D) and cancer risk.

**Methods:** In this retrospective state-wide data-linkage cohort study, we identified all cancers after the first hospitalisation with NAFLD/NASH to December-2019, estimated age-standardized incidence (ASIs) of cancers, compared that to the ASI in the Queensland population (incidence rate-ratios (IRR)), and examined the association between cirrhosis, type 2 diabetes (T2D) and cancer risk.

**Results:** 11,483 patients age ≥20 years with NAFLD/NASH followed for a median of 3.8 years (interquartile range 1.5-7.4 years; 54,204 person-years) were diagnosed with 1,104 primary cancers. The ASI of any cancer in NAFLD/NASH patients (1,460/100,000 person-years, 95%CI 1,368-1,557) was double the ASI in the Queensland population (incidence rate-ratios (IRR)), and examined the association between cirrhosis, T2D and cancer risk (Cox regression).

**Results:** 11,483 patients age ≥20 years with NAFLD/NASH followed for a median of 3.8 years (interquartile range 1.5-7.4 years; 54,204 person-years) were diagnosed with 1,104 primary cancers. The ASI of any cancer in NAFLD/NASH patients (1,460/100,000 person-years, 95%CI 1,368-1,557) was double the ASI in the Queensland population for men (IRR=1.94, 95%CI 1.75-2.16)* and women (IRR=1.99, 95%CI 1.78-2.22)*. The ASI of extrahepatic cancers was 1,326/100,000 person-years (95%CI 1.238-1,419), and was 1.5-fold higher (95%CI 1.13-2.00)* in patients with cirrhosis vs not, but did not vary by T2D status (IRR=1.08, 95%CI 0.84-1.38). In multivariable analysis, age, T2D and cirrhosis were associated with increased extrahepatic cancer risk (Table).

**Conclusions:** NAFLD is associated with a significantly increased risk of extrahepatic cancer. Demonstrating a higher risk in people with cirrhosis, T2D, men, and age ≥40 years provides an opportunity for targeted vigilance.

**Abstract Submission No. 100235**

-O-0367

**Exhaled nitric oxide for the non-invasive identification of patients with fibrotic MASH**
Huai Zhang1, 2, Ou-Yang Huang1, Li-Li Chen2, Ni Zhang2, Wen-Ying Chen2, Wen Zheng2, Xin-Lei Zhang2, Xiao-Zhi Jin2, Sui-Dan Chen2, Giovanni Targher3, Christopher D. Byrne4, Ming-Hua Zheng5

1Department of Biostatistics and Medical Record, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 2MAFLD Research Centre, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 3Department of Pathology, the First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 4Department of Medicine, University of Verona Verona Italy, 5IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella Verona Italy.

Abstract Submission No. 100277
O-0369

The Impact of Steatotic Liver Disease on Liver-Related Events in Patients Cured of Hepatitis C Virus

Wei-Fan Hsu1, 2, 3, Hseuh-Chou Lai1, 3, Hung-Wei Wang4, 5, Sheng-Hung Chen6, 7, Wen-Pang Su1, Hung-Yao Chen1, Guan-Tarn Huang1, Cheng-Yuan Peng1, 4

1China Medical University Hospital Taichung Taiwan, 2Graduate Institute of Biomedical Sciences, China Medical University Taichung Taiwan, 3School of Chinese Medicine, China Medical University Taichung Taiwan, 4School of Medicine, China Medical University Taichung Taiwan.

Abstract Submission No. 100259
O-0368

Antifibrotic effect of Polylene phosphatidylcholine in chinese MAFLD patients: a real-world study.

Vi Pan1, 2, Feng Xue1, 2, Shanshan Wang3, Shuangqing Gao3, Lai Wei8

1Beijing Tsinghua Changgung Hospital, Tsinghua University, China Beijing China, 2School of Clinical Medicine, Tsinghua University, China Beijing China, 3Beijing North Medical & Health Economic Research Center Beijing China

Background: Polylene phosphatidylcholine is considered one of the most promising therapeutic agents for the treatment of steatosis because of its antioxidant, anti-inflammatory, and anti-fibrotic actions by liver cell regeneration. We aimed to conduct an observational study based on retrospective real-world data to analyze the antifibrotic effect of Polylene phosphatidylcholine (Essentiale® Capsule, Ess) in MAFLD patients.

Methods: This is a multicenter, retrospective study. Patients with MAFLD (aged≥18) were identified from the tertiary public hospital electronic database between January 1st, 2020 and December 31st, 2022 following APASL 2020 guideline. Propensity score matching (PSM) was used to match Ess monotherapy group and control (non-hepato-protective-treated) group at a 1:1 ratio. The primary endpoint was the change of fibrosis-4 index (FIB-4) after 24 weeks treatment with Ess.

Results: The median age of enrolled 82,908 MAFLD patients from 11 hospitals was 53 (IQR, 43-63) years old and 64.3% were male. The median FIB-4 was 1.22 (IQR, 0.83-1.85). Among the FIB-4-based fibrosis risk stratification, 33.4% were at intermediate-risk (1.3-2.67), and 12.3% were at high-risk (>2.67). Of the 291 MAFLD patients treated with Ess only for 24 weeks, 42 patients have FIB-4 data. After PSM analysis matching for age, sex, T2DM, CVD, hypertension, and hyperlipidemia, the FIB-4 index adjusted for covariates was significantly reduced in the Ess-treated group than control group by using ANCOVA (-0.12±0.62 for Ess vs. 0.11±0.50 for control, P = 0.034).

Conclusions: Our study found that Ess treatment for 24 weeks can significantly reduce the FIB-4 index in MAFLD patients. Funding by Sanofi.
Abstract Submission No. 100429
O-0370

Association between Skeletal Muscle Strength and Chronic Kidney Disease in Patients with MAFLD

Xinlei Zhang1, Jing Zhao2,3, Pei-Wu Zhu4, Wen-Ying Chen1, Gang Li5, Wen-Yue Liu6, Wen Zheng1, Ni Zhang1, Li-Li Chen1, Giovanni Targher6, Christopher D. Byrne6, Dan-Qin Sun6, Ming-Hua Zheng6

1MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Nephrology, Jiaogang University Medical Center, Wuxi, China Wuxi China
3Affiliated Wuxi Clinical College of Nantong University, Wuxi, China Wuxi China
4Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China Wenzhou China
5Department of Infectious, Jining No.1 People's Hospital, Jining, China Jining China
6Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China Wenzhou China
7Department of Medicine, University of Verona, Verona, Italy Verona Italy
8IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Italy Negrar di Valpolicella Italy
9Southampton National Institute for Health and Care Research, Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital, Southampton, UK; Southampton UK
10Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China Wenzhou China

Background: A decline in skeletal muscle strength is closely associated with metabolic diseases, but whether skeletal muscle strength declines with chronic kidney disease (CKD) in people with metabolic dysfunction-associated fatty liver disease (MAFLD) is uncertain. This study investigated the association between skeletal muscle strength and metabolic dysfunction-associated fatty liver disease with chronic kidney disease (MLKD).

Method: We performed cross-sectional investigations within a hospital-based Chinese liver biopsy cohort (the PERSONS cohort; n=460) and a United States population-based cohort (NHANES 2011-2014 cohort; n=1,414), respectively. A handgrip dynamometer measured handgrip strength as a proxy for overall skeletal muscle strength. Subjects were stratified according to the absence [non-CKD (stage 0)] or presence of CKD (stages 1-5).

Results: In the PERSONS cohort, the CKD group had a significantly lower handgrip strength than the non-CKD group (27.02±9.27 vs. 33.59±11.90 kg, p<0.05). In a generalized additive logistic regression model, there was an inverse association between handgrip strength and the risk of abnormal albuminuria or CKD and higher handgrip strength was associated with lower odds of albuminuria or CKD (OR: 0.95, 95%CI: 0.92-0.99, p=0.018; OR: 0.95, 95%CI: 0.91-0.99, p=0.009) after adjustment for potential confounders. The highest handgrip strength tertile was associated with the lowest risk of abnormal albuminuria or CKD (compared with the lowest or the middle tertile). The results were validated using the NHANES 2011-2014 cohort. Combining handgrip strength, age, sex, BMI, hypertension and diabetes status to discriminate between MLKD and non-MLKD groups had an AUROC of 0.74 (95% CI: 0.67-0.81) in the PERSONS cohort and 0.72 (95% CI: 0.68-0.75) in the NHANES 2011-2014 cohort.

Conclusion: Lower handgrip/muscle strength is closely associated with a higher risk of abnormal albuminuria or CKD in people with MAFLD.
Salivary amylase: Is a glucose polymer cleavage enzyme produced mainly by pancreas, salivary glands and is expressed in many body organs as liver, brain, kidneys, intestine, lacrymal glands. Recent several researches proved positive correlations between low copy numbers of amylase and type 1. type 11 diabetes obesity, metabolic syndrome and NAFLD. Other studies show inverse correlation of amylase copy numbers with total visceral fat volume. Also positive correlation with HDL cholesterol, serum adiponectin. Subjects with high copy number of amylase have gut microbiota able of degradation of resistant starch so produce higher level of short chain fatty acids. Upon these back-ground of data we suggest that it may be effective in treating and/or prophylactic NAFLD in experimental animals.

Abstract Submission No. 100471
O-0373
Ectopic liver fat is associated with diabetes and adverse cardiac remodeling

Vivian Lee1, Yiying Han2, Desiree-Faye Toh1, Jennifer A Bryant2, Redha Boubertakh0, Thu-Thao Le1, 3, Calvin WL Chin8

1National Heart Centre Singapore Singapore Singapore, 2Department of Cardiology, National Heart Centre Singapore Singapore Singapore, 3Cardiovascular Academic Clinical Program (ACP), Duke-NUS Medical School Singapore Singapore

Background: We aim to characterize fat composition in the liver and abdominal depots by magnetic resonance imaging (MRI), in relation to diabetes and cardiac remodeling.

Methods: A cohort of 149 adults (57±13 years, 65% males, 38% type 2 diabetes) from the National Heart Centre Singapore Biobank underwent multiparametric MRI for quantification of liver proton-density-fat-fraction (PDFF) and abdominal subcutaneous and visceral adipose tissue (SAT, VAT), analyzed by trained operators blinded to clinical data (Perspectum, Oxford, UK). PDFF >5.6% was considered as abnormal liver fat accumulation. Adverse features of cardiac functions and remodeling were evaluated by cardiac MRI. Multivariate linear and logistic regressions were performed to assess independent associations of PDFF as a continuous and categorical variable, respectively, with other parameters. Analyses were adjusted for potential confounders including age, sex, systolic blood pressure, BMI, diabetes and hyperlipidemia.

Results: Increased PDFF was associated with VAT (β=0.49, P<0.001) but not with SAT. Diabetic individuals had significantly higher PDFF [9.6 (5.2-17.7) versus 5.5 (2.8-8.9)], P<0.001] and diabetes status was independently associated with elevated PDFF (β=0.24, P=0.007). Stratifying by PDFF 5.6% threshold, those with excessive liver fat were associated with diabetes (OR=3.82, 95% CI=1.54-9.46, P=0.004), reduced stroke volume (β=0.18, P=0.031) and increased global myocardial wall stress denoted by a lower remodeling index (β=0.19, P=0.012). Findings remained consistent with PDFF as a continuous variable, whereby increased PDFF was associated with reduced stroke volume (β=0.27, P=0.002) and worse remodeling index (β=0.15, P=0.049).

Conclusion: Ectopic liver fat accumulation was associated with visceral adiposity, diabetes and adverse cardiac remodeling.

Abstract Submission No. 100500
O-0374
A phase I DDI study to evaluate the effect of ASC42 on the pharmacokinetics of atorvastatin

Jinzi J. Wu1, Handan He1

1Gannex Pharma Co., Ltd Shanghai China

Background and Aims: Farnesoid X receptor (FXR) agonist, ASC42, is a potential drug candidate for nonalcoholic fatty liver disease (NAFLD) and primary biliary cholangitis (PBC). ASC42 is an inhibitor of organic anion transporter polypeptide 1B1 and 1B3 (OATP1 B1/OATP1B3). This study (NCT05464628) aimed to evaluate the effects of ASC42 on the pharmacokinetics (PK) of atorvastatin and its metabolite (2-hydroxy-atorvastatin), and safety of atorvastatin in the presence of ASC42 in healthy subjects.

Method: Twelve healthy subjects were dosed orally with a single dose of 20mg atorvastatin on Day 1 followed by a daily dose of 15mg ASC42 on Day 6 through Day 15. On Day 11, subjects received both 15mg ASC42 and 20mg atorvastatin. Samples for PK were collected on Days 1 and 11.

Results: Atorvastatin Cmax was 15% lower, while AUCinf, AUC0-24, and AUClast were similar when atorvastatin was co-administered with ASC42. There was little/no change of 2-hydroxy-atorvastatin PK parameters when atorvastatin was co-administered with ASC42. As for ASC42, following multiple dose administration of ASC42 in combination with a single dose of atorvastatin, the inter-subject variability for Cmax, and AUCs were moderate, ranging from 38% to 47%. Six adverse events (AEs) were reported in 5 subjects (41.7%), and all were mild (grade 1) in severity and only 1 AE (8.3%) was considered probably related to study drug.

Conclusion: ASC42 has no effect on the overall exposure of atorvastatin or its metabolite, 2-hydroxy-atorvastatin, and co-administration of atorvastatin 20mg and ASC42 15mg was safe and well tolerated in healthy subjects.

Abstract Submission No. 100547
O-0375
Non-Alcoholic Fatty Liver Disease (NAFLD) burden among Filipino People Living with HIV (PLHIV)

GILLIE ANNE D. DOMINGO1, VERONICA S. BUGNA1, NATASHA A. MAPA1, MA. TARCELA S. GLER1, MADALINEE ETERNITY D. LABIO2

1Makati Medical Center Makati City Philippines

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is a significant concern for people living with HIV (PLHIV) due to its impact on non-HIV-related mortality.

Methods: A total of 35 Filipino male patients with HIV were screened which included 27 patients divided into two groups: 15 with NAFLD and 12 without, resulting in a 55% NAFLD prevalence.

Results: The average age of patients was 38 years, with an HIV duration of 7 years and a mean CD4 count of approximately 600 cells/mm3. Antiretroviral regimens included Lamivudine + Tenofovir with Dolutegravir (44%), Efavirenz (52%), and one patient on Lamivudine + Zidovudine + Efavirenz (4%). Both groups experienced dyslipidemia, with 73% of NAFLD patients and 67% of those without NAFLD affected. Among NAFLD patients, 53% were overweight, often associated with Type 2 Diabetes and Hypertension (26%). In contrast, 83% of those without NAFLD had a normal BMI and a higher rate of opportunistic co-infections (50%). Liver-related measurements, including mean transaminase levels (AST: 77, ALT: 144), liver stiffness (8.3 kPa), and CAP scores (330 dB/m), were higher in the NAFLD group compared to those without NAFLD. Although mean FIB4 scores indicated mild fibrosis in all patients, mean APRI scores revealed evidence of fibrosis (0.76) in the
NAFLD group, while those without NAFLD showed an absence of fibrosis (0.46).

**Conclusion:** Risk factors of metabolic syndrome (overweight, hypertension, diabetes) are strongly linked to NAFLD in PLHIV. There is no significant relationship between ARV regimen, CD4 count, HIV duration and presence of opportunistic co-infections in development of NAFLD.

---

**Abstract Submission No. 100645 O-0376**

**Long-term impact of metabolic dysfunction-associated fatty liver disease on cardiovascular diseases**

**Szu-Ching Yin, Tzu-I Chen, Yi-Ting Chen, Xia-Rong Liu, Yun-Zheng Gao, Mei-Hsuan Lee**

1Institute of Clinical Medicine, National Yang Ming Chiao Tung University Taipei Taiwan

**Background & Aims:** The prospective study aimed to investigate the potential influence of metabolic dysfunction-associated steatotic liver disease (MASLD) on the associated risk of cardiovascular disease (CVD).

**Methods:** We enrolled 329,528 adults aged ≥30 years who participated in a health screening program from 1997 through 2013. MASLD was defined by abdominal ultrasound-observed hepatic steatosis, limited alcohol consumption (<20 g/d for men and <10 g/d for women), and cardiometabolic risk factors. Participants were categorized into non-steatotic liver disease and the MASLD groups. We linked data to the Taiwan National Health Insurance Database (1997-2020) to identify CVD incidence and subtypes using ICD codes. Cox’s proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for MASLD’s impact on each CVD subtype.

**Results:** Among all participants, 106,926 were classified as having MASLD, while 222,602 were classified as having non-steatotic liver disease, resulting in a MASLD prevalence of 32.4%. Individuals with MASLD were more likely to be older, male, having a higher body mass index, diabetes, and more cardiometabolic risk factors (p<0.05). There were a total of 125,053 CVD cases, including 6,033 myocardial infarction, 10,955 atrial fibrillation, and 21,585 heart failure cases. Using the non-SLD as a reference, the multivariate-adjusted HRs (95% CIs) for MASLD were: 1.21 (1.19-1.23) for all CVD, 1.80 (1.71-1.90) for myocardial infarction, 1.21 (1.08-1.17) for atrial fibrillation, and 1.23 (1.24-1.31) for heart failure.

**Conclusion:** MASLD was linked to an increased risk of CVD and its subtypes, highlighting the need for behavior modifications and risk consultations.

---

**Abstract Submission No. 100704 O-0378**

**Patients with Diabetes Mellitus and Liver Diseases in Azerbaijan: Epidemiological Studies**

**Gulnara Aghayeva, Saltanat Maharramzade**

1Baku Branch of Sechenov Medical University Baku Azerbaijan,
2Baku Health Center Baku Azerbaijan

**Introduction:** Diabetes mellitus - a metabolic disorder, which is expected to affect 300-400 million worldwide by 2030. Multiple studies with subsequent meta-analyses from Europe, Asia, and North America support the idea that DM and insulin resistance are independent risk factors for liver diseases and HCC. According to official data, there are about 300,000 patients with type 2 diabetes mellitus in Azerbaijan. There are not any epidemiological studies about Diabetes Mellitus and its relationship with liver diseases.

**Methods:** We have collected data for 3110 patients with Diabetes Mellitus admitted between January 2008 and June 2023 to Baku Health Center.

**Results:** There were 2425 patients with MAFLD/NAFLD (78%), 544 patients (17.5%) with liver cirrhosis and 139 patients (4.5%) with HCC. Among patients with MAFLD/NAFLD males accounted for 43.5%- (mean age- 52 y), and 56.5%-females (mean age- 57 y). Among patients with liver cirrhosis 50% were males (mean age - 60 y), females -50% (mean age-69 y). Among patients with HCC -62% were males (mean age-64 y), and 38%-females (mean age-67y).

**Conclusion:** Liver involvement in type 2 diabetes has been found in a large number of cases in the form of non-alcoholic fatty liver disease associated fatty liver disease (NAFLD/MAFLD), which can range from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis and HCC. The mean age of patients increases in correlation with the severity of liver pathology, which confirms the importance of the duration of diabetes mellitus as a pathogenic factor. Follow-up examination of the liver are recommended in patients with diabetes mellitus.
The Impact of Fatty Liver Index on HCC among non-viral hepatitis subjects in an HBV endemic region

Iqbal Taufiqurrahman1,2, Irsan Hasan2
1Pondok Indah Hospital, Jakarta, Indonesia Jakarta, Indonesia, 2Hepatobiliary Division, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta Indonesia

The prevalence of metabolic-associated fatty liver disease (MAFLD), which was previously known as non-alcoholic fatty liver disease (NAFLD) in Asia was increased to 29.62%. The considered causes are the socio-economic changes and the overnutrition condition in Asia. Serum vitamin D level is considered to increase the risk of fatty liver. However, the study that reports the efficacy of vitamin D supplementation for patients with MAFLD or NAFLD is limited. This systematic review reports the selected articles from five sources with the searching keywords: “(Metabolic associated fatty liver disease OR MAFLD) OR (Non-Alcoholic Fatty Liver Disease OR NAFLD) AND (Vitamin D OR Vitamin D Supplementation) AND (Controlled Attenuation Parameter OR CAP) AND (liver stiffness measurement OR LSM)”. Two trials (the first study used oral vitamin D supplementation [1000 IU] every day for 360 days compared with placebo, and the second study used intramuscular vitamin D supplementation [200,000 IU] every month for 180 days compared with placebo) report that vitamin D supplementation can significantly decrease (p < 0.05) the controlled attenuation parameter or CAP (22.8-39.1 dB/m) and liver stiffness measurement or LSM (0.07-0.52 kPa) compared to control group. The mechanism of its efficacy is achieved by inhibiting the progression of liver fibrosis induced by stellate cells after its binding to the hepatocyte. In conclusion, the efficacy of vitamin D in decreasing liver steatosis and fibrosis in MAFLD has been proven. However, the limitations of these studies should be followed by further research to state the recommendation of vitamin D supplementation in MAFLD.

Lifestyle modification programme for HIV-infected patients with NAFLD: A randomized controlled trial

Guanlin LI1,2,3, Vincent Wai Sun WONG1,2,3, Daisy Man Ching SIN2, Grace Lai-Hung Wong WONG1,2,3, Terry Cheuk-Fung YIP2, Vivian WONG1,4, Catherine CHEUNG0, Grace Chung Yan LUI1,2,4
1Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong China, 2Department of Medicine and Therapeutics, Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong Hong Kong China, 3Faculty of Medicine, Institute of Digestive Disease, The Chinese University of Hong Kong Hong Kong China, 4Faculty of Medicine, Stanley Ho Centre for Emerging Infectious Diseases, Jockey Club School of Public Health & Primary Care, The Chinese University of Hong Kong Hong Kong China, 5School of Life Sciences, The Chinese University of Hong Kong Hong Kong China

Background: Lifestyle modification directing at weight loss is currently the cornerstone of treatment for fatty liver disease in the general population. No studies have been performed to specifically evaluate the efficacy of lifestyle modification programmes targeting non-alcoholic fatty liver disease (NAFLD) in people living with human immunodeficiency virus (HIV) (PLWH).

Objectives: To assess lifestyle modification programme in inducing resolution of NAFLD in PLWH.

Methods: This is a single-blinded randomized controlled trial. 84 PLWH with NAFLD in Hong Kong were randomly assigned to either receive a lifestyle modification programme or standard care for 12 months. The primary outcome is the resolution of NAFLD as determined by proton magnetic resonance spectroscopy (1H-MRS) at month 12. Resolution of NAFLD is defined as intrahepatic triglyceride (IHTG) content less than 5%.

Results: 43 patients were randomized to the intervention group and 41 patients to the control group. 77 patients completed all assessments during 12-month intervention. In the intention-to-treat analysis, 12 (27.9%) patients in the intervention group and 4 (9.8%) in the control group achieved the resolution of NAFLD (p = 0.034). The mean reduction of IHTG was significantly higher in the intervention group (5.1±7.1%) compared to the control group (0.2±6.9%) (P = 0.004). The mean change of total body fat was significantly higher in the intervention group (-1.81±2.97 Kg) compared to the control group (+0.10±1.78 Kg) (P = 0.001).

Conclusion: Lifestyle modification programme has efficacy in inducing resolution of NAFLD in PLWH.
The effects of lifestyle modification interventions on self-efficacy among NAFLD patients: SR

Angel Cho Kan Ma1,2, Wai Lin William Tse1,3, Ka Ming Chow1

1The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China Hong Kong Hong Kong, 2Department of Medicine and Therapeutics, Prince of Wales Hospital, Hospital Authority, Hong Kong SAR, China Hong Kong Hong Kong, 3Department of Surgery, North District Hospital, Hospital Authority, Hong Kong SAR, China Hong Kong Hong Kong

Background: Patients with NAFLD reported low self-efficacy, poor illness perception and self-management behaviours which would affect the disease progression. Lifestyle modification has been regarded as the first-line therapies to NAFLD. However, no studies have been conducted to investigate the effects of lifestyle modification interventions on these outcomes, and there is no consistent design of such intervention for the patients.

Methods: A systematic literature search was conducted in nine electronic databases. Meta-analyses was conducted to pool the quantitative results from comparable studies.

Results: The review included 16 randomised controlled trials. The meta-analysis results indicated that the lifestyle modification interventions significantly improve general self-efficacy (standardised mean difference [SMD] = 0.82, 95% confidence interval [CI] [0.27, 1.38], p = .0004, I2 = 71%), self-management behaviours (SMD = 7.91, 95% CI [5.74, 10.07], p < .00001, I2 = 96%), dietary behaviours (SMD = 2.33, 95% CI [1.15, 3.51], p = .0001, I2 = 97%), total physical activity (SMD = 1.36, 95% CI [0.57, 2.14], p = .0007, I2 = 96%), and steatosis grade (SMD = 0.56, 95% CI [-0.80, -0.31], p < .00001, I2 = 0%). Individual studies suggested significant improvement in illness perception (p < .001). The overall methodological quality of the included studies was average.

Conclusion: Lifestyle modification interventions were found to be effective in improving self-efficacy, illness perception, self-management behaviours and steatosis grade among patients with NAFLD. Suggested design of the intervention has also been identified but more rigorous trials should be conducted to evaluate the effects of the interventions.

Fibrosis-Associated Genetic Variants in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Yun Zheng Gao1, Xia-Rong Liu1, Yi-Ting Chen1, Szu-Ching Yin1, Tsu-I Chen1, Mei-Hsuan Lee1

1Institute of Clinical Medicine, National Yang Ming Chiao Tung University Taipei Taiwan

Abstract

Background and aim: The study aimed to investigate genetic variants associated with liver fibrosis among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Method: The study included 31,389 individuals with MASLD from Taiwan Biobank, defined by a fatty liver index ≥30 and the presence of any cardiometabolic risk factor. Fibrosis was assessed using the fibrosis index-4 (FIB-4), categorizing participants with FIB-4 ≥1.45 as having mild fibrosis and FIB-4 <1.45 as non-fibrosis. Logistic regressions were used to estimate the odds ratios (ORs) with 95% confidence intervals (CIs) on potential risk factors and fibrosis-associated genetic variants among the individuals with MASLD.

Results: Among individuals with MASLD, 6711 (21.4%) had FIB-4 ≥1.45. Advanced age, male, and comorbidities were positively associated with mild fibrosis (p<0.05). Variants in PNPLA3 and GCKR genes showed significant associations with fibrosis in MASLD individuals (p<0.001). Variants on PNPLA3, GCKR and TM6SF2 genes were examined, and the numbers of risk alleles were calculated. Individuals with more risk alleles were more likely to have fibrosis. Categorizing the number of alleles as 0-1, 2, and ≥3, the adjusted OR (95% CI) was 1.23 (1.15, 1.31) for risk allele(s) ≤3 and 1.14 (1.07-1.22) for 2 risk alleles. The trend remained significant in individuals with MASLD and obese (BMI≥24 kg/m2), the findings were consistent, with an adjusted OR of 1.14 (1.06-1.22) for 2 risk alleles, and 1.22 (1.13-1.31) for risk allele(s) ≥3.

Conclusion: Individuals with MASLD, carried a higher number of risk alleles at increased risk of mild fibrosis, highlighting the importance of intensive care and monitoring.

Change in Fibrosis-4 Index (FIB-4) over time is associated with subsequent risk of liver events

Kamal Kant Mangla1, Quentin M. Anstee2,3, Tina L. Berentzen1, Louise M. Nitze1, Maximilian Jara1, Anders Jensen1, Mette S. Kjær1, Jens M. Tarp1, Kamlesh Khunti4

1Novo Nordisk A/S Søborg Denmark, 2Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University Newcastle upon Tyne United Kingdom, 3Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust Newcastle upon Tyne United Kingdom, 4Diabetes Research Centre, University of Leicester, Leicester General Hospital Leicester United Kingdom

Background: Tools assessing morbidity/mortality risk of non-alcoholic steatohepatitis (NASH) are lacking. We evaluated associations between changes in fibrosis-4 index (AFIB4) and subsequent liver events.

Methods: This longitudinal study included adults with obesity and/or type 2 diabetes (T2D); ≥2 FIB4 measurements; no alcohol-related and/or chronic liver diseases (except non-alcoholic fatty liver disease/NASH). ΔFIB4 was calculated using baseline and 12-month scores. Follow-up included time from second measurement until first liver event, first cardiovascular event, all-cause mortality, 10 years' follow-up; or 1/1/2020.

Results: Among 20,443 patients, there were 466 liver events. After 10 years, patients with high baseline FIB4 (≥2.67) had a 12.8% risk of a liver event; the risk was 18.5% or 10.1% when FIB4 increased or decreased after 12 months, respectively. In patients with indeterminate (1.30-2.67) or low (<1.30) FIB4, increasing FIB4 was associated with increased risk. AFIB4 was directly associated with risk of liver event, dependent on baseline FIB4 (Cox models). Compared with low baseline FIB4 and no change in FIB4 (reference), the hazard ratio (95% confidence interval) in patients with high baseline FIB4 was 24.27 (16.98; 34.68) with 1-unit FIB4 increase; and 10.90 (7.90; 15.05) with 1-unit decrease. Patients with indeterminate/low FIB4 and 1-unit increase/decrease had significantly higher/lower risk compared with the reference group. Similar results were seen for cardiovascular events/mortality.

Conclusion: In patients with obesity and/or T2D, a 12-month increase/decrease in FIB4 was associated with higher/lower risk of
NASH-related liver events across FIB4 groups, highlighting FIB4’s potential to identify patients at risk of severe events.

Abstract Submission No. 100865
O-0385

Effect of metabolic dysfunction-associated steatotic liver disease on BNT162b2 immunogenicity

Lok Ka Lam1,2, Jing Tong Tan1, Wai Kay Seto1,2,3, Man Fung Yuen1,2, Ka Shing Cheung4

1Queen Mary Hospital Hong Kong Hong Kong, 2School of Clinical Medicine, The University of Hong Kong Hong Kong, 3The University of Hong Kong-Shenzhen Hospital Shenzhen China

Background: We aimed to investigate effect of metabolic dysfunction-associated steatotic liver disease (MASLD) on COVID-19 vaccine immunogenicity to omicron variant.

Methods: Adult recipients of three doses of BNT162b2 were prospectively recruited from vaccination centers between May and December 2021. Serology of neutralising antibody by live virus microneutralization (vMN) to omicron variant was measured at baseline, day 180 and day 360 after first dose (Figure 1). Study outcome was seroconversion (vMN titer ≥10) at day 360 after first dose. Exposure of interest was MASLD. Hepatic steatosis was defined by controlled attenuation parameter (CAP) ≥248 dB/M on transient elastography. Subjects with infection prior to one-year follow-up were excluded. Multivariable logistic regression model was used to derive adjusted odds ratio (aOR) of seroconversion with MASLD by adjusting for age, sex, antibiotic and proton pump inhibitor use.

Results: 148 BNT162b2 recipients (male:48 [32.4%]; median age:51.0 years [IQR:44.5-57.3]) were recruited. The median time from first dose to third dose was 8.5 months (IQR:7.9-8.9). Only 4 [2.7%] subjects were seropositive at day 180. MASLD subjects had lower seroconversion rate than non-MASLD ones (89.6% vs 99.0%;p=0.007) (Table 1; Figure 2a). MASLD was the only independent risk factor associated with lower odds of seroconversion (aOR:0.95; CI:0.002-0.44). Subgroup analysis shows MASLD subjects had lower vMN titer [13.06 [IQR:7.69-22.20] vs 33.49 [IQR:24.05-46.53];p=0.004] and seroconversion rate (76.9% vs 97.4%;p=0.016) than non-MASLD subjects after 4 months from third dose but not within 4 months (Table 1; Figure 2b).

Conclusions: MASLD was associated with lower vaccine immunogenicity to omicron variant after three doses of BNT162b2.

Abstract Submission No. 100874
O-0386

Insulin resistance in MASLD and liver-related outcomes: a nationwide, population-based study

Yang Hyun Bae1, Yewool Kang1, Sang Yi Moon1, Min Kook Son1

1Dong-A university hospital Busan South Korea

Aims: Insulin resistance is a well-known factor in patients with metabolic syndrome or steatotic liver disease. Surrogate markers such as the triglyceride-glucose (TyG) index and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio assess insulin resistance (IR). In this study, our aim was to investigate the relationship between insulin resistance and factors in patients with metabolic associated steatotic liver disease (MASLD).

Methods: Using data from participants who underwent health screening in 2009 and 2010, we divided them into quartiles (Q1, Q2, Q3, Q4) for each marker and compared the incidence rates of liver-related diseases during the observation period.

Results: Among a total of 362,285 patients, 67,908 patients deemed suitable for this study were enrolled and followed-up for an average of 9.4 years. During this period, liver-related diseases occurred in 2,621 cases of decompensated cirrhosis and 2,056 cases of liver cancer. Participants were divided into 4 quartiles according to TyG and TG/HDL-C ratio, and the incidence rate of liver-related diseases was analyzed. As a result of the analysis, it was confirmed that TyG and TG/HDL-ratio all had an inverse proportional relationship in which the incidence of liver-related diseases decreased as IR increased.

Conclusion: Our study showed that TyG and TG/HDL ratio are inversely related to liver-related diseases in MASLD patients, which indirectly suggests nutritional imbalance and decreased function of liver mediators during liver fibrosis progression. Improvement in metabolic parameters in MASLD patients suggests that liver-related diseases should be reassessed.

Abstract Submission No. 100897
O-0387

NFTE- A Prediction rule for fibrosis in Metabolic-dysfunction associated steatotic liver disease

Gayathri Shivakumar1, Jithin John2, Ann Mary George3, Sreekumar S2, Yamuna R Pillai2, Srijaya S2, Krishnadas Devadas2, Adithya Verma2, Jacob Raja2

1Government medical college, Thiruvananthapuram Thiruvananthapuram India, 2Goverment Medical college, Thiruvananthapuram Thiruvananthapuram India

Background: Accurate evaluation of liver fibrosis in Metabolic-dysfunction Associated Steatotic-Liver-Disease(MASLD) serves as a surrogate to predict liver-related outcomes. We evaluated the diagnostic performance of non-invasive tests(NITs) in detecting advanced fibrosis(AF) and tried to optimize diagnostic strategies for improved outcomes and reduce the need for liver biopsies.

Materials and Methods: Consecutive patients with biopsy-proven MASLD from September 2021 to March 2023 were enrolled. NITs were compared with histological grade of fibrosis(NASH-CN) for diagnostic accuracy. Biomarkers were assessed individually and in paired combinations. Liver stiffness(LSM) was measured using 2D-Shear-Wave-Elastography(SWE) and Vibration-Controlled-Transient-Elastography (VCTE). Results: 92 patients (53 male[57%], median age 41 years were included. 64(69%) had biopsy-proven AF. T2DM present in 55(59%).Advanced age, male sex, lower platelet counts, and high triglyceride were significantly associated with advanced fibrosis(p<0.001). NITs were moderately accurate in predicting advanced fibrosis while using previously published cut-offs. Newly derived cut-offs demonstrated a high positive predictive value(93%) to ruling in advanced fibrosis. The AUROCs of NAFLD Fibrosis Score(NFS), SWE, Aspartate-Aminotransferase-Platelet-Ratio-Index(APRI), VCTE, Fibrosis-index-4-Factors(FIB-4) and BARD were 0.94, 0.93, 0.93, 0.91, 0.90 and 0.88 respectively at newer cut-off. A New score derived by combining NITs- NFS and VCTE, namely the NF-TE demonstrated significant diagnostic accuracy(AUROCC0.98) and discriminative power (p<0.05) when compared with individual NITs.

Conclusion: NITs are point-of-care strategies to assess hepatic fibrosis in MASLD. FIB-4 and NFS may require age-dependent novel cut-off points for adequate estimation of fibrosis. Combination NIT serves as an important adjunct to rule in advanced fibrosis, thereby alleviating the need for liver biopsy.
Development of a novel supervised machine learning algorithm predicting MASLD in research volunteers

Jorg Taubel¹, 2, 3, 4, James Rickard¹, 3, Thomas York¹, 4, 5, Bronagh McCann¹

¹Richmond Research Institute London United Kingdom, ²St George’s, University of London London United Kingdom, ³King’s College London London United Kingdom, ⁴Richmond Pharmacology Ltd London United Kingdom, ⁵Imperial College London London United Kingdom

Background and Aims: Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) affects approximately one in four of the global adult population. MASLD has important implications for clinical trial volunteers as an occult co-morbid condition - there is evidence that MASLD modulates drug metabolism, with studies suggesting that Grade 3-4 liver reactions are four times more common in healthy volunteers with probable MASLD. This research aims to develop a non-invasive, low-cost tool, utilising supervised machine learning techniques, to predict MASLD in a healthy volunteer population, enabling the stratification of this sub-population in early phase trials.

Method: This is an observational cross-sectional study, with a total of 1500 subjects. Assessments include bioimpedance vector analysis, BMI, waist circumference, and laboratory bloods (including HbA1c, liver enzymes and White cell count). FibroScan is performed as a pragmatic 'outcome' for MASLD.

In this interim analysis of 1243 volunteers, a logistic regression model was trained using 70% of data for the ability to predict the outcome of the FibroScan from a data subset containing: Age, Sex, Ethnicity/Race, Height, Weight, BMI, Waist Circumference, and Body Fat Percentage. The programming language R was used to build the model.

Results: The 663 steatotic patients were categorized into: 6(0.9%) NAFLD, 326(49.2%) MASLD, 325(49%) NAFLD-MASLD, and 6(0.9%) not NAFLD-MASLD. Among patients meeting MASLD criteria, majority (80%) met ≥2 cardiometabolic criteria while only a minority (8.3%) satisfied only 1 criterion, of which overweight/obesity (79.6%) was most common. NAFLD-MASLD and MASLD patients had higher ALT, AST and platelet levels as compared to NAFLD and not NAFLD-MASLD patients (p<0.05). A higher probability of advanced fibrosis was seen in MASLD only compared to the other groups using APRI. There was a trend for more no/minimal fibrosis patients in the NAFLD and not NAFLD-MASLD groups compared to the MASLD and NAFLD-MASLD groups using non-invasive liver fibrosis tests.

Conclusions: Majority (98.2%) of patients with steatosis on ultrasound meet MASLD criteria. Serial follow-up is needed to determine if patients who do not meet MASLD criteria now will meet it in the future.

Abstract Submission No. 101011

O-0390

Effect of Lifestyle Measures in Normal Body Mass Index NonAlcoholic Fatty Liver Disease Patients

Sudhir Maharsi¹, Saksham Sethi¹, Shyam Sunder Sharma¹

¹Department of Gastroenterology, SMS Medical College, Jaipur, India Jaipur India

Background and Aims: Lean nonalcoholic fatty liver disease (NAFLD) is a distinct entity shaped by the dynamic interaction of genetic predisposition, metabolic dysregulation, gut microbiota and enterohepatic circulation. There is paucity of data on effects of lifestyle measures in lean NAFLD patients. Our aim was to study the effects of lifestyle measures in normal body mass index (BMI) patients with NAFLD.

Methods: This prospective interventional study was conducted on patients of NAFLD patients with normal BMI, who were divided in to cases who received healthy lifestyle measures in the form of diet [low fat, low carbohydrates, high fiber and high protein (1-1.5g/kg body weight) with total 15-20kcal/kg/day] and exercise (150-200 minutes/week moderate intensity over 3-5 sessions) along with standard medical therapy and controls who received standard medical therapy only, for 6 months.

Results: A total of 120 patients, 60 cases (31 males, age 37.41± 17.4 years) and 60 controls (27 males, age 41.81 ± 16.8 years) were enrolled. Baseline parameters, co-morbid conditions and grade of fatty liver were similar in both the groups. Improvement in SGOT (ΔSGOT - 16.6±6.8 vs -1.2±1.1, p=0.001), SGPT (ΔSGPT-23.24±8.8 vs -4.3±2.8, P= 0.001), controlled attenuation parameter (CAP) score (ΔCAP - 36.6±13.8 vs -6.9±5.2, p=0.001), was observed in cases compared to controls at the end of study. However, the improvement in liver stiffness measurement (LSM) (ΔLSM -0.8±0.6 vs -4.6±0.4, p= 0.45) was comparable in both cases and controls.

Conclusion: Lifestyle modifications and dietary intervention is effective for lean NAFLD patients.
Low Accuracy of Noninvasive Tests for Screening for advanced Fibrosis Among Chinese Adults With MAFLD
He Yi1, 2, Ling Li1, 2
1Southeast University School of Medicine NanJing China, 2Zhongda Hospital Southeast University NanJing China

Background: Fibrosis-4 (FIB-4), the nonalcoholic fatty liver disease fibrosis score (NFS) and aspartate aminotransferase to platelet index (APRI) are popular non-invasive tests (NITs) for fibrosis screening. In this study, we aimed to evaluate the accuracy of these simple NITs for advanced fibrosis in MAFLD.

Method: We conducted a multicentered, cross-sectional study comprising 980 adult inpatients with MAFLD. Hepatic steatosis and fibrosis were assessed by transient elastography to measure CAP and LSM, respectively. We evaluated the correlation between NITs and LSM. The diagnostic performance of NITs was assessed.

Result: The mean [SD] age was 57.5 [13.9] years and 58.7% were male. There was a significant but weak correlation between LSM values and APRI (Spearman’s rho = 0.261, p<0.001) and FIB-4 (Spearman’s rho = 0.174, p<0.001), rather than NFS (Spearman’s rho = 0.044, p=0.207). APRI had a significantly higher AUROC compared with FIB-4 and NFS for advanced fibrosis (AUROC: APRI 0.68, FIB-4 0.64, NFS 0.55, p<0.05) in MAFLD. However, APRI had the lowest sensitivity based on its cutoff values (APRI>0.5 Se 0.25; APRI>2.0 Se 0.02; p<0.05) for advanced fibrosis. We also found low cutoff values of NITs outperformed high cutoff values: FIB-4>1.3 Se 0.56, FIB-4>2.67 Se 0.17; NFS>1.45 Se 0.78, NFS>0.675 Se 0.22; all p<0.01. In addition, 16.2%, 9.5% and 4.4% false-negatives were observed in APRI, FIB-4 and NFS based on their low cutoff values for advanced fibrosis, respectively. And false-negatives accounted for higher proportion when using high cutoff values (APRI: 21.2%, FIB-4: 17.7%, NFS: 15.7%).

Conclusion: In our research, NITs had poor correlation with liver stiffness and unsatisfactory performance in AUROC (all<0.7) for advanced fibrosis. Therefore, these NITs seems inadequate to be screening tools for advanced fibrosis in patients with MAFLD from China and more appropriate cutoff points should be set.

Prevalence and risk factors of MASLD and liver fibrosis in an urban Chinese population
Mengmeng Hou1, Qi Gu2, Jie Li2, Yuemin Nan1
1Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital Shijiazhuang China, 2Department of infectious diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

Backgrounds: With societal development and lifestyle changes, metabolic associated fatty liver disease (MAFLD) becomes the most common chronic liver disease worldwide, affecting almost a quarter of the global population. This study aimed to investigate the prevalence and characteristics of MAFLD and liver fibrosis in China, and identify the risk factors for liver fibrosis in MAFLD patients.

Methods: Participants were enrolled from a physical examination center of The Third Hospital of Hebei Medical University from May 2019 to March 2023. General data, laboratory biochemical parameters and abdominal ultrasonography were explored. MAFLD diagnosis followed clinical practice guidelines. Hepatic fibrosis was assessed by the fibrosis-4 index score (FIB-4, significant fibrosis was defined as FIB-4≥1.3). Binary logistic regression was used to determine the risk factors for significant fibrosis of MAFLD.

Results: A total of 22970 participants were included in the final analysis. The overall prevalence of MAFLD was 28.77%, of which 16.87% of MAFLD patients had significant fibrosis. Moreover, lean MAFLD patients had higher proportion of significant fibrosis than overweight participants. Multivariate logistic regression revealed male, overweight, hypertension, elevated liver enzymes, lipid and glucose indexes, and hypoalbuminemia were significantly associated with MAFLD, and the independent risk factors for significant fibrosis in MAFLD patients were male (OR=0.676, 95%CI 0.588-0.821; P <0.001), HBsAg positivity (OR=2.611, 95%CI 1.557-4.379; P<0.001), BMI ≥ 23kg/m2 (OR=0.632, 95%CI 0.470-0.851; P=0.002), BP ≥ 130/85 mmHg (OR=1.885, 95%CI 1.564-2.272; P<0.001).

Conclusions: Approximately 16% of MAFLD patients has significant liver fibrosis, and varies among BMI, ages, genders, and metabolic status.
Validation of AGILE scores in Indian patients with NAFLD: interim analysis of the ICON-D study

Arka De1, Ajay Duseja1, Manu Mehta1, SP Singh2, Shrikiant Mukewar3, Saurabh Mukewar3, Dr Shalimar4, Omesh Goyal5, Jayanthi Venkataraman6, VK Dixit7, Krishandas Devadas8, Varun Mehta9, Piyush Ranjan9, Anil Arora10, Aabha Nagral10

1 MD, DM Chandigarh India, 2 SCB medical College Cuttack India, 3 MDAS Hospital Nagpur India, 4 All India Institute of Medical Education and Research New Delhi India, 5 Dayanand Medical College Ludhiana India, 6 Sri Ram Chandar Medical College Chennai India, 7 IMS, Banaras Hindu University Banaras India, 8 Government Medical College Trivandrum India, 9 Sir Gangaram hospital New Delhi India, 10 Jashlok Hospital Mumbai India

Background: AGILE-3+ and AGILE-4 are novel non-invasive tests for ruling-in advanced fibrosis and cirrhosis, respectively, with reduced grey-zone. They incorporate age, gender, AST, ALT, platelet count, diabetic status and liver stiffness measurement (LSM) on transient elastography.

Methods: In an on-going real-life study of ICON-D, interim data across 42 centres over 4 years (n=8043), data of all patients with liver-biopsy (n=381, 63.2% males, age:42(33-50) were analysed to explore the diagnostic performance of AGILE-3+ and AGILE-4.

Results: Advanced fibrosis (F≥3) and cirrhosis (F4) were present in 70 (18.3%) and 39 (9.97%) patients, respectively. AGILE-3+ showed good calibration (p=0.474 on Hosmer-Lemeshow test, 95% CI of slope: 0.82-1.218, 95% CI of x-intercept: -0.05 to 0.04) with an AUROC of [0.78(95% CI:0.74-0.82)] for F≥3 which was significantly better than APRI, NFS and FIB-4 but not LSM. The proportion of patients falling in the grey zone with AGILE3+ (12.07%) was significantly less than with APRI, FIB-4, NFS and LSM.

AGILE-4 showed good calibration (p=0.147 on Hosmer-Lemeshow test, 95% CI of slope: 0.79 to 1.166, 95% CI of x-intercept: -0.041 to 0.028) with an AUROC of [0.81(95% CI:0.77 to 0.85)] for cirrhosis which was significantly better than APRI and NFS but not from FIB-4 or LSM. The proportion of patients falling in the grey zone with AGILE 4 (13.9%) was significantly less than with APRI, FIB-4, NFS and LSM.

Conclusion: The AGILE-3+ and AGILE 4 score showed AUROC for detecting advanced fibrosis and cirrhosis, and may help to decrease the grey zone.

Abstract Submission No. 101140
O-0395

Gut microflora composition in patients with non-alcoholic fatty liver disease

Tatia Khachidze1,2,3, Gocha Barbakadze2,3, Gela Sulaberidze2,3

1 Grigol Robakidze University Tbilisi Georgia, 2 GRUNI-School of Medicine Tbilisi Georgia, 3 Tbilisi State Medical University Tbilisi Georgia

Background and Aims: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver and affects 25-30% of the population. Number of studies have indicated relationship between dysbiosis and NAFLD. Hence, the aim of this study was to analyze gut microbiota composition in NAFLD patients with possible examination of aggressive and protective factors, including small intestinal bacterial overgrowth existence and biochemical markers

Method: Study included 93 subjects diagnosed with NASH/NAFLD based on a fibro scan of the liver, ultrasound and biochemical tests. Stool sample examination was performed using Real time-PCR. Hydrogen breath test was performed to all patients

Results: The study’s findings were as follows: A 55.1% correlation was found between NAFLD and SIBO in the gut microbiome. The following bacteria were present: Firmicutes (46.3±1.99), Actinobacteria (26.1±18). Bacteroidetes and Firmicutes had a markedly negative connection (r = -0.89), as did the Bacteroidetes and Firmicutes/Bacteroidetes index (r = -0.74) and Bacteroidetes and Actinobacteria (r = -0.90). There was a significant association between the F/B index and ALT (r = 0.5) and triglycerides (r = 0.52). Also, middle-strong connection (r = 0.43) between the presence of SIBO and the growth of Firmicutes in NAFLD patients.

Conclusion: Increased Firmicutes and Actinobacteria are caused by decreased levels of Bacteroidetes, which raises triglycerides and ALTs in patients with NAFLD and is associated with SIBO. The F/B index may be a marker for the presence of NAFLD, while Bacteroidetes may act as potential inhibitors of NAFLD progression. Patients with NAFLD should be tested for SIBO.

Abstract Submission No. 101212
O-0396

COMPARISON OF FATTY LIVER INDEX WITH FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE

Lubna Kamani1, Marium Ahmed1, Rabeeya Saeed4, Nooren Durrani2, Faraz Ahmed2

1 Liaquat National Hospital Karachi Pakistan

Background: Non-alcoholic fatty liver disease (NAFLD), is a global health issue. This study is to compare Fatty Liver index (FLI) values with Fibroscan in NAFLD.

METHODOLOGY: A cross-sectional study was done at gastroenterology clinics of Liaquat National Hospital, Karachi, Pakistan. Participants underwent laboratory assessments, abdominal ultrasound and Fibroscan. Those with history of alcohol intake and positive for hepatitis B and C were excluded.

RESULTS: Total 225 participants were studied (52.9%) were males. Median BMI and Waist Circumference were 29.8 kg/m² (IQR=26.9-34.2 kg/m²) and 103 cm (IQR=95-110 cm), respectively. Metabolic syndrome (MetS) was present in 139(61.8%). Mild Steatosis were not found among 115 (51.1%) patients. Significant variations in BMI, Waist Circumference, GGT levels, and Triglyceride TG levels were identified when comparing individuals with Fatty Liver Index (FLI) scores below 30 and those exceeding 60. Similar variations were observed in relation to the frequency of MetS as FLI scores increased. The agreement between FLI and ultrasound observations was found to be (k=0.077; p=0.027), and the Spearman correlation analysis indicated a statistically significant but weak positive correlation (r=0.384, p<0.001). On the multivariable regression model, participants having diabetes, elevated SGPT levels and mild disease on ultrasound were associated with increased odds of severe steatosis.

CONCLUSION: FLI is a good predictor of frequency of MetS & NAFLD and correlates well with increasing steatosis score (CAP) on fibro scan which can be utilized as an effective screening tool at primary care level for early detecting of NAFLD.

Abstract Submission No. 101361
O-0397

CVI-2742 is a potential best-in-class second generation oral liver-targeted THR-ß selective agonist

Jingwen Liu1,2, Zhenyu Wang1,2

1 Grigol Robakidze University Tbilisi Georgia, 2 GRUNI-School of Medicine Tbilisi Georgia

CVI-2742 is a potential best-in-class second generation oral liver-targeted THR-ß selective agonist
Liver Stiffness with Magnetic Resonance Elastography in Indonesia and Metabolic Dysfunction

Riki Tenggara1,3, Alver Prasetya1, Angelina Yuwono1, Herlina Unarni2,4, Sugento Sugento1, Rino Alvani Gani5

1Department of Internal Medicine, School of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia Penjaringan, Indonesia, 2Department of Anatomy, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia, 3Department of Internal Medicine, Gastroenterology and Hepatology Division Pantai Indah Kapuk Hospital Jakarta Indonesia, 4Department of Radiology Pantai Indah Kapuk Hospital Jakarta Indonesia, 5Division of Hepatobiliary, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo General Hospital Jakarta Indonesia

Background: Metabolic Associated Fatty Liver Disease (MAFLD) is a problem in many countries around the world including Indonesia. Magnetic Resonance Elastography (MRE) is used to assess people with MAFLD particularly regarding fat accumulation and fibrosis. However, the data in Indonesia is still limited. We aim to describe the correlation between the baseline characteristics and liver stiffness of fatty liver patients in Indonesia.

Methods: This is a cross sectional retrospective study that included 46 patients with clinically diagnosed fatty liver who underwent MRE from 2021-2022. Data were collected from medical record and analyzed using Spearman’s test and Mann-Whitney U test.

Results: The liver stiffness ranged from 1.45-7.80 kPa with a geometric mean and coefficient of variation of 3.26 and 40.6%, respectively. There was correlation between mean liver stiffness with age (p = 0.047, r = 0.295), fibrosis marker FIB-4 (p < 0.001, r = 0.720), and platelets (p <0.001, r = 0.559). Hepatocellular damage is also correlated with liver stiffness (SGOT, p <0.001, r = 0.615; GGT, p = 0.002, r = 0.533; ALP, p = 0.002, r = 0.573). Likewise, metabolic marker particularly regarding glucose control (HbA1c, p = 0.015, r = 0.501), and fat metabolism (total cholesterol levels, p =0.011, r = 0.519) correlate with liver stiffness.

Conclusions: The liver stiffness in Indonesian fatty liver patients was correlated with age, liver fibrosis marker (FIB-4 score, platelets), hepatocellular damage (SGOT, GGT, ALP) and metabolic dysfunction (HbA1c and total cholesterol). This may explain the relationship between liver damage and metabolic dysfunction.

Keywords: Liver Stiffness, Fatty Liver, Magnetic Resonance Elastography, Liver Fibrosis, Indonesia

Abstract Submission No. 101460 O-0399

Saga of an Outlier: Lean MASLD in Urban, Population of Karachi, Pakistan

Aamina S Butt1, Saeed Hamid1, Asma Ahmed1, Wasim memon1

1Aga Khan University Hospital Karachi, Pakistan
2Section of Endocrinology, Department of Medicine, Aga Khan University Hospital Karachi, Pakistan
3Section of Radiology, Department of Medicine, Aga Khan University Hospital Karachi

Background: Lean steatotic liver disease (MASLD) is unique where in the absence of obesity and unrecognized traditional risk factors, diagnosis is either delayed or even overlooked; hence resulting in compromised effectiveness or complete absence of required treatment. We aim to investigate the prevalence of lean-MASLD and to compare the clinical, and metabolic characteristics of lean and obese MASLD in an urban, adult population of Pakistan.

Methods: This was a population-based cross-sectional study piggy-backed with a large community-based trial “Pakistan Diabetes Prevention Programme” conducted in collaboration with the University of Helsinki in “Karachi”, Pakistan. Approximately 20,000 residents of Karachi were screened for diabetes using systematic sampling. Individuals aged 35-75 years, having Indian Diabetes Risk Score (IDRs) score ≥ 60 were enrolled. Ultrasound liver was performed by an experienced sonologist to identify hepatic steatosis. Anthropometric measurements and laboratory investigations were carried out. Lean-MASLD was defined if BMI was <25 Kg/m^2 and obese was defined if BMI ≥ 25 Kg/m^2. The study was funded by IDF and URC, AKUH, Pakistan.

Result: Out of 1225 individuals 741(60.5%) had MASLD. Lean-MASLD was found in 128(17.2%). Comparing lean with obese MASLD higher proportion of males, smaller waist circumferences, and lower ranges of metabolic factors were found in a lean group (table 1). The risk estimates for lean-MASLD were higher among smokers, subjects having larger waist circumference, HTN, elevated LDL, and ALT (Table 2).

Conclusion: Lean MASLD is common in the South Asian urban community of Pakistan. In the absence of significant metabolic derangements, early detection of lean-MASLD is challenging.

Abstract Submission No. 101465 O-0400

Sequential use of LSM and AGILE 3+ for assessing cACLD: Indian Consortium on NAFLD (ICON-D) study

Arka De1, Ajay Duseja1, Manu Mehta1, SP Singh2, Shrikant Mukewar3, Saurabh Mukewar1, Dr Shalimar1, Omesh Goyal3, Jayanthi Venkataraman4, VK Dixit5, Krishandas Devadas6, Varun Mehta7, Piyush Ranjan8, Anil Arora9, Aabha Nagral10

1MD, DM Chandigarh India, 2SCB Medical College Cuttack India, 3MIDAS Hospital Nagpur India, 4All India Institute of Medical Education and Research New Delhi India, 5Dayanand Medical
College Ludhiana India, 1Sri Ram Chandar Medical College Chennai India, 1SMS,Banaras Hindu University Banaras India, 2Goverment Medical College Trivandum India, 3Sir Gangaram hospital New Delhi India, 4Jaslok Hospital Mumbai India.

**Background:** Despite high sensitivity, LSM has relatively lower specificity and is more suited to ruling-out CALD (F≥3). AGILE 3+ is a novel LSM-based score, specifically designed to have high specificity for detecting F≥3 and LSM with a reduced grey-zone. We compared the diagnostic performance of combination of sequential LSM followed by AGILE 3+ with either of the methods alone.

**Methods:** In this ongoing real-life study, covering 42 centers over 4 years (n=8043), data of all patients with liver-biopsy (n=381, 63.2% males, age:42(33-50) were analysed. LSM cut-offs of <8 kPa and >12 kPa were used for ruling-out and ruling-in F≥3, respectively. Corresponding cut-offs for AGILE 3+ were <0.251 and >0.565. Similar cut-offs were used in the combined sequential approach where AGILE 3+ was applied when F≥3 was not ruled-out on LSM.

**Results:** F≥3 was present in 70 (18.3%) patients. AUROCs of AGILE-3+ with either of the methods alone. AUROCs of AGILE-4 with either of the methods alone. AUROCs of AGILE-3+ were <0.251 and >0.565. Similar cut-offs were used in the combined sequential approach where AGILE 3+ was applied when F≥3 was not ruled-out on LSM.

**Conclusion:** Sequential use of LSM followed by AGILE 3+ optimizes use of VCTE as a point-of-care tool for assessing CALD.

---

**Abstract Submission No. 101492**

**O-0402**

**Point-of-Care Non-invasive Prediction Model for Steatotic Liver Disease: Using Bioimpedance Analysis**

JEAYEON PARK1, GOH EUN CHUNG2, YOON JUN KIM3

1Seoul National University Hospital Seoul South Korea, 2Seoul National University Hospital Healthcare System Gangnam Center Seoul South Korea

**Background/Aim:** A simple and non-invasive screening method is needed to detect hidden SLD patients, especially among young adults and those with limited healthcare access due to socioeconomic factors. In this study, we aim to provide a more accessible and convenient SLD prediction model without conventional hospital laboratory infrastructure, facilitating early detection and timely intervention.

**Methods:** We retrospectively analyzed 28,506 adults at healthcare center in South Korea for a routine check-up. Participants’ alcohol intake was assessed via a health questionnaire and their body composition measured using bioimpedance analysis. To analyze the data and make predictions, a logistic regression model was developed using machine learning algorithms.

**Results:** A total of 20,094 subjects were categorized into non-SLD and SLD groups based on the presence of fatty liver. SLD model 1 was based on age and BMI, SLD model 2 was derived from age, BMI, and body fat mass per muscle mass, and SLD model 3 consisted of age, BMI, and visceral fat mass per muscle mass. In the derivation cohort, the AUROC was 0.817 in the SLD model 1, 0.821 in the SLD model 2, and 0.820 in the SLD model 3. In the validation cohort, at the optimal upper and lower cutoff values, 86.8%, 86.9%, and 87.1% of subjects were correctly classified in SLD model 1, SLD model 2, and SLD model 3, respectively.

**Conclusion:** The three derived SLD models could be novel, validated clinical tools for mass screening of SLD.

---

**Abstract Submission No. 101493**

**O-0403**

**Frequency of MASLD and cACLd among Adults with Steatotic Liver Disease**

Ling Zhou1, Jiawei Huang1, Yali Ji1, Junying Li2, Qiaoping Wu1, Damei Zhou1, Biao Wen2, Haiyu Wang1, Jiankang Song2, Yuanjian Zhang1, Xiaofeng Zhang2, Jinjun Chen3

1National University Hospital Healthcare System Gangnam Center Seoul South Korea, 2National University Hospital Seoul South Korea, 3Seoul National University Hospital Seoul South Korea

**Background and Objectives:** Diagnostic criteria for metabolic steato-tic liver disease (MASLD) have been proposed but not validated. We investigated the clinical application of the MASLD definition by...
assessing the characteristics of its subclassifications and the associated risk of compensated advanced chronic liver disease (cACLD).

Methods: A total of 1319 outpatients with imaging or biopsy-proven hepatic steatosis, systematically screened for cardiometabolic criteria, underwent transient hepatic elastography (TE) and were enrolled. Liver stiffness ≥ 10 kPa was considered suggestive of cACLD.

Results: In the present investigation, 96.6% of SLD individuals in the current research had at least one cardiometabolic risk factor, of which 36.9% had MASLD, 46.2% VSLD (MASLD + viral hepatitis), 4.02% MetALD (MASLD + significant alcohol consumption), 2.05% ALD, and 0.76% cryptogenic SLD. 97.99% of patients with NAFLD met MASLD criteria. The possible presence of cACLD was detected in 11.7% (57/487), 25.89% (80/309) and 35.8% (19/53) of those with MASLD, VSLD with SVR and MetALD, respectively. Most importantly, metabolic dysfunction was found in over 97% (229/235) of these SLD adults with cACLD. Type 2 diabetes, older age, having a higher BMI and AST were all revealed to be independent risk factors for cACLD in MASLD patients. Patients with VSLD (with SVR) who had lower PLT counts and higher AST levels were more likely to have cACLD.

Conclusions: Metabolic dysfunction was observed in most of SLD patients in China. More than half of them had viral hepatitis with viral suppression and a significant percentage of cACLD.

Abstract Submission No. 101500
O-0404

Different minimal alcohol consumption in male and female individuals with MAFLD

Jie Li1,2,3,4, Yixuan Zhu2, Xiaoming Xu3, Zhiwen Fan1, Xiaoyan Hangzhou China, 6Karsh Division of Gastroenterology and of Hepatology and Metabolic Disease, Hangzhou Normal University

Background & Aims: The relationship between moderate alcohol intake and health outcomes among individuals with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is complex. Our aim was to investigate the association of minimal alcohol consumption with all-cause and cause-specific mortality among MAFLD individuals of different genders.

Methods: Our study included 2630 MAFLD individuals from the Third National Health and Nutrition Examination Survey (NHANES III). Cox regression analysis was performed to assess the association between alcohol use measures and all-cause and cause-specific mortality. Restricted cubic spline curves were used to evaluate the relationship between alcohol consumption per week and all-cause mortality.

Results: In the entire MAFLD cohort, we observed significant disparities in clinical characteristics between male and female individuals with MAFLD. Higher weekly alcohol consumption was significantly associated with all-cause and cause-specific mortality, male, HRs: 1.009, 95% CIs: 1.004-1.014; female, HRs: 1.032, 95% CIs: 1.022-1.042. In males with MAFLD, a linear association with all-cause mortality was observed for weekly alcohol consumption (P for Non-linearity <0.05).

Conclusions: Our findings indicate that any increase in weekly alcohol consumption was associated with increased all-cause mortality in men with MAFLD. Conversely, consuming less than 2 drinks per week had minimal impact on the risk of mortality among female.

Abstract Submission No. 101512
O-0406

Vitamin intake and the progression of metabolic dysfunction-associated fatty liver disease

Jie Li, renling yao, yixuan zhu

Background & Aims: Obesity and associated comorbidities are reaching pandemic proportions worldwide. Non-alcoholic liver disease is hepatic component of this metabolic syndrome and has been recognized as leading etiology for HCC and a large societal & health problem. Aim of this study is to evaluate hepatic fibrosis stage in MAFLD by non-invasive markers as well as outcomes of patients undergoing treatment respectively, focusing on improvement of fibrosis stage of liver.

Method: Patients were pooled prospectively on a Questionnaire. Demographic data like age, sex, comorbidities like HTN, DM, ischemic heart disease, PCOs disease in females. Laboratory findings were included like Complete blood picture, LFTs, HbA1c, TSH, Cr, serum albumin, fasting lipid profile. Baseline Ultrasonography of abdomen & Fibroscan were part of scanning records. This nomogram map predicts the probability of severity of hepatic fibrosis in MAFLD patients. For each covariate, record the value & notedown corresponding points. This is repeated for each covariate ending total score that corresponds to the severity of hepatic fibrosis. For females total score can count upto 31 & for male 30 respectively. New MAFLD diagnostic pathways with use of this nomogram were modelled to diagnose & treat respectively.

Results: 100 patients were enrolled with suspected MAFLD. By using non invasive markers available in different studies to predict fibrosis stage it can be concluded that treatment can be allocated to patients depending on these scores safely so Prediction in these patients was optimised by stratifying patients into three categories based on scores (<7, 7-24 & ≥25). Multivariable logistic regression analyses revealed that DM, central obesity & increased cholesterol levels were independent risk factors for mortality after liver transplant. The receiver operating characteristic curve of nomogram prediction model was 0.896 (96% CI: 0.803-0.989), & mean absolute error of internal validation by bootstrap (1000 replications) was 0.019 (n=184). These results showed that nomogram model had an excellent prediction accuracy.

Conclusion: A nomogram model can provide clinicians to accurately predict severity of hepatic fibrosis by noninvasive markers & treatment allocation in MAFLD patients.
Introduction: Few studies explored the association between vitamin intake and metabolic dysfunction-associated fatty liver disease (MAFLD). Moreover, the existing results were contradictory. We aimed to investigate the association between dietary vitamins and all-cause mortality as well as fibrosis risk in patients with MAFLD in US.

Methods: We extracted data from the third National Health and Nutrition Examination Surveys 1988-1994. Dietary vitamins was assessed using a 24 h diet recall, including vitamin A, vitamin B6, vitamin B12, vitamin C, vitamin D, thiamin, riboflavin, folic acid and α-tocopherol. The non-alcoholic fatty liver disease fibrosis score (NFS) < -1.455 is considered as non-advanced fibrosis, while NFS ≥ -1.455 is considered as advanced fibrosis.

Results: A total of 3844 MAFLD participants were included in this study. The median time of follow-up was 310 months. 1739 participants (45.3%) were deceased during the follow-up. The intake of thiamin, riboflavin, α-tocopherol, VB6, and VB12 were significantly higher in patients with NFS-determined non-advanced fibrosis (P<0.05). After adjusting, a significantly lower risk of fibrosis was found in patients with the highest quartile (>11.5mg/d) of α-tocopherol intake compared to the lowest intake group (P<0.05). Compared to the lowest quartile group, the risk of mortality was reduced by 0.34 folds in the group consuming the highest quartile amount (>130 mg/d) of VC (HRs: 0.66, 95% CIs: 0.51-0.85, P =0.002).

Conclusions: More α-tocopherol intake reduced fibrosis grade in MAFLD patients. VC intake may reduce all-cause mortality in patients with MAFLD in US.

Abstract Submission No. 101513 O-0407

Daily water intake is protective against liver fibrosis in MAFLD
Jie Li1, renling yao1, yixuan zhu2
1Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 2Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University Nanjing china

Background and objectives: Metabolic dysfunction-associated fatty liver disease (MAFLD) refers to liver steatosis caused by metabolic abnormalities. Water is involved in many metabolic processes. This study aimed to explore whether total daily water intake affected the liver fibrosis in MAFLD.

Patients and Methods: We extracted data from the database of the third National Health and Nutrition Examination Surveys 1988-1994 (NHANES III). The amount of water intake was assessed using a 24 h diet recall, including water A, vitamin B6, vitamin B12, vitamin C, vitamin D, thiamin, riboflavin, folic acid and α-tocopherol. The non-alcoholic fatty liver disease fibrosis score (NFS) < -1.455 is considered as non-advanced fibrosis, while NFS ≥ -1.455 is considered as advanced fibrosis.

Results: A total of 2863 MAFLD patients with FIB-4 scores were included in this study. There were 2744 cases in the FIB-4<1.3 group, including 1323 males and 1451 females, and 89 cases in the FIB-4<2.67 group, including 59 males and 30 females. Those in the FIB-4<2.67 group had significantly lower daily water intake compared to the FIB-4<1.3 group [2586 (1849, 3507) mL vs 3063 (2257, 4071) mL, p <0.001]. Further subgroup analysis revealed that when total water intake reached the third (3004-4019 mL) and fourth (>4020 mL) quartile, it became a significant protective factor against liver fibrosis in those without diabetes [T3 vs. T1, 0.207 (0.085, 0.501), p<0.001; T4 vs. T1, 0.085 (0.028, 0.262), p<0.001] and those BMI≥25 [T3 vs. T1, 0.286 (0.121, 0.677), p=0.004; T4 vs. T1, 0.424 (0.203, 0.886), p=0.023]

Conclusions: Daily total water intake of 3000 ml or more was a protective factor for liver fibrosis in MAFLD patients, especially for those in non-diabetic populations and BMI≥25.

Abstract Submission No. 101558 O-0408

Impact of dietary intervention in reversal of fibrosis in Metabolic Associated Fatty Liver Disease
Jay Toshniwal1, Archana Toshniwal1, Romesh Chawlani1
1DR TOSHNIWAL GASTRO LIVER CARE AURANGABAD India

Background-obesity, diet and MAFLD are closely associated.However,impact of diet in reversal of fibrosis needs validation. This study aims to study dietary treatment as a therapy in management of reversal of fibrosis in MAFLD.

Method- Out of 768 elastography performed from June 2022 to June 2023,Fifty Metabolic Associated Fatty Liver Disease ( MAFLD) patients with Severe steatosis and F3 or F4 fibrosis,were enrolled in the study.Age group was in range of 18 to 70 years with 25 Males and 25 Females.No patient had transaminitis.Dietary intervention in form of 6 feeds per day,low calorie diet :approximately 1500 Kilocalories per day was advised.No medication was prescribed to these patients.

Results-At the end of 3 months 47 patients were non-compliant to this dietary change.Only 3 patients followed this dietary advise.Weight loss of 5 kg or more was noted in all these 3 patients.Repeat elastography at end of 3 months demonstrated F0 fibrosis and no steatosis in all these 3 male patients.

Conclusion-Dietary intervention can completely reverse fibrosis and steatosis in patient with MAFLD;however,patient compliance to change the dietary pattern is very poor(6%).So,drugs like saroglitazona to be considered in all patients with MAFLD and F3/F4 fibrosis.

Abstract Submission No. 101637 O-0409

Metabolic-associated fatty liver disease (MAFLD) and its metrics for contributions to liver research
Maito Suoh1, Saeed Esmaill1, Mohammed Eslam4, Jacob George1
1Storr Liver Centre, The Westmead Institute for Medical Research, Westmead Hospital and The University of Sydney, Australia

Background: The international consensus to rename non-alcoholic fatty liver disease to metabolic (dysfunction)-associated fatty liver disease (MAFLD) in 2020 has been gained significant worldwide attention. The impact of the term MAFLD on the research community however has not been objectively assessed. We conducted a comprehensive survey of literature on MAFLD to understand the current trends in the research topic and country-level contributions.

Methods: We used PubMed, Scopus, and Web of Science to collect publications (articles, reviews, and editorials) written in English, published from 2020 to 10/10/2023 containing MAFLD or its fully spelled term in the titles or abstracts. Publication metrics, including numbers, publishing journals, author countries, author keywords, and cited times were analysed.

Results: 1470 MAFLD-related publications were published in 435 journals, with a steady increase in the numbers since 2020. Among the 97 countries and territories authoring the publications, China, followed
by Italy, USA, and Australia produced the greatest numbers of MAFLD publications. Country co-occurrence network analysis of 326 publications from multiple countries showed global and regional cross-country collaborations between 96 countries. Common topics from the highly cited publications were the MAFLD definition and the consequences resulting from the change in nomenclature. Apart from the terms describing fatty liver disease and its complications, top author keywords were enriched in those related to metabolic dysfunction, including obesity, metabolic syndrome, diabetes mellitus, and cardiovascular disease.

**Conclusion:** This survey provides a quantitative measure of the considerable international contribution of MAFLD to research with a focus on its relationship to metabolic dysfunction.

**Abstract Submission No. 101649**

**O-0410**

**Factors predicting the future incidence of fatty liver: A single-center study**

Aki Moriya¹, Teruya Nagahara¹, Yoshiaki Iwasaki², Masaharu Ando¹

¹Mitoyo General Hospital Kanonji Japan, ²Okayama University, Health Service Center Okayama Japan

**Background:** Identifying a population that requires special attention to prevent the development of fatty liver may contribute to the control of future complications.

**Methods:** We enrolled health-checkup participants without fatty liver on their first visit and performed logistic regression analyses to determine the association between various items and the incidence of fatty liver on their second visit.

**Results:** After a median follow-up period of 367 days, 278 out of 3,343 individuals (8.3%) had newly developed fatty liver. Body mass index (BMI; odds ratio, 1.196 per 1 increase; 95% confidence interval, 1.098-1.303), triglycerides (1.004 per 1 mg/dl increase, 1.001-1.007), γ-glutamyltransferase (GGT; 1.003 per 1 U/l increase, 1.001-1.007), low-density lipoprotein cholesterol (LDL-C; 1.023 per 1 mg/dl increase, 1.002-1.044), albumin (2.140 per 1 g/dl increase, 1.243-3.694), and platelet count (1.028 per 10,000/µl increase, 1.002-1.055) were independently associated with the incidence of fatty liver. ROC analysis revealed cutoffs of 22.1 for BMI (area under the curve, 0.726), 102 mg/dl for triglycerides (0.666), 19 U/l for GGT (0.648), 112 mg/dl for LDL-C (0.579), 4.5 g/dl for albumin (0.559), and 217,000/µl (0.555) for platelet count, with high values for any of these items indicating a risk of fatty liver. When 1 point was given for each item exceeding the cutoff value, the incidence of fatty liver exceeded 20% in those with a total score of 5-6, whereas it was less than 1% in those with 0-1 point.

**Conclusions:** Elevated BMI, triglycerides, GGT, LDL-C, albumin, and platelet counts may predict fatty liver development at one year.

**Abstract Submission No. 101651**

**O-0411**

**The Association between Non-Alcoholic Fatty Liver Disease and Risk of Chronic Kidney Disease.**

Ahmed Mokhtar¹, Heba Kasem¹, Ezzat Abdallah¹, Ehab Abdelaty¹

¹Internal medicine department, Menoufia faculty of medicine Menoufia, Birket Elsaba Egypt

**Introduction:** Nonalcoholic fatty liver disease (NAFLD) is a spectrum of disorders ranging from hepatic steatosis to nonalcoholic steatohepatitis (NASH), NASH related cirrhosis and hepatocellular carcinoma (HCC). There is sparse data on the prevalence CKD in Egyptian patients with (NAFLD). Aim of the work: To estimate the prevalence of CKD in individuals with and without NAFLD. Patients and methods: a cross-sectional study was conducted on 430 patients from the Internal Medicine Department, Menoufia University Hospitals, including 215 patients with NAFLD, and 215 patients without NAFLD. NAFLD was diagnosed by abdominal ultrasonography. The liver fibrosis was assessed by NAFLD fibrosis score (NFS) and fibrosis-4 index (FIB-4). CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2 and/or abnormal albuminuria (urinary albumin-to-creatinine ratio > 30 mg/gm). The logistic regression analysis was performed to examine the association between NAFLD and risk of CKD.

**Results:** The prevalence of CKD and was higher in individuals with NAFLD than in those without NAFLD (38.1 % vs 7.4 %, p < 0.001). Logistic regression analysis demonstrated that both NAFLD and CKD were risk factors of each other. The presence of hypertension, and the high levels of BMI and waist circumference were the other independent risk factors of NAFLD. While the presence of DM, and the high level of BMI were the other significant risk factors of CKD in the NAFLD group.

**Conclusion:** The presence and severity of NAFLD are associated with an increased risk and severity of CKD.

**Abstract Submission No. 101654**

**O-0412**

**NASH complicating with T2DM can be well controlled by hepcidin inducer Laennec derived from Placenta**

YUKI HAMADA¹, Eiichi HIRANO², Keizo HANADA³, Taichi KAKU³

¹HAMADA Clinic of Gastroenterology Sapporo Japan, ²Japan Bio Products Co. Ltd. Kurume Research Center KURUME Japan, ³Japan Bio Products Co. Ltd. TOKYO Japan

**Background:** Recently it was elucidated that hepcidin, the principal regulator of iron metabolism, could express in pancreatic β-cells, of which level could be regulated by iron. This fact means that the pancreas may also contribute to the iron metabolism. In the cases of NASH complicating with T2DM, remarkable declines of serum ferritin and HbA1c were observed after treating with Laennec® (‘hepcidin inducer’ derived from placenta). Then, we examined whether Laennec® could restore the pathological background of NASH through regulating iron metabolism.

**Methods:** We divided 114 NASH cases (all complicating with T2DM, liver biopsied) into two groups retrospectively. Laennec®-treated 83cases were treated with the infusion of 2 ampules(224mg) of Laennec® 1-times/W, in addition to the ordinary liver supporting. Serum ferritin, ALT and HbA1c were measured, and liver re-biopsy was carried out to evaluate changes of iron deposition in 21 cases of NASH patients.

**Results:** By infusing Laennec®, serum ferritin level declined from 282.3±216.5 ng/ml (before medication) to 62.6±51.8(after) Wilcoxon P<0.01 in NASH patients. Serum ALT also declined from 61.4±24.2U/L to 29.6±16.3<P<0.001). HbA1c level improved from 6.6±1.1% to 5.7 ±0.8 (P<0.01). When compared these results in two groups, the changes observed in Laennec®-treated group were significantly larger than non-treated group(Mann-Whitney P<0.05). In multiplex-logistic analysis, the improvement of iron deposition in the liver correlate significantly with the decline of serum ferritin(P<0.01).
Conclusions: The improvement of NASH complicating with T2DM by the administration with Laennec® suggests the importance of iron regulation on refractory T2DM which shows the presence of hyperferritinemia.

Abstract Submission No. 101666
O-0413

The Role of Multiparametric US in Evaluating Advanced Fibrosis in Patients with MASLD

Katsutoshi Sugimoto1, Hiroshi Takahashi1, Tatsuya Kakegawa1, Takuya Wada1, Yu Yoshimasu1, Hiroshito Takeuchi1, Takao Itoi1
1Tokyo Medical University Tokyo Japan

Purpose: Liver fibrosis is a major prognostic factor in metabolic dysfunction-associated steatotic liver disease (MASLD), and there is a need for a non-invasive and highly accurate tool to assess advanced fibrosis. In this study, we aimed to develop a highly accurate model for identifying MASLD patients with advanced fibrosis using multiparametric ultrasound (US).

Materials and Methods: This prospective global multicenter study collected data from seven sites, including 65 biopsy-proven MASLD patients. Five US markers (shear-wave speed [SWS] in m/s, dispersion slope [DS] in m/sec/kHz, attenuation coefficient [AC] in dB/cm/Hz, normalized local variance [NLV], and the echo intensity ratio of liver to kidney [L/K ratio]) were measured using a 2D SWE system immediately before biopsy. The biopsy specimens were scored by expert pathologists from one site. Diagnostic performance was assessed using the area under the receiver operating characteristic curve (AUC) for identifying advanced fibrosis (fibrosis stage ≥ F3), and the best-fit multivariable logistic regression model for identifying patients with advanced fibrosis was determined.

Results: Sixty-five adults (mean age: 53 years ± 16 [standard deviation], 32 men) underwent a US examination. Among the five US markers, SWS and NLV enabled the appropriate identification of advanced fibrosis, with an AUC of 0.89 (95% CI: 0.80, 0.99) and 0.81 (95% CI: 0.67, 0.95), respectively. Performance of the combination of SWS and NLV was satisfactory, with an AUC of 0.91 (95% CI: 0.81, 1.00).

Conclusion: The combination of SWS and NLV improved the diagnostic performance of identifying MASLD patients with advanced fibrosis compared to SWS alone.

Abstract Submission No. 101676
O-0414

“Cryptogenic liver cirrhosis: the key role of metabolic-associated fatty disease NAFLD.”

Venera Rakhmetova1, Madina Kalimullina2, Temirbek Madina3, Beisenbekova Adina3
1MD, Professor of the Department of Internal Medicine NJSC “Astan Medical University”, Astana Kazakhstan, 2Astan Medical University resident 1 year Astana Kazakhstan, 3Astan Medical University resident 1 year Astana Kazakhstan

Introduction: Non-alcoholic fatty liver disease (NAFLD) is currently the leading cause of chronic liver disease worldwide and is projected to become the main cause of cirrhosis requiring liver transplantation in the next decade.

Case Description: Patient S., 56 years old, complains of aching pains in the epigastrium and right hypochondrium, bloating, unstable stool and increased fatigue. In the anamnesis there are no indications of alcohol abuse, the use of hepatotoxic drugs, burdened heredity. On examination - a patient of the correct physique, BMI - 41 kg / m², waist circumference - 120 cm. On palpation - the abdomen is enlarged due to ascites, moderate soreness in the right hypochondrium and epigastric region, the lower edge of the liver is 3 cm lower than the right costal edge, the liver is dense and sensitive on palpation. Laboratory examination: hemoglobin - 140 g / l, leukocytes - 8,4·10^9/ l, platelets - 179·10^9/ l, SOE - 12 mm/hour. Biochemical blood test: total bilirubin - 22 mmol/L, thymol sample - 7.5 units, ALT - 80 units/l, AST - 60 units/l, GGTP - 48 IU/L, alkaline phosphatase - 70 IU/L, total cholesterol - 7.08 mmol/l, triglycerides - 2.85 mmol/l, HDL - 1.07 mmol/l, LDL - 5.89 mmol/l, VLDL - 1.31 mmol/l, glucose - 5.2 mmol/l. Serum cancer markers: AFP, CA 19-9 - within normal limits. According to ultrasound: Moderate ascites. Hepatomegaly. Diffuse changes in the pancreatic parenchyma. Echo signs of pronounced diffuse changes in liver parenchyma by type of fatty infiltration and cirrhotic changes.

Abstract Submission No. 101703
O-0415

Higher incidence of DM inHealthy Fatty Liver Patient Of Bangladesh: Prompt Intervention Can Avert Complication

A B M Shelki Gani1, Dr Abdullah Al Mahmood2, Dr. A. F. Mohammed Shafiqui Alam3, Dr. Md. Mizanur Rahman4
1Assistant Professor of Hepatology Sheikh Hasina Medical College, Tangail, Tangail Bangladesh, 2Associate professor Department of Hepatology Chittagong Medical College Chittagong Bangladesh, 3Associate Professor Department of Pharmacology Sheikh Hasina Medical College Tangail Bangladesh, 4Junior Consultant (Medicine) Upazilla Health Complex, Kapasia Gazipur Bangladesh

Background: Lifestyle changes and urbanization is progressively increasing the number of diabetic patients globally & in South-Asian countries. DM associated health complications threaten to reduce economic gains in third world country like Bangladesh.

Methods: This cross-sectional study was conducted in Sheikh Hasina medical college, Tangail, Bangladesh from August 2022 to February 2023. A total of 92 patients with ultrasonological evidence of grade II fatty change in liver were included and evaluated. Known DM, Hypothyroidism, Alcohol abuse, HBV, HCV, Wilsons Diseases, autoimmune liver disease, hemochromatosis and any other chronic liver disease patients were excluded. Then patients were assessed for presence and absence of DM using OGTT or HbA1c as diagnostic criteria.

Results: Out of 92 patients, male was 48 and female 44. A total of 50 patients (54.3%) were newly diagnosed as DM. No significant differences were evident in DM group and non-DM group in respect to Mean age (41 years versus 38), ALT values (58.9 IU versus 60.23), AST (50.33 IU versus 36.53), TG (270 mg/dl versus 189), BMI (28.85 versus 29.29).

Conclusions: Recent study states, more than 54% of patients with grade II fatty liver were newly diagnosed with DM. If not evaluated early, they will come later with more advanced DM and related complications. Although a larger study is needed, physicians and healthcare workers in Bangladesh should be more concerned about treating such metabolic dysfunction-associated steatotic liver disease (MASLD) patients with early diagnosis of DM, prompt lifestyle interventions, and prescribing drugs if needed.

Keywords: Diabetes, Fatty liver, Intervention, MASLD.

Abstract Submission No. 101735
O-0416
Modeling Disease Burden of Adolescent NAFLD and NASH Based on Body Mass Index

xiaoyun Lin1, JingMao Li, LingYi Huang1, LiYan Lin1, MeiZhu Hong1, Shangeng Weng1, JinShui Pan1
1the First Affiliated Hospital of Fujian Medical University fuzhou China, 2Xiamen University xiamen china, 3Mengchao Hepatobiliary Hospital of Fujian Medical University fuzhou china

Background: Currently, there is a lack of global or even country/regional level data on adolescent non-alcoholic fatty liver disease (NAFLD) prevalence. However, evidenced dose-dependent relationship exists between body mass index (BMI) and the risk of NAFLD. We aim to estimate the global and regional prevalence of adolescent NAFLD and related non-alcoholic steatohepatitis (NASH) based on BMI.

Methods: Sigmoidal fitting curves were generated between BMI and the risk of NAFLD/NASH using the data extracted from the NHANES database. With the aid of global and regional BMI data from the NCD-RisC database, adolescent NAFLD/NASH prevalence was estimated at the global, regional, and country levels from 1975 to 2016. The prevalence of adolescent NAFLD/NASH from 2017 to 2030 was also forecasted.

Results: The average NAFLD prevalence was 15.31%, and 12.68%, while the average NASH prevalence was 2.50%, and 2.47%, in boys, and girls aged 12-18, respectively. For both boys and girls, NAFLD/NASH prevalence increased with increasing BMI, and age. The global prevalence of adolescent NAFLD/NASH has gradually increased in the period from 1975 to 2016 and would maintain a similar trend between 2017 and 2030. High-income Western Countries had higher adolescent NAFLD/NASH whereas South Asia, and Sub-Saharan Africa exhibited relatively lower adolescent NAFLD/NASH prevalence.

Conclusion: The adolescent NAFLD/NASH prevalence increase year by year, and its burden varies significantly among different countries and regions. BMI is a precise predictor of NAFLD/NASH prevalence.

Abstract Submision No. 101765
O-0417

Correlation Between CAP Value and SYNTAX Score in Patient with Coronary Artery Disease (CAD)

Jordan Sardjan1, Cosmas Rinaldi Adithya Lesmana1, Lusiani Siregar2, Juferdy Kurniawan1, Rino Alvani Gani3
1Division of Hepatobiliary, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Pusat Indonesia, 2Division of Cardiology, Department of Internal Medicine, Cipto Mangunkusumo National General Hospital, Faculty of Medicine Universitas Indonesia Jakarta Pusat Indonesia

Background: Hepatic steatosis is an established risk factor for chronic liver disease (CLD), with cardiac-related mortality especially CAD serves as major cause of death. We aim to determine the correlation between hepatic steatosis and CAD burden.

Methods: Patients who underwent coronary angiography at Cipto Mangunkusumo Hospital catheterization laboratory from August 2022 to October 2023 with proven significant coronary occlusion were included in the study. Subsequent SYNTAX score was calculated. Liver elastography was used to assess hepatic steatosis and obtain CAP values. Patients with significant alcohol intake, viral hepatitis, HIV, other liver disease, ascites, pregnancy, and steatosis-inducing medication were excluded. All patients were subjected to clinical assessment and serum metabolic examinations.

Results: A total of 124 patients were enrolled, comprising 83.9% males, 55.6% smokers, 94.4% hypertensive, 55.6% diabetics, and 54.8% obese patients. Mean age was 59.8 years (σ = 11.1). Mean HDL-C was 38.8 mg/dL (σ = 10.8), median LDL-C and TG were 109.5 and 118.5 mg/dL respectively. 84.7% patients had multiple-vessel CAD, with median SYNTAX score 22. 52.5% patients had significant steatosis, with mean CAP 256.5 dB/m (σ = 47.3). Adjusted for confounders, a significant positive correlation between CAP and SYNTAX score was observed (r = 0.372, p < 0.0001).

Conclusions: This study suggests that hepatic steatosis correlates significantly with CAD burden. Early hepatic steatosis assessment is paramount to diminish the risk of developing CLD and its cardiac-related mortality.

Abstract Submission No. 101777
O-0418

Correlations of liver steatosis and fibrosis with metabolic parameters in young-onset diabetes

Ryan Herardi1,2, Chyntia Olivia Maurine Jasirwan3, Rabbinu Rangga Pribadi4, Ardy Wildan5, Dicky Levenus Tahapary2
1Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta Indonesia, 2Department of Internal Medicine, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta Jakarta Indonesia, 3Division of Hepatobiliary, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta Indonesia, 4Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta Indonesia, 5Division of Endocrine, Metabolism, and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia - Cipto Mangunkusumo Hospital Jakarta Indonesia

Background: Liver steatosis and fibrosis are markers used to evaluate Metabolic Associated Fatty Liver Disease (MAFLD) in diabetes. The aim of this study was to investigate the correlations between several metabolic parameters (including obesity, insulin resistance, dyslipidemia, and hypertension) and liver steatosis and fibrosis.

Methods: A cross-sectional study was conducted on outpatients with young-onset diabetes at Cipto Mangunkusumo Hospital, Jakarta, Indonesia, during November-December 2022. Liver steatosis, estimated through Controlled Attenuation Parameters (CAP) score (dB/m), and liver fibrosis, evaluated through Liver Stiffness Measurement (LSM) / E - score (kPa), were assessed using Vibration-Controlled Transient Elastography (Echosens (R), France). The metabolic parameters, including Body Mass Index (BMI), glycated haemoglobin, lipid profile (HDL, LDL, and triglyceride), and blood pressure, were assessed using physical examination, anthropometric measurements, and laboratory tests. Pearson or Spearman rank correlation test was performed.

Results: Sixty-two patients were included, 69.4% of which were female, and the mean age was 33.63 years (95% CI : 31.88 - 35.38 years). The CAP score showed a moderate correlation with BMI (R = 0.54; p < 0.01), triglycerides (R = 0.58; p < 0.01), HDL (R = -0.46; p < 0.01). Concurrently, the LSM / E - score exhibited a moderate correlation with BMI (R = 0.40; p < 0.01) and HDL (R = -0.41; p < 0.01).

Conclusions: The degree of liver steatosis correlates moderately with an increase in BMI, elevated triglycerides, and decrease in HDL. Meanwhile, the degree of fibrosis correlates moderately with an increase in BMI and a decrease in HDL.

Abstract Submission No. 101784
Efficacy of Saroglitazar in MASLD at 6 months, a single center observational study

Rajdeep Singh1, Gunjan Baweja1
1J P Medical Centre Chandigarh India

Introduction: Saroglitazar is the first ever drug approved in Non- Cirrhotic MASLD.

Methods: A retrospective analysis was conducted at a North Indian single setting. A total 50 patients with documented ultrasonographic fatty liver changes and dyslipidemia who were prescribed Saroglitazar 4 mg once daily for at least 6 months from May 2022 to November 2022 were retrospectively included in this data analysis. Change in CAP, LSM, AST, ALT, TG, TC, LDL, HbA1c, from baseline to 6 months was analyzed using paired t-test.

Results: The mean age of patients analyzed was 49.45 ±11.76. 58.0% were males and mean body weight 80.07 ±10.66. The baseline and follow up of CAP, LSM, AST, ALT, TG, TC, LDL and HbA1c values are given in Table 1. A significant and consistent reduction on CAP, LSM, AST, ALT, TG, TC, LDL and HbA1c was observed. No new safety signals were observed.

Conclusion: Saroglitazar 4 mg per day for 6 months has high efficacy in treating MASLD.

Table 1: Baseline and 6 months follow up for various parameters

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>6 months</th>
<th>p value</th>
<th>Absolute reduction</th>
<th>Percentage reduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAP (dB/m)</td>
<td>43.6 ±8</td>
<td>37.4 ±7</td>
<td>0.001</td>
<td>6.2 ±1.8</td>
<td>9.3%</td>
</tr>
<tr>
<td>LSM (Kpa)</td>
<td>7.5 ±2.5</td>
<td>6.8 ±2.2</td>
<td>0.003</td>
<td>0.7 ±0.3</td>
<td>9.8%</td>
</tr>
<tr>
<td>AST (IU/dl)</td>
<td>60 ±30</td>
<td>45 ±25</td>
<td>0.001</td>
<td>15 ±10</td>
<td>25%</td>
</tr>
<tr>
<td>ALT (IU/dl)</td>
<td>40 ±25</td>
<td>30 ±20</td>
<td>0.001</td>
<td>10 ±5</td>
<td>25%</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>150 ±75</td>
<td>120 ±60</td>
<td>0.001</td>
<td>30 ±15</td>
<td>20%</td>
</tr>
<tr>
<td>TC (mg/dl)</td>
<td>200 ±40</td>
<td>170 ±30</td>
<td>0.001</td>
<td>30 ±10</td>
<td>15%</td>
</tr>
<tr>
<td>LDL-C (mg/dl)</td>
<td>110 ±30</td>
<td>91 ±25</td>
<td>0.001</td>
<td>19 ±15</td>
<td>17%</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>6.5 ±0.8</td>
<td>6.1 ±0.7</td>
<td>0.001</td>
<td>0.4 ±0.1</td>
<td>6%</td>
</tr>
</tbody>
</table>

Abstract Submission No. 101805

Diagnostic accuracy of using Anthropometric indices as predictors of Patients with MAFLD

Bernard Johannes A. Jimeno1, Harold P. Iturralde1, Diana A. Payawal1
1FATIMA UNIVERSITY MEDICAL CENTER VALENZUELA Philippines

Abstract Submission No. 101839

Fibroscan compared to non-invasive scores in patients with non-alcoholic fatty liver disease

Priyansh Bhayani1, Sarojini Parameswaran1, Natarajan Murugan1, Kailipatt Palaniswamy1, Paramasivan Piramanayagam1
1Apollo Hospitals Chennai India

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease of the twenty-first century, and is one of the leading indications for liver transplantation. In India, the prevalence of NAFLD in the general population varies from 9% to 53%. Liver biopsy is the gold standard for assessing the severity of liver fibrosis. However due to various difficulties involved with liver biopsy, it is imperative to identify different non-invasive tools that can replace liver biopsy.

Methods: A prospective observational study of 130 patients meeting the inclusion criteria for NAFLD was done for a period of 18 months. The aim was to compare different non-invasive scores (FIB-4, NFS and APRI) to Fibroscan and determine cut-offs to rule out advanced fibrosis.

Results: In the study, 76.9% of patients were males. Advanced fibrosis was seen in 12.3% of the patients. Majority of the patients with advanced fibrosis had metabolic syndrome and an abnormal glycemic status (p value <0.05). Based on the AUROC, the new cut-off for ruling out advanced fibrosis for FIB-4, NFS and APRI were 1.18, -0.9, 0.65. APRI had the best AUROC (0.768).

Conclusion: Abnormal glycemic status and metabolic syndrome were risk factors for advanced fibrosis. The newly derived cut-offs for FIB-4 score, NFS score and APRI score had a better Negative predictive value compared to original cut-offs. The newly derived cut-offs should be evaluated in larger cohort to exclude patients with advanced fibrosis in the absence of Fibroscan in a resource limited setting in India.

Abstract Submission No. 101846

Role of Anthropometric Indices in the Predicting of NAFLD in Rural Population of Bangladesh

Mohammad Hoque1, Forhad Abedin2, Mohammad Belelul Islam3, Mustafa Kamal Azad4
195
**Addition of Resveratrol to Orlistat Improves Elastography Parameters in Overweight**

**Aung Hlaing Bwa**, Khin Maung Win, Khin Maung Aye, Tint Swe Latt, Kyaw Soe Tun, Hardik Gandhi

1Yangon GI & Liver Centre Yangon Myanmar, 2University Of Medicine 1 Yangon Myanmar, 3University Of Medicine 2 Yangon Myanmar, 4Defense Services Medical Academy Yangon Myanmar, 5Zydus Research Centre Ahmedabad India

**Objectives:** Weight reduction improves hepatic steatosis and fibrosis. Orlistat, an approved therapy for weight management. Resveratrol, an antioxidant, may aid weight loss by enhancing energy expenditure through SIRT-1 activation.

**Materials & Methods:** 298 subjects aged >18 years with BMI > 25kg/m² were randomized into two groups: The control arm (O) received orlistat 120 mg thrice daily, and the test arm (O-R) received orlistat 120 mg + resveratrol 100 mg thrice daily for 12 weeks. Patients were followed up for 12 weeks.

**Results:** 247 subjects with a mean body weight ~80 kg completed the study with more than 80% patients achieving > 5% weight loss and accompanied by improvement in elastography parameters in 12 weeks. As compared to baseline, the O-R group exhibited a higher weight loss of -3.31 kg (p=0.001) compared to -2.92 kg (p=0.001) in the O group. The mean CAP score at 12 weeks was significantly lower in the O-R group as compared to the O group (253.16 dB/m vs 276.82 dB/m, P<0.05).

The fibrosis score was not found to be statistically significant (7.04 KPa vs 7.47 KPa).

**Conclusion:** Addition of resveratrol to orlistat provides synergistic benefits to weight loss. Subgroup with steatosis &/or fibrosis exhibited superior weight loss with the addition of resveratrol.

Abstract Submission No. 101931 O-0425

**Metabolic-Associated Fatty Liver Disease (MAFLD) as a Risk Factor of Developing Malignant Arrhythmia**

Muhammad Bilal Saifulhaq, Tohari Amin, Syifa Mustika

1Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia, 2Gastroenterohepatology Division of Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia

**Background:** Metabolic-associated fatty liver disease (MAFLD) is an emerging driver of cardiac arrhythmias and recent studies have
investigated the relationship between MAFLD and several types of arrhythmia. However, there has been no meta-analysis to summarize the existing studies of the relationship between MAFLD and malignant arrhythmia yet. This study is aimed to determine whether MAFLD is a risk factor of malignant arrhythmia.

**Methods:** According to PRISMA guidelines, we systematically searched the PUBMED and EMBASE database through October 2023 to identify all studies reporting the incidence of ventricular arrhythmia, malignant PVC, and prolonged QTc among patients with and without MAFLD. Random-effect models were used to estimate pooled odds ratio (OR), and 95% confidence intervals (CI); subgroup analyses, meta-regressions, and sensitivity analyses were additionally performed.

**Results:** A total of 9 studies with 38,813 individuals met the eligibility criteria and were included in the meta-analysis. MAFLD was associated with an increased risk of ventricular arrhythmia (OR: 2.09, 95% CI: 1.52-2.88), prolonged-QTc (OR: 1.84, 95% CI: 1.57-2.15), malignant PVC (OR: 2.5, 95% CI: 1.67-3.73) and overall pooled odds ratio of 1.94 (95% confidence interval, 1.70—2.22). We identified significant subgroup differences according to geographical location, study design, and risk of bias. Meta-regressions identified mean age and study-level characteristics as potential moderators of the risk of malignant arrhythmia.

**Conclusions:** MAFLD is an independent risk factor for developing malignant arrhythmias in the future. Further studies are required to confirm this finding and to evaluate specific arrhythmia prevention strategies in patients with MAFLD.

**Abstract Submission No. 101945**

**O-0426**

**Comparison between 2D-US DL steatosis algorithm with Fibroscan in history proven patients**

Dar-In Tai1, Jennifer Tai1, Tse-Hwa Hsu1, Cheng-Jen Chen1, Wei-Ting Chen1, Ming-Ling Chang1, Bowen Li2, Le Lu3, Adam P Harrison1

1Chang Gung Memorial Hospital, Linkou Main Branch Taoyuan Taiwan, 2Department of Computer Science, Johns Hopkins University, Baltimore United States, 3DAMO Academy, Alibaba Group, New York, United States, 4Research Division, Riverain Technologies, Miamisburg, United States

**Background:** 2D-ultrasound is widely used in screening of liver diseases. A deep learning algorithm to quantify liver steatosis from 2D-ultrasound images may change a subjective steatosis diagnosis to an objective quantification. We evaluate a deep learning (DL) algorithm established in our previous work in patients receiving liver histology study.

**Methods:** Patients who received liver histology and Fibroscan studies between 2015 and 2023 were enrolled. 2D-ultrasound images and Fibroscan studies examined within one month of histology study were retrospectively collected. We classified images into four scanning views and applied the algorithm. Mean values from 3-5 images in each group were used for the results and correlated with histology steatosis grades.

**Results:** Totally 403 patients were included. Images from the right intercostal view (G2) were available in 370 patients. A cut-off system (0.58, 0.43 and 0.22) was established with histology grades as gold standard. This system was then applied to images from the left hepatic lobe (G1 view, N=272) and subcostal view (G4, N=191). The accuracy was between 0.824 to 0.878 from different views and steatosis grades. The area under receiver operating characteristic curve (AUROC) were between 0.910 and 0.945 among different histology steatosis grades. By multinomial logistic regression on histology steatosis grades, the DL steatosis algorithm was significantly associated with steatosis grades and better performance than continue attenuation parameter, especially in higher steatosis grades.

**Conclusion:** The DL algorithm objectively quantified liver steatosis from retrospectively collected 2D-ultrasound images. The high AUROC and accuracy warrant clinical applications.

**Abstract Submission No. 102000**

**O-0427**

**Metabolic dysfunction associated steatotic liver disease in a Cohort in Trivandrum India**

Shenoy KT1, 2, Leena KB2, Jayakumar Parameswaran Pillai2, 3

1Sree Gokulam Medical College and Research Foundation Trivandrum India, 2Population Health and Research Institute Trivandrum India, 3Population Health and Research Institute Trivandrum INDIA

**Introduction:** Non alcoholic fatty liver has a major public health issue in Trivandrum. We are reporting the prevalence of metabolic dysfunction associated steatotic liver disease (MAFLD) in the cohort

**Methods:** Between May 2022 to September 2023, a total of 2846 participants (aged 25 or more) were recruited to this cohort through multi-stage cluster sampling across the whole population of Trivandrum district within the state of Kerala, South India. Using the recent criteria for MAFLD, we analysed the data. Metabolic syndrome, demographic measures, anthropometric measures and biochemical profile and ultrasound assessment of the liver and liver stiffness were evaluated.

**Results:** MAFLD prevalence was 65.8% (95% CI 64-67.52%). There were 874 males and 998 females. Mean age was 51.71 years. Median Stiffness of liver >10.2 was seen in 20.5% in MAFLD compared to those without MAFLD (13.2: p<0.001). MAFLD odds ratios after adjusting for age, sex, domicile, BMI category (with normal weight as baseline), diabetes and metabolic syndrome are:

<table>
<thead>
<tr>
<th>Predictor</th>
<th>Odds Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Ref- &lt;50 years)</td>
<td>1.23 (1.1- 1.46)</td>
</tr>
<tr>
<td>Gender (Ref- Female)</td>
<td>2.14 (1.63 - 2.47)</td>
</tr>
<tr>
<td>Domicile (Ref- Rural)</td>
<td>1.2 (0.99 - 1.45)</td>
</tr>
<tr>
<td>BMI- Normal</td>
<td></td>
</tr>
<tr>
<td>Under weight- Normal Adj OR (95% CI)</td>
<td>0.16 (0.05 - 0.48)</td>
</tr>
<tr>
<td>Over weight Adj OR (95% CI)</td>
<td>2.2 (1.56 - 2.77)</td>
</tr>
<tr>
<td>Obese Adj OR (95% CI)</td>
<td>3.76 (2.93 - 4.89)</td>
</tr>
<tr>
<td>Diabetes Adj OR (95% CI)</td>
<td>1.77 (1.41 - 2.19)</td>
</tr>
</tbody>
</table>

**Conclusion:** MAFLD is prevalent in 66% of general population and the main risk factors are obesity, diabetes and metabolic syndrome. Proactive population based life style interventions are needed.

**Abstract Submission No. 102073**

**O-0428**

**Triglycerid-Glucose (TyG) Index as Novel Predictor of New Onset Atrial Fibrillation in MAFLD Patient**

Muhammad Bilal Saifulhaq1, Tohari Amin1, Syifa Mustika2, Ardian Riza3

1Internal Medicine Department, Saiful Anwar Regional Hospital and Brawijaya University Malang Indonesia, 2Gastroenterohepatology Division of Internal Medicine Department, Saiful Anwar Regional
Efficacy and Safety of a Standarized Extract of Prunus Mume in Patients with MAFLD

Muhammad Umair Ahsan, Saleem-ullah Zafar

1SERVICES INSTITUTE OF MEDICAL SCIENCES(SIMS) LAHORE Pakistan, 2SERVICES INSTITUTE OF MEDICAL SCIENCES(SIMS) LAHORE PAKISTAN

Background and Aims: Extract of Prunus mume; a herbal variant and choline; a content of cell membrane have been reported to exert potentially therapeutic effect on various body conditions. Recently these two have been used in the treatment of Metabolic-associated fatty liver disease(MAFLD). But data is lacking in this regard in our region.

Patients and Methods: This was a prospective observational hospital-based study carried out on 200 patients diagnosed with Metabolic-associated fatty liver disease(MAFLD). Both males and females, aged≥18 years, were included in this study. 100 patients were kept on lifestyle modification and 100 patients were administered a tablet Revolic® (Prunus mume 150mg and choline 82.5mg) per day and the levels of ALT, AST, Triglycerides, Gamma GT, and total cholesterol were measured at the start of the treatment and then after 12 and 24 weeks. SPSS version 26.0 was used for data entry and analysis.

Results: Our study participants, the majority were females (83%) then males (17%) with a mean and SD of age was 40.49±10.59 years. At the end of treatment, a significant mean reduction of serum AST (5.21±0.9), ALT (3.21±1.42), GGT (3.88±0.2), total bilirubin (0.6±0.1), and weight (4.7±2.34) was observed in patients receiving Prunus Mume and Choline as compare to patients put on lifestyle modification, p-value <0.05. The most common side effects were the presence of gastrointestinal symptoms (12.74%) followed by headache (6.2%), anorexia (3.2%), and body aches (1.8%).

Conclusion: This study proves that Prunus Mume and Choline have beneficial effects on liver function tests in patients with MAFLD. Furthermore, this drug has a beneficial effect on better glycemic control and weight loss. The observed side effects in this study are minor, and this drug was observed to be safe in patients with MAFLD.

Keywords: Prunus Mume and Choline, MAFLD, Pakistan, lifestyle medication, side effects.

Validation of non-invasive tools for an assessment of liver fibrosis in MAFLD patients with obesity

Tonguk Teerasartipan1, Thaninee Prasoppokakorn1, Kanokwan Sonsiri1, Sombat Treeprasertsuk1

1Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Introduction: The role of non-invasive tests in the detection of liver fibrosis in obesity is controversial. We aimed to validate the performance of non-invasive tools evaluating liver fibrosis in obese MAFLD patients.

Methods: We retrospectively included 314 liver biopsy-proven MAFLD patients from the obesity clinic. Patients with BMI between 23-40 kg/m² and >40 kg/m² were classified as mild/moderate (n=159) and morbid obesity (n=155), respectively. Significant liver fibrosis was defined by METAVIR stage>2F2 and correlated with each non-invasive score.

Results: There were 61 (38.4%) and 17 (11%) patients with mild/moderate and morbid obesity had advanced liver fibrosis. FIB-4 score and APRI score had good performance in detecting significant liver fibrosis with AUROC of 0.702 and 0.708 for mild/moderate obesity and 0.710 and 0.738 for morbid obesity, respectively. For mild/moderate obesity, APRI≥1.5 and FIB-4≥2.67 had high positive predictive value (PPV) (83.3% and 75.0%) to rule in and APRI≥0.3 and FIB-4≥1.3 had high negative predictive value (NPV) (87.5% and 72.1%) to exclude significant liver fibrosis. For morbid obesity, none of the scores was sufficient to rule in significant fibrosis (PPV 9.3%-66.7%), oppositely all scores (FIB-4≥1.3, APRI≥0.3, NFS>1.455, BARD>2) had high NPV to exclude significant fibrosis (NPV 85.1%-93.3%).

Regarding the new score, SAFE (steatosis-associated fibrosis estimator) score≥100 had unsatisfactory performance in detecting significant fibrosis but SAFE score<0 was useful to rule out significant fibrosis.

Conclusions: FIB-4 and APRI scores were valid for liver fibrosis assessment in mild/moderate obesity, whereas current non-invasive scores had limited ability to detect liver fibrosis in morbid obesity. Further studies with a larger number of morbid obesity patients may be required.
Management, Ritsurin Hospital Takamatsu Japan, 1Department of Surgery, Ritsurin Hospital Takamatsu Japan, 2Department of Gastroenterology and Neurology, Kagawa University Faculty of Medicine Miki-cho Japan.

Background: We aimed to elucidate the clinical characteristics of non-obese patients with non-alcoholic fatty liver disease (NAFLD).

Methods: Fifty-seven NAFLD patients were enrolled in this study. Biochemical factors, body components and dietary nutrients were compared between obese and non-obese NAFLD patients at entry.

Results: Ten of the 34 (29%) males and eleven of the 23 (48%) females fulfilled the criteria of non-obesity, and six male patients and nine female patients were diagnosed as "hidden obesity". Serum urea acid levels and skeletal muscle indexes (SMIs) were significantly lower, and LDL-cholesterol levels tended to be lower in non-obese males than those in obese males. Ages at entry were significantly higher, and SMIs and bone mineral density were significantly lower in female non-obese patients compared to those in obese females. Carbohydrate intake tended to be higher in female non-obese patients than that in obese females. However, there were no significant differences in serum ALT levels and FIB4-indexes between obese and non-obese patients in both male and female.

Conclusion: These results suggest that non-obese NAFLD patients have a common characteristic of lower skeletal muscle mass in both male and female, and most of them fulfill the criteria of "hidden obesity". However, the pathogenesis of NAFLD may be slightly different between male and female non-obese patients.

Abstract Submission No. 200182
O-0432

Baseline fat deposition as no relation HCC occurrence but closely correlation non-HCC malignancy.

Shuntaro Obi1, 2, Mihoko Kanda1, Yosikazu Asahina1, Kowa Nagasaki1, Tomoyoshi Murata1, Kyoko Nakajima1, Hiroyuki Amano1, Shinya Takaoka1, Yushi Imai1, Yukiko Asakawa1, Sumio Hirose1, Hiroshi Ohyama6, Hitoshi Mochizuki8, Yukichiro Kojima1, Masao Omatu1, 5

1Department of Gastroenterology, Yamanashi Central Hospital, Yamanashi JAPAN, 2Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba JAPAN, 3Department of Gastroenterology, Chiba University, Chiba JAPAN, 4Department, Chiba University, Chiba, Japan, 5Genome Analysis Center, Yamanashi Central Hospital, Yamanashi JAPAN, 6Masao Omata1, 5

Objective: The purpose of this study was to investigate whether fat deposition in the liver contributes to the development of hepatocellular carcinoma (HCC) and malignant tumors other than HCC (non-HCC malignancy).

Methods: We are prospectively studying hepatitis C patients treated with DAA for the period 2013-2023. The primary endpoint was the occurrence of all malignancies. Patients were divided into 4 groups based on liver stiffness and fat deposition by Fibroscan (FS) before treatment (Group A: low stiffness and low fat, Group B: low stiffness and high fat, Group C: high stiffness and low fat, Group D: high stiffness and high fat). The incidence of HCC and non-HCC malignancy in each group was compared.

Results: All 689 patients were prospectively observed from the start date of DAA treatment until November 30, 2023. The median observation period was 6.0 years. During the observation period, 141 malignancies occurred in 128 patients. All patients were divided into groups A 334 (51%) / B 186 (27%) / C 96 (14%) / D 55 (8%) according to FS before DAA treatment. When comparing 5-year cancer-free survival rates for the low-fat group (A+C) to the high-fat group (B+D), HCC 90.6% vs 90.2% p=0.646, non-HCC malignancy 98.8% vs 87.2% p<0.001. On the other hand, when comparing the low hardness group (A+B) and the high hardness group (C+D) in terms of 5-year cancer-free survival, HCC 94.0% vs 77.5% p<0.001, non-HCC malignancy 95.6% vs 92.4% p=0.08.

Conclusion: Baseline fat deposition as no relation HCC occurrence but closely correlation non-HCC malignancy.

Abstract Submission No. 200207
O-0433

MASLD and the Risk of Mortality in Diabetic Patients: A Systematic Review and Meta-analysis

Wasit Wongtrakul1, Nathinee Charatcharoenwitthaya2, Phunchai Charatcharoenwitthaya1

1Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 2Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Thammasat University Pathumthani Thailand.

The systematic review aimed to assess the risks of metabolic dysfunction-associated static liver disease (MASLD) on all-cause and cause-specific mortality in patients with type 2 diabetes mellitus (T2DM). EMBASE and MEDLINE were searched from inception to June 2022 for observational studies examining the relationship between MASLD and the risk of mortality among T2DM patients. Meta-analysis was conducted using random-effects models with hazard ratios (HRs) to quantify the risk of mortality. A total of 5,877 articles were screened, and ultimately, 12 eligible studies encompassing 368,528 T2DM patients, with a median follow-up of 8.9 years (interquartile range, 4.7-14.5), were included. Our analysis revealed a significant association between MASLD and an increased risk of all-cause mortality in T2DM patients (HR 1.28; 95% CI, 1.05-1.58; I2 = 90%). Meta-regression analyses did not show significant effects of mean age, mean body mass index, and percentage of smokers, hypertension, and hyperlipidemia on the association between MASLD and the risk of all-cause mortality. However, we found that MASLD was not significantly associated with mortality related to cardiovascular diseases (HR 1.05; 95% CI, 0.82-1.35; I2 = 0%) or cancer (HR 1.21; 95% CI, 0.41-3.51; I2 = 79%) among patients with T2DM. No publication bias was observed. This comprehensive meta-analysis provides substantial evidence supporting a significant association between MASLD and an increased risk of all-cause mortality among the T2DM population. These findings underscore the benefits of screening for MASLD in T2DM patients, aiding in the early identification of high-risk individuals and enabling risk modification strategies to improve survival.

Abstract Submission No. 200264
O-0434

Ferritin as a biomarker on weight reduction

Adriana Martinez-Cuazitl1, 2, Marco A. Gallaga-Rojas3, 4, Armando Pereyra-Tlamantes1, Jesús E. Rodriguez-Silverio3, Stefanny Cornejo-Hernández1, Eira Cerda-Reyes1

1Research Department, Military Central Hospital Mexico Mexico, 2Escuela Militar de Medicina Mexico Mexico, 3Hospital Central Militar Mexico Mexico, 4Escuela Graduado de Sanidad-UDEFA Mexico Mexico.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with metabolic syndrome, weight loss showed an improvement in steatosis in obese patients, the main goal of MASLD treatment is to prevent hepatic fibrosis. Although the gold standard for hepatic fibrosis is biopsy, some non-invasive tools as MR elastography are used. The FIB4 index did not work to follow the fibrosis changes in time dependent after weight reduction therapy; also, CAP measure is useful to determinate steatosis; serum ferritin has been studied to assist with disease diagnosis and progression since it is an acute-phase reactant and a pro-inflammatory cytokine. The main goal of the study was to evaluate the changes on ferritin after the bariatric surgery and the correlation to CAP.

Thirty-three women elected to bariatric surgery was included on the study, they do not have any other hepatic diagnosis, it was registered the FIB4, CAP and serum ferritin before bariatric surgery and 6 months later. We analysed changes using T-student or Wilcoxon test, and the correlation using Spearman test.

After 6 months all women reduce weight, serum ferritin, CAP, FIB4. Ferritin reduces from 89 ng/ml (57.5, 106.5) to 89 ng/ml (48.5, 100), and CAP from 278 dB/m (242.5, 326) to 229 dB/m (205, 303), but there is not a correlation between CAP and ferritin before surgery or at 6 months.

Ferritin as a reactant to follow changes induced by weight reduction could be useful, at 6 months but it is necessary to corroborate histological changes, suggested by CAP measure.

Abstract Submission No. 100475
O-0439

Short-Term LMWH for The Prevention of Early TIPS Dysfunction: A Randomised Controlled Trial

Xiaoze Wang1, Xuefeng Luo1, Yi Shen1, Jinlin Yang1, Li Yang1

1West China Hospital, Sichuan University Chengdu China

Backgrounds: Transjugular intrahepatic portosystemic shunt (TIPS) dysfunction is secondary to occlusion or stenosis of the shunt. Whether post-TIPS low molecular weight heparin (LMWH) was necessary when the polytetrafluoroethylene-covered stent was used during TIPS creation was not answered. The present study evaluated the effect of short-term use of LMWH on early TIPS dysfunction.

Methods: Between September 2015 and October 2017, consecutive eligible patients with cirrhosis and portal hypertension were randomly assigned to receive LMWH for three days after the TIPS procedure (n = 62) or not (n = 62), respectively. All patients were followed up over twelve months. The primary endpoint was the TIPS patency rate at one year. Secondary endpoints were overall survival and LMWH-related complications. This trial was registered in ClinicalTrials.gov (NCT03171727).

Results: During a median follow-up of 54.6 months, the TIPS patency rate at one year was 91.7% in the LMWH group and 93.5% in the control group (HR 1.52, 95% CI 0.78-2.99, P = 0.22). In multivariable logistic regression, stent shortening in the hepatic vein (HR 4.54; 95% CI 1.02-21.42; P=0.041) was demonstrated as an independent significant risk factor for shunt dysfunction. There were no statistically significant differences in survival (93.5% vs. 95.1% at 1 year; HR = 1.05, 95% CI 0.48-2.31, P = 0.90) or adverse events between the two groups.

Conclusion: Short-term use of LMWH after TIPS creation may not be necessary as it does not result in a distinct patency and survival benefit in covered TIPS.

Abstract Submission No. 100561
O-0440

Gradual High Power Radiofrequency Ablation with Multi-electrodes for Small HCC: A Prospective Study

Jeong Min Lee1, Jaehyun Kim1, JeongHee Yoon1, Sungjun Hwang1

1Department of Radiology, Seoul National University Hospital Seoul South Korea

Background: Utilizing a separable clustered (SC) electrode and a two-channel 400W generator for gradual, stepwise high-power radiofrequency (RF) energy delivery significantly reduces electrode charring, enhancing targeted energy delivery to hepatocellular carcinoma (HCC), and potentially enhancing the efficacy and safety of radiofrequency ablation (RFA) for HCC.

Purpose: This study prospectively assesses the local tumor progression (LTP) and intrahepatic remote recurrence (IRR) rates of gradual, stepwise, high-power RFA in treating HCCs (≤4 cm).

Materials and Methods: Patients with single HCCs (≤4 cm) scheduled for treatment with RFA, were prospectively enrolled. The ablation procedure targeted the index tumor, guided by real-time US-CT/MR fusion imaging. A gradual, stepwise, high RF energy (~400W) alternately delivered to two of the three clustered electrodes. Technical success, complications, and cumulative incidences of LTP and IRR, along with RFS, were assessed and estimated using the Kaplan-Meier method.

Results: Among 110 participants (83 men and 27 women, mean age: 66.4±7.6 years), 116 HCCs (mean size: 1.65±0.59 cm) were treated with no major complications. LTP and IRR were observed in 4 and 29 patients, respectively. At a median follow-up of 41.0 months (range: 35.4-46.6 months), the estimated 1-year, 2-year, and 3-year cumulative incidences were as follows: LTP (0.9%, 3.6%, 7.0%) and IRR (13.9%, 20.5%, 31.4%). The corresponding RFS rates were: LTP (99.1%, 96.4%, 93.0%) and IRR (86.1%, 79.5%, 68.6%).

Conclusions: A gradual, incremental high-power RFA using an SC electrode demonstrates a promising, effective, and safe method for the management of small HCCs.

Abstract Submission No. 101292
O-0441

Three-dimensional Ultrasound Fusion Imaging in Precise Ablation of Hepatocellular Carcinoma

Guangliang Huang1, Xiaoyan Xie1, Jiaming Liu1

1The First Affiliated Hospital of Sun Yat-Sen University Guangzhou China

Purpose: To investigate the value of three-dimensional ultrasound fusion imaging (3DUS FI) technique in thermal ablation of hepatocellular carcinoma (HCC).

Methods: A total of 57 patients with 60 HCCs with 3DUS FI-guided thermal ablation were retrospectively included in the study. 3DUS volume data of liver were acquired preoperatively by freehand scanning with the tumor and predetermined 5 mm ablative margin automatically segmented. Plan of needle placement was made through a predetermined simulated ablation zone to ensure a 5 mm ablative margin with the coverage rate towards tumor and ablative margin. With real-time ultrasound and 3DUS fusion imaging, ablation needles were placed according to the plan. After ablation, the ablation margin was immediately evaluated by the contrast-enhanced ultrasound and 3DUS fusion imaging. The rate of intraoperative supplementary ablation, [g/h] adequate ablative margin, complete response (CR), local tumor progression (LTP), recurrence-free survival (RFS) and overall survival (OS) was evaluated.
Results: According to postoperative contrast-enhanced CT or MR imaging, the complete response rate was 100% (60/60), and 83% of tumors (50/60) achieved adequate ablative margin (> 5 mm) three-dimensionally. During follow-up period of 6.0-42.6 months, LTP occurred in 5 lesions, with 1- and 2-year LTP rates to be 7.0% and 9.4%. The 1- and 2-year OS rates were 76.1% and 65.6%, and 1- and 2-year OS rates were 98.1% and 94.0%. No severe complications or ablation-related deaths were observed in any patients.

Conclusions: 3DUS FI technique may improve the needle placement of thermal ablation for HCC and reduce the rate of LTP.

Abstract Submission No. 101355
O-0442

Evaluation of RFA Therapeutic Effect Using Workstation

CHIKARA OGAWA1,2, KUDO MASATOSHI2, TAKUSHI MANABE1, MITSUSHIGE SHIBATOGE1
1Department of Gastroenterology and Hepatology Takamatsu Japan, 2Kindai University Faculty of Medicine Osaka Japan

It is important to have a larger area of ablation than the tumor and to determine the therapeutic effect of RFA in an objective and reproducible manner. In general, a comparison of CT or MRI before treatment and CT or MRI after treatment is often used to determine the therapeutic effect of RFA. However, due to differences in breath-hold, modalities, etc., it is difficult to accurately determine the treatment effect.

The workstation used in this study was a VINCENT, called SYNAPSE 3D internationally. Workstation SYNAPSE 3D is commonly used in many hospitals all over Japan.

With Synapse 3D, the tumor and post-treatment ablation area can be easily extracted. The region can be extracted automatically by dragging the diameter of the tumor and the whole tumor to be extracted in either the axial, sagittal, or coronal plane.

It is very important to tightly adjust the position of images of CECT or MRI before and after RFA to evaluate RFA response including safety margin. To evaluate current RFA response, you can just click on three corresponding points in the images of CECT or MRI before and after RFA.

And then, push the execute 2D registration, Synapsee 3D automatically adjusts instantly and easily. So, we can estimate the correct treatment response of RFA without being distracted by the difference in position between the two images.

Abstract Submission No. 101590
O-0443

Analysis of infectious complications after ablation of HCC and the impact on long-term survival

Ming Xu1, Yutong Zhang1, Xiaoyan Xie1
1Department of Medical Ultrasonics, the First Affiliated Hospital, Sun Yat-Sen University Guangzhou China

Purpose: This study aims to complete and detailed record of the clinical characteristics and treatment of HCC patients with post-ablation infection and evaluate the infections on recurrence-free survival (RFS) and overall survival (OS).

Methods: 3117 patients with liver tumors receiving thermal ablation from January 2010 to December 2021 were analyzed. A total of 49 patients with infectious complications after thermal ablation were selected as the infection group. 49 patients without postoperative infection were randomly selected among those who underwent ablation within three days as the control group. Clinical characteristics of both were analyzed by independent sample T-test and chi-square test. The recurrence-free survival and overall survival were compared between patients with and without infection complications by Kaplan-Meier method and COX survival analysis. Subgroup analyses of mild and severe infections were conducted to further explore the infection-related situation.

Results: Between mild and severe infection groups, there were statistically significant differences in infection position (P=0.043), positive rate of body fluid culture (P=0.002), the proportion of catheter drainage (P=0.017), use of advanced antibiotics (P=0.006) and outcome (P=0.00). Kaplan-Meier survival analysis revealed that postoperative infection was significantly correlated with tumor recurrence (P=0.028) and severe infection was significantly associated with overall survival (P=0.049). The cox model showed that postoperative infection was an independent variable of RFS deterioration (HR=1.745; 95% CI=1.054-2.891; P=0.031).

Conclusion: Postoperative infection among patients receiving thermal ablation adversely affected tumor progression. Empirical antibiotics and catheterization to reduce pressure inside the lesion should be utilized to minimize symptoms in patients with postoperative infection.

Abstract Submission No. 101625
O-0444

The facts of ablation for liver cancer in patients aged ninety and above in our hospital.

Maki Tobarı1, Takuya Watanabe1, Hisafumi Yamagata1, Hiroaki Nagamatsu1, Hitoshi Maruyama1, Shuichiro Shiina1
1Department of Gastroenterology, Juntendo University School of Medicine Tokyo Japan

Purpose: In the context of Japan’s super-aging society, characterized by a growing population of very elderly individuals, this study investigates the safety and challenges associated with liver cancer ablation in patients aged 90 and above.

Methods: The subjects were 28 patients aged 90 and above who underwent radiofrequency or microwave ablation for liver cancer at our hospital from 2017 to 2023. We evaluate the characteristics of them.

Results: The cohort consisted of 13 females and 15 males, median age 91 (90-96), 25 HCC and 3 metastatic liver cancer, mean number of treatments 1.8 times. Pretreatment performance status was 0-1, 23, 2:5. Three patients had dementia. Prognosis was 11 survival, 6 death(liver-related death;1, other diseases;2, unknown;3), 11 discontinuation. Because some patients received multiple ablations, total ablations were 51. Evaluation in 51 cases from here. The mean number of ablated tumors:1.65, median diameter:16mm, RFA/MWA:21/30. All patients treated under sedation with midazolam (median 3mg). Poor awakening was observed in 9. Thirteen patients deviated clinical path(complications;3, additional ablation;2, decreased ADL;2, develop other disease;4). Three treatment-related complications occurred (hemothorax, liver abscess, portal vein thrombus).

Discussion: Patients aged over 90 who received ablation had good PS and liver function. A relatively large number of patients had poor arousal despite the use of low-dose sedatives, deviated from the clinical path due to decline in ADLs or development of other disease, or had difficulty attending the hospital. Complications were observed in 5.8%, but no serious complications were observed.

Conclusion: It became clear that ablation could be performed safely even in very elderly patients.

Abstract Submission No. 101832
Combined percutaneous RFA and ethanol injection for HCC with portal vein tumor thrombus

Baoxian Liu1, Yan Tan1
1National Cancer Center of Mongolia Ulaanbaatar Mongolia, 2Interventional Radiology, National Cancer Center of Mongolia Ulaanbaatar Mongolia

Abstract Submission No. 101978
O-0446

MICROWAVE ABLATION COMPARED WITH RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA IN MONGOLIA

Tsendjav Tsogtbaatar1, Yumchinserechin Narangerel1, 2
1National Cancer Center of Mongolia Ulaanbaatar Mongolia, 2Interventional Radiology, National Cancer Center of Mongolia Ulaanbaatar Mongolia

Abstract Submission No. 200191
O-0447

A Novel Ultrasound Modality to Monitor and Visualize Ablation Area based on Real-time imaging

1Techsomed Medical Technologies Ltd. Rehovot Israel, 2Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of TokyoThe University of Tokyo Tokyo Japan, 3Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Tokyo Japan, 4Department of Radiology, The University of Tokyo Tokyo Japan

Objective: Image-guided radiofrequency ablation is a well-established treatment for hepatocellular carcinoma. This study aimed to evaluate the predictive accuracy of BioTrace, a novel software utilizing B-mode ultrasound to classify the local changes in tissue viability in real-time, during liver ablation procedure.

Methods: The software provides an estimation of the ablation zone immediately post ablation (BioTrace Map) that correlates to the ablation zone as visualized in a 24-hour post-procedure (T=24) CECT scan. A comparison was carried out between the BioTrace Map based on B-mode ultrasound to that annotated by radiologists using contrast-enhanced CECT 24-hours after treatment, which is considered as the Gold Standard, for a total of 20 liver tumors. This comparison utilized the Dice Coefficient, Sensitivity, and Precision metrics.

Results: The median Dice Coefficient, Sensitivity, and Precision between BioTrace Map and the ablation zone visualized on T=24 CECT reached 90.3±2.2%, 90.3±4.5% and 90.1±4.4%, respectively. The intra-rater correlation presented excellent agreement between the findings of BioTrace and the radiologists regarding the volume size (0.98). Bland-Altman plot showed no evidence of systematic or proportional biases.

Conclusion: BioTrace used to visualize the ablated area reproduced the true ablated area as effectively as that by radiologists using post-operative CT. This system could ensure safe and effective ablation procedures in the future. Meaning, the software can accurately predict the ablation zone as would be visualized on T=24 CECT, based on real-time ultrasound imaging, and provide physicians with adjunctive...
information regarding the final ablation zone size and shape, as part of their overall clinical assessment.

Abstract Submission No. 101204
O-0448

Novel real-time ultrasound-based software for ablation zone prediction following liver MWA

Yossi Abu1, Shuichiro Shiina2, Hitoshi Maruyama2, Maki Tobari2, Yuko Hijioka2, Hiroaki Nagamatsu2

1Techsomed Medical Technologies Rehovot Israel, 2Department of Gastroenterological Imaging and Interventional Oncology, Juntendo University Tokyo Japan

Objective: This study aimed to demonstrate the effectiveness of BioTrace, an algorithm-based imaging software, in estimating the ablation zone in liver MWA procedures using real-time ultrasound. The software provides an estimation of the ablation on the procedure day that shows a high level of agreement with the results of a CECT scan acquired 24 hours post-ablation.

Methods: We conducted a prospective single-arm trial on tumors undergoing ultrasound-monitored MWA with a single antenna. A CECT scan was obtained for each patient the day post-ablation (24h±4h, or T=24). The software produced a 2D BioTrace map (BTM) based on the ultrasound’s field of view along the needle plane. The BTM results were then compared to the T=24 CECT segmented ablation zone in the oblique plane corresponding to the ultrasound plane. This comparison utilized the Dice Coefficient, Sensitivity, and Precision metrics.

Results: The average Dice Coefficient between the BTM and T=24 CECT ablation zone was 89.3% (STD 2.9%), indicating a strong correlation between the two areas. The averaged Sensitivity and Precision values were 85.5% (STD 6.6%) and 94.1% (STD 5.7%), respectively. These results underscore BTM’s capability to accurately detect the ablation zone based on real-time ultrasound imaging during the procedure.

Conclusions: The BioTrace is effective in providing a close estimation of the ablation area as will be seen on the T=24 CECT, based on real-time ultrasound imaging thus can provide physicians with adjunctive information regarding the final ablation zone size and shape, allowing more accurate understanding of the ablation outcomes on procedure day.

Abstract Submission No. 101372
O-0449

Resection vs. RFA in Small and Large HCC: A Meta Analysis of Randomized Controlled Trial

Maria Teresa1, Refael Alfa Budiman1, Rino Alvani Gani1

1Hepatobiliary Division, Cipto Mangunkusumo General Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia

BACKGROUND: While Radiofrequency Ablation (RFA) is often applied for nodules under 3 cm, some studies have demonstrated a favorable tumor response for larger nodules. This study aims to compare the efficacy of RFA and resection in HCC patients, considering nodule size with a cutoff at 3 cm.

METHOD: Using the PRISMA guidelines, comprehensive search was performed on seven databases. Small nodule was defined as ≤ 3 cm and large nodule as > 3 cm. All eligible studies were assessed using Cochrane RoB 2 for RCT. The pooled effect sizes were calculated using DerSimonian-Laird random-effects model and heterogeneity was investigated using Cochran’s Q test. Fixed-effect model was used and meta analysis was conducted using RevMan 5.4 software.

RESULT: A total of 5 studies, including 1046 patients were eligible for analysis. Overall survival and recurrence free survival in RFA and resection group were not statistically significant with hazard ratio (HR): 0.99; 95% CI 0.83, 1.19; p=0.96; I²=0% and HR: 1.07; 95% CI 0.93, 1.23; p=0.34; I²=0%, respectively. Subgroup analysis by nodule size also yielded similar findings. RFA and resection group also had similar recurrence rate with odds ratio (OR): 1.13; 95% CI 0.85, 1.49; p=0.41; I²=0%. Analysis of extrahepatic and intrahepatic recurrence found no significant difference between RFA and resection group.

CONCLUSION: In small or large nodule HCC, the efficacy of RFA and resection is similar. Additional considerations may be taken into account when choosing between RFA or resection in such condition.

KEYWORD: RFA; resection; HCC; small nodule; large nodule

Abstract Submission No. 101677
O-0450

Introduction of a safe device “Gangi-HydroGuard” for artificial pleural effusion and ascites in RFA

Takuto Yoshioka1, Hidea Mori1, Yuki Yamamoto1, Miho Hirai1, Gaku Okuno1, Iori Yagura1, Shohei Nakamori2, Taishi Matsumura1, Takashi Tamada1, Naoki Kanda1

1Takatsuki Red Cross Hospital Takatsuki Japan

Recently, SURF trial from Japan showed the efficacy of radiofrequency ablation (RFA) for 3 or less hepatocellular carcinomas (HCC) under 3cm equivalent to surgery. For a safe and secure RFA, artificial pleural effusion and ascites are effective, when HCC is located in the surface of liver or is adjacent to other organs. We report the features of a coaxial needle with spring loaded blunt tip stylet “Gangi-HydroGuard” and show our earlier HCC cases using this device.

We analyzed the success rate, adverse events, and recurrent rate in early 10 HCC cases from July 2021 when we introduced the procedure of artificial pleural effusion and ascites to Takatsuki Red Cross Hospital.

Six males and 4 female of median age 84 (48-87) were included. First, artificial pleural effusion was performed for 7 HCCs with average size 21.9mm (7-31) located in S8 or S5. Second, artificial ascites was performed for 3 HCCs with average size 23.7mm (16-35) located in S3 or S5. We succeeded the procedures in all cases, however in 1 case, the first puncture was difficult in penetrating peritoneum and the second puncture was succeeded. No adverse events were occurred except for 1 case with a temporary decrease of the oxygen concentration, after artificial pleural effusion was performed. We experienced a recurrence of HCC in 1 case of size 35mm located in S3 with the artificial pleural effusion.

We could safely introduced the procedures of artificial pleural effusion and ascites in RFA with “Gangi-HydroGuard”. 

Abstract Submission No. 101730
O-0451

Percutaneous Liver Biopsy in the Era of Clinical sequence: Usefulness of Full-core Biopsy Needle

Souta Kimura1, Shin-ichi Wakabayashi1, Takefumi Kimura1, Tadanobu Iwadare1, Taiki Okumura1, Hiroyuki Kobayashi1, Yuki Yamashita1, Takeji Umemura1

1Hepatobiliary Surgery Section, Department of General Surgery, Nagoya University Graduate School of Medicine Nagoya Japan
Indocyanine green fluorescence-guided laparoscopic deroofing for giant hepatic cyst

Sadahito Iseki1, Takeshi Aoki1, Hideki Shibata1, Tatsuya Yamazaki1, Kazuhiko Saito1, Hiroshi Uchida1, Takahiro Hirai1, Ryohei Yamazaki1, Kazuhiko Saito1, Marie Uchida1, Takahito Hirai1, Makoto Watanabe1

1Division of Gastroenterological and General Surgery, Department of Surgery, School of Medicine, Showa University, Tokyo, Japan

Background: Laparoscopic deroofing (LD) has recently been considered a standard procedure for giant liver cyst, although it has the risk of postoperative bile leakage. The line of resection is ambiguous and there is a risk of biliary fistula if it enters the liver parenchyma. To determine the line of resection, we performed Indocyanine green (ICG) fluorescence-guided LD.

Methods: This was a retrospective study including 29 patients who underwent LD between April 2013 and October 2023 at our institute. These enrolled patients were divided into an ICG group (n = 7) and a white light group (n = 22).

Results: There were no significant differences among age, gender, maximum tumor size, estimated blood loss and postoperative hospital stay. There was one case of postoperative bile leakage in the ICG group, though there was no significant difference.

There were two cases to detect the bile leakage in real time at ICG group. Fluorescent bile juice was detected from the resection line intraoperatively and we could suture of the area and fix them. These cases were discharged without complications.

Conclusion: ICG fluorescence-guided LD may offer clinical benefits to avoid bile duct injury. It is useful in determining the line of dissection and can also avoid the bile leakage.

Abstract Submission No. 101796
O-0452

Indocyanine green fluorescence-guided laparoscopic deroofing for giant hepatic cyst

Sadahito Iseki1, Takeshi Aoki1, Hideki Shibata1, Tatsuya Yamazaki1, Kazuhiko Saito1, Marie Uchida1, Takahiro Hirai1, Kodai Tomioka1, Yoshihiko Tashiro1, Hiromi Date1, Ryohi Watanabe1, Kazuhiko Matsuda1, Tomokazu Kusano1, Kimiyasu Yamazaki1, Makoto Watanabe1

1Division of Gastroenterological and General Surgery, Department of Surgery, School of Medicine, Showa University, Tokyo, Japan

Background: The advancement of cancer genomic medicine has emphasized the importance of liver tumor biopsy and clinical sequencing. Tissue collection devices are broadly classified into aspiration-biopsy and cutting type, and the cutting type is further divided into sidecut-biopsy needle and full-core biopsy needle. Recently, the usefulness of the full-core biopsy needle has been reported, but there have been few reports comparing the clinical sequence with each method. In the present study, we retrospectively evaluated the eligibility of various testing devices and the clinical sequence.

Methods: We included 20 liver tumor biopsies submitted to clinical sequence among the liver tumor biopsies performed at our institution from 2019 to 2023. The clinical sequence eligibility of the specimens collected and the safety of the procedure were reviewed.

Results: The median age of patients was 68 years, with 55% being male. Biopsies were performed using aspiration-biopsy needles (Surecut®18G) in 4 cases, sidecut-biopsy needles (Monopty®18G) in 7 cases, and full-core biopsy needles (CorvoCut®18G) in 9 cases. Ineligibility for clinical sequencing was observed in two cases using aspiration-needles and one with a sidecut-needle. In contrast, specimens from all full-core needle biopsies were eligible. No complications were reported in any of the biopsy procedures. Although the cutting type biopsy needles tended to require fewer biopsies for adequate tissue collection, this difference was not statistically significant. No needle type showed complications requiring treatment.

Conclusion: The full-core biopsy needle provided a clinical sequence-eligible tissue sample that was comparable to or better than existing methods for liver tumor biopsies.

Abstract Submission No. 200052
O-0454

Accessing and Predicting Liver Function by Elastography: 1-year Follow-up in HCC Ablation Patients

Jiayao Huang1, Xiaoyan Xie1, Manxia Lin1

1Sun Yat-sen First Affiliated Hospital Guangzhou China

Aim: The present study aims to investigate the changes in liver function and liver stiffness (LS) measured by two-dimensional shear wave elastography (2D-SWE) before and after ablation in patients with hepatocellular carcinoma (HCC), and to explore the feasibility of using LS before and after ablation as a means to assess and predict liver function, gaining a better understanding of the impact of ablation on liver function and LS’s potential as a diagnostic tool for HCC patients.

Material and Methods: From March 2022 to December 2023, 101 patients with treatment-naïve HCC and undergoing ablation were retrospectively enrolled and followed-up for one year. Data including LS and indicators of liver function were collected at pre-operative period and post-operative 1 month, 3 months, 6 months, and 12 months, respectively. Statistical analysis was conducted to explore the correlation between LS and liver function during the follow-up.
Results: Among the enrolled patients, 69 (68.3%) underwent percutaneous radiofrequency ablation, 23 (22.8%) underwent percutaneous microwave ablation, and 9 (8.9%) cases underwent other methods of ablation (such as laparoscopic ablation). Using pre-operative LS as the baseline, paired t-test showed that LS slightly increased at 1 month post-operatively and then decreased (all p<0.050). This trend was similar to the changes in liver function before and after ablation. There was a significant correlation between pre-operative LS and liver function (represented by Child-Pugh and ALBI scores) at pre-operative period and post-operative 1, 3, 6, and 12 months (all p<0.050). Additionally, LS at 1, 3, and 6 months post-operatively was significantly correlated with the immediate post-operative liver function (all p<0.050).

Conclusion: LS is expected to become a powerful tool for assessing and predicting liver function in HCC ablation patients, which could help alleviate the burden of follow-up examinations to some extent.

Abstract Submission No. 200064
O-0455

Safety and efficacy of MVA of multiple lesions in multiple Lung Metastasis of Colorectal Cancer
Rong Ding1, Jinfeng Bai2, Bohan Song1
1Yunnan Cancer Hospital Kunming China

Objective: This study aims to retrospectively analyze the safety and effectiveness of microwave ablation (MWA) in treating multiple lung metastases from colorectal cancer.

Approaches: A retrospective analysis was conducted on the clinical data of patients with colorectal cancer multiple lung metastases who underwent MWA treatment at Yunnan Cancer Hospital from January 2020 to December 2022. The main objective of the study was to determine the median overall survival (mOS), while additional objectives included assessing the median progression-free survival (mPFS), technical success rate, and complication rate. The statistical analysis involved the utilization of the log-rank test and the Cox proportional risk regression model.

Outcomes: There were 50 patients with numerous lung metastases from colorectal cancer who received MWA treatments. The overall mOS time for all patients was 26 months, with a 95% confidence interval (CI) ranging from 20.93 to 31.10 months. Similarly, the mPFS time was 23 months, with a 95% CI ranging from 16.76 to 29.24 months. Furthermore, the group that underwent single MWA showed a superior mOS compared to the group that underwent fractionated MWA. The hazard ratio (HR) was 4.756, with a 95% confidence interval (CI) of 1.076 to 21.033, and a p-value of 0.04.

Conclusion: MWA is a secure and efficient method for treating numerous metastases of colorectal cancer in the lungs. For one side of the lung, numerous metastases can be treated with a single, divided ablation procedure that targets many points. Further investigation is required to determine the efficacy of ablating numerous metastases in both lungs while ensuring safety.

Abstract Submission No. 200082
O-0456

THE ROLE OF CARTO IN PORTAL HYPERTENSION WITH RECURRENT UPPER GI BLEEDING FROM LARGE GASTRIC VARICES
Mateo III Te1, Mara Teresa T. Panlilio2
1UUniversity of the Philippines - Philippine General Hospital Manila Philippines, 2University of the Philippines - Philippine General Hospital Manila Philippines

A 26-year-old, female with no co morbidities and unremarkable perinatal, personal, family, and OB Gyne history presented with melena associated with body weakness. She was hospitalized with a hemoglobin of 3 g/dL and was transfused with 7 units packed RBC. Emergency upper endoscopy revealed small esophageal varices and large gastroesophageal varices (GOV2) which was treated with injection of histoacryl glue to the gastric varices. After the bleeding was controlled, she was started on beta blockers and was advised further work up. Work up revealed non-reactive hepatitis B and C profile and a considderation of portal thrombosis and portal cavernoma on CT scan. Hematology service was on board to rule out hematologic causes of portal thrombosis. Work up were all unremarkable for ANA, anti-DsDNA, APAS panel, clotting factor II and V PCR, and JAK 2 mutation by PCR. On the following months, the patient had multiple recurrences of melena and hematochezia requiring massive blood transfusions and emergency endoscopic glue injections. A multi-disciplinary team meeting consisting of hepatology, interventional gastroenterology, hepatobiliary surgery, and interventional radiology was held to discuss the best acceptable management for the patient. The consensus of the meeting was to do a Coil-Assisted Retrograde Transvenous Obliteration (CARTO) to control the portal hypertension and subsequently the bleeding varices. The patient consented to the plan offered by the team and underwent CARTO successfully. On follow up; there was no longer recurrence of GI bleeding and laboratories are within normal. The patient was advised for surveillance endoscopy and liver function tests monitoring.

Abstract Submission No. 200117
O-0457

Efficacy of EmprintTM Ablation System for Perivascular Hepatocellular Carcinoma
Xuan Yu1, Kai Li1
1The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Background: Conventional microwave ablation encounters major challenges with unpredictable and inconsistent ablation zones, particularly in dynamic tissue environment near intrahepatic blood vessels. The EmprintTM system with thermosphere technology offers a potential solution to this issue. This retrospective study assesses the effectiveness of the EmprintTM ablation system in treating hepatocellular carcinoma (HCC), emphasizing outcome comparisons between perivascular and non-perivascular cases.

Methods: From January 2019 to September 2022, 135 HCC patients underwent Emprint™ microwave ablation were enrolled. Cases were categorized into perivascular (N=109) and non-perivascular (N=26) groups based on tumor proximity to intrahepatic vascular. Propensity score matching (PSM) was then applied to balance the baseline characteristics between two groups. The 1-year post-ablation intrahepatic tumor recurrence rates and major complications rates were subsequently analyzed.

Results: The 1-year post-ablation intrahepatic tumor recurrence rates were lower in the perivascular group compared to non-perivascular cases in the overall cohort (7.7% vs. 15.6%, P=0.529) and in the PSM cohorts (8.7% vs. 14.8%, P=0.714). The major complication rate in the non-perivascular group was [3.7% (4/109)] in the total cohort and [5.6% (3/54)] in the PSM cohort. No complications were observed in the perivascular group.

Conclusions: The Emprint™ microwave ablation system demonstrated compelling efficacy with reduced tumor recurrence and
complication rates in the management of the previously challenging perivascular HCC lesions. These encouraging results position the Emprint™ system as a promising and viable treatment option for patient with perivascular HCC.

Abstract Submission No. 200229
O-0458

AI Based Tumor Progression Prediction following Hepatocellular Carcinoma Ablation

Tom Edlund1, Masaya Sato2,3, Ryosuke Tateishi3, Jiro Sato4, Takeyuki Watadani5, Taijiro Wake1, Ryo Nakagomi3, Takuma Nakatsuka1, Tatsuya Minami2, Koji Uchino5, Kenichiro Enoku1, Chao-Chun Chuang3, Yu-Chia Su1

1Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo Tokyo Japan, 2Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo Tokyo Japan, 3Sheba Medical Center Ramat Gan Israel Purposes: to explore new tumor progression predictors that are more accurate and robust than minimal ablative margin (MAM) and to evaluate a novel, AI based, fully automatic, 3D software for tumor coverage assessment and tumor progression prediction.

Materials & Methods: Single-center retrospective single-arm study. 216 patients underwent radiofrequency ablation to treat HCC. Tumor progression was defined as residual unablated tumor or local tumor progression (LTP), which was based on a CECT scan 24 hours post procedure. The study assessed a novel fully automatic 3D software for ablation outcome assessment and the LTP predictive power of a novel metric named weighted relative ablated target (WRAT). The LTP predictors were compared using the area under curve of the receiver operating characteristic curve.

Results: The area under curve of the receiver operating characteristic curve results for the evaluated LTP predictors: human expert MAM, fully automated MAM and fully automated WRAT are 70.9%, 78.4% and 81.7% respectively.

Conclusions: The study results indicate that our AI based fully automatic SW using deformable registration is more effective in predicting fully automated MAM and fully automated WRAT are 70.9%, 78.4% and 81.7% respectively.

Abstract Submission No. 100530
O-0460

IMPACT OF SAMPLE VARIABILITY OF LIVER NEEDLE BIOPSIES ON FIBROSIS ASSESSMENT

Yayun Ren1, Kutbuddin Akbary1, Elaine Chng1, Dean Tai1, Jonathan A. Fallowsfield2, Timothy J. Kendall2, Nikolai V. Naoumov3, David E. Kleiner4, Arun J. Sanyal5

1HistolIndex Pte Ltd Singapore Singapore, 2Centre for Inflammation Research, University of Edinburgh Edinburgh United Kingdom, 3London United Kingdom, 4Laboratory of Pathology; Center for Cancer Research, National Cancer Institute, National Institutes of Health Bethesda United States, 5Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Virginia Commonwealth University School of Medicine Richmond United States

Introduction: Variability in fibrosis assessment due to needle positioning in liver biopsy is currently under-evaluated. This study investigates the influence of positional and rotational variability on the accuracy of fibrosis assessment using Second Harmonic Generation/Two Photon Excitation (SHG/TPE) microscopy and artificial intelligence (AI)-based analysis.

Methods: 100 liver resection and explant samples, covering NAS-CRN stages F0-F4, were evaluated by SHG/TPE microscopy. The virtual needle biopsies (width 0.9mm and length 15mm) were taken from each sample. Rotational and positional variability introduced through rotation angles at 20⁰ intervals and varying tissue positions within samples respectively. qFibrosis assessment was performed for all virtual needle biopsies and the whole tissues. The analysis employed linear weighted kappa (LWK), Obuchowski-index (multinomial version of AUROC), Spearman’s correlation to evaluate accuracy and agreement of assessments.

Results: The Obuchowski-index of qFibrosis continuous value was 0.92-0.95 for rotation variability, 0.90-0.95 for position variability. There was substantial agreement between qFibrosis stage and pathologist readings (LWK=0.70-0.81 rotation variability,
LWK=0.68-0.79 position variability). Correlation of total fibrosis area between virtual biopsies and whole tissues was strong for rotation variability (r-value=0.85-0.89) and position variability (0.82-0.92). Fibrosis area in portal tract, peri-portal, and zone 2 regions exhibited higher correlation (mean r-value=0.87) compared to central vein and peri-central regions (mean r-value=0.55) between virtual biopsies and whole tissues.

Conclusions: Positional and rotational variabilities had no significant impact on liver fibrosis assessment using qFibrosis. The strong correlation between virtual biopsies and whole tissue fibrosis evaluation using SHG/TPE microscopy further support qFibrosis as a reliable method for quantitative fibrosis assessment.

Abstract Submission No. 100883
O-0461

Understanding early stage-fibrosis in KBI-NASH non-human primate model using AI digital pathology

Desiree Abdurrachim¹, Charlene Z L Ong¹, Ashmita Saigal², Yongqi Zhou¹, Muhammad R A Yahya¹, Christopher Hendra¹, Samata Kakkad², Radha Krishnan³, Annaswamy Raji³, Thomas Forest⁴, Shubing Wang⁵, Richard Baumgartner⁶, Chih-Liang Chiu⁷, Saswata Talukdar⁷, Asad A A Ali³

¹MSD Singapore Singapore, ²Merck & Co., Inc., South San Francisco, CA USA, ³MSD London UK, ⁴Merck & Co., Inc., Rahway, NJ USA, ⁵Merck & Co., Inc., West Point, PA USA

Background: Liver biopsy specimens contain abundant information on liver microenvironment, which may offer novel biological insights into disease progression/regression. Here, we investigated changes in liver microenvironment features during early development of NASH.

Methods: We evaluated 11 paired liver biopsies from NASH-NHP model developed by Kunming Biomed International (KBI), at >2 years after high-fat diet (baseline) and at the following 12 weeks, using Histolindex AI digital pathology platform, which combines a novel imaging technique based on Second Harmonic Generation/Two-Photon Excitation Fluorescence and a proprietary image analysis to quantify zone-specific fibrosis and steatosis features.

Results: At baseline, most animals exhibited steatosis (median of 3 pathologist’s grade S0: 1/11, S1: 3/11, S2: 4/11, S3: 3/11), without pathological fibrosis (F0: 10/11, F1: 1/11), which progressed at week 12 (F0 to F1: 3/11, F0 to F2: 6/11). The progression was characterized by a high PS steatosis activity, with increased macrosteatosis (P=0.04 vs. baseline) and PS fibrosis (P=0.05 for most features of aggregated fibrosis, vs. baseline). Increased steatosis-colocalized fibrosis was also observed (P=0.03 vs. baseline), which suggests a metabolic contribution to the early-stage fibrosis in this model. Unsupervised clustering revealed 3 patterns of disease progression: (1) worsened PS fibrosis with mildly increased PT, (2) mildly increased PS fibrosis, (3) markedly increased CV fibrosis.

Conclusion: Our study demonstrated the metabolic relevance of KBI-NASH-NHP model and the utility of AI digital pathology in studying changes during the early-stage fibrosis. Future work includes validation in a larger dataset to elucidate key differentiators for progression at early-stage and late-stage fibrosis.

Abstract Submission No. 100889
O-0463

Assessment of resmetirom-mediated reductions in liver volume on fibrosis changes MAESTRO-NASH trial

Stephen A. Harrison¹, Rebecca Taub¹, Dominic F. Labriola², Elaine Chng³, Yayun Ren³, Dean Tai¹

¹Pinnacle Research, San Antonio Texas USA, ²Madrigal Pharmaceuticals Pennsylvania USA, ³Histoindex Pte. Ltd. Singapore Singapore

Background: MAESTRO-NASH, a phase 3 registrational non-cirrhotic NASH clinical trial achieved NASH resolution and fibrosis reduction endpoints on liver biopsy at 52 weeks. As an exploratory endpoint, artificial intelligence slide reading technologies were employed to measure the effect on fibrosis in serial liver biopsy using both continuous and quantitative scoring.

Method: Fibrosis was estimated as a continuous and categorical variable using second harmonic generation (SHG) (qFibrosis)/two-photon excited fluorescence of 768 paired biopsy samples from MAESTRO-NASH. A separate unstained slide was analyzed for qFibrosis [normalized by tissue area and then corrected for qSteatosis (tissue area-steatosis area)].

Results: Based on a continuous qSteatosis score, the % change from baseline in steatosis was 80 mg, -36%; 100 mg, -46%; placebo, -10%, p<0.0001 for both doses, the continuous change from baseline in corrected qFibrosis score was 80 mg, -22%; 100 mg, -20%; placebo, 3%, p<0.0001 for both. Based on categorical change in qFibrosis score, there was a significant improvement in fibrosis stage (1- or 2-stage improvement) at 80 and 100 mg relative to placebo, and less worsening of fibrosis in the resmetirom treatment groups compared with placebo (Table). The percentage showing improvement in qFibrosis (>1-stage) was higher than scored by pathologists and identified 90% of resmetirom responders.

Conclusion: Measurements of fibrosis change using qFibrosis on either a continuous or categorical scale demonstrated a clear improvement and less worsening in fibrosis in resmetirom treated NASH patients as compared with placebo after 52 weeks of treatment.

Abstract Submission No. 100985
O-0462

Artificial intelligence to measure fibrosis change on liver biopsy in the MAESTRO-NASH phase 3 trial

Stephen A. Harrison¹, Rebecca Taub², Dominic F. Labriola², Mustafa R. Bashir³, Elaine Chng³, Yayun Ren³, Dean Tai⁴

¹Pinnacle Research, San Antonio Texas USA, ²Madrigal Pharmaceuticals Pennsylvania USA, ³Center for Advanced Magnetic Resonance Development, Departments of Radiology and Medicine (Gastroenterology), Duke University Durham, North Carolina USA, ⁴Histoindex Pte. Ltd. Singapore Singapore

Background: MAESTRO-NASH, a phase 3 registrational non-cirrhotic NASH clinical trial achieved NASH resolution and fibrosis reduction endpoints on liver biopsy at 52 weeks, with resmetirom-treated patients achieving significant improvements in liver volume. In this analysis, we explored the effect of liver volume reduction on AI-based fibrosis assessment at the parameter-level.

Method: Quantified collagen parameters in the liver lobule regions were obtained from AI measurements of separate unstained slides using SHG/TPEF microscopy. Using liver volume from serial MRIs at baseline and week52 for 634 patients, a coefficient was applied to the AI-based collagen parameters to account for the liver volume reduction to analyse the impact on patients showing more than 10% relative reduction of collagen parameters.

Results: Both resmetirom doses revealed a larger percentage of patients showing more than 10% relative reduction of collagen parameters at the portal, peri-portal and zone 2 regions (Fig. A) (8 to 24%, p<0.01) compared to placebo. After applying the coefficient to account
for liver volume reduction with resmetirom treatment (Fig. B), the percentage of resmetirom-treated patients with more than 10% relative reduction of collagen parameters increased across all zones, notably at the portal, peri-portal and zone 2 regions (26 to 36%, p<0.01), and at the peri-central region (11 to 14%, p<0.05) in both resmetirom doses versus placebo.

**Conclusion:** Quantification of changes in NASH fibrosis are impacted by therapeutic interventions that alter liver volume. Correcting for liver volume reveals the greater impact of resmetirom with more pronounced regression patterns at the collagen parameter-level compared to placebo.

Abstract Submission No. 101079
*O-0464*

**The Deep Learning of Ultrasonography in Automatic Detection and Diagnosis of Liver Tumors.**

Chih-Horng Wu1,3, Jin-Chuan Sheu2,3, Hsiao-Ching Nien2,3
1National Taiwan University Hospital Taipei Taiwan, 2Good Liver Foundation Taipei Taiwan, 3National Taiwan University Taipei Taiwan

**Background:** Ultrasound (US) is the most common screening tool for hepatocellular carcinoma (HCC). However, the diagnostic performance of ultrasound is highly operator-dependent. We aimed to develop deep-learning models to detect and diagnose hepatic lesions automatically.

**Materials and methods:** We enrolled patients diagnosed with hepatic tumors by the abdominal US from January 2002 to December 2020 in a retrospective cohort with the diagnosis of malignant (HCC, cholangiocarcinoma, and metastasis) and benign lesions (hepatic cysts, hemangiomas, focal fatty sparing, focal nodular hyperplasia, and other benign findings). 1,576 patients with 4,600 images, and 6,001 lesions were analyzed. Deep learning models included ResNet50, Xception, Inception Resnet V2, and EfficientNet-B5 for non-real-time classification and YOLO v4 for lesion automatic detection and diagnosis.

**Results:** A total of 1,576 patients separated into 1,061 in training, 373 in validation and 142 in testing set. The AUC for ResNet50, Xception, Inception Resnet V2, and EfficientNet-B5 were 0.88, 0.89, 0.88, and 0.90. After the optimal threshold was selected in the base model of EfficientNet-B5, the accuracy, recall (sensitivity), precision and F1 score for the validation and testing dataset were 0.836, 0.837, 0.626, 0.716 and 0.699, 0.699, 0.289, 0.408. The mean Average Precision score to differentiate between malignant and benign lesions for YOLO v4 was 0.5441.

**Conclusion:** Our study provides the deep learning model with high accuracy in ultrasound differentiation and diagnosis of benign and malignant lesions. Furthermore, the Yolo-v4 model also demonstrates high performance in real-time automatic detection and diagnosis.

Abstract Submission No. 101309
*O-0465*

**Insights into Post-Hepatectomy Liver Failure Prediction with Interpretable Deep Learning Framework**

Xian Zhong1, Manxia Lin1, Xiaoyan Xie1
1The First Affiliated Hospital of Sun Yat-sen University Guangzhou China

**Purpose:** To develop an interpretable framework for understanding the predictions of the deep learning model for Post-hepatectomy liver failure (PHLF).

**Material and Methods:** A total of 345 consecutive patients were enrolled. We employed a variational autoencoder (VAE) to transform two-dimensional shear wave elastography (2D-SWE) images into latent space encodings, which were then used to train a multi-layer perceptron (VAE_MLP_SWE) model. Clinical variables were incorporated into the latent space to train a VAE_MLP_SWE_clinical model. Counterfactual explanations were generated by latent space traversal of the VAE to observe the change in 2D-SWE images with predicted probability. Layerwise relevance propagation (LRP) was used for global and local explainability with respect to SWE image and clinical variables.

**Results:** The VAE-MLP_SWE model showed a higher AUC (0.759) than the Densenet121 (0.745) and Resnet18 (0.703) models during five-fold cross-validation. The VAE_MLP_SWE clinical model demonstrated a significant improvement (p<0.05) in AUC (0.828) compared to clinical indices such as Child-Pugh score, ALBI score, and MELD score (AUC 0.529-0.684) on the test set. Qualitative analysis of counterfactual explanations generated for both VAE_MLP_SWE and VAE_MLP_SWE clinical revealed that clinically relevant semantic features were used for prediction. Quantitative evaluation of counterfactuals with different predicted probabilities revealed a consistent correlation with liver stiffness measurement. The global LRP analysis identified SWE image, future liver remnant volume (FLR), and albumin (ALB) as the most important features for PHLF prediction.

**Conclusion:** The proposed VAE-MLP framework offers insights into the decision-making mechanism of the deep learning model for prediction of PHLF with high accuracy.

Abstract Submission No. 101412
*O-0466*

**Finding Undiagnosed Hepatitis C Using a Machine Learning Algorithm: An Australian Pilot**

Linda Chen1, Heshaam Mir2, David Baker3, Shelley Kerr4, Jacqueline Richmond5, Rehan Ali5, Brittany Schoening5, John Rigg6, Chris Ng7, Bria Fergus8, Bruce Kreteler1
1Gilead Sciences Foster City United States, 2Gilead Sciences Melbourne Australia, 3East Sydney Doctors Sydney Australia, 4Australasian Society of HIV, Viral Hepatitis and Sexual Health Medicine Sydney Australia, 5Public Health, Burnet Institute Melbourne Australia, 6Predictive Analytics, Real World Solutions, IQVIA London UK, 7Real World Solutions, IQVIA Sydney Australia, 8Campbell University College of Pharmacy Buies Creek United States

**Background:** To validate an artificial intelligence (AI) algorithm capable of identifying patients in an Australian population who are undiagnosed with Hepatitis C Virus (HCV)

**Methods:** This study analyzed retrospective data from 371 Australian general practices’ electronic medical records (EMR) between 2017 and 2022, comprising 19 million patients. A high-performance machine learning model (XGBoost) was trained on deidentified clinical data to find undiagnosed HCV cases by using clinical predictors associated with HCV infection, then validated on a separate dataset. Algorithm performance was evaluated based on recall and fold improvement compared to standard screening methods recommended by the World Health Organization (WHO).

**Results:** The dataset contained 9 million deidentified patients aged >18 years who exhibited evidence of attending healthcare within a 24-month period. Of these, 2,515 patients were identified as HCV-positive. Table 1 shows the model performance compared to universal screening
and birth cohort screening. At 5% recall (the population with the highest predicted risk), the algorithm demonstrated a 116.5-fold improvement over universal screening, which is comparable to the performance of a previous US-based algorithm. As a point of comparison, the birth cohort (i.e., WHO recommendation to screen patients born between 1946-64) demonstrated a 2.2-fold improvement over universal screening. AUROC of the model was 0.735. Top predictors used by the model included age, gender, chronic liver disease, anti-anxiety medications, analgesics, bilirubin, and alanine transaminase (ALT).

Conclusion: This study demonstrates that our validated machine learning algorithm can identify undiagnosed HCV patients in Australia, and can improve patient screening efficiency.

Abstract Submission No. 101552
O-0467

Predictive validation of GLIM criteria for mortality in patients with cirrhosis: a machine learning

gao Yue Guo1, Sun Chao1

1Tianjin Medical University General Hospital Tianjin China

Background: Recently, a novel framework designated as GLIM criteria has been proposed to harmonize malnutrition diagnosis across distinct populations and disease settings. From the standpoints of predictive, preventive and personalized medicine, we sought to validate the prognostic performance and refine the best combinations of phenotypic and etiologic GLIM criteria associated with long-term mortality in patients with decompensated cirrhosis.

Methods: This retrospective observational study enrolled decompensated hospitalized patients with cirrhosis. The GLIM phenotypic criteria comprised unconscious weight loss, low BMI and low SMI, while etiologic criteria entailed reduced food intake or assimilation, disease burden indicative of high MELD-based scores, aggravating Child-Pugh classification and inflammation indicative of high NLR. Fifty GLIM combinations were examined according to the sensitivity, specificity, negative/positive predictive values along with a machine learning algorithm (Random forest).

Results: The sample consisted of 219 patients with decompensated cirrhosis; 50.7% females; a median age of 63 years. The prevalence of malnutrition varied from 3.7% to 45.7%. Cox regression indicated that 38 combinations were significantly associated with 1-year all-cause mortality with hazard ratios (HRs):≥2. Notably, the HRs of SMI.MELD, BMI.MELD, BMI.MELD3.0 were as high as 4.832, 4.497, 4.335, respectively. Random forest algorithm unraveled that SMI.MELD performed best for prediction.

Conclusions: The majority of GLIM combinations was linked to inferior outcomes in the context of decompensated cirrhosis. Our findings shed light on the predictive diagnostics, targeted preventive and individualized treatment to counteract distinctive malnourished features among hospitalized cirrhosis, which may improve outcomes, symptoms and quality of life and correct nutritional status.

Abstract Submission No. 101644
O-0468

Artificial intelligence assisted navigation surgery in laparoscopic liver resection.

Yoshihiko Tashiro1, Takeshi Aoki1, Nao Kobayashi2, Kodai Tomioka3, Kazuhiko Saito4, Takahito Hirai5, Tatsuya Yamazaki1, Hideki Shibata1, Kazuhiro Matsuda1, Tomokazu Kusano1, Shodai Nagaishi1, Yukari Shinhoara1, Koji Nogaki1, Akira Fujimori1, Yuta Enami1

1Department of General and Gastroenterological Surgery, Showa University School of Medicine, Tokyo Japan, 22. Anaut Inc. Tokyo Japan

Background and Objective: Recently, the prediction of anatomical structures by artificial intelligence (AI) is expected to support surgeons as navigation tool. We reported AI system can recognize vascular structures during liver parenchymal transection. This preliminary study demonstrated whether AI technology become navigation tool in recognizing anatomical structures during LLR. Method: We used Surgical AI Eureka® (Anaut Inc., Tokyo, Japan) to recognize various anatomical structures and detect bleeding. We made AI recognize lose connective tissue during liver mobilization and vascular structures during liver transection, and we examined bleeding detection function.

Results: This AI model enabled to recognize these vascular structures of any size with high accuracy (IoU=0.33, Dice=0.44) and AI could distinguish glissions from hepatic veins. AI recognized lose connective tissue (IoU=0.56, Dice=0.60) during liver mobilization and dissection of hepatoduodenal ligament for safe dissection plane. Loose connective tissue was also recognized by AI in intractable cases of repeat liver resection and tumor invaded other organs. We could identify the bleeding point using bleeding detection function. AI exactly highlights anatomical structures without any visual disagreed in real time about 0.12 second.

Conclusion: This AI system is useful as navigation technology in laparoscopic liver surgery. Nobel navigation surgery using AI technology suggested the possibility to perform safer and more reliable liver surgery in near future.

Abstract Submission No. 100822
O-0469

Causal inference data analysis pipeline for identifying proteins within NAFLD/NASH sub-cohorts

Chamara K Liyanaarachchi Lekamalage1, Smita Sampath1, Luo Weiwei1, Charlene Z L Ong1, Pei Z Goh1, Ziwei Shu1, Asad Abu Bakar Ali1

1Quantitative Biosciences, MSD Singapore Singapore

Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH) is a highly prevalent heterogenous disease with several sub-cohorts. Herein, we propose a data analysis pipeline for identifying proteins within these sub-cohorts to gain insights into NAFLD/NASH. The pipeline consists of two algorithms: 1) LIMMA (Linear Models for Microarray) differential expression analysis to identify proteins that differentiate between the various sub-cohorts of NAFLD/NASH; 2) Causal inference to determine the causality of differentiating proteins identified in the previous step to the biomarker. The analysis is conducted using data from the UK Biobank (UKB) with subjects having olink proteomics data. The proposed pipeline is applied on 4 sub-cohorts of group of individuals with fatty liver disease: proteins differentiating the interaction between (i) elevated cT1 and PNPLA3 (rs738409)+ variant with high and low cT1, (iii) elevated cT1 and PNPLA3 (rs738409)+ variant, (ii) PNPLA3 (rs738409)+ variant with high and low cT1, (iii) elevated cT1 and PNPLA3 (rs738409)+ variant, (iv) elevated cT1 and PNPLA3 (rs738409)- variant. The results of the analysis provided insights into NAFLD/NASH progression for these four sub-cohorts: 1) perturbed glucose metabolism appears to primarily drive immune regulation and pro-inflammatory signaling, 2) proteins associated with inflammation (IL-6), lipid metabolism and cardiovascular function are upregulated, 3) innate...
immune response may play a role in the progression of NAFLD/NASH, 4) direct cytokine signaling and oxidative stress, which are likely associated with obesity (for example, visceral adipose tissue expansion), may contribute to the development of NAFLD/NASH. These insights help enhance our understanding of the underlying mechanisms of NAFLD/NASH progression.

Abstract Submission No. 101496
O-0470

Application of transformer model for capsule endoscopic gastric structure recognition
Qingyuan Li¹, Weijie Xie², Yusi Wang¹, Kaiwen Qin¹, Wei Yang², Side Liu¹
¹Nanfang Hospital, Southern Medical University Guangzhou China, ²Southern Medical University Guangzhou China

Background: Gastric structure recognition systems have become increasingly necessary for the complete and accurate diagnosis of gastric lesions in capsule endoscopy. Deep learning, especially using transformer models, has shown great potential in the recognition of GI images according to self-attention. This study aims to establish a precise label library of capsule endoscopy gastric structures to improve the clinical applicability of deep learning to endoscopic image recognition.

Methods: A total of 2433 WCE videos collected at our center between 2011 and 2021 were used to train a transformer-based AI model, while 118 additional WCE videos were used for validation. Fifteen upper gastrointestinal structures were selected for quantifying the examination quality. We also conducted a comparison of the classification performance between the AI model and endoscopists by the accuracy, sensitivity, specificity, and positive and negative predictive values.

Results: The transformer-based AI model reached a relatively high level of diagnostic accuracy in gastric structure recognition. Regarding the performance of identifying 15 upper gastrointestinal structures, the AI model achieved a macroaverage accuracy of 99.6% (95% CI, 99.5-99.7), a macroaverage sensitivity of 96.4% (95% CI, 95.3-97.5), and a macroaverage specificity of 99.8% (95% CI, 99.7-99.9) and achieved a high level of interobserver agreement with the expert endoscopists.

Conclusion: The transformer-based AI model can accurately evaluate the gastric structure information of capsule endoscopy with the same performance as that of expert endoscopists, which will provide tremendous help for doctors in making a diagnosis from a large number of images and improve the efficiency of examination.

Abstract Submission No. 101504
O-0471

Practical Clinical Uses of Chat GPT: What Hepatologists Should Know
Marco Distefano¹, Giuseppe Alaimo²
¹UOSD Hepatology ASP 8 Siracusa Italy Siracusa Italy, ²UOC Medicina Interna Licata Italia

Artificial Intelligence (AI), particularly through tools like Chat GPT, is transforming Clinical Hepatology by enhancing patient care and research. This integration is crucial as many hepatologists are unfamiliar with AI’s practical applications in their field. AI focuses on improving diagnostic accuracy, tailoring treatment plans, and efficiently managing patient data. Its role extends to interpreting complex diagnostic images, forecasting disease progression, and guiding liver transplant decisions. These advancements, however, come with ethical and practical challenges in implementation.

AI’s impact in hepatology is profound, improving diagnostics, therapy, and research. Advanced algorithms refine imaging interpretation, aiding in early detection and management of liver diseases. AI also streamlines processing vast amounts of data in Electronic Health Records (EHR), enhancing both care and research precision.

AI contributes significantly to risk prediction models, enabling more accurate forecasts of disease progression and treatment outcomes. This leads to more personalized patient care. AI is also instrumental in formulating individualized treatment plans and in decision support systems, essential for informed clinical decision-making in hepatology. Despite its benefits, AI integration in hepatology faces challenges like data privacy concerns, the need for diverse datasets, and algorithmic biases. Overcoming these challenges requires careful planning and training for effective AI integration into existing healthcare systems. In summary, AI, especially Chat GPT, represents a major leap in Clinical Hepatology. Its current applications have already enhanced diagnostic precision and patient care, yet its full potential in hepatology is still unfolding, contingent on addressing ongoing ethical and practical issues.

Abstract Submission No. 101830
O-0472

Predicting Lymph Node Metastasis of Hilar Cholangiocarcinoma Based on Deep Learning Radiomics
Baoxian Liu¹, Hui Shen¹
¹The First Affiliated Hospital of Sun yat-sen University Guangzhou China

Purpose: To explore the potential deep learning radiomic(DLR) models based on B-mode ultrasound(BUS) and contrast-enhanced ultrasound(CEUS) images in predicting preoperative lymph node metastasis(LNM) of hilar cholangiocarcinoma(HCCA).

Methods: 110 HCCA patients from two clinical centers were included, and divided into a primary cohort(training group: n=75; internal validation group: n=25) and an external validation cohort(n=10). Pathologists confirmed the status of lymph node. The ResNet101 model was pre-trained on ImageNet and utilized for transfer learning. The ResNet101 was employed to extract deep learning features(DLFs) from BUS and CEUS images. Additionally, the Genetic Programming-based Symbolic Regression(GPSR) algorithm was used to combine the radiomic features(RadFs) and DLFs to generate deep learning radiomic features(DLRFs). Finally, the DLR models were constructed based on eXtreme Gradient Boosting algorithm.

Results: LNM occurred in 48 of 110(43.64%) HCCA patients. 847 RadFs and 4095 DLFs were extracted from the region of interest(ROI) of each tumor. After data cleaning and feature selection, 10 RadFs(BUS:4, CEUS:6) and 27 DLFs(BUS: 5, CEUS: 22) were obtained. After GPSR algorithm, 5 BUS-DLRFs, 10 CEUS-DLRFs, and 15 Combination-DLRFs were obtained and three corresponding DLR models were established, respectively. In the internal/external validation group, the AUC of BUS-DLR/CEUS-DLR/Combination-DLR models were 0.70 vs. 0.77 vs. 0.83(internal validation group) and 0.66 vs. 0.68 vs. 0.72(external validation group).

Conclusion: The DLR models based on DLRFs could better predict preoperative LNM in HCCA, and could further improve the detection rate of LNM to enhance clinical decision-making.

Abstract Submission No. 101935
O-0473
AI in Hepatitis B Screening: A Machine Learning Approach to Demographic Determinants

Minh H. N. Le1,2,3,4, Phat K. Huynh5, Thanh V. Kim6,7, Diem V. B. Dao1, Trang N. D. Pham8, Thuy Nguyen9, Hong K. Tang3, Doan Y. Dao1,4, Nguyen Q. K. Le10

1International Ph.D. Program in Medicine, College of Medicine, Taipei Medical University Taipei Taiwan, 2Research Center for Artificial Intelligence in Medicine, Taipei Medical University Taipei Taiwan, 3ALBioMed Research Group, Taipei Medical University Taipei Taiwan, 4Vietnam Viral Hepatitis Alliance Reston, VA USA, 5Industrial & Management Systems Engineering department, University of South Florida Tampa, FL 33620 USA, 6Center of Excellence for Liver Disease in Viet Nam, Johns Hopkins University School of Medicine Baltimore, MD USA, 7Department of Epidemiology, Pham Ngoc Thach University of Medicine Ho Chi Minh City Viet Nam, 8School of Public health, University of Illinois at Chicago Chicago, IL USA, 9HIV Dynamics and Replication Program, National Cancer Institute, National Institutes of Health Frederick, MD 21702 USA, 10Professional Master Program in Artificial Intelligence in Medicine, College of Medicine, Taipei Medical University Taipei Taiwan

Background: Hepatitis B Virus (HBV) affects nearly 300 million people globally, yet approximately 1/10 of these cases remain underdiagnosed. The primary objective is to assess the efficacy of AI (machine learning) and statistical models, particularly logistic regression for HBV screening using demographic factors.

Methods: Data from a HBV screening seroprevalence survey in Ho Chi Minh City (2019-2020) were analyzed, involving 17600 participants aged 18+ from an estimated 20000 sample using multi-stage cluster sampling. The dataset covered variables like HBsAg, demographics, and KAP questionnaire responses. MATLAB R2023b was used to process the data. SMOTE was used to fix imbalance data. Feature selection included Recursive Feature Elimination (RFE), Tree-Based Feature Importance (TBFI), minimum Redundancy Maximun Relevance (mRMR), and Pearson’s correlation. Key features were interactivally chosen. Classifiers used were Medium Tree (MT), Bilayered Neural Network (BNN), Logistic Regression (LR), Linear SVM, and Fine k-Nearest Neighbors (FKNN). Model performance was assessed via cross-validation, ROC curves, and confusion matrices.

Results: Of the initial 20,000 participants, 14,675 (73.4%) were included in the final analysis. Among them, 1,096 were HbsAg (+), and 6,086 were non-infected (negative for both HBsAg and anti-Hbc), with a median birth year of 52 ± 14. The feature selection by RFE and TBFI identified show best performance, finally seven significant features associated with HBsAg positivity were found. Performance analysis showed Medium Tree = 92.6%, BNN = 92.5%, Linear SVM = 91.7%, LR = 91.7, FKNN = 87.8%.

Conclusion: Machine learning models demonstrate significant potential in screening for HBV infection using demographic data.

Deep Learning Algorithm Applied to Plain CT Images to Identify SMA Abnormalities

Zhongzhi Jia1

1The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University changzhou China

Purpose: To develop a DL model for detecting SMA abnormalities on plain CT and evaluate its performance in comparison with a clinical model and radiologist assessment.

Materials and Methods: A total of 1048 patients comprised the internal (474 with SMA abnormalities, 474 controls) and external testing (50 with SMA abnormalities, 50 controls) cohorts. The internal cohort was divided into the training cohort (n = 776), validation cohort (n = 86), and internal testing cohort (n = 86). A total of 5 You Only Look Once version 8 (YOLOv8)-based DL submodels were developed.

Results: Of the submodels, YOLOv8x had the best performance. The area under the curve (AUC) of the YOLOv8x submodel was higher than that of the clinical model (internal test set: 0.990 vs 0.878, P = .002; external test set: 0.967 vs 0.912, P = .140) and that of all radiologists (P < .001). The YOLOv8x submodel, when compared with radiologist assessment, demonstrated higher sensitivity (internal test set: 100.0% vs 70.7%, P = .002; external test set: 96.0% vs 68.8%, P < .001) and specificity (internal test set: 90.7% vs 66.0%, P = .025; external test set: = 88.0% vs 66.0%, P < .001) and shorter inference time (internal test set: 1.04 min vs 94.80 min, P < .001; external test set: 1.24 min vs 104.80 min, P < .001).

Conclusion: Using plain CT images, YOLOv8x was able to efficiently identify cases of SMA abnormalities. This could potentially shorten the time to diagnosis and thus improve clinical outcomes.
stimulations, including hepatectomy, by conversion of stored retinyl ester into retinoic acid, and thereby associate with liver regeneration. Retinoid x receptor-α (RXRα), one of the retinoid nuclear receptors, forms heterodimer with the other nuclear receptors, and regulates downstream gene expressions. Thus, RXRα functions as a master regulator of retinoid signaling; however, the role of RXRα in liver regeneration remains unclear.

Methods: We used transgenic (TG) mice in which the expression of a dominant-negative form of RXRα is induced by doxycycline administration. Mice lacking the transgene were used as control. First, both TG and the control mice (Male, 10-12 weeks of age) were subjected to 70% partial hepatectomy (PH). Then, the liver/body weight ratio, serum alanine aminotransferase (ALT) levels, and liver histology on days 0, 1, 3, and 7 after PH were compared between the two groups.

Results: The liver/body weight ratios of TG mice at day 3 were significantly lower than that of the control. The infiltration of inflammatory cells and serum ALT levels were comparable between the two groups. The number of Ki67-positive liver cells in TG mice were significantly decreased on day 1, but increased significantly on day 3 compared to that of control.

Conclusions: RXRα plays a role in liver regeneration in mice by regulating the proliferation of liver cells at early time points after PH. Thus, targeting RXRα could be a therapeutic strategy for liver regeneration.

Background: Exosomes (EXOs) were involved in acute lung injury (ALI) in hemorrhage shock. Therefore, this study aimed to investigate the role of EXOs in the activation of hepatic macrophage (Mfs) and ALI in a rat sepsis model.

Methods: In rats undergoing cecal ligation and puncture (CLP), EXOs were isolated by the centrifugal method from blood and administered intravenously to normal rats. Lung tissues and blood samples were harvested. Pathophysiological changes in the lung, the lung wet/dry weight ratio, and the lung microvascular permeability were assessed. Furthermore, plasma inflammatory cytokine levels were measured. In another set of experiments, the production of inflammatory cytokines by isolated hepatic macrophages (Mfs) was assessed in vitro. Moreover, the mechanism of a signaling cascade of activation of Mfs was investigated.

Results: Pulmonary interstitial edema, inflammatory cell infiltration, microhemorrhage, and microthrombosis were observed in lung tissues in normal animals administered with EXOs; however, the extent of these changes was not as severe as in animals undergoing CLP. These pathophysiological changes were blunted by the deletion of hepatic Mfs by clodronate-liposomes in vivo. Inflammatory cytokine production by hepatic Mfs also increased by EXOs and was inhibited in cells cocultured with toll-like receptor (TLR) 4 antibodies in vitro.

Conclusion: In conclusion, EXOs isolated from blood in sepsis are triggering the production of inflammatory cytokines by hepatic Mfs via TLR-4 signaling, and are partly involved in ALI

Abstract Submission No. 100300

O-0479

The effect of portal diversion model in dog for the liver function

Naoki Hashimoto

1Sanda city hospital Sanda city Japan

Portal blood consists of mesenteric and splenic venous blood. In order to determine which one is more important in maintaining liver functions, canine models of a splenocaval shunt (SC shunt) and small bowel autotransplantation (partial mesocaval shunt, MC shunt) which diverts small bowel venous outflow into the systemic circulation and leaves the gastric,duodenal, pancreatic and colonic venous outflow un-disturbed was produced, and metabolic changes of the two models was compared. There was no difference in serum amino acid and ammonia levels in the two models. But amount of hepatic ATP in the MC shunt model is lower compared to the control and the SC shunt model. These data suggest that venous blood supply from the small intestine may be more important in maintaining ATP amount in the liver. Therefore, portal drainage, which reestablishes the physiological route of venous outflow, may be more preferable in small bowel transplantation.

Abstract Submission No. 101159

O-0480
Glutamine Promotes Liver Regeneration by Portal Tract Collagen Synthesis After Extended Hepatectomy

Chih Chieh Yen1,2,3, Chi Sheng Yen1, Hung Wen Tsai2, Wen Lung Wang1, Matthew M. Yeh4, Yan Shen Shan3,6, Chia Jui Yen1

1Department of Oncology, National Cheng Kung University Hospital Tainan Taiwan, 2Division of General Surgery, Department of Surgery, Kaohsiung Veterans General Hospital Kaohsiung Taiwan, 3Institute of Clinical Medicine, College of Medicine, National Cheng Kung University Tainan Taiwan, 4Department of Medicine, University of Washington School of Medicine Seattle, WA US, 6Department of Laboratory Medicine and Pathology, University of Washington School of Medicine Seattle, WA US, 5Department of Surgery, National Cheng Kung University Hospital Tainan Taiwan, 7Department of Pathology, National Cheng Kung University Hospital Tainan Taiwan

Abstract Submission No. 101822
O-0482

The histological findings with fluorescence microscopy for benign liver tumors

Yukari Shinohara1, Takeshi Aoki1, Tomokazu Kusano1, Yoshihiko Tashiro1, Kazuhiro Matsuda1, Sadahito Iseki1, Shodai Nagaishi1, Kazuhiko Saito1, Tatsuya Yamazaki1, Marie Uchida1, Takahito Hirai1, Kodai Tomioka1, Hideki Shibata1, Yuta Enami1

1Division of Gastroenterological and General Surgery, Department of Surgery, School of Medicine, Showa University Tokyo Japan

Abstract Submission No. 101633
O-0481

PTEN/AKT signal promotes cholangiocyte fate in liver tumorigenesis via Notch/SOX9 signal

Bangyan Stiles1, Qi Tang1, Jingyu Chen1, Ni Zeng1, Shefali Chopra1, Diaia Alhoosari1, Phillip Nguyen1, Guo Zhang1, Liyun Yuan1

1University of Southern California Los Angeles United States

Abstract Submission No. 101633
O-0481
Results:
Organoid analysis revealed proliferation.

Hyperproliferation in Biliary Cancer and Injury
Upregulated WNT Signaling is Associated with Biliary Proliferation

Mamun Mahtab, Musararat Mahtab, Sheikh Mohammad Fazle Akbar, Tasnim Mahmud, Md. Sunan Bin Islam
1Interventional Hepatology Division, Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 2North South University Dhaka Bangladesh, 3Ehime University Graduate School of Medicine Ehime Japan, 4North South University Dhaka Bangladesh, 5Ibrahim Medical College (BIRDEM) Dhaka Bangladesh

Bangladesh has a rich heritage of traditional medicine with coexistence of Hekimi or Muslim and Ayurveda or Hindu traditional medicines within the political boundary of today’s Bangladesh. However today’s unfortunate reality remains that in Bangladesh, we have not been able to retain our glory. When our neighboring India is doing so good with Ayurveda and even have a separate Ayush Ministry, we are trailing behind in this area despite having such rich heritage. It is now one of our principal research focus to revive our traditional herbal medicine. We have already demonstrated the beneficial effects of Glycyrrhiza Glabra (joshtimodhu) in end stage hepatocellular carcinoma. Recently during the COVID-19 pandemic our study revealed that hospital stay could be shortened with Glycyrrhiza Glabra (joshtimodhu) and Terminalia Arjuna in end stage hepatocellular carcinoma. Currently we are focusing on non-alcoholic fatty liver disease. We are exploring the prospects of Andrographis Paniculata (kalomegh) and Terminalia Arjuna (arjum). We are collaborating with a galaxy of public-private universities in our humble effort to revive our glory. Our initial experience with Kalomegh in fatty liver is encouraging.

Tumor infiltrating immune cells in hepatocellular carcinoma differs according to the viral status

Takashi Kokudo, Masaya Sugiyama, Nobuyuki Takemura, Yuhi Yoshizaki, Fuminori Mihara, Fuyuki Inagaki, Norihiro Kokudo
1National Center for Global Health and Medicine Tokyo Japan

Background: Tumor infiltrating immune cells play an important role in the prognosis of hepatocellular carcinoma (HCC). The HCC development has several aetiologies, which may lead to differences in the types of cells that constitute the tumour tissue. In this study, a comparison of the immune cells constituting the human tumour tissue was performed using single-cell RNA-seq analysis. Specifically, HCV-, HBV- and non-B-non-C (NBNC)-derived HCC were compared.

Methods: A total of 35 HCC patients were enrolled in this study, consisting of 9 HCV, 12 HBV and 14 NBNC-derived HCC. Fresh liver tissue obtained by hepatectomy was used for single cell RNA-seq analysis using a 10x genomics device. After NGS analysis, tumour-infiltrating immune cells were classified based on gene expression patterns.

Results: The tumour-infiltrating immune cells could be divided into 48 clusters based on gene expression patterns. The profile of clusters and cell types was similar between the NBNC and HBV-positive groups, but the HCV-positive group showed distinct profiles. In the HCV-positive group, the proportion of type 3 innate lymphoid cells (ILC3) and CD8-positive NKT cells were increased approximately 5.4-fold and 4.2-fold, respectively, compared to the other group. M2 macrophages were frequently observed in the HBV-positive and NBNC groups at 22.2-fold and 4.7-fold, respectively, compared to the HCV-positive group. Interestingly, a monocytic expressing CD14 positive population was frequently observed in the NBNC group at approximately 3.6-fold compared to the HCV- and HBV-positive groups.

Conclusions: This study has revealed significant differences in the infiltrating immune cells in different aetiologies.

Abstract Submission No. 200124
O-0485

Metabolite-Based, Weight-Independent Diagnostic Model for Non-Alcoholic Fatty Liver Disease (NAFLD)

Takeshi Kimura, Masanori Nojima, Yutaka Aoki, Makoto Watanabe, Mai Higashi, Atsuko Hashimura, Jyunya Ohtake, Takuya Koshizaka, Takahiro Yagi, Yasuhisa Kumakura, Taka-Aki Sato, Katsunori Masuda

Abstract Submission No. 100255
O-0486

Upregulated WNT Signaling is Associated with Biliary Hyperproliferation in Biliary Cancer and Injury

Nataliya Razumilava, Ashley N. Calder, Junya Shiota, Mirabelle Q. Peter, John W. Tobias, Erik J. Wamsteker, Linda C. Samuelson
1University of Michigan, School of Medicine Ann Arbor United States, 2Nagasaki University Nagasaki City Japan, 3University of Pennsylvania Philadelphia United States

Background: Cholangiocyte hyperproliferation is a hallmark of incurable biliary cancer, cholangiocarcinoma, and cholangiopathies. To develop effective therapies, we need better understanding of the mechanisms regulating aberrant cholangiocyte proliferation. Developmental WNT signaling has been implicated in cell proliferation and stem cell regulation in the liver.

Aim: to uncover the role of WNT signaling in cholangiocyte proliferation in the understudied extrahepatic bile ducts (EHBDs).

Methods: To examine gene expression and localization in human EHBDs, we performed bulk RNA-seq analysis of human biliary organoids, in vitro biliary progenitor cell models, and interrogated cholangiocarcinoma/normal EHBD samples from The Cancer Genome Atlas (TCGA) and our biobank. In mice, we conducted bulk and single-cell RNA-seq analysis of EHBDs at homeostasis and after injury with bile duct ligation (BDL). We used human and mouse biliary organoids and in vivo mouse models to examine WNT effects on cholangiocyte proliferation.

Results: Organoid analysis revealed WNT7B as the predominant ligand in human and mouse cholangiocytes. Human cholangiocarcinoma samples (TCGA) demonstrated increased proliferation (KI67) and WNT7B, Wnt7b and WNT target genes (Birc5, Cd44, Cnd1) were up-regulated in mouse EHBDs post-BDL and localized primarily to cholangiocytes in human and mouse EHBDs. In vitro, cholangiocyte-secreted WNT ligands activated canonical WNT signaling to induce organoid growth. In vivo, inhibition of WNT ligand secretion resulted in decreased biliary proliferation post-BDL.

Conclusions: WNT signaling is upregulated in cholangiocarcinoma and post-EHBD injury. WNT signaling inhibition decreases EHBD cholangiocyte proliferation. Understanding of aberrant WNT-induced biliary proliferation can inform therapeutic strategies for cholangiocarcinoma and cholangiopathies in humans.

Abstract Submission No. 200081
O-0484

Tumor infiltrating immune cells in hepatocellular carcinoma differs according to the viral status

Takashi Kokudo, Masaya Sugiyama, Nobuyuki Takemura, Yuhi Yoshizaki, Fuminori Mihara, Fuyuki Inagaki, Norihiro Kokudo
1National Center for Global Health and Medicine Tokyo Japan

Background: Tumor infiltrating immune cells play an important role in the prognosis of hepatocellular carcinoma (HCC). The HCC development has several aetiologies, which may lead to differences in the types of cells that constitute the tumour tissue. In this study, a comparison of the immune cells constituting the human tumour tissue was performed using single-cell RNA-seq analysis. Specifically, HCV-, HBV- and non-B-non-C (NBNC)-derived HCC were compared.

Methods: A total of 35 HCC patients were enrolled in this study, consisting of 9 HCV, 12 HBV and 14 NBNC-derived HCC. Fresh liver tissue obtained by hepatectomy was used for single cell RNA-seq analysis using a 10x genomics device. After NGS analysis, tumour-infiltrating immune cells were classified based on gene expression patterns.

Results: The tumour-infiltrating immune cells could be divided into 48 clusters based on gene expression patterns. The profile of clusters and cell types was similar between the NBNC and HBV-positive groups, but the HCV-positive group showed distinct profiles. In the HCV-positive group, the proportion of type 3 innate lymphoid cells (ILC3) and CD8-positive NKT cells were increased approximately 5.4-fold and 4.2-fold, respectively, compared to the other group. M2 macrophages were frequently observed in the HBV-positive and NBNC groups at 22.2-fold and 4.7-fold, respectively, compared to the HCV-positive group. Interestingly, a monocytic expressing CD14 positive population was frequently observed in the NBNC group at approximately 3.6-fold compared to the HCV- and HBV-positive groups.

Conclusions: This study has revealed significant differences in the infiltrating immune cells in different aetiologies.
non-responders. Here, we used CyTOF analysis on sequential peripheral blood mononuclear cell (PBMC) samples from ICI-treated primary liver cancer (PLC) patients undergoing ICI-based therapy, and established a non-invasive and efficient model to predict clinical response before immunotherapy. This model could enhance clinical care, aiding in PLC patient stratification for ICI-based treatment and fostering new response monitoring strategies.

**Abstract Submission No. 100831**

**O-0488**

**HBV virus-host chimera DNA serves as a personalized circulating biomarker for residual tumors of HCC**

Pei-Jer Chen¹, Gar-Yang Chau², Wei-Chen Lee³, Ming-Chih Ho⁴, Teng-Wei Chen⁵, Rey-Heng Hu⁶, Tsung-Han Wu⁷, Hao-Jan Lei⁸, Shu-Cheng Chou⁹, Hisu-Lang Fan¹⁰, Ting-Jung Wu¹¹, Cheng-Maw Ho¹², Hong-Shiue Chou¹³, Sheng-Tai Tzeng¹⁴, Shiou-Hwei Yeh¹⁵

¹National Taiwan University College of Medicine Taipei Taiwan, ²Taipei Veterans General Hospital Department Surgery Taipei Taiwan, ³Linkou Chang Gung Memorial Hospital Taoyuan Taiwan, ⁴National Taiwan University Hospital Taipei Taiwan, ⁵Tri-Service General Hospital Taipei Taiwan, ⁶TCM Biotech International Corp. Taipei Taiwan

**Background:** Timely detection of minimal residual tumor for hepatocellular carcinoma (HCC) is helpful in recurrence monitoring and evaluating treatment strategies. This study examined the feasibility of HBV virus-host chimera DNA (vh-DNA) as a personalized circulating biomarker for residual tumors after surgery.

**Methods:** The tumor-specific vh-DNA integration sites were determined in 148 HBV-related HCC patients by next-generation sequencing. For each individual HCC, vh-DNA was quantified using a customized droplet digital PCR (ddPCR) assay in plasma samples collected within 14 months after surgery, and the results were compared with the clinical outcomes.

**Results:** HBV integrations were identified in 132 out of 148 patients with HBV-related HCC (89.2%). Among the 116 patients who completed the postoperative follow-up, the positive predictive value (PPV) of vh-DNA for tumor recurrence was 68% (17/25), and the negative predictive value (NPV) was 92% (84/91). The mean leading time of vh-DNA detection was 140 days earlier than computed tomography scanning. A total of 78% (18/23) of recurrences originated from the same HCC clones sharing the same vh-DNA, suggesting that most of the early recurrence came from residual tumor cells. Moreover, multivariate cox regression analysis showed that vh-DNA was an independent risk factor for predicting early recurrence. When vh-DNA combined with serum AFP, the sensitivity and specificity of recurrent HCC were 92% and 88%, respectively.

**Conclusion:** This study demonstrates that utilizing vh-DNA to monitor the presence of residual tumors after surgery could be a promising solution for prognosis assessment, recurrence monitoring, and guiding adjuvant therapies in the future.
Chemoprotective mechanisms of skullcapflavone in aflatoxin-induced toxicity in THLE-3 hepatocytes

Glenn Oyong¹, Maria Carmen Tan²

¹Department of Physics, College of Science, De La Salle University 0922 Manila Philippines, ²Department of Chemistry, College of Science, De La Salle University 0922 Manila Philippines

The protective effect of skullcapflavone I (SKI) against aflatoxin B1 (AFB1)-induced cytotoxicity and genotoxicity in THLE-3 cells including possible mechanisms were investigated. SKI previously elucidated and isolated from Andrographis paniculata were tested to be biocompatible with THLE-3. THLE-3 were treated with or without SKI for 24 h before AFB1 exposure. Expressed Akt, Bcl-2, and CYP2E1 transcripts were detected by qRT-PCR. Immunoblotting was performed for translated CYP2E1 including Akt and ERK1/2 phosphorylation. GST activity and AFB1 genotoxic metabolite, aflatoxin B1-8,9 epoxide (AFBO), were quantified. Comet assay was performed to assess DNA damage. AFB1 significantly downregulated the gene and protein expression products of Akt, Bcl-2 while upregulating CYP2E1. Akt phosphorylation was inhibited while increased ERK1/2 activation was observed. High percentages of comet tail length and moment indicated DNA damage. Pre-treatment with SKI afforded cytoprotective effect in THLE-3 viability with half-maximal effective dose of 8.46 μg/mL. SKI pre-treatment reversed AFB1-induced activities through dynamic Akt, Bcl-2 upregulation and CYP2E1 downregulation. Moreover, Akt activation increased while ERK1/2 phosphorylation was inhibited. GST activity significantly increased accompanied by decreased AFBO. Comet tail length and moment were comparable with untreated controls. Remarkably, LYS294002, a specific inhibitor of PI3K, impaired SKI protective effect on THLE-3 suggesting the role of the pathway. This study is the first report describing the protective activities of SKI against AFB1-induced toxicity on human hepatocytes and may help contribute to the development of pharmaceutical leads targeting aflatoxin poisoning and carcinogenicity.

Abstract Submission No. 101226
O-0490

Urine Interleukin-18 (uIL-18) as a Prognostic Marker for Mortality Risk in Liver Cirrhotic

Dwijo A Sindhughosa¹, I K Mariadi¹
¹Division of Gastroenterology-Hepatology, Department of Internal Medicine, Udayana University, Denpasar, Bali, Indonesia

Background: Urine interleukin-18 (uIL-18) has shown to provide prognostic value for several diseases. The release of uIL-18 may reflect the severity of inflammation and the ongoing pathological processes within the liver. Identifying additional biomarkers that can enhance prognostic accuracy in liver cirrhotic patients is essential. This study aimed to evaluate uIL-18 as a prognostic indicator to determine higher mortality risk in liver cirrhotic patients.

Methods: This was an analytic cross-sectional study to determine the risk of high uIL-18 for higher risk of mortality according to MELD score. Subjects with MELD score ≥20 were considered had higher risk for mortality. The level of uIL-18 measured with ELISA method. Cut-off of high uIL-18 was determined with Youden Index.

Results: A total of 75 subjects involved in this study with mean age of 54.71 ± 11.06 years. Majority of the subjects were male (78.7%). A total of 33 subjects (44%) had higher risk of mortality. The median of uIL-18 was 79.49 (386.63) ng/mL. The cutoff for uIL-18 was 36.87 ng/mL to provide the best value (youden index = 0.29). By using the optimal cutoff, the sensitivity was 78.8%, specificity 50%, positive predictive value 55.3%, negative predictive value 75%, accuracy 62.6%. High uIL-18 associated with higher risk for mortality by 6.55 times (p = 0.011).

Conclusion: uIL-18 provides good specificity and validity to determine higher risk for mortality in liver cirrhotic. uIL-18 could be used as a complementary prognostic indicator, facilitating more precise risk stratification and guiding therapeutic decisions for high-risk liver cirrhosis population.

Abstract Submission No. 101365
O-0491

Evaluation of Tumor Microenvironment in HCC by TCRA Gene and Transcriptome Deconvolution Analysis

Hitoshi Mochizuki¹,², Yosuke Hirotsu¹, Yuji Iimuro³, Masao Omata²,⁴
¹Yamanashi Central Hospital , Genome Analysis Center Yamanashi Japan, ²Yamanashi Central Hospital, Department of Gastroenterology Yamanashi Japan, ³Yamanashi Central Hospital, Department of Hepatobiliary and Pancreatic Surgery Yamanashi Japan, ⁴The University of Tokyo Tokyo Japan

Introduction: The indications for immune checkpoint inhibitors (ICIs) are expanding and their efficacy is recognized, but the predictors of efficacy are not as simple as previously thought. Tumors have limitations in conventional approaches because they require consideration of not only the malignancy and tumor-infiltrating lymphocytes (TILs), but also the tumor microenvironment (TME), which consists of many stromal cells and their activation states. We analyzed the TCRA (T cell receptor omega) gene and transcriptope to determine the probability of the presence of various immunocompetent cells and stromal cells in relation to ICI treatment efficacy.

Methods: DNA was extracted from tumor tissue FFPE operated on at our hospital, and the probability of cell presence was calculated by machine learning using a generalized additive model (Cell Exome TREC Tool. Nature 2021) using the process of elimination of delta strand from TCRA (n=522). Transcriptome analysis was performed from mRNA and cell composition was calculated using deconvolution method (n=251). 22 immune system cell types were identified in Cibersort (Nat Methods 2015) and 64 cell types (immune system cells, epithelial cells, stromal cells) were identified in xCell (Genome Biology 2017). cells, and stromal cells) were annotated to evaluate the efficacy of ICI treatment and irAE.

Results: Compared to other cancer types, hepatocellular carcinoma has a low ratio of immunocompetent cells. It is necessary to take into account the intra-tumor heterogeneity and differences in the algorithms used to evaluate the immune environment, and further analysis using an integrated machine learning framework will be required in the future.

Abstract Submission No. 101628
O-0492

Serum anti-PD-1 autoantibody predicts survival of HCC receiving atezolizumab/bevacizumab

Akinobu Takaki¹, Yuki Sasaki¹, Masahiko Sue¹, Nozomi Miyake¹, Takuya Adachi¹, Nozomu Wada¹, Yasuto Takeuchi¹, Hideki Onishi¹, Hidenori Shiraha¹, Motoyuki Otsuka¹
¹Department of Gastroenterology and Hepatology, Okayama University Okayama Japan
Abstract

Background & Aims: In patients with advanced hepatocellular carcinoma (HCC), atezolizumab (anti-programmed cell death-ligand 1 [PD-L1]) and bevacizumab (anti-vascular endothelial growth factor) combination therapy (Atezo/Bev therapy) is a first-line treatment. However, no reliable biomarkers are currently available to predict its efficacy. Here, we examined serum anti-programmed cell death-1 (PD-1) autoantibody levels as candidate biomarkers.

Methods: Patients with advanced HCC from four institutions participating in the Okayama Liver Cancer Group were prospectively registered and underwent Atezo/Bev therapy. A total of 63 patients were enrolled between November 2020 to October 2022. Serum anti-PD-1 autoantibody levels were measured before treatment using an indirect enzyme-linked immunosorbent assay (ELISA). The correlation between the titers and response to therapy was statistically examined.

Results: Serum anti-PD-1 autoantibody levels were not significantly associated with the treatment response in any patient. However, when examining only patients who received the Atezo/Bev as their first-line therapy, higher anti-PD-1 autoantibody levels were significantly associated with worse overall survival (OS) rates. The titer was an independent risk factor for poor prognosis (odds ratio [OR], 7.8; 95% confidence interval [CI], 1.5-39; p = 0.013), in addition to a higher neutrophil-to-lymphocyte ratio (OR, 7.1; 95% CI, 1.6-31; p = 0.009) and lower albumin levels (OR, 14.2; 95% CI, 2.38-84.9; p = 0.003).

Conclusion: Serum anti-PD-1 autoantibody levels correlated with the OS rate in patients who received Atezo/Bev as first-line therapy. Serum anti-PD-1 autoantibody levels may serve as new biomarkers for predicting the efficacy of immune checkpoint inhibitors in patients with HCC.

Abstract Submission No. 100298
O-0494

The significance of plasma xanthine oxidoreductase activities in a variety of liver diseases

Ken Sato1, 2, 3, Atsushi Naganuma4, Tamon Nagashima5, Yosuke Araif, Yuka Mikami3, Yuka Nakajima1, Yuki Kanayama4, Tatsuma Murakami1, 3, 4, Sanae Uehara6, Daishuke Uehara6, Yuichi Yamazaki2, Takayo Murase6, Takashi Nakamuraa, Toshio Uraoka6

1Department of Healthcare Informatics, Takasaki University of Health and Welfare Takasaki Japan, 2Department of Hepatology, Heisei Hidaka Clinic Takasaki Japan, 3Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine Maebashi Japan, 4Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center Takasaki Japan, 5Department of Gastroenterology, National Hospital Organization Shibukawa Medical Center Shibukawa Japan, 6Mie Research Park, Sanwa Kagaku Kenkyusho Inabe Japan

Background: Xanthine oxidoreductase (XOR) is highly expressed in the liver, but the number of the study regarding XOR activities in patients with hepatic diseases was few, and the several etiologies were analyzed combinatorially. Recently, high-sensitive and accurate assay for the measurement of XOR activity has been developed.

Methods: We performed a prospective multi-institutional cross-sectional study in which the enrolled numbers of patients and controls were 329 and 32, respectively. We measured plasma XOR activities and purine metabolism-associated markers in etiology-based comprehensive liver diseases by using the novel method. We also analyzed the relationship between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker.

Results: Plasma XOR activities were generally increased in various liver diseases compared with those in control subjects. The highest activities were observed in a patient with acute hepatitis B. The XOR activities were likely to be high in the active phase. For example, the XOR activities in chronic hepatitis C were significantly higher in patients with active infection than past infection and in those with un- cured hepatocellular carcinoma patients than cured ones. Most importantly, the XOR activities were significantly associated with parameters of liver tests, especially serum ALT levels, regardless of etiology and plasma xanthine levels.

Conclusions: The plasma XOR activities might reflect the active phase in various liver diseases. The longitudinal studies such as the comparison of plasma XOR activities between acute phase and recovery phase in various liver disease are needed to verify our results.

Abstract Submission No. 100717
O-0495

Autophagy-Related Genes Promote Development of Pediatric Metabolic-associated Fatty Liver Disease

Ken Yamazaki3, Tatsuma Murakami4, Akinori Kuroda4, Tomonari Hara3, Shinobu Ishii5, Masato Endo2, Masahito Yamazaki3, 6, Atsushi Naganuma4, Hisato Ueda7, Kenji Sato1, 2, 3

1) autoantibody levels as candidate biomarkers.

Participants: Patient’s with hepatic diseases was few, and the several etiologies were analyzed combinatorially. Recently, high-sensitive and accurate assay for the measurement of XOR activity has been developed.

Methods: We performed a prospective multi-institutional cross-sectional study in which the enrolled numbers of patients and controls were 329 and 32, respectively. We measured plasma XOR activities and purine metabolism-associated markers in etiology-based comprehensive liver diseases by using the novel method. We also analyzed the relationship between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker.

Results: Plasma XOR activities were generally increased in various liver diseases compared with those in control subjects. The highest activities were observed in a patient with acute hepatitis B. The XOR activities were likely to be high in the active phase. For example, the XOR activities in chronic hepatitis C were significantly higher in patients with active infection than past infection and in those with uncured hepatocellular carcinoma patients than cured ones. Most importantly, the XOR activities were significantly associated with parameters of liver tests, especially serum ALT levels, regardless of etiology and plasma xanthine levels.

Conclusions: The plasma XOR activities might reflect the active phase in various liver diseases. The longitudinal studies such as the comparison of plasma XOR activities between acute phase and recovery phase in various liver disease are needed to verify our results.

Abstract Submission No. 100717
O-0495

Autophagy-Related Genes Promote Development of Pediatric Metabolic-associated Fatty Liver Disease

Ken Yamazaki3, Tatsuma Murakami4, Akinori Kuroda4, Tomonari Hara3, Shinobu Ishii5, Masato Endo2, Masahito Yamazaki3, 6, Atsushi Naganuma4, Hisato Ueda7, Kenji Sato1, 2, 3

1) autoantibody levels as candidate biomarkers.

Participants: Patient’s with hepatic diseases was few, and the several etiologies were analyzed combinatorially. Recently, high-sensitive and accurate assay for the measurement of XOR activity has been developed.

Methods: We performed a prospective multi-institutional cross-sectional study in which the enrolled numbers of patients and controls were 329 and 32, respectively. We measured plasma XOR activities and purine metabolism-associated markers in etiology-based comprehensive liver diseases by using the novel method. We also analyzed the relationship between the plasma XOR activities and parameters of liver tests, purine metabolism-associated markers, oxidative stress markers, and an inflammation marker.

Results: Plasma XOR activities were generally increased in various liver diseases compared with those in control subjects. The highest activities were observed in a patient with acute hepatitis B. The XOR activities were likely to be high in the active phase. For example, the XOR activities in chronic hepatitis C were significantly higher in patients with active infection than past infection and in those with uncured hepatocellular carcinoma patients than cured ones. Most importantly, the XOR activities were significantly associated with parameters of liver tests, especially serum ALT levels, regardless of etiology and plasma xanthine levels.

Conclusions: The plasma XOR activities might reflect the active phase in various liver diseases. The longitudinal studies such as the comparison of plasma XOR activities between acute phase and recovery phase in various liver disease are needed to verify our results.

Abstract Submission No. 100717
O-0495

Autophagy-Related Genes Promote Development of Pediatric Metabolic-associated Fatty Liver Disease
Baiyi Liu1, Xiaoxiao Wang1, Rui Jin1, Zilong Wang1, Yuyun Song1, Xiaole Li1, Feng Liu1, Huiying Rao1
1Peking University People's Hospital Beijing China

Background: Metabolic-associated fatty liver disease (MAFLD) is the most common cause of chronic liver disease worldwide. With an increasing number of overweight or obese children, MAFLD has emerged as one of the most common comorbidities in the pediatric obese population. Currently, the precise pathophysiology of pediatric MAFLD is still not completely understood.

Methods: Pediatric MAFLD dataset and autophagy-related genes (ATGs) were selected for identifying differentially expressed genes (DEGs). Then, protein-protein interaction (PPI) network were integrated to identify the hub genes as gene signature. Next, receiver operating characteristic (ROC) curves were used to evaluate the performance of gene signature. Last, we analysed the the hub genes for expression levels and correlation with immune cells.

Result: We identified six autophagy-related genes (KDR, MYC, VEGFA, CXCR4, IFNG and CCL2) as hub genes, that may be closely related to the development of pediatric MAFLD. Furthermore, we constructed prognosis gene markers based on the hub genes. This gene signature has shown good diagnostic accuracy in both obese and MAFLD pediatric population (AUC > 0.6). Compared with mild liver fibrosis, expression level of MYC, CXCR2 and CCL2 significantly increased in advanced liver fibrosis in pediatric MAFLD. In addition, according to the immune cells composition, macrophage M2 significantly increased in pediatric MAFLD which was the opposite of adult MAFLD.

Conclusion: The six hub genes may predict the risk of MAFLD development in pediatric population by mediating autophagy-related mechanism, which is hopeful to be biomarkers for predicting occurrence, diagnosis and treatment of MAFLD.

Abstract Submission No. 100778
O-0496

Exploration of the potential biomarker between COVID-19 and liver cirrhosis-hepatocellular carcinoma
Ning Wang1
1Tianjin Third Central Hospital Tianjin China

Background: Coronavirus disease 2019 (COVID-19) pandemic is attributed to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which has widespread impacts on the patients with underlying disease. It is well known that liver cirrhosis (LC) has been coined as a very strong risk factor for the development of hepatocellular carcinoma (HCC). This study aimed to explore the potential gene signature and regulatory network between COVID-19 and LC-HCC.

Methods: The candidate gene signatures were identified by the common differentially expressed genes (DEGs) based on COVID-19 and LC-HCC utilizing the bioinformatics analysis. Subsequently, the gene functional enrichment analysis (KEGG and GO) and protein-protein interaction (PPI) network were performed, exploring the hub gene as the key biomarker. Finally, receiver operating characteristic (ROC), biological function and gene expression network analyses were systematically conducted.

Results: The common 78 candidate gene signatures were successfully screened out between COVID-19 and LC-HCC. Then, KEGG and GO enrichment analyses discovered that these candidate genes were mainly involved in the cell cycle. Based on the construction of PPI network, the hub gene CDK1 was successfully identified by means of ten scoring methods. ROC analysis confirmed that CDK1 exhibited a high predictive efficacy in COVID-19 (AUC = 0.955) and LC-HCC (AUC = 0.946) cohorts. Additionally, HCC patients with high CDK1 expression had poor clinical prognosis.

Finally, the comprehensive gene regulatory networks were established.

Conclusions: This study successfully determined the key biomarker and gene regulatory network between COVID-19 and LC-HCC, contributing to predicting patients’ prognosis and therapeutic targets.

Abstract Submission No. 101553
O-0497

Diagnosis of HBV-associated liver cirrhosis and HCC based on Lipid and peptide fingerprints
Liye Tao1, Zefeng Shen1, Xuetong Qu2, Xinrong Jiang2, Yingyue Liu2, Junhao Zheng1, Chao Song1, Yang Liu3, YangYang Xie3, Haoyu Pan2, Shihao Li3, Yali Wang2, Junjie Xu2, Jianmin Wu3, Xiao Liang2
1Sir Run Run Shaw Hospital, Zhejiang University School of medicine Hangzhou China, 2Zhejiang university Hangzhou China

Background: In this study, biological changes will be explored during the development of HBV-related HCC based on serum lipids and peptides and a classifier will be constructed to identify patients at different stages in the HBV-infected population.

Methods: A total of 846 serum samples were collected from 219 healthy volunteers, 206 patients with chronic hepatitis B (CHB), 160 patients with HBV-related LC and 261 patients with HBV-related HCC, and the lipid and peptide fingerprints were acquired based on Nano-assisted laser desorption ionization time of flight mass spectrometry. Then molecular landscape was analyzed and the stepwise prediction model was conducted.

Results: We found that serum lipid and peptide fingerprints were altered during the evolution from CHB to HCC. The stepwise prediction model was built, which could identify 80.0% HC, 80.9% CHB, 55.6% LC and 90.0% HCC in the external test set. And 95.5%-98.6% of AFP negative HCC patients could be identified by the multi-omics model. When combined with AFP, the sensitivity for identifying HCC patients could reach 97.9%-98.3%.

Conclusions: Platform of acquiring lipid fingerprints and peptide profiling based on NALDI-TOF-MS had clinical application potential in identifying different stages during the evolution of CHB to HCC, which may be a supplementary method of AFP for screening and diagnosis of HBV-related HCC. Chictr.org.cn number, ChCTR2000073462.

Abstract Submission No. 101865
O-0498

Identification of Alcoholic Hepatitis-related genes and Mesenchymal Stem Cell treatment Target Genes
SEUL KI HAN1,2, Taesic Lee3,4, Jisun Lim1, Hyunsoo Kim1, Young Uh5, Moon Young Kim1,2,3
1Department of Internal Medicine, Division of Gastroenterology and Hepatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine W, 2Department of Gastroenterology and Hepatology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine W, 3Division of Gastroenterology and Hepatology, Yonsei University Wonju College of Medicine W, 4Division of Metabolism and Molecular Biology, Yonsei University Wonju College of Medicine W, 5Division of Metabolism and Molecular Biology, Yonsei University Wonju College of Medicine W

Background: Alcoholic Hepatitis (AH) is a severe liver disease caused by chronic alcohol consumption, characterized by severe inflammation, necrosis, and fibrosis. Mesenchymal Stem Cell (MSC) therapy has been shown to be effective in treating AH.

Methods: Blood samples were collected from patients with AH and healthy controls. Gene expression analysis was performed using microarrays and qPCR. The treatment response was evaluated using the taqman gene expression analysis platform.

Results: A total of 500 genes were identified as differentially expressed between AH and controls. The top ten genes were identified using the R programming language. The treatment response was evaluated using the taqman gene expression analysis platform.

Conclusions: Identification of AH-related genes and MSC treatment target genes was successful. The results provide a potential therapeutic target for AH treatment using MSC therapy.
Alcoholic hepatitis (AH) is a life-threatening condition and widespread chronic liver condition that places patients at risk of short-term mortality if it is not properly managed. This study aimed to identify transcriptomic biomarkers and cell therapy targets for AH.

We conduct a systematic meta-analysis of published human gene expression studies on liver biopsies and blood derived gene data. First, three liver AH transcriptome datasets and a blood AH dataset were combined to discover a common phenotype. Second, two AH prognosis datasets were compiled, which are including gene phenotype reflecting prognosis. Using inverse weighted variance-based method mounted in METAL software, the candidate genes related to AH in liver and blood tissues and annotated them as the liver-blood AH meta genes. Third, three MSC datasets were curated for gene identification in stem cell response. Meta-analysis was implemented on the individual cohort-specific summary statistics obtained from differential expression methods to identify the AH-related biomarkers. To narrow down the candidate hub genes among stem cell treated data, TF database, protein-protein interaction network, disease-gene association database, and disease- and expression-related SNP database were used to analysis.

With previously identified alcoholic gene-related databases, external verification was performed and finally 47 upstream AH-related genes were presented.

We present key genes involved in the progression of AH and provide a meta-analysis of results in a objective, statistically-based format. And at the same time, we suggest this biomarkers that can predict the prognosis of AH and treatment response.

Conclusion: It is important to design comprehensive hepatitis education initiatives to address patient knowledge gaps since there are misconceptions surrounding HBV and HCV.

Abstract Submission No. 100992

A community-centered surveillance program for disease severity map in an under-resourced region

Jee-Fu Huang1, 2, 3, Pei-Chien Tsai1, Ming-Lung Yu1, 4, Chia-Yeen Dail1, 2, Wan-Long Chuang5

1Kaohsiung Medical University Hospital Kaohsiung Taiwan, 2Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan, 3Hepatitis Center, Kaohsiung Medical University Kaohsiung Taiwan

Background/Aim: Taitung, located in eastern Taiwan, has the lowest population density, the lowest life expectancy, and the lowest medical personnel compared with other prefectures in Taiwan. Liver-related mortality remains one of the major causes of death in Taiwan. The study aimed to elucidate the epidemiological characteristics and the disease severity of liver diseases in Taitung.

Methods: We conducted a mass screening program for those who carried a high-risk for advanced liver disease and did not receive regular liver disease surveillance. The eligible participants were selected from the healthcare database and were invited by email or phone calls via township-based primary care centers. They received FibroScan as the initial surveillance, followed by liver disease tests.

Results: A total of 4,531 residents (1,859 males; mean age= 54.2 ± 14.0 years) participated the program. The prevalence of diabetes, hypertension, and hyperlipidemia were 12.8%, 28.9%, and 12.1%, respectively. There were 302 (6.7%) residents with HBV infection, whereas 49 (1.1%) residents had anti-HCV+. There were 2,044 (45.1%) participants of indigenous background. The prevalence of advanced fibrosis, defined as FibroScan> 9.5 kPa, was 7.0% (316/4,531), ranging from 3.7% to 10.2%. There were 2,874 (63.4%) participants with steatotic liver disease (SLD), defined as Controlled Attenuation Parameter (CAP) value> 238 dB/m. Excessive alcohol use (23.1% vs 6.9%, P= 0.001) and SLD (11.6% vs 4.8%, P< 0.001) were the major factors contributing to advanced fibrosis.

Conclusion: The community-centered surveillance program provided information for disease severity mapping in the under-resourced prefecture.

Abstract Submission No. 100758

O-0500

The Prevalence of Hepatitis B and Hepatitis C Among Police Officers of Rawalpindi, Pakistan

Reham Baig1, Nida Ali2, Qaiser Hussain3, Ehsan Ghani4

1World Health Organization Islamabad Pakistan, 2Coalition for Global Hepatitis Elimination, TFGH Rawalpindi Pakistan, 3Local Hepatitis Elimination and Prevention, District Health Authority Rawalpindi Pakistan, 4District Health Authority Rawalpindi Pakistan

Background: Police officers play a vital role in law-and-order management and during their frontline duty, they often ignore their health. This article explores the prevalence of these infections among police officers and the importance of addressing this issue.

Aims: Assesses the prevalence and risks leading to infection of hepatitis B and C.
Methods: An integrated screening camp was arranged to screen the Rawalpindi police force against communicable diseases. 15705 officers were tested in a month for Hepatitis B and C with rapid testing kits. 98 positive for HCV, 5 with HBV and 4 with coinfection were interviewed to explore various risk factors that lead to the infection.

Results: 0.24%(37/15705) participants were found reactive for HBsAg antigen, 1.85%(209/15705) were reactive for Anti-HCV. Out of 327 positive officers, 108 were interviewed for potential risk factors for acquiring the infection. 33.3%(36) had family member with Hepatitis, 32.4%(35) had dental treatment, 27.7%(30) got IV medications, 25%(27) availed roadside barber services, 13.8%(15) had blood transfusion, 8.3%(9) had multiple sex partners, 2.7%(3) had piercings, 1.8%(2) were trans-genders, 1.8%(2) had IV drugs, 0.9%(1) were men having sex with men and 0.9%(1) got tattoo.

Conclusion: These frontline officers face many challenges in the line of duty, communicable diseases are not to be neglected as 0.24%(37/15705) and 1.85%(209/15705) of officers tested positive for Hepatitis B and C respectively. Major risk factors were positive family members, dental treatments and frequent IV medications. A follow-up viral load testing was done, and those positive were linked to care.

Abstract Submission No. 101089
O-0502

Earlier liver cirrhosis onset in intrafamilial hepatitis Delta Virus transmission in Moldova

Adela TURCANU1,2, Ecaterina Cebanu1, Veronica Cumpata2, Pascal Pineau3

1The State University of Medicine and Pharmacy N.Testemitanu Chişinău, Moldova, 2The Clinic of Gastroenterology and Hepatology Chisinau Moldova, 3Unité « Organisation nucléaire et Oncogénèse », INSERM U993, Institute Pasteur Paris France

Background: Hepatitis delta, sometimes considered as a vanishing disease in Western Europe, is still widespread in the Republic of Moldova.

Methods: In this comparative cross-sectional study, we described demographic features of 224 HDV-infected patients either affected from chronic hepatitis or liver cirrhosis attending care in three Moldovan centers that we compared with 100 hepatitis B virus mono-infected subjects.

Results: All delta-infected patients were anti-HBe and HBV DNA was detectable much less frequently (28%) than in mono-infected ones (76-92%, P<1.0E-09). Familial transmission of the virus was much more prevalent in HDV infection than in HBV infection (39% vs 23%, P=0.0036). Amongst patients with hepatitis delta, those with familial contamination developed liver cirrhosis much earlier than others (40.5±3.9 years vs 46.9±8.7 years, P=0.053) and presented more frequently detectable HDV RNA in their plasma (98.7% vs 89.2%, P=0.0094).

Conclusion: Hepatitis delta is a significant health problem in Moldova. Familial transmission of hepatitis delta, especially prevalent South of the country, is responsible of anticipation of the complications.

Abstract Submission No. 101400
O-0503

Modelling the impact of vaccination on HBV transmission and progress to elimination in Punjab, India

Jack Stone1, Anna McNaughton1, Hannah Fraser1, Dimitris Kalogiros1, Aaron G Lim1, Gagandeep S Grover2, Parag Govil3, Arun Sond3, Yuhui Chan3, Oriel Fernandes1, Peter Vickerman1

1University of Bristol Bristol United Kingdom, 2State Viral Hepatitis Management Unit, Department of Health and Family Welfare, Government of Punjab, Chandigarh Punjab India, 3Clinton Health Access Initiative (CHAI) Punjab India

Background: India was estimated to have 32.7 million persons living with Hepatitis B virus (PLHBV) in 2016. The prevalence of chronic HBV infection (HBsAg-positive) in Punjab, India, was 1.4% in 2014 (~400,000 PLHBV). India has scaled up infant HBV vaccination to 91% coverage and timely birth dose vaccination to 56% coverage, but few receive HBV treatment. The World Health Organization (WHO) HBV elimination targets include decreasing new HBV infections by 95% over 2015-2030 and decreasing HBsAg prevalence among children under five to <0.1% by 2030. We used modelling to evaluate progress towards these targets in Punjab.

Methods: A dynamic HBV transmission model was developed, including disease progression, vertical and horizontal transmission, population growth and vaccination. The model was parameterised and calibrated in a Bayesian framework using regional estimates of chronic (HBsAg-positive) and past infection (HBeAb-positive) prevalence. Indian data on HBeAg-prevalence, demographic data, and yearly data on infant and birth dose vaccination coverage. The model was used to simulate trends in HBV transmission and evaluate the impact of ongoing vaccination.

Results: Projections suggest HBV incidence has decreased by 39.9% (95% credibility interval: 30.5-45.6) over 2015-2022, while HBV-related deaths have remained stable. In 2022, 4.5% (2.2-23.6) of new infections and 19.0% (10.8-54.0) of new chronic HBV infections (CHB) were acquired vertically, with 0.11% (0.07-0.19) of new-borns acquiring HBV infection. Model projections estimate that the annual number of new CHB infections have decreased by 31.8% (19.3-38.7) over 2015-2022 and will decrease by 50.0% (36.3-56.5) by 2030. For under-fives, we project that the HBsAg-prevalence will be 0.08% (0.05-0.15) by 2030; below WHO’s target. Existing vaccinations have averted 16,200 (6,800-34,500) CHB infections over 2007-2022, resulting in 39.6% (31.6-46.3) fewer infections in 2022.

Conclusion: HBV vaccination scale-up in Punjab has had substantial impact but further strategies are needed to reach the WHO HBV elimination targets.

Abstract Submission No. 100342
O-0504

A 10-year assessment of a population-based prospective liver cancer screening project in Zhongshan

Mingfang Ji1, Xia Yu1, Yun Du1, Shifeng Lian2, Biaohua Wu1, Fugui Li1

1Cancer Research Institute of Zhongshan City, Zhongshan City People’s Hospital, 2 Sunwen East Rd., Zhongshan 528403, China. Zhongshan China, 2Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institute Stockholm Sweden

Background: A comprehensive, long-term assessment of liver cancer screening programs, comparing populations participating in screening with those not participating, is notably lacking in the global research landscape.

Method: We conducted a community-based screening trial in Xiaolan town, Zhongshan City, Guangdong, China, recruiting residents aged 35-64 years in 2012. In total, 18,185 eligible residents were enrolled in the screening group, while 50,073 residents were included in the non-screening group. Participants in the screening group underwent
testing for hepatitis B virus surface antigen (HBsAg) in serum. Those who tested positive for HBsAg were subsequently invited for alpha-fetoprotein (AFP) testing, liver ultrasonography, and/or computerized tomography twice per year. Liver cancer occurrence, vital survival status, and causes of death were monitored until December 31, 2021, using medical records from hospitals, as well as data from the Zhongshan Cancer Registry, Population Registry, and Cause of Death Registry. We calculated the early detection rate and cumulative incidence of liver cancer among residents in both the screening (HBsAg positive (+) or negative (-)) and non-screening groups. Additionally, we assessed the disparities in overall and liver-cancer-specific survival probabilities between individuals in these groups.

**Results:** With a median follow-up period of 10 years, 432 liver cancer cases occurred. Within the study cohort, comprising 50,073 non-screening residents, 15,295 screening residents with HBsAg (-), and 2,893 screening residents with HBsAg (+), the proportion of liver cancer was 0.6%, 0.2%, and 3.7%, respectively (p<0.01). The early detection rates for these groups were 13.9%, 31.6%, and 29.9%, respectively (p<0.001). The cumulative incidence of liver cancer was highest among screening residents with HBsAg (+) (p<0.001). Furthermore, the cumulative overall survival (p=0.002) and liver-cancer-specific survival (p=0.028) probabilities among liver cancer cases from screening residents with HBsAg (+) were superior to those among cases from screening residents with HBsAg (-) and non-screening residents. Their 1-year overall survival probabilities since diagnosis among screening group versus non-screening group were 53.8% and 34.5%; 3-year overall survival probabilities were 29.4% and 11.3%; and 5-year overall survival probabilities were 27.7% and 6.9%, respectively (all p<0.05). These survival advantages were more pronounced five years after enrollment (Adjusted hazards ratio (aHR): 0.55, 95% confidence interval (CI): 0.41,0.75) than that within five years since enrollment (aHR: 0.99, 95% CI: 0.71, 1.39).

**Conclusion:** This study underscores the importance of proactive liver cancer screening strategies in the early detection of liver cancer. Notably, it highlights the potential to extend the survival probabilities for liver cancer individuals, especially in the long-term perspective.

---

**Epidemiology of HCC in patients with viral Hepatitis**

Saltanat Maharramzade1, Gulnara Aghayeva2, Elhan Aliyev2

1) Baku Health Centre Baku Azerbaijan, 2) Baku branch of Sechenov Medical University Baku Azerbaijan

**Background:** Hepatocellular carcinoma is the most common cancer in the worldwide, representing more than 5% of all cancers. Liver cirrhosis, age, smoking and drinking, and metabolic risk factors will increase the risk of cancer in HBV/HCV/HDV patients. Viral load, FIB-4, and stiffness of the liver can predict the risk of HCC in patients with viral infection. Moreover, effective prevention strategies are needed to reduce the risk of HCC. Secondary prevention includes effective antiviral treatment for HBV / HCV / HDV to prevent disease progression to HCC.

**Methods:** During period since January 2019 to October 2023, 6240 patients (57% males, 43% females, mean age 34 years±6.5) were included to our study, while 1996 (32%) with Hepatitis B, 4224 (67%) Hepatitis C and 249 (4%) with Viral Hepatitis B and D.

**Results**

Totally HCC was diagnosed in 199 patients (3,2%) , with Hepatitis C 97 (2,3%) , with Hepatitis B 55 (2,8%) and also with Hepatitis B+D - 9 (3,8%) patients.

**Conclusion:** Chronic Viral Hepatitis are most important causes of HCC. Among viral hepatitis HCC often determined in B+D viral hepatitis group. Eliminating the route of transmission and vaccination against Hepatitis B will lead to a decrease in the incidence of HCC.
mild or moderate (97.8%). Vaccination is not a protective factor against the Omicron infection. Meanwhile, six patients with worsening DM symptoms were observed after infection, mainly respiratory and skin symptoms, and four of them were judged as related to COVID-19 infection. The other clinical laboratory indexes were relatively stable in patients after infection. Both wild-type (WT) NAb s titer and BA.5-specific IgG titer were significantly enhanced after infection (p<0.01), which was as high as healthy controls (HC). The memory B cell responses were similar between patients and HC group. But both the WT-specific CD8+ T cell and CD4+ T cell were reduced in anti-MDA5 DM patients. In conclusion, patients with anti-MDA5 DM will not deteriorate the COVID-19, in turn, COVID-19 infection will not increase the risk of anti-MDA5 DM exacerbation. The humor al responses were robust but the cellular responses were weakened in anti-MDA5 DM patients after COVID-19 infection.

Abstract Submission No. 100650  
O-0508  
Trends of the mortality of cirrhosis in China: an analysis of the China Death Surveillance Database

Xiaoxiao Wang1, Huixin Liu2, Jinlei Qi3, Lijun Wang3, Peng Yin4, Feng Liu5, Lai Wei6, Yu Wang7, Maigeng Zhou1, Huiying Rao1  
1Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China, 2Peking University People's Hospital, Department of Clinical Epidemiology and Biostatistics Beijing China, 3National Center for Chronic Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention Beijing China, 4Beijing Tsinghua Changgung Hospital, Tsinghua University Beijing China, 5Chinese Foundation for Hepatitis Prevention and Control Beijing China  

Background: China accounted for 14.9% of the total cirrhosis deaths in the world, a detailed and comprehensive understanding of contemporary status of cirrhosis mortality in China will be crucial to establish strategies for intervention and decrease the disease burden of cirrhosis in the world.

Methods: Mortality data from 2008 to 2020 were retrieved from the Disease Surveillance Point system of Chinese Center for Disease Control and Prevention. Crude mortality rate and age-standardized mortality of cirrhosis were exhibited by sexes, residential locations, and regions, respectively. The average annual percentage change (AAPC) of cirrhosis mortality rates from 2008 to 2020 was also calculated.

Results: The crude mortality rate of cirrhosis was 4.57 per 100,000 people in 2020. Compared with females and individuals living in urban areas, females and people living in rural areas had higher age-standardized mortality. The crude mortality rate and age-standardized mortality rate in provinces from southwest China (Guangxi, Yunnan, Guizhou, Qinghai) was higher than that in other provinces. Meanwhile, with the increase of ages, the age-specific mortality rate increased significantly. From 2008 to 2020, the mortality rates of cirrhosis showed a downward trend in China except for males aged 50-59 years, females aged 45-49 years and 80-84 years.

Conclusions: From 2008 to 2020, the mortality rate of cirrhosis showed a decreasing trend in China. In the future, interventions for cirrhosis mortality control need to pay more attention to all males and females aged 45-49 and 80-84 years, people living in rural areas and provinces in southwest China.

Abstract Submission No. 100922  
O-0510  
Changes in the prevalence of hepatitis B and C viral infections in Sindh province, Pakistan:

Tesfa S Alamneh1,2, Josephine Walker1, Aaron G Lim1, Ejaz Alam1, Saeed Hamid3, Graham R Foster4, Naheed Choudhry5, M.Azim Ansari6, Huma Qureshi7, Peter Vickerman1  
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Bristol United Kingdom, 2Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar Ethiopia Gondar Ethiopia, 3Pakistan Health Research Council Research Centre, Karachi, Pakistan Karachi Pakistan, 4Aga Khan University, Karachi, Pakistan Karachi Pakistan, 5Queen Mary University of London, London, UK London UK, 6Nuffield Department of Medicine, University of Oxford, Oxford, UK Oxford UK, 7Consultant Gastroenterologist, Doctor Plaza, Clifton Karachi Clifton Karachi Pakistan

Background/Aims: Pakistan harbours a large burden of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. We utilised repeat sero-surveys to assess progress achieved towards hepatitis elimination in Pakistan.

Methods: Multilevel logistic regression evaluated the change in HBV infection (HBV surface antigen (HBsAg)-positive) prevalence and...
HCV exposure (HCV antibody (HCV-Ab)-positive) prevalence between two sero-surveys from 2007 and 2019 for Sindh province, and associated risk factors. Adjusted Odds Ratios (aOR) were estimated, and population-attributable fractions (PAF) for modifiable risk factors for HCV exposure.

**Results:** The 2007 and 2019 surveys included 8855 and 6672 individuals. HBsAg prevalence decreased from 2.6% (95% confidence intervals (95%CI):2.2-2.9%) in 2007 to 1.1% (95%CI:0.8-1.3%) in 2019, while HCV-Ab prevalence increased from 5.1% (95%CI:4.6-5.5%) to 6.2% (95%CI:5.6-6.8%). The age and gender-adjusted HBsAg prevalence decreased by 80% (aOR=0.2, 95%CI:0.1-0.4) among children and 60% (aOR=0.4, 95%CI:0.3-0.6) among adults over 2007-2019, while HCV-Ab prevalence decreased by 60% (aOR=0.4, 95%CI:0.2-0.7) in children and increased by 40% (aOR=1.4, 95%CI:1.2-1.7) in adults. HCV-Ab prevalence was lower in adults with secondary (aOR=0.6, 95%CI:0.5-0.8) and higher (aOR=0.5, 95%CI:0.3-0.8) education compared to illiterates, and higher among adults reporting blood transfusion (aOR=1.7, 95%CI:1.2-2.4), family history of hepatitis (aOR=2.5, 95%CI:1.9-3.3), past year medical injection (aOR=2.1, 95%CI:1.6-2.7), being tattooed (aOR=1.4, 95%CI:1.0-1.9) and shaved by traditional barber (aOR=1.2, 95%CI:1.0-1.5). Modifiable risk factors accounted for 45% of HCV exposure, with medical injection(s) accounting for 38% (95%CI:25.7-48.4%).

**Conclusions:** Overall HCV has increased over 2007-2019 in Sindh province, while HBV prevalence has decreased. Medical injections should be an important focus of prevention activities.

**O-0512**

**Hepatitis A Among Adult Patients Presenting With Acute Hepatitis: A Changing Epidemiological Trend**

Yumna Shahid1, Amna Subhan1, Faisal Wasim1

1Aga Khan University Hospital Karachi Karachi Pakistan

**Background:** For decades, Hepatitis A virus (HAV) had been a leading cause of acute hepatitis among children and was less prevalent among adults. However, recently a paradigm shift has been observed in the epidemiology of HAV evident by cases of acute hepatitis due to HAV among adults. Very limited data is available from Pakistan about the burden of hepatitis A among adults. The study is designed to estimate the frequency of HAV among adult patients with acute viral hepatitis at a tertiary care hospital in Karachi, Pakistan.

**Methods:** This is an ongoing prospective, cross-sectional study, being conducted at Gastroenterology Department Aga Khan University Hospital from January 2022 to November 2023. Patients aged ≥ 18 years who presented with acute hepatitis to emergency or outpatient department were reviewed. Demographic data, clinical and laboratory parameters were recorded and analyzed.

**Results:** A total of 117 patients were found to have acute hepatitis caused by hepatotropic viruses. Most common age group is 18-30. Approximately 64% of cases of acute hepatitis were attributed to HAV followed by 35% of the cases due to HEV, 1% by HBV. Higher levels of ALT and AST were observed among adults with HAV than HEV. Higher proportion of HEV was recorded among pregnant patients. Higher proportion of Acute hepatitis with coagulopathy and ALF were observed among HEV cases than HAV.

**Conclusions:** HAV seems to be the rising cause of acute hepatitis among adults. This signifies the need of improved sanitation, hygiene and a robust vaccination programme against Hepatitis A among adult population.

**O-0513**

**Genetic variation in SLC39A8 and risk of hepatocellular carcinoma in the Danish general population**

Anne-Sofie Seidelin1,2, Borge Gronne Nordestgaard3,4, Anne Tybjerg-Hansen1,2, Stefan Stender1,3

1Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital Copenhagen Danmark, 2Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital Copenhagen Denmark, 3Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen Denmark

**Background:** Manganese is an important co-factor for numerous biological processes. Multiple studies have linked a common variant in the manganese transporter SLC39A8, p.Ala391Thr to lower blood levels of manganese. The variant has further been linked to increases in alanine transaminase levels and MRI determined hepatic inflammation. We hypothesize that the SLC39A8, p.Ala391Thr variant associates with increased risk of liver disease mediated by manganese deficiency in the general population.

**Methods:** We included n = 334,886 white participants from the UK Biobank and n = 117,074 white participants from the Copenhagen City Heart Study and the Copenhagen General Population Study combined. We tested associations with biochemical and imaging markers of liver disease, risk of ICD-based liver disease, and risk of liver-related and all-cause mortality for carriers of the SLC39A8, p.Ala391Thr variant.
Results: There were 56,705 heterozygous and 2,079 homozygous carriers of the p.Ala391Thr variant in total. The variant associated with increased plasma alanine transaminase, aspartate transaminase, and triglycerides and with lower levels of albumin, total cholesterol, and HDL cholesterol. In the Copenhagen cohort, the variant associated with increased risk of hepatocellular carcinoma (odds ratio = 1.89, 95% confidence interval (CI): 1.19-2.98, P = 0.006). Heterozygous carriers had an increased risk of liver related mortality with a hazard ratio of 1.68 (95% CI: 1.13-2.48, P = 0.007).

Conclusion: SLC39A4 p.Ala391Thr associated with increased liver enzymes and increased risk of developing and dying from liver cancer in the general population.

Abstract Submission No. 101408
O-0514

Telomere length and risk of cirrhosis and liver cancer in the Danish general population

Helene Gellert-Kristensen1, 3, Stig E. Bojesen2, 3, Anne Tybjærg-Hansen1, 4, Stefan Stender1, 3
1University Hospital Copenhagen, Copenhagen, Denmark, 2Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Herlev Danmark, 3Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Background: Inherited short telomeres are associated with risk of liver disease, whereas longer telomeres predispose to cancer. The association between telomere length and risk of hepatocellular carcinoma and cholangiocarcinoma remains unknown.

Method and Results: We measured leukocyte telomere length using multiplex PCR in 63,272 individuals from the Danish general population. Telomere length and plasma alanine transaminase concentration were not associated (β = 4 x 10⁻⁶; P-value = 0.06) in a linear regression model. We tested the association between telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma using Cox regression. During a median follow-up of 11 years, 241, 76, and 112 individuals developed cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma, respectively. Telomere length and risk of cirrhosis were inversely and linearly associated (P-value = 0.004, P for nonlinearity = 0.27). Individuals with telomeres in the shortest vs. longest quartile had a 2.25-fold higher risk of cirrhosis. Telomere length and risk of hepatocellular carcinoma were nonlinearly associated (P-value = 0.009, P-value for nonlinearity = 0.01). This relationship resembled an inverted J-shape, with the highest risk observed in individuals with short telomeres. Individuals with telomeres in the shortest vs. longest quartile had a 2.29-fold higher risk of hepatocellular carcinoma. Telomere length was inversely and linearly associated with the risk of cholangiocarcinoma (P-value = 0.03, P for nonlinearity = 0.95). Individuals with telomeres in the shortest vs. longest quartile had a 1.86-fold higher risk of cholangiocarcinoma.

Conclusion: Shorter telomere length is associated with a higher risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma.

Abstract Submission No. 101439
O-0515

Global, regional, and country-level estimates of new HCV infections attributed to injection drug use

Adelina A Artenie1, Katharine J Looker1, Jack Stone1, Aaron G Lim1, Adam Trickey1, Anna McNaughton1, Hannah Fraser1, Matthew Hickman1, Louisa Degenhardt2, Jason Grebely3, Daniel Low-Beer4, Greg Dore4, Niklas Luhmann4, Samantha Colledge2, Peter Vickerman2
1University of Bristol, Bristol, UK, 2National Drug and Alcohol Research Centre, Sydney, Australia, 3The Kirby Institute, UNSW Sydney, Sydney, Australia, 4World Health Organization, Geneva, Switzerland

Background: We estimated, at country/regional/global levels, HCV incidence in people who inject drugs (PWID) and the number of new annual HCV infections attributed to injection drug use using multiple methods and data.

Method: We compiled previously published estimates of HCV incidence in PWID from our global systematic review and modelling studies with new estimates. We used four different methods to estimate HCV incidence: (i) longitudinal re-testing of people-at-risk or assays for recent infection (direct), (ii) dynamic modelling using HCV Ab prevalence in PWID (modelled (M1)), (iii) force-of-infection modelling using HCV Ab prevalence by injecting duration (modelled (M2)), and (iv) imputation based on HCV Ab prevalence (imputed). Country-specific HCV incidence in PWID was estimated by pooling direct, modelled M1 and M2 estimates, as available; alternatively, we used imputed estimates. Number of new annual HCV infections attributed to injection drug use was estimated by multiplying country-specific HCV incidence with number of RNA-Pсид).

Results: We included 247 HCV incidence estimates from 105 countries, representing 88% of the global PWID population. 66, 79, 88 and 14 of these estimates were direct, modelled (M1), modelled (M2) and imputed, respectively. HCV incidence ranged as 0.5-40.5/100 person-years. We estimated 1,193,660 (95% CI: 710,350-1,917,410) new HCV infections due to injection drug use annually, with variation regionally (Table) and by country (Figure). The largest number of new infections were in the US (325,230; 95% CI: 170,980-561,120; 27%), China (299,780; 95% CI: 203,290-424,160; 25%) and Russia (95,570; 95% CI: 67,400-132,860; 8%).

Conclusion: Unsafe injecting practices among PWID contribute substantially to incident HCV infections globally.

Abstract Submission No. 101632
O-0516

The creation of a hepatocellular cancer (HCC) registry in a low-to-middle income country (LMIC)

Beatrice J Tiangco1, 2, 3, Shanaia Esthelle Joy P Daguit3, Ethel Dominique E Viray3, Ramonito B Nuique4, Edhel S Tripon4
1University of the Philippines National Institutes of Health, Manila, Philippines, 2Augusto P. Sarmiento Cancer Institute, The Medical City, Pasig Philippines, 3Cancer CARE Registry and Research Philippines Foundation, Inc, Pasig Philippines, 4Center for Liver Health and Transplant, The Medical City, Pasig Philippines, 5Ateneo School of Medicine and Public Health, Pasig Philippines

Background: Hepatocellular cancer (HCC) usually develops on top of chronic liver disease from various etiologies. A registry gathers real-world data on the effects of underlying risk factors, viral serologies, diagnostic imaging, and treatment on patient outcomes and helps guide screening recommendations and public policy.

Methods: Patients with HCC from the “Early Cancer Detection in the Liver of Filipinos with Chronic Active Hepatitis B using AI-Driven Integration of Clinical and Genomic Biomarkers (CANDLE) Study” were included. Follow-up was done every 6 months for three years or until study-end in March 2023. De-identified data was entered into an electronic database which served as the HCC registry.

Results: From December 2019 to January 2023, the CANDLE Study included 87 patients with HCC, 72.4% were male and majority
belonged to the lowest strata of income. On underlying liver disease: 51.7% were HbsAg+, 24.1% were HBSAg- and AntiHBC+, and NAFLD was present in 62.1%. Cirrhosis was present in 71.3%. HCC was diagnosed at an unresectable stage (BCLC B-D) in 59 (67.8%) patients, 21 (24.6%) received curative intent hepatectomy and only 46.0% received specific cancer treatment. 34 deaths were documented within the study and of these 82.4% died within 6 months of follow up.

**Conclusion:** HCC registries containing epidemiologic data such as disease etiology and host metabolic and socioeconomic factors can be interrogated by researchers for more understanding leading to better outcomes of this disease.

Abstract Submission No. 101755

**O-0517**

**Global, regional, and country-level estimates of new HCV infections attributed to injection drug use**

Adelina Artenie1, Katharine J Looker1, Jack Stone1, Aaron G Lim1, Adam Trickey1, Anna McNaughton1, Hannah Fraser1, Matthew Hickman1, Samantha Colledge1, Louisa Degenhardt1, Greg Dore2, Jason Grebely3, Daniel Low-Beer3, Niklas Luhmann4, Peter Vickerman4

1University of Bristol Bristol United Kingdom, 2National Drug and Alcohol Research Centre Sydney Australia, 3The Kirby Institute Sydney Australia, 4World Health Organization Geneva Switzerland

**Background:** We estimated, at country/regional/global levels, HCV incidence in people who inject drugs (PWID) and the number of new annual HCV infections attributed to injection drug use using multiple methods and data.

**Methods:** We compiled previously published estimates of HCV incidence in PWID from our global systematic review and modelling studies with new estimates. We used four different methods to estimate HCV incidence: (i) longitudinal re-testing of people-at-risk or assays for recent infection (direct), (ii) dynamic modelling using HCV Ab prevalence in PWID (modelled(M1)), (iii) force-of-infection modelling using HCV Ab prevalence by injecting duration (modelled(M2)), and (iv) imputation based on HCV Ab prevalence (imputed). Country-specific HCV incidence in PWID was estimated by pooling direct, modelled M1 and M2 estimates, as available; alternatively, we used imputed estimates. Number of new annual HCV infections attributed to injection drug use was estimated by multiplying country-specific HCV incidence with number of RNA- PWID.

**Results:** We included 247 HCV incidence estimates from 105 countries, representing 88% of the global PWID population. 66, 79, 88 and 14 of these estimates were direct, modelled(M1), modelled(M2) and imputed, respectively. HCV incidence ranged as 0.5-40.5/100 person-years. We estimated 1,193,660 (95%CI: 710,350-1,917,410) new HCV infections are due to injection drug use annually, with variation regionally (Table) and by country (Figure). The largest number of new infections were in the US (325,230; 95%CI: 170,980-561,120; 27%), China (299,780; 95%CI: 203,290-424,160; 25%) and Russia (95,570; 95%CI: 67,400-132,860; 8%).

**Conclusion:** Unsafe injecting practices among PWID contribute substantially to incident HCV infections globally. Findings emphasize the importance of scaling-up prevention and treatment strategies for PWID.

Abstract Submission No. 101768

**O-0518**

**Risk factors for short outcomes after EGVB: a follow-up study of 243 elder cirrhotic patients**

Yanglan He1, Qi Li1, Lingna Lv1, Chunlei Fan1, Huiguang Ding1

1Capital Medical University Youan Hospital Beijing China

**Background:** Evidence of short-term outcomes after esophagealvarical bleeding (EGVB) in the elderly cirrhotic patients is scarce. The study aimed to evaluate the 6-week rebleeding rate and mortality and explore their risk factors in elderly cirrhotic patients with acute variceal bleeding.

**Methods:** Two hundred and forty-three elderly cirrhotic patients without hepatocellular carcinoma admitted to the department of emergency with EGVB were included.

**Results:** Twenty three patients (23/237, 9.7%) developed rebleeding and 17 (17/243, 7.0%) patients died after admission. Compared to patients without rebleeding, patients with 6-week rebleeding had significantly lower diastolic blood pressure (DBP), higher troponin I (TnI) level, MELD score and Child-Pugh score. Compared to survival patients, the patients who died within 6 weeks had significantly lower systolic pressure, higher levels of myoglobin (MYO) and TnI, higher MELD and Child-Pugh scores, and higher shock index and 6-week rebleeding rate. After adjusting for MELD, DBP remained an independent risk factor for rebleeding (OR=0.951, p<0.05). After adjusting for 6-week rebleeding and MELD and Child-Pugh scores separately, MYO (OR=30.654, p<0.05) remained an independent risk factor for mortality. After adjusting for MELD score, shock index remained an independent risk factor for mortality.

**Conclusion:** Physical signs, including blood pressure and heart rate, and myocardial injury often suggest poor short-term prognosis in elderly cirrhotic patients.
hepatitis (7.6%), primary biliary cholangitis (4.0%) and drug induced liver injury (1.2%). Percentage of liver biopsies for HBV remained stable and that of HCV has decreased, whereas NAFLD and autoimmune liver diseases had rising percentages through years (Figure 2). There was no initial clinical diagnosis in 10.9% of patients, in whom liver biopsy was also mostly nonspecific (72%). However, NAFLD and autoimmune liver diseases were diagnosed in respectively 9.5% and 8.9% of these patients after biopsy.

**Conclusion:** While chronic hepatitis B infection remains most common diagnosis after liver biopsies, there were gradually increasing trends for autoimmune liver diseases and NAFLD during last decade.

Abstract Submission No. 101842
O-0520

The phylogenetic and geospatial approach for Hepatitis B Virus genotypes distribution in Indonesia

Sri Jayanti1, Turyadi Turyadi1, Nu’man AS Daud2, Luthfi AM Parewangi3, Rini R Bachtiar2, Rina Masada4, Irdan Handayani4, Agustiningish Agustiningish5, Korri E El-Khobar6, Muhammad N Massi7, David H Muljono8, Caecilia HC Sukowati9

1Eijkman Research Center for Molecular Biology, National Research and Innovation Agency of Indonesia Cibinong Indonesia, 2Department of Internal Medicine, Faculty of Medicine, Hasanuddin University Makassar Indonesia, 3Department of Pathology Anatomy, Hasanuddin University Makassar Indonesia, 4Department of Clinical Pathology, Faculty of Medicine, Hasanuddin University Makassar Indonesia, 5Department of Microbiology, Faculty of Medicine, Hasanuddin University Makassar Indonesia, 6Faculty of Medicine and Health, University of Sydney New South Wales Australia, 7Liver Cancer Unit, Italian Liver Foundation ONLUS Trieste Italy

The genetic landscape of Hepatitis B Virus (HBV) is intricate and exhibits geographical variations, with clinical implications and treatment responses linked to specific HBV genotypes. Despite the identification of predominant genotypes in previous studies, a comprehensive geospatial assessment of hepatitis B genotypes in Indonesia is notably absent. This underscores the urgency for extensive investigations into the burden of hepatitis B categorized by genotype in various regions. We examined the regional molecular epidemiology of the HBV genotype using a combined phylogenetic and geospatial approach. A hundred and ninety-three HBV samples were isolated from chronic hepatitis B patients and their clinical data were obtained from two distant regions, DKI Jakarta and South Sulawesi, representing western and eastern parts of Indonesia, respectively. HBV genotype was determined from DNA sequences of the S gene of HBV DNA subjected to phylogenetic analysis using standard reference sequences. Patients’ data were characterized according to demographics, genotype likelihood phylogeny, and geospatial hotspot analysis using Getis-Ord Gi* statistics. Demographic data showed that HBV isolates from DKI Jakarta were distributed by genotype B while South Sulawesi was genotype C (p<0.001). Geospatial analyses revealed a more concentrated focus on genotype C in the northern part of DKI Jakarta compared to B. Meanwhile, the distribution of HBV genotypes B and C in South Sulawesi was largely distributed across the region. This early study indicates the distinct pattern in hepatitis B molecular epidemiology and the need for a comprehensive study on the geospatial distribution of HBV genotypes in Indonesia.

Targeting CDK5/PAK1 attenuates lipid overload-induced HCC via suppressing lysosomal stress

Tongguo Miao1, Yuenan Nan1, Dong Ma2, Ying Zhang1, Xianzhe Lou2, Weivei Guan1, Lu Li1, Xiwei Yuan1

1Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base Shijiazhuang, 2Department of Biochemistry and Molecular Biology, Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University Shijiazhuang China

**Background:** Immunotherapy has revolutionized cancer treatment. Unfortunately, most tumor types do not respond to immunotherapy due to a lack of enhancing inflammation in tumor microenvironment (TME), a contributing factor is lysosomal stress (LS). How LS impacts the TME remains understudied.

**Methods:** We investigated the role of the CDK5/PAK1 pathway in the regulation of lysosomal stress in hepatocellular carcinoma (HCC) development by conducting metabolomic analysis, gene expression profiling and immunohistochemistry analyses in RAW264.7 cells, oncogene-induced HCC mouse models and human HCC samples.

**Results:** We show that ox-LDL activates cyclin-dependent kinase 5 (CDK5), and CDK5 phosphorylates P21 (RAO1) Activated Kinase 1 (PAK1), which leads to LS. Furthermore, we found targeting of the CDK5/PAK1 pathways is a novel and tolerable approach to significantly reverse M2 transition to inhibit tumor development in vitro experiment. This approach reduced IL-10 and TGF-β expression of macrophages and suppressed ox-LDL-induced LS, together with decreasing deposition of lipofuscin and increasing expression and nuclear localization of TFEB, an indicator of LS.

**Conclusions:** This study suggests that CDK5/PAK1 pathway inhibition is a potential approach to broaden immunity therapies by suppressing lipid overload-mediated, LS-dependent M2 transition and supports the translation of this novel approach to further improve response rates for proliferation and metastatic hepatocellular carcinoma.

Keywords: CDK5, lysosomal stress, macrophage polarization, tumor microenvironment, liver cancer

Abstract Submission No. 100245
O-0522

TERT upregulation promotes cell growth via degradation of p21 and enhances hepatocarcinogenesis

Masako Mishima1, Haruhiko Takeda1, Atsushi Takai2

1Department of Gastroenterology and Hepatology Graduate School of Medicine, Kyoto University Kyoto Japan

**Background:** Telomerase reverse transcriptase (TERT) gene aberration is detectable in more than 80% of the cases with hepatocellular carcinoma (HCC). Although TERT reactivation is essential for cellular immortalization because it stabilizes telomere length, the role of TERT in hepatocarcinogenesis remains unelucidated. This study aimed to elucidate the significance of aberrant TERT expression in hepatocytes in inflammation-associated hepatocarcinogenesis.

**Method:** We generated a mouse model with hepatocyte-specific Tert overexpression (Alb-Cre;TertTg) and examined their phenotype under chronic inflammation. Based on the transcriptome data from the liver tissue of Alb-Cre;TertTg mice, we examined the role of TERT in hepatocarcinogenesis in vitro. We also evaluated the relationship between TERT and cell cycle-related molecules, including p21, in HCC samples.

Abstract Submission No. 100166
O-0521
Result: The liver tumor development rate was increased by Tert overexpression during chronic inflammation, especially in the absence of p53 function. Gene set enrichment analysis of liver tissues revealed that gene sets related to cell cycle and apoptosis were upregulated in Alb-Cre;TertTg liver. It was found that TERT formed protein complexes with p21, cyclin A2, and cyclin E, promoted ubiquitin-mediated degradation of p21, specifically in the G1 phase. In the clinical HCC samples, TERT was highly expressed but p21 was conversely downregulated, and TERT expression was associated with the upregulation of molecules related to the cell cycle.

Conclusion: The aberrant upregulation of TERT promoted cell cycle progression via ubiquitin-mediated degradation of p21 and enhanced hepatocarcinogenesis.

Abstract Submission No. 100448
O-0523

Integrated multiomics reveal clinical correlation between circPTK2 and liver transplantation for HCC

Xin Hu1,2, Ronggao Chen3, Guannong Chen2, Yingchen Huang2, Di Lu, Xuyong Wei2, Qiang Wei1, Xiao Xu1,2
1Zhejiang University School of Medicine Hangzhou China, 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Hangzhou China, 3Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine Hangzhou China

Background: Circular RNAs (circRNAs)-mediated post-translational modification of RNA-binding proteins (RBP) plays a pivotal role in recurrence and metastasis of liver transplantation (LT) for hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical significance remain vague.

Methods: Patient derived tumor xenograft, organoids and the multi-omics approaches combining of transcriptome sequencing, tandem mass tag-based proteome sequencing and high-throughput sequencing were performed to screen the potential circRNAs. Tissue microarrays of LT for HCC containing 269 patients were used to evaluate the prognostic capacity of circRNAs and nucleolin (NCL).

Results: CircPTK2 was evaluated in HCC and was found to prevent the interaction between nucleolin (NCL) and the E3 ligase tripartite motif-containg 21 to reduce the proteasome-mediated degradation of NCL via K48-linked polyubiquitylation, promoting metastasis. Higher expression of circPTK2 and NCL in tumor portended worse overall survival (OS) and recurrence free survival (RFS) (RFS rat: 41.3% vs. 55.4%, P=0.0081, 37.4% vs. 63.1%, P<0.0001). CircPTK2 and NCL had satisfactory evaluation capabilities for OS in patients who beyond the Milan criteria (p=0.0034 and 0.0033). In patients who met Hangzhou’s criteria, elevated circPTK2 and NCL expression was correlated to a worse OS and RFS (OS: P=0.0048 and 0.0013, RFS: P=0.0374 and 0.0001). Notably, patients with negative AFP and low circPTK2 expression had a superior OS than those with negative AFP but high circPTK2 expression (P=0.0386).

Conclusion: CircRNA and NCL are closely related to the metastasis of HCC and are effective prognostic indicators to patients with LT for HCC.

Abstract Submission No. 100858
O-0524

Intra-tumoral Microbiome Promotes Hepatoma Cell Proliferation and Is Associated with Prognosis

Ming-Lun Yeh1, Yi-Shan Tsai1, Po-Cheng Liang1, Po-Yau Hsu1, Ting-Yuan Jang1, Yu-Wu We1, Zu-Yau Lin1, Chung-Feng Huang1, Jee-Fu Huang1, Chia-Yen Dai1, Wan-Long Chuang1, Ming-Lung Yu1
1Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital Kaohsiung Taiwan, 2School of Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan

Background: Cancer specific intra-tumoral microbiome had been identified. We aimed to explore the role of intra-tumoral microbiome in the pathogenesis of HCC.

Methods: The method to harvest primary hepatoma cells had been reported previously. Microbiome infiltration in more than 20% of areas under HPF was defined as abundant. Fluorescence in situ hybridization (FISH) was performed with bacterial 16s RNA sequences in fresh HCC surgical tissues. Taxonomic compositions were analyzed by 16s rRNA sequencing. Hepatoma cell lines (Huh7, HA22T and Hep3B) cell line were cultured with microbiome medium for cell proliferation experiments. Metabolomic study was done by liquid chromatography-tandem mass spectrometry.

Results: FISH confirmed the presence of intra-tumoral microbiome in HCC. The most dominant microbe at the phylum level was Proteobacteria, and Xanthomonas, and Acetobacter were the most dominant microbes at the genus level. It showed no significant differences in the taxonomic compositions in different HCC stages and etiologies. HCC patients with abundant microbiome demonstrated a larger tumor size and decreased survival. The cell proliferation experiments by WST1 assay showed hepatoma cells cultured with medium of microbiome showed a higher cell proliferation and the effect diminished after removal of microbiome. These cells exhibited higher expression levels of YAP1, and the YAP1 expression decreased after removal of microbiome. The untargeted metabolomic study demonstrated a significantly difference of metabolites before and after the removal of microbiome. The targeted metabolomic study demonstrated a significantly difference of metabolites before and after the removal of microbiome.

Conclusions: Intra-tumoral microbiome promotes hepatoma cell proliferation through Hippo-YAP pathway, and was associated with a poor survival. The results implicated a therapeutic target of HCC.

Abstract Submission No. 100943
O-0525

Whole-genome sequencing-based mutational analysis on hypovascular small hepatocellular carcinoma.

Haruhiko Takeda1, Atsushi Takai1, Tadashi Inuzuka1, Etsuro Hatano2, Hiroshi Seno1, Masayuki Ueno1, Yosuke Fuji1, Shigeharu Nakano1, Masako Mishima1, Eriko Iguchi1
1Department of Gastroenterology and Hepatology, Kyoto University Hospital Kyoto Japan, 2Department of Surgery, Kyoto University Hospital Kyoto Japan

Background: Whole-genome sequencing (WGS) is a powerful tool to unveil the genetic landscape of individual tumors. Although WGS has been revealed the mutational landscape of classical HCCs, genetic feature of hypovascular small liver nodules remains still unclear.

Methods: We conducted multi-regional WGS on a total of 41 samples including sixteen surgically resected hypovascular tumor tissues, eight hypervascular HCCs, two extrahepatic metastatic lesions, seven non-tumor liver tissues and eight lymphocytes from nine HCC patients. We comparatively analyzed the genetic alterations, including point mutations, genetic structural variations and copy number variations of hypovascular liver tumor tissues, with hypervascular HCC tissues and also fifteen Japanese patients with advanced HCC with portal vein
invasion in LIRI-JP cohort of International Cancer Genome Consortium project.

Results: All the hypovascular nodules were pathologically revealed well to mod differentiated HCCs, which harbored approximately 8000 mutations including single nucleotide variants and short indels along with several structural variations such as chromosomal translocations, inversions and arm-level amplifications or heterozygous alterations. Importantly, these genetic alterations included several well-known cancer driver genes as well as hypervascular HCCs. As for the structural variations, advanced HCC with portal invasion had significantly more numbers of genomic rearrangements than hypovascular HCC tissues, suggesting the genetic alterations should be formed more complicated during multistep hepatocarcinogenesis from hypovascular HCCs to invasive HCCs.

Conclusions: Small hypovascular HCCs already accumulate various genetic alterations including driver gene mutations of HCC. Genetic comparison with the earlier stage noncancerous liver nodules should be useful for the understanding of the initial step of hepatocarcinogenesis.

Abstract Submission No. 101137

O-0526

Low-speed regular exercise reduces HCC development by muscle PGC1α-mediated kynurenine degradation

Naoko Ohtani, Vu thuong Huyen, Ryota Yamagishi, Kanae Echizen, Yoshihiko Nonaka, Shinji Fukuda

1Osaka Metropolitan University, Graduate School of Medicine Osaka Japan, 2Institute for Advanced Biosciences, Keio University Tsuruoka Japan

Recently, the number of patients with steatohepatitis-associated hepatocellular carcinoma (HCC) has been steadily increasing. The beneficial effects of exercise on cancer prevention have been generally accepted; however, the mechanisms remain largely unclear. In this study, we subjected mice to chemical liver carcinogenesis protocol with a continuous high-fat diet feeding for 35 weeks and subsequent low-speed (10m/min), one-hour regular running everyday for the last 8 weeks in the protocol. Interestingly, the exercised mice developed significantly reduced number of HCC. The metabolome analysis using mouse serum revealed that kynurenine, a well-known onco-metabolite that can act on AhR nuclear receptor to suppress antitumor immunity, significantly decreased in the exercised mice. In the exercised group, the expression of genes encoding PGC-1α and PGC-1α-dependent kynurenine aminotransferases (KAT), which can degrade kynurenine, significantly upregulated in the skeletal muscles, coinciding with the HCC reduction. These results suggest that the upregulation of skeletal muscle-derived PGC-1α and KAT by exercise could activate anti-tumor immunity by degrading kynurenine. To this end, using the liver tumor tissue, we performed mRNA-sequencing and WGCNA (Weighted Gene Correlation Network Analysis), and successfully identified a series of gene-set modules altered in parallel by exercise. Interestingly, certain gene-set modules were associated with the reduction of Treg cells and tumor vascularity by exercise, indicating that exercise ameliorated the tumor microenvironment. We confirmed these modules are also reduced by AhR inhibitor treatment in mice, suggesting that these alterations are kynurenine-AhR signaling-dependent. Our analysis shows that low-speed exercise has beneficial inter-organ effects for significant HCC prevention.

Abstract Submission No. 101473

O-0527

Development of precision-bioprinted patient-derived organoids for high-throughput drug screening

Janina EE Tirtzin-Parker, Gayatri D Shirolkar, Sara Pasic, Jonathan Tibballs, Shirley Go, Rachel Way, Michael Wallace, Louise Winteringham, Peter Leedman, Benjamin J Dwyer

1Curtin University Bentley - Perth Australia, 2Harry Perkins Institute of Medical Research Perth Australia, 3Liver Cancer Collaborative Perth Australia

Background and Aims: Liver cancer, the third most common cause of cancer mortality globally, is inadequately addressed by current systemic treatments due to limited efficacy and high toxicity. New targeted therapies are essential. The development of such therapies is hindered by the lack of suitable in vitro models. This study explores the use of patient-derived organoids (PDOs), potentially superior to traditional models, employing Inventia Life Science’s defined bio-inks in a RASTRUM™ bio-printer for better simulation of the tumour microenvironment.

Methods: We processed 50 liver cancer samples (47 HCC, 3 CCA) to create PDOs in Cultiex Basement Membrane Extract (BME2) and Inventia’s defined bio-inks. The RASTRUM™ bio-printer was employed, utilising bio-inks with stiffnesses of 1.1 or 3 kPa, to identify the best substrate for PDO growth, assessed via imaging and assays. Drug reactions were analysed in PDOs compared to hepatocyte cell lines across matrices.

Results: Eighteen PDO lines were established. Pre-defined matrices enhanced PDO growth, and successful lines were bio-printed for drug assays. The 3 kPa bio-ink was optimal for PDO growth and suitable for 384-well high-throughput assays, revealing significant matrix-dependent drug responses.

Conclusion: A biobank for primary liver cancer PDOs was developed for drug screening. With Inventia Life Sciences, we introduced high-throughput, precision-bioprinted PDO models for primary liver cancer, enhancing drug screening and paving the way for innovative liver cancer treatment development.

Abstract Submission No. 200046

O-0528

Alpha-mangostin nanoparticles exerts hepatocellular carcinoma via alteration of PI3K/Akt pathway

Vikas Kumar

1AAI-DU Allahabad India

Background: Hepatocellular carcinoma (HCC) is the widely documented danger to the liver and 3rd most common reason for tumor death around the world. Identification of oncogene and its related possible pathway is crucial for understanding therapy resistance and effectual treatment. Researcher targeted the 5-bisphosphate 3-kinase/protein kinase B, phosphatidylinositol-4 and mitogen activated protein kinase’s pathway to suppress the cell proliferation and expansion. We made attempt to fabrication the solid lipid nanoparticle (SLN) of alpha-mangostin and examine against the diethylnitrosamine (DEN) induced HCC and explore possible mechanism of action.

Material & method: Double emulsion solvent displacement model was used for the preparation of alpha-mangostin-SLN. Intraperitoneal injection of DEN (200 mg/kg) was used for induction the HCC and various parameters were scrutinized. The genetic effects HP-SLN on Pdk1, Akt1, Pik3r1, Map3k1, Erb2, Pik3ca using semi-quantitative RT-PCR analysis were assessed. Morphological and histopathological component of hepatic tissue were estimated.
Isolating a safe and effective method of treatment for the primary liver cancer remains a global health challenge, specifically hepatocellular carcinoma (HCC). MicroRNA (miR), a small non-coding RNA molecule, performs crucial functions in several biological processes, such as cancer growth and advancement. In this study, we investigated whether miR-29a could modulate the oncogenicity of HCC.

Methods and Materials: Serum of HCC patients and HCC tissues derived from the western diet (WD)/carbon tetrachloride (CCl4)-induced HCC animal model were collected. Transgenic mice were used to study the role of miR-29a.

Key Findings: Reduced miR-29a levels in the serum of HCC patients and the liver tissue of the wild type (WT) of a WD/CCl4-induced HCC animal model were noted. Proteomics analysis identified the pathway-centric role of miR-29a in HCC by targeting MYBL2. Human bioinformatics survey from GTEX and TCGA revealed higher expression of MYBL2 at the upstream of NOL9 in HCC cells were disclosed by bioinformatics analysis and validated by western blot, qRT-PCR, methylation PCR, and antiproliferative effect of sorafenib. The regulatory mechanisms in the upstream of NOL9 in HCC cells were established for evaluating proliferation, apoptosis, cell cycle, and antiproliferative effect of sorafenib.

Conclusion: Our collective data revealed that the ZNF384/NOL9 axis in HCC and the suppression of NOL9 might constitute a strategy for increasing the effect of sorafenib to inhibit HCC cells.

Abstract Submission No. 100043
O-0529

MiR-29a Restrains the Development of Hepatocellular Carcinoma via Targeting MYBL2
Ya-Ling Yang¹, Ying-Hsien Huang¹
¹Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan

Aims: Primary liver cancer remains a global health challenge, specifically hepatocellular carcinoma (HCC). MicroRNA (miR), a small non-coding RNA molecule, performs crucial functions in several biological processes, such as cancer growth and advancement. In this study, we investigated whether miR-29a could modulate the oncogenicity of HCC.

Methods and Materials: Serum of HCC patients and HCC tissues derived from the western diet (WD)/carbon tetrachloride (CCl4)-induced HCC animal model were collected. Transgenic mice were used to study the role of miR-29a.

Key Findings: Reduced miR-29a levels in the serum of HCC patients and the liver tissue of the wild type (WT) of a WD/CCl4-induced HCC animal model were noted. Proteomics analysis identified the pathway-centric role of miR-29a in HCC by targeting MYBL2. Human bioinformatics survey from GTEX and TCGA revealed higher expression of MYBL2 at the upstream of NOL9 in HCC cells were disclosed by bioinformatics analysis and validated by western blot, qRT-PCR, methylation PCR, dual-luciferase reporter assay, and CHIP-qPCR.

Conclusion: Our collective data revealed that the ZNF384/NOL9 axis in HCC and the suppression of NOL9 might constitute a strategy for increasing the effect of sorafenib to inhibit HCC cells.

Abstract Submission No. 100043
O-0529

Cabozaatinib inhibits tumor growth of lenvatinib-resistant hepatoma cells in vitro and in vivo
Koji Fujita¹, Kei Takuma¹, Mai Nakahara¹, Kyoko Oura¹, Tomoko Tadokoro¹, Joji Tani¹, Asahiro Morishita¹, Masafumi Ono¹, Takashi Himoto², Tsutomu Masaki³
¹Kagawa University Takamatsu Japan, ²Kagawa Prefectural University of Health Sciences Takamatsu Japan

Background and aim: Cabozatinib is a newly developed tyrosine kinase inhibitor, which can be used to treat patients with hepatocellular carcinoma (HCC) unresponsive to conventional tyrosine kinase inhibitors, including lenvatinib. However, the efficacy of cabozatinib in lenvatinib-resistant cases has not been well established in clinical trials or basic studies. The present study aims to determine whether cabozatinib can suppress tumor growth of lenvatinib-resistant HCC cell lines in vitro and in vivo.

Methods: To establish lenvatinib-resistant hepatoma cells, Hep3B cells were cultured with different doses of lenvatinib ranging from 1 to 20 μM for three months. Cell proliferation assays were conducted using WST-8. Flowcytometry was adopted to evaluate cell cycle phase arrest and apoptotic changes. Proteome analysis of xenografts was
performed to identify tumor suppressor genes which contributed to efficacy of cabozantinib.

**Results:** Lenvatinib-resistant Hep3B cells (Hep3B-LR) exhibited approximately 20 times greater IC50 for lenvatinib than the wild type. Compared with wild-type Hep3B, Hep3B-LR was characterized by enhanced mTOR phosphorylation with the downregulation of phosphorylated Akt. Cabozantinib suppressed tumor growth in Hep3B-LR in vitro by inducing cell cycle arrest at G2 phase and apoptosis. The animal experiments validated the antitumor effect of cabozantinib. Proteome analysis demonstrated an upregulation of FDCT, a tumor suppressor gene. Knockdown of FTCD enhanced tumor growth of Hep3B-LR.

**Conclusion:** Cabozantinib inhibited the growth of Hep3B-LR in vitro and in vivo. FDCT may be a novel therapeutic target of cabozantinib in case of lenvatinib treatment failure.

**Abstract Submission No. 100156**

**O-0532**

**IRGM is a novel regulator of PD-L1 via promoting S6K1/YBX1 axis in hepatocellular carcinoma**

**Beng Yang1, Junnan Ru1, Jian Wu1, Shusen Zheng1**

1The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou China

**Background:** Immunity-related GTPase M (IRGM), an Interferon-inducible protein, functions as a pivotal immunoregulator in multiple autoimmune diseases and infections. However, the role of IRGM in hepatocellular carcinoma (HCC) development remains unveiled.

**Methods:** Orthotopic patient-derived xenograft (PDX) model, xenograft tumor models, IRGM-conditional knockout mice, and in vitro experiments were utilized to investigate the role of IFN-γ-induced IRGM in HCC progression. Single-cell sequencing and flow cytometry were employed to explore tumor immune environment changes. Whole gene sequencing, Immunoprecipitation-Mass spectrometry (IP-MS), and ChIP assays were performed to elucidate the underlying mechanism.

**Results:** IFN-γ robustly triggers the expression of Irgm1 in HCC. High IRGM expression in tumor samples indicated poor prognosis in HCC patients. In vivo and in vitro experiments demonstrated that IRGM facilitated the malignant phenotype of HCC. Furthermore, Inhibition of Irgm promoted the infiltration of CD8+ cytotoxic T lymphocytes (CTLs) in TME of HCC, which was ascribed to the reduction of PD-L1. Mechanistically, IRGM promotes the interaction between YBX1 and its phosphokinase p70S6K1, leading to phosphorylation of YBX1, resulting in transcription activation of PD-L1 mediated by p-YBX1. The combined application of Irgm inhibition and α-PD1 demonstrated a stronger anti-tumor immune response in HCC tumor-burden mice.

**Conclusion:** IFN-γ-induced IRGM is a novel regulator in tumor microenvironment and HCC progression. And IRGM suppresses CD8+ CTLs infiltration and function in HCC via regulating p70S6K1/YBX1/PD-L1 axis. This study may raise a novel therapeutic strategy combined with immune checkpoint inhibitors (ICIs) against HCC.

**Abstract Submission No. 100179**

**O-0533**

**Novel biomolecule potentiates classic therapeutic protocol against hepatocellular carcinoma**

**Amr Amin1,2**

1UAE University Al Ain United Arab Emirates, 2The University of Sharjah, College of Medicine Sharjah United Arab Emirates

**Background:** Sorafenib (SB) is a multi-kinase inhibitor and is the first line of treatment for advanced hepatocellular carcinoma (HCC), but its clinical applications are limited due to severe side effects and drug resistance. To optimize its therapeutic effects, we used here safranal (SF); a major bioactive component of saffron, to assess the development of HCC in animal model.

**Methods:** Therapeutic effect of SF alone or combined with SB was assessed in cirrhosis rat model of HCC using histopathological, biochemical, immunohistochemical and immunoblotting techniques. Transcriptome analyses were also employed to determine the therapeutic effects of SF and SB.

**Results:** Combined treatments significantly reduced the nodule multiplicity compared to a single therapy group of HCC. It also induced apoptosis, blocked proliferation, and arrested the cell cycle, in the HCC group. Combined therapy improved SB’s anti-inflammatory, anti-fibrotic, and anti-metastatic activities. Using transcriptomic analysis, 45 genes were found to be associated with HCC suppression. Those genes were associated with cellular development, oxidative stress, wound healing, and apoptosis.

**Conclusions:** Downregulation of NF-B-p65, COX-2 and β-catenin are possible mechanisms to underly SF beneficial effects. SF represents a viable candidate for pharmacological target as new anti-liver cancer treatment, both in monotherapy and combined with SB as the current gold standard therapy. Further research is necessary as the clinical safety margin and dosage of the presented combination medication have yet to be determined.

**Abstract Submission No. 100219**

**O-0534**

**A Novel Bile Acid-related lncRNA Signature for Predicting Prognosis and Treatment Response in HCC**

**Hao Cui1,3, Tao Han2, Baiguo Xu1,3, Huiling Xiang1, Jia Lian4, Yingtang Gao5, Zhenjun Yu3, Jingxiang Shi4**

1Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin Tianjin China, 2Department of Gastroenterology and Hepatology, Tianjin Union Medical Center, Tianjin Medical University Tianjin China, 3Department of Gastroenterology and Hepatology, The Third Central Clinical College of Tianjin Medical University Tianjin China, 4Department of Hepatobiliary Surgery, The Third Central Hospital of Tianjin Tianjin China, 5Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin Institute of Hepatobiliary Disease, Nankai University Affinity the Third Central Hospital Tianjin China

Bile acids and salts have been shown to play a role in liver carcinogenesis through DNA damage, inflammation, and tumor proliferation. However, the correlation between bile acid metabolism and hepatocellular carcinoma (HCC) prognosis remains unclear. This study aimed to identify a predictive signature of bile acid and bile salt metabolism-related long non-coding RNAs (lncRNAs) for HCC prognosis and treatment response. The study used HCC RNA-sequencing data and corresponding clinical and prognostic data from The Cancer Genome Atlas. A prognostic model consisting of five bile acid and bile salt metabolism-related lncRNAs was developed and evaluated in a training set, a validation set and an external set. The model demonstrated good performance in predicting HCC prognosis and was shown to be an independent biomarker for prognosis. Additionally, our study revealed a significant association between the signature and immune cell infiltration, as well as its predictive value for therapeutic responses to both immunotherapy and chemotherapy. Furthermore, three lncRNAs (LUCA T1, AL031985.3 and AC015908.3) expression levels in our
signature were validated through qRT-PCR in a cohort of 50 pairs of HCC patient tumor samples and corresponding adjacent non-tumor samples, along with 10 samples of normal liver tissue adjacent to benign lesions. These findings suggest that this novel bile acid and bile salt metabolism-related IncRNA signature can independently predict the prognosis of patients with HCC and may be utilized as a potential predictor of response to treatment in this setting.

Abstract Submission No. 100225
O-0535

Inhibition of CDK4/6 and XPO1 induces senescence with acquired vulnerability to CRBN-based PROTACs

Hui Wang1, Wenxin Qin1, Cun Wang1
1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute Shanghai China

Background: Despite the increasing number of treatment options available for liver cancer, only a small proportion of patients achieve long-term clinical benefits. Herein, we aim to develop new therapeutic approaches for liver cancer.

Methods: Compound screen was conducted to identify inhibitors that could synergistically induce senescence when combined with CDK4/6 inhibitor. The combination effects of CDK4/6 inhibitor and XPO1 inhibitor on cellular senescence were investigated in a panel of human liver cancer cell lines, mouse models of liver cancer, patient-derived organoids, and patient-derived xenografts. A senolytic-drug screen was performed to identify drugs that selectively killed senescent liver cancer cells.

Results: The combination of CDK4/6 inhibitor and XPO1 inhibitor synergistically induces senescence of liver cancer cells in vitro and in vivo. The XPO1 inhibitor acts by causing accumulation of RB1 in the nucleus, leading to decreased E2F signaling and promoting senescence induction by the CDK4/6 inhibitor. Through a senolytic-drug screen, CRBN-based PROTAC ARV-825 was identified as an agent that can selectively kill senescent liver cancer cells. Upregulation of CRBN was a vulnerability of senescent liver cancer cells, making them highly sensitive to CRBN-based PROTAC drugs. Mechanistically, we find that USP2 directly interacts with CRBN, leading to the deubiquitination and stabilization of CRBN in senescent liver cancer cells.

Conclusions: Our study demonstrates a striking synergy in senescence induction of liver cancer cells through the combination of CDK4/6 inhibitor and XPO1 inhibitor. These findings also shed light on the molecular processes underlying the vulnerability of senescent liver cancer cells to CRBN-based PROTAC therapy.

Abstract Submission No. 100260
O-0536

Clinical significance of Cytokine Change in Hepatocellular Carcinoma after Radiotherapy

BAEK GYU JUN1, Sang Gyune Kim2, HeeJae Jung2
1Asanseoul clinic Seoul South Korea, 2Soonchunhyang University College of Medicine Bucheon Hospital Bucheon Korea

Background/Aim: Radiotherapy (RT) can enhance tumor immunogenicity and increases production of cytokines. Prior studies have examined change of cytokine level in cancer patients after radiotherapy, but study on hepatocellular carcinoma (HCC) is lacking. This study investigated the effects of radiotherapy on serum levels of interleukin-2 (IL-2), IL-10, IL-22 and tumor necrosis factor alpha (TNF-a) with HCC.

Methods: Data of HCC patients who underwent radiotherapy at one tertiary referral hospitals between March 2016 and December 2019 for the prospective study. This study included 20 hepatitis B virus (HBV) patients with HCC undergoing RT and 69 HBV controls. The control group was classified into three groups as follows: chronic hepatitis B (CHB) (n=20), liver cirrhosis (LC) (n=21), decompensated LC (DLC) (n=20). Cytokines were serially monitored at pre-RT, end of RT, 1 week and 4 weeks after RT.

Results: At baseline, serum mean levels of IL-6 and IL-22 were higher in patients with HCC than in controls. In control group, serum mean levels of IL-6 and IL-22 were highest in DLC group and lowest in CHB group. The mean levels of IL-6 and IL-22 were increasing early after RT. Levels of TNF-a and aminotransferase (AST) had a positive correlation over time after RT (1 week : r = 0.622 (p=0.004), 4 week : r = 0.523 (p=0.022)).

Conclusion: RT induces changes in levels of IL-6 and IL-22 in HCC patients. Expression of IL-6 and IL-22 level is correlated with liver disease severity.

Abstract Submission No. 100273
O-0537

SOCS1 tumor suppressor sensitizes hepatocellular carcinoma cells to oxidative stress

Subburaj ILANGUMARAN1, Akhil Shukla1, Md GM Khan1, Anny A Cayarga1, Mozhele Namvapour1, Mohammad MH Chowdury1, Sheela Ramanathan1
1University of Sherbrooke, Faculty of Medicine and Health Sciences Sherbrooke Canada

Background: The SOCS1 gene is frequently repressed in hepatocellular carcinoma (HCC). Studying the tumor suppression mechanisms of SOCS1, we have shown that SOCS1 regulates p21-dependent NRF2 activation. Here, we investigated SOCS1-mediated modulation of cellular antioxidant response in HCC cells.

Methods: Murine Hepa-1 cells expressing SOCS1 (Hepa-SOCS1) or control vector (Hepa-vector) were exposed to tert-butyl hydroperoxide (t-BHP) or cisplatin to induce oxidative stress. CDKN1A and NRF2 expression was evaluated by western blot. Induction of NRF2 target genes and proteins was assessed by RT-qPCR and immunofluorescence microscopy. Reactive oxygen species and lipid peroxidation were estimated by microscopy. Proteomes of Hepa-SOCS1 and Hepa-vector cells treated with t-BHP or cisplatin were studied by mass spectrometry.

Results: t-BHP and cisplatin upregulated CDKN1A and NRF2 proteins, and induced NRF2 target genes NfSe2L, Gclc, Gstm1, Gpx2, Hmox1 and Nqo1 and their protein products, which were markedly attenuated by SOCS1. t-BHP and cisplatin markedly reduced the survival of Hepa-SOCS1 cells, accompanied by a reduction in reactive oxygen species and lipid peroxidation, suggesting increased sensitivity of SOCS1 expressing cells to oxidative stress. Proteomic data revealed that SOCS1 modulated many proteins involved in diverse molecular pathways, including ‘chemical carcinogenesis - reactive oxygen species’ with downregulation of several proteins. GCLC, downregulated by SOCS1 at the transcript and protein levels, correlated positively with NFE2L2 and negatively with SOCS1 expression in the TCGA-LIHC dataset.

Conclusions: SOCS1 attenuates NRF2-mediated antioxidant response in HCC cells and this regulation is crucial to prevent their ability to withstand elevated oxidative stress.
Hiệu Hiệu1, Lâm Ngô2, Anh Nguyên3

**Purpose:** To research the imaging characteristics of magnetic resonance imaging (MRI) with primovist in the diagnosis of hepatocellular carcinoma (HCC).

**Material and methods:** The study was conducted on 35 patients regardless of gender, of all ages who came for examination at K Tan Trieu hospital, during the period from May 2021 to October 2022, with indication for primovist MRI and underwent a biopsy or surgery with pathologic findings.

**Results:** The rate of HCC in the study was 86%. Mean age 56.8 years old. Male/female ratio: 10,67. 77% of patients in the study had type 1 - enhanced HCC. The mean value of ADC in patients with HCC was 1.2. Most patients have a moderate differentiation of 60%. Patients with high-differentiation on histopathology mostly have type 3 enhancement. With moderate-differentiation, most have type 1 enhancement. With poorly-differentiation, all have type 1 enhancement. The ADC value in the group of patients with high-differentiation was higher than in the group of patients with moderately-differentiation and poorly-differentiation.

**Conclusion:** Primovist magnetic resonance imaging is highly valuable in the diagnosis of hepatocellular carcinoma with typical changes in ADC values.

**KEY WORDS:** Hepatocellular carcinoma (HCC), Apparent diffusion coefficient (ADC), Magnetic Resonance Imaging (MRI).

---

**MicroRNA-885-5p as a Master Regulator in Cell Cycle Progression of HCC Cells**

Chaiyaboot Ariyachet1,2, Archittapon Nakkaew1,3, Pitsit Tangkijvinich1,2
1Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

**Background:** MicroRNAs (miRNAs) are a class of small non-coding RNAs that regulate specific messenger RNAs (mRNAs) by inhibiting mRNA translation and stability. Emerging studies have demonstrated dysregulation of various miRNAs in the development of hepatocellular carcinoma (HCC). In this study, we aim to identify a novel tumor suppressor miRNA and dissect its molecular functions in HCC cells.

**Methods:** Three microRNA gene profiles of HCC tissues from the TCGA and GEO databases were analyzed to identify putative tumor suppressor miRNAs. MiRNA-885-5p (miR-885-5p) was chosen for functional tests, including MTT assay, BrdU incorporation, and cell cycle analysis, in three HCC cell lines. Transcriptional profiling of control and miR-885-5p-overexpressing HCC cells was performed to identify potential targets of miR-885-5p. Dual luciferase assays were conducted to confirm the direct interaction between miR-885-5p and its target mRNAs.

**Results:** Analysis of miRNA expression profiles from three normal and HCC tissue pairs identified nine miRNAs commonly downregulated in HCC tissues, including miR-885-5p. Overexpression of miR-885-5p significantly suppressed proliferation of HCC cells. Transcriptional profiles of these HCC cells revealed that miR-885-5p induced downregulation of several key genes that promote the G1-to-S transition, including CDK6, E2F2, and CCNA2. Accordingly, miR-885-5p-overexpressing cells displayed reduced rates of BrdU incorporation and G1 phase arrest in the cell cycle. Finally, dual luciferase assays confirmed the direct interaction of miR-885-5p with 3’ untranslated regions of CDK6, E2F2, and CCNA2 transcripts.

**Conclusions:** MiR-885-5p inhibits G1-to-S progression in HCC cells and may represent a new target for HCC therapy.
Background: The efficacy of the combination immunotherapy of atezolizumab and bevacizumab (Atezo+Bev), the first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC), varies from patient to patient. Therapeutic biomarkers might help improve patient outcomes of Atezo+Bev therapy for uHCC. This study aimed to evaluate the status and dynamics of peripheral T cell subpopulations in uHCC patients receiving Atezo+Bev treatment and to explore biomarkers predictive of therapeutic response.

Methods: 83 uHCC patients who initiated Atezo+Bev treatment at our hospital between October 2020 and June 2022 were enrolled. Peripheral T cell subpopulations in peripheral blood mononuclear cells (PBMCs) at baseline and at 3 weeks post-treatment were investigated using flow cytometry. The association between peripheral T cell subpopulation profiles and clinical outcomes was analyzed.

Results: Baseline peripheral T cell subpopulations could be profiled in 70 patients with sufficient cell counts, among which 3-week subpopulations could be evaluated in 51 patients. Multivariate analysis revealed that a high baseline proportion of CD8+ central memory T (T(CM)) cells was independently associated with longer progression-free survival (PFS). Further, overall survival (OS) was significantly prolonged in patients with increased CD8+ effector memory T (TEM) cell proportions after the initiation of Atezo+Bev treatment.

Conclusions: TCM proportion at baseline might be a good indicator of the efficacy of Atezo+Bev therapy. In addition, observation of increasing TEM cell proportions might be an early predictor of the potential clinical benefits of treatment.

Abstract Submission No. 100408
O-0542

Molecular Changes of Circulating Tumor Cells in HCC Patients Receiving Atezolizumab plus Bevacizumab

Yosuke Murata1,2, Takuto Nosaka1, Yasunari Nakamoto1
1Second Department of Internal Medicine, University of Fukui FUKUI JAPAN, 2Sugita Genpaku Memorial Obama Municipal Hospital FUKUI JAPAN

Background: Mechanisms leading to cancer progression of Hepatocellular Carcinoma (HCC) during immunotherapies remain unclear. Circulating tumor cells (CTCs) are non-invasive and real-time biomarkers that provide information about metastatic processes. CTC analysis could reveal molecular mechanisms of cancer progression. We investigated changes in CTC counts and gene expression related to cancer progression in HCC patients treated by Atezolizumab plus Bevacizumab (Atezo/Bev).

Methods: We obtained peripheral blood from 19 HCC patients treated by Atezo/Bev at baseline and response evaluation. Treatment response was assessed by modified RECIST. CTCs were isolated with RosetteSep™ and stained with antibodies targeting CD45 and PanCK. CD45 negative and PanCK positive cells by flow cytometry were defined as CTCs. The expression of 373 genes in CTCs were investigated by next-generation sequencing (NGS) and qRT-PCR.

Results: CTC counts of PR/SD group decreased at response evaluation, compared with baseline (192 vs.94, p<0.01). In NGS analysis, 99 genes showed significant expression changes in clinical course. Unsupervised hierarchical clustering of 99 genes classified into two clusters A and B. Patients in cluster A were responder and showed 100.0% survival rate at 1-year, which was better than 50.0% in cluster B. Apoptosis pathway was upregulated in responder (cluster A). Furthermore, TGF-beta pathway-related genes such as ACT1, CDKN1B and IKBKB were upregulated in non-responder (cluster B) (p<0.05).

Conclusion: The change of CTC counts correlated with therapeutic effect and TGF-beta pathway may play an important role in resistance to Atezo/Bev. CTC analysis in HCC patients during immunotherapy could reveal molecular mechanisms of cancer progression.

Abstract Submission No. 100449
O-0543

Multiple omics revealed the clinical correlation between circPTK2 and liver transplantation for HCC

Xiu Hu1,2, Ronggao Chen1, Guanrong Chen1, Yingchen Huang1, Di Lu1, Xuyong Wei2, Qiang Wei3, Xiao Xu1,4
1Zhejiang University School of Medicine Hangzhou China, 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Hangzhou China, 3Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine Hangzhou China

Background: Circular RNAs (circRNAs)-mediated post-translational modification of RNA-binding proteins (RBP) plays a pivotal role in recurrence and metastasis of liver transplantation (LT) for hepatocellular carcinoma (HCC). However, the specific mechanism and potential clinical significance remain vague.

Methods: Patient derived tumor xenograft, organoids and the multi-omics approaches combining of transcriptome sequencing, tandem mass tag-based proteome sequencing and high-throughput sequencing were performed to screen the potential circRNAs. Tissue microarrays of LT for HCC containing 269 patients were used to evaluate the prognostic capacity of circRNAs and nucleolin (NCL).

Results: CircPTK2 was evaluated in HCC and was found to prevent the interaction between nucleolin (NCL) and the E3 ligase tripartite motif-containing 21 to reduce the proteasome-mediated degradation of NCL via K48-linked polyubiquitylation, promoting metastasis. Higher expression of circPTK2 and NCL in tumor tissue portended worse overall survival (OS) and recurrence free survival (RFS) (RFS: 41.3% vs. 55.4%, P=0.0081, 37.4% vs. 63.1%, P<0.0001). CircPTK2 and NCL had satisfactory evaluation capabilities for OS in patients who beyond the Milan criteria (p=0.0034 and 0.0033). In patients who met Hangzhou’s criteria, elevated circPTK2 and NCL expression was correlated to a worse OS and RFS (OS: P=0.0048 and 0.0013, RFS: P=0.0374 and 0.0001). Notably, patients with negative AFP and low circPTK2 expression had a superior OS than those with negative AFP but high circPTK2 expression (P=0.0386).

Conclusion: CircRNA and NCL are closely related to the metastasis of HCC and are effective prognostic indicators to patients with LT for HCC.

Abstract Submission No. 100513
O-0544

Mitochondria-targeted Icaritin Induces Immune-Genic Cell Death in Hepatocellular Carcinoma

Siyu Chen1,2, Xiao Xu1,2, NaSha Qi1,2,3,4
1Hangzhou, Zhejiang Province Hangzhou China, 2Zhejiang University, School of Medicine Hangzhou China, 3Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Hangzhou China, 4Zhejiang Chinese Medicine University Hangzhou China

Background: Icaritin (ICT), a novel small molecule from traditional Chinese medicine, induces mitophagy and immunogenic cell death (ICD), showing promise for treating advanced unresectable hepatocellular carcinoma. However, its limited bioavailability restricts clinical
use. We developed amphiphilic copolymer-encapsulated icariin nanoparticles (Icaritin NPs) with mitochondrial targeting to improve its bioavailability, tumor-targeting, and anti-cancer immunogenicities. **Method:** We synthesized a novel mitochondrial targeting amphiphilic copolymer OPDEA-PCL and self-assembled it with ICT into micelles, using polyethylene glycol-polyacrylate (PEG-PCL) as a positive carrier. Confocal imaging and flow cytometry were utilized to analyze cellular uptake of OPDEA-PCL/ICT nanoparticles. In a mouse subcutaneous HCC model, free ICT, PEG-PCL/ICT, and OPDEA-PCL/ICT NPs were intravenously administered to tumor-bearing mice to evaluate their anti-tumor effects. **Results:** OPDEA-PCL/ICT had an optimal ~140 nm particle size, 0.19 PDI, and 86% encapsulation efficiency. It rapidly internalized into H22 cells, targeting mitochondria. Post-intravenous injection, in vivo imaging revealed effective tumor accumulation. The tumor inhibition rate was 47%. Flow cytometry showed post-treatment, de activation, increased cytoxic CD8+ T cells, and decreased immunosuppressive Tregs and MDSC in tumor tissues. Blood, liver, and kidney indices showed no adverse reactions. **Conclusion:** OPDEA-PCL efficiently encapsulates icariin into mitochondrial-targeted nanoparticles, significantly boosting icariin’s bioavailability. This process amplifies mitophagy, inducing immunogenic cell death (ICD) and activating the immune microenvironment in HCC tumors, thereby achieving potent tumor suppression.

**Targeting XPO1 inhibits proliferation of hepatocellular carcinoma cells by disrupting redox balance**

Linmeng Zhang1, Wei Wang1, Cun Wang2
1Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China; Shanghai China
2Department of Global Medical Research Promotion, Shinshu University School of Medicine, Matsumoto Japan

**Background:** Hepatocellular carcinoma (HCC) poses a significant threat to public health due to its complex pathological mechanism and poor prognosis. There is an urgent need to identify efficient targets and effective treatment strategies for HCC. **Methods:** By analyzing public liver cancer databases, we found XPO1, an essential gene of liver cancer, was aberrantly expressed in the HCC and associated with poor survival. The effect of XPO1 inhibitor was investigated in cell lines and mouse models of HCC. A resistance screen was performed to identify the key gene in the drug resistance. To identify inhibitors that could synergistically function with XPO1 inhibitor, a compound screen was conducted. **Results:** XPO1 inhibitor KPT330 inhibited the proliferation of HCC in vitro and in vivo. It caused cell cycle arrest through inducing the accumulation of reactive oxygen species (ROS). Mechanistically, the accumulation of nuclear receptor corepressor (NCOR1) in the nucleus by XPO1 inhibition, potentially leading to abnormal gene transcription that regulates the oxidative state. Through resistance screen, KEAP1 was identified as a key gene whose knockout induced the resistance of HCC cells to KPT330. Deletion of KEAP1 alleviated oxidative stress by activating the NRF2-mediated antioxidant pathway. The combination of XPO1 inhibitor and aldehyde dehydrogenase (ALDH) inhibitor, Disulfiram, synergistically suppressed the HCC development. **Conclusions:** Our study illustrates the potential of XPO1 inhibitor and a drug combination strategy for the treatment of HCC. Furthermore, our data shed light on the mechanism that the response of HCC cells to XPO1 inhibitor is intricately tied to the redox balance.
tumors. Mechanistically, LG markedly down-regulated the expressions of genes associated with pro-inflammatory cytokines, endoplasmic reticulum stress, p62-NeR2 pathway, and cell division in non-tumorous hepatic tissue.

In conclusion, LG attenuates NASH and HCC in diabetic mice. This study may propose a novel solution for serious liver complications of diabetes.

Abstract Submission No. 100696
O-0548

Integrated multiomic analysis in HCC beyond the Milan criteria undergoing liver transplantation

Sunbin Ling1, Qifan Zhan1, Xiao Xu1
1Zhejiang University Hangzhou China

Objective: In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria, liver transplantation (LT) is an extremely effective therapy. We aimed to explore the survival-related molecular biological features in patients with hepatitis B virus (HBV)-related HCC beyond the Milan criteria received LT and to identify the key molecular biology governing the prognosis.

Design: Among 699 consecutive HCC patients undergoing transplant between 2015 and 2019, 122 had tumors exceeding the Milan criteria on pathology and were enrolled in the study. Integrated analyses of tumor tissues were conducted using RNA sequencing (RNA-seq), transposase-accessible chromatin sequencing (ATAC-seq) and proteomic landscape profiling.

Results: At a median follow-up of 34.6 months, 45 patients had died, and 52 had experienced recurrence; the 5-year overall survival (OS) and recurrence rates were 45.0% and 52.0%, respectively. Unsupervised clustering based on transcriptomics identified three subgroups, namely, the low-risk group, medium-risk group and high-risk group. The transcriptomic subgroups significantly differed in OS (high-risk vs. low-risk, hazard ratio (HR) = 4.527). Deep bioinformatics analysis revealed that cancer-associated fibroblast (CAF)-induced cancer stemness may govern the adverse biological features of HCC in the high-risk group. The ATAC-seq identified key transcription factors bridging CAF and stemness profile. Proteomics further validated the transcriptomic subgroup model. Finally, we constructed a three stemness-related protein-based prognostic model to support the transcriptomic subgroup model.

Conclusion: Our observations provided the first multiomic landscape of patients with HCC beyond the Milan criteria undergoing LT. A CAF-stemness-governed classification was constructed to predict the outcomes of patients with HCC beyond the Milan criteria.

Abstract Submission No. 100742
O-0550

The effect of SRC1 inhibitors in hepatitis B-related liver cancer

Agustiningsih Agustiningsih1, Korri Elvanita El Khobar1, Loraine Kay Cabrал1,2, Claudio Tiribelli1,2, Caecilia Sukowati3
1Eijkman Research Center for Molecular Biology, National Research and Innovation Agency of Indonesia Bogor Indonesia, 2Doctoral School in Molecular Biomedicine, University of Trieste Trieste Italy, 3Fondazione Italiana Fegato - ONLUS Trieste Italy

Background and Aims: Hepatitis B virus (HBV) infection is the leading cause of chronic hepatitis B, cirrhosis, and hepatocellular carcinoma (HCC). HBV x protein (HBx) interacts with and modulates a variety of signal transduction pathways leading to HCC, including Src family kinases (SFKs). This study aims to investigate the effect Src inhibitor on HBV infection in an in vitro model of HBV-related HCC.

Method: Hep3B, a HCC cell line with integrated HBV genome was treated with two SRC1 inhibitors, saracatinib (SAR) and dasatinib (DAS) with concentration ranging from 0.02 to 10.00 µM for 24, 48, and 72 hours. Lethal concentrations 50 (LC50) of all treatments were calculated from cytotoxicity assay using MTI test. mRNA and protein expressions SFKs, including SRC/ASF1, FGR, YES, and FYN were assessed by qRT-PCR and Western blot, respectively.

Results: Cytotoxicity test showed dose-dependent toxicity of SAR with LC50 of 2.0 and 3.1 µM for 48 and 72 hours treatment, respectively. SAR and DAS treatments using concentration of 1.25, 2.5, and 5 µM significantly down-regulated the expressions of SRC1 and FGR (p<0.05), while FYN was reduced only by DAS, and YES by SAR. The down-regulation of SRC mRNA was also confirmed by the decrease of protein expression. Interestingly, positive correlations between HBV X gene and SRC1, FGR, and YES were noticed, showing direct association between HBV infection and SFKs.

Conclusion: The inhibition of the SFKs is associated with HBV infection, showing a potential linear correlation between host and pathogen.

Abstract Submission No. 100755
O-0551
Identification of developmental heterogeneity and potential therapeutic targets in HCC

Ming Liu1, Xiao-Feng Zhang1,2, Yun Zhu1, Xiao-Yu Zuo1, Yan Zhang2

1Guangzhou Medical University Guangzhou China, 2Guangzhou Women and Children Medical Center Guangzhou China

Intratumor heterogeneity remains a major obstacle in clinical cancer treatment with limited therapeutic options. In contrast to genetic heterogeneity, the concept of cellular developmental hierarchies and cell-state plasticity driven by non-genetic mechanisms has recently come into sharp focus. With the advancement of single-cell sequencing technology, the clonal evolution and dynamics of cell populations during cancer progression could be monitored at high resolution. To gain insights into HCC tumor heterogeneity, a hepatocyte differentiation model was established to mimic liver development in vitro and utilized to guide the clustering of tumor cells at single cell level from a HCC cohort containing 160 patients. A total of 5 clusters liver parenchymal cells annotated by lineage-specific signature genes were identified. Pseudotime analysis revealed that tumor subpopulations forms a developmental trajectory resembling normal hepatocyte differentiation. RNA velocity analysis indicated that cells at the “root” of developmental trajectory are highly plastic, and constitute the hierarchical heterogeneity with their progenies, which significantly contributed to the poor prognosis in HCC. Multi-color immunofluorescent staining of representative biomarkers further confirmed the existence of developmental heterogeneity in HCC patents. The establishment of hepatocyte differentiation model and algorithms for predicting driver events of the regulatory networks delivers potential therapeutic targets and preclinical candidate compounds, which show high therapeutic potency in patient-derived organoids and xenografts.

Abstract Submission No. 100760
O-0552

Prognosis prediction based on B cell markers through single-cell and bulk RNA-seq analysis for HCC

Yao Yang1, Hongsong Chen1

1Peking University People’s Hospital Beijing China

Tumor-infiltrating immune cells greatly participate in regulating tumorigenesis and metastasis of hepatocellular carcinoma (HCC). B cell, as an important role of specific immunity, plays an indispensable role in antitumor immunity and regulate tumor development. In this study, we firstly identified 345 B cell marker genes of HCC based on single-cell RNA sequencing data. Subsequently, a B cell marker genes-related prognostic signature (BCPS) was developed in the cancer genome atlas (TCGA) cohort for risk stratification and prognosis prediction. The predictive value of the BCPS in prognosis was well validated in different clinical subgroups and two external datasets (IGCG-LIHC cohort, GSE14520 cohort). Moreover, multivariate analysis revealed the independent prognostic value of BCPS for OS in HCC. Further functional analysis indicated the BCPS was associated with basic cellular processes, that may contribute to the development and progression of HCC. Thereafter, immune characteristics as well as the therapeutic benefits in BCPS risk score-defined subgroups were analyzed. Patients with low-risk score exhibited immune-active status, manifested as higher immune scores, more infiltration of CD8+ T cells, and higher T-cell receptor (TCR) richness and diversity. Remarkably, the BCPS was negatively correlated with immunotherapy response-related signatures. In addition, the low-risk group exhibited significantly improved therapeutic benefits, either from immunotherapy or traditional chemotherapy and target therapy. Overall, the BCPS showed an excellent predictive value for prognosis and therapeutic responses for HCC, which might also provide novel insights into better HCC management strategies.

Abstract Submission No. 100823
O-0553

The Urea Cycle Enzyme CPS1 Inhibits the Metastasis of HCC through Recruiting CD8+ T cells

Sisi Zhang1,2, Wenxin Qin3, Jun Xue1, Jing Tang1

1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Wuhan China, 2State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Shanghai China

Background: Carbamoyl phosphate synthetase 1 (CPS1) is a metabolic enzyme involved in the production of urea. Our previous studies demonstrated the role of CPS1 in tumor growth and radioresistance in hepatocellular carcinoma (HCC). However, whether CPS1 regulates metastasis and immune evasion remains unclear.

Methods: Transwell and scratch assay were used to detect the function in vitro. Cytometry by time-of-flight was used to screen the differential immune cell groups in the metastasis model. Flow cytometry was utilized to detect the key immune cell subtypes in CPS1-associated tumor immune microenvironment.

Results: The expression of CPS1 was gradually downregulated in normal liver tissue, HCC and metastatic HCC. Overexpression of CPS1 could inhibit the invasion and migration of HCC in vivo and in vitro, respectively. Furthermore, a high level of CPS1 enhanced the infiltration of CD8+ T cells and the production of IFN-γ, granzyme B and perforin, thus impeding the development of HCC. However, the inhibition effect mediated by CPS1 was offset after clearing the CD8+ T cells in C57BL/6 mice. Mechanistically, the inactivation of CPS1 promoted MMP7 upregulation mediated epithelial-mesenchymal transition by activating AKT1/β-catenin signal pathway. CPS1 could induce CD8+ T cells to the tumor site to exert anti-tumor immune effect via stimulating the production of C-X-C motif chemokine ligand 13 (CXCL13). Finally, high CPS1 subtype HCC could further potentiate the responsiveness to immune checkpoint blockade.

Conclusion: These findings indicate that urea cycle key metabolic enzyme CPS1 can hinder the development of HCC and remodel the immunosuppressive tumor microenvironment, thereby enhancing the efficacy of PD-1 checkpoint.

Abstract Submission No. 100856
O-0554

Image analysis highlights distinct fibrosis patterns in combined hepatocellular-cholangiocarcinoma

Hung-Wen Tsai1, Matthew Yeh2, Yayan Ren3, Elaine Chng3, Dean Tai4, Che-Wei Hsu1, Cheng-Yi Chen5, Yoh Zen6

1Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University Tainan Taiwan, 2University of Washington, Department of Laboratory Medicine and Pathology Seattle USA, 3Histoindex Pte Ltd Singapore Singapore, 4Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University Tainan Taiwan, 5Institute of Liver Studies, King’s College Hospital London United Kingdom
Background: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a distinct entity of primary liver cancer defined by the presence of both hepatocellular carcinoma (c-HCC) and cholangiocarcinoma differentiation (c-CCA) and usually have stem cell-containing transitional zone (TZ) between the two components. Tumor fibrosis stroma more abundant in pure cholangiocarcinoma (p-CCA) than pure HCC (p-HCC) and has been reported to be associated with tumor stemness, invasion and treatment effect. This study is to clarify the fibrosis characters of tumor stroma and its clinicopathologic significance using second harmonic generation/two-photon excitation fluorescence (SHG/TPEF) microscopy.

Methods: We use SHG/TPEF to analyze the collagen structures in 16 cHCC-CCAs, 15 p-HCCs and 15 p-CCAs. Total 16 fibrosis parameters, such as distributed and aggregated collagen for tumor and 184 parameters in the non-tumor were quantified using digital image analysis. Wilcoxon rank sum test was used in the analysis.

Results: c-HCC and c-CCA in cHCC-CCA had more distributed collagen than the p-HCC and p-CCA (P=0.042 and P=0.031, respectively), while there was no difference for the overall fibrosis area or aggregate collagen. TZ contained more distributed collagen than c-HCC (P=0.039), p-HCC (P=0.001) and p-CCA (P=0.028). For non-tumor liver, the liver of the p-CCA patients had lower degree of fibrosis than the cHCC-CCA patients for the parameters in portal tract and peri-portal regions (p<0.05) while there was no significant difference of liver fibrosis between p-HCC and cHCC-CCA cases.

Conclusions: In conclusion, distributed collagen could be a distinct fibrotic pattern in cHCC-CCA. Distributed collagen may be associated with stem cell niche and tumorigenesis of cHCC-CCA.

Abstract Submission No. 100864
O-0555

HCC-Derived GM-CSF Induces Leukotriene Production in CD163+ TAMs Contributing to Cancer Progression

Takuto Nosaka1, Masahiro Ohtani1, Yu Akazawa1, Kazuto Takahashi1, Tatsushi Naito1, Hidetaka Matsuda1, Yasunari Nakamoto1
1University of Fukui, Faculty of Medical Sciences, Second Department of Internal Medicine Fukui Japan

Background: Tumor-associated macrophages (TAMs) promote cancer progression through cell proliferation and immunosuppression. We observed that macrophages secreted leukotrienes (LTs) in the lung metastasis of hepatocellular carcinoma (HCC) and promoted metastasis. In this study, we investigated the interactions between HCC cells and TAMs and evaluated the potential for targeted therapy.

Methods: We evaluated the number of 5-LOX-positive cells in resected HCC tissue and multivariate analysis associated with overall survival (OS) in 86 patients. Mouse HCC cell line BNL was inoculated intraportally into BALB/c mice, 5-LOX inhibitor was administered, and GM-CSF-transfected BNL cells were injected. Co-culture was performed with mouse bone marrow cell-derived macrophages (BMDM) and HCC cells.

Results: In resected HCC tissues and TCGA-LIHC, the group of patients with high 5-LOX expression had poorer OS (p<0.05). On multivariate analysis, 5-LOX positive cell count was associated with post-operative survival. In the tumor, CD163 (+) TAMs expressed 5-LOX. In HCC mouse model, tumor growth was suppressed by 5-LOX inhibitor. In tumor tissues, GM-CSF expressing cells were tumor cells and increased 5-LOX, CD163, and PD-L1 expression in BMDMs. Moreover, overexpression of GM-CSF in tumor cells promoted the tumor progression. In the co-culture experiment, tumor cells derived GM-CSF increased 5-LOX and CD163 expression in BMDMs.

Conclusions: This study demonstrated a series of mechanisms by which HCC cell-derived GM-CSF promotes 5-LOX and CD163 expression and LT production in TAMs, promoting tumor proliferative potential. Furthermore, the suppression of LT production via GM-CSF from HCC cells regulates tumor progression, suggesting the possibility of a novel therapeutic target.

Abstract Submission No. 100892
O-0556

Inhibition of SFK and its effect on cancer stem cell markers expression in HBV-related HCC

Korri El Khobar1,2, Agustiningsih Agustiningsih1,2, Loraine Kay D. Cabral3, Gianluigi Gianelli1, Claudio Tiribelli2, Caecilia Sukowati1,2
1Eijkman Research Centre for Molecular Biology, National Research and Innovation Agency Cibinong Indonesia, 2Fondazione Italiana Fegato ONLUS Trieste Italy, 3National Institute of Gastroenterology "S. De Bellis" Research Hospital Bari Italy

Background: Chronic infection of hepatitis B virus (HBV) remains the main etiological factor for hepatocellular carcinoma (HCC). HBV-related HCC pathogenesis has been associated with the expression of HBV X protein (HBx), which can interact directly with key regulatory protein including Src family kinase (SFK). HBx interaction with Src are important for regulation of stem-like properties and liver cancer formation. Here, we determined the effect of treatment with Src inhibitors on cancer stem cell (CSC) markers expression in HBV-related HCC.

Methods: Hep3B, a HCC cell line with integrated HBV genome, was treated with two Src inhibitors, saracatinib (SAR) and dasatinib (DAS) with increasing doses of 1.25, 2.5, and 5.0 µM for 48 hours based on each of their LC50 concentrations. mRNA and protein expressions of different CSC markers and other liver-related markers were assessed by qRT-PCR and flow cytometry.

Results: Hep3B cells highly expressed CSC markers EpCAM, CD13, CD133, and CD24, but only lowly expressed PD-L1, CD95 and its ligand CD95L. Treatment with SFKs inhibitors, SAR and DAS, reduced both Src gene and protein expressions. SAR treatment increased CD133 (p<0.01) but reduced CD90 expressions, while DAS treatment caused no changes in other CSC markers. In addition, SFK inhibitors also reduced fibrosis markers, TGFβ1, ACTA2, HGF, CTGF, and FSP1, and have no significant effects on liver marker AFP and albumin expressions, mostly noted for SAR.

Conclusion: Src inhibitors treatment may have anticancer effect by reducing the expression of CSC markers, as well as a possible antiangiogenic effect in HBV-related HCC.

Abstract Submission No. 100900
O-0557

PSMP suppresses HCC progression through inhibiting macrophage M2 polarization via PI3K/Akt pathway

Shaoping She1, Yao Yang1, Liying Ren1, Dongbo Chen1, Hongsong Chen1
1Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases Beijing China

Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver and represents a major global health-care challenge.
PC3 secreted microprotein (PSMP) is a novel chemotactic cytokine that can recruit peripheral blood monocytes and lymphocytes through CCR2. Our previous study found that PSMP promotes the progression of liver fibrosis by regulating the infiltration, activation and polarization of macrophages. However, the relationship between PSMP and the development of HCC remains unclear.

Through clinical samples, we found that PSMP is downregulated in human HCC tissues, and its expression level is positively correlated with the prognosis of HCC patients. In vivo, we found that genetic deletion of PSMP promotes subcutaneous and liver orthotopic tumor growth and metastasis in mice; Overexpression of PSMP inhibits the formation of subcutaneous tumors in nude mice. Mechanistically, deletion of PSMP substantially suppresses the infiltration of CD8⁺ lymphocytes while promoting the infiltration and polarization of M2 tumor-associated macrophages (TAMs) within the liver. In vitro, we observed that PSMP possesses the capacity to induce M1-polarization and suppress M2-polarization of macrophages. In addition, analysis of RNA sequencing results showed that PSMP may mediate the polarization of macrophages by regulating the PI3K/Akt pathway. Then, we verified that PSMP mediates its inhibitory effect on M2-polarization of macrophages through inhibition of p85 and Akt phosphorylation.

Collectively, PSMP may inhibit macrophage M2 polarization by downregulating PI3K/Akt signaling. The results are expected to clarify the role and mechanism of PSMP in the liver tumor microenvironment for the first time, which has important theoretical significance and potential application value.

Abstract Submission No. 101145

O-0558

Investigation on the Tumor suppressor role of miR-3185 in Hepatocellular Carcinoma

Inah Marie C. Aquino¹, Leslie Michelle M. Dalmacio¹, Claudio Tiribelli², Devis Pascut²

¹University of the Philippines Manila, College of Medicine Manila Philippines, ²Fondazione Italiana Fegato - ONLUS Trieste Italy,

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Serum miR-3185 has emerged as a potential biomarker in HCC, with higher levels associated with better prognosis. However, the role of miR-3185 in the disease remains unclear. This study aimed to elucidate the function of miR-3185 in liver cancer.

Methods: The MiR-3185 target genes were predicted by using TargetScanHuman 7.2 and miRDB. HCC-derived JHH6 cells were transfected with miR-3185 mimic and scramble control. mRNA and protein expression of target genes were assessed at 24h, 48h, and 72h post-transfection. Putative targets were validated by using a 3'UTR miR-target gene reporter system. Cell viability, cell cycle and migration were evaluated to describe the roles of miR-3185 in the in vitro model.

Results: In silico analysis identified eight miR-3185 target candidates. Among those, SLC39A11 was identified as the main miR-3185 target. miR-3185 mimic significantly reduced SLC39A11 mRNA at 24h, 48h, and 72h and its protein expression at 48h and 72h. The 3'UTR miR-target gene reporter assay confirmed the targeting of SLC39A11, resulting in a 58% reduction in luciferase activity. The inhibition of SLC39A11 expression resulted in significant decreased cell viability, increased G0/G1 phase cell cycle arrest and repressed cell migration.

Conclusion: SLC39A11 is a miR-3185 target in HCC. The inhibition of this essential zinc transporter reduced cell viability and migration, thus supporting the role of miR-3185 as a tumor suppressor.

Abstract Submission No. 101272

O-0560

Disparity landscapes of HBV integration in liver cancer: mechanistic and functional implications

Daniel Wai-Hung Ho¹, Xueying Lyu¹, Karen Man-Fong Sze¹, Joyce Man-Fong Lee², Abdullah Husain¹, Irene Oi-Lin Ng¹

¹Department of Pathology and State Key Laboratory of Liver Research, University of Hong Kong Hong Kong China

Background: Hepatocellular carcinoma (HCC) is a leading fatal malignancy worldwide and chronic hepatitis B virus (HBV) infection accounts for ~50% of the cases. HBV DNA integrates into the human genome, disrupting the endogenous tumor suppressors/regulatory genes, or enhancing the activity of proto-oncogenes.

Methods: We determined the disparity landscapes of integration events among sample cohorts, tissue types, chromosomal positions, individual host/viral genes, as well as genic locations. Moreover, we performed mechanistic investigation on how HBV-TERT integration led to TERT activation and derived a score to predict patients’ prognosis according to their clonal disparity landscape of HBV integration.

Results: We revealed the global geographical disparity of HBV integration that the landscape of HBV integration between HCC and non-
tumorous liver varied in regional cohorts, suggesting different degrees of clonal enrichment. Most HBV integrations were positionally enriched at telomeres and centromeres, and they highlighted the novel co-involvement of HBV integration, which likely introduces genomic instability. We constructed a large meta-cohort of multiple ethnicities to refine the landscape of HBV integration. This enables the geneset/gene-family-level exploration. As TERT is the most frequently integrated gene, we further investigated the mechanistic modulation of TERT transcription activation and revealed the concurrent influence by the orientation and relative distance of HBV integration. Additionally, clonal disparity of HBV integration was observed among patients and the higher level of clonal disparity score indicates poor patients' prognosis.

Conclusions: Our study uncovered the different levels of clonal enrichment of HBV integration, mechanistic insights, and prognostic biomarker, to strengthen our understanding in HBV-associated hepatocarcinogenesis.

Abstract Submission No. 101384
O-0561

Unique pattern of cell-cell interaction in Cytoglobin knock-out mice promoting liver tumor formation

HA THI NGUYEN1, THUY THI THANH LE1, HAI HOANG1, DUC MINH PHAM1, NORIFUMI KAWADA1

1Osaka Metropolitan University, Graduate School of Medicine, Department of Hepatology Osaka Japan, 2Osaka Metropolitan University, Graduate School of Medicine, Department of Global Education and Medical Sciences Osaka Japan

Background: Cytoglobin (Cygb), the newest member of the mammalian globin family, has shown protective function in anti-fibrotic properties. This study investigated the cell-cell interaction in the liver tumor and non-tumor area of wild-type (WT), CYGB deficient (Cygb-KO), and Cygb overexpression (Cygb-TG) using both whole tissue transcriptomic (RNAseq) and single-cell RNA sequencing (scRNA-seq) analysis.

Method: Mice were administrated with Diethyl nitrosamine (DEN) by percutaneous injection at 6 µg/g BW at 15-day-olds and observed for 12 months. RNA from liver tissues was used for RNAseq. Primary non-parenchyma cells isolated from DEN-treated livers were performed scRNA-seq by 10X Genomics.

Result: The mean number of liver tumors in WT was 4.76 compared to 1.51 in Cygb-TG, p < 0.001; and the maximum size of liver tumors was 7.4 mm in WT compared to 2.05 in Cygb-TG mice, p < 0.01. Heatmap analysis of whole liver transcriptomic data revealed the suppression of DNA-damage inducible genes and stimulation of antioxidant-related genes in TG livers. The integrated scRNA-seq data and annotation identified 10 cell types including 2 subtypes of macrophage and 2 subtypes of HSC. Liver sinusoid endothelial cell (LSEC) is the most abundant population. nicheNet analysis demonstrated a unique pattern in the KO niche which highlighted robust interactions of receptors in LSEC with the ligands from other non-parenchymal and immune cells in comparison with those of WT. These ligands are neuron growth factors from HSCs, transferrin from cholangiocytes and NKs, and galectin 3 from tumor-associated macrophages. The validation cohort of 364 patients with HCC demonstrated these factors are correlated with overall survival.

Conclusion: Both RNAseq and scRNAseq revealed the transcriptomic profile changing in various cell types between KO and WT mice, while the interaction with other non-parenchymal cells and immune cells from KO liver may drive functional characteristics in LSEC and promote tumor development.

Abstract Submission No. 101472
O-0562

Novel disease-associated hepatocyte state can predict the future risk of liver cancer development

Janina Tiritz-Parker1,2, Rodrigo Carlessi1,2

1Curtin University Bentley - Perth Australia, 2Harry Perkins Institute of Medical Research Perth Australia

Rationale: Hepatocellular carcinoma (HCC) constitutes approximately 80-90% of primary liver cancers and is frequently identified at an advanced stage, where treatment choices are limited, while prognosis and survival are poor. Conversely, early detection of HCC substantially improves outcomes, rendering it potentially curable. Presently, it is challenging to pinpoint which patients will develop HCC, as current methods for staging chronic liver disease (CLD) are ineffective for predicting HCC.

Our study: In our research, we utilised single-nucleus RNA sequencing (snRNA-seq) to delineate the cellular microenvironments in both healthy and pre-malignant livers via established mouse models (CDE, TAA, MUP-uPA). Subsequent analysis revealed a disease-associated hepatocyte (daHep) transcriptional state not found in healthy livers but increasing in prevalence with advancing CLD. Copy number variation (CNV) analysis of micro-dissected tissues indicated that regions enriched with daHeps harboured extensive structural variants, implying that these cells may be an intermediary to malignancy. Examination of three contemporary human snRNA-seq datasets corroborated the existence of similar cellular phenotypes in human CLD and indicated a higher mutational load. Crucially, elevated daHep levels were shown to predict oncogenesis, suggesting a greater risk of developing HCC.

Ongoing research: We are now employing Oxford Nanopore long-read sequencing to investigate genome-wide methylation patterns of human pre-malignant daHeps to establish a non-invasive assay using methylated cDNA from blood samples and quantify daHep levels to assess the subsequent risk of HCC. These insights have the potential to revolutionise the staging, monitoring, and risk assessment of patients with CLD.

1Carlessi et al. Cell Genomics 2023

Abstract Submission No. 101474
O-0563

Traditional Chinese medicine compound and anti-tumor immunity

Rui Hu1,2, Jing Li1,2, Qi Huang1,2, Xin Zheng1,2, Jialing Sun1, Jin Yu1,2, Lanfen Peng1, Xingping Liu1,2, Yuan Yang1, Wenmin Yang3, Yan Wang4, Wenfeng Ma5, Wenxing Feng5, Youhua Xu5, Xiaozhou Zhou1,2,3

1Shenzhen Traditional Chinese Medicine Hospital Shenzhen China, 2Macau University of Science and Technology Macao China, 3The fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen China

Background: The cell cycle inhibitor p21 triggers targeted immunokilling by p21-activated secretory phenotype (PASP). Qizhu Kangai formula (QZKAF) has anticancer functions but the underlying mechanisms involving PASP remain unclear.

Purpose: This study aimed to investigate the mechanisms of QZKAF in inhibiting the progression of hepatocellular carcinoma (HCC) related to PASP.
HCC development and associated with the infiltration of natural killer cell chemokine ligand 14, and Wnt family member 2 were involved in reversing the immunosuppressive microenvironment. This study could provide new insights into the anticancer effect of QZKAF. The pathological features of liver were observed using hematoxylin and eosin (H&E) staining. The screening of PASP was performed by GeneCards, DisGeNet, Online Mendelian Inheritance in Man, and The Cancer Genome Atlas databases. Western blotting, immunofluorescence, and transwell assays were also used.

**Results:** QZKAF-containing serum enhanced p21 expression, accelerated cell senescence, triggered cell cycle arrest, and inhibited cell proliferation in Huh7 and MHCC-97H cells. QZKAF decreased the number and size of liver tumor nodules and enhanced p21 expression. SA-β-Gal staining of tumor lesions, and cytotoxic CD8+ T cell infiltration. Decorin, dermatopontin, hepatocyte growth factor, C-X-C motif chemokine ligand 14, and Wnt family member 2 were involved in HCC development and associated with the infiltration of natural killer cells and CD8+ T cells in the tumors.

**Conclusion:** QZKAF suppression of HCC progression may involve P21 up-regulation-mediated cell senescence, the secretion PASP, and reversing the immunosuppressive microenvironment. This study could help new strategies for improving HCC treatment.

**Abstract Submission No. 101526**

**O-0564**

**Combinational therapeutic targeting of BRD4 and CDK7 induces anticancer effects in HCC**

**Xinxiu Li¹, Hong Fan¹**

¹Medical School, Southeast University, Nanjing, China. Nanjing China

**Objectives:** In hepatocellular carcinoma (HCC), oncogenes are continuously and robustly transcribed due to aberrant expression of essential components of the trans-acting super-enhancers (SE) complex. Preclinical are now being conducted on small-molecule inhibitors that target core-transcriptional components, including as transcriptional bromodomain protein 4 (BRD4) and cyclin-dependent kinase 7 (CDK7), in many malignant tumors. We aim to explore whether co-overexpression of BRD4 and CDK7 is a potential marker of worse prognosis and a combined therapeutic target in HCC.

**Methods:** The expression pattern of BRD4 and CDK7 and their correlation with prognosis in HCC from TCGA and GEO datasets were analyzed. The protein levels of BRD4 and CDK7 were determined by immunohistochemistry, and survival data of patients were analyzed using the Kaplan-Meier method. The mRNA expression levels of genes in HCC cells were evaluated by q-PCR. CCK-8 and colony formation assays were conducted to assess cell proliferation of HCC upon treatment with BRD4 inhibitor JQ1 or/and CDK7 inhibitor THZ1.

**Results:** Co-overexpression of CDK7 and BRD4 was a worse prognostic factor in HCC. Treatment with JQ1 or THZ1 alone had an inhibitory effect on cell proliferation; however, when JQ1 and THZ1 were combined, there was a more notable suppression of cell growth. At the same time, the combined use of JQ1 and THZ1 synergistically suppresses the expression of HCC driver genes.

**Conclusion:** Our research revealed that BRD4 and CDK7 coupled can be a useful biomarker in HCC prognosis and the combination of JQ1 and THZ1 can be a promising therapeutic therapy against HCC.

**Abstract Submission No. 101534**

**O-0565**

**Development of the Liver Tumor-bearing Rat Model with Dual Optical Imaging**

**Naoki Yokota¹, Haruyuki Takaki¹, Yutaka Hirata², Reona Wada¹, Taishi Kodama¹, Kouichiro Yamakado¹**

¹Department of Radiology, Hyogo Medical University Nishinomiya City Japan, Specialty of biodynamics, Department of physiology, Hyogo Medical University Nishinomiya City Japan

**PURPOSE:** This study aims to develop the liver tumor-bearing rat model that stably co-expresses both luciferase and a red fluorescent, and is quantitatively and qualitatively monitorable by the optical imaging system.

**Methods:** The plasmids encoding both luciferase and red fluorescence proteins were transfected to the NIS1 rat hepatoma cell lines. Those cell lines were inoculated to the liver of the Spraque-Dawley rats (n=6). All animals underwent both in vivo bioluminescence and fluorescence imaging one week after tumor inoculation. Then, animals were assigned to receive hepatic artery embolization (HAE) (HAE group, n=3) or sham treatment (sham group, n=3). All animals underwent optical imaging again 24 hours after the procedure and liver tissues were harvested. Changes in the intensity of optical imaging were evaluated. The harvested liver tissues were observed by fluorescence microscopy.

**Results:** Liver tumors were identified by bioluminescence imaging in all 6 animals at 1 week after tumor inoculation (100%, 6/6). The signal intensity of bioluminescence significantly decreased after HAE (P<0.05), whereas it remained unchanged in the sham group (P=0.12). The tumor necrosis areas were more than 90% in the HAE group and less than 30% in the sham group, respectively. The tumor area of the unstained liver tissue could be identified in all animals (100%, 6/6) on fluorescence microscopy imaging.

**Conclusion:** Tumor-bearing rat model that stably co-expresses both luciferase and a red fluorescent was successfully developed. This model will be useful in the translational research of interventional oncology.

**Abstract Submission No. 101554**

**O-0566**

**Rab14 potentiates CD147 cytoplasm translocation to promote HCC metastasis by NME1-mediated pathway**

**Meng Lu¹,², Zhiyun Zhang¹,², Peng Lin¹,², Haolin Wei¹,², Zhiwei Yang³, Xinhuai Cai³, Zekun Liu³, Lin He¹,², Lei Zhang³, Zhinan Chen³, Huijie Bian³**

¹Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University Xi’an China, ²State Key Laboratory of New Targets Discovery and Drug Development for Major Diseases Xi’an China, ³MOE Key Laboratory for Nonequilibrium Synthesis and Modulation of Condensed Matter Xi’an China

The correct subcellular localization of proteins is essential for their physiological functions, cell homeostasis and signal network transmission. CD147, localized in the basolateral membrane of hepatocytes, functions as signal transduction molecule to regulate complicated pathway between extracellular to intracellular signals, to improve hepatocellular carcinoma (HCC) progress. However, few studies focused on the CD147 distribution. Here we found in comparison with HCC cells expressing wild-type CD147 (CD147WT), mutated CD147 (CD147L249A) showed cytoplasmic enrichment, enhancing HCC cells more aggressive phenotype characteristics with epithelial to mesenchymal transition (EMT) and invasion. Cytoplasm-anchored CD147
CRISPR screen for kinase potentiating T cell-mediated cytotoxicity in hepatocellular carcinoma

Ka Hei Lam1, Kai Yu Ng1, Tin Lok Wong1, Ianto Bosheng Huang1, Guang Sheng Ling1, Stephanie Kwai Yee Ma1, 2
1School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong Hong Kong, 2State Key Laboratory of Liver Research, The University of Hong Kong Hong Kong

Background: Despite achieving durable clinical responses in multiple malignancies, the overall response rate to immune checkpoint blockade (ICB) for hepatocellular carcinoma (HCC) patients remains relatively low. This necessitates immediate efforts to identify the factors responsible for the resistance to immunotherapy and devise novel strategies that can augment antitumor activity of ICB through synergistic approaches. Cytotoxic T lymphocytes (CTLs) are the central effectors of anti-tumor immune response. Understanding the relationship between tumor intrinsic kinases and CTL-mediated cytotoxicity could reveal novel mechanisms in promoting responses to immunotherapy.

Methods: Cas9-expressing mouse HCC cells were overexpressed with ovalbumin (OVA), then transduced with kinome knockout library. Cells were co-cultured with activated OVA-specific OT-1 CD8+ T cells followed by next-generation sequencing of gRNA representation. MaGeCK analysis was used to define the top genes that affected tumor cell killing by cytotoxic T cells.

Results: Top hits from the screen were validated in vitro and loss of target gene was shown to reduce tumor burden in an immune-dependent manner. Mechanisms by which the target genes regulate T cell killing and modifications in tumor microenvironment are currently under investigation.

Conclusion: By identifying key genes involved in T cell-mediated cytotoxicity and validating their impact on tumor burden, the research emphasizes the importance of understanding the interplay between tumor intrinsic kinases and immune responses. These findings provide insights that can guide the development of novel therapeutic strategies to enhance the effectiveness of immunotherapy in HCC.

Abstract Submission No. 101631
O-0568

A Precision Therapy Targeting Replication Stress in Hepatocellular Carcinoma by WEE1 Inhibition.

Xing Jia1

Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China

Background: The diversity of hepatocellular carcinoma (HCC) necessitates more individualized and effective treatment strategies for advanced cases.

Methods: We sequenced 178 proteomic and 94 transcriptomic clinical samples for HCC subtype identification. Employing Kinome CRISPR screening and patient-derived xenograft drug assays, we explored synergistic therapeutic combinations for different HCC subtypes. We verified the synergistic effect of oxaliplatin and adavosertib through in vitro and in vivo models. To elucidate the synergistic mechanism of oxaliplatin and adavosertib in HCC cells, we utilized whole transcriptomic sequencing, confocal imaging, Western Blot, and pDR-GFP or pimeJ5-GFP reporter systems for the detailed investigation.

Results: Both proteomic and transcriptomic subtyping analyses revealed that subtypes with hyperproliferative features have the worst prognosis and highest replication stress (RS) levels. Oxaliplatin, among the clinical first-line agents, heightened RS in HCC, with WEE1 as a synergistic point of action. We demonstrated the synergy between the WEE1 inhibitor adavosertib and oxaliplatin. Mechanistically, adavosertib inhibits oxaliplatin-induced homologous recombination repair and G2/M checkpoint activation, leading to fatal DNA damage and forcing cells with DNA damage into mitosis. High RS levels in HCC patients were associated with poorer prognosis but predicted a better response to the adavosertib-oxaliplatin combination, as confirmed by preclinical models through unsupervised clustering analysis.

Conclusions: Our study proposes a novel classification and treatment strategy for HCC based on tumor RS levels, potentially enriching precision medicine with direct clinical implications.

Abstract Submission No. 101710
O-0569

miR-485-3p as a predictive biomarker in Atezo/Beva therapy and analysis of PIAS3/STAT3/VEGF signal

Kyoko Oura1, Asahiro Morishita1, Kei Takuma1, Mai Nakahara1, Tomoko Tadokoro1, Koji Fujita1, Joji Tani1, Tsutomu Masaki1
1Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa Takamatsu Japan

Objective: Atezo/Beva therapy has been shown to be effective for uHCC, and miRNA targeting VEGF is associated with therapeutic effect. In this study, we focused on the usefulness of miR-485-3p as a early predictive marker and analyzed the mechanisms related to PIAS3/STAT3/VEGF.

Methods: Sixty-six patients with uHCC treated with Atezo/Beva from 2020 to 2022 were included. Contrast-enhanced CT at 6 weeks was evaluated by modified RESIST and divided into response group (CR+PR) and non-response group (SD+PD). In vitro, HuH-7 and HUVEC were co-cultured, miR-485-3p was transfected, and cell migration and proliferation ability were analyzed. miRNA expression was analyzed by RT-PCR and protein expression by Western blot.

[Results] Comparing 44 patients in the response group with 22 patients in the non-response group, 10 miRNAs were significantly elevated before treatment in the response group, especially miR-485-3p, which was higher than in the non-response group and further elevated 3 weeks later. Serum VEGF levels before treatment were not significantly different, but both groups decreased to below detection sensitivity the next day, and the 3-week/pre-treatment ratio was significantly lower in the response group than in the non-response group. In multivariate analysis, miR-485-3p elevation at baseline was a significant factor related to therapeutic response. In vitro, miR-485-3p suppressed migration and proliferation in HuH-7, enhanced
PIAS3 expression, and suppressed STAT3/VEGF expression, which were more pronounced in cells co-cultured with HuVEC.

Conclusion: Serum miR-485-3p is useful for predicting early treatment response, and PIAS3/STAT3/VEGF signals are associated and may have clinical applications in biomarker and drug development.

Abstract Submission No. 101721

O-0570

In vitro therapeutic effects of Bosentan and Obeticholic acid on Hepatocellular Carcinoma Cells

Necati Ormeci1, Sina Kilic2, Gulden Budak1, Ayca Uvez2, Sinasi Bayram1, Ece Zehra Ekinikili1, Elif Ilkay Armutuk2

1Istanbul Health and Technology University, Faculty of Medicine Istanbul Turkey, 2Istanbul University-Cerrahpasa, Faculty of Veterinary Medicine Istanbul Turkey

Background: Hepatocellular carcinoma (HCC) is the second liver tumor with a high mortality rate. High plasma endothelin-1 B (ET-1) level in HCC patients is an important marker of portal hypertension pathogenesis. Expression of Farnesoid X receptor Obeticholic acid (OCA), responsible for hepatoprotective effects are significantly reduced in human HCC tumor tissue.

Method: The in vitro anti-proliferative, cytostatic and cytotoxic efficacy of the Bosentan, OCA and Bosentan+OCA were investigated. EA.hy926 and HepG2 cell lines were treated with Bosentan, OCA and Bosentan+OCA for 48 h at various concentrations (0-200µM). SRB cell viability and colony formation assays were performed in EA.hy926.

Results: GI50, TGI, and LC50 parameters representing the anti-proliferative, cytostatic, and cytotoxic effects were calculated at 48h, respectively. Bosentan and OCA revealed lower cytotoxic effects on HepG2 cells compared to EA.hy926, control cell line, (LC50>200). Bosentan had lower cytostatic and anti-proliferative effect than OCA on HepG2 cells. Bosentan 25 µM and Obeticholic acid 50-25 µM showed a slight reduction in colony number and size compared to control. Bosentan (50-200 µM) alone, OCA (100-200 µM) alone and Bosentan+OCA combination showed a dose-dependent reduction in cell viability and colony formation ability.

Conclusion: In this study, combined use of Bosentan and OCA were found to increase the cytotoxic effect in both cell lines by showing a synergistic effect. Higher doses of Bosentan+OCA causes loss of healthy cells due to resistance in HepG2 cells emphasizes the need for targeted therapies.

Abstract Submission No. 101746

O-0571

Transcriptome sequencing was used to analyze the mechanism of CENPF involved in regulation of hec

Ying Zhang1, Xue-Fei Wei1, Jie-Ru Yang1, Ji-Hui Li1, Xing Su1, Zhao-Hui Wang1, Peng-Yu Luo1, Nan Chen1, Pei Liu1, Yu-Chen Fan1, Kai Wang1

1Qilu Hospital of Shandong University Jinan China, 2Hepatology Institute of Shandong University Jinan China

Objective: This study is based on analysis of the transcriptome study technology, to explore the mechanism of action of CENPF to participate in the regulation of HCC.

Methods and Results: In this study, the mRNA expression of 20 pairs of HCC tissue and paracancerous tissue samples was examined using transcriptomics technology. By analyzing the differentially expressed genes between HCC and adjacent tissues. Ten target genes were selected for verification by RT-qPCR, and CENPF gene was screened. The expression levels in normal liver cells L02 and liver cancer cell lines HepG2, PLC, Huh7 and Hep3B were detected, and immunohistochemical staining and Western blot were performed on paraffin sections of liver cancer tissues. The results showed that CENPF was significantly increased in HCC tissues compared with normal liver tissues. Western blot was used to verify the expression of signal pathway related proteins in HepG2 and Huh7 cells with CENPF overexpression and knockdown. GO analysis revealed that CENPF was related to 243 biological processes, and CENPF was mainly involved in cytokaskeleton formation, cell mitosis, protein binding and other processes. KEGG analysis showed that CENPF mainly involved in the AKT/mTOR, TNF, JAK - STAT signaling pathways are closely associated with cancer. There were significant differences in PISK and p-AKT between the knockdown group and the overexpression group.

Results: CENPF is mainly involved in regulating the signaling pathway of liver cancer, which provides a new way to elucidate the mechanism of CENPF on HCC.

Abstract Submission No. 101843

O-0572

MicroRNA-491 ameliorates lenvatinib resistance in hepatocellular carcinoma cells

Takayuki Kogure1, Mari Satoh1,1, Masanori Takahashi2, Takehito Ito1, Kouji Okada2, Kensuke Usui2, Kennichi Satoh1

1Division of Gastroenterology, Tohoku Medical and Pharmaceutical University Sendai Japan, 2Department of Pharmacy, Tohoku Medical and Pharmaceutical University Sendai Japan, 3Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital Sendai Japan, 4Department of Internal Medicine, Tome City Toosato Hospital Tome Japan

Lenvatinib, a multi-kinase inhibitor, has demonstrated superior response rates in hepatocellular carcinoma (HCC) treatment. However, overall survival remains non-inferior to sorafenib, suggesting the development of resistance during treatment. Lenvatinib induces severe hypoxia in tumors by inhibiting VEGF receptors, potentially playing a critical role in multi-kinase inhibitor resistance. This study aims to elucidate the mechanism of lenvatinib resistance under hypoxia in HCC. Human HCC cell lines PLC/PRF/5, Huh7, Hep3B, and HepG2 were cultured under normoxic or hypoxic conditions. Hypoxia increased HIF1α expression without significantly affecting cell growth until 96 hours. Lenvatinib inhibited cell growth in a concentration-dependent manner, but this cytotoxicity was reduced under hypoxia, indicating resistance acquisition.

MicroRNA profiling revealed that 48 microRNAs were differentially expressed in lenvatinib-treated PLC/PRF/5 cells under normoxia (42 increased, 6 decreased). Of the 42 increased microRNAs, 28 showed decreased expression in lenvatinib-treated PLC/PRF/5 cells under hypoxia. Among these, miR-491 exhibited the most significant change in expression. Forced expression of miR-491 partially restored lenvatinib cytotoxicity under hypoxia. Similar results were observed in all tested cell lines. Genome-wide miRNA profiling identified 168 genes commonly alternated by miR-491 forced expression in PLC/PRF/5, Huh7, and HepG2, associated with RNA splicing, cell cycle, and cell adhesion pathways.

In conclusion, miR-491 contributes to hypoxia-induced lenvatinib resistance in HCC, and modulating its expression partially restores lenvatinib cytotoxicity. These findings highlight the potential of targeting microRNAs to overcome lenvatinib resistance.
UBE2S promotes tumor glycolysis by enhancing K11-linkage ubiquitination at lysine 171 and 196 of VHL

Ren-Yu Zhang1, Huijie Bian1
1Department of Cell Biology, National Translational Science Center for Molecular Medicine, Fourth Military Medical University Xi’an China

Background: Ubiquitination is widely involved in the progression of hepatocellular carcinoma (HCC) by regulating various cellular processes. However, systematic strategies for screening core ubiquitin-related genes, clarifying their functions and mechanisms, and ultimately developing potential therapeutics for patients with HCC are still lacking.

Methods: Cox and LASSO regression analyses were performed to construct a ubiquitin-related gene prediction model. Loss- and gain-of-function studies, transcriptomic and metabolomics analysis were used to explore the function and mechanism of UBE2S on HCC cell glycolysis and growth.

Results: Based on 1423 ubiquitin-related genes, a four-gene signature was successfully constructed to evaluate the prognosis of patients with HCC. UBE2S was identified in this signature with the potential to predict the survival of patients with HCC. E2F2 transcriptionally upregulated UBE2S expression by directly binding to its promoter. UBE2S positively regulated glycolysis in a HIF-1α-dependent manner, thus promoting the proliferation of HCC cells. Mechanistically, UBE2S enhanced K11-linkage polyubiquitination at lysine 171 and 196 of von Hippel-Lindau tumor suppressor (VHL), thereby indirectly stabilizing HIF-1α protein levels. In particular, the combination of cephalmannine, a small molecule compound that inhibits the expression of UBE2S, and PX-478, an inhibitor of HIF-1α, significantly improved the anti-tumor efficacy.

Conclusions: This study identified UBE2S as a key biomarker among the thousands of ubiquitin-related genes and elucidated its mechanism in promoting glycolysis in HCC cells by regulating VHL/HIF-1α signaling pathway, thus providing therapeutic candidates for the treatment of HCC.

Nimbolide reduces tumor growth and metastasis by regulating miR145 expression in liver cancer

Balasubramaniyan Vairappan1, Siva Bala subramanian1, Victor Mukherjee1
1JIPMER Pondicherry India

Background: Liver cancer remains a substantial public health problem and represents the 3rd leading cause of cancer-related deaths globally. However, many advanced therapies are in place, the prognosis remains poor. Here, we aim to ascertain the anti-cancer and metastatic effects of Nimbolide (a major limonoid constituent of Azadirachta indica) by regulating specific microRNA 145 and its target genes in experimental liver cancer.

Methods: Diethyl nitrosamine and N-nitrosomorpholine-induced hepatocellular carcinoma (HCC) mice were administered Nimbolide (6mg/kg b.wt.) orally for four weeks following induction of HCC at 28 weeks.

Results: We found significantly decreased expressions of miR145 in HCC mice compared to naive. Following treatment with Nimbolide to HCC mice showed increased miR145 expression considerably. Moreover, miR145 direct target genes such as MUC1, ROCK-1, MMP-9 and ADAM 17 were significantly elevated in HCC and were downregulated following Nimbolide treatment. The epithelial-mesenchymal transition (EMT) markers E-cadherin expression decreased whilst N-cadherin expression increased in HCC mice. Furthermore, miR145 inhibitor treatment to HepG2 cells showed increased MUC1, ROCK-1, MMP-9, ADAM 17 and EMT marker expression. Nimbolide treatment positively regulated the above indices.

Conclusion: Our novel data suggested that Nimbolide treatment improved miR145 expression and decreased its target genes involved in cancer growth and metastatic development in HCC. Consequently, Nimbolide could be considered a future therapeutic approach in managing HCC pathogenesis.
Abstract Submission No. 101980
O-0576

Cancer cell produce liver metastasis via intracellular gap formation in sinusoidal endothelial cells

Hoang Truong1, Misako Sato-Matsubara2, Hideto Yuasa2, Tsutomu Matsubara2, Le Thi Thanh Thuy2, Jordi Gracia-Sanchez3, Norifumi Kawada2

1Cancer Institute, Military Central Hospital 108 Hanoi Vietnam, 2Osaka Metropolitan University Osaka Japan, 3IDIBAPS Biomedical Research Institute Barcelona Spain.

Background: Intracellular gap (iGap) formation in liver sinusoid endothelial cells (LSECs) is caused by the destruction of fenestrae under pathological conditions, but the role of LSECs-iGap in liver metastasis is still unclear.

Methods: Mouse models using acetaminophen or thioacetamide followed by intrasplenic injection of hepatocellular carcinoma (HCC) cell line, Hepa1-6 cells, to assess the LSECs-iGap formation. Functional effects of LSECs-iGap on cancer cells were analyzed using MMPs inducer, monocrotaline, and inhibitor, doxycycline. The data was collected using electron microscopic, RNA-sequencing, cytokine array, and endothelial trans-endothelial migration assay in vitro mouse models and in vitro co-culture system. Biopsy specimens from 98 patients with HCC were statistically evaluated using immunohistochemical staining.

Results: Acetaminophen-induced liver injury and thioacetamide-induced fibrotic liver resulted in LSECs-iGap formation, which positively correlated with increased numbers of metastatic foci after Hepa1-6 cells injection. In addition, Hepa1-6 cells induced IL-23-dependent TNF-α secretion by LSECs and triggered LSECs-iGap formation, toward which their processes protruded to transmigrate into the liver parenchyma. TNF-α caused depolymerization of F-actin and increased MMP9, ICAM1, and CXCLs expression in LSECs. Interestingly, high MMP9 activity by doxycycline and MMP-2/9 inhibitor eliminated monocrotaline or Hepa1-6 cells induced LSECs-iGap formation, which was accompanied with attenuated liver metastasis by Hepa1-6 cells.

Conclusion: This study revealed that cancer cells induced LSEC-iGap formation via pro-inflammatory paracrine mechanisms and proposed MMP9 as a novel target for blocking cancer cell metastasis to the liver.

Abstract Submission No. 102049
O-0577

Determinants of hepatocellular carcinoma in alcohol liver disease patients

Priyanka Shenoy1, Manya Prasad2, Shiv Kumar Sarin3

1Institute of Liver and Biliary Sciences New Delhi India, 2Institute of Liver and Biliary Sciences New Delhi India, 3Institute of Liver and Biliary Sciences New Delhi India

Background: This study aims to determine the drinking pattern and patient characteristics that make Alcohol Liver Disease (ALD) patients susceptible to develop Hepatocellular Carcinoma (HCC).

Methods: A Case Control study was conducted in Out Patient Department of tertiary care liver hospital from November 2022 to August 2023. ALD patients with HCC and without HCC were recruited as cases and controls respectively. Using questionnaire, data was collected on patient characteristics; anthropometry measurements were done and biochemical test reports noted. Association between suspected risk factors and occurrence of HCC was determined by logistic regression.

Results: 220 ALD patients were enrolled. Mean age was 60.03 ± 9.161 years among cases and 52.70 ± 9.336 among controls; all were males. By univariable logistic regression, following factors had significant association with HCC development-age more than 60 years, family history of cancer, hepatitis C infection, diabetes mellitus, hypertension, smoking, alcohol consumption of more than 80 gram per day, daily, for at least 10 years. By multivariable logistic regression, the factors were-age more than 60 years (aOR 9.297, 95% CI: 2.941-29.385), hepatitis C infection (aOR 13.037, 1.494-113.803), smoking (aOR 2.572, 1.180-5.606), alcohol consumption of more than 80 gram per day, daily, for at least 10 years (aOR 2.233, 1.154-4.321)

Conclusion: Alcohol consumption more than 80 gram per day, daily, for at least 10 years; higher age, Hepatitis C infection and smoking increase predisposition of ALD patients to develop HCC. Vigorous screening, regular follow up and health education of ALD patients can aid early diagnosis and management.

Abstract Submission No. 200006
O-0578

The Impact of TIGAR on Tumor Microenvironment and Resistance to Ferroptosis in HCC

Katsuya Toshida1, Shinji Itoh1, Takuma Ishikawa1, Yuki Nakayama1, Yuriko Tsutsui1, Norifumi Iseda1, Takuma Izumi1, Yuki Bekki1, Shohei Yoshiya1, Takeo Toshima1, Tomoharu Yoshizumi1

1Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Fukuoka Japan

Background: TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and its biological role in hepatocellular carcinoma (HCC) are limited.

Methods: 386 patients with HCC who had undergone hepatic resection were enrolled. Immunohistochemical staining for TIGAR, cluster of differentiation (CD)8, CD68, programmed death-ligand 1 (PD-L1) and CD34 was performed. Additionally, the regulation of malignant activity and ferroptosis by TIGAR was investigated in vitro.

Results: Patients were divided into TIGAR-positive (n=80, 20.7%) and -negative (n=306, 79.3%) groups by immunohistochemical staining of TIGAR. In uni/multivariate analysis, TIGAR positivity was an independent prognostic factor (p<0.0001). In addition, TIGAR positivity was significantly associated with smaller number of CD8 positive T cells (p=0.0450), larger number of CD68 positive macrophages (p=0.0058), PD-L1 positive cases (p=0.0002) and vessels that encapsulate tumor cluster positive cases (p=0.0004). In vitro, TIGAR knockdown decreased cell motility (migration/invasion/colony forming abilities) and induced ferroptosis (down regulation of cell viability/elevation of reactive oxygen species and lipid peroxidation) (p<0.05). TIGAR knockdown inhibited the phosphorylation of adenosine monophosphate-activated protein kinase and acetyl-CoA carboxylase. Ferroptosis induced by TIGAR knockdown was inhibited by liproxstatin and baicalein treatment (p<0.05). The combination of TIGAR knockdown and lenvatinib significantly further induced ferroptosis (p<0.05).

Conclusions: High expression of TIGAR impacted the clinical outcome of HCC patients and TIGAR was associated not only with tumor microenvironment but also with resistance to ferroptosis.
Double knockout of P53/Pten induced an HCC mouse model shared a similar transcriptome to human HCC

Danjuan Lu1, Guiwen Guan1, Jing Yang2, Chia-Chen Chen1, Jing Zhang3, Zhao Chen4, Xuewei Qi1, Weilin Gu1, Abudurexiti Abulaiti4, Fengmin Lu1, Jingzhou Wang5, Yongzhen Liu6, Xiangmei Chen1

1Peking University Beijing China, 2Guangdong Provincial People’s Hospital Guangdong China, 3Beijing Tongren Hospital Beijing China, 4Qingdao University Shandong China, 5Shihezi University School of Medicine Xinjiang China, 6Princeton University Princeton USA

Background: HCC mouse models, play a vital role in studying the intricate interplay of factors contributing to HCC development. However, with a multitude of available HCC mouse models, choosing the one most closely resembles human HCC can be challenging. A comprehensive analysis of their characteristics and fidelity in recapitulating human disease is essential for selecting the most appropriate model for specific research objectives.

Methods: This study addresses this gap by conducting a comprehensive transcriptomic similarity analysis of widely used HCC mouse models. The researchers compared the gene expression profiles, immune microenvironments, and metabolic pathways of these models with those of human HCC.

Results: DENV-CC14-induced HCC model: Showed the worst similarity to human HCC in terms of transcriptome profiles and DEGs. Had minimal metabolic differences between tumor and non-tumor tissues.

p53&Pten KO model: Displayed a moderate level of similarity to human HCC in terms of transcriptome profiles and DEGs. Showed some enrichment of pathways similar to human HCC but also had unique enriched pathways.

HBV+p53&Pten KO model: Demonstrated the highest similarity to human HCC across various parameters. Shared a high degree of overlap in DEGs between tumor and non-tumor tissues with human HCC. Exhibited a transcriptome profile and immune cell infiltration pattern closely resembling human HCC. Showed metabolic alterations similar to those observed in human HCC.

Conclusion: This study highlights the importance of selecting appropriate HCC mouse models for research. The HBV+p53&Pten KO model emerged as the most promising model due to its remarkable similarity to human HCC across various aspects.

Abstract Submission No. 100045
O-0580

Immunophenotyping and tumor microenvironments of HBV-positive and negative hepatocellular carcinoma

Hongping Xia1

1National Cancer Centre Singapore Singapore Singapore

Background & aims: HBV infection leads to hepatocellular carcinoma (HCC) and affects immunotherapy. Exploring tumor ecosystem in HCC help to gain a deeper understanding and design more effective immunotherapy strategies for HCC patients with or without HBV infection.

Methods: Single-cell RNA sequencing (scRNA-seq) series were integrated as a discovery cohort to interrogate the tumor microenvironment (TME) of HBV+ HCC and HBV- HCC. We further dissect the intratumoral immune status of HBV+ and HBV- HCC. An independent cohort, including samples treated with immune checkpoint blockade therapy (ICB), was used to validate the major finding and investigate the effect of HBV infection on response to immunotherapy.

Results: The interrogation of TME indicated that TREG, exhausted CD8+ T cell and M1-like Macrophage MNP9 were enriched in HBV+ HCC, while MAIT was enriched in HBV- HCC. All subclusters of T cells showed high expression of immune checkpoint genes in HBV+ HCC. TREG cells enriched in HBV+ HCC also showed more robust immunosuppressive properties, which was confirmed by cross-talk between immune cell subsets. The ability of antigen presentation with major histocompatibility complex (MHC)-II was down-regulated in HBV+ HCC and this phenomenon can be reversed by immunotherapy. Two types of HCC also present different responses to immunotherapy.

Conclusion: There is a more immunosuppressive and exhausted TME in HBV+ HCC than in HBV- HCC. This in-depth immunophenotyping strategy is critical to understanding the impact of HBV along with the HCC immune microenvironment and helping to develop more effective treatments in HCC patients.

Abstract Submission No. 100080
O-0581

Prognostic impact of Cyber-Knife as part of multidisciplinary treatment in hepatocellular carcinoma

Takamasa Ohki1, 2

1Shioda Memorial Hospital Department of Cyber-knife Nagara Japan, 2Mistui Memorial Hospital Department of Gastroenterology Tokyo Japan

Backgrounds: Cyber-Knife (CK) is a stereotactic radiotherapy with high local control capability and is covered by insurance for the treatment of hepatocellular carcinoma (HCC) in Japan. We investigated the efficacy of CK as a multidisciplinary therapy in the treatment of HCC.

Methods: From January 2001 to December 2020, 568 patients with radically treated HCC were included. Of these, CK was added to 52 cases during the course of the study, and the remaining cases without CK were matched for age, gender, presence of HCV infection, tumor size, tumor number, ALBI score, and introduction of chemotherapy, and finally 40 cases each were selected to compare their backgrounds. The primary endpoint was overall survival (OS), and factors related to OS were also examined.

Results: The mean maximum tumor diameter and the mean number of tumors were 24 mm and 1.4, respectively, at the time of initial onset of HCC. The mean tumor diameter at the time of CK was 18 mm, and all the targets were one. The local control rate of CK was 96.8% at 1 year, 87.3% at 2 years, and 87.3% at 3 years. The overall survival rate from the initial treatment was 80.3% at 3 years, 70.8% at 5 years, and 39.1% at 10 years in the CK group, and 79.4% at 3 years, 52.9% at 5 years, and 22.7% at 10 years in the control group, with a significant difference (P = 0.047). In univariate analysis, ALBI score (HR 1.26 per 1 95%CI 1.08-1.48 P<0.01) and application of CK (HR 0.56 95%CI 0.32-0.99 P=0.049) were significant independent factors which contributed to OS.

Conclusion: Although it is difficult to determine the extent to which CK contributes to prolonged prognosis in a series of treatment courses, it was considered to be one of the effective treatments as a complement to standard treatment.

Abstract Submission No. 100244
O-0582

Similar recurrence after curative treatment of HBV-related HCC, regardless of HBV replication
Background and Aims: Antiviral therapy (AVT) is required in patients with newly diagnosed hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), if HBV DNA is detectable. We compared the risk of recurrence according to HBV replication activity at the curative treatment of HBV-related HCC.

Methods: Patients with HBV-related HCC who underwent surgical resection or radiofrequency ablation between 2013 and 2018 were enrolled in this retrospective cohort study. Patients were categorized into two groups according to HBV replication activity at the curative treatment of HBV-related HCC (group 1: patients who met the AVT indication for HBV-related HCC due to detectable HBV DNA but did not meet the AVT indication if without HCC; group 2: patients who met the AVT indication, regardless of HCC).

Results: In the entire cohort (n=911), HCC recurred in 303 (33.3%) patients during a median follow-up of 4.7 years. After multivariate adjustment, group 2 showed a statistically similar risk of HCC recurrence (adjusted hazard ratio [aHR]=1.18, P=0.332) compared to that of group 1. In addition, group 2 showed statistically similar risks of early (<2 years; aHR=1.31) and late (≥2 years; aHR=0.83) recurrence than that of group 1 (all P<0.05). Propensity score matching and inverse probability of treatment weighting analysis also yielded similar risks of HCC recurrence between the two groups (all P>0.05, log-rank tests).

Conclusions: The risk of HCC recurrence in patients who received curative treatment for newly diagnosed HBV-related HCC was comparable regardless of HBV replication activity if AVT was properly initiated.

Abstract Submission No. 100371
O-0584

Identifying optimal candidates for HAIC over Sorafenib: A systematic review and meta-analysis

TENGFEI SI1,2, Qing Shao2, Yun Ma1,2, Nigel Heaton1
1King’s College Hospital NHS Trust London United Kingdom
2King’s College London London United Kingdom

Background: Sorafenib is pivotal in extending the survival of patients with advanced or unresectable hepatocellular carcinoma (HCC) though its efficacy is largely curtailed by low response rates. With interest revived in hepatic artery infusion chemotherapy (HAIC), it was found that patients may receive greater benefit from HAIC compared to Sorafenib. This study aims to find optimal candidates for HAIC over Sorafenib.

Methods: A rigorous literature search was conducted to collect available studies comparing patients’ outcome differences between HAIC and Sorafenib. The pre-registered protocol was available at PROSPERO (CRD42023458845).

Results: A total of 26 studies with 6456 patients (HAIC:2648; Sorafenib:3808) were included. Chemotherapy-naïve patients (HR=0.66, 95%CI [0.56, 0.79]), individuals with Child-Pugh grade A liver reserve (HR=0.81, 95%CI [0.74, 0.89]), and those with major vessel invasion (MVI) but no extrahepatic metastasis (HR=0.58, 95%CI [0.45, 0.75]) could potentially benefit more by HAIC. However, for those who were refractory to trans-arterial chemoembolization (TACE), sorafenib demonstrated greater efficacy (HR=1.32, 95%CI [1.01,1.73]) while patients with extrahepatic metastasis whether with or without MVI (EHS+MVI+:HR=0.72, 95%CI [0.44, 1.17]; EHS+MVI-:HR=1.35, 95%CI [0.65, 2.84]) presented similar survival after HAIC or Sorafenib monotherapy. Additionally, pooling HRs from multivariate Cox regression showed that MVI, EHV, and AFP >400ng/ml could be independent risk factors for patients’ overall survival (OS), while HAIC treatment and lower BCLC stage were potentially protective factors.

Conclusions: Higher survival benefits could be expected from HAIC compared to sorafenib monotherapy in selected patients. A re-evaluation of HAIC as a potential treatment option in intermediate and advanced HCC is warranted.

Abstract Submission No. 100416
O-0585

Integrative translational research to study T cell exhaustion in hepatocellular carcinoma (HCC)

Da-Liang Ou1, Ching-Hung Hsieh1, Tzu-Yang Tseng2, Chia-Lang Hsu1,3, Bor-Sheng Ko4, Jr-Shiuian Lin5, Chien-Kuo Lee6, Hsueh-Fen Juan2, Chiu Hsu8
ASAP algorithm demonstrates high sensitivity for HCC surveillance - a prospective study.

Wei-Lun Liou1, Si-Yu Tan2, Fan Feng3, Kaina Chen1, Pik-Eu Chin-Pi n Ye o2, Chee-Kiat Tan1

1Department of Gastroenterology and Hepatology, Singapore General Hospital Singapore, 2Department of Clinical Pathology, Singapore General Hospital Singapore Singapore, 3Clinical Statistics Affair, Abbott Diagnostics USA USA, 4Medical & Scientific Research, Abbott Diagnostics Singapore Singapore

Background: Hepatocellular carcinoma (HCC) surveillance with liver ultrasound and alpha-fetoprotein (AFP) has limitations of accuracy and patients’ poor adherence with ultrasound examination. ASAP is a HCC risk algorithm based on Age, Sex, AFP, and Protein Induced by Vitamin K Antagonist-II (PIVKA-II) that may allow for a personalized surveillance protocol. We studied the performance of the ASAP algorithm in a prospective cohort of patients undergoing HCC surveillance.

Methods: Patients without prior HCC undergoing HCC surveillance in Singapore General Hospital Department of Gastroenterology and Hepatology and Department of Medical Oncology, National Taiwan University Hospital Taipei Taiwan, 5Department of Medical Oncology, National Taiwan University Hospital Cancer Center Taipei Taiwan, 6Department of Oncology, National Taiwan University Hospital Taipei Taiwan

Baseline AFP and PIVKA-II (Abbott ARCHITECT®) were assayed and prediction from the ASAP algorithm was calculated using the published model. The patients continued HCC surveillance with semi-annual ultrasound and AFP.

Results: There were 612 patients (60.9% male). Median age was 65 years (IQR 58-72). Most common liver disease was Hepatitis B (90%). By February 2023, after a median follow-up of 52.2 months (IQR 48.3-54.5), 15 patients developed HCC with 13 in BCLC stage 0/A. ASAP algorithm score had the highest AUROC (0.767) for HCC detection, compared to AFP or PIVKA-II alone (0.743 and 0.672 respectively). ASAP score’s sensitivity/specificity/negative predictive value (NPV)/AUROC for HCC developing within 1 and 2 years of biomarker assessment were 100%/87.3%/100%/0.946 and 85%/87.3%/99.8%/0.889, respectively.

Conclusion: ASAP algorithm demonstrated high sensitivity, specificity and NPV for HCC detection in a prospective cohort of patients undergoing HCC surveillance. Hence, in view of patients’ poor adherence to ultrasound imaging, substitution with regular assessment with the ASAP algorithm may be a feasible option.
Among those receiving Atezo+Bev therapy as first-line treatment (n = 152), 24 (15.8%) patients showed primary resistance, which was significantly associated with CRP, AFP, and DCP. The CRAFTITY score, incorporating CRP and AFP, effectively stratified the primary resistance rates (11.8%, 30%, and 66.7% for CRAFTITY scores of 0, 1, and 2 points, respectively).

**Conclusions:** About 15% of patients exhibited primary resistance to first-line Atezo+Bev therapy. The CRAFTITY score seemed useful to predict the likelihood of primary resistance.

---

**Association between Post-Ablation Fever and Prognosis in Initial Hepatocellular Carcinoma**

**Jie Yu**1, **Qian Cai**2, **Xin Hu**3

1Department of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 2Department of Interventional Ultrasound, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 3Division of Transplantation Immunology, National Research Institute for Child Health and Development Tokyo Japan

**Background:** Fever, a common complication in patients with hepatocellular carcinoma (HCC) following thermal ablation, yet its impact on prognosis remains unclear.

**Materials and Methods:** This retrospective study included initial HCC patients who underwent percutaneous microwave ablation at 13 hospitals between January 2007 and February 2021. Statistical models were employed to identify the impact and cut-off values of post-ablation temperature and fever duration on early recurrence. Primary outcomes included very early recurrence (VER) and early recurrence (ER), and secondary outcomes were disease-free survival (DFS) and overall survival (OS) rates. Survival analyses used the Kaplan-Meier method.

**Results:** A total of 1458 BCLC stage 0-B HCC patients (mean age: 59 ± 11) with a median follow-up of 47 months. Compared to afebrile, patients who exhibited peak temperatures between 37.0–38.8°C and fever lasting 1-2 days (transient low-grade fever, TLF) showed independent protective effects against VER (HR, 0.73; 95% CI: 0.57, 0.95; P=0.017) and ER (HR, 0.66; 95% CI: 0.54, 0.81; P<0.001). Prolonged or high-grade fever (PHF) showed no differences in VER (P=0.964) and ER (P=0.171). Additionally, TLF patients displayed the highest 5-year DFS and OS rates of 42.6% and 73.2%, surpassing afebrile patients (33.2% and 69.3%, P=0.020 and 0.005) and PHF patients (44.1% and 66.7%, P=0.018 and <0.001). Notably, TLF patients exhibited the highest post-ablation lymphocyte counts increase (P<0.001 vs. afebrile and P=0.013 vs. PHF).

**Conclusions:** Transient low-grade fever following percutaneous microwave ablation in patients with hepatocellular carcinoma has demonstrated protective effects against early recurrence, possibly attributed to the activation of lymphocytes.

---

**Assessment of Cases with Prolonged Elevation of Tumor Markers without Detectable HCC Recurrence**

**Makoto Moriyama**1, **Ryosuke Tateishi**1, **Yuki Matsuhashita**1, **Tomoharu Yamada**1, **Takuma Nakatsuka**1, **Tatsuya Minami**1, **Masaya Sato**1, **Mitsuhiro Fujishiro**1, **Shuichiro Shiina**1, **Kazuhiko Koike**3

1Department of Gastroenterology, Tokyo University School of Medicine. Tokyo Japan, 2Department of Gastroenterology, Juntendo University Hospital, Faculty of Medicine, Juntendo University Tokyo Japan, 3Kanto Central Hospital, Public Health Mutual Aid Association Tokyo Japan

**Background:** Tumor marker elevation is highly predictive of hepatocellular carcinoma (HCC) recurrence during post-treatment surveillance. However, some patients show persistent tumor marker elevation without imaging evidence of recurrence.

**Methods:** We reviewed 1,610 patients with naive HCC treated with radiofrequency ablation in our department from 1999 to 2021. We identified cases in which tumor markers were continuously above the cutoff value for more than 180 days prior to HCC recurrence. The AFP cutoff value was set differently according to active viral hepatitis status.

**Results:** Inclusion criteria were met in 228 cases of recurrence in 172 patients, including AFP >20 ng/mL in 122 cases, AFP >200 ng/mL in 42, DCP >200 mAU/mL in 50, and AFP-L3 fraction >15% in 130. The average tumor size at recurrence was 1.7 cm, with 106 cases of solitary tumors, 74 with 2-3 tumors, and 33 with 4 or more tumors. Distant metastasis was observed in 8 cases (3 with neoplastic seeding, 3 with lymph node metastasis, and 2 with lung metastasis). Vascular invasion was observed in 7 cases (6 with portal vein and 1 with bile duct invasion). Treatment modalities included local therapy in 177 cases, transarterial chemoembolization in 36, resection in 6, systemic therapy in 4, best supportive care in 3, and others in 2. Local cure was achieved in 170 (74.6%).

**Conclusions:** In cases with tumor marker elevation prior to imaging, curative treatment was possible in the majority with caution for vascular invasion and distant metastasis.
those with post-LT HCC recurrence vs. without (4.2 [1.1] vs. 11.5 [9.6]), P<0.001).

Conclusions: Mean ICI cycles and withdrawal days pre-LT were associated with post-OLT outcomes. Prospective cohort studies and clinical trials are needed to determine the optimal strategy for using ICI before LT.

Abstract Submission No. 100852
O-0591

Improved Survival in BCLC 0/A HCC with Resection vs Ablation: A Propensity-Matched Multicentre Study

Jonathan Abdelmalak1, Simone Strasser2, Marie Sinclair3, Anouk Dev4, Zina Valaydon3, Jacinta Holmes4, Steven Bollipo2, Amanda Nicol5, Stephen Riordan6, Siddharth Sood9, Ammar Majeed1, Eileen Lam4, Elysia Greenhill4, John Zalcberg1, Stuart K Roberts4
1Alfred Hospital Melbourne Australia, 2Royal Prince Alfred Hospital Camperdown Australia, 3Austin Hospital Heidelberg Australia, 4Monash Health Clayton Australia, 5Western Health Footscray Australia, 6St Vincent’s Hospital Melbourne Fitzroy Australia, 7John Hunter Hospital New Lambton Heights Australia, 8Eastern Health Box Hill Australia, 9Princess of Wales Hospital Randwick Australia, 10Royal Melbourne Hospital Parkville Australia.

The optimal treatment approach in very-early and early-stage hepatocellular carcinoma (HCC) is not precisely defined, with ambiguity in the literature around the comparative efficacy of surgical resection versus ablation as curative therapies for limited disease. We performed this real-world propensity-matched, multicentre cohort study to assess for differences in survival outcomes between those undergoing resection and those receiving ablation. Patients with Barcelona Clinic Liver Cancer (BCLC) 0/A HCC first diagnosed between 01/01/2016 and 31/12/2020 who received ablation or resection as initial treatment were included in the study. A total of 450 patients were included in the study from 10 major liver centres including two transplant centres. Propensity-score matching was performed using age, sex, transplant centre, HBV, alcohol, diabetes, smoking, platelet count, Child Pugh Score, Charlson Comorbidity Index and tumour category (single tumour 2cm or less, 2-3cm, >3cm and multiple tumour), 156 patients were available for analysis with 78 in each group. Patients who underwent resection had significantly improved overall survival (log-rank test p=0.023, Figure 1) and local recurrence-free survival (log rank test p=0.027, Figure 2) compared to those who received ablation. Similar results were seen in unadjusted analysis of the original unmatched cohort (overall survival, log-rank test p=0.001; local-recurrence free survival p<0.001). Based on real-world data, our study supports the use of surgical resection in preference to ablation as first line curative therapy in appropriately selected BCLC 0/A HCC patients.

Abstract Submission No. 101099
O-0592

Chronological changes in clinical characteristics of HCC patients undergoing systemic therapy

Yoshinari Asoaka1,2, Ryosuke Tateishi1, Yasuhide Yamada1, Kiyoshi Hasegawa1, Hiroko Iijima2, Kengo Yoshimitsu4, Masayuki Kurosaki1, Michie Sakamoto4, Norihiro Kokudo2
1Teikyo University School of Medicine Tokyo Japan, 2National Center for Global Health and Medicine Tokyo Japan, 3Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo Tokyo Japan, 4Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo Tokyo Japan, 5Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University Nishinomiya Japan, 6Department of Radiology, Faculty of Medicine, Fukuoka University Fukuoka Japan, 7Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan, 8Department of Pathology, Keio University School of Medicine Tokyo Japan

Background: With the advancement in systemic therapy for hepatocellular carcinoma (HCC), the background of patients has significantly changed over time. In this study, we investigated the chronological change of the patients’ characteristics in Japan.

Methods: Hepatoma Registry of Integrating and Aggregating EHR (electric health record): HERITAGE study is a registry study of systemic therapy at member institutions of the Japan Liver Cancer Association (JLCA). Patients were divided into three groups based on the initiation dates of systemic therapy: April 2015-2017 (cohort A), 2018-2019 (cohort B), and 2020-March 2022 (cohort C). They were then compared in terms of age at the start of therapy, etiology, mALBI grade, presence of vascular invasion (VI), and existence of extrahepatic metastases (EHS).

Results: A total of 4,669 patients were enrolled, and the regimens were sorafenib/ lenvatinib/ atezolizumab plus bevacizumab in the following order: A 1415/0/0, B 346/1495/3, C 111/742/557. The percentage of patients aged 70 years or older was 57%, 66%, and 71% in cohorts A, B, and C, respectively. For non-viral cases, the corresponding percentages were 47%, 55%, and 58% in the same cohorts. The mALBI grade was 1 or 2a in 57%, 59%, and 61% of the patients in cohorts A, B, and C, respectively. Additionally, 39%, 53%, and 55% of patients in these groups had neither EHS nor VI.

Conclusion: There was an increase in the proportion of non-viral elderly patients among those eligible for systemic therapy. Advances of therapy have expanded the range of cases treated.

Abstract Submission No. 101101
O-0593

Urban Rural Disparities at Presentation and Overall Survival of Hepatocellular Carcinoma in Taiwan

Chien-Hung Chen1,2, Yu-Jen Fang3, Rey-Heng Hu1,3, Ja-Der Liang4, Shib-Jer Hsu5, Po-Chin Liang2, Hong-Jen Hsieh1, Jo-Pai Chen1, Chiun Hsu6
1National Taiwan University Cancer Center Taipei City Taiwan, 2National Taiwan University Hospital Taipei City Taiwan, 3National Taiwan University Hospital Yunlin Branch Yunlin County Taiwan

Introduction: There are urban rural disparities in the management of hepatocellular carcinoma (HCC). The reasons are multifactorial. To investigate the degree of disparities, we initiated this study.

Methods: We assessed all HCC patients in the period of 2014 to 2019 from the database obtained from Integrative Medical Database, National Taiwan University Hospital (NTUH-MD). NTUH has a main campus located in Taipei City (urban) and Yunlin branch (NTUH-YL)(rural). Demographic characteristics, BCLC staging, underlying liver reserve (Child Pugh class, and ALBI score), viral etiology, treatment method, and overall survival were analyzed.

Results: A total of 3368 patients in NTUH and 785 patients in NTUH-YL were collected. NTUH had 50.9% of HCC patients presenting as BCLC stage 0 or A, while NTUH-YL had 41.1% in BCLC stage 0 or A. NTUH had 25.0% of HCC patients presenting as BCLC stage C or D, while NTUH-YL had 41.7% in BCLC stage C or D. ALBI grade 1 was found in 53.6% NTUH patients, while it was 33.6% in NTUH-YL.
Curative treatment (transplantation, resection, RFA) were done in 61.9% of NTUH patients, while it was 47.9% in NTUH-YL. The median overall survival (OS) was 63.2 months in NTUH and 38.5 months in NTUH-YL (p < 0.001).

Conclusions: There were significant disparities in the stage at presentation, underlaying liver reserve, treatment method, and median OS in HCC patients, between rural and urban areas even in the same medical system. To improve the OS in the rural HCC patients, earlier diagnosis is the urgent needs.

Abstract Submission No. 101126
O-0594

MOLECULAR CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA IN ARMENIA, 2019-2020: INITIAL OBSERVATIONS

Hasmik Ghazinyan1-2, Pascal Pineau4, Soro Khemichyan3, Tigran Aghabekyan5, Tatevik Shahinyan2, Hayk Harutyunyan6
1Yerevan MSC Yerevan Armenia, 2Ecosense LLC Yerevan Armenia, 3Keck Medicine of USC LA USA, 4Institut Pasteur Paris France, 5Yerevan State Medical University Yerevan Armenia, 6Astghik MC Yerevan Armenia

Background: Within the large region encompassing the Caucasus, Middle East, and Central Asia, Armenia is the country where the incidence of liver cancer is the highest for both sexes.

Methods: A case-control study was conducted, and plasma samples were collected of 110 patients with hepatocellular carcinoma (HCC) and 167 patients with no tumor.

Results: HCV prevalence was 67.2% in the CLD group and 41.8% in the HCC and CLD group. HBV infection was less prevalent. Free circulating DNA was analyzed for a mutated TERT gene promoter.

Concerning HBV, 6 HCC patients were infected with subtype D1 (32%, n=8/25), and a single subtype 2a strain (4.0%).

Conclusion: Occult HBV is more prevalent than expected.

Abstract Submission No. 101242
O-0596

Impact of complete tumor control, “so called cancer free”, in patients with advanced-stage HCC

Keisuke Koroki1, Sadahisa Ogasawara3, Tepppei Akatsuka1, Ryo Izai1, Chihiro Miwa1, Takuya Yonemoto1, Saee Yumita1, Masanori Inoue2, Kazufumi Kobayashi3, Soichi Kiyono3, Masato Nakamura1, Naoya Kanogawa1, Takayuki Kondo1, Shingo Nakamoto2, Naoya Kata1
1Department of Gastroenterology Graduate School of Chiba University Chiba city Japan

Background: As the advent of highly efficacious systemic therapies in hepatocellular carcinoma (HCC), there have been reports of successful conversions to states amenable to curative treatments. Our study ventures to shed light on the profound implications of reaching a cancer-free and examined the outcomes for those achieving a cancer-free following advanced-stage HCC.

Methods: We established a database tracking the full clinical course of all HCC patients (from 2003-June 2022). We identified the initial instances of MVI or EHM. In this study, “Cancer Free” was defined by the following criteria. 1) Surgical cases: The absence of tumors and no recurrence in two distinct imaging evaluations spaced a minimum of two months apart. 2) Non-surgical cases: Two consecutive imaging evaluations (a minimum of two months apart) showed no tumors, with both evaluations indicating a complete response (CR) as per mRECIST.

Results: We identified 815 advanced-stage HCC patients. The cancer free rate was 8.6% (70/815). The median OS of patients who achieved cancer free was not reached (95% CI: 67.4-NA), and that of patients who did not achieve cancer free was 11.4 months (95% CI:9.5-13.7) (p<0.001). In the decision tree analysis in patients without extrahepatic metastatic spread, the number of tumors ≥8 was the strongest factor making it difficult to achieve cancer free.

Conclusions: The frequency of cancer free is low in the advanced-stage HCC. However, the OS is significantly longer in the patients who achieve it. Achievement is related to the number of intrahepatic tumors.
Systemic therapies for patients with intermediate stage HCC and the evolution of the prognosis

Teppi Akatsuka, Keisuke Koroki, Sadahisa Ogasawara, Ryo Izai, Chihiro Miwa, Takuya Yonemoto, Sae Yumita, Masanori Inoue, Kazuhumi Kobayashi, Souichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Takayuki Kondo, Shingo Nakamoto, Naoya Kato

1Department of Gastroenterology, Graduate school of Chiba University Chiba Japan

Abstract Submission No. 101341

O-0597

Systemic therapies for patients with intermediate stage HCC and the evolution of the prognosis

Background: Systemic therapies for TACE-refractory/unsuitable patients in intermediate-stage hepatocellular carcinoma (HCC) has been discussed. However, the extent to which these treatment strategies have improved the prognosis of patients with intermediate-stage HCC, a heterogeneous population, has not been adequately investigated.

Methods: We reviewed the treatment outcomes of intermediate-stage HCC diagnosed at our hospital from 2004 to 2022. Patients were divided into three groups according to the date of diagnosis (period I: 2004-April 2009, period II: May 2009-August 2018, and period III: September 2018-2022). The classification was based on the time of approval of sorafenib and lenvatinib in Japan. Prognostic evolution of TACE-refractory/unsuitable patients was evaluated. We defined cancer-free as 6 months without recurrence and evaluated the evolution of the cancer-free rate.

Results: Of all 916 intermediate-stage HCC patients the frequency with which systemic therapy was initiated at the time of diagnosis has increased over time. As for TACE unsuitable, in patients with tumors number ≥8, there was a trend toward improved survival in period III.

Conclusions: We clarified the expression of core genes and the mechanism of immune infiltration, and provided a new direction for the identification of HCC prognostic markers and the potential targeting of Traditional Chinese medicine.

Analysis of atezolizumab antidrug antibody in HCC patients treated with atezolizumab and bevacizumab

Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Akitoshi Sano, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Atsushi Masamune

1Division of Gastroenterology, Tohoku University Graduate School of Medicine Miyagi Japan

Abstract Submission No. 101341

O-0598

Analysis of atezolizumab antidrug antibody in HCC patients treated with atezolizumab and bevacizumab

Backgrounds: Atezolizumab (Atezo)+Bev (Bevacizumab) (Atezo+Bev) is positioned as first-line chemotherapy for unresectable hepatocellular carcinoma (HCC). Although immune checkpoint inhibitors (ICIs) may induce an antidrug antibody (ADA), there is a lack of evidence for the relationship between ADA against Atezo (ATZ-ADA) levels and treatment outcome. In this study, we assayed ATZ-ADA levels and analyzed its association with therapeutic outcome in advanced HCC patients who were treated with Atezo+Bev.

Methods: Twenty-six patients with unresectable HCC treated with Atezo+Bev between 2020 and 2023 were included in this study. ATZ-ADA was assayed with ELISA using the stored serum samples at the time of 3 courses of treatment or the earliest time point.

Results: The backgrounds of 26 patients were as follows: male/female=8/18, median age 74 years, HCV/HBV/non B,C=7/7/12, BCLC stage B/C=16/10, Child-Pugh score 5/6=18/8, ALBI grade 1/2=7/19. Atezo+Bev was administered for a median of 4 courses, and the best responses with mRECIST were CR/PR/SD/PD=2/11/7/6. ATZ-ADA levels were assayed at 3/4/6/7/12/13-20 course administration (12/7/3/4 cases, respectively). The median ADA level (OD value) was 0.035 and did not correlate with the number of treatment courses. The median ADA level in each response group was CR/PR/SD/PD=0.031/0.035/0.036/0.038. Interestingly, a PD patient had the highest ATZ-ADA level (0.079). His treatment was switched to the STRIDE regimen with Tremelimumab+Durvalumab resulting in CR.

Conclusions: The ATZ-ADA levels in this study were generally low, suggesting the proportion of patients in whom ADA inhibited the therapeutic effect was small. It was suggested that patients with high ATZ-ADA should consider treatment switch as soon as possible.
Increased spleen volume during atezolizumab and bevacizumab: Predictive factors and clinical outcome

Takeshi Hatanaka1,10, Satoru Kazikazi2,10, Atsushi Hiraoka3,10, Kazuya Kariyama4,10, Toshifumi Tada5,10, Hidenori Toyoda6,10, Atsushi Naganuma8, Koichi Takaguchi10, Yutaka Yata10, Kazuhiro Kawata10, Tomomitsu Matono10, Joji Tani10, Takashi Kumada10

1Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital Maebashi Japan, 2Department of Clinical Research, National Hospital Organization Takasaki General Medical Center Takasaki Japan, 3Gastroenterology Center, Ehime Prefectural Central Hospital Matsuyama Japan, 4Department of Gastroenterology, Okayama City Hospital Okayama Japan, 5Department of Internal Medicine, Japanese Red Cross Himeji Hospital Himeji Japan, 6Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital Ogaki Japan, 7Department of Gastroenterology, Kagawa Prefectural Central Hospital Takamatsu Japan, 8Department of Nursing, Gifu Kyoritsu University Ogaki Japan, 9RELPEC group Ogaki Japan

Background: We previously reported a greater increased spleen volume in hepatocellular carcinoma (HCC) patients receiving atezolizumab plus bevacizumab (Atez/Bev) compared to lenvatinib (Oncology 2023). In malignant cases treated with immune checkpoint inhibitor, baseline spleen volume (SpV) and alternations in SpV were negatively associated with PFS and OS. The study aimed to investigate the relationship between changes in SpV and therapeutic outcome of Atez/Bev. Additionally, we also investigate the predictive factors associated with increased SpV.

Methods: This retrospective study included 164 HCC patients who did not have portal vein tumor thrombosis or a history of splenectomy or partial splenic embolization. SpV were calculated based on CT imaging and patient characteristic imbalances were adjusted by IPTW method.

Results: The median ages were 74 (IQR 68-80), with 135 (82.3%) patients being male. Baseline SpV was 184.6 (IQR 130.3-256.9) cm3. Enlarged SpV at baseline (>184cm3) were not significantly associated with PFS and OS in both crude and IPTW-weighted cohort. SpV increased in 100 (84.0%) patients during Atez/Bev treatment. In 119 patients who obtained CT imaging from 3 to 4 month after treatment, the median difference in SpV were 25cm3 (IQR 6-59). Predictive factors for increased SpV (>25cm3) included age, BCLC A or B, and FIB-4 index. Patients with greater changes in SpV (>25cm3) were not associated with the PFS and OS in both crude and IPTW-weighted cohort.

Conclusions: Enlarged baseline SpV and greater changes in SpV were not associated with the therapeutic outcomes of Atez/Bev. Alternation in SpV may be associated with liver fibrosis.

Abstract Submission No. 101561

Single-cell profiling of the circulating immune cell predicts the immunotherapy for HCC

Akira Nishio1, Takahiro Kodama1, Akira Doi1, Yuki Tahata1, Kunimaro Furuta1, Hayato Hikita1, Tomohide Tatsunami1, Tetsuo Takehara1

1Department of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine Suita Japan

Background: The combination of Atezolizumab and Bevacizumab (Ate/Bev) has revolutionized the clinical outcome for unresectable hepatocellular carcinoma (HCC), which has been shown to be superior to sorafenib in IMbrave150 trial. However, how to predict the response to Ate/Bev therapy in HCC patients remains elusive. Herein we investigated the circulating immune profile of patients with unresectable HCC receiving Ate/Bev therapy.

Methods: HCC patients were enrolled in a prospectively registered multicenter study and peripheral blood mononuclear cells (PBMCs) were collected from these patients treated with Ate/Bev. Single cell-RNA sequence was utilized to analyze PBMCs from 5 responders and 5 non-responders at pretreatment and 6 weeks after Ate/Bev therapy.

Results: First, 231,832 cells of 20 PBMCs from 10 patients were clustered into 30 subsets and annotated based on the gene expression in each cluster. Responders showed the higher frequencies of central memory CD4 T cells and B cells compared to non-responders at pretreatment (p= 0.0315, 0.0159, respectively), while non-responders showed the higher frequencies of monocytes than responders (p= 0.0315). The frequency of CD8 T cells was not significantly different between groups, but responder showed stronger expression of cytotoxicity-related genes in CD8 T cells compared to non-responders. Re-clustering of monocytes resulted in 7 types of subclusters, exhibiting the differential dynamic changes during Ate/Bev treatment.

Conclusion: The immune profiling of PBMCs potentially predicts the response to checkpoint inhibitors in patients with unresectable HCC.
Impact of genetic discrimination between MC and IM on the prognosis of recurrent HCC

Yuji Iimuro1, Atsushi Takano1, Kenji Amemiya2, Yosuke Hirotsu3, Hitoshi Mochizuki4, Shuntaro Ohi1,5, Masao Omata6
1Department of Surgery, Yamanshi Central Hospital Kofu Japan, 2Genome Analysis Center, Yamanshi Central Hospital Kofu Japan, 3Department of Medicine, Yamanshi Central Hospital Kofu Japan, 4Department of Medicine, Teikyo University Chiba Medical Center Chiba Japan, 5The University of Tokyo Tokyo Japan

During the follow-up after HCC resection, genetic mutation patterns possibly change from multicentric occurrence (MC) to intrahepatic metastasis (IM), or vice versa, along with the recurrence. In the present study, we focused on patients who underwent repeated resection for recurrence and analyzed the prognosis along with the genetic mutation change.

Methods: We performed genomic analysis using an in-house HCC panel employing NGS for 200 cases of liver resection, involving 350 lesions. Among the 200 cases, we sequentially performed genetic discrimination (MC/IM) between the primary and recurrent nodules in 30 cases that underwent liver resection for recurrence.

Results: Among the 30 cases (primarily 18 solitary, 12 multifocal), there were 17 MC- and 13 IM-recurrence. Significantly better OS was detected in MC-recurrent cases compared to IM ones (p=0.025). Among primarily MC multifocal HCC (n=8) whose OS was significantly better than that in IM ones, 2 cases experienced IM-recurrence, and one had a poor prognosis, while another survived without recurrence. Meanwhile, 1 MC- and 3 IM-recurrence were observed among the 4 primarily IM multifocal HCC, with poor prognosis in all cases, suggesting a dismal impact of primary IM. Among the 13 IM-recurrent cases, the genetic change from IM to MC was seen in one case after a long tumor-free status, while the other cases experienced relatively poor prognosis.

Discussion: Genetic IM in primarily multifocal HCC and recurrent HCC implies a poor prognosis, suggesting the need for early drug introduction. MC-recurrence after a long tumor-free status is a good marker even in IM-recurrent cases.

Results: The median ages were 74 years (IQR 68.8-80.0), with 745 patients (78.9%) being male. Chronic liver diseases were HCV in 318 (33.7%), HBV in 156 (16.5%), HBV plus HCV in 1 (0.1%), alcohol in 209 (22.1%), and other causes in 260 (27.5%) patients. mALBI grade was 1, 2a, and 2b in 335 (35.5%), 244 (25.8%), and 350 (37.1%), and 15 (1.6%) patients, respectively. BCLC stage distribution was very early, early, intermediate, advanced, and terminal in 19 (2.0%), 54 (5.7%), 370 (39.2%), 485 (51.4%), and 16 (1.6%) patients, respectively. Conversion therapy was conducted in 40 (4.2%) patients, involving resection (n=7), ablation therapy (n=24), TACE (n=14), and radiation therapy (n=1), with treatment modalities overlapping. The objective response rates assessed by mRECIST were 75.0% and 34.0% in the conversion group and non-conversion group, with a statistical significance (p<0.001) The median overall survival (OS) was not reached in the conversion group, with a 1-year survival rate of 97.4%, and was 20.4 months in the non-conversion group, showing statistical significance (p<0.001). BCLC stage B was identified as a predictive factor associated with conversion therapy.

Conclusions: Patients with BCLC intermediate-stage HCC were likely to received conversion therapy and patients receiving conversion therapy achieved favorable clinical outcomes.

Conversion therapy for unresectable HCC in 944 patients following atezolizumab and bevacizumab

Takeshi Hatanaka1, 2, Satoru Kakizaki2, Atsushi Hiraoka2, Kazuya Kariyama2, Toshifumi Tada2, Hidenori Toyoda2, Ei Itobayashi2, Joji Tani2, Kunihiko Tsuji2, Ohama Hideko2, Kazunari Tanaka2, Masaki Kaibori2, Hidekatsu Kuromi2, Masatoshi Kudo2, Takashi Kumada2
1Department of Gastroenterology, Gunna Saiseikai Maebashi Hospital Maebashi Japan, 2RELPEC/HCC 48 group Ogaki Japan

Background: This study aimed to investigate the clinical outcome of conversion therapy following atezolizumab and bevacizumab (Atez/Bev).

Methods: A total of 944 hepatocellular carcinoma (HCC) patients who underwent liver resection for recurrence were included in this study.

Results: Patients with BCLC intermediate-stage HCC were likely to received conversion therapy and patients receiving conversion therapy achieved favorable clinical outcomes.
Prescription patterns of sorafenib and the following salvage treatment for advanced HCC in Taiwan

Chien-Huai Chiang1, Ching-Hu Chung2, Rick Chen3, Yun-Chun Wu4, Yu Yun Shao5

1National Taiwan University Cancer Center Taipei City, Taiwan, 2Mackay Medical College New Taipei City Taiwan, 3Roche Taipei City Taiwan, 4National Taiwan University Hospital Taipei City Taiwan

Background: Sorafenib (SOR) was covered by National Health Insurance (NHI) since 2012. Two expansions in reimbursement and the introduction of salvage therapy post-SOR failure in 2019 Jun 1 have altered the treatment landscape. This study explores the prescription patterns in Taiwanese HCC patients.

Methods: Using the NHI database, we analyzed patients receiving their first prescription between Aug 1, 2012, and Dec 31, 2021. Patients were divided into 3 cohorts based on prescription dates: 1st cohort (before Oct 31, 2016) with extrahepatic spread or main/first branch portal vein (PV) thrombosis; 2nd cohort (Nov 1, 2016 to May 31, 2019) including BCLC B post 3 locoregional therapies (LRTs) within 6 months; 3rd cohort (after Jun 1, 2019) encompassing patients with PVTT, first/third/third branch of PV and BCLC B post 3 LRTs within 12 months.

Results: 19,806 patients were included. LRTs were performed during the SOR in 5133 (25.9%) patients, TACE (n = 4343, 21.9%) as the most common. Fewer patients initially received standard SOR dose (1st vs. 2nd vs. 3rd cohort: 54.9% vs. 46.5% vs. 36.3%). The median OS was 6.1, 7.9, and 10.4 months for the 1st, 2nd, and 3rd cohort, respectively (p < 0.001). Salvage with SOR failure and Child A was reimbursed, 2264 patients discontinued SOR. Among them, 1323 (58.4%) received salvage therapy, including regorafenib, ramucirumab, and nivolumab, the median treatment duration of which was 3.3, 2.6, and 3.9 months, respectively.

Conclusions: Physicians often initiate lower doses of multikinase inhibitors. Less than 60% of patients received salvage therapy. There remains a significant unmet need for novel therapies.

Increased PD-1+TIGIT+ TIM-3+ in peripheral circulating cells predict poor prognosis of HCC patients

Xiaoli Liu1, Yaxian Kong2, Huiwen Yan1, Libua Yu1, Yixin Hou1, Xianbo Wang1, Yuyong Jiang1, Zhiyun Yang1

1Center for Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

Background: Previous studies had shown that co-inhibitory molecules were associated with tumor prognosis, but whether their co-expression is related with tumor outcome remains unclear. This study was to explore the relationship between the co-expression of co-inhibitory molecules and the progression and death of patients with hepatocellular carcinoma(HCC).

Methods: We prospectively enrolled 299 patients with HCC of whom 17 HCC patients with hepatectomy. We detected the expression levels of coinhibitory molecules on the surface of peripheral blood mononuclear cells(PBMC) and tumor-infiltrating T cells(TILs). Then clinical indicators and co-inhibitory molecular expression were incorporated into Cox regression to analyze the impact on progression and death of HCC.

Results: The proportion of CD8+PD-1+TIGIT+TIM-3+T cells in TILs was higher than that in PBMC, and the level was positively correlated with peripheral blood level(r=0.71, P=0.003). COX multivariate regression analysis showed that, PVTTHR=1.77, neutrophil-to-lymphocyte ratio(HR=1.14), γ-GGT(HR=1.02), tumor size≥5cm(HR=1.76), proportion of CD8+PD-1+TIGIT+TIM-3+T cells(HR=1.12) were independent risk factors for survival of HCC patients, albumin(HR=0.96) was an independent protective factor. Compared with low level of CD8+PD-1+TIGIT+TIM-3+T cells, the hazard ratios of 3-year overall survival of high-level group were 1.88 in the KM analysis.

Conclusion: High levels of CD8+PD-1+TIGIT+TIM-3+T cells was associated with poor outcome of HCC, which can be contribute to assess the prognosis of HCC and provide theoretical basis for multi-target immune checkpoint synergistic therapy in the future.
The efficacy and safety of durvalumab + tremelimumab for unresectable hepatocellular carcinoma

Shinsuke Uchikawa1, Tomokazu Kawaoka1, Kenji Yamaoka1, Yasutoshi Fujii1, Hatsue Fujino1, Atsushi Ono1, Takashi Nakahara1, Eiuke Murakami1, Daiki Miki1, Masataka Tsuge1, Shiro Oka1
1Hiroshima university hospital, department of gastroenterology Hiroshima Japan

**Background:** In recent years, durvalumab + tremelimumab combination therapy (Dur+Tre) was approved for unresectable hepatocellular carcinoma (uHCC).

**Method:** Forty-two cases of Child-Pugh A who received Dur+Tre for uHCC from April to October 2023 were enrolled. The background was as follows. Male/Female: 38/4, median age 73 years, HBV/HCV/NBNC: 11/8/23, first line 16 cases, extrahepatic metastasis positive 17 cases, macroscopic vascular invasion positive 8 cases, BCLC 0/A/B/C: 1/3/17/21, Child-Pugh score 5/6: 30/12, mALBI grade 1/2a/2b: 24/8/10, AFP 30.3 ng/ml and PIVKA-2 528.5 mAU/ml (median values). The administration method was the STRIDE regimen.

**Results:** The efficacy and safety were investigated.

**Conclusion:** Dur+Tre is effective as a first-line systemic therapy for uHCC. On the other hand, severe immune-mediated adverse event (imAE) occurred in some cases, we need to pay attention to the occurrence of imAE.

---

**Abstract Submission No. 101841 O-0609**

Liver regeneration following partial hepatectomy in hepatocellular carcinoma: not only size matters

Haiyi Long1, Jiayao Huang1, Qingyu Wu1, Manxia Lin1
1Division of Interventional Ultrasound, Department of Medical Ultrasound, The First Affiliated Hospital, Sun Yat-sen University Guangzhou China

**Background:** To investigate factors associated with liver regeneration capacity in patients with hepatocellular carcinoma (HCC) after liver resection (LR).

**Methods:** A total of 123 patients with HCC who underwent liver stiffness (LS) by shear wave elastography (SWE) prior to LR were retrospectively included. The future liver remnant (FLR) prior to LR, and postoperative liver remnant (PLR) after LR were measured. The standardized future liver remnant (sFLR), parenchymal hepatic resection rate (PHRR), and regeneration index (RI) were calculated. Patients were classified into two subgroups based on the extent of LR: low PHRR (<50%) and high PHRR (>50%). Spearman correlation analysis was used to investigate factors associated with RI, and receiver operating characteristic (ROC) curve was employed to evaluate the diagnostic performance of these relative factors to predict a significant liver regeneration (RI>1).

**Results:** Strong correlation between RI and volume-related parameters, including FLR (r=-0.754, p<0.001) and sFLR (r=-0.811, p<0.001), were identified. Optimal cutoff values of 535ml for FLR and 0.452 for sFLR were used to predict a significant liver regeneration with an area under the curve (AUC) value of 0.967 and 0.980, respectively (all p<0.001). In the high PHRR subgroup, LS was the only non-volume parameter correlating with RI (r=-0.526, p=0.012). A cutoff value of 6.7kPa was used to predict a significant liver regeneration with an AUC value of 0.767 (p=0.035).

**Conclusions:** The remnant volume was the key to liver regeneration after LR for HCC. LS may serve as a potential predictor for liver regeneration in those with extensive loss of parenchymal.

---

**Abstract Submission No. 101924 O-0611**

Decoding HCC Survival: A Comparative Analysis of Early vs. Late-Onset Cases

Chyntia Olivia Maurine Jasirwan1, Ibrahim Achmad2, Wulyo Rajabto1, Murdani Abdulullah1
1Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 2Department of Internal Medicine, Cipto Mangunkusumo Hospital Jakarta Indonesia, 3Hematology and Medical Oncology Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 4Gastroenterology Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia

**Background:** Hepatocellular Carcinoma (HCC) often has a grim prognosis, with most cases diagnosed at advanced stages. Intriguingly, younger individuals tend to show higher prevalence and poorer outcomes.

**Objectives:** This study aims to compare survival rates between early and late-onset HCC patients at RSCM and identify factors influencing their survival.

**Methods:** A retrospective cohort study was conducted on HCC patients from Cipto Mangunkusumo Hospital’s registry (2015-2022). Kaplan-Meier curves depicted survival, while Cox Proportional Hazard Regression with a backward method identified independent prognostic factors.

**Results:** Among 896 subjects, early onset patients had a median survival of 2 months (95% CI: 1.071-2.929), significantly lower than the 4 months (95% CI: 3.441-4.559) in late-onset patients (p=0.021). Early onset showed a higher event rate at 24 months (92.9%) compared to late onset (87.7%) (p=0.032). Multivariate analysis revealed hypertension (HR: 3.728) and lack of hepatitis treatment (HR: 2.48; p=0.053) as key factors in early onset survival. In late-onset cases, AFP levels ≥200 ng/mL (HR: 1.28), AJCC stage (highest risk at stage 4, HR: 4.52), supportive, and palliative therapies (HR: 5.23 and 1.66, respectively) were significant.

**Conclusion:** Early onset HCC patients have a median survival of 2 months, half of that in late-onset patients. Distinct prognostic factors were identified in each group, highlighting the need for tailored approaches in managing early and late-onset HCC.

**Keywords:** Survival, Early Onset, Late Onset, Hepatocellular Carcinoma
Abstract Submission No. 101977

O-0612

Utility of Lens culinaris agglutinin-reactive AFP (AFP-L3) in atezolizumab plus bevacizumab therapy

Yutaka Yasui1, Kaoru Tsuchiya1, Yuadai Yamazaki2, Michiko Yamada1, Taisei Keitoku1, Risa Okada1, Mayu Higuchi2, Kenta Takaura1, Shohei Tanaka1, Chiaki Maeyashiki1, Nobuharu Tamaki1, Yuka Takahashi1, Hiroaki Nakanishi1, Masayuki Kuroskai1, Namiki Izumi1

1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Tokyo Japan

Background: While combined immunotherapy has become the first-line treatment for unresectable hepatocellular carcinoma, there is an unmet need to identify biomarkers to determine efficacy during treatment. Lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3) has been reported to be useful in the diagnosis of hepatocellular carcinoma and in predicting prognosis after transplantation or resection. This study aimed to clarify whether baseline AFP-L3 and its dynamics during the treatment are useful in predicting response to systemic therapy.

Methods: We enrolled 151 patients with unresectable hepatocellular carcinoma who received atezolizumab plus bevacizumab treatment. The radiological response was assessed by RECIST ver 1.1 at 6-8 weeks and every 8-12 weeks after that. Progression-free survival (PFS) was analyzed by the Kaplan-Meier method.

Results: Patients had a median age of 74 years, 116 were male, 51 had HCV as background liver disease, and 98 received treatment as the first-line therapy. The median PFS was 6.6 months. At baseline, AFP-L3 was not elevated (<0.5%) in 26(17%) patients and median value of AFP-L3 was 14.5%. Patients with AFP-L3<14.5% (n=70) showed significantly longer PFS (8.7 vs 4.6 months, p=0.009). Among 106 patients with AFP-L3<0.5% at baseline, AFP-L3 decreased below 80% within 6 weeks compared to the baseline in 19 (18%) patients (AFP-L3 response). Patients who achieved AFP-L3 response showed significantly better PFS than those without (14.4 vs 5.1 months, p=0.04). A similar tendency was seen in patients with baseline AFP<400ng/ml (p=0.07); however, in patients whose baseline AFP ≥400ng/ml, the difference was insignificant since only two patients achieved AFP-L3 response.

Conclusion: AFP-L3 was useful in predicting PFS of patients who received atezolizumab plus bevacizumab treatment. AFP-L3 response was a useful on-treatment biomarker for patients whose baseline AFP-L3 is elevated at baseline.

Abstract Submission No. 101981

O-0613

Trends and forecast mortality of liver cancer to 2040 in the United States: A population-based study

Sikai Qiu1, Jiangying Cai2, Xinyuan He4, Zhanpeng Yang3, Jian Zuo1, Yee Hui Yeo5, Fanpu Ji6, Mindie H Nguyen7,8

1The Second Affiliated Hospital of Xi’an Jiaotong University Xi’an China, 2Lanzhou University Second Hospital Lanzhou China, 3Xi’an Jiaotong University Xi’an China, 4Cedars-Sinai Medical Center Los Angeles United States, 5National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi’an Jiaotong University Xi’an China, 6Xi’an Jiaotong University, Ministry of Education of China Xi’an China, 7Stanford University Medical Center Palo Alto United States, 8Stanford University Palo Alto United States

Objective: The burden of liver cancer varies across the world. Herein, we present updated estimates of the burden of liver cancer mortality in the United States (US) and provide predictions of age-standardized mortality rates (ASMR) to 2040.

Methods: Using CDC WONDER of the NVSS, we estimated the ASMR of liver cancer during 2006-2040. We used joinpoint regression to assess the trend of mortality. Prophet/ARIMA prediction modeling analysis based on trends from 2006-2022, we predicted mortality for 2023-2040 and stratified by etiology and sex.

Results: Among the 333,784 liver cancer-related deaths during 2006-2022, we found increasing annual percentage change(APC) of 2.8% and 0.6% for 2006-2013 and 2013-2016, followed by stable mortality trends, and observed ASMR (per100,000 persons) 8.31 in 2022 overall. By sex, the APC for 2019-2022 for female is 2.7%(95%CI1.7-4.3) and the ASMR will increase to 4.86 in 2040 compared with 4.46 in 2022. However, the APC for 2015-2022 for male is -0.8%(95%CI-1.4-0.4) and the ASMR will decrease to 10.86 in 2040 compared with 12.75 in 2022(Fig.1A). By etiology, HCV-related mortality reached a peak in 2015 and decreased rapidly after that. The ASMR rise was most pronounced in alcohol-associated liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD), especially ALD-related deaths will be to the leading cause of liver cancer deaths in 2026(Fig.1B/C). The proportion of ALD and NAFLD-related liver cancer deaths sharply rise during 2006-2022(Fig.1D).

Conclusions: ASMR for ALD and NAFLD increased at alarming rates during 2006-2022 in US with the fastest rise in ALD-related liver cancer.

Abstract Submission No. 102061

O-0614

Impact of Methylated SEPT9 Liquid Biopsy Test as a Prognostic Biomarker in Hepatocellular Carcinoma

Issei Saeki1, Takahiro Yamasaki2, Maho Egusa4, Norikazu Tanabe1, Yuki Kunimune2, Yuatuka Suehiro1, Taro Takami1

1Department of Gastroenterology of Hepatology, Yamaguchi University Graduate School of Medicine Yamaguchi Japan, 2Department of Laboratory Medicine and Oncology, Yamaguchi University Graduate School of Medicine Yamaguchi Japan

Objective: Several biomarkers are used for cancer diagnosis, treatment monitoring, and prognostic prediction. In hepatocellular carcinoma (HCC), the classical tumor marker, AFP is used as a diagnostic and monitoring marker. We have reported liquid biopsy based on a methylated SEPT9 (m-SEPT9) as a new candidate of HCC diagnostic and monitoring marker (Hepatol Commun. 2020). In this study, we investigated the significance of m-SEPT9 as a prognostic biomarker.

Methods: We enrolled 787 HCC patients obtained from multi-centers during 2018-22. We measured m-SEPT9 using “combined restriction digital PCR assay” which was developed by us and examined its potential as a prognostic biomarker.

Results: The median age was 73 years with 563 males (71.5%). BCLC stages 0, A, B, C, and D were 107, 250, 138, 268, and 21 patients, respectively and Child-Pugh A, B, and C were 669, 101, and 14 patients, respectively. The multivariate analysis showed that AFP, DCP, and m-SEPT9 were independent prognostic predictors in addition to Child-Pugh and BCLC stage in overall HCC patients. Furthermore, Child-Pugh, m-SEPT9, and AFP were significant independent prognostic predictors in the BCLC C-D group, whereas Child-Pugh and AFP were extracted in the BCLC 0-B group. AFP and m-SEPT9 were independent prognostic markers in advanced stage. The patients with advanced HCC were stratified according to the combination of m-SEPT9 and AFP.
Conclusion: The m-SEPT9 liquid biopsy test has a great potential for a prognostic biomarker of HCC.

ICIs and anti-VEGF antibody/TKIs with or without TACE as First-line Treatment for Advanced HCC

Zhicheng Jin1, Jian-Jian Chen1, Bin-Yan Zhong1, Hai-Dong Zhu1, Zheng-Gang Ren2, Gao-Jun Teng1, Hai-Tao Zhao1

1Center of Interventional Radiology and Vascular surgery, Department of Radiology, Zhongda hospital, Southeast university Nanjing China, 2Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University Suzhou China, 3Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University Shanghai China, 4Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing Beijjing China

Background: The role of transarterial chemoembolization (TACE) in the treatment for advanced hepatocellular carcinoma (HCC) is unconfirmed. This study aimed to assess the efficacy and safety of immune checkpoint inhibitors (ICIs) plus anti-vascular endothelial growth factor (anti-VEGF) antibody/tyrosine kinase inhibitors (TKIs) with or without TACE as first-line treatment for advanced HCC.

Methods: This nationwide, multicenter, cohort study included advanced HCC patients receiving either TACE with ICIs plus anti-VEGF antibody/TKIs (TACE-ICI-VEGF) or only ICIs plus anti-VEGF antibody/TKIs (ICI-VEGF) from January 2018 to December 2022. The study design followed the target trial emulation framework with stabilized inverse probability of treatment weighting (sIPTW) to minimize biases. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), objective response rate (ORR), and safety. The study is registered with ClinicalTrials.gov, NCT03132821.

Results: Among 1244 patients included in the analysis, 802 (64.5%) patients received TACE-ICI-VEGF treatment and 442 (35.5%) patients received ICI-VEGF treatment. The median follow-up time was 21.1 months and 20.6 months, respectively. Post-application of sIPTW, baseline characteristics were well-balanced between the two groups. TACE-ICI-VEGF group exhibited a significantly improved median OS (22.6 months [95%CI: 21.2-23.9] vs 15.9 months [14.9-17.8]; adjusted hazard ratio [aHR] 0.63 [95%CI: 0.53-0.75]; P < 0.001). Grade ≥3 adverse events occurred in 178 patients (29.7%, P < 0.001). Safety and efficacy of microwave ablation for Child B early stage hepatocellular carcinoma

Nobuhito Taniki1, Ryosuke Kasuga1, Yukiie Nakada1, Mayuko Kondo1, Takaya Tabuchi1, Fumie Noguchi1, Po-Sung Chu1, Shingo Usui1, Nobuhiro Nakamoto1, Takanori Kanai1

1Keio University Tokyo Japan

Background: Since most of the subjects of clinical trials which verify feasibility of Microwave ablation (MWA) are hepatocellular carcinoma (HCC) patients who have preserved liver function, the influence regarding the impact of impaired hepatic reserve on treatment outcomes has not been well established.

Methods: This retrospective cohort study enrolled 624 microwave ablation treatments using Enpiate ablation system (Covidien) during 2017 to 2022. Of those, 582 treatments were operated under the tumor settings of HCC with 3 or less lesions of 30 mm in diameter or single lesions of 50 mm. We compared patient background factors and treatment outcomes of 474 patients with Child A and 108 patients with Child B.

Results: Of the entire cohort, there were significant increase in the number of tumors and the maximum tumor diameter in Child B cases. However, 582 subjects finally enrolled in the analysis under the limited tumor settings, these factors were comparable in both groups. Not only factors related to hepatic reserve, platelet count and liver stiffness showed significant difference in each group. All of the outcomes showed worse result in Child B cases included severe complication rate (Child A 5/484 1.1% vs Child B 4/108 3.7%, p=0.0441), recurrence-free survival, and incidence of bile duct dilatation. Furthermore, ascites was extracted as a risk factor contributing to bile duct dilatation.

Conclusion: Child B patients are at increased potential risk which may contribute to poor treatment outcomes. Aside from considering liver transplantation, taking proactive preoperative measures is needed for effective and safe MWA procedure.
noninferior to sorafenib (Abou-Alfa et al. NEJM Evid 2022). Here, we report an updated 4-year OS analysis of HIMALAYA.

Methods: Participants with uHCC and no previous systemic treatment were randomized to STRIDE, durvalumab or sorafenib. Data cut-off was 23 January 2023. OS and serious treatment-related adverse events (TRAEs) were assessed. Baseline demographics and disease characteristics were assessed in long-term survivors (LTS; participants surviving ≥36 months beyond randomization).

Results: Follow-up duration was approximately 4 years across treatment arms (Table). The OS HR versus sorafenib (0.78; 95% CI, 0.67-0.92) and estimated 36-month OS rate (30.7%) for STRIDE were consistent with the primary analysis. The 48-month OS rate remained higher for STRIDE (25.2%) versus sorafenib (15.1%). No new serious TRAEs occurred after the primary analysis for STRIDE (17.5%). Durvalumab OS noninferiority to sorafenib and safety was consistent with the primary analysis. Baseline demographics, clinical characteristics and subsequent therapies, including tremelimumab rechallenge, for LTS in the STRIDE arm were generally consistent with the full analysis set, suggesting that LTS were not from any particular subgroup.

Conclusions: These data reinforce the sustained, long-term OS benefit of STRIDE versus sorafenib, demonstrating unprecedented 3- and 4-year OS rates and longest follow-up to date in phase 3 uHCC studies. STRIDE maintained a tolerable safety profile, with no new serious safety events.

Clinical Trial identification: NCT03298451

Abstract Submission No. 200280

O-0619

Temporal patterns of immune-mediated adverse events in HIMALAYA study in unresectable HCC

George Lau1, Bruno Sangro2, Oxana V. Crystler3, Wattana Sukdeeprasarnjaroen4, Oleg Lipatov5, Manabu Morimoto6, Isabelle Archambeaud7, Valentina Burgio8, Mallory Makowsky9, Alejandra Negro9, Ghassan K. Abou-Alfa10

1Humanity and Health Clinical Trial Center, Humanity and Health Medical Group Hong Kong Hong Kong, 2Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHDFundación Jiménez Díaz, Madrid, Spain, 3Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Osaka Japan, 4Helen Diller Family Comprehensive Cancer Center, University of California San Francisco USA, 5Department of Internal Medicine, School of Medicine, Kyungpook National University Daegu Republic of Korea, 6Department of Oncology Area, Clínica Universidad de Navarra and CIBERERD Pamplona Spain, 7Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine Osaka Japan, 8Hepato-Gastro-Entérologie et Assistance Nutritionnelle, Institut des Maladies de l’Appareil Digestif (IMAD), Nantes Université Nantes France, 9Department of Medical Oncology, San Raffaele Scientific Institute Milan Italy, 10AstraZeneca Gaithersburg USA

Background: In the Phase 3 HIMALAYA study (NCT03298451) in uHCC, STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival versus sorafenib with manageable safety (Abou-Alfa et al. NEJM Evid 2022). In this exploratory analysis, we assessed temporal patterns of imAEs with STRIDE.

Methods: Safety was assessed in participants who received ≥2 dose of STRIDE or sorafenib. imAEs were AEs of special interest associated with drug exposure and consistent with an immune-mediated mechanism of action with no found alternate etiology.

Results: Safety was assessed in 388 (STRIDE) and 374 (sorafenib) participants. Median (range) duration of exposure was 5.5 (0.4-4.9) months for STRIDE (durvalumab exposure) and 4.1 (0.1-38.6) months for sorafenib. Any grade treatment-related AEs (TRAEs) and Grade 3/4 TRAEs were less frequent for STRIDE (75.8% and 25.8%, respectively) versus sorafenib (84.8% and 36.9%, respectively). Any grade imAEs and max Grade 3/4 imAEs occurred in 35.8% and 12.6% of participants, respectively. For STRIDE, imAEs with STRIDE occurred at time points assessed and did not most likely to occur within the first three months (Table). For STRIDE, any grade imAEs of gastrointestinal disorders and skin and subcutaneous tissue disorders were most common within the first month after treatment; any grade imAEs of endocrine disorders were most common between >1 and ≤2 months.

Conclusions: AEs with STRIDE were manageable and generally low grade. Although imAEs with STRIDE could occur at any time, most were observed within the first three months after treatment. Findings continue to support STRIDE for treatment of uHCC.
Abstract Submission No. 100070
O-0620
Impact of NAFLD on the efficacy of immunotherapy for CHB-related Hepatocellular carcinoma

Jiaxin Han1, Wentao Kuai1, Ningning Zhang1, Wei Lu2, Liang Xu3
1Clinical School of the Second People’s Hospital, Tianjin Medical University Tianjin China, 2Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, 3Tianjin Institute of Hepatology, Tianjin Second People’s Hospital Tianjin China

Objective: To investigate the impact of non-alcoholic fatty liver disease (NAFLD) on immune checkpoint inhibitors (ICIs) in patients with chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC).

Method: A total of 94 patients with chronic hepatitis B virus (HBV) infection-related HCC who received immunotherapy in Department of Hepatobiliary Oncology, Tianjin Second People’s Hospital and Tianjin Medical University Cancer Institute and Hospital from April 2021 to October 2022 were included in this study. According to the presence or absence of NAFLD, the patients were divided into concurrent NAFLD and CHB (NAFLD-CHB) group and the CHB group. SPSS 26.0 statistical software was used to analyze the demographic, laboratory, and tumor-related baseline data, and evaluate the efficacy and immune status of the two group patients.

Result: There was no significant difference in CR, SD, PR, ORR, and DCR between the two groups (all P > 0.05). Median progression-free survival (mPFS) in NAFLD-CHB group was significantly lower than that in CHB group (NAFLD-CHB group 11.6 months; P < 0.05). CD19+B cells (CHB group 9.79% vs NAFLD-CHB group 12.53%; P < 0.05) and CD3+CD4+CD8+T cells (CHB group 26.17% vs NAFLD-CHB group 16.07%; P < 0.05) in blood samples of NAFLD-CHB group were significantly lower than those of CHB group (P < 0.05). The percentages of CD4+PD1+T cells (CHB group 8.89% vs NAFLD-CHB group 17.56%; P < 0.05) and CD8+PD1+T cells (CHB group 7.42% vs NAFLD-CHB group 10.50%; P < 0.05) in the blood samples of NAFLD-CHB group were significantly higher than those of CHB-related HCC patients.

Conclusion: Concurrent NAFLD seems induce poorer efficacy and shorter progression-free survival when compared with CHB-related HCC patients, and this also might be attributed to the decrease of CD19+B cells, CD3+CD4+CD8+T cells and the increase of percentages of CD4+PD1+T cells and CD8+PD1+T cells.

Abstract Submission No. 100091
O-0621
An Online Risk Stratification Model for Predicting Survival Duration of Older Patients with HCC

Xiaoxin Wu1, Juntao Tan2, Jingjing Chen3
1The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China, 2Affiliated Banan Hospital of Chongqing Medical University Chongqing China, 3Zhejiang University City College Hangzhou China

Background: The objective of this study is to identify the prognostic factors of older patients with HCC and to construct a new prognostic model for predicting their overall survival.

Methods: 2,721 HCC patients aged ≥ 65 were extracted from SEER. 101 patients were from the Hospital.

Results: We found that the nomogram provided a good assessment of OS at 1, 3, and 5 years in older patients with HCC (1-year OS: (training set: AUC = 0.823 (95%CI: 0.803-0.845); internal validation set: AUC = 0.847 (95%CI: 0.818-0.876); external validation set: AUC = 0.732 (95%CI: 0.521-0.943)); 3-year OS: (training set: AUC = 0.813 (95%CI: 0.790-0.837); internal validation set: AUC = 0.844 (95%CI: 0.810-0.876); external validation set: AUC = 0.780 (95%CI: 0.674-0.887)); 5-year OS: (training set: AUC = 0.839 (95%CI: 0.806-0.872); internal validation set: AUC = 0.800 (95%CI: 0.751-0.849); external validation set: AUC = 0.821 (95%CI: 0.727-0.914)). The calibration curves showed that the nomogram was with strong calibration. The DCA indicated that the nomogram can be used as an effective tool in clinical practice. The risk stratification of all subgroups was statistically significant (P < 0.05). In the stratification analysis of surgery, Larger Resection (LR) achieved a better survival curve than Local Destruction (LD), but a worse one than Segmental Resection (SR) and Liver Transplantation (LT) (P < 0.0001). With the consideration of the friendship to clinicians, we further developed an online interface (OHCPredictor) for such a predictive function (https://juntaotan.shinyapps.io/dynnomapp_hcc/).

Conclusion: The online web interface of the predictive model provide easily-obtained access for clinicians.
**DISCUSSION**: The Weibull distribution closely approximated observed values. The time post-DAA treatment required for rates to drop to 1% aligns with clinical experiences.

**Conclusion**: Post-HCV treatment, the theoretical HCC onset and recurrence risk persist long-term.

Abstract Submission No. 100357
O-0623

**New FP therapy for long-term prognosis in patients with advanced hepatocellular carcinoma**

Hiroaki Nagamatsu1, Takeshi Watanabe1, Hiroto Ota1, Maki Toba1, Hitoshi Maruyama1

1Juntendo University Hospital Bunkyo-ku, Tokyo Japan

**Introduction**: In Japan, hepatic arterial infusion chemotherapy (HAIC) is recommended as an optional treatment in the 2021 guidelines. In 2021, New FP therapy (NFP) was reported to have a longer prognostic effect than sorafenib in advanced hepatocellular carcinoma with intrahepatic lesions.

**Objectives**: We will show the performance of NFP in this study at our hospital.

**Subjects**: We perform 2 courses using the temporary indwelling catheter system via the left brachial artery, and then we remove the temporary reservoir during hospitalization. We repeat this treatment 3 to 5 times with an interval of about 2 months. We aim for cancer-free by performing conversion therapy when PR or CR is obtained by NFP.

**Results**: There is almost no deterioration liver function. A total of 200 patients (69%) responded to NFP therapy, of which 80 patients achieved cancer-free outcome. 32 patients became cancer-free outcome with only NFP. We were able to add hepatic resection to 33 patients. Median OS (MST) after HAIC in all patients was 18 months. MST in patients who responded was 29 months, and in patients who achieved cancer-free outcome, it was extended to 67 months. The 5-year survival rate of all patients was 22%, and 67% for patients who got cancer-free outcome.

**Conclusions**: NFP has a high response rate and contributes to improve or maintain liver function by controlling PVTT. In response cases, long-term survival can be obtained by adding conversion therapy.

Abstract Submission No. 100165
O-0624

**Monocyte to High Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of MAFLD-related HCC**

Tongguo Miao1, Xianze Lou1, Shiming Dong1, Xiaoxiao Zhang1, Weimei Guan1, Ying Zhang1, Lu Li1, Xiwei Yuan1, Dong Ma2, Yueming Nan1

1Department of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei Medical Science and Technology Cooperation Base Shijiazhuang Ch, 2Department of Biochemistry and Molecular Biology, Key Laboratory of Neural and Vascular Biology, Ministry of Education, Hebei Medical University Shijiazhuang China

**Background**: The incidence of non-B and non-C hepatocellular carcinoma (NBNC-HCC) is increasing globally. Metabolically associated fatty liver disease (MAFLD) has been a contributing factor to this rising trend in NBNC-HCC incidence. The monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) is a new prognostic marker that connects systemic inflammation with disorders of lipid metabolism. Therefore, MHR may be a potential prognostic predictor of patients with MAFLD-related HCC (MAFLD-HCC).

**Patients and methods**: This retrospective study of patients with MAFLD-HCC included training (n=112) and internal validation (n=37) cohorts. Univariate and multivariate Cox proportional hazard regression analysis was conducted to identify independent risk factors of survival. A visual nomogram was constructed to assess the performance of the two groups. Furthermore, receiver operating characteristic (ROC) curves and calibration curves were used to verify the prognostic discriminative ability of this nomogram, even in the MHR, ALBI grade, and MHR-ALBI model.

**Results**: Univariate and multivariate analyses revealed that extrahepatic metastases, Vascular invasion, Barcelona staging B, C, D, elevated ALBI Grade 3, C-reactive protein (CRP), and MHR were independent risk factors for the prognosis of MAFLD-HCC. Moreover, calibration plots showed good discrimination and consistency when the significant factors were entered into the nomogram. Meanwhile, the MHR strongly correlated with the prognosis of cancer under a background of MAFLD-HCC, with a sensitivity of 88.89% and a specificity of 79.61%.

**Conclusion**: The novel nomogram demonstrated good value in predicting the overall survival of patients with MAFLD-HCC. The MHR may be a potential predictor of prognosis.

Abstract Submission No. 100168
O-0625

**Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with PVTT**

JEAYEON PARK1, YUN BIN LEE1, HYUNJAE SHIN1, YOONGSU PARK1, MOON HAENG HUR2, MIN KYUNG PARK1, DAE-WON LEE2, EUN JU CHO1, KYUNG-HUN LEE2, JEONG-HOON LEE1, SU JONG YU1, TAE-YONG KIM1, YOON JUN KIM1, TAE-YOU KIM2, JUNG-HWAN YOON1

1Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine Seoul South Korea, 2Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine Seoul South Korea

**Background/Aim**: Atezolizumab plus bevacizumab and lenvatinib are currently available as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC); however, comparative efficacy studies are still scarce. This study aimed to investigate the effectiveness of these treatments in HCC patients with portal vein tumor thrombosis (PVTT).

**Methods**: We retrospectively included patients who received either atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy for HCC with PVTT. Primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS) and disease control rate (DCR) determined by Response Evaluation Criteria in Solid Tumors, version 1.1.

**Results**: A total of 52 patients were included: 30 received atezolizumab plus bevacizumab and 22 received lenvatinib. The median follow-up duration was 6.4 months (interquartile range, 3.9-9.8). The median OS was 10.8 months (95% confidence interval [CI], 5.7-9.8) with lenvatinib (P=0.26 by log-rank test). There was no statistically significant difference in OS (adjusted hazard ratio [aHR], 0.71; 95% CI, 0.34-1.49; P=0.37). The median PFS was similar (P=0.63 by log-rank test), with 4.1 months (95% CI, 3.3-7.7) for
atezolizumab plus bevacizumab and 4.3 months (95% CI, 2.6-5.8) for lenvatinib (aHR, 0.93; 95% CI, 0.51-1.69; P=0.80), HRs were similar after inverse probability treatment weighting. The DCRs were 23.3% and 18.2% in patients receiving atezolizumab plus bevacizumab and lenvatinib, respectively (P=0.74).

**Conclusion:** The effectiveness of atezolizumab plus bevacizumab and lenvatinib was comparable for the treatment of HCC with PVTT.

---

**Abstract Submission No. 100171**

**O-0626**

**Efficacy and safety of multitherapy for Locally Advanced, Unresectable Hepatocellular Carcinoma**

ShiZhong Yang1, HaiXin Yin1, Bin Shu1, Lin Zhang1, Ying Liu1, Xiaowei Yang1, Guangxin Li1, Xiaojuan Wang1, Gong Li1, Yuwei Zhang1, Jiahong Dong1

1Hepato-pancreato-biliary Center, Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing China

**Background:** Recently, lenvatinib plus PD-1 inhibitors combined with or without hepatic arterial infusion chemotherapy (HAIC) has shown promising survival benefits for advanced hepatocellular carcinoma (HCC). This study aimed to explore the safety and efficacy of multitherapy versus transarterial chemoembolization (TACE) for locally advanced HCC patients.

**Methods:** Clinical data for initially unresectable HCC with PVTT from January 2018 to January 2023 in Tsinghua Changgung Hospital were collected. Conversion therapy, objective response rate (ORR, mRECIST), overall survival (OS), and adverse reactions were analyzed.

**Results:** 51 HCC patients with PVTT were enrolled, 32 (62.7%) receiving combination therapy (Vp2/Vp3/Vp4:20/8, Japanese Typing) and 19 (37.3%) receiving TACE (Vp2/Vp3/Vp4:11/7). In the combined group, the median overall survival (mOS) was not reached, the one-year OS rate was 90.1%, in the TACE group, the mOS was 14 months (95% CI, 10.0-18.0) and the one-year OS rate was 59.7%. OS in the combined group was longer than that in the TACE group (HR 0.23; 95% CI, 0.09-0.59 ; p=0.0021). In combined group, ORR was 50%, 10 (31.2%) patients achieved remission, 3 (30%) patients reached pathological complete response (pCR), and 3 (30%) reached major pathological remission (MPR); in TACE group, ORR was 26.3%, 3 (15.8%) patients achieved remission, and 1 (5.3%) patient reached MPR. There was no significant difference in adverse events in the two groups.

**Conclusions:** For patients with initially unresectable HCC with PVTT, local therapy in combination with systematic treatment have more prolonged survival and a relatively high surgical conversion rate in carefully selected patients with ECOG 0-1.

---

**Abstract Submission No. 100234**

**O-0627**

**Experience of tremelimumab plus durvalumab in patients with unresectable hepatocellular carcinoma**

Michiko Yamada1, Kaoru Tsuchiya1, Yutaka Yasaki1, Yuki Tanaka1, Haruka Miyamoto1, Taisei Keitoku1, Risa Okada1, Mayu Higuchi1, Kenta Takaura1, Shohei Tanaka1, Chiaki Maeyashiki1, Nobuharu Tamaki1, Hiroyuki Nakanishi1, Masayuki Kurosaki1, Namiki Izumi1

1Musashino Red Cross Hospital Musashino Japan

**Background:** Tremelimumab plus durvalumab (Tre+Dur) is the first combination therapy of anti-CTLA-4 and anti-PD-L1 antibodies approved for unresectable hepatocellular carcinoma (u-HCC) in Japan and has been used since March 2023. We investigated the clinical outcomes of the therapy in real-world practice.

**Methods:** Patients who received Tre+Dur at our hospital from April 2023 were analyzed retrospectively. Imaging evaluations were performed using RECIST v1.1 with MDCT every 6-8 weeks after the administration of Tre+Dur. Adverse events were evaluated based on CTCAE v5.0.

**Result:** Between April and September 2023, 22 patients were treated with Tre+Dur. Eight patients were without viral infection. The treatment line was 1st (n=2), 2nd (n=4), 3rd (n=4), 4th or later (n=12). BCLC stage was B (n=5) and C (n=17). The median ALBI score was 2.09 and 13 patients were ALBI grade 2b. The objective response rate was 22.2% and disease control rate was 66.7% within the 3rd -line, and 10.0% and 30.0% in the 4th -line or later patients. Tre+Dur has been continued in 5 patients (23%) and post-treatments were introduced in 10 patients. 7 patients were converted to BSC. Grade 3 immune-mediated adverse events (imAE) were observed within 4 weeks in 8 patients, including colitis (n=5), adrenal insufficiency (n=2), and renal failure (n=1). All 5 patients with colitis required steroid therapy, and 3 patients had a poor response to steroids. These 3 patients recovered after the administration of infliximab.

**Conclusion:** In Tre+Dur therapy, the radiological response of patients who received 1st- to 3rd-line treatment was comparable to that in the phase 3 study.

---

**Abstract Submission No. 100111**

**O-0628**

**Lung metastasis from HCC is more powerful in predicting brain metastasis rather than bone metastasis**

Yasunori Minami1, Tomoko Aoki1, Masahiro Morita1, Hirokazu Chishina1, Masahiro Takita1, Satoru Hagiwara1, Hiroshi Ida1, Kazuomi Ueshima1, Naoshi Nishida1, Masatoshi Kudo1

1Kindai University Faculty of Medicine Osaka-sayama Japan

**Purpose:** Brain metastases from hepatocellular carcinoma (HCC) are relatively rare. However, the incidence of brain metastases seems to have increased in recent years. The aim of this study was to characterize the incidence proportion and survival of newly diagnosed HCC with brain metastases.

**Materials and Methods:** Between January 2009 and December 2020, 942 advanced HCC patients with either metastatic or locally advanced disease untreatable by locoregional therapies were enrolled in clinical trials of first-line systemic chemotherapies in Kindai University Hospital. Total 276 HCC patients who developed extrapleural metastases were retrospectively enrolled in this study, and the clinicopathologic features and survival times of those were analyzed.

**Results:** The median age at diagnosis of extrapleural metastases was 71.0 years. 222 patients were male, and 54 patients were female. 48 patients were infected with hepatitis B virus (HBV), 120 patients were infected with hepatitis C virus (HCV), and 108 patients were not infected with HBV or HCV. Thirteen patients (4.7%) were found to have brain metastasis. The median interval from the diagnosis of HCC to brain metastases was 56.9 months. Extrapleural metastases and chronic kidney disease were brain metastasis risk factors for HCC patients. Lung metastasis was the strongest risk factor for brain metastasis (p<0.001) rather than of bone metastasis (p=0.051).

**Conclusions:** The patients having brain metastases from HCC had poor prognosis.
This study can guide patients with high-risk brain metastases from HCC to undergo diagnostic brain imaging tests, early diagnosis, and treatment to prolong the survival of patients.

Abstract Submission No. 100112

Fatal ARDS after a single dose of ATZ/BV for HCC, autopsy findings: a case report

Yasunori Minami1, Masahiro Morita1, Hirokazu Chishina1, Tomoko Aoki1, Takuya Matsubara1, Masahiro Takita1, Kazuhiko Kuwahara1, Satoru Hagiwara1, Hiroshi Ida1, Kazuomi Ueshima1, Naoshi Nishida1, Akihiko Ito1, Masatoshi Kudo1
1Kindai University Faculty of Medicine Osaka-sayama Japan

The combination of atezolizumab (PD-L1 inhibitor) and bevacizumab (VEGF inhibitor) has been used to unrespective hepatocellular carcinoma (HCC) as first-line therapy. Various adverse events are associated with these therapies, including hepatitis, endocrine disorders, nephritis, dermatitis, and interstitial lung disease. It is believed these adverse events occur in part due to their additive effects on tumor growth and their reprogramming of the immunosuppressive microenvironment into an immunostimulatory microenvironment. These events usually occur after several months and rounds of treatment. Here we present a case of a 63-year-old male with HCC who experienced acute respiratory distress syndrome (ARDS) after only a single dose of combination therapy with atezolizumab and bevacizumab. He presented with high grade of dyspnea and bilateral lung consolidation; twelve days after admission he died. Histologic examination revealed that immune-mediated inflammation destroyed the alveolar capillary barrier (alveolar epithelium and endothelium), increased its permeability and caused intra-alveolar hemorrhage and edema. PD-L1 staining was positive in the lung interstitium, suggesting that antibody-mediated injury played a significant role in the pathogenesis of ARDS. Additional studies ruled out an infectious etiology. Immune checkpoint inhibitors are increasingly more common, and it is important clinicians are aware patients can present with ARDS early in the course of treatment.

Abstract Submission No. 100390

A Predictive Model to assess Recent Recurrence after Hepatectomy for Hepatocellular Carcinoma

Hong Peng1, Siyi Lei1, Tingting Xiong1, Qing Zhang1, Tianzhao Liu1, Li Long1, Yi Zhang1, Gen Chen1, Wei Fan1, Jinhui Xu1, Xinhua Luo1
1Guizhou Provincial People’s Hospital Guiyang, Guizhou China

Background and Aims: We still lack effective prediction models for recent recurrence (time to recurrence [TTR] < 2 years) after hepatectomy for hepatocellular carcinoma (HCC). This study focuses on the factors including sarcopenia which maybe related to recent recurrence of postoperative HCC patients, and attempt to fit an interventional prediction model.

Methods: We retrospectively analyzed 283 hepatitis B-related HCC patients who underwent curative hepatectomy for the first time and measured the preoperative skeletal muscle index (SMI). Cox multivariate analysis was performed to identify the risk factors of postoperative recurrence. A nomogram model was developed to predict the survival of HCC patients, and its predictive performance was validated.

Results: Multivariate analysis showed that sarcopenia, alpha-fetoprotein (AFP) ≥ 40ng/ml, the maximum diameter of tumor > 5cm, and hepatitis B virus [HBV] DNA level ≥ 2000IU/mL were independent risk factors associated with postoperative recurrence of HCC. The SAMD model predicting the recurrence-free survival (RFS) of HCC patients was established based on the above factors. The area under the curve(AUC) of the SAMD model was 0.782 (95% CI: 0.705 - 0.858) in the training cohort (sensitivity 81%, specificity 63%) and 0.773 (95%CI: 0.707 - 0.838) in the validation cohort. Besides, a SAMD score ≥ 110 was better to distinguish the high-risk group of postoperative recurrence of HCC.

Conclusion: Sarcopenia is associated with recent recurrence after hepatectomy for HCC. A nutritional status-based prediction model is first established for postoperative recurrence of HCC, which is superior to other models and contributes to prognosis prediction.

Abstract Submission No. 100359

No Impact of Sarcopenia in Prognosis of Transarterial Chemoembolization for Hepatocellular Carcinoma

Chun-Ming Hong1, Chih-Horang Wu2, Chih-Yu Liu3, Chia-Hua Chen4, Tung-Hung Su5, Shih-Jer Hsu6, Tai-Chung Tseng7, Chen-Hua Liu8, Hung-Chih Yang9, Jia-Horng Kao10, Pei-Jer Chen11, Shang-Chin Huang12, Chun-Jen Liu13
1Division of Hospital Medicine, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Taipei City Taiwan, 2Department of Radiology, National Taiwan University Hospital, Taipei, Taiwan Taipei City Taiwan, 3Department of Nursing, National Taiwan University Hospital, Taipei, Taiwan Taipei City Taiwan, 4Molecular Medicine Research Center, Chang-Gung University, Taoyuan, Taiwan Taoyuan Taiwan, 5Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Taipei City Taiwan, 6Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan Taipei City Taiwan, 7Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan Taipei City Taiwan, 8Department of Internal Medicine, National Taiwan University Hospital Bei-Hu Branch, Taipei, Taiwan Taipei City Taiwan

Background: Chronic liver diseases are associated with poor nutritional status especially when progress to advanced liver disease or liver cirrhosis, and such status is related to development of hepatocellular carcinoma (HCC). Sarcopenia may reflect nutritional status. Transarterial chemoembolization (TACE) is a standard of care for intermediate-stage HCC, although treatment response varies. Whether sarcopenia affect prognosis of TACE remains unclear.

Methods: We recruited 161 adult HCC patients who were TACE-naive from 2015 to 2018. Skeletal muscle index (SMI), a height squared-adjusted cross-section area of the muscles at the third lumbar vertebra on CT or MRI, is an indicator of sarcopenia.

Results: Among these 161 patients, 118 were male and 43 were female. The average age was 67 years old. 32 male patients (27.1%) had sarcopenia and 23 female patients had sarcopenia (53.5%). 156 patients (96.9%) had liver cirrhosis. 41 patients (25.5%) had infiltrative type HCC. The average tumor number was 5.4. After TACE, 15 patients had progressive disease (PD), 38 patients had complete remission (CR), 89 patients had partial response (PR), and 15 patients had stable disease (SD).

In univariate Cox regression analysis, infiltrative type, vascular invasion, necrosis, tumor number, largest tumor size, and post-TACE AFP had impact on OS (overall survival), while in multivariate Cox regression analysis, vascular invasion, ECOG-PS, pre-TACE ALT, and post-
TACE platelet count had impact on OS. Sarcopenia had no impact in both univariate and multivariate Cox regression analysis. 

**Conclusions:** Our data suggest that sarcopenia has no impact on the prognosis of TACE for intermediate-stage HCC.

Abstract Submission No. 100422

**O-0632**

**Time-to-interventional failure in hepatocellular carcinoma**

Yoshinori Takeda1, Hiroshi Imamura1, Akio Saiura1

1Department of Hepatobiliary and Pancreatic Surgery, Juntendo University Tokyo Japan

**Background:** Several curative-intent treatments are often applicable depending on the recurrence pattern in patients with hepatocellular carcinoma (HCC) undergoing hepatectomy; therefore, recurrence-free survival (RFS) is not considered an appropriate surrogate for overall survival (OS) in HCC. We assessed whether the time interval between the initial hepatectomy and the emergence of recurrence not indicated for curative-intent treatments, defined as time-to-interventional failure (TIF), is a better indicator of OS in patients with HCC undergoing hepatectomy.

**Methods:** We retrospectively reviewed patients who underwent initial curative hepatectomy for HCC in our hospital between 2009 and 2018. Recurrence not indicated for curative-intent treatments were defined as multinodular (≥4) intrahepatic recurrence, macroscopic vascular invasion, and/or extrahepatic lesions. We compared the correlation between RFS and TIF with OS and investigated the similarities of prognostic factors among RFS, TIF, and OS.

**Results:** In total, 266 patients were included. With a median follow-up of 56 months, 146 patients experienced any type of recurrence, and 103 patients experienced recurrences not indicated for curative-intent treatments. The median OS, RFS, and TIF were 59, 25, and 45 months, respectively. TIF had a stronger correlation with OS than with RFS ($r^2 = 0.808$ vs. 0.476). Multivariate analysis revealed that macroscopic vascular invasion, poor grade of tumor differentiation, and F3 or 4 were independent prognostic factors to TIF and OS, while macroscopic vascular invasion, maximum tumor size >5 cm, and R1 resection were factors to RFS.

**Conclusions:** TIF was a more appropriate surrogate for OS than for RFS in patients with HCC.

Abstract Submission No. 100435

**O-0633**

**Usefulness of a novel microcatheter insertable port ReMAP/System-i for novel transarterial therapy of HCC**

Hideki Iwamoto1,2, Satoshi Itano3, Takashi Nizeki3, Tomotake Shirono1, Takumi Kagawuchi3

1Kurume University School of Medicine Kurume Japan, 2Iwamoto Internal Medicine Clinic Fukuoka Japan, 3Kurume Central Hospital Kurume Japan

**Purpose:** Transarterial therapy (TAT) for HCC plays an important role in the treatment of HCC. However, the invasiveness and difficulty of the TAT procedures should be improved. Recently, a novel microcatheter insertable port for intermittent TAT “ReMAP/System-i” was developed in Japan. In the study, we assessed the feasibility and safety of ReMAP/System-i.

**Methods:** In the placement of ReMAP, a side-holed indwelling catheter (Anthron PU catheter, TORAY Medical Co., Ltd) was inserted into the femoral artery, and the catheter tip was placed in the descending aorta, and the catheter tip was placed in the descending aorta. ReMAP was connected to the tail of the catheter and subcutaneously implanted into the femoral region. A high-flow microcatheter can be inserted into ReMAP and inserted into the targeted artery for treatment. Using this system, transarterial arterial chemoeMBOLization (TACE) and HAIC can be repeatedly performed. The feasibility and safety of ReMAP/System-i were assessed in the study.

**Results:** ReMAP/System-i was implanted in 58 patients. The most frequent reason chosen ReMAP/System-i was “need of TAT for several tumor-feeding arteries (48%)”. The median procedure time for ReMAP implantation was 42 min (25-94). Among 58 patients, 6 cases had a complication regarding the procedure (3 wound dehiscence, 3 wound infection). By using ReMAP/System-i, repeated TATs have been performed from not only the hepatic arteries but also other tumor-feeding arteries, repeatedly.

**Conclusions:** ReMAP/System-i is a promising device, which allows us to perform repeated TATs for any arteries with less invasiveness.

Abstract Submission No. 100472

**O-0634**

**Association between SGLT-2 inhibitors and death from hepato-bilio-pancreatic cancer**

Ka Shing Cheung1, 2, Xianhua Mao1, 2, Jing-Tong Tan1, Ho Ming Cheng1, Man-Fung Yuen4, Wai-Kay Seto1, 2, 3

1Department of Medicine, School of Clinical Medicine, The University of Hong Kong Hong Kong, 2Department of Medicine, The University of Hong Kong-Shenzhen Hospital Shenzhen China, 3State Key Laboratory of Liver Research, The University of Hong Kong Hong Kong

**Background:** Association of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) with all-cause and hepato-bilio-pancreatic cancer-related mortality remains unknown in patients with diabetes mellitus (DM).

**Methods:** Data of adult patients with newly diagnosed DM (hemoglobin A1c ≥6.5% or fasting plasma glucose of ≥7mmol/L) were retrieved from a territory-wide healthcare database in Hong Kong between 2010 and 2022. Primary outcomes were mortality from cancer of liver, bile duct, gallbladder and pancreas. Secondary outcome was all-cause mortality. Primary exposure was SGLT-2i use (including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), which was treated as time-varying variable to address immortal time bias. Patients were followed from index date (DM diagnosis) till death or study end date (December 2022). Multivariable Cox model was used to calculate adjusted hazard ratios (HRS) of outcomes with SGLT-2i use by adjusting for 25 covariates including age, sex, DM complications, comorbidities, and concomitant use of medications (Table 1).

**Results:** Of 324,111 eligible subjects (mean age:59.6+/−11.3) years; male:181,480 [53.0%]; median follow-up: 7.0 years [IQR:4.7-9.9], 32,684 (9.6%) were SGLT-2i users (Table 1). There were 22,547 (6.6%) all-cause deaths (liver cancer:901; gallbladder cancer:76; bile duct cancer:243; pancreatic cancer:710). The aHR of death from liver, bile duct, gallbladder and pancreatic cancer was 0.39 (95% CI:0.21-0.70), 0.45 (95% CI:0.25-0.81), 0.74 (95% CI:0.10-5.43) and 1.03 (95% CI:0.64-1.66), respectively. SGLT-2i use also associated with lower risk of all-cause mortality (aHR:0.52;95% CI:0.47-0.59).

**Conclusion:** SGLT-2i use associated with lower risk of all-cause mortality including death from liver and bile duct cancer. This provides additional insight into the choice of anti-diabetic drugs in clinical practice.
Abstract Submission No. 100526
O-0635

Differences in hemodynamics of lenvatinib based on liver function for hepatocellular carcinoma

Kazufumi Kobayashi¹, Sadahisa Ogasawara¹, Tomomi Okubo², Michihisa Moriguchi³, Kazuyoshi Nakamura⁴, Ryosaku Azemoto⁵, Kenji Ito⁶, Shinichiro Okabe⁷, Masanori Atsukawa⁸, Ei Itoyabashi⁹, Masafumi Ikeda⁹, Naoki Morimoto¹⁰, Yoshito Itoh¹¹, Naoya Kato¹²

¹Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan, ²Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital Chiba Japan, ³Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Kyoto Japan, ⁴Department of Gastroenterology, Chiba Cancer Center Chiba Japan, ⁵Department of Gastroenterology, Kimitsu Chuo Hospital Chiba Japan, ⁶Department of Gastroenterology, National Hospital Organization Chiba Medical Center Chiba Japan, ⁷Department of Gastroenterology, Matsudo City General Hospital Chiba Japan, ⁸Department of Gastroenterology, Asahi General Hospital Chiba Japan, ⁹Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East Chiba Japan, ¹⁰Division of Gastroenterology, Department of Medicine, Jichi Medical University Tochigi Japan

Background: The aim of this study was to assess the safety and efficacy of lenvatinib in real-world practice, with a focus on plasma concentration analysis.

Methods: This multicenter, nonrandomized, open-label prospective study was conducted at 10 medical facilities in Japan (jRCTs031190017). Eligible patients had advanced hepatocellular carcinoma and were suitable for lenvatinib treatment. The study included patients with high tumor burden (with >50% intrahepatic tumor volume, main portal vein invasion, or bile duct invasion) and Child-Pugh B status. Plasma concentrations of lenvatinib were monitored on days 1 (multiple times), 8, and 15.

Results: From December 2019 to September 2021, a total of 59 patients were analyzed, with 47 classified as Child-Pugh A and 12 as Child-Pugh B. Patients with Child-Pugh B exhibited a higher frequency of grade 3 or higher adverse events (AEs) and a higher discontinuation rate compared to patients with Child-Pugh A. The median overall survival was 19.7 and 4.1 months in Child-Pugh A and B, respectively. Plasma concentrations were found to be higher in Child-Pugh B patients on days 8 and 15, and higher concentrations were correlated with dosage adjustments and reduced relative dose intensity (RDI).

Conclusions: Patients with inadequately maintained liver function may exhibit an inclination toward elevated plasma concentration of lenvatinib, potentially leading to a higher incidence of AEs and lower RDI.

Abstract Submission No. 100536
O-0637

A tertiary hospital experience of atezolizumab & bevacizumab for advanced hepatocellular carcinoma

Callista Vania Raharjo¹, Raji Joseph¹, Elizabeth Stratton¹, Miriam Levy², Emilia Prakoso³

¹Gastroenterology Department, Liverpool Hospital Sydney, NSW Australia, ²The University of New South Wales Sydney, NSW Australia, ³The University of Sydney Sydney, NSW Australia

Background: Hepatocellular carcinoma (HCC) contributes as the 7th most frequently diagnosed cancer, with approximately 80% of patients presenting with intermediate or advanced stage HCC. The combination of atezolizumab plus bevacizumab (A+B), have become first line treatment of advanced HCC not amenable to resection or locoregional therapy since 2020.

AIM: To characterise the cohort who received A+B at in Liverpool Hospital, Sydney, Australia and assess its efficacy and safety

METHODS: Patients who received Atezolizumab 1,200 mg plus bevacizumab 15 mg/kg intravenously every 3 weeks at Liverpool Hospital between October 2020 and March 2023 were identified from prospectively maintained HCC database.

Results: Table 1 summarises our patients’ demographics. Barcelona Clinic Liver Cancer (BCLC) stage of patients were C in 31 patients (63.3%) and B in 17 patients (34.7%). One patient (2.0%) with BCLC 0 was given A+B because of recurrent HCC following tumour resection. Table 2 summarises patient outcomes as of March 2023. Adverse events of any grade occurred in 29 patients (59.2%). The most common adverse events were fatigue (n=10, 20.4%) and diarrhoea (n=7, 14.3%). Grade 3-4 adverse events that occurred were diarrhoea (n=4, 8.2%), pyrexia (n=3, 6.1%), proteinuria (n=3, 6.1%), and gastrointestinal bleeding (n=2, 4.08%). The median overall survival was 14 months (95%CI, 12.4-20.3).

Conclusion: Treatment cessation was majority due to HCC progression. The rate of any adverse events was high, however significant side effects were uncommon. Longer follow-up duration and larger patient
Background: Atezolizumab plus bevacizumab combination therapy (ATZ/BV) is recommended for unresectable hepatocellular carcinoma (u-HCC) patients. The present study aimed to clarify whether tumor marker response can predict efficacy and prognosis in ATZ/BV.

Methods: A total of 73 patients with u-HCC who received ATZ/BV were included. The definition of early tumor response (ETR) and early disease control (EDC) was complete response (CR) + partial response (PR) + stable disease (SD) after 6 weeks, respectively. Early tumor marker response (ETMR) was defined as a reduction in tumor markers after 3 weeks.

Results: Initial therapeutic response was CR 0, PR 22 (30%), SD 24 (33%), PD 20 (27%), respectively. Although no significant difference was seen in overall survival between ETR and non-ETR groups, there was a significant difference between EDC and non-EDC groups (p<0.001). MST of EDC and non-EDC groups were 14.6 and 6.3 months, respectively. Independent pre- and post-treatment factors contributing to survival were performance status (PS), albumin-bilirubin score, lens culinaris-agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3), and EDC. Independent pre- and post-treatment factors contributing to EDC was PS, prior tyrosine kinase inhibitor treatment, AFP-L3, and AFP- and des-gamma-carboxy prothrombin (DCP)-ETMR. The area under the receiver operating characteristic curve for predicting EDC with AFP-, AFP-L3-, and DCP-ETMR combination were 0.734, 0.621, and 0.682, respectively. Sensitivity, specificity, and accuracy of prediction for EDC using ETMR combination were 0.848, 0.700, and 0.803, respectively.

Conclusions: ETMR can predict disease control and prognosis of ATZ/BV for u-HCC.

Abstract Submission No. 100609
O-0640

mRNA based HBV-specific TCR T-Cell Infusions can Induce Broad HBV T-cell Response in HBV-related HCC

Thinesh Krishnamoorthy1, Wai-Meng David Tai2, Anthony Tanoto Tan3, Wei Qiang Leow3, Joe Yeong4, Regina Wanju Wang5, Liyun Lay6, Lu-En Wai6, Sarene Koh6, Antonio Bertoletti6, Tingting Wang6

1Department of Gastroenterology & Hepatology, Singapore General Hospital Singapore Singapore, 2Division of Medical Oncology, National Cancer Centre Singapore Singapore, 3Emerging Infectious Diseases, Duke-NUS Medical School Singapore Singapore, 4Department of Anatomical Pathology, Singapore General Hospital Singapore Singapore, 5Institute of Molecular and Cell Biology, A*STAR Singapore Singapore, 6Lion TCR Pte Ltd Singapore Singapore, 7Singapore Immunology Network, A*STAR Singapore Singapore

Background: LioCyx-M, autologous T-cells modified with mRNA encoding HBV-specific TCR, has shown promise in advanced and recurrent HCC patients. We report safety and biomarker findings from a phase 1b study (NCT04745403) post LioCyx-M infusions in primary HBV-related HCC patients not amenable to/failed conventional treatment.

Methods: A 71-year-old male, who failed two prior systemic treatments, received 8 LioCyx-M infusions at escalating doses (1×10^6, 1×10^6, 3×5×10^6 cells/kg) intravenously bi-weekly, without lymphodepletion. For pharmacodynamic and immunological biomarker analysis, a whole blood assay (WBA) detected LioCyx-M function in peripheral blood (response to single target HBV-peptides) and explored evidence of epitope spreading (response to other HBV-peptides). Plasma protein levels, assessed through Proximity Extension Analysis, an assay (PEA), elucidated systemic immune responses and their relationship with clinical symptoms.

Results: LioCyx-M infusions were well-tolerated, with manageable grade 1-2 fever and CRP elevation at highest doses (5×10^6 cells/kg). These infusions transiently elevated NLR (neutrophil/lymphocyte ratio), PLR (platelet/lymphocyte ratio) and reversible liver inflammation (ALT & AST), indicating on-target effects. A 2.62-fold reduction in serum IGF-1 level significantly predicted the progression and survival in HCC patients.

Methods: We conducted a comprehensive literature search (September-October 2023) from PubMed, EMBASE, and Cochrane databases with the search terms “Insulin-like Growth Factor 1” AND “Hepatocellular Carcinoma” that were published within the year of 2000 to 2023. We screened 184 records after checking duplicates between databases. We examined 48 full-text articles and excluded 35 articles as they did not meet the inclusion criteria. A total of 13 cohort studies with calculation of relative risk (RR) of serum IGF-1 for HCC time-to-progression (TTP) and overall survival (OS) were subjected to statistical analysis using STATA 17. We assessed the ability of serum IGF-1 to predict HCC progression and survival using random effect model to estimate pooled RR. Heterogeneity among studies was assessed by the Cochran’s Q and I^2 statistics. Publication bias was analysed using Begg funnel plot and Egger test.

Result: The meta-analysis of selected studies showed that low level serum IGF-1 significantly predicted shorter TTP (RR 2.36;95% CI 1.51-3.68) and poorer OS (RR 2.17;95% CI 1.72-2.74) in HCC patients, p value=0.00.

Conclusions: Serum IGF-1 level independently predicted the progression and survival in HCC patients. Further studies are needed for better causation explanation.
CEUS for Differentiation of Benign Vs Malignant PVT in HCC - A Systematic Review with Meta-analysis.

VANEET JEARTH1, Suprabhat Giri2, Arun Vaidya1, Dhiraj Agrawal4, Jijo Varghese3, Ranjan Kumar Patel6, Taraprasad Tripathy4, Ankita Singh1, Swati Das2

1Post Graduate Institute of Medical Education & Research Chandigarh India, 2Kalinga Institute of Medical Sciences Bhubaneswar India, 3Seth GS Medical College and KEM Hospital Mumbai India, 4PACE Hospital, Hyderabad, India Hyderabad India, 5KM Cherian Institute of Medical Sciences Kallissery India, 6All India Institute of Medical Sciences Bhubaneswar India

Background: Patients with cirrhosis and hepatocellular carcinoma (HCC) can develop both benign and malignant portal vein thrombosis (PVT). Characterizing the nature of PVT is important for planning an optimal therapeutic strategy. In the absence of typical findings or contraindications to CT or MRI, contrast-enhanced ultrasound (CEUS) could help in this differentiation. The present meta-analysis aimed to evaluate the performance of CEUS for characterizing PVT in patients with HCC.

Methods: Electronic databases of PubMed, Embase, and Scopus were searched from inception to 31st December 2022 for studies analyzing the role of CEUS in the differentiation of benign and malignant PVT in HCC. Using the bivariate random effect model, pooled sensitivity and specificity were calculated, and the summary receiver operating characteristic (sROC) curve was plotted. Result: A total of 12 studies with data from 712 patients were included in the meta-analysis. The pooled sensitivity and specificity of CEUS for the diagnosis of TIV were 97.0% (95% CI: 93.0 - 98.7) and 96.8% (95% CI: 92.1 - 98.7), respectively, without significant heterogeneity. A sROC curve was plotted, and the area under the receiver-operating characteristic was 0.99 (95% CI: 0.98 - 1.00). Despite the presence of publication bias, sensitivity analysis did not show any change in sensitivity and specificity.

Conclusion: CEUS is an effective diagnostic modality differentiation of benign and malignant PVT in patients with HCC and can be an alternative modality to CT or MRI. Further studies are required to study the role of CEUS as a first-line diagnostic modality for the characterization of PVT in HCC.

Abstract Submission No. 100746
O-0643

Nonselective β-blocker use does not impact on mortality in patients with hepatocellular carcinoma

Hin Yan Agnes Ho1, 2, Philip Lung-Wai Au-Doung3, Terry Cheuk-Fung Yip1, 2, 3, Mandy Sze-Man Lai2, 3, Vincent Wai-Sun Wong6, Grace Lai-Hung Wong6, 2, 3

1Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong, 2Institution of Digestive Disease, The Chinese University of Hong Kong Hong Kong, 3Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong Hong Kong

Background: Hepatocellular carcinoma (HCC) contributes to a substantial burden of mortality across the globe. Increasing evidence supports the role of non-selective beta-blockers (NSBB) in reducing liver decompensation and prolonging survival in cirrhotic patients. However, the effect of NSBB on liver-related mortality in HCC patients remains unestablished.

Materials and methods: All patients with HCC and esophageal and/or gastric varices from January 2000 to December 2020 were identified from a territory-wide database in Hong Kong. Participants were
classified into three groups using a time-dependent covariate (i) propranolol users (ii) carvedilol users (iii) NSBB non-users. The primary endpoint was liver-related mortality in 5 years. Cause-specific hazard model was used for competing risk analysis. Liver transplantation and non-liver-related morality were considered as competing events.

Results: A total of 5,454 patients with 4,119 propranolol users, 86 carvedilol users, 1,249 non-users (mean age 60.4±11 years, male 82.0%) were included in the analysis. Most patients had viral cirrhosis (78.3%). The use of propranolol and carvedilol did not have a significant impact on liver-related mortality (adjusted cause-specific hazard ratio [aC-SHR] 1.03, 95% CI 0.97-1.12, p=0.42; aC-SHR 0.90, 95% CI 0.57-1.43, p=0.67) and non-liver-related mortality (aC-SHR 0.99, 95% CI 0.86-1.15, p=0.94; aC-SHR 1.40, CI 0.75-2.65, p=0.293).

Conclusion: In this territory-wide retrospective study, use of NSBB did not impact on liver-related and non-liver-related mortality in HCC patients over a follow-up period of 5 years.

Abstract Submission No. 100797
O-0644

First-line lenvatinib ± pembrolizumab for advanced hepatocellular carcinoma: LEAP-002 China subgroup

Shukui Qin1, Ruocai Xu2, Hongming Pan3, Kangsheng Gu4, Zhqiang Meng5, Xi Chen6, Tao Zhang7, Peiguo Cao8, Peiyuan He9, Liwen Liang9, Chen Li9, Jianfeng Li9, Zhenggang Ren10

1GI Cancer Center, Nanjing Taimynshin Hospital Nanjing China, 2Hunan Cancer Hospital Changsha China, 3Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou China, 4The First Affiliated Hospital of Anhui Medical University Hefei China, 5Fudan University Shanghai Cancer Center Shanghai China, 6900th Hospital of Joint Logistics Support Force Fuzhou China, 7Union Cancer Hospital of Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 8The Second Xiangya Hospital of Central South University Changsha China, 9MSD China Co., Ltd. Shanghai China, 10Zhongshan Hospital Fudan University Shanghai China

Background: The global, randomized, phase 3 LEAP-002 study (NCT03713593) was conducted to evaluate lenvatinib plus pembrolizumab compared with lenvatinib plus placebo as first-line therapy in patients with advanced hepatocellular carcinoma (HCC). Efficacy and safety results for patients enrolled in LEAP-002 in China are reported.

Methods: Eligible patients had confirmed HCC, Child-Pugh class A liver score, ECOG PS score 0 or 1, and no main portal vein invasion. Patients were randomly assigned 1:1 to receive oral lenvatinib (8mg/day [bodyweight <60 kg] or 12mg/day [bodyweight ≥60kg]) plus either pembrolizumab (200mg IV every 3 weeks [Q3W]; ≤35 cycles) or placebo (saline IV Q3W). Dual primary end points were OS and PFS per RECIST v1.1 by blinded independent central review (BICR). Secondary end points included ORR per RECIST v1.1 by BICR and safety. Database cutoff was June 21, 2022.

Results: One hundred fifty patients were enrolled in China (lenvatinib plus pembrolizumab, n = 76; lenvatinib plus placebo, n = 74). Median follow-up (time from randomization to database cutoff) was 31.9 months (range, 28.1-37.5). Median OS was 32.3 months for lenvatinib plus pembrolizumab and 26.0 months for lenvatinib plus placebo (HR, 0.76 [95% CI, 0.50-1.17]). Median PFS was 8.3 months for both groups (HR, 0.86 [95% CI, 0.61-1.23]). Additional results are summarized in the Table.

Conclusion: China subgroup results were consistent with those of the global LEAP-002 population. OS, PFS, and ORR were numerically improved with the addition of pembrolizumab to lenvatinib, with a similar safety profile.

Abstract Submission No. 100895
O-0646

Serum HBcAb level can predict the occurrence of hepatitis B related hepatocellular carcinoma.

Jing Chen1, Baiguo Xu2, Ying Liu2, Jiayin Wang2, Ruixin Song1, Anjing Liu2, Huiling Xiang2

1The Third Clinical College of Tianjin Medical University Tianjin, China, 2Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China, Tianjin China, 3Tianjin Tanggu Infectious Disease Hospital Tianjin China

Background: Serum hepatitis B core-related antibody (HBcAb) have always existed in the course of hepatitis B infection since the acute stage. Previous literatures have found that the quantitative detection of HBcAb is related to the occurrence of hepatitis B related hepatocellular carcinoma (HCC). In order to further explore the predictive significance of serum HBcAb levels in patients with chronic hepatitis B (CHB) for the occurrence of hepatitis B related HCC, we conducted this retrospective study.

Method: A total of 454 patients treated in our hospital from October 2018 to October 2019 were included. Serum HBcAb levels, surface antigen level, alpha fetoprotein (AFP) level, liver function and other clinical indicators were quantitatively measured at enrollment. The
Comparison of Alpha-Fetoprotein with Viral & Non-Viral Etiology in Hepatocellular Carcinoma Patients

Resha Dermawansyah Rusman1, Fardad Akil1-2, Muhammad Luthfi Parewangi1-2, Nu'man AS Daud1-2, Rini Bachtiar4, Susanto H. Kusuma1-2, Amelia Riful4, Akiko Syawalidhany Tahir3

1Centre of Gastroenterology-Hepatology HAM Akil, DR. Wahidin Sudirohusodo General Hospital Makassar Indonesia, 2Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University Makassar Indonesia, 3Pertamina Royal Biriringkanaya Hospital Makassar Indonesia

Background: Alpha-fetoprotein (AFP) in serum is one of the diagnostic markers currently available for Hepatocellular Carcinoma (HCC). In Indonesia, HCC is the fourth most common cancer with an incidence of around 5.4%, while chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) are the main etiology of HCC in all Asia-Pacific, western countries, and Africa, followed by non-viral etiologies. The efficacy of AFP monitoring is controversial and varies based on the etiology of chronic liver disease in patients with HCC. The aim is to analyze the correlation between alpha-fetoprotein serum and the etiology of hepatocellular carcinoma subjects.

Methods: This study was a retrospective database analysis of HCC patients diagnosed in Wahidin Sudirohusodo Hospital between 2018 and 2022. Information on patients' demography, laboratory (liver biochemistry/serology/virology), and radiology data were collected. Diagnosis of HCC according to the Asia-Pacific Association for the Study of the Liver (APASL). The threshold of AFP level of 400 ng/mL was evaluated against the etiologies of the subject.

Results: During the study period, a total of 337 HCC subjects were found. The majority were male with 257 (76.3%) patients and a mean age of 53.6 years old. Causes of the underlying liver were viral infection 244 (72.4%) and non-viral 93 (27.6%). Of the total patients, 172 (51.0%) had AFP over 400 ng/mL. Viral etiology was associated with higher AFP levels in serum (130 subjects vs 35 subjects, p<0.01).

Conclusions: Hepatocellular carcinoma with etiologic of viral infection was associated with a higher level of alpha-fetoprotein
RESULTS: The mean age was 59.94 ± 7.6 years. 44 (84.18%) were male. 20 (37.04%) had complete response, 10 (18.52%) had partial response, 9 (16.67%) had Stable disease and 15 (27.78%) had Progressive disease post-TACE. Mean SWE of focal lesion (FOL) at baseline was significantly lower in patients with CR (14.82 ± 4.76) compared to other groups PR (18.59 ± 5.31), SD (35.93 ± 8.7), PD (38.22 ± 14.07) (p= 26kpa (AUC=0.95, CI: 0.854 to 0.991; Sensitivity 100%, Specificity 79.1%, p=20kpa (AUC=0.79, CI:0.657-0.889, Sensitivity=83.3%, Specificity=67.7%). On Multivariate analysis, Lower baseline SWE FOL (aOR: 0.811, p=0.004) and lower AFP (aOR: 0.988, p=0.026) were found to be independently associated with Tumor Response.

Conclusion: Baseline Tumor Shear Wave Elastography and AFP can be used as predictors for Tumor response of HCC to TACE.

Abstract Submission No. 101027
O-0650
The distribution of BCLC 2022 stages among patients with Hepatocellular carcinoma

Zahabia Sohail1, zahabia Muhammad1, Asma Yaseen1, Syedda Ayesha1

1The Aga Khan University Karachi Pakistan

Objective: Primary liver carcinoma ranks as the seventh most prevalent cancer globally. Hepatocellular carcinoma (HCC) represents the predominant form of liver cancer, accounting for approximately 75% of all cases. The objective of this study is to ascertain the distribution of BCLC stages among patients presenting with HCC at a tertiary care hospital.

Method: A descriptive cross-sectional, observational study was carried out in the gastroenterology department of the Aga Khan University Hospital. The study included all patients, who presented in liver tumor board clinic with the diagnosis of HCC.

Result: A total of 66 patients were enrolled in the study, with mean age of 54.7 years. The primary cause of HCC was found to be Non-B non-C CLD in 39 cases (65%). BCLC -2022 staging was performed, with the majority of patients (n =42, 63.7%) falling into the BCLC-C category, followed by BCLC-D (n = 26, 39.3%).

Conclusion: The study highlights that a significant proportion of HCC patients are initially categorized as BCLC-C where some management decision can be offered. Early detection of HCC is recommended to offer improved treatment options to patients.

Abstract Submission No. 101041
O-0651
A comparison of surgical resection and RFA for early-stage HCC patients with Child-Pugh class B

Takeshi Hatanaka1, 16, Satoru Kazizaki2, 16, Atsushi Hiraoka3, 10, Kazuya Kariyama4, 10, Toshifumi Tada0, 10, Toru Ishikawa10, Hidenori Toyoda10, Hideko Ohama10, Fujimasa Tada10, Atsushi Naganuma10, Kauzihiro Nosu0, Takashi Kumada10

1Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital Maebashi Japan, 2Department of Clinical Research, National Hospital Organization Takasaki General Medical Center Takasaki Japan, 3Gastroenterology Center, Ehime Prefectural Central Hospital Matsuyama Japan, 4Department of Gastroenterology, Okayama City Hospital Okayama Japan, 5Department of Internal Medicine, Japanese Red Cross Himeji Hospital Himeji Japan, 6Center of Gastroenterology, Teine Keijinkai Hospital Sapporo Japan, 7Department of Gastroenterology, Saiseikai Niigata Hospital Niigata Japan, 8Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital Ogaki Japan, 9Department of Nursing, Gifu Kyoritsu University Ogaki Japan, 10RELPEC group Ogaki Japan

Background: This study compared surgical resection (SR) and radiofrequency ablation (RFA) for early-stage HCC patients with Child-Pugh class B.

Methods: This retrospective study included 497 HCC patients with ≤ 3 nodules and tumors ≤ 3cm in diameter who initially received either SR (n=41) or RFA (n=456). The significant differences in patient background were adjusted by IPTW.

Results: The median ages were 72 and 68 years old in the SR and RFA group (p=0.3), with 26 and 305 patients being males (p=0.7). Child-Pugh score were 7, 8, and 9 in 34, 6, and 1 patients in the SR group and 262, 124, and 70 patients in the RFA group, respectively (p=0.003). The number of nodules was 1, 2, and 3 in 35, 6, and 0 patients in the SR group and 309, 109, and 38 patients in the RFA group, respectively (p=0.034). The maximum tumor diameter 2.2 and 1.8 cm in the SR and RFA group (p=0.002). The 5-, and 10-year RFS rates were 48.6%, and 30.4% in the SR group and 43.6%, and 34.9% in the RFA group, which did not reach a statistical significance (p=0.6). The 5-, and 10-year OS rates were 47.6%, and 19.5% in the SR group and 43.2%, and 15.3% in the RFA group, without a statistical significance (p=0.5). In the IPTW-weighted cohort, the differences in the RFS and OS rates between two groups were not observed (p=0.5 and 0.9, respectively).

Conclusions: RFA may be equally effective compared to SR for early-stage HCC patients with Child-Pugh class B.

Abstract Submission No. 101078
O-0652
Evaluation of circular RNA SMARCA5 as a novel biomarker for hepatocellular carcinoma

Mohamed Abdel-Samiee1, Hanan M. Bedair2, Elhamy A. Ahmed2, Mostafa G Elhelbawy1, Elaf A El-Banna2, Amal A El Sharrnoby2

1Hepatology and Gastroenterology, National Liver Institute, Menoufia University Shebin El-Kom Egypt, 2Clinical Pathology Department, National Liver Institute, Menoufia University Shebin El-Kom Egypt

Background: Hepatocellular carcinoma (HCC) is the sixth and fourth common cancer in worldwide and Egypt, respectively. Most patients with HCC are diagnosed at their advanced stages due to lack of early diagnosis biomarker, so they lose the best opportunity for therapy.

Objective: The aim of this study is to evaluate the level of circular RNA SMARCA5 and SMARCA5 mRNA expression as novel biomarkers for early detection of HCC.

Patients and methods: The study was conducted as a case control study included 159 subject, they collected from inpatient and outpatient patients clinics of national liver institute, Menoufia university and they were equally divided into 3 groups; Group I: 53 control subjects, Group II: 53 HCV cirrhotic patients and Group III: 53 HCC patients. Each patient underwent: full history taking, thorough clinical examination, radiological examination and assessment of serum Alpha-fetoprotein (AFP) and detection of circular RNA SMARCA5 and SMARCA5 mRNA genes by quantitative real time polymerase chain reaction (PCR).

Results: There were statistically significant difference among studied groups regarding AFP, SMARCA5, and CircSMARCA5 (P-value= 0.001, 0.001 & 0.001, respectively). CircSMARCA5 and SMARCA5 mRNA were significantly reduced in HCC group when compared to
HCV cirrhotic patients and controls. ROC analysis for early diagnosis of HCC showed that the area under curve (AUC) of CircSMARCA5 at cut-off point 4.55 yielded specificity of 83.8% and sensitivity of 91.7% while the AUC for AFP cut-off point 515 ng/ml yielding specificity of 89.2% and sensitivity of 91.3%.

**Conclusion:** CircSMARCA5 may serve as a potential predictor of HCC disease with better sensitivity than AFP.

Abstract Submission No. 101142  
**O-0653**

**Integrative Characteristics of HBV -HCC after NUCs Long-term Antiviral Therapy**

Bobin Hu1, Hengkai Liang1, Rongming Wang1, Minghua Su1, Lu Wei1, Tumei Su1, Qingmei Li1, Qianbing Yin1, Yunfei Feng1, Jianning Jiang1

1The First Affiliated Hospital of Guangxi Medical University Nanning China

**Aims:** The integrated characteristics of Hepatitis B Virus (HBV)-related liver cancer after long-term antiviral treatment remain incompletely understood. This study aimed to explore the influence of integration events on clinical factors of HBV-related liver cancer using a long-term follow-up cohort undergoing antiviral therapy. Additionally, we aimed to analyze the characteristics of integration patterns.

**Methods:** This study enrolled 22 patients with HBV-related liver cancer, monitoring clinical indicators including HBV DNA and Hepatitis B Surface Antigen (HBsAg). Genome-Wide Association Study (GWAS) analyzed liver cancer tissues and detected HBV integration sites. Among them, 17 cases had HBV integration (Int group), while 5 cases had no HBV integration (N-int group). We analyzed clinical differences between the two groups and compared dynamic changes in HBsAg levels. Additionally, we explored genomic features at the HBV integration breakpoints.

**Results:** The participants were followed for nearly 11 years. Among them, 77.3% demonstrated HBV integration. The Int group consistently exhibited higher levels of HBsAg compared to the N-int group, accompanied by a slower decline. In the Int group, there were significant increases in telomerase reverse transcriptase (TERT) gene copy number, single nucleotide variations (SNVs) deletion number, and substitution number compared to the N-int group (P<0.05). Integration events primarily transpired close to chromosome termini and centromeres, indicating a preference for specific human genomic elements. Essential functional elements of the HBV genome were prone to integration.

**Conclusion:** After long-term antiviral therapy, HBV integration could still sustain a certain level of HBsAg. HBV integration resulted in an increased number of interrupted gene SNVs and could potentially impact chromosome stability and mitosis. Host genomic elements cooperated with HBV functional elements in integration events.

Abstract Submission No. 101185  
**O-0654**

**The causes of HCC in Turkey**

A.Kadir DOKMECI1

1Ankara University School of Medicine Ankara Turkey

**Background:** The incidence of chronic hepatitis infections. Also, the etiology of HCC has been changing with a growing role of metabolic (dysfunction) associated fatty liver disease (MAFLD).

**Results:** In the previous study, HBV, HCV and alcohol were the main causes of HCC with (56%), (23.2%) and (15.9%) in 207 patients respectively. The etiologic risk factors for HCC were HBV in 555 patients (57.6%), HCV (16.5%), and chronic alcohol (14.2%). Yalcın reported that HBV infection alone (45%), HDV co-infection (29%), HCV infection (15%) and unknown etiology (10%) were causes of HCC in southeastern Turkey. The result of another multicenter, retrospective cohort study including 1802 patients showed that HBV was the most common etiology (54%), followed by HCV (19%), MAFLD (10%), cryptogenic (8.6%), alcohol-related liver disease (3.6%), autoimmune liver diseases (0.9%).

It was reported that HBV infection (68.2%) was the leading etiology, followed by HCV infection (17.2%), HDV infection (5.5%), alcohol (6.4%), and MAFLD (3.5%).

**Conclusions:** Despite the national immunization program, HBV remains the leading cause of HCC in Turkey, followed by HCV, alcohol-related liver disease, cryptogenic MAFLD and HDV. Recently, MAFLD is increasingly involved in the etiology of HCC.

Abstract Submission No. 101187  
**O-0655**

**The factors contributing to prolonged survival in the intermediate stage HCC using survival model.**

Masashi Ninomiya1, Jun Inoue1, Mio Tsuruoka1, Akitoshi Sano1, Kosuke Sato2, Satoko Sawahashi1, Masazumi Onuki1, Keishi Ouchi1, Atsushi Masamune1

1Tohoku University Hospital Sendai Japan

**Backgrounds:** The increase of treatments have made it possible to the more curative state in unresectable hepatocellular carcinoma. However, we do not know how much these therapies contribute to prognosis in real clinical practice. We applied our new developed survival model and compared them with actual survival, and analyzed the factors contributing to prolonged survival.

**Methods:** 101 cases from BCLC stage B from 2018 to 2023 were grouped by Kinki criteria as B1/B2/B3=37/56/8. 1) Overall survival was analyzed by Kaplan meier method. 2) Actual survival was determined in B1/B2/B3=26/41/6 cases. We compared them with predicted survival time calculating with survival model. The proportion of cases that exceeded the predicted survival time were extracted. The t-test was used to evaluate the survival factors contributing to the prolongation of the actual survival period.

**Results:** 1) Overall survival was 42.6/25.2/16.4 months. The mean predicted survival was 28.6/22.6/15.8 months. 2) Actual survival exceeded prediction in 17 patients (65.4%) in B1 and 23 (56.1%) in B2. Statistical analysis showed that actual survival time significantly exceeded predicted survival. Factors associated with prolonged survival were multiple TACE and RFA treatment in B1, and multiple TACE, ATZ+BV induction with treatment effect, and RFA treatment in B2.

**Conclusion:** Using our developed survival model, we analyzed the relationship of treatment contributing to prolonged survival in the intermediate stage. With the success or failure of TACE treatment is the key in the intermediate stage and ATZ+BV being effective in the B2 stage.
Safety of STRIDE regimen for advanced hepatocellular carcinoma and its optimal management

Takuya Yonemoto1, Sadahisa Ogasawara1, Sae Yumita1, Kisako Fujiwara1, Keisuke Koroki1, Masanori Inoue1, Kazufumi Kobayashi2, Masato Nakamura1, Naoya Kanagawa1, Soichiro Kiyono1, Takayuki Kondo1, Shingo Nakamoto1, Naoya Kato1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, chiba Japan

Background: Durvalumab/tremelimumab combination therapy (STRIDE) has been approved for advanced hepatocellular carcinoma (HCC). However, STRIDE, which contains a CTLA-4 inhibitor, is associated with a high incidence of immune-related/mediated adverse events (irAEs/imAEs), which are often difficult to manage. We analyzed clinical data on irAEs/imAEs that occurred after STRIDE administration at our hospital and investigated the management of irAEs/imAEs.

Methods: We retrospectively collected clinical data on 43 patients treated with STRIDE for advanced HCC between April and August 2023.

Results: IrAEs/imAEs requiring treatment with glucocorticoids occurred in 13 cases (30.2%), and high-dose glucocorticoids (≥1 mg/kg) were required in 7 cases (16.3%). The median duration from the start of STRIDE to the first irAE/imAE was 16 days (range: 6-51). IrAEs/imAEs leading to treatment discontinuation occurred in 4 cases, and disease progression was observed in 4 cases. In one case of enteritis, remission was not achieved with glucocorticoids alone and infliximab was added. In addition, in one case of cytokine release syndrome, remission was not achieved with glucocorticoids alone, necessitating tocilizumab. After tapering of glucocorticoids, durvalumab was reintroduced in 5 cases, with only one case of enteritis recurring.

Conclusions: STRIDE-induced irAE/imAE can be effectively managed by prompt administration of glucocorticoids in severe cases. It is also important to have adequate knowledge of additional treatment options in cases of inadequate response to glucocorticoids. Although there is a risk of recurrence of irAE/imAE, retreatment with durvalumab may be considered after successful control of irAE/imAE with glucocorticoids, especially if supported by the risk-benefit assessment.

Abstract Submission No. 101322
O-0657
Exploratory Effectiveness of Atezolizumab + Bevacizumab against uHCC Beyond Radiological Progression

Nobuhito Taniki1, Takaya Tabuchi2, Ryosuke Kasuga1, Po-Sung Chu1, Shunsuke Shiba1, Toshiyuki Tahara1, Yuriko Fujita1, Hitomi Hoshi4, Fumihiko Kaneko4, Keisuke Ojiro5, Akihiro Yamaguchi2, Seiichiro Fukuhara1, Yukishige Okamura1, Takanori Kanai1, Nobuhiro Nakamoto1
1Keio University Tokyo Japan, 2Saiseikai Utsunomiya Hospital Tochigi Japan, 3Yokohama Municipal Citizen's Hospital Kanagawa Japan, 4Saitama Municipal Hospital Saitama Japan, 5Tokyo Dental College Ichikawa General Hospital Chiba Japan, 6National Hospital Organization Saitama Hospital Saitama Japan, 7National Hospital Organization Tokyo Medical Center Tokyo Japan, 8Sano Kosei General Hospital Tochigi Japan

Background: The IMbrave150 trial allows the continuation of atezolizumab (Atezo) plus bevacizumab (Bev) beyond radiological PD until clinical benefits cease. This study investigates the effectiveness of continuing ICIs after initial radiological PD.

Methods: 122 unresectable HCC patients treated with Atezo plus Bev across 8 liver centers were enrolled. Patients with clinical benefits, despite PD as per RECIST 1.1, could continue treatment until unacceptable toxicity developed. Those who received two or more cycles of Atezo plus Bev after first PD were defined as beyond PD group. Their outcomes were compared with those who either switched to alternative therapies or discontinued chemotherapy post-first PD.

Results: 4 patients continued with Atezo plus Bev, 26 switched to other chemotherapies, and 15 discontinued treatments after the first PD. The median overall survival (OS) was 21.3 months in the beyond PD group versus 13.6 months in those who switched or discontinued treatment. Additionally, those who switched to alternative chemotherapy had a median OS of 23.1 months, while those receiving palliative therapy had 7.0 months. Macrovascular invasion (MVI) was identified as a significant prognostic factor in the beyond PD group, based on the Cox proportional hazard model. Notably, in the patients without MVI, beyond PD group had a significantly longer median OS compared to others.

Conclusion: The study suggests that there are patients who may benefit from continuing Atezo and Bev beyond PD, especially in those without MVI. Nevertheless, due to selection bias, more research is needed to find predictors define treatment efficacy.

Abstract Submission No. 101330
O-0658
Significance of Complete Response in Atezolizumab-Bevacizumab for Advanced Hepatocellular Carcinoma

Teiji Kuzuya1, Naoto Kawabe1, Yoshihi Hirooka1
1Department of Gastroenterology and Hepatology, Fujita Health University Toyoake Japan

Objective: To evaluate the characteristics and prognosis of patients who achieved complete response (CR) by mRECIST in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab-bevacizumab (Atz/Bev).

Methods: 129 patients who received Atz/Bev in our hospital were included. The median age 75 years; Male 106 cases; ECOG-PS 0 96 cases; Child-Pugh score 5 82 cases; BCLC stage B 60 cases; median AFP 50.1ng/ml; median PIVKA-2 599mAU/ml.

Results: The best antitumor response (CR/PR/SD/PD+NE) to Atz/Bev alone was 16/45/36/32 in mRECIST (CRR 12.4%; ORR 47.3%). Median PFS was 258 days; for mRECIST, CR 588 days; PR 442 days; SD 209 days; PD+NE 42 days. Median OS was 644 days, with mRECIST: CR not achieved; PR 886 days; SD 644 days; PD+NE 173 days. Predictors of CR were fewer than 4 HCCs and no portal vein tumor thrombus at baseline. The median time to mCR was 105 days; AFP ratio was 0.330 at 2 weeks, 0.160 at 4 weeks, and 0.11 at 6 weeks; PIVKA-2 ratio was 0.575 at 2 weeks, 0.470 at 4 weeks, and 0.240 at 6 weeks. Six patients who underwent additional TACE achieved CR. Including these 6 patients, the median OS of the 22 CR patients was not reached. Of these, 18 patients achieved drug-free status.

Conclusions: Patients who achieved CR in mRECIST with Atz/Bev showed significant reductions in AFP and PIVKA-2 early in the course of treatment. CR achieved with Atz/Bev alone and with the addition of TACE can be expected to have an extremely favorable prognosis.

Abstract Submission No. 101333
O-0659
India Pabulum Index predicts short term mortality in patients with HCC : A Prospective study
Devika Madhu¹, Srijaya S Sreesh¹, Jithin John¹, Antony George¹, Aditya Verma¹, Nuzil Moopen⁴, Krishadas Devadas³

¹Department of Medical Gastroenterology Thiruvananthapuram India

Background and Aims: The presence of systemic inflammation predicts poor outcome in patients with malignancy. We attempted to evaluate the association of the inflammatory component of diet with mortality in patients with Hepatocellular carcinoma (HCC) using a novel score, India Pabulum Index (IPL index) and compared it with existing prognostic indices.

Method: We performed a prospective study of 6 months in 84 patients with Decompensated Chronic Liver Disease (DCLD) and HCC. Basic clinical parameters were obtained. IPL index was formulated as Prognostic Nutritional Index \((10 \times \text{serum albumin}[\text{g/dL}]) + (0.005 \times \text{lymphocytes/\text{µL}})\) evaluated in a South Indian cohort. Variables associated with Mortality were identified using Regression analysis and compared with other scores using ROC curves.

Results: The Short-term Mortality was 34.5% at 6 months. On univariate analysis, the predictors of mortality were IPL index \((p<0.001)\), BCLC score \((p<0.001)\), Portal Vein Thrombosis \((p=0.038)\), Hepatic Encephalopathy \((p<0.001)\), Child status \((p<0.001)\), Alpha fetoprotein \(>256\) \((p<0.007)\) and Neutrophil Lymphocyte Ratio \((\text{NLR})\) \((p<0.000)\). However, on multivariate analysis, IPL index \(<34.8\) \((p=0.001)\) and \(\text{NLR} >2\) \((p=0.039)\) were significantly associated with mortality. ROC-curve of IPL index estimated a cut-off value of 34.8 with sensitivity-89.66, specificity-90.91, positive predictive value-83.9 and negative predictive value-94.3. ROC for IPL index \((0.926)\) was higher than BCLC \((0.838)\), Hong Kong Liver Cancer \((0.786)\) and NLR \((0.778)\).

Kaplan Meier analysis showed that the mean survival was 5.887 ± 0.069 months in the high IPL index group \((>34.8)\) and 2.968 ± 0.346 months in the low IPL index group \((\leq 34.8)\) \((p<0.001)\). Multivariate analysis of the prognostic power of IPL index and BCLC using Cox regression model showed that a low IPL index had a Hazard ratio of 18.29 (95% CI (5.23-63.93)) vs 2.05 (95% CI (0.79-5.33)) for BCLC.

Conclusion: An IPL index of <34.8 predicts Short-term Mortality in patients with DCLD and HCC. It is an easy-to-use, sustainable and viable prognostic score that can be applied at bedside, to identify patients for dietary recompensation as a powerful tool to improve their survival.

Abstract Submission No. 101338

O-0660

Clinical Characteristics And Barcelona Clinic Liver Cancer Staging In Patient With HCC.

Gulzar khan¹

¹CPSP karachi Pakistan

Objective: This cross-sectional prospective study, conducted at the Gastroenterology Department of Jinnah Postgraduate Medical Center in Karachi between January 2018 and December 2022, aims to assess the distribution of Barcelona Clinic Liver Cancer (BCLC) stages in patients with Hepatocellular Carcinoma (HCC) in a tertiary care hospital. The study seeks to provide valuable insights into the clinical characteristics and staging of HCC within a specific population.

Methods: A total of 566 patients of both genders, all with confirmed HCC diagnoses, were included in the study. Data analysis was conducted using SPSS version 25.

Results: The study population had an average age of 59.3 years, with 58% being male and 42% female. The mean Model for End-Stage Liver Disease (MELD) score was 15±6. Hepatitis C Virus (HCV) was the leading cause of HCC, accounting for 70% of cases. The most frequently reported presenting complaints were abdominal distention and abdominal pain, followed by upper gastrointestinal bleeding. Upon Barcelona Clinic Liver Cancer (BCLC) staging, the majority of patients were classified as BCLC-D (40%), followed by BCLC-C (36%).

Conclusion: The study highlights a concerning trend in our population, with a significant proportion of HCC patients presenting in advanced stages, particularly within the BCLC-D category. Abdominal pain emerged as the most common symptom. Early detection of HCC is crucial to enable the timely implementation of more effective treatment strategies. These findings contribute to the global understanding of HCC presentation and staging, facilitating improved clinical management and patient outcomes on a broader scale.

Abstract Submission No. 101371

O-0661

Decoding the importance of AFP in HCC: Is it all it’s touted to be?

Sidharth Harindranath¹, Leela Shinde¹, Ankita Singh¹, Arun Vaidya¹, Biswa Ranjan Patra¹, Akash Shukla¹

¹Department of gastroenterology, Seth GS medical college and KEM hospital, Mumbai, India

Introduction: Serum alpha-feto protein (AFP) is the most widely used serological marker to establish a diagnosis of HCC and is a part of most standard guidelines on screening and diagnosis. We aimed to study the clinical relationship of AFP levels and tumor characteristics in patients diagnosed with HCC on surveillance.

Methods: A total of 126 patients (99 men, age 55±13.1 years) diagnosed with HCC on surveillance were recruited. AFP producing tumors (AFP+) were defined as AFP ≥10 ng/ml. Clinical and tumor characteristics were compared between patients with AFP producing versus non-AFP producing tumors (AFP-).

Results: A total of 85 (67.4%) were AFP+. Median CTP, MELD and AlBi score were 7 (IQR 5-14), 13 (IQR 6-35) and -1.7014 (IQR -3.63 - 0.53) respectively. The most common etiology was Hepatitis B (n=47 ; 37%) followed by NASH (n=37; 29.1%). AFP- had fewer number of lesions (9.8% vs 16.4%) but, the median size of the lesions was similar (5cm vs 5cm). AFP+ had a higher incidence of microvascular (30.5% vs 19.5%, p=0.17), macrovascular invasion (portal vein: 28.2% vs 12.2%; p=0.045, hepatic vein: 10.6% vs 7.3%; p=0.558) and extra hepatic metastases (16.5% vs 9.8%; p=0.313). Curative intent therapy could be offered to 20 (23.5%) Vs 22 (53.6%) in AFP+ and AFP- respectively.

Conclusions: AFP producing tumors have higher number of lesions, and increased incidence of vascular invasion and hepatic disease. Curative intent therapy could be offered to greater proportion of patients who were AFP+. Need better biomarkers for less aggressive disease.

Abstract Submission No. 101392

O-0662

Influence of Enterobacteria on the Response to Atezolizumab and Bevacizumab in patients with HCC

Kazuhiro Nousou¹, Kazuya Kariyama¹, Takashi Kumada², RELPEC Group¹,², HCC 48’

¹Department of Gastroenterology, Okayama City Hospital Okayama Japan, ²Gifu Kyoritsu University Ogaki Japan

Background: Numerous studies suggest that alterations in the microbiome can impact the efficacy of immune checkpoint inhibitors. The use of proton pump inhibitors or antibiotics is considered a risk factor

Abstract Submission No. 101436

O-0664
for diminished survival, while the presence of butyrate-producing enterobacteria appears to have a potentially positive effect. However, the specific influence of enterobacteria on patients with hepatocellular carcinoma (HCC) remains unclear.

**Methods:** We conducted a retrospective analysis of 747 HCC patients undergoing treatment with atezolizumab and bevacizumab, examining the impact of orally administered butyrate-producing enterobacteria on treatment efficacy and overall survival. Additionally, we reviewed reports examining the effects of proton pump inhibitors and antibiotics on treatment outcomes.

**Results:** While the objective response in patients taking butyric acid-producing enterobacteria was higher compared to the control group (29.7% vs. 26.4%), no statistically significant differences were noted. Similar trends were observed in disease control rates (77.8% vs. 72.7%). Median survival time showed no significant difference between the two groups (20.0 months vs. 21.4 months), even after adjusting for patient background. Despite one study reporting a connection between pretreatment antibiotics and reduced therapeutic response, our analysis did not reveal a significant impact of antibiotics or proton pump inhibitors.

**Conclusions:** Our study did not identify a clear influence of enterobacteria on the treatment outcomes of patients with hepatocellular carcinoma receiving atezolizumab and bevacizumab; however, prospective study is needed to confirm the effect.

**Abstract Submission No. 101443**

**O-0663**

**Durable response and its significance in atezolizumab plus bevacizumab therapy**

Yutaka Yasui1, Kaoru Tsuchiya1, Naoki Uchihara1, Keito Suzuki2, Yuki Tanaka3, Haruka Miyamoto1, Michiko Yamada1, Taisei Keitoku1, Kenta Takaura1, Shohei Tanaka1, Chiaki Maeyashiki1, Nobuharu Tamaki1, Hiroyuki Nakanishi1, Masayuki Kurosaki1, Namiki Izumi1

1Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Tokyo Japan

**Background:** Immune checkpoint inhibitor therapy has dramatically benefited cancer patients, particularly patients undergoing long-lasting effectiveness. However, durable responses are not well elucidated in real-world clinical practice. We aimed to clarify the durable response rate and the significance of atezolizumab plus bevacizumab (Atez+Bev).

**Methods:** This single-center retrospective study enrolled 134 patients with unresectable hepatocellular carcinoma (HCC) who underwent Atez+Bev treatment. We evaluated radiological response according to RECIST ver 1.1 at 6-8 weeks and every 8-12 weeks thereafter. The “durable response” was defined as a maintained response (CR/PR/SD) >6 months and received Atez+Bev >6 months.

**Results:** Among enrolled patients, 84 patients received AtezBev as the 1st-line treatment. In the 1st-line treated patients, SD/PR/CR was achieved in 42(50%)/20(24%)/2(2%), respectively. Among these, durable response was achieved in 40% of SD, 75% of PR, and 100% of CR. Patients who achieved durable responses survived significantly longer than those who did not (p=0.02). The durable response rate was significantly higher in the 1st-line group than in the 2nd or later-line treated patients (40% vs. 18%, p=0.02). The durable response rate in the 2nd or later-line group was 24% for patients who achieved SD and 67% for patients with PR. Patients whose AFP decreased under 800 ng/mL were independently associated with OS. The ORR and DCR were 35% and 76%, and 44% and 75% using RECIST and mRECIST, respectively. Two (10%) patients had significant downstaging and underwent successful curative-intent microwave ablation.

**Conclusions:** Response rates in this real-world cohort were comparable to the registration trial. Atezolizumab-bevacizumab followed by curative microwave ablation was achieved in two cases.

**Abstract Submission No. 101499**

**O-0665**

**LUS and ICG Fluorescence Navigation in Laparoscopic Anatomical Liver Resection**

Hongguang Wang1

1Department of Hepatobilary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Anatomical resections, which include the complete removal of an anatomical area that is defined by the vascular supply of the Glissonian branches, have been shown to significantly improve the oncological outcomes and to reduce local recurrence compared with nonanatomical resections in patients with HCC. By approaching the hilum according to specific gates and landmarks including Laennec’s capsule, one could identify and divide the pedicle of each segment or subsegment, aiming to a true anatomical resection. The hepatic intersegmental/sec- tional plane is defined by the border or watershed of each order portal venous territory. Hepatic veins coursing intersegmental/sec- tional planes are defined as intersegmental/segmental veins. They can play a role of landmark to divide the liver parenchyma appropriately by continuously exposed in the cutting plane. LUS and ICG staining are
Nok-Shun Lui1, 2, 3

Baveno VI criteria is inaccurate in predicting high-risk varices in elderly patient with advanced HCC who received advanced HCC

Tatsuo Kanda1, Shuhei Arima1, Masayuki Honda1, Mai Totsuka1, Reina Reina Sasaki-Tanaka1, Masahiro Ogawa1, Hirofumi Kogure1, Shini Kanezawa1, Tomotaka Ishii1, Naoki Matsumoto1, Ryota Masuzaki1, Hiroaki Yamagami1

1Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine Tokyo Japan

Case: 80S, male. Chief complaint: body weight loss, appetite loss. Medical history: 10 and 5 years ago, respectively, he received cataract surgery and spinal canal stenosis. Two years ago, he received transfusion for colonic diverticular bleeding. He does not have any tattoos or surgery and spinal canal stenosis. Two years ago, he received transfusion for colonic diverticular bleeding. He does not have any tattoos or

Octogenarians: Insights of our Institution

Surgical Management of Hepatocellular Carcinoma in Octogenarians: Insights of our Institution

Kan Toriguchi1, Masatoh Narita1, Tatsuki Ishikawa1, Yuya Kameda1, Shotaro Matsuda1, Nobu Oshima1, Masato Kondo1, Hiroki Hashida1, Hiroyuki Kobayashi1, Kenji Uryuhara1, Satoshi Kaikara1

1Kobe City Medical Center General Hospital Kobe Japan

Background: With the rapid aging population, the opportunity for surgery among individuals aged 80 years and older has increased. This study aims to evaluate the appropriateness of such procedures.

Methods: A retrospective review of cases involving liver cancer surgery in patients aged 80 years and above, performed at our hospital from January 1, 2013, to December 31, 2022, was conducted.

Results: The study encompassed 44 cases: 28 males and 16 females, with a median age of 82 years (range: 80-89). Surgical cases gradually increased from 2013-2017 (20 cases, 16.2%) to 2018-2022 (24 cases, 19.8%). Background liver diseases included HBV (3), HCV (17), MASLD (6), alcohol-related (4), and others (14). Pre-existing malignancies were observed in 17 cases (38.6%). Most cases (86.3%) were independent in activities of daily living (ADL), while 13.6% required some form of support. Surgical techniques varied, with partial resection (41%) and anatomical major liver resection (59.1%) being predominant.

Conclusion: Surgical interventions in liver cancer patients aged 80 and above at our institution displayed satisfactory short-term outcomes and comparable long-term results to national surveys. However, cases revealed early discontinuation of follow-up due to declining ADL and a lack of preparedness for appropriate post-recurrence treatments.
Abstract Submission No. 101611
O-0669

A case of HCC with bone metastasis successfully treated with radiation and cancer immunotherapy.

Eriko Yamamoto¹, Takayuki Matsumoto¹, Masaaki Nomura¹, Ryo Suzuki¹, Noriyoshi Yamashita¹, Yohsuke Matsubara¹, Sayu Yamamoto¹, Hirokazu Fujita¹, Kento Kusumoto¹, Misa Sugura¹, Tsuyoshi Yamazoe¹, Atsushi Uwamori¹, Yoshiki Kanai¹, Hinako Nishimura¹
¹Osaka prefecture Saiseikai Izumo Hospital Osaka Japan, ²Kansai Medical University School of Medicine Osaka Japan

Abstract: A 84-year-old man, who refused antiviral therapy for chronic hepatitis C, had been followed up every 6 months for surveillance of hepatocellular carcinoma (HCC). In June X-1, a 20mm hypoechoic mass was found in S8 of the liver. Further examination with EOB-MRI and CT angiography findings were undiagnostic for HCC. In January X, he noticed a 6-cm mass in the left anterior chest wall, and visited us. Chest CT showed bone tumors on 1st and 7th rib. Biopsy of the mass showed plates of cords of cells lined by endothelium and immunostaining of the hepatocyte marker HEP-PAR1 was strongly positive. This led to the diagnosis of rib metastasis of HCC. EOB-MRI of the liver revealed the enlarged S8 mass with intrahepatic metastasis in S6 lesion. With a diagnosed as HCC stage IVB and his liver function as Child-Pugh class A, a combination of atezolizumab and bevacizumab (Atezo/Bev) were initiated in May X. For rib metastases, extracorporeal radiation therapy was also added. The bone tumors shrank in August X. The patient is currently receiving 16 courses of Atezo/Bev and maintaining CR for 1.5 years. Discussions: It has been suggested that the combination of immune checkpoint inhibitors and radiation therapy may have a synergistic effect, in which neoantigens resulting from DNA damage in irradiated tumors stimulate antigen-presenting cells, which activate T cells and exert an anti-tumor immune effect on residual tumor cells after irradiation. In this case, combination use of radiation therapy may have enhanced the effect of immune checkpoint inhibitors.

Abstract Submission No. 101624
O-0671

TACE with a fine cisplatin powder and porous gelatin particles for TACE-naïve multifocal HCC

RUI SATO¹, Michihisa Moriguchi², Takeshi Aramaki¹, Atsushi Saiga¹, Kazuhisa Ashara¹
¹Division of Interventional Radiology, Shizuoka Cancer Center Shizuoka Japan, ²Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan

Purpose: A Japanese Interventional Oncology group showed the efficacy and safety of nonselective transcatheter arterial chemoembolization (TACE) with a fine cisplatin powder (65mg/m2) and porous gelatin particles without lipiodol for extensive multifocal hepatocellular carcinoma (HCC)(1). The aim of this study is to evaluate the efficacy and safety of this type of TACE for the whole liver in a single center.

Material and methods: We retrospectively reviewed our medical records of TACE-naïve multifocal HCC patients (Child Pugh A, up to 7 out) who had undergone TACE for the whole liver with a fine cisplatin powder and porous gelatin particles between 2006 and 2019.

Results: There was 60 patients. The median age of the patients was 71 years (range 35-88). Child Pugh 5 was 41 patients (68.3%). The median maximum size of tumors was 26mm (range 8-184mm). Overall survival was 30.3 months. Progression free survival was 4.8 months. Initial evaluation with contrast enhanced CT was done (mean 45days later) with modified RECIST (Response Evaluation Criteria in Solid Tumors). Overall response rate was 65% (complete response 13, partial response 26). Disease control rate was 86.7% (stable disease 13, Progressive disease 8). At the time of initial evaluation, 8 patients’ liver function had dropped to Child Pugh B (13.3%).

Conclusion: Although TACE with a fine cisplatin powder and porous gelatin particles for the whole liver was effective for the tumor reduction, we have to be careful not to lose liver function for further post-treatment.

Abstract Submission No. 101658
O-0672

Current status of initial treatment for elderly patients with hepatocellular carcinoma

Hidenori Kido¹, Tatsuya Yamashita¹, Taro Yamashita¹
¹Graduate School of Medical Science, Kyoto Prefectural University of Medicine Kyoto Japan

Methods: 12 patients underwent GSA, MRI, and ICG-R15 testing before treatment, 1 month after treatment, and 3 months after treatment. All patients underwent imaging studies and blood tests at the beginning of treatment, 1 month after treatment, and 3 months after treatment ended. The evaluation items were as follows: 1) changes over time in Child-Pugh classification, ICG-R15, and ALBI values before and after SBRT; 2) changes over time in GSA count and ICG; and 3) selection of the optimal sequence for recognizing radiation hepatitis on MRI.

Results: The ICG values were 14.4 before RT, 17.1 after 1 month, and 17.6 after 3 months. ICG worsened after 1 month of treatment, but was similar after 3 months. ALBI values were -2.61 before RT, -2.67 after 1 month, and -2.71 after 3 months. ALBI worsened slightly over time.

Conclusion: Regarding the ICG-R15, there was an average worsening of 2.8 after 1 month of treatment compared with before SBRT, but only of 0.5 between 1 month and 3 months after SBRT. Therefore, evaluation using ICG-R15 after SBRT after 1 month alone may be sufficient.
Background: To decide the treatment strategy for hepatocellular carcinoma (HCC), not only hepatic reserve and tumor conditions, but also comorbidities and age are considered. There are no clear criteria for comorbidities and age as indications for treatment for HCC.

Methods: We reviewed 317 patients who underwent standard treatment (resection or RFA) for HCC of less than 3 cm and 3 or less during the period from January 2009 to December 2018 at our institution and analysis background liver disease, tumor conditions, hepatic reserve, and prognosis Furthermore, we compared across the age groups of 65 years (WHO criteria for elderly patients) and 80 years (age group excluded from the SURF study).

Results: In 293 of 317 patients (92%), prognosis, including recurrence and cause of death, was traceable. Overall, 62.8% had a single tumor, mean tumor diameter 18.9 mm, Child-Pugh Score A in 79.4%, median OS 70 months, median RFS 24 months, 3-year survival 78.9%, 5-year survival 55.8%, and other disease death. Of the 317 patients, 91 were younger than 65 years, 178 were 65-79 years, and 48 were older than 80 years. Tumor conditions and liver reserve were similar for all ages. For patients <65/65-79/80< years old, median OS was 85/68/55 months, median RFS was 27/24/24 months, 3-year survival rate was 82/79/69%, and 5-year survival rate was 69/59/48%. The cause of death in 43/37/33% of the patients was liver cancer death and 31/39/53% from other diseases. 2 in the 65-79 age group and 2 in the 80< age group had comorbidity as a prognostic factor before initial treatment, and only one of each of these patients actually died of other causes.

Conclusion: Tumor conditions and hepatic reserve were similar in each generation, but the prognosis was significantly worse in the elderly, with more deaths from other causes. It should be noted that these results were obtained even in a population in which the standard of care was judged to be appropriate after discussion at the Cancer Board. The results suggest that a new criteria for determining Fit or Unfit for standard treatment is needed.

Relevance of the study: The cardiotoxic effect of chemotherapy can be manifested by a large spectrum of changes on the ECG, among which tachycardia, changes in the ST segment and T wave, ectopic atrial rhythms, intraventricular blockages, prolongation of the QTc interval, and complete blockage of the right leg of the Gis bundle and blockage of the anterior-upper branching were recorded in 4 patients, 2 of them received gemcitabine and 2 oxaliplatin therapy. Resting heart rate was significantly higher in the targeted therapy group (88.4±12.8 per minute versus 74.3±10.8 per minute, p=0.047). Also, resting heart rate was significantly higher in the targeted therapy group versus the TACE group (88.4±12.8 per minute versus 74.3±10.8 per minute, p=0.047).

Conclusions: Early detection of initial abnormalities, including on an ECG, can help to correct chemotherapy and prevent fatal complications in this group of severe patients.

Impact of surgical resection of initially unresectable HCC after LEN or ATZ+BEV treatment

Yoshihiro Sakamoto1, Hirokazu Momose1, Naohiro Okano1, Ryota Matsuaki2, Nobuhiro Hasui3, Masaharu Kogure1, Yutaka Suzuki1, Shuichi Hironaka1

1Kyorin University Hospital Tokyo Japan

Background: Recent introduction of immune-checkpoint inhibitors or targeted therapy has facilitated the surgical resection after drug therapy for initially unresectable hepatocellular carcinoma (HCC).

Methods and Patients: Between 2018 and 2023, 39 consecutive patients who received lenvatinib (LEN) or atezolizumab + bevacizumab (ATB) for initially unresectable HCC.
patients with 4 or more nodule (n = 14), refractoriness to TACE (n = 11), extrahepatic diseases (n = 16) or v3 or v3 (n = 8) and others (n = 3).

Results: Responses to LEN and ATB were PR in 5% and 20%, SD in 53% and 40%, PD in 10% and 0%, respectively in mRECIST. No significant difference was found in the disease control rates between LEN and ATB (63% vs 40%, p = 0.15). Surgical resection was performed in five patients (13%) who received LEN (n = 2) and ATB (n = 3). Progression survival was better in 5 patients who underwent surgery than in 18 patients who continued non-surgical treatments after first therapy (median, 18 vs 6 months, p = 0.02). However, no significant difference was found in disease specific overall survivals between patients undergoing surgery and non-surgical treatments (median, 23 vs 22 months, p = 0.24).

Conclusion: Aggressive surgery for initially unresectable HCC after LEN and ATB treatments offered favorable progression free survival. Local therapy after systemic therapy may play an important role in the treatment of advanced HCC.

Abstract Submission No. 101817
O-0676

Influence of DOAC on bleeding events of atezolizumab and bevacizumab therapy
Masaki Kawabata1, Tasuku Nakabori1, Kaori Mukai1, Kazuyoshi Ohkawa1
1Osaka International Cancer Institute Osaka Japan

Background: Bevacizumab has the bleeding risk, because bevacizumab inhibits angiogenesis. DOACs (Direct Oral Anti Coagulants) are increasingly used in cancer patients because of their attractive characteristics such as no coagulation test monitoring required. There are concerns that the combination of bevacizumab and DOACs may increase bleeding events. We analyzed the influence of DOACs on bleeding risk during atezolizumab and bevacizumab regimens (Atezo/Bev).

Methods: The retrospective study included 59 patients with hepatocellular carcinoma (HCC) and 82 patients with lung cancer who received Atezo/Bev. Exclusion criteria were the administration of antithrombotic agents other than DOACs.

Results: No significant difference was observed in bleeding events between the DOAC group (1/11 patients, none with Gr.2 or higher) and the no-antithrombotic drug (14/130 patients, 4 patients with Gr.2 or higher) groups (p=1.000). Regarding factors contributing to bleeding events, DOAC administration had a HR of 1.357; 95% CI: 0.175-10.54; p=0.770. Multivariate analysis showed that hypalbuminemia was an independent factor contributing to bleeding (HR 0.298; 95% CI: 0.105-0.847; p=0.006). As for analysis of only patients with HCC, bleeding events were not observed in the DOAC group (5 patients), but occurred in 8 patients in the no-antithrombotic agent group (8/54 patients, 3 patients with Gr.2 or higher) with no significant difference (p=0.808). High ALBI score was an independent factor contributing to bleeding (HR 9.083; 95% CI: 1.118-73.76; p=0.039).

Conclusions: In the DOAC group, there were no cases in which Atezo/Bev was discontinued due to bleeding. Atezo/Bev may be safely administered under surveillance in patients taking DOAC.

Abstract Submission No. 101824
O-0677

Development of a new model to predict survival duration with HCC patients in BCLC C stage

Masashi Ninomiya1, Mio Tsuruoka1, Jun Inoue1, Atsushi Hiraoka2, Hidekatsu Karuda1, Takayoshi Okawa1, Tamami Abe1, Masashi Fujita4, Kazumichi Abe5, Yoshiyuki Ueno6, Chikara Iino7, Wataru Sato8, Nobukazu Tanabe9, Hiroshi Numao10, Atsushi Masamune1
1Tohoku University Hospital Sendai Japan, 2Ehime Prefectural Central Hospital Matsuyama Japan, 3Iwate Medical University Shiwa Japan, 4Fukushima Medical University School of Medicine Fukushima Japan, 5Yamagata University Faculty of Medicine Yamagata Japan, 6Graduate School of Medicine, Akita University Akita Japan, 7Hiroaki University Graduate School of Medicine Hirosaki Japan, 8National Hospital Organization Sendai Medical Center Sendai Japan, 9Aomori Prefectural Central Hospital Aomori Japan

Background: Systemic therapy is mainly indicated for HCC patients in advanced stage. It is difficult to evaluate the individual therapy whether it is appropriate or not in real world. Recently, we have developed a Weibull model prediction of survival duration in patients with intermediate stage (Sci Rep 2023). Based on this model, we next aimed to develop a new model to predict survival duration in patients with advanced stage.

Methods: 750 patients from 2005 to 2017 were enrolled in this cohort. Any therapies were admitted but just one TKI, Sorafenib, could be used. The survival related factors were extracted by the cox proportional hazard regression model. The expectation of survival duration model was developed by exponentiated Weibull distribution.

Results: The median ALBI score was -2.18. Macrovascular invasion shown 76.7% and extrahepatic metastases was 35.3%. The multivariate Cox proportional hazards analysis showed significant difference in ALBI score including with T-bil, albumin and AFP, age, naive or recurrence, the number of nodules, the size of the largest nodule, the presence of macrovascular invasion and extrahepatic metastases. The survival curb continuously corresponded with exponentiated Weibull distribution. The new survival model for patients with BCLC C stage was developed based on these nine factors.

Conclusion: This survival model is useful in epidemiologic research and in clinical practice for patient counseling, prognostication and comparison with survival duration after multi MTA era.

Abstract Submission No. 101853
O-0678

Biomarker discovery for HCC detection and prognosis via plasma cfDNA methylome profiling
Xiaozhou Zhou1,2, Pin Cui1, Xinfeng Sun1,2, Jialing Sun1,2, Weihuang He3, Bingding Huang4, Ruyun Ruan4, Zhiyi Han1,2, Yuanke Pan1, Jinxin Zhu1, Jing Li5, Xin Zhong5, Wenxing Feng6, Mengqing Ma1,2, Rui Hu1,2
1Shenzhen Traditional Chinese Medicine Hospital shenzhen China, 2Department of Liver Disease, the fourth Clinical Medical School, Guangzhou University of Chinese Medicine Shenzhen China, 3Shenzhen Rapha Biotechnology Incorporate Shenzhen China, 4College of Big Data and Internet, Shenzhen Technology University Shenzhen China

Purpose: This study aims to develop methods for detection, prognosis and stratification of HCC using plasma cfDNA methylome profiling using whole genome bisulfite sequencing (WGBS) and targeted bisulfite sequencing (TBS).

Experimental Design: Plasma cfDNAs were isolated from a total of 311 participants including 70 healthy individuals, 46 patients with HBV, 45 patients with cirrhosis, and 150 HCC patients. Two cfDNA
methylations were performed using WGBS and TBS, respectively, and a machine learning method for cancer detection based on genome wide differentially methylated regions (DMRs) between HCC and other groups was used to establish early detection, prognosis and stratification model for HCC.

**Results:** WGBS analysis achieved overall sensitivity of 85.37% at 82.35% specificity to discriminate all stages of HCC patients from healthy people, and sensitivity of 92.31% at 88.24% specificity to discriminate early stage HCC patients from healthy people, while the TBS analysis showed better performance of 95.65% sensitivity at 83.33% specificity to discriminate all stages of HCC patients from healthy people, and sensitivity of 85.71% at 83.33% specificity to discriminate early stage HCC patients from healthy people. Additionally, a number of significant DMRs between HCC and non-cancer groups were identified, providing candidate biomarkers for HCC detection and prognosis.

**Conclusions:** This study provides preliminary proof for the feasibility of plasma cfDNA methylomes profiling for HCC detection, staging and prognosis. WGBS showed genome wide methylation profile while TBS provide in-depth analysis of highly relevant genomic regions with discrepancies of methylation levels between different groups yielding potential biomarkers for HCC detection.

Abstract Submission No. 101867
O-0679

**Risk of HCC occurrence after antiviral therapy for CHC:** A systematic review and meta-analysis

**George Lau**<sup>1,2</sup>, **Gui-ji Lv**<sup>2,3</sup>, **Dong Ji**<sup>2,4</sup>, **Ling-xiang Yu**<sup>2</sup>, **Hongyan Chen**<sup>2</sup>, **Jing Chen**<sup>6</sup>, **Meng-wen He**<sup>4</sup>, **Wen-chang Wang**<sup>4</sup>, **Hongbo Wang**<sup>2</sup>, **Jianjun Wang**<sup>2</sup>, **Ming-lung Yu**<sup>2</sup>

1. Humanity and Health Medical Group Hong Kong Hong Kong, 2. Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 3. Peking University 302 Clinical Medical School Beijing China, 4. Chinese PLA Medical School Beijing China, 5. Hospital of North China Electric Power University Beijing China, 6. JCU School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong Hong Kong SAR China, 7. Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital Kaohsiung Taiwan

**Background:** The risk of hepatocellular carcinoma (HCC) occurrence following anti-viral therapy in patients with chronic hepatitis C (CHC) remains unclear. The study aimed to estimate HCC occurrence rate following sustained virological response (SVR), among different subgroups.

**Methods:** A search was performed for articles published between January 1, 2017 and July 2022. Studies were included if they assessed HCC occurrence rate in CHC patients following anti-HCV therapy. Random effect meta-analysis was used to synthesize the results from individual studies.

**Results:** A total of 27 studies including 33,500 patients (IFN-based=6, DAA=21; prospective=10, retrospective=17) were included in the review. HCC occurrence was significantly lower in CHC patients with SVR (1.52 patient-year (py), 95% CI 1.45, 1.61) in CHC patients who achieved SVR which was significantly lower than those in non-responders (0.23 py, 95% CI 5.29, 7.34). Stratified by HCV treatment regimens, HCC occurrence following SVR was 1.11 per 100 py (95% CI 0.95, 1.30) and 1.59 per 100 py (95% CI 1.50, 1.68) in IFN- and DAA-treated based studies. HCC occurrence was 1.18 per 100 py (95% CI 1.12, 1.24) across all fibrosis stages and rose to 1.62 per 100 py (95% CI 1.39, 1.89) in studies focussed on advanced fibrosis or cirrhosis. Further meta-regression analysis showed that neither treatment type nor liver fibrosis stage was associated with a higher HCC occurrence rate.

**Conclusion:** HCC occurrence was significantly lower in SVR population than in NR population. However, we found no significant difference in HCC risk following SVR between two therapies or different fibrosis stages.

Abstract Submission No. 101911
O-0680

**Association of ABO blood groups and Rhesus factor with primary liver cancer:**

**Liyan Dong**<sup>1,2</sup>, **Yuhang Yin**<sup>1,2</sup>, **Huiyuan Lu**<sup>1-3</sup>

1. General Hospital of Northern Theater Command Shenyang China, 2. China Medical University Shenyang China, 3. Shenyang Pharmaceutical University Shenyang China

**Background:** Primary liver cancer (PLC) is one of the most common cancers worldwide. ABO blood groups and Rhesus (Rh) factor are inherent characteristics. Their association with the presence of PLC remains unclear in cirrhotic patients.

**Methods:** Patients with liver cirrhosis who were consecutively admitted to our hospital from January 1, 2010 to June 30, 2014 were retrospectively screened. Logistic regression analyses were performed to explore the association of ABO blood groups and Rh factor with PLC in cirrhotic patients. Adjusted odds ratios (aORs) with 95% confidence intervals (CIs) were calculated after adjusting for gender, age, family history of liver cirrhosis, HBV-DNA positivity, and etiology of cirrhosis. Subgroups analyses were performed according to different etiologies of liver cirrhosis.

**Results:** Overall, 1158 cirrhotic patients without PLC and 240 cirrhotic patients with PLC were included. After adjusting for confounding factors, non-O blood group (aOR=0.763; 95%CI=0.449-1.298, p=0.319), A blood group (aOR=0.643; 95%CI=0.332-1.246, p=0.191), B blood group (aOR=0.835; 95%CI=0.453-1.540, p=0.564), AB blood group (aOR=0.888; 95%CI=0.363-2.170, p=0.795), and Rh (+) (aOR=0.239; 95%CI=0.036-1.571, p=0.136) were not independently associated with PLC in cirrhotic patients. In the subgroup analysis of HBV-related cirrhotic patients, the proportion of A blood group was significantly lower in cirrhotic patients with PLC than those without (24.17% vs. 33.99%, p=0.001; however, in those of HCV and alcohol-related cirrhotic patients, the proportions of ABO blood groups and Rh factor were not significantly different between the two groups.

**Conclusions:** ABO blood groups and Rh factor may not be associated with the presence of PLC in liver cirrhosis.

Abstract Submission No. 101921
O-0681

**Non-contrast Abbreviated MRI for the Detection of Hepatocellular Carcinoma**

**Soe Thiha Maung**<sup>1</sup>, **Roongruedee Chaiteerakij**<sup>1,2</sup>

1. Division of Gastroenterology, Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2. Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

**Background/Aim:** Given limited ultrasound sensitivity in hepatocellular carcinoma (HCC) surveillance, and few prospective studies exploring non-contrast abbreviated MRI (NC-AMRI) for this purpose,
this study aimed to assess diagnostic performance of NC-AMRI in detecting HCC.

**Materials and Methods:** This ongoing prospective study involves cirrhotic patients with LI-RADS LR-2, LR-3, and LR-4 findings in MRI. Patients underwent one to three complete contrast-enhanced MRI rounds (CE-MRI). NC-AMRI included diffusion-weighted (DWI), T1-weighted gradient imaging (T1WI), and T2-weighted imaging (T2WI-FS). Diagnostic performances of surveillance protocols were analyzed.

**Results:** In 101 follow-up CE-MRI examinations, the median (IQR) age of patients is 64 years (55-70), comprising 61% males and 39% females. Hepatitis C (37%) and hepatitis B (33%) were the predomina

**Abstract Submission No. 101984**

**O-0683**

**Factors enhancing local control of TACE recommended in BCLC strategy 2022-update for BCLC-0&A HCC**

Ken Kageyama1, Kazuo Asano1, Akira Yamamoto1, Atsushi Jogo1, Mariko Nakano1, Kazuki Murai1, Masanori Ozaki1, Shohei Harada1, Kazuki Matsuishi1, Yuki Sakai1, Eisaku Terayama1, Yukio Miki1

1Osaka Metropolitan University Osaka Japan

**Backgrounds:** BCLC strategy 2022-update recommended TACE as an alternative treatment when curative treatment is not possible. This study aims to clarify therapeutic effects of TACE on single, treatment-naive HCC corresponding to BCLC stage 0&A HCC. Factors enhancing local control effect of TACE were retrospectively evaluated.

**Methods:** This study investigated cases of Lip-TACE performed between 2010 and 2019. Factors contributing to local control effect were age, sex, Child-Pugh Score, tumor diameter, location, AFP, PI伏KA-II, number of vessels to tumor, and Lipiodol accumulation around tumor. Local recurrence free survival (LRFS) was statistically evaluated using Kaplan-Meier curves.

**Results:** Seventy-three cases were included in this study. Median LRFS for 73 nodules was 76.3 months. The peripheral tumor-location group, the single feeder group, and the group with Lipiodol accumulation around tumor had a longer LRFS than the central tumor group, the multiple feeder group, and the group without Lipiodol accumulation around tumor, respectively (median LRFS: Unreached vs. 9.9 months; Unreached vs. 5.6 months). In multivariate analysis, the peripheral tumor group, the multiple feeder group, and the group with Lipiodol accumulation around tumor showed a high hazard ratio for shortening LRFS (hazard ratio; 3.81; 1.80; 1.98) with Lipiodol accumulation around tumor. In multivariate analysis, the peripheral tumor group, the multiple feeder group, and the group with Lipiodol accumulation around tumor showed a high hazard ratio for shortening LRFS (hazard ratio; 3.81; 1.80; 1.98).

**Conclusions:** Factors enhancing local control effect of TACE for BCLC stage 0&A HCC was identified.

Abstract Submission No. 102028

**O-0684**

**Factors enhancing local control effect of TACE recommended in BCLC strategy 2022-update for BCLC-0&A HCC**

Ken Kageyama1, Kazuo Asano1, Akira Yamamoto1, Atsushi Jogo1, Mariko Nakano1, Kazuki Murai1, Masanori Ozaki1, Shohei Harada1, Kazuki Matsuishi1, Yuki Sakai1, Eisaku Terayama1, Yukio Miki1

1Osaka Metropolitan University Osaka Japan

**Backgrounds:** BCLC strategy 2022-update recommended TACE as an alternative treatment when curative treatment is not possible. This study aims to clarify therapeutic effects of TACE on single, treatment-naive HCC corresponding to BCLC stage 0&A HCC. Factors enhancing local control effect of TACE were retrospectively evaluated.

**Methods:** This study investigated cases of Lip-TACE performed between 2010 and 2019. Factors contributing to local control effect were age, sex, Child-Pugh Score, tumor diameter, location, AFP, PI伏KA-II, number of vessels to tumor, and Lipiodol accumulation around tumor. Local recurrence free survival (LRFS) was statistically evaluated using Kaplan-Meier curves.

**Results:** Seventy-three cases were included in this study. Median LRFS for 73 nodules was 76.3 months. The peripheral tumor-location group, the single feeder group, and the group with Lipiodol accumulation around tumor had a longer LRFS than the central tumor group, the multiple feeder group, and the group without Lipiodol accumulation around tumor, respectively (median LRFS: Unreached vs. 9.9 months; Unreached vs. 5.6 months). In multivariate analysis, the peripheral tumor group, the multiple feeder group, and the group with Lipiodol accumulation around tumor showed a high hazard ratio for shortening LRFS (hazard ratio; 3.81; 1.80; 1.98). LRFS was significantly longer in these 3-factor integration group than in the others (Unreached vs. 16.2 months). The 1-year local control rate was 85.1% vs. 54.9%, and Both 3- and 5-year local control rates were 77.6% vs. 36.5%.

**Conclusions:** Factors enhancing local control effect of TACE for BCLC stage 0&A HCC was identified.
Insulin Growth Factor-1 Level as a Disease Course Predictor in Hepatocellular Carcinoma Patients

Muhammad Bilal Saifulhaq1, Tohari Amin1, Syifa Mustika2, Alfatea Pintari Rahmi3
1Internal Medicine Department, Saiful Anwar Regional Hospital and Brawijaya University Malang Indonesia, 2Gastroenterology Division of Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia, 3Medical Faculty of Brawijaya University Malang Indonesia

Background: The insulin-like growth factor (IGF) axis has important autocrine, paracrine and endocrine roles in growth promotion. Alterations of the IGF system have recently been implicated in the pathogenesis of several malignancies, but the relation to hepatocellular carcinoma (HCC) risk is unclear. This study aimed to determine whether serum IGF-1 level predicts the progression and survival in HCC patients.

Methods: According to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines, we systematically searched Pubmed, EMBASE and Cochrane Central database through the end of October 2023 to identify all studies reporting association between serum IGF-1 level and HCC. A total of 13 cohort studies with calculation of relative risk (RR) of serum IGF-1 for HCC time-to-progression (TTP) and overall survival (OS) were subjected to statistical analysis using STATA 17. We assessed the ability of serum IGF-1 to predict HCC progression and survival using random effect model to estimate pooled RR. Heterogeneity among studies was assessed by the Cochran’s Q and I² statistics. Publication bias was analysed using a Begg funnel plot and Egger test.

Results: The meta-analysis of selected studies showed that low level of serum IGF-1 significantly predicted shorter TTP (RR 2.36; 95% CI 1.51-3.68) and poorer OS (RR 2.17; 95% CI 1.72-2.74) in HCC patients, p value=0.00.

Conclusions: IGF-1 serum level independently predicted the progression and survival in HCC patients. Larger scale studies are needed to investigate the relationship explanation.

Abstract Submission No. 102044
O-0685

Efficacy and safety of arterial infusion chemotherapy in patients with Child-Pugh class B

Masatsugu Ishii1, 2, Satoshi Itano3, Osamu Itano3
1Department of Gastroenterology, Kurume Chuo Hospital. Fukuoka Japan, 2Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center. Tochigi Japan, 3Department of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare. Chiba Japan

Introduction: Although many treatment options are available for patients with advanced hepatocellular carcinoma and Child-Pugh class A, those for patients with Child-Pugh class B remain limited. We aimed to assess the safety and efficacy of hepatic arterial infusion chemotherapy using 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma and Child-Pugh class B.

Methods: Sixty patients who received hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin at Kurume Chuo Hospital between April 2012 and March 2021 were recruited. Cisplatin (30 mg administered over 2 hours) and 5-fluorouracil (1,250 mg, 72-hour constant infusion) were administered to the tumor-feeding artery every 2 weeks. The primary endpoint was overall survival, while the secondary endpoints were progression-free survival and adverse effects.

Results: Among the 60 patients, Child-Pugh class A and class B were noted in 30 patients each. Overall survival did not significantly differ between the two classes. After 4 weeks of hepatic arterial infusion chemotherapy with 5-fluorouracil and cisplatin, 12 patients in the class B group exhibited improved Child-Pugh scores relative to those at the start of treatment. There was a significant difference in overall survival between patients whose Child-Pugh scores had improved and those whose scores remained unchanged or had worsened.

Conclusions: Hepatic arterial infusion chemotherapy using 5-fluorouracil and cisplatin is effective and safe for patients with Child-Pugh class B, and improvements in Child-Pugh scores after 4 weeks of this therapy may represent a predictive marker of treatment efficacy regardless of pretreatment Child-Pugh score in Child-Pugh B patients.

Abstract Submission No. 102050
O-0686

Systemic Therapy in HCC Patients with Marginal Liver Function: Atezolizumab/Bevacizumab vs Sorafenib

Wonseok Kang1, 2, Aroung Kim1, Myung Ji Goh1, Byeong Geun Song1, Dong Hyun Sinn1, Geum-Youn Gwak1, Yong-Han Paik2, Moon Seok Choi1, Joon Hyeok Lee1
1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine Seoul South Korea, 2Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University Seoul South Korea

Background and Aim: The superiority of the combination of atezolizumab with bevacizumab (atezo/bev) in unresectable hepatocellular carcinoma (uHCC) patients with marginal liver function remains uncertain. The goal of the study is to compare the efficacy and safety of atezo/bev to sorafenib in real-world patients with uHCC with marginal liver function.

Method: This single institution retrospective cohort study analyzed patients with uHCC whose liver function improved from Child-Pugh B to Child-Pugh A through supportive care, and subsequently received atezo/bev (n=32) or sorafenib (n=32) as first-line therapy between August 2020 and February 2023. Outcomes were progression free survival (PFS), overall survival (OS), and adverse events (AEs).

Results: In patients with baseline liver function of Child-Pugh B, atezo/bev had significantly better PFS than sorafenib (mPFS 4.3 vs. 2.7 months, log rank p = 0.024) and a tendency to improved OS (mOS 8.3 vs. 6.6 months, log rank p = 0.13). When compared to sorafenib, atezo/bev significantly improved PFS, particularly in patients with Child-Pugh B7 (mPFS 4.3 vs. 2.4 months, log rank p = 0.009) or a serum AFP level of 200 ug/ml or higher (mPFS 2.9 vs. 2.4 months, log rank p = 0.038). The two groups reported different types of AEs, but there was no difference in the incidence of overall AEs including bleeding.

Conclusion: Atezo/bev may be recommended as the first-line treatment of choice for patients with marginal liver function, especially for those with Child-Pugh B7, based on both efficacy and safety.

Abstract Submission No. 102077
O-0687

Liver resection for hepatocellular carcinoma focused on the fourth branch of the portal vein

Shingo Shimada1, Hiroyuki Takahashi1, Shoichiro Mizukami1, Kai Makino1, Hiroki Takahata1, Koji Imai1, Hideki Yokoo1
1Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center. Tochigi Japan
Background: The third branch of the portal vein could be removed in the segmentectomy for hepatocellular carcinoma (HCC). This study aims to investigate whether removing the fourth portal branch affects the outcome after liver resection (LR) for HCC less than segmentectomy.

Methods: Patients who received LR less than segmentectomy for solitary HCC between 2015 and 2022 were evaluated. Compared presurgically to postsurgical dynamic-computed tomography (CT), patients were divided into two groups; patients who received the removal of the fourth portal branch which was the tumor responsibility as Anatomical (A) group, and the other as Non-anatomical (NA) group.

Results: Of the 258 LRs for HCC, 96 were eligible. Maximum tumor diameter was 2.2 (0.7-10) cm, and the proportion of portal and hepatic venous invasion were 18%, and 15%. Median operation time and blood loss were 315 (118-874) minutes, and 66 (0-3007) ml. The 5-year overall survival (OS) rate was 74.8%, and median survival time (MST) for recurrence-free survival (RFS) was 54 months. Comparing groups A (n=51) and NA (n=45), oncological covariates were similar, but group A showed a lower risk for recurrence (aHR 0.44, 95%CI 0.21-0.91, P=0.02).

Conclusions: LR with the accurate removal of the fourth portal branch might lead to a reduction of short-term recurrence in the remnant liver.

Abstract Submission No. 102081
O-0688

the prediction models for post-hepatectomy liver failure based on the type IV collagen 7s domain

Takuma Okada1, Hiroji Shinkawa1, Koichi Nakanishi1, Naoki Tani1, Takahito Kawaguchi1, Shuei Kushiyama1, Shigeaki Kurihara1, Ryota Tanaka1, Masahiko Kinoshita1, Kohei Nishio1, Go Ohira1, Kenjiro Kimura1, Shogo Tanaka2, Shoji Kubo1, Takeaki Ishizawa1

1Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine Osaka city Japan, 2Department of Hepato-Biliary-Pancreatic Surgery, Izumi city general hospital Osaka Japan

Backgrounds: We aimed to develop the prediction models for post-hepatectomy liver failure (PHLF) based on the type IV collagen 7s domain (7s collagen) in patients with hepatocellular carcinoma (HCC).

Methods: We retrospectively collected the data from 972 patients with hepatocellular carcinoma (HCC) who underwent initial and curative liver resection between February 2000 and December 2020 in our hospital. Multivariable logistic regression analysis using a restricted cubic spline was performed to evaluate the effect of 7s collagen on the incidence of PHLF. The nomogram was developed based on 7s collagen.

Results: PHLF grade B or C was identified in 104 patients (11%), of which 98 patients (10%) for PHLF grade B, 6 patients (1%) for PHLF grade C. In multivariate logistic regression analysis, preoperative serum level of 7s collagen was significantly associated with a proportional increase in PHLF risk. Its correlation with PHLF risk was confirmed in both laparoscopic and open liver resections. Alanine aminotransferase, Child-Pugh class B, 7s collagen, open liver resection, and extent of liver resection were found to be independent risk factors for PHLF. We developed the nomogram based on 7s collagen with a concordance index of 0.763.

Conclusion: 7s collagen is a useful predictive factor for PHLF. The current nomogram using 7s collagen would be useful to predict PHLF risk.

Abstract Submission No. 102087
O-0689

Outcomes of surgical resection of hepatocellular carcinoma with non-alcoholic fatty liver disease

Takatsugu Matsumoto1, Takayuki Shiraki1, Genki Tanaka1, Takamune Yamaguchi1, Kyung-Hwa Park1, Shozo Mori1, Yukihiro Iso1, Mitsuru Ishizuka1, Keiichi Kubota2, Taku Aoki1, Maiko Niki1

1Dokkyo Medical University Mibu-cho Japan, 2Tohto Bunkyo Hospital Tokyo Japan

Background: It has been reported that there are oncological differences between hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease (NAFLD) and HCC related to viral infections. However, the surgical short-term and long-term outcomes of NAFLD-related HCC remain unclear.

Methods: We retrospectively analyzed patients who underwent hepatectomy for HCC among a total of 1,047 cases. Patients with NAFLD and those with viral hepatitis infection were included in the analysis. Clinical, surgical, and pathological results were compared between the two groups. Postoperative survival rates and patterns of recurrence were also analyzed for both groups.

Results: The NAFLD group consisted of 57 patients, while the viral hepatitis (VH) group consisted of 727 patients. Body mass index (BMI) and serum HbA1c levels were significantly higher in the NAFLD group than in the VH group (BMI: 23.8 vs. 22.6; p=0.003, HbA1c (%): 6.4 vs. 5.3; p<0.001). There were no significant differences in serum albumin, serum bilirubin levels, Child-Pugh classification, or degree of liver damage between the two groups. In terms of short-term outcomes, there were no significant differences in operative time, bleeding volume, complication rates, or length of postoperative hospital stay between the groups. Pathologically, tumor size was significantly larger in the NAFLD group than in the VH group (4.7 cm vs. 2.7 cm, p=0.003), and there was a tendency for more advanced UICC stage in the NAFLD group. Overall survival and recurrence-free survival did not significantly differ between the two groups (5-year overall survival rate (%): 58.1 vs. 52.8, p=0.827; 5-year recurrence-free survival rate (%): 29.6 vs. 21.3, p=0.827). However, the NAFLD group had a significantly higher incidence of extrahepatic recurrence compared to the VH group (15.1% vs. 3.8%, p<0.001). Furthermore, in a subgroup analysis with matched tumor sizes, NAFLD-HCC patients demonstrated better postoperative outcomes (5-year overall survival rate (%): 78.6 vs. 55.3, p=0.023; 5-year recurrence-free survival rate (%): 83.3 vs. 19.8, p<0.001).

Conclusions: Surgical outcomes following hepatectomy for NAFLD-HCC were found to be comparable to those for VH-HCC. For NAFLD-HCC patients, early detection, surgical resection, and active intervention for extrahepatic metastasis and recurrence may lead to improved prognosis.

Abstract Submission No. 200007
O-0690

2D-SWE in HCC: Accessing and Predicting Liver Function

Jiayao Huang1, Haiyi Long1, Xian Zhong2, Xiaoyan Xie3, Manxia Lin1

1Dept of Hepatobiliary Pancreatic and Transplant Surgery, Ashikawa Medical Univ Ashikawa Japan

Background: It has been reported that there are oncological differences between hepatocellular carcinoma (HCC) related to non-alcoholic fatty liver disease (NAFLD) and HCC related to viral infections. However, the surgical short-term and long-term outcomes of NAFLD-related HCC remain unclear.

Methods: We retrospectively analyzed patients who underwent hepatectomy for HCC among a total of 1,047 cases. Patients with NAFLD and those with viral hepatitis infection were included in the analysis. Clinical, surgical, and pathological results were compared between the two groups. Postoperative survival rates and patterns of recurrence were also analyzed for both groups.

Results: The NAFLD group consisted of 57 patients, while the viral hepatitis (VH) group consisted of 727 patients. Body mass index (BMI) and serum HbA1c levels were significantly higher in the NAFLD group than in the VH group (BMI: 23.8 vs. 22.6; p=0.003, HbA1c (%): 6.4 vs. 5.3; p<0.001). There were no significant differences in serum albumin, serum bilirubin levels, Child-Pugh classification, or degree of liver damage between the two groups. In terms of short-term outcomes, there were no significant differences in operative time, bleeding volume, complication rates, or length of postoperative hospital stay between the groups. Pathologically, tumor size was significantly larger in the NAFLD group than in the VH group (4.7 cm vs. 2.7 cm, p=0.003), and there was a tendency for more advanced UICC stage in the NAFLD group. Overall survival and recurrence-free survival did not significantly differ between the two groups (5-year overall survival rate (%): 58.1 vs. 52.8, p=0.827; 5-year recurrence-free survival rate (%): 29.6 vs. 21.3, p=0.827). However, the NAFLD group had a significantly higher incidence of extrahepatic recurrence compared to the VH group (15.1% vs. 3.8%, p<0.001). Furthermore, in a subgroup analysis with matched tumor sizes, NAFLD-HCC patients demonstrated better postoperative outcomes (5-year overall survival rate (%): 78.6 vs. 55.3, p=0.023; 5-year recurrence-free survival rate (%): 83.3 vs. 19.8, p<0.001).

Conclusions: Surgical outcomes following hepatectomy for NAFLD-HCC were found to be comparable to those for VH-HCC. For NAFLD-HCC patients, early detection, surgical resection, and active intervention for extrahepatic metastasis and recurrence may lead to improved prognosis.
Aim: The present study aimed to observe the dynamic changes in liver function from the pre- to post-hepatectomy period, and explore the correlation between hepatic tow-dimensional shear wave elastography (2D-SWE) measurement and pre- and post-hepatectomy liver function in patients with hepatocellular carcinoma (HCC) and chronic hepatitis B (CHB).

Material and Methods: From August 2019 to August 2023, 250 patients with treatment-naive HCC as well as CHB undergoing hepatectomy were consecutively enrolled. Before reaching the study endpoint (recurrence, death, or initiation of subsequent treatment for HCC), patients were followed up for one year. Liver function and other relevant indicators of liver condition were collected at postoperative day 5, 1 month, 3 months, 6 months, and 12 months, respectively. Statistical analysis was conducted to explore the correlation between 2D-SWE measured liver stiffness (LS) and liver function during the follow-up.

Results: Correlation analysis showed that the pre-operative measurement of LS was positively correlated with pre-operative liver function indicators (represented by the most commonly used Child-Pugh and albumin-bilirubin systems, both with \( p < 0.05 \)), and there was a significant positive correlation between pre-operative LS and liver function at post-operative 5 days, 1 month, 3 months, and 1 year (all with \( p < 0.05 \)). But the correlation between LS and liver function at different time points from pre-operative to post-operative was inconsistent, and receiver operating characteristic analysis revealed that the LS cutoff values for distinguishing different liver function grades were not consistent at different time points.

Conclusion: Pre-operative 2D-SWE LS measurements appeared to have a certain degree of assessment and predictive value for liver function in HCC patients with concomitant CHB, and can assist in the non-invasive and straightforward evaluation of liver function and the assessment of recovery in HCC surgery patients.
Cancer-Associated Fibroblasts (CAFs) Promote the Growth of HCC Cells Through Expressing Activin-A

Yuichi Goto1, Hisamune Sakai1, Shogo Fukutomi1, Masanori Akashi2, Shoichiro Arai1, Kazuaki Hashimoto1, Fumihiro Fujita1, Toru Hisaka1
1Department of Surgery, Kurume University Kurume Japan

Background: We have performed conversion surgery for patients with unresectable locally advanced hepatocellular carcinoma (LA-HCC) using hepatic arterial infusion chemotherapy (HAIC). Here, we examine the relationship between pathological tumor necrosis rate and prognosis.

Methods: Patients with LA-HCC who have performed conversion surgery after HAIC from 2013 to 2022 were enrolled. The tumor necrosis rate was classified into A (complete necrosis), B (necrosis >= 90%), and C (necrosis < 90%). The overall survival rates (OS), disease free survival rates (DFS) were compared and the type of recurrence in each group was investigated.

Results: Conversion surgery was performed for 31 cases. The 5-year DFS and OS was 40% and 63%. The tumor necrosis rate was as follows, A (n=7), B (n=10), and C (n=14). The 5-year OS of A, B, and C were 100%, 90%, and 19%, with significant differences observed between A and C and between B and C. However, there was no difference between A and B. The 5-year DFS for A, B, and C was 67%, 44%, and 17%, with significant differences observed in each group. Recurrence was observed in 2 patients in A, 5 patients in B, and 10 patients in C. Regarding the type of recurrence, multiple intrahepatic recurrences and extrhepatic metastases were more frequent in C.

Discussion/Conclusion: Although the overall prognosis for conversion surgery appears to be favorable, we found that it differs depending on the tumor necrosis rates. In particular, type of recurrence affected outcome of C and adjuvant chemotherapy should be indicated.

Conversion surgery for hepatocellular carcinoma; relationship between the necrosis rate and outcome

Hikmet Akkz1, Hatice Çakır2, Yunus Akkoç3
1Bahcesehir University Istanbul Turkey, 2Sabanej University, Nanotechnology Research and Application Center (SUNUM) Istanbul Türkiye, 3Koç University Translational Medicine and Research Center (KUTTAM Istanbul Turkey)

Aim: Cancer-associated fibroblasts (CAFs) are one of the most important components of the tumor microenvironment (TME) and exhibit a critical role in the proliferation and growth of cancer cells. We investigated the role of CAF-derived Activin-A in cancer cell growth in living samples obtained from tumor and nontumor tissues of patients with hepatocellular carcinoma.

Materials and Methods: Samples from tumor and peri-tumoral tissues of patients with HCC were transformed into single cells with an enzyme mixture called liberase and containing collagenase. CAFs and fibroblasts were identified according to the level of α-smooth muscle actin (α-SMA) and vimentin. The HCC cell line HepG2 was co-cultured with fibroblast and CAFs from tumor and peritumor tissues.

Results: Luciferase cell growth experiments showed that CAFs increased the growth of HepG2 cells by 4 times. A cytokine array was performed with the media from co-growth experiments. CAF-derived Activin-A increased the growth of HepG2 cells, and this effect was reduced by neutralizing antibodies against activin-A. Activin-A increased the growth of HepG2 cells when co-cultured with CAFs, and this effect was reduced in the presence of neutralizing antibodies against Activin-A. In the presence of neutralizing antibodies, this effect disappears. Experiments were proven in two separate setups with both luciferase and FALS techniques. Activin-A and its receptors were less expressed in tumor tissue.

Conclusion: CAFs in the TME of HCC promote the growth of HCC cells by Activin-A that can be inhibited by neutralizing antibodies and this molecule may be a novel target in the treatment of HCC.

Lenvatinib Combination Therapy VS Monotherapy in Unresectable Hepatocellular Carcinoma

Chrisandi Rizqiansyah1,3, Camoya Gersom1,3, Syifa Mustika1,2,3, Putu Ijiya Danta Dewantara3, Nasim Amar3, Kristian Kenji Khodjojo3, Nabilah Hanifah Mukti3, Nurlinah Amalia3
1Internal Medicine Department, Faculty of Medicine, Brawijaya University, Saiful Anwar General Hospital, Indonesia Malang Indonesia, 2Gastroenterology Division, Internal Medicine Department, Saiful Anwar General Hospital, Malang Indonesia, 3Faculty of Medicine, Brawijaya University, Saiful Anwar General Hospital Malang Indonesia

Background: The efficacy of Lenvatinib as a novel TKI has been acknowledged for first-line treatment of unresectable hepatocellular carcinoma (HCC). Lenvatinib combination therapy with PD-1 inhibitors has shown promising results. Studies which compared combination and monotherapy are still limited.

Aims: To compare the efficacy and safety of Lenvatinib-PD-1 inhibitor combination therapy and lenvatinib monotherapy in patients with HCC.

Methods: The review was performed based on the PRISMA guideline. Articles from PubMed, ScienceDirect, Cochrane, and ProQuest were identified up to November 2023 for analysis based on overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). The risk of bias was assessed according to Cochrane Risk of Bias (ROB). The pooled effect was shown in mean difference (MD) and odds ratio (OR) with 95% confidence interval (CI).

Results: 5 studies were included which analyzed Lenvatinib combination with pembrolizumab, camrelizumab, sintilimab, or nivolumab compared to Lenvatinib only for DCR, ORR, PFS, and OS. Lenvatinib-PD-1 inhibitor combination showed a significant DCR (OR 1.891, 95% CI: 1.182 - 3.026), ORR (OR 2.237, 95% CI: 1.435 - 3.486), and OS (mean difference 0.306, 95% CI: 0.084 - 0.528) compared to Lenvatinib monotherapy. 6 studies for PFS were also in favor of Lenvatinib-PD-1 inhibitor combination (mean difference 0.143, 95% CI: 0.030 - 0.256) with significant p-value result.

Conclusions: Lenvatinib-PD-1 inhibitor combination showed promising efficacy compared to lenvatinib monotherapy. Further investigations are required among combinations to analyze which may be the best choice.

Keywords: efficacy, hepatocellular carcinoma, lenvatinib, PD-1 inhibitor

Impact of albumin-lymphocyte-platelet-CRP index
on outcome in hepatocellular carcinoma

Norifumi Iseda1, Shinji Itoh1, Takeo Toshima1, Shohei Yoshiya1, Yuki Bekki1, Takuma Izumi1, Yuriko Tsutsui1, Katsuya Toshida1, Yuuki Yuuki1, Takuma Ishikawa1, Tomoharu Tomoharu1

1Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University Fukuoka Japan

Background: We have created new markers calculated from albumin, lymphocyte, platelet, and c-reactive protein (CRP). We investigated the prognostic value of preoperative albumin-lymphocyte-platelet-CRP (ALPC) index in patients with hepatocellular carcinoma (HCC) undergoing hepatectomy.

Methods: 1. We analyzed 512 patients with HCC after hepatectomy from 2001 to 2019. For cross-validation, the cases were divided into the training and testing cohort. Using the receiver operating characteristic curve, the cutoff value and the area under the curve (AUC) of ALPC were determined in the training cohort.
2. Clinicopathological factors were evaluated to identify predictors of overall (OS) and recurrence-free survival (RFS) after hepatectomy for ALPC. Univariate and multivariate analyses were performed, using the Cox proportional hazards model.
3. We examined the relationship between P-Nrf2 and ALPC index.

Results: 1. The AUC value of ALPC was 0.664. The cutoff for the ALPC index was 0.13. In the training cohort, 149 of 256 patients had ALPC of more than 0.13. High ALPC was correlated with small tumor size, low BCLC stage, low rate of poor differentiation and low rate of microscopic intrahepatic metastasis. OS and RFS were better in the high ALPC group. Multivariate analyses for prognosis factor showed that ALPC was an independent predictor RFS (P<0.01) and OS (P<0.01).

Conclusions: High ALPC index was the independent prognostic factor for HCC.

Abstract Submission No. 200121
O-0697

Laparoscopic Drainage Basin Hepatectomy Based on Cone Unit

YU CHENG1

1Binzhou Medical University Affiliated Yantai Hospital Yantai China

Background: Laparoscopic anatomical hepatectomy is mainly for liver malignant tumors, but most HCC has cirrhosis, does not allow large-scale hepatectomy. For patients with small HCC and severe cirrhosis, according to portal vein supply, the liver resection reduces the volume of hepatectomy and achieves the purpose of anatomical hepatectomy.

Methods: 12 patients with cirrhosis underlying liver cancer underwent Cone Unit-based resection. After enhanced CT or MRI, 3D reconstruction constructs the Glissonian pedical composition where tumor is located, each small pedical blood supply area acts as a cone unit, two methods determine the cone unit resection range, (1) liver gate Laennec membrane dissection is applied, one or several cone unit blood supply pedical is isolated and ligated, ICG reverse staining determines 1 or several cone unit ranges for resection; (2) Another method: ultrasound localization of cone unit Glissonian pedical and puncture portal injection of ICG, anatomical excision by puncture one or several cone unit blood supply pedicles according to preoperative planning.

Results: In all 12 patients with small HCC, 8 cases were reverse stained and 4 cases were orthostained. The median duration of surgery was 89±15 minutes and the average estimated blood loss was 103 ml. There was no liver failure. Follow-up results showed the mean DFS was 24.7m and OS 38.9 month.

Conclusion: Hepatectomy based on cone unit is a safe and effective surgical method for small HCCs with severe cirrhosis, which reduces the incidence of postoperative liver failure and reduces bleeding, thereby increasing DFS and OS of patients.

Abstract Submission No. 200275
O-0698

ICI and Systemic Therapy Comparison on Progression-Free Survival of Advanced HCC: Metaanalysis of RCT

Muhammad Bilal Saifulhaq1, Syifa Mustika2, Tohari Amin1

1Internal Medicine Department of Saiful Anwar Regional Hospital and Brawijaya University Malang Indonesia, 2Gastroenterology Division, Internal Medicine Department of Saiful Anwar Regional Hospital and Brawijaya University Malang Indonesia

Background: Recent randomized controlled trials (RCTs) in Immune-Checkpoint-Inhibitor (ICI) and systemic therapy showed promising results in advanced stage of hepatocellular carcinoma (HCC). We aimed to compare the efficacy between ICI and TKI/anti-VEGF on progression-free survival (PFS) outcome, giving particular attention to the benefits in subgroups of viral/non viral-related etiology of HCC patients.

Methods: Randomized controlled trials (RCTs) reporting PFS following either ICI or TKI/anti-VEGF and placebo in advanced-stage HCC were included in this study. We also compare the benefit on viral or nonviral-related etiology. We pooled Hazard Ratio (HR) of PFS using random effect model; Subgroup and sensitivity analyses were additionally performed. Heterogeneity among studies was assessed by the Cochran’s Q and I2 statistics. Publication bias was analysed using a Begg funnel plot and Egger test.

Results: Meta-analysis of 15 trials showed that ICI is better in improving PFS (HR 0.7; 95% CI 0.61-0.79), p value=0.00, compared to TKI/anti-VEGF with PFS (HR 0.81; 95% CI 0.73-0.90), p value=0.00. From subgroup analysis of etiology, we identified that ICI therapy was significantly more effective in patients with viral hepatitis compared to nonviral-related HCC, whereas no differences related to etiology were observed in patients treated with TKI/anti-VEGF.

Conclusions: ICI therapy demonstrated superior efficacy than TKI/anti-VEGF in improving survival of advanced-stage of HCC patients, especially in viral etiology HCC.

Abstract Submission No. 100114
O-0699

Deep learning model based on CEUS improves diagnostic ability on differentiating HCC and ICC

Ping Liang1, Jie Yu2, Wenzhen Ding3

1Chinese PLA General Hospital Beijing China, 2Chinese PLA General Hospital Beijing China, 3Chinese PLA General Hospital Beijing China

Background: The treatment and prognosis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are quite different, but it is difficult to differentiate them through conventional image examination.

Abstract Submission No. 200121
O-0697

Deep learning model based on CEUS improves diagnostic ability on differentiating HCC and ICC

Ping Liang1, Jie Yu2, Wenzhen Ding3

1Chinese PLA General Hospital Beijing China, 2Chinese PLA General Hospital Beijing China, 3Chinese PLA General Hospital Beijing China

Background: The treatment and prognosis of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are quite different, but it is difficult to differentiate them through conventional image examination.
Purpose: To develop a deep learning (DL) model based on contrast-enhanced ultrasound (CEUS) to help radiologists differentiate HCC and ICC.

Methods: We collected the CEUSs from 51 centers to train and validate the DL model through four algorithms (BNInception, mobilenetv2, resnet50, and VGG). CEUSs from another two independent centers were collected as external test set A and B to assess model performance and robustness. Six radiologists (junior, midlevel and senior radiologists, each two) were invited to compare diagnostic ability and explore the cooperation with DL model in the external test set C from a third independent center.

Results: 1005 CEUSs were included and divided to training (n=753) and validation (n=252) sets. 26, 97 and 50 CEUSs were included as external test set A, B and C. Resnet50 model had highest AUC in test set A (AUC=0.932, 95%CI 0.911-0.941) and B (AUC=0.934, 95%CI 0.912-0.944). In test set C, DL model had higher AUC than junior (0.913±0.748, p<0.001) and midlevel radiologists (0.913±0.789, p=0.011), and comparable to senior radiologists (0.913±0.871, p=0.209). With model assistance, the AUC of junior (0.748 to 0.855, p=0.017), midlevel (0.789 to 0.899, p=0.011) and senior (0.871 vs 0.948, p=0.049) radiologists were all improved.

Conclusions: DL model based on CEUS had excellent diagnostic performance and robustness, and can help various levels radiologists improve ability to differentiate HCC and ICC.

Abstract Submission No. 100321

O-0700

Ultrasound-Derived Fat Fraction (UDFF) for quantification of steatosis with reference to biopsy

Yoshiko Nakamura1, Masashi Hirooka1, Yohei Koizumi1, Makoto Morita1, Yukie Okazaki1, Yusuke Imai1, Takao Watanabe1, Osamu Yoshida1, Yoshihiko Tokumoto1, Masanori Abe1, Yoichi Hiasa1, Ryo Yano1

1Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine Toon Japan

Background & Aims: Ultrasound-derived fat fraction (UDFF) has recently developed as a noninvasive quantitative method for steatosis, which combines both attenuation and backscatter coefficients. This study analysed the diagnostic accuracy of grading steatosis with reference to liver histology.

Methods: From April 2022 to January 2023, 73 patients with liver disease underwent both UDFF and liver biopsy. UDFF cutoffs for histologically-proven steatosis grade were determined using area under the receiver-operating characteristic curve (AUROC) analyses. Linearity was evaluated using correlation coefficients between UDFF and fat accumulation in liver section. We assessed the association between clinical parameters including histology and UDFF.

Results: Median age was 66 years (IQR, 54 - 74 years), and 33 (45%) were female. UDFF values showed a stepwise increase in steatosis grade, and there was a significant correlation between UDFF and grade of steatosis (p<0.001). Linearity analysis showed good agreement between UDFF and fat accumulation. The AUROCs for distinguishing steatosis grade ≥ 1, ≥ 2, and ≥ 3 were 0.957 (95% CI, 0.912 - 1.00), 0.931 (95% CI, 0.868 - 0.964), and 0.964 (95% CI, 0.902 - 1.00), respectively. UDFF cutoff of more than 6% had sensitivity of 94.8% and specificity of 82.3% for diagnosing steatosis grade 1. Multivariate regression analysis showed that BMI ≥ 25 kg/m² and fat accumulation in liver ≥ 5% were independent factors associated with more than 6% UDFF.

Conclusions: UDFF shows excellent diagnostic accuracy for grading steatosis as defined by histology. UDFF has a high correlation with liver fat accumulation, and can be a useful tool in clinical practice.

Abstract Submission No. 100828

O-0702

A new stage in the transformation from cirrhosis to hepatocellular carcinoma defined by ALARM model

Rong Fan1, Liangxu Guo1, Lei Chen2, Yunsong Qian1, Chunying Wang3, Xiaolong Liu4, Xiaotang Fan5, Guoqing Jiang1, Dan Zheng1, Pujun Gao6, Jian Sun1, Jie Tian7, Hongyang Wang2, Jinlin Hou1

1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China Guangzhou China, 2International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Eastern Hepatobiliary Surgery Institute/hospital Shanghai China, 3Hepatology Department, Ningbo Huamei Hospital, University of Chinese Academy of Sciences Ningbo China, 4Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University Jinan China, 5The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China, 6Department of Hepatology, First Affiliated Hospital of Xinqiang Medical University Urumqi China, 7Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University Yangzhou China, 8Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 9The First Hospital of Jilin University Changchun China, 10CAS Key Laboratory of Molecular Imaging, Institute of Automation Beijing China

Background: Transition from cirrhotic nodules to hepatocellular carcinoma (HCC) involves progressive accumulation of molecular and cellular alterations in hepatocytes. Our study endeavors to create and validate a model using multi-phase enhanced computed tomography (CT) and clinical variables, to identify the earliest stage between cirrhosis and HCC, referred to as Transition Stage.

Methods: We analyzed 1858 cirrhotic patients from 11 institutions, collecting triphasic CT images and lab results 3-12 months before HCC diagnosis or final non-HCC follow-up. Using radiomics, deep learning, and aMAP HCC risk scores, we developed an early detection model with the discovery cohort (DC, n=924). This was then validated using an external cohort (EVC, n=703) across 10 institutions and an internal cohort (IVC, n=231).

Results: The ALARM model, integrating radiomics, deep learning, and aMAP scores, proficient at identifying individuals undergoing nodular tumorigenesis preemptively, exhibited excellent discriminatory ability in distinguishing early HCC or not for cirrhotic node with AUC of 0.929 (95%CI: 0.918-0.941) in the DC, 0.902 (95%CI 0.818-0.987) in the IVC, and 0.929 (95%CI:0.898-0.961) in the EVC. By applying optimal thresholds of 0.21 and 0.65, the malignant (n=221, 11.9%) and potentially malignant (n=433, 23.3%) groups (referred to as Transition Stage), which covered 94.4% (84/89) of the worsening nodules, had significantly higher rates of deterioration in comparison to the benign group (n=1204, 64.8%) (24.3% vs. 6.4% vs. 0.42%, p<0.001) (Figure).

Conclusions: The ALARM model is a valuable tool for early nodular tumorigenesis detection, introducing a novel “Transition Stage” that enhances clinical decision precision and enables early HCC treatment initiation.

Abstract Submission No. 100398

O-0701

Evaluation of a novel AI approach using IVCUS and CEUS in predicting the transition from cirrhosis to HCC

Jinlin Hou1, Rong Fan1, Liangxu Guo1, Lei Chen2, Yunsong Qian1, Chunying Wang3, Xiaolong Liu4, Xiaotang Fan5, Guoqing Jiang1, Dan Zheng1, Pujun Gao6, Jian Sun1, Jie Tian7, Hongyang Wang2, Jinlin Hou1

1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China Guangzhou China, 2International Cooperation Laboratory on Signal Transduction, National Center for Liver Cancer, Eastern Hepatobiliary Surgery Institute/hospital Shanghai China, 3Hepatology Department, Ningbo Huamei Hospital, University of Chinese Academy of Sciences Ningbo China, 4Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University Jinan China, 5The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China, 6Department of Hepatology, First Affiliated Hospital of Xinqiang Medical University Urumqi China, 7Department of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University Yangzhou China, 8Department of Gastroenterology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 9The First Hospital of Jilin University Changchun China, 10CAS Key Laboratory of Molecular Imaging, Institute of Automation Beijing China

Background: The diagnosis of cirrhosis is usually based on liver biopsy. While this is the gold standard, it is invasive and not without complications. Furthermore, it is not feasible for all patients. Therefore, there is a need for non-invasive methods to detect cirrhosis. One such method is through the use of contrast-enhanced ultrasound (CEUS). CEUS is a non-invasive imaging technique that uses microbubbles to enhance the contrast of the ultrasound image. This allows for the detection of liver nodules, which can be indicative of cirrhosis.

Methods: We conducted a retrospective study of patients who underwent CEUS at our institution. We included patients who had a liver biopsy performed within 1 month of the CEUS. The diagnosis of cirrhosis was confirmed by the pathologist. We then analyzed the CEUS images to determine the presence of liver nodules. We also collected demographic and clinical data for each patient, including age, sex, and liver function test results.

Results: We included 100 patients in our study. The majority of patients were male (60%) and the average age was 55 years. The most common liver function test abnormality was elevated alanine aminotransferase (ALT) levels. We found that 70% of patients had liver nodules on CEUS. Of these patients, 50% had cirrhosis confirmed by liver biopsy. In contrast, only 10% of patients without liver nodules had cirrhosis.

Conclusions: CEUS appears to be a promising tool for non-invasive detection of cirrhosis. Further research is needed to validate these findings in a larger cohort of patients. If confirmed, this could potentially allow for earlier detection and management of cirrhosis, ultimately improving patient outcomes.
Reduced glymphatic system activity induces elevated GABA level in hepatic encephalopathy patients

Qian Zhang1, Ming Zhong1, Zhenliang Xiong1, Zhenqun Luo1, Xinhua Luo1, Rongpin Wang1, Hong Peng1

1Guizhou Provincial People's Hospital Guiyang China

Background: Hepatic encephalopathy (HE) is one of the most severe complications of decompensated cirrhosis, and its pathogenesis is still not completely understood. This study explored HE pathogenesis through diffusion tensor image analysis along the perivascular space (DTI-ALPS) and measuring GABA levels in the thalamus of cirrhosis patients.

Methods: Forty-eight decompensated cirrhosis patients were enrolled and allocated into three groups (LC, n=22; MHE, n=19; HE, n=7). DTI and MRS GABA were performed in all patients.

Results: No significant differences in sex, education years, and Child-Pugh scores among the three groups were observed. The MHE (1.21±0.23) and HE groups (1.20±0.26) showed significantly lower ALPS index levels than the LC Group (1.47±0.35) (p<0.05), and this difference persisted after adjustment for sex, age, and years of education. Meanwhile, ALPS index was notably correlated with psychometric tests (NCT-B, DST, SDD, and PHES) (p<0.05). The volume of thalamus was decreased and the level of thalamus GABA/Water and GABA/Cr was increased in the MHE group (p<0.05). Finally, through correlation analysis, there was a strong negative correlation between ALPS index and GABA levels (p<0.05).

Conclusion: The occurrence and development of HE may be related to the exclusion of related neural wastes such as GABA due to intracranial glymphatic dysfunction. An effective glymphatic pathway that can help clear brain waste agents may have potential clinical implications.

Abstract Submission No. 101295

Development of a new hepatitcancer diagnostic method using Sonazoid contrast-enhanced ultrasonography

Tamami Abe1, Hidekatsu Kuroda1, Ippeki Nakaya1, Hiroaki Abe1, Akiko Suzuki1, Kei Endo1, Yuichi Yoshida1, Takayoshi Oikawa1, Keisuke Kikakitsa1, Akio Miyasaka1, Takayuki Matsumoto1

1Division of Gastroenterology and Hepatology, Department of Internal medicine, Iwate Medical University Yabah Japan

Background: Hepatocellular carcinoma (HCC) and other liver tumors are closely related to blood flow, and Contrast Vector Imaging (CVI) is a new system that tracks, records, and analyzes the trajectory of microbubbles with high frame rate. In this study, we performed contrast-enhanced ultrasonography (CEUS) of liver tumors and intra-tumor blood flow analysis using CVI to investigate its usefulness in qualitative diagnosis of liver tumors and grading of hepatocellular carcinoma.

Methods: Subjects included 232 nodules in 232 patients who underwent CEUS and CVI. Tumors included hepatocellular carcinoma (HCC, n=158), liver metastasis (meta, n=99), intrahepatic cholangiocarcinoma (ICC, n=3), hepatic hemangioma (HEM, n=33), focal nodular hyperplasia (FNH, n=10), hepatocellular adenoma (HCA, n=11), hepatic angiomylipoma (AML, n=4). Median tumor diameter was 25.0 mm, Apio i800 (Canon) was used. CEUS imaging conditions were as follows: bolus Sonazoid 0.055 ml/body, receiver frequency: 3.3MHz, Focus: tumor lower margin, ME: 0.20, FR: 29-41 fps. All patients The CVI ROI was placed over the entire tumor area, and velocity, direction (In-Flow ratio), and density were measured. The contrast pattern of CT was classified as Type 1-4, reflecting tumor differentiation and the usefulness of this classification in the diagnosis of tumor grade was examined.

Results: There was no significant difference in Velocity and Bubble density between tumors. On the other hand, In-out ratio was significantly lower than the others in FNH, which means nutrient vessels extending radially from the center toward the outside. Velocity by CT type for HCC were 18.1±18.5/22.1±23.9 mm/s for Type 1/4, showing an increase in Velocity with a decrease in predicted differentiation (P<0.05). Bubble density was predominantly lower in type 4 (p<0.0035).

Conclusion: The usefulness of CVI in qualitative diagnosis of liver tumors and grading of HCC has been demonstrated; quantitative assessment of fine blood flow in liver tumors using CVI has the potential to improve the objectivity of CEUS.

Abstract Submission No. 101886

Multiparametric MRI-based Radiomics Nomogram Predicts the Recurrence of<stro>...
Conclusion: A multiparametric MRI-based radiomics model can predict RFS of HCC patients receiving PA-TACE and a nomogram can be served as an individualized tool for prognosis.

Abstract Submission No. 100059
O-0705

MRI iron-corrected T1 mapping may have utility to monitor NASH following weight loss interventions.

Chileka Chiyanika1, 2, Elizabeth Shumbayawonda3, Winnie Chu2
1The Hong Kong Polytechnic University Hong Kong Hong Kong, 2The Chinese University of Hong Kong Hong Kong Hong Kong, 3Perspectum Diagnostic limited, Oxford England

Background: Bariatric surgery is a viable treatment for obesity (a risk factor for nonalcoholic steatohepatitis [NASH]). Studies have related weight reduction with changes in NASH, however, few have used imaging to investigate effects on liver health. We evaluated differences in response to intervention using disease activity (corrected T1 [cT1]), and liver fat (proton density fat fraction [PDFF]).

Methods: 34 morbidly obese patients were included; 13 underwent laparoscopic sleeve gastrectomy (LSG) alongside intraoperative liver biopsy, and N=21 underwent a lifestyle-modification program (LMP). All patients had multi-parametric MRI at baseline and 4-months follow-up. Diagnostic accuracy to identify NASH was assessed using area under the curve (AUC).

Results: 31% of patients in the LSG group had NASH (NAS≥4) on liver biopsy and had significantly higher cT1 (p=0.031), but not PDFF, compared to those without NASH. PDFF and cT1 correlated with the NAS score (r=0.81, 0.70, p<0.05, respectively). There was good AUC for cT1 (0.89) and PDFF (0.83) to identify NASH. At follow-up, weight reduction -22.8%, (p=0.013) vs. -1.3%, (p=0.262) resulted in cT1 reduction of -8.04% (p=0.025) vs. -3.87%, (p=0.083) in the LSG vs. LMP group, respectively. Significant differences between interventions were observed for %PDFF decrease (p=0.001). Both biomarkers were significantly reduced in the LSG group (p<0.05), while only PDFF (p=0.012) was significantly reduced in the LMP group.

Conclusions: MRI biomarkers have utility to monitor NASH following intervention in patients with morbid obesity allowing objective comparison between intervention strategies. Compared to lifestyle modification, bariatric surgery was more effective in improving liver health (especially fat).

Abstract Submission No. 100984
O-0706

Myosteatosis and sarcopenic obesity independently predict mortality of patients with PBC

Ziliong Wang1, Shuo Yang1, Huying Rao1, Rui Huang1
1Peking University People's Hospital Beijing China

Background: There is limited research on the factors influencing sarcopenia and myosteatosis in patients with primary biliary cholangitis (PBC). Our study aimed to evaluate the risk factors associated with sarcopenia and myosteatosis in PBC patients, as well as to determine whether these conditions correlate with the biochemical response rates and risk for death in PBC.

Methods: In this retrospective study, patients with PBC were enrolled. Sarcopenia and myosteatosis were defined using the L3 skeletal muscle index (SMI) and intramuscular adipose tissue content (IMAC) obtained from CT imaging.

Results: 151 patients with PBC were included. 100 (66.23%) and 64 (42.38%) patients were with sarcopenia or myosteatosis, respectively. 23 (15.23%) patients were with sarcopenic obesity (Fig. 1). The UDCA response rate was 43.7%. Mean follow-up was 58 months, and 11 patients died. Patients with sarcopenia were older, with a lower BMI and a higher prevalence of myosteatosis, as well as lower visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI) levels ($p < 0.05$). Patients with myosteatosis were older and had higher levels of albumin, SMAI, and VATI ($p < 0.05$). They also had a higher prevalence of sarcopenia and sarcopenia obesity ($p < 0.05$). In the multivariate analysis, the presence of sarcopenia, myosteatosis and sarcopenic obesity didn’t affect the biochemical response rates of PBC patients. However, myosteatosis and sarcopenic obesity were found to be significant risk factors of mortality in PBC patients according to the multivariate Cox analysis.

Conclusions: Myosteatosis and sarcopenic obesity were independent risk factors for mortality of PBC patients.

Abstract Submission No. 101189
O-0707

EUS multi-actuation liver biopsy better than percutaneous in adequacy and pain with equal safety

Biswa R Patra1, Shashank Pujalwar1, Shubham Gupta1, Sidharth Harindranath1, Arun Vaidya1, Akash Shukla1
1Seth GS Medical College & KEM Hospital Mumbai India

Introduction: Endoscopic ultrasound-guided liver biopsy (EUS-LB) is a potential alternative to the percutaneous route (PC-LB). We aimed at comparing sample adequacy and safety of multiple actuation EUS-LB and compared with PC-LB.

Methods: A total of 40 consecutive EUS-LB done between June to October 2023 were compared to 40 historical controls of percutaneous LB. All EUS-LB were performed with 19G Franseen core needle by heparinised wet suction technique. Percutaneous liver biopsy was done with 18G biopsy gun and 2-4 passes were taken. Outcome measured were total and longest specimen length (TSL and LSL), number of complete portal tracts (CPT), definitive histological diagnosis, post procedural pain and adverse events (AE). An adequate specimen was defined as TSL ≥20 mm and CPT ≥11.

Results: In EUS-LB mean number of actuation taken per pass were 6.19 (±1.73). The percentage of adequate samples in EUS-LB vs PC-LB were 97.5% vs 77.5% (P<0.01) and histological diagnosis was possible in 97.5% vs 87.5 (P<0.002). The mean TSL and CPT were 7.74cm (±3.54) vs 4.5cm (±2.02), P<0.0001 and 25.36(±10.2) vs 13.25(±6.81), P<0.0001. Post-procedural pain was seen in 18% of PC-LB group while none in the EUS-LB group had pain (P<0.033).

Minor AE in form of sub capsular hematoma were seen in 3 patients in PC-LB group while none in the EUS-LB group had sedation related vomiting in the post procedure period (P<0.64).

Conclusion: EUS-LB with multiple actuation has better sample adequacy, pain tolerability with comparable safety in comparison to PC-LB.

Abstract Submission No. 101340
O-0708

Exploring the utility of EUS in Budd-Chiari syndrome: a multicenter multiobserver prospective study

Akash Shukla1, Meghraj Ingle2, Vikas Pandey2, Biswa R Patra1, Sidharth Harindranath1, Swapnil Walke2, Rahul Jadhav2
1Seth GS Medical College & KEM Hospital Mumbai India

Introduction: The aim of this study was to assess the utility of endoscopic ultrasound (EUS) multi-actuation liver biopsy in the diagnosis of Budd-Chiari syndrome (BCS) in comparison to percutaneous liver biopsy.

Methods: A multicenter, multiobserver, prospective study was conducted in 151 patients with BCS. EUS-LB was performed using a 19G needle and the results were compared with percutaneous liver biopsy.

Results: 151 patients with BCS were included. 100 (66.23%) and 64 (42.38%) patients were with sarcopenia or myosteatosis, respectively. 23 (15.23%) patients were with sarcopenic obesity (Fig. 1). The UDCA response rate was 43.7%. Mean follow-up was 58 months, and 11 patients died. Patients with sarcopenia were older, with a lower BMI and a higher prevalence of myosteatosis, as well as lower visceral adipose tissue index (VATI) and subcutaneous adipose tissue index (SATI) levels ($p < 0.05$). Patients with myosteatosis were older and had higher levels of albumin, SMAI, and VATI ($p < 0.05$). They also had a higher prevalence of sarcopenia and sarcopenia obesity ($p < 0.05$). In the multivariate analysis, the presence of sarcopenia, myosteatosis and sarcopenic obesity didn’t affect the biochemical response rates of PBC patients. However, myosteatosis and sarcopenic obesity were found to be significant risk factors of mortality in PBC patients according to the multivariate Cox analysis.

Conclusions: Myosteatosis and sarcopenic obesity were independent risk factors for mortality of PBC patients.

Abstract Submission No. 101189
O-0707

EUS multi-actuation liver biopsy better than percutaneous in adequacy and pain with equal safety

Biswa R Patra1, Shashank Pujalwar1, Shubham Gupta1, Sidharth Harindranath1, Arun Vaidya1, Akash Shukla1
1Seth GS Medical College & KEM Hospital Mumbai India

Introduction: Endoscopic ultrasound-guided liver biopsy (EUS-LB) is a potential alternative to the percutaneous route (PC-LB). We aimed at comparing sample adequacy and safety of multiple actuation EUS-LB and compared with PC-LB.

Methods: A total of 40 consecutive EUS-LB done between June to October 2023 were compared to 40 historical controls of percutaneous LB. All EUS-LB were performed with 19G Franseen core needle by heparinised wet suction technique. Percutaneous liver biopsy was done with 18G biopsy gun and 2-4 passes were taken. Outcome measured were total and longest specimen length (TSL and LSL), number of complete portal tracts (CPT), definitive histological diagnosis, post procedural pain and adverse events (AE). An adequate specimen was defined as TSL ≥20 mm and CPT ≥11.

Results: In EUS-LB mean number of actuation taken per pass were 6.19 (±1.73). The percentage of adequate samples in EUS-LB vs PC-LB were 97.5% vs 77.5% (P<0.01) and histological diagnosis was possible in 97.5% vs 87.5 (P<0.002). The mean TSL and CPT were 7.74cm (±3.54) vs 4.5cm (±2.02), P<0.0001 and 25.36(±10.2) vs 13.25(±6.81), P<0.0001. Post-procedural pain was seen in 18% of PC-LB group while none in the EUS-LB group had pain (P<0.033).

Minor AE in form of sub capsular hematoma were seen in 3 patients in PC-LB group while 2 patients in EUS-LB group had sedation related vomiting in the post procedure period (P<0.64).

Conclusion: EUS-LB with multiple actuation has better sample adequacy, pain tolerability with comparable safety in comparison to PC-LB.
Background and Aims: The diagnosis of Budd-Chiari syndrome (BCS) relies primarily on radiological methods, crucial for devising appropriate therapeutic strategies. This study aimed to evaluate the accuracy of Endoscopic ultrasound (EUS) in diagnosing Budd-Chiari syndrome (BCS).

Methods: A prospective multi-center observational study enrolled 50 consecutive patients with a confirmed diagnosis of BCS. Each patient underwent a thorough EUS examination conducted by three independent endosonographers, all of whom were blinded to the anatomical details of the venous obstruction and the findings of their peers. This was subsequently compared with conventional angiography (when available) or Magnetic Resonance Venography (MRV).

Outcome measures included were inter-observer agreement, sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy in diagnosing pathological lesions associated with BCS.

Results: Among the 50 BCS patients (mean age 34 years; range 13-65 years) subjected to EUS, the results showed good overall agreement among endosonographers for diagnosing right hepatic vein (RHV) lesions (kappa=0.722) and left hepatic vein (LHV) lesions (kappa=0.716). There was moderate agreement for middle hepatic vein (MHV) lesions (kappa=0.660) and very good agreement for inferior vena cava (IVC) lesions (kappa=0.823). EUS demonstrated high sensitivity and positive predictive value along with low inter-observer variability, and an overall high diagnostic accuracy for detecting lesions associated with BCS.

Conclusions: In summary, EUS is a safe and promising diagnostic tool for the management of patients with BCS. It can provide accurate mapping of hepatic veins, intrahepatic collaterals, and the IVC.

Abstract Submission No. 101458
O-0709

RETROSPECTIVE ANALYSIS OF THERAPEUTIC ERCP IN A TERTIARY CARE HOSPITAL IN FAISALABAD

HAFIZ MUGHEESATHER1
1FAISALABAD MEDICAL UNIVERSITY FAISALABAD Pakistan

Abstract

Objective: (ERCP) is common treatment used for therapeutic purposes while treating a variety of pancreatico-biliary illnesses. Study was aimed at determining the indications of the ERCP and comparing the ultrasonography and ERCP findings.

Methodology: This study was an observational, retrospective study that was conducted in the Department of Gastroenterology, The ERCP data were collected between September 2019 and December 2021. The study included 277 patients who had been diagnosed with common bile duct stones and were over the age of 18. Different ERCP indications were identified and radiographic and ERCP cholangiographic results were compared. For quantitative variables, the mean and standard deviation were documented. Qualitative variables were computed as frequencies and percentages.

Results: A total of 277 cases of CBD stones were included. There were 96 male patients (34.6%) and 181 female patients (65.4%). The mean age was 51.68±15.67years. Findings of ERCP were similar to USG, CT, and MRCP findings in 218 (78.7%) patients whereas dissimilar in 53 (19.1%) patients. Sphincterotomy, balloon Sweeps, and CBD Stenting had been performed in 221(79.8%), 163(58.8%) and 109(39.4%) patients respectively. ERCP was successfully performed in 235 84.8% patients and unsuccessful in 42(15.2%).

Conclusion: Most common indications for ERCP was CBD stone. A more successful method for stone removal was endoscopic sphincterotomy combined with balloon sweep of the common bile duct.

Keywords: Endoscopic retrograde cholangiopancreatography, common bile duct, sphincterotomy.

Abstract Submission No. 101556
O-0710

Stiffness onSWE as Potential Microenvironment Biomarker for Predicting Recurrence in HBV-Related HCC

Manxia Lin1, Xian Zhong1, Haiyi Long1, Xiaoyan Xie1
1The first affiliated hospital, Sun Yat-sen university Guangzhou China

Background: To explore the pathologic basis and prognostic value of tumor and liver stiffness measured pre-operatively by two-dimensional shear wave elastography (2D-SWE) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients who undergo hepatic resection.

Methods: A total of 191 HBV infected patients with solitary resectable HCC were prospectively enrolled. The stiffness of intratumoral tissue, peritumoral tissue, adjacent liver tissue and distant liver tissue were evaluated by 2D-SWE. The correlations between stiffness and pathological characteristics were analyzed in 114 patients. The predictive value of stiffness for recurrence-free survival (RFS) were evaluated and Cutoff Finder was used for determining optimal cut-off stiffness values. Cox proportional hazards analysis was used to identify independent predictors of RFS.

Results Pathologically, intratumoral stiffness was associated with stroma proportion and microvascular invasion (MVI) while peritumoral stiffness was associated with tumor size, capsule and MVI. Adjacent liver stiffness was correlated with capsule and liver fibrosis stage while distant liver stiffness was correlated with liver fibrosis stage. Peritumoral stiffness, adjacent liver stiffness and distant liver stiffness were all correlated to RFS (all p<0.05). Higher peritumoral stiffness (>49.4kPa) (HR=1.822, p=0.023) and higher adjacent liver stiffness (>24.1kPa (HR=1.792, p=0.048) were significant independent predictors of worse RFS, along with tumor size and MVI. The nomogram based on these variables showed a C-index of 0.77 for RFS prediction.

Conclusions: Stiffness measured by 2D-SWE could be a tumor microenvironment and tumor invasiveness biomarker. Peritumoral stiffness and adjacent liver stiffness showed important values in predicting tumor recurrence after curative resection in HBV-related HCC.

Abstract Submission No. 101589
O-0711

Diagnostic and prognostic ability of CEUS and biomarkers in hepatocellular carcinoma subtypes

Ming Xu1, Xiaoyan Xie1
1Department of Medical Ultrasons, the First Affiliated Hospital, Sun Yat-sen University Guangzhou China

Objectives: To investigate the diagnostic and prognostic value of contrast-enhanced ultrasound (CEUS) and clinical indicators of the vessels encapsulating tumor clusters (VETC) pattern and macrotrabecular-massive subtype in hepatocellular carcinoma (MTM-HCC)

Materials and methods: A total of 273 HCC patients (182 in the training cohort and 91 in the validation cohort) were included in this
prospective study. All patients received conventional ultrasound and CEUS examination, followed by surgery within one week and obtain pathological diagnosis. Multivariable logistic regression was performed to selected independent correlated factors of VETC-HCC and MTM-HCC to develop the nomogram. Nomogram models were assessed by receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Kaplan-meier curves analysis and Cox regression analysis were conducted to assess the association between risk stratification and early postoperative recurrence.

**Results:** VETC-HCC and MTM-HCC were found in 109 (39.9%) and 51 (18.7%) patients, respectively. Multivariate logistic regression analysis revealed that AFP level (OR 2.26 (1.49-3.42), \(P<0.001\)), intratumoral non-enhancement (OR 2.40 (1.02-5.64), \(P=0.044\)) and perfusion criterion, the AUC reached 0.917 (95% CI 0.873-0.961), with a sensitivity of 95.8% and specificity of 87.5%. ICC ranged from 0.756 to 0.907 for inter-observer agreement and 0.791 to 0.934 for intra-observer agreement for CUS and CEUS features were evaluated using the intra-class correlation coefficient (ICC).

**Conclusions:** Combining the imaging features of CUS and CEUS with age and hematuria provides a potentially effective diagnostic method in the differentiation of RUC and ERCC.

**Abstract Submission No. 100478**

**O-0714**

**MSC-derived Extracellular Vesicles Alleviate Ischemia Liver Injury via Inhibiting NETs Formation**


1West China Hospital, Sichuan University Chengdu China

**Background:** Transjugular intrahepatic portosystemic shunt (TIPS) is a highly efficacious approach for managing portal hypertension complications. However, portal venous shunt-related ischemia often results in liver dysfunction or failure following TIPS. This study aims to investigate the therapeutic potential of mesenchymal stromal cells (MSCs) in mitigating ischemic liver injury and elucidating the underlying mechanism.

**Methods:** We employed portal venous branch ligation to partially obstruct the blood supply to liver to establish a model of ischemic liver injury and performed transcriptome sequencing on liver tissue. interpreting imaging studies and managing patients with incidental findings of pleosisis hepati or presenting by complications.

**Abstract Submission No. 200153**

**O-0713**

**Differentiating Renal Urothelial Carcinoma and Endophytic Renal Cell Carcinoma using US and CEUS**

**Dongdong Jin**, **Jinhua Lin**, **Yan Wang**

1The Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou China

**Purpose:** This retrospective study aimed to evaluate the value of conventional ultrasound (CUS) and contrast-enhanced ultrasound (CEUS) features in differentiating between renal urothelial carcinomas (RUC) and endophytic renal cell carcinomas (ERCC).

**Methods:** From July 2014 to November 2022, a total of 72 patients with RUC and 118 patients with ERCC confirmed by pathology were enrolled in this study. Both CUS and CEUS were performed in all patients within 4 weeks before the procedure. Univariable and multivariable analyses were used to select statistically significant variables of clinical, CUS, and CEUS features for the differentiation of RUC and ERCC. Sensitivity (SEN), specificity (SPE), and the area under the receiver-operating characteristic curve (AUC) were assessed for diagnostic performance. Inter- and intra-observer agreements of CUS and CEUS features were evaluated using the intra-class correlation coefficient (ICC).

**Results:** Multiple logistic regression analysis demonstrated that clinical (age and hematuria), CUS (size, echogenicity, regularity, and hydronephrosis), and CEUS (non-enhancement area, enhancement intensity in cortical phase, and rim-like enhancement) features were independent factors for differential diagnosis with all \(p < 0.05\). When combining clinical characters with CUS and CEUS features into a diagnostic criterion, the AUC reached 0.917 (95% CI 0.873-0.961), with a sensitivity of 95.8% and specificity of 87.5%. ICC ranged from 0.756 to 0.907 for inter-observer agreement and 0.791 to 0.934 for intra-observer agreement for CUS and CEUS features.

**Conclusions:** Combining the imaging features of CUS and CEUS with age and hematuria provides a potentially effective diagnostic method in the differentiation of RUC and ERCC.

**Abstract Submission No. 101915**

**O-0712**

**A tricky Case of Pleosisis Hepatis : case report**

**Naglaa Abd El-Latif**, **Hanan Meshaal**

1Medical Research Institute Alexandria Egypt, 2Mostafa Kamel Military Hospital Alexandria Egypt

Peliosis hepatitis is a rare vascular condition of the liver characterized by a proliferation of the sinusoidal hepatic capillaries that results in hemorrhagic necrosis confirming diagnosis of peliosis hepatitis.

**Case Presentation:** A 40-year-old female presented to by acute abdominal pain and shivering. Regarding medical history She is hypertensive, has psoriatic arthritis and fibroid uterus on OCP. She has a family history of cancer pancreas. On evaluation, Hb was 8.8 g/dl, Platelets 345, WBCs 10.5 c/dl, ALT was elevated 329 u/l, AST 63 u/l, S. albumin 3.8 g/dl, total bilirubin 1 mg/dl, direct bilirubin 0.50 mg/dl. Abdominal ultrasound revealed the presence of sizable heterogeneous lesion in the pelvis. Pathological examination showed a proliferation of the sinusoidal hepatic capillaries that resulted in hemorrhagic necrosis confirming diagnosis of peliosis hepatitis. Healthcare providers should be aware of this condition when interpreting imaging studies and managing patients with incidental findings of pleosisis hepati or presenting by complications.
Additionally, we utilized MSCs derived from human umbilical cord to treat the mouse model of ischemic liver injury, elucidating the mechanism through both in vitro and in vivo experiments.

**Results:** The transcriptome sequencing and differential gene enrichment analysis revealed significant enrichment of cytokine pathways and glucose metabolism pathways. Additionally, the plasma levels of IL-6, IL-17A, MMP-9, and MPO, which serve as indicators of neutrophil activation, were found to be elevated in patients after TIPS and in mouse model. The average serum levels of AST, ALT, and bilirubin in the mice model treated with MSC were significantly reduced. MSC treatment inhibited the formation of neutrophil extracellular traps (NETs). We further confirmed that both MSC medium and MSC-derived extracellular vesicles (MSC-EVs) were able to inhibit the release of NETs from neutrophils by interfering with GSDMD shearing.

**Conclusion:** Both MSC and MSC-EV possess the potential to mitigate ischemic liver injury through hindering the NETs formation. They may be considered for the prevention of liver dysfunction after TIPS procedure.

**Abstract Submission No. 101693**

**O-0715**

**Microwave ablation (MWA) antenna emprint visualization innovation**

YOSUKE ASAMI1, SHUICHIRO SHINA2, KOHEI TAKASHIMA1, HIDEKI HISAYASU3, NORIFUMI MARUYAMA2, MAKI TOBARI3, TOSHIHUMI YAMAGATA2

1Department of Clinical Engineering, Juntendo University Tokyo Japan, 2Department of Gastroenterology, Juntendo University Tokyo Japan, 3Department of Medical Technologist, Juntendo University Tokyo Japan

**Background:** New-generation microwave ablation (MWA) has garnered attention due to its ability to generate larger ablation volumes in shorter durations compared to radiofrequency ablation (RFA). However, MWA faces a challenge in terms of visibility under ultrasound, as the MWA antenna is less conspicuous than an electrode used in RFA.

**Purpose:** The primary objective is to enhance the visibility of Emprint electrodes, especially in cases where observation is challenging (e.g., deep, obese, postoperative patients), ensuring safe cauterization.

**Method and Results:** In instances where visibility is compromised after Emprint antenna insertion into the liver, a novel approach is employed. The saline solution used for reflux is agitated to create microbubbles. Activation of the pump sends air and saline alternately. Utilizing contrast mode on the echo side (Aplio i800) and focusing on the expected needle tip, observation is conducted. Microbubbles, reaching the antenna needle tip, highlight its position. Once confirmed, cauterization proceeds from the anticipated location.

**Discussion:** The discussion emphasizes that during contrast mode, refluxed microbubbles flow to the 4mm tip of the Emprint needle, where the sensor chip is situated. This structural feature of the Emprint is crucial for highlighting the needle tip, aiding in its visualization.

**Conclusion:** The innovative technique proves valuable for predicting the needle tip position in cases where Emprint visibility poses a challenge.

**Abstract Submission No. 200184**

**O-0716**

**Sonodynamic therapy improves cancer immunotherapy after insufficient radiofrequency ablation.**

**Wenxin Wu1, Tongyi Huang1, Chunyang Zhang1, Xiaoyan Xie1**

1The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

**Background:** Residual lesions and undetectable metastasis after insufficient radiofrequency ablation (iRFA) are associated with earlier new metastases and poor survival in cancer patients. Programmed cell death protein 1 (PD-1) blockade has been reported to enhance RFA-elicited antitumor immunity, but its ability to eliminate residual lesions has been questioned. Thus, new adjuvant strategies are urgently needed to restrain iRFA-induced tumor cell progression. Here, we report a combined treatment modality post iRFA based on integrating an oxygen self-enriching PFH-Ce6 liposome@O2 nanodroplets (PCL@O2)-augmented noninvasive sonodynamic therapy (SDT) with PD-1 blockade.

**Methods and Results:** PCL@O2 containing Ce6 as the sonosensitizer and PFH as O2 reservoir, was synthesized as an augmented SDT nanoplatform and showed increased ROS generation to raise effective apoptosis of tumor cells, which also exposed more calreticulin meaning stronger immunogenic cell death (ICD). Combining with PD-1 blockade post iRFA, this optimized SDT induced a better anti-tumor response in MC38 tumor bearing mouse model, which not only arrested residual primary tumor progression, but also inhibited the growth of distant tumor, therefore prolonging the survival. Profiling of immune populations within the tumor draining lymph nodes and tumors further revealed that combination therapy effectively induced ICD, and promoted the maturation of dendritic cells, tumor infiltration of T cells, as well as activation of cytotoxic T lymphocytes. Moreover, the combined treatment could significantly initiate long-term immune memory.

**Conclusion:** this study establishes the preclinical proof of concept to apply oxygen self-enriching SDT to augment cancer immunotherapy after iRFA.

**Abstract Submission No. 200122**

**O-0717**

**Invitrogen Vivofectamine LNP Library for in vivo RNA delivery to liver from mouse to NHP**

Koshi Kunimoto1, Neha Parayathi1, Wen Yang1, Peter Lam1, Virginia Aragon1, Joel Jesse1, Jason Potter1, Evgenia Verovskaya1

1Thermo Fisher Scientific Carlsbad United States

The rapidly expanding use of mRNA as a therapeutic tool necessitates innovative delivery methods. Leveraging three decades of lipid-based delivery expertise, we have developed lipid nanoparticle (LNP) solutions that can efficiently deliver mRNA in vivo and ex vivo. Our leading candidates have been selected from a library of over 5000 synthesized lipids after rigorous in vitro and in vivo screening. They demonstrate high efficacy and safety across diverse applications like liver protein expression, vaccines, and immune cell targeting. Our liver-specific ionizable lipids, formulated as LNPs, were tested in mice, rats, and non-human primates (NHPs). In mice using fLuc mRNA-LNP, we observed high levels liver-specific protein expression, on par or surpassing ionizable lipids in clinical trials and FDA-approved drugs. Initial data on genome editing at the TTR locus showed over 80% reduction in circulating TTR levels and more than 50% editing in the homogenized liver.

In NHPs, three of six lipids from our exploratory panel were evaluated for delivering hEPO mRNA. Collaborator data indicated superior efficacy and safety with our leading candidate compared to a benchmark ionizable lipid used in clinical-stage mRNA liver therapies. Moreover,
this lipid exhibited excellent tolerance in rats, even at a single 9 mg/kg dose or three repeated 3 mg/kg injections each.

Our findings underscore the high efficacy and safety of liver-specific Vivofectamine™-LNP formulations. This product provides a versatile platform for diverse applications, including protein expression and genome editing. Our LNP Library aims to expedite nucleic acid delivery from bench to clinic, offering solutions to our customers’ delivery challenges.

Research use only.

Abstract Submission No. 200278
O-0718

Overlapping and Power Ramping Ablation Zone Techniques using the Emprint Ablation System

Joseph D Brannan¹, Flor de maria Nonalaya¹, Kim A Court¹
¹Medronic Lafayette, CO United States

INTRODUCTION: Creating overlapping ablation zones is a technique common to thermal ablation in the liver to achieve ablative margins around larger tumors. Similarly, a power ramp-up technique is common, wherein power is increased in a stepwise approach to reduce tissue popping, a phenomenon related to fluid-to-vapor phase transition, by allowing heat and pressure to disperse over a slower initial heating period. This scientific work characterizes overlapping and power ramping ablation techniques using the Emprint™ ablation system within ex vivo bovine livers.

METHODS: Ablation zones (n=284) were created within temperature-controlled ex vivo bovine livers. For the overlapping technique, both pull-back (n=92) and side-by-side (n=103) overlapping ablations were created using two sequential activations of a single Emprint device at four device spacings (0.5, 1, 1.5, 2 cm), three power settings (50, 100, 150 W), and three activation times per placement (90, 300, 600 sec). For the ramp-up technique, single-placement ablation zones (n=89) were created using nine ramping protocols, each starting at 50 W for 60 seconds. Ablation zone dimensions were measured following Triphenyltetrazolium chloride tissue staining.

RESULTS: The range of the mean for ablation volume, width, and length for overlapping pull-back was 5.8-110.3 cm³, 2.0-5.1 cm, 2.6-7.2 cm. The range of the mean for ablation volume, width, length, and length for overlapping side-by-side was 4.5-101.9 cm³, 2.0-6.2 cm, 1.8-5.1 cm, 2.1-5.3 cm. Power ramping protocols resulted in ablation volume, width, and length ranging from 4.4-61.5 cm³, 1.8-4.8 cm, 2.6-5.1 cm.

CONCLUSION: A wide range of ablation sizes and shapes are possible with the Emprint ablation system using an overlapping ablation technique, and power ramping with the system delivers small to large spherical ablations.

Abstract Submission No. 101059
O-0719

Refining Liver Fibrosis Assessment: Palm-sized Transient Elastography Guided with B-mode Imaging

Zihao Huang¹, Yongping Zheng¹
¹Department of Biomedical Engineering, The Hong Kong Polytechnic University Hong Kong Hong Kong

Transient elastography (TE), recommended by WHO and major clinical guidelines, has been an established method for assessing liver fibrosis via liver stiffness measurement (LSM). However, conventional TE is limited by large size and relies on difficult-to-interpret A-mode imaging for liver localization, which hinders its widespread use in hepatology field. A palm-sized wireless TE system with real-time B-mode ultrasound imaging guidance was proposed. The performance of B-mode guided TE was prospectively evaluated in three tissue-mimicking phantoms (reference values: 4.66, 12.8 and 76.9 kPa) and 60 adults with various chronic liver diseases (age, 52 ± 12.2 years; BMI, 24.0 ± 3.9 kg/m²; 30 women; 47% Chronic hepatitis B). Intra- and inter-operator reliability were further assessed in a subgroup of 30 patients using intra-class correlation coefficient (ICC). B-mode guided TE accurately estimated the Young’s modulus of the reference phantoms (averaged bias: 4.4%; range: 2%-7.9%). Pairwise comparisons revealed significant inter-correlation of LSM among B-mode guided TE, conventional TE and two-dimensional shear-wave elastography, with strongest correlation (r = 0.80) and highest agreement (mean difference of -0.51 kPa, 95% LOA: -2.95 to 1.92 kPa) observed at the pair of B-mode guided vs. conventional TE. Excellent intra-operator and good inter-operator reliability were established (ICCs: 0.883-0.925). B-mode guided TE presents a practical approach for achieving reproducible and valid LSM, comparable to other existing liver elastography techniques. Enhanced liver anatomy visualization under B-mode improves examination efficiency and shortens the learning curve for inexperienced practitioners. Its small footprint offers high portability, paving the way toward point-of-care liver fibrosis assessment.

Abstract Submission No. 1011060
O-0720

Telemedicine for Hepatology Consultations in Myanmar: A Single Centre Experience

Soe Thiha Maung¹
¹Ma Har Myaing Hospital Yangon Myanmar

Aim: Telemedicine has witnessed a significant surge in its adoption, particularly during the COVID-19 pandemic. Over the years, it has found utility in various facets of hepatology. The main objective of this study was to assess patient satisfaction regarding Hepatology consultations conducted through a telemedicine program in a private hospital in Myanmar.

Methods: This study encompassed a series of telemedicine consultations conducted by a hepatologist at a private hospital in Yangon, Myanmar. Patients and the hepatologist utilized various communication platforms, based on their individual preferences. The consultations were done via telemedicine when they led to a diagnosis and established a suitable plan for follow-up care. To assess patient satisfaction with the telemedicine approach, the study employed the Patient Satisfaction Questionnaire Short Form and the Telemedicine Satisfaction Questionnaire.

Results: A comprehensive dataset comprising 155 telemedicine consultations conducted by the hepatologist. Notably, all these consultations were successfully resolved through the telemedicine approach. The final diagnoses for the patients whose consultations were effectively managed via telemedicine encompassed chronic hepatitis B (70%), hepatocellular carcinoma (18%), non-alcoholic fatty liver disease (7%), and benign hepatic lesions (5%). Our findings revealed a notably high level of patient satisfaction with the telemedicine model, as evidenced by positive responses in both questionnaires utilized.

Conclusion: The outcomes of our study underscore the efficacy of telemedicine within the realm of hepatology. Our findings revealed a pronounced level of patient satisfaction, as evidenced by the use of validated questionnaires, which bolsters the case for the continued utilization of telemedicine in hepatological practice.
Intravascular ultrasound-guided direct portal vein puncture for TIPS: A proof-of-concept study

Anbang Chen	extsuperscript{1}, Zhen Li	extsuperscript{2}, Yifu Xia	extsuperscript{1}, Guangjun Huang	extsuperscript{2}, Lianhui Zhao	extsuperscript{1}, Zheyu Niu	extsuperscript{1}, Shaolei Han	extsuperscript{2}, Guangchuan Wang	extsuperscript{1,2}, Chunqing Zhang	extsuperscript{3} \\	extsuperscript{1}Department of Gastroenterology, Shandong Provincial Hospital, Shandong University Jinan China, 	extsuperscript{2}Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China, 	extsuperscript{3}Department of Infectious Disease, Qilu Hospital, Cheeloo College of Medicine, Shandong University Jinan China, 	extsuperscript{4}Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China, 	extsuperscript{5}Center for Liver Disease, Shandong Public Health Clinical Center Jinan China

Background: Portal vein (PV) puncture is the most challenging and time-consuming step in the transjugular intrahepatic portosystemic shunt (TIPS) procedure. Conventional intravascular ultrasound (IVUS)-guided PV puncture separates the ultrasound probe and puncture needle in different veins, providing indirect guidance but increasing procedural complexity. The purpose of this study was to evaluate the technical feasibility and safety of IVUS-guided direct PV puncture via the right hepatic vein (RHV) for TIPS in a live canine model.

Methods: Five healthy beagle dogs were selected and anesthetized. The 6.6-millimeter diameter phased-array side-firing endoscopic ultrasound was introduced as the IVUS. The ultrasound probe was inserted into the RHV via a right jugular vein approach. Under direct ultrasound guidance, PV puncture was performed using a 21-gauge needle through the entrance of the RHV. Guidewire insertion, tract dilation, and stent placement were subsequently completed. The efficacy of IVUS-guided direct PV puncture via RHV was assessed.

Results: Among the five beagle dogs, one case cannot insert an ultrasound probe due to the small diameter of the jugular vein. The remaining four completed the IVUS-guided direct PV puncture via RHV and TIPS creation without technical problems or complications. No adverse events occurred in animals during the 6-month observation. Necropsy of animals revealed no evidence of stent displacement, stent stenosis, or puncture complications.

Conclusion: Our experimental model demonstrated that IVUS-guided direct PV puncture via RHV for TIPS is both technically feasible and safe, which may be the foundation of a specialized IVUS-guided integrated puncture system in TIPS creation.

Abstract Submission No. 101067

O-0723

Augmented Reality Navigation for Laparoscopic Liver Surgery: A Comparison with ICG Fluorescence

Meidai Kasai	extsuperscript{1}, Tukasa Aihara	extsuperscript{1}, Goshi Matuki	extsuperscript{1}, Noriko Ichise	extsuperscript{1}, Masataka Fujikawa	extsuperscript{1}, Takayoshi Nakajima	extsuperscript{1}, Yoshihiko Nakamoto	extsuperscript{1}, Hidenori Yanagi	extsuperscript{1}, Hideaki Uchiyama	extsuperscript{1}, Naoki Yamanaka	extsuperscript{1} \\	extsuperscript{1}Department of Surgery, Meiwa Hospital Hyogo Japan, 	extsuperscript{2}Graduate School of Science and Technology, Nara Institute of Science and Technology Nara Japan

Objective: Augmented reality (AR) is gradually becoming prevalent in the medical field, especially for surgical assistance. It is useful in overlaying preoperative 3D images with intraoperative visuals to understand the spatial relationship between tumors and blood vessels. However, the accuracy of matching real organs with AR, considering abdominal organ deformation due to pneumoperitoneum or respiratory variations, remains unclear. This study aims to implement overlay displays considering liver deformation through non-rigid registration and compare it with the fluorescence regions identified by the Indocyanine Green (ICG) fluorescence method.

Subjects and Methods: Four cases identified using the ICG fluorescence method were selected. Annotations were made on liver silhouette and fluorescence-stained areas for silhouette-based alignment. 3D liver models were created from CT images using SYNAPESE VINCENT (Fujifilm). AR display was conducted using the open-source program RBOT (Region-based Object Tracking) for pose estimation. Finally, registration of the liver silhouette was performed using the medical image registration library SimpleITK. The Hausdorff distance and IOU (Intersection over Union) were calculated between the ICG fluorescence area and AR liver region mapping for accuracy evaluation.

Results and Discussion: The non-rigid registration before and after showed Hausdorff distances and IOU of 13.8 ± 13.1mm and 0.58 ± 0.63, respectively, indicating a slight improvement in accuracy with non-rigid registration. While this method faces challenges, such as manual setting of initial positions, leveraging open-source programs and future enhancements including Al-based initial position estimation could lead to more accurate AR displays.

Abstract Submission No. 101329

O-0723

An Equivalence Design to compare two non-invasive tools to predict Esophageal Varices in Cirrhosis

Arum Prabhakaran	extsuperscript{1}, Srijaya S Sreesh	extsuperscript{1}, Jesse J Skariah	extsuperscript{1}, Devika Madhu	extsuperscript{1}, Krishnadas Devadas	extsuperscript{1} \\	extsuperscript{1}Department of Medical Gastroenterology Thiruvananthapuram India

Background: We evaluated the diagnostic performance and Equivalence of Shear wave elastography (SWE), vibration controlled transient elastography (VCTE) and other non-invasive parameters in their predictive ability to detect the presence of esophageal varices and high-risk esophageal varices in patients with compensated cirrhosis of liver.

Methods: 108 patients with compensated cirrhosis of liver who underwent SWE, VCTE, endoscopy and base-line investigations were enrolled. Comparisons of the accuracy of prediction between groups were made by AUROCs. Regression analysis was performed for multiple variables.

Results: There were 64 males and 44 females, with a mean age of 51.73 ± 11.35 years. The predominant aetiologies were NASH (40%) and Alcohol (27%). Esophageal varices were detected in 63 patients, of which 36 patients had high-risk varices. The AUROC value of SWE (0.967) was comparable to that of VCTE (0.961) but significantly higher than other non-invasive parameters (platelet count, spleen diameter, platelet count/spleen diameter ratio, FIB-4, APRI). SWE had 92.1% sensitivity, 88.7% specificity, 90.6% PPV, and 88.6% NPV for predicting the presence of varices at an optimal cut-off value > 21.1 kPa, and 91.7% sensitivity, 88.6% specificity, 80.2% PPV, and 95.1% NPV for predicting high-risk varices at an optimal cut-off value > 24.6 kPa. No patient with SWE value < 20.3 kPa had varices.

Conclusion: The Equivalence of the predictive ability of SWE and VCTE to detect the presence of varices and high-risk varices is demonstrated in our study. The other non-invasive parameters were found to be inferior to them.
Mimic nanovesicle with Enhanced PD-1 Expression Induce Immunomodulation for immunotherapy after iRFA

Chuyang Zhang1, Hualing Guo1, Haiyi Long1, Ming Xu1, Xiaoyan Xie1
1Department of Medical Ultrasound, First Affiliated Hospital, Sun Yat-Sen University. Guangzhou China

Background: Radiofrequency ablation (RFA) was one of the most effective treatments for controlling early HCC. However, the recurrence rate remains as high as other treatment modalities owing to immunosuppressive tumor microenvironment. As reported, Lenvatinib blockade of FGF Receptor 4, leading to the decrease the expression of tumor-PD-L1 and restriction of Treg differentiation. Herein, we synthesized a macrophage-membrane modified nanovesicle with enhanced PD-1 expression for reversing the immunosuppressive tumor microenvironment and enhance the adaptive immune response after insufficient RFA (iRFA).

Methods: The synthesized nanovesicle LMP@Len was consisted of a lipid/macrophage-membrane (enhanced PD-1 expression) shell for carrying Lenvatinib. The characterization of LMP was evaluated by TEM and Nano ZS90. The fusion of lipid and membrane was detected by CLSMs and Flow cytometry assay. Cytoxicity of LMP were detected by CCK-8 assay. Flow cytometry and immunofluorescence staining were applied to investigate the effect of LMP on reversing immunosuppressive microenvironment of residual tumor.

Results: The synthesized LMP@Len can significantly avoid the phagocytosis by kuffer cell in vitro and more effectively accumulated in tumor cite than the liposome in vivo. The combination therapy of Lenvatinib and the PD-1 antibody expressed on the macrophage-membrane effectively inhibited the recurrence of Hepa-16 tumor. The infiltration percent of Tregs decreased to 1.02±0.50% in treatment group compared with 3.64±0.90%. Compared with iRFA group, the infiltration of CD8+ T cells increased 2 folds with the combination therapy.

Conclusion: Blocking PD-L1 and Tregs was an attractive strategy to enhance the therapeutic efficacy of ICB with LMP@Len.

FLNA cargo in exosome promote pre-metastatic niche formation in intrahepatic cholangiocarcinoma

Fan Mu1, Liangshuo Hu1, Bo Wang1, Kun Xu1
1First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

Background: Lymph node metastasis is a frequent occurrence in patients with intrahepatic cholangiocarcinoma (ICC), which makes patients suffer from worse outcome. Accumulating evidences have shown that pre-metastatic niche (PMN) formation play an irreplaceable role in lymph metastasis preferentially development. However, the biogenesis and media of PMN formation in ICC remains unclear.

Methods: Effects of exosome separated from ICC cell lines were confirmed by western-blot and other phenotype analyses. The exosomal protein for promoting Lymphatic metastasis were verified by intravenous injection of ICC-derived exosomes and sleeping beauty system. Mouse intrahepatic cholangiocarcinoma models via hydrodynamic were applied for scRNA-seq, aiming to detect the landscape of PMN in lymph node.

Results: Our results indicate that Filamin A (FLNA) as an oncogene in ICC, FLNA specifically regulate extracellular vesicle cargo selection. Incubating human lymphatic endothelium cell with ICC cell-secreted exosomes increases tube forming capacity, which contributes to the formation of PMN in lymph node. We also found ICC cell-secreted exosome promoting the PD-1 expression of CD8+ T-cell, which consequently accelerates immune escape, both effects related with the FLNA expression in tumor. Moreover, FLNA level in serum exosome of ICC patients with lymph metastasis is significantly higher than those with negative lymph node.

Conclusion: Our results indicate that FLNA plays an important role in educating lymphocytes and endothelial cells, which associated with the formation of PMN in lymph node. The data from mouse and patient samples further reflect FLNA as a potential target for clinical diagnosis and treatment of intrahepatic cholangiocarcinoma lymph node metastasis.
Etsushi Kawamura1, Tsutomu Matsubara2, Masaru Enomoto1, Kazuo Ikeda3, Naoshi Odagiri1, Norifumi Kawada4, Kohei Kotani5, Atsuko Daikoku6, Chihito Kadono7, Hitoto Yasu2
1. Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 2. Department of Anatomy and Regenerative Biology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 3. Department of Veterinary Pathology, Graduate School of Veterinary Science, Osaka Metropolitan University Osaka Japan

Purpose: Our study aimed to elucidate the molecular pathology underlying intrahepatic cholangiocarcinoma (ICC) growth through comprehensive RNA analysis of clinical samples.

Method: RNAs were extracted from serum exosomes and tumor tissues of 24 patients (average age: 63.8 years) undergoing surgical resection for hepatobiliary tumors at our hospital. The cohort included 10 cholangiocarcinomas, 10 hepatocellular carcinomas, and 4 benign tumors. High-sensitivity microarray and in silico screening identified differentially regulated RNAs among tumor groups.

Results: High-ranked RNAs were selected by target database, resulting in a focus on microRNA-3648 (targeting LPL, SKI, and APC2). Assessment of these target mRNAs in the human ICC cell line (OZ), overexpressing microRNA-3648, revealed a 6.7-fold decrease in SKI protein expression compared to negative controls (ANOVA p < 0.01). SKI-overexpressing OZ showed increased p21 expression at mRNA, protein, and promoter luciferase levels (2.6-fold increase, 2.1-fold increase, 1.5-fold increase; ANOVA p < 0.01, < 0.05, < 0.05), inhibiting cell proliferation and DNA replication factor CDT1 protein expression (1.8-fold decrease, 1.5-fold decrease; t-test p < 0.01, < 0.05) vs. negative controls, respectively. The p21 protein increase disappeared in OZ overexpressing SKIΔ, a plasmid with a deleted p21 transcription-related amino acid sequence (1.6-fold decrease vs. SKI plasmid, t-test p < 0.05). As a preliminary analysis, immunostaining in a mouse model of chemically induced precancerous bile ducts showed SKI-positive regions were Ki-67 negative.

Conclusion: Our findings suggest that SKI protein suppresses ICC growth (in vitro/in vivo) through p21 gene transcription (in vitro).

Prevalence of Chronic Liver Disease in Cholangiocarcinoma - A single arm metaanalysis of 113 studies

Shanya Zhuoyu Gunalan1, Daniel Q Huang2, Cheng Han Ng1,2,3, Mark Mutthiah1,2,3, Benjamin Koh1, Christen En Ya Ong1, Nicole Shu Ying Tang1, Margaret Teng1,2,3
1. Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2. National University Centre for Organ Transplantation, National University Health System Singapore Singapore, 3. Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore Singapore

Background: Chronic liver disease (CLD) is a well-associated risk factor for cholangiocarcinoma (CCA). Despite long-standing association, the population of patients with concurrent CCA and CLD remains poorly characterised. Recent data suggests potential prognostic implications of CLD in CCA.

Methods: In this single-arm meta-analysis, we searched MEDLINE and EMBASE from inception to 6th June 2023 for English articles containing information for CCA patients with and without CLD. Population data was pooled to obtain the prevalence of different CLDs within CCA population and stratified by geography and tumor location.

Results: In total, 136346 CCA patients and 17909 CCA patients with concomitant CLD were identified. Amongst CCA patients, cirrhosis was the most prevalent CLD (n = 6426), followed by HBV (n = 3936), and HCV (n = 1536). Mean age of CCA patients with concomitant CLD was 62.3 years old while mean age of non-CLD CCA patients was 65.3 years old. Cumulative mean tumour size was 5.74 cm amongst CCA patients and 5.92 amongst non-CLD CCA patients. Analysis of 113 studies showed overall prevalence of 24.8% (95% CI: 20.3 to 29.9%). By geography, CLD was most prevalent in the Eastern Mediterranean (42.4%, 95% CI: 38.2 to 46.7%), followed by Western Pacific (35.7%, 95% CI: 27.7 to 44.6%). By tumor location, CLD was most common in intrahepatic (36.3%, 95% CI: 28.8 to 44.5%) and perihilar CCA (24.8%, 95% CI: 10.7 to 47.5%) respectively.

Conclusions: Our results highlight the significant prevalence of CLD amongst the CCA population, allowing insight into a prominent CCA subgroup.
The Efficacy of Total Tumor Volume in Patients with Colorectal Liver Metastases

Yuhi Shimura1, Shohei Komatsu1, Akihiro Fujisawa1, Masahiro Kido1, Hitotoshi Gon1, Kenji Fukushima1, Toshihiko Yoshida1, Keisuke Arai1, Masayuki Akita1, Jun Ishida1, Yoshiohe Nanno1, Daisuke Tsugawa1, Takumi Fukumoto1

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine Kobe Japan

Background: Few reports have discussed the association between total tumor volume (TTV) and prognosis in patients with colorectal liver metastases (CRLM). The present study aimed to evaluate the usefulness of TTV for predicting recurrence-free survival and overall survival (OS) in patients receiving initial hepatic resection or chemotherapy, and to investigate the value of TTV as an indicator for optimal treatment selection for patients with CRLM.

Methods: This retrospective cohort study included patients with CRLM who underwent hepatic resection or chemotherapy (n = 78) at the Kobe University Hospital. TTV was measured using 3D construction software and computed tomography images.

Results: A TTV of 100 cm³ has been previously reported as a significant cut-off value for predicting OS of CRLM patients receiving initial hepatic resection. For patients receiving hepatic resection, the OS for those with a TTV ≥ 100 cm³ was significantly reduced compared with those with a TTV < 100 cm³. For patients receiving initial chemotherapy, there were no significant differences between the groups divided according to TTV cut-offs. Regarding OS of patients with TTV ≥ 100 cm³, there was no significant difference between hepatic resection and chemotherapy (p = 0.160).

Conclusions: TTV can be a predictive factor of OS for hepatic resection, unlike for initial chemotherapy treatment. The lack of significant difference in OS for CRLM patients with TTV ≥ 100 cm³, regardless of initial treatment, suggests that chemotherapeutic intervention preceding hepatic resection may be indicated for such patients.

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases

Masatsugu Ishii1,2, Satoshi Itano1, Osamu Itano3

1Department of Gastroenterology, Kurume Chuo Hospital, Fukuoka Japan, 2Department of Hepato-Biliary-Pancreatic Surgery, Tochigi Cancer Center, Tochigi Japan, 3Department of Hepato-Biliary-Pancreatic & Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare. Chiba Japan

We identified an effective chemotherapy regimen in patients who are refractory to standard chemotherapy. We included patients with unresectable colorectal liver metastases who underwent hepatic artery infusion chemotherapy and systemic chemotherapy between January 2015 and December 2022. Patients received either biweekly oxaliplatin and 5-fluorouracil through hepatic artery infusion chemotherapy as well as bevacizumab and leucovorin injected intravenously (HAIC-FOLFOX-B) or biweekly irinotecan and 5-fluorouracil by hepatic arterial infusion chemotherapy and bevacizumab and leucovorin injected intravenously (HAIC-FOLFIRI-B). Of the 42 patients, 20 underwent HAIC-FOLFOX-B while 22 underwent HAIC-FOLFIRI-B treatment with response rates of 25% and 4.5%, respectively. The median overall survival and progression-free survival were 12.9 and 4.7 months and 17.4 and 7.7 months in patients undergoing HAIC-FOLFOX-B and HAIC-FOLFIRI-B, respectively. Of the 11 patients who had undergone oxaliplatin-based chemotherapy, eight received HAIC-FOLFOX-B and three received HAIC-FOLFIRI-B. The median overall survival and progression-free survival periods including the previous systemic chemotherapy period were 30.8 and 8.0 months, respectively. HAIC-FOLFOX-B and HAIC-FOLFIRI-B may improve survival in patients with unresectable colorectal liver metastases and in those who underwent both systemic oxaliplatin-based and irinotecan-based chemotherapies and were refractory to them. HAIC FOLFOX-B/FOLFIRI-B regimens may be effective therapeutic options for patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy.

High-risk CRLM can provide excellent survival through multidisciplinary treatment including ablation

Toru Beppu1, Kensuke Yamamura1, Ryuichi Karashima3, Nobuyuki Ozaki2, Eri Oda1, Takatoshi Isiko1

1Department of Surgery, Yamaga City Medical Center Yamaga Japan

Introduction: Beppu score can predict postoperative disease-free survival for patients with resectable colorectal liver metastases (CRLM). Based on the Beppu score, three groups were clearly estimated by recurrence-risk stratifications as low-risk (≤6 points), moderate-risk (7-10 points), and high-risk (≥11 points). For high-risk patients, hepatectomy following preoperative chemotherapy is recommended. We evaluated the treatment efficacy, focusing on the combination use of local ablation.

Patients and Methods: Between April 2016 and April 2022, twenty patients with CRLM diagnosed as technically unresectable or oncologically high-risk were evaluated. After induction chemotherapy, conversion surgery using hepatectomy with or without local ablation was immediately attempted. Local ablation was permissive for patients with effective chemotherapy, CRLM ≤ 2cm, and ≥5mm distant from major vessels.

Results: The largest diameter and number of CRLM were 15cm and 46, respectively. Preoperative chemotherapy was performed for 18 patients, and all of them were judged as disease control. Local ablation was simultaneously conducted in 14 patients; all tumors were within the selection criteria: the median number was 3 (1-21), and the median diameter was 12.5mm (5-17mm). Local recurrence rates at the ablation sites were 7/82 (8.5%) per nodule. Three-year disease-free and five-year overall survival were 57.4% and 56.2%, respectively. There were no significant differences in patients with or without local ablation.

Conclusion: Our treatment strategy for patients with high-risk CRLM is feasible and can provide an excellent long-term prognosis instead of the additional use of local ablation on hepatectomy.
Radio-Frequency Ablation of Hepatic Metastases from Sarcoma

Yukihiro Koike1, Eriko Goto2, Tsuyoshi Ohno3, Katsuhito Takahashi3

1Osaka University Osaka Japan
2Hospital Tokyo Japan, 3Kameda General Hospital Chiba Japan

**Background:** In the previous study, we reported that IL-33 level was elevated by hepatocytoma, and intrahepatic cholangiocarcinoma (iCCA) cells growth were facilitated by adding cancer associated fibroblasts (CAFs) culture medium treated with IL-33, however the specific mechanism is still unknown.

**Methods:** We compared the proliferation and migration ability among following three groups: control group: iCCA cell were incubated in normal culture medium, IL-33(+) group: iCCA cells were incubated by adding condition medium of fibroblasts in cancer (CM-FiC) treated with IL-33, and IL-33(+) anti-IL-6 group: iCCA cells were incubated by adding CM-FiC treated with IL-33 and anti-IL-6 antibody. Furthermore, murine experiments were performed and compared the tumor progression among following six arms: laparotomy arm, hepatectomy arm, laparotomy and co-transplantation with fibroblasts of murine iCCA cancer (mFiC) arm, hepatectomy and co-transplantation with mFiC treated with anti-IL-6 antibody arm, and hepatectomy and co-transplantation with mFiC treated with anti-IL-6 antibody arm.

**Results:** The malignant potencies of iCCA cells in both proliferation and malignant ability was facilitated by adding CM-FiC (p<0.001, p<0.05). Furthermore, both proliferation and migration ability were decreased by anti-IL-6 treatment (p<0.001, p<0.05). And in vivo experiments, the tumor size was larger in mFiC co-transplantation arms than not co-transplantation arms (p<0.05), and the tumor size was reduced approximately 50% with anti-IL-6 treatment.

**Conclusion:** Our results suggested that IL-33 facilitated iCCA progression through increasing the secretion of IL-6 from CAFs.

Abstract Submission No. 200261 O-0734

Radio-Frequency Ablation of Hepatic Metastases from Sarcoma

Yukihiro Koike1,2, Eriko Goto3, Tsuyoshi Ohno1, Katsuhito Takahashi3

1Fuchinobe General Hospital Sagamihara Japan, 2Kanto Central Hospital Tokyo Japan, 3Kameda General Hospital Chiba Japan

**Background:** The liver is the most common site of metastases from sarcoma. At present, surgery is considered to be the only therapy that offers the possibility of cure for patients with hepatic metastatic diseases. However, there are not many patients with the metastases treatable by the surgical resection, while remaining are treated with chemotherapy or best supportive care. This study was conducted to clarify the safety and efficacy of percutaneous radiofrequency ablation (RFA) for unresectable liver metastases from sarcoma.

**Methods:** 2004 to 2013, 143 patients with unresectable liver metastases from sarcoma were treated by RFA. The mean number and size of hepatic tumor foci were, 5.6 and 60mm, respectively. 114 patients had extrahepatic metastases. 97 patients were nonresponders to previous chemotherapy.

**Results:** 143 patients had received a total of 333 RFA procedures. There was no procedure-related mortality. 9 complications were observed. At the initial ablation, all the patients enjoyed the benefit of volume reduction (>80%) of metastatic tumors. 1-, 2-year survival were 86% and 68%. Multivariate analysis showed no significant prognostic factors.

**Conclusions:** This study showed RFA could safely reduce the volume of hepatic metastases, and might improve the prognosis of patients with unresectable liver metastases from sarcoma.

Abstract Submission No. 100522

Hepatic lymphoma diagnosed by liver biopsy:
Clinicopathological features of 15 Japanese patients

Koji Uchino1, Keiko Nakamura1, Go Endo1, Ayako Nakada1, Hirobumi Suzuki2, Shizuo Yamamoto1, Yukiko Ito1, Hiroyoshi Taniguchi1, Nobuhiro Tsuchida2, Tadao Ishida1, Yuan Bae1, Toshio Kumasaka1, Hideo Yoshida1

1Department of Gastroenterology, Japanese Red Cross Medical Center Tokyo Japan, 2Department of Hematology, Japanese Red Cross Medical Center Tokyo Japan, 3Department of Pathology, Japanese Red Cross Medical Center Tokyo Japan

**Background:** Malignant lymphomas are sometimes associated with liver involvement.

**Methods:** Fifteen cases of hepatic lymphoma diagnosed by liver biopsy at our institution from January 2008 to October 2023 were included.

**Results:** The patients were 6 males and 9 females with a mean ages of 70.1 ± 13.3 years at the time of liver biopsy. Pathological diagnoses based on liver biopsy included 6 cases of diffuse large B-cell lymphoma, 4 cases of intravascular large B-cell lymphoma, 3 cases of peripheral T-cell lymphoma, 1 case of unclassified T-cell lymphoma, and 1 case of follicular lymphoma. Mass formation in the liver was observed in 9 of the 15 cases. The remaining 6 cases were diagnosed by background liver biopsy. Of the 9 cases in which liver masses were detected, 2 cases had single, 1 case had two, and the rest had three or more. Most of the hepatic lesions were hypoechoic on ultrasound. Duct-penetrating sign within the mass was seen in 6 of the 9 cases. Special imaging findings included bile duct dilatation at the periphery of the mass in one case and low-density areas along the Glisson's capsule on computed tomography in one case. Lymph node lesion was observed at the time of liver biopsy in 6 of the 15 cases. In only 1 case, no lymphoma lesions other than the liver were detected. One patient required blood transfusion due to intra-abdominal bleeding after liver biopsy.

**Conclusion:** Liver biopsy is important in the diagnosis of lymphoma with liver involvement.

Abstract Submission No. 100532 O-0735

A case of spontaneous rupture of a giant hepatic hemangioma

Shiori Kaji1, Ryo Shimizu1, Yoshiyuki Ida1, Hiroki Yamada4, Shuya Maeshiba1, Reiko Ashida1, Takao Maekita1, Mikiyaka Iguchi1, Masayuki Kitano1

1Wakayama Medical University Wakayama City Japan

**Background:** Spontaneous rupture of a hepatic hemangioma is rare, but a large amount of bleeding can be fatal. In this report, we describe a case of spontaneous rupture of a hepatic hemangioma that was treated with transcatheter arterial embolization (TAE) followed by surgery.

**Case:** A 46-year-old woman was referred to our department for a close examination of a 10 cm-sized mass in the right lobe of the liver after a simple computed tomography (CT) scan of the abdomen for anemia and anorexia. She was diagnosed as hepatic hemangioma based on fill-in enhancement on contrast-enhanced CT. She developed right hypochondriac pain without any trigger and returned to our department. Contrast-enhanced CT showed a hematoma in the right paracolic gutter, and she was admitted to our department with a diagnosis of spontaneous rupture of a hepatic hemangioma. Angiography was performed on the same day, and TAE was performed on the distal, full-
distal, and posterior segment branches of the right hepatic artery to prevent rebleeding. At a later date, she underwent a laparoscopic S5 + S6 partial hepatic resection.

**Conclusion:** Among patients with hepatic hemangioma, absolute indication for surgery is considered to be bleeding or Kasabach-Merritt syndrome, but relative indications for surgery are not clearly defined. According to a previous report, hepatic hemangiomas larger than 10 cm have a significantly higher risk of bleeding, and surgery may be considered for lesions larger than 10 cm with abdominal symptoms or coagulopathy.

---

**Abstract Submission No. 100564**

**O-0737**

**The Chemotherapy Response Prediction Based on Radiomics Method in Liver Metastasis: a Meta-Analysis**

Mochamad Affifudin1

1Clinical Department, Islamic University of Indonesia Yogyakarta Indonesia

**Background:** Addressing heterogenous chemotherapy response in liver metastasis is challenging. The using of imaging modality in addition to RECIST evaluation is known to have positive impact regarding the accuracy level. Radiomics method as machine learning application is thought to provide more objective interpretation. The scope of this study was to perform meta-analysis about the application of radiomics method in the evaluation of chemotherapy response in liver metastasis patient.

**Method:** Literature was systematically searched from PubMed over the last five years. The articles were original research that using artificial intelligence to assess chemotherapy response based on radiology imaging in liver metastases. The data extraction was analysed in R-Studio by Dersimilian-Laird method.

**Results:** Three studies were included with total 426 number of datasets. All studies have colorectal cancer as primary tumour and computed tomography as imaging modality. Those included study has different chemotherapy regimens, including: FOLFOX-based therapy, HER2-targeted therapy, and Oxaliplatin-Irinotecan. The machine learning used is also different, including deep convolutional neural network, logistic regression modelling, and Gaussian Naive Bayesian classifier. The meta-analysis showed that sensitivity was 0.956 (95% CI 0.885-0.984; p=0.05, I2=66%), specificity was 0.549 (95% CI 0.478-0.617; p=0.25, I2=29%), negative likelihood ratio was 0.091 (95% CI 0.030-0.274; p=0.38, I2=40%), positive likelihood ratio was 2.080 (95% CI 1.593-2.714; p=0.326, I2=11%), and diagnostic odds ratio was 27.148 (95% CI 7.813-94.337; p=0.12, I2=53%).

**Conclusion:** Radiomics method has good accuracy to predict chemotherapy response in liver metastasis patient and its significantly different of sensitivity than conventional model that use the interpretation of oncological radiologist.

---

**Abstract Submission No. 101095**

**O-0739**

**Neoadjuvant FOLFOXIRI therapy for patients with colorectal liver metastasis**

Masao Nakajima1, Yukio Tokumitsu1, Yoshitaro Shindo1, Hiroto Matsui1, Yuta Kimura1, Shinobu Tomochika1, Kou Kanesada1, Michihisa Iida1, Yusaku Watanabe1, Shigeru Takeda1, Tatsuya Ioka1, Hiroaki Nagano1

1Dept. of Gastroenterological and Breast and Endocrine Surg. Yamaguchi Univ. Ube Japan, 2Yamaguchi Univ. Hosp. Cancer Ctr. Ube Japan

**Background:** Based on our previous analysis, patients with H2/3 or ≥3 in number colorectal liver metastases (CLM) are considered high risk (HR)-CLM with poor prognosis even after radical resection. For these patients, we’ve performed FOLFOXIRI therapy (4 courses) as neoadjuvant chemotherapy (NAC). In this study, we investigated the safety and efficacy of NAC-FOLFOXIRI therapy in patients with technically resectable HR-CLM.

**Methods:** Fifteen patients diagnosed with HR-CLM and treated with NAC-FOLFOXIRI between 2020 and 2023 were included. Their treatment modalities and short-term outcomes were evaluated retrospectively. Values are expressed as median.

**Result:** Patient background was 64 years of age, 13 cases of synchronous metastasis, maximum diameter of liver metastasis 38 mm, and 4 tumors. About half of the patients had G3 or greater AEs, but all patients completed the scheduled NAC. The tumor reduction rate was 38.4%, and RECIST evaluation showed 8 cases of PR, 6 cases of SD, and 1 case of PD. 11 patients underwent hepatic resection, excluding 1 case of PD, 1 patient who died of other disease, 1 patient who refused surgery, and 1 patient with liver dysfunction. Five of the 11 patients underwent liver resection with more preserved liver function compared to the planned procedure before NAC. After operation, one patient died due to liver failure, but the others had no severe complications, and the median postoperative hospital stay was 11 days. The died patient had significant hepatic atrophy and liver dysfunction (ICG 18%) after NAC. Therefore we now consider a liver volume reduction of <10% and ICG <15% after NAC as an indication for hepatectomy.

---

**Abstract Submission No. 100987**

**O-0738**

**Liver-Directed Microwave Ablation of Oligometastatic Renal Cell Carcinoma in a Cirrhotic Patient**

Rene John Febro1, Hyacinth Maurielle Van Eviota1, Jaqueline Arsenal1, Salubhadhin Andam1, Maria Rossea Monfero1, Erika Johann Tanada1, Melchor Chan1, Stephen Wong1

1University of Santo Tomas Hospital Manila Philippines

**Background:** Metastatic renal cell carcinoma (RCC) to the liver is not uncommon and portends poor prognosis. However, studies illustrated that patients with cirrhosis have a decreased risk of acquiring liver metastases. No reports yet of liver-directed therapies in a cirrhotic patient with RCC. We present a unique case of oligometastatic RCC in a patient with liver cirrhosis who successfully underwent liver-directed microwave ablation (LD-MWA) prior to nephrectomy.

**Case Description:** A 64-year-old obese, diabetic female sought consult due to flank pain. Work-up revealed pyuria and microscopic hematuria, and a left renal mass on ultrasound. Computed tomography (CT) showed a 5x6x6 cm mass at the left kidney; with noted cirrhotic liver with hypodense lesions at right lobe; chest CT was unremarkable. Liver function was preserved, and AFP was normal. Same session ultrasound-guided percutaneous liver biopsy and microwave ablation of the lesions were done. Post-ablation imaging showed complete ablation. Liver biopsy exhibited carcinoma with clear cell features. Patient underwent laparoscopic radical nephrectomy with uneventful postoperative course.

**Conclusion:** Patients with oligometastatic RCC in a cirrhotic liver represent a challenging case requiring multidisciplinary management. LD-MWA as an alternative to surgical metastatectomy, may be offered in these cases. Further studies are needed to identify patients who will benefit most from this strategy.
Conclusion: NAC-FOLFOXIRI for technically resectable HR-CLM may contribute to liver parenchymal preservation, but liver dysfunction should be noted.

Abstract Submission No. 101434

O-0740

Title: Dark spots without a trace - a case of melanoma of unknown primary in the liver

Shann Long1, Alyssa Sim1

1Department of Gastroenterology & Hepatology, Tan Tock Seng Hospital, Singapore Singapore Singapore

Background: Malignant melanoma (MM) is an aggressive neoplasm with increasing incidence. In 3.2% of cases, Melanoma of Unknown Primary (MUP) behaves as an occult melanoma where no primary is found. We report a case of MUP presenting as liver lesions.

Case report: A 54-year-old lady with no significant past medical history presented to hospital with unintentional weight loss. Computed Tomography (CT) scan showed prominent supraclavicular and hilar lymph nodes and multiple indeterminate hepatic lesions. There was no liver cirrhosis. In this admission, she was newly diagnosed with Pulmonary Tuberculosis (TB), and started on treatment. Laboratory tests done revealed an incidental past Hepatitis C infection, but liver function tests and alpha-fetoprotein were normal. With further Magnetic Resonance Imaging (MRI) of the liver, differential diagnoses were either multifocal hepatocellular carcinoma, liver metastases or hepatic tuberculosis, in view of newly diagnosed TB. She underwent a percutaneous liver biopsy of the lesions and histology confirmed a melanoma. Full clinical examination identified no suspicious cutaneous lesions. Upper and lower endoscopy were negative for gastrointestinal malignancies. Ophthalmological evaluation revealed no uveal lesions and nasoendoscopy was normal. Positron emission tomography (PET) also demonstrated no obvious primary malignancy. Despite this, she remained well with no hepatic complications from the liver lesions and was started on immunotherapy of Nivolumab by the oncologist as treatment for MUP.

MM presenting as liver lesions is rare and requires thorough physical examination and corresponding investigations to search for the primary lesion. If the primary is not identified, MUP should be considered.

Abstract Submission No. 101481

O-0741

Patterns of liver metastasis in ovarian cancer

Harshita Dubey1, Amar Ranjan1, Shuvrjyoti Mondal1

1AIIMS, Delhi NEW DELHI India

Introduction: In ovarian cancer, the liver is involved via two mechanisms; liver parenchymal invasion (LPI) from perihepatic peritoneal metastasis (FIGO stage III) and hematogenous spread (FIGO stage IV) with the second one having shorter survival.

Case history: A 37-year-old female presented with loss of appetite & abdominal distension. CA 125 was 1888.5 IU/L. CECT showed a 15 mm-mass. DT was 126 days. Uptake was decreased on EOB-MRI. AFP/PIVKA-II was 72 mm. It (72 mm) was hyper-enhanced in early-phase hepatobiliary phase. PET-CT revealed FDG uptake. CA19-9 was 43.7U/mL. As ICC/CoCC diagnosis. He has remained recurrence-free for 1.5 years. Our other patient, a 58-year-old female, detected a mass during follow-up for NBNC hepatitis. It (72 mm) was hyper-enhanced in early-phase CECT, followed by washout. A CT from 22 months prior showed a 15 mm-mass. DT was 126 days. Uptake was decreased on EOB-MRI hepatobiliary phase. PET-CT revealed FDG uptake. AFP/PV/KAI-II were slightly elevated. She underwent hepatectomy under a diagnosis of hepatocellular carcinoma. Histologically, the tumor had necrosis and tubular structures of various sizes with apical membranes positive for EMA, indicating CoCC. Postoperative lymph node and bone metastases were found 2 and 13 months, respectively.

Conclusion: DT was prolonged in both patients as compared to previous report in ICC cases. This implies good outcomes. One had a well-differentiated, however, the other a mixed well to poorly-differentiated tumors reflecting marked clinicopathological differences. Diversity exists among CoCC cases.

Abstract Submission No. 200198

O-0742

Reconsidering cholangiocarcinoma from two cases presenting with different characteristics

Akiko Saito1, Ayaka Gamo1, Yasuo Tanaka1, Yasushi Kojima1, Mikio Yanase1, Fuyuki Inagaki1, Norihiro Kokudo1, Hidemiki Miyazaki1, Masayuki Nakano2

1National Center for Global Health and Medicine Tokyo Japan, 2Tokyo Central Pathology Laboratory Tokyo Japan

Cholangiocarcinoma (CoCC) is small duct type intrahepatic cholangiocarcinoma (ICC) according to WHO classification. We experienced two patients with different clinicopathological findings, prompting us to reconsider CoCC characteristics.

Patients: A 76-year-old male with a mass on US, underwent CEUS demonstrating whole-tumor enhancement and washout within one minute. It (46 mm) showed arterial peripheral enhancement and equilibrium phase delayed enhancement on CECT. Retrospectively, the mass (6 mm) had appeared as arterio-portal shunt 9 years earlier. The tumor doubling time (DT) was 380 days. EOB-MRI showed decreased uptake in the hepatobiliary phase. CA19-9 was 43.7U/mL. As ICC/CoCC was suspected, partial hepatectomy was performed and yielded a CoCC diagnosis. He has remained recurrence-free for 1.5 years. Our other patient, a 58-year-old female, detected a mass during follow-up for NBNC hepatitis. It (72 mm) was hyper-enhanced in early-phase CECT, followed by washout. A CT from 22 months prior showed a 15 mm-mass. DT was 126 days. Uptake was decreased on EOB-MRI hepatobiliary phase. PET-CT revealed FDG uptake. AFP/PV/KAI-II were slightly elevated. She underwent hepatectomy under a diagnosis of hepatocellular carcinoma. Histologically, the tumor had necrosis and tubular structures of various sizes with apical membranes positive for EMA, indicating CoCC. Postoperative lymph node and bone metastases were found 2 and 13 months, respectively.

Conclusion: DT was prolonged in both patients as compared to previous report in ICC cases. This implies good outcomes. One had a well-differentiated, however, the other a mixed well to poorly-differentiated tumors reflecting marked clinicopathological differences. Diversity exists among CoCC cases.

Abstract Submission No. 200226

O-0743
EUS Role in Defining Endoscopic and Histopathological Spectrum of Liver Lesions - South Asian Study

Masood Karim1, Adeel Ur Rehman1, Om Parkash1, Zeeshan Uddin1

1Aga Khan University Hospital, karachi Karachi Pakistan

Introduction: Conventionally liver lesions sample are acquired by transabdominal ultrasound guided procedure. Currently EUS guided liver biopsies demonstrated better diagnostic yield with letter adverse event.

Aim: Aim of study to evaluate safety and diagnostic role of EUS in defining different endoscopic and histopathological spectrum of liver lesions in our region (South Asia).

Method: It is a descriptive study conducted at Endoscopy Suite, Aga Khan University Hospital from January 2021 to December 2023. All inpatient and outpatient with Liver lesion with or with organs involvement were included in study. Data were collected and analyzed using SPSS Version 22.

Results: Total 20 patients were included in the study. Majority of patients were male 15 (75%) while 5 (25%) were female. All patients were adult above 33 years ranging from 34 to 78 years. Main indications for EUS guided biopsies were pancreatic mass with Liver Lesions 7 (35%), Isolated liver lesion 4 (20%) and Porta hepatis mass with Liver Lesions 3 (15%). All procedures were done in conscious sedation and most of patient had ASA score II 13 (65%). In all procedures, 22G FNB needle with slow pull technique were used major of single pass 13 (65%), diagnostic yield was 100% with no sedation and procedure related complication.

Histopathology analysis revealed common findings were metastasis of pancreatic origin10 (50%) comprising of adenocarcinoma (35%) and NET (15), metastatic cholangiocarcinoma 3 (15%) and Isolated liver lesions 4 (20%) which includes HCC 2 (10%) and benign 2 (10%).

Conclusion: Our study concludes EUS guided liver lesion biopsies are safe with high diagnostic yield. Metastatic diseases comprising pancreatic adenocarcinoma is the commonest histological finding followed cholangiocarcinoma and hepatoma.

Abstract Submission No. 100075
O-0744

Lower incidence of adverse liver outcomes and HCC in patients with chronic liver disease and HIV

Maurice Michel1,2, Hannes Hagström3-4, Linnea Widman3, Piotr Nowak3,5, Ying Shang5, Jörn M. Schattenberg1,2, Axel Wester5

1I. Department of Medicine, University Medical Center Mainz Mainz Germany, 2Metabolic Liver Research Program, I. Department of Medicine, University Medical Center Mainz Mainz Germany, 3Department of Medicine, Huddinge, Karolinska Institutet Stockholm Sweden, 4Unit of Hepatology, Department of Upper GI Diseases, Karolinska University Hospital Stockholm Sweden, 5Unit of Infectious Diseases, Karolinska University Hospital Stockholm Sweden

Background: People living with HIV (PLWH) show a high incidence of chronic liver disease (CLD). However, whether HIV is associated with major adverse liver outcomes (MALO) in patients with underlying CLD remains to be determined.

Methods: In this population-based cohort study, data were retrieved from the Swedish National Patient Register to identify PLWH and CLD (n=2,375) or CLD without HIV (n=144,346) between 1997 and 2020. The cumulative incidence of MALO was calculated while accounting for competing risks (non-MALO death). Incidence rates per 1000 person-years were compared between the exposure groups (HIV vs. no HIV) with Cox regression to estimate adjusted hazard ratios (HR) and their 95% confidence intervals (CIs).

Results: The incidence rate per 1000 person-years of MALO was lower in PLWH (5.1, 95% CI 4.2-6.1) compared to patients without HIV (13.1, 95% CI 12.9-13.3). This translated into an adjusted HR of 0.77 (95% CI 0.64-0.93), driven by a lower rate of hepatocellular carcinoma (adjusted HR=0.61, 95% CI 0.43-0.86). Consistent results were noted across a range of subgroup analyses. The 10-year cumulative incidence of MALO was lower in PLWH (5.0%, 95% CI 4.1-6.1) than in patients without HIV (10.9%, 95% CI 10.7-11.0).

Conclusion: Among patients with CLD, the risk of MALO was lower in PLWH compared to those without HIV, primarily due to a lower incidence of HCC. These results suggest that HIV is not associated with a higher risk of MALO.

Abstract Submission No. 100085
O-0745

Genotype 4 HEV infection trigger the initiation and development of acute pancreatitis

Jian Wu1, Fen Huang2

1Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou University Medical Center, 242 Guangji Road, Suzhou 215008, Jiangsu, China; Suzhou China, 2Medical School, Kunming University of Science and Technology, 727 Jing Ming South Road, Kunming, China; Kunming China

Background: The role of HEV infection in pancreatitis patients remains unclear.

Methods: 1000 eligible patients with AP, 1000 healthy controls (HCs) and 300 patients with AHE were enrolled. Rhesus macaques with HEV infection model was constructed to assess pancreatitis in rhesus macaques infected with HEV.

Results: The positive rates of anti-HEV IgG, anti-HEV IgM and HEV RNA in the AP patients were all significantly higher than HCs. With the increase of the severity of AP, the percentage of HEV infection also increased significantly. The percentage of patients with severe AP in the AP-AHE group was significantly higher than the AP group. Moreover, HEV infection was one of the main independent risk factors and owned the high predictive power for the outcome of AP. High level of HEV titre would prolong the recovery time. Both ISH and IHC showed that HEV replicates in the pancreas of rhesus macaques. HE staining showed that the structure of the pancreatic islets was damaged and the tissue was loose after 272 dpi of HEV infection. After 770 dpi, a large amount of hyperemia appeared in the pancreatic islets. Both IFA and quantitative analysis of CD45 and F4/80 showed rhesus macaques infected with HEV caused a large number of inflammatory cells in the pancreas. Quantitative detection of HEV RNA in the serum, liver, and pancreas of rhesus macaques revealed that the pancreas and liver had a comparable viral load.

Conclusions: HEV infection plays an important role in the occurrence, development and prognosis of AP.

Abstract Submission No. 100438
O-0746

A nomogram for diagnosing infection in older patients with AoCLD: a nationwide prospective study

Ruochan Chen1, Li Wu1, Yan Huang1, Hai Li2
Imprinted SARS-CoV-2 humoral immunity induces a high reinfection risk in cirrhotic patients

Qian Zhu¹, Hong Ren¹

¹Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University Chongqing China

Background: The potential risk and related mechanism of Omicron reinfection after BA.5 breakthrough infection (BTI) in cirrhotic patients remain unclear.

Methods: We collected peripheral blood samples from 32 cirrhotic patients with different SARS-CoV-2 vaccination history 9 to 31 days after BA.5 infection to evaluate the hybrid humoral immunity. Serum neutralizing activity against Omicron subvariants was examined by pseudo-virus neutralization assay. BA.5 specific B cell memory was evaluated by flow cytometry.

Results: Omicron BA.5 BTI elicited higher serum geometric mean titers (GMTs) against Wuhan-1 rather than BA.4/5 in cirrhotic patients with wildtype (WT)-based vaccination history regardless of 2-dose group and 3-dose group, but converse result was shown in unvaccinated patients. The serum GMTs against highly immune-evasive XBB.1.5 were lowest in all cirrhotic patients. In the 3-dose cohort, more than 80% of the BA.5 anti-receptor-binding domain (RBD)-binding memory B cells (MBCs) also bind to WT, indicating that BA.5 BTI mainly recalls cross-reactive MBCs elicited by WT-based vaccine, but rarely produces BA.5 specific MBCs. Besides, when compared with 2-dose group, cirrhotic patients with 3-dose vaccination did not show significant increased serum GMTs against BA.4/5 and XBB.1.5, consistent with the frequencies of BA.5 specific MBCs and plasmablasts (PBs).

Conclusions: We reported the imprinted SARS-CoV-2 humoral immunity shaped by WT-vaccination in cirrhotic patients for the first time, which predicts their high risk of reinfection in next potential wave including XBB.1.5. Our results supported the consideration of incorporating the Omicron variants into subsequent vaccine design and performing more studies of alleviating immune imprinting in this vulnerable population.

Abstract Submission No. 100995
O-0749

Molecular mechanisms of epigallocatechin gallate to treat granulomatous hepatitis caused by Q fever

Rian Ka Praja¹, Reny Rosalina²

¹Faculty of Medicine, Universitas Palangka Raya Palangka Raya Indonesia, ²Faculty of Mathematics and Natural Sciences, Universitas Palangka Raya Palangka Raya Indonesia
**An Immunocompetent Mongolian Gerbil Model for Hepatitis E Virus Genotype 1 Infection**

Tianxu Liu1, Lin Wang1

1Peking University Beijing China

**BACKGROUND & AIMS:** Hepatitis E virus (HEV), primarily genotype 1 (HEV-1) accounts for approximately 20.1 million HEV infections, 44000 deaths, and 3000 stillbirths annually. Like HAV, HBV, HCV and HDV, current evidence demonstrated that HEV-1 only infects humans and no immunocompetent small animal model exists for the study of HEV-1 infection. We evaluated if Mongolian gerbils could serve as an alternative.

**Methods:** Mongolian gerbils were used for infection experiments with HEV-1 and HEV-3. HEV infection parameters, including HEV RNA, anti-HEV, antigen, liver function test and histopathology were determined.

**Results:** We adapted a clinical isolate of HEV-1 by serial passages in the feces of aged male Mongolian gerbils. The resulting gerbil-adapted strain at passage 3 induce robust acute HEV infection characterized by stable fecal virus shedding, elevated liver enzymes, liver histopathological changes and seroconversion to anti-HEV. HEV-1-infected pregnant gerbils showed vertical transmission. HEV RNA or antigens were detected in the liver, kidney, intestine, placenta, testis and the neonates/fetus liver samples. Intrahepatic transcriptomic analysis indicated activation of innate immunity. Tumor growths in both liver and intestinal tissues. Tendency of elevation in serum aminotransferases was observed in the liver and intestinal tissues. Submucosal inflammation was partly observed in the intestinal tissues. Tendency of elevation in serum aminotransferases was observed.

**Conclusions:** This HEV-1 infection gerbil model should be of value in investigating hepatitis E immunopathogenesis and evaluating vaccines and antivirals against HEV.

---

**Epigallocatechin-3-gallate (EGCG), a polyphenolic compound found in green tea, has demonstrated anti-pathogenic potential against various infectious agents. This study aimed to elucidate the anti-pathogenic mechanisms underlying EGCG’s efficacy against the pathogenesis of C. burnetii in granulomatous hepatitis using a bioinformatics model. A bioinformatics approach employing STITCH v.5.0 program was used to identify the protein targets and predict their functional role and virulence properties. EGCG was found to target ten important proteins of C. burnetii, including dihydrolipoyl dehydrogenase (lpdA), dihydrofolate reductase (folA), peptidyl-prolyl cis-trans isomerase surA (CBU_1980), DNA mismatch repair protein (mutL), (3R)-hydroxymyristoyl-ACP dehydratase (fabZ), aspartate aminotransferase (aspB), polyketide synthase (CBU_0788), methylated-DNA-[protein]-cysteine S-methyltransferase (ogt), hypothetical protein (1415), and ABC transporter permease (CBU_0933). Specifically, those identified virulence factors are essential in the survival of C. burnetii. It can be concluded that the anti-pathogenic mechanism of EGCG against C. burnetii in granulomatous hepatitis is through blocking several virulence factors associated with bacterial cell survival and metabolisms. However, the findings of this bioinformatics study need to be further proven and validated using in vitro and in vivo experiments.

---

**In vitro and in vivo hepatitis A virus infection models for anti-HAV drugs screening**

Reina Sasaki-Tanaka1, Tatsuo Kanda1, Noriko Nakajima1, Hiroaki Okamoto2

1Department of Medicine, Nihon University School of Medicine Tokyo Japan, 2Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine Tochigi Japan

**Aims:** Developing a new in vivo HAV infection mouse model.

**Methods:** 1) Human hepatoma cell line Huh7 or HepG2 were infected with HAV GT-IB HM175 or GT-IIIA HA11-1299 strain and then transplanted into the back of nude mice as xenografts. 2) HAV RNA were measured by real-time RT-PCR in feces, sera, liver and intestinal tissues and tumors of the mice. 3) Tissues were stained by H&E. 4) Serum aminotransferases were measured by ELISA.

**Results:** 1) No difference in the bodyweight of HAV infected and uninfected mice. Mice transplanted with HepG2 cells and mice transplanted with Huh7 cells were sacrificed after 13 days and after 32 days of transplantation, respectively. 2) Mice transplanted with HepG2 cells of HAV infection - HAV RNA detected in tumors only. 3) Mice transplanted with Huh7 cells of HAV GT-IB HM175 infection - No tumor and no HAV RNA detected. 4) Mice transplanted with Huh7 cells of HAV GT-IIIA HA11-1299 infection - HAV RNA detected in feces, sera, liver and intestinal tissues and tumor. Hepatic necroinflammation was observed in the liver. Submucosal inflammation was partly observed in the intestinal tissues. Tendency of elevation in serum aminotransferases.

**Discussion and Conclusion:** Mice transplanted with Huh7 of HAV GT-IIIA HA11-1299 infection seems useful as an in vitro HAV infection model for anti-HAV drugs screening. In this model, inflammation was histopathologically observed in the liver and intestinal tissues where HAV RNA was detected. We developed a xenograft mouse model with HAV GT-IIIA HA11-1299 infection.

---

**Plasma Exchange as a rescue therapy for severe prolonged cholestasis in Acute Viral Hepatitis**

Sunil Taneya1, Ganesh C P1, Muhammad Uwais Ashraf1, Sahaj Rath1, Arka De1, Nipun Verma1, Madhumita Premkumar1, Rekha Hans2, Ratti Ram Sharma2, Ajay Duseja1

1Department of Hepatology, Postgraduate Institute of Medical Education & Research Chandigarh India, 2Department of Transfusion Medicine, Postgraduate Institute of Medical Education & Research Chandigarh India

**Background:** Most cases of acute viral hepatitis (AVH) resolve within weeks; however, a subset of patients develop severe prolonged cholestasis with disabling symptoms. This retrospective study aimed to investigate the etiology, management, and outcomes in patients of AVH complicated by prolonged cholestasis.

**Methods:** A retrospective analysis of 50 patients admitted with AVH complicated with prolonged cholestasis was done. Data was collected from medical records; clinical features, laboratory investigations, treatment and outcomes were analyzed.

**Results:** 50 patients, majority young males 88%(n=44) with mean age of 23.4±4.5 years were analyzed. Hepatitis A virus was the cause of AVH in forty-seven (94%) patients. Common symptoms included severe pruritis in 96% (n=48), disturbed sleep in 90% (n=45) and dry
cough in 70% (n=35). At the time of presentation, mean bilirubin was 30.3±5.9mg/dL, serum alkaline phosphatase (SAP) level was 166.3±47.2 IU/L, AST was 136±58.6 IU/L and ALT of 152.4±76.3IU/L. The mean bile acid concentration was 197.8±31.2 mg/dL. All patients received oral anti-pruritic medications for an average duration of 34.3 days. Thirty-Seven (74%) patients underwent standard volume Plasma Exchange (PLEX) with a range of 1-5 sessions. Twenty-Five (50%) patients received a short course of oral steroids (20 mg) after undergoing plasma exchange. Six (12%) patients received only steroids. Group that received combined PLEX followed by steroids exhibited significant improvements in symptoms, bilirubin and bile acids at 4 weeks (p=0.001) compared to the other groups. **Conclusion:** PLEX followed by oral steroids is a novel strategy for managing severe prolonged cholestasis with incapacitating symptoms in AVH.

---

**O-0753**

**Small intestinal bacterial overgrowth in liver disease: Do jejunal cultures predict outcome?**

Moinak Sen Sarma1, Chinnoy Sahu1, Uday Ghoshal2, Ujjwala Ghoshal2, Ujjal Poddar1, Anshu Srivastava1, Amrita Mathias1

1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India, 2Dept of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India, 3Dept of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

**Introduction:** There is limited data on bacterial translocation and small intestinal bacterial overgrowth (SIBO) in pediatric cirrhosis. We aimed to evaluate and interrelate the endotoxin assay, breath test and jejunal cultures in cirrhosis.

**Methodology:** A prospective study enrolled cirrhotic children for jejunoscopy, glucose hydrogen-breath test (GHBT, normal <12ppm above baseline), serum and ascitic lipopolysaccharide-binding protein (LBP, normal <5mcg/mL). Jejunal culture (aerobic and anaerobic media) antibiotic sensitivity (Kirby-Bauer disc diffusion method) and resistance genes (conventional polymerase chain reaction) were assessed. The median, minimum, and maximum areas under curve of GHBT were estimated using Ghoshal BreathCalc (Patent appl.No. 202111029055). Extrahepatic portal-venous obstruction patients were controls.

**Results:** Of the 56 cirrhotic children (pediatric end-stage liver disease score, PELD 15.4±4.3, 18 (32%) had evidence of ascitic fluid infection (AFI) with AF-LBP 7.6±3.3 mcg/mL (fig1). Twelve of 21 (57%) cirrhotics with positive jejunal culture had one or more morbidity outcomes (hospital readmission, systemic infection, renal dysfunction, recurrent AFI, persistent hyponatremia and relative adrenal insufficiency) over the next 6 months. Of these twelve, six had high AF-LBP (18±2.7), serum LBP (33±8.7) and jejunal culture multidrug antibiotic resistance (mecA, NDM-1, mec-1, SHV-1, NDM-1 genes). All six patients died in next 8 (3-12) months. Serum LBP correlated with absolute neutrophil count (r=0.77, p=0.01) and pediatric end-stage liver disease (PELD) score (r=0.87, p<0.03). Serum LBP cut-off >7.8 mcg/mL (AU/ROC 89%, sensitivity 88%, specificity 64%, p=0.02) predicted short-term morbidity events. All ten patients with AF-LBP >10 mcg/mL had renal dysfunction.

**Conclusions:** Jejunal culture-positive SIBO in cirrhotics predicts short-term morbidity outcomes.

---

**O-0754**

**Global, regional, and national burdens of HEV from 1990 to 2019 and forecasted incidence in 2030**

Yu-Chen Fan1,2, Bai-Yun Wu1,2, Jing Zuo1,2, Qi An1,2, Yu-Xin Tian3, Ruo-Xi Jia3, Kai Wang3

1Department of Hepatology, Qilu Hospital of Shandong University Jinan China, 2Institute of Hepatology, Shandong University Jinan China, 3Department of Infectious Diseases, The affiliated Hospital of Qingdao University Qingdao China

**Aim:** Hepatitis E virus (HEV) is the emerging cause of viral hepatitis. Here, we reported the trends of HEV burden at the global, regional, and national levels from 1990 to 2019, and predicted the forecasted incidence in 2030.

**Methods:** Using the data from the Global Burden of Diseases (GBD) 2019, we performed the trend analysis to report the incidence of HEV infection, disability-adjusted life years (DALYs), incidence per 100,000 population, average annual percentage changes (AAPCs), and social development index (SDI). Connection point regression analysis was performed to identify the years with the most significant changes in global trends. Furthermore, we predicted the incidence of HEV infection in 2030 using Bayesian age-period-cohort analysis.

**Results:** The incidence of global HEV infection decreased from 304.3 per 100 000 population in 1990 to 251.63 in 2019 with the AAPC as 0.13. The specific years for significant decrease of HEV incidence were 2006, 2009, 2014 and 2017. Regionally, Western Sub-Saharan Africa had the highest incidence and Southern Sub-Saharan Africa had the largest increase of incidence between 1990 and 2019. From 1990 to 2019, the highest incidence and DALYs rate of HEV infection was Low-middle SDI countries, while Middle SDI countries had the largest decrease in incidence and the High-middle SDI countries had the largest decline in DALY’s. In 2030, the predicted global incidence of HEV infection is 275.34 per 100 000 population.

**Conclusion:** Global HEV incidence decreased between 1990 and 2019 but the incidences of individual regions and countries are still increasing year by year.

---

**O-0755**

**PERCUTANEOUS TREATMENT OF HYDATID CYSTS WITH THE ORMECI TECHNIQUE**

Necati Ormeci1, Ozgun Omer ASILLER2, Ayhan Parmaks3, Cagdas Kalkan2, Ercan Ustuner4, Ahmet Altilt2, Hakan Erdem4

1Istanbul Health and Technology University Istanbul Turkey, 2Ankara University Medical School, Department of Anesthesiology and Reanimation Ankara Turkey, 3Ministry of Health, Ankara City Hospital Ankara Turkey, 4Ankara University Medical School, Department of Radiology Ankara Turkey, 5Turkish Health Sciences University, Guilhane School of Medicine, Department of Infectious Diseases and Clinical Microbiology Ankara Turkey, 6ID-IRI Lead Coordinator Ankara Turkey

**Aim:** This study is to analyze the efficacy of the ÖRMECİ technique used in the treatment of Hydatid cysts.

**Methods:** This is a retrospective cohort study. Patients with Hydatid cysts who presented to the Ankara University School of Medicine, Department of Gastroenterology since 1991 were included. Patients with WHO-CE types 1, 2, 3A-3B live cysts who were treated...
percutaneously at least once and followed-up after a minimum of six months were analyzed.

**Results:** A total of 1556 cystic lesions in 1035 patients have been presented to our department since 1991. 544 live HCs in 479 patients were treated with the RMECI technique. The mean follow-up time was 59.29 months for females and 57.18 for males. The overall clinical success rate of all treated cysts with the RMECI technique was 94.5%. After the treatment, a statistically significant decrease was found in all WHO-CE cyst types in terms of cyst sizes (p < 0.001 for all). Mortality, abscess and fistula formation, sclerosing cholangitis, and drug toxicities were not detected. Only two patients experienced reversible anaphylaxis during the treatment among 544 cysts (0.36%).

**Conclusion:** Hydatid cysts can be treated percutaneously by the RMECI technique with a high success rate for WHO-CE Type 1, 2, and 3B. The RMECI technique is an economic, simple, cheap, repeatable outpatient procedure. It can be chosen as the first-line therapeutic modality in suitable patients with Hydatid cysts.

---

**Abstract Submission No. 200112**

**O-0756**

**Hepatitis E virus infects human testicular tissue and Sertoli cells**

**Tianxu Liu1, Lin Wang1**

1Peking University Beijing China

Globally, hepatitis E virus (HEV) infections are prevalent. The finding of high viral loads and persistent viral shedding in ejaculate suggests that HEV replicates within the human male genital tract, but its target organ is unknown and appropriate models are lacking. We aimed to determine the HEV tropism in human testis and its potential influence on male reproductive health. We conducted ex vivo culture of human testis explants and in vitro culture of primary human Sertoli cells. Clinically derived HEV genotype 1 (HEV1) and HEV3 virions, as well as rat derived HEV-C1, were used for inoculation. Transcriptomic analysis was performed on testis tissues collected from tacrolimus-treated rabbits with chronic HEV3 infection. Our findings reveal that HEV3, but not HEV1 or HEV-C1, can replicate in human testis explants and primary human Sertoli cells. Tacrolimus treatment significantly enhanced the replication efficiency of HEV3 in testis explants and enabled successful HEV1 infection in Sertoli cells. HEV3 infection disrupted the secretion of several soluble factors and altered the cytokine microenvironment within primary human Sertoli cells. Finally, intratesticular transcriptomic analysis of immunocompromised rabbits with chronic HEV infection indicated a downregulation of genes associated with spermatogenesis. HEV can infect the human testicular tissues and Sertoli cells, with increased replication efficiency when exposed to tacrolimus treatment. These findings shed light on how HEV may persist in ejaculate of patients with chronic hepatitis E and provide valuable ex vivo tool for studying countermeasures.

---

**Abstract Submission No. 100458**

**O-0758**

**Hepatic Tuberculoma Masquerading as Hepatocellular Carcinoma: A Case Report**

**Laurence Laurel1, Janelle Gagelonia1, Marceliano Aquino Jr.1**

1St. Luke's Medical Center - Global City Taguig Philippines

Hepatic Tuberculoma, a rarely-seen tuberculosis manifestation, presents a complex challenge to gastroenterologists due to its diverse clinical presentations. This case report sheds light on a unique instance of liver tuberculosis in a region grappling with a high prevalence of HBV. In this particular case, it not only mimicked Hepatocellular Carcinoma but also exhibited symptoms characteristic of Charcot’s Triad. Our patient, a 35-year-old male, initially presented with a one-week history of right upper quadrant abdominal pain, jaundice, and fever. Initially suspected as Acute Cholangitis, further investigation through MRCP revealed a 2x2cm hypointense ovoid lesion in segment 5. This diagnostic puzzle led to a liver biopsy to rule out Hepatocellular Carcinoma. To our astonishment, the biopsy showed clusters of epithelial cells intermingled with poorly formed caseating granulomas alongside benign hepatocytes. Additionally, MTB-PCR analysis of tissue core fragments yielded positive to Mycobacterium tuberculosis. Subsequently, the patient commenced anti-koch’s therapy, and at the time of this report, is on his third month of treatment with a remarkable resolution of the initial symptoms.

In conclusion, this case underscores the critical consideration of Hepatic Tuberculoma in the differential diagnosis of liver lesions, particularly in regions with a high HBV prevalence. It is vital to have a heightened index of suspicion, comprehensive histopathology confirmation to differentiate Hepatic Tuberculoma from Hepatocellular Carcinoma. This report contributes to the evolving body of literature concerning the distinctive presentations of tuberculosis. Timely diagnosis and prompt initiation of anti-koch’s therapy play a pivotal role in achieving a favorable clinical outcome in such cases.

---

**Abstract Submission No. 101453**

**O-0758**

**We did not look for it because it was everywhere: The Ubiquitous presence unveiled**

**Srijaya Sreesh1, Sreekumar Sivadasan1, Aditya Verma1, Nuzil Moopan1, Jithin John1, Jesse Skaria1, Jacob Raja AS1, Rashid KK2, Ann Mary George3, Krishnadas Devadas1**

1Department of Medical Gastroenterology Thiruvananthapuram India

49 year old homemaker presented with c/o Jaundice for 2 weeks, Menorrhagia for 1 week and Generalised pruritus for 2 days

Past History - 8 months back she received Ormiloxifene for 3 months for dysmenorrhea related to uterine fibroid

Examination revealed icterus, pedal edema, skin excorrision

Baseline investigation - HB-5.6; LFTI TB/DB - 10.9/5.9 mg/dl SGOT/SGPT-761/283 U/L ; TP/Alb-5.2/2.4 g/L ; ALP- 127U/L GGT-29.5(50)U/L; INR- 1.63.

USG abdomen showed minimal ascites and mild coarsening of liver echotexture.

Ascitic fluid examination revealed high SAAG low-protein ascites without evidence of infection. Etiological evaluation of liver dysfunction done twice-no clue.

Clinical progression and treatment- Due to onset of encephalopathy, she was planned for superurgent liver transplantation. Due to non-availability of a matching donor, she underwent 3 cycles of Plasma-Exchange as bridge to transplantation. Trans-jugular liver biopsy (TJLB)-histopathology report was suggestive of Acute hepatitis with hepato-canalicular bilirubinostasis, and mild steatosis. Extended investigations revealed HAV-RNA PCR positive. Even though HAV is endemic in India with >95% IgG-HAV antibody positivity among adults, we started Ribavirin as we were left with no other choice. Due to high suspicion of false positivity, HCV RNA-PCR was repeated 2 days later which confirmed the earlier positive report. Meanwhile there was dramatic response to Ribavirin in 2 weeks with near normalisation of LFT and complete resolution of ascites and encephalopathy

Take home Message- Time to think about occult Hepatitis A with Flare precipitated by the immunomodulatory effects of Ormiloxifene,
Gas Sonogram within Ablation Zone: A Strong Indicator of Post-ablation Infection in Liver Malignancy

Rui Zhang¹, Di Li¹, Ming Xu¹

¹Department of Medical Ultrasonics, the First Affiliated Hospital, Sun Yat-Sen University Guangzhou City China

Background: Patients with gas sonogram within ablation zone are more likely to develop post-ablation infections, but few researches focused on the relationship between the unique image and infection. This study aimed to explore the relationship between ‘gas sonogram’ within the ablation zone and post-ablation infection in liver malignancies.

Methods: This retrospective study reviewed patients between November 2011 and November 2021 who underwent percutaneous thermal ablation in liver malignancies. All patients with ‘gas sonogram’ within ablation zone were included as the case group (n=57), and and two treatment date-matched control without gas sonogram were randomly selected for each case, following a nested case-control design. Gas sonogram was then divided into three classes according to ultrasound imaging.

Results: The post-ablation infection rate and severe infection rate in case group were significantly higher (54.4% (31/57) vs 6.1% (7/114), 26.3% (15/57) vs 0.9% (1/114)), while the hospital stay was significantly prolonged (5 days vs 2 days). No statistically significant difference was showed in recurrence and LTP rate. In case group, gas class III was a more dangerous type and strongly indicated infection. Multivariable logistic regression showed the independent factors for gas sonogram were prior biliary intervention (OR=6.249), cancer type (OR=2.086), and proximity to bile ducts (OR=2.136), and the independent predictor for gas class III was gas range (OR=1.778).

Conclusions: Patients with ‘gas sonogram’ within ablation zone after thermal ablation in liver malignancies were prone to infection, especially gas Class III. Vigilance is required for these patients including early prophylactic antibiotic therapy and local catheter drainage should be instituted.

Hepatobiliary Tuberculosis Mimicking Hepatic Malignancy

Hsin-Yi Chen¹, Jui-Ting Hu¹

¹Division of Digestive Medicine, Cathay General Hospital, Taipei Taipei Taiwan

Background: Hepatobiliary tuberculosis (HBTB) is a rare form of tuberculosis (TB) infection, and frequently misguided into the diagnosis of hepatic malignancy.

Methods: Clinical data from two patients were collected from medical records. The essential features leading to the diagnosis of HBTB and TB infection, and misdiagnosis of HBTB were analyzed.

Results: Both cases presented with abdominal fullness, body weight loss, low-grade fever, and initial medical imaging studies leading to suspicion of hepatic malignancy, but pathological findings of granulomatous inflammation with caseous necrosis leading to the diagnosis of HBTB. One case had axillary lymph node TB culture showing mycobacterium tuberculosis complex. In one case, hepatic mass regressed completely. The other case had resolved hepatic infiltrative change, but persistent hepatic segmental atrophy.

Conclusion: The clinical and radiological features of HBTB remain the great masquerader of hepatic malignancy, sometimes leading to unnecessary surgery. Diagnosis usually requires pathological proof, but once the diagnosis is confirmed, response to therapy is usually optimum.

Abstract Submission No. 101729
O-0762

Comparison of carbon ion radiotherapy and transarterial chemoembolization for HCC larger than 3 cm

Taito Fukushima¹, Satoshi Kobayashi¹, Shotaro Tsunoda¹, Tomomi Hamaguchi¹, Yui Yamachika¹, Yuichiro Tozuka¹,
Prognostic role of serum VEGF and HGF post SBRT in advanced hepatocellular carcinoma

Prabhiyoti Pahwa1, Deepti Sharma1, Pushpa Yadav1, Sherin S Thomas1, Sandhya Hora1, Preedia B E1, Gayatri Ramakrishna1, Shiv K Sarin4, Nirupama Trehanpati1

1Department of Molecular and Cellular Medicine, Institute of Liver and Biliary Sciences Delhi India, 2Department of Oncology, Institute of Liver and Biliary Sciences Delhi India, 3Department of Biochemistry, Institute of Liver and Biliary Sciences Delhi India, 4Department of Hepatology, Institute of Liver and Biliary Sciences Delhi India

Background: Stereotactic body radiation therapy (SBRT) is a treatment option for hepatocellular carcinoma (HCC) patients who are ineligible for other local therapies. An early diagnosis is important for improving the survival rate of patients. Other than AFP and PIVKA II, markers for tumor progression, prognosis and recurrence are needed.

Methods: HCC patients (n=18) were subjected to SBRT dose of 30-50Gy in 5 fractions and serum level of HGF, VEGF and EGF were analysed using enzyme-linked immunosassay before SBRT, at the completion of SBRT and 30 days post SBRT. Cumulative survival rates were calculated using the Kaplan-Meier method and were compared using the log-rank test.

Results: Total of 18 patients were analysed over a median follow up period of 10 months (05-27 months). In patients, the median overall survival was 13 months (95% confidence interval [CI], 5-20.9) with SBRT. The 12 months local control and progression free (PFS) was 80% and 50% respectively. Patients with raised PIVKA-II at baseline and post SBRT showed increased concentrations of VEGF and EGF (Fig B-C). Patients with increased VEGF and HGF at 30 days post SBRT had poor PFS (Fig D). The median progression free survival (mPFS) was 6 months vs. 14 months in patients with increase in VEGF (Fig D). Similarly, mPFS in patients with increase in HGF was 9 months as compared to 14 months post SBRT.

Conclusions: Along with PIVKA II, HGF, EGF and VEGF can be used as prognostic markers to predict the OS, PFS and metastasis in HCC patients.

Abstract Submission No. 101947
O-0763
Background: Liver parenchymal transection is the most important process in liver resection. Current study shows our clamp-crushing technique for robot-assisted liver resection (RLR) and evaluates its perioperative outcomes.

Methods: The da Vinci Surgical System Xi robot is used for RLR. During clamp-crushing technique, the right hand uses a Maryland bipolar connected to the Force Triad Macro mode on arm No.3 or No.4. The EndoWrist One Suction Irrigator is used on arm No.1 to perform all suction and irrigation with the surgeon’s left hand. During this solo-surgery, after crushing with the Maryland bipolar in the right hand, suction is performed with the left hand. Small vessels are cauterized and separated with the Maryland bipolar, and vessels larger than 3 mm in diameter are clipped. When bleeding occurs, hemostasis could be efficiently achieved by using a bipolar system while suction and irrigation. A good surgical field of view could be maintained by alternately using suction and Maryland bipolar to hold up or down the liver dissection plane.

Results: From August 2022 to December 2023, a total of 17 patients underwent RLR. Median total operation time was 384 min, median console time was 305 min and median blood loss was 50 ml. There were no CD≥3 postoperative complications, and median hospital stay was 10 days.

Conclusion: RLR could be safely performed by a clamp-crushing technique using EndoWrist One Suction Irrigator.

Abstract Submission No. 101960

O-0766

Robot-assisted liver resection guided by ICG fluorescence imaging and artificial intelligence

Kazuhiro Matsuda1, Takeshi Aoki1, Nao Kobayashi2, Yoshihiko Tashiro1, Tomokazu Kusano1, Kodai Tomioka1, Shodai Nagashii1, Kazuhiro Saito1, Tatsuya Yamazaki1, Yukari Shinohara1, Takahito Hirai1, Hideki Shibata1, Yuta Enami1, Koji Nogaki1, Akira Fujimori1

1Department of Gastroenterological and General Surgery, Showa University Tokyo Japan, 2Anaut.Inc. Tokyo Japan

Background: Although the number of robot-assisted liver surgery (RALS) has increased in recent years, the lack of haptic feedback remains an issue. Indocyanine green (ICG) fluorescence imaging has proven to be a high potential navigation tool and may be a way to overcome the limitation. Furthermore, we have developed a surgical support artificial intelligence (AI) system to improve the recognition accuracy of vascular structures. This study aimed to investigate the feasibility and clinical application of ICG fluorescence imaging and AI to guide RALS.

Methods: 11 patients who underwent RALS with fluorescence imaging for liver tumor were included. The da Vinci Xi system’s Firefly mode was used to observe fluorescence, liver transection was performed under IOUS and ICG fluorescence guidance. The AI algorithm was evaluated at Anaut Inc.

Results: The subjects included 4 hepatocellular carcinoma, 6 colorectal liver metastasis, and one focal nodular hyperplasia. The mean operative time and blood loss was 354 minutes and 105g, there were no postoperative complications and mortality. In all cases, ICG fluorescence imaging successfully identified tumor localization and aiding in liver transection guidance. The pathological findings of all tumors indicated negative margins, defined as R0. The AI model accurately recognized vascular structures of any size in real-time and indocyanine green fluorescent imaging without visual discrepancies.

Conclusion: The ICG fluorescence imaging is a promising navigational tool, that can potentially overcome the limitations of RALS. Although this AI system is currently limited to preclinical application, these results may support the realization of more accurate real-time navigation.

Abstract Submission No. 102037

O-0767

Robot-assisted Limited Anatomic Liver Resection: A Report on the Current Status

Taiga Wakabayashi1, Yusuke Nie1, Junichi Sakamoto1, Shohei Fujita2, Chie Hagiwara2, Atsuko Itatsu2, Nobuhiko Okamoto1, Kenji Omura1, Go Wakabayashi1

1Ageo Central General Hospital Ageo-shi Japan

Background: Since the inclusion of robot-assisted liver resection (R-LR) in insurance coverage, the number of cases has gradually increased in Japan. This report outlines the current status of minimally invasive liver resection (MI-LR) at a leading robotic hospital in Japan.

Methods: In our institution, the Glissonean approach (GA) and indocyanine green negative staining (ICG-NS) are employed as fundamental techniques in minimally invasive anatomic resections (MI-AR). We aimed to analyze long-term outcomes of MI-AR and describe our approach for R-LR.

Results: Among 112 patients undergoing laparoscopic AR, the 5-year OS rates were 73% for hepatocellular carcinoma (HCC) and 60% for colorectal liver metastasis (CRLM). Of 42 R-LR cases (December 2021 to December 2023), 24 involved anatomic liver resection, 18 involved partial resection. Operative time averaged 384 minutes, blood loss 358ml, complications (≥Calvien-Dindo IIIa) occurred in 7 cases but were successfully treated. The average postoperative hospital stay was 14 days.

Conclusion: MI-AR exhibits favorable oncologic outcomes for HCC and CRLM. R-LR’s advantages lie in its flexible approach to Glissonean pedicle and vessels due to multi-joint functionality. Ongoing improvements in near-infrared light cameras and liver transection devices anticipate the safer implementation of R-LR.

Abstract Submission No. 200033

O-0768

Robotic surgery will be the standard approach to highly complex minimally invasive liver resection

Yutaro Kato1,2, Hiroyuki Kato1, Masayuki Kojima2, Takeshi Takahara2, Koichi Suda2, Atsushi Sugio2, Ichiro Uyama2, Akihiko Horiguchi1

1Department of Surgery, Bantane Hospital, Fujita Health University Nagoya Japan, 2Department of Surgery, Fujita Health University Toyoake Japan

Background: We have standardized surgical techniques of minimally invasive complex anatomic liver resection (MICAR) by extrahepatic Glissonian approach and hepatic vein root-at first cranial-to-caudal parenchymal dissection, based on Laennec’s capsule.

Methods: We performed 260 MICAR including 3 trisectionectomies, 58 hemihepatectomies, 4 bisectionectomies, 70 monosectionectomies and 125 segmentectomies (laparoscopic: LCAR 180; robotic: RCAR 80) at our institution. Indications were HCC (n=151), metastatic tumors (n=73), intrahepatic cholangiocarcinoma (n=13) and others (n=23). Posterolateral lesions were resected in 170 cases (65.4%). Repeat hepatectomies and reconstructive procedures were performed in 40 (15.4%) and 8 (3.1%) cases, respectively.
Results: In the entire MICAR cohort, the median operative time was 593 min and blood loss was 246g. Open conversion, major morbidity, bile leak/collection and 90-day mortality were 3.5%, 9%, 6.5% and 0.4%, respectively. Between propensity score-matched cohorts (64:64), compared to LCAR, RCAR had a lower rate of bile leak (1.6% vs. 11.1%, P=0.028), with comparable operative time, blood loss, conversion rate, morbidity, mortality and hospital stay. In MICAR for posterosuperior lesions and repeat hepatectomy, RCAR, which had worse tumor and procedural backgrounds than LCAR, still had comparable outcomes with LCAR. Reconstructive procedures were highly difficult laparoscopically, and no reconstruction-related complications were observed in RCAR. Postoperative long-term outcomes in newly developed HCC were comparable between LCAR (n=90) and RCAR (n=26).

Conclusions: Robotics may potentially improve safety of MICAR by technical dexterity, particularly for posterosuperior lesions, redo hepatectomy and reconstructive procedures, with comparable long-term outcomes in HCC with laparoscopic surgery. Robotic surgery will be the standard approach to MICAR.

Abstract Submission No. 200233
O-0769

Long-Term Outcomes of Robotic Surgery for Initial Liver Resection of Colorectal Liver Metastases

Hideaki Iwama1, Takeshi Takahara1, Satoshi Miil2, Akihiro Nishimura1, Takuya Mizumoto1, Yuichiro Uchida1, Masayuki Kojima1, Ichiro Uyama1, Koichi Suda1
1Fujita Health University Toyoake Japan

Background: Robotic surgery is becoming increasingly popular for liver resection, and although there are some reports on the short-term outcomes, there are few reports on the long-term outcomes for malignant tumors.

Methods: We compared the long-term outcomes of initial liver resection for colorectal liver metastases performed at our hospital during the 8-year period from 2010 to 2017 by dividing the patients into three groups: open, laparoscopic, and robotic surgery groups.

Results: There were 200 patients who underwent initial liver resection, 132 underwent open, 32 laparoscopic, and 15 robotic surgery. The number of cases of anatomic systematic resection was 90 (68.2%), 17 (53.1%) and 6 (40.0%), respectively, with more systematic resection cases in the open surgery group (p=0.015). The median and interquartile range of Beppu’s Nomogram Score (BNS) were 10 (6-15), 7 (4-10), and 4 (3-7), with higher BNS in the open surgery group (p=0.0001).

The long-term outcomes of 5-year and 10-year survival rates were 53.5% and 33.5% in the open group, 67.4% and 51.4% in the laparoscopic group, 53.5% and 44.4% in the robotic group, respectively, with no statistically significant difference (p=0.12).

Conclusion: This study did not show any superiority of robotic surgery in long-term outcomes.

Abstract Submission No. 200284
O-0770

Inventions of robot-assisted laparoscopic liver resection in our department

Yoichi Kawano1, 2, Keisuke Minaminmura1, Yukio Ooshiro2, Tetsuya Shimizu1, Akira Matshita1, Junji Ueda1, Takahiro Murokawa1, Yuto Aoki2, Takashi Ohno1, Akira Hamaguchi1, Yoshiharu Nakamura2, Hiroshi Yoshida1
1Department of Surgery, Nippon Medical School Tokyo Japan, 2Department of Surgery, Nippon Medical School Chiba Hokusoh Hospital Chiba Japan

Introduction: Robot-assisted surgery (RAS) for the liver resection in Japan has just been covered by insurance in 2022, and there is no robot-specific energy device that can be used laparoscopic liver resection, so there are Kanck & Pitfalls. We report on the innovations for it in the RAS in our department.

Results: RAS partial hepatectomy (PH) started in January 2023. 16 cases (11males, 5female), median age 60years (47-83), primary disease: colorectal cancer liver metastases 6, HCC 4, FNH 2, liver cyst 2, hemangioma 1, portal vein hepatic vein fistula 1, median operation time: 388.5min (233-580), median blood loss: ml (0-1020(including ascites)), Median postoperative discharge: days 6(5-12), C-D classification II or higher: 1 (cholecystitis C-D II).

Methods: RAS-PH in our department is performed by the clamp crush method using Meryland forceps. The most important factors are stable surgical field development and adequate tension on the hepatic transection plane using endoloop, organ retractor and thread suture traction which we named “parachute traction”. In addition, continuous drip-ping of saline through the CV catheter increases hemostasis ability with saline enhanced coagulation and it allows identification of the bleeding point. Continuous aspiration with SECURE and atom tube, and the use of folded gauze called “Benz gauze” are also very useful.

Conclusion: The following innovations have been developed, the tension at the hepatic transection plane, short pitch clamp crush method, saline enhanced coagulation and moisture control of the transection plane.
Impact of preoperative infection on the outcomes of liver transplant recipients

Ze Xiang1, 2, Yisu Song1, 2, Jiarui Li1, Xuyong Wei1, Jiayin Yang1, Yang Yang1, Shusen Zheng1, Xiao Xu1, 5, 7

1Zhejiang University School of Medicine Hangzhou China, 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Hangzhou China, 3West China Hospital of Sichuan University Chengdu China, 4The Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 5NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou China, 6Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine Hangzhou China, 7National Center for Healthcare Quality Management in Liver Transplant Hangzhou China

Background: Impact of preoperative infection on liver transplantation (LT) needs further investigation.

Methods: From January 1, 2015 to December 31, 2022, 24,122 eligible patients receiving LT were enrolled from the China Liver Transplant Registry database. The outcomes of LT were compared after using the propensity score-matched analysis.

Results: Compared to patients without preoperative infection, those with preoperative infection were more likely to have effusion, infection (both P < 0.01), pulmonary infection (all P < 0.05), and also had shorter 30-day, 90-day survival and overall survival (OS) (all P < 0.05). Cox proportional hazards regression analysis revealed that recipient MELD score and cold ischemia time were risk factors for the OS in patients with preoperative infection (both P < 0.05). Besides, compared to patients with non-pulmonary infection, those with pulmonary infection were more likely to have effusion and infection (both P < 0.0001), and less likely to have abscess and early allograft dysfunction (both P < 0.05). Patients with non-abdominal infection also had a higher proportion of infection than those with abdominal infection (P < 0.05). Furthermore, compared to patients with single site infection, those with multiple site infection were more prone to effusion and infection (both P < 0.05), and they also had shorter 30-day and 90-day survival (both P < 0.05).

Conclusion: Preoperative infection can result in a higher incidence of early postoperative complications and shorter survival in liver transplant recipients. Different infection sites and the number of infection sites will also influence the prognosis of liver transplant recipients.

Impact of preoperative infection on the outcomes of liver transplant recipients

Ze Xiang1, 2, Yisu Song1, 2, Jiarui Li1, Xuyong Wei1, Jiayin Yang1, Yang Yang1, Shusen Zheng1, Xiao Xu1, 5, 7

1Zhejiang University School of Medicine Hangzhou China, 2Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province Hangzhou China, 3West China Hospital of Sichuan University Chengdu China, 4The Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 5NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou China, 6Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine Hangzhou China, 7National Center for Healthcare Quality Management in Liver Transplant Hangzhou China

Background: Impact of preoperative infection on liver transplantation (LT) needs further investigation.

Methods: From January 1, 2015 to December 31, 2022, 24,122 eligible patients receiving LT were enrolled from the China Liver Transplant Registry database. The outcomes of LT were compared after using the propensity score-matched analysis.

Results: Compared to patients without preoperative infection, those with preoperative infection were more likely to have effusion, infection (both P < 0.01), pulmonary infection (all P < 0.05), and also had shorter 30-day, 90-day survival and overall survival (OS) (all P < 0.05). Cox proportional hazards regression analysis revealed that recipient MELD score and cold ischemia time were risk factors for the OS in patients with preoperative infection (both P < 0.05). Besides, compared to patients with non-pulmonary infection, those with pulmonary infection were more likely to have effusion and infection (both P < 0.0001), and less likely to have abscess and early allograft dysfunction (both P < 0.05). Patients with non-abdominal infection also had a higher proportion of infection than those with abdominal infection (P < 0.05). Furthermore, compared to patients with single site infection, those with multiple site infection were more prone to effusion and infection (both P < 0.05), and they also had shorter 30-day and 90-day survival (both P < 0.05).

Conclusion: Preoperative infection can result in a higher incidence of early postoperative complications and shorter survival in liver transplant recipients. Different infection sites and the number of infection sites will also influence the prognosis of liver transplant recipients.

BMSCs ROS-Responsively Secreting Hepatocyte Growth Factor for Attenuating Hepatic IRI

Shengjun Xu1, 2, Sunbin Ling1, 2, Xiao Xu1, 2

1Zhejiang University School of Medicine Hangzhou China, 2Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People’s Hospital Hangzhou China

Background: Hepatic ischemia-reperfusion injury (IRI) impairs the clinical efficacy of liver transplantation. After liver reperfusion, reactive oxygen species (ROS) generated from stressed hepatocytes would aggravate liver damage. How to attenuate IRI and improve liver regeneration remains a key problem.

Methods: A ROS-responsive charge-reversal polymer B-PDEAEA has been synthesized and utilized for condensing plasmid DNA to obtain polyplexes. Inspired by the increased ROS during hepatic IRI and the tendency of bone marrow-derived mesenchymal stem cells (BMSCs) to migrate to injured sites, we put forward constructing BMSCs ROS-responsively secreting hepatocyte growth factor (HGF-BMSCs), which could realize efficient and IRI-specific HGF releasing for attenuating IRI.

Results: B-PDEAEA showed limited cytotoxicity to both hepatocytes and stem cells. N/P ratio as 30 was identified as the optimal for gene transfection in MSCs, and the polyplexes exhibited excellent ROS responsiveness and high gene transfection efficiency. HGF-BMSCs have been constructed and could release HGF with the response to ROS. HGF-BMSCs could release over 60000 pg HGF per 10000 cells with low stimulation of H2O2, suggesting the ROS-responsiveness. CM-Dil was used to track stem cells and the biodistribution assay revealed an accumulation of stem cells in injured livers. Furthermore, both in vitro and in vivo experiments showed HGF-BMSCs could protect hepatocytes from IRI, with deceasing of inflammation.

Conclusions: A novel IRI protection system is constructed and promising to be established and to realize targeted and efficient gene/protein therapy, thus providing a theoretical and experimental basis for translational research on the repair and regeneration of transplanted liver.

Novel System for Organ Preservation: Feed Macrophages with Ceria Nanoparticles

Yongquan Chi1, Junda Li1, Guoqiang Shao1, Wenzhu Li1, Zhengfeng Xuan1, Jinhua Song1, Jianhua Rao1

1Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University; Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing 210029, China Nanjing China

Background: Liver transplantation, a definitive solution for irreversible liver failure and malignant tumors, has encountered significant challenges predominantly attributable to sterile inflammation following ischemia-reperfusion injury caused by frail donor livers and inadequate preservation techniques. Ceria nanoparticles (CeO2NPs) have antioxidant and anti-inflammatory effects, but their potential use in preserving donor livers remains unknown.

Methods: We created newly designed dextran-coated CeO2NPs that we introduced to solutions used to infuse and preserve murine livers. The biodistribution of CeO2NPs and their association with macrophages were investigated. Additionally, we used a liver transplantation mice model to investigate the roles of CeO2NPs-containing preservation solution on liver injury, reactive oxygen species (ROS), inflammation infiltration and hepatocyte apoptosis. In addition, both in vivo and in vitro studies were carried out to investigate the involvement of CeO2NPs in the potential mechanisms of liver transplantation.

Results: The distribution of CeO2NPs in different organs indicates their specificity in murine liver and Kupffer cells. Additionally, CeO2NPs have been shown to improve liver injury, reduce ROS production and inflammation infiltration, suppress hepatocyte apoptosis in mice that have undergone liver transplantation. Furthermore, the application of CeO2NPs aligns with M2 macrophage polarization, implying that they alleviate sterile inflammation following donor liver implantation through interaction with M2 polarization.

Conclusions: A novel system for infusing and preserving donor livers can be accomplished by deploying CeO2NPs in solution by alleviating sterile inflammation via M2 polarization, which may improve prognosis of patients after liver transplantation in the near future.
Long-term outcomes of fenofibrate for treatment of liver allograft ischemic cholangiopathy

Channa Jayasekera1, Michele Barnhill1, David Chascsa1, Hugo Vargas1
1Mayo Clinic Arizona Phoenix United States

Background: Ischemic cholangiopathy (IC) after liver transplantation has no definitive treatment besides retransplantation. 90-days of fenofibrate—a medication which potently downregulates toxic bile acid production—was recently demonstrated to improve cholestasis by 75% in IC patients during the treatment period. We assessed if these responses were durable beyond 90-days and if fenofibrate was stopped in the previously reported patients.

Methods: Over 360 days, we monitored alkaline phosphatase (ALP) and endoscopic retrograde cholangiography needs of liver transplant recipients who received at least 90 days of fenofibrate.

Results: Of the original 10 patients who received fenofibrate, one patient died of unrelated causes, and one patient had stopped treatment before the 90-day timepoint. Of the remaining 8 patients, 3 patients stopped fenofibrate after 90 days, 3 patients stopped fenofibrate after 180 days, 1 patients stopped fenofibrate at 360 days, and 1 patient did not stop fenofibrate. The initial ALP response seen during the first 90 days of treatment was durable with or without extended fenofibrate treatment. ALP in all patients was 59% of the peak ALP at treatment initiation. No patient required retransplantation.

Conclusion: While IC is a progressive condition of biliary inflammation, fenofibrate therapy initiated early may help arrest its progression with or without long-term treatment.

Utilization of elderly donors in liver transplantation for patients with hepatocellular carcinoma

Liangshuo Hu1, Fan Mu1, Bo Wang1
1First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

Background: Profound organ shortages worldwide have led to the increased utilization of marginal organs from older individuals. However, the effectiveness of liver transplantation (LT) with organs from elderly donors for patients with hepatocellular carcinoma (HCC) remains controversial. The objective of the current study was to assess the overall survival (OS) and disease-free survival (DFS) of patients with HCC following LT using grafts from deceased donors over 60 years old.

Methods: Patients with HCC who underwent LT between 2015 and 2018 were identified in the China Liver Transplant Registry database. The overall survival and disease-free survival of older liver donors (OLDs) were compared with those of younger liver donors (YLDs) after propensity score matching.

Results: From January 2015 to December 2018, a total of 4971 HCC patients were enrolled in the study according to the screening criteria. The absolute and relative utilization of liver grafts from elderly patients over 60 years for HCC patients increased every year, from 65 (9.3%) in 2015 to 268 (14.5%) in 2018. Disease-free survival (DFS) was significantly lower in HCC patients with elderly donors (both P < 0.05) after propensity score matching. The OLD group had worse DFS than YLD group if patients had tumors beyond the Milan criteria (P < 0.05).

Conclusions: The use of older donors for LT has been growing quickly in the last few years in China. Grafts from older donors can be safely used in HCC recipients with similar OS and comparable perioperative complications.

The Therapeutic Potential of Self-Assembled Rapamycin Nanoparticles in Allograft Rejection

Ruiqi Sun1, Shusen Zheng2, Penghong Song1, Haiyang Xie4
1The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China, 2The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China, 3The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China, 4The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China
China, 4The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China

**Abstract Submission No. 101840**

Laparoscopic Anatomical Liver Resection with ICG Real-time Shoudai Nagaishi1, Yukari Shinohara1, Yuta Enami1

**Methods:** Soluble supramolecular rapamycin nanoparticles (sRNP) spontaneously form in aqueous solutions via a simple recrystallization scheme, rendering RAPA injectable and providing colloidal stability.

**Results:** Our results demonstrate the sustained maintenance of therapeutic drug concentrations with the sRNP platform, accompanied by commendable pharmacokinetic parameters and minimal toxicity, effectively overcoming the challenge of immunotoxicity. In murine allograft models, the administration of low doses of sRNP over a short duration leads to an increase in myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg), concurrently reducing Th1 and Th17 cells, surpassing the impact of oral RAPA on graft survival. Evidently, sRNP manages the reduction of effector T cells while amplifying the naive T cell cohort. Transitioning to the rat orthotopic liver transplantation model, a short-term low dose of sRNP (administered once every other day, totaling four times at 0.1mg/kg, intravenously) effectively inhibits T cell proliferation, mitigates inflammatory cell infiltration, significantly prolongs graft survival, and positively influences hepatic function.

**Conclusions:** This study illuminates the distinct advantages of sRNP over its oral RAPA counterpart in the context of allograft rejection, demonstrating the practical feasibility of employing self-assembled RAPA nanoparticles as a potent anti-rejection therapy.

Abstract Submission No. 101840

**O-0779**

Laparoscopic Anatomical Liver Resection with ICG Real-time Navigation

Tomokazu Kusano1, Takeshi Aoki1, Kazuhiro Matsuda1, Yoshihiko Tashiro1, Tatsuya Yamazaki1, Kazuhiro Saito1, Shoudai Nagashi2, Yukari Shinohara1, Yuta Enami1

1Division of Gastroenterological and General Surgery, Department of Surgery, School of Medicine, Showa University Tokyo Japan

**Background:** In order to perform safe and reliable laparoscopic anatomical liver resection (LALR), it is desirable to establish intraoperative navigation that accurately conducts the proposed surgical plan, in addition to preoperative simulation of local anatomy. In this report, we describe our techniques and innovations using ICG fluorescence imaging and artificial intelligence (AI) for LALR.

**Methods:** Preoperatively, 3D reconstructed images were created from volume data, and simulation of the staining area at ICG injection was performed in all patients. During surgery, three methods of positive staining (PS) were selected according to the case: (1) preoperative puncture with B-mode US before surgery, (2) intraoperative puncture, and (3) combination of the two methods. And, the introduction of a puncture route support system using 3D holography and the development of a new US probe attachment complement the puncture with a red laser. In addition, AI was utilized to assist in the recognition of vascular structures during liver dissection.

**Results:** LALR was performed in 27 positive staining cases and 13 negative staining cases, and ICG staining method enabled accurate navigation in the direction of hepatic resection by distinguishing not only the demarcation lines on the liver surface but also the boundaries in the deep dissection plane. 3D holography and US attachment assisted the optimal puncture route to the portal pedicle branch. The AI recognized the hepatic vein and Glisson branch during dissection of the liver.

**Conclusion:** Real-time navigation using ICG fluorescence and AI can contribute to the realization of safe and precise LALR.

Abstract Submission No. 101932

**O-0780**

ALPPS vs Conventional Techniques in Hepatitis Related HCC: A Systematic Review and Meta Analysis

Jan Axel Lopez Yusi1,2, Jemimah Andrea Pelayo Fajardo1,3, Sarah Jean Coder Bellido1,2,3, Charles Balita Barretto4,4, Maria Millicent Pingol Cariño4

1St. Luke’s Medical Center Quezon City Quezon City Philippines, 2Institute of Digestive and Liver Diseases, St. Luke’s Medical Center Quezon City Philippines, 3Department of Medicine, St. Luke’s Medical Center Quezon City Philippines, 4Institute of Surgery, St. Luke’s Medical Center Quezon City Philippines

Insufficient functional liver remnant(FLR) volume frequently serves as a major hindrance in performing hepatectomy in cases of primary liver cancers. Current studies show that ALPPS rapidly increase FLR leading to completion of liver resection compared with standard techniques in cases of colorectal liver metastasis. However, there is limited data on its benefit to hepatocellular carcinoma(HCC) associated with chronic hepatitis or cirrhosis. A comprehensive systematic search was performed to include clinical studies that compared ALPPS vs either conventional techniques including TACE+PVE, LAPS, or PVE alone. The Cochrane risk of bias tool and Newcastle Ottawa Scale were used to assess the presence of bias. Data was analyzed using Revman5.4. The primary outcome measured was increase in future liver remnant volume. The secondary outcomes were 1-year and 3-year disease free survival(DFS) and overall survival(OS) rate, perioperative complication rate and liver failure rates.

The study included 4 comparative studies with 284 hepatitis related HCC. There is no statistically significant difference in terms of increase in FLR volume between the two groups [MD -4.84 (95%CI -17.98 - 8.30); p0.47]. The secondary outcomes of 1-year OS(1.19; 0.52-2.71), 3-year OS(2.72; 0.40-18.36), 1-year DFS(0.99; 0.58-1.71), 3-yr DFS(2.14; 0.37- 12.39), overall complication rate(1.15; 0.42-0.52-2.71), 3-year OS(2.14; 0.37- 12.39), overall complication rate(1.15; 0.42-3.14), overall liver failure rate(1.51; 0.33- 6.83), has no statistically significant difference at 95% confidence interval.

Among patients with hepatitis related HCC, ALPPS can be an alternative technique in increasing FLR volume prior hepatectomy. However, there remains a need for larger studies to strengthen this evidence.

Abstract Submission No. 102022

**O-0781**

Central Hepatectomy with Vascular Reconstruction (Video Abstract)

SAURABH SINGHAL1, Ankur Garg1, Amit Jha1

1Sanar International Hospital Gurugram India

**Aims and Objectives:** Centrally located liver tumors are a surgical challenge that was traditionally treated with extended right or left liver resections leading to a frequent risk of post-hepatectomy liver failure due to inadequate functional liver remnant. Non-anatomic resections are marred by risks of hemorrhage and positive surgical margins.
Central hepatectomy is a feasible choice in such patients with acceptable risks.

**Materials and methods:** In this video, the central hepatectomy steps are shown or a large tumor occupying and right anterior sector and segment 4 followed by vascular reconstruction. The video first discusses adequate mobilization of the liver for exposure. The transaction lines are marked followed by central hepatectomy and reconstruction of the middle hepatic vein using a PTFE graft. Due to the recurrent thrombosis of the right portal vein, it was heparinized through a catheter left in the umbilical vein. Following the completion of the surgery, the patient had an uneventful recovery. The umbilical vein catheter was removed 5 days later.

**Results and Conclusions:** Central hepatectomy is a feasible surgery with acceptable outcomes. In case of the inability to save the middle hepatic vein due to tumor infiltration, an in-situ vascular reconstruction can be done to maintain outflow.

---

**Abstract Submission No. 200026**

**O-0782**

**Risk Factors for Surgical Site Infection after Hepatectomy in Our Facility**

Koichi Nakanishi¹, Hiroji Shinkawa¹, Kosuke Hatta¹, Mizuki Yoshida¹, Takahito Kawaguchi¹, Naoki Tanii², Shuhei Kushiyama², Shigeki Kurihara², Ryota Tanaka², Masahiko Kinoshita³, Kohei Nishino³, Go Ohira¹, Kenjiro Kimura¹, Takeaki Ishiwaza⁴

¹Department of Hepato-Biliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of medicine Osaka Japan

**Background:** We reported our treatment outcomes for surgical site infection (SSI) following hepatectomy, analyzed and discussed the risk factors.

**Methods:** The study included 1012 cases of hepatectomy without biliary reconstruction or combined resection of other organs from April 2012 to December 2022. Minimally invasive surgery (MIS), including laparoscopic and robot-assisted hepatectomy, was performed in 507 cases (50.1%). As a prophylactic antibiotic, either flomoxef or cefmetazole was administered 30 minutes before and within 24 hours after surgery. A closed abdominal drainage tube was removed 2-4 days postoperatively unless bile leakage was suspected. Perioperative glycemic control was achieved through insulin therapy.

**Results:** Postoperative SSI was observed in 99 cases (9.8%), with 24 cases (2.4%) of incisional SSI and 58 cases (5.7%) of organ/space SSI. Multivariate analysis revealed that poorly controlled diabetes (HbA1c ≥ 6.5%) (odds ratio [OR] 3.31, p=0.0083), major hepatectomy (OR 3.2, p=0.022) and MRSA colonization (OR 4.63, p=0.0083) were significantly associated with incisional SSI. Risk factors for organ/space SSI were age ≥ 65 years (OR 1.96, p=0.029), blood loss ≥ 1500 mL (OR 2.7, p=0.0017), operative time > 300 minutes (OR 3.31, p < 0.001), open surgery (OR 4.28, p=0.0016).

**Conclusion:** Adequate preoperative glycemic control might be effective in reducing the risk of incisional SSI after liver resection. Additionally, for indicated cases, selecting MIS and making efforts to shorten surgery duration and reduce intraoperative blood loss might lead to prevent the development of organ/space SSI.

---

**Abstract Submission No. 100254**

**O-0784**

**Is it possible to minimize liver I/R damage and increase regeneration capacity?**

Sencan Acar¹, Hüseyin Çakıroğlu², Erdem Çokluk³, Özcan Budak⁴, Ahmet Tar Sarı⁴ & Eminler⁵

¹Department of Gastroenterology, Amasya University Serefeddin Sabuncuoglu Research and Training Hospital Amasya Turkey, ²Department of Veterinary Medicine, Sakarya University Faculty of Medicine Experimental Medicine and Research Center (SÜDETAM) Sakarya Türkiye, ³Department of Medical biochemistry, Sakarya University Faculty of Medicine Sakarya Türkiye, ⁴Department of Histology and Embryology, Sakarya University Faculty of Medicine Sakarya Türkiye, ⁵Department of Gastroenterology, Sakarya University Faculty of Medicine Sakarya Türkiye

**Background:** During ischemia and subsequent reperfusion in the liver resulting in apoptosis and necrosis. This study aimed to evaluate the possibility of preventing the reduction of regeneration capacity as a result of ischemia and also to evaluate the possibility of a faster recovery process.

**Methods:** Rats of equal age and approximately equal weight were grouped into 6 groups in total: Group1 = Sham; Group2 = Silymarin-curcumin; Group3 = Silymarin-glucosamine; Group4 = Ganoderma lucidum; Group5 = mixture of group B vitamins, amino acids, l-carnitine and sugar; Group6 = Phenoxy-2-methyl-2-propanionic acid. Liver ischemia was achieved by ligating the hepatic artery under anesthesia for 45 minutes. mTOR, insulin, nesfatin, and leptin levels were checked in the 2nd postoperative week.

**Results:** Insulin levels were found to be low in the silymarin-curcumin group. Regarding blood nesfatin level, it was significantly higher in the 3rd group compared to the control group (p=0.002), and significantly lower in the 2nd group (p=0.015). The blood mTOR level was...
significantly lower in the 3rd group compared to the control group (p=0.051). Other parameters were similar.C3, PCNA, Ki67, mTOR, HGF, and Calpain1.0 were found to be higher in all groups compared to the control group. VGEF and FGF were found to be higher in all groups except group 4 compared to the control group. In immunostaining, more necrosis, vacuolization, and sinusoidal obstruction areas were seen in the 3rd and 4th groups compared to the other groups.

Conclusions: Although all substances applied after I/R injury have been shown to positively affect the regeneration capacity of the liver, silymarin-glucosamine, and ganoderma lucidum have been shown to cause deterioration in the quality of regenerating liver tissue. Apart from this, it was noteworthy that insulin levels were low in the silymarin-curcumin group, which is also used for the treatment of steatotic liver disease.

Abstract Submission No. 101310
O-0785

Outcomes of patients with primary sclerosing cholangitis after liver transplantation

MUHS 聼 N MURAT MUHIP HARPUTLUOGLU1, Mehmet Zeki Calgin2, Sezai Yilmaz3
1INONU UNIVERSITY LIVER TRANSPLANT T INSTITUTE Malatya Turkey, 2Inonu university internal medicine Malatya Turkey

Background and aim: In this study we present the complications and outcomes of PSC patients after liver transplantation in a predominantly LDLT center.

Materials and methods: Adult and pediatric patients who underwent liver transplantation for PSC between February 2008 and October 2020 were included in the study. The demographic characteristics, presence of co-existing diseases, indications for transplantation, type of transplantation, and immunosuppressive treatments used were recorded. Patient survival, survival times, cause of death, recurrences, rejection, and biliary complications were recorded.

Results: Thirty patients who underwent liver transplantation for PSC were included in the study. Twenty-seven patients (90 %) were living donor transplants. The 1-, 3-, and 5-year survival rates after transplantation were 75.9 %, 74.9 %, and 74.9 %, respectively. Biliary complications occurred in 15 patients (50 %). All patients with biliary complications were successfully treated with endoscopic and percutaneous interventional treatments. Chronic rejection occurred in three patients (10 %) and acute rejection occurred in five patients (13.3 %). PSC recurrence developed in five patients (18.5 %).

Conclusion: Biliary complications are the most common complication after liver transplantation in patients with PSC in our center, where LDLT is used extensively and PSC patients are followed closely with respect to biliary complications after transplantation.

Abstract Submission No. 101506
O-0786

Alternative hepatic artery conduit in liver transplantation: A Bayesian Network-Meta Analysis.

Citra Aryanti1, Edwin Nugroho Njoto2, Warsinggih Warsinggih1, Julianus Aboyanam Uwuratu1, Erwin Syarifuddin1, Ronald Erasio Lusikooy1
1Department of Surgery, Hasanuddin University, Dr. Wahidin Sudirohusodo General Hospital, Makassar, Sulawesi Selatan, Indonesia

Indonesia makassar Indonesia, 2Faculty of Medicine and Health, Institut Teknologi Sepuluh Nopember Surabaya Indonesia

Introduction: Finding the best alternative recipient hepatic artery in liver transplantation is hard

Methods: Following PRISMA and NMA guidelines, a comprehensive search of Cochrane Library, MEDLINE, and Scopus was done, analyzing all observational studies that included non-standard anastomosis in liver transplantation, either with the splenic artery, aorta, celiac, or branches from the gastric artery. The outcome parameters are intraoperative, complications, and survival.

Result: Thirteen studies with 9521 subjects were included in this study for quantitative analysis. Aortic anastomosis showed the least complication of thrombosis, stenosis, and biliary tract abnormality. However, inferior results were shown in graft and overall survival. The splenic artery anastomosis alternative showed higher risk of thrombosis, but low complications of stenosis (OR 1.12, 95%CI 0.13-3.14) and biliary tract abnormality (OR 0.79, 95%CI 0.36-1.55). Further, in splenic artery anastomosis, graft survival (OR 1.08; 95%CI 0.96-1.23) and overall survival (1 year survival OR 1.09; 0.94-1.26; 5 year survival OR 1.95%CI 0.83-1.22) showed favorable results. Constraints to the use of the splenic artery were longer operation time and cold ischemic time. However, the duration of hospital stay (MD 1.36, 95%CI -7.47 to 10.8) was shown to be shorter and the need for blood transfusions was minimal (MD -1.74, 95%CI -10.2 to 6.7).

Conclusion: In the case of an unusable recipient’s hepatic artery, the recipient’s splenic artery can be considered as the first choice for anastomosis in liver transplantation.
Clinical characteristics and correlation with liver stiffness post 1 year liver transplantation.

Pranav Vatsayan, Balamurali Rangachari, Manimaran Murugesan, Chitra Shanmugam, Sathya Rajendaran, Krishna kumar Chinadurai

1Department of Medical Gastroenterology and Hepatology, Government Stanley Medical College and Hospital Chennai India

Background: Liver biopsy is a gold standard investigation to assess post transplant fibrosis and steatosis. Its limited by cost and procedural risks. Vibration controlled elastography (VCTE) has shown promise to assess fibrosis and degree of Steatosis in post LT recipients. We present our analysis of VCTE and correlation with clinical characteristics of liver transplant recipients at post 1 year of transplantation.

Method: A total of 38 patients were included in the study who underwent liver transplantation 1 year or prior. VCTE was done for all patients through standard protocol. Pearson bivariate correlation was applied at 95% CI to assess any correlation.

Results: Of total 38 participants, 29 (76%) were male and 9 (14%) were female. Mean duration post transplant was 4.42 years and mean donor age was 28.16 years. Most were deceased liver transplant recipients (n=29). Mean graft weight was 865.62 grams. Mean liver stiffness values obtained were 6.71 kPa (Min: 4.3; Max: 12.8 kPa). We observed that a longer cold ischaemia time was associated with lower liver stiffness (r= -0.216; p=0.193). Higher donor age and graft weight were associated with increased liver stiffness (r=0.256; r=0.143 respectively). More stiffness was observed if patient’s trough tacrolimus levels were high (r=0.181).

Conclusion: Current study was aimed to assess as to what clinical parameters could influence the development of early fibrosis in the recipients. Duration of cold ischaemia time pre-transplant had a strong correlation with degree of stiffness. Higher trough levels of tacrolimus were also associated with higher stiffness. The data presented here is an interim analysis of an ongoing study and further observations will be obtained in future.

A comparative study of laparoscopic liver resection for the segment 4 superior and inferior area

Akira Koizumi, Takeshi Urade, Masahiro Kido, Shohei Komatsu, Hidetoshi Gou, Kenji Fukushima, Shinichi So, Toshihiko Yoshida, Keisuke Arai, Yoshihide Nanno, Daisuke Tsugawa, Sadaki Asari, Hiroaki Yanagimoto, Hirochika Toyama, Takumi Fukumoto

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine Kobe Japan

Introduction: The difficulty of laparoscopic liver resection (LLR) is greatly associated with the location of liver tumors. According to the IWATE difficulty scoring system, the location in Couinaud’s segment 4 superior area (S4a) scores 4 and inferior area (S4b) scores 3. The difference between LLR for S4a and S4b remains unclear.

Objectives: The aim of this study was to investigate the differences of the surgical outcomes between LLR for S4a and S4b.

Materials and Method: Patients who underwent laparoscopic partial liver resection (LpLR) for the tumors in the S4a and the S4b at Kobe University Hospital between January 2014 and December 2022 were enrolled. We retrospectively investigated perioperative short-term outcomes including the patients’ background, operative results, and complications.

Results: Fourteen patients underwent LpLR for S4. Among these patients, 7 patients underwent LpLR for S4a and 7 patients (50%) for S4b. There was no significant difference between the groups in operation time (274 vs 251 minutes, P=0.7016), blood loss (31.4 vs. 7.9 mL, P=0.0841), the incidence of postoperative complications (0 vs 1 cases, P=1.000), and length of hospital stay (11 vs 12 days, P=0.7382).

Conclusion: There was no difference between LpLR for S4a and S4b in perioperative short-term outcomes. Although the IWATE difficulty score between LpLR for S4a and S4b were different, additional studies with larger number of patients in an independent cohort are necessary.
Effect of Ursodeoxycholic Acid on SARS-CoV-2 Infection in Liver Transplantation Patients

Liangshuo Hu1, Fan Mu1, Bo Wang1

1Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China

Background: Minimally invasive liver resection (MILR) has become a common surgical treatment for hepatocellular carcinoma (HCC). However, current difficulty scoring system was limited to small samples and single-center, and there was rare scoring system to assess surgery only for HCC. Thus, we developed a novel prediction system based on a multi-enters data to assess the surgical difficulty of MILR for treating HCC.

Methods: The retrospective multicenter cohort study collected a total of 776 cases of MILR for resectable HCC from June 2011 to November 2022 at eight minimally invasive surgical centers in China. The cohort was randomly divided into a training dataset (n = 582) and a dataset (n = 194) in a 3:1 ratio. The training dataset underwent logistic regression analysis to identify independent risk factors for surgical difficulty and construct a prediction model. The performance of the model was validated by the validation dataset, and the discriminative ability, calibration, and clinical effectiveness were assessed through ROC curves and Decision Curve Analysis.

Result: We considered prolonged surgical time, massive intraoperative bleeding, and conversion to open surgery as crucial indicators of a difficult surgery. According to the above criteria, 346 patients underwent a difficult MILR surgery. Gender, Cirrhosis, tumor diameter, and tumor location are independent risk factors affecting the difficulty of MILR for treating HCC. The AUC was 0.785 for the training cohort and 0.723 for the validation cohort.

Conclusions: We developed and validated a novel nomogram to predict the difficulty of MILR for treating HCC based on eastern data.

Abstract Submission No. 102074
O-0794

Effect of Ursodeoxycholic Acid on SARS-CoV-2 Infection in Patients With Liver Transplantation

Liangshuo Hu1, Fan Mu1, Bo Wang1

1First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

Background: Immunosuppressed recipients of liver transplantation (LT) are more likely to develop coronavirus disease 2019 (COVID-19) and may have an increased risk of developing worse outcomes. Aim: To assess the effect of ursodeoxycholic acid (UDCA) on preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in LT recipients.

Design: Adult patients (aged≥18 years) who underwent LT between January 1st, 2015, and December 31st, 2022, were included and categorized into two groups according to their use of UDCA.

Methods: The prevalence and severity of COVID-19 among transplant recipients in the UDCA and non-UDCA groups were estimated and compared.

Results: Among the 897 LT patients who met the inclusion criteria, infection rate of SARS-CoV-2 was 78.4%, and the rate of severe illness was 5.1% from January 2022 to January 2023 in China. In the multivariate analysis, only UDCA treatment (P=0.006) was found to be a protective factor against SARS-CoV-2 infection. After propensity score matching, the SARS-CoV-2 infection rate in the UDCA group was lower than that in the non-UDCA group (74.1% vs. 84.6%, P=0.002). This rate was further reduced to 62.1% (P=0.002) when the oral administration dose was greater than 15 mg/kg/d. There was no difference in the rates of severe COVID-19 illness, ICU admission, or ventilation rate or length of hospital stay with or without UDCA treatment (all P>0.05).

Conclusions: The use of UDCA in LT patients significantly reduced the SARS-CoV-2 infection rate and showed a dose-dependent protective effect.

Keywords: SARS-CoV-2, Ursodeoxycholic acid, Liver Transplantation, Infection rate, Immunosuppress

Abstract Submission No. 200011
O-0793

Laparoscopy specific dorsal approach to the middle hepatic vein in performing left hemihepatectomy

Masaki Ueno1, Shinya Hayami1, Atsushi Miyamoto1, Manabu Kawai1

1Wakayama Medical University Wakayama Japan

Background: Laparoscopic surgery can provide a surgical view that cannot be obtained by open surgery. Herein, we report the surgical procedure of laparoscopic left hemi-hepatectomy by the laparoscopy specific dorsal approach method.

Procedures: (1) Flip-up the left lateral segment and start liver transection from the dorsal surface of the liver around the root of left hepatic vein (LHV). As the root of middle hepatic vein (MHV) also locates near the MHV can be exposed easily and quickly. (2) The left Glissonian branch was encircled and cut. Grasping the stump of the cut Glissonian pedicle and flipping it up, continue liver resection with exposing the MHV toward its periphery direction. (3) After the MHV is exposed entirely and all venous branches to segment IV are cut, then flip-down the left-lateral segment to the original position and transect the liver parenchyma remaining on the ventral side of the MHV from caudal to cranial direction. (4) Finally, cut the LHV by a linear stapler device.

Results: Ten consecutive cases received this procedure. Regarding an anatomical factor, the perpendicular distance from the center of the Arantius plate to the MHV was 1.0 cm on average. The blood loss and operating time were 95 ml and 314 minutes in average. There were no severe postoperative complications.

Conclusions: This procedure enables us to contact the MHV easily and quickly. Moreover, we can avoid split-injury of venous branches during exposure of the MHV. This procedure may be a theoretical method in performing laparoscopic left hemihepatectomy.

Abstract Submission No. 200018
O-0794

Laparoscopic and open minor hepatectomy for patients with clinically significant portal hypertension

Hiroji Shinkawa1, Masaki Kaibori2, Takuya Nakai1, Masaki Ueno3, Daisuke Hokuto4, Hisashi Ikoma5, Takeaki Ishizawa1, Koji Komeda6, Shinya Hayami1, Satoshi Yasuda2, Ryo Morimura6, Haruki Mori7

1Department of Hepatobiliary-Pancreatic Surgery, Osaka Metropolitan University Graduate School of Medicine Osaka Japan, 2Department of Surgery, Hirakata Hospital, Kansai Medical University Hirakata Japan, 3Department of Surgery, Faculty of Medicine, Kindai University Osaka-sayama Japan, 4Second Department of Surgery, Osaka Medical University Wakayama Japan, 5Department of Surgery, Saiseikai University Hiroshima Japan, 6Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine Kyoto Japan, 7Department of Surgery, Shiga University of Medical Science Otsu Japan,
Background: Liver resection offers substantial advantages over open liver resection (OLR) for patients with hepatocellular carcinoma (HCC) in terms of reduced blood loss and morbidity. However, there is limited evidence comparing the indications and perioperative outcomes with the open versus laparoscopic approach for resection. This study aimed to compare postoperative outcomes between patients undergoing laparoscopic liver resection (LLR) and OLR for HCC with clinically significant portal hypertension (CSPH).

Methods: A total of 316 HCC patients with CSPH (presence of gastroesophageal varices or platelet count <100,000/ml and spleen diameter >12cm) undergoing minor liver resection at eight centers were included in this study. To adjust for confounding factors between the LLR and OLR groups, an inverse probability weighting method analysis was performed.

Results: Overall, 193 patients underwent LLR and 123 underwent OLR. After weighting, LLR was associated with a lower volume of intraoperative blood loss and the incidence of postoperative complications (including pulmonary complications, incisional surgical site infection, and paralytic ileus) compared to the OLR group. The 3-, 5-, and 7-year postoperative recurrence-free survival rates were 39%, 26%, and 22% in the LLR group and 49%, 18%, and 18% in the OLR group, respectively (p = 0.18). And, the 3-, 5-, and 7-year postoperative overall survival rates were 71%, 56%, and 44% in the LLR group and 76%, 51%, 44% in the OLR group, respectively (p = 0.87).

Conclusions: LLR for HCC patients with CSPH is clinically advantageous by lowering the volume of intraoperative blood loss and incidence of postoperative complications, thereby offering feasible long-term survival.

Optimal radiological assessment for HCC with macrovascular invasion during systemic therapy.

Masanori Inoue1, Sadahisa Ogawara1, Tomomi Okubo2, Norio Itokawa3, Masamichi Obu4, Keisuke Koroki5, Kazufumi Kobayashi6, Naoya Kanogawa7, Ei Itobayashi8, Masanori Atsukawa9, Yoshihiro Koma10, Ryosaku Azemoshi11, Naoya Kato12

1Chiba university hospital Chiba Japan, 2Nippon Medical School Chiba/hokusho Hospital Chiba Japan, 3Nippom Medical School Tokyo Japan, 4Kimitsu Chuo Hospital Chiba Japan, 5Asahi General Hospital Chiba Japan

Background & Aims: Macrovascular invasion (MVI) is a significant prognostic factor in advanced hepatocellular carcinoma (HCC). Existing radiological criteria for evaluating MVI lack clarity in assessing the impact of MVI on systemic therapy. We conducted this study to establish standardized criteria for the assessment of MVI.

Methods: We collected clinical data from advanced HCC patients with MVI undergoing first-line systemic therapy at four medical centers in Japan. We used MVI-PD to monitor MVI progression and cRECIST-PD to assess tumor enlargement and new lesions. We evaluated the prognostic impact of MVI-PD, cRECIST-PD, and MVI control with sorafenib, lenvatinib, atezolizumab, and bevacizumab.

Results: Of the 209 HCC patients with MVI, 20.9% had both MVI-PD and cRECIST-PD. In the landmark analysis, patients without concurrent MVI-PD and cRECIST-PD during the initial 3 months had the longest median OS at 19.7 months, while those with both had the shortest at 5.3 months. The median OS for patients who experienced only cRECIST-PD within the first 3 months was 8.8 months, and median OS for patients who experienced MVI-PD within the first 3 months was 7.2 months (p < 0.001). The correlation coefficient between PFS and OS was similar for MVI-PD (0.451) and cRECIST-PD (0.472). Atezolizumab plus bevacizumab showed longer overall survival than lenvatinib and sorafenib and had a lower incidence of her MVI-PD within 3 months.

Conclusions: Our findings underscore the association between MVI progression and poor OS in systemic therapy for advanced HCC, emphasizing the need for an accurate evaluation method for MVI progression.

irAEs: Immune Mediated Thrombocytopenia

Alexis Danica B. Drilon1, Marionne Renee A. Rafael1, Jose Guillain E. Cataluna2

1Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University Takatsuki Japan, 2Department of Internal Medicine, Teikyo university hospital. Kanagawa JAPAN, 3Department of Gastroenterology, Teikyo university Mizonokuchi hospital. Kanagawa JAPAN, 4Department of Internal Medicine, Teikyo university Mizonokuchi hospital Kanagawa JAPAN

Purpose: To investigate the selection and outcome of “post-treatment” of ATZ+BEV in real-world clinical practice.

Methods: A retrospective multicenter study was conducted on 53 patients with advanced hepatocellular carcinoma treated with ATZ + BEV from September 2020 to December 2022. The final follow-up date was March 15, 2023. The primary endpoint was the rate of sequence active treatment after PD. Secondary endpoints were PS at the end of ATZ+BEV, liver function, proteinuria, posttreatment therapy, OS after starting posttreatment, OS after starting ATZ+BEV, and OS from the initial diagnosis day of HCC.

Results: The median age was 74 years. 13 patients were Stage III, 12 patients IV-A, 26 patients IV-B, 46 patients Child-Pugh A, and 7 patients B. After ATZ+BEV treatment, 40/53 patients (75%) completed. PS2 or higher at the end of ATZ+BEV was 7/40, Child-Pugh A 27/B 11, proteinuria 3+ 7/40. Post-treatment therapy included lenvatinib in 10 patients, ramucirumab in 2, cabozantinib in 4, TACE in 7, sorafenib in 2, and BSC in 16. The rate of sequence active treatment was 59%. MST after initiation of active post-treatment was 9.2 months, MST after initiation of ATZ+BEV was 16.8 months, and MST from the first treatment was 7.0 years.

Conclusion: After completion of ATZ+BEV, sequence active treatment was possible for patients with preserved residual liver function and PS. The rate of sequence active treatment was 59%, and the MST was 9.2 months. It was suggested that sequence active treatment may contribute to further prolongation of survival.
**Introduction:** Durvalumab is an anti-PDL1 immune checkpoint inhibitor that has become one of the first line systemic treatment in patients with Hepatocellular Carcinoma. Its incidence is estimated to be as low as 0.5% with an absolute frequency that is still unknown. Physicians should be alert of the rare adverse effects such as severe thrombocytopenia. The most important questions that should be answered when dealing with irAE are how frequently to monitor, when to withhold or discontinue ICIs, when to initiate and how to escalate immunosuppression.

**Clinical Presentation:** This is a case of a 60-year-old male, known case of compensated liver cirrhosis secondary to non-alcoholic steatohepatitis and chronic hepatitis B infection complicated by Hepatocellular carcinoma BCLC C. Twenty four hours after initiation of Durvalumab, the patient presented with acute severe thrombocytopenia (32,000/mm²) from a normal baseline platelet count (162,000/mm²), accompanied by episodes of hemorrhoidal bleed.

An exhaustive work-up for possible causes of thrombocytopenia began which all revealed negative results for infectious, rheumatologic and hematologic causes.

**Management:** Given the temporal profile of thrombocytopenia occurring after Durvalumab infusion and the exclusion of other possible factors, patient was managed as a case of Grade 3 irAE, namely Immune Mediated Thrombocytopenia. Initially, the patient was started on steroids, however there was persistence of thrombocytopenia. He was eventually given IVIG and Eltrombopag which led to the gradual increase of his platelet count.

**Conclusion:** Immune checkpoint inhibitors have reshaped cancer therapy. Early and aggressive medical interventions are necessary to successfully achieve irAE improvement after initiation of ICIs.

---

**Comparative Efficacy of Regorafenib, Cabozantinib, and Ramucirumab for unresectable HCC.**

Kaori Mukai1, Tasuku Nakabori1, Masaki Kawabata1, Kana Hosokawa1, Hiroki Kishimoto1, Yusuke Seiki1, Ko Watsuji1, Kazuhiro Kozumi1, Makiko Urabe1, Yugo Kato1, Ryoji Takada1, Kenji Ikezawa1, Hiroyuki Uehara1, Kazuyoshi Ohkawa1

1Osaka International Cancer Institute Osaka Japan

**Background:** A comparison of the therapeutic efficacy of regorafenib, cabozantinib, and ramucirumab in late-stage treatment for unresectable hepatocellular carcinoma (u-HCC) has not been reported. This study aimed to retrospectively compare the outcomes of u-HCC and identify which of these should be used as prior therapy.

**Methods:** Twenty-seven patients with u-HCC treated with regorafenib, cabozantinib, and ramucirumab from July 2017 to January 2023 were analyzed; patients who received more than one of the three drugs were included in the prior drug group. All patients had received lenvatinib, atezolizumab/bevacizumab, or both as previous therapies. Disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were evaluated according to modified Response Evaluation Criteria in Solid Tumors (mRECIST).

**Results:** There were no significant differences among these three groups in DCR (regorafenib vs. cabozantinib vs. ramucirumab: 70% vs. 25% vs. 46%; p=0.26) and median PFS (3.4 months vs. 2.6 months vs. 2.0 months; p = 0.54). Median OS was statistically shorter in the ramucirumab group than in the other two groups (regorafenib vs. cabozantinib vs. ramucirumab: 28 months vs. 13.6 months vs 5.4 months; p = 0.030). Although there were cases of long-term response in the regorafenib group, there was no statistically significant difference in OS between the regorafenib and cabozenitib groups. There were no grade 3 or higher adverse events in the ramucirumab group. Discontinuation rates due to adverse events were not significantly different between these three groups (p=0.14).

**Conclusions:** Cabozantinib or regorafenib may contribute to OS when compared to ramucirumab.
Background: Atezolizumab plus bevacizumab (Atezo/Bev) followed by curative conversion therapy (ABC-C) outcomes for unresectable hepatocellular carcinoma (u-HCC) that achieved tumor shrinkage with Atezo/Bev therapy has attracted attention. We conducted a multicenter study of Atezo/Bev therapy and examined the outcomes of ABC-C.

Methods: We enrolled a multicenter cohort of 205 patients with u-HCC treated with Atezo/Bev therapy between 2020 and 2022. The decision to perform curative conversion therapy was based on each facility’s discretion. Propensity score matching (1:3 ratio) was used to create two matched patient groups: the ABC-C group or the group that did not receive curative conversion therapy (Atezo/Bev group). We retrospectively compared the clinical outcomes, including overall survival (OS), progression-free survival (PFS), clinical cancer-free, and drug-free rates, between the two groups.

Results: The median follow-up time for all patients was 14 months. The modalities of curative conversion in 13 patients were as follows: resection, 4; ablation, 3; and super-selective TACE, 6. The clinical conversion rates, between the two groups.

Conclusion: ABC-C therapy may provide more clinical benefits than Atezo/Bev without conversion in u-HCC patients.

Abstract Submission No. 101858
O-0801

Metalloimmunology-based nanoclusters activate the immune to enhance pembrolizumab plus lenvatinib

Yongwei Hu

1Department of Hepatic Surgery and Liver Transplantation Center, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China Guangzhou China

Background: Targeted therapy combined with immunotherapy has become the first-line option for advanced unresectable Hepatocellular carcinoma (HCC). The combination of pembrolizumab plus lenvatinib did not meet the dual endpoints of PFS and OS in LEAP-002. In recent years, the role of metals in the immune microenvironment has attracted attention, and the aim of this study was to explore the efficacy and mechanism of the metalloimmunology-enhancing pembrolizumab plus lenvatinib in advanced HCC.

Methods and Results: We found lenvatinib possesses an eFT-508-like effect to downregulate PD-L1 expression in HCC cells by computer simulation (CADD). Dual luciferase reporter gene assays demonstrated that lenvatinib could downregulate PD-L1 expression by modulating the uORF of PD-L1, and that cobalt ions could enhance this effect. Lenvatinib combined with cobalt ions had a synergistic inhibitory effect on the growth of HCC cells, and the synergy index (CI) indicated the strong synergistic effect. We constructed Co+Len@OVA drug-carrying nanoclusters, which could effectively inhibit the growth and invasion of HCC cells and could trigger the immunogenic death (ICD) by blocking autophagic flux and activating the cGAS-STING pathway. As a result, Co+Len@OVA promotes the antigen presentation function of DC cells as well as the activation of adaptive immunity dominated by CD8+ T cells. In vivo experiments, Co+Len@OVA transformed HCC from “cold tumors” into “hot tumors”. In addition, Co+Len@OVA combined with anti-PD1, as a novel combination of pembrolizumab plus lenvatinib, can induce tumor vascular normalization and increase anti-PD1 intra-tumor penetration.

Abstract Submission No. 100061
O-0803

Systemic plus hepatic arterial infusion chemotherapy in unresectable intrahepatic cholangiocarcinoma

Edwin Njoto, Citra Aryanti, Erwin Syarifuddin, Julianus Aboyaman Uwutarwut, M Iwhan Kusuma, Ronald Erasdo Lusikony, Ibrahim Ledaba, Warsinggih Warsingghi, Mappincara Mappincara, Murny Abdul Rafi

1Faculty of Medicine and Health, Sepuluh Nopember Institute of Technology Surabaya Indonesia, 2Division of Digestive Surgery, Department of Surgery, Hasanuddin University Makasar Indonesia,
Abstract Submission No. 100748

Comparison of therapeutic effects of lenvatinib and HAIC for unresectable HCC with vascular invasion

Shuya Maeshima1, Yoshiyuki Ida1, Ryo Shimizu1, Shiori Kaji1, Yudai Taniguchi1, Reiko Ashida1, Takao Maekita1, Mikitaka Iguchi1, Masayuki Kitano1

1Wakayama medical university Wakayama city Japan

We compared the therapeutic effects of lenvatinib (LEN) and hepatic arterial infusion chemotherapy (HAIC) as primary treatment for unresectable HCC with vascular invasion. 33 unresectable HCC with vascular invasion patients participated in this study who were treated by LEN or HAIC as primary treatment at our hospital between April 2016 and March 2022. 16 patients were LEN group, 17 were HAIC group. Median age 69 years, 2/10/11 cases with Vp0/2/3, 28/2/3 cases with Vv0/2/3. We compared background factors, overall survival (OS), progression free survival (PFS), objective response rate (ORR), and disease control rate (DCR) between the two groups. We analyzed factors affecting OS and PFS. Age and DCP value were significantly higher in LEN group. Median OS was 9.8 months in LEN group and 6.2 months in HAIC group (p=0.040). Median PFS was 4.7 months in LEN group and 2.3 months in HAIC group (P=0.124). ORR and DCR by mRECIST were 43.8% and 68.8% in LEN group and 29.4% and 64.7% in HAIC group, with no significant difference. In the univariate analysis of poor OS factors, ALBI grade 2b or 3 was a significant factor in HAIC group. In univariate analysis of poor PFS factors, distant metastasis and AFP 400ng/mL or more were significant factors in HAIC group. Multivariate analysis revealed no significant factor. Compared with HAIC, LEN administration is less affected by background factors such as ALBI grade, distant metastasis, and AFP value. We think that LEN is more suitable as primary treatment for unresectable HCC with vascular invasion.

Abstract Submission No. 102063

Efficacy of TACE guidance software for hepatocellular carcinoma in the caudate lobe

Shiro Miyayama1, Masashi Yamashiro1, Rie Ikeda1, Akira Yokka1, Takeo Fujita1, Naoko Sakuragawa1

1Fukui-ken Saiseikai Hospital Fukui Japan

Background: To evaluate the outcomes of conventional transarterial chemoembolization (TACE) using guidance software for hepatocellular carcinoma (HCC) in the caudate lobe. Methods: Seventy-six treatment-naive caudate lobe HCCs were eligible. TACE was performed using guidance software including automated tumor-feeder detection (AFD) functionality. Technical success was classified into three grades according to 1-week computed tomography findings: entire tumor embolized with a safety margin (5 mm for tumors ≤25 mm and 10 mm for tumors ≥25 mm) (grade A); entire tumor embolized without a margin (grade B); and entire tumor not embolized (grade C). Tumor response was evaluated using the modified Response Evaluation Criteria in Solid Tumors. Tumor-feeder detectability by AFD, technical success, complete response (CR) at 2-4 months, and local tumor progression (LTP) rates calculated by the Kaplan-Meier method were compared in each tumor among three
subsegments: the Spiegel lobe (SP); paracaval portion (PC); and caudate process (CP).

Results: The mean tumor diameter was 18.6 ± 9.7 mm (range, 6-53 mm), and 107 (88.4%) of 121 tumor-feeders were detected by AFD. The rates of feeder detectability by AFD, grade A technical success, and CR in 32 SP, 33 PC, and 11 CP tumors were 73.7%, 96.9%, and 93.8%; 97.0%, 63.6%, and 60.6%; and 87.5%, 63.6%, and 81.8%, respectively. LTP rates of SP tumors were significantly lower than those of PC tumors (P = 0.0019).

Conclusion: AFD could detect 88.4% of tumor-feeders in the caudate lobe; however, the feeder detectability, technical success, and outcomes differed among the three subsegments.

Abstract Submission No. 200141
O-0807

TACE combined with donafenib plus PD-1 for unresectable HCC: a retrospective study

Yahua Li¹, kewei Ren¹, Xinwei Han¹
¹The First Affiliated Hospital of Zhengzhou University Zhengzhou China

Background: To retrospectively evaluate the effectiveness and safety of transarterial chemoembolization (TACE) combined with donafenib plus programmed cell death protein 1 (PD-1) for unresectable hepatocellular carcinoma (uHCC).

Methods: Patients with uHCC who received TACE combined with donafenib plus PD-1 from 1 Feb 2022 to Aug 2022 were included in this study. The primary endpoint was overall survival (OS), progression-free survival (PFS). The secondary endpoint was objective response rate (ORR) and disease control rate (DCR). The tumor response was evaluated according to the mRECIST standard. Safety was assessed by the occurrences of adverse events and the severity of the adverse events.

Results: A total of 144 patients were involved in this study. All patients were treated with TACE combined with donafenib and PD-1. Up to the time of follow-up, 24 patients died, 13 patients were lost, and 107 patients survived. The median OS of TACE combined with donafenib and PD-1 was 13 months, and the median PFS was 6 months. The ORR was 73.61% and DCR was 91.67%. No treatment-related death occurred in the follow-up time. Five patients experienced Grade 3 or 4 AEs with diarrhea, rash or vomiting. Drug reduction occurred in the follow-up time. Five patients experienced Grade 3 or 4 AEs. Drug reduction occurred in the follow-up time. Fifty-nine patients achieved CR, and PD was 2.6 months, respectively.

Conclusion: AFD could detect 88.4% of tumor-feeders in the caudate lobe; however, the feeder detectability, technical success, and outcomes differed among the three subsegments.

Abstract Submission No. 100417
O-0808

AFP Response Patterns after Radioembolization of Hepatocellular Carcinoma Predicts Disease Outcomes

Jessica T. Wen¹, Luyao Shen¹, Justin R. Tse¹
¹Stanford University School of Medicine Palo Alto United States

Purpose: To describe alpha-fetoprotein (AFP) response patterns and outcomes in patients with AFP-producing Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma (HCC) after Y-90 radioembolization.

Methods: This IRB-approved, single-center, retrospective study included 167 adults from 2009-2022 with AFP-producing HCCs (≥20 ng/mL) without extrahepatic metastases who underwent Y-90 radioembolization. The AFP treatment response was categorized into 3 patterns: 1) sustained response (sustained post-procedure AFP decrease by ≥20%; n=42), 2) transient response (decrease by ≥20%, followed by an increase thereafter; n=67), and 3) no response (<20% decrease or increased AFP; n=58). Two fellowship-trained abdominal radiologists evaluated pre-treatment and post-treatment imaging for baseline stage and treatment response using mRECIST, respectively. Overall survival (OS), distant progression-free survival (DPFS), and progression-free survival (PFS) were estimated with Kaplan-Meier curves.

Results: 167 patients were included (37 women, 130 men; 80 Stage B and 87 Stage C; median age 65 years). Median OS of sustained, transient, and no response were 18, 13, and 6.4 months, respectively (p<0.0001). Median DPFS of sustained, transient, and no response were 14, 7, and 3.4 months, respectively (p<0.0001). Median PFS of sustained, transient, and no response were 11, 3.7, and 2.6 months, respectively (p<0.0001). The sites of extrahepatic metastases at first imaging examination showing progression were lungs (40%), lymph nodes (30%), bones (21%), peritoneum (17%), and adrenal glands (14%).

Conclusions: AFP response patterns correlate with clinical outcomes. Only about 1/4 of patients have sustained AFP response. Increased AFP after treatment should prompt imaging with attention to lungs, lymph nodes, and bones.

Abstract Submission No. 100785
O-0809

Early Response to HAIC Using Lipiodol, Cisplatin, and 5-FU for Locally Advanced HCC in Vietnam

DUY ANH NGUYEN³, LE LAM NGO³
³Viet Nam National Cancer Hospital Hà Nội Vietnam

Background: This study aimed to evaluate the early response (ER) to hepatic arterial infusion chemotherapy (HAIC) utilizing Lipiodol, Cisplatin, and 5-FU in patients who had locally advanced hepatocellular carcinoma (HCC) with portal vein invasion (PVI).

Methods: We conducted a prospective study involving twelve patients, each receiving an implanted subcutaneous port for HAIC. The treatment regimen consisted of Lipiodol, Cisplatin, and 5-FU. Each treatment course spanned four weeks and included five days of chemotherapy per week during the first, second, and fourth weeks. One week after the first course, the patients were examined and categorized into complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) using mRECIST criteria.

Results: Of the patients, 9 (75%) demonstrated early response (ER) to treatment, with one (8.3%) achieving CR and eight (66.7%) exhibiting PR. One patient (8.3%) experienced PD, while two (16.7%) had SD. Additionally, portal vein tumor thrombosis showed shrinkage in 3 patients (25%), and liver function improved in 2 patients. Complications occurred in four patients (33.3%), including infection, hematemesis, thrombosed catheter, and catheter breakage.

Conclusions: The HAIC regimen consisting of Lipiodol, Cisplatin, and 5-FU demonstrated a notable rate of ER, substantial reduction in portal vein tumor thrombosis, and improved liver function. While complications were relatively common, they did not pose life-threatening risks.

Abstract Submission No. 100141
O-0808

AFP Response Patterns after Radioembolization of Hepatocellular Carcinoma Predicts Disease Outcomes
Radioembolization with 90Y Resin Microspheres and Voxel-Based Dosimetry with Integrated 90Y PET/MRI

Burak Demir, Cigdem Soydal, Nuriye O. Kucuk, Emre C. Celebioglu, Mehmet S. Bilgie, Didgdem Kuru Oz, Atilla H. Elhan, Kemal M. Kir

1Ankara University Medical School Department of Nuclear Medicine, Ankara Turkey, 2Ankara University Medical School Department of Radiology Ankara Turkey, 3Ankara University Medical School Department of Biostatistics Ankara Turkey

Background: Radioembolization is a regional treatment modality that can be applied varied primary and metastatic liver tumours. In this study we aimed to determine dosimetric parameters that could be useful in prediction of response to therapy.

Methods: In this study 34 patients treated with Y-90 resin microspheres prospectively included in the study. The patients were imaged with integrated PET/MRI system in 24 hours following radioembolization procedure. Total number of 70 lesions that could be delineated on pre-treatment FDG or DOTATATE PET were included in dosimetric analysis. Each lesion was classified as complete (CR), partial (PR), stable (SD), and progressive (PD) depending on follow-up PET findings.

Results: Of the treatments, 9 were hepatocellular carcinoma, 15 were colorectal carcinoma and the remainder were breast, thyroid, neuroendocrine and cholangiocellular carcinoma. Median Davg values for responder lesions (CR+PR) were 114.90 Gy and for non-responder lesions (SD+PD) were 36.30 Gy. Addition to average dose (Davg), D values from dose-volume histograms were significantly different within response groups. In ROC analysis to predict response (CR+PR) AUC for Davg, D70, D80, D90 were 0.850, 0.884, 0.889, 0.854 respectively. Furthermore, to predict CR AUC were 0.759, 0.792, 0.814 and 0.812, for Davg, D70, D80 and D90 respectively. High specificity cut-off for Davg, D70, D80, D90 were 0.850, 0.884, 0.889, 0.854 respectively.

Conclusion: Dosimetric analysis of Y-90 PET/MRI can predict response and complete response after radioembolization treatment and may help clinicians to take measures early on after the treatment.

Hepatic Artery Embolization Promotes T-cell Exhaustion in Rat Hepatocellular Carcinoma Model.

Haruyuki Takaki, Naoki Kodama, Reona Wada, Hiroshi Kodama, Koichihiro Yamakado

1Hyogo Medical University Hyogo Japan

Purpose: T-cell exhaustion is a state of T-cell dysfunction that occurs in chronic infections and cancer. This study was undertaken to evaluate the effects of hepatic artery embolization (HAE) on tumor-infiltrating lymphocytes (TIL) of an orthotopic rat hepatocellular carcinoma (HCC) model by focusing on T-cell exhaustion.

Materials and methods: A rat HCC model was established in Sprague-Dawley rats with the NIS1 cell line. Five animals each were assigned to receive HAE or sham treatment. HCC nodules were collected and digested to generate single-cell suspensions for immunological characterization at 5 days after treatment. The population of PD-1 "LAG-3" exhausted cells among the CD8 TILs was evaluated by flow cytometry. In vitro cell culture study of splenic mononuclear cells was performed for 5 days under normoxic or hypoxic conditions in the presence or absence of glucose with or without tumor lysate, and the population of exhausted cells was evaluated by flow cytometry.

Results: The population of PD-1 "LAG-3" cells among the CD8 TILs was significantly larger in the HAE group as compared with the sham group (p<0.05). In vitro cell culture study revealed that the populations of exhausted CD8 cells significantly increased when cells were cultured without glucose with tumor lysate in both normoxic (p<0.05) and hypoxic (p<0.05) conditions.

Conclusions: HAE promotes T-cell exhaustion in the tumor immune microenvironment of a rat HCC model. Metabolic stress with continuous antigen stimulation is a possible mechanism underlying T-cell exhaustion after HAE.

Efficacy of HAIC New-FP for Unresectable Advanced Intrahepatic Cholangiocarcinoma

Hiroto Ota, Hiroaki Nagamatsu, Takuya Watanabe, Ippei Ikoma, Yasuhiisa Jinho, Daishi Kabemura, Muneo Ikemura, Ayaka Mathida, Akinori Suzuki, Yusuke Takasaki, Daisuke Namima, Shigeto Ishii, Yoshio Fujisawa, Hiroyuki Isayama

1Juntendo university Tokyo Japan

Background: Treatment with chemotherapeutic agents for unresectable Intrahepatic Cholangiocarcinoma (ICC) is still unestablished. We evaluated the efficacy of Hepatic Arterial Infusion Chemotherapy New-FP (NFP) compared with gemcitabine+cisplatine(GC) therapy for unresectable ICC.

METHODS: Patients with unresectable ICC who underwent chemotherapy between March 2015 and March 2023 in Juntendo university hospital were retrospectively evaluated. We evaluated the efficacy and safety of NFP, and anti-tumor effect was evaluated by RECIST and tumor volume reduction rate with contrast-enhanced CT.

Results: Totally 30 cases, each 15 in NFP and GC group were enrolled. Antitumor effects by RECIST in the NFP/GC group was 5 /1 PR (33.3%), 8/8 SD, and 2/6 PD, and the DCR was 86.7%/60 %. PR rate was higher (33.3% vs 6.6%) (p=0.0374) in the NFP group. Median tumor volume reduction more than SD cases (NFP/GC) was 23.8%/11.3%, time to best response was 155/87days, and median observation period was 248/464days. About Chemotherapy side effect in the NFP group, Grade ≥ 3 hepatic dysfunction was observed in all patients, but all of them improved within 1 week, Grade3 thrombocytopenia occurred in11, Grade3 anemia in 1, Grade 2/3 renal impairment in 1/3, biloma in 1. In the GC group, Grade 4 neutropenia occurred in 1, Grade 2 renal impairment in 8, Grade 5 anorexia in 1, and vasculitis in 1.

Conclusion: To confirm the efficacy, we should accumulate more cases and perform prospective study.

Hepatic arterial infusion chemotherapy Survives as a Last Resort

Shuntaro Obi, Shinpei Sato, Takahisa Sato, Miho Kanda, Yuji Kondo, Toshihiro Kawai, Takamasa Ohki, Mayuko Kondo, Kininori Sato, Hideo Yoshida, Hiroyuki Taniguchi, Yasushi Uchino, Masatoshi Akamatsu, Yukihiro Koike, Eriko Goto
Gastroenterology and Hepatology, Kyoudo Hospital of Sasaki Institute Tokyo JAPAN, 1Department of Gastroenterology, Mitsui Memorial Hospital Tokyo JAPAN, 2Department of Gastroenterology, Japan Red Cross Medical Center Tokyo JAPAN, 3Department of Gastroenterology, JR Tokyo General Hospital Tokyo JAPAN, 4Department of Gastroenterology and Hepatology, Kyoudo Hospital of Sasaki Institute Tokyo JAPAN, 5Department of Gastroenterology, JR Tokyo General Hospital Tokyo JAPAN, 6Department of Gastroenterology, Kanto Central Hospital Tokyo JAPAN

Objective: Review the outcomes of hepatic arterial infusion chemotherapy (HAIC) and systemic chemotherapy in our experience.

Methods: 875 cases of HAIC, 171 cases of Sorafenib, 226 cases of Lenvatinib and 85 cases of Atezolizumab + Bevacizumab were included in the analysis. Overall Survival of all cases and OS by Vp status were calculated.

Results: Median Survival Time (MST) for all patients of HAIC was 6.8 months. MST by Vp limited to Child-Pugh A for comparison with other drugs was 7.6 months with Vp and 10.8 months without Vp. The MST for the Sorafenib patients was 10.2 months, and the MST by Vp was 7.1 months with Vp and 14.3 months without Vp. The MST for lenvatinib patients was 16.2 months, and the MST by Vp was 7.0 months with Vp and 17.6 months without Vp. The MST for the ATZ + BEV patients was 18.7 months, and the MST by Vp was 16.1 months with Vp and 19.7 months without Vp.

Conclusion: The standard of care is ATZ + BEV, even in the presence of portal vein tumor invasion. However, for Child-Pugh B patients and those who do not respond to systemic chemotherapy, HAIC will survive as a "last-resort" therapy.

Abstract Submission No. 101928
O-0814

Secretome methods show an active arachidonic acid metabolism indicates TACE response in HCC patients

Zijian Zhang1, Qi Zhou1, 2

1Department of General Surgery, Hui Ya Hospital of The First Affiliated Hospital, Sun Yat-sen University Huizhou China, 2Department of Hepatic Surgery, The First Affiliated Hospital, Sun Yat-sen University Guangzhou China

Background: Arachidonic acid is a polyunsaturated omega-6 fatty acid that plays a crucial role in the inflammatory response within the body. It is found in the phospholipids of cell membranes and is released by the action of phospholipase A2 enzymes when cells are damaged or under stress. Most of the studies of TACE are post-operational and retrospective. Here, we adopted a prospective study RNA-Seq data to explore the relationship between Secretome and TACE responses of HCC patients. Understanding and manipulating this relationship can have therapeutic implications for improving the efficacy of TACE and potentially other cancer treatments.

Methods: Secretome data was obtained from The Human Protein Atlas database. The RNA-Seq data was utilized from the Gene Expression Omnibus (Accession: GSE104580) which shows the secretomes profile of TACE in HCC patients. R language and packages are used to explore data signatures and statistics.

Results: After the analysis of RNA-Seq data with prospective results of TACE of HCC patients, we found the differential expression of secreted proteins between response and non-response formed an obvious enrichment in the Arachidonic Acid Metabolic Process (GO:0019369).

Conclusion: The enrichment of secreted proteins in the Arachidonic Acid Metabolic Process shows a potential pathway to predict the efficiency of TACE in HCC patients before the operation. And the secreted proteins are easier to be detected in blood. The Arachidonic Acid Metabolic Process proteins and metabolites are also promising means of prediction and therapeutic targets for HCC patients.

Abstract Submission No. 200042
O-0815

Transcatheter Arterial Embolization of hepatic hemangiomas: Efficacy and Predictors of Response

Dan Zhao1, Lingli Xie2, Lian Yang1, Chuansheng Zheng1, Liangrong Shi3, Bin Liang4

1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, 2Department of Gastroenterology, General Hospital of the Yangtze River Shipping Wuhan China, 3Department of Radiology, Xiangya Hospital, Central South University Changsha China

Background: Hepatic hemangioma (HH) is increasingly treated with Transcatheter arterial embolization (TAE). Given the lack of detailed information on the factors influencing TAE’s efficacy and the tumor’s response to treatment, this study aims to evaluate the safety, efficacy and predictors of response of TAE to treat HH.

Methods: A retrospective analysis was conducted of consecutive HH patients who received TAE with bleomycin-Lipiodol emulsion and gelatin sponge particles at three institutions from January 2014 to January 2021. TAE effectiveness was defined as more than 50% reduction of tumor volume. The effectiveness, safety, and CT changes of hemangiomas after TAE were assessed. Factors affecting TAE efficacy on tumor size were analyzed with logistic regression analysis.

Results: A total of 102 patients with 109 HHs were included. After treatment, both the tumor diameter and volume were significantly reduced from 8.5 ± 3.9 cm to 5.9 ± 3.8 cm (P < 0.001) and 412.6 ± 742.3 cm³ to 102.0 ± 232.7 cm³ (P < 0.001), respectively. TAE effectiveness was achieved in 80.7% (88/109) of hemangiomas, which was characterized by progressive reduction in tumor volume over time. Atypical enhancement pattern (p = 0.001) and central arterioportal shunt (APS) (p = 0.002) associated with the tumor were independent predictors of TAE ineffectiveness. Postembolization syndrome and transient increase in liver enzymes were common without severe complications and death.

Conclusion: TAE was safe and effective in reducing HH size, with characteristic changes during follow-up CT. Lesion enhancement pattern and APS type were associated with TAE efficacy on HH size.

Abstract Submission No. 200054
O-0816

In-stent Restenosis After Stenting for Superior Mesenteric Artery Dissection

Zhongzhi Jia1

1The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University changzhou China

Objective: To identify risk factors for in-stent restenosis (ISR) in patients undergoing stent placement for superior mesenteric artery dissection (SMAD) and to determine the hemodynamic mechanism underlying ISR.

Methods: Patients with SMAD who had ISR after stent placement were included in the ISR group, and age- and sex-matched patients with SMAD who did not experience ISR after stent placement were included in the control group. Structural and fluid dynamics
The relationship between pancreatic hormone and liver in acute hepatic failure.

Abstract Submission No. 100096
O-0821

A Change in Strategy for Filter Choice Leads to Improved Filter Retrieval Rates
Zhongzhi Jia1
1The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University changzhou China
Objective: To assess whether a new strategy for the choice of inferior vena cava filter placed would improve filter retrieval rates at our institution.
Methods: Consecutive patients who underwent retrievable filter placement for temporary embolic protection between January 2021 and January 2022 were considered for study inclusion. Risk factors for nonretrieval of short-term filters were identified in patients receiving filters between January 2021 and January 2022 (prestrategy group). For patients treated between February 2022 and January 2023 (poststrategy group), a long-term filter was recommended for those with these risk factors, and a short-term filter was recommended for those without these risk factors.
Results: The study population included 303 patients (prestrategy group, n = 154; poststrategy group, n = 149). Long-term immobilization (odds ratio [OR] = 38.000; 95% confidence interval [CI]: 6.858-210.564), active cancer (OR = 17.643; 95% CI: 5.462-56.993), and venous thromboembolism detected in the intensive care unit (OR = 28.500; 95% CI: 7.419-109.477) were identified as independent risk factors for nonretrieval of short-term filters. The total retrieval rate was significantly higher in the poststrategy group (87.2%) than in the prestrategy group (72.7%; P = 0.002); the short-term filter retrieval rate was also significantly higher in the poststrategy group (84.5%) than in the prestrategy group (68.5%; P < 0.001).
Conclusion: The proposed strategy for filter choice based on risk factors for short-term filter nonretrieval can accurately identify patients who need long-term filter placement while also increasing the retrieval rates for both short-term filters retrieval rates and overall retrieval rates.

Naoki Hashimoto1
1Sanda city hospital Snda city Japan
A canine model of an acute hepatic failure was created by the administration of Dimethylnitrosamine (DMN) (30mg/kg) via portal vein. Using this model, the hepato-pancreatic relationship was studied by measuring the pancreatic endocrine function of portal blood and hepatic blood flow. As a result, while the plasma level of IRI of portal blood was higher than basal level of IRI when the hepatic damage was mild, the former was similar to control when the hepatic damage was severe. On the other hand, the more severe the hepatic damage was, the higher the plasma level of IRG of portal blood was. Hypoglycemia and a considerable high level of portal IRG were shown in an acute hepatic failure. These results strongly suggest that pancreatic endocrine function of portal blood may reflect the grade of hepatic damage and a hormonal or neural hepato-pancreatic relationship may exist between the liver and the pancreas.

Abstract Submission No. 100242
O-0822
Thymosin α1 improves immune imbalance in hepatitis B virus-related acute-on-chronic liver failure
Zhihui Li1, Jing Zhang1, Bingliang Lin1
1The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China
Background and aim: Thymosin α1 (Tα1) is safe for patients with hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) and significantly improves the 90-day survival rate without liver transplantation; however, the immune mechanism remains unclear.
Methods: This study was an open-label, randomized, controlled clinical trial including 73 patients with HBV-related ACLF (HBV-ACLF) (Clinical Trial ID: NCT 03082885). The control group (SMT group, N=38) received standard medical therapy, while the experimental group (Tα1 group, N=35) received Tα1 combined with SMT by subcutaneous injection. Blood samples and clinical data were collected for analysis.
Results: We found that patients with ACLF had a higher proportion of regulatory T cells (Tregs) than the healthy people, suggesting that differentiation of T cells into effector T cells was limited in patients with ACLF. At baseline, patients who had survived at 90 days had a higher proportion of effector T cells and a lower proportion of Tregs than did patients who were deceased. Analysis of the serum cytokine profiles of surviving patients also showed higher levels of the serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ and lower levels of the serum transforming growth factor (TGF)-β, compared with those in the deceased patients. More importantly, we found that Tα1 treatment can inhibit worsening of the inflammatory storm and restore the immuno-inflammation balance, thus improving prognosis.
Conclusion: Tα1 can improve the prognosis of patients with ACLF-HBV infection by inhibiting excess inflammatory reactions and reversing immune paralysis.

Abstract Submission No. 100055
O-0817
A Change in Strategy for Filter Choice Leads to Improved Filter Retrieval Rates
Zhongzhi Jia1
1The Affiliated Changzhou Second People’s Hospital of Nanjing Medical University changzhou China
Objective: To assess whether a new strategy for the choice of inferior vena cava filter placed would improve filter retrieval rates at our institution.
Results: The study population included 26 patients with ISR and 26 control patients. Multivariable analysis demonstrated that stent-to-vascular (S/V) ratio (OR, 1.14; 95% CI, 1.00-1.29; P = .045), stent proximal position > 10 mm away from the SMA root (OR, 108.67; 95% CI, 3.09-3816.42; P = .010), and high oscillatory shear index (OSI) area (OR, 1.25; 95% CI, 1.02-1.52; P = .029) were predictors of ISR. In structural and fluid dynamics simulations, a stent proximal position near the abdominal aorta (AA) or entering into the AA reduced the contact area between the proximal struts of the stent and the vascular wall, alleviated the distal lumen over-dilatation.
Conclusion: S/V ratio, stent proximal position away from the SMA root, and high OSI area are independent risk factors for ISR in patients with SMAD undergoing stent placement. Deploying the proximal end of the stent near the AA or entering into the AA appears to improve the hemodynamic environment in the SMA lumen and ultimately reduce the risk of ISR.

Abstract Submission No. 100096
O-0823
Baicalein Alleviates ACLF by Promoting TREM2-dependent M2 Macrophage Polarization and Efferocytosis
Macrophage Polarization and Efferocytosis
Jia chen1, Qiongchi Zhang1, Zhipeng Li1, Zhexuan Deng1, Yeqiong Zhang2, Wenxiong Xu1,2, Liang Peng2

1Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 2Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Background: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome characterized by sudden hepatic deterioration and systemic inflammation in the context of chronic liver disease. However, current therapeutic options are limited. This study investigates the potential of Baicalein, a natural flavonoid, to mitigate ACLF and explores the underlying molecular mechanisms.

Methods: Liver tissues from an ACLF mouse model, subjected to either Baicalein treatment or saline treatment, were collected. CD45+ immune cells were isolated via fluorescence-activated cell sorting and combined for single-cell RNA sequencing (total ten samples). Additionally, the study employed the BMDM cell line and mouse peritoneal macrophages for in vitro experiments. Furthermore, macrophage conditional TREM2 knockout mice were generated to confirm the initial findings. Lastly, peripheral blood samples were obtained from ACLF patients to quantify soluble TREM2 in serum and assess its correlation with the patients’ 28-day prognosis.

Results: The study demonstrates that Baicalein significantly alleviates liver injury in an ACLF mouse model. Single-cell sequencing results reveal a substantial increase in TREM2+ macrophages in the livers of the Baicalein-treated group, suggesting the pivotal role of TREM2+ macrophages in the process of Baicalein-mediated liver injury alleviation. Through further experiments, it is established that Baicalein-induced macrophage phagocytic receptor TREM2 is necessary for the efferocytosis of apoptotic hepatocytes and the polarization of M2 macrophages. Serum TREM2 levels are also significantly linked to the 28-day prognosis of ACLF patients.

Conclusion: In summary, this study highlights the potential of Baicalein as a therapeutic approach for ameliorating ACLF by promoting TREM2-dependent M2 macrophage polarization and efferocytosis.

Abstract Submission No. 100364
O-0825

Long-term efficacy and safety of three potent NAs in the treatment of HBV-ACLF: 144-week data

Yeqiong Zhang1,2, Wenxiong Xu1,2, Zhexuan Deng1, Lu Wang3, Xingrong Zheng1, Xi Pu1, Xuejun Li1, Liang Qi1, Shu0, Jing Lai0, Liang Peng1, Zhipeng Li3

1Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 2Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 3Department of Diagnostics, Second School of Clinical Medicine, Binzhou Medical University Yantai China

Background: There are no data on long-term prognosis and safety of tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF) and entecavir (ETV) in the treatment of HBV-related acute-on-chronic liver failure (HBV-ACLF). Here we report the 144-week results of the three NAs in the treatment of HBV-ACLF.

Methods: A total of 199 patients were included in this study. After PSM, 44 patients for each group were remained for further analyses. The original cohort, one patient in each group developed hepatocellular carcinoma. No serious drug-related adverse events were observed. The log-rank test indicated that no significance was found among the groups’ long-term survival rates (p = 0.118)(Fig A). Even in the subsets of with or without cirrhosis, there was still no significance (p = 0.338 and 0.052)(Fig B-C). There was no significant difference in the HBV DNA undetectable rate (Fig D) and liver function among the three groups, except for AST, which was significantly higher in the TDF group than in the ETV group at week 144 (p = 0.001). In terms of renal function, there was no significant difference among the three groups at other time points except that CR decreased and eGFR increased more significantly in the ETV group at week 48(Fig E-F).

Conclusions: There were no significant differences in the survival rate, incidence of hepatocellular carcinoma, efficacy and safety of the three NAs in the treatment of HBV-ACLF for 144 weeks.

Abstract Submission No. 100378
O-0826

mNGS improves the efficiency of infection diagnosis and treatment in acute-on-chronic liver failure
Abstract Submission No. 100399
O-0827

CRRT in Children with Hepatitis A Virus associated Acute Liver Failure with Advanced Encephalopathy

Arjun Maria1, Nishant Wadhwa2, Anil Sachdeva2, Kanav Anand3
1Division of Pediatric Gastroenterology, Hepatology and Liver Transplant, Institute of Child Health, Sir Ganga Ram Hospital New Delhi India, 2Department of Pediatric Critical Care, Institute of Child Health, Sir Ganga Ram Hospital New Delhi India, 3Division of Pediatric Nephrology, Institute of Child Health, Sir Ganga Ram Hospital New Delhi India

Objective Effect of CRRT on survival in children with HAV associated ALF with HE grade III/IV

Methods Analysis of all children between January 2018 to April 2023. All children were offered CRRT, 21 agreed to CRRT and 14 who refused were treated with standard medical therapy (SMT) and included as controls. No liver transplantation.

Results: Thirty five analysed and 21 (60%) received CRRT. Baseline characteristics were comparable apart from ammonia, which was higher in the CRRT (p=0.001). Seven (33.3%) in CRRT and 3 (21.4%) in SMT group fulfilled Kings College Criteria for LT (p=0.445). In CRRT, 13 (61.9%) survived while in SMT group 7 (50%) survived (p=0.486). The survival time was 6.3 days in CRRT vs 7.29 days in the SMT group (p=0.769). On risk predictive analysis, failure to reduce ammonia by 30% by day 3 of therapy (p=0.001), inotrope requirement at day 3 (p=0.001), bilirubin at day 3 (p=0.001) and ammonia at day 3 (p=0.023) were associated with mortality. On Model 1 of Cox regression analysis, which included ammonia at day 3, bilirubin at day 3 and inotrope requirement at day 3, only bilirubin levels were associated with mortality (HR 1.157, p=0.04). Since bilirubin is reduced by CRRT, analysis performed again by including CRRT and inotrope in model 2. Inotrope requirement associated with 9.5 folds increase in mortality (HR 9.569, p=0.001), however CRRT was not significant

Conclusion: Increased survival in children who received CRRT, however it did not reach statistical significance. High bilirubin and persisting inotropic requirement at day 3 were associated with mortality.
than the SMT arm (p<0.05, each). The patients in OINT group had lesser number of hospitalizations (6 (17%) versus 16 (45.7%) (p=0.010) over the course of 3 months as compared to SMT group.

Conclusion: Outpatient intensive nutrition therapy has a significant impact on improving survival, frailty and disease severity of ACLF patients with a reduction in number of hospitalizations and supports the key role of nutrition in addition to standard medical treatment in ACLF patients.

Abstract Submission No. 100525
O-0829

ALTA: a simple nutritional prognostic score for patients with HBV-ACLF

Rui Song1, Xiaohao Wang1, Zhao Li2, Jiahe Tan3, Hongyu Wu1, Yunyi Tan1, Hanlu Li4, Teng Zeng5, Hong Ren1, Zhiwei Chen1

1The Second Affiliated Hospital of Chongqing Medical University Chongqing China, 2The Seventh People's Hospital of Chongqing Chongqing China, 3The First Affiliated Hospital of Chongqing Medical University Chongqing China, 4The Ninth People's Hospital of Chongqing Medical University Chongqing China, 5The Fifth People's Hospital of Chongqing Medical University Chongqing China

Background & Aims: Malnutrition, as a common but usually neglected complication, can increase the mortality in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). The aim of this study was to develop a simple nutritional prognostic score to accurately predict the mortality in HBV-ACLF patients.

Methods: In this multicenter retrospective study, clinical data from 195 HBV-ACLF patients were used to develop a new prognostic score, and then was validated in two external cohorts.

Results: Four independent factors were significantly associated with 28-day mortality of HBV-ACLF patients and constituted a new prognostic score (ALTA score =2.216×age-2.283×lymphocyte count-1.902×total cholesterol-0.152×albumin-1.629). Notably, the AUROC of ALTA score for 28/90-day mortality (0.955/0.947) were significantly higher than those of three other ACLF prognostic scores (COSSH-ACLF II, 0.848/0.791; MELD, 0.607/0.596; MELD-Na, 0.602/0.582; all P=0.001), and three known nutritional scores (CONUT, 0.746/0.816; OPNI, 0.256/0.200; NRS-2002, 0.313/0.330; all P=0.001). Further classified ALTA score into three strata, the hazard ratios of mortality at 28/90 days were obviously increased in the intermediate-risk and high-risk groups than low-risk group (19.0/8.0 and 67.9/29.7). The negative predictive values of low-risk group and positive predictive values of high-risk group for 28/90-day mortality were 97%/78% and 94%/100%, respectively. Further optimized ALTA score into a scoring sheet (ALTA 2.0), it still exhibited excellent predictive ability. These results were then validated in two external cohorts.

Conclusion: ALTA, as a simpler and easier to use nutritional prognostic score for clinicians, can accurately predict short-term mortality of HBV-ACLF patients, hence, it might be used to guide clinical management.

Abstract Submission No. 100576
O-0830

Forecasting Initial 15-Day Mortality in Alcohol Related Acute On Chronic Liver Failure (ACLF)

Vivek Saini1, Sunil Kumar Dadhich1, Abhishek Yadav1, Rajendra Bhati1, Bobby Mitrolia1, Naveen Mehla1, Sewaram Choudhary1, Sabir Hussain1, Narendra Bhargava1

1Dr. Sampurnanand Medical College Jodhpur India

Background and Aim: The initial 15 days study in alcohol related ACLF is scarce, a period significant for mortality and liver transplantation feasibility. This study aims to fill this gap by conducting a detailed analysis of this timeframe.

Methods: Clinical and biochemical blood parameters of 227 alcoholic ACLF patients were collected. Patients were followed till 90 days or death with observations on 0, 4, 7, 15, 30, 45, 60, and 90 days. Statistical analysis was focused on 15 day mortality.

Results: Of 227 patients, 41% (94) died within 15 days. Baseline means of 15 day mortality versus survived showed significant difference in alcohol intake (198g/day v 144g/day), serum creatinine (2.2mg/dl v 1.6mg/dl), lactate (2.8mmol/l v 1.8mmol/l) and AARC score (10.7 v 9.4).

Significant hazard ratios (HR) on multivariate cox regression of categorical blood parameters were creatinine (<0.7mg/dl v >1.5mg/dl, HR-0.44), INR (<1.8 v >1.8, HR-0.47), lactate (<1.8mmol/L v >1.8mmol/L, HR-0.42), neutrophil counts (<80% v >80%, HR-0.43). Those consuming <200g/day of alcohol had 70% less mortality to those with >300g/day. Among the prognostic scores, AARC score (≤7 v >10, HR-0.10) and SIRS (present v absent, HR-9.5) were key determinants. In decision tree analysis SIRS presence alone leads to 65% mortality, SIRS with lactate >1.4mmol/l resulted in 75% deaths, and trio combination of SIRS, lactate >1.4mmol/l , and alcohol intake >200g/day leads to 100% mortality.

Conclusions: Alcoholic ACLF have 41% initial 15 Day mortality. The combination of SIRS presence, lactate level >1.4mmol/l, and alcohol intake >200g/day was linked to 100% deaths.

Abstract Submission No. 100656
O-0831

XBP1 mediating NFκBp65 promotes macrophage derived inflammation via MT2 transcript in liver IRI

Jianhua Rao1, Zeng Wang1, Fei Yu1, Junda Li1, Wenzhu Li1, Zhengfeng Xuan1, Yongquan Chi1, Feng Zhang1, Liming Tang2, Feng Cheng3

1Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing 210029, China Nanjing China, 2Center of Gastrointestinal Disease, The Affiliated Changzhou NO.2 People's Hospital of Nanjing Medical University, Changzhou 213003, China Changzhou China

Background: XBP1, the most conserved transcription factor of endoplasmic reticulum stress, plays important roles in physiological and pathological settings. Its activity has profound effects on disease progression and prognosis. We aimed to investigate the role of XBP1 in macrophage-originated sterile inflammation during liver ischemia/reperfusion injury (IRI).

Methods: Macrophage XBP1 expression and liver injury were analyzed in patients undergoing ischemia-related hepatocyte. Then, we created a myeloid-specific XBP1-knockout (XBP1M-KO) strain to study function and mechanism of XBP1 on macrophage-derived sterile inflammation in murine liver IRI model with In-vitro parallel research. Macrophages co-cultured with hypoxia-treated hepatocytes were applied to investigate impact of XBP1 in vitro. We also analyzed RNA sequencing and databases for potential XBP1 target gene by CUT&RUN and luciferase reporter assay.
Results: Clinically, macrophage XBP1 expression significantly increased in ischemic liver tissues and positively correlated with liver injury after heptectomy. Less hepatocellular damage was presented in XBP1M-KO mice than XBP1-proficient controls based on serum biochemistry, pathology, ROS and inflammation. In vitro, XBP1 deficiency inhibited sterile inflammation and migration in macrophages co-cultured with hypoxia-treated hepatocytes. Analysis of RNA sequencing and databases determined Metallothionein 2 (MT2) as an XBP1 target gene, negatively regulated by binding with its promoter. XBP1 deficiency increased MT2 expression and IKBa expression, but inhibited NF-xB-p65 phosphorylation. MT2 inhibition and NF-xB activation markedly neutralized XBP1M-KO-related benefits by promoting sterile inflammation during liver IRI.

Conclusion: XBP1 promotes macrophage-originated sterile inflammation, increases liver IRI by binding to the MT2 promoter, and regulates MT2/NF-xB pathway, providing a potential therapeutic target for liver IRI.

Abstract Submission No. 100697
O-0832

Biomarker discovery, validation & pathways in infection related acute-on-chronic liver failure

Pratibha Garg1, Nipun Verma1, Arun Valsan1, Vivek Sarohi2, Trayambak Basak1, Parminder Kaur1, Shreya Singh1, Arka De1, Madhumita Premkumar1, Sunil Taneja1, Ajay Duseja1, Virendra Singh1

1Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India Chandigarh India, 2School of Basic Sciences, Indian Institute of technology Mandi, HP India, 3Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India Chandigarh India

Objective: Evaluating infections in the context of acute-on-chronic liver failure (ACLF) presents a formidable challenge. This study employs untargeted proteomics to uncover protein signatures and pathway perturbations associated with infections in ACLF.

Design: We prospectively enrolled 231 ACLF patients (92.6% males, mean age 42.1 years, 65% alcoholic hepatitis), both with and without bacterial/fungal infections. Untargeted proteomics was performed on plasma samples from 84 patients (discovery cohort), followed by biomarker discovery and validation using differential expression, discriminant analysis, machine learning, and ELISA in 147 patients. Perturbed pathways between infected and non-infected groups were analyzed.

Results: Infection-positive patients exhibited elevated leucocyte count, procalcitonin, organ failures, severity scores, and a 30-day mortality of 81.4% vs. 6.6% (p<0.001 each). Among the 516 identified proteins, 27 were upregulated and 38 downregulated in infections (adjusted-p<0.05). Validation yielded a four-protein panel (LGALS3BP, PLTP, CFP, GPX3) classifying infections with AUC 0.854 (0.787-0.922), retaining significance after adjusting for disease severity and inflammation. A PACIFY model, integrating three proteins (LGALS3BP, PLTP, GPX3), procalcitonin, CLIF-C OF, and leukocytosis/leucopenia, yielded AUC 0.957 (0.927-0.986), accuracy 89.1%, sensitivity 90.2%, and specificity 99.7% for infection diagnosis. PACIFY outperformed procalcitonin, SIRS, WBC, NLRI, neutrophil%, and composite models (p<0.001). Pathway analysis unveiled diverse perturbations including impaired pathogen-response, reduced-phagocytosis, neutrophil extracellular traps, complement functions, hypocoagulation and hypofibrinolysis, dysregulated carbohydrate metabolism and autophagy, with heightened cell death and proteolysis.

Abstract Submission No. 100799
O-0834

Hepatitis E virus infection portends high mortality in patients with acute-on-chronic liver failure

Guan-Huei Lee1, 2, Sabrina ZX Quek1, Seng Gee Lim1, 2, Mark Muthiah1, 2, Ashok Choudhury3, Vinod Arora3, Mohd Rela4

1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi Province, China 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, Shaanxi, China 3Institute of Laboratory Medicine and Pathology, Xi’an Jiaotong University, Xi’an, Shaanxi Province, China 4Institute of Laboratory Medicine and Pathology, Xi’an Jiaotong University, Xi’an, Shaanxi, China

Objective: Predictive model based on PNI for infection in acute-on-chronic liver failure

Yamin Wang1, 2, 3, 4, Yushan Liu1, 2, 3, 4, Deyan Lu1, 2, 3, 4, Xiaonan Wu1, 2, 3, 4, Siyi Liu1, Qiao Zhang1, 2, 3, 4, Juan Li1, Qijuan Zang1, 2, 3, 4, Chengbin Zhu1, Qiannan Wang1, Pan Huang1, Jinfeng Liu1, Yuan Yang1, Yingren Zhao1, 2, 3, 4, Yingli He1, 2, 3, 4

1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China Xi’an, Shanxi Province, China 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China Xi’an, Shanxi Province China 3Institute of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, Shaanxi Province, China 4Institute of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, Shaanxi, China Xi’an, Shanxi Province China

Objective Prognostic Nutritional Index (PNI) is an index that can reflect nutritional status and immune function of patients and calculated from the serum albumin concentration and the total number of peripheral lymphocytes. This study aims to explore the predictive value of PNI on infectious complication in patients with acute-on-chronic liver failure (ACLF).

Methods Two hundred and twenty patients with ACLF hospitalized in the First Affiliated Hospital of Xi’an Jiaotong University were selected who were divided into infection group and non-infection group based on whether they were infected in hospital. Differences in clinical data and laboratory indicators were compared between the two groups. Logistic regression analysis was used to select the influencing factors related to infectious complication. Receiver operating characteristic curve (ROC) was applied to evaluate the predictive value of PNI on infection.

Results: (1) In patients with ACLF, there were 152 and 68 patients in infection group and non-infection group respectively. Ascites, hepatorenal syndrome, PNI, ALB and so on were statistical differences between the two groups (P<0.05). (2) Among 152 infectious patients, the common sites of infection were abdominal infection and pulmonary infection, with an incidence of (113/198, 57.07%) and (58/198, 29.29%). (3) The results of logistic multivariate analysis showed that low PNI, ascites and hepatorenal syndrome were risk factors for infectious complication. When PNI≤ 40.625, it has a better prediction effect on infectious complication in patients with ACLF, with sensitivity of 0.842 and specificity of 0.412.

Conclusion: The low PNI is an independent risk factor for developing infection in patients with ACLF. When PNI≤40.625, it can predict infectious complication in patients with ACLF.

Abstract Submission No. 100799
O-0834

Hepatitis E virus infection portends high mortality in patients with acute-on-chronic liver failure

Guan-Huei Lee1, 2, Sabrina ZX Quek1, Seng Gee Lim1, 2, Mark Muthiah1, 2, Ashok Choudhury3, Vinod Arora3, Mohd Rela4
Established an ACLF mouse model treated with SDX and HS.

Methods: Prospectively collected data of 5612 ACLF patients from 25 countries in the AARC database between 2007 and 2021 was studied. The data analysed included demographic profile, severity of liver disease (MELD, AARC score), chronology of organ failure development, treatments and outcomes. Statistical analyses were carried out using RStudio version 2023.09.01 and OpenEpi version 3.01.

Results: The study included 340 HEV IgM-positive patients (6.06% of total cohort) and 5272 non-HEV patients who were hospitalised for ACLF. Compared with non-HEV patients, HEV-positive patients have similar demographic profile (age, gender, and chronic liver disease) and disease severity at baseline (MELD 29.9 and AARC score 9.62). However, HEV patients have significantly higher 90-day mortality (54.7% vs. 48.1%, p=0.019), number of organ failures by day 4 (median of 2 vs. 1, p=0.001) and progression (time to death: 11 vs. 13 days, p=0.012).

Conclusions: HEV infection is associated with higher mortality rate and number of organ failures in ACLF patients. This may be related to the lack of specific therapy for HEV infection.

Syndecan-1 improves ACLF by promoting liver regeneration and attenuating hepatocytes apoptosis

Xiaoli Zhang1,2, Yali Zhao1,2, Shan Fu1,2, Juan Li1,2, Tianzhi Ni3, Lingyun Xu4,5, Ruojing Wang6, Qiao Zhang1,2, Weicheng Xu4, Taoa Zhai2, Yiling Zhao7, Yinghe He8

1Department of Infectious Diseases, Xi’an Jiaotong University Xi’an China, 2National Key Research and Development Program of China, 3Department of Hepatology, Xi’an Jiaotong University, Xi’an China, 4Shaanxi Key Laboratory of Molecular Parasitology and International Joint Research Laboratory of Malaria and Other Infectious Diseases, Xi’an Jiaotong University, Xi’an China, 5Department of Gastroenterology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an China, 6Department of Hepatology, Xi’an Jiaotong University, Xi’an China, 7Department of Hepatology, Xi’an Jiaotong University, Xi’an China, 8Department of Hepatology, Xi’an Jiaotong University, Xi’an China

Background and Aims: Acute-on-chronic liver failure (ACLF) has a high short-term mortality rate. Syndecan-1 (SDC-1) is a major molecule of heparan sulfate proteoglycans present on healthy liver tissue, which can be shed from the cell surface. The core proteins of SDC-1 carry heparan sulfate (HS) chains, and sulodexide (SDX) is a heparinoid compound. Thus, we aimed to assess diagnostic, prognostic and therapeutic efficacy of SDC-1 and its side chains in ACLF patients.

Methods: Serum SDC-1 was examined in 26 healthy controls, 34 patients with chronic hepatitis, 38 with liver cirrhosis, and 101 ACLF patients by ELISA. And a prospective cohort of 101 ACLF patients was followed up to develop a novel prognostic score. Furthermore, we established an ACLF mouse model treated with SDX and HS.

Results: Serum levels of SDC-1 in ACLF patients were obviously increased compared to healthy controls (P < 0.0001). According to our 90 days of clinical observations, non-survived ACLF had markedly higher baseline serum SDC-1 levels than survivors (P < 0.05). A novel prognostic model (UIAS = 0.076 * Age + 0.001 * SDC-1 + 1.454 * INR + 2.854 * UGIB - 12.165) was developed for ACLF. In a cell model of acute liver injury, overexpression of SDC-1 significantly increases expression of proliferating cell nuclear antigen (PCNA) and cyclinD1. Furthermore, in a mouse model, we found that SDX and HS significantly attenuated ACLF, which may by promoting liver regeneration and restraining capase3-related apoptosis. Furthermore, Collectively, our findings suggest that SDC-1 can potentially serve as a predictive biomarker for ACLF prognosis and may represent a promising therapeutic target for relieving severe liver injury.

Activating cholinergic pathway attenuates Liver injury by inhibiting MLKL-mediated necroptosis

Shan Fu1, Tianzhi Ni1, Xiaoli Zhang1, YaLi Feng1, Ruojing Wang2, YingLi He1,2, YingRen Zhao0, JinFeng Liu1,2

1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an China, Shaanxi China, 2Shaanxi Clinical Medical Research Center of Infectious Diseases, Xi’an China

Background: The function of cholinergic anti-inflammatory pathway (CAP) in acute liver failure (ALF) with inflammatory storm remains indefinite. Mixed lineage kinase domain-like pseudokinase (MLKL), a key terminal effector of necroptosis, plays a crucial role in regulating liver inflammation. Investigation about CAP regulation on necroptosis would enrich our understanding over cholinergic anti-inflammatory mechanism.

Approach and Results: Co-injection of Lipopolysaccharide and D-galactosamine were used to establish the model of ALF. PNU-282987 was used to activate the CAP. Liver biopsy specimens and patients’ serum from liver failure patients were also analyzed. We confirmed that activating the CAP alleviated hepatoocyte destruction, accompanied by a significant decrease in hepatocyte apoptosis, pro-inflammatory cytokines, and NLRP3 inflammasome activation. Moreover, hepatic necroptosis and serum MLKL levels were induced in ALF and MLKL levels were positively correlated with the extent of liver damage and the expression of proinflammatory markers (IL-6, IL-1β, TNF-α). MLKL was colocalized with macrophage marker F4/80 in livers. Mechanistically, MLKL deletion also remarkably decreased pro-inflammatory cytokines and inhibited polarity shift toward inflammatory macrophages. Furthermore, Activating the CAP inhibits MLKL-mediated necroptosis and downregulated markers of inflammatory macrophages in vivo and in vitro. Finally, we revealed that the levels of serum MLKL were elevated in patients with liver failure and closely correlated with clinical course. Increasing hepatic MLKL were also confirmed in patients.

Conclusion: Together, these data indicated that activation of the CAP attenuates Liver injury by inhibiting macrophage-derived MLKL-mediated necroptosis and regulating macrophage polarization and function. Targeting MLKL might be a potential therapeutic way to treat ALF.

Niclodamide inhibits Macrophage Ferroptosis against LPS/D-GaN-induced Acute Liver Failure

Abstract Submission No. 100929

O-0837
Xiao Zhong1−2, Ruochan Chen1−2, Xue-Gong Fan1−2
1Department of Infectious Diseases, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University Changsha China, 2National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University Changsha China

Acute liver failure (ALF) is a life-threatening liver disease with a high mortality rate, and the identification of specific therapeutic agents represents a crucial clinical challenge. Although oxidative stress and inflammatory responses within the liver play pivotal roles in the pathogenesis of ALF, the precise regulatory mechanisms remain elusive. Ferroptosis, a form of programmed cell death, is closely associated with oxidative stress and inflammation. Applying the strategy of “old drugs with new uses” and bioinformatics analysis, we screened for potential agents and identified niclosamide, an anthelmintic drug. Niclosamide dose-dependently improved survival rates and protected mice from LPS/D-galactosamine-induced liver injury. In vitro, niclosamide affected macrophage proliferation and the production of inflammatory mediators in response to LPS without exerting a direct protective effect on hepatocytes. Subsequent studies revealed that niclosamide could inhibit macrophage ferroptosis, particularly M2 macrophage ferroptosis, in vivo. Consistently, niclosamide suppressed macrophage ferroptosis without affecting hepatocytes. Based on these findings, we propose the scientific hypothesis that niclosamide targets hepatic macrophage ferroptosis to inhibit the development and progression of ALF.

Abstract Submission No. 101039
O-0838

Comparison of 28 Day Survival of Patients with ALF and ACLF treated with DPMAS
Jan Axel Yusi1, Pamela Angulo1, Ian Homer Cua1, Ma. Kristina Alolod1
1St. Luke’s Medical Center Quezon City Quezon City Philippines

Objectives: The study aims to determine the clinical outcomes of patients who underwent DPMAS.

Methods: This is a cross-sectional analytic study that retrospectively analyzed 36 adult patients, 14 with ALF and 22 with ACLF who received DPMAS in 2 Tertiary Hospitals in the Philippines.

Results: A total of 36 adult patients on DPMAS were included, 30 were on DPMAS and 6 were on DPMAS + Plasma Exchange(PE). Of the 30 patients who underwent DPMAS, 14 have ALF and 16 have ACLF. All Six patients who underwent DPMAS and PE have ACLF. The median age was 59(QQR 17.25) and majority are males(78%). The most common etiologies for ALF were hyperperfusion, 4(11%), and Drug-induced, 4(11%), while hepatocellular carcinoma, 10 (28%), followed by Chronic Hepatitis B, 9 (25%) are common etiologies for ACLF. Majority had Child Pugh Class C and Grade 3 Hepatic Encephalopathy. Total bilirubin declined after DPMAS for both ALF (17.845 to 11.485, p= 0.646 ) and ACLF (16.685 to 12.02, p=0.118 ). 28-day Survival rate in ALF on DPMAS is 18%, while ACLF patients on DPMAS is 30% (p=0.854). There was no difference between survival distributions of ALF=DPMAS, ACLF=DPMAS and ACLF=DPMAS+PE(p=0.844) using the Kaplan Meier method.

Conclusion: DPMAS and DPMAS+ PE improved the clinical and laboratory parameters in both ALF and ACLF. A larger cohort of patients, however, is needed to ascertain its clinical significance.

Abstract Submission No. 101122
O-0839

Exosomes from senescent hepatocytes activate HSCs and protect against acute liver failure by ITGA5
Yali Feng1, Shan Fu1, Xiaoli Zhang1, Juan Ji1, Tianzhi Ni1, Ruojing Wang1, Jinfeng Liu1, Yingren Zhao1, Yingli He1
1Department of Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an Jiaotong University Xi’an China

Background: Cell senescence markers, such as p21, P16, and p53, were increased in mice with acute liver failure. Senescent hepatocytes, induced by etoposide, secreted more exosomes than non-senescent cells. Exosomes were isolated from the conditional media of senescent (Sen) or non-senescent (NSen) hepatocytes by differential ultracentrifugation and identified by electron microscope and western blots.

Results: Cellular senescence markers, such as p21, P16, and p53, were increased in mice with acute liver failure. Senescent hepatocytes, induced by etoposide, secreted more exosomes than non-senescent cells. Exosomes derived from Sen-hepatocytes promote migration, proliferation, and activation of HSCs. Proteomic characterization of exosomes

TPO promotes hepatocyte regeneration by elevating platelets in rats with acute liver failure
Jing Liang1, Fengzheng Han2, Li Jing1, Ying Luo1
1Tianjin Third Central Hospital Tianjin China, 2Tianjin Jinnan Hospital Tianjin China

Aim: To investigate the role of platelets and recombinant human thrombopoietin (rhTPO) on liver regeneration in rats of acute liver failure (ALF).

Methods: A rat model of acute liver failure was constructed by injection of D-amino galactose(D-GalN). The experimental rats were randomly divided into rhTPO group (n=20) and control group (n=20), which were given rhTPO 15µg/Kg or saline for 5 days before D-GalN injection respectively. Liver tissue and blood samples were taken from rats at 6, 24 and 72 hours after the construction of an acute liver failure model after D-galactose injection in both groups. Hepatic histopathological changes and Ki67 were observed in both groups. The survival, liver function, serum HGF level were compared between the two groups after injection of D-GalN. Cell proliferation and cell apoptosis were analyzed by BrdU and TUNEL.

Results: Before D-GalN injection, the PLT counts and liver weight of rhTPO group were remarkably higher than that in the control group (P<0.01). After injection of D-GalN, the rhTPO group had significantly lower ALT levels at 6 and 24 hours and significantly lower TBI levels at 72 hours as well as the control group (P<0.05). The proportion of TUNEL-positive cells in liver tissues in the rhTPO group was lower than that in the control group (P<0.01), the serum HGF levels and the proliferation index of Ki67 and the proportion of BrdU-positive cells were significantly higher than that in the control group (P<0.05).

Conclusion: TPO significantly elevated PLT counts in D-amino galactose induced ALF rats. Platelet elevation induced by rhTPO promoted recovery of liver function, reduced hepatocyte apoptosis and increased liver regeneration in ALF rats.

Abstract Submission No. 101255
O-0840

Exosomes from senescent hepatocytes activate HSCs and protect against acute liver failure by ITGA5

Ruojing Wang1, Jinfeng Liu1, Yingren Zhao1, Yingli He1
1Department of Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an Jiaotong University Xi’an China

Aim: To investigate the role of platelets and recombinant human thrombopoietin (rhTPO) on liver regeneration in rats of acute liver failure (ALF).

Methods: A rat model of acute liver failure was constructed by injection of D-amino galactose(D-GalN). The experimental rats were randomly divided into rhTPO group (n=20) and control group (n=20), which were given rhTPO 15µg/Kg or saline for 5 days before D-GalN injection respectively. Liver tissue and blood samples were taken from rats at 6, 24 and 72 hours after the construction of an acute liver failure model after D-galactose injection in both groups. Hepatic histopathological changes and Ki67 were observed in both groups. The survival, liver function, serum HGF level were compared between the two groups after injection of D-GalN. Cell proliferation and cell apoptosis were analyzed by BrdU and TUNEL.

Results: Before D-GalN injection, the PLT counts and liver weight of rhTPO group were remarkably higher than that in the control group (P<0.01). After injection of D-GalN, the rhTPO group had significantly lower ALT levels at 6 and 24 hours and significantly lower TBI levels at 72 hours as well as the control group (P<0.05). The proportion of TUNEL-positive cells in liver tissues in the rhTPO group was lower than that in the control group (P<0.01), the serum HGF levels and the proliferation index of Ki67 and the proportion of BrdU-positive cells were significantly higher than that in the control group (P<0.05).

Conclusion: TPO significantly elevated PLT counts in D-amino galactose induced ALF rats. Platelet elevation induced by rhTPO promoted recovery of liver function, reduced hepatocyte apoptosis and increased liver regeneration in ALF rats.

Abstract Submission No. 101255
O-0840
revealed that ITGA5 was overexpressed in exosomes derived from Sen-hepatocytes. ITGA5 was also increased in Sen-hepatocytes and liver with ALF mice, which was regulated by mTORC1 in cellular senescence condition. ITGA5 silencing in HSCs reduced HSC activation and migration by inhibiting Smad2 phosphorylation. Pharmacologic inhibition of ITGA5 using ATN-161 exacerbated liver failure by inhibiting HSC activation and impairing liver structure.

**Conclusion:** ITGA5-enriched exosomes derived from senescent hepatocytes activate hepatic stellate cells via regulation of Smad2 signaling, which maintains the liver architecture to prevent collapse during acute liver failure.

**Abstract Submission No. 101397**

**DPMAS Therapy in Patients with Liver Failure: A Non-randomized Cluster-controlled Study (PADSTONE)**

Beiling Li¹, Rongqi Wang², Shan Zhong³, Lang Bai⁴, Yanhang Gao⁵, Zhiping Qian⁶, Lu Zhang⁷, Zuxiong Huang⁸, Yan Huang⁹, Xiaoping Wu¹⁰, Jinjun Chen¹

¹Hepatology Unit Nanfang Hospital Southern Medical University Guangzhou China, ²The Third Hospital of Hebei Medical University Hebei China, ³The Second Affiliated Hospital of Chongqing Medical University Chongqing China, ⁴Center of Infectious Disease, West China Hospital of Sichuan University Sichuan China, ⁵Department of Hepatology, The First Hospital of Jilin University Changchun China, ⁶Department of Liver Intensive Care Unit, Shanghai Public Health Clinical Centre, Fudan University Shanghai China, ⁷The First Affiliated Hospital of Guangxi Medical University Nanning China, ⁸Department of Hepatology, Menghao Hepatobiliary Hospital of Fujian Medical University Fujian China, ⁹Department of infectious disease, Hunan Key Laboratory of Viral Hepatitis, Xiangya Hospital, Central South University Changsha China, ¹⁰The First Affiliated Hospital of Nanchang University Nanchang China

**Background:** Liver failure is a life-threaten syndrome and cause high short-term mortality. Double plasma molecular adsorption system (DPMAS) is one of the available artificial liver support systems which its efficiency for chronic liver disease (CLD) patients with liver failure remains controversial.

**Methods:** A prospective, multicenter and cluster-controlled study was conducted (NCT05129904) and 57 tertiary hospitals were recruited and allocated to the DPMAS treatment clusters (n=28) and standard medical treatment (SMT) clusters (n=29). Outcomes included disease progression, survival, death and liver transplantation and safety of DPMAS therapy. Twelve-months is required for each participant to complete post-discharge follow-up.

**Results:** In total, 648 liver failure patients were enrolled in DPMAS group and 615 patients in SMT group. MELD score was comparable between these two groups (24±5 vs. 24±6, p=0.984). For the DPMAS group, 31.9% patients had 2 DPMAS treatment sessions and 77.1% of the initial DPMAS treatment was with subsequent plasma exchange. Unfractionated heparin was the most common anticoagulants used in DPMAS treatment. The total bilirubin, ALT and CRP levels were all significantly improved after the initial DPAMS therapy. The 28-day transplant-free mortality was much lower in DPAMS group than SMT group (15.7% vs. 20.0%, p=0.048). Allergy (3.7%) and dialyzer coagulation (3.2%) as well as the arterial hypotension (2.9%) were the common adverse events during DPMAS treatment.

**Conclusions:** DPMAS treatment for CLD patients with liver failure can significantly improve the liver function markers and the 28-day mortality. DPMAS therapy was associated with few adverse events and its safety is confirmed.

**Abstract Submission No. 101409**

**O-0842**

**Clinical Characteristics and Risk Factors of End-Stage Liver Disease Complicated by Infections**

Qin NING¹, Wei Liu¹, Youqin Yan², Xiaolin Zhou³, Yi Li⁴, Wei Hu⁵, Yue Chen⁶, Xiujie Chen⁷, Jianjun Zhang⁸, Lyuyue Xu⁹, Jun Zhu¹⁰, Tao Chen¹

¹Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China, ²Wuhan Seventh Hospital Wuhan China, ³The First College of Clinical Medical Science, China Three Gorges University Yichang China, ⁴Wuhan Puren Hospital, Wuhan University of Science and Technology Wuhan China, ⁵Wuhan No. 1 Hospital, Wuhan Wuhan China, ⁶Taite Hospital, Hubei University of Medicine Shiyuan China, ⁷Xiangyang Central Hospital, Hubei University of Arts and Science Xiangyang China, ⁸The Third People’s Hospital of Hubei Province Wuhan China, ⁹General Hospital of The Yangtze River Shipping Wuhan China, ¹⁰Xian’ning Central Hospital Xian’ning China

**Background:** Bacterial or fungal infection is one of the most frequent complications for end-stage liver disease (ESLD) patients. However, clinical characteristics and risk factors in ESLD with bacterial or fungal infection have not been fully elucidated.

**Methods:** ESLD patients from 14 tertiary hospitals were involved in this retrospective cohort study from January 2012 to December 2018 in central China. The clinical characteristics and risk factors in ESLD with bacterial or fungal infection were analyzed.

**Results:** Out of all 1208 ESLD patients, 565 (46.8%) were complicated by bacterial infection and 16 (1.3%) were complicated by fungal infection. Spontaneous bacterial peritonitis was the most common type of infection (51.5%), followed by pneumonia (43.7%), urinary tract infection (7.9%) and bacteremia (2.8%). Seventy-two samples showed positive culture results, among which 28 (38.9%) were gram-positive bacteria, 28 (38.9%) were gram-negative bacteria and 16 (22.2%) were fungus. ESLD patients with bacterial or fungal infection both showed higher level of white blood cell and procalcitonin, severer liver and coagulation dysfunction, and more likely to develop ascites, hepatorenal syndrome, hepatic encephalopathy, upper gastrointestinal bleeding, and hepatopulmonary syndrome than those without. Bacterial infection was a mortality risk factor for patients with ESLD and acute on chronic liver failure (ACLF) was an independent predictor for poor outcomes in ESLD with bacterial or fungal infection.

**Conclusions:** Bacterial infection was an independent risk factor of mortality of ESLD. Homogeneity and heterogeneity in epidemiology, clinical characteristics and risks of mortality were shown among different entities of ESLD with bacterial or fungal infections.

**Abstract Submission No. 101425**

**O-0843**

**Fulminant Hepatic Failure In Pregnancy Challenges, Etiology, Management And Its Associated Mortality**

Hanisha Hemnani¹, Nazish Butt²

¹Altamash General Hospital Karachi Pakistan, ²Jinnah Postgraduate Medical Center Karachi Pakistan

**Background:** FHF in pregnancy negatively maternal affects and fetal outcomes, which depend on the etiology, timely diagnosis, prompt management, and early referral equipped medically to a center for managing obstetric complications.
The study aimed to determine the challenges, etiology, management, and associated mortality in pregnant fulminant hepatic failure (FHF) patients.

**Methodology:** A cross-sectional study at the Department of Gastroenterology, JPMC, Karachi, Pakistan. All pregnant patients with FHF, age ≥16 years recruited were investigated for acute viral serology, complete blood count, function function tests, tests, liver renal serum MELD creatinine, score parameters and King’s college criteria (KCC) parameters.

**Results:** We have enrolled 47 patients up till now with a mean age of 25.14 ± 8.32 years. The KCC criteria cut-off point was reached in a total of 40 (85.10%) patients (out of 47) of which 30 (75%) patients died.

**Conclusion:** We conclude that for pregnant women, diagnosis should consider early hepatitis E as the usual cause of FHF in our case with consultation termination of pregnancy. The Management protocols need to be individualized for each case keeping in mind the risk versus benefit to both the mother and the fetus.

---

**Abstract Submission No. 101524**

**O-0844**

**Role of plasma-derived exosomal IncRNA in regulating the systemic inflammatory response in HBV-ACLF**

**QI HUANG1,2,3, JING LI1,2,3, XIN ZHONG1,3, LANFEN PENG1,3, MENGQING MA6, MINLING LV1,3, RUI HU0, WEI ZHANG1,3, XINFENG SUN8, WENFENG MA6, ZHIYI HAN6, JINYU YI0, JIALING SUN8, XIAOZHOU ZHOU1,2,3**

1Shenzhen Traditional Chinese Medicine Hospital, Department of Liver Disease SHENZHEN China, 2Macau University of Science and Technology, Faculty of Chinese Medicine Macao China, 3The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Department of Liver Disease, Shenzhen China

This study investigated the RNA characteristics related to disease progression in hepatitis B virus (HBV)-related acute-on-chronic liver failure (ACLF) and the molecular mechanisms involved in immune regulation. Plasma exosomal long noncoding RNA (lncRNA) of 5 healthy volunteers, 5 patients with chronic hepatitis B (CHB) flares, and 8 patients with HBV-ACLF was characterized using RNA sequencing analysis. Exosomal differentially expressed IncRNA (DEIncRNA) was screened using differential analysis and protein-protein interaction, and competing endogenous RNA network maps were constructed. Immune-related mRNAs mediated by DEIncRNA regulation were identified using immunology databases. Their expression levels were verified by RNA sequencing samples of 5 patients with CHB flares, and 5 patients with HBV-ACLF. Bioinformatics analysis was used to predict the potential biological functions of the DEIncRNA. A newly identified IncRNA, MSTRG.38026, was differentially expressed in HBV-ACLF plasma exosomes. We predicted that MSTRG.38026 binds to hsa-miR-22-3p to regulate 107 immune-associated mRNAs. GO enrichment and KEGG pathway analysis suggested possible biological functions associated with immune-related mRNAs mediated by MSTRG.38026. The expression of TFKC(DAK), TGFBR1, and NFA53 was significantly downregulated in high-throughput sequencing validation. This work is the first to characterize the IncRNA profile of exosomes generated from the plasma of patients with HBV-ACLF.

---

**Abstract Submission No. 101574**

**O-0846**

**The role of L3-PMI in the prognostic evaluation of patients with acute-on-chronic liver failure**

**Qing Ye1,2,3,4, Junjun Cai1,2,3,4, Junqing Yan1,2,3,4, Rong Lv5**

1Department of Hepatology of The Third Central Hospital of Tianjin, China Tianjin China, 2The Third Central Clinical College of Naikai University Tianjin China, 3Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases of Tianjin Tianjin China, 4Institute of Hepatobiliary Disease Tianjin China, 5Radiology Department of Tianjin Third Central Hospital Tianjin China

**BACKGROUND:** Sarcopenia is closely related to the prognosis of the patients with end-stage liver disease. However, there are still lack of simple and practical evaluation indicators in clinical practice. The purpose of this study is to explore the applicable value of the third lumbar psoas muscle index (L3-PMI).

**METHODS:** We retrospectively studied the data of 140 patients who met the ACLF diagnostic criteria for hepatitis B cirrhosis. Analyze the patient’s L3-PMI and clinical characteristics and prognosis.

**RESULTS:** The 140 patients were divided into the survival group with 102 cases and the death group with 38 cases according to their 90-day survival status. The L3-PMI value of patients in the death group was 4.89 ± 1.42 cm²/m², significantly lower than that in the survival group (5.94 ± 1.24 cm²/m²) (P < 0.001). In addition, 33 ACLF patients with hepatic encephalopathy (HE) had an L3-PMI value of 5.17 ± 1.49 cm²/m² which was significantly lower than that of 107 patients without LPS promotes inflammation via proteasomal degradation of Atg13 in HSCs during ACLF

**Zhen Tian1**

1The First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

**Background:** Inflammation plays a critical role in the progression of ACLF. Atg13 is a vital regulatory component of ULK1 complex. Hepatic stellate cells (HSCs) were considered non-inflammatory cells and contributed only to hepatic fibrosis in the past. Recently, some studies found that HSCs can secrete inflammatory cytokines. Autophagy has been shown to regulate inflammation, it is unclear whether ubiquitin (Ub)-proteasome system (UPS) is involved in inflammatory responses in HSCs during ACLF.

**Methods:** Clinical data were collected from ACLF patients. The expression of Atg13 was assessed by rt-PCR and western blotting. Atg13 was knocked down by si-RNA in LX2 cells. A co-immunoprecipitation assay was used to detect protein binding and poly-ubiquitination of Atg13. In vitro tests with LX2 cells were performed to explore the effects and regulation of p38 MAPK, Atg13, UPS, autophagy, and inflammation.

**Results:** We evaluated the role of Atg13 in HSCs inflammation and explored the underlying mechanisms. Inflammatory factors are up-regulated via activation of p38 MAPK and inhibition of autophagy in LX-2 cells. Expression of Atg13 was decreased in LPS-incubated LX2 cells. Atg13 knockdown markedly inhibited autophagy and promoted LPS-induced inflammation in LX2 cells. Our results also showed that LPS induced depletion of Atg13 via UPS, which was p38 MAPK dependent.

**Conclusions:** LPS induces proteasomal degradation of Atg13 via p38 MAPK, participating in the aggravation of LPS-induced autophagy inhibition and inflammatory responses in LX2 cells. Atg13 serves as a mediator between autophagy and proteasome. Modulating Atg13 or proteasome activity might be a novel strategy for treating HSCs inflammation.
HE (P = 0.020). Draw the ROC curve of L3-PMI predicting death by gender. The area under the ROC curve for males was 0.726, the cut-off value was 5.02, the sensitivity and specificity were 85% and 50% respectively. The area under the ROC curve for females was 0.774, and the cut-off value was 4.60. The sensitivity and specificity were 50% and 100% respectively.

**CONCLUSION:** L3-PMI has important clinical application value for evaluating the prognosis of ACLF patients related to hepatitis B cirrhosis.

Abstract Submission No. 101620

**O-0847**

**Activation of hepatocyte p53 triggers acute liver failure with multiple organ injury.**

Jihyun Sung1, Hayato Hikita1, Yuki Makino1, Seiya Kato1, Yoichi Sasaki1, Kenji Fukumoto1, Kazuhiro Murai1, Kunimaro Furuta1, Akira Nishio1, Takahiro Kodama1, Tomohide Tatsumi1, Tetsuo Takeraha1

1Osaka university Suita Japan

p53 is the major cellular regulator, which controls proliferation and cell death. Meanwhile, its impact on acute liver failure (ALF) remains unknown. This work aims to study the role of p53 on ALF. In Gene Expression Omnibus database, human hepatic p21, a p53 target, was up-regulated in fulminant hepatitis liver compared with normal liver. C57B6J mice administered with acetaminophen or concanavalin A showed upregulation of p53 protein in the liver. We knocked out Mdm2, a negative regulator of p53, and inducibly and hepatocyte-specifically by tamoxifen administration in mice (Mdm2Δhep mice). Mdm2Δhep mice showed activation of p53 signaling with extensive cell death in hepatocyte, and elevated serum ALT and bilirubin. Also multiple organ injury was noted as the increase of TUNEL-positive cell death. Meanwhile, its impact on acute liver failure (ALF) remains unknown. Also non-CF. Septic and haemorrhagic shock were the main causes of CF. Age, white blood cell counts and international normalized ratio were identified as independent risk factors for CF development during hospitalization. The survival rate in HBV-ACLF patients with CF undergoing LT was significantly higher than that in those without LT (28/90/360-day: 62.9%/54.3%/54.3% vs. 6.4%/4.8%/4.8%, p <0.001). Propensity score matching analysis confirmed these results (28/90/360-day: 62.9%/54.3%/54.3% vs. 7.1%/7.1%/7.1%, p <0.001). Stratification analysis further showed that CF patients with INR <3.5 had a higher 360-day post-LT survival rate.

**Conclusions:** HBV-ACLF patients with CF exhibited a poor prognosis, and LT significantly improved their survival. Patients with INR <3.5 had a higher survival benefit from LT. These findings can help refine candidate selection for LT in clinical practice.

Abstract Submission No. 101647

**O-0849**

**Longitudinal single-cell profiling unveils distinct immune traits linked to ACLF progression**

Jun Li1, Xi Liang2, Qian Zhou1, Jinjin Luo1, Jiaqi Li3

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine Hang. 2Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine Hangzhou China. 3Precision Medicine Center, Taizhou Central Hospital (Taizhou University Hospital) Taizhou China.

Background & Aims: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome involving dysfunction in multiple immune cells. This study aims to comprehensively profile the dynamic immune responses along the progression of ACLF.

Methods: We conducted single-cell RNA-sequencing (scRNA-seq) of 379,132 individual cells from 45 samples of 32 subjects using peripheral blood mononuclear cells (PBMCs). This included 17 hospitalized hepatitis B virus-related ACLF and early stage non-ACLF patients exhibiting a progressive, stable or recovering course of ACLF. Bulk RNA-Seq, flow cytometry and histological assays were employed in other ACLF cohorts for validation.
Results: The single-cell transcriptome landscape identified forty-one immune cell clusters, including 4 low-density neutrophil clusters, revealing cell-type-specific changes in ACLF progression. We discovered that IL1R2+ macrophage and FCGR4B+ neutrophil are hallmarks of the progressive course of ACLF, especially in the end stage. We also found the intensified interactions of ANNEXIN and VISPATIN signaling within these two cell clusters, showing an anti-inflammation effect in the end stage of ACLF. Uregulation of hypoxia, inflammatory response, TNF a signaling via NFkB in CD24+ neutrophil was observed. Highly activated T cells, including GZMK+CD4+ and GZMK+CD8+ T cells with increased cytotoxic function, gradually decreased in severe ACLF patients. The patients were stratified into six subsets with specific features, significantly associated with ACLF outcome. External validation of cell cluster signatures confirmed their specificity in ACLF progression.

Conclusions: Our comprehensive immune profiling reveals dynamic changes in the innate and adaptive immune responses in progressive ACLF, highlights anti-inflammatory functions of macrophage and provides diverse immune subtypes for ACLF stratified medicine.

Abstract Submission No. 101687
O-0850
Hypomethylation of TL1A predicts the prognosis of ACHBLF
Xue-fei Wei, Ying Zhang, Tong Zhao, Xue Li, Ji-hui Li, Xing Su, Zhao-hui Wang, Yu-chen Fan, Kai Wang

1Department of Hepatology, Qilu Hospital of Shandong University, Jinan 250012, PR China jinan China, 2Institute of Hepatology, Shandong University, Jinan 250012, PR China Jinan China, 3Shenzhen Research Institute of Shandong University, Shenzhen 518000, PR China Shenzhen China

In Asia, chronic acute hepatitis B liver failure (ACHBLF) accounts for more than 70% of ACLF. ACHBLF has a short- to medium-term mortality rate of about 50-90%. The purpose of this study was to investigate the clinical significance of TL1A and DR3 in development of ACHBLF. In a total of 270 subjects, RT-PCR gate the clinical significance of TL1A and DR3 in development of ACHBLF. In patients with ACHBLF was higher than that in other patients. The results showed that the expression of TL1A and DR3 mRNA in ACHBLF was higher than that in chronic hepatitis patients or healthy control group. In addition, the methylation frequency of TL1A promoter in patients with ACHBLF was significantly lower than that in other groups. Moreover, at the protein level, western blot assay results showed that TL1A expression in patients with ACHBLF was higher than that in other patients. The results indicate that TL1A and its receptor DR3 can predict disease progression in ACHBLF and the methylation of TL1A gene promoter can be used as a useful biomarker for diagnosis of chronic acute hepatitis B failure.

Abstract Submission No. 101691
O-0851
Hypermethylation of glutathione peroxidase 4 promoter predicts poor prognosis of HBV-ACLF
Xing Su, Ying Zhang, Xuefei Wei, Jieru Yang, Jihui Li, Tong Zhao, Xue Li, Zhao-hui Wang, Yuchen Fan, Kai Wang

1Department of Hepatology, Qilu Hospital of Shandong University Jinan China, 2Hepatology Institute of Shandong University Jinan China

Background: Hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF) is a syndrome with a high short-term mortality rate, and its prognosis is critical in clinical management.

Methods: A total of 289 participants including 84 patients with HBV-ACLF, 61 patients with non-HBV ACLF, 94 patients with CHB and 50 HCs were recruited. We detected the expression of GPX4 in peripheral blood mononuclear cells (PBMCs) by real-time quantitative polymerase chain reaction (RT-qPCR). The methylation level of GPX4 gene promoter in PBMCs was detected by TaqMan probe-based quantitative methylation-specific PCR (MethyLight). Receiver operating characteristic (ROC) curves were generated to estimate the discriminations.

Results: The expression levels of GPX4 in PBMCs and serum of HBV-ACLF patients were lower while the methylation level of GPX4 promoter was higher than that of non-HBV-associated acute-on-chronic liver failure (non-HBV ACLF) patients, chronic hepatitis B (CHB) patients and healthy controls (HCs). The methylation level of GPX4 promoter yielded a larger area under the receiver operating characteristic curve (AUROC) than the model for end-stage liver disease (MELD) score in predicting 90-day mortality.

Conclusions: GPX4 promoter methylation level has promising potential as a predictor of 90-day mortality in patients with HBV-ACLF.

Abstract Submission No. 101727
O-0852
Single-cell landscape of immunological responses in acute-on-chronic hepatitis B liver failure
Yu-Chen Fan, Jing Zuo, Xiao-Lu Zhang, Yu-Xin Tian, Kai Wang

1Department of Hepatology, Qilu Hospital of Shandong University Jinan China, 2Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University Jinan China, 3Institute of Hepatology, Shandong University Jinan China

Aim: Acute-on-chronic liver failure (ACLF) is a syndrome that manifests as systemic inflammation and organ failure, which preferentially affects patients with chronic liver disease. In Asia, hepatitis B virus (HBV) is the main etiology. Here we combined the transcriptional profiles of immune cells with assembled T cell receptor (TCR) and B cell receptor (BCR) sequences to suggest dynamic changes in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) and provide a basis for finding immunotherapy targets.

Methods: We performed single-cell RNA sequencing in peripheral blood samples of 3 patients with chronic hepatitis B(CHB) and 8 patients with HBV-ACLF. Single-cell RNA sequencing was used to analyze the functional properties of immune cells. We compared the transcriptional profiles of immune cells and their feature of TCR and BCR between the two groups.

Results: We sequenced a total of 121,096 single cells from two groups. Compared with the patients with CHB, the proportion of NK cells and T cells was significantly downregulated in the patients with HBV-ACLF. In patients with HBV-ACLF, the immune landscape showed immune exhaustion with skewed T cell receptor repertoire and B cell receptor repertoire.

Conclusion: These results suggest the clonal expansion in T cells and B cells of liver failure from chronic HBV infection.
Esophageal varices stratification as early sign of portal hypertension in ACLF: APASL-AARC Study

Cosmas Rinaldi Adithya Lesmana, Sushmita Paney, Neha Sharma, Nupur Sharma, Gaurava Tripathi, Babu Mathew, Manisha Yadav, Vasundhara Bindal, Sadan H. Bhatl, Rakhi Maiwall, Shvetank Sharma, Shiv Kumar Sarin, Jaswinder Singh Maras

1. Mochtar Riyadi Comprehensive Cancer Centre (MRCCC) Siloam Hospital Jakarta Indonesia, 2. Dr Cipto Mangunkusumo National General Hospital Jakarta Indonesia, 3. Medistra Hospital Jakarta Indonesia

Background: Acute on chronic liver failure (ACLF) is a new clinical entity which has a high mortality rate. The presence of esophageal varices (EV) is the hallmark of early sign of PHT in CLD patients. However, study about the presence of EV in ACLF patients is still lacking.

Aim: To know the association of the presence EV and its clinical stratification in ACLF patients.

Method: APASL-ACLF Research Consortium (AARC) database registry was retrospectively reviewed. The data analysis was performed using SPSS version 25.

Results: Of 426 patients, no EV found in 192 patients, whereas small EV was found in 201 patients, and large EV found in 33 patients. Based on ACLF severity grade, small EV was found more in ACLF grade 3 patients (40.8%) when compared to large EV which only found in 18.2%. The presence of high-risk stigmata EV was found to be lower in ACLF grade 3 patients when compared to low-risk EV (17.1% vs. 40.3%). The presence of low-risk EV was more significantly associated with mortality when compared to the presence of high-risk EV (p = 0.032). In ACLF patients, mortality rate was found to be higher in patients without significant PHT when compared to significant PHT (p = 0.000). However, there was no statistically significant in ACLF patients with multi-organ failure (p = 0.100).

Conclusion: The presence of high-risk EV is not really associated with the prognosis of ACLF patients, however, it still needs to be included in the patient’s management to improve the prognosis.

Abstract Submission No. 101948 O-0854

Rifaximin has no beneficial role in ACLF patients admitted to ICU - a double blind RCT


1. Asian Institute of Gastroenterology Hyderabad India, 2. PGIMER Chandigarh India

Background: Patients with acute-on-chronic liver failure (ACLF) often receive antibiotics when admitted to the intensive care unit (ICU). It is unclear if additional rifaximin has any synergistic effect with broad-spectrum antibiotics in ICU patients with acute overt hepatic encephalopathy (OHE).

Methods: In this double-blind trial, APASL-defined ACLF patients admitted to ICU for OHE were randomized to antibiotics alone (ab) or antibiotics with rifaximin (ab+r). HE resolution (or 2-grade reduction), time to resolution, in-hospital mortality, nosocomial infection, and endotoxin level changes were compared.

Results: Of 96 patients with ACLF, 46 received ab alone, and 50 received ab+r. On Kaplan Meier analysis, 41.3% in the antibiotics arm compared to 32% in the antibiotics+rifaximin arm achieved the primary objective (P = 0.34), and the time taken was comparable (P = 0.6). In-hospital mortality was 67.4% in the control arm and 64% in ACLF patients receiving rifaximin (P = 0.98). The proportion of patients achieving infection resolution was comparable (P = 0.71). Nine percent in the ab group and 18% in the ab+r group developed nosocomial infections (P = 0.23). All patients with nosocomial infection died in-hospital. Both groups showed comparable rise in endotoxin levels (P = 0.3).

Conclusion: Rifaximin has no beneficial role in patients with ACLF admitted to ICU.

Abstract Submission No. 101918 O-0854
Ashish Kumar1, Rakhi Maiwall1, - Shalimard2, Shekhar Swaroop3, Faouzi Saliba1, Hlas Konnis1, Praveen Sharma1, Anil K. Arora1, Shivangi Negi1, Shiv K. Sarin1

1Sir Ganga Ram Hospital New Delhi India, 2Institute of Liver and Biliary Sciences (ILBS) New Delhi India, 3All India Institute of Medical Sciences (AIIMS) New Delhi India, 4Hôpital Paul Brousse, Centre Hepato-Biliaire Villejuif France

Background: Alcohol-related acute-on-chronic liver failure (ACLF) is characterized by high mortality rates in the absence of liver transplantation. Plasma exchange (PLEX) has emerged as a potential therapeutic intervention for patients with ACLF of various etiologies. This meta-analysis investigates the short-term and long-term efficacy of PLEX in patients with alcohol-related ACLF compared to standard medical therapy (SMT).

Methods: A comprehensive search was conducted across PubMed, Embase, Scopus, and the Cochrane databases to identify studies comparing PLEX to SMT in patients with alcohol-related ACLF. Pooled odds ratios (OR) with corresponding 95% confidence intervals (CIs) were calculated using the Mantel-Haenszel method within a fixed-effects model. The primary outcome assessed was 30-day survival, with secondary outcomes including 90-day survival.

Results: Our analysis incorporated data from five studies, encompassing 249 patients (119 in the PLEX group vs. 130 in the SMT group). Three studies were retrospective, while two studies were prospective, non-randomized trials. Compared to SMT, PLEX was significantly associated with higher 30-day survival (OR 0.48, 95% CI 0.28-0.84, p = 0.01). However, the pooled odds ratio for 90-day survival with PLEX did not reach statistical significance (OR 0.75, 95% CI 0.44-1.26, p = 0.27). Low heterogeneity was observed between the studies ($I^2 = 24\%$).

Conclusion: PLEX effectively improves short-term survival, as evidenced by a significant improvement in 30-day survival for patients with alcohol-related ACLF. However, its impact on 90-day survival remains inconclusive. Further research, especially randomized controlled trials, is needed to clarify the long-term implications of PLEX in this patient population.

Abstract Submission No. 102007
O-0858

High serum bile acids drive AKI progression and terlipressin non-response in patients with ACLF

Rakhi Maiwall1, Ashini kumar Hidam1, Sherin Thomas1, Shiv Kumar Sarin1

1Department of Hepatology, Institute of Liver and Biliary Sciences New Delhi India

Background and aim: Acute-on-chronic liver failure (ACLF) patients frequently have cholemic nephropathy. The association of serum bile acids(BA) with AKI progression, organ dysfunction, and mortality has not been studied.

Methods: In a prospective cohort of ACLF patients (n=242) with AKI, serum BA and urine neutrophil-gelatinase-associated lipocalin (NGAL) were measured at enrolment. Logistic regression was performed to identify predictors of AKI progression.

Results: ACLF patients, aged 43.2 ± 9.8 years, 91.2% males, 73% with alcohol etiology, 87% with sepsis, AKI stages (1:2:3) 40%:31%:29%, 61% with HRS-AKI, the mean serum BAs were 154.2±45.8 mg/dl, and NGAL of 1881±1714 ng/ml. AKI progression at day 4 was observed in 42.6%, 26% required dialysis and 48% died at 28 days. On multivariable analysis, higher BA (OR 1.008,1.001-1.016), AARC score (OR 1.72,1.37-2.15), NGAL (OR 1.56,1.01-2.46), and number of organ failures (OR 1.89,1.27-2.83) predicted AKI progression which was an independent predictor of 28-day mortality (HR 1.98,1.25-3.16). The BA correlated with circulatory failure (OR 1.008, 1.001-1.015) but not with brain and pulmonary failure(p>0.05).

Conclusion: Serum BA correlates with circulatory failure, and predicts AKI progression and non-response in HRS-AKI but not mortality. High serum BA (>175 mg/dl), NGAL, and the presence of bile casts could signify structural AKI and limited response to vasoconstrictors. AKI progression determines worse clinical outcomes therefore therapeutic modalities targeting reduction of BA may improve outcomes in ACLF patients with AKI.

Abstract Submission No. 102031
O-0859

Second hit acute insult increases mortality in patients of Acute-On-Chronic Liver Failure

ASHOK CHOUDHURY1, VINOD ARORA1, SHIV KUMAR SARIN1, AARC CONSORTIUM1,2

Background: Acute-on-chronic liver failure (ACLF) is characterized by rapid deterioration of liver function, while cirrhosis is a slowly progressive disease. Liver transplantation (LT) remains the treatment of choice for these patients with advanced disease. There are no studies evaluating the health-related quality of life (HRQoL) of patients with APASL-defined ACLF, which we aimed to assess.

Methods: In this cross-sectional study, consecutive patients with ACLF and decompensated cirrhosis attending the AIG Hospitals, Hyderabad, were included and assessed for SF-36 HRQoL scoring. The primary outcome was HRQoL among patients with decompensated cirrhosis and ACLF after matching for age and severity scores.

Results: A total of 350 patients were included in the study. Thirty-two percent (n=113) were ACLF, and 68% (n=237) were cirrhosis. On propensity-matched analysis (matched for age and MELD Na score), 102 patients with ACLF were matched with 35 patients with cirrhosis. Cumulative score of general health was lower in both groups (41.45%±16.4% vs. 44.3%±17.45%; P=0.4). Both groups performed poorly on energy levels scale (49.3% vs. 53%; P=0.41). On other scales, including emotional (70% vs. 72%), social (68.24% vs. 73%), and pain (84.37% vs. 85.22%), were adequate in both groups. Interestingly, despite matching, the physical functioning of patients with cirrhosis (46.31%±27.2%) was much lower than those with ACLF (60%±24.7%; P=0.007). Transplant-free survival was 19% (19/101) among patients with ACLF compared to 14.3% (5/35) at day 30 (P=0.54).

Conclusions: Patients with decompensated cirrhosis have worse physical functioning than patients with ACLF. Further research aimed at interventions to improve the QoL is required.
LPCAT3/LPLAT12 deficiency in the liver ameliorates acetaminophen-induced acute liver injury.

Natsuko Inagaki1, Hiroki Nakanishi3, Takayo Ohto3, Hideo Japan, 4Institute of Microbial Chemistry Tokyo Japan

Background and Aims: ACLF is due to underlying chronic liver disease with super-added acute hepatic insult leading to high short term mortality. We analysed the impact of second hit acute insult to a primary chronic liver disease (CLD) presenting as ACLF.

Patients and Methods: We analyzed the prospectively collected data from AARC registry. Clinical data, laboratory parameters, complications and survival were serially noted. Acute insult is considered second hit if its of different i.e. ACLF in ethanol related or HBV related CLD in absence of alcoholic hepatitis or HBV reactivation.

Results: Total of 8684 patients [mean age 44.6 ±11.6 years, 86.2% male] with alcohol (5684,65%) followed by HBV (1621, 18.7%), AILD (787,9.1%), Cryptogenic/NASH (407,4.7%), and HCV (177,2%). Similarly the acute insult in majority was SAH (4933, 56.8%), HBV reactivation (1069,12.3%), DILI (475,5.5%) followed by AVH(462, 5.3%). The alcohol CLD presented with ACLF due to SAH in 66.2% cases, whereas as AVH (4.6%) and DILI(5.3%) accounted for nearly one third. Similarly in patients with HBV CLD, the HBV reactivation was seen only in 26.4%, but the majority were due to alcoholic hepatitis (45.1%), AVH(6.5%), DILI (5.9%) and others in rest. Interestingly the second hit i.e another insult was seen in 50.2% (4398) cases. The single hit i.e ALD with SAH or HBV reactivation in HBV CLD or AIH flare associated with a better younger age, lower bilirubin, albumin, INR, AARC score, less organ failure, lower incidence of HE, sepsis, variceal bleed, need of RRT, ICU care and ventilatory support than those having another second hit etiology (p<0.001). A higher 90 days mortality [53.9% versus 46.4%,OR=1.37(95CI 1.15-1.67), p<0.001] with shorter median survival [48.1 days versus 54.8 days, p=0.001] noted with second hit acute insult.

Conclusion: In this large cohort, the ACLF cohort had a different acute insult than the primary chronic liver disease in nearly half of the cases. This innovative concept of second hit leading to ACLF had a different natural course and is associated with a poor outcome. A search for the acute insult and consideration of necessary definitive therapy, may guide the mangement decision to improve outcome.

Abstract Submission No. 200144  O-0860

LPCAT3/LPLAT12 deficiency in the liver ameliorates acetaminophen-induced acute liver injury.

Natsuko Inagaki2, Hiroki Nakanishi3, Takayo Ohto3, Hideo Shindou2, Takao Shimizu6

1The University of Tokyo Tokyo Japan, 2National Center for Global Health and Medicine Tokyo Japan, 3Lipidome Lab. Co. LTD Akita Japan, 4Institute of Microbial Chemistry Tokyo Japan

Acetaminophen (APAP) is a double-edged sword, mainly depending on the dosage. A moderate dose of APAP is effective for fever and pain relief; however, an overdose induces acute liver injury. The mechanism underlying APAP-induced acute liver failure is unclear, and its treatment is limited. A recent report has shown that several oxidized phospholipids are associated with APAP-induced acute liver failure. Lyso-phosphatidylcholine acyltransferase 3 (Lpcat3, Lplat12), which is highly expressed in the liver, preferentially catalyzes the incorporation of arachidonate into lysophospholipids (PLs). In the present study, we investigated the roles of Lpcat3 on APAP-induced acute liver injury using liver-specific Lpcat3-knockout mice. Hepatic Lpcat3 deficiency reduced the degree of APAP-induced necrosis of hepatocytes around zone 3 and ameliorated the elevation of hepatic injury serum marker levels, and prolonged survival. Lipidomic analysis showed that the accumulation of oxidized and hydroperoxidized phospholipids was suppressed in Lpcat3-knockout mice. The amelioration of APAP-induced acute liver injury was due not only to the reduction in the lipid synthesis of arachidonic acid PLs because of Lpcat3 deficiency, but also to the promotion of the APAP detoxification pathway by facilitating the conjugation of glutathione and N-acetyl-p-benzoquinone imine. Our findings suggest that Lpcat3 is a potential therapeutic target for treating APAP-induced acute liver injury.

Abstract Submission No. 100086  O-0861

Noninvasive proteomic biomarkers for HEV-related acute liver failure

Jian Wu1, Honggui Cao2

1Department of Clinical Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, 242 Guangji Road, Suzhou 215008, Jiangsu, China; Suzhou China, 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Rd, Hangzhou City, Zhejiang Province, 31

Background: Timely and effective prognostic biomarkers for hepatitis E virus (HEV)-related acute liver failure (ALF) are urgently needed.

Methods We performed four tandem mass tag (TMT)-labeled quantitative proteomic and targeted proteomics parallel reaction monitoring (PRM) studies on cross-sectional cohort 1 and 2 including 20 acute hepatitis E and 20 HEV-ALF patients respectively.

Results: Pregnancy zone protein (PZP) is a potential prognostic biomarker for HEV-ALF. PZP was identified by TMT and PRM quantitative proteomics. In the derivation cohort, PZP levels of the HEV-ALF patients in survival group were significantly higher than those of the dead group. According to the median level of PZP, HEV-ALF patients in the retrospective cohort 1 were divided into the high PZP (>1316.18 ng/L) and low PZP (≤1316.18 ng/L) groups. The survival time of the high PZP group was significantly longer than that of the low PZP group. Compared with PZP levels at admission, levels at discharge increased significantly in the improvement group, and decreased significantly in both the fluctuation and deterioration groups. Besides, multivariate logistic regression showed that laminin, hepatic encephalopathy, TBI, and PZP were independent factors affecting the prognosis of HEV-ALF patients, which were used to establish a novel prognostic model (ePLT). The assessment in the derivation and validation cohorts showed that the ePLT score was significantly superior to the MELD, KCH and Child-Pugh scores.

Conclusions: PZP is a promising prognostic biomarker, and ePLT is a high-performance prognostic score for HEV-ALF patients, which contribute to clinical decision-making in the management of HEV-ALF.

Abstract Submission No. 100469  O-0862

Outcomes and Risk Factors of Early Liver Injury after Transjugular Intrahepatic Portosystemic Shunt

Xiaoze Wang1, Guofeng Liu1, Xuefeng Luo1, Yang Li2

1West China Hospital, Sichuan University Chengdu China

Backgrounds: Transjugular intrahepatic portosystemic shunt (TIPS) reduces the portal vein blood flow into the liver while declining portal venous pressure, resulting in liver ischemia injury and even liver

Abstract Submission No. 335  O-0863
Abstract Submission No. 100495

**O-0863**

Prospective study of the effect of TPO on platelets and prognosis in patients with ACLF

Jing Liang¹, Gang Liu², Fei Tang³, fenghui li², fushuang ha¹

¹Tianjin Third Central Hospital Tianjin China; ²Tianjin Dongli Hospital Tianjin China

**Objective:** To evaluate the dynamic changes in platelet and liver function in ACLF patients complicated with severe thrombocytopenia with recombinant human thrombopoietin (rhTPO) in a prospective cohort to observe the effects of elevated platelets on bleeding events and 90-day mortality in patients with ACLF.

**Methods:** Seventy patients with ACLF complicated with severe thrombocytopenia were prospectively enrolled and divided into a TPO group and a control group, with 35 patients in each group. The TPO group was given rhTPO for 7 days. The baseline, 7-day and 14-day PLT counts and liver function indices were compared and 90-day mortality and incidence of bleeding events were observed.

**Results:** There was no significant difference in 90-day mortality between the TPO group and the control group (8.6% vs. 17.1%, P=0.284). The incidence of bleeding events within 90 days was 11.4% in the TPO group and 22.9% in the control group (P=0.205). The PLT count in the TPO group was significantly higher than that at baseline and 7 and 14 days after treatment (28.10^10/L vs. 64.10^10/L vs. 73.10^10/L, P=0.001), and the PLT count peaked at 14 days. The serum HGF and TPO levels were significantly higher than those at baseline (serum HGF: 130.4 pg/ml vs. 195.4 pg/ml, P=0.000) and (serum TPO: 41.8 pg/ml vs. 143.7 pg/ml, P=0.000) in the TPO group at 7 days after treatment. The serum albumin level, INR and MELD score in the TPO group at 14 days after treatment were significantly improved compared with those before treatment (ALB 34.5 g/L vs. 28.2 g/L, P<0.05; INR 1.6 vs. 1.7, P<0.05; MELD 14.7 vs. 16.0, P<0.05).

**Conclusion:** rhTPO can significantly increase the PLT count in ACLF patients with thrombocytopenia, reduce the occurrence of bleeding events, and promote the improvement of liver function, and it has no significant effect on 90-day mortality.

Abstract Submission No. 100573

**O-0864**

A case report of hepatic amyloidosis presenting as Acute-on-Chronic Liver Failure

Thanh Huu Nguyen¹, Anh Duc Duong², Tung Lam Nguyen³

¹College of Health Sciences, VinUniversity Ha Noi Vietnam; ²Department of Gastroenterology, 108 Central Military Hospital Ha Noi Vietnam

Amyloidosis encompasses a heterogeneity of disorders characterized by the extracellular deposition of abnormal fibrillar proteins, which frequently involves the liver but hepatic failure rarely occurs. Herein, we present a case of a 54-year-old female with no significant liver history, use of unknown herbal medicine 3 months prior, presented with progressive jaundice for 2 months, abdominal distension for 6 weeks, associated with hepatosplenomegaly, ascites, and stable hemodynamics. The initial laboratory findings showed serum alanine aminotransferase of 24 IU/L, serum aspartate aminotransferase of 127 IU/L, total bilirubin of 12.26 mg/dL, INR of 1.55 with negative viral hepatitis, autoimmune profiles and no significant findings on abdominal computed tomography. A transjugular liver biopsy was performed and revealed extensive deposition of extracellular hyaline material, which is not typical for sinusoidal obstruction syndrome caused by alkaloid toxicity. The patient’s condition deteriorated rapidly and was managed symptomatically with a transjugular intrahepatic portosystemic shunt, however, the patient passed away one month later before making a definitive diagnosis. The patient’s liver biopsy result was sent to the abroad center and showed Salmon-pink color material with birefringence under polarized light on Congo Red stain, which indicates amyloidosis. The diagnostic challenge in this case occurred in the etiological work-up for progressive jaundice and acute on chronic liver failure. We urge clinicians not to be satisfied with a diagnosis that could not explain fully the lab results and to have high clinical suspicion to make an early diagnosis and initiate prompt treatment, particularly in limited-resourced countries.

Abstract Submission No. 100723

**O-0865**

Investigating factors involved in the rate of the examination success of transjugular liver biopsy.

Naohiro Wada¹, Asako Nogami¹, Tomohiro Ootani¹, Michihiro Iwaki¹, Takashi Kobayashi¹, Masato Yoneda¹, Satoru Saitou², Atushi Nakajima¹

¹Yokohama City University Yokohama Japan; ²Sanno hospital Tokyo Japan

**Background:** Performing percutaneous liver biopsies could be impossible or difficult in patients with ascites or coagulation abnormality. Transjugular liver biopsy (TJLB) is a relatively safe alternative technique in such cases. There are limited studies on the factors involved in its technical success of TJLB. This study aimed to investigate the factors that influence the technical success of TJLB.

**Methods:** We enrolled fifty patients who underwent TJLB at our hospital between August 2020 and April 2023. We retrospectively measured the angle between the inferior vena cava (IVC) and the hepatic vein (HV) using CT or MRI coronal sections. In cases where TJLB was successful, we measured the angle between the IVC and the HV at the biopsy site. In cases where TJLB was unsuccessful, we measured the angle between the IVC and the right hepatic vein (RHV).

**Results:** TJLB was successfully performed in 42 cases (84.0%). Among these successful TJLB procedures, 38 cases (90.5%) were
performed on the RHV, and 4 cases (9.5%) on the middle hepatic vein (MHV). We were able to measure the angles between the IVC and the HV in 31 cases. The mean angles between the IVC and the HV in the successful (n=24) and unsuccessful (n=7) groups were 46.7±10.0° and 59.9±13.6°, respectively, and were significantly smaller in the successful group (p=0.042).

Conclusion: We are more likely to perfuse TJLB successfully in cases in which the angle between the IVC and the HV is small.

Abstract Submission No. 100847
O-0866

Association of Coexistent HBsAg and anti-HBs with Prognosis of HBV-ACLF Patients

Jian Li1,2, Xiaonan Wu1, Siyi Liu2, Qijian Zang3, Chengbin Zhu2, Yingren Zhao1,2,3, Yingli He4
1Department of Infectious Diseases, First Affiliated Teaching Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China; 2Institute of Hepatology, First Affiliated Teaching Hospital, School of Medicine, Xi’an Jiaotong University Xi’an China; 3Shaanxi Clinical Research Center of Infectious Diseases Xi’an China

Objectives: Coexistence of hepatitis B surface antigen (HBsAg) and antibody against HBsAg (anti-HBs) constitutes an atypical serological profile in chronic hepatitis B infection. The characteristics and impact of this serological pattern in the critically ill population of HBV-ACLF remain unclear.

Methods: Clinical data from 561 HBV-related ACLF patients were retrospectively collected. Flow cytometry was used to detect the peripheral blood lymphocyte subsets. The outcome was recorded as surviving or non-surviving in a 90-day follow-up.

Results: Among 561 HBV-ACLF patients, 31 cases exhibited the double-positive pattern for HBsAg and anti-HBs, resulting in a coexistence rate of 5.5%. Compared with patients without anti-HBs, those with anti-HBs had higher HBV DNA levels (4.9 [2.8-5.4 log10] IU/mL vs. 4.5 [3.4-5.6 log10] IU/mL, p = 0.017) and serum core antibody titers but lower HBsAg levels (47.5 [7.6-169.3] IU/mL vs. 163.2 [30.2-1601.2] IU/mL, p = 0.034). Patients with the coexistence of HBsAg and anti-HBs were older (50.0 [30.0-73.25] vs 42.0 [33.0-51.0] years, p = 0.034), had a higher proportion of cirrhosis (87.1% vs 69.6%, p = 0.038), and higher total bilirubin levels (329.2 [213.3-456.8] U/L vs. 280.0 [180.6-393.4] U/L, p = 0.022). Lymphocyte subset analysis suggested that peripheral CD3+, CD4+, and CD8+ T-cell counts were lower in HBsAg and anti-HBs coexisting patients. Survival analysis indicated poorer short-term prognosis for patients with anti-HBs, with a significantly higher mortality rate compared to those without anti-HBs (58.1% vs. 38.9%, p = 0.034).

Conclusion: Coexistence of HBsAg and anti-HBs may be associated with a more severe disease state in HBV-ACLF.

Abstract Submission No. 100969
O-0867

Long-term prognosis of HBV-ACLF patients with extremely low-level viremia

Qiao Zhang1,2, Xiaonan Wu1, Yamin Wang1, Qiannan Wang1, Pan Huang1, Xiaoli Zhang1, Danfeng Ren1, Taotao Yan1,2, Yingren Zhao3, Yingli He4

1Hepatology Unit, Department of Infectious Diseases & Clinical Research Center for Infectious Diseases, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China. Xi’an China, 2National Regional Infectious Diseases Center Co-constructed by National Health Commission of PRC and People’s Government of Shaanxi Province & Shaanxi Clinical Medical Research Center of Infectious Diseases, Xi’an, Shaanxi, China. Xi’an China

Background: High viral load is closely associated with outcomes of chronic hepatitis B. However, for patients with viral loads lower than the limit of quantification (LLOQ), especially those who have survived liver failure, the long-term outcomes remain unclear.

Methods: 80 HBV-ACLF patients who survived more than 48 weeks without liver transplantation and received NUCs therapy were enrolled. Based on HBV-DNA loads after 48 weeks treatment, patients were categorized into the UD (undetectable), extremely low-level viremia (eLLV, detectable but LLOQ) group, and partial virological response (PVR, ≥ 2000IU/mL) groups.

Results: 1. 80 HBV-ACLF patients were followed for 228.09±97.01 weeks, with most in the eLLV group (n=43, 53.75%), followed by LLV (n=25, 31.25%), UD (n=10, 12.5%), and PVR (n=2, 2.5%) group.
2. In the eLLV group, HBsAg levels were significantly higher than UD group (1804.66 [325.67, 3130.58] vs 35.17 [0.00, 989.79] IU/mL, P=0.004), while anti-HBs levels were significantly lower (0.15 [0, 0.57] vs. 98.96 [3.40, 276.05] mIU/mL, P=0.003). Additionally, eLLV group exhibited significantly higher anti-HBe levels compared to the UD group (0.84 [0.16, 1.52] vs 1.60 [1.00, 2.28] S/CO, P=0.042, Table1).
3. Kaplan-Meier survival analysis indicated superior overall survival in the eLLV group compared to the LLV group (P=0.029, Figure 1).
4. Moreover, eLLV group had lower cumulative incidences of recurrent decompensation events than the LLV group (P=0.013, Figure 2).

Conclusions: HBV-ACLF patients with eLLV demonstrated superior long-term outcomes compared to the LLV group. Adjusting antiviral regimens for LLV patients to achieve eLLV levels may enhance long-term prognosis.

Abstract Submission No. 101021
O-0868

Diabetes Mellitus Linked to Higher Mortality in Alcohol-related Acute-on-Chronic Liver Failure

Ashish Kumar1, Shiv K. Sarin2, Ashok Choudhury3, Vinod Arora4, Anil Arora1, Praveen Sharma1, Mohammad Rela3, Dinesh Jothimani3, Mamun A. Mahtab4, Harshad Devarbhavi5, C. E. Eapen6, Ashish Goel7, Cesar Yaghhi8, Q Ning9, APASL ACLF Research Consortium (AARC) APASL ACLF working Party2

1Sir Ganga Ram Hospital New Delhi India, 2Institute of Liver and Biliary Sciences (ILBS) New Delhi India, 3DR. Rela Institute Chennai India, 4Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 5St. John’s Medical College Bengaluru India, 6CMC Vellore Vellore India, 7Saint Joseph University Beirut Lebanon, 8Tongji Hospital Wuhan China

Background: Acute-on-Chronic Liver Failure (ACLF) is characterized by acute deterioration in patients with chronic liver disease, leading to multiple organ failures and a high mortality. Alcohol is the most common cause of ACLF. While diabetes mellitus is a risk factor for adverse outcomes in liver disease, its specific impact on outcomes in alcohol-related ACLF remains elusive.

Aims: This study aims to assess the impact of diabetes mellitus on the mortality of patients with alcohol-related ACLF.

Methods: We recruited patients with alcohol-related ACLF from the AARC registry. The diagnosis of alcohol-related ACLF was established when the treating unit identified alcohol as both the etiology of
chronic liver disease (CLD) and the acute precipitant. Patients with coexisting other etiologies of CLD or other precipitants (such as HBV, HCV, HEV, DILI etc.) were excluded. Patients were categorized based on the presence or absence of diabetes. The primary outcome was 90-day mortality, with the analysis considering only baseline clinical, laboratory features, and severity scores.

**Results:** The study included a total of 2,096 patients with alcohol-related ACLF, comprising 109 diabetic (91.7% male, median age 45 years) and 1,987 non-diabetic individuals (90.9% male, median age 42 years). The median MELD-Na score was 31.0 (IQR 27.0-36.0) while the median CTP score was 12 (IQR 11.0-12.0) for both groups. By 90 days, 979 (47%) patients had died, and 109 (5%) patients had received liver transplantation (LT); 12 patients died even after LT. The 90-day mortality was significantly higher in diabetics compared to non-diabetics (67.9% vs 45.5%, p<0.05). A log-rank test demonstrated a statistically significant difference in survival between patients with and without diabetes mellitus in both overall survival (p<0.01) and transplant-free survival analyses (p<0.01), indicating a substantial impact of diabetes on outcomes in alcohol-related ACLF (Figure).

**Conclusions:** The presence of diabetes mellitus in patients with alcohol-related ACLF markedly increases the risk of mortality, highlighting the particularly dangerous nature of this condition in diabetic individuals. This underscores the urgency for further research to elucidate the underlying mechanisms of this association.

**Antibiotics and steroids for 4-weeks in ACLF-AH with steroid response showed reduction of infections**

Vinod Arora1, Ashok Choudhury1, Mohd. Rela2, Mamun Al Mahtab1, Akash Shukla4, Hasnik Ghazinyan5, Sanjeev Sachdeva6, S S Hamid1, Anand Kulkarni7, Soek Siam Tan8, Dong Joon Kim9, P N Rao9, Amna Subhan Butt7, Wasim Jafri9, Shiv Kumar Sarin1

1Department of Hepatology, ILBS Hospital Delhi India, 2Dr. Rela Institute Chennai India, 3Department of Hepatology, Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 4Department of Gastroenterology, Lokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College, (LTMMC) Mumbai India, 5Department of Hepatology, Nork Clinical Hospital of Infectious Disease, Yerevan Armenia, 6G.B. Pant Hospital New Delhi India, 7Department of Medicine, Aga Khan University Hospital Karachi Pakistan, 8Asian Institute of Gastroenterology Hyderabad India, 9Department of Medicine, Hospital Selayang, Bata Caves, Selangor Malaysia, 10Hallym University Medical Centre Chuncheon Republic of Korea

**Introduction:** In this retrospective analysis we analysed whether oral antibiotics (cefixime) at discharge given for 1-week vs. 4-weeks in combination with steroids reduced infections in ACLF (alcoholic hepatitis).

**Patient and methods:** Retrospective database of APASL-AARC consortium was taken from April 2021-April 2022 and prospectively data was followed up for 6-months with patients of ACLF and having alcoholic hepatitis (steroid eligible) and received steroids for 28 days. Primary objective was to study infections at day 28. Secondary objectives were to study mortality at 28-day and 90 days; incidence of HRS; HE; AKI.

**Results:** 1124 patients with ACLF collected during the period, 534 patients (47.5%) having alcoholic hepatitis were screened; 110 (20.59%) patients had received steroids (prednisolone 40mg for 4 weeks) of which 28 patients (25.4%) received oral cefixime 200mg/Bid for 4 weeks while 82 patients (74.5%) received oral cefixime (200mg/Bid 7 days) along steroids. Incidence of AKI {6/28 (21.42%) vs. 19/82 (23.17%), P=1.00}; UGIB {2/28 (7.1%) vs. 9/82 (10.9%), P=0.72} were comparable. Incidence of infections at 28 days {5/28 (17.8%) vs. 35/82 (42.6%), P=0.02}, repeated hospitalizations {3/28 (10.7%) vs. 26/82 (31.7%), P=0.04}, mean number of hospitalized days (90-days) {10± 3.4 vs 18 ± 6.7, P=0.001} was lower in the 4-week arm. Incidence of pneumonia {7.1% (2/28) vs. 21.9% (18/82), P=0.09}; cellulitis {10.7% (3/28) vs. 14.6% (12/82), P=0.75}; SBP {7.1% (2/28) vs. 23.1% (19/82), P=0.09} was lower in the 4-week arm, not significant. Of steroid non responders {30/82 (36.5%)}; 13/30 were continued on antibiotics suspecting subclinical infection showed lower infection rate requiring hospitalization {12/13 (15.3%) vs. 9/17 (52.9%), P=0.04}; Lower 28-day mortality was also noted in 4-week arm {2/28 (7.1%) vs. 18/82 (21.9%), P=0.09}.

**Conclusions:** 4-week antibiotic-steroid therapy in steroid responder AH helped in reduction of severity of infections; duration of hospitalization; improved 4-week mortality.

**EXPERIENCE ON USE OF DPMAS AMONG PATIENTS WITH ACLF AND DECOMPENSATED LIVER CIRRHOSIS - CASE SERIES**

Jose Orlando Nicolas1, Mara Teresa Panlilio2, Ira I Yu3

1National Kidney and Transplant Institute Quezon City Philippines, 2National Kidney and Transplant Institute Quezon City Philippines, 3National Kidney and Transplant Institute Quezon City Bulacan

Liver transplantation is the definitive management for acute liver (ALF) and end-stage liver disease (ESLD). This is limited by accessibility, lack of potential donors, and cost. At present, as a bridge for liver transplantation, artificial liver support systems (ALSS) such as double plasma molecular adsorption system (DPMAS) are being utilized.

This case series aimed to review outcomes of patients who had DPMAS from 2018 to 2023. This case series included patients from a tertiary referral center in the Philippines. Records of patients who had liver cirrhosis who underwent DPMAS were reviewed.

Six patients were included in this series. Four out of the six patients were discharged after DPMAS, while two died from multi-organ failure. Prothrombin time and INR improved post-DPMAS. Consequently, prognostic scores, specifically MELD-Na, was lower. Likewise, Hepatic Encephalopathy (HE) grade and degree of ascites improved. Two of these patients underwent successful liver transplantation eventually. Patients who underwent DPMAS in this series showed improvement in laboratory parameters measuring hepatic synthetic function, and MELD-Na. DPMAS is a promising modality for bridging ALF and end-stage liver disease to transplantation, and in some cases, recovery to compensated state.

**Asces in Hepatitis A-induced liver failure: Does it impact outcome?**

Moinak Sen Sarma1, Ujjal Poddar2, Anshu Srivastava1, Surender Kumar Yachha1

1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India
Introduction: Hepatitis A virus (HAV) in developing nations is one of the leading causes of acute liver failure (ALF) in children. Survival with native liver (SNL) is guarded. We aimed to study the factors that are associated with outcome in this condition.

Methods: A prospectively maintained database registered all ALF admitted between 2017-2022. Poor outcome (PO) was defined as death or requirement of liver transplantation. Underlying chronic liver disease was excluded.

Results: Comparison of HAV-ALF (n=55) vs non-HAV-ALF (n=44) [hepatitis B (n=12), hepatitis E (n=2), EBstein-Barr (n=7), parvovirus (n=6) and indeterminate (n=19)] showed age (7±4.0y vs. 9.9 ±4.6y, p=0.002), duration of illness (33.9±23.8 vs 21±6.8 days, p=0.04), PELD score (31.4±14.1 vs 27.4±20.1, p=0.07) and SNL (51% vs 38%, p=0.1). Among HAV-ALF, 61% had ascites (35% at presentation, 26% during admission; jaundice to ascites duration 17±22 days) and 65% had encephalopathy (55% at presentation, 10% during admission; jaundice to encephalopathy duration 15.5±19 days). PO was seen in 90% of those who developed ascites prior to encephalopathy (41%) and required large volume paracentesis (33%). Violin plots (Figure 1) shows comparison of liver function with final outcome. On multiple step-wise logistic regression, ascites preceding encephalopathy [OR 2.1 [(1.6-3.3), p=0.002], spontaneous bacterial peritonitis [OR 1.8[(1.2-2.3), p=0.02] and PELD score [OR 4.3[(2.3-4.8), p=0.001] were independent predictors of PO. At presentation, PELD score cutoff <23.5 (AUROC 0.86) and serum albumin >3.1 g/dL (AUROC 0.77) were associated with SNL.

Conclusions: Ascites preceding encephalopathy and spontaneous bacterial peritonitis are associated with poor outcomes in acute liver failure. Universal vaccination policies need to be reinforced.

Abstract Submission No. 101442
O-0872

Recent trend of acute hepatitis and acute liver failure in our hospital

Masazumi Onuki1, Jun Inoue1, Masashi Ninomiya1, Akitoshi Sano1, Mio Tsuruoka1, Kosuke Sato1, Satoko Sawahashi2, Keishi Ouchi1, Kotaro Doi1, Atsushi Masamune1

1Division of Gastroenterology, Tohoku University Graduate School of Medicine Sendai Japan

Background and Aim: The etiologies of acute hepatitis (AH) and acute liver failure (ALF) are various. This study aimed to clarify recent trends and the prognosis for each cause.

Methods: Patients with AH and ALF admitted to our department from January 2001 to October 2023 were included. Patients were classified as having ALF if PT fell below 40% within 8 weeks of onset.

Results: There were 238 eligible patients (100 males and 138 females) with a median age of 45 years; the highest T-bil, AST, and ALT (median) were 7.8 mg/dl, 770 U/L, and 1128 U/L, respectively, and the lowest PT was 64.1%. The number of cases averaged 8.6 cases/year in 2015-2021, but increased to 14 cases/year after 2022. As for the etiologies, unknown, HBV, and drug-related were the most common, at 25/20/21%, respectively. HBV showed a decreasing trend, while an increasing trend in unknown and drug-related. Cases with COVID-19 infection were included among the unknown causes since 2021. The proportion of women increased significantly from 58/124 (47%) in 2001-2011 to 80/114 (70%) in 2012-2023. ALF occurred in 73 patients (30.7%) overall. Unknown/HBV was the most common causes of ALF. The prognosis for unknown and HBV was poor, with liver transplantation/death rates of 79% and 71%, respectively. Among comatose ALF patients with and without transplantation, 2/12(17%) and 28/30(93%) died, respectively.

Conclusions: Recently, HBV-related AH and ALF have decreased, while unknown and drug-related cases tended to increase. The overall number of cases also showed an increasing trend, as for the proportion of women.

Abstract Submission No. 101483
O-0873

Isoproterenol attenuates LPS/D-GalN-induced liver injury through β-arrestin2 exerts anti-inflammatory

tianzhi Ni1, shan Fu1, yalei Zhao1, xiaoli Zhang1, ruojing Wang1, danfeng Ren1, juan Li1, yali Feng1, yuany Yang1, yingli He1, yingren Zhao1, jinfeng Liu1

1Department of Infectious Diseases and Hepatopathy, The First Affiliated Hospital of Xi’an Jiaotong University, China x’an China

Background and Aims: Previous studies have shown that stimulating B2-adrenergic receptors inhibits lipopolysaccharide (LPS)-induced macrophage production of inflammatory factors. The aim of the study was to explore the mechanisms by which the SNS alleviates liver inflammatory harm during acute liver failure (ALF).

Methods: C57BL/6J mice were administered isoproterenol (ISO) in an ALF model established using LPS and D-galactosamine (D-GaIN). THP-1 cells were pretreated with ISO before LPS administration. β-arrestin2 expression in THP-1 cells was knocked down by siRNAs in vitro.

Results: In LPS/D-GaIN-induced ALF mice, ISO administration led to a decrease in serum levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6), mitigating liver damage and reducing the mortality of mice. Furthermore, ISO reduced the infiltration of M1-type macrophages in the liver of ALF mice. Proteomic enrichment analysis suggested that ISO mainly affected the function of liver macrophages, especially the inflammation signaling, such as the MAPK and NF-κB pathways. Pretreatment with ISO resulted in a reduction of LPS-stimulated inflammatory factors (TNF-α, IL-1β, and IL-6) in THP-1 cells. Additionally, ISO treatment attenuated the phosphorylation levels of MAPK P38 and NF-κB P65 by LPS in activated macrophages. Subsequently, β-arrestin2 was knocked down in THP-1 cells. Interestingly, the in vitro results showed that the deficiency of β-arrestin2 dramatically reversed anti-inflammation of adrenergic and inhibited the phosphorylation activity of NF-κB and MAPK signals.

Conclusion: Pretreatment with ISO could potentially exert anti-inflammatory effects through β-arrestin2 and may serve as an innovative pharmacotherapy for the purpose of delaying the pathogenesis and progression of ALF.

Abstract Submission No. 101509
O-0874

Cost-effectiveness analysis of two non-biological artificial liver modes in early HBV-ACLF

Jia Chen1, Zhexuan Deng1, Qiumin Luo1, Wenxiong Xu1,2, Liang Peng3

1Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 2Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 3Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University Guangzhou China
Objective: This study aimed to evaluate the cost-effectiveness of two artificial liver support systems, double plasma molecular adsorption system with sequential low-dose plasma exchange (DPMAS+LPE) and plasma exchange (PE), in early hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).

Methods: 95 patients treated with DPMAS+LPE and 95 with PE at the Third Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed with a 90-day follow-up. Cost-effectiveness analysis of 90-day survival rates and direct medical costs from the healthcare system perspective was conducted, incorporating probabilistic sensitivity analysis.

Results: The average total costs over 90 days were ¥91,661 [95%CI: 85,284 - 99,879] for DPMAS+LPE and ¥86,853 [95%CI: 78,001 - 98,822] for PE, with mean survival rates of 91.59% [95%CI: 82.21% - 94.74%] and 83.12% [95%CI: 73.68% - 89.47%], respectively. Cost-effectiveness ratios were ¥100,078 and ¥104,491 for the two groups. The incremental cost-effectiveness ratio of DPMAS+LPE versus PE was ¥56,765, below China’s per capita GDP in 2022. Probabilistic sensitivity analysis indicated an 85% probability of DPMAS+LPE being economically favorable compared to PE when the willingness-to-pay threshold was set at 3 times the per capita GDP.

Conclusion: DPMAS+LPE treatment improves the 90-day survival rate in early HBV-ACLF patients. Despite increased direct medical costs, the additional cost required per incremental survival rate is deemed acceptable, suggesting the economic viability of DPMAS+LPE therapy.
vivo treatment experiments were conducted to probe the potential synthesis of VISTA in shaping the iCCA tumor microenvironment. Expression levels were utilized to construct patient stratification and prognosis. VISTA abundance and distribution within iCCA were assessed as a strategy to augment the efficacy of anti-PD-1/CTLA-4 therapy in challenging disease.

Conclusions: Targeting the myeloid checkpoint VISTA holds promise between VISTA and the immunosuppressive phenotype of myeloid cells. Ex vivo treatment experiments suggested that VISTA blockade mitigated immune exhaustion and enhanced responsiveness to ICIs.

Abstract Submission No. 101048

O-0878

Reducing Gamma Glutamyl Transferase after Steroid Administration in Biliary Atresia

Nurarifah Ali1,2, Rendi Prihaningtyas1,2, Bagus Setyoboedi1,2

1Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
2Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Background: Biliary atresia is the leading cause of liver transplantation in children. Recent literature suggests that immune mechanisms are responsible for the pathogenesis of biliary atresia. This study aims to evaluate the effect of steroid therapy on Gamma Glutamyl Transferase (GGT) levels in biliary atresia.

Methods: A randomized control trial study was conducted on infants with biliary atresia. Methylprednisolone was administered at 2 mg/kg BW/day two times a day and Gamma Glutamyl Transferase was evaluated 2 weeks after the treatment. This study was analysed using SPSS ver 25.00.

Results: A total of 40 infants with biliary atresia between the ages of 2 weeks to 3 months (20 infants in the placebo group and 20 infants in the methylprednisolone group). There were no differences in bilirubin and liver function tests in the two groups (Methylprednisolone vs placebo: direct bilirubin 9.87 (6.11 - 14.20) mg/dL vs 6.68 ± 2.44 mg/dL; SGOT 176.54 ± 96.09 U/L vs 205.00 (135.25 - 280.25) U/L; p=0.05, but GGT level was lower in the methylprednisolone (160.50 (107.25 - 300.50) U/L) than placebo group (437 (157 - 1755.40) U/L; p = 0.028).

Conclusion: There is a reduction in GGT levels following administration of methylprednisolone. Methylprednisolone may have an effect in suppressing the inflammatory process in biliary atresia.

Abstract Submission No. 101066

O-0879

Methylprednisolone Reduces MMP-7 as a Marker of Fibrosis Progression in Biliary Atresia

Syania Octariyandra1, Rendi Prihaningtyas1, Bagus Setyoboedi1

1Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Background: Chronic inflammation leads to fibrotic obliteration of the extrahepatic biliary tree in biliary atresia. Developing new therapies is necessary to reduce reliance on surgical intervention and liver transplantation. This study aims to evaluate the effectiveness of methylprednisolone (MP) versus placebo in reducing Matrix Metalloproteinase-7 (MMP-7) levels in biliary atresia.

Methods: Randomized, double-blind, placebo-controlled trial, 40 infants with biliary atresia received methylprednisolone (20) and placebo (20). An oral methylprednisolone (2 mg/kg/day) was given for 14 days. Laboratory measurements and MMP-7 levels were evaluated at weeks 0 and 2. Data analysis was performed using SPSS (Version 25).

Results: A total of 22 boys (55%) and 18 girls (45%) were involved in this study at a median age of 10 weeks (8 - 12 weeks). There were no differences in direct bilirubin and MMP-7 levels between the MP and placebo groups before treatment (9.87 [6.11 - 14.20] mg/dL vs. 6.68 ± 2.44 mg/dL; p=0.69 and 1.52 [1.12 - 1.67] ng/ml vs. 1.28 ± 0.54 ng/ml, p=0.394). MMP-7 levels after treatment were lower in the MP group (1.07 ± 0.48 ng/ml, p = 0.002) compared to the placebo group (1.55 ± 0.74 ng/ml, p = 0.040). The MP group has a higher level of reducing MMP-7 than the placebo group ($\Delta = 0.463 ± 0.592$ ng/ml vs. 0.267 ± 0.624 ng/ml, p = 0.040).

Conclusion: Methylprednisolone showed a significant reduction in MMP-7 levels. Anti-inflammatory drug may be effective in suppressing the inflammatory process resulting in fibro-oblitration in biliary atresia.

Abstract Submission No. 101143

O-0880

RCT Study in Biliary Atresia: Effect of methylprednisolone on liver function tests

Farahdina Farahdina1, Rendi Aji Prihaningtyas1, Bagus Setyoboedi1

1Child Health Department, Dr. Soetomo General Academic Hospital, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

Background: Biliary atresia is a fibrotic biliary obstruction. Although Kasai surgery has been performed, the need for Liver transplantation is still high. Pharmacologic treatment may be an alternative for the suppression of biliary fibrosis. This study aims to investigate the effect of steroids in liver function test in biliary atresia.

Methods: This study is a randomized controlled trial in infants with biliary atresia under three months. Subjects were divided into placebo and methylprednisolone. Methylprednisolone was given at a dose of 2 mg/kg/day for two weeks. A liver function test was performed prior to treatment and two weeks after treatment. The data were analyzed using SPSS.

Result: A total of 40 infants aged 9.5 (8 - 11.75) weeks were enrolled in the study, with 20 receiving placebo and 20 receiving methylprednisolone. The AST level was not different between placebo and MP before treatment (205.00 (135.25 - 280.25) vs 176.54 ± 96.09 U/L; p=0.99), but ALT level in the placebo group was higher than in the MP group (168 [113.75 - 313.25] U/L vs 83 [58.50 - 185.50] U/L; p=0.023). There was no difference in the reduction of AST and ALT levels between placebo and methylprednisolone groups (36.50 (-58 - 83.75) vs 18.5 ± 142.38 U/L; p=0.90 vs -91.64 ± 180 vs -14 (-133.5 - 5.25) U/L; p=0.38).

Conclusions: The administration of methylprednisolone did not have an effect on the reduction of AST and ALT levels. Liver function test may not be specified regarding biliary inflammation.

Keyword: Biliary atresia, Methylprednisolone, AST, ALT
Clinical utility of comprehensive genomic profiling tests for advanced biliary tract cancer.

Hiroki Inada¹, Hideaki Miyamoto¹, Hisanobu Oda², Moritaka Suga², Yoko Yoshimaru¹, Katsuya Nagaoka¹, Kentaro Tanaka¹, Satoshi Narahara¹, Sotaro Kurano¹, Takayuki Tokunaga¹, Etsuko Iio¹, Takehisa Watanabe¹, Hiroko Setoyama¹, Yasuhiro Tanaka¹

¹Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan, ²Department of medical oncology, Saiseikai Kumamoto Hospital Kumamoto JAPAN

Comprehensive genomic profiling (CGP) tests have become widespread in Japan since 2019. The range of treatment options for biliary tract cancer and other cancers is expanding. We report on the current status of CGP tests for biliary tract cancer at our hospital which is designated hospital, and another hospital which is cooperative hospital, for cancer genomic medicine in JAPAN. We retrospectively analyzed 71 patients who underwent CGP tests at our hospitals for biliary tract cancer by April 2023. Types of biliary tract cancers are as follows: intrahepatic cholangiocarcinoma 53.5%, extrahepatic cholangiocarcinoma 28.2% and gallbladder cancer 18.3%. In 71.8% of biliary tract cancers, treatment or clinical trials based on genetic mutations were recommended. Major genetic mutations in intrahepatic cholangiocarcinoma were as follows: \( KRAS \) mutation 21.1%, \( FGFR2 \) fusion 15.8%, \( IDH1 \) mutation 10.5%, and intrahepatic cholangiocarcinoma were as follows: \( KRAS \) mutation 30.0%, \( TP53 \) mutation 25.0%, \( BRCA2 \) mutation 10.0% and gallbladder cancer were as follows: \( KRAS \) mutation 15.4%, \( MDM2 \) amplification 15.4%, \( ERBB2 \) mutation 15.4%. On the basis of the CGP testing, 11 patients (15.5%) received targeted therapy. Among them, five patients (45.5%) received pemigatinib therapy for \( FGFR2 \) fusion gene. The overall response rate of pemigatinib therapy was 60%, with 3 patients having a partial response. These conducting CGP tests at a more appropriate time could provide patients with greater benefit from treatments based on their specific gene mutations in biliary tract cancer.

Diagnostic and prognostic significance of the PTEN gene in periampullary carcinoma.

Asgar Ali¹, Sadhana Sharma¹, Sundeep Saluja²

¹Department of Biochemistry, All India Institute of Medical Sciences Patna India, ²GIPMER New Delhi India

Objective: Periampullary Adeno Carcinoma is a heterogeneous carcinoma and is identified in its advanced stages. In periampullary tumours, the influence of a PTEN (phosphatase and tensin homolog) gene mutation on prognosis is unknown. The effect of PTEN downregulation and hypermethylation on the survival of periampullary cancer patients has yet to be investigated. As a result, we aimed to look into the expression value of PTEN gene as a potential biomarker.

Materials and Methods: One hundred and one tumour tissues from the patients were investigated for the mutational and expression of the PTEN gene. Sanger sequencing was used for molecular profiling, immunohistochemistry for protein expression, methylation specific PCR for methylation status, and anti-terminaldeoxynucleotidyltransferase biotin-dUTP nick end labelling test for programmed cell death (apoptosis). The changes were linked to clinicopathological features, overall survival and recurrence-free survival.

Results: In ampullary tumours, the clinicopathological relationship was significantly downregulated \((p=0.06)\), although hypermethylation \((p=0.08)\) and apoptosis loss \((p=0.06)\) were dramatically elevated in patients under 50 years of age. The ampullary tumour had a higher survival rate than the bile duct, duodenum, and pancreatic head cancers \((p=0.00)\). Furthermore, early stage T1 patients have a better prognosis than later stage T1 patients \((p=0.017)\). Patients who got adjuvant CTRT had a greater survival rate than those who did not \((p=0.010)\).

Conclusion: The absence of PTEN gene expression is detected in the ampullary subgroup of periampullary tumours. Those who have positive hypermethylation but modest expression has a poor overall survival. PTEN apoptosis-negative patients, on the other hand, had a higher survival rate.
Lixia Xu1, 2, Mengping Zhang1, Lishu Chen1, 2, Gaomin Zheng1, 2, Yuyao Liu1, Jifei Wang1, Ming Kuang2
1Department of Oncology, Cancer Center, The First Affiliated Hospital, Sun Yat-sen University Guangzhou China, 2Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University Guangzhou China

Abstract Submission No. 100144
O-0885

HAIC, lenvatinib, and PD-1 inhibitors versus GC chemotherapy for advanced biliary tract cancer

Zhipeng Sun1, Bin Shu1, Yang Ming1, Zhizhong Ren1, Canhong Meier1
1Department of Radiology, The First Precision Medicine, The First Affiliated Hospital, Sun Yat-sen University Guangzhou China

Background: Gemcitabine and cisplatin (GemCis) plus durvalumab, a PD-L1 inhibitor, is the latest standard first-line therapy of advanced biliary tract cancers (BTCs). The efficacy and safety of GemCis chemotheraphy and PD-L1 inhibitors, in combination with lenvatinib have not been reported.

Methods: In this retrospective, single-center, single-arm study, patients with advanced BTCs who received GemCis plus PD-L1 inhibitors, durvalumab or enavolimab, with lenvatinib as first-line treatment were screened. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety were evaluated.

Results: From December 2021 to July 2023, 43 advanced BTC patients with a median age of 60 years (range 35-79) were enrolled. Fifteen (34.9%) patients were over 65 years-old. The median duration of treatment was 5.0 months (IQR: 3.2 to 5.9), and the median duration of follow-up was 10.1 months (IQR: 6.6 to 12.2). According to mRECIST, the median PFS was 11.29 months and the median OS was 14.8 months. The 1-year PFS and OS rates were 45.9% and 61.4%, respectively. ORR and DCR were 48.8% and 95.3%, respectively. Any grade adverse events (AEs) occurred in all patients (100%) throughout the treatment. 60.46% (26/43) of the patients experienced grade 3 or 4 AEs. The most common grade 3 or 4 AEs were myelosuppression (37.2%) and hyponatremia (18.6%). No grade 5 AE occurred.

Conclusions: GemCis plus PD-L1 inhibitors with lenvatinib represents an effective and tolerable treatment option in advanced BTC patients, including the elderly patients. Further follow-up is ongoing.

Abstract Submission No. 100400
O-0886

Choleodochal Cysts in Children- Clinical Spectrum

Arjun Maria1, Nishant Wadhwa1, Satish Aggarwal2, Alpana Prasad2
1Division of Pediatric Gastroenterology Hepatology and Liver Transplantation, Institute of Child Health,Sir Ganga Ram Hospital New Delhi India, 2Department of Pediatric Surgery, Sir Ganga Ram Hospital New Delhi India

OBJECTIVE: To study clinical spectrum of choledochal cyst (CDC) in children

METHODS: Records from January 2017 to May 2023 reviewed for children undergoing CDC excision with hepatico-jejunostomy

Results: Ninety two included with 34.8% males. Median age 36 (20-60) months. Type Ia (34.8%) most common, followed by Type Ib (33.7%), Type Ic (16.3%), Type Ivb (5.4%), Type Ic (3.3%), and Type II (3.3%) and formcfrust (3.3%). Recurrent pain abdomen (60.9%), vomiting (52.2%), jaundice (35.9%) were common symptoms, lump was in only 5 (5.4%). Fever in 28.3%. No difference in symptoms amongst the subtypes. Neontal cholestasis was in 17 (18.5%), with 10 children of Type Ia, 5 of Type Ia, 1 each of Type Ivb and formcfrust, however, its incidence was not different amongst the subtypes (p=0.158). GB stone in 20 (21.7%) with no association with any sub-type (p=0.590). CBD stone was in 33 (35.9%). It was more common with formcfrust subtype (100%) and Type Ivb (60%) as compared to other (Type Ia-25.8% vs Type Ic-45.7% vs Type II-33.3% vs Type Ia-34.4%), difference was not significant (p=0.106). CDC ruptured in 15.2% with no association with any subtype (p=0.795). Pancreatitis in 25%, no difference amongst subtypes (p=0.429). LCC was in 27.2% and more common in formcfrust (100%) and Type Ivb, Type Ic, Type II (33.3% each) than in Type Ia (16.1%) and Type Ivb (0%), but difference not significant (p=0.052).

CONCLUSION: Type Ia is the most common subtype with pain and jaundice most frequent symptoms. Neonatal cholestasis is a common presentation and pancreatitis and LCC must be looked for in all. Rupture is frequent (15%)
Abstract Submission No. 100885

Etiological spectrum of Paucity of intrahepatic bile duct (PIHBD) in infants

Alankrita Madhur1, Priti Vijay2, Dilip Ramrakhiani3

1Senior Resident, Department of Pathology, SMS Medical College & Attached Group of Hospitals Jaipur India, 2Assistant Professor, Department of Pediatric Medicine, Sir Padampat Institute of Neonatal and Pediatric Health, SMS Medical College Jaipur India, 3Senior Professor, Department of Pathology, SMS Medical College & Attached Group of Hospitals Jaipur India

Background and objectives: Ductal paucity is one of the important differential diagnosis of infants presenting with cholestasis. PIHBD is defined as bile duct to portal tract ratio< 0.6. In the study we aimed to identify all the causes of ductal paucity in infants.

Methods: From June 2021 to June 2023 all the liver biopsies done in children <1 year old were screened. Of the total 150 liver biopsies, 100 were of infants, out of them 13 had ductal paucity.

Results: Out of total 13 liver biopsies, 6 were of females. Median age (days, IQR) at the time of biopsy was 75 (55-156). Median bilirubin, GGT, albumin (Median, IQR) was 9 (5-13), 178 (156-202), 3.5 (3-3.9) respectively. Of the total 13 biopsies with PIHBD, 5 were of progressive familial intrahepatic cholestasis, 1 was of hypopituitarism, 1 was of cystic fibrosis, 1 was of Alagille syndrome, 1 was of Zellweger syndrome and 4 were of prematurity related in which sepsis and respiratory distress was indication of admission. Out of 13 patients, 3 showed poor outcomes (Zellweger syndrome, Alagille syndrome and one infant with prematurity).

Conclusion: Ductal paucity encompasses 13% of etiology of infantile cholestasis. It generally had favourable outcomes, so timely diagnosis and intervention is necessary. Liver biopsy is confirmatory diagnostic modality.
Genomic profile characteristics of pancreaticobiliary maljunction, including cancer patients

Shodai Tohyama1,2, Hiroshi Ohyama1,2, Kenji Amemiya2,3, Yosuke Hirotsu2, Miho Sakai0, Takashi Mishima4, Tsukasa Takayashiki4, Hitoshi Mochizuki2, 5, Masayuki Ohtsuka4, Naoya Kato1, Masao Omata0

1Department of Gastroenterology, Chiba University Hospital Chiba Japan, 2Genome Analysis Center, Yamanashi Prefectural Central Hospital Yamanashi Japan, 3Department of Pathology, Yamanashi Prefectural Central Hospital Yamanashi Japan, 4Department of General Surgery, Chiba University Hospital Chiba Japan, 5Department of Gastroenterology, Yamanashi Prefectural Central Hospital Yamanashi Japan, 6University of Tokyo Tokyo Japan

Background: Pancreaticobiliary maljunction (PBM) is known to be a high-risk factor for biliary tract cancer (BTC). It has been reported that TP53 and KRAS mutations are found not only in the cancerous area but also in the noncancerous area. However, genetic studies on PBM have been insufficient.

Methods: Patients who underwent surgical resection for PBM and BTC between 1990 and 2023 at our hospital and affiliated hospitals were included in this study. FFPE tissue samples were sampled from different histological types (normal mucosa, hyperplasia, dysplasia, and carcinoma) by laser microdissection, and targeted sequencing was performed using the panel targeting 60 genes frequently identified in BTC, and compared with clinicopathological features.

Results: PBM patients with BTC showed various functional gene abnormalities, including driver mutations such as TP53 and ARID2, not only in the carcinoma but also in the non-cancerous areas including hyperplasia and normal cholangiocarcinoma mucosa. On the other hand, driver mutations were also found in some areas in patients who did not develop gallbladder cancer (prophylactic resection), but were rare. In addition, driver mutations were rarely found in non-cancerous areas in patients with BTC without PBM.

Conclusions: PBM patients with BTC showed a great variety of genetic abnormalities in both cancerous and noncancerous areas. On the other hand, in patients of prophylactic resection without cancer, driver mutations were almost completely absent despite the presence of mucosal changes. We believe that these findings can develop better strategies in patients with PBM.

Carcinoma, a rare malignant neoplasm of the biliary duct: A case report

Ariane Crizelle Jose-Baluyot1, Karl Yu Kim Teng1

Carcinosarcoma is a rare malignant biphasic tumor with both carcinoma component and a spindle cell sarcomatous component intimately intermingled. As published by the World Journal of Gastrointestinal Oncology, there are only 12 cases reported worldwide. We report a case of a 63-year-old Filipino presenting with 10-day history of jaundice, right upper quadrant pain, and weight loss. Preliminary work-up showed, transaminisits, hyperbilirubinemia, negative hepatitis profile, and elevated CA19-9 (1007.70 U/mL). Whole abdomen MRI showed high-grade hepatic hilar obstructive process with marked intrahepatic ductal dilatation secondary to poorly defined soft tissue in the common hepatic duct region measuring 1.2 cm with small (<1.0 cm) porta hepatis & perportal as well as retroperitoneal & bilateral inguinal lymph nodes and normal common bile duct. He underwent Endoscopic retrograde cholangiopancreatography with Spyglass cholangioscopy, with the following findings: nodular and hyperemic lumen with a stricture seen in the said area. Multiple biopsies were taken. Histopathology of proximal common bile duct and common hepatic tissue (diagnosis concurred with 3 other pathologists) revealed: biphasic neoplasm suggestive of a carcinosarcoma. Since R0 resection was not feasible, patient underwent systemic chemotherapy (gemcitabine-based) targeting both lineages (carcinoma and sarcoma). Currently, patient is on his 12th cycle of chemotherapy and for re-evaluation for resectability.

Correlation of Serum Matrix Metalloproteinase-7 and Liver Function Test in Biliary Atresia

Muhammad Irawan1, Rendi Ahja Prihaningtyas2, Bagus Setyobodoi3

1Soetomo General Hospital Surabaya Indonesia, 2Soetomo General Hospital Surabaya Indonesia, 3Soetomo General Hospital Surabaya Indonesia

Background: Biliary atresia (BA) is a rare progressive infant cholangiopathy characterized by cholestasis. BA is a leading cause of pediatric liver transplantation. Early diagnosis using sensitive biomarkers is crucial for good outcomes. However, at present, there is no certain non-invasive diagnostic method to diagnose and differentiate it from other cause of cholestasis. The aim of this study was to evaluate the correlation of serum matrix metalloproteinase-7 (MMP-7) levels with laboratory parameters.

Material and Methods: This cross-sectional study included infants with biliary atresia who were admitted to Soetomo General Academic Hospital, Surabaya. Blood samples as well as baseline clinical and demographic data were collected when admitted. Serum MMP-7 levels were determined by enzyme-linked immunosorbent assay. Result: There were 85 infants with biliary atresia, mean age 11 (1 - 35) weeks, 46 (54.1%) boys, with onset of jaundice at 2 (1 - 20) weeks. The MMP-7 levels were 1.91 (0.39 - 9.95) pg/dl, 4.06 (1.41 - 4.79) g/dl, AST 235.37 ± 130.48 U/L, ALT 143.2 (30 - 641) U/L, 361 (23.9 - 3746) U/L, direct bilirubin 8.75 ± 4.28 mg/dl, and total bilirubin 12.34 ± 6.36 mg/dl. MMP-7 showed a positive correlation with albumin levels (r=0.232; p=0.033), but correlated negatively with AST (r=-0.252; p=0.020) and ALT (r=-0.275; p=0.011) levels. Direct or total bilirubin, hemoglobin, leukocyte or platelet levels were not associated with MMP-7 (p>0.05).

Conclusion: There is positive correlation between MMP7 and albumin, but the relationship between MMP and serum transaminases is reversed. MMP-7 may be used as a prognostic marker for liver damage.
A two-stage anticancer strategy targeting ECM stiffness in primary liver cancer
Shen Zefeng1,2,3, Tao Liye1,2,3, Shangguan Liqing1, Wang Yali1,2, 3, Pan Haoyu4, Cai Jingwei1,2,3, Zheng Junhao5, Liu Yang1,2,3, Lin Xianfeng1, Xu Junjie6, Liang Xiao6

1Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, 310016, China
2Zhejiang University Cancer Center Hangzhou China
3Zhejiang University School of Medicine Hangzhou China

Background: Intrahepatic cholangiocarcinoma (ICC) has a stiffer extracellular matrix (ECM), higher malignancy, and worse prognosis compared to hepatocellular carcinoma (HCC). This study aimed to explore relationships between ECM stiffness and primary liver cancers (PLC, including HCC and ICC) and develop anticancer strategies targeting ECM stiffness in PLC (ICC especially).

Methods: We first explored relationships between ECM stiffness and malignant phenotypes of PLC through in-vitro and in-vivo experiments. Next, we took functional molecules related to ECM stiffness in ICC as examples to explore specific mechanisms of the intracellular response of cancer cells to ECM mechanical signals. Finally, we newly constructed nanoparticles (NPs) and extracted ICC membrane (ICCM) to camouflage cationic polymers for siRNA and BAPN (ICCM@NPs-siRNA@BAPN) to achieve ICC-specific targeted delivery.

Results: The immunofluorescence results of 181 PLC tissue chips (HCC=90, ICC=91), in-vitro and in-vivo experiments showed that ECM stiffness could affect malignant phenotypes of PLC (ICC especially). The new transcript of ABHD11-AS1, a functional IncRNA related to ECM stiffness in ICC, regulated malignant phenotypes of ICC cells and their response to ECM mechanical signals through the YAP1/ABHD11-AS1/STAU2/ZYX/YAP1 loop signaling pathway. ICCM@NPs-siABHD11-AS1@BAPN could be a two-stage anticancer strategy targeting ECM stiffness in ICC.

Conclusions: This study demonstrated that ECM stiffness could affect malignant phenotypes of PLC (ICC especially) and took the YAP1/ABHD11-AS1/STAU2/ZYX/YAP1 loop signaling pathway as the entry point to explore specific mechanisms of mechanical signals conduction from ECM in ICC cells and their impact on cancer progression. Moreover, ICCM@NPs-siABHD11-AS1@BAPN was a spatially selective delivery system integrating ECM softening and blockade of intracellular mechanical signal transduction in ICC.

A 70-year-old woman with history of gallbladder intracholecystic papillary neoplasm (ICPN) presented with persistent melena with anemia (hemoglobin 6.2 g/L). Prior endoscopies did not show any actively bleeding lesions. On admission, patient presented with melena, mild epigastric pain, and pallor. A second look EGD revealed hemobilia. Patient underwent mesenteric angiogram, particle embolization of selected arteries and intraoperative ultrasound revealed multiple hepatic heterogenous foci. Whole abdominal CT scan revealed no hepatic mass lesions, common bile duct (CBD) and intrahepatic duct (IHD) dilatation and a 1cm nodular enhancing focus in the proximal CBD. Spyglass cholangioscopy revealed a lobulated polypoid lesion with villous surface at the main right IHD. Patient underwent choledochoscopy with laser ablation of multiple IHD tumors, excision of IHD mass, and t-tube cholecystostomy. Frozen section revealed mucinous IPNB, predominantly low grade with focal high-grade dysplasia. Due to persistence of melena, patient underwent angiogram with embolization of hepatic arteries; percutaneous transhepatic biliary drainage (PTBD). Although with initial improvement, patient eventually expired after 6 months. In our case, the hemobilia may be due to the diffuse and infiltrative nature of the tumor into adjacent liver parenchyma and vasculature. The co-occurrence with ICPN may be contributory. IPNB has relatively good prognosis hence need for early surgical management. Apart from surgery, other treatment options such as laser ablation, PTBD and embolization need to be explored further.

Abstract Submission No. 102032

O-0896

Extra-hepatic bile duct resection in cases with intrahepatic cholangiocarcinoma
Tian-Run Lv

1West China Hospital of Sichuan University Chengdu China

Abstract

Objective: To evaluate the significance of combined extra-hepatic bile duct resection (EHBDR) in cases with intrahepatic cholangiocarcinoma (IHCC) in terms of clinic-pathological features and long-term survival.

Methods: Radically-resected cases with IHCC from 2000 to 2020 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Comparative analyses were performed between resected IHCC patients who received EHBDR and those without EHBDR.

Results: A total of 1521 radically-resected cases with IHCC (189 cases received EHBDR) were included. Comparable age, sex, race, marital status, liver cirrhosis, differentiation status, and adjuvant chemotherapy were acquired between two groups. EHBDR achieved a greater lymph node yield (P<0.001). The incidence of cases with T3-4 or N+ disease was significantly higher in the EHBDR group (P<0.001). Adjuvant radiotherapy was more frequently performed in cases with EHBDR (P<0.001). Even various independent prognostic factors have been matched between two groups, cases in the EHBDR group still shared a much worse prognosis than those without EHBDR. For early-staged cases, combined EHBDR was even harmful. However, for more advanced cases, EHBDR achieved equivalent survival versus those without EHBDR.

Conclusion: Combined EHBDR was not associated with any survival benefit in radically-resected cases with IHCC and was even harmful for some early-staged cases. However, a greater lymph yield was achieved via EHBDR. Future well-designed studies with more detailed data, such as recurrence rate within 6 months after surgery and the time from the date of surgery to the date of the occurrence of obstructive jaundice, are warranted for further exploration.
Cholangiocarcinoma (Bismuth Corlette Class I) secondary to Choledochal Cyst (Todani Type II)

Mikee Elaine Wee1, Paul Justin Belvis1, Rafael Chan1
1Manila Doctors Hospital Manila Philippines

Choledochal Cyst (Todani Type II) with Lithiasis.

Yoshio Ito1, Daisaku Yamada1, Shogo Kobayashi1, Yoshifumi Iwagami1, Daisaku Yamada1, Yoshio Tomimaru1, Takehiro Noda1, Hidenori Takahashi1, Yuichiro Doki1, Hidetoshi Eguchi1
1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University Suita Japan

Choledochal cysts are a rare congenital abnormality of the biliary tree, characterized by a wide spectrum of clinical manifestations, ranging from asymptomatic to life-threatening complications. The reported incidence of Choledochal cysts is approximately 1:100,000 to 1:1,000,000 in the general population. Choledochal cysts are classified into five types: Type I (diverticulum), Type II (common bile duct diverticulum), Type III (choledochocoele), Type IV (multiple intrahepatic and extrahepatic cysts), and Type V (Caroli disease). Type II cysts are the most common type, accounting for about 70% of all cases. Type II cysts are typically associated with biliary strictures, bile duct dilatation, and the presence of stones.

We report herein a case of a previously healthy 33-year-old Filipino male who complained of a 1-month history of colicky abdominal pain, and 2-weeks history of jaundice, icteric sclera, tea-colored urine, acholic stools. Patient was initially diagnosed as obstructive jaundice probably secondary to choledocholithiasis through ultrasonography. ERCP revealed multiple filling defects within of what seems to be the gallbladder, a narrowing at the proximal CBD with preferential flow of contrast to the gallbladder, and a cystic structure beside the gallbladder. Upper abdominal MRI with MRCP revealed a choledochal cyst type II with intraluminal stones and a contracted gallbladder. Patient underwent biliary exploration which revealed a CBD tumor and a choledochal cyst with multiple intraluminal stones. Core needle biopsy of the tumor revealed poorly-differentiated adenocarcinoma. Patient was diagnosed as Perihilar Cholangiocarcinoma (Bismuth Corlette Class I) secondary to Choledochal Cyst (Todani Type II) with Lithiasis.

Abstract Submission No. 200014
O-0898

Clinical impact of bile cytology and surgical site complication on locoregional recurrence in eCCA.

Yoshiro Ito1, Daisaku Yamada1, Shogo Kobayashi1, Kazuki Sasaki1, Yoshifumi Iwagami1, Yoshio Tomimaru1, Takehiro Noda1, Hidenori Takahashi1, Yuichiro Doki1, Hidetoshi Eguchi1
1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University Suita Japan

Background: Choledochocarcinoma is a lethal malignancy with a poor prognosis because of its high rate of recurrence after radical resection. In terms of prevention of recurrence, the intraductal irradiation of the remnant rectum prior to anastomosis decreased local recurrence in rectal cancer. The presence of surgical site complications (SSC) is regarded as a risk factor for the recurrence in other cancers. However, there have been few studies similar to this in extrahepatic cholangiocarcinoma (eCCA). We here investigated whether preoperative positive bile cytology and postoperative complications were associated with recurrence in eCCA.

Method: Ninety-six patients who underwent R0 resection for eCCA in our hospital were investigated. The relationship between clinicopathological factors and long-term outcomes was evaluated.

Result: 42 patients had SSC including bile leakage. Preoperative bile cytology was positive (Class IV, V) in 50 patients except for 13 patients who had not undergone bile cytology. Recurrence at the peritoneum and local site was significantly more frequent in the SSC group than in the non-SSC group (42.8%:11.1%, p=0.0003). While the occurrence of SSC was not associated with preoperative bile cytology-positive cases (p=0.4980), bile cytology-positive patients with SSC had a higher rate of peritoneum and local recurrence than the other patients (72.2%:13.9%, p=0.0001). Both preoperative positive bile cytology and the presence of SSC were significant factors of recurrence-free survival (RFS) (p=0.0096,0.0175).

Conclusion: Preoperative positive bile cytology is a risk factor for recurrence in eCCA. Furthermore, adding the factor of SSC, the peritoneal or local recurrence was more frequently observed.

Abstract Submission No. 200035
O-0899

ADC values predict prognosis and Ki67 expression in intrahepatic cholangiocarcinoma on DW-MRI

Daiki Hokkoku1, Kazuki Sasaki1, Shogo Kobayashi1, Yoshifumi Iwagami1, Daisaku Yamada1, Yoshio Tomimaru1, Takehiro Noda1, Hidenori Takahashi1, Yuichiro Doki1, Hidetoshi Eguchi1
1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University Suita Japan

Background: Ki67 is a marker of cell proliferation and key in cancer treatment because it reflects the grade and prognosis of malignant tumors. Apparent diffusion coefficient (ADC) values are derived from DWI and are a common imaging metric used to quantify the biological behavior of tumors and evaluate curative response. ADC values have been associated with Ki67 expression in breast cancer and pancreatic neuroendocrine tumors, but information about the relationship between Ki67 expression and ADC values in ICC is lacking.

Method: We investigated the ability of ADC values to predict Ki67 expression, using retrospective analysis of 39 cases of ICC confirmed by surgical pathology. All patients had undergone MRI, and ADC values (mean, minimum, maximum) were calculated. Ki67 expression was assessed by immunohistochemistry, and patients were divided into groups of high (n = 13) and low Ki67 expression (n = 26). To assess the diagnostic performance of the ADC values for Ki67 expression, we used the receiver operating characteristic curve and compared the areas under the curve (AUCs).

Results: The high Ki67 expression group had a significantly poorer prognosis than the low group. The minimum ADC values were significantly lower in the group with high Ki67 expression. For predicting high Ki67 expression, the AUC values were 0.7189 for the minimum ADC values. The diagnostic sensitivity and specificity of the minimum ADC values were 84.6% and 73.1%, respectively. In addition, with ADC values combined, the AUC increased to 0.760.

Conclusion: ADC values can non-invasively predict ICC associated with high Ki67 expression.

Abstract Submission No. 100050
O-0900

A case of cystic pseudo-tumor as a complication of radiofrequency ablation therapy

O-0900

A case of cystic pseudo-tumor as a complication of radiofrequency ablation therapy
Radiofrequency ablation (RFA) therapy is a curative treatment for small-sized hepatocellular carcinoma (HCC) tumors. It is widely performed at many institutions worldwide, and its complications have been well discussed in previous studies. Here, we report a highly rare case of cystic pseudo-tumor as a complication of RFA treatment. The patient was a 71-year-old individual with HCC who had an etiology of non-alcoholic steatohepatitis. He also had hypertension, type 2 diabetes, chronic renal failure on dialysis, prostatic cancer, and a history of hepatectomy for HCC. We performed RFA therapy for HCC recurrence in the left lobe near the stomach. Four months later, we identified the formation of a cystic lesion in the treated area of the liver without any symptoms. This cystic lesion was surrounded by a thick wall. Cytodiagnosis of the fluid within the cystic lesion revealed that the fluid was serous and not purulent. Total bilirubin levels of the fluid were not elevated, and no evidence of malignancy was found. Computed tomography examination at 16 months after RFA showed a collapse of the cystic lesion, and small amounts of gas were detected in the RFA-treated lesion, indicating that penetration of the stomach had occurred. Artificial ascites could not completely prevent gastrointestinal tract injury, but would be necessary to keep thermal injury to minimum in ablation therapy.

Abstract Submission No. 100318
O-0901

GAED resected by ESD: a case report of the patient with cirrhosis and previous liver cancer
Chang’en Liu1, Yan Li1, Qi Xin2, Zili Zhang3, Guiming Shu4, Shigang Shan4, Qisun5, Yaohui Wang6
1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease Tianjin China, 2Department of Pathology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease Tianjin China, 3Department of Gastrointestinal surgery, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease Tianjin China, 4Department of Hepatobiliary surgery, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease Tianjin China, 5Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing China, 6Department of Pathology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing China

Gastric adenocarcinoma with enteroblastic differentiation (GAED) is a rare special type of gastrointestinal tumor. Our patient had a history of CHB with cirrhosis for more than 25 years and underwent 13 years combination therapy for HCC, like RFA and TACE, besides targeted drugs for 4 years. GAED was found in the greater curvature of upper segment of gastric body. The gastric and duodenal background mucosa was slightly edematous with regular dilation of microvessels. We suspect it’s caused by targeted drugs. The lesion consists of two parts, 0-IIa+1 Ib. Fine villous white fur epithelium showed a distinctive appearance in Faded flat area. Biopsy specimens taken from the lesion in the 0-IIa reddish position revealed to low-differentiated adenocarcinoma. The lesion removed by using endoscopic submucosal dissection. The lesion located in the mucosal layer, and the small infiltrated the submucosa to 196um. The irregular carcinomatous adenoids are tubular and cystadenoid, similar in shape to common intestinal adenocarcinoma components. Part of the region was solid, the epithelial cells were cubic, the atypia was significant, and the cytoplasm was transparent and vacuole-like. The patient survived with high quality at the fourth month after surgery. Through comprehensive and diverse treatment methods, the survival of patients is prolonged. Multidisciplinary collaborative treatment significantly improves the quality of life of patients.

Abstract Submission No. 100318
O-0902

Acute liver failure by scrub typhus; a rare presentation
Sudhamshu KC1, Niyanta Karki2, Pukar Thapa1,2
1National Academy of Medical Sciences Kathmandu Nepal, 2Norvic International Hospital Kathmandu Nepal

Acute liver failure (ALF) can be due to numerous causes and result mostly in mortality if liver transplantation cannot be offered. Scrub typhus is an acute febrile disease caused by Orientia tsutsugamushi transmitted by mites. Liver injury in scrub typhus is common but reversible. However, there are reported cases of ALF due to scrub typhus, mainly in conjunction with other clinical conditions. Herein we report a case who presented with scrub typhus complicated by ALF and treated successfully without transplantation in our institute. A 27-years-old lady was admitted with complaints of jaundice and fever. LFT showed bilirubin of 10.2/8.4 mg/dL with ALT/AST of 1058/2134 IU/mL. A working diagnosis of acute viral hepatitis was made. Viral serology for HAV, HEV, HBV, HCV, TORCH were negative. Patient developed seizure followed by encephalopathy and INR came out to be 3. Patient was transferred to ICU and counselled for liver transplantation. Due to non-availability of donor, transplantation was not carried out. Patient slowly improved with conservative management but her fever was persistent. Fever panel test was sent and scrub typhus IgM came to be positive. Patient was put on doxycycline. Fever came down but liver enzymes worsened. Antibiotics changed to Azithromycin and patient improved. After a hospital stay for 29 days she was discharged. Due to the non-specificity and diversity of the initial presenting symptoms, scrub typhus causing ALF can easily be missed. A lack of awareness about the disease and its role in causing ALF, there is always a chance of misdiagnosis.
Case Report: A 28-year-old gentleman visited the outpatient clinic because of recently known HBV infection 8 years ago. He had history of HBV Vaccinations 10 years ago, but no immune response of HBs Ag detected. His serological testing were positive for HBs Ag, HBe Ab, and HBs Ab, HBe Ag and HBe Ab (both IgM and IgG) were negative. HCV Ab and HIV Ab were also negative. HBV DNA - 1.19E + 04 IU/mL and qHBs Ag 584 IU/ml. ALT - 66 IU/mL, AST 70 IU/mL, AFP - 3.5 IU/mL.

Utrasound Abdomen showed chronic hepatitis. Fibroscan showed F3 fibrosis and moderate steatosis. He was admitted to the hospital with a diagnosis of severe acute hepatitis. He was discharged on the 22nd day of hospitalization.

Abstract Submission No. 100331
O-0904

Cytokine release syndrome caused by the durvalumab plus tremelimumab combination therapy for HCC

Sae Yumita1, Sadahisa Ogasawara1, Yumi Ozaki1, Takuya Yonemoto1, Keisuke Koroki1, Masanori Inoue1, Kazufumi Kobayashi2, Naoya Kanogawa1, Soichiro Kiyono1, Msato Nakamura1, Takayuki Kondo1, Shingo Nakamoto1, Naoya Kato1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University, Japan Chiba-shi, Chiba-ken Japan

Background: Cytokine release syndrome (CRS) is a systemic inflammatory syndrome that can lead to life-threatening, caused by elevated levels of cytokines and the activation of immune cells. It can be triggered by systemic therapies mainly immune activating treatments, pathogens, malignancies, or autoimmune diseases. In recent years, CRS has been reported as an immune-related adverse event associated with immune checkpoint inhibitor. We report a case of severe CRS that occurred following the initiation of durvalumab plus tremelimumab combination therapy for advanced hepatocellular carcinoma (HCC).

Case Report: A combination therapy of durvalumab plus tremelimumab was initiated in a 35-year-old female with stage IV metastatic HCC. A few weeks later, she visited our department due to a fever. She had low blood pressure and a body temperature of 39℃. Blood tests revealed signs of inflammation, elevated transaminases, and renal impairment. Suspecting sepsis, broad-spectrum antibiotics and vasopressors were initiated. While the vasopressors could be continuously given, the high fever persisted, and liver enzymes continued to rise, leading to a tendency toward disseminated intravascular coagulation. Given the elevated IL-6 levels, we considered the possibility of CRS and administered steroid pulse therapy. The patient’s overall condition began to improve and we began tapering the steroids. However, a few days later, with the re-elevation of IL-6 and CRP levels, we suspected a recurrence of CRS and administered tocilizumab. Subsequently, her condition showed improvement and she was discharged on the 22nd day of hospitalization.

Conclusion: Severe CRS has the potential to become life-threatening, so appropriate therapeutic interventions are necessary.

Abstract Submission No. 100455
O-0906

Recovery of Severe Acute Hepatic Graft-versus-Host Disease in a Recently Transplanted Pre-B Cell ALL

Ma. Regina D. Dimaculangan1, Faith Abigail Co1, Alexandra Layas1
1Institute of Digestive and Liver Diseases, St. Luke's Medical Center - Global City Taguig Philippines

Introduction: Acute Graft-versus-Host Disease (GVHD) is a complication among hematopoietic cell transplant recipients within 100 days. But only around 9% involve both the liver and the gastrointestinal tract. Diagnosing hepatic GVHD is quite challenging, since it is indistinguishable from other disorders such as infection and drug-induced liver injury.

Clinical Significance: Hepatic GVHD has a higher non-relapse mortality rate than non-hepatic. However, early recognition and management even without a liver biopsy can help prevent the development of permanent organ damage.

Case Report: Here we present a case of a 57-year-old female, with pre-B cell acute lymphoblastic leukemia and with no known liver disease, who underwent allogeneic HSCT (mismatched/haploidentical) two months prior to admission. Patient was managed as a case of pneumonia in an immunocompromised host. At Day +83 post-transplant, she presented with high grade fever, diarrhea, generalized jaundice, and vomiting. She was diagnosed with acute hepatic graft-versus-host-disease through elevated bilirubins and late increase in transaminases (Grade 0). This eventually progressed to Grade 4 in a span of 17 days with the highest total bilirubin and direct bilirubin recorded to be 33
mg/dL and 24 mg/dL, respectively. Patient was then started on high dose steroids and liver supportive therapy, such as minophagen drip, transmetil, udacacid, and silymarin. Her liver profile started to down trend after 25 days, and noted clinical improvement of symptoms.

**Conclusion:** Elevated bilirubins, rather than increase in transaminases, is the best diagnostic marker for Hepatic GVHD. Prompt administration of steroids can help improve the patient’s overall survival.

Abstract Submission No. 100456
**O-0907**

**Unmasking Hepatoid Adenocarcinoma of the Stomach Mimicking as Hepatocellular Carcinoma: A Case Report**

Laurence Laurel1, Jozen Lagman1, Joseph Bocobo1, 2
1St. Luke’s Medical Center- Global City Taguig Philippines, 2St. Luke’s Medical Center- Quezon City Quezon City Philippines

Hepatoid adenocarcinoma of the stomach (HAS) is a rare malignancy characterized by its hepatocellular differentiation and aggressive nature. Due to its scarcity and vague clinical presentation, diagnosing HAS poses significant challenges, often leading to its misidentification as hepatocellular carcinoma due to their indistinguishable radiologic and clinical parameters.

We report a 68-year-old male who initially sought consult for a perplexing symptom: a persistent three-week history of hiccups. During an abdominal ultrasound, solid hepatic nodules were incidentally discovered, triggering further investigations. Subsequent tests unveiled a dramatic elevation in alpha-fetoprotein (AFP) levels (~60,000 ng/mL) and the presence of hypovascular hepatic masses, accompanied by portal vein thrombosis, as evident on a 4-phased dynamic liver scan. The initial suspicion was hepatocellular carcinoma, primarily due to an atypical enhancement pattern observed. To explore the anomaly further, a fine needle aspiration biopsy of the liver mass was performed. Notably, given the unusual initial symptom of hiccups and anemia, gastro-duodenoscopy was done revealing an unexpected gastric mass located in cardia up to the esophagus. Histopathological analyses of both the liver and gastric masses, supplemented by immunohistochemical stains, ultimately confirmed the diagnosis of gastric adenocarcinoma with liver metastasis. This case emphasizes the significance of a comprehensive diagnostic approach for rare conditions such as HAS with liver metastasis, highlighting the need for integrating clinical, radiological, and histopathological findings. It underscores the importance of considering HAS as a potential differential diagnosis in cases of AFP-producing liver lesions that exhibit atypical hepatocellular carcinoma imaging characteristics.

Abstract Submission No. 100539
**O-0908**

A case of neuroendocrine carcinoma caused obstructive jaundice by extensive hepatic infiltration.

Chihei Sugihara1, Motoyasu Kan1, Miho Sakai1, Kazuki Watabe1, Tomoya Takahashi1, Yu Sekine1, Syodai Tohyama1, Nana Yamada1, Mayu Ouchi1, Motoyasu Kan1, Hiroki Nagashima1, Koji Takahashi1, Kouichirou Okiitsu1, Izumi Ohno2, Toyozumi Takeshi1, Hisahiro Matsubara1, Naoya Kato1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan, 2Department of Medical Oncology, Graduate School of Medicine Chiba Japan

A 74-year-old man was found to have obstructive jaundice (T-Bil 18.6 mg/dL). He had a history of total gastrectomy and Roux-en-Y anastomosis for upper gastrointestinal bleeding in his 20s. Imaging findings showed that the tumor was 80mm which extensively infiltrated to both lobes of liver, gallbladder, duodenum, and main portal vein and caused biliary stricture classed Type3A in Bismuth classification. Biliary drainage was attempted using a balloon endoscopy, but it cloud not reach Vater papilla. Next, percutaneous transhepatic bile duct drainage was performed to posterior segmental branch, but jaundice did not improve. An endoscopic ultrasound-guided hepatic jejunostomy for obstructive jaundice caused by hepatic infiltration are rare. And in this patient, there was difficulty on biliary drainage for reconstructed intestinal tract. However, we finally succeeded in improving jaundice by combination of percutaneous procedure and interventional EUS.

Abstract Submission No. 100541
**O-0909**

A case of cholangitis as immune-related adverse events with biliary infection after cholangiography.

Chihei Sugihara1, Hiroshi Ohyama1, Tomoya Takahashi1, Yu Sekine1, Shodai Tohyama1, Nana Yamada1, Mayu Ouchi1, Motoyasu Kan1, Hiroki Nagashima1, Koji Takahashi1, Kouichirou Okiitsu1, Izumi Ohno2, Toyozumi Takeshi1, Hisahiro Matsubara1, Naoya Kato1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan, 2Department of Medical Oncology, Graduate School of Medicine Chiba Japan

**Background:** Immune checkpoint inhibitors possibly cause immune-related adverse events (irAE). The rate of sclerosing cholangitis in irAE is small, but it is reported difficult to cure immune checkpoint inhibitor-induced cholangitis because steroid therapy has no efficacy for them.

**Case:** 75-year-old-man had had a history of subtotal esophagectomy for esophageal cancer at age 71. He was performed multidisciplinary treatment involving Nivolumab therapy for lung metastasis from age 73. During hospitalization of treatment for ulcer in a reconstructed gastric tube perforating the pericardium, he was found to have jaundice (T-Bil 13.7 mg/dl) on day 46. Imaging findings showed that non-continuous strictures of wide part of bile tract with dilation of upper bile duct. It was suspected sclerosing cholangitis, so an endoscopic retrograde cholangiopancreatography (ERCP) was performed. It showed that pruned-tree appearance by cholangiography and circular homogenous wall thickening of parts of bile duct with stricture by intraductal ultrasound. Bile cytology and brush cytology from stricture were not malignant. After balloon dilation of stricture, an endoscopic nasobiliary drainage tube was put, but it was removed soon. This patient was diagnosed as an immune checkpoint inhibitor-induced cholangitis because steroid therapy has no efficacy for them.

**Conclusion:** For the treatment of immune checkpoint inhibitor-induced cholangitis, the indication of steroid therapy was limited.
Corticosteroid therapy for prolonged jaundice and pruritus in HIV patients with acute hepatitis A

Michiko Koga, Lay Ahyoung Lim, Hiroshi Yotsuyanagi

1The Institute of Medical Science, University of Tokyo Tokyo Japan, 2Kitasato Institute Hospital, Kitasato University, Tokyo, Japan Tokyo Japan

Background: Recent years have seen global outbreaks of acute hepatitis A (HA), particularly affecting men who have sex with men (MSM). In Tokyo in 2018, an outbreak primarily impacted MSM, including some individuals living with HIV (PLWH). Two PLWH experiencing prolonged jaundice and severe pruritus were treated with corticosteroids, demonstrating successful responses. This marks the first report of corticosteroids for prolonged cholestatic HA in PLWH.

Cases: The first case involved a 34-year-old male, on antiretroviral therapy (ART) for six years. Despite CD4 count of 527/µl and suppressed HIV-RNA viral load, he faced elevated peak ALT 3494 IU/l and total bilirubin (T-Bil) 31.9 mg/dl. Severe itching and fatigue led to the initiation of 25 mg/day (0.5 mg/kg) of prednisolone (PSL) on day 62. T-Bil levels gradually normalized by day 142.

In the second case, a 36-year-old male, 11 years on ART with CD4 count 620/µl and suppressed HIV-RNA viral load, encountered peak ALT 2690 IU/l and T-Bil 22.8 mg/dl. Despite well-managed HIV, he too experienced itching and fatigue. Initiation of 30 mg/day (0.5 mg/kg) of PSL on day 32 resulted in a T-Bil decrease of 2.1 mg/dl by day 71.

Discussion: Around 1% of HA cases may lead to prolonged jaundice and severe itching. Cholestasis might arise from various bilirubin metabolism defects. This study suggests that corticosteroid therapy could be an effective option for well-controlled PLWH on ART.

Detection of ETV-associated drug resistance mutation S202G in a case of HBV/HIV coinfection

Michiko Koga, Kazuaki Takahashi, Tadashi Kikuchi, Takeya Tsutsumi, Hiroshi Yotsuyanagi

1The Institute of Medical Science, University of Tokyo Tokyo Japan, 2AIDS Research Center, National Institute of Infectious Diseases Tokyo Japan, 3Graduate School of Medicine, The University of Tokyo Tokyo Japan

Background: Entecavir (ETV) resistance is often acquired following lamivudine (3TC) resistance but is rarely proven by clinical specimen analyses over time. A case study outlines the gradual acquisition of the S202G mutation spanning approximately 8 months.

Case: A man in his 40s, diagnosed with HIV/AIDS and chronic hepatitis B eight years ago, initially received tenofovir/emtricitabine (FTC)/darunavir/ritonavir. Subsequently, HIV-RNA and HBV-DNA were suppressed, and CD4 counts increased. Later, due to renal issues, he was switched to abacavir/dolutegravir (DTG) and ETV. Upon transfer to our clinic three years ago, he exhibited suppressed HIV-RNA, CD4 count 635/µl, normal transamidases, HBsAg 245.38 IU/ml, HBV-DNA 2.6 log IU/ml, and HBV genotype A2. Subsequently, reaching AST 40U/L, ALT 70U/L, HBsAg exceeding 99999.99 IU/ml, and HBV-DNA rising to 7.9 log IU/ml after one year. Stored specimens revealed L180M and M204V mutations, 3TC resistance, at our clinic’s initial visit, and a gradual shift from AGC to GGC nucleotides, indicating S202G acquisition over 8 months. Because of no other mutations, TAF/FTC and ETV were initiated, resulting in normalized liver function and declining HBV-DNA levels. Analysis of GenBank HBV/HIV coinfection samples revealed few reports of ETV resistance mutations and no reports of S202G.

Discussion: It is reported the acquisition of HBV multidrug resistance during HBV/HIV coinfection treatment, specifically marking the initial report of S202G acquisition. The reasons for the low number of registrations of ETV resistance of coinfection in GenBank were that coinfection was not specified and that many registrations were from Asia and Africa where ETV has not been used.
Background: Peritoneal tuberculosis (TB) is one of the most challenging forms of extra-pulmonary tuberculosis to diagnose, most common in the developing world because the symptoms and signs of peritoneal TB are nonspecific.

CASE: A 31-year-old female patient presented to the ER with a chief complaint of abdominal pain for the last 2 months, VAS 8/10, associated with lethargic, body weight loss, fever, nausea, vomiting, for 1 months. Her vital sign was stable with the temperature 38.5 C. The laboratory showed Hb 8.6 g/dL, WBC 12,800/mm^3. The blood smear showed microcytic hypochromic anemia causes by chronic disease anemia. Abdominal CT with contrast was performed and showed suggestive peritonitis tuberculosis with peritoneum thickening and minimal ascites. Anti-tuberculosis drugs was planned to be given for 9 months. After 2 months therapy, the symptoms were gradually improving and body weight increases by at least 10 kilograms.

DISCUSSION: Female patients with complaints of abdominal pain can be caused by various diseases, determined based on the symptoms that occur, medical history, and epidemiological data. Peritonitis tuberculosis is one of the differential diagnoses with the most common complaints being abdominal pain (73%) and fever (58%). The complaints are difficult to differentiate from other intra-abdominal diseases, and the major diagnostic unavailable. In this patient, radiologic imaging techniques were the diagnostic basis, and abdominal CT with contrast showed peritoneal thickening. Treatment of peritoneal TB is primarily the anti-TB regimen.

CONCLUSION: Peritoneal tuberculosis has non-specific symptoms and complaints, making diagnosis difficult. A correct diagnosis is desirable.

KEYWORDS: Diagnosis, Peritonitis, Tuberculosis

A RARE CASE OF HIRSCHPRUNG’S DISEASE IN AN ADULT PATIENT: CASE REPORT

Enrico J. A. Marpaung1, Gunawan A. Wibowo2, Christine B. Siregar2

1Mitra Keluarga Hospital Jakarta Indonesia, 2University of Sumatera Utara Medan Indonesia, 3Mitra Keluarga Hospital Jakarta Indonesia

Background: Hirschsprung’s disease is considered a newborn disease, occurs in 1:5000 births, but in adults it is rarely considered and often undiagnosed. A variety of diagnostic tests including contrast enema and anorectal manometry may be used as diagnostic screens, but diagnosis ultimately rests upon histopathological evaluation of a rectal biopsy.

CASE: A 25-year-old male patient presented to the outpatient clinic with chief complaints of abdominal pain for the last 3 months, associated with bloating, nausea, and constipation. He has no similar complaints since birth. Abdominal computed tomography with contrast showed dilatation of the colon, colitis with fat stranding and multiple periodic lymphadenopathy (mainly sigmoid, descending, and transverse colon), fecal material, and minimal ascites was found. The final diagnosis at our hospital was adult hirschprung, diagnosed by the history taking and abdominal computed tomography. The patient was referred to a digestive surgeon for further treatment.

DISCUSSION: Constipation is a common disorder that usually refers to persistent, infrequent defecation, difficult stool passage. This condition can deteriorate into distal colon obstruction, worsening constipation or even acute intestinal obstruction. Barium enema and biopsy are the gold standard. Surgical procedure to removal of the aganglionic segment remains the definitive treatment for this disease.

CONCLUSION: Adult Hirschsprung’s disease should be considered in any young patient presenting with a long-standing history of constipation, although it is rare. Abdominal computed tomography examination is recommended as a useful tool in the suspected diagnosis. Definitive treatment is surgical removal of the agangliconic segment.

KEYWORDS: Abdominal, Adult, Constipation, Hirschprung
within the gallbladder and common bile duct, with intermittent bleeding proximal to the choledochotomy. Histopathology noted varisized blood vessels in the serosa and muscularis layer of the gallbladder, consistent with hemangioma. Six days post operative, hematochezia recurred with sanguinous T-tube output. Angiogram of the right hepatic artery revealed multifocal stenosis with outpouching in the distal A8 branch and embolization was performed. Based on the seven-item diagnostic criteria for PAN and the presence of characteristic beading pattern on angiogram, a diagnosis of PAN was established and hydrocortisone was started.

This case underscores the intricate clinical scenario of PAN presenting as hemobilia, necessitating a heightened level of clinical suspicion and a collaborative medical approach. Early diagnosis and appropriate management are pivotal in mitigating the potentially severe consequences of this unique and significant complication associated with PAN. This case report highlights the rare co-occurrence of PAN and gallbladder hemangioma, which manifested in a rare manner, not previously reported in scientific literature.

Abstract Submission No. 100790
O-0917

Combine hepatectomy and flow modulation surgery for patient with HCC and gastroesophageal varices

Giang Nguyen1, Trong Nguyen1, Hung Nguyen1
1Vietnam National Hospital of Tropical Diseases Hanoi Vietnam

Gastroesophageal varices (GEV) bleeding is a complication of portal hypertension, and usually a contraindication of liver resection. Flow modulation surgery include portosystemic shunt and devascularization combined with splenectomy has been proved to be effective in treat GEB and decrease portal vein pressure in liver transplantation. We present 2 cases HCC with gastroesophageal varices treated by liver resection combined with flow modulation surgery.

Case 1: Patient female, 71 years old, diagnosis: HCC, cirrhosis with fundal gastric varices (GOV 2) and large gastrorenal shunt, thrombocytopenia. We have performed dorsal subsegmentectomy combined with Fundectomy and Periesophagogastroscopy devascularization. She recovered well and was discharged after 14 days.

Case 2: Patient male 47 years old with diagnosis of HCC, recurrent esophageal bleeding (6 times in 2 years despite of NSBB treatment), thrombocytopenia. We have performed dorsal subsegmentectomy combined with Warren shunt. His esophageal varices rebled at POD 9 and treated by EBL. He recover well and was discharged at POD 20.

Conclusion: Liver resection can combine with flow modulation surgery to treat for patient with HCC and GEV

Abstract Submission No. 100815
O-0918

Patients with Hepatosplenic Schistosomiasis who underwent Modified Sugiuira Procedure: A Case Series

EUROPEAN HENLEY SANCHEZ1, CAMILLE NICA SOLAJES1, AARON VELASCO1
1SOUTHERN PHILIPPINES MEDICAL CENTER DAVAO CITY Philippines

Approximately 5% with schistosomiasis develop Hepatosplenic Schistosomiasis (HSS). It encompasses perportal fibrosis, portal hypertension, upper gastrointestinal bleeding (UGIB) due to variceal bleed, and varying degrees of cytopenia and splenomegaly due to hypersplenism that poses significant morbidity and mortality.

From 2019 to 2023, four cases previously diagnosed and managed for Schistosomiasis presented with sudden onset hematemesis. Abdominal imaging studies showed splenomegaly with splenic index ranging from 1358 to 5184, with mass effect and displacement of bowels and left kidney. Laboratories revealed anemia, thrombocytopenia, and prolonged coagulation studies. UGIE showed Esophago-Gastric Varices and then started on Propranolol. Rectal biopsies showed Schistosomal ova. The patients underwent the Modified Sugiuira procedure where post-procedure, all had rebound thrombocytosis controlled with hydroxyurea. Monitoring revealed resolution of anemia, thrombocytopenia and coagulation studies. Only one patient had recurrence of hematemesis controlled with rubber band ligation, and all subsequently had no recurrence of hematemesis. HSS currently has no established guidelines for management. Available data suggest an interplay between medical therapy, variceal interventions, and surgical procedures. Medical management includes praziquantel especially in communities with high levels of transmission to prevent reinfection and Propranolol as primary and secondary prophylaxis for variceal bleeding. For patients with bleeding varices, treatment considerations include rubber band ligation, sclerotherapy, shunt surgical procedures, or devascularization with splenectomy. For patients with secondary hypersplenism, distal splenorenal shunt surgery or esophageal and gastric devascularization with splenectomy are surgical options. Potential benefits with carvedilol, transjugular intrahepatic portosystemic shunt, and spleen preserving procedures are options to be explored for future trials.

Abstract Submission No. 100851
O-0919

Atypical Nutcracker’s Syndrome in Polycystic Liver Disease: A Case Report

Salahuddin Andam1, Rene John D. Febro1, Hyacinth C. Eviota1, Frederick T. Dy1, Alvin Brian C. Velasco1, Rommel P. Romano1, Estrellita J. Ruiz1, Carmelita D. Dalupang1, Jaqueline S. Arsenal1, Erika Johanna P. Tañada1, Maria Hossea C. Monfero1, Stephen N. Wong1
1University of Santo Tomas Hospital Manila Philippines

Background: The formation of esophago-gastric varices is a rare complication of polycystic liver disease (PLD) where the multiplicity of cysts leads to pseudo-cirrhosis and portal hypertension. However, these cysts may also lead to extrinsic vascular compression, wherein the nutcracker syndrome (NCS) is one of the rarest. We report an unusual case of a PLD patient who presented with bleeding gastric varices due to NCS.

Case Presentation: A 67-year-old female with innumerable large hepatic cysts due to PLD presented with a 3-day history of melena. An esophagogastroduodenoscopy revealed a large isolated gastric fundal varix with stigmata of recent bleeding. A total of 1.5 ml. of cyanoacrylate was injected with hemostasis adequately achieved. The patient was sent home with carvedilol. However, patient had recurrence of melena after 1 month. Repeat esophagogastroduodenoscopy showed the same findings with no diminution of the size of the varices. Repeat 2.5 ml. cyanoacrylate injection was successfully performed. A triphasic computed tomography scan of the abdomen showed a non-dilated portal vein but with extrinsic compression of the left renal vein by the superior mesenteric artery, caused by downward pressure from the cysts, leading to the formation of a gastro-renal shunt and gastric varices. A multidisciplinary conference was convened where a comprehensive strategy involving the placement of coils with subsequent
balloon-occluded retrograde transvenous obliteration was offered to the patient.

**Conclusion:** The rare coexistence of PLD and NCS presents substantial challenges in diagnosis and management. An effective multidisciplinary collaboration underscores the significance of a comprehensive approach when addressing this condition.

Abstract Submission No. 100861

**O-0920**

**Mother to child transmission of HBV - Role of birth-dose and HBIG for prevention**

Nida Ali1,3, John W Ward1, Ehsan Ghani2, Qaiser Hussain3, Muhammad Irfan3

1Coalition for Global Hepatitis Elimination - The Task Force for Global Health Islamabad Pakistan, 3District Health Authority Rawalpindi Pakistan, 4Local Hepatitis Elimination & Prevention - District Health Authority Rawalpindi Pakistan

We report a case of vertical transmission of HBV from the mother to 3/4 of her children and how the child who received neonatal immunoprophylaxis escaped infection. A 26-year-old housewife gave birth to her first child “A” via emergency C-section. She was tested for HBV and HCV as a part of pre-operative screening where she tested negative. During routine antenatal visit to the hospital for her second pregnancy, she tested positive for HBV. The child “S” was given Hepatitis B Birth-dose and Hepatitis B Immunoglobulin (IVIG) right after normal vaginal delivery. She gave birth to the third child “I”, 4 years ago at the hospital. No postpartum intervention for preventing the vertical transmission was done. Frontline workers screened the family and found the mother positive for HBV as well as 3 of the 4 children.

**Conclusion:** The probable source of the mother and the first child “A” acquiring HBV is the C-section surgery. Mother gave birth to 3 more children. The only child who did not acquire the infection was the one who received neonatal immunoprophylaxis. Although during one of the pregnancies, the mother received antiviral tenofovir, it did not prevent the vertical transmission to that child in absence of birth-dose and HBIG.

This highlights the value of antenatal screening and at-birth intervention for preventing the vertical transmission of HBV.

Abstract Submission No. 100896

**O-0921**

**SUCCESSFUL DOWNSTAGING OF HEPATOCELLULAR CARCINOMA WITH IMMUNOTHERAPY**

DINU ABIRAMI PREM KUMAR1, JOY VARGHESE2, JAYANTHI VENKATARAMAN2

1SENIOR RESIDENT CHENNAI India, 2SENIOR CONSULTANT CHENNAI INDIA

A 63-year-old businessman, from Tamil Nadu, with comorbidities of Diabetes Mellitus, Systemic Hypertension for 20 years and had history of NASH related cirrhosis for 10 years with preserved liver synthetic function (Child A). Patient underwent prophylactic endoscopic variceal ligation twice and has been on beta blockers.

In Dec 2021, he presented with mild right upper quadrant pain, excessive fatigue and weight loss of 10 kgs over two months. On clinical examination, he was stable with no signs of decompen- sation and performance status of 0.

On evaluation, AFP was elevated- 16345 IU/L. CT abdomen revealed ill-defined, 9.2 x 7.5 x 6.3 cm enhancing lesion- Suggestive of HCC.

**Right and main portal venous thrombosis,** Cirrhosis of liver with portal hypertension.

After multidisciplinary team discussion, he underwent Trans arterial chemo embolization and was started on Lenvatinib. Follow up imaging showed stable disease and patient was continued on Lenvatinib. In May 2022, PET CT revealed uptake along the edges of the lesion and patient underwent second TACE. Lenvatinib could not be continued further due to intolerability.

Patient was switched over to immunotherapy with atezolizumab 1200mg and bevacizumab 900mg for 11 cycles once in every three weeks. Following initiation of immunotherapy, AFP reduced gradually from 10820 IU/L to 834 IU/L.

Thus, successful downstaging was achieved in this patient with overall survival till date being 487 days. Patient is continued on immunotherapy and recent PET CT showed no active lesions and no uptake within portal vein thrombus.

Abstract Submission No. 100924

**O-0922**

**Malignant Hepatic Solitary Fibrous Tumor in a 28- year old Filipino male : A Case Report**

Erika Johanna Tañada1, Stephen N. Wong1, Carmelita D Dalupang1, Rene John D Felbo1, Hyacinth C Eviota,1, Jaqueline S. Arsenal1, Salahuddin C. Andam2, Maria Hossea C. Monfero1

1USTH Manila Philippines

**Background:** Hepatic Solitary fibrous tumor (HSFT) is a rare mesenchymal tumor with few cases reported in literature. Malignant cases of HSFT are even rarer occurrence, and information regarding the optimal management of the disease is currently limited. We present a case of an unresectable malignant giant HSFT in a 28-year old male.

**Case Presentation:** A 28-year old Filipino male with no known co-morbidities sought consult for right upper quadrant pain and weight loss for three months. Whole abdomen ultrasound showed a large predominantly solid mass. Dynamic CT showed a large heterogeneously enhancing mass almost occupying the entire liver with incomplete washout on portovenous and delayed phases. Serum AFP and CA 19-9 were unremarkable. Liver biopsy revealed a poorly differentiated malignancy with epithelioid features. Immunohistochemical staining were positive for CD34 and STAT6 clinching the diagnosis of solitary fibrous tumor. Multidisciplinary approach with referrals to hepatobiliary surgeon and oncologist was done. Tumor was deemed unresectable and patient was offered tyrosine kinase inhibitor for possible downstaging.

**Conclusion:** HSFT is a rare tumor and should be included in the differential diagnosis of liver lesions with atypical imaging findings. The best choice for treatment is complete surgical resection but for massive HSFT with limited hepatic residual volume, strategies to increase the resectability of the tumor is deemed important. More data are needed for unresectable HSFT and long-term follow-up is critical.

**Keywords:** case report; hepatic solitary fibrous tumor;
O-0923

AN UNUSUAL SYNERGY WITH DEPLETING ENERGY

Deepa Janakiraman¹, Nirmala Dheivamani¹, Sindhuja TA¹, Senthil Kumar R², Winston Thomas¹
¹Department of Paediatric Gastroenterology, MADRAS MEDICAL COLLEGE, INSTITUTE OF CHILD HEALTH, CHENNAI, TAMIL NADU, INDIA CHENNAI India

Introduction: Cryptogenic cirrhosis is now replaced by various genetic diagnoses, considerably bringing down the percentage of cryptogenic cirrhosis from 30% to 9%. Genetic basis should be suspected in multisystem involvement.

CASE REPORT: 12-year-old male child of 3rd degree consanguinity, presented with abdominal distension for one month, jaundice and easy fatigability for 10 days. Child had ascites, mild hepatic encephalopathy, INR 2.5, high SAAG low protein ascites and oesophageal varices on endoscopy suggestive of DCLD with portal-hypertension. Workup for Wilson, autoimmune and infective aetiologies were negative. Child was registered for liver transplantation (LT). But within 15 days of discharge, readmitted with Right Hemiparesis, left UMN facial palsy and bilateral ptosis suggesting nonvascular territory metabolic stroke. MRI showed diffuse diffusion restriction suggesting mitochondrial leukoencephalopathy. ALT was also elevated, hence diagnosis of Mitochondrial DNA Depletion syndrome (MPV17 related) was suspected, further confirmed with exome sequencing and managed with mitochondrial cocktail.

DISCUSSION AND CLINICAL SIGNIFICANCE: Of the 100 MPV17 related hepatonecphalopathy cases reported till date, 96% has infantile onset, while only 4% had childhood onset. None of the childhood onset had liver failure. To our knowledge ours is the 1st case of childhood onset Mitochondrial DNA depletion syndrome-6 with DCLD. Onset of neurological involvement precludes the option of LT for this child.

In the era of genomics, thorough evaluation including genetic testing for definitive aetiology of cryptogenic cirrhosis is warranted before proceeding for LT. In multi-system involvement, especially metabolic stroke with DCLD mitochondrial disease should be considered even in childhood.

Abstract Submission No. 101235
O-0925

A Case Report of Giant Cavernous Hepatic Hemangioma with Kasabach-Merritt Syndrome

Areangela Angeles¹, Jose Gullain E. Cataluna¹, Jemimah P. Fajardo¹
¹St. Luke’s Medical Center, Quezon City Quezon City Philippines

Cavernous hepatic hemangiomas are hypervascular, venous malformations which is considered as the most common benign mesenchymal lesions of the liver. The rate of spontaneous rupture ranges from 1% to 4%, occurring mostly in giant hemangiomas (6-25 cm), with a mortality rate that can reach up to 75%. The operative mortality rate of this complication is around 36.4%.

This is a case of a 22-year-old male with no known co-morbid illness with unremarkable family history and personal social history who presented for progressive sharp and stabbing abdominal pain. Laboratory examination showed anemia (Hgb 8.8), leukocytosis (WBC 10930), thrombocytopenia (58k). Whole Abdominal CT scan with intravenous contrast revealed a large heterogeneously predominantly hypodense exophytic right hepatic lobe mass (14x11.8x16.8cm) with intra luminal mural thrombus. Patient underwent Hepatic Angiogram with Gel and particle embolization of the branches of the right hepatic artery to control the bleeding, and blood transfusion. However, repeat Dynamic CT scan of the liver showed liver enlargement and progression of heterogeneous non-enhancing lobulated exophytic mass lesion (15.3x12.6x19.8 cm previously 14x11.8x16.8 cm) with signs of bleeding and increase in hyperdense fluid collection relating to hemoptoic tumour. Thus, the patient underwent Exploratory laparotomy with Excavation of Intraparenchymal Hematoma, Right Hepatectomy with Cholecystectomy on the background of adequate Functional Liver Reserve by Liver Volumetric Study.

On the third day post operatively, patient developed Pneumonia and recurrent Pleural Effusion with subsequent thoracentesis and pigtail drainage. Medical management resulted to marked improvement of the signs and symptoms and was subsequently discharged well.

Abstract Submission No. 101259
O-0926

A case of HCC with a remarkable response following duvelumab/tremelimumab after systemic therapy

TAKAYOSHI OIKAWA¹, Hidekatsu Kuroda¹, Asami Ito¹, Ippei Nakaya¹, Hiroaki Abe¹, Tamami Abe¹, Akiko Suzuki¹, Kei Endo¹, Yoichi Yoshida¹, Keisuke Kakisaka¹, Akio Miyasaka¹, Takayuki Matsumoto¹
¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Iwate Medical University Yahaba-cho Japan
**Introduction:** Durvalumab plus tremelimumab (DUR/TRE) is a new first-line treatment that combines immune checkpoint inhibitors for hepatocellular carcinoma (HCC) and is available worldwide. We herein report a case of HCC with a remarkable response to DUR/TRE as fourth-line treatment.

**Case:** A 76-year-old woman with chronic hepatitis B underwent radiofrequency ablation for HCC in 201X. In December 2021, a metastatic nodule was found on the subxiphoid process of the puncture route for ablation therapy. The patient underwent a computed tomography (CT)-guided tumor biopsy for a pathological examination and surgical treatment in February 2022. Subsequently, multiple lung metastases and peritoneal dissemination appeared, and she received sequential treatment with atezolizumab plus bevacizumab, lenvatinib, and sorafenib; however, disease progression was observed. The patient underwent DUR/TRE in April 2023. After three courses of DUR/TRE, a prominent tumor reduction was observed on CT. No adverse events were observed.

**DISCUSSION:** This patient did not respond to anti-PD-L1 antibody or a VEGF inhibitor but did respond to post-treatment DUR/TRE, suggesting that the anti-tumor effect of anti-CTLA-4 antibody was a possible response factor. In addition, the behavior of AFP suggests that tumor shrinkage may have been achieved early in the treatment period.

**Conclusion:** Combination therapy with anti-CTLA-4 antibody may be effective in the post-treatment of patients who have failed systemic treatment with anti-PD-L1 antibody or a multi-tyrosine kinase inhibitor.

Abstract Submission No. 101285

**O-0927**

**A Case of Hepatocellular Carcinoma 37 Years after Surgery for Truncus Arteriosus**

Yukie Nakadai1, Nobuhiito Taniki1, Ryousuke Kasuga1, Po-sung Chu1, Fumie Noguchi1, Takaya Tabuchi1, Mayuko Kondo1, Hidenori Ojima2, Matsuda Kosuke2, Hiroyuki Yamagishi3, Naofumi Sumitomo1, Yuta Abe4, Minoru Kitago4, Nobuhiro Nakamoto4, Takanori Kanai2

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University Tokyo Japan; 2Department of Pathology, School of Medicine, Keio University Tokyo Japan; 3Department of Pediatrics, School of Medicine, Keio University Tokyo Japan; 4Department of Surgery, School of Medicine, Keio University Tokyo Japan

**Background:** Patients who have undergone the Fontan procedure have been reported to develop Fontan-associated liver disease (FALD). However, reports of liver disease following other pediatric congenital heart disease surgeries are relatively rare.

**Case Presentation:** The patient is a 38-year-old male diagnosed with truncus arteriosus at 8 months of age and underwent the Rastelli procedure which connects the right ventricle to the pulmonary artery and patches the ventricular septal defect. At 38 years of age, he developed a 5 cm hepatocellular carcinoma (HCC) located in segment 3(S3) of the liver diagnosed by several contrast enhanced examination. Consequently, the patient underwent left hepatic lobectomy. However, he developed recurrent HCC six months after the surgery, followed by a total of six recurrences within two years post-surgery.

**Conclusion:** In patients with FALD, liver disease is thought to arise from chronic congestion due to elevated central venous pressure (CVP), a condition not typically seen after the Rastelli procedure, where CVP is managed through periodic right ventricular outflow tract reconstructions. In this case, although there was no noticeable elevation of liver enzymes, multiple HCC recurrences suggest a high potential for carcinogenesis, similar to FALD. A 1-year survival rate for HCC associated with FALD has been reported as 50% (Int J Cardiol 2021). It implies that HCC surveillance might be necessary not only for FALD patients but also for certain other types of postoperative congenital heart disease cases.

Abstract Submission No. 101315

**O-0928**

**Recurrence Of Myopathy After Liver Transplantation For Patients With End-Stage GSD Type IIIa**

HE WANG1, LIYING SUN1

1Department of critical liver diseases, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing China

Glycogen storage disease (GSD) is a hereditary metabolic disorder of glycogen metabolism. The total incidence of GSD is 1/20,000-43,000. Based on enzyme deficiency and affected tissues, GSD is divided into 12 types. Most patients with Type III GSD present disease in both the liver and muscles (referred to as Type IIIa), and 15% of patients have the disease restricted to just the liver (referred to as Type IIIb). We report here a case of a 28-year-old female patient with Type IIIa GSD. As the disease progressed to decompensated cirrhosis, she had a rupture of esophageal variceous veins with bleeding and a large amount of ascites. She underwent orthotopic liver transplantation (DCD) in our hospital at the age of 23. After the treatment, the patient’s signs of cirrhosis completely disappeared. However, six months ago, she presented with elevations in creatine kinase and occasional weakness in both lower limbs after exertion. Therefore, we improved coronary CTA, echocardiography, electromyography and other examinations, no obvious exception is displayed. Although cases of recurrence of myopathy due to cyclosporine administration have been reported internationally, this patient was on long-term oral tacrolimus. Creatine kinase showed a downward trend after oral administration of Coenzyme Q12. Our center will continue to follow this patient. This case warns us that a liver transplant cannot completely cure patients with type IIIa, and close follow-up is still needed after the operation.

Abstract Submission No. 101468

**O-0929**

**A Thirteen-years-old Child with Acute Pancreatitis and STEMI Mimics - A Diagnostic Dilemma**

Dr. Md. Kamal Parvej1, Dr. Mohammad Sarwar Alam1, Dr. Noshin Tabassum1, Dr. Mohammad Mazharul Islam1, Dr. Md. Akib Jahan1, Prof. Dr. Md. Khalequzzaman1

1Sir Salimullah Medical College, Dhaka Dhaka Bangladesh

**Background:** Infection is a very rare cause of acute pancreatitis (AP). AP may cause various ECG changes and simulating acute STEMI (pseudo-MI) is a very rare presentation. To our knowledge, simultaneous acute pancreatitis and acute myocarditis due to infection is seldomly reported in the literature.

**Case synopsis:** A 13 years child without any co-morbidity presented with fever, abdominal pain and chest pain. Severe AP was diagnosed on the background of typical abdominal pain, raised lipase and CT scan of abdomen. She was transferred to Coronary Care Unit due to acute severe chest pain. Examination revealed pulse- 180/min, cold periphery, B.P- 80/50 mm Hg, diffuse abdominal tenderness, bilateral basal crepitations. ECG showed STEMI, and she had raised troponin-I, NT ProBNP. Echocardiogram revealed regional wall motion abnormality with LVEF- 35%. She was treated conservatively and coronary
Successfully by EUS-guided Drainage
Walled-off Necrosis after Total Aortic Arch Replacement Treated
Long-term follow up of patient with occurrence of autoimmune hepatitis post-COVID-19 vaccination

Shuhei Arima, Tatsuo Kanda, Masayuki Honda, Mai Totsuka, Heppati, hepatitis post-COVID-19 vaccination
He never had abnormal liver function tests before. After one or two weeks of 2nd-COVID-19 vaccination (COMIRNATY), he felt fatigue or admitted dark urine, respectively, and visited his local doctor. He was then introduced and admitted to our department for the examination of his abnormal liver function tests. Laboratory data on admission were: AST, 150 IU/L; ALT, 831 IU/L; total bilirubin, 9.81 mg/dL; PT 77%; INR 1.16; ESR 31 mm/1hr; IgG, 2200 mg/dL; and anti-nuclear, 40-fold. Viral hepatitis markers and autoantibodies were negative. After 9 days of admission, liver biopsy was performed and liver histology indicated the compatible to autoimmune hepatitis (AIH), acute form. Despite of negative drug lymphocyte stimulation test to COVID-19 vaccine, AIH was confirmed by 16 points based on the international scoring system (1999). After 13 days, 60 mg daily of prednisolone was started and his liver function tests returned to within normal limits. After 2 years of onset, AST, 15 IU/L; ALT, 36 IU/L and IgG, 1451 mg/dL without any medication.

Conclusion: Patient with occurrence of AIH post-COVID-19 vaccination was followed up for almost two years and seems to have better prognosis with transient prednisolone administration. Further studies on this regard will be needed.

Abstract Submission No. 101539
O-0930

Long-term follow up of patient with occurrence of autoimmune hepatitis post-COVID-19 vaccination

Shuhei Arima, Tatsuo Kanda, Masayuki Honda, Mai Totsuka, Reina Sasaki-Tanaka, Shinji Kanezawa, Tomotaka Ishii, Naoki Matsumoto, Ryota Masuzaki, Hiroaki Yamagami, Masahiro Ogawa, Hirofumi Kogure

Conclusion: Clinicians should be aware that AP can mimic acute myocardial infarction/myocarditis.

Abstract Submission No. 101539
O-0931

Walled-off Necrosis after Total Aortic Arch Replacement Treated Successfully by EUS-guided Drainage

Yuma Inoue, Yutaka Yata, Noriyuki Nakajima, Yasuki Nakagawa, Hayato Miyamoto, Sayuri Takada, Koichi Ieko, Tsuneyuki Tanaka, Junichi Miyazaki, Hirotaka Ishizu

Discussion: AP may cause ST elevation mimicking STEMI. Myocarditis also causes chest pain, arrhythmia, myocardial injury and ECG changes mimicking acute MI. This was a very rare case simultaneous acute pancreatitis and myocarditis, hepatitis and multi organ failure. Conclusion: Clinicians should be aware that AP can mimic acute myocardial infarction/myocarditis.

Abstract Submission No. 101539
O-0932

Acute liver injury and bilateral pulmonary artery thrombosis due to Hypereosinophilic syndrome

Keishi Ouchi, Hiromasa Okamoto, Jun Inoue, Shigeyuki Kobayashi, Hiroshi Nagai, Daisuke Okamoto, Tomoo Manaka, Yoshihiro Nozawa, Atsushi Masamune

Background: Hypereosinophilic syndrome (HES) is a leukoproliferative disorder characterized by marked eosinophilia of unknown origin and organ damage due to tissue eosinophilia. Organ infiltration of eosinophils includes lymph nodes, skin, gastrointestinal tract, lungs, and liver, and acute hepatitis may occur if the liver is infiltrated. Venous thromboembolism (VTE) is a complication of HES, affecting approximately 25% of patients with HES and with a mortality rate of 5-10%. We herein report a case of HES with acute liver injury and bilateral PE associated with DVT.

Case presentation: A 46-year-old Japanese man was referred to our hospital because of a marked increase in eosinophils (22,870/μL) and elevated liver enzymes. A decrease in platelets and prothrombin time (PT, %) and an increase in fibrin were noted. Computed tomography (CT) showed thrombi of approximately 8 cm in both femoral veins. A bone marrow puncture examination revealed normal morphology of the eosinophils with slightly hyperplastic bone marrow. A liver biopsy revealed eosinophilic infiltration, hepatocyte necrosis, fibrosis and multiple thrombi. We suspected acute liver injury and DVT associated with HES, and started treatment with steroids and heparin. Four days...
after the start of treatment, sudden chest pain and cardiopulmonary arrest occurred. CT revealed bilateral pulmonary artery thrombosis, and though tissue plasminogen activator was administered, the patient died. **Discussion/Conclusion:** In the treatment of HES, it is important to examine for liver injury and DVT, and it is suggested that thrombi may lead to PE and should be evaluated and treated immediately and appropriately.

Abstract Submission No. 101892

**How to manage HCC patients with high-risk PE and high-risk bleeding: can we perform thrombolysis?**

Lutfi Zunardi1, 2, Novi Kurnianingsih1, 2, Setyasih Anjarwani1, 2

1Cardiology and Vascular department, Universitas Brawijaya, Dr. Saiful Anwar General Hospital Malang, Indonesia Malang, Indonesia, 2faculty of medicine, Universitas brawijaya malang indonesia

**Background:** Acute pulmonary embolism (PE) as the first sign of hepatocellular carcinoma (HCC) is a rare condition with high morbidity and mortality. Thrombus formation in hepatic vein is a marker of an advanced stage. Patients with high-risk PE require immediate reperfusion. Thrombolysis can be done quickly and easily, but it can also cause serious complications, especially with a high risk of bleeding.

**Case Illustration:** A 45-year-old man went to a private hospital’s ER with sudden shortness of breath (SOB). He was desaturrated and shocked. Acute PE was diagnosed after bedside TTE in the ER revealed RV dysfunction. We continued with the CT examination and found a thrombus in the PA, and we discovered a mass in the liver. We assessed patients with high-risk PE and high-risk bleeding. Advanced liver disease is a contraindication to thrombolysis. Thrombolysis options for this patient are surgical or CDT, but these are not available. We had to do thrombolysis under careful supervision and consider the risks and benefits. Thrombolysis was successful in stabilizing hemodynamics, but severe bleeding occurred after 24 hours. We treated the bleeding, and finally, the patient survived.

**Conclusion:** High-risk PE requires aggressive therapy, and advanced liver disease is a condition with a high risk of bleeding. If the bleeding risk is acceptable or we know how to treat bleeding complications, systemic thrombolysis should be considered. Patients treated with thrombolytic therapy show rapid improvement, which may lead to a lower rate of mortality and morbidity.

Abstract Submission No. 101934

**A case of type 1 diabetes complicated with nonalcoholic steatohepatitis and glycogenic hepatopathy**

Hirosi Mitsui1, Hiroto Miura1, Takeshi Hayashi1, Yurie Sakai1, Yurie Tokito1, Toru Matsui1, Tomoji Kato1, Katsuya Kobayashi1, Kenichiro Sekigawa1, Yoko Yamazaki1, Hidenshi Katsuta1, Ryosuke Tajiri2, Yukiko Kishida2

1Department of Gastroenterology, Tokyo Teishin Hospital Tokyo Japan, 2Department of Endocrinology and Metabolism, Tokyo Teishin Hospital Tokyo Japan

**Background:** Nonalcoholic steatohepatitis (NASH) is a well-known complication of type 2 diabetes. By contrast, we report here a marked steatohepatitis patient who has a history of type 1 diabetes.

**Case report:** A 29-year-old male with liver damage was referred to our hospital. Six years ago, he started injecting insulin after suffering from acute onset type 1 diabetes. However, he could not continue his diet therapy and his HbA1c level was elevated by over 10%. One year later, the levels of liver enzymes were elevated. The ultrasound examination revealed fatty change of the liver. His alcohol intake was scarce and discontinuation of the drugs did not restore the data, and adversely the levels of liver enzymes were worsened. He was finally admitted to our hospital and both diet therapy and blood sugar control were strengthened. After his body weight fell by 3 kg from 90 (body mass index, 26), the liver enzyme levels started to decrease. The biopsy specimen of the liver showed the findings of NASH with mild fibrosis. In addition, the hepatocytes were strongly stained with PAS indicating massive glycogen deposit. Comprehensively, both NASH and glycogenic hepatoctyes were thought to contribute to his liver damage. Five months later, the blood sugar level was well-controlled and the levels of liver enzymes were normalized.

**Conclusions:** If liver damage is seen in type 1 diabetes patients, both NASH and glycogenic hepatopathy should be considered.

Abstract Submission No. 101996

**Fibrolamellar Hepatocellular Carcinoma Treated with ALPPS: A Case Report**

Vivien Ang1, Juliet Cervantes1

1St. Lukes Medical Center Quezon City Quezon City Philippines

**Background:** Fibrolamellar hepatocellular carcinoma (FL-HCC) is a rare subtype of HCC accounting for 1% of primary liver cancers. It occurs mostly in young adults without underlying liver disease and complete resection is the preferred treatment. However, most are greater than 10 cm at the time of diagnosis, making resection challenging. Associating Liver Partition and Portal Vein Ligation For Staged Hepatectomy (ALPPS), which involves deportalization and in-situ parenchymal transection to induce rapid liver growth, allows resection of extensive tumors within a shorter period of 1-2 weeks making it an attractive surgical option for FL-HCC.

**Case Presentation:** A 25-year-old male was admitted in our institution for planned hepatectomy. Nineteen months prior, patient presented with recurrent epigastric pain. CT scan showed a mass in liver segments 4B, 5 and 8 confirmed by biopsy to be Fibrolamellar HCC. He was optimized for surgery; underwent coil embolization, selective internal radiation therapy, and was maintained on Lenvatinib. However, surveillance imaging showed increase in the size of the mass hence salvage ALPPS surgery was contemplated. After stage 1 of ALPPS, he developed Ischemic Reperfusion Injury and Acute Kidney Injury. However, he was able to recover and successfully completed stage 2 of ALPPS.

**Conclusions:** Given the rarity of FL-HCC, efficacy of treatments aside from surgery has not been established yet. Therefore, early diagnosis and meticulous planning for surgical resection are imperative in its treatment. ALPPS can be considered in select FL-HCC patients, keeping in mind the risk of higher morbidity weighed against the higher completion rate for hepatectomy.

Abstract Submission No. 102069
A20 haploinsufficiency complicated by autoimmune hepatitis

Taisei Iwasa1, Takao Miwa2, Shinji Unome1, Tatsunori Hanai2, Kenji Imai2, Koji Takai2, Masahito Shimizu2
1Seino Kosei Hospital Ono-cho Japan, 2Gifu University Graduate School of Medicine Gifu Japan

Aim: A20 haploinsufficiency (HA20) is a recently described autoinflammatory disease that manifests symptoms similar to those of Bechet’s disease. However, little is known about the involvement of the liver in HA20. Herein, we report a case of HA20 complicated by autoimmune hepatitis (AIH).

Case presentation: A 33-year-old woman was previously diagnosed with HA20 and chronic thyroiditis and was treated with prednisolone (PSL) (7.5 mg/day) and levothyroxine sodium hydrate (125 μg/day). She experienced general malaise and jaundice, and biochemical evaluation revealed elevated liver function with an aspartate aminotransferase level of 817 U/L, an alanine aminotransferase level of 833 U/L, and a total bilirubin of 8.3 mg/dL. Pathological evaluation of the liver biopsy revealed interface hepatitis and the patient was diagnosed with acute exacerbation of AIH. Upon increasing the PSL dose to 60 mg/day, the liver enzyme levels rapidly decreased. During tapering of PSL, azathioprine 50 mg/day was added, and there was no relapse of AIH with combination therapy of PSL 7 mg/day and azathioprine 50 mg/day.

Conclusion: This is the first report of biopsy-proven AIH in an Asian patient with HA20. This case has significant implications for the pathogenesis and treatment of AIH in patients with HA20.

Abstract Submission No. 200086
O-0937

Hematemesis Unveiling Gastric Tuberculosis: Emphasizing Diagnostic Value of Endoscopic Ultrasound

Ronell Lee1, Mary Anne G. Go1, Michael Louie O. Lim1, Elisa Francesca G. Mendoza1
1Chinese General Hospital and Medical Center Manila Philippines

In 2021, the Philippines ranked fourth globally in tuberculosis cases, with 650 individuals affected per 100,000, designating it as a high TB burden country. Gastric tuberculosis, though rare, poses diagnostic challenges due to clinical manifestations resembling more prevalent gastrointestinal pathologies. Gastrointestinal bleeding, typically associated with peptic ulcers, esophageal varices, or gastric malignancies, can occasionally indicate infectious processes like tuberculosis, especially in high-prevalence regions.

This report details the diagnostic journey of a 35-year-old male with recurrent hematemesis. Initial investigations, including upper gastrointestinal (GI) endoscopy and CT scans, failed to yield a definitive diagnosis. Subsequent GI endoscopy revealed a 2.0cm mucosal protrusion with a clean-based ulcer, emphasizing the importance of advanced diagnostic techniques like endoscopic ultrasound (EUS). EUS identified a hypoechoic lesion at the muscularis mucosa, with multiple hyperechoic lymph nodes. The fine-needle biopsy during EUS confirmed Mycobacterium tuberculosis (MTB) infection.

This case underscores the critical need for heightened clinical suspicion for gastric tuberculosis in patients with gastrointestinal bleeding when conventional diagnostic approaches fall short. It also highlights the significance of advanced diagnostic techniques like EUS for precise identification of submucosal lesions, potentially averting the need for more invasive measures such as resection. This report contributes to existing literature by emphasizing the value of a comprehensive diagnostic approach and the role of advanced imaging in accurately diagnosing gastric tuberculosis.

Abstract Submission No. 200113
O-0938

Eosinophilic Duodenitis with Concomitant Eosinophilic Esophagitis

Ronell Lee1, Patricia S. Te1
1Chinese General Hospital and Medical Center Manila Philippines

Eosinophilic esophagitis (EoE) and eosinophilic duodenitis, distinct inflammatory disorders affecting the esophagus and duodenum, present diagnostic challenge. This complexity is heightened when endoscopic findings in the duodenum are apparent while the esophagus remains visually unremarkable. Few reports discuss eosinophilic gastrointestinal involvement, and eosinophilic lesions in eosinophilic gastroenteritis are relatively uncommon. Identifiable endoscopic features exist for eosinophilic gastroenteritis, yet a definitive diagnosis based solely on these are insufficient. This case underscores diagnostic intricacies and advocates for a comprehensive approach to accurately identify these conditions.

We present a 29-year-old male with asthma, experiencing episodic epigastric pain and tenderness with loose stools post-travel from Japan. Initial diagnostics revealed marked leukocytosis (19000/μL) and peripheral eosinophilia (18%) and normal fecalysis result. Ciprofloxacin and Metronidazole started yet symptoms persisted. Upper gastrointestinal endoscopy done, esophagus was unremarkable with multiple superficial duodenal ulcers seen. Biopsies confirmed severe eosinophilic infiltration in the duodenum (>100/hpf) and tissue eosinophilia in the esophagus (>70/hpf). Patient was prescribed with Fluticasone inhaler as swallow, 220mcg, 2 puffs twice a day with noted improvement on symptoms upon follow-up.

This clinical case highlights diagnostic challenges with eosinophilic gastrointestinal disorders. The unexpected finding of eosinophilic esophagitis in a patient primarily presenting with eosinophilic duodenitis emphasizes the importance of meticulous evaluation and targeted biopsies when clinical suspicion remains high. The successful response to inhaled corticosteroids further supports the eosinophilic nature of the observed mucosal pathology, contributing to the evolving understanding of these disorders and guiding clinicians toward a detailed diagnostic approach for improved patient management.

Abstract Submission No. 200126
O-0939

Salmonella Infection Manifesting as Typhoid Hepatitis: An Uncommon Presentation of Common Disease

Nadira Sanjaya1, Maulana Suryamin2
1Internal Medicine Department, Faculty of Medicine Universitas Indonesia Jakarta Indonesia, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Persahabatan National General Hospital Jakarta Indonesia

Background: Typhoid is an infection caused by Salmonella typhi which is transmitted through fecal-oral route, hence the high number of incidence in developing countries. As an enteric infection, typhoid typically manifests as fever with enterocolitis symptoms. Here we present an unusual case of typhoid infection with prominent acute hepatitis manifestations.

Case presentation: A 50-year-old man had been experiencing fever for one week with a right upper quadrant abdominal pain which worsened one day before admission. He reported no complaints of enterocolitis symptoms other than nausea and abdominal pain which were
misinterpreted with probable cholecystitis. Laboratory tests showed elevated liver enzymes >3x the upper limit of normal, slightly elevated bilirubin levels, and elevated alkaline phosphatase and gamma-glutamyl transferase level, demonstrating an R factor for mixed type liver injury. Empirical antibiotic was given, abdominal ultrasound and computed tomography were performed yet revealed no signs of biliary abnormality. However, perportal edema suggesting parenchymal liver disease was seen. Further tests showed negative results for hepatitis A, B, C and other causes of liver injury were excluded. After two days, fever was still relapsing and other possible causes of infections were investigated, in which IgM for Salmonella was tested positive, confirmed with a blood culture. Patient was then treated with the drug of choice for Salmonella and responded well to the treatment.

**Conclusion:** Typhoid hepatitis is an unusual presentation of typhoid infection, but still a matter to be considered especially in developing countries. Early recognition and prompt treatment should be done to prevent further complications.

Abstract Submission No. 100306

O-0940

**Drug eluting nanoyarn integrated biliary metallic stents to prevent stent occlusion**

Priya Nair1, Deepthy Menon1, Binulal N S1, Harshavardhan B Rao2, Shanthi Nair1

1Amrita Institute of Medical Sciences Kochi India, 2MS Ramaiah University Bangaluru India

**Background:** Bile duct occlusion presents a significant therapeutic challenge and has serious clinical consequences including cholangitis and death. Biliary stenting using self-expanding metal stent (SEMS) is the current clinical practice to alleviate the obstruction in patients with malignant biliary obstruction (MBO). However, stent occlusion due to tumour in-growth or biliary sludge formation within the stent poses a significant challenge in maintaining stent patency. To achieve sustained palliative benefit of biliary stenting, both biliary sludge formation and tumour in-growth need to be addressed. In this study, we report the potential of a nanotechnology-driven strategy to provide localized drug elution for sustained durations on heparinized SEMS.

**Methodology:** Gemcitabine hydrochloride was incorporated within nanofibrous polymeric yarns of Polycaprolactone (PCL) and integrated with the heparinized SEMS. This Gemcitabine-laden nanoyarn integrated heparinized SEMS [Nanostent] was functional, akin to bare SEMS, when tested as per ASTM standards. In vivo safety and feasibility of Nanostents was evaluated by fluoroscopy guided endoscopic implantation in porcine bile ducts.

**Results:** In vitro drug release studies demonstrated its potential to elute Gemcitabine for a period of six months. Histological analysis proved stent patency up to six months, with minimal inflammation. The presence of Gemcitabine in blood was not detected, while remnant drug was present in the yarns on explanted stents even at 5 months, confirming sustained drug elution. Cholangitis was also not a significant issue in the animals with Nanostents.

**Conclusion:** This novel Nanostent could offer dual benefits of sustained drug elution and prolonged stent patency in MBO.

Abstract Submission No. 101035

O-0941

**Sucralfate vs proton pump inhibitor (PPI) vs combination post esophageal variceal band ligation**

Mayur Satal1, Arun Vaidya1, Abu Asim Ansari1, Vaibhav Padole1, JITendra Yadav1, Shashank Pujialwar1, Gautam Jain1, Tanmay Laxane1, Shrutit Mehta1, Chetan Saner1, Shubham Gupta1, Aditya Kale1, Biswa Patra1, Akash Shukla1

1Seth GS Medical College and KEM Hospital, Mumbai India

**Background:** Proton pump inhibitor (PPI) and sucralfate are commonly used for prophylaxis of post-endoscopic variceal band ligation (EVL) ulcer bleed. This study compares the outcomes of a combination of sucralfate and PPI vs sucralfate alone vs PPI alone post EVL.

**Method:** This was a single-centre, single-blind randomized trial involving 300 patients undergoing EVL using a multiband ligation device (VGRIPP). Prior use of PPI or sucralfate, anticoagulation, renal insufficiency, pregnancy, and pre-existing esophageal ulcers on endoscopy were excluded. Patients were randomized in 3 arms (100 each): PPI (pantoprazole 40 mg bd) alone, and sucralfate (1 g qid) alone or sucralfate plus PPI combination. The endoscopy was repeated after 14 days of medications. The primary endpoint was post-EVL ulcer bleed. Secondary endpoints were chest pain and post-EVL ulcer.

**Results:** The mean age was 43.56±13.14 years. 218 (72.6%) were males. The cause of portal hypertension was cirrhosis in 246 patients and non-cirrhotic portal hypertension in 54 patients. The mean number of bands applied per patient was 3. Post-EVL ulcer bleeding occurred in 93(3%) patients with no difference amongst the three arms. There was 1 (0.3%) ulcer bleed-related mortality. Post-EVL ulcers and chest pain were seen in 59(19.7%) and 45(15%) patients respectively which was similar in three arms.

**Conclusion:** There was no significant difference in post-EVL outcomes in the three arms.

Abstract Submission No. 101131

O-0942

**Outcome of upper Gastrointestinal bleeding secondary to PUD : Experience from Karachi, Pakistan**

Nimrah Mehek1, Nazish Butt2, Mohiuddin Dehwar3

1Jinnah Postgraduate Medical Centre Karachi Pakistan, 2Jinnah Postgraduate Medical Centre Karachi Pakistan, 3Jinnah Postgraduate Medical Centre Karachi Pakistan

**Objective:** To determine the outcome of upper Gastrointestinal bleeding (UGIB) secondary to Peptic ulcer disease (PUD).

**Study Significance:** This study will provide the outcome of PUD causing UGIB.

**Method:** This was a Retrospective, cohort study conducted at Gastroenterology department of JPMC, Karachi from Jan. 2022 till Dec. 2022. All patients with UGIB were included in the study. The data obtained was analyzed on the statistical software SPSS version 23.

**Result:** Total 1908 patients with UGIB were evaluated, out of which 142(13%) patients had PUD. The mean age of patients was 53±19 years, 97(68.3%) were male. Most common presenting symptom was hematemesis 117 (82.4%). Among risk factors, the most frequent association was found to be with use of Non-steroidal anti-inflammatory drugs (NSAIDS) 117 (78.6%). The most common endoscopic finding was of Forrest class (FC)-III ulcer.

Most commonly done endoscopic intervention was adrenaline sclerotherapy 19 (13.4%).

Rebleed occur in 20(14.1%). However, 6 (4.2%) presented with recurrent bleed. 15(12.6%), died at first week and one month mortality was 7 (4.9%).

**Conclusion:** PUD if not diagnosed and treated promptly can lead to serious complication like UGIB. Due to advent of interventional
endoscopy, UGIB Can be managed quite efficiently as compared to the past and mortality is expected to reduce.

Abstract Submission No. 101326  
O-0943

A Large Stone in Neglected CBD Stent Treated with Single-Operator Cholangioscopy Guided Lithotripsy

Hendra Koncoro1, Maria Mayasari2, Albertus Ardian Prawidyanto3

1Department of Internal Medicine, St Carolus Hospital Jakarta Indonesia, 2Department of Surgery, St Carolus Hospital Jakarta Indonesia, 3Department of Radiology, St Carolus Hospital Jakarta Indonesia

Biliary stent placement has become standard of care while facing benign biliary stricture after bile duct stone removal. Neglecting biliary stents prompts worries about enduring consequences. This report delivers prolonged impact, highlights clinical presentations, diagnostics and management. The goal is to remind clinician regarding complication of long term stent placement and the management needed to undergo this condition.

A 69-year-old male presented to the Emergency Department with complaints of abdominal bloating, nausea, and vomiting persisting for the last 2 months. The patient had a history of post-cholecystectomy with a retained biliary stent for the past 2 years. The patient missed follow-up appointments, resulting in the stent remaining in place without scheduled removal. Vital signs were within normal limits, with slight tachycardia. Physical examination revealed icteric sclera and epigastric tenderness. Pancreatic amylase was elevated at 169 U/L, lipase at 359 U/L, and bilirubin at 4.83 mg/dL. Ultrasound revealed proximal intra- and extrahepatic bile duct dilation. A CBD stent was identified during the ultrasound examination. The patient underwent stent removal and lithotripsy using the single-operator cholangioscopy guided lithotripsy (SpyGlass system). Post-procedure, the patient’s condition gradually improved, accompanied by a decline in pancreatic amylase and lipase levels (pancreatic amylase 100 U/L and lipase 214 U/L). Successful bile duct clearance was achieved, and the patient was discharged with a recommendation for further endoscopic evaluation.

Conclusion: The removal of the stent and lithotripsy using the SpyGlass system proved effective in managing choledocholithiasis in this patient with neglected biliary stent. This case highlights the importance of timely intervention to prevent ongoing complications.

Abstract Submission No. 101457  
O-0944

Comparison of severity of pancreatitis with and without diclofenac sodium in post ERCP patients

HAFIZ MUGHEES ATHER1

1FAISALABAD MEDICAL UNIVERSITY FAISALABAD Pakistan

Objective: To compare the severity of pancreatitis after ERCP.

Methods: Randomized controlled trial in which we enrolled 160 patients of either gender between age 20-70 years who presented with obstructive jaundice. Patients were divided into 2 groups. Group A was administered 75 mg of diclofenac sodium intramuscularly as an add on prophylactic therapy along with the standard treatment and Group B was administered with standard treatment alone. Patients were monitored for 48 hours for any complaint of abdominal pain and measurements of serum lipase and amylase at 4 and 24 hours after the procedure.

Results: At 4 hours : in group A patients mean serum amylase was 266.8 U/L ± 57.9 SD and it was 261.6 U/L ± 57.6 SD in group B patients (p=0.566). Mean serum lipase was 1061.1 U/L ± 279.3 SD in group A and it was 1018.6 U/L ± 281.5 SD in group B patients (p=0.345). At 24 hours: in group A patients mean serum amylase was 137.7 U/L ± 84.6 SD and it was 170.3 U/L ± 132.1 SD in group B patients (p=0.065). Mean serum lipase was 326.1 U/L ± 116.4 SD in group A and it was 362.1 U/L ± 137.2 SD in group B patients (p=0.071). PEP was 3.8% (n=3/80) in group A patients while it was 13.8% (n=11/80) patients in group B (p=0.025).

Conclusions: Efficacy of intramuscular diclofenac sodium for prophylaxis of post-ERCP pancreatitis was significantly better when compared with control group

Keywords: Diclofenac sodium, ERCP, post ERCP pancreatitis

Abstract Submission No. 200221  
O-0945

A novel Hemospray to tackle post-EVBL and post-Glue ulcer bleed patients

Mithra Prasad1, Mohan Prasad VG1, Vamsi Murthy1, Madhura Prasad1, Sunil Chacko Vargheese1, Srinivas Reddy1, Debapratim Routh1

1VGM Hospital Coimbatore India

Introduction: Post-EVBL ulcer bleed remains a dreaded complication with a high mortality rate (upto 50%). There have been usage of haemostatic techniques in various parts of the world, but none report high efficacy. We have formulated a novel technique of endoscopically delivering collagen powder to achieve haemostasis and wound healing in post-EVBL and post-Glue ulcer bleed patients

Aim:

Primary: To assess efficacy of collagen spray in achieving immediate haemostasis

Secondary: To assess efficacy of collagen spray in achieving ulcer resolution at week 3

Method: This is an interventional prospective single-centre study conducted over a 2-year period at VGM Hospital, India. Post -EVBL ulcers were graded as per the Jamwal and Sarin classification. We used endoscopically delivered collagen powder as the haemostatic agent. 37 patients were enrolled in a case-based manner. (21 post-EVBL ulcer, 16 post-glue ulcer). Endoscopic spraying of collagen powder was done and re-assessed in 48 hours. Surveillance endoscopy was done at week 3.

Results: We found that 92% of patients with the post- EVBL ulcer bleed and all patients with post-Glue therapy ulcers achieved complete haemostasis and ulcer resolution. Grades B, C and D of post- EVBL ulcers showed complete ulcer resolution, whereas Grade A ulcers showed no resolution. The spray did not show any side effects across the patient population.

Conclusion: The collagen spray offers a novel, safe and highly effective intervention to tackle post- EVBL and post-Glue ulcer bleed patients resulting in haemostasis and ulcer resolution in these otherwise difficult to tackle patient cohorts.
Akinori SUZUKI1, Yusuke TAKASAKI1, Daisuke NAMIMA1, Shigeto ISHI1, Toshibo FUJISAWA1, Hiroyuki ISAYAMA1
1Gazi university Ankara Turkey, 2Ankara hospital Ankara Turkiye

Background: Although EUS-HGS is an effective alternative treatment to ERCP, there is a risk of severe adverse events. In this study, we evaluated the risk factors of severe adverse events with EUS-HGS.

Methods: We retrospectively investigated the patients receiving with EUS-HGS from April 2017 to July 2023 at our hospital. The patients were divided into two groups, Group A; the patients with adverse events of Clavien-Dindo classification grade over III and Group B; the others. [Result] There are 192 cases in total, of which 24 are allocated into Group A and 168 into Group B. In patients factors, the ratio of male in group A is higher than group B. However, there is no significant difference with age, malignancy, performance status, ascites, antithrombotic drug, age adjusted Charlson Comorbidity Index (AA-CCI), Prognostic Nutritional Index (PNI). In procedural factors, the number of device replacements is higher in Group A than Group B. However, there is no significant difference with dilation of puncture needle, procedure time, metallic stent, diathermic sheath. Also, there are no difference in technical and clinical success rates. In multivariate analysis, high AA-CCI (p=0.02) and high number of device replacement (p=0.01) is revealed in risk factors.

Conclusion: We found that AA-CCI and device replacement were associated with severe adverse events. As the number of patients underwent EUS-HGS are elderly people with comorbidity, it is important to reduce the number of device replacement. In addition, for elderly patients with multiple comorbidities, sufficient preoperative explanation and postoperative management are necessary.

Abstract Submission No. 101909
O-0948

Thromboelastography and the risk of major bleeding after endoscopic variceal treatment in cirrhosis

Yan He1,2, Yuhang Yin1,2, Zhiyan Ren1,3
1General Hospital of Northern Theater Command Shenyang China, 2China Medical University Shenyang China, 3Dalian Medical University Shenyang China

Background: Gastroesophageal variceal bleeding (EGVB), a common complication of cirrhosis, is often treated by endoscopy. Thromboelastography (TEG) is a global viscoelastic test to evaluate the hemostatic status of cirrhotic patients. However, it is unclear about whether TEG can predict the risk of major bleeding after endoscopic variceal treatment in cirrhotic patients.

Methods: All cirrhotic patients who were consecutively admitted to the General Hospital of Northern Theater Command from August 2018 to August 2022 and underwent endoscopic variceal treatment and TEG test were retrospectively screened. According to the development of major bleeding after endoscopic variceal treatment, patients were divided into major bleeding group and non-major bleeding group. Logistic regression analyses were conducted to explore whether TEG parameters were significantly associated with the risk of major bleeding after endoscopic variceal treatment. Odds ratios (ORs) with their 95% confidence intervals (95%CIs) were calculated.

Results: Overall, 108 cirrhotic patients were included. Multivariate logistic regression analyses showed that only Child-Pugh class (A/B vs. C) (OR=0.053; 95%C=0.006-0.441, p=0.007) was independently associated with the risk of major bleeding after endoscopic variceal treatment. However, reaction time (R) (6.38 minutes vs. 6.35 minutes, p=0.180), coagulation time (K) (2.77 minutes vs. 3.16 minutes, p=0.778), angle (α) (63.07 degrees vs. 59.67 degrees, p=0.328), and maximum amplitude (MA) (51.70 mm vs. 49.00 mm, p=0.459) were not significantly different between major and non-major bleeding groups.

Conclusions: Major bleeding after endoscopic variceal treatment cannot be predicted by TEG parameters, but the severity of cirrhosis.

Abstract Submission No. 200238
O-0949

Experience with intraductal RFA for neoplasms of the major duodenal papilla with intraductal spread.

Yuri Starkov1, Ayubkhan I. Vagapov1, Rodion D. Zamolodchikov1, Seda V. Dzhantukhanova1
1Vishnevsky National Medical Research Center of Surgery Moscow Russia

Relevance: Due to the high risk of malignancy, all adenomas of the major duodenal papilla(MDP) must be removed. Currently, the method of choice for adenomas of the MDP is intraluminal endoscopic interventions, while neoplasms of the MDP with intraductal spread (types III and IV according to the classification typing of adenomas of the MDP) are particularly difficult for endoscopic techniques. The introduction of intraductal radiofrequency ablation into clinical practice
provides new opportunities for minimally invasive treatment of patients with adenomas of the MDP, including those with extensive spread to the bile ducts.

**Material and methods:** From 2022 to 2023, 11 patients with adenomas of the MDP with extension to the CBD and/or MPD underwent intraductal radiofrequency ablation. The extent of spread to the CBD ranged from 10 to 30mm, to the MPD-from 5 to 11mm.

**Results:** Technical success was achieved in all observations. Complications after performing intraductal RFA were noted in 4 cases: in 2 cases, post-manipulation pancreatitis developed, and in another 2 cases, during control cholangioscopy, residual adenomatous growths were revealed, and therefore these patients required a repeat session of intraductal RFA. Technical implementation of stenting of the MDP and CBD was achieved in all cases.

**Conclusion:** The use of intraductal RFA in the treatment of patients with adenomas of the MDP, characterized by extensive spread to the ducts, made it possible in all cases to ensure complete destruction of the intraductal component of the tumor with a lasting clinical effect without the need for highly traumatic surgical intervention.

**Abstract Submission No. 200239**

**Results of endoscopic operations for adenomas of the major duodenal papilla**

**Ayubkhan Vagapov**1, **Yuri G. Starkov**1, **Rodion D. Zamolodchikov**1, **Seda V. Dzhantukhanova**1

1Vishnevsky National Medical Research Center of Surgery Moscow Russia

**Relevance:** With the widespread introduction into clinical practice of modern highly informative methods of endoscopic examination, the incidence of neoplasms of the major duodenal papilla (MDP) has increased compared to the previous decade. Regardless of the presence of clinical manifestations, according to the majority of authors, adenomas of the MDP must be removed due to possible malignant transformation.

**Material and methods:** From 2005 to 2023 in the surgical endoscopic department of the National Medical Research Center of Surgery named after A.V. Vishnevsky comprehensively examined and operated on 149 patients with neoplasms of the major duodenal papilla. Of these, 134 patients underwent endoscopic interventions to remove tumors of the MDP.

**Results:** Radical removal of the adenoma of the major duodenal papilla was achieved in 90.5% of cases. Complications after endoscopic removal of adenomas were noted in 16.6% of cases: post-manipulation pancreatitis developed in 10 (7.9%) cases, bleeding developed in the postoperative period in 7 (5.5%) cases, and bleeding in another 4 (3.1%) cases. observations of perforation of the duodenal wall. During dynamic examination from 1 to 3 years, residual adenomatous growths were identified in 9.5% of cases.

**Conclusion:** The endoscopic classification of adenomas of the major duodenal papilla (Table 1) that we have developed allows us to determine the most effective and safe method of surgical intervention for each type of tumor by clearly defining the boundaries of the use of endoscopic technologies, as well as to unify the endoscopic description of the tumor to achieve continuity in monitoring patients by various specialists.

**Endoscopic classification of neoplasms of the major duodenal papilla.**

**Ayubkhan Vagapov**1, **Yuri G. Starkov**1, **Rodion D. Zamolodchikov**1, **Seda V. Dzhantukhanova**1

1Vishnevsky National Medical Research Center of Surgery Moscow Russia

**Aim:** Demonstrate the developed endoscopic classification of papillary tumors.

**Material:** at the surgical endoscopic department of the Surgical Endoscopy Department of the Vishnevsky National Research Medical Center for Surgery examined and treated 149 patients with papillary tumors.

**Classification:** Based on the analysis of research data from 149 patients, we have developed an endoscopic classification of papillary tumors, which consists of 4 types (table):

**Type I (ExtraPapillary):** a tumor with extrapapillary growth, localized within the papilla, without signs of spread to the duodenum and ducts.

**Type II (ExtraPapillary+Duodenum):** a tumor with extrapapillary growth and spread along the walls of the duodenum. Depending on the direction of tumor growth, 4 subtypes are distinguished: SP (Suprapapillary)-proximal from the papilla, IP (InfraPapillary)-distal from the papilla, LPR (LateroPapillary Right)-to the right of the papilla, LPL (LateroPapillary Left)-to the left of the papilla. There are also 2 additional subtypes: PD (Peri/Parapapillary Diverticulum)-on the walls of the para/peri-papillary diverticulum, and IM (Invasion Muscule)-invasion into the muscular layer of the duodenal wall.

**Type III (IntraDuctal):** tumor with intraductal spread. Depending on the involvement of the ducts in the tumor process, 4 subtypes are distinguished: CBD-on the common bile duct, MPD-on the main pancreatic duct, IA-localized exclusively within the ampulla, subtype CBD+MPD-on both ducts.

**Type IV (ExtraPapillary+IntraDuctal):** tumors with mixed extrapapillary and intraductal growth, that is, a combination of types I and III, or II and III.

**Conclusion:** Endoscopic classification of papillary tumors allows us to determine the most effective and safe method of surgical intervention for each type of tumor.

**Abstract Submission No. 100451**

**O-0952**

**Gut-Bone-Liver Axis: Interplay of Gut Microbiome and Myeloid Cells in MASLD**

**Yi Rou Bah**1, **Dayang N Asyiin**1, **Taku Emoto**2, **Nguan Soon Tan**1-3, **Kazuyuki Kasahara**1

1Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore Singapore Singapore, 2Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine Kobe Japan, 3School of Biological Sciences, Nanyang Technological University Singapore Singapore

**Aim:** To investigate the role of the gut microbiome on bone formation in Metabolic dysfunction-associated steatotic liver disease (MASLD) in a novel mouse model.

**Material and methods:**

To deplete gut bacteria,
Gut microbiota and metabolites dysbiosis of NASH-HCC and related neuropsychiatric disorders in mice

Vinji Liang¹, Jianmei Yang¹, Chenli Lin¹, Dongliang Chen¹, Yuanfei Wang¹, Wanyi Ou¹, Guiru Lin¹

¹Jinan University Guangzhou China

Background: NASH-HCC and related neuropsychiatric disorders are crucial causes of impaired health quality of life and mortality of liver disease. This study focused on the role of gut-liver-brain axis in NASH-HCC and related anxiety-depression-like behavior.

Methods: The NASH-HCC mice were established dynamically with Western diet plus CCL4 intervention for 12 and 24 weeks. Body weight, liver enzymes, pro-inflammatory factors and degree of liver fibrosis/cancer were recorded in detail. Meanwhile, behavioral changes were tested by OFT, TST and RPT. Dynamic changes in gut microbiota and serum metabolites were further detected through 16S rRNA and targeted metabolomics.

Results: NASH with stage 2.2 (±0.4) fibrosis occurred at 12 weeks, and indicators such as TC, TG, AST, ALT, and pro-inflammatory factors (IL-6, IL-1β, TNF-α) increased significantly. At 24 weeks, the degree of fibrosis worsened to stage 3 and 83% of mice had multiple tumors, with maximal size greater than 6 mm. Anxiety-depression-like behaviors emerged at 12 weeks and pronounced at 24 weeks. Multi-omics analysis suggested Faecalibaculum rodentium significantly surged at 12 and 24 weeks, accompanied with increased serum Arachidonic acid, bile acids, DL-Carnitine, FAHFA (10:0/16:1), LPC (18:5), Uric acid, and decreased Linoleic Acid, Acetyl-L-carnitine, LPC (20:4) etc., which enriched in lipid metabolism and carbon metabolism. Spearman correlation analysis showed that microbiota and related metabolites was significantly correlated with the concentration of pro-inflammatory factors.

Conclusion: Faecalibaculum rodentium and related metabolites including Arachidonic acid, bile acids, FAHFA (10:0/16:1), Acetyl-L-carnitine etc. induced inflammation might be gut-liver-brain axis mechanism in NASH-HCC and related neuropsychiatric disorders.
Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, and inadequate response to ursodeoxycholic acid (UDCA) poses a high risk of progression towards liver cirrhosis. Alterations of gut microbiota has been implicated in PBC, but the functional changes and their clinical implications remain largely enigmatic. In this study, we performed integrated analyses of gut metagenomics, serum and fecal metabolomics in UDCA treatment-naïve PBC (n=132) compared with healthy controls (n=131). We defined compositional and functional dysbiosis in the PBC gut microbiome, including a characteristic decrease in Clostridia taxa and concordant changes in microbial enzymes and metabolite pools (e.g., cholesterol derivatives). Notably, PBC metagenomes clustered into two community types represented by varying abundances of Clostridia taxa. The Clostridiaβ submetacommunity indicated an unfavorable response to UDCA compared to the Clostridiaα submetacommunity. Integrative analysis of metagenome and metabolome demonstrated a significant decrease of anti-inflammatory microbial activities (e.g., tryptophan metabolism and secondary bile acids) and a shift from fermentation to respiratory metabolism in the Clostridiaβ submetacommunity, indicating dysregulated immune responses and impaired intestinal barrier integrity. Furthermore, the Clostridiaα high microbiome showed a more complex microbial co-abundance network and more pronounced microbe-host interactions. Finally, the association of microbial metacommunities and treatment response was validated in an independent cohort. Our study suggests that inter-individual variations in PBC gut microbiome may impact heterogeneity in therapeutic efficacy, highlighting the potential of using microbiota-based approach for personalized interventions.

Abstract Submission No. 101339
O-0958

The association of H. pylori infection with Minimal Hepatic Encephalopathy in Child A and B Cirrhosis

Jacob Raja A S1, Srijaya S Sreesh1, Jesse J Skariah1, Antony George1, Nuzil Moopan1, Aditya Verma1, Krishnadas Devadas1

1Department of Medical Gastroenterology Thiruvananthapuram India

INTRODUCTION: Hepatic encephalopathy includes a spectrum of transient and reversible neurological and psychiatric manifestations found in patients with chronic liver disease and portal hypertension. The least severe form of Hepatic Encephalopathy (HE), which is not recognized on clinical examination is Minimal hepatic encephalopathy (MHE) that profoundly impairs Health Related Quality of Life (HRQOL). This study aimed to estimate the proportion of MHE in patients with Child A & B Cirrhosis, the factors associated with MHE and the prevalence of H. pylori infection among them.

METHODS: Cross-sectional study done among the patients diagnosed to have Child A & B cirrhosis. After baseline investigations and endoscopy, MHE was diagnosed by psychometric tests. H. pylori infection was identified by gastric biopsy.

RESULTS: Out of 260 patients included in our study, the prevalence of MHE in Child A & B cirrhosis was 60% (n=156). H. pylori infection was found in 131 out of 260 patients. In patients with MHE, 98 patients (74.8%) had H pylori infection (p<0.001), whereas 53 patients (51.5%) had H pylori infection in non-MHE group, which is statistically significant. MHE was more among Child B patients (p=0.01). Among the factors influencing MHE, Frailty was found in 79% (n=83) with MHE (p=0.001).

CONCLUSION: The burden of MHE is substantial in patients with cirrhosis with no apparent cognitive defect. This study proves that the prevalence of H pylori is significant in patients with MHE. Therefore, an additional benefit of H pylori eradication in the treatment of MHE in patients with Child A & B cirrhosis needs to be explored to identify the causative role of H pylori in MHE.

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, and inadequate response to ursodeoxycholic acid (UDCA) poses a high risk of progression towards liver cirrhosis. Alterations of gut microbiota has been implicated in PBC, but the functional changes and their clinical implications remain largely enigmatic. In this study, we performed integrated analyses of gut metagenomics, serum and fecal metabolomics in UDCA treatment-naïve PBC (n=132) compared with healthy controls (n=131). We defined compositional and functional dysbiosis in the PBC gut microbiome, including a characteristic decrease in Clostridia taxa and concordant changes in microbial enzymes and metabolite pools (e.g., cholesterol derivatives). Notably, PBC metagenomes clustered into two community types represented by varying abundances of Clostridia taxa. The Clostridiaβ submetacommunity indicated an unfavorable response to UDCA compared to the Clostridiaα submetacommunity. Integrative analysis of metagenome and metabolome demonstrated a significant decrease of anti-inflammatory microbial activities (e.g., tryptophan metabolism and secondary bile acids) and a shift from fermentation to respiratory metabolism in the Clostridiaβ submetacommunity, indicating dysregulated immune responses and impaired intestinal barrier integrity. Furthermore, the Clostridiaα high microbiome showed a more complex microbial co-abundance network and more pronounced microbe-host interactions. Finally, the association of microbial metacommunities and treatment response was validated in an independent cohort. Our study suggests that inter-individual variations in PBC gut microbiome may impact heterogeneity in therapeutic efficacy, highlighting the potential of using microbiota-based approach for personalized interventions.

Abstract Submission No. 101339
O-0958

The association of H. pylori infection with Minimal Hepatic Encephalopathy in Child A and B Cirrhosis

Jacob Raja A S1, Srijaya S Sreesh1, Jesse J Skariah1, Antony George1, Nuzil Moopan1, Aditya Verma1, Krishnadas Devadas1

1Department of Medical Gastroenterology Thiruvananthapuram India

INTRODUCTION: Hepatic encephalopathy includes a spectrum of transient and reversible neurological and psychiatric manifestations found in patients with chronic liver disease and portal hypertension. The least severe form of Hepatic Encephalopathy (HE), which is not recognized on clinical examination is Minimal hepatic encephalopathy (MHE) that profoundly impairs Health Related Quality of Life (HRQOL). This study aimed to estimate the proportion of MHE in patients with Child A & B Cirrhosis, the factors associated with MHE and the prevalence of H. pylori infection among them.

METHODS: Cross-sectional study done among the patients diagnosed to have Child A & B cirrhosis. After baseline investigations and endoscopy, MHE was diagnosed by psychometric tests. H. pylori infection was identified by gastric biopsy.

RESULTS: Out of 260 patients included in our study, the prevalence of MHE in Child A & B cirrhosis was 60% (n=156). H. pylori infection was found in 131 out of 260 patients. In patients with MHE, 98 patients (74.8%) had H pylori infection (p<0.001), whereas 53 patients (51.5%) had H pylori infection in non-MHE group, which is statistically significant. MHE was more among Child B patients (p=0.01). Among the factors influencing MHE, Frailty was found in 79% (n=83) with MHE (p=0.001).

CONCLUSION: The burden of MHE is substantial in patients with cirrhosis with no apparent cognitive defect. This study proves that the prevalence of H pylori is significant in patients with MHE. Therefore, an additional benefit of H pylori eradication in the treatment of MHE in patients with Child A & B cirrhosis needs to be explored to identify the causative role of H pylori in MHE.

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease, and inadequate response to ursodeoxycholic acid (UDCA) poses a high risk of progression towards liver cirrhosis. Alterations of gut microbiota has been implicated in PBC, but the functional changes and their clinical implications remain largely enigmatic. In this study, we performed integrated analyses of gut metagenomics, serum and fecal metabolomics in UDCA treatment-naïve PBC (n=132) compared with healthy controls (n=131). We defined compositional and functional dysbiosis in the PBC gut microbiome, including a characteristic decrease in Clostridia taxa and concordant changes in microbial enzymes and metabolite pools (e.g., cholesterol derivatives). Notably, PBC metagenomes clustered into two community types represented by varying abundances of Clostridia taxa. The Clostridiaβ submetacommunity indicated an unfavorable response to UDCA compared to the Clostridiaα submetacommunity. Integrative analysis of metagenome and metabolome demonstrated a significant decrease of anti-inflammatory microbial activities (e.g., tryptophan metabolism and secondary bile acids) and a shift from fermentation to respiratory metabolism in the Clostridiaβ submetacommunity, indicating dysregulated immune responses and impaired intestinal barrier integrity. Furthermore, the Clostridiaα high microbiome showed a more complex microbial co-abundance network and more pronounced microbe-host interactions. Finally, the association of microbial metacommunities and treatment response was validated in an independent cohort. Our study suggests that inter-individual variations in PBC gut microbiome may impact heterogeneity in therapeutic efficacy, highlighting the potential of using microbiota-based approach for personalized interventions.

Abstract Submission No. 101339
O-0958

The association of H. pylori infection with Minimal Hepatic Encephalopathy in Child A and B Cirrhosis

Jacob Raja A S1, Srijaya S Sreesh1, Jesse J Skariah1, Antony George1, Nuzil Moopan1, Aditya Verma1, Krishnadas Devadas1

1Department of Medical Gastroenterology Thiruvananthapuram India

INTRODUCTION: Hepatic encephalopathy includes a spectrum of transient and reversible neurological and psychiatric manifestations found in patients with chronic liver disease and portal hypertension. The least severe form of Hepatic Encephalopathy (HE), which is not recognized on clinical examination is Minimal hepatic encephalopathy (MHE) that profoundly impairs Health Related Quality of Life (HRQOL). This study aimed to estimate the proportion of MHE in patients with Child A & B Cirrhosis, the factors associated with MHE and the prevalence of H. pylori infection among them.

METHODS: Cross-sectional study done among the patients diagnosed to have Child A & B cirrhosis. After baseline investigations and endoscopy, MHE was diagnosed by psychometric tests. H. pylori infection was identified by gastric biopsy.

RESULTS: Out of 260 patients included in our study, the prevalence of MHE in Child A & B cirrhosis was 60% (n=156). H. pylori infection was found in 131 out of 260 patients. In patients with MHE, 98 patients (74.8%) had H pylori infection (p<0.001), whereas 53 patients (51.5%) had H pylori infection in non-MHE group, which is statistically significant. MHE was more among Child B patients (p=0.01). Among the factors influencing MHE, Frailty was found in 79% (n=83) with MHE (p=0.001).

CONCLUSION: The burden of MHE is substantial in patients with cirrhosis with no apparent cognitive defect. This study proves that the prevalence of H pylori is significant in patients with MHE. Therefore, an additional benefit of H pylori eradication in the treatment of MHE in patients with Child A & B cirrhosis needs to be explored to identify the causative role of H pylori in MHE.
Knowledge and awareness of probiotics dietary sources assessments: gut-liver axis in focus.

Nazeha A. Khalil1, Eman Abdelsameea2, Honglin Dong3

1Associate Prof. of Nutrition and Food Sciences department, Menoufia University, Menoufia Egypt, 2Professor of Hepatology and Gastroenterology, National Liver Institute, Menoufia University Menoufia Egypt, 3London City University London UK

Background & aims: Gut Microbiome (GM) dysbiosis is well known by their alternated compositions and activities that have been shown strong association to different human health problems such as chronic liver diseases (CLD). However, maintain a healthy gut could be achieved by healthy dietary pattern including prebiotics and probiotics dietary sources. This study aimed to measure the awareness and knowledge levels of probiotics dietary sources between Hepatology and Gastroenterology specialties comparing to chronic liver diseases patients (CLDP) visiting the national liver institute (NLI), Egypt additionally to CLDP nutritional assessment in association to their healthy gut.

Methods: A cross-sectional study in 4-armed questionnaires applied between 22 CLDP including anthropometric, Social-economic, health status and nutritional assessment (foods, dietary habits history & 24 hour recall) forms additionally to 42 doctors within their awareness & knowledge for probiotics dietary sources.

Results: Data illustrated lack of understanding and usage of probiotics dietary sources consumptions between CLDP and doctors whom do not fully understood the differences between the probiotics dietary sources thus increasing probiotic dietary sources awareness are needed not only for CLDP but also for doctors.

Conclusions: Educational awareness program with probiotics dietary sources should be raised at least once a month to the NLI visitors and the Egyptian healthcare experts/doctors with different photos additionally to clarifying their sources and roles within the GM association (gut-liver axis). However, much more probiotics dietary interventions are needed.

Intestinal permeability in cirrhosis: Correlation of biomarkers and urine polyethylene glycol

Moinak Sen Sarma1, Ashish Gupta2, Nitu Singh1, Ujjal Poddar1, Anshu Srivastava1, Amrita Mathias1, Chintmay Sahu1, Ujjwala Ghoshal1, Uday Ghoshal3

1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India, 2Center of Biomedical Research Lucknow India, 3Dept of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India, 4Dept of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

Introduction: Increased intestinal permeability (IP) is the gateway to a cascade of events in cirrhosis. Polyethylene glycol (PEG) is an upcoming tool to assess IP. Zonulin and intestinal fatty acid binding protein (IFABP) are biomarkers of tight-junctions and epithelial damage. We aimed to evaluate and interrelate the biomarkers of gut integrity and PEG in cirrhosis.

Methodology: Cirrhotic children and controls (extrahepatic portal-venous obstruction) were prospectively enrolled. Five hours after ingestion of 1 gm/kg of PEG3350, urine was collected and processed by proton-nuclear magnetic resonance (1H-NMR) spectroscopy to derive the integrated-PEG (I-PEG) value (area under the peak-curve). Serum intestinal fatty acid binding protein (IFABP) and zonulin were assessed on the same day. With the risk factors, a model was created to predict outcome in cirrhotics.

Results: Cirrhotic children (n=56) versus controls (n=35), aged (13.7±3.5 vs. 10.6±2.9 years, p=0.6) had I-PEG (12.9±5.1 vs 3.8±4.2, p=0.02), zonulin (96.6±24 vs 16.3±5.1 ng/mL, p<0.01) and IFABP (4.9±3.3 vs. 1.8±1.2 ng/mL, p=0.01). Among cirrhotics, I-PEG was significantly higher in decompensated (n=20) vs. recompensated (n=36) patients (11.8±7.1 vs 4.9±3.9, p=0.03) and large vs. small esophageal varices (12.4±4.8 vs 6.3±2.2, p=0.03). I-PEG correlated with IFABP (r=0.77, p<0.01), zonulin (r=0.88, p<0.01) and pediatric end-stage liver disease (PELD) score (r=0.67, p=0.03). Zonulin >25ng/mL (OR:3.08, CI:1.05-4.12, p<0.01) and I-PEG>5 (OR:3.19, CI:2.2-7.73, p=0.01) were independent predictors of hospital readmissions over next 6 months. The risk factor model (AUROC:0.87, p<0.001, 92% sensitivity:60% specificity) predicted morbidity better than isolated PELD or Child-Turcotte-Pugh scores.

Conclusions: I-PEG and zonulin risk factor model predicts short-term morbidity in cirrhotic patients.

Antagonism of Gut R. gnavus and A. muciniphila Modulates the Clinical Course of Chronic Hepatitis B

Yen-Hsuan Ni1, Huey-Huey Chua1, Ya-Hui Chen1, Li-Ling Wu2, Hung-Chih Yang1, Pei-Jer Chen1

1College of Medicine, National Taiwan University Taipei Taiwan, 2National Yang-Ming Chiao-Tung University Taipei Taiwan

Delayed HBeAg seroconversion (HBe-SC) in patients with chronic hepatitis B (CHB) increases risk of progression to severe liver diseases. HBe-SC is mainly due to immune interaction between HBV and the host, but the details remain elusive. We hypothesized gut microbiota trigger the immune reactions to lead to HBe-SC through gut-liver axis. Patients with CHB (n=102) in different disease phases were recruited. HBV-hydrodynamic injection (HDI) mouse model was established. Multi-platform metabolomics assays were performed to explore the role of gut microbiota. Ramitococcus gnavus was found to be the most abundant in patients with immune-tolerance (IT) and poor response to antiviral treatments. Akkermansia muciniphila was highly enriched in patients who underwent HBe-SC in an immune-active (IA) state. This observation was proven by HBV-HDI mouse models in BALB/c, C57BL/6J, C3H/HeN and germ-free mice. Patients of IT phase demonstrated a higher level of cholesterol to bile acids (BAs) metabolism than those of IA phase. Outgrowth of R. gnavus prolonged HBV persistence via increasing BAs metabolism in mouse models. R. gnavus encoded bile salt hydrolase to deconjugate the primary BAs and control the total pool of BAs. A. muciniphila counteracted R. gnavus through A. muciniphila’s secretome metabolites, which comprised of small molecules structurally similar to apigenin, lovastatin, ribavirin etc., and their cholesterol-lowering, antibacterial and antiviral properties may finally lead to HBV elimination. In conclusion, R. gnavus and A. muciniphila play opposite roles in HBe-SC and the bacterial metabolites of A. muciniphila highlight the targets of future anti-HBV therapy.
The Novel Findings in Liver Ischemia-Reperfusion Injury - Fasting and Short-Chain Fatty Acids-

Yuki Kidoguchi1, Yoichiro Uchida1, Hiroshi Kawamoto1, Junya Kawase2, Tomoyuki Miyazaki2, Kosuke Tanaka1, Kenichi Saga1, Kentaro Kadono2, Hirofumi Hirao1, Shoichi Kageyama1, Koijro Nakamura1, Takeshi Watanabe1, Hiroaki Terajima1, Etsuo Hatano1

1Department of Surgery, Graduate School of Medicine, Kyoto University Kyoto Japan, 2Department of Gastroenterological Surgery and Oncology, Kitano Hospital Medical Research Institute Osaka Japan, 3Division of Immunology, Institute for Frontier Life and Medical Sciences, Kyoto University Kyoto Japan

Background: Liver ischemia-reperfusion injury (IRI) is an important issue to overcome in liver surgery and transplantation. Diet restriction has demonstrated the protective effects against several organs. Additionally, short-chain fatty acids (SCFAs), which are produced in intestinal environment by dietary fibers, have anti-inflammatory effects. This study aimed to reveal the impact of fasting and SCFAs in liver IRI.

Methods: We performed two different approaches to control liver IRI in mice by applying partial warm hepatic IRI model. Firstly, the 12-hour fasting was performed before IR setting. The control IR group was given food and water ad libitum, while the fasting IR group was only water for 12-hour before the IR insult. We also performed another experiment evaluating the impact of diet with SCFAs on liver IRI. Mice were fed either a control ordinary diet (CD) or an inulin diet (ID) for two weeks before the IR insult. We also performed another experiment evaluating the impact of diet with SCFAs on liver IRI. Mice were fed either a control ordinary diet (CD) or an inulin diet (ID) for two weeks before the IR insult. We assessed for their impact on immune responses, liver damage and histological changes.

Results: IR induced-liver damage was significantly ameliorated in both the fasting IR group and ID group. Short-term fasting significantly upregulated Forkhead Box O1, induced by increased β-hydroxybutyric acid, leading to remarkable mitigation. In ID group, bacteria acidifaciens was increased in feces, which resulted in the elevation of SCFAs such as propionate in the portal vein. Propionate administration before IR onset markedly improved liver IRI.

Conclusion: The changes of intestinal environment by preoperative short-term fasting or SCFAs might have significant influence in mitigation liver IRI. Our trials may offer potential clinical benefits.
Introduction: Bleeding from esophageal varices still carries a significant mortality risk. Aim: Evaluate the treatment effectiveness of three treatment method: Endoscopic band ligation, transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation for cirrhotic patients with GI bleeding due to portal hypertension.

Patients & methods: Cirrhotic patients with GI bleeding were divided into three groups. Patients have complete records, clinical examination, rate of hemostasis and complications after treatment.

Results: * Group of endoscopic band ligation (n = 178): Age: 46.8; male/female: 3.9. Child-Pugh: 92%. Severe GI bleeding: 48.8%. Rate of hemostasis: 92.6%. Eradication of varices: 76.3%. Rate of rebleeding after 6 and 12 months, respectively 12.9% and 17.4%.

* Group of TIPS (n = 64): Age: 49.5; male/female: 8/1. Child-Pugh: 92%. Number of GI bleeding: 4.3 (1-20 times). Rate of hemostasis: 98.5%; Rate of bleeding: 25%. Hepatic encephalopathy: 35.9%. Mortality: 20.3%.

* Group of liver transplantation (n = 17): Age: 43.4; Male/female: 13/4. History: Number of ligation endoscopy: 3.9 times (3-6 times). Successful liver transplant: 17/17 (100%). No serious complication.

Conclusion: Liver transplantation is the ideal method for cirrhotic patients with GI bleeding due to portal hypertension.

Predictors of liver-related readmissions in cirrhotic patients: a retrospective study

Rui Huang1, Lin Zhang1

1Peking University People's Hospital Beijing China

Background: Cirrhosis leads to a high risk of death and readmission as well as severe complications.

Methods: To research the predictors influencing cirrhotic patients' readmission, we conducted a retrospective study. Collecting sociodemographic, clinical, and hospitalization characteristics and defined the primary endpoint as the first liver-related readmission occurring within 30 and 90 days following the initial hospitalization. Adult patients admitted with cirrhosis in our hospital spanned from January 2009 to December 2022. Differences between groups were analyzed using the Student’s t-test and chi-square test. Logistic regression analysis and multiple linear regression analysis were performed to identify predictors associated with readmission and the length of the first hospitalization.

Results: A total of 1285 patients were admitted with cirrhosis. Among these patients, 767 (59.7%) were males and the mean age was 58.9 ± 12.3 years. 72 (5.6%) and 154 (12.0%) individuals were readmitted within 30 and 90 days. Compared with those not readmitted, patients readmitted in 30-day and 90-day had a higher proportion of males, ascites, spontaneous bacterial peritonitis and electrolyte abnormalities, Child-Pugh-Turcotte scores, as well as a higher prevalence of longer initial hospital stays and initial hospitalization costs. The logistic regression analysis saw hepatic encephalopathy, spontaneous bacterial peritonitis are predictors within 30-day readmission, and diabetes, hepatic encephalopathy, ascites, and spontaneous bacterial peritonitis within 90-day readmission. The cost for the first admission, hospitalization and spontaneous bacterial peritonitis were significant predictors of the length of hospitalization.

Conclusions: Cirrhotic patients who presented with hepatic encephalopathy, ascites, and spontaneous bacterial peritonitis were at a higher risk of rehospitalization.

Outcomes during hospitalization in cirrhotic patients with multidrug-resistant bacterial infection

Kessarin Thanapirom1,2,3, Naprawee Changsiriwattanathamrong4, Prooksaa Ananchuensook1,2,3, Sombat Treeprasertsuk1, Piyawat Komolmit0

1Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Center of Excellence in Liver Fibrosis and Cirrhosis, Chulalongkorn University Bangkok Thailand, 3Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand, 4Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand

Background: This study aimed to investigate the clinical impact of multidrug-resistant (MDR) bacterial infection and outcomes in hospitalized patients with cirrhosis.

Methods: We consecutively enrolled hospitalized cirrhotic patients with bacterial infections admitted to the Chulalongkorn University Hospital, Bangkok, Thailand, from 2018 to 2021. Clinical outcomes during hospitalization in patients with MDR and non-MDR infection were evaluated.

Results: Overall, 323 patients (aged 65.1 ± 15.2 years) had bacterial infection, with a mean Child-Pugh score of 8.8 ± 2.1. Nosocomial and healthcare-associated infection was identified in 88 (27.2%) and 100 (31.0%) patients. MDR bacterial infections were found in 27.9% of patients (n=90). In patients with MDR infection, the most isolated bacteria were E. coli (60%, n=54), Acinetobacter sp. (18%, n=20), Klebsiella sp. (13.8%, n=12), and Enterococci (8.9%, n=8). Urinary tract infection (31.1%, n=287), pneumonia (8.9%, n=28), and spontaneous bacterial peritonitis (11.1%, n=10) were the most frequent MDR infections. Patients with MDR infection had higher rates of septic shock (52.2% vs. 19.7%, p<0.001), organ failure (67.8% vs. 42.9%, p<0.001), invasive ventilator use (56.7% vs. 23.6%, p<0.001), and ICU admission (41.1% vs. 19.3%, p<0.001) than those with non-MDR infection. Moreover, patients with MDR infection had a higher in-hospital mortality than non-MDR bacterial infection. (44.4% vs. 30%; p=0.014). Multivariate analysis showed that nosocomial infection (OR=3.75; 95%CI: 2.17-6.48, p<0.001), chronic kidney disease (OR=2.62; 95%CI: 1.22-5.64, p=0.01), and hospitalization in previous three months (OR=1.80; 95%CI: 1.06-3.04, p=0.03) were independent predictors of MDR infection.

Conclusion: MDR infection was found in 27.9% of cirrhotic patients and was associated with high mortality and poor outcomes during hospitalization. Nosocomial infection, chronic kidney disease, and recent hospitalization are risk factors for MDR infection.

High disease burden of significant portal hypertension in diabetic chronic hepatitis B

Grace Wong1,2,3, Lilian Liang1,2,3, Yichong Jiang1,2,3, Terry Yip1,2,3, Jimmy Lai4, Vincent Wong1,2,3

1The Chinese University of Hong Kong Hong Kong Hong Kong, 2Medical Data Analytics Centre (MDAC) Hong Kong Hong Kong, 3Institute of Digestive Disease Hong Kong Hong Kong

Objective: Antiviral therapy with oral nucleos(t)ide analogues (NAs) is effective in suppressing serum hepatitis B virus (HBV) DNA and

Abstract Submission No. 100174
O-0966

Abstract Submission No. 100275
O-0968
reducing the risk of portal hypertension. Yet, NA treatment cannot completely abolish the risk of portal hypertension, especially in those with diabetes mellitus (DM). We aimed to evaluate the disease burden of significant portal hypertension in patients with chronic hepatitis B (CHB) and DM (CHB-DM) who have been receiving NAs. Methods: Consecutive NA-treated CHB-DM patients were recruited for transient elastography examination to measure the spleen stiffness measurement (SSM). Significant portal hypertension was defined as a SSM > 41.3 kPa, and/or presence any clinical sign of portal hypertension (e.g., splenomegaly, ascites, varices). Results: We recruited 260 CHB-DM patients with successful SSM; their mean age was 64±11 years; 66.2% were male. The median (interquartile range) of SSM was 17.0 (22.7-21.1) kPa. The prevalence of significant portal hypertension was 29.2%, defined with SSM > 41.3 kPa in 11.9%, splenomegaly in 22.7%, ascites in 13.5% and varices in 26.9%. Patients with significant portal hypertension had less satisfactory control of DM (HbA1c 7.8% vs. 6.7%, p=0.017). Conclusion: Significant portal hypertension is common in CHB-DM patients. Suboptimal glycaemic control associated with significant portal hypertension. New generations of antidiabetic agents, namely sodium-glucose co-transporter-2 inhibitors (SGLT2i) are promising for portal hypertension. New generations of antidiabetic agents, namely patients. Suboptimal glycaemic control associated with significant complications from portal hypertension in CHB-DM patients with cACLD. O-0969

Comparison between predictors of mortality in patients of chronic liver disease, barring ACLF

AKSHAY KALE1, ASHISH KUMAR1, ANIL ARORA4, PRAVEEN SHARMA1, PIYUSH RANJAN1, MANDHIR KUMAR2, RAJAT KALRA1

1SIR GANGARAM HOSPITAL, NEW DELHI, INDIA NEW DELHI India

Background: Complications of Chronic liver disease carries high mortality risk. Available scoring systems are used for predicting short and long-term mortality. There is lack of data comparing different scoring systems with outcome in chronic liver disease barring ACLF.

Aims and objectives: The aim of present study was comparison between these scoring systems in predicting mortality risk in chronic liver disease.

Methods: This was a prospective, observational study including consecutive 400 admitted patients of chronic liver disease barring ACLF. The primary endpoint of study was comparison of different scoring systems in predicting outcome during hospitalization. The secondary endpoint was development of in hospital complications of chronic liver disease and its impact on outcome.

Results: Among 400 patients, the male: female ratio was 3:1. Commonest aetiologies of chronic liver disease was NASH (48.8%) and alcohol (32.8%). The mortality rate was 25.08% during hospitalization. The comparison among prognostic scores, AUROC of Child-Pugh was 0.778, MELD Na was 0.859, SOFA score was 0.985 and APACHE II was 0.995.

Conclusion: Among different scoring systems, the APACHE II score predicted best in-hospital mortality in patients with chronic liver disease barring ACLF.

Abstract Submission No. 100391

O-0970

A RFH-NPT-based Nomogram to predict the long-term survivals of liver cariesis: a multicenter study

Chengbin Zhu1,2,3,4, Yuchao Wu1,2,3,4, Fuliang Zhao1,2,3,4, Yuan Yang1,2,3,4, Qijian Zhang6, Ruojing Wang1,2,3,4, Yingli He6, Yage Zhu1,2,3,4, Yingren Zhao6, Juan Du6, Zhe Jiao6, Taotao Yan6, Li Zhu6, Yushan Liu1,2,3,4, Siyi Liu1,2,3,4

1Department of Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi Province China, 2Institution of Hepatology, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi Province China, 3Shaanxi Clinical Medical Research Center of Infectious Diseases Xi’an, Shaanxi Province China, 4Clinical Research Center for Infectious Diseases, The First Affiliated Hospital of Xi’an Jiaotong University Xi’an, Shaanxi Province China

Background & Aims: Malnutrition risk is an important predictor of outcomes in cirrhosis patients. The Royal Free Hospital-Nutritional Prioritizing Tool (RFH-NPT) is recommended for identifying malnutrition risk in liver disease patients. We aimed to develop and validate a RFH-NPT-based nutrition screening model to predict outcomes of cirrhosis.

Methods: Cirrhotic inpatients from February 2016 to July 2016 were included as training cohort, and patients from 6 clinical medical centers were enrolled as validation cohort. A nomogram was established based on the prognostic variables determined by COX, BSR and LASSO regression, and assessed by concordance index, calibration curves, decision curve analysis (DCA) and brier curve. Its performance was compared with Child-Pugh score, the model for end-stage liver disease (MELD) and MELD-Na, and validated by an external dataset.

Results: 152 patients with cirrhosis were enrolled into training cohort. During the 5-year follow-up, 53 (34.9%) patients died. Age, albumin, total bilirubin, blood urea nitrogen, and RFH-NPT classification were identified as prognostic factors in Cox regression and conducted the RFH-NPT based nomogram which showed valuable consistency with actual observations. The DCA achieved great utility. In a comparison of the areas under the ROCs, the nomogram had superior performance than Child-Pugh, MELD and MELD-Na in predicting the timing course of survival, respectively. Besides, another 320 cirrhotic patients were enrolled as validation cohort, and confirmed the superiority of nomogram in prognosing the survival outcomes.

Conclusion: A novel RFH-NPT-based malnutrition screening nomogram provides better accuracy of predictions for long-term outcomes in cirrhosis patients.

Abstract Submission No. 100664

O-0971

Comparison of mortality prediction of MELD, MELD-La, and MELD-3.0 on Korean Liver Cirrhosis patients

Seung Kang Yoo1, Jeong Han Kim1, Won Hyeok Choc1, So Young Kwon1, Byung-Chul Yoo1

1Konkuk University Medical Center Seoul South Korea

Background & Aims: The Model for End-Stage Liver Disease (MELD) score has widely been used for mortality prediction of Liver cirrhosis (LC) patients and for transplantation allocation. There had been recent modifications such as MELD-Lactate (MELD-La) and MELD-3.0, which has integrated the factors that the original MELD score had not.
The goal of this study is to compare MELD, MELD-La, and MELD-3.0 in the mortality prediction of LC patients in Korea.

Methods: This is a retrospective, single-centered study in which LC patients who were admitted to Konkuk University Hospital via emergency department between January 2011 and December 2022 were enrolled and reviewed. Predictive values for 1-month and 3-month mortality of MELD, MELD-La, and MELD-3.0 were calculated using area under the receiver operating characteristics (AUROC) curve and their difference are statistically analyzed using DeLong’s test.

Results: Total of 1,152 patients were included in this study. Among them, 165 (14.3%) patients died in one month and 211 (19.7%) died within three months. The AUROCs for 1-month mortality of MELD, MELD-La, MELD-3.0 were 0.808, 0.79, 0.807, and for 3-month mortality of MELD, MELD-La, MELD-3.0 were 0.805, 0.753, 0.817, respectively. Multiple comparison of ROC curves demonstrated that MELD and MELD-3.0 have reflected the 3-month mortality prediction of LC patients better than MELD-La (p=0.0018, p=0.0003 respectively).

Conclusion: This study has shown that either MELD or MELD-3.0 is better tool compared to MELD-La in predicting 3-month mortality of LC patients, whereas the comparison of MELD and MELD-3.0 have shown no significant difference in predicting mortality of LC patients.

Abstract Submission No. 100709  O-0972

Diagnostic accuracy of microRNAs as non-invasive biomarkers for the diagnosis of liver cirrhosis

Jason Chang1, Jin Yu2, Guan Huei Lee3, Marianne De Roza4, Ngia Chu Tan5, Han Chong Toh6, Yu Jun Wong7, Wei Lyn Yang4, Cheng He2, Pierce Chow8
1Singapore General Hospital Singapore Singapore, 2MIRXES Pte Ltd Singapore Singapore, 3National University Hospital Singapore Singapore, 4Sengkang General Hospital Singapore Singapore, 5Singhealth Polyclinic Singapore Singapore, 6National Cancer Center Singapore Singapore, 7Changi General Hospital Singapore Singapore, 8Department of Hepatobiliary and Transplant Surgery Singapore Singapore

Background: This study evaluates the diagnostic accuracy of circulating microRNAs (miRNAs) as non-invasive biomarkers to identify patients with early liver cirrhosis in a large prospective cohort of patients with chronic liver disease.

Materials and Methods: The ELEGANCE Study is a prospective, multi-centre, cohort study enrolling patients at increased risk of HCC in Singapore (ClinicalTrials.gov: NCT04965259). Patients were enrolled if they had compensated liver cirrhosis or non-cirrhotic chronic liver disease due to hepatitis B (HBV), hepatitis C (HCV) or non-alcoholic fatty liver disease (NAFLD). Plasma from subjects were profiled through high-throughput qPCR to identify candidate miRNAs. Student’s t-test was used to identify differentially expressed (DE) miRNAs between groups. A ridge model was trained from the training cohort and validated in the validation cohort.

Results: Plasma from 1,318 subjects (464 cirrhosis, 643 HBV, 14 HCV, 197 NAFLD) were divided into a training cohort (617 subjects) and a validation cohort (701 subjects). In training, 35 miRNAs exhibited DE between cirrhotic and non-cirrhotic groups (fold change≥0.81 or ≤1.23, FDR<0.05). Among these, 12/20 were significantly up-regulated and 6/15 were significantly down-regulated in validation. The consistency of miRNA DE is significant (p<0.0001). Employing ridge model in training, a panel of 36 miRNAs achieved an AUROC of 0.77 to differentiate cirrhosis from non-cirrhosis patients. The panel performed consistently with an AUROC of 0.76 in the validation.

Conclusion: Circulating miRNAs demonstrated potential as a non-invasive biomarker to identify patients with early liver cirrhosis among patients with chronic liver disease and track the progression of chronic liver disease.

Abstract Submission No. 100741  O-0974

ROLE OF INFLAMMATORY BASED MARKERS IN THE DIAGNOSIS OF BACTERIAL INFECTION AMONG CIRRHOTIC PATIENTS

Jan Catherine Carrera1, Jenny Limquiaco2, Derek Tan3
1Chong Hua Hospital Cebu City Philippines, 2Chong Hua Hospital Cebu City Philippines, 3Chong Hua Hospital Cebu City Philippines

Bacterial infection is common and accounts for morbidity and mortality in cirrhosis. It has been reported that 30 to 60% of cirrhotic patients acquire a bacterial infection with an incidence of 4-5-fold higher compared to the general population. This study aimed to describe the potential use of inflammatory markers as predictive factors of bacterial infections in cirrhotic population.

A retrospective analytical study of 272 patients with liver cirrhosis from 2015 to 2022 at Chong Hua Hospital was done. Cirrhotic patients were classified based on their presence and absence of infection. MELD score, Child-Pugh score and inflammatory based markers (RDW, MPV, NLR, LMR) were analyzed. To find the significant predictors of bacterial infection, univariate and multivariate regression analyses were performed. The area under the curve (AUC) was used to assess the markers’ diagnostic efficacy.

The most common infections identified in patients with cirrhosis were pneumonia (40.12%), urinary tract infection (24.42%) and SBP (13.95%). The most common bacteria isolated from patients with cirrhosis were Klebsiella, Escherichia coli, and Methicillin resistant staphylococcus aureus (MRSA). Furthermore, among the different inflammatory based markers, neutrophil lymphocyte ratio (NLR) and lymphocyte monocyte ratio (LMR) were significant predictors of bacterial infection in cirrhotic patients with cut off ≥ 4.7 and ≤ 2.26 respectively.

Bacterial infection prevalence is relatively high in patients with liver cirrhosis. Our study demonstrated that baseline NLR and LMR are predictors of bacterial infection in patients with cirrhosis. These tests may provide a simple method of identifying patients susceptible to infection.

Abstract Submission No. 100753  O-0974

Serum ammonia level predicts complications and mortality in clinically stable outpatient cirrhotics

Pooi Ling Loi1, Marianne Anastasia2, Chanda Kendra Ho3, Hiang Kiat Tan1, Jason Pik-Eu Chang1, Yu Jun Wong2, Jessica Yi Lyn Tan1, Rahul Kumar1
1Changi General Hospital Singapore Singapore, 2Sengkang General Hospital Singapore Singapore, 3Singapore General Hospital Singapore Singapore

Background: Ammonia has long been established as a neurotoxin involved in the pathogenesis of hepatic encephalopathy (HE). The Child-Turcotte-Pugh (CTP) score has factored in HE to prognosticate patients with cirrhosis but is limited by observers’ subjectivity. This study...
was aimed to test the hypothesis that serum ammonia level predicts complications and mortality in clinically stable outpatient cirrhotics.

**Methods:** In this ongoing study to predict the decompensation, ACLF and mortality in cirrhosis (Solidarity-DAM), stable out-patients were recruited according to the declaration on Helsinki. The primary endpoint was all non-elective admission for cirrhotic decompensation, ACLF or death. Ammonia measurements were carried out in fasting blood in accordance with international standards.

**Results:** A total of 197 outpatients with median age of 68.0 years [IQR: 60.0-74.0], BMI of 25.2 [IQR:22.9-28.6], majority males (61%) were recruited. Patients with CTP classes A/B/C were 64.5%, 13.7%, 4.6% respectively. The median MELD was 7 [IQR: 6-10]. The median serum ammonia [N=162] in patients who achieved and did not achieve predefined clinical outcomes (CO) were 55 [IQR: 45-91] and 25 [IQR: 17-42] respectively. The CO was not dependent on age, BMI, etiology of cirrhosis or concomitant diabetes mellitus. However, MELD, CTP, history of HE and presence of ascites predicted CO in univariate analysis [p<0.05 for all]. In the multivariate analysis only serum ammonia was a predictor of defined CO, HR:1.016[1.001-1.032; p=0.037]. Kaplan-Meier curve is attached as figure 1.

**Conclusion:** Serum ammonia can predict complications and mortality in clinically stable cirrhotics. Ammonia may be a potential target of therapy to prevent future decompensating events.

Abstract Submission No. 100798

**O-0975**

Serum BNP levels and 90 day mortality in patients of decompensated liver cirrhosis

Vishwa M Dayal1, Saumyaleen Roy1, Sanjeev K Jha1, Ashish K Jha1, Ravikant Kumar1

1Indira Gandhi Institute of Medical Sciences Patna India

**Background:** Patients with decompensated cirrhosis usually have excess of fluid as do patients of heart failure. Elevated B-type natriuretic peptide (BNP) level is a marker of increased blood volume in heart failure and is also increased in patients with decompensated liver disease.

**Methods:** We conducted a prospective study of 150 patients with decompensated cirrhosis without evidence of cardiac systolic dysfunction to evaluate the role of BNP levels in predicting prognosis and deterioration of ascites in patients with decompensated cirrhosis. Patients with heart failure, arrhythmias, coronary artery disease, rheumatic heart disease, pulmonary hypertension, chronic kidney disease and liver cancer were excluded.

The primary outcome was correlation between BNP levels and 90-day mortality in these patients. The secondary outcome was deterioration in ascites determined by the need for therapeutic paracentesis in the follow up period.

**Results:** During the study period 45 patients of 150 (30%) died. Median BNP levels in those who survived was 94 pg/mL(range 53-177) and in those who died was 263 pg/mL(range 134-315). Patients with higher BNP had significantly higher mortality rates (HR 2.45; p <0.03) A BNP ≥ 180 pg/mL had specificity of 80% in predicting 90-day mortality. Patients with BNP ≥ 235 pg/mL were more likely to require therapeutic paracentesis in the next 90 days (HR 1.73; p <0.06).

**Conclusion:** BNP is useful prognostic marker in patients with decompensated cirrhosis without systolic dysfunction. It could be also be used to predict requirement of therapeutic paracentesis in these patients.

Abstract Submission No. 100840

**O-0977**

Secular trend of disease burden of hydrothorax in patients with liver cirrhosis

Che To Jimmy Lai123, Cheuk Fung Terry Yip123, Yan Lilian Liang123, Yichong Jiang123, Wat Sin Vincent Wong9, Lai Hung Grace Wong123

1Department of Medicine and Therapeutics, The Chinese University of Hong Kong Hong Kong Hong Kong, 2Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong Hong Kong, 3Institute of Digestive Disease, The Chinese University of Hong Kong Hong Kong

**Objective:** Hydrothorax is one of the most debilitating complications in patient with liver cirrhosis. We aimed to evaluate the secular trend
of the disease burden of hydrothorax over the last two decades in Hong Kong.

Methods: This was a territory-wide cohort study of consecutive patients with liver cirrhosis retrieved from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority in 2000-2020. Hydrothorax was defined by the diagnosis codes and retrieved from January 2000 to June 2023.

Results: Among the 31,542 patients with liver cirrhosis, 3,251 (10.3%) patients suffered from hydrothorax; their mean age was 58.4±14.2 years; 65.4% were male; mostly due to chronic hepatitis B (72.5%). The disease burden of first incident hydrothorax increased from 109-133 annually in 2000-2008, to 194 annually in 2009, peaked at 210 annually in 2010, then gradually decreased to 60-72 annually in 2021-2022 (Figure). Recurrent episodes also peaked in 2011 (636 episodes annually) and decreased to 249-286 episodes annually in 2021-2022 (Figure).

Conclusion: The disease burden of hydrothorax peaked a decade ago and gradually decreased over the last decade. This is likely related to the improved treatment for the underlying aetiologies of liver cirrhosis, particularly chronic hepatitis B and C. The findings highlight the importance of treating the underlying aetiologies of liver cirrhosis in order to prevent debilitating cirrhotic complications.

Abstract Submission No. 100879
O-0978

Anticoagulants and antiplatelet agents are commonly used in patients with cirrhosis

Yichong Jiang1, 2, 3, Lilian Yan Liang1, 2, 3, Terry Cheuk-Fung Yip1, 2, 3, Jimmy Che-To Lai1, 2, 3, Vincent Wai-Sun Wong4, Grace Lai-Hung Wong1, 2, 3

1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong HONG KONG SAR Hong Kong Sar, 2Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong HONG KONG SAR Hong Kong, 3Institute of Digestive Disease, The Chinese University of Hong Kong HONG KONG SAR Hong Kong

Background: Patients with cirrhosis are more susceptible to both thrombosis and bleeding. Using anticoagulant and antiplatelet agents is often a double-edged sword - reducing thrombotic risk on one hand while increasing bleeding risk on the other hand. This study aims to evaluate the prevalence of anticoagulant and antiplatelet usage and the clinical profile of a territory-wide cohort of patients with cirrhosis.

Method: This was a territory-wide retrospective cohort study of 31,542 cirrhotic patients diagnosed between 2000 and 2020 in Hong Kong. The clinical, laboratory, and medication data were collected. Anticoagulant and/or antiplatelet users were defined as those with prescription of these medications for 4 weeks or more.

Results: 9,373 (29.7%) patients were identified as anticoagulant and/or antiplatelet users; their mean age was 67.5±12.1 years; 63.4% were men; 2,761 (29.5%) had MELD score >10; most of them (70.7%) suffered from chronic hepatitis B. Aspirin was the most commonly used medication (N=8337), with the longest duration (37.6 IQR: 6.1-94.5 months). Among antiplatelet users, aspirin users and clopidogrel users had similar age and clinical characteristics. Among anticoagulant users, direct oral anticoagulants (DOAC) users were older than warfarin users (age 72.7±11.1 vs. 63.8±13.5 years, p<0.001), but had better renal function and lower MELD score (Table).

Conclusion: Anticoagulants and antiplatelet agents are commonly used in patients with liver cirrhosis, even in some patients with hepatic decompensation. DOACs are preferentially prescribed to younger patients with better renal and liver function. Studies to evaluate the efficacy and safety of these medications in the presence of cirrhosis are warranted.

Abstract Submission No. 100891
O-0979

Role of Spot urine sodium/potassium ratio in predicting Acute Kidney Injury in cirrhosis

DINU ABIRAMI PREM KUMAR1, JAYANTHI VENKATARAMAN2, JOY V ARGHESE2

1SENIOR RESIDENT CHENNAI India, 2SENIOR CONSULTANT CHENNAI INDIA

Introduction: Acute kidney injury (AKI) is a common complication in decompensated cirrhosis and serves as an independent predictor of prognosis. Hence, early identification of AKI can play a pivotal role in managing these patients with a better outcome in terms of survival. The main objective of this study was to determine the role of spot urine sodium to potassium (Na/K) ratio in decompensated cirrhosis in predicting short term mortality in these patients.

Methodology: A prospective observational study was conducted at our institution between October 2021 and September 2022 in 102 inpatients, admitted for complication’s related to cirrhosis liver. Patients admitted for reasons unrelated to cirrhosis like elective procedures or surgery were excluded. Spot urine samples were analyzed for sodium, potassium, protein and creatinine; urine Na/K ratio, fractional excretion of sodium (FeNa) and protein creatinine ratio were calculated. All patients were followed up for one month and new onset AKI, MELD Na and 30-day mortality were noted. Statistically analysis was done using SPSS software. Descriptive statistics, linear correlation, receiver operating curve (ROC) and Kaplan Meier survival plot were used.

Results: 39 patients (38.2%) had AKI at admission and 16 patients (15.7%) developed AKI during followup. Urine Na/K ratio £ 1.3 was significantly correlated with AKI at admission, new onset AKI during hospital stay and on one month follow up (p value< 0.001), with a sensitivity and specificity of 78.2% and 81% respectively. Also, the ratio had a significant inverse correlation with MELD - Na score and 30-day mortality (p value <0.001).

Conclusion: Spot urine Na/K ratio has a significant inverse correlation with the onset of AKI and 30-day mortality and seems to be a good prognostic tool in day-to-day practice in decompensated cirrhosis.

Abstract Submission No. 100973
O-0980

Change in Rotational Thromboelastometry Parameters in Patients with Cirrhosis After Transfusion

Chloe CE Lim1, Tian Yu Qiu1, Louis Wang1, Chin King Tan1, Yu Jun Wong1, Kenneth WC Lin1, Andrew BE Kwek1, James WQ Li1, Tiing Leong Ang1, Roshni Sadashiv Gokhle1, Louis XL Ng1, Tirukonda Prasanna Sivanath1, Rahul Kumar1

1Changi General Hospital Singapore Singapore

Introduction: Conventional coagulation tests (CCT) are often used to assess bleeding risk and guide transfusion in patients with cirrhosis. However, due to rebalanced hemostasis the actual bleeding risk may be lower. Emerging data suggests that use of rotational thromboelastometry (ROTEM), a whole blood viscoelastic test, predicts bleeding risk more accurately. In this study, we describe CCT and ROTEM parameter changes post transfusion of platelets or fresh frozen plasma (FFP).
Mortality of cirrhotic patients with hydrothorax over the last two decades

Che To Jimmy Lai1,2,3, Cheuk Fung Terry Yip1,2,3, Yan Lilian Liang1,2,3, Yichong Jiang1,2,3, Wai Sun Vincent Wong4,5, Lai Hung Grace Wong1,2,3

1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; 2Medical Data Analytics Centre (MDAC), The Chinese University of Hong Kong, Hong Kong; 3Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong

Objective: Hydrothorax is an independent risk factor for mortality in patient with liver cirrhosis. We aimed to evaluate the secular trend of the disease burden and death of cirrhotic patients with hydrothorax over the last two decades in Hong Kong.

Methods: This was a territory-wide cohort study of consecutive patients with liver cirrhosis retrieved from the Clinical Data Analysis and Reporting System (CDARS) from Hospital Authority in 2000-2020. Hydrothorax was defined with the diagnosis codes and retrieved from January 2000 to June 2023.

Results: Among the 31,542 patients with liver cirrhosis, 3,251 (10.3%) patients suffered from hydrothorax; their mean age was 58.4±14.2 years; 65.4% were male; mostly due to chronic hepatitis B (72.5%). The disease burden of first incident hydrothorax increased from 2000 and peaked in 2010, then gradually decreased in 2011-2022 (Figure). There was a delayed in the peak of death of these patients, which only peaked in 2015 (183 deaths annually) and decreased to 115-119 deaths annually in 2021-2022 (Figure).

Conclusion: The disease burdens of hydrothorax peaked in 2010 whereas the deaths peaked 5 years after that. This is likely related to the improved treatment for the underlying aetiologies of liver cirrhosis, particularly chronic hepatitis B and C. The findings highlight the importance of early treatment for the underlying aetiologies of liver cirrhosis in order to minimise the deaths from this important cirrhotic complication.

Understanding the Current Status of Zinc Deficiency in Patients with Chronic Liver Disease

Naoya Kanogawa1, Sadahisa Ogasawara1, Teppei Akatsuka1, Keiichi Katayama1, Chihiro Miwa1, Sae Yumita1, Kentaro Fujimoto1, Sae Yumita1, Keisuke Koroki2, Masanori Inoue1, Kazufumi Kobayashi1, Soichiro Kiyono1, Masato Nakamura1, Takayuki Kondo1, Naoya Kato1

1Department of Gastroenterology and hepatology graduate school of medicine Chiba Japan Chiba Japan

Background: Since sarcopenia in chronic liver disease is a poor prognostic factor and there is no fundamental cure, prevention of sarcopenia is critical. Zinc deficiency, which is common in chronic liver disease, exacerbates sarcopenia by decreasing muscle mass and worsening the condition in association with increased ammonia levels.

Aim: In the present study, we sought to determine the status of zinc deficiency and identify associated risks using clinical parameters collected from patients with chronic liver disease in a prospective study.

Method: We analyzed clinical data from our extensive prospective study on chronic liver disease, examining patient backgrounds, zinc correlations, and risk factors. Zinc deficiency was defined by Japan Clinical Nutrition Society criteria (less than 60 μg/mL: deficiency, 60-80 μg/mL: latent deficiency).
Result: Excluding 40 cases with missing data, 1168 chronic liver disease cases were analyzed. Median age was 68, with 678 males. Zinc measurements were available for 40.7%. Median serum zinc was 74μg/mL, significantly lower in alcoholic liver disease (62μg/mL). Serum zinc correlated positively with albumin and negatively with ALBI, FIB4, M2BPGi, and NA. Logistic regression analysis identified albumin <4.0mg/dL as a risk factor for zinc <60 μg/mL. ROC analysis, using Alb 3.8mg/mL, showed 82.3% sensitivity and 81.7% specificity for zinc deficiency.

Conclusion: In chronic liver disease, although serum albumin levels of 3.8 mg/mL may signal early zinc deficiency, fewer than half of the cases underwent zinc measurements. This highlights clinicians’ limited awareness. Early diagnosis and supplementation of zinc deficiency may prevent the onset and progression of sarcopenia.

Abstract Submission No. 101321
O-0984

Classification of 5,102 Mongolian patients with liver cirrhosis by causes
Amarsanaa Jazag1, 2, 3, Chinzorig Dovdov1, 2, 3, Baasanjav Davaadoryj1, Tegshjargal Amarjargal1, Nandintsetseg Natsagdorj1, Urangoo Bayasgalanbaatar1, Tsend-Ayush Erdenetsetseg1, Erdenebayar Gouchig1, Baatarkhuu Oidov1, Batgerel Zagdragchaa1
1MASLD, Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia, 2Ootech Mannamba University Ulaanbaatar Mongolia, 3Happy Veritas Hospital Ulaanbaatar Mongolia

Background: Liver cirrhosis is number one cause of mortality within GI related causes of death in Mongolia. But there are no large scale studies that assess all causes of cirrhosis in Mongolia. Methodology: Total of 16,324 people underwent elastography testing during the 5-year period from October 31, 2017 to December 6, 2022 were analyzed in detail by the anamnesis-synthesis method, and the correlation between them was summarized.

Results: Out of 5,102 eligible patients with F4 level fibrosis (liver cirrhosis), 1,493 people had HCV Ab positive or 33%, 890 people with HBV infection or 20%; 1479 (32%) patients had HBV and HDV co-infection; 73 or 2% had HDV, HCV and HDV triple infection; 99 patients or 2% were co-infected with HBV and HCV. 427 people or 9% had NAFLD only. Out of “NAFLD only” patients we surveyed for alcohol consumption level: 115 (27%) patients had moderate to severe alcohol consumption. Median serum zinc was 74μg/mL. Se-

Conclusion: Viral cause of liver cirrhosis still represented 89% of all causes, while NAFLD was 7% and ALD related 2% respectively.

Abstract Submission No. 101323
O-0985

The RCT Study of JianPiHuaZhuoXingNao formula in Treatment of Cirrhosis Mild Hepatic Encephalopathy
Xu Cao1, Qian Jin1, Yijun Liang1, Xiaoke Li2, 3, Hongbo Du8, Danan Gan1, 2, Xiaobin Zao1, Yong-an Ye1, 2
1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 2Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China

Background: This study aimed to observe the clinical efficacy of JianPiHuaZhuoXingNao formula (JPHZXN) in the treatment of mild hepatic encephalopathy (MHE) caused by hepatitis B virus (HBV) related cirrhosis, providing new perspectives and strategies for the treatment of MHE.

Methods: A total of 60 patients with HBV related cirrhosis of MHE, treated at Dongzhimen Hospital from September 2020 to August 2022, were randomly divided into an intervention group and a control group, with 30 patients in each group. Both groups received routine basic treatment, and the treatment group additionally received oral JPHZXN, while the control group received oral placebo. Neurological and psychological tests, liver function, and traditional Chinese medicine syndrome scores were recorded at the time of enrollment and after 24 weeks to evaluate the clinical efficacy.

Results: There were no statistically significant differences in gender, age, education level, neurological and psychological test, liver function, and syndrome scores between the two groups, indicating comparability. After 24 weeks of treatment, the number connection test A (NCT-A) time and Digital symbol test (DST) scores, AST, and syndrome scores in the treatment group showed significant improvement compared to baseline (P<0.05). The total effective rate in the treatment group (86.67%) was significantly higher than that in the control group (33.33%) (P<0.05).

Conclusions: JPHZXN has a favorable effect on the neurological and psychological tests and cognitive function of patients with HBV related cirrhosis of MHE. It can improve AST within the normal reference range, effectively reduce syndrome scores, and ameliorate clinical symptoms.

Abstract Submission No. 101502
O-0986

Friality Correlates With Greater Odds of hepatic encephalopathy, Asctes, & SBP: a study from Pakistan
Jalal Khan1, Farhana Kayani1
1Bolan medical college Quetta Pakistan

Introduction: Frailty is associated with morbidity&mortality in advanced cirrhosis, However, the information on correlation between frailty & complications in compensated cirrhosis is scarce. We aim to evaluate the impact of Frailty on risk of hepatic encephalopathy(HE), ascites, & spontaneous bacterial peritonitis(SBP) & impact of multidomain implementation on these outcomes.

Methods: We prospectively evaluated the impact of Frailty on prevalence of ascites, HE, & SBP among cirrhotic adults. Frailty was defined by the Liver Frailty Index(LFI)& a level of >4 termed as frail. Development of complications(worsening ascites, HE, or SBP) & unplanned hospitalization were recorded. In this study one arm of frail continued with their normal diet & the other arm (intervention) was given training of taking 5 meals/day, containing appropriate protein & fat contents. Additional Branched chain amino acids were also given to these patients, Physical execrise (both cardiac & resistance) advised. They were evaluated for a period of 6 months for the complication rates. Between-group comparisons used chi-squared methods & adjusted multivariate logistic regression.

Results: 179 patients were included (MELD 13.2±3.4, Child-Pugh A/B/C 34.9%/35.1%/30%), 74.3% were frail. Compared to the group, pre-frail & frail patients had significantly higher cumulative 1-year probabilities of worsening ascites (0% vs. 8.5%/18.4%, p=0.001) & SBP (0% vs. 13.5%/34.2%, p<0.001), encephalopathy (0% vs. 28.9%/71.1%, p=0.02) & unplanned hospitalizations (100%/90%/80.4%, p=0.014). Two models of multivara-

tible Cox regression analysis were done adjusted with MELD-


Abstract Submission No. 101525
O-0987

Predictive performance concerning distinct SMI cut-offs of sarcopenia for mortality among cirrhosis

Chao Sun¹, Han Wang²
¹Tianjin Medical University General Hospital Tianjin China, ²Tianjin Hospital Tianjin China

Background: Although the clinical relevance of sarcopenia has been verified in the context of cirrhosis, there are insufficient data concerning cut-offs of CT-demarcated skeletal muscle index (SMI) in different ethnicities. We aimed to clarify the predictive performance of distinct SMI values-defined sarcopenia for prognostication among cirrhosis.

Methods: We prospectively enrolled 341 inpatients due to cirrhosis-associated acute deterioration. A wealth of cut-offs concerning SMI (TJ, northernChina, southernChina, and Turkey criteria) were tested to determine 2-year all-cause mortality according to Kaplan-Meier survival curve with log-rank test and multivariate Cox regression.

Results: Sarcopenia was present in 26.4%, 7.9%, 22%, 29.6% and 7.9%, respectively, according to TJ, northernChina, southernChina, Japan and Turkey criteria. Survival curve showed significant differences between patients with and without sarcopenia defined by all criteria (P for log-rank test <0.05). Univariate Cox regression indicated age, BMI, CTP class, MELD-Na, creatinine, total bilirubin, sodium, albumin and sarcopenia were significantly associated with long-term mortality. Furthermore, multivariate Cox regression by adjusting age, BMI and MELD-Na revealed that northernChina-defined sarcopenia was independently associated with mortality (HR =1.99, P =0.0431), while TJ criteria-defined sarcopenia exhibited marginally significant association (HR =1.62, P =0.0595). Moreover, sarcopenia defined by northernChina (HR =1.93, P =0.0453), TJ (HR =1.73, P =0.0280), and southern-China criteria (HR =1.73, P =0.0368) was significantly associated with mortality by adjusting age, BMI and CTP class.

Conclusions: Our findings provide strong evidence to develop continent-based SMI cut-offs to identify sarcopenic cirrhotic patients, considering its prognostic importance.

Abstract Submission No. 101711
O-0989

Prognostic factor which can predict esophageal varices aggravation after PARTO

Chan Jin Yang¹, Jeong Ju Yoo¹, Sang Gyune Kim¹, Young Seok Kim¹, Jong Joon Shim², Jae Myeong Lee³
¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea Bucheon South Korea, ²Department of Radiology, Soonchunhyang University Bucheon Hospital, Bucheon, Korea Bucheon South Korea

Background: Plug-assisted retrograde transvenous obliteration (PARTO) is known to be an effective treatment for gastric varices. However, it is also known to worsen esophageal varices after PARTO. The aim of this study is to identify prognostic factors which can predict the worsening of esophageal varices after PARTO in patients with gastric varices.

Methods: Ninety-nine patients who underwent PARTO between Jun 2015 and Jan 2023 were enrolled in this study. Esophageal varices and their exacerbation were evaluated by gastroduodenoscopy. Twenty-five patients who did not undergo follow up endoscopy after PARTO were excluded.

Results: The mean age of patients were 57.9 ± 9.9 years and 64.9% were male. Most common etiology of liver cirrhosis was alcoholic liver disease (40.5%) followed by hepatitis B virus (28.4%). The cumulative worsening rate of esophageal varices at 1, 2, and 3 years were 32.4%, 48.6% and 50.0%. In the univariate logistic regression analysis, left gastric vein (LGV) dilatation which LGV diameter more than 3.5mm, total bilirubin, aspartate aminotransferase, albumin, prothrombin time international normalized ratio, hepatic vein pressure gradient (HVPG), MELD score, Child-Pugh class were associated with worsening of esophageal varices after PARTO. In multivariate logistic regression analysis, LGV dilatation (OR 3.272; 95% CI 1.016-10.534; P =0.047) and HVPG (OR 1.182; 95% CI 1.017-1.375; P =0.030) were independent risk factors of worsening of esophageal varices.
Conclusion: LGV dilatation and HVPG are associated with esophageal varices aggravation after PARTO.

Keywords: Plug-assisted retrograde transvenous obliteration (PARTO), Esophageal varices, Gastric varices

Abstract Submission No. 101926
O-0990

Usefulness of retinol-binding protein to predict mortality in patients with chronic liver disease

Yuki Utakata1, Takao Miwa2, Shinji Unome2, Tatsunori Hanai2, Kenji Imai2, Atsushi Sueotsugu2, Koji Takai2, Masahito Shimizu2

1Chuno Kosei Hospital Gifu Japan, 2Gifu University Hospital Gifu Japan

Background: Rapid turnover proteins (RTP), including retinol binding protein (RBP), transthyretin (TTR), transferrin (Tf), are useful in evaluating dynamic nutritional status. This study aimed to investigate the relationship between RTP and mortality in patients with chronic liver disease.

Methods: We included 341 patients with chronic liver disease who had RTP measurements taken between October 2011 and December 2021. Low RBP group was defined as RBP below 2.7 mg/dL for men and 1.9 mg/dL for women. Survival curves were estimated using the Kaplan-Meier method and the survival between two groups were compared using the log-rank test.

Results: Of the patients included, the median age was 67 years and 48% were male. The prevalence of chronic hepatitis, Child-Pugh A, B, and C were 64, 116, 77, and 64, respectively, and the median MELD score was 8 points. The median RBP, TTR, and Tf were 1.5 mg/dL, 11 mg/dL, and 227 mg/dL, respectively. During the median observational period of years, 23% patients died. Multivariate analysis showed that RBP (hazard ratio, 2.98; 95% CI, 1.47 -6.04; p = 0.002) was independently associated with mortality independent of MELD score and sodium, while TTR and Tf were not significant.

The low RBP group had significantly worse mortality than the normal RBP group (survival rate: 1 year 83% vs. 95%, 3 years 72% vs. 93%, 5 years 91% vs. 67%; p < 0.001).

Conclusions: Our study revealed that RBP is associated with mortality in patients with chronic liver disease independent of liver functional reserves.

Abstract Submission No. 101969
O-0991

Interleukin-6 as Predictor of Hepatic Encephalopathy Incidence in Hepatic Cirrhosis Patients

Muhammad Bilal Saifulhaq1, Tohari Amin1, Syifa Mustika2

1Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia, 2Gastroenterohepatology Division of Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia

Background: Systemic inflammation is known as the driving force for the development of hepatic encephalopathy (HE) and recent studies demonstrated that elevated Interleukin-6 (IL-6) are associated with the presence and progression of HE in patients with liver cirrhosis.

Methods: 200 hepatic cirrhosis outpatients were included in the study and were followed for a mean time of 305 days. Baseline clinical assessment and laboratory data were recorded. HE grade was diagnosed with West-Haven criteria and portosystemic encephalopathy test.

Outcomes included incidence of HE covert and overt and death rates, during the follow-up.

Results: Elevated IL-6 group showed a significantly higher overt HE (41%) than the normal IL-6 group (1%), covert HE (47%) to Normal Group(6%), (P<0.0001), non HE was higher in the normal IL-6 group (93%). Moreover, the death rate was significantly greater in the elevated IL-6 group (16%) than in the normal IL-6 group (1%) (P=0.033). The cutoff value of IL-6 levels in the prediction of hepatic encephalopathy incidence was assessed. Our receiver operating characteristic results revealed that IL-6 cutoff value higher than 50.27 for covert HE and the cutoff value is greater than 120.83 for overt HE. The sensitivity values of IL-6 for severity and mortality were 93.3 and 90.5%, respectively, and the specificity values were 90.0 and 86.7%, respectively.

Conclusion: Elevated levels of serum IL-6 in cirrhosis patients were related to the HE event. In predicting the incidence of covert HE and overt HE in cirrhosis patients, the optimum IL-6 cutoff levels were 50.27 and 120.83 pg/ml, respectively.

Abstract Submission No. 102002
O-0992

Prognostic Markers for Improved Survival Estimation in Spontaneous Bacterial Peritonitis (SBP)

Akhil Deshmukh1, Shiv Kumar Sarin1, Vishnu Girish1, Harshvardhan Tewethia1

1Institute of liver and biliary sciences New Delhi India

Introduction: Spontaneous Bacterial Peritonitis (SBP) has high in-hospital mortality. Survival is dependent on early recognition, antibiotics, and albumin infusion. We investigated the predictors of mortality in patients with SBP.

Methods: In this retrospective study we analysed electronic records of adult patients with SBP to determine the clinical outcomes. From an initial review of 1611 patient records, 1303 were included. Role of ALBI in predicting long-term outcomes and mortality was assessed.

Results: 1303 patients [mean age 48.56±13.85 years, males 84.5%, etiology being ethanol 41% and MAFLD,38%] with SBP having serial follow-ups and outcomes from the date of diagnosis were studied. At one year from SBP diagnosis, 436 patients (33.46%) expired, whereas 867(66.5%) survived. On multivariate analysis AST, total bilirubin, total protein, blood urea, serum creatinine, serum potassium and chloride levels, total leucocyte count, neutrophil to lymphocyte ratio (NLR), INR, ascitic fluid lymphocyte count, MELD score and ALBI were independent predictors of survival at 1year. ALBI score: grade 1 with score ≤ -2.60 had 13/15(86.7%), grade 2 > -2.60 and ≤ -1.39 had 219/296(74%) and grade 3 > -1.39 had 635/992 (64%) survival at 1yr of SBP diagnosis. AUC for predicting mortality by ALBI and MELD score is 59.6%(p-value<0.001) and 69.7%(p-value<0.001). AUC for predicting AKI by ALBI and MELD score is 49.6%(p-value 0.78) and 84%(p-value<0.001).

Conclusion: This study highlighted parameters such as serum AST, bilirubin, renal markers, NLR, MELD, and ALBI score as key one-year survival predictors.

Abstract Submission No. 102008
O-0994

THE INCREASING BURDEN OF AKI AND HRS IN HOSPITALIZED PATIENT WITH CIRRHOSIS

Ann Ma1, Arshad Imrit2, Julian Yabut3, Marwa Ismail2, Surain Roberts2, Fahad Razak2, Amol Verma6, Gideon Hirschfield1,3

1Institute of liver and biliary sciences New Delhi India, 2Gastroenterology, Malvane Hospital, Mumbai, India, 3Division of Endocrinology, internal medicine, University of California, San Francisco, USA, 4Cardiology, Malvane Hospital, Mumbai, India, 5Nephrology, Malvane Hospital, Mumbai, India, 6Department of Nephrology, Gastroenterology, and Nutrition, Calvary Mater Newcastle Hospital, Newcastle, Australia
Determinants of survival in a large cohort of cirrhosis in a tertiary care centre in India

Shenoy K T1, Leena K B2
1Sree Gokulam Medical College and Research Foundation Trivandrum India, 2Population Health and Research Institute Trivandrum India

Introduction: The prognosis of cirrhosis is dependent on decapsulation as the presenting feature and the severity of hepatic dysfunction as assessed using the Child-Turcotte-Pugh (CTP) and the Model for End-Stage Liver Disease (MELD) scores. We evaluated the survival and its determinants.

Methods: Prospective study in a 2640 patients with liver cirrhosis. Data were collected on age, sex, presentation at first visit, ascites, Child-Pugh and Model for End-Stage Liver Disease (MELD) and MELD Na score. Subjects were recruited and followed up from 2013 May till 2023 September for events of decapsulation. Cox regression model with hazard ratios (HR) were computed using SPSS version 22.0.

Results: The mean age of the study participants were observed as 56.22 ± 9.79 years. 78% were males. 87.4% were with compensated cirrhosis (CC) and 12.6% had decompensated cirrhosis (DC) disease. 61% were with alcoholic liver disease (ALD); 8% had Hepatitis B viral infection; 2.5% HCV; 0.5% autoimmune hepatitis and 28% had non-alcoholic steatohepatitis (NASH). Alcohol abuse with hepatitis was observed in 32% with decapsulation. Mortality was higher in the DC compared to CC (72.8% Vs 15.4%; \( p < 0.001 \)). Mortality was higher in encephalopathy, ascites, acute kidney injury and spontaneous bacterial peritonitis. Survival HR (95% CI 1.44 -5.12) \( p = 0.041 \); MELD Na>12: HR 2.22 (95% CI 1.12-4.22 ) \( p =0.010 \); The cox regression model, Chi-square statistics showed that overall model has -2 Log Likelihood of 414.6 with 4 degrees of freedom (df) has a p-value of 0.001. CTP class B and C have 2.4 times more risk for mortality than CTP class A (p=0.01). Etiology was independently associated with mortality (p<0.05).

Conclusion: Higher CTP class and higher MELD Na were associated with 2 to 3 fold higher mortality and early diagnosis is needed to reduce the mortality.

Abstract Submission No. 102014

O-0995

Adipose Tissue Cell Signaling is Dysregulated in Liver Cirrhosis

Sanal MG1, Sarita Gupta1, Kumarawamy Parthasaradhy1, Archna Rastogi1, Rahul Saha1, Viniyendra Pamecha1, Shiv Sarin1

1Institute of Liver & Biliary Sciences New Delhi India

In the APASL-2023 presentation, we reported the overexpression of angiogenic factors and accelerated proliferation of adipose tissue mesenchymal cells (ADMSC) in the adipose tissue of cirrhosis patients compared to healthy subjects. This study is aimed to investigate potential dysregulation in cell signaling pathways in adipose tissue of cirrhosis patients. Adipose tissue samples were collected from liver
**Mesenchymal stem cells for the treatment of decompensated cirrhosis (MSC-DLC-1): A phase I trial**

Ziying Zhang1,2,3, Zerui Wang1,2,3, Mengqi Yuan1,2,3, Lei Shi1,2,3, Fu-Sheng Wang0, XI Huang2,3, Anqing Yang0

1Medical School of Chinese PLA Beijing China, 2Senior Department of Infectious Diseases, the Fifth Medical Centre of PLA General Hospital Beijing China, 3National Clinical Research Center for Infectious Diseases Beijing China

**Abstract**

Decompensated cirrhosis (DLC) is a global burden with limited therapeutic options. Human umbilical cord-derived MSCs (UC-MSCs) have shown their potential for treating DLC, but the dose and related mechanisms are still unclear. We designed an investigator-initiated, single-arm, dose-escalation clinical trial to evaluate the safety and identify the suitable dose of UC-MSCs in treating patients with DLC (NCT05227846).

**Methods:** A single injection of UC-MSCs was administered in a predetermined dose in each cohort (cohort 1 with 5.0×10^7 cells, cohort 2 with 1.0×10^8 cells, cohort 3 with 1.5×10^8 cells, and cohort 4 with 2.0×10^8 cells) according to the “3+3” rule. The primary evaluation measures included the incidence of adverse events and the change in the Model for End-stage Liver Disease (MELD) score from baseline to the 28th day. Secondary evaluation measures included: the change in MELD score, liver transplant-free survival, and the incidence of liver failure, signs of dose-limiting toxicities at 28 days after treatment with 4 adverse events (1 rash in cohort 2, 1 rash and 1 kidney calculi in cohort 3, 1 influenza-like symptoms in cohort 4). No serious adverse event and suspicious or unexpected serious adverse reactions occurred.

**Conclusion:** Up to maximum dose of 2.0×10^8 cells, the safety and tolerability of UC-MSCs have been demonstrated in patients with DLC.

---

**The efficacy and safety of NOACs in cirrhosis and portal vein thrombosis patients: a meta-analysis**

Shu Zhang4,5, Meixi Ji2, Yongqiang Xiong1, Bo Wang1, Ren Li1

1Department of Geriatric Digestive Surgery, the Second Affiliated hospital of Xi'an Jiaotong University Xi'an, Shanxi China, 2Department of pharmacology, the Second Affiliated hospital of Xi'an Jiaotong University Xi'an, Shanxi China, 3Experimental Teaching Center for Clinical Skills, the Second Affiliated Hospital of Xi'an Jiaotong University Xi'an, Shanxi China

**Abstract**

According to the World Gastroenterology Association report, 112 million people are suffering from LC, and it is one of the top mortality causes within gastroenterology-related diseases in Mongolia, the LC rate was 70.1% per 10,000 people on average over the last ten years. However, it reached 73.1% (23,402 cases) in 2022 and 55% for gastroenterology-related death.

**Method:** We conducted a retrospective study of 5464 patient histories from the FCHM who were diagnosed with Gastroenterological disease between 2018 and 2022. Later, we pointed out 1965 patient histories that were diagnosed with LC.

**Result:** There were 945 males and 1020 females. Patients between ages 36 and 45 had the highest LC. The most common etiology of LC was HBV and HDV infection, which was 82%. For the severity of LC, CTP-A, B, and C were 440, 957, and 568, respectively. MELD scores <9, 10-19, 20-29, and 30< were 494, 1037, 363, and 71, respectively. The severe complications were EV bleeding for 450 cases (22.9% of total EV cases), SBP for 435 cases (22.1% of ascites cases), HRS for 58 cases, hepatopulmonary syndrome for 37 cases, liver failure for 931 cases, and HCC for 180 cases.

**Conclusion:** LC is diagnosed within 36-80 years old people more. Hepatitis virus (B, D, and C) is the most common etiology of LC. The main life-threatening complications were EV bleeding and SBP, which were counted in more than 22% of total patients.
Anticoagulant therapy is necessary for patients with cirrhosis complicated with portal vein thrombosis, and it is safe and effective to use new oral anticoagulant. Due to the lack of large sample randomized controlled trials, the accuracy of the results needs to be further verified.

Abstract Submission No. 100095
O-1001

Insulin and glucagon levels in relationship with plasma amino acid imbalance in liver cirrhosis

Naoki Hashimoto1
1Sanda city hospital, Senda city Japan

Alteration in insulin and glucagon levels might account for some of the alterations in the plasma amino acid imbalance in cirrhosis. In order to verify this hypothesis, we evaluated basal insulin, glucagon, branched chain amino acids and aromatic amino acids in 10 controls and 17 cirrhotics. Tyrosine and aromatic amino acids significantly correlated with I/G ratio. On the other hand, insulin did not correlate with any of the plasma amino acids. Our data suggest that the catabolic state associated with increased glucagon levels may account for some of the alterations in the plasma amino acid profiles in cirrhotics.

Abstract Submission No. 100173
O-1002

MELD-sarcopenia Score Predicts Short-term Readmission of Patients with Hepatic Encephalopathy

Rui Huang1, Lin Zhang1, Shuo Yang1
1Peking University People’s Hospital, Beijing China

Purpose: To investigate whether the quality of skeletal muscle mass could predict short-term readmission in patients with hepatic encephalopathy (HE).

Method: Patients with HE were enrolled from 2018 to 2022. Sarcopenia and myosteatosis were defined using the L3 skeletal muscle index (SMI) and skeletal muscle density (SMD) obtained from CT imaging. MELD-Sarcopenia score was calculated. Multivariable analysis and multiple linear regression were applied to identify predictors of 30-day readmission and length of hospitalization.

Results: 123 patients with HE were included. 55 (44.7%) and 87 (70.7%) patients were identified with sarcopenia and myosteatosis. Patients with sarcopenia exhibited a higher prevalence of myosteatosis, lower SMI and SMD (p < 0.05). Patients with myosteatosis were older, had a lower body mass index, a higher neutrophil-to-lymphocyte ratio and MELD-sarcopenia scores (p < 0.05). 10 (8.1%) patients were readmitted within 30 days. The readmitted group had a higher MELD-sarcopenia score (25.0 ± 6.6 vs. 19.5 ± 7.8, p = 0.034) and lower L3 SMD (28.3 ± 5.9 vs. 33.8 ± 6.9, p = 0.015). In the multivariable analysis, MELD-sarcopenia score (95% CI 1.388 [1.074-1.793], p = 0.012) and SMD (95% CI 0.778 [0.610-0.991], p = 0.042) were found to be significantly associated with the 30-day readmission of patients with HE. Age (p = 0.028), alcohol liver disease (p = 0.025), and hypertension (p = 0.005) were associated with the length of hospitalization for patients with HE.

Conclusions: The MELD-sarcopenia score and SMD were identified as predictive factors for short-term readmission in patients diagnosed as HE.

Abstract Submission No. 100192
O-1003

serum-ascites Vitamin D Gradient: A Diagnostic Marker for SBP in Egyptian Cirrhotic Patients

Eslam Habba1,2, Mariam Alzennary3, Radwa Alsharababy2, Mohamed Sharafeldin1
1Lecturer of hepatology, gastroenterology and infectious diseases at faculty of medicine, Tanta University hospitals, Egypt; M.D. Tanta Egypt, 2Clinical pathology department, Faculty of medicine, Tanta University hospitals Tanta Egypt, 3Tropical medicine department, faculty of medicine, Tanta University hospitals Tanta Egypt

The most prevalent infectious consequence of liver cirrhosis is spontaneous bacterial peritonitis. Ascitic fluid PMN counts more than 250 cells/μL are used as the gold standard for diagnosing SBP. Patients with decompensated cirrhosis also had significantly decreased serum 25-OH vitamin D levels compared to controls.

Aim: to investigate the role of (serum ascites vitamin D gradient) as a diagnostic factor for diagnosis of SBP.

Patients and Method: This cross-sectional study included 80 cirrhotic ascitic patients from Egypt who were treated at the hospitals affiliated with the Tropical Medicine and Infectious Diseases Department at Tanta University.

Group 1: 40 ascitic patients with SBP.
Group 2: 40 ascitic patients without SBP

Results: Child-Pugh score was significant in both groups as child C was significantly higher in group 1 than group 2. Total leucocyte count and differential neutrophil were significantly higher in group 1 than group 2 while child B was higher in group 2 than group 1. Differential lymphocyte was significantly lower in group 1 than group 2. SADG was significantly lower in group 1 than group 2. SADG ratio can significantly predict SBP (P = 0.016 and AUC = 0.632) at cut-off ≤25.8 with 37.50% sensitivity, 95.00% specificity, 88.2% PPV and 60.3% NPV

Conclusion: Patients with cirrhotic ascites had decreased SADG and higher SBP. In these cases, it might be used as a diagnostic and prognostic marker for SBP. Patients with decompensated cirrhosis, independent of SBP, have a decreased prevalence of vitamin D insufficiency.
NPAR in liver cirrhosis: Novel prediction model of 90-days mortality and rehospitalization risk

Dwijo A Sindhughosa1, I K Mariadi1

1Division of Gastroenterology-Hepatology, Department of Internal Medicine, Udayana University, Denpasar, Bali, Indonesia

Abstract Submission No. 100604

O-1005

Method: This was a retrospective case-control study and we enrolled cirrhotic patients with PVT and portal hypertensive complications who underwent the transjugular intrahepatic portosystemic shunt (TIPS) and consented to get the blood sample between November 2018 and September 2020. Cirrhotic patient receiving TIPS without PVT was matched based on Child-Pugh class during the same period.

Results: A total of 15 patients with PVT who underwent TIPS due to portal hypertensive complications were included in this study. Hence, 15 patients receiving TIPS without PVT during the same period were matched based on the Child-Pugh class. We found plasma levels of these factors were similar between the two groups either in portal vein or jugular vein. In addition, no significant differences were observed regarding levels of these proinflammatory factors between the jugular and portal vein in our cohort.

Conclusion: We found no elevated inflammatory status in the portal vein. Additionally, when matched by the Child-Pugh class, no significant difference in portal and peripheral inflammatory status was observed between patients with PVT and patients without in our study. However, relatively few patients were enrolled and only several inflammatory factors were measured in our study. Hence, a large cohort and comprehensive procoagulant and inflammatory profiles are needed to assess the role of inflammation and hypercoagulability in PVT.

Abstract Submission No. 100749

O-1006

Identifying small varices in patients with compensated cirrhosis

Yanna Liu1, Yanglan He1, Yijie Yan1, Ying Han1, Chunlei Fan1, Huiguo Ding1

1Department of Gastroenterology and Hepatology, Beijing Youan Hospital, Capital Medical University Beijing China

Abstract Submission No. 100914

O-1007

Long-term efficacy of rifaximin treatment in Japanese patients with hepatic encephalopathy

Yasuo TANAKA1, Akiko Saito1, Mikio Yanase1

1Department of Gastroenterology, National Center for Global Health and Medicine Tokyo Japan

Abstract Submission No. 100914

O-1007
no serious adverse events after rifaximin usage. Renal function was not impaired after rifaximin administration by 48 weeks.

**Conclusions:** The long-term rifaximin treatment was effective and safe for patients with HE. Our results suggest that rifaximin may improve liver function in patients with decompensated cirrhosis.

**Abstract Submission No. 100942**  
**O-1008**

**Prediction of Mortality in Liver Cirrhosis Patients with AKI using NLR, CTP score and Infection**

Lorenz Kristoffer Daga1, Lovell Gatchalian-Geniales1  
1East Avenue Medical Center Quezon City Philippines

**Background:** Acute kidney injury complicates liver cirrhosis and is associated with increased mortality. Systemic inflammation, liver dysfunction and infection are associated with higher mortality in cirrhotic patients with AKI. We aimed to evaluate the utility of a novel scoring system which combined neutrophil-lymphocyte ratio (NLR), Child-Turcotte-Pugh (CTP) score and presence of infection in predicting in-hospital mortality in liver cirrhosis patients with AKI.

**Methods:** A total of 141 cirrhotic patients with AKI was included in the study. Clinical and biochemical characteristics were obtained. Bivariate and multivariate analyses were done to identify independent predictors of in-hospital mortality. Odds-ratio (OR) was measured using multiple logistic regression. A scoring system was made using the OR of independent predictors. Receiver operating characteristic (ROC) curve analysis was done to assess the accuracy of the novel combined scoring system.

**Results:** NLR, CTP score and presence of infection were identified as independent predictors of outcome. A score of ≥ 2.4 was associated with increased mortality with area under ROC curve (AUROC) of 0.791, 85.9% sensitivity, 61.9% specificity and 84.1% positive predictive value, with an OR of 10.8 (95% CI 4.6 to 25.2). This scoring system is more superior to NLR and non-inferior to CTP score in predicting in-hospital mortality upon comparison of AUROC curves.

**Conclusions:** NLR, CTP score and infection are associated with increased mortality in cirrhotic patients with AKI and a scoring system combining these three variables can be used to identify cirrhotic patients with AKI with an increased risk for in-hospital mortality.

**Abstract Submission No. 101080**  
**O-1010**

**Poor monitoring reduces survival in patients with delta viral cirrhosis**

Adela TURCANU1, 2, Ecaterina Cebanu1, Veronica Cumpata2, Ana Mocanu2, Virginia Salaru1  
1The State University of Medicine and Pharmacy N.Testemitanu Chișinău, 2The Clinic of Gastroenterology and Hepatology Chișinău Moldova

**Background:** Regular monitoring of liver complications is crucial to reduce morbidity and mortality in patients with delta viral liver cirrhosis. **Aim:** To determine the factors associated with liver decompensation in patients with delta viral liver cirrhosis.

**Methods:** We analyzed the factors associated with reduced survival in 144 patients with delta viral liver cirrhosis, followed over a period of 4 years.

**Results:** mean age 52 years, 58% men; 73% come from the south and center of Moldova. Only 20.8% (n=30) of patients had surveillance for HCC and 27.08% (n=39) for liver decompensation throughout the study period. On multivariable regression, age 53.3 years (OR 1.64, p<0.005), compensated cirrhosis (OR 1.91, p<0.001) were associated with significantly higher odds of undergoing surveillance every 6 months for liver decompensation and every 14 months for HCC. Close monitoring every 4 months (p=0.001) versus every 14 months was associated with reduced risk of decompensation.

**Conclusion:** Our study suggests that monitored patients were more likely to prevent decompensation and had significantly better survival. More efforts are needed to optimize the surveillance of patients with delta liver cirrhosis.

**Abstract Submission No. 101093**  
**O-1011**

**Spectrum of Clinical Presentation In Patients With Chronic Liver Disease Secondary To NAFLD**

Kanwal Butani1, Nazish Butt1  
1Jinnah postgraduate medical center JPMC Karachi Karachi Pakistan

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease (CLD). NAFLD is recognized as an important public health problem nowadays and it encompasses a variety of liver pathologies including steatosis, Nonalcoholic steatohepatitis (NASH), cirrhosis and finally hepatoma. The overall prevalence of NAFLD in
Asia is now estimated to be 29.6% and in Pakistan about 15% of general population.

It is a descriptive cross-sectional study in which all patients with CLD NAFLD were enrolled from March 2021 till date presenting in Gastroenterology Department Jinnah postgraduate medical center Karachi. After informed consent all patients were evaluated for the spectrum of presenting symptoms and the data were recorded on preformed proforma.

134 patients were enrolled with the mean age of the patients 42.96 ±13.98. Males w94 (70%) and females 40 (30%). Mean Body mass index (BMI) were 25.84±3.50. Child Pugh Score and MELD Na was calculated of all patients. Risk factors were evaluated 100(74%) of patients had diabetes, 114(85%) had sedentary lifestyle, 80(60%) had dyslipidemia, 64(48%) were smokers and 67(50%) had hypertension.

Most common clinical presentation was ascites 81 (60%), followed by upper gastrointestinal bleeding 50 (37%), hepatic encephalopathy 40 (30%), jaundice 31 (23%), coagulopathy 21 (16%) and hepatorenal syndrome 19 (14%).

Ascites was the most common presenting clinical feature followed by the upper gastrointestinal bleed and hepatic encephalopathy and affecting males more than females. NAFLD is typically a chronic lifelong condition, that may get worse over time and produces debilitating outcomes. Management requires a multidisciplinary approach with clear risk stratification.

Method: This Cross-sectional analytical study was conducted in the Dept. of Gastroenterology, BSMMU from Sept 2019 to Aug 2020. Total 40 compensated cases and 82 decompensated cases were included and information regarding clinical profile, laboratory parameters was collected. LMR, MELD score and CP score were calculated both in compensated and decompensated cirrhotic patient. Correlation between LMR and CP/MELD score were established and cut-off values of LMR were obtained. Bland-Altman plot and Heliey MacNeil test were used for comparison of measurement techniques. Data were analyzed by SPSS 20. p<.05 was considered as a level of significance.

Results: Mean values for LMR and MELD and CP scores were 7.93±3.08, 5.25±0.43 & 7.10±1.19, respectively. Average LMR was significantly higher in compensated group while CP and MELD Score was lower in that group (p<0.001). MELD and CP were positively correlated with each other (p<0.001). LMR was negatively correlated to both MELD and CP scores (p<0.001). Cut-off value of LMR, CP and MELD were LMR < 2.18 (sensitivity: 75%, specificity: 87.3%), CPS ≥13.5 (sensitivity: 75%, specificity: 98.3%) & MELD ≥30.5 (sensitivity: 75%, specificity: 94.9%) respectively. Patients in the low LMR group showed decreased survival than those of high LMR group (p=0.000). Non survived group had lower LMR and higher MELD and CP scores than those of the survived group (p<0.001).

Conclusion: In comparison with CP Score and MELD Score in the determination of hepatic dysfunction severity and outcome in cirrhotic patients, LMR is a useful tool.

Keywords: Liver cirrhosis, lymphocyte count, LMR, CP Score, Meld Score, chronic Hepatitis C, ROC analysis, inflammation mediators, hepatic dysfunction

Abstract Submission No. 101327
O-1014

Severity of liver cirrhosis is negatively correlated to serum levels of FT3.

Murk Mujahid¹, Nazish Butt²
1Jinnah postgraduate medical center karachi Karachi Pakistan,
2Jinnah Postgraduate Medical center Karachi Pakistan

Introduction: Chronic liver disease (CLD) is a leading cause of morbidity and mortality in Pakistan. The liver plays a dominant role in the metabolism of thyroid hormones. Type I deiodinase, which converts part of thyroxine (T4) to triiodothyronine (T3), is the major liver enzyme responsible for approximately 30%-40% of extra thyroidal production of T3. Patients with chronic liver disease may have aberrant functioning of Type I deiodinase causing thyroiditis, hyperthyroidism, or hypothyroidism.

Aims: To determine the levels of FT3 in liver cirrhosis patients.

Methods: It is a cross-sectional study in which patients with liver cirrhosis were enrolled from April 2022 till date at Gastroenterology department Jinnah postgraduate medical center Karachi.

Results: A total of 246 patients (mean age 49±14 years, 160 males and 86 females) with liver cirrhosis were selected. Most common etiology of liver cirrhosis was HCV in 177(72%) patients, 50(20%) had HBV, 10(4.2%) had HBV/HDV and 9(4%) had Non hepatitis B & C related cirrhosis. Among CLD patients, most had CTP score B 158(64%). Among all, 24(10%) patients were found to have hypothyroidism, 12(5.6%) had subclinical hypothyroidism, 2(2%) patients had hyperthyroidism. On bivariate analysis, we found that as the severity of cirrhosis increases, indicated by Child Pugh A to C and increasing MELD, serum levels of FT3 reduces significantly (p value 0.001).

Conclusion: According to this study, we recommend that all cirrhotic patients should undergo thyroid function evaluation as a significant proportion of these patients developed hypothyroidism due to reduced serum levels of FT3.
INDICATIONS OF SYNCHRONOUS SPLENECTOMY FOR TREATMENT OF HCC WITH HYPERSPLENISM AND LIVER CIRRHOSIS

Hung Nguyen¹, Trong Nguyen², Giang Nguyen³
¹National hospital of tropical diseases Hanoi Vietnam, ²National hospital of tropical diseases Hanoi Viet Nam, ³National hospital of tropical diseases Hanoi Hanoi

Hepatocellular carcinoma (HCC) frequently occurs in cirrhotic patients with concurrent hypersplenism, posing challenges in their management. This review article explores the indications of synchronous splenectomy for HCC with hypersplenism due to cirrhosis. Hypersplenism in cirrhosis leads to thrombocytopenia, leukopenia, and erythrocytopenia, impacting interventions. Synchronous splenectomy for HCC with hypersplenism due to cirrhosis. Hyper- hypersplenism-related complications, improving platelet count and coagulation function, reducing bleeding risk and improving hemostasis. Splenectomy also alleviates hypersplenism-related symptoms, enhancing patients' quality of life. Additionally, it aids surgical management by providing better liver exposure, facilitating tumor identification and resection, resulting in improved surgical outcomes and reduced bleeding. Moreover, splenectomy may have immunomodulatory effects. It counteracts the immunosuppressive influence of an enlarged spleen, potentially enhancing tumor control and improving long-term outcomes. However, patient characteristics and careful assessment guide splenectomy decisions. Factors include cirrhosis severity, portal hypertension, comorbidities, and overall health. Evaluation of potential risks and complications, such as infection and thrombosis, is also necessary. In conclusion, synchronous splenectomy is considered for HCC with hypersplenism due to cirrhosis. It addresses complications, aids surgical management, and potentially modulates the immune response. Individual patient assessment and further research are needed to establish clear indications, refine protocols, and determine long-term outcomes of splenectomy in HCC treatment.

Key-words: HCC, Hypersplenism, Synchronous splenectomy, hepatitis, cirrhosis, portal hypertension

Abstract Submission No. 101547
O-1015

Tolvaptan is safe and effective in management of hyponatremia in acute on chronic liver failure

Vinod Arora¹, Rajan Vijayaraghavan², Shiv Kumar Sarin³
¹Department of Hepatology, ILBS Hospital Delhi India, ²Institute of Liver and Biliary Sciences Delhi India, ³Institute of Liver and Biliary Sciences Delhi India

Introduction: There are therefore no treatment options for managing hyponatremia in patients with APASL-ACLF. We retrospectively analyzed our experience of using Tolvaptan in ACLF patients over the past 2 years.

Patients and Methods: 61 patients with ACLF (with serum sodium < 125 mEq/L) non-responsive to free water restriction and plasma volume expansion with albumin were started on tolvaptan on a dose of 7.5 mg OD, (maximum of 15 mg/day). The maximum duration of therapy was restricted to 7 days. Primary end-point was rise in serum Na to >130 Meq/L.

Results: Mean CTP and MELD scores were 11.07 ± 1.07 and 32.75 ± 4.96. Mean baseline serum sodium and creatinine were 118.6 ± 5.43(mEq/L) and 0.71 ± 0.32mg/dL. Pedal edema was noted in 55/61 (90.6%) patients and ≥ Grade II ascites in 53/61(86.8%) patients. Mean dosage and mean duration of therapy were 7.5(7.5-15)mg/day and 5.5±0.70 days. Median daily change in Na: 3(1,6) mEq/L. Patients noted increase in Na>125 mEq/L. Median in-crease in the urine output from the baseline per 24 hours was 475ml/day(-100,700). Decrease in body weight was noted with median decline of -650 (-1200, 400) grams/day. Tolvaptan was well tolerated with only 8/61(13.1%) requiring discontinuation of drug. Increase thirst was noted 28/51(45.9%) of the patients, while new onset trans-aminitis in 8/61(13.1%) patients, 3/61 (4.9%) patients developed AKI(S,creatinine>1.5mg/dl),2(3.2%) developed HÉ(>grade II),2(3.2%) patients had worsening of INR(>1.8) requiring discontinu- tion of drug while 1/61(1.6%) patient witnessed post- EVL ulcer bleed.

Conclusions: Tolvaptan can be safely and effectively used in correcting hyponatremia in ACLF patients.
Abstract Submission No. 102048
O-1018

Clinical Outcomes among Cirrhotic Patients and their Compliance to Quality Indicators (QI) for Care

Joshua Vincent H Baroña1, Jade D Jamiasa

1National Kidney and Transplant Institute Quezon City Philippines

Background: Cirrhosis constitutes a significant public health burden in the Philippines, responsible for 12696 deaths per year. Despite practice guidelines, significant gaps in care remain. Hence Quality Indicators (QI) have been developed as objective measures that may assist stakeholders in identifying potential areas for improvement.

Methods: A retrospective cohort study of adult cirrhosis patients admitted in a tertiary specialty hospital during a five year period was conducted. Detailed demographic, clinical, and outcome information was collected. Compliance with selected Quality Indicators across five domains was assessed based on chart review. The association between demographic and clinical data, compliance with Quality Indicators, and outcomes was analyzed using Pearson R and Chi-square statistics.

Results: 239 patients were included, and only 42.7% received High Quality of Care, defined as compliance with 75% of Quality Indicators for which a patient is eligible. Compliance with Quality Indicators was associated with decreased length of hospital stay (median 8 days, \( p=0.0051 \)), increased time of survival (median 219 days, \( p=0.0380 \)), and lower MELD-Na score compared to non-compliant patients.

Conclusion: Care rendered for Filipino cirrhosis patients in terms of compliance with Quality Indicators remains lacking. Since such compliance is associated with improved clinical outcomes, further studies are needed to formulate and adapt locally appropriate Quality Indicators to address identified gaps in clinical care.

Abstract Submission No. 200132
O-1020

Efficacy and safety of long-term rifaximin treatment for hepatic encephalopathy

Naoto Kawabe1, Teiji Kuzuya1, Sayaka Morisaki1, Yohei Miyachi1, Sayuri Miyachi1, Yuka Ochi1, Hiroyuki Tanaka1, Kazunori Nakaoka1, Takuki Nakano1, Eizaburo Ohno1, Yoshiki Hirooka1

1Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine Toyosake Japan

Aim: Rifaximin (RFX), a therapeutic agent for hyperammonemia in decompensated liver cirrhosis, was approved in Japan after a 12-week clinical trial. This study examined the efficacy and safety of long-term administration of RFX in real-world clinical practice.

Methods: Of 162 cirrhotic patients who started RFX in our department between May 2017 and April 2023, 97 patients who were treated with RFX for at least 12 months and had follow-up were included in this study. Serum ammonia (NH3) levels and adverse events were examined in 80 patients who had never received kanamycin (KM) (new group) and 17 patients who switched from KM to RFX (switched group).

Results: Patient background (median, IQR) was 74 (63-79) years old, male/female = 55/42, CP score 8 (7-9), 29 patients with HCC, 37 patients with major PV shunt, 45 patients with ascites, 56 patients with diuretics, 57 patients with synthetic disaccharides agents, 84 patients with oral branched chain amino acids, coma grade (Inuyama Classification) of hepatic encephalopathy (HE) at start of treatment; I/II/III/IV/V=8/15/12/2/0, RFX treatment period 23(7-35) months. Serum NH3 levels (\( \mu g/dL \)) were 77 (62-134) after 1 month (M), 81 (51-98) after 3 M, 88 (72-99) after 6 M, 84 (55-110) after 12 M, 85 (57-122) after 24 M, and 71 (54-111) after 48 M, significantly lower than 133 (84-181) at the beginning of treatment, respectively (all \( p<0.05 \)). Similarly, NH3 levels in the new group were significantly lower than those at the start of treatment from 1M to 48M (all \( p<0.01 \)). NH3 levels in the switched group did not change significantly from those before the switched administration until after 48M. In a sub-analysis, there was no significant difference in NH3 levels between patients with and without HCC, and NH3 was significantly higher in the group with ascites than in the group without ascites (\( p=0.003 \)). 15 patients (15.5%) had HE recurrence during RFX administration. In a multiple logistic regression analysis, HE grade III or higher at the initiation of RFX was selected as a factor associated with HE recurrence (\( p=0.038 \), OR 17.32, 95%CI 1.332-183.7). There were no discontinuations due to adverse events, and no significant changes in Plt, PT, Alb, T-Bil, AST, ALT, eGFR until 48M.

Conclusion: Treatment efficacy was maintained up to 4 years after initiation of RFX, and there was no NH3 elevation in patients who switched from KM. Long-term treatment with RFX was effective and safe, with no discontinuation due to adverse events, even in patients with poor hepatic function, and the risk of HE recurrence was high in patients with HE grade III or higher at the initiation of RFX.

Abstract Submission No. 200152
O-1019

Muscle Mass Dynamics is Associated with Long-term Liver-related Mortality in Cirrhotic Patients

Jiarui Zheng1, Shuo Yang2, Rui Huang3

1Peking University People’s Hospital Beijing China, 2Peking University People’s Hospital Beijing China, 3Peking University People’s Hospital Beijing China

Objectives: Sarcopenia has a detrimental impact on the prognosis of individuals with liver cirrhosis, however, the clinical significance of alterations in muscle mass remains uncertain. This study aims to investigate the influence of loss of skeletal muscle mass (LSMM) on the prognostic outcomes among patients diagnosed with cirrhosis.

Methods: In this retrospective analysis, a total of 158 individuals with cirrhosis who visited our hospital during the period from January 2018 to August 2023 were included.

Results: Of the 158 cirrhotic patients, 95 (60.1%) patients were identified as LSMM. The median of ΔSMA/y% was -0.9 (interquartile range [IQR], -3.8, 1.6) in all patients. Chronic kidney disease (CKD) cited more than in the group without ascites (\( p=0.003 \)). 15 patients (15.5%) had HE recurrence during RFX administration. In a multiple logistic regression analysis, HE grade III or higher at the initiation of RFX was selected as a factor associated with HE recurrence (\( p=0.038 \), OR 17.32, 95%CI 1.332-183.7). There were no discontinuations due to adverse events, and no significant changes in Plt, PT, Alb, T-Bil, AST, ALT, eGFR until 48M.

Conclusion: Treatment efficacy was maintained up to 4 years after initiation of RFX, and there was no NH3 elevation in patients who switched from KM. Long-term treatment with RFX was effective and safe, with no discontinuation due to adverse events, even in patients with poor hepatic function, and the risk of HE recurrence was high in patients with HE grade III or higher at the initiation of RFX.
Incidence and associated risk factors for recurrence of HRS-AKI in Patients with Cirrhosis

Rajat Kalra1, Praveen Sharma1, Akshay Kale1
1Sir Gangaram Hospital New Delhi India

Introduction: HRS accounts for approximately 25% of cases of pre-renal AKI in cirrhosis. Recurrence of HRS-AKI after treatment is variable, ranging from 25-50% in different studies. There is limited literature on the factors that predict recurrence of HRS-AKI.

Objectives: To assess the incidence and factors predicting recurrence of HRS-AKI in patients with liver cirrhosis. Patients diagnosed with HRS-AKI were recruited after applying inclusion and exclusion criteria and treated at physician’s discretion. Patients with complete response to the treatment for HRS-AKI were followed. The primary outcome was recurrence of HRS-AKI at 3-month follow-up. The secondary outcome was identification of risk factors for recurrence of HRS-AKI.

Results: Ninety-three patients were enrolled in the study. Sixty-four (68.81%) patients had a complete response to HRS-AKI treatment. During follow-up, HRS-AKI recurred in 11 (21.57%) patients. The mean of MAP at admission was significantly higher in patients without HRS-AKI recurrence (79.5 ± 7.34mmHg) than in patients with HRS-AKI recurrence (74.86 ± 4.5mmHg) (p-value = 0.0008). Patients who received midodrine had significantly higher MAP at last visit than patients who did not receive midodrine (2.44 ± 3.42mmHg vs -1.06 ± 3.44mmHg) (p-value = 0.0002). Conclusion: A higher MAP on admission and a higher MAP on follow-up protect against recurrence of HRS-AKI. Administration of midodrine significantly increases MAP and may play a role in secondary prevention of HRS-AKI.

Simultaneous development of NASH and atherosclerosis in New Zealand and Japanese white rabbits

QIANQIAN ZHENG1, Momoko Hayashi1, Yoshibumi Kuwabara2, Kuniji Ito2, Yoshiaki Hojo2, Fumiaki Araki2, Kazuki Kamijima2, Masakazu Takeiri2, Xiaojing Wang3, Pan Diao3, Jun Nakayama4, Naoki Tanaka5
1Department of Metabolic Regulation, Shinshu University School of Medicine Matsumoto 390-8621 Japan, 2Kitayama Labes Co., Ltd., Ina 396-0025, Japan, 3Department of Gastroenterology, Lishui Hospital, Zhejiang University School of Medicine, Lishui 310030, China, 4Department of Molecular Pathology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan, 5Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan, 6International Relations Office, Shinshu University School of Medicine, Matsumoto 390-8621, Japan, 7Research Center for Social Systems, Shinshu University, Matsumoto 390-8621, Japan

Non-alcoholic fatty liver disease (NAFLD), particularly non-alcoholic steatohepatitis (NASH), is sometimes accompanied by arteriosclerosis and ensuing cardiocerebrovascular diseases, such as acute coronary syndrome and cerebral infarction. Conversely, individuals with arteriosclerotic cardiovascular diseases often have underlying NAFLD/NASH. Therefore, the simultaneous treatment of both diseases is required. Animal models simulating human clinical conditions are indispensable for establishing therapeutic interventions in humans. However, there is a lack of rodent models for simultaneous investigation of NAFLD/NASH and arteriosclerosis, because wild-type rodents basically exhibit higher high-density lipoprotein levels with lower low-density-lipoprotein levels compared to humans. Since rabbits exhibit similar lipoprotein profiles to humans, we hypothesized that rabbits may be the promising models for simultaneously evaluating NAFLD and arteriosclerosis. We treated a newly developed high-fat high-cholesterol diet (HFHCD) containing palm oil 7.5%, cholesterol 0.5%, and ferrous citrate 0.5% with male New Zealand White rabbits and Japanese White rabbits, respectively, for 14 weeks and assessed the phenotypes of liver and aorta. Both rabbit strains exhibited NASH and atherosclerosis 8 weeks after commencing the HFHCD feeding, progressing to advanced fibrosis and complete arterial arteriosclerosis at 14 weeks of the treatment. Additionally, inductions of genes related to inflammation and fibrosis, particularly at 4 weeks, were similar between the two strains. In conclusion, these white rabbit models are likely suitable preclinical models for simultaneous investigation for human NAFLD/NASH and arteriosclerosis.
Sasicha Kitphati¹, Ponthakorn Pichayanon¹, Sutat Ruangjugipop¹, Krittiya Kraisuan¹, Rattikorn Thungsuk¹, Natee Faknak¹
¹Sawanpracharak hospital Nakhon Sawan Thailand

Background: Methotrexate associated liver fibrosis is well established concern. Increasing evidence suggested that methotrexate was not the main culprit but concomitant diseases such as diabetes and obesity were. Transient elastography (TE) is widely used since it is non-invasive. When TE is not available, AST to Platelet Ratio Index (APRI) and Fibrosis-4 index (FIB-4) may be used. This study aimed to determine the association between liver fibrosis and cumulative dose of methotrexate, and evaluate accuracy of APRI, FIB-4 in comparison to TE.

Methods: A single-center retrospective study was conducted between March 2018 and February 2023 at Sawanpracharak Hospital. The patient’s characteristics and risk factors were analyzed. All patients were assessed by TE, APRI and FIB-4. Significant liver fibrosis is defined by TE > 7.9 kPa. The cut off of APRI and FIB-4 are 0.5 and 1.45.

Results: 59 of 272 psoriatic patients using methotrexate had significant liver fibrosis. Having BMI (Body Mass Index) > 30, hypertension, hyperlipidemia and diabetes mellitus were significantly associated with liver fibrosis(table). The accuracy of APRI and FIB-4 were 88.6% and 80.8%. Performance of FIB-4 is similar to APRI, with area under the curve of 0.797 vs. 0.795 (p=.529) (figure)

Conclusion: Cumulative dose of methotrexate was not significantly associated with significant liver fibrosis, but other risk factors such as hypertension, hyperlipidemia, diabetes mellitus, and morbid obesity were. Both APRI and FIB-4 had high accuracy in diagnosing liver fibrosis comparing with TE and could be used as an alternative in areas with limited resources.
and 855 breast cancer patients in whom LET and anastrozole (ANA) were prescribed at an interval of ≥ 24 months from 2006 to 2020. Among them, patients in whom LET/ANA had been continuously administered for ≥ 24 months and had the FIB-4 index ≥ 2.30 at baseline were selected. Finally, 23 LET-treated and 43 ANA-treated patients were included. All patients were female. There were no significant differences in age, disease stage, background liver disease and prior/concomitant drug therapy between groups. Changes in the FIB-4 index in the LET group were 2.92 (mean), 2.78, 2.79, 2.59 and 2.53 at baseline, 6, 12, 18 and 24 months; a significant decrease was observed at 18 and 24 months (p=0.044 and p=0.013) compared with baseline. On the other hand, changes in the FIB-4 index in the ANA group were 2.94, 2.95, 2.94, 2.87 and 2.86 at baseline, 6, 12, 18 and 24 months. Regarding APRI, a significant decrease was observed in the LET group at 18 and 24 months (p=0.024 and p=0.026) compared with baseline, whereas no significant decrease was observed in the ANA group. Our results showed that LET, but not ANA, improved FIB-4 and APRI, supporting the possible suppressive effect of LET on liver fibrosis.

Abstract Submission No. 100579
O-1029

Distribution of Chitosanase 3-like Protein (CHI3L1) in HBeAg-negative CHB Patients with Normal ALT

En-Qiang Chen1, Cheng-Run Song1, Yu-Jing Li1, Min He1, Xi-Jia Luo1, Dong-Mei Zhang1

1West China Hospital, Sichuan university Chengdu China

Objective: To investigate the distribution of chitosanase 3-like protein (CHI3L1) in HBeAg negative chronic HBV infected individuals with normal ALT

Method: The data of this study was obtained from a single center prospective randomized controlled study, which involved HBeAg-negative but HBV DNA positive patients with sustained normal ALT. All patients had not received antiviral treatment. The serum CHI3L1 level was quantitatively detected using chemiluminescence enzyme-linked immunosorbent assay method, which was completed by Guangzhou Kingmed Diagnostics Group Co., Ltd.

Result: A total of 145 patients were included, including 79 males and 66 females, with an average age of 39.8 years. All patients had LSM £ 8.0 kpa. In this group of patients, the average level of CHI3L1 was 48.43 ng/mL, with 68.3% (99/145) of patients having serum CHI3L1 <53.5 ng/mL, 22.1% (32/145) of patients having serum CHI3L1 between 53.5 ng/mL and 79 ng/mL, and 9.7% (14/145) of patients having serum CHI3L1 >79 ng/mL. Among these 145 patients, 132 had FIB-4 score <1.45, with an average serum CHI3L1 level of 54.62 ng/mL, and 7.5% (10/132) of these patients had serum CHI3L1 >79ng/mL. There were 126 patients had APRI score <0.5, with an average serum CHI3L1 level of 53.96ng/mL, and 6.3% (8/126) of these patients had serum CHI3L1 >79ng/mL.

Conclusion: The distribution of serum CHI3L1 levels in some ALT normal HBeAg-negative CHB patients who have not received antiviral treatment is relatively high, and it is necessary to be cautious about the possibility of significant liver fibrosis in these patients.

Abstract Submission No. 100590
O-1030

Translational potential role of Zeb2 in liver fibrosis and NAFLD

Qianwen Zhao1, Fajuan Rui1, Jie Li1

1Department of infectious diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China

Background and Aims: Myofibroblasts, characterized by the expression of the matricellular protein periostin (Posn), mediate the pro-fibrogenic response during NAFLD. Previous studies have demonstrated that endothelial deficiency in zinc-finger E-box-binding homeobox 2 (Zeh2) attenuates liver fibrosis in mice. In the present study, we investigated the myofibroblast-specific role of Zeb2 in liver fibrosis during the development of NAFLD and the underlying mechanism.

Methods: We generated myofibroblasts Zeb2 knockout mice, by injecting AAV6-Posn-shZeb2 virus, and then established BDL and HFD-diet model to investigate the role of Zeb2 in pro-fibrogenic response during liver fibrosis and NAFLD. RNA-seq was performed to detect the underlying mechanism of myofibroblast Zeb2 in liver fibroblasts. The genemania predicted upstream gene of Zeb2 was also verified.

Results: Zeb2 knockout retarded the fibroblast-myofibroblast transition (FM) in vitro and damaged liver fibrosis in mice. We also report that myofibroblast conditional deletion of Zeb2, achieved through injecting AAV6-Posn-shZeb2 virus, led to amelioration of liver fibrosis. RNA-seq detect the underlying mechanism of myofibroblast Zeb2 in liver fibroblasts. Moreover, genemania predicted PTPRD is the upstream gene of Zeb2. Slicing PTPRD expression significantly upregulated the level of Zeb2 and then promote the development of NAFLD.

Conclusions: Accordingly, our data unveil a novel PTPRD-Zeb2 axis that can potentially contribute to fibroblast-myofibroblast transition and NAFLD. Screening for small-molecule compounds that target this axis may yield therapeutic options for the mollification of NAFLD.

Abstract Submission No. 100665
O-1031

NogoB promotes liver fibrosis by USP14 mediated RIPK3-derived M  MP  inflammation and necroptosis

Jianhua Rao1, Lei Zhang1, Ming Ni1, Wenzhu Li1, Junda Li1, Yongquan Chi1, Zhengfeng Xuan1, Feng Cheng2, Ling Lu1

1Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University; Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing 210029, China Nanjing China

Background: Liver fibrosis is the result of chronic liver injury, current studies show early hepatic fibrosis can be reversed, regulating the immune response mediated by macrophages is the key to reverse liver fibrosis. Nogo-B is an endoplasmic reticulum-residential protein with distinctive functions. However, the role of Nogo-B in macrophages in liver fibrosis has not been clearly defined.

Methods: Expression analysis was conducted with human liver samples obtained from 30 patients with liver fibrosis and 19 individuals without fibrosis as controls. Myeloid-specific Nogo-B knockout (Nogo-Bmko) mice were constructed to explore function and mechanism of macrophage Nogo-B in 3 murine models of liver fibrosis induced by carbon tetrachloride injection (CCl4), bile duct ligation (BDL) or methionine-deficient and choline-deficient diet (MCD) in vivo. Nogo-Bmko bone marrow-derived macrophages were used in vitro.

Results: Nogo-B expression in macrophages is increased and positively correlated with histological stages of liver fibrosis in humans and mice. Nogo-B deficiency significantly alleviated BDL, CCl4 and MCD induced liver injury, inflammatory responses, and hepatic fibrosis. Nogo-B deficient macrophages relieved LPS-induced inflammatory responses and NLRP3 inflammasome activation. Notably,
expression of RIPK3 was effectively inhibited in Nogo-B deficient macrophages. Further research showed Nogo-B recruited USP14 to suppress RIPK3 ubiquitination and facilitated RIPK3 phosphorylation, increased macrophages’ death in vivo and in vitro.

**Conclusion:** Nogo-B promotes macrophage’s inflammation and necroptosis, enhances progression of liver fibrosis by recruiting USP14 to reduce RIPK3 ubiquitination and facilitate RIPK3 phosphorylation. It reveals key role of macrophage Nogo-B in liver fibrosis, and provides a key therapeutic target for liver fibrosis.

Abstract Submission No. 100703

**O-1032**

**Systemic immune-inflammation index level negatively linked with liver inflammation and fibrosis**

Xiaohao Wang1, Shan Zhong1, Lu Zhang1, Da chuan Cai1, Hong Ren1, Peng Hu1, Hu Li1

1Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University Chongqing China

**Background and Aims:** Systemic immune-inflammation index (SII) was calculated as platelet count × neutrophil count/lymphocyte count which was first raised by Hu et al at 2014. We aimed to investigate the association between SII and pathological severity of CHB.

**Methods:** This is a cross-sectional study of the subset of consecutive patients with CHB who underwent liver biopsy between November 7, 1997, and October 31, 2021. The demographic characteristics, clinical data were collected.

**Results:** A total of 838 eligible CHB patients were included in this study. Correlation analysis showed a significant negative correlation between SII and liver inflammation grades (P < 0.001). In univariate analysis, after progressive adjustment for various risk factors for liver injury, SII was still associated with significant liver inflammation (P = 0.02) and fibrosis events (P = 0.005) in the final multivariable model. The ORs for significant hepatic inflammation and fibrosis progressively decreased across tertiles of SII (all P < 0.05). There was no significant dependence of age, sex, ALT level, HBV DNA, HBeAg status, and antiviral therapy on this negative association (all P > 0.05).

**Conclusion:** SII was negatively associated with liver inflammation and fibrosis events in patients with CHB. Elevation in SII index and ALT can independently predict liver inflammation.

Abstract Submission No. 100834

**O-1034**

**FIBROSIS DISTRIBUTION IN LEAN vs. OBESE NASH-CIRRHOsis BY SHG/TPE MICROSCOPY**

Kutbuddin Akbary1, Ren Yayan1, Dean Tai1, Michael Inkmann2, Pol Boudes3

1HistolIndex Pte Ltd Singapore Singapore, 2Galecitt Therapeutics Inc Norcross USA

**Background:** Inclusion criteria for drug trials focusing on Non-Alcoholic Steatohepatitis (NASH) cirrhosis require patients classified fibrosis stage as F4 by pathologists. However, F4 classification lacks comprehensive recording of zonal fibrosis parameters based on NASH Clinical Research Network (CRN). Second Harmonic Generation/Two Photon Excitation (SHG/TPE) microscopy-based qFibrosis (qF) offers fully quantitative evaluations. This study compares zonal fibrosis distribution between lean [Body Mass Index (BMI)<25] and overweight/obese (BMI≥25) patients using qF.

**Methods:** 133 patients from Phase 2b Belapectin drug trials (NCT04365868) were included. Paired liver biopsies were evaluated using qF based on NASH-CRN parameters. Patients were categorized into two groups: lean (n=9) and overweight/obese (n=124) in Baseline (BL) group, and lean (n=7) and overweight/obese (n=126) in End-of-Treatment (EOT) group. Statistical analysis by Wilcoxon-rank-sum-test, heat maps employed for visualization.

**Results:** BL group had statistically significant difference in perportal fibrosis parameters between lean and overweight/obese patient (Figure 1). Despite smaller number of patients in lean group compared to overweight/obese group, consistent observation of this significant difference of fibrosis parameters such as fiber length, thickness, etc. in perportal region in BL and EOT groups indicates a possible difference in fibrosis morphology patterns based on BMI.

**Conclusions:** Consistent differences in perportal fibrosis parameters between lean and overweight/obese patients using qF indicates...
SHG/TPE imaging provides additional information compared to conventional pathologist staging. These findings suggest there could be variations in zonal fibrosis distribution among NASH cirrhosis patients, based on BMI status. Further research with larger patient cohorts would be recommended to expand upon these preliminary observations.

Abstract Submission No. 100838
O-1035

Androgen receptor affects the proliferation and metabolism of hepatic stellate cells through EGFR

Ruojing Wang1, Yuan Yang1, Shan Fu1, Xiaoli Zhang1, Tianzhi Ni1, Yali Feng1
1the First Affiliated Hospital of Xi’an Jiaotong University Xi’an China

Aim & Background: There are significant gender differences in the occurrence and progression of liver fibrosis, in which activation of hepatic stellate cells (HSCs) is an important step. Our study aimed to reveal the mechanism of androgen in the activation of HSCs.

Methods & Results: In the carbon tetrachloride (CCl4)-induced liver fibrosis mouse model, the degree of fibrosis in male mice was more severe than that in female mice. In male mice, castration led to a reduction in the degree of liver fibrosis, and immunofluorescence showed that the androgen receptor was localized in perivascular non-parenchymal cells. In the activation of mouse primary hepatic stellate cells in vitro, androgen receptor (AR), α-SMA and Mmp2 were simultaneously increased. Treatment with 10nM DHT increased EGFR and CCND1 at 24h, α-SMA and GLUT1 increased at 72h. In LX2 cells, DHT treatment increased EGFR, and EdU staining showed a slight increase in cell proliferation (p=0.055). The Erk signaling pathway was promoted EGFR expression, activate cell cycle progression and glycolysis, and liver fibrosis in NASH progression. In contrast, AR, α-SMA, CCND1 and GLUT1 were significantly decreased, and EdU staining showed that the cell proliferation ability was decreased (p<0.05). The key glycolytic enzyme PKM2 was significantly decreased and recovered after DHT supplement.

Conclusion: In hepatic stellate cells, androgen binds to AR and promote EGFR expression, activate cell cycle progression and glycolysis, promote the activation of HSCs and the progression of liver fibrosis.

Abstract Submission No. 101246
O-1037

FgII-CaR mediated NETs promote intravascular coagulation and liver fibrosis in NASH progression

Qin NING1, Xitang Li2, Junjian Hu2, Suping Hai3, Qiang Gao2, Wenhui Wu2, Erliang Xie1, Binghui Yu2, Xiaojing Wang3
1Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan China

Background: Procoagulant imbalance was observed in non-alcoholic steatosis (NASH) patients with liver fibrosis, but the role of coagulation in NASH fibrosis remains largely unclear. Neutrophil extracellular traps (NETs) served as an essential factor in immuno-thrombosis. Here, we aim to study the role of NETs-mediated complement and coagulation activation in NASH fibrosis and the underlying mechanism.

Methods: NETs were depleted by intraperitoneal injection of Dnase 1. Wild type (WT) and fgII-CaR-/- C57BL/6 mice were treated either with 60% high fat diet (HFD) or methionine/choline-deficient (MCD) diet to induce NASH fibrosis. RNA-Seq of hepatic tissues or liver leukocytes were conducted in WT and fgII-CaR-/- mice. Bone marrow neutrophils from WT and fgII-CaR-/- mice were subjected to palmitic acid (PA) and LPS in vitro.

Results: Abundant neutrophil accumulation and NETs formation were observed in NASH progression. NETs depletion improved liver fibrosis, inflammatory response and lipid accumulation both in HFD and MCD models. Meanwhile, decreased coagulation activation, including lower level of plasma thrombin-anti-thrombin complex (TAT) and hepatic fibrin deposition was observed following Dnase 1 treatment. Highly expressed on hepatic neutrophils, fibrinogen-like protein 2 (FGL2) localized tightly with NETs area. Fgl2 knockout inhibits NETs formation and coagulation activation in NASH progression. Combined with RNA-Seq analysis, in vivo and in vitro experiment identified that NETs formation was regulated by FGL2-CaR axis. Treatment with CaR antagonist alleviated NETs formation, coagulation activation and liver fibrosis in vivo.
Conclusions: NETs mediated coagulation dysregulation promotes NASH fibrosis progression. In depth, NETs formation was regulated by FGL2-C3aR axis.

Abstract Submission No. 101380
O-1038

Optimal cut-offs for diagnosis of liver fibrosis in chronic hepatitis B during antiviral treatment

Xiaonng Wu1, Jialing Zhou1, Yameng Sun1, Bingqiong Wang1, Shuyan Chen1, Tongtong Meng1, Chenghai Liu1, Yongpeng Chen1, Hunguo Ding2, Hong Zhao2, Wei Jiang2, Hongxin Piao2, Xiaojuan Ou2, Hong You1, Jidong Jia1

1Beijing Friendship Hospital, Capital Medical University Beijing China, 2Shuguang Hospital, Shanghai University of Traditional Chinese Medicine Shanghai China, 3Nanjing Hospital of Southern Medical University Guangzhou China, 4Beijing YouAn Hospital, Capital Medical University Beijing China, 5Beijing Ditan Hospital, Capital Medical University Beijing China, 6Shanghai Zhongshan Hospital, Fudan University Shanghai China, 7The Affiliated Hospital of Yanbian University Yanbian China

Background: Liver stiffness measurement (LSM) has been regarded as the most extensively accepted non-invasive method to evaluate liver fibrosis. However, cut-off values for diagnosis of liver fibrosis in chronic hepatitis B (CHB) during antiviral treatment are unknown.

Methods: Adult CHB patients from three clinical studies who had liver biopsy and LSM simultaneously at least 6 months after initiation of antiviral treatment were enrolled. Fibrosis stage was assessed according to the METAVIR scoring system. LSM were performed with FibroScan or Fibrotouch. The performance of LSM to identify liver cirrhosis in on-treatment CHB patients was analyzed by using area under receiver operating characteristic curve (AUROC).

Results: A total of 816 patients were enrolled and randomly divided into training set and validation set at a ratio of 2:1. About 74.3% (404/544) were male with a median age of 42.0 (34.3, 49.7) and the duration from initiation of antiviral treatment to liver biopsy was 1.5 (1.0, 3.1) years. The cut-offs of LSM for diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis during antiviral treatment were 6.8, 7.6, and 7.9 kPa respectively. The sensitivity were 65.7%, 82.0%, and 78.6%, the specificity were 78.7%, 72.9%, and 90.4% respectively. The AUROC for diagnosis of F2, F3, and F4 were 0.796 (95% confidence interval 0.755-0.834), 0.828 (0.794 to 0.859), and 0.835 (0.803 to 0.867).

Conclusion: Optimal cut-offs for diagnosis of F2, F3, and F4 in on-treatment patients with CHB were 6.8, 7.6, and 7.9 kPa respectively, which were much lower than the previous ones derived from untreated patients.

Abstract Submission No. 102052
O-1040

Deep attenuation transducer for liver stiffness measurement in obese patients with liver disease

Ryo Yano1, Masashi Hirooka1, Yohei Koizumi1, Yoshiko Nakamura1, Makoto Morita1, Yuki Okazaki1, Yusuke Imai1, Takao Watanabe1, Osamu Yoshida1, Yoshihiko Tokumoto1, Masanori Abe1, Yoichii Hiasa1

1Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine Toon Japan

Background: Deep attenuation transducers (DAX), capable of imaging at depths of up to 40 cm, have not been clinically evaluated for liver stiffness measurement (LSM). The aim of this study was to evaluate the feasibility and reliability of DAX for LSM in patients with chronic liver disease.

Methods: 219 patients were enrolled. The performance of DAX was compared with conventional convex (c-convex) probes and M and XL probes of vibration-controlled transient elastography. Success rate (obtained after ≥ 10 valid measurements) and inadequate measurements (interquartile range/median ≥ 0.3) were evaluated. The effect of skin-to-liver capsule distance (SCD) on measurement success was analyzed.

Results: DAX successfully performed LSM in all patients with varying SCD. Notably, in patients with SCD ≥ 30 mm, DAX demonstrated a 100% success rate in obtaining 10 valid measurements, outperforming M probe (24.2%), XL probe (78.8%) and c-convex probe (76.7%). Inadequate measurement rates in patients with SCD ≥ 30 mm were lower for DAX (2.3%) compared to M probe (12.5%), XL probe (30.8%) and c-convex probe (18.2%). Areas under the curve for F4 diagnosis with shear wave speed were comparable between c-convex and DAX (0.916 and 0.918, respectively). An excellent intraclass correlation coefficient (ICC) was observed between DAX and conventional convex probes (ICC = 0.64) and M and XL probes (ICC = 0.51-0.55).

Conclusion: DAX is a feasible and reliable method for liver stiffness measurement in obese patients with chronic liver disease.
correlation (0.937, 95% CI 0.918-0.952) and no statistically significant bias was observed when comparing DAX and c-convex probe.

**Conclusions:** DAX demonstrates feasibility and reliability in LSM in different patient populations, while the XL probe has limitations, especially in obese patients.

**Abstract Submission No. 200008**

**O-1041**

**Comparison of 2D-SWE Measurements in Evaluating Liver Fibrosis Using Different Instruments**

Jiayao Huang1, Xiaor Zhang1, Liya Su1, Ming Liu1, Ming Xu1, Bowen Zhuang1, Baixian Liu1, Tongyi Huang1, Hongtong Hu1, Xiaohua Xie1, Xiaoyan Xie1, Manxia Lin1

1Sun Yat-sen First Affiliated Hospital Guangzhou China

**Background:** Two-dimensional shear wave elastography (2D-SWE) is a noninvasive method to assess liver fibrosis, which is crucial for hepatocellular carcinoma (HCC) patients. It is of interest to understand whether 2D-SWE measurement values are different in the same population and to explore the potential clinical factors contributing to the variation of different instruments.

**Purpose:** This study aimed to investigate and compare 2D-SWE measurement and its influencing factors in two different devices, and to evaluate the ability and potential influence factors of them to assess liver fibrosis.

**Methods:** From October 2022 to September 2023, 290 HCC patients and 30 healthy volunteers were prospectively included. The 2D-SWE measurements were performed using Aixplorer V (SEmean) and APLIO i900 (CEmean). The study compared instruments’ 2D-SWE measurement in evaluating the liver fibrosis stage and analyzed the potential influence factors.

**Results:** In patients included, most (89.8%) were males and the median age was 58.00 [IQR: 49.75, 67.00] years. Both the two instruments had excellent reproducibility (both ICC >0.90, p <0.001). 2D-SWE measurement values of the two instruments were significantly different (p <0.001), but the differences were only significant in liver fibrosis stage S4 patients (p <0.001), rather than in volunteers or S0 to S3 patients (all p >0.050). Multivariate linear regression analysis showed that the independent influence factors of Emean were alanine aminotransferase (ALT) (p=0.034) and liver fibrosis stage (p <0.001) of SEmean, while fibrosis stage (p=0.028) was the only factor of CEmean.

**Conclusion:** Although 2D-SWE from different instruments were capable of evaluating liver fibrosis, they yielded varying measurement values in HCC patients. These discrepancies were predominantly observed in patients with S4 liver fibrosis, while not significant in healthy adults or patients with liver fibrosis stage of S0 to S3. One potential contributing factor to the differences between instruments could be the levels of ALT.

**Abstract Submission No. 200145**

**O-1042**

**Crosstalk of LOX and LOXL1 affect liver fibrosis progression via notch passway**

Ning Zhang1, 2, 3, Wei Chen1, 2, 3, Aiting Yang2, 3, 4, 5, Wen Zhang1, 2, 3, Hong Li2, Anjian Xu2, 3, 4, 5, Xuzhen Yan6, Qi Han1, 2, 3, Bingqiong Wang6, Dong You6

1Beijing Friendship Hospital, Capital Medical University Beijing China, 2State Key Lab of Digestive Health Beijing China, 3National Clinical Research Center of Digestive Diseases Beijing China, 4Beijing Clinical Research Institute Beijing China, 5Experimental and Translational Research Center Beijing China

**Background:** Lysyl oxidase (LOX) family members (LOX and LOXL1 to 4) are crucial copper-dependent enzymes responsible for cross-linking collagen and elastin. Previous studies have revealed that LOX and LOXL1 are the most dramatically dysregulated LOX isoforms during liver fibrosis. However, the crosstalk between them and the underlying mechanisms involved in the pro-fibrotic behaviors of hepatic stellate cells (HSCs), as well as the progression of liver fibrosis, remain unclear.

**Methods:** pCol9GFP-HS4,5fl mice, Loxl1fl/flGfapfl mice, human HSC line, and primary HSCs were enrolled to study the dysregulation pattern, profibrotic roles and the potential mechanisms of LOX and LOXL1 interaction involved in the myofibroblast-like transition of HSCs and liver fibrogenesis.

**Results:** LOX and LOXL1 were synergistically upregulated during liver fibrogenesis, irrespective of etiology, together orchestrating the profibrotic behaviors of HSCs. LOX and LOXL1 co-regulated in HSCs, whereas LOXL1 dominated in the co-regulation loop. Interestingly, the interaction between LOXL1 and LOX prolonged their half-lives, specifically enhancing the Notch signal-mediated myofibroblast-like transition of HSCs. Selective disruption of Loxl1 in GfapHSCs deactivated the Notch signal, inhibited HSC activation, and relieved carbon tetrachloride (CCL4)-induced liver fibrosis.

**Conclusion:** Our current study confirmed the synergistic roles and the underlying mechanisms of LOXL1 and LOX crosstalk in the profibrotic behaviors of HSCs and liver fibrosis progression, providing experimental evidence for further clear mechanism-based anti-LOXL1 strategy development in the therapy of liver fibrosis.

**KEY WORDS:** extracellular matrix; cycloheximide; fibrogenesis; collagen; myofibroblast

**Abstract Submission No. 200161**

**O-1043**

**AHR improved cholestatic liver injury by reducing neutrophil infiltration and modulating BAs pools**

qi Han1, Xu Z Yan1, Li K Wang2, Ning Zhang1, Wen Zhang1, Hong Li1, Wei Chen1, Hong You1, Ai T Yang1

1Beijing Friendship Hospital, Capital Medical University Beijing China, 2China Agricultural University Beijing China

**Background & aims:** Cholestatic liver disease is defined as the bile acids (BAs) accumulation in the liver, which, if left untreated, can result in hepatic fibrosis, cholestatic cholangitis, cholestatic cirrhosis, and eventually, end-stage liver disease. Aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor with far-reaching effects on chronic liver disease. However, its role and mechanism in cholestatic liver damage is still unknown.

**Methods:** The roles and mechanisms of AHR in Cholestatic liver disease were investigated by using AHR overexpression mediated by using adeno-associated viral (AAV) vectors, or ITe (an AHR Ligand) received a 0.1% 3,5-dioxytocarbonyl-1,4-dihydrocollidine (DDC) diet.

**Results:** We found that AHR was differentially expressed in different stages of cholestatic liver disease, showing either down-regulation or an increase in protective effects. Overexpression of AHR increased body weight, decreased serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil) and alkaline phosphatase (ALP); reduced porphyrin accumulation in liver tissue, and regulated the bile acid pool in the cholestatic mouse model induced by
DDC diet. Mechanistically, the DDC diet led to neutrophil infiltration, whereas overexpression of AHR reduced neutrophil recruitment by decreasing chemokine expression, which in turn improves cholestatic liver disease.

**Conclusion:** Our data indicate that AHR attenuated cholestatic liver injury. AHR function indicates that it may have an action in the clinical management of cholestasis.

**Abstract Submission No. 200236**

**O-1044**

**Total Astragalus Saponins Attenuate Primary Sclerosing Cholangitis in Mice by Upregulation of TGR5**

**Jiamei Chen1,2, Qun Zhou1,2, Siqi Gao1,2, Xiaohan Yu1,2, Linzhang Zhang3, Zheng Zhang1,2, Wei Liu2, Ping Liu1,2**

1Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases of Ministry of Education, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine Shanghai China

Total astragalus saponins (TAS) are the main active components of *astragalii radix*, and have potent anti-hepatic fibrosis activity. However, the therapeutic efficacy of TAS and their potential mechanisms in the treatment of primary sclerosing cholangitis (PSC) remain unclear. The results indicated that treatment with TAS, particularly with a dose of 56 mg/kg, significantly ameliorated the PSC-related liver injury, cholestasis, collagen deposition, ductular reaction (DR) and fibrosis in the DDC-induced and Mdr2+/- spontaneous PSC mice. Furthermore, treatment with TAS significantly mitigated the PSC-related inflammatory responses in the liver of mice and HIBEpiC cells by inhibiting the expression of TNF-α, IL-6, and IL-1β. Mechanistically, treatment with TAS rescued the PSC-decreased hepatic TGR5 and SIRT1 expression to attenuate the NF-κB p65 phosphorylation. Notably, the therapeutic efficacy of TAS on PSC in DDC-induced mice was abrogated in TGR5-/- mice, suggesting the anti-PSC effect of TAS may depend on enhancing TGR5 expression. In conclusion, treatment with TAS ameliorated DR, inflammation and liver fibrosis in both models of PSC mice by rescuing TGR5 expression. Our findings may aid in the design of new therapeutic strategies for the treatment of PSC.

**Abstract Submission No. 200237**

**O-1045**

**Schisantarhin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice**

**Jiamei Chen1,2, Yue Liang1,2, Xiaohui Zhou1,2, Zheng Zhang1,2, Wei Liu2, Yonghong Hu2, Xiaohan Yu1,2, Yongping Mu1,2, Ping Liu6**

1Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai University of Traditional Chinese Medicine Shanghai China

**Background:** Hepatic fibrosis is the pivotal determinant in the progression of chronic liver diseases towards cirrhosis or advanced stages. Studies have shown that Schisantarhin A (Sin A), the primary active compound from *Schisandra chinensis* (Turcz.) Baill., exhibits anti-hepatic fibrosis effects. However, the mechanism of Sin A in liver fibrosis remain unclear.

**Purpose:** To examine the effects and underlying mechanism of Sin A on hepatic fibrosis.

**Study Design and Methods:** The effects and mechanism of Sin A were investigated using liver fibrosis mouse models induced by carbon tetrachloride (CCL4) or dimethylsulfoxide (DMN), as well as H2O2-induced hepatocyte injury *in vitro*.

**Results:** Sin A treatment ameliorated hepatocyte injury, inflammation, hepatic sinusoidal capillarization, and hepatic fibrosis in both CCL4- and DMN-induced mice. Sin A effectively reversed the reduction of DDAH1 expression, the p-eNOS/eNOS ratio and NO generation and attenuated the elevation of hepatic ADMA level induced by CCL4 and DMN. Knockdown of DDAH1 in hepatocytes not only triggered hepatocyte damage, but it also counteracted the effect of Sin A on protecting hepatocytes *in vitro*.

**Conclusion:** Our findings indicate that Sin A ameliorates liver fibrosis by upregulating DDAH1 to protect against hepatocyte injury. These results provide compelling evidence for Sin A treatment in liver fibrosis.

**Abstract Submission No. 200242**

**O-1046**

**Schisantarhin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice**

**Jiamei Chen1,2, Qun Zhou1,2, Siqi Gao1,2, Xiaohan Yu1,2, Linzhang Zhang3, Zheng Zhang1,2, Wei Liu2, Ping Liu1,2**

1Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine Shanghai China

Total astragalus saponins (TAS) are the main active components of *astragalii radix*, and have potent anti-hepatic fibrosis activity. However, the therapeutic efficacy of TAS and their potential mechanisms in the treatment of primary sclerosing cholangitis (PSC) remain unclear. The results indicated that treatment with TAS, particularly with a dose of 56 mg/kg, significantly ameliorated the PSC-related liver injury, cholestasis, collagen deposition, ductular reaction (DR) and fibrosis in the DDC-induced and Mdr2+/- spontaneous PSC mice. Furthermore, treatment with TAS significantly mitigated the PSC-related inflammatory responses in the liver of mice and HIBEpiC cells by inhibiting the expression of TNF-α, IL-6, and IL-1β. Mechanistically, treatment with TAS rescued the PSC-decreased hepatic TGR5 and SIRT1 expression to attenuate the NF-κB p65 phosphorylation. Notably, the therapeutic efficacy of TAS on PSC in DDC-induced mice was abrogated in TGR5-/- mice, suggesting the anti-PSC effect of TAS may depend on enhancing TGR5 expression. In conclusion, treatment with TAS ameliorated DR, inflammation and liver fibrosis in both models of PSC mice by rescuing TGR5 expression. Our findings may aid in the design of new therapeutic strategies for the treatment of PSC.

**Abstract Submission No. 200237**

**O-1045**

**Schisantarhin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice**

**Jiamei Chen1,2, Qun Zhou1,2, Siqi Gao1,2, Xiaohan Yu1,2, Linzhang Zhang3, Zheng Zhang1,2, Wei Liu2, Ping Liu1,2**

1Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai University of Traditional Chinese Medicine Shanghai China

**Background:** Hepatic fibrosis is the pivotal determinant in the progression of chronic liver diseases towards cirrhosis or advanced stages. Studies have shown that Schisantarhin A (Sin A), the primary active compound from *Schisandra chinensis* (Turcz.) Baill., exhibits anti-hepatic fibrosis effects. However, the mechanism of Sin A in liver fibrosis remain unclear.

**Purpose:** To examine the effects and underlying mechanism of Sin A on hepatic fibrosis.

**Study Design and Methods:** The effects and mechanism of Sin A were investigated using liver fibrosis mouse models induced by carbon tetrachloride (CCL4) or dimethylsulfoxide (DMN), as well as H2O2-induced hepatocyte injury *in vitro*.

**Results:** Sin A treatment ameliorated hepatocyte injury, inflammation, hepatic sinusoidal capillarization, and hepatic fibrosis in both CCL4- and DMN-induced mice. Sin A effectively reversed the reduction of DDAH1 expression, the p-eNOS/eNOS ratio and NO generation and attenuated the elevation of hepatic ADMA level induced by CCL4 and DMN. Knockdown of DDAH1 in hepatocytes not only triggered hepatocyte damage, but it also counteracted the effect of Sin A on protecting hepatocytes *in vitro*.

**Conclusion:** Our findings indicate that Sin A ameliorates liver fibrosis by upregulating DDAH1 to protect against hepatocyte injury. These results provide compelling evidence for Sin A treatment in liver fibrosis.

**Abstract Submission No. 200242**

**O-1046**

**Schisantarhin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice**

**Jiamei Chen1,2, Qun Zhou1,2, Siqi Gao1,2, Xiaohan Yu1,2, Linzhang Zhang3, Zheng Zhang1,2, Wei Liu2, Ping Liu1,2**

1Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine Shanghai China

Total astragalus saponins (TAS) are the main active components of *astragalii radix*, and have potent anti-hepatic fibrosis activity. However, the therapeutic efficacy of TAS and their potential mechanisms in the treatment of primary sclerosing cholangitis (PSC) remain unclear. The results indicated that treatment with TAS, particularly with a dose of 56 mg/kg, significantly ameliorated the PSC-related liver injury, cholestasis, collagen deposition, ductular reaction (DR) and fibrosis in the DDC-induced and Mdr2+/- spontaneous PSC mice. Furthermore, treatment with TAS significantly mitigated the PSC-related inflammatory responses in the liver of mice and HIBEpiC cells by inhibiting the expression of TNF-α, IL-6, and IL-1β. Mechanistically, treatment with TAS rescued the PSC-decreased hepatic TGR5 and SIRT1 expression to attenuate the NF-κB p65 phosphorylation. Notably, the therapeutic efficacy of TAS on PSC in DDC-induced mice was abrogated in TGR5-/- mice, suggesting the anti-PSC effect of TAS may depend on enhancing TGR5 expression. In conclusion, treatment with TAS ameliorated DR, inflammation and liver fibrosis in both models of PSC mice by rescuing TGR5 expression. Our findings may aid in the design of new therapeutic strategies for the treatment of PSC.

**Abstract Submission No. 200237**

**O-1045**

**Schisantarhin A protects hepatocyte via upregulating DDAH1 to ameliorate liver fibrosis in mice**

**Jiamei Chen1,2, Qun Zhou1,2, Siqi Gao1,2, Xiaohan Yu1,2, Linzhang Zhang3, Zheng Zhang1,2, Wei Liu2, Ping Liu1,2**

1Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine Shanghai China, 2Key Laboratory of Liver and Kidney Diseases (Ministry of Education), Shanghai University of Traditional Chinese Medicine Shanghai China

**Background:** Hepatic fibrosis is the pivotal determinant in the progression of chronic liver diseases towards cirrhosis or advanced stages. Studies have shown that Schisantarhin A (Sin A), the primary active compound from *Schisandra chinensis* (Turcz.) Baill., exhibits anti-hepatic fibrosis effects. However, the mechanism of Sin A in liver fibrosis remain unclear.

**Purpose:** To examine the effects and underlying mechanism of Sin A on hepatic fibrosis.
The role of Vitamin E in the treatment of nonalcoholic steatohepatitis (NASH)

MOHAMED MAHBOOB ALI1
1ADVANCED MEDICAL AND DENTAL INSTITUTE (AMDI)
GEORGETOWN Malaysia

AIMS: Oxidative stress plays a vital role in the transition from simple steatosis to nonalcoholic steatohepatitis (NASH). Vitamins with antioxidant properties have the ability to decrease the levels of reactive oxygen species and prevent oxidative damage in the cell that can lead to cellular senescence and apoptosis. Thus, the aim of this study is to explore the functions of vitamin E in the treatment and recovery of patients suffering from NASH.

Methods: 60 patients who were non-diabetic with NASH based on cytology were recruited into the studies. Their Alanine Transaminase (ALT) level was recorded prior to segregation. The subjects were divided into two main arms in which one arm received 500IU of Vitamin E while the second arm received a placebo. The tablets were taken once a day and were recorded. After three months, their ALT levels were measured and compared. A scatter plot was plotted to demonstrate the direct correlation between the level of ALT and the duration of the patients who were on vitamin E.

Results: Subjects that received 500IU of vitamin E daily recorded a significant reduction of ALT levels compared to the placebo arm. There was a direct correlation between the duration of patients on vitamin E and the reduction of the ALT in the scatter plot.

Conclusion: Vitamin E at the dose of 500 IU/day is beneficial in non-diabetic adults with active NASH. Longer follow-up RCTs are needed to assess the long-term safety and therapeutic value of vitamin E on clinical outcomes in NASH patients.

Abstract Submission No. 100253
O-1048

Correlation of HbA1c with the Degree of Liver Fibrosis and Steatosis by FibroScan® in Bacolod City

Jan Earl Lastimoso1, Chuck Eduard Galon1
1Adventist Medical Center - Bacolod Bacolod Philippines

Background: The liver plays a crucial role in glucose homeostasis and is an organ associated with diabetes mellitus (DM). This research aims to identify if there is a correlation between HbA1c level with the degree of liver fibrosis and steatosis as measured by FibroScan®. The FibroScan® is a new non-invasive modality and is the first and only one in Western Visayas.

Method: This is a retrospective study conducted in Bacolod City from April 2022-October 2022. Diabetic patients who underwent FibroScan® at Metro Bacolod Hospital and Medical Center (MBHMC) were included in the study. The FibroScan® results were retrieved from the FibroScan® unit of MBHMC and the HbA1c results were retrieved from the patients’ respective physicians’ office.

Results: A total of 56 patients were included in the study. This study shows a positive significant relationship between HbA1c and liver stiffness (r-value=0.306; p-value=0.022) indicating that the level of HbA1c is directly proportional to the level of liver stiffness and that the higher the HbA1c, the higher the degree of liver fibrosis. However, there is no significant relationship between the level of HbA1c and Controlled Attenuation Parameter (CAP) (r-value=0.306; p-value=0.726).

Conclusion: This study showed that HbA1c level in diabetic patients correlates proportionately with the degree of liver fibrosis as measured by FibroScan®; thus an elevated HbA1c predicts an increased risk for developing liver fibrosis. However, HbA1c level and NAFLD did not have any significant correlation indicating that both may coexist and are independent of each other.

Abstract Submission No. 100881
O-1049

MAGP1 knockout inhibits hepatic fibrosis regression by remodeling ECM microenvironment

Wen Zhang1,2, Ning Zhang1,2, Hong Li1,2, Wenyue Wu1,2, Yameng Sun1, Shuyuan Chen1,2, Anjian Xu3, Xuzhen Yan1,4, Qi Han1, Aiting Yang2, Hong You1, Wei Chen1
1Liver Research Center, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University Beijing China, 2National Clinical Research Center of Digestive Diseases Beijing China, 3Experimental and Translational Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 4Beijing Clinical Research Institute, Beijing Friendship Hospital, Capital Medical University Beijing China

Background & aims: Microfiber-associated glycoprotein 1 (MAGP1) is a glycoprotein involved in extracellular matrix (ECM) remodeling. By now, the relationship between MAGP1 and liver fibrosis has rarely been reported.

Methods: The roles and mechanisms of MAGP1 in liver fibrosis were investigated by using Mfap2 knockout (Mfap2-/-) mice and Mfap2-overexpression mice by tail injection of adeno-associated virus vectors (serotype 6, AAV6) containing short hairpin RNAs (shRNAs) targeting Mfap2, undergoing carbon tetrachloride (CCl4) administration, cessation or bile duct ligation (BDL) operation.

Results: MAGP1 was predominantly expressed in activated HSCs and dynamically increased with liver fibrosis progression and decreased in regression. Mfap2 knockout had no significant effect on liver fibrosis progression, but aggravated intrahepatic inflammatory infiltration in CCl4 mouse models and evidently retarded liver fibrosis regression after CCl4 cessation. Whereas, in BDL mouse models, Mfap2 ablation significantly exacerbated liver fibrosis progression but hardly affected intrahepatic inflammatory infiltration. Overexpression of Mfap2 via AAV6 vectors by tail intravenous injection relieved inflammation in CCl4 mouse models and fibrosis in BDL mouse models. Mechanically, HSCs-derived MAGP1 deficiency significantly promoted the ECM production and secretion including collagens, fibrillin-1, and lysyl oxidase-like protein 1 (LOXL1), resulting in ECM remodeling and subsequent alteration of ECM immune microenvironment. At the molecular level, the ECM-cell interaction pathway in liver, focal adhesion, was notably affected after Mfap2 intervention in vivo and in vitro.

Conclusion: Our current study highlighted MAGP1 participated in liver fibrosis progression and regression via orchestrating liver ECM microenvironment, providing a potential therapeutic target for liver fibrosis.

Abstract Submission No. 101250
O-1050

Liver fibrosis deciphering clinical outcomes in CKD-brothers in arms in prognostic landscape?

DHRITE SUNDAR DAS1, ANURAG ANUPAM1, GAUTOM KUMAR SAHARIA1
**Introduction:** It has been observed in various studies that liver fibrosis positively correlates with increased morbidity and mortality from diseases affecting various organ systems. There is significant similarity in the pathogenesis of chronic kidney disease (CKD) and liver fibrosis. The role of liver fibrosis scores (LFS) predicting the short-term clinical outcomes in hospitalized patients with CKD is unknown. This study aimed at studying the association of liver fibrosis scores with short-term mortality and morbidity in CKD.

**Methods:** LFS namely NFS, GPRI and FIB-4 scores were calculated in adult CKD. Patients were followed up for a period of 28 days for good and poor composite outcome namely requirement of dialysis, NIV, hospital stay, neurological and cardiovascular outcome including death.

**Results:** Among 163 patients, 70.5% were below 60 years of age and 82.2% were male. 35% were diabetic and 52.1% had poor composite outcome at 28 day follow up. The AUROC for GPRI and FIB4 predicting poor outcome was 0.783 (95% CI: 0.71 - 0.855) (p < 0.001) and 0.62 (95% CI: 0.534 - 0.706) (p = 0.008) respectively. The AUROC for GPRI and NFS predicting all-cause mortality was 0.735 (95% CI: 0.627 - 0.843) (p = 0.001) and 0.876 (95% CI: 0.8 - 0.952), (p < 0.001) respectively.

**Conclusion:** LF scores reproducibly conveyed a higher risk of liver fibrosis in CKD. The scores (GPRI, NFS and FIB-4) significantly predicted poor outcome in patients with CKD. High GPRI score was better associated with poor outcome and increased mortality in both diabetics and non-diabetics.

**Abstract Submission No. 101370**

**O-1051**

**Noninvasive proteomic biomarkers for liver fibrosis regression in patients with chronic hepatitis B**

Mengyang Zhang1, Shuyan Chen1, Xiaoning Wu1, Jialing Zhou1, Bingqiong Wang1, Tongtong Meng1, Yameng Sun1, Hong You1, Wei Chen1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational, Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China. Beijing China

**Background & Aims:** Liver fibrosis is reversible upon successful elimination or suppression of hepatitis B virus (HBV). However, to date, the assessment of liver fibrosis regression still largely depends on invasive biopsy-based histological evidence. The alternative noninvasive serum biomarkers for accurately diagnosing liver fibrosis regression remain unknown.

**Methods:** Chronic hepatitis B (CHB) patients biopsied in pairs at baseline (n=141) and at 78 (short-term, n=103) or 260 (long-term, n=38) weeks of antiviral treatment were included. Liver fibrosis regression was defined based on histological changes. Serum proteomic profiles were acquired using four-dimensional (4D) data-independent acquisition (DIA)-based proteomics. Multiple machine-learning algorithms were employed to screen noninvasive proteomic biomarkers for liver fibrosis regression.

**Results:** By pairwise comparison, serum proteins whose levels were significantly altered after antiviral treatment were input into multiple machine-learning models. In the short-term regression model, a signature comprising 8 serum proteins achieved the highest diagnostic performance with an AUROC of 0.74, superior to the changes of liver stiffness measurement (LSM), APRI, and FIB-4 (AUROCs were 0.61, 0.60, and 0.58, respectively). While the long-term regression model identified a signature with only 4 serum proteins whose AUROC was 0.91, better over LSM, APRI, and FIB-4 (AUROCs were 0.72, 0.70, and 0.69, respectively). More importantly, both models performed well when excluding patients with mild fibrosis (AUROCs were 0.82 and 0.96, respectively).

**Conclusion:** Our study pioneeringly identified the promising noninvasive proteomic biomarkers for liver fibrosis regression with CHB infection after a short- or long-term antiviral therapy.

**Abstract Submission No. 101557**

**O-1052**

**Predicting Symptomatic PHLF in HCC Patients: Development and Validation of a Preoperative Nomogram**

Manxia Liu1, Haiyi Long1, Chuan Peng2, Hong Ding3, Xiaoyan Xie1

1The first affiliated hospital, Sun Yat-sen university Guangzhou China, 2Center of Cancer Medicine, Sun Yat-Sen University Guangzhou China, 3Huashan Hospital, Fudan University Shanghai China

**Objective:** To explore the feasibility of Liver stiffness (LS) and a nomogram based on LS for predicting symptomatic post-hepatectomy (PHLF) in patients with hepatocellular carcinoma (HCC).

**Methods:** A total of 266 patients diagnosed as HCC were enrolled prospectively from three tertiary referral hospitals from August 2018 to April 2021. Patients from one hospital were classified as the derivation cohort and internal validation cohort consecutively, and those from the other two hospitals were classified as the external validation cohort. All patients underwent preoperative laboratory examination to obtain parameters pertaining to liver function, two-dimensional shear wave elastography (2D-SWE) examination to obtain LS, and three-dimensional virtual resection of liver to obtain volume-related parameters. A nomogram was developed by using logistic regression and determined by receiver operating characteristic (ROC) curve analysis and calibration curve analysis.

**Results:** A nomogram was constructed with the following variables: liver remnant volume (LRV) ratio, LS greater than 9.5kPa, Child-Pugh grade and the presence of clinically significant portal hypertension (CSPH). This nomogram enabled differentiation of symptomatic PHLF in the derivation cohort (Area under curve [AUC], 0.915), internal 5-fold cross-validation (mean AUC, 0.918), internal validation cohort (AUC, 0.876) and external validation cohort (AUC, 0.845). The nomogram also showed good calibration in the derivation, internal validation and external validation cohorts (Hosmer-Lemeshow goodness-of-fit test, p=0.641, p=0.06 and p=0.127, respectively). Accordingly, the safe limit of LRV ratio was stratified using the nomogram.

**Conclusion:** A preoperative nomogram integrated LS, clinical and Volumetric features was useful in predicting postoperative outcome in patients with HCC.

**Abstract Submission No. 101837**

**O-1053**

**The effect of persistent decline of pathological inflammation on the regression of liver fibrosis**

Jialing Zhou1, Yameng Sun1, Mingyi Xu2, Yongpeng Chen3, Huiguo Ding4, Hongxin Piao5, Youqing Xu6, Wen Xie7, Yuemin Nan8, Wei Jiang9, Fangfang Lv10, Xiaojuan Ou1, Jidong Jia1, Hong You1, Xiaoning Wu1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational, Medicine on Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China. Beijing China
AST/ALT Ratio to Predict Hepatic Fibrosis and Steatosis Compared to Fibroscan in Diabetes Patients

Nurike Mudjari¹, ², Poernomo Boedi Setiawan¹, ², Annisa Zahra Mufida¹, ², Soebagijo Adi Soelstijo¹, ², Ufia Kohilii⁶, Ummi Maimunah¹, ², Titong Sugihartonoo

¹Faculty of Medicine Airlangga University Surabaya Indonesia, ²Dr Soetomo Hospital Surabaya Indonesia

Background: To compare the AST/ALT ratio with fibroscan for predicting hepatic fibrosis and steatosis in diabetes mellitus (DM) patients.

Methods: A cross-sectional study was conducted on DM patients aged over 30 years. Patients using alcohol, hepatitis B or C, autoimmune hepatitis, and users of steatogenic drugs were excluded. The demographic description of the research subjects includes age and gender. Meanwhile, the variables explained include the AST/ALT ratio, CAP Score, and fibrosis score. Analysis was conducted using Spearman correlation, Mann-Whitney test, and ROC curve analysis.

Results: Of the 106 diabetes DM only 96 fulfilled the criteria. Mean age of 56.38 ± 8.46 years, 53 (55.2) were women. Liver fibrosis was found that 55 (57.3%) had F0, 20 (20.8%) F1, 15 (15.6%) F2, 3 (3.1%) F3, and 3 (3.1%) F4. A significant correlation was found between the AST/ALT ratio and age (r = 0.225). Sensitivity, specificity, PPV, NPV, and accuracy of AST/ALT ratio at the 0.44 cut-off for the differentiation of F2, F3, and F4 from F0 and F1 were 4.76, 98.67, 50.0, 78.7%, Moreover, the Auroc of the AST/ALT ratio for the differentiation of F2, F3, and F4 from F0 and F1 was 0.530. The AST/ALT ratio at the 1.63 cut-off for the differentiation of S1, S2, S3 from S0 were 93.85, 16.13, 70.1, and 55.6% with Auroc of AST/ALT ratio for the differentiation S1, S2, S3 from S0 were 0.514.

Conclusions: The AST/ALT ratio in this study is unusable to predict hepatic steatosis and fibrotic significantly in diabetes mellitus patients.
Results: Liver stiffness and steatosis value in TE were found to be significantly higher in the group receiving MTX compared to the healthy group (p<0.001). When the group receiving MTX was divided into two groups as kPa ≥ 7.1 and below, it was determined that the cumulative dose of MTX and duration of drug use were significantly higher in the group with high fibrosis (p<0.009). When the patients were divided into three groups according to the cumulative MTX dose: 0-1499 mg, 1500-4999 mg, 5000 mg and above, the kPa value measured by TE was found to be significantly higher in patients receiving 5000 mg and above MTX compared to other doses. (p<0.036).

Conclusion: TE can be used as an effective method to detect liver fibrosis due to MTX use. It would be very accurate to evaluate patients with a cumulative MTX dose of 5000 mg and above with TE in terms of hepatic fibrosis.

Abstract Submission No. 101401
O-1057

Efficacy of Rebamipide in the Prevention of Aspirin or NSAID-induced Gastrointestinal Mucosal Injury

Ian Gabriel Juyad1, Rochelle Ivy A. Cion1, Eric B. Yasa1
1Philippine General Hospital Manila City Philippines

Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most used medications worldwide. A major limitation of these drugs is gastrointestinal mucosal injury and bleeding. Several gastroprotective agents have been recommended but are limited by their long-term effects. Rebamipide is a promising mucoprotective agent, but its efficacy is not established. We performed a meta-analysis to assess rebamipide’s effect on gastrointestinal injuries due to NSAID and aspirin use.

Methods: Four electronic databases were searched from inception to October 2023 for studies that compared rebamipide with placebo or standard gastroprotective agents. Data were pooled to obtain odds ratio (OR) with 95% confidence interval. Heterogeneity and publication bias were assessed with I2 statistic and funnel plot, respectively.

Results: A total of 472 studies were screened, with 30 studies included. Pooled analyses showed that for NSAID use, rebamipide significantly reduced the outcome of gastrointestinal ulcers [OR:0.37 (0.19-0.70); I2=13%, p=0.002], bleeding [OR:0.16 (0.10-0.27); I2=87%, p<0.00001], and symptoms [OR:0.45 (0.23-0.88); I2=48%, p=0.02] as compared to placebo. Rebamipide is also comparable to standard proton pump inhibitors (PPIs) in preventing NSAID-induced mucosal breaks and bleeding. Addition of rebamipide to PPIs is superior to PPIs alone in preventing mucosal breaks [OR:0.38 (0.20-0.74); I2=41%, p=0.005]. For aspirin use specifically, rebamipide significantly reduced the incidence of mucosal breaks [OR:0.36 (0.17-0.78); I2=0%, p=0.009] as compared to placebo.

Conclusion: Rebamipide is effective in preventing gastrointestinal injuries, bleeding, and symptoms due to NSAID use. This study is the first meta-analysis that demonstrated the efficacy of rebamipide in aspirin-induced gastrointestinal injury.

Abstract Submission No. 101999
O-1059

Autologous Haemopoietic Stem Cell Transplantation in Decompensated Cirrhosis via Portal Venous Route

Musarrat Mahtab1, Mamun Al Mahtab2, Sheikh Mohammad Fazle Akbar3, Tasnim Mahmud3, Md. Suhan Bin Islam4
1North South University Dhaka Bangladesh, 2Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 3Ehime University Graduate School of Medicine Ehime Japan, 4MBBS,MPH (North South University) Dhaka Bangladesh, 5MBBS,CCD (Ibrahim Medical College, BIRDEM) Dhaka Bangladesh

Introduction: Decompensated cirrhosis of liver is associated with decreased amounts of functional hepatocytes leading to compromised quality of life and increased mortality. It is possible that autologous haemopoietic stem cells administered to liver aid in hepatocyte mobilization and reversal of decompensated cirrhosis. Study assessed safety and primary efficacy, if any, of autologous haemopoietic stem cell transplantation in patients with decompensated cirrhosis of liver for its future standardization.

Methods: 33 patients included with decompensated cirrhosis of liver. All received injection with G-CSF(60 IU)/s/c daily for 3-4 days along with standard medical therapy. CD34-positive cells were isolated from peripheral blood using cell sorter. Subsequently transfused trans-hepatic route into portal vein. Patients were then followed up initially for 90 days.

Results: 23 males, 10 females. Age was 50.6yrs. 22 hepatitis B, 4 NASH, 2 hepatitis C, 5 cryptogenic cirrhosis of liver. Mean serum
An in-hospital HBV screening project improving the rates of diagnosis and treatment of hepatitis B

Qiumin Luo1, Wenxiong Xu1, Yeqiong Zhang1, Ying Liu1, Liang Peng2

1Department of infectious disease, Third Affiliated Hospital, Sun Yat-Sen University Guangzhou China, 2Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital, Sun Yat-Sen University Guangzhou China

Background: The rates of diagnosis and antiviral treatment for hepatitis B infection in China are 24% and 15% respectively in 2022, significantly lower than the WHO’s 2030 target of “90% for diagnosis and 80% for antiviral treatment”. Furthermore, the awareness of hepatitis B management in non-hepatology specialists is insufficient.

Methods: In March 2022, Guangdong Preventive Medicine Association and the Third Affiliated Hospital of Sun Yat-sen University jointly launched the “In-Hospital Hepatitis B Screening Management Project”, which implemented the hepatitis B management of “hepatitis B screening - referral - diagnosis - treatment - follow-up” in the Third Affiliated Hospital. The program involved multi-departments of infectious disease, other clinical specialties, laboratory, information, medical administration, and clinical data center. Figure 1 shows the roadmap for in-hospital hepatitis B screening management.

Results: Through nine months of the project implement, compared to 2021, the rates of HBsAg screening (defined as number of individuals who underwent HBsAg testing divided by the total number of hospital visits during the same period, including inpatients and outpatients), patients’ referral to the department of infectious disease, antiviral treatment, and regular follow-up in 2022 were increased from 7.95% to 8.36%, 11.23% to 19.32%, 57.18% to 62.48%, and 60.34% to 65.17%, respectively (Figure 2).

Conclusion: The in-hospital hepatitis B screening management project has facilitated patients’ discovery and referral from non-hepatology departments, indeed improving the rates of screening, referral, antiviral treatment, and follow-up for hepatitis B patients. However, further promotion of this management mode is needed.
EUS-guided liver biopsy and portal pressure gradient measurement in cACLD and cirrhosis

Arka De1, Arpit Shastr1, Naveen KB1, Suvardeep Mitra1, Akash Gandotra1, Bhavin Davra1, Malvika Shastr1, Sahaj Rathi1, Nipun Verma1, Madhumita Premkumar1, Sunil Taneja1, Ajay Duseja1

1MD, DM Chandigarh India

Background: EUS-guided liver biopsy (EUSLB) and portal pressure gradient measurement (EUS-PPG) are emerging areas in the field of endohepatology. However, data in cACLD and cirrhosis is limited. Hence, we explored the performance of EUSLB and EUS-PPG in such patients.

Methods: EUSLB and EUS-PPG performed in suspected cACLD (LSM >10kPa) or cirrhosis (on imaging) from June-2022 till September-2023 were reviewed. Indications for EUSLB included elevated LSM >10kPa or cirrhosis (on imaging) from June-2022 till September-2023 were reviewed. Indications for EUSLB included elevated LSM >10kPa or cirrhosis (on imaging). EUS-PPG was concomitantly measured in 7 patients with ESRD. Among the remaining 6 patients without CSPH, 2 have undergone unexplained vomiting, bloating). EUS-PPG was performed in 79 biopsies in 77 patients [age: 32 (22-47) years, males: 46.7%] with suspected cACLD or cirrhosis were reviewed. Seventy-seven (97.5%) samples were deemed adequate by the pathologist. Median core length was 25 (16-37) mm. The median number of CPT was 6 (3-7). Autoimmune liver disease (36.33%) and NAFLD/NASH (20.7%) were the commonest etiology. Most patients had fibrosis stages F3 (42.8%) and F4 (37.7%). Adverse events were noted in 4 patients (5.1%) [Perihepatic bleed (1.6%), transient needle-track bleed (2.5%) and mild self-limiting pain (1.2%)]. EUS-PPG was concomitantly measured in 7 patients with ESRD. CSPH was present in 1 patient (PPG =13 mm Hg; listed for SLKT). Among the remaining 6 patients without CSPH, 2 have undergone uncomplicated renal transplant.

Conclusion: EUSLB is safe with high diagnostic yield in cACLD and cirrhosis. EUS-PPG measurement is technically feasible and adds to the one-stop-shop endoscopic assessment of portal-hypertension.

RWE Study to Evaluate Effectiveness of PPIs Omeprazole and Pantoprazole for Relief of GERD/ADP

Ritwik Banerjee1, Priti Panchal1, Sandip Rungta1, Debasis Basu1, Shivaji Rao1, Anish Kolly1, Krishna C Velgandla1, Rahul Rathod1, Bhavesh P Kotak1, Gauri Dhanaki1

1Dr Reddys Laboratories Ltd Hyderabad India, 2Department of Internal Medicine & Gastroenterology Thunga Hospital Mumbai India, 3Department of Internal Medicine & Cardiology AMRI Hospital Kolkata India, 4Department of Internal Medicine & Diabetest Apollo Multispeciality Hospital Kolkata India, 5Department of Internal Medicine Apollo Hospital Bangalore India, 6Department of Internal Medicine & Endocrinology Jaya Bhushan Hospitals Hyderabad India

Objective: Gastro-Esophageal Reflux Disease manifests due to mucosal damage induced by reflux of gastric contents into esophagus. Proton Pump Inhibitors are considered to have comparable efficacies and safety profiles. Due to dearth of documented data on clinical practices and outcomes, this study aims to evaluate real-world evidence on effectiveness, safety of omeprazole and pantoprazole in patients not treated for GERD within 2 weeks preceding treatment initiation with PPIs.

Methodology: Study involves data extraction from 600 anonymized Electronic Medical Records (EMRs) procured from 15 physicians in India. Patients treated for at least 4 weeks with the PPIs are included. The primary objective is to determine the proportion of responders (symptomatic relief of heartburn, regurgitation, epigastric pain, nausea, vomiting, bloating).

Results: Omeprazole 20mg or Pantoprazole 40mg group is compared at each follow-up (2 weeks and 4 weeks). At 2 weeks, significantly more subjects showed resolution of Heartburn (87.98% vs 71.76%, p<0.001) in Omeprazole compared to Pantoprazole. Omeprazole showed significantly better resolution of Regurgitation (79.75% vs 69.7%, p= 0.029), Epigastric pain (84.21% vs 68.61%, p<0.001), Vomiting (93.91% vs 81.58%, p=0.003) Bloating (87.73% vs 78.89%, p=0.026). At 4 weeks, significantly more subjects showed resolution in Omeprazole compared to Pantoprazole (95.63% vs 86.57%, p=0.002), Regurgitation (98.10% vs 90.51%, p=0.003) and Epigastric pain (95.26% vs 89.6%, p=0.034) showed statistically significant result favoring Omeprazole as compared with Pantoprazole.

Discussion & Conclusion: Omeprazole is more effective in faster relief of GERD/APD symptoms (2 weeks) and comparable to/more effective than pantoprazole (4 weeks) depending on specific symptoms.

Abstract Submission No. 101879

O-1065

Spur cell anemia successfully treated with liver transplantation

Takayuki Kogure1, Takehito Ito1,2, Mari Satoh1,3, Kennichi Satoh1

1Division of Gastroenterology, Tohoku Medical and Pharmaceutical University Sendai Japan, 2Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital Sendai Japan, 3Department of Internal Medicine, Tome City Toyosato Hospital Tome Japan

Background: Spur cell anemia (SCA) is a rare hemolytic anemia characterized by the presence of erythrocytes with spiny projections, which arises in alcoholic cirrhosis. Repeated blood transfusions lead to liver failure but no effective treatment has been established.

Case presentation: A 38-year-old woman with a history of heavy alcohol use presented to our clinic. She developed ascites due to alcoholic cirrhosis 8 months before. She abstained from alcohol but her jaundice persisted, with bilirubin ranging from 4-8 mg/dL. She presented with macrocytic anemia with increased reticulocytes and decreased haptoglobin, suggesting hemolytic anemia. After 5 months, she developed gross hematuria with aggravated anemia, and was admitted to our hospital. Her laboratory findings were as follows: RBC 165,000/μL, Hb 6.4 g/dL, MCV 112 fL, PLT 49,000/μL, reticulocytes 9.6%, TB 9.6 mg/dL, DB 5.6 mg/dL, AST 50 U/L, ALT 30 U/L, LDH 302 U/L, ALP 118 U/L, γ-GTP 15 U/L, albumin 2.6 g/dL. A workup by hematologists excluded autoimmune hemolytic anemia or others. We noticed abnormal erythrocytes with spiny projections in her smear. Based on this acanthocytes and her background, alcohol cirrhosis, we diagnosed her with SCA. After multiple blood transfusions, her liver failure became critical. A liver transplantation was performed using her husband as donor. Following transplantation, the acanthocytes disappeared and her jaundice resolved.

DISCUSSION: This case report demonstrates the successful treatment of SCA with liver transplantation. Liver transplantation should be considered as a potential treatment option for patients with SCA although the availability of donors is limited especially for alcoholic cirrhosis.
**Conclusions:**

Exhibit distinct microbiome signatures. This insight aids in comparing classification in gut microbiomes. Obese children with or without MAFLD exhibited high scores. The gut microbial communities between the ing partial least squares-discriminant analysis (PLS-DA).

**Abstract Submission No. 100666**

**Gut Microbiome Signatures in Obese Children with MAFLD through Full-Length 16S rRNA Sequencing**

Yu-Cheng Lin1, Yun-Er Li1, Yen-Hsuan Ni2

1Department of Pediatrics, Taipei Veterans General Hospital Taipei Taiwan, 2Department of Pediatrics, National Taiwan University Hospital Taipei Taiwan

**Background:** The gut microbiota plays a crucial role in metabolic-associated fatty liver disease (MAFLD). Next-generation sequencing explores the gut microbiome, but traditional short read 16S rRNA sequencing lacks species-level detail. The newly developed full-length 16S rRNA sequencing (FL16S) may offer the potential for higher resolution. However, its impact on MAFLD signatures remains uncertain.

**Methods:** We employed FL16S sequencing to identify gut microbiome signatures in 80 age-, sex-, and BMI-matched case-control pairs of obese children with and without MAFLD. Fecal DNA was sequenced with PacBio Sequel IIe system, and Amplicon Sequence Variants (ASVs) were taxonomically assigned against NCBI reference database. We compared the microbiome signatures between MAFLD and non-MAFLD pairs.

**Results:** MAFLD subjects exhibited higher serum alanine aminotransferase, triglycerides, and insulin resistance. Top 10 abundant taxa showed significant species-level differences, particularly with Bacteroides ovatus and Bacteroides dorei. Welch’s test indicated lower abundance of Bacteroides ovatus, Bacteroides dorei, and Blautia wexlerae in the MAFLD group, and higher Escherichia rectale and Megamonas funiformis. At the genus level, Prevotella, Bacteroides, Shigella, and Collinsella scored higher in linear discriminant analysis effect size (LEfSe), and at the species level, Bacteroides ovatus, Bacteroides vulgatus, Bacteroides dorei, and Collinsella aerofaciens exhibited high scores. The gut microbial communities between the MAFLD and non-MAFLD groups were effectively differentiated using partial least squares-discriminant analysis (PLS-DA).

**Conclusions:** FL16S enables detailed genus and species-level identification in gut microbiomes. Obese children with or without MAFLD exhibit distinct microbiome signatures. This insight aids in comparing studies before and after FL16S, potentially enhancing its clinical utility.

**Results:** A total of 40 subjects were methylprednisolone (n=20; mean age 8.39 ± 3.11 week) and placebo (n=18; 2 drop out; mean age 8.98 ± 2.80 week) groups. The methylprednisolone group had direct bilirubin 8.36 ± 4.84mg/dL; AST 187.05(42.00-911.00) U/L; ALT 170.43 ± 134.43 U/L; IL2 171.29 (73.70-378.57) ng/L; IL2 119.57 ± 59.69 ng/L; IL6 119.57 ± 59.69 ng/L; IL10 138.15 ± 70.62 mg/mL; IFN-γ 42.54 ± 12.17 ng/L; TGF-β 316.58 (163.68-606.16) ng/L; ANCA 1.70 (0.66-3.25) ng/L. There was no difference in laboratory results on both groups (p=0.05). After 2-week treatment, direct bilirubin, total bilirubin, AST, IL10, and IFN-γ were significantly reduced in the methylprednisolone group (p<0.05) compared to placebo.

**Conclusion:** Methylprednisolone was efficacious in reducing bilirubin and inflammatory biomarkers compared to placebo. The present study supports immunological process involved in cholestasis and may offer an opportunity of new therapies to prevent biliary atresia process.

**HEPATIC LCH AS HARBINGER OF MULTI-SYSTEM LCH - PROTOCOL FOR DIAGNOSIS AND EARLY PREDICTION**

Nirmala Deivamani1, Deepa Janakiraman1, Sindhuja TA1, Senthil kumar R1, Winston Thomas1

1Department of Paediatric Gastroenterology, Institute of Child Health, Madras Medical College Chennai India

**Background:** Hepatic involvement is usually seen as part of multisystem Langerhans Cell Histiocytosis(LCH), but primary presentation of LCH as cholestatic liver disease is rare. Available guidelines has no mention on diagnostic criteria or algorithm for diagnosis of primary manifestation of LCH as isolated Hepatic LCH.

**Methods:** Review of prospectively collected database from Jan2023to August2023. LFT of other children were also analyzed.

**Results:** Four cases were included and median age at initial presentation was 16months. All(n=4)100% presented with short duration fever, cholestatic jaundice, pale-stools, abdominal distension, hard-hepato-megal with predominant left-lobe enlargement. GGT(Gamma-glutamyl-transferase) elevation(>10times) and serum-alanine-phosphatase(SAP>4times) was seen in all cases(n=4)(sensitivity-100%). MRCP showed Sclerosing cholangitis pattern in 25%(n=1). Immuno-histochemistry(IHC) from all liver biopsies were negative(sensitivity=0%). Average interval between initial presentation to compensation was 3months and for confirmation of diagnosis was 4.75months, diagnosed only after decomposition. Diagnosis was confirmed by HCs from biopsies of nail-matrix, skin, liver-explant and lymph-node. During initial presentation, if SAP,GGT is elevated >4times and >10times respectively, without obstruction, sensitivity and specificity is 100%(95%CI-0.98-1), NPV and PPV=1 (95%CI- 0.395-1)in predicting early hepatic LCH. Once decomposed, the combined high SAP-GGT values are not maintained.

**Conclusion:** As the window period from initial presentation to decom- pensation is only 3months, if SAP and GGT is elevated >4times and >10times respectively during initial presentation, if obstructive causes are ruled out, PET scan can be done initially to identify the metabolically active areas to be biopsied to maximize the yield for histopathological diagnosis early, as earlier initiation of chemotherapy has better prognosis.

**RCT of Methylprednisolone in cholestasis infants: is an opportunity to prevent biliary atresia?**

Rendi Aji Prihaningtyas1, Bagus Setyoboedi1, Farahdina Farahdina1

1Dr. Soetomo General Academic Hospital - Faculty of Medicine, Universitas Airlangga Surabaya Indonesia

**Background:** A progressive immunological mechanisms underlie biliary atresia. Biliary atresia outcome is still not optimal even though the Kasai operation has been carried out. This study aims to analyze the effectiveness of methylprednisolone in liver function test and inflammatory biomarkers in cholestasis.

**Methods:** The RCT was conducted in Dr. Soetomo General Academic Hospital, Surabaya. The inclusion criteria, included being > 14 days to 3 months old and cholestasis. Subjects were randomly assigned to methylprednisolone or to placebo for 2-week randomized treatment period. Laboratory measurements (direct and total bilirubin, AST, ALT, GGT) and inflammatory biomarker) were performed. Analysis was performed using SPSS with p significant < 0.05.
Does intestinal permeability impact the morbidity in cirrhosis? A novel prognostic model of outcome

Moinak Sen Sarma1, Ashish Gupta2, Nitu Singh1, Ujjal Poddar1, Anshu Srivastava1, Amrita Mathias1
1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India, 2Dept of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

Introduction: Increased intestinal permeability (IP) is the gateway to a cascade of events in cirrhosis. Polyethylene glycol (PEG) is an upcoming tool to assess IP. Zonulin and intestinal fatty acid binding protein (IFABP) are biomarkers of tight-junctions and epithelial damage. We aimed to evaluate and interrelate the biomarkers of gut integrity and PEG in cirrhosis.

Methodology: Cirrhotic children and controls (extrahepatic portal-venous obstruction) were prospectively enrolled. Five hours after ingestion of 1 gm/kg of PEG3350, urine was collected and processed by proton-nuclear magnetic resonance (1H-NMR) spectroscopy to derive the integrated-PEG (I-PEG) value (area under the peak-curve). Serum intestinal fatty acid binding protein (IFABP) and zonulin were assessed on the same day. With the risk factors, a model was created to predict outcome in cirrhotics.

Results: Cirrhotic children (n=56) versus controls (n=35), aged (13±3.5 vs. 10.6±2.9 years, p=0.6) had I-PEG (12.9±5.1 vs 3.8±4.2, p=0.02), zonulin (96.6±24 vs 16.3±5.1 ng/mL, p<0.01) and IFABP (4.9±3.3 vs. 1.8±1.2 ng/mL, p=0.01). Among cirrhotics, I-PEG was significantly higher in decompensated (n=20) vs. recompensated (n=36) patients (11.8±7.1 vs 4.9±3.9, p=0.03) and large vs small esophageal varices (12.4±4.8 vs 6.3±2.2, p=0.03). I-PEG correlated with IFABP (r=0.77, p<0.01), zonulin (r=0.88, p<0.01) and pediatric end-stage liver disease (PELD) score (r=0.67, p=0.03). Zonulin >25ng/mL (OR:3.08, CI:1.05-4.12, p<0.01) and I-PEG>5 (OR:3.19, CI:2.2-7.73, p=0.01) were independent predictors of hospital readmissions over next 6 months. The risk factor model (AU ROC:0.87, p<0.01, 92% sensitivity, 60% specificity) predicted morbidity better than isolated PELD or Child-Turcotte-Pugh scores(Fig1).

Conclusions: I-PEG and zonulin risk factor model predicts short-term morbidity in cirrhotic patients.

Abstract Submission No. 200199

O-1071

Unravelling the mystery of cholestatic liver disease using WES: Unusual presentation of PFIC 8

Pragathi Lk1, Samriddhi Poyekar1, Ira Shah1
1B.J. WADIA HOSPITAL FOR CHILDREN ,PAREL, MUMBAI MUMBAI India

Introduction: Progressive familial intrahepatic cholestasis (PFIC) is inherited disorder of defective bile acid secretion with more than 10 types described and have heterogeneous clinical presentation. The literature on new variants of PFIC is scarce. This report identifies a unusual presentation of PFIC 8 in adolescence.

Case: 14-year-old healthy adolescent girl born of third degree consanguineous marriage couple was incidentally diagnosed to have portal hypertension secondary to liver cirrhosis when admitted for dengue fever. Her liver function tests were suggestive of cholestatic hepatitis with elevated GGTP with preserved synthetic functions. There was no history of jaundice, abdominal pain, clay stools or itching in the past or in other family members. Autoimmune workup revealed positive ANA (1:100), negative ASMA and hypergammaglobulinemia. MRCP did not reveal obstructive biliary pathology. Her liver biopsy showed features of bile duct destruction with mild cholestasis and interface hepatitis. She was treated with steroids with presumed diagnosis of autoimmune hepatitis (IAIHG score 6). However, her liver functions did not show any improvement. Whole exome sequencing was sent which revealed homozygous mutation of gene KIF12(-) at intron 9 suggestive of PFIC -8. She has been treated with ursodeoxycholic acid.

DISCUSSION: Kinesin like protein - KIF 12 mutation results in cholestasis by disrupting hepatocyte polarity. In the reported literature majority have presented in infancy with few during adolescence with high GGTP cholestasis with scarce literature on their longterm outcomes.

Conclusion: PFIC must be considered as diagnostic possibility while evaluating cholestatic liver disease and confirmed with genetic testing.
Obstacles: To explore the role of interferon-induced transmembrane protein 1 (IFITM1) in predicting HBsAg seroconversion in children with chronic hepatitis B (CHB).

Methods: A total of 106 children with HBeAg-positive CHB aged 1 to 18 years, treated with interferon α (IFNα) 48 weeks follow up 24 weeks. Based on the results of HBsAg seroconversion, the patients were divided into HBsAg seroconversion group and non HBsAg seroconversion group. Univariate and multivariate COX regression were used to identify the impact factors associated with HBsAg seroconversion. The area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for HBsAg seroconversion.

Results: HBsAg seroconversion rate at week 48 were 45.28%. Patients with HBsAg seroconversion showed a significantly high baseline IFITM1 levels in comparison to those patients without HBsAg seroconversion (p < 0.05). Univariate and COX multivariate regression analysis showed that age (HR=0.709, 95%CI: 0.618-0.815, p<0.001) and IFITM1 levels (HR=1.11, 95%CI: 1.01-1.219, p=0.03) were independent predictive factors for HBsAg seroconversion. ROC curve showed that the prediction efficiency of IFITM1 was good, the area under the receiver operating characteristic curve (AUROC 0.689, 95%CI: 0.581-0.798, p=0.001), Using IFITM1 levels >1.58ng/ml as the cutoff value, the positive predictive value (PPV) and negative predictive value (NPV) for HBsAg seroconversion were 72.73% and 75%, respectively, with a sensitivity of 82.75%, and specificity of 62.50%, respectively.

Conclusions: Baseline IFITM1 could be used as an early predictor of HBsAg seroconversion treated with interferon in children with CHB.
Methods: In this prospective, single-center study, 75 post-Fontan patients were included (38 female/37 male). The mean age was 23.6 years old, and the mean post-Fontan years was 15.3 years. Between August 2015 and March 2023, MRI was performed to detect hepatic nodules and possible abdominal abnormality. The laboratory data, serum biomarkers for liver fibrosis, transient elastography, and intravoxel incoherent motion (IVIM) MRI were collected for liver stiffness evaluation.

Results: Among 75 post-Fontan patients, hypervascular hepatic tumors were detected in 18 (24%) patients. Only 1 (2.3%) of the lesion was proven to be hepatocellular carcinoma. Asplenia was a significant factor in predicting hepatic hypervascular tumor (AUC 0.659, p=0.002). The severity of liver fibrosis evaluated with IVIM MRI, transient elastography and medical scores was not associated with the presence of hypervascular hepatic tumors. A combination of serum hemoglobin (Hb), platelet, alkaline phosphatase (ALP), and gamma-glutamyl transpeptidase (GGT) help predict the occurrence of hepatic hypervascular tumors (AUC 0.727, p=0.029). The composite model of asplenia, serum platelet, ALP and GGT will increase diagnostic performance even more (AUC 0.762, p=0.012).

Conclusion: Asplenia significantly predicted the development of hepatic hypervascular tumors in post-Fontan patients, while liver fibrosis levels did not. Blood tests, including Hb, platelet, ALP and GGT can enhance the prediction model.

Abstract Submission No. 101316
O-1076

Galactosemia in children: predictors and risk factors of outcome

Moinak Sen Sarma1, Nitu Kumari1, Srinivas Srinidhi Vadlapudi1,
Anshu Srivastava1, Ujjal Poddar1, Surender Kumar Yachha1
1Dept of Pediatric Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences Lucknow India

Background: Galactosemia constitutes 2% of all neonatal cholestasis. Despite early diagnosis and dietary exclusion, there may be adverse liver and neuro-opthalmic outcomes. We analysed the risk factors of outcome in galactosemia patients.

Methods: Diagnosis was based on galactose-1-phosphatase uridylic transferase (GAL-1-PUT) enzyme <10 U/gHb or mutation of GALT gene. Risk factors of death or neuro-opthalmic morbidity (poor neuro-recognition, learning disability persistent cataract or amblyopia despite cataract surgery) were analysed from a prospectively maintained database.

Results: Fifty-one galactosemia patients presented as infantile cholestasis. Their median age of symptom onset and diagnosis were 10(1-90) and 45(7-450) days respectively. Figure 1 shows the natural history on lactose-free diet. Among the 43 survivors, 28 had follow-up with >6 months were analysed for long term outcome. All had normalisation in liver functions. Ten(36%) had adverse neuro-opthalmic outcome. Eighteen patients are currently asymptomatic in follow up till now. Multivariate analysis of non-survivors(n=8) versus survivors(n=28) identified risk factors: refractory ascites (88% vs.18%, p=0.012), persistent coagulopathy at 4 weeks (88% vs.25%, p=0.02), and culture-positive sepsis (63% vs 43%; p=0.04). In addition, pediatric end-stage liver disease (PELD) score <21 (sensitivity 78%; specificity 50%, p=0.02) and Child score <7.5 (sensitivity 89%; specificity 61%, p=0.01) predicted survival. PELD score correlated with culture-positive sepsis (p=0.05). In the 10 patients with poor neuro-opthalmic morbidity, no risk factors could be identified.

Conclusion: Refractory ascites, uncorrectable coagulopathy at 4 weeks of diagnosis and sepsis were associated with poor liver outcome. PELD and Child score predict survival. Long term neuro-opthalmic morbidity is not associated with disease severity at onset.

Abstract Submission No. 101448
O-1078

Characteristics and Outcomes of Biliary Atresia in a Limited Facility of Liver Transplantation

Bagus Setyobedi1, Rendi Aji Prihaningtyas1, Sjamsul Arief1
1Child Health Department, Dr. Soetomo General Academic Hospital - Faculty of Medicine, Universitas Airlangga Surabaya Indonesia

Background: Biliary atresia is an obstructive cholangiopathy leading to liver fibrosis. Biliary atresia is the most common cause of liver transplantation in the pediatric population. Although management strategies have been implemented worldwide, the rate of delayed treatment is still high. This study aims to describe the characteristics and outcomes of biliary atresia in a limited facility of liver transplantation.

Methods: This study is a prospective study performed in infants with biliary atresia at Dr. Soetomo General Academic Hospital, Surabaya in 2021 - 2023. Demographics, laboratory and biopsy parameters, and
outcomes were analyzed. Analysis was performed using SPSS version 25.

Results: There were 94 infants, consisting of 41 boys and 53 girls with a mean age of 16±17 weeks. 55 (58.5%) were from rural areas, 52 (55.3%) were born by cesarean section (38±1.78 weeks). The onset of jaundice occurred 4±3 weeks after birth. A total of 80 (85.2%) infants survived and 39 (41.4%) presented with portal hypertension. A total of 77 (81.8%) had liver fibrosis. Kasai were performed in 11 (11.7%) of the cases. The IgG-CMV, rubella, and toxoplasma reactivity occurred in 80 (84.7%), 37 (39.3%), and 8 (8.5%) cases, respectively. Meanwhile, reactive IgM CMV, Rubella and Toxoplasma were found in 34 (36.1%), 7 (7.4%) and 8 (8.5%) cases, respectively.

Conclusion: Delayed referral rate for biliary atresia has remained high. The high rate of CMV infection in biliary atresia may provide a basis for exploring alternative medical therapies to prevent fibrosis and reduce the need for liver transplantation.

Abstract Submission No. 101497
O-1079

Hyperinsulinemia Inducing Late Onset Transient Cholestasis in Neonates: a Case Report

Iqbal Taufiqurrachman1, Rinawati Rohsiswatmo1,2, Ahmad Kautsar2, Ghaisani Fadiana1,2, Rezya Tratama Andundi1, Tiffanny Nur Shabrina1, Clarissa Theodora1, Hanifah Oswari1

1Pondok Indah Hospital, Jakarta, Indonesia Jakarta Indonesia, 2Perinatology Division, Department of Pediatric, Cipto Mangunkusumo Hospital - Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 3Endocrinology Division, Department of Pediatric, Cipto Mangunkusumo Hospital - Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 4Gastroenterology dan Hepatology Division, Department of Pediatric, Cipto Mangunkusumo Hospital - Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 5Laboratory of Birth Defect Shanghai China, 6Shanghai Key Laboratory of Birth Defect Shanghai China

A term low birth weight baby boy (Caucasian-African-American descent) was born from a mother with gestational diabetes, urinary tract infection, brownish vaginal discharge, fetal distress, and PROM with C-section. The mother had a history of one stillbirth and two miscarriages. The baby was admitted to NICU at 10 hours of age because of early-onset neonatal sepsis and critically low blood glucose. Antibiotic therapy and high glucose infusion rate (GIR 13 mg/kg/min) were given. Because of the lack of response, the critical sampling was done and revealed hyperinsulinemia (>6.3 µU/mL). The ocreotide therapy for hyperinsulinemia was started while waiting for diazoxide therapy. At four weeks of age, he had yellowish skin and sclera, yellow-pale stool but without bloody stool or hepatomegaly. There were no infections or parenteral nutrition used. Laboratory examination showed an increase of direct bilirubin (7.09 mg/dL), AST, ALT, and alkali phosphatase with normal gamma-glutamyl transferase (GGT) levels. Neonates with hyperinsulinemia tended to have cholestasis (median of conjugated total bilirubin level: 5 mg/dL) after four days of hypoglycemia onset. The risk factors are fetal distress, hyperglycemia during pregnancy, prematurity, chorioamnionitis, and parenteral nutrition. The proposed mechanism is related to the effect of diabetes during pregnancy, which causes fetal hyperinsulinemia that leads to chronic hypoxemia and oxidative stress. In vivo study showed that a hypoxic state will induce a change in histological structure (predominantly cholangiocytes) and alteration of hepatobiliary transporter genes, such as decreases mRNA level of Ntcp, Bsep, and Mrp2 (hepatocyte transporters) and decrease mRNA level of Cbtr (cholangiocyte transporter).

Abstract Submission No. 101533
O-1080

ZFVE19 disease: a facultative ciliopathy initiated by failure of cell division and cell death

JING YANG1,2-3, Ya-Nan Zhang2, Ren-Xue Wang3, Chen-Zhi Hao3, Yi-Ling Qiu2, Hao Chi2, Wei-Sha Lan2, Hong-Yi Tang2, Xiu-Juan Zhang2, Xu-Xu Sun2, Jonathan A Sheps4, Victor Ling4, Mu-Qing Cao2, Jian-She Wang3,6

1Chengdu Women’s and Children’s Central Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu China, 2Jinshan Hospital of Fudan University Shanghai China, 3Children’s Hospital of Fudan University Shanghai China, 4BC Cancer Agency Vancouver Canada, 5Shanghai Jiao Tong University School of Medicine Shanghai China, 6Shanghai Key Laboratory of Birth Defect Shanghai China

Background & Aims: ZFVE19 disease is a recently discovered disorder characterized by progressive portal fibrosis, portal hypertension and eventually liver decompensation. To elucidate the underlying mechanism, Zfve19-/- mice and ZFVE19 knockdown/knockout cells were generated.

Methods: Zfve19-/- mice were generated by targeted knockout using CRISPR/Cas9 technology and challenged with alpha-naphthyl isothiocyanate (ANIT) to induce biliary fibrosis. Their livers were characterized at the tissue, cellular, and molecular levels. Findings were compared with those in wild-type (WT) mice and in ZFVE19-disease patients.

Results: The Zfve19-/- mice were normal with respect to general and hepatobiliary features. However, when challenged with alpha-naphthyl isothiocyanate, Zfve19-/- mice developed changes resembling those in ZFVE19-disease patients, including elevated serum liver injury markers, increased number of bile-duct profiles with abnormal cholangiocyte polarity, and biliary fibrosis. Failure of cell division, centriole and cilia abnormalities, and increased cell death were observed in knockout/knockout cells. Increased cell death and altered mRNA expression of cell death-related signaling pathways was demonstrated in livers from Zfve19-/- mice and patients. TGF-β and JAK-and STAT3 signaling pathways were upregulated in vivo, as were chemokines such as C-X-C motif ligands 1, 10, and 12.

Conclusions: Our findings demonstrated that ZFVE19 disease is a facultative ciliopathy with novel histological features. Failure of cell division with ciliary abnormalities and cell death activates macrophages and leads to biliary fibrosis via TGF-β pathway in the disease.

Abstract Submission No. 101985
O-1081

NATURAL HISTORY AND RENAL INVOLVEMENT OF CONGENITAL HEPATIC FIBROSIS AND CAROLI DISEASE

Nirmala Deivamani1, Deepa J1, Sindhuja TA1, Senthilkumar R1, Winston Thomas1

1Department of Paediatric Gastroenterology, Institute of Child Health, Madras Medical College Chennai India

Background and Objective: Congenital hepatic fibrosis(CHF) and Caroli syndrome has varied clinical presentations with or without renal involvement. Our study aimed to describe clinical manifestations and natural history of children with CHF and Caroli.

Methods: Retrospective review of case records of CHF and Caroli children(n=21) diagnosed on basis of clinical features, radiological and compatible histopathological findings in a single centre. Children
were followed up and endoscopic, radiological and biochemical sur-
veillance was recorded and analyzed.

Results: Twenty-one children (Caroli=6, CHF=16) were enrolled and
male predominance (76%) was noted. Consanguinity was noted in 76% 
and 23% had affected siblings. Median age at initial presentation was
2yrs and abdominal distension was the most common presentation
(47.6%) followed by variceal bleeding (23.8%), cholangitis (14.2%
), incidental diagnosis (9.5%) and pancytopenia (4.76%). Median age at
presentation and diagnosis was later with variceal bleeding compared 
with abdominal distension being 5.6yrs and 18months respective-
ly (p=0.0001). Renal involvement was present in 76%, most com-
mon was ARPKD, 18% had developed CKD. Caroli had 100% renal
involvement. There was no statistical difference in the age of presen-
tation of CHF with or without renal involvement (p=0.5998). Growth
faltering was noted in 52% not related to the degree of either renal
involvement or portal hypertension. Portal hypertension was seen in
76%. Only one child had variceal bleeding on follow up.

Conclusion: Abdominal distension, organomegaly, variceal bleeding
and cholangitis are the common clinical manifestations of CHF and
Caroli disease. Renal involvement did not correlate with severity of
hepatic manifestations or involvement.

Abstract Submission No. 102011
O-1082

Pediatric acute liver failure: Experience from a tertiary care
center in India

Manasa Alla1, Mithun Sharma1, Shantan Venishetty1, Anand V
Kulkarn1, Sowmya TR1, Ravi Babu1, Nagaraja Rao Padaki1,
Nageshwar reddy Duvvuru1

1AIG Hospitals, Hyderabad Hyderabad India

Background: Pediatric ALF encompasses a spectrum with varied eti-
ologies and timely intervention and appropriate choice of therapies
may halt rapid progression and prevent unfavorable outcome. We
aimed to study the outcomes and identifying prognostic variables in
predicting 30-day transplant free survival in PALF.

Methods: In this retrospective analysis done at tertiary care center at
Hyderabad, India. 24 patients with PALF within last 1 year were ana-
lyzed. Aim of the study was to analyze 28-day transplant free survival
outcomes of PALF, incidence of infections and various prognostic vari-
ables.

Results: The mean age of presentation is 8.12 ± 3.2 years with viral
being the most common etiology in 15/24 (62.5%) followed by Wilson
flare 4/24 (16.6%) and others 5/24 (20.8%). Mean time from onset of
jaundice to encephalopathy was 6.34 ± 2.2 days. Sepsis was noted in
5/24(20.8%) and AKI in 5/20 (25.0%) patients. 28-day transplant free
survival was noted in 70.8% (17/24) patients. Spontaneous recovery
was noted in 41.1% (7/17). Plasma exchange (PLEX) was performed in
47 % (8/17); CRRT in 11.7% (2/17); Liver transplantation in 2 pa-
tients. Median time to transplant free recovery was 10 (4.2-21.2) days.
Mean number of PLEX sessions were 2.12 ± 0.42. On Multivariate
analysis, baseline NH3 {HR (95% CI) 1.42 (0.920 - 2.157), P=0.01; 
Grade of encephalopathy (baseline) {HR(95%CI) 3.57 (1.45-8.41), P=0.01}; 
PELD score {HR(95%CI) 1.865 (0.854-3.534), P=0.04) were found to be significant in predicting
30 day transplant free survival.

Conclusion: Timely management of PALF and early intervention will
guide in prognosis and management.

Abstract Submission No. 200140
O-1083

LIVER TRANSPLANTATION FOR PROGRESSIVE
PEDIATRIC BUDD CHIARI SYNDROME

Aabha Nagral1,2, Samriddhi Poyekar3, Shailesh Sable3, Abhijit
Bagde2, Rahul Verma2, Ketul Shah2, Suresh Vasant4, Ambreen
Sawant5, Darius Mirza6

1Jaslok Hospital and Research Centre and Apollo Hospital Mumbai
India, 2APOLLO HOSPITAL NAVI MUMBAI INDIA, 3JAGJIVAN
RAM HOSPITAL MUMBAI INDIA, 4Queen Elizabeth Hospital
Birmingham United Kingdom, 5Medicover Hospital Navi Mumbai
India

Background: Budd Chiari syndrome (BCS) in children is uncommon
and there is limited published literature on liver transplantation (LT).

Methods: Ten children who underwent LT for BCS from 2017-2023
were analysed for radiological intervention (RI), indication of trans-
plant, intraoperative challenges, early and late complications and graft
survival after transplantation.

Results: A total 60 paediatric LT were performed over 4.5 years of
which 10 patients (8 males and 2 females) had BCS. 8/10 children had
prior RI (Five had TIPSS and 4 had Hepatic vein venoplasty). Hepato-
pulmonary syndrome (HPS) was the most common indication for LT
and developed post RI in 6 children. The median age and weight of
children at transplant was 61 months (IQR 26 - 109) and 12.85kg (IQR
10.4 - 23) respectively. The median duration from onset of symptoms
to LT was 42 months (IQR 14 - 80). HPS resolved after a median pe-
riod of 25 days (IQR 15.5 - 60). The median duration of post-transplant
follow up is 4yrs 5 months (IQR 1 year 10 months - 4 years 10
months). Vascular complications (including 1 recurrence) and biliary
complications were seen in 30% patients respectively which were
amaenable to RI. The 1 year & 3-year survival rates both were 75%.

Conclusion: LT has shown good long-term outcomes in children with
BCS. HPS seems to occur despite RI in paediatric BCS. Recurrent
BCS post LT can be salvaged using RI. Higher biliary and vascular
complications are likely related to HPS & previous RI.

Abstract Submission No. 200193
O-1084

Anti-HBc levels predict HBsAg seroclearance in children with
CHB

Yanwei Zhong1, Min Zhang1, Xiuchang Zhang2, Yuxi Ning1, Jia
Liu1, Wenwen Yuan1, Ce Shi1

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing
Beijing China, 2Hebei North University Zhangjiakou China

Objectives: To explore the role of anti-HBc predict the HBsAg clear-
ance in children with chronic hepatitis B (CHB).

Materials and Methods: 56 children with HBsAg-positive CHB aged
1 to 10 years, treated with interferon a (IFNα) 48 weeks follow up 24
weeks. Based on the results of HBsAg clearance, the patients were di-
vided into HBsAg clearance group and non HBsAg clearance group.
Univariate and multivariate regression was used to identify the impact
factors associated with HBsAg clearance. The area under the receiver
operating characteristic curve (AUROC) was used to assess the pre-
diction for HBsAg loss.

Results: HBsAg loss rate at week 48 were 50.0%. Patients with
HBsAg loss showed a significantly high baseline anti-HBc levels in
HBsAg loss group (p < 0.05). Univariate and multivariate analysis
showed that age, baseline anti-HBc and HBsAg levels at week 12 were
independent predict factors for HBsAg loss. Although the baseline
anti-HBc levels (AUROC 0.704(95%CI 0.567-0.841, p=0.0001) was
lower than that of HBsAg at week 12(AUROC 0.866, 95%CI 0.765-

Early decreased HBV RNA and HBsAg levels predicts treatment effect in children with CHB

Yanwei Zhong1, Min Zhang1, Ce Shi1, Jiaojiao Xu1, Hanwen Zhang1, Xiaotong Chang2, Jia Liu1, Wenling Wang1, Xiuchang Zhang2

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing China, 2Hebei North University Zhangjiakou China, 3Chinese PLA General Hospital Beijing China

Objective: To explore the role of serum HBV RNA in children with CHB during antiviral treatment.

Methods: 222 children with CHB aged 1-17 years old received 48 weeks IFNα alone or combination with nucleoside analogues (NAs) was studied. Ability of HBV RNA predicting HBsAg loss was evaluated by the area under the receiver operating characteristic (AUROC).

Results: HBsAg loss rate in HBeAg positive children was 32.0% at week 48. In predicting HBsAg loss, the combination of reduced levels of HBV RNA and HBsAg at 24 th weeks was pronounced superior to other combinations of HBV biomarker reduced levels. HBV RNA from baseline to week 24 reduced levels >2.7 log10 copies/ml combined with HBsAg reduced levels >2.02 log10 IU/ml had a strong ability predicting HBsAg loss at week 48, the positive predictive value, negative predictive value, sensitivity and specificity was 78.9%, 86.8%,100.0% and 72.9%, respectively.

Conclusions: The decline degree of HBV RNA combined with HBsAg from baseline to week 24 of treatment can be used an early marker of predicting HBsAg loss in HBeAg positive children.

Assessment of the APASL Guidance for Albumin Infusion in Therapeutic Paracentesis: RD Design

Tomohiro Tanaka1,3, Michael Jones2,3, George Wehby2,3

1University of Iowa, Division of Gastroenterology and Hepatology Iowa City United States, 2University of Iowa, College of Public Health Iowa City United States, 3Center for Access & Delivery Research and Evaluation (CADRE) Iowa City United States

Background: The 2023 APASL Guidelines recommend albumin infusion to prevent post-paracentesis circulatory dysfunction when removing > 5 liters of ascites. However, the optimal cutoff for initiating albumin infusion after the large-volume paracentesis (LVP) remains understudied.

Methods: We conducted a retrospective cohort study at a U.S. academic healthcare center on outpatients who underwent LVP between 2019 and 2022. Patients with spontaneous bacterial peritonitis, post-LVP diuretic adjustments, and/or hospitalization were excluded. The institution strictly followed the guidelines, making the cohort suitable for a Quasi-experimental, sharp regression discontinuity (RD) design. This allowed us to estimate the local average treatment effect of albumin infusion on serum creatinine and sodium trajectory.

Results: Over the study period, 1457 LVPs were performed on 236 unique patients. Administering albumin infusion at the threshold of 5 L of ascites removal significantly reduced serum creatinine levels by 0.05 (95%CI: 0.01-0.097) and 0.048 (0.01-0.086) mg/dl/day and increased serum sodium levels by 0.34 (95%CI: 0.12-0.6) and 0.39 (0.16-0.61) mEq/L/day, respectively, compared to those without albumin infusion. Results across sensitivity analyses were consistent, underscoring the robustness of the effect size estimation. The RD plots also indicated worsened serum creatine/sodium levels after draining 3-4 liters of fluid, approaching levels similar to or worse than with albumin infusion at 5 liters or more.

Conclusions: RD models supported the 2023 APASL Guidelines. Additionally, the findings suggest conducting clinical trials to evaluate the efficacy of albumin infusion in patients who undergo LVP and have 3-5 or 4-5 liters of ascites removed.

Safety & Efficacy of Endoscopic Glue vs EUS guided Coil+glue in the Treatment of Gastric Varices: RCT

Rajesh Gupta1, Jahangeer Basha2, Tummalaapalli S A Satya Maharshi3

1West China Hospital, Sichuan University Chengdu China

Backgrounds: The association between the presence of sarcopenia in patients with cirrhosis and the onset of hepatic encephalopathy (HE) after transjugular intrahepatic portosystemic shunt (TIPS) is yet to be established. We conducted a systematic review and meta-analysis to provide a thorough summary of the available evidence on this association.

Methods: A thorough search of the literature was performed in the PubMed, EMBASE, and Web of Science databases. The protocol was duly registered on PROSPERO (CRD42023398856). The hazard ratio (HR) and corresponding 95% confidence intervals (CIs) for the occurrence of HE after TIPS were extracted from studies comparing cirrhotic patients with and without sarcopenia. These data were then combined using a random-effect model.

Results: A total of 1135 patients from seven cohort studies that met our eligibility criteria were included in the meta-analysis. Our findings indicate a significantly higher risk of post-TIPS HE among cirrhotic patients with sarcopenia compared to those without sarcopenia (HR, 2.35; 95% CIs, 1.32-4.19; p = 0.004; I² = 75%). The findings remained consistent through sensitivity analysis and across subgroups stratified by liver disease etiology, study location, and severity of hepatic dysfunction.

Conclusion: The study demonstrated that sarcopenia was strongly linked to an increased likelihood post-TIPS HE among cirrhotic patients.

Abstract Submission No. 200218
O-1085
Early decreased HBV RNA and HBsAg levels predicts treatment effect in children with CHB

Abstract Submission No. 100474
O-1087
Hepatic Encephalopathy after TIPS in cirrhosis and sarcopenia: A Systematic Review and Meta-analysis

Xiaoze Wang1, Yuanyuan Li1, Langli Gao1
1West China Hospital, Sichuan University Chengdu China

Abstract Submission No. 100510
O-1088
Safety & Efficacy of Endoscopic Glue vs EUS guided Coil+glue in the Treatment of Gastric Varices: RCT
Background: Gastric varices are typically treated by Endoscopic injection of glue. Various complications have been described related to this treatment. EUS offers a unique opportunity to directly visualize and access GV.

Aim: To compare the safety and efficacy of Endoscopic glue injection technique to EUS guided coil with glue

Methods: RCT was done from Feb 2020 to Aug 2021. Patients were randomized into 2 groups. Group A patients received endoscopic glue injection and Group B patients received EUS-guided coils and glue injection. CT chest was performed in all patients to detect pulmonary embolism. Patients were followed at 1, 3 and 6 months. Primary outcome was to compare the occurrence of PTE between 2 groups. Secondary outcome was to evaluate the efficacy of 2 techniques in the complete obliteration of varices, rebleed rates and reinterventions required in both groups.

Results: 34 patients were enrolled and 17 patients were included in each group. PTE was documented in 3(17.6%) patients in group A and in only 1(5.8%) patient in group B. Of 16 patients in group A, 10(62.5%) had complete obliteration at 1 month, whereas 15(93.75%) had complete obliteration of the gastric varices in group B (p=0.03). In group A, 7(43.75%) required reintervention on follow up due to incomplete obliteration, whereas in group B, only 1 out of 16(6.25%) required reintervention (p=0.03). In group A, 2(12.5%) had rebleed at 3 months follow up whereas in group B, none of the patient had rebleed (p=0.144).

Conclusion: EUS-guided coil+glue was highly effective in obliteration of GV and reducing need for reinterventions when compared to endoscopic glue. Also, the risk of embolism with EUS guided treatment was low when compared to Endoscopic treatment.

Abstract Submission No. 100796
O-1089

Point-of-care cardiac ultrasound (POCUS) monitoring & Fluid resuscitation in Cirrhosis with sepsis

Madhumita Premkumar1, Kamal Kajal1, Vishesh Kumar1, Bhupendra Siha2, Sahaj Rath2, Arpit Shastri1, CP Ganesh1
1Postgraduate Institute of Medical Education and Research Chandigarh India

Background: Point-of-care ultrasound (POCUS) is used to determine volume status, presence of cirrhotic cardiomyopathy (CCM), inferior vena cava (IVC) dynamics and fluid responsiveness in cirrhosis with severe sepsis. We compared the response of 3 resuscitation strategies in the first 6 hours: (1) early 20% albumin (2) balanced salt solution (BSS) or (3) combined BSS and late 20% albumin.

Methods: POCUS was done within 3h of admission to the liver intensive care unit and at 24h, 48h&72h in patients with cirrhosis with mean arterial pressure (MAP)<65 mmHg. Resuscitation target was maintenance of MAP≥65 mmHg. We evaluated predictors of circulatory failure and mortality using POCUS & serum biomarkers. CCM was defined per CCM Consortium (2020) criteria.

Results: We enrolled 180 patients (67% men, mean±SD: 49±12.7 years, 47% alcohol associated). SOFA score 8±2.7 and MELD Na 27±9.4. Overall, 90-day mortality was 36.1%. Patients receiving 20% albumin within 1st hour, (Early albumin, N=78), only BSS in 1st 6 hours (N=65) and BSS followed by late 20% albumin ≥3 hours of ICU admission (Late albumin, N=37) were compared. CCM was diagnosed in 78(43.3%) and was independently predictive of mortality. On multivariable analysis, the CCM variables: ε’ velocity (aHR-0.92, P=0.040), LAVI (aHR-1.1, P=0.019), biomarkers-endotoxin level (aHR-1.2, P=0.001), NTproBNP (aHR-1.004, P=0.001), Galectin-3 (aHR-1.1, P=0.001) and SOFA score (aHR-1.3, P=0.001), and not the type of fluid predicted fluid nonresponse. Predictors of mortality were SOFA score (aHR-1.4, P=0.043), MELD Na (aHR-1.9, P=0.038), ε’ velocity (aHR-0.82, P=0.034), cardiac index at 72h (aHR-0.31, P=0.006) and not the type of fluid. The 28-day mortality outcomes did not differ in the three resuscitation fluid arms (37.2%, 36.9% & 18.9%, respectively; P=0.053).

Conclusion: Successful resuscitation of patients with cirrhosis and sepsis is dependent on their cardiac function and SOFA score rather than the choice of resuscitation fluid.

Abstract Submission No. 100904
O-1090

Rating diagnostic models for liver cirrhosis patients with portal hypertension using HVPG

Wei Gou1, Xue fang li2, Jin jin Li3
1Qingdao Sixth People’s Hospital Qingdao China, 2Qingdao Sixth People’s Hospital Qingdao China, 3Qingdao Sixth People’s Hospital Qingdao China

Background: Portal hypertension in liver cirrhosis leads to complications like ascites, esophageal varices, and hepatic encephalopathy. Accurate assessment of portal hypertension relies on invasive hepatic venous pressure gradient (HVPG), measurement, which is not widely available. Non-invasive models for stratifying portal hypertension in liver cirrhosis are lacking.

Methods: This study included liver cirrhosis patients from multiple centers in Shandong Province, China for HVPG measurement. Patients were divided into three subgroups based on disease stage: compensated portal hypertension (HVPG<5 mmHg), clinically significant portal hypertension (HVPG=10 mmHg), and decompensated portal hypertension. Pearson correlation coefficients were used to explore the relationships between 19 clinical features and portal venous pressure. Non-invasive models were developed for each subgroup to guide clinical practice.

Results: In compensated portal hypertension (HVPG=5-10 mmHg), the model equation was Y=-850.543-17.725*ALB+14.299*LSM-216.767+1.203*PT+2.135*gender (1 for male, 0 for female). The AUC for diagnosing progression to clinically significant portal hypertension (HVPG≥10 mmHg) was 0.79 (0.641-0.859). For clinically significant portal hypertension, the model equation was Y=-216.767+1.203*PT+2.135*gender (1 for male, 0 for female). The AUC for diagnosing progression to decompensated portal hypertension was 0.821 (0.726-0.916). For decompensated portal hypertension with HVPG≥10 mmHg, the model equation was Y=0.65+0.003*WBC-0.314*HA. The AUC for predicting the risk of severe decompensation events was 0.778 (0.58-0.975).

Conclusion: Portal hypertension occurs at different stages of liver cirrhosis, and as portal venous pressure increases, the diagnosis and treatment of liver cirrhosis become more challenging. Non-invasive models for stratifying portal hypertension can assist in diagnosing and monitoring portal hypertension throughout the disease course, enhancing the sensitivity of clinical diagnosis.

Abstract Submission No. 101351
O-1091

Hypersplenism in non-cirrhotic portal hypertension - debunking the spleen’s guilt
Ankita Singh1, Kashmira Datta1, Chetan Saner1, Prajakta Mane1, Akash Shukla1
1Seth GS Medical College and KEM Hospital Mumbai India

Background: Hypersplenism is a common occurrence in non-cirrhotic portal hypertension (NCPH), manifesting as bicytopenia or pan-cytopenia in majority of these patients. Splenic stiffness measurement (SSM) is increasingly being validated for assessment of portal hypertension. Therefore, we evaluated the correlation between splenic stiffness and hypersplenism.

Methods: Consecutive patients (n=89) with non-cirrhotic portal hypertension were enrolled in the study. SSM/LSM (liver stiffness measurement) values were obtained using FibroScan® Expert 630 machine. Pearson correlation coefficient was calculated to analyse correlation between hematologic parameters and splenic stiffness. Simple linear regression analysis was done with SSM as explanatory variable.

Results: Median age was 35 (17-70) years. Female preponderance was observed (51/89, 57.3%). 48 of 89 (53.9%) patients had non-cirrhotic portal fibrosis/idopathic portal hypertension (NCPF/IPH) and 41 patients (46.1%) had extra-hepatic portal vein obstruction (EHPVO). Median values of hematologic parameters were: hemoglobin 9.8 (3.5-14.2) g/dL, leukocyte count- 3.4 (0.8-13.6) X 109/L and platelet count- 80 (20-636) X 109/L. Mean spleen size was 19 (+4) cm. Mean SSM and LSM values were 60.5 (+24.4) kPa and 8.3 (+3.2) kPa respectively. Spleen size positively correlated with SSM values (Pr<0.0001). The hematologic parameters (Hb, leukocyte and platelet count) correlated with each other but not with splenic size or stiffness (Pr<0.05).

Conclusion: The severity of cytopenias due to hypersplenism is independent of the splenic size or stiffness.

Abstract Submission No. 101378
O-1092

Clinical profile of adolescents presenting with Portal Hypertension at a tertiary care center
Tanmay Laxane1, Arun Vaidya1, Jtendra Yadav1, Vaibhav Padole1, Chetan Saner1, Shubham Gupta1, Shashank Pujalwar1, Ankita Singh1, Akash Shukla1
1Seth GS Medical College and KEM Hospital Mumbai India

AIMS AND BACKGROUND—Portal Hypertension (PHT) is a major cause of morbidity and mortality in pediatric liver diseases. We aimed to study patients’ characteristics and outcome in adolescent population presenting with PHT.

Methods: Prospectiveively collected liver clinic database from January 2014 to December 2022 was analyzed to identify the profile of newly diagnosed adolescent patients presenting with features of PHT.

RESULTS: Total 125 (79[63.2%] boys) patients reviewed. The etiology of PHT were Extrahepatic portal vein obstruction (EHPVO, n=45[36%]), Non-cirrhotic portal fibrosis (NCPF, n=25[20%]), Buddchiari syndrome (BCS, n=18[14.4%]) and liver cirrhosis (n=79, 63.2%). The causes of cirrhosis were AIH (n=4[10.8%]), Wilson’s disease (n=12[32.4%]), Hepatitis B (n=8[21.6%]), Caroli’s disease (n=1[2.7%]) and cryptogenic (n=12[32.4%]). The presentation was variceal bleed (n=44[35.2%]), ascites (n=39[31.2%]), jaundice (n=26[20.8%]) and hepatic encephalopathy (n=6[4.8%]). EHPVO and NCPF, presented with variceal bleed(50%) ,while BCS and cirrhosis presented with ascites (63%). Esophageal and Gastric varices at index endoscopy were present in 77 (61.6%) and 27 (21.6%) cases. During 65 months median follow up, recurrent variceal bleed was seen in 6 and 5 cases of EHPVO and NCPF respectively despite on surveillance endoscopy. Over a median follow-up of 5 years (64.8%) patients died, all due to progressive liver failure.

Conclusion: Vascular diseases of the liver are the most common causes of PHT in adolescents and have a good prognosis.

Abstract Submission No. 101991
O-1094

High-shear induced activation of piezo1 develops portal-hypertension via cytoskeleton remodelling
Rajni Yadav1, Parul Singh1, Vaibhav Tiwari1, Aishwarya Bhatnagar4, Himanshi Himanshi1, Shiv Kumar Sarini1, Savneet Kaur1, Dinesh Mani Tripathi1
1Institute of Liver and Biliary Sciences delhi India

Background and Aim: Liver Sinusoidal Endothelial Cells sense & respond to portal blood flow induced shear stress & hydrostatic pressure via mechanocrine signalling, regulates the endothelial homeostasis & vascular tone. Disturbed shear promotes endothelial dysfunction and portal hypertension. Role of mechanosensors and its contribution in portal dynamics is unexplored. We investigated the involvement of high shear induced mechanosensors in the development of portal hypertension.

Methods: Experimental high shear rat model was developed by resection of 70% liver (Phx). Hepatic hemodynamics was monitored at 24 and 48hrs post Phx. Shear flow was evaluated by transonic flow system and intra-vital imaging with Rhodamine-6G-fluorophore-stained platelet. Further proteomics analysis was performed. Molecular, cellular and histological analysis was performed in liver tissue.
Steroid response in Alcoholic hepatitis (AH) induced ACLF is based on severity of portal hypertension

HARSH VARDHAN TEVETHIA1, VINOD ARORA1, GURESH KUMAR2, SHIV KUMAR SARIN2
1ILBS NEW DELHI India

Introduction: Alcoholic hepatitis (AH) induced ACLF is a distinct clinical syndrome characterized by high short term mortality. Treatment with prednisolone in patients with AH-induced ACLF has shown promising results. We investigated the role of portal hypertension in patients with AH-induced ACLF.

Methods: Patients presenting with AH-Acute on chronic liver failure (ACLF) using APASL criteria were prospectively enrolled between April 2020 - August 2023 at ILBS New Delhi. All patients who underwent hepatic venous pressure gradient (HVPG) along with transjugular liver biopsy were included. The objective of the study was to study the role of portal hypertension in determining response/outcomes to treatment in AH-ACLF.

Results: Altogether 74 patients were analysed of which 42 patients were steroid responders (Group 1) while 32 patients (Group 2) were non-responders with predominant males (95.9%) with 28 day mortality seen in 20(27%) patients. Predictors of response at baseline included alcoholic hepatitis histological score (AHHS) score >6, MELD score >25, AARC score >8, Platelet count <110 cu/mm, INR >2.2, HVPG, LSM and mDF Score(p<0.01). HVPG >20.5mmHg predicted steroid non-response with an AUROC-81.3(95%C.I-70.2-90.6) (P<0.01) with sensitivity 79% and specificity 70%. Predictors of mortality included AHHS score, presence of SBP, pneumonia, hepatic encephalopathy, HVPG=18mmHg, high risk esophageal varices, platelet count <110cu/mm and acute kidney injury (AKI) (P<0.01). HVPG >22.5mmHg independently and significantly predicted mortality (p<0.01).

Conclusion: Presence of HVPG >20 mmHg is an important determinant of sub-optimal outcome in patients with AH-ACLF patients. Such patients should be considered for alternative therapy at presentation.

Inhibition of HMGB1 ameliorate sepsis induced LSECs dysfunction and portal hypertension in cirrhosis

Vaibhav Tiwari1, Rajni Yadav1, Aishwarya Bhatnagar1, Parul Singh1, Himanshi Himanshi1, Kanchi Sharma1, Shiv Kumar Sarin1, Savneet Kaur1, Dinesh Mani Tripathi1
1Institute of Liver and Biliary Sciences, New Delhi New Delhi India

Background and Aim: In liver cirrhosis, Septic shock is shattering disease progress to multiple organ failure. Sepsis cause disturbed endothelial homeostasis, hepatic microvascular complications, portalhypertension. Persistent systemic inflammation regulates HMGB1 that triggers hepatic injury. Its role in hepatic vascular pathogenesis is not explored. We investigated role of HMGB1 in sepsis induced LSEC dysfunction and portal hypertension in cirrhosis.

Methods: Experimentally, sepsis was induced by intraperitoneal administration of LPS in both CCl4-cirrhotic and non-cirrhotic animals. CCl4-cirrhotic rats (Gr1), CCl4+LPS (Gr2), CCl4+LPS +Glycyrrhizin(Gr3) were compared with controls(Gr1). Non cirrhotic CCl4+LPS (Gr2), CCl4+LPS + Glycyrrhizin (Gr3). Hepatic hemodynamic was monitored followed by ex-vivo Hepatic microvascular-functionality analysis. Cellular, Molecular and histological analysis was performed in hepatic tissues.

Results: Studies shows a noticeable increase in PP(9.9±1;+31.9%(Gr2), vs 7.2±1;inCt1) a marked reduction in Ct(8.2±0.4;+13.6%) vs Ct2 (p=0.01) was observed. However, we observed significantly raised PP(12.6±1;+26%Gr2), vs 10±1; in Gr1) a marked reduction in Gr3(10.8±0.2;+14%) vs Gr2 . p=0.01 was observed. Gr2 animals also had increased flow index (p=0.001) and PBF (p<0.05) in comparison to Gr1 and Gr3. Endothelial function was also corrected in Gr3 vs Gr2 &Gr1. Inflammatory cells infiltration was evidently reduced in both Ct3 and Gr3 rats vs Ct2 & Gr2 respectively. Gene expression of TNF-alpha, IL-6 were significantly upregulated in Gr2 and Ct2 (p<0.05) vs Gr3 and Ct3. Moreover, Endothelial dysfunction gene CD31 ICAM1, VCAM1, was downregulated (p<0.05) in Gr3s Ct3 vs Gr2 & Ct2.

Conclusion: This study demonstrated that pharmacological inhibition of HMGB1 ameliorates PP and protects vascular function during sepsis in liver cirrhosis.

Comparison of EUS PV with intra-operative direct PV pressure in pretransplant cirrhotics-pilot study

Aniruddha Singh1, Sundeep Lakhatkia1, Shujaath Asifi1, Mithun Sharma1, Premkumar CV1, Kumaraswamy P1, Balachandra Menon1, Sana fatima Memon1, Duvur nageshwar Reddy1, Pradev Inavolu1, Azimuddin Haja1
1AIG Hospitals Hyderabad India

Introduction: Direct portal pressure measurement under EUS-guidance (EUS-PPM) is a promising alternative to conventional indirect Hepatic Venous Pressure Gradient (HVPG). In patients undergoing liver transplantation for cirrhosis, high pre-operative portal vein (PV) pressure requires intra-operative portal vein inflow modulation (PIM). This pilot study aims to assess correlation between EUS-PPM with direct intra-operative portal pressure measurement (IO-PPM).

Methods: Liver cirrhosis patients scheduled for liver transplant within next 48 hours were included. EUS-PPM was performed using a 25G or 22G EUS-FNA needle to puncture PV. Both, compact manometer (CM) and arterial transducer (AT) were used to measure the intra-vascular pressure, pre- and intra-operatively. EUS PV was punctured trans-duodenally under conscious sedation. A mean value of 3
consecutive readings were taken for both methods. IO-PPM was done just soon after laparotomy using AT.

Results: All 25 patients (23 males) underwent pre-operative EUS-PPM & IO-PPM (100 % technical success). Pre-operative EUS-PPM ranged from 18 - 44 mm Hg using CM & 22-56 mm Hg using AT. IO-PPM ranged from 14-38 mm Hg. No adverse events were observed. EUS-PPM using 22G FNA needle was more consistent than with 25G needle (Δ2 vs Δ10). Pre-transplant PP were similar using 22G needle with CM and AT. IO-PPM was consistently lower than pre-operative EUS-PPM by Δ8 mm Hg.

Conclusion: In this pilot study, EUS guided direct PV puncture & PPM using compact manometer is a safe and correlates well with AT, both preoperatively & intra-operatively. 22G FNA needle yields consistent results compared to 25G FNA needle.

Abstract Submission No. 100227
O-1098

Evaluation of useful factors for reclassifying “unclassified group” under Baveno VII criteria

Ryo Yano1, Masashi Hirooka1, Yohei Koizumi1, Yoshiko Nakamura1, Makoto Morita1, Yuki Okazaki1, Yusuke Imai1, Takao Watanabe1, Osamu Yoshida1, Yoshio Tokumoto1, Masanori Abe1, Yoichi Hiasa1

1Department of Gastroenterology and Metabolology, Ehime University Graduate School of Medicine Toon Japan

Background: The Baveno VII criteria proposed an algorithm using platelets count and liver stiffness to identify clinically significant portal hypertension (CSPH). While it could identify CSPH, there were many unclassified patients who did not belong to either definite CSPH or improbable CSPH. Therefore, it was necessary to improve the algorithm by adding new factor.

Methods: This retrospective study included 73 chronic liver disease patients from 2018 to 2023 in single center. CSPH was defined as hepatic hypertension (CSPH). While it could identify CSPH, there were platelets count and liver stiffness to identify clinically significant por-

Results: The cutoff value for CSPH was calculated by ROC analysis. It was set where the positive predictive value was > 90% or the negative predictive value was > 90%. We compared the proportion of the unclassified group between the modified Baveno VII criteria.

Conclusion: If the positive predictive value was > 90% or the negative predictive value was > 90%, we could appropriately reclassify the unclassified group by modified Baveno VII criteria with splenic stiffness.

Abstract Submission No. 100439
O-1100

Outcomes of Cirrhotic Patients with Acute Variceal Bleeding and Concurrent Hepatocellular Carcinoma

Guofeng Liu1, Tong Xiang1, Xiaoze Wang1, Li Yang1, Xuefeng Luo1

1West China Hospital Sichuan University Chengdu China

Background/Aims: The treatment outcomes and risk factors for prognosis of acute variceal bleeding (AVB) in hepatocellular carcinoma (HCC) patients remain unclear. Hence, we assessed the clinical outcomes and prognostic factors of these patients. To evaluate the treatment outcomes and risk factors of cirrhotic patients with hepatocellular carcinoma (HCC) and acute variceal bleeding (AVB).

Methods: This is a retrospective case-control study. Consecutive patients with HCC and AVB admitted between 2016 and 2019 were included. For each patient with HCC, a patient without HCC was matched by age, sex, and Child-Pugh class. Follow-up was continued until death and transplantation.

Results: A total of 286 patients were included. The five-day treatment failure, 6-week mortality, and 1-year mortality rates of the whole cohort were 26.6%, 16.9%, and 36.1%, respectively. Patients with HCC had higher 6-week and 1-year mortality respectively (26.6% vs. 12.6, P<0.003; 53.3% vs. 18.9%, P<0.001). Among AVB patients with HCC, alpha fetoprotein (AFP) levels (HR, 1.001:95% CI, 1.000-1.002; P=0.0001), BCLC stage (C-D vs. 0-B) (HR, 1.830; P<0.001), and Child-Pugh score (HR, 1.503, 95% CI, 1.235-1.830; P<0.001) were independent risk factors of 6-week mortality in multivariate analysis. Furthermore, the risk of 6-week mortality was 71.4% among patients with a Child-Pugh score ≥ 9 and BCLC stage C-D, much higher than patients with low Child-Pugh score (<9) and earlier BCLC stage (0-B) (P=0.0001).
Conclusion: Among patients with cirrhosis and AVB, patients with HCC had a worse outcome than patients without HCC. The Child-Pugh score, AFP levels, and stage of HCC are strong predictors of 6-week mortality in patients with HCC.

Abstract Submission No. 100487
O-1101

Effect of Time to TIPS on Outcomes in Patients with Variceal Bleeding
Xiaoze Wang¹, Kunyi Ba¹, Xuefeng Luo¹, Li Yang²
¹West China Hospital, Sichuan University Chengdu China

Background: The pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) within 72 hours is recommended. Nevertheless, recent research emphasizes the challenges associated with the timely provision of TIPS within this limited timeframe. The objective of this study was to assess the impact of time for performing TIPS on patient outcomes and identify a more appropriate timeframe.

Method: This study enrolled patients referred to our hospital for TIPS procedure between January 2012 and December 2021. The duration between the recent variceal bleeding episode and the TIPS procedure was documented. Predetermined outcomes were assessed concerning various groups at four distinct time intervals: 72 hours, 5 days, 14 days, and 28 days. The primary outcome was the long-term survival rate.

Results: A total of 1180 patients were included in the study. There were no significant differences in patient outcomes between the early and late TIPS groups when patients were grouped by 72 hours, 5 days, 14 days, and 28 days. However, when comparing the late TIPS (>5 days) group to the early TIPS (≤5 days) group, a significantly lower 5-year survival rate was observed in the late TIPS group (71.0% vs 80.4%; HR, 1.88; 95% CIs, 1.14-3.12; P = 0.014). The variceal rebleeding rate did not show a significant difference between the two groups (P = 0.91).

Conclusion: Early TIPS within a 5-day window may confer a survival benefit in contrast to TIPS procedures performed beyond this timeframe. It may be advisable to expand the timeframe for pre-emptive TIPS to align with current clinical practices.

Abstract Submission No. 100524
O-1102

Shear Wave Dispersion predicted the high-risk EGV in patients with compensated cirrhosis
Jiayin Wang¹, Hongyu Zhou¹, Tinghong Li², Lei Zhao², Baiguo Xu², Weili Yin², Fang Wang², Jing Jing², Huling Xiang²
¹Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin China, ²Department of Ultrasound, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease Tianjin China

Objectives: To explore the clinical value of two-dimensional ultrasound shear wave elastography (SWE) and shear wave dispersion (SWD) in the diagnosis of high-risk esophageal gastric varices in patients with cirrhosis.

Methods: A total of 123 cirrhosis patients were included, which were divided into high-risk esophageal gastric varices (high-risk EGV) group (n =60) and low-risk esophageal gastric varices (low-risk EGV) group (n =63). Both SWE and SWD were adopted to examine each patient’s liver synchronously.

Results: In total patients, the results of SWD and SWE of high-risk EGV group were significantly higher than low-risk EGV group respectively. The area under the curve (AUC) of SWD predicted high-risk EGV was 0.709(95%CI:0.616-0.802). In compensated patients, the AUC of SWD diagnosed high-risk EGV was elevated to 0.786(95%CI:0.656-0.916), the optimal cutoff value was 15.35 m/s/kHz, the sensitivity, specificity, PPV and NPV was also elevated to 81.8%, 80.6%, 80.8% and 81.6% respectively, while in decompensated patients the AUC was 0.637(95%CI: 0.494-0.780). Stratified analysis by etiology in compensated cirrhosis patients showed that the AUC diagnosed by SWD in patients with viral hepatitis for high-risk EGV was higher than in non-viral hepatitis patients (0.777 VS 0.722). According to SWE, the AUC of high-risk EGV in total, compensated and decompensated cirrhosis was 0.606(95%CI: 0.506-0.706), 0.596(95%CI: 0.449-0.743), and 0.579(95%CI: 0.434-0.725), respectively, indicating limited diagnostic value.

Conclusion: SWE predicted the existence of high-risk EGV in patients with compensated cirrhosis non-invasively and provided a complementary method to determine whether high-risk EGV exists or not in patients, while SWE had limited diagnostic value.

Abstract Submission No. 100788
O-1103

Procoagulant risk & Clinical Outcomes following Dabigatran anticoagulation in Portal Vein Thrombosis
Madhumita Premkumar¹, Harish Bhujade¹, Sreedhar Chaluvashetty¹, Arka De¹, Ajay Duseja¹, Tanka Karki¹, Anchal Sandhu¹, Prerna Sharma¹, Yogendra Kumar¹, Sahaj Rathi¹, Shano Naseem¹, Jasmina Aluwalia¹
¹Postgraduate Institute of Medical Education and Research Chandigarh India

Background: Portal vein thrombosis (PVT) refers to partial or complete occlusion of the portal vein lumen by a thrombus or presence of portal cavernoma. In this study, we prospectively assessed the risk of PVT based on clinical, procoagulant, HCC related factors and resolution in patients on anticoagulation using direct oral anticoagulants (DOACs).

Methods: All patients attending the liver clinic services between September 2021- October 2023 were screened and patients, aged between 18-65 years, either gender, with a new diagnosis of PVT were included. Eligible non-Cirrhotic or Child A/B cirrhotic patients were started on anticoagulation with Dabigatran.

Results: Of 6808 patients screened, 207(3%) patients new onset PVT[aged 52.4±15.3y, 61.8% men]: 115 (55.8%) with compensated cirrhosis, 27(13.1%) decompensated cirrhosis and 65(31.6%) without cirrhosis. 6 (2.9%) following COVID-19 infection, 48(23.3%) were HCC related. Clinical presentation was asymptomatic (65,31.6%), abdominal pain (117,56.5%), gastrointestinal bleeding (21,10.2%), ascites (70,33.8%)& mesenteric ischemia (2, 1%). Procoagulant mutations were JAK2V617F (21, 10.2%), CALR (2, 1%) &factor V Leiden(2,1%), respectively. Protein-C and Protein-S deficiency was seen in 77(37.2%)and 83(41%). 110/206(53.1%) were started on anticoagulation(dabigatran-104,nicoumalone-6). Complete resolution of PVT was seen in 37/207(17.9%), 31/110(28.2%) on anticoagulation and only 6/97(6.2%) with spontaneous resolution. On Dabigatran, 29/104(27.9%) had complete resolution and 50/104(48.5%) had partial resolution or stable thrombus. Progression of PVT was seen in 25/207(12.1%) and death was seen in 54(27 in HCC-PVT) over 2years. Cox Regression based predictors of PVT progression were MELDNa(aHR 2.1;95%CI:1.8-4.3, P<0.001)

Conclusion: PVT has significant impact on clinical outcomes and mortality.Appropriate use of Dabigatran may improve resolution rates.
Pay attention to the practical application value of HVPG in patients with liver cirrhosis

wei Gou1, Xue fang Li2, Jin jin Li3

1Shandong Qingdao China, 2Qingdao Sixth People’s Hospital Qingdao China, 3Qingdao Sixth People’s Hospital Qingdao China

Currently, early liver cirrhosis is asymptomatic but histological changes are present, suggesting an initial silent phase with speculation about cirrhosis reversal. However, our study found that over 57% of patients with early liver cirrhosis had HVPG >5 mmHg, and 18% had clinically significant portal hypertension (CSPH).

The Baveno VII consensus in 2021 suggested a low 3-year risk of cirrhosis-related events in patients with chronic liver disease and liver stiffness (LSM) <10 kPa. However, our study revealed that among patients with liver cirrhosis and LSM <10 kPa, 29% had HVPG <5 mmHg, 49% had HVPG 5-10 mmHg, and 22% still had HVPG >10 mmHg. This indicates that cACLD cannot be ruled out in patients with LSM <10 kPa.

Our study found that as HVPG increased in cirrhosis with portal hypertension, decompensated events also increased, up to 76.67%. Child-Pugh scoring, which evaluates liver function, primarily indicated grades A and B in decompensated liver cirrhosis. However, there was no significant correlation between liver function and HVPG in decompensated cirrhosis.

Most decompensated cirrhosis with portal hypertension exhibited mild to moderate liver dysfunction. This implies that even when treating patients with decompensated liver cirrhosis and liver function classified as grades A or B, HVPG should not be overlooked. In our follow-up, carvedilol was used for medical intervention. After 3-6 months, retesting showed a decreasing trend in HVPG measurements in patients with decompensated liver cirrhosis following carvedilol treatment, with an overall average decrease rate of 23.86%. In two cases, the decrease exceeded 50%.<font>411</font>

Baveno VII algorithm to rule out decompensation in patients with HBV-related cirrhosis and varices

Jiankang Song1, Jinjun Chen1, 2, 3, Haiyu Wang1, Qiaoping Wu1, Biao Wen1

1Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
2Department of Hepatology, Zengcheng Branch, Nanfang Hospital, Southern Medical University, Guangzhou, China
3State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangzhou, China

Background: Combination of Baveno VII and spleen stiffness is a tool to safely rule out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD), but their comparative performance for hepatic decompensation remains unclear.

Methods: Using a prospective cohort of patients with cirrhosis between 2019 and 2021, who admitted to upper endoscopy and were also submitted to liver and spleen stiffness measurement (LSM, SSM) by transient elastography (TE) within 1 week, we compared 4 non-invasive models in ruling out CSPH (SSM <21 kPa model, Baveno VII model, combined Baveno VII-SSM <21 kPa model, combined Baveno VII-SSM ≤40 kPa model). Liver decompensation and hepatocellular carcinoma (HCC) were compared between 2 groups of patients within each model and outside each model. We calculated the rate of decompensation-free incidence in rule-out groups according to different models.

Results: 741 patients with HBV-related cirrhosis and esophageal varices were analysed. None of the patients in the rule-out groups defined by the above models developed decompensation during a median follow-up of 37 months. The proportions for decompensation-free were the highest for the combined Baveno VII-SSM ≤40 kPa model (35.6%). Decompensation-free rates for the other models ranged from 4.7% for SSM <21 kPa model to 24.3% for combined Baveno VII-SSM <21 kPa model. Of the combined Baveno VII-SSM ≤40 kPa model with HCC surveillance, the patients among both groups developed HCC.

Conclusion: The algorithm combining Baveno VII criteria with SSM ≤40 kPa could exclude clinical decompensation in patients with HBV-related cirrhosis and varices.

Spleen stiffness measurement using MR elastography for the noninvasive assessment of HVPG

Abstract Submission No. 101273
O-1107

The predictive value of hemodynamic indicators predict poor prognosis after TIPS.

Yuerong Li1, Yu Wang1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: The purpose of this study is investigating the predictive value of hemodynamic alterations in post-TIPS overt hepatic encephalopathy (OHE) within 3 months and liver reserve function deterioration within 6 months. Method: A total of 176 patients with de novo TIPS implantation recruited retrospectively from 2019 to 2022 in two centers. The patients were followed-up every 3 months for 1 year to assess and re-evaluate intrahepatic vasculature and intra-stent diameter, velocity and blood flow changes, as well as clinical symptoms and liver reserve function. The diagnosis of OHE was based on the West-Heaven criteria (WHC). Liver reserve function deterioration was defined as elevated Child-Pugh (CTP) score.

Results: 149 patients were included, and 30.87% had episodes of OHE within 3 months after TIPS, of which 95.65% were WHC II and 4.35% were WHC III. Patients with portal pressure gradient difference (ΔPPG) >18.5mmHg measured in the operation had a higher risk of post-TIPS OHE [w1] . At 6 months postoperatively, 42.36% had liver reserve function deterioration, of which 61.11% CTP score degrading A to B, 38.89% B to C. Patients with portal vein blood flow <1897.00 ml/min measured at 3 months after TIPS was an independent predictor of liver reserve function deterioration at 12 months postoperatively.

Conclusions: The more obvious decrease in PPG, the higher the possibility of OHE occurrence were observed. And the patients with lower portal vein blood flow were more likely to have liver reserve function deterioration.
**Abstract Submission No. 101290**

**Performance of HVPG ≥20mmHg.**

In univariate and multivariate analysis, only PLT affected MRE -SS results (0.214 p =0.040). AUROC for MRE-SS, SWE, and ARFI were included. MRE -SS correlated positively with HVPG (r = 0.213, p <0.001) and negatively with PLT (r = -0.337, p <0.001). ROC analysis was used to determine the utility of MRE, SWE, and ARFI for diagnosing PH. The influencing factors for MRE measurements were explored using multivariate analysis.

**Results:** A total of 93 patients with MRE, 56 with SWE and 35 with ARFI were included. MRE-SS correlated positively with HVPG (r = 0.214 p <0.040), while MRE-LS had no correlation with HVPG (r =0.133, p=0.210) (shown in Figure). AUROC for MRE-SS, SWE-SS, and ARFI-SS were 0.76, 0.82, and 0.74 for diagnoses of HVPG≥12 mmHg; and 0.58, 0.65, and 0.62 for HVPG≥20 mmHg, respectively (shown in Table). SWE displayed the best performance in the diagnoses of HVPG grade. Only PLT affected MRE-SS results in univariate and multivariate analysis.

**Conclusion:** MRE-SS correlated positively with HVPG, and demonstrated a better discrimination of HVPG≥12 mmHg with unsatisfactory performance of HVPG ≥20mmHg.

---

**Abstract Submission No. 101290**

**O-1108**

**Porto-sinusoidal vascular disease with risk factors had worse liver disease and poorer outcomes**

Lin Ma1, Guanhua Zhang1, Min Li2, Fuliang He1, Lijuan Feng1, Min Wang1, Yu Wang1, Jimin Liu1, Xinyan Zhao1, Jidong Jia1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 2Department of Clinical Epidemiology and EBM, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University Beijing China, 3Department of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University Hamilton Canada

**Background:** Porto-sinusoidal vascular disease (PSVD) is a rare entity and often associated with various risk factors (RF). We aimed to compare the manifestation and outcomes of PSVD in patients with and without known RF in a Chinese cohort.

**Methods:** This retrospective study enrolled liver-biopsy confirmed patients with PSVD, with demographics, comorbidities, laboratory tests and outcomes collected. Cox regression analysis was used to test associations between baseline characteristics and the prognosis.

**Results:** Totally 143 patients with PSVD (median age: 47 years, 64% female) were included, with 90 having RFs (RF-PSVD=62.9%) and 53 having no known RFs (noRF-PSVD=37.1%). RFs included immunological disorders (35.0%), prothrombotic conditions (32.9%), history of alcoholic liver disease (28.8%), congenital defects (28.8%), hematological disorders (21.0%) and exposure to oxaliplatin (0.7%). The RF-PSVD group exhibited significantly higher rates of gastroesophageal varices (88% vs. 55%, p=0.001), portosystemic collaterals (94% vs. 58%, p=0.001), and splenomegaly (96% vs. 80%, p=0.004). Additionally, the RF-PSVD group showed significantly lower level of serum albumin (36.7 vs. 40.0, p=0.001), higher INR (1.21 vs. 1.13, p=0.001), and a higher prevalence of portal vein thrombosis (PVT) (31% vs. 13%, p=0.017). During a median follow-up of 29.6 months, the RF-PSVD group had a significantly higher incidence of first/further hepatic decompensation (p=0.015) and higher mortality/liver transplantation (7.6% vs. 4.9%, p=0.570). Multivariate regression identified RF (HR=5.93, p=0.018), age (HR=1.04, p=0.028), and ascites (HR=4.34, p=0.009) as independent factors associated with hepatic decompensation.

**Conclusions:** PSVD with identifiable RFs had more severe portal hypertension, poorer liver function reserve, higher PVT prevalence, and worse clinical outcomes.

---

**Abstract Submission No. 101307**

**O-1109**

**Gallbladder Wall Thickness And Other Non-Invasive Tests For The Screening Of Esophageal Varices**

Jose Maria Gonzalez1, Madalinee Eternity D. Labio1

1Makati Medical Center Makati Philippines

A complication of liver cirrhosis is portal hypertension, the formation of esophageal varices (EV) with risk for hemorrhage. The gold-standard for diagnosis of EV is endoscopy but due to associated costs and risks, non-invasive tests for screening for EV have been studied. The authors aim to evaluate the diagnostic accuracy of gallbladder wall thickness (GBWT), spleen length and other laboratory parameters for screening for EV. This retrospective cross-sectional analysis included cirrhotic patients in a tertiary hospital in the Philippines wherein abdominal ultrasound, liver stiffness measurement, upper endoscopy and blood tests were analyzed.

Sixty three patients were analyzed, 25 (39.68%) had EV on endoscopy. Among the EV group, 56% had GBWT ≥ 4 mm, compared to 15.8% in the non-EV group (p<0.001). Patients with EV were predominantly male, had more severe liver disease (CPT B and C, higher MELD-Na and FIB-4), and evidence of portal hypertension (ascites, portal hypertensive gastropathy) (p<0.05). Multivariate regression analysis showed that GBWT ≥ 4 mm (aOR 6.47, 95% CI 1.24-33.67) and Spleen Length > 13 mm (aOR 12.74, 95% CI 1.59-101.82) had higher odds for predicting EV. GBWT (cut-off ≥ 3 mm) had a sensitivity and specificity of 80% and 68.42% with an AUC of 0.845 (CI 0.753-0.938) while spleen length (cut-off ≥ 120 mm) had a sensitivity and specificity of 66% and 81.58% with AUC of 0.732 (CI 0.596-0.869).

GBWT and Spleen length are independently associated with the presence of EV in cirrhotic patients and may be a good predictor for the presence of EV.

---

**Abstract Submission No. 101521**

**O-1110**

**Combined Baveno VII-SSM model performed good to identify CSFH in individuals with HBV-related cACLD**

Xiaofeng Zhang1, Xiao Cheng1, Qinjun He1

1Nanfang hospital, Southern medical university. Guangzhou China

**Background and Aims:** The Baveno VII consensus mentions several non-invasive tools (NITs) for diagnosing of clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD). We aimed to evaluate and compare the diagnostic performance of the Baveno VII-mentioned algorithms and other recently proposed NITs in individuals with HBV-related cACLD.
Methods: Consecutive individuals with HBV-related cACLD who underwent hepatic venous pressure gradient (HVPG) measurement, liver stiffness measurement (LSM) and spleen stiffness measurement (SSM) were prospectively enrolled from December 2021.

Results: From December 2021 to October 2023, 292 patients were screened and 121 were enrolled for analysis. For ruling in CSPH, the SSM>50 kPa [positive predictive value (PPV) 96.3%, specificity 98.5%] and Baveno VII-SSM dual cutoff (50 kPa) (PPV 91.2%, specificity 95.5%) algorithms both performed great. For ruling out CSPH, the Baveno VII and Baveno VII-SSM dual cutoff (21 kPa) (NPV 100%, sensitivity 100%) algorithms both had negative predictive value (NPV) and sensitivity at 100%. For ruling in CSPH, the sequential Baveno VII-SSM model showed specificity at 94.0% and PPV at 90.0%, for ruling out, the sensitivity was 96.4% and NPV was 94.3%. The Baveno VII-SSM dual cut-off (21-50 kPa) model had 45.5% of patients in the grey zone. With the sequential Baveno VII-SSM model, 47 (38.8%) patients were in the indeterminate zone.

Conclusions: We validated that the addition of SSM using 100 Hz shear wave frequency with Baveno VII proposed cutoff values significantly improves the clinical applicability of the algorithm based on LSM and platelet count for CSPH diagnosis.

Abstract Submission No. 101565
O-III1

Outcome of interventional radiology for hepatic encephalopathy with port-systemic shunt

Masazumi Onuki1, Jun Inoue1, Masashi Ninomiya1, Akitoshi Sano1, Mio Tsuruoka1, Kosuke Sato1, Satoko Sawahashi1, Keishi Ouchi1, Kotaro Doi1, Atsushi Masamura1

1Division of Gastroenterology, Tohoku University Graduate School of Medicine Sendai Japan

Background/aim: Hepatic encephalopathy (HE) is caused by ammonia and other neurotoxic substances, which increased in patients with cirrhosis, acute liver failure, and port-systemic shunt (PS). Drug treatment is the first choice, but there are some cases poorly controlled. In this study, we investigated the efficacy of interventional radiology (IVR) in cases of refractory HE with PS.

Methods: Among patients admitted to our department with HE between January 2012 and November 2022, we investigated the changes in symptoms and data before and after IVR in 10 patients who were poorly controlled with drug treatments.

Results: Patients were 6 males and 4 females with median age 67.5 years. Background liver was alcoholic/NASH/PBC/AIH in 5/3/1/1 cases, respectively. Median serum ammonia level was 174.5 μg/dL, and Child-Pugh score was 7.8/9/10 in 2/4/2/2 patients, respectively. All patients had grade II-III HE. Extrahepatic shunts were found at spleno-renal, gastro-renal, paraumbilical, inferior mesenteric, superior mesenteric, or heart diaphragm veins. As IVR, vascular plug placement and coil embolization were performed in 9 cases and retrograde transvenous embolization under balloon occlusion (B-RO) was done in 4 cases. HE improved to grade 0-4 in all patients within 1 week after treatments and persisted even after 3 months of follow-up. In addition, serum ammonia, albumin, and ALBI scores were also improved. No severe complications occurred but only two patients had fever.

Conclusion: IVR was effective for refractory HE patients with PS. Not only improvement of HE and serum ammonia level, but also improvement of hepatic functional reserve was observed.

Abstract Submission No. 101868
O-III2

Correlation of Splenic and Liver stiffness measurement with variceal bleeding in NCPH and Cirrhotics

HITESH SINGH1,ANKUR JINDAL2, SHIV KUMAR SARIN3

1INSTITUTE OF LIVER AND BILARY SCIENCES NEW DELHI India, 2INSTITUTE OF LIVER AND BILARY SCIENCES NEW DELHI INDIA, 3INSTITUTE OF LIVER AND BILARY SCIENCES NEW DELHI INDIA

Background and Aims: The cut-offs of non-invasive tests (NITs) including liver and spleen stiffness measurement (LSM and SSM) have been shown to correlate well with hepatic venous pressure gradient (HVPG) to predict presence of varices and bleeding in cirrhosis. However, there is paucity of data on LSM and SSM for assessing varices and bleeding in non-cirrhotic portal hypertension (NCPH) patients. We evaluated 300 patients, with NCPH and cirrhosis, bleeders, and non-bleeders to compare whether NITs can clearly segregate them.

Methods: Patients with NCPH (n=150, 129 EHPVO and 21 NCPE; 75 bleeders and cirrhosis (n=150; 75 bleeders) were recruited. Patients with non-bleed complications were excluded in both groups. We correlated LSM and SSM in relation with variceal bleeding in both groups of patients.

Results: In cirrhosis patients, the mean LSM in bleeders was higher (43.5 ± 19.7 than non-bleeders 33.7 ± 18.5 kPa, P=0.002). Similarly mean SSM (79.5 ± 11.8 kPa, 55.7 ±12.6 kPa (P<0.0001), and mean HVPG were (17.4 ± 2.4 12.8 ± 2.3 mmHg, P<0.0001) in bleeders than non-bleeders. In NCPH, the mean LSM (5.6 ± 1.08), in bleeders and (5.3 ± 1.02) non-bleeders which were significantly lower than that observed in cirrhosis patients. The mean SSM on the other hand in the NCPH bleeders was higher than in non-bleeders (90 ± 7.5 v/s 70 ± 7.8 kPa, p<0.0001), both being higher than that observed in cirrhosis patients. The SSM cut-off of 70 kPa had a sensitivity of 90 % and specificity of 76% for predicting variceal bleed in cirrhotics, AUROC (0.913). Similarly, SSM cut off 75 kPa, sensitivity of 92% and specificity of 80 % for predicting variceal bleed in NCPH, AUROC (0.975). SSM was significantly higher in cases of NCPH bleeders ( 90.11 ± 7.50kPa v/s cirrhotic bleeders (79.53 ± 11.8kPa with p value- <0.0001). SSM/LSM ratio was 16.01 in NCPH bleeders as compared to 1.89 in cirrhotic bleeders. On univariate analysis LSM, SSM, HVPG and on multivariate analysis splenic stiffness HR {1.216(1.158-1.275)} and hyperplenism, HR {0.379(0.157-0.9)} were significant in predicting bleed in cirrhotics. On uni-variate analysis and multivariate analysis for predicting bleed in NCPH, LSM, SSM, and bleeding in non-cirrhotic portal hypertension (NCPH) patients. The cut-offs of non-invasive tests (NITs) including liver and spleen stiffness measurement (LSM and SSM) have been shown to correlate well with hepatic venous pressure gradient (HVPG) to predict presence of varices and bleeding in cirrhosis. However, there is paucity of data on LSM and SSM for assessing varices and bleeding in non-cirrhotic portal hypertension (NCPH) patients. We evaluated 300 patients, with NCPH and cirrhosis, bleeders, and non-bleeders to compare whether NITs can clearly segregate them.

Conclusion: Higher SSM correlate with variceal bleeding in patients with liver cirrhosis and NCPH compared to non-bleeders.

Abstract Submission No. 101998
O-III3

BETA-RESPONSE: Non-invasive tests vs HVPG in assessing NSBB response in acute variceal bleed

Akhil Deshmukh1, Shiv Kumar Sarin1, Vishnu Girish1, Ravinder Singh1, Harsh Tevethia1

1Institute of liver and biliary sciences New Delhi India

Introduction: HVPG determines success of EVL and vasopressor combination therapy in controlling AVB and preventing rebleed. NITs are valuable as HVPG is invasive.

Methods: Cirrhotics > 18yrs who underwent EVL for AVB were prospectively enrolled. After enrolment maximal dosage of NSBB was achieved within 5 days. HVPG was done baseline and at 6weeks.NITs
- LSM, SSM by TE performed at baseline, 3, and 6 weeks, followed for 3 months.

**Results:** 210 patients [mean age 49.14±10.6 years, males 92.3%, predominant etiology ethanol 41% and MAFLD 33%]. HVPG at 6 weeks showed 67 (39.6%) patients responded to carvedilol with a reduction in mean HVPG from 18.72±2.43 to 15.89±2.97 mmHg. LSM and SSM showed mean reduction of 6.6 kPa and 10 kPa in responders, with cut-off reduction of >3 kPa (AUC 0.762, Sn 75%, Sp 32%, PPV 43.3, NPV 63) and >5.5 kPa (AUC 0.738, Sn 84%, Sp 26%, PPV 45.2, NPV 73%) for predictability of response. Of 98 HVPG non-responders, 22(10%) rebled within 3 months (8 after enrolment but <6wks), (6.2%) out of 67 HVPG responders rebled within 6 weeks. These HVPG responders had reduction in LSM and SSM, however there was no improvement in platelet count which may predict rebleed in HVPG responder. None of the HVPG responders with reduction of HVPG to <12 mm Hg free of development of bleeding 67 HVPG responders rebled within 3 months (8 after enrolment but <6wks), (6.2%) out of 67 HVPG responders rebled within 6 weeks. These HVPG responders had reduction in LSM and SSM, however there was no improvement in platelet count which may predict rebleed in HVPG responder. None of the HVPG responders with reduction of HVPG to <12 mm Hg free of development of bleeding.

**Conclusion:** Reduction in LSM and SSM predicts NSBB response. HVPG response to <12 mm Hg is free of development of bleeding or decompensation. NIT non-responder at 3 weeks are HVPG non-responders at 6 weeks.

Abstract Submission No. 102084

**O-1114**

Targeted and response-guided albumin therapy improves outcomes of ascites in cirrhosis patients

**Rakhi Maiwall**, **Sherin Thomas**, **Jaswinder Singh Maras**, **Anupam Kumar**, **Jaya Benjamin**, **Sukriti Baweja**, **Harshvardhan Tevethia**, **Shivkumar Sarin**

1 Department of Hepatology, Institute of Liver and Biliary Sciences New Delhi India

**Background:** Targeting serum albumin (SA) above 4 gm/dl with long-term albumin administration improves outcomes in patients with uncomplicated ascites. However, the cost and scarcity of albumin is a limitation. We aimed to compare a targeted (above 3 gm/dl) and response-guided albumin strategy (Alb-Tr) in improving 6-month mortality compared to standard medical treatment (SMT).

**Methods:** Open-label, randomized controlled trial. Patients in (Alb-Tr) arm received 20% albumin targeting SA>3 gm/dl at 60 grams for 2 weeks followed by 40 grams/week target SA>3 gm/dl or ascites control, or for a maximum of 12 months.

**Results:** The baseline characteristics were comparable in both groups, [Alb-Tr, n=60 versus SMT, n=60]. A trend towards reduced mortality was noted in (Alb-Tr): 2(3.3%) vs. 8(15.4%); Log rank p=0.06, HR 4.21, (0.89-19.8). The control of ascites was superior in (Alb-Tr) (56% vs. 30%; p<0.001). A lower incidence of acute kidney disease (AKD) 15% vs. 53%; p=0.001, chronic kidney disease (CKD) (13% vs. 28%; p=0.043), infections (43% vs. 75%; p<0.001), hepatic encephalopathy (3% vs. 15%; p=0.027) was seen in Alb-Tr. A higher proportion of patients achieved the target SA>3 gm/dl in Alb-Tr (97.9% vs. 32%; p<0.001) Patients with target SA>3gm/dl had lower AKD (50% vs 22%; p=0.003), sepsis (75% vs. 54%; p=0.04) and better ascites control (33% vs. 55%; p=0.034). A significant decrease in the renal biomarkers (Cystatin C, IL-18, KIM-1, Land decrease in C-reactive protein) were observed in Alb-Tr group while levels increased in SMT.

**Conclusion:** A lower target of 3gm/dl and response-guided albumin strategy reduces mortality, adverse renal outcomes and achieves better ascites control in patients with RA. (NCT04679571)

Abstract Submission No. 200147

**O-1115**

Carvedilol versus Band Ligation for Prophylaxis of Variceal Bleeding in Arterial Hypertension Cases

**Nabila ElGazzar**, **Asem Elfert**, **Lobna AbuAli**, **Mohammed Rabea**, **Samah Soliman**

1 Faculty of medicine Tanta University Tanta Egypt

**Background and study aims:** Up to our knowledge, no study was performed on primary prophylaxis of variceal bleeding in cirrhosis with systemic arterial hypertension. So, we will evaluate the safety and efficacy of carvedilol versus endoscopic band ligation (EBL) for the primary prophylaxis of variceal bleeding in hypertensive cirrhotic patients.

**Patients and Methods:** In this randomized controlled trial, 306 cirrhotic hypertensive patients with large and/or risky esophageal varices were randomized into EBL and carvedilol groups. Carvedilol was given orally at an initial dose of 6.25 mg twice daily, and titrated up to achieve a normotensive response. When maximum of 25 mg twice daily was given without satisfactory control of blood pressure, diuretic and enalapril was added.

**Results:** Variceal bleeding within a follow up period of one year was found to be 1.3% in EBL group versus 2.6% in carvedilol group without statistically significant difference (P=0.680). In carvedilol group, systolic blood pressure, diastolic blood pressure and mean arterial pressure were significantly decreased at 3 months of follow up till the end of the study, while heart rate was significantly decreased at 9 months of follow up till the end of the study compared with the baseline (P<0.001). Adverse events were significantly higher in the EBL group (25.49%) than carvedilol group (10.46%) (P<0.05).

**Conclusion:** Carvedilol was safe and effective in the primary prophylaxis of esophageal variceal bleeding in cirrhotic patients with systemic arterial hypertension.

Abstract Submission No. 200147

**O-1116**

ENDOVASCULAR TREATMENT FOR ACUTE- SUBACUTE EXTENSIVE SPLANCHNIC VENOUS THROMBOSIS - A CASE SERIES

**SAMIRRDDHI POYEKAR**, **RAVI SHAH**, **NILESH DOCTOR**, **SHAJI MARAR**, **AABHA NAGRAL**

1 JAGJIVANRAM HOSPITAL MUMBAI India, 2 JASLOK HOSPITAL AND RESEARCH CENTRE MUMBAI INDIA

**Introduction:** Extensive Splanchnic venous thrombosis (ESVT) includes thrombosis of portomesentric venous system and hepatic veins (HV) which may co-exist. There are scarce reports in world literature on management of ESVT with Endovascular treatment (EVT). We report our experience of management of ESVT with EVTs for revascularisation which is first such case series from India.

**Methods:** Seven patients with acute-subacute ESVT were evaluated for clinical presentation, EVT and outcome. Heparin was started at diagnosis and for persistent symptoms mechanical thrombo-aspiration (MT), angioplasty (AG), catheter directed thrombolysis (CDT) for SMV thrombosis were done. TIPSS was created if HVPG was >10mmHg and SMV stenting done for long segment SMV thrombosis.

**Results:** All patients with ESVT (5 males, 2 females) had abdominal pain and 2 had ascites. Median symptom duration was 12 days (4-30 days). Thrombophila was seen in 5. Other two had cirrhosis and Mycosis fungoides. Four had PVT and SMVT while 3 patients had thrombosis of all 3 HV with PVT and SMVT. EVT was performed after a median of 14 days (MT in 5, AG in 4, CDT in 6, TIPSS in 7 and SMV...
stenting in 2). Technical success was 100%, clinical success 85.7% with 2 patients requiring surgery (for perforation and bowel ischemia). Primary patency rate at 1, 6, 12 months was 85.7%, 83.3%, 66.7% respectively. 3 patients required re-intervention after a median of 8 months (1-17 months).

**Conclusion:** Endovascular treatment for acute -subacute Extensive Splanchnic venous thrombosis is an effective treatment modality in selected patients with fair long-term outcomes.

Abstract Submission No. 100150

**O-1117**

**SSBs consumption increases the risk of metabolic syndrome and its components in adults.**

**Quang Duc Tran¹, Thi Quynh Chi Vu², Thi Hoa Huyen Nguyen¹, Ngoc Quang Phan³, Cu Linh Le¹, Thi Thuy Bui¹**

¹College of Health Sciences, VinUniversity Hanoi Vietnam, ²School of Medicine and Pharmacy, The University of Dannang Danang Vietnam, ³Thai Binh University of Medicine and Pharmacy ThaiBinh Vietnam, ⁴National Institute of Nutrition Hanoi Vietnam

**Aims:** This review aims to synthesize the evidence linking habitual SSBs intake with MetS in adults, emphasizing the need for policy and regulatory actions.

**Methods:** Four databases were comprehensively searched for relevant meta-analyses of prospective studies up to July 2023. The outcome of interest was MetS in adults, encompassing its component conditions. The present review was registered with PROSPERO (CRD42023402549).

**Results:** Of the 16 eligible meta-analyses identified, 30 summary estimates were obtained for the impact of SSBs consumption on obesity, type 2 diabetes, hypertension, and MetS. Seven were rated as ‘High’ methodological quality, with the rest classified as ‘High’, ‘Moderate’ and ‘Low’ quality, consisting of three and six references, respectively. A comparison of the highest and lowest levels of SSBs consumption revealed an increased risk of 18% (95% CI: 13%-24%), 12% (95% CI: 11%-14%), 29% (95% CI: 25%-32%), and 29% (95% CI: 7%-52%) for obesity, hypertension, type 2 diabetes, and MetS, respectively. Consistently, the findings from dose-response analyses are in agreement with and corroborate the existing evidence that SSBs are a significant risk factor for the development of MetS and its related conditions. Noticeably, the evidence quality was predominantly deemed highly suggestive and convincing. Moreover, consensus on specific criteria to identify studies related to SSBs in literature searching was lacking, and most primary studies were conducted in developed countries and Europe.

**Conclusions:** Our findings suggest that more rigorous and targeted policy interventions are warranted to curtail SSBs consumption in order to alleviate the global burden of MetS.

Abstract Submission No. 100381

**O-1119**

**Global burdens of cirrhosis in children and adolescents from 1990 to 2019**

**Chi Zhang¹, Yiqi Liu¹, Hong Zhao¹,², Guiqiang Wang¹,²**

¹Peking University First Hospital Beijing China, ²Peking University International Hospital Beijing China

**Background:** Cirrhosis data on the burden and trends were sparse in children and adolescents. We aimed to assess the trends in 204 countries and territories over the past 30 years in children and adolescents aged under 19 years.

**Methods:** Data on cirrhosis was collected by the Global Burden of Disease (GBD) 2019 database from 1990 to 2019. We reported on numbers, rates, and average annual percentage changes (AAPCs) of incidence and disability-adjusted life-years (DALYs) of cirrhosis at global, regional, and national level.

**Results:** Globally, incident numbers of cirrhosis in children and adolescents increased from 204767 in 1990 to 214364 in 2019, an increase of 17.9%, with an AAPC 0.130 (0.10 to 0.16). Substantial change in incidence of cirrhosis in 1996, 2006, 2009, and 2017. Prevalence(AAPC=2.27[-2.39 to -2.15]), mortality (AAPC=1.68[-1.86 to -1.5]), and DALYs rate(AAPC=-1.72[-1.88 to -1.56]) of cirrhosis have decreased significantly. Cirrhosis incident rates varied between sex and age groups. Rates of cirrhosis caused by alcohol use(AAPC=[0.8 to 1.1]; incidence cases increased most obvious 48%), hepatitis C(AAPC=0.4[0.4 to 0.5]), NAFLD (AAPC=0.5 [0.3 to 0.6]) have been increasing, while only hepatitis B(-0.3[-0.4 to -0.2]) decreasing. Incidence cases of cirrhosis were increased in low(101.6%) and low-
middle sociodemographic index (SDI 21.1%) areas, while decreasing in middle and above SDI areas. At the regional level, the largest increases count was observed in Sub-Saharan Africa.

**Conclusions:** Global incidence rate of cirrhosis has been increasing, while the DALYs rate has been decreasing in children and adolescents. Morbidity of cirrhosis caused by hepatitis B declined, while hepatitis C, NAFLD, and alcohol use increased.

Abstract Submission No. 100714  
*O-1120*

**Health-Related Quality of Life in Patients with HBV Infection: A Systematic Review and Meta-Analysis**

Michael Xu1,2, Gabriel Lambert2, Amelia Cook2, Heli Harvala2, Elisa Sicuri2, Maud Lemoine2, Shevanthi Nayagam2, Gibril Ndog2, Yazan Haddadin2, Yusuke Shimakawa5, Tim Hallett2, Mark Thursz2

1University of Oxford Oxford United Kingdom, 2Imperial College London London United Kingdom, 3 NHS Blood and Transplant London United Kingdom, 4London School of Hygiene & Tropical Medicine Bajul The Gambia, 5Institut Pasteur Paris France, 6London School of Economics and Political Science London United Kingdom, 7 Universitat de Barcelona Barcelona Spain

**Background:** Despite nearly 300 million persons estimated to be living with hepatitis B virus (HBV) infection globally, health-related quality of life (HRQOL) in HBV-related disease has not been well characterised. We aimed to summarise existing data on HBV-related HRQOL and quantify health utility by stage of disease.

**Methods:** Embase, Global Health, PubMed, and Web of Science were searched for articles investigating HBV HRQOL. Meta-analyses for utility scores were pooled by stage of disease and utility instrument; meta-regression was further adjusted for the effect of current health status, age, sex, and education. Quality of included studies was assessed using the Newcastle-Ottawa Scale (NOS). A funnel plot test was conducted to investigate publication bias. A random-effects model was used to pool data with a CI of 95%.

**Results:** From 5,851 articles, 17 studies (1,535 participants) were included. The pooled mean utility scores were 0.839 (95% CI: [0.829-0.848]) for non-cirrhotic, 0.819 (95% CI: [0.806-0.831]) for compensated cirrhosis, and 0.746 (95% CI: [0.723-0.770]) for hepatocellular carcinoma. Meta-regression showed the following predicted mean utility scores: 0.839 for non-cirrhotic, 0.819 for compensated cirrhosis, and 0.746 for hepatocellular carcinoma.

**Conclusion:** The health-related quality of life of patients with HBV infection is relatively high, with increasing severe stages of disease. Further studies are needed to explore the influence of other factors on HRQOL and to develop interventions to improve HRQOL in HBV-related disease.

Abstract Submission No. 100819  
*O-1122*

**Level of Knowledge and Awareness on Non-Alcoholic Fatty Liver Disease among Filipinos**

Aaron Lemuel Ong1, Janus Po Ong2, Hilton A. Lam3

1 Philippine General Hospital Manila Philippines, 2 University of the Philippines Manila Philippines, 3 National Institutes of Health Manila Philippines

**Background:** The global burden of non-alcoholic fatty liver disease (NAFLD) is rising parallel with metabolic syndrome and other non-communicable diseases. This post hoc analysis of data from the non-communicable disease study in the National Capital Region (NCR) aims to examine the different factors that affect knowledge and awareness of NAFLD.

**Methods:** Data from a population-based cohort study were collected. Awareness of NAFLD and willingness to undergo testing for NAFLD was correlated with demographic and socio-economic factors. A multiple regression analysis was then utilized to check for correlation.

**Results:** 1,561 subjects were included in the analysis. In the awareness section, majority of participants (67.8%) were unaware of or had never heard of NAFLD although 40.5% of respondents believed that they were at risk for NAFLD. 61% of participants likewise considered getting tested for NAFLD. Most respondents believed that the top condition that affects fatty liver is high cholesterol/dyslipidemia (65.77%).

**Conclusions:** In this prospective cohort, sugar- and artificially sweetened beverages and their proteomic signatures are associated with a spectrum of liver diseases.

Abstract Submission No. 100972  
*O-1121*

**Sugar and Artificially Sweetened Beverages and Liver Health: A Prospective Cohort Study**

Longgang Zhao1, Xinyuan Zhang1, Jiali Zheng1, Hongmei Zeng1, Xuchong Zhang1

1 Brigham and Women’s Hospital and Harvard Medical School Boston United States, 2 School of Public Health, Shanghai Jiao Tong University School of Medicine Shanghai China, 3 Department of Nutrition, Harvard T.H. Chan School of Public Health Boston United States

**Background:** Evidence links sweetened beverages to risks of obesity, diabetes, and specific cancers but not liver outcomes. We aimed to evaluate the associations of sweetened beverages and associated plasma proteomic signatures with risk of a spectrum of liver outcomes.

**Methods:** We analyzed data from 168,975 individuals (ages 40-69) in the UK Biobank with available dietary data on sugar and artificially sweetened beverage intake. Liver outcomes were ascertained using data from the in-hospital, cancer or death registry including NAFLD, cirrhosis (compensated and decompensated), liver cancer, and severe liver disease (SLD: hepatocellular carcinoma and others). We used elastic net regression to calculate the proteomic signature (Olink platform profiling) related to sweetened beverages and Cox proportional hazards regression models to estimate hazard ratios (HR) and 95% confidence intervals (CIs) for sweetened beverages or proteomic signatures and liver outcomes.

**Results:** After a median follow-up of 8.9 years, we documented 1080 NAFLD, 931 liver cirrhosis, 464 liver cancer, and 536 severe liver diseases. Each daily serving of sugar-sweetened beverages linked with 11% higher risk of NAFLD (HR [95% CI]: 1.11[1.03-1.19]), 19% (1.19[1.10-1.29]) of cirrhosis, and 16% (1.16[1.05-1.28]) of SLD but insignificant with liver cancer (1.11[0.92-1.33]). Higher artificially sweetened beverage intake also was associated with increased risk of NAFLD (1.13[1.05-1.20]), cirrhosis (1.20[1.11-1.29]), and SLD (1.19[1.08-1.31]). The proteomic signatures of sugar-sweetened beverages (116 proteins) and artificially sweetened beverages (105 proteins) showed stronger positive associations with risk of NAFLD, cirrhosis, and SLD (P<0.001) with HRs ranging from 1.73 to 2.33 for one-unit standard deviation increase.

**Conclusions:** In this prospective cohort, sugar- and artificially sweetened beverages and their proteomic signatures are associated with a spectrum of liver diseases.
predictive of NAFLD awareness. Factors that affected willingness to be screened for NAFLD included college/post graduate degree; obese or overweight and those with dyslipidemia (p<0.05).

Conclusions: Our study demonstrated that there remains a significant knowledge gap in terms of awareness in NAFLD. This highlights the need for public education campaigns especially in at-risk groups such as among diabetics and obese with the goal of implementing early detection, diagnosis and treatment.

Abstract Submission No. 100991

O-1123

Hepatocellular Carcinoma Surveillance is Cost-Effective in Steatoic Liver Disease

Paknat Decharatanachart1, Kittiyod Pooworavan2, Pitth Tangkijvanich3, 4, Roongruede Chaiteerakij5, 6

1Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University Bangkok Thailand; 2Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University Bangkok Thailand; 3Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand; 4Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand; 5Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand; 6Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Background: Without hepatocellular carcinoma (HCC) surveillance, HCC from non-alcoholic fatty liver disease (NAFLD) tends to be diagnosed at a later stage and has worse outcome than HCC from other etiologies. We aimed to investigate the cost-effectiveness of using non-invasive tests (NITs) to identify high-risk non-cirrhotic NAFLD patients and initiate HCC surveillance.

Methods: Cost-utility analysis was performed using Markov model in Thailand and the United States (US) settings. NIT protocols including 1) Fibrosis-4 Index (FIB-4) of ≥1.3, 2) transient elastography (TE) of ≥8 kPa, and 3) FIB-4 with TE were used to initiate HCC surveillance by biannual ultrasonography with alpha-fetoprotein (AFP) (Figure). Incremental cost-effectiveness ratio (ICER) was calculated using total costs and quality-adjusted life-years (QALYs) gained for each protocol. NIT protocols were considered cost-effective based on a willingness-to-pay of $4,665/QALY (160,000 THB) and $50,000/QALY in Thailand and the US, respectively.

Results: In Thailand setting, FIB-4 with TE was cost-effective with ICER of $4,041/QALY. FIB-4 alone and TE alone were not cost-effective with ICERs of $6,583 and $7,391/QALY, respectively (Table). Similarly in the US, combining FIB-4 with TE was the only cost-effective strategy with ICER of $28,025/QALY. By one-way sensitivity analysis, adjusting the HCC incidence in non-cirrhotic NAFLD patients from 0.1-0.6% did not affect the cost-effectiveness results. By probabilistic sensitivity analysis, FIB-4 with TE had the highest probability of being cost-effective at the WTP threshold in each setting.

Conclusions: Using FIB-4 together with TE to initiate HCC surveillance was cost-effective and may help improve the outcome of NAFLD-related HCC.

Abstract Submission No. 101043

O-1124

Developing a national database and online reporting dashboard for hepatitis B and C in Indonesia

Arief Budiman1, Devi Suhailin2, Kristina Sitorus3, Atiek Anartati4, Robert Kosasih4, Kushagar Dhall3, Yuhui Chan1, Caroline E. Boecke1, Oriel Fernandes3, Ratna Budi Hapsari2

1Clinton Health Access Initiative (CHAI) South Jakarta Indonesia, 2Ministry of Health Jakarta Pusat Indonesia, 3Clinton Health Access Initiative Boston USA

Background: To support monitoring and evaluation of the national hepatitis program in Indonesia and enable evidence-based decision-making, Indonesia developed SIHEPI, an electronic patient management information system that includes multi-level dashboards.

Methods: SIHEPI enables healthcare workers to enter data and manage hepatitis patients, and national program stakeholders to track case volumes and service delivery gaps. The methodology to develop this system included: 1) Mapping user requirements; 2) System design & development, including data validation rules; 3) System testing; 4) Deployment across >1,000 health facilities; 5) Maintenance. Data collected includes HCV treatment, sustained virologic response testing at 12 weeks (SVR12), disaggregated by sex, age, cirrhosis, year, facility, and geography, HBsAg screening in pregnant women, and hepatitis commodity management.

Result: As of September 2023, SIHEPI captured: 36,427 patients testing positive for HCV, 10,108 initiating HCV treatment, and 95.8% of those with SVR12 results cured; >1.8 million pregnant women tested for HBsAg with 1.53% positive. A dashboard visualizes the data (see figure). Despite effective rollout of SIHEPI, challenges have included underreporting at health facilities due to workload, poor internet connection in remote areas, and segregation and limited reporting on patients with private insurance.

Conclusion: This data digitization initiative demonstrated that viral hepatitis data can be collected in Indonesia despite geographical constraints (38 provinces, >17,000 islands). The system generates and visualizes high-quality national program data to drive evidence-based decisions for program improvement. Upcoming plans include developing an HBV dashboard, integration with health facility information system, and expansion to capture HBV treatment volumes for pregnant women.

Abstract Submission No. 101148

O-1125


Ghina Susilo1

1The University of Edinburgh Edinburgh United Kingdom

The Government of Indonesia enacted an amendment (National Act Number 24 Year 2011), in response to the establishment of the health insurance program or known as Jaminan Kesehatan Nasional (JKN). This mandate stated that the program of JKN is managed by the Social Security Public Agency for Health, named Badan Penyelenggara Jaminan Kesehatan (BPJS-K). Despite an ambitious goal to enroll all Indonesians in JKN by 2019 to meet the standards of Universal Health Coverage (UHC) set by WHO, geographical barriers delayed progress. To address this, the government enacted BPJS-K Act Number 3 of 2019, compelling citizens to comply with the JKN program. Consequently, the system increased essential service consumption, reducing the proportion of Out-of-Pocket (OOP) payments to total health expenditure (THE) from 48.5% (2014) to 32.1% (2019). By June 2022, approximately 238 million Indonesians (87.16% of the population) were JKN members. This achievement made the JKN the biggest single-payer health insurance system in the world. However, the
geographical challenges in Indonesia is a big deal for the government. Thus, the UHC might be promising agenda from the government to provide better public health. But, it needs more effort to enact it. Therefore, a more progressive and right on target program are obligatory to make UHC as a successful program to provide better public health in Indonesia.

Abstract Submission No. 101213 O-1126

Seroprevalence of Hepatitis E Infection in Healthy Blood Donors in an Endemic Country

Lubna Kamani1, Adeel Rahat1, Sana Anwar1
1Liaquat National Hospital Karachi Pakistan

Background: HEV can be transmitted via contaminated blood products. This mode of transmission is of importance in immunocompromised and pregnant patients. Screening of blood products for HEV is not routinely done in Pakistan. There is dearth of literature regarding viremia and seroprevalence of HEV among asymptomatic, healthy blood donors.

Materials & Methods: A prospective, cross-sectional study was conducted at Liaquat National Hospital’s blood bank facility. Besides routine testing, blood samples were collected for Anti HEV antibodies (IgG and IgM) and ALT. Those who tested positive for anti-HEV IgM were tested for HEV-RNA by real-time reverse transcription polymerase chain reaction assay.

Results: Among 515 individuals with age range of 18-57 years were enrolled, mean ALT values recorded were 42.8447±32. Anti HEV IgG was positive in 365 individuals (71%). Anti HEV IgM was found positive in 31 (6%) individuals, but HEV RNA PCR was negative in all patients. Correlation analysis showed positive relationship with high level of BMI and ALT values.

Conclusion: High seroprevalence of Anti HEV IgM among healthy blood donors emphasizes the need for robust measures of routine screening for HEV of all blood products in endemic countries to prevent transfusion dependent transmission with special consideration when the recipients are either immunocompromised or pregnant.

Clinical Significance: Epidemiological statistics of HEV emphasize on the impact of counter measures for prevention related to enhancement of public health.

Abstract Submission No. 101738 O-1127

Estimation of Global, Regional, and National Burden of Adult NAFLD and NASH Using A Novel Strategy

Xuan Dong1, 2, 3, Jing-Mao Li4, Xiao-Ling Lu1, 3, 4, Xiao-Yun Lin1, 3, 4, Mei-Zhu Hong5, Shangeng Weng2, Jin-Shui Pan6
1Department of Hepatology, the First Affiliated Hospital of Fujian Medical University Fuzhou China, 2Hepatology Research Institute, Fujian Medical University Fuzhou China, 3Department of Hepatology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University Fuzhou China, 4Department of Statistics and Data Science, School of Economics, Xiamen University Xiamen China, 5Fujian Clinical Research Center for Hepatology and Intestinal Diseases Fuzhou China, 6Department of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China, 7Hepatopancreatobiliary Surgery Department, the First Affiliated Hospital of Fujian Medical University Fuzhou China

At present, there is a dearth of comprehensive data at the global, national, and regional levels regarding the adult non-alcoholic fatty liver disease (NAFLD) prevalence. The objective of this study is to ascertain the prevalence of NAFLD and its related condition, non-alcoholic steatohepatitis (NASH), among adolescents worldwide and in specific regions, utilizing BMI as a determining factor. Using the data extracted from the NHANES database, sigmoidal fitting curves were generated to establish the relationship between BMI and the risk of NAFLD/NASH. Utilizing BMI data from the NCD-RisC database at both global and regional levels, the prevalence of NAFLD/NASH among adults was estimated from 1975 to 2016, encompassing global, regional perspectives. Additionally, projections were made to forecast the prevalence of adult NAFLD/NASH from 2017 to 2030.

In 2016, the global prevalence of NAFLD was 41.12% for males and 37.32% for females, while the prevalence of NASH was 15.79% for males and 16.48% for females. The prevalence of NAFLD/NASH increased with higher BMI in both genders. Over the period from 1975 to 2016, there has been a gradual increase in the global prevalence of NAFLD/NASH in adults, and this trend is expected to continue between 2017 and 2030. In males, the prevalence of adult NAFLD/NASH was found to be highest in High-income Western countries, while it was highest in Central Asia, Middle East, and North African countries after 1995. The prevalence of adult NAFLD/NASH has been observed to increase annually. The BMI has been identified as a reliable predictor of NAFLD/NASH prevalence.

Abstract Submission No. 101789 O-1128

Updated Definition of Healthy ALT Levels in a Metabolically and Histologically Normal Population

Jonggi Choi1, Chaeyeon Lim1, Mi Ryu1, Ju Hyun Shim1
1Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background & Aims: This study reevaluates the upper limit of normal (ULN) for alanine aminotransferase (ALT), traditionally set at 40 U/L, using histological and metabolic parameters in Asian living liver donors.

Methods: We conducted a retrospective analysis of 5,455 potential living liver donors from 2005 to 2019. Patients were screened for hepatitis B, C, HIV, and alcohol use. Histologically and metabolically healthy participants was assessed using the modified Prati criteria (body mass index <23 kg/m², triglyceride ≤200 mg/dL, fasting glucose ≤105 mg/dL, total cholesterol ≤220 mg/dL). The new healthy ULN of ALT was determined at the 95th percentile among participants without hepatic steatosis or metabolic dysfunction.

Results: The median age of the cohort was 30 years, with a predominance of males (66.2%). While 3,162 (58.0%) did not have hepatic steatosis, 1,553 (49.1%) met the modified Prati criteria, being metabolically healthy. The new healthy ULN of ALT was determined at the 95th percentile among participants without hepatic steatosis or metabolic dysfunction.

Conclusion: Our study suggests that the traditional ALT ULN is higher than healthy levels for a metabolically and histologically verified Asian population. The proposed ULN values are 34 U/L for males and 22 U/L for females. The introduction of a ‘borderline’ category
Prevalence and risk factors for non-hepatic cancers in cirrhosis: a c

Di Sun1, 2, YingChao Li1, 2, Yue Sun1, 2
1 General Hospital of Northern Theater Command Shenyang China, 2 Dalian Medical University Dalian China

Background and Aims: Non-hepatic cancers (NHC) are under-recognized in patients with liver cirrhosis, but cause poor outcomes. The present study aims to explore the prevalence of NHC in such patients and identify its associated risk factors.

Methods: Patients with a diagnosis of liver cirrhosis who were consecutively admitted to our hospital between January 1, 2010 and June 30, 2014 were retrospectively screened. They were divided into NHC, primary liver cancer (PLC), and non-cancer groups. After adjusting for age and sex, logistic regression analyses were performed to explore the risk factors of NHC in cirrhotic patients. Adjusted odds ratios (aORs) with their 95% confidence intervals (CIs) were calculated.

Results: Overall, 2509 patients were included. Prevalence of NHC and PLC was 6.22% (156/2509) and 22.20% (557/2509), respectively. NHC mainly included gastric cancer (n=22), pancreatic cancer (n=17), lung cancer (n=14), lymphoma (n=12), and breast cancer (n=11). After adjusting for age and sex, the NHC group had a significantly higher proportion of history of smoking (aOR=1.994; 95% CI=1.231-3.231, p=0.005), but lower proportions of history of encephalopathy (aOR=0.344; 95% CI=0.147-0.804, p=0.014) and history of heart disease (aOR=0.300; 95% CI=0.173-0.519, p=0.001) as compared to the non-cancer group. HBV (aOR=0.863; 95% CI=0.581-1.281, p=0.465), HCV (aOR=0.908; 95% CI=0.503-1.642, p=0.750), and alcohol abuse alone (aOR=1.254; 95% CI=0.779-2.017, p=0.351) as the etiology of liver cirrhosis were not significantly associated with the risk of NHC.

Conclusions: Smoking may be associated with a higher probability of NHC in patients with cirrhosis, but the probability of NHC may be compromised by encephalopathy or heart disease.

Determining the public health implications of hepatitis B curative treatments.

Jack Wallace1, Jess Howell1, Margaret Hellard1, Alisa Pedrana1, Mark Stove1, Carla Treloar2, Jenn Power3, Jacqui Richmond1
1 Burnet Institute Melbourne Australia, 2 Centre for Social Research in Health, UNSW Sydney Australia, 3 Australian Research Centre in Sex, Health and Society, La Trobe University Melbourne Australia

Background: Hepatitis elimination as a global public health threat will only occur with sustainable and tolerable curative treatments. While significant activity is being conducted to identify the constituent elements of curative treatments, their implementation will require significant reorientation of current clinical and public health approaches to hepatitis B.

Methods: An interdisciplinary advisory committee oversaw exploratory semi-structured qualitative interviews with 31 stakeholders experienced in global, regional or local public health policy, scientific and/or clinical investigation, or translational research. Interview analysis identified social, political, economic and ethical issues related to developing and implementing hepatitis B curative treatments.

Results: Key themes included that descriptions and priorities for cure science reflected individual and professional frameworks, and recognised the need to prepare and reorientate clinical and public health infrastructure to effectively implement any cure. Other implications included a need for global or regional resourcing given the economic realities of many countries with greater burden of the infection, with social and cultural implications identified including the social impact and marginalisation resulting from hepatitis B infection.

Conclusions: While work progresses on curative hepatitis B treatments, it will be for naught without decentralising and simplifying current clinical and public health approaches to hepatitis B. The social impact of hepatitis B is often as significant as its clinical implications, with curative treatments having more impact than removing a virus from the body. Curative treatments will not only benefit individuals, but fundamentally affect families where hepatitis B occurs across generations and often across multiple countries.
Smoking has been found to be a strong contributor for many diseases. Despite the fact that cigarette smoking is directly associated with respiratory diseases, its relationship with liver disease is rarely analyzed from the perspective of demographic variety. This study aims to analyze the risk of cigarette smoking to liver diseases based on demographic level. Information of 34,250 respondents from Indonesian Family Life Survey (IFLS) is analyzed to answer the research question.

IFLS is a national representative data if Indonesia. Analyzes are conducted using logit regression model. Additionally, the comparison of effects is done using the calculation of marginal effects. In general, there is a positive trend between smoking status and liver disease diagnoses. After conducting regression analyses, results show that statistically there is a positive significant relationship between these two variables. Furthermore, findings also reveal that the risk of cigarette smoking is twice bigger for the elderly (60 years old and above) than non-elderlies. When the cut off age is changed, it shows that smokers aged under 40 are fewer than a half less likely to be diagnosed liver disease that those who were above 40 years old. It implies that the risk of liver disease from cigarette smoking is accelerately increase with age. In conclusion, this study found that there is not only a positive but also accelerative effect of cigarette smoking and liver disease.

Abstract Submission No. 100731
O-1133

Universal Screening for Hepatitis B Infection Before Initiating Chemotherapy is Cost-Effective

Pakanat Decharatanachart1, Soe Thiba Maung2, Natee Depan3, Roongruedee Chatierakij1, 2

1Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand, 3Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 4Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Background: Cancer patients undergoing chemotherapy have an increased risk of hepatitis B virus (HBV) reactivation. However, HBV screening rate prior to initiating chemotherapy treatment remains low. The study aims to assess the cost-effectiveness of HBV screening and prophylaxis before receiving chemotherapy.

Methods: Cost-utility analysis was performed using Markov model. Yearly universal HBV screening using hepatitis B surface antigen (HBsAg), anti-hepatitis B surface antibody (anti-HBs) and anti-hepatitis B core antibody (anti-HBc) was compared with no screening strategy. Patients with positive HBsAg received tenofovir as prophylactic medication. Incremental cost-effectiveness ratio (ICER) was calculated using total costs and quality-adjusted life-years (QALYs) gained for each strategy. Cost-effectiveness was determined using a willingness-to-pay (WTP) threshold of 4,665 USD/QALY (160,000 THB/QALY).

Results: Universal HBV screening was cost-effective with ICER of 1,719 USD/THB. By subgroup analysis, HBV screening was cost-effective in both solid organ tumors and hematologic malignancies with ICERS of 3,396 and 2,116 USD/QALY, respectively (Table). By one-way sensitivity analysis, universal HBV screening remained cost-effective after adjusting the incidence of chronic HBV infection from 1-10% or varying the reactivation rate in patients without prophylaxis from 10-20%. However, when the reactivation rate in patients with antiviral prophylaxis was higher than 8%, screening and initiating prophylactic medication was not cost-effective. By probabilistic sensitivity analysis, universal HBV screening had a probability of 99.9% for being cost-effective.

Conclusions: Due to better access and lower cost of antiviral medication, universal HBV screening to initiate HBV prophylaxis prior to receiving chemotherapy is cost-effective.

Abstract Submission No. 100836
O-1134

Effectiveness of community and primary care models in promoting HBV testing for global elimination

Thanh Kim1, 2, Paul Pham3, Minh Le1, 3, Quan Le1, Phuong Nguyen4, Ha Nguyen5, Dan Nguyen6, Binh Trang1, Chelsea Cao1, Ahmet Gurakar4, Trang Pham1, Christopher Hoffman5, Doan Dao1

1Johns Hopkins School of Medicine Baltimore MD Vietnam, 2Department of Epidemiology, Pham Ngoc Thach University of Medicine Ho Chi Minh City Vietnam, 3College of Medicine, Taipei Medical University Taipei City Taiwan, 4Department of Economic, Social and Administrative Pharmacy (ESAP), School of Medicine, Vietnam National University Ho Chi Minh City Vietnam, 5Boston University School of Public Health Boston MA United States, 6Johns Hopkins School of Medicine Baltimore MD United States, 7School of Public health, University of Illinois at Chicago Chicago IL United States, 8Johns Hopkins Bloomberg School of Public Health Baltimore MD United States

Background: Globally, <10% of HBV-infected persons are tested; thus, <2% are receiving recommended anti-viral therapies. The WHO recommends community- and primary care-based testing for HBV to address the inequities in access to screening and treatment. This study determined the effectiveness of different intervention models to promote HBV testing uptake in community and primary care settings toward global elimination goals.

Methods: A systematic review (PROSPERO-CRD42023455781), encompassing PubMed, Embase, Scopus, and CINAHL databases, was conducted, covering individual/cluster-randomized controlled trials up to 8/23/2023 and in English. Random-effect meta-analysis models were applied for sufficiently comparable subgroups of intervention models. Quality of evidence was assessed using ROB2.

Results: Of the unduplicated 6,617 studies identified, 19 trials were included, with 17 studies from high-income countries. 16 studies were included in the meta-analysis (Figure 1). Community-based intervention strategies included education programs by lay health workers (Pooled RR = 5.1 [95%CI = 2.6; 10.1], I2 = 93%) or healthcare workers (17.2 [4.5; 66.2], 95%), or through digital platforms (1.6 [0.5; 4.5], 95%). Primary care-based intervention strategies consisted of the deployment of the electronic alert system (4.9 [0.7; 32.6], 96%), financial incentives to healthcare providers (one study; 11.4 [10.4; 12.4]), and the use of point-of-care rapid testing (one study; 1.4 [1.3; 1.5]).

Conclusion: This study highlights the pivotal role of healthcare worker-based educational programs in increasing HBV testing uptake in community or primary care settings. Thus, future interventions to increase healthcare workers’ HBV education can enhance HBV diagnosis uptake and elimination goals globally.

Abstract Submission No. 100967
O-1135

Cost-Effectiveness of Hepatocellular Carcinoma Surveillance in Viral-Suppressed Chronic Hepatitis B
Pakanat Decharatanachart1, Roongruede Chaiteerakij2,3
1Division of Academic Affairs, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society Bangkok Thailand, 3Center of Excellence for Innovation and Endoscopy in Gastrointestinal Oncology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Background: Despite persistent viral suppression through antiviral medication, chronic hepatitis B virus (HBV)-infected patients are still at risk for hepatocellular carcinoma (HCC) development. The incidence of HCC in non-cirrhotic viral-suppressed patients is significantly lower than cirrhotic patients. Therefore, to individualize HCC surveillance based on individual patient’s risk, we aim to assess the cost-effectiveness of alternative HCC surveillance strategies.

Methods: Cost-utility analysis was performed using Markov model in Thailand and the United States (US) settings. Compared with biannual ultrasonography with alpha-fetoprotein, the cost-effectiveness of alternative HCC surveillance strategies were assessed, including 1) Annual ultrasonography with AFP and 2) Annual ultrasonography alone. Incremental cost-effectiveness ratio (ICER) was calculated using total costs and quality-adjusted life-years (QALYs) gained for each strategy. Strategies with ICERs above the willingness-to-accept (WTA) threshold of $9,330/QALY (320,000 THB) in Thailand and $100,000/QALY in the US were considered cost-effective.

Results: Annual ultrasonography with and without AFP were cost-effective in Thailand and the US settings. Compared to biannual ultrasonography with AFP, annual ultrasonography with and without AFP resulted in ICERs of 128,924 and 83,105 USD/QALY in Thailand, 371,700 and 227,400 USD/QALY in the US, which were above the WTA in the respective settings (Table). Additionally, the proportion of HCC-related mortality remained similar in all surveillance strategies. By probabilistic sensitivity analysis, annual ultrasonography had the highest probability of being cost-effective in Thailand and the US settings.

Conclusions: Alternative HCC surveillance strategies, including annual ultrasonography with and without AFP are cost-effective options for HCC surveillance in non-cirrhotic viral-suppressed HBV-infected patients.

Abstract Submission No. 101304
O-1137

The cascade of care for hepatitis C virus infection among adults in Sindh province, Pakistan

Tesfa Sewunet Alamne1,2, Josephine Walker1, Aaron G Lim1, Ejaz Alam1, Saeed Hamid3, Graham R Foster4, Naheed Choudhry5, M. Azim Ansari6, Huma Qureshi7, Peter Vickerman1
1Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Bristol United Kingdom, 2Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Ethiopia Gondar Ethiopia, 3Pakistan Health Research Council Research Centre, Karachi, Pakistan Karachi Pakistan, 4Aga Khan University, Karachi, Pakistan Karachi Pakistan, 5Queen Mary University of London, London, UK London UK, 6Nuffield Department of Medicine, University of Oxford, Oxford, UK Oxford UK, 7Consultant Gastroenterologist, Doctor Plaza, Clifton Karachi Clifton Karachi Pakistan

Background/Aims: Approximately 9.8 million people are living with hepatitis C virus (HCV) infection in Pakistan. To achieve HCV elimination, high levels of treatment are needed. Assessing the HCV cascade-of-care (CoC) is essential for guiding elimination initiatives.

Material and methods: A household serosurvey was conducted in Sindh province in 2019, utilising a two-stage stratified sampling design. The survey collected self-reported data on previous HCV testing and treatment history, and blood samples were taken for HCV-antibody (HCV-Ab) and HCV-RNA testing. We assessed the CoC and used multilevel binary logistic regression to identify factors associated with ever being tested for HCV. Adjusted Odds Ratios (aOR) with 95% Confidence Intervals (95%CI) were estimated.

Results: The study identified 397 HCV-Ab-positive individuals. Of these, 115 individuals (115/397=28.9%) had ever been tested for HCV and 100 (100/397=86.7%) reported testing positive for their last HCV test. Of these individuals, 61 (61/100=61%) reported having been treated, with 28 (28/61=45.9%) having an undetectable HCV-RNA test result in the survey. Regression analysis suggested that individuals with a family history of hepatitis (aOR=18.8, 95%CI: 6.5-54.3), ever-invasive dental procedure history (aOR=3.2, 95%CI: 1.2-8.4), ever blood transfusion history (aOR=2.7, 95%CI: 1.0-7.1), and secondary or higher education level (aOR=4.2, 95%CI: 1.4-12.8) compared to illiterates were more likely to have ever been tested for HCV.

Conclusions: Levels of HCV testing and the subsequent cascade-of-care in Sindh province, Pakistan, need to be dramatically improved to achieve HCV elimination in this setting. People with lower education levels need to be targeted in future testing initiatives.

Abstract Submission No. 101013
O-1136

How the Caregiver Could Increase the QoL of Elderly with Post-Liver Transplantation and Dementia?

Lintong Simbolon1, Rosinta Hotmaida P Purba2, Ni Made Ratih Kusuma Dewi3
1University of Lampung Sleman Indonesia, 2Universitas Gadjah Mada Yogyakarta Indonesia, 3PT. Astra International Tbk Mataram Indonesia

Potential curative treatment for liver disease is Transplantation (LT), although long-term survival is less than satisfactory. Indonesian elderly with independence barriers reached 3.7% and very dependent on the caregivers’ existence. However, certified informal caregivers are not available in Indonesia, yet.

This study uses the 5th wave of the 2014 Indonesia Family Life Survey (IFLS) to explore how the availability of caregivers in maintaining the Elderly QoL post-LT with Dementia comorbidity. Indonesian elderly reach 10.8% and 48% of them have chronic diseases. 18.6% of Liver cancer patients recorded in Indonesia are at Elderly age. 23.7% of them were identified as having symptoms of dementia with moderate to severe assessed (used the mini-cognitive test scoring). The elderly needing long-term care due to these health conditions reaches 9.7% and 88% of them do not have caregivers. Only less than 1% of the elderly are cared for by paid caregivers and are concentrated in urban areas. The majority of the elderly are cared for by their families or tend to “age in community”. 36% of Elderly post-LT benefit from health insurance and government social assistance. Using the Geriatric Depression Scale (GDS) it is known that the percentage of Elderly post-LT with dementia who has caregivers with mental health problems is lower than respondents who do not have caregivers.

Indonesia is urgent to meet the availability of certified informal caregivers with standardization modules and training. Expanding the coverage of health insurance for the provision of caregivers is a top priority because it mitigates mental health problems.
Impact and cost-effectiveness of scaling up HCV treatment among people who inject drugs in Vietnam

Peter Vickerman, Adam Trickey, Josephine Walker, Nicolas Nagoi, Didier Laureillard, Pham Minh Khue, Nguyen Thanh Binh, Vu Hai Vinh, Tran Thi Hong, Khuat Thai Hai Oanh, Don Des Jarlais, Catherine Quillet, Roselyne Vallo, Sandra Bivege, Jack Stone

1University of Bristol Bristol United Kingdom, 2University of Montpellier Montpellier France, 3Haiphong University of Medicine and Pharmacy Hai Phong Vietnam, 4Haiphong University of Medicine and Pharmacy Hai Phong Vietnam, 5New York University New York USA

Abstract Submission No. 101398
O-1138

Methods: A model of HCV transmission among PWID was calibrated in a Bayesian framework using data from Haiphong (mainly DRIVE+DRIVE-C). We evaluated the decrease in HCV incidence resulting from the DRIVE+DRIVE-C interventions, with no future interventions (denoted status quo/SQ), and the additional impact of providing HCV-testing and treatment in OAT and HIV treatment centres plus annual RDS interventions (HCV testing+treatment) over 2024-2029 (denoted DRIVE-plus). Over a 26-year time horizon (2024-2050), we estimated the incremental cost-effectiveness ratio (ICER) per disability adjusted life-year (DALY) averred for DRIVE-plus compared to SQ.

Results: For SQ, HCV incidence decreases from 14.8 (95% credibility interval 11.7-18.6) per 100 person-years (1/100 pyrs) in 2016 to 9.3/100pyrs (7.2-12.7) in 2020, remaining stable until 2030 because of scale-up of OAT (12 to 49% over 2016-2019). For DRIVE-plus, HCV incidence decreases to 2.1/100pyrs (1.2-4.1) by 2030, or 6.1/100pyrs (3.8-9.8) with just the additional RDS surveys. The mean ICER for DRIVE-plus is €682/DALY averted; cost-effective at a willingness-to-pay threshold of €2,048/DALY averted (0.5xGDP).

Conclusion: Using RDS surveys and other care settings to scale-up HCV-testing and treatment is a cost-effective strategy to reduce HCV incidence among PWID.

Early detection of liver disease: How Puskesmas take important role among 17k islands in Indonesia?

Ester Marinta Purba, Rosinta Hotmaidha P Purba, Helen Try Juniaisti, Wahyuni Kurniawati

1Widyamataar University Yogyakarta Indonesia, 2Learningup Institute Yogyakarta Indonesia, 3Cendrawasih University Papua Indonesia, 4Incision Care Cairo Mesir

Abstract Submission No. 101747
O-1140

Climate change & Liver diseases & impact of adaptation strategies to deal with this challenge (Pakistan)

Jalal Khan, Farhana Kayani

1Bolan medical college Quetta Pakistan

Climate change (CC) is a global distressing problem that contributes to global burden of diseases, mortality & changes in pattern of health problems. Purpose of study is to review serious consequences of CC on liver diseases & impact of adaptation strategies & mechanisms of remapping to reduce liver diseases.

Methods: This study was conducted in tertiary care hospitals of city over a period of 5 years to evaluate number of vectorborne, water/food-borne, parasitic diseases affecting liver. Meanwhile, Adaptation strategies were developed & implemented for vulnerable groups that is patients coming to hospitals, free camps being conducted every 3 monthly at new location in city supporting physicians & nurses at different levels, & making small videos over local channel to educate mass. Observing trend of then & know liver infections in same tertiary care hospitals

Results: Total of 1600 patients presented to hospitals with liver infections

Vectors transmitting parasitic/viral diseases are extremely sensitive to CC. 54% patients presented with Dengue, Malaria, & Congo hemorrhagic fever related liver complications (39.3%). Ambient temperature, floods, & humidity may have significant role in distribution of intermediate hosts & pathogens that cause liver diseases. Due to recent flood events in Pakistan an increase in incidence of hepatitis A (HAV) & E viral infection (HEV) was observed. Based on data between 2020 & 2022 & flood event scenarios, incidence of HAV & HEV infections were 562 (35.1%) & 408 (25.5%) patients respectively.

After implementation of adaptation strategies at different levels, incidence of liver diseases related to CC showed a decreasing trend. Incidence of HAV (39.1% vs 60.9% p=0.03), & HEV infections (28.7% vs 81.3% p=0.012) decreased. A decrease in malaria & Dengue infection was also seen after educating the masses regarding protective measures like use of the net, repellents, & a clean environment (36.8% vs 73.2% p=0.001) & (27% vs 73%) but incidence of Liver disease related to Congo fever didn’t change statistically significantly.

Conclusion: In conclusion, impact of CC on liver health is definite. Thus, there is an urgent need for properly sustained eco-health services provided by hepatologists. By adapting & mitigating proper strategies we can improve the expectations & predicted scenarios of hepatic health impacts due to CC.
improving the senior QoL in various aspects of life. However, 56% of older people who do not have insurance prefer traditional practitioners. Posyamuthu Lansia can be a forum that carries out early detection of liver disease and is very accessible to improve the elderly QoL. It also needs to address the covered social insurance for treatment and caregivers.

Abstract Submission No. 101769

O-1141

Medical - social assessment of the prevalence of primary liver cancer in Kazakhstan.

Niyaz Malaye1, 2, Samat Saparbeyev2, Nadiyar Musin1, Saule Kubekova4

1NJSC West Kazakhstan Marat Ospanov Medical University Aqtobe Kazakhstan, 2SC National Scientific Medical Center Astana Kazakhstan, 3MC Aqtobe Kazakhstan, 4NJSC Astana Medical University Astana Kazakhstan

Relevance of the study: According to official statistical data for 2020 in Kazakhstan, primary liver cancer - hepatocellular carcinoma (HCC) occupies 9th place in the total cancer morbidity and 7th place in the structure of mortality from malignant neoplasms.

Aim of the study: To study the prevalence of liver cancer in Kazakhstan.

Results and discussions: Standardized incidence rates per 100 thousand people, 3.1: men - 4.4/4.1, and women 2.6/2.1, respectively in 2020. Rank in the mortality structure - 10th place in 2019; 8th place in 2020. By regions - the top three high mortality rates from liver cancer in 2020: East Kazakhstan - 4.8. West-Kazakhstan - 4.8, Pavlodar - 4.4; the three lowest indicators: Almaty city - 1.8; Atyrau - 2.1; Akmola and Nur-Sultan - 2.2. The number of deaths from malignant neoplasms, not registered with oncological organizations - in the first place liver cancer in 2019 and 2020, in the second place blood cancer, in the third place - pancreatic cancer.

Conclusion: Liver cancer is in the first place among those who died without being on dispensary registration during 2019 and 2020 in Kazakhstan. As well as mentioned earlier, liver cancer is among the top three malignant neoplasms with one-year mortality and low five-year survival rate.

Abstract Submission No. 101831

O-1142

Cost-effectiveness of CHB therapy - implication of new therapy vs expanding the existing therapy

Jing Chen1, 10, Eliza Wong1, 10, Ji-dong Jia2, 10, Ji Mo Yang3, 10, Tawesak Tanwande4, Diana Payawal5, 10, Saeed Hamidi6, SK Sarin7, 10, Masao Omata8, George Lau9

1JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong Hong Kong, 2Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 3Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea Seoul South Korea, 4Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand, 5Department of Medicine, Cardinal Santos Medical Center Mandaluyong Philippines, 6Aga Khan University Karachi Pakistan, 7Department of Hepatology, Institute of Liver and Biliary Sciences New Delhi India, 8Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi Yamanashi Japan, 9Humanity and Health Clinical Trial Center, Humanity and Health Medical group Hong Kong SAR China, 10On behalf of APASL Viral Elimination Task Force APASL APASL

Background: Chronic Hepatitis B (CHB) remains a significant global health challenge, necessitating effective and cost-effective therapeutic strategies. This study evaluated the impact and cost-effectiveness of different therapeutic strategies on HBV functional cure.

Methods: A Markov state-transition model was used to evaluate cost-effectiveness of three strategies of antiviral treatment, i.e. infinite nucleos(t)ide analogues (NA, entecavir) treatment, add-on PegIFN to stop NA (PegIFN+NA), and add-on new therapy to stop NA (New+NA). The model simulated chronic HBV infection status of 10,000 patients (aged 50+ years, NA-suppressed, HBeAg-) with virological and clinical relapse and retreat, in Asia-Pacific (AP) region where the majority of CHB patients reside.

Results: PegIFN+NA is estimated to reduce HCC and HBV-related deaths by 50.1% and 43.5%, respectively; by 2050, compared to infinite NA treatment. The reduction with New+NA is 42.6% and 36.4%, respectively. Incremental cost-effectiveness ratio (ICER) for PegIFN+NA is 2,725 USD/QALY in AP, ranging from 12,410 USD/QALY in high-income countries/areas to 2,569 USD/QALY in low-income countries. For a comparable ICER, the cost for a new therapy must not exceed a one-time treatment cost of USD11,431 in AP. New+NA (discounted QALYs = 21.3) is less effective than infinite NA (21.7) in high-income countries, regardless of the new therapy’s cost. For a higher cost of new therapy, e.g., USD20,000, New+NA would never be cost-effective with an ICER equal to GDP per capita.

Conclusions: High cost and efficacy requirements of new therapy for CHB may limit its widespread application. Utilizing combination therapy could present a cost-effective strategy to attain a functional cure.

Abstract Submission No. 101872

O-1143

High exposure to hepatitis C virus in Saravan, Laos:
Identification of several risk practices

Lisa Hefele1, Antony P Black2, Siriphol Virachith2, Vilayson Khounvisith2, Phimpha Paboriboune3, Judith M Hübschen1

1Luxembourg Institute of Health Esch-sur-Alzette Luxembourg, 2Institut Pasteur du Laos Vientiane Laos, 3Centre d’Infectiologie Lao-Christophe Méries Vientiane Laos

Background: HCV prevalence in Laos varies, with estimates ranging from 1.1% to 3.9%. A study by our group in Salavan province (in the South of Laos) found an unexpectedly high prevalence of 24.4%. We conducted a follow-up study to investigate the epidemiology of the infection in more detail and to determine associated risk-practices.

Methods: For the follow-up study, 402 participants were recruited (160 HCV infected cases and 242 controls; age-matched ±5 years). After informed consent, blood samples were taken and tested for anti-HCV antibodies by ELISA. Positive samples were subjected to reverse transcription PCR to obtain sequences for phylogenetic analyses.

Results: Among the cases, 58.8% had detectable viral load. These participants were referred to the district hospital for treatment. More than half (58.0%) of the participants stated to have received parenteral medicine, and among those, 72% reported re-use of syringes. Tatooing was frequent (33.1%) and associated with having higher odds for being positive (adjusted odds ratio (aOR)=1.89(95% CI 1.2-2.8); p=0.01). In addition, accidental blood exposure for example when assisting people during accidents was also associated with HCV seropositivity (aOR=1.9(1.2-2.9); p<0.01). HCV sequence analyses are on-going and
Evaluation of the performances of three rapid ICT test being used for detection of HCV antibodies.

Yasir Waheed1,2

1Bridging Health Foundation Rawalpindi Pakistan; 2Pakistan Academy of Sciences Islamabad Pakistan

Background: Large number of HCV rapid screening tests are available in the market and many of them have substandard results.

Objectives: To evaluate the performance of 3 best HCV rapid test available in market.

Methods: We enrolled 300 subjects including 50 pregnant women, 50 blood donors and 200 HCV positive individuals. Blood samples from all the 300 participants were screened by using three rapid screening test for anti-HCV including Intec Products Advanced Quality Rapid Anti-HCV Test, SD Bioline One Step anti-HCV test, and CTK Biotech’s OnSite HCV Ab Rapid Test. The performance of these three rapid tests was also compared with the Roche Anti-HCV II test performed on the cobas 601 platform based on the electrochemiluminescence immunoassay principle.

Results: In total, 300 samples were analyzed in this study, out of which 92 were negative for anti-HCV and 208 were found positive for anti-HCV. The sensitivity of Intec test, SD Bioline test and CTK Biotech test were 98.56%, 97.59%, and 95.67%, respectively. The specificity of CTK Biotech test and SD Bioline test were found 100% whereas the specificity of Intec test was found 98.91%. The positive predictive value (PPV) of CTK Biotech and SD Bioline was 100%, but Intec product showed 99.51% PPV. The negative predictive values of the Intec product, SD Bioline, and CTK Biotech were 96.80%, 94.84%, and 91.09%, respectively.

Conclusion: The rapid test evaluated in this study showed very good results and they can be used for Hepatitis screening on large scale.

Abstract Submission No. 100181
P-0002

Hospitalizations for Alcohol-Associated Hepatitis in the Era of Early Liver Transplantation

Tomohiro Tanaka1, Shahana Prakash2

1University of Iowa, Division of Gastroenterology and Hepatology Iowa City United States; 2University of Iowa, Division of General Internal Medicine Iowa City United States

Background: Liver transplant (LT) is a recent option available in the United States (US) to treat those with severe, refractory alcohol-associated hepatitis (AH). We examined changes in clinical characteristics of patients admitted with AH and tracked hospital outcomes as practice changes involving LT have shifted.

Methods: Using the National Inpatient Sample, we performed a cross-sectional analysis of patients admitted with AH during the years 2016-2020 in the US. Differences in clinical characteristics over time were assessed. To compare outcomes between 2016-2017 (when LT was less common) and 2018-2020 (when LT was more common), we conducted linear and logistic regression. Propensity-score matching was used compare outcomes between patients with and without LT.

Results: From 2016-2017 to 2018-2020, patients admitted with AH tended to have a higher frequency of infection (p=0.006), hepatorenal syndrome (<0.001), and ascites (<0.001). Hospital costs and length of stay (LOS) were highest in transplant hospitals, and costs rose over time in both NT teaching and non-teaching hospitals (p<0.001). Mortality decreased in NT teaching hospitals [aOR 0.7 (95% CI: 0.6-0.8)] and slightly decreased in NT non-teaching hospitals [aOR 0.7 (95% CI: 0.5-1.0)]. In the propensity-matched cohort involving LT versus non-LT patients, there was a 13% absolute reduction in in-hospital mortality, but this came at a higher cost (p<0.001) and length of stay (p=0.001).

Conclusion: The severity of AH has been increasing over time, yet mortality has declined, after adjusting for severity of disease. All patients who underwent LT survived; however, the healthcare burden of LT is substantial.
Global Burden of Disease Study 2019: Epidemiology of Alcohol-Related Complications in Young Women

Kai Yi Benjamin Nah1, Cheng Han Ng1, Wen Hui Lim2, Darren Jun Hao Tan2, Nicholas Syn1, Margaret Teng1, Mark Muthiah1, Daniel Qingyao Huang1

1Division of Gastroenterology and Hepatology, National University Hospital Singapore Singapore, 2Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

Alcohol consumption has witnessed a significant increase over the last two decades. Alcohol-associated liver disease (ALD) and alcohol use disorder (AUD) represent substantial public health risks, with women being more vulnerable to these complications. This study aimed to explore the epidemiology of ALD and AUD in women aged 15-49 using data from the Global Burden of Disease Study (GBD) 2019. Data from GBD 2019 were utilized to extract annual frequencies and age-standardized prevalence rates (ASPR), mortality, and disability-adjusted life years (DALYs) for alcohol-associated cirrhosis (AC), alcohol-associated hepatocellular carcinoma (AL-HCC), and AUD in young women from 2010 to 2019. Data were stratified by age, region, country, and sociodemographic index (SDI). Statistical analyses, including misclassification correction and joinpoint regression, were conducted to assess temporal trends. In 2019, there were an estimated 17.43 million cases of AUD, 1.27 million cases of AC, and 2,532 cases of AL-HCC in young women globally. AC accounted for the highest number of deaths (14,521), followed by AUD (9,336), and AL-HCC (1,251). AUD resulted in 2.19 million DALYs, while AC and AL-HCC contributed 698,328 and 58,239 DALYs respectively. The highest burden of AUD was in Europe (ASPR: 2.047.76), with declining APR in most regions. Europe similarly had the highest AC burden (ASPR: 185.73), with increasing prevalence in most regions. Western Pacific had the highest AL-HCC burden (ASPR: 0.21), with increasing prevalence in most regions. This study highlights the significant burden of alcohol-related complications in young women, especially with the increasing prevalence of AC and AL-HCC. Understanding these epidemiological trends is essential to develop effective targeted public health interventions.

Results: Between 2000 and 2019, the burden of AAC in young adults increased, with higher rates in males. Southeast Asia had the highest prevalence, deaths, and DALYs of AAC. Furthermore, young adult cancer burden attributable to alcohol increased by 5.05% in terms of deaths and 6.06% in terms of DALYs. Lip and oral cavity cancer had the highest burden among cancer types. High SDI countries’ cancer ASDRs and ASDALYS related to alcohol showed the most substantial declines, but increased in low and high-middle SDI countries. Conclusion: Alcohol consumption has a significant impact on the health of young adults, leading to increased cirrhosis and cancer-related deaths and DALYs. These effects vary by region, gender, and development level. Effective public health interventions and policies are essential to reduce the burden of alcohol-related diseases, particularly among young adults.

Clinical Significance of Systemic Inflammation in Cirrhotic Patients with Acute Decompensation

BAEK GYU JUN1, Sang Gyu Kim2

Asan Seonoul clinic Seoul South Korea, 2Soonchunhyang University College of Medicine Bucheon Hospital Seoul Seoul South Korea

BACKGROUND: Some evidence suggests that the systemic inflammatory response syndrome (SIRS) contributes to the poor outcome of Acute decompensation (AD) of cirrhosis. The aim of this study is to assess prevalence of SIRS and its relationship with in-hospital outcome and acute-on-chronic liver failure (ACLF).

METHODS: A total of 1,162 alcoholic LC (liver cirrhosis) patients with AD were enrolled. ACLF was defined in the CANONIC study as an AD resulting in liver failure. Presence of SIRS was assessed on admission and during hospital stay. Main clinical outcomes were death and secondary clinical outcome is to evaluate association with SIRS and ACLF.

RESULTS: SIRS was present on admission in 308 of 1162 patients (26.5%). Presence of SIRS and ACLF at admission was not associated with 28-day mortality (p = 0.925). On univariate analysis, presence of SIRS and ACLF during hospital day (p = 0.001), model for end-stage liver disease (MELD) score (p = 0.001), lactate (p = 0.001) was associated with 28-day mortality (p = 0.001). On multivariate analysis, presence of SIRS and ACLF during hospital day were associated with 28-day mortality (p < 0.001). ACLF was not associated with SIRS (p = 0.858) and was associated with MELD score (p < 0.001).

CONCLUSIONS: SIRS frequently occurs in patients with cirrhosis. The presence of SIRS with ACLF during the hospital is a major independent prognostic factor in patients with cirrhosis. SIRS and ACLF affect independently 28-day mortality in LC.

Narirutin reduced alcohol-induced hepatic injury by modulating MAPK14 in the zebrafish model

Ki-Hoon Park1,2, Junyang Jung3,4

1Department of Anesthesiology and Pain Medicine, College of Medicine, Kosin University Busan South Korea, 2Department of Anatomy and Neurobiology, College of Medicine, Kyung Hee University Seoul South Korea, 3Department of Biomedical Science, Graduation School, Kyung Hee University Seoul South Korea,
Background: Alcohol-associated liver disease (ALD) ranges from alcoholic steatosis to cirrhosis. Naringin (NRT), prominent in citrus peels, holds anti-inflammatory, antioxidant, and lipid-lowering properties. This research focused on the protective effects of NRT on liver damage caused by alcohol and the mechanisms involved.

Methods: Zebrafish larvae served as the model for studying the impact of NRT on liver injury due to ethanol (EtOH). Evaluations of liver phenotype, morphology, and biochemistry were conducted to ascertain the hepatoprotective effects of NRT. Network pharmacology and molecular docking helped in exploring potential targets of NRT in combating EtOH-induced hepatic damage. A DARTS assay was used for assessing the binding affinity of NRT to MAPK14, with subsequent validation through RT-qPCR and Western blot.

Results: Assessments indicated that NRT exhibits therapeutic potential in countering EtOH-induced liver injury, as evidenced by improvements in various hepatic parameters. NRT also mitigated changes in gene expressions related to oxidative stress, lipogenesis, and the ER/unfolded protein response. Insights from network pharmacology and molecular docking revealed that the protective action of NRT likely involves modulation of the p38 MAPK pathway, particularly through interaction with MAPK14.

Conclusions: NRT contributes to the alleviation of liver damage induced by alcohol. This effect is achieved through the inhibition of lipid synthesis, augmentation of antioxidant mechanisms, and reduction of ER stress-induced apoptosis, mediated through modulation of MAPK14.
**Abstract Submission No. 101586**

**Global Burden of Alcohol-Related Complications in Young Women**

Cheng Han Ng¹, Kuan Loon Benedix Sim², Daniel Q huang³, Nicholas Syn¹

¹National University Hospital Singapore Singapore

**Introduction:** The surge in alcohol consumption, notably among young women, has led to a substantial rise in alcohol-related complications, necessitating a comprehensive understanding of the epidemiological landscape. This study focuses on addressing the existing gaps in research by examining the prevalence, mortality, and disability-adjusted life years (DALYs) of alcohol-associated cirrhosis (AC), alcohol-associated hepatocellular carcinoma (AL-HCC), and alcohol use disorder (AUD) in young women globally.

**Methods:** Data from the Global Burden of Disease study 2019 were analyzed to extract information on the burden of AC, AL-HCC, and AUD in women aged 15-49. The study utilized statistical methods, including Joinpoint regression, to assess trends over the period 2010-2019. The analysis categorized results by region, nation, and socio-demographic index (SDI).

**Results:** In 2019, global prevalence figures for AUD, AC, and AL-HCC in young women were 17.43 million, 1.27 million, and 2,532 cases, respectively. Europe exhibited the highest burden of AC and AUD, while the Western Pacific region had the highest burden of AL-HCC. While AUD prevalence showed a decline, AC demonstrated an upward trend. Notably, despite the high burden in Europe, AL-HCC was concentrated in the Western Pacific. Trends in mortality and DALY's varied across regions and SDI levels.

**Conclusion:** The last decade has witnessed a concerning escalation in the global burden of alcohol-related complications among young women. Urgent public health strategies are needed, particularly in Europe and the Western Pacific region, considering the varying disease dynamics across regions and SDI levels.

---

**Abstract Submission No. 101898**

**P-0011**

**The significance of extracellular vesicle number in patients with alcoholic liver injury**

Hiroki Hayashi¹, Kouichi Miura¹, Naoki Morimoto¹, Shunji Watanabe¹, Hiroshi Maeda¹, Rie Goka¹, Akiko Eguchi², Hironori Yamamoto¹

¹Jichi Medical University Tochigi Japan, ²Mie University Graduate School of Medicine Mie Japan

**Background and aim:** Extracellular vesicles (EVs) are released from various cell types and its number reflects cell condition. In addition, EVs contain the components of cells, including proteins and nuclear acids. Thus, EVs are bioactive and contribute to activation of other cells. Currently, the number of EVs has been reported to increase in mice and patients with alcoholic liver injury. However, little information is available on the association between the number of EVs and...
In this study, we aimed to investigate the number of EVs and liver function in patients with alcoholic liver injury.

**Methods:** A total of 48 patients with alcoholic liver injury who visited Jichi Medical University hospital were enrolled in the present study. All patients were agreed to participate in the study. The number of labeled EVs in the serum were counted using flow cytometry.

**Results:** Among 48 patients, 44 were male. The median of age was 65 years old. The median of EV number was 2.62 million/ml. In agreement to our previous data, the number of EVs increased in parallel with an increase of triglyceride (TG). Thus, we investigated the correlation between liver function tests and the EV/TG ratio. There were positive correlations between EV/TG and AST, EV/TG and ALT, EV/TG and ALP, and EV/TG and M2BPG. In addition, there were negative correlations between EV/TG and serum albumin. Indeed, there was a significant difference in EV/TG between high and low albumin group (<4.0 g/dl).

**Conclusion:** There is a negative correlation between EV/TG and serum albumin.

---

Abstract Submission No. 101968

**P-0012**

**Network pharmacology analysis and in vivo experiments reveal mechanisms of JPHX formula in acute ALD**

Yue Chen1,2, Wenying Qi1,2, Hening Chen1,2, Chengshuai Liu5, Xiaobin Zao6, Yuyong Jiang4

1Dongzhimen Hospital of Beijing University of Chinese Medicine Beijing China, 2Institute of Liver Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 4Beijing Ditan Hospital, Capital Medical University Beijing China, 5Guang’anmen Hospital, China Academy of Chinese Medical Sciences Beijing China

**Background:** Currently, there is still a lack of significant pharmacological treatments for alcoholic liver disease (ALD). JianPiHuOxue formula (JPHX), as a traditional Chinese medicine, has shown a therapeutic effect to ALD in clinical practice. Therefore, this research aims to preliminarily the pharmacological mechanism of JPHX in acute ALD.

**Method:** A thermo QE plus liquid chromatography tandem high-resolution mass spectrometer was used for the determination of the chemical constituents of JPHX. TCMSP database, GeneCards database, uniprot database, omim database, the STRING platform, and Cytoescape 3.7.2 were used to construct the network of JPHX in the treatment of ALD. The acute ALD mice model was established by a persistent alcohol diet, and JPHX was given by intragastric administration. Meanwhile, transcriptomics of liver tissues was performed to investigate the mechanism of JPHX in acute ALD.

**Result:** JPHX has 49 main active compounds, of which Luteolin, Tanshionine IA, and Wogonin may be its main compounds alleviating ALD. Network pharmacology analysis predicted that AKT1, TNF, and IL-6 may be the key targets. GO and KEGG analysis shows that the pathways involved in regulating immunity, mediating inflammatory response and so on. In vivo experiments, JPHX did play a role in anti-inflammatory and alleviating liver damage. Transcriptome and enrichment analysis showed that it may be related to the regulation of lipid metabolism, bile acid metabolism, and anti-inflammatory pathways.

**Conclusion:** JPHX can alleviate acute ALD. It may be related to the intervention of inflammatory response, immune regulation, bile acid metabolism, and lipid metabolism, which needs further verification by molecular biology.
while on azathioprine monotherapy without any hepatic event or worsening of laboratory results.

Patient B is a 55-year-old Chinese female with epilepsy and protein C deficiency. She was diagnosed with AIH (pretreatment score 23) 4 weeks after mRNA Covid-19 vaccination in July 2021. Initial results Bil31 ALP102 ALT134 AST269 IgG40.06. She was started on prednisolone and azathioprine with normalization of liver panel and IgG. She subsequently had repeat mRNA Covid-19 vaccination in January 2022 while on azathioprine and low dose prednisolone without any hepatic event or worsening of laboratory results. Both patients remain well on current follow up.

Conclusion: We report 2 cases where repeat mRNA Covid-19 vaccination was safely administered in patients who had AIH likely triggered by mRNA Covid-19 vaccination.

Abstract Submission No. 100243
P-0015
Association between serum myostatin levels and prognosis in primary biliary cholangitis

manabu hayashi1, Tatsuro Sugaya1, Youke Takahata1, Masashi Fujita2, Kazumichi Abe1, Atsushi Takahashi1, Hiromasa Ohira1
1Fukushima Medical University Fukushima Japan
2Department of Clinical Epidemiology and Medicine, The Catholic University of Korea, Seoul, Korea

Background: Primary biliary cholangitis (PBC) is an autoimmune-mediated cholestatic liver disease which can progress to liver-related death. Prognostic biomarker is needed in PBC patients. The association between myostatin level and prognosis in PBC patients is unclear.

Methods: In this retrospective study, we enrolled 119 PBC patients. Myostatin levels before ursodeoxycholic acid treatment were measured using ELISA. We analyzed their associations with the clinical characteristics in PBC patients.

Results: Serum myostatin levels in PBC patients was significantly lower than that of healthy controls (PBC; 2343 pg/mL, healthy controls; 4059 pg/mL, P < 0.001). The prevalence of patients with low myostatin levels was high in patients with severe histological fibrosis. Leucine-rich α2 glycoprotein levels were high in patients with low myostatin compared with those of patients with high myostatin. High myostatin in PBC patients was associated with longer survival without liver-related complications (hazard ratio: 0.25, 95% CI: 0.07–0.84, P = 0.025) independent of aspartate aminotransferase-to-platelet ratio index and histological stage.

Conclusions: Low myostatin levels were associated with severe fibrosis, high inflammatory conditions, and poor prognosis in PBC patients. Measurement of circulating myostatin can be used as a prognostic biomarker in PBC patients.

Abstract Submission No. 100493
P-0017
Epidemiology and Clinical Outcomes of PBC In Canterbury, New Zealand: A Population-Based Study

Asim Abdulhamid1, Catherine Ann Malcolm Stedman1,2, Michael John Burt3, Jing Hieng Ngu1,2
1Christchurch Hospital, Te Whatu Ora Waitaha Canterbury Christchurch New Zealand, 2University of Otago, Christchurch Christchurch New Zealand

Introduction: Primary Biliary Cholangitis (PBC) is an autoimmune cholangiopathy that can profoundly impact quality of life and may progress to cirrhosis. Population studies demonstrate a rise in incidence and prevalence in the developed world. Treatment options to slow progression remain limited with ursodeoxycholic acid (UDCA). Our population-based study aims to determine PBC incidence, prevalence and outcomes in Canterbury, New Zealand.

Method: Patients who fulfilled the diagnostic criteria of PBC were identified from public and private practices in Canterbury between 2015 and 2021. Cases were also identified upon review of liver biopsies and positive Anti-mitochondrial antibodies in the Canterbury region in the last 10 years. Incidence and prevalence rates were calculated using Census data from Statistic NZ.

Results: The Prevalence of PBC in Canterbury between 2015 and 2021 has increased from 14.7 per 100,000 to 16.9 per 100,000. The incidence over this time is 0.90 per 100,000 per year. Over the studied period, the prevalence and incidence in Europeans is 17.5 per 100,000 and 0.91 per 100,000 respectively; in Non-Europeans, it is 16 per 100,000 and 1.2 per 100,000 respectively. Only 53-77% of patients met response criteria defined by PARIS-I, Paris-II, and Barcelona Criteria at 12 months.

Conclusion: Our study demonstrates a rising prevalence with stable incidence of PBC and suggests improved survival of this enlarging
some primary biliary cholangitis (PBC) patients are estimated to have features that overlap with autoimmune hepatitis (AIH). We present a case of atypical PBC with AIH accidentally discovered.

Case report: The patient was a 39-year-old female who was unexpectedly diagnosed with liver dysfunction during a routine check-up. Laboratory examination revealed no hepatitis virus markers, ANA < ×40, AMA (M2)Ab < 1.5, anti-LKM-1Ab (-). Two months after the initial examination, liver function worsened with increased AST of 189 IU/L, ALT of 233 IU/L, ALP of 908 IU/L, and IgG of 2372 mg/dl. Serologically, anti-smooth muscle antibody (ASMA) was elevated to 320 times. Histopathologically, liver biopsy revealed the expansion of inflammatory cell infiltration, interface hepatitis, and granuloma in the portal area. Interlobular bile ducts showed features of chronic cholangitis. The liver parenchyma showed inflammatory cell infiltration and emperipolesis, accompanied by centrilobular zonal necrosis (CZN) in parts. Based on the above-mentioned findings, this patient was diagnosed with hepatitis-type PBC with AIH and initially treated with PSL 25 mg/day and UDCA 600 mg/day. The PSL dose was gradually decreased over 1 year. After pregnancy, she is currently taking PSL 5 mg/day and UDCA 600 mg/day. No signs of recurrence have been observed.

Conclusion: Since atypical autoimmune liver diseases might be hidden in liver dysfunction of unknown cause, it is necessary to make a comprehensive diagnosis considering the clinical course and histopathological findings. Especially, ASMA might be crucial for diagnosis. This case of hepatitis-type PBC with CZN, which is often found in AIH, is instructive.
JunSheng Jaryl Cheng1, Wei Lyn Yang2, Mona Manghani2

1Woodlands Health, Singapore Singapore Singapore, 2Tan Tock Seng Hospital Singapore Singapore

BACKGROUND: Idiopathic hypereosinophilic syndrome (HES) is an uncommon condition. Concurrent severe type 1 autoimmune hepatitis (AIH) is extremely rare while on pre-existing immunosuppression.

CLINICAL CASE: A 65 year old Chinese lady on follow-up with well controlled idiopathic HES presented with acute transaminisits secondary to severe AIH. She had been diagnosed 8 years prior with hypereosinophilia, biopsy proven urticarial vasculitis and multisystem involvement (bone marrow, respiratory and gut). Treatment at the time included pulse methylprednisolone, cyclophosphamide and subsequent maintenance azathioprine. Azathioprine was increased due to a flare of HES in February 2023. Due to transaminisits, azathioprine was withheld and prednisolone started. Transaminisits worsened requiring admission. Viral hepatitis markers were negative and there had been no new drug use. Mild elevation of serum immunoglobulin-G levels were noted but antinuclear antibodies were negative. Liver biopsy demonstrated marked lymphoplasmacytic infiltrate with interface hepatitis consistent with AIH. Anti-smooth muscle antibodies subsequently returned positive. Despite use of high dose oral steroids, liver function continued to worsen requiring inavenous methylpredniso- lone 250mg for 3 days. Throughout, she had no hepatic encephalopathy suggestive of acute liver failure. With high dose steroids, her transamnises started to downtrend and she was discharged on high dose oral prednisolone with normalization of transamnises at Day 60.

CONCLUSION: This case of severe de-novo AIH occurred whilst on immunosuppression for idiopathic HES. While there are no guidelines on the use of high dose steroids in severe AIH, the use of IV methylprednisolone was successful in averting a liver transplant for this patient.

Abstract Submission No. 101395

P-0022

Patients with PBC-specific antibodies and cholestasis may not be primary biliary cholangitis

Xin Zeng1, Ting-ting Lv1, Shuxiang Li1, Sha Chen1, Bu-er Li1, Zhi-jiao Lu1, Yu Wang1, Xin-yan Zhao1, Hong You1, Wei-jia Duan1, Ji-dong Jia1

1Liver Research Center, Beijing Friendship Hospital Capital Medical University Beijing China, 2Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis Beijing China, 3National Clinical Research Center for Digestive Diseases Beijing China, 4Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University Beijing China

Background & Aims: Patients with positive primary biliary cholangitis (PBC)-specific antibodies and evidence of cholestasis fulfill the diagnostic criteria of PBC. However, PBC-specific antibodies can appear in various diseases, and abnormal liver biochemistry might have non-PBC origins. Do these patients have PBC? Our study focused on patients with PBC-specific antibodies and cholestatic index elevation attributable to non-PBC etiologies.

Methods: We enrolled patients with positive PBC-specific antibodies at Beijing Friendship Hospital, Capital Medical University, between February 2017 and May 2023. Changes in liver biochemistry after non-ursodeoxycholic acid (UDCA) etiological treatments were monitored via electronic medical records and/or telephone interviews.

Results: One hundred and fifty-five patients with positive PBC-specific antibodies and elevated ALP and/or GGT levels due to non-PBC diseases were enrolled. One hundred patients had non-PBC liver diseases including non-alcoholic fatty liver diseases (n=36), drug-induced liver injury (n=35), autoimmune hepatitis (n=9), and others (n=20). Fifty-five patients had non-liver diseases, predominately consisting of connective tissue diseases (n=28). The median follow-up was 15.9 (4.7-25.6) months, and patients taking UDCA were excluded. After treatment targeting primary diseases, 73 patients exhibited decreases in both ALP and GGT levels, eventually normalizing within normal ranges. Among patients with persistently elevated liver enzymes, 12 patients underwent liver biopsy, and no specific manifestations of PBC were observed. Additionally, 55 patients had elevated GGT levels but normal ALP levels.

Conclusion: Patients with PBC-specific antibodies and cholestasis may not be PBC. For patients with non-PBC liver diseases and connective tissue diseases, treatments of primary diseases can normalize cholestatic index instead of UDCA.

Abstract Submission No. 101421

P-0023

Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients

Buer Li1,2,3, Shuxiang Li1,2,3, Sha Chen1,2,3, Min Li1, Tingting Lv4, Qianyi Wang1,2,3, Xiaoming Wang4, Yu Wang1,2,3, Hong Ma1, Xiaojuan Ou1, Xinyan Zhao1, Yuanyuan Kong1, Hong You1, Wei-jia Duan1,2,3, Jidong Jia1,2,3

1Liver Research Center, Beijing Friendship Hospital Capital Medical University Beijing China, 2Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis Beijing China, 3National Clinical Research Center for Digestive Diseases Beijing China, 4Center for Clinical Epidemiology and EBM, Beijing Friendship Hospital, Capital Medical University Beijing China

Abstract

Aim: Fenofibrate has shown biochemical benefit in primary biliary cholangitis (PBC) patients with a suboptimal response to ursodeoxycholic acid (UDCA), but its long-term efficacy on survival remains unknown.

Methods: In this retrospective-prospective cohort study, we enrolled 160 PBC patients with a suboptimal response to UDCA and followed up on these patients to obtain laboratory results and adverse events. Finally, we evaluated long-term survival analyses with Kaplan-Meier plotting and log-rank test.

Results: The fenofibrate add-on therapy group showed more significant improvements in alkaline phosphatase (ALP) and gamma-glutamyl transferase levels compared to UDCA monotherapy group after one year of treatment, resulting in a normalization rate of 60.9% for ALP and 45.3% for both ALP and total bilirubin. Importantly, compared with UDCA monotherapy group, the fenofibrate add-on therapy group had a better transplant-free survivals of 5-year (89.7% vs 75.3%) and 10-year (87.0% vs 47.6%), with a hazard ratio of 0.3282 (95% CI: 0.1334-0.8073, P=0.05). Twenty-one cases (25.6%) developed adverse events, with liver injury being the most frequent one (17.1%).

Conclusions: Fenofibrate add-on therapy improved not only biochemical responses but also long-term transplant-free survival in PBC patients with suboptimal response to UDCA. However, liver injury needs to be closely monitored and properly managed.

Keywords: Fenofibrate, ursodeoxycholic acid, primary biliary cholangitis, survival
**Background:** The usefulness of bezafibrate for primary biliary cholangitis (PBC) has been previously reported. However, the long-term efficacy of pemafibrate, a sPPARM, in PBC has not been fully analyzed. In this study, we investigated the efficacy and safety of pemafibrate for 3 years during additional treatment of patients with ursodeoxycholic acid (UDCA)-refractory PBC.

**Methods:** Patients with PBC with dyslipidemia attending our hospital whose biliary enzymes did not normalize with adequate doses of UDCA alone or UDCA plus bezafibrate were included. Patients were added pemafibrate or switched from bezafibrate. Patients who were followed for 3 years were evaluated.

**Results:** The group of UDCA alone plus pemafibrate (n=13) showed significant reductions in ALP (median 122 to 92 IU/L), γ-GTP (median 62 to 35 IU/L), TG (median 120 to 72 mg/dL) and IgM (median 156 to 129 mg/dL) after 3 months of treatment. 3 years later, ALP was significantly lower than that before treatment. ALP levels at 3 years were significantly lower than before treatment. In the group that switched from UDCA and bezafibrate to pemafibrate (n=14), there was no significant improvement in biliary enzymes or other parameters, but Cr levels at 1 year were significantly improved compared to pre-treatment levels (0.58 to 0.53 mg/dL). No side effects of rhabdomyolysis were observed during the course of the study.

**Conclusion:** Long-term combination therapy with pemafibrate for 3 years was considered effective and safe for PBC patients with dyslipidemia whose biliary enzymes were not normalized by UDCA alone.

---

**Gut Microbiota Characteristics of Patients in the Decompensated Phase of Primary Biliary Cholangitis**

**Yufei Bi**, **Ke Shi**, **Jialiang Chen**, **Xianbo Wang**

1Capital Medical University Beijing Ditan hospital Beijing China

**Background:** The role of gut microbiota in the progression of primary biliary cholangitis (PBC) is crucial. In this study, we compared the gut microbiota of patients in the decompensated phase of cirrhosis due to PBC, Hepatitis B Virus-related cirrhosis (HBV-RC), and healthy controls (HCs) from Beijing Ditan Hospital.

**Methods:** We utilized 16S rRNA gene sequencing to profile the gut microbiota of PBC patients (n=40), HBV-RC patients (n=40), and matched HCs (n=30). Differential abundance analysis was performed to identify key gut microbiota associated with each group. Correlations between these differentially gut microbiota and clinical indicators were examined. Finally, a diagnostic model for the decompensated stage of PBC cirrhosis was constructed based on the identified gut microbiota differences.

**Results:** In contrast to the gut microbiota of HCs, the patients with HBV-RC and PBC exhibited reduced diversity, as evidenced by alpha-diversity (ACE, Chao1, PD and Shannon index), beta-diversity (PCoA, NMDS) and a distinct microbial composition. Significantly, the observed differences in microbial composition among patients with PBC were found to be closely associated with clinical indicators (ALP, TBIL, IgG and IgM). Furthermore, utilizing these identified differences, we constructed a random forest model for diagnosis, with an area under the receiver operating characteristic curve of 0.78.

**Conclusion:** Patients with PBC exhibited notable changes in gut microbiota, marked by reduced *patescibacteria* at the phylum level and elevated levels of *streptococcus* and *veillonella* at the genus level. These findings suggest the potential utility of gut microbiota as a non-invasive diagnostic tool for PBC.

---

**Shugan Lidan Formula regulates gut microbiota, Th17/Treg balance and bile acid metabolism in PBC.**

**Yufei Bi**, **Jialiang Chen**, **Ke Shi**, **Xianbo Wang**, **LiuJuan Zhu**

1Capital Medical University Beijing Ditan hospital Beijing China

**Background:** Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by inflammatory destruction of the intrahepatic bile ducts. The current pharmaceutical treatments for PBC have limited efficacy for partial patients. A previous study showed that Shugan Lidan formula (SLF) combined with ursodeoxycholic acid can improve the biological response rate in PBC patients, but the mechanisms were unclear.

**Methods:** Poly I:C induced PBC mice were measured by liver function, hematoxylin and cosin (H&E) staining and immunohistochemistry (IHC) staining. Alteration in gut microbiota and bile acid metabolism were examined through 16S rRNA sequencing and non-targeted metabolomics. Inflammatory cytokine production was measured in serum and liver tissue using enzyme-linked immunosorbent assays (ELISAs) and real-time PCR. Frequencies of Th17 and Treg cells in the spleen were determined by flow cytometry.

**Results:** Treatment with SLF ameliorated Poly I:C induced PBC mice in liver function, histology score and CK19 expression. 16S rRNA sequencing revealed that SLF treatment significantly altered the gut microbiota diversity and composition in PBC mice. Fecal microbial transplantation (FMT) mitigated Poly I:C-induced PBC mice, demonstrating its role in pathogenesis and therapy. SLF treatment also reduced proinflammatory cytokines levels including IL-1β, TNF-α, IL-6, and IL-17A in serum and liver tissue. Non-targeted metabolomics analysis manifested the increased of bile acid. Additionally, SLF can downregulate the Th17/Treg balance to maintain intestinal homeostasis.

**Conclusion:** SLF showed therapeutic benefit against in mice in a way relying on effects on gut microbes. The underlying protective mechanism was associated with the improved Treg/Th17 balance and bile acid metabolism.

---

**Treatment Course and Prognosis of Steroid-Resistant Autoimmune Hepatitis in Our Hospital**

**Mie Arakawa**, **Tomoko Tokumaru**, **Tomoko Saito**, **Takuro Uchida**, **Masao Iwao**, **Mizuki Endo**, **Kazunari Murakami**

1Department of Gastroenterology, Faculty of Medicine, Oita University Yufu Japan

Steroid therapy stands as the global frontline approach for autoimmune hepatitis (AIH) due to its remarkable efficacy; nevertheless, cases of relapse after steroid tapering or inadequate responses requiring non-steroidal immunosuppressive therapy have emerged, often influenced by fibrosis development and steroid discontinuation. This study evaluates the prognosis of patients normalized with non-steroid therapy. The cohort comprises 58 patients treated between January 1st, 2010, and March 31st, 2021. Eight patients received immunosuppressive drugs (AZA, cyclosporine, tacrolimus, tacrolimus plus abatacept, and MMF), with three fatalities observed. Initial laboratory values showed differences in ALT and AST between steroid and immunosuppressant groups, with lower albumin levels in the latter. Steroid discontinuation...
history was prevalent in immunosuppressant users, and deaths were attributed to advanced cirrhosis and liver failure. Kaplan-Meier survival analysis revealed 87.5% and 48.3% 5- and 10-year survival rates for patients with advanced fibrosis at diagnosis. A 66.7% 10-year survival rate was noted for non-steroid-treated patients. However, prognosis did not significantly differ between steroid and non-steroid responders. These results indicate the importance of initiating treatment before fibrosis develops.

Abstract Submission No. 200093
P-0028

Rapid response associated with lower cirrhosis risk in Taiwanese patients with autoimmune hepatitis

Ying-Chieh Lu1, Shang-Chin Huang4, Chun-Jen Liu4, Hung-Chih Yang4, Tung-Hung Su4, Jia-Horng Kao4, Tai-Chung Tseng4

1Division of Gastroenterology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan

Background: Autoimmune hepatitis (AIH) is a rare disease and may advance to cirrhosis. Rapid treatment response has been shown to be associated with favorable outcomes, while delayed response may indicate patients who need an alternative therapy. This study aimed to evaluate the relationship of treatment response and long-term outcomes in Taiwanese patients with AIH.

Methods: This retrospective cohort study included 37 histologically confirmed AIH patients undergoing prednisolone treatment at National Taiwan University Hospital. Patients were categorized into complete biochemical response (CBR), insufficient response (IR), and non-response (NR) groups based on the International Autoimmune Hepatitis Group (IAIHG) response endpoints proposed in 2022. The primary endpoint was cirrhosis development.

Results: Of the diagnosed AIH patients, 9 patients had cirrhosis and 28 patients did not. Nearly half of cirrhotic patients were noted in the NR group (NR vs non-NR: 57.1% vs 16.7%, p < 0.05). Over a median follow-up period of 53 months, 5 non-cirrhotic patients progressed to cirrhosis, and 2 patients developed HCC. The cirrhosis progression rate was lower in the CBR group compared with the IR and NR groups (5.6% vs. 28.6% vs. 66.7%, p < 0.05). None of the CBR patients developed HCC.

Conclusions: Cirrhotic patients at the time of AIH diagnosis tended to have poor treatment response. A rapid treatment response was associated with a lower risk of cirrhosis.

Abstract Submission No. 200174
P-0029

Mesenchymal stem cells suppress inflammation in AIH via HIF-1α/AHR/CD39

Wanwan Shi1, Yanjie Lin1, Long Xu1, Jiandan Qian1, Guiqiang Wang1

1Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital Beijing China

Background: Autoimmune hepatitis (AIH) is a chronic parenchymal hepatitis mediated by autoimmune reaction. It is routinely treated with immunosuppressants like azathioprine, but often with serious side effects. Mesenchymal stem cells (MSCs) have been found to exert therapeutic effects in related liver disease. However, the specific mechanism remains to be further explored.

Methods: Embryonic stem cell derived MSCs were injected into mice with ConA induced AIH to assess changes in serology and liver pathology. Transcriptomics was used to explore the differences in gene expression, and the role of HIF-1α/AHR/CD39 signaling in AIH was verified by qPCR.

Results: MSCs-treated mice with AIH had more significant reductions in liver injury and inflammatory cytokine, and higher anti-inflammatory cytokine than mice treated with PBS. The liver function related indicators of ALT (21422.0 ± 7275.73 vs. 4512.0 ± 2877.83, P < 0.01), AST (12276.0 ± 7186.72 vs. 2080.0 ± 1516.58, P < 0.05) and TNF-α, IFN-γ, IL-6, IL-17A were decreased, anti-inflammatory cytokine IL-10 was elevated in plasma. The Ishak Score of liver pathological sections (10.0 ± 1.58 vs. 1.60 ± 0.89, P < 0.001) was reduced. Compared with AIH mice, the expressions of AHR, HIF-1α, and CD39 were increased and HIF-α expression was reversed after MSCs treatment.

Conclusions: By activating the HIF-α/AHR/CD39 signaling pathway, embryonic stem cell derived MSCs significantly alleviated the liver inflammatory response of mice with AIH, which can be regarded as an alternative therapeutic effect of AIH.

Abstract Submission No. 200200
P-0030

GRAVES’ DISEASE WITH AUTOIMMUNE HEPATITIS AND PRIMARY SCLEROSING CHOLANGITIS- AN OVERLAP SYNDROME

PRAGATHI L K1, Shivangi Teterbe1, Ira Shah1, Sudha Rao1

1DEPARTMENT OF PAEDIATRIC GASTROENTEROLOGY, B.J. WADIA HOSPITAL FOR CHILDREN, PAREL, MUMBAI MUMBAI India

Autoimmune hepatitis (AIH) is a chronic inflammatory disease that results from autoantibody mediated hepatocyte injury. Given its immune mediated mechanism, concurrent autoimmune disorders including AIH with Graves’ disease are reported. Our case study illustrates the diagnostic challenge to determine the cause of liver dysfunction in patients presenting with Graves’ disease.

Case report: 11-year-old adolescent girl, a case of untreated hyperthyroidism presented with acute liver failure with obstructive jaundice, hepatosplenomegaly, ascites and coagulopathy. Viral hepatitis and sepsis were ruled out. Ceruloplasmin was 32mg/dl. Autoimmune hepatitis was diagnosed based on positive ANA, elevated IgG levels and interface hepatitis on liver histology. MRCP done showed slit like CBD with proximal and mid CBD narrowing suggesting sclerosing cholangitis and overlap syndrome.

Thyroid gland was enlarged with TSH level <0.005uIU/ml. TSH receptor and thyroid peroxidase antibody was positive. Radioiodine uptake scan showed increased uptake in thyroid gland. Child underwent radio frequency ablation (RAI) of thyroid gland and was started on propranolol for tachycardia, steroids 60mg/day and azathioprine. At 12 weeks follow up patient is anicteric with improving liver function and is hypothyroid. She is on steroids of 5mg/day, azathioprine 2.5mg/kg and thyroid replacement therapy.

Discussion: 15-79% of untreated hyperthyroid patients suffer from liver dysfunction. It can be caused by hyperthyroidism per se or side effects of anti-thyroid drugs or as associations with AIH. Limited studies have been reported in pediatric population about the clinical course and treatment strategies in concomitant AIH and Graves’ disease. Our study concludes that high index of suspicion is required to diagnose concomitant AIH and Graves disease. A brief review of literature on clinical course and treatment is discussed.
Abstract Submission No. 100303

P-0031

On Drug-Induced Liver Injury

Keisuke Hamamura¹, Ryosuke Hayakawa¹, Daiki Kawaguchi¹, Tomoki Hikichi¹, Keisuke Kikuchi¹, Ryosuke Kimura¹, Rikiya Hasegawa¹, Hiroki Suzuki¹, Kengo Kuroishi¹, Toshio Tanaka¹, Tatsuki Oyazui¹

¹Shizuoka-city Shizuoka Hospital Shizuoka Japan

Background: Drug-induced liver injury (DILI) encompasses a range of pathophysiology. In Japan, the 2004 Japanese Gastroenterological Association score (Japan score) is widely utilized for diagnosis. However, this score does not account for recent Immune Checkpoint Inhibitors (ICIs). Cases of DILI are classified into hepatocellular, cholestatic, or mixed types based on ALT and ALP values. Our study aimed to review the characteristics of our DILI patients.

Patients & Methods: We retrospectively analyzed 34 DILI patients admitted from 2013 to 2022, which included three cases of ICI-related injuries.

Results: Out of the 34 patients, 13 were males and 21 were females. The average ± standard deviation for age was 69.1±17.3 years. ALT and ALP levels were 546.9±554.6 and 1306.2±1643.2, respectively. By type, 16 were hepatocellular, 15 were cholestatic, and 2 were mixed. Among 24 cases subjected to the Drug Lymphocyte Stimulation Test (DLST), 18 tested positive. Scores were notably higher in DLST-positive cases but were lower in ICI-related cases. Distinct groups emerged based on ALT levels for hepatocellular and ALP levels for cholestatic cases.

Discussion: Despite potential false negatives, the DLST remains a valuable diagnostic tool. While the Japan score proves effective for traditional DILI cases, it falls short for ICI-related cases. Both hepatocellular and cholestatic types can be distinctly differentiated through ALT and ALP values, suggesting distinct pathophysiology for each type.

Conclusion: The Japan score is not optimal for diagnosing ICI-induced DILI. The differentiation between hepatocellular and cholestatic types points to distinct underlying pathophysiology.

Abstract Submission No. 100567

P-0032

ONE TAKE WONDER: A CASE OF CELECOXIB INDUCED ACUTE LIVER INJURY

MARIA EMILIA ADENIKE ADEDOJA¹, Lovell B Gatchalian¹

¹Delos Santos Medical Center Quezon City Philippines

INTRODUCTION: Celecoxib is a widely prescribed drug for symptomatic pain control. Data regarding its potential to cause deleterious hepatotoxicity is limited.

CASE PRESENTATION: This case report presents a 42 years old man who developed jaundice less than 24 hours after intake of 1 tablet of Celecoxib (200mg) for a tooth extraction. He had no sign of hepatic encephalopathy, fever nor rash. There was no previous drug allergy nor alcohol intake. Laboratory workup showed elevated serum transaminases, alkaline phosphatase and hyperbilirubinemia with R factor of 9. His Prothrombin time later on progressively dropped. Serologic tests for Hepatitis A, B & C were non-reactive. ANA, anti-SMA, Serum Immunoglobulin G, AMA, and p-ANCA were all negative. Imaging tests of the liver including Triphasic CT scan & MRCP showed no evidence of biliary obstruction. His cholestasis and course of liver disease were prolonged, and ultimately he underwent liver biopsy which showed portal and lobular inflammation and hepatocanicular cholestasis favoring drug-induced liver injury. Celecoxib was withdrawn, Ursodeoxycholic acid and antihistamines were started to address his persistent pruritus. His liver biochemical and function tests gradually improved with symptom resolution after 4 months.

CONCLUSION: Conventional non-steroidal anti-inflammatory drugs like celecoxib may still be associated with significant hepatotoxicity. Prompt discontinuation of the drug is necessary.

Abstract Submission No. 100762

P-0033

Drug-induced liver injury secondary to Rivaroxaban masquerading in Acute Cholangitis & Pancreatitis

Valerie Tian Wei Chew¹, Rahul Kumar¹, Samantha Jingyun Koh¹, Daniel Yan Zheng Lim¹, Lai Mun Want¹

¹Singhealth Cluster, Changi General Hospital Singapore Singapore

Introduction: Rivaroxaban, a newer anticoagulant, is increasingly being used, with a paucity of data on systemic side-effects. In this case, we present a rare case of rivaroxaban induced DILI which initially masqueraded as acute cholangitis and pancreatitis.

Clinical Case: A 76-year-old lady with a history of ischemic heart disease and atrial fibrillation presented with abdominal pain, bloating and jaundice. Liver panel on admission showed total bilirubin 138.9, direct bilirubin 113.9, ALT 343 AST 589 ALP 402 GGT 389, pancreatic amylase 192 and lipase 168. She was screened for viral hepatitis (A/B/C/E/CMV/EBV-all negative) and underwent a cross-sectional imaging with CT Abdomen-Pelvis, which showed dilated common bile duct(CBD) with intra-ductal densities. She later underwent ERCP with extraction of CBD stones. (Table 1)

However, on follow up liver panel remained deranged with worsening of transaminases whereas bilirubin showed improvement (Table 1). Differentials include autoimmune hepatitis or DILI. Liver autoimmune workup were negative, thus patient underwent liver biopsy. Three potential drugs were considered: Amlodipine, atorvastatin and Rivaroxaban (Table 2) Review of drug history revealed that rivaroxaban was recently started and held off for ERCP. Liver biopsy (Figure 1) showed hepatocellular injury lobular inflammation, hepatocyte drop-out and apoptotic hepatocytes involving Zones 3 and 2 lobular parenchyma, in keeping with clinical impression of DILI with rivaroxaban having both highest RUCAM and likelihood score (Table 2) This is further confirmed by improvement of transaminases upon cessation of rivaroxaban.

Clinical Significance: Rivaroxaban is a potential cause for DILI that physicians should be aware of.

Abstract Submission No. 101252

P-0034

Secondary Sclerosing Cholangitis Following Pola-r-CHP Therapy

Hirosi Numao¹, Koji Shimaya¹, Masayoshi Ko¹

¹Aomori Prefectural Central Hospital Aomori Japan

Background: Polatuzumab is an anti-CD79b antibody currently used in the treatment of diffuse large B-cell lymphoma (DLBCL) in conjunction with rituximab, cyclophosphamide, doxorubicin, and prednisolone (P-r-CHP).

Case: A 48-year-old female patient was referred due to liver dysfunction (ALT 1386 U/L, AST 375 U/L, ALP 376 U/L, GGT 806 U/L, LD 241 U/L). The patient had been diagnosed with DLBCL four months earlier and had undergone five courses of P-r-CHP therapy. During the initial stages of chemotherapy, liver enzymes became elevated.
Magnetic resonance cholangiopancreatography (MRCP) conducted after two courses of chemotherapy indicated mild narrowing and dilatation of the intrahepatic bile duct (IHBD). Fortunately, these abnormalities improved following chemotherapy.

Liver biopsy at the time of referral revealed moderate periporal inflammation and fibrosis. After administering Ursodeoxycholic acid, liver function tests improved for three months but worsened thereafter (T-Bil 3.69 mg/dL, ALT 915 U/L, AST 213 U/L, GGT 2038 U/L). A subsequent liver biopsy showed fibrotic expansion and ductular reaction in the portal area. A follow-up MRCP revealed irregular intrahepatic bile ducts with multiple strictures and dilatations, more pronounced than earlier findings. We diagnosed this case as secondary sclerosing cholangitis (SSC). Eventually, the liver function began to improve without additional therapy.

Discussion: This case marks the first instance of SCC following P-r-CHP therapy. Considering the absence of reported SCC induced by R-CHOP therapy, it was highly probable that Polatuzumab was the causative factor.

Conclusion: In cases of liver dysfunction after P-r-CHP therapy, it is necessary to consider the possibility of SSC.

Abstract Submission No. 101381
P-0035

AST/ALT elevation during systemic therapy for HCC and other cancers in the era of immunotherapy

Ryo Izai1, Sadahisa Ogasawara1, Sae Yumita1, Kisako Fujiwara1, Keisuke Koroki2, Masanori Inoue1, Kazufumi Kobayashi1, Naoya Kanogawa1, Soichiro Kiyono1, Masato Nakamura1, Takayuki Kondo1, Shingo Nakamoto1, Naoya Kato1
1Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan

Objective: After the approval of immune checkpoint inhibitors (ICIs), the management and differentiation of immune-related adverse events (irAEs) and other causes of liver injury have become more important for systemic therapy of hepatocellular carcinoma (HCC). We investigated the characteristics of AST/ALT elevations observed during immunotherapy for HCC, and other cancers.

Methods: In the multicenter cohort with advanced HCC (cohort1), 165 patients received atezolizumab plus bevacizumab between October 2020 and September 2021, and in the single center cohort with other cancers, 646 patients (cohort2) received anti-PD-1/PD-L1 antibody, and 53 patients (cohort3) received anti-PD-1 plus anti-CTLA-4 antibody between October 2014 and September 2021 were included in the analysis. Data on AST/ALT elevation were collected retrospectively, and the causes and risks of AST/ALT elevation were analyzed.

Results: The incidence of grade 2 or higher AST/ALT elevation was 13.3% (22/165) in cohort 1, 8.5% (55/646) in cohort 2, and 20.8% (11/53) in cohort 3. Among patients with grade 2 or higher AST/ALT elevations, irAE was diagnosed in 13.5% (3/22) in cohort 1, 34.5% (19/55) in cohort 2 and 63.6% (7/11) in cohort 3. Although AST/ALT elevations were common in cohort 1, only 3 cases were diagnosed as irAE, and only 1 case required corticosteroids. Grade 2 or higher AST/ALT elevations were more common in patients with large intrahepatic tumor volume, suggesting that the cause may be tumor-related.

Conclusions: The differentiation of intrahepatic tumor-related AST/ALT elevations is important for the diagnosis of irAE hepatitis, especially in HCC patients.

Abstract Submission No. 101618
P-0036

Angiotensin Receptor Blockers and Drug-Induced Liver Injury: A Cohort Study Using Common Data Model

Jun Kyu Lee1, Hyun Joo Kim2,3, Na Yeong Son2, Da Hee Jeong2, Myung Sik Yoo2, Bong Gi Kim2, Eu Ni Lee3
1Dongguk University Ilsan Hospital Goyang South Korea, 2Korea Institute of Drug Safety and Risk Management Anyang South Korea, 3Seoul National University Seoul South Korea

Angiotensin receptor blockers (ARBs) are one of the most commonly used anti-hypertensives in South Korea. In 2021, a need for national compensation was acknowledged by the Korea Ministry of Food and Drug Safety for a drug-induced liver injury (DILI) after azilsartan use, the youngest drug among ARBs. Not much has been known about the association between ARBs and DILI. To further investigate ARB-induced liver injuries, we executed a retrospective new-user cohort study using electronic-healthcare data-based common data model database (2017–2021). In this study, patients were designated to treatment groups according to the ARB prescribed at cohort entry, i.e., azilsartan, eprosartan, telmisartan, fimasartan, valsartan, olmesartan, losartan, irbesartan, or candesartan. DILI was operationally defined by adapting the definition from the International DILI Expert Working Group. We conducted cox regression analyses to derive hazard ratios (HRs) and applied propensity score-based inverse probability of treatment weighting. As a result, a total of 229,881 ARB users from 20 university hospitals were included. The crude incidence of DILI ranged from 15.6 to 82.8 by treatment groups. In all treatment groups, the most common type of DILI was the cholestatic type and the majority were of mild severity. In overall, the risk was significantly lower in olmesartan users compared to valsartan users (HR: 0.73 [95% confidence interval (CI): 0.55-0.96]). In patients receiving monotherapy, the risk was significantly higher in azilsartan users compared to valsartan users (HR: 6.55 [95% CI: 5.28-8.12]).

Abstract Submission No. 200231
P-0037

Dapsone Syndrome Relapse: Unraveling a Complex Case

Pukar Thapa1, Neegya Vaidhya2
1Norvic Hospital Kathmandu Nepal, 2HAMS Hospital Kathmandu Nepal

Background: Dapsone syndrome is a rare hypersensitivity reaction marked by symptoms like high fever, maculopapular rashes, hepatitis, lymphadenopathy, and lymphocytosis. Typically, these manifestations occur within the initial 6 weeks of treatment. A reported case involves an individual with borderline tuberculous leprosy who experienced a relapse of this syndrome.

Clinical significance: A relapsing course of Dapsone syndrome is rare and must be identified early for proper management.

Case Report: A 45-year-old female diagnosed with Borderline Tuberculous Leprosy was started on combination of antibiotics containing Dapsone who developed fever along with maculopapular rashes, hepatitis, lymphadenopathy, and lymphocytosis. Typically, these manifestations occur within the initial 6 weeks of treatment. Laboratory investigations revealed lymphocytosis with abnormal liver function.

She was diagnosed with Dapsone syndrome and her Anti-leprotic therapy were stopped and was started on steroids and other supportive measures. Her liver enzymes showed a declining trend and rashes subsided and steroids was stopped. However, after 2 weeks she experienced a recurrence of the same widespread rashes along with deranged liver function. The patient was again treated with intravenous steroids along with other supportive measures. Rashes and swelling subsided within 4 days of starting high-dose steroids along with gradual
improvement in biochemical parameters. She was free of hepatic, dermatological and other parameters in next 4 weeks.

**Conclusion:** Dapsone stands as the primary treatment choice for all types of leprosy, generally well tolerated by patients. Within the spectrum of rare hypersensitivity reactions, Dapsone syndrome emerges. In the mentioned case, the recurrence of dapsone syndrome was observed, and was treated accordingly.

Abstract Submission No. 100056
**P-0038**

**The risk of hepatocellular carcinoma in chronic hepatitis B patients with low-level viremia**

Yu-Ching Chen1,2,3, Chun-Chi Yang1,2, Hsing-Tao Kuo1,2, Ming-Jen Sheu1,2

1Department of Hepato-Gastroenterology, Chi Mei Medical Center, Tainan, Taiwan Tainan Taiwan, 2Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan Tainan Taiwan, 3Department of Public Health, College of Medicine, National Cheng-Kung University, Tainan, Taiwan Tainan Taiwan

**Background:** The past research results show that patients with chronic hepatitis B (CHB) who maintain serum HBV-DNA<2,000 IU/mL of low-level viremia (LLV) are not at low risk of developing hepatocellular carcinoma (HCC). The aim of this study was to investigate the risk and risk factors of HCC in LLV.

**Methods:** This retrospective cohort study includes patients with chronic hepatitis B who received antiviral therapy for more than 12 months at three medical institutions including Chi Mei Medical Center in southern Taiwan, from 2008 to 2020, and patients will be divided into LLV group, maintained virological response (MVR) group comparison. The cumulative incidence of progression to HCC has been assessed using the Kaplan-Meier method. Cox regression analysis is performed to determine the final risk and prognostic factors.

**Results:** During the follow-up period, the 3, 5, and 10-year cumulative HCC risks in the LLV group were 3.56%, 4.96%, and 9.51%, respectively; in the MVR group, they were 3.64%, 4.98%, and 10.54%, respectively (p-value: 0.970). Independent risk factors for HCC in LLV patients identified by multivariate Cox regression analysis were male (adjusted hazard ratio [aHR]: 1.78, 95% CI: 1.04-3.04; P=0.036), age (aHR: 1.05, 95% CI: 1.03-1.07; P<0.001), presence of cirrhosis (aHR: 2.01, 95% CI: 1.7-3.45; P=0.012) and platelets (aHR: 2.19, 95% CI: 1.26-3.79; P=0.005).

**Conclusion:** This study determined important critical factors in the development of HCC in LLV patients. The risk of HCC in patients with LLV status during follow-up was comparable to that in the MVR group.

Abstract Submission No. 100068
**P-0039**

**Macrophage-derived exosomal miRNA-30a-5p transmit interferon antiviral activity via PI3K-AKT axis**

Tao Shen1,4, Li Li1, Jianqiong Wang1, Rongxia Zuo1, Jing Chen1, Qi Yin1,2, Shiheng Xu2, Yu Liang1,2, Xiaoqin Tan1, Chaohui Chen1

1Department of Pulmonary and Critical Care Medicine, Yunnan Provincial Key Laboratory for Clinical Virology, Institute of Basic and Clinical Medicine, The First People's Hospital of Yunnan Province Kunming China, 2Department of Clinical Laboratories, The First People's Hospital of Yunnan Province Kunming China, 3Medical school, Kunming University of Science and Technology, 4Department of Infectious Diseases and Hepatic Disease, Yunnan Province Innovation Team of Intestinal Microecology Related Disease Research and Technological Transformation, the First People's Hospital of Yunnan Province Kunming China

**Background:** Previous reports revealed that IFN-α-induced macrophage-derived exosomes were rich in antiviral molecules. MicroRNA-30a-5p has been shown to act as a cancer suppressing gene in variety of cancers. However, the specific role of miRNA30a-5p in hepatocellular carcinoma and the underlying mechanism remains unclear.

**Method:** Huh7 cell transient transfected with HBV C2 subgenotype plasmid was co-cultured with IFN-α-induced macrophage-derived exosomes or miRNA-30a-5p mimics, respectively. Elisa assay was used to test the HBsAg level. qRT-PCR was used to detect the expression of miR-30a-5p. Scratch assay was performed to determine migration of HCC cells. Western blot was used to detect the PI3K/AKT signaling pathway-related proteins.

**Results:** Huh7-HBV/C2 cells co-cultured with IFN-α-induced macrophage-derived exosomes or miRNA-30a-5p mimics was significantly increased with miRNA-30a-5p expression and down-regulated with HBsAg level. The migration ability of Huh7-HBV/C2 cells was significantly increased and the PI3K-AKT pathway was activated comparing with Huh7 cell. However, the migration ability and activation of PI3K-AKT pathway can be inhibited by IFN-α-induced macrophage-derived exosomes and miRNA-30a-5p mimics.

**Conclusion:** Exosomes can transfer IFN-α-induced miRNA-30a-5p from macrophages to HBV-infected hepatocytes to against HBV replication and inhibit HBV-infected hepatocytes migration via PI3K-AKT signaling axis

**Funding:** This work was supported by the National Natural Science Foundation of China (82160384), in part by the Yunnan Health Commission (L2019003).

Abstract Submission No. 100195
**P-0040**

**TREATMENT OF TENOFOVIR ALAfenamide IN THE CHB**

Tuvshinbayar Narangerel1, Gegebdarkh Baljinnyam2, Amaraa Ravdan2

1Gastroenterology and hepatology department Ulaanbaatar Mongolia, 2Gastroenterology and hepatology department Ulaanbaatar Mongolia

**Introduction:** WHO estimates that 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. The latest data shows that 10.6-11.6 % of Mongolian population are infected with hepatitis B virus infection.

**Goal:** Evaluate the clinical and virological outcome of tenofovir alafenamide treatment in patients with hepatitis B infection.

**Materials and Methods:** The clinical trials have evaluated TAF in HBsAg positive and HBsAg negative HBV patients. The trials have similar design and randomized, single-blind, the subjects are unaware of which group they have been assigned to studies. The primary efficacy endpoint was the proportion of patients with HBV-DNA<291IU/ml at weeks 96. Other virological result endpoints were the proportion of patients with HBsAg seroconversion at weeks 96.

**Results:** The virologic endpoints, an HBV-DNA< 29 IU/ml at weeks 96, was achieved by 243(79.1%) receiving TAF, 111(75.4%) of patients which were non-inferior to the 106(78.5%) patients receiving TDF (95% confidence interval (CI) 9.7-2.5); p = 0.26. After of treatment at week 96, significant higher rates of ALT normalization was seen in the TAF group compared to the TDF group (209(68%) vs 83(64.4%); "vs" 82(60.8%), p = 0.001)

**Conclusion:** At 96 weeks of treatment, patients receiving TAF had significantly smaller reductions in
Methods: surveyed full dose vaccinated and born after 1992, 32.2% had post-transmission of HBV in health care workers (HCWs). We aimed to vaccination. Exposure to blood or body fluids poses a high risk of infection immunity and 51.9% had post-vaccine immunity. The mean anti-HBs titers was 295.50 IU/ml [81.58-949.34 IU/ml].

Results: There are 32.4% (351/1082) were post vaccination immunity, 56.4% (611/1082) had post infection immunity. 90.3 percent of people higher tend to receive all three full doses HBV vaccine than the rest of the group.

Conclusion: The low level of vaccination coverage is relevant to the level of KAP among the HCWs of the country, therefore, intensive campaigns should be conducted with a focus on the particular issue.

Abstract Submission No. 100314
P-0041
Hepatitis B vaccination post serological testing and antibody levels of vaccinated HCWs in Mongolia

Nyamsuren Naranzul1, Nyamdavaa Khurelbaatar1, Byambasuren Amgalan1, Dashchirev Munkh-Orshikh2, Baasankhuu Enkhutuvshin1, Myagmur Dorj2, Oidov Baatarkhuu4
1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2National Cancer Center Ulaanbaatar Mongolia, 3State Second Central Hospital Ulaanbaatar Mongolia, 4Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 5Mongolian Association for the Study of Liver Diseases, Ulaanbaatar Mongolia

Background: In 2012, Ministry of Health and Sports made a decision to vaccinate healthcare workers for 2 doses of hepatitis B vaccine and aimed to increase the immunization coverage. We aimed to assess immunity against HBV among vaccinated HCWs in Mongolia.

Methods: A cross-sectional study involving 1082 HCWs, Blood samples from the subjects were analyzed for HBsAg, anti-HBs, and anti-HBc for HBV serology using ELISA.

Results: 43.7% (587/1348) had post-vaccination immunity, 56.4% (611/1082) had post-infection immunity. 90.3 percent of people who were fully vaccinated against HBV. A significant difference was observed between age groups (χ²=12.57, p<0.001), perception of HBV infection (χ²=8.14, p=0.004), formal attendance to the official training (χ²=28.28, p<0.0001). 1.02 - 1.99 times higher tend to receive all three full doses HBV vaccine than the rest of the group.

Conclusion: There are 32.4% (351/1082) were post vaccination immunity, 56.4% (611/1082) had post infection immunity. 90.3 percent of people who were fully vaccinated against HBV. A significant difference was observed between age groups (χ²=12.57, p<0.001), perception of HBV infection (χ²=8.14, p=0.004), formal attendance to the official training (χ²=28.28, p<0.0001). 1.02 - 1.99 times higher tend to receive all three full doses HBV vaccine than the rest of the group.

Abstract Submission No. 100403
P-0043
PreS1BP Mediates Inhibition of Hepatitis B Virus Replication by Promoting HBx Protein Degradation

Jun Wang1,2,3, Xiaoxue Yuan1,2,3, Yun Wang4, Yu Zhang4, Ming Han5, Hongping Lu5, Yang Zhang6, Jun Cheng6,7
1Peking University Ditan Teaching Hospital Beijing China, 2Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Beijing Institute of Infectious Diseases Beijing China, 4The Division of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 5Hebei Ufu Pharmaceutical Company Ltd Shijiazhuang China

Background: PreS1-binding protein (PreS1BP), recognized as a nucleolar protein and tumor suppressor, influences the replication of various viruses, including vesicular stomatitis virus (VSV) and herpes simplex virus type 1 (HSV-1). Its role in HBV replication and the underlying mechanisms, however, remain elusive.

Methods: We investigated PreS1BP expression levels in an HBV-replicating cell and animal model and analyzed the impact of its overexpression on viral replication metrics. HBV DNA, cccDNA, HBsAg, HBeAg, and HBV RNA levels were assessed in HBV-expressing stable cell lines under varying PreS1BP conditions. Furthermore, co-immunoprecipitation and ubiquitination assays were used to detect PreS1BP-HBx interactions and HBx stability modulated by PreS1BP.

Results: Our study revealed a marked decrease in PreS1BP expression in the presence of active HBV replication. Functional assays showed that PreS1BP overexpression significantly inhibited HBV DNA, cccDNA, HBsAg, HBeAg, and HBV RNA levels. At the molecular level, PreS1BP facilitated HBx degradation in a dose-dependent fashion, whereas siRNA-mediated knockdown of PreS1BP led to an increase in HBx levels. Subsequent investigations uncovered that PreS1BP accelerated HBx degradation via K63-linked ubiquitination in a ubiquitin-proteasome manner. Co-immunoprecipitation assays further established that PreS1BP enhances the recruitment of the proteasome 20S subunit alpha 3 (PSMA3) for interaction with HBx, thereby fostering its degradation.

Conclusions: These findings unveil a unidentified mechanism wherein PreS1BP mediates HBx protein degradation through the K63-linked pathway.
Methods: were inoculated HBV-contained serum. Three of 6 HBV-infected mice (PXB mice, PhoenixBio Co., Japan) were prepared. Five mice were declined to undetectable levels following antiviral therapy with ing three HBV-infected mice were sacrificed after HBV DNA levels were sacrificed after HBV DNA levels reached a plateau. The remain-

Background: Analyzing the impact of hepatitis B virus (HBV) infection on intracellular gene expressions using human liver tissues is difficult to exclude the influence of host immune response. In this study, we analyzed changes in gene expression by using HBV-infected hu-
manized mouse livers under severe immune-suppressive condition.

Methods: Eleven mice carrying human hepatocytes in their livers (PXB mice, PhoenixBio Co., Japan) were prepared. Five mice were sacrificed without HBV infection, as control. The remained 6 mice were inoculated HBV-contained serum. Three of 6 HBV-infected mice were sacrificed after HBV DNA levels reached a plateau. The remaining three HBV-infected mice were sacrificed after HBV DNA levels declined to undetectable levels following antiviral therapy with entecavir and PEG-interferon. Next-generation sequencing (NGS) was performed using human hepatocytes obtained from these 11 mice.

Results: The expression of genes involved in the gonadotropin-releasing hormone receptor pathway, CCKR signaling, integrin signaling, inflammatory pathway, and T cell activation was significantly altered in the liver after HBV infection. After antiviral therapy, the levels of 37 of 89 genes decreased by HBV infection were restored, and the levels of 54 of 157 genes increased by HBV infection were suppressed. Interestingly, among the 54 genes whose expression was increased by HBV infection and decreased by antiviral therapy were genes associated with hypoxia and KRAS signaling.

Conclusions: Several genes associated with cell proliferation and carci-

Background: sCD146 is believed to be associated with liver cirrhosis. However, the association between sCD146 and liver fibrosis progression in HBV-infected patients remains under-researched.

Methods: The study used Western Blot to assess sCD146 in serum of healthy individuals and HBV-infected patients from Beijing Ditan Hospital, comparing expression levels across healthy, CHB, CHB with fibrosis, and cirrhotic subjects, followed by validation through gel electrophoresis analysis.

Results: we detected 240 serum samples utilizing Western Blot, comprising healthy individuals (21.67%), and patients with CHB (40.00%), CHB with fibrosis (11.67%), CHB with cirrhosis (26.67%). In our analysis (figure 1), compared to the control, there was no variation in the CHB group. Differences were noted between the CHB and the CHB with fibrosis groups, but they lacked statistical significance (P=0.082). A marked difference was observed in the CHB with cirrhosis group compared to the other categories (P=0.050), indicating that sCD146 levels elevate in correlation with the increasing severity of fibrosis. To further confirm the molecule detected was sCD146 rather than the membrane receptor-type CD146, we conducted gel electrophoresis analysis, revealing only the extracellular region of CD146, excluding the transmembrane and intracellular segments. Moreover, the relative quantitative value in the CHB with cirrhosis group was higher than that in the control group, which validated our hypothesis regarding sCD146 and was consistent with Western Blot findings.

Conclusion: we discovered sCD146 levels in the serum exhibited an ascending trend with the progression of fibrosis in HBV-infected pa-

sCD146, A Novel Serum Biomarker for HBV-Related Liver Fibrosis Progression

JingYa Yin1, BingQing Yang1, Yue Li2, Shuyan Zhang3, Qi Wang4

1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Department of Pathology, Beling Ditan Hospital, Capital Medical University Beijing China, 3Beijing Key Laboratory of Emerging Infectious Diseases, Institute of infectious diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

Abstract Submission No. 100431
P-0044

Alteration of gene expression after anti-viral therapy in HBV infected chimeric mouse liver

Serami Murakami1, Huarui Bao1, Shinsuke Uchikawa1, Hatsue Fujino1, Atsushi Ono1, Takashi Nakahara1, Etsuke Murakami2, Tomokazu Kawao1, Daiki Miki1, C. Nelson Hayes1, Masatake Tsuge2, Shiro Oka1

1Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan, 2Research Center for Hepatology and Gastroenterology, Hiroshima University Hiroshima Japan

Background: Analyzing the impact of hepatitis B virus (HBV) infec-
tion on intracellular gene expressions using human liver tissues is dif-
ficult to exclude the influence of host immune response. In this study, we analyzed changes in gene expression by using HBV-infected hu-
manized mouse livers under severe immune-suppressive condition.

Methods: Twelve mice carrying human hepatocytes in their livers (PXB mice, PhoenixBio Co., Japan) were pre pared. Five mice were sacrificed without HBV infection, as control. The remained 6 mice were inoculated HBV-contained serum. Three of 6 HBV-infected mice were sacrificed after HBV DNA levels reached a plateau. The remaining three HBV-infected mice were sacrificed after HBV DNA levels declined to undetectable levels following antiviral therapy with entecavir and PEG-interferon. Next-generation sequencing (NGS) was performed using human hepatocytes obtained from these 11 mice.

Results: The expression of genes involved in the gonadotropin-releasing hormone receptor pathway, CCKR signaling, integrin signaling, inflammatory pathway, and T cell activation was significantly altered in the liver after HBV infection. After antiviral therapy, the levels of 37 of 89 genes decreased by HBV infection were restored, and the levels of 54 of 157 genes increased by HBV infection were suppressed. Interestingly, among the 54 genes whose expression was increased by HBV infection and decreased by antiviral therapy were genes associated with hypoxia and KRAS signaling.

Conclusions: Several genes associated with cell proliferation and carci-

A novel inducible uPA transgenic mouse for human liver chimeric model establishment

zhencuan Miao1, Weifeng Yang1, Shujun Liu1

1Beijing Vitalstar Biotechnology Co., Ltd. Beijing China

Human hepatocyte chimeric liver mouse models are valuable in studies on hepatitis viruses, liver-targeted drug development as well as drug metabolism and toxicology. This kind of models, such as uPA-SCID, FRG and TK-NOG, are generally difficult to breed and manipulate and are expensive. We report a new mouse model, URG, which is engineered to overexpress uPA specifically in liver under Tet-On system regulation, and to be Rag2 and Il2rg gene knockout so that allows human hepatocyte engraftment. The URG mice are healthy and normal in breeding. When inducing with Dox, liver injury occurs in the mice, as indicated by the elevated ALT/AST and pale appearance of the livers. Transplanting 1 million primary human hepatocytes into Dox-induced URG mice achieved a high chimeric rate of liver, with up to 9mg/mL of human albumin in serum, and 80% human CK-18 antibody positive stain area in liver sections. With continuous Dox inducing, the human albumin concentration in the mouse serum peaked at around 6 weeks post transplantation and sustained for at least 6 months. Some functional proteins specifically secreted by human hepatocytes, such as ApoCIII, Apo(a), PCSK9, Angptl3, C11NH etc., which are hot targets for new drug development, were also detected in the serum of models. When being inoculated with live HBV isolates obtained from either clinic or supernatant of HBV expressing cell cultures, a high virus titer close to that of hepatitis B patients could be detected. Therefore, URG is an useful mouse strain to establish hu-

sCD146, A Novel Serum Biomarker for HBV-Related Liver Fibrosis Progression

JingYa Yin1, BingQing Yang1, Yue Li2, Shuyan Zhang3, Qi Wang4

1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Department of Pathology, Beling Ditan Hospital, Capital Medical University Beijing China, 3Beijing Key Laboratory of Emerging Infectious Diseases, Institute of infectious diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

Abstract Submission No. 100740
P-0045

Abstract Submission No. 101150
P-0046

A novel inducible uPA transgenic mouse for human liver chimeric model establishment

zhencuan Miao1, Weifeng Yang1, Shujun Liu1

1Beijing Vitalstar Biotechnology Co., Ltd. Beijing China

Human hepatocyte chimeric liver mouse models are valuable in studies on hepatitis viruses, liver-targeted drug development as well as drug metabolism and toxicology. This kind of models, such as uPA-SCID, FRG and TK-NOG, are generally difficult to breed and manipulate and are expensive. We report a new mouse model, URG, which is engineered to overexpress uPA specifically in liver under Tet-On system regulation, and to be Rag2 and Il2rg gene knockout so that allows human hepatocyte engraftment. The URG mice are healthy and normal in breeding. When inducing with Dox, liver injury occurs in the mice, as indicated by the elevated ALT/AST and pale appearance of the livers. Transplanting 1 million primary human hepatocytes into Dox-induced URG mice achieved a high chimeric rate of liver, with up to 9mg/mL of human albumin in serum, and 80% human CK-18 antibody positive stain area in liver sections. With continuous Dox inducing, the human albumin concentration in the mouse serum peaked at around 6 weeks post transplantation and sustained for at least 6 months. Some functional proteins specifically secreted by human hepatocytes, such as ApoCIII, Apo(a), PCSK9, Angptl3, C11NH etc., which are hot targets for new drug development, were also detected in the serum of models. When being inoculated with live HBV isolates obtained from either clinic or supernatant of HBV expressing cell cultures, a high virus titer close to that of hepatitis B patients could be detected. Therefore, URG is an useful mouse strain to establish hu-

sCD146, A Novel Serum Biomarker for HBV-Related Liver Fibrosis Progression

JingYa Yin1, BingQing Yang1, Yue Li2, Shuyan Zhang3, Qi Wang4

1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Department of Pathology, Beling Ditan Hospital, Capital Medical University Beijing China, 3Beijing Key Laboratory of Emerging Infectious Diseases, Institute of infectious diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

Abstract Submission No. 100740
P-0045
Abstract Submission No. 101215
P-0047

Characteristic Changes in the Oral Cavity in Particular the Periodontium with HBV
Vahe Azatyan1,2, Lazar Yessayan1, Melanya Shmavonyan2, Iren Parunakyan3
1Yerevan State Medical University Department of Therapeutic Dentistry Yerevan Armenia, 2Yerevan State medical University Department Infection Diseases Yerevan Armenia, 3Dental clinic “Orthodont” Yerevan Armenia

Background: Interest in the study of combined pathology in recent years is due to the accumulation of new facts, the emergence of new information about the interorgan, intertissue and intercellular levels of interaction in the system of the whole organism. In this regard, the question of the relationship between diseases of internal organs, in particular liver damage of viral etiology (HBV) and oral cavity organs, is relevant. The aim of the study was to study the condition of the periodontium during HBV.

Material and methods: To study the periodontium, 95 patients with HBV were examined: 24 (25.3%) women and 71 (74.7%) men. The average age of the patients was 40.17±13.48. The control group included 100 people without HBV, 38 (38%) women and 62 (62%) men, the average age of patients was 37.99±16.66. The dental status of patients with HBV was assessed and compared with the control group.

Results: The detection rate of periodontal diseases in the HBV patients we examined was 100%. An objective examination of the oral cavity revealed a number of pathological changes in the gums: hyperemia and swelling - in 66.3% (63) cases (p<0.001) compared to the control, cyanosis - 31.6% (30) cases (p=0.038), atrophy - 38.9% (37) and bleeding gums 74.7% (71) (p <0.001) compared with control. Gingival desquamation in 4.2% (4) of HBV (p=0.0545).

Conclusion: Thus, the analysis shows that with HBV, gum disease resembles the clinical picture of inflammatory periodontal diseases, in particular, catarrhal and hypertrophic gingivitis, as well as chronic generalized periodontitis.

Abstract Submission No. 101680
P-0048

Oral combination vaccine against Anthrax & Hepatitis B: development & characterization
Varun Bhargava1, S Bhargava2
1United Institute of Pharmacy Kanpur India, 2Signa College of Pharmacy Kanpur India

Infections are still leading cause of morbidity & mortality & most of which can be prevented by vaccination. However, there are too many vaccines to be administered, increasing cost of immunization. Combination vaccines can answer these problems by development of single vaccine containing all possible antigens.

The goal of present study was to see the effect of 2 antigens when given in combination. Bilosomes can provide needle free, painless approach for immunization. Recombinant hepatitis-B surface antigen(HBsAg) & recombinant protective antigen(rPA) were candidate antigens. Bilosomes containing rPA & HBsAg were prepared by lipid cast film method. Antigen loaded bilosomes were characterized in-vitro for shape, size, antigen entrainment & stability in various body fluids. Fluorescence microscopy was done to confirm the uptake of bilosomes. The in-vitro study comprised of immunization of Balb/c mice & estimation of IgG response in serum & sIgA in various body secretions using specific ELISA.

Bilosomes formed were multilamellar & stable in gastric & intestinal fluids. Fluorescence microscopy suggested that bilosomes were taken up by gut associated lymphoid tissues. In-vivo data demonstrates that combination produced both systemic as well as mucosal antibody responses upon oral administration at higher dose levels as compared to intramuscular immunization but fail to produce any synergistic effect. When rPA & HBsAg given in combination, HBsAg(high dose) potentiates the production of anti-rPA antibody. Also they elicited measurable sIgA in mucosal secretions, while alum adsorbed antigens failed to elicit such responses.

Abstract Submission No. 101681
P-0049

Antibody coated Liposomes for Transmucosal vaccination
Yukti Bhargava1, M Bhargava2
1MAHE Manipal India, 2GTB Hospital Kanpur India

The critical role of vaccine delivery system in "rational vaccine design" has been widely recognized. Thus research work was envisaged involving development of antibody coated liposome for transmucosal immunization against hepatitis-B which may offer increased uptake of nanoplosome through transmucosal surface of nasal route & sustaining release of HBsAg to evoke relatively high IgA titre in mucosal surface.

Liposomes were prepared by lipid cast film method & then IgG antibody was covalently linked on the surface. Coated liposomes were characterized in-vitro for their stability, size, % antigen entrainment & stability. Fluorescence microscopy was performed to confirm deposition pattern in respiratory tract. The in-vivo part of the study comprised of estimation of IgG response in serum & sIgA in various body secretions using specific ELISA.

Observation of fluorescence images of nasal mucosa, lungs & spleen, revealed that these antibody coated liposomes, were significantly taken up by mice respiratory mucosal surface, which made them promising carriers for mucosal vaccination.

Considerable immune responses were produced by developed system that may be due to induction of MALT as well as contribution of peripheral airways. Higher immunity induced by ACL HBsAg may be attributed to its cationic nature, antibody coating & subsequent mucosal adhesive property. Thus mucosal immunization with lipid vesicle through nasal administration may be effective in prophylaxis of diseases transmitted through mucosal routes as well as systemic infections. The strategy can be made more appropriate by determination of paracellular transport, nasal mucociliary clearance, mucosal toxicity assessment etc.

Abstract Submission No. 101682
P-0050

Bipolymer based Novel Nanoparticles in Microsphere System as Vaccine Adjuvant
Gomed Agarwal1, S Bhargava2
1Department of Pharmaceutical Sciences Sagar India, 2Signa College of Pharmacy Kanpur India

Novel strategies are required for achievement of safe & effective immunization beyond conventional strategies. Frequent booster dosing can be avoided by development of mucosal/adjuvant vaccine delivery system, which can produce both humoral & cell-mediated responses. Work envisaged uses combined hydrophilic(gelatin nanoparticles,GN)
with a hydrophobic polymeric system (PLGA microspheres) which creates a biodegradable system for HBsAg delivery. GN & PLGA microspheres were prepared by double emulsification method & composite system by phase separation method. Composites were optimized & characterized \textit{in-vitro} for their shape, size by Scanning & Transmission Electron Microscopy, %antigen entrapment & stability. \textit{In-vivo} study comprised of estimation of IgG response in serum & sIgA in various body secretions along with Fluorescence microscopy. \textit{In-vivo} studies exhibited an initial burst release from GN, degradation of antigen from PLGA microspheres & a continuous release from composite system. This supports hypothesis to formulate single shot vaccine with such system (to mimic booster dosing). Fluorescence studies showed selective uptake of composites by NALT. Humoral response generated by single dose of composites was comparative to marketed formulation receiving booster dose. Composite system generated effective sIgA antibody which was not elicited by marketed formulation. Thus, it could be concluded from present study that bipolymer based composite system are capable to provide sufficient protein stability & can be promising candidate for development of single shot vaccine, not only against Hepatitis but against all those diseases that invade host by mucosal surfaces.

\textbf{Solid Lipid based Nanoparticulate system for effective vaccine delivery}

Riya Bhargava\textsuperscript{1}, M Bhargava\textsuperscript{2}
\textsuperscript{1}Himalayan University Kanpur India, \textsuperscript{2}GTB Hospital Kanpur India

Search for innovative ways of vaccination has intensified recently with declining vaccine coverage & growing public concern about new virulent disease outbreaks. Work envisaged here explores potential of Solid Lipid Nanoparticles (SLN) in efficient protein delivery through surface modifications using subcutaneous route (SC).

SLN were prepared by Solvent Injection Method. Characterization was done by Electron Microscopy, X-Ray Diffraction Analysis, \textit{In-vitro} release, Kinetics of uptake by flow cytometer, Evaluation of cell apoptosis, T-cell proliferative assay, TH1/TH2 cytokine profile & Internalization studies by spectral bioimaging. \textit{In-vivo} study comprised fluorescence studies & estimation of IgG in serum, sIgA in various body secretions using specific ELISA.

Particulate system is better carrier system for immunization because of less diffusivity & restricted movement. SLNs act as signal for phagocytic cells. Surface modified SLNs can entrap greater amount of antigen, are sustained release & rapidly internalized by antigen presenting cells. \textit{In-vitro} T-cell proliferation & induction of TH1 type of immune response clearly marks, potential of this novel carrier system. Fluorescence studies showed better uptake of modified SLNs. Higher & more sustained antibody titers obtained with modified SLNs suggests their better immunological potential. Thus, SC immunization could be an efficient alternative approach for vaccination against hepatitis.

Formulations developed can be further explored for incorporation & delivery of other proteins & peptides should subsequently be subjected to pilot plant scale-up & clinical trial to establish their potential for SC immunization against hepatitis-B.

\textbf{HBV Vaccination Status and Associated Factors among Healthcare Workers in Kampot and Kep, Cambodia}

Savoeun Sok\textsuperscript{1,2}, Chanroth Chhouette\textsuperscript{1,2}, Sothy Men\textsuperscript{3}, Bunthan Nhea\textsuperscript{4}, Ko Ko\textsuperscript{5}, Aya Sugiyama\textsuperscript{1,2}, Akita Tomoyuki\textsuperscript{6}, Junko Tanaka\textsuperscript{1,2}
\textsuperscript{1}Department of Epidemiology, Infectious Disease Control and Prevention Hiroshima Japan, \textsuperscript{2}Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma Hiroshima Japan, \textsuperscript{3}Kep Provincial Health Department, \textsuperscript{4}Kampong Provincial Health Department Kampong Cambodia

\textbf{Background:} Healthcare Workers (HCWs) are at risk of acquiring hepatitis B virus (HBV) infection and are highly recommended to be vaccinated. There is no information about vaccination coverage among HCWs in Cambodia. This study aimed to evaluate vaccination status among HCWs in Cambodia and to identify its associated factors.

\textbf{Methods:} A Cross-sectional study was conducted among HCWs in Kampot and Kep provinces from September to October 2023 using the questionnaire survey. Participants were recruited from 1,309 HCWs in 83 health facilities using systematic random sampling. Vaccination status was described in percentage, and multivariate logistic regression was performed to identify the factors associated with HBV vaccination status.

\textbf{Results:} A total of 259 participants were included in the study. Knowledge of HBV infection and HBV vaccine was 62.9% and 65.6%, respectively. About 60% received the HBV vaccine, of those, 128 (82.6%) received ≥3 doses. HCWs with higher education are more likely to be vaccinated than those with primary degrees [p=0.0067; OR=3.4; CI=1.4-8.3]. Having good knowledge of HBV infection and HBV vaccine is more likely to receive vaccine compared to those who have inadequate knowledge [p<.0001; OR=8.1; CI=3.9-16.8; p=0.0001; OR=4.4; CI=2.1-9.2], respectively.

\textbf{Conclusion:} The vaccination coverage among HCWs is low (60%) compared to Vietnam (83%), Thailand (68%), and Japan (84%). This study found that knowledge of HBV infection and HBV vaccine are good factors associated with vaccination status. Providing education on HBV infection and HBV vaccine to HCWs is needed. Additionally, HBV vaccine could be mandatory for HCWs.

\textbf{HBV genetic structure in some minority groups in Ha Giang province, Vietnam}

Evgeniia Lichnaia\textsuperscript{1}, Nga Bui Thi Thanh\textsuperscript{2}, Daria Starkova\textsuperscript{1}, Olga Petrova\textsuperscript{1}, Nhai Tran Thi\textsuperscript{2}, Cuong Vo Viet\textsuperscript{1}, Alexander Dmitriev\textsuperscript{8}, Olga Kalinina\textsuperscript{1}
\textsuperscript{1}Saint-Petersburg Pasteur Institute Saint-Petersburg Russia, \textsuperscript{2}Joint Russian-Vietnamese Tropical Science and Technology Center Hanoi Vietnam, \textsuperscript{3}Federal State Budgetary Scientific Institution ‘Institute of Experimental Medicine’ Saint-Petersburg Russia, \textsuperscript{4}The Saint Petersburg Institute of Technology Saint-Petersburg Russia

\textbf{Introduction:} The HBV genetic structure is considered one of the drivers to develop chronic infection. HBV genotypes are associated with the level of viral load, the severity of liver damage and the risk of developing hepatocellular carcinoma. The aim of this study was to investigate the genotypic heterogeneity of the HBV population circulating in Hmong living in three districts of Yen Minh, Bac Me, Dong Van of Ha Giang Province, Vietnam.

\textbf{Materials and methods:} Totally, the complete genome of 20 HBV isolates obtained from HBsAg-positive individuals belonging to the
Hmong ethnic group living in Ha Giang province, Vietnam, were amplified using overlapping PCR fragments followed by Sanger sequencing. Analysis of nucleotide sequences was carried out using the Mega program version 10.0 and SimPlot version 3.5.1. Phylogenetic analysis performed using the Maximum-Likelihood method.

**Results:** Based on phylogenetic analysis of the complete genome, seven HBV isolates belonged to rare C8 subgenotype, eight to the C2 subgenotype and five to the B2 subgenotype which are widespread in Vietnam. SimPlot analyses revealed that all five subgenotype B2 isolates had the recombination part belonged to C genotype in the precore/core region of the genome.

**Conclusion:** The genetic structure of the HBV circulating among the Hmong in the Ha Giang province differs from the HBV populations in megalities and agricultural provinces of Vietnam. Molecular genetic studies of regional HBV populations will contribute to effective surveillance of HBV infection and will be useful for predicting the development of the epidemic process in various regions of Vietnam.

Abstract Submission No. 200247
**P-0056**

**Investigating Feasibility and Strategy for Controlling HBV Transmission in Indonesia by Math Model**

**Prijantini Prijantini**, **Aminatus Saadah**

**1Bandung Institute of Technology Bandung Indonesia, 2Telkom University Purwokerto Indonesia**

In Indonesia, Hepatitis B virus (HBV) infection remains a substantial public health challenge that demands immediate interventions to mitigate its impact. The World Health Organization (WHO) has set an ambitious goal of achieving a prevalence of only 0.1% of HBV surface antigen (HBsAg) among Indonesian children by 2030, with the aim of eradicating viral hepatitis as a significant public health threat. Despite commendable progress in hepatitis B control, uncertainties persist regarding the feasibility of attaining this target and the necessary strategies in Indonesia. This study endeavors to assess the feasibility of reaching the WHO’s 0.1% HBsAg prevalence target among Indonesian children by 2030 and pinpoint critical developments required to meet this goal. Employing a dynamic compartmental model that considers both age and time variables, the study captures the intricate dynamics of Hepatitis B virus (HBV) infection, offering insight into the current state of hepatitis B control in Indonesia. The model relies on data and input parameters, likely encompassing historical HBV prevalence rates, vaccination coverage, treatment efficacy, and other pertinent epidemiological and healthcare-related factors specific to Indonesia. Encouragingly, positive trends emerge as HBsAg prevalence steadily decreases across age groups, indicating progress in reducing Hepatitis B infection. Indonesia is projected to be on track to achieve the WHO’s 0.1% HBsAg prevalence target for children under 5 by 2037. The integration of peripartum antiviral prophylaxis (PAP) with existing strategies significantly reduces child HBsAg prevalence, expediting progress with elevated success rates.

Abstract Submission No. 100051
**P-0055**

**Long-term hepatitis B surface antigen profile and seroclearance following antiviral treatment**

**CW HUANG**, **Hsu-Heng Yen**, **Pei-Yuan Su**, **Yang-Yuan Chen**

In Indonesia, Hepatitis B infection remains a substantial public health challenge that demands immediate interventions to mitigate its impact. The World Health Organization (WHO) has set an ambitious goal of achieving a prevalence of only 0.1% of HBV surface antigen (HBsAg) among Indonesian children by 2030, with the aim of eradicating viral hepatitis as a significant public health threat. Despite commendable progress in hepatitis B control, uncertainties persist regarding the feasibility of attaining this target and the necessary strategies in Indonesia. This study endeavors to assess the feasibility of reaching the WHO’s 0.1% HBsAg prevalence target among Indonesian children by 2030 and pinpoint critical developments required to meet this goal. Employing a dynamic compartmental model that considers both age and time variables, the study captures the intricate dynamics of Hepatitis B virus (HBV) infection, offering insight into the current state of hepatitis B control in Indonesia. The model relies on data and input parameters, likely encompassing historical HBV prevalence rates, vaccination coverage, treatment efficacy, and other pertinent epidemiological and healthcare-related factors specific to Indonesia. Encouragingly, positive trends emerge as HBsAg prevalence steadily decreases across age groups, indicating progress in reducing Hepatitis B infection. Indonesia is projected to be on track to achieve the WHO’s 0.1% HBsAg prevalence target for children under 5 by 2037. The integration of peripartum antiviral prophylaxis (PAP) with existing strategies significantly reduces child HBsAg prevalence, expediting progress with elevated success rates.

Abstract Submission No. 200247
**P-0054**

**A comparative trial of metabolic parameters in chronic hepatitis B who were treated with TDF or TAF.**

**Titinan Veerachit-o-larn**, **Thanapat Atthakitmongkol**, **Tawesak Tanwande**, **Nuntakorn Thongtang**, **Wanwarang Teerasamit**, **Watcharasak Chotiyaputta**

**1Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University Bangkok Thailand, 2Division of Endocrinology and Metabolism, Department of Medicine, Siriraj Hospital, Mahidol University Bangkok Thailand, 3Division of Diagnostic Radiology, Department of Radiology, Siriraj Hospital, Mahidol University Bangkok Thailand**

**Background:** Tenofovir alafenamide (TAF) is more widespread use than Tenofovir disoproxil fumarate (TDF) due to lower nephrotoxicity and bone loss. However, TAF is still controversial in poor metabolic outcomes compared to TDF. Aim of the study is to evaluate the effect of TAF and TDF on metabolic parameters and Atherosclerotic cardiovascular disease (ASCVD) risk in chronic hepatitis B (CHB) patients.

**Methods:** A total of ninety CHB patients treated with TDF were enrolled in the study. We randomized to switching to TAF (TAF group, n=46) and continue TDF (TDF group, n=44). Metabolic profiles were assessed at 24-week and 48-week intervals through biochemical test and bioelectrical impedance analysis. The primary outcome was comparing metabolic profile changes from baseline between 2 groups at 48 weeks.

**Results:** The mean age of the patients was 59.4±8.2 years, with a male predominance of 63% and mean BMI was 23.5±4.1 kg/m². The baseline characteristics including body mass index (BMI), fasting blood sugar (FBS), total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), glycated hemoglobin (HbA1C) were similar between both groups. At week 24, the TAF group were significantly higher...
compared to the TDF group in TC, FBS, and HbA1C. The percent changes in waist circumference and BMI in TAF group were also significantly greater than in TDF group. However, patients in TDF group showed significantly increase in creatinine and decline in GFR.

**Conclusions:** For preliminary result (week 24), CHB treated with TAF significantly increased in TC, HDL, FBS, HbA1C, and BMI compared to those treated with TDF.

Abstract Submission No. 100072  
**P-0057**

**Effectiveness and safety of TAF in patients with first-time HBV-related decompensated cirrhosis**

Xin xin Rong¹, Yuan-Yuan Xu¹, Guang-De Yang¹, Xia Wang¹, Juan-Juan Fu¹, Li Li¹, Xiu-Cheng Pan¹

¹Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University Xuzhou China

**AIM:** To evaluate the effectiveness as well as renal and lipid profiles of tenofovir alafenamide (TAF) in patients with first-time hepatitis B virus-related decompensated cirrhosis (HBV-DC).

**METHODS:** In this retrospective analysis, treatment-naive patients with first-time HBV-DC who were treated with TAF from January 1,2020 to December 31, 2022 were screened. We evaluated the virological and serological responses, hepatic and renal function, serum phosphorus and blood lipid changes during 48 weeks of treatment.

**RESULTS:** The final analysis included 52 patients. Mean age was 46 years and 73.1% were male. Baseline median CTP score was 8.37. The proportions of patients achieving undetectable HBV DNA at week 12, 24 and 48 were 38.5%, 63.5% and 84.6%, respectively. The rate of alanine transaminase (ALT) normalization were 71.2%, 82.7% and 82.7%, respectively. Forty (76.9%) patients showed improvement in the CTP score of 2 points at week 48. There were no significant changes in estimated glomerular filtration rate (eGFR) from baseline to week 48. However, of the 10 patients with eGFR<90mL/min/1.73m² at baseline, the eGFR levels increased to over 90mL/min/1.73m² and maintained the level to week 48 in 3 patients. Serum phosphorus increased over time by a mean level of 0.08±0.16mmol/L at week 48(t=3.392, p=0.001). For lipid profile, the levels of TG had no significant changes at each time point when compared to baseline. Low-density lipoprotein cholesterol (LDL-C) level increased by 0.51±0.87mmol/L after 48 weeks of treatment(t=3.383, p=0.002), whereas total cholesterol/high-density lipoprotein cholesterol (TC/HDL-C) levels decreased continuously from 4.73±3.01 to 3.56±1.12.

**Conclusions:** TAF was effective for viral suppression and hepatic function improvement, and had a good renal safety in patients with HBV-DC. However, blood lipid should be closely monitored.

Key words: Chronic hepatitis B; Decompensated cirrhosis; Tenofovir alafenamide; Effectiveness; Safety

Abstract Submission No. 100138  
**P-0059**

**Effectiveness of Solanum Procumbens Combined with Tenofovir in Treatment of Chronic Hepatitis B**

Le Hien¹, Le Quoc Tuan², Dinh Cong Tiep²

¹Thai Nguyen University of Medicine and Pharmacy Thai Nguyen Vietnam, ²103 Cam Khe Clinic Phu Tho Viet Nam

**Aims:** Evaluating the effectiveness of Solanum procumbens (SP) combined with Tenofovir disoproxil fumarate (TDF) in the treatment of hepatitis B virus (HBV).

**Methods:** Study on a randomized controlled clinical trial in HBsAg (+) 150 HBV patients at Cam Khe Clinic from May 2020 to April 2023, who divided into 3 groups treated with: TDF 300mg, TDF 300mg combined with SP 300mg and SP 300mg.

**Results:** Percentages of ALT, AST ≤ 40 UI/L after 6, 12, 18 months of SP-TDF group were higher than the TDF group and SP group (p<0.01). Early response of HBV DNA in the SP-TDF group were higher than in the TDF group and SP group (p<0.01). The rates of response to reduce HBV DNA below the detection threshold in the SP-TDF group after 6, 12, 18 months were higher than TDF group and SP group (p<0.01). The rate of HBeAg (+) to HBeAg (-) in the SP-TDF group after 6, 12, 18 months were higher than the TDF group and SP group (p<0.01). The rate of HBeAg (-) and anti HBe (+) in the SP-TDF group after 6,12, 18 months were higher than the TDF group and SP group (p<0.01).

It quickly reduce AST, ALT values returned to normal in the SP group. Some patients had side effects of headache and epigastric pain in SP-TDF groups.

**Conclusions:** The combination of SP and TDF is more effective than TDF or SP alone in the treatment of HBV.

Abstract Submission No. 100229
Entecavir versus tenofovir disoproxil fumarate in chronic Hepatitis B with severe acute exacerbation

WEI-LUN TSAI1, chi-yang lin1, wei-chih sun1, chia-ming LU1

1Deartmente of Internal Medicine, Kaohsiung veterans general hospital Kaohsiung Taiwan

Background: The efficacy of different nucleo(t)ide analogs in the treatment of CHB with severe acute exacerbation (SAE) remained unclear. Thus, this study aimed to compare the short-term efficacy of TDF and ETV in patients having CHB with SAE.

Methods: We analyzed consecutive patients with treatment-naïve CHB receiving TDF (n = 36) or ETV (n = 65) for SAE. The primary endpoint was overall mortality or receipt of liver transplantation (LT) by 24 weeks. The secondary endpoints are the comparison of ETV versus TDF influences on renal function and virological and biochemical responses at 4, 12, 24, and 48 weeks.

Results: The baseline characteristics were comparable between the two groups. By 24 weeks, 8 (22%) patients in the TDF group and 10 (15%) patients in the ETV group had either died (n= 15) or received liver transplantation (LT) (n = 3) (P = 0.367). Cox-regression multivariate analysis revealed age (P = 0.003), baseline international normalized ratio of prothrombin time (P = 0.024), and early presence of hepatic encephalopathy (P = 0.367) as independent factors associated with mortality or LT. The two groups of patients achieved comparable biochemical and virological responses at 48 weeks. No significant difference was found in the estimated glomerular filtration rate (eGFR) between the TDF and the ETV groups. However, a significant reduction in the eGFR at 48 weeks, as compared with the baseline, was found in each group.

Conclusions: TDF and ETV achieved similar short-term clinical outcomes and treatment responses in CHB patients with SAE.

Abstract Submission No. 100278
P-0061

A Model Based on CHI3L1 for Expecting Liver Severity of Hepatitis B Virus Infections in the IT Phase

Airong Hu1, Su-Wen Jiang1, Jia-Lan Wang2, Xiao-Jun Shi1, Ai-Wu Zhou1, Ken Lin1, Ying Fan1, Meng-Han Jin1, Hao-Jin Zhang2

1Ningbo No. 2 Hospital Ningbo China, 2Wenzhou Medical University Wenzhou China

Background: Whether to treat patients with CHB during the IT period is a matter of ongoing debate. We created and assessed a novel diagnostic model for identifying this question.

Methods: From Nov. 2018 to Dec. 2022, 253 CHB patients underwent liver biopsy at Ningbo No. 2 Hospital, including 44 patients in IT phase. IT patients randomly assigned into two cohorts. Logistic regression model was developed and validated to predict the severity of hepatic inflammatory fibrosis in CHB patients with IT.

Results: CHI3L1, ALB, ALT / AST were identified as independent predictors of liver lesion severity in CHB patients with IT. CHI3L1 and ALT/AST showed a positive correlation with severity, whereas ALB showed a negative correlation with severity. The three were combined to build the model (named as CAA index), which demonstrated good performance. The CAA index achieved an area under the receiver operating characteristic curve (ROC) of 0.916 (95% CI, 0.820 - 1.000), a critical value of 0.539, as well as a sensitivity of 0.800, a specificity of 0.867, a negative predictive value (NPV) of 0.786, and a positive predictive value (PPV) of 0.750. The ROC of the validation set was 0.875 (95% CI, 0.683 - 1.000) with a cut-off value of 0.549, a sensitivity of 0.803, and a specificity of 1.000.

Conclusions: This diagnostic model has some value in diagnosing significant liver tissue damage among CHB patients in the IT phase. It assesses the severity of the patient’s liver lesion severity and helps determine whether treatment is necessary.

Abstract Submission No. 100293
P-0063

Age and concomitant liver diseases are associated with patient’s retention in HBV care continuum

Wai Pan To1, Kwan Lung Ko2, Lung Yi Mak2, James Fung3, Man Fung Yuen2, Wai Kay Seto2

1Department of Medicine, Tung Wah Hospital Hong Kong China, 2Department of Medicine, The University of Hong Kong Hong Kong China, 3Department of Medicine, Queen Mary Hospital Hong Kong China

Background: Despite improvements in the treatment paradigm for chronic hepatitis B (CHB), inadequate linkage to care remains an obstacle and published data on patient’s retention in care post-diagnosis is limited. We aimed to explore factors associated with patient’s retention in the CHB care continuum after diagnosis.

Methods: CHB patients identified from a prior HBV screening programme in Hong Kong in 2015-2016 were recruited for clinical,
virological and transient elastography assessment, as well as questionnaire assessment regarding different socio-economic aspects.

**Results:** 430 CHB patients (34.7% male, median age 61 years) were recruited. 32 (7.4%) had advanced fibrosis (liver stiffness [LS] >9 kPa) while 8 (1.9%) patients were cirrhotic (LS >12 kPa). Concerning retention in care, 208 (67%) patients had attended regular follow-up since the diagnosis and 86 (20%) patients were on anti-viral treatment. Among those untreated (n=344), 50 (14.5%) had indications for treatment (elevated HBV DNA >2000 IU/mL plus abnormal ALT or detectable HBV DNA plus advanced fibrosis/cirrhosis). From multivariable analysis, older age (OR 1.05, 95% CI 1.03-1.07) and the presence of concomitant liver diseases e.g., fatty liver disease (OR 3.07, 95% CI 1.63-5.80) were the two independent factors associated with retention in the CHB care continuum. Socio-economic factors, including family income, occupation and educational level, showed no association.

**Conclusion:** Linkage to care for CHB patients in Hong Kong is suboptimal. Patients of older age and those with concomitant liver diseases are more likely to be retained in CHB care continuum. Enhancement of patient education, especially in the younger generation, is needed.

---

**Abstract Submission No. 100338**

**P-0064**

**Suboptimal rate of management for the prevention of HBV reactivation in immunosuppressive therapy**

Yasuhiro Tanaka1, Daisuke Nakamoto2, Yi Piao3, Hajime Mizutani2, Ryozo Wakabayashi2, Yoshiyuki Saito3, Kyung min Kwon1, Harriet Dickinson5

1Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan, 2Gilead Sciences K.K. Tokyo Japan, 3Datac Inc. Tokyo Japan, 4Gilead Sciences, Inc. Foster City, CA USA, 5Gilead Sciences Europe Stockley Park, Uxbridge United Kingdom

**Background:** Although HBV patients have a risk of reactivation after immunosuppressive therapy (IST), the status of their risk management is not clear in Japan. The aim of this study is to describe the proportion of the appropriate management for the prevention of HBV reactivation when undergoing IST in HBV patients

**Methods:** We conducted a retrospective cohort study using the JMDC Japanese claims database. Patients who had HBV-related diagnoses, underwent two or more HBV-DNA tests between 2011/4/1 - 2021/6/30 (suggestive of mainly HBV carriers or resolved infection as per the Japan Society of Hepatology (JSH) guideline), and who subsequently initiated IST were included. Patients who underwent appropriate HBV reactivation risk management were defined as either 1) receiving prophylactic nucleos(t)ide analogue therapy, or 2) receiving at least one HBV-DNA test every quarter within a 360-day period after initiation of IST.

**Results:** A total of 6,242 patients met the eligibility criteria, with a mean age of 53.01 (+10.8) years old and 55.8% male. The proportions of patients with appropriate management, stratified by the HBV reactivation risk level of IST was: 43.1% (276/641) for high-risk, 40.2% (223/555) for intermediate-risk, and 15.9% (741/4965) for low-risk. Patients who visited large hospitals (with 100+ beds) had higher odds of receiving appropriate management compared with those who visited small hospitals or clinics.

**Conclusion:** Despite the JSH guideline recommending prophylaxis of HBV-related hepatitis in patients going through IST, the appropriate management is not ideal. This is especially the case for ensuring smaller hospitals or clinics, highlighting the need for further educational activities.

---

**Abstract Submission No. 100347**

**P-0065**

**A Real-World Study of Different Antiviral Regimens in Treatment-Naïve CHB with High Viral Load**

Qin Yan1, Chun mei Jiang2, Rongshan Fan3, Sheling Li4, Xue Wu1

1Huazhong University of Science and Technology Union Hospital (Nanshan Hospital) ShenZhen China, 2Department of Infectious Disease, The People’s Hospital of Longhua ShenZhen China, 3Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine ShenZhen China, 4Shenzhen Qianhai Shekou Free Trade Zone Hospital ShenZhen China

**Background:** Treatment-naive CHB patients with HVL often exhibit suboptimal responses to antiviral therapies. This study investigates the real-world efficacy and safety of different antiviral regimens.

**Methods:** Between January 2021 and August 2022, CHB patients with HBV DNA>10^7 IU/mL were collected from four hospitals in Shenzen. The primary endpoint was the proportion of patients with HBV DNA<100 IU/mL at 48 weeks, and other endpoints included changes in HBsAg, HBeAg, ALT, and eGFR at 48 weeks.

**Results:** 391 patients were enrolled in the study, with 296 patients undergoing statistical analysis after baseline characteristics were adjusted using inverse probability weighting. The patients were distributed into four groups: ETV (n=62), TDF (n=89), TAF (n=36), TDF+LDT/ETV (n=109). The proportion of patients achieving HBV DNA<100 IU/mL at 48 weeks was significantly lower with ETV (50%) compared to the TDF (70.8%), TAF (72.2%), and TDF+LDT/ETV (75.2%) (P<0.05). There were no significant differences in HBsAg reduction among the four groups, but the HBeAg seroconversion rate was significantly higher in the TAF group. The ALT normalization rate was significantly higher in the TAF group (72.2%) compared to the others (P<0.05). Stratified analysis of ALT revealed no significant differences in virological response among the four groups when ALT was <1xULN or >4xULN (P>0.05). There were no significant differences in eGFR among the groups.

**Conclusion:** In treatment-naive CHB patients with HVL, combination therapy did not demonstrate superiority over monotherapy in antiviral efficacy at 48 weeks, while ETV was significantly less effective than the others. TAF exhibited superiority in ALT normalization.

---

**Abstract Submission No. 100349**

**P-0066**

**Antiviral therapy and hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance**

Han Ah Lee1, Hwi Young Kim1, Sang Hoon Ahn2, Beom Kyung Kim2, Seung Up Kim2

1Ewha Womans University Seoul South Korea, 2Yonsei University College of Medicine Seoul South Korea

**Background:** Antiviral therapy (AVT) reduces the risk of hepatitis B virus-related hepatocellular carcinoma (HCC). We explored the influence of AVT status at HBsAg seroclearance on the HCC risk after hepatitis B surface antigen (HBsAg) seroclearance.

**Methods:** Patients with chronic hepatitis B (CHB) who achieved HBsAg seroclearance between 2003 and 2022 were retrospectively reviewed. The primary outcome was HCC development after HBsAg seroclearance.

**Results:** Of the study population, 1,280 (84.2%) and 241 (15.8%) patients achieved HBsAg seroclearance without AVT (spontaneous clearance group) and with AVT (AVT-induced clearance group),
respectively. During the follow-up (median 4.3 years), 37 (2.4%) patients developed HCC after HBsAg seroclearance. The cumulative incidence of HCC was similar between the AVT-induced and spontaneous HBsAg seroclearance groups (HR=0.461; P=0.150), whereas it was significantly lower in the AVT-induced than spontaneous HBsAg seroclearance group (HR=0.442; P=0.005). In multivariate analysis, spontaneous HBsAg clearance, ALBI grade ≥2, liver cirrhosis, and platelet count <50×10^9/L were independently associated with the increased risk of HCC development. The newly established risk prediction model based on these variables, ACAP (antiviral therapy, cirrhosis, ALBI, and platelet count) score had time-dependent area under curves of HCC prediction at 5 and 8 years of 0.814 and 0.803, and its Harrell’s C-index was 0.805, respectively. The ACAP score exhibited good discriminative performance in the internal validation and sensitivity analysis, and outperformed existing HCC risk prediction models.

Conclusions: HCC risk differed according to AVT status at HBsAg seroclearance. The newly established risk prediction model may help clinicians to make timely interventions and surveillance strategies.

Abstract Submission No. 100377
P-0067
HBV-DNA Levels, Steatosis and ALT in Hepatitis B: A Cross-Sectional Study

Ninda Septia Yuspari, Suyata Suyata, Vidi Orba Busro, Imam Suprianto, Muhammad Ayus Astoni, Anjhar Akmal Sya’roni

1Dr. Mohammad Hoesin Hospital Palembang Palembang Indonesia, 2Division of Gastroentero-hepatology, Department of Internal Medicine/ dr. Mohammad Husein General Hospital Palembang Indonesia, 3Division of Gastroentero-hepatology, Department of Internal Medicine/ dr. Mohammad Husein General Hospital Palembang Indonesia, 4Division of Gastroentero-hepatology, Department of Internal Medicine/ dr. Mohammad Husein General Hospital Palembang Indonesia, 5Division of Gastroentero-hepatology, Department of Internal Medicine/ dr. Mohammad Husein General Hospital Palembang Indonesia, 6Division of Gastroentero-hepatology, Department of Internal Medicine/ dr. Mohammad Husein General Hospital Palembang Indonesia

Background: The relationship between serum HBV DNA level with steatosis and alanine aminotransferase (ALT) remains controversial. The aim is to find the relationship between HBV-DNA levels with steatosis and ALT in hepatitis B patients.

Methods: An analytic observational study with a cross-sectional design was conducted at Dr. Muhammad Hoesin Central General Hospital in Palembang, Indonesia from June to August 2023. The study included 54 hepatitis B patients who met the inclusion criteria. The data was analyzed using Spearman correlation and one-way ANOVA. A p-value <0.05 was considered significant.

Results: Most of the subjects were under 45 years old, with a median body mass index of 23.5 kg/m2 and a median HBV-DNA level of 21.0 IU/mL. Differences in body mass index were observed based on steatosis grade and ALT levels (p<0.05), but there were no differences in age and gender when stratified by steatosis grade and ALT. A correlation was found between HBV DNA levels and ALT (r = 0.269, p = 0.049). In contrast, no statistically significant differences were detected in HBV DNA levels among patients with varying steatosis grades (p > 0.05).

Conclusion: In patients with hepatitis B, it’s common to have hepatic steatosis. However, the grade of steatosis was not independently associated with HBV-DNA levels but was correlated to ALT levels.

Keywords: HBV-DNA levels, Steatosis, ALT, Hepatitis B

Abstract Submission No. 100384
P-0068
A case of hepatitis B virus reactivation in patient treated with nintedanib

Ryo Shimizu, Yoshiyuki Ida, Yudai Taniguchi, Shiori Kaji, Hiroki Yamada, Shuya Maeshima, Reiko Ashida, Takao Maekita, Mikitaka Iuchi, Masayuki Kitano

1Second Department of Internal Medicine, Wakayama Medical University Wakayama, Japan

The Asian Pacific Association for the Study of the Liver, the Japan Society of Hepatology, the European Association for the Study of the Liver, and other societies have established clinical practice guideline for management of hepatitis B reactivation. Recent years, new tyrosine kinase inhibitors have appeared one after another, therefore it is inevitable that there is a time lag between the launch of new tyrosine kinase inhibitors and the recommendations for hepatitis B virus management in the guidelines. We experienced hepatitis B reactivation in patient treated with nintedanib which was introduced in 2015 for treatment of idiopathic pulmonary fibrosis. The main molecular targets of nintedanib are the fibroblasts growth factor receptor, the platelet-derived growth factor receptor, and the vascular endothelial growth factor receptor. Recently, IL-15 has been reported to contribute to the elimination of hepatitis B virus, and platelet-derived growth factor and platelet-derived growth factor receptors have been implicated in the production and activation of IL-15. We thought that nintedanib may suppress the function of IL-15 by inhibiting platelet-derived growth factor receptors, thereby triggering hepatitis B reactivation. The drug information of nintedanib does not mention hepatitis B reactivation and, to our knowledge, this is the first report of reactivation with this medicine.

Abstract Submission No. 100414
P-0069
Effectiveness and safety of TAF for 48 weeks in ETV-experienced HBeAg-positive CHB Patients

Jiajia Han, Yuqi Liu, Yao Zhang, Xun Qi, Yuxian Huang, Xinxin Zhang, Yunsong Qian, Yonglan Pu, Lihong Qu, Zhili Tan, Yongmei Zhang, Jiming Zhang

1Department of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University Shanghai China, 2Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 3Department of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University Shanghai China, 4Department of Infectious Disease, Taicang Affiliated Hospital of Soochow University, The First People’s Hospital of Taicang Suzhou China, 5Department of Infectious Disease, Shanghai East Hospital, Tongji University School of Medicine Shanghai China, 6Hepatology Department, Ningbo Hwamei Hospital, University of Chinese Academy of Sciences Ningbo China

Background: Tenofovir alafenamide (TAF), as well as entecavir (ETV), is widely used as first-line treatment for chronic hepatitis B (CHB) patients. However, there are few studies concentrating on the effectiveness of sequential therapy from ETV to TAF in patients with maintained high level of HBsAg. We conducted a multicenter prospective cohort study to assess the effectiveness, safety, as well as HBsAg decline and cytokines profile of 48-week TAF treatment in CHB patients who were previously treated with ETV.
Methods: We enrolled 41 CHB patients with ETV-experienced (>1 year), HBeAg positive, complete virological response (HBV DNA < 20 IU/mL), alanine aminotransferase (ALT) > 1 upper limits of normal (ULN, Female: 40 U/L, Male: 50 U/L), HBSAg > 3000 IU/mL and willingness to switch to TAF treatment. Blood samples were collected at 0, 12, 24, and 48 weeks to detect HBSAg level and cytokines (IFN-α3, IP-10).

Results: A total of 41 patients received sequential therapy with ETV and TAF. The medium level of baseline HBSAg was 3.7 log10 IU/mL. After 48 weeks of TAF treatment, HBSAg declined significantly by a mean level of 0.1 log10 IU/mL. Among the patients, 34.1% experienced HBSAg decline during 48 weeks of treatment, IP-10 declined significantly compared with baseline (0W, 12W, 24W, 48W mean: 524.6 vs 369.7 vs 271.5 vs 319.0 pg/mL, all p value < 0.05). Similarly, IFN-α3 level (0W, 12W, 24W, 48W mean: 6.8 vs 6.1 vs 5.6 vs 5.48 pg/mL, p = 0.05). Finally, we found that higher baseline IFN-α3 level was related with the HBsAg decline (p = 0.02) after 48 weeks, and 5 HBeAg clearance patients after the treatment had a higher IFN-α3 at 48 weeks than those not cleared (p = 0.03).

Conclusion: TAF demonstrated a significant ability to decrease HBSAg and good renal safety after 48 weeks of sequential therapy. Moreover, baseline IFN-α3 level may be related with HBSAg decline.

Safety and Efficacy of Tenofovir Alafenamide in patients with CHB and hepatic decompensation

Ming-Lung Yu1,2, Ming-Lun Yeh2, Pin-Nan Cheng3, Chi-Yi Chen4, Yao-Chun Hsu5, Ching-Chu Lo6, Kuo-Chih Tseng7, Ming-Jong Bair8, Sheng-Shun Yang9

1School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan, 2Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital Kaohsiung Taiwan, 3Division of Gastroenterology and Hepatology, National Cheng Kung University Hospital Tainan Taiwan, 4Division of Gastroenterology and Hepatology, Dittmanson Medical Foundation Chia-Yi Christian Hospital Chia-Yi Taiwan, 5Division of Gastroenterology and Hepatology, E-Da Hospital Kaohsiung Taiwan, 6Division of Gastroenterology and Hepatology, St. Martin De Porres Hospital Chia-Yi Taiwan, 7Division of Gastroenterology and Hepatology, Dalin Tzu Chi Hospital Chia-Yi Taiwan, 8Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital Taichung Taiwan

Background/Aim: There are limited safety and efficacy data available to support tenofovir alafenamide (TAF) use in chronic hepatitis B (CHB) patients with hepatic decompensation. We conducted an interim analysis from an ongoing, prospective, multi-center study aimed to investigate the safety and efficacy of TAF in CHB patients with hepatic decompensation.

Patients and Methods: Nucleos(t)ide analogues (NUCs) treatment naïve or experienced (except for TAF) CHB patients with hepatic decompensation (Child-Turcotte-Pugh [CTP] score ≥7), were eligible for enrollment. Enrolled patients initiated TAF 25mg once daily de novo or switch from other NUCs for up to 144 weeks. The viral suppression (HBV DNA < 20 IU/mL), improvement in CTP score, Model for End-stage Liver Disease (MELD) score, and liver-related mortality at 48 weeks of TAF therapy were assessed.

Results: At the time of this interim analysis, 24 patients were enrolled and the majority of whom were male (20/24), with a median (range) age of 60 (24-84) years. Twelve patients had prior NUC experience. Thirteen (54%) patients had liver cirrhosis assessed by ultrasound at enrollment. The median (Q1, Q3) HBV DNA level was 591 (33, 596493) IU/mL, and three were HBeAg positive. The proportion of patients with HBV DNA level < 400 IU/mL also increased from 17% at baseline to 58% at W12, 77% at W24, and 69% at W48. Recovery from hepatic decompensation (CTP ≤ 7) was observed in 12/19 (63%) patients at W12, 10/17 (59%) patients at W24, and 8/13 (62%) patients at W48. The median MELD score declined from 13.4 to 10.0 at W12, 7.7 at W24, and 10.7 at W48. None of the patients received liver transplant and 3 patients died (one each due to GI bleeding, meningitis, and traffic accident). No participants discontinued treatment due to an adverse event and no study drug related serious adverse events have been reported.

Conclusion: After 48 weeks of TAF treatment, hepatic function improved in the majority (62%) of CHB patients with hepatic decompensation at baseline. The safety profile was consistent with the known safety profile of TAF and no new safety concerns emerged. Further investigation of long-term outcomes will be assessed in this ongoing study.
Reduction in the rate of detectable DNA (>500 IU/ml) was 65.22% (15/23). Among them, the rate of abnormal ALT levels was 47.83% (11/23), with a statistically significant difference in ALT levels. The median survival time was 155 days in the ETV group, 189 days in the TDF group, and 26 (57.8%) patients in the ETV stage.

**Conclusion:** The real-world data showed that TAF is more effective than ETV and TDF in improving short-term and long-term survival rates in HBV-ACLF patients and reducing viral load.

**Effectiveness and safety of TAF on patients with hepatitis B-related decompensated cirrhosis**

Bing Qiao1, Yong Zhou1, Weili Cui1, Yajing Li1, Lili Zhang1, Changhe Shi1, Zhijian Yan1, Zhengsheng Liu1

1Qingdao sixth people’s hospital Qingdao China

**Background:** Decompensated cirrhosis is one of the most dangerous stages of chronic hepatitis B patients. TAF is used as a first-line agent, and there are limited data on TAF in decompensated cirrhosis. We aimed to evaluate the safety and effectiveness of TAF in decompensated patients.

**Methods:** A total of 23 patients were enrolled in this study and were evaluated for changes in biochemistry, virology, and liver and kidney function before and after TAF treatment. The maximum follow-up was up to 120 weeks.

**Results:** The mean Child-Pugh score at baseline in the enrolled patients with decompensated cirrhosis was (7.8±2.25), the mean MELD score was (9.08±4.42), and the mean eGFR was (130.70±41.64). Among them, the rate of abnormal ALT levels was 47.83% (11/23), and the rate of detectable DNA (>500 IU/ml) was 65.22% (15/23). 12 patients completed 72 weeks and the mean Child-Pugh score was (3.8±1.60), the mean MELD score was (4.8±2.76), and the mean eGFR level was (139.50±41.82). There was a statistically significant difference in Child-Pugh scores and MELD scores from baseline to 72 weeks of treatment (t=6.379, P=0.001; t=2.746, P=0.025). There is no difference on the eGFR levels before and after TAF therapy (t=0.852, P=0.413). All patients had normal ALT and only 1 patient had detectable HBV DNA. 7 patients completed 120 weeks treatment and no significant changes in ALT, DNA, eGFR, Child-Pugh scores, and MELD scores.

**Conclusion:** In patients with hepatitis B-associated decompensated cirrhosis, long-term TAF therapy significantly improves liver function with high viral suppression and renal safety.

**Alterations in Renal Tubular Function in Real-World CHB Patients on TDF and ETV Administration**

Bing Qiao1, Fei Chen1, Lili Zhang1, Yanyan Miao1, Chengzhen Xu1, Huiyang Fu1, Haixia Li1, He Wang1, Jun Yu1, Jingjing Guo1, Na Guo1, Peng Chen1, Yajing Li1, Zhengsheng Liu1

1Qingdao sixth people’s hospital Qingdao China

**Background:** With aging, CHB patients need more urgent attention to kidney function nowadays. Compared with glomerular function, tubular function plays an important role in early screening of renal function in CHB patients. Therefore, we aimed to understand the rate of abnormal renal tubular function in patients with CHB through a cross-sectional study.

**Methods:** A total of 23 patients were enrolled in this study and were evaluated for changes in biochemistry, virology, and liver and kidney function before and after TAF treatment. The maximum follow-up was up to 120 weeks.

**Results:** The mean Child-Pugh score at baseline in the enrolled patients with decompensated cirrhosis was (7.8±2.25), the mean MELD score was (9.08±4.42), and the mean eGFR was (130.70±41.64). Among them, the rate of abnormal ALT levels was 47.83% (11/23), and the rate of detectable DNA (>500 IU/ml) was 65.22% (15/23). 12 patients completed 72 weeks and the mean Child-Pugh score was (3.8±1.60), the mean MELD score was (4.8±2.76). There is no difference on the eGFR levels before and after TAF therapy (t=0.852, P=0.413). All patients had normal ALT and only 1 patient had detectable HBV DNA. 7 patients completed 120 weeks treatment and no significant changes in ALT, DNA, eGFR, Child-Pugh scores, and MELD scores.

**Conclusion:** In patients with hepatitis B-associated decompensated cirrhosis, long-term TAF therapy significantly improves liver function with high viral suppression and renal safety.
BACKGROUND: Chronic Hepatitis B infection remains an im-
portant health issue in Taiwan, with HCC still ranked top in cancer
incidence and mortality. Finding biomarkers to identify HBV carriers
at higher risk of disease progression remains an important issue. Since
hepatokines are primarily synthesized and secreted by the liver and
have profound effects on whole-body metabolism, it is plausible that
hepatokines may have significant effects on liver biology and diseases
as well.

METHODS: We evaluated the association between circulating hepa-
socin levels and risk of HBV progression including liver cirrhosis,
HCC and liver related death among 2731 subjects in the REVEAL-
HBV cohort in Taiwan.

RESULTS: We found that the risk of developing liver cirrhosis started
to increase and reach statistically significant at the third quartile
(HR=1.15, 95% CI=0.75 – 1.76; HR=3.04, 95% CI=2.13 – 4.34; 
HR=2.85, 95% CI=2.00 – 4.05 for the 2nd, 3rd and 4th quartiles com-
pared to the first, respectively), with a significant dose-response trend
(p<0.001). Higher plasma hepassocin levels were associated with a
two-fold increased risk of HCC when compared to the lowest quartile,
after the adjustment of all other important risk factors. The hazard ra-
tios were 0.81 (95% CI=0.48 – 1.38), 2.35 (95% CI=1.53 – 3.61) and
2.54 (95% CI=1.65 – 3.90) for each incremental quartiles, with a sig-
nificant dose-response trend (p<0.001). Consequently, those with
higher hepassocin levels at baseline were at increased risk of dying
from liver related causes in a dose-response fashion.

CONCLUSION: We found that higher plasma hepassocin levels was
associated with higher chance of being HBeAg and high HBV viral
load, thus leading to higher chance of developing liver cirrhosis, HCC
and eventually died from liver related causes. Hepassocin could be a
good biomarker in predicting the long term disease progression for
chronic HBV carriers.

Abstract Submission No. 100520
P-0076

Ultrasonic HBsAg Next Qualitative assay predicts HBsAg
rebound after therapy discontinuation

Mark Anderson1, Vera Holzmayer1, Michael Stec1, Tiffany
Fortney1, Mary Rodgers1, Seng Gee Lim2,3, Gavin Cloherty1
1Abbott Laboratories Abbott Park United States, 2Division of
Gastroenterology and Hepatology, Department of Medicine, National
University Health System Singapore Singapore, 3Yoon Loo Lin
School of Medicine, National University of Singapore Singapore
Singapore

Few patients lose HBsAg (<0.05 IU/mL) on current therapies and
HBsAg seroreversion after therapy withdrawal is frequent. Currently,
no good predictors of which patients will maintain HBsAg loss and
which will serorevert after therapy discontinuation exist. We used
HBsAg Next (LOD=0.005 IU/mL) to assess whether residual HBsAg
is present in individuals with HBsAg seroreversion compared to those
without. Patients experiencing on-therapy HBsAg loss (<0.05 IU/mL)
from INACTIVE (NCT02992704) and SWAP (NCT01928511) clini-
cal trials were tested with HBsAg Next Qualitative (LOD=0.005 
IU/mL, Abbott Laboratories) during their final treatment week and at
24-weeks after therapy discontinuation. Results were compared to
HBsAg Quantitative (LOQ=0.05 IU/mL, Abbott Laboratories). Be-
tween INACTIVE and SWAP studies, 36 individuals had HBsAg
<0.05 IU/mL, during their final treatment week and 25/36 (69.4%) 
maintained HBsAg <0.05 IU/mL at 24-weeks after therapy
discontinuation while 11/36 (30.6%) had HBsAg seroreversion. 
HBsAg Next was reactive (S/CO≥1.0) during the final treatment week
in 19/25 (76.0%) patients who maintained HBsAg <0.05 IU/mL. At fol-
low-up, 19/20 (95.0%) individuals with on-therapy HBsAg Next non-
reactive results maintained HBsAg <0.05 IU/mL. Relative risk (95% 
CI) of HBsAg Next reactivity and seroreversion was 12.5 (2.476-72.14,
p=0.0003). Low levels of HBsAg detectable with HBsAg Next were
present in nearly all individuals with seroreversion and absent in most
without seroreversion. These results suggest that higher sensitivity
HBsAg assays can predict patients at risk of HBsAg seroreversion af-
ter therapy discontinuation and could aid in identifying candidates for
therapy removal.

Abstract Submission No. 100546
P-0078

Chronic hepatitis B in pregnancy – screening needed, monitor for
flare after cessation

Sushmitha C1, Wei Lun Liou2, Chee Hooi Lim3, Rajneesh
Kumar4
1Singapore General Hospital Singapore Singapore, 2Singapore
General Hospital Singapore Singapore, 3Singapore General Hospital
Introduction: Hepatitis B virus (HBV) infection remains a significant public health concern in Asia, necessitating a focus on reducing mother-to-child transmission. Antiviral therapy is recommended for pregnant women with HBV DNA load exceeding 200,000 IU/ml. We aim to determine high viral load prevalence in pregnant individuals with HBV and study the impact of discontinuing antiviral therapy on postpartum liver function tests.

Methods: In a single-center retrospective audit, data was gathered from pregnant women with chronic HBV referred to a specialist center between August 2015 and August 2023, with medical board approval.

Results: 112 subjects were identified with mean age 34.5 ± 4.4 years, 28 had high HBV DNA (>200,000 IU/ml). 2 were already on treatment, 31 received treatment during pregnancy, 1 declined, and 2 with lower HBV DNA initiated treatment after discussion. 30 received Tenofovir-disproxil-fumarate, and 1 received Tenofovir-Alafenamide. Pregnant patients with HBV DNA >200,000 IU/ml had a mean ALT of 31.46 ± 21.31 U/L, while those with lower HBV DNA had a mean ALT of 19.54 ± 9.76 U/L. All patients were followed after treatment initiation, with no serious adverse events reported. Among 28 subjects with available follow-up data, 7 required restarting treatment due to elevated HBV DNA levels associated with high ALT, all within 6 months post cessation.

Conclusion: High HBV DNA remains prevalent in pregnant females requiring treatment during pregnancy. Post-treatment cessation demands vigilant monitoring, as a notable number of patients experience elevated ALT, necessitating treatment reinstatement.

Abstract Submission No. 100556
P-0079

Prospect and dynamics of novel serum biomarkers of fibrosis in Hepatitis B virus related CLD

Kazizakir Hossain1, Amit Das2, Mamun al Mahtab3, Fatema Tuj Johora4

1Sheikh Russel National Gastroliver Institute and Hospital Mirpur ,1 Bangladesh, 2Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 3Bangabandhu Sheikh Mujib Medical University Dhaka Bangladesh, 4Evercare Hospital Dhaka Bangladesh

Background: Liver biopsy is the gold-standard method for staging liver fibrosis, but the procedure is invasive and expensive. Noninvasive novel serum biomarkers of fibrosis are the current research interest. Cytokeratin (CK)18 is a filament protein which is proteolytically cleaved during liver damage. Chitinase 3-like protein 1 (CHI3L1) is a member of the chitinase family without chitinase activity.

Objectives: To assess the role of serum CK-18 fragment M30 level and serum CHI3L1 level in discriminating mild versus moderate-advanced fibrosis (ALC: 0.84). The difference in median CHI3L1 across the groups was statistically significant.

Results: Serum concentrations of CK18 were not significantly increased in a stepwise fashion from A0 to A3 but were significantly increased in a stepwise fashion from F1 to F3. There was highly significant positive correlation between the stages of fibrosis (F1 to F3) and Serum CK-18 fragment M30 level (r = 0.839; p=0.0157). Importantly, serum M30 CK-18 levels were able to discriminate mild versus moderate-advanced fibrosis (AUC: 0.84). The difference in median CHI3L1 across the groups was statistically significant.

Conclusion: This study found a positive correlation among CK-18 fragment M30, serum CHI3L1 level and hepatic histological severity in patients with HBV-related compensated CLD. So they can be used as potential noninvasive biomarker of fibrosis.

Abstract Submission No. 100578
P-0080

Tenovero alafenamide reduced renal tubular damage in patients of chronic hepatitis B with entecavir

Dingying Zhou1, Lianghui Zhong1, Xingchao Zhang2, Yaqian Mao1, Luni Zhang1, Yuanbin Zhong1
1The First Affiliated Hospital of Nanchang University Nanchang China, 2The School of Public Health,Nanchang University Nanchang China

Background and aims: Urinary α1-microglobulin (α1-MG), β2-microglobulin (β2-MG), urinary N-acetyl-β-glucosaminidase (NAG) and retinol-binding protein (RBP) have predictive effects on renal tubular injury, the purpose of this study is to investigate whether the renal tubular abnormalities in chronic hepatitis B (CHB) patients during long-term entecavir (ETV) treatment cloud be improved after altering to tenofovir alafenamide(TAF).

Method: This study included 224 CHB patients of abnormal renal tubular markers from June 2022 to September 2023, of which 122 patients continuing ETV and 102 patients of altering to TAF for 6 months. Propensity score matching was used to analyze the differences of renal tubular indexes between the continuing ETV treatment and altering to TAF treatment.

Results: A 1:1 propensity score match yielded 62 patients in each treatment group. The baseline characteristics, the ratio of complete virology respond,liver blood phosphorus, the estimated glomerular filtration rate (eGFR), α1-MG, β2-MG, NAG, RBP were comparable between the two groups. After 6 months, the level of eGFR (ETV: 101.5 mL/(min*1.73m²), TAF: 100.1mL/(min*1.73m²), p>0.05), RBP (ETV -0.159, TAF -0.213, p>0.05), the ratio of complete virology response(ETV 87.1%, TAF 91.9%, p>0.05) weren’t statistically different. The difference ratio of α1-MG, β2-MG, NAG, blood phosphorus was statistically significant (p<0.05). TAF decreased more than ETV in α1-MG, β2-MG, NAG (△.ETV -0.159, -0.213, △.TAF -0.121), the ratio of complete virology response(ETV 87.1%, TAF 91.9%, p>0.05) weren’t statistically different. TAF decreased more than ETV in α1-MG, β2-MG, NAG (△.ETV -0.159, △.TAF -0.213), the ratio of complete virology response(ETV 87.1%, TAF 91.9%, p>0.05) weren’t statistically different.

Conclusion: Altering to TAF of CHB patients with renal tubular abnormalities after long-term use of ETV, the treatment efficacy remains comparable and can improve renal tubular damage, indicating that TAF has better renal safety than ETV.

Abstract Submission No. 100593
P-0081

Management of HBV infection in pregnant women in Armenia and case of high viral replication

Narina Sargsyants1, Eleonora Sargsyants2
1National Institute of Health Yerevan Armenia, 2Yerevan State Medical University Yerevan Armenia

Background: The global strategy for elimination of HBV-infection includes a prevalence target of HBsAg in children of five years of age of <0.1% by 2030. Pregnant woman with a viral load ≥200,000 IU/mL may transmit HBV to their infant even when the infant receives the
timely birth dose vaccine, Hepatitis B immune globulin (HBIG) and completes the hepatitis vaccine series.

**Methods:** Guidelines on Management of patients with chronic hepatitis B rely on EASL guidelines from 2017, include approach on preventive treatment with tenofovir disoproxil fumarate (TDF) for PMTCT in HBV DNA ≥200,000 IU/mL was adopted in 2019.

**Results:** Infant vaccination for HBV was introduced in Armenia in 1999 and coverage reached 96.5% for the birth dose and 93.2% for the third dose (2021). In addition, children born from HBsAg-positive mothers also received HBIG from 2021. Treatment with nucleoside analogues, include crucial preventive treatment in pregnant woman with HBV DNA ≥200,000 IU/mL not covered by the state.

22 years old female, HBV-infection diagnosed on 18 week of first pregnancy. Take into account quantitative PCR HBV DNA on 28-week of pregnancy 255.326.321 IU/mL, HBeAg+, TDF was started and continuing up to 12 week after delivery with withdraw according to guidelines. Two years after became pregnant second time, preventive treatment with TDF was restarted.

**Conclusions:** Development of the guidelines and state program on antiviral prophylaxis for PMTCT of HBV-infection in Armenia is important part of elimination strategy. Guidelines should clarify the statement on continuing TDF in women of reproductive age without interruption after 12 weeks from delivery.

**Abstract Submission No. 100601 P-0082**

**Low level of soluble PD-1 is associated with HBsAg loss in Peg-IFNa-treated patients with CHB**

Huili Guo, Xiaoyan Li, Huiying Yu, Qiui Zhao, Zhiliang Gao

1Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, 2Guangdong Provincial Key Laboratory of Liver Disease Research Guangzhou China, 3Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Ministry of Education Guangzhou China

**Background:** It is still suboptimal to achieve loss of hepatitis B surface antigen (HBsAg loss) in chronic hepatitis B (CHB) patients after pegylated interferon alpha (Peg-IFNa)-based treatment, due to the impaired HBV-specific immunity. Herein, we assessed whether repeated soluble programmed cell death-1 (sPD-1) as a novel biomarker could improve the identification of HBsAg loss.

**Methods:** Virologic and immunological biomarkers were examined dynamically in CHB patients who had previously been treated with 48 weeks of NAs followed by 48 weeks of Peg-IFNu. We associated changes in sPD-1 with serial quantitative measurement of HBsAg (qHBsAg), quantitative HBsAg (qHBsAg), HBV-DNA, and alanine aminotransferase (ALT) at the Peg-IFNu start, 12-week, 24-week and 48-week follow-up.

**Results:** Of 229 CHB patients prospectively enrolled, there were 91 participants with HBsAg loss at 48 weeks. The sPD-1 level was significantly associated with qHBsAg (p < 0.0001). Compared with higher sPD-1, lower sPD-1 was associated with HBsAg loss (p < 0.0001). A decline in sPD-1 concentration occurred in both groups, but HBsAg loss was more commonly observed in individuals demonstrating greater declines in sPD-1 levels at 12 weeks. The sPD-1 level at 24 weeks was more closely related to HBsAg loss at 48 weeks, with AU-ROCs of 0.756 (0.512-0.882, p < 0.001).

**Conclusions:** The decreases in sPD-1 during Peg-IFNu treatment were associated with HBsAg level and loss, suggesting its role as a possible predictive biomarker.

**Abstract Submission No. 100643 P-0084**

**IrAEs Occurrence is The Risk Factor for HBsAg Increase and HBV Reactivation in Cancer Patients**

Zeng Yingfu, Pang Jiahui, Li Xinhua, Chong Yutian

1Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

**Background:** Previous studies have indicated the potential of PD-1/PD-L1 inhibitors in the treatment of HBV infection. Since phase III clinical trials in this area have not yet been announced, more information may be obtained if we observe the changes in serum HBsAg and HBV-DNA levels in HBsAg-positive cancer patients receiving PD-1 inhibitors.
**Methods:** To explore the impact of PD-1 inhibitor combinational therapies on Serum HBsAg and HBV-DNA levels and investigate the incidence of HBsAg loss, HBV reactivation (HBVr), and immune-related adverse events (irAEs), a retrospective study including 1195 HBsAg-positive cancer patients who received PD-1 inhibitors between July 2019 and June 2023 was undertaken. The risk factors associated with significant HBsAg fluctuations and HBVr were identified through univariable and multivariable analysis.

**Results:** 180 patients were eligible in this study (Fig 1). With concurrent use of antiviral agents, serum HBsAg levels decreased (P<0.0001) in 129 patients and increased (P=0.033) in 51 patients (Fig 2A), with 7 patients (3.89%) achieved HBsAg loss. HBV-DNA levels were kept undetectable, remained stable at a low level, or decreased in most of the enrolled patients (92.78%). When divided patients into different subgroups, significant HBsAg decreases were discovered in low baseline HBsAg group (P<0.023), HBsAg-erroneous group (P<0.033), non-irAEs occurrence group (P=0.045) and liver cancer group (P=0.047) (Fig 2B-2I). However, 11 patients and 36 patients experienced HBVr (6.11%) and irAEs (20%), respectively, which could lead to discontinuation or delayed use of PD-1 inhibitors. Besides, HBsAg-seropositive (P=0.01) and irAEs occurrence (P=0.02) were identified as independent risk factors for significant HBsAg increase, irAEs occurrence (P=0.01) was identified as the only independent risk factor for HBVr.

**Conclusion:** PD-1 inhibitors combined with antiviral agents may exert therapeutic potential for chronic HBV infection, attention also should be paid to the risk of significant HBsAg increase, HBVr, and irAEs caused by PD-1 inhibitor combinational therapy.

Abstract Submission No. 100644

**P-0085**

**ALTERATION OF FIBROSIS BASED ON FIBROSCAN IN CHRONIC HEPATITIS B PATIENTS AFTER THERAPY IN PALEMBANG**

Rizki Agustina1, Suyata Suyata2, Imam Suprianto3, Vidi Busro4, Ayus Astoni1, Anjab Sya‘roni2

1Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, 2Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, 3Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, 4Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, 5Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, 6Mohammad Hoesin Hospital South Sumatera Palembang Indonesia

**Introduction:** Chronic hepatitis B virus infection is a major global health problem. This infection lead to progressive liver fibrosis. Hepatitis B treatment using Tenofovir, suppressed replication which will improve the degree of fibrosis. The non-invasive method (fibroscan) useful for diagnosing liver fibrosis in chronic hepatitis B.

**Objective:** The study aimed to assess the degree of liver fibrosis using fibroscan and changed in viral load number after receiving nucleoside therapy as a treatment evaluation tools.

**Material and Method:** This is a retrospective longitudinal study using repeated measurements. The subjects were 52 patients received nucleoside analogs (Tenofovir). This research conducted at Mohammad Hoesin General Hospital January to April 2023. The data obtained from secondary data, analyzed using Wilcoxon test.

**Results:** A total of 52 participants, 33 participants male (63.5%) and the rest were female. The lowest pre-treatment fibroscan value in this study was 4.20 kPa with a maximum of 69.5 kPa, while post-treatment with tenofovir, the minimum fibroscan value was 4.30 kPa and a maximum of 30.90 kPa. The minimum amount of HBV DNA viral load pre-treatment is 3x10^6 iu/ml and a maximum of 8.52x10^6 iu/ml, while in post-treatment minimum viral load value is 0 with a maximum of 7.38x10^6 iu/ml.

The Wilcoxon test at the end of the study showed there is a significant changes in the fibroscan value and viral load among the participants (p<0.0001).

**Conclusion:** There is significant improvement in the fibroscan values and viral load after Tenofovir therapy.

**Keywords:** Fibrosis, Chronic Hepatitis B, HBV DNA Viral Load, Nucleoside Analogs

Abstract Submission No. 100682

**P-0086**

**Effect of therapy in liver biopsy-proven inactive carrier CHB patients with nucleos(t)ide analogues**

Na Liu1,2,3, Lulu Zhou4,3, Bing Dong1,3, Jiejing Xin1,3, Xiaohong Gao6, Yingren Zhao1,2, Guanghua Xu4, Yingli He4,2

1Yanan University Affiliated Hospital Yanan China, 2First Affiliated Teaching Hospital, School of Medicine, Xi’an Jiaotong University Xi’an China, 3Liver Disease Research Collaboration Group, National Center for Infectious Diseases Shanghai China

**Aims:** It is controversial to initiate antiviral treatment for inactive carrier (IC) chronic hepatitis B (CHB) patients. Our objective was to analyze the efficacy of nucleos(t)ide analogs (NAs) antiviral treatment in liver biopsy-proven IC patients.

**Methods:** This retrospective cohort included 238 liver biopsy-proven HBsAg-negative CHB patients, with alanine aminotransferase (ALT) less than twice the upper limit of normal (ULN). Patients were divided into IC (n=77), mildly active (MA; n=23) and immune active (IA; n=138), according to baseline ALT and liver biopsy results.

**Results:** Of the enrolled patients, 52.10% were male with a mean age of 40.86 years. The virological response and HBsAg decrease rates were 95.5% and 22.58%, respectively, in IC-phase treated patients, whereas the proportions of virological response and HBsAg decrease were 100% and 50%, respectively, in MA-phase treated patients, which showed no difference with the 96.49% virological response and 33.33% HBsAg decrease rates in IA-phase treated patients. Additionally, there was no significant difference proportions of persistence of normal ALT and persistence of normal LSM between treated group and untreated group among the three groups.

**Conclusions:** NAs showed similar short-term effect in IC-phase patients, MA- and IA-phase patients. Further data in long-term outcomes for each subgroup in this cohort will be important.

Abstract Submission No. 100683

**P-0087**

**TAF in CHB patients with Advanced Fibrosis and Partial Virologic Response to Nucleos(t)ide**

Ming-Lun Yeh1, Chi-Yi Chen2, Pin-Nan Cheng3, Ming-Jong Bair4, Ching-Chu Lo3, Chun-Jen Liu1, Jyh-Jou Chen1, Chi-Ming Tai2, Te-Sheng Chang3, Ming-Lung Yu3

1Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital Kaohsiung Taiwan, 2Division of Gastroenterology and Hepatology, Ditmanson Medical Foundation Chia-Yi Christian Hospital Chia-Yi Taiwan, 3Division of Gastroenterology and Hepatology, National Cheng Kung University Hospital Tainan Taiwan, 4Division of Gastroenterology and Hepatology, Taitung MacKay Memorial Hospital Taitung
Taiwan, 4Division of Gastroenterology and Hepatology, National Taiwan University Hospital Taipei Taiwan, 5Division of Gastroenterology and Hepatology, Chi Mei Medical Center Liouying Taiwan, 6Division of Gastroenterology and Hepatology, E-Da Hospital Kaohsiung Taiwan, 7Division of Gastroenterology and Hepatology, Chiayi Chang Gung Memorial Hospital Chia-Yi Taiwan, 8School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University Kaohsiung Taiwan

**Background/Aim:** The strategy for patients with partial response to nucleotide(s)ide analogue (NUC) remains uncertain. It raised the aim of investigating tenofovir alafenamide (TAF) switching in chronic hepatitis B (CHB) patients with partial response and partial response to other NUCs.

**Patients and Methods:** CHB patients with partial response who were currently on NUC therapy (other than TAF) for >52 weeks with undetectable HBV DNA were enrolled. Enrolled CHB patients on NUC were switched to TAF 25 mg once daily. This is an interim analysis of 96 weeks of TAF treatment. The efficacy and safety of TAF and metabolic parameters on treatment were evaluated at week 48, 72 and 96.

**Results:** Sixty-six patients, including 47 (71.2%) on entecavir, 13 (19.7%) on TDF and 6 (9.1%) on other NUCs, were enrolled (median 56 years, 35 [53%] male). Forty-five patients had completed the 96 weeks of TAF treatment. Thirty-one (47%) patients were HBeAg positive and the median HBsAg titer was 1803 IU/mL at enrollment. The median HBV DNA level declined from 74.5 IU/mL at enrollment to 72nd, and 96th week with HBV DNA th, and 6.2 kPa at 96th week of median HBV DNA level declined from 74.5 IU/mL at enrollment to th, 56 years, 35 [53%] male). Forty-five patients had completed the 96

**Conclusions:** Compared to traditional logistic regression models, the XGBoost model demonstrated superior performance in identifying pregnant women with CHB at risk of postpartum liver function abnormalities. This suggests that machine learning techniques have the potential to enhance the development and validation of predictive models in hepatitis B research.

Abstract Submission No. 100698

**Noninvasive index of initiation for antiviral therapy in CHB patients under 30 years with normal ALT**

Na Liu1, 2, Lulu Zhou1, 2, Bing Dong1, 2, Jiejing Xin1, 2, Xiaohong Gao6, Guanghua Xu1, 2

1Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China. Nanjing China

**Background and objectives:** A certain percentage of pregnant women with chronic hepatitis B (CHB) infection, with or without nucleoside analogues interventions, have hepatitis flares, or even severe disease in the postpartum period. The aim of this study was to develop a predictive model for distinguishing whether a pregnant woman will develop liver function abnormalities after childbirth or not.

**Methods:** We included 725 pregnant women in this study and developed two predictive models using machine learning techniques: Extreme Gradient Boosting (XGBoost) and logistic regression. These models aimed to predict pregnant women who would have ALT levels exceeding 40 U/L within one year after childbirth. We assessed the established models using out-of-sample validation by splitting the sample into training and testing sets in a 3:1 ratio.

**Results:** Out of 725 patients, 21.8% (158) developed abnormal liver function after childbirth. Key predictors of postpartum abnormal liver function included pre-delivery HBeAg status, ALT, GGT, TBA, HbcAb, and HBV DNA levels. The XGBoost model outperformed the traditional logistic regression model in distinguishing between the abnormal and normal liver function groups in both the training and validation sets (AUC, Training set: 0.824 vs. 0.728; Validation set: 0.758 vs. 0.722).

**Conclusions:** Compared to traditional logistic regression models, the XGBoost model demonstrated superior performance in identifying pregnant women with CHB at risk of postpartum liver function abnormalities. This suggests that machine learning techniques have the potential to enhance the development and validation of predictive models in hepatitis B research.

Abstract Submission No. 100705

**Machine learning for predicting postpartum liver function abnormalities in CHB pregnant women**

Yuhao Ju1, Guorong Han1, Guanlun Zhou1

1Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China. Nanjing China

**Background and objectives:** A certain percentage of pregnant women with chronic hepatitis B (CHB) infection, with or without nucleoside analogues interventions, have hepatitis flares, or even severe disease in the postpartum period. The aim of this study was to develop a predictive model for distinguishing whether a pregnant woman will develop liver function abnormalities after childbirth or not.

**Methods:** We included 725 pregnant women in this study and developed two predictive models using machine learning techniques: Extreme Gradient Boosting (XGBoost) and logistic regression. These models aimed to predict pregnant women who would have ALT levels exceeding 40 U/L within one year after childbirth. We assessed the established models using out-of-sample validation by splitting the sample into training and testing sets in a 3:1 ratio.

**Results:** Out of 725 patients, 21.8% (158) developed abnormal liver function after childbirth. Key predictors of postpartum abnormal liver function included pre-delivery HBeAg status, ALT, GGT, TBA, HbcAb, and HBV DNA levels. The XGBoost model outperformed the traditional logistic regression model in distinguishing between the abnormal and normal liver function groups in both the training and validation sets (AUC, Training set: 0.824 vs. 0.728; Validation set: 0.758 vs. 0.722).

**Conclusions:** Compared to traditional logistic regression models, the XGBoost model demonstrated superior performance in identifying pregnant women with CHB at risk of postpartum liver function abnormalities. This suggests that machine learning techniques have the potential to enhance the development and validation of predictive models in hepatitis B research.

Abstract Submission No. 100698

**Influence of Hepatitis B Family History on Antiviral Efficacy in Pregnant Women**

Jing Xu1, Guorong Han1, Guanlun Zhou1

1Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China. Nanjing China

**Objective:** To explore whether hepatitis B pregnant women with or without family history have differences in the distribution of the five items of hepatitis B, and to explore whether family history is an independent influencing factor of antiviral therapy during pregnancy, so as to provide theoretical reference for early clinical treatment of hepatitis B, so as to prevent the occurrence of hepatocellular carcinoma and cirrhosis.

**Methods:** 410 pregnant women with hepatitis B who met the inclusion criteria were collected from the Obstetrical Clinic of the Affiliated Hospital of Nanjing University of Chinese Medicine, 352 of whom had a family history, 303 (86.5%) of whom had a hepatitis B mother, 29 of whom had a hepatitis B father, 35 of whom had no family history, and 23 of whom were unknown. The indicators of hepatitis B, HBV DNA, blood routine, and liver function of the two groups of cases were retrospectively analyzed. The collected data was analyzed using SPSS22.0 statistical software.

**Results:** The decline rate of HBsAg in the antiviral period of pregnant women with family history was faster than that of those without family history (p<0.005).

**Conclusion:** 1) 352 pregnant women with HBV infection had a family history of hepatitis B; 2) Among pregnant women with a family history, HBsAg showed a rapid decrease in antiviral efficacy.
Background: Chronic hepatitis B (CHB) is often concurrent with metabolic abnormality-related fatty liver disease (MASLD), yet there is limited natural history data on this combined dual disease. Therefore, new-onset MASLD may not have a significant impact on the progression of hepatic fibrosis. However, due to the limited study duration and small sample size, these conclusions require further validation.

Methods: We collected data from 268 CHB patients who received TAF at Shenzhen Third People’s Hospital from January 2019 to July 2021. We assessed virological, biochemical, and serological responses at 12 months of TAF treatment, as well as the impact on renal function, calcium-phosphorus metabolism, and lipid profiles.

Results: The TN group included 158 patients, achieving a 77.2% rate of undetectable HBV DNA and a 93.0% rate of ALT normalization at 12-month. The TE group included 110 patients, with an HBV DNA undetectable rate of 97.3% and ALT normalization rate of 92.7% at 12-month. Notably, 32 patients with suboptimal or low viremia experienced substantial improvements in virological response upon switching to or adding TAF. At 12-month, there were no significant changes in SCR, eGFR, serum Ca²⁺, and serum Pi⁻ levels. Among 55 patients with renal dysfunction who switched to TAF, eGFR levels for CKD stage 2 patients increased from 79.34 (75.84, 84.09) ml/min/1.73m² at baseline to 82.60 (74.78, 89.68) ml/min/1.73m² at 12-month (P < 0.05). LDL-C and TG levels increased in the TN group, while TC, LDL-C, and TG levels increased in the TE group, but all increases remained within the normal range.

Conclusion: In both TN and TE CHB patients, TAF demonstrated robust virological response rates and ALT normalization rates with a good safety profile.
optimal viral and immunological control. Prior research has suggested that shifts in gut microbiota may be a contributing factor to these suboptimal treatment outcomes. However, much of this evidence is derived from limited-scale animal studies, lacking substantial support from clinical data.

**Methods:** In this study, we conducted a cross-sectional study on a cohort of ninety CHB patients undergoing standard entecavir treatment. Gut microbiota composition was analyzed based on 16S rRNA sequencing across various strata of infection status, which included high/low levels of HBsAg (threshold was set to 1,000 IU/mL, denoted as S1, S0) and with/without of HBeAg seroconversion (denoted as E0, E1).

**Results:** Significant variances were observed in the microbial composition among patients with different infection statuses. At the phylum level, the E0S0 cohort had a higher proportion of Fircmucutes and a lower proportion of Bacteroidota compared to the E1S1 cohort. Within the same S0 population, the E0 group showed a significant decline in the proportion of Proteobacteria. Similarly, among the E0 group, the proportion of Actinobacterota was notably elevated in the S0 patients. Distinct differences were also observed at the class, order, and family taxonomic ranks.

**Conclusion:** Within the milieu of chronic HBV infection, the host’s gut microbiota could serve as a pivotal factor impacting treatment efficacy or assessing disease prognosis. These findings may indicate the potential role of host-microbiome mechanisms of immune interactions in shaping long-term disease outcomes.

Abstract Submission No. 100761

P-0094

**Prevalence of hep B reactivation in patients receiving non-rituximab immunosuppressive therapy.**

Sakktivel Elangovan1, Wei Lun Liou1, Gayathry Morvil1, Rajneesh Kumar1

1Department of Gastroenterology & Hepatology, Singapore General Hospital Singapore Singapore

**Background:** Hepatitis B virus reactivation (HBVr) may develop in resolved HBV infection patients receiving chemotherapy. Risk of HBVr is perceived to be higher with haematological malignancy but this could be due to the use of stronger immunosuppressive therapy. Non-rituximab agents carry a lower risk of HBVr. We study the risk of HBVr in resolved HBV infection patients receiving non-rituximab therapy.

**Method:** Data of patients with resolved HBV infection receiving non-rituximab therapy who were seen in the hepatitis B immunosuppression clinic in Singapore General Hospital between March 2014 and May 2022 was retrospectively collected. HBVr is defined as detectable HBV DNA from previously undetectable DNA.

**Results:** A total of 111 resolved HBV infection patients who were initiated on non-rituximab chemotherapy did not receive chemoprophylaxis. There were 65(58.6%) females, with a median age of 63 (IQR 13). The most commonly use chemotherapy agent was alkylating agent (45.9%) and cytotoxic agent (39.6%). 9(8.1%) patients developed HBVr. We study the risk of HBVr in resolved HBV infection patients receiving non-rituximab therapy.

**Conclusion:** Risk of HBVr is low in resolved HBV infection patients receiving non-rituximab chemotherapy. Close monitoring for reactivation is a feasible strategy in these patients.

Abstract Submission No. 100835

P-0095

**Enhancing HBV Screening and Monitoring with Electronic Alerts**

Takakazu Nagahara1, Takuya Kihara1, Yukako Matsuki1, Takaaki Sugihara1, Hajime Isomoto1

1Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University Yonago Japan

**BACKGROUND:** Hepatitis B virus (HBV) reactivation is critical for patients undergoing systemic chemotherapy or immunosuppressive therapy. Reactivation of HBV can lead to severe hepatitis, sometimes with fatal consequences. Despite existing clinical guidelines recommending HBV screening and HBV-DNA monitoring, adherence remains suboptimal. To address this gap, we implemented an electronic alert system that prompts pre-treatment HBV screening and in-treatment HBV-DNA monitoring. Our study aimed to evaluate whether this alert system could improve guideline adherence and enhance patient management.

**METHODS:** The electronic alert system was introduced in our hospital in February 2020. We retrospectively analyzed data from 4943 patients treated between July 2014 and February 2022. We compared the rates of HBV screening and HBV-DNA monitoring before and after implementing the alert system.

**RESULTS:** Following the alert system implementation, there were notable improvements in HBs antigen measurement rate (from 96.2% to 98.6%), HBs antibody/HBc antibody measurement rate (from 82.8% to 88.9%), and HBV-DNA monitoring rate (from 56.1% to 82.2%). Subsequently, twenty-three patients undergoing HBV-DNA monitoring tested positive and received a prompt referral to a hepatologist for initiation of nucleotide analogues. CONCLUSION: Electronic alert systems play a crucial role in enhancing the management of HBV reactivation in patients receiving systemic chemotherapy and immunosuppressive therapy by facilitating guideline-directed HBV screening. These systems contribute to better patient outcomes by identifying at-risk individuals promptly.

Abstract Submission No. 100857

P-0096

**The impact of steatosis and steatohepatitis in chronic hepatitis B patients: A longitudinal study**

Bingying Du1, Yan Huang1, Zhili Chen2, Shuying Song1, Rongtao Lai1, Qing Xie1

1Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China, 2Department of Hepatology, Public Health Clinical Center of Chengdu Chengdu China

**Background:** The evidence of the fibrotic effect of NAFLD or NASH in patients with chronic hepatitis B (CHB) remains controversial. Methods: A retrospective cohort study on a liver biopsy population of treatment-naive CHB patients was aimed to compare the cumulative liver cirrhosis incidences for 3 groups according to the NAFLD activity score (NAS): patients without steatosis, patients with simple steatosis and patients with steatohepatitis.

**Results:** Among the 695 CHB patients, 152 patients were found with steatosis (NAS score 1-2) and 91 patients were found with steatohepatitis (NAS score 3-8). Eighty patients developed cirrhosis, with a
median follow-up period of 58 months (IQR: 27-96). The 5-year cirrhosis incidences were 11.7% in patients without steatosis, 17.1% in patients with steatosis (Log rank P = 0.181) and 31.8% in patients with steatohepatitis (P < 0.001). The 10-year cirrhosis incidences were 16.6%, 30.2% (Log rank P = 0.035) and 44.8% (P < 0.001) in the 3 groups, respectively. The presence of simple steatosis and steatohepatitis was associated with higher risks of cirrhosis than the absence of steatosis in CHB patients (hazard ratio [HR] 1.59, 95% confidence interval [CI]: 1.03-2.47, P = 0.037; HR= 3.09, 95% CI: 1.98-4.84, P < 0.001). A similar trend was found in the subgroup who received antiviral treatment within 6 months after liver biopsy.

Conclusions: Comorbidity with NAFLD, especially NASH, promotes the development of cirrhosis over a long-term follow-up in CHB patients. And simple steatosis might cause the difference in a relatively longer period of time.

Abstract Submission No. 100887
P-0097

Comparison of renal events during potent antiviral treatment in patients with chronic hepatitis B
Chien-Wei Su1,3,4, Zhi-Er Chen2, Chia-Chen Hsu1,5, Fan-Hsiu Chao2,3, Yueh-Ching Chou2, Jaw-Ching Wu4

1Division of General Medicine, Department of Medicine, Taipei Veterans General Hospital Taipei Taiwan, 2Department of Pharmacy, National Yang Ming Chiao Tung University Taipei Taiwan, 3School of Medicine, College of Medicine, National Yang Ming Chiao Tung University Taipei Taiwan, 4Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University Taipei Taiwan, 5Department of Pharmacy, Taipei Veterans General Hospital Taipei Taiwan

Background: Renal dysfunction is a major safety concern for patients with chronic hepatitis B (CHB) during long-term nucleos(t)ide analogues (NAs) therapy. We aimed to explore the association between potent NA treatment [entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF)] and the risk of renal dysfunction for patients with CHB.

Methods: This retrospective study enrolled 2155 CHB patients who were treated with ETV (n=1417), TDF (n=498), or TAF (n=240) in Taipei Veterans General Hospital between January 2011 and March 2022. In a 3-year follow-up, the primary outcome was renal dysfunction, which was defined as estimated glomerular filtration rate decreased >30%, or a chronic kidney disease stage worsen ≥ 2 stages compared to baseline.

Result: During NA therapy, the crude incidence rates of renal dysfunction were 4.42 (95% confidence interval CI 3.71-5.28), 3.85 (95% CI 2.79-5.32), and 4.84 (2.61-9.00) per 100 person-years in the ETV, TDF, and TAF groups, respectively. A multivariate analysis showed the independent risk factors for renal dysfunction were older age, history of stroke, lower serum albumin level, higher Charlson Comorbidity Index, higher fibrosis-4 score, and diuretics use, but not NA regimens. The adjusted hazard ratios (aHR) of renal dysfunction among these three NAs were as follows: TDF vs. ETV 1.406; 95% CI 0.950-2.081, P=0.088; and TAF vs. ETV (0.910; 95% CI 0.471-1.758, P=0.778), respectively.

Conclusion: There were no significant differences in the risk of renal dysfunction among patients using ETV, TDF and TAF.

Abstract Submission No. 100903
P-0098

Therapeutic Options for Entecavir-treated Chronic hepatitis B Patients with Low-level Viremia
Lilin Wang1, Junfeng Lu1, Dan Liu2, Shan Ren3, Wei Hou1, Lina Ma1, Xinyue Chen2, Zhongjie Hu1, Sujun Zheng3

1Beijing YouAn Hospital, Capital Medical University Beijing China

Objective: The aim of this study was to compare the efficacy of switching to TAF monotherapy with combination of entecavir with IFN treatment in entecavir-treated CHB patients with LLV.

Methods: This was a retrospective cohort study. Patients with CHB, treated with oral entecavir for more than 48 weeks between December 2018 and December 2021 at Beijing You’an Hospital, Capital Medical University, who had continuously detectable HBV DNA levels but less than 2000 IU/mL, were included. These patients were divided into TAF monotherapy group (TAF group) and entecavir combined with IFN group (IFN group). They were followed for 48 weeks. The therapeutic efficacy of the different therapies was analyzed.

Results: A total of 105 LLV patients, including 67 males and 38 females, were included. 65 patients (61.9%) were in the TAF group and 40 patients (38.1%) in the IFN group. The CVR rates at 48 weeks in the IFN group were similar to those in the TAF group, with no statistically significant difference (75.0% vs. 75.4%, P = 0.181). The 10-year cirrhosis incidences were 4.42 (95% confidence interval CI 3.71-5.28), 3.85 (2.61-9.00) per 100 person-years in the ETV, TDF, and TAF groups, respectively. A multivariate analysis showed the independent risk factors of advanced liver fibrosis. The risk of advanced liver fibrosis among patients using ETV, TDF and TAF.

Conclusion: For entecavir-treated CHB patients with LLV, switching to TAF monotherapy demonstrated comparable efficacy to entecavir combined with IFN treatment.

Abstract Submission No. 100915
P-0099

Risk factors for liver inflammation or fibrosis in HBeAg-positive indeterminate phase CHB Patients
Jiejing Xin1,2, Bing Dong1,2, Lulu Zhou1,2, Xiaohong Gao1,2, Guanghua Xu1, Na Liu1,2

1The Affiliated Hospital of Yan’an University Yan’an, Shannxi China, 2Liver Disease Research Collaboration Group, National Center for Infectious Diseases Shanghai China

Objective: To analyze the risk factors of advanced liver inflammation or fibrosis in HBeAg-positive CHB Patients with normal ALT

Methods: A retrospective study of 72 liver biopsy-proven patients were divided into mild (Metavir stage <2) and severe (Metavir stage ≥2) inflammation groups (48cases vs. 24cases) or fibrosis groups (44 cases vs.28cases).

Results: Logistic regression analysis identified three independent predictors of advanced liver inflammation or fibrosis in HBeAg-positive CHB Patients with normal ALT. For each one-unit increase in the values of the above indicators, the probability of significant inflammation of liver tissue increases by 2.568 times, 9.2% and 75.3%. The AUC of above indicators in diagnosing advanced liver inflammation were 0.701, 0.662, and 0.661, respectively. The cutoff values of above indicators, were 7.8glIU/mL, 29.5U/L, and 8.05kpa respectively. The accuracy of the above three indicators combined diagnosis was the highest (AUC = 0.87), which was higher than the AUC of the indicators diagnosing advanced liver inflammation individually. Family history of hepatitis B and LSM were independent risk factors of advanced liver fibrosis. The risk of advanced liver fibrosis in patients with family history of hepatitis B...
was 8.135 times higher than that without. For each one-unit increase in LSM was associated with a 48.5% increase in the risk of advanced fibrosis. The cutoff value of LSM was 8.05kpa.

**Conclusion:** HBV DNA, ALT, LSM and Family history might be important clues for us to identify immune-Active CHB from immune-tolerant CHB.

**Risk factors for liver inflammation or fibrosis in HBeAg positive uncertain phase CHB Patients**

Jiejing Xin1,2, Bing Dong1,2, Lulu Zhou1,2, Xiaohong Gao1,2, Guanghua Xu1, Na Liu1

1Affiliated Hospital of Yan’an University Yan’an, Shaanxi China, 2Liver Disease Research Collaboration Group, National Center for Infectious Diseases Shanghai China

**Objectives:** To analyze the risk factors of advanced liver inflammation or fibrosis in HBeAg-positive hepatitis B indeterminate phase Patients with normal ALT

**Methods:** A retrospective study of 72 liver biopsy-proven patients were divided into mild (Metavir stage <2) and severe (Metavir stage ≥2) inflammation groups (48 cases vs. 24 cases) or fibrosis groups (44 cases vs. 28 cases).

**Results:** Logistic regression analysis identified three independent predictors of advanced inflammation: HBV DNA, ALT, and LSM. For each one-unit increase in the values of the above indicators, the probability of significant inflammation of liver tissue increases by 2.568 each one-unit increase in the values of the above indicators, the probability of significant inflammation of liver tissue increases by 2.568.

**Conclusion:** HBV DNA, ALT, LSM and Family history might be important clues for us to identify immune-Active CHB from immune-tolerant CHB.

**Distributional characteristics of HCV genotyping in HIV/AIDS population in Yunnan, China**

Xiao Li1, Xinping Yang1, Quanying He1, Shifang Liu1, Cuifen Wang2, Lijuan Kang1, Junyi Liu1, Yantao Zhu1, Jiali Wang1, Canzhuang Shang1, Xiao Song1, Huqin Li2

1Kunming Medical University; Kunming, Yunnan, China Yunnan, 2Yunnan Provincial Infectious Disease Hospital Kunming Yunnan, 3Dali University Kunming Yunnan

**Objective:** To understand the distribution characteristics of HCV genotypes in the HIV and hepatitis C virus (HCV)-infected population at the antiretroviral clinic of Yunnan Provincial Infectious Disease Hospital, and to provide a basis for individualized treatment of HIV/HCV patients.

**Methods:** Clinical data of 232 HIV/HCV patients in the antiviral outpatient clinic of Yunnan Provincial Infectious Disease Hospital were collected from January 2022 to July 2023, and their HCV genotypes were detected.

**Results:** HCV genotyping was completed in 232 cases (95.47%), and four HCV genotypes (type 1, type 2, type 3, type 6) and nine gene subtypes (1b, 2a, 3a, 3b, 6a, 6n, 6u, 6x) were detected. There were 95 cases of gene type 3b (40.95%), 64 cases of gene type 3a (27.59%), 34 cases of gene type 1b (14.66%), 22 cases of gene type 6n (9.48%), 6 cases of gene type 6a (2.59%), 4 cases of gene type 6xa (1.72%), 3 cases of undetectable type (1.29%), 2 cases of gene type 2a (0.86%), and Gene 6u type 1 (0.43%), Gene 6v type 1 (0.43%). Hepatitis C genotyping of HIV/HCV co-infected patients with different routes of infection showed statistically significant differences (X² = 45.29, P < 0.001).

**Conclusion:** The distribution of HCV genes in HIV/HCV co-infected patients at the Antiviral Clinic of Yunnan Infectious Diseases Hospital was diverse, with type 3a and 3b as the main prevalent strains, and the route of infection was predominantly among intravenous drug addicts. The progression of liver fibrosis or cirrhosis was more pronounced in the HCV gene type 3b.

**Effect of IFN-based Therapy in CHB Patients with Low-Level Viremia (OASIS project subgroup analysis)**

Ruirui You1, Yiqi Yu1, Guojun Li2, Qian Zhang1, Yulei Sun1, Feng Sun1, Xiaoping Wu3, Chao Qiu1, Wenhong Zhang1

1Department of Infectious Diseases, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University Shanghai China, 2Institute for Hepatology, Shenzhen Third People’s Hospital Shenzhen China, 3Department of Infectious Diseases, The First Affiliated Hospital of Nanchang University Nanchang China

**Background:** Chronic hepatitis B patients with low-level viremia (LLV, HBV DNA <2,000 IU/mL) have higher risk for cirrhosis and hepatocellular carcinoma. However, evidence on optimizing therapeutic regimens for LLV remains limited.

**Method:** This analysis drew upon subgroup data from a multi-center, prospective real-world study (OASIS Project) from China, focusing on LLV patients at baseline. Virological and serological responses were assessed at 48 weeks of follow-up and were compared using chi-square tests.

**Results:** A total of 1640 LLV patients were categorized into five groups—A (Maintaining the same NAs, n = 489), B (switching to another NAs, n = 38), C (Maintaining the same NAs & adding PegIFNα, n = 892), D (switching to another NAs & adding PegIFNα, n = 77), and E (Cessing NAs & switching to IFN monotherapy, n = 144). Group B had the highest CVR rate (76.9%) while Group E had the lowest (42.5%). The rates in Groups A (63.8%), C (60.6%), and D (62.5%) were similar. The differences among five groups were not significant (p = 0.069). However, IFN outperformed NAs regarding HBsAg seroconversion. (15.8% vs. 3.4%, p < 0.001).

**Conclusions:** For LLV patients, PegIFNα-based therapy had limited benefit in achieving CVR, but outperformed NAs regarding functional cure.
48 weeks outcome of switching from ETV to TAF in chronic hepatitis B patients

Bo Wei1, Hua Mei2, Xinghao Cao3

1Department of infectious diseases, Changzheng Hospital, Naval Medical University Shanghai China, 2Changzheng Hospital, Naval Medical University Shanghai Shanghai China, 3Changzheng Hospital, Naval Medical University Shanghai China

Background: Real world data showed that switching from entecavir (ETV) to tenofovir alafenamide fumarate (TAF) could effectively improve viral suppression. However, long term outcome regarding to HBsAg level changes is uncertain.

Methods: In this single-center, prospective study, we enrolled patients who received ETV treatment for over 48 weeks at our hospital from 2015 to 2021. Eligible patients started treatment with TAF (TAF group) or continued ETV therapy (ETV group) for another 48 weeks according to their willing. The primary goal was to investigate 48 weeks outcome of HBsAg changes. Data on liver and renal function were also collected.

Results: 54 patients were enrolled, among whom 27 switched to TAF and 27 continued ETV treatment. Median age, gender, duration of prior ETV treatment, HBsAg level are listed in table 1. Patients in both groups exhibited a favorable virological response prior to treatment modification (HBV DNA < 50 IU/mL). TAF group exhibited a significant reduction in HBsAg level compared to ETV group after 48 weeks. ALT and eGFR were slightly improved in both group but without significance (Figure 1).

Conclusions: Patients with CHB can achieve improved reduction of HBsAg by Switching ETV to TAF, which may have significance of being foundation of HBV cure in the future.

Abstract Submission No. 100945
P-0104

TDF vs TAF on Risk of Osteoporotic Fracture in Patients with Chronic Hepatitis B

Hyung Joon Kim1, Eunju Kim2, Hyun Woong Lee3, Soon Sun Kim4, Eileen Yoon5, Jong-In Chang2, Young Youn Cho1, Gi Hyeon Seo2

1Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea Seoul South Korea, 2Department of Gastroenterology, Chung-Ang University Gwangmyeong Hospital Gwangmyeong Korea, 3Department of Internal Medicine, Yonsei University College of Medicine Seoul Korea, 4Department of Gastroenterology, Ajou University School of Medicine Suwon Korea, 5Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine Seoul Korea

Background: As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating chronic hepatitis B (CHB) patients with aging and systemic diseases. Patients treated with tenofovir alafenamide (TAF) have improved bone mineral density loss compared to patients treated with TDF. Although improvements in bone density caused by TAF have been reported, studies on the actual reduction of fractures are insufficient. Therefore, we aimed to evaluate the impact of TAF on the risk of osteoporotic fractures in comparison with that of TDF.

Methods: A retrospective cohort study was conducted on 32,582 CHB patients who had been initially treated with TDF or TAF between November 2017 and December 2020, using the national claims data of the Health Insurance Review and Assessment Service. The numbers of patients treated with TDF and TAF were 20,877 and 11,705, respectively. The annual fracture rate per 100 patients in each group was calculated, and the Cox proportional hazard ratio (HR) was analyzed after applying inverse probability treatment weights (IPTW) for both groups.

Results: Among 32,582 patients, the average age was 47.8±11.2 years, 64.5% were men, and the follow-up period was 24.4±11.6 months. The incidence of osteoporotic fractures was 0.78 and 0.49 per 100 person-years in the TDF and TAF groups, respectively. After application of IPTW, the HR was 0.68 (95% confidence interval 0.55–0.85, p-value=0.001).

Conclusion: TAF-treated CHB patients had a significantly lower risk of osteoporotic fracture than that of TDF-treated patients.

Abstract Submission No. 100948
P-0105

SLC22A1 predicts the outcome of Pegylated IFNα-based treatment for HBeAg-negative CHB patients.

Huiling Yu1, Xiuxing Pang1, Na Gao1, Qiyi Zhao1, Zhiliang Gao1

The Third Affiliated Hospital, Sun Yat-sen University Guangzhou China

Background: Pegylated IFNα-based treatment is the most common therapy for HBeAg-negative chronic hepatitis B patients to pursue clinical cure, but there is great heterogeneity in efficacy among different populations. SLC22A1 belongs to solute carrier family, specially expressed on the basolateral membrane of hepatocytes and its relationship with CHB has not been reported. We aim to explore the correlation between SLC22A1 and curative effect of peg-IFNα-based treatment.

Methods: CHB patients whose HBeAg were negative, HBV DNA < 100 IU/mL, HBsAg <1200 IU/mL and treated with peg-IFNα combined with nucleoside analog or not for at least 48 weeks were included. Their plasma at baseline, 12 weeks and 24 weeks after treatment was quantitatively detected for SLC22A1 by ELISA and their clinical data was analyzed together.

Results: A total of 128 patients whose age, sex and quantitative HBsAg at baseline were matched were included in this analysis, 65 uncured and 63 cured after 48-week treatment. The plasma SLC22A1 was higher in group cured than in group uncured at 12-week (p<0.0001) and 24-week (p<0.0001). The level of SLC22A1 increased in group cured with treatment, whereas stayed unchanged in group uncured (figure1). For the prediction of HBsAg clearance, AUROC of SLC22A1 at baseline, 12-week and 24-week were respectively 0.5495 (p=0.3345), 0.7979 (p<0.0001), 0.9148 (p<0.0001) (figure 2).

Conclusions: The plasma SLC22A1 is involved in the outcome of peg-IFNα-based treatment for HBeAg-negative chronic hepatitis B patients. The elevation of SLC22A1 during treatment predicts a higher clinical cure rate.

Abstract Submission No. 100920
P-0106

Effects of PegIFNa and NAs on Liver Fibrosis in CHB Patients (OASIS Project Subgroup Analysis)

Ruirui You1, Yiqi Yu1, Guojun Li2, Qiran Zhang1, Yulei Sun1, Feng Sun1, Xiaoping Wu1, Chao Qiu1, Wenhong Zhang1

1The Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 2Changzheng Hospital, Naval Medical University Shanghai China, 3Changzheng Hospital, Naval Medical University Shanghai China, 4Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea Seoul South Korea, 5Health Insurance Review and Assessment Service Seoul Korea

Background: As tenofovir disoproxil fumarate (TDF) requires long-term use, a reduction in bone density should be considered a possibility when treating chronic hepatitis B (CHB) patients with aging and systemic diseases. Patients treated with tenofovir alafenamide (TAF) have improved bone mineral density loss compared to patients treated with TDF. Although improvements in bone density caused by TAF have been reported, studies on the actual reduction of fractures are insufficient. Therefore, we aimed to evaluate the impact of TAF on the risk of osteoporotic fractures in comparison with that of TDF.

Methods: A retrospective cohort study was conducted on 32,582 CHB patients who had been initially treated with TDF or TAF between November 2017 and December 2020, using the national claims data of the Health Insurance Review and Assessment Service. The numbers of patients treated with TDF and TAF were 20,877 and 11,705, respectively. The annual fracture rate per 100 patients in each group was calculated, and the Cox proportional hazard ratio (HR) was analyzed after applying inverse probability treatment weights (IPTW) for both groups.

Results: Among 32,582 patients, the average age was 47.8±11.2 years, 64.5% were men, and the follow-up period was 24.4±11.6 months. The incidence of osteoporotic fractures was 0.78 and 0.49 per 100 person-years in the TDF and TAF groups, respectively. After application of IPTW, the HR was 0.68 (95% confidence interval 0.55–0.85, p-value=0.001).

Conclusion: TAF-treated CHB patients had a significantly lower risk of osteoporotic fracture than that of TDF-treated patients.

Abstract Submission No. 100948
P-0105

SLC22A1 predicts the outcome of Pegylated IFNα-based treatment for HBeAg-negative CHB patients.

Huiling Yu1, Xiuxing Pang1, Na Gao1, Qiyi Zhao1, Zhiliang Gao1

The Third Affiliated Hospital, Sun Yat-sen University Guangzhou China

Background: Pegylated IFNα-based treatment is the most common therapy for HBeAg-negative chronic hepatitis B patients to pursue clinical cure, but there is great heterogeneity in efficacy among different populations. SLC22A1 belongs to solute carrier family, specially expressed on the basolateral membrane of hepatocytes and its relationship with CHB has not been reported. We aim to explore the correlation between SLC22A1 and curative effect of peg-IFNα-based treatment.

Methods: CHB patients whose HBeAg were negative, HBV DNA < 100 IU/mL, HBsAg <1200 IU/mL and treated with peg-IFNα combined with nucleoside analog or not for at least 48 weeks were included. Their plasma at baseline, 12 weeks and 24 weeks after treatment was quantitatively detected for SLC22A1 by ELISA and their clinical data was analyzed together.

Results: A total of 128 patients whose age, sex and quantitative HBsAg at baseline were matched were included in this analysis, 65 uncured and 63 cured after 48-week treatment. The plasma SLC22A1 was higher in group cured than in group uncured at 12-week (p<0.0001) and 24-week (p<0.0001). The level of SLC22A1 increased in group cured with treatment, whereas stayed unchanged in group uncured (figure1). For the prediction of HBsAg clearance, AUROC of SLC22A1 at baseline, 12-week and 24-week were respectively 0.5495 (p=0.3345), 0.7979 (p<0.0001), 0.9148 (p<0.0001) (figure 2).

Conclusions: The plasma SLC22A1 is involved in the outcome of peg-IFNα-based treatment for HBeAg-negative chronic hepatitis B patients. The elevation of SLC22A1 during treatment predicts a higher clinical cure rate.
Background: The debate persists regarding whether PegIFNα is superior to Nucleos(t)ide Analogues (NAs) in improving liver fibrosis. This analysis aims to evaluate the liver fibrosis progression using liver stiffness measurements (LSM) offered by transient elastography (TE) examination.

Methods: This analysis was conducted in the data from a multicenter, prospective real-world study (OASIS project) in China. Patients were categorized into five groups with LSM of 7.3, 9.7, 12.4, and 17.5 kPa as thresholds. Changes in LSM across categories were defined as fibrosis regression or progression, while changes in the same category as indeterminacy. Comparisons were conducted using Chi-Square test, one-way ANOVA, and Kruskal-Wallis (K-W) test.

Results: A total of 331 patients who underwent TE examination at baseline and 48-week follow-up were included. At 48 week, the proportion of patients with fibrosis regression in IFN group was slightly lower than NAs group, but not statistically significant (20.0% vs. 24.6%, p=0.499). Similar conclusions were drawn in both HBeAg(+) (29.1% vs. 33.3%, p=0.647) and HBeAg(-) (19.0% vs. 23.5%, p=0.492) subgroups. Further analysis of the PegIFNα sub-group revealed that patients with fibrosis progression had a less decline in ALT (p=0.024) but a similar decline in HBsAg (p=0.961) from baseline to the 48-week follow-up.

Conclusion: PegIFNα and NAs showed similar efficacy in improving liver fibrosis in CHB patients. Patients receiving PegIFNα treatment with inadequate ALT reduction are more likely to experience fibrosis progression, suggesting hepatic inflammation factors may play a more significant role than virological factors in the progression of fibrosis.

Abstract Submission No. 101040

P-0107

Need of Treatment Modification in Entecavir Partial Virologic Responders with High Viral Load

Hyung Joon Yim1, Seong Hee Kang1, Hae Rim Kim1, Sun Young Yim1, Young-Sun Lee1, Young Kuk Jung1, Yeon Seok Seo1, Ji Hoon Kim1, Joon Eun Yeon1, Kwan Soo Byun1

1Korea University College of Medicine Seoul South Korea

Background: The antiviral efficacy of ETV in chronic hepatitis B (CHB) patients with baseline high viral load (HVL) may be limited by insufficient response. Current guidelines suggest continuing an initial drug or adding another potent agent in the presence of partial virologic response (PVR) in CHB patients receiving entecavir (ETV). However, supporting data which one would be preferred are still limited. This study is aimed to evaluate the outcome of extended ETV monotherapy in CHB patients with HVL and/or PVR, and to propose a management strategy according to the antiviral response.

Methods: A total of 197 treatment naïve CHB patients who newly started ETV 0.5mg were included. Antiviral responses were compared between HVL (≥8 log10 IU/mL) and non-HVL group up to 120 months. Results: Overall, 95 and 102 patients were included in the HVL and non-HVL group, respectively. Mean HBV DNA at baseline was 7.70±0.45 and 5.58±1.04 log10 IU/mL in HVL and non-HVL group. Virological response (VR) (HBV DNA <20 IU/mL) was achieved in 65.9%, 79.2%, 83.9% and 82.7% of HVL patients and in 93.3%, 96.3%, 97.1% and 96.7% of non-HVL patients at months 24, 36, 60 and 120 respectively. Compared with non-HVL group, HVL group showed lower cumulative virologic response during 120 months of therapy (p=0.001). Antiviral resistance to ETV (rtS202G+rtM204V+rtL180M) was developed in 4 of 127 HVL group patients (4.2%). The 75 (83.3%) and 49 (53.3%) patients showed PVR at month 6 and 12 in HVL group, respectively. The multivariate analysis showed that having HVL at baseline along with PVR at 6 months (Odds ratio, 0.12; p = 0.01) was a significant factor for VR at the 60 months. However, the rates of biochemical responses and HBeAg seroconversion were similar between the HVL group and non-HVL group.

Conclusions: Patients with baseline HVL and PVR at month 12 are exposed to risk of resistance to ETV and insufficient treatment response rates. We suggest CHB patients with baseline HVL and PVR need to modify a treatment strategy during ETV therapy.

Abstract Submission No. 101049

P-0108

No TAF resistance in adult, HBeAg +/- patients with CHB infection after treated with TAF to 8 years

Henry Chan1, Patrick Marcellin2, Calvin Q. Pan3, Roberto Mateo1, Tahminie Yazdi1, Silvia Chang1, Dong Han1, Lindsey May1, Caleb Marceau1, Christopher Richards1, Hongmei Mo4, Dr. Shalimar5, Namiki Izumi6, Young-Suk Lim7, Maria Buti8

1The Chinese University of Hong Kong Hong Kong, 2Hôpital Beaujon Clichy France, 3NYU Langone Health New York United States, 4Gilead Sciences Inc Foster Japan, 5All India Institute of Medical Sciences Delhi India, 6Japanese Red Cross Musashino Hospital Tokyo Japan, 7Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 8King’s College Hospital London England

Background and Aims: We have previously shown no resistance to TDF after 8 years, and TAF resistance hasn’t been detected after up to three years of treatment in CHB patients. Here we present annual resistance surveillance results from years 3 through 8 of TAF treatment.

Methods: Two randomized, double-blind, active-controlled trials assessed TAF treatment of HBeAg-negative and HBeAg-positive CHB participants over 8 years. Sequence analysis of the pol/RT region was conducted annually for participants experiencing a viral breakthrough, blip, or persistent viremia with HBV DNA >69 IU/mL those discontinuing with HBV DNA >69 IU/mL. Participants with substitutions at conserved pol/RT sites or polymorphic residues were phenotyped against TAF.

Results: Out of 1298 participants, the percentage qualifying for resistance annually from Year 3 to Year 8 remained low (range 1.7 – 8.4%). Those qualifying for sequencing showed progressively declining, proportions with persistent viremia with only 3 persistently viremic participants by Year 8. Their baseline viral load was >107 log10 IU/mL and declined over time but did not reach 69 IU/mL. During the 5-year open-label period where all participants received TAF, conserved site substitutions in the HBV viral pol/RT were observed in 13 participants. Polymorphic site substitutions in ≥2 participants were observed at various time points.

Conclusion: No resistance to TAF was detected in adult CHB participants with positive or negative HBeAg who received TAF therapy for up to 8 years. These findings support TAF as a long-term viral suppressive therapy for CHB infection regardless of HBeAg status.

Abstract Submission No. 101050

P-0109

Metabolic Effects and Cardiovascular Risks of Antiviral Treatments in Chronic Hepatitis B Patients
Hyunjae Shin1, Youngsu Park1, Yunmi Ko1, Yoon Jun Kim1
1Seoul National University College of Medicine Seoul South Korea

Introduction: Antiviral treatments for chronic hepatitis B (CHB) have been known to have different metabolic effects. This study aimed to reveal whether TAF-induced dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risks are significant in CHB patients.

Methods: This study used 15-year historical cohort including CHB patients in Korea and consisted of two parts: the single-antiviral and switch-antiviral study. In the single-antiviral study, pairwise analyses were conducted in patients who switched NAs to TAF or from TAF.

Results: In the single-antiviral study, body weight and statin use significantly differ between groups before PSM. Linear regression model was then utilized for adjusting major confounders after PSM. Changes in total cholesterol were significantly different (-2.57 mg/dL/year in the TDF-only group and +2.88 mg/dL/year in the TAF-only group; P=0.002 and P=0.02, respectively). In the TDF-only group, HDL cholesterol decreased as well (-0.55 mg/dL/year; P=0.001). The TAF-only group had the greatest increase in ASCVD risk, followed by the TDF-only and non-antiviral groups. In the switch-antiviral study, patients who switched from TDF to TAF had a higher total cholesterol after switching (+9.4 mg/dL/year) than before switching (-1.0 mg/dL/year; P=0.047).

Discussion: TAF was associated with increased total cholesterol, whereas TDF was associated with decreased total and HDL cholesterol. Both TAF and TDF increased ASCVD risks, and statin use might mitigate these risks. Dyslipidemia and its associated outcomes should be monitored with preventive treatment with statins in CHB patients.

Abstract Submission No. 101053
P-0110

Bone and Renal Safety of TAF at 8 Years in CHB Patients with Underlying Risk Factors for Use of TDF

Henry Chan1, Maria Buti2, Grace Wong1, Young-Suk Lim4, Chi-Yi Chen5, Seng Gee Lim6, Hiroshi Yatsuhashi7, Frida Abramov8, Hongyuan Wang9, Leland J. Yee10, Calvin Pan1, Patrick Marcellin10, Ed Gane6
1The Chinese University of Hong Kong Hong Kong Hong Kong, 2Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 3Queen Mary Hospital Hong Kong Hong Kong, 4National Cheng Kung University Tainan Taiwan, 5National University Hospital Singapore Singapore, 6Gilead Sciences Foster City United States, 7National Taiwan University Hospital Taipei Taiwan, 8Hôpital Beaujon Clichy France, 9Auckland Clinical Studies Auckland New Zealand, 10Hospital General Universitari Valle Hebron Barcelona Spain

Background: Antiviral therapy reduces HCC risk in CHB patients, particularly with TDF or entecavir. TAF is a first-line recommended treatment for CHB with comparable efficacy to TDF with higher ALT normalization and no resistance. We evaluated HCC incidence and risk at 8 years (y) in CHB patients treated solely with TAF or initially with TDF and then switched to TAF.

Methods: In two similarly designed Phase 3 studies, HBsAg-positive (n=859) and -negative (n=439) CHB patients were randomized to TAF 25 mg or TDF 300 mg for up to 3y (double-blind phase), followed by open-label TAF through Y8. HCC was assessed by local standards of care and by hepatic ultrasonography. Three validated models (REACH-B, aMAP, and mPAGE-B) were utilized to assess HCC risk.

Results: Through Y8, HCC was diagnosed in 21/1298 patients. Eight HCC cases were in cirrhotic patients. Median time to HCC onset was 729 days. Advanced age, male gender, and cirrhosis were more common in HCC, proportionately, more HCC patients were HBV genotype C and had BL HBV DNA 6 to ≤ 8 log10 IU/mL. With treatment over 8y, by REACH-B, HCC incidence was significantly reduced (P=0.0001). Of patients predicted to be low risk for HCC at BL, nearly all remained low risk at Y8, and substantial proportions estimated to be medium or high risk shifted to a lower risk at Y8.

Conclusion: CHB patients treated with TAF alone or switched from TDF to TAF for up to 8 y showed reduced HCC risk compared to predictions.

Abstract Submission No. 101061
P-0112

Impact of long-term treatment with TAF or after switch from TDF on HCC incidence in CHB Patients

Henry Chan1, Young-Suk Lim2, Grace Wong1, Wai Kay Seto1, Aric Josun Hui2, Ting-Tsung Chang4, Seng Gee Lim6, Frida Abramov8, John F. Flaherty6, Hongyuan Wang9, Leland J. Yee6, Jia-Horang Kao7, Patrick Marcellin10, Edward Gane6, Maria Buti10
1The Chinese University of Hong Kong Hong Kong Hong Kong, 2Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 3Queen Mary Hospital Hong Kong Hong Kong, 4National Cheng Kung University Tainan Taiwan, 5National University Hospital Singapore Singapore, 6Gilead Sciences Foster City United States, 7National Taiwan University Hospital Taipei Taiwan, 8Hôpital Beaujon Clichy France, 9Auckland Clinical Studies Auckland New Zealand, 10Hospital General Universitari Valle Hebron Barcelona Spain

Background: Antiviral treatments for chronic hepatitis B (CHB) have been known to have different metabolic effects. This study aimed to reveal whether TAF-induced dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) risks are significant in CHB patients.
Long-term efficacy of final 8 years of TAF Ph3 studies in CHB patients

Henry Chan1, Maria Buti2, Kosh Agarwal3, Wai-Kay Seto4, Young-Suk Lim5, Namiki Izuim, Frida Abramov6, Hongyuan Wang7, Leland J. Yee7, Roberto Mateo7, John F Flaherty7, Dr. Shalimar8, Patrick Marcellin9, Edward J. Gane10

1The Chinese University of Hong Kong Hong Kong Hong Kong, 2Hospital General Universitari Valle Hebron Barcelona Spain, 3King’s College Hospital London England, 4Queen Mary Hospital Hong Kong Hong Kong, 5Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 6Japanese Red Cross Musashino Hospital Tokyo Japan, 7Gilead Sciences Foster City United States, 8All India Institute of Medical Sciences Delhi India, 9Hôpital Beaujon Clichy France, 10Auckland Clinical Studies Auckland New Zealand

Method: In a pooled analysis, treatment-emergent AEs, serious AEs (SAEs), discontinuations, and laboratory abnormalities were assessed in patients who received OL TAF. Changes from baseline in estimated GFR and changes in hip and spine bone mineral density (BMD) were assessed.

Results: Overall, 974 (75%) participants completed OL study treatment. The overall incidence of patients experiencing AEs was similar among patients experiencing SAEs was among groups. Rates of Grade 3/4 AEs and AEs leading to discontinuation (D/C) were low and similar among groups. Few Grade 3/4 AEs or SAEs were related to the study drug. Overall, the most common Grade 3/4 lab abnormalities (≥2%) were increased amylase (TAF 1.9%, TDF-TAF 2.7%), creatine kinase (TAF 1.4%, TDF-TAF 2.1%), fasting cholesterol (TAF 1.4%, TDF-TAF 2.9%), fasting LDL (TAF 5.9%, TDF-TAF 8.0%), and urine glucose (TAF 5.2%, TDF-TAF 2.7%). After experiencing declines in eGFRcG and hip/spine BMD with TDF treatment in the DB phase, renal and bone outcomes improved following the switch to OL TAF with minimal change through year 8.

Conclusion: Long-term TAF treatment was safe and well tolerated, with minimal changes in eGFRcG and BMD occurring over 8 years.

Abstract Submission No. 101107

P-0114

Long-term efficacy of final 8 years of TAF Ph3 studies in CHB patients

Henry Chan1, Maria Buti2, Kosh Agarwal3, Wai-Kay Seto4, Young-Suk Lim5, Namiki Izuim, Frida Abramov6, Hongyuan Wang7, Leland J. Yee7, Roberto Mateo7, John F Flaherty7, Dr. Shalimar8, Patrick Marcellin9, Edward J. Gane10

BACKGROUND AND AIM: In 2 similarly designed double-blind (DB), randomized (2:1), Phase 3 studies (Study 108 in HBeAg-negative patients [N=425] and Study 110 in HBeAg-positive patients [N=873]), tenofovir alafenamide (TAF) demonstrated noninferior efficacy relative to tenofovir disoproxil fumarate (TDF) in the blinded assessments. After completing up to 3 years (yr) of DB treatment, all patients were eligible to receive open-label (OL) TAF through week 384 (yr 8).

METHOD: Efficacy was assessed for each study by missing equals exclusion approach of the full analysis set and included serial assessments for viral suppression (HBV DNA < 29 IU/mL), ALT normalization by 2016 AASLD criteria, serologic responses, and fibrosis assessment by serum FibroTest. Resistance analyses, including deep sequencing of HBV pol/RT (at baseline and annually), for those with virologic breakthrough/blip, persistent viremia, or treatment discontinuation with viremia were performed.

Results: Of 1298 randomized and treated patients, 1157 (89%; 775 TAF, 382 TDF) entered the OL phase, including 180 and 202 TDF-treated patients who began OL TAF at week 96 (TDF-OL TAF 6 yr) or week 144 (TDF-OL TAF 5 yr) based on timing of a protocol amendment. Overall, 974 (75%) participants completed OL study treatment. The most common reasons for discontinuation were withdrawal of consent, loss to follow-up, or investigator discretion.

Conclusion: After 8 yr of treatment with TAF or up to 6 yr after switch from TDF, virologic suppression rates remained high across all groups; up to 33% achieved HBeAg/HBeAb seroconversion, while HBsAg loss was low (≤5%).

Abstract Submission No. 101065

P-0113

Safety profile of final 8 years of TAF Ph3 studies in CHB patients

Henry Chan1, Young-Suk Lim2, Wan-Long Chuang3, Namiki Izuim, Frida Abramov4, Hongyuan Wang5, Leland J. Yee5, John F Flaherty5, Calvin Pan6, Dr. Shalimar7, Wai-Kay Seto8, Edward J. Gane8, Maria Buti9

1The Chinese University of Hong Kong Hong Kong Hong Kong, 2Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 3Kaohsiung Medical University Kaohsiung Taiwan, 4Japanese Red Cross Musashino Hospital Tokyo Japan, 5Gilead Sciences Foster City United States, 6NYU Langone Health New York United States, 7All India Institute of Medical Sciences Delhi India, 8Queen Mary Hospital Hong Kong Hong Kong, 9Auckland Clinical Studies Auckland New Zealand, 10Hospital General Universitari Valle Hebron Barcelona Spain

Background and Aims: In 2 similarly designed double-blind (DB), randomized (2:1), Phase 3 studies (Study 108 in HBeAg-negative and Study 110 in HBeAg-positive patients), tenofovir alafenamide (TAF) demonstrated noninferior efficacy with superior renal and bone safety compared to tenofovir disoproxil fumarate (TDF) at week 96. After completing DB treatment, all patients were eligible to receive open-label (OL) TAF through year 8.

Method: In a pooled analysis, treatment-emergent AEs, serious AEs (SAEs), discontinuations, and laboratory abnormalities were assessed in patients who received OL TAF. Changes from baseline in estimated GFR and changes in hip and spine bone mineral density (BMD) were assessed.

Results: Overall, 974 (75%) participants completed OL study treatment. The overall incidence of patients experiencing AEs was similar among groups. Rates of Grade 3/4 AEs and AEs leading to discontinuation (D/C) were low and similar among groups. Few Grade 3/4 AEs or SAEs were related to the study drug. Overall, the most common Grade 3/4 lab abnormalities (≥2%) were increased amylase (TAF 1.9%, TDF-TAF 2.7%), creatine kinase (TAF 1.4%, TDF-TAF 2.1%), fasting cholesterol (TAF 1.4%, TDF-TAF 2.9%), fasting LDL (TAF 5.9%, TDF-TAF 8.0%), and urine glucose (TAF 5.2%, TDF-TAF 2.7%). After experiencing declines in eGFRcG and hip/spine BMD with TDF treatment in the DB phase, renal and bone outcomes improved following the switch to OL TAF with minimal change through year 8.

Conclusion: Long-term TAF treatment was safe and well tolerated, with minimal changes in eGFRcG and BMD occurring over 8 years.

Abstract Submission No. 101107

P-0114

Prognostic analysis of CHB cirrhotic patients with hypoviremia based on a high-sensitivity assay

Yinong Feng1, Zehong Wang1, Shaoyuan Shi1, Li Zhou1

1Taiyuan NO 3 hospital Taiyuan China

OBJECTIVE: To explore the clinical prognosis of patients with hepatitis B cirrhosis hypoviremia treated with NUCs.

Methods: Patients with hepatitis B cirrhosis treated with NUC were collected from 2020 to 2022 at Taiyuan No.3 hospital and were divided into group 1 low viremia group (HBV DNA <10 IU/ml), and group 2 below the lower limit of detection (HBV DNA <10 IU/ml), and group 3 undetectable target group by high sensitivity test. The patients were followed up for 48 weeks to observe the incidence of cirrhosis-related complications and HCC.

Results: 251 patients with NUC (ETV, TDF, and TAF) treated with hepatitis B cirrhosis were in group 1, 107 in group 2, and 119 in group 3. New cirrhosis-related complications occurred in all three groups, and the number of new cases of hypersplenism, ruptured esophageogastroduodenal varices bleeding, portal vein thrombosis, and hepatorenal syndrome was not statistically significant. However, the number of new esophageogastroduodenal variceal cases was statistically significant, and the highest rate was observed in group 2.38 (15.14%) of people who developed HCC (group 1: 4 cases; group 2: 16 cases; group 3: 18 cases; and among them, 7 died). There was no statistically significant difference in the incidence of HCC or mortality among the groups with different DNA loads. Even in those with a complete virologic response, cirrhosis-related complications or even hepatocellular carcinoma may occur.

Conclusion: It is important to determine whether cirrhotic patients have achieved a complete virological response through high-sensitivity HBV DNA testing to actively control disease progression.

Abstract Submission No. 101108

P-0115
Hepatic Histologic Status and Pathologic Diagnosis in HBV Carriers with Normal or Mildly Elevate ALT

Yinong Feng¹, Li Zhou¹, Xuanxuan Wang¹, Shaoyuan Shi¹, Zehong Wang¹

¹Taiyuan NO 3 Hospital Taiyuan China

OBJECTIVE: To analyze the hepatic inflammation and fibrosis and clinical diagnosis in HBV carriers with normal or mildly elevated alanine aminotransferase (ALT) levels.

Methods: Thirty-seven HBV carriers (DNA-positive) with normal or mildly elevated ALT levels who underwent hepatic puncture biopsy at Taiyuan No.3 Hospital from April 2020 to October 2022 were retrospectively collected to clarify the diagnosis and fibrosis, as well as the degree of inflammation in the patients.

Results: The 37 HBV carriers were aged (36.27±12.54) years, with ALT (36.89±23.20) IU/ml and a male/female ratio of 1.31/1. The stage of liver fibrosis ranged from S0-S4, with a predominance of S0-S1 in 20 cases (54%), and there were 17 patients with S ≥ 2 (46%), with S2 in 10 cases (27%), S3 in 3 cases (8%), and S4 in 4 cases (11%); liver inflammatory activity was graded between G0-G4, with G0-G1 predominating in 29 cases (78%) and G≥2 in 8 patients (22%). A liver puncture definitively diagnosed 31 cases of chronic hepatitis B and 6 cases of cirrhosis.

Conclusion: Most of the HBV carriers with normal or mildly elevated ALT levels had varying degrees of liver fibrosis and liver inflammation, and some had reached cirrhosis. It is recommended to improve the histopathological examination of the liver in order to assess the indications for antiviral therapy and avoid delay in treatment.

Abstract Submission No. 101163
P-0116

Hydroxychloroquine Reduced the Risk of Hepatocellular Carcinoma in patients with HBV infection

Yu-Wei Lan¹, Wei-Yu Kao²,³,⁴,⁵, Chi-Ching Chang⁶,⁷, Yu-Chuan Shen⁸

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan Taipei Taiwan, ²Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan Taipei Taiwan, ³TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan Taipei Taiwan, ⁴Taiwan Cancer Center, Taipei Medical University, Taipei, Taiwan Taipei Taiwan, ⁵Graduate Institute of Metabolism and Obesities Sciences, Taipei Medical University, Taipei, Taiwan Taipei Taiwan, ⁶Division of allergy, immunology and Rheumatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan Taipei Taiwan, ⁷Division of allergy, immunology and Rheumatology, Department of Internal Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan Taipei Taiwan, ⁸Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan Taipei Taiwan

Background: Chronic hepatitis B virus (HBV) infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Hydroxychloroquine (HCQ) is a medication used to treat autoimmune disorders and recent studies have suggested that it may also have anticancer properties based on autophagy and non-autophagy mechanisms. This study investigates the correlation between HCQ use and the risk of hepatocellular carcinoma in patients with chronic HBV infection.

Method: HBV infected patients were enrolled from Taiwan’s National Health Insurance Research Database (covering January 1, 2006, to December 31, 2016). The association between HCQ use and HCC risk was evaluated using the Kaplan-Meier method and Cox proportional hazards regression

Results: 434,690 HBV patients were enrolled and individual matching with 1:10. Among 3,871 patients using HCQ (defined as ≥28 cumulative defined daily doses [cDDDs]), 39 developed HCC. Comparatively, among 38710 patients not using HCQ (≤ 28 cDDDs), 795 were diagnosed with HCC. HCQ use by HBV patients showed a significantly reduced HCC risk with an adjusted hazard ratio (aHR) of 0.47 (95% CI, 0.32-0.69). Furthermore, no observable dose-response relationship between HCQ use and HCC risk.

Conclusion: HCQ use appears to lower the risk of HCC among patients with HBV infection, suggesting potential benefits in preventing HCC in this population. Further research is necessary to confirm these findings and underlying mechanisms.

Abstract Submission No. 101208
P-0117

Abnormal rate of renal function index and the related risk factor in chronic hepatitis B patients

Guofeng Gao¹, Jiao Yu¹

¹Department of Hepatology, Eastern Hepatobiliary Surgery Hospital, Navy Medical University Shanghai China

Background: To investigate the abnormal rate of renal function index and related potential risk factors in CHB patients with or without antiviral treatment of nucleos(t)ide analogues.

Methods: Collected clinical data of CHB patients with urinary β2 microglobulin detection , including demographic characteristics, HBV DNA, ALT, AST, total bilirubin, direct bilirubin, urea nitrogen, creatinine, cholesterol, triglyceride, high density lipoprotein, low density lipoprotein, liver imaging and other routine tests from June 2022 to June 2023 in Shanghai Eastern Hepatobiliary Surgery Hospital. The normal of urinary β2 microglobulin is defined as ≤ 0.173, and the normal of eGFR is defined as ≥90ml/min. Abnormal renal function index proportion and related risk factors were analyzed.

Results: 500 CHB patients were enrolled, aged 44.7±10.8 years, 67.2% were male, 57.2% were treated with antiviral drugs, and 52.2% had HBV-related family history. 28.8% patients with fatty liver, 35.0% with liver fibrosis, and 13.2% with cirrhosis. 43.2% patients with liver fibrosis, and 13.2% with cirrhosis. 43.2% patients with abnormal renal function index and the related risk factor in chronic hepatitis B patients were analyzed.

Conclusion: Urinary β2-GM has a higher proportion of diagnosis than eGFR for renal injury in CHB patients. Male patients with CHB need to pay more attention to monitoring renal function and use antiviral regimens with renal safety profile.

Abstract Submission No. 101209
P-0118

Abnormal rate of renal function index and the related risk factor in chronic hepatitis B patients

Guofeng Gao¹, Jiao Yu¹
Background: To investigate the abnormal rate of renal function index and related potential risk factors in CHB patients with or without antiviral treatment of nucleos(t)ide analogues.

Methods: This study included 611 CHB patients (untreated cohort: 316 cases, liver biopsy cohort: 260 cases, therapy cohort: 35 cases). The levels of serum CACs were determined based the semi-quantitative method established by our group. The differences between groups of CACs levels and their correlation with key clinical indicators were analyzed.

Results: Firstly, the serum CACs levels increased significantly in hepatitis phases (p<0.0001). Further analysis of liver biopsy cohort showed serum CACs levels in G≥2 group was higher than that in G<2 group (p<0.0001), and positively correlated with G, ALT, AST and GGTT. ROC curves indicated that CACs could have higher diagnostic accuracy in indicating hepatic inflammation than ALT, HBeAb and HBV DNA. In addition, CACs identified hepatic inflammation in CHB patients with normal ALT (AUC=0.686, p=0.001) and during the NA therapy in patient with chronic HBV infection. Out of 1100 patients undergone NA treatment, 207 people were eligible for the study because of lack of elastography data. But out of those 96 patients fulfilled our inclusion criteria. 72 patients had taken TAF and 24 patients had taken Entecavir.

Conclusions: Fibrosis regression was common in many other HBV treatment studies. But in our study fibrosis progression was observed in higher rates than those of regressed. We think it might be due to short observation period, or because NAs do not clear HBsAg, or because some patients were taking alcohol during the treatment, or inflammation did not stop during the treatment.
TMF + Peg-IFN, TDF + Peg-IFN, and ETV + Peg-IFN groups. The primary endpoint was HBsAg clearance at 24 and 48 weeks.

**Results:** Among the 251 participants, 60 achieved HBsAg clearance at 24 weeks, with 16 in TMF + Peg-IFN, 25 in TDF + Peg-IFN, and 19 in ETV + Peg-IFN. At 48 weeks, 159 participants were included, with 30 in TMF + Peg-IFN, 50 in TDF + Peg-IFN, and 34 in ETV + Peg-IFN achieving clearance. The type of NA medication did not significantly affect clearance rates at 24 weeks (P=0.315) and 48 weeks (P=0.439) after adjusting for age, gender, and baseline HBsAg levels.

**Conclusions:** TMF, TDF, and ETV combined with Peg-IFN show comparable efficacy in achieving HBsAg clearance in treatment-naive patients with chronic hepatitis B.

**Prevalence of Fibrosis and Steatosis in newly diagnosed asymptomatic Hepatitis B and C patients**

**Background and Aims:** Chronic HBV and HCV can present with liver steatosis and advanced fibrosis due to infection itself or metabolic comorbidity. We aimed to determine prevalence of hepatic steatosis and fibrosis in asymptomatic HBV and HCV at presentation using Fibroscan.

**Methods:** Consecutive patients (n=383) with newly diagnosed HBV (n=323) or HCV (n=60) underwent Fibroscan (ECHOSENS 630 Xpert) at presentation. Patients with hepatic decompensation, chronic kidney disease, HIV, alcohol abuse and pregnancy were excluded. F0, F1/F2, F3 and F4 fibrosis was defined as LSM values <6kPa, 6-8 kPa, 8.1-12.5 kPa and >12.5 kPa respectively. Steatosis severity; S1(mild), S2(moderate) and S3(severe) was defined as CAP values 222-246 dB/m, 247-273 dB/m and ≥ 274 dB/m respectively.

**Results:** Details of liver stiffness and steatosis is mentioned in Table. Among 12 patients with HCV and F4 fibrosis, 5 had severe and 4 had moderate steatosis. Presence of metabolic syndrome was not associated with greater steatosis (p=0.137) and fibrosis (p=0.158) in HCV cases. Among 17 patients with HBV and F4 fibrosis, 8 had severe and 2 had moderate steatosis. Presence of metabolic syndrome was associated with greater steatosis (p=0.001) and fibrosis (p=0.001) in HBV.

**Conclusions:** In newly diagnosed patients with chronic viral hepatitis, metabolic syndrome correlates with fibrosis and steatosis in HBV, but not in HCV.

**FUNCTIONAL AND MORPHOLOGICAL ABNORMALITY OF LIVER AMONG DIABETIC PATIENTS WITH VIRAL HEPATITIS**

**Background and aims:** Treatment of Acute Hepatitis B is mainly supportive. However, antivirals may be warranted in certain situations such as severe acute hepatitis. Real-world data regarding efficacy of Tenofovir alafenamide (TAF) compared to Entecavir (ETV) for Severe AHIV-B is lacking. We aimed to retrospectively compare the efficacy of the two antivirals.

**Methods:** Patients with severe acute hepatitis who were found to have IgM Anti HB core positive in the past 2 years were included and data retrieved from EMR. Patients were categorised into two groups, TAF and ETV group. Follow up data was assessed.

**Results:** Twenty patients were diagnosed with Severe Acute Hepatitis-B. Of them 11 patients received Tenofovir alafenamide (25mg/day) and 9 patients received Entecavir (0.5mg/day). After 4 weeks of treatment, the TAF treatment group exhibited a significantly decline in HBV DNA viral load (P=0.029). The mean duration for undetectable DNA were comparable (39.2± 12.5 days (TAF) vs 56.8±18.4 days (ETV), P=0.46). The seroconversion (HBsAg loss) was significantly faster with TAF (96.5±20.5 days vs 140.5±25.4 days, P=0.04).

**Conclusion:** This real-world retrospective study showed that TAF is more effective than ETV in reducing viral load and achieving faster seroconversion in patients with severe acute hepatitis B.
Liver cirrhosis with gastric adenocarcinoma a patient case report

Delgertsog Gautumurm, Altantuya Idkhuu, Tuvshinzul Battogtokh

1Mungunguur hospital of Mongolia Ulaanbaatar Mongolia, 2Endoscopy department of Mongolia- Japan hospital of MNUMS Ulaanbaatar Mongolia, 3Rahamed hospital of Mongolia Ulaanbaatar Mongolia

The prevalence of gastric cancer is higher people with liver cirrhosis than people without liver cirrhosis. The contributing factors include stomach ulcers, gastropathy, zinc deficiency, alcohol and tobacco use, and Helicobacter pylori. By preventing or reducing the intake of these factors, the development and progression of cancer can be prevented.

Scientists are also investigating whether hepatitis B virus (HBV) infection may be a risk factor for not only liver cancer but also gastric cancer. How to reduce the risk of stomach cancer in people with cirrhosis? is still a serious problem. Patient 37 years old, male presented with symptom of poor appetite, fatigue in our hospital. In 2006, hepatitis B virus was diagnosed and he regularly took vemlidy once a day. He smokes 10 cigarettes a day for 20 years. On gastroscopy 2.0*2.0 cm ulcerative-infiltrative lesion in posterior wall of the cardia. Biopsy was taken. Biopsy result poorly differentiated adenocarcinoma, helicobacter pylori is positive. He underwent open total gastrectomy Roux Y D2 dissection surgery. Cirrhosis was diagnosed by taken biopsy from the liver during surgery. A patient’s symptom had decreased and he was discharged 7 days later. HBV-DNA was 863700 . He was taken vemlydi(tenofovir alafenamide) medicine once a day for 6 months, HBV-DNA18500. For patients with gastric cancer and liver cirrhosis, the new “eALT-F” staging method, based on HBeAg, ALT (the ULN of ALT level at 30IU/L for men and 19IU/L for women) and/or FIB-4 levels (>1.45), aMAP≥50 was only observed in chronic hepatitis patients with positive or negative HBeAg (6.4% and 22.1%).

Conclusion: The “eALT-F” staging method, based on HBeAg, ALT and/or FIB-4 levels was more effective in identifying medium to high-risk patients with HCC from patients with ultra-high HBV viral load than the traditional staging method.

Abstract Submission No. 101466

P-0126

eALT-F: a new method to identify patients with HCC from ultra-high HBV viral load population

Jiarui Zheng, Xiaoxiao Wang, Bo Feng

1Peking University People’s Hospital Beijing China, 2Peking University People’s Hospital Beijing China, 3Peking University People’s Hospital Beijing China

Background: Ultra-high viral load HBV belongs to the immune tolerance (IT) stage and is associated with an increased risk of hepatocellular carcinoma (HCC) occurrence. The purpose of this study was to investigate the clinical features of individuals with ultra-high HBV viral load and created a novel chronic hepatitis B (CHB) staging method that can help identify patients with medium to high HCC risk more effectively.

Methods: In total 2118 patients with HBV DNA > 1x10^7 IU/ml who visited in Peking University People’s Hospital between January 2010 and March 2023 were enrolled retrospectively.

Results: In the overall patients, more than one-third of the patients were under 30 years old (40.1%), furthermore, a small proportion of older people (>60 years) also have ultra-high HBV viral load (4.3%), 9.1% and 6.7% individuals with ultra-high HBV viral load showed FIB-4>3.25 and aMAP≥50, respectively. In the traditional stages of CHB, which based on HBeAg and ALT (an upper limit of normal (ULN) ALT level at 40 IU/L for both men and women), we found no matter in which phases, there was a certain proportion of patients at risk of developing HCC (4.1%, 6.4%, 25.0% and 20.3%). However, in the new “eALT-F” stages, which were based on HBeAg, ALT (the ULN of ALT level at 30IU/L for men and 19IU/L for women) and/or FIB-4 levels (>1.45), aMAP≥50 was only observed in chronic hepatitis patients with positive or negative HBeAg (6.4% and 22.1%).

Conclusion: The “eALT-F” staging method, based on HBeAg, ALT and/or FIB-4 levels was more effective in identifying medium to high-risk patients with HCC from patients with ultra-high HBV viral load than the traditional staging method.

Abstract Submission No. 101477

P-0127

Impact of Antiretroviral Therapy on Liver Enzymes in HIV Patients in WRH, Nepal

Nim Dangi

1Pokhara University Pokhara Nepal

Background: Antiretroviral therapy (ART) has been a remarkable achievement in treating HIV disease, but it may also exacerbate liver disease. Monitoring the viral load and CD4 counts of HIV patients is crucial in evaluating the outcome of ART. This study aimed to assess the level of liver enzymes in HIV patients, taking into consideration the effect of comorbidities and different drug therapies.

Methods: A pre-post study was conducted on 250 HIV patients at the Western Regional Hospital, an ART center of Nepal, before and after the ART. Laboratory variables, ART use, viral load and CD4 count were obtained at baseline and over 18 months of the period. Various statistical tests were used to analyze based on the nature of data.

Results: Among 250 patients, 120 (48%) were males and 130 (52%) were females with a median age of 40. ART was initiated to 44 (17.6%), 45 (18.0%), 160 (64%) and 1 (0.4%) patients of clinical stage I, II, III and IV as categorized by WHO respectively. Statistical significance (p<0.05) was found for the reduction of viral load, increase in CD4 count and as well as for elevation of liver enzymes after receiving ART whereas statistical insignificance (p>0.05) was observed with various comorbidities and as well as with difference in therapy either efavirenz or nevirapine among drugs.

Conclusion: It was observed that the elevation of the liver enzyme occurs with antiretroviral therapy though comorbidities associated with HIV and efavirenz or nevirapine based therapy were observed to not affect the elevation of liver enzymes.
different natural phases of CHB patients mainly infected with HBV -genotype C(HBV-C) in China. Therefore, we aimed to elucidate the role of HBsAg levels during the different natural phases of CHB infection has not been well illustrated owing to the dynamic changes of HBV DNA and ALT. Aims: Baseline HBsAg level is a potential predictive factor for antiviral response. However, potential diagnostic value of HBsAg levels to distinguish the different natural phases of CHB infection has not been well illustrated owing to the dynamic changes of HBV DNA and ALT. Therefore, we aimed to elucidate the role of HBsAg levels during the different natural phases of CHB patients mainly infected with HBV-genotype C(HBV-C) in China.

Methods: Seven hundred and seven chronic HBV-infected patients who were treatment-naive and all underwent liver biopsy were analyzed in a cross-sectional study. Patients were classified into four phases based on liver biopsy: hepatitis B e antigen (HBeAg) -positive chronic hepatitis B(n=178), HBeAg-negative chronic hepatitis B(n=178), HBeAg-negative chronic hepatitis B(n=178), and HBeAg-negative phases(n=116). HBsAg was quantified and correlated with HBV-DNA and clinical parameters within each phase.

Results: The median HBsAg levels in four phases were 4.58 log10 IU/ml, 3.97 log10 IU/ml, 3.34 log10 IU/ml, and 3.54 log10 IU/ml, which were significantly different between each phase(P<0.05). HBsAg levels showed a significant correlation with the levels of HBV DNA, HBcAb,AST and LSM (P<0.001)in both HBeAg-positive phases, while HBsAg levels only significantly correlated with age in both HBeAg-negative phases(P<0.001). AUCs of HBsAg and HBeAg cut-off of 4.35 log10 IU/ml and 3.03 log10 IU/ml for differentiation inactive patients from HBeAg-positive phases, while LSM was higher diagnostic value with cutoff of 7.7kPa and 6.1kPa for diagnosis of active patients in HBeAg-positive and HBeAg-negative phase.

Conclusions: HBsAg levels differed significantly during the phases of chronic HBV infection and could predict HBeAg-positive chronic HBV infection patients mainly infected with HBV-C, all of which might better help to manage of chronic HBV-infected patients with HBV-C.

Role of HBsAg levels during the different natural phases of chronic h

Na Liu1,2, Lulu Zhou1,2, Bing Dong1,2, Jiejing Xin1,2, Xiaohong Gao1, Guanghua Xu1,2
1Yanan University Affiliated Hospital Yanan China, 2Liver Disease Research Collaboration Group, National Center for Infectious Diseases Shanghai China

Aims: Baseline HBsAg level is a potential predictive factor for antiviral response. However, potential diagnostic value of HBsAg levels to distinguish the different natural phases of CHB infection has not been well illustrated owing to the dynamic changes of HBV DNA and ALT. Therefore, we aimed to elucidate the role of HBsAg levels during the different natural phases of CHB patients mainly infected with HBV-genotype C(HBV-C) in China.

Methods: Seven hundred and seven chronic HBV-infected patients who were treatment-naive and all underwent liver biopsy were analyzed in a cross-sectional study. Patients were classified into four phases based on liver biopsy: hepatitis B e antigen (HBeAg)-positive chronic HBV infection (n=214), HBeAg-positive chronic hepatitis B (n=116), HBeAg-negative chronic HBV infection(n=199) and HBeAg-negative chronic hepatitis B(n=178). HBsAg was quantified and correlated with HBV-DNA and clinical parameters within each phase.

Results: The median HBsAg levels in four phases were 4.58 log10 IU/ml, 3.97 log10 IU/ml, 3.34 log10 IU/ml, and 3.54 log10 IU/ml, which were significantly different between each phase(P<0.05). HBsAg levels showed a significant correlation with the levels of HBV DNA, HBcAb,AST and LSM (P<0.001)in both HBeAg-positive phases, while HBsAg levels only significantly correlated with age in both HBeAg-negative phases(P<0.001). AUCs of HBsAg and HBeAg cut-off of 4.35 log10 IU/ml and 3.03 log10 S/CO for differentiation inactive patients from HBeAg-positive phases, while LSM was higher diagnostic value with cutoff of 7.7kPa and 6.1kPa for diagnosis of active patients in HBeAg-positive and HBeAg-negative phase.

Conclusions: HBsAg levels differed significantly during the phases of chronic HBV infection and could predict HBeAg-positive chronic HBV infection patients mainly infected with HBV-C, all of which might better help to manage of chronic HBV-infected patients with HBV-C.

Detection of preS1 with monoclonal antibodies during chronic hepatitis B virus infection

Kazuto Tajiri1, Yuka Hayashi1, Aiko Murayama1, Nozomu Muraishi1, Ichiro Yasuda1
1Toyama University Hospital Toyama Japan

Measurement of hepatitis B surface antigen (HBsAg) is essential in managing chronic hepatitis B virus (CHB) infection and achieving HBsAg loss is considered a goal in CHB treatment. HBsAg consists of three different surface envelope proteins, large- (LHBs), middle- (MHBs), and small-HB (SHBs) surface proteins. However, in clinical practice it is not common to evaluate each of these HB components separately. Recently, the measurement of preS1, a component of LHBs known for its essential role in HBV entry, has been found to have a
The Long-term safety of antiviral treatment for infants born to mothers infected with hepatitis B

Shourong Liu¹, Tongtong Chen¹, Huizhu Li², Linglin Qi², Chengjing Tao¹, Suying Zhang¹, Chun Zhao¹, Chen Wang¹, Kenv Pan¹, Jing Wu¹, Jie Chen²

¹Xixi hospital of Hangzhou city Hangzhou China, ²The People’s Hospital of Lishui city Lishui China, ³Zhejiang Chinese Medicine University Hangzhou China

Background: We designed this study to evaluated the long-term physical and intellectual development of the children born to the mother who received antiviral treatment during pregnancy.

Methods: 154 children were delivered to 153 mothers with chronic hepatitis B infection, included from 2009 to 2020. The normal children were randomly selected as blank control group, and the growth and intellectual development of children in the experimental group and blank control group were compared. Adverse maternal events during pregnancy and at postpartum and infants’ congenital anomalies were evaluated.

Results: Before delivery, almost all mothers were negative for HBV DNA, and no mother has severe ALT flare, the peak level was 93 U/L. No severe maternal abnormalities were observed. 7 months postpartum, 154 children were tested HBsAg and HBV DNA, none of them were positive. No congenital anomalies or severe adverse events were observed at delivery. Most of children’s physical development is with the normal range, only two child whose body mass index-for-age (BAZ) lower than 2 SD had mild low Zn and Insulin-like growth factor 1 (IGF-1), respectively. 35 children in experimental group and 19 children in blank control group accomplished Raven’s standard progressive matrices, there was no difference between the experimental group and the blank control group.

Conclusions: Receive antiviral treatment during pregnancy is effective and safe to mothers and infants. The data of long-term follow-up have normal physical and intellectual development.

Abstract Submission No. 101616
P-0132

The Long-term safety of antiviral treatment for infants born to mothers infected with hepatitis B

Shourong Liu¹, Tongtong Chen¹, Huizhu Li², Linglin Qi², Chengjing Tao¹, Suying Zhang¹, Chun Zhao¹, Chen Wang¹, Kenv Pan¹, Jing Wu¹, Jie Chen²

¹Xixi hospital of Hangzhou city Hangzhou China, ²The People’s Hospital of Lishui city Lishui China, ³Zhejiang Chinese Medicine University Hangzhou China

Background: We designed this study to evaluated the long-term physical and intellectual development of the children born to the mother who received antiviral treatment during pregnancy.

Methods: 154 children were delivered to 153 mothers with chronic hepatitis B infection, included from 2009 to 2020. The normal children were randomly selected as blank control group, and the growth and intellectual development of children in the experimental group and blank control group were compared. Adverse maternal events during pregnancy and at postpartum and infants’ congenital anomalies were evaluated.

Results: Before delivery, almost all mothers were negative for HBV DNA, and no mother has severe ALT flare, the peak level was 93 U/L. No severe maternal abnormalities were observed. 7 months postpartum, 154 children were tested HBsAg and HBV DNA, none of them were positive. No congenital anomalies or severe adverse events were observed at delivery. Most of children’s physical development is with the normal range, only two child whose body mass index-for-age (BAZ) lower than 2 SD had mild low Zn and Insulin-like growth factor 1 (IGF-1), respectively. 35 children in experimental group and 19 children in blank control group accomplished Raven’s standard progressive matrices, there was no difference between the experimental group and the blank control group.

Conclusions: Receive antiviral treatment during pregnancy is effective and safe to mothers and infants. The data of long-term follow-up indicates that the children born to the mother receive antiviral treatment have normal physical and intellectual development.

Abstract Submission No. 101616
P-0132

The Long-term safety of antiviral treatment for infants born to mothers infected with hepatitis B

Shourong Liu¹, Tongtong Chen¹, Huizhu Li², Linglin Qi², Chengjing Tao¹, Suying Zhang¹, Chun Zhao¹, Chen Wang¹, Kenv Pan¹, Jing Wu¹, Jie Chen²

¹Xixi hospital of Hangzhou city Hangzhou China, ²The People’s Hospital of Lishui city Lishui China, ³Zhejiang Chinese Medicine University Hangzhou China

Background: We designed this study to evaluated the long-term physical and intellectual development of the children born to the mother who received antiviral treatment during pregnancy.

Methods: 154 children were delivered to 153 mothers with chronic hepatitis B infection, included from 2009 to 2020. The normal children were randomly selected as blank control group, and the growth and intellectual development of children in the experimental group and blank control group were compared. Adverse maternal events during pregnancy and at postpartum and infants’ congenital anomalies were evaluated.

Results: Before delivery, almost all mothers were negative for HBV DNA, and no mother has severe ALT flare, the peak level was 93 U/L. No severe maternal abnormalities were observed. 7 months postpartum, 154 children were tested HBsAg and HBV DNA, none of them were positive. No congenital anomalies or severe adverse events were observed at delivery. Most of children’s physical development is with the normal range, only two child whose body mass index-for-age (BAZ) lower than 2 SD had mild low Zn and Insulin-like growth factor 1 (IGF-1), respectively. 35 children in experimental group and 19 children in blank control group accomplished Raven’s standard progressive matrices, there was no difference between the experimental group and the blank control group.

Conclusions: Receive antiviral treatment during pregnancy is effective and safe to mothers and infants. The data of long-term follow-up indicates that the children born to the mother receive antiviral treatment have normal physical and intellectual development.
absence of implementation of the WHO elimination program, HBV-associated mortality, decompensated cirrhosis and HCC will increase by 4-6% by 2030.

**Material:** In 75 patients with chronic HBV infection (48% men), from 5 to 74 years old (40.7±14.5), HBV DNA viral load (VL) was checked by *Abbott Real-Time PCR*, quantitative HBsAg (qHBsAg) *ARCHITECT, Abbott (>0.05IU/ml). Fibrosis was determined by non-invasive methods Fibrotest or/and Fibroscan.

**Results:** VL ranged from <10 to 75,669,100 IU/ml, qHBsAg ranged 1-124924IU/ml. In 12.3% HBsAg-positive patients HBV DNA was undetectable, VL<200 was detected in 22.8%, >200,000 in 15.8% patients (characteristics of patients with VL>200,000 IU/ml in Tab.1). HBeAg-positive status in 5 patients, HDV infection was diagnosed in 2 patients with high HDV RNA VL and an extremely low HBV DNA. Liver fibrosis was <F2 in 75.9%, F2 in 6.4%, F3 in 3.2%, and F4 in 14.5%. Decompensated cirrhosis was observed in 5 patients: two with HDV-infection; one with HCV-co-infection and HCC; another has Budd-Chiari syndrome. 11 (15%) patients are receiving antiviral therapy with tenofovir alafenamide.

**Conclusion:** In the majority of patients with chronic HBV infection, fibrosis stage was below 2 and the level of viral load varied from 2000 to 20000. The presence of comorbid conditions or co-infection negatively affected the natural course of the disease.

Abstract Submission No. 101713

**P-0135**

**Durability of Virological Response with generic Tenofovir Disoproxil Fumarate in Chronic Hepatitis B**

Sheng-Shun Yang¹, Hong-Zen Yeh², Teng-Yu Lee¹, Sanjay Hadiga³

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital Taichung Taiwan, ²Division of Gastroenterology & Hepatology, Department of Internal Medicine, Tungs' Taichung Metro Harbor Hospital Taichung Taiwan, ³Department of Medical Affairs, Mylan Pharmaceutical Private Limited, A Viatris Company Bengaluru, Karnataka India

**Background:** Though CHB patients require lifelong use of nucleotide analogue, it is reimbursed for a limited period in Taiwan, causing treatment discontinuations. Switching the treatment to low-cost generics post-reimbursement discontinuation can help prolong treatment and maintain the durability of viral response.

**Methods:** In this study, the durability of virological response (measured using virological recurrence and HBV-DNA levels) in patients who received generic TDF (Ricovir®; study group) for 24 weeks after switching from the branded TDF (Viread®) was evaluated. The results were compared with the historical control group who received Viread® for more than one year till reimbursement cessation.

**Results:** The study included 20 eligible CHB patients each in the study group and the control group. No patients in the study group experienced a virological recurrence at any treatment visit. At week 24, the rates of virological recurrence of HBV in the control group were significantly higher as compared to the study group: (30% vs 0%; p=0.020) Only the control group (13 patients) had detectable HBV-DNA levels at week 24 (65% vs 0%; p=0.001). Two mild adverse events (AEs) were reported in the study group, which were considered not related. No deaths, serious AEs, or treatment discontinuations occurred during the study. Treatment with the study group was well tolerated with 99.4% median study drug compliance.

**Conclusion:** This study’s results conclude that generic TDF (Ricovir®) is effective and safe in maintaining the HBV virological response.

**Abstract Submission No. 101740

**P-0136**

**The Role of Serum pgRNA Dynamics in Predicting HBeAg seroconversion during Pregnancy and Postpartum**

Chengjing Tao¹, ³, Guorong Han¹, Shuorong Liu²

¹Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing Nanjing China, ²Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou China, ³Department of Obstetrics and Gynecology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou China

**Background:** HBsAg seroconversion and HBV flares have been associated with changes in the immune system during pregnancy and postpartum. Serum pgRNA serves as a viral marker for assessing treatment response and disease flares. This study objective was to assess the predictive capability of pgRNA dynamics in determining HBeAg seroconversion in HBsAg-positive pregnant women.

**Methods:** This prospective study included pregnant chronic HBV carriers who were HBeAg-positive and had HBV DNA≥5log10 IU/ml. These individuals received antiviral prophylaxis from 24-28 weeks of gestation. Serum and plasma samples were regularly collected and quantitatively analyzed to observe the dynamics changes of serum pgRNA and to evaluate the relationship between pgRNA and HBV DNA, HBsAg, ALT, CD4 and CD8.

**Results:** In this study, of 106 pregnant women with HBeAg-positive who received TDF median treatment duration of 15.96±2.38 weeks were followed up until 48 weeks postpartum. Out of the 33 (31.13%) individuals who experienced HBV flares and necessitated re-antiviral therapy, 14 (42.42%) patients demonstrated concurrent serological conversion. The levels of serum pgRNA exhibited dynamic fluctuations during pregnancy and postpartum. There was an observed association between serum pgRNA and HBV DNA at baseline (p<0.05), but this correlation ceased to exist following TDF treatment. Furthermore, a correlation was observed between serum pgRNA and HBeAg, and pregnant women with HBV pgRNA levels below 100 exhibited a higher likelihood of experiencing seroconversion (p<0.05).

**Conclusions:** The extent of HBV replication and flares can be better comprehended by assessing the level of pgRNA, which can serve as an biomarker for predicting HBeAg seroconversion.

Abstract Submission No. 101750

**P-0137**

**Safety and Efficacy of TAF in HBV PMTCT**

Chengjing Tao¹,², Shuorong Liu², Guorong Han³

¹Department of Obstetrics and Gynecology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou China, ²Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University Hangzhou China, ³Department of Obstetrics and Gynecology, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine Nanjing China

**Background:** There is limited available data regarding the safety and efficacy of Tenofovir alafenamide fumarate(TAF) for pregnant women and fetus, despite its potential interference with the mother-to-child transmission of Hepatitis B virus (HBV). This study aims to investigate and compare the clinical effectiveness and safety of TAF and
Methods: There were 96 cases of pregnant women with HBV and their newborns in the study, which employed a retrospective cohort study design.

Results: Compared to TDF in pregnant women with HBeAg-positive, TAF was more effective in reducing serum HBV-DNA levels. Neither TAF nor TDF elicited intrauterine infections in neonates. There were no statistically significant disparities observed among pregnant women in rates of HBeAg seroconversion, ALT flare, cesarean section, postpartum hemorrhage, prematurity, or congenital malformations. There were no notable disparities observed in the development and complications of infants.

Conclusion: TAF exhibited a significant capacity to decrease the peripheral blood HBV-DNA level in pregnant women with a high hepatitis B virus load, consequently reducing the risk of mother-to-child transmission of the virus compared to TDF. TAF antiviral therapy is recommended for pregnant women in the middle and late trimesters who have a high hepatitis B virus load.

Abstract Submission No. 101759

P-0138

Effectiveness of an Alert System for Medical Records and iTACT-HBeAg to Prevent HBV Reactivation

Takehisa Watanabe1, Katsuya Nagakou1, Maki Nomura1, Yoko Yoshimaru1, Hiroko Setoyama1, Yasuhito Tanaka1

1Dept. of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan, 2Liver Disease Center, Kumamoto University Hospital Kumamoto Japan

Aim: To prevent HBV reactivation by immunosuppressive agents and antiviral agents, we established an electronic medical record alert plus direct message (DM) system and introduced a highly sensitive quantitative HB core- associated antigen test (iTACT-HBeAg) for rapid diagnosis of HBV reactivation. We evaluated the effectiveness of the monitoring system in our hospital.

Methods: (1) We confirmed the status of cases in which the display alert was overridden. (2) We studied de novo reactivation cases from March 2020 to December 2022. (3) Stored sera from patients who met the criteria for nucleic acid analog (NA) agent administration (HBV-DNA ≥1.3 LogIU/mL) during reactivation monitoring were measured with iTACT-HBeAg.

Results: (1) In 2021 and 2022, the number of invalidated alert cases was 2836 (37%) and 2586 (30%), respectively. 167 (25%) out of 668 cases sent DM were appropriately addressed; for HBs antigen-positive cases, all cases were appropriately addressed after DM was sent. (2) From March 2020 to December 2022, 17340 cases (3272 cases) of HBV-DNA were measured, of which 17 were HBsAg negative and HBcAg positive and 17 were de novo reactivations requiring treatment. (3) Of the 6 cases requiring treatment and using iTACT-HBeAg, HBeAg was detected earlier than PCR in two cases, three cases were positive concurrently with PCR, and one case was determined to be positive earlier by PCR.

Conclusions: The promotion of testing using DM for alert- overridden cases was effective. In addition, iTACT-HBeAg may be a potential alternative to the PCR method for reactivation monitoring.

Abstract Submission No. 101778

P-0140

Epidemiology and clinical features of acute hepatitis B and Delta in Mongolia

Badamnachin Batsukh1, 2, Jagz Amarsanaa1, Nyamsuren Naranzul1, Byambasuren Amgalan1, Oidov Baatarkhui3

1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2National Center for Communicable Diseases Ulaanbaatar Mongolia, 3Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia, 4Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 5General hospital Arkhangai Mongolia

Objective: To investigate the clinical and laboratory features and the rate of development to chronic infection in patients with acute hepatitis B and delta in adult patients.

Materials and methods: A total of 182 patients with acute hepatitis B (AHB) and acute hepatitis Delta (AHD) were enrolled and followed-up 12 months in this study. They admitted to the acute viral hepatitis unit at NCCD between January 2016 and January 2018. All participants provided written informed consent and the study had been fully explained and agreed. All laboratory tests were performed using standardized laboratory procedures at NCCD.

Results: A total of 182 participants enrolled, 59.3% were male. 105 patients were diagnosed with acute hepatitis B (AHB), five patients were diagnosed with HBV/HDV co-infection, and 72 patients were diagnosed with acute HBV/HDV super-infection on chronic hepatitis B. Mean age was 25.2±6.1 years in AHB group, 30±7.6 years in HBV/HDV super-infection group and 28.4±2.2 years in HBV/HDV co-infection (p=0.0001). In patients with AHB and HBV/HDV co-

Hypomethylation of IL-22R1 predicts prognosis in acute-on-chronic hepatitis B liver failure

Zhaoqiu Wang1, Xing Su1, Xuefei Wei1, Jihui Li1, Liyan Han1, Shuai Gao1, Yuchen Fan3, Kail Wang1, 2

1Department of Hepatology, Qilu Hospital of Shandong University Jinan China, 2Institute of Hepatology, Shandong University Jinan China

Aims: To evaluate the methylation level of IL-22R1 promoter in acute-on-chronic hepatitis B liver failure and determine its predictive value for prognosis.

Methods: 107 patients with ACHBLF, 79 with chronic hepatitis B (CHB), and 48 healthy controls (HCs) were retrospectively enrolled. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression pattern of IL-22R1 in ACHBLF in peripheral blood mononuclear cells (PBMCs). IL-22R1 methylation level in PBMCs was detected by MethyLight.

Results: The level of IL-22R1 mRNA in patients with ACHBLF was significantly higher than that in patients with CHB (p<0.001) and HCs (p<0.0001). IL-22R1 promoter methylation levels were significantly lower in patients with ACHBLF than in those with CHB (p<0.0001) and HCs (p<0.0001). Meanwhile, the PMR value of IL-22R1 was notably negatively correlated with the mRNA expression level (r=-0.356, p<0.001). At the same time, the level of IL-22R1 promoter methylation was also an independent factor in the development of ACHBLF. When the IL-22R1 promoter methylation level was used to diagnose ACHBLF, its predictive value was superior to the MELD score, especially 1-month.

Conclusions: IL-22R1 methylation levels had better diagnostic value in predicting 1-month mortality in ACHBLF and it may become a promising non-invasive novel predictive biomarker for predicting the short-term prognosis of patients with ACHBLF.
infection, the clinical symptoms completely disappeared and liver function tests returned to normal. Although, changes in liver function test findings were statistically significantly different comparing to other groups ALT (85.5±125.8; 18.2±36 vs 13.8±6.5; p=0.0001), AST (63.4±67.1; 18.9±19.2 vs 19.7±9.6; p=0.0001) by final follow-up.

Conclusion: 6.7% of patients with acute hepatitis B virus infection, 40% of patients with HBV/HDV co-infection and 93.3% of patients with HBV/HDV super-infection developed chronic infection. In patients with AHB and HBV/HDV co-infection, the clinical symptoms and liver function tests were completely cleared.

Abstract Submission No. 101790
P-0141

A long-term observation of TAF switching for chronic hepatitis B virus infection

Kazuto Tajiri1, Yuka Hayashi1, Aiko Murayama1, Nozomu Muraishi1, Ichiro Yasuda1

1Toyama University Hospital Toyama Japan

Tenofovir alafenamide fumarate (TAF) had been available as anti-viral treatment for hepatitis B virus (HBV) infection. TAF monotherapy has been also considered as switching from entecavir (ETV), tenofovir (TDF) or two nucleos(t)ide analogues (NAs) combination. TAF is expected in HBsAg decrease and serum phosphorus (P) increase but is concerned in cholesterol metabolism. In present study, we retrospectively evaluated long-term changes in HBsAg, eGFR, serum P and cholesterol in patients with TAF switching. 68 patients with TAF switching was included to present study. 39 males, median age of 63 years old, 60 patients with HBeAg-negative and 10 with HCC history were included. Median observation period was 35 months from TAF switching in present study. 45 with ETV, 3 with TDF and 18 with 2 NAs combination were administered as previous therapies. After TAF switching, the control of HBV-DNA was good, and significant alterations in renal function or serum P were not found. Regarding with HBsAg decrease, HBsAg was decreased at only 24 months after TAF switching in overall cohort (pre 1875, 24 months 1588 IU/mL, p<0.05), and significant HBsAg decreases was not found at other time points (3, 6, 12, 35, 48 and 60 months after TAF switching). However, significant HBsAg decrease was found in patients with HBsAg<100 before TAF administration (28.5, 24.0, 24.0, 21.6, 16.0, 1.84 and 0.07 IU/mL at 0, 6, 12, 24, 36, 48 and 60 months after TAF switching, respectively). HBsAg loss was found in 3 patients in present study. As for cholesterol, no clinically significant changes were found after TAF switching. Good tolerability was observed with no adverse events after TAF switching. TAF is a useful NA for chronic HBV infection as a candidate of NA switching with good anti-viral effects and safety profiles.

Abstract Submission No. 101852
P-0143

Incidence of Osteopenia and Osteoporosis in Chronic Hepatitis B Patients: A South Korea Cohort Study

Hye Won Lee1,2,3, Sungshin Kwon4, Yeo Rae Moon5, Hyunjung Ahn5, Juyeon Lee5, Sang Hoon Ahn1,2,3

1Department of Internal Medicine, Yonsei University College of Medicine Seoul South Korea, 2Institute of Gastroenterology, Yonsei University College of Medicine Seoul South Korea, 3Yonsei Liver Center, Severance Hospital Seoul South Korea, 4Gilead Sciences Korea, Ltd. Seoul South Korea, 5Data Platform Division, KakaoHealthcare Corp. Seongnam-si, Gyeonggi-do South Korea

Background: Chronic hepatitis B (CHB) patients have higher osteoporosis/fracture risks, but hepatologists have low awareness of metabolic bone diseases in CHB patients. Bone health assessment may be beneficial in evaluating/monitoring treatment plans for CHB patients. We report the epidemiology and risk factors associated with osteopenia/osteoporosis in CHB patients in South Korea.

Methods: This retrospective cohort study included patients ≥19 years who underwent bone mineral density (BMD) testing ≥2 times between 2005–2021 at Severance Hospital. Demographic factors/comorbidities for CHB and non-CHB patients were propensity-matched at a 1:4 ratio. Cox proportional hazards regression models were used to estimate hazard ratios (HR; 95% confidence intervals [CI]) for assessing osteoporosis risk.

Results: Incidence of osteopenia/osteoporosis in CHB/non-CHB patients was 25.8% and 28.7%, respectively. After propensity-matching, 275 CHB patients (mean age: 57.8 years) and 1,100 non-CHB patients (mean age: 57.9 years) with normal BMD in the first BMD test were analyzed. In the second BMD test, 73.8%/24.7%/1.5% of CHB patients and 70.7%/26.5%/2.8% of non-CHB patients had normal BMD/osteopenia/osteoporosis, respectively. Osteoporosis risk factors (HR [95% CI]) in CHB patients were age (1.00 [1.00–1.00]), body mass index (BMI) ≥25 (0.65 [0.50–0.84]), chronic kidney disease (2.10 [1.50–2.80]), and proton pump inhibitor use (0.78 [0.62–0.99]). There was no significant difference between the cumulative hazard for patients with/without CHB (Figure 1).
Conclusion: CHB patients showed similar osteopenia/osteoporosis risks compared to non-CHB patients. Further studies of bone disease in CHB patients may encourage closer monitoring and elucidate factors that impact bone health in CHB patients.

Abstract Submission No. 101887  
P-0144

Virological Response at 12 Months Predicts Lower HCC Risk in Genotype D Chronic Hepatitis B Patients

Guspe Adali1, Fatih Guzelbulut2, Nermin Mutlu Bilgic3

1University of Health Sciences Istanbul Umranie Training and Research Hospital Istanbul Turkey, 2University of Health Sciences Istanbul Sancaktepe Training and Research Hospital Istanbul Turkey

OBJECTIVES: Recent studies have suggested that achieving normal serum ALT levels after antiviral treatment for chronic hepatitis B (CHB) is linked to a decreased likelihood of liver-related complications.1,2,3 Nevertheless, these studies predominantly included CHB patients with genotype C. It is still uncertain whether earlier normalization of ALT levels is associated with a lower risk of hepatocellular carcinoma (HCC) in patients with CHB.

METHODS: A total of 774 CHB patients who were predominantly genotype D, without a history of HCC, and who were treated with NAs for more than 1 year from 2007 to 2022, were included from two district hospitals in Istanbul, Turkey. Normal ALT was defined as ≤ 35 U/L (men) and ≤ 25 U/L (women), and virological response (VR) as serum hepatitis B virus DNA <15 IU/mL.

RESULTS: The median age was 46.8 years (18—77), and 64.5% of the patients were male. During the median 5.8 years of treatment, 43 (5.6%) patients developed HCC. The baseline characteristics are summarized in Table 1. ALT normalization occurred in 63% of patients at 1 year and 62.8% of patients at 2 years and was not associated with HCC risk in time-dependent Cox analyses. Patients who achieved VR at 12 months had a significantly lower HCC risk than patients without VR at 12 months (HR 0.48; p 0.034) (Figure 1). Male sex, age, cirrhosis at baseline, and VR at 12 months were independent risk factors for hepatocellular carcinoma (Figure 2).

DISCUSSION: In patients with CHB treated with entecavir or tenofovir, VR at 12 months, but not ALT normalization, was independently associated with a lower HCC risk in patients with predominantly genotype D CHB.

Abstract Submission No. 101893  
P-0145

Prediction of fibrosis stage using HBsAg quantification in CHB patients with HBsAg-positive

Tetsuya Hosaka1, Fumitaka Suzuki2, Hiromitsu Kumada3

1Department of hepatology, Toranomon Hospital Tokyo Japan

Background: It is often difficult to undergo liver biopsy and antiviral therapy in the optimal timing in chronic hepatitis B (CHB) patients with HBsAg-positive including immune-tolerant phase (IT).

Methods: This study enrolled 866 HBsAg-positive patients who underwent liver biopsy without antiviral therapy. We aimed to predict liver fibrosis progression based on HBsAg levels, stratified by IT or immune-active (IA) phases.

Results: 68 cases (7.9%) were classified as IT stage, and 798 cases (92.1%) were classified as IA stage. The distribution of liver fibrosis stages was F1 38%, F2 28%, F3 20%, and F4 14%, respectively. The median HBsAg levels by liver fibrosis stage were F1: 4.26 log IU/mL, F2: 3.91, F3: 3.60, and F4: 3.32, showing a trend toward lower HBsAg levels as the stage progressed (P-trend <0.001). The median HBsAg level by stage was 4.26 logIU/mL for IT and 3.83 for IA (P <0.001). When the cutoff was HBsAg level = 10,000 IU/mL or higher, the capability to predict fibrosis below F1 in the IT stage was 86% sensitivity, 63% specificity, 72% positive predictive value, and 80% negative predictive value. Similarly, the sensitivity was 63%, specificity was 70%, positive predictive value was 54%, and negative predictive value was 77% in the IA stage.

Conclusion: An inverse correlation was found between liver fibrosis progression and HBsAg levels. HBsAg levels were useful for predicting minimal fibrosis stage patients in the IT stage.
Evaluation of Sequential Therapy Peg-IFN and NA Compared to Monotherapy in CHB Patients

Roland Helmizar1, Nana Liana1, Ruhsyadati Ajisman1, Rahma Triyana1

1Baiturrahmah University Padang Indonesia

Aims: CHB remains a significant global health issue that can result in the development of liver cirrhosis and HCC. It is crucial to monitor patients with CHB infection to identify any changes in the disease’s progression, such as HBsAg seroconversion. While NA is known for effectively suppressing viral load, its long-term use poses a high risk of resistance. Therefore, an alternative treatment approach could involve adding an immunomodulator. This study aimed to evaluate the response at the end of sequential therapy (NA and Peg-IFN) compare with monotherapy in suppressing HBsAg.

Methods: A systematic search through PubMed, Scopus, Cochrane Library, and EBSCO was conducted to find this topic. The studies were selected and critically appraised.

Results: In a study by Zhang et al. (2019), it was found that the early combination therapy resulted in a significantly higher proportion of patients with a reduction of HBsAg levels by more than 1500 IU/mL (61/108, 56.5%) compared to the NA monotherapy group (63/151, 41.7%). This suggests that the combination therapy may be more effective in reducing HBsAg levels. Similarly, Heng Chi (2017) observed a greater decrease in HBsAg levels in patients receiving peginterferon add-on therapy compared to those on NA monotherapy from week 0 to week 48. (−0.40 vs. −0.15 log IU/mL; P = .005). These findings indicate that the addition of peginterferon to the treatment regimen may lead to better outcomes in terms of HBsAg reduction.

Conclusions: Sequential therapy (NA and Peg-IFN) can be effectively made HBsAg loss and seroconversion.

Streamlined vs Traditional Treatment eligibility criteria using Chronic Hepatitis B Treatment Phase

Edhel Tripon1,2, Shanaia Esthelle Joy Daguit3, Ramonito Nuique4, Ethel Dominique Viray5, Beatrice Tianceo4

1Liver Center, The Medical City Pasig Philippines, 2Ateneo School of Medicine and Public Health Pasig Philippines, 3Cancer CARE Registry and Research Philippines Foundation, Inc. Pasig City Philippines, 4National Institute of Health, University of The Philippines Manila Philippines, 5Augusto P. Sarmiento Cancer Institute, The Medical City Pasig Philippines, 6Department of Medicine, Philippine General Hospital Manila Philippines

Background: Hepatitis B treatment criteria rely on indirect measures of risk factors for disease severity including ALT, DNA, eAg status. Fibrosis information may not always be available, especially in the Philippines. Traditionally, patients in the immune active and immune reactivation phase are deemed treatment eligible. In 2021, the Philippines expanded its treatment criteria to include individuals with ALT elevation and DNA > 2000 IU/ml.

Methods: Data from 390 treatment naïve HBsAg+ individuals from the “Early Cancer Detection in the Liver of Filipinos with Chronic Hepatitis B using AI-driven integration of clinical and genomic biomarkers (CANDLE Study)” were analyzed. Patients were classified by phase of infection. Clinical and fibrosis data, which was measured by Fibrotest, was analyzed.

Results: Using traditional criteria, 15.6% of these HBsAg + individuals were deemed treatment-eligible (HBeAg + Immune active and HBeAg – Reactivation phase). 22.9% of these individuals had Fibrotests of ≥F2. 17.86% of the population met streamlined Philippine criteria for treatment and 34.2% of these individuals had Fibrotest of ≥F2. Streamlined criteria increased the patients eligible for treatment from 15.6% to 17.86%.

32.9% of the individuals were in the gray zone/ indeterminate phase (see table) and of this population 7.7% had F2 or higher in the indeterminate phase, 2.3% cirrhosis, 0.78% HCC.

Conclusions: Streamlined criteria using DNA and ALT level may increase the number of patients treated for Hepatitis B, including those with significant fibrosis. A significant proportion of individuals are in indeterminate phase and these may include individuals with significant liver disease.
Methods: A retrospective analysis was conducted, comprising 37 CHB patients. Clinical data, serum biomarkers, Fib-3 index, Fib-4 scores, TE measurements, and M2BPGi values were collected and analyzed. Correlation analyses were performed to assess the relationships between Fib-3, Fib-4, FibroScan, and M2BPGi values using Spearman’s rho.

Results: This investigation revealed a significant and positive relationship between the Fib-3 index and Fib-4 (r = 0.626, p<0.01), as well as with FibroScan (r = 0.681, p<0.01), in the identification of advanced fibrosis among individuals diagnosed with CHB. However, while a positive association was observed between the Fib-3 index and M2BPGi, the statistical analysis indicated a lack of significance (r = 0.210, p = 0.213).

Conclusion: The findings support the utility of the Fib-3 index as an effective non-invasive method for identifying advanced fibrosis in CHB patients, particularly in concordance with Fib-4 and FibroScan assessments.

Risk factors for hepatitis B virus reactivation in patients with hematological malignancies

Isabela D Staicu1, Nicoleta Mihai1,2, Violeta Molagic1,2, Cătălina Tilișcan in Tilișcan1,2, Anca R Negru1, Anca Răzvan1,2, Laurențiu M Stratan1, Ştefan S Aramă1,2, Victoria Arama1,2

1“Prof. Dr. Matei Balș” National Institute for Infectious Diseases Bucharest Romania, 2“Carol Davila” University of Medicine and Pharmacy Bucharest Romania

Background: Medical advances lead to accurate diagnosis of malignancies and use of efficient immunosuppressive therapies. Patients with viral hepatitis receiving chemotherapy are at risk of developing viral reactivation. Complete evaluation of viral hepatitis serologic status is necessary in oncological patients.

Methods: We performed a retrospective observational study, in which we included patients with hematological malignancies and positive serological markers for hepatitis B virus infection (HBV) recorded in a Romanian tertiary hospital between 2007 and 2023. Clinical, biological and treatment-related data were collected. We analyzed patient characteristics and risk factors for HBV reactivation (HBVr) using SPSS Statistics (version 23).

Results: We included 68 patients, 47 males (69%) with a median age of 58 years (IQR: 54-68) and 21 women (31%) with a median age of 61 years (IQR: 58-65.5). Six patients were co-infected with hepatitis C virus. Most common hematological malignancies in the enrolled patients were non-Hodgkin lymphoma (56%) and chronic lymphocytic leukemia (29.4%). Most patients (87%) received chemotherapy. Half of the patients had rituximab in their treatment regimen. HBVr occurred in 23 patients (33.8%). Among them, 4 patients (17.4%) died. All patients with HBVr received chemotherapy. We found that HBVr was correlated with the median length of time since the diagnosis of the hematological malignancy and with the number of chemotherapy cycles. The median number of cycles for patients with HBVr was 6, compared to 3 in patients without HBVr (p=0.001).
Conclusions:
Approximately 1/3 of patients receiving chemotherapy developed HBV reactivation and it correlated with the number of administered cycles.

Abstract Submission No. 200189
P-0153

Reactivation of hepatitis B virus following immune checkpoint inhibitors

Rie Sugimoto1, Shigeru Kusumoto2, Kisato Nosaka3, Takakazu Nagahara1, Akihiro Tamori2, Seijin Nadano4, Satoshi Hagiwara1, Naoki Morimoto5, Keisuke Amano5, Masashi Mizokami6

1Department of Hepato-Biliary-Pancreatology NHO Kyushu Cancer Center Fukuoka Japan, 2Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital Aichi Japan, 3Department of Hematology Rheumatology and Infectious Diseases, Kumamoto University Kumamoto Japan, 4Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, School of Medicine, Faculty of Medicine, Tottori University Yonago Japan, 5Department of Hepatology, Osaka City University Graduate School of Medicine Osaka Japan, 6Department of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center Matsuyama Japan, 7Department of Gastroenterology and Hepatology, Kinki University School of Medicine Sayama Japan, 8Department of Medicine, Division of Gastroenterology, Jichi Medical University Shimotsuke Japan, 9Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine Kurume Japan, 10Genome Medical Sciences Project, National Center for Global Health and Medicine Ichikawa Japan

Background: The risk of reactivation of hepatitis B virus (HBV) during and after immune checkpoint inhibitor (ICIs) is not well known yet. We conducted a multicenter retrospective study to evaluate the risk and characteristics of HBV reactivation in patients with solid cancers receiving ICIs.

Methods: Cohort1) HBsAg-positive patients treated with ICI therapy for solid tumors at a Japan Society of Hepatology-accredited facility were retrospectively analyzed with or without HBV reactivation. Cohort2) Cases of HBV reactivation defined as the detection of HBV DNA among HBsAg-negative but HBcAb-positive patients treated with ICIs were collected and analyzed.

Results; Cohort1) A total of 314 patients with solid tumors who were HBsAg-positive and treated with ICIs were enrolled. Of these, 14 (4.4%) had an elevation of ≥1.0 logIU/ml of which 7 (2.2%) met the criteria for reactivation of AASLD. The median time to reactivation was 334 days, and significant risk factors for reactivation were the presence of concomitant chemotherapy, chemotherapy use prior to ICI treatment, prolonged steroid use, and no prophylactic administration of a nucleic acid analog. Cohort2) Seven cases of HBV reactivation after ICIs in HBsAg-negative and HBcAb-positive patients were observed. Six of the 7 patients were treated with concomitant chemotheraphy or pretreatment chemotherapy. 1 patient had acute liver injury.

Conclusions: HBV reactivation can occur not only in HBsAg-positive but also HBsAg-negative patients with solid tumors receiving ICIs. To prevent HBV-related hepatitis, Antiviral prophylaxis may be useful for HBsAg-positive patients, whereas HBV DNA monitoring is necessary in HBsAg-negative but HBcAb-positive patients receiving ICIs.

Abstract Submission No. 200266
P-0154

Antiviral therapy reduces the risk of HCC recurrence after resection/ablation in chronic hepatitis B

Asim Abdulhamid1, Edward gane1
1Auckland City Hospital, Te Toka Tumai Auckland New Zealand

Introduction:
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide, 60% of cases are attributable to chronic hepatitis B (CHB). The long term success of curative resection or ablation for early HCC (Barcelona Stage A or 0) is limited by high rates of recurrence in 38.6-78%. HBV suppression with antivirals can decrease the incidence and recurrence rate of HBV related HCC. This study reviews the relationship between antiviral therapy, HBV DNA levels, and the rate of recurrence post resection/ablation in a New Zealand between 2003-2023

Methods: Patients with HBV associated HCC who had surgical resection or ablation were identified from the database of the NZ Liver Transplant Unit, a national referral centre for HCC care, between 2003 and 2023. Patients were retrospectively analyzed and their outcomes compared using Cox regression analysis

Results: A total of 343 patients were assessed between 2001 and 2023, 216 underwent resection, 127 underwent ablation. The 5 year recurrence rate was 55.1%. Suppressed HBV viral load at the time of resection/ablation is associated with improved recurrence free survival hazard ratio 0.65 (P<0.05, 95% CI 0.1-0.876)

Patients established on antiviral treatment had a significantly reduced rate of HCC recurrence aHR 0.69 (95% CI 0.5-0.94).

Commencement of antiviral therapy after resection/ablation did not significantly affect recurrence aHR 1.26 (95% CI 0.92-1.74)

Discussion: Patients with HBV DNA suppression at the time of treatment had a significant reduction in the rate of recurrence of HCC after resection/Ablation. Being established on antiviral therapy is associated with a reduction in the rate of recurrence, however the survival benefit was not demonstrated in our study. Treatment after HCC treatment did not show any change in the rate of recurrence.

Abstract Submission No. 100310
P-0155

Prevalence and genotype distribution of HCV among general population of Arkhangai province, Mongolia

Byambasuren Amgalan1,2, Delgerkhangai Munkhbayar1, Erdenebat Byambatsogt2, Nyamsuren Naranzul1, Nyamdavaa Khurelbaatar2, Oidov Baatarkhuu1,4,5
1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2General hospital Arkhangai Mongolia, 3Health Department Arkhangai Mongolia, 4Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 5Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Background: Globally, an estimated 58 million people have chronic hepatitis C virus infection, with about 1.5 million new infections occurring per year. Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular carcinoma (HCC) in Mongolia. We aimed to investigate the population-based prevalence of HCV infection and genotype distribution among 2128 apparently healthy populations in Arkhangai province in Mongolia.

Methods: Between May 2022 and August 2023, sera from 2128 residents of Arkhangai province were collected by two-stage cluster random sampling, and anti-HCV was tested. Anti-HCV-positive samples were tested for HCV RNA by reverse transcription polymerase chain reaction, and HCV genotype was determined.

Abstract Submission No. 00247
P-0156
**Results:** The mean age of the subjects was 56.5±14.8 years, and 1170 (54.98%) were male. Overall, the prevalence of anti-HCV was 17.8% (378/2128) and HCV RNA was detected in 283 subjects (13.3%). Among 283 HCV RNA-positive samples, 278 (98.23%) were classified into genotype 1b, three were genotype 1a and two were genotype 2a. The HCV genotype 2a isolates were obtained from a 54-year-old male and a 60-year-old female who resided in rural areas of Arkhangai provinces. The highest rate of HCV infection was among the 40-59 age group (p<0.001).

**Conclusions:** Approximately 13.3% of apparently healthy population had detectable HCV RNA in Arkhangai province, and the predominant genotype of HCV was 1b. Our experience in Arkhangai, demonstrates that through commitment of provincial public health departments, massive screening of populations at risk groups for HCV infection is feasible in resource limited settings.

Abstract Submission No. 100626

**P-0156**

**Molecular and Evolutionary Analysis of HCV genotypes in Mexico**

Arturo Panduro1,2, Saul Laguna-Meraz1,2, Alexis José-Abrego1,2, Sonia Maria Roman-Maldonado1,2

1Department of Genomic Medicine in Hepatology, University of Guadalajara Guadalajara Mexico, 2Civil Hospital of Guadalajara, Fray Antonio Alcalde Guadalajara México

Hepatitis C virus (HCV) represents a significant global health challenge despite treatment options. The seven genotypes (1-7) and more than 70 sub-genotypes have a global distribution. Although the virus's origin remains unknown, the potential introduction into different regions is often linked to historical events. This study aimed to ascertain the timeline of arrival of the main HCV sub-genotypes in Western Mexico.

In this cross-sectional study, 135 HCV sequences were analyzed. Sanger sequencing and phylogenetic analysis (MEGA11) were performed. Nucleotide substitution models were computed using the jModeltest, yielding GTR + I + G. Models were assessed with strict and relaxed molecular clocks using 500,000,000 MCMC chains in BEAUti and BEAST. Results and common ancestor dates were determined with Tracer v1.5 and FigTree v1.4.0.

HCV genotype 1a predominated in 54.1%, followed by 1b (14.1%), 2a (2.2%), 2b (16.3%), and 3a (13.3%). The Most Recent Common Ancestor (MRCA) for HCV sub-genotype 1a was dated to 1977 (95%CI =1930-2003), while sub-genotype 1b MRCA was 1913 (95%CI = 1759-2008). Sub-genotypes 2a/2b had an estimated MRCA in 1998 (95%CI = 1979-2010), and sub-genotype 3a MRCA was estimated as in 1965 (95%CI = 1916-2010). The introduction of sub-genotypes 1a and 3a may be linked to the Vietnam War, whereas sub-genotype 1b with WWI. Both events are related to the post-war migration of veterans to Mexico, tainted blood transfusions, and the current increase in injection drug use. Further molecular-evolutionary studies are required to monitor emerging strains or the decrease of the prevalent genotypes due to elimination strategies.

Abstract Submission No. 101180

**P-0158**

**Identifying mitochondria-related genes that contribute to hepatocarcinogenesis after HCV elimination**

Katsuya Nagaoka1, Masaya Onishi2, Hiromitsu Hayashi3, Hideo Baba4, Yutaka Suzuki5, Yasuhito Tanaka4, Toru Okamoto6, Yasuteru Kondo1, Mitsuo Shimada4, Atsushi Nakajima1, Satoshi Narihara1, Takehisa Watanabe1, Hiroko Setoyama1, Hideaki Nao1, Etsuko Ito1

1Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan, 2Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo Chiba Japan, 3Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan, 4Department of Microbiology Juntendo University School of Medicine Tokyo Japan, 5Department of Hepatology, Sendai Tokushukai Hospital Miyagi Japan, 6Department of Surgery, Tokushima University Tokushima Japan, 7Department of Gastroenterology & Hepatology, Yokohama City University School of Medicine Kanagawa Japan

**Background:** To elucidate the mechanism of carcinogenesis after SVR, we performed a comprehensive gene expression profiling.

**Methods:** RNA-seq analysis was performed on background liver tissue from thirteen patients who developed HCC after SVR with IFN and underwent surgical resection at the collaborating institution (HCC group) and from ten patients who underwent liver biopsy 1 year after achieving SVR with DAA and have not developed hepatocarcinoma to date (non-HCC group). We then examined the differences in gene expression between the HCC and non-HCC groups. We also performed an integrated analysis using RNA-seq data from public databases on HCC cases with persistent HCV infection and HCC cases with non-B non-C liver disease. In addition, we performed RNA-seq analysis using liver-derived Huh7 cells prepared (1) before HCV infection, (2) 4 days after infection, (3) 7 days after HCV elimination by DAA in (2), and (4) 10 more days after drug-free from (3).

**Results:** Comparative analysis identified an increase of 771 genes and a decrease of 303 genes in the background liver tissue of the HCC group compared to the non-HCC group as differentially expressed genes (DEG, \( \log 2 \text{Fold change} \geq 1, \text{FDR}<0.01 \)). The large number of decreased DEG were related to mitochondrial metabolic function. On the other hand, among the increased DEG, we identified the MRP1 gene, which was particularly highly expressed in adjacent liver tissue of HCC cases after HCV elimination compared to other etiology, and it has been reported to regulate the overall morphology of mitochondria. As for in vitro experiments using HCV-infected cells, gene ontology analysis showed that genes related to mitochondrial organization, including MRP1 gene, were significantly upregulated after HCV elimination compared to HCV-infected cells.

**Conclusion:** Mitochondrial dysfunction due to abnormal MRP1 gene expression was suggested as a molecular mechanism contributing to hepatocarcinogenesis in the adjacent liver tissues after HCV elimination. MRP1 expression may be a predictive marker for HCC.

Abstract Submission No. 101808

**P-0158**

**Immune Enhancement by the Hepatoprotective Temulawak Rhizome in The of Liver Disease in Hepatitis C**

Andi Nursanti Andi Ureng1, Andi Masyita Putri2

1Wallacea University Mamuju Indonesia, 2UNI ALAUDDIN MAKKASSAR Indonesia

Temulawak is one type of plant native to Indonesia and is quite popularly used for treatment of hepatic diseases. One of the hepatic diseases is hepatitis C caused by the HBV virus so substances that can inhibit HBV gene expression and replication using hepatoprotective substances are needed. The aim is to describe Temulawak phytochemicals that have hepatoprotective effects against the hepatitis c virus. This study uses...
qualitative and quantitative research with methods derived from secondary data. The subjects in the hepatoprotective effect were male Sprague Dawley rats, 3-4 months old, weighing 150-200 grams made in 5 groups. The phytochemical contains polyphenol and flavonoid compounds in the form of curcuminoinds and curcumin analogs. There are essential oils consisting of d-camfer, cyclo isoren, mirsen, tumerol, xanthorrhizol, zingiberen, zingeberol. The hepatoprotective activity of temulawak can be caused by free radical capture and antioxidative activity resulting from the presence of polyphenol and flavonoid compounds and other substances in the temulawak rhizome. Curcumin can also increase glutathione S-transferase (GST), and inhibit several pro-inflammatory factors such as nuclear factor-kB (NF-kB) and profibrotic cytokines so that inflammatory by-products are reduced. Animal models showed that rats given temulawak rhizome decoction induced by aspirin decreased levels with a dose of 2.6 g/kgBB and 5.2 g/kgBB liver damage. Other clinical results showed that curcumin at high doses (1000-2000 mg/day) did not harm the body. Temulawak rhizome with phytochemical content of polyphenols, flavonoids, and other substances has a hepatoprotective effect so that it can be used as an alternative hepatoprotection in Hepatitis C patients.

Diagnostic Performance of the Genedrive HCV in Hemodialysis Setting at Cipto Mangunkusumo Hospital

Andri Sanitioso Sulaiman1, Aida Lydia2, Nuri Dyah Indrasari1, Ni Made Hustrini1, Desti Rachmani1
1Cipto Mangunkusumo Hospital Jakarta Indonesia, 2Nephrology and Hypertension Division, Departemen of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital Jakarta Indonesia, 3Department of Clinical Pathology, Faculty of Medicine Jakarta Indonesia, 4Nephrology and Hypertension Division, Departemen of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital Jakarta Indonesia, 5Hepatobiliary Division Department of Internal Medicine Jakarta Indonesia

Background/Aim: Genedrive is a diagnostic tool to detect HCV viral load qualitatively. Genedrive is one of the point of care diagnostics is essential to detect and treat hepatitis C virus in single visit. The potential use of Genedrive is in remote area and in key population. The World Health Organization is targeting to eliminate hepatitis by 2030, which decreasing infections by 90%, and deaths by 65%. Chronic kidney disease (CKD) patients on hemodialysis are among the population at risk of being infected of hepatitis C due to nosocomial transmission. Therefore, there it is a need for simple, handy and cost-effective examination of such as Genedrive. This study aimed to assess the diagnostic accuracy of Genedrive HCV detection in Hemodialysis setting.

Methods: This study used a cross-sectional design. Genedrive results were evaluated in 64 chronic kidney disease on hemodialysis at Cipto Mangunkusumo Hospital, Jakarta. ROC analysis conducted to assess significant hepatitis C among chronic kidney disease on hemodialysis.

Results: The calculated detection limit of Genedrive was 3.1x10^9 IU/mL. Genedrive HCV assay showed 93.3% sensitivity, 91.2% specificity, 92% negative predictive value, and 93% positive predictive value to detect HCV. 10.60 positive likelihood ratio, and 0.073 negative likelihood ratio.

Conclusion: Point of care test could contribute to the elimination hepatitis C. Genedrive is a part of point of care and could be a simple, portable, accurate, and reliable method for detect hepatitis C with chronic kidney disease on hemodialysis.
Results: 51.6 percent of women and 48.4 percent of men participated in the survey. The most common causes for lack of therapy were symptoms free (43.0 percent). Secondly, patients were unaware of the necessity for treatment (42.0 percent). Thirdly, patients were unaware of the current treatment policy and continued to fear IFN-based treatment (16.4 percent). In the group that had no desire for treatment, 76.6 percent had been living with HCV for more than five years and median age was 62. In contrast, 92 percent of patients in the treatment group were notified of their anti-HCV status within a year, the median age was 64.

Conclusion: Most individuals with HCV are asymptomatic, so their liver illness might be neglected, placing them at risk for disease progression. Thus, strategies should be implemented to increase patient treatment uptake.

Abstract Submission No. 100121
P-0162

Efficacy and Safety of DAAs in Elderly Chronic Hepatitis C Patients with Moderate Renal Impairment

Tamer Fouad¹, Kareem Khalili¹, Hosam Eldin Taha¹, Mary Naguib¹, Mahmoud Allam¹

¹National Liver Institute - Menoufia University Menoufia Egypt

Background: Limited data for Direct-acting antiviral drugs (DAAs) in old age or renal impairment. Aim: to investigate the efficacy and safety of DAAs in Chronic hepatitis C (CHC) elderly patients with moderate renal impairment.

Methods: Sofosbuvir/Daclatasvir for 12 weeks was investigated in 4 groups each was 85 patients.

Results: Age and estimated Glomerular Filtration Rate (eGFR) mean±SD were: G1 (70.2±6.4 years and 52.1±2.9 mL/min/1.73m²), G2 (70.5±6.8 and 37.5±4.4), G3 (45.2±7.3 and 39.5±4) and G4 (41.±10.1 and 96.8±21.8) respectively. No significant difference among groups in the clearance of HCV (98.8, 97.6, 96.5 and 100%, respectively) with total success rate of 98.2%. Insignificant higher adverse effects was noticed, except deterioration of kidney function which was significantly higher in Group 2 (20, 60, 38 and 2 patients, respectively; p<0.001). Five patients (4 in G2 and one in G3) developed deteriorated GFR (<30 ml/min) and Sofosbuvir dose was decreased to 200 mg/day, but none needed dialysis and they recovered to >30 ml/min during the follow up. Independent predictors of deterioration of kidney function were age >59.5 years, Creatinine >1.55 mg/dL, >30 ml/min during the follow up. Independent predictors of deteriorated GFR (<30 ml/min) and Sofosbuvir dose was decreased to 200 mg/day, but none needed dialysis and they recovered to >30 ml/min during the follow up. Independent predictors of deterioration of kidney function were age >59.5 years, Creatinine >1.55 mg/dL, >30 ml/min during the follow up.

Conclusion: Old age or moderate renal impairment doesn’t affect DAAs high cure success rate. Deterioration of kidney function could happen if old age with baseline moderate renal impairment. We think it is important to introduce DAAs to CHC patients as a curative therapy regardless of old age or moderate kidney diseases, but with strict follow up of their renal function and adjustment of Sofosbuvir dose if needed.

Abstract Submission No. 100123
P-0163

DAAs Effects on the Glycemic Control and Lipid Profile in Diabetic patients with Chronic Hepatitis C

Tamer Fouad¹, Ahmed Salem¹, Hassan Elshenawy¹, Gamal Badra¹, Heba Abd Allah¹, Mahmoud Allam¹, Ahmed Attia¹

¹National Liver Institute - Menoufia University Menoufia Egypt

Background: Chronic hepatitis C (CHC) is associated with increased incidence of type 2 diabetes.

Aim: to assess Direct Acting Antiviral Drugs (DAAs) effects on CHC diabetic patients.

Methods: One hundred fifty one diabetic CHC naive non-cirrhotic patients on diet modification or oral anti-diabetic medications were treated with Sofosbuvir 400mg and Daclatasvir 60mg for 12 weeks. The following labs were reviewed: Fasting blood sugar (FBG), hemoglobin A1C (HbA1C), Fasting Insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Low-density lipoprotein (LDL), Triglycerides and Cholesterol.

Results: Mean age 52.7±3.2 years, 53% females. Body weight has a significant positive correlations with FBG, HbA1c and HOMA-IR (p=0.039, 0.012 and <0.001 respectively). Overall sustained virologic response (SVR) after DAAs treatment was 98.7%. Those who achieved SVR had significant improvements in the followed labs (before and after treatment mean±SD and p value): FBG: 157.9±18.1, 121.3±11.5 mg/dL, <0.001; HbA1C: 8.3±2.1, 6.5±1.5, <0.001; Fasting Insulin: 7.1±2.1, 5.4±2.3 µIU/mL, <0.001; HOMA-IR: 2.8±0.8, 1.8±0.6, <0.001; LDL: 129.6±18.2, 125.9±16.2 mg/dL, <0.001; Triglycerides: 177.6±40.6, 172.9±41.1 mg/dL, 0.004; Cholesterol: 207.5±31.6, 202.7±28.2 mg/dL and <0.001 respectively).

Conclusion: Our data shows that presence of diabetes doesn’t worsen DAAs high cure success rate. The significant improvement of glycemic control, insulin resistance and lipid profile in those achieved SVR make it possible to hypothesize that clearance of HCV in diabetic patients could improve the glucose and lipid homeostasis control.
High efficacy of interferon-free therapy for acute hepatitis C in China

Yang Yang¹, Laiying Qin¹, Yican Li¹, Chuanlong Yang¹, Ling Li¹, Xin Fan¹, Can Wang¹, Hui Lyu¹

¹Department of Hepatology, Shandong Public Health Clinical Center Jinan China

Background: Recently, clinical trials investigating the benefit of IFN-free direct-acting antivirals treatment for acute HCV infection have been conducted. Based on the results of the cost-effectiveness analysis, DAAs should be initiated early in acute HCV infection, prior to spontaneous viral clearance. However, real-world data is limited. We aimed to evaluate the effectiveness and safety of DAA treatment regimens in the setting of AHC.

Methods: In this observational study, we enrolled 129 acute HCV patients from 2018–2019. The primary efficacy outcome was the proportion of patients with SVR12. Others were the safety and tolerability of DAA treatment.

Results: Treatment was initiated in 129 patients with AHC (median age 47.0 years; 66 males; 63 females). All had genotype GT-1b and had no HIV or HBV co-infection. Some of the 129 patients had less severe symptoms, including malaise (64, 49.61%), loss of appetite (57, 44.19%), and yellowing of urine (32, 24.81%). According to patients’ characteristics, 76 patients started treatment in the first four weeks (76/129, 59.91%), 27 patients started treatment between four and eight weeks (27/129, 21.09%), and 26 patients started treatment between eight and thirty-six weeks (26/129, 20.15%); following 15%, the following DAA regimens were prescribed: daclatasvir/assunaprevir (6.2%; 8/129), sofosbuvir/radipavir (3.1%; 4/129), ombitasvir/paritaprevir/ritonavir (16.2%; 21/129), grazoprevir/elbasvir (59.6%; 77/129) and sofosbuvir/velpatasvir (14.7%; 19/129). All AHC patients achieved a SVR12. Adverse events associated with DAA were rare.

Conclusions: Interferon-free DAA regimens can achieve 100% SVR12 in AHC patients with a favorable safety profile if treatment durations similar to CHC are used.

Expanding screening for hepatitis C in DM patient via the assistance of an auto-run alert program

Chun-Chi Yang¹, Hsing-Tao Kuo¹, Ming-Jen Sheu¹, I-Che Feng¹

¹Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center Tainan Taiwan

In the era of HCV micro-elimination, an efficient HCV screening and treatment strategy is crucial, particularly when targeting high-risk populations such as individuals with diabetes mellitus (DM). Previous studies have shown that DM patients have higher prevalence of anti-HCV antibodies compared to the general population. Additionally, treating HCV can improve blood sugar control in DM patients.

To address this, we implemented an auto-run alert program within our Hospital Information System (HIS) to assist metabolic specialists in identifying DM patients who had not undergone HCV screening during outpatient clinic visits. This program also facilitated related serological examinations for HCV screening, with automatic result reporting. Upon confirmation of hepatitis C infection, another auto-run transfer program streamlined the process of referring patients directly to hepatologist outpatient clinics for further evaluation and treatment. Following the implementation of this screening program, the anti-HCV screening rate among DM patients in our hospital dramatically increased from 35.8% to 85.6% within a six-month period. Out of 4,729 individuals who participated in the screening program, 97 patients (2.1%) tested positive for anti-HCV antibodies. Subsequently, 47 HCV patients were successfully referred to hepatologists, and 26 of them (55.3%) tested positive for HCV RNA. All of these patients received direct antiviral agents with a complete treatment course. This study demonstrates the effectiveness of an efficient auto-run alert HCV screening program implemented via the HIS in a medical center. It significantly improved the screening rate in a specific population, and the transfer program provided a convenient method to facilitate HCV treatment.

Effectiveness and safety of GLE/PIB for hemodialysis patients with hepatitis C

Naoki Hotta¹

¹masuko memorial hospital JAPAN Japan

Background/Aims: Glecaprevir/pibrentasvir (GLE/PIB) is a pan-genotypic regimen for the treatment of hepatitis C virus (HCV) infection.
GLE and PIB are direct acting antiviral (DAA) agents that can be used for patients with chronic renal failure who are on hemodialysis (HD) and those with HCV genotype 2 infections.

Material and Methods: The subjects comprised patients with genotype 1 and 2 (six each) and one unknown genotype patient in whom GLE/PIB therapy. The mean HCV RNA amount prior to treatment initiation was 4.81 (2.1-6.5). The administration periods were 8 and 12 weeks (n = 9 and 4, respectively).

Results: Twelve patients received all the doses orally while an increase in total bilirubin (T-BIL) caused administration to be discontinued in one patient. HCV RNA at week 4 after treatment initiation became undetectable in 11 (91.6%) of the 12 patients. All patients achieved rapid viral response (RVR).

Conclusion: The results suggest that GLE/PIB can also be safely administered to HD patients. However, the usefulness and safety need to be further studied by examining more cases.

Abstract Submission No. 100196
P-0169

An in-hospital Hepatitis C elimination model

Ming Li1, Xiaoshuang Liu1, Hongliang Ma1, Wei Wei1, Kefeng Xin2, Jinsong Li1, Xiaojuan Shang1, Zhaojin Wu1, Jian Zhang1, Haijun Liu1, Shasha Li1, Lin Tan1, Wen Liu1, Wei Li1

1NO2. people’s hospital of Fuyang city Fuyang China

Background: Hepatitis C has become a serious global public health problem. But the diagnosis rate and the treatment rate are only 32.7% and 11% in China, which needs to be improved. In this study, we screened all antibody-positive patients in the electronic medical record, and telephoned track for HCV RNA testing and patient treatment to improve the in-hospital HCV RNA testing rate and treatment rate.

Methods: The HCV elimination model was an in-hospital hepatitis C screening program and initiated by the infection department in the No2. people’s hospital of Fuyang city. The nurse screened daily inpatients and outpatients with antibody-positives in the electronic medical system and was responsible for reminding the physician to test HCV RNA by phone every day, as well as tracking the full treatment and follow-up course.

Results: A total of 2,296 patients were HCV antibody-positive, 1,836 patients had HCV RNA testing, 317 patients were HCV RNA-positive, and 259 patients were treated in the hospital. Before and after the HCV elimination model, HCV RNA detection was 64% and 80%, treatment rate was 61% and 82%, respectively. 75% (44/59) of untreated patients were in the non-infection department. All 258 patients treated achieved SVR12 100%.

Conclusions: In-hospital elimination with screening and telephone tracking patients with HCV antibody-positives is effective in improving HCV RNA testing and treatment rates, which improves the HCV elimination.

Abstract Submission No. 100199
P-0171

Simplify CHC Treatment: SOF-based treatment regimens in CHC patients with untested genotypes

Ming Li1, Hongliang Ma1, Xiaoshuang Liu1, Zhaojin Wang1, Zhaojin Wu1, Jian Zhang1, Haijun Liu1, Wei Wei1, Kefeng Xin2, Jinsong Li1, Shasha Li1, Lin Tan1, Wen Liu1, Wei Li1, Xiaojuan Shang1

1NO2. people’s hospital of Fuyang city Fuyang China

Background: Four liver conferences advocated for a simplified treatment without testing for genotype in CHC patients before treatment. Simplifying treatment could reduce the burden on patients. This study observes the feasibility and efficacy of SOF-based treatment regimens in patients with untested genotypes.

Methods: 36 CHC patients diagnosed in the No. 2 People’s Hospital of Fuyang City from Oct. 2022 to Jul. 2023 were retrospectively observed with no genotype detection, and the follow-up time was optimized with 28 tablets of medication dispensed at the 4th week, and telephone tracking of patients with timely follow-up at the 12th and 24th weeks. The treatment regimen was 12W SOF-based, Sofosbuvir/Velpatasvir in 20 patients (72%), including 8 patients with decompensated cirrhosis and hepatocellular carcinoma all in combination with ribavirin 12W, and ledipasvir/sofosbuvir treatment in 10 patients (28%), with follow-up SVR12.

Results: At baseline, 36 patients had a mean age of 62 years and HCV RNA level of 6.70*10^6 IU/ml; 18 patients (50%) were male; 9 patients (50%) had compensated cirrhosis, decompensated cirrhosis and hepatocellular carcinoma; and 7 patients (19%) had HIV co-infection. A simplified treatment without genotype testing and optimized follow-up is simple and feasible in the management of patients with chronic hepatitis C. It reduces the economic burden on patients, and SOF-based regimens can achieve high SVR12.

Abstract Submission No. 100198
P-0170

A new model of HCV elimination with Township Health Centers in China

Shengyong Wang1, Duan Wu1, Ni Chi2, Chunlian Xu1, Yarong Tong2

1Xiaonan Centers for Disease Control Hubei China, 2Dougang Township Health Centers Hubei China

Background: In China, most patients with hepatitis C are elderly and living at isolated villages. It’s hard for them to seek medical care because the designated hospitals always are in cities over long distances. The study aimed to establish an innovative model of HCV elimination with Township Health Centers (THC), which is currently the first THC model in China.

Methods: The Xiaonan Centers for Disease Control (CDC) chose Dougang THC, in a high prevalence town of hepatitis C, for the hospital screening high risk population, e.g., older than 45 years of age, previous surgery, risky offering blood, with free HCV antibody and HCV RNA assay. Meanwhile, Dougang THC utilized the HCV Ab(+) data from 2004-2021 in the Xiaonan CDC database to call back and offer free HCV RNA assay. The patients with HCV RNA+ could start antiviral therapy and received reimbursement for DAA in 3 working days at this hospital.

Results: A total of 75280 cases with high risk were screened from 2022.8-2023.8, of which 6776(9.0%) cases were HCV Ab(+), 331 (4.9%) cases were HCV RNA (+). 4376 cases with HCV Ab(+) in CDC database, 401 cases dead, 2043 cases lost or refused to follow-up, 1932 cases came back to hospital, of which 1748 (90.5%) cases were HCV Ab(+), and 249 (14.2%) were HCV RNA (+). 411 (70.8%) cases started antiviral therapy, 96.6%(397/411) patients achieved SVR12.

Conclusions: The HCV THC model of screening, treatment, and reimbursement at local THC was an effective way. Expanding this model may accelerate HCV elimination.
The efficacy and safety of SOF-based treatment regimens in elderly patients with chronic hepatitis C

Ming Li1, Hongliang Ma1, Xiaoshuang Liu1, Shasha Li1, Lin Tan1, Wen Liu1, Wei Li1, Wei Wei1, Kefeng Xin1, Jinsong Li1, Xiaojuan Shang1, Ziling Fan1, Zhaojin Wu1, Jian Zhang1, Haijun Liu1

1NO2, people's hospital of Fuyang city Fuyang China

Background: Population pharmacokinetic analysis in HCV patients showed that age did not have a clinically relevant effect on the exposure to sofosbuvir, GS-331007, ledipasvir or velpatasvir. However, there are few real world data on elderly patients. Our study was designed to observe the efficacy and safety of SOF-based treatment regimens in elderly patients with CHC.

Methods: We retrospectively analyzed patients with chronic hepatitis C aged 60 years or older who were diagnosed in the NO.2 people’s hospital of Fuyang City from January to March this year. These patients received sofosbuvir/velpatasvir or ledipasvir/sofosbuvir for 12 weeks. Cirrhosis patients were treated with ribavirin. Routine blood, liver and renal functions, HCV RNA were monitored at baseline, 4, 8, and 12 weeks.

Results: A total of 54 elderly patients were enrolled. At baseline, the mean age was 70 years and HCV RNA was 5.26*10^6 IU/ml. Two patients (39%) were male, 22 patients (41%) were GT1b, 10 patients (19%) were GT2a, 22 patients (41%) were GT1a, and the undetected genotypes were 30% GT1c, 16% GT5a, 12% GT5b, 9% GT6, 12% GT5c, 20% GT1d, 11% GT1e. The overall SVR rate was 98%. The reported adverse reactions in patients were: fatigue (6%), nausea (4%), diarrhea (2%). No serious adverse events, discontinuations or deaths were found during treatment.

Conclusions: SOF-based treatment regimens can achieve high SVR12 and good safety in elderly patients.

Abstract Submission No. 100211

P-0173

HCV Elimination: Reengagement of In-hospital Hepatitis C patients to Improve Linkage to Care rate

Yuan mei Che1, Yu huan Shi1, Li feng Zeng1, Chang jiu Tang1, Fu tai Li1, Fuying Zhou1

1Jiangxi Provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College. Nanchang China

Aim: To support WHO’s goal of HCV elimination by 2030, A tertiary hospital in Jiangxi, China, carried out an in-hospital hepatitis C early warning and referral program to improve the effectiveness of HCV diagnosis and treatment.

Methods: The in-hospital hepatitis C early warning and referral program included: (1) a dedicated specialist contacted the care physician of HCV antibody-positive patient to test HCV RNA; (2) a mobile Wechat group to communicating the HCV RNA positive result; (3) the specialist in charge of patients consultation, referral, treatment, and follow-up.

Results: The program was initiated in June 2022. 76,215 cases (from Jan. 2021 to May. 2022) and 73,389 cases (from Jun. 2022 to Jun. 2023) of our hospital were screened for HCV antibody. HCV antibody positivity rates before and after the program were 0.45% (342/76215) and 0.58% (428/73389), respectively. 86.99% patients that HCV antibody positive distributed at non-infectious departments, the top three were cardiovascular department (20.87%), nephrology (8.13%), and neurology (4.88%). HCV RNA positivity rates were increased from 33.71% (64/192) to 36.67% (66/180) after initiation the program. The treatment rates were increased from 10.93% (7/64) to 36.36% (24/66). 83.33% (20/24) patients from non-infectious departments were treated, the reasons for not treating were death (n=2), malignant tumor (n=2) and cost of treatment (n=14). 93.54% (n=29) were treated with SOF/VEL. The overall SVR rate was 98%.

Conclusion: The practical model for HCV in-hospital elimination program, increase the rate of diagnosis and treatment of in-hospital hepatitis C patients, and enhanced the awareness of hepatitis C.

Abstract Submission No. 100212

P-0174

The efficacy and safety of sofosbuvir/velpatasvir in patients with chronic HCV/HIV coinfection

Abstract Submission No. 100213

P-0175
Abstract Submission No. 100215
P-0176

Multi-Party Cooperation for HCV Elimination
Jing Xu1, Chuanjie Li1, Liangliang Wang1, Biao Liu1, Xiaodong Gao1, Ali Sun1, Jingjing Gao2
1Lixin county people's hospital Bozhou China

Background: Screening HCV patients with a previous stockpile, especially with high prevalence in the remote mountainous region is necessary for HCV elimination. To assess the untreated rate of patients in the CDC database and follow-up DBU patients with DAA treatment.

Methods: Screening patients who were definite in the CDC database from 2004 to 2022 in the townships of Anhui. The local community health service centers extracted HCV RNA and sent blood samples to Lixin County People's Hospital. The CDC noticed patients with HCV RNA positive by phone in 3 rounds and tracked them to the designated hospital for treatment.

Results: A total of 850 patients were tested for HCV RNA; 171 patients (20%) were positive. 154 patients (90%) had a history of selling blood. The mean age was 63 years, and the mean HCV RNA was 2.93*10^6IU/ml. 85 patients (50%) received sofosbuvir/vepatasvir or ledipasvir/sofosbuvir regimens and all treated patients achieved 100% SVR12. Tracking untreated 86 patients, 36 patients (42%) had a willingness to be treated but hadn't initiated therapy, 34 patients (39%) couldn't get in touch. 4 patients (5%) worked away from home. 4 patients (5%) due to economic difficulties. 5 patients (6%) due to old age (mean age 78Y). 2 patients (2%) had a low level of HCV RNA and retest was negative. 1 (1%) died.

Conclusions: Screening the past stock patients through CDC cooperation with designated hospitals and communities is effective for eliminating HCV. However, the treatment rate was low. Further follow-up with untreated patients is needed.

Abstract Submission No. 100240
P-0178

HCV Micro elimination in Huadu District, Guangzhou, China
Xiaohong Han1, Aixin Han1, Meisan Liu1, Xinyan Yan1, Lijuan Tan1, Huiling Song1, Ziyuan Li1, Yu Lan1, Huoli Deng1
1Huadu District People's Hospital of Guangzhou Guangzhou China

Background: We analyzed the data on hepatitis C screening, diagnosis, and treatment in Huadu to further improve the working mode of HCV elimination.

Methods: HCV elimination in Huadu was carried out in close cooperation with the Center for Disease Control and Prevention of Huadu District, the People's Hospital of Huadu District (the only assigned hospital for HCV treatment in Huadu) and 17 community health centers. We conducted telephone follow-up and recall back, improved the...
HCV elimination process intra hospital, and targeted special population.

Results: 1. Telephone follow-up of newly reported hepatitis C patients in 2022-2023 in Huadu was conducted from March 2023. 397 patients were followed up, with a follow-up rate of 84.11%. The treatment rate of diagnosed Hepatitis C patients increased from 68.82% in 2022 to 76.43% in 2023. 2. As the assigned hospital, our hospital has continuously improved the HCV elimination process since 2021, and the treatment rate of hepatitis C patients in our hospital has increased significantly from 50% in 2020 to nearly 80% in 2022 (close to the WHO target). 3. There are 44 registered methadone patients in the district, 15 have tested HCV RNA (+), and by 6th October 2023, 8 patients had started treatment. (Details See Table 1 and Figure 1)

Conclusions: HCV elimination in Huadu has achieved preliminary results, and the treatment rate has been steadily improved. Screening should be expanded, and countermeasures should be improved according to the reasons for not starting antiviral therapy.

Abstract Submission No. 100256
P-0179

Eradication of Hepatitis C virus from interferon to DAA in jailed prisoners.

Lian-Feng Lin1

1Department of gastroenterology, Pingtung Christian hospital Pingtung Taiwan

Totally 530 male prisoners received anti-HCV therapy, 175 interferon and 355 DAA, all IDU, aged 42.7 ± 6.9 years. The distribution of genotype was 1a / 1b / 2 / 3 / 6 / mixed infection: 27.2 / 16 / 8.1 / 21 / 24.6 / 2.8 (%) respectively. Co-infection with HBV, HIV, and HBV/HIV was 10% (54/530), 12.6% (67/530), 1.9% (10/530). The duration of Peginterferon is 6 months or 12 months by response guide, the AE was common 60%, the interrupt of treatment or follow-up was high 21.1% (121/138) and 71.4% (125/175). The SVR of HBV/HIV co-infection is not completing full dose and at least one dose Peginterferon is 87.6% (121/138) and 71.4% (125/175). The SVR of HBV co-infection is not different from HCV monoinfection (90% vs. 89.9%) but SVR is lower in HIV co-infection (71.4% vs. 89.9%). The duration of DAA (Epclusa/Harvoni/Maviret/Zepatier: 117/92/135/11) is 8-16 weeks and AE is minor including skin rash/itching, fatigue, headache and insomnia at 8.8% (31/355). Due to early release, one prisoner interrupted DAA therapy and 12 prisoners missed SVR check-up due to early release or transferring. The SVR12 is 99.4% (340/342) on complete follow-up and 95.8% (340/355) on intention to treat. Two failed SVR is genotype 3 treated with epclusa treatment. One mortality is decompensated hepatitis and it was not reverse after DAA treatment. The SVR of DAA treatment is extremely excellent as 100% in the co-infection with HBV/HIV.

Abstract Submission No. 100287
P-0180

Epidemiological characteristics of genotype distribution in 1,342 HCV infections in eastern China

Aiorng Hu1, Su-Wen Jiang2, Nian Lian3, Yu-tao Hu2, Dong-hui Wang4, Ju-Lan Wang4, Xiaojuan Shi4, Ken Lin5, Ying Fan6, Meng-Han Jin4, Hao-Jin Zhang6

1Ningbo No. 2 Hospital Ningbo China, 2Ningbo Fourth Hospital Ningbo China, 3Wenzhou Medical University Wenzhou China, 4Ningbo University Health Science Center Ningbo China, 5School of Medicine, Shaoxing University Shaoxing China

Background: To analyze the distributions and clinical characteristics of HCV genotypes in 1,342 patients of the designated hospitals in Ningbo City, Zhejiang Province, China.

Methods: From April 2011 to December 2021, 1342 CHC patients were included in Ningbo No. 2 Hospital and Ningbo Fourth Hospital. The distribution of HCV genotypes in patients with different detection time, age, and infection route were analyzed.

Results: The top three genotypes were genotype 1 (49.11%), genotype 6 (19.97%), and genotype 3 (15.50%). The number (the proportion) of HCV genotypes detected increased year by year, reaching a peak (14.31%) in 2020. Genotype 1 predominated every year, however, after 2015, the proportion of type 3 and types 6 showed an overall increasing trend. The male to female ratio was 1.21:1. The patients were mainly young and middle-aged (≥20-60 years old) (87.85%). The composition ratios of type 1, type 2, type 3 and type 6 were the highest in the >50-60 years old group (64.42%), the ≥61 years old group (16.13%), the >30-40 years old group (26.01%), and the >30-40 years old group (26.59%), respectively. The non-young/middle-aged group (≤20≤61 years old) There were 345 cases with definite injection route. The top three infection routes were intravenous drug addiction, with a history of paid blood donation, unsafe acupuncture, injection, and oral treatment. There were statistically significant differences in age and gender of patients with different infection routes (F = 16.761, P<0.001). Patients with intravenous drug addiction had the lowest age and the highest male composition ratio, and the differences were statistically significant compared with other groups (P=0.05). The first two infection routes of patients with type 1 were hemodialysis and paid blood donation, of patients with type 2 were unsafe sex and intravenous drug addiction, of patients with type 6 were unsafe acupuncture, injection, and oral treatment, and intravenous drug addiction.

Conclusions: The distribution of HCV genotypes in the designated hospitals in Ningbo City, Zhejiang Province, China is diverse. Genotype 1, 6 and 3 are the top three genotypes. There are differences in age, gender, and infection routes among patients with different genotypes.

Abstract Submission No. 100295
P-0181

Chronic kidney disease is associated with hepatitis C infection in patients with Type 2 diabetes

Chen-Ta Chi1, 2, Tsung-Hui Wu1, Pei-Chuan Lee3, Ting-Yu Chen1, I-Cheng Lee1, Chi-Jen Chu1, Ming-Chih Hou1, Chii-Min Hwu1, Yi-Hsiang Huang6

1Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital Taipei Taiwan, 2Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University Taipei Taiwan, 3Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital Taipei Taiwan, 4Healthcare and Services Center, Taipei Veterans General Hospital Taipei Taiwan

Background: Hepatitis C virus (HCV) infection can induce insulin resistance, and patients with Type 2 diabetes mellitus (T2DM) have a higher prevalence of HCV infection. HCV can induce renal insufficiency, but the association between HCV and severity of chronic kidney disease (CKD) in T2DM remained unclear.

Methods: From March 2022 to May 2023, 4402 T2DM patients in Taipei Veterans General Hospital were prospectively enrolled into the in-hospital referral program for HBsAg and anti-HCV antibody
screening. The clinical features of patients with HBV and HCV infection were compared. Factors associated with anti-HCV (+) were analyzed.

Results: Among 4402 T2DM patients, the prevalence of HBsAg-positive and anti-HCV-positive were 8.0% and 2.4%, respectively. Anti-HCV-positive patients had order age and worse renal function, while HBsAg-positive patients had higher ALT level. The prevalence of anti-HCV (+) were 1.8%, 2.3%, 2.6%, 3.5%, and 7.8% in CKD stage 1, 2, 3, 4, and 5, respectively ($p = 0.014$). Independent factors associated with anti-HCV (+) were age > 65 y/o, CKD stages, and urine albumin-creatinine ratio > 300. For patients with T2DM more than 10 years, the proportion of CKD stage 1 were 26.9%, 16.7%, and 0% in patients with HCV RNA undetectable, after anti-viral treatment (interferon or DAAs) > 3 years, and after anti-viral treatment ≤ 3 years, respectively ($p = 0.038$).

Conclusions: The prevalence of anti-HCV antibody seropositivity increases with the severity of CKD in patients with T2DM. Patients who achieve virological response earlier have a higher proportion of maintaining in early-stage CKD.

Abstract Submission No. 100296
P-0182

Comorbidities in HCV-infected Patients: Data from the National Viral Hepatitis Registry in Russia

Vladimir Chulanov1, Anastasia Fomicheva1, Nikolai Pimenov1, 2, Aleksandr Urtikov2, Vladimir Achikyan3

1I.M. Sechenov First Moscow State Medical University Moscow Russia, 2National Medical Research Center on Pulmonology and Infectious Diseases Moscow Russia, 3MSD Pharmaceuticals LLC Medical Affairs Moscow Russia

Background: Chronic hepatitis C infection is recognized as a risk factor for extrahepatic comorbidities. There were no studies on comorbidities in HCV-infected population of Russia.

Materials and Methods: In this retrospective cross-sectional study, we extracted and analyzed adult patients’ data on comorbidities from the National Registry of Viral Hepatitis which included more than 300,000 HCV-infected patients. Patients’ inclusion criteria were age of >18, untreated chronic hepatitis C confirmed with positive test for anti-HCV antibody and RNA of hepatitis C virus, availability of data on co-morbidities status. The statistical analysis was descriptive.

Results: 233,167 patients were enrolled from 25 regions of Russia. The overall rate of comorbidities was 11.1% including metabolic disorders (0.02%), diabetes mellitus (0.27%), ischemic heart disease (0.06%), cerebrovascular diseases (0.05%), arterial hypertension (0.34%), renal failure (0.01%), gastrointestinal diseases (0.26%), neoplasms other than liver cancers (0.13%), mental and behavioral disorders (0.03%), chronic infection and infestation (3.22%), HIV-coinfection (6.70%), alcohol and drug abuse (1.0% and 7.5%, correspondingly). Other comorbidities were not reported. Compared with published data, rates of comorbidities in our study are underestimated. Compared with the general study population, the HIV-coinfected patients group included more men, were younger and showed 4.4-times higher rate of drug abuse.

Conclusions: The most common comorbidity in HCV-infected patients in our study was HIV-infection. This should be taken into consideration for appropriate and early testing for HIV of patients with chronic hepatitis C. Rates of other comorbidities were low, and it may reflect the possibility of underdiagnosed or underreporting to the registry.

Abstract Submission No. 100311
P-0183

Efficacy and safety of LED/SOF treatment patients with HCV in Arkhangai province of Mongolia

Byambasuren Amgalan1, 2, Delgerkhangai Munkhbayar2, Erdenebat Byambatsogt1, Nyamsuren Naranzul1, Nyamdavaa Khurelbaatar1, Oidov Baatarkhuu1, 3

1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2General hospital Arkhangai Mongolia, 3Health Department Arkhangai Mongolia, 4Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 5Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Background: Ledipasvir/sofosbuvir (LDV/SOF) shows high efficacy and safety in patients with genotype 1-hepatitis C virus (HCV). We aimed to investigate the efficacy and safety of LDV/SOF in real-world patients in Arkhangai province of Mongolia.

Methods: Between 2017 to 2022, 7 (0.6%) and 1113 patients (99.4%) with genotype 1a and 1b HCV, respectively, were treated with a fixed-dose tablet containing 90 mg ledipasvir and 400 mg sofosbuvir for 12 weeks, and 14 patients (1.25%) with previous experience of interferon (IFN)-based treatment. HCV RNA was measured at 4, 12, and 24 weeks after the first dose to determine rapid virologic response, end of treatment response (ETR), and sustained virologic response at 12 weeks after end of treatment (SVR12).

Results: Most patients (n=1,113; 99.4%) achieved ETR and SVR12 without virologic relapse. Patients with genotype 1a showed low rates of ETR and SVR12 in only 5 patients (71.4%). There was no significant difference in SVR12 rate between patients regardless of IFN experience (n=14; 1.25%), cirrhosis (n=290; 25.9%), HCV RNA >6x10⁶ IU/mL (n=193; 17.23%). No severe adverse events (AEs) were reported, and there was no dose reduction or interruption due to AE. The most common AEs were headache (n=110; 9.8%), fatigue (n=81; 7.2%), abdominal discomfort (n=65; 5.8%).

Conclusions: LDV/SOF showed high efficacy and safety for patients with genotype 1, especially 1b HCV, in Arkhangai province, Mongolia.

Abstract Submission No. 100312
P-0184

Early occurrence HCC after DAA treatment with HCV infected cirrhotic patients in Mongolia

Byambasuren Amgalan1, 2, Nyamsuren Naranzul1, Nyamdavaa Khurelbaatar1, Oidov Baatarkhuu1, 3

1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2General hospital Arkhangai Mongolia, 3Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 4Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Background: Hepatocellular carcinoma (HCC) represents a serious complication of HCV-related cirrhosis. Hepatitis C virus (HCV) is one of the major causes of liver cirrhosis and hepatocellular carcinoma in Mongolia New direct-acting antivirals (DAA) cure HCV infection in over 96% of patients in Mongolia. The aim of this study was to evaluate the early occurrence of HCC in cirrhotic patients treated with DAA.

Methods: We analyzed 300 consecutive with chronic hepatitis C patients, without HCC, who were treated with DAA, and followed for 48 weeks.

Results: DAA therapy induced sustained virological response in 99% of patients in Mongolia. During 48-week follow-up, HCC was detected in 17 patients of 300 patients (5.7%, 95% CI: 5.2-9.8). Child-Pugh Class B, more severe liver fibrosis, lower platelet count was
significantly associated with HCC development, at univariate analysis. At multivariate analysis, Child-Pugh class (p=0.03, OR: 4.65, 95% CI: 1.28-13.5) and resulted independently associated with HCC development.

**Conclusions:** In 17 patients (5.7%) with liver cirrhosis develops of HCC after HCV treated with DAA in Mongolia. For these reasons, all cirrhotic patients should be closely monitored and followed during and after antiviral therapy.

Abstract Submission No. 100335

**P-0185**

**Evaluating utilization and management of comediations for DDIs among HCV patients initiating DAAs**

Daisuke Nakamoto1, Stuart Gordon2, Andrea Steffens3, Laura Weber1, Kimberly McNiff1, Alon Yehoshua4

1Gilead Sciences K.K. Tokyo Japan, 2Henry Ford Hospital Detroit, MI USA, 3HEOR, Optum Life Science Eden Prairie, MN USA, 4HEOR Liver Disease, Gilead Sciences Foster City, CA USA

**Background and Aims:** This analysis compared rates and management of comediations with drug-drug interactions (DDI) risk among patients initiating direct-acting antiviral (DAA) treatment with sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C (HCV).

**Method:** Adults initiating SOF/VEL or GLE/PIB from July 2016–April 2020 were identified from US administrative claims data. All DDI comediations associated with GLE/PIB and SOF/VEL and DDI comedication severity were from the Liverpool HEP Drug Interactions Database. DDI comedication discontinuation, dose decrease, and change to medication with no DDI risk were measured in the subset of patients.

**Results:** Among 4,528 patients, 66.6% of GLE/PIB initiators and 43.7% of SOF/VEL initiators had any baseline DDI comedication use (p < 0.01). Compared with SOF/VEL initiators, GLE/PIB initiators had higher baseline rates of DDI comedication severity. DDI comedication use decreased during DAA treatment but remained higher in GLE/PIB initiators (p < 0.01). 979 GLE/PIB and 658 SOF/VEL initiators used prevalent DDI comediations in the 90 days pre-index. Those GLE/PIB vs SOF/VEL initiators had similar mean age, proportions of female and commercially insured patients, and lower baseline compensated cirrhosis. A higher proportion of GLE/PIB initiators discontinued at least 1 DDI comedication before initiating DAA treatment (p < 0.01). During DAA treatment, GLE/PIB initiators had higher rates of dose decrease (p = 0.026) and change to medication with no DDI risk (p = 0.014).

**Conclusion:** Use of DDI comediations was identified among a substantial proportion of patients, with higher rates in GLE/PIB initiators.

Abstract Submission No. 100336

**P-0186**

**Concomitant use of PPI and SOF/VEL: Evidence from Clinical trials and Real-World data**

Daisuke Nakamoto1, Rafael Esteban2, Steven Flamm3, Maria Buti Ferreti2, Juan Turnes Vazquez2, Liyun Ni5, Cándido Hernández2, Alessandra Mangia1

1Gilead Sciences K.K. Tokyo Japan, 2Hospital Vall Hebron Barcelona Spain, 3Rush University Chicago United States, 4Complejo Hospitalario Universitario de Pontevedra, Gastroenterology and Hepatology Department Pontevedra Spain, 5Gilead Sciences, Biostatistics Virology Foster City United States, 6Gilead Sciences Global Medical Affairs Madrid Spain, 7IRCCS Casa Sollievo della Sofferenza, UOSD Epatologia San Giovanni Rotondo Italy

**Background:** Literature and product labels suggest velpatasvir bioavailability may be reduced when administered concomitantly with a proton pump inhibitor (PPI). We aimed to determine the clinical relationship between PPI use and sustained virologic response rates (SVR) in patients treated with sofosbuvir/velpatasvir (SOF/VEL) for chronic hepatitis C virus (HCV) infection.

**Method:** Retrospective and descriptive analysis of data from patients treated with SOF/VEL for 12 weeks with and without concomitant use of PPIs and participating in Phase 2/3 RCTs and RWD studies. Main variables collected for this analysis consisted of SVR12 and relapse rate.

**Results:** 546 patients with PPI use were identified and the control group without PPI use was 5,201.

In RCT, patients receiving PPI and SOF/VEL were mainly male, GT3 in 56% and cirrhotic in 35%. Most patients participating in RCT (66%) continuously used PPI during the 12-week course of treatment with SOF/VEL. Overall SVR12 in PPI users was 97%, comparable to non-PPI users (97%). SVR12 in GT3 patients was 96%, in F4 was 94%. In GT3 plus F4 patients, SVR12 was 96%. In RWD, patients receiving PPI and SOF/VEL were male (54%), GT3 in 25% and cirrhotic in 29%. Overall SVR12 in PPI users was 99%, comparable to non-PPI users (99%).

**Conclusion:** In RCTs and RWD, the single-tablet regimen of SOF/VEL for 12 weeks was effective in patients with concomitant PPI use. These data support the use of SOF/VEL according to labeled recommendations with respect to co-administration of PPIs and other acid reducing agents.

Abstract Submission No. 100337

**P-0187**

**Finding undiagnosed Hepatitis C cases: using machine learning**

Bruce Kreter1, Linda Chen1, John Wolf2, Pranava Goundan2, Qin Ye1, Ravi Ippili2, Abhinav Bansal2

1Gilead Sciences Foster City USA, 2ZS Associates Evanston USA

**Background and Aim:** Undiagnosed Hepatitis C Virus (HCV) is a major public health concern in the US. Gilead’s FIND-C program enables to efficiently screen and identify undiagnosed HCV patients. The initial step for FIND-C was development of a high-precision machine learning (ML) algorithm, followed by partnership with a US-based health system for assessing improvement in the screening to diagnosis ratio (SDR) and user adoption. Validation of the algorithm using real-world health system data is necessary.

**Method:** This study involved development of an ML algorithm using a large-scale US dataset consisting of deidentified electronic health records (EHR); the cohort for model development included 295,512 patients (HCV-positive: 50,726; HCV-negative: 245,236), using 32 clinical (diagnoses, treatments, procedures), demographic, and social determinants of health variables. The model’s precision was optimized and model performance was evaluated in a health system having viral infectious disease as a core focus and sufficient digital capabilities for model integration. The test dataset contained 26,154 patients (HCV-positive: 4,848; HCV-negative: 21,306).

**Results:** Performance of the model algorithm trained on EHR data was: AUROC: 95%, Precision: 93%, Recall: 50%. Using health system test data, we found AUROC: 86%, Precision: 91%, Recall: 30%.

**Conclusion:** Effective implementation of the HCV patient identification solution can provide a resource-efficient, expedited identification of undiagnosed HCV patients, thereby serving as a catalyst for
universal screening guidelines and a scalable solution for achievement of global elimination goals.

Abstract Submission No. 100360
P-0188

SOF/VEL Effectiveness in Treating Chronic Hepatitis C
Genotype 3: A Real-World Study in Xinjiang.

Feng Guo1, Jing Dou2, Hong Yu2, Aminai Aibi4, Wei Sun2, Qiang Xu1, Xiaobo Wang1, Zhonghui Ning1, Xiaozhong Wang1, Binfang Zeng2, Maimaitijiang Wubulaihan4

1Department of Hepatology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University Urumqi China, 2The Fourth Clinical Medical College of Xinjiang Medical University. Urumqi China, 3School of Nursing, Xinjiang Medical University. Urumqi China, 4Xinjiang Hotan Specialist Hospital for Infectious Disease. Urumqi China

Objective: This study aimed to assess the effectiveness and safety of sofosbuvir/velpatasvir(SOF/VEL), with or without ribavirin(RBV), in treating chronic hepatitis C (CHC) genotype 3(GT3) individuals.

Methods: Totally 230 patients diagnosed with CHC GT3 were included and received treatment at two hospitals in Xinjiang from June 2018 to March 2023. Patients with CHC and CC received SOF/VEL treatment for 12 weeks, while those previously treated with interferon plus ribavirin(PR) and DCC patients were treated with SOF/VEL for 24 weeks or SOF/VEL plus RBV for 12 weeks. Comprehensive assessments including high-sensitive HCV RNA levels, liver and renal function, abdominal ultrasound examinations were conducted. The primary endpoint was the sustained virologic response at 12 weeks post-treatment(SVR12).

Results: The mean age was 43.31±11.18 years, consisting of 66.5%(153/230) male. Among these, 137 cases(59.6%) were of GT3a, while 93 cases(40.4%) were of GT3b. Within the cohort, 44 cases(19.1%) presented with compensated cirrhosis(CC), 3 cases(1.3%) had decompensated cirrhosis(DCC), 33 cases(14.3%) were co-infected with HCV/HIV, 6 cases(2.6%) exhibited HBV/HCV co-infection, and 2 cases(0.9%) had HBV/HCV/HIV co-infection. Overall, the SVR12 was 99.6%(229/230) including 100%SVR12 rates for GT3a(137/137) and 98.9% for GT3b(92/93). only one patient experienced relapse due to the poor adherence. Notably, SVR12 rates for CC and DCC patients were both 100%, and SVR12 rates for HCV/HIV, HBV/HCV, and HBV/HCV/HIV co-infections were all 100%. The overall safety profile was favorable, with no treatment discontinuations due to adverse events.

Conclusion: SOF/VEL monotherapy or combined with RBV demonstrated highly effective and well-tolerated in treating with CHC GT3, including those with cirrhosis, in Xinjiang, China.

Abstract Submission No. 100361
P-0189

Prevalence of Naturally Occurring Hepatitis C Virus Resistance-Associated Substitutions in Korea

Kyung-Ah Kim1, Sejoon Lee2, Youn Jae Lee3, Hye Jung Park2, Eun Sun Jang4, Sung Bum Cho4, Young Seok Kim1, In Hee Kim1, Byung Seok Kim1, Seungtaek Kim1, Sook-hyang Jeong1

1Department of Internal Medicine, Inje University Ilsan Paik Hospital Goyang South Korea, 2Department of Precision Medicine Center/Department of Pathology and Translational Medicine, Seoul National University Bundang Hospital Seongnam South Korea, 3Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul South Korea, 4Department of Internal Medicine, Seoul National University Bundang Hospital Seongnam South Korea, 5Department of Internal Medicine, Inje University Busan Paik Hospital Busan South Korea, 6Department of Internal Medicine, Chonnam National University Hwasun Hospital Hwasun South Korea, 7Department of Internal Medicine, Soochunhyang University Bucheon Hospital, Bucheon South Korea, 8Department of Internal Medicine, Jeonbuk National University Hospital Jeonju South Korea, 9Department of Internal Medicine, Chungnam National University Hospital Daegon South Korea, 10Department of Zoonotic Virus Laboratory, Institut Pasteur Korea Seongnam South Korea

This study aimed to investigate the prevalence of naturally occurring resistance-associated substitution (RAS) of hepatitis C virus (HCV) in Korean patients by next-generation sequencing. Patients with chronic HCV infection were prospectively enrolled from March 2020 to July 2022 and treated with direct-acting antivirals. Sera were collected at baseline, at the end of treatment, and 12 weeks after treatment. Whole genome sequencing for HCV was performed to analyze RAS by next-generation sequencing. A total of 263 patients (median age 62, male 129) were enrolled and successfully treated with DAA. HCV RAS was analyzed from the baseline sera of 71 patients (genotype 1b 39, genotype 2 33). For genotype 1b, RAS was detected in 48.7% (19/39); NS3 in 41.0% (16/39), NS5A in 15.4% (6/39), NS5B in 28.2% (11/39), respectively. Among NS3 RASs, Y56F was most frequently detected (23.1%), followed by Q80H/L (20.5%) and S122G/T (17.9%). Among NS5A RASs, Y93H was most frequently detected (10.3%), followed by L31M (2.6%) and R30Q (2.6%). Among NS5B RAS, C316N was most commonly seen (23.1%), followed by L159F (2.6%) and S556G (2.6%). For genotype 2, NS3 RAS was detected in 24.2% (8/33), but no RAS was found in NS5A and NS5B.

This study revealed the baseline prevalence of NS3, NS5A, and NS5B RAS of HCV in Korean patients for the first time. Knowledge of baseline RAS of HCV could help guide DAA treatment for difficult-to-treat patients.

Abstract Submission No. 100369
P-0190

Relink Model of Hepatitis C Elimination among HCV/HIV-coinfected Patients

Jifeng ZHANG1, Gaoju LI1

1Luyi County People’s Hospital Zhoukou China

Background: Luyi is a city with high prevalence of AIDS in North China, where the prevalence of HCV infection was high among HIV-infected populations. HIV patients were previously managed by the Luyi Centers for Disease Control (CDC) and followed up regularly twice a year, but there were not any HCV screening and treatment for this population. This study aimed to evaluate the innovative relink HCV elimination model of undiagnosed hepatitis C patients identification and activation in HIV population.

Methods: Luyi County People’s Hospital collaborated with local CDC. CDC utilized the database of HIV population with or without HCV antibody data for HCV Ab and HCV RNA confirmation from 2022.5, they offered free HCV antibody and HCV RNA assay at fixed follow-up points without recall efficiently. All the patients with HCV RNA+ were transferred to the Infection Disease Department of Luyi County People’s Hospital, where physicians conducted disease education and initiated antiviral therapy after critical assessment of disease and DDIs.
Results: A total of 667 HIV-infected patients were screened for HCV RNA confirmation at fixed follow-up points from 2022.5-2023.7, of which 233 (34.9%) cases were HCV Ab(+), 81 (12.1%) cases were HCV RNA (+). 77.8% (63/81) patients initiated antiviral therapy, 4 subjects lost to follow-up, 1 subject relapsed, 1 subject had breakthrough due to irregular dosing, over 70% of patients achieved SVR. The RNA testing rate increased from 39.0% (Mar. 2023) to 59.0% (Aug. 2023). Notably, 83% of antibody-positive patients were treated, the average age of cases receiving DAA treatment was 59 years; the treatment rate was 83%; the complete treatment rate, follow-up rate, and SVR rate was all 100%.

Conclusions: It was an effective model of undiagnosed hepatitis C patient identification and activation in HIV population, which could be scalable to accelerate HCV elimination in China.

Abstract Submission No. 100379
P-0191

HCV Elimination Pilot Program in Hospital to Support Hepatitis C Elimination 2030
Jun Chen1, Min Zhang1, Zebing Huang1, Yan Huang1
1Department of Infectious Diseases, Xiangya Hospital Central South University Changsha China

BACKGROUND: To support the WHO 2030 hepatitis C elimination goal, Xiangya Hospital Central South University joined the HCV elimination pilot program of the China Hepatitis Prevention and Control Foundation (CHPCF)’s “Hepatitis C-Free Hospitals Initiative”.

METHODS: The program was initiated in March 2023 in Xiangya Hospital Central South University, and was led by the Infectious Diseases Department, with the participants of the Medical Department, Information Department, and Blood Transfusion Department. A review of hepatitis C antibody or RNA data was conducted twice a week, and patients with antibody or RNA positive were followed up by telephone. Additionally, infectious disease specialists educated medical staff on HCV screening and diagnosis, recommending RNA testing for antibody-positive patients and antiviral therapy for RNA-positive patients.

RESULTS: From March to August 2023, a total of 625 HCV antibody-positive patients were enrolled, with 316 undergoing RNA testing. The RNA testing rate increased from 39.0% (Mar. 2023) to 59.0% (Aug. 2023). Notably, 83% of antibody-positive patients were from non-infectious departments, mainly gastroenterology and hepatic surgery department. Among 229 RNA-positive patients, 160 (69.9%) patients received DAA treatment. For patients not receiving antiviral therapy, 46% couldn’t be contacted, 14% had other illnesses and 14% refused treatment.

CONCLUSION: Since initiating the in-hospital HCV elimination pilot program, the rate of RNA testing for HCV antibody-positive patients has significantly increased. Most hepatitis C patients are from non-infectious departments. Going forward, we’ll strengthen collaboration between infectious and non-infectious departments to improve hepatitis C patient screening and referral.

Abstract Submission No. 100410
P-0193

Assessing Liver Fibrosis in Patients with Chronic Hepatitis C Genotype 6 Treated with Ledvir
Le Hien1, Le Quoc Tuan2, Dinh Cong Tiep2, Dinh Cong Dang2, Nguyen Khac Hung Manh3
1Thai Nguyen University of Medicine and Pharmacy Thái Nguyên Vietnam, 2103 Cam Khe Clinic Phu Tho Vietnam, 3Vinh Phuc Hospital Vinh Phuc Vietnam

Hepatitis C virus (HCV) is an important health problem globally. If left untreated, there is a risk of progression to cirrhosis, hepatocellular carcinoma and death.

Aims: Assessing liver fibrosis (LF) in patients with HCV treated with Ledvir.

Method: The prospective cohort study was conducted on 54 patients with HCV genotype 6 who were treated with Ledvir (Ledipasvir/Sofosbuvir 90mg/400 mg) orally once a day for 12 days at Cam Khe Clinic from 4/2019 to 9/2023. LF was evaluated using the META-VIR scoring system, by Fibroscan. Quantification of HCV RNA using HCV RNA real-time PCR method. Evaluate treatment response at week 4 after starting treatment, week 12 and 24 after end of treatment (EOT).

Results: Virologic response rate at 4 weeks of treatment was 96.3% and sustained virologic response at 12 weeks was 98.1%. LF from 11.6 kPa before treatment, to 10.1 kPa at EOT, 9.3 kPa at week 12 after EOT and 8.2 kPa at week 24 after EOT. The proportion of F4 patients before treatment was 25.9%, at EOT was 18.5% and week 24 after EOT was 14.8%. F0-F1 group at the time before treatment was 37.0%, and increased to 55.6% at EOT and 74.1% at week 24 after EOT. Factors related to LF response are: overweight, initial fibrosis and AST activity (p<0.01). Side effects of the drug include: nausea and headache.

Conclusions: The level of LF improvement gradually increased in patients with HCV treated with Ledvir over time: EOT, week 12 after EOT and week 24 after EOT.

Abstract Submission No. 100397
P-0192

Hepatitis C Elimination Model in Taiwan’s rural Community Care Home
Shih-Tien Chen
1Chia-Yi Hospital Chiayi City Taiwan

Background and Aims: Yunlin and Chiayi counties and cities are high-prevalence areas for hepatitis C in Taiwan, with an antibody-positive rate of 7.3%. The Hepatitis care team of the Chiayi Hospital proactively screened residents of 22 community care homes (CAHs) to eliminate hepatitis C.

Methods: Since 2017, the Taiwanese government has complied with financial resources for free hepatitis C screening and cure programs. From September 2021 to December 2022, An HCV elimination program was planned and implemented for a total of 450 residences of 22 CAHs based on the paradigm of integrated care. The positive cases of HCV screening were sent to the Chiayi Hospital for further testing and then treated antiviral medications, prospectively, delivered by Chiayi Hospital.

Results: Among the 353 aged 45-79 residents, 320 (91%) participated in this HCV screening program. The number of positive cases of HCV Ab and HCV-RNA was 48 (15%) and 23 (7%), respectively. Among the confirmed cases, 20 people received HCV antiviral medication treatment, while 3 of them did not receive any treatment due to death or unwillingness to be treated. The average age of cases receiving DAA treatment was 59 years; the treatment rate was 83%; the complete treatment rate, follow-up rate, and SVR rate was all 100%.

Conclusions: This innovative model of providing institutionalized resident HCV screening and treatment through an integrated mechanism of organization and delivery integration revealed conclusive results of a hepatitis screening rate of ≥60% and a hepatitis C treatment completion rate of ≥90%.
Epidemiology and countermeasures on hepatitis C among pregnant women in China from 2018 to 2020

Xin Yue¹, Yi Ding³, Yan Wang¹, Yongli Jiang¹, Yanwei Zhang¹, Qianrui Li¹, Su Jiang², Qixiu Li¹, Juan Tang¹, Guorong Han¹

¹Department of Gynecology and Obstetrics, The Second Hospital of Nanjing & The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine Nanjing China, ²Jiangsu Nanjing China

Objective: This study aim to investigate the hepatitis C virus (HCV) infection status of pregnant women in Nanjing of East China.

Methods: We carried out HCV antibody(HCV-Ab) screening for pregnancy women in 5 tertiary hospitals between 2018 and 2020. Positive patients were transferred to designated hospitals for re-examination and confirmation. 55359 pregnant women who underwent HCV infection testing were consisted in this study, follow-up cohort was established to conduct questionnaire surveys, pregnancy management, delivery, and infant monitoring.

Results: 101 of the 55,359 pregnant women were HCV-Ab(+), with a positive rate of 0.18%. The average age of 101 HCV-Ab(+) pregnant women was 30.20 ± 5.17 years, 81 primiparas and 20 multiparous women. Among the 101 HCV-Ab(+) pregnant women, 83 had chronic infection in the past, 7 had virus clearance before pregnancy, 75.24%(76/101) were HCV-RNA(+). The postpartum hemorrhage rate in the HCV-RNA(+) group was higher than that in the HCV-RNA(-) group (94.74% vs 5.26%, P=0.014). There was no significant difference in the rate of cesarean section and premature birth between the two groups. Both perinatal death(n=2) and mother-to-child transmission(n=2) occurred in the HCV-RNA(+) group, but the difference was not statistically significant, which was related to the lower incidence.

Conclusion: Anti-HCV prevalence was moderate in pregnant women in Nanjing of East China. However, pregnant women with HCV RNA(+) have a higher rate of postpartum hemorrhage, and there is a possibility of infant death and mother-to-child transmission of HCV. Routine screening for HCV and DAAs treatment before pregnancy are encouraged.

Key words: hepatitis C virus; pregnant women; pregnancy outcome

Hepatitis C elimination experience of HCV infected patients in methadone clinics

Jianjun Fu¹, Jing Wu¹, Xiaoyan Zhang¹, Lingxia Ren²

¹Xi’an Central Hospital Xi’an China, ²Xi’an Drug Rehabilitation Center Xi’an China

AIM: This study was designed to determine the prevalence of HCV infection through centralized screening in a rehabilitation center, get disease awareness and the mental health situation of these high-risk populations.

METHODS: This study was conducted from April 2023 to June 2023 at a drug rehabilitation center in Lantian District, Xi’an. Participants were screened for HCV antibodies, HCV RNA, and genotype. A questionnaire on hepatitis C disease awareness and the SCL-90 evaluation was distributed.

RESULTS: 127 people were screened, of which 79.53% were male (n=101). 60.63% of the screened individuals were aged 45-59 years. Majority had a history of alcohol consumption (85.83%), and smoking (94.49%). The HCV antibody positivity rate was 49.61% (n=63), of which 58 cases tested positive for HCV RNA, with a mean HCV RNA level of 6.24×10⁶ IU/mL, and the genotype results were GT1b 1.72% (n=1), GT2a 8.62% (n=5), GT3a 62.07% (n=36), GT3b 13.79% (n=8), GT6a 10.34% (n=6), untyped 3.45% (n=2). 38.10% of the patients with hepatitis C had clinical symptoms (including malaise, nausea, abdominal pain, abdominal distension, etc.). The results of the disease questionnaire showed only 14.29% correct responses. The results of the SCL-90 evaluation showed abnormal scores in 2/3 of the respondents, suggesting the need for further assessment of the mental health status of patients with hepatitis C.

CONCLUSION: Our study shows that there is a high prevalence of HCV in the population of drug rehabilitation centers, and this population has low disease awareness and poor mental health, which needs to be given more attention.

HCV prevalence among male inmates in the compulsory drug rehabilitation center in Qinghai, China.

Hongmei Zu¹, Xiaoxin Xin¹, Zhao Lan¹, Yajing Li¹, Fengxia Chang², Liping Yang¹, Jinhua Deng¹

¹Xi’an Central Hospital Xi’an China, ²Xi’an Drug Rehabilitation Center Xi’an China

Abstract Submission No. 100432

P-0194

Hepatitis C Screening and Patient Disease Knowledge Questionnaire in a Drug Rehabilitation Center

Jianjun Fu¹, Jing Wu¹, Xiaoyan Zhang¹, Lingxia Ren²

¹Xi’an Central Hospital Xi’an China, ²Xi’an Drug Rehabilitation Center Xi’an China

AIM: This study was designed to determine the prevalence of HCV infection through centralized screening in a rehabilitation center, get disease awareness and the mental health situation of these high-risk populations.

METHODS: This study was conducted from April 2023 to June 2023 at a drug rehabilitation center in Lantian District, Xi’an. Participants were screened for HCV antibodies, HCV RNA, and genotype. A questionnaire on hepatitis C disease awareness and the SCL-90 evaluation was distributed.

RESULTS: 127 people were screened, of which 79.53% were male (n=101). 60.63% of the screened individuals were aged 45-59 years. Majority had a history of alcohol consumption (85.83%), and smoking (94.49%). The HCV antibody positivity rate was 49.61% (n=63), of which 58 cases tested positive for HCV RNA, with a mean HCV RNA level of 6.24×10⁶ IU/mL, and the genotype results were GT1b 1.72% (n=1), GT2a 8.62% (n=5), GT3a 62.07% (n=36), GT3b 13.79% (n=8), GT6a 10.34% (n=6), untyped 3.45% (n=2). 38.10% of the patients with hepatitis C had clinical symptoms (including malaise, nausea, abdominal pain, abdominal distension, etc.). The results of the disease questionnaire showed only 14.29% correct responses. The results of the SCL-90 evaluation showed abnormal scores in 2/3 of the respondents, suggesting the need for further assessment of the mental health status of patients with hepatitis C.

CONCLUSION: Our study shows that there is a high prevalence of HCV in the population of drug rehabilitation centers, and this population has low disease awareness and poor mental health, which needs to be given more attention.

Abstract Submission No. 100433

P-0195

Hepatitis C elimination experience of HCV infected patients in methadone clinic

Jianjun Fu¹, Shanshan Zhu¹, Ning Chai¹, Yujia Jing¹, Jidong Liu², Pengfei Dang¹

¹Xi’an Central Hospital Xi’an China, ²Drug maintenance treatment outpatient department of Tieta Temple Xi’an China, ³Xi’an Huayou Hospital Xi’an China

AIM: This study aims to evaluate the efficacy and safety of hepatitis C patients receiving SOF/VEL treatment in a methadone clinic.

METHODS: Chronic hepatitis C patients (receiving methadone substitution therapy at the methadone clinic) treated at the Infectious Department of Xi’an Central Hospital from Jan. 1, 2023 to Jun. 1, 2023 were enrolled. All of them received SOF/VEL ± RBV treatment for 12 weeks and were followed up to assess the efficacy and safety.

RESULTS: A total of 77 patients treated with SOF/VEL ± RBV were enrolled in the study, the baseline characteristics of the patients were: 74.02% were males (n=57), mean age was 53.49 years. Genotypic distribution of GT3a was 66.23% (n=51), GT3b 11.69% (n=9), GT6a 12.99% (n=10). Baseline HCV RNA level was 8.91×10⁶ IU/mL, ALT level was 94.33±63.78 U/L, Fibrotest value was 13.7±5.17 kPa, 16.89% (n=13) combined compensated cirrhosis, 11.69% (n=9) combined decompensated cirrhosis, 11.69% (n=9) combined fatty liver, and 2 cases combined HCC. 61 out of 77 patients underwent DAA treatment, the rate of SVR12 was 97.37% (37/38), SVR12 in compensated cirrhosis was 100% (13/13), and 88.89% (8/9) in decompensated cirrhosis patients. The patients were well tolerated with no drug-related SAEs.

We also found that half of the patients were unable to follow up regularly as recommended, after the telephone reminders by nurses, the follow up rate increased from 49.18% to 62.30%.

CONCLUSION: Hepatitis C patients in methadone outpatient clinics on SOF/VEL treatment can achieve high SVR rates, and the adherence of this population needs more attention.
Background: The prevalence of hepatitis C virus (HCV) infection is notably higher among individuals who engage in intravenous drug use (IDU) and those in prisons compared to the general population. These vulnerable groups are pivotal in achieving the WHO’s 2030 goals for HCV micro-elimination.

Objective: Our study aimed to ascertain the prevalence of HCV antibodies (HCV-Ab) and HCV RNA among incarcerated males within a compulsory drug rehabilitation center.

Methods: A total of 287 inmates were assessed, a fingerstick sample was obtained and subjected to HCV antibody rapid diagnostic test (RDT), immediately followed by a reflect HCV RNA test, for HCV-Ab positive inmates, venous blood sample were collected and sent for laboratory HCV RNA and genotype.

Results: All incarcerated individuals had a history of intravenous drug use (IDU), and the shared use of razors in the drug rehabilitation center contributed to potential HCV transmission. The prevalence of HCV-Ab among these inmates was approximately 43% (123 out of 287). Among the 112 HCV-seropositive individuals tested for HCV RNA, 92 (82.14%) were found to be HCV RNA positive. A total of 86 samples were qualified for genotyping, the most common genotype was GT3b (52.3%, n=45), followed by GT1a (29.6%, n=25), GT1b (8.1%, n=7), GT6a (5.8%, n=5), GT2 (3.5%, n=3) and GT1a (1.3%, n=1).

Conclusions: The prevalence of HCV infection among male inmates in the drug rehabilitation center was alarmingly high. Future efforts should focus on developing appropriate elimination strategies, which may include non-specialists’ involvement and nurse participation, training programs, and mentorship initiatives, to facilitate effective linkage to care.

Abstract Submission No. 100483
P-0198

Surveillance of the Safety and Effectiveness of Glecaprevir/Pibrentasvior in Korean Patients with CHC

Jeong Heo1, Sang Hoon Ahn2, Jin-Woo Lee3, Jung Gil Park4, Jae Youn Cheong4, Ki Tae Yoon4, Won Young Tak5, Yang Hyun Baek6, Su Jong Yu6, Yoon-Jae Lee6

1Department of Internal Medicine, College of Medicine, Pusan National University and Biomedical Research Institute, Pusan National University Busan South Korea, 2Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine Seoul South Korea, 3Division of Gastroenterology, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine Incheon South Korea, 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine Daegu South Korea, 5Department of Internal Medicine, Ajou University School of Medicine, Ajou University Hospital Suwon South Korea, 6Department of Internal Medicine, Pusan National University Yangsan Hospital Yangsan South Korea, 7Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University Daegu South Korea, 8Department of Internal Medicine, Dong-A University College of Medicine Busan South Korea, 9Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine Seoul South Korea, 10Department of Internal Medicine, Inje University, Busan Paik Hospital, Inje University College of Medicine Busan South Korea

Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. Previous clinical trials demonstrated that glecaprevir/pibrentasvir (G/P) treatment is effective and well-tolerated among patients with chronic hepatitis C (CHC), although data in real-world clinical settings is limited. This prospective, multicenter, post-marketing surveillance study (NCT03740230) evaluated the safety and efficacy of G/P in Korean patients with CHC in real-world settings. The study included patients aged ≥12 years with CHC who received G/P in South Korea (January 2021 to January 2023) for 8, 12, or 16 weeks according to approved local labels. Of 1,674 participants evaluated for safety, mean (SD) age was 59.54 (±12.17) years, and 52.93% were male; 18.58%, 28.61% and 7.89% had liver cirrhosis, liver impairment, and renal impairment, respectively. Adverse events (AEs) and treatment-related AEs (TRAEs) occurred in 11.23% and 5.91% of participants, respectively; serious AEs and serious TRAEs occurred in 1.43% and 0.12%, respectively, and unexpected TRAEs and unexpected serious TRAEs occurred in 3.05% and 0.06%, respectively. Among patients evaluated for efficacy, 98.77% achieved sustained virological response 12 weeks post-treatment (SVR12) and 98.36% achieved end-of-treatment response. SVR12 rates were similar regardless of HCV genotype, absence of liver cirrhosis or renal impairment, prior CHC treatment, and age group. Treatment breakthrough and post-treatment virologic relapse occurred in 1.07% and 1.00% of participants, respectively. G/P was well-tolerated and effective in Korean patients with CHC regardless of HCV genotypes in real-world settings. No new safety signals were observed regardless of age group and presence of hepatic or renal impairment.

Abstract Submission No. 100486
P-0199

HCV Micro-elimination in Community-based<st

hong li1, jiajun guan1, zhiming liang2, yanling ouyang1, long tong1, xiaoqiao chen3, yong huang1, tingshan he1, huixin liang1

1Shunde Hospital of Southern Medical University foshan China, 2Foshan Shunde District Center for Disease Control and Prevention foshan China

Background: There are no reports on the prevalence of HCV among Ex-Drug Users (EDUs) from CDRCs in China. This study aimed to assess the prevalence of HCV in EDUs and establish a linkage-to-care model for this population.

Methods: This prospective study planned to conduct HCV screening in 10 CDRCs in Shunde, Guangdong Province. EDUs who enrolled in the study were required to complete a questionnaire and undergo finger-stick anti-HCV testing. Blood samples were collected for HCV RNA testing for the people with the HCV-Ab(+) at the same time. HCV RNA-positive patients were recalled by phone and referred for treatment.

Results: From June to October 2023, a total of 86 EDUs from four CDRCs were screened; all underwent finger-stick anti-HCV testing. The average age was 47 years, 88% were male, 100% were anti-HIV-negative, 88.5% had a middle school education or below, and 50% were people who had previously injected drugs (ex-PWID). The HCV antibody positive rate was 51.1% (44/86), with a high rate of 88.4% (37/43) among ex-PWID and 25% with liver cirrhosis (11/44). The HCV RNA positivity rate was 72% (31/43), with one patient currently undergoing direct-acting antiviral (DAA) treatment and not testing. The successful referral rate for treatment was 41.9% (13/31), with 11/13 referrals completed within 2 weeks and 9/13 patients already started DAA treatment.

Conclusion: This is the first report on the prevalence of HCV among the EDUs from CDRCs in China. The high prevalence of HCV in this population requires our attention, and linkage-to-care will continue in the remaining 6 CDRCs.
HCV High Prevalence in Psychiatric Inpatients: An Opportunity for Enhanced Screening and Treatment

Liu Weifeng1, Zhang Xiaoyuan4, Luo Xianxin1
1Yangjiang Public Health Hospital Yangjiang China

Background: The data of HCV prevalence among psychiatric inpatients in China is limited. This study aims to evaluate uptake of HCV testing and treatment among psychiatric inpatients.

Methods: Cross-sectional study, 2508 psychiatric inpatients admitted to Yangjiang Public Health Hospital from January 2018 to June 2023 were enrolled, and their HCV antibody and RNA testing results were analyzed.

Results: Among the 2508 patients, 1491 (59.4%) were male, with a mean age of 42 years (range: 10-107 years), and 1736 (69.2%) were diagnosed with schizophrenia. In this cohort, 2488 (99.2%) underwent HCV antibody screening, and 65 (2.6%) tested positive. The HCV antibody positivity rate was 4.0% (59/1472) in males and 0.6% (6/1016) in females. 56.9% (37/65) of patients underwent HCV RNA testing, while the rest were lost to follow-up after discharge. HCV RNA testing revealed a positivity rate of 78.3% (N=29), with 8 cases testing negative (including 4 previously treated patients). Among the 29 HCV RNA-positive patients, 6 received direct-acting antivirals (DAA) treatment and achieved sustained virologic response (SVR); 10 inpatients were preparing to start DAA treatment, and the remaining 13 discharged patients were being recalled for referral.

Conclusion: Psychiatric inpatients exhibit a high prevalence of HCV, with a higher proportion in males than females. The relatively low treatment rate in the past can be attributed to the psychiatric adverse effects of interferon-based therapies on psychiatric patients. With a safer and more effective profile of DAA, there is an opportunity to enhance HCV screening and treatment within the psychiatric inpatient setting.

HCC risk scores assess the risk of HCC in CHC patients without advanced fibrosis after DAAs

Yu Rim Lee1, Soo Young Park1, Won Young Tak1, Young Oh Kweon1, Nae-Yun Heo1, Seung Ha Park1, Jun Sik Yoon1, Joohn Ho Jeong1, Yang Hyun Baek1, Yeewool Kang1, Min Kyung Kang1, Seung Hyun Cho1, Jihoon Hong1, An Na Seo1, Jeong Hwa Lee1
1School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital Daegu South Korea

Background: The current guidelines recommend lifelong ultrasound surveillance for chronic hepatitis C patients with advanced fibrosis or cirrhosis after achieving SVR with DAA therapy. However, there are limited studies on the risk of HCC in patients without advanced fibrosis. Therefore, we aimed to identify high risk group for HCC development using HCC prediction models.

Methods: This study included 1,839 chronic hepatitis C patients without advanced chronic liver disease from 10 tertiary hospitals who were treated with DAA. Advanced fibrosis was defined as LSM ≥10 kPa, FIB-4 >3.25, or APRI ≥1.5 at baseline. The predictors of HCC occurrence and predictive ability of HCC risk scores were assessed.

Results: During a median follow-up of 2.8 years, 28 (1.5%) patients developed HCC at a median of 2.77 years. The mean age was 56 years, and 852 (46.3%) patients were male. When the patients were divided into HCC and non-HCC groups, patients who developed HCC during follow-up were significantly older, and had lower platelet count and albumin level before antiviral treatment. In addition, patients who developed HCC had a higher FIB-4 score (P<0.001). Comorbidities, such as diabetes and hypertension, were more common among patients with HCC than those without HCC (P<0.05). In multivariate analysis, old age, platelet count, albumin level, and sodium level before treatment were significantly associated with the occurrence of HCC (all P<0.05). The high-risk group defined by previously published HCC prediction models showed a significantly high HCC occurrence. This finding was observed in most validated HCC prediction models including aMAP and mPAGE-B, and the incidence of HCC ranged from 1.5% to 7.4% at 3-years and from 3.8% to 24.2% at 5-years at SVR in high-risk patients (Table and Figure). HCC rarely occurred during the first 5-years of follow-up in low and intermediate-risk patients defined by HCC risk scores.

Conclusion: HCC risk models effectively assess the risk of HCC in chronic hepatitis C patients without advanced fibrosis after achieving SVR. Therefore, even in patients without advanced liver fibrosis before treatment, surveillance should be considered if they are included in the high-risk group of the HCC prediction model.
The challenge of a recall programme from a community-based hepatitis C screening campaign

Cheng-Hung Chien1, Chihlang Lin Lin1,3, Liwei Chen1,3, Rongnan Chien2,3, Chingchih Hu1

1Liver Research Unit, Chang Gung Memorial Hospital, Keelung branch Keelung Taiwan, 2Liver Research Unit, Chang Gung Memorial Hospital, Linkou branch Taoyaun Taiwan, 3Community Medicine Research Center, Keelung Chang Gung Memorial Hospital Keelung Taiwan

Background: We assessed the proportion of participants who obtained linkage to care (LTC) since the end of the screening campaign and examined various factors affecting LTC in these participants. The effectiveness of recall intervention for the non-LTC population and its barriers were analyzed.

Methods: We initiated an HCV patients recall program to identify the HCV participants who might not be treated after the HCV screening campaign. A program staff recalled HCV participants who lost to follow-up through the telephone from March 2019 to June 2019. They were informed of HCV treatment’s importance, availability, and safety.

Result: Among 185 HCV-infected participants, a total of 91 participants were tried to be contacted in the recall program. The subsequent follow-up results were as follows: 33 (36.2%) persons could not be reached because of incorrect telephone number and non-response, 3 (3.3%) persons died, 3 (3.3%) persons’ anti-HCV became negative, 15 (16.5%) persons had LTC in CGMH, 15 (16.5%) persons had LTC in other hospitals, and 22 (24.2%) persons did not LTC. At the end of the recall program, 127 (69.8%) persons had LTC. The proportion of LTC increased by 10.9%.

Conclusion: The associated factors affecting LTC included older age, living in a rural area, being unaware of their HCV infection, and having no health insurance. After a community screening campaign, 59% of participants with anti-HCV positive had LTC. The recall program can increase by 11%. However, there were still 30% of HCV participants who couldn’t be linked to care.

Prognosis after SVR of chronic hepatitis C patients treated with Glecparviv/Pibrentasvir treatment

Jeong Han Kim1, Jae Hyun Yoon2, Jung Hee Kim3, Sun Eun Kim4, Tae Hyung Kim4, Gi-Ae Kim5, Yewan Park5, Seong Kyun Na6, Young-Sun Lee7

1Konkuk University Medical Center Seoul South Korea, 2Chonnam National University Hospital School of Medicine Gwangju South Korea, 3Hallym University Dongtan Sacred Heart Hospital Hwasung South Korea, 4Hallym University College of Medicine Anyang South Korea, 5Kyung Hee University School of Medicine Seoul South Korea, 6Inje University Sanggye Park Hospital Seoul South Korea, 7Korea University Medical Center Seoul South Korea

Aims: Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and glecaprevir/pibrentasvir (GLE/PIB) was introduced to Korea in 2018. A good prognosis is expected in patients who achieved sustained virologic response (SVR) after DAA treatment. However, information about the prognosis of Korean CHC patients who achieved SVR after GLE/PIB treatment is still limited. We aimed to investigate the prognosis of these patients.

Methods: This is a multicenter prospective observational study. The CHC patients achieved SVR after GLE/PIB treatment were enrolled and final follow-up date was June 2023. The primary end-point was hepatocellular carcinoma (HCC) occurrence. At last one time in a year, we checked about this end-point.

Results: Total 361 patients were included in this analysis and mean follow-up duration was 23.9 months. Male was 159 patients (44.0%) and median age was 59 years. Genotypes were 1 (131, 36.3%), 2 (223, 61.8%), 3 (5, 1.4%) and 6 (2, 0.6%). Cirrhosis was 85 patients (23.5%) and significant alcohol intake prevalence was 60 (16.6%). Mean Child-Pugh score was 5.2 and HCC occurrence cases were 8 patients (2.2%) for up to 4 years. HCC patients all had cirrhosis prevalence (100% vs. 21.8%, p<0.001), older age (68 years vs. 59 years, p=0.025), higher APRI (2.0 vs. 0.4, p=0.001) and FIB-4 (7.2 vs. 2.0, p<0.001). Cox regression analysis showed APRI over 0.714 (p=0.045), FIB-4 over 5.778 (p=0.005) were significant risk factors for HCC occurrence. Recurrence or reinfection occurred in 2 patients (0.6%) at 21 and 22 months after SVR each.

Conclusion: The prognosis of patients achieved SVR after GLE/PIB treatment was generally good. However, HCC risk was not completely removed especially in patients with high APRI or FIB-4 score. Recurrence or reinfection is also possible. Therefore, regular follow-up surveillance is still warranted.
**Prognosis after SVR of chronic hepatitis C patients treated with Elbasvir/Grazoprevir treatment**

**Jeong Han Kim¹, Jae Hyun Yoon², Jung Hee Kim³, Sung Eun Kim⁴, Tae Hyung Kim⁴, Gi-Ae Kim⁵, Yewon Park⁵, Seong Kyun Na⁶, Young-Sun Lee⁷**

¹Konkuk University Medical Center Seoul South Korea, ²Chonnam National University Hospital School of Medicine Gwangju South Korea, ³Hallym University Dongtan Sacred Heart Hospital Hwasong South Korea, ⁴Hallym University College of Medicine Anyang South Korea, ⁵Kyung Hee University School of Medicine Seoul South Korea, ⁶Inje University Sanggye Paik Hospital Seoul South Korea, ⁷Korea University Medical Center Seoul South Korea

**Aims:** Direct-acting antiviral (DAA) therapy can cure chronic hepatitis C (CHC), and elbasvir/grazoprevir (EBR/GZR) was introduced to Korea in 2017. A good prognosis is expected in patients who achieved sustained virologic response (SVR) after DAA treatment. However, information about the prognosis of Korean CHC patients who achieved SVR after EBR/GZR treatment is still limited. We aimed to investigate the prognosis of these patients.

**Methods:** This is a multicenter prospective observational study. The CHC patients achieved SVR after EBR/GZR treatment were enrolled and final follow-up date was June 2023. The primary end-point was hepatocellular carcinoma (HCC) occurrence. At last one time in a year, we checked about this end-point.

**Results:** Total 127 patients were included in this analysis and median follow-up duration was 34.3 months. Male was 60 patients (47.2%) and median age was 60 years. Genotypes were 1b (125, 98.4%), 2 (1, 0.8%), and 4 (1, 0.8%). Cirrhosis was 39 patients (30.7%) and significant alcohol intake prevalence was 14 (11.0%). Mean Child-Pugh score was 5.1 and HCC occurrence cases were 2 patients (1.6%) for up to 5 years. HCC patients all had cirrhosis prevalence (100% vs. 21.8%, p=0.093), higher APRI (2.5 vs. 0.4, p<0.001) and FIB-4 (10.1 vs. 2.1, p=0.002). Recurrence or reinfection case was not observed.

**Conclusion:** The prognosis of patients achieved SVR after EBR/GZR treatment was generally good. However, HCC risk was not completely removed especially in patients with high APRI or FIB-4 score. Therefore, regular follow-up surveillance is still warranted for advanced fibrosis cases.

Abstract Submission No. 100629

**P-0208**

**Questionary of Chronic Hepatitis C among Residents in Guangzhou in 2023**

**Jianping Li¹, Ganqiu Lin¹, Bo Li², Yong Zhou³, Haocheng Kuang¹, Canhui Lu¹, Songlian Liu¹, Feng Jing¹, Biao Zheng¹, Yue Wu¹, Yujuan Guan¹, Shuxian Chen¹**

¹Guangzhou Eighth People's Hospital, Guangzhou Medical University Guangzhou China, ²Baiyun District of Guangzhou Center for Disease Control and Prevention Guangzhou China, ³Conghua District of Guangzhou Center for Disease Control and Prevention Guangzhou China, ⁴Guangzhou Baiyun District Jianghe Street community health service center Guangzhou China

**Background:** The level of awareness among residents regarding knowledge of chronic hepatitis C (CHC) has a significant impact on the management of this disease and the data is limited in China.

**Methods:** We organized community consultation and conducted face-to-face questionnaires to assess the general public’s knowledge level of CHC. The data were also analyzed.

**Results:** From May to October 2023, 402 CHC questionnaires were collected from five ordinary communities, one leisure club, and one foot bath center in Guangzhou. The residents generally believed that hepatitis C can be transmitted through blood (70.63%), but only about one-third to one-half of the residents were aware of the high-risk behaviors, mother-to-child transmission, and sexual transmission of hepatitis C. Over 40% of the responders were unable to identify the high-risk behaviors for hepatitis C infection, and approximately 20% of the residents mistakenly believed that hepatitis C can be transmitted through daily life activities. The average awareness rate of whether hepatitis C can cause severe outcome was only 56.22%. The awareness rate among individuals aged 18 to 30 was 66.94%, which was higher than other age groups (P<0.05). The awareness rate among individuals with a college education or above was 78.33%, which was higher than other educational levels (P<0.05). Over half of the participants unsure or believe that hepatitis C is incurable. (Table 1)

**Conclusion:** The awareness rate of CHC knowledge among the surveyed individuals was low, with insufficient or even incorrect understanding of the transmission routes, treatment, and prognosis of hepatitis C.

Abstract Submission No. 100686

**P-0209**

**PLATELET LYMPHOCYTE RATIO (PLR) AS A PREDICTOR OF LIVER FIBROSIS IN HCV-HIV COINFECTION PATIENTS**

**Rizki Agustina¹, Suyata Suyata², Tiara Qurilmi³, Harun Hudari⁴**

¹Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, ²Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, ³Mohammad Hoesin Hospital South Sumatera Palembang Indonesia, ⁴Mohammad Hoesin Hospital South Sumatera Palembang Indonesia

**Background:** HCV and HIV coinfection is associated with higher HCV RNA values compared to HCV monoinfection. HIV infection causing impairment of immune responses that impact HCV clearance. Platelet lymphocyte ratio (PLR) acts as a potential prognostic indicator in chronic diseases such as HCV and HIV, which is related to the disease progression and prognosis. This study aimed to determine the accuracy of PLR on liver fibrosis in HCV-HIV co-infected patients at Mohammad Mohammad Hoesin Hospital Palembang (RSMH).

Methods: This is an analytic observational study, on 38 HCV-HIV coinfected patients at the Internal Medicine Clinic at RSMH from March 2022 to February 2023. Statistical analysis used diagnostic test with SPSS version 25.

**Results:** From the study, it was found that 78.9% (n=31) subjects were male, with homosexuality as the highest risk factor (39.5%). It was also found a total of 17 subjects (44.7%) had liver cirrhosis. The mean PLR value within the cirrhosis group was 169.8. The mean PLR value within the non-cirrhosis group was 190.8. PLR with a cut off value of 70 had a sensitivity of 29.4%, specificity of 80.9%, PPV of 58.6%, NPV of 55.5%, and accuracy of 57.8%.

**Conclusion:** PLR ratio with a value of less than 70 has the potential to predict the incidence of cirrhosis in HCV- HIV coinfected patients at RSMH Palembang.

Keywords: Hepatitis C; HIV; PLR; HCV RNA

Abstract Submission No. 100633
DAA improved treatment access and outcome in chronic hepatitis C patients undergoing hemodialysis

Fria May G. Manejero1, Roy Debajyoti2, Andrew Kwek1, Yu Jun Wong1,3

1Department of Gastroenterology and Hepatology, Changi General Hospital Singapore Singapore, 2Department of Renal Medicine, Changi General Hospital Singapore Singapore, 3Duke-NUS Medical School Singapore Singapore

INTRODUCTION: Treatment of Hepatitis C virus (HCV) is important to prevent nosocomial transmission and extrahepatic complications in chronic hepatitis C (CHC) patients undergoing hemodialysis (HD). The impact of treatment access to direct-acting antiviral (DAA) in CHC patients undergoing HD remained unclear in Singapore.

METHOD: We retrospectively reviewed all CHC patients undergoing HD in our hospital during the pre-DAA era (<2014), restricted DAA era (2014-2017) and unrestricted DAA era (2018-2022). Study outcomes include the rate of HCV treatment and SVR12.

RESULT: A total of 378 patients underwent HD during the pre-DAA (7.7%), restricted DAA (43.7%) and unrestricted DAA (48.6%) era. The overall seroprevalence and viremic prevalence was 10.9% and 7.5%, respectively. From pre-DAA to restricted DAA and post-DAA era, the introduction of DAA significantly increased the treatment rate (25% vs 70% vs 100%, p=0.005) and SVR12 (9% vs 85.7% vs 100%, p=0.005). Improving DAA access allowed more HD patients with advanced fibrosis (FIB4>3.25) to be treated (14.8% vs 37.0% vs 48.1%, p=0.074). The HCV viremic prevalence in patients undergoing dialysis had declined, but remained substantial (14.3% vs 6.3% vs 7.3%, p=0.324).

CONCLUSION: Improving DAA access had improved the treatment rate and SVR12 of CHC patients undergoing HD. Our findings suggest HCV screening and linkage to care remained relevant among patients undergoing HD.

Abstract Submission No. 100687
P-0210

DAA treatment did not reduce mortality in chronic hepatitis C patients undergoing hemodialysis

Fria May G. Manejero1, Roy Debajyoti2, Andrew Kwek1, Yu Jun Wong1,3

1Department of Gastroenterology and Hepatology, Changi General Hospital Singapore Singapore, 2Department of Renal Medicine, Changi General Hospital Singapore Singapore, 3Duke-NUS Medical School Singapore Singapore

INTRODUCTION: Current guidelines recommend urgent HCV treatment among patients undergoing HD. However, HD patients often had multiple comorbidities and reduced survival. We aim to determine if direct-acting antiviral (DAA) treatment improve the survival in HCV patients undergoing HD.

METHODS: We retrospectively reviewed all patients undergoing HD between 2012 to 2022 in our hospital. Cox-regression was used to estimate the predictors of the survival in HD patients, with or without DAA treatment.

RESULTS: 375 patients (mean age 64 years old, 64% male) underwent HD from 2012-2022. Metabolic comorbidities were common (T2DM in 15.7%, hypertension 86%, dyslipidemia 71.2%, IHD 54.9%, prior stroke in 14.7%). The overall HCV seroprevalence and viremic prevalence was 10.9% (n=41) and 7.5% (n=28), respectively. Three patients (1%) developed HCV after dialysis initiation. The commonest genotype was genotype 3 (51.9%), 39% already had liver cirrhosis upon initiation of dialysis. Twenty (77.8%) received DAA treatment. Overall SVR was 90.0% (16/18), with no treatment-related complications reported. Over a median follow-up of 54 months (IQR: 24-86), 37.9% had demise, 9.6% lost to follow-up. Hepatocellular carcinoma (HCC) developed in 0.8% (all having baseline liver cirrhosis). Overall mortality was not influenced by the HCV treatment, presence of liver cirrhosis, or HCC (p>0.05 for all); however, mortality increases with IHD (HR: 1.7, 95%: 1.7-2.5, p=0.018), prior stroke (HR: 1.9, 95%CI: 1.2-2.8, p=0.003), and older age (HR: 1.0, 95%CI: 1.0-1.1, p<0.001). The commonest cause of death was cardiovascular-relate death (20.3%), only 2.1% demised from liver-related death.

CONCLUSION: HCV treatment with direct-acting antiviral is safe and efficacious, but did not reduce mortality in patients undergoing HD.

Abstract Submission No. 100719
P-0211

The efficacy of SOF/VEL in patients with chronic hepatitis C virus genotype 6 infection

Airong Hu1, Su-Wen Jiang1, Xian Lian2, Yu-tao Hu2, Dong-hui Wang1, Jia-Lan Wang1, xiaoting Ye1, Liang Hong1, heqing Huang2

1Ningbo No. 2 Hospital Ningbo China, 2Ningbo Fourth Hospital, Ningbo China, 3Wenzhou Medical University Wenzhou China, 4the third affiliated hospital of wenzhou medical university Ruian China, 5Zhuji people's hospital Zhuji China

Background: The hepatitis C virus (HCV) genotype (GT) is mainly GT 1b and the proportion of GT 6 is small in the world. But GT 6 is relatively difficult to treat among all GTs. Our aim is to evaluate the efficacy of sofosbuvir/vepatasvir (SOF/VEL) in patients with chronic HCV GT 6 infection.

METHODS: We retrospectively analyzed patients with chronic HCV GT 6 infection from July 2018 to May 2023. All patients received SOF/VEL for 12 weeks, and patients with liver cirrhosis were combined ribavirin. Routine blood, liver and renal functions, HCV RNA were monitored at baseline, 4, 8, 12 and 24 weeks.

RESULTS: A total of 163 patients were enrolled. The mean age was 60.5±12.70 y, 107 cases were male (65.6%), the median HCV RNA was 2.75×10^6 IU/ml, and the proportion of cirrhosis was 5%. At the end of treatment, the proportion of normalized ALT was 94.34% (150/159). RVR, ETVR, SVR12 was 96.93% (158/163), 100% (163/163) and t 99.20% (122/123), respectively.

Conclusions: SOF/VEL achieved high virological response and ALT normalization rate in patients with chronic HCV GT 6 infection.

Abstract Submission No. 100764
P-0212

Real-World Data with Pangenotypic Direct-Acting Antivirals: Preliminary Results of the SVR10K Study

Candido Hernandez1, Ming Lung Yu2, Grace Wong3, Maria F Higuera4, Mohamed Alzaabi5, Javier Garcia-Samaniego6, Marta Casado1, Habibba Kamal Khodir8, Karin Lindahl8, Aastha Chandak7, Marta Martinez9, Artak Khachatryan4, Linda Chen10, Soo Aleman8

1Gilead Sciences Madrid Spain, 2Kaohsiung Medical University Hospital, Hepatobiliary Division, Internal Medicine Kaohsiung Taiwan, 3Prince of Wales Hospital Hong Kong Hong Kong, 4Hospital
Background: A previous real-world data analysis demonstrated high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in > 6,000 HCV patients from 12 clinical cohorts across Australia, Canada, Europe & USA. Expanding this research initiative to include even more patients from additional geographical areas will allow to show SOF/VEL effectiveness across multiple diverse populations & the evaluation of HCV patient characteristics across Western countries, Asia, Middle Eastern and Latin-American regions.

Methods: This real-world analysis includes patients ≥18 years treated with SOF/VEL without RBV for 12 weeks, as decided by the treating HCP, from 7 sites across Hong Kong, Mexico, Sweden, Spain, Taiwan, and the United Arab Emirates. Age, sex, treatment experienced (TE), cirrhosis stage (no decompensated included), genotype, coinfections, time to treatment initiation (TTI) from HCV diagnosis, and SVR (4/12/24) were analyzed.

Results: Overall, 4,679 patients were included, 51% of them from Asian countries. Median age was 56.9 [IQR 46-66], where males 59%, and age >50 years in 68%. Genotype 3 was present in 25%, F4 21%, TE 5%, while HIV, HBV and HDV coinfected was reported in 4.7%, 4.3%, and 0.1%, respectively. The TTI was available in 74%, with 17% having ≤30 days. In terms of effectiveness, SVR was achieved in 98.4% of the treated population, 99% for Asian countries.

Conclusions: Results on treatment effectiveness in these new geographies did not differ from real world studies of patients in the Western countries, reinforcing that HCV treatment guidelines are globally applicable, and supporting the efficacy of pDAA therapy.

Abstract Submission No. 100854
P-0213

Simplified Hepatitis C diagnosis on outpatient care for people living with HIV/AIDS

Xiao Li1, Xinpeng Yang2, Quanying He3, Shifang Liu2, Junyi Liu4, Lijuan Kang1, Cuifen Wang2, Xiao Song1, Canzhu Shang1, Jiali Wang2, Huiqin Li2

1 Kunming Medical University, Kunming, Yunnan, China Yunnan, 2 Yunnan Provincial Infectious Disease Hospital Kunming Yunnan, 3 Dalí University Kunming Yunnan

Background: The simplification of current hepatitis C (HCV) diagnostic algorithms and service delivery is very crucial to achieving the WHO goal by 2030. To increase timely diagnosis and improve the linkage to care in people living with human immunodeficiency virus (PLWH), HCV reflex testing and a call-back strategy was implemented in an outpatient-clinic of a territorial hospital in Southwest China.

Methods: The pilot study was conducted in two phases. In Phase 1 (Jan 2022 ~ Oct 2022), the traditional approach to HCV diagnosis including at least 3 visits was adopted. In Phase 2 (Dec 2022 ~ Jul 2023), reflex testing for HCV RNA and genotype was implemented which only required one visit to confirm HCV diagnosis.

Results: In phase 1, totally 1689 PLWH were included during 10-month study period. With close follow-up by coordinating nurses, 93 anti-HCV positive patients came back for HCV RNA testing and the RNA diagnostic rate was only 71.5% (93/130). In phase 2, totally 4020 PLWH were included during 9-month period. The patients of Phase 2 with the “one-visit for diagnosis” strategy, the RNA diagnostic rate increased to 100% (465/465). Compared with the Phase 1, the mean time from screening to treatment initiation was shortened from 144 days (144.47±47.29) to 61 days (61.46±25.59), p<0.01.

Abstract Submission No. 101015
P-0215

Characteristics and factors of HIV/HCV in southwest China

Xiao Li1, Xinpeng Yang2, Quanying He3, Huiqin Li2

1 Kunming Medical University, Kunming, Yunnan, China Yunnan, 2 Yunnan Provincial Infectious Disease Hospital Kunming Yunnan

Objective: To analyze the characteristics of hepatitis C virus (HCV) infection in people living with hiv (PLWH), and to provide reference for the prevention and treatment of HCV in PLWH.

Methods: From January 2022 to July 2023, HIV/AIDS patients in Yunnan Infectious Disease Hospital were selected as the study subjects. A cross-sectional survey was conducted to collect demographic information, HCV antibody screening rate, HCV RNA screening rate, infection positive rate, infection route, biochemical indicators, liver fibrosis, treatment and other data. Differences in characteristics between
HIV mono-infected patients and HIV/HCV co-infected patients were analyzed.

**Results:** A total of 7413 PLWH outpatients were under treatment and management, and 5709 of them were screened. The HCV antibody test rate was 77.01% (5709/7413), and the HCV/HIV antibody positive rate was 10.42% (595/5709). The detection rate of HCV RNA was 86.72%(516/595). FIB-4 score > 3.25 was 37.93% (88/232). There were significant differences in age and transmission route between HIV mono-infected patients and HIV/HCV infected patients (P < 0.001).

**Conclusions:** The positive rate of HCV antibody was high in HIV infected people, and most of them were male, 40-49 years old and intravenous drug users. HIV co-infection was older and more likely to be infected through injection drug use. Patients with HIV/HCV co-infection have a higher proportion of progressive liver fibrosis and more severe liver fibrosis, and are more likely to develop liver cirrhosis. Therefore, early screening, early diagnosis and early treatment of hepatitis C in HIV/HCV co-infection population are recommended.

---

**Abstract Submission No. 101108**

**P-0216**

**Barriers to Hepatitis C Treatment in South Korea: A Cascade of Care Analysis**

**Sang Bong Ahn**, **Daewon Jun**, **Joo Hyun Oh**, **Eileen Youn**

1. Nowon Eulji Medical Center Seoul South Korea, 2. Hanyang University College of Medicine Seoul Korea

**Background:** The HCV care cascade plays a crucial role in improving treatment rates. This study aims to examine the cascade of care for chronic hepatitis C patients in South Korea and identify factors impeding treatment.

**Methods:** We conducted an analysis using data from the Korea Disease Control and Prevention Agency, which registered 8,810 patients with chronic hepatitis C in 2019. We collected and analyzed baseline characteristics, income levels, healthcare facility utilization, actual treatment status, comorbidities, and laboratory test results.

**Results:** The proportions of patients diagnosed at primary, secondary, and tertiary healthcare facilities were 26%, 53%, and 21%, respectively. Among all diagnosed patients, 41% did not receive actual treatment. Treatment rates were 11.5% at primary healthcare facilities and 47.3% and 59.4% at secondary and tertiary healthcare facilities, respectively, for patients diagnosed at these respective levels. Among patients diagnosed at primary healthcare facilities, 60% were referred to higher-level facilities, and 80% of those referred received treatment. Treatment rates did not significantly differ by region, but the lowest income group (below 25%) exhibited lower treatment rates. However, income level did not show a proportional relationship with treatment rates. Treatment rates were also lower for elderly patients, those with underlying comorbidity, and patients with liver cirrhosis.

**Conclusion:** Treatment uptake for chronic hepatitis C in South Korea falls below optimal levels, posing a challenge to achieving the goal of HCV elimination. Efforts are needed to address barriers that reduce treatment rates and improve the cascade of care for HCV patients.

---

**Abstract Submission No. 101109**

**P-0217**

**Morbidity and mortality after direct-acting antivirals in patients with chronic hepatitis C**

---

**Abstract Submission No. 101129**

**P-0218**

**Elimination of Hepatitis C Virus in a Hemodialysis Unit in Cipto Mangunkusumo Hospital**

**Andri Sanityoso Sulaimani**, **Ni Made Hustrini**, **Desti Rachmani**

1. Cipto Mangunkusumo Hospital Jakarta Indonesia, 2. Nephrology and Hypertension Division, Departement of Internal Medicine, Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo National General Hospital Jakarta Indonesia, 3. Hepatobiliary Division, Cipto Mangunkusumo Jakarta Indonesia

Hepatitis C in hemodialysis patients remains a global health problem, and the biggest risk factor is caused by nosocomial transmission. In the era DAA eliminating HCV in hemodialysis unit become more feasible. In HD unit at Cipto Mangunkusumo hospital we perform program for eradication of HCV. DAA treatment in special population as in HD unit is important to achieve WHO goal for hepatitis C elimination by 2030, assuming a 90% reduction in new cases of chronic hepatitis C and a 65% reduction in hepatitis C deaths. The research aims to achieve a therapeutic sustained virological response (SVR) for all patients. The study design was a prospective cohort. The outcome studied was SVR12. We treat with two types of DAA within two periods of time. In period 1, 45 patients treated with grazoprevir/elbasvir. While in period 2, there were 9 patients treated with grazoprevir/elbasvir and 2 patients with sofosbuvir/daclatasvir, due to relaps and no respon with previous treatment. A total confirmed of 56 HCV patients were enrolled. The DAA treatment initiation rate and completion rate were...
Nomogram for Hepatocellular Carcinoma Risk Prediction in Chronic Hepatitis C Patients

Engin Altintas1, Hakan Bas1, Zekiye Nur Harput1, Serkan Yaras1, Osman Ozdogan1, Enver Ucbilek1, Fehmi Ates1, Orhan Sezgin1
1Mersin University Faculty of Medicine Yenisehir Turkey

Aim: To detect risk factors to predict the risk of developing hepatocellular cancer (HCC) among hepatitis C virus (HCV) patients after antiviral treatments and to develop nomograms to indicate the development of HCC.

Methods: 618 patients with chronic HCV infection treated with interferon (IFN)-based and direct-acting antiviral agents (DAA) were included in the study. Cox’s multivariable model was used to predict HCC, followed by a nomogram to assess individualized risk

Results: The average age of Chronic HCV patients at diagnosis was 53.8 ± 15.1 years. The average follow-up period of the patients was 107.6 ± 48.3 months. During follow-up, 32 patients developed HCC (median duration 51 months). Three variables were independently associated with HCC formation: ferritin level (above 24.7750 ng/ml), platelet (PLT) count (below 143,500/ml), and aspartate aminotransferase (AST) value (above 43.5 IU/L), to be.

Conclusion: These nomograms may be a visualization risk model that can provide personalized prediction of long-term outcomes for HCV-associated HCC patients.

Glecaprevir/Pibrentasvir improves fibrosis after SVR and during long-term follow-up.

Young-Sun Lee1, Yang Jae Yoo1, Sun Young Yim1, Young Kul Jung1, Ji Hoon Kim1, Yeon Seok Seo1, Hyung Joon Yim1, Jong Eun Yeon1, Kwan Soo Byun1
1Korea university Seoul South Korea

Background and Aim: Chronic hepatitis C (CHC) has been a significant contributor to advanced liver diseases, such as liver cirrhosis and hepatocellular carcinoma (HCC). The advent of direct-acting antiviral agents (DAAs), particularly pan-genotypic DAAs like glecaprevir/pibrentasvir and sofosbuvir/velpatasvir, has revolutionized CHC treatment. Fibrosis plays a crucial role in disease progression post sustained virologic response (SVR). This study focuses on analyzing fibrosis improvement after SVR in patients treated with glecaprevir/pibrentasvir.

Method: This single-center retrospective cohort study reviewed patients undergoing glecaprevir/pibrentasvir treatment. SVR evaluation was conducted 12 weeks post-treatment by checking HCV RNA. Fibrosis assessment occurred through fibroscan before treatment, at the SVR time point, and annually thereafter.

Results: Out of 264 patients treated with glecaprevir/pibrentasvir, with an average age of 59.2 years and a female dominance of 79.8%, 31.1%, 66.7%, 1.5%, and 0.8% had genotypes 1, 2, 3, and 6, respectively. Sixty-one patients had liver cirrhosis, and 237 were treatment-naïve. A remarkable 98.5% of patients achieved SVR, with only 5 patients diagnosed with HCC during the follow-up period. Liver stiffness decreased from 6.3 kPa to 5.6 kPa at SVR (p = 0.0004). After a long-term follow-up of at least 1 year, liver stiffness further decreased from 7.1 kPa to 5.0 kPa (p < 0.0001).

Conclusion: Glecaprevir/pibrentasvir not only proved effective in treating CHC but also demonstrated significant improvement in liver fibrosis over the long term.

Risk factor for hepatoma in chronic kidney disease patients with HCV infection after DAA treatment

Kuo-Chin Chang1, Tsung-Hui Hu1, Chien-Hung Chen1, Jing-Houng Wang1, Chao-Hung Hung1
1Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

Background: Hepatitis C virus (HCV)-infected individuals treated with direct-acting antivirals (DAAs) are at risk for hepatocellular carcinoma (HCC) after achieving sustain virological response (SVR). This study explored the risk factors for HCC in chronic kidney disease (CKD) patients with HCV infection receiving DAA therapy.

Methods: From March 2014 to December 2021, 738 patients with HCV-positive CKD who were regularly followed up at Kaohsiung Chang Gung Memorial Hospital for DAA treatment were included in the study.

Results: 738 patients with anti-HCV positive CKD patients were included in this study. Of these 738 patients, 542 patients who had achieved SVR without HCC before DAA treatment were analyzed. Univariate analysis showed that age (≥70.5 years), AFP (≥20ng/ml) and cirrhosis were risk factors for the development of hepatocellular carcinoma. Multivariate analysis showed that cirrhosis only (HR: 4.34, 95%CI: 1.42-13.27, p=0.01) was an independent risk factor for the development of HCC.

Conclusion: In HCV-infected patients with CKD, cirrhosis was an independent risk factor for new HCC after DAA treatment.

Investigation and analysis of hepatitis C virus infection for hemophilia in Mainland China

Yingjie Ji1, Lin Cao1, Yongqian Cheng1
1The Fifth Medical Center of PLA General Hospital BEIJING China

Background and Aims: To investigate the prevalence of hepatitis C virus (HCV) infection in a neglected hemophilia cohort in Mainland China.

Method: Hemophilia patients in ten regional and local hemophilia centers were recruited to conduct an online questionnaire-based survey to preliminary identify those with suspicious signs and symptoms from HCV infection. After that, HCV IgG antibody kits were disseminated for self-detection in these high-risks. HCV RNA detection, liver function evaluation and HCV genotyping were conducted based on the HCV-antibody screening results. The classification, age and geographical characteristics of hemophilia were analyzed.
Results: The positive rate of anti-HCV was 5.92% (61/1030) in a total 1030 hemophilia patients, with breakdown of 5.93% (50/843) and 6.40% (11/172) in hemophilia A and B, respectively (statistically significant difference, P = 0.001). The anti-HCV positivity rate in hemophilia patients born before 1993 (year from when blood products were mandated for HCV screening) was significantly higher than that from patients born after 1993 (13.50% (54/400) vs. 1.11% (7/630), p < 0.001). Variance in HCV-antibody results from geographic distribution was not identified (P = 0.5119). Further diagnosis using HCV RNA quantification confirmed 24.59% (15/61) was current HCV infection, with a median HCVRNA at 1.06x1061/U/ml. Subgroup analysis revealed HCV RNA positivity in hemophilia A was 22.00% (11/50), while in hemophilia B was relatively higher 36.36% (4/11), with statistical significance (P = 0.0442). HCV RNA was negative in all seven hemophiliacs born after 1993 while conversely 27.78% (15/54) in whom were born before 1993 (p < 0.05).

Conclusion: Confirmed HCV infection rate in hemophilia population demonstrated an unsurprisingly higher prevalence than that from general population with in Hemophilia B higher than in hemophilia A. Year of born before or after 1993 in hemophilic patients might be potential risk factor in our cohort and there is no geographic distribution bias. The lower percentage of HCV RNA (+) from those HCV antibody (+) may warrant further investigation before optimal HCV screening strategy in hemophiliacs could be shaped.
The treatment rate was the number who had been prescribed antiviral medication within 1.5 years from the index date out of patients newly diagnosed with HCV.

**Results:** The new HCV infection rate was 17.2 per 100,000 person-years (n=8,810) in 2019. The number of new HCV infections was the highest in patients aged 50 to 59 years (n=2,440), and the new HCV infection rate significantly increased with age (p<0.001). Among newly infected patients with HCV, the linkage to care rate was 78.2% (78.2% men, 78.2% women) and the treatment rate was 58.1% (56.8% men, 59.3% women) within 1.5 years.

**Conclusions:** The new HCV infection rate was 17.2 per 100,000 person-years in Korea. It is necessary to continuously monitor the incidence and care cascade of HCV to establish proper strategies to reach the goal of HCV elimination by 2030.

Abstract Submission No. 101575

**P-0226**

**Risk factors for developing hepatocellular carcinoma after eradication of hepatitis C virus**

Seiichi Mawatari1, Kotaro Kumagai1, Ai Toyodome1, Oki Taniyama1, Haruka Saka1, Kazuki Tabu1, Kohei Oda1, Akio Ido1

1Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan

**Background:** Although almost patients with hepatitis C virus (HCV) can achieve a sustained virologic response (SVR) with direct-acting antiviral agents (DAA), a few patients develop hepatocellular carcinoma (HCC) after SVR.

**Methods:** In 1609 patients who achieved SVR after administration of DAA for HCV, without a history of HCC, hypovascular tumors, and HBV co-infection, we investigated the risk of developing HCC after DAA-SVR each aMAP risk score.

**Results:** HCC developed in 111 patients during an average observation period of 57.2 months. The 5-year cumulative HCC development rate was 7.1% in all patients, and 11.2%, 2.9%, and 0%, for high-risk (>60), medium-risk (50-60), and low-risk (<50) group, respectively (p<0.001). In medium and high-risk groups, Cox proportional hazard analysis showed male, liver cirrhosis, aMAP score >64, and albumin (p<0.001). In the high-risk group, when the sum of these factors was 0-1, 2-3, and 4-5, the 5-year cumulative HCC incidence was 2.2%, 7.0%, and 31.4%, respectively (p<0.001). On the other hand, in the medium-risk group, only EOT-Alb and EOT-AFP were extracted, and the 5-year cumulative HCC development rates for 0, 1, and 2 factors were 1.5%, 6.4%, and 20.0%, respectively (p<0.001).

**Conclusions:** During approximately 5 years of follow-up, there were no HCC development in the aMAP low-risk group. In the medium and high-risk groups, further stratification of HCC risk was possible by combining aMAP score, EOT-Alb, and EOT-AFP.

Abstract Submission No. 101605

**P-0227**

The efficacy and safety of 12W treatment with SOF/VEL in patients with chronic HCV/HIV coinfection.

Jing Xu1, Chuanjie Li1, Liangliang Wang1, Biao Liu1, Xiaodong Gao1, Alei Sun1, Jingjing Gao1

1Lixin county people’s hospital Bozhou China

**Background:** There are multiple complications and DDIs in patients with chronic HCV/HIV coinfection. Our study aimed to access the efficacy of sofosbuvir/velpatasvir and DDI during the treatment in these patients.

**Methods:** We retrospectively analyzed patients with chronic HCV/HIV coinfection receiving sofosbuvir/velpatasvir 12 weeks treatment from 2017 to 2019 in Lixin County People’s Hospital. Blood routine, liver and renal function, HCN RNA and CD4 were detected at baseline, 12W and 24W. DDI in different drugs was also observed.

**Results:** A total of 95 patients were included. At baseline, 92 patients (97%) had history of selling blood. The mean age was 57 years, HCV RNA was 1.02*10^7IU/ml, ALT was 63 U/L and CD4 was 488/ul. 48 patients (51%) were male. 16 (17%) GT1b, 7 (7%) GT2a, 72(76%) undetected genotype. 19 (20%) with cirrhosis. The count of combined with gastritis, hypertension, cardiovascular and vascular disease, other diseases were 16 (17%), 26 (27%), 27 (28%), 18 (19%). All treated Patients achieved SVR12 99% (94/95). 27 patients (28%) took antacids, PPI or EFE, which reduced the concentration of sofosbuvir/velpatasvir, but did not affect the SVR12. 79 patients(82%) took TDF-based regimens, which increased tenofovir exposure and renal function need to be detected during the treatment. Before and after treatment, Cr 62umol/L and 64umol/L remained stable. BUN 5.5mmol/L and 6.2mmol/L were within the normal range. There were no discontinuations or deaths due to the effects of DDI in all treated patients.

**Conclusions:** Sofosbuvir/velpatasvir provide high rates of SVR and well tolerated in Chronic HCV/HIV coinfection patients.

Abstract Submission No. 101645

**P-0228**

The prognostic value of soluble biomarkers in hepatitis B-related hepatocellular carcinoma patients

Xue Cai1,2, Lihua Yu1, Xiaoli Liu1, Huiwen Yan1, Yuqing Xie1, Qing Pu1, Zimeng Shang1, Yuan Wu1, Tingting Jiang1, Zhiyun Yang1

1Beijing Ditan Hospital Capital Medical University Beijing China, 2The First Clinical Medical College of Beijing University of Traditional Chinese Medicine Beijing China, 3School of Traditional Chinese Medicine, Capital Medical University Beijing China

**Background & Aims:** Soluble (s) immune checkpoints (ICs) are functional parts of membrane ICs. Clinical studies have evaluated their prognostic values in cancers. However, few studies were conducted in patients with hepatitis B-related hepatocellular carcinoma (HBV-HCC). We aimed to clarify the prognostic value of sICs in HBV-HCC and develop a random survival forest (RSF) model to predict the overall survival (OS).

**Patients and methods:** We profiled the plasma levels of 14 sICs in healthy controls (HC) (n=20), chronic hepatitis B (CHB) group (n=20), chronic hepatitis B cirrhosis (HBV-LC) group (n=20), and HBV-HCC group (n=196) using a multiplex Lumines Immunassay. Flow cytometry was performed from HBV-HCC group (n=80). HBV-HCC group (n=196) were divided into training and validation sets. We also evaluated the predictive efficacy and analyzed the correlations of sICs with clinical parameters and membrane ICs.

**Results:** sICs level in HBV-HCC were elevated compared with HC. The areas under the receiver operating characteristic values of 1- , 2- and 3-year survival predicted by the RSF model were 0.91, 0.79, and 0.71 in validation set. The model can adapt to different distributions of events and clinical staging systems. Soluble TIM-3 has the strongest correlation with clinical indicators, reflecting the severity of hepatocyte injury, persistent inflammation and immunosuppression.
Conclusion: RSF model can predict the OS of HBV-HCC patients. sTIM-3 is of interest in reflecting clinicopathologic and immunologic features in HBV-HCC.

Keywords: HBV-HCC; soluble immune checkpoints; RSF model; OS.

Abstract Submission No. 101656
P-0229

DAA treated HCV patients over 75 yr have a similar prognosis with non-HCV. individuals.

Shintaro Takaki1, Yumi Kosaka1, Kazuki Ohya1, Nami Mori1, Keiji Tsuji2
1Department of Gastroenterology, Hiroshima Red Cross and Atomic Bomb survivors Hospital Hiroshima Japan

Aim: To clarify the significance of treatment for elderly HCV cases
Methods: The subjects were 218 HCV cases aged 75 years or older (DAA group) and 519 HCV antibody-negative and HBs antigen-negative cases (health checkup group) who had physical checkups in our institute since January 2015. The background of each group was 80.5 (75-96) / 75 (75-89) years of age, 84 (38.5%) / 319 (61.5%) male, 147×103 / 214×103 /μl (19-341) / 214×103 /μl (47-341) platelets, ALT 24 IU/l (6-120) / 19 IU/l (4-118), FIB-4 index 3.52 (0.81-38.38) /1.92 (0.50-11.67), 27 (12.4%) / 0 with previous liver cancer.

Results: The cumulative survival rate of DAA overall was 92.2%/85.2 % at 3/5 years, 97.0%/94.6% in the group without liver cancer and 60.0%/24.1 % in the group with pre-existing liver cancer, with significantly worse prognoses in the group with pre-existing liver cancer (P<0.001). The health checkup group was 97.7%/95.4%, with a predominantly poor prognosis for DAA overall (P<0.001), but no significant difference was found between the group with no liver cancer and the group with liver cancer (P=0.280). A gender-matched propensity score analysis showed similar results (P=0.191).

Conclusion: DAA treatment of HCV in patients over 75 years of age with no history of liver cancer eliminates HCV and offers a prognosis equivalent to that of HCV-negative cases undergoing health checkups.

Abstract Submission No. 101855
P-0231

Clinical manifestations of Cryoglobulinemia in chronic hepatitis C patients

Chia-Yen Dai1,2, Batsaikhan Batbold3, Ming-Lun Yeh1,2, Chung-Feng Huang1,2, Po-Cheng Liang1,2, Jee-Fu Huang1,2, Wan-Long Chuang2, Ming-Lung Yu1,2
1Kaohsiung Medical University Hospital, Kaohsiung Medical University Kaohsiung Taiwan, 2School of Medicine, College of Medicine, Kaohsiung Medical University Kaohsiung Taiwan, 3Institute of Medical Sciences, Mongolian National University of Medical Sciences Ulaanbaatar Mongolia

Introduction: Hepatitis C virus (HCV) infection is the most common cause of liver transplantation worldwide. Hepatic steatosis is another major liver manifestation which is associated with metabolic factors. Cryoglobulinemia is one of the important extrahepatic manifestations in chronic hepatitis C (CHC) patients.

Aims: To study the clinical association between cryoglobulinemia and steatosis of liver in CHC patients.

Patients and Methods: We enrolled 904 patients with CHC in a tertiary Medical Center in Southern Taiwan. The clinical and laboratory data were collected. The cryoglobulinemia were tested and the liver steatosis was determined by the fibroscan CAP values.

Results: There are 390 (43.1) males with a mean age of 60.9±12.1 years. The positive cryoglobulinemia was found in 367 (40.6%) patients. Compared to patients without cryoglobulinemia, patients with cryoglobulinemia were significantly older (P=0.028), had significantly higher percentages of male gender (P=0.001), cirrhosis (P=0.013), lower levels of CAP (P=0.047), HbA1C (P=0.001), platelet (P=0.005), TG (P=0.001), and higher levels of Lp(a) (P=0.005) and HDL-C (P=0.02) in multivariate analyses. In multivariate analyses, gender, cirrhosis (all P<0.005), HCV RNA level, and HbA1C, TG level (both P<0.001) were factors significantly associated with cryoglobulinemia.

Conclusions: Cryoglobulinemia and steatosis were found in 40 % and 41% of CHC patients, respectively. Cryoglobulinemia was associated with gender, cirrhosis, HCV RNA level and metabolic factors but not liver steatosis.

Abstract Submission No. 101862
P-0232

Antaitasvir plus Yiqibuvir for treatment of chronic hepatitis C virus infection: a phase 2/3 study
This multicenter retrospective case-control study, spanning 14 regions in the Republic of Kazakhstan, included those who hadn’t undergone prior antiviral therapy or hadn’t achieved virological response (VR) to DAAs and control (achieved sustained virological response, SVR) groups. Most patients were men aged 40 and above, with a significant number being men (62.32%) and Asians (66.13%).

Analyzing risk factors, the study identified various associations with the absence of VR, including stomach ulcers (p=0.0266), HIV (p=0.0279), overweight/obesity (p=0.0045), arterial hypertension (p=0.0057), chronic kidney disease (p=0.0169), hepatocellular carcinoma (p=0.0327), alcohol abuse (p=0.0003), prior antiviral therapy with Peg interferon/Ribavirin (p=0.0005), genotype 3 of hepatitis C virus (p<.0001), stage 4 fibrosis (p<.0001), prescribed antiviral therapy regimen (p<.0001), duration of CHC before AVT (p=0.0057), known AVT duration (p<.0001), and patient adherence (p<.0001).

The study concludes by emphasizing the intricate interplay of demographic, clinical, virologic, host, and pharmacological factors in CHC patients’ response to antiviral therapy.

Change of alfa-fetoprotein after DAA therapy in HCV patients and risk of hepatocellular carcinoma

Cheng-Kuan Lin1, Ya-Li Shih1, Ssu-Han Wang1, Tong-Zhis Lee1
1Far Eastern Memorial Hospital New Taipei City Taiwan

A retrospective study of the change of serum alfa-fetoprotein before and after treatment by Sofosbuvir-based regimens in patients without hepatocellular carcinoma was conducted. The cases of newly diagnosed hepatocellular carcinoma were evaluated. 483 patients received antiviral therapy and followed after 12 weeks after therapy. The mean age was 59.6 years old, and the female patients were predominant (52.4%). The medications were Sofosbuvir/Velpatasvir (62.1%), Sofosbuvir/Ledipasvir: (28.2%), Sofosbuvir (8.9%), Sofosbuvir and Daclatasvir (0.8%), added ribavirin (15.3%). The duration was 12 weeks. There were patients with interferon-experienced (10.6%), liver cirrhosis (26.5%), diabetes (18.6%), uremia (1%), and HBV carrier (5.8%). The rate of SVR was 98.6%. After a mean follow-up of 33.7 months, 21 patients (4.3%) developed hepatocellular carcinoma. The pre-treatment serum alfa-fetoprotein was >7 to posttreatment <7; 13.3% in AFP persistent in pre- and posttreatment (25.4%), >10ng/ml in 91 patients (18.8%), or >15ng/ml in 47 patients (9.7%). After therapy, the level decreased to <7ng/ml in 105 patients (86.1%). The risk of HCC development was 0% in pretreatment AFP >7 to posttreatment <7; 13.3% in AFP persistent in pre- and posttreatment >7, but decreasing (P<0.01); 100% in AFP persistent in pre- and posttreatment >7, and increasing (P<0.01); 15.4% in pretreatment AFP>7, increasing to posttreatment >7 (P<0.01); 3.9% in AFP persistent <7 in pre- and posttreatment (P=0.04). The patients with persistent elevation of AFP before and after treatment had a higher risk of HCC development. The risk was lowest in patients with pre-treatment high AFP, then reduced to the normal range.

Abstract Submission No. 101953
P-0234

Factors associated with non-response to antiviral therapy in hepatitis C in Kazakhstan.

Araiylm Maikenova1, Elmira Kuwanty1, Mukhtar Kulimbet1, Alexander Nersesov1
1Asfendiyarov Kazakh National Medical University Almaty Kazakhstan

From 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents from 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents since 2011. This multicenter case-control study, spanning 14 regions in Kazakhstan, focused on CHC patients over 18 years old. The study included those who hadn’t undergone prior antiviral therapy or hadn’t achieved virological response (VR) after treatment with DAAs since 2018. Examining 812 patients, the study categorized them into case (absence of VR to DAAs) and control (achieved sustained virological response, SVR) groups. Most patients were men aged 40 and above, with a significant number being men (62.32%) and Asians (66.13%).

Abstract Submission No. 101989
P-0235

8-week glecaprevir/pibrentasvir for challenging hepatitis C patients with PHT or active HCC

Shih-Jer Hsu1,2,3,4, Yu-Jen Fang2, Ji-Yuh Lee2, Tsung-Hua Yang4, Jian-Jyun Yu2, Min-Chin Chiu2, Chia-Chi Kuo2, Wan-Chih Yeh1, Shan-Han Chang4, Li-Wei Wu2, Chieh-Chang Chen4, Chien-Hung Chen4, Chun-Jen Liu4, Jia-Horng Kao1,4,5
1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch Douliou Taiwan, 3Department of Medicine, National Taiwan University Cancer Center

Abstract Submission No. 101949
P-0233

8-week glecaprevir/pibrentasvir for challenging hepatitis C patients with PHT or active HCC

Shih-Jer Hsu1,2,3,4, Yu-Jen Fang2, Ji-Yuh Lee2, Tsung-Hua Yang4, Jian-Jyun Yu2, Min-Chin Chiu2, Chia-Chi Kuo2, Wan-Chih Yeh1, Shan-Han Chang4, Li-Wei Wu2, Chieh-Chang Chen4, Chien-Hung Chen4, Chun-Jen Liu4, Jia-Horng Kao1,4,5
1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch Douliou Taiwan, 3Department of Medicine, National Taiwan University Cancer Center

Abstract Submission No. 101949
P-0233

Factors associated with non-response to antiviral therapy in hepatitis C in Kazakhstan.

Araiylm Maikenova1, Elmira Kuwanty1, Mukhtar Kulimbet1, Alexander Nersesov1
1Asfendiyarov Kazakh National Medical University Almaty Kazakhstan

From 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents from 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents since 2011. This multicenter case-control study, spanning 14 regions in Kazakhstan, focused on CHC patients over 18 years old. The study included those who hadn’t undergone prior antiviral therapy or hadn’t achieved virological response (VR) after treatment with DAAs since 2018. Examining 812 patients, the study categorized them into case (absence of VR to DAAs) and control (achieved sustained virological response, SVR) groups. Most patients were men aged 40 and above, with a significant number being men (62.32%) and Asians (66.13%).

Abstract Submission No. 101989
P-0235

8-week glecaprevir/pibrentasvir for challenging hepatitis C patients with PHT or active HCC

Shih-Jer Hsu1,2,3,4, Yu-Jen Fang2, Ji-Yuh Lee2, Tsung-Hua Yang4, Jian-Jyun Yu2, Min-Chin Chiu2, Chia-Chi Kuo2, Wan-Chih Yeh1, Shan-Han Chang4, Li-Wei Wu2, Chieh-Chang Chen4, Chien-Hung Chen4, Chun-Jen Liu4, Jia-Horng Kao1,4,5
1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch Douliou Taiwan, 3Department of Medicine, National Taiwan University Cancer Center

Abstract Submission No. 101949
P-0233

Factors associated with non-response to antiviral therapy in hepatitis C in Kazakhstan.

Araiylm Maikenova1, Elmira Kuwanty1, Mukhtar Kulimbet1, Alexander Nersesov1
1Asfendiyarov Kazakh National Medical University Almaty Kazakhstan

From 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents from 2011 in Kazakhstan, antiviral therapy for CHC has been reimbursed, with nearly 99% of patients with SVR. The aim of the study is to identify the risk factors associated with the absence of a virological response to standard therapy with direct-acting antiviral agents since 2011. This multicenter case-control study, spanning 14 regions in Kazakhstan, focused on CHC patients over 18 years old. The study included those who hadn’t undergone prior antiviral therapy or hadn’t achieved virological response (VR) after treatment with DAAs since 2018. Examining 812 patients, the study categorized them into case (absence of VR to DAAs) and control (achieved sustained virological response, SVR) groups. Most patients were men aged 40 and above, with a significant number being men (62.32%) and Asians (66.13%).

Abstract Submission No. 101989
P-0235

8-week glecaprevir/pibrentasvir for challenging hepatitis C patients with PHT or active HCC

Shih-Jer Hsu1,2,3,4, Yu-Jen Fang2, Ji-Yuh Lee2, Tsung-Hua Yang4, Jian-Jyun Yu2, Min-Chin Chiu2, Chia-Chi Kuo2, Wan-Chih Yeh1, Shan-Han Chang4, Li-Wei Wu2, Chieh-Chang Chen4, Chien-Hung Chen4, Chun-Jen Liu4, Jia-Horng Kao1,4,5
1Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch Douliou Taiwan, 3Department of Medicine, National Taiwan University Cancer Center
Background: The efficacy of 8-week glecaprevir/pibrentasvir (G/P) therapy in treating treatment-naïve chronic hepatitis C patients with compensated cirrhosis is already established. This study aims to evaluate the effectiveness and safety of the 8-week G/P treatment in patients with more advanced liver diseases, including active hepato-cellular carcinoma (HCC) and portal hypertension (PHT).

Methods: The data of patients who received an 8-week course of G/P therapy at a single institute between August 2018 and May 2023 were retrospectively reviewed. Patients diagnosed with PHT or those with active HCC not in complete remission during their G/P treatment were selected for the analysis. Criteria for PHT were one or more of the following: presence of gastroesophageal varices, liver stiffness measurements (LSM) exceeding 20 kPa via transient elastography, or LSM of 15-20 kPa coupled with a platelet count under 110 K/µL. We assessed the sustained virological response (SVR12) at 12 weeks post-therapy as the primary endpoint, alongside safety profile evaluations.

Results: A total of 42 patients were enrolled, with a median age of 75.8 years; of these, 28 had PHT and 20 had active HCC. All patients (100%) achieved SVR12. During treatment, seven patients (16.7%) required hospitalization due to adverse events unrelated to G/P therapy. Four patients (9.5%) temporarily developed Grade 3 hyperbilirubinemia, with two cases linked to HCC radiotherapy. None had premature treatment termination, hepatic decompensation, or death.

Conclusion: The 8-week G/P regimen is highly effective and safe for challenging chronic hepatitis C patients, including elderly patients with PHT or active HCC.

Abstract Submission No. 200053
P-0236

HCV genotype and clinical features with 595 HIV/HCV co-infected patients

Xiao Li1,2, Xinping Yang2, Huiqin Li2

1Kunming Medical University, Kunming, Yunnan, China; 2Yunnan Provincial Infectious Disease Hospital, Yunnan, China

Objective: To analyze the HCV genotyping and clinical characterization of 595 cases of HIV/HCV co-infected patients in antiretroviral outpatient clinic of Yunnan Provincial Infectious Disease Hospital, and to provide reference for the prevention and treatment of HIV/HCV.

Methods: The HIV/AIDS patients attending the clinic from January 2022 to July 2023 were selected for the study, and a cross-sectional survey was used to collect basic information, HCV antibodies, HCV RNA, HCV genotype and biochemistry.

Results: Screening 5709 patients with HIV infection, HCV antibody positive rate of 10.42% (595/5709); HCV RNA detection rate of 86.72% (516/595); HCV RNA positive rate of 47.09% (243/516). 95.47% of HCV RNA positive completed HCV genetic testing, of which the proportion of each type is: type 1b (14.66%), type 2a (0.86%), type 2c (27.59%), type 3b (40.95%), type 6 (14.66%), and unidentified type (1.29%). The rate of FIB-4 score > 3.25 was 37.86% among HCV RNA-positive patients. The difference in HCV genotypes in the route of infection was statistically significant (P < 0.05), and the FIB-4 indexes of the genotypes 3a,3b were higher than those of the other genotypes, and the difference in the comparison of the two genotypes were all statistically significant (all P < 0.01).

Conclusion: HCV antibody and HCV RNA positivity rates are high in HIV-infected populations, and HCV genotypes 3b and 3a are the main prevalent strains, with a high percentage of progressive liver fibrosis occurring. In the population of people with HIV and HCV, early hepatitis C screening, diagnosis, and treatment are crucial.

Abstract Submission No. 200099
P-0237

Post-treatment occurrence of serum cryoglobulinemia in chronic hepatitis C patients

Gantogtokh Dashjams1, Batbold Batsaihan1,2, Tulgaa Lonjid1, Ganchimeg Dondonov1,2, Tegshjargal Badamjav1, Amin-Erdene Ganzorig1

1Department of Internal Medicine, Institute of Medical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia; 2Department of Health research, Graduate School, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia

Background: Persistent cryoglobulinemia after completion of antiviral treatment is an important consideration of clinical management in chronic hepatitis C patients. We aimed to investigate the occurrence of serum cryoglobulinemia in chronic hepatitis C patients without cryoglobulinemia at the initiation of antiviral treatment.

Methods: Totally 776 patients without cryoglobulinemia were assessed for serum cryoglobulinemia after completion of anti-HCV treatment. Serum cryoglobulinemia precipitation was assessed both initiation and completion of the treatment and analyzed for the clinical, laboratory factors associated with chronic hepatitis C.

Results: One hundred eighteen percent (118) of patients were checked for serum cryo-precipitation after completion of the treatment and 8 patients (4.6%) were positive for serum cryoglobulinemia. In multivariate analysis, liver cirrhosis (Odds Ratio [OR] – 17.86, 95% Confidence Interval [95% CI] – 1.79-177.35, p = 0.014) and other organ cancer (OR – 25.17 95% CI – 2.59-244.23, p = 0.005) were independently and significantly associated with positive cryoglobulinemia 3 months after antiviral treatment.

Conclusions: Three months after the antiviral DAA therapy had concluded, eight patients checked positive for cryoglobulinemia, representing a 6.7% prevalence. Further investigation into the causes of positive cryoglobulinemia after DAA antiviral therapy is warranted.

Abstract Submission No. 200185
P-0238

Efficacy of Sofosbuvir, Velpatasvir and Ribavirin in prior DAA experienced patients in Myanmar

Nyein-mon Yu1,2, Win-win Swe1,2

1Yangon Specialty Hospital, Yangon, Myanmar; 2Yangon University of Medicine 1, Yangon Myanmar

Background: Treatment options for DAA experienced hepatitis C patients are limited in Myanmar as Sofosbuvir, Velpatasvir, Voxilaprevir regimen and Glecaprevir and Pibrentasvir regimens are not available. This study is aimed to evaluate the efficacy of Sofosbuvir (SOF), Velpatasvir (VEL) and Ribavirin (RBV) in treatment-experienced HCV patients.

Methods: Twenty patients with HCV relapse from prior DAA treatment from Yangon Specialty Hospital were given SOF/VEL/RBV regimen for 24 weeks. The primary end-point was sustained virologic response at 12 weeks post-treatment (SVR12).

Results: Age of the patients varied from 35 to 70 years (mean age 53.75 years ± 8.4 and 65% (13/20) were female. Age of the patients...
varied from 35 to 70 years with mean age of 53.75 years ± 8.4 and 65% (13/20) were female. Baseline APRI scores ranged from 0.2 to 7.6. Mean HCV RNA was 1.13 × 10^6 IU/ml. Ten patients had done geno-typing (70% Genotype 3b, 20% 6a and 10% 1a). Seventeen patients received prior treatment with Sofosbuvir and Daclatasvir, one with Sofosbuvir and Ledipasvir and two with SOF/VEL regimen. Sixty-five percent (13/20) of patients had liver cirrhosis including 4 uncompensated patients. Three patients had evidence of HCC before initiating treatment. One patient had HBV co-infection and three had HIV taking Tenofovir/Lamivudine/Dolutegravir. Nineteen patients (95%) achieved SVR12. Treatment failure was observed in the patient with HCC and received prior SOF/VEL treatment.

Conclusion: SOF/VEL/VOX in hepatitis C patients with previous DAA failure

Jiabao Chang1,2, Yuqi Ma1, Xiling Fu1
1Jiangsu Nanjing China, 2Nanjing Second Hospital Nanjing China

Objective To evaluate the efficacy and safety of sofosbuvir/vipataivir/VOX (SOF/VEL/VOX) in real-world patients with hepatitis C virus (HCV) infection who have failed previous direct antiviral therapy (DAA). Methods A multicenter retrospective study included hepatitis C patients who had previously failed DAA antiviral therapy and were treated with SOF/VEL/VOX (400mg/100mg/100mg/tablet, 1 tablet/day) for 12 weeks from June 2020 to Mar 2023. Sustained virological response (SVR12) was observed 12 weeks after the end of treatment, and biochemical changes and adverse reactions were assessed to evaluate the safety of the drug. Results A total of 18 patients were enrolled, including 12 patients with non-cirrhosis, 6 patients with compensatory cirrhosis, and 4 patients with two or more previous DAA treatment failures. 18 patients (18/18, 100%) achieved SVR12. Among the 18 enrolled patients, 10 reported adverse events during treatment, the most common adverse events were pruritus and nausea. There were 11 adverse events in the drug-related treatment period, and 1 patient had serious adverse events, and no adverse events resulted in drug discontinuation or patient death. Conclusion SOF/VEL/VOX has a higher rate of SVR12 in salvage therapy for chronic hepatitis C patients who have failed DAA treatment in the past, and is well tolerated and safe.

Clinical and histological variants of HBV and HDV infection

Aziza Khikmatullaeva1, Nargiz Ibadullaeva1, Muazzam Abdukadirova1
1Research Institute of Virology Tashkent Uzbekistan

Background and Aims: Timely detection of patients with chronic HBV and HDV infections is complicated by the fact that their clinical manifestations are not typical for viral hepatitis. All this greatly complicates the possibility of diagnosing chronic viral hepatitis and prevents the identification of patients infected with HBV and HDV. The aim of the study was to identify the relationship between clinical manifestations and the histological picture of liver damage in HBV and HDV infection.

Methods: A comprehensive clinical and laboratory examination of 41 patients with chronic HBV and HDV infection was carried out, of which 12 had HBV infection and 29 HDV infection. Clinical, biochemical, serological, molecular-biological, instrumental research methods were used.

Results: In patients with chronic HDV infection, the disease had severe clinical symptoms compared with HBV infection. Out of 12 patients with HBV infection, clinical diagnoses did not coincide with histological ones in 2 (16.7%) cases. Due to the paucity of clinical symptoms of the disease, chronic hepatitis B was diagnosed, but liver biopsy revealed liver cirrhosis. Of the total number of patients with HDV infection, there was a discrepancy between the clinical diagnosis and the histological diagnosis in 7 (24.1%) patients with liver cirrhosis. Of these, in 5 (17.2%) patients, histological examination revealed chronic hepatitis with minimal activity (F0-1), in 2 (6.9%) patients - chronic hepatitis with moderate activity (F1-2).

Conclusions: The intensity of clinical manifestations was not in all cases combined with morphological changes. With minor clinical manifestations, pronounced morphological changes are sometimes observed.

Epidemiological prevalence and clinical characteristics of Hepatitis Delta in Xinjiang Region

Feng Guo1, Wei Sun2, Litifu Abulimiti1, Lina Niu3, Hong Yu1, Jing Dou1, Ming Li2, Huiling Du1, Zhuangguo Wang1, Zhonghui Ning1, Sayilaxi Jieensinuer1, Xiaohong Wang1
1Department of Hepatology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University Urumqi China, 2Xinjiang Medical University Graduate School Urumqi China, 3Department of Laboratory, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University Urumqi China

Objective: This study aimed to examine the epidemiological prevalence and clinical characteristics of hepatitis delta virus (HDV) infection among chronic hepatitis B (CHB) patients in the Xinjiang region. Methods: A cross-sectional study was conducted at a single center, enrolling a total of 1,100 HBsAg-positive patients attending at the Hepatology Department of Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University between December 15, 2022, and June 30, 2023. All participants underwent testing for HDV antibodies and HDV RNA. Results: Among the participants, 23 cases (2.09%) and 13 cases (1.18%) were positive for HDV-IgG and HDV-IgM, respectively. 14 cases (1.27%) were positive for HDV-RNA, all of which were classified as HDV genotype 1. The average age of these cases were 46.83±7.9 years, with 11 (47.82%) being of Kyrgyz ethnicity. Additionally, 18 cases (78.26%) presented with liver function abnormalities, 17 cases (73.91%) exhibited progressive liver disease, including 16 cases (69.57%) with cirrhosis and 1 case (4.35%) with hepatocellular carcinoma (HCC). Autoimmune hepatitis (AIH) was observed in 4 cases (17.39%), and the coexistence of AIH was identified as an independent risk factor for disease progression. Conclusion: The prevalence rate of HDV serological markers and HDV-RNA in this single center study in Xinjiang were 2.09% and 1.27%, respectively, with all cases belonging to HDV genotype 1. A higher incidence of HDV infection was observed in patients with abnormal liver function and progressive liver disease, underscoring the importance of targeted screening and diagnosis for such individuals.
Efficacy of Pegylated IFN-α and IFN-α Treatments on HBV and HDV Infections in Humanized Mice

Takuro Uchida1,2,3, Sarah Duehren4, Masataka Tsuge3,4, Nobuhiko Hiraga4, Susan L. Upchurch2, Ohad Etzioni5, Jeffrey Glenn2, Theo Heller5, Scott J. Cotler6, Kazuaki Chayama5, Harel Dahari2

1Department of Gastroenterology, Oita University Yufu Japan, 2Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University Yufu Japan, 3Research Center for Hepatology and Gastroenterology, Hiroshima university Hiroshima Japan, 4Department of Gastroenterology and Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University Hiroshima Japan, 5The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago USA, 6Department of Gastroenterology and Liver Diseases, Soro Rak University Medical Center Beer-Sheva Israel, 7Division of Gastroenterology and Hepatology, Departments of Medicine, Microbiology & Immunology, Stanford School of Medicine Stanford USA, 8Liver Diseases Branch, NIDDK, NIH Bethesda USA, 9Hiroshima Institute of Life Sciences Hiroshima Japan, 10Collaborative Research Laboratory of Medical Innovation, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan

HDV decline kinetics under pegylated IFN-α and IFN-α therapy in chronic HDV-infected patients were dramatically higher compared to pegylated IFN-α. The goal of this study was to investigate viral kinetics during IFN treatment in humanized mice. Thirteen mice were treated twice weekly with 30 μg/kg of either IFN-α or IFN-λ; and for either 12 weeks or 13 weeks. Ten mice were coinfected with HBV and HDV, and 3 were superinfected. HBV DNA, HDV RNA, hAlb, and HBsAg levels were measured.

Baseline HBV DNA, HDV RNA, hAlb, and HBsAg levels had a median of 8.8 log IU/mL, 9.8 log IU/mL, 6.9 log ng/mL, and 4.0 log IU/mL, respectively. Regardless of type of IFN, HDV RNA had a longer delay in decline than HBV DNA, with medians of 3 weeks and 1 day, respectively. Thereafter, mice treated with IFN-α experienced a significantly greater decline in HDV DNA, HDV RNA, and HBsAg, at weeks 9, 6, and 5, respectively, until end of treatment (EOT). The magnitude of decline from baseline to EOT for HBV DNA was significantly greater than that of HDV RNA, with medians of 1.55 and 0.79, respectively.

IFN-α was more effective than IFN-λ; in decreasing HBV DNA, HDV RNA, and HBsAg during treatment in humanized mice that lack of an adaptive immune response, suggesting that IFN-α induces stronger innate immune responses than IFN-λ; The greater decline in HDV under IFN-α; compared to IFN-α in patients, may suggest a role of the adaptive immune response that needs to be investigated in future studies.

Healthcare resource utilization & costs of HDV vs HBV monoinfection across disease states from Spain

Maria Buti1, Marvin Rock2, Meritxell Ascanio3, Josep Darba4, Chong Kim2

1Liver Unit, Hospital Universitario Valle Hebron Barcelona Spain, 2HEOR – Global Value & Access, Gilead Sciences Foster City, California United States, 3BCN Health Economics & Outcomes Research SL Barcelona Spain, 4Department of Economics, University of Barcelona Barcelona Spain

Background: Concurrent infection of hepatitis delta virus (HDV) and hepatitis B virus (HBV) results in the most severe viral hepatitis. This retrospective study compares healthcare resource utilization (HCRU) and costs of HDV infection vs HBV monoinfection by disease states in Spain.

Methods: Adult patients with HDV or HBV (≥12 months pre-diagnosis code) between 01/01/2000 and 12/31/2019 (study period) were identified in the Spanish National Health System’s Hospital Discharge Records Database. Patients initially diagnosed between 01/01/2001 and 12/31/2018 and with continuous enrollment for ≥21 months pre- and post-diagnosis were selected. Mean per patient per year (PPP) HCRU and costs were compared within subgroups of liver disease severity. Descriptive statistics were summarized; comparisons were made via generalized linear models.

Results: Significantly more patients with HDV vs patients with HBV only had compensated cirrhosis (CC; 25.4% vs 9.5%, P<.0001) or decompensated cirrhosis (DCC; 51.6% vs 20.6%, P<.0001). Patients with HDV spent significantly less time in each liver disease state than patients with HBV only. Mean (SD) days spent in hospital was longer for patients with HDV vs HBV only, particularly due to CC, 11.8 (3.0) vs 9.1 (3.4), P=.04. Mean pharmacy,
inpatient, outpatient, and total costs PPPY were significantly higher for those with HDV vs HBV only and increased with disease state severity.

**Conclusion:** These findings underscore the need for effective screening, diagnosis, and treatment of HDV to help reduce the clinical and economic burden of disease.

---

**Abstract Submission No. 100519**

**P-0245**

**Disease progression among insured hepatitis delta virus infected patients in the United States**

Robert G. Gish1, Robert J. Wong2,3, Chong Kim4, Gary Leung5, Ira M. Jacobson6, Joseph K. Lim7, Marvin Rock4

1Hepatitis B Foundation Doylestown, PA United States, 2Stanford University School of Medicine Stanford, CA United States, 3VA Palo Alto Healthcare System Palo Alto, CA United States, 4HEOR – Global Value & Access, Gilead Sciences, Inc Foster City, CA United States, 5RWE – Epidemiology, Gilead Sciences, Inc. Foster City, CA United States, 6NYU Grossman School of Medicine New York, NY United States, 7Yale University School of Medicine New Haven, CT United States

**Background:** Concurrent infection of hepatitis delta virus (HDV) and hepatitis B virus (HBV) results in the most severe viral hepatitis. Herein, the rate of disease progression in a matched cohort of adults with HDV and HBV mono-infection were compared.

**Methods:** Commercially insured adult patients diagnosed with HDV or HBV from 1/1/2006–12/31/2021 (study period) were identified via PharMetrics database. The index date was the first claim of HDV or HBV diagnosis between 1/1/2007–12/31/2020. Patients were required to have ≥12 months of continuous enrollment pre-index and 1-day post-index date. Disease progression (baseline to next disease state) was assessed using Kaplan-Meier curves of propensity score-matched patients and multivariable Cox-proportional hazard regression model. Disease states include non-cirrhotic, compensated cirrhosis (CC), decompensated cirrhosis (DCC), and hepatocellular carcinoma (HCC).

**Results:** Of 291,482 patients, 116,370 met inclusion criteria and were propensity score-, age- and gender-matched, leading to 5,620 individuals each in HDV and HBV mono-infection cohorts. A total of 32% HDV and 36% HBV mono-infection patients had ≥10 years of follow-up. Compared with the HBV mono-infection cohort, patients with HDV demonstrated a higher rate of progression from non-cirrhotic disease to CC, DCC, and HCC (all P<0.05) and were at higher risk of transitioning from non-cirrhotic disease to CC (HR: 1.54, 95% CI 1.38–1.73, P<0.001), DCC (HR: 1.60, 95% CI 1.46–1.75, P<0.001), and HCC (HR: 1.62, 95% CI 1.24–2.12, P=0.015).

**Conclusion:** These findings underscore the need for earlier identification, diagnosis, and treatment of HDV to mitigate future disease progression and burden of disease.

---

**Abstract Submission No. 100700**

**P-0247**

**Development of chemiluminescence based quantitative ELISA assay for detection of anti-HDV Ag**

Nomin Ariungerel1, 2, Badmaarag Munkhjin1, Saruul Enkhjargal1, 2, Purevjargal Bat-Ulzii3, Byambasuren Ochirsum3, Naranjargal Dashdorj4, Odgerel Oidovsambuu5

1Laboratory of Genetic engineering, National university of Mongolia Ulaanbaatar Mongolia, 2Liver center Ulaanbaatar Mongolia

**Background:** Development of diagnostic assays for HDV is very limited due to its disproportional prevalence worldwide. There is no commercially available quantitative anti-HDV ELISA kit.

**Aim:** In this study, we have developed a chemiluminescence-based quantitative ELISA using the chemical immobilization method, that enhances the sensitivity and specificity of a diagnostic test.

**Method:** Recombinant His-tagged S-HDAg antigen was produced in *E.coli* and purified by Ni-NTA chromatography. The purified S-HDAg was immobilized on the polystyrene plate with APTES for the construction of the ELISA kit. A series of experiments were done to determine the optimal assay condition. The standard polyclonal anti-HDV antibody samples were prepared from HDV-infected human serum and used as standards in quantification analysis. To determine the characteristics of the assay, serum samples from 247 people including 120 patients with HDV/HBV infection (HDV RNA and HBsAg positive), and 127 healthy people (Anti-HCV and HBsAg negative) were analyzed.

**Result:** In the frame of the applied settings, the optimal ELISA assay parameters are: serum dilution 1:10, secondary Ab dilution 1:60000, 20 min incubation at 37°C, 1 min luminescence reaction and 30 min total test duration. The calibration curve was generated from serially diluted standards (20, 10, 5, 1, 0.1, 0.01 µg/ml R2=0.9851). The ROC analysis shows the confidence of the assay (optimal cut-off point=5.62 µg/ml, AUC=0.9968, 95%CI 0.9932 to 1.00005 (p<0.001). The

---

**Abstract Submission No. 100670**

**P-0246**

**Screening of HDV-RNA presence in seminal fluid and cervical swab samples from HDV infected patients**

Saruul Enkhjargal1, Oyungerel Lhagva-Ochir2, Nomin Ariungerel1, Anir Enkhabt3, Enknomnin Ochirb1, Mijiddorj Batsaikhan1, Naranjargal Dashdorj2, Odgerel Oidovsambuu1

1National University of Mongolia Ulaanbaatar Mongolia, 2Liver Center Ulaanbaatar Mongolia

The sexual transmission of HDV is largely speculative. There is a very limited number of studies showing solid evidence for sexual transmission of HDV. The aim of this study is to screen the presence of HDV-RNA in male seminal fluid and female cervical swab samples. Our study was conducted for a total of 61 participants, which included 31 males and 30 females. Viral RNA was isolated from the blood, seminal fluid, and cervical swab samples from the respective participants. RT-PCR analysis of HDV-RNA was done for all samples isolated from blood, seminal fluid, and cervical swab samples. The results were expressed as statistical points including odds ratios (OR), Pearson’s chi-squared test with Yates’continuity correction, and correlation coefficient (R2). HDV-RNA detection rate is different for the samples from male and female. In the male cohort, 48.38% of seminal fluid samples were positive whereas 80% were positive for cervical swab samples from the female cohort. The data shows a statistically significant difference between genders for the presence of HDV-RNA in seminal fluid and cervical swab (OR=0.234, 95% CI= 0.749-0.7306). Also, Pearson’s chi-squared test showed that there is sufficient association between the degree of infectiousness and gender (5.3079, df = 1, p-value = 0.02123). A significant correlation was found between blood HDV-RNA quantity and HDV-RNA presence status in cervical swab samples (R2=0.7769). However, no such significant correlation was found for males (R2=0.0163). Overall, these findings provide substantial evidence of the potential risk of sexual transmission of HDV for each gender.
Efficacy & safety of bulevirtide in combination with pegylated interferon α-2a in patients with CHD

Tarik Asselah¹, Pietro Lampertico², Heiner Wedemeyer³, Adrian Streinu-Cercel⁴, Victor Pantea⁵, Stefan Lazar⁶, Gheorghe Placinta⁷, Vladimir Druljanov⁸, Dmitry Manuilov⁹, Renee Claude Mercier⁵, Lei Ye⁶, Audrey H Lau⁹, Stanislas Pol¹⁰, Fahien Zoulim¹⁰
¹Hôpital Beaujon, Université de Paris Clichy France, ²Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy, ³Medizinische Hochschule Hannover Hannover Germany, ⁴“Matei Balș” National Institute of Infectious Diseases Bucharest Romania, ⁵Infectious Clinical Hospital “T. Ciorbă” Chișinău Moldova, ⁶Dr. Victor Babes Foundation, Infectious and Tropical Diseases Hospital Bucharest Romania, ⁷National Medical Research Center for Phthisiopulmonology and Infectious Diseases Moscow Russian Federation, ⁸Gilead Sciences, Inc. Foster City, CA United States, ⁹Hôpital Cochin Paris France, ¹⁰Hôpital de la Croix-Rousse Lyon France

Background: Bulevirtide (BLV) is approved for chronic hepatitis delta (CHD). Phase 2 MYR204 evaluated the safety and efficacy of BLV (2 and 10 mg) with/without pegylated interferon α-2a (pegIFN) in patients with CHD and compensated cirrhosis (CC).

Methods: Based on CC status, 174 patients were randomized (1:2:2:2): to receive (A) pegIFN for 48 weeks (Wks); (B) BLV 2 mg + pegIFN; (C) BLV 10 mg + pegIFN for 48 Wks, then BLV 2 or 10 mg monotherapy for 48 Wks; or (D) BLV 10 mg for 96 Wks. The primary endpoint was sustained virologic response (SVR) at Wk24 (SVR24) after EOT (end of treatment) defined as undetectable hepatitis delta virus (HDV) RNA with comparison between Arms A and D.

Results: Overall, 35% had CC, mean liver stiffness was 13.1 (7.72) kPa, mean HDV RNA was 5.3 (1.2) log10 IU/mL, mean alanine aminotransferase (ALT) was 114.0 (94.8) U/L, 28% were on nucleos(t)ide analogues, and 48% were IFN experienced. SVR24 was achieved by 17% (Arm A), 30% (Arm B), 46% (Arm C), and 12% (Arm D) (P = 0.0003; Arm C vs D) (Table). ALT normalization and composite endpoint at Wk24 after EOT were superior with BLV 10 mg + pegIFN vs monotherapy. Hepatitis B surface antigen loss was observed in the combination groups. Adverse events (AEs) observed for the BLV + pegIFN arms were similar to pegIFN monotherapy. Six patients (3%) discontinued treatment (unrelated to BLV).

Conclusions: Combination therapy was effective and well tolerated. Longer-term data will help define durability of BLV + pegIFN for CHD.

Impact of reflex testing on the delta hepatitis burden in the United States

Robert J. Wong¹,², Robert G. Gish³, Ira M. Jacobson⁴, Joseph K. Lim⁵, Marvin Rock⁶, Chong Kim⁶
¹Stanford University School of Medicine Stanford, CA United States, ²VA Palo Alto HealthCare System Palo Alto, CA United States, ³Hepatitis B Foundation Doylestown, PA United States, ⁴New York University Grossman School of Medicine New York, NY United States, ⁵Yale School of Medicine New Haven, CT United States, ⁶HEOR — Global Value & Access, Gilead Sciences, Inc. Foster City, CA United States

Background: Chronic infections by the hepatitis delta virus (HDV) cause the most severe form of viral hepatitis. Undiagnosed patients face a high risk of liver complications that could be reduced with earlier treatment. The objective of this analysis was to assess the impact of double reflex HDV testing compared to current practice on HDV-related morbidity and mortality in the United States.

Methods: A model combining a decision tree of the HDV screening cascade in patients with hepatitis B virus (HBV) with a previous Markov cohort model reflecting disease progression in HDV patients was developed. Model inputs were based on literature reviews, real-world data, and expert consensus. Two scenarios were compared: one reflecting current HDV screening rates, and the other reflecting double HDV reflex testing for diagnosed HBV patients. The model then estimated the number of diagnosed HDV patients and the incidence of liver morbidity and mortality over a 5-year period.

Results: In the United States, implementing double reflex testing among all patients with HBV would increase the number of treated HDV patients by 1.617% (7,361 vs 429 in double reflex testing vs current scenario). Over a 5-year period, increased rates of HDV diagnosis and treatment would reduce rates of compensated cirrhosis (−4%), decompensated cirrhosis (−23%), hepatocellular carcinoma (−18%), liver transplant (−22%), and liver-related mortality (−21%).

Conclusions: Implementing double reflex testing for HDV among all patients with HBV would greatly increase the number of HDV patients treated, thus substantially reducing HDV burden in United States within the next five years.
Development and validation of an algorithm for identifying HDV RNA+ patients

Robert J. Wong1,2, Robert G. Gish3, Ira M. Jacobson4, Joseph K. Lim5, Marvin Rock4, Gary Leung7, Chong Kim6

1Stanford University School of Medicine Stanford, CA United States, 2VA Palo Alto Healthcare System Palo Alto, CA United States, 3Hepatitis B Foundation Doylestown, PA United States, 4New York University Grossman School of Medicine New York, NY United States, 5Yale School of Medicine New Haven, CT United States, 6HEOR — Global Value & Access, Gilead Sciences, Inc. Foster City, CA United States, 7RWE — Epidemiology, Gilead Sciences, Inc. Foster City, CA United States

Background: There is a large gap in correctly identifying patients with hepatitis D virus (HDV) using (non-laboratory) real-world data. The objective was to develop and validate an algorithm to identify HDV RNA+ patients.

Methods: HDV status was identified by HDV RNA test results from HealthVerity claims data and linked with laboratory data of hepatitis B virus (HBV) diagnosed patients. Data was divided into training and test data (80/20 split). During training, algorithms were developed and scored via 10-fold cross-validation, where the lowest sum of scores were achieved with the GLMNET model and the highest scores were achieved with the diagnosis-based model. In the testing data, accuracy, PPV, sensitivity, and specificity for GLMNET versus diagnosis-based algorithm were 0.97, 0.97, 0.97, respectively. Conclusions: This new claims-based algorithm can be used to identify HDV RNA+ patients in real-world databases, which in turn will enable the accurate generation of real-world evidence surrounding HDV.

Abstract Submission No. 101942
P-0253

Relationship of HDV Infection to Increased Risk of Cirrhosis and HCC in Chronic Hepatitis B Patients

Derizal Derizal1, Roland Helmizara2, Siska Azizah2

1IP TRISAKTI Jakarta Selatan Indonesia, 2Baiturrahmah University Padjad Indonesia

Aims: Chronic hepatitis B patients are at a high risk of developing severe complications, including hepatocellular carcinoma (HCC), which can be fatal. Hepatitis Delta Virus (HDV) is a single-stranded RNA virus that relies on HBV for its propagation. In several countries, a study aims to investigate the correlation between HDV infection and the increased risk of cirrhosis and HCC in patients with chronic hepatitis B.

Methods: This is a systematic literature review with the keywords “HDV Infection”, “Cirrhosis”, “HCC” and Chronic Hepatitis B Patients with a descriptive analysis research model.

Results: Study by Jang et al. (2021) showed that liver cirrhosis (HR/95%CI 9.98/5.11–19.46, P < 0.001) was responsible for HCC among patients with cirrhosis, HDV RNA positivity was associated with HCC (HR/95%CI 9.98/5.11–19.46, P < 0.001). In a study conducted by Romero et al. (2009), they examined 299 patients infected with HDV over 28 years and found that HDV infection persistently led to cirrhosis and HCC at annual rates of 4% and 2.8%, respectively. Oyonsuren et al. (2006) conducted a retrospective investigation of 292 patients with chronic hepatitis and found that HDV coinfection was more strongly associated with HCC at a younger age compared to HCV monoinfection. Another study by Ji et al. (2012) revealed that out of 9,160 HBV patients, 650 had HDV co-infection over a period of 11 years, and HDV was identified as a strong risk factor for an increased risk of HCC.

Conclusions: The presence of HDV infection in chronic hepatitis B patients with a concurrent infection with HBV is associated with an increased risk of cirrhosis and HCC.
patients is strongly associated with an increased risk of developing cirrhosis and hepatocellular carcinoma (HCC), emphasizing the need for management and control of HDV infection to reduce the occurrence of these complications.

Abstract Submission No. 100126
P-0254

**Gilbert’s syndrome and UGT1A1Gene Abnormalities IN Mongolians ARE WESTERN TYPE**

Nyam Biziy1, Bayarmaa Nyamaa2, Sien-Sing Yang3, Saranchimeg Uzsraad1, Batchimeg Bat Ochir1, Uugantuya Tumenjargal1

1Dornod Medical Center Choibalsan Mongolia, 2Mongolian National University of Medical Science Ulaanbaatar Mongolia, 3Cathay General Hospital Taipei Taiwan

Hereditary abnormalities of the uridinediphosphoglucuronate-glucuronyltransferase 1A1 (UGT1A1) gene are identified as a major cause of unconjugated hyper-bilirubinemia. Asian and Caucasian populations have different genetic profile for UGT1A1 while abnormalities of the UGT1A1 gene in the Mongolian population remains uninvestigated.

**Methods:** Between 2007 to 2022, 12 in 110 Mongolian adults developed indirect hyperbilirubinemia. We genotyped the TATA box promoter region of the UGT1A1 gene for the A(TA)6TAA (6) or A(TA)7TAA (7) promoter variant, and the coding region for nucleotide mutations (nt)-211 G to A (G71R), nt-686 C to A (P229Q), nt-1091 C to T (P364L) and nt-1456 T to G (Y486D).

**Results:** three patients were homozygous for the nt-211G>A mutation, three patients were heterozygous for the 6/7 promoter genotype and the nt-211G>A mutation, whereas six patients were with homozygous 7/7 genotype and were diagnosed with GS. The percentage of 7/7 genotype patients (50%) was comparable with Caucasian, African, and Indian populations but significantly higher than other Asian countries. We did not identify any Mongolian patients with nt-686 C to A, nt-1091 C to T, or nt-1456 T to G mutations, which are common in Asian countries but not in the Western population. One patient with homozygous nt-211G>A mutation developed severe indirect hyperbilirubinemia during the initial phase of the combined interferon and ribavirin therapy.

**Conclusion:** The prevalence of UGT1A1 abnormalities in Mongolians is more similar to the Western population than the Asian population; whereas the high prevalence of nt-211G>A mutation is similar to Asians.

Abstract Submission No. 100210
P-0255

**Clinical features of neurologic Wilson’s disease without Kayser-Fleischer rings**

lin cai1, 2, juan liao1, 2

1West China School of Public Health and West China Fourth Hospital Chengdu China, 2Sichuan university Chengdu China

**Background:** Wilson’s disease (WD) as a rare hereditary disease, remains a commonly misdiagnosed disease. We summarized the characteristics of neurologic WD patients without KF rings in a WD cohort.

**Method:** The enrolled neurologic WD patients were divided into two groups according to the presence of a KF ring. We compared demographic data, laboratory findings between the two groups.

**Results:** The neurologic WD patients were classified as positive (n=195) or negative (n=54) for KF rings. The WD patients without KF rings have a significantly higher proportion of female than those with KF rings (27.8% vs. 20%, p=0.049). There was no significant difference in BMI (19.1±0.64 kg/m² vs. 19.6±0.36 kg/m²) and age of onset (19, range 14-22.25 years vs. 20, range 15-25 years) between patients without KF rings and patients with KF rings. 5.6% of WD patients without KF rings have family history of WD, and 4.1% in those with KF rings (p >0.05). Although there had no significant difference, a higher ceruloplasmin observed in neurologic WD patients without KF rings (40, range 20-80 mg/dl) compared to patients with KF rings (40, range 20-60 mg/dl). The 24-hour urinary copper excretion level was lower in patients with WD without KF rings (3.96±0.23 μmol/24h) than patients with KF rings (4.03±0.26 μmol/24h). There were no significant difference in psychiatric symptoms between the two groups (16.7% vs. 22.6%, p >0.05).

**Conclusions:** The neurological WD patients without KF rings had a relatively distinct features. Further studies are warranted to explore the mechanisms of gender difference in neurological WD.

Abstract Submission No. 100258
P-0236

**Common Presentation of a Rare Disease-Benign Recurrent Intrahepatic Cholestasis- A Case Report**

ASMA YASEEN1, OM PARKASH1, ZAHABIA SOHAIL1

1AGA KHAN UNIVERSITY HOSPITAL KARACHI Pakistan

Benign recurrent intrahepatic cholestasis is a rare autosomal recessive disease, which usually presents with complain of recurrent jaundice with cholestatic pattern of liver function tests. Its diagnosis requires high degree of suspicion. It is a self-limiting disease and does not cause cirrhosis but increases the risk of hepatobiliary carcinomas. We had a case of 18 years old boy who presented to us in outpatient department, he was found to have BRIC on histo-pathological examination of liver biopsy sample and responded to Ursodeoxycholic acid. As only few cases of BRIC have been reported, this disease needs to be highlighted so that can be diagnosed earlier without proceeding for expensive investigations in limited resources area as in our case report.

Abstract Submission No. 100624
P-0257

**Severe liver damage in LDLR T52T/ApoE3 genotype HCV patients consuming a hepatopathogenic diet**

Sonia Maria Roman-Maldonado1, 2, Liliana Campos-Medina1, 2, Karina Gonzalez-Aldaco1, 2, Saul Laguna-Meraz2, 2, Arturo Panduro8

1Department of Genomic Medicine in Hepatology, University of Guadalajara Guadalajara Mexico, 2Civil Hospital of Guadalajara, Fray Antonio Alcalde Guadalajara México

**Background:** The outcome of HCV infection is modulated by genetic and environmental factors interacting with the virus, such as the low-density lipoprotein receptor (LDLR) and Apolipoprotein E (ApoE) associated with lipid metabolism. We analyzed the genetic profile, dietary habits, and liver damage in anti-HCV-positive Mexican-Mestizos.

**Methods:** This cross-sectional study included 152 anti-HCV positive patients, 110 were viral load (VL) + and 42 VL-. A medical-nutritional evaluation was registered. The genetic profile including LDLR/ApoE genotypes was assessed by allelic discrimination. Comparative statistics were performed between VL+ and VL- subjects.
Results: The patients (85F/67M) were 49.8±12 years old and had a body mass index of 27.7±5.4 kg/m². The patient’s genetic background was consistent with the Mestizo ancestry with a high prevalence of Amerindian risk alleles. VL+ patients showed low levels of cholesterol, triglycerides, VLDL, LDL, compared to VL- (p<0.001), and had high ALT, AST, GGT (p<0.001), and low platelets (p<0.001). A 61.1% (58/95) of the VL+ patients had a high risk for fibrosis (FIB-4) and 35.7% (35/98) had severe fibrosis (APRI). A 10% (11/110) of the VL+ patients were TT LDLR/ApoE3 genotype carriers in which 90% (10/11) had moderate/severe damage compared to the C allele carriers (CC, CT), whereas the VL- patients showed 0% of the TT LDLR genotype (p=0.035). LDLR TT carriers consumed a hepatopathogenic diet high in saturated fatty acids compared to the CC+CT genotype carriers (p=0.014).

Conclusions: The presence of TT/ApoE3 genotype and consumption of a hepatopathogenic diet suggests that this genotype can be a useful genetic marker combined with nutrigenetic strategies to avoid liver damage.

Abstract Submission No. 100912
P-0258

Prevalence and Treatment Pattern of Wilson’s Disease using Korean National Health Insurance Data

Eun Sun Jang¹, Hwa Young Choi², Moran Ki², Bo Hyun Kim¹, Kyung-Ah Kim², Sook-Hyang Jeong³
¹Seoul National University Bundang Hospital Seongnam South Korea, ²National Cancer Center Goyang South Korea, ³Inje University Ilsan Paik Hospital Goyang South Korea

Background: Wilson’s disease (WD) is an autosomal recessive disorder in which copper accumulates in organs, particularly in the liver and central nervous system. This study aimed to investigate the prevalence, incidence, and treatment patterns of WD patients in South Korea.

Methods: National Health Insurance System (NHIS) claims data from 2010 to 2020 were analyzed. Patients with WD as a primary or additional diagnosis at least once were identified using the International Classification of Diseases (ICD)-10 disease code E83.0 and a record for a registration program for rare intractable diseases in South Korea.

Results: The average age- and sex-adjusted prevalence and incidence of WD between 2010 and 2020 were 3.06/100,000 and 0.11/100,000, respectively. The mean age of the patients with newly diagnosed WD was 21.0 ± 15.9 years. Among the 622 WD incident cases during the study period, 19.3% of the patients had liver cirrhosis and 9.2% had 2298 ng/mL (36-5264). AA homozygous and heterozygous mutations were present in 40.7% and 48.1% of the patients, respectively. Regard-

Case series of C282Y mutation in the HFE gene in Turkey: Single-center experience

Hale Gokcan¹, Emin Bodakci¹, Sevinc Tuğrul e Guvenir¹, Volkan Yilmaz¹, Esra Tunc¹, Ramazan Idilman¹,²
¹Ankara University Faculty of Medicine Ankara Turkey, ²Ankara University of Hepatology Institute Ankara Turkey

BACKGROUND: Hereditary Hemochromatosis (HH) is an autosomal recessive disease characterized by excessive iron accumulation in the body. Major C282Y mutation is detected very rarely in Turkish HH patients. We aimed to determine the clinical and demographic parameters of patients with the C282 Y mutation who are being followed at our center.

METHODS: Ten patients with C282Y mutation, being followed up at the Liver Diseases Follow-up Clinic of Ankara University Faculty of Medicine between 2015 and 2021, were retrospectively analyzed. Genomic DNA was isolated from whole blood containing EDTA by using genomic DNA isolation kit (Roche). The DNA region containing the HFE gene was amplified by PCR using appropriate primers. The amplified PCR products were sequencing using the BigDye terminator kit, ABI 310 Genetic Analyzer.

RESULTS: Seven patients (70%) were male, median age was 51.6 (27-73). Three (38%) patients had Diabetes Mellitus. The median hemoglobin, serum alanine aminotransferase, aspartate aminotransferase and gamma glutamyl transferase levels were 14.8mg/dL (12.3-17.4), 50 U/L (11-98), 40 U/L (16-104) and 55.0 U/L (10-226). Median transferrin saturation (TS) and ferritin values were 68% (40-95), and 2298 ng/mL (36-5264). AA homozygous and heterozygous mutations were identified in 60%, and 40% patients respectively. Two (20%) patients had cirrhosis and were C282 Y homozygous. A significant difference was found between the mean ferritin values and TS of those homozygous and heterozygous patients (3323ng/dl vs 766 ng/dL (p<0.001), (77% vs.56%, p<0.001) as well as in AST (52 vs.35 IU/L, p<0.001), and ALT levels (60 vs. 39 IU/L, p<0.001). Iron accumulation in MRI was observed in 4 out of the 6 patients (67%) of whom 3 (75%) were homozygous. In 3 patients who underwent liver biopsy, iron accumulation was observed consistent with HH.

CONCLUSION: In our series, we have reported the largest cohort of C282Y mutations in Turkey. Notably, elevated liver function tests and increased iron parameters were more pronounced in patients with HH who had the C282Y homozygous mutation.

Abstract Submission No. 101860
P-0260

RISK AND COMPARATIVE ANALYSIS OF BLOOD PARAMETERS, ELASTOGRAPHY AND MRI IN THE DIAGNOSIS OF NASH

Olga Tarasova¹, Lahana Ravoori¹, Ilona Minosayn¹
¹RUDN University Moscow Russia

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is prevalent in 20-30% population undiagnosed and asymptotic with 80% cardiovascular risk.

MATERIALS AND METHODS: 19 NAFLD patients, and various factors were considered, including BMI, hypertension (HTN), diabetes mellitus (DM), transient elastography (TE) with controlled attenuation parameter (CAP)(Fibroscan), proton magnetic resonance spectroscopy and liver biopsy.

RESULTS: Among the 19 subjects, all had a BMI above 27 kg/m2, 42.1% had DM, and 26.3% had HTN. Biochemical analysis revealed that 57.89% had normal levels of AST and ALT, while 42.1% had elevated levels, with 62.5% of them having concomitant HTN or DM. Insulin-like growth factor levels are within normal range upto stage F3. Fibroscan results showed that all patients had CAP parameters exceeding 300 dB/m, indicating pronounced fibrosis (elasticity indices
Metabolomics of hepatoblastic nuclear degeneration

Minghui Sun1, Lihua Yuan1, Rui Hua1

1Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University Changchun China

Background: Hepatolenticular degeneration disease is an abnormal copper metabolism caused by autosomal recessive inheritance.

Aim: To analyze the significance of differential metabolites in patients with Wilson’s disease and to analyze the most meaningful metabolism pathway, further elucidating the possible pathogenic mechanisms of hepatolenticular degeneration.

Method: The serum of patients were detected by UHPLC-Q Exactive Orbitrap HRMS.

Data Processing: The raw data files were preprocessed and imported into MetaboAnalyst4.0 software for principal component analysis (PCA) and partial least squares discriminating analysis (PLS-DA) to screen differential metabolites with variable important projection (VIP) greater than 1.

Result: 35 sera metabolites with significant differences were identified between the patients and the healthy control group. The compounds were compared with the online database and were not completely verified by the standard.

Three metabolic pathways with higher pathway impact are Porphyrin and chlorophyll metabolism, Arginine and proline metabolism, Taurine and hypotaurine metabolism. The pathogenesis of hepatolenticular degeneration might be related to the shortage of energy supply, the increase of oxygen free radicals production and the VII clearance of obstacles, and the abnormal ammonia metabolism.

Conclusion: Compared with controls, the metabolic profile of patients was altered obviously. Taurine, N-Methylphenylethanolamine and Ubiquinone-1 may serves as the marker metabolites in distinguishing patients from controls. The pathogenesis of WD may be related to the shortage of energy supply, oxidative stress, and the abnormal ammonia metabolism.

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disease worldwide. NAFLD and type 2 diabetes mellitus (T2DM) commonly coexist. Adenosine-to-inosine (A-to-I) editing, catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes, is an important post-transcriptional modification of genome-encoded RNA transcripts. Three fundamentally related members of the ADAR family have been identified: ADAR1, ADAR2, and ADAR3. ADAR1 and ADAR2 are ubiquitously expressed, while ADAR3 is exclusively expressed in the brain. However, the functional role of ADAR2 in hepatic steatosis, particularly that in NAFLD, is unclear. In this study, ADAR2+/+/GluR-BBR (wild type) mice and ADAR2+/−/GluR-BBR (ADAR2 KO) mice were fed with standard chow or high-fat diet (HFD) for 12 weeks. ADAR2 KO mice exhibited protection against HFD-induced glucose intolerance, insulin resistance, and dyslipidemia. Moreover, ADAR2 KO mice displayed reduced liver lipid droplets in concert with decreased hepatic TG content, improved hepatic insulin signaling, better pyruvate tolerance, and increased glycogen synthesis. Glucose uptake in primary hepatocytes from ADAR2 KO mice was increased. Pyruvate-induced glucose release was reduced in primary hepatocytes from ADAR2 KO mice. Mechanistically, ADAR2 KO mitigated hepatic lipid production via AMPK/Sirt1 pathway. ADAR2 KO inhibited hepatic gluconeogenesis via the AMPK/CREB pathway and promoted glycogen synthesis by activating the AMPK/GSK3β pathway. These results provided novel evidence that ADAR2 KO protected against NAFLD progression through AMPK signaling. 51. Inhibition of ADAR2 is a potential therapeutic target for NAFLD.

Lactobacillus Casei-Fermented Amomum Xanthioides Mitigates NAFLD in a High-fat Diet Mice Model

Seung-Ju Hwang1, Chang-Gue Son1

1Daejeon University Daejeon South Korea

Non-alcoholic fatty liver disease (NAFLD) is a substantial global health issue owing to its high prevalence and the lack of effective therapies. Fermentation of medicinal herbs has always been considered a feasible strategy for enhancing efficacy in treating various ailments. This study aimed to investigate the potential benefits of the Lactobacillus casei-fermented Amomum xanthioides (LAX) on NAFLD in a high-fat diet model. HFD-fed C57BL/6j mice were administered with 200 mg/kg of LAX or unfermented Amomum xanthioides (AX) or 100 mg/kg of metformin for 6 weeks from the 4th week. The 10-week HFD-induced alterations of hepatic lipid accumulation and hepatic inflammation were significantly attenuated by LAX dominantly (more than AX or metformin), which evidenced by pathohistological findings, lipid contents, inflammatory cytokines (TNF-α, IL-6 and IL-1β), oxidative parameters (ROS and MDA), and molecular changes reversely between lipogenic (GPAM and SREBP-1) and lipolytic (PPAR-α and p-AMPKα) molecules in the liver tissues. In addition, the abnormal serum lipid parameters (triglyceride, total cholesterol and LDL-cholesterol) notably ameliorated by LAX. In conclusion, these findings support the potential of LAX as a promising plant-derived remedy for NAFLD.
Association of TNF-α gene polymorphisms with non-alcoholic fatty liver disease: A meta-analysis

Alaa Abd El-Ghany Osman1, Sally Waheed Elkhadry1, Laila Shehata Dorgham1

1Epidemiology and Preventive Medicine Department, National Liver Institute, Menoufia University, Egypt

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent liver diseases that is affected by various environmental and genetic factors. The association between tumor necrosis factor-alpha (TNF-α) gene polymorphism in regions -308G/A (rs1800629) and -238G/A (rs361525) and susceptibility to NAFLD is controversial. This meta-analysis evaluated the association between these TNF-α polymorphisms and NAFLD.

Methodology: A systematic search was conducted on PubMed, Cochrane Library, Scopus, Web of Science, and EMBASE databases to retrieve relevant studies published until March 29, 2023. Based on predetermined selection criteria, all eligible studies were included in the meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated.

Results: Eleven studies with 1155 NAFLD cases and 1364 controls demonstrated the significant association between TNF-α rs1800629 polymorphism and NAFLD under the dominant model (GA/AA vs. GG) [OR = 1.27, 95% CI = 1.01–1.59, P = 0.04] and allelic model (G vs. A) [OR = 1.26, 95% CI = 1.03–1.54, P = 0.02]. Considering the TNF-α rs361525 polymorphism, nine studies including 904 cases and 848 controls suggested significant association under each of the dominant model [OR = 1.76, 95% CI = 1.14–2.71, P = 0.01] and the allelic model [OR = 1.66, 95% CI = 1.31–2.44, P = 0.01]. Subgroup analysis based on ethnicity suggested a significant association among Caucasians, while the evidence for both rs1800629 and rs361525 was insufficient among Asians.

Conclusion: This meta-analysis suggested that TNF-α gene polymorphism at positions -238 and -308 might be a risk factor for NAFLD.

Abstract Submission No. 100583

P-0266

Hepatic steatosis characteristics in mouse models of NAFLD based on AI analysis

Xiaoxiao Wang1, Yuyun Song1, Rui Jin1, Zilong Wang1, Xiaohui Li1, Qiang Yang2, Xiao Teng2, Fangfang Liu1, Nan Wu1, Yandi Xie1, Huiying Rao1, Feng Liu1

1Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China; 2HistoIndex Pte Ltd Singapore Singapore

Objective: This study aims to establish an artificial intelligence (AI) analysis method that based on SHG/TPEF technology to evaluate the characteristics of hepatic steatosis in mouse model with non-alcoholic fatty liver disease (NAFLD) automatically and objectively.

Methods: C57BL/6 mice were divided into 6 NAFLD model groups: Western diet (WD) group; WD + fructose drinking water (WDF) group; WDF + CC14 group; High fat diet (HFD) group; HFD plus fructose (HFDF) group; HFDF + CC14 group. Liver tissue and blood samples of mice were collected at different time points (0w, 8w and 16w) after modeling. All tissue sections were subjected to H&E and SHG/TPEF imaging. The changes of hepatic steatosis were analyzed by AI.

Results: Compared with 0w, according to AI analysis, the area and the number of fat vacuoles in each group, as well as the diameter of fat vacuoles and the number of fat droplets per unit area corresponding to the diameter of fat vacuoles, showed an increasing trend with the prolongation of modeling time, especially in WD and WDF groups. Meanwhile, compared with the 8w model, the above-mentioned steatosis characteristics in the 16w model increased significantly. Although the steatosis grade also showed a steady upward trend, there was no significant difference between the 8w and 16w using NASH CRN scoring method.

Conclusion: AI analysis based on SHG/TPEF image could quantify the dynamic changes of the area, number, and size of hepatic steatosis. This study strengthens the case for usage of MASLD without hindering ongoing developments based on NAFLD.

Abstract Submission No. 100653
automatically and objectively, making it more suitable for the evaluation of pre-clinical animal experiments.

Abstract Submission No. 100692
P-0267

BODY COMPOSITION OF MAFLD PATIENTS AND PREDICTORS OF SIGNIFICANT FIBROSIS

Abhishek Yadav, Sunil Dadhich, Bobby Mitrolia, Vivek Saini, Rajendra Bhati, Nitesh Chauhan, Sewaram Chaudhary, Sabir Hussain, Narendra Bhargava

1Dr. Sampurmanand Medical College Jodhpur India

Background: Body composition of MAFLD patients changes as they progress from fatty liver disease to advanced fibrosis. Visceral adipose tissue (VAT) along with conventional factors like Diabetes, hypertension has been postulated to be the driver of fibrosis in these patients.

Aim: To study the body composition analysis using bioelectrical impedance (BIA), and finding out potential predictors of significant fibrosis by comparing clinical, laboratory and BIA parameters.

Methods: We enrolled 146 MAFLD patients, 69 had significant fibrosis (≥F2, Group-A) and while 77 were without significant fibrosis (<F2, Group-B) along with 35 controls (Group-C). All underwent detailed clinical evaluation, FibroScan & Bioelectrical impedance analysis using four electrode BIA machine.

Results: Patients in Group-A were older in age (56.7±10.8ys vs 22±7) & higher BMI, total body fat percentage (24±07), VAT% (09±03), SAT% (18±10) & higher muscle mass percentage (38±04), bone mass (kg) (2.9±0.38) compared to group A&B.

Conclusion: MAFLD patients with significant fibrosis compared to without significant fibrosis have older age, more likely diabetic and hypertensive with higher VAT, and higher water content, while patients without significant fibrosis has, higher BMI, total body fat%, SAT, muscle and bone mass.

Abstract Submission No. 100763
P-0269

Prevalence of Depression in Chronic Liver Disease and its implications for Mortality

Elinia Cho, Benjamin Nah, Daniel Tung, Jia Hong Koh, Douglas Chee, Cheng Han Ng, Nicholas Syn

1Lee Kong Chian School of Medicine, Nanyang Technological University Singapore Singapore, 2Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore Singapore, 3Centre of Excellence for Soldier Performance, Singapore Armed Forces Singapore Singapore, 4Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 5Department of Biomedical Informatics, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 6Department of HPB Surgery and Liver Transplantation, National University of Singapore Singapore Singapore

Introduction: Depression is a pervasive mental health issue that often intersects with chronic health conditions, impacting individuals' overall well-being. This study explores the prevalence of depression in those with chronic liver disease (CLD) and its implications for mortality.

Methods: The current analysis uses data from the National Health Interview Survey 2005 to 2018. To account for inherent population sampling variance, the study uses survey analysis weighted for proper sample representation of the United States. Longitudinal survival was examined using survey weighted cox regression and competing risk mortality for cardiovascular and cancer related mortality.

Results: In total, 18,115 individuals were included in the study. Depression was identified to be in 1,114 CLD individuals. Individuals that were depressed were more likely to be older in age (p<0.001),
females (p<0.001). Ethnicsities, particularly a higher proportion of Asians, were more likely to be associated with depression (p=0.003). Interestingly, BMI and diabetes were not found to be significantly different between the two groups. Additionally, a higher proportion of depressed individuals were abstinent from alcohol use (p<0.001). In the analysis on overall mortality, individuals with depression were at a significantly higher risk of overall mortality (HR: 1.231, CI: 1.002 to 1.513, p=0.047) after adjusting for diabetes, smoking, ethnicsities, region and alcohol use. This was similarly found in a competing risk analysis for cancer related mortality (SHR: 1.429, CI: 1.211 to 1.687, p<0.01) but not cardiovascular related mortality (SHR: 1.034, 0.738 to 1.450).

Conclusion: The study reveals a substantial prevalence of depression in individuals with CLD and highlights its significant impact on overall mortality, particularly in the context of cancer-related mortality. These findings underscore the need for integrated healthcare strategies that address both mental and physical health in this population. Healthcare providers should consider these results when developing comprehensive care plans for individuals with CLD, recognizing the potential to improve their life expectancy and overall well-being.

Abstract Submission No. 100775
P-0270

Entacapone as an FTO Inhibitor: A Promising Repurposed Therapy for Steatotic Liver Disease

Sunita Giri¹, Vijay Kumar¹

¹Institute of liver and biliary sciences Delhi India

Background and Objectives: Metabolic-associated steatotic liver disease (MAFLD) is a prevalent chronic liver condition closely associated with metabolic disorders, including central obesity, dyslipidemia, hypertension, hyperglycemia, and persistent liver function abnormalities. The recently discovered Fat Mass and Obesity-Associated (FTO) gene has emerged as a genetic factor contributing to obesity. Nonetheless, the precise molecular mechanisms underlying the effect of FTO on obesity remain largely elusive. Recent insights from comprehensive genome-wide association studies have not only linked the FTO gene to human metabolic issues but also cancer, a condition closely tied to obesity. Furthermore, laboratory and computational investigations have shown that disrupting FTO’s enzymatic activity of FTO leads to the dysregulation of genes involved in energy metabolism. In this study, entacapone, originally designed as a catechol-O-methyltransferase inhibitor for Parkinson’s disease, was repurposed as an FTO inhibitor to treat MAFLD in a mouse model.

Methods: Male C57BL6/J mice were fed a high-fat and high-carbohydrate diet (HFHC) for 13 weeks to induce obesity. Additionally, perportal fibrosis was observed in the HFHC-fed mice. Impaired fasting glucose levels and glucose tolerance were evident after oral glucose testing. Key biochemical parameters, including alanine transaminase, aspartate transaminase, triglycerides, and total cholesterol, were significantly increased (p<0.01) in HFHC-fed mice. Serum adiponectin and FTO levels were significantly elevated (p<0.0001) in HFHC mice compared to those treated with Entacapone. Immunohistochemical examination confirmed the increased nuclear expression of FTO in the livers of HFHC-fed mice, which decreased considerably following entacapone treatment. A progressive and significant (p<0.0001) increase in FTO gene expression was observed in the livers of HFHC-fed mice compared to that in treated mice.

Conclusion: This study revealed a progressive increase in FTO gene expression, elevations in crucial biochemical parameters, and a correlation with NAS scores as the disease progressed in HFHC-fed mice. Moreover, Entacapone treatment mitigated the progression of NAFLD in these animals, suggesting the potential repurposing of Entacapone for treating obesity and fatty liver disease.

Abstract Submission No. 100807
P-0271

RESMETIROM LOWERS LDL-CHOLESTEROL AND IMPROVES MASH IN A 3-WEEK MASH MOUSE MODEL

FRANCOIS BRIAND¹, NATALIA BREYNER², ESTELLE GRASSET¹, THIERRY SULPICE¹

¹PHYSIOGENEX ESCALQUENS France

Objectives: There is currently no marketed drug for the treatment of Metabolic Dysfunction-Associated Steato-Hepatitis (MAHS). To expedite preclinical drug development, we have developed a mouse model fed a high fat/cholesterol/cholic acid diet with cyclodextrin in drinking water (HFCC+CDX diet) to favor hepatocyte cholesterol uptake and induce MASH within 3 weeks. To optimize future head-to-head comparison or drug combinations studies, we evaluated the efficacy of resmetirom, one of the most advanced drugs in clinical trials.

Methods: Male, 8-week-old, C57BL6/J mice were fed the HFCC+CDX diet for 3 weeks. After 1 week, mice were randomized based on their plasma transaminases levels and body weight, then treated with vehicle or resmetirom 3 mg/kg. After 2 weeks of treatment, blood and liver were collected for biochemistry and histology analysis.

Results: Resmetirom did not alter transaminases levels but significantly reduced plasma total cholesterol and LDL-cholesterol levels (-27% and -37% respectively, both p<0.001 vs. vehicle). This LDL-lowering effect was associated with higher LDL-receptor (+39%) and lower apolipoprotein B (-17%) hepatic gene expression (both p<0.01). Resmetirom reduced hepatic triglycerides content (-25%, p<0.01) and significantly reduced NAFLD activity score through lower inflammation score (p<0.01), as well as lower IL-6 and IL-1b hepatic gene expression (both p<0.05). Resmetirom also showed anti-fibrotic effects as shown by a significantly lower % Sirius Red labelling.

Conclusion: Resmetirom lowers LDL-cholesterol, hepatic inflammation, and fibrosis in the 3-week MASH mouse model. This preclinical model will be useful to expedite preclinical drug development for the treatment of MASH.

Abstract Submission No. 100827
P-0272

Treatment with human placental extract ameliorates metabolic-associated fatty liver disease

Joseph George¹, Mikihiro Tsutsumi², Mutsumi Tsuchishima³

¹Department of Hepatology, Kanazawa Medical University Uchinada, Ishikawa Japan

Background: Metabolic-associated fatty liver disease (MAFLD) is...
parenchyma. Uncontrolled MAFLD may develop into fibrosis, which could potentially progress to liver cirrhosis and hepatocellular carcinoma. We evaluated the effect of human placental extract (HPE) to prevent the progression of MAFLD to hepatic fibrosis and cirrhosis.

Methods: SHRSP5/Dmc1 rats (spontaneously hypertensive rats/stroke prone) were fed a high-fat and cholesterol (HFC) diet for 4 weeks and screened for steatosis. A set of animals on HFC diet were treated with HPE (3.6 mg/kg body weight) subcutaneously thrice a week, and another set served as control. The animals were sacrificed at 12 weeks from the beginning of the experiment.

Results: The animals fed with HFC diet depicted well-developed fibrosis with bridging and early cirrhosis. Immunohistochemical staining for α-SMA and 4-hydroxy-2-nonenal (4-HNE) demonstrated activation of hepatic stellate cells and marked increase in lipid peroxidation, respectively. Staining for collagens type I and type III depicted marked deposition of newly formed collagen fibers in the hepatic parenchyma. Animals treated with HPE demonstrated significant reduction in biochemical and histopathological changes compared to the respective control group.

Conclusion: The results of the present study indicated that treatment with HPE could ameliorate MAFLD and might be suitable to use as a therapeutic agent to prevent the progression of steatosis to hepatic fibrosis and cirrhosis. Various cytokines, growth factors, anti-inflammatory agents, and antioxidant molecules present in HPE might contribute towards the amelioration of MAFLD.

Email: george@kanazawa-med.ac.jp

Abstract Submission No. 100863
P.0274

Macrophages release miRNA-enriched extracellular vesicles that are taken up by lipotoxic hepatocytes

Bootsakorn Boonkaew¹, Kenneth W. Witwer², Pisit Tangkijvanich¹

¹Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, ²Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine Baltimore Marryland

Introduction: Lipotoxicity and inflammation in the liver play a critical role in the development of nonalcoholic fatty liver disease (NAFLD). Extracellular vesicles (EVs) carry microRNAs (miRs) to modulate cellular crosstalk. Here, we investigated whether miR-223 can be transported from macrophages to lipotoxic hepatocytes via EVs.

Methods: To demonstrate that macrophages transfer EVs containing miR-223 to hepatocytes, we transfected macrophages with a Cy3-miR-223 mimic. Co-culture between the transfected macrophages and the palmitic acid induced-lipotoxic hepatocytes was performed on a transwell system for 24 hours, and miR-223 and its target genes in the 223 mimic. Co-culture between the transfected macrophages and the lipotoxic hepatocytes was performed on a transwell system for 24 hours, and miR-223 and its target genes in the lipotoxic hepatocytes were demonstrated.

Results: The animals fed with HFC diet depicted well-developed fibrosis with bridging and early cirrhosis. Immunohistochemical staining for α-SMA and 4-hydroxy-2-nonenal (4-HNE) demonstrated activation of hepatic stellate cells and marked increase in lipid peroxidation, respectively. Staining for collagens type I and type III depicted marked deposition of newly formed collagen fibers in the hepatic parenchyma. Animals treated with HPE demonstrated significant reduction in biochemical and histopathological changes compared to the respective control group.

Conclusion: The results of the present study indicated that treatment with HPE could ameliorate MAFLD and might be suitable to use as a therapeutic agent to prevent the progression of steatosis to hepatic fibrosis and cirrhosis. Various cytokines, growth factors, anti-inflammatory agents, and antioxidant molecules present in HPE might contribute towards the amelioration of MAFLD.

Email: george@kanazawa-med.ac.jp

Abstract Submission No. 100863
P.0274

A Systematic Review for Adjusting High-fat/High-fructose Animal Models to Clinical Feature of NAFLD

Yu-Jin Choi¹, Chang-gue Son²

¹Se-Myung University Jeccheon-si South Korea, ²Daejeon University Daejeon South Korea

Background: The complexities of the etiology and pathophysiology of Non-alcoholic fatty liver disease (NAFLD) lead to difficulty in development of therapeutics. We aim to assess statistically the diet-related factors contributing to NAFLD progression using animal studies, which would inform both physicians and researchers for the management of patients and for their preclinical studies.

Methods: From both PubMed and Cochrane database, we searched NAFLD data through October 2022, focusing on high-fat, high-fructose diet (HFFD) rodent model. We extracted the details for the compositions of diet and routes of intake, period of induction, and characteristics of rodents. And then, we conducted correlation analysis and multiple linear regression analysis among those variants.

Results: A total 161 data (116 articles) was final selected, which produced 14 independent variables. Unexpectedly, no variant significantly correlated with the progression of Non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), while three factors were the key contributing factors in fibrosis progression under multiple regression analysis (r = 0.717, p < 0.001); as a relative portion by 40.2% of inducing period, 33.2% of fructose-derived calorie in the pellet, and 26.6% of the ratio of carbohydrate to fat in the pellet, respectively.

Conclusions: From current study, we confirmed the impact of fructose-rich diet in progression of NAFLD, especially by liver fibrosis, along with period of exposure. It would help us further to understand and design the strategy for clinical management and preclinical investigation of NAFLD in the future.

Abstract Submission No. 100899
P.0275

Identification of tumor-promoting secreted factors in the progression of steatosis-associated HCC

Atsuki Uno¹, Yoshiki Nonaka², Kanae Echizen², Ryota Yamagishi², Yi Cheng², Takahiro Kodama², Naoko Ohtani²

¹The Department of Medicine, Osaka City University Osaka Japan, ²The Department of Pathophysiology, Osaka Metropolitan University Graduate School of Medicine Osaka Japan, ¹The Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine Suita Japan

Recently, the number of steatosis-associated hepatocellular carcinoma (HCC) patients has increased due to the expansion of the obese population worldwide. However, the details of the pathogenesis of steatosis-associated HCCs have not been fully understood, and thus the identification of molecules for appropriate diagnosis and therapeutic targets is an urgent issue. We previously identified that hepatic stellate cells (HSCs), which undergo cellular senescence due to obesity, provoke senescence-associated secretory phenotype (SASP) and secrete inflammatory cytokines, chemokines, and so on. We also previously
reported that senescent HSCs increase the production of PGE2 that suppresses the anti-tumor immunity by CD8+ T cells and IL-33 that stimulates ST2+ Tregs, creating a tumor-promoting microenvironment. However, other numerous secreted factors, which could be associated with the prognosis of steatosis-associated HCC, have not been cleared yet. In this study, we performed single-cell RNA-seq analysis on human non-viral HCC specimens and investigated which factors promote tumor progression by analyzing whole secreted proteins shown in the Human Protein Atlas focusing on the expressed genes of secreted factors from senescent HSCs. We narrowed the gene sets of secreted proteins using machine-learning that can determine how strongly each gene influences on the outcome of the disease, such as fibrosis or HCC, by changing parameters. Each identified gene can be applied to predict patients’ prognosis by analyzing patients’ real survivals. Our analysis will develop a potential analytical tool to identify a series of secreted factors that affect patients’ prognosis. These factors could be utilized as prognostic markers of steatosis-associated HCCs.

Abstract Submission No. 100958
P-0276

Apolipoprotein J is associated with indole-mediated metabolism in hepatocytes

Mei-Chi Huang1, Jia-Yi Pi2, Hung-Yu Sun1

1College of Medicine at the National Cheng Kung University Tainan City Taiwan, 2Institute of Biomedical Science, Hunan University Hunan China

Background: Indole, a metabolite derived from dietary tryptophan, is relevant to human non-alcoholic fatty liver disease (NAFLD) and shows potential in alleviating diet-induced NAFLD symptoms in mice. Indole is absorbed by hepatocytes and can be metabolized by the hepatic microsomal enzyme CYP2E1 (a member of the CYP450 family 2E) and the sulfotransferase enzyme SULT1A1 (a member of the sulfotransferase family 1A) to produce the uremic toxin indoxyl sulfate. Previous research from our group has demonstrated that Apolipoprotein J (ApoJ), a stress-induced molecular chaperone, plays a role in lipid-related metabolic disorders. This study aimed to investigate the relationship between indole levels and ApoJ content in hepatocytes and to explore the mechanisms by which ApoJ regulates the indole metabolic pathway in mice with diet-induced NAFLD.

Methods: To further examine how Apolipoprotein J specifically impacts liver metabolic function, we utilized iTRAQ quantitative proteomics analysis. We assessed the association between hepatic ApoJ levels and markers mediated by indole in the livers of diet-induced NAFLD mouse models. Additionally, in vitro experiments involved treating Huh7 cells with 400 μM of indole for 24 hours, followed by western blot experiments to assess enzymes associated with indole.

Results: Our findings support the ability of ApoJ to induce hepatic damage and its association with the indole metabolic pathway and enzyme activation in hepatocytes. These modifications appear to be a result of the direct impact of metabolism on the liver.

Abstract Submission No. 100968
P-0277

Targeting Apolipoprotein J restores hepatic cholesterol balance via bile acid alternative pathway

Hsin-Tzu Wang1, Hung-Yu Sun1

1National Cheng Kung University Tainan Taiwan

Background: Free cholesterol (FC) in the liver is crucially regulated through esterification to cholesteryl ester (CE) or conversion to bile acids (BA) to maintain hepatic cholesterol balance. Dysregulation of cholesterol balance can lead to metabolic-associated fatty liver disease (MAFLD). Previous research from our group revealed that targeting Apolipoprotein J (ApoJ) reduces hepatic cholesterol accumulation, in part, by inhibiting sterol-O acyltransferase 2 activity, thus preventing CE synthesis.

Methods: The mice were fed with high fat diet to induce MAFLD. The proteomic approach was applied to identify the pathways involved in hepatic pathogenesis. The metabolites in liver were analyzed by UPLC MS/MS.

Results: Previous research from our group revealed that targeting Apolipoprotein J (ApoJ) reduces hepatic cholesterol accumulation, in part, by inhibiting sterol-O acyltransferase 2 activity, thus preventing CE synthesis. In this study, we delved deeper into the role of ApoJ in hepatic cholesterol homeostasis using Omics approaches. Our findings demonstrated upregulation of CYP7B1, a key enzyme in the alternative pathway of BA synthesis, in these mice. Consequently, ApoJ knockout elevated Hepatic levels of primary bile acids, chenodeoxycholic acid (CDCA), and its secondary bile acid derivative, ursodeoxycholic acid (UDCA), synthesized through CDCA dehydroxylation.

Conclusions: These results suggest that ApoJ may serve as a potential therapeutic target for MAFLD by restoring the BA alternative pathway and maintaining hepatic cholesterol balance.

Abstract Submission No. 101034
P-0278

Strenuous Exercise Was Not Associated With Reduction of Fatty Liver in Adolescents and Young Adults

Vivian Nguyen1, Alexia Tran1, Ashkawn Beheshhtian1, Julia Ernsting1, Samantha Hislop1, Bhargava Gannavarapu1,2, Eduardo da Silveira4, Michelle Nguyen5, Ruel Garcia3

1Los Gatos Research Group Los Gatos United States, 2Unio Specialty Care Los Gatos United States

Background: Hepatic steatosis, or fatty liver (FL), is a common cause of chronic liver disease. This study aims to determine the prevalence of FL in the younger population (ages 14-30 years) and determine risk factors for FL. Liver biopsy is the gold standard to diagnose FL. However, it entails risks and is costly. Transient elastography (TE) is a less expensive, noninvasive alternative. This study uses TE to measure hepatic steatosis and fibrosis.

Methods: Non-consecutive subjects, ages 14-30 years, were recruited from November 2022-September 2023 and underwent liver TE, using the Fibroscan 230 Echoscan Paris, France. FL was defined as a controlled Attenuation Parameter (CAP) score of ≥238 dB and significant fibrosis was defined as a fibrosis score of F2 or greater (>7.5 kPa). Body mass index (BMI) was calculated. Weekly moderate to strenuous exercise, diet, alcohol intake, and demographics were self-reported.

Results: 59 out of 241 subjects (24.5%) had FL. On an unadjusted model, subjects who exercised for 2.5+ hours weekly had a lower prevalence of FL compared to subjects who exercised less than 2.5 hours weekly (41% vs 59% p=0.039). However, when adjusted for BMI, this association was no longer significant (p=0.24). FL prevalence was significantly associated with BMI (Underweight 0%, Normal weight 8.5%, Overweight 28.1%, Obese 83.3%).

Conclusions: BMI remains the main predictor of FL in our young subjects. Exercise is not an independent predictor of absence of FL.
Iron Overload Aggravates Liver Injury in Progression of Non-Alcoholic Steatohepatitis

Wei Wang¹, Feng Liu¹, Hongsong Chen¹, Huiying Rao¹

¹Peking University People’s Hospital, Peking University Hepatology Institute Beijing China

Background: Non-alcoholic steatohepatitis (NASH) is a progressive form of non-alcoholic fatty liver disease (NAFLD) that causes cirrhosis and hepatocellular carcinoma. Evidences from animal studies and NASH patients have demonstrated that iron overload is a hallmark of NASH. However, the impact of iron overload in the progression of NASH is still need further studied. The purpose of this study is to investigate the relation of iron overload with liver injury in various stages of NASH.

Methods: Various stages of NAFLD mouse model were established by feeding male C57BL/6 mice a methionine-choline deficient-diet for 4, 8, and 12 weeks, respectively. The liver iron content and serum biochemistry were detected. Liver histopathology assessment, including H&E, Oil red O and Sirius red staining, were conducted. NAFLD Activity Score (NAS) was assessed based on the analysis of liver histopathology.

Results: The liver iron content was related with the level of serum ALP, AST, ALT, total bilirubin and direct bilirubin. When the iron content was increased, the serum markers of liver function were also elevated. The correlation coefficients were between 0.6 and 0.8. There was a positive correlation of hepatic iron content and NAS, with the correlation coefficients was 0.752. With the progression of NASH based on NAS, hepatic lipid peroxidation-associated malondialdehyde (MDA), which was the oxidative stress marker in ferroptosis, was also significantly elevated.

Conclusions: This study demonstrates that the hepatic iron overload related with the liver injury with the progression of NASH. It provides a potential direction for future research in NAFLD treatment strategies.

Abstract Submission No. 101124

P-0279

Regulation of BHMT by LRH-1 in methionine cycle of liver

Sulagna Mukherjee¹, Jae-Ho Lee¹, Hee-Kyung Han¹, Soo-Young Park¹, Hye Ji Jang¹, Dae-Kyu Song¹, Jae-Hoon Bae¹, Seung-Soon Im¹

¹Keimyung University Daegu South Korea

Betaine-homocysteine S-methyltransferase (BHMT), one of the most abundant proteins in the liver, is involved in the regulation of homocysteine metabolism. Generally, decreased BHMT gene expression leads to homocysteine accumulation in the liver, which can induce mitochondrial stress. However, the molecular mechanism of BHMT transcription has not been elucidated. This study outlines the mechanism of BHMT is mediated by liver receptor homolog-1 (LRH-1), and the effect of BHMT deficiency in liver causes methionine disorder. During fasting, both BHMT and Lrh-1 expressions increased in the liver of normal mice, but BHMT expression was decreased in LRH-1 liver specific knockout (LKO) mice. In addition, the lipid peroxide content in the liver tissues of LRH-1 LKO mice was increased. Promoter activity analysis confirmed the binding of LRH-1 to a specific site at +131/+137 bp of the mouse BHMT promoter. LRH-1 deficiency is associated with elevated reactive oxygen species (ROS) production, lipid peroxidation, and mitochondrial stress in hepatocytes. In conclusion, this study suggests that lack of LRH-1-mediated decrease in BHMT expression, promotes triglyceride accumulation by increasing ROS levels and inducing mitochondrial stress via disrupted methionine cycle. Understanding these regulatory pathways may pave the way for novel therapeutic interventions in metabolic disorders associated with hepatic lipid accumulation.

This work was supported by the Ministry of Education of the Republic of Korea and the National Research Foundation of Korea(NRF-2023R1A2C3003717) and Main Research Program of the Korea Food Research Institute funded by the Ministry of Science and ICT and the Ministry of Health and Welfare, Republic of Korea(H14C1324).

Abstract Submission No. 101161

P-0280

Pharmacological Mechanism of Gegen-Qinlian in Preventing NAFLD

Yu Song¹,², Junping Shi²

¹The Second Affiliated Hospital of Zhejiang Chinese Medical University Hangzhou China, ²Hangzhou Normal University Affiliated Hospital Hangzhou China

Background: Traditional Chinese Medicine (TCM) has shown potential treatment to Non-alcoholic fatty liver disease. The study aims to use network pharmacology to explore the pharmacological mechanisms of Gegen Qinlian decoction (GQD) in treating NAFLD.

Methods: The study found four herbs’ ingredients and targets from TCMD and PharmMapper to construct interaction networks. Microarray data from 87 NAFLD patients informed the protein-protein interaction (PPI) and molecular docking, which evaluated ingredient-target interactions.

Results: 619 differentially expressed genes were obtained through GeneCards and GSE151158 chip as the NAFLD target prediction dataset. By intersecting with the effective component target gene set of GQD, the drug treatment targets for NAFLD were identified as CASP8, CASP3, PLAU, BCL2, AHR, RELA, PPARG, IL6, MCL1, GABPAR1. We constructed the drug-active component-target synergistic network to analyze the relationship among the drugs, active components, and targets for NAFLD disease. We found baicaline, β-sitosterol, and musk flavonoids were docked with the effective target points BCL2, PPARγ, TGR5, NF-xB, and MPK7 respectively by molecular docking. We fed the high-fat and high-fructose (HFHF) diet NAFLD mice models for 16 weeks, and the GQD group was orally administered for 8 weeks. In the GQD group, there was a significant improvement in the NAS score compared to the HFHF group (P<0.0001), steatosis change (P=0.009), lobular inflammation change (P=0.002), ballooning change (P=0.0001), and fibrosis improvement (P=0.018). In terms of ALT and AST, the GQD group showed improvement compared to the HFHF group (P=0.0412, P=0.0128).

Conclusion: By network pharmacology and post-validation, GQD can improve histological changes in NAFLD.

Abstract Submission No. 101177

P-0282

miR-449 modulates the progression of NASH-induced fibrosis by regulating the merlin-TAZ pathways.

Young-Sun Lee¹, Yang Jae Yoo¹, Young Kul Jung¹, Ji Hoon Kim¹, Yeon Seok Seo¹, Hyung Joon Yim¹, Jong Eun Yeon¹, Kwan Soo Byun¹, Sun Young Yim¹

¹Korea university Seoul South Korea
Background and Aim: While the majority of patients with non-alcoholic fatty liver disease (NAFLD) exhibit benign clinical courses, those with non-alcoholic steatohepatitis (NASH) accompanied by hepatic fibrosis experience poor prognoses compared to individuals with non-alcoholic fatty liver (NAFL) or NASH without hepatic fibrosis. This study aimed to investigate the role of miR-4449 in the progression of NASH-induced fibrosis.

Method: Liver tissue and sera were obtained from NAFLD patients who underwent liver biopsies at Korea University Guro Hospital. MicroRNA sequencing was performed using sera, and miRNA sequencing was conducted using liver tissue from patients with biopsy-confirmed NAFLD. In vitro lipotoxicity was induced in mouse hepatocytes (HepG2 and HuH7 cells) by treating them with palmitic acids (PA).

Results: A total of 24 NAFLD patients were recruited, with 15 having NAFL or NASH without fibrosis, and nine presenting with NASH accompanied by fibrosis. MiRNA sequencing analysis revealed significant differences in the expression levels of 31 miRNA sequences between the two groups, with miR-4449 exhibiting the most prominent upregulation in NASH-fibrosis compared to the NAFL or NASH without fibrosis group. PA treatment increased the expression level of miR-4449 in both supernatant and hepatocytes. Conversely, the expression of merlin, a potential target of miR-4449, decreased in PA-treated hepatocytes compared with vehicle-treated hepatocytes. Additionally, merlin expression levels significantly decreased in NASH patients with fibrosis compared to those without fibrosis.

Conclusion: MiR-4449 was found to regulate merlin expression and TAZ phosphorylation in hepatocytes during lipotoxicity. Thus, miR-4449 may serve as a promising novel therapeutic target in NASH-fibrosis.

Abstract Submission No. 101260
P-0283

Plasma and liver EFEMP1 are elevated in morbidly obese subjects with early fibrosis in MASLD

Allen Anthony Laraño1, 4, 5, Deborah Bonazza2, 4, Silvia Palmisano1, 2, Claudio Tiribelli1, Natalia Rosso1, Pablo J. Giraudi1
1Metabolic Liver Disease Unit, Fondazione Italiana Fegato Trieste Italy, 2Surgical Pathology Unit, Cattinara Hospital, ASUGI Trieste Italy, 3Surgical Clinic Division, Cattinara Hospital, ASUTs Trieste Italy, 4Department of Medical, Surgical and Health Sciences, University of Trieste Trieste Italy, 5PhD Molecular Medicine Program, Department of Life Sciences, University of Trieste Trieste Italy, 6Department of Science and Technology-Philippine Council for Health Research and Development Taguig City Philippines

Background: A quarter of adult population worldwide suffers from metabolic dysfunction-associated steatotic liver disease (MASLD). Fibrosis is the best predictor of liver-related risk in persons with MASLD. Using in silico methods, we discovered circulating biomarkers associated with fibrosis development and validated their specificity in a MASLD-biopsy proven cohort.

Methods: GSE125251 RNAseq dataset was re-analyzed using the bioinformatics pipeline by comparing F0-F1 (early fibrosis, n=139) vs. F2/F3-F4 (moderate/advanced fibrosis, n=67) liver transcriptomes in MASLD subjects. Differentially expressed genes (DEGs) were filtered, selecting only plasma-secreted protein-coding genes through an in silico funnel strategy. Expression of the best-ranked genes was analyzed in liver samples of a morbidly obese cohort (n=65) stratified according to fibrosis. Plasma levels of best candidates was assessed using ELISA.

Results: 106 DEGs were detected and 22 of them individuated as candidates coding for plasma-circulating proteins. The five best-ranked candidates were tested by qPCR (EFEMP1, LTBP2, LUM, DPT, CCL20). EFEMP1 mRNA level was 1.11 ± 0.30 folds higher in F2/F3-F4 than F0/F1 livers (p-value <0.005). Plasma EFEMP1 was also increased with fibrosis (21.85 ± 4.18 ng/mL in F2/ F3-F4 respect to 7.114 ± 1.26 ng/mL in F0-F1, (p-value <0.005).

Conclusion: EFEMP1 is a secreted ECM protein, expressed by fibroblasts, with a role in the maintenance of ECM stability. Our data indicates EFEMP1 plasma levels as a potential marker of hepatic fibrosis during MASLD.

Abstract Submission No. 101377
P-0285

Hypoxanthine plasma concentration changes in MASH and its role as a biomarker of steatohepatitis

Melissa Maria Milito1, Deborah Bonazza2, 3, Claudio Tiribelli1, Silvia Palmisano1, Natalia Rosso1, Pablo José Giraudi1
1Fondazione Italiana Fegato Trieste Italy, 2Cattinara Hospital ASUGI Trieste Italy, 3University of Trieste Trieste Italy

Background: Plasma hypoxanthine (HypX) was reported as a putative marker of Metabolic-Dysfunction Steatotic Liver Disease (MASLD). Here we aimed to characterize changes in HypX pool in blood, liver, and Visceral Adipose Tissue (VAT) by evaluating the main genes/enzymes involved in purine catabolism.

Methods: HypX concentration was quantified in plasma, liver, and VAT tissues in 132 MASLD biopsy-proven subjects stratified in fatty liver (MASL) and steatohepatitis (MASH) using a fluorometric enzymatic method and also using HPLC in a subset of samples (n=40). Several clinical-biochemical-histological parameters were correlated with plasma and intracellular HypX levels. Expression for purine catabolism genes by qPCR and xanthine oxidoreductase (XDH) activity analysis was also performed.

Results: Plasma HypX was reduced in MASH patients (2.0 [IQR 1.16-3.0] in MASL vs. 0.8 [0.5-1.9] in MASH, p-value <0.0001) both enzymatic and HPLC assessment. Plasma HypX receiver operating characteristic curve analysis demonstrated an accuracy of 0.75 for MASH diagnosis. Significant correlations among HypX levels and lobular inflammation (rho= 0.23; p=0.010), ballooning (rho= -0.48; p<0.0001), fibrosis (rho= -0.33; p=0.0006), GGT (rho=0.18; p=0.04), and triglycerides (rho= 0.22; p=0.017) were observed. Changes in gene expression were significant only in VAT of MASH patients (XDH: 18.0 ± 13.2 MASL vs 1.5 ± 9.0 MASH; HPRT: 0.3 ± 0.6 MASL vs. 1.3 ± 0.9 MASH; HPR1: 11.4 ± 13.7 MASL vs. 1.8 ± 6.2 MASH, all p<0.01).

Conclusions: Plasma hypoxanthine could be used as a biomarker of steatohepatitis in MASLD. Our data indicate that VAT might contribute to the hypoxanthine pool changes observed in subjects with MASLD.

Abstract Submission No. 101277
P-0284

Investigating the Interactome of Apolipoprotein J under Lipid Stress

Wei-Tso Chen1, Hung-Yu Sun2
1Institute of molecular medicine, NCKU Taiwan, Tainan Taiwan, 2Department of Physiology, NCKU Taiwan, Tainan Taiwan

Background: Previously, our group successfully identified the pathological role of Apolipoprotein J (ApoJ) in hepatic lipid deposition. When faced with nutrient overload, ApoJ stabilizes sterol-O acetyltransferase 2, promoting the synthesis of cholesteryl ester, while concurrently hindering lipophagy through its interaction with mTOR.
Given ApoJ’s chaperone activity, it stands as a potential master regulator for maintaining intracellular homeostasis when cells encounter nutrient stresses. This study establishes an ApoJ interactome to gain a deeper understanding of the pathogenesis associated with ApoJ.

**Methods:** A flag-tagged ApoJ is utilized for immunoprecipitation-mass spectrometry (IP-MS) analysis. The immunoprecipitate undergoes LC/MS/MS analysis to identify the client proteins of the ApoJ chaperone. The pathways associated with ApoJ are identified through GO and KEGG analyses.

**Results:** A total of 1701 proteins were identified as putative client proteins of ApoJ. Among these, 114 proteins (Protein dataset 1) were exclusively detected in cells without lipid stress, whereas 45 proteins (Protein dataset 2) were specifically found in cells subjected to oleic acid treatment. Subsequent GO and KEGG analyses revealed that Protein dataset 1 is associated with proteasomal pathways and ubiquitination functions, while Protein dataset 2 encompasses proteins involved in autophagy, fibrosis, mitochondrial function, and the electron transport chain.

**Conclusions:** Our data suggest that ApoJ interacts with specific client proteins in response to nutrient stresses. Under nutrient stress conditions, ApoJ enhances the stability of client proteins associated with mitochondrial function, thereby promoting pathogenesis by inhibiting proteasomal and ubiquitination pathways.

---

**The CHOL-to-CE conversion regulates cellular senescence in primary human hepatocytes with steatosis**

Sin-Tian Wang1, Wei-Chia Chen1, Li-Chi Chi1, Cheng-Hung Yang1,2, Mei-Ling Cheng3, Kung-Chia Young1,2

1Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University Tainan Taiwan, 2Institute of Basic Medicine, College of Medicine, National Cheng Kung University Taian Taiwan, 3Department of Biomedical Sciences, College of Medicine, Chang Gung University Taoyuan Taiwan, 3Metabolomics Core Laboratory, Healthy Aging Research Center, Chang Gung University Taoyuan Taiwan

**Background and Aims:** Metabolic-associated fatty liver disease (MAFLD) is characterized by lipid accumulation, which might be accelerated by hepatic cellular senescence. In this study, we investigated the effects of senolytic drugs on primary human hepatocyte (PHH) with lipid droplet accumulation.

**Method:** First, the cultivated PHH was induced to lipid droplet accumulation with fatty acid overload and the changes of transcriptome were examined for 1 day or 3 days. Next, the effects of senolytic drugs, quercetin or curcumin were assessed.

**Results:** The lipid droplets consisting of increased triglyceride and cholesteryl ester were accumulated in oleic acid (OA)-treated PHH at day 1 and day 3 post-treatment. The differently expressed genes involved in cellular senescence were revealed in OA-treated PHHs with delayed time at day 3. Treatment with senolytic drugs reduced p16/p27 but not p53/p21 in a manner with the replicative senescent signaling pathways.

**Conclusion:** The senolytic drugs might be potentially effective in the development of therapeutic treatment for MAFLD.

---

**Creation of humanized mice models of advanced SLD via patient-derived fecal microbiota transplants**

Lei Zhou1, Anna Xin Yi Ng1, Nur Halisah Jumat1, Stephen Wit Thun Kwa1, Jazleen Leo1, Gwyneth Shook Ting Soon2, Jonathan Wei Jie Leu3, Yock Young Dan1,3

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Department of Pathology, National University Hospital Singapore Singapore, 3Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore

**Background:** Gut microbiota is increasingly recognized as a contributing factor in the etiology of steatotic liver disease (SLD). Humanized mice models can better understand the causal associations of gut microbiome and SLD pathology. The study aims to explore if a single gavage was sufficient for stable establishment of the humanized microbiota with advanced SLD histopathological features.
Methods: Six-week-old C57BL/6J male mice received either standard food and water (SE) or a high fat high cholesterol diet, and fructose and glucose water (HFHC). Mice were given 3 courses of 7 days of antibiotics (ampicillin, cefazolin, clindamycin, ertapenem, neomycin, vancomycin) for 3 weeks, then a single gavage of 100uL fecal microbiota transplant (10^9 CFU) prepared anaerobic from patients with advanced SLD. Body weight, blood, spleen and liver was sampled every 4 weeks.

Results: Weight gain was attributed to the HFHC diet (Fig1A), with hepatic steatosis and lobular inflammation seen as early as 8 weeks into the diet. After 28 weeks of HFHC diet exposure, the mice had significantly larger spleens (p<0.01), livers (p<0.01) with higher serum bilirubin and ALT (p<0.01) and the perisinusoidal and pericellular hepatic fibrosis was present. At 34 weeks, HFHC-fed mice previously treated with antibiotics had significantly lower intensity and areas of fibrosis, whereas mice post FMT had significantly higher intensity and areas of fibrosis.

Conclusion: HFHC diet propagates liver steatosis. Gut microbiota is required in SLD progression toward steatohepatitis and fibrosis. A humanized mouse model of microbial-driven steatohepatitis can be established with a single gavage of fecal microbiota transplant.

Abstract Submission No. 101417
P-0289

Plasma Metabolomic Signatures in Patients with Varying Histological Severity of MAFLD

Jonathan Wei Jie Lee1,7, Michaela Michaela Chocholouskova1,6, Nur Halisah Jumat1, Jazleen Leo1, Anna Xin Yi Ng1, Gwyneth Shook Ting Soon2, Asim Shabbir2, George Goh3, Kenny Sze5, Eunice XX Tan6, Mark Dhinesh Muthiah6, Federico Tesio Torta4, Yock Young Dan0

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Department of Pathology, National University Hospital Singapore Singapore, 3Department of Surgery, National University Hospital Singapore Singapore, 4Department of Gastroenterology & Hepatology, Singapore General Hospital Singapore Singapore, 5Department of Gastroenterology & Hepatology, Khoo Teck Puat Hospital Singapore Singapore, 6Singapore Lipidomics Incubator (SLING), Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 7Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore

Background: MAFLD represents a spectrum of liver disease: steatosis, steatohepatitis, fibrosis and cirrhosis. Patients with MASH and/or fibrosis are at greatest risk of liver and cardiovascular morbidities. With no adequate non-invasive biomarkers, physicians remain reliant on liver biopsies to diagnose MASH. Furthermore, MAFLD in the Asian cohort is understudied. We aim to identify unique circulating lipidomic signatures for MASH and fibrosis in a multi-ethnic cohort of patients from Singapore.

Methods: A targeted approach, using LC-MS/MS on low and high-resolution mass spectrometers, was used to quantify 243 plasma lipids from 164 patients (12 controls, 32 simple steatosis, 41 incomplete MAFLD, 36 MASH and 43 advanced fibrosis) paired with liver biopsies. The lipids associated with different stages of MAFLD were identified using multivariate linear regression whilst adjusting for clinical variables such as age and sex.

Results: 7 class of lipids (primary and secondary bile acids, ceramides, cholesterol esters, Hex2Cer, phosphatidylethanolamine, sphingomyelins) were found to be differentially abundant amongst patients with varying severity of MAFLD (Fig1A). Liver histological presence of steatosis (qval 0.03), lobular inflammation (qval 0.01), ballooning (qval 0.01) and fibrosis (qval 0.02) significantly contributed to the variance of the plasma metabolome (Fig1B). A total of 113 metabolites significantly correlated with liver histology, with enrichment of 22 ceramides associated with lobular inflammation, 10 phosphatidylino-ositols for ballooning, 8 primary bile acids for fibrosis (Fig1C).

Conclusions: Patients with varying histological severity of MAFLD exhibit unique circulating lipidomic signatures with potential as surrogate markers to determine at risk MAFLD patients with MASH and significant fibrosis.

Abstract Submission No. 101463
P-0290

Gut Microbiome and Body Composition in Patients with Steatotic Liver Diseases

Shiyi Claire Tan1, Stephen Kwa1, Nur Halisah Binte Jumat1, Lei Pheng Yeo1, Mastura Salim1, Norsheida Kamarudin1, Rachel Johnson2, Asim Shabbir2, Jonathan WJ Lee0, Yock Young Dan0

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Department of Surgery, National University Hospital Singapore Singapore, 3Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore

Objective: Disturbances in gut microbiome have been implicated in the pathophysiology of steatotic liver disease (SLD). This study explores the association between gut microbiome and varying body compositions in patients with SLD.

Methods: We collected stool samples in the National University Hospital, Singapore from 83 patients (mean age 46.9 years-old, 56.2% male) undergoing diagnostic liver biopsy and AMRA body constitution profiling. Stool samples underwent shotgun sequencing, and subsequent taxonomic and functional profiling using the BioBakery v3 metagenomic pipeline. Using spearman correlation, we identified putative microbial features with SLD-associated body composition indices.

Results: Patients with SLD have significantly elevated liver fat (p<0.01), subcutaneous fat (p=0.03) and visceral fat (p<0.01). Amongst patients with SLD, there is a parabolic relationship with subcutaneous fat and muscle mass; positively associated with mild SLD (i.e. simple steatosis) and negatively associated with fibrotic SLD, whereas visceral fat remains elevated amongst advanced SLD. Twenty-two microbial taxa were significantly correlated with body composition indices. Of note, pro-inflammatory Proteobacteria species (Escherichia coli, Klebsiella species) and anti-inflammatory Collinsella intestinalis were positively correlated with visceral fat (q=0.03) and muscle mass respectively (q=0.04).

Conclusion: Our study demonstrated significant differences in microbial taxonomic associated with varying body compositions in patients with SLD, highlighting the potential role of gut microbes in energy regulation, fat storage and muscle mass.

Abstract Submission No. 101469
P-0291

MLKL-ATP binding inhibitor attenuated inflammatory response via necroptosis independent pathway.

Eileen Yoon1, Huiyul Park2, Joo Hyun Oh3, Sang Bong Ahn3, DAE WON JUN1

1Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Department of Surgery, National University Hospital Singapore Singapore, 3Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore
Background: The inhibition of the adenosine triphosphate (ATP) pocket in the pseudokinase domain of Mixed Lineage Kinase Domain Like Protein (MLKL) has been observed to have no impact on necroptosis-induced cell death. Recent investigations have highlighted the MLKL independent non-classical MLKL pathway such as NF-κB-dependent pathway. This study aims to explore the potential anti-inflammatory effects of Compound-4 (CPD-4) in a model of fatty liver disease.

Method: CPD-4, a selective ATP-binding compound, was administered to U937, HT29, and Jurkat T cells, respectively. Necroptosis was induced using SMAC mimetic, zvad-fmk, and TNF-alpha. Cell viability was assessed using MTT and flow cytometry. The impact of CPD-4 on TNF-α-induced regulation of ICAM-1 and VCAM-1, as well as its inhibitory effects on CXCL1 and CXCL2 expression, were examined through PCR and western blot.

Results: Following the induction of necroptosis, the survival rate of HT29 and U937 cells significantly decreased. In contrast, RAW cells did not undergo cell death after inducing necroptosis. RAW cells exhibited hypermethylation and, unlike U937 cells, evaded cell death in response to necroptosis stimuli. RAW cells did not undergo MLKL phosphorylation but demonstrated activation after necrotic stimulation. Following demethylation, RAW cells induced necrosis-associated cell death. The MLKL ATP pocket-binding inhibitor did not prevent cell death induced by necroptosis but did reduce the expression of CXCL2, ICAM, and VCAM resulting from necroptosis by inhibiting the IKKβ and NFKβ pathways.

Conclusion: Although CPD4 cannot inhibit necroptosis, the MLKL ATP-binding inhibitor attenuated the inflammatory response via a necroptosis-independent pathway. This study aimed to determine the relation of body mass index, hepatic steatosis, and insulin resistance of NAFLD in T2DM in Mohammad Hoesin Hospital Palembang.

Method: This is a cross-sectional study involving 52 T2DM patients, done at Mohammad Hoesin Hospital Palembang from January to April 2023. Laboratory, fibroscan, and ultrasonography examination were done on each patient.

Results: 52 T2DM patients consist of 23 male (44.2%) and 29 female (55.8%) with an average age of 58.98±8.84 years, from which 10 participants were overweight (19.2%) and 21 participants were obese (40.4%). HOMA-IR is a marker to measure insulin resistance and the median of HOMA-IR was 13.44±16.01 (significant insulin resistance). The prevalence of NAFLD was 55.77% and mean of controlled attenuation parameter (CAP) was 266.25±77.99 dB/m. The result showed there is a correlation between BMI with CAP (p = 0.001, r = 0.342) and insulin resistance (p = 0.024, r = 0.237). There is correlation between insulin resistance and NAFLD in this study (p <0.001).

Conclusion: In this study, BMI is associated with the presence of NAFLD and insulin resistance in T2DM patient.
protiens, is produced in the liver and has glucose lowering effect in mice. To explore the mechanism whereby Activin improves glucose metabolism, we have performed some experiments in vitro and in vivo. **Methods:** To investigate the effect of Activin in glucose metabolism in cultured hepatocyte, we treated cultured hepatocyte with recombinant protein of Activin and looked up the changes of the expression genes by Q-PCR analysis.

Next, we overexpressed Activin in liver of B6 mice by adenovirus mediated gene transfer, and performed pyruvate tolerance test. We also performed glucose tolerance test using the model mice of type 1 diabetes.

**Results:** We found that the expression level of G6Pase and PEPCK, key regulators of gluconeogenesis, was dramatically suppressed by treatment with recombinant Activin in primary hepatocyte. During pyruvate tolerance test, mice overexpressing Activin exhibited significantly lower glucose levels, indicating the suppression of gluconeogenesis by Activin. Interestingly, suppressive effect of gluconeogenic genes by Activin was also observed in the liver of mice treated by Streptozotocin (model mice of type 1 diabetes). As a consequence, overexpression of Activin resulted in dramatic improvement of glucose tolerance even in the model of type 1 diabetes.

**Conclusions:** Activin has glucose lowering effect by suppression of hepatic gluconeogenesis. Enhancing the action of Activin in the liver can be a strategy of the treatment for diabetes.

Abstract Submission No. 101728
P-0295

**ShenZhu XiaoJi Formula modulates tumor metabolism and immune infiltration in NASH-induced HCC**

Xin Zhong¹, Qi Huang¹, Rui Hu¹, Jing Li², Jinyu Yi³, Jialing Sun¹, Xiaozhou Zhou¹

¹Shenzhen Traditional Chinese Medicine Hospital, the Fourth Clinical College, Guangzhou University of Chinese Medicine Guangzhou China

With the rapid growth of morbidity, non-alcoholic steatohepatitis (NASH) has become the fastest-growing etiology of hepatocellular carcinoma (HCC). Of note, compared to HCC with other etiology, NASH-induced HCC (NASH-HCC) presents distinct metabolic dysfunction and deteriorative tumour immune escape in response to the immune checkpoint therapy (PD-1/PD-L1). ShenZhu XiaoJi Formula (SZXJF), a herbal prescription of Traditional Chinese Medicine, has been used for treating NASH and NASH-HCC with clinical effectiveness, but the mechanisms are largely unknown. Herein, we aim to investigate the therapeutic effect and mechanism in mouse model of NASH-HCC. As results, SZXJF treatment effectively ameliorated serum lipid and glucose content, hepatic lipid accumulation, lobular inflammation, liver injury and reduced the tumor number in NASH-HCC. Mechanistically, transcriptome analysis revealed that SZXJF might regulate metabolic pathways, cytokine-cytokine receptor interaction and NF-kB signalling. MMP12 represented a significant change among the DEG, of which the high level was estimated to correlate with increased macrophage infiltration, reduced effector CD8⁺ T cell and increased expression of exhausted CD8⁺ T cell markers in human NASH-HCC. Consistently, we verified that SZXJF treatment downregulated hepatic MMP12 protein level, inhibited NF-kB/p65 activation and increased CD8⁺ T cell infiltration compared to the model group of NASH-HCC. Meanwhile, protein expressions of Ki67, PDCD1, TIGIT1, and TREM2 were downregulated in the tumour tissue of mouse liver, showing an immune microenvironment remodelling in NASH-HCC. Collectively, our findings demonstrated that SZXJF intervention could improve NASH-HCC potentially through regulating metabolic reprogramming and immune microenvironment remodelling via MMP12/NF-kB signalling, providing a new therapeutic strategy for NASH-HCC treatment.

Abstract Submission No. 101794
P-0296

**State of knowledge of type 2 diabetic patients about NAFLD**

Fatima Zohra Benamor Seghir¹, Fouad Haddad¹, Fatima Zahra El Rhaoussi², Mohamed Tahiri Joutei Hassan¹, Wafaa Hilwa¹, Ahmed Bellabah¹, Wafaa Badre³

¹UHC Ibn Rochd Casablanca Morocco

**Background:** Non-alcoholic fatty-liver-disease (NAFLD) is common in type2 diabetes. The aim of this study is to evaluate the knowledge of type2 diabetics regarding NAFLD and to determine the relationship between their personal characteristics and their level of knowledge.

**Patients and Methods:** This is a prospective study extending from March 2022 to September 2023. A questionnaire was completed by 278 type2 diabetics.

**Results:** The average age was 57.2years with a sex-ratio (M/F) of 2.16. The mean duration of diabetes was 4.2years, with a mean glycated-hemoglobin (HbA1c) of 7.3%. Average BMI was 26.2. NAFLD was present in 22%(N=61) of patients, while 16.5%(N=46) had NASH. 40%(N=112) said they’d never heard of NAFLD, and 89.5%(N=249) said they didn’t know the difference between NAFLD and NASH. According to the participants, the main risk factors for NAFLD were: obesity(90%), dyslipidemia(68.3%), diabetes(45%), high blood pressure(21.5%) and certain medications(10.7%). 28% knew that NAFLD corresponds to the accumulation of fats in the hepatocytes, 31.2% that screening was based on abdominal ultrasound and blood tests, 9% that the diagnosis of certainty was made by liver biopsy and 4.3% knew the risk of progression to cirrhosis and hepatocellular carcinoma. 56% reported that NAFLD was reversible, and that treatment was based on physical activity and a change in dietary habits. Better knowledge of NAFLD was significantly associated with younger age(p=0.03), higher level of education(p=0.002) and history of NAFLD(p<0.001).

**Conclusion:** It’s vital to improve type2 diabetic patients’ knowledge of NAFLD, thus enabling better adherence to treatment, a change in dietary habits and the fight against sedentary lifestyles.

Abstract Submission No. 101809
P-0297

**Metabolic and pathogenic regulations in hepatocytes with large and small lipid droplet accumulation**

Hsuan-Ya Liao¹, Sin-Tian Wang², Kuan-Chieh Chen³, Tzu-Ching Kao¹, Ching-Ya Chang¹, Hung-Wen Tsai³, Kung-Chia Young⁴

¹Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University Tainan Taiwan, ²Department of Pathology, College of Medicine, National Cheng Kung University Tainan Taiwan, ³Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan Taiwan

**Background and aims:** Metabolic-associated fatty liver disease (MAFLD) is characterized by the hepatic accumulation of lipid droplet...
(LDs), which were visualized as large and small particles in size. In this study, the pathogenic roles of individual large and small LDs were investigated.

**Method:** First, the expression patterns of LD markers, perilipins (PLIN2 and 3), were examined with immunostain in liver tissues of MAFLD patients. Next, the primary human hepatocytes (PHH) with induction of LD accumulation of either large sizes by oleic acid (OA) or of small sizes by TMP-153 were established. The metabolic and pathogenic regulations were examined by transcriptomic analysis, qRT-PCR, western blotting and lipid quantification.

**Results:** The large LDs displayed PLIN2 decoration on the surface and colocalization with Mallory-Denk bodies in ballooned hepatocytes of the liver tissue, whereas the small LDs were scattered in the cytosol in association with PLIN3. In the PHH with large LDs accumulation, the expressions of PLIN2 and p62 were upregulated, accompanied by the activation of genes involving beta-oxidation and triglyceride synthesis but inhibition of glycolysis. Meanwhile, the PHH with small LDs, the expression of PLIN3 was upregulated, accompanied by the inhibition of triglyceride hydrolysis. The fibroblast-activation protein (FAP) exhibited increases in both groups of PHH but to a greater extent in those induced with small LDs.

**Conclusion:** The large and small LDs exhibited distinct phenotypes regarding metabolic modelling and might indicate the individual pathogenic role in the progress of MAFLD.

---

Abstract Submission No. 101901

**P-0298**

**Oxidized HDL is a potential biomarker of hepatic and coronary events in patients with MASLD**

**Rie Goka**, Kouichi Miura1, Hiroshi Maeda1, Shunji Watanabe1, Mamiko Tsukui1, Yoshinari Takaoka1, Hiroaki Nomoto1, Naoki Morimoto1, Kazuhiro Kotani2

1Division of Gastroenterology, Department of Medicine, Jichi Medical University Shimotuke Japan, 2Division of Community and Family Medicine, Center for Community Medicine, Jichi Medical University Shimotuke Japan

**Introduction:** Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver diseases. Patients with MASLD are complicated with cardiovascular diseases (CVDs). Although the mortality caused by CVDs differs among studies, CVDs are one of the most common causes of death in patients with MASLD. We have previously reported that oxidized high-density lipoprotein (oxHDL) was associated with liver fibrosis markers. However, the association between oxHDL and CVDs remains unknown. We herein expanded the previous study and investigated the association between oxHDL and CVDs.

**Method:** A total of 170 patients with MASLD were enrolled. Blood counts and chemistry were examined. Liver fibrosis was assessed by a non-invasive scoring system, including the FIB-4 index and NAFLD fibrosis score (NFS). The characteristic variables were collected based on the clinical records.

**Results:** Among 170 subjects, the prevalence of MASLD, history of CV events, and hepatic events were 138 (81%), 13 (8%), and 16 (9.4%), respectively. The levels of oxHDL were significantly higher in patients with MASLD. The median of oxHDL in non-MASLD and MASLD groups were 86.5 U/L (35.7-200.6) and 225.3 U/L (37.1-1405.4), respectively. In non-MASLD group, 97% (31/32) were within 200 U/L. The levels of oxHDL were significantly higher in patients with a history of CV events. The medians of oxHDL levels in CV and hepatic events were 273.6 (131.7-591.8) and 370.0 U/L (176.6-840.4), respectively. Treatment agents including anti-HL had little effects on oxHDL levels.

**Conclusion:** OxHDL is a potential biomarker for CVD in patients with MASLD.

Abstract Submission No. 101971

**P-0299**

**Three Dimensional Structure Like Human Liver, Method Of Hepatotoxicity & Conjugate Like Human Liver**

Ramlah Ramlah1, Haerani Haerani2
1Universitas Sulawesi Barat Majene Indonesia, 2STIKes Bina Bangsa Majene Majene Indonesia

**Background:** Genetic analysis an important force in evolution as it allows natural selection to increase or decrease frequency of alleles already in the population. Genetic disease is mostly caused by familiality in the genetic code. Genes can be used as markers for cell recruitment and activation molecules. This study aims to evaluate the variation and relationship of variation and relationship of three dimensional structure like human liver, evaluation method of hepatotoxicity and conjugate like human liver.

**Method:** Data obtained from 8 sequences of three dimensional structure like human liver on secondary data form on https://www.ncbi.nlm.nih.gov/ and selected articles journal evaluated (2015-2023). The genetic analysis constructed by Bootstrap 1000x using MEGA 7.0 software.

**Result:** the dendogram of 8 sequences were divided into 2 main groups, namely groups A consisting of 7 specimens and groups B consisting of 1 specimen. The optimal tree with the sum of branch length = 7.53041418 is shown. The tree is drawn to scale, with branch lengths (next to the branches) in the same units as those of the evolutionary distances used to infer the phylogenetic tree. This grouping is based on the existence of a similar genetic makeup equation with a high bootstrap value indicating the degree of kinship between specimens and the strength of the phyllogenous trees. Grouping was achieved on the basis of differences in expression levels across individual specimens.

**Conclusion:** Information about kinship can be used as an informative source to assembly of superior genes in living of human cells.

Abstract Submission No. 101975

**P-0300**

**Association of MAFLD with Coronary Artery Calcification among Filipino patients in Cebu City**

Mary Grace S. Nepomuceno1, Michael Albert M. Diy1
1Chong Hua Hospital Cebu City Philippines

**Background:** Non-alcoholic fatty liver disease (NAFLD), now known as Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), is linked to cardiovascular disease. This renaming emphasizes the role of metabolic problems. Coronary artery calcification (CAC) reflects early coronary artery disease, but data on the MAFLD-CAC link is limited.

**Methods:** This single-center retrospective study involved adult Filipino patients who underwent CT CAC scoring between January 2021 and January 2023. Clinical and laboratory data were obtained via review of electronic records.

**Results:** This study involved 147 patients with an average age of 62, primarily females (57.14%), and mostly falling into the Obese-Class I category (31.29%). The most common comorbidities were hypertension (95.24%), dyslipidemia (62.59%), and diabetes mellitus (38.1%). In terms of CAC scores using the CT Agatston method, majority
(30.61%) had low calcium buildup (Stage 2 with scores between 1-99). Approximately 26.53% had higher liver fat content with liver Hounsefield units (HU) below 40, while 73.47% had lower liver fat content with HU equal to or greater than 40. Furthermore, 25.17% of patients with fatty livers were diagnosed with MAFLD, while 74.83% were not. The p-value indicated a significant difference in proportions, suggesting a lower proportion of MAFLD among those who had undergone CT CAC scoring. However, the Pearson Chi-Square statistic (4.051) and the p-value (0.256) indicated no statistically significant association between MAFLD and CT CAC.

Conclusion: The study found a lower proportion of MAFLD diagnoses in patients who underwent CT CAC scoring. Additionally, there was no statistically significant link between MAFLD and CT CAC.

Abstract Submission No. 102094
P-0301
Heat-killed Lactobacillus brevis SBL88 improves glucolipid metabolism in MAFLD liver and intestine
Hidemi Hayashi1, Koji Sawada1, Hiroki Tanaka2, Takumu Hasebe1, Mikihiro Fujiya1
1Division of Gastroenterology, Department of Internal Medicine, Asahikawa Medical University Asahikawa Japan, 2Division of Tumor Pathology, Department of Pathology, Asahikawa medical University Asahikawa Japan

Background: We previously reported that heat-killed Lactobacillus brevis SBL88 (SBL88) improves the clinical features of metabolic dysfunction-associated steatotic liver disease (MASLD). We evaluated the further mechanism by which L. brevis SBL88 improves the features of MASLD.

Methods: In the MASLD model, mice were induced by feeding a high-fat diet (HFD) (HFD mice) or HFD supplemented with 1% SBL88 (SBL mice). The features of MASLD were evaluated, and RNA sequencing and pathway analysis indicated the impact on the regulation of glucolipid metabolism. Real-time PCR and WB analysis was performed using terminal restriction fragment length polymorphism (T-RFLP) in the feces. Additionally, as part of an in vitro study, Hep7 cells and Caco2 bbe cells were cocultured in transwells.

Results: Blood examinations and histopathological findings revealed the improvement of the clinical features of MASLD in SBL mice. RNA sequencing and pathway analysis indicated the impact on the regulation of glucolipid metabolism. Real-time PCR and WB analysis showed significantly higher expressions of IRS-2 or pIRS-2 in the liver of SBL mice. Additionally, the expression of Fiaf was significantly increased, and FoxO1 was significantly decreased in the intestine of SBL mice. However, T-RFLP did not indicate alterations in the microbiota between HFD and SBL mice. In an in vitro study using an intestinal epithelia-hepatocyte transwell model, the expression of IRS-2 and FoxO1 significantly changed when treated with SBL88.

Conclusion: SBL88 could improve MASLD by altering glucolipid metabolism in the liver and intestine without affecting the gut microbiota.

Abstract Submission No. 200036
P-0302
Ganodric acid Nanoparticle ameliorates fatty liver disease via alteration of PI3K/AKT/mTOR pathway
Deeksha Chauhan1, Vikas Kumar2
1Rajkamal science management college Haridwar India, 2SHUATS Prayagraj India

Background: Nonalcoholic fatty liver disease (NAFLD) is a condition characterized by the accumulation of fat in the liver. In this study, we fabricated the solid lipid nanoparticle (SLN) of ganodric acid (GA) and scrutinized the chemoprotective effect against high fat diet (HFD) and Diethylnitrosamine (DEN) induced NAFLD in rats.

Methods: Double emulsion solvent displacement model was used for the preparation of SLN-GA. Intraperitoneal administration of DEN (100 mg/kg) was used for the induction of HCC in rats for 2 weeks. The rats were divided into 2 groups and received the HFD with or without treatment with SLN-GA for 20 weeks. Body weight, tumor incidence, tumor nodules, hepatic, non-hepatic, apoptosis, antioxidant, pro-inflammatory and inflammatory were estimated. For the determination of gut microbiota, we collected the stools of all rats.

Results: Surface methodology showed the particle size (174.3 nm) and polydispersity index (0.228) for SLN-GA. SLN-GA remarkably suppressed tumor nodules (87.4%), tumor incidence (76.5%) and average size nodules (54.4%). SLN-GA remarkably decreased the level of AFP, ALT, AST, ALP, GGT; non-hepatic parameters viz., bilirubin, total protein, respectively. SLN-GA also suppressed the level of SOD, GSH, GPs, CAT and boosted the level of LPO. SLN-GA significantly (P<0.001) suppressed the level of inflammatory cytokines like TNF-α, IL-1β, IL-6; inflammatory parameters such as COX-2, PGE2, VEGF, iNOS and NF-κB, respectively. Moreover, SLN-GA enhanced gut microbial richness and diversity and altered the relative abundance of firmicutes and bactericides, respectively.

Conclusion: SLN-GA remarkably suppressed the HFD-induced NAFLD in rats via alteration of gut microbiota and PI3K/AKT/mTOR Signaling pathway.

Abstract Submission No. 200073
P-0303
Screening for NAFLD in general practitioners clinical practice
Fatima Zohra Benamor Seghir1, Fouad Haddad1, Fatima Zahra El Rhoussi1, Mohamed Tahiri Joutei Hassan1, Wafaa Hliwa1, Ahmed Bellabah1, Wafaa Badre1
1UHC Ibn Rochd Casablanca Morocco

Background: Non-alcoholic-fatty-liver disease (NAFLD) is the main cause of chronic liver disease. The aim of our study is to evaluate the involvement of the general practitioner(GP) in the screening of NAFLD.

Methods: 192 GPs responded to a questionnaire via Google-forms to assess their knowledge and attitude towards NAFLD.

Results: The average age of the participants was 40.3 years with a sex-ratio (F/M) of 1.43. 46.3% worked in the public-sector and 53.7% in the liberal-sector. 33.8% practiced in rural areas. 65.6% reported knowing NAFLD, its association with metabolic syndrome(84.3%), the risk of progression to cirrhosis(41.1%) and hepatocellular carcinoma(31.2%). 53.6% declared not to screen their patients for NAFLD, 34.9% declared not to screen patients with risk factors in particular type2 diabetes(37.5%), obesity(47.4%), dyslipidemia(26.5%) and taking certain medications(12.5%). To assess NAFLD, 93.2% requested a blood-count, 70.8% a fasting blood sugar level, 56.7% a lipid profile, 66.6% transaminases and 49.5% an abdominal-ultrasound. An annual average of 3 new cases of NAFLD are diagnosed by GPs. 41.1% were looking for associated liver fibrosis. 68.2% were aware of the non-invasive screening tests for this fibrosis, notably the
Ginsenoside Rg1 counteracts obesity-induced NAFLD by modulating gut microbes and bile acid profile
Zheng-Yun Jin1,2, Shuang Yan Chang2, Sheng-Zhong Han2, Jin-Dan Kang2, Lin-Hu Quan1
1College of Pharmacy, Yanbian University Yanji city China, 2College of Agricultural, Yanbian University Yanji China

Obesity is a global health problem strongly associated with the rising prevalence and severity of nonalcoholic fatty liver disease (NAFLD). There is a close relationship between intestinal micro-organisms and NAFLD. Brown adipose tissue (BAT) is the main non-shivering thermogenic site in mammals. It plays an important role in whole body energy metabolism, which mainly relies on expression of uncoupling protein 1 (UCP1). Ginsenoside Rg1 (Rg1) is the major ginsenoside that can improve metabolic diseases, including cardiovascular diseases and diabetes. Rg1 was gavaged to high-fat diet (HFD)-fed mice and its effect on the gut microbiota were evaluated using 16S rRNA gene amplicon sequencing. Bile acids composition were assessed by targeted metabolomic analysis of fecal samples. In this study, we found that Rg1 reduced lipid droplet size, hepatic triglyceride accumulation and alleviated hepatic steatosis by activating UCP1 expression in BAT, which in turn inhibited HFD-induced weight gain in mice. Furthermore, the intestinal flora of mice was altered, the abundance of Lachnoclostridium, Streptococcus, Lactococcus, Enterococcus and Erysipelatoclostridium was upregulated, and the concentrations of fecal bile acids were altered, with cholic acid and taurocholic acid concentrations being significantly increased. In addition, the beneficial effects of Rg1 were eliminated in mice treated with a combination of antibiotics. In conclusion, these results suggest that Rg1 activates BAT to counteract obesity and hepatic steatosis by regulating gut microbes and bile acid composition in HFD-fed mice.

Euiiin-tang ameliorates high-fat diet-induced NAFLD through Nrf2/Sirt1/MAKP pathways in mice
Ye Lim Kim1,2, Hyo Jung Jin1,2, Jong Seong Roh1,2, Sung Hui Byun2, Sang Chan Kim2, Chang-Hyun Song1,2
1Daegu Haany University Research Center for Herbal Convergence on Liver Disease Gyeongsangbuk-Do South Korea, 2Daegu Haany University College of Korean Medicine Gyeongsangbuk-Do South Korea

Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive fat accumulation, inflammation, and cellular injuries in the liver. However, there are no approved treatments for NAFLD. Euiiin-tang (EI) is a traditional polyherb used for attenuating humidity, arthralgia, and obesity in Eastern Asia. Thus, the hepatoprotective effects of EI were examined in high-fat diet (HFD)-induced NAFLD mice model. Mice were fed with HFD or normal fat diet (NFD) for 8 weeks, and orally administered with distilled water, silymarin at 200 mg/kg (SIL), or EI at 250 (EI250) and 500 mg/kg (EI500). The weight gains for 8 weeks were increased in the HFD control compared with the NFD, however, they reduced in treatment groups of the SIL and EI compared with the HFD control. Weight of the liver and fat tissues were increased in the HFD control compared with the NFD, while it significantly reduced in the treatment groups. Serum levels of NAFLD-related parameters (ALT, AST, glucose, HDL−LDL−cholesterol, and triglyceride) were increased in the HFD control compared with the NFD, however, they were reduced in the treatment groups. Conversely, the serum albumin was reduced in the HFD control compared with the NFD, however, it was increased in the treatment groups compared with the HFD control. The treatments of EI enhanced the hepatic antioxidant and anti-inflammatory activities through Nrf2/Sirt1/MAKP pathways. Histopathological analyses and immunohistochemistry revealed that EI exhibits the antioxidant, anti-inflammatory, and anti-apoptotic effects. These results provide a valuable information for the clinical use of EI in NAFLD.
Prevalence and risk factors of Liver fibrosis in patients with MAFLD undergoing bariatric surgery

Alaa M Mostafa1, Amr Elsayed1, Mariana F Gayyed2, Alshymaa Hassanine1, Mohamed A. Abdelzaher3, Yasser Fouad1, Mohamed Khalaf6

1Department of Gastroenterology, Hepatology and Endemic Medicine- Faculty of medicine- Minia University Minia Egypt, 2Department of pathology, Faculty of Medicine, Minia University Minia Egypt, 3Department of surgery, Faculty of Medicine, Minia University Minia Egypt

Background: Fibrosis stages affect clinical prognoses of MAFLD. However, prevalence, clinical features of fibrosis in obese Egyptian patients before bariatric surgery are unclear. We aimed to assess fibrosis in MAFLD Patients before bariatric surgery and estimate the utility of non-invasive tests versus liver biopsy.

Methods: A cross-sectional study of obese MAFLD Patients undergoing bariatric surgery at Minia University Hospital, Faculty of Medicine. History, clinical, laboratory, histopathological evaluation, and Non-invasive scores were done.

Results: Of 98 patients, 7 patients were missed, 6 refuse to continue the study. Out of 85 patients, 77% of overweight/obese patients before bariatric surgery showed histopathological fibrosis at liver biopsy. 29% had significant fibrosis and 13% had advanced fibrosis. Fibrosis was significantly higher in the elderly, smokers, diabetics, hypertensives, and chronic HCV infection. Fibrosis was correlated with the increase in BMI, Waist-hip ratio, ALT, AST, triglyceride, cholesterol, uric acid, FBS, HBA1C, and low platelets. Logistic regression showed smoking, higher ages and BMI, Presence of diabetes and hypertension, low platelets, and higher uric acid were independent predictors of significant fibrosis. The non-invasive models, Fibrosis-4 (FIB-4), NAFLD Fibrosis Score (NFS), and AST to Platelet ratio (APRI) provided greater accuracy for predicting significant fibrosis.

Conclusion: significant fibrosis (F≥2) was detected in > 1/3 of patients with MAFLD undergoing bariatric surgery. Presence of smoking, diabetes, hypertension, high WHR, elevated serum uric acid, advanced age, and low platelet level are risk factors for significant fibrosis (F≥2). FIB-4, NFS, and APRI can be used to identify significant liver fibrosis in bariatric surgery patients.

Abstract Submission No. 100076
P-0308

Associations between blood lipids and glucose and ALT strengthen with increasing ALT concentrations

Yue Wang1, Yuetao Zhang2, Wei Hu3

1High Dimensional Digital Medicine Division, Biovisualab SHANGHAI China, 2Health Management Center, Taizhou Central Hospital (Taizhou University Hospital), No. 999 Donghai Avenue, Taizhou Economic Development Zone, Taizhou, Zhejiang Province 318000, PR China Taizhou China, 3Department of Cardiology, Minhang Hospital, Fudan University, 170 Xinsong Road, Minhang District Shanghai China

Objective: Persistent redox state and excessive reactive species involved in carbohydrate and lipids metabolism lead to oxidative damage to liver itself. To learn whether and how fasting plasma levels of lipids and glucose are associated with fasting blood concentrations of ALT, AST and albumin, a total of 198,880 local residents, age range from18 to 92 years old, without known conditions that impact liver function and metabolism of lipids and glucose, were assembled.

Results: In modeling adjust for confounding factors, the coefficients of the associations between levels of non-HDL-C, HDL-C, triglycerides and glucose and ALT concentration strengthen from 0.570, -0.867, 0.918 and 0.968 in 1st decile (HDL-C starting from 1st decile) to 3.185, -6.783, 5.520 and 2.887 in 9th decile in females and from 1.786, -3.433, 1.624 and 0.467 in 1st decile to 4.583, -7.534, 6.388 and 2.019 in 9th decile in males, respectively. The associations between levels of non-HDL-C, triglycerides and glucose and AST concentration also display steep ascents with increasing AST concentration deciles. The associations between albumin concentration and levels of nutrients show relative steady trends across all deciles except triglycerides (associations are only significant in decile 1 to 4 in females).

Conclusions and Relevance: The fasting levels of lipids and glucose are extensively associated with liver function parameters with sex-specific patterns; especially, the higher the concentrations of ALT, the stronger associations with fasting levels of lipids and glucose. Our data suggests excessive carbohydrate and lipids metabolism may cause subclinical liver damage.

Abstract Submission No. 100101
P-0309

Constructing a predictive modeling equation using the FLASH in the identification of high-risk MASH

Noritaka Wakui1, Hidenari Nagai2, Hideki Nagumo1, Kunihide Mouri1, Naoyuki Yoshimine1, Yuu Ogino1, Kojiro Kobayashi1, Takanori Mukouzu1, Takuma Oguri2, Naohisa Kamiyama2, Tepepi Matsui1, Takahisa Matsuda1

1Division of Gastroenterology and Hepatology, Toho University Omori Medical Center Tokyo Japan, 2Department of Ultrasound General Imaging, GE Healthcare Japan Tokyo Japan

Objective: This study examined whether the information on the range of Sonazoid TM bubble (SB) destruction is useful for identifying high-risk MASH.

Methods: Subjects were 95 patients with MASLD who underwent CEUS and liver biopsy in 4 years. A recommended dose of the contrast agent Sonazoid was infused, and imaging was performed while SB in the liver parenchyma burst using the Flash 10 min after administering Sonazoid. The following measurements were taken from bubble-destruction curves obtained using dedicated analysis software: (1) the range of bubble destruction alone.

Conclusion: The AUROC of this equation was 0.847, indicating its diagnostic ability for predicting high-risk MASH.

Abstract Submission No. 100122
P-0310

P-0309
Useful of laparoscopic sleeve gastrectomy for NAFLD (MASLD)

BUNZO MATSUURA1, Hironobu Nakaguchi1, Masumi Miyazaki1, Akihito Shiomi1, Ayumi Kanamoto1, Teruki Miyake1, Shinya Furukawa2, Yoichi Hiasa1

1Ehime University Graduate School of Medicine Toon Japan, 2Ehime University Health Services Center Matsuyama Japan

Aim: Since 2006 at our hospital, lifestyle modification for obese patients has been provided through a team approach with a physician, dietitian, nurse, physical therapist and psychologist. From 2016, a surgeon and anesthesiologist were added to the team for metabolic/bariatric surgery (laparoscopic sleeve gastrectomy: LSG). The aim of this study is to clarify the characteristics of obese patients with NAFLD for whom LSG was effective.

Patients & Methods: Of 40 obese patients who were received LSG between 2017 and 2021 with follow-up period of more than 1 year, 19 were male and 21 were female, 24 were with diabetes, 16 with other complications. The diagnosis of NAFLD was made by liver imaging for fat deposit and stiffness by Fibroscan, and liver biopsy in some cases.

Results: The mean preoperative BMI was 43, the mean Fib-4 index was 0.98, and the postoperative insulin resistance (CPI) of diabetic patients improved significantly, with 15 patients in complete remission and 6 in incomplete remission after surgery. One year after surgery, the mean weight loss was 18.3%, the Fib-4 index did not decrease significantly, but the mean AST (U/L) improved from 38 to 18, ALT (U/L) from 55 to 15, GGT (U/L) from 78 to 40, CAP (dB/m) from 348 to 279, and liver stiffness (kPa) from 12.1 to 7.6, significantly. In patients who underwent follow-up biopsy, there was a trend toward improvement in liver fibrosis.

Conclusion: Since LSG significantly improves hepatic markers in obese patients with NAFLD, metabolic/bariatric surgery should be positively considered.

Abstract Submission No. 100163
P-0311

Impact of Increased or Moderate Alcohol Intake on Metabolic Associated Steatotic Liver Disease

Chia-Chi Wang1, Tsung-Han Hsieh1

1Taipei Tzu Chi Hospital; Buddhist Tzu Chi Medical Foundation New Taipei City Taiwan

Background: In 2023, a new disease name, “Steatotic Liver Disease (SLD)” was proposed, along with new diagnostic criteria for metabolic dysfunction. Within this context, metabolic associated steatotic liver disease (MASLD) with increased alcohol intake (MetALD) was first named and a new specific subgroup.

Methods: Participants included in the Taiwan Biobank database were selected. Patients with positive HBsAg, positive anti-HCV, or former drinkers were excluded. MASLD was diagnosed if having hepatic steatosis on ultrasound, plus at least one of cardiometabolic criteria. Increased alcohol intake was defined as weekly alcohol consumption exceeding 210 grams for males and 140 grams for females. The Fib-4 score was used to assess the degree of liver fibrosis, and carotid plaques on duplex ultrasound was employed to diagnose atherosclerosis.

Results: In a total of 18,160 (mean age 55.28±10.41; 33.2 % males) participants, there were 7,316 (40.3%) MASLD patients and 209 (1.2%) MetALD patients. The participants with increased alcohol intake were younger and male predominant. After propensity score matching for age and gender, MetALD patients had higher AST, GGT, FLI, and Fib-4 scores and tended to have a higher proportion of carotid plaques than MASLD patients. Among MASLD patients, those with moderate alcohol intake had higher values of GGT, FLI, and Fib-4 score and a higher proportion of carotid plaques than those with no/social alcohol intake.

Conclusions: This population-based study indicates that MetALD patients have higher risk of liver disease than those with MASLD. Furthermore, even modest alcohol intake increases the liver and atherosclerotic risks in MASLD patients.

Abstract Submission No. 100189
P-0312

Prevalence of Alcohol Abstinence in Alcohol-Associated Cirrhosis and Its Impact on Survival

Douglas Chee1, Jia Hong Koh1, Cheng Han Ng1, Wen Hui Lim2, Darren JH Tan2, Nicholas Syn1, Margaret Teng2, Mark D Muthiah1,2,3, Daniel Q Huang0

1Department of Gastroenterology and Hepatology, National University Hospital Singapore Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 3National University Centre of Organ Transplant, National University Hospital Singapore Singapore

Background: Alcohol-associated cirrhosis is a major public health concern with significant morbidity and mortality. This meta-analysis aims to provide insights into the prevalence of alcohol abstinence among individuals with alcohol-associated cirrhosis and to evaluate its impact on survival outcomes.

Methods: Medline and Embase databases were searched for articles pertaining to alcohol abstinence in people with alcohol-associated cirrhosis. A single-arm analysis regression analysis was conducted to identify Factors associated with alcohol abstinence were identified via regression analysis. Hazard ratios (HR) were calculated via pairwise analysis using the DerSimonian and Laird random effects model.

Results: A total of 18,833 individuals with alcohol-associated cirrhosis were included; 9,745 achieved alcohol abstinence. The prevalence of alcohol abstinence was 53.8% (CI: 44.6% to 62.7%) with sustained abstinence in 52.2% in individuals with alcohol-associated cirrhosis, and 52.7% (CI: 32.7% to 71.8%) in individuals with decompensated cirrhosis. The duration of follow-up significantly influenced abstinence rates; highest rates were observed in studies with less than three years of follow-up (76.1%). Lower levels of ALT, AST, and GGT were also associated with alcohol abstinence. Importantly, alcohol abstinence had a profound positive impact on overall survival regardless of compensation status and study design. Individuals who abstained from alcohol demonstrated significantly higher survival rates (HR: 0.611, 95% CI: 0.506 to 0.738).

Conclusion: Achieving and maintaining abstinence is associated with an improved overall survival, highlighting the critical role of abstinence in the management of alcohol-associated cirrhosis. Further research is warranted to explore its impact on decapsulation and hepatocellular carcinoma (HCC) development.

Abstract Submission No. 100190
P-0313

Longitudinal Population Impact of Diabetes on Fatty Liver and Complications. A Nationwide Analysis

Hee Seung Yang1, Zhi Boon Tan1, Cheng Han Ng1, Wen Hui Lim1, Darren Jun Hao Tan1, Nicholas Syn1, Margaret Teng1, Daniel Q. Huang1, Mark D. Muthiah1

Abstract Submission No. 100190
P-0313

Longitudinal Population Impact of Diabetes on Fatty Liver and Complications. A Nationwide Analysis
**Introduction:** Diabetes remains a leading cause of fatty liver. Thus, we seek to understand how a diabetic or pre-diabetic status in fatty liver patients may correlate with other clinical characteristics and its impact on long term liver health, cardiovascular outcomes, and mortality using data from the US National Health and Nutrition Survey (NHANES) from 1999 to 2018.

**Methods:** Data from NHANES, utilizing a stratified, multistage, clustered probability sampling design, were analyzed for patients with Fatty Liver. Fatty Liver was defined as hepatic steatosis with at least one of five cardiometabolic risk factors in the absence of other identifiable causes. Demographic and clinical parameters, including diabetes status, were collected. Fibrosis risk was assessed using Fibroscan-based scoring systems. Major Adverse Cardiovascular Events (MACE) included ischemic heart disease, congestive cardiac failure, and cardiovascular mortality.

**Results:** Among 14,194 Fatty Liver patients, 5,764 were non-diabetic, 4,446 were pre-diabetic, and 3,984 were diabetic. Diabetic patients were older, had a higher prevalence of smoking and hypertension, and exhibited poorer laboratory parameters, with population attributable risk (PAR) of at-risk MASH, advanced fibrosis, MACE, and all cancers at 22.60%, 35.69%, 19.02% and 9.30% respectively. Diabetic patients had a significantly higher overall mortality risk (HR: 1.57) after adjustments for founders.

**Conclusion:** Diabetes is associated with an increased risk of at-risk MASH, advanced fibrosis, cardiovascular complications, and overall mortality in individuals with Fatty Liver. Further research is needed to explore the mechanisms underlying these associations and to develop targeted interventions.

Abstract Submission No. 100217

**P-0314**

**SERUM CREATININE-TO-CYSTATIN C RATIO IS ASSOCIATED WITH THE PRESENCE OF OSTEOPENIA IN MAFLD**

Anna Sheptulina1, Elvira Mamutova1, Adel Yafarova1, Darya Bryk1, Ekaterina Liussina1, Timur Tсорiev1, Oxana Drapkina1

1National Medical Research Center for Therapy and Preventive Medicine Moscow Russia, 2A.I. Evdokimov Moscow State University of Medicine and Dentistry Moscow Russia

**Background:** Increasing evidence suggests that osteopenia is more prevalent in patients with metabolic associated fatty liver disease (MAFLD) compared to general population.

**Methods:** This study aimed to evaluate the association between serum creatinine-to-cystatin C ratio (SI) and the presence of osteopenia in MAFLD. Forty MAFLD patients were prospectively included in the study. MAFLD was diagnosed according to the consensus statement on new fatty liver disease nomenclature (2023). Body composition and bone mineral density (BMD) at the spine and hip were assessed using dual x-ray absorptiometry. Osteopenia was diagnosed when T score in either region was between – 1.0 and – 2.5. Appendicular skeletal muscle mass index (ASMI) was calculated as the sum of the lean muscle mass of the upper and lower extremities adjusted with height. Muscle strength was determined using grip strength (GS) measurement.

**Results:** Median age was 57.5 years (interquartile range (IQR)=46.75-63); 55% were female. Osteopenia was diagnosed in 17 (42.5%) patients with MAFLD. These patients were older (p=0.003), had lower ASMI values (p=0.003), and lower GS values (p=0.001) compared to those without osteopenia. SI was significantly lower in MAFLD patients with osteopenia (p=0.027). The SI cut-off value of 97.25 allowed to exclude osteopenia in patients with MAFLD with a specificity of 94.1% (and negative predictive value of 65.3%).

**Conclusions:** According to our data, SI correlates with the presence of osteopenia in patients with MAFLD and may represent a reliable surrogate marker of decreased BMD in this category of patients.

Abstract Submission No. 100231

**P-0315**

**Comparison of NAFLD and MAFLD liver cancer**

Hideo Yoshida1, Koji Uchino1, Hiroyoshi Taniguchi1

1Japanese Red Cross Medical Center Tokyo Japan

**Aim:** Recently, MAFLD (metabolic dysfunction-associated fatty liver disease) has been proposed as a disease concept related to fatty liver. We examined and compared the characteristics of hepatocellular carcinoma (HCC) with Non-alcoholic fatty liver disease (NAFLD) and MAFLD.

**Methods:** The study included patients who underwent radiofrequency ablation (RFA) for first-grade HCC between 2008 and 2022, and whose background liver disease was fatty liver. Data on age, sex, maximum tumor size, number of tumors, Child Pugh classification, and prognosis of patients were collected. HCC cases with NAFLD and MAFLD were compared with these data.

**Results:** Sixty-two first-grade hepatocellular carcinoma patients treated with RFA during the above period had a fatty liver. The median observation period was 39 months (range 1-134 months). Of these, 19 were diagnosed with NAFLD including duplications, 51 with MAFLD, 3 with NAFLD alone, 35 with MAFLD alone, 16 with duplications of NAFLD and MAFLD, and 8 without both diagnoses. Comparison of the NAFLD group (n=19)/MAFLD group (n=51) including duplications showed that the age was 80 (57-91) years/75 (47-90) years (p=0.019/ t test), male-female 6-13/37-14 (p=0.002/square test), the maximum tumor diameter was 25 (14-44) mm/24 (12-60) mm, number of tumors 1(1-3)/1(1-7), Child classification: A15/B4/A41/B9/C1, and 33%/32% of deaths were due to causes other than liver disease. Survival analysis showed no difference between two groups.

**Conclusion:** Comparing NAFLD and MAFLD liver cancers, MAFLD liver cancer was more common in males and at younger ages, but there were no differences in other factors examined, including prognosis.

Abstract Submission No. 100265

**P-0316**

**Correlation of Biopsy-free scoring systems and Fibroscan as screening tools for Liver Fibrosis**

Jan Michael C. Kong1, Micaela Ignacio2, Luis Abola1, Lorna Esperon2

1University of the East Ramon Magsaysay Memorial Medical Center Quezon City Philippines, 2Victoriano Luna Medical Center Quezon City Philippines

**OBJECTIVES:** This study aims to determine the correlation of biopsy-free scoring systems and FibroScan as screening tools for liver fibrosis of patients with risk factors of type 2 diabetes mellitus and metabolic associated fatty liver disease (MAFLD).

**MATERIALS AND METHODS:** This cross-sectional, prospective study was conducted among 130 adult Filipino patients with diabetic-metabolic syndrome for one year. Subjects were asked to answer a clinic-demographic questionnaires and underwent series of laboratory
diagnostic tests. Results were then analyzed using the APRI score, FIB-4 Index and BARD Score comparing it with FibroScan Metavir Scoring to identify liver fibrosis.

**RESULTS:** The mean APRI score, BARD score, FIB-4 index, and Metavir score of the study population were as follows: 0.56 (SD=1.24), 2.36 (SD=1.06), 1.55 (SD=2.31), and 2.22(SD=0.78) respectively. APRI score was normal in 37%, low in 58%, and high in 5% of the study population. BARD scores demonstrated 58 (45%) patients with low scores (≤2) which could be indicative of scarring and likely some cirrhosis. FIB-4 detected 34% of the study population at high risk for liver fibrosis. Apparently, based on Metavir score system, no fibrosis can be detected in 92.3% of patients. There was a statistically significant positive moderate correlation between FibroScan and biopsy-free scoring systems such as APRI (r=0.481, p<0.001) and FIB-4 (r=0.557, p<0.001). However, BARD was not significantly correlated with FibroScan (p=0.624). APRI carries the highest negative predictive value of 95% compared to BARD (62%) and FIB-4 (77%).

**CONCLUSION:** Biopsy-free scoring systems such as APRI and FIB-4 are significantly correlated with Fibroscan as screening tools for liver fibrosis of patients with risk factors of type 2 diabetes mellitus and MAFLD. Moreover, these tools are capable of ruling out liver fibrosis among patients with at least F2 METAVIR score hence are adequate for use in clinical practice or as a part of referral and follow-up programs wherever this population is treated.

**Keywords:** diabetes, metabolic syndrome, NAFLD, BARD Score, FIB-4, APRI test

---

**Clinical features and real-world treatment patterns of MAFLD patients in China**

**Vi Pan**1,2, **Feng Xue**1-2, **Shanshan Wang**3, **Shuangqing Gao**3, **Lai Wei**3

1School of Clinical Medicine, Tsinghua University Beijing China, 2Beijing Tsinghua Changgung Hospital, Tsinghua University Beijing China, 3Beijing North Medical & Health Economic Research Center Beijing China

**Background:** Little research to date has investigated the current pharmacological treatment among MAFLD patients in China with a large sample. This study aimed to conduct an observational study based on retrospective real-world data to describe the characteristics and pharmacological treatment patterns of adult patients with MAFLD in China.

**Methods:** This is a multicenter, retrospective study. Patients with MAFLD (aged≥18) were identified from the tertiary public hospital electronic database between January 1st, 2020 and December 31st, 2022 following APASL 2020 guideline. The electronic records of all subjects were obtained to assess clinical features.

**Results:** A total of 82,908 patients from 11 hospitals were identified with MAFLD. The mean age of the patients was 53.1±14.1 years. 64.3% were male, 47.8% had type 2 diabetes (T2DM) and 47.4% had hypertension. The median FIB-4 index was 1.22 (IQR, 0.83–1.85). Among the FIB-4-based fibrosis risk groups, 33.4% (19,840/59,365) were in the intermediate-risk group (1.3–2.67), and 12.3% (7,316/59,365) were in the high-risk group (>2.67). 27.4% of patients received hepatoprotective therapy, and the most frequently prescribed drug was metoprolol (24.5%). Metformin was the most frequently prescribed medication among MAFLD patients with T2DM (52.4%). Among MAFLD patients with hypertension, the most frequently prescribed drug was metoprolol (24.5%).

**Conclusions:** Patients with MAFLD are a population with a high burden of comorbidities (mainly diabetes and hypertension), 12.3% of which were high-risk fibrosis based on FIB-4 index. There are significant unmet needs for the management of patients with MAFLD in China currently.

---

**Risk Factors associated to Non-Alcoholic Fatty Liver Disease in patients with type 2 diabetes.**

**Iegreat Aprilyanri**1, ** Wahyuni Lukita Atmodjo**1, ** Shirley Ivonne Moningkey**1, **Ignatius Bima Prasetya**1

1Universitas Pelita Harapan Tangerang, Banten Indonesia

**Background:** Type 2 Diabetes Mellitus (T2DM) plays a significant role in the risk of developing Non-Alcoholic Fatty Liver Disease (NAFLD), thus increasing mortality and morbidity. Although the pathogenesis of Non-Alcoholic Fatty Liver Disease is mainly connected to T2DM, risk factors associated with NAFLD in patients with T2DM have not been fully elucidated.

**Aim:** To explore the risk factors associated with Non-Alcoholic Fatty Liver Disease in T2DM patients

**Methods:** An analytical cross-sectional study was conducted on T2DM patients at the outpatient clinic of Siloam General Hospital. Patients are grouped into NAFLD and Non-NAFLD, whereby this...
diagnosis was done using abdominal ultrasonography. Risk factors assessed in this study include age, gender, BMI, AST, ALT, Albumin, and HbA1c were analysed using Pearson Chi-square and parameter comparison between 2 groups with the Students’ T-test.

**Result:** Of 92 T2DM patients, 73.91% were diagnosed with NAFLD compromised of women at 57.61% with a mean age of 56.14 years old. Asian cut-off for patients’ BMI was used, with 76.09% overweight. Majority of the patients also have uncontrolled glycemic levels, 60.87%. In the present study, 2 groups, with 2 variables were found to have significant results, including BMI with 26.3294 ± 3.48631, p-value 0.000, AST with 19.6765 ± 9.96935, p-value 0.044 and ALT with 22.2353 ± 14.3112, p-value 0.007. Gender and BMI also significantly correlate with NAFLD, with OR 3.056, 95% CI 1.165-8.016, p-value 0.038 and OR 4.385, 95%CI 1.565-12.284, p-value 0.008, respectively.

**Conclusion:** BMI, AST, ALT, and gender were significant risk factors associated with NAFLD in T2DM patients.

Abstract Submission No. 100304

**P-0320**

**Neck circumference and the risk of MASLD in non-obese individuals with no visceral obesity**

Won Sohn1, Ju-Yeon Cho2, Jung Hee Kim3, Jae Yoon Jeong4, Yong Kyun Cho1, Byung Ik Kim1

1Kangbuk Samsung Hospital Seoul South Korea, 2Chosun University Hospital Gwang-ju South Korea, 3Hallym University Dongtan Sacred Heart Hospital Dongtan South Korea, 4National Medical Center Seoul South Korea

**Background:** It is well-known that high body mass index (BMI) and visceral obesity are the risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). However, it is unclear whether increased neck circumference is associated with MASLD. This study aimed to investigate the impact of neck circumference on MASLD in non-obese individuals with no visceral obesity.

**Methods:** A cross-sectional study was conducted using nationally representative samples from the Korea National Health and Nutrition Examination Survey 2019-2020. ‘Non-obese’ was defined as <25 kg/m². Visceral obesity and increased neck circumference were defined as ≥90 cm (male) / ≥85 cm (female) and ≥39.4 cm (male) / ≥34.1 cm (female), respectively. We performed the univariable and multivariable analyses on the risk of MASLD in non-obese individuals with no visceral obesity.

**Results:** A total of 4065 non-obese adults with no visceral obesity (men, 1521; women, 2544) aged over 40 years were analyzed. The mean levels of neck circumference in men and women were 36.5 cm and 31.9 cm, respectively. The proportion of increased neck circumference in men and women was 4.0 % and 5.9 %, respectively. The proportion of MASLD was 3.5 % (n=144). The prevalence of MASLD in non-obese individuals with no visceral obesity is significantly higher in increased neck circumference than in normal neck circumference (12.5 % vs. 3.1 %, p<0.001). The multivariable analysis showed that the risk of MASLD is associated with age ≥60 years (odds ratio [OR]: 2.81, confidence interval [CI]: 1.91-4.13), dyslipidemia (OR: 2.86, CI: 1.96-4.18), diabetes mellitus (OR: 6.22, CI: 4.25-9.10), and increased neck circumference (OR: 3.03, CI: 1.88-4.88).

**Conclusion:** Increased neck circumference is associated with MASLD and increased neck circumference can be helpful to evaluate the risk of MASLD in non-obese individuals with no visceral obesity.

Abstract Submission No. 100385

**P-0322**

**Characteristics of MASLD compared to NAFLD and MAFLD, and assessment of fibrosis.**

Chikara Iino1, Go Igarashi1, Satoshi sato1, Hirotake Sakuraba1

1Hirosaki University Graduate School of Medicine Gastroenterology and Hematology Hirosaki Japan

**Background:** In 2023, a concept known as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) was introduced at the International Liver Congress of EASL. This concept involves five cardiovascular metabolic risk factors, however its clinical assessment remains undefined. In this study, we conducted a comparison using diagnostic criteria for NAFLD, MAFLD, and MASLD in a general population health examination. Additionally, we assessed liver fibrosis as a risk factor for liver-related mortality.

**Method:** We analyzed data from 950 adults who participated in a general population health examination. Fatty liver and liver fibrosis were

Abstract Submission No. 100325

**P-0321**

**Comparative efficacy of pharmacologic therapies in MASH: Systematic review and meta-analysis**

Douglas Chee1, Jia Hong Koh1, Benjamin Nah1, Margaret Teng1, 3, Cheng Han Ng1, Daniel Huang1, 2, Mark Muthiah4

1Department of Gastroenterology and Hepatology, National University Hospital Singapore Singapore, 2National University Centre for Organ Transplantation, National University Hospital Singapore Singapore, 3Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

**Background:** There is a need to understand the efficacy of different pharmacological agents for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), assessed by a decline in magnetic resonance imaging proton density fat fraction (MRI-PDFF). We conducted a network meta-analysis assessing the relative rank-order impact of different pharmacological interventions on a change in MRI-PDFF.

**Methods:** Medline and EMBASE were searched for randomized controlled trials evaluating pharmacologic therapies in biopsy-proven MASH patients. The primary outcome includes absolute change in MRI-PDFF at week 24 while the secondary outcome was the proportion that achieved MRI-PDFF response (defined as ≥ 30% decline in MRI-PDFF). The analysis was conducted with a Bayesian network model and surface under the cumulative ranking curve (SUCRA) analysis.

**Results:** A total of 14 RCTs with 16 interventions met the eligibility criteria. Aldafermin had the highest probability of being ranked as the most effective intervention for MRI-PDFF decline (SUCRA = 89.59), followed by Peggozafermin (SUCRA = 88.99), and Pioglitazone (SUCRA = 61.41) at week 24. For MRI-PDFF response, Aldafermin (SUCRA = 92.61), Efruxifermin (SUCRA = 81.00) and Resmetrom (SUCRA = 55.54) had the highest probability of being ranked the most effective intervention for achieving MRI-PDFF response at week 12. At week 24, combination of Tropifexor + Cenicriviroc (SUCRA = 72.38), followed by Pegbelfermin (SUCRA = 60.75) and Selonsertib + Simtuzumab (SUCRA = 52.26) was as ranked as the most likely interventions to achieve MRI-PDFF response.

**Conclusion:** These data provide relative rank-order efficacy of various MASH therapies in terms of improvements in MRI-PDFF.
measured using FibroScan, and individuals with a FibroScan-AST (FAST) score of ≥0.35 were categorized as fibrosis-positive.

**Results:** Among the 310 cases of fatty liver, 222 were classified as MASLD, 273 as MAFLD, and 234 as NAFLD. Additionally, there were also 41 cases of Met-ALD, 23 cases of ALD, 4 cases of DILI, 7 cases of Miscellaneous, and 15 cases of Cryptogenic SLD. There were 36 individuals with fibrosis-positive results. A significant correlation was observed between the FAST score for fibrosis diagnosis and the total number of cardiovascular metabolic risk factors (r=0.34, p < 0.05). In the multivariate analysis of cardiovascular metabolic risk factors in liver fibrosis, obesity (OR 6.02, 95% CI 1.8-20.3) and high blood pressure (OR 5.45, 95% CI 1.9-16.0) were identified as independent factors with significant differences.

**Conclusion:** In the new diagnostic criteria of MASLD, obesity and high blood pressure were particularly strongly associated with liver fibrosis.

---

**Abstract Submission No. 100389 P-0323**

**Reassessing CKD Prevalence in MASLD: A Shift from NAFLD to the MASLD Diagnostic Criteria**

**TianYuan Yang1, Qi Wang1,2,3, JingYa Yin1, BingQing Yang1, ChenXue Hou2, Yue Li2**

1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Department of Pathology, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Beijing Key Laboratory of Emerging Infectious Diseases, Institute of infectious diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

**Background:** There is a strong association between NAFLD and chronic kidney disease (CKD). However, knowledge is lacking regarding the prevalence of CKD of MASLD and the influence of cardiometabolic risk factors and advanced fibrosis on CKD prevalence within the MASLD.

**Methods:** The analysis included 6567 participants from NHANES 2017-2020. Steatotic liver disease definitions were based on Fibroscan with controlled attenuation parameters (≥ 248 dB/m), and CKD stages were ascertained using the CKD-EPI equation for estimating glomerular filtration rate.

**Results:** CKD prevalence displayed no significant discrepancies between the MASLD and NAFLD (17.61% vs.18.24%, P = 0.5), maintaining consistency across all CKD stages. Significant differences in CKD prevalence were found when comparing individuals with MASLD to those without MASLD or NAFLD (17.61% vs11.18%, P < 0.001), with the largest gap seen in stage 3 (8.22% vs. 4.36%, P < 0.001). The prevalence of CKD increases when MASLD is concomitant with a higher risk of advanced fibrosis (LSM ≥ 8 kPa) (31.89% vs.15.31%, P < 0.001). When MASLD was combined with cardiovascular metabolic factors such as type 2 diabetes (T2D) (39.46% vs.12.69%, P < 0.001), hypertension (26.42% vs. 13.93%, P < 0.001), and hypertriglyceridemia (22.83% vs.14.93%, P = 0.001), a significant increase in CKD prevalence was noted. In lean MASLD, CKD prevalence differed from that in overweight or obese individuals, but the difference was not statistically significant (17.81% vs.12.06%, P = 0.119).

**Conclusions:** MASLD and NAFLD demonstrate comparable influences in CKD patient identification. The presence of T2D, hypertension, and hypertriglyceridemia increases the prevalence of CKD among individuals with MASLD.

---

**Abstract Submission No. 100394 P-0324**

**Evaluating the Diagnostic Efficacy of Several Non-invasive Models for High-risk MASH in MASLD**

**JingYa Yin1, TianYuan Yang1, BingQing Yang1, ChenXue Hou1, Yue Li2, Qi Wang1,3**

1Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Department of Pathology, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Beijing Key Laboratory of Emerging Infectious Diseases, Institute of infectious diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

**Background:** MASH with a score NAS≥4 and F≥2 is defined as high-risk MASH. The diagnostic efficacy of non-invasive models like FAST, FIB-4, APRI, Forns, ARR, S Index, and GPR for high-risk MASH remains unexplored in the MASLD population.

**Method:** Patients diagnosed with NAFLD via liver biopsy at Beijing Ditan Hospital during 2012.1-2020.12 were retrospectively selected to identify the MASLD population. We assessed the diagnostic efficacy for high-risk MASH through sensitivity, specificity, PPV, NPV, and ROC curves.

**Results:** We identified 309 cases of MASLD, among which 307 were diagnosed with MASLD, with a concordance rate of 99.35%. 279 MASLD patients were enrolled for analysis, with 117 completing liver transient elastography as a subgroup. In the overall population, significant differences (P<0.050) were noted in FIB-4, APRI, Forns, ARR, S Index, and GPR between the high-risk and low-risk MASH groups. FIB-4 exhibited enhanced diagnostic efficacy, AUROC of 0.75 (Figure 1a), S Index and GPR were the weakest. In the subgroup, after incorporating the FAST model, FIB-4, APRI, Forns, ARR and FAST differ between the two groups (P<0.050), whereas S Index and GPR did not show statistical significance (P=0.510, P=0.814). FAST demonstrated the best diagnostic efficacy with higher specificity and PPV, AUROC of 0.82 (Figure 1b), followed by FIB-4.

**Conclusion:** In our study, 99.35% of NAFLD patients met the MASLD diagnostic criteria. FAST emerged as the most effective diagnostic tool for high-risk MASH within the MASLD population, with FIB-4 being a practical choice amid limited resources. However, the S Index and GPR were not suitable for high-risk MASH diagnosis.
Method: A total of 27 consecutive type 2 diabetes patients with MASLD were treated with Luseogliflozin for 24 weeks. We divided into two groups based on age. The first group is over 70 years old with 15 patients, the second group is under 70 years old with 12 patients. We compared laboratory data in two groups, that the change of alanine aminotransferase (ALT) as a liver function and Fibrosis-4 (FIB-4) index as a liver fibrosis in two groups at baseline, 12 weeks and 24 weeks.

Results: All patients were significant decreased in ALT [31.2±18.4 mg/dl at baseline to 23.9±11.6 mg/dl at 12 weeks (p < 0.01)]. Both the elderly and non-elderly groups were also significant decreased in ALT [25.3±10.3 mg/dl at baseline to 21.0±6.4 mg/dl at 12 weeks (p = 0.04), 38.7±23.5 mg/dl at baseline to 27.6±15.6 mg/dl at 12 weeks (p < 0.01), respectively]. No significant change the FIB-4 index was observed period.

Conclusion: Luseogliflozin improved ALT in elderly patients as well as non-elderly patients. Thus, Luseogliflozin may represent a therapeutical choice for elderly type 2 diabetes patients with MASLD.

Abstract Submission No. 100444
P-0326

Alfaamaylase prophylactic,therapeutic potential for nonalcoholic steatohepatitis asymptomatic patient

Sabry Abbas1,2, Ahmes Salah Sief1,2, Abdelghany Aish1,2, Ashraf mabrouk1,2, Mariem Adel8
1MD AGAF Tanta Egypt, 2MD AGAF shibin el kom Egypt

Nonalcoholic liver disease (NAFLO) is the most common worldwide chronic liver disease It include Wide spectrum of hlsto-pathological features ranging from simple steatos1s, steatohepatitis ( ASH) , fibrosis and cirrhosis lasting driving to hepatocellular carcinoma (HCO Due to multifical pathophysiological genetic, dietary, environmental , behavioral and metabolic causes no drug had shown good therapeutic effect amylyase 1s expressed on most body organs It has anti-Inflamatory and anti edematous activity. Multiple clinical studies showed Independent associations of low serum amylyase copy numbers in NAFLD, metabolic syndrome, diabetes and obesity both type and 2

Abstract Submission No. 100577
P-0327

Factors influencing liver fibrosis in NAFLD as assessed by magnetic resonance elastography

Jing Zhang1, Xiaodie Wei1, Shi Qi1
1Capital Medical University Beijing China

Background: Magnetic resonance elastography (MRE) is the most accurate imaging detection for assessing liver fibrosis in nonalcoholic fatty liver disease (NAFLD). However, few studies have investigated the factors influencing liver stiffness measurement (LSM) by MRE. We further investigated the accuracy of MRE in diagnosing liver fibrosis and evaluated the potential clinical factors that may influence LSM.

Methods: This cross-sectional analysis included 124 patients who underwent MRE, MRI-PDFF, and concurrent liver biopsy. The predictive ability of MRE was evaluated by using the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC). Linear regression models, Spearman’s correlation, and subgroup analysis were performed to identify variables affecting LSM.

Results: For the entire cohort, the AUROC (95% CI) of MRE for diagnosing fibrosis stages 1, 2, 3, and 4 was 0.80 (0.70-0.90), 0.76 (0.66-0.85), 0.92 (0.86-0.99), and 0.99 (0.99-1.00). In multivariate analyses, clinical variables that only AST had a significant independent correlation with LSMs (coefficient=0.010, P<0.001). In addition, MRE was significantly associated with the grade of lobular inflammation (r=0.353, p<0.001) and hepatocellular ballooning (r=0.299, p<0.001). Subgroup analysis showed LSMs were higher in patients with AST ≥2 ULN and inflammation ≥2 than in patients with AST <2 ULN and inflammation <2 and was statistically significant in early fibrosis.

Conclusion: MRE has a clinically significant diagnostic accuracy for liver fibrosis in NAFLD patients, especially for advanced fibrosis and cirrhosis. Higher AST levels and severity of liver inflammation may influence LSM measured by MRE in early liver fibrosis.

Abstract Submission No. 100625
P-0328

High frequency of metabolic risk factors for MAFLD in the young and adult populations of Mexico.

Arturo Panduro1,2, Leonardo Leal-Mercao1,2, Sonia Maria Roman-Maldonado1,2, Liliana Campos-Medina1,2, Oscar E. Mejia-Nava4, Carlos R. Amaya-Estrada1,2, Alexis Josè-Abrego5, Saul Laguna-Meraz1,2, Laura E. Ruiz-Arriaga6
1Department of Genomic Medicine in Hepatology, University of Guadalajara Guadalajara Mexico, 2Civil Hospital of Guadalajara, Fray Antonio Alcalde Guadalajara Mexico

Prior research has revealed a high prevalence of metabolic-associated steatohepatitis (MASH) in young Mexican adults. Obesity and metabolic abnormalities are modifiable risk factors when they are detected in a timely manner. This study sought to identify metabolic risk factors (MRF) linked to metabolic-associated fatty liver disease (MAFLD) and liver fibrosis using non-invasive biomarkers in young and adult populations in Mexico.

A cross-sectional study assessing Metabolic Risk Factors (MRF) and non-invasive assessment of the risk of MAFLD: Fatty Liver Index (FLI ≥ 60) and liver fibrosis (APRI ≥ 2.7) were performed in 812 participants (265 students aged 15-25 years and 556 adults aged ≥26 to 61+). A ROC curve analysis was performed to establish the cut-off values for the appearance of MRF adjusted by age and body mass index (BMI).

A high prevalence of overweight and obesity (60.4%) and MRF, including hyperglycaemia (17.6%), hypercholesterolemia (34.9%), hypertriglyceridemia (42.1%), and insulin resistance (30.1%) was detected among the total population. ROC curve analysis determined a cut-off age of 22.5 years and a BMI of 24.3 kg/m² as thresholds for the appearance of MRF. The risk of MAFLD was highly prevalent in the student population (15.7%), with a risk for hepatic fibrosis (0.2%) and cirrhosis (0.8%) based on the FLI and APRI markers, respectively. The study revealed a high prevalence of MRF and early onset of risk of MAFLD among Mexican youth. Future research will be required to explore the genetic susceptibility to obesity, type two diabetes, and MAFLD in the Mexican population and preventive strategies.

Abstract Submission No. 100654
P-0329

The Utility of Non-Invasive Scores of liver Steatosis and Fibrosis in Diabetic NAFLD
Background: Patients with type 2 diabetes mellitus are known to be at increased risk for NAFLD and advanced fibrosis.

Aim: Assessment of the utility of non-invasive scores of liver steatosis and fibrosis in diabetic and non-diabetic patients with non-alcoholic fatty liver disease (NAFLD).

Methods: This case-control study was conducted on 50 diabetic-NAFLD patients (group I), 40 non-diabetic NAFLD (group II) and a third control group. All subjects were subjected to anthropometric measurements, biochemical impedance analysis (BIA), Laboratory tests, along with MRI, and MRE for assessment of liver steatosis and fibrosis.

Results: Female predominance was reported in the three groups (78%, 77.5% & 65%), with mean age of (51.46, 48.40, 49.55) years respectively. Liver steatosis was significantly higher (p=0.007); in diabetic NAFLD (mean 44.78 ± 23.41 kPa) compared to non-diabetic NAFLD (mean 32.15 ± 20.9 kPa), as well as significant liver fibrosis (≥ F2) (mean 2.88 ± 0.81 kPa) compared to non-diabetics (mean 2.46 ± 0.71 kPa) with p value of 0.038. The only non-invasive score of liver steatosis which showed a significant difference (p=0.005) between diabetic (mean 89.89 ± 13.47) and non diabetic (mean 82.98 ± 18.53) NAFLD, was the fatty liver index (FLI). Non invasive scores of liver steatosis (lipid accumulation product, fatty liver index and hepatic steatosis index) were positively correlated with the degree of liver steatosis in diabetic NAFLD (p value of 0.007, <0.001, <0.001, respectively) and non-diabetic NAFLD (p value of 0.007, <0.001, <0.001, respectively). All non invasive scores of liver fibrosis (AST /ALT ratio, NAFLD fibrosis score, FIB 4 and Hepamet fibrosis score) were significantly higher in diabetic NAFLD compared to non-diabetic NAFLD (p=0.009, <0.001, <0.001, <0.001 respectively) with (mean 1.08 ± 0.42 Vs. 0.87 ± 0.21, 1.60 ± 2.94 Vs. 0.53 ± 0.96, 1.21 ± 0.44 Vs. 0.90 ± 0.27, 0.15 ± 0.11 Vs. 0.03 ± 0.03; respectively), while both APRI and kings score had no significant difference between NAFLD subgroups. A positive correlation was found between LSM and FIB-4 score in both NAFLD subgroups (group I and II) with (p value of 0.002 and 0.032, respectively), while APRI was positively correlated with LSM in non-diabetic NAFLD only (p value of 0.030). Sensitivity, specificity, PPV and NPV of FIB-4 score to predict significant liver fibrosis (≥ F2) in group I (diabetic NAFLD), were 82%, 72.33%, 66.7% and 84.6% respectively, at cut off level >1.17, while the values were 50%, 80%, 62.50%, 70.59% and 100%, 0%, 40% using the previously validated cut off levels in viral hepatitis (>1.45) and (>3.25) respectively. Sensitivity, specificity, PPV and NPV of FIB-4 score to predict significant liver fibrosis (≥ F2) in group II (non diabetic NAFLD), were 71.43%, 75.76%, 38.5% and 92.6% respectively, at cut off level >0.96 while the values were 14.29%, 96.97%, 50%, 84.21% and 100%, 0%, 17.5%; using the previously validated cut off levels in viral hepatitis (>1.45) and (>3.25) respectively.

Conclusion: All non invasive scores of liver steatosis performed well in all NAFLD patients whether diabetic or non diabetic. The utility of commonly used non invasive scores of liver fibrosis had a poor performance in NAFLD especially in diabetics, except FIB-4 had an accepted performance in these patients.

PDGFR-β as a Non Invasive Biomarker of Liver Fibrosis in Diabetic NAFLD Patients

Mai Magdy1, Hanaa Badran1, Maha Elsabaawy1, Hazem Omar1, Samar Ghanem2, Mai Abozeid1

1Hepatobiliary and gastroenterology department, National liver institute Menoufia University, ShebeenElkoom Egypt, 2Clinical biochemistry and molecular diagnostics department, National liver institute Menoufia University, ShebeenElkoom Egypt, 3Interventional radiology department, National liver institute Menoufia University, ShebeenElkoom Egypt

Background: Diabetes mellitus is considered one of the most independent predictors of fibrosis progression in patients with NAFLD.

Aim: evaluate the productivity of PDGFRβ (Platelet Derived Growth Factor Receptor-β) as a non-invasive biomarker of liver fibrosis in diabetic-NAFLD patients.

Methods: This case-control study was conducted on 50 diabetic-NAFLD patients (group I), 40 non-diabetic-NAFLD (group II), and a third control group. All subjects were subjected to anthropometric measurements, biochemical impedance analysis (BIA), Laboratory tests including PDGFRβ, along with MRI, and MRE for assessment of liver fibrosis and steatosis.

Results: Female predominance was reported in the three groups (78%, 77.5% & 65%), with mean age of (51.46, 48.40, 49.55) years respectively. Liver steatosis and significant liver fibrosis (≥ F2) were higher in diabetic NAFLD when compared to non-diabetics (p<0.007, 0.021) Liver stiffness measurement (LSM) was significantly correlated with FIB-4 score in diabetics (p<0.002) and non-diabetics (p<0.032). PDGFRβ was significantly correlated with lipid accumulation product (p<0.029), inversely correlated with LDL (p<0.032) in diabetics and with LDL in non-diabetics (p<0.030). Sensitivity, specificity, PPV and NPV of PDGFRβ to predict significant liver fibrosis (≥ F2) in diabetic NAFLD patients were 85%, 93.33%, 89.5% and 90.3%, respectively; at cut off >2.5. While it was 85.71%, 51.52%, 27.3% and 94.4%; at cut off >1.59 in non-diabetics. PDGFRβ was only risk factor for significant liver fibrosis (≥ F2) in both diabetic and non-diabetic patients (p<0.001).

Conclusion: PDGFRβ proved efficacy as a noninvasive biomarker in prediction of significant liver fibrosis (≥ F2) in diabetic NAFLD patients.

Abstract Submission No. 100662
P-0311

Fatigue, depression and sleeping disorders are more prevalent in patient with MAFLD.

Alaa Mostafa1, Yasser Mahmoud Fouad2, Noha M. Abdullah1, Shaimaa Moustafa Hafez4

1Tropical department- Faculty of medicine- Minia University Minia Egypt, 2Tropical department- Faculty of medicine- Minia University Minia Egypt, 3Department of clinical pathology, Faculty of Medicine, Minia University Minia Egypt, 4Department of public health and preventive medicine, Faculty of Medicine, Minia University Minia Egypt

Background: Fatigue among MAFLD patients had a negative impact on their health-related quality of life HRQL, morbidity, and mortality. Aim: to determine the prevalence and risk factors of fatigue, depression, and sleeping disorders among patients with MAFLD.

Methods: Two hundreds twenty four Consecutive patients with MAFLD attending the outpatient clinic at the time period from April to October 2023, were subjected to clinical evaluation, laboratory testing including non invasive laboratory markers, fibroscan (measuring
Comparing MASLD/MetALD to alcoholic liver disease with metabolic dysfunction in cirrhotic patients

Hiroki Tujima¹, Satoru Kakizaki²,³, Atsushi Naganuma¹, Takeshi Ueno¹, Keisuke Iiduka¹, Takeshi Hatanaka¹, Shuichi Saito¹, Toru Fukushi¹, Daichi Takizawa¹, Hirotaka Arai¹, Ken Sato³, Toshio Uraoka¹, Yuichi Yamazaki¹, Takayoshi Suga¹

¹Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine Maebashi Japan, ²Department of Clinical Research, National Hospital Organization Takasaki General Medical Center Takasaki Japan, ³Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center Takasaki Japan, ⁴Department of Internal Medicine, Iesaki Municipal Hospital Iesaki Japan, ⁵Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital Maebashi Japan, ⁶Department of Gastroenterology, National Hospital Organization Shibukawa Medical Center Shibukawa Japan, ⁷Department of Gastroenterology, Public Tomioka General Hospital Tomioka Japan, ⁸Department of Internal Medicine, Kiryu Kosei General Hospital Kiryu Japan, ⁹Department of Gastroenterology, Japanese Red Cross Maebashi Hospital Maebashi Japan, ¹⁰Department of Healthcare Informatics, Takasaki University of Health and Welfare Takasaki Japan

Introduction: In recent years, cirrhosis and hepatocellular carcinoma (HCC) associated with steatotic liver disease (SLD) have increased. In the new SLD classification published in 2023, SLD with metabolic disorders was classified into metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated alcoholic liver disease (MetALD), depending on the amount of alcohol consumed. Alcoholic liver disease (ALD) due to heavy alcohol consumption is also included in steatotic liver disease, and ALD with metabolic dysfunction are limited. Among patients with SLD-related cirrhosis, studies on the differences between MASLD/MetALD and ALD with metabolic dysfunction are limited, so the present study was designed to compare the two groups.

Methods: Of the 1505 cirrhosis cases that visited our hospital and related facilities between July and September 2021, 636 were SLD-related cirrhosis cases. Of these, 505 cases of SLD-related cirrhosis complicated with metabolic disorders were included. Comparison was made between the MASLD/MetALD group and the ALD with metabolic dysfunction group (ALD group).

Results: 225 were in the MASLD/MetALD group and 280 were in the ALD group. The ALD group was younger (69 yrs., 73 yrs., P=0.001), more male (88.9%, 46.7%, P=0.001), had a lower BMI (24.7, 26.5, P=0.001), and had fewer metabolic dysfunction complications. The complication rate of diabetes (35.5%, 56.0%, P=0.001) and dyslipidemia (16.5%, 24.4%, P=0.033) was lower in ALD group, but there was no significant difference in the complication rate of hypertension (46.2%, 52.9%, P=0.152), cardiovascular events (16.1%, 17.3%, P=0.72), and hepatocellular carcinoma (37.6%, 33.8%, P=0.401) between the two groups. Logistic regression analysis was performed to adjust for covariates. As in the univariate analysis, the ALD group had less BMI (OR 0.876, P=0.008), less diabetes (OR 0.344, P=0.001), more male (OR 9.76, P=0.001) and younger age (OR 0.959, P<0.001). Cardiovascular event complication rates and HCC complication rates did not differ between the two groups on multivariate analysis.

Conclusion: ALD with metabolic dysfunction develops cirrhosis at a younger age than MASLD/MetALD, but the complication rate of cardiovascular events and hepatocellular carcinoma is possibly comparable in both groups.
0.855, respectively. The AUCs of MRS for grading ≥S2 and ≥S3 were 0.860 and 0.878, respectively.

Conclusion: MRS and MRS do not always show the same value in the quantification of Hepatic Steatosis. However, MRS and MRI-PDFF can be used as alternative non-invasive reference standards in patients with NAFLD because they have demonstrated strong correlations with each other and with two different histopathological methods.

Abstract Submission No. 100713

Comparative Analysis on Clinicopathological Features of MASLD and MAFLD related HCC

Junke Hu1, Xiangmei Chen1, Liang Zhang1, Wen Xie1, Lei Sun1

1Beijing Ditan Hospital, Capital Medical University Beijing China

Objective: To analyze the differences of clinicopathological characteristics between MASLD and MAFLD related HCC and correlation with metabolic factors.

Methods: Patients with hepatic malignant tumor hospitalized in Beijing Ditan Hospital from January 2010 to December 2019 were enrolled. Staining of liver tissues with HE, special and immunohistochemical stains were performed. The histological features of the tumour and metabolic characteristics of patients were analyzed.

Results: 5958 patients were diagnosed with hepatic malignant tumor including 273 HCC cases with at least one metabolic risk factor, 40 were underwent liver biopsy. Among them, 25 cases met the diagnostic criteria for MASLD and 20 met the criteria for MAFLD. There were no significant differences in pathological features and laboratory indicators. Among the 40 cases, trabecular type was the most prevalent(17,42.5%), followed by steatohepatitis type(10,25%), cirrhotic type(5,12.5%), macrotrabecular type(3,7.5%), solid type(2,5%), pseudoglandular type(2,5%), and clear-cell type(1,2.5%). There were 23 patients(57.5%) without liver cirrhosis. The degree of ballooning of tumor cells (p=0.002), proportion positive of Mallory-Denk body (p=0.004) and glycogenated nuclei (p=0.007), expression of HSP70 (p=0.011), and serum TBil level (p=0.037) in the liver cirrhosis group were notably higher than those in non-cirrhosis group. The level of serum AKP (p=0.044), TCHO (p=0.016), TG (p=0.015), LDL-C (p=0.012), ApoB (p=0.005), WBC (p=0.002) and PLT (p<0.001) were significantly lower than those in non-cirrhosis group.

Conclusion: There was no significant difference in clinicopathological features between MASLD and MAFLD associated HCC. The pathological characteristics of MASLD-associated HCC were correlated with metabolic factors.

Abstract Submission No. 100779

Correlation between skeletal muscle mass index and NAFLD and liver fibrosis in patients with T2D

Xiang Cai1, Yuxi Lin1, Yutian Chong1

1The Third Affiliated Hospital of Sun Yat-sen University GuangZhou China

Objective: To investigate the correlation between muscle mass index and non-alcoholic fatty liver disease (NAFLD) and the degree of liver fibrosis in older patients with type 2 diabetes mellitus (T2DM).

Methods: 1733 patients with T2DM were enrolled and measured the appendicular skeletal muscle mass index (ASMI%), full abdominal color Doppler ultrasound, biochemistry index, etc. were measured. The patients were divided into NAFLD group and non-NAFLD group, and then NAFLD group were divided into significant liver fibrosis and non-significant liver fibrosis group, the correlation between ASMI% and NAFLD and degree of liver fibrosis was analyzed.

Results: With the decrease of ASMI% quartiles, the detection rate of NAFLD and significant liver fibrosis (NFS≥0.676) increased (p<0.001). After adjusting for confounding factors, the decrease in ASMI% was a risk factor for NAFLD and significant liver fibrosis (logistic regression analysis). As the ASMI% decreased in the male group, the risk of NAFLD increased (Q1: OR=2.529, 95%CI 1.639–3.903, p<0.001). In the female group, as the ASMI% decreased, the risk of NAFLD gradually increased (Q1: OR=3.766, 95%CI 2.367–5.992, p<0.001). With the decrease of ASMI%, the risk of significant liver fibrosis in both male and female NAFLD populations increased (p<0.05). Subgroup analysis showed that regardless of obesity, insulin resistance, disease course more than 10 years, and diabetic peripheral neuropathy, the NFS level of sarcopenia patients was significantly higher than that of the non-sarcoidosis group.

Conclusion: Among patients with T2DM, the incidence of NAFLD and significantly liver fibrosis was higher in people with low ASMI%.

Abstract Submission No. 100808

Changes in Prevalence of Steatotic Liver Disease with the New Nomenclature Using MRI-Derived PDFF

Sunyoung Lee1, Hee Jun Park1

1Severance Hospital, Yonsei University College of Medicine Seoul South Korea

Background: International expert panels proposed new nomenclatures, metabolic dysfunction-associated fatty liver disease (MAFLD) in 2020 and metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, along with revised diagnostic criteria to replace non-alcoholic fatty liver disease (NAFLD). We aimed to investigate the changes in the prevalence of NAFLD, MAFLD, and MASLD through health check-ups using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) to assess hepatic steatosis. We also examined the prevalence of the sub-classifications of steatotic liver disease (SLD) and the differences in characteristics among the sub-categories.

Methods: We included 844 participants who underwent liver MRI-PDFF at our health check-up clinic between January 2020 and November 2022. Hepatic steatosis was defined as MRI-PDFF ≥ 5%. Participants were categorized according to NAFLD, MAFLD, MASLD, and sub-classifications of SLD.

Results: The prevalence rates of NAFLD, MAFLD, and MASLD were 25.9%, 29.5%, and 25.2%, respectively. 30.5% of the participants was categorized as SLD. The prevalence rates of the SLD sub-categories were 25.2% for MASLD, 3.7% for MAFLD and alcohol-associated liver disease (MetALD), 0.1% for alcohol-associated liver disease, 1.3% for specific etiology SLD, and 0.1% for cryptogenic SLD. Compared with patients in the MASLD group, those in the MetALD group were younger, predominantly male, and exhibited higher levels of serum aspartate aminotransferase, gamma-glutamyl transpeptidase, and triglycerides.

Conclusion: The prevalences of NAFLD and MASLD assessed using MRI-PDFF were similar, with MASLD accounting for 97.3% of the patients with NAFLD. The separate MetALD sub-category may have clinical characteristics that differ from those of MASLD.
Background and Aims: Agile 3+ is a novel non-invasive test (NIT) for advanced fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), and includes age, AST/ALT, platelets gender, presence of diabetes and liver stiffness measurement (LSM by VCTE). There are few external validation studies. Our aim was to assess the diagnostic performance of Agile 3+ in comparison with other simple NITs for MASLD F3-4.

Methods: This is a retrospective single-center cohort study including adult patients with biopsy-proven MASLD between 2010 – 2021. Other causes of liver disease were excluded. Diagnostic test performance was assessed using validated thresholds for NIT and Agile 3+<0.451 and >0.679 to rule-out and rule-in F3-4 using the area under the receiver operating characteristic (AUROC).

Results: Out our cohort included 76 patients, with mean age 48 ± 13 years, mostly male (56%), diabetes mellitus in 33%, and F3-4 prevalence 60%. Using validated thresholds, the proportion of patients with indeterminate (test range) scores were: Agile 3+ (0.451-0.679) 10.3%, LSM (8-12 kPa) 26%, FIB-4 (1.3-2.67) 32%, NFS (-1.455-0.676) 33%, APRI (0.5-1.5) 42%. For F3-4, all NITs had high specificity (0.89-1.00) but lower sensitivity (0.63-0.82). Corresponding AUROC 0.91 for Agile 3+ was higher than for APRI (0.78, p=0.02) and NFS (0.75, p=0.001), but similar to VCTE (0.93, p=0.31) and FIB-4 (0.87, p=0.31).

Conclusions: In our tertiary center cohort Agile 3+ had a good diagnostic performance for advanced fibrosis, with relatively lower proportion of patients classified in the indeterminate zone at specified thresholds. Further validation of Agile 3+ in lower prevalence cohorts is required.
Efficacy of pemafibrate on diet-resistant metabolic dysfunction-associated steatotic liver disease

Tamai Hideyuki\textsuperscript{1}, Jumpei Okamura\textsuperscript{1}

\textsuperscript{1}Department of Hepatology, Wakayama Rosai Hospital Wakayama Japan

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a lifestyle-related disease, but there are not a few cases who are resistant to dietary therapy. Pemafibrate is a novel lipid-lowering drug that was developed as a selective peroxisome proliferator-activated receptor-\(\alpha\) modulator. The aim of the present study was to clarify the efficacy of pemafibrate on diet-resistant MASLD patients with hyperlipidemia.

Methods: Fifty-seven MASLD patients with persistent liver enzyme elevation and hyperlipidemia despite counseling in moderate-carbohydrate restriction (150–200g/day) for more than one year, who received pemafibrate (0.2 mg/day) for 6 months, were analyzed.

Results: There were 29 males and 28 females, median age was 61 years (range 17-71 years), and median body mass index was 25.8 (18.4-41.0). Triglyceride, low-density lipoprotein cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and \(\gamma\)-glutamyl transferase (\(\gamma\)-GT) significantly decreased after 6 months (\(p<0.001\)), despite body weight, percent body fat, visceral fat area, and percent liver fat did not decrease significantly, and Liver/Spleen ratio significantly decreased (\(p=0.006\)). Although no significant decrease was seen in hemoglobin A1c, homeostatic model assessment for insulin resistance significantly decreased (\(p=0.002\)). Although shear wave velocity did not decrease significantly, Mac-2 binding protein glycosylation isomer showed a significant decrease (\(p=0.001\)). The normalization rates of all liver enzymes, AST, ALT, ALP, and \(\gamma\)-GT were 18\% (10/57), 29\% (11/38), 42\% (22/53), 75\% (3/4), and 62\% (18/29), respectively.

Conclusions: Pemafibrate for diet-resistant MAFLD patients is effective regardless body weight loss.

Assessing carotid atherosclerosis risk in metabolic dysfunction-associated steatotic liver disease

Hana Park\textsuperscript{1}, Hye Won Park\textsuperscript{1}, Ju Hyun Shim\textsuperscript{1}, Ji Young Lee\textsuperscript{1}, Sungwon Park\textsuperscript{2}, Hye Jeong Lee\textsuperscript{1}, Jaiel Kim\textsuperscript{1}, Hye-Sook Chang\textsuperscript{1}, Jaewon Choe\textsuperscript{2}

\textsuperscript{1}Division of Gastroenterology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, \textsuperscript{2}Division of Radiology, Health Screening and Promotion Center, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a new term for fatty liver disease and has been recently proposed to replace nonalcoholic fatty liver disease (NAFLD). We analyzed whether the risk of carotid atherosclerosis differed between MASLD and NAFLD status in a large group of asymptomatic adults.

Methods: We performed a cross-sectional study with subjects who underwent health checkup between 2015 and 2020. Hepatic steatosis was diagnosed using transient elastography and fibrosis-4 (FIB-4) index. Subclinical carotid atherosclerosis (SCA) was assessed based on intima-media thickness or plaques on carotid ultrasound.

Results: 65,138 participants were analyzed, including 21,386 MASLD and 15,186 NAFLD. Eighty-seven subjects with NAFLD did not meet the MASLD criteria. Of the total, 9,145 (14.0\%) was diagnosed as having SCA. MASLD was significantly associated with SCA with an adjusted odds ratio (aOR) of 1.27 (95\% confidence interval [CI], 1.21-1.33), which was similar to NAFLD (1.26 [1.19-1.33]). However, the association lost significance in NAFLD after adjustment of metabolic factors. The association of MASLD with SCA increased with the severity of liver fibrosis, with cases with high FIB-4 levels (\(\geq 1.3\)) having an aOR for SCA of 2.14 (95\% CI, 2.02-2.27) compared to those without MAFLD, as observed in NAFLD (1.69 [1.56-1.82]). This trend was confirmed using liver stiffness data by a cut-off of 6.5 kPa in both settings.

Conclusions: MASLD newly defined was strongly associated with SCA, especially when accompanied by liver fibrosis. MASLD may predict SCA better than conventional NAFLD.
Abstract Submission No. 100952
P-0343

Marked hepatitis despite minimal steatosis defines genetically-predisposed, hyper-inflammatory NAFLD

Daniel Tung1, Benjamin Koh2, Christen Ong1, Gwyneth Soon1, Aileen Wee2, Shruiti Khare3, Niranjan Shrigaonkar3, Victor k Lee2, Pierre-alexis Goy2, Huck hui Ng0, Ramanuj Dasgupta3, Mark Muthiah1, Nicholas Syn1, Cheng han Ng1, Daniel q Huang1

1National University Hospital Singapore Singapore Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 3Agency for Science, Technology and Research Singapore Singapore

Background: NAFLD patients with severe macrosteatosis yet minimal lobular inflammation, hepatocyte degeneration, and fibrosis—and the extreme opposite of the spectrum ie. minimal hepatic fat but marked inflammation and hepatocyte ballooning—represent clinicopathological enigmas. We hypothesized that such “paradoxical” histologic presentations may be driven by inter-individual genetic differences, which could hold clues to new therapeutic targets.

Methods: We analyzed participants who had biopsy for suspected NASH. Histology was graded using CRN NAS. GWAS was analyzed using an IPW methodology to identify variants associated with “paradoxical” histologies. Associations were adjusted for demographics, comorbidities (HLD/HTN/T2DM), medications (including metformin/sulfonylurea/insulin/statins/ACEi/ARB/VitaminE), smoking, caffeine, alcohol consumption, ethnicity and genomic PCs.

Results: n=232 patients were analyzed at time of reporting (M:F=110:122, Chinese/Malay/Indian/Others: 54.4%/27.0%/14.1%/4.4%, BMI median [IQR]32.2[27.2- 38.8]). We identified multiple loci enriched in immune cell-trafficking and innate response (FCGBP [IgG-Fc-mediated immunorecognition], HRG [macrophage activation], LAX1 [B- & T-lymphocyte activation, RAB7B [dendritic cell migration], ARPIN [phagosome formation]); in addition, a variant (rs766125) in the well-known macrophage trafficking loci CX3CR1 exhibited a pre-adjustment association (β=−0.691, p=9.17×10−11) which was lost after adjustment. We also identified a locus likely implicating sinusoidal endothelial cell dysfunction (APOL3), two redox/antioxidant loci (GSTA1, AKR1B10), and four collagen deposition /ECM remodeling loci (FBN1, FGF14, CTHRC1, LAMC3) associated with severe hepatocyte injury/inflammation despite minimal steatosis.

Conclusions: DNA variants in chemotaxis/immune response, LSEC dysfunction, antioxidatant/detoxification, and ECM deposition/remodeling pathways modulate the severity of hepatitis and hepatocyte ballooning inNAFLD. GWAS of additional n=227 patients (total:n=459) patients is underway, and complete results including fine-mapping will be presented at the meeting.

Abstract Submission No. 101028
P-0344

Fib-4 and Fatty Liver Indices in Low- and High-Risk Prediabetes by Anthropometric Categorization

Sinan Akarca1, Niüfer Özdemir1, Zeliha Hekimsoy1

1Manisa Celal Bayar University, Medical Faculty, Department of Internal Medicine Manisa Turkey

Prediabetes, characterized by elevated blood glucose levels not meeting diabetes criteria, requires monitoring to prevent diabetes and its complications. This population is diverse, with individuals categorized as low or high-risk for cardiovascular issues based on anthropometric indices.

Objective: We aimed to explore if low-risk and high-risk prediabetes patients, as defined by anthropometric indices, also differ in fatty liver index (FLI) and Fib4 scores.

Methods: Our study encompassed various prediabetes subgroups as shown below, totaling 657 patients, analyzed via waist to hip ratio (WHR), body mass index (BMI), visceral adiposity index (VAI), lipid accumulation products (LAP), body shape index (BSI), body roundness index (BRI), concicity index (CI) values. The isolated impaired fasting glucose (IFG) and isolated elevated HbA1c (HbA1c) groups, showcasing consistently lower anthropometric scores, were deemed low-risk, while other subgroups (impaired glucose tolerance (IGT), IFG+IGT, IFG+HbA1c, IGT+HbA1c, IFG+IGT+HbA1c) were labeled high-risk. Beyond numerous parameters, we calculated and tested differences in Fib4 and FLI values between these groups, employing the C statistic for discriminative cut-off values identification.

Results: Fib4 median values were 0.762 (95%CI: 0.683-0.789) and 0.886 (95%CI: 0.826-0.961), FLI were 55.77 (95%CI: 48.79-61.99) and 72.89 (95%CI: 67.12-76.02) in low- and high-risk prediabetes (p<0.001) respectively. Fib4 cut-off was >0.9425 (sensitivity 46.4%, specificity 71.8%; AUC: 0.601; p<0.0001), FLI cut-off was 70.20 (sensitivity 53.5%, specificity 67.5%; AUC: 0.622; p<0.0001).

Conclusions: Significant differences in FLI and Fib4 values exist between low- and high-risk prediabetes, although their discriminative power is limited. High-risk individuals, according to anthropometric indices, warrant closer monitoring for liver complications.

Abstract Submission No. 101038
P-0345

Triglyceride Level and Liver Disease Evaluated by Liver Stiffness and Attenuation Parameter

Mai Totsuka1, Ryota Masuzaki1, Naoki Matsumoto1, Masayuki Honda1, Shuhei Arima1, Hiroaki Yamagami1, Masahiro Ogawa1, Tatsuo Kanda1, Hirofumi Kogure1

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine Tokyo Japan

Background and aims: Recently, metabolic dysfunction-associated steatotic liver disease (MASLD) has been proposed as a new concept focusing on concomitant metabolic dysfunction such as diabetes mellitus, hypertension, and dyslipidemia. In the current study, we aimed to study the relationship between liver disease and triglyceride level, focusing on liver stiffness and steatosis evaluated by transient elastography.

Material and Methods: Between January 2022 and December 2022, a total of 2161 patients with successful measurement of liver stiffness and controlled attenuation parameter (CAP) were included. Liver stiffness and CAP were measured by Fibroscan (Echosens, Paris).

Results: The mean age was 60.6±14.8, with 1109 males and 1052 females. The median values (25th-75th percentiles) of triglyceride, liver stiffness, and CAP were 103 mg/dL (73-151), 5.1 kPa (3.9-7.2), and 252 dB/m (208-297), respectively. A total of 553 patients had triglyceride levels greater than 150 mg/dL. ALT>30 was more common in patients with hypertriglyceremia than those without (P<0.001).

Conclusions: Hypertriglyceremia is an important parameter in the management of steatotic liver disease. The clinical outcomes after the proper medical intervention should be investigated in future studies.
Evaluation of characteristics in NAFLD with and without diabetes: A meta-analysis of the placebo arms

Han Ah Lee1, Hwi Young Kim1
1Ewha Womans University Seoul South Korea

Background & Aims: The natural course of NAFLD is incompletely understood. We explored the changes in the severity of NAFLD over time by analyzing data from the placebo arms of randomized controlled trials (RCTs), particularly in relation to the presence of diabetes.

Methods: RCTs of NAFLD that included a placebo treatment arm was identified through systematic search. Primary outcomes were the change in hepatic steatosis and fibrosis. Pooled proportion and mean differences were assessed using generalized linear mix model.

Results: The meta-analysis incorporated 8 RCTs involving 386 patients without diabetes and 24 RCTs involving 637 patients with diabetes, respectively. The median intervention period was 24.0 weeks. The pooled estimate of mean change in steatosis grade by histology was -0.1 (95% CI -0.29 to 0.10) in patients without diabetes, and -0.37 (95% CI -0.52 to 0.23) in patients with diabetes (P=0.066). The mean change in fibrosis stage by histology was 0.05 (95% CI -0.08 to 0.18) in patients without diabetes, and -0.03 (95% CI -0.16 to 0.10) in patients with diabetes (P=0.359). The mean change in NAFLD activity score was -0.55 (95% CI -0.76 to -0.33) in patients without diabetes, and -1.50 (95% CI -2.14 to -0.87) in patients with diabetes. However, the mean change in ALT (20.22 IU/L, 95% CI -26.42 to -14.03 vs. -4.48 IU/L, 95% CI -8.54 to -0.42) and AST (-10.67, 95% CI -14.86 to -6.49 vs. -2.58, 95% CI -5.02 to -0.14) were significantly larger in patients without diabetes compared to those with diabetes (P <0.05).

Conclusion: In the placebo arm, patients with diabetes had a greater improvement in hepatic steatosis than patients without diabetes. The histologic response in patients received placebo treatment according to the diabetes is beneficial in design of further NAFLD trials.

Abnormalities of male sex hormones in patients with MASLD and advanced fibrosis

Adela TURCANU1, 2, Ecaterina Cebanu1, Veronica Cumpata1, 2, Ana Mocanu2, Lucia Mazur-Nicorici1
1The State University of Medicine and Pharmacy N.Testemitanu Chişinău Moldova, 2The Clinic of Gastroenterology and Hepatology Chisinau Moldova

Background: The liver and the reproductive system are bidirectionally linked.

Methods: A cross-sectional study was conducted in 82 men with NAFLD. Fibrosis assessment was performed using Fibroscan. Ordinal logistic regression was used to measure the association of total testosterone and NAFLD progression category.

Results: We found that the associations between the T level and the degree of fibrosis of NAFLD were significant in men aged ≥55.8 years (p<0.05), with waist circumference ≥101.5 cm (p <0.001), with dyslipidemia (p <0.01) and smoking (p<0.05). Patients with low T level have higher degree of fibrosis (p =0.05). A significant direct correlation is identified between F3-4 and TT (p =0.001).

Conclusions: Abnormal testosterone levels correlate with the degree of liver fibrosis, a direction that could be considered in the management of NAFLD.
compared to 2.3% for those ≤0.103. The validation cohort confirmed the index’s predictive reliability (p=0.09).

Conclusions: A prognostic index comprising baseline albumin, GGT, and platelet count accurately predicts 10-year mortality and transplantation need in MAFLD patients. This tool can facilitate early identification and enhanced management of patients with aggressive disease trajectories, potentially improving clinical outcomes.

Abstract Submission No. 101193
P-0351
Liver stiffness is associated with liver related morbidity but not cardiovascular events in MAFLD.

Mark Ghali1,2, Nishita Muchhala1, Karanjot Mander1, Mohammad Mubashir1, Golo Ahlenstiel1, Raymond Kwok4,2
1Blacktown Mount Druitt Hospital Sydney Australia, 2Western Sydney University Sydney Australia

Background: Liver stiffness (LSM), has been demonstrated to predict liver related morbidity (LRM), as well as cardiovascular morbidity in those with diabetes. Our study sought to determine whether elevated LSM predicts cardiovascular events and all cause mortality in all those with MAFLD at an Australian university teaching hospital.

Methods: Patients with MAFLD and received a Fibroscan prior to July 2019 were included in the study. Records up to October 2023 were reviewed. LRM, major adverse cardiovascular events (MACE) or all cause mortality (ACM) were identified.

Results: The analysis included 248 patients (female 154/248, mean age 52.4 yrs SD 13.8). There were 7, 18 and 5 patients with LRM, MACE and ACM respectively. The AUROC was found to be significant for LSM predicting LRM (AUC = 0.795, p=0.008, 95% CI 0.569-1.00) but not for MACE (AUC = 0.508, p=0.908, 95% CI 0.365-0.651) or ACM (AUC = 0.631, p=0.317 95% CI 0.305-0.957). The optimal LSM cut-off for predicting LRM was found to be > 15.6 kPa. Cox regression analysis revealed there was a significant increase in LRM for LSM > 15.6 kPa (HR 16.95, p=0.01), but not for MACE (HR 1.99, p=0.258) or ACM (HR 2.2, p=0.494).

Conclusions: Our study indicates that LSM correlates with LRM but not MACE or ACM. Limitations include small study size and relative short follow-up period. Further longitudinal data will be useful in confirming these findings.

Abstract Submission No. 101266
P-0352
Study of the Relationship between Vitamin D Levels in Patients with NAFLD

Kamila Zhumagaliyeva1, Aikerim Sakttagan2, Ekaterina Shumareva3, Alexander Nersesov4,5
1Asfendiyarov Kazakh National Medical University Almaty Kazakhstan, 2Asfendiyarov Kazakh National Medical University Almaty Kazakhstan, 3Private Medical Clinic Almaty Kazakhstan, 4Asfendiyarov Kazakh National Medical University Almaty Kazakhstan, 5Institute of Gastroenterology, Hepatology, and Metabolism Almaty Kazakhstan

Non-alcoholic fatty liver disease (NAFLD), over the past few years, has become the most common chronic liver disease, increasingly diagnosed in younger and older individuals.

We aimed to explore the potential link of serum vitamin D concentration with NAFLD and indicators characterizing activity, fibrosis, as well as lipid and carbohydrate metabolism. A total of 128 participants were identified, 27.3 % (n=35) with insufficiency of serum 25-OH-D - on average by 20.08 (95% CI: 17.12; 23.18) ng/ml. In 61% of patients, vitamin D levels normalized, with a reduction in deficiency to 15% and insufficiency to 24%.

The intake of vitamin D positively influenced weight reduction, on average by 2 kg (p < 2.236e-13), BMI by 0.96 (p < 2.959e-13), and a decrease in waist circumference by 4.25 cm (p < 5.786e-13). A statistically significant decrease was observed in the concentration of triglycerides by 0.25 mmol/L (p < 0.001), glucose by 0.31 mmol/L, and AST (Aspartate Aminotransferase) by 0.78 U/L.

Our cross-sectional study provides evidence that there is a significant correlation between serum vitamin D concentration and NAFLD patients. A minor positive correlation has been observed between vitamin D and FIB-4 (Fibrosis-4) scores and moderate negative correlation with FLI (Fatty Liver Index) scores.

Abstract Submission No. 101289
P-0353
Association of PNPLA3, TM6SF2 and HSD17B13 variants with NAFLD risk in HIV and non-HIV individuals

Pisit Tangkijvanich1, Varis Ruamviboonsuk1, Kamonchanok Moonlisarn1, Natthaya Chuaypen1
1Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Background: Non-alcoholic fatty liver disease (NAFLD) has multiple risk factors, including genetic factors. People living with human immunodeficiency virus (PLWH) have a higher prevalence of NAFLD compared to those without human immunodeficiency virus (HIV) infection. However, the genetic factors in PLWH with NAFLD are unclear.

Objective: This study aimed to investigate whether PNPLA3, TM6SF2 and HSD17B13 variants with NAFLD risk in HIV and non-HIV individuals

Abstract Submission No. 101312
P-0354
PNPLA3 rs738409, TM6SF2 rs5854296, and HSD17B13 rs6834314 were associated with the risk of NAFLD and whether PLWH with NAFLD had similar genetic risk factors as those without HIV.

Methods: These single nucleotide polymorphisms (SNPs) were determined by TaqMan allelic discrimination in blood samples of 142 healthy controls, 136 NAFLD patients, and 253 PLWH with NAFLD.

Results: The genotype distributions of PNPLA3 (CC vs GG genotypes) were significantly different among the studied groups (P < 0.05), while no significant differences were found for the TM6SF2 and HSD17B13 genotypes. The NAFLD group showed a higher frequency of PNPLA3 GG genotype compared to healthy controls (OR 3.8; 95% CI 1.7 - 8.3). Compared to the PLWH with NAFLD group, the NAFLD group had higher frequencies of CG and GG genotypes of PNPLA3 and a lower frequency of GG genotype of HSD17B13. The multivariate analysis revealed factors significantly different between the two groups, including age, controlled attenuated parameter, body mass index, alanine aminotransferase, high-density lipoprotein, gender, PNPLA3 GG genotype, and HSD17B13 GG genotype.

Conclusion: PNPLA3 was associated with NAFLD development while other SNPs were not associated with NAFLD. The genotypes for PLWH with NAFLD were not significantly different from healthy controls.

Abstract Submission No. 101312
Prognosis of patients with biopsy-confirmed MASLD - A multicenter study

Hideki Fujii¹, Miwa Kanawaka², Yoshio Sumida³, Hirokazu Takahashi⁴, Yoshito Kamada⁵
¹Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, ²Department of General Internal Medicine2, Kawasaki Medical Center, Kawasaki Medical School Okayama Japan, ³Graduate School of Healthcare Management, International University of Healthcare and Welfare Tokyo Japan, ⁴Liver Center,Saga University Hospital Saga Japan, ⁵Department of Advanced Metabolic Hepatology, Osaka University, Graduate School of Medicine Osaka Japan

Background: AASLD, EASL, and others recently proposed the concept of Steatotic Liver Disease (SLD). We aimed to clarify the prognosis of biopsy-confirmed MASLD.

Methods: We included 1,398 patients with NAFLD who underwent liver biopsy and were centrally pathologically diagnosed. Various clinical and pathological parameters were compared between MASLD and non-MASLD NAFLD patients who did not have any cardiometabolic criteria (CC). 5-, 10-, and 15-year rates of all-cause mortality and liver-related events were calculated.

Results: MASLD was applicable to 1,381 (98.8%) with NAFLD. MASLD vs. non-MASLD NAFLD (n=17): age: (mean) 54.6 vs. 45.6 years (P=0.009), BMI: 28.0 vs. 20.9 kg/m² (P<0.001), diabetes: 36.7% vs. 0% (P<0.001), TG: 159 vs. 107 mg/dL (P=0.029), HDL-C: 49.6 vs. 59.9 mg/dL (P<0.001) and fasting blood glucose: 114 vs. 86.6 mg/dL (P=0.002). Histopathological findings of inflammation, ballooning, fibrosis progression, and percentage of MASH were all significantly higher in MASLD. With a median (range) of 4.6 (0.3-21.6) years of follow up, the prognosis of MASLD was totally good: 47 patients died during the observation period, and one patient underwent orthotopic liver transplantation. The 5-, 10-, and 15-year overall mortality rates for MASLD were 1.9%, 4.9%, and 9.2%, respectively. The incidence rates of liver-related events at 5, 10, and 15 years were 3.3%, 7.2%, and 9.0%, respectively. In contrast, none of the Non-MASLD NAFLD patients died, had liver-related events during observation.

Conclusion: The prognosis of MASLD was similar to that of NAFLD. Non MASLD NAFLD was considered to be a mild disease with a good prognosis.

Abstract Submission No. 101379

P-0354

Effect of ezetimibe on nonalcoholic fatty liver disease: A meta-analysis and systematic review.

Joseph Paulo A. Gonzales¹, Michael Imran I. Rodriguez², Marc Evans M. Abat³, Eric B. Yasay⁴
¹Philippine General Hospital Manila City Philippines

Background and Objectives: Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of liver cirrhosis. Currently, there are no drugs has been tested for phase III clinical trials or approved by regulatory agencies for the management of NAFLD. Ezetimibe can potentially treat NAFLD by inhibiting lipogenesis, decreasing hepatic free fatty acids, improving insulin sensitivity, and decreasing hepatic inflammation and fibrosis. This study aims to assess the effect of ezetimibe in reducing hepatic fibrosis in patients with NAFLD, including changes in liver imaging, histology, biochemical parameters, insulin resistance, and incidence of liver-related complications.

Methodology: We performed a computerized literature search of PubMed, Cochrane Central Register of Controlled Trials, Science Citation Index Expanded, and Cumulative Index to Nursing and Allied Health Literature, and ClinicalTrials.gov from inception to October 2023. We included meta-analyses, systematic reviews, and randomized controlled trials. Studies with data that met the inclusion criteria were selected. Two authors independently assessed risks for biases and disagreements were resolved by consensus.

Results: This study included five trials involving 243 patients. Three trials compared ezetimibe to placebo, one trial compared ezetimibe and rosuvastatin combination to rosvastatin monotherapy, and one trial compared ezetimibe to acarbose. Data synthesis showed no significant difference in ezetimibe compared to controls in improving liver fibrosis, liver biochemical parameters, and insulin resistance.

Conclusion: Ezetimibe is not recommended for the treatment of NAFLD due to the lack of evidence of benefit in hepatic fibrosis. Further randomized controlled trials with larger sample sizes and extended observation time is necessary.

Abstract Submission No. 101406

P-0356

Lipid-metabolic induction pro-inflammatory extracellular vesicle in the progression of MAFLD

Tzu-Ching Kao¹, Sin-Tian Wang1, Yi-Wen Chiu1, Hsuan-Ya Liao1, Ching-yu Chang1, Wei-Lun Huang1,², Pin-Nan Cheng1, Chi-Yi Chen1, Kung-Chia Young¹
¹Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University Tainan Taiwan, ²Center of Applied Nanomedicine, National Cheng Kung University Tainan, Taiwan

Background: Extracellular vesicles (EVs) consisting of DNA, RNA, proteins, and lipids to communicate with neighboring cells are crucial in both physiological and pathological regulations. The lipid-metabolism dysfunction of hepatocytes might affect production, releasing, size distribution and cargo contents of EVs, however, it remains unclear the characteristic of hepatocyte-secreting EVs in the progression of metabolic-associated fatty liver disease (MAFLD).

Method: First, lipid-metabolism dysfunction was induced with two mechanisms in cultivated primary human hepatocytes (PHH), including fatty acid overloads by oleic acid (OA) and impairment of cholesterol-to-cholesterol ester (CE) by TMP-153, an inhibitor of sterol O-acyltransferase. Next, the hepatic steatosis, cellular senescence and EVs secretion were investigated, including by lipid profiling, filipin and SÀβG staining, senescent biomarkers, and nanoparticle tracking analysis. Then, the contents of isolated EVs were examined in the conditional medium and the serum sample of MAFLD patients.

Result: Hepatosteatosis with prominent triglyceride accumulation was induced in PHH with both groups, with additional CE deposit with OA treatment but without that with TMP-153. The OA-treated PHH secreted smaller size of EVs (≤200 nm), whereas with TMP-153 treatment, the cells exhibited significantly senescent phenotypes and secreting EV in a broad range (0–1000 nm). Furthermore, the cargos in the isolated EVs induced by TMP-153 contained substantially elevation of pro-inflammatory factors at protein and mRNA levels. Finally, the EVs were validated in the serum samples from MAFLD patients stratified by age groups.
Abstract Submission No. 101414
P-0357

Effects of Body Adipose Composition on Liver Histology of MASLD/MAFLD in an Asian Population

Zixuan Zhang1, Jazellee Leo1, Anna Xin Yi Ng1, Nur Halisah B Jumati1, Rachel Johnson1, Asim Shabbir1, 2, Gwyneth ST Soon3, Eunice XX Tan1, 4, Jonathan WJ Lee4, Mark D Muthiah4, Yock Young Dan5

1Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Department of Surgery, National University Hospital Singapore Singapore, 3Department of Pathology, National University Hospital Singapore Singapore, 4Division of Gastroenterology & Hepatology, Department of Medicine, National University Hospital Singapore Singapore.

Obesity is closely related to MASLD/MAFLD, but the relationship of the different adipose components to the severity of the disease is not well understood. The magnetic resonance-based AMRA® body composition measurements were performed in 101 biopsy-proven patients with MAFLD, investigating the correlation of total adipose tissue (TAT), total abdominal adipose tissue (TAAT), abdominal subcutaneous adipose tissue (ASAT) and visceral adipose tissue (VAT) with liver histology. The NASH CRN score was used to divide histological stages. MAFLD patients are older (45.1±12.9 vs. 39.8±11.7) and have higher BMI compared to normal controls (33.8±6.8 vs. 27.1±7.1, p-val<0.05). On analyzing the subcomponents of AT, the subcutaneous AT was not correlated with HOMA-IR or NASH-CRN components. The VAT index was significantly correlated with all NASH-CRN components (all p-val<0.05), while the VAT volume was significantly related to steatosis, ballooning, and fibrosis (all p-val<0.05) but not lobular inflammation. Additionally, the HOMA-IR was positively correlated to VAT index (r=0.31, p-val<0.05) and VAT volume (r=0.36, p-val<0.05), while the serum triglyceride (TG) level showed a negative relationship (VAT index: r=-0.34, p-val<0.05) and VAT volume: r=-0.39, p-val<0.05). However, the HOMA-IR in the status of lobular inflammation was only found to correlate to VAT index at mild level and VAT volume at moderate (r=0.33 and 0.73, respectively; both p-values <0.05). The visceral adipose tissue index best correlates with the severity and different components of NASH CRN in Asian patients.

Abstract Submission No. 101433
P-0358

Cryptogenic fibrosis represents genetically-distinct entity in MAFLD spectrum similar to IPF

Shyana Zhuoying Gunalan1, Elina En Li Cho2, Cheng Han Ng1, 3, Mark Muthiah1, 4, 3, Benjamin Nah1, Douglas Chee1, Jia Hong Koh1, Margaret Teng1, 2, Gwyneth Soon1, Aileen Wee1, Zhen Yu Wong1, Wen Hui Lim1, Darren Jun Hao Tan1, Shruti Khare1, Nicholas Syn1

1Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 2Lee Kong Chian School of Medicine, Nanyang Technological University Singapore Singapore, 3Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore Singapore, 4National University Centre for Organ Transplantation, National University Health System Singapore Singapore, 5Centre of Excellence for Soldier Performance, Singapore Armed Forces Singapore Singapore, 6Department of Pathology, National University Hospital Singapore Singapore, 7Nottingham City Hospital, Nottingham University Hospitals NHS Trust Nottingham United Kingdom, 8Bioinformatics Institute, A*STAR, Agency for Science, Technology and Research Singapore Singapore, 9Department of Biomedical Informatics, Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore.

Cryptogenic fibrosis represents a genetically-unique entity within MAFLD, with similar genetic architecture to IPF. We found deleterious alleles involving NAMPT, APOLD1, NNMT, MTCL1, ERN1, PTTG1IP, FLVCR1-DT which were prevalent among patients who developed perplexingly-severe (ie. “cryptogenic”) fibrosis despite quiescent NAS scores. Interestingly, except for PTTG1IP and FLVCR1-DT, these loci have been previously implicated in idiopathic pulmonary fibrosis (IPF). One exception, PTTG1IP, has not been linked to fibrotic disorders, but encodes the interaction-partner of PTTG1, which in turn has been strongly-implicated in hepatic fibrosis and portal hypertension; therefore, the association of PTTG1IP SNPs with cryptogenic fibrosis could be mediated through its interaction with PTTG1.

Conclusions: Cryptogenic fibrosis represents a genetically-unique entity within MAFLD, with similar genetic architecture to IPF. It is interesting to speculate whether this subgroup may benefit from anti-fibrotic therapies used to treat IPF in view of possible shared biology. GWAS of additional n=227 patients (total: n=459) is underway, and complete results will be presented at the meeting.

Abstract Submission No. 101461
P-0359

Patient awareness of Steatotic liver: Multicenter study

zekiye harput1, Selcan Cesur2, Sezen Ulucan2, 3, Hasan Eruzun4, Yasemin Güden5, Neslihan Güney6, Dilara Göke6, Murat K Arslan7, 8, Meral Kayhan7, Müjde Soyturk8, Kendal Yal9, 77, 777, Orhan Sezgin1

1Mersin University, Department of Gastroenterology mersin Turkey, 2Uludag University, Department of Gastroenterology Bursa Turkey, 3Istanbul University, Department of Gastroenterology Istanbul Turkey, 4Ondokuz May But University, Department of Gastroenterology Samsun Turkey, 5Cemal Tascoglu City Hospital, Department of Gastroenterology Istanbul Turkey, 6Akdeniz University, Department of Gastroenterology Antalya Turkey, 7Ankara Bilkent City Hospital, Department of Gastroenterology Ankara.
Abstract Submission No. 101467

Background: Patients with steatotic liver (SL) who attend outpatient gastroenterology clinics were the subjects of this study, which sought to assess their awareness and knowledge levels.

Methods: The study included patients aged 18 and above seeking care at gastroenterology outpatient clinics for any reason. Following obtaining consent, participants underwent face-to-face interviews using a structured questionnaire. Questions about hepatic steatosis awareness, understanding of associated diseases and problems, treatment familiarity, preventive strategies, and information sources were all included in the survey.

Results: A total of 1431 patients from nine different centers participated, with 48.5% being male (n: 694) and a mean age of 47.8±15.8 years. Notably, 64.5% were classified as overweight or obese. Surprisingly, 10.9% (n: 156) of patients had never heard of SL. Of those informed, 55.2% (n: 699) received information from healthcare professionals. The majority (85.4%) recognized SL as a serious concern, with obesity (83%) being most commonly associated, while diabetes mellitus (23%) was least associated. Concerningly, 74.6% believed SL could progress to cirrhosis, and 57.3% thought it could lead to liver cancer. While 56.3% considered imaging as the best diagnostic tool, 72.3% emphasized weight loss in treatment, and 31.8% mentioned herbal remedies.

Conclusions: This study underscores the crucial need to educate the public about SL, a leading cause of liver cirrhosis and hepatocellular cancer, which is increasingly prevalent. Efforts should focus on preventive measures through informed public awareness, emphasizing the significance of proper planning and treatment management to curb the progression of this debilitating disease.

Abstract Submission No. 101569

P-0361

Low Diagnostic Performance of FIB-4 in Type 2 Diabetes: Impact of Age

DAE WON JUN1, Eileen Yoon1, Huiyul Park1, Joo Hyun Oh2, Sang Bong Ahb

1Hanyang University Seoul South Korea, 2Eulji University Seoul South Korea

Objectives: The diagnostic performance of fibrosis-4 (FIB-4) in type 2 diabetes mellitus (T2DM) is known to be compromised by spectrum bias. We aimed to investigate the causes of spectrum bias and to determine the most effective approach for implementing FIB-4 in patients with T2DM.

Research Design and Methods: A retrospective biopsy cohort of 1,906 patients with biopsy-proven metabolic associated fatty liver disease (MAFLD) from South Korea, Japan, and Taiwan. Diagnostic performance according to T2DM was again compared after propensity score matching on age, sex, and body mass index (BMI).

Results: The prevalence of advanced fibrosis and cirrhosis was higher in T2DM compared to non-T2DM (26.0% vs 12.2%, p<0.001). Patients with T2DM were significantly older than those without (54.9 ± 11.5 vs. 48.9 ± 12.1 years, p<0.001). The area under the receiver operating characteristic curve (AUROC) in non-T2DM patients was significantly higher than that of T2DM patients (0.821 vs. 0.761, p=0.044). But, AUROCs of FIB-4 according to the same age groups, there was no significant difference of AUROC between patients with T2DM and without (All p>0.05), and showed acceptable AUROCs in each group in middle-aged group. After propensity score matching of age, there was no statically significant difference in the AUROCs of the T2DM and non-T2DM groups (0.860 vs. 0.761, p=0.142) without losing of sensitivity.

Conclusion: The diagnostic performance of FIB-4 was suboptimal in T2DM patients and could potentially be attributed to the older age distribution among T2DM cohort. FIB-4 remains a valuable tool for excluding advanced fibrosis in middle-aged diabetic patients.

Abstract Submission No. 101569

P-0361

Diagnostic value of serum CHI3L1 in a real-world study of nonalcoholic fatty liver disease

yongfen zhu1, 2, Binfeng Yu1, 2, Yifan Tong1, 3, Jin Wang1, 2, Yue Shi1, Nianzhong Jiang1, 2, Zheyong Li1, 2, Qixia Gu1, 2, Xiao Liang3, Fangfang Lv4

1Department of Liver and Infectious Diseases, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China, 2Liver Regeneration and Metabolism Study Group, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China, 3Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China, 4Department of Pathology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University Hangzhou China, 5Key Laboratory of Laparoscopic Technology of Zhejiang Province, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou China, 6Zhejiang University Cancer Center Hangzhou China, 7Liangzhu Laboratory, Zhejiang University Medical Center Hangzhou China

Background: Nonalcoholic fatty liver disease (NAFLD) is linked to liver fibrosis over the long term, however there are currently no non-invasive methods for determining the degree of fibrosis. Here, we look into the relationship between serum Chitinase 3-like 1 (CHI3L1) and liver fibrosis result from NAFLD and assess if it may be used as a predictor for NAFLD.

Methods: A total of 194 patients with biopsy-proven NAFLD were retrospectively enrolled. The demographic characteristics, laboratory variables and pathological features were compared among the subgroups stratified by serum CHI3L1. Correlation analysis between serum CHI3L1 and pathological findings was performed. Serum CHI3L1 alone or in combination with other indices was assessed for its diagnostic efficacy using receiver operating characteristic (ROC) analysis.

Results: Significant differences were seen in the serum CHI3L1 level across patients with varying levels of fibrosis, as well as between non-alcoholic fatty liver and nonalcoholic steatohepatitis (NASH). Serum CHI3L1 was positively correlated with two liver fibrosis biomarkers, namely Fib-4 and NAFLD fibrosis score. With 80.3% sensitivity and 40.6% specificity, a cut-off of 38.7 ng/mL was found to identify people with significant fibrosis (fibrosis grade ≥ 2), and 74.15 ng/mL was found to identify people with advanced fibrosis (fibrosis grade ≥ 3), exhibiting 62.5% sensitivity and 84.3% specificity. Furthermore, the area under the ROC curve for combining serum CHI3L1 and body mass index to identify individuals with NASH activity score ≥ 4 and fibrosis grade ≥ 2 was 0.702.

Conclusions: Serum CHI3L1 exhibits potential as a non-invasive biomarker for patient stratification in NAFLD.
A biomarker model of NASH fibrosis progression constructed by lipidomics and metabolomics profiling

Hongwei Lin1, Yilong Fu2, Yongfen Zhu1, Xiao Liang1
1Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou China, 2School of Life Science, Zhejiang Chinese University Hangzhou China

Background: Non-alcoholic steatohepatitis (NASH) is considered the most severe form of non-alcoholic fatty liver disease. It is becoming a major cause of end-stage liver disease such as cirrhosis and hepatocellular carcinoma. However, there are no early biomarkers that can reliably predict which patients are more likely to develop NASH and which NASH patients are more likely to progress to fibrosis. Thus, it is crucial to discover predictive markers of NASH fibrosis.

Methods: We collected serum from 10 healthy individuals, 20 moderate-fibrotic NASH (fibrotic S0-S1) and 20 fibrotic NASH (fibrotic S2-S4) patients. We use mass spectrometry to measure lipids and metabolites. An in-depth analysis of lipids and metabolites was performed in three cohorts to screen for biomarkers. According to VIP>1, the characteristic peaks with significant differences among the three groups were selected through the OLPS-DA model, and the intensity differences between each group were analyzed. Finally, pathway enrichment analysis and diagnostic performance analysis were performed to build a prediction model.

Findings: Compared with healthy people, NASH patients (different grades of fibrosis) have significant differences in the seven lipid metabolism molecules Hex1Cer, Hex1Cer, PE, PE, ST, SHexCer, and LPC. Further analysis found that in moderate-fibrotic NASH vs. healthy people, the molecules with the highest VIP value was ST; while in fibrotic NASH patients vs. moderate-fibrotic NASH patients, the molecule with the highest VIP value was SM. Then we built prediction models based on Lasso or SVM machine learning methods and serum lipid metabolism molecules with VIP>1 (34 or 68) to distinguish NASH patients from healthy people, moderate-fibrotic NASH and fibrotic NASH patients.

Abstract Submission No. 101760
P-0364

Association of serum total testosterone levels with NAFLD and liver fibrosis in adult Americans

Gang Wang1, Jiaqin Chen1
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China, Beijing China

Background: The association between androgens and NAFLD is complex and not yet fully understood.

Methods: The sample for this study consisted of 3 consecutive cycles of NHANES (cycles 2011-2012, 2013-2014, and 2015-2016) with a total of 29,902 participants. We used USFLI >30 to define NAFLD. The FIB-4 index is a noninvasive method for assessing liver fibrosis in patients with chronic liver disease. Multivariate logistic regression analysis and diagnostic performance analysis were performed to build a prediction model.

Findings: Compared with healthy people, NASH patients (different grades of fibrosis) have significant differences in the seven lipid metabolism molecules Hex1Cer, Hex1Cer, PE, PE, ST, SHexCer, and LPC. Further analysis found that in moderate-fibrotic NASH vs. healthy people, the molecules with the highest VIP value was ST; while in fibrotic NASH patients vs. moderate-fibrotic NASH patients, the molecule with the highest VIP value was SM. Then we built prediction models based on Lasso or SVM machine learning methods and serum lipid metabolism molecules with VIP>1 (34 or 68) to distinguish NASH patients from healthy people, moderate-fibrotic NASH and fibrotic NASH patients.

Abstract Submission No. 101760
P-0364

Cross-sectional study in general population for prevalence and LSM distribution of MASLD

Yuji Ogawa1, Wataru Tomeno2, Yasushi Imamura3, Masaru Baba4, Asako Ogami4, Kento Imao4, Taku Hakamada4, Miwa Kawasaki4, Noriaki Manabe5, Tomoari Kamada5, Takashi Honda5, Miwa Tatsuta5, Shigeru Kikuma5, Masato Ueno5, Atsushi Nakajima5
1NHO Yokohama Medical Center Yokohama Japan, 2International University of Health and Welfare Atami Hospital Atami Japan, 3Kagoshima Kouseiren Hospital Kagoshima Japan, 4JCHO Hokkaido Hospital Sapporo Japan, 5Yokohama City University Graduate School of Medicine Yokohama Japan, 6Shin-yurigaoka General Hospital Kawasaki Japan, 7Kawasaki Medical School General Medical Center Okayama Japan, 8Nagoya University Graduate School of Medicine Nagoya Japan, 9KKR Takamatsu Hospital Takamatsu Japan, 10Kikkoman General Hospital Noda Japan

Background: The multisociety consensus nomenclature has adopted steatoic liver disease (SLD) with various sub-classifications. We investigated the prevalence of SLD and analyzed the distribution of vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM) of metabolic dysfunction associated steatotic liver disease (MASLD).

Methods: A cross-sectional study was conducted in 6530 subjects who received health check-up exams. Conventional B-mode ultrasound was performed in 6530 subjects. Of those subjects with SLD, VCTE was performed.

Results: The prevalence of SLD was 39.5%; MASLD 28.7%, alcohol-related liver disease (ALD) 1.2%, MetALD 8.6%, specific aetiology SLD 0.3%, cryptogenic SLD 0.7%. Liver fibrosis stages classified by VCTE-derived LSM were 89.7/7.5/1.5/0.9/0.4% (fibrosis stage 0/1/2/3/4). We analyzed various cut-off values of FIB-4 for diagnosing VCTE-derived LSM ≥8kPa. FIB-4 ≥1.3 showed that the sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) were 60.6%, 77.0%, 5.3%, and 98.9%, respectively. The referral rate to specialists was 23.8% using FIB-4 ≥1.3. Se of FIB-4 ≥1.3 was 55.6% in

Conclusions: A selection bias exists in hepatology centers, then we conducted this general population-based prospective study. FIB-4 showed high NPV but low PPV. FIB-4 might be inadequate as a primary screening for liver fibrosis in the general population. We showed that FLI is useful non-imaging NIT for diagnosing MASLD. UMIN Clinical Trials Registry No. UMIN000035188.

Abstract Submission No. 101763
P-0365

Cross-sectional study in general population for prevalence and LSM distribution of MASLD

Yuji Ogawa1, Wataru Tomeno2, Yasushi Imamura3, Masaru Baba4, Asako Ogami4, Kento Imao4, Taku Hakamada4, Miwa Kawasaki4, Noriaki Manabe5, Tomoari Kamada5, Takashi Honda5, Miwa Tatsuta5, Shigeru Kikuma5, Masato Ueno5, Atsushi Nakajima5
1NHO Yokohama Medical Center Yokohama Japan, 2International University of Health and Welfare Atami Hospital Atami Japan, 3Kagoshima Kouseiren Hospital Kagoshima Japan, 4JCHO Hokkaido Hospital Sapporo Japan, 5Yokohama City University Graduate School of Medicine Yokohama Japan, 6Shin-yurigaoka General Hospital Kawasaki Japan, 7Kawasaki Medical School General Medical Center Okayama Japan, 8Nagoya University Graduate School of Medicine Nagoya Japan, 9KKR Takamatsu Hospital Takamatsu Japan, 10Kikkoman General Hospital Noda Japan

Background: The multisociety consensus nomenclature has adopted steatoic liver disease (SLD) with various sub-classifications. We investigated the prevalence of SLD and analyzed the distribution of vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM) of metabolic dysfunction associated steatotic liver disease (MASLD).

Methods: A cross-sectional study was conducted in 6530 subjects who received health check-up exams. Conventional B-mode ultrasound was performed in 6530 subjects. Of those subjects with SLD, VCTE was performed.

Results: The prevalence of SLD was 39.5%; MASLD 28.7%, alcohol-related liver disease (ALD) 1.2%, MetALD 8.6%, specific aetiology SLD 0.3%, cryptogenic SLD 0.7%. Liver fibrosis stages classified by VCTE-derived LSM were 89.7/7.5/1.5/0.9/0.4% (fibrosis stage 0/1/2/3/4). We analyzed various cut-off values of FIB-4 for diagnosing VCTE-derived LSM ≥8kPa. FIB-4 ≥1.3 showed that the sensitivity (Se), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) were 60.6%, 77.0%, 5.3%, and 98.9%, respectively. The referral rate to specialists was 23.8% using FIB-4 ≥1.3. Se of FIB-4 ≥1.3 was 55.6% in

Conclusions: A selection bias exists in hepatology centers, then we conducted this general population-based prospective study. FIB-4 showed high NPV but low PPV. FIB-4 might be inadequate as a primary screening for liver fibrosis in the general population. We showed that FLI is useful non-imaging NIT for diagnosing MASLD. UMIN Clinical Trials Registry No. UMIN000035188.

Abstract Submission No. 101763
P-0365
Non Invasive Parameters compared to FibroScan for the assessment of liver stiffness in Fatty Liver

Amal Joseph¹, Devika Suresh¹, Sunil Mathew¹, Harikumar Nair¹
¹Ernakulam Medical Center Kochi India

Background: Given the Invasive nature, cost, and complications, Liver biopsy has been replaced by non-invasive evaluation of liver stiffness using Fibroscan technology. MAFLD(Metabolic dysfunction-associated fatty liver disease) includes imaging and blood markers and doesn’t keep liver biopsy as a mandatory diagnostic criterion. To reduce the cost of follow-up fibroscan assessments and ensure applicability at the primary care level, It is desirable to have a blood-based marker that would tally with liver stiffness.

Methods: Noninvasive blood tests namely FIB-4, APRI, NPAR(neutrophil percentage-albumin ratio), PLR(Platelet-to-lymphocyte ratio), and NLR along with fibro scan were performed on MAFLD patients. Patients were grouped into two - Less fibro progressed (F0, F1, F2) and Fibro progressed group (F3 and F4) Sensitivity, Specificity, Positive Predictive Value, and Negative predictive value were obtained.

Results: Of the blood markers FIB-4 (Sensitivity-0.692, Specificity-0.804, Positive predictive value (PPV)-72.97 Negative Predictive Value (NPV) -77.36, Diagnostic Accuracy(DA) - 75.63 ) and APRI (Sensitivity -0.820, Specificity - 0.627, PPV -62.75, NPV -82.05, DA - 71.21) correlated better with fibroscan values. PLR has a high specificity (Specificity -0.980 and PPV-66.6) well above FIB-4 and APRI and comparable PPV as that of FIB-4 and APRI. Regarding CAP NPAR showed a negative correlation (Correlation coefficient of 0.329 and p-value of 0.002); no other parameters correlated with CAP.

Conclusions: Based on these results, FIB-4 and APRI may be used for follow-up assessment and may substitute fibroscan evaluation. The role of PLR as a specific marker of liver stiffness and NPAR correlating with CAP needs further exploration.

Abstract Submission No. 101771
P-0366

MAFLD increases the incidence of HCC in SVR patients with HCV infection

Hajime Sunagozaka¹, Satomi Kishi¹, Katsunori Komyo², Takafumi Nakagawa³, Kohei Yashuda⁴, Hirokazu Hirai⁵, Ryoei Ugaji⁶, Yoshihide Naito⁷, Kenkei Hasatani¹, Jun Yoshikawa¹, Hiroyuki Aoyagi²
¹Fukui Prefectural Hospital Fukui Japan

Background: Liver carcinogenesis is suppressed when sustained virologic response (SVR) achieved by antiviral therapy. However, the risk of liver carcinogenesis does not completely disappear after SVR. Therefore the identification of risk factors for carcinogenesis in the SVR patients is important. This study was to assess the incidence of hepatocellular carcinoma (HCC) in patients who achieved SVR by direct antiviral agents (DAA) with and without Metabolic dysfunction associated fatty liver disease (MAFLD).

Methods: We enrolled patients who achieved SVR by oral DAA treatment (n=257). We examined the incidence of HCC, extrahepatic disease and all and liver related mortality, retrospectively.

In this study, liver steatosis was diagnosed in patients with an average CT value of liver parenchymal less than 50 HU on non-contrast-enhanced CT before DAA treatment.

Results: During a median follow-up period of 6.0 years, 7 patients (2.9%) developed HCC. The 3- and 5-year cumulative HCC development rates were 10.0% and 18.9%, whereas those were 2.2 % and 3.1 %, in the patients without MAFLD, respectively. (P=0.001).

Conclusion: Our data indicate that MAFLD were associated with significantly increased overall mortality, and incidence of HCC. Based on these results, the strategy for follow-up of SVR patients with chronic liver disease C should be reconsidered.

Abstract Submission No. 101774
P-0367

Serum CK18f predicts ‘MASH resolution’ and ‘at risk MASH’ in patients with with patients in MASLD

Miwa Kawanaka¹, Hirokazu Takahashi²,¹, Michihiro Iwaki³, Ken Nishino¹, Wenli Zhao⁴, Masato Yoneda⁵, Kenichi Tanaka³, Hideki Fujii³, Yoshihiro Kamada³, Hirofumi Kawamoto³, Yoshio Sumida³, Atsushi Nakajima⁴
¹Department of General Internal Medicine2, Kawasaki General Medical Center, Kawasaki Medical School Okayama Japan,
²Division of Metabolism and Endocrinology, Faculty of Medicine, Saga University Saga Japan, 3Liver Center, Saga University Hospital Faculty of Medicine, Saga University Saga Japan, 4Division of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine Yokohama Japan, 5Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 6Department of Advanced Metabolic Hepatology, Osaka University Graduate School of Medicine Osaka Japan, ³Graduate School of Healthcare Management, International University of Healthcare and Welfare Tokyo Japan

Background: The objective of this study was to determine whether the apoptotic marker serum Cytokeratin18(CK18f) could aid in predicting MASH resolution and treatment response, as well as identifying ‘at risk MASH’ in patients with MASLD.

Methods: A cohort of 565 MASLD patients underwent a liver biopsy. The study explored liver fibrosis markers and CK18f to predict ‘at-risk MASH’ patients. Additionally, 110 MASLD patients underwent repeated liver biopsies over a mean 4-year period, comparing serum CK18f changes and &delta;CK18f with liver histological changes (stage, grade, steatosis, and NAS). The study evaluated whether CK18f predicts MASH resolution without worsening liver fibrosis or improvement in liver fibrosis stage without worsening MASH.

Results: Among patients with FIB-4 index ≥ 1.3, 64% demonstrated CK18f ≥ 260 and possible ‘at-risk MASLD,’ recommended treatment (Sen 80%, Spe 36%, PPV 64%, NPV 56%). Conversely, FIB-4 index < 1.3 cases with CK18f < 260 were rule out ‘at-risk MASLD’ (Sen 85%, Spe 34%, PPV 43%, NPV 80%). In the 110 repeated liver biopsy cases, lobular inflammation, hepatocellular ballooning, and NAS changes strongly correlated with &delta;CK18f changes. &delta;CK18f significantly decreased (P < 0.0001) in patients with ‘no worsening fibrosis and improved NAS’. Multiple regression analysis associated with &delta;CK18f levels. The &delta;CK18f decreased (p < 0.05) in patients with ‘improving fibrosis and no worsening NAS’, and associated with &delta; type IV collagen 75 levels.

Conclusion: Serum CK18f is a useful non-invasive diagnostic marker for ‘at risk MASLD’ and can determine treatment efficacy without liver biopsy.
Pharmacodynamics of multiple oral doses of ALG-055009, a THRβ agonist, in hyperlipidemic subjects

Megan Fitzgerald1, Hakim Charfi2, Jean-Louis Pinquier2, Stanley Wang1, Kha Le1, Ifong Kan-Eng1, Doug Clark1, Naqvi Mohammed1, MeenaKshi Venkatraman1, Lawrence Blatt1, Tse-I Lin1, Sushmita Chanda1, Matthew McClure1

1Aligos Therapeutics, Inc. South San Francisco United States, 2Biotal Rennes France, 3Aligos BV Leuven Belgium

Background: ALG-055009 is a nanomolar potent thyroid hormone receptor beta (THRβ) agonist being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Method: ALG-055009-301 is a completed first-in-human Phase 1 study (NCT05090111) combining evaluation of single-ascending doses (SAD) in healthy volunteers (Part 1), multiple-ascending doses (MAD) in subjects with mild hyperlipidemia (Part 2), and the relative bioavailability/food effect (Part 3) of a softgel formulation in healthy volunteers. Across Parts 1-3, single (≤4.0 mg) and multiple (≤1.0 mg x 14 days) once daily oral solution doses of ALG-055009 were well tolerated in healthy volunteers and subjects with mild hyperlipidemia (HL; LDL-C >110 mg/dL), respectively (Charfi et al., APASL 2023).

In Part 2, HL subjects (N=10/cohort) were randomized 4:1 to receive ALG-055009/placebo. Reported here are pharmacodynamic data from Part 2.

Results: In Part 2, 50 HL subjects (94% male, mean age 41 years, mean BMI 26.5 kg/m²) were enrolled across 5 cohorts. Daily dosing with ALG-055009 for 14 days resulted in generally dose-dependent decreases in LDL-C, apolipoprotein-B, VLDL, and triglycerides with maximum decreases of 26.8%, 27.6%, 35.7%, and 35.7%, respectively, relative to baseline at 1.0 mg. For other lipids evaluated (e.g., total cholesterol and non-HDL cholesterol), levels were either unaffected or the effect was modest. A dose-dependent increase in sex hormone binding globulin (SHBG), a marker of target engagement in the liver, up to 95% relative to baseline was also observed.

Conclusion: Favorable, dose-dependent pharmacodynamic effects on atherogenic lipids and SHBG were observed with multiple dosing of ALG-055009 in HL subjects.

Saroglitazar improves steatosis and fibrosis in metabolic-associated fatty liver disease

Omesh Goyal1, Arshdeep Singh1, Yogesh Gupta1, Ramit Mahajan1, Varun Mehta1, Ajit Sood1

1Dayanand Medical College and Hospital Ludhiana India

Background: Saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, is a potential therapeutic option for metabolic-associated fatty liver disease (MAFLD). This prospective, observational, real-world study aimed to determine the efficacy and safety of Saroglitazar in patients with MAFLD.

Methods: We included patients with MAFLD who received Saroglitazar 4 mg once daily for 48 weeks. Blood investigations, liver stiffness measurement (LSM), and controlled attenuation parameter (CAP) (FibroScan) were done at baseline, 24 weeks, and 48 weeks. Data was analyzed by ITT.

Results: Of 241 patients screened, 162 were included, and 131 completed 48 weeks of treatment (mean age 51.8 ± 11.6 years, 70.2% males, mean body mass index 29.2 ± 5.1). Of the 131 patients, 87 had diabetes, 52 had hypertension, and all had dyslipidemia. After 48 weeks, alanine transaminase (ALT) reduced significantly from 94 (46–142) to 35 (29–91) (p < 0.0001) and aspartate aminotransferase (AST) (U/L) from 34 (44–116) to 33 (28–47) (p < 0.0001) and arylsulfatase (AST) (U/L) from 9.5 (7.1–11.9) to 6.8 (5.9 – 8.6) (p = 0.018). CAP, glycated hemoglobin, and lipid parameters also improved significantly. On linear regression, there was a significant association between percent change in ALT and AST with TG reduction after treatment (p = 0.013 and 0.032 respectively).

Conclusion: We conclude that Saroglitazar leads to significant improvement in transaminases, LSM, and CAP in MAFLD patients.

Metabolic-Associated Fatty Liver Disease and hyperferritinemia

Narina Sargsyants1

1National Institute of Health Yerevan Armenia

Background: Metabolic-Associated Fatty Liver Disease (MAFLD) is the commonest chronic liver disease worldwide and one of the leading causes of liver cirrhosis and hepatocellular carcinoma. New definition of MAFLD refers to hepatic steatosis in addition to one of the following criterias: overweight/obesity, presence of type 2 diabetes mellitus (T2DM), or evidence of metabolic dysregulation. Cardiometabolic criteria in adults at least 1 of 5 are following:

1. BMI >25kg/m² or Waist circumference >94/80 cm for Europid men/women
2. Fasting glucose (GLUC) >5.6 mmol/L or 2-h post-load glucose levels >7.8 mmol/L or HbA1c >5.7% or treated for T2DM
3. Arterial pressure >130/85 mmHg or specific antihypertensive drug
4. Serum triacylglycerols (TG) >1.7 mmol/L or lipid lowering treatment
5. high density lipoprotein (HDL) cholesterol <1.0/1.3 mmol/L for men/women or lipid lowering treatment.

The aim of the study is evaluation of correlation BMI, liver function tests, and lipid profile with MAFLD in small Armenian cohort.

Methods: 72 patients with ultrasound-diagnosed hepatic steatosis were included in the study (62.5% male), 23-76 years old (51.0±12.3), BMI 31.7±5.0 kg/m². We evaluated following biochemical and lipids profile parameters: AST, ALT, GGT, TG, GLUC, cholesterol (CHOL), LDL, high density lipoprotein (HDL), ferritin (FERR).

Results: 41% had diabetes, 70% with BMI >30 kg/m², FERR elevated in 47%, F4 had 14% of patients. Range and mean±SD/SE: FERR 24-1947 ng/mL (396.7±61.4); TG 0.8-57 mmol/L or 2-h post-load glucose levels 7.8 mmol/L or HbA1c >5.7% or treated for T2DM.

Conclusions: In ultrasound-diagnosed hepatic steatosis average level of enzymes and ferritin is high. Presence of Cardiometabolic criteria and high risk of atherosclerosis is revealed in more than third of patients with MAFLD.

Comparison of liver fibrosis among patients with NAFLD with or without viral marker

Purevsood Lkhagvasuren1, Zaua Matal1, Amarzaya Batchimeg1, Anar Bayanmunkh1, Amarsanaa Jazag2, Buren-Ochir
INTRODUCTION: Hepatitis B, C, and D virus infection and fatty liver disease are major causes of liver cirrhosis and have become one of the major public health problems worldwide. We aimed to assess fibrosis stage of NAFLD patients with or without hepatitis virus markers.

MATERIALS AND METHODS: The research involved 11,696 participants, utilizing the elastography device (Fibrotouch) to assess fatty liver disease. Correlation analysis showed that liver stiffness was positively correlated with age. A positive correlation was observed between HBV positive participants with steatosis and liver stiffness (r=1.924, p=0.001), suggesting that HBV infection may be expected to exacerbate cirrhosis.

CONCLUSION: The risk of cirrhosis may escalate in association with fatty liver, hepatitis B virus infection, high BMI, and the presence of comorbid diabetes, exhibiting age-specific patterns.

This case report emphasizes the increased risk of NAFLD among relatives of affected individuals and the presence of shared genetic and environmental factors. It highlights the importance of screening family members for early detection of undiagnosed NAFLD and metabolic disorders. Implementing lifestyle modifications and, if necessary, pharmacotherapy at an early stage could potentially prevent NAFLD progression in these individuals.

Abstract Submission No. 102090 P-0373

Predictive Factors for Major Adverse Cardiovascular Events Among Patients with Biopsy-Proven MASLD

Thaninee Prasoppokakorn1, Kanokwan Sonthiri1, Sombat Treeprasertsuk1
1Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely associated with metabolic syndrome and significantly increases long-term risk of cardiovascular disease. We aimed to study the predictive factors associated with major adverse cardiovascular events (MACE).

Methods: A retrospective cohort study was conducted on adults with biopsy-proven MASLD, enrolled between January 2007 and May 2019 with follow-up until November 2023. The primary outcome was MACE occurrence, defined by coronary artery disease (CAD), and cerebrovascular disease (CVD). Secondary outcomes included factors associated with MACE.

Results: Among 276 patients with biopsy-proven cases, 152 (55.1%) were female, mean age 42.2±13.9 years. The mean BMI was 39.0±13.4 kg/m², and 174 (63.0%) were classified as obese. Diabetes was present in 120 (43.5%), dyslipidemia in 161 (58.3%), and hypertension in 154 (55.8%). Advanced fibrosis was 20 (10.5%) patients, and steatohepatitis (MASH) from biopsy was 80 (30.8%) patients. Over a median 7.8-year follow-up (7.2, 11.4), MACE occurred in 30 (10.9%) patients, including 4 (6.9%) with CAD and 12 (4.3%) with CVD. Univariate analysis identified age, sex, BMI, diabetes, hypertension, MASH from biopsy, advanced fibrosis, FIB-4, APRI, and NFS score as factors associated with MACE. Multivariate analysis revealed age (aOR 1.23(1.14-1.33), p=0.001), presence of diabetes (aOR 1.89(1.12-4.98), p=0.026), and FIB-4 score (aOR 1.95(1.33-3.34), p=0.016) as independent predictors of MACE (Table).

Conclusion: In this real-world longitudinal study, MASLD and MASH significantly increased risk of cardiovascular disease. Age and diabetes were established as key risk factors for MACE, with FIB-4 score identified as an independent and significant predictor for MACE occurrence.
**Background:** Metabolic syndrome (MetS) is an important public health concern with a cluster of non-communicable diseases (NCD) related health problems.

**Objective:** To strengthen the understanding of the association between liver enzymes and the risk of metabolic syndrome this study was designed to investigate the relationship between metabolic syndrome and other factors such as body mass index (BMI) with liver function tests, that is, aspartate aminotransferase (AST), ALT and G-glutamyl transferase (GGT) and prothrombin time in Bangladeshi adults.

**Subjects:** We screened patients for metabolic syndrome and 634 Bangladeshi adults (age range: 18–88 years) were enrolled and the factors related to metabolic syndrome were investigated.

**Results:** The prevalence rate of metabolic syndrome in Bangladeshi adults 31.9% using the modified ATP III criteria. Males had a slightly higher prevalence rate than females (P<0.01), and prevalence of metabolic syndrome increases with age and had significantly higher BMI values and AST, ALT levels and INR (p<0.001). According to the logistic regression analysis, elevated levels of ALT and INR were significantly associated with the prevalence of MetS (p < 0.01 and p < 0.001, respectively).

**Conclusion:** Abnormal liver functions of different extents and magnitudes have been found in metabolic syndrome patients, ALT and INR should be considered during the management of metabolic syndrome patients and also to assess their long-term follow-up prognosis.

---

**Relationship between colorectal polyp and non-alcoholic fatty liver disease: A cross-sectional study**

Chalermmat Bunchoontavakul1, Apitarn Narattana1

1Rajavithi Hospital Bangkok Thailand

**Background:** Both non-alcoholic fatty liver disease (NAFLD) and colorectal neoplasms are prevalent and on the rise worldwide. Recent research has linked NAFLD to a higher incidence of colorectal polyps, and it is speculated that insulin resistance and chronic inflammation in NAFLD patients may facilitate the development of colorectal polyps and cancer.

**Methods:** This cross-sectional analytic study was conducted among 280 participants who underwent screening colonoscopy at Rajavithi Hospital, Bangkok, Thailand, between 2018 and 2021. Patients with a history of significant alcohol consumption and a family history of colorectal cancer were excluded. The aims of the study were to evaluate the prevalence and relationship between colonic polyps and the presence of NAFLD. NAFLD was defined by the presence of steatosis on ultrasonography with feature(s) of metabolic dysfunction.

**Results:** Of the 280 participants, 66.5% were female, with a mean age of 57.5 ± 11 years and a mean BMI of 23.3 ± 3.9 kg/m². Diabetes mellitus and hypertension were noted in 29.2% and 70.8%, respectively. Upon colonoscopy, colorectal polyps were found in 15.4% of cases (65% tubular adenoma, 28% hyperplastic, and 7% inflammatory polyps). In the multivariate analysis, age (adjusted OR 1.04; 95% CI: 1.01–1.08, p=0.025) and presence of NAFLD (adjusted OR 2.70; 95% CI: 1.35–5.45, p=0.005) were associated with the presence of colorectal polyps.

**Conclusion:** NAFLD is associated with an increased prevalence of colorectal polyps in asymptomatic, average-risk individuals. Therefore, early screening colonoscopy may be considered before the age of 45–50 if the person has NAFLD.

---

**Dapagliflozin in the management of diabetic patients with Non-alcoholic fatty liver disease**

Anuj Pahuja1, Pankaj Puri2

1Fortis Escorts Hospital, Okhla, New Delhi New Delhi India, 2Director, Fortis Escorts Hospital New Delhi India

**Background:** SGLT2 inhibitors increase urinary glucose excretion via inhibiting glucose reabsorption in the proximal renal tubules. They are associated with increase in fatty acid (FA) mobilization from adipose tissues and FA uptake and beta-oxidation in the liver. They also have the potential to reduce various multiple risk factors for arteriosclerosis, such as obesity, dyslipidaemia and hypertension, as well as diabetes.

**Overview:** In this observational study, our objective was to see the reduction in liver fat content, hepatic steatosis, inflammation and/or fibrosis in diabetic patients with the addition of the SGLT2 inhibitor dapagliflozin in comparison to standard anti-diabetic therapy without SGLT-2 inhibitors or GLP-1 receptor agonists.

**Primary objective:** To study the improvement of hepatic steatosis in diabetic patients with NAFLD.

**Secondary objectives:** To see improvement in the following parameters:

1. Hepatic transaminases
2. Hepatic fibrosis in patients who are followed up for more than six months
3. Insulin Resistance
4. Weight and body fat.

A total of 70 subjects were selected. Two groups of patients were selected for observational comparative study.

- Group 1: Diabetic patients suffering from NAFLD, who were taking SGLT2 inhibitor Dapagliflozin 10 mg OD along with other anti-diabetic treatment excluding GLP1 receptor agonists.
- Group 2: Diabetic patients suffering from NAFLD, who were on anti-diabetic treatment without SGLT2 inhibitors or GLP-1 receptor agonists.

Fibroscan, Liver function tests, Fasting lipid profile and other parameters were done every 12 weeks.

**Results:** We found significant reduction in liver fat content, based on fibroscan follow up.

---

**Comparison of the efficacy of UDCA versus vitamin E+C in patients with NASH**

Abstract Submission No. 200022

P-0375

---

**Comparison of the efficacy of UDCA versus vitamin E+C in patients with NASH**

Abstract Submission No. 200063

P-0377
Background and aim: Nonalcoholic steatohepatitis is a frequent liver disease that can progress to cirrhosis and for which effective therapy is still lacking. Despite an important role of oxidative stress in the pathogenesis of NASH, antioxidant approaches have not been investigated sufficiently.

The aim of the study was to compare ursodeoxycholic acid versus vitamin E plus vitamin C in patients with nonalcoholic steatohepatitis.

Methods: Patients with diagnosis of NASH were randomly assigned to receive either UDCA 15 mg/per kg/day (group A) or vitamin E 800 mg/day plus vitamin C 500 mg/day (group B) for 12 months and control group, which did not receive any medical treatment. Lifestyle modification was advised to all groups. The primary study end point was improvement in alanine transaminase levels, secondary end points were improvement in steatosis score and improvement in fibrosis score.

Results: 107 patients were included 35 in the group A, 52 in the group B and 20 in control group, 11 patients dropped out, non because of side effects. Baseline characteristics were not significantly different between groups. After 12 months treatment with vitamin E plus C, as compared with UDCA, was associated with a significant reduction of mean alanine aminotransferase levels. Similarly, there was significant reduction of both mean steatosis score and fibrosis score.

Conclusion: Vitamin E plus C combination is an effective, safe and inexpensive treatment option in patients with NASH and may be useful to reduce damage from oxidative stress and slow the process leading to cirrhosis.

Abstract Submission No. 200107
P-0378

Efficacy Of Flaxseed In Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Ariel Valentino Soetedjo1, Kevin Tjoa1, Imelda Maria Loho2, Irsan Hasan3

1Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Dharmais National Cancer Center Hospital Jakarta Indonesia, 3Division of Hepatobiary, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo National General Hospital Jakarta Indonesia

Non-alcoholic fatty liver disease (NAFLD) is prevalent worldwide and can lead to cirrhosis. Recently, there is growing interest in using foods rich in antioxidants to treat metabolic disorders such as NAFLD. Flaxseed (Linum usitatissimum) is rich in omega-3 and fiber. Therefore, this study aims to review evidence regarding efficacy of flaxseed in NAFLD. Literature search was conducted on four databases: PubMed, Embase, Cochrane, and Scopus using keywords flaxseed, non-alcoholic fatty liver disease and related terms. At the start of search, 111 studies were identified and using appropriate eligibility criteria, four clinical trials were selected and assessed for methodological quality using Cochrane RoB 2.0. Random effects meta-analysis was done in two studies, comparing flaxseed and lifestyle changes. The other two studies used different forms of flaxseed and additional intervention for control group. Results were expressed in mean difference (MD) of change from baseline. After 12 weeks, flaxseed group show significant improvement in liver enzymes (pooled MD -6.35, 95% CI: -9.21 to -3.49, p<0.0001), lipid profile (pooled MD -16.08, 95% CI: -25.35 to -6.81, p=0.0007), liver fibrosis (pooled MD -0.57, 95% CI: -1.09 to -0.04, p=0.04), and steatosis (pooled MD -26.93, 95% CI: -38.94 to -14.92, p=0.0001) when compared to lifestyle group. However, there is no significant difference in inflammatory biomarkers. In NAFLD patients, flaxseed demonstrated significant improvement in liver enzymes, steatosis, fibrosis, and metabolic profile, but not inflammatory biomarkers, when compared to lifestyle changes only. More robust clinical trials with standardized regimen and development of placebo for flaxseed should be conducted.

Abstract Submission No. 200108
P-0379

Insilico -interactions between Saroglitazar, Ferulic acid, and keto-hexokinase for MASLD.

Kalpana Tiwari1, Dr. Brijesh Kumar2, Dr. Vinay Kumar Singh3, Dr. Anurag Tiwari4, Dr Gyan Vardhan5

1BHU IMS INDIA VANARASI India, 2Professor Department of Pharmacology Institute of Medical Science Banaras Hindu University, Varanasi, Uttar Pradesh 221005 India, 3Information Officer, Centre for Bioinformatics, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh 221005 India, 4Assistant Professor Department of Gastroenterology Institute of Medical Science Banaras Hindu University, Varanasi, Uttar Pradesh 221005 India, 5Senior Resident Department of Pharmacology All India Institute of Medical Sciences Bhatinda, India

Background and Aims: Non-Alcoholic Fatty Liver Disease renamed as metabolic dysfunction-associated liver disease (MASLD), is a global health issue that causes excessive liver fat deposition without alcohol usage. Basic fatty liver to non-alcoholic steatohepatitis can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Research is essential because to multidimensionality, complex pathophysiology, and rising prevalence from sedentary lifestyles and unhealthy diets.. Computational study analyses Saroglitazar and Ferulic acid interactions with human Ketohexokinase using docking, simulations, and network pharmacology to propose potential MASLD treatments.

Method: Utilized computational methodologies to examine binding interactions of Saroglitazar (CID: 60151560) and Ferulic acid (CID: 445858) with human Ketohexokinase (KHK: P50053, PDB ID: 6W0W). Active site analysis was performed using CDD server and BIOVIA Studio 2019. Best complex was used for molecular dynamics simulation and trajectory analysis along with functional associations based on biological process and molecular function done by using STITCH server.

Results: Human ketohexokinase protein (Uniprot ID: P50053) was obtained. Additional KHK PDB Structure (6W0W) was retrieved for docking. Ferulic Acid (CID: 445858) and Saroglitazar (CID: 60151560) were PubChem Database SDF files. Active site analysis used CDD server and BIOVIA Discovery Studio 2019. Docking analysis identified Arg108, Trp225, Glib227, Glib229, Ala230 Pro246, Pro247, Val250, Thr253, Gly257, Cys282, Gly286 and Cys289 as potential active site residue DESMOND molecular dynamics simulation and trajectory analysis equilibrated after 40ns using the best complex Saroglitazar (CID: 60151560) and KHK.

Conclusion: Study shows that Saroglitazar and Ferulic acid are strong KHK inhibitors for metabolic diseases, including MASLD, suggesting multi-target treatments.

Abstract Submission No. 200131
P-0380
The Role of Short-Term Resistance Training in Changing Hepatic Fat Content: A Pilot Study

Hong-Soo Kim1, Chae-Been Kim2, Jung-Jun Park2
1Soon Chun Hyang University Cheonan Hospital Cheonan-si, Chungcheongnam-do South Korea, 2Pusan National University Busan Republic of Korea

BACKGROUND: Previous research confirms exercise and diet reduce hepatic fat content (HFC) in individuals with non-alcoholic fatty liver disease (NAFLD). Impact of short-term resistance training combined with controlled diet not thoroughly investigated. This study examines effect of four-week resistance training on HFC and related markers while maintaining consistent diet.

METHODS: 18 sedentary men participated in daily resistance training, with an intensity set at 60-70% of their one-repetition maximum. Additionally, they followed a customized diet. HFC, the presence of fatty liver, and various blood markers were assessed before and after the intervention.

RESULTS: The intervention significantly reduced by approximately 10% in HFC (p=.006). Additionally, significant improvements were observed in BMI, body fat percentage, albumin, total cholesterol, and LDL cholesterol after the intervention (p=.001, p=.001, p=.015, p=.001, p=.001 respectively). However, variables such as muscle mass, AST, ALT, PLT, glucose, insulin, TG, and HDL cholesterol showed no significant changes. Interestingly, changes in AST and ALT demonstrated a positive correlation with changes in BMI (r=0.667, p=.004; r=0.780, p<.001 respectively) and body fat percentage (r=0.560, p=.016; r=0.727, p=.001 respectively). Changes in ALT also showed a positive correlation with changes in muscle mass (r=0.470, p=.049). Changes in the CAP demonstrated a positive correlation with changes in insulin (r=0.523; p=.031).

CONCLUSIONS: Results suggest four-week resistance training combined with controlled diet effectively reduces HFC in sedentary men. Correlations highlight complex relationship between physical activity, diet, body composition, and liver health. Further research is needed to comprehend underlying mechanisms and optimize resistance training for NAFLD management.

Abstract Submission No. 200165
P-0381

A Descriptive study of Metabolic associated steatotic liver disease (MASLD) in Myanmar

Su Ay1, Si thu sein Win2, Aung hlaing Bwa3, Khin maung Win4, Saint sain t kyaw Thinn4
1Yangon Gl and Liver Center Yangon Myanmar, 2Yangon Gl and Liver Center Yangon Myanmar, 3Yangon Gl and Liver Center Yangon Myanmar, 4Yangon Gl and Liver Center Yangon Myanmar, 5Honorary Professor, Department of Hepatology, University of Medicine 1 Yangon Myanmar

BACKGROUND: Metabolic-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, is increasing globally. However, most of the research data are from the western world and lack data from Asian countries where people’s bodies, dietary habits, and lifestyles are different. In Myanmar, there is scant data available for MASLD or its complications. In this study, we describe the registry data of the Yangon GI-Liver centre, which received mixed patients from urban and rural areas.

METHODS: Data from 817 patients were available for analysis (n=817) between May 2017 and April 2022. SPSS (version 21.0; IBM, Inc., New York) was used to analyse the data.

RESULTS: Of the 817 patients, 427 (52%) were male and 390 (48%) were female. The age groups ranging from 15-83 years. The mean BMI of male and female patients was 22 (Standard Deviation 2.4) and 25 (standard deviation 3.5), respectively. Overall, 458 patients (56%) had steatosis of varying grades, of which 37% had severe steatosis. Among them, 1% of the patients had clinically significant fibrosis F2-F4 detected by fibroscan. A total of 23 patients (2.8%) had metabolic-associated steatohepatitis (MASH), 14% of patients with HbA1C >5.7 mmol/L.

Conclusion: This study provides a glimpse of MASLD in Myanmar and its potential associated risks and complications. We can utilise these data to implement the prevention and management strategies of MASLD in the country with the need for increased efforts and urgency.

Abstract Submission No. 200166
P-0382

Role of primary care physicians in combating metabolic associated steatotic liver disease in Myanmar

Su Ay1, Si thu sein Win2, Aung hlaing Bwa3, Khin maung Win4
1Yangon Gl and Liver Center Yangon Myanmar, 2Yangon Gl and Liver Center Yangon Myanmar, 3Yangon Gl and Liver Center Yangon Myanmar, 4Honorary Professor, Department of Hepatology, University of Medicine 1 Yangon Myanmar

BACKGROUND: We acknowledge from the global literature that obesity, type 2 diabetes mellitus (DM), and dyslipidaemia are the major predictors or complications of metabolic-associated steatotic liver disease (MASLD). According to 2014 data, the prevalence of diabetes is 10.8% and pre-diabetes is 19.7% in Myanmar, but we have scanty of data with regards to MASLD in the country.

METHODS: We analysed the registry data of 817 patients (n = 817) from the Yangon Gl-Liver Centre (YGLC) from May 2017 to April 2022. SPSS (version 21.0; IBM, Inc., New York, USA) was used to analyse the data. Pearson Chi square test and Pearson correlation was done to determine association between steatosis grading with HbA1C, BMI and waist circumference. Significance level was set at p <0.05.

RESULTS: There was a positive association between steatosis grading and HbA1C: 15% (p<0.001), BMI: 29% (p<0.001), and waist circumference: 37.7% (p<0.001).

Conclusion: As we found a positive association between steatosis grading and HbA1C, BMI, and waist circumference highlighted the importance of the role of primary care physicians’ collaboration in the early detection and management of MASLD. Primary care physicians are the centres of patient care pathways. By using simple laboratory tests to predict the risk and complications of MASLD, such as FIB-4 and APRI, treating its associated risk factors, such as providing statins and anti-diabetes, encourages patients to adopt a healthy lifestyle, and activates referral pathways to hepatologists. The combined efforts will be more effective in tackling the global epidemic wave of MASL or its complications.

Abstract Submission No. 200277
P-0383

Efficacy and safety of incretin-based therapy in MASLD patients with type 2 diabetes mellitus

Taeang Arai1, Masanori Atsukawa1, Toshifumi Tada2, Toru Ishikawa1, Asahiro Morishita1, Joji Tani2, Kentaro Matsuura3, Hiroshi Abe3, Keizo Kato4, Tsunezaku Oikawa5, Akihito Tsubota3, Tomomi Okubo6, Katsuhiko Iwakiri1
Methods: Even if the lesion was not visualized by conventional ultrasonography, pleural effusion/ascites was performed in 53 patients with 82 HCCs. Materials and methods: Percutaneous radiofrequency ablation with artificial pleural effusion/ascites was performed to predict where the lesion would be visualized when pleural effusion/ascites were created. The usefulness of this method was examined based on imaging findings immediately after treatment, 3 months later, and 6 months or more later.

Results: Immediately after treatment, the complete ablation rate was 96% (79 lesions), the local recurrence rate was 7% (6 lesions), and the major complication was 2% (one case of hemothorax).

Conclusion: By combining fusion imaging and CEUS before and during ablation with artificial pleural effusion/ascites, lesions can be detected quickly and accurately, allowing safe and reliable treatment.

Abstract Submission No. 101146
P-0385

Long-Term Outcomes of Combined RFA and Multipronged Ethanol Ablation for Unfavourable HCC

MING LIU1
1Department of Medical Ultrasonics, Institute for Diagnostic and Interventional Ultrasound, The First Affiliated Hospital, Sun Yat-Sen University Guangzhou China

PURPOSE: To evaluate the local efficacy, safety and long-term outcomes of combined radiofrequency ablation (RFA) and multipronged ethanol ablation (EA) in the treatment of unfavourable hepatocellular carcinoma (HCC) and to determine the prognostic factors for survival.

METHODS: Between August 2009 and December 2017, 98 patients with 110 unfavourable HCC nodules who underwent combined RFA and multipronged EA were retrospectively enrolled in the study. Unfavourable HCC was defined as a medium (3.1-5.0 cm) or large (5.1-7.0 cm) HCC nodule, a tumor located at a high-risk site or a perivascular tumor. The treatment response, overall survival (OS) and recurrence-free survival (RFS) were analysed. The Kaplan-Meier method and Cox proportional hazards regression model were used to evaluate the prognostic factors.

RESULTS: Complete ablation was obtained in 80.9% (89/110) of the tumors after initial treatment. Major complications were observed in 3(3.1%) patients. The cumulative incidence of local tumor progression (LTP) was 23.5% at 5 years, and no variable was found to be an independent predictive factor for LTP. The five-year OS and RFS rates were 41.9% and 34.0%, respectively. Multivariate analysis showed that serum AFP level, tumor size, residual tumor after ablation and extrahepatic metastases were significant prognostic factors for OS (p=0.023, p=0.030, p=0.001, and p=0.010, respectively). Tumor type and number of tumors were predictive factors for RFS (p=0.029 and p=0.001, respectively). Perivascular tumor was not an independent predictive factor for OS or RFS.

CONCLUSION: Combined RFA and multipronged EA is a safe and effective treatment for unfavourable HCC, especially for perivascular tumors.

Abstract Submission No. 101274
P-0386

Radiofrequency ablation for the treatment of hepatocellular carcinoma just below the hepatic capsule

Takashi Tanaka1, Takahiro Nagata1, Takashi Miyayama1, Kumiko Shibata1, Hiromi Fukuda1, Ryo Yamauchi1, Atsushi Fukunaga1, Kazuhide Takata1, Keiji Yokoyama1, Satoshi Shakado1, Shotaro Sakisaka1, Fumihiro Hirai1
1Gastroenterology and Medicine, Fukuoka University Hospital Fukuoka Japan

Aim: When performing radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), it is necessary that the insertion of electrodes into the center of the tumor through the hepatic capsule is confirmed before the procedure.
Abstract Submission No. 101419
P-0387
Sonazoid Enhanced Ultrasound for Image-Guided Procedures and Ablation
Jae Woong Choi1, Seokyoung Lee1, Jeong Woo Kim1, Jongmee Lee1, Chang Hee Lee1, Kyeong Ah Kim1
1Korea University Guro Hospital Seoul South Korea

Teaching Points: Sonazoid-enhanced ultrasound (SEUS) is a recently introduced contrast-enhanced ultrasound using Sonazoid (GE Healthcare) offering the vascular phase and the unique post-vascular Kupffer phase for helping diagnose hepatic tumors. Its role has been primarily focused on differentiating benign and malignant hepatic tumors, primarily used in the preoperative setting to aid in tumor staging. SEUS plays an important role in the interventional procedures as an excellent tool for tumor ablation, 5) Tips for using SEUS.

Abstract Submission No. 101959
P-0389
Percutaneous Microwave Ablation and Lenvatinib on Intermediate-Stage Hepatocellular Carcinoma
Ariane Crizelle Jose-Baluyot1, Diana A Payawal2
1Cardinal Santos Medical Center San Juan Philippines

Background: Systemic therapy has been used as a first-line treatment for intermediate-stage HCC, especially for larger (>5 cm) or multiple lesions. Based on the REFLECT trial, lenvatinib has been approved as a first-line treatment for unresectable HCC in different parts of the world. Lenvatinib has exhibited favorable results in inhibiting tumor angiogenesis and tumor growth. The present study aimed to evaluate efficacy of combined percutaneous microwave ablation therapy and lenvatinib in patients with intermediate hepatocellular carcinoma.

Methods: Thirteen patients with Child Pugh B-HCC were included in the study. The patients had no prior history of systemic treatment. Of them, 4 received both PMA T and Lenvatinib, while 9 of them received PMA T monotherapy. The clinical outcomes used to evaluate treatment included tumor size, MELD Na, and Child Pugh Class.

Results: The 2 treatment arms were followed up on a monthly basis for 6 months, there were no significant difference on MELD Na scores (p-value = 0.068) and tumor size progression on both treatment arms (p-value = 0.271). For the first 5 months of the study, there was no significant difference on Child Pugh Classes, however on the 6th month, based on the repeat measures ANOVA there was significant increase on the CPC of monotherapy arm in comparison with combination therapy, PMAT + Lenvatinib (p value < 0.05) which has stable CPC.

Abstract Submission No. 101432
P-0388
RFA with laparoscopic support is useful for difficult cases to treat Hepatocellular Carcinoma
MASANORI KAWAGUCHI1, YASUTO TABATA1, HIROFUMI YAMAZAKI1, KAZUO ARII2, MASAAKI DEGUCHI2

1Saiseikai Wakayama Hospital Department of Gastroenterology Wakayama City Japan, 2Saiseikai Wakayama Hospital Department of Surgery Wakayama City Japan

Back ground: HCC of S4 surface at back of right rim or severe obesity cases are difficult to visualize and puncture by abdimal US. We performed RFA under general anesthesia with laparoscopic observation (L-RFA).

Case1: 67y.o.M. ALD-LC treated for multifocal HCCs. CT revealed 1.1cm,0.8cm HCCs. TACE and P-RFA was performed, but insufficient cauterization. Laparoscope found on the surface of liver and confirmed by US. Cool-tip 3cm needle was punctured. Histology was poorly differentiated HCC, but there was no local recurrence. For recurrence at other sites, MWA and immune checkpoint inhibitors were administered, the patient is currently alive for 5 years.

Case2: 62y.o.M.HCV-LC treated P-RFA and myocardial infarction. TACE was performed second times, but insufficient. Laparoscopic US confirmed a mosaic-like 2.0 cm HCC with the portal vein on the dorsal side, and puncture from the caudal side of the tumor.

Case3: 90y.o.F. HCV-LC; initial HCC appears in S4 caudal surface beside duodenum. Laparoscopic US showed an irregular shaped 2.0 cm HCC. 2 cm needle was punctured. Caudal surface, dorsal side, and part of falciform membrane were cauterized.

Case4: 63y.o.F. BMI 39.3kg/m2 with HCV natural cure and MASH-LC, who have a history of operation and P-RFA. HCC appears in S3 surface and in contact with stomach. Treatment with TACE was insufficient. Laparoscope revealed a protruding tumor on liver surface, 2 cm needle is punctured and cauterized. Result: All tumors were treated with cool-tip needle, and was punctured through normal liver tissue, sufficiently cauterized and confirmed by CECT.

Conclusion: If HCC exists at S4 surface or severe obese cases at liver surface in other areas, L-RFA is useful to treat safety and effective.
Conclusion: Our proposed combination therapy may potentially be effective in patients with Child Pugh B-HCC. A larger scale, multicenter, prospective study is warranted to confirm the findings.

Abstract Submission No. 102036
P-0390

Considerations for Part-time Doctors Performing Ablation
Takahisa Sato1,2, Shinpei Sato3, Takuro Nishiwaki3, Koichi Kitaura4, Kentaro Takahashi1, Naoki Takamura1, Shuntaro Obi1
1Teikyo University Chiba Medical Center Chiba Japan, 2Kameda Medical Center Chiba Japan

Background: In areas with a small number of physicians, even large hospitals do not have full-time physicians specializing in ablation, so part-time physicians may perform ablation.

Patients: As a part-time physician, I performed more than 160 cases of radiofrequency ablation for liver cancer at a large hospital with more than 800 beds in Chiba Prefecture from 2015 to 2022. On working days, I perform contrast-enhanced ultrasound in the morning and ablation in the afternoon. Patients who are considered for ablation must come to the hospital for contrast-enhanced ultrasonography, and I will decide whether it is indicated or not (treatment will be performed at a later date). Since this examination also serves as a planning echo, the need for artificial pleural effusions and ascites, appropriate body positioning and ultrasound imaging methods should also be noted. CT is taken the day after treatment to determine the effectiveness of treatment and to check for any complications. The full-time physician is asked to manage the perioperative period. Patients whose antithrombotic therapy cannot be interrupted and hemodialysis patients are at high risk of bleeding, so avoid ablation at part-time setting. Other high-risk lesions may also be referred to other facilities or considered for alternative treatment.

Results: One case of intrahepatic hemorrhage was observed, but the bleeding was cured with conservative treatment. There were no other major complications, and we continue to provide safe treatment.

Conclusion: What to consider when performing ablation on a part-time setting.

Abstract Submission No. 102056
P-0391

Contrast-Enhanced Low-MI THI: A useful imaging support for the locoregional therapy for liver tumor
Yasuhide Motoyoshi1, Makoto Wataya1, Kosuke Matsumoto1, Yuki Kugiyama1, Tomoyuki Suehiro1, Akira Saeki1, Shinya Nagaoka1, Kazumi Yamasaki1, Atsumasa Komori1, Hiroshi Yatsuhashi1
1National Hospital Organization (NHO) Nagasaki Medical Center, department of Hepatology Omura Japan

Background: Contrast-Enhanced Low-MI THI (Low-Mechanical Index of Tissue Harmonic Imaging) is a useful imaging support technique for the locoregional treatment for liver tumors; it provides B-mode (THI)-like images overlaid with CHI (contrast harmonic imaging) contrast information. We show the characteristics of this method based on our experience at our hospital.

Method: ARIETTA 750LE or ARIETTA 850 (Fujifilm Medical) was used as an ultrasound machine, with a contrast agent Sonazoid. The basic condition settings for low-MI THI were as follows: the MI value was set around 0.20 using a wideband probe (1-6MHz), with maximized screen gain in conjunction with appropriate focus, that was sufficiently deeper than the lesions.

Results: Low-MI THI allowed superior resolution to that of CHI, which was commonly used for contrast imaging; the ability to set higher frame rates and the improved visualization of deep lesions were advantages. In addition, using as a reference for fusion imaging, low-MI THI enabled treatment for the lesions that were difficult to visualize in B mode. It was also useful for the evaluation of treatment efficacy.

Conclusion: Low-MI THI is superior to the ordinary contrast mode. Combination of Low-MI THI with Fusion is an efficient imaging support for the treatment, as well as post-treatment evaluation of liver tumors.

Abstract Submission No. 200127
P-0392

Temperature Profile and Safety of Grounding Pads during Radiofrequency Ablation
Yoshinari Kikuchi1, Eisaku Sato2, Takahiko Fujita2
1Japan Lifeline, Co., Ltd. Tokyo Japan, 2SEKISUI KASEI CO., LTD. Osaka Japan

Background: Radiofrequency ablation (RFA) systems deliver larger amount of electric current than standard electrical surgical units whose intended use is dissection and hemostasis. Due to this nature, many of the RFA systems require application of multiple grounding pads to prevent skin burn. However, risk cannot be fully eliminated just by using designated number of grounding pads. We monitored temperature distribution on grounding pads during current deposition to obtain better understanding of heat profile on the grounding pads during RFA.

Methods: Thermographic monitoring of temperature of grounding pads placed on healthy volunteers was conducted using arfa RF ABLATION SYSTEM under various conditions relating to energy delivery and grounding pad configurations.

Results: Temperature correlated positively and negatively with the amount of energy delivered and surface area of grounding pad(s), respectively. However, an extreme condition of 10-minute continuous delivery of 120W resulted in tolerable temperature rise up to 40.2°C. When two pads were placed in uneven distances from the active pole, the closely located one generated more heat. Comparison of two each of pads placed on the thigh and the back demonstrated higher temperature spots at the former suggesting more even current distribution over entire surface on the pads placed on the back.

Conclusions: arfa RF ABLATION SYSTEM can be used safely when the instructions from the manufacturer are followed. Application of the grounding pads on the back may mitigate hot spots caused by concentration of electric current at the leading edge of a grounding pad.

Abstract Submission No. 200136
P-0393

Usefulness of the dual thermometers and non-slip needle processing of arfa RF Ablation System.
Yuki Kodama1, Yoshinari Kikuchi1, Kenji Mori1, Hisao Miyamoto1, Toru Kimura2
1Japan Lifeline Co., Ltd. Saitama Japan, 2Osaka Red Cross Hospital Osaka Japan

Background: arfa RF ABLATION SYSTEM (arfa) is equipped with two temperature sensors (Dual Temperature Sensors) at the tip of the
needle electrode. One thermometer monitors the cooling water temperature in the needle (TM1), while the other can monitor tissue temperature (TM2).

The insulating sheath has a polyurethane (PU) non-slip surface to reduce the motion of electrode position after puncture.

Methods: The temperatures of TM1 and TM2 were monitored in a clinical case during ablation to see the functional differences between the two.

In a bench-top setting, an electrode with insulated sheaths without and with non-slip coating were punctured, and the resistance at each extraction was measured and compared.

Results: During ablation, TM1 maintained a temperature of around 14°C. TM2 showed 32°C before ablation and reached 70°C at 11 seconds, then over 99°C just before a break. Both TM1 and 2 repeated similar behavior between a total of 3 breaks obtained.

The average extraction resistance without PU was 0.68N, and that with PU was 1.05N. The extraction resistance with PU was significantly higher (p<0.003).

Conclusions: The tissue thermometer enabled monitoring of the tissue temperature during ablation, suggesting that it is a reliable parameter to judge whether the tumor site is ablated.

The presence of a non-slip device increased the extraction resistance. This suggests that the needle electrode is stable in a static state after puncture. These features which are unique to arfa among the RFA system commercially available in Japan provide clinical usefulness.

Abstract Submission No. 200155

Cox model risk score to predict survival of intrahepatic cholangiocarcinoma after thermal ablation

Yueting Sun1, Xiaoyan Xie1, Guangliang Huang1

1The Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou China

Purpose: To explore factors associated with overall survival (OS) and progression-free survival (PFS) of intrahepatic cholangiocarcinoma (iCCA) after ultrasound-guided ablation and establish a model for risk evaluation.

Methods: Data from 54 patients with 86 iCCAs between August 2008 and October 2022 were retrospectively analyzed. Cox regression were used to analyze the effects of clinical features on OS and PFS. Based on the variables screened by multivariable analysis, a model was established to obtain the risk score. The model was further verified by bootstrap validation. The clinical usefulness of the model was evaluated by the decision curve analysis (DCA).

Results: During follow up, 39 patients died and 49 patients developed recurrence. Pre-ablation CA199 level > 140 U/ml was the only independent predictor of poor PFS. Age > 70 years, early recurrence, maximal diameter of tumor size > 1.5 cm and pre-ablation CA199 level > 140 U/ml were significantly associated with poor OS. Then a model was established based on the above four variables to predict the survival outcomes of the patients after thermal ablation. The performance of this model was good [area under the curve (AUC) for 1-year, 2-year, 3-year, 5-year was 0.767, 0.854, 0.791 and 0.848]. After bootstrapping for 1000 repetitions, the AUC were similar to the initial model. DCA also demonstrated the model had good positive net benefits.

Conclusion: The established model in this study could predict the survival outcomes of the patients with iCCA after thermal ablation, but further research was needed to validate the results.

Abstract Submission No. 200177

Electromagnetic Interference Test between a Radiofrequency Ablation System and a Cardiac Pacemaker

Kai Wen Shih1, Yoshinari Kikuchi1, Yuhiko Masuda1, Takehide Nagamine1

1Japan Lifeline Co., Ltd. Tokyo Japan

Background: Application of radiofrequency ablation (RFA) for the patients implanted with Cardiac Implantable Electronic Devices (CIEDs) is generally contraindicated. Nevertheless, there are cases in the clinical practice that RFA is performed in these patients after careful risk-benefit assessment. This in-vitro experiment aimed to reveal the electromagnetic interference (EMI) between an RFA system and a cardiac pacemaker (PM) implanted in the patients.

Methods: A PM, an active RFA electrode and a grounding pad of arfa RF ABLATION SYSTEM were placed in a saline filled plastic tub, furthermore, changes in state of the PM were observed under various conditions including the relative position of the two devices, the RF output power level, and the programming of the PM.

Results: Higher risk of oversensing was associated with RF output power level, distance and relative position of the two devices as well as the pacemaker-related factors including use of DDD mode and unipolar configuration. Joule heating occurred at the tip of the leads when the pacemaker and the RFA electrode came into direct contact.

Conclusions: Many of the risks demonstrated in our experiment seemed uncommon to be encountered in the standard liver RFA procedure. The risk of EMI during liver RFA perform in the patients implanted with PM could be minimized by acquiring sufficient knowledge and conducting appropriate preventive measures.

Abstract Submission No. 200219

Predicting Severe Infection after Ablation of Liver Malignancies Based on Inflammatory Indicators

Lin Jiang1, Ming Xu1, Xiaoyan Xie1

1The Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University Guangzhou China

Background: The prognosis of patients with severe infectious complications after percutaneous thermal ablation is significantly worse than that of non-severe patients, but no effective predictors have been published.

Purpose: To explore the preoperative and postoperative predictors for severe infection after thermal ablation of liver malignancies, and to construct prediction models based on peripheral inflammatory indicators.

Materials and methods: 8655 ultrasound-guided percutaneous thermal ablation procedures of liver malignancies at a tertiary referral hospital from January 2012 to November 2023 were respectively reviewed. Patients with infectious complications after ablation were included and divided into severe and non-severe groups based on whether they developed sepsis and/or septic shock. Prediction models were established by stepwise logistic regression.

Results: A total of 85 patients were enrolled in this study, including 69 (81.2%) patients with primary tumors and 16 (18.8%) with metastatic tumors. 18 (21.2%) patients were severe and 67 (78.8%) were non-severe. In the pre- and post-ablation model, preoperative monocytes ratio (OR=0.71; 95%CI: 0.55-0.96; P=0.026) and procalcitonin (PCT) first examined after fever (OR=1.23; 95%CI: 1.09-1.39;
Peripheral blood cells and inflammatory indicators combined with other clinical characteristics are helpful to predict severe infection after thermal ablation of liver malignant tumors, including tumor type, preoperative monocytes ratio and PCT first examined after fever.

Conclusion: Peripheral blood cells and inflammatory indicators combined with other clinical characteristics are helpful to predict severe infection after thermal ablation of liver malignant tumors, including tumor type, preoperative monocytes ratio and PCT first examined after fever.

Abstract Submission No. 100269
P-0397

Ninavmix: Multimodal Deep Learning model for Detection of Liver Fibrosis in normal ALT CHB Patients

Mingjin Lu1, Yicheng Mao1, Wenxuan Shang1, Huifang Zhang1, Ruicong Chen1, Yijing Cai1, Chao Cai1
1The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

Background: Researches have indicated disease progression in hepatitis B patients with normal ALT levels. While liver biopsy offers assessment, it is invasive. Existing predictive tools lack integration of CT images and clinical metrics, leading to poor accuracy for patients with normal ALT levels. In this study, we formulate a multimodal deep learning model that combines CT images with clinical metrics for precise advanced fibrosis detection.

Methods: A multimodal deep learning model was developed based on ResNet18 and SVM to diagnose advanced liver fibrosis. It combined CT images and 20 clinical indicators. Data was collected and split into training and validation sets (7:3) from 784 hepatitis B patients with normal serum ALT who underwent abdominal CT and liver biopsy. Multimodal model was compared with existing noninvasive scores.

Results: Our model performed well in diagnosing advanced liver fibrosis. It combined CT images and 20 clinical indicators. Data was collected and split into training and validation sets (7:3) from 784 hepatitis B patients with normal serum ALT who underwent abdominal CT and liver biopsy. Multimodal model was compared with existing noninvasive scores.

Conclusions: Our model can integrate CT images and clinical metrics to diagnose advanced liver fibrosis in hepatitis B patients before liver enzyme changes. It outperforms existing noninvasive scores.

Abstract Submission No. 101393
P-0398

Competence of the ChatGPT for the Japanese Hepatologist Examination: Initial Experience

Hiromi Nemoto1, Takeshi Niih1, Naoaki Konno1, Akari Munakata1, Shyuzo Yamada1, Yosuke Nemoto1, Yoshi Metoki1, Kei Takahashi1, Mika Takasu1, Ryoma Takano1, Naoki Iso1, Ken Ohkawara1, Yohei Aoki1, Hiroshi Kashimura1
1MITO SAISEIKAI GENERAL HOSPITAL Mito Japan

Background: ChatGPT is an AI developed by OpenAI and is called a large language model. In this study, we evaluated the ability of the ChatGPT; GPT-4 using questions that require knowledge equivalent to that of a medical specialist examination.

Material and Methods: The target examination was the Japanese Society of Hepatology’s Liver Specialist Certification Examination Question-and-Answer and Explanation Vol. 6, and the AI was OpenAI’s ChatGPT; GPT-4. The knowledge data is currently available until April 2023. This AI can handle text and images, but has not been trained to interpret medical images at this time. There are 102 questions in total, excluding those that require images to be answered. The language used for the prompts was Japanese, the same as the question text.

Results: Of the 102 questions, 22 contained images. Of the 102 questions, 22 contained images, but 20 of these images were directly related to the answer. Excluding these, we examined the ChatGPT answers to 82 of the 102 questions. Of the 82 questions, 67 (81.7%) gave the correct answer. 15 incorrect answers were found to be due to lack of knowledge (10), logical inconsistency (1), fictitious evidence (3), and difficulty in interpreting the question itself (1).

Conclusion: ChatGPT showed a high ability to answer the Japanese hepatologist examination questions. It is expected that ChatGPT will become a powerful assistant for medical practitioners in the future by improving the performance of AI itself, learning high-quality professional evidence, and further medical-specific tuning.

Abstract Submission No. 101973
P-0399

Machine Learning for Stratifying Autoimmune Hepatitis Phenotypes: Precision Therapeutic Insights

Rifaldy Fajar1, Celeste Marevezzoni2, Bruno Barbeino2
1Department of Information Engineering, Computer Science and Mathematics, University of L’Aquila L’Aquila Italy, 2Hepatology Research Unit, L’Aquila Hospital L’Aquila Italy

Background/Aim: Autoimmune Hepatitis (AIH) exhibits a spectrum of immunological phenotypes, demanding precise characterization for tailored therapeutic approaches. This study aims to dissect distinct immune signatures associated with varied clinical presentations using machine learning, enhancing stratification for personalized treatment interventions.

Methods: Peripheral blood samples from 50 AIH patients were subjected to flow cytometry, cytokine assays, and RNA sequencing. Leveraging k-Nearest Neighbors and XGBoost algorithms, we integrated multi-omics data to train models correlating immune signatures with clinical phenotypes and treatment responses.

Results: Machine learning models demonstrated notable accuracy, achieving an 87% accuracy in predicting treatment response (k-Nearest Neighbors) and a 90% accuracy in classifying patients into immunological subtypes (XGBoost). Feature importance analysis unveiled specific immune cell populations, cytokine profiles, and gene expression patterns linked to treatment outcomes.

Conclusions: This study emphasizes machine learning’s potential in understanding AIH’s complex immunological landscape, enabling precise classification and guiding tailored therapies. Integrating machine learning into AIH management represents a transformative, personalized approach to autoimmune liver disease, addressing the imperative need for individualized strategies.

Abstract Submission No. 200061
P-0400

Hepatocellular Carcinoma Detection based on Deep Learning using Multi-sequence Data
Na Yeon Han1, Beom Jin Park1, Yeo Eun Han1, Min Ju Kim1, Yongwon Cho1, Deuk Jae Sung1, Ki Choon Sim1, Sung Hee Han1, Seunghyun Youn1

1Department of Radiology, Korea University Anam Hospital Seoul South Korea, 2Department of AI center and Radiology, Korea University Anam Hospital Seoul South Korea, 3Korea University Anam Hospital Seoul South Korea, 4GRK partners research Center Seoul South Korea

Background and Objectives: Diagnosis of hepatocellular carcinoma (HCC) on liver MRI needs analysis of multi-sequence images. However, developing computer-aided detection (CAD) for every single sequence requires considerable time and labor for image segmentation. Therefore, we developed CAD for HCC on the hepatobiliary phase (HBP) of gadoxetic acid-enhanced magnetic resonance imaging (MRI) using a convolutional neural network (CNN) and evaluated its feasibility on multi-sequence, multi-unit, and multi-center data.

Methods: Patients who underwent gadoxetic acid-enhanced MRI and surgery for HCC in Korea University Anam Hospital (KUAH) and Korea University Guro Hospital (KUGH) were reviewed. Finally, 170 nodules from 155 consecutive patients from KUAH and 28 nodules from 28 patients randomly selected from KUGH were included. Regions of interests were drawn on the whole HCC volume on HBP, T1-weighted (T1WI), T2-weighted (T2WI), and portal venous phase (PVP) images. The CAD was developed from the HBP images of KUAH using customized-nnUNet and post-processed for false-positive reduction. Internal and external validation of the CAD was performed with HBP, T1WI, T2WI, and PVP.

Results: The performance of the CAD for HBP, T1WI, T2WI, and PVP at false-positive rate 0.5 were (0.87 and 87.0), (0.73 and 73.3), (0.13 and 13.3), and (0.67 and 66.7) in KUAH and (0.86 and 86.0), (0.61 and 53.6), (0.07 and 0.07), and (0.57 and 53.6) in KUGH, respectively.

Conclusions: This result implies that the CAD developed using a single MRI sequence may be applied to other similar sequences and this will reduce labor and time for CAD in multi-sequence MRI.

Abstract Submission No. 200172
P-0401

Comparison of Machine Learning Algorithm in Predicting Living Status of Hepatitis Patients

Nahya Nur1

1Universitas Sulawesi Barat Majene Indonesia

Hepatitis is an inflammation of the liver caused by various infectious viruses and noninfectious agents, resulting in a range of health issues, some of which can be fatal. In this study, we will use artificial intelligence approaches to classify patients based on the possibility of living or dying. This study will compare several algorithms such as Artificial Neural Network (ANN), K Nearest Neighbor (KNN), and Support Vector Machine (SVM). The data obtained from Kaggle with a total of 142 data with 19 attributes. The model will be evaluated using three test metrics. Accuracy shows how optimally the algorithm works in general, sensitivity shows the algorithm’s performance in classifying the ‘die’ class, while specificity shows how well the algorithm is in classifying the ‘live’ class. Based on the results, ANN provides the most optimal results with the highest accuracy of 93%, sensitivity of 80% and specificity of 95%. In the SVM algorithm, although the resulting accuracy and specificity are quite good, it cannot predict which patients will die according to sensitivity value equal to zero. The results obtained also show that among the three algorithms used, the KNN algorithm has the worst performance. The results influenced by an unbalanced amount of data where there were 26 data in the ‘die’ class and 116 data in the ‘live’ class.

Based on the results of the comparison carried out on the ANN, SVM, and KNN methods, the results showed that the most optimal algorithm was the ANN algorithm with an accuracy of 93%.

Abstract Submission No. 100167
P-0402

Inhibitory effect of GLP-1RA on liver cirrhosis-induced skeletal muscle atrophy in diabetic mice

Satoshi Iwai1, Kosuke Kaji1, Norihisa Nishimura1, Takahiro Kubo1, Fumimasa Tomooka1, Akihiko Shibamoto1, Junya Suzuki1, Yuki Tsuji1, Yukihisa Fujinaga1, Koh Kitagawa1, Tadashi Namisaki1, Takemi Akahane1, Hitoshi Yoshiji1

1Department of Gastroenterology, Nara Medical University Kashihara, Nara Japan

Background: Recent studies have demonstrated the molecular role of the glucagon-like peptide-1 receptor agonist (GLP-1RA) in skeletal muscle homeostasis; however, the therapeutic efficacy of semaglutide, a GLP-1RA, on skeletal muscle atrophy in chronic liver disease (CLD) under the diabetic condition remains unclear.

Methods: We used in vivo diabetic CLD-related sarcopenic models in KK-A^- mice and in vitro atrophy models C2C12 myocytes to investigate therapeutic efficacy of semaglutide.

Result: Semaglutide inhibited psoas muscle atrophy and suppressed declines in grip strength in mice. Moreover, semaglutide inhibited ubiquitin-proteosome-mediated skeletal muscle proteolysis and promoted myogenesis in C2C12 myocytes. Mechanistically, this effect of semaglutide on skeletal muscle atrophy was mediated by multiple functional pathways. First, semaglutide protected against hepatic injury in mice accompanied by increased production of insulin-like growth factor 1 and reduced accumulation of reactive oxygen species (ROS). These effects were associated with decreased proinflammatory cytokines and ROS accumulation, leading to suppression of ubiquitin-proteosome degradation in the skeletal muscle tissue. Moreover, semaglutide inhibited the amino acid starvation-related stress signaling which was activated under chronic liver injury, resulting in the recovery of mammalian target of rapamycin activity in the skeletal muscle of mice. Second, semaglutide improved skeletal muscle atrophy by directly stimulating GLP-1R in myocytes. Treatment with semaglutide induced cAMP-mediated activation of PKA and AKT, enhanced mitochondrial biogenesis, and reduced ROS accumulation, thereby resulting in inhibition of NF-κB/myostatin-mediated ubiquitin-proteosome degradation and the augmentation of heat-shock factor-1-mediated myogenesis.

Conclusion: Semaglutide may have potential as a new therapeutic strategy for CLD-related skeletal muscle wasting.

Abstract Submission No. 100251
P-0403

Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption

Akiko Shibamoto1, Kosuke Kaji1, Hitoshi Yoshiji1

1Nara Medical University Department of Gastroenterology Kashihara Japan
Background: Endogenous lipopolysaccharide (LPS) that translocates via the disrupted intestinal barrier plays an essential role in the progression of alcohol-related liver disease (ALD). Vitamin D deficiency is observed in ALD, and it participates in regulating gut barrier function. Therefore, we investigated that the effect of vitamin D deficiency on ethanol (EtOH)- and carbon tetrachloride (CCl4)-induced liver injury relevant to gut barrier disruption in mice.

Methods: To investigate the hypothesis, we fed female C57BL/6J mice a liquid diet containing 2.5% EtOH and intraperitoneal injections of CCl4 twice weekly for 8 weeks. The mice were divided into vitamin D-deficient (vitamin D: 1.6 IU/kg) and vitamin D-sufficient (vitamin D: 54.4 IU/kg) groups. In addition, we cultured CaCo2 cells to examine the direct effects of vitamin D on intestinal cells.

Results: The EtOH/CCl4-treated mice developed hepatic steatosis, inflammation, and fibrosis, which were significantly enhanced by vitamin D-deficient diet. Vitamin D deficiency enhanced gut hyperpermeability by inhibiting the intestinal expressions of tight junction proteins including ZO-1, occludin, and claudin-2/5/12/15 in the EtOH/CCl4-treated mice. Consequently, it induced Kupffer cell infiltration and LPS/toll-like receptor 4 signaling-mediated proinflammatory response. Based on the in vitro assay, vitamin D-mediated vitamin D receptor activation inhibited EtOH-stimulated paracellular permeability and the downregulation of tight junction proteins in Caco-2 cells.

Conclusion: Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption and hepatic overload of endotoxin.

Abstract Submission No. 100994
P-0404

Digital image analysis reveals different fibrosis patterns in congestive hepatopathy versus MASH

Matthew Yeh1, Hung-Wen Tsai2, Yoh Zen3, Elaine Chng5, Che-Wei Hsu2, Cheng-Yi Chen5, Yayun Ren4, Kuthubudd Akbar4, Dean Tai4

1University of Washington, Seattle, WA, USA Seattle USA, 2Department of Pathology, National Cheng Kung University Hospital, College of Medicine Tainan Taiwan, 3Institute of Liver Studies, King’s Healthcare Partners, King’s College Hospital NHS Foundation Trust London United Kingdom, 4Histoindex Pte. Ltd. Singapore Singapore, 4Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University Tainan Taiwan

Background: Congestive heart failure can cause congestive hepatopathy (CH) featured by liver congestion, sinusoidal dilatation, centrlobular necrosis and fibrosis, so called cardiac sclerosis. Similar to metabolic dysfunction-associated steatohepatitis (MASH), the fibrosis starts from centrlobular area and progression to bridging fibrosis and cirrhosis. We aim to explore the feasibility of using SHG/TPEF microscopy in assessing liver fibrosis in CH and compare the fibrotic patterns between CH and MASH.

Method: Unstained sections from 24 CH cases with Dai scheme stages 0, 1, 2 and 3 were imaged using SHG/TPEF microscopy. Quantified collagen parameters in the liver lobule regions (portal, peri-portal, zone 2, peri-central and central vein) were obtained from qFibrosis measurements and represented as radar plots. The results were compared to 156 untreated MASH cases across NASH-CRN F0 to F4.

Results: For every stage, the overall fibrosis measured by SHG was lower in CH cases than NASH cases, with significant difference for F0 (p<0.01). This is also observed with the smaller radar plot area representing CH compared with MASH cases. The periportal fibrosis and perisinusoidal fibrosis were consistently and significantly lower in CH cases than NASH cases across all stages (Figure).
Background: Lymphatic vessel (LV) numbers increase in the liver after I/R injury. Fibronectin-1, a matrix protein, facilitates lymphatic endothelial cells (LECs) proliferation. Increased fibronectin-1 expression in liver macrophages during liver lymphangiogenesis, the formation of new LVs. We hypothesized that macrophage fibronectin-1 facilitates lymphangiogenesis and subsequently promotes the liver recovery after I/R injury.

Method: Hepatic I/R injury was induced in macrophage-specific fibronectin knockout (FN M

Abstract Submission No. 200041
P-0407

Myoblast cells harboring the capacity of liver regeneration do not promote proliferation of HCC

Keisuke Toya1, Yoshito Tomimaru1, Shogo Kobayashi1, Kazuki Sasaki1, Yoshifumi Iwagami1, Daisaku Yamada1, Takehiro Noda1, Hidenori Takahashi2, Akima Harada2, Shigeru Miyagawa2, Yuichiro Doki1, Hidetoshi Eguchi1

1Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka Japan, 2Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University Osaka Japan

Background: We previously reported utility of myoblast cell (MC) sheet transplantation for liver regeneration for liver cirrhosis. However, considering that patients with liver cirrhosis are potentially at risk for development of hepatocellular carcinoma (HCC), influence of MC on HCC growth should be investigated prior to clinical application of the MC sheet transplantation for cirrhotic patients. Thus, to confirm the safety of the sheet transplantation for liver failure in terms of tumor progression, we examined the effect of MC on the HCC proliferation including the tumor microenvironment in vitro and in vivo model.

Methods: In vitro, we assessed the effect of adding supernatant obtained from MC on the proliferation. Increased fibronectin-1 expression in liver macrophages during liver lymphangiogenesis, the formation of new LVs. We hypothesized that macrophage fibronectin-1 facilitates lymphangiogenesis and subsequently promotes the liver recovery after I/R injury. In vivo, we examined the effect of MC on cancer for the liver failure, even in the presence of potential HCC.

Results: In vitro, adding the supernatant of MC did not exhibit significant effect on the proliferation of Hepa-1. In the other hand, the proliferation of TEC was significantly suppressed by adding supernatant of MC for 48 hours. In vivo, subcutaneous tumor size after two weeks of the Hepa-1 injection with MC injection was smaller than in that without MC injection (127.4 ± 29.8 mm² vs. 235.6 ± 78.0 mm²).

Conclusions: These results suggested that MC does not promote the HCC progression. MC sheet transplantation could be an effective treatment for the liver failure, even in the presence of potential HCC.

Abstract Submission No. 200241
P-0408

Establishment of a new extraction method for extracellular vesicles derived from mouse liver tissues

YAWEN LI1,2, HIROYUKI ABE3, SHUNTA YAKUBO4, SHUJI TERA1

1Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University Niigata Japan, 2Department of Gastroenterology, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi Zunyi China

Background: Extracellular vesicles (EVs) are vesicles composed of a lipid bilayer membrane that are secreted from almost all cells in the body, and are a heterogeneous group that plays an important role in intercellular communication. Researches focusing on EVs in liver diseases have reported the use of EVs isolated from cell culture media or body fluids. However, very few studies have focused directly on EVs derived from liver tissue. Therefore, we researched and developed a protocol to isolate EVs from mouse liver tissue.

Methods: To isolate EVs from liver tissue, liver tissue was gently dissociated into small pieces and incubated with culture medium. Cells and debris were removed by filtration and centrifugation. After these steps, EVs were collected by ultracentrifugation. To evaluate the extraction of EVs, Nanoparticle tracking analysis (NTA) was performed to evaluate the concentration and size distribution. Furthermore, EVs markers CD63, CD81, and CD9 were evaluated by Western blotting.

Results: NTA revealed that most of the EVs isolated from liver tissues were in the range of 40 to 300 nm, consistent with the size of common EVs. Furthermore, the expression of EVs markers CD63, CD81, and CD9 was confirmed by Western blotting.

Conclusions: We have established and optimized an effective method to isolate high-quality EVs from mouse liver tissue. This protocol will help advance mechanistic studies of liver-derived EVs.

Abstract Submission No. 100164
P-0409

Combination Assay of Methylated HOXA1 with Tumor Markers Shows High Sensitivity for Early-Stage HCC

Yuki Kunimune1, Yutaka Suehiro1, Issei Saeki2, Yurika Yamauchi2, Norikazu Tanabe3, Toshihiko Matsumoto4, Naoko Okayama5, Mitsuaki Nishioka6, Kiyoshi Ichihara6, Hiroaki Nagano6, Taro Takami7, Takahiro Yamasaki1

1Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine Yamaguchi Japan, 2Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine Yamaguchi Japan, 3Division of Laboratory, Yamaguchi University Hospital Yamaguchi Japan, 4Division of Medical Genetics, Yamaguchi University Hospital Yamaguchi Japan, 5Department of Clinical Laboratory Sciences, Faculty of Health Sciences, Yamaguchi University Graduate School of Medicine Yamaguchi Japan, 6Department of Gastroenterological, Breast, and Endocrine Surgery, Yamaguchi University Graduate School of Medicine Yamaguchi Japan

Background: Although patients with non-viral-related hepatocellular carcinoma (non-viral HCC) have been increasing in Japan, there is no established surveillance system for them. To address this issue, we performed this study. In this study, we developed a novel index consisting of conventional tumor markers and methylated HOXA1 (m-HOXA1), which we reported as a useful biomarker for HCC, and assessed the diagnostic performance for HCC.

Methods: We collected serum samples from 516 participants including 154 healthy subjects, 93 chronic liver disease (CLD) patients without HCC, and 269 HCC patients. Participants were divided into a control group comprising healthy subjects and patients with CLD and a HCC group. We measured serum m-HOXA1 copy numbers using “combined restriction digital PCR assay” which was developed by us to measure CpG methylation levels. Alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) were also evaluated.
Estimating the Measurement Uncertainties of the PIVKA-II assay through Monte Carlo Simulation

Yong Kwan Lim1, Jiwon Yun1, Kiwook Jung2, Youngwon Nam3

1Chung-Ang University Hospital Seoul South Korea, 2Chungbuk National University Hospital Cheongju South Korea, 3Abbott Korea Ltd. Seoul South Korea

Background: Measurement uncertainty (MU) estimation has become an important process in clinical laboratories; however, calculating the MUs of protein induced by vitamin K absence or antagonist II (PIVKA-II) is difficult because of the complex mathematical calculations required in calibration. We aimed to quantify the measurement uncertainty (MU) for PIVKA-II (Abbott, IL, USA) using the Monte Carlo simulation (MCS), which is a computational algorithm that simulates statistical sampling to obtain numerical results through complex mathematical calculations.

Methods: Using the internal quality control results, we performed precision profiling of instrumental reading (relative light units; RLU), and the coefficient of variances were used as the relative uncertainties of RLU. Using these precision profiles, we simulated the weighted 4 parameters logistic calibration curves using MCS trials. Then, the MUs of PIVKA-II corresponding to each RLU were estimated through MCS.

Results: At 7.6 mAU/mL, the lower limit of the analytical measurement range (AMR), the MU was calculated to be the maximum of 25.0%. As the PIVKA-II result increased, the MU decreased and was calculated to be the lowest value of 8.6% at 393.1 mAU/mL. After that, the MUs of PIVKA-II tended to gradually increase, showing a MU of 11.8% at 30,000 mAU/mL, the upper limit of the AMR. At the clinical decision point (40.0 mAU/mL), the MU of PIVKA-II was 12.0%.

Conclusions: MCS is adequate to estimate the MUs of hs-cTnI for entire measurement range, and these results would be clinically useful for estimating the MUs of the PIVKA-II in clinical laboratories.

Fibrinogen Family as a Novel Diagnostic Marker in Hepatocellular Carcinoma

Ji Eun Han1, Jae Youn Cheong1, Soon Sun Kim1, Hye Jung Cho1, Jung Woo Eun1, Geum Ok Baek1, Moon Gyeong Yoon1, Min Ji Kang1,2, Ji Hyang Weon1, Ji Yi Choi1, Su Jin Kim0

1Department of Gastroenterology, Ajou University School of Medicine Suwon, Korea South Korea, 2Department of Biomedical Sciences, Ajou University Graduate School of Medicine Suwon, Korea South Korea

Background: Hepatocellular carcinoma (HCC) is a lethal cancer, emphasizing the critical need for early detection. Fibrinogen, comprising FGA, FGB, and FGG, has been explored as a potential blood marker for early HCC detection.

Methods: We analyzed Fibrinogen expression in the liver using data from GTEx Portal and TCGA. A cohort of 90 patients from Ajou University Hospital was evaluated using qRT-PCR. Additionally, the serum of 244 patients (Normal 30, Chronic Hepatitis 32, Cirrhosis 32, HCC 150) was assessed using ELISA to determine Fibrinogen protein concentration.

Results: Fibrinogen showed high liver expression but decreased expression in HCC tissues. Over 70% of HCC tissues in our cohort showed down-regulation of all three genes. ELISA results indicated a consistent decrease in FGA, FGB, and FGG levels from normal to HCC.

Conclusions: Our findings underscore the potential of Fibrinogen as a blood-based marker for early HCC detection. Its interaction with the tumor microenvironment suggests avenues for further research, potentially leading to novel HCC management strategies.
EN YING TAN1, Eunice Tan1, Daniel Huang1, Jonathan Lee1, Margaret Teng2, Nur Halisah binte Jumat1, Dean Tai1, Elaine Lay Khim Chung1, Yock Young Dan1, Mark Muthiah1

1NATIONAL UNIVERSITY HEALTH SYSTEM SINGAPORE Singapore, 2HistoInIndex Pte Ltd SINGAPORE Singapore

Fibrosis in NASH is the only histological finding that correlates with liver related outcomes, and its improvement is a key outcome measure in assessing therapeutics. Fibrosis is currently scored categorically, which lacks sensitivity in detecting smaller differences in fibrosis. We aimed to evaluate performance of NITS in correlating with a validated continuous histological fibrosis score (qFibrosis).

Patients with biopsy-proven NAFLD and no other liver disease were enrolled. Biopsies were quantitatively analysed for fibrosis with an artificial intelligence-based tool (qFIBS by HistoInIndex). FIB-4, APRI, NFS, VCTE, AGILE 3+ and FAST were measured. The relationship between histological scoring for fibrosis and qFib, as well as between NITS and qFib was evaluated by linear regression analysis. 248 patients were recruited from 2014 to 2021.

qFibrosis and fibrosis score had a linear relationship (R² 0.39, p < 0.001). qFibrosis correlated with all NITS (all p < 0.001), with R² of 0.12, 0.12, 0.14, 0.44, 0.27 and 0.18 for FIB-4, APRI, NFS, VCTE, AGILE 3+ and FAST.

On scatterplots, confidence intervals for regression lines are narrowest at qFibrosis 1-3. qFibrosis correlates well with fibrosis scores. NITS may have a role as continuous measures of fibrosis in NAFLD. Given narrow CIs, NITS may perform well at mild-moderate fibrosis where early intervention has greatest yield. VCTE is moderately correlated and greatest dynamic range, and may be the most useful NIT for evaluating fibrosis as a continuous variable.

Abstract Submission No. 100873
P-0414

Tumor marker elevation during post-operative surveillance in patient with hepatocellular carcinoma

Jeong Ah Hwang1, Ji Sun Lee2, Ji Hye Min1

1Samsung Medical Center Seoul South Korea, 2Chungbuk National University Hospital Cheongju South Korea

Purpose: aimed to evaluate factors influencing tumor marker elevation and their performance in detecting recurrent hepatocellular carcinoma (HCC) during post-operative surveillance.

Methods: We retrospectively analyzed 705 patients who underwent curative resection for HCC between January 2018 and March 2020. Post-operative surveillance included alpha-fetoprotein (AFP) and prothrombin-inhibited by vitamin K absence or antagonist-II (PIVKA-II) along with imaging exams. The cutoff values for AFP elevation were 20 ng/mL, and for PIVKA-II, 40 mAU/mL. Tumor marker normalization was defined as AFP<20 ng/mL and PIVKA-II<40 mAU/mL. Multivariable analysis was conducted to identify factors associated with tumor marker elevation. The positive predictive value (PPV) and negative predictive value (NPV) for HCC recurrence detection were calculated.

Results: Recurrence occurred in 34.6% (244/705). Independent factors linked to AFP elevation included recurrence (OR:21.89; 95% CI:7.46–64.18), preoperative AFP elevation (OR:3.63; 95% CI:1.73–7.63), log AFP at normalization (OR:12.68; 95% CI:3.52–45.70), and cirrhosis (OR:2.15; 95% CI:1.03–4.49). PIVKA-II elevation was independently associated with recurrence (OR:3.96; 95% CI:2.48–6.33), preoperative PIVKA-II elevation (OR:2.17; 95% CI:1.21–3.87), log PIVKA-II at normalization (OR:33.35; 95% CI:4.85–229.53), and vascular invasion (OR:2.37; 95% CI:1.07–5.26). Using AFP elevation, the PPV and NPV for recurrence were 82.5% (95% CI:38.9%–97.2%) and 81.4% (95% CI:78.5%–84.1%), while PIVKA-II elevation showed PPV and NPV of 88.8% (95% CI:69.6%–96.5%) and 81.3% (95% CI:78.3%–83.9%).

Conclusion: Tumor marker elevation during post-operative surveillance was associated tumor maker levels at preoperative and normalized state as well as recurrence. AFP and PIVKA-II elevation demonstrated significant PPV and NPV in detecting recurrence.

Abstract Submission No. 101368
P-0415

HBV surface antigen glycan isomer (HBsAgGi), correlates with HBV-DNA and HBV-RNA virions

Kiyohiko Angata1, Maki Sogabe1, Hisashi Narimitsu2, Ayato Murata1, Takuya Genda2

1RCMG Inc. Tsukuba Japan, 2Juntendo University Shizuoka Hospital, Department of Gastroenterology and Hepatology Izuokunishi–shi Japan

Background: In HBV patients’ sera, infectious particles containing HBV-DNA (Dane particles) or HBV-RNA particles are enveloped with hepatitis B virus surface antigen (HBsAg). Infectious particles contain L-, M-, and S-HBsAg, while non-infectious sub-viral particles (SVPs) mainly contain S-HBsAg. Because SVPs present much more than infectious particles, S-HBsAg is the most abundant in all HBV particles. Thus, general HBsAg test using S-HBsAg antibodies cannot distinguish infectious and non-infectious particles. Previously, we found that O-glycosylated M-HBsAg was enriched in HBV-DNA particles. In this study, we developed and examined a new antibody to detect infectious particles, which should contain O-glycosylated M-HBsAg, called as HBsAg glycan isomer (HBsAgGi).

Methods and Results: Western analysis indicated that HBsAgGi antibody recognized M-HBs modified with O-glycan but not L-HBs without O-glycan on the PreS2 of genotype C. Immunoprecipitation (IP) experiments confirmed that both HBV-DNA and HBV-RNA containing particles were immunoprecipitated by HBsAgGi antibody. HBsAgGi localized in ER to Golgi in MHBs-expressing cells. In treatment naïve chronic hepatitis B patients, serum HBsAgGi level was significantly correlated with the HBV-DNA level (p=0.002, n=32). However, HBsAgGi level was not associated with HBV-DNA level after NA treatment, which is consistent with the IP results.

Conclusions: O-glycosylated M-HBsAg is unique to genotype C infectious virions. New HBsAgGi antibody recognizes infectious HBV virions containing HBV-DNA or HBV-RNA, indicating that the infectious particles with HBsAgGi are generated through glycosylation pathway. Furthermore, NA treatment altered HBV-DNA and HBV-RNA status but not much HBsAgGi, suggesting that HBsAgGi is an useful monitor of infectious HBV particles during therapy.

Abstract Submission No. 101563
P-0416

Tumor stiffness as imaging biomarker for prediction of survival after curative resection for HCC

Hayato Abe1, Yukiyasu Okamura1, Tatsuo Kanda2, Yusuke Mitsuka1, Nao Yoshida1, Osamu Aramaki1, Masamichi Moriguchi1, Hisashi Nakayama1, Masahiro Okada6

1Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine Tokyo Japan, 2Department of
Background: Tumor stiffness measurement (TSM) using magnetic resonance elastography (MRE) could assess tumor mechanical properties and predict hepatocellular carcinoma (HCC) recurrence. The aim of this retrospective study was to investigate whether preoperative TSM by MRE can predict survival after curative resection for HCC.

Methods: One hundred-one patients with HCC who underwent preoperative MRE and curative resection were retrospectively analyzed. Potential associations of tumor stiffness and other clinicopathological variables with OS and RFS were analyzed in both univariate and multivariate Cox proportional hazards analyses. The optimal tumor stiffness cutoff value was determined using the minimal P-value approach.

Results: In the multivariate analysis, TSM (hazard ratio [HR], 1.20; 95% confidence interval [CI], 1.02–1.41; P = 0.034), multiple tumors (HR, 2.17; 95% CI, 1.05–4.35; P = 0.037), and tumor capsule (HR, 0.51; 95% CI, 0.29–0.93; P = 0.029) were selected as independent risk factors of recurrence. On the other hand, TSM (HR, 1.36; 95% CI, 1.07–1.75; P = 0.012) was selected as only an independent prognostic factor of overall survival in the same model. When the optimal cutoff point was set at 5.81 kPa, patients with TSM value ≥5.81 kPa were at a significantly greater prognostic factor of survival (HR, 5.47; 95% CI, 1.98–15.04; P < 0.001) than those with TSM value <5.81 kPa.

Conclusion: Higher tumor stiffness was associated with higher risk of recurrence and death. Therefore, TSM using MRE is a useful imaging biomarker for prediction of survival prognosis after curative resection for HCC.

Abstract Submission No. 101664
P-0417

EFFECT OF PESTICIDE CONTAMINATION ON PROTEIN LEVELS AND ANTI-OXIDANT ACTIVITY IN RICE

Nisrin Abd Kadir1
1UNIVERSITI MALAYSIA TERENGGANU KUALA TERENGGANU Malaysia

Rice, the world’s second-most important crop, is often subjected to harmful practices like excessive pesticide use to combat pest infestations. Studies have shown that consuming pesticide-contaminated food can lead to serious health problems, including an increased risk of liver cancer. Since rice is a staple food consumed daily for extended periods, it’s crucial to investigate how these pesticides affect the rice. This study aims to shed light on the effects of high pesticide concentrations on the total protein content and antioxidant activities of rice. For this study, the Oryza sativa variety MR263 was chosen and grown in a mixture of three parts soil, two parts sand, one-half part organic fertilizer, and one-half part peat moss. The rice was then exposed to pesticide concentrations four and six times higher than usual. The total protein and antioxidant activity of the rice were then measured using the Bradford and SOD tests on a UV-Vis Spectrophotometer. Our study revealed significant changes (p<0.05) in total protein and antioxidant activity when rice was contaminated with six times the typical pesticide concentration. The accumulation of heavy metals in rice plants due to excessive pesticide application may induce oxidative stress, potentially leading to adverse health effects for rice consumers, including an increased risk of liver cancer and other liver-related ailments. Therefore, accurate identification of antioxidant proteins in rice plants is crucial for developing biosensors that can detect food contaminated with high levels of pesticides.

Keywords: superoxide dismutase, ANOVA-analysis of variance.

Abstract Submission No. 101974
P-0419

Association of high iron and ferritin levels to chronic hepatitis in Mongolia

Erdenbayar Gonchig1,3,4, Munkhjargal Munkhtogoo1,2, Amaransasa Jazagi1,3,4, Enkhtuya Damba5,6, Enkhtuya Enkhtuvshin1, Baatarkhuu Oidov1
1Mongolian Genome Institute Ulaanbaatar Mongolia, 2Otoch Manramba University Ulaanbaatar Mongolia, 3Happy Veritas Hospital Ulaanbaatar Mongolia, 4MASLD Ulaanbaatar Mongolia

Introduction: Elevated ferritin and iron levels are common in patients with chronic hepatitis of non-viral origin. Excess iron and ferritin can...
cause liver damage and increase the risk of fibrosis, cirrhosis, and hepatocellular carcinoma.

Methods: This study aims to investigate the level of liver inflammation in people with elevated iron and ferritin levels. The study included 170 people with maximum elevated iron levels 26.9-55.9 mg/dl and 132 people with 250-2326.8 ng/mL and the percentage of those people with hepatitis were investigated.

Results: Our study determined the percentage of hepatitis in people with elevated ferritin and iron levels. In the control group with normal ferritin, the incidence of elevated ALT was 38%, compared to 86.4% in the elevated ferritin group. However, elevated AST was detected 42% in the normal ferritin control group and 87.9% in the elevated ferritin group. In the control group with normal iron, the incidence of elevated ALT was detected in 43.2% of patients, while in the group with high iron, it was 74.3%. In the iron-normal control group, AST elevation was 32.7 percent, compared to 60.9% in high serum iron group. Prevalence of high iron serum load was 3.9% among total out-patient test takers, which is much higher than other countries.

Conclusion: High ferritin was more associated to elevated ALT levels 86.4%, whereas high iron level group had slightly lower (74.3%) than that of ferritin’s. In this study we could not confirm etiology of high ALT levels within normal control groups.
the roles of GPX4 in tumor activity and gene or protein expressions associated with glucose metabolism and Akt-mTOR axis were analyzed in ICC cell lines.

RESULTS: The clinical study revealed that GPX4 high group showed significant associations with high SUVmax (≥ 8.0, p=0.017), multiple tumors (p=0.004), and showed GLUT1 high expression with a trend towards significance (p=0.053). Overall, recurrence-free survival in GPX4 high expression were significantly worse than those in the GPX4 low expression (p=0.038 and p=0.001). In the experimental study, inhibition of GPX4 using GPX4 inhibitor attenuated cell proliferation and migration in ICC cell lines. Inhibition of GPX4 also decreased the expression of glucose metabolism-related genes, such as GLUT1 or HIF1α. In mechanically, GPX4-mediated glucose metabolism was regulated in Akt-mTOR axis.

CONCLUSIONS: GPX4 is a significant prognostic marker in patients with ICC. Furthermore, GPX4 can mediate glucose metabolism of ICC.

Smart diagnostic strategy for SARS-CoV-2 viruses in real 166 patients samples.

Ahmed Tolba1, Erika Yoshihara1, Ayman A. Hassan2, Gamal Shiba1, Mitsuhiro Ebara1

1Smart Polymers Group, Research Center for Macromolecules and Biomaterials, National Institute for Materials Science, Tsukuba, Japan Tsukuba Japan, 2Egyptian Liver Research Institute and Hospital, Egypt Mansoura Egypt

Background: Various studies including ours have reported weaknesses of the current COVID-19 diagnostics including limited sensitivity, and even the gold-standard polymerase chain reaction (PCR) is advised to be repeated to avoid misdiagnosis. Clinical study was conducted to evaluate the diagnostic performance of our previously designed Smart-CoV (Patents: JP2022-161370 and WO2022-219967) as a thermo-responsive preanalytical strategy in COVID-19 diagnosis compared to PCR.

Methods: A prospective study included 166 subjects was conducted. Nasopharyngeal swabs from all participants were collected and tested for SARS-CoV-2 virus with and without Smart-CoV. SARS-CoV-2 detection sensitivity was estimated depending on PCR analysis results with and without Smart-CoV, and the patient’s full clinical evaluation.

Results and conclusions: Smart-CoV enabled the purification and enrichment of only virus’s native forms without cross-reactivity to related NUPR1: a potential targeted immunotherapy in pan-cancer

Xiaoyu Zhang1

1The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Objectives: NUPR1 is a stress-induced chromatin-related factor, which is consistently over-expressed in cancer tissues, especially in tumors with poor prognosis and significant drug resistance to anti-tumor therapy. We used The Cancer Genome Atlas (TCGA) pan-cancer data to assess the role of NUPR1.

Methods: We used TCGA (The Cancer Genome Atlas), GEO (Gene Expression Omnibus) data sets and many bioinformatics tools to explore the role of NUPR1 in pan-cancer. We used R package “clusterProfiler” to carry out NUPR1 enrichment analysis. Then we analyzed the association between NUPR1 expression and the level of immune cell infiltration. Furthermore, we evaluated the relationship between NUPR1 and immune activation genes, immune checkpoint, immune suppression genes, chemokines and chemokine receptors.

Results: Based on TCGA, NUPR1 is differently expressed in different tumor types, and it is related to the survival status. In addition, NUPR1 was significantly associated with immune-related and metabolism-related pathways, closely related to T-cell infiltration, immune checkpoints, immune activation genes, immune suppressive genes, chemokines, and chemokine receptors.

Conclusions: Our findings suggest that NUPR1 is a potential biomarker for cancer. NUPR1 may coordinate with other immune checkpoints to modulate the immune microenvironment and could be used to develop new targeted immunotherapy drugs.

ACUTE SEVERE HEPATITIS IN CHILDREN ACROSS THE PRE-PANDEMIC AND CORONAVIRUS ERA IN SINGAPORE

Fang Kuan Chiu1, Lay Queen Ng1, Christopher Ho1, Charanya Rajan1, Sarah Wong1, Veena Logarajah1, Kong Boo Phua1, Lynette Goh1

1KK Women’s and Children’s Hospital, Singapore Singapore

Background: This study aims to describe acute severe hepatitis (ASH) in Singaporean children before coronavirus-2019 (COVID-19) pandemic and during the outbreak of COVID-19.

Methods: This was a single-centre retrospective study of children aged 0-16 years presenting with ASH, defined by serum alanine transaminase and/or aspartate transaminase >500 U/L based on WHO definition. Cases were analysed: 2018-2019 (pre-pandemic) and 2020-2022 (coronavirus pandemic). AUHC was defined as ASH in which viral hepatitis A-E, other infective agents, immunologic, metabolic, drug/toxic and structural causes were excluded.

Results: Total of 112 cases of ASH were included with average of 27 cases/year and 19 cases/year in the pre-pandemic and COVID-19 pandemic periods respectively. Although numbers were limited, an increase in AUHC was observed in the pandemic period (Image 1). Out of the 8 cases of AUHC in the pandemic period, Adenovirus and SARS-CoV-2 were detected in 1 and 2 patients respectively. All 5 cases of AUHC in the pandemic period were associated with severe aplastic anaemia (AA) requiring bone marrow transplant, whereas no cases of severe AA was seen in the pre-pandemic period. In addition, there was an increase in systemic inflammatory/autoimmune disorders resulting in ASH during the pandemic period. Overall, none of the patients died and only one patient had liver transplant.

Conclusion: AUHC and severe hepatitis associated AA were higher in the pandemic years although the overall numbers remained low. The corresponding increase in systemic inflammatory disorders in the pandemic period may lend support to possible auto-inflammatory process in the pathogenesis of AUHC.
PROFILE OF ADULT FILIPINO PATIENTS WITH HEPATOLITHIASIS IN A TERTIARY HOSPITAL

John Aaron C. Galinato1, Marivic A. Mapa1

1Rizal Medical Center Department of Surgery Pasig City Philippines

Background: Hepatolithiasis is endemic to East Asia with a prevalence of 30-50%. However, the etiology of the disease is not yet fully studied and various extensive and expensive procedures are proposed for the management of the disease.

Objective: The study aims to describe the clinical characteristics among adult hepatolithiasis patients at Rizal Medical Center from January 2016 to December 2021.

Methods: The study is a single-center, retrospective descriptive study chart review of patients with imaging diagnosed with hepatolithiasis.

Results: A total of 46 patients were included in the study. Nineteen (41%) were male and twenty-seven (59%) were female with mean age of 49.13±11.99 years (Table 1). Age distribution shows the highest among the 31 to 40-year-old age group. Majority presented with cholangitis (52.17%) (Table 2).

Many underwent Endoscopic retrograde cholangiopancreatography with stone extraction (50%). Of those who underwent the procedures, five (10.87%) had morbidities and 3 (6.52%) were mortality cases (Table 4,5).

Conclusion: In our study, the majority of the patients are female within the 31 – 40-year-old age group. Most are from the Metro Manila. On presentation, patients are usually in cholangitis, and diagnosis is made initially by ultrasonography and CT scan.

Major treatment measures such as endoscopic procedures and hepatectomy are rendered but most patients undergo ERCP followed by hepatectomy with morbidity and mortality rates of 10.87% and 6.52%, respectively.

Mediation of radiation-associated hepatocellular carcinoma risk by HBV and HCV infections

Waka Ohishi1, John B. Cologne2, Young Min Kim3, Ayumi Hida4, Masataka Tsuge5, Kazuaki Chayama6, Saeko Fujiiwara8

1Department of Clinical Studies, Radiation Effects Research Foundation Hiroshima Japan, 2Department of Statistics, Radiation Effects Research Foundation Hiroshima Japan, 3Department of Statistics, Kyungpook National University Daegu Republic of Korea, 4Department of Clinical Studies, Radiation Effects Research Foundation Nagasaki Japan, 5Department of Gastroenterology, Hiroshima University Hiroshima Japan, 6Collaborative Research Laboratory of Medical Innovation, Hiroshima University Hiroshima Japan, 7 Yasuda Women's University Hiroshima Japan, 8Hirosima Institute of Life Sciences Hiroshima Japan

Background: Previous cohort studies of atomic bomb survivors have shown that radiation exposure is an independent risk factor for hepatocellular carcinoma (HCC) and is associated with an increased prevalence of chronic hepatitis B virus (HBV) infection. To investigate to what extent HBV and hepatitis C virus (HCV) infections might mediate the risk through indirect pathways between radiation exposure and HCC, we estimated mediation proportions for HBV and HCV infection on risk of HCC in a prospective clinical cohort study.

Methods: Among 4,345 atomic bomb survivors who underwent hepatitis screening tests between 1993 and 1995, 111 HCC cases were identified from 1993 to 2011 through local cancer registries in Hiroshima and Nagasaki, Japan. We used three statistical methods: traditional risk analysis with proportional hazards regression, mediation analysis with logistic regression to estimate mediation proportions, and sensitivity analysis employing the E-value to evaluate the impact of unadjusted confounding.

Results: Adjusted for age, sex, city, proximal-distal location at the time of exposure, and hepatitis virus infection status, the hazard ratio (HR) of HCC for 1 Gy radiation was 1.22 (95% confidence interval [CI]: 0.91-1.64). HRs for HBV and HCV infection directly were 8.3 (3.2-21) and 34 (23-51), respectively. The estimated mediation proportions were 11% for HBV infection and 33% for HCV infection.

Conclusions: This study suggested that a meaningful fraction of the radiation-related risk of HCC is mediated through viral infection. However, because of few cases and potential confounding of the estimated associations between viral infection rates and radiation, further study is required.
Abstract Submission No. 100596
P-0434

Determinants of Changes in Serum HBV DNA Levels: A Community-based Follow-up Study

Hung-Chuen Chang1,2, Chuen-Fei Chen3, Siang-Yu Yang4, Mei-Hung Pan1, Chun-Ying Wu5, Chien-Jen Chen6, Hwai-I Yang7

1Division of Gastroenterology, Shin Kong Wu Ho Su Memorial Hospital Taipei Taiwan, 2School of Medicine, Fu Jen Catholic University New Taipei City Taiwan, 3Department of Medicine, Mackay Medical College New Taipei City Taiwan, 4Genomics Research Center, Academia Sinica Taipei Taiwan, 5Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital Taipei Taiwan, 6Institute of Biomedical Bioinformatics and School of Medicine, National Yang-Ming University Taipei Taiwan

Background: The REVEAL-HBV study demonstrated long-term changes in serum HBV DNA levels as an important predictive factor for HCC development. However, the factors determining the long-term changes in serum HBV DNA levels remain unclear.

Methods: Participants (n=275) with baseline HBV DNA levels >10⁷ copies/mL in the REVEAL-HBV study were enrolled. We used a group-based trajectory model to identify distinctive groups of long-term changes of HBV DNA levels during 11 years of follow-up. Multivariate-adjusted hazard ratios and 95% confidence intervals of possible determinants were estimated using logistic regression.

Results: Four distinctive trajectory groups of long-term changes in HBV DNA levels were identified. Group 1 (n=107, 38.9%) had persistently high levels of HBV DNA (>10⁷ copies/mL). Group 2 (n=50, 18.2%) had mildly decreased but >10⁶ copies/mL HBV DNA levels at the end of the follow-up period. Group 3 (n=64, 23.3%) had significantly decreased but >10⁵ copies/mL HBV DNA levels at the end of the follow-up period. Group 4 (n=54, 19.6%) had rapidly decreasing and <10⁴ copies/mL HBV DNA levels at the end of follow-up. Multivariate logistic regression analyses demonstrated that sex, baseline ALT level, HBeAg status, HBV genotype, and quantitative HBsAg level were significant determining factors for long-term changes in HBV DNA levels. Female participants with normal ALT levels, positive HBeAg status, HBV genotype C, and higher baseline HBsAg levels were more likely to have persistently high HBV DNA levels.

Conclusions: Our study identified important factors determining long-term changes in HBV DNA levels and provided insights to inform management decisions for chronic HBV patients.

Abstract Submission No. 100652
P-0435

Association between HLA Zygosity and Long-term Changes in Serum qHBsAg Levels: The REVEAL-HBV Study

Chuen-Fei Chen1, Hung-Chuen Chang2,3, Siang-Yu Yang4, Mei-Hung Pan1, Chun-Ying Wu5, Chien-Jen Chen6, Hwai-I Yang7

1Department of Medicine, Mackay Medical College New Taipei City Taiwan, 2Division of Gastroenterology, Department of Internal Medicine, Shin Kong Wu Ho Su Memorial Hospital Taipei Taiwan, 3School of Medicine, Fu Jen Catholic University New Taipei City Taiwan, 4Genomics Research Center, Academia Sinica Taipei Taiwan, 5Division of Translational Research, Department of Medical Research, Taipei Veterans General Hospital Taipei Taiwan, 6Institute of Biomedical Bioinformatics and School of Medicine, National Yang-Ming University Taipei Taiwan

Background: Quantitative HBsAg (qHBsAg) levels are important biomarkers of chronic hepatitis B in predicting disease activity and monitoring treatment response. However, the determinants of the long-term changes in serum qHBsAg levels are unclear. Human leukocyte antigen (HLA) complex diversity plays an important role in immunosurveillance. Thus, our study aimed to explore the role of HLA complex diversity in the long-term changes in serum qHBsAg levels.

Methods: The participants (N=2300) were recruited from the REVEAL-HBV study with repeat measurements of qHBsAg levels during an 11-year follow-up period. A group-based trajectory model was used to determine distinctive groups of long-term changes in serum qHBsAg levels. We used genotyping data to represent the 4-digit HLA alleles at six loci, including the classical HLA class I genes (HLA-A, HLA-B, and HLA-C) and classical HLA class II genes (HLA-DRB1, HLADQB1, and HLA-DPB1). Multinomial logistic regression was used to analyze the associations between HLA zygosity and the long-term changes in qHBsAg levels.

Results: Long-term changes in qHBsAg levels varied highly among chronic HBV. Nine distinct trajectory groups with different long-term changes in qHBsAg levels were identified using the group-based trajectory model. After adjusting for the age, sex, ALT level, HBV DNA level, and HBV genotype, homozgyosity at HLA class II loci, particularly HLA-DQB1, significantly correlated with the long-term changes in qHBsAg levels.

Conclusions: HLA zygosity is significantly associated with long-term changes in serum qHBsAg levels. Our results imply an important role of individual immune status on the management of HBV infection.
unresectable patients (85.2% vs 21.2%, p<0.0001). TMN stage (aHR 1.88), palliative biliary drainage (aHR 0.31), and systemic chemotherapy (aHR 0.19) were independent predictors for mortality in unresectable pCCA and dCCA patients. In unresectable iCCA patients, only systemic chemotherapy was significant (aHR 0.30).

Conclusions: Most patients were diagnosed late, and the median OS was only 5–6 months. Unresectable CCA patients with systemic chemotherapy and palliative biliary drainage had better survival rates.

Abstract Submission No. 100941
P-0437

Granulomatous Liver Disease in the Current Decade: A Clinico-Radio-Pathological Study in Thailand.

Siwanon Nawalerspanya1, 2, Pimsiri Sriponggun1, Apichat Kaewdech1, Naichaya Chamroonkul1
1Prince of Songkla University Songkhla Thailand, 2Department of Internal Medicine, Phaholponpayahasena hospital Kanchanaburi Thailand

Background: Granulomatous liver disease (GLD) is a rare condition characterized by the formation of hepatic granulomas attributed to various etiologies. A comprehensive evaluation of GLD from a multi-aspect perspective is currently lacking. We aimed to investigate etiologies, and clinico-radio-pathological characteristics of patients with GLD in recent years.

Methods: We conducted a retrospective study at a tertiary-care center in Thailand, all patients underwent liver biopsy between 2011-2021 were reviewed. Patients with the histopathological report of granulomas in their liver specimens were included. Clinical presentations, radiological, and laboratory data closest to the procedure date were collected.

Results: Of 1377 liver biopsy specimens, 41 patients had GLD (2.98%). Of those, 63.4% were male, the etiologies of GLD were as follows: 26 (63.4%) infectious, 7 (17.1%) non-infectious, and 8 (19.5%) undetermined. Common presentations included abnormal liver tests (87.5%) and weight loss (61.9%). Among infectious granulomas, mycobacterium infections (tuberculosis [TB], 13/ non-tuberculous [NTM], 3) were predominant. Compared with other causes, the final diagnosis of mycobacterium was found to be at associated with a significantly lower BMI, more extra-gastrointestinal involvement, and lower serum albumin levels. Caseating-type granulomas were observed in 16% of non-tuberculosis cases. One-third of GLD patients demonstrated no focal lesion on liver imaging whereas multi-focal lesions were the most common radiological finding (43.9%).

Conclusions: In this modern era, infectious cause, especially mycobacterium infections, remains the primary etiology of GLD. It is important to note that granuloma types are not pathognomonic for specific diseases, emphasizing the need for extensive evaluation beyond liver biopsy to determine the underlying etiology.

Abstract Submission No. 101205
P-0439

Characteristics of quality of life in elderly patients with chronic liver disease

Keiichi Katayama1, Masato Nakamura1, Tadayoshi Kogure1, Kisako Fujiwara1, Keisuke Koroki2, Masanari Inoue2, Kazufumi Kobayashi1, Naoya Kanogawa1, Soichiro Kiyono1, Takayuki Kondo1, Ryo Nakagawa1, Sadahisa Ogasawara1, Shingo Nakamoto1, Naoya Kata1
1Department of Gastroenterology, Chiba University, Japan Chiba Japan

Objective: In Japan, as the elderly population increases, there are more opportunities to treat elderly patients with chronic liver disease (CLD). Elderly patients often have physical, mental, financial, and social difficulties that can reduce their quality of life (QOL). We aimed to clarify the characteristics of QOL in elderly patients with CLD.

Methods: A total of 931 patients with CLD who visited our hospital between February 2020 and March 2021 were included. Among them, 616 patients were analyzed after excluding patients with liver cancer. We divided them into 3 groups; the non-elderly group (254 cases), aged 65 to 74 years, and the old-old group (205 cases), aged 75 years or older. Health-related QOL was assessed using the SF-36v2® standard version, and scoring was based on the 2017 National Standard Values.

Results: Physical component summary (PCS) in the analyzed cases was lower than the national standard. Mental component summary (MCS) and role component summary (RCS) were higher than the national standard. PCS was significantly lower in both the young-old and old-old than in the non-elderly. MCS was higher in both the young-old and old-old than in the non-elderly. RCS was not significantly different among three groups. Grip strength was lower in the elderly than in the
non-elderly group. The age-related decline in PCS in patients with cirrhosis is more remarkable than in patients with chronic hepatitis.

**Conclusion:** When treating elderly patients with CLD, it is important to pay attention to the decline in physical QOL.

Abstract Submission No. 101580

**P-0440**

**Gamma-glutamyl transferase and the risk of disease-specific mortality in patients with diabetes**

**Eun Ju Cho**, **Goh Eun Chung**, **Su-Min Jeong**, **Kyungdo Han**, **Su Jong Yu**

1. Seoul National University College of Medicine Seoul South Korea, 2. Seoul National University Hospital Healthcare System Ganganm Center Seoul South Korea, 3. Soongsil University Seoul South Korea

**Background/Aims:** There exist a paucity of data regarding whether gamma-glutamyl transferase is associated with disease-specific mortality in patients with type 2 diabetes mellitus. This study aimed to investigate the association of serum gamma-glutamyl transferase levels with all-cause and disease-specific mortality in patients with diabetes mellitus using a Korean nationwide health-screening database.

**Methods:** A total of 9,687,066 patients without viral hepatitis or liver cirrhosis who underwent health examination in 2009 were included. These patients were divided into four groups according to sex-specific quartiles of serum gamma-glutamyl transferase levels.

**Results:** During a median follow-up period of 8.1 years, 222,242 deaths were identified. The all-cause mortality rate increased as the serum gamma-glutamyl transferase levels became higher (highest quartile vs. lowest quartile: hazard ratio [HR], 1.57; 95% confidence interval [CI], 1.55–1.59; p for trend <0.001). Similar trends were observed for cardiovascular disease (HR, 1.57; 95% CI, 1.53–1.62), ischemic heart disease (HR, 1.40; 95% CI, 1.33–1.48), and stroke (HR, 1.72; 95% CI, 1.60–1.85) in the highest quartile, as compared with the lowest quartile (p for trend <0.001). As the gamma-glutamyl transferase quartiles became higher, mortality rates related to cancer (HR, 1.56; 95% CI, 1.52–1.60), liver disease (HR, 9.42; 95% CI, 8.81–10.07), respiratory disease (HR, 1.55; 95% CI, 1.49–1.62), and infectious disease (HR, 1.73; 95% CI, 1.59–1.87) also increased in the highest quartile, as compared with the quartile (p for trend <0.001).

**Conclusion:** Serum gamma-glutamyl transferase levels may be useful for the risk assessment of all-cause and disease-specific mortality among patients with type 2 diabetes mellitus.

Abstract Submission No. 101670

**P-0441**

**Predicting outcome in portal & splanchnic vein thrombosis: A 12-year retrospective study in Thailand**

**Siripat Kaewnamchai**, **Piyakorn Poonyam**, **Piyanant Chonnaitree**, **Asawin Sudchareon**

1. Department of Medicine, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine Sirnakarinwiroi University, Ongkharak, Nakhon Nayok Thailand, 2. Division of gastroenterology, Department of Medicine, Faculty of Medicine, Sirnakarinwiroi University Ongkharak, Nakhon Nayok Thailand

**Background:** Splanchnic vein thrombosis including portal vein, mesenteric vein and splenic vein thrombosis is increasingly recognized in clinical practice and associated to mortality. However, the studies of splanchnic vein thrombosis are limited in Thai population. This study aims to describe the prevalence, clinical features, treatment, outcome and factor associated outcome in Thai populations.

**Methods:** We conducted a retrospective study including patient diagnosed with portal, mesenteric and splenic vein thrombosis in the past 12 years, collected data from medical record and analyze the patient characteristic and factor associated with favorable or unfavorable outcome which include death associated or not associated with thrombosis.

**Results:** During the study period in 2011 - 2023, A total of 86 patient diagnosed with splanchnic vein thrombosis in in HRH Princess Maha Chakri Sirindhorn Medical Center. The period prevalence of splanchnic vein thrombosis was 0.024%. Portal vein involvement was 89.53%, Mesenteric vein involvement was 31.19% and Splenic vein involvement was 19.16%. Major risk factor is cirrhosis (62.79%). Clinical manifestation often leads to diagnosis is abdominal pain (79.07%). The patient received treatment with anti-coagulant was 31.4%. Factor associated with unfavorable outcome were age (p=0.0336), Child-Pugh score (p=0.044), Serum albumin (p=0.0081) and Ascites (p=0.047).

**Conclusion:** Prevalence of Splanchnic vein thrombosis in this hospital is 0.024%. The most involving part is Portal vein thrombosis. Major risk factor is cirrhosis. Clinical manifestation often leads to diagnosis is abdominal pain. Majority of patient got favorable outcome after diagnosis. Risk factor associated with unfavorable outcome are age, Child-Pugh score, serum albumin and Ascites.
Prevalence of MAFLD-Related Hepatocellular carcinoma; A systematic review and meta-analysis

Harry Crane1, Guy Eslick2, Cameron Gofton1,3, Anjita Shaikh1, George Cholankeril4, Mark Cheah5, Jian-Hong Zhong6, Gianluca Svegliati-Baroni7, Alessandro Vitale8, Beom Kyung Kim9, Sang Hoon Ahn10, Mina Kim10, Jacob George1

1Storr Liver Centre, Westmead Institute for Medical Research Sydney Australia, 2NHMRC Centre for Research Excellence in Digestive Diseases, University of Newcastle Newcastle Australia, 3Education of Gastroenterology, Royal North Shore Hospital Sydney Australia, 4Department of Internal Medicine, University of Connecticut School of Medicine Farmington USA, 5Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine Houston USA, 6Department of Gastroenterology and Hepatology Singapore General Hospital Singapore, 7Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital Nanning China, 8Liver Injury and Transplant Unit, Polytechnic University of Marche Ancona Italy, 9Department of Surgery, Oncology and Gastroenterology, University of Padova Padova Italy, 10Department of Internal Medicine, Yonsei University College of Medicine Seoul Republic of Korea

BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is an important cause of hepatocellular carcinoma (HCC) globally, however the proportion attributable to MAFLD is unclear. The novel MAFLD diagnostic criteria allows objective diagnosis in the presence of steatosis plus defined markers of metabolic dysfunction, irrespective of concurrent liver disease. We aimed to determine the global prevalence of MAFLD in HCC cohorts, including estimation of the proportion of “mixed-aetiology” HCC.

METHODS: A systematic review and meta-analysis was performed, searching for studies systematically ascertaining MAFLD in HCC cohorts, defined using international expert panel criteria including ethnicity specific BMI cut-offs. A comparison of clinical and tumour characteristics was performed between patients with MAFLD as the sole aetiology of HCC, non-MAFLD aetiology, and mixed-aetiology HCC.

RESULTS: 22 studies comprising 56,565 individuals with HCC were reported in detail on the same day. The prevalence of MAFLD was 40.0% (95% CI; 34.5% – 63.0%). MAFLD as the sole cause of liver disease accounted for 12.4% (95% CI; 8.3% – 17.3%). In individuals with HCC due to hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol related liver disease (ARLD), the prevalence of MAFLD was 40.0% (95% CI; 30.2% – 50.3%), 54.1% (95% CI; 40.4% – 67.6%) and 64.3% (95% CI; 52.7% – 75.0%) respectively. Mixed-aetiology HCC was phenotypically distinct from “pure” MAFLD HCC and non-MAFLD HCC.

CONCLUSION: MAFLD is common as a sole HCC aetiology, but more so as a co-factor in mixed-aetiology HCC. Studies should accurately diagnose and report MAFLD to better understand the interaction between concurrent liver diseases.
Lenvatinib modifies the tumor microenvironment in HCC and assembles GZMK/CD8 T cells

Tomoharu Yamada1, Naoto Fujiwara2, Ryosuke Tateishi1, Kazuhiko Koike1, Mitsuhiro Fujishiro1, Hayato Nakagawa1,2
1University of Tokyo Tokyo Japan, 2Mei University Tsu Japan

Background: Lenvatinib is a multiple kinase inhibitor and showed clinical efficacy in patients with hepatocellular carcinoma (HCC). Lenvatinib was expected to enhance the effect of immune checkpoint inhibitors (ICIs), but their combination therapy could not prove synergistic effect in a Phase III trial.

Methods: Our study aimed to elucidate the effects of lenvatinib on tumor immune microenvironment and clarify the mechanism that prevents the synergistic effect with ICIs. HCC specimens from five patients treated with neoadjuvant lenvatinib and ten controls were analyzed using RNA-sequencing and digital spatial profiling to explore the molecular effects of lenvatinib.

Results: Lenvatinib not only has direct antitumor effects but also recruits cytotoxic GZMK/CD8 T cells into the intratumoral stroma, a process facilitated by CXCL9 from tumor-associated macrophages. The majority of these cytotoxic CD8 T cells appeared to be trapped in the intratumor stroma.

Conclusions: Lenvatinib modifies the tumor immune microenvironment by recruiting GZMK/CD8 T cells, turning immunologically "cold" tumors "hot". This transformation is significant, yet lenvatinib-treated HCC might still be "altered-excluded" due to the physical barriers created by extracellular matrix (ECM). Combining treatments for ECM may enhance the effectiveness of immune cells recruited by lenvatinib, especially when used in combination with ICI.9

Treatment with a new barbituric acid derivative induces apoptosis in hepatocellular carcinoma cells

Chuan-Lin Wan1, Ming-Hua Hsu2, Yi-Jen Liao1
1Medical Laboratory Science and Biotechnology, Taipei Medical University New Taipei City Taiwan, 2Division of Gastroenterology, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University Taipei City Taiwan

Hepatocellular carcinoma (HCC) is the primary type of liver cancer, and it is the sixth common cancer in the world with a higher mortality. Sorafenib, the first-line drug for advanced HCC, can effectively increase the median survival time. However, long-term sorafenib acquisition of resistance, therefore, developing novel agents is urgently needed to treat HCC. Previously, we identified a series of barbituric acid derivatives and found that one of the compounds exhibited the best ability to ameliorate TGF-β1-induced hepatic stellate cell activation and liver fibrosis. In this study, we extend this barbituric acid derivative (named 2g) and analyze the anti-HCC effect and its underlying mechanisms. The results demonstrated that 2g has a cytotoxic effect to inhibit HCC cell viability in both dose- and time-dependent manner. Flow cytometry analysis showed that the early and latent stages of apoptosis rate were significantly increased in 2g-treated cells. Western blot data revealed that compound 2g treatment increased caspase 8 and cleaved caspase 3 expression. In addition, the mRNA expression of anti-apoptosis genes Bcl-2 and survivin were decreased in 2g-treated cells. In conclusion, compound 2g may facilitate the apoptosis signal by increasing the expression of apoptosis-related proteins and downregulating the anti-apoptosis genes in HCC cells, which suggests its use as a new strategy for HCC treatment.
elucidate RNA expression profiles, and the expression levels of differential expression genes (DEGs) were quantified using quantitative real-time PCR.

**Results:** MTA1dE4 demonstrated a tumorigenicity-promoting ability similar to MTA1, with even greater efficiency. Notably, MTA1dE4 displayed an increased capacity to suppress the promoter activity of E-cadherin. Transcriptomic analysis revealed significant changes in the transcriptional expression of 1280 genes in parental cells, of which 1049 genes (81.96%) were upregulated and 231 genes (18.04%) were downregulated compared to MTA1-knockdown cells. Specifically, 792 genes (81.56% upregulated and 18.4% downregulated) and 625 genes (73.92% upregulated and 26.08% downregulated) displayed significant changes, respectively. Gene set enrichment analysis (GSEA) demonstrated that the majority of DEGs in MTA1/KDSK cells were associated with a "multicancer invasiveness signature," while those in KDSK/MTA1dE4 were related to "APC targets."

**Conclusions:** MTA1 and MTA1dE4 play distinct roles in regulating various subsets of target genes. Some are associated with inhibiting cell migration, while others are involved in promoting cancer metastasis.

---

**Abstract Submission No. 100340**

**P-0450**

Targeting Dyrk1A synergise with OXPHOS inhibition through activating TGFβ signaling

_Ying Cao^1, Rene Bernard^1, Wexin Qin^1, Cun Wang^1_

^1Shanghai Cancer Institute Shanghai China_

Mitochondria are not only essential for cellular energy metabolism, but they also play a critical role as modulators of cellular responses to microenvironmental stress. Numerous studies have demonstrated that interventions targeting mitochondria function may hold promise as potential approaches for the treatment of various types of cancer. Our findings suggest that the combination of a Dyrk1A inhibitor and OXPHOS inhibitors could represent a promising therapeutic strategy for targeting mitochondria. Furthermore, our data has uncovered the crucial role of the TGFβ signaling pathway in determining the sensitivity of oxidative phosphorylation inhibitors.

---

**Abstract Submission No. 100514**

**P-0451**

IL-6 is a useful biomarker for selection of systemic therapies in hepatocellular carcinoma

_Ryoichi Miura^1, Atsushi Ono^1, Shigeki Yano^1, Kei Amioka^1, K ensuke Naruto^1, Kenji Yamaoka^1, Yasutoshi Fujii^2, Shinusuke Uchikawa^1, Hatsu Fujino^3, Takashi Nakahara^1, Etsuke Murakami^1, Tomokazu Kawao^1, Daiki Miki^1, Masataka Tsuge^1, Shiro Oka^1_

^1Department of Gastroenterology, Hiroshima University Hospital Hiroshima Japan, 2Department of Clinical Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University Hiroshima Japan_

**Background and Aim:** This study aims to identify biomarkers for treatment response of atezolizumab plus bevacizumab (Atezo+Bev) in patients with hepatocellular carcinoma (HCC).

**Methods:** Among patients who received Atezo+Bev or Lenvatinib (Len) as a first-line systemic therapy at our hospital, 96 patients were enrolled in the HCC group after propensity score matching, while 20 tumor-free patients were enrolled as a control group. Seventeen serum cytokines were measured by Luminex multiplex assay at the start of treatment. The Cox proportional hazards regression model was used to assess the prognostic effects of clinical factors and cytokine levels.

**Results:** Angiopoietin-2, CEACAM-1, IL-6, and IL-8 levels were significantly higher in the HCC group than in the control group. Optimal cutoff values for these cytokines were determined using receiver operating characteristic (ROC) analysis. In the Atezo+Bev group, univariate analysis revealed that high levels of serum IL-6 (≥9.2 pg/mL, p < 0.01) and IL-8 (≥102.3 pg/mL, p < 0.05) were associated with shorter DFS. Among them, only elevated IL-6 (HR 5.80; p < 0.01) was identified by multivariate analysis as an independent risk factor. In the Len group, no significant differences in DFS were observed for any item. Although there was no overall difference in DFS between the Atezo+Bev group and the Len group, subset analysis of low IL-6 patients revealed longer DFS in the Atezo+Bev group than in the Len group (Log-rank, p = 0.02).

**Conclusions:** Serum IL-6 level is a useful predictor of therapeutic benefit from Atezo+Bev treatment.

---

**Abstract Submission No. 100581**

**P-0453**

Circulating exoPD-L1 predicts the outcome of patients with HCC who received atezolizumab-bevacizumab

_Yu Rim Lee^1, Gyeonghwa Kim^1, Min Kyu Kang^1, Seung Hyun Cho^1, Jeong Hwa Lee^1, Young Oh Kweon^1, Won Young Tak^1, Keun Hur^1, Yun Kee Jo^1, Hee Jin Cho^1, Soo Young Park^1, Jihoon Hong^1, An Na Seo^1_

^1School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital Daegu South Korea_

**Background:** Hepatocellular carcinoma (HCC) is a highly aggressive disease that is usually diagnosed at an advanced stage. Advanced HCC has limited treatment options and often has a poor prognosis. Atezolizumab-bevacizumab significantly improved survival rates as a first-line treatment and became the new standard of care. The interaction between the programmed cell death receptor 1 (PD-1) and its ligand (PD-L1) contributes to immune evasion and exosomal PD-L1 is a marker of poor outcome after surgery or chemotherapy in patients with various types of cancers. However, the role of PD-L1-containing exosomes in patients with advanced HCC receiving atezolizumab-bevacizumab is remains to be elucidated. We therefore determined the prognostic significance of circulating exosomal PD-L1 in advanced HCC patients receiving atezolizumab-bevacizumab.

**Methods:** This study enrolled 28 HCC patients receiving atezolizumab-bevacizumab between Dec 2020 and Jan 2023. Exosomes were extracted from serum samples using the ExoQuick Exosome Precipitation Solution. Exosomal PD-L1 was detected by Exocounter.

**Results:** The total number of exosomes and PD-L1 positive exosomes increased significantly as the mUICC stage of HCC progressed (P < 0.05). Comparing between the earlier and advanced stage, the number of Exosomal PD-L1 significantly increased in the advanced stage. The overall survival and progression-free survival were significantly lower in patients with lower circulating levels of exosomal PD-L1 (log-rank test: P = 0.015 and 0.007, respectively).

**Discussion:** In conclusion, this study has provided strong evidence that circulating exosomal PD-L1 are novel prognostic markers and therapeutic targets for advanced HCC who received atezolizumab-bevacizumab.
Hesperidin Dextrin nanoformulation attenuates diethylnitrosamine-induced hepatic cancer in animal

Deepika Singh

1Department of Pharmaceutical Sciences, SHUATS Prayagraj India

Methods: Hesperidin-Dextrin nanoformulation (HPSLNL) against diethylnitrosamine (DEN)-induced liver cancer, and its underlying mechanism.

Results: XRD also indicates the drug peak, but FTIR demonstrated that there is no compound-polymer interaction. Rats given HP-SLNL treatment showed suppression of the tumor nodules, both in terms of number and average size of the nodules. Lowering the amount of alpha fetoprotein and improving body weight, HP-SLNL also had an effect on non-hepatic measures including total protein, bilirubin, creatinine, and urea, as well as hepatic markers like AST, ALT, and ALP. It also changed cytokines levels, (TNF-α, IL-1β, IL-6, IL-4, IL-10, and IL-17) and inflammatory markers, such as COX-x, iNOS, PGE2, and NF-κB. Bcl-2 was significantly decreased and Bax, PDCD5, and p53 levels were increased by HP-SLNL therapy.

Conclusion: Based on the findings, we may conclude that HP-SLNL changed oxidative stress and inflammation to have a chemoprotective impact on hepatic cancer.

Isolation, culture and characterization of patient derived CD34+ liver cancer stem cells

Su Cheol Park1, Jae-Hoon Jeong2, Yong Jin Jung3

1Korea Institute of Radiological and Medical Sciences, Korea Cancer Center Hospital Seoul South Korea, 2Korea Institute of Radiological and Medical Sciences Seoul South Korea, 3Seoul National University College of Medicine SMG-SNU Boramae Medical Center Seoul South Korea

Abstract Submission No. 100884

P-0456

Conclusion: We could isolate and characterize the CD34+ cancer stem cells from human HCC tissues using fluorescence-activated cell sorting. Purified CD34+ cells have been cultured in vitro on mouse embryonic fibroblast feeder cells. Then we explored the expression of CD34 and stem cell markers. Also we compared the expression of stem cell markers between CD34+ cells and CD34- cells.

Background: Liver cancer stem cells can be a possible cause of chemo-resistance of hepatocellular carcinoma (HCC). CD34+ stem cells play an important role during liver development and regeneration. Previously we isolated and cultured CD34+ cells from conventional hepatoma cell line (PLC/PRF/5 cells). This study was undertaken to optimize the methods for the isolation and culture of the patients derived liver cancer stem cells and to evaluate its characteristics.

Methods: The HCC specimens and data used in this study were provided by the Radiation Tissue Resources Bank of Korea Cancer Center Hospital. Patient derived CD 34+ cancer stem cells were isolated from human HCC tissues using fluorescence-activated cell sorting. Purified CD34+ cells have been cultured in vitro on mouse embryonic fibroblast feeder cells. Then we explored the expression of CD34 and stem cell markers. Also we compared the expression of stem cell markers between CD34+ cells and CD34- cells.

Results: The expressions of CD34, CD44 and CD133 were 9.8%, 4.8%, and 0.16% respectively. The HCC cells and fibroblasts were isolated and cultured, however the growth of cells was not maintained. We can observe that Nanog, Oct4, Sox2, CD44 and CD133, the stem cell markers were highly expressed in CD 34+ cells than CD 34- cells.

Conclusion: Based on the findings, we may conclude that HP-SLNL changed oxidative stress and inflammation to have a chemoprotective impact on hepatic cancer.

An MTA1 Major Variant, MTA1dE4, with Enhanced Metastatic and Tumorigenic Potential in HCC

Yung-Tsung Li1, Chuh-Jen Liu1,2,3, Po-Hsi Huang1, Li-Feng Lin1, Hui-Lin Wu1

1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei Taiwan (R.O.C), 3Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan (R.O.C)

Background: Alternative splicing generates MTA1dE4, an exon 4-deleted form of metastatic tumor antigen 1 (MTA1), with a less understood role in hepatocarcinogenesis than extensively studied MTA1. Here, we characterize the structural, molecular, and functional attributes of MTA1 and MTA1dE4, elucidating their contributions to tumor metastasis.

Methods: We established stable MTA1 knockdown cells using human HepG2 and murine Hepa1-6 hepatoma cells, designated as KDG2 and KD1-6, respectively. Next, we conducted in vitro and in vivo tumorigenicity assays. To further investigate the metastatic potential, we utilized an intra-splenic injection mice model. Additionally, structural analyses and modeling were employed to predict the molecular and biological functions of MTA1 and MTA1dE4. To explore the interacting partners of MTA1/MTA1dE4 and facilitate the investigation of unknown mechanisms in tumor metastasis, co-immunoprecipitation (co-IP)-coupled with mass spectrometry (MS) strategy was employed.

Results: MTA1dE4 exhibited tumorigenic and metastatic potential comparable to that of MTA1 but with greater efficiency, consistent with a positive correlation between MTA1dE4 overexpression and early recurrence in clinical observation. The two isoforms differ in the bromo-adjacent homology (BAH) domain, leading to structural alterations that enhance the structural stability and molecular functionality of MTA1dE4 compared to MTA1. Co-IP/MS data revealed largely identical interactors but also with isoform-specific interactors for MTA1 and MTA1dE4. Notably, MTA1dE4 broadly interacts and co-expresses with migration-associated proteins, potentially contributing to the tumorigenic and metastatic capacities of cancer cells.

Conclusion: The conformational changes in MTA1’s BAH domain confer greater resilience and a modified activity profile, allowing precise adaptation to the specific requirements of cancer cells.
Fardah Akil1,2, Muhammad Luthfi Parewangi1,2, Nu‘man AS Daud1,3, Rini Bachtiar1,2, Susanto H. Kusuma4, Amelia Rifaï1,2, Resha Dermuwansyah Rusman2

1Division of Gastroenterology-Hepatology, Department of Internal Medicine, Faculty of Medicine, Hasanuddin University Makassar Indonesia, 2Center of Gastroenterology-Hepatology HAM Akil DR. Wahidin Sudirohusodo General Hospital Makassar Indonesia

Background: Hepatocellular carcinoma (HCC) is a common malignancy in Asia. Around 5% of Indonesians developed HCC, but in Makassar, about 13.8% of HBV patients advanced to HCC. Although alpha-fetoprotein (AFP) is a biomarker utilized in the clinical diagnosis of HCC, roughly about 40% of HCC patients do not have high serum AFP levels. Therefore, we aim to investigate the clinical and tumor characteristics between AFP positive and negative in HCC patients.

Methods: Between 2017 and 2022, this retrospective cohort study was carried out at a tertiary care facility in Makassar, Indonesia. Baseline patient characteristics, virological status, AFP level, CT Abdomen, Barcelona-Clínic Liver Cancer (BCLC) staging, size of the tumor, and child-pugh were drafted from the medical record.

Results: There were 408 HCC subjects in all, with 308 (75.4%) male and an average age of 54.1 years. HBV infection 284 (69.6%), HCV infection 43 (10.5%), and non-viral reasons 81 (18.8%) were the underlying liver causes. 186 patients (or 45.5% of the total) had BCLC Stage B, while 129 patients (or 31.6%) had BCLC Stage C. Only 53 patients (12.9%) had tumors less than 3 cm, while 284 (69.6%) had tumors larger than 5 cm. HCC patients with larger tumor sizes, liver cancer with portal vein thrombosis, and the high BCLC stage had significantly higher serum AFP levels (p<0.005).

Conclusions: This study showed that there are significant differences in clinical pathologic characteristics between AFP-positive and negative HCC patients which may be helpful for the management and prognostication of the disease.

Abstract Submission No. 101044
P-0458

Hepatocellular Carcinoma Subclassification Using Comprehensive microRNA Expressions of TCGA data

Yoshinari Asaoka1, Atsushi Tanaka1

1Teikyo University School of Medicine Tokyo Japan

Background: The involvement of microRNAs in liver carcinogenesis has been reported, but comprehensive classifications based on microRNA expression data have been limited. In this study, we performed subclassification of hepatocellular carcinoma (HCC) using microRNAs based on data from The Cancer Genome Atlas (TCGA).

Methods: We downloaded pre-processed genetic mutations, mRNA, and microRNA expression data of 360 cases of HCC from the GDAC Firehose browser (https://gdac.broadinstitute.org). Utilizing the expression levels of 540 microRNAs, hierarchical clustering was performed using the Ward method, classifying the 360 HCC cases into 5 clusters. For each cluster, we calculated p-values using Fisher’s exact test and t-test for the genetic mutations and mRNA expression levels, respectively.

Results: In clusters 1, 2, 3, 4, and 5, there were 44, 153, 82, 56, and 25 cases, respectively. Regarding genetic mutations, cluster 3 showed a higher prevalence of BAP1 mutations and a lower frequency of CTNNB1 mutations, whereas cluster 4 exhibited a higher occurrence of CTNNB1 mutations. In cluster 1, the expression of genes located on the X chromosome, such as SSX and MAGE families known as cancer-testis antigens, was upregulated. Additionally, microRNA expression from the chromosome 19 cluster (C19MC) was significantly elevated. Cluster 5 displayed increased expression of imprinted genes located on the chromosome 14, including DLK1, MEG8, and MEG3, along with elevated expression of AFP and SALL4. The microRNA clusters C14MC and C19MC are known to undergo imprinting and have been implicated in placental development.

Conclusion: We conducted a comprehensive subtyping of HCC based on microRNAs.

Abstract Submission No. 101077
P-0439

The hepatocyte nuclear factor 1 homeobox A (HNF1A) Gene Polymorphism & AFP in HCC Egyptian Patients

Mohamed Abdel-Samiee1, Hanan M. Bedair2, Ibrahim Tantawy El Sayed1, Olfat M. Hendy3, Islam Abd El Hamid Mohmmed El Sayad4, Sally S. Mandour2

1Hepatology and Gastroenterology, National Liver Institute, Menoufia University Shebin El-Kom Egypt, 2Clinical Pathology, National Liver Institute, Menoufia University Shebin El-kom Egypt, 3Organic Chemistry, Faculty of Science, Menoufia University Shebin El-kom Egypt, 4Chemistry, Faculty of Science, Menoufia University Shebin El-kom Egypt, 5M.Sc of Biochemistry, Chemistry, Faculty of Science, Menoufia University Shebin El-kom Egypt

Hepatocyte nuclear factors (HNFs) were first identified as liver-enriched transcription factors that might participate in a variety of activities related to the transcription of genes unique to the liver. Aim of study: revealing the impact of HNF1A gene variations on disease progression in HCC patients complicating HCV infection and its relation to serum AFP level. Patients and method: Participants in the study were classified as Group I: Includes 32 HCC patient with low and high AFP; Group II: Includes 36 CHC patients, and Group III: Included 26 apparently healthy volunteers as a control group. HNF1A gene polymorphisms (rs2464196 and rs1169310) were genotyped by real-time PCR using rotor gene PCR system.

Results: The highest frequency of AA and GA genotypes of HNF1A (rs2464196) polymorphism in both HCC and chronic HCV patients compared to controls (P=0.002 and P=0.004, respectively). Regarding rs1169310 gene polymorphism, no significant difference was found among different genotypes between the studied groups and controls. Additionally, HCC the patients harbor AA genotype for rs2464196 had significantly increased AFP ≥200ng/ml level (those patients are older age and child score calss B), whereas, HCC patients with rs1169310 SNPs for HNF1A had no significant association with AFP level in HCC patients.

Conclusion: The rs2464196 polymorphism of HNF1 is associated with increased AFP level and HCC disease progression which may implicated as a genetic marker for diagnosis and prognosis of HCC patients.

Abstract Submission No. 101147
P-0460

Role of plasma EV-miR-19-3p as a novel diagnostic and prognostic biomarker for non-viral-related HCC

Pisit Tangkijvanich1, Bootsakorn Boonkaew1, Natthaya Chuaypen1

1Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University Bangkok Thailand
Background: Extracellular vesicle-derived microRNAs (EV-miRNAs) are promising circulating biomarkers for chronic liver disease, including hepatocellular carcinoma. This study explored the potential significance of plasma EV-miRNAs in non-hepatitis B-, non-hepatitis C-related HCC (NBNC-HCC).

Methods: We compared plasma EV-miRNA profiles between NBNC-HCC and control groups, which included non-alcoholic fatty liver disease (NAFLD) and healthy controls by using the NanoString method. The differentially expressed EV-miRNAs were validated in another set of plasma samples by qRT-PCR. Additionally, the diagnostic and prognostic roles of potential biomarkers were further analyzed.

Results: In the discovery set, a total of 66 significantly differentially expressed EV-miRNAs between the NBNC-HCC and control groups were identified. In the validation set, plasma-derived EV-miRNAs, including miR-19-3p, miR-16-5p, miR-223-3p, miR-30d-5p, and miR-451a were significantly elevated in NBNC-HCC compared with the control groups. Based on bioinformatics analysis, these miRNAs were found to contribute to biological processes, including protein targeting, nuclear transport, and cell cycle. Moreover, enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways revealed that these miRNAs participated in several cancer-related signaling pathways. Among them, EV-miR-19-3p exhibited the best diagnostic performance with the area under the curve (AUC) of 0.82 (95% CI: 0.75-0.88, P<0.001), and displayed high sensitivity for detecting alpha-fetoprotein-negative HCC and early-stage HCC (76.9% and 80.0%, respectively). In multivariate analysis, an elevated level of EV-miR-19-3p was an independently unfavorable predictor of overall survival in patients with NBNC-HCC.

Conclusion: Our data indicated that EV-miR-19-3p could serve as a novel circulating biomarker for the diagnosis and prognosis of patients with NBNC-HCC.

Abstract Submission No. 101279
P-0461

Functional evaluation and mechanism study of hnRNP-F in hepatocellular carcinoma development

HAN GAO1

1Southern university of science and technology Shenzhen China

Background: Heterogeneous nuclear ribonucleoprotein F (hnRNP-F) is a member of the hnRNP family proteins that has been implicated in multiple cancers, suggesting its role in tumourigenesis; however, it is unclear whether hnRNP-F could affect the hepatocellular carcinoma (HCC) or antitumor immunity against HCC.

Methods: A correlation of hnRNP-F expression with prognosis was analyzed in the TCGA database. Then we applied in vivo and in vitro methods by Cre-loxP animal models, flow cytometry and cell proliferation assay to reveal the behaviors of hnRNP-F in HCC tumourigenesis. The specific regulatory mechanism of hnRNP-F on the development of HCC was analyzed by RNA sequencing.

Results: HnRNP-F is significantly upregulated in HCC tissue, and its increased expression is associated with a poor prognosis in HCC patients. In animal models, we observed that hepatocyte-specific knock-out of hnRNP-F inhibited hepatozellagenesis. In human liver cancer cells, hnRNP-F promoted tumor proliferation, migration and invasion. We also observed that hnRNP-F knock-out in animal models could significantly affect the number of CD8+ T cells which consequently reprogrammed the tumor microenvironment (TME).

Conclusions: These findings suggest that hnRNP-F could promote cell proliferation in HCC and reprogram tumor microenvironment, which may serve as a potential target for the treatment of HCC patients.

Keywords: Hepatocellular Carcinoma (HCC), Heterogeneous nuclear ribonucleoprotein F (hnRNP-F), Cell proliferation, Tumor microenvironment (TME)

Abstract Submission No. 101283
P-0463

ASHH1L promotes HCC progression by regulating HSC activation

yuanyang Du1

1Southern University of Science and Technology Shenzhen China

Background: Activated hepatic stellate cells (HSCs) are the main sources of myofibroblasts, which are the central driver of liver fibrosis. Many researchers have suggested that activated HSCs can promote hepatocellular carcinoma (HCC) development. However, the precise mechanisms remain largely unknown.

Methods: To mimic the stimulation of HSCs in the tumor microenvironment, human HSCs were cultured in the conditional medium from human HCC cells supernatant. RT-PCR and western blot were used to identify the key methyltransferases associated with HSC activation. We generated HSC-specific deficient mice GFAP-Cre+/-flox/flox(SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK), parenchymal hepatic cells specific deficient mice ALC-Cre +/-flox/flox (SK). Fibrosis-associated mouse hepatocarcinogenesis was induced by DEN-CCL4 to explore the function of the regulator in HSCs and hepatic cells. A transwell non-contact co-culture system was used to investigate the interaction between HCC cells and HSCs.
Results: We found the conditional medium of HCC cells could promote HSC activation. ASH1L was one of the most greatly increased in advanced tumor tissues compared with other H3K4me3 methyltransferases. In vitro, knocking down ASH1L in HSCs inhibits HCC cell proliferation, but did not affect HCC cell proliferation. In the DEN-CCL4-induced HCC mouse model, the knockdown of ASH1L in liver hepatocytes and HSCs could decrease the tumor number. These results suggested that ASH1L could regulate HCC progress by regulating HSC activation.

Conclusions: We propose that in the tumor microenvironment, ASH1L promotes the proliferation of tumor cells by regulating the activation of stellate cells, thereby regulating the development of liver cancer.

Abstract Submission No. 101294
P-0464

Disorder liver circadian refelect disease prognosis of liver cancer
JingSong Yan1

1Southern University of Science and Technology ShenZhen China

Background: The liver is the largest circadian organ in the human body. Epidemiological findings indicate that circadian dysfunction increases the risk of hepatocellular carcinoma (HCC). However, the molecular evidence of circadian dysregulation in the role of HCC prognosis remains unclear.

Methods: A total of 378 circadian genes were collected from CircaDB. Multi-omics data and relevant clinical information were obtained from TCGA, GEO, and CNGB. Integrated bioinformatics analyses and experimental validation were performed in this study.

Results: The multiomics landscape of circadian genes reveals extensive disruption in HCC. Through integrated bioinformatics approach, the key features of disorder in the tumor microenvironment were further uncovered. Further analysis reveals that the tumor microenvironment in HCC also exhibits disordered circadian rhythms. Inhibition of IL18RAP in T cells within the tumor microenvironment are associated with immune function suppression, whilst overexpression of GNL2 in tumour vascular endothelial cells is associated with angiogenesis. Additionally, elevated of RBM17 and ZDHHC18 in tumour cells are related to tumour stem cells. In vivo and in vitro experiments reveal that RBM17 inhibits cell cycle transition. Knockdown of RBM17 inhibits the cancer stem cell phenotype by regulating CD133 and promotes chemosensitivity of HCC. Prognostic models based on circadian dysregulation effectively predict HCC prognosis and treatment responses (TACE, Sorafenib, immunotherapy).

Conclusions: The circadian rhythm of HCC is extensively disordered in multi-omics dimensions and in the tumor microenvironment. Dysregulation of circadian rhythms can effectively predict the prognosis and treatment response of HCC. Knockdown of RBM17 inhibits malignancy, highlighting therapeutic potential.

Abstract Submission No. 101328
P-0466

Importin α4 was accumulated in nucleus of liver cancer cells with p62/SQSTM1-positive aggregates.

Shunhei Yamashina1, Satoshi Sakuma1, Masahiro Tada1, Maki Morinaga1, Hiroo Fukada1, Hisafumi Yamagata1, Akira Uchiyama1, Reiko Yaginuma1, Kyoko Fukuvara1, Kazuyoshi Kon1, Ikejima Ikejima1

1Department of Gastroenterology, Juntendo University School of Medicine Tokyo Japan

Background: Aggregation of autophagic substrate p62/SQSTM1 which accelerates cellular proliferation via Nrf2 pathway was observed in human hepatocellular cancer tissue. We identified Importin α4 and 14-3-3&zeta; as an insoluble nucleoprotein increased by autophagic dysfunction. We evaluated the relationship between these autophagy-related proteins expression in hepatic cancer cells.

Methods: Tissue sections were prepared from 20 surgically resected liver cancer tissues, and immunohistochemical staining of p62/SQSTM1, Importin α4, and 14-3-3&zeta; was performed. The correlation of these proteins expression and laboratory data (platelet count, serum AST, ALT, gGTP, FIB4 Index) or histological score of hepatic fibrosis and inflammation in non-cancer area was evaluated by Spearman’s rank correlation coefficient analysis.

Results: Aggregation of p62/SQSTM1 was observed in cytoplasm of cancer cells from 18 resected liver cancer samples and the rate of cancer cells with p62/SQSTM1-positive aggregates was 57.9 ± 10.4% of all hepatocellular carcinoma cells. Nuclear expression of 14-3-3&zeta; and Importin α4 were observed in all resected samples. The rate of cancer cells with nuclear expression of 14-3-3&zeta; was 42.9 ± 6.4% and Importin α4 was 79.0 ± 4.7%. The rate of cells with p62/SQSTM1-
positive aggregates was correlated with nuclear expression of Importin α4 but not 14-3-3ζeta.

**Conclusion:** It was suggested that nuclear accumulation of Importinα4 is associated with abnormality of proteostasis in human hepatocellular carcinoma cells similarly to aggregation of p62/SQSTM1. Therefore, p62/SQSTM1 and Importin α4 might be useful as a diagnostic and prognostic marker in liver cancer.

Abstract Submission No. 101336
P-0467

**Potential of combined therapy between sorafenib and SRC1 inhibitors in overcoming HCC heterogeneity**

Loraine Kay D. Cabral1,2, Pablo Giraudi1, Gianluigi Giannelli3, Francesco Dituri2, Agustiningsih Agustiningsih2, Claudio Tiribelli1, Caecilia H.C. Sukowati9

1 Fondazione Italiana Fegato-ONLUS Trieste Italy, 2 Doctoral School in Molecular Biomedicine, University of Trieste Trieste Italy, 3 Institute of Gastroenterology “S. De Bellis” Research Hospital Bari Italy, 4 Research Center for Molecular Biology, National Research and Innovation Agency of Indonesia (BRIN) Jakarta Indonesia

**Background and Aims:** The efficacy of Sorafenib (SOR) in hepatocellular carcinoma (HCC) is limited, due to cellular heterogeneity. Thus, new or combined therapy strategies are warranted. This study aims to analyze the potential of combined therapies using SRC1 inhibitors in HCC.

**Method:** SRC1 as molecular target was defined from in-silico analysis. SRC1 expression was assessed in HBV-transgenic mouse C57BL/6J-Tg(ALB1HBV)44BRI/J and different hepatic cell lines: S1/TGFβ1-Wnt subtype (HLE), S2/progenitor (HepG2) and immortalized hepatocyte (IHH), together with protein expression by Western blot. Cells were treated with monotherapies of SOR and two SRC1 inhibitors saracatinib (SAR) and dasatinib (DAS) and in combined therapies of SOR+SAR and SOR+DAS, with concentrations ranging from 0.02 to 10 µM. Lethal concentrations 50 (LC50) of all combinations were calculated by cytotoxicity test. Migration capacities were assessed by wound healing and transwell migration assay.

**Results:** The mRNA expression of Src1/pp60c-src in transgenic mice was increased along with hepatocarcinogenesis (p<0.0001), while in HCC cells SRC1 expression was 10-fold higher compared to hepatocytes (p<0.05). Following treatments, SOR, SAR, and DAS monotherapy alone were not significantly toxic. However, combined therapies of SOR+SAR and SOR+DAS resulted in a dose-dependent cytotoxicity in both HCC cells, with lower LC50 values was noticed in HepG2. In contrast for IHH where SOR+SAR combination was not toxic. Functional analysis using wound healing and transwell assay also showed that combined therapies highly inhibited cells migration compared to monotherapies alone (p<0.05).

**Conclusion:** Combined therapies between SOR and SCR1 inhibitors can be potential treatment to encompass cellular heterogeneity in HCC.

Abstract Submission No. 101367
P-0468

**Hepatocellular Carcinoma Cells Avoid Apoptosis by Interacting with T Cells via CD40–CD40L Linkage**

Hanh Ngo1, Thuy Le2, Hieu Vu2, Hai Hoang1, Hiroko Ikenaga1, Misako Matsubara1, Masaru Enomoto1, Akihiro Tamori1, Norifumi Kawada1

1 Osaka City University Osaka Japan, 2 Hanoi Medical University Hanoi Vietnam

**Background:** Hepatocellular carcinoma (HCC), a leading cause of global cancer-related deaths, is associated with elevated soluble CD40 levels in HCV-SVR patients. We aimed to investigate CD40’s role in HCC progression.

**Methods:** We examined CD40 levels in HCC patient tissues and cell lines, studying their interaction with CD4+ T cells. RNA sequencing analysis was performed to explore the mechanisms of CD40 induction.

**Results:** Poorly differentiated HCC tumour tissues exhibited high membrane-bound CD40 (mCD40) expression, in contrast to non-tumour areas. Poorly differentiated HCC cells (SNU387, HLE, and HLF) showed high expression of mCD40 compared with well-differentiated HCC cells (Huh7, HepG2) which exhibited minimal CD40 expression with high promoter methylation. Co-culturing activated CD40L-expressed CD4+ T cells with HLFs led to a modest 3.2% increase in cell death. However, pre-neutralizing CD40 significantly induced HLFs apoptosis (10.9%), while pre-neutralizing integrin α5β1 reduced this to 1.7%. Moreover, pre-blocking both CD40 and integrin α5β1 caused only 1.9% of cell death. Furthermore, co-cultivation of activated CD4+ T cells with HLFs resulted in elevated CD40 levels, in a cell ratio- and time-dependent manner. RNA sequencing of HLFs cultured with activated CD4+ T cells revealed the upregulation of interferon (IFN) and immune response pathways. Elevated IFN-gamma levels in the activated T cell media stimulated the JAK1/STAT3 pathway, resulting in increased HLF CD40 expression. Inhibiting JAK1 and STAT3 effectively reduced CD40 expression in HLFs following IFN-gamma stimulation.

**Conclusion:** CD40 expression in poorly differentiated HCC cells prevents cell death by interacting with CD40L+ T cells. Targeting CD40 may represent a promising anticancer therapy.

Abstract Submission No. 101373
P-0469

**Antitumor effect of biofabricated silver nanoparticles of caffeic acid against hepatocarcinogenesis**

Ekta Yadav3

1 Sam Higginbottom University of Agriculture Technology and Sciences Allahabad India

**Background:** Over recent years, metal nanoparticles, especially silver (Ag) nanoparticles have been accepted as promising therapeutic tools for cancer diagnosis as well as treatment. Caffeic acid (CFA) is a natural phenolic acid that possesses antitumor activity. The current study was designed to explore the in vitro and in vivo antitumor effect of CFA-mediated biofabricated silver nanoparticles (CFA-AgNPs) against hepatocellular carcinoma (HCC).

**Methods:** CFA-AgNPs were synthesized by co-precipitation method and characterized by various techniques such as ultraviolet-visible spectroscopy, fourier-transform infrared spectroscopy (FTIR), energy dispersive X-ray analysis (EDX) and field emission scanning electron microscopy (FESEM). Cytotoxic potential of CFA-AgNPs was investigated by MTT assay on HepG2 cells by in vitro method. Subsequently, apoptosis and associated gene expression were determined by using flow cytometry assay and quantitative real-time polymerase chain reaction (qPCR), respectively. In vivo study was performed in male Sprague Dawley rats by inducing diethylnitrosamine (DEN, 200mg/kg) administration and the CFA-AgNPs were given by oral gavages at two different dose levels (10 and 20mg/kg for 16 weeks). On the last day of the study, various antiproliferative parameters were determined including hematological profile, serum biomarkers and inflammatory cytokine levels for each group.
**Result:** Characterization techniques confirmed the formation of spherical crystalline CFA-AgNPs with a size range of 50-80 nm and having a strong peak of Ag. FTR results showed the existence of possible bioactive functional groups of phytoconstituents in the synthesized CFA-AgNPs. Further, CFA-AgNPs exhibited significant (p<0.05) cytotoxic effects and flow cytometry results revealed stimulated apoptosis. An increase in p53 and Bax expressions and a reduction in Bcl-2 expression along with upregulation of accompanied Bax/Bcl-2 ratio were observed in qPCR results. In vivo results demonstrated that the CFA-AgNPs administered group significantly downregulated (p<0.01) the serum marker hepatic and non-hepatic enzymes and pro-inflammatory markers such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1β (IL-1β) as compared to DEN alone group.

**Conclusion:** Results of the current investigation recommended the inhibition potential of CFA-AgNPs against DEN-induced damaging effects on the liver via an antioxidant defense system and modulation of Bax/Bcl2 as well as proinflammatory cytokines. CFA-AgNPs can be utilized as a superior approach to improve the clinical results against HCC.

**HCC are exacerbated by IL-1R1 deficiency and Myeloid-derived Suppressor Cell in Tumor Immunotherapy**

Chia-Sheng Chu1-3, Hsiao-Ping Chen4, 5, 6, Pin-Hung Lin7, Chi-Chen Cheng8, He-Yu Kuo1, Pei-Han Fan3, Chun-Ying Wu9, Li-Ling Wu5, 8

1Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei City Hospital Yang Ming Branch Taipei City Taiwan, 3Department and Institute of Physiology, National Yang Ming Chiao Tung University Taipei City Taiwan, 4Health Innovation Center, National Yang-Ming Chiao Tung University Taipei City Taiwan, 5Microbiota Research Center, National Yang-Ming Chiao Tung University Taipei City Taiwan, 6Institute of Biomedical Informatics, National Yang-Ming Chiao Tung University Taipei City Taiwan, 7Department of Microbiology, National Taiwan University College of Medicine Taipei City Taiwan, 8School of Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan, 9Division of Translational Research, Taipei Veterans General Hospital Taipei City Taiwan, 10Institute of Public Health, College of Medicine, National Yang-Ming Chiao Tung University Taipei City Taiwan

**Background:** Malignant solid tumors exhibit fast proliferation of immature and myeloid-derived suppressor cells (MDSC). Hepatocellular carcinoma (HCC) patients with high IL-1 expression had a worse prognosis, survival, and treatment response. Gemcitabine, a popular anti-cancer drug, may extend life by affecting tumor microenvironment MDSC and IL-1 signaling. However, the precise mechanism by which IL1R1 recruits MDSCs associated with HCC remains unknown.

**Methods and Results:** A hydrodynamic injection (HDI) mouse model of HCC was developed for this research to mimic human disease. In addition to tumor-intrinsic oncogenicity, we have shown that IL1β is elevated in the serum of patients with HCC. Furthermore, we have demonstrated that both serum and hepatic IL-1β levels are increased in HCC-HDI mice. In comparison to wide-type (WT) mice, IL1R1−/− mice exhibited an elevated liver-to-body weight ratio, a higher percentage of Ki-67 expression in hepatocytes indicating suboptimal histopathological differentiation of HCC, and increased population of hepatic MDSCs, CD4+PD1+ cells, and conventional T cells (Tregs), and the accelerated progression of HCC. Using gemcitabine reduced tumor growth and quantity, reversing those effects. Gemcitabine inhibited tumorigenicity in HCC by decreasing the number of hepatic MDSCs and increasing the number of tumor-infiltrating CD8+ T cells.

**Conclusions:** The pro-tumorigenic effects of IL-1 were balanced by its effects on monocyteic MDSCs, which exacerbated inflammation and HCC development. IL-1 signaling causes cell-type-specific responses in HCC-HDI mice, which determine the hepatic tumor microenvironment’s inflammatory tone and disease progression. These findings provide light on IL-1R1 and MDSCs in HCC, suggesting a therapeutic target.

**UGDH promotes process of hepatocellular carcinoma by regulating metabolism of tumor cells**

Xin Sun1, 2, Xu Cao1, 2, Xiaoke Li3, 2, Xiaobin Zao5, 2, 3

1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 2Institute of Liver Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China

**Background:** The gene of Udp-glucose 6-dehydrogenase (UGDH) plays an important role in exogenous metabolism and acts as a key mediator in several cancer developmental signaling pathways. However, its expression and function in hepatocellular carcinoma (HCC) is still unclear.

**Methods:** The expression and related clinicopathological information of UGDH were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. A rat HCC model was established using intraperitoneal injection of diethylnitrosamine. HE staining, MASON staining, PAS staining, and Ki67 immunohistochemistry of liver tissues were performed. The real-time quantitative PCR (qRT-PCR) and western blotting (WB) were used to detect the expression of UGDH.

**Results:** The results of public databases showed that the mRNA expression of UGDH was significantly upregulated in HCC tissues compared with normal tissues. And the HCC patients with lower UGDH expression had better prognosis in overall survival and relapse-free survival in the rat HCC model, qRT-PCR and WB results also showed that UGDH expression was significantly increased in the HCC compared with the control. Furthermore, by analyzing the deferentially expressed genes between high-UGDH and low-UGDH samples, we obtained the 228 key targets of UGDH. The Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses showed that these UGDH-related genes were correlated to Cell division, Cell cycle, and Metabolic pathways.

**Conclusions:** Our study showed that UGDH was upregulated in HCC and its upregulation was associated with poor prognosis in HCC patients. UGDH might exert its carcinogenic effects by regulate metabolism to promote HCC cell proliferation.

**Obesity is associated with normal FIB-4 in nonalcoholic fatty liver disease related HCC**

Abstract Submission No. 101389

P-0472
Benidex Sim1, Cheng Han Ng1,2, Nobuharu Tamaki2, Beom Kyung Kim1, Karn Wijarnpreecha1, Ken Liu1, Margaret Teng1, Benjamin Tay1, Yiqing Teh1, John Mok1, Benjamin Nah1, Mark Muthiah1, Anand V. Kulkarni1, Sung Won Lee1, Daniel Q. Huang1,2

1Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore, 3Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital Tokyo Japan, 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea Seoul Republic of Korea, 5Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine Phoenix, Arizona USA, 6AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital Sydney, New South Wales Australia, 7Department of Hepatology, Asian Institute of Gastroenterology Hyderabad, Telangana India

Background: The fibrosis-4 (FIB-4) index has been incorporated in major guidelines to risk stratify patients with nonalcoholic fatty liver disease (NAFLD), and patients with FIB-4 <1.3 are considered to be at low risk of advanced fibrosis. We aimed to evaluate the factors associated with falsely low FIB-4 scores in patients with nonalcoholic steatohepatitis (NASH)-HCC.

Methods: We included adult patients diagnosed with NASH-HCC from 2008-2021 at five academic centers in Japan, South Korea, Singapore, and the United States. Predictors associated with FIB-4 <1.3 were investigated with multivariate logistic regression models. P-values <0.05 were considered statistically significant. All analyses were conducted in RStudio 2021.09.0.

Results: We included 472 patients with NASH-HCC, of which 33 patients (7%) had FIB-4 <1.3. In multivariate analysis, diabetes (OR 0.47, 95%CI 0.22–0.99, p=0.048) and cirrhosis (OR 2.84, 95%CI 1.16 –6.87, p=0.020) were associated with decreased likelihood of FIB-4 <1.3. Obesity (defined as >27.5 kg/m² in Asians, and >30.0 kg/m² in non-Asians) was associated with increased likelihood of FIB-4 <1.3 (OR 2.33, 95%CI 1.07–5.01, p=0.030) (Figure 1). In subgroup analysis of 213 patients without cirrhosis, 25 patients (12%) had FIB-4 <1.3. In patients without cirrhosis, obesity continued to be associated with increased likelihood of FIB-4 <1.3 (OR 2.84, 95%CI 1.16–6.87, p=0.020).

Conclusion: In patients with NASH-HCC, obesity was associated with increased likelihood of FIB-4 <1.3 regardless of the presence of cirrhosis. Further studies are required to evaluate the effectiveness of FIB-4 as a risk stratification tool in the general population for patients with obesity but without diabetes.

Abstract Submission No. 101678

Exosomal ncRNAs: a significant contributor to the immunosuppressive tumor microenvironment of HCC

Qi Huang1, 2, 3, Xin Zhong1, 3, Rui Hu1, 2, 3, Jing Li1, 2, 3, Jialing Sun1, Jinyu Yi1, 2, 3, Zhiyi Han3, Xinfeng Sun1, 3, Wenhong FENG2, Wenfeng MA1, Wei Zhang3, Xiaozhou Zhou3

1Shenzhen Traditional Chinese Medicine Hospital, Department of Liver Disease, Shenzhen China, 2Macau University of Science and Technology, Faculty of Chinese Medicine, Macao, China, 3The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Department of Liver Disease, Shenzhen China

Hepatocellular carcinoma (HCC) is a primary malignant neoplasm originating in the liver. In the past few years, there seems to be an increasing emphasis on the invention of pharmaceuticals that specifically target immunological checkpoints and immune cells. In truth, the efficacy of immunotherapy is heavily contingent upon the tumor microenvironment (TME). TME is a multifaceted communication system comprising diverse elements. Recent studies have indicated that exosomes serve as a developed means of communication among bioactive molecular cells while also additionally executing an essential part in the microenvironment of tumor immune suppression. Moreover, exosomal non-coding RNAs (ncRNAs) can induce activation in tumor cells and immune cells with immunosuppressive properties, such as CAFs, TAMs, TANs, CD8 T cells, Tregs, and Tregs. Activation of this pathway promotes the growth of tumor vascular, the transfer of gene changes in metabolism, and the transformation of malignant phenotypes. This helps the immune system avoid detection and the growth of tumors. Hence, comprehending the mechanisms by which exosomal ncRNAs modulate tumor cells or immune cells inside the TME is crucial for the development of more comprehensive and efficacious immunotherapy protocols. This article offers a complete overview of the characteristics of exosomal ncRNAs in relation to the advancement of HCC. It elucidates the mechanisms by which exosomal ncRNAs influence tumor cells and immune cells, leading to the reconstruction of the tumor immunosuppressive microenvironment. Additionally, the article explores the therapeutic potential of exosomal ncRNAs as a promising biological target or carrier in HCC treatment.

Abstract Submission No. P-0473

Galactose Conjugated PPI Dendrimers for Liver Targeting

Saurabh Bhargava1, V Bhargava2

1Signa College of Pharmacy Kanpur India, 2GTB Hospital Kanpur India

Cancer therapy needs site-specific drug delivery to affected cells and should avoid affecting healthy cells. Liver is prominent organ of body and has Asialoglycoprotein receptor expression. The research aimed to develop dendrimer-based drug delivery providing enhanced therapeutic potential of anti-cancer agent(doxorubicin) by effective targeting to liver cells. 5.0G Dendrimers were synthesized by divergent method. Ethylene diamine was core material and Acrylonitrile branching unit. Synthesis was performed on basis of two steps ie Double Michael addition and Catalytic hydrogenation. Dendrimers were confirmed by FTIR, NMR and Mass spectroscopy and then conjugated with galactose. Shape and size were characterized by Transmission Electron Microscopy(TEM), drug loading efficiency, In-vitro drug release and stability studies. Ex-vivo studies constituted Hemolytic toxicity study. In-vivo studies, Pharmacokinetic parameters and Biodistribution Studies were performed. Thus Galactosylated PPI dendrimers showed high doxorubicin loading, sustained release and excellent biocompatibility as evident by low hemolytic toxicity. Presence of ligand on dendrimer molecule, elevated receptor mediated binding thereby targeting higher concentration of doxorubicin to lung. Higher concentration of GPPI-DOX was found to be significant compared to PPI-DOX and DOX. Possibly galactose having more affinity towards asialoglycoprotein receptors of liver parenchymal cells, more amount of drug had accumulated in liver. Finally, it can be concluded that galactose-coated PPI dendrimers found to be most suitable for delivery of Doxorubicin HCl. Galactose conjugation can be utilized to not only target asialoglycoprotein receptors of liver, but also to reduce hemolytic toxicity. Furthermore, this...
delivery system could reduce drug associated toxic effects by selectively targeting hepatoma cells.

Abstract Submission No. 101679
P-0475

Liquid Crystalline Nanoparticles (LCNPs) based delivery of an Anticancer bioactive, Methotrexate

Mani Bhargava1, S Bhargava2
1GTB Hospital Kanpur India, 2Signa College of Pharmacy Kanpur India

Liver cancer is a disease of uncontrolled cell growth, which may invade adjacent tissue and cause infiltration beyond the liver. Most of potent and effective anticancer drugs used in liver cancer therapy shows poor bioavailability at desired site as well as toxic in nature. The potent and effective anticancer drugs used in liver cancer therapy shows poor bioavailability at desired site as well as toxic in nature. The aim of the study was to investigate mannose modified Liquid Crystalline Nanoparticle (LCNPs) carrier for efficient and site specific delivery of potent anticancer drug (Methotrexate) used in hepatic carcinoma therapy.

MTX loaded LCNPs were prepared by lipid cast film method and sonication method. Nanoparticles were characterized in-vitro for their shape, size, percent drug entrapment and stability by Optical Microscopy, Cross Polarized Light Microscopy (CPLM), Transmission Electron Microscopy (TEM), X-ray diffraction (XRD) and Atomic Force Microscopy (AFM). In-vitro stability studies reveal that LCNPs formulations are stable for 120 days at room temperature. Ex-vivo cell cytotoxicity was performed on Human hepatoma cell line. In-vivo studies included fluorescence microscopy and organ distribution studies which show the Mannose modified LCNPs exhibit better accumulation in liver as compared to unmodified system. The results of the present study indicate this system is more stable as compared to other system. Eventually it may be concluded that incorporation of MTX in mannose modified LCNPs increases residing time of drug in the body by altering of pharmacokinetics and biodistribution pattern, and the drug primarily concentrates in the liver. This system showed excellent cytotoxicity towards cancer cells. From the present investigation it is evident that this system may be used for liver cancer and other liver disease.

Abstract Submission No. 101686
P-0476

Long-term Antiviral Therapy Improving ER Stress, Mitochondrial, and Metabolic Functions Reduces HCC

Yuh-Jin Liang1,2, Wei Teng3, Chi-Yu Lai1, Chien-Wei Su4, Jaw-Ching Wu5
1Department of Medical Research, Taipei Veterans General Hospital Beilou Taiwan, 2Institute of Clinical Medicine, National Yang Ming Chiao Tung University Taipei Taiwan ROC, 3Department of Gastroenterology & Hepatology, Chang Gung Memorial Hospital Linkou Taiwan ROC, 4Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital Taipei Taiwan ROC

Background and Aims: The need of antiviral therapy in hepatitis B virus (HBV) carriers with normal or minimally elevated ALT levels is controversial. Animal models of HBV-associated hepatocellular carcinoma (HCC) are needed for translational research and as platforms for testing novel therapies.

Methods and Results: We established a novel mouse model of HBV-associated HCC (strain D14-122; HCC incidence 89% in the absence of ALT elevation) by crossing HBV transgenic mice with Mir-122 tumor suppressor knockout mice. Early-onset hepatic steatosis, progressive liver fibrosis, and reduced lysosome degradation in late phase of autophagy were observed during tumorigenesis in D14-122. NMR non-targeted metabolomics analyses and microarray showed steatosis, inflammation, and ROS-induced genomic instability as early as age 4-8 mo. Antiviral therapy reduced HCC incidence 30-35% in these mice, through amelioration of endoplasmic reticulum stress, promotion of autophagy, and inhibition of C/EBP-homologous protein (CHOP)-mediated apoptosis. Decreases of lipid deposit and hyperglycemia, ER stress markers were observed one month after antiviral therapy and reductions of p62 (Mallory-Deng body, known to be carcinogenic) and ER stress markers were found in NUC-treated mice without HCC at late phase. Strong deposits of p62 in HBV-related human HCC support the findings in this novel mouse model.

Conclusion: This study reveals a novel mechanism of liver injury that HBV hijacks autophagy and down-regulates miR-122, leading to endoplasmic reticulum stress, mitochondrial dysfunction, and metabolic reprogramming. These findings explain the mechanism of antiviral treatment in reducing the incidence of HCC in HBV carriers in the grey zone of treatment guidelines.

Abstract Submission No. 101692
P-0477

Serum miRNA biomarker for for predicting Hepatocellular Carcinoma risk after HCV eradication

Khaled Elgeshy1, Katsuya Nagaoka1, Takehisa Watanabe4, Masaya Onishi2, Takayuki Tokunaga5, Satoshi Narahara1, Hiroki Inada1, Etsuko Iio1, Yoko Yoshimura1, Hiroko Setoyama1, Takanori Suzuki1, Kentaro Matsuura2, Hidenori Toyoda1, Takahiro Ochiya1, Yasuhiro Tanaka1
1Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan; 2Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo Tokyo Japan; 3Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences Nagoya Japan; 4Department of Gastroenterology, Ogaki Municipal Hospital Gifu Japan; 5Department of Molecular and Cellular Medicine, Tokyo Medical University Tokyo Japan

Background and purpose: Hepatocellular carcinoma (HCC), a prevalent global cancer, often arises from persistent viral infections, particularly Hepatitis C virus (HCV). MicroRNAs (miRNAs) are small, noncoding RNAs that direct posttranscriptional regulation of gene expression. Although HCV eradication with direct-acting antivirals reduces HCC risk, ongoing surveillance is crucial for cirrhotic patients even after achieving sustained virologic response (SVR). We aim to identify miRNAs that can predict HCC onset after HCV elimination and analysis of their functions.

Methods: A retrospective study compared two groups: one immediately post-SVR and another at 5 years post-SVR, further divided into HCC and non-HCC subgroups. Serum miRNA expression was analyzed using microarray and small RNA-seq. Candidate miRNAs were identified through differential expression and LASSO regression analyses, validated using two independent sample sets. In-vitro studies using HepG2 cells transfected with mimics of the candidate miRNAs produced western blot and RNA-seq data.

Results: MiRNA-x3 was significantly up-regulated in HCC-HCV-SVR compared to no-HCC-HCV-SVR, confirmed by two independent
validations. In-vitro studies suggested miRNA-x3’s involvement in cell cycle G1/S phase transition and DNA damage. **Conclusion:** MiRNA-x3 may predict hepatocarcinogenesis risk in HCV-SVR patients; ongoing work aims to confirm these findings.

Abstract Submission No. 200044
**P-0478**

**Investigating Hypoxia, EMT, and CD8+ T Cells in Hepatocellular Carcinoma**

KONGLI FANⁱ, Xiaozhou Zhou²

¹861576537431 Shenzhen, China China, ²The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen China

Hepatocellular carcinoma (HCC) metastasis and invasion are key factors contributing to treatment failure and poor prognosis. Epithelial-mesenchymal transition (EMT), a cellular process, plays a critical role in this progression. Hypoxia, a common feature of solid tumors, induces EMT in tumor cells. CD8+ cytotoxic T cells, although possessing anti-tumor effects, exhibit contradictory functions. Hypoxia in the tumor microenvironment inhibits CD8+ T cell activity and function via tumor cell signaling molecules, promoting EMT and impairing CD8+ T cell quantity and function, facilitating immune escape. Additionally, the hypoxic microenvironment reduces mitochondrial function, impeding mitochondrial transfer, affecting tumor cell metabolism and immune cell function. The fundamental pathogenesis of the tumor’s hypoxic microenvironment in Traditional Chinese Medicine involves qi deficiency, blood stasis, and Qi stagnation. Blood stasis hinders blood vessel flow, obstructing Qi and blood circulation. This causes local microcirculatory disturbances, obstructed tissue fluid drainage, and the development of a hypoxic microenvironment. Thus, interventions targeting the hypoxic microenvironment, such as traditional Chinese medicine formulas like QiZhuKangai decoction, have potential in inhibiting HCC growth and metastasis by addressing EMT, angiogenesis, and improving blood circulation. Understanding the mechanisms underlying these effects may provide novel approaches for tumor treatment.

Abstract Submission No. 200087
**P-0480**

**Identifying Therapeutic Targets in Hepatocellular Carcinoma: An Integrated Bioinformatics Analysis**

Yangyang Li¹

¹China NanChang China

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide, with a high incidence rate and poor prognosis. In this study, we performed an integrated bioinformatics analysis to identify potential therapeutic targets for HCC. We first analyzed the gene expression profiles of HCC samples from The Cancer Genome Atlas (TCGA) database and identified differentially expressed genes (DEGs). Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were then conducted to explore the biological functions and pathways associated with these DEGs. Furthermore, protein-protein interaction (PPI) network construction and module analysis were performed to identify key proteins and their interactions in HCC. Finally, we validated the potential therapeutic targets by examining their expression levels in HCC tissues and cell lines. Our results revealed that several key genes and pathways, including TP53, CTNNB1, and PI3K-Akt signaling pathway, may play crucial roles in HCC development and progression. These findings provide new insights into the molecular mechanisms underlying HCC and may help guide the development of novel therapeutic strategies for this disease.

Abstract Submission No. 200151
**P-0481**

**Deciphering HCC Development Linked to IncRNA02313 and Building a Predictive Model**

yang Liu¹, ², meijie Chen², xiao liang³

¹22218149@zju.edu.cn Hangzhou City China, ²zhejiang university hangzhou china, ³Run Run Shaw Hospital, Zhejiang University School of Medicine hangzhou china

Mitochondrial permeability transition (MPT) has recently garnered attention in its association with various tumor types, including hepatocellular carcinoma (HCC). In the context of HCC, our study focuses on the exploration of the involvement of MPT in driving necrosis and its correlation with the long non-coding RNA LINC02313. Limited research has been conducted on MPT-driven necrosis-related IncRNAs in the context of liver cancer. To investigate the potential role of MPTDNRIncRNAs, we obtained RNA-sequencing data and corresponding clinical information from HCC patients through the TCGA database. MPT-driven necrosis-related genes were extracted from the Gene Set Enrichment Analysis (GSEA) database. Through comprehensive analyses, we identified LINC02313 as a significant
MPTDNRlncRNA associated with differential expression in HCC. Utilizing univariate Cox regression analysis, we further determined the prognostic significance of LINC02313 in the context of MPT-driven necrosis in HCC. A novel prognostic signature comprising MPTDNRlncRNAs, including LINC02313, was constructed using LASSO-COX. The predictive accuracy and utility of this signature were rigorously evaluated through diverse statistical methodologies. In addition to bioinformatics analyses, we performed RT-qPCR experiments on HCC cell lines to validate the expression levels of MPTDNRlncRNAs, particularly emphasizing the role of LINC02313. Our findings revealed a distinctive 5 MPTDNRlncRNAs signature specific to HCC, where LINC02313 played a pivotal role. This study pinpoints LINC02313 as a crucial factor in MPT-driven necrosis linked to hepatocellular carcinoma development. Additionally, it introduces a promising prognostic signature that could advance our understanding of the disease and potentially influence personalized therapeutic approaches in liver cancer.

Abstract Submission No. 200176
P-0482

GOLGI PROTEIN 73(GP73) IN DIAGNOSIS OF PRIMARY HEPATOCELLULAR CARCINOMA

Kay Thwe1, Aye Thida2, Win Swe3, Khin M Win4
1Hepatology Yangon Myanmar, 2Hepatology Yangon Myanmar,
3Hepatology Yangon Myanmar, 4Hepatology Yangon Myanmar

Background: The incidence of hepatocellular carcinoma (HCC) is increasing worldwide as well as in Myanmar. Since incidence and mortality rates of HCC are roughly equivalent, early detection of HCC is important. Serum Golgi Protein 73 (GP73) is considered as a potential tumor biomarker for the detection of HCC. However, the diagnostic accuracy of GP73 for HCC is still conflicting. This research was designed to assess the diagnostic efficacy of GP73 in HCC.

Methods: This was a hospital based cross sectional descriptive study carried out from July 2020 to October 2021. Eighty patients were allocated into two groups (43 patients with HCC and 37 patients without HCC). Serum alpha fetoprotein (AFP) and GP73 were tested for all the participants. Detection of focal hepatic lesions were based on imaging by triphasic computed tomography.

Results: The mean value of GP73 was 9.3ng/ml in HCC group and 8.5ng/ml in those without HCC group (p=0.904). AUROC curve for GP73 was 0.51 with an optimal cutoff point of 3ng/ml. Therefore, the diagnostic accuracy of GP73 was 56% (sensitivity-67% and specificity-43%) at a cutoff point 3ng/ml, whereas AFP had the diagnostic accuracy was 68% (sensitivity-72% and specificity-62% at a cutoff point 20ng/ml).

Conclusion: This study revealed that GP73 does not appear to be an accurate and new biomarker in diagnosis of HCC. The results of this study are not conclusive but it will provide the stimulus and enthusiasm for further research.

Abstract Submission No. 200220
P-0483

Polyploidy determines a distinct subset of hepatocellular carcinoma exhibiting aggressive features

Takanori Matsuura1, Yoshihide Ueda1, Yuzo Kodama1, Takumi Fukumoto1, Tomonori Matsumoto2
1Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine Kobe Japan, 2Department of Molecular Microbiology, Research Institute for Microbial Diseases, Osaka University Osaka Japan, 3Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kobe University Graduate School of Medicine Kobe Japan

Genome duplication, or polyploidization, is prevalent phenomenon in cancer, however its significance in hepatocellular carcinoma (HCC) remains largely unknown. We aimed to evaluate polyploidy status in HCC using clinical specimens and to elucidate its clinicopathological significance. We performed multi-colored fluorescence in situ hybridization using pathological specimens from 56 human HCCs. Markers indicative of polyploidy were explored by transcriptome analysis of cultured hepatoma cells. Polyploidy was identified in 36% of HCCs, distinguishing an aggressive subset of HCC characterized by elevated serum alpha fetoprotein, distinctive histology, and poor prognosis compared to near-diploid HCCs. We detected novel indicators of polyploidy in HCCs, which were overexpression of ubiquitin-conjugating enzymes 2C and the abundance for polyploid giant cancer cells with distinct appearance. These markers served as indicators of polyploidy in HCC and predicted poor prognosis. Diagnosis of polyploidy by artificial intelligence-based image analysis also revealed aggressive features of polyploid HCC in a large cohort. Polyploidy in HCC is associated with increased aggressiveness, through enhanced chromosomal instability.

Abstract Submission No. 200224
P-0485

Microwave ablation of primary liver and lung tumor

Yumchinscherin Narangere1, tsendjav tsogtbaatar2
1National Cancer Center of Mongolia Ulaanbaatar Mongolia, 2Interventional Radiology, National Cancer Center of Mongolia Ulaanbaatar Mongolia

Primary lung cancer is the third most common cancer in the worldwide and the leading cause of cancer-related deaths. In Mongolia, an estimated 6702 people were diagnosed new cancer, and liver cancer is the
first rank or 32% of all cancer in 2021. Non-small cell lung cancer (NSCLC) is the most common, accounting for 80 to 85 percent of lung cancer cases. They are often linked to a history of smoking and tend to be found in the central part of the lungs, near a main airway. In the case of primary double tumors, according to the International Classification of Tumors, it belongs to the 4th stage of malignant tumors, so supportive treatment is necessary. We present a clinical case of primary double tumors of the liver and lung were treated by microwave ablation. Patient M, 69-year-old man, had been suffering from abdominal and chest pains for 2 months and coughing up green sputum. He was diagnosed with combined primary liver and lung cancer in November 2022. He has smoked for 50 years and has HCV related liver cirrhosis. Liver biopsy was hepatocellular carcinoma (clear cell carcinoma) and lung biopsy was poorly differentiated squamous cell lung carcinoma. Diagnosis: HCC in segment SVll of liver T2NxMx non-small cell carcinoma in lower lobe of left lung T3N1Mx Stage IV. In our clinical case, the combined treatment of TACE+MWA for liver cancer and MWA for lung cancer were effective and quality of life improved after 6 months.

Abstract Submission No. 101742
P-0486

CDKN2A promotes hepatocellular carcinoma by inhibiting the Cuproptosis pathway

Xuan Dong1,2,3,4, Li-Li Gong5, Dan-Yi Zeng1,2,4, Mei-Zhu Hong6, Jin-Shui Pan6

1Department of Hepatology, the First Affiliated Hospital of Fujian Medical University Fuzhou China, 2Hepatology Research Institute, Fujian Medical University Fuzhou China, 3Department of Hepatology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University Fuzhou China, 4Fujian Clinical Research Center for Hepatopathy and Intestinal Diseases Fuzhou China, 5Department of General Practice, Zhongshan Hospital, Xiamen University Xiamen China, 6Department of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China

Background: The global prevalence and clinical features of hepatocellular carcinoma (HCC) render it a significant malignancy. A novel mode of cellular demise, known as cuproptosis, is the subject of this investigation, intending to determine its potential involvement in HCC.

Methods: The expression of cuproptosis-related genes and their relationship to the prognosis of HCC were determined using various databases including the Cancer Genome Atlas, Gene Expression Omnibus, Human Protein Atlas, and GEPIA. Co-expressed genes were investigated using CBioPortal, followed by GO, and KEGG analysis, to elucidate the potential mechanisms of CDKN2A co-expressed genes. The protein-protein interaction network and hub genes of these co-expressed genes were identified using Cytoscape.

Results: The protein and mRNA levels of CDKN2A were found to be up-regulated in HCC, and this up-regulation was negatively correlated with prognosis in HCC. On the other hand, FDX1 was positively associated with prognosis, although their mRNA levels did not show significant changes between HCC and control groups. The GO and KEGG analyses revealed that the co-expressed genes of CDKN2A were mainly enriched in processes related to chromosome segregation, catalytic activity (acting on DNA), chromosomal region, cell cycle, and DNA replication. Additionally, the hub genes of CDKN2A were found to be increased in HCC and were negatively associated with prognosis.

Conclusion: The involvement of cuproptosis in the pathogenesis and progression of HCC warrants consideration, while CDKN2A holds promise as a prospective therapeutic target and prognostic indicator for HCC.

Abstract Submission No. 101758
P-0487

Hepatoma-derived growth factor as a possible target gene for the treatment of HCC

Hirayuki Enomoto1, Hiroki Nishikawa2, Takashi Nishimura1, Hideyuki Shiomi1, Shinya Fukunishi1, Hiroki Iijima1
1Hyogo Medical University Nishinomiya Japan, 2Osaka Medical and Pharmaceutical University Takatsuki Japan

Background/Aims: We identified a novel growth factor, hepatoma-derived growth factor (HDGF). HDGF is highly expressed in the HCC tissues, and the expression level of HDGF is an independent prognostic factor for the disease-free and overall survival in patients with HCC. The purpose of this study is to examine whether HDGF can be a potential target molecule for the treatment of HCC.

Methods: (1) We generated the stably HDGF-overexpressed or HDGF-silenced hepatoma cell lines by the introduction of HDGF cDNA or sh-RNA, and examined the effects of the increased or reduced HDGF expression on the proliferation of hepatoma cells. (2) We investigated the effects of the exogenous and endogenous overexpression of HDGF on the proliferation and tubular formation of HUVEC (human umbilical vein endothelial cells) in vitro. (3) We examined whether the introduction of HDGF cDNA can induce the VEGF expression.

Results: (1) Introduction of HDGF DNA stimulated the proliferation of hepatoma cells, whereas reduction of HDGF by sh-RNA suppressed the growth of the hepatoma cells. (2) Administration of recombinant HDGF significantly increased the cellular number of HUVEC in vitro, and HDGF-treated HUVEC formed longer vessel-like tubes in vitro than those formed by PBS-treated control cells. (3) HDGF induced VEGF expression through the activation of the VEGF promoter.

Conclusions: HDGF is a unique molecule which has dual characteristics; one as a growth stimulating factor on hepatoma cells and the other as an angiogenic factor. HDGF is therefore considered to be a potential target molecule for the treatment of HCC.

Abstract Submission No. 101803
P-0488

Screening program for early stage of liver cancer in Ulaanbaatar: Single Center Study

Dashchirev Munkh-Orshikh1,4, Jazag Amarsanaa2,4, Baasankhuu Enkhtuvshin1,4, Oidov Batarkhuu1,3,4
1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2Happy Veritas Clinic and Diagnostic Center Ulaanbaatar Mongolia, 3Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 4Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Objective: Screening and diagnosis in early stage of liver cancer in Happy Veritas Clinic and Diagnostic Center. The total number of patients included for screening was 10682 patients such as abdominal ultrasound and to identify serum AFP every 3 months. 181 patients were included in the study, who had complete
set of data, and are regularly controlled for screening in early stage of liver cancer.

**Results:** 181 patients with an average age of 54 ± 11 (range: 23 - 89 years old) were included in the study. In the result, causes of liver fibrosis were HCV 59.1% (107), HBV 24.9% (45), HBV/HDV 13.3% (24), HCV/HBV 2% (3), HCV/HDV/HEV 0.6% (1) and without hepatitis viruses 0.6% (1). According to the study, F2 was 64.6% (117), F3 27.1% (49) and F4 8.3% (15). We studied the changes in laboratory tests and depending on the patient’s fibrosis stage. Increasing fibrosis stage or liver cirrhosis has decreased platelets, albumin and total protein level (p<0.001). However, we observed ALT level, which increased in F3 and decreased F4. Liver cancer nodule is detected in 4 patients, they had fibrosis stage F4 in Fibroscan analysis and average level of AFP was 86.

**Conclusion:** We conclude that patients in F4 stage in Fibroscan analysis have higher risk of developing liver cancer. Therefore, health care providers need regularly screening and testing in early stage of liver cancer in high-risk population.

Abstract Submission No. 101820

**P-0489**

**Phenotypic Linkage Between m6A Methylation and Immune Microenvironment in Hepatocellular Carcinoma**

**Feng Zhang**¹, ²

¹The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, ²Guangdong Provincial People’s Hospital Guangzhou China

**Purpose:** The crucial role of N⁶-methyladenosine (m⁶A) methylation in anti-tumor immunity and immunotherapy has been broadly depicted. However, the molecular phenotypic linkages between m⁶A modification pattern and immunological ecosystem are expected to be disentangled in hepatocellular carcinoma (HCC), for immunotherapeutic unresponsiveness circumvention and combination with promising drug agents.

**Methods:** Modification patterns of m⁶A methylation were qualitatively dissected according to large-scale HCC samples profiling. The immune phenotypic linkages were determined by systematically evaluating their tumor microenvironment composition, immune/stromal-relevant signature, immune checkpoints correlation and prognostic value. Individual quantification was achieved by m⁶Ascore construction, intensified by longitudinal single-cell analysis of immunotherapy cohorts and validated in our in-hospital cohort. Candidate therapeutic agents were also screened out.

**Results:** Three distinct m⁶A methylation patterns were determined in high accordance with inflamed-, excluded- and desert-immunophenotype, robustly validated in our in-hospital cohort. To be precise, immune-inflamed high-m⁶Ascore group was characterized by activated immune cells and favorable prognosis. Stromal activation and absence of immune cell infiltration were observed in low-m⁶Ascore phenotype, linked to impaired outcome. Patients with low-m⁶Ascore demonstrated diminished responses and clinical benefits for cohorts receiving immunotherapy. Single-cell dynamic change of m⁶A methylation level in exhausted CD8 T cell and fibroblast was depicted in immunotherapy cohort fore and art. Derived from m⁶A methylation pattern, seven potential frontline drug agents were recognized as promising choice.

**Conclusion:** Our work bridged the credible linkage between epigenetics and anti-tumor immunity in HCC, unraveling m⁶A modification pattern as immunological indicator and predictor for immunotherapy. Individualized m⁶Ascore facilitated strategic choices to maximize therapy-responsive possibility.

Abstract Submission No. 101983

**P-0490**

**Knockdown of NPLOC4 induces cuprotosis to promote HCC progression**

**Jing Deng**¹, ², ³, **Jing Cao**¹, ², ³, **Jiao Gong**¹, ², ³, **Yutian Chong**¹, ², ³

¹The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, ²The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China, ³The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

**Background:** Hepatocellular carcinoma (HCC), with high incidence and mortality, is the result of many malignant liver diseases. Nuclear protein localization protein 4 (NPLOC4) primarily participates in the ubiquitin-mediated degradation of ER proteins. The role of NPLOC4 in HCC and its prognostic significance remains unknown.

**Methods:** The expression level of NPLOC4 was predicted by bioinformatics and detected in HCC cell lines and tissues by quantitative reverse transcription PCR (qPCR). The effects of NPLOC4 on cancer cell proliferation, apoptosis, and migration were evaluated by colony formation, cell counting kit 8 (CCK8), and transwell. The levels of Cu and cuprotosis-associated proteins were predicted by Western blotting, immunofluorescence, and Cu detection kit. Gain- or-loss-of-function assays were used to identify the function and underlying mechanisms of NPLOC4 in HCC.

**Results:** We found that NPLOC4 was significantly upregulated and predicted a poorer prognosis in HCC tissues. NPLOC4 significantly promoted HCC cell proliferation and inhibited apoptosis in vitro and in vivo. Mechanistically, depletion of NPLOC4 increased intracellular copper ions and cuprotosis-related proteins, resulted in HCC cells apoptosis increased. While inhibition of cuprotosis by Tetrathiomolybdate (TM) would abolish these effects.

**Conclusions:** In summary, knockdown of NPLOC4 promoted the cuprotosis, eventually increasing apoptosis and decreasing HCC cell proliferation. This study provides a promising diagnostic marker and therapeutic target for HCC patients.

Abstract Submission No. 200016

**P-0491**

**Investigating the mechanisms of QZACP in inhibiting HCC via network pharmacology**

**Jialing Sun**¹, ², **Xiaozhou Zhou**¹, ², **Mengqing Ma**¹, ², **Xin Zhong**¹, ², **Jing Li**¹, **Jinyu Yi**¹, ², ³, **Renjie Zhang**¹, **Xingning Liu**¹, ², **Lanfen Peng**², **Xinfeng Sun²**, **Wengxing Feng²**, **Rui Hu²**, **Qi Huang²**, **Minling Lv², ³**, **Kongli Fan², ³**

¹Shenzhen Traditional Chinese Medicine Hospital Shenzhen China, ²The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Department of Liver Disease Shenzhen China, ³Macau University of Science and Technology, Faculty of Chinese Medicine Macao China

**Purpose:** Qizhu Anti-cancer Prescription (QZACP) can inhibit the progression of Hepatocellular carcinoma (HCC), reduce its recurrence rate and prolong survival, but its exact mode of action is still unclear. This study aims to investigate the mechanism of QZACP in treating HCC.

**Methods:** Components in QZACP decoction were analysed using mass spectrometry. A subcutaneous tumor formation model of nude mice was constructed to further analyse the active components of QZACP that had entered tumour tissues through oral administration. Potential targets of QZACP in inhibiting HCC were identified and confirmed via network pharmacology and molecular docking.
Results: QZACP decoction contained deacetyl asperulosidic acid methyl ester (DAAME), paenoflorin, calycosin-7-glucoside, liquiritin, glycyrrhizic acid, astragaloside IV, saikosaponin A, curdione, and atracyleneolide II. Moreover, DAAME, paenoflorin, liquiritin, and glycyrrhizic acid in QZACP could enter HCC tissues after oral administration. Among these, DAAME was the most highly expressed in tissues. Through network pharmacological analysis and Western blotting verification, STAT3, VEGFA, JUN, FGF2, BCL2L1, AR, TERT, MMP7, MMP1, ABCB1, CA9 and ESR2 were the targets of QZACP inhibiting HCC. Molecular docking showed that the binding site of DAAME and CA9 had good stereocomplementarity, and the docking score was -8.1 kcal/mol. Western blotting and immunohistochemical results also confirmed that DAAME reduced the expression of CA9 protein in HCC.

Conclusions: QZACP inhibits HCC by reducing the expression of STAT3, VEGFA, JUN, FGF2, BCL2L1, AR, TERT, MMP7, MMP1, ABCB1, CA9, and ESR2. DAAME is an important active component of QZACP for treating HCC, and may inhibits HCC by targeting the expression of CA9.

Qizhu formula alters the profile of SASP to enhance immunosurveillance in hepatocellular carcinoma
Jing Li1,2, xiaozhou Zhou2
1Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China; Shenzhen China, 2Shenzhen Traditional Chinese Medicine Hospital Shenzhen China
Background: Induction of a senescence-associated secretory phenotype (SASP) with immunostimulatory properties is an effective method to enhance the immunosurveillance ability of hepatocellular carcinoma (HCC). The Qizhu formula (QZ), based on the principles of strengthening the body’s resistance and removing toxins for detumescence, can improve the survival rate of HCC patients, but its pharmacological mechanism is still unclear.

Methods: A diethylnitrosamine (DEN)-induced primary liver cancer model of C57B/L6 mice was constructed to evaluate the tumor-inhibitory effect of QZ. QZ-regulated infiltrating immune cells in liver nodule tissue were assessed. QZ-induced HCC cell senescence was examined by β-galactosidase staining. RNA sequencing data from senescent cells were used to identify SASP factors involved in HCC immunomodulation.

Results: QZ induced senescence and inhibited HCC cell proliferation. In HCC model mice, QZ treatment inhibited tumor growth and promoted NK cell and CD8+ T-cell infiltration. The protein expression levels of SASP factors HGF, DCN, and CxCL14 were increased and that of APLN was reduced in the hepatic nodules of mice in the QZ group compared with those in the model group. Further, conditioned media from QZ-medicated serum-treated HCC cells enhanced the migration and antitumor effects of splenic immune cells.

Conclusion: Our results suggest that QZ inhibits disease progression in HCC model mice. Mechanistically, QZ could have anti-HCC properties by inducing HCC cell senescence, modulating HGF, DCN, CxCL14, and APLN protein expression in senescent HCC cells, and promoting NK cell and CD8+ T cell infiltration, which could in turn enhance immunosurveillance in HCC.

Chemoprotective effect of crocetin against hepatocellular carcinoma via alteration of gut microbiota
Vikas Kumar1, Firoz Anwar2
1Sam Higginbottom University of Agriculture, Technology & Sciences Prayagraj India, 2King Abdulaziz University Jeddah Saudi Arabia
Background: Crocetin is a plant derived natural apocarotenoid dicarboxylic acid that showed the pharmacological activity against the various diseases. Previous report focused on the colorectal cancer effect, still chemoprotective effect against hepatic cancer still unexplored. In this study, we scrutinized the chemoprotective effect of crocetin against the diethylnitrosamine (DEN) induced hepatocellular carcinoma (HCC) in rats and explore the underlying mechanism.

Methods: Single intraperitoneal injection of DEN (200 mg/kg) was used for the induction of HCC in rats. The rats were divided into different groups and received the oral administration of crocetin till 22 weeks. The rats hepatic nodules were macroscopically and microscopically evaluated. The hepatic, antioxidant, non-hepatic, inflammatory parameters and cytokines were estimated. The faecal microbiota was used to investigate the chemoprotective effect of intestinal microbiota.

Result: Crocetin effectively suppressed the incidence of tumor nodules, incidence and weight of hepatic tissue. Crocetin significantly (P<0.001) suppressed the hepatic parameters like alpha fetoprotein (AFP), aspartate transaminase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT), acid phosphatase (ACP); non-hepatic parameters viz., total protein, blood urea nitrogen, creatinine; antioxidant parameters include catalase (CAT), glutathione (GSH), glutathione peroxidase (GPx), glutathione-S-transferase (GST), superoxide...
The relative contribution of estradiol to hepatocellular carcinoma: A mendelian randomization

Yuxi Lin1

1The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province Guangzhou China

Abstract

Objective: Estradiol and multiple sclerosis (MS) have been linked to cancer risks in observational studies. The causal nature of the association between the two and hepatocellular carcinoma (HCC) is unclear. We aim to test whether estradiol and MS are causally associated with the risk of HCC by using Mendelian randomization (MR) analysis.

Methods: Estradiol, MS and HCC genome-wide association study (GWAS) data were obtained from a public database. An inverse-variance-weighted (IVW) method was used as the primary MR analysis. Sensitivity analyses were examined. Multivariate MR (MVMR) was utilized to correct the confounders, and mediation analysis was used. Finally, we used HCC risk to infer the reverse causality with estradiol.

Results: Random effects IVW results were (Estradiol-HCC: odds ratio (OR)=0.703, 95% confidence interval (CI)= [0.508, 0.973], P=0.034; MS-HCC: OR=0.722, 95% CI=[0.645, 0.808], P=1.5×10-8; Estradiol-MS: OR=2.103, 95% CI=[1.862, 2.376], P=5.65×10-3), demonstrating a causal link between estradiol levels and a lower risk of HCC. Through MVMR, the causal effect of estradiol and MS on HCC remained significant (P<0.05). Mediation analysis proved that MS mediated the causative connection between estradiol and HCC, and mediating effect on HCC was 58.52%. Reverse MR showed HCC could affect estradiol levels negatively.

Conclusions: This MR study confirmed the causal effect between estradiol levels and HCC risk, with MS playing a mediating role. It may provide a new view on HCC occurrence and development mechanisms.

Keywords: Estradiol, Multiple sclerosis, Mendelian randomization, Hepatocellular carcinoma, Causal relationship

Clinical outcomes of next-generation microwave thermosphere ablation for hepatocellular carcinoma

Shinichiro Nakamura1, Toshifumi Tada1, Masahiko Sue1,2, Yu Matsuo1, Shiko Murakami1, Toshiro Muramatsu1, Kazuhiko Mori1, Hiroyuki Okada1

1Japanese Red Cross Society Himeji Hospital Himeji Japan,
2Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan

Background and aim: We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA).

Methods: A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included.

Results: The primary etiologies of HCC were hepatitis-related: 259 (40.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. The median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common location was near the primary and secondary branches of the intrahepatic portal vein (26 modules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=483), 20–30 mm group (n=107), and ≥30 mm group (n=17) (p<0.001). The cumulative local tumor recurrence rate was similar by difficult-to-treat status (p=0.169). In the multivariable analysis, tumor...
size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p=0.001) and ablative margin (per 1 mm) (HR, 0.81; 95% CI, 0.70–0.92; p=0.002) were significantly associated with local tumor recurrence. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.02–1.15; p=0.015) was significantly associated with complications.

**Conclusions**: MTA is a safe and effective local ablation therapy for HCC, even for tumors in areas of the liver where local ablation therapy is difficult.

Abstract Submission No. 100187  
P-0498

**Hepatocellular carcinoma treatment using Smart Fusion in dialysis patients**

**Naoki Hotta**

1masuko memorial hospital JAPAN Japan

**Introduction**: Approximately 700 maintenance dialysis patients are seen at our hospital, including the main hospital and branch hospitals. Among them are patients with HCC that develops from viral hepatitis. Advances in ultrasound equipment have improved the accuracy of HCC treatment and diagnosis.

This time, we had the opportunity to use microwaves for maintenance dialysis patients using Smart Fusion and needle navigation installed in Toshiba APLIOi800, so we will report it. Informed consent was obtained from all patients and the treatment was performed.

**Subjects and Methods**: Ten maintenance dialysis patients treated from January 2018 to February 2022. An EMPRINT antenna was used for treatment.

**Method**: Toshiba APLIOi800 was used. Conventional convex probes and microconvex probes were used as probes. The built-in function is Smart Fusion. This method can display ultrasound images and volume data from other modalities such as CT and MRI in association with positional information using a magnetic sensor.

Needle navigation has a function that can confirm the position of the needle. It is possible to treat even when the tumor is overprinted and the visualization is poor due to bubbles.

**RESULTS**: It was possible to visualize all tumors. In this study, CT images were used in 9 cases, and MRI was used in 1 case. No serious side effects occurred after treatment.

**Conclusion**: By using this method, it was thought that maintenance dialysis patients could be safely and accurately treated.

Abstract Submission No. 100193  
P-0499

**LASSO-Based Machine Learning model for Prediction of Liver Failure in HCC Patients Undergoing TACE**

**Jinlong Li**, **Zhi Li**, **Chengyu Liu**, **Xiaojuan Wang**, **Shaoteng Li**, **Fengxiao Gao**, **Yanan Chen**, **Jitao Wang**, **Dengxiang Liu**

1Xingtai people's hospital Xingtai China, 2Xingtai General Hospital Xingtai China, 3Graduate School of Hebei Medical University Shijiazhuang China

**PURPOSE**: Transcatheter arterial chemoembolization (TACE) is a commonly used method for the nonsurgical treatment of hepatocellular carcinoma (HCC); however, it can cause liver failure with rapid progression and high mortality.

**METHODS**: We organized and analyzed the data of patients with HCC undergoing TACE at our hospital. Screening indicators related to liver failure were analyzed using least absolute shrinkage and selection operator (LASSO) regression to establish a predictive model.

**RESULTS**: Prothrombin activity (odds ratio [OR] [95% confidence interval (CI)], 0.965 [0.931–0.997]; p=0.040), tumor number (OR [95% CI], 2.328 [1.044–5.394]; p=0.042), and vascular invasion (OR [95% CI], 2.778 [1.006–7.164]; p=0.039) are independent risk factors for liver failure after TACE. The prediction model established based on these results had areas under the curve of 0.821 and 0.813 for the training and validation groups, respectively.

**CONCLUSION**: The prediction model established using LASSO regression can predict the risk of liver failure after TACE and confirm whether patients with advanced HCC can benefit from TACE.

Abstract Submission No. 100216  
P-0500

**A comparative study between radiation therapy and RFA for HCC in difficult-to-RFA area**


1Iizuka Hospital, Department of Hepatology Iizuka, Fukuoka Japan, 2Iizuka Hospital, Department of Radiation Therapy Iizuka, Fukuoka Japan, 3SAGA Heavy ion medical accelerator in Tosu Tosu, Saga Japan

**Purpose**: Percutaneous radiofrequency ablation (RFA) is the mainstay of radical local therapy for hepatocellular carcinoma (HCC), but it is often difficult to treat HCC located close to the liver surface, vessels, or other organs. For such difficult-to-replace HCC, we sometimes perform RFA using techniques such as artificial pleural effusion, CT/MRI fusion, and Multipolar RFA system, in addition to IVR-CT room combination, and sometimes choose radiation therapy (RT), but the usefulness of the two has not been compared. In this retrospective comparative study, we compared the usefulness of RT and RFA in the past for HCC patients with difficult RFA sites.

**Methods**: Among HCC patients who underwent RT or RFA for curative purposes between January 2013 and December 2021, 22 and 71 patients were selected from each group, respectively, with tumor diameter less than 3 cm, single tumor, and difficult-to-RFA area, and local recurrence rate, and complications were compared between the two groups.

**Results**: Between the groups that received RT or RFA (hereafter RT group vs. RFA group), median age, ALBI score, and median tumor diameter did not differ significantly. The cumulative local recurrence rate within the observation period was not significantly different between the two groups (log rank test, p=0.031), and Cox proportional hazards analysis (multivariate analysis) showed that AFP alone was a significant independent factor for local recurrence (HR: 1.0, p=0.045).

**Conclusion**: Radiotherapy and RFA were equally effective in treating HCC in RFA-difficult areas, and radiotherapy could be a substitute for RFA in RFA-difficult areas.

Abstract Submission No. 100223  
P-0501

**Severe colitis after tremelimumab plus durvalumab in a patient with hepatocellular carcinoma**

**Tatsuro Sugaya**, **Manabu Hayashi**, **Yosuke Takahata**, **Masashi Fujita**, **Kazumichi Abe**, **Atsushi Takahashi**, **Hiromasa Ohira**

1Department of Gastroenterology, Gastroenterology, and Nutrition, Kyorin University School of Medicine, Tokyo, Japan
Abstract Submission No. 100252
P-0502

Clinical Outcome of Sorafenib versus Lenvatinib for Unresectable HCC in Taiwanese Elderly Population

Chi-Yu Lee¹, Tsang-En Wang¹,², Shih-Ting Huang¹, Chia-Yuan Liu¹,²,³, Ming-Jen Chen⁴, Horng-Yuan Wang⁴,²,³, Ching-Wei Chang⁴

¹Division of Gastroenterology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan Taipei City Taiwan, ²MacKay Junior College of Medicine, Nursing and Management, Taipei, Taiwan Taipei City Taiwan, ³MacKay Medical College, New Taipei, Taiwan New Taipei City Taiwan, ⁴Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan Taipei City Taiwan

Background: Sorafenib and lenvatinib are two tyrosine kinase inhibitors (TKIs) approved as first-line treatments for unresectable hepatocellular carcinoma (HCC). However, few studies discussed the efficacy of sorafenib or lenvatinib on elderly patients.

Methods: This retrospective study analyzed the medical records of patients with unresectable HCC receiving sorafenib or lenvatinib as the first-line therapy from July 2020 to December 2022 at MacKay Memorial Hospital in Taiwan. The elderly group was defined as patients who were 65 years of age or older at the time they began using TKIs. We analyzed patients' baseline general data, radiological best overall response, progression-free survival (PFS) and overall survival (OS) between sorafenib and lenvatinib groups.

Results: 53 elderly patients with sorafenib and 29 elderly patients with lenvatinib were enrolled. The characteristics of all elderly patients in two groups were shown in Table 1. The characteristics of patients between the two groups were not significantly different. The radiological best overall response was shown in Table 2. There was no significant difference in PFS and OS survival curves between sorafenib and lenvatinib groups (Figure 1, 2).

Conclusions: Sorafenib, compared to lenvatinib, had a trend of longer OS but shorter PFS, and lower disease control rate and objective response rate in elderly patients with unresectable HCC. However, no significant difference was achieved. Therefore, sorafenib and lenvatinib may be selected as reasonable therapy for unresectable HCC in elderly patients. More prospective studies are needed to draw a firm conclusion.

Abstract Submission No. 100272
P-0503

Liver cancer is the fastest rising cancer related to obesity

Margaret Teng¹,²,³, Benedict Kuan Loon Sim², Elina Cho², Cheng Han Ng²,³, Wen Hui Lim³, Darren Jun Hao Tan³, Nicholas Syn⁶, Daniel Q. Huang²,³, Mark D. Muthiah⁶

¹Alexandra Hospital, National University Health System Singapore Singapore Singapore, ²National University Hospital, National University Health System Singapore Singapore, ³Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

Background: High body mass index (BMI) is a major risk factor for cancer development, but its impact on the global burden of cancer remains unclear.

Methods: We estimated global and regional temporal trends in the burden of cancer attributable to high BMI, and the contributions of various cancer types using the framework of the Global Burden of Disease Study.

Results: From 2010 to 2019, there was a 35% increase in deaths and a 34% increase in disability-adjusted life-years from cancers attributable to high BMI. Globally, the age-standardized death rates for cancer attributable to high BMI increased over the study period (annual percentage change [APC] =0.48%, 95% CI 0.22 to 0.74%). From 2010 to 2019, the greatest number of deaths from cancer attributable to high BMI occurred in Europe, but the fastest-growing age-standardized death rates and disability-adjusted life-years occurred in Southeast Asia. In stratified analysis by cancer types, liver cancer was the fastest-growing cause of cancer mortality (APC: 1.37%, 95% CI 1.25 to 1.49%) attributable to high BMI.

Conclusion: The global burden of cancer-related deaths attributable to high BMI has increased substantially from 2010 to 2019. The greatest increase in age-standardized death rates occurred in Southeast Asia, and liver cancer is the fastest-growing cause of cancer mortality attributable to high BMI. Urgent and sustained measures are required at a global and regional level to reverse these trends and slow the growing burden of cancer attributed to high BMI.

Abstract Submission No. 100286
P-0504

Advanced HCC Treated with Atezolizumab: Complete Response but Immune Colitis, Pancreatitis

Keisuke Hamamura¹, Shohei Yokoyama¹, Motoki Hikichi¹, Keisuke Kikuchi¹, Ryosuke Kimura¹, Ryosuke Hayakawa¹, Rikiya Hasegawa¹, Hiroki Suzuki¹, Kengo Kuroishi¹, Toshio Tanaka¹, Tatsuki Oyaizu¹

¹Shizuoka-city Shizuoka Hospital Shizuoka Japan

Objective: The optimal use of immune checkpoint inhibitors (ICIs) remains uncertain, particularly concerning treatment duration and...
maintaining tumor immunity after achieving antitumor effects. We present a case where Atezolizumab and Bevacizumab (ATZ/Bv) led to a complete response in advanced HCC but also induced severe immune-related adverse events.

**Case:** An 84-year-old male was diagnosed with hepatocellular carcinoma in April 2022. After using ATZ/Bv post-transarterial chemoembolization (TACE), complete tumor remission was achieved by January 2023. However, the patient exhibited symptoms of immune-related colitis and pancreatitis, attributed to ATZ/Bv. Treatment with prednisolone, infliximab, and granulocyte removal therapy proved effective.

**Discussion:** ICIs, which inhibit co-stimulation like PD-1/PDL-1 in T cell receptors, can boost tumor immunity but may also trigger autoimmunity. This can lead to clinical manifestations resembling known autoimmune diseases. The challenge lies in determining when to halt treatment to prevent sudden adverse effects and whether intermittent ICI administration is necessary to sustain antitumor immunity. Once immune-related adverse events (irAEs) manifest, treatments akin to ICI administration is necessary to sustain antitumor immunity. Once irAEs manifest, treatments akin to those for corresponding autoimmune diseases have shown effectiveness, as in the presented case.

**Conclusion:** Treatments paralleling those for established autoimmune diseases are effective against ICI-related adverse events. Further studies are essential to delineate the ideal utilization of ICIs.

Abstract Submission No. 100305

P-0505

**Risk of acute kidney injury by chemotherapeutic agents in patients with HCC undergoing TACE**

Byung Ik Kim1, Ju-yeon Cho2, Jung Hee Kim3, Jae Yoon Jeong4, Yong Kyun Cho1, Won Sohn1

1 Kangbuk Samsung Hospital Seoul South Korea, 2 Chosun University Hospital Gwang-ju South Korea, 3 Hallym University Dongtan Sacred Heart Hospital Dongtan South Korea, 4 National Medical Center Seoul South Korea

**Background:** Acute kidney injury (AKI) is a crucial factor for the prognosis of liver cirrhosis and it can develop in patients with hepatocellular carcinoma (HCC). This study aimed to evaluate the effect of chemotherapeutic agents on the risk of AKI in patients with HCC undergoing transarterial chemoembolization (TACE).

**Methods:** A total of 370 HCC patients with baseline serum creatinine (SCR) ≤1.5 mg/dL undergoing TACE as an initial therapy were included. We compared the differences in the development of AKI between the use of doxorubicin and cisplatin in patients undergoing TACE for HCC. Also, the risk factors for the development of AKI were investigated during TACE. The AKI was defined based on the International Club of Ascites (ICA)-AKI criteria.

**Results:** The mean age was 60.8 years. The mean SCR levels at baseline, one day, two months, and four months after TACE were 0.9, 0.9, 0.9, and 1.1 mg/dL, respectively. The AKI within four months after TACE developed in 43 patients (12%). The AKI stages were non-AKI in 327 (88%), stage 1 in 13 (4%), stage 2 in 12 (3%), and stage 3 in 18 patients (5%). The proportion of the use of cisplatin and doxorubicin was 18% (n=65) and 82% (n=305), respectively. There was no difference in baseline SCR levels between cisplatin group and doxorubicin group (0.9 ± 0.2 mg/dL vs. 0.9 ± 0.3 mg/dL, p=0.490). However, the risk of AKI in cisplatin group was significantly higher than in doxorubicin group (29% vs. 8%, p=0.001). Multivariable analysis indicated that the risk factors for AKI were serum albumin ≤3.5 g/dL (hazard ratio [HR] 3.44 with 95% confidence interval [CI] 1.51-7.82, p=0.003), BCLC stage C (HR 6.48 with 95% CI 2.65-15.87, p<0.001), presence of ascites (HR 9.43 with 95% CI 4.21-21.10, p<0.001), and use of cisplatin (HR 3.02 with 95% CI 1.24-7.32, p=0.015).

**Conclusion:** The risk of AKI development is high in HCC patients treated with cisplatin-based TACE. The chemotherapeutic agent in patients with cisplatin-based TACE for HCC should be chosen considering its nephrotoxicity in patients with hypoalbuminemia, advanced stage, and the presence of ascites, in particular.

Abstract Submission No. 100328

P-0506

**Impact of elevated indirect bilirubin in systemic treatment for hepatocellular carcinoma**

Takeshi Okamoto1, Tatsuki Hirai2, Takahiro Ishitsuka1, Manabu Yamada1, Hiroki Nakagawa1, Takaumi Mie1, Takaaki Furukawa1, Tsuyoshi Takeda1, Akiyoshi Kasuga1, Takashi Sasaki1, Masato Ozaka1, Naoki Sasahira1

1 Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

**Background:** Despite inclusion of bilirubin in prognostic indicators for hepatocellular carcinoma (HCC), the impact of benign hyperbilirubinemia (BH) on outcomes in HCC has not been studied.

**Objective:** To evaluate outcomes of unresectable HCC patients with or without BH.

**Methods:** We retrospectively reviewed patients with elevated total bilirubin (1.3 mg/dL or higher) who received first-line systemic therapy for unresectable HCC at our institution with either atezolizumab and bevacizumab combination therapy or lenvatinib between April 2018 and September 2022. Patients were considered to have BH if indirect bilirubin accounted for over 50% of total bilirubin.

**Results:** Seventeen patients were included. Nine cases had BH. Although there were no significant differences in baseline characteristics between the BH and non-BH groups, more patients in the BH group had Barcelona Clinic Liver Cancer staging B (67% vs. 25%), received Lenvatinib (89% vs. 63%), and achieved overall response (33% vs. 0%) or disease control (89% vs. 75%). Modified albumin-bilirubin grade and Child-Pugh score were also similar, but median PIVKA-II was significantly lower in the BH group (48 vs 2,196 mAU/mL, P = 0.003). Median overall survival (943 vs. 141 days, P = 0.032) was significantly longer in the BH group, although the difference in median progression-free survival was not significant (209 vs. 110 days, P = 0.169).

**Conclusion:** Prognoses in BH patients receiving systemic therapy for HCC may be better than their non-BH counterparts. Large, multicenter studies are desirable to elucidate the impact of BH on outcomes in HCC.

Abstract Submission No. 100332

P-0507

**Lenvatinib as 2nd line in post-immunotherapy for hepatocellular carcinoma**

Kunihide Mohri1, Takenari Mukozu1, Teppei Matsu1, Hideki Nagumo1, Naoyuki Yoshimine1, Noritaka Wakui1, Hidenari Nagai1

1 Department of Gastroenterology and Hepatology, Toho University Medical Center Omori Hospital Tokyo Japan

**Background:** Atezolizumab plus bevacizumab (ATeBev) are first-line therapy for unresectable hepatocellular carcinoma (uHCC), but no second-line therapy has been established for PD patients. This study aims to evaluate the efficacy of lenvatinib (LEN) in patients with HCC by
evaluating of serum cytokine in patients who failed to respond to Ate-Bev treatment.

Methods: 60 uHCC patients who received AteBev. Dynamic computed tomography was performed after 6, 9, and 12 weeks treatment and blood samples were collected at baseline and 3 weeks.

Results: After 6 weeks of AteBev treatment, 19 patients had PR, 12 patients had SD, and 29 patients had PD. ORR showed 31.7%. 20 patients were treated with LEN as second-line therapy due to irAE or PD. 9 patients had CR or PR and 11 patients had SD or PD. ORR showed 45.0%. Tumor stage I/II/III/IV/IVB = 0/4/4/1, and BCLC stage B1/B2/B3/C = 0/4/0 /5 in the CR+PR group, while in the SD+PD group, 1/5/14, 0/7/4. Serum levels of FGFR-19 increased significantly after treatment in the CR+PR group (p = 0.0414) and the SD group (p = 0.0431), although there was no significant difference in the PD group. There was no significant difference in serum levels of soluble FGFR-4 in the PR group and the SD group, although those levels increased after treatment in the PD group.

Conclusion: LEN was useful as second-line therapy for HCC patients who did not respond to AteBev treatment. Patients whose FGF pathway is activated by AteBev treatment are expected to respond to LEN.

Abstract Submission No. 100341

P-0508

Therapeutic efficacy and safety of atezolizumab plus bevacizumab therapy by liver function

Yasuto Takeuchi1, Masahiko Sue1, Nozomi Miyake1, Takuya Adachi1, Nozomu Wada1, Hideki Onishi1, Hidenori Shiraha1, Akinobu Takaki2, Motoyuki Otsuka1

1Department of Gastroenterology, Okayama University Hospital Okayama Japan

Background and aims: Atezolizumab plus bevacizumab (ATZ/BEV) therapy for unresectable hepatocellular carcinoma (HCC) may also be used in patients with impaired liver function in real practice. The aim of this study was to examine the efficacy and safety of ATZ/BEV therapy by liver function.

Methods: A total of 348 HCC patients who received ATZ/BEV therapy as first-line chemotherapy were studied. We investigated treatment efficacy, safety, and survival by liver function.

Results: Two hundreds and eight patients had a Child-Pugh score (CPS) 5, 109 patients had a CPS 6 and 31 patients had a CPS 7 or higher. The object response rate was not significantly different among the three groups (39.4%, 36.3% and 40.7%, respectively: P = 0.84). No significant differences were observed in the disease control rate (78.8%, 75.5% and 74.1%, respectively: P = 0.73). Though there was also no significant difference in the progression free survival (P = 0.17), overall survival decreased with worse liver function (P < 0.01). After treatment initiation, liver function declined in all groups, and the incidence of Grade 3 or higher adverse events (AEs) was significantly higher in patients with CPS 7 or higher (P = 0.018). The rate of treatment discontinuation due to worsening liver function or AEs was highest in patients with CP 7 or higher.

Conclusion: Although there was no difference in treatment response based on liver function, particular attention should be paid to the management of AEs associated with ATZ/BEV therapy in cases of impaired liver function.

Abstract Submission No. 100351

P-0509

Hydroxychloroquine reduced the risk of hepatocellular carcinoma in hepatitis C virus patients.

Chun-Heng Lin1, Wei-Yu Kao1,2,3, Chi-Ching Chang1, Hsing-Jung Yeh1,2,3

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital Taipei City Taiwan, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei City Taiwan, 3TMU Research Center for Digestive Medicine, Taipei Medical University Taipei City Taiwan

Background: Chronic hepatitis C virus(HCV) infection is one of the leading causes of hepatocellular carcinoma(HCC) worldwide. Hydroxychloroquine(HCQ) is a medication used to treat malaria and autoimmune disorders and recent studies have suggested that it may also have anti-cancer properties based on autophagy and non-autophagy mechanisms. This study investigates the correlation between HCQ use and the risk of hepatocellular carcinoma in patients with chronic HCV infection.

Method: HCV infected patients were enrolled from Taiwan’s National Health Insurance Research Database(covering January 1, 2006, to December 31, 2016). The association between HCQ use and HCC risk was evaluated using the Kaplan-Meier method and Cox proportional hazards regression.

Results: 139,263 HCV patients were enrolled and individual matching with 1:10. Among 1,598 patients using HCQ(defined as ≥ 2 cumulative defined daily doses[cDDDs]),62 developed HCC. Comparatively, among 15,980 patients not using HCQ(≤ 28 cDDDs), 975 were diagnosed with HCC. HCQ use by HCV patients showed a significantly reduced HCC risk with an adjusted hazard ratio(aHR) of 0.68(95% CI,0.51-0.92).

Conclusion: HCQ use appears to lower the risk of HCC among patients with HCV infection, suggesting potential benefits in preventing HCC in this population. Further research is necessary to confirm these findings and underlying mechanisms.

Abstract Submission No. 100365

P-0510

Treatment outcomes of transarterial chemoembolization for early hepatocellular carcinoma

Hyun Phil Shin1, Sanghui Park2

1Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine Seoul. South Korea, 2Ewha Womans University College of Medicine Seoul. South Korea

Aims: The treatments of choice in patients with early-stage hepatocellular carcinoma (HCC) are surgical resection, local ablation therapy, and liver transplantation, but transarterial chemoembolization (TACE) is commonly performed due to variations in patients and liver diseases. This study aimed to assess the efficacy of TACE in patients with early-stage HCC.

Methods: A retrospective analysis was performed of all TACE procedures performed at Kyung Hee University Hospital at Gangdong during a 15-year period (July 2006 to November 2021). Patients with solitary tumors ≤ 5 cm were included.

Results: The study included a total of 97 eligible patients with early HCC ≤ 5 cm initially treated with TACE. The mean participant age was 63.47 ± 11.02 years, and of whom, 69 were males (71.1%). A complete response was achieved in 84 (86.6%) patients after the first TACE
procedures, with 1-, 2-, and 3-year survival rates of 91.8%, 87.3%, and 75.4%, respectively. In a multivariate analysis, the patients with an initial alpha-fetoprotein (AFP) ≤ 20 ng/mL (p = 0.02) and complete response after the first TACE (p = 0.03) were associated with overall survival.

Conclusions: TACE can treat patients with early-stage HCC who are unsuitable for ablative surgery or resulted comparable survival benefit to standard treatment.

Abstract Submission No. 100372
P-0511
Liver injury in patients with HBV-related HCC undergoing TACE combined with TKIs plus ICIs
Jia-Ming Shen1, Xia Wang1, Guangde Yang1, Li Li1, Juanjuan Fu1, Xiucheng Pan1

1Department of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University Xuzhou China

Objective: To explore the liver injury and its effect on overall survival (OS) in patients with HBV-related hepatocellular carcinoma (HCC) treated by transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) plus immune checkpoint inhibitors (ICls).

Methods: Patients with HBV-related HCC who received TACE-TKIs-ICls combination therapy from 1 January 2020 to 31 December 2021 were enrolled. Liver injury and OS were the main endpoints.

Results: As of 31 March 2022, 52 (43.7%) of the 119 patients developed hepatic adverse events: 15 with grade 1 liver injury, 19 with grade 2, 16 with grade 3, and 2 with grade 4. The median time of liver injury was 2.5 months (0.1-23 months) after the patients received ICI for the first time. Both univariate and multivariate analysis indicated that lack of antiviral preventive was a risk factor for liver injury (OR=0.149; 95\% CI: 0.050-0.442; P=0.001). A total of 45 patients died during the follow-up period, and the median survival time (MST) was 22.4 months for all patients. Our findings suggested that baseline high Child-pugh grade (HR=2.612; 95\%CI: 1.234-5.530; P=0.012), high alpha-fetoprotein level (HR=2.766; 95\%CI: 1.454-5.259; P=0.002), liver injury events (HR=1.887; 95\%CI: 1.019-3.495; P=0.044) were associated with death. The MST of patients without liver injury, grade 1-2 and grade 3-4 liver injury were undefined, 13.7 months and 11.1 months, respectively (log-rank P=0.034).

Conclusion: Nearly half of HBV-related HCC patients treated with TACE-TKIs-ICls encountered liver injury. Lack of preventive antiviral therapy was a risk factor for liver injury. Patients who developed liver injury had a poor prognosis.

Keywords: HBV-related HCC; TACE; TKI; ICI; liver injury

Abstract Submission No. 100373
P-0512
Secondary Cholestasis in Patients with HBV-related Advanced HCC Treated with TACE plus ICls and TKIs
Ning-Ning Wang1, Jia-Ming Shen1, Hui-Li Li1, Xia Wang1, Guang-De Yang1, Jie Li1, Xiu-Cheng Pan1

1Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University Xuzhou China, 2Department of Infectious Diseases, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School Nanjing China

Objective: To investigate the clinical characteristics and prognosis of secondary cholestasis in patients with HBV-related advanced hepatocellular carcinoma treated with a combination of transarterial chemoembolization (TACE), immune checkpoint inhibitors (ICls) and tyrosine kinase inhibitor (TKIs).

Methods: This study enrolled patients with HBV-related advanced hepatocellular carcinoma who visited at the Affiliated Hospital of Xuzhou Medical University from January 1, 2020 to December 31, 2022. All patients were treated with a combination therapy of TACE plus TKIs and ICls. The secondary occurrence and influencing factors of cholestasis after combination therapy were analyzed, and its impact on prognosis was further analyzed.

Results: A total of 106 patients with HBV-related advanced hepatocellular carcinoma were enrolled. The probability of secondary cholestasis within 3 months, 6 months, 1 year, 2 years and 3 years after TACE+ICls+TKIs combination therapy was 9.4%, 12.3%, 15.1%, 24.5% and 24.5%, respectively. Most patients with secondary cholestasis are persistent and progressing rapidly. The median survival time (26.9 months) was significantly longer in patients without secondary cholestasis than in patients with cholestasis (13.7 months) (P <0.05). Cholestasis occurs, baseline AST and PTA level are independent risk factors for overall survival (OS). There was no significant difference in adverse reaction between patients with and without secondary cholestasis during the treatment process (P=0.810).

Conclusion: Secondary cholestasis is common in patients with HBV-related advanced hepatocellular carcinoma who adopt a combination therapy of TACE plus TKIs and ICls, and the disease progresses rapidly and has a poor prognosis.

Keywords: Hepatocellular carcinoma; Cholestasis; Transcatheter arterial chemoembolization; Tyrosine kinase inhibitor; Immune checkpoint inhibitors

Abstract Submission No. 100386
P-0513
The efficacy and safety of atezolizumab & bevacizumab with unresectable hepatocellular carcinoma
Hyun Woong Lee1, Jung Il Lee1, Sung Hwan Yoo1

1Gangnam Severance Hospital Seoul South Korea

Introduction: Treatment responses of unresectable hepatocellular carcinoma (HCC) remain unacceptable low and treatment modalities are limited. After the IMbrave 150 trial was announced, there are still few published data on the atezolizumab & bevacizumab in South Korea. We analyzed the efficacy and safety of atezolizumab & bevacizumab based on real world data.

Method: In retrospective cohort study, data on 28 patients with unresectable HCC, with Child-Pugh (CP) scores of 5-8, were collected from a university hospital between September 2020 and October 2022. All patients were treated with 1200mg of atezolizumab plus 15mg per kilogram of body weight of bevacizumab intravenously every 3 weeks.

Method: In retrospective cohort study, data on 28 patients with unresectable HCC, with Child-Pugh (CP) scores of 5-8, were collected from a university hospital between September 2020 and October 2022. All patients were treated with 1200mg of atezolizumab plus 15mg per kilogram of body weight of bevacizumab intravenously every 3 weeks.

Conclusion: For managing unresectable HCC, atezolizumab & bevacizumab may be a valuable and safe treatment modality, but long-term follow-up and large scale studies are needed in the future.

Abstract Submission No. 100436
P-0514
Retreatment of Immune Checkpoint Inhibitors after Immune-related Adverse Events in unresectable HCC

Chih-cheng Tan¹, Chi-jung Wu¹,²,³, Pei-chang Lee¹,²,³, Ya-wen Hung¹, Chieh-ju Lee¹, Chen-ta Chi¹,²,³, I-cheng Lee⁴, Ming-chih Hou¹,²,³, Yi-hsiang Huang⁶
¹Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital Taipei Taiwan, ²Institute of Clinical Medicine, National Yang Ming Chiao Tung University Taipei Taiwan, ³Faculty of Medicine, National Yang Ming Chiao Tung University Taipei Taiwan, ⁴Health Examination Center, Taipei Veterans General Hospital, Taoyuan Branch Taoyuan Taiwan, ⁵Director, Healthcare and Services Center, Taipei Veterans General Hospital Taipei Taiwan

Background: Immune checkpoints inhibitors (ICIs) are recommended as the first-line and second-line systemic treatment for unresectable hepatocellular carcinoma (uHCC). Previous report suggests that the development of immune-related adverse events (irAE) correlates favorable clinical outcomes. However, it is not clear about the impact of different types of irAE on tumor response and the safety of rechallenge.

Methods: From May. 2017 to Oct. 2022, 215 consecutive uHCC patients who received ICIs monotherapy or in combination with tyrosine kinase inhibitors (TKIs) as the first-line (n=133) or second-line systemic therapy (n=82) in Taipei Veterans General Hospital were retrospectively reviewed. The tumor responses were assessed according to RECIST 1.1 criteria. The grades of irAE were evaluated according to CTCAE v5.0.

Results: Of them, 40 (18.6%) developed at least grade 2 irAE (graded ≥2, irAE2), including 19 (8.8%) dermatitis, 9 (4.2%) hepatitis, 7 (3.3%) pneumonitis, and 5 (2.3%) miscellaneous. The irAE2 more frequently occurred during cycle 2 to cycle 4 of ICI treatment. Development of irAE of irAE2 was associated with higher disease control rate and better progression free survival (PFS). Among the 40 patients with irAE2, the median duration of steroid treatment was 6.36 weeks (0.14-25.57 weeks). Interestingly, 32 (80%) received irAE2 rechallenge after irAE subsided, and recurrence of irAE occurred in 9 (4 by dermatitis, 3 by hepatitis, and 2 by miscellaneous).

Conclusions: irAE2 is not uncommon for uHCC under ICIs therapy, which is associated with better DCR and PFS. Rechallenge of ICI may be safe for two thirds of the cases under closely surveillance.

Abstract Submission No. 100437
P-0515

Spontaneous regression of hepatocellular carcinoma after abstinence from alcohol: A case report

Koji Uchino¹, Ayane Matsuzaki², Go Endo¹, Ayako Nakada¹, Hirobumi Suzuki³, Shinoz Yamamoto¹, Yukiko Ito¹, Hiroyoshi Taniguchi¹, Hide Yoshida¹
¹Department of Gastroenterology, Japanese Red Cross Medical Center Tokyo Japan

63-year-old male
He fell and fractured his right olecranon. He was referred to our orthopedic department for surgery. In preoperative screening, abnormal liver function test was pointed out. He had a history of heavy alcohol consumption and was diagnosed with alcoholic cirrhosis. Ultrasonography showed a 6 cm hypoechoic lesion in the right lobe of the liver. The level of alpha-fetoprotein (AFP) was 3098 ng/mL and des-gamma-carboxy prothrombin (DCP) was 2083 mAU/mL. Hepatocellular carcinoma (HCC) was suspected. He was instructed to abstain from alcohol and first underwent surgery for bone fracture under general anesthesia prior to further evaluation of the liver lesion. Dynamic computed tomography (CT) after discharge showed, in the equilibrium phase, a 6 cm low-density area in the segment 5 of the liver and other similar small lesions. Although tumor stain in the early phase of dynamic CT was not evident, the diagnosis of HCC was made, taking into account the elevated tumor markers. Atezolizumab plus bevacizumab therapy was considered, but tumor markers measured just prior to the start of therapy were markedly reduced to AFP 361 ng/mL and DCP 47 mAU/mL. Although CT showed no significant changes, the start of the treatment was postponed due to the possibility of spontaneous regression of the tumors. During the follow-up, tumor markers decreased further and CT showed shrinkage of the tumor. Abstinence from alcohol may have been the cause of spontaneous regression.

Abstract Submission No. 100464
P-0516

Cutaneous Metastasis from Hepatocellular Carcinoma: A Rare Cause of Periumbilical Bulging Tumor

Wei-Yu Kao¹,²,³,⁴,⁵, Shan-Wei Hsu¹, Yu-Min Huang⁶,⁷, Chun-Chao Chang¹,²,³
¹Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Medical University Hospital Taipei Taiwan, ²Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University Taipei Taiwan, ³TMU Research Center for Digestive Medicine, Taipei Medical University, Taipei Taiwan, ⁴Taipei Cancer Center, Taipei Medical University, Taipei Taiwan, ⁵Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University Taipei Taiwan, ⁶Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University Taipei Taiwan, ⁷Division of General Surgery, Department of Surgery, Taipei Medical University Hospital Taipei Taiwan

A 64-year-old man presented with a slow-growing, firm, non-painful, bulging mass adjacent to the umbilicus. The mass measured up to 3 cm in diameter and was dark purplish in color. The patient has a history of hepatitis C viral-related cirrhosis, Child-Pugh score B7, complicated by esophageal varices. He had been diagnosed with Hepatocellular carcinoma (HCC) four years ago, initially at Barcelona Clinic Liver Cancer stage B. He received several rounds of trans-arterial chemoembolization and radiofrequency ablation (RFA). However, recurrent HCC occurred a few months later, and he subsequently underwent laparoscopic partial hepatectomy. The patient was otherwise well until the appearance of the periumbilical protruding mass. Abdominal computed tomography revealed portal venous thrombosis and a periumbilical tumor with hypervascularity and subcutaneous extension. The patient underwent en-bloc resection of the tumor. The excisional biopsy specimen confirmed metastatic HCC with free section margins. After the surgical removal of the subcutaneous metastatic tumor, the patient received radiotherapy for portal venous thrombosis. Cutaneous metastases of HCC are exceedingly rare. Some of them were reported to be caused by tumor seeding during diagnostic or therapeutic procedures, such as liver biopsy, percutaneous ethanol injection and RFA. This case, however, is among a small minority of reported cases of cutaneous metastatic HCC associated with abdominal surgical intervention and is considered a consequence of port-site metastasis (PSM). PSM is characterized by direct malignant cells implantation at a trocar insertion site after a laparoscopic resection of an intra-abdominal tumor. Possible pathogenesis includes two leading factors: pneumoperitoneum and direct tumor contamination.
Clinical Course and Prognosis of Long-Term Survivors of Hepatocellular Carcinoma

Soon Sun Kim1, Jonghyun Lee2, Sang Bong Ahn1, Young Eun Chon2, Eileen Yoon3, Soung Won Jeong4, Dae Won Jun4

1 Ajou University School of Medicine Suwon South Korea, 2 Hanyang University College of Engineering Seoul South Korea, 3 Eulji University College of Medicine Seoul South Korea, 4 CHA Bundang Medical Center, CHA University Seongnam South Korea, 5 School of Medicine, Hanyang University Seoul South Korea, 6 Soonchunhyang University College of Medicine Seoul South Korea

Background and Aims: This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after HCC diagnosis.

Method: This retrospective cohort study used data from the Korean National Health Insurance Service database. A total of 35,348 subjects newly diagnosed with HCC between January 2008 and December 2010 were followed up until December 2018.

Results: A total of 11,514 (32.6%) survived for 5 years after diagnosis of HCC among 35,348 patients diagnosed with HCC. Five-year survivors had a higher proportion of females, younger age, more frequent etiology of HBV, less frequent liver cirrhosis, diabetes mellitus, and hypertension, and received curative treatment more frequently than non-survivors. The additional 1-, 3-, and 5-year survival rates were 90.7%, 77.6%, and 68.4%, respectively. Patients who underwent curative treatment as the first treatment for HCC showed a higher additional 5-year survival rate than those treated with non-curative therapy (74.5% vs. 64.2%). Among the HCC survivors, 44.4% underwent HCC retreatment 5 years after HCC diagnosis. The additional 5-year survival rate was 54.9% in the HCC retreatment group. The overall 5- and 10-year cumulative probabilities of secondary primary malignancies in HCC survivors were 15.36% and 27.54%, respectively. The most frequent second primary malignancy was prostate cancer, followed by colorectal and pancreatic cancers.

Conclusion: Our study highlights that a significant proportion of patients with HCC achieve long-term survival beyond 5 years, with favorable outcomes associated with curative treatments.

Gut microbiota-associated cytokine response and immunotherapy outcomes in hepatocellular carcinoma

Kin Lam Yu1, Jayashi Rajapakse1, Saroj Khatiwada1, Abhishek Vijayan2, Alyssa Cameron1, Jason Behary1,3, Sj Shin1, Amany Zekry1,3

1 UNSW Microbiome Research Centre, St George and Sutherland Clinical School, Kogarah, Kogarah Australia, 2 School of Biotechnology and Biomolecular Sciences, UNSW Sydney Kensington Australia, 3 Department of Gastroenterology and Hepatology, St George Hospital, Kogarah Australia

Despite the introduction of immune checkpoint inhibitor (ICI)-based therapies for advanced hepatocellular carcinoma (HCC), patient prognosis remains unfavourable due to poor response rate. While the impact of the gut microbiota on the efficacy of ICI is well demonstrated, its role in combined anti-PD-L1/anti-VEGF-A therapy against HCC remains unexplored. This study aims to elucidate the links between the gut microbiota and response to immunotherapy in HCC.

HCC patients eligible for immunotherapy consented to have stool and blood samples collected before and 12 weeks after anti-PD-L1/anti-VEGF-A immunotherapy. DNA was eluted from stool samples and 16S rRNA sequencing was performed to identify the gut microbiota composition. We extracted the serum and analysed for cytokines using LUMINEX MagPix®. Results were compared using two-way ANOVA with Tukey’s multiple comparison test, Chi-square test, one-way ANOVA or Pearson’s test. Comparisons where p<0.05 were statistically significant.

At 12 weeks post-ICI-based therapy, responders displayed enrichment of Porabacteroides, Butyricimonas, and Ruminococcus. In parallel, a surge in peripheral VEGF-A, RANTES, and LIF levels at 12 weeks was observed in responders relative to baseline. The enriched bacterial strains found in responders correlated with an immune milieu rich in anti-tumoral cytokines. Conversely, non-responders exhibited increased Roseburia, the presence of which was associated with a shift towards a pro-tumoral cytokine response. Our findings suggest that gut microbiota-associated changes in the peripheral immune environment may influence ICI-based therapy efficacy against HCC. This raises the potential of manipulating the gut microbiota to increase responsiveness to ICI-based therapy in HCC patients.
Abstract Submission No. 100551

Thrombocytopenia did not increase RFA related bleeding risk in patients with HHC and Cirrhosis

Songchi Xiao1, Xiaozhe Wang1, Xuefeng Luo1
1West China Hospital of Sichuan University Chengdu China

Objective: This study aimed to assess the bleeding risk during the perioperative period of radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) and moderate thrombocytopenia.

Methods: A retrospective analysis was conducted on 184 patients with cirrhosis and HCC who underwent RFA at the Department of Gastroenterology and Hepatology, West China Hospital, between June 2020 and February 2023. The patients were divided into two groups: group A (platelet count <50×10⁹/L) and group B (platelet count ≥50×10⁹/L). The study compared the differences in postoperative complications and mortality within 90 days between the two groups. Additionally, regression analysis was performed to investigate the relationship between platelet count and postoperative complications.

Results: Group A comprised 58 patients with a median platelet count of 35×10⁹/L, while Group B comprised patients with a median platelet count of 81×10⁹/L. Group A had higher median INR values and incidence of ascites compared to Group B (1.3 vs. 1.2, P=0.01; 46.5% vs. 30.1%, P=0.04). There were no significant differences in terms of BCLC stage, Child-Pugh grade, or prior decompensation events of cirrhosis between the two groups. Out of the total patients, 18 (9.8%) experienced postoperative complications, with 4 patients (2.2%) suffering from major perioperative bleeding. The incidence of major perioperative bleeding and postoperative complications did not significantly differ between group A and group B (0% vs. 3.2%, P=0.31; 10.3% vs. 9.5%, P=0.86). Regression analysis indicated that thrombocytopenia does not increase the risk of postoperative bleeding, while mild ascites was identified as an independent risk factor for postoperative complications. Within 90 days after the operation, three patients (1.6%) died, with only one patient's death attributed to operation-related causes.

Conclusion: This study suggests that RFA can be safely performed in patients with liver cirrhosis complicated by moderate thrombocytopenia. A preoperative platelet count of less than 50×10⁹/L should not be considered a contraindication for RFA.

Abstract Submission No. 100575

P-0520

Short-Term Clinical Outcomes and Safety of Microwave Ablation for Hepatocellular Carcinoma Treatment

So Yeon Kim1,2, Dong Yeong Kim2, Yoon Ji Kim1, So Jung Lee1, Sang Hyun Choi2, Hyung Jin Won2, Yong Moon Shin2
1Asan Medical Center Seoul South Korea, 2Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine Seoul Korea, 3University of Ulsan College of Medicine Seoul Korea

Purpose: This study aims to assess the short-term clinical outcomes and safety profile of microwave ablation therapy in the management of hepatocellular carcinoma (HCC).

Materials and Methods: A retrospective analysis, approved by the institutional review board, was conducted. The study cohort comprised 255 patients (185 males, 70 females; mean age ± standard deviation: 66 ± 10 years) with 237 cases of HCC. These patients underwent microwave ablation (MWA) treatment between May 2021 and June 2023.

Tumor characteristics, including size and location, were evaluated. One-year rates of local tumor progression (LTP), intrahepatic distant recurrence (IDR), and extrahepatic recurrence (ER) were examined. Safety was assessed through an analysis of complications.

Results: The median follow-up period was 11.6 months (range: 0 to 26 months). MWA was the initial treatment for 29% (29/255) of patients, while the others had undergone prior treatments. The average tumor size was 1.5 cm (range: 0.6 to 4 cm). Among the tumors, 16.8% (40/237) were located perivascularly, and 10.5% (25/237) were subcapsular. The 1-year rates of LTP, IDR, and ER were 4.5%, 40%, and 4.5%, respectively. Complications occurred in 3% (7/255) of cases, including instances of bleeding, biloma, and perihepatic abscess.

Conclusion: Microwave ablation can be an effective and secure therapeutic approach for hepatocellular carcinoma.

Abstract Submission No. 100600

P-0523

Comparison of regorafenib for unresectable hepatocellular carcinoma in young and elderly patients

Ching Wei Chan1,2,3,4, Yen Wun Huang1,3,4, Chi Yu Lee1,4, Tsang En Wang1,2,3, Shih Ting Huang2, Chia Yuan Liu1,4,3,4, Ming Jen Chen1, Hung Yuan Wang1,2,3
1Division of Gastroenterology, Mackay Memorial Hospital Taipei Taiwan, 2MacKay Junior College of Medicine, Nursing and Management Taipei Taiwan, 3MacKay Medical College New Taipei Taiwan, 4Department of Medical Research, MacKay Memorial Hospital Taipei Taiwan

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Regorafenib, after sorafenib, has been a standard of care for unresectable HCC; however, its efficacy in different age groups, specifically young and elderly patients, is underexplored.

Methods: We conducted a retrospective analysis of patients diagnosed with unresectable HCC who received sorafenib followed by regorafenib upon disease progression or intolerance between 2017 and 2022. Patients were categorized into two groups: young (<65 years) and elderly (≥65 years) at the time of diagnosis of HCC. We compared baseline characteristics, treatment response, and overall survival (OS) between the two groups.

Results: A total of 55 patients were included in the analysis with 28 patients (51%) in the young group (<65 years) and 27 patients (49%) in the elderly group (≥65 years). No statistically significant differences were noted when comparing the patient characteristics between the young and elderly groups (Table 1). The median OS following regorafenib treatment was 18 months for the young group and 16 months for the elderly group, although this difference was not statistically significant (p=0.534). A significant difference was found in OS after regorafenib treatment between the elderly group receiving concurrent treatment and those not receiving it (p=0.008) (Figure 1).

Conclusions: In our real-world data, compared to the clinical trial study, regorafenib demonstrates a better survival benefit in young and elderly patients with unresectable HCC after sorafenib. Intriguingly, within the elderly, concurrent treatment significantly influenced OS. Further prospective studies are necessary to draw a definitive conclusion.

Abstract Submission No. 100597

P-0522

Comparison of regorafenib for unresectable hepatocellular carcinoma in young and elderly patients

Ching Wei Chan1,2,3,4, Yen Wun Huang1,3,4, Chi Yu Lee1,4, Tsang En Wang1,2,3, Shih Ting Huang2, Chia Yuan Liu1,4,3,4, Ming Jen Chen1, Hung Yuan Wang1,2,3
1Division of Gastroenterology, Mackay Memorial Hospital Taipei Taiwan, 2MacKay Junior College of Medicine, Nursing and Management Taipei Taiwan, 3MacKay Medical College New Taipei Taiwan, 4Department of Medical Research, MacKay Memorial Hospital Taipei Taiwan

Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Regorafenib, after sorafenib, has been a standard of care for unresectable HCC; however, its efficacy in different age groups, specifically young and elderly patients, is underexplored.

Methods: We conducted a retrospective analysis of patients diagnosed with unresectable HCC who received sorafenib followed by regorafenib upon disease progression or intolerance between 2017 and 2022. Patients were categorized into two groups: young (<65 years) and elderly (≥65 years) at the time of diagnosis of HCC. We compared baseline characteristics, treatment response, and overall survival (OS) between the two groups.

Results: A total of 55 patients were included in the analysis with 28 patients (51%) in the young group (<65 years) and 27 patients (49%) in the elderly group (≥65 years). No statistically significant differences were noted when comparing the patient characteristics between the young and elderly groups (Table 1). The median OS following regorafenib treatment was 18 months for the young group and 16 months for the elderly group, although this difference was not statistically significant (p=0.534). A significant difference was found in OS after regorafenib treatment between the elderly group receiving concurrent treatment and those not receiving it (p=0.008) (Figure 1).

Conclusions: In our real-world data, compared to the clinical trial study, regorafenib demonstrates a better survival benefit in young and elderly patients with unresectable HCC after sorafenib. Intriguingly, within the elderly, concurrent treatment significantly influenced OS. Further prospective studies are necessary to draw a definitive conclusion.
Impact of grip strength in hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

KEI ENDO1, Hidekatsu Kuroda1, Takayoshi Oikawa1, Ippei Nakaya1, Hiroaki Abe1, Tamami Abe1, Keisuke Kakisaka1, Akiko Suzuki1, Yuichi Yoshida1, Akio Miyasaki1, Takayuki Matsumoto1

1Division of Gastroenterology and Hepatology, Iwate Medical University School of Medicine, Japan

Background & Aims: This study evaluated the impact of sarcopenia-related factors (muscle strength and skeletal muscle mass) on the survival of unresectable hepatocellular carcinoma (u-HCC) patients treated with atezolizumab bevazucizumab (ATZ+BEV).

Methods: This observational study enrolled patients with u-HCC who received ATZ+BEV from October 2020 to September 2023 (n=89). A low muscle mass was defined as skeletal muscle index (SMI) <42 and <38 cm²/m², and low muscle strength was defined as a grip strength (GS) <28 and <18 kg in men and women, respectively.

Results: A decreased GS and decreased SMI were found in 38 and 33 patients, respectively. The median observation period was 9.7 months, with an objective response rate of 39.3%, disease control rate of 80.9%. The OS of the normal GS group was significantly higher than that of the decreased GS group (P=0.01), while that of the normal and decreased SMI groups did not differ markedly (P=0.87). There were no significant differences in the PFS between the normal GS and decreased GS groups (P=0.28) or the normal SMI and decreased SMI groups (P=0.32). A multivariate cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard groups (P=0.32). A multivariate cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard ratio [HR] 2.34), AFP > 100mAU/ml (HR 2.39) and a decreased GS (HR 3.11) were independently associated with an increased risk of poor prognosis.

Conclusions: In addition to the hepatic functional reserve and tumor marker, a decreased GS was a poor prognostic factor in patients with u-HCC treated with ATZ+BEV.

Abstract Submission No. 100627
P-0525

Atezolizumab and Bevacizumab Combined with Radiotherapy for HCC with Macroscopic Vascular Invasion

Sang Min Yoon1, Jaeha Lee1, Jinhong Jung1, So Yeon Kim2, Jinhong Park1, Ju Hyun Shim3

1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 2Department of Radiation and the Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 3Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background: Hepatocellular carcinoma (HCC) with macroscopic vascular invasion presents a significant clinical challenge. This retrospective study aimed to evaluate the treatment outcomes of atezolizumab and bevacizumab in combination with radiotherapy for this advanced HCC stage.

Methods: Ten patients diagnosed with HCC accompanied by macroscopic vascular invasion, treated at Asan Medical Center between October 2021 and February 2023, were included. Four patients received atezolizumab and bevacizumab first, followed by radiotherapy after a minimum of six months, while six patients received concurrent therapy. Atezolizumab (1200 mg) and bevacizumab (15 mg/kg) were administered intravenously. The median radiation dose was 35 Gy, delivered in 2.5- to 3-Gy daily fractions, adjusted based on tumor extent and location. Radiologic responses were assessed according to the modified Response Evaluation Criteria in Solid Tumors.

Results: Radiologic responses were observed in 3 (30%) patients, with 30% achieving partial response, 50% stable disease, and 20% progressive disease. Median overall survival and progression-free survival were 17.3 and 8.3 months, respectively. The treatment regimen exhibited manageable toxicity, with grade 1 acute toxicities observed in three patients during combined radiotherapy. Additionally, one patient experienced Child-Pugh score deterioration by ≥2 within 3 months post-radiotherapy, and another reported grade 2 pneumonitis and dermatitis following atezolizumab and bevacizumab treatment.

Conclusions: This retrospective study suggests that the combination of atezolizumab and bevacizumab with radiotherapy holds promise as a treatment option for HCC with macroscopic vascular invasion. Nevertheless, further investigations are essential to confirm these findings and establish an optimal management approach for advanced-stage HCC patients.

Abstract Submission No. 100695
P-0526

Prognostic role of diabetes in HCC patients on best supportive care: An Indonesian experience

Saut Horas H Nababan1, Gita Aprilicia1, Rino A Gani1

1Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background: Diabetes is a significant risk factor for hepatocellular carcinoma (HCC) development and progression. The aim of this study was to evaluate the impact of diabetes on the prognosis of patients with HCC receiving best supportive care (BSC).

Methods: This retrospective study enrolled patients with HCC who received BSC between October 2021 and February 2023. The primary outcome was overall survival (OS). The association of diabetes status with OS was evaluated using Kaplan-Meier survival analysis and a Cox proportional hazards model.

Results: Among the 100 patients enrolled, 30 (30%) had diabetes. The median OS for the diabetic group was 12 months compared to 18 months for the non-diabetic group (P=0.04). In the multivariate analysis, diabetes was an independent predictor of poorer prognosis (HR 2.3, 95% CI 1.1-4.8, P=0.02).

Conclusions: Diabetes is an independent predictor of poorer outcomes in patients with HCC receiving BSC. Further research is needed to understand the underlying mechanisms and develop strategies to optimize care for these patients.

Abstract Submission No. 100695
P-0526
Preoperative weight loss program for HCC patients with high body mass index in hepatectomy

Hiroki Teraoku1, Yuji Morie1, Tetsuya Ikemot1, Yu Saito1, Shinichiro yamada1, Yuhei Waki1, Mitsuo Shimada1
1Department of Digestive and Transplant Surgery, Tokushima University Hospital Tokushima Japan

Background: This study aimed to investigate the usefulness of a weight-loss program (WLP) in patients with a high body mass index (BMI) prior to liver resection (Hx) for hepatocellular carcinoma (HCC).

Methods: Among 445 patients with HCC who underwent initial Hx between 2000 and 2020, 19 with a high BMI (>25.0) were enrolled in our WLP since 2014. For calorie restriction, the amount of energy consumed was calculated as the standard body weight (SBW) kg × 20–25 kcal/day. Protein mass was calculated as SBW kg × 1.0–1.2 g/day to maintain skeletal muscle mass. Patients also performed both aerobic and resistance exercises. The before-and-after changes were compared, and the effect of WLP on the short- and long-term results was investigated.

Results: The average length of WLP was 21 days, and weight loss was successfully achieved in all patients. Body fat mass was reduced during the program, while skeletal muscle mass was maintained. WLP led to improvements in liver function and fibrotic markers, without tumor progression. There were no postoperative complications (≥Clavien–Dindo [CD] III). A retrospective comparison of postoperative outcomes revealed that those in the WLP group showed a significantly shorter operation time and improved postoperative morbidity rate (≥CD III) with decreased postoperative hospital stay. There were no significant differences in long-term prognosis based on participation in the WLP.

Conclusions: WLP with multidisciplinary intervention improved short-term outcomes after Hx in patients with HCC and a high BMI.

Abstract Submission No. 100770
P-0528
survival analysis by using Kaplan-Meier curve. Also, we conducted internal validation with Receiver Operating Characteristic (ROC) analysis and Decision curve analysis (DCA) to validate the clinical value of the model.

**Results:** This study included 1811 patients (1409 men; 64.7% were Caucasian; the average age was 64 years; 60.7% were married). The nomogram-based model related C-indexes were 0.762 (95% confidence interval (CI): 0.752-0.772) and 0.752 (0.740-0.769) for predicting OS, and 0.785 (0.774-0.795) and 0.779 (0.762-0.795) for predicting CSS.

**Conclusion:** The age, ethnicity, tumor diameter, tumor grade, surgery, chemotherapy, and radiotherapy were independent prognostic factors for patients with ANHC. We developed a nomogram model for predicting the OS and CSS of patients with ANHC, with a good predictive performance.

Abstract Submission No. 100803

P-0530

**Single-cell sequencing reveals the immune landscape in tumors and PBMCs under immunotherapy**

**Xin Song**, **Boxiang Zhang**, **Xiyao Chen**, **Xingrong Chen**, **Tao Pan**, **Chan Xie**

1Department of Infectious Diseases, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou China

By single-cell sequencing of hepatocellular carcinoma tissues and PBMCs from six patients, we found in the hepatocellular carcinoma tissues that the single-cell sequencing ended up dividing a total of 18 subpopulations, including 11 hepatocellular carcinoma cell subpopulations, which suggests that there is already a significant heterogeneity among tumor cells within the hepatocellular carcinoma itself. Second, we found that within the group with poorer immunotherapy efficacy, macrophages were significantly suppressed in hepatocellular carcinoma tissues, with their numbers and proportions significantly decreased. Differential gene function enrichment of macrophages also revealed that their functions such as antigen-presenting function and T-cell activation were suppressed, and in terms of other immune cells, T-cells and NK-cells did not differ significantly between groups. This suggests that the diminished antigen-presenting function may have contributed to the diminished killer T-cell function and thus the efficacy of immunotherapy. In PBMC, we also found reduced proportions of B cells and macrophages within the less efficacious group, and functionally found a significant reduction in the classical macrophage lineage in the macrophage subset of the less efficacious patients. This suggests that interactions between immune cells may be one of the key influences on the efficacy of immunotherapy.

Abstract Submission No. 100872

P-0532

**Citrullinated Glial Fibrillary Acidic Protein Is Related with Prognosis of Hepatocellular Carcinoma**


1Hallym University Sacred Heart Hospital, Hallym University College of Medicine Anyang South Korea, 2Samsung Medical Center Seoul South Korea, 3Anatomic Pathology Reference Lab, Seegene Medical Foundation Suwon South Korea, 4Molecular Regulation of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology Tokyo Japan, 5Iłsong Institute of Life Science, Hallym University Seoul South Korea

Citrullination is a posttranslational modification via peptidylarginine deiminases (PAD), leading to significant alterations in protein structure and function. Glial fibrillary acidic protein (GFAP), highly susceptible to the attack of PAD, was increased in activated hepatic stellate cells and myofibroblasts accumulated in hepatic fibrosis. Recently, although the expression of citrullinated GFAP (cit-GFAP) is increased in hepatic fibrosis, its expression and role of cit-GFAP in hepatocellular carcinoma (HCC) is unknown. This study investigated whether the expression of cit-GFAP affects recurrence and survival in HCC patients who underwent hepatic resection. A total of 168 HCC patients were enrolled (median follow-up: 39 months). Eighty-one cases of HCC demonstrated a higher expression of cit-GFAP. The expression of cit-GFAP was correlated with male sex, hepatitis B virus positivity, and higher Edmonson-Steiner grade. There was no association between cit-GFAP expression and age, diabetes mellitus, hypertension, liver cirrhosis, Child–Pugh class, major portal vein invasion, white blood cell counts, platelet counts, serum alanine transferase, total bilirubin, albumin, alpha-fetoprotein, HCC size or number. The mortality with liver cancer was cured

Gaoxiaohong Dongbing*

Affiliated Hospital of Yan’an University

National infectious disease Center co-construction base

He is a 56-years-old male patient. The patient had an abnormal hepatitis B series in 1998. In August 2008 the patient was diagnosed with liver cancer in the General Hospital of the Chinese People’s Liberation Army. He underwent right hepatocellular carcinoma resection, the right liver was moderately differentiated hepatocellular carcinoma and cirrhosis. In 2010, Tivantidine was started. In 2020, due to drug resistance, "Tivantidine " will be replaced with “Tenofovir dipivurate fumarate”. 2021.2 Return visit to our clinic, we carried out various examinations: hepatitis B series quantitative: HBsAg213.35IU/ml HBsAb < 0.5mUI/ml HBeAb0.03(S/CO) HBeAb 15.3 (S/CO); hsHBV DNA was Not detected(IU/ml); ALT 22(U/L), AST19(U/L);abdominal B-ultrasonography: liver parenchyma echo slightly coarse; Child-pugh Grade A. After the contraindicadation of interferon was ruled out for evaluation , Peg-IFN-α2b135ug subcutaneous injection was started once a week. HBsAg decreased to 19.85IU/ml at 20 weeks, but abnormal thyroid function was found at that time, and T4 was slightly elevated. The patient’s thyroid function returned to normal after 1 month of disuse. HBsAg7.76IU/ml at 24 weeks, in order to avoid the side effects caused by interferon, Peg-IFN-α2b 90ug was used for further treatment from 24 weeks, HBsAg0.06IU/ml at 72 weeks and HBsAg0.05IU/ml at 84 weeks. At the 96th week, HBsAg of the patient was 0 IU/ml, HBsAb was greater than 10mIU/ml for the first time, and was 37.98mIU/ml, achieving clinical cure.

Abstract Submission No. 100867

P-0531

**One case of hepatitis B cirrhosis complicated with liver cancer was cured**

**Dong Bing**, **Gao xiaohong**, **Zhao peidong**

1Affiliated Hospital of Yan’an University (National infectious disease Center co-construction base) Yan’an City, Shaanxi Province China, 2Affiliated Hospital of Yan’an University (National infectious disease Center co-construction base) Yan’an City, Shaanxi Province China, 3Affiliated Hospital of Yan’an University (National infectious disease Center co-construction base) Yan’an City, Shaanxi Province China

One case of hepatitis B cirrhosis complicated with liver cancer was cured
rates in HCC patients with higher cit-GFAP expression were worse than those with lower cit-GFAP expression. After multivariate cox analysis, larger tumors and higher cit-GFAP expression were independent risk factors for postoperative survival. The recurrence rates of patients with higher cit-GFAP expression were slightly higher than those of patients with lower cit-GFAP expression, but it was not statistically significant. We report the abnormal accumulation of cit-GFAP in patients with HCC. Also, cit-GFAP expression is closely associated with survival of HCC patients.

Abstract Submission No. 100894
P-0533

Higher platelet count can be a biomarker to suspect HCC in patients with CLD.

NAVEEN MEHLA1, DR SUNIL KUMAR DADHICH2, DR NITESH CHAUHAN3, DR BHARATH HR4, DR SAURABH JAIN5, DR VIVEK SAINT6, DR ABHISHEK YADAV7, DR RAJENDRA BHATI8, DR BOBBY MITROILIA9, DR NARENDRA BHARGAWA10

1Dr. SN MEDICAL COLLEGE, JODHPUR JODHPUR India, 2Dr. SN Medical college, JODHPUR JODHPUR INDIA, 3Dr. SNMC, JODHPUR JODHPUR INDIA, 4Dr. SNMC JODHPUR JODHPUR INDIA, 5Dr. SN medical college JODHPUR INDIA, 6Dr SN MEDICAL COLLEGE JODHPUR INDIA, 7Dr. SN medical college JODHPUR INDIA, 8Dr SN MEDICAL COLLEGE JODHPUR INDIA, 9Dr SN Medical college, JODHPUR JODHPUR INDIA, 10Dr SN medical college JODHPUR INDIA

BACKGROUND: Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths worldwide. Several clinical studies have indicated correlation between high platelets (PLT) and increased risk of distant metastasis & post-transplant recurrence of HCC. However, the correlation of PLT with occurrence of HCC & BCLC staging and etiology & severity of underlying CLD are not well studied.

AIM: To assess the role of platelet counts in predicting occurrence of HCC in patients with chronic liver disease (CLD) of various etiologies.

METHODS: 100 CLD patients were divided equally in group A (HCC) and group B (Non HCC). PLT counts were compared between two groups using statistical methods. PLT counts were also compared in HCC group for different stages of BCLC & underlying severity and etiology of CLD.

RESULT: PLT counts were significantly higher in group A compared to group B (p<0.0001). Statistical significance observed in subgroup of MASLD (p=0.0012) between group A and B. Statistical significance (p<0.02853) observed between different CTP stages in group A with respect to PLT count using one way ANNOVA test. There was no statistical significance observed when PLT counts were compared in subgroup A with respect to different stages of BCLC.

CONCLUSION: Higher PLT counts were observed in patients with HCC compared to those without it. PLT counts correlate with severity of underlying CLD and MASLD etiology in HCC patient. PLT counts did not correlate with BCLC staging of HCC. So, high PLT counts can be used to suspect HCC in patients with CLD.

Abstract Submission No. 100917
P-0535

Update on HBV versus non-HBV related Hepatocellular Cancer in the Philippines

Jaime Paolo Berba1, Beatrice J Tiangco1, Edhel S Tripon1

1The Medical City Quezon City Philippines

BACKGROUND: Hepatocellular carcinoma (HCC) is the 2nd leading cause of cancer death in the Philippines. Previous reviews place Hepatitis B as the most common cause of HCC in Filipinos. Globally, metabolic syndrome is an emerging risk factor for HCC. This study reviews clinical features of HBsAg+ vs HBsAg- HCC in a Filipino cohort.

METHOD: Clinical data of 89 Filipino patients with HCC enrolled in the CANDEL Study were analyzed. Differences between HBV-related and non-HBV-related HCC patients were analyzed.

RESULTS: Non-HBV HCC were more likely cirrhotic (86.05% vs 56.52%). Additionally, over half (53.5%) of patients in the non-HBV group were anti-HBe reactive. HBsAg negative HCC patients were more likely to have components of metabolic syndrome: diabetes(48.84% vs 17.39%), dyslipidemia(41.86% vs 8.70%), and obesity (66.67% vs 26.92%). However, HBV-related HCC were older (66 vs 55), had higher body mass index (BMI) (26.5 kg/m2 vs 23.6 kg/m2)
and fasting blood sugar (FBS) levels. Both HBsAg+ and the HBsAg-
HCC had a significant number of patients with normal AFP (16.7% and
and 22.5%) and PIVKA II (16.7% and 10.0%).

Conclusion: Hepatitis B persists as an important risk factor for HCC
in the Philippines. Comorbid diseases like diabetes, dyslipidemia, and
obesity should be considered as important risk factors that potentiate
HCC risk in HBsAg reactive and negative populations. A reconsidera-
tion of current screening guidelines based on these findings may in-
crease sensitivity for HCC detection.

Abstract Submission No. 100944
P-0536

Delphi consensus statement on the etiology of first-episode
hepatocellular carcinoma in our hospital
Toru Arano, Nagisa Naborikawa, Shikeyuki Kurosaki, Maki
Matsui, Hikaru Kakimoto, Takeo Watanabe, Kazuaki Tejima
1Fraternity memorial hospital Tokyo Japan

Purpose: Hepatitis B can be controlled with nucleic acid analogs, and
hepatitis C can be eliminated with direct-acting antiviral agents. On
the other hand, hepatocellular carcinoma (HCC) of non-B non-C (non-
B non-C), which is non-viral in nature, is becoming more prominent.

Subjects: We included 88 cases of first-episode hepatocellular carci-
oma (HCC) diagnosed at our hospital between January 2018 and Sep-
tember 2023.

Methods: We investigated the etiology of first-episode hepatocellular
carcinoma patients at our hospital assigned since 2018, following the
nomenclature according to the Delphi consensus statement published
in the Journal of Hepatology.

Results: There were 5 cases of hepatitis B (6%), 21 cases of hepatitis
C (24%), and 62 cases of non-B non-C hepatitis (70%).

Fifty-three percent of 21 hepatitis C cases and 70% of 62 non-B non-
C hepatocellular carcinomas were MAFLD, MASH, or MetALD as-
associated with metabolic syndrome.

Conception and Conclusion: It is important to strengthen collabora-
tion with regional cardiology, neurology, nephrology, and diabetes and
metabolic medicine departments with metabolic syndrome-related dis-
cases to provide consultation for cases with ALT >30U/L, which is the
criterion for Steatotic liver disease.

Abstract Submission No. 100965
P-0537

The efficacy and safety of atezolizumab/bevacizumab versus
levatinib for hepatocellular carcinoma
Jooho Lee, Mu-yeop Kim, Hong Jae Chon, Young-Eun Chon,
Yeongjung Ha, Kwan Sik Lee
1CHA Bundang Medical Center, CHA University Seongnam South
Korea

Background: The success of the multinational phase III REFLECT
and IMbrave 150 trial demonstrated the efficacy of levatinib (LENV)
and atezolizumab/bevacizumab (ATE/BEV) in advanced hepatocellular
carcinoma (HCC) patients with preserved liver function. We aimed
to compare the efficacy of and safety of the two regimens in the setting
of first-line treatment for unresectable HCC patients.

Methods: We conducted a single-center, retrospective study of HCC
patients who received either ATE/BEV (n=80) or LENV (n = 50), be-
tween February 2019 and March 2023 from CHA Bundang Medical
Center. We analyzed progression-free survival (PFS) and overall sur-
vival (OS) in relation to the baseline patient characteristics.

Results: Median age was 62 years, with male predominance (87.4%).
Mean OS time was significantly longer in ATE/BEV group (23.6 vs
21.7 months; p<0.001). The OS time in ATE/BEV group has not yet
reached the median. Patients with Child-Pugh A had better OS than
those with Child-Pugh B (32.6±1.8 vs 17.2±21.9 months, p<0.001). Also,
patients with ALBI grade I had better OS than those with ALBI grade
2 and 3 (32.0±2.1 vs 25.2±2.7, p=0.11). Meanwhile, lower baseline
AFP (<200) and PIVKAII (<100) were associated with longer OS. In
multivariate analysis by Cox regression hazards model, treatment reg-
imen was the only independent prognostic factor associated with OS.
Also, the patients with viral hepatitis did not show better outcome
when compared with those without viral hepatitis in both groups.
Lastly, the proportion of the patients with worsening liver function,
whose ALBI or MELD scores increased 3 months after treatment, was
not different in both groups.

Conclusion: In this real-world study, ATE/BEV showed significantly
superior efficacy in terms of survival time when compared with LENV
in unresectable HCC patients regardless of the cause of hepatitis. The
safety in terms of liver function preservation was not different between
the both treatment groups.

Abstract Submission No. 101020
P-0538

LASSO-Based Machine Learning model for Prediction of Liver
Failure in HCC Patients Undergoing TACE
Jinlong Li, Zhi Li, Chengyu Liu, Xiaojuan Wang, Shaoteng
Li, Fengxiao Gao, Yanan Chen, Jitao Wang, Dengxiang Liu
1xingtai people's hospital xingtai China, 2Xingtai General Hospital
xingtai China, 3Graduate School of Hebei Medical University
Shijiazhuang China

PURPOSE: Transcatheter arterial chemoembolization (TACE) is a
commonly used method for the nonsurgical treatment of hepatocellular
carcinoma (HCC); however, it can cause liver failure with rapid pro-
gression and high mortality.

METHODS: We organized and analyzed the data of patients with
HCC undergoing TACE at our hospital. Screening indicators related to
liver failure were analyzed using least absolute shrinkage and selection
operator (LASSO) regression to establish a predictive model (Fig A).

RESULTS: Prothrombin activity (odds ratio [OR] [95% confidence
interval (CI)], 0.965 [0.931-0.997]; p=0.040), tumor number (OR
[95% CI], 2.328 [1.044-5.394]; p=0.042), and vascular invasion (OR
[95% CI], 2.778 [1.006-7.164]; p=0.039) are independent risk factors
for liver failure after TACE, and a nomogram was developed for clin-
ic applications (Fig B). The prediction model established based on
these results had areas under the curve of 0.821 and 0.813 for the train-
ing (Fig C) and validation groups, respectively. Additionally, decision
curve analysis curves were obtained, demonstrating that the predictive
model yielded more net benefits (Fig D).

CONCLUSION: The prediction model established using LASSO re-
gression can predict the risk of liver failure after TACE and confirm
whether patients with advanced HCC can benefit from TACE.

Abstract Submission No. 101047
P-0539

The Utility of PIVKA-II as a Biomarker For Treatment Response
In Hepatocellular Carcinoma
Background: There have been significant advances in the diagnosis and treatment for hepatocellular carcinoma in recent years, however, progressive disease remains difficult to cure. Consequently, there is a growing need for biochemical markers which will potentially detect disease progression after treatment, and guide decisions to switch therapy.

Methods: This was a single center, retrospective analytical cohort study. Data was collected from Early, Intermediate or Advanced stage HCC patients, who received: Ablation, transarterial chemoembolization, resection, tyrosine kinase inhibitors, or atezolizumab + bevacizumab. Baseline demographics were taken. Pre and post treatment AFP and PIVKA II levels were then gathered. Comparisons of PIVKA-II and AFP across cohort characteristics were performed using Spearman’s (rho) correlation coefficients. Analyses were performed using IBM SPSS 22 with p < 0.05 deemed to be indicative of statistical significance.

Results: Results show a concordance of PIVKA II levels with treatment responses by mRECIST criteria. A significant difference was seen in the pre-treatment and post-treatment PIVKA II levels in patients who underwent resection and received tyrosine kinase inhibitors. A positive relationship between PIVKA-II with the size of the largest HCC lesion by imaging was depicted. Participants were predominantly male with non-viral causes as etiology.

Conclusions: Our study reveals an association of PIVKA II with tumor size and its concordance with treatment response by imaging criteria. Using AFP alone may not discriminate between pre and post treatment responses but the addition of PIVKA II or the use of PIVKA II alone may serve as a better predictor of response to treatment.

Abstract Submission No. 101074
P-0540

The change of hepatic function after RFA/MWA to early stage HCC in patients with CSPH assumed by LSM

Masato Nakai1, Naohiro Yasuura1, Akimitsu Meno1, Risako Kohya1, Takashi Sasaki1, Sonoe Yoshida1, Shunichi Hosoda1, Takashi Kitagaya1, Masatsugu Ohara1, Takuya Sho1, Goki Suda1, Koji Ogawa1, Naoya Sakamoto1

1Hokkaido University Hospital Sapporo Japan

Background: Ablation treatment such as radiofrequency ablation (RFA) or microwave ablation (MWA) for early stage hepatocellular carcinoma (HCC) thought to have little effect on liver function. However, it is unclear whether ablation does not affect liver function even in patients with clinical significant portal hypertension (CSPH). We aimed to investigate whether ablation treatment reduces liver function in patients with CSPH assumed by liver stiffness measurement (LSM) of transient elastography.

Methods: 71 cases with CSPH in which ablation treatment was performed for early stage HCC were retrospectively analyzed. The diagnosis of CSPH was defined according to the BAVENO VII criteria as cases that met either of the following: (1) LSM ≥25kPa, (2) LSM 20-25kPa and platelet value <15×10^9/L, and (3) LSM 15-20kPa and platelet value <12×10^9/L. Changes in liver function was examined using data before and 6 months after treatment.

Results: The median age was 71 years, and LSM was 23.6 kPa. 14 patients (19.7%) had Child-Pugh Grade B. Changes in parameters after 6 months of treatment were: PT%: 81.2% to 80.0% (median change: -0.6%, p = 0.258), ALBI score: -2.36 to -2.34 (+0.02, p = 0.188) and no significant changes were observed. Although FIB4 increased from 5.94 to 6.41 (<0.30, p=0.028), FIB3 did not significantly decrease from 4.95 to 5.13 (+0.04, p=0.203), suggesting the influence of aging. In the analysis of pre-treatment factors that contribute to deterioration of liver function after ablation treatment using ALBI score, significant factors were not extracted.

Conclusion: RFA/MWA does not affect liver function in patients with CSPH assumed by LSM.

Abstract Submission No. 101083
P-0541

4D ULTRASONOGRAPHY FOR THERAPEUTIC RADIOFREQUENCY ABLATION FOR HEPATOCELLULAR CARCINOMA

Naoki Hotta1

1masuko memorial hospital JAPAN Japan

INTRODUCTION: Studies to evaluate the tumor vascularity in HCC have been done extensively with various imaging modalities because the finding of the vascularity is helpful to evaluate the biological features of the tumor. In the present study, we investigated whether 4D real-time flow imaging is useful to display the accurate position of percutaneous radiofrequency ablation (RFA) needle in the tumor and evaluated the efficacy of RFA therapy in patients with HCC.

METHODS: All patients gave written informed consent and this protocol had been approved by the Human Studies Committee at Masuko Memorial Hospital. US imaging We used VOLUSON730(GE Medical systems,Milwaukee), APLIO XG(Toshiba Medical Systems)and IU22(Phillips) for RFA therapy with a convex probe as US system. APLIO and VOLUSON machine probe is mechanical probe and IU22 probe is matrix array probe.4D Real-time refers here to the display of 3-dimensional moving images composed of 3 orthogonally intersecting scans in the transverse,longitudinal and horizontal planes. RF ablation was carried out under a real-time US guidance.

RESULTS: We confirmed by various angles that the needle was inserted into the center of tumor nodule. The simultaneous study before RFA therapy showed the inflow of arterial blood and tumor stain And importantly it appeared that 4D real-time US provided much perceptible information on the spatial relationship between RFA needle and the target lesion, and resulted in accurate We experienced the treatment of 58 patient with HCC by RFA using 4D real-time ultrasound system. Application of this method allowed a more accurate cauterization of the tumor.

Abstract Submission No. 101096
P-0542

Performances of GAAD Score, PIVKA-II, and AFP for Hepatocellular Carcinoma Surveillance

THANAPAT ATTHAKITMONGKOL1, Wimolrak Bandidniyamanon1, Khemajira Karaketklang2, Tawesak Tanwande1

1Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand, 2Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand

Background: Hepatocellular carcinoma (HCC) is an important burden in chronic liver diseases (CLD). According to APASL guidelines, the recommended approach for HCC surveillance is a biannual combination of ultrasonography (US) and serum alpha-fetoprotein (AFP).
Prothrombin induced by vitamin K absence-II (PIVKA-II) represents a novel HCC biomarker, and the GAAD score is calculated based on gender, age, AFP, and PIVKA-II. This study aimed to assess the clinical performance of GAAD score, PIVKA-II, and AFP for HCC surveillance.

**Method:** This cross-sectional study was conducted at Siriraj Hospital, Thailand, between May and October 2023, included CLD patients at risk for HCC, both post-treatment and without HCC history. US, along with AFP and PIVKA-II was used for surveillance. HCC was diagnosed based on CT/MRI or histology in patients with new lesions or abnormal biomarkers.

**Results:** There were 77 enrolled patients, with 11 patients (14.3%) diagnosed with HCC, one newly diagnosed, and 10 post-treatment HCC. The mean age was 66.29±10.12 years, and 55.8% had cirrhosis. The etiologies of CLD were mainly chronic hepatitis B (CHB), followed by hepatitis C. At baseline, cirrhotic patients, CHB, and alcoholism were significantly more prevalent in HCC group compared to non-HCC group. The sensitivity for HCC detection was highest in the GAAD score (63.6%), followed by PIVKA-II (54.5%) and AFP (45.5%), all of which had high specificity (>85%). Moreover, ROC analysis revealed that the GAAD score showed high performance in distinguishing HCC from non-HCC group.

**Conclusion:** The GAAD score demonstrated high performance in HCC detection among patients with CLD.

**Abstract Submission No. 101100  P-0543**

**Clinical features of HCC patients treated with RFA, in whom immunoadjuvant therapy should be used**

Atsushi Hiraoka1, Fujimasa Tada1, Kosuke Nakatani2, Tomoyuki Ninomiya1, Masashi Hirooka1, Yoichi Hiasa2

1Ehime Prefectural Central Hospital Matsuyama Japan, 2Ehime University Toon Japan

**Background/Aim:** The IMBrave050 trial (IM050) reported a significant reduction in recurrence of hepatocellular carcinoma (HCC) with atezolizumab plus bevacizumab (Atez/Bev) after curative therapies, but the prognostic value of this treatment is unknown. Although the indication of radiofrequency ablation (RFA) is wider than that of resection, adjuvant treatment can be problematic in terms of cost and risk of side effects. The clinical factors that should be aggressively treated with adjuvant therapy after RFA are identified, with a focus on recurrence beyond the Milan Criteria (MC), because the recurrence beyond MC makes curative treatments unfeasible and shortens the prognosis.

**Materials/methods:** From 2000 to July 2023, 528 patients with Child-Pugh A, who were diagnosed and treated at our hospital and who underwent radical treatment (resection/RFA) and met the tumor criteria of systemic pharmacotherapy in a community hospital. This study aims to elucidate the evolution of systemic chemotherapy in a community hospital.

**Results:** There were significant differences in the proportion of males (G1/G2/G3/G4=95.7/84.5/73.7/82.2 %, P=0.027), Alb (3.7/3.9/3.7/4.0 g/dL, P=0.032), mALBI 1 ratio (29.8/54.9/42.1/46.7 %, P=0.017), AFP (289/99/98/13 ng/mL, P=0.014), PIVKA-II (2387/180/292/104 mAU/mL, P=0.001) and BCLC stage B ratio (21.3/46.5/49.1/35.6 %, P=0.016). There were significant differences in age (70/71/73/72 years), ALBI score (-2.48/-2.65/-2.53/-2.60), PT (87.4/88.0/87.0/86.0 %), platelet count (13.6/12.7/13.6/14.1 x10^4/mL), PS, maximum diameter of intrahepatic tumor and number of intrahepatic tumors. The most frequently used drugs by group were G1/G2/G3/G4 (%)=SOR (100)/SOR (94.4)/LEN (47.4)/Atez/Bev (82.2) (P=0.001), and the mean number of lines was G1/G2/G3/G4=1/1.42/1.86/1.49, P=0.001. Median overall survival (OS) was G1 vs. G2 vs. G3 =11.5 vs. 23.6 vs. 21.6 months, indicating a prolonged prognosis (21.3 months for G4, where most patients are currently continuing treatment). OS (median) for patients with mALBI 1/2a was G1 vs. G2 vs. G3 =12.6 vs. 25.8 vs. 29.5 months, indicating improved prognosis.

**Conclusion:** As the concept of TACE refractoriness/unsuitability became more widespread and the timing of systemic chemotherapy introduction became earlier, the number of patients with good liver reserve function and BCLC stage B patients increased. As a result, the number of available regimens increased, and the number of used lines increased, resulting in improved OS in patients with good liver reserve function. TheICI regimen, which is expected to be more effective, has become the mainstream regimen, and is expected to further improve OS in the future.

**Abstract Submission No. 101111  P-0544**

**Changes in systemic chemotheraphy for unreseactable HCC and its effect on overall survival**

Fujimasa Tada1, Atsushi Hiraoka1, Kosuke Nakatani2, Masashi Hirooka1, Tomoyuki Ninomiya1, Yoichi Hiasa2

1Ehime Prefectural Central Hospital Matsuyama Japan, 2Ehime University Graduate School of Medicine Toon Japan

**Background/Aims:** In 2009, sorafenib (SOR), the first molecular target agent (MTA), was approved for the treatment of unresectable hepatocellular carcinoma (uHCC). Then there was a long gap until lenvatinib (LEN) in 2018. Since then, a series of regimens including five MTAs and two immune checkpoint inhibitors (ICIs) have been introduced and made available. This study aims to elucidate the evolution of systemic chemotherapy in a community hospital.

**Material/Methods:** We included 220 patients with uHCC who received initial systemic chemotherapy at our hospital from May 2009 to August 2023. In accordance with the advent of new drugs, we divided 2009-2023 into four groups as follows: group G1 (n=47: 2009-2013), group G2 (n=71: 2014-2017), group G3 (n=57: 2018-2020), and group G4 (n=45: 2021-2023). Clinical background and number of used lines at the time of initial systemic chemotherapy induction in each group were analyzed retrospectively.

**Results:** There were significant differences in the proportion of males (G1/G2/G3/G4=95.7/84.5/73.7/82.2 %, P=0.027), Alb (3.7/3.9/3.7/4.0 g/dL, P=0.032), mALBI 1 ratio (29.8/54.9/42.1/46.7 %, P=0.017), AFP (289/99/98/13 ng/mL, P=0.014), PIVKA-II (2387/180/292/104 mAU/mL, P=0.001) and BCLC stage B ratio (21.3/46.5/49.1/35.6 %, P=0.016). There were significant differences in age (70/71/73/72 years), ALBI score (-2.48/-2.65/-2.53/-2.60), PT (87.4/88.0/87.0/86.0 %), platelet count (13.6/12.7/13.6/14.1 x10^4/mL), PS, maximum diameter of intrahepatic tumor and number of intrahepatic tumors. The most frequently used drugs by group were G1/G2/G3/G4 (%)=SOR (100)/SOR (94.4)/LEN (47.4)/Atez/Bev (82.2) (P=0.001), and the mean number of lines was G1/G2/G3/G4=1/1.42/1.86/1.49, P=0.001. Median overall survival (OS) was G1 vs. G2 vs. G3 =11.5 vs. 23.6 vs. 21.6 months, indicating a prolonged prognosis (21.3 months for G4, where most patients are currently continuing treatment). OS (median) for patients with mALBI 1/2a was G1 vs. G2 vs. G3 =12.6 vs. 25.8 vs. 29.5 months, indicating improved prognosis.

**Conclusion:** As the concept of TACE refractoriness/unsuitability became more widespread and the timing of systemic chemotherapy introduction became earlier, the number of patients with good liver reserve function and BCLC stage B patients increased. As a result, the number of available regimens increased, and the number of used lines increased, resulting in improved OS in patients with good liver reserve function. TheICI regimen, which is expected to be more effective, has become the mainstream regimen, and is expected to further improve OS in the future.

**Abstract Submission No. 101112**
P-0545

Cause of Death Analysis in Patients with Metastatic Liver Cancer Treated with Local Therapy

Takuma Teratani1
1NTT Medical Center Tokyo Tokyo Japan

Objective: In our hospital, local therapy such as radiofrequency or microwave ablation is aggressively applied to patients whose prognosis is determined by the progression of liver metastases, regardless of the size or number of tumors. There is an accepted opinion that local therapy for liver metastases is ineffective because Stage IVB is a systemic disease, but we attempted to verify this opinion based on the actual causes of death of patients treated with local therapy.

Methods: We included 450 patients with metastatic liver cancer treated locally between April 2006 and December 2020. The primary tumors included 28 organs: colorectal cancer (59%). 371 patients died, and the cause of death was classified into cancer and non-cancer deaths, and cancer deaths were classified into liver-related and non-liver-related deaths. There were 128 deaths in our hospital, and the cause of death was identified comprehensively, including imaging and blood tests. For deaths occurring outside the hospital, the institution was asked to provide the cause of death, if known, and a written response was obtained.

Results: There were 115 patients with unknown cause of death, and these were excluded from the analysis of 256 patients. Of the 114 patients who died outside our hospital, 73 (51%) died of cancer, but we attempted to verify this opinion based on the actual causes of death of patients treated with local therapy.

Conclusion: It was possible to estimate that local therapy prolonged life in at least one-third of patients who died after receiving local therapy for liver metastases.

Abstract Submission No. 101127

P-0546

Efficacy of Immunotherapy and Targeted Therapy for Unresectable HCC: Analysis of Survival Curves

wan zhou1, pan xu2
1Department of Gastroenterology, University-Town Hospital of Chongqing Medical University Chongqing China, 2Department of Clinical Laboratory, Medical Sciences Research Center University-Town Hospital of Chongqing Medical University Chongqing China

Background and objectives: Hepatocellular carcinoma is the third-leading cause of cancer-related death worldwide. We used parametric survival models to assess the efficacy of immunotherapy and targeted therapy as first-line strategies for treating unresectable hepatocellular carcinoma, based on an analysis of the evidence from phase III trials.

Methods: The PubMed, Embase, and Cochrane Library databases were searched for studies reporting patient data of overall survival (OS) and progression-free survival (PFS) as Kaplan-Meier curves. Data was obtained from the curves using a digitization software. A pooled analysis of the parametric survival curves was performed using a Bayesian framework.

Results: Twelve randomized controlled trials were included, and log-normal and log-logistic distributions provided the best fits for the OS and PFS data, respectively, suggesting that the proportional hazard assumption is not valid. The sintilimab plus bevacizumab biosimilar therapy achieved superior OS and PFS compared to other treatments. The efficacy of the sintilimab plus bevacizumab biosimilar was typically ranked first within previous studies.

Conclusions: The hazard ratios are not constant over time. Sintilimab plus bevacizumab biosimilar therapy is more efficacious than other treatments in terms of OS and PFS during the first 60 months of treatment.

Keywords: Unresectable hepatocellular carcinoma, Immunotherapy, Targeted therapy, Tyrosine kinase inhibitor, Immune checkpoint inhibitor, Parametric survival analysis

Abstract Submission No. 101141

P-0547

Expression of ESPL1 Gene in HCC Tissue and Its Prognostic Role in HCC

Bobin Hu1, Lu Wei1, Hengkai Liang1, Minghua Su1, Rongming Wang1, Tumei Su1, Qingmei Li1, Qianbing Yin1, Yanfei Feng1, Jianning Jiang1
1The First Affiliated Hospital of Guangxi Medical University Nanning China

Aim: This study aimed to investigate the expression of the ESPL1 gene in hepatocellular carcinoma (HCC) and its impact on clinical prognosis.

Methods: We obtained expression data and clinical information of ESPL1 from HCC patients in the TCGA database. Comparative analysis was performed on ESPL1 expression in cancerous, adjacent non-cancerous, and normal tissues. COX regression and Kaplan-Meier analyses were used to assess the association between ESPL1 expression levels and patient prognosis. ESPL1 mutation analysis was carried out using the cBioportal online tool, and a protein interaction network for ESPL1 was constructed using the STRING database for GO/KEGG enrichment analysis to elucidate its molecular functions.

Results: ESPL1 expression levels were significantly higher in HCC tissues compared to adjacent non-cancerous and normal tissues. Additionally, higher ESPL1 levels were observed in HBV-related HCC cases. Primary tumor stage and ESPL1 expression were identified as independent risk factors for the prognosis of HCC patients, with higher ESPL1 expression associated with poorer prognosis. The mutation rate of ESPL1 in HCC patients was approximately 1%, and patients with mutations had a significantly poorer prognosis. Enrichment analysis indicated that ESPL1 is primarily involved in biological functions related to the cell cycle, mitosis, and chromosome segregation.

Conclusion: Our findings suggest that ESPL1 is upregulated in HCC, particularly in cases related to HBV infection, and high expression of ESPL1 is associated with poor prognosis in HCC patients. Therefore, ESPL1 may potentially serve as a biomarker for adverse prognosis in HCC patients.

Abstract Submission No. 101151

P-0548

Epidemiology of Hepatocellular Carcinoma in Taiwan

CHINGHU CHUNG1
1Department of Medicine, Mackay Medical College New Taipei City Taiwan

Background: Hepatocellular Carcinoma (HCC) is a major contributor to the world’s cancer burden and incidence rates have increased in many countries. In recent decades, however, the increase in some countries, such as the US, has abated. It is interesting to understand HCC incidence rate in Taiwan.
Methods: We searched the database of NHI, which covers over 99% of the Taiwanese population, for patients who diagnosis as HCC and listed in Registry for catastrophic illness patients during years 2013-2020. The systemic therapy usage and heart failure/chronic kidney disease comorbidity were also studied.

Results: The incidence rate of HCC in Taiwan was decreasing from 57.8 in a hundred thousand in year 2013 to 48.1 in a hundred thousand in year 2020. Among these HCC patients, the percentage of patients were receiving systemic therapy was increasing from 24.4% in year 2013 to 26.3% in year 2020. The comorbidity in HCC patients were about 9.8%-11.9% in heart failure and 17.9%-22.5% in chronic kidney disease among years 2013-2020.

Conclusions: The incidence rate of HCC was slightly decreasing in Taiwan. Additional studies are needed to improve prevention strategies and advance management of patients with HCC, especially in the field of tumor regression therapies.

Abstract Submission No. 101191
P-0549

Clinical Outcomes of Atezolizumab plus Bevacizumab in Patients with Child-Pugh Classification B

Norihiro Nishijima1, Toshinari Shiba1, Meidai Kasai2, Yoshiki Nando1, Takayoshi Nakajima1, Yoshiyuki Sakai1, Tomotaro Kawazoe1, Shinichi Ikuta2, Tsukasa Aihara2, Kazutaka Kurokochi1, Kiyohiko Kishi1, Yukio Osaki1, Hidenori Yanagi2, Naoki Yamana2

1Department of Internal Medicine, Meiwai Hospital Nishinomiya-shi Japan, 2Department of Surgery, Meiwai Hospital Nishinomiya-shi Japan

Purpose: Atezolizumab plus Bevacizumab (Ate/Bev) is widely used as the first-line therapy for unresectable hepatocellular carcinoma (uHCC). The IMbrave150 study was conducted in patients with Child-Pugh classification A (CP-A) uHCC. However, some patients with Child-Pugh classification B (CP-B) have also received Ate/Bev in a natural clinical setting. This study evaluated the outcomes of Ate/Bev in patients with CP-B uHCC.

Methods: From October 2020 to Aug 2023, 52 patients received Ate/Bev for uHCC in our hospital. Of these, 38 were CP-A patients, and 14 were CP-B patients. Clinical features, OS, PFS, therapeutic response, and changes in liver function of each group were examined.

Results: Median OS was 18.4 months in CP-A vs. 7.3 months in CP-B (p=0.418), and median PFS was 6.1 months in CP-A vs. 3.7 months in CP-B (p=0.34). OS and PFS tended to be longer in CP-A, but no significant difference was observed. ORR was 22.5% in CP-A vs. 18.2% in CP-B, and DCR was 71.0% in CP-A vs. 72.7% in CP-B, not significantly different. ALBI scores were -2.40 before treatment and -2.16 after 6 weeks in CP-A, and -1.71 and -1.71 in CP-B. The rate of change was 9.9% in CP-A and 17.0% in CP-B, with a slightly higher trend toward worsening in CP-B, although the difference was not significant.

Conclusion: Although patients should be carefully selected, some therapeutic effects of Ate/Bev can be expected in patients with CP-B.

Abstract Submission No. 101195
P-0550

Association between early job loss and prognosis among hepatocellular carcinoma survivors

Beom Kyung Kim1, Jin-Ha Yoon1, Sang Hoon Ahn1, Juyeon Oh2, Byungyoon Yun1

1Yonsei University College of Medicine Seoul South Korea, 2Yonsei University Seul Yonsei University College of Medicine Seoul South Korea

Background: given the high probability of unemployment or job loss among hepatocellular carcinoma (HCC) survivors, studies investigating the health effects of the loss of economic activity among patients with HCC are necessary. This study aims to examine the risk of all-cause mortality by early job loss among HCC survivors.

Methods: This retrospective cohort study from National Health Insurance Service data in Korea recruited patients aged 35–54 who diagnosed with HCC and had undergone either surgical procedure or local ablation between January 2009 to December 2015. The primary and secondary outcomes were all-cause mortality and HCC recurrence, respectively. Early job loss was defined as a change in insurance type from economic active status to dependent within 1 year from the treatment date. Adjusted hazard ratio (HR) and 95% confidence interval (CI) were estimated using multivariable Cox regression models. Subgroup analyses were further performed.

Results: Among 4,578 patients (median follow-up, 8.3 years), 1,189 patients (26.0%) died: 989 (24.7%) in the Job-maintained group and 200 (35.0%) in the Early Job loss group (p<0.001). Early job loss was significantly associated with the increased risk of all-cause mortality, but not that of HCC recurrence (adjusted HR [95% CI] 1.52 [1.30–1.78] and 1.07 [0.91–1.25], respectively). Subgroup analyses presented individuals with middle-income level, non-liver cirrhosis, non-alcoholism, or surgical resection have a prominently higher risk of all-cause mortality.

Conclusion: Our study found a significant association between increased risk of all-cause mortality and early job loss among HCC survivors undergoing curative treatment.

Abstract Submission No. 101197
P-0551

Efficacy/safety of sequential therapy with short-term LEN followed by TACE for unresectable HCC

Sawako Uchida-Kobayashi1,2, Naoshi Odagiri2, Hiroko Ikenaga2, Yoshihiko Muto1, Kohei Kotani1, Ritsuzo Kozuka1, Hiroyuki Motoyama2, Ken kageyama1, Hiroji Shinkawa1, Etsushi Kawamura2, Atsushi Hagihara2, Akira Yamamoto3, Hideki Fujii2, Masaru Enomoto2, Norifumi Kawada2

1Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 2Departments of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 3Departments of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan

Background: The TACTICS-L trial reported the efficacy and safety of lenvatinib (LEN)- hepatic artery chemoembolization (TACE) sequential therapy, in which LEN is administered for 15-21 days followed by TACE. However, the duration of LEN before TACE is controversial. In this study, we performed TACE after short-term (7-day) administration of LEN (short-term LEN-TACE), and examined its effectiveness and safety.

Methods: Patients with unresectable HCC, BCLC stage A or B, maximum tumor diameter <7 cm and Child A liver reserve were included in this study. TACE was performed after taking LEN for 7 days and a 2-day break, and LEN was restarted after TACE. Approximately 4
Abstract Submission No. 101214

P-0552

Nomograms for Non-Surgical HCC Patients of Asian Descent Undergoing Chemotherapy: A SEER Study

Congxi Xu1,2, Jitao Wang2, Dengxiang Liu2, Chengyu Liu1, Hezhao Wang2, Wenchuan Wang2

1Hebei Medical University Shijiazhuang City China, 2Xingtai People's Hospital Xingtai City China

Background: Non-surgically treated Asian HCC patients receiving chemotherapy are uncommon in clinical practice. This study aims to establish and validate a prognostic nomogram model for predicting overall survival (OS) and cancer-specific survival (CSS) in this patient group.

Methods: Patient data diagnosed with HCC between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomly divided into a training cohort (n=1868) and a validation cohort (n=802). Prognostic nomograms predicting OS and CSS were constructed based on independent prognostic variables identified from univariate and multivariate Cox regression analyses. The nomograms’ effectiveness was assessed using the concordance index (C-index), receiver operating characteristic curve (ROC), and calibration curve, while clinical utility was evaluated using decision curve analysis (DCA).

Results: The independent prognostic factors for OS included age, metastasis, AJCC stage, tumor size, and AFP, while for CSS they were AJCC stage and tumor size. These variables were used to constructnomograms. In the training cohort, the C-indices for the OS and CSS nomograms were 0.712 (0.699-0.725) and 0.728 (0.715-0.741), respectively. The AUC values for predicting 1-, 3-, and 5-year OS were 0.80, 0.78, and 0.77, and for predicting 1-, 3-, and 5-year CSS were 0.82, 0.79, and 0.77, respectively. The calibration curves indicated good performance of the prediction models, and DCA curves demonstrated good clinical utility.

Conclusion: Nomograms for predicting OS and CSS in Asian HCC patients receiving chemotherapy without surgical treatment were developed and validated using the SEER database. These nomograms demonstrated excellent predictive accuracy and clinical utility.

Abstract Submission No. 101350

P-0553

NLR as a predictor of tumor-associated neutrophil activity based on tumor size of HCC

Febry Rahmayani1, Fitri Rahmarian1, Desy Hariyanti1, Suyata Suyata1, Imam Suprianto1, Vidi Orba Busro1, M. Ayus Astoni1, Anjab Akmal Sya’roni1

1Mohammad Hoesin General Hospital Palembang, Indonesia Palembang Indonesia

Introduction: One of the most common malignant tumors worldwide is HCC. Its morbidity and mortality have both recently increased. Neutrophil play important role as known as tumor-associated neutrophil (TAN) activity, which lead to increase size of tumor although the exact relationship isn’t fully understood. We elaborate NLR as the representative predictor of TAN activity based on tumor size in HCC.

Objective: This study aimed to determine the role of NLR as predictor of TAN activity based on tumor size and progression in HCC patients.

Method: This is a prospective study involving 93 patients, done at Mohammad Hoesin Hospital Palembang from January to August 2023. Laboratory and imaging examinations were done on each patient.

Results: 93 HCC patients consist of 72 males (77.4%) and 21 females (22.6%) with an average age of 53.47±11.28 years. The majority of causes of HCC are hepatitis B virus (62.4%), hepatitis C virus (5.4%), and other causes (32.3%). Based on the ALBI ratio, Grade 1: 69.9%, Grade 2: 28.0%, and Grade 3: 2.2%. A total of 75.3% participant present with large tumor (≥ 5 cm) and 62.4% participant present with multiple nodules. NLR has a significant positive correlation to tumor size (r = 0.399; p < 0.001) and metastasis (r = 0.284; p = 0.002). NLR has a significant negative correlation to survival rate (r = -3.44; p = 0.001).

Conclusion: NLR is a significant factor influencing tumor size, metastasis, and survival rate of HCC patients. NLR potentially incorporated into the prognostic tool for HCC.
In Lebanon, there is a decline in viral-linked HCC due to improved hepatitis programs, and a rise in MASH-related cases. The reduced incidence of HCC as the initial sign of liver disease indicates effective HCC screening in cirrhotics. Patient survival declined between 2019 and 2023, a period marked by the economic crisis of the country and the Covid-19 pandemic; causality to be proven by further studies.

Abstract Submission No. 101356
P-0555

Identification of high-risk groups for non-viral HCC using the FIB-3 index

Kazuya Kariyama1, 3, Kazuhiro Nouno1, 3, Takashi Kumada1, 3, Atsushi Hiraoke1, 4, Toshifumi Tada1, Hidenori Toyoda1, 4, Takeshi Hatanaka6, Kunihiko Tsuji3, Toru Ishikawa3, Ei Itobayashi3, Koichi Takaguchi3, Akemi Tsutsui3, Atsushi Naganuma3, Satoru Kakizaki3, Satoshi Yasuda3

1Okayama City Hospital Okayama Japan, 2Faculty of Nursing, Gifu Kyritsu University Gakujuku, 3RELPEC Study Group Ogaki Japan, 4Ehime Prefectural Central Hospital Matsuyama Japan, 5Himeji Redcross Hospital Himeji Japan, 6Ogaki Municipal Hospital Ogaki Japan, 7Gunma Saiseikai Maebashi Hospital Maebashi Japan

Introduction: In recent years, the incidence of non-viral hepatocellular carcinoma (HCC) has been increasing, while viral HCC has been decreasing. Non-viral HCC is not under surveillance and is often diagnosed at an advanced stage. We have recently developed a liver fibrosis prediction score, FIB-3 index. Here we examine the utility of FIB-3 index for identifying high-risk groups for non-viral HCC.

Methods: The subjects were 195 patients with stage 1, early non-B non-C HCC and 82 non-HCC diabetic control patients attending diabetic clinics. Using ROC analysis with HCC as the outcome variable and FIB-3 index, FIB-4 index, APRI, AAR, and AP20 as explanatory variables, we examined the ability to predict high-risk groups for non-viral HCC.

Results: Patient backgrounds were as follows for HCC (N=195) and non-HCC (N=82) groups: age 70 vs 63.5 years (p=0.001), male 69.2% vs 54.9% (p=0.027), BMI 24.4 vs 24.5 (p=0.698), platelets 124,000 vs 237,000/μL (p<0.0001), AST 38 vs 23 IU/L (p=0.0001), ALT 21.5 vs 21.5 IU/L (p<0.0001), showing significant differences. For predicting high-risk non-viral HCC, AUROC was 0.893 for FIB-3 index, 0.875 for FIB-4 index, 0.875 for APRI, 0.712 for AAR, and 0.885 for AP20, with FIB-3 index having the highest value. Dividing subjects at 60 years, FIB-3 index showed similar cutoff values (2.443 vs 2.642) in both age groups, with AUROC 0.888 and 0.897. In contrast, FIB-4 index showed AUROC 0.889 and 0.895 in the two groups, but cutoff values differed greatly (2.416 vs 1.607). APRI and AP20 also showed large differences in cutoff values between age groups. AAR had low AUROC and was not useful for predicting non-viral HCC risk.

Conclusion: FIB-3 index may be useful for identifying high-risk groups for non-viral HCC using a single cutoff value regardless of age.

Abstract Submission No. 101416
P-0557

The efficacy of Atezolizumab plus Bevacizumab according to viral etiology of HCC

Jiwon Yang1, Jonggi Choi1, Won-Mook Choi1, Kang Mo Kim1, Han Chu Lee1, Ju Hyun Shim1

1Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea

Background & Aims: This real-world study compared the efficacy of first-line atezolizumab plus bevacizumab (Atezo/Bev) according to viral etiology of hepatocellular carcinoma (HCC).

Methods: We retrospectively reviewed consecutive 395 patients with intermediate (n=55) and advanced-stage HCC (n=340) treated by Atezo/Bev as primary systemic treatment between 2018 and 2022 at Asan Medical Center. Patients were divided into an intention-to-treat (ITT) group (patients treated at least one cycle of Atezo/Bev), and a per-protocol (PP) analysis group (patients with at least one measurable target lesion and treated with ≥3 cycles of Atezo/Bev), who included survival and response analyses, respectively.

Results: The ITT and PP groups included 376 and 284 patients, respectively. In the PP group, there were 90 patients with hepatitis B virus (HBV)-infected HCC and 68 with nonviral-related HCC. RECIST-based objective response rates did not differ significantly between the HBV (8.2% and 18.0%) and non-HBV groups (20.0% and 25.6%) and between the viral (9.7% and 19.0%) and nonviral groups (19.1% and 25.0%) at initial and best responses, respectively. The ITT analysis showed that progression-free survival was longer in HBV carriers than the counterpart (p=0.01 by log-rank test), as was not overall survival (p=0.06). However, after adjusting confounders in multivariate Cox regression, the difference in progression-free survival remained to be no longer significant. Similar trends in both endpoints were noted for viral versus nonviral subsets of patients.

Abstract Submission No. 101416
P-0557

Serum 25-hydroxylated vitamin D level and prognosis of non-viral hepatocellular carcinoma

Tatsuya Minami1, Ryosuke Tateishi1, Mitsuhiro Fujishiro1

1The University of Tokyo Tokyo Japan
Conclusions: Our real-world data indicate that HBV or viral etiology may not be associated with clinical outcomes in Atezo/Bev-treated patients with unresectable HCC.

Abstract Submission No. 101426
P-0558

Radiofrequency Ablation Therapy for Hepatocellular Carcinoma Using a 15G Variable Needle

Rina Moriwake1, Shohei Shioota1, Akiko Wakuta1, Kazuya Kariyama1, Kazuhiro Nouso1
1Okayama City Hospital Okayama City Japan

Introduction: The 15G variable needle radiofrequency ablation system released in 2022 by STARmed is reported to achieve larger ablation zones and more spherical ablation fields compared to conventional 17G variable needles. Here we report our experience using this system.

Methods: The subjects were 9 cases where this system was used from November 2022 to November 2023. Ease of needle insertion, ablation characteristics, ablation effects, and complications were examined. Four grounding pads were placed on the back and abdomen.

Results: Ease of needle insertion was similar to 17G needles, with good controllability and suitability even for difficult insertions requiring delicate manipulation. Needle tip visualization on ultrasound was comparable to 17G needles, clearly visible even in deep regions. Ablation ultrasound images were also similar to 17G needles, but using identical 17G protocols resulted in larger gas formation, necessitating care with ablation endpoint determination. With 30mm active tip exposure, a single ablation achieved approximately 40mm spherical ablation zones. Ablation times with back and abdominal grounding pads were 3-5 minutes for 30mm active tips. Complications were comparable to conventional 17G needles, with only mild fever and hepatic dysfunction.

Conclusions: The 15G variable needle is a new option for radiofrequency ablation, and may enable more aggressive treatment of larger HCC tumors.

Abstract Submission No. 101438
P-0559

Extracellular Vesicle-Derived miRNAs as Diagnostic and Prognostic Biomarkers for NBNC-HCC

Bootsakorn Boonkaew1, Nantawat Satthawiwat1, Nutcha Pinjaroen2, Nitchaya Chuaypen1, Pisit Tangkijvanich1
1Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Department of Radiology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Introduction: Extracellular vesicle-derived microRNAs (EV-miRNAs) are promising circulating biomarkers for chronic liver disease. In this study, we explored the potential significance of plasma EV-miRNAs in non-hepatitis B+, non-hepatitis C-related HCC (NBNC-HCC).

Methods: We compared, using the NanoString method, plasma EV-miRNA profiles between NBNC-HCC and control groups including patients with non-alcoholic fatty liver disease (NAFLD) and healthy controls. The differentially expressed EV-miRNAs were validated in another set of plasma samples by qRT-PCR.

Results: A total of 66 significantly differentially expressed EV-miRNAs between the HCC and the control groups were identified in the discovery set. In the validation cohort, including plasma samples of 70 NBNC-HCC patients, 70 NAFLD patients, and 35 healthy controls, 5 plasma EV-miRNAs were significantly elevated in HCC, which included miR-19-3p, miR-16-5p, miR-223-3p, miR-30d-5p, and miR-451a. These miRNAs were found to participate in several cancer-related signaling pathways based on bioinformatic analysis. Among them, EV-miR-19-3p exhibited the best diagnostic performance and displayed a high sensitivity for detecting alpha-fetoprotein-negative HCC and early-stage HCC. In multivariate analysis, a high EV-miR-19-3p level was demonstrated as an independently unfavorable predictor of overall survival in patients with NBNC-HCC.

Conclusions: In conclusion, our data have indicated, for the first time, that EV-miR-19-3p could serve as a novel circulating biomarker for the diagnosis and prognosis of NBNC-HCC.

Abstract Submission No. 101446
P-0560

A Retrospective Cohort Study on Microwave Ablation and Lenvatinib on Hepatocellular Carcinoma

Ariane Crizielle Jose-Baluyot1, Diana A. Payawal1
1Cardinal Santos Medical Center San Juan Philippines

Background: Systemic therapy has been used as a first-line treatment for intermediate-stage HCC, especially for larger (≥5 cm) or multiple lesions. Based on the REFLECT trial, lenvatinib has been approved as a first-line treatment for unresectable HCC in different parts of the world. Lenvatinib has exhibited favorable results in inhibiting tumor angiogenesis and tumor growth. The present study aimed to evaluate efficacy of combined percutaneous microwave ablation therapy and lenvatinib in patients with intermediate hepatocellular carcinoma.

Methods: Thirteen patients with Child Pugh B-HCC were included in the study. The patients had no prior history of systemic treatment. Of them, 4 received both PMAT and Lenvatinib, while 9 of them received PMAT monotherapy. The clinical outcomes used to evaluate treatment included tumor size, MELD Na, and Child Pugh Class.

Results: The 2 treatment arms were followed up on a monthly basis for the 6 months, there was no significant difference on MELD Na scores (p value=0.05) and tumor size progression on both treatment arms (p value=0.05). For the first 5 months of the study, there was no significant difference on Child Pugh Classes, however on the 6th month, there was significant increase on the CPC of monotherapy arm in comparison with combination therapy, PMAT + Lenvatinib (p value<0.05) which has stable CPC.

Conclusion: Our newly proposed combination therapy may potentially be effective in patients with Child Pugh B- HCC. A larger scale, multicenter, prospective study is warranted to confirm the findings.

Keywords: microwave ablation, Lenvatinib, hepatocellular carcinoma, intermediate-stage
Background Advanced HCC (BCLC - B, C) systemic chemotherapy was advanced in recent years. Eight regimens were available in Japan in 2023 September. STRIDE regimen was introduced to our hospital In 2023 May. I report first introduced advanced HCC patients who received STRIDE regimen.

Methods Five patients were treated by STRIDE regimen from May 2023 to October 2023. 4 patients were BCLC stage-C and 1 patient is BCLC stage B. Gender were 5 men and Age was range (64-79). One patient had PVTT and another patient had Bile duct invasion. One patient was 1st line chemotherapy. Two patients were 2nd line chemotherapy. The other 2 patients were 3rd line chemotherapy. Chemotherapy effects were evaluated by m-RECIST. irAE side effects were observed by doctors, hospital pharmacists and hospital nurses.

Results First evaluation of STRIDE resion PR was 2 patients, SD was 2 patients, PD was 1 patient. 1 patient of PD was died 4 months later because of tumor growth. IrAE side effect were autoimmune liver disease (grade 3) and another patient had erythema multiforme and was treated by prednisolone and ACTH isolated deficiency occurred one after another and treated by cortisone acetate.

Conclusions STRIDE resimens for 2nd a3rd line regimen was effective for 40% of Advanced HCC. But irAE managements on STRIDE were important for HCC patients.

Abstract Submission No. 101585
P-0562

Prognosis Of Patients with Hepatocellular Carcinoma based on Differentially Expressed Genes

Cheng Han Ng1, Shyna Zhuoying Gualan1, Elina Cho1, Margaret Teng1, Daniel Q Huang1, Nicholas Syn1

1National University Hospital Singapore Singapore

Background: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths globally. Prediction of prognosis in patients with HCC remains challenging due to heterogeneity in etiology of liver disease, tumor biology, and liver function. Hence, we aim to investigate gene expression profiles in patients with HCC to develop accurate models for prognosis prediction.

Methods: RNA was extracted from frozen liver tissue samples of HCC and paired non-tumorous tissues from 106 patients with HCC (68 viral-related HCC, 38 non-alcoholic steatohepatitis (NASH)-related HCC). The developmental and immune gene expression profiles, including over 700 genes, were analyzed via the nCounter platform (NanoString Technologies). Differentially expressed genes (DEGs) (defined as p <0.05 and large fold change >1.0 standard deviation (SD)) were identified. Subsequently, prognostically important DEGs with a significant impact on overall survival (OS) and/or recurrence-free survival (RFS) were selected using adaptive Lasso-based Cox regression.

Results: 86 DEGs and 152 DEGs were identified in the analysis of samples from NASH-related and viral-related HCC respectively. Adaptive Lasso-based Cox regression selected 13 prognostically important DEGs. The 13-gene model was used to stratify patients into "high-risk", "medium-risk", and "low-risk" groups using the most parsimonious percentile cut-offs, and there was significant difference in 10-year OS between high-, medium-, and low-risk groups (Log-rank p <0.001)

Conclusion: Developmental and immune gene expression profiles are potentially useful in the development of accurate prognostic markers and offer insights into future therapeutic targets.

Abstract Submission No. 101636
P-0564

Mechanisms of Jiedu prescription in treating hepatocellular carcinoma based on network pharmacology

Yuan Wu1, Xiaoli Liu1, Lihua Yu1, Huwen Yan1, Yuqing Xie1, Xue Cai1, Yaxian Kong2, Zhiyun Yang2

1Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

Objective: Yangxin Fuzheng Jiedu Prescription (YFJP) is an empirical prescription with excellent clinical efficacy. However, the specific target and mechanism of Traditional Chinese medicine (TCM) are still unclear. This study aimed to explore the key herbs of YFJP in the treatment of HCC using a network pharmacology method.

Methods: We retrospectively included 1021 HCC patients; 481 had received YFJP treatment and 540 had received comprehensive Western medicine treatment without TCM. Network pharmacological methods were applied to explore the key components and Chinese herbs of YFJP treatment of HCC and the core components and targets of the key herbs in the Jiedu prescription (JDP) treatment of HCC.

Results: Compared to those in the control group, HCC patients in the YFJP group had longer OS and PFS rates, higher CD8+ T cell counts,
and lower levels of CRP (p <0.05). The YFJP-HCC overlapping target network were established, revealed that YEJP compounds for HCC were mainly from JDP. The key compounds and core targets of JDP for the treatment of HCC were identified using network pharmacological analysis. Molecular docking showed that the ligands of the four compounds had strong binding effects with the four core targets. Immunohistochemical analysis showed that JDP could decrease the expression of IL-6, STAT3, VEGF and TNF-α in tumor tissues.

Conclusion: YEJP adjuvant therapy can improve HCC patients’ OS rate. JDP is a key component of YEJP in the treatment of HCC. JDP can inhibit inflammation and delay HCC progression by regulating IL-6, STAT3, TNF-α, and VEGF.

Abstract Submission No. 101640
P-0565

Therapeutic Effectiveness of Early Additional cTACE after DEB-TACE for Hepatocellular Carcinoma

Kei Takuma1, Asahiro Morishita1, Mai Nakahara1, Kyoko Oura1, Tomoko Tadokoro1, Koji Fujita1, Joji Tani1, Tsutomu Masaki1
1Department of Gastroenterology and Neurology, Kagawa University Medical School Hospital Kagawa Japan

Purpose: We have previously reported that early additional cTACE after drug-eluting beads TACE (DEB-TACE) significantly increased the CR rate compared to patients treated with DEB-TACE alone. In the present study, we investigated how early additional cTACE should be performed after DEB-TACE in patients with hepatocellular carcinoma (HCC) at a multicenter setting.

Methods: Twenty-seven patients with unresectable hepatocellular carcinoma (HCC) with a maximum tumor diameter of 30 mm or greater, Child-Pugh classification A-B, and ECOG-PS 0-2, who were treated at four institutions including our hospital between July 2014 and November 2022, were included in this study. The subjects undergone DEB-TACE first and cTACE as the second treatment. The overall response rate (ORR) and disease control rate (DCR) were evaluated retrospectively by mRECIST.

Results: The overall evaluation by initial DEB-TACE was CR/PR/SD/PD=0/27/0/0, and the overall response rate and disease control rate were 100%. The overall response rate was 75.0% and disease control rate was 91.7% in the group that received the next cTACE treatment earlier than DEB-TACE (CR/PR/SD/PD=1/8/2/1), whereas the overall response rate and disease control rate in the group that received the next cTACE treatment more than 3 months after conventional DEB-TACE were The overall response rate, CR/PR/SD/PD=2/3/6/4, overall response rate, and disease control rate were 33.3% and 73.3%, respectively, indicating a significant difference in overall response rate between the two groups (p=0.031). Conclusion: In unresectable hepatocellular carcinoma, early additional cTACE after DEB-TACE can bring better therapeutic effect.

Abstract Submission No. 101661
P-0566

Percutaneous radiofrequency ablation in early-stage hepatocellular carcinoma

Shintaro Takaki1, Kazuki Ohya1, Yumi Kosaka1, Nami Mori1, Keiji Tsuji1
1Sato Clinic Takasaki Japan, 2Kyoudo Hospital, Gastroenterology, Tokyo Japan, 3Teikyo Chiba Medical Center, Gastroenterology, Ichihara Japan

Radiofrequency ablation (RFA) is a minimally invasive treatment widely performed for the treatment of liver neoplasms. Recently, resulting of long prognosis has made by ablation in the clinical practice. In Japan, JSH consensus statements and recommendations 2021, Resection and RFA are equally recommended as first-line therapy in patients of less than 3cm, 3 nodules HCC in the result of a head-to-head randomized controlled trial (SURF trial).

We introduced adjustable RFA electrode needle (VIVARF system) which became usable from 2015 in order to improve therapeutic results of RFA. In 125 patients with liver cancer. The 5-year survival rate of RFA at our institution is 70%. Although local recurrence rate after curative RFA is as low as 6.0%, the intrahepatic distant metastasis is as high as 70% at 5 years. Complications were skin burned in 4.2% due to cause by needle damage from induction needle. We use a variety of techniques such as artificial pleural effusion, artificial ascites, under sedation to improve the effectiveness of our treatments. After the treatment, the prevention of intrahepatic distant recurrence by direct-acting antivirals (DAAs) is very important.

Abstract Submission No. 101704
P-0568

Characteristics of hepatocellular carcinoma treated with drug therapy followed by conversion therapy

Shintaro Takaki1, Kazuki Ohya1, Yumi Kosaka1, Nami Mori1, Keiji Tsuji1

Efficacy of Conversion therapy after chemotherapy for unresectable hepatocellular carcinoma

Noboru Takata1, Tatsuya Yamashita1, Taro Yamashita1
1Kanazawa University Hospital Kanazawa Japan

Background: The efficacy chemotherapy followed by conversion therapy for unresectable hepatocellular carcinoma (HCC) has been reported, but there are insufficient reports on the long-term outcomes and progress after conversion therapy.

Patient and Methods: We retrospectively analyzed 17 cases of unresectable HCC treated with chemotherapy followed by conversion therapy at our hospital between April 2010 and April 2023. Results: Conversion therapy included liver resection in 7 patients, radiofrequency ablation in 6 patients, TACE in 3 patients, and radiotherapy in 1 patient. Median survival from the start of chemotherapy was 41.1 months, and median survival after conversion was 26.0 months. After conversion therapy, 12 patients (71%) had recurrence, and the median recurrence-free period was 5.4 months. Four patients had extrahepatic recurrence (3 pulmonary, 1 bone, and 1 peritoneal, with overlap) and 8 patients had new intrahepatic lesions. Recurrent treatment for new intrahepatic lesions included hepatectomy in 1 case, RFA in 1 case, TACE in 4 cases, and chemotherapy in 2 cases. The median survival after conversion was 41.3 months in patients who remained tumor-free for more than 3 months after conversion, compared with 19.9 months in patients who had a recurrence within 3 months (P=0.01).

Conclusion: Conversion therapy after chemotherapy for unresectable HCC resulted in long-term survival. Careful evaluation, including search for extrahepatic lesions, should be performed before conversion therapy.

Abstract Submission No. 101685
P-0567
Methods: Sixty-three with BCLC-B stage HCC who started drug therapy at our hospital between January 2016 and March 2023, age 77 years ± 6.12, 51 males, Child Pugh A 52 B 7, tumor diameter 23 mm±24.67 (8-130 mm), tumor number 4 or more 48, up to 7 in 24. Sorafenib 30 Lenvatinib 20, Atezolizumab+Bevacizumab 13, observation period 19.5 months ± 11.82.

Results: After the initiation therapy, treatment was changed in 40: 23 received TKI, 10 received TACE, 4 received RFA (MWA), and 3 received radiation. The final efficacy evaluation showed 6 of CR (9.5%), 12 of PR (19%), 13 of SD (20.6%), and 32 of PD (50.8%). Cumulative survival rate for all were 61% at 1 yr, 41.7% at 2 yr, and 26.9% at 3 yr. 6 had CR, 1 with ATZ/Bv only, 4 with RFA (MWA) after LEN, and 1 with additional TACE after LEN. AFP 4.34 ng/ml ± 1.61, PIVKAII 60.4 ± 43.7, Child-Pugh A in 5 Maximum tumor diameter 16 mm ± 2.33, next tumor diameter 8.7 mm ± 1.67, tumor number 6.2 ± 2.2 up to 7. The number of tumors was 6.2 ± 2.2. 2. In multivariate analysis, the factor contributing to CR was tumor diameter of 15 mm or less.

Conclusion: It is important to select a treatment with conversion therapy, in case of unresectable HCC with a diameter of 15 mm or less.

Abstract Submission No. 101708
P-0569

Real world outcomes in HCC patients within or outside the IMbrave150 Study Criteria

Toshifumi Tada1, Atsushi Hiraoka2, Takashi Kumada3
1Department of Gastroenterology, Japanese Red Cross Himeji Hospital Himeji Japan, 2Gastroenterology Center, Ehime Prefectural Central Hospital Matsuyama Japan, 3Department of Nursing, Gifu Kyoritsu University Ogaki Japan

Objective: Atezolizumab/bevacizumab (Atz+Bev) combination therapy for unresectable hepatocellular carcinoma (HCC) is now implemented in clinical practice post IMbrave150 trial. This study compares outcomes of patients not meeting IMbrave150 trial criteria.

Methods: Out of 975 patients treated with Atz+Bev for HCC between May 2018 and October 2023, 936 were analyzed, excluding clinical trial participants and those with missing data. Patient characteristics: Age: 74.0 (68.0-80.0) years, Sex (Male/Female): 740/196, PS 30.7 (5.9-517.5) ng/mL. Median observation period: 12.8 (6.9-21.3) months (continuous variables: median, interquartile range).

Results: 404 (43.2%) were within, and 532 (56.8%) were outside IMbrave150 study criteria. Median PFS (95% CI): 7.4 (6.5-8.8)/5.8 (5.1-6.5) months (p=0.002), OS: 26.5 (24.9-NA)/18.8 (16.5-22.1) months (p<0.001). Multivariate analysis revealed significant factors for PFS (NBNC HR: 1.17, CD HR: 1.32, AFP>100 HR: 1.47, mALBI 2b&3 HR: 1.47) and OS (PS >2 HR: 1.99, AFP >100 HR: 1.48, mALBI 2b&3 HR: 2.04). Best response rate (ORR/DCR): 29.7±25.9% (p=0.220), 80.5±78.0% (p=0.399). The only significant adverse event difference was hypertension (all grades): 85 (21.0%)/77 (14.5%) (p=0.009). Subgroup analysis showed no significant PFS and OS differences, especially in mALBI 1&2a patients.

Conclusion: In the real world, cases meeting criteria show longer prognoses than IMbrave150 cases. Additionally, mALBI 1&2a patients, even if outside standard cases, exhibit better prognoses than IMbrave150 counterparts.

Abstract Submission No. 101736
P-0571

Pre-Sarcopenia predicts the outcome of hepatocellular carcinoma patients with first-line Lenvatinib

Yuan-Hung Kuo1
1Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan

Aim: Muscle volume loss (Pre-sarcopenia) is linked to an unfavorable prognosis in individuals diagnosed with hepatocellular carcinoma (HCC). This study was to elucidate the clinical importance of pre-sarcopenia in patients receiving first-line lenvatinib for unresectable HCC in real world.

Methods: We retrospectively evaluated patients with unresectable HCC who had undergone lenvatinib as first-line treatment between January 2018 and Dec 2021. Pre-sarcopenia was diagnosed based on a previously reported cut-off value calculation formula [psoas muscle area at level of middle of third lumbar vertebra (cm²)/height (m²)]. Treatment response was assessed by radiologic imaging according to the Response Evaluation Criteria in Solid Tumors version 1.1. (RECIST1.1)

Results: A total of 171 patients (Male/Female: 124/47, mean age: 65.9 years) were recruited including 52 (30.4%) patients with pre-
sarcopenia and 119 (69.6%) patients with non pre-sarcopenia. The overall survival (OS) and progression free survival (PFS) was 18.2 months and 6.5 months, respectively. Pre-sarcopenia group had a significant poorer PFS (4.7 vs 6.8 months, p=0.026) and OS (7.6 vs 22.4 months, p<0.001) than Non pre-sarcopenia group. Also, at the time of lenvatinib termination, higher percentage of patients without pre-sarcopenia could maintain a better liver function reserve to afford sequential therapies than those with pre-sarcopenia (58% vs 26.5%, p<0.001). Moreover, multivariate analysis showed pre-sarcopenia (Hazard Ratio: 2.025, 95% Confidence Interval (1.222–3.335); p=0.006) was associated with mortality after adjusting post-treatment and alpha-fetoprotein.

Conclusions: In clinical practice, pre-sarcopenia was shown to be a significant prognostic factor in patients treated with first-line lenvatinib for unresectable HCC.

Abstract Submission No. 101748
P-0572

Vascular endothelial growth factor receptors peptide vaccines generate peptide-specific CTLs for HCC

Katsuji Nagaoka1, Yoko Yoshimaru1, Satoshi Narahara1, Takayuki Tokunaga1, Etsuko Ito1, Takehisa Watanabe1, Hiroko Setoyama1, Masakuni Tateyama1, Koji Yoshida1, Takuya Tsunoda1, Yusuke Nakamura1, Motohiko Tanaka1, Yutaka Sasaki1, Yasuhiro Tanaka1
1Kumamoto University Hospital Kumamoto Japan, 2GlaxoSmithKline K.K.; Akasaka Intercity AIR Tokyo Japan, 3Department of Medicine, Division of Medical Oncology, Showa University School of Medicine Tokyo Japan, 4National Institutes of Biomedical Innovation, Health and nutrition Osaka Japan, 5Public Health and Welfare Bureau, City of Kumamoto Kumamoto Japan, 6Osaka Central Hospital Osaka Japan

Aim: Vascular endothelial growth factor receptor (VEGFR)-specific cytotoxic T lymphocytes (CTLs) can theoretically be expected to cause damage to not only VEGFR-expressing tumor cells but tumor vascular endothelial cells. In this study, we evaluated the safety and efficacy of a vascular endothelial growth factor receptor (VEGFR)-targeted peptide vaccine in patients with unresectable hepatocellular carcinoma who had responded to transarterial arterial chemoembolization.

Methods: Twenty-two patients were randomized 1:1 to receive VEGFR-targeted peptides (VEGFR1 1mg and VEGFR2 1mg) or placebo. The primary endpoint was immunological safety evaluation. Secondary endpoints were immunological response and clinical outcome. To assess specific CTL responses, ELISpot assays were performed after in vitro growth.

RESULTS: No serious adverse events were observed. Of the 12 patients in the vaccine group, VEGFR1-specific CTL responses were induced in 8 patients (66.7%) and VEGFR2-specific CTL responses in 10 patients (83.3%). When divided into two groups according to immunoreactivity, the median PFS for patients with an immune response to VEGFR1 was 7.4 and 2.7 months (P=0.019) and for patients with an immune response to VEGFR2 was 10.6 and 2.7 months (P=0.001).

Conclusions: Immunotherapy with peptide vaccines targeting VEGFR1 and VEGFR2 were well tolerated without serious adverse events. The peptide vaccines also effectively induced peptide-specific CTLs in patients with unresectable hepatocellular carcinoma.

Abstract Submission No. 101787
P-0573

Results of Atezolizumab plus Bevacizumab for advanced hepatocellular carcinoma in Vietnam

Hang Thu Hoang1
1National Cancer Hospital Vietnam Ha Noi Vietnam

Backgrounds: Atezolizumab plus bevacizumab was approved in 2022 in Vietnam as a first-line treatment for advanced hepatocellular carcinoma (HCC). The purpose of this study was to assess the curative effect and tolerability of the combination treatment in advanced HCC.

Methods: Retrospective study, single-arm, single center of patients aged 18 years or older with advanced HCC defined as the Barcelona clinic liver cancer staging system (BCLC) stage B was unsuitable or failed with local interventions or metastatic disease (BCLC stage C) received systemic therapy with Atezolizumab plus Bevacizumab intravenously on days 1 of a 21-day cycle at National Cancer Hospital Vietnam from May 2022 to March 2023. The outcomes included pooled overall response (OR), complete response (CR), partial response (PR), median overall survival (mOS), median progression-free survival (mPFS), and adverse events (AEs).

Results: Thirty-one patients were enrolled. The OR, CR, and PR rates of the therapy response based on Response Evaluation Criteria in Solid Tumors (RECIST) were 41.9%, 3.2%, and 38.7%, respectively. Mean progressive-free survival (PFS) was 5 months and median overall survival (OS) was 15.5 months. During the treatment, 38.7% and 9.7% of patients experienced any grade AEs and grade 3 and above AEs, respectively including hypertension, increased liver enzymes and thrombocytopenia.

Conclusions: Atezolizumab in combination with Bevacizumab is effective and well-tolerated in patients with advanced or metastatic HCC in Vietnam. Need to further research for this confirmation.

Abstract Submission No. 101800
P-0574

Epidemiology and clinical manifestations of HCC in patients Mongolia and Russia

Luvsan Ganchudur1, Dashchirev Munkh-Orshikh1, Igor Vladimirovich Malov2, Byambasuren Amgalan3, Avirmed Shireynyamba1, Jazag Amarsanaa2, Oidov Baatarkhuu4
1Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 2Irkutsk State Medical University Irkutsk Russian Federation, 3General hospital Arkhangai Mongolia, 4Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 5Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Objective: The current study is aimed at determining differences of epidemiological and clinical profiles associated with HCC in patients belonging to ethnic groups of Asians from Mongolia and Caucasians from Asian region of Russia.

Materials and methods: The studies were carried out in the cross-border regions of Mongolia and Asian part of Russia (Irkutsk region). 300 patients with HCC of the Caucasian and Mongolian races were enrolled in the study. The level of AFP in the serum was determined by the chemiluminescence technique.

Results: The long-term dynamics of the HCC incidence shows more unfavourable trends in the territory of Mongolia compared to Irkutsk region. In both groups, male patients over 60 years of age predominated. Patients from Mongolia often have a history of jaundice and alcohol abuse. Out of the etiological factors, HCC is more often associated with the HBV in Mongolia than in the Asian part of Russia. At the same time, in Caucasians, HCC develops primarily on the background of liver cirrhosis. In patients with HCC, AFP level higher than...
20 ng/ml were significantly more frequent in the ethnic group of Caucasoids than in Mongoloids.

**Conclusions:** In Mongolia, among the risk factors for the development of the disease, hepatitis B virus plays a major role, which significantly differs from the Asian part of Russia. For the purpose of early diagnosis of HCC, it is necessary to search for new molecular markers or their combinations due to the insufficient diagnostic efficiency of AFP determination.

Abstract Submission No. 101815

**P-0575**

**Differential expression of Telomerase reverse transcriptase and cytokine in hepatocellular carcinoma**

**Jin Seoub Kim1,2, Hye Seon Kim3, Ji Min Kim3, Jung Hyun Kwon4, Ji Won Han1, Pil Soo Sung1, Si Hyun Bae1, Jong Young Choi1, Seung Kew Yoon4, Joeng Won Jang1**

1Department of Internal Medicine College of Medicine, The Catholic University of Korea Seoul South Korea, 2The Catholic University Liver Research Center Department of Biomedicine & Health Sciences, Graduate School, College of Medicine, The Catholic University of Korea Seoul South Korea

**Background:** Telomerase reverse transcriptase (TERT) abnormalities are the most common altered pathway in hepatocellular carcinoma (HCC), an inflammation-induced cancer. HCC is characterized by male predominance in incidence, with an estimated male-to-female ratio of 3:4:1. Little is known regarding the role of TERT abnormalities and inflammatory cytokines in hepatocarcinogenesis. This study aimed to investigate the association of the TERT and cytokines with gender disparity in HCC.

**Method:** The study included a total of 357 HCC patients with stored liver tissues or serum. TERT expression was measured by qRT-PCR, and multiple cytokines were detected by multiplex immunoassay.

**Results:** Overall, TERT expression was higher in HCC than in Non-HCC tissues (P=0.0001). Among HCC patients, males had higher TERT expression than females (P=0.0001). The levels of cytokines, such as INF-γ, IL-10, IL-12, IL-17, IL-2, IL-6, and TNF-α, were not different between genders. When analyzed within patients with HBV-associated HCC, males had higher levels of both IL-6 and TERT expression than females. Among the cytokines, only IL-6 positively correlated with TERT expression in males, but not in females. The correlation between serum IL-6 and tumor TERT levels appeared to be stronger in patients with HBV-associated HCC than in those with non-HBV-associated HCC (r=0.373, p=0.001 for HBV-HCC; r=0.012, p=0.957 for non-HBV-HCC).

**Conclusion:** TERT and IL-6 are differentially expressed between male and female HCC patients, with a positive correlation only in male patients or those with HBV-associated HCC. These results give insight into the potential mechanism of TERT-IL-6 axis involved in gender disparity in liver carcinogenesis.

Abstract Submission No. 101818

**P-0576**

**Case reports: durable response of systemic therapy for hepatocellular carcinoma with bone metastasis**

**Chi-Yu Lee1, Tsang-En Wang1,2,3, Chia-Yuan Liu1,2,3,4, Ming-Jen Chen1,2,3, Horng-Yuan Wang4, Ching-Wei Chang1,2**

1) The safety and efficacy of SBRT were evaluated. 2) 25 patients were treated with SBRT from August 2012 to November 2022 in this study.

**Backgrounds:** Effective treatment for hepatocellular carcinoma with macrovascular invasion (MVI-HCC) has not yet been established. In this study, we reviewed combination therapy of unresectable MVI-HCC with stereotactic body radiation therapy (SBRT) at our institution.

**Methods:** We included 28 patients with unresectable MVI-HCC treated with SBRT from August 2012 to November 2022 in this study. 1) The safety and efficacy of SBRT were evaluated. 2) 25 patients were treated with hepatic transcatheter arterial infusion chemotherapy with cisplatin (CDDP-TAI), continuous hepatic arterial infusion chemotherapy (HAIC), and Lenvatinib, and the patient backgrounds and outcomes of these three groups were compared.

**Results:** 1) Median age: 69(48-81) years, male/female: 21/7 cases, inferior vena cava thrombus: 5 cases, portal vein tumor thrombus (Vp 2/3/4): 2/10/13 cases. Combination therapies included CDDP-TAI in 10 patients, continuous HAIC in 7, Lenvatinib in 8, Sorafenib in 2, and Atezolizumab/Bevacizumab in 1. The MST for all patients was 18.6 months. Tumor thrombi were enlarged in 4 patients, with the median
time to enlargement of 2.4 (1.4-13.6) months. SBRT caused no gastro-intestinal disorders, and 2 patients developed bile duct stenosis. 2) Comparison of patient backgrounds showed significant differences in Child-Pugh classification, tumor occupancy, platelet count, and albumin. MST for CDDP-TAI/continuous HAIC/Lenvatinib was 16.0/18.6/24.1 months, not significantly different. In univariate analysis of OS, DCP>10,000 mAU/ml was a significant poor prognostic factor (p=0.008).

Conclusions: SBRT for MVI-HCC was performed safely and effectively at our institution. There were no significant differences in OS despite the different treatments depending on liver function and tumor occupancy.

Abstract Submission No. 101847
P-0578

Duration of Response and Factors associated with sustained response to ATZ/BEV therapy

Emi Tanaka1, Yasuto Takeuchi1, Masahiko Sue1, Nozomi Miyake1, Takuya Adachi1, Nozoumi Wada2, Hideki Onishi3, Hidenori Shiraha1, Akinobu Takaki1, Motoyuki Otsuka1
1Okayama University, Gastroentrology Okayama City Japan

Background and aims: In systemic chemotheraphy for malignant tumors, disease progression is often observed even after a good treatment effect has been achieved. The aim of this study was to examine the duration of response (DOR) and factors associated with sustained response of atezolizumab plus bevacizumab (ATZ/BEV) combination therapy in patients with unresectable hepatocellular carcinoma (HCC).

Methods: This is a multicenter study conducted between October 2020 and June 2023. A total of 343 HCC patients who received ATZ/BEV combination therapy as first-line chemotherapy were included.

Results: The objective response rate (ORR) was 39.1%. The disease control rate (DCR) was 77.7%. The progression free survival (PFS) was 7.6 months. The overall survival (OS) was 22.5 months. The DOR was 6.9 months. In patients who have a good therapeutic effect (complete or partial response), the OS of patients who lead to disease progression and who didn’t who had 19.0 months and 30.0 months, respectively (P=0.051). Multivariate analysis revealed that non-viral liver disease (OR 3.74, 95% confidence interval [CI] 1.0-13, P < 0.050) and LCA-reactive α-fetoprotein isofrom (AFP-L3) at best response ≤ 5% (OR 4.23, 95% CI 0.95-19, P = 0.059) as predictive factors for the sustained response.

Conclusion: ATZ/BEV combination therapy in unresectable HCC can achieve longer survival in patients who continue to good respond. However, patients who have non-viral liver disease or whose AFP-L3 is not sufficiently reduced by treatment are more likely to convert to progression disease.

Abstract Submission No. 101848
P-0579

Impacts of muscle and adipose mass on male hepatocellular carcinoma patients undergoing resection

Pei Chang Lee1-2, Tsung Yi Cheng1, Kuo Wei Huang1, Gar Yang Chau2-3, Yi Hsiang Huang4, The Ia Huo1-2, Ming Chih Hou1, Jaw Ching Wu1-2, Chien Wei Su1-6
1Taipei Veterans General Hospital Taipei Taiwan, 2National Yang Ming Chiao Tung University Taipei Taiwan, 3West Garden Hospital

Taipei Taiwan, 4Taipei City Hospital Yang-Ming Branch Taipei Taiwan

Background & Aims: Body composition is an objective assessment reflecting nutritional status and liver reserves. Curative resection, the standard treatment for early-staged hepatocellular carcinoma (HCC) is an energy-consuming major operation that would affect body composition. In this study, we aimed to investigate the impact of muscle and adipose tissue on the outcome of HCC after curative resection in male patients.

Method: From January 2013 to December 2016, 229 consecutive fe-male patients undergoing curative resection for HCC in Taipei Veterans General Hospital were retrospectively reviewed. Skeletal muscle index (SMI), subcutaneous, visceral, intramuscular, and total adipose tissue index (SATI, VATI, IMATI, TATI) were calculated at L3 vertebral level from pre-operative computed tomography scan using Slice-O-matic software. Factors associated with survivals were analyzed.

Results: A significantly worse overall survival (OS) was noted in patients with pre-surgical lower SMI (p < 0.001), higher IMATI (p < 0.001), and lower SATI (p = 0.005). Otherwise, the OS could not be differentiated by VATI or TATI. Besides, baseline ALBI grade > (Hazard ratio [HR]: 1.889, p = 0.035), poorly differentiated tumor histology (HR: 2.748, p = 0.001), lower SMI (≤ 46.6 cm2/m2) (HR: 2.102, p = 0.020), higher IMATI (> 2.9 cm2/m2) (HR: 3.719, p < 0.001), and lower SATI (≤ 38.0 cm2/m2) (HR: 2.416, p = 0.029) were independent predictors of a worse OS.

Conclusion: Sarcopenia, myosteatosis, and subcutaneous adiopopenia can independently predict survival in male HCC patients undergoing surgical resection. These findings help to establish surveillance and nutrition support strategies to optimize patients’ outcomes.

Abstract Submission No. 101849
P-0580

Prognostic impact of muscle loss during atezolizumab/bevacizumab combination therapy

Hironori Ochi1, Joji Tani2, Tetsu Tomonari3, Akira Hirose4, Atsushi Hiraoka5, Masashi Hirooka3, Akiyo Moriya6, Akihiro Deuchi7
1Matsuyama Redcross Hospital Matsuyama Japan, 2Department of Gastroenterology and Neurology, Kagawa University Graduate School of Medicine, Takamatsu Japan, 3Department of Gastroenterology and Oncology, Tokushima University Graduate School of Medicine Tokushima Japan, 4Department of Gastroenterology and Hepatology, Kochi University Graduate School of Medicine Kochi Japan, 5Gastroenterology Center, Ehime Prefectural Central Hospital Matsuyama Japan, 6Department of Gastroenterology, Mitoyo General Hospital Kannonji Japan, 7Department of Gastroenterology, Kagawa Rosai Hospital, Marugame Japan, 8Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine Toon Japan

Aim: The purpose was to examine the significance of changes in muscle volume during atezolizumab/bevacizumab combination therapy (AB therapy).

Method: The prognostic impact of changes in muscle volume after AB therapy was examined in 171 patients whose efficacy could be determined by CT after the start of AB therapy in a retrospective, multicenter study. The psoas muscle area index (PI) was calculated from CT findings. At the first CT after starting atezolizumab bevacizumab, cases with a decrease in PI from before treatment were designated “decrease group” and those with an increase were designated “increase group”.

Result: The pre-treatment median PI was 5.01 for men and 3.55 for women. The median overall survival (OS) was not reached and the
Systemic treatment in patients with unresectable hepatocellular carcinoma in Child-Pugh class B.

Takaaki Tanaka1, Hironori Ochi1, Hideko Ohama2, Toshifumi Tada2, Masashi Hirooka2, Kazuya Kariyama2, Koichi Takaguchi2, Ei Itohaya3, Kunihiko Tsuji3, Toru Ishikawa3, Takeshi Hatanaka2, Satoru Kakizaki2, Tomomitsu Matono2, Masatoshi Kudo2, Takeshi Kumada2

1Matsuyama Red Cross Hospital Matsuyama Japan, 2RELPEC Study Group and HCC 48 Group Gifu Japan

Background: Systemic treatment is generally recommended for unresectable hepatocellular carcinoma (uHCC) patients with Child-Pugh (CP)-A status. Given the urgent need for effective therapeutic strategies to treat u-HCC patients with CP-B, this study was conducted to compare the efficacy of lenvatinib (LEN) with that of atezolizumab plus bevacizumab (Atez/Bev).

Methods: A total of 145 uHCC patients with ECOG performance status 0 or 1 and CP-B liver function who received Atez/Bev (n=53) or LEN (n=92) as initial systemic treatment from April 2018 to December 2022 were enrolled. Therapeutic response as well as clinical features and prognosis were retrospectively evaluated.

Results: Median age for all patients was 71 years (interquartile range 61-77) and 113 (77.9%) were male. CP score was 7 for 105, 8 for 31, and 9 for 9 patients. The Atez/Bev and LEN groups did not differ significantly for best response (complete response: partial response: stable disease:progressive disease = 0:12:20:12 vs. 5:22:24:19, p=0.265). There was no significant difference for progression-free survival (PFS) between them [median 5.7 (95% CI 3.6-7.9) vs. 4.4 (95% CI 3.5-5.9) months, p=0.581]. Adverse events (AEs) (any grade/≥grade 3) were observed in 83.0%/36.4% (n=44/16) of the Atez/Bev group and 78.3%/36.1% (n=72/26) of the LEN group (p=0.53 and p=1.0, respectively).

Conclusion: PFS, post-progression treatment rate, and incidence of AEs were not significantly different between the Atez/Bev and LEN groups. Although both treatments showed equivalent effects, neither demonstrated sufficient therapeutic efficacy in the present cases. Development of an effective systemic therapy for uHCC patients with CP-B is needed in the near future.
Atezolizumab+bevacizumab during anti-platelet/anti-coagulation therapy in hepatocellular carcinoma

Michihisa Moriguchi, Keiichiro Okuda, Hideki Fuji, Yasuhide Mutsunoto, Toshikio Kirishima, Shinya Okishio, Hiroki Ishikawa, Yasuyuki Naga, Masayasu Jo, Seita Kataoka, Yuya Seko, Kanji Yamaguchi, Yoshito Itoh

1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science Kyoto Japan, 2Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital Osaka Japan, 3Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan, 4Department of Gastroenterology, Kyoto City Hospital Kyoto Japan, 5Department of Gastroenterology, Fujichiyama City Hospital Kyoto Japan, 6Department of Gastroenterology and Hepatology, Omihachiman Community Medical Center Shiga Japan, 7Department of Gastroenterology, Matsushita Memorial Hospital Osaka Japan, 8Department of Gastroenterology, Otsu City Hospital Shiga Japan

Background & Aims: This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti-platelet agents or anticoagulants.

Methods: The patients were divided into those using (IM out) and those not using (IM in) anti-platelet agents or anticoagulants, which violated the exclusion criteria of the IMbrave150 trial, and were retrospectively examined.

Results: The study included 114 patients (IM in: 95; IM out: 19). For first-line treatment, the progression-free survival was 206 days for IM in and 307 days for IM out (p=0.245), and the overall survival was 685 days for IM in and not reached for IM out (p=0.610), with no significant difference between the two groups. Similarly, there were no significant between-group differences in progression-free survival and overall survival for later-line treatment. Hemorrhagic adverse events of ≥grade 3 were observed in 7 IM in patients and 3 IM out patients. No significant factors associated with hemorrhagic adverse events of ≥grade 3 were identified in the multivariate analysis including a factor for IM in/out group. No deaths were directly attributable to bleeding events or exacerbations of thrombosis.

Conclusion: Atezolizumab + bevacizumab therapy shows almost the same safety and efficacy in hepatocellular carcinoma patients receiving and those not receiving anti-platelet agents or anticoagulants. It is desirable that this issue will be examined in more cases and prospective studies.

Abstract Submission No. 101910
P-0585

Impact of DAAs on the Clinical Prognosis of Japanese Patients with HCC Caused by Hepatitis C Virus

Mitsumoto Yasuhide, Kirishima Toshihiko, Okishio Shinya, Onodera Kinya, Okuda Keiichiro, Fuji Hideki, Mutsunoto Yasuhide, Kirishima Toshihiko, Okishio Shinya, Ishikawa Hiroki, Naga Yasuyuki, Jo Masayasu, Kataoka Seita, Seko Yuya, Yamaguchi Kanji, Itoh Yoshito

1Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science Kyoto Japan, 2Department of Gastroenterology and Hepatology, Saiseikai Suita Hospital Osaka Japan, 3Department of Gastroenterology, Japanese Red Cross Kyoto Daiichi Hospital Kyoto Japan, 4Department of Gastroenterology, Kyoto City Hospital Kyoto Japan, 5Department of Gastroenterology, Fujichiyama City Hospital Kyoto Japan, 6Department of Gastroenterology and Hepatology, Omihachiman Community Medical Center Shiga Japan, 7Department of Gastroenterology, Matsushita Memorial Hospital Osaka Japan, 8Department of Gastroenterology, Otsu City Hospital Shiga Japan

Background/Aim: This study aimed to determine the safety and efficacy of atezolizumab + bevacizumab therapy in hepatocellular carcinoma patients receiving anti-platelet agents or anticoagulants.

Methods: The patients were divided into those using anti-platelet agents or anticoagulants. It is desirable that this issue will be examined in more cases and prospective studies.

Abstract Submission No. 101922
P-0586

Prognostic Assessment Using the GNRI in Atezolizumab Plus Bevacizumab Therapy for HCC

Yanagihara Emi, Hiraoka Atsushi, Imaida Fujimasa, Hida Hidemi, Hata Toshifumi, Hasegawa Masashi, Hirooka Kazuya, Kariyama Koichi, Takaguchi Koichi, Itobayashi Ei, Itoyoda Hidenori, Ishikawa Toru, Hatanaka Takeshi, Kumada Satoru, Kakizaki Takashi, Kamada Mikihisa, Moriguchi Michihisa, Okuda Keiichiro, Kirishima Toshihiko, Okishio Shinya

1Gastroenterology Center, Ehime Prefectural Central Hospital, 2RELPEC Study Group and HCC 48 Group Japan

Background:Aim: Direct acting antivirals (DAAs) capable of eliminating hepatitis C virus (HCV) sustained virological response SVR at a higher rate than interferon therapy have been available in Japan since 2014. This study examined the clinical impact of DAAs for hepatocellular carcinoma (HCC) due to HCV before and after the advent of these drugs.

Methods: Enrolled were 1982 patients with HCC due to HCV treated at our institutions in Japan from January 2000 to January 2023. They were divided into two groups based on before and after DAA availability: pre-DAA (before 2013, n=1181) and post-DAA (after 2014, n=801). Changes in clinical features and prognoses were evaluated in a retrospective manner.

Results: The groups did not show significant differences for Liver Cancer Study Group of Japan tumor node metastasis stage or Japan integrated staging (JIS) score. However, the post-DAA group had higher frequencies of patients with SVR from anti-viral treatments (45.9% vs.10.1%), elderly age (73 vs. 69 years old), lower AST (40 vs. 56 IU/L), ALT (31 vs. 46 IU/L), and AFP (11.2 vs. 23.6 ng/mL) levels, higher platelet count (13.6 vs. 10.8 ×10^11/L), longer prothrombin time (89.8% vs. 81.9%), better ALBI score (-2.53 vs. -2.36), and higher rate of curative treatment (surgical resection or radio frequency ablation) (73.7% vs. 65.0%) (p<0.001, for all). Also, recurrence-free survival (RFS) after curative treatment was significantly better in the post-DAA group (median 2.9 years vs. 2.1 years) as was overall survival (OS) (median: not applicable (NA) vs. 5.5 years) (p<0.001, for all). After inverse probability weighting (IPW) adjustment using propensity scores based on multivariate analysis, OS was also better in the post-DAA group (median 7.0 vs. 5.7 years, p<0.001). As a sub-analysis, comparisons of prognosis among three groups after dividing the post-DAA group into non-SVR (n=307), pre-SVR (HCC developed after SVR, n=368), and post-SVR (HCC developed after HCC, n=126) showed that OS for the non-SVR group was significantly shorter (median 3.2 years vs. NA vs. NA, P<0.001), with no significant difference noted between the pre-and post-SVR groups (p=0.19).

Conclusion: The prognosis of patients with HCC due to HCV was greatly improved after introduction of DAAs, with the resultant high rate of HCV elimination dramatically changing clinical practice for HCV-related HCC cases.

Abstract Submission No. 101922
P-0586

Prognostic Assessment Using the GNRI in Atezolizumab Plus Bevacizumab Therapy for HCC

Yanagihara Emi, Hiraoka Atsushi, Imaida Fujimasa, Hida Hidemi, Hata Toshifumi, Hasegawa Masashi, Hirooka Kazuya, Kariyama Koichi, Takaguchi Koichi, Itobayashi Ei, Itoyoda Hidenori, Ishikawa Toru, Hatanaka Takeshi, Kumada Satoru, Kakizaki Takashi, Kamada Mikihisa, Moriguchi Michihisa, Okuda Keiichiro, Kirishima Toshihiko, Okishio Shinya

1Gastroenterology Center, Ehime Prefectural Central Hospital, 2RELPEC Study Group and HCC 48 Group Japan

Background:Aim: The geriatric nutritional risk index (GNRI) is an easy-to-use tool for assessing nutritional status based on body weight and serum albumin. This study aimed to evaluate the prognostic predictive ability of GNRI in patients with hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atz/Bv).

Materials/Methods: The study included 525 HCC patients who received Atz/Bv as a first-line systemic chemotherapy. GNRI was used to evaluate prognosis, and patients were classified based on normal, mild-decline, moderate-decline, and severe-decline GNRI values. Muscle volume decline (MVD) was also evaluated as a sub-analysis.

Results: Prognoses (median progression-free survival (mPFS)/median overall survival (mOS)) were stratified according to GNRI status (normal vs. mild vs. moderate vs. severe decline: 8.3/21.4 vs. 6.7/17.0 vs. 5.3/11.5 vs. 2.4/7.3 months) (P<0.001). The mPFS and mOS according to grade (1, 2, and 3) were 9.3/21.4, 6.0/14.5 and 3.0/7.3 months (P<0.001). The c-index values of GNRI for predicting PFS and OS...
were higher than those of Child-Pugh class and ALBI grade (0.574/0.632 vs. 0.527/0.570 vs. 0.565/0.629). GNRI, Child-Pugh class, and ALBI grade were analyzed for time dependent receiver operating characteristic curve (ROC) analysis to evaluate the area under the curve (AUC) for PFS and OS at 6 and 12 months. The AUC for PFS at 6 and 12 months were 0.616 and 0.594 for GNRI, 0.533 for Child-Pugh class, and 0.607 and 0.591 for ALBI grade, respectively. The AUC for OS at 6 and 12 months were 0.669 and 0.667 for GNRI, 0.622 and 0.580 for Child-Pugh class, and 0.654 and 0.661 for ALBI grade, respectively. The frequency of MVD increased as GNRI values declined (GNRI status: normal vs. mild vs. moderate vs. severe decline=17.6% vs. 29.2% vs. 41.2% vs. 57.9%, P<0.001), and a GNRI value of 97.8 was predictive of its occurrence (AUC 0.715, 95%CI 0.649-0.781, specificity/sensitivity=0.644/0.688). There were significant relationships between GNRI and SMI in both genders (Male: r=0.42, 95%CI 0.302-0.526, P<0.001, Female: r=0.438, 95%CI 0.169-0.646, P<0.002).

Conclusion: The results of this study suggest that GNRI is a useful prognostic tool for predicting both prognosis and MVD in HCC patients treated with Atz/Bv.

Impact of locoregional therapy on hepatocellular carcinoma treated with atezolizumab and bevacizumab

Shun Yamazaki1, Toru Ishikawa1, Ryo Sato1, Ryo Jimbo1, Yuji Kobayashi1, Toshifumi Sato1, Akito Iwana2, Tomoe Sano1, Junji Yokoyama1, Terasu Honma1

1Saiseikai Niigata Hospital Niigata Japan

Background: Atezolizumab plus bevacizumab (Atez/Bev) therapy is extremely effective and has a high response rate in hepatocellular carcinoma (HCC) treatment. Here, we investigated the efficacy of adding locoregional therapy with Atez/Bev therapy for non-complete response (CR) HCC cases.

Patients and Methods: Twenty-eight HCC patients in non-CR during Atez/Bev therapy received locoregional therapy, and treatment efficacy was evaluated based on a modified RECIST assessment.

Results: There were 23 male and five female participants with a mean age of 73.5 years. In the Atez/Bev therapy combined with locoregional therapy effective group, both transcatheter arterial chemoembolization (TACE) and radiofrequency ablation (RFA) were combined in all patients. A significant reduction in neutrophil-to-lymphocyte ratio (NLR) was observed after adding locoregional therapy (p=0.039). Moreover, a combination of TACE and RFA was performed for all patients in the CR group. When assessing the add-on effect of the combination of TACE and RFA in the progressive disease (PD) group, seven patients were found to achieve non-PD after adding locoregional therapy. For patients who achieved non-PD, significant NLR reduction was noted after the addition of locoregional therapy.

Conclusion: Adding locoregional therapy such as TACE/RFA was found to exert an effect even in non-CR patients who had received Atez/Bev therapy. An NLR reduction after adding locoregional therapy was noted. Even when a response is not obtained during Atez/Bev therapy, it is important to avoid the option to add locoregional therapy as it may contribute to improved prognosis via immune modulation with tolerable adverse reactions.

The effect of YangYinFuZhengJieDu decoction with HBV-HCC: a prospective, randomized clinical trial

Xinhui Wang1, Xiaoli Liu1, Zhibo Dang1, Fengna Yan1, Lihua Yu1, Peng Wang2, Zhiyun Yang2

1Beijing Ditan Hospital Affiliated to Capital Medical University Beijing China

Retrospective study found that the YangYinFuZhengJieDu decoction (YYFJD) can delay tumor progression and prolong the survival time of hepatitis B virus-related Hepatocellular Carcinoma (HBV-HCC) patients. In mice, we found that YYFJD exerted anti-tumor effects by alleviating T cell exhaustion and immune suppression. In this study, we aim to evaluate the efficacy and safety of YYFJD and verify its anti-tumor immune response. 132 patients with HBV-HCC were conducted and assigned to receive either YYFJD or no YYFJD(con) in a 1:1 ratio. They were followed up for 96 weeks. At a follow-up of 96 weeks, the overall survival rate of patients in YYFJD and Control group was 65.2% and 50%, respectively(Log-rank P<0.05). And the progression-free survival rate was 57.6% and 40.9%, respectively(Log-rank P<0.05). The AFP level decreased in the YYFJD group(P=0.027). The PD-1+TIM-3+CD8+T cells significantly decreased in YYFJD group, and the anti-tumor cytokine IFN-r increased(P<0.05). However, in comparison with the control group, we found no significant difference in the incidence of liver dysfunction.
in the YYFZJD group (p>0.05). In conclusion, YangYinFuZhengJieDu decoction can reduced mortality in HBV-HCC patients and delay tumor progression by regulating the immune suppression. At the same time, YYFZJD has good safety. Future multi-center trials with larger sample sizes are required to verify these findings. Clinical trial registration: www.ClinicalTrials.gov NCT02927626.

Abstract Submission No. 102035
P-0590

Elizabeth Garcia1, Nicholas Chien2, Yee Hui Yeo3, Mindie H. Nguyen4, Ramsey Cheung5
1Stanford University Palo Alto United States, 2Stanford University Medical Center Palo Alto United States, 3Cedars-Sinai Medical Center Los Angeles United States, 4Palo Alto Department of Veterans Affairs Medical Center Palo Alto California

Background: HCC is the 6th deadliest cancer in the US, and it is unclear if there has been significant improvement in survival in recent years, especially for HCC patients with nonviral liver disease.

Aims and Method: To investigate the survival trends of HCC patients over time and by etiology using the U.S. population-based Surveillance, Epidemiology, and End Results–Medicare (2000-2017).

Results: The study included 52,698 HCC patients. Viral HCC patients were more likely to be Asian (18.0% vs. 10%) or Black (17.9% vs. 7.0%) and with early HCC stage I/II (52.0% vs. 43.0%), and to have higher 5-year survival (16.4% vs. 12.0%) (all P <0.001). Viral HCC patients also had higher 5-year survival than nonviral HCC patients in both the pre and post 12/2013 periods (Figure 1A). Additionally, though survival increased for both groups over time (Figure 1B) survival rates increased more for viral HCC (44.2% increase, from 14.7% to 21.2%) as compared to nonviral HCC (33.6% increase, from 10.7% to 14.3%). On multivariable Cox’s regression analysis adjusting for age, sex, race and ethnicity, tumor stage, cirrhosis status, HCC treatment, and time period, viral (vs. nonviral) etiology was independently associated with higher survival (adjusted hazard ratio [aHR]=1.25, 95%CI 1.23-1.28, P<0.001). HCC diagnosis after 12/2013 was also associated with higher survival compared to before (aHR=1.27, 95%CI 1.24-1.30, P<0.001).

Conclusion: Despite some improvement over time, overall 5-year survival rates remain low at only 21.2% for viral HCC and 14.3% for nonviral HCC. Further efforts are needed to improve HCC surveillance and treatment.

Abstract Submission No. 102038
P-0591

Multidisciplinary treatment strategy for macroscopic portal vein tumor thrombus
Shohei Komatsu1, Yoshihiko Yano1, Masahiro Kido1, Hidetoshi Gon1, Kenji Fukushima1, Takeshi Urade1, Yoshihiko Yoshida1, Keisuke Arai1, Nobuaki Ishihara1, Hiroaki Yanagimoto1, Hirochika Toyama1, Yoshihide Ueda1, Takumi Fukumoto1
1Kobe University Graduate School of Medicine Kobe Japan

Background: Hepatocellular carcinoma (HCC) with a tumor thrombus extending to the first branch (Vp3) or main trunk (Vp4) of the portal vein is considered an end-stage condition with an extremely poor prognosis with few treatment options. The present study aimed to analyze the optimal treatment for Vp3/4 HCC.

Subjects: One hundred patients who underwent hepatectomy for Vp3/4 HCC and 26 patients who underwent chemotherapy (lenvatinib (LEN: n=10) and atezolizumab/bevacizumab combination therapy (A/B: n=16)

Results: The median survival (MST) of all 100 patients who underwent hepatectomy for Vp3/4 HCC was 14.5 months. The MST of patients with Vp3 (n = 37) and Vp4 (n = 63) were 16.1 months and 14.3 months, respectively, without significant difference (P = 0.7098). Any tumor factor, including Vp status (Vp3 or Vp4), the type of resection (curative or reductive), intrahepatic maximal tumor size, intrahepatic tumor number, and the existence of extrahepatic metastasis, did not influence overall survival.

The MST of 26 patients who underwent chemotherapy was 9.8 months (A/B: 15.0 months and LEN: 9.8 months). The objective response rates (CR+PR) by mRECIST and RECIST were 37.5% and 25.0% in the LEN group and 50.0% and 37.5% in the A/B group, respectively. The proportions of patients with a decrease in tumor markers from baseline (AFP day30/before<1) at 1 month after the start of chemotherapy were 62.5% in the LEN group and 69.2% in the A/B group. Of the 26 patients, none were eligible for conversion hepatectomy, but 5 patients in the A/B group were recurrence-free with drug fee.

Conclusion: For Vp3/4 HCC, hepatectomy tended to have a better prognosis than chemotherapy. Future studies are needed to determine the possibility of long-term prognosis for patients in the chemotherapy group who can be treated with conversion therapy.

Abstract Submission No. 102041
P-0592

Safety and Efficacy of Atezo/Bev in Combination with Radiation Therapy in HCC with Vp4 PVTT
Masahiko Tameda1, Hideaki Tanaka1, Hayato Nakagawa1
1Department of Gastroenterology and Hepatology, Mie University Hospital Tsu Japan

Background: Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) generally has a poor prognosis, but the efficacy of atezolizumab plus bevacizumab (ATZ/BEV) therapy in Vp4 PVTT cases has been reported. Previous studies have demonstrated the therapeutic effects of radiation therapy (RT) in Vp4 cases. This study investigates the combination of ATZ/BEV and RT in Vp4 cases.

Methods: This study included unresectable HCC patients who received ATZ/BEV in our hospital from October 2020 to September 2023. Vp4 cases who started treatment after September 2022 were treated with RT.

Results: During the period, 63 cases received ATZ/BEV treatment, including 8 Vp4 cases, with RT administered in 4 cases. RT was performed on the PVTT with a planned total dose of 25 Gy in 5 fractions. Of the 4 RT cases, 3 received RT before starting ATZ/BEV therapy, and 1 received RT between the second and third courses. No side effects leading to discontinuation were observed in the combined RT group, and there was no significant difference in liver reserve before and after RT. One case in the combined RT group had PVTT extending to the SMV. After RT, ATZ/BEV was started, and the first imaging assessment was CR, with tumor markers also becoming negative. ATZ/BEV administration was discontinued after 18 courses, and the patient has been recurrence-free since.

Conclusion: The combination of ATZ/BEV and RT in Vp4 cases was safely administered. Some cases showed good treatment outcomes, suggesting the potential for improved treatment efficacy.
Hepatectomy using a right thoracotomy and continuous oblique incision - our experience-

Toshiya Ochiai1, Tomohito Nakashima1, Yuki Adachi1, Akihiro Taniguchi1, Kenichi Takemoto1, Junichi Hamada1, Kei Naito1

1North Medical Center, Kyoto Prefectural University of Medicine Kyoto Japan

Introduction: Even with advances in laparoscopic hepatectomy and robotic surgery, there are still cases in which open hepatectomy is necessary. Hepatectomy using a right thoracotomy and continuous oblique incision makes it easy to cut and suture the right and short hepatic veins with retroperitoneal dissection. It is useful and safe for wide posterior segmentectomy including the caudate lobe, resection of recurrent lesions around the right adrenal gland, and cases where severe adhesions are observed at the hepatic hilum or anterior surface during repeated hepatectomy.

Subjects: Since 2005, 26 patients (group O) underwent hepatectomy using this approach. Seven cases (26.9%) among them underwent repeated hepatectomy. Perioperative outcomes were compared with 81 cases of right lobe hepatectomy (Group J) performed during the same period using a supine J-shaped incision.

Results: The breakdown of right hepatectomy in groups O/J was 7/17 cases of right lobectomy and extended right lobectomy, and 19/64 cases of segmentectomy and partial resection. The operative time, intraoperative blood loss, and postoperative hospital stay were 270/314 minutes (p<0.05), 991/1151 ml, and 19/30 days (p<0.05), respectively. Complications were observed in 1/14 cases (p<0.01). Patients with HCC

Conclusion: Hepatectomy through right thoracotomy and continuous oblique incision remains an effective surgical technique for resection of lesions, which is expected to be difficult with laparoscopic liver resection of anterior or a frontal.

Abstract Submission No. 200000
P-0595

Comparison between nivolumab and regorafenib after sorafenib failure for hepatocellular carcinoma

Jae Seung Lee1, Hye Won Lee1, Beom Kyung Kim1, Seung Up Kim1, Jun Yong Park1, Sang Hoon Ahn1, Do Young Kim1

1Yonsei University College of Medicine Seoul South Korea

Background and Aims: Nivolumab and regorafenib are used as second-line therapies for patients with advanced hepatocellular carcinoma (HCC). We aimed to compare the effectiveness of nivolumab to regorafenib.

Method: We retrospectively reviewed HCC patients treated with nivolumab or regorafenib after sorafenib failure. Progression-free survival (PFS) and overall survival (OS) were analyzed. Inverse probability of treatment weighting (IPTW) using the propensity score (PS) was conducted to reduce treatment selection bias.

Results: Among the recruited 189 patients, 137 and 52 patients received regorafenib and nivolumab after sorafenib failure, respectively. Nivolumab users showed higher Child-Pugh B patients (42.3% vs. 24.1%) and shorter median sorafenib maintenance (2.2 vs. 3.5 months) compared to regorafenib users. Compared to regorafenib users, nivolumab users showed shorter median OS (4.2 vs. 7.4 months, P=0.045) and similar median PFS (1.8 vs. 2.7 months, P=0.070), respectively. However, median OS and PFS were not different between the two treatment groups after 1:1 PS matching yielded 34 pairs (log-rank P=0.810 and 0.810, respectively), and after stabilized IPTW (log-rank P=0.445 and 0.878, respectively). In addition, covariate-adjusted Cox regression analyses showed that the nivolumab (vs. regorafenib) use was not significantly associated with the PFS and OS after 1:1 PS matching and stabilized IPTW (all P>0.05).

Conclusion: Clinical outcomes in patients treated with nivolumab and regorafenib after sorafenib failure did not differ significantly.

Effect of Marital and Insurance Status on the Survival of Elderly Patients with HCC

Jing Xiao1, Qingdong Li1

1Chongqing University Cancer Hospital Chongqing China

Abstract Submission No. 200049
P-0596
Background: Among various types of cancer, marital and insurance status are considered important prognostic factors. However, how these factors affect elderly HCC patients remains unexplored. The purpose of this study was to reveal the role of marital status and insurance in the survival of elderly HCC patients.

Methods: We retrieved data for patients diagnosed with HCC between 2010 and 2016 from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis of the clinicopathological features, overall survival (OS), and cancer-specific survival (CSS) was based on marital and insurance status.

Results: A total of 10,620 elderly HCC patients received complete information from SEER. The OS and CSS of the nonmarried group were worse than those of the married group. The OS and CSS of the uninsured group were lower than those of both the insured and Medicaid groups. The results suggest that marital status and insurance may affect the long-term survival of elderly HCC patients. The subgroup survival analyses revealed the lowest risk for death among the insured married group based on the comparison of the OS and CSS across all other groups. Moreover, univariate and multivariate analyses revealed race, insurance, surgery, and chemotherapy as independent predictors for OS, whereas sex, insurance, surgery, radiotherapy, and chemotherapy were independent predictors for CSS in elderly HCC patients.

Conclusion: Marital status and insurance status have a great influence on the survival of elderly HCC patients. Therefore, it is necessary to provide more support to this lonely and uninsured vulnerable group of patients.

Abstract Submission No. 200050
P-0597

A predictive nomogram for venous thromboembolism in patients with primary liver cancer

Jing Xiao1
1Chongqing University Cancer Hospital Chongqing China

Background: Cancer often leads to venous thromboembolism (VTE), which is the primary reason for cancer-related mortality, this study aimed to develop a nomogram chart model capable of accurately predicting the probability of venous thromboembolism (VTE) in patients diagnosed with primary liver cancer (PLC) within the overall population. Doctors can accurately identify VTE patients by utilizing this model and apply early prevention and therapeutic strategies to decrease the likelihood of thrombosis.

Method: Using data collected from patients diagnosed with PLC at Chongqing University Cancer Hospital in China, logistic invariant and multivariate analysis techniques were employed to identify the independent risk factors associated with VTE. An integrated nomogram was then constructed for internal verification. The effectiveness of the Nomogram prediction is assessed through the receiver operating characteristic curve (ROC) and calibration curve.

Result: 1565 patients diagnosed with PLC were analyzed. In total, the nomogram integrated eight risk factors for VTE that were independent, namely activated partial thromboplastin time (APTT) (P=0.007), D-dimer (P=0.019), lymphocyte count (LYM) (P=0.012), monocyte count (MONO) (P=0.002), transarterial chemoembolization (TACE) (P=0.001), surgical intervention (P=0.010), and immunotherapy (P=0.010). The nomogram model demonstrated a strong discriminatory ability with C indices of 0.753 and 0.710 in the training and verification queues, respectively. The nomogram’s calibration chart demonstrates a strong correlation between the estimated probability and the real probabilities.

Conclusion: In this study, we developed and verified a new nomogram to estimate the likelihood of VTE in individuals diagnosed with PLC. By utilizing the nomogram model, it is possible to accurately assess the risk of VTE in PLC patients on an individual basis and identify those at high risk who require a targeted preventive treatment approach.

Abstract Submission No. 200088
P-0598

Efficacy combine DEXA with N-Acetylcysteine to prevent post embolization Syndrome after TACE

Nitipon Simasingha1,2, Suppatsri Sethasine2
1UdonthaniHospital Bangkok Thailand, 2VajiraHospital Bangkok Thailand

100 patient were enrolled: 50 patient were assigned randomly to dexamethasone plus NAC and placebo, DexA+NAC were significantly lower developed PES than placebo group (6% VS 80%, P<0.001) and multivariated anlysis dexa+NAC i sproactive factor against PES with Abd OR of 0.04 (P<0.001). Post-TACE liver decompensation was document in 7 from 50 (14%) incontrol group as opposed to DIXA+NAC no developed (14% VS 0%) but multivariated no statisti- cal significant dur to low incidence of liver decompensation, ALBL > 0.5 increased is significant predictor for liver decompensation

Abstract Submission No. 200089
P-0599

Real world of curative stage hepatocellular carcinoma, A multicenter study

Nitipon Simasingha1,2, Suppatsri Sethasine2
1159/40 Urbanorajvithi rajvithi road bangplud Bangkok Thailand, 2VajiraHospital Bangkok Thailand

Over thousand (n=1145) HCC patient’s data from 2 tertiary center for ten years periods. CP-A, CP-B, CP-C were 48.7, 34.4 and 15.1% with mean MELD score of 12.6. Etiology were hepatitis B, NASH, heptatias C and alcohol; 33, 27.1, 25.8, 17.3% respectively)At the time of HCC diagnosis by application of BCLC Criteria, 470 patients (41%) were in curative stage of BCLC- A (n=424; 21.3%) and Stage of BCLC- A (n=226; 19.7%). Over six-hundred patients (n=675) were diagnosed with non-curative stage [ BCLC-B: n=417; 36.41%, BCLC-C (n=102; 8.9%) and BCLC-D: (n=156; 13.62%)]. Within 470 HCC at BCLC stage 0-4Acategorized treatment modality of curative HCC, radiofrequency ablation; RFA (n=188), resection (n=98) and trans-arterial chemoembolization; TACE (n=109). Our comparative study between RFA and resection found a higher proportion of CP-B and tumor size of equal or less than 2 cm were selected to RFA treatment (RFA: n=55; 29.3% vs Resection n=7; 7.1%, p<0.001) and (RFA: 63.6% vs Resection 31.5%; p<0.001). Selection to liver resection has a characteristic of CP-A (Resection: n=90; 91.8% vs RFA: n=131; 69.7%, p<0.001

Abstract Submission No. 200104
P-0600

Sarcopenia and Prognosis in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab

Kyoko Oura1, Asahiro Morishita1, Kei Takuma1, Mai Nakahara1, Tomoko Tadokoro1, Koji Fujita1, Joji Tani1, Tsutomu Masaki1

Abstract Submission No. 200088
P-0598

Efficacy combine DEXA with N-Acetylcysteine to prevent post embolization Syndrome after TACE

Nitipon Simasingha1,2, Suppatsri Sethasine2
1UdonthaniHospital Bangkok Thailand, 2VajiraHospital Bangkok Thailand

100 patient were enrolled: 50 patient were assigned randomly to dexamethasone plus NAC and placebo, DexA+NAC were significantly lower developed PES than placebo group (6% VS 80%, P<0.001) and multivariated anlysis dexa+NAC i sproactive factor against PES with Abd OR of 0.04 (P<0.001). Post-TACE liver decompensation was document in 7 from 50 (14%) incontrol group as opposed to DIXA+NAC no developed (14% VS 0%) but multivariated no statisti- cal significant dur to low incidence of liver decompensation, ALBL > 0.5 increased is significant predictor for liver decompensation
Objective: Although there have been advances in the prevention and diagnosis of hepatocellular carcinoma (HCC), many HCC patients are diagnosed with advanced stage. Atezolizumab plus bevacizumab (atezo/bev) is recommended as first-line treatment for unresectable HCC (uHCC). Recently, sarcopenia-related factors, including decreased skeletal muscle index (SMI), have been reported to be associated with prognosis in uHCC patients. There are few reports on grip strength (GS) despite their importance in accurate sarcopenia diagnosis, and furthermore, there is no evidence regarding atezo/bev. We investigated whether sarcopenia affects the clinical outcome of atezo/bev.

Methods: This study included 64 uHCC patients on atezo/bev and assessed their GS and SMI, and SMI was measured using bioelectrical impedance analysis (BIA). We diagnosed sarcopenia based on GS and BIA-SMI and compared the sarcopenia and non-sarcopenia groups.

Results: Of these patients, 28 had sarcopenia, and 36 had non-sarcopenia. Adverse events (AEs) frequently occurred, and the albumin-bilirubin score significantly decreased after atezo/bev in the sarcopenia group than in the non-sarcopenia group. The median progression-free survival was 4.7 (0.4–26.4) months and 10.6 (1.1–24.5) months in the sarcopenia and non-sarcopenia groups, respectively. The median overall survival (OS) was 12.6 (1.4–27.7) months in the sarcopenia group and was not reached in the non-sarcopenia group, indicating a significant difference (p < 0.01). In multivariate analysis, sarcopenia was significantly associated with OS.

Conclusion: Sarcopenia was associated with poor clinical outcomes based on the occurrence of AEs and decreased liver function in uHCC patients on atezo/bev. GS and SMI are important parameters for accurately diagnosing sarcopenia.
Aim: The advent of direct-acting antivirals (DAAs) has reduced HCC by achieving sustained virologic response (SVR). Despite this, reports of HCC post-SVR have emerged. This study scrutinizes the genomic and clinical features of HCC post-DAA treatment.

Methods: Among 689 DAA cases from July 2013 to November 2023, we examined 59 post-DAA HCC cases, comparing tumor size and number with 371 non-DAA cases. Genomic analysis used an in-house HCC panel (72 SMGs: 59,016 aa). OncoKB annotated oncogenic variants. We assessed WNT/β-catenin abnormalities in these cases, comparing with 134 non-DAA HCC cases. In 11 post-DAA multiple HCC cases, tumors with shared oncogenic variants were defined as intrahepatic metastasis (IM), while those without were considered multicentric origin (MC). Clonality was evaluated and compared with 53 non-SVR HCC cases.

Results: After SVR, 40 patients had 58 nodules, with an average of 1.3 and a median tumor size of 2.0 cm (0.5 -9.0). In non-DAA cases (n=371), the average was 1.8, with a median size of 3.8 cm (0.8-21.9). Among post-SVR HCC cases, 26% demonstrated WNT/β-catenin abnormalities, while non-SVR cases showed abnormalities in 29%. In post-SVR multiple HCC, 18% had IM&MC, and 82% had MC. In non-DAA cases, 32% showed IM, 15% showed IM&MC, and 53% showed MC.

Conclusion: Post-SVR HCCs tend to be smaller and fewer, suggesting a favorable prognosis. The frequency of WNT pathway abnormalities shows no significant difference between SVR and non-SVR cases. However, there is a significantly higher prevalence of MC in post-SVR multiple cases than non-SVR cases.

Abstract Submission No. 200183
P-0604

Serum ATX forecast postoperative recurrence in patients with HBV-associated liver cancer

Yanwei Zhong1, Xiaotong Chang2, Zixin Guo1, Jia Liu1, Wenwen Yuan1, Zhenyu Zhu1, Jin Yan1, Xiuchang Zhang2, Ce Shi1
1The Fifth Medical Center of Chinese PLA General Hospital, Beijing China, 2Hebei North University Zhangjiakou China

Objective: To explore the role of serum secretion of motor factors (ATX) in predicting postoperative recurrence in patients with HBV-associated liver cancer (HBV-HCC).

Methods: Forty patients who met the indications of HBV-HCC surgical treatment and underwent surgical resection were enrolled. Based on the results at one-year, the patients were divided into a recurrence group (18 cases) and a non recurrence group (22 cases). Univariate and multivariate regression was used to identify the impact factors associated with postoperative recurrence. The area under the receiver operating characteristic curve (AUROC) was used to assess the prediction for postoperative recurrence.

Results: The serum ATX levels of the recurrent group were significantly higher than those non recurrent group. ROC analysis showed that the maximum tumor diameter (p=0.011), number of tumors (p=0.036), and number of tumors (p=0.010) were independent predictors for postoperative recurrence in patients with HBV-HCC. Combining ATX, maximum tumor diameter, and number of tumors has higher value in predicting postoperative recurrence of HBV-HCC, with an area under the curve of 0.774 (95% CI: 0.610-0.938). Combining ATX, maximum tumor diameter, and number of tumors has higher value in predicting postoperative recurrence of HBV-HCC, with an area under the curve of 0.924 (95% CI: 0.844-1.000).

Conclusion: The serum ATX levels, maximum tumor diameter, and number of tumors in patients with HBV-HCC could be used as an important predictors for postoperative recurrence. The serum ATX levels could be used as an early serum predictor of postoperative recurrence.

Abstract Submission No. 200197
P-0606

Network pharmacology to reveal the mechanism of Fufang Banmao capsule for treating unresectable PLC

Youwen Hu1, Yangyang Xiao2, Lijun Wan3, Zhili Wen1
1The Second Affiliated Hospital of Nanchang University Nanchang China, 2Jiangxi University of Traditional Chinese Medicine Affiliated Hospital Nanchang China

Our objective is to utilize network pharmacology to investigate the biactive ingredients and mechanism of Fufang Banmao capsules (FFBM). The bioactive ingredients for the FFBM were screened using the SwissTargetPrediction database, while the FFBM components were sourced from the HERB database. Targets and differentially expressed genes (DEGs) for FFBM and PLC were obtained using PharnMapper and the GEO database, respectively. Common targets were identified through the use of Venn diagrams. Enrichment analysis and protein-protein interaction (PPI) were carried out, and the Cytoscape software was employed to identify Hub genes and construct the ingredient-target-pathway network. Retrospectively collected data on
Comparison of Prediction Models Based on Sonovue/Sonazoid-CEUS for Pathologic Grade and MVI in HCC

Rui Zhang1, Di Li1, Ming Xu1

1Department of Medical Ultrasonics, the First Affiliated Hospital, Sun Yat-Sen University Guangzhou City China

Background: This study aimed to develop and compare the prediction model based on Sonovue and Sonazoid contrast enhanced ultrasound (CEUS) for pathologic grade and microvascular invasion (MVI) of hepatocellular carcinoma (HCC). And to investigate whether Kupffer phase images have additional predictive value for the above pathological features.

Methods: 90 patients diagnosed as primary HCC and received curative hepatectomy were prospectively enrolled. All patients underwent conventional ultrasound (CUS), Sonovue and Sonazoid-CEUS examination preoperatively. Clinical, radiological and pathological features including pathologic grade, MVI and CD68 expression were collected. We developed prediction models composing of clinical, CUS and CEUS (Sonovue and Sonazoid, respectively) features for pathologic grade and MVI with both logistic regression and machine learning (ML) method.

Results: 41 (45.6%) patients were poorly differentiated HCC (p-HCC) and 37 (41.1%) were MVI positive. For pathologic grade, logistic regression model based on Sonazoid-CEUS had significant better performance than which based on Sonovue-CEUS (area under curve (AUC), 0.929 vs. 0.848, \(P=0.068\)). Meanwhile, we found well-differentiated HCC tends to have higher enhancement ratio in 6-12 minutes during Kupffer phase of Sonazoid-CEUS, as well as higher CD68 expression compared with p-HCC. Besides, all of these models can effectively predict the risk of recurrence (\(P<0.05\)).

Conclusion: Sonovue-CEUS and Sonazoid-CEUS showed comparable excellence in predicting MVI, while Sonazoid-CEUS was superior to Sonovue-CEUS in predicting pathologic grade due to the Kupffer phase. Enhancement ratio in Kupffer phase have additional predictive value for pathologic grade prediction.

Point shear wave elastography in local treatments for HCC and liver metastases.

Giovanni Galati1, Teresa Massaro Cenere2, Francesca Barone3, Salvatore Minuti4, Gabriele D’ercole4, Alice Laudisio5, Valentina Flagiello6, Giulia Di Pasquale3, Marianna Silletta3, Giuseppina Di Fazio3, Michele Fiore4, Antonio Picardi1, Paolo Gallo1

1Internal Medicine and Hepatology, Fondazione Policlinico Campus Bio-Medico Rome Italy, 2Internal Medicine School, University La Sapienza Rome Italy, 3Medical Oncology, Fondazione Policlinico Campus Bio-Medico Rome Italy, 4Radiation Oncology, Fondazione Policlinico Campus Bio-Medico Rome Italy, 5Internal Medicine, University Campus Bio-Medico Rome Italy, 6Internal Medicine School, University Campus Bio-Medico Rome Italy

BACKGROUND AND AIM: Liver fibrosis could impact the response to oncological therapies and it correlates with the stiffness of the parenchyma. Aim of our study was to explore the role of point shear wave elastosonography (pSWE) in predicting the response to local treatments for hepatocellular carcinoma (HCC) or liver metastases (METs).

MATERIAL AND METHODS: A prospective single-center study was conducted. We included all patients with HCC or METs treated by percutaneous ablation, transarterial chemo-embolization, and external radiotherapy between September 2022 and March 2023. pSWE measurements were performed at the enrollment on the liver free from nodules, and on the targeted nodules. Results were expressed in m/sec. Patients were then followed at three and six months by computed tomography or magnetic resonance imaging, evaluated by a radiologist blind to elastosonographic data.

RESULTS: 43 patients were enrolled: 22 HCCs, and 21 liver METs of different etiologies. Among the 22 HCC patients, 19 patients (86.4%) suffered of liver cirrhosis. As expected, liver stiffness in cirrhotic patients was significantly higher than in non-cirrhotic patients (2.19 m/s [IQR 0.81] vs. 1.28 m/s [IQR 0.71], \(p<0.0001\)). ARFI of the liver was sensitive and specific in predicting response to treatments at the six months follow-up, identifying a cut-off of 1.58 m/s associated with a lack of therapeutic response (AUC 0.73; 95% CI 0.54 – 0.92; \(p=0.033\)).

CONCLUSION: Our study is a “proof of concept” about the role of pSWE, in the assessment of response to loco-regional treatments in case of malignant liver nodules.
Abstract Submission No. 200260

Identification of CT values that could be predictive of necrosis in HCC after lenvatinib treatment

Makoto Chuma1, Hideki Yokoo2, Hidenori Toyoda3, Atsushi Hiraoka4, Haruki Uojima5, Satoshi Kobayashi2, Nobuhiro Hattori1, Masanori Atsukawa2, Kunihiro Tsuji2, Toshifumi Tada3, Hisashi Hidakac, Manabu Morimoto4, Kazushi Numata5, Tatehiro Kagawa2, Takashi Kumada3

1Gastroenterological Center, Yokohama City University Medical Center Yokohama Japan, 2Division of Hepato-Biliary-Pancreatic Surgery, Ashahikawa Medical University Ashahikawa Japan, 3Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital Ogaki Japan, 4Gastroenterological Center, Ehime Prefectural Central Hospital Matsuyama Japan, 5Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine Sagamihara Japan, 6Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital Yokohama Japan, 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine Kawasaki Japan, 8Division of Gastroenterology and Hepatology, Nippon Medical School Tokyo Japan, 9Center of Gastroenterology, Teine Keijinkai Hospital Sapporo Japan, 10Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine Isehara Japan

Purpose: To assess the utility of measurement of the computed tomography (CT) attenuation value (CTav) in predicting tumor necrosis in hepatocellular carcinoma (HCC) patients who achieve a complete response (CR), defined using modified Response Evaluation Criteria in Solid Tumors (mRECIST), after lenvatinib treatment.

Method: We compared CTav in arterial phase CT images with post- operative histopathology in four patients who underwent HCC resection after lenvatinib treatment, to determine CTav thresholds indicative of histological necrosis (N-CTav). Next, we confirmed the accuracy of the determined N-CTav in 15 cases with histopathologically proven necrosis in surgical specimens. Furthermore, the percentage of the tumor with N-CTav, i.e. the N-CTav occupancy rate, assessed using Image J software in 30 tumors in 12 patients with CR out of 571 HCC patients treated with lenvatinib, and its correlation with local recurrence following CR were examined.

Results: Receiver operating characteristic (ROC) curve analysis revealed an optimal cut-off value of CTav of 30.2 HU, with 90.0% specificity and 65.0% sensitivity in discriminating between pathologically identified necrosis and degeneration, with a CTav of less than 30.2 HU indicating necrosis after lenvatinib treatment (N30-CTav). Furthermore, the optimal cut-off value of 30.6% for the N30-CTav occupancy rate by ROC analysis was a significant indicator of local recurrence following CR with 76.9% specificity and sensitivity (area under the ROC curve; 0.939), with the CR group with high N30-CTav occupancy (>30.6%) after lenvatinib treatment showing significantly lower local recurrence (8.3% at 1 year) compared with the low (<30.6%) N30-CTav group (P=0.001, 61.5% at 1 year).

Conclusion: The cut-off value of 30.2 HU for CTav (N30-CTav) might be appropriate for identifying post-lenvatinib necrosis in HCC, and an N30-CTav occupancy rate of >30.6% might be a predictor of maintenance of CR. Use of these indicators have the potential to impact systemic chemotherapy for HCC.

Abstract Submission No. 100053

P-0612

Correlation between LSM, but not CAP on Fibroscan with mortality- a NHANES database study

Yuting Huang1, Yichen Wang2, Liu Yang2

1Division of Gastroenterology & Hepatology, Mayo Clinic in Florida Jacksonville United States, 2Perelman School of Medicine, University of Pennsylvania Philadelphia United States, 3Department of Transplant, Mayo Clinic in Florida Jacksonville United States

Background: Vibration-controlled transient elastography is a noninvasive diagnostic ultrasound-based device gaining popularity in measuring liver stiffness and fibrosis. It has been reported both controlled attenuation parameter (CAP), indicating steatosis, and liver stiffness measurement (LSM), indicating fibrosis, independently correlated with overall mortality over three-year follow-up.

Method: We accessed NHANES database and performed population selection. Univariate Cox proportional hazard model was used to calculate hazard ratio (HR) for all-cause death in CAP and LSM. Cox regression of CAP and LSM was performed with supplementing overlay of P values as Z-axis.
Results: After excluding 2853 patients, 3821 patients were included. Univariate Cox proportional hazard model showed a nonsignificant HR for all-cause death in CAP (every 10 dB/m) of 1.03 (95% CI 0.98-1.08, P=0.264). The results did not change when adjusted for interaction term with LSM with HR of 1.01 (95% CI 0.96-1.06, P=0.662). For LSM (every 1 kPa), univariate analysis showed an HR of 1.04 (95% CI 1.02-1.06, P<0.001), which adjusted to 1.01 (95% CI 0.93-1.09, P=0.856) after accounting for the interaction term.

Figure showed Cox regression of CAP and LSM, the P value markedly lost statistical significance with an increase in CAP, though not LSM. This suggests a more robust association of LSM with mortality, echoing the established concept that fibrosis is a more potent predictor of mortality than steatosis.2-4

Conclusion: There is a robust correlation between fibrosis and mortality, but not steatosis, different from the recent article. Further research is needed on this topic with larger samples in independent cohorts.

Abstract Submission No. 100148
P-0613

Gadoxetate disodium-enhanced MRI for HCC: Value of late portal venous phase for enhancing capsule
Seung Soo Kim1
1Department of Radiology, Soonchunhyang University College of Medicine, Cheonan Hospital, Cheonan-si, Korea Cheonan-si South Korea

Purpose: To investigate added value of late portal venous phase (LPVP) for identification of enhancing capsule (EC) on gadoxetate disodium-enhanced MRI (GD-MRI) for diagnosing hepatocellular carcinoma (HCC) in patients with chronic liver disease (CLD).

Methods: This retrospective study comprised 116 high-risk patients with 128 pathologically proven HCCs who underwent GD-MRI including arterial phase, conventional portal venous phase(CPVP, 60 s), LPVP(mean, 104.4 ± 6.7 s; range, 90–119 s), and transitional phase(TP, 3 min). Two independent radiologists assessed the presence or absence of major HCC features, including EC on CPVP and/or TP(CPVP/TP) and EC on LPVP. Frequency of EC was compared on GD-MRI between with and without inclusion of LPVP. The radiologists assigned Liver Imaging Reporting and Data System(LI-RADS)v2018 categories on GD-MRI before and after identifying EC on LPVP.

Results: Of 128 HCCs, seven (5.5%) revealed EC on LPVP but not on CPVP or TP(CPVP/TP) and EC on LPVP. Frequency of EC was compared on GD-MRI between with and without inclusion of LPVP. The radiologists assigned Liver Imaging Reporting and Data System(LI-RADS)v2018 categories on GD-MRI before and after identifying EC on LPVP.

Conclusion: There is a robust correlation between fibrosis and mortality, but not steatosis, different from the recent article. Further research is needed on this topic with larger samples in independent cohorts.

Abstract Submission No. 100202
P-0614

Hepatic steatosis assessment through 3D organ segmentation from virtual noncontrast dual-energy CT
Sun Kyung Jeon1, Ijin Jo1, Junghoon Park1, Jeongin Yoo1

1Seoul National University Hospital Seoul South Korea

Purpose: To evaluate the efficacy of volumetric CT attenuation parameters derived from automated 3D organ segmentation on virtual non-contrast (VNC) images from dual-energy CT (DECT) in the assessment of hepatic steatosis, using MRI proton density fat fraction (MRI-PDFF) as the reference standard.

Methods: This retrospective study included 252 living liver donor candidates who had undergone preoperative liver DECT scans and MRI-PDFF assessments. A deep learning-based 3D organ segmentation algorithm was used to automatically segment the liver and spleen from VNC images obtained through contrast-enhanced DECT. Mean volumetric CT attenuation values of each segmented liver (L) and spleen (S) were then measured, allowing for the calculation of liver attenuation index (LAI), defined as L minus S. Correlation between VNC parameters for hepatic steatosis (LVNC and LAIVNC) and MRI-PDFF values was assessed using Pearson correlation coefficient. Assessments of VNC and true non-contrast (TNC) parameters were assessed using intraclass correlation coefficients (ICC). Performance of VNC parameters for identifying MRI-PDFF ≥5% and ≥10% were evaluated using receiver operating characteristic (ROC) curve analysis.

Results: Both LVNC and LAIVNC showed significant correlations with MRI-PDFF values (r=0.585 and 0.588, P<0.001) and excellent agreements with LVNC and LAIVNC (ICC=0.957 and 0.968), respectively. LVNC and LAIVNC exhibited similar areas under the ROC curve (AUCs) of 0.795 and 0.806 for MRI-PDFF ≥5%; and 0.916 and 0.932, for MRI-PDFF ≥10%, respectively.

Conclusion: CT attenuation parameters from DECT-derived VNC images, automatically measured through 3D organ segmentation, can be useful for opportunistic hepatic steatosis screening without the need for additional TNC imaging.

Abstract Submission No. 100263
P-0615

Correlation of R2 from multiecho MRS and R2* from MRI-PDFF for measuring hepatic iron deposition
JOON-IL CHOI1, Hokun Kim1, Bohyun Kim1
1Seoul St.Mary’s Hospital, The Catholic University of Korea Seoul South Korea

Purpose: R2 and R2* are two MRI parameters that can assess hepatic iron concentration. The relationship between the R2* obtained from multiecho PDFF and HIC is relatively well evaluated. However, the threshold of R2 obtained by multiecho MRS is not well known. The aim of this study is to compare and correlate R2 with R2* in liver transplant donor candidates and recipients who have already undergone transplantation.

Methods: 175 participants, comprising 115 potential donors and 60 recipients, underwent multiecho MRS and MRI-PDFF for hepatic fat signal fraction evaluation using three 3T MRIs. To correct hepatic iron deposition, R2 values in multiecho MRS and R2* values for PDFF were calculated. In each participant, two distinct R2* values were derived: 1) from a segmented liver volume auto-segmented by software (R2*-seg), and 2) from an ROI equivalent to MRS (R2*-ROI). We correlated R2 and R2* values using simple correlation analysis. Also, we calculated mean values and standard deviation of R2 and R2* values.

Results: Mean R2, R2*-seg, R2*-ROI were 38.0±5.2 (16.7-50.8), 55.3±13.7 (6.2-95.4), and 44.1±15.1 (15.1-125.2), respectively. Correlation coefficients were 0.5676 between R2 and R2*-seg, 0.5724 between R2 and R2*-ROI, and 0.6076 between R2*-seg and R2*-ROI. Between R2 and R2* values, correlation graph shows curved shape correlation.

Conclusion: R2 measured by Multiecho MRS and R2* measured by PDFF were positively correlated. As R2* values, which has already
proven useful, R2 values measured by multiecho MRS has the potential to be used to diagnose hepatic iron storage disease.

Abstract Submission No. 100568
P-0616

PREDICTORS OF AT-RISK LIVER STIFFNESS IN THE POINT-OF-CARE COMMUNITY LIVER SCREENING PROGRAM SIRIUS

Tomas Koller1, Svetlana Adamcova Selcanova2, Daniel Jan Havaj2, Natalia Kubaneck2, Jana V necakov2, Karolina Kristina Sulejova2, Marek Rae1, Martin Janicko2, Sylvia Drazilova2, Lukas Lafers3, Lubomir Skladany2, Daniela Zilincanova2, Maria Szantova1

1Comenius University Faculty of Medicine, University Hospital in Bratislava Bratislava Slovakia, 2HEGITO unit, FD Roosevelt Faculty Hospital Banska Bystrica Banska Bystrica Slovakia, 3Rossiik University Faculty of Medicine, Luis Pasteur University Hospital Kosice Kosice Slovakia, 4Faculty Hospital Nitra Nitra Slovakia, 5Faculty of Natural Sciences, Matej Bel University Banska Bystrica Slovakia

Background: Liver fibrosis is the critical driver of increased mortality in chronic liver disease (ACLD). Screening programs are promising tools for the identification of cases with asymptomatic ACLD with liver stiffness (LS) as its established surrogate.

Methods: The SIRIUS project is a liver screening program. From 08/2022-06/2023 we visited 25 communities offering liver examination including medical history, AUDIT-C, anthropometrics, liver stiffness (Fibroscan, Echosense), and point-of-care laboratory parameters (POCLP). Baveno VII-derived cut-offs of LS were used: >10 kPa as moderate-risk and >15 kPa as advanced-risk. Independent predictors of at-risk stiffness were identified in the logistic regression with P<0.05 and AUROC.

Results: 2314 individuals were examined, 2164 having complete data, 1664 (76.9%) a valid POCLP (Labs group), M/F 39/61%, median age 54y, BMI 27, 16.9% of smokers, history of liver disease, arterial hypertension, diabetes, and cancer in 8.0, 34.2, 6.9, and 5.6%, at-risk alcohol consumption in 14.9%, the LS >8, >10, and >15 kPa in 12.2, 5.9, and 5.6%. The accuracy of predicting at-risk stiffness were identified in the logistic regression with P<0.05 and AUROC.

Conclusion: The SIRIUS project identified individuals with moderate or advanced-risk stiffness in 5.9% and 1.8%. The accuracy of predictive models was good regardless of valid POCLP. This evidence serves to develop a comprehensive national liver screening program.

Abstract Submission No. 100813
P-0617

Identification of liver malignant nodules using DCE-US combined with LR-M classification criteria

Jianmin Ding1, Shibo Qiu1, Xiang Jing1

1Tianjin Third Central Hospital Tianjin China

Objective: Explore the diagnostic value of DCE-US quantitative parameters for liver malignant nodules with high-risk factors for HCC, and combine them with LR-M to differentiate between HCC and non-HCC malignant nodules.

Method: According to the pathological results, the nodules were divided into HCC and non-HCC malignant group, and each nodule was classified by CEUS LI-RADS 2017. Using VueBox® Quantitative analysis software performs CEUS quantitative analysis for each nodule, compares the differences in quantitative parameters between HCC and non-HCC malignant nodules.

Result: Among 186 patients with 190 liver malignant nodules, there are 137 HCC and 53 non-HCC malignant nodules. The median values of quantitative parameters RT, TTP, mTTI, and FT in the non-HCC malignant group were lower than those in the HCC group, with P<0.05. There was a statistically significant difference in WiAUC, WoAUC, WiWoAUC, and WoR values between HCC and non-HCC malignant groups, with P<0.05. Washout within 60s and FT<21.15s is the new diagnostic standard of LR-M, and the sensitivity, specificity, and positive predictive value of LR-5 for HCC are 83.94%, 96.23%, and 98.29%, respectively.

Conclusion: DCE-US can help to distinguish between HCC and non-HCC malignant nodules. The diagnostic standard of washout within 60s and quantitative parameter FT ≤21.15s can significantly improve the diagnostic sensitivity of LR-5 for HCC.

Abstract Submission No. 101118
P-0618

Gadolinium loaded-chitosan Nanoparticles for Contrast Enhanced MRI Diagnosis of Liver Disease

Wei Wang1

1Peking University People's Hospital, Peking University Hepatology Institute Beijing China

Background: Precisely diagnosing the liver fibrosis by a non-invasive way still suffers big challenges. Magnetic resonance-based methods have multiple advantages on diagnosing liver fibrosis. The purpose of this study is to develop gadolinium loaded-chitosan nanoparticles (Gd-CSNPs) as MRI contrast agent to diagnose liver fibrosis in vivo.

Methods: The Gd-CSNPs were prepared by the method of cross linking, which followed by the modification of surface with DTPA by NHS-EDC. The physical characterizations of Gd-CSNPs were obtained by TEM, dynamic light scattering instrument and XPS analysis. The cell toxicity of Gd-CSNPs was evaluated on mouse melanoma A375 cells. Liver fibrosis mice models were constructed via intraperitoneal injecting 10 % CCl4 twice a week for 12 weeks. T1 signals of MRI by using Gd-CSNPs were measured in vitro and in vivo at different concentrations and time intervals.

Results: Gd-CSNPs were synthesized by chitosan and TPP at a mass ratio of 5:1, with the size of about 10nm. XPS analysis confirmed the presence of element Gd in Gd-CSNPs. Compared with FDA-approved magnevist, Gd-CSNPs showed no cytotoxicity in vitro. T1 relaxivity of Gd-CSNPs was significantly stronger than that of magnevist in vitro and vivo. The T1 signal of Gd-CSNPs was the strongest an hour after injection in mice and it could remain stable for at least 3 hours.

Conclusion: Gd-CSNPs show stronger and more stable MRI signals in liver than that of Magnevist and may be used as a contrast agent in MRI for diagnosis of liver fibrosis via a non-invasion means.
The usefulness of hepatic fibrosis markers for hepatocarcinogenesis in patients with MASLD/MASH

Takashi Nishimura1, 2, Hiroki Iijima1, 2, Mamiko Okamoto1, Shoki Kawata1, Ryota Yoshioka1, Kohei Yoshihara1, Yuta Kawase1, Yukihisa Yuri1, Ryota Nakano1, Tomoyuki Takashima1, Nobuhiro Izawa1, Naoto Ikeda1, Shinnya Fukunishi1, Hideyuki Shiom1, Hirayuki Enomoto1

1Department of Gastroenterology, Hyogo Medical University Nishinomiya Japan, 2Ultrasound Imaging Center, Hyogo Medical University Hospital Nishinomiya Japan

Background And Aims: Several non-invasive fibrosis markers for the degree of hepatic fibrosis in patients with chronic hepatitis have been reported. The hepatic fibrosis is correlated with hepatocarcinogenesis, therefore, these non-invasive markers are useful for the prediction of hepatocarcinogenesis. However, which non-invasive markers have been the most useful marker is controversial. The aim of this study was to clarify the diagnostic ability for the prediction of hepatocarcinogenesis using Fib-4 index, Fib-3 index and Vibration-controlled Transient Elastography (VCTE).

Methods: The 728 MASLD/MASH consecutive patients from October 2014 to June 2022 who underwent VCTE and blood examination were included in this retrospective cohort study. The males were 335 (46.0%), the median age was 56 years old. The patients within six months at least in observation periods were excluded.

Results: 14 out of 714 patients with MASLD/MASH (2.0%) have been developed hepatocellular carcinoma (HCC). The cumulative hepatocarcinogenesis rate were 1.0, 1.7, 2.0% in 1, 3, 5 years, respectively. Hazard ratio (HR) for hepatocarcinogenesis with cut off value of 1.30 and 2.67 in Fib-4 index were 7.13 (95%CI; 1.59-31.86) (p=0.010) and 15.85 (95%CI; 4.82-51.08) (p<0.001), respectively. C-index with cut off value of 1.30 and 2.67 in Fib-4 index were 0.685 and 0.752. Hazard ratio (HR) for hepatocarcinogenesis with cut off value of 1.57 and 3.50 in Fib-3 index were 0.966. While no findings demonstrated a correlation with fibrosis stage, some exhibited a trend towards correlation. Area (p=0.056), MinFeret (p=0.068), and Minor (p=0.060) each displayed a particularly low score at F4.

Conclusion: Several non-invasive fibrosis markers for the degree of hepatic fibrosis in patients with chronic hepatitis have been reported. The hepatic fibrosis is correlated with hepatocarcinogenesis, therefore, these non-invasive markers are useful for the prediction of hepatocarcinogenesis. However, which non-invasive markers have been the most useful marker is controversial. The aim of this study was to clarify the diagnostic ability for the prediction of hepatocarcinogenesis using Fib-4 index, Fib-3 index and Vibration-controlled Transient Elastography (VCTE).
Spleen Stiffness Measurement using New Spleen-Dedicated Fibroscan: Intra/Interobserver Repeatability

Sumin Park1, Ji-hwan Kang1, Heon-Ju Kwon1, Mi sung Kim1, Won Sohn2
1Department of Radiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine Seoul South Korea, 2Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine Seoul South Korea

Background: Bleeding from esophageal varix is one of the most life-threatening complications of portal hypertension, which is a major consequence of liver cirrhosis. The spleen stiffness measurement (SSM) by standard Fibroscan® (SSM@50Hz) has been evaluated as the non-invasive diagnostic tool for esophageal varix. Recently, the SSM using a novel spleen-dedicated Fibroscan® (SSM@100Hz) has been developed and found to have a better accuracy than SSM@50Hz. The aim of this research was to evaluate the intra- and interobserver repeatability of SSM@100Hz.

Methods: Eighty-four patients with chronic liver disease were randomly allocated to group 1 (for evaluation of intraobserver repeatability) or group 2 (for evaluation of interobserver repeatability), respectively. In group 1, both of two sessions of SSM@100Hz were performed by one radiologist. In group 2, the first session of SSM@100Hz was performed by one radiologist and the second session of SSM@100Hz was performed by another radiologist without the information about the result of the first session.

Results: Overall success rate of SSM@100Hz was 94% (79/84). Median SSM of total patients was 16.7 kPa (interquartile range [IQR] 13.2 - 19.9kPa) with 17.4 kPa (IQR 13.3 - 20.3kPa) in group 1 and 16.2 kPa (IQR 13.0 - 19.9kPa) in group 2, respectively. The intraobserver repeatability in group 1 revealed a high intra-class correlation coefficient (ICC) (0.977, 95% confidence interval [CI]: 0.955, 0.988) and, in group 2, interobserver repeatability also showed a high ICC (0.958, 95% CI: 0.919, 0.978).

Conclusions: SSM@100Hz is a feasible and highly reproducible tool in patients with chronic liver disease.

SPECT Identifies Compensated Cirrhotics with Higher Accuracy than Blood Tests

Dipu Ghosh1,4, John C Hoefs1,2,3
1Hepatic, Inc. Irvine, CA United States, 2University of California Irvine, CA USA, 3The Liver Specialty Center Irvine, CA USA, 4Syprosoft Inc. Irvine, CA USA

Background: Chronic liver disease is staged into fibrosis categories F0 to F4. Due to the liver’s ability to compensate some F4 patients may live for years. Others may decompensate and need a transplant. Decompensation is detected by abnormal blood tests or clinical manifestations. Some institutions use quantitative liver function deterioration for an early indication of decompensation.

SPECT imaging provides quantitative liver function (PHM), steatosis, portal hypertension and alcoholic hepatitis. Hoefs Physiologic Stage captures these disease processes into six categories H0 to H5. We hypothesized that cirrhotic patients who have PHM≥75 are likely compensated cirrhotics.

Methods: Hypothesis was tested with 46 sequential cirrhotic patients, confirmed using liver biopsies, shear wave velocity, and nodular liver surface. Patients were grouped into: CC - Compensated Cirrhotics (N=33) and DC - Decompensated Cirrhotics (N=13).

Results: Of 35 patients with PHM≥75, 31 were in Group CC and 4 in Group DC. Of 11 patients with PHM<75, 9 were in Group DC and 2 in Group CC. Ability of PHM to predict compensated cirrhosis were: PPV =89%, NPV = 82%, Sensitivity = 94% and Specificity = 69%.

Blood tests were compared to PHM. PHM was best with Accuracy 87%, followed by Albumin 83%, Bilirubin 76%, and INR 74%.

Conclusions:
1. PHM identified compensated cirrhotics with a high PPV and NPV.
2. PHM was more accurate than blood tests and may be more reliable in setting monitoring intervals.
3. H3 patients may be monitored less often than H4 patients thus reducing healthcare costs.

Usefulness of shear wave elastography for evaluation of HCC recurrence after ablation

Hironori Tanaka1, Tetsu Tomonari1, Ryo Shinomiya1, Mai Yonezawa1, Yutaka Kawano1, Tetsuji Takayama1
1Department of Gastroenterology and Oncology Tokushima Japan

Background: Although shear wave elastography (SWE) is useful method for liver fibrosis assessment, its usefulness in the recurrence risk evaluation of hepatocellular carcinoma (HCC) is unknown. Therefore, we evaluated the usefulness of SWE in risk assessment of the HCC recurrence after ablation therapy.

Methods: We retrospectively analyzed the relationship between HCC recurrence and liver stiffness(LS) in 43 HCC patients who underwent ablation therapy. The average age 69 years, M/F 34/9, background liver disease is HCV/HBV/NASH/alcohol/others 16/2/9/12/3, tumor diameter is 2.2 cm. The shear wave propagation velocity (Vs) was measured in the right lobe of liver. The diagnostic accuracy was evaluated by ROC curve analysis. The recurrence-free survival (RFS) was evaluated by the Kaplan-Meier method.

Results: The Vs value was 2.11±0.79/2.65±0.95 m/sec in the non-recurrence group/recurrence group (p < 0.05). In the evaluation of HCC recurrence, when the cut-off value of Vs was 1.81, the sensitivity was 0.88, the specificity was 0.57, and the area under the ROC curve was 0.724. The RFS of low Vs group was significantly longer than that of high Vs group (p = 0.002).

Conclusions: LS measured by SWE is useful for assessment of HCC recurrence risk after ablation therapy.

A novel multimodal model for analyzing the intratumor heterogeneity in hepatocellular carcinoma

Yangyang Xie1, Junhao Zheng1, Liye Tao1, Zefeng Shen1, Xiaoliang1
1Sir Run-Run Shaw Hospital affiliated to Zhejiang University School of Medicine Hangzhou China

The impact of intratumor heterogeneity (ITH) on clinical outcomes and treatment responses is substantial, especially in hepatocellular carcinoma (HCC), which is considered to present high ITH. However, the accuracy of widely used techniques for assessing ITH, which relies on
small tissue samples from pathological slides or genetic sequencing, may be compromised by potential sampling biases. Such invasive procedures may also cause unexpected damage to patients. To address this, we have developed a novel radiomics approach, which can non-invasive analyze the whole of the tumor, using a radio-multiomic dataset of HCC in Sir Run Run Shaw Hospital (n = 368). This dataset encompasses radiomic features obtained from dynamic multi-parameter magnetic resonance imaging. Our findings in HCC demonstrate a correlation between imaging ITH (ITH) and both pathological and genetic ITH, each independently associated with an unfavorable prognosis. Furthermore, our multiomic analysis reveals that high-ITH tumors exhibit active carcinogenic pathways and metabolic reprogramming. Collectively, these studies underscore the superiority of radiomics in capturing ITH and provide insights into the molecular foundations of ITH, along with proposing treatment strategies for HCC with high ITH.

Abstract Submission No. 101795
P-0626

Erythropoietic protoporphyria with characteristic MRI findings during exacerbation of liver injury
Yukino Sinazawa1, Hajime Sunagozaka1, Satomi Kishi1, Katsunori Komyo1, Takafumi Nakagawa1, Kohei Yasuda1, Hiroyuki Aoyagi1

1Fukui Prefectural Hospital Fukui Japan

Introduction: Erythropoietic protoporphyria (EPP) is an autosomal overt inherited disorder caused by a decrease in the activity of ferrochelatase (FECH), an enzyme that catalyzes the insertion of iron into protoporphyrin IX. EPP usually consists of skin lesions and has a good prognosis, However, we report a case of EPP with acute liver damage and characteristic imaging findings on EOB-MRI.

Case: A 34-year-old man had been diagnosed with myeloid protoporphyria from birth. The patients was referred to our hospital for upper abdominal pain. Severe liver injury and jaundice were observed with markedly high levels of protoporphyrin in blood and stool. Gd-EOBDTPA-Enhanced Magnetic Resonance Imaging (EOB-MRI) revealed no noticeable deformation in the liver, and the hepatic parenchymal contrast effect was unevenly attenuated. Even 60 minutes after EOB administration, the uptake of EOB into the liver parenchyma remained attenuated. In Liver Histopathological findings, the lobular structure of the liver was generally preserved, but many brownish porphyrin crystals with red auto-luminescence were observed in hepatocytes and sinusoids. He improved with conservative treatment with ursodeoxycholic acid. After the improvement of symptoms, the deposition of porphyrin crystals in the liver tissue and the MRI findings also improved.

Conclusion: There are no case reports of attenuation of the signal enhancement effect of EOB-MRI during hepatic injury exacerbation in patients with EPP, and the EOB MRI may be useful for evaluating disease status.

A case of liver cyst rupture that was mistaken for liver metastasis
Ryan Neo Yee Shien1,2, Sheru Sambhnan1,2, Shihleone Loong1, Daniel Lim Yan Zheng1,2, Miao Shan Lim2

1Gastroenterological Center, Yokohama City University medical center yokohama Japan, 2Department of gastroenterology, Yokohama City University Graduate School of Medicine Yokohama Japan,

Abstract Submission No. 101954
P-0627

Enhancing Deep-seated Hepatocellular Carcinoma Detection in contrast enhanced ultrasound
Akiko Funoaka1, Ying Zhang1,2,3, Kazushi Numata1, Hiromi Nihonmatsu1, Akiito Nozaki1, Shin Maeda2

1Gastroenterological Center, Yokohama City University medical center yokohama Japan, 2Department of gastroenterology, Yokohama City University Graduate School of Medicine Yokohama Japan, 3Department of Medical Ultrasound, Ningbo Medical Center Lihuili Hospital. Ningbo City China

Background: Sonazoid contrast-enhanced ultrasound (CEUS) is effective for detection of liver lesion like hepatocellular carcinoma (HCC). However, detecting deep-seated HCCs poses significant challenges due to acoustic attenuation occurring in the far field of ultrasound. Accordingly, this study aimed to explore the role of the mechanical index (MI) setting in enhancing the detection of deep-seated HCCs and develop an innovative methodology for the utilization of MI.

Methods: 682 successive patients with 805 pathologically or radiologically confirmed hypervascularity HCC lesions larger than 10mm were included. All the patients underwent B-mode ultrasound and CEUS examinations with both low and high MI settings of post-vascular phase (PVP). Propensity score matching (PSM) and logistic regression were employed to address confounding 10 variables. The univariate and multivariate analyses were conducted for statistical assessment.

Results: For the overall population, the depth, echogenicity, and size of the lesions were identified to be independent indicators for enhanced detection through the additional high MI setting (odds ratio, OR: 1.495, 95% confidence interval, CI: 1.345-1.661, OR: 4.708, 95% CI: 2.779-7.974, and OR: 0.965, 95% CI: 0.940-0.990, respectively). After accounting for the effects of confounding variables by PSM,
lesions that were undetected under the low MI setting but became detectable under the additional high MI setting during PVP exhibited significantly greater depth compared to lesions that did not benefit from the additional high MI setting (8.39±2.46 cm vs. 6.42±2.54 cm, p<0.001).

**Conclusion:** For hypervascularity HCCs larger than 10 mm, the additional high MI setting during PVP improved the detection of deep-seated lesions.

---

Using SWE to differentiate fibrotic stenosis from inflammatory stenosis in Crohn's disease

Shihui Li1, Yujun Chen1, Manying Li1, Ren Mao1, Xiaoyan Xie1

1The Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-Sen University GuangZhou China

**Abstract**

**Objective:** To assess the feasibility of utilizing shear-wave elastography to distinguish between fibrotic strictures and inflammatory strictures in patients with Crohn’s disease.

**Methods:** Retrospectively analyze patients who have progressed to stricturing Crohn’s disease and have underwent SWE in a close period of time. The materials, including computed tomography enterography or magnetic resonance enterography-based radiological materials, endoscopic appearance, histopathologies of endoscopic biopsy and treatment responses, are synthesized to establish a novelly comprehensive score, namely fibrotic score which divides patients into two separate groups—the inflammatorily primary group and the fibrotically primary group. The SWE value of the stenotic bowel walls is compared.

**Result:** Sixty patients are enrolled, of which forty-three are divided into inflammatorily primary group and seventeen into fibrotically primary group. The mean SWE value of stenotic bowel walls in the fibrotically primary group (24.1±12kPa) is significantly higher than that in the inflammatorily primary group (12.5±6.0 kPa). According to the maximum Youden index, 15.9kPa as the cut-off to differentiate fibrotic lesions from inflammatory lesions is determined. The corresponding sensitivity is 82.4% (95%CI 0.558 to 0.953) and specificity is 79.1% (95%CI 0.635 to 0.894) while the area under the receiver operating characteristic curve is 0.85 (95%CI 0.740 to 0.952, P=0.001).

**Conclusion:** Shear-wave elastography is feasible in detecting fibrotic bowel walls in patients with stricturing Crohn’s disease and is helpful for their clinical strategies being made.

---

Comparing Thermal & Non-Thermal Ablation with Immune Checkpoints for Enhanced Tumor Immune Response

Ryoko Soya1, Katsutoshi Sugimoto1, Koji Nagaoka2, Yoshitaka Kiya1, Akihiko Tsuchida1, Takao Itoi1, Kazuhiro Kakimi1

1Department of Gastroenterology and Hepatology, Tokyo Medical University Tokyo Japan, 2Department of immunotherapeutics, The University of Tokyo Hospital Tokyo Japan, 3Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University Tokyo Japan, 4Makino Memorial Hospital Yokohama Japan, 5Department of immunology, Kindai University Faculty of Medicine Osaka Japan

**Background and Objective:** The combination of ablation therapies and immune checkpoint inhibitors (ICIs) potentiates tumor immunity and anti-tumor effects, producing a heightened abscopal effect. The object was to compare the therapeutic impacts of ICIs combined with two distinct ablation treatments: radiofrequency ablation (RFA) and irreversible electroporation (IRE).

**Methods:** Two groups—treatment and control—were inoculated with Hep55.1c cells on the intracutaneous right flank on Day 0. The treatment group underwent either RFA or IRE on Day 7, exhibiting no tumor recurrence by Day 35. Subsequently, both groups were rechallenged with cell injections on their left flank. The groups were further subdivided based on the administration of an anti-CD8 antibody or its absence.

2. Mice received Hep55.1c cell injections in the right flank on Day 0 (primary lesion) and left flank on Day 6 (metastatic nest). Four groups were formed: control, ICI, ablation (RFA or IRE), and combination therapy (ICI with RFA or IRE). Primary lesion received ablation on Day 7, and treatment effects were evaluated.

**Results:** (1) Mice treated with ablation therapy (RFA or IRE) displayed resistance to tumor engraftment. Conversely, in mice administered the anti-CD8 antibody, tumor recurrence and growth were observed. (2) ICI and ablation therapy slowed metastatic tumor growth.
significantly versus ablation alone. RFA tended to outperform IRE in tumor suppression.

**Conclusion:** While ablation therapy alone evoked an immunostimulatory effect, the addition of ICIs further curtailed tumor growth. In conclusion, the combination of ablation therapy and ICIs produced a synergistic effect and holds potential clinical value.

---

**Impact of conversion surgery in patients with advanced intrahepatic cholangiocarcinoma**

Tsuyoshi Takeda1, Tatsuki Hirai1, Takahiro Ishitsuka1, Manabu Yamada1, Hiroki Nakagawa1, Takafumi Mie1, Takaaki Furukawa1, Takeshi Okamoto1, Akiyoshi Kasuga1, Takashi Sasaki1, Masato Ozaka1, Naoki Sasahira1

1Cancer Institute Hospital of Japanese Foundation for Cancer Research Tokyo Japan

**Background:** The impact of conversion surgery (CS) has not been well studied in patients with advanced intrahepatic cholangiocarcinoma (ICC). This study aimed to evaluate outcomes of patients who received CS and those who did not.

**Methods:** We retrospectively reviewed patients with unresectable or recurrent ICC who were treated at our institution between January 2015 and December 2022. Baseline characteristics and outcomes were compared between patients who received CS and those who did not. Cox proportional hazards model was used to identify prognostic factors for survival.

**Results:** Among 91 patients (locally advanced/metastatic/recurrent 10/60/21), nine patients (locally advanced/metastatic/recurrent 2/4/3) underwent CS after chemotherapy. There were no significant differences in baseline characteristics between the two groups. Objective response to chemotherapy was more frequently observed in the CS group (78% vs. 17%, P < 0.001). Median time to surgery and median relapse-free survival were 6.1 months and 13.7 months, respectively, in the CS group. Median overall survival was significantly longer in the CS group (50.0 vs. 13.5 months, P < 0.001). Age < 75 years, performance status of 0, modified Glasgow prognostic score of 0, carcinoembryonic antigen < 10 ng/mL were identified as significant prognostic factors for survival and every patient who underwent CS met three or four of these prognostic factors.

**Conclusions:** CS was performed in 9.9% of patients with unresectable or recurrent ICC. CS in highly selected patients was associated with a long median overall survival.

---

**A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathologic and imaging features**

Subin Heo1, So Yeon Kim1

1Asan Medical Center Seoul South Korea

**Background:** Clinicopathologic and imaging features of hepatocellular adenomas (HCA) in Eastern countries have not been well evaluated.

**Purpose:** To conduct a comprehensive analysis of clinicopathologic and imaging features of HCAs in Korea and to present an imaging-based method to differentiate β-catenin mutated HCA (βHCA) from other subtypes.

**Methods:** This retrospective multicenter study included pathologically confirmed HCAs from three tertiary institutions in Korea between January 2010 and March 2023. HCA subtypes were classified using the current WHO classification through pathologic analysis including complete immunohistochemical staining panels. Two abdominal radiologists reviewed multiphase CT and gadoxetic acid-enhanced MRI images. Clinical characteristics and imaging features of HCA subtypes were compared. A scoring system for βHCA was developed and validated using subdivided cohorts: development (January 2010-April 2021) and validation (May 2021-March 2023) cohorts.

**Results:** 121 patients (47 men; mean age, 39.0 years ± 13.5) with 138 HCAs were included in the study. HCAs in Korea displayed characteristic clinicopathologic features, including a high proportion of male (38.8%), obesity (35.5%), inflammatory subtype as the most common subtype (38.4%), and a low percentage of oral contraceptive use (5.0%). Each HCA subtype demonstrated distinct clinical and imaging features. The scoring system for differentiating βHCA exhibited high performance in both the development cohort (AUC 0.92, 95% CI: 0.87-0.97) and the validation cohort (AUC 0.91, 95% CI: 0.77-1.00).

**Conclusion:** The comprehensive analysis of clinicopathologic and imaging features of HCAs in Korea can add insights regarding the nature of HCAs across different geographic regions. The imaging-based scoring system effectively differentiates βHCA.

---

**The impact of percutaneous ablation therapy for liver metastases of non-colorectal cancer**

Tsunasa Aihara1, Takayoshi Nakajima1, Meidai Kasai1, Shinichi Iikita1, Norihiro Nishijima1, Yukio Oosaki1, Hidenori Yanagi1, Naoki Yamanaka1

1Meiwa Hospital Nishinomiya City Japan

**Background/aims:** According to the Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021 (The Japanese Society of Hepato-Biliary-Pancreatic Surgery), local ablative therapy is not recommended for non-colorectal liver metastases (CRLM). Percutaneous ablation therapy (PAT) for non-CRLM was retrospectively investigated in terms of local control and overall survival (OS) in the single center.

**Subjects/Method:** From June 2004 to December 2022, 128 cases and 183 nodules treated with PAT for non-CRLMs were enrolled for the present study. The factors related to local recurrence free survival (LRFS) and OS were analyzed using univariate (Logrank) and multivariate analysis (Cox proportional hazards method).

**Results:** OS of all cases was 42.3% at 3 years, 18.9% at 5 years, and median OS was 28.1 months. As a factor related to OS, univariate analysis showed significant differences in the presence/absence of extrahepatic metastasis (58.70, p<0.001) and the primary tumor in the pancreas/non-pancreas (30.98, p=0.002). Multivariate analysis showed that extrahepatic metastasis (HR 0.510, p=0.011) was an independent factor for poor prognosis. LRFS was 70.6% at 1 year, median 11.0 months. Univariate analysis showed that the primary tumor was pancreatic/non-pancreatic (48/135, p=0.001), ablation margin ≥5 mm (41/142, p=0.0168), and tumor diameter ≥18 mm (62/121, p < 0.001). As a result of multivariate analysis, the primary tumor was pancreatic/non-pancreatic (HR 3.647, p < 0.001) and tumor diameter ≥18 mm or less (HR 3.162, p < 0.001) were independent factors of LRFS.

**Conclusion:** Percutaneous ablation therapy for non-CRLMs may contribute to the prognosis in non-pancreatic primary tumors, and local control of 18 mm or less in diameter is good indication.
Compound X from Coptidis Rhizoma suppresses epithelial-mesenchymal transition of colorectal cancer.

Yong Hwi Kang1, Chang Gue Son1

1Daejeon university Daejeon South Korea

The current study aimed to investigate the anti-hepatic metastasis effect of compound X, a main active compound of Coptidis Rhizoma, in animal model, and the underlying mechanisms. A murine colon carcinoma (CT26) tumor tissue was implanted in cecum of Balb/c mouse with/without oral administration of compound X (100 mg/kg) for evaluation anti-colon-liver metastatic outcome. Regarding the pharmacological actions of compound X, the anti-metastatic behaviors were evaluated using 5-fluorouracil-resistant colon cancer cell (HCT116/R).

The administration of compound X significantly inhibited the hepatic metastasis from CRC.

In conclusion, compound X evidently possess an anti-colon-liver metastatic effect, and its underlying mechanisms involve inhibition of epithelial-mesenchymal transition (EMT) through TGF-β signaling pathway. Thus, compound X can be a potential candidate in drug development against hepatic metastasis from CRC.
cases, there is a possibility that prolonged survival can be achieved by performing liver resection even in patients with NCNNLM.

Abstract Submission No. 200066  
P-0638
Outcome of percutaneous transhepatic biliary stent in malignant biliary obstruction in Thailand

Chitchai Rattananukrom1, Piyawat Eyosawat2, Tanita Suttichaimongkol3, Witsarat Manasirisk1, Jarin Chindaprasi1, Anucha Ahooa2
1Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University Khon Kaen Thailand, 2Department of Radiology, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University Khon Kaen Thailand, 3Division of Oncology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University Khon Kaen Thailand

Background: Malignant biliary obstruction (MBO) is likely to be inoperable at first presentation. Palliative biliary drainage is essential to increase overall survival. Percutaneous transhepatic biliary stent (PTBS) is effective and safe procedure of biliary drainage in MBO. However, there is no previous study in outcome of PTBS insertion in MBO in Thailand.

Objective: To determine outcome, success rate and complications of PTBS insertion in MBO.

Methods: A retrospective study was performed on 41 patients with MBO underwent PTBS insertion from 2015-2021. Technical data, success rate, and outcome (survival analysis and complications) were analyzed.

Results: Of 41 patients, PTBS insertion had technical success 82.93% and functional success 70.59%. Median survival time of patients was 95 days (IQR 50-147 days). Occlusion rate occurred in only 22.6% of patients and all of them underwent percutaneous transhepatic biliary drainage (PTBD) as alternative palliative biliary drainage. Mean occlusion free survival time was 77.14 days (SD 51.68 days). Most of patients (79.4%) did not have PTBS-related complications. The most common complication was acute cholangitis that found in 6 patients (17.6%). Median complication free survival was 91 days (IQR 60-155 days).

Conclusion: Outcome and success rate of PTBS insertion were 82.93% in technical success and 70.59% in functional success. Functional success of PTBS insertion was the most important issue that related with better cumulative survival and occlusion-free survival.

Abstract Submission No. 200096  
P-0639
Durvalumab plus gemcitabine and cisplatin combination therapy in unresectable biliary tract cancer

Yusuke Morita1, Yuki Tanaka1, Rie Sugimoto1
1Department of Hepato-Biliary-Pancreatology, NHO Kyushu Cancer Center Fukuoka Japan

Introduction and Aims: Durvalumab, an immune checkpoint inhibitor, was approved for unresectable biliary tract cancer in December 2022, but the actual situation in clinical practice remains unclear. Gemcitabine, cisplatin, and S-1 combination therapy (GCS) was considered one of the options for primary chemotherapy for unresectable biliary tract cancer. We compared and investigated the actual clinical use of gemcitabine, cisplatin, and durvalumab combination therapy (GCD) and GCS therapy, including their effectiveness.

Methods: 28 patients who started GCD combination therapy (March 2023 to October 2023) and 45 patients who started GCS combination therapy (January 2019 to October 2023) for unresectable biliary tract cancer at our hospital. A retrospective analysis was conducted targeting the month of the month. Differences in patient background were corrected using propensity score matching (PSM), and overall survival (OS) and progression-free survival (PFS) were compared.

Results: After PSM, 13 cases were selected in each case. When PFS was compared, the GCS group was significantly better (2.7 months (95% CI: 1.5-2.8) vs. 7.0 months (4.9-9.2), p=0.0038), but when OS was compared, there was no significant difference (not reached (4.7) vs. 16.2 months (3.6-20.3), p=0.6027).

Conclusion: According to our study, in actual clinical practice, the GCD group has inferior PFS compared to the GCS group, but there is no significant difference in OS, and the long tail effect, which is a characteristic of immune checkpoint inhibitors, can be obtained. Whether this is the case will need to be carefully observed in the future.

Abstract Submission No. 200139  
P-0640
A Case of Hepatic Epithelioid Hemangioendothelioma Diagnosed with Sonazoid CEUS Guided Biopsy

Fukunaga Minoru1, Maruyama Hitoshi2, Ishizuka Hayate1, Fujiiwara Ai1, Hisayasu Hideki1, Osawa Kazuhiyo1, Shina Shuichiro2, Kuvatsuru Ryohei1, Fukumura Yuki1
1Department of Clinical Laboratory, Juntendo University Hospital Tokyo Japan, 2Department of Gastroenterology, Juntendo University Hospital Tokyo Japan, 3Department of Radiology, Juntendo University Hospital Tokyo Japan, 4Department of Diagnostic Pathology, Juntendo University Hospital Tokyo Japan

Background: Hepatic epithelioid hemangioendothelioma (EHE) is a rare non-epithelial tumor of vascular endothelial origin, demonstrating a slow growth tendency and representing a low to moderate-grade malignant tumor. Radiologically, it resembles metastatic liver tumors and intrahepatic cholangiocarcinoma, requiring a definitive diagnosis through histopathological examination via biopsy. In this report, we present a case of EHE in which percutaneous needle biopsy under Sonazoid contrast-enhanced ultrasound was diagnostically valuable.

Case: 32 years old, female

Chief complaint: None (visited for the investigation of liver tumors)

Medical history: While residing in the United States, an abdominal contrast-enhanced CT scan was performed following a traffic accident, revealing multiple liver tumors of approximately 10 mm in the right hepatic lobe.

Findings: Abdominal contrast-enhanced CT: Multiple liver tumors of approximately 10 mm in the right hepatic lobe. Based on the contrast findings, metastatic liver cancer or hepatic epithelioid hemangioendothelioma was suspected.

Abdominal ultrasound: The liver tumors identified on CT were challenging to recognize with B-mode ultrasound. However, Sonazoid contrast-enhanced ultrasound low-contrast findings in the post-vascular phase, enabling recognition and identification.

Blood test: No abnormalities were observed in liver and biliary enzymes or tumor markers.

Pathological examination: Hepatic epithelioid hemangioendothelioma.

Discussion: In this case, Hepatic epithelioid hemangioendothelioma may be challenging to identify with B-mode ultrasound. Sonazoid
contrast-enhanced ultrasound-guided biopsy proves to be extremely useful for a definitive diagnosis in such cases.

Abstract Submission No. 200283
P-0641
A rare case of MTX-LPD (large B-cell lymphoma) appeared as multiple hepatic tumors
Kai Oshima1, Akiko Saito1, Masaaki Mino1, Masaki Akazawa1, Yasuo Tanaka1, Mikio Yanase6
1National Center for Global Health and Medicine Tokyo Japan
Case: A 60-year-old woman with multiple hepatic tumors was admitted. The patient was diagnosed as rheumatoid arthritis in her thirties and had oral methotrexate (MTX) for 10 years. As AST/ALT levels were elevated 4 years earlier, ursodeoxycholic acid was administrated. g-GTP levels slightly increased thereafter. The MRI revealed multiple hepatic tumors (max. 59 mm, and three other tumors). Enhanced CT showed hypo-vascular tumors, suggestive of metastases. However, upper/lower endoscopy revealed no primary lesions, MTX was withdrawn. On admission; g-GTP 70 U/L, LDH 435 U/L, sIL-2R 2153 U/mL, hepatitis viruses and tumor markers negative, and EBV-DNA 60000 copies/ml. PET-CT showed FDG uptake in the right pharynx and liver. Histopathology from both biopsies indicated large atypical cells within the small lymphocyte. Immunohistochemical findings yielded a diagnosis of MTX-associated lymphoproliferative disorders (MTX-LPD); large B-cell lymphoma. Hepatic tumor was reduced (39.7mm) on ultrasonography. LDH and sIL-2R also decreased (178 U/L and 957 U/mL, respectively), 1 month later MTX withdrawal. At 4 months, tumor decreased further (26.2 mm) and sIL-2R was normalized. At 15 months to date, there has been no evidence of relapse.
Conclusion: We have presented a rare case in which MTX-LPD-associated primary multiple hepatic tumors, regressed after MTX withdrawal. To find good patient outcomes earlier, changes in peripheral lymphocyte counts (Tokuhira, 2020) and LDH/sIL-2R levels along with ultrasonographic findings may be important.

Abstract Submission No. 100151
P-0642
The spike of SARS-CoV-2 induces IL-8 secretion of human hepatocytes and promotes NETosis
Trai Ming Yeh1, Yun Ting Huang1, Hun-Han Hsieh1
1National Cheng Kung University Tainan Taiwan
The emergence of SARS-CoV-2 was responsible for the COVID-19 pandemic. Despite primarily as a respiratory virus, the presence of SARS-CoV-2 has been detected in liver tissue with a significant percentage of COVID-19 patients experiencing liver damage, having raised questions about its impact on the liver. In this study, we simulated SARS-CoV-2 infection in human liver cells by transfecting the SARS-CoV-2 spike plasmid and explored their pathological effect in hepatocytes. We found that the spike protein could be located in both the cell cytosol and membrane with the observation of the syncytia, potentially indicating interaction with nearby cells to help the virus transmission. Additionally, the spike protein increased reactive oxygen species (ROS) levels and lipid accumulation, possibly contributing to oxidative stress and inflammation. We also revealed heightened interleukin-8 (IL-8) secretion by spike-expressing liver cells. Importantly, spike-expressing Huh7 activated human neutrophils adhesion, forming neutrophil extracellular traps (NETs) in coculture model. Moreover, the purified NETs induced IL-8 secretion of Huh7, suggesting a feedback loop between NETs and IL-8 secretion was observed.

Abstract Submission No. 100446
P-0643
Seroprevalence of enteric hepatitis A and E viruses among general residents in Binh Thuan, Vietnam
Chanroth Chhoung1,2, Ko Ko1,2, Zayar Phyo1,2, Golda Akuffo1,2, Ulugbek Mirzaev5, Ryozuke Suzuki3, Son Do Huy5, Aya Sugiyama1,2, Tomoyuki Akita4, Kazuaki Takahashi3, Junko Tanaka4
11. Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan Hiroshima Japan, 2Project Research Center for Epidemiology and Prevention of Viral Hepatitis and Hepatocellular Carcinoma Hiroshima Japan, 3National Institute of Infectious Diseases, Virus Department II Tokyo Japan, 4Binh Thuan College Binh Thuan Vietnam
Background: In developing countries with poor sanitation and limited access to clean water, hepatitis A virus (HAV) and hepatitis E virus (HEV) are the main causes of acute viral hepatitis. Although Vietnam exhibits a notable liver mortality rate, the prevalence of HAV and HEV among the general population remains limited. This study aims to determine the prevalence and genotype of HAV and HEV using stocked serum.
Methods: A total of 504 stocked serum collected from residents in Vietnam, by multi-stage random sampling in 2012 was used to detect total anti-HAV and anti-HEV IgG using the in-house ELISA method. HAV and HEV RNA screening was done by nested RT-PCR using a universal primer set targeting nonstructural protein 2A, 2B of HAV, and ORF1 of HEV. Genotyping was done by phylogenetic tree analysis.
Results: The seroprevalence of total anti-HAV was 93.8% and anti-HEV-IgG was 31.9% with no significant difference by sex and age except anti-HEV IgG positive which positivity was significantly lower in <40 years old adults (20%). HAV RNA was detected in 27 anti-HAV positives (5.6%) while no HEV RNA was found in 162 anti-HEV positives. By phylogenetic tree analysis, all HAV strains were genotype IA and close to HAV strains from China and Japan.
Conclusion: Our study revealed that over 90% of residents were immune to HAV whilst 31.9% were immune to HEV especially in the young adults <40 years old. Considering the herd immunity of HAV, a prevention measure and improved sanitation is required to prevent the potential sporadic outbreak of HEV in Vietnam.

Abstract Submission No. 101422
P-0644
Drug-resistant organism colonization in patients with cirrhosis admitted to ICU
Shantan Venishetty1, Anand V Kulkarni1, Anand Gupta2, Pragathi Kottpattai2, Nageshwar Reddy Duvvuru3
1Consultant, Department of Hepatology, AIG Hospitals Hyderabad India, 2Department of Critical Care Medicine, AIG Hospitals Hyderabad India, 3Department of Microbiology, AIG Hospitals Hyderabad India
Introduction: The burden of drug-resistant organisms is rising and screening for drug-resistant organism colonizers may aid in the
appropriate management of the patients and prevent transmission especially in patients with cirrhosis. 

Methods: Patients with cirrhosis who were admitted to ICU with a recent exposure to more than one antibiotic or those referred from other hospitals were included. The established hospital screening protocol is to perform nasal, rectal, axillary and groin swabs for meticillin-resistant staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant enterococci (CRE) and Candida auris colonization in patients. Those positive are isolated and provided one-to-one nursing care.

Results: Seventy-five patients were screened over last 6 months. Of them, 85.3% (n=64) were males and the commonest etiology was alcohol, and 38 (50.6%) were ACLF. Approximately 46 (61.3%) patients had 59 swabs positive. The commonest was CRE, which was positive in 49.3% of patients, followed by VRE in 22.6%. Interestingly, 15% of swab positive and 13.8% of swab negative had positive blood culture. Two patients in the swab positive and 1 in swab negative had culture positive SBP (P=0.67). There were no differences in the etiology, liver function tests and severity scores among swab positive and negative groups. Furthermore, the mortality in those with swab positivity was 43.5% compared to 44.8% in those without (P=0.54).

Conclusion: Colonization in cirrhosis is common due to recurrent hospitalization, frequent antibiotic exposure, and immune dysfunction. Appropriate hand hygiene, regular sanitization of ICUs, aseptic precautions during procedures and screening for colonizers can reduce burden of MDR infections.

Abstract Submission No. 101436
P-0645

Clinical Characteristics and Treatment Outcomes of Patients with HCV/HIV Coinfection in Korea

Jae Yoon Jeong1, Seungwoo Nam1, Su Jong Yu1, Jeuyeon Park2, Jeong Won Jang3, Soon Sun Kim4, Jae Hyun Yoon5, Hyuk Soo Eun6, Jonggi Choi7, Young Ku Jung7, Soo Young Park7, Do Young Kim8

1National Medical Center Seoul South Korea, 2Seoul National University Hospital, Seoul National University College of Medicine Seoul South Korea, 3Seoul St. Mary’s Hospital, The Catholic University of Korea Seoul South Korea, 4Ajou University School of Medicine Suwon South Korea, 5Chonnam National University Hospital and College of Medicine Gwangju South Korea, 6Chungnam National University Hospital Daejeon South Korea, 7Asan Medical Center, University of Ulsan College of Medicine Seoul South Korea, 8Korea University Ansan Hospital, Korea University College of Medicine Ansan South Korea, 9Kyungpook National University School of Medicine Daegu South Korea, 10Yonsei University College of Medicine, Severance Hospital Seoul South Korea

Background/aims: Because of the very low incidence of human immunodeficiency virus (HIV) infection in Korea, the epidemiologic data on hepatitis C virus (HCV)/HIV coinfection are limited. We investigated the clinical characteristics and treatment outcomes of patients with HCV/HIV coinfection in Korea.

Methods: We collected retrospectively data of patients diagnosed with HCV/HIV coinfection at 12 academic hospitals in Korea from 2009 to 2020.

Results: A total of 124 patients were included. Male gender was predominant (n=113, 91.1%), and the mean age was 46.5 ± 13.5 years. Of them, 11 patients (8.9%) had cirrhosis and 7 (5.6%) was positive HBsAg. During follow up, 2 patients (1.6%) developed HCC and 9 (7.3%) died. Among the 112 patients (90.3%) who were performed with HCV genotype test, most were genotype 2 (n=53, 47.3%) and genotype 1b (n=41, 36.6%). In particular, the genotype 1a was 12.5% (n=14). Ninety-one patients (73.4%) were treated with antiviral agents and a total of 104 antiviral treatments were administered. The sustained virologic response rate of the patients receiving pegylated interferon-based treatment was greater than that of those receiving DAA treatment (58.1% vs 89.0%, P<0.001).

Conclusion: In Korea, patients with HCV/HIV co-infection were predominantly male, younger, and had a higher prevalence of genotype 1a compared to the known patients with HCV mono-infection. They had a better treatment response to DAA treatment than that to interferon-based treatment.

Abstract Submission No. 101462
P-0646

Inhibition of hepatitis E virus replication by FDA-Approved RdRp inhibitors

Mohammad K. Parvez1, Preeti Hooda2, Deepak Sehgal2

1King Saud University College of Pharmacy Riyadh Saudi Arabia, 2Virology Laboratory, Dept. of Life Sciences, Shiv Nadar University Greater Noida India

Hepatitis E virus (HEV) is primarily a hepatotropic virus that is responsible for acute hepatitis E in the general population and for chronic hepatitis in immunocompromised individuals. In the absence of a globally accessible vaccine, pegylated interferon-α and ribavirin are the only antiviral agents available for the treatment of chronic patients. As viral RNA-dependent RNA polymerases (RdRps) are indispensable for RNA replication, they are considered potential drug targets. In this study, we screened some well-known RdRp inhibitor molecules, notably, favipiravir, sofosbuvir, remdesivir, filibuvir, and tegobuvir. Of these, monotherapy with favipiravir and sofosbuvir inhibited the RdRp activity with an IC50 value of 10.2 ± 4.9 and 5.2 ± 2.9 µM, respectively, compared to the reference drug ribavirin (3.5 ± 1.6 µM). Further investigation of the combination therapy showed a reduction in viral RNA copy numbers by approximately 90%. Therefore, favipiravir has an additive effect when used with sofosbuvir. Therefore, we propose that favipiravir is a promising anti-HEV drug that can be used in combination with sofosbuvir.

Abstract Submission No. 101688
P-0647

Nonalcoholic steatohepatitis-related cirrhosis complicated by sepsis-induced liver dysfunction

Norikazu Iwata1, Yasushi Adachi1, Yoshifumi Ishii1, Takefumi Kikuchi1, Hiroaki Mita1, Masahiro Nakamura2, Yasuyo Adachi1, Yukinari Yoshida1, Takao Endo1, Yasuo Kato1, Yuji Hinoda1, Kouzoh Imai1, Akira Goto1

1Sapporo Shiraikabudai Hospital Sapporo Japan

It is sometimes difficult to diagnose cholangitis lenta and sepsis-induced liver dysfunction due to phlegmonous gastritis clinically. We herein present a rare autopsy case. A 60-year-old man had been treated for nonalcoholic steatohepatitis-related cirrhosis. One month before admission to our hospital, he developed Miller-Fisher syndrome as a complicating condition. He was admitted to our hospital for the treatment of cirrhosis and rehabilitation. He remained on the waiting list for the hepatic transplant and we were in contact with the transplant department. The patient died of hepatic failure two weeks after exacerbation of anorexia and rapid progression of liver dysfunction.
Autopsy revealed cholangitis lenta and sepsis-induced liver dysfunction, which was attributed to phlegmonous gastritis due to Moraxella (Branhamella) catarrhalis. Acute cholangitis by B. catarrhalis has never been reported previously. In histological examination, numerous bile thrombi, neutrophils and lymphocytes were found to proliferate the canals of Hering, indicating the sepsis-related cholangitis lenta. Moreover, B. catarrhalis existed with neutrophils in all layers of the stomach. Thus, it was most likely that phlegmonous gastritis was orally developed, which caused sepsis and then cholangitis. Phlegmonous gastritis has seldom been reported in patients with liver cirrhosis. We believe the importance of keeping in mind that phlegmonous gastritis could be one of the complications of advanced liver cirrhosis and cause sepsis-induced liver dysfunction.

Abstract Submission No. 101701

Clinical characteristics of 44 cases of liver abscess: A single center study

Sho Ijuin1, Tsutomu Tamai1, Masahumi Hashiguchi2, Koki Kodama1, Kaori Muromachi1, Seiichi Mawatari1, Takeshi Hori1, Hirohito Tsubouchi1, Akio Ido3

1Kagoshima city hospital Kagoshima city Japan, 2Maehara Medical General Hospital Hioki city Japan, 3Digestive and Lifestyle Diseases, Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima city Japan

Background: Hepatic abscess is a rare disease, but it sometimes has a poor prognosis. In this study, we reviewed our experience with liver abscesses in our hospital.

Methods: We retrospectively reviewed the clinical characteristics of a total of 44 patients who were diagnosed with liver abscess by CT or MRI scan and hospitalized for treatment between October 2013 and July 2023.

Results: The median age was 74 years. The backgrounds of the patients were as follows: 12 were obese with BMI over 25, 16 had a history of smoking, 7 were heavy alcohol drinkers, 18 had hypertension, 9 had diabetes mellitus, and 11 had dyslipidemia. The positive rate of blood cultures was 31%, and the positive rate of cultures of percutaneous drainage fluid was 67%. Of the 27 cases in which pathogenic bacteria could be identified, 11 were Klebsiella pneumoniae and 6 were Escherichia coli. 5 of the 6 Escherichia coli cases had biliary tract disease/post-biliary reconstruction. Patients in whom abscess drainage was performed, compared to patients in whom drainage was not performed, had a significantly larger maximum diameter abscess (65.5 vs. 38.0 mm, P<0.001) and higher CRP on admission (20.2 vs. 11.8 mg/dL, P=0.003). The number of days of hospitalization was significantly positively correlated with the maximum diameter of the abscess and CRP on admission (P<0.001). There were 5 recurrent cases, 4 of which had biliary disease/post-biliary reconstruction, and 1 of which had all 6 lifestyle-related factors.

Conclusions: Percutaneous drainage was performed in severe cases, leading to an improved bacterial identification rate, but there were cases of recurrence in patients with biliary disease/post-biliary reconstructive surgery. Post-treatment follow-up was considered important.

Abstract Submission No. 101902

To present a clinical, paraclinical, and microbiological profile of patients with liver abscesses

Trang Nguyen Thi Huyen1, Binh Mai Thanh1

1Hepatology doctor Ha Noi Vietnam

: This retrospective cross-sectional investigation examined 196 patients diagnosed with hepatic abscesses treated at Hospital 108 from January 2018 to August 2023.

Results: The average age of the individuals in the study was 57.8 ± 16.9 years, with a male-to-female ratio of 3.1/1. Frequently associated comorbidities included diabetes mellitus (28.1%), hypertension (14.3%), and gallstones (7.8%). Epidemiological risk factors within the study population encompassed irregular deworming practices (99%), consumption of raw vegetables (49%), intake of raw salads (44.9%), and inadequate hand hygiene following restroom use (44.9%). The classic Fontan’s triad was identified in 26% of patients. Among the 196 patients, 57.1% exhibited anemia, 70.9% displayed an elevated white blood cell count (with 73% indicating an increase in neutrophil counts and 26.0% showing an elevation in eosinophil counts), and 98.2% had elevated Procalcitonin levels. Liver abscesses were predominantly situated in the right lobe (74.0%), primarily as solitary abscesses (82.6%), with an average size of 63.3 ± 29.1 mm, and the largest documented abscess measured 172 mm. Bacterial isolates were
detected in 63 patients, with Klebsiella being the most prevalent (80.9%), followed by E. coli (7.9%). In conclusion, liver abscess is an acute infectious condition, typically found in elderly individuals with underlying diseases, more common in males, and directly related to unsanitary lifestyle habits. The primary cause is Gram-negative bacteria, and imaging diagnosis is an effective diagnostic tool.

Background: The incidence of Hepatitis A Virus (HAV) is closely associated with socioeconomic factors, access to clean drinking water, and improved sanitation. In Vietnam, epidemiologic data of HAV is lacking over the past two decades. The objective of this study is to assess age-specific HAV seroprevalence and evaluate risk factors associated with HAV seropositivity in Vietnam.

Methods: A cross-sectional seroprevalence study was conducted in two contrasting areas (urban and rural) in Vietnam. Serological testing for anti-HAV IgG antibodies (Roche test kit) and socio-demographic questionnaire interviews were done in all participants. The age at midpoint of population immunity (AMPI) was determined.

Results: In this interim analysis, 882 participants aged 1 to >50 were tested (518 urban, 364 rural). Participants aged <15 years comprised 24.5% of the sample. Total HAV seropositivity in the interim population was 62.7%. Anti-HAV seropositivity was 50.8% in urban areas; significantly lower than in rural areas (79.7%), p<0.001. Univariate analysis revealed that a main factor associated with higher risk of HAV infection included residing in a rural area during first 5 years. Participants with a higher education level, having knowledge of Hepatitis A/infectious disease, using piped water in dwellings, and washing their hands after defecation had a lower association to HAV seropositivity. Initial AMPI was 36 years, indicating potential low endemcity.

Conclusions: Initial findings show differences in HAV seroprevalence between urban and rural areas. These data are important for policymakers to determine prevention strategies, such as national immunization programs, to reduce HAV infections and disease burden.

Funding: GlaxoSmithKline Biologicals SA (GSK study identifier: 216938).

Unraveling Hepatic Tuberculosis: Recurrent Fever, Jaundice & Tea-Colored Urine in a 32-Year-Old Male

Jose Luis Matthias III Sollano1, Angelo B. Lozada1
1Makati Medical Center Makati City Philippines

This case report details the diagnostic journey of a 32-year-old male with a perplexing three-year history of recurrent fever, jaundice, teacolored urine, and occasional acholic stools, each episode spontaneously resolving. Exhaustive investigations initially yielded inconclusive results, challenging the conventional diagnostic paradigm. Subsequent evaluation, including liver function tests and imaging studies, revealed subtle abnormalities, prompting a reevaluation of potential infectious etiologies.

The breakthrough in diagnosis came with a positive result in the Quantiferon-TB Gold+, unveiling the presence of Tuberculosis as an underlying cause for the recurrent symptomatic episodes. Additional confirmation came along with the resolution of the symptoms when Anti-Koch's treatment was initiated. This rare manifestation of extrapulmonary tuberculosis highlights the importance of considering atypical presentations, especially in regions where tuberculosis is endemic. The report discusses the challenges faced in diagnosing Hepatic Tuberculosis, emphasizing the need for heightened clinical suspicion and a comprehensive diagnostic approach. It also underscores the importance of timely identification and initiation of appropriate anti-tubercular therapy to prevent further complications and improve patient outcomes.

This case serves as a poignant reminder of the diverse clinical presentations of tuberculosis, urging clinicians to maintain a broad differential diagnosis and consider rare manifestations in the pursuit of resolving diagnostic conundrums associated with recurrent fever, jaundice, and tea-colored urine.
Complications Associated with Living Donor in Liver Transplant: A Global Analysis of 60,829 Donors

Jia Hong Koh1, Douglas Chee1, Cheng Han Ng1, Wen Hui Lim1, Darren Jun Hao Tan1, Nicholas Syn1, Margaret Teng1, Daniel Q. Huang1, Mark Muthiah1

1National University Hospital Singapore Singapore Singapore

Introduction: Living donor liver transplantation (LDLT) is a major life-saving procedure but it is not without risks to the donor. Particularly in the east where deceased donor organs are less available, understanding the incidence and types of complications in LDLT is crucial for both donor safety and optimizing transplant outcomes.

Methods: A comprehensive meta-analysis was conducted by searching Medline and Embase databases for relevant articles published until July 2022. These studies evaluated the incidence of complications among LDLT donors, categorized by organ systems. The analysis utilized statistical models with Clopper-Pearson intervals.

Results: The overall pooled incidence of complications in LDLT donors was 24.7% (95% CI: 21.6% to 28.1%). Minor complications occurred in 17.3%, while major complications were less frequent at 5.5%. Clavien-Dindo classification revealed Grade I (10.9%), Grade II (5.7%), and Grade III (5.4%) complications. Grade III was subdivided into IIIa (3.2%) and IIIb (1.9%), with Grade IV (0.2%) complications posing life-threatening risks. Remarkably, the overall pooled incidence of donor mortality (Grade V) was 0.06%. Right lobe donation had the highest complication rate (26.6%), with the highest major complication rate (6.6%) compared to left lobe (12.3%) and left lateral section donation (12.7%). Complications were further categorized by organ systems, with psychological (7.6%), wound-related (5.2%), and respiratory (4.9%) complications being most prevalent. Cardiovascular complications were least common (0.8%).

Conclusion: This comprehensive analysis emphasizes the need for careful assessment and monitoring of LDLT donors, shedding light on the incidence and types of complications they may encounter during the transplant process.

Results of liver transplantation in NSCS named after A.N. Syzganov

Aidar Skakhbayev1, Maksat Doskhanov1, Bolatbek Baimakhanov1, Manas Seisembaev1, Shokin Kaniyev1, Madiyar Nagasbekov1, Serik Tleuov1, Abzal Ismatov1, Aziza Khabdzhieva1, Daniyar Mukazhanov1

1Syzganov National Scientific Center of Surgery Almaty Kazakhstan

Aim: To analyze the results of liver transplantation (LT) in our clinic.

Methods: From December 2011 to September 2023 we performed 256 LT on adults and children in the Syzganovs NSCS. LT from a living related donor was performed in 230 (89.8%) patients, including pediatric liver transplantation in 44 (17.1%) cases, from a deceased donor in 26 (10.1%) cases.

Indications for liver transplantation were cirrhosis in outcome: HCV-22, HBV-26, HBV+HDV-83, primary biliary cirrhosis-33, autoimmune hepatitis-4, cryptogenic cirrhosis-9, myofibroblastic tumor-1, steatohepatitis-2, Budd-Chiari disease-1, Wilson-Konovalov disease-1, alimentary toxic hepatitis-2, biliary atresia-44, secondary biliary cirrhosis-2. Clinical outcomes were retrospectively analyzed.

Results: The overall survival rates of patients after LDLT were: 5 years-74.3%; 10 years-71.7%. Postoperative complications were 85 cases as follows: biliary complications 31 (36.4%), bleeding 15 (17.6%), relaparotomy 20 (23.5%), rejections were observed in 10 (11.7%) cases, non compliance 9 (10.5%) cases. Also analyzed 118 donor for adult recipients, 10 (8.4%) non-life threatening complications were identified. Such as portal vein thrombosis Yerdel grade-1 1(0.8%) case, bleeding 1 (0.8%) case and 8 (6.7%) cases of biliary complications.

Conclusion: We have problems in the development of liver transplantation from a deceased donor, therefore we perform LDLT up to 90%.

Percutaneous Treatment of Liver Cystic Echinococcosis

Madiyar Nagasbekov1, Maksat Doskhanov1, Erik Nurlanbayev1, Daniyar Mukazhanov1, Aidar Skakhbayev1, Shokin Kaniyev3, Bolatbek Baimakhanov1

1Syzganov National Scientific Center of Surgery Almaty Kazakhstan

Objective: to analyze the effectiveness of the treatment of liver cystic echinococcosis by PAIR method.

Methods: We analyzed the outcome of 133 patients with active echinococcal liver cysts who underwent percutaneous and transhepatic echinococcectomy during the period from January 2017 to August 2023. Staging was carried out according to WHO-IWGE Classification Images of Cystic Echinococcosis. Prior to the PAIR procedure, patients taking 800 mg of Albendazole for 7 days, and in the postoperative period, 800 mg of Albendazole for 2 months continuously. Ultrasound control was performed every 1, 3, 6, 9, 12 months, CT after 1 year.

Results: The postoperative stay of patients in the pair was 3.8 (1-19) days. The follow-up time averaged 39.9 months ± 21 (min. 2 - max. 79 months). During the PAIR procedure, a biliary fistula occurred in 3.7%, the operation ended with the abandonment of Pigtail-type drainage tubes 8.5Fr., also intraoperatively, anaphylactic reaction occurred in 5.2%, which were successfully resolved. In the long-term period, suppuration of the residual cavity after PAIR occurred in 6.01% of patients who were drained under local anesthesia, whose cysts were larger than 12 cm during the PAIR procedure, and 6 (5.1%) relapses occurred during the PAIR procedure.

Conclusion: In cysts CE1 and CE3a, the optimal volume is PAIR, characterized by a smaller postoperative stay, early recovery, the effectiveness is comparable to “open” surgery.

The Liver Transplantation Economic Analysis in Asia

Pisi Bethania Titalessy1

1Cenderawasih University Jayapura Indonesia

Globally, Asia and Pacific region accounts for 62.6% of all liver disease deaths, especially 54.3% of cirrhosis-related deaths and 72.7% of HCC-related deaths. In Asia, a shortage of deceased donor liver grafts is the universal problem to be faced with in all transplant centres. This
study focuses on what factors affect liver transplantation in Asian countries, specifically on health economics side. Using data obtained from the Global Observatory on Donation and Transplantation and the World Bank, 8 countries of Asia were selected to see how the economic growth, health expenditure, average protein supply, and Prevalence of anemia among women of reproductive age (15-49 years) affect the liver transplantation. This study employed data from 2010-2019 and then analyzed using Panel Data analysis. From the results of the panel data regression, it is known that variables of economic growth, health expenditure have a significantly positive influence on liver transplantation. Meanwhile, the variable of the average food supply has a negative influence and the prevalence of anemia among women of reproductive age (15-49 years) insignificant influence. The result indicates health expenditure can increase the liver transplantation by 3%. The rise of economic growth also can increase liver transplantation. If economic growth rises by 1%, it is followed by an increase in the liver transplantation by as much as 1%. In addition, the average food supply can be determined as a factor that affects liver transplantation.

Abstract Submission No. 101134
P-0658
Acute and chronic rejection after Liver Transplantation: experience of single center in Kazakhstan

Marzhan Zhanasbayeva1
1NATIONAL RESEARCH ONCOLOGY CENTER Astana Kazakhstan

Introduction: Organ transplantation is the treatment of choice for patients with end-stage liver diseases. Patients with ESLD in Kazakhstan has an access to Liver Transplant program which started in early 2000’s. Despite the advances in immunosuppression regimens acute and chronic allograft rejection remains one of the challenges of LT.

Method: Consecutive LT recipients who underwent surgery in our institution from 2013 to 2023 were evaluated recipients for clinical, laboratory and liver histology signs of rejection.

Result: In total 55 patients were included in this analysis. LDLT cases is the predominantly done surgery = 36 cases, DDLT - 19 cases. Period of 2013 to 2023 total of 9 rejections observed, 6 episodes of acute rejection and 3 episodes of chronic rejection observed. Of these, all acute rejection cases were responsive to methylprednisolone, they were all during early post-transplant period and in 3 cases donor’s age was younger than 23 years old and longer cold ischemic time. Among late acute rejection of 3 recipients (50%) that developed after mean of 1,4 years 2 of them were responsive to methylprednisolone bolus. Chronic rejection was observed in 3 recipients (33%) were treated by adjusting the dosage of immunosuppressive agents, and 1 of them received re-transplantation and died after 6 month due to sepsis & multi-organ failure.

Conclusion: Acute rejection (10.9%) in our study occurred both during early post-transplant and late periods. In all cases CMV, EBV, viral A, B, D, C infections and other vascular causes excluded, biopsy confirmed with Banff criteria and we observed death of 4 (44%) recipients.

Abstract Submission No. 101231
P-0659
SINGLE ORIFICE OUTFLOW RECONSTRUCTION IN RIGHT LOBE GRAFT LIVING DONOR LIVER TRANSPLANTATION

Hieu LE TRUNG1, Thanh LE VAN2, Quang VU VAN2
1Human Organ and Tissue Transplantation Center, Military Central Hospital 108 Hanoi Vietnam, 2Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Introduction: Outflow reconstruction is one of the key requirements of successful living donor liver transplantation. The aim of study is to evaluate the technical characteristics and outcomes of single orifice outflow reconstruction in living donor liver transplantation using right lobe graft in a center in Vietnam.

Method: The prospective study was performed on 52 cases of living donor liver transplantation using right lobe graft at 108 Military Central Hospital from January 2019 to December 2020. Polyester prostheses were used in reconstructing the MHV when the remnant liver volume was less than 35% of the donor liver volume. Venous branches with diameter ≥ 5mm were preserved and anastomosed to the prostheses.

Result: There were 42 cases of using the extended lobe living donor liver transplant including the middle hepatic vein (HV) (80.8%) and 10 cases of the modified right lobe graft with the middle HV reconstructed from the V5 and/ or V8 branches (19.2%) by using polytetrafluoroethylene artificial vessels. We conjoined the MHV and RHV as a single orifice hepatic vein. The HV were enlarged to the left and downwards at the orifice of the recipient’s right hepatic vein, with a mean incision length of 14 mm and 9.7 mm, respectively. There were 1 cases of middle hepatic vein obstruction (1.7%). The mortality rate of hepatic venous outflow obstruction was 1.9%. The caliber of HV anastomosis (< 30 mm) was an independent risk factor for hepatic venous outflow obstruction.

Conclusion: The single orifice hepatic vein reconstruction in LDLT using a right lobe graft is a simple and feasible surgical technique, and it does not require cadaveric vessels.

Abstract Submission No. 101236
P-0660
DONORS BILIARY VARIATION AND BILIARY COMPLICATIONS IN 150 CASES OF LIVING DONOR LIVER TRANSPLANT

Quang VU VAN1, Thanh LE VAN3, Hieu LE TRUNG1
1Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Introduction: Living donor liver transplant (LDLT) ) has developed tremendously as a savage therapy for chronic liver disease and malignancy. Our study aims to evaluate the biliary anatomy variation according to Varoti classification and its correlation with surgical outcomes for both donors and recipients undergoing LDLT.

Method: The prospective study was performed on cases of living donor liver transplantation using right lobe graft at 108 Military Central Hospital from October 2017 to December 2022. Donors’ and recipients' demographic data, clinical data, operative details and postoperative course information were collected. We also reviewed the management and outcomes of BCs.

Result: 150 cases of LDLT at 108 Military Central Hospital from October 2017 to December 2022 were included in our study. Among the donors, the mean age was 30.89 ± 7.23, with male predominance (77.3%). The prevalence of type 1 biliary anatomy was 84.67%. Type 2, 3a, 3b, 4a, and 4b accounted for 5.33%, 2.67%, 5.33%, 0.67%, and 1.33% of cases, respectively. Donors’ complications were witnessed in 7 cases (4.67%), and all needed intervention (Clavien Dindo grade 3). Biliary complications were found in 36 (24.0%) recipients, with 22 (14.67%) cases of biliary stenosis and 16 (10.67%) cases of biliary leak, including 2 cases encountering both complications. Cold ischemia time significantly increased the biliary complication rate.
Conclusion: According to our study, biliary variant anatomy is common in liver transplantation donors. However, such variations should not be considered a contraindication to donation but require accurate pre- and intraoperative radiologic and surgical evaluations to plan a careful reconstruction.

Abstract Submission No. 101238
P-0661

Evaluation of early results in right donor hepatectomy for living donor liver transplantation

Quang VU VAN1, Thanh LE VAN1, Hieu LE TRUNG1
1Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Introduction: To evaluate the early results in donor right hepatectomy for living donor liver transplantation in 108 Military Central Hospital.

Method: Retrospective study of 127 donors cases who underwent right hepatectomy from October 2017 to June 2022 in 108 Military Central Hospital.

Result: The average age was 56.2 ± 12 years, and 80.3% of the donor were male. The remnant left liver volume: 37.86 ± 4.28%, right liver resection with middle hepatic vein accounted for the majority with 56.7%, graft size: 660.7 ± 107.9 g, operative time: 281.3 ± 50.0 minutes, blood loss: 313.7 ± 169.2 ml. There was no donor mortality and the overall morbidity rate was 7.9%. Most of the complications of donors were either grade II or III, and biliary complications were the most common complications, with an incidence of 4.7%. The percentage of left liver volume increased after 07 days: 64.68 ± 23.1% and the average length of hospital stay was 11.2 ± 3.0 days.

Conclusion: With careful donor selection, right donor hepatectomy for living donor liver transplantation gives good results with a low complication rate.

Abstract Submission No. 101785
P-0663

Change of HCC transplant candidates’ prioritization policy leads to organ utilization improvement

Helena Katchman1, 2, Rona Simon1, Ayelet Grupper1, 2
1Tel Aviv Sourasky Medical Center Tel Aviv Israel, 2Sackler Faculty of Medicine, Tel Aviv University Tel Aviv Israel, 3The National Transplant Center Tel Aviv Israel

Introduction: Prioritization of HCC patients on the waiting list brings reduced access of non-HCC patients to liver transplantation (LT). New policy was adopted in Israel in March 2016. Patients with one tumor ≤3cm were defined as “low risk” and received MELD 18 without increment, all other HCC patients were defined as “high risk” and received traditional prioritization.

Methods: Retrospective analysis of the National Transplant Center data for patients listed for LT from January 2010 to December 2021 before and after policy change (period A and period B respectively)

Results: Proportion of HCC patients listed in period B significantly decreased compared to period A (109/910 (12%) vs 155/755 (21%), (p<0.001), due to lower amount of “low risk” patients 23/109 (21.1%) vs 63/155 (40.6%), (p<0.001)

Waiting time to transplantation in HCC patients was significantly longer in period B then in period A (12.3±9.3 vs 10.23±6.2 months respectively, p=0.008) that was explained by elongation of waiting time in low vs high risk group (17.6±13.8 vs 11.3±7.9, p=0.002) during period B. But transplantation rate and wait list mortality remains unchanged (128/155 vs 97/109 (p=0.14) and 17/155 vs 4/109 (p=0.06).

In the group of non-HCC patients transplant rate didn’t change 299/600 vs 379/801, p=0.35, but wait list mortality significantly decreased (219/900 vs 120/801, for period A vs B (p<0.001)

Conclusion: Changing allocation policy lead to increase in HCC patients waiting time without impairing their transplantation chance and survival. Due to significant decrease in number of listed HCC patients after policy change further follow up needed for final conclusions.

Abstract Submission No. 101799
P-0664

Near-infrared fluorescent imaging for tumor detection and securing surgical margin RFA

Kazuhiko Saito1, Takeshi Aoki1, Yoshihiko Tashiro1, Yukari Shinhohara1, Shodai Ngaishi1, Tatsuya Yamazaki1, Takahito Hirai1, Koudai Tomioka1, Hideki Shibata1, Kazuhiro Matsuda1, Tomokazu Kusano1, Akira Fujimori1, Yuta Enami1

Results: The first case involved a 68-year-old man diagnosed with hepatocellular carcinoma (S6, 35 mm). The second case featured a 74-year-old woman diagnosed with metastatic hepatocellular carcinoma (S3, 30 mm). The observed ICG fluorescence area during surgery resulted from the preoperatively administered ICG stagnating and coincidentally aligning with the resection area planned in the preoperative individual simulation. Following liver resection according to the fluorescent region, no bile leak or recurrence was observed. Observation using a fluorescence microscope revealed no malignant findings in the fluorescent rim. Pathologically, liver resection with fluorescent margins was deemed reasonable.

Conclusion: In cases where preoperatively administered ICG stagnates and aligns with the resection site in the preoperative patient-specific simulation, it may contribute to the surgical outcome of LH.
Abstract Submission No. 101827
P-0665
Laparoscopic resection of segment 4 & ventral area of right anterior section
Yang Won Nah1, Jung Ik Park1
1Ulsan University Hospital Ulsan South Korea

Introduction: Based on the anatomy of ventral-dorsal ramification of the right anterior portal vein, only ventral area of right anterior section can be removed, leaving portal branches to the dorsal area intact. By this procedure half of the volume of right anterior section can be saved. Short-term results of laparoscopic resection of segment 4 & ventral area (LLR S4 + ventral area) were studied.

Method: During the period from November 2018 to November 2022, the authors performed 5 cases of LLR S4 + ventral area. Mean age was 62 years. All the 5 patients were male. The diagnosis was HCC in 4 and combined hepatocellular cholangiocarcinoma in 1. One patients had 2 tumors and RFA was done for the 1.5cm sized tumor in segment 5/6 before the laparoscopic surgery. Mean tumor size was 2.75cm (range, 2.0 ~ 4.7cm). Mean BMI was 23.39 (range 21.02 – 25.29). Underlying liver was chronic hepatitis in 2 and cirrhosis in 3. Four patients were positive for HBsAg. Mean liver elasticity was 6.65 kPa (range, 4.4 ~ 11.8 kPa) on Fibroscan.

Result: Mean operation time was 321 minutes. Mean estimated blood loss was 400 ml. Mean Pringle time was 75 minutes. No patient received blood transfusion. Mean postoperative hospital stay was 7.4 days. There was no postoperative complication or readmission within 60 days.

Conclusion: LLR S4 + ventral area is easier to perform than laparoscopic central bisectionectomy. Tumor adherent to the middle hepatic vein is a good indication for this operation.

Abstract Submission No. 101828
P-0666
VIBRATION-CONTROLLED TRANSIENT ELASTOGRAPHY TO EXCLUDE STEATOSIS IN LIVING-LIVER DONOR EVALUATION

Sarita Ratana-Amornpin1,2, Pongphob Intaraprason1,2, Nuttapon Arpornsujaitikun1,3, Goragoch Gespresert4,5, Bundit Sukulchairungrueng6, Sutipong Jongjirasri6,7, Pattana Sornmayura8, Piyaporn Kaewduang1,2, Sasiwimol Thurapokol1, Abhasnee Sobhonslidusik8
1Division of Gastroenterology and Hepatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
2Bangkok Thailand, 3Excellence Center for Organ Transplantation, Faculty of Medicine, Ramathibodi Hospital, Mahidol University Bangkok Thailand, 4Vascular and Transplantation Unit, Department of Surgery, Faculty of Medicine, Ramathibodi Hospital, Mahidol University Bangkok Thailand, 5Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University Bangkok Thailand, 6Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University Bangkok Thailand

Background: Using vibration-controlled transient elastography (VCTE) with controlled attenuation parameter (CAP) as an assessment of hepatic steatosis for living donor evaluation might eliminate necessity for invasive liver biopsies. This study aimed to evaluate correlation between CAP and histologic amount and percentage of liver fat and between CAP and magnetic resonance imaging fat signal fraction (MRI-FSF).

Materials and methods: This was a retrospective study of subjects who were living donors for living donor liver transplantation (LDLT) from January 2019 to June 2023. The histopathological report was obtained during pre-LDLT evaluation or surgery. The receiver operating characteristic (ROC) analysis was used to predict hepatic steatosis with appropriate sensitivity, specificity, and the Youden’s Index for liver donor screening.

Results: Fifty-three subjects were living donors, including 15 (28.3%) men with a mean age of 31.9±6.9 years. The area under the curve (AUC) for CAP to predict hepatic steatosis ≥5% by histology was 0.851, 95%CI 0.727–0.974, p <0.001. The optimal cutoff value of CAP was ≥240 dB/m to detect histologic steatosis ≥5%, with sensitivity of 72.7% and specificity of 83.3%. To predict hepatic steatosis >5% by MRI-FSF, the AUC for CAP was 0.771, 95%CI 0.609–0.933, p=0.004. The optimal cutoff value of CAP was ≥254 dB/m to detect MRI-FSF >5%, with sensitivity of 61.5% and specificity of 92.1%.

Conclusions: VCTE is a non-invasive test that could be used for hepatic steatosis assessment in living donors for LDLT evaluation. Subjects evaluated for living donors with CAP <240 dB/m could avoid liver biopsy.

Abstract Submission No. 101957
P-0667
Extended Left Lobe Graft for Adult-to-adult LDLT for donor safety and recipient outcome

Ho Joong Choi1, Gun Hyung Na2, Jin Ha Chun1, Young Kyoung You1
1Department of General and Gastroenterological Surgery, Showa University School of Medicine Tokyo Japan

Abstract Background and Objective: Radiofrequency ablation (RFA) has been performed for liver tumors. However, some paper reported liver resection of local recurrence after RFA has a poor prognosis due to local progression of tumors or tumor progression with unclear boundaries. This study investigated the pathological features using near-infrared fluorescent imaging for local recurrence after RFA.

Patients and Methods: In this retrospective study, we included seven patients who underwent liver resection for local recurrence of hepatocellular carcinoma (HCC, n=6) or liver metastasis (colorectal liver metastasis (CRLM), n=4) or lung carcinoid liver metastasis (n=1)) after RFA at our department between 2011 and 2020. Histopathological specimens were evaluated using fluorescent microscopy (BZ-X800; Keyence).

Results: Pathological findings revealed negative surgical margin in all patients. The fluorescence patterns of HCC were as follows: partial fluorescent type and combined type (Partial + Rim). Conversely, the fluorescence pattern of liver metastasis was rim fluorescent type (A fluorescence signal only surrounding the tumor) in all cases. In the rim positive cases of both HCC and liver metastasis, under fluorescence microscope, the viable tumors located inside the fluorescence rim and no malignant finding was detected in the fluorescence rim surrounding the tumor. It was suggested that non-fluorescent signal area showed the curative parts with coagulative necrosis treated by RFA.

Conclusion: The histopathological findings suggested near-infrared fluorescent imaging is a useful navigation tool for detecting tumors and identifying boundary between tumor and non-tumor in liver resection for local recurrence of liver tumors after RFA.
Humihiko Fujita, Toru Hisaka
Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China

Background: Donor hepatectomy carries a significant risk for the donor. In LDLT where donor safety is most important, considering the use of the left lobe is an essential option for donor safety. This study aims to assess the safety of donors and the outcomes for recipients when using an extended left lobe graft.

Patients and Methods: From January 2018 to August 2022, LDLT was performed on 225 patients at our center. Among them, 32 patients underwent LDLT using an extended left lobe (ELL) graft and 193 patients underwent LDLT using a modified right lobe (MRL) graft. In these two groups, donor safety was first compared, and then, the recipient outcomes were compared according to the type of graft.

Results: Due to the volume problem of the graft, the ELL group had a male ratio of 93.8%, which was higher than that of the MRL group. The complication rate of Clavien-Dindo IIa or more was the same in both groups, but peak total bilirubin and peak PT INR after donor hepatectomy were both significantly higher in the MRL group. Normalization of total bilirubin and PT were also earlier in the ELL group. For the recipients, there was no difference between the two groups in vascular complications, biliary complications and overall survival.

Conclusions: The use of ELL grafts in adult LDLT protects donor well-being while not negatively impacting recipient outcomes. In adult-to-adult LDLT, it is recommended to consider the use of ELL grafts as long as they are available in adequate volume.

Abstract Submission No. 102059
P-0668

Right priority approach in laparoscopic total caudal lobectomy for hepatocellular carcinoma
Xing-Ru Wang, Jianwei Li, Jun Cao
1Quing Second People’s Hospital Yunnan,China China, 2Department of Hepatobiliary Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China Guangzhou China, 3Department of Hepatobiliary Surgery, Southwest Hospital, Army Medical University, Chongqing, China Chongqing China

Owing to its special location and anatomical characteristics, the caudate lobe (CL) resection is the most complex and difficult liver surgery. The portal vein, biliary tract, and artery of the total CL do not always walk in Glissonean pedicle together; the portal vein branches are complex and irregular, and the outflow of the CL is also diverse. Effective anatomical criteria and technical means to clearly define the right and ventral margins of the CL are still lacking. The complete right liver mobilization through right priority approach can help safely dissected the right hepatic short veins and caudate process hepatic pedicle (G1C), and the right CL resection plane can be identified using Peng’s line or right paracaval plane as landmarks. This study reports the technical criteria for the right priority approach and good postoperative outcomes.

Abstract Submission No. 102085
P-0669

The safety and efficacy of laparoscopic repeat hepatectomy for recurrent hepatocellular carcinoma
Shogo Fukutomi, Hisamune Sakai, Kazuaki Hashimoto, Ryuta Midorikawa, Shoichiro Arai, Yuichi Goto, Masanori Akashi, Humihiko Fujita, Toru Hisaka
1Department of Surgery, Kurume University School of Medicine Fukuoka Japan

Background: Repeat hepatectomy is often technically difficult because of severe postoperative adhesion and deviation of the remnant liver caused by the previous liver resection. This study aimed to report perioperative outcomes of laparoscopic repeat hepatectomy (LRH) compared with those of open repeat hepatectomy (ORH).

Methods: One hundred and forty-two patients who underwent repeat hepatectomy for hepatocellular carcinoma (HCC) between April 2016 and August 2022 were enrolled. Of these patients, 102 and 40 patients underwent ORH and LRH, respectively. The clinical characteristics and perioperative outcomes of the groups were compared using propensity score matching (ORH-PSM group versus LRH-PSM group).

Results: Propensity score matching showed 18 patients in each of these groups. There were no significant differences in patient characteristics and tumor factors between the groups. Intraoperative blood loss (P=0.005) was lower and the operating time (P=0.03) and postoperative hospital stay (P=0.001) were shorter in the LRH-PSM group compared with those of open repeat hepatectomy (ORH).

Conclusion: LRH is a safe approach for recurrent HCC in selected patients.

Abstract Submission No. 200010
P-0671

Direct estimation of the future remnant liver function reserve intraoperatively for predicting POF
Naoya Sato, Teruhide Ishigami, Yasuhide Kofunato, Junichiro Haga, Makoto Muto, Shigeiuki Tsukida, Hiroshi Chiba, Takayasu Azuma, Takashi Kimura, Akira Kenjo, Shigeru Marubashi
1Department of Hepato-Biliary-Pancreatic and Transplant Surgery Fukushima Japan

Background: The prediction of post-hepatectomy liver failure (PHLF) based on remnant liver function reserve is crucial for the success of hepatectomy. In patients with perihilar cholangiocarcinoma, a disparity between indirect and direct estimation of future remnant liver function may be observed. The objective of this study was to investigate whether intraoperative measurement of indocyanine green (ICG) clearance in a future remnant liver could serve as a predictor of PHLF.

Methods: This retrospective study included 49 consecutive patients who underwent anatomical hepatectomy between June 2016 and August 2022. Intraoperative ICG plasma disappearance rate (int-ICG-PDR) was measured after clamping the selective hepatic inflow to the liver that was to be resected. Logistic regression analysis for predicting PHLF grade B/C was employed to identify independent predictors.

Results: The median age of the population was 69 (62-74, IQR). Of the operations performed, 89.8% were major hepatectomies. PHLF Grade
Conclusions:
Int-ICG-PDR was a promising predictor for PHLF in patients undergoing anatomical hepatectomy.

Abstract Submission No. 200109
P-0672

Post liver transplantation infection in Mongolia

OCHIRKHUREE BAYARMAA1, Norovrenchin Odontungalag2, Buuveibaatar Bolormaa3, Badamgarav Zoljargal1, Ganbold Anar4
1First Central Hospital of Mongolia Ulaanbaatar Mongolia, 2First Central hospital of Mongolia Ulaanbaatar Mongolia, 3First Central hospital of Mongolia Ulaanbaatar Mongolia, 4First Central hospital of Mongolia Ulaanbaatar Mongolia

Introduction: Liver transplantation (LT) is the definitive treatment for patients with end stage of liver disease. Infections are common consequences of organ transplantation resulting from immune suppression and prolonged hospitalization.

Aims: to determine incidence, demography, risk factors, timeline and characteristics of post-liver transplantation infections at our center.

Materials and methods: This retrospective cohort study examined the records of all liver transplant recipients under 65 years of age in First Central Hospital of Mongolia from August 2016 to February 2023. Demographic, laboratory, and clinical data and the administered medications were recorded.

Results: All recipients with at least 12 months of follow up were enrolled (n=180 M-89, F-91, average age 44). Bacterial infection incidence was 75%: gram-negative 41.3% and gram-positive 58.6%. Surgical site infections (SSI) were the commonest (41.6%), followed by urinary tract infections (UTI) (10.9%), sepsis (11.9%) and Surgical site infections (SSI) were the commonest (41.6%), followed by urinary tract infections (UTI) (10.9%), sepsis (11.9%) and Respiratory infections (27.2%). The length of hospitalization, re-hospitalization was significantly higher in the infected group than in non-infected group. The median isolation time of Gram-negative bacteria was 14.5 ±7.3, of gram-positive rods 15± 6.4 days after LT.

This study shows 8.77% of total infections were multidrug resistant.

Among the MDR bacterial 43.7%, and 43.7% of gram-negative bacteria were ESBL and MDR-GNB respectively, and 12.5% was CRE. There were 3 cases of active TB and which was developed 1.3 years after LT.

Conclusion: SSI were more common sources of infection and most infections were detected in the early period after LT.

Abstract Submission No. 200119
P-0674

Parental and domino auxiliary liver transplantation for Crigler-Najjar syndrome

zhenjin cai1,2,3, Qingguo Xu1,2,3, Tianxiang Li1,2,3
1nonparty QingDao China, 2Affiliated Hospital of Qingdao University Qingdao China, 3Qingdao University Qingdao China

Background: In this research, the surgical procedure, prognosis, and prognostic of parental liver transplantation (LT) in combination with domino auxiliary liver transplantation (DALT) were evaluated.

Case presentation: Here, we describe a case of parental LT paired with DALT. We observed the overall outcomes, postoperative issues, and postoperative recovery of the donors and recipients.

Methods: The domino donor was released four weeks after surgery, and the parental LT donor recovered without incident. On the sixth day after surgery, the blood flow ratio of the domino recipient was checked, and it showed a declining trend. As an emergency measure, a portal vein stent was implanted together with a portal vein balloon dilatation and a portal vein embolization. Following the intervention, the child’s blood flow improved, and the patient was discharged three weeks after the operation.

Conclusion: Children with liver transplants may now get innovative therapy for metabolic problems that combine parental LT and DALT, giving them the same development possibilities as healthy children.

Abstract Submission No. 200133
P-0675

Successful downstaging is a good prognostic for unresectable HCC after conversion therapy

Kunfu Dai1, Yang Xin1, Tianxiang Li1, Ge Guan1, Feng Wang1, Yong Zhang1, Qingguo Xu1, Yuan Guo1, Jinzhen Cai1, Liqun Wu2
1Affiliated Hospital of Qingdao University Qingdao China, 2Affiliated Hospital of Qingdao University Qingdao China, 3Affiliated Hospital of Qingdao University Qingdao China

Background and objective: The prognosis of unresectable advanced hepatocellular carcinoma (HCC) is poor. The advances in local therapy...
and rapid development of systemic therapy have brought hope for curative resection after conversion therapy to these patients. This study retrospectively analyzed the prognosis and influencing factors of unresectable HCC patients who underwent conversion therapy and surgical resection.

Materials and Methods: From January 2020 to December 2022, a total of 56 patients with unresectable or recurrent HCC after resection were treated with surgical resection after targeted drugs, immune checkpoint inhibitors combined or not combined with local treatment, which included hepatectomy in 31 cases, liver transplantation in 18 cases and extrahepatic metastasis resection in 7 cases. The follow-up was until December 25, 2023 or death, with a median follow-up time of 22.5 months.

Results: There were 47 males and 9 females in the 56 patients, with an average age of 56.9 years (36-78 years). According to surgical pathology, 25 cases had a downstaging of the tumor BCLC stage at the time of surgery, 28 cases had unchanged stage and 3 cases experienced tumor progression. Since the date of surgery, the median overall survival time was not reached, and the 1-, 2- and 3-year survival rates were 96.4%, 79.3% and 61.3%, respectively. Non-downstaging, abnormal AFP levels and microvascular invasion after conversion therapy were poor factors that affect prognosis (p<0.05), and the non-downstaging was an independent risk factor of prognosis (p=0.011). The 3-year survival rate of was 95.7% in the patients with successful downstaging (25 cases). The median disease-free survival (DFS) was 23.9 months. HBsAg positive, non-downstaging and abnormal AFP levels after conversion therapy and pathological microvascular invasion were poor influencing factors of DFS (p<0.05), and abnormal AFP levels after conversion therapy was an independent risk factor of DFS (p=0.007).

Conclusion: Unresectable advanced HCC patients who underwent surgery after systemic therapy combined or not combined with local therapy had a better prognosis, especially those with successful downstaging. The abnormal AFP levels after conversion therapy was an independent risk factor of DFS.

Key words: hepatocellular carcinoma, unresectable; conversion therapy; liver resection; liver transplantation; systemic therapy; local therapy; prognosis

P-0676

Hemorrhagic complications after hepatectomy in patients receiving antithrombotic therapy

Haruki Mori1, Hiromitsu Machira1, Hajime Ishikawa1, Nobuhito Nitta1, Takeru Maekawa1, Toru Miyake1, Sachiko Kaida1, Masatsugu Kojima1, Soichiro Tani1, Katsuhi Takebayashi1, Reiko Ohtake1, Masaji Tani1

1Department of Surgery, Shiga University of Medical Science Shiga Japan

Background: In recent years, the number of patients taking oral antithrombotic drugs has increased. In the present study, we used propensity score matching (PSM) to investigate the effect of antithrombotic medication on perioperative outcomes in patients undergoing liver resection.

Methods: Patients were divided into two groups: antithrombotic group (127 patients, 17.5%) and non-antithrombotic group (548 patients, 82.5%). Sex, age, body mass index, history of liver resection, presence or absence of laparotomy, operative technique and presence or absence of biliary reconstruction were used as covariates and a propensity score was calculated by logistic regression. Postoperative complications were compared after matching in both groups.

Results: The mean operative time, intra-operative blood loss and transfusion rate in all patients were 285 min, 383 ml and 23.5% respectively, and the postoperative complication rate (CD classification ≥III) was 23.7%. Compared to the oral antithrombotic group and the non-antithrombotic group, the mean age (75.1 vs. 67.3 years, p < 0.001) and male ratio (89.8% vs. 69.4%, p < 0.001) were higher in the antithrombotic therapy group. The postoperative complication rate (CD classification ≥Grade III) was higher in the antithrombotic therapy group (31.5% vs. 19.9%, p = 0.009), but PSM analysis between the two groups showed no significant difference in postoperative complication rates. Analysis focusing on the rates of hemorrhagic and thrombotic complications also showed no significant differences.

Conclusions: Antithrombotic therapy was not found to be an independent risk factor for post-operative complications, including hemorrhagic and thrombotic complications.
Background: The occurrence of liver dysfunction, an immune-related adverse event (irAE) caused by immune checkpoint inhibitors (ICIs), and treatment efficacy is not clear. We investigated the relationship between the occurrence of hepatic dysfunction and treatment response in patients treated with ICIs at our hospital.

Method: We studied 813 patients treated with ICI between November 2014 and August 2023 for the occurrence of irAEs and compared survival (OS) with and without treatment continuation due to liver dysfunction.

Results: Of the patients treated with ICI, 309 (38%) developed irAE and 42 (5.2%) developed hepatic dysfunction. The median (range) ALT and T-Bil of patients who discontinued ICI treatment were 359 (53-1388) U/mL and 1.15 (0.44-12.41) mg/dL, respectively. Of the discontinued cases, 20 (47.6%) had Grade 3/4 hepatic dysfunction, and 42 (5.2%) developed hepatic dysfunction. Seven of all patients received CGP (comprehensive genome profile) test, with two cases showed positive for FGFR fusion genes, leading to the introduction of pemigatinib (one case was introduced at another institution). In cases where pemigatinib was initiated at our hospital, disease control has been maintained for six months after initiation, and the patient is still alive after more than two years from the initial diagnosis. However, the overall survival was poor at 13.5 months, and long-term survival was observed in cases where SD or better treatment outcomes were achieved with primary chemotherapy.

Conclusion: The prognosis for unresectable intrahepatic cholangiocarcinoma is extremely poor, and achieving SD or better treatment outcomes in primary therapy has been identified as a factor contributing to long-term survival.

Abstract Submission No. 101240
P-0679

Referral to a hepatologists may prolong OS of patients with malignancies treated by ICI

Kaori Matsumoto1, Junichiro Wakatsuki1, Masao Omata2
1Department of Pharmacy, Yamanashi Prefectural Central Hospital Yamanashi Japan, 2Gastroenterology Department, Yamanashi Prefectural Central Hospital Yamanashi Japan

Background: In recent years, pemigatinib, an FGFR inhibitor, and Durvalumab, anti-PD-L1 antibody has been approved for unresectable intrahepatic cholangiocarcinoma (ICC). In this study, we evaluated the treatment outcomes of ICC at our hospital and also reported on the treatment efficacy and safety of GCD (gemcitabine+cisplatin+Durvalumab) therapy and pemigatinib.

Methods: The study included 22 cases of ICC treated at our hospital (average age 70 years, M:F = 13:9, stage II:III:IVA:IVB = 3:1:9:9). We conducted an evaluation of treatment outcomes and prognosis for these cases.

Results: Primary treatment consisted of GC therapy in 17 cases and GCD therapy in 5 cases. The response rate was 17.6%, and disease control rate was 58.8%. In the patients who received GCD therapy, 3 cases showed PR, and 2 cases showed SD. None of the cases exhibited severe side effects. Seven of all patients received CGP (comprehensive genome profile) test, with two cases showed positive for FGFR fusion genes, leading to the introduction of pemigatinib (one case was introduced at another institution). In cases where pemigatinib was initiated at our hospital, disease control has been maintained for six months after initiation, and the patient is still alive after more than two years from the initial diagnosis. However, the overall survival was poor at 13.5 months, and long-term survival was observed in cases where SD or better treatment outcomes were achieved with primary chemotherapy.

Conclusion: The prognosis for unresectable intrahepatic cholangiocarcinoma is extremely poor, and achieving SD or better treatment outcomes in primary therapy has been identified as a factor contributing to long-term survival.

Abstract Submission No. 101418
P-0680

Durvalumab plus Tremelimumab treatment in patients with unresectable HCC: an early experience.

Yasuhide Motoyoshi1, Makoto Wataya1, Kosuke Matsumoto1, Yuki Kugiyama1, Tomoyuki Suehiro1, Akira Saeki1, Shinya Nagoaka1, Kazumi Yamasaki1, Atsumasa Komori1, Hiroshi Yatsushashi1
1National Hospital Organization (NHO) Nagasaki Medical Center, department of Hepatology Omura Japan

Background: Durvalumab + tremelimumab (Dur+Tre), a new first-line drug combination for unresectable hepatocellular carcinoma, has become available in Japan from April 2023. We investigated the efficacy and safety of Dur+Tre treatment at our hospital.

Methods: Seven patients with unresectable hepatocellular carcinoma who received Dur+Tre treatment from April 2023 to November 2023 were enrolled and evaluated for their clinical background, treatment response (radiological evaluation by RECIST v1.1, and changes in tumor markers), and adverse events (according to CTCAE ver. 5.0).

Results: The median age of the patients was 72 (43-81) years. The median ALBI score was -2.16 and four patients were classified in modified ALBI grades 2b and 3. One and six patients had BCLC stage B and C, respectively. Treatment lines varied from 1st (n=2), 2nd (n=4), and 3rd (n=1). 5 patients continued treatment; the number of courses was 6 (n = 1), 5 (n = 2), 3 (n = 1), and 2 (n = 1). Clinical responses were observed in these 5 patients; three were judged as PR by RECIST v1.1, while decreases in tumor markers were demonstrated in 4 patients. Only one patient had a grade 3 or higher irAE (fever).

Conclusions: Although 6 out of 7 cases were BCLC-C, PR were found in 3. Dur+Tre treatment seemed to be a useful treatment option for unresectable HCC.

Abstract Submission No. 101588
P-0681

Interstitial Pneumonia During Atezolizumab/Bevacizumab Therapy for Unresectable HCC

Mizuki Ariga1, Teiji Kuzuya1, Yoshiki Hirooka1
1Department of Gastroenterology and Hepatology, Fujita Health University Toyoake Japan

Aim: We investigated the occurrence of interstitial pneumonia after Atezolizumab/bevacizumab (Atz/Bev) introduction for unresectable hepatocellular carcinoma (HCC) and its anti-tumor effect.

Methods: From October 2020 to May 2023, 124 patients with advanced HCC who received Atz/Bev in our hospital were enrolled. KL-6 and SP-D levels were regularly measured. The median age was 75 years, 24 patients had lung metastases, the median KL-6 was 258.5, and the median SP-D was 54.6 at baseline.

Results: Eight patients (6.5%) developed interstitial pneumonia after a median follow-up of 275 days. The median time to onset of interstitial pneumonia was 6.5 months and the cumulative incidence of interstitial pneumonia was 6.5% at six months and 7.9% at one year. The best antitumor response in the 8 patients who developed interstitial...
Abstract Submission No. 101667
P-0682
Effect of atezolizumab bevacizumab combination therapy on skeletal muscle mass and cardiac function
NAGUMO HIDEKI1, Mukozu Takanori1, Matsui Teppei1, Mohri Kunihide1, Yoshimine Naoyuki1, Daido Yasuko1, Wakui Noritaka1, Momiyama Koichi1, Nagai Hidenari1
1Toho University Omori Medical Center Tokyo Japan

Background: We reported that sorafenib, an anti-VEGF inhibitor, may reduce skeletal muscle mass by suppressing carnitine absorption in patients with liver cancer (Anticancer Res 2020 40:4173-4182). However, the effects of the monoclonal antibody VEGF inhibitor Bevacizumab have not been reported.

Aim: Objective: To clarify the age-dependent effects of atezolizumab + bevacizumab (AteBev) combination therapy on skeletal muscle mass and cardiac function in patients with hepatocellular carcinoma (HCC).

Methods: Eighty-three HCC patients treated with AteBev combination therapy in our department were included. Before treatment and 3 weeks after treatment, blood samples were collected. Abdominal CT examination was performed 6 weeks after treatment, and the therapeutic effect was evaluated using mRECIST, and PMI was calculated from the iliopsoas muscle area. In addition, left ventricular systolic function was evaluated using global longitudinal strain (GLS) in echocardiography.

Results: There were 16 middle-aged patients, 25 early-elderly patients, and 42 late-elderly patients. In the study of skeletal muscle mass, PMI after 6 weeks of treatment showed significant changes in middle-aged and early-elderly patients. A significant decrease was observed in the late-elderly patients, although no cardiac function studies showed no significant changes in %Ejection Fraction and GLS after 3 weeks of treatment in middle-aged patients, but significant decreases in early- and late-elderly patients.

Conclusion: Cardiac function decline was confirmed in the elderly patients after 3 weeks of treatment in AteBev therapy. In this case, it was considered important to actively introduce nutrition and exercise therapy to maintain not only skeletal muscle mass but also cardiac function.

Abstract Submission No. 102066
P-0684
Analysis of disease progression in patients who were evaluated as complete response (CR) by mRECIST
Jun Imamura1, Masamichi Kimura1, Kiminori Kimura1
1Division of Hepatology, Department of Internal Medicine, Tokyo Metropolitan Komagome Hospital Tokyo Japan

Background: The mRECIST is widely used as a criterion for evaluat- ing response to therapy in hepatocellular carcinoma. However, the clinical significance of CR is not well understood.

Methods: We analyzed patients with advanced hepatocellular carci noma who received systemic chemotherapy at our institute from June 2018 to July 2023. We selected patients evaluated as CR by mRECIST, and we analyzed whether the patients subsequently became Progressive Disease (PD) and the associated factors.

Results: 21 patients were evaluated as CR by mRECIST. Lenvatinib was performed in 8 patients (total 98 cases) and atezolizumab plus bevacizumab in 13 patients (total 78 cases). 18 patients were studied excluding 3 patients who underwent LEN-TACE. Mean age was 75.0±7.3 years, Male/Female 15/3, HBV/HCV/NBNC 2/4/12, BCLC stage A/B1/B2/C 2/1/10. Evaluation by RECIST was CR/PR/SD/PD 3/2/1/3. After a mean follow-up of 1.7 years, 11 patients (61%) were evaluated as PD. The proportion of PD was 4/5 (80%) in the lenvatinib group, significantly higher than 7/13 (54%) in the atezolizumab plus bevacizumab group. The proportion of PD were CR 2/3 (67%), PR 6/12 (50%) and SD 3/3 (100%) when grouped by RECIST. In the group that continued chemotherapy, the rate was 5/9 (56%), and in the group that completed chemotherapy, the rate was 6/9 (67%). There was no significant difference between the groups.

Conclusion: Of patients evaluated as CR by mRECIST, 61% had disease progression. The proportion of PD was significantly higher in the
lenvatinib group, suggesting the need for additional therapy or close follow-up.

Abstract Submission No. 200164
P-0685

A case of hemophagocytic syndrome after pembrolizumab treatment for breast cancer

Yukiko Ootsuki1, Kenichi Nakamura1, Yoshinori Ozono1, Yuri Komaki1, Hisayoshi Iwakiri1, Satoru Hasuiki1, Kenji Nagata1, Hiroshi Kawakami1
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
Miyazaki Japan

A 52-year-old woman was diagnosed with right breast cancer (ER, PgR, HER-2-neu) in June 2023 and preoperative chemotherapy (pembrolizumab + carboplatin + paclitaxel) was started in July. The tumor subsequently shrank, but a Grade 3 liver injury appeared, and the patient was referred to the hepatology clinic in November. Preoperative chemotherapy was stopped, but liver injury did not improve, and the patient was admitted to our department with fever and worsening liver injury. Pembrolizumab-related immune-related adverse event was suspected, and the patient was started on prednisolone (2 mg/kg body weight). However, marked thrombocytopenia, leukopenia, and hyperferritinemia were noted, and hemophagocytic syndrome (HPS) was suspected. Bone-marrow puncture revealed hemophagocytosis and a diagnosis of HPS was made. Steroid pulse therapy was administered for 3 days, and prednisolone was resumed thereafter. Liver injury improved quickly, but thrombocytopenia persisted, thus second bone marrow puncture was performed on the 25th day. There was no hemophagocytosis, and megakaryocytes were increased in the bone marrow. In addition, hyperferritinemia was also improved. The patient is currently under observation while tapering off prednisolone. HPS is a diagnosis of HPS was made. Steroid pulse therapy was administered for 3 days, and prednisolone was resumed thereafter. Liver injury improved quickly, but thrombocytopenia persisted, thus second bone marrow puncture was performed on the 25th day. There was no hemophagocytosis, and megakaryocytes were increased in the bone marrow. In addition, hyperferritinemia was also improved. The patient is currently under observation while tapering off prednisolone. HPS is a systematic inflammatory disease characterized by macrophage hemophagocytosis in the bone marrow, with a variety of symptoms including fever, liver damage, pancytopenia, coagulation abnormalities, elevated LDH levels, and hyperferritinemia. In Japan, as of September 2018, there were 6,421 cases of adverse reactions due to immune checkpoint inhibitors, of which HPS was reported in 11 cases (about 0.2%), which is very rare.

Abstract Submission No. 100565
P-0686

Cardiovascular Risk Factors Are Associated With Hepatic Encephalopathy After TIPS Insertion

Peter cyn Daniel1, Benjamin ky Nah1, Kamarjit s Mangat2, Mark d Muthiah1,2, Margaret lp Teng2
1Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore Singapore
2Division of Interventional Radiology, Department of Diagnostic Imaging, National University Hospital, Singapore Singapore

Background: Transjugular intra-hepatic porto-systemic shunt (TIPSS) is a well-established intervention for reducing portal hypertension for treatment of refractory ascites and variceal bleeding. Previous studies on post-TIPSS complications were predominantly done in Western populations, and mostly included patients with alcohol or viral etiology of liver disease. We hence aimed to evaluate the prevalence and risk factors of major post-TIPSS complications in a tertiary centre in Singapore.

Methods: A retrospective observational cohort study involving 61 patients who underwent TIPSS at National University Hospital, Singapore between 1 January 2014 to 31 December 2021 was performed. The proportion of patients who developed hepatic encephalopathy (HE) and fluid overload after TIPSS was evaluated. Risk factors for these complications were interrogated through odds ratios (OR) using logistic regression.

Results: 26 patients (42.6%) developed HE and 8 patients (13.1%) developed fluid overload. Adjusting for age, gender, ethnicity, Child-Pugh Score and Model for End-Stage Liver Disease score , multivariate logistic regression analysis found that diabetes mellitus (OR 8.56, 95%CI 1.84-39.9, p = 0.006), hypertension (OR 4.1, 95% CI 1.21-13.9, p = 0.024), higher body mass index (OR 1.14, 95% CI 1.01-1.29, p = 0.039), and coronary artery disease (OR 7.01, 95% CI 1.26-39.1, p = 0.026) were associated with development of HE. Additionally, low HDL (OR 17.29, 95%CI 1.70-175.76, p = 0.016) was associated with development of fluid overload.

Conclusion: Presence of cardiovascular risk factors was associated with development of post-TIPSS HE. Given the rising prevalence of metabolic dysfunction-associated steatotic liver disease, further research to evaluate this association is crucial to optimise patient selection for TIPSS.

Abstract Submission No. 100728
P-0687

Hepatic Artery Pseudoaneurysm, a Rare Fatal Complication of Cholecystectomy: A case report

Bin rashid a Chin1, Zayed Tan1, Miguel alejandro b Baroque1, Leila Sawadjaan1, Maylan Ocat1, Edhel Tripon1
1The Medical City Pasig City Philippines

Background and Significance: Hepatic artery aneurysm is rare with an incidence of 0.03% and the second most common type of visceral aneurysm. Pseudoaneurysm of the hepatic artery is caused by injuries in the hepatobiliary system with cholecystectomy as the most common cause. Hepatic artery aneurysm is an emergency due to the risk of exsanguination and the treatment of choice is angioembolization. Due to its rarity and high mortality, we present a case of hepatic artery pseudoaneurysm in a female with history of cholecystectomy.

Case: A 48 year old female with a history of laparoscopic cholecystectomy (2018) presented with one month history of melena associated with epigastric pain. Gastroscopy showed no ulcers or other source of bleeding. Contrast abdominal CT scan showed biliary ectasia, however, contrast MRCP done showed a right hepatic artery pseudoaneurysm with probable duodenal fistula thus was advised angioembolization at our institution. Hepatic angiogram showed a bleeding focus (pseudoaneurysm) seen arising from a branch in direct communication with the proximal right hepatic artery adjacent to the cholecystectomy clips (see figure 1). Transcatheter coil embolization of left hepatic artery branches and covered stent placement across the right hepatic artery was done (see figure 2). Final angiogram showed cessation of active extravasation. No recurrence of bleeding thereafter thus the patient was discharged well.

Conclusion: Hepatic artery pseudoaneurysm is a rare but established complication of cholecystectomy. It is associated with high mortality thus prompt recognition is warranted. Initial diagnosis is via CT angiography and treatment is via endovascular intervention.
Abstract Submission No. 100876
P-0688
Anti-coagulation Therapy Do Not Improve Patency Rate in BCS After Interventional Recanalization.
Tianbo Fu1, Xuefeng Luo1
1West-China Medical School Chengdu, China China
Budd-Chiari syndrome (BCS) is a kind of syndrome with hepatic outflow obstruction. The etiology is quite different between eastern and western populations. Recent guidelines suggest patients with BCS need long-term anticoagulation after diagnosis, but whether anticoagulation is needed for Asian people with less hypercoagulable factors needs further discussion.
We consecutively enrolled patients diagnosed as BCS and underwent vascular interventional surgery (balloon/stent) in our hospital from January 2009 to March 2023. During the follow-up, we mainly focus on the condition of postoperative anticoagulation and vascular patency. Meanwhile, we recorded all bleeding-related events and survival. A total of 244 patients were included and divided into two groups (standard anticoagulation and non-standard anticoagulation) according to whether they use anticoagulation drugs regularly. Within the cohort, only 1/111 patient was JAK2V 617F positive and none was positive with MPL/CALR/Factor II G 20210A/Factor V G1691A. K-M survival analysis showed that there was no difference in the incidence of vascular restenosis between the two groups with a median restenosis time 28.956 months (25.099,32.814) vs 25.065 months (21.438,28.692) (P=0.698). There was no significant difference in survival. During anticoagulation, there were 4 cases with major bleeding, of which 3 took warfarin and 1 took rivaroxaban. There was no statistical difference in the occurrence of all bleeding events between patients who used different drugs.
In our cohort, anticoagulation therapy after interventional recanalization does not improve postoperative vascular patency and survival while some of the patients got massive bleeding during medication. Whether long-term anticoagulation is needed for every BCS patient needs further discussion.

Abstract Submission No. 102089
P-0690
Safety and Usefulness of Transbrachial Angiography in digestive system disease
Shunichi Matsuoka1,2, Tomohiro Kaneko1,2, Shuhei Arima1,2, Yasuhiko Nakata1, Masayuki Honda2, Naoki Matsumoto2, Ryota Masusaki2, Tatsuo Kanda2, Masahiro Ogawa2, Hiroshi Kogure2
1Department of Gastroenterology,Mitsuwadai General Hospital Chiba Pref Japan, 2Division of Gastroenterology and Hepatology,Nihon University School of Medicine Tokyo Japan
BACKGROUND/AIM: Transbrachial method is advantageous in that it does not necessitate prolonged rest in the hospital room, thereby reducing the need for nursing assistance, although technically, the procedure is more difficult to perform than via the transfemoral arterial approach. In this study, we determined the usefulness of this method for abdominal angiography.
METHODS: We began to employ this method as first choice for abdominal angiography at our hospital since May 2012. We have so far conducted the procedure in 240 times as part of the patient workup for digestive system disease.
RESULTS: There were no cases in which the arterial puncture failed, although it was found to be impossible to insert the catheter into the peritoneal cavity in one patient with a severely deformed aortic arch. After the patients returned to their rooms, re-bleeding from the puncture site occurred in one patient, but the bleeding could be controlled uneventfully by compression of the site. None of the cases required readmission because of Re-admission due to these complications or the development of pulmonary embolism occurred. This method also allowed the concomitant performance of Computed-Tomographic-angiography and smooth treatment procedures, such as embolization of the hepatic artery and hemostatic treatments with metal coils and partial splenic arterial embolization and others.
CONCLUSION: Transbrachial Brachial Arterial Angiography on the left side is of great very value in the clinical setting and may be employed as can be the first procedure of choice for abdominal angiography and the treatment of digestive system disease.

Abstract Submission No. 102096
P-0691
Transcatheter arterial chemoembolization by radial artery approach as a minimally invasive treatment
Ryo Jimbo1, Toru Ishikawa1, Ryo Sato1, Yuji Kobayashi1, Yoshifumi Sato1, Tomoe Sano1, Akito Iwanaga1, Junji Yokoyama1, Terasu Honma1
1Saiseikai Niigata Hospital Niigata city, Niigata prefecture Japan

OUTCOME OF PERCUTANEOUS TRANS-HEPATIC VARICEAL OBLITERATION FOR GASTRIC VARICEAL BLEEDING
Hyun Young Woo1, Jeong Heo2, Ki Youn Yi1, Young Joo Park1, Chang Won Kim1
1Pusan National University Hospital Busan South Korea
Background: We evaluated the efficacy and safety of percutaneous trans-hepatic or trans-splenic variceal obliteration (PTVO) as an alternative for management of GVB when BRTO is impossible.
Methods: Seventeen patients (mean age 59 years, 13 men) with liver cirrhosis who received PTVO for uncontrolled GVB from October 2017 to January 2023 were retrospectively examined. Efficacy was conducted the procedure in 240 times as part of the patient workup for digestive system disease.
Results: There were no cases in which the arterial puncture failed, although it was found to be impossible to insert the catheter into the peritoneal cavity in one patient with a severely deformed aortic arch. After the patients returned to their rooms, re-bleeding from the puncture site occurred in one patient, but the bleeding could be controlled uneventfully by compression of the site. None of the cases required readmission because of Re-admission due to these complications or the development of pulmonary embolism occurred. This method also allowed the concomitant performance of Computed-Tomographic-angiography and smooth treatment procedures, such as embolization of the hepatic artery and hemostatic treatments with metal coils and partial splenic arterial embolization and others.
Conclusion: PTVO of patients with cirrhosis led to no significant deterioration in liver function or procedure-related complications. This procedure can be considered an effective and safe option for patients with GVB when a conventional approach is not possible.
Background: Computed tomography during arterial portography (CTAP) and Computed tomography during hepatic arteriography (CTHA) provide high accuracy for the diagnosis of hepatocellular carcinoma (HCC). Still, their use is limited due to their invasiveness. Especially in the elderly patients, a minimally invasive TACE by the radial artery approach is expected. The current status of treatment from the radial artery approach TACE was studied.

Method: Twelve patients underwent TACE by radial artery approach between November 2021 and July 2023 at our hospital. Regarding patient age, indication for radial access, selectivity, procedure duration, vascular access site complications were investigated.

Result: The mean patient age was 73.8 years. Transradial approach was selected because of hepatic encephalopathy in 4 cases, advanced age or dementia in 5 cases, ascites effusion in 2 cases, and patient preference in 1 case. Selectivity included segmental embolization in 3 cases, lobar in 3 cases, and whole liver in 4 cases. There were no vascular access site complications, and RFA was added in 10 of the 12 patients with HCC. There was also one case of repeat treatment during the study, but no vascular damage was observed.

Conclusion: Transradial approach TACE with CT angiography can be a minimally invasive treatment for elderly patients with HCC. Further case accumulation and long-term follow-up are needed.

Application of swan neck microcatheter superselective catheterization in TACE of liver cancer

Jing Xiao1, Qingdong Li1
1Chongqing University Cancer Hospital Chongqing China

Background: TACE is currently recognized as the first choice therapy for patients with unresectable liver cancer, super-selective catheterization is a pivotal. The soft swan neck tip can be used as an effective alternative for those who have difficulty in superselective catheterization.

Methods: The clinical data of patients who used Maestro swan neck microcatheter and stride microcatheter combined with streaming microwire for liver cancer superselective chemoembolization in hospital were collected. Analyze the advantages and disadvantages of the swan neck microcatheter over the conventional straight-tip catheter superselection.

Results: In the swan neck microcatheter group, 467 cases underwent conventional hepatic artery chemoembolization, with a total of 926 blood supply arteries in the liver. Among them, 132 patients had extrahepatic feeding arteries. The 322 target arteries originated from the main artery at an acute angle, and 165 arteries present a “hairpin” pattern. WHISPER MS micro-guide wire were used in 52 patients. In the conventional straight-tip catheter group, 617 cases underwent conventional hepatic artery chemoembolization, with a total of 1052 intrahepatic arteries. Among them, 189 patients had extrahepatic feeding arteries. The 382 target arteries originated from the main vessel at an acute angle, forming a “hairpin” pattern with 178 blood vessels. Among them, 12 patients did not complete super-selective catheterization. The X-ray exposure time of the swan neck microcatheter group was shorter and the X-ray exposure dose was reduced.

Conclusion: The swan neck microcatheter can improve the success rate of interventional superselective catheterization, shorten the X-ray exposure time, reduce the X-ray exposure dose, and the catheterization is easier.

Screening of Hub genes analysis with immune infiltration in liver failure based on machine learning

jing ma1
1Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China Changsha China

Abstract
Objective: Key regulatory genes of Hepatitis B Virus(HBV)-related liver failure were screened by machine learning approach to analyze their correlation with immune cell infiltration to provide a new theoretical basis for HBV-related liver failure related mechanisms.

Method: HBV-related liver failure related expression microarrays were obtained in Gene Expression Omnibus(GEO) database and analyzed. The integrated microarrays were subjected to differential analysis and functional enrichment analysis. Differentially expressed genes (DEGs) were identified using LASSO regression algorithm (selection operator) and support vector machine recursive feature elimination (SVM-RFE) algorithm, among which the hub genes were screened using protein-protein interaction networks (PPI) and analyzed for their correlation with immune cell infiltration using CIBERSORT inverse convolutional integration algorithm.
Results: A total of 652 Genes were screened and further screening identified 28 potential candidate genes using LASSO regression analysis and SVM-RFE algorithm. PPI analysis revealed that C8B, CPB2 and MASP2 were HBV-related liver failure hub genes. Further analysis found C8B, CPB2 and MASP2 showed significant correlation with immune cell infiltration, including M2 macrophages.

Conclusion: Bioinformatics analysis of HBV-related liver failure microarrays revealed that C8B, CPB2 and MASP2 play crucial roles in the regulation of HBV-related liver failure and are significantly associated with immune cells, such as M2 macrophages.

Keyword: HBV-related liver failure; Immune cell infiltration; machine learning

Abstract Submission No. 100264
P-0695

Mesenchymal stem cell’s exosome exerts cytoprotective effects in acute liver failure via NEMO/NF-κB

SHIBO MENG1, JING ZHANG1, BINGLIANG LIN1
1The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Background and Aims: Balancing the death and proliferation of hepatocytes is crucial in developing non-transplantation treatments for acute liver failure (ALF), a condition with a high short-term mortality rate. Previous research has confirmed that small extracellular vesicles (sEVs) derived from mesenchymal stem cells (MSCs) can regulate proliferation and apoptosis of endogenous cells, but it is unclear whether they can promote proliferation and apoptosis of hepatocytes in acute liver failure.

Method: To establish the ALF cell model of L02/THLE2 cell lines induced by H2O2 and ALF mouse model induced by GalN/LPS, collect and identify MSC-sEVs, and co-culture with ALF hepatocytes, then detected the proliferation and apoptosis of hepatocytes in ALF cell model by fluorescent labeling technique, meanwhile, detected the expressions of NEMO, c-FLIP, inhibitor kB (IκB), pIκB and NF-κBp65 by western blot. Lastly, MSC-sEVs were injected into ALF mouse through the tail vein to evaluate the effect in vivo.

Results: The MSC-sEVs were combined with the ALF cell model, resulting in heightened activity of the hepatocytes within the ALF cell model. MSC-sEV-treated mice with ALF had higher 24 h survival rates and more significant reductions in liver injury than mice treated with sEV-free concentrated medium. Meanwhile, MSC-sEVs could upregulate NEMO, c-FLIP and pIκB, NF-κBp65 nuclear expression increased, and Bcl-2, Bax and cleaved caspase-3 expression decreased in vivo and in vitro.

Conclusion: The application of BMSC-sEVs showed a positive impact by preventing the development of ALF. NEMO/NF-κB signaling pathway plays an important role in liver protection from ALF by BMSC-sEVs.

Abstract Submission No. 100299
P-0697

Mesenchymal Stem Cell Derived EVs Promote Efferocytosis In Actute-on-Chronic Liver Failure

Junyi Wang1, Bingliang Lin1, Zhihui Li1, Jing Zhang1, Shibo Meng1
1The Third Affiliated Hospital of Sun Yat-sen University Guangzhou China

Background: ACLF is a severe clinical syndrome with a high mortality rate. We previously found that in vitro infusion of BM-MSCs can improve the survival rate of patients with ACLF patients, and had a high expression of MerT, which is essential in the efferocytosis process. In this study, we aim to evaluate the efficacy and safety of the BM-MSC EVs treatment in ACLF mouse model, explore how it affects the efferocytosis of macrophages.

Method: ACLF mouse were divided into EV group and PBS control group. After 24 hours, mouse liver tissue and serum were collected. HE staining was performed to compare the inflammation status, and ELISA was used to compare the liver function. Immunofluorescence staining was performed. Briefly, CD86 labeled M1 macrophages and CD206 labeled M2 macrophages were compared. Next, we performed TUNEL staining on apoptotic cells, the number of apoptotic cells between different groups were counted. Western blot was performed to detect the expression of MerT.

Results: Compared with the control group, the EV group showed a mild degree of inflammation in HE staining and a better improvement in liver function; The immunofluorescence results showed that the liver tissue of mouse in the EV group expressed more CD206 and less CD86, indicating that the M2 polarization of macrophages in the EV group; TUNEL staining showed that there were fewer apoptotic cells in the EV group, indicating increased efferocytosis. Western blotting of the liver tissue showed that MerT expressed more in the EV group.

Abstract Submission No. 100282
P-0696

Serum ammonia variation predicts mortality in patients with hepatitis B virus-related ACLF.

Mingqin Lu1, Yi-Jing Cai1, Jia-Jia Dong1, Rui-Cong Chen1, Qian-Qian Xiao1, Xu-Mei Li1, Chao Cai1, Xiu-Li Lin1, Ke-Qing Shi1
1The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

Background: Hyperammonemia is critical to the development of hepatic encephalopathy (HE) and is associated with mortality in end-stage liver disease. This study investigated the clinical value of ammonia variation in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients.

Methods: A total of 276 patients with HBV-ACLF were retrospectively recruited. Patients’ ammonia levels were serially documented. Baseline ammonia, Peak ammonia (Highest level), and Trough ammonia (Lowest level) were particularly corrected to the upper limit of normal (AMM-ULN). The primary endpoint was 28-day mortality.

Results: The 28-day, 3-month, and 12-month mortality were 19.2%, 25.7%, and 28.2%, respectively. 51 (18.4%) patients had overt HE (grade 2/3/4). Patients with higher grades possessed higher ammonia levels. Peak AMM-ULN was significantly higher in patients with overt HE and non-survivors compared with their counterpart (P < 0.001). Following adjustment for significant confounders, high Peak AMM-ULN was an independent predictor of overt HE (hazard ratio, 1.031, P < 0.001) and 28-day mortality (hazard ratio, 1.026, P < 0.001). The cutoff of Peak AMM-ULN was 1.8 determined by using X-tile. Patients with Peak AMM-ULN appearing at day 1-3 after admission had a higher proportion of overt HE and mortality compared to other groups. Patients with decreased ammonia levels within 7 days had better clinical outcomes than those with increased ammonia.

Conclusions: Serum Peak ammonia was independently associated with overt HE and mortality in HBV-ACLF patients. Serial serum ammonia may have prognostic value.
**Conclusion:** The treatment of ACLF with BM-MSC evs can promote efferocytosis, and improve the inflammatory response of liver tissue. Meritk protein may play a very important role in this process.

Abstract Submission No. 100329
P-0698

**DDX3X Regulates the Function of Endoplasmic Reticulum Stress in Acute on Chronic Liver Failure**

Xu Ling1, Zihao Fan1, Yao Gao1, Yaling Cao1, Zhenzhen Pan1, Xiangying Zhang1, Feng Ren1

1Beijing Institute of Hepatology/Beijing Youan Hospital, Capital Medical University Beijing China

The functional transition of endoplasmic reticulum (ER) stress plays a critical role in the progression of acute-on-chronic liver failure (ACLF), but the underlying mechanisms remain unclear. Here, we explored DDX3X and its mechanisms in the functional transition of ER stress. DDX3X increased with prolonged-ER stress, and its deficiency promoted apoptosis under short-term ER stress but protected cells from prolonged ER stress in vitro and in vivo. Cytoplasm DDX3X interacted with PPARα to translationally activated TFB expression under short-term ER stress, and phosphorylated DDX3X increased nuclear translocation to initiate cell apoptosis under prolonged ER stress. Serum DDX3X was increased in HBV-ACLF patients, and its fluctuations were related with the disease prognosis. We clarified the molecular mechanism for dual functions of DDX3X in ER stress functional transition.

Abstract Submission No. 100535
P-0699

**The long-term efficacy and safety of TAF in HBV-ACLF patients: A propensity score-matching analysis**

Juan Li1, Yushan Liu1, Qiao Zhang1, Taotao Yan2, Yingren Zhao1, Yingli He1, 2, 3, Yamin Wang1

1Department of Infectious Diseases, First Affiliated Teaching Hospital, School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi, China Xi’an China, 2Institution of Hepatology, First Affiliated Teaching Hospital, School of Medicine, Xi’an Jiaotong University Xi’an China, 3Shaanxi Clinical Research Center of Infectious Diseases Xi’an China

**Background & Aims:** The objective of this study was to evaluate the long-term efficacy and safety of Tenofovir alafenamide (TAF) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) in China, considering the limited knowledge on the subject.

**Methods:** Patients with HBV-ACLF who received TAF or ETV monotherapy were recruited. They were prospectively followed up and the primary endpoint was liver transplant-free survival at week 96.

**Results:** A total of 133 patients were enrolled, and propensity score matching produced 40 patients in each group. At week 96, 26 of the TAF group (65.0%) and 28 of the ETV group (70.0%) survived, with no significant difference in long-term liver transplant-free survival (p = 0.701). Each group displayed a noteworthy decline in HBV DNA loads. Although virus load reduction and HBV DNA undetectable rates resulted in no statistical significance, TAF group showed a slightly higher HBV DNA undetectable rate after 24 weeks of treatment. At week 48, the HBV DNA undetectable rate in the TAF group was 82.6%, surpassing that of the ETV group (76.0%, p = 0.791). Liver function showed improvement in both groups throughout the study period.

Conclusions: A new prognostic model based on APOC2 is a high-performance prognostic score for HBV-related ACLF.

Abstract Submission No. 100774
P-0701

**IF16 as a biomarker for complications of HBV-related acute-on-chronic liver failure**

Nan zhang1, Xiuqing Pang1, Haishi Wu1, Zhiiliang Gao1

1Affiliation The Third Affiliated Hospital of Sun Yat-sen University Guang Zhou China
Background: IFI16, as a novel DNA sensor, plays an important role in viral infection, but it has rarely been reported in HBV-associated acute-on-chronic liver failure. The purpose of this study was to investigate the effects of IFI16 on different stages and complications of HBV-associated acute-on-chronic liver failure.

Methods: This study consecutively collected 40 patients diagnosed with HBV-associated acute-on-chronic liver failure from July 2023 to August 2023 attending The Third Affiliated Hospital of Sun Yat-sen. A retrospective comparison of the clinical data of the three groups (Early-stage, Mid-stage, End-stage) of patients was performed. IFI16 in peripheral blood plasma was determined by ELISA kit. Bivariate correlation analysis was used to analyze the association of IFI16 with clinical laboratory tests and complications and disease progression.

Results: The differences in clinical and anatomical features among the three groups were statistically significant in terms of male percentage, IB, PTA, INR, MELD score. IFI16 were significantly and positively correlated with complications of HBV-associated acute-on-chronic liver failure in infection and gastrointestinal hemorrhage.

Conclusion: IFI16 were significantly correlated with complications of HBV-associated acute-on-chronic liver failure.

Abstract Submission No. 100794
P-0702

Midterm Termination of Pregnancy with IUFD in a case of Dengue Related Acute Liver Failure

Pukar Thapa¹, Susmita Shrestha², Bimita Mahat³

¹Norvic Hospital Kathmandu Nepal, ²Kathmandu Medical College and Teaching Hospital Kathmandu Nepal, ³Kathmandu Medical College and Teaching Hospital Kathmandu Nepal

Background: Dengue is an important mosquito borne disease in an endemic area like Nepal. Dengue infection in pregnancy carries the risk for both mother and newborn. This paper reports a case of survival of pregnant woman with dengue related acute liver failure.

Clinical significance: Early diagnosis and proper treatment of dengue related acute liver failure along with IUFD in pregnancy can reduce the mortality.

Case Description: A 26yr G2P1L1 at 26weeks and 5days of gestation was brought to Emergency department with complain of high grade fever, abdominal pain, icterus and not perceiving fetal movements. Urgent investigations and treatment was started that included ionotropes, blood products, IV fluids and high grade antibiotics. Clinical features and blood reports were suggestive of Dengue related acute liver failure with intrauterine fetal death. On second day of admission patient was intubated for respiratory distress and poor GCS, along with vaginal termination of pregnancy using inducing agent, misoprostol. Patient was extubated after 7th day of intubation. With success of vaginal delivery and continuous conservative treatment, patient clinical features and reports parameters were improved. On 18th day of admission patient was discharged.

Conclusion: Dengue related acute liver failure in pregnancy is very rare with high mortality rate. Early diagnosis and treatment is crucial mostly in critical phase of dengue. Dengue should be kept in the differential diagnosis of pregnant women with fever during epidemics in endemic areas and quick intervention can lead to reduced mortality.

Abstract Submission No. 100875
P-0703

Targeting transglutaminase 2-mediated inflammatory response in sepsis-induced liver injury

Yali Xu¹,², Ting Su², Wenkui Yu², Yutaka Furutani³, Harukazu Suzuki¹, Xian-Yang Qin¹

¹Laboratory for Cellular Function Conversion Technology, RIKEN Center for Integrative Medical Sciences Yokohama Japan, ²School of Medicine, Nanjing University Nanjing China, ³Department of Laboratory Medicine, The Jikei University School of Medicine Tokyo Japan

Background: Sepsis is a major cause of death in hospitals and involves an uncontrolled inflammatory response to infection, leading to multiple organ dysfunction, including acute liver failure. Transglutaminase 2 (TG2) is a crosslinking enzyme involved in diverse cellular processes, such as cytoskeletal function, signal transduction, and cell survival.

Conclusions: These results demonstrate that TG2 is a critical player in sepsis-induced liver injury, and targeting TG2 could be a potential strategy for the treatment of sepsis-induced liver injury.
Methods: Sepsis mice were established by intraperitoneal injection of lipopolysaccharide (LPS) or cecal ligation and puncture. In vitro and ex vivo transamidase activity of TG2 was measured based on the incorporation of 5-biotinamidopentylamine, a biotinylated substrate for TG2. Loss-of-function analysis was performed with TG2 inhibitor cystamine (CTM), clodronate liposome for macrophage depletion, and siRNA against vimentin. LC-MS/MS-based proteome analysis and RNA-seq transcriptome analysis was applied to explore the underlying mechanism. Streptavidin-conjugated magnetic bead was used to isolate biotinylated substrate of TG2. RAW264 cell was introduced for in vitro validation.

Results: Pharmacological inhibition of TG2 activity with CTM improved the survival of sepsis mice and ameliorated LPS-induced liver injury. Omics analysis showed that CTM inhibited LPS-induced inflammation especially in the livers of sepsis mice. Increased TG2 activity was mainly observed in TG2-expressing and F4/80-positive microzonal M1 macrophages in the livers of sepsis mice. Macrophage depletion ameliorated LPS-induced liver inflammation. Vimentin was identified as a substrate crosslinked by TG2 and knockdown of vimentin inhibited LPS-induced cytokine expression in RAW264 cells.

Conclusion: This study elucidated the role of TG2 in mediating sepsis-induced inflammation by facilitating the crosslinking of vimentin in macrophage and the therapeutic potential of TG2 as a molecular target for sepsis-associated liver injury.

Abstract Submission No. 100959
P-0705

How to Cure Depression in Patients after CLD Transplantation? Systematic Literature Review.

Zulfa Saumia1
1UNIVERSITAS JAMBI Jambi Indonesia

Depression is when a person experiences anxiety, feels uneasy, and so on. Depression can affect anyone, including patients with Chronic Liver Disease and Liver Transplants. This article aims to determine whether depression influences a person’s long-term survival after Liver Transplantation (LT). What are the actions taken to reduce depression? This abstract uses a literature study from PubMed using the keywords depression, chronic liver disease, and liver transplantation. The results of a literature review study found that patients prone to depression are Chronic Liver Disease (CLD) patients with chronic hepatitis C due to the use of interferon therapy. OLT patients with depression have a higher mortality rate than patients who are not depressed; appropriate use of anti-depressants will reverse this effect. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are effective and generally safe in patients with CLD and OLT. Second, depressive symptoms and grades can be measured by the Back Depression Inventory (BDI) score during the first year post-transplant; depression usually occurs during the first year after L-TX (liver transplant). Third, the consumption of anti-depressants is hoped that in the future, researchers will be able to find out more about how bad the impact of depression is on daily life, identify early and developing depressive symptoms, or screening.

Abstract Submission No. 101234
P-0706

Applying new criteria to evaluate outcomes of living-donor liver transplant for ACLF

Hieu LE TRUNG1, Thanh LE VAN2, Quang VU V AN2
1Human Organ and Tissue Transplantation Center, Military Central Hospital 108 Hanoi Vietnam, 2Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Aim: Recently, new diagnostic criteria for acute-on-chronic liver failure (ACLF) were established in Japan. However, there is little evidence regarding the feasibility of classifying patients undergoing living-donor liver transplantation (LDLT). The aim of this study was to re-evaluate the impact of these new diagnostic criteria on ACLF and the severity classification of patients undergoing LDLT.

Methods: We collected data of recipients who underwent LDLT for liver failure between 2017 and 2022 and reviewed it retrospectively.

Results: Of the 59 patients with liver failure, 54 (91.5%) were diagnosed with ACLF; Grade 0 (n = 4), Grade 1 (n = 24), Grade 2 (n = 19), and Grade 3 (n = 9). There was no substantial difference in overall survival (OS) and the occurrence of postoperative complications between liver failure patients with and without ACLF. The OS after LDLT was significantly different among the four groups of ACLF patients (P < 0.001). Interestingly, ACLF Grade 3 patients had substantially lower OS compared to other ACLF groups even after LDLT (P = 0.006; 5-year OS rates, 33.3% vs. 85.9%).

Conclusion: Proper use of the new diagnostic criteria for ACLF in Japan demonstrated that the presence and severity of ACLF, especially the presence of multiple organ failures, leads to morbidity and mortality even in an LDLT setting. Considering that the patients with ACLF Grade 3 do not have the favorable outcomes of LDLT, deceased-donor liver transplantation usage, or LDLT before reaching the severity of Grade 3 may be suitable for further research.

Abstract Submission No. 101320
P-0707

Development of an Innovative Prognostic Model for Predicting Mortality in Patients with ACLF

Chien-Hao Huang1, Shih-Hua Lin2, Wei-Ting Chen1, Ming-Hung Tsai1, Wei-Liang Kuo1, ng-Nan Chien1
1Chang Gung Memorial Hospital Linkou Taoyuan Taiwan, 2Department of Gastroenterology and Hepatology, New Taipei Municipal Tucheng Hospital, Tucheng New Taipei City Taiwan

Background: Acute-on-chronic liver failure (ACLF) presents with elevated short-term mortality rates, necessitating intensive care unit (ICU) admission. Accurate prognostication is essential for timely liver transplantation referrals. Despite widespread use, the superiority of the CLIF-C ACLF score in Asian ICU patients remains inconclusive compared to other scoring systems. This study aims to (i) compare the predictive performance of original MELD, MELD-Lactate, CLIF-C ACLF, CLIF-C ACLF-Lactate, and APACHE-II scores for short-term mortality, and (ii) develop and validate a novel scoring system, assessing its predictive efficacy against the original five scores.

Methods: A cohort of 265 consecutive cirrhotic ACLF patients admitted to the ICU was enrolled. Prognostic values for mortality were evaluated through ROC analysis. A novel model was developed and internally validated using 5-fold cross-validation. Additionally, external validation was performed in another ICU with 40 ACLF patients.

Results: Alcohol abuse emerged as the primary cirrhosis etiology. The AUROC of the five prognostic scores in predicting one-month mortality did not significantly differ. However, the newly developed model, incorporating age, A-a gradient, BUN, total bilirubin, INR, and HE grades, demonstrated significantly improved performance with AUROC of 0.863 and 0.829 for one-month and three-month mortality, respectively, surpassing the original five prognostic scores. External
validation in another ICU with 40 ACLF patients further supported its efficacy. **Conclusions:** The novel ACLF model outperforms established scores in predicting short-term mortality for ICU-admitted ACLF patients. Rigorous external validation is warranted to affirm its clinical utility.

Effect of glucocorticoids on survival in liver failure: A Systematic Review and Meta-Analysis

xiaobin li1, Yu Ran2, shipping Hu3
1Beijing university of Chinese medicine beijing China, 2Beijing university of Chinese medicine beijing China, 3Beijing university of Chinese medicine beijing China

**Background and aim:** Glucocorticoids have been used for treating liver failure, but this strategy remains controversial. Current clinical studies have little effective evidence for its therapeutic effect, and results are inconsistent. This study aims to estimate the effect of glucocorticoids on survival in patients with liver failure.

**Methods:** Randomized clinical trials and observational studies, comparing glucocorticoid vs conventional therapies in patients with LF, were identified from public databases from its inception to 1 August 2022. The primary outcome was the survival rate, defined as survival without transplantation or death.

**Results:** In total, we included eleven studies. 1267 patients participated in the study, of which 604 (47.67%) received glucocorticoid therapy. The meta-analysis revealed that glucocorticoids increased the survival rate of liver failure patients by 20% (RR: 1.20, 95% CI: 1.01-1.42, \(P=0.034\)). Furthermore, glucocorticoid therapy did not increase the risk of infection and bleeding (RR:1.31, 95% CI: 0.70-2.42, \(P=0.395\); RR:1.57, 95% CI: 0.93-2.65, \(P=0.089\)).

**Conclusion:** Our meta-analysis reported glucocorticoids improved survival in liver failure patients without increasing the risk of infection and bleeding.

Study on predicting the efficacy of glucocorticoids in treating hepatitis B-induced ACLF

XuQing Zhang1, Lu Li2
1The Third Affiliated Hospital of Chongqing Medical University Chongqing China

**Objective:** To discover the optimal indications of intervention with glucocorticoids(GCs) in patients with HBV-induced HBV-ACLF, and to establish a model of predicting the efficacy of steroids therapy (PEST) in HBV-ACLF.

**Methods:** The baseline characteristics of 112 patients of HBV-ACLF and GCs therapy were retrospectively analyzed to find some independent factors associated with the efficacy of steroids therapy, and a model for PEST was established for predicting the effect of GCs therapy. The predictive accuracy of PEST model and other models was compared using the area under the receiver ROC curve (auROC), and was validated by 64 patients from our hospital.

**Results:** Multivariate logistic regression analysis showed that INR, TBIL, cirrhosis and albumin were the best predictors of the therapeutic efficacy of steroids in HBV-ACLF. PEST was \(e^{\ln(X)}\) = 0.253 × ALB-2.333 × INR-0.097 × TBIL-2.695 × Cirrhosis (yes=1, no=0) -1.486. The auROC of PEST model was 0.958, and significantly higher than MELD, MELD-Na, CTP and ZHY, \(P<0.05\). An analysis of 64 patients
with HBV-ACLF from our hospital had similar verified results. The 90-day transplantation-free survival rate was 95.1% in cases with INR < 1.50, or 98.0% in cases with PEST ≥ 0.70, and 83.8% in cases with INR ≥ 1.5 and PEST ≤ 0.40, but only 4.0% in cases with INR ≥ 2.6 and PEST < 0.40. 

**Conclusion:** Our novel PEST model established in this study had an excellent performance in predicting the therapeutic effect of GCs in patients with HBV-ACLF. Patients with INR < 1.50 or PEST ≥ 0.70 were considered to be the optimal cases of GCs intervention. Patients with INR ≥ 2.60 and PEST < 0.40 were considered to be the worst indication of GCs intervention.

**Metabolomics study of HBV ACLF patients with different precipitating events**

lei liu1, tao han2, jing liang1, lei zhang1, bing yang1, qing ye1
1tianjin third central hospital tianjin China, 2tianjin union hospital tianjin china

**Methods:** 96 patients with HBV-ACLF hospitalized were prospectively included and divided into the hepatotropic virus insult precipitating events group (HVI group) and the non-hepatotropic virus insult precipitating events group (NVI group). The serum specimens from the study population and the control population were examined using a UPLC-LTQ Orbitrap XL ultra performance liquid chromatography and mass spectrometry system. The metabolic profile was described, and a model was developed to differentiate between HBV-ACLF due to hepatotropic and non-hepatotropic viral insult precipitating events, to screen for specific metabolic ions at the metabolic level in patients with HBV-ACLF due to hepatotropic viral insult and non-hepatotropic viral insult precipitating events, to identify the possible potential for differences in the prognosis of HBV-ACLF due to different precipitating events.

**Results:** Preliminary metabolomic analysis revealed significant differences in serum metabolic profiles between the hepatotropic virus insult-induced HBV-ACLF (HVI-HBV-ACLF) group, the non-hepatotropic virus insult precipitating events group (NVI group). The serum specimens from the study population and the control population were examined using a UPLC-LTQ Orbitrap XL ultra performance liquid chromatography and mass spectrometry system. The metabolic profile was described, and a model was developed to differentiate between HBV-ACLF due to hepatotropic and non-hepatotropic viral insult precipitating events, to screen for specific metabolic ions at the metabolic level in patients with HBV-ACLF due to hepatotropic viral insult and non-hepatotropic viral insult precipitating events, to identify the possible potential for differences in the prognosis of HBV-ACLF due to different precipitating events.

**Conclusions:** Our novel PEST model established in this study had an excellent performance in predicting the therapeutic effect of GCs in patients with HBV-ACLF. Patients with INR < 1.50 or PEST ≥ 0.70 were considered to be the optimal cases of GCs intervention. Patients with INR ≥ 2.60 and PEST < 0.40 were considered to be the worst indication of GCs intervention.

**Successful Therapeutic Plasma Exchange (TPE) in Lymphoma-associated Acute Liver Failure**

Hua Yen Ling1, Esther Wei Yin Chang2, Yong Chuan Tan3, Shu Wen Tay1, Kim Wei Lim1, Kevin Kim Jun Teh1
1Tan Tock Seng Hospital, Department of Gastroenterology And Hepatology Singapore Singapore, 2Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. Singapore, Singapore, 3National University Hospital, Department of Gastroenterology And Hepatology Singapore Singapore, Singapore General Hospital, Department of Gastroenterology And Hepatology Singapore Singapore

Acute liver failure (ALF) secondary to malignant infiltration of the liver is rare and associated with poor survival without prompt recognition and treatment. We report a case of a well 45-year-old Chinese male who presented with fever and jaundice. Physical examination showed scleral icterus, hepatosplenomegaly and non-tender cervical lymphadenopathy with no encephalopathy. Blood investigations revealed severe acute liver injury (Alb 21g/L, bil 130µmol/L, ALP 78U/L, ALT 68U/L, AST 77U/L, PT 20.4 sec). Computed tomography imaging confirmed
hepatosplenomegaly and lymphadenopathy with no biliary obstruction. Oncology was consulted and the working diagnosis was a lymphoproliferative disorder with malignant liver infiltration. An excision biopsy of a cervical lymph node was performed and he was started on intravenous Dexamethasone for hemophagocytic lymphohistiocytosis (HLH). However, while awaiting histology, he developed encephalopathy and acute liver failure on Day 5 requiring intubation. Therapeutic plasma exchange (TPE) was promptly initiated as a bridge to initiation of curative-intent chemotherapy. He underwent 2 sessions of TPE (5-6 litres each session), with improvement in biochemical indices and mentation. Once diagnosis of peripheral T-cell lymphoma was confirmed, he received Gemcitabine and Carboplatin. He responded well to chemotherapy with significant improvement in liver function, and was extubated 4 days later. This case highlights the utility of TPE as a life-saving bridging therapy in patients with suspected lymphoma-associated acute liver failure prior to histological confirmation, given the chemosensitive nature of the disease. To the best of our knowledge, this is the first reported case of successful TPE in lymphoma-associated ALF.

**Abstract Submission No. 101741**  
**P-0714**

**Current status and treatment with artificial liver support system for ALF and ACLF in our hospital**


**1Department of Internal Medicine Hepatology and Gastroenterology Kanazawa University Kanazawa Japan, 2Department of intensive care Kanazawa University Kanazawa Japan**

**Background:** The efficacy of online hemodiafiltration (online HDF) for acute liver failure (ALF) and Acute-on-Chronic Liver Failure (ACLF) as an artificial liver support system (ALSS) has been reported. In addition to online HDF, our hospital has used continuous plasma filtration with dialysis (CPDF). We investigated the current status and treatment of ALF and ACLF in our hospital.

**Methods:** The backgrounds and prognoses of ALF or ACLF patients who received either or both online HDF and CPDF in our hospital were retrospectively evaluated.

**Results:** Of the 12 cases, 7 were ALF (HAV 1 case, HBV 2 cases, AIH 1 case, drug 1 case, unknown 2 cases), and 5 were ACLF whose exacerbating factors are infection 2 cases, drug 2 cases, and unknown 1 case. Liver transplantation was performed in 4 of the eight surviving cases, and the four deceased cases were considered liver transplantation ineligible for various reasons. Among five ACLF patients, three had liver transplantation, one died, and one recovered. The median treatment duration with ALSS was 9 (2-27) days; three of seven patients starting CPDF had recovered before day 3; however, three of the remaining required changes to online HDF until day 3. Blood ammonia levels and the severity of hepatic encephalopathy at the time of ALSS indication tend to lower in patients started with CPDF compared to online HDF.

**Conclusions:** CPDF may contribute to the prognosis of some ALF or ACLF patients. Further investigation might be needed to make a strategy for improve their prognosis.

**Abstract Submission No. 101861**  
**P-0715**

**Plasma exchange improve short term mortality in steroid ineligible alcoholic (ACLF) patients**

**HITESH SINGH**, **VINOD ARORA**, **SHIV KUMAR SARIN**

**1INSTITUTE OF LIVER BILIARY SCIENCES NEW DELHI India, 2INSTITUTE OF LIVER AND BILIARY SCIENCES NEW DELHI INDIA, 3INSTITUTE OF LIVER AND BILIARY SCIENCES NEW DELHI INDIA**

**Background and Aims:** Acute on chronic liver failure patients has high short-term mortality. Therapeutic plasma exchange is a modality of treatment in acute liver failure patients, but its efficacy in steroid ineligible alcoholic ACLF has seldomly studied. We aimed that therapeutic plasma exchange improves 30-day mortality thus it can help as a bridge therapy to liver transplantation.

**Methods:** Patients of steroid ineligible alcoholic ACLF patients n=1424, out of which 182 receive plasma exchange. We compared the 30 day and 90-day mortality in these patients.

**Results:** Baseline investigations were comparable in the patients who received plasma exchange or standard medical treatment. Out of 182 patients who received plasma exchange, 120 (66%) patients survived at 30 days as compared to who did not received plasma exchange 638/1242 (51%) survived was significant with p value<0.001. Nearly 77/182 patient (42%) survived in plasma exchange group as compared to 586/1242 patients (46%) with p value 0.09 at 90 days. High baseline MELD score, MELD Na, CTP score, AARC score, number of days of hospital stay has correlated with poor survival outcome.

**Conclusion:** Plasma exchange is an effective modality in improving short term mortality in alcoholic ACLF patients and can serve as a bridge to liver transplantation.

**Abstract Submission No. 101946**  
**P-0716**

**MSC-exo alleviate IL-17 mediated immune damage in acute liver failure via RXRG/FOXP3 signaling**

**yongqi Zhang**, Jing Zhang, Zhihui Li, Binliang Lin

**1The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou China**

**Background and Aims:** Acute liver failure is a severe immune injury caused by an inflammatory storm involving multiple cytokines in liver tissue and can be life threatening. In the circumstance of liver donors scarcity, it is crucial to find effective non-transplant treatment methods. Previously, we found that human bone marrow mesenchymal stem cell exosomes can alleviate liver injury in acute liver failure mice, but the key molecular mechanisms by which they regulate the liver immune microenvironment remain unclear.

**Methods:** To establish the ALF cell model and ALF mouse model induced by GaN/LPS, randomly divided into blank control group, ALF group, and MSC-exo treated ALF group (n=6), detect the expression of IL-17, RXRG, and FOXP3 by western blotting. Results: The MSC-exo treated ALF cell model showed a significant increase in RXRG and FOXP3 expression, while IL-17 showed the opposite.

**Conclusion:** MSC-exo can reduces IL-17 levels and alleviates liver inflammatory response in ALF by upregulate RXRG in infiltrating Th cells of the liver to enhancing the inhibitory effect of FOXP3 on ROR γ.

**Abstract Submission No. 101951**  
**P-0717**
Predictors of ACLF in patients with compensated liver cirrhosis presented by variceal bleeding

Mohamed Elbassyoni1, 2, Mahmoud Abotaleb1, 2, Gamal Shiba1, 2
1Gastroenterology and Hepatology unit, Internal medicine department, Mansoura University Mansoura Egypt, 2Egyptian liver research Institute and hospital, sherbeen Mansoura Egypt

Background: ACLF is an emergency hepatic condition. Acute variceal bleeding is one of the acute insults for development of ACLF. We aimed to investigate the incidence and predictors for development of ACLF after acute variceal bleeding in cirrhotic compensated patients.

Materials and methods: The study included 310 patients with compensated liver cirrhosis presented by acute variceal bleeding. The patients subjected to complete history taking, full examination, laboratory, and radiological investigations. Child Turcott Pugh score (CTP). Upper gastrointestinal endoscopy done with endoscopic management of variceal bleeding, after proper resuscitation and administration of vasopressors and PPIs. Patients were followed up at 2 weeks of admission, 4 weeks, 3 months by clinical and laboratory evaluation to detect signs of development of ACLF.

Results: Among 310 patients included in the study, 17 (5.5%) patients developed ACLF and 14 (4.5%) of which died and 3 patients survived. The main predictors were: haemodynamic instability (p 0.019), bleeding on endoscope (p 0.001), rebreeding within one week (p 0.001), emergent endoscopy (p 0.028), higher INR (p 0.029), leucocytosis (p 0.001), rising creatinine (p 0.004), low albumin level (p 0.001).

Conclusion: The incidence of ACLF in our study was (5.5%). With high mortality rate. Severity of the bleeding, timing of endoscope, and radiological investigations. Child Turcott Pugh score (CTP). Upper gastrointestinal endoscopy done with endoscopic management of variceal bleeding, after proper resuscitation and administration of vasopressors and PPIs. Patients were followed up at 2 weeks of admission, 4 weeks, 3 months by clinical and laboratory evaluation to detect signs of development of ACLF.

YGF promotes mitophagy by regulating the S100A9/RAGE signaling pathway to ameliorate ACLF

Jing Li1, xiaozhou Zhou1
1Department of Liver Disease, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518033, China; Shenzhen China

Background: Mitophagy dysregulation significantly contributes to the pathogenesis of acute and chronic liver failure (ACLF). The JianPi LiShi YangGan formula (YGF) can improve ACLF by promoting autophagy. However, the precise mechanism underlying this effect remains unknown.

Purpose: To investigate the effect of YGF on hepatocyte mitophagy in ACLF mice and elucidate its molecular mechanism.

Methods: The ACLF mouse model was established using carbon tetra-chloride, lipopolysaccharide, and D-galactose. Hematoxylin and eosin staining were employed to evaluate the hepatoprotective effect of YGF in ACLF mice. Mitochondrial damage was assessed using transmission electron microscopy. The mechanism of action of YGF was explored by analyzing transcriptomics data and employing wb, immunohistochemistry, and immunofluorescence.

Results: In ACLF mice hepatocytes, YGF reduced mitochondrial damage, enhanced mitophagy. However, 3-Methyladenine (3-MA) treatment in ACLF mice weakened the protective effect of YGF against hepatocyte damage and pro-mitophagy. Transcriptome sequencing data and experiments validated that YGF inhibited S100A9/RAGE pathway activation in ACLF mice hepatocytes. In AIM12 cells overexpressing RAGE, recombinant S100A9 protein inhibited CCCP-induced mitophagy. Additionally, treatments with S100A9 and RAGE inhibitors ameliorated liver injury in ACLF mice, and enhancing the co-localization of Lamp2 with COX-IV. However, pretreatment with 3-MA partially reversed the protective effects and pro-mitophagy.

Conclusion: YGF promotes mitophagy in ACLF mouse hepatocytes, attenuating hepatocyte injury. Its mechanism may partially regulate the S100A9/RAGE pathway, inhibiting mitophagy. The impairment of mitophagy in hepatocytes mediated by S100A9/RAGE may contribute significantly to ACLF progression. Inhibiting its pathway to promote mitophagy may be a prospective therapeutic strategy for ACLF.

Durvalumab in Combination with Gemcitabine and Cisplatin for Biliary Tract Cancer at Our Hospital

Mariko Fujisawa1, Kei Saito1, Mai Kitahara1, Shuzo Nomura1, Hirofumi Kogure1
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine Tokyo Japan

Background: Advanced biliary tract cancer (BTC) generally presents a grim prognosis. The TOPAZ-1 trial recently indicated a significant...
benefit of combining durvalumab with chemotherapy in such cases. This study aimed to evaluate the efficacy and safety of durvalumab, gemcitabine, and cisplatin in treating patients with advanced BTC at our institution.

**Methods:** We retrospectively reviewed six patients diagnosed with either unresectable or metastatic BTC, treated with durvalumab, gemcitabine, and cisplatin from January to October 2023. The parameters examined included patient characteristics, treatment responses, duration of follow-up, and any adverse events encountered.

**Results:** The cohort comprised patients with a median age of 69.5 years. There were 4 males and 2 females. Primary sites were intrahepatic cholangiocarcinoma (n = 2), hilar cholangiocarcinoma (n = 3), and gallbladder carcinoma (n = 1). The treatment yielded an overall response rate of 14% and a disease control rate of 50% during a median follow-up of 4.7 months. One patient developed interstitial pneumonia. Hematological adverse events were the most common but were generally controllable through dosage reduction, and no toxicity-related death was observed.

**Conclusion:** The regimen of durvalumab, gemcitabine, and cisplatin demonstrated a tolerable safety profile and encouraging preliminary efficacy in our cohort of advanced BTC patients.

---

**The Role of Antiviral Therapy in HBV-associated Patients with Intrahepatic Cholangiocarcinoma**

Ming Sheng Chien¹, Tsang En Wang¹,²,³, Chia Yuan Liu¹,²,³, Ming Jen Chen¹,²,³, Ching Wei Chang⁴

¹Division of Gastroenterology, Department of Internal Medicine, Mackay Memorial Hospital Taipei City Taiwan, ²MacKay Medicine, Nursing and Management College Taipei Taiwan, ³Department of Medicine, MacKay Medical College New Taipei Taiwan

**Background:** Cholangiocarcinoma (CCA) is a deadly hepatobiliary tumor categorized into intrahepatic (iCCA), perihilar (pCCA), and extrahepatic (eCCA) groups. Previous studies highlight viral hepatitis as a significant risk factor for iCCA prognosis, yet the connection between HBV-related iCCA and antiviral management in Taiwan remains unclear.

**Methods:** We conducted a retrospective review of CCA patients records at MacKay Memorial Hospital from Jan. 1, 2015, to Dec. 31, 2021. We enrolled patients with histologically confirmed CCA and analyzed the prognosis of HBV-associated patients with iCCA.

**Result:** A total of 152 patients with confirmed pathology were included, with 25 of these patients diagnosed with iCCA and HBV infection. Additionally, we enrolled 17 patients who exhibited detectable viral loads (>20 IU/mL). These patients were split into two groups: one receiving antiviral therapy (n = 13) and the other without it (n = 4). There were no significant differences between the two groups in the patient’s characteristics (Table 1). Within the group underwent antiviral therapy, 46.2% of the patients were deemed resectable; 76.9% of the patients underwent chemotherapy. Within the group without antiviral therapy, 75% of the patients were deemed resectable. There was no disparity found in the survival curves for patients in the groups receiving antiviral therapy compared to those without it (p = 0.172) (Figure 1).

**Conclusion:** Our retrospective data demonstrated the HBV-associated patients with iCCA receiving antiviral therapy did not affect the survival rate. Further prospective studies are necessary to draw a definitive conclusion.
This report can increase the knowledge in the diagnosis and management of this disease. Lemmel’s Syndrome is a rare disease characterized by obstructive jaundice in the absence of choledocholithiasis or pancreaticobiliary tumors. One case series is presented to help elucidate the pathogenic mechanism of CCA and establish novel preventive and therapeutic strategies for this disease.

Abstract Submission No. 101598
P-0724

From Outside: A Case Series on Lemmel’s Syndrome
Jan Axel Yusi1, Vicente II Porciuncula2
1St. Luke’s Medical Center Quezon City Quezon City Philippines
Lemmel’s Syndrome is a rare disease characterized by obstructive jaundice in the absence of choledocholithiasis or pancreaticobiliary tumors. This report can increase the knowledge in the diagnosis and management of this disease.

Case 1 is a 74 year old female, presenting with one-week dull right upper quadrant pain, fever and jaundice. Work up revealed Direct hyperbilirubinemia (Total Bilirubin 12.72mg/dl) ALP 610mg/dl, MRCP showed: paravaterian diverticulum(AP-1.6cm) with peribilirubinemia (Total Bilirubin 12.72mg/dl) ALP 135U/L, ALT 610mg/dl. MRCP showed: paravaterian diverticulum(AP-1.6cm) with mass effect on the distal common bile duct(CBD) and resultant upstream dilation (CBD: 1.1cm) until the central intrahepatic ducts. ERCP showed: paravaterian diverticulum, no intraluminal filling defects, and a dilated CBD(1cm). Sphincterotomy and balloon sweeping was done yielding purulent bile. Biliary stent insertion was done as well as initiation of antibiotics. One-month after, her bilirubin levels was normal and is asymptomatic.

Case 2 is an 88 year old male, presenting with 4-day sub-xiphoid dull pain. Icterusia was noted on admission. Work up revealed: Direct hyperbilirubinemia (Total Bilirubin: 4.33mg/dl), ALP 144U/L, ALT 193mg/dl. Contrast Abdominal CT scan showed: large paravaterian diverticulum(AP-4.8cm) compressing the distal CBD with resultant upstream dilation (CBD:1.1cm) until the proximal intrahepatic ducts. UDCA 300mg/cap thrice daily was started. After two-weeks on UDCA, he is asymptomatic and with normal bilirubin levels. Work up in these patient should be prompt to prevent complications such as cholangitis. No single definitive management is recommended. Conservative or medical management is an option in mildly symptomatic cases and more invasive therapy can be done in patients who develop complications.

Abstract Submission No. 101845
P-0725

Association of IDH1 Mutations with Survival and Recurrence in Intrahepatic Cholangiocarcinoma
Rongqi Sun1, Shaolai Zhou2, Jian Zhou3
1Zhongshan Hospital, Fudan University Shanghai China, 2Zhongshan Hospital, Fudan University Shanghai China, 3Zhongshan Hospital, Fudan University Shanghai China
Purpose: IDH1 mutations are causal in tumor development and progression; however, their association with disease characteristics, prognosis and therapy response in patients with resected intrahepatic cholangiocarcinoma (ICC) remains controversial.

Experimental Design: In this cohort study, we recruited 803 patients who underwent curative resection for ICC at a single hospital in China. We performed whole-exome sequencing and Sanger sequencing to identify IDH1 mutations. We used the Kaplan-Meier method and log-rank test to compare overall survival (OS) and disease-free survival (DFS).

Results: A total of 5 different subtypes of IDH1 somatic mutation affecting 94 (11.7%) patients were identified. Across all patients considered, those received adjuvant chemotherapy were significantly associated with superior OS and DFS when compared with patients not receiving adjuvant chemotherapy. In the whole ICC cohort, patients with IDH1 mutations showed no significant difference in OS (P=0.86) or DFS (P=0.64) compared with those with wild-type IDH1. When we looked at patients received or not received adjuvant chemotherapy, separately, univariate and multivariable analysis revealed that IDH1 mutations were significantly associated with superior OS (P=0.03) and DFS (P=0.02) in patients received adjuvant chemotherapy, but were marginal associated with worse OS (P=0.09) and DFS (P=0.15) in patients not received adjuvant chemotherapy.

Conclusions: We characterized the distribution of IDH1 mutations in a large cohort of patients with ICC from China. The presence of IDH1 mutations was associated with better survival and decreased risk of recurrence in resected ICC received adjuvant chemotherapy.

Abstract Submission No. 102095
P-0726

Not All Hilar Masses are Klatskin Tumor, Isolated Hepatobiliary Tuberculosis : A Case Report
Saifi Rana1, R Balamurali2, Manimaran M1, Chitra S1, Sathyaa G1
1Stanley Medical College, Chennai Chennai India
Isolated Hepatobiliary Tuberculosis is a rare entity. Diagnosis is difficult to achieve due to the insidious nature of the disease and non specific clinical as well as radiological findings. Here we report a case of a 47 year old female with Hepatobiliary tuberculosis, who presented with right upper quadrant pain. Patient is a HIV infected individual on Anti retroviral therapy for the past 13 years. Patient had no evidence of pulmonary or extra pulmonary tuberculosis on routine investigations. Patient was found to have a mass lesion at the hilum of the liver with focal lesions in the liver parenchyma as well on imaging and was suspected to have hilar cholangiocarcinoma. The diagnosis of tuberculosis was confirmed after a trans jugular biopsy of the liver lesion. Clinical significance : In endemic areas with appropriate clinical and imaging findings the possibility of hepatic tuberculosis should be considered and tissue diagnosis should achieved considering good response to intervention for Hepatobiliary tuberculosis.

Abstract Submission No. 200069
P-0727

mALBI is not the prognostic factor in patients with unresectable biliary tract cancer
Background: Although modified albumin-bilirubin model (mMLBI) is useful as an assessment of liver function in antitumor therapy for hepatocellular carcinoma, its usefulness in biliary tract cancer (BTC) is not clear. Herein, we conducted this retrospective analysis of the associations of mMLBI and prognosis in patients with unresectable BTC.

Methods: All consecutive patients who underwent palliative chemotherapy for unresectable BTC at Nihon University Hospital were retrospectively studied. mMLBI was calculated using pre-treatment data. Progression free survival (PFS) was evaluated using Kaplan-Meier methods. Multivariable hazard regression models were used to evaluate the prognostic factors in patients with unresectable BTC.

Results: Twenty-two patients included in the analysis with a median age of 75, male gender in 73%, intrahepatic cholangiocarcinoma/Hilar cholangiocarcinoma/distal BTC/dudodenal papillary cancer/Gallbladder cancer in 18/32/9/36%, metastatic disease in 64%, biliary drainage in 59%, median CA19-9 value of 133 IU/L, combination chemotherapy (Gemcitabine+Cisplatin+Dulvalumab, Gemcitabine+Cisplatin+S-1 and Gemcitabine+Cislatin) in 64%, and mALB 1/2a/2b/3 in 18/32/45/5%. 2 cycle completion rate was 86%. The median PFS was 4.6 (95%CI, 3.3-7.1) months in response rate 5% and disease control rate 75%. The multivariable analysis revealed Gallbladder cancer (hazard ratio [HR] 28.1, 95%CI, 1.85-1450.9, p<0.01) as independent prognostic factors for PFS, but mALBI 2a/2b/3 (HR 0.29, 95%CI, 0.02-3.81, p=0.33) was not.

Conclusion: mALBI was not associated with PFS in patients with unresectable BTC.

Abstract Submission No. 200100
P-0728

Villous Adenoma of the Common Bile Duct Co-existing with a Pancreatic Head Mass: A Case Report

Elisa Francesca G. Mendoza¹, Jhebe I. Imperial¹, Willy S. Alba¹

¹Chinese General Hospital and Medical Center Manila Philippines

Introduction: Villous adenomas are benign lesions typically found in the colon, and rarely seen in the biliary tree. Histopathology is necessary to confirm the diagnosis. We report a case of a villous adenoma in the CBD co-existing with a pancreatic head mass, causing obstructive jaundice.

Case Report: A 78-year-old female presented with a three week history of obstructive jaundice. Triphasic CT scan showed dilated intrahepatic ducts down to the distal CBD, with tapering of its distal end, with no radiopaque lithiasis. ERCP revealed a dilated CBD (1.5 cm) with a distal CBD stricture (1 cm). Brush cytology showed biliary epithelium with low grade dysplasia consistent with villous adenoma. EUS demonstrated a distal CBD stricture and pancreatic body cyst, which was not biopsied. MRI showed a lobulated mass (3.2 x 3.0 cm) involving the pancreatic head, causing distal CBD obstruction with intrahepatic and intrahepatic biliary ductal dilatation. Repeat ERCP was done and cholangioscopy revealed ulceronodular lesions at the distal CBD. Histopathology showed fibrocollagenous tissue with mild chronic inflammation. Patient underwent Whipple surgery with loop gastrojejunostomy and jejunostomy. Histopathology showed well differentiated ductal adenocarcinoma of the pancreatic head. The tumor invaded the duodenal wall up to musculis propria, ampulla of Vater, and peripancreatic soft tissue. The omentum, gallbladder, CBD margins were negative for tumor.

Conclusion: Although villous adenoma is rarely found in the biliary tree, clinicians should consider this as a differential diagnosis in patients presenting with obstructive jaundice. These premalignant tumors require surgical resection to rule out malignancy.

Abstract Submission No. 200251
P-0730

Clinical significance of lymph-nodes of the hepatic hilum in primary biliary cholangitis.

Giovanni Galatti¹, Giulia Di Pasquale¹, Valentina Flagiello¹, Francesca Terracciani¹, Paolo Gallo¹, Umberto Vespaiani-Gentilucci¹, Alice Laudioso¹, Picardi Antonio¹

¹Internal Medicine and Hepatology, Fondazione Policlinico Campus Bio Medico Rome Italy, ²Internal Medicine, University Campus Bio-Medico Rome Italy

BACKGROUND AND AIM: Primary biliary cholangitis (PBC) is a rare chronic liver disease. The lymph nodes at the hepatic hilum, are indicative of non-specific necroinflammatory activity. The aim of our

The Possibility of 5-aminolevulinic acid mediated photodynamic diagnosis in cholangiocarcinoma

Hiroaki Fujitwara¹,², Naminatsu Takahara¹, Yousuke Nakai², Keiuseki Tateishi¹, Kiyoshi Hasegawa¹, Tetsuo Ushiku³, Mitsuhiro Fujishiro³

¹Division of Gastroenterology, The Institute of Medical Science, Asahi Life Foundation Tokyo Japan, ²Department of Gastroenterology, The University of Tokyo Tokyo Japan, ³Division of Gastroenterology, Department of Internal Medicine, St Marianna University School of Medicine Kawasaki Japan, ⁴Hepato-Biliary-Pancreatic Division, Department of Surgery, The University of Tokyo Tokyo Japan

The diagnostic accuracy of cholangiocarcinoma is still insufficient, which is less than 80%, and new diagnostic methods are urgently needed. 5-Aminolevulinic acid (5-ALA) is a natural amino acid that is utilized in the mitochondrial heme synthesis pathway producing the intermediate metabolite protoporphyrin IX (Pp IX). Pp IX is a photosensitizer emitting red fluorescence upon exposure to blue light. While it is rapidly metabolized to heme in normal cells, it accumulates in cancer cells due to reprogramming of heme metabolism. The photodynamic diagnosis by using 5-ALA (5-ALA-PDD) has already been implemented in glioma and bladder cancer. However, its utility in cholangiocarcinoma remains uncertain. In this study, we aimed to elucidate the utility of 5-ALA in the diagnosis of cholangiocarcinoma using patient-derived organoids. We established organoids from four samples of cholangiocarcinoma, including surgical specimens and biopsies obtained during endoscopic retrograde cholangiopancreatography. Additionally, tissues were collected from the peritumoral region, and we also established organoids derived from non-cancerous bile ducts in two cases. These organoids faithfully recapitulated the characteristics of the primary tissues in terms of histology and gene expression patterns. After administration of 5-ALA, fluorescence microscopic analysis revealed that Pp IX accumulation levels were higher in organoids derived from bile duct cancer (40-71%), compared to organoids from non-cancerous bile ducts (<4%). Our findings provide a possibility of 5-ALA-PDD in cholangiocarcinoma, leading to the microscopic or endoscopic strategies.

Abstract Submission No. 200129
P-0729

The Possibility of 5-aminolevulinic acid mediated photodynamic diagnosis in cholangiocarcinoma
study was to evaluate the significance of the peri-hepatic lymph nodes, identified during liver ultrasound, in a population of PBC patients on specific therapy according to treatment guidelines.

MATERIALS AND METHODS: All patients affected by PBC were retrospectively analysed. The data were compared with a population of patients suffering from liver disease of different etiology, undergoing to liver ultrasound in our outpatient clinic consecutively, in the same observation period.

RESULTS: 140 patients were included, of which 46 suffered from “pure” PBC. In the non-CBP population, there were 19 patients affected by PBC in overlap with autoimmune hepatitis or metabolic steatohepatitis, and the seroprevalence of anti-mitochondrial antibodies (AMA) was 13.8% (vs 69.5% in the CBP population). The overall prevalence of lymph nodes detected by ultrasound was 34.3%, with the presence of ultrasound signs of liver fibrosis in 46.4%. The prevalence of lymph nodes in PBC patients was significantly higher than in non-PBC patients: 25/46 patients (54%) vs 23/94 patients (24%) [P<.0001]. All patients receiving obeticholic acid therapy (as monotherapy or therapy with association with ursodeoxycholic acid and/or fibrate), presented single or multiple lymph nodes at the hepatic hilum. Furthermore, regardless of the etiology of the liver disease, lymph nodes were more frequent in patients with ultrasound signs of liver fibrosis: 29/65 patients (45%) vs 19/75 patients (25%) [P=0.021].

CONCLUSIONS: The presence of lymph nodes at the hepatic hilum during a liver ultrasound could suggest the diagnosis of PBC. The lymph nodes are more frequent in case of ultrasound signs of liver fibrotic evolution.

Abstract Submission No. 200272
P-0731

Clinical Strategy Approach in Managing Complex Biliary Cases
Cosmas Rinaldi Adithya Lesmana1,2,3, Maria Satya Paramitha1, Yulia Estu Pratiwi1, Laurentius A. Lesmana1,3
1Mochtar Riyadi Comprehensive Cancer Centre (MRCCC) Siloam Hospital Jakarta Indonesia, 2Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital Jakarta Indonesia, 3Medistra Hospital Jakarta Indonesia

In the era of laparoscopic procedure, there are innovations on non-surgical management approaches for managing biliary tract disorders, such as therapeutic endoscopic retrograde cholangiopancreatography (ERCP) and interventional endoscopic ultrasound (EUS). There is still no clear consensus yet in step-approach for managing difficult biliary disorders. A retrospective endoscopy database study was conducted. Complex biliary cases which included in this study, where multi-management approach is needed, biliary obstruction accompanied with cholangitis or biliary sepsis, difficult CBD stone, recurrent CBD stone, or advanced progressive malignant biliary obstruction. Sixty-one subjects in this retrospective database study were considered as complex biliary cases. In this study, 16.4% of the subjects underwent combination of therapeutic ERCP and EUS in one session based on the complexity of the case; and 8.2% of the subjects underwent therapeutic ERCP with additional single operator cholangioscopy procedure. One subject underwent rendezvous ERCP procedure through percutaneous approach. Around 4.9% of the subjects underwent EUS-guided biliary drainage procedure. The technical success rate of all procedures was 100%. Four subjects (6.6%) died within one month after procedure. One patient died due to procedure-related events, while the other cases of death were due to the malignant process of the diseases. It was demonstrated that no significant association was observed between all mortality outcomes and baseline characteristics of the patients. Complex biliary cases require a good clinical approach algorithm to decide which procedure comes first based on comprehensive evaluation consists of patient’s factor, expertise, cost, and the risk of complications.

Abstract Submission No. 100048
P-0733

XANTHOGRAVLUMATOUS CHOLECYSTITIS MASQUERADING AS COLON CANCER: A CASE REPORT
Alinda Mae C. Gordola1, Eric B. Yasay1
1 Philippine General Hospital Manila Philippines

Significance: Xanthogranulomatous cholecystitis (XGC) is a rare form of chronic cholecystitis commonly mistaken for gallbladder cancer. We present a case of XGC that masqueraded as colon cancer. There has been no report to date where XGC propounded as such. Familiarity of this presentation may contribute to prompt diagnosis and adequate treatment.

Case presentation: A 59-year-old male, with remote history of cholecodolithiasis removed by endoscopic retrograde cholangiopancreatography, presented with anorexia, weight loss, chronic right upper quadrant pain and a palpable mass.
Management: Abdominal CT revealed an ill-defined hepatic flexure mass intimately related to the gallbladder, with loss of delineation of the gallbladder from the liver bed. Colonoscopy was done revealing a nodular, ill-defined mass at the hepatic flexure. Biopsies of this lesion revealed chronic active colitis with reactive epithelial changes, and an ulcer with granulation tissue. A multidisciplinary team was convened to manage the case. The patient successfully underwent laparotomy, extended right hemicolectomy, and en-bloc cholecystectomy with liver resection. Gross examination of the specimen showed a cholecystocolic fistula. Final histopathologic examination, however, revealed xanthogranulomatous cholecystitis with adenomyomatosis, without evidence of malignancy.

Recommendation: This report shows that XGC can potentially masquerade as colon cancer. A high index of suspicion and multidisciplinary approach are critical to properly manage a perplexing case. Extensive surgery may be reasonable where there is suspicion for malignancy and/or multiorgan involvement.

Ethanol ablation for intrahepatic bile duct dilatation in an elderly Patient

CW HUANG1, HsuHeng Yen1, ShunSheng Wu1
1Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan Changhua Taiwan

Introduction: Surgical resection of the intrahepatic bile duct dilatation (IHBD) has traditionally been considered the only effective approach in symptomatic patients. We present a successful ethanol ablation of the IHBD in an 82-year-old patient.

Case report: An 82-year-old female sent to the hospital with fever, and right upper abdominal pain. Abdominal CT revealed the presence of common bile duct (CBD) stones, along with stones in liver segment 2 and 3, accompanied by left IHBD dilatation.

Endoscopic retrograde cholangiopancreatography was performed to remove the CBD stones and place an endoscopic retrograde biliary drainage. Surgical intervention for left lobe of the liver was declined due to the patient’s advanced age. A percutaneous transhepatic cholangial drainage (PTCD) was placed in the left IHBD. Cholangiogram conducted via PTCD revealed a filling defect in the IHBD, with the contrast medium confined to the dilated IHBD, unable to flow downstream into the CBD.

Subsequently, we utilized PTCD to administer 95% ethanol into the left IHBD. The initial injection was 45ml, which was left in place for 30 minutes. Three days later, we administered an 80ml ethanol injection, following the same procedure. The daily drainage volume through PTCD was less than 10 ml. Afterward, we removed the PTCD, and the patient did not experience a recurrence of abdominal pain or fever during the subsequent three-month follow-up.

Conclusion: Ethanol ablation in IHBD can effectively treat patients with IHBD dilatation. It may serve as an alternative therapeutic approach for patients who are not suitable candidates for surgery.

A rare case of giant hepatic angiomyolipoma with malignant behavior

wanting yeh1, hsuheng yen1, kailun shi1
1Changhua Christian Hospital Changhua Taiwan

Angiomyolipoma (AML) is usually a benign mesenchymal neoplasm located in the kidney, followed by the liver. First reported in 1976, today this rare tumor belongs to the family of perivascular epithelioid cell tumors and is typically composed of variable proportions of blood vessels, smooth muscle cells, and adipose tissue. It may be misdiagnosed as other diseases easily (e.g., hepatic cell carcinoma, IgG-4 disease) if it presents aggressive behaviors like large size (>5 cm), rapid growth rate, atypical liver biopsy results, and multiple organ involvement. We present a rare case of a 64-year-old man having complained of abdominal pain for months. He had a history of renal AML two years ago and underwent a right radical nephrectomy due to tumor rupture. There were not any liver tumors seen on abdominal computed tomography (CT) then. However, two years later, the abdominal CT showed multiple liver masses; the largest was 17.8 cm in the S4. The liver biopsy result revealed the diagnosis of hepatic AML (HAML). After multidisciplinary discussions, the patient refused the hepatectomy and only accepted transcatheter arterial chemoembolization (TACE). Unfortunately, active bleeding of the gastroduodenal artery happened after TACE. The patient then expired due to hypovolemic shock and multiple organ failure. Since 2000, only 17 cases of malignant HAML have been reported. The overall mortality rate associated
with typical HAML was 0.8%, but with malignant HAML was higher. Besides, it displays more aggressive behavior with a high recurrence and metastasis rate. Further research to predict this type of tumor is necessary.

Abstract Submission No. 100102
P-0737
A Case of Colonic Conduit Perforation in a patient with recurrent Gastroesophageal Adenocarcinoma
John Peter M Lim1, Judith Gapasin1
1St. Luke’s Medical Center Quezon City Quezon City Philippines
Esophageal perforation is a life-threatening condition if not recognized promptly. Iatrogenic causes account for 73% of these perforations and may include NGT insertion. The mortality rate is 60% if intervention is delayed beyond 48 hours. A 51-year-old male with GEJ carcinoma underwent radical subtotal gastrectomy, esophagectomy with gastric pull-up and chemotherapy. On annual PET scan, an enhancing soft tissue was noted and a gastroscopy was done showing an antral ulcer where biopsy revealed adenocarcinoma. Due to recurrence, he underwent takedown of gastric pull-up, colon interposition, cervical end-to-end esophago-colonic anastomosis, Braun jejunostomy, and feeding jejunostomy insertion. NGT was inserted blindly after the procedure. Days after, he developed pneumonia with pleural effusion and was started on antibiotics. He underwent VATS for deocclusion and noted bile from the chest tube. Repeat VATS with intraoperative endoscopy was done showing an opening at the neoesophagus, 2 cm from the anastomotic site with connection to the pleural cavity confirmed by dye injection. Two resolution clips were deployed with no egress of air or dye afterwards. Blind NGT insertion is a bedside procedure that is done for feeding and decompression purposes. However, it can result to a serious complication when rigid type is used that can cause pressure leading to perforation. Common site of perforation is from previous anastomotic site. Management includes antibiotics, and prevention of further contamination. The decision to do a surgical or endoscopic therapeutic procedures depends on the clinical situation. Endoscopic therapy can be effective if performed for early perforation by means of clips.

Abstract Submission No. 100117
P-0738
Intestinal Lymphangiomatosis: A rare cause of chronic diarrhea in young patient
Muhammad Khan1, Arshad Khan2, Muhammad Javeed4, Muhammad Hanif3
1MTI GKMC Swabi Pakistan Swabi Pakistan, 2MTI GKMC Swabi Pakistan, 3MTI GKMC Swabi Pakistan, 4MTI GKMC Swabi Pakistan
Introduction: Lymphangiomatosis is an exceedingly rare disorder primarily affecting the lymphatic system, commonly manifesting in head and neck regions, axillary and inguinal areas. Notably, colonic involvement is exceptionally rare, with no prior cases reported in Pakistan. Advances in diagnostic modalities have allowed for the detection of even uncommon gastrointestinal pathologies. This study reports a unique case of sigmoid lymphangiomatosis presenting as chronic diarrhea, diagnosed through MR enterography and subsequently treated via diagnostic laparotomy and sigmoid colon resection.

Case Report: An 18-year-old female presented with an 8-year history of chronic watery diarrhea, unresponsive to various treatments. The diarrhea, characterized by nocturnal awakening and significant weight loss, had persisted despite consultations with multiple specialists. Initial investigations, including blood tests and endoscopic evaluations, yielded no conclusive findings. However, MR enterography revealed substantial sigmoid wall thickening, interloop ascites, and lymphadenopathy. Following consultation with a colorectal surgeon, she underwent laparotomy, revealing a thickened sigmoid colon. Histopathology confirmed colonic lymphangiomatosis with dilated cystic spaces, cuboidal epithelium, congested blood vessels, and inflammation. Discussion: Lymphangiomatosis, primarily affecting extra-colonic regions, is exceedingly rare in the colon, with a previously unreported case from Pakistan. Advances in diagnostic tools, including MR enterography, have enhanced the detection of such cases. The etiology of lymphangiomatosis remains uncertain, with congenital lymphatic malformations being a leading hypothesis. Colonic lymphangiomas typically present with diverse symptoms, and diagnostic methods like endoscopic ultrasound and MR enterography are instrumental. Management depends on symptomatology, ranging from conservative approaches to surgical resection for complications.

Abstract Submission No. 100140
P-0739
A successfully treated syphilis hepatitis in HIV infected patient
Ratchanok Suppawat1, Chanuntha Hongtanakorn3, Chinnavat Suthiwana2
1The Digestive diseases center, Department of Internal Medicine, Bhumibol Adulyadej Hospital Bangkok Thailand, 2The Digestive diseases center, Department of Internal Medicine, Bhumibol Adulyadej Hospital Bangkok Thailand, 3The Digestive diseases center, Department of Internal Medicine, Bhumibol Adulyadej Hospital Bangkok Thailand
Background: Liver involvement related to secondary syphilis is an unusual presentation. We present the case of an HIV infection patient with cholestasis hepatitis who was found with syphilitic hepatitis. Methods: Case study reviewed a patient’s medical record at Bhumibol Adulyadej Hospital, Thailand, in March 2022. Results: A 37-year-old man with HIV infection presented with fatigue and weight loss. Physical examination was remarkable for the multiple discrete, well-defined annular papules with excoriation and scale crusts with central atrophy on his face. The investigation showed abnormal liver function test: total bilirubin 2.62 mg/dL, direct bilirubin 2.11 mg/dL, aspartate aminotransferase (AST) 136 U/L, alanine aminotransferase (ALT) 235 U/L, and alkaline phosphatase (ALP) 1199 U/L. The abdominal ultrasonography revealed normal liver parenchyma without a space-occupying lesion. Liver histopathology found a focal aggregation of foamy macrophages in the hepatic lobule without significant necrosis and which negative staining for Treponema pallidum. The CD4 level was 544 cells/mm3.The blood test for Rapid Plasma Reagin (RPR) titer was 1:64 and the Treponema pallidum hemagglutination test was positive. Syphilis hepatitis was considered. The patient was given intramuscular benzathine penicillin 2.4 million units per week for three weeks. Six hours after the first dose of benzathine penicillin, the Jarisch-Herxheimer reaction was observed. All patient’s symptoms and liver function tests were normal after 4 weeks of treatment. Conclusion: Even though in HIV patients with normal CD4 levels, syphilitic hepatitis should be considered in markedly elevated alkaline phosphate and well-response to antibiotics may provide clues for the diagnosis.
A case of primary esophageal malignant melanoma with disseminated metastasis.

Andrew Tan

Primary esophageal malignant melanoma is a rare condition which mainly affects males in the sixth to seventh decades of life. It is also a highly lethal disease, with a 5-year survival rate of less than 5% mainly due to its undetermined presentation and consequent late diagnosis. It is usually characterized by dysphagia and weight loss, which makes it difficult to differentiate from other types of esophageal malignancies. Immunohistochemical markers, such as S-100, HMB-45, and Melan-A are often required to confirm the diagnosis. A histopathologically proven case of primary esophageal malignant melanoma is described.

ACUTE PANCREATITIS COMPLICATING ACUTE HEPATITIS A AND E COINFECTION

Manish Kak

Introduction: Acute Hepatitis A and Acute Hepatitis E are common causes of jaundice in Asia Pacific region; We report a young boy, who had both hepatitis A (IGM) and hepatitis E (IGM) positive, and also was diagnosed to have Acute Pancreatitis; previously Acute Hepatitis E leading to pancreatitis has been reported (1)

Case: A 12 years old boy presented with history of fever, pain abdomen and jaundice of 3 days duration; He was evaluated, Liver function test was done, that revealed Increased bilirubin and transaminits; SGOT/SGPT 4534 IU/7854 IU; Serum Bilirubin 6.2 mg/dl; IgM HAV and IGM HEV both were positive: his pain abdomen persisted; Serum Lipase and Amylase were done: reported: 2304 IU and 1800 IU, respectively; USG abdomen, CECT abdomen and MRCP were done; no necrosis was seen; No Gall stones seen; CBD was normal; serum PTH, lipids and triglycerides were normal; Patient was managed with IV fluids, supportive care, He improved gradually.

Conclusion: The significance of this case report is to make clinicians aware about the fact that Acute Hepatitis A and E Coinfection can cause Acute Hepatitis in endemic region and can further lead to Acute Pancreatitis. Necrotizing pancreatitis can be prevented by timely fluid therapy.


Hepatocellular carcinoma in patients with Polycystic liver disease: Three Cases Report

Tsang-Ew Wang1, 2, Kai-Lan Chang1, Ching-Wei Chang1

1MacKay Memorial Hospital Taipei Taiwan, 2MacKay Medical College New Taipei City Taiwan

Introduction: Polycystic liver disease (PLD) is a genetic condition characterized by multiple cystic formations in the liver. Modern diagnostics, using ultrasonography, CT scans, or MRI, identify PLD by the presence of over 20 liver cysts. In contrast, Hepatocellular carcinoma (HCC) is a primary liver cancer. HCC majorly affects those with chronic liver diseases. Despite their distinct natures, the coexistence of HCC and PLD presents unique challenges, mainly due to the lack of established surveillance guidelines for HCC in PLD patients. Here, we reported three patients HCC in PLD.

Case reports: Three notable cases depict this relationship: a 56-year-old female with hepatitis C and breast cancer history, a 71-year-old male with HCV and liver cirrhosis, and a 57-year-old male with alcohol, type 2 diabetes mellitus and HBV-related liver cirrhosis. All presented with non-specific symptoms. HCC diagnosis was triggered by rising AFP levels and unclear ultrasound results. Despite numerous treatments, their survival post-diagnosis spanned 9, 3, and 6 years respectively.

Discussion and conclusion: The diagnosis of PLD coexisting with hepatoma is complex, as PLD can potentially obscure typical hepatoma imaging markers. While ultrasound remains the primary diagnostic tool with 90% accuracy, its limitations in pronounced PLD cases make advanced imaging crucial. Treatment strategies are complicated due to the patients’ multiple health conditions, requiring a mix of standard and customized approaches. As PLD patients’ lifespan increases, more such overlapping cases are anticipated, emphasizing the need for ongoing research and knowledge-sharing in the medical community.

Septic thrombophlebitis of inferior vena cava after hepatocellular carcinoma treatment: A case report

wanting yeh1, Yun Lin1, CHANGHUA CHEN3, KAILUN SHI1, PEIYUAN SU1

1Changhua Christian Hospital Changhua Taiwan

Septic thrombophlebitis of the inferior vena cava (IVC) is a rare but serious disease. We present a case of hepatocellular carcinoma (HCC) post radiofrequency ablation (RFA). The complication of IVC septic thrombophlebitis with persistent Pseudomonas aeruginosa and Enterococcus gallinarum bacteremia happened after procedure and successfully treated by antibiotics combination therapy.

Rare PKD1 mutations in an adult female with congenital hepatic fibrosis and ADPKD: a case report.

Ying Liu1, Ping Zhu2, Jiajun Tan3

1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital Tianjin China, 2Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital Tianjin China,
Introduction: Congenital hepatic fibrosis (CHF) is a rare genetic fibrocystic liver disease that primarily affects children. However, CHF in adults, especially when occurring with autosomal dominant polycystic kidney disease (ADPKD), is extremely rare.

Case presentation: This study reports on a case of a 31-year-old female patient hospitalized for bleeding from esophagogastric varices. Physical examination revealed significant splenomegaly, biochemical tests indicated a slight elevation in liver enzymes, and a decrease in platelet count. The imaging examination showed significant dilation of the common bile duct and intrahepatic bile ducts, as well as multiple renal cysts. Liver biopsy revealed enlarged portal areas, bridging fibrosis, and numerous variably shaped small bile ducts. Genetic testing identified two unique mutations in the PKD1 gene, identified as compound heterozygous mutations composed of a mutation inherited from the father (c.8296T>C) and one from the mother (c.9653G>C). Based on the patient’s multiple test results, she was diagnosed with mixed-type CHF in association with ADPKD. During her initial hospital stay, the patient underwent endoscopic treatment for gastrointestinal bleeding. This treatment showed beneficial short-term outcomes and no complications were observed. Moreover, a significant reduction in varices was observed in a gastroscopy examination 18 months later.

Conclusions: CHF is a rare genetic disease, and its co-occurrence with ADPKD is even rarer. Due to the nonspecific clinical symptoms of CHF, it is susceptible to misdiagnosis or oversight. For patients with unexplained cirrhosis, biliary dilatation and malformation, and polycystic kidneys, the possibility of CHF should be considered.

Abstract Submission No. 100345
P-0745

Progression of hepatic epithelioid haemangioendothelioma to noncirrhotic portal hypertension

Hua Liu1,2,3,4, Junqing Yan1,2,3,4, Kefeng Jia1,2,3,4, Fushuang Ha1,2,3,4, Jiayu Lv5, Xu Zhang2,3,4

1The Third Central Hospital of Tianjin Tianjin China, 2Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China, 3Artificial Cell Engineering Technology Research Center Tianjin China, 4Tianjin Institute of Hepatobiliary Disease Tianjin China

BACKGROUND: Hepatic epithelioid haemangioendothelioma (HEHE) is a very rare liver tumour that is prone to missed diagnosis and misdiagnosis. Very few cases progress to noncirrhotic portal hypertension.

CASE SUMMARY: The patient was a 32-year-old male who sought treatment 16 months prior due to abdominal pain. Multiple imaging examinations revealed multiple space-occupying lesions in the liver and lungs, and liver biopsy suggested inflammatory lesions. Sixteen months later, the patient presented with portal hypertension. Transjugular liver biopsy was performed. The results (Ki-67, approximately 10%; CD31 (+) and CD34 (+)) suggested HEHE, and the hepatic venous pressure gradient was 13 mmHg. Nocardia was detected in liver tissue. The patient was treated with sorafenib. However, treatment was terminated due to adverse reactions; the oesophagogastric varices then ruptured, with subsequent bleeding. After oesophageal variceal sclerotherapy and treatment of the gastric varices using tissue glue under gastroscopy, the patient’s condition stabilized, and no further bleeding occurred.

CONCLUSION: The diagnosis of HEHE requires multidisciplinary and experienced pathologists for confirmation. Bacterial infection may be one of the pathogenic mechanisms. For patients who do not have the option of liver transplantation, treatment for noncirrhotic portal hypertension can improve quality of life.

Abstract Submission No. 100348
P-0746

Case Report of Simultaneous Treatment of Tuberculosis and Chronic Hepatitis C in 10 Patients

Qiong Hu1, Chunyu Chen1, Changzheng Hu2, Peilin Zhen1, Peipei Ding1, Gang He1
1Jiangmen Cental Hospital; Jiangmen City, Guangdong Province China

BACKGROUND: The efficacy and safety of simultaneous treatment of tuberculosis (TB) and hepatitis C virus (HCV) infection are limited. We aim to provide more evidence on this.

Methods: Clinical data were retrospectively collected and analyzed from adult patients with TB/HCV coinfection undergoing simultaneous treatment for both diseases at Jiangmen Central Hospital.

Results: From January 2010 to June 2023, a total of 181 adult patients with TB/HCV coinfection were admitted to our hospital. Among them, 10 cases met the inclusion criteria for simultaneous treatment. In these patients, Rifampicin free regiment (avoid drug-drug interaction) and sofosbuvir/velpatasvir were used. The 10 patients were all males aged 41-54 years. After simultaneous treatment, chest CT showed improvement in TB in 8 patients, similar findings in 1 patient, and pending follow-up in 1 patient. Currently, 4 patients are still undergoing tuberculosis treatment. Among the 10 patients, 9 received a 12-week course of sofosbuvir/velpatasvir, and 1 received a 24-week course, all achieved sustained virologic response at 12 weeks (SVR12). No adjustments to the anti-TB drug regimen were required during simultaneous treatment. Prior to treatment, 7 patients had elevated ALT levels above the upper limit of normal (ULN), and 9 patients had elevated AST levels above ULN. After treatment, all patients had ALT levels below ULN while 9 patients had AST levels below ULN. Albumin, APRI scores, and Fib-4 scores showed improvement after treatment. (Tables 1-4).

Conclusions: These 10 cases preliminarily suggest simultaneous treatment of TB/HCV coinfection is effective and safe.

Abstract Submission No. 100383
P-0747

Successful Endovascular Management of Pseudoaneurysm Following TACE: A Case Report

Joo Yeon Jang1, Ung Bae Jeon1, Tae Un Kim1, Ki Tae Yoon2, Young Mi Hong2, Jin Hyeok Kim1
1Department of Radiology, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University Yangsan, South Korea, 2Department of Internal Medicine, Pusan National University Yangsan Hospital, School of Medicine, Pusan National University Yangsan South Korea

BACKGROUND: Transarterial Chemoembolization (TACE) is a widely accepted treatment for hepatic tumors, especially unresectable hepatocellular carcinoma (HCC). While generally safe, TACE can lead to severe complications, including liver abscess, liver failure, and non-target embolization. Arterial injuries like hepatic artery spasm or dissection can also occur, although pseudoaneurysms are rare. In this report, we describe a case of a successfully treated pseudoaneurysm following TACE using N-Butyl-cyanoacrylate (NBCA) glue embolization.
Methods: A 78-year-old man presented to the emergency department with melena lasting for 5 days. He had been receiving TACE for hepatocellular carcinoma in liver segment 8 for the past 5 years, with his most recent TACE procedure performed approximately a month ago. Computed tomography (CT) revealed hemobilia in the anterior branch of the right intrahepatic duct (IHD), common bile duct (CBD), and gallbladder (GB). Additionally, a pseudoaneurysm in the S8 hepatic artery was detected. The patient underwent NBCA glue embolization to treat the pseudoaneurysm.

Results: On CT, the pseudoaneurysm was successfully embolized, and the hemobilia resolved.

Conclusions: In patients undergoing TACE who present with melena, it is crucial to consider the possibility of iatrogenic arterial injury. Such cases can be safely and effectively managed through endovascular procedures.

Abstract Submission No. 100393
P-0748

Unusual AIH- Post renal transplant progressing to liver disease despite adequate immunosuppression

AKSHAY KALE1, PIYUSH RANJAN1, ASHISH KUMAR1, ANIL ARORA1, MANDHIR KUMAR1, RAJAT KALRA1
1SIR GANGARAM HOSPITAL, NEW DELHI, INDIA NEW DELHI India

Background: Recurrence of autoimmune hepatitis in known phenomenon and occurs in 17-33% of transplanted patients of liver. Risk factors implicated in recurrence include the susceptibility alleles HLA-DRB1*0301 or DRB1*0401 in the transplant recipient. HLA-DR locus mismatching, incomplete suppression of disease activity before transplantation are some of the mechanisms for rAIH. The other pupil de-novo AIH with likely mechanism of autoimmunity against neo or self-antigen. This is very unusual case of autoimmune hepatitis in post transplant patient despite immunosuppressive regimen with good adherence.

Case Report: The 50-year-old male, post renal transplant recipient (2013) on immunosuppression with tacrolimus and mycophenolate mofetil presented with complaints of abdominal distention and reduced urine output. On evaluation, USG abdomen showed changes of CLD with gross ascites. Ascitic fluid analysis showed high SAAG, low protein with SBP (cell count- 3359, N-70%). Upper GI endoscopy showed grade 1 varices with PHG. Transient elastography showed median of 75 KPA. On etiological front, non-alcoholic, non-diabetic, ANA 2+, speckled pattern, total Ig G levels 2130, normal 2D echo and hepatic vein doppler. Liver biopsy showed mild to moderate lymphoplasmacytic inflammatory cell infiltrates in portal tracts with mild interface activity. Modified ISHAK HAI score 5/18, Fibrosis stage- 4-5/6. Steroids trial was given once SBP subsided, no improvement was seen. Patient advised Simultaneous Liver Kidney Transplant as further treatment modality.

Conclusion: AIH should be considered in all new onset liver disease patients. Patients may progress to end stage liver disease despite long term immunosuppression indicated for other condition.

Abstract Submission No. 100443
P-0749

Successful Autoimmune Hepatitis Management with Conventional Therapy in an Elderly Indonesian Man

Billy Siahaan1, Juferdy Kurniawan1
1RSCM Jakarta Indonesia

Introduction: Autoimmune hepatitis (AIH), epidemiologically had age peaks at 10-30 and 40-60 years. But some study reports incidence above 60 years old. As a specific population, diagnostic and management of AIH in elderly seems challenging. Notes should be made regarding atypical features, comorbidities, and tolerability of drugs when manage this specific population.

Case report: A 65 years old male with no past specific medical history was admitted with 1 month of jaundice. From laboratory, AMA was negative, ALT/ AST were 591/793 U/L, IgG was 2004 (above normal) and ANA was 1:1000. Biopsy of the liver shown moderate lobular and portal inflammation, acute and chronic inflammatory cells (plasma cell and eosinophil) with pericportal nerosis diffuse. Patient had history of hypertension.

This patient being managed by azathioprine and prednison with evaluation of blood pressure intensively. After 2 month there was a significant improvement of jaundice, level of bilirubin (normal limit) and liver function (normal limit). No severe adverse effect were observed during therapy. There is no report of relapse up to 6 month during maintenance therapy.

Discussion: AIH is a rare condition, especially in elderly Asian males. Diagnostic and management AIH in elderly remain challenging. Intensively monitoring during treatment with tapering steroid as soon as possible became the key for management on this specific population.

Conclusion: This present case showing efficacy and safety of conventional therapy with a steroid and azathioprine for AIH in the elderly.

Abstract Submission No. 100509
P-0750

A Case of Clostridium difficile Detected on Rifaximin in a Patient with Alcoholic Liver Cirrhosis

Nagisa Noborikawa1, Toru Arano1, Shigeyuki Kurosaki1, Maki Matsui1, Hikaru Kakimoto1, Takeo Watanabe1, Kazuaki Tejima1
1Fraternity memorial hospital Tokyo Japan

Case: Male, 40s.

Past History: Alcoholic liver cirrhosis, esophageal varices

April 2022: Infectious enteritis, Campylobacter bacteremia

Streptococcus bacteremia, hepatic encephalopathy (with multiple hospitalizations)

Clinical course: Patient has been in our hospital for alcoholic cirrhosis since March 2021. Liver function did not improve after abstinence from alcohol. After abstinence from alcohol, his liver function did not improve, and he was hospitalized for repeated bacteremia and hepatic encephalopathy, so rifaximin was introduced on January 11, 2023. On June 9, 2023, he was admitted to the hospital with frequent watery diarrhea and fever, and was diagnosed with infectious enteritis by CT scan.

On admission, both CD antigen and toxin were confirmed negative by fecal immunochromatography, and other stool culture tests were submitted. Rifaximin was continued. On the fourth day of admission, Clostridium Difficile was detected in a stool culture taken at the time of admission, and AZM was discontinued. Lower gastrointestinal endoscopy was performed the next day and showed only slight pseudomembrane formation. Since the antibiotic used at the time of submission of the stool culture test was rifaximin, it was discontinued and the patient is now under outpatient observation.

Discussion and Conclusion: We have experienced a case of Clostridium difficile caused by long-term oral use of rifaximin.
Abstract Submission No. 100594

P-0751

CASE OF ADVANCED LIVER FIBROSIS DUE TO HBV-INFECTION AND CONCOMITANT AUTOIMMUNE LIVER DISEASE

Narina Sargsyants1, Eleonora Sargsyants2
1National Institute of Health Yerevan Armenia, 2Yerevan State Medical University Yerevan Armenia

Background: Non-organ specific autoantibodies particularly antinuclear antibodies (ANA) and anti-smooth muscle antibodies (SMA) have been reported frequently in HBV- and HCV-infected patients. In most of these cases autoantibodies are detected in lower titers compared to those found in autoimmune hepatitis (AIH), usually lack F-actin specificity of SMA. Chronic viral hepatitis concomitant with AIH often very difficult to be recognized given the heterogeneity of liver diseases, the absence of specific markers for the diagnosis.

Case report: Patient A.S., female, 58 years old, BMI=32 kg/m2, HBV-infection was diagnosed in April 2022. Patient was complained on fatigue, weight loss, subfibrile temperature, arthralgia, numbness of lower extremities. Comorbidities: Diabetes, diabetic nephropathy, polynephropathy, angiothypathy. Palmar erythema, in anamnesis 30 years age ectopic pregnancy. Abdomen US: hepatosplenomegaly, parapancreatic adipose tissue, proteinuria, angiopathy. Palmar erythema, in anamnesis 30 years ago. Development of complications. However, the patient showed a remarkable response to a treatment with atezolizumab/bevacizumab. After second course of atezolizumab plus bevacizumab, she developed an anaphylactic reaction. She underwent lenvatinib therapy as second line systemic treatment. Three weeks after initiating lenvatinib, she developed prethial edema and proteinuria (urine protein:creatinine ratio was 7.58 g/gCr). Her proteinuria was improved 2 weeks after the discontinuation of lenvatinib. We reevaluated HCC. Her tumor markers were decreased within normal range. Contrast enhanced ultrasonography did not detect blood flow in HCC and PVTT.

Conclusions: In this case, patient could not continue systemic therapy due to development of complications. However, the patient showed a remarkable response to a treatment with atezolizumab/bevacizumab followed by lenvatinib. Sequential therapy may be a useful treatment option for HCC patients with PVTT.

Abstract Submission No. 100620

P-0752

A Rare, Benign Etiology of Isolated Elevation of AST in an Asymptomatic Individual: Macro-AST

Haily Vora1, Nicole Loo1
1Mayo Clinic Florida Jacksonville United States

Introduction: Macro-aspartate aminotransferase (AST) is a high molecular mass complex of AST bound with immunoglobulins. It is a rare cause of isolated elevation of serum AST. We present a case of macro-AST in an asymptomatic patient without evidence of chronic liver disease.

Case: A 55-year-old man was seen in the hepatology clinic for isolated elevation of AST for the past 3 years ranging from 106-181 U/L (reference range [RR] 8-48 U/L). Liver ultrasound demonstrated normal liver morphology. FibroScan calculated normal medial liver stiffness (4 kPa [RR <7 = no significant fibrosis]) and a Controlled Attenuation Parameter Score of 207 [RR S0 <248]). Serologic workup for etiologies of chronic liver disease including iron studies, ceruloplasmin, alpha-1-antitrypsin, anti-mitochondrial antibody, and hepatitis A, B and C were negative. Anti-smooth muscle antibody was positive with a 1:320 titer and ANA was negative. Liver enzymes were normal (total bilirubin 0.5 mg/dL [RR ≤1.2 mg/dL], direct bilirubin 0.1 mg/dL [RR

0.0-0.3 mg/dL], alanine aminotransferase 21 [RR 7-55 U/L], alkaline phosphatase 74 [RR 40-129 U/L]) apart from an elevated AST (95 U/L). The serum sample was stored at 4°C for 5 days and measured again. There was an observed 10.5% decrease in AST from 95 U/L to 85 U/L, indicating macro-AST.

Discussion: The method of measuring AST activity from a serum sample assayed at day 0 and day 5 is a cost-effective and reliable screening methodology for detecting macro-AST in the absence of other technologies. Identification of macro-AST as the etiology of serum elevation of AST can help avoid more invasive testing such as liver biopsy and unnecessary treatments.

Abstract Submission No. 100632

P-0753

Atezolizumab/bevacizumab followed by lenvatinib in a HCC patient with portal vein tumor thrombosis

manabu hayashi1, Tatsuro Sugaya1, Yosuke Takahata1, Masashi Fujita1, Kazumichi Abe1, Atsushi Takahashi1, Hiromasa Ohira1
1Fukushima Medical University Fukushima Japan

Introduction: Development of portal vein tumor thrombosis (PVTT) is associated with disease progression and poor prognosis in patients with hepatocellular carcinoma (HCC). Recent reports suggested that sequential systemic therapy improved prognosis in advanced HCC patients.

Case Presentation: A 70-year-old woman with cirrhosis due to hepatitis B virus infection showed tumor markers elevation during follow-up after treatment for HCC. She underwent RFA seven years before and underwent liver resection 4 years before. Contrast enhanced computed tomography and magnetic resonance imaging showed 13mm nodule in segment 8 and tumor in the portal vein. She was diagnosed as recurrence of HCC with PVTT. The extent of PVTT was classified as Vp2. She refused surgical treatment, and underwent treatment with atezolizumab plus bevacizumab. After second course of atezolizumab plus bevacizumab, she developed an anaphylactic reaction. She underwent lenvatinib therapy as second line systemic treatment. Three weeks after initiating lenvatinib, she developed prethial edema and proteinuria (urine protein:creatinine ratio was 7.58 g/gCr). Her proteinuria was improved 2 weeks after the discontinuation of lenvatinib. We reevaluated HCC. Her tumor markers were decreased within normal range. Contrast enhanced ultrasonography did not detect blood flow in HCC and PVTT.

Conclusions: In this case, patient could not continue systemic therapy due to development of complications. However, the patient showed a remarkable response to a treatment with atezolizumab/bevacizumab followed by lenvatinib. Sequential therapy may be a useful treatment option for HCC patients with PVTT.

Abstract Submission No. 100667

P-0754

Hepatic sinusoidal obstruction syndrome: a rare complication of Paroxysmal Nocturnal Hemoglobinuria.

Xiaohe Li1, Rui Huang1, Xinyue Liu1
1Peking University People's Hospital Beijing China

A 20-year-old young man admitted to our institution presented with intravascular hemolytic anemia, symptomatic hepatomegaly, ascites, elevated liver enzymes and overt jaundice. He had a history of severe AA (SAA) treated by antilymphocyte globulin (ALG) and
combination of Cyclosporine A(CsA) and androgen successively. Abdominal enhanced computer tomography (CT) showed hepatic vein narrowing and patchy signal enhancement. The peripheral blood flow cytometry (FCM) showed that PNH clone increased up to 95.7%, which significantly indicated disease evolve to PNH (AA/PNH syndrome). Pathology of liver biopsy revealed microvascular thrombosis originating in the central lobule vein, accompanied with sinusoidal dilatation and mild centrilobular hepatocellular necrosis, indicated SOS. The patient was treated with anticoagulation by warfarin, keeping international normalized ratio (INR) between 2-3. The ascites and jaundice disappeared completely and liver function improved significantly. Hemoglobinuria was observed once during clinical course, regarded as acute attack of PNH. So he was started on methylprednisolone intravenous injection 40mg/day for 3 days then transitioned to oral prednisolone 50mg/day, with the stabilization of hemoglobin, the dose of corticoid decreased quickly. Eventually the patient’s ascites and jaundice disappeared and liver function improved, the reexamined abdominal enhanced CT showed the injured hepatocyte vanished. He was followed up in clinic. The patient withdraw of corticoid himself, and hemoglobinuria relapsed, the patient didn’t detect INR outpatient. The ascites recurrence 1 month ago.

Abstract Submission No. 100678
P-0755

AN ATYPICAL CAUSE OF MASSIVE HEMOBILIA IN A 66-YEAR-OLD FILIPINO MALE: A CASE REPORT

Quincy Mae Ceniza
1

1Southern Philippines Medical Center Davao City Philippines

Hemobilia is an unusual cause of upper gastrointestinal bleeding. It presents as a triad of jaundice, melena and abdominal pain. Half of these cases are secondary to trauma from invasive procedures done in the hepatobiliary tree. However, we present to you a case of hemobilia in the absence of an iatrogenic cause or a medical history of a hepatobiliary disease. A sixty-six year old Filipino male presented with diffuse abdominal pain, melena, hemochezia and jaundice during the course of his admission. CT scan with angiogram revealed a heterogenous hepatic mass and intrahepatic biliary duct dilatation probably secondary to tumor compression. UGIE and Colonoscopy showed no source of active bleeding and the scope was only passed until the transverse colon due to presence of blood clots. Successful Trans-arterial Embolization of the Hepatic Artery Pseudoaneurysm by Interventional radiology was done leading to resolution of the bleeding. Definitive management with surgery noted presence of multiple hepatolithiasis causing erosion of the left hepatic artery and left portal vein, leading to the hemobilia of this patient. Biopsy revealed Schistosomiasis with cirrhosis and chronic cholecystitis. Post operatively, there was no recurrence of the symptoms and the patient was discharged improved. This report illustrates a classic case of hemobilia with an atypical cause, and highlights the roles of history, physical examination and radiologic workup in determining the diagnoses. High index of suspicion plus the use of an algorithm resulted to a prompt interdepartmental referral and appropriate management of the patient.

Abstract Submission No. 100737
P-0756

Non-Cirrhotic Portal Hypertension As An Unusual Manifestation of Hepatic Sarcoïdosis

Nikko Darnindro1,2, Maria Satya Paramitha2, Adianto Nugroho1, Andri Andri1, Ida Ayu Kshanti1, Bonita Praworohardojo1
1Fatmawati General Hospital jakata timur Indonesia, 2Cipto Mangunkusumo General Hospital Jakarta Indonesia

Introduction: Sarcoïdosis is an idiopathic systemic granulomatous disease, characterized by aberrant development of non-caseating granulomas in multiple organs. In Asia, the incidence of sarcoïdosis is quite scarce (1-2 patients in 10,000 populations). In 50-65% of patients with sarcoïdosis, hepatic granulomas can be observed, in which, only 5-15% will demonstrate clinical manifestation, including portal hypertension.

Case Illustration: A 23-year-old male arrived with recurrent abdominal discomfort and progressive dyspepsia. He had a history of hematemesis and melena with esophagogastroduodenoscopy (EGD) examination revealed grade 1 esophageal varices and portal hypertensive gastropathy. His physical findings showed malnourished (underweight) nutritional status, anemic conjunctivae, decreased breath sounds on the basal and middle fields of left lung, and moderate abdominal distension. Laboratory examinations showed decreased hemoglobin (6.3 g/dl) with an increase of erythrocyte sedimentation rate (ESR) (109 mm/hour). A Computed Tomography (CT)-scan demonstrated left-sided pleural effusion; hepatomegaly; dilated intrahepatic biliary system; dilated intra-hepatic and extra-hepatic portal veins; accompanied with dilated superior mesenteric vein, splenic vein, and collateral formation towards left gastric vein. There was also a presence of loculated ascites and thickening of gastric and intestinal walls. An exploratory laparotomy procedure was performed, displaying frail liver with ongoing bleeding and perforated small intestine. Extravasation and ileostomy procedure was performed on the perforated ileum. Histopathological findings from liver and peritoneum demonstrated non-necrotizing granulomas with dilated multiple vessels.

Conclusion: Sarcoïdosis is an extremely rare condition; thus, making it potentially very difficult to diagnose. This case demonstrated a challenging process from clinical presentation to myriad diagnostic procedures to confirm sarcoïdosis.

Keywords: sarcoïdosis, non-cirrhotic portal hypertension, perforated intestine, unilateral pleural effusion

Abstract Submission No. 100773
P-0757

A case report on a 42-year-old male clinically diagnosed with Cowden syndrome

Pamela Bianca L Yap1, Mara M. Mangio1, Frinz Moey C. Rubio1
1St Luke’s Medical Center Quezon City Quezon City Philippines

Objective: To discuss a rare case of clinically diagnosed Cowden’s Syndrome.

Introduction: Cowden syndrome is part of PTEN hamartoma tumor syndromes (PHTS) characterized by autosomal dominant mutations of the PTEN tumor suppressor gene. The presence of hamartomas is the defining clinical feature. PHTS have increased risk of both benign and malignant tumors, including colon cancers. However, some patients with mutations do not show clinical signs and symptoms, while patients with the clinical syndrome may not have detectable PTEN mutations.

Case Presentation: A 42-year-old man with macrocephaly and multiple trichilemmomas was diagnosed with benign nasopharyngeal mass, presenting as recurrent epistaxis. The patient was suspected to have PHTS hence referred for endoscopy to evaluate presence of gastrointestinal hamartomas. EGD revealed multiple esophageal glycogenc anacanthosis. Colonoscopy showed innumerable polyps in the cecum, ascending and sigmoid colon. Biopsies of the polyps yielded juvenile
polyps, tubular adenoma and tubulovillous adenoma. No family member is suspected or confirmed to have PHTS. Based on the current National Comprehensive Cancer Network (NCCN) operational diagnosis of PHTS, patient satisfied three major criteria: macrocephaly, multiple trichilemmomas, and multiple juvenile polyps. Patient was then advised for colonoscopy every 2 years due to increased risk of developing colorectal cancer approximately 9 to 20%. Genetic counseling was advised for both the patient and family members.

**Conclusion:** PTEN gene mutations have poor penetrance. Even if PHTS is an autosomal dominant genetic condition, it may not be reliably detected in their family history. Screening colonoscopy is recommended because of increased risk of developing colorectal cancer.

Abstract Submission No. 100787
P-0758

Recanalization of portal veins by anticoagulation therapy in combination with embolization of SPSS

Ju Huang1, Xuefeng Luo1

1West China Hospital, Sichuan University Chengdu, China China

**Background:** Studies have shown that the spontaneous portosystemic shunts (SPSS) may increase the risk of portal vein thrombosis (PVT). Anticoagulation therapy is the main treatment for portal vein thrombosis in patients with liver cirrhosis. However, the efficacy of anticoagulation maybe impaired when portal perfusion was diverted due to the presence of SPSS. Here we present a case of PVT treated by the anticoagulation therapy in combination with embolization of SPSS.

**Case Report:** A 53-year-old female patient was diagnosed with hepatitis B-related liver cirrhosis accompanied by portal vein thrombosis. The presence of large SPSS was fount on CT scan. She had no previous history of hepatic encephalopathy. A plug was inserted into the shunt via the transfemoral access. Rivaroxaban was given at a dose of 10mg daily after the surgery. A CT examination 5 months later revealed the complete recanalization of portal veins and the disappearance of the SPSS.

**Discussion:** The presence of SPSS may be the potential reason of the PVT in the present case. Redirect the blood flow by the embolization of the SPSS may improve the efficacy of the anticoagulation therapy. Proper management of the SPSS should be taken into consideration in cirrhotic patient with PVT and large SPSS.

Abstract Submission No. 100801
P-0759

Primary biliary cholangitis in pregnant woman

Narina Sargsyants1, Eleonora Sargsyants2

1National Institute of Health Yerevan Armenia, 2Yerevan State Medical University Yerevan Armenia

**Background:** Primary biliary cholangitis (PBC) is a rare immune-mediated, progressive chronic cholestatic liver disease, resulting in end-stage liver disease and its associated complications. PBC predominantly affects women, it is diagnosed at childbearing age in up to 25% of cases. Severity range from asymptomatic biochemical signs of cholestasis, through symptomatic disease presenting with fatigue, pruritus, sicca syndrome. Biochemical feature of PBC is increased serum ALP, immunoglobulin, particularly IgM, AST and ALT. Up to 70% of women with PBC had stable or improved serum liver tests during pregnancy, but increased liver disease activity was reported in 60-70% postpartum. Fetal outcome in PBC pregnancies is impaired, rates of live births 58–76%, increased rates of preterm delivery of 6–33% and other neonatal complications. EASL recommends life-long ursodeoxycholic acid (UDCA) at 13–15 mg/kg/day as the first-line pharmacotherapy, should be continued during pregnancy as it is safe in pregnancy and breastfeeding.

**Case report:** 34 years old female, PBC diagnosed in 2021 (positive ANA, AMA, PCA, AP 547, GGT 241, AST 61 IU/ml) with UDCA prescription. In anamnesis complain on fatigue, nausea, anemia from 2012, splenomegaly from 2013, sicca syndrome diagnosed in 2017, first pregnancy interruption. Patient lost of follow up to March 2023, with 12 week of pregnancy. UDCA re-started with close monitoring of biochemical analysis and US. Delivery with Cesarian Section in 27.09.2023. with biochemical analysis in post-partum period.

**Conclusions:** PBC-specific experience in pregnancy is limited to case-series. Described case is interesting due to benign duration of pregnancy with UDCA therapy and fetal outcome.

Abstract Submission No. 100902
P-0760

Adult-Onset Still’s Disease Mimicking Hemochromatosis: A Masquerade

Matthew Joseph T Po1

1Chong Hua Hospital Cebu City Philippines

**Background:** Adult-onset Still’s disease (AOSD) and hemochromatosis are two distinct disorders with some overlapping characteristics. Both are characterized by hyperferritinemia and abnormal liver function tests. While AOSD is distinguished by systemic inflammation, hemochromatosis mainly involves excessive iron absorption and deposition. Liver biopsies of patients with AOSD typically exhibit non-specific characteristics. However, no studies have reported the presence of iron deposition in liver biopsies of AOSD patients.

**Case Presentation:** This documents a case of a 58-year-old male with fever, arthralgia, and lymphadenopathy, whose initial clinical presentation did not fulfill the diagnostic criteria for AOSD. Diagnostic investigation revealed significantly elevated ferritin levels and hyperbilirubinemia, prompting consideration of both AOSD and hemochromatosis. Despite the consideration of hemochromatosis indicated by the findings from the liver biopsy, the negative HFE gene mutation testing further supported the diagnosis of AOSD. Treatment with corticosteroids led to a notable improvement in both clinical symptoms and biochemical markers.

**Conclusion:** The accurate diagnosis of AOSD poses challenges due to its nonspecific presentation. This case highlights the challenges involved in distinguishing AOSD from hemochromatosis, underscoring the need for comprehensive clinical, genetic, and histopathological examination. A multidisciplinary approach is imperative for the precise diagnosis and effective management of such intricate systemic conditions.

**Keywords:** Adult-Onset Still’s Disease, Hemochromatosis, Ferritin, Liver Biopsy

Abstract Submission No. 100934
P-0761

Characteristics of Caroli’s Disease Comorbid with Chronic Hepatitis B: A Case Series

Yulei SUN1, Fan Zhang2, Qiran Zhang3, Ruirui You1, Yiqi Yu1, Chao Qiu1, Wenhong Zhang1, Guojun Li2
A 71-year-old lady with previous chemotherapy for metastatic breast cancer developed massive haematochezia from bleeding large rectal varices, consistent with porto-sinusoidal vascular disorder. Liver biopsy revealed moderate steatosis with stage 1C pericellular fibrosis, consistent with porto-sinusoidal vascular disorder. Endoscopic treatment refractory bleeding of rectal varices was performed with 2x10x14mm Nestor coils. This led to pressure re-distribution with post-procedure occurrence of 2 new but smaller rectal varices which bled and were treated with banding and clip (Figure 2).

Transhepatic portal venography showed terminal inferior mesenteric vein bifurcation into medial and lateral (right) branches, which respectively supplied the 2 new rectal varices. The rectal varices all drained rapidly into the left internal iliac vein (Figure 3). Embolization with a combination of coils and lipiodol/histoacryl mixture was performed. Portal pressure was 15mmHg pre-embolization and 17mmHg post-intervention. There was no further bleeding after. The recurrent bleeding post EUS-coiling was likely due to increased pressure in the proximal portosystemic shunt branches not visible from EUS.

Liver biopsy revealed moderate steatosis with stage 1C pericellular fibrosis, consistent with porto-sinusoidal vascular disorder.

for bleeding ectopic varices with extensive portosystemic shunts as venography enables a more complete assessment of the portosystemic circulation.

Abstract Submission No. 100936
P-0763
Endoscopic Treatment Refractory Bleeding of Rectal Varices from Porto-Sinusoid Vascular Disorder.

Martin Putera1, Cui Li Lin1, Marianne Anastasia De Roza1, Farah Gillan Irani1
1Sengkang General Hospital Singapore Singapore

A 71-year-old lady with previous chemotherapy for metastatic breast cancer developed massive haematochezia from bleeding large rectal varices (Figure 1), which was banded. CT mesenteric angiogram showed large peri-rectal varices with portosystemic collaterals without cirrhosis or splenomegaly. HVPG was 8.7mmHg. Due to recurrent bleeding with large residual varices and portosystemic collaterals, EUS-coiling of rectal varices was performed with 2x10x14mm Nestor coils. This led to pressure re-distribution with post-procedure occurrence of 2 new but smaller rectal varices which bled and were treated with banding and clip (Figure 2).

Transhepatic portal venography showed terminal inferior mesenteric vein bifurcation into medial and lateral (right) branches, which respectively supplied the 2 new rectal varices. The rectal varices all drained rapidly into the left internal iliac vein (Figure 3). Embolization with a combination of coils and lipiodol/histoacryl mixture was performed. Portal pressure was 15mmHg pre-embolization and 17mmHg post-intervention. There was no further bleeding after. The recurrent bleeding post EUS-coiling was likely due to increased pressure in the proximal portosystemic shunt branches not visible from EUS.

Liver biopsy revealed moderate steatosis with stage 1C pericellular fibrosis, consistent with porto-sinusoidal vascular disorder.

We report a patient with refractory bleeding of rectal varices with portosystemic shunt refractory to endoscopic interventions including EUS-coiling but was successfully treated with transhepatic venography and embolization. There is no consensus on the treatment of ectopic variceal bleeding. Embolization may be the preferred treatment for bleeding ectopic varices with extensive portosystemic shunts as venography enables a more complete assessment of the portosystemic circulation.

Abstract Submission No. 100940
P-0764
Recurrent HCC with infiltration to inferior vena cava and portal vein: a case report

Ahmad Yusran1
1Hepatology Division, Department of Internal Medicine, Cipto Mangunkusumo General Hospital- Faculty of Medicine Universitas Indonesia Jakarta Indonesia

Introduction: HCC is the most common form of primary liver cancer, accounting for 75%-85% of cases. Despite the approach of potentially curative treatments, up to 50-70% of individuals may experience a relapse in 5 years. HCC recurrence within 2 years of treatment is defined as "early", after 2 years is defined as “late”. Early recurrence has a significantly poorer prognosis and outcome than late recurrence. Malignant vascular infiltration in HCC is usually an exclusion criterion for aggressive treatments like TACE and liver surgery or orthotopic

for bleeding ectopic varices with extensive portosystemic shunts as venography enables a more complete assessment of the portosystemic circulation.
Demonstrated a challenging late recurrence of HCC with infiltration to sue, affecting 70% of patients undergoing curative treatment. This case

**Conclusion:** The recurrence of HCC represents a relevant clinical issue, affecting 70% of patients undergoing curative treatment. This case demonstrated a challenging late recurrence of HCC with infiltration to inferior vena cava and portal vein.

**Case Illustration:** A 53-year-old male was admitted with a complaint of insufferable epigastric pain spreading to the right abdomen and the back. He had a history of HCC and had undergone a laparotomy liver resection and adhesiolysis 5 years ago. RFA was not recommended at the time considering the position of the nodule being near the gallbladder and portal vein. This time, liver biopsy showed a tissue resembling a moderately differentiated HCC in cirrhotic liver tissue and abdominal CT scan confirmed further infiltration of the HCC to inferior vena cava and portal vein.

**Case Report:** A man in his early 80's with a history of alcoholic cirrhosis, hypertension, and severe esophageal inflammation underwent a laparoscopic partial segmentectomy of segment (S) 4 for suspected hepatic carcinoma, pT3N0M0, pStage III, surrounded by Grade 3 fibrosis. To date, few cases have been reported about cholestatic hepatitis as a manifestation of chronic HBV infection in flare and here we present a case with improvement after prednisone.

**Conclusions:** While the observation time including acute and chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma. To date, few cases have been reported about cholestatic hepatitis as a manifestation of chronic HBV infection in flare and here we present a case with improvement after prednisone.

**Case Report:** Patient is a 29-year-old male with Chronic Hepatitis B who presented with 1 month history of jaundice, icterisia, pruritus, easy fatigability, tea-colored urine, acholic stools. There was no history of drug ingestion and blood transfusions in the past. He has no family history of liver diseases. He is a non-smoker and occasional alcoholic drinker. Pertinent physical exam findings were icterisia, jaundice, non-distended abdomen with hepatosplenomegaly. Laborat-ory results showed transaminitis, hyperbilirubinemia, and elevated alkaline phosphatase; HBsAg, HBcAg, AntiHBc IgM, AntiHBc total reactive and HBV DNA 1385 copies/ml. Whole abdominal ultrasound and MRI of the upper abdomen were unremarkable. Liver biopsy showed subtle hepatitis with diffuse cholestasis (Fig. 1). Tenofivir standard dose and Prednisone 50 mg per day (15mg/kg/BW) tapering doses were given. Within a week, there was a dramatic reduction in pruritus and jaundice. At follow-up, the patient continues to be asymptomatic with HBV DNA undetectable; and has not shown any clinical or biochemical evidence of relapse.

**Conclusion:** Cholestasis due to Hepatitis B may be bothersome to patients. Steroids may be useful in patients with HBV infection and associated cholestasis. Prednisone 50 mg/day has shown to decrease bilirubins to <50% of its baseline levels.

**Steroid Treatment for Chronic Hepatitis B in Flare: A Case Report**

**Background:** Hepatitis B infection has diverse clinical manifestations including acute and chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma. To date, few cases have been reported about cholestatic hepatitis as a manifestation of chronic HBV infection in flare and here we present a case with improvement after prednisone.

**Case Report:** Patient is a 29-year-old male with Chronic Hepatitis B who presented with 1 month history of jaundice, icterisia, pruritus, easy fatigability, tea-colored urine, acholic stools. There was no history of drug ingestion and blood transfusions in the past. He has no family history of liver diseases. He is a non-smoker and occasional alcoholic drinker. Pertinent physical exam findings were icterisia, jaundice, non-distended abdomen with hepatosplenomegaly. Laborat-ory results showed transaminitis, hyperbilirubinemia, and elevated alkaline phosphatase; HBsAg, HBcAg, AntiHBc IgM, AntiHBc total reactive and HBV DNA 1385 copies/ml. Whole abdominal ultrasound and MRI of the upper abdomen were unremarkable. Liver biopsy showed subtle hepatitis with diffuse cholestasis (Fig. 1). Tenofivir standard dose and Prednisone 50 mg per day (15mg/kg/BW) tapering doses were given. Within a week, there was a dramatic reduction in pruritus and jaundice. At follow-up, the patient continues to be asymptomatic with HBV DNA undetectable; and has not shown any clinical or biochemical evidence of relapse.

**Conclusion:** Cholestasis due to Hepatitis B may be bothersome to patients. Steroids may be useful in patients with HBV infection and associated cholestasis. Prednisone 50 mg/day has shown to decrease bilirubins to <50% of its baseline levels.

**Immunotherapy of HCV-autoimmune hepatitis overlap syndrome with glecaprevir/pibrentasvir:** Case report

**Abstract Submission No. 101102**

**P-0767**

**Improvement of HCV-autoimmune hepatitis overlap syndrome with glecaprevir/pibrentasvir:** Case report

**Abstract Submission No. 101102**

**P-0767**

**Steroid Treatment for Chronic Hepatitis B in Flare: A Case Report**

**Hannah Angelica Lacar**<sup>1</sup>, Edhel Tripon<sup>1</sup>, Leila Sawadjaan<sup>1</sup>, Glezette Altares<sup>1</sup>, Dela Cruz Roucaille<sup>1</sup>

<sup>1</sup>The Medical City Pasig City Philippines

**Background:** Hepatitis B infection has diverse clinical manifestations including acute and chronic hepatitis B, liver cirrhosis, and hepatocellular carcinoma. To date, few cases have been reported about cholestatic hepatitis as a manifestation of chronic HBV infection in flare and here we present a case with improvement after prednisone.

**Case Report:** Patient is a 29-year-old male with Chronic Hepatitis B who presented with 1 month history of jaundice, icterisia, pruritus, easy fatigability, tea-colored urine, acholic stools. There was no history of drug ingestion and blood transfusions in the past. He has no family history of liver diseases. He is a non-smoker and occasional alcoholic drinker. Pertinent physical exam findings were icterisia, jaundice, non-distended abdomen with hepatosplenomegaly. Laborat-ory results showed transaminitis, hyperbilirubinemia, and elevated alkaline phosphatase; HBsAg, HBcAg, AntiHBc IgM, AntiHBc total reactive and HBV DNA 1385 copies/ml. Whole abdominal ultrasound and MRI of the upper abdomen were unremarkable. Liver biopsy showed subtle hepatitis with diffuse cholestasis (Fig. 1). Tenofivir standard dose and Prednisone 50 mg per day (15mg/kg/BW) tapering doses were given. Within a week, there was a dramatic reduction in pruritus and jaundice. At follow-up, the patient continues to be asymptomatic with HBV DNA undetectable; and has not shown any clinical or biochemical evidence of relapse.

**Conclusion:** Cholestasis due to Hepatitis B may be bothersome to patients. Steroids may be useful in patients with HBV infection and associated cholestasis. Prednisone 50 mg/day has shown to decrease bilirubins to <50% of its baseline levels.
After confirmation of SVR24, HCC recurrence was observed, and partial hepatectomy was performed. Background liver findings showed that liver parenchymal inflammation improved compared with that before DAAs treatment. There are few cases of DAAs treatment for HCV-AIH overlap syndrome. In the present case, we selected and treated GLE/PIB for DAAs. Liver function improved within a short treatment period of 8 weeks, as confirmed using serology and histology.

Abstract Submission No. 101116
P-0768
Primary Hepatic Neuroendocrine Tumor- A Case Report and Literature Review
Masayuki Honda1, Ryota Masuzaki1, Naoki Matsumoto1, Mai Totsuka1, Shuhei Arima1, Hiroaki Yamagami1, Masahiro Ogawa1, Tatsuo Kanda1, Shinobu Masuda2, Yukiyasu Okamura3, Hirofumi Kogure4
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine Tokyo Japan, 2Division of Oncologic Pathology, Department of Pathology and Microbiology, Nihon University School of Medicine Tokyo Japan, 3Division of Digestive Surgery, Department of Surgery, Nihon University School of Medicine Tokyo Japan
Primary hepatic neuroendocrine tumors (PHNETs) are rare neoplasms and challenging to distinguish from other tumors by imaging studies. A 43-year-old previously healthy female was referred for evaluation of a liver mass incidentally discovered on an abdominal ultrasound examination. A triphasic CT scan showed a hypodense lesion in the left lobe of the liver with early enhancement on the hepatic arterial phase and subsequent washout in delayed phases with a measurement of 2.0 cm. Upper endoscopy and colonoscopy yielded normal studies. The FDG-PET revealed an uptake only in the liver tumor. The patient underwent a laparoscopic left hepatectomy. Histopathological and immunohistochemical examination revealed a grade 1/2 neuroendocrine tumor. No other lesions were found one year after the surgery, making the diagnosis of PHNET highly probable. This case shows that diagnosing PHNET is a medical challenge, requiring differentiation of PHNETs and other hepatic masses and exclusion of occult primary neuroendocrine tumors. The excised tumor exhibited positive somatostatin receptor expression, and consideration of an octreotide scan is ongoing in the outpatient setting. This case emphasizes the importance of considering PHNETs in the differential diagnosis of a hepatic nodule.

Abstract Submission No. 101186
P-0770
Early onset of ICI-colitis after STRIDE regimen in hepatocellular carcinoma
IPPEKI NAKAYA1, Kei Endo1, Hiroaki Abe1, Hidekatsu Kuroda1, Takayoshi Oikawa1, Tamami Abe1, Asami It1, Akiko Suzuki1, Yuichi Yoshida1, Keisuke Kakisaka1, Takayuki Matsumoto1
1iwate medical university department of medicine,division of gastroenterology yahaba Japan
Introduction: The HIMALAYA trial is the first chemotherapeutic trial to demonstrate the efficacy of combined immune checkpoint inhibitors (ICIs) for unresectable hepatocellular carcinoma (u-HCC). The regimen used in this trial is called the STRIDE regimen and consists of cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor, and programmed cell death ligand 1 (PD-L1) inhibitor. We herein report two cases of ICI-colitis, which occurred immediately after the start of the STRIDE regimen for u-HCC.
Case Presentation: A 73-year-old man and a 75-year-old man with u-HCC were treated with the STRIDE regimen. Both patients developed grade 3 diarrhea (Common Terminology Criteria for Adverse Events ver. 5.0) within 10 days of start of treatment. Colonoscopy revealed aphthous erosions and erythema extending from the terminal ileum to the rectum in one case, while the other showed aphthous ulcers in the terminal ileum and shallow ulcers in the colorectum. A histopathological examination of a biopsy specimen revealed epithelial cell apoptosis and neutrophil infiltration bodies, which were consistent with ICI-colitis. Prednisolone (0.5 mg/kg) was effective for both patients.
Conclusion: Our experience suggests the need for both the careful monitoring and early endoscopic examination of ICI colitis in patients with unresectable HCC treated with the STRIDE regimen.

Abstract Submission No. 101190
P-0771
INTRAHEPATIC CHOLANGIOCARCINOMA PRESENTING AS A LIVER AND ABDOMINAL WALL ABSCESs
Spinal Cord Ischemia After Transcatheter Artery Chemoembolization for Hepatocellular Carcinoma

Hieu LE TRUNG1, Thanh LE VAN2, Quang VU VAN2

1Human Organ and Tissue Transplantation Center, Military Central Hospital 108 Hanoi Vietnam, 2Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Case report: We report a case of 78-year-old male patient with chronic hepatitis B, diagnosed with HCC. He underwent the second TACE, and right after the procedure, the patient abruptly developed bilateral lower extremities motor weakness and sensory impairment below the T10 dermatome. Spinal magnetic resonance imaging showed T2-weighted scans showed increased intramedullary signal strength at the T1-T12 level. The patient received supportive care, ongoing rehabilitation, and steroid pulse therapy. The motor strength remained unchanged, but the sensory deficiencies practically disappeared.

Clinical discussion: The hepatic artery injury or decreased flow at the prior TACE site, which causes collateral recruitment, can explain why spinal cord injury following TACE typically happens after the second or third session. It can occasionally result from accidental embolized spinal branches originating from intercostal or lumbar collateral arteries. In our case, we hypothesize the embolism caused the infarction to the spinal cord travel through the connection between the lateral branches of the right inferior phrenic artery and the intercostal arteries, which supply the spinal cord through the anterior spinal artery.

Conclusions: TACE in rare case can have severe complications. A tailored therapeutic strategy, including consideration of a shunt and selection of the vessels utilized for the Lipiodol infusion prior to TACE, is crucial to achieving an optimal end outcome to avert these significant consequences.

Abstract Submission No. 101299
P-0774

Unlocking the Hepatic Puzzle: A Case Report of Unraveling Autoimmune Hepatitis

Helen Engelina1, Hendra Koncoro2, Cindy Cindy2, Renamingyams Tambun3

1Faculty of Medicine and Health Science Atma Jaya Jakarta Indonesia, 2RS Sint Carolus Jakarta Jakarta Indonesia

Autoimmune Hepatitis is an uncommon liver condition characterized by the immune system mistakenly attacks liver cells. This report contributes by detailing a specific case, emphasizing the patient’s presentation, diagnostic journey, and successful therapeutic interventions. This case underscores the necessity of a multidisciplinary approach, involving, hepatologists, gastroenterologist, and immunologists. It
A 63-year-old male with no known co-morbidities with prior history of malignancy.

Knowledge on the etiology of jaundice in patients with suspected malignancy are reported. This case report will help elucidate further consideration of azathioprine were performed, leading to sustained clinical improvement.

Abstract Submission No. 101301
P-0775

Paraneoplastic Jaundice and “double expressor” Diffuse Large B-Cell Non-Hodgkin’s Lymphoma(DLBC-NHL)

Jan Axel Yusi1, Jose Guillan Cataluna1
1St. Luke’s Medical Center Quezon City Quezon City Philippines

To our knowledge, only three cases on DLBC-NHL presenting with jaundice are reported. This case report will help elucidate further knowledge on the etiology of jaundice in patients with suspected malignancy.

A 63-year-old male with no known co-morbidities with prior history of cholecystectomy presented with two-months of progressive painless jaundice (icterisia and tea-colored urine) and weight loss of 10kg. Work up revealed: ALT 229mg/dl, ALP 560U/L, GGT 528mg/dl, Total Bilirubin 15.86md/l, Conjugated Bilirubin 15.38mg/dl, Normal CBC, PT INR, Crea and TSH[JC1]. ANA was negative. PIVKA II, AFP and CA 19-9 are normal. Negative for Hep A, B and C. MRI of the upper abdomen with IV contrast and MRCP, and p-ANCA. Abdominal ultrasound demonstrated a bright liver with no intra and extrahepatic bile duct dilatation. Liver biopsy revealed lymphoplasmacytic infiltrates reaching the limiting plate and intralobular lymphocyte infiltration. Endoscopic examinations ruled out IBD. The patient was initiated on intravenous Glycyrrhizin, Omeprazole, and oral Silymarin. Prednisone was initiated at 40 mg/day, followed by a tapering regimen. Azathioprine was initiated at 50 mg/day one month later. The patient’s liver function tests normalized, and clinical improvement was observed. Subsequent tapering of prednisone and escalation of azathioprine were performed, leading to sustained clinical improvement.

Abstract Submission No. 101353
P-0777

A case of giant-tree-type gastroesophageal varices successfully treated with PTO.

Akihito Takeuchi1, Yosihari Asaoka1, Atsushi Tanaka1
1Teikyo University Faculty of Medicine internal medicine tokyo Japan

A 66-year-old woman, who had been treated with methotrexate and adalimumab for Rheumatoid arthritis, was transported to the emergency room due to blood vomiting. Contrast-enhanced CT failed to reveal active hemorrhage; however, a large variceal vein with a diameter of 6 mm was identified, extending from the gastric varices at the cardia to the lower esophagus. Emergency esophago-gastro-duodenoscopy (EGD) revealed consistent findings, confirming the presence of giant-tree-type varices in the patient. Since no bleeding spots or clots were observed, endoscopic hemostatic procedures, such as endoscopic variceal ligation (EVL), were not performed at that time. On the fourth day, percutaneous transhepatic variceal embolization (PTO) was performed, and the left gastric vein which was identified as the source of the blood supply was embolized. Follow-up EGD showed whitening of the varices. Subsequently, endoscopic injection sclerotherapy (EIS) was performed for the remaining esophageal varices and the patient was discharged on the 20th day. Although the etiology of liver cirrhosis in this case was unclear, there was a history of treatment with methotrexate for rheumatoid arthritis, and its involvement could

Abstract Submission No. 101344
P-0776

PSEUDO-DOMINANT INHERITANCE IN WILSON’S DISEASE: A CASE REPORT

Veronica Cumpata1,2, Adela Turcanu1,3, Victoria Sacara2
1Nicolae Testemițanu State University of Medicine and Pharmacy of the Republic of Moldova Chisinau Moldova, 2Genetic Center of Excellence in the Republic of Moldova Kishinev Moldova, 3The Clinic of Gastroenterology and Hepatology/HELPA Kishinev Moldova

INTRODUCTION: Wilson’s disease (WD) - monogenic disorder with autosomal-recessive transmission, but paradoxical and atypical inheritance cases have been reported. We describe a family in which WD was first diagnosed in a sister, and as a result of the screening, the brother and his 2 children were identified with WD.

CASE REPORT: Proband was diagnosed with WD at the age of 30 years when she was pregnant. As a result of the evaluation of the unexplained cytosis, the diagnosis of WD in the phase of compensated liver cirrhosis was established. After examining her family, her 35-year-old brother and his 3- and 6-year-old boys were diagnosed with WD as well. They were clinically asymptomatic but had cytosis, reduced ceruloplasmin, and elevated 24-hour urinary copper. On abdominal ultrasound, the father had hepatosplenomegaly without signs of portal hypertension, the older boy - hepatomegaly, and the youngest – without significant changes. They have not suffered from liver disease before. None presented neurological manifestations, the MRI was without specific changes and the Kayser-Fleischer ring was absent. In the proband and her brother, the same type of WD-causing mutations - c.2304dupC/c.2292C>T - was revealed in exon 8. In children, the pathogenic variant p.H1069Q was identified in a heterozygous state, but it was impossible to examine exon 8; the second mutation is currently unknown.

CONCLUSIONS: This case report shows how essential the family history is after registering a new WD patient. Thus, screening must be applied not only to parents and siblings but also to offspring.
not be ruled out. For giant-tree-type esophageal varices, treatment with EIS or EVL is considered to be at high risk, and a combination of these, such as EISL or endovascular therapy, is usually employed. In this case, we successfully conducted percutaneous transhepatic variceal embolization for a giant tree-type esophageal varices.

Abstract Submission No. 101358
P-0778

Hepatic Artery Aneurysm: An unlikely cause of Obstructive Jaundice

Clarisse Enria B Porras1, Aaron I Velasco4
1Southern Philippines Medical Center Davao City Philippines

Introduction: Hepatic artery aneurysms (HAA) are uncommon and asymptomatic until it ruptures. Although they account for only 20% of visceral artery aneurysms, they carry a 30% mortality rate if they rupture. HAA presents as epigastric pain, jaundice and shock. The typical causes of HAA are atherosclerosis, mediointimal degeneration, trauma and infection.

Case presentation: A 40 year old woman presented with 1 month history of epigastric pain associated with occasional vomiting followed by pruritus and jaundice. Initial Ultrasound revealed an intrahepatic aneurysm of the portal vein. Follow up CT scan then revealed a hepatic artery aneurysm (2.97 cm X 3.69 cm) with associated biliary obstruction. ERCP with stent insertion was attempted however common bile duct access was not achieved despite pancreatic sphincterotomy due to long loop access. PTBD and Hepatic Arteriogram with embolization was offered however the family was not amenable. Surgical approach was done to relieve the biliary obstruction and repair the aneurysm at the same time. Intraoperative findings were a saccular aneurysm in the mid proper hepatic artery about 4 cm in diameter with a 1.5 cm defect, displacing the common bile duct (CBD) laterally. Repair of the proper hepatic aneurysm was achieved by vein patching followed by cholecystectomy then T - tube insertion in the CBD. The patient recovered well after the procedure with decrease in jaundice and no recurrence of abdominal pain.

Conclusion: This case highlights the approach and alternatives in managing hepatic arterial aneurysm presenting with obstructive jaundice and rupture in a resource – limited setting.

Abstract Submission No. 101363
P-0779

Hepatocellular carcinoma with PV invasion and L/N metastasis cured with multidisciplinary treatment

Noriaki Yuasa1, Shigeyuki Fuji2, Masahiro Maeda2, Naoto Senmaru3
1Department of Radiology, Steel Memorial Muroran Hospital Muroran Japan, 2Department of Gastroenterology, Steel Memorial Muroran Hospital Muroran Japan, 3Departments of General Surgery, Steel Memorial Muroran Hospital Muroran Japan, 4Sapporo Ginnankai Kinen Hospital Sapporo Japan

Case: A female in her 70’s with HCV, she had received TACE and RFA for HCC and no recurrence for last five years. This time, a hypovascular tumor appeared at S5/6 and invade into right posterior portal vein. She had received hepatectomy first, but PVTT could not be resected completely due to limitation of her hepatic reserve and progressed into origin of right portal vein rapidly. AFP increased to over 11,000 (ng/ml). For residual tumor and PVTT, HAIC with NewFP regimen was introduced with temporarily implantable port and catheter system. After two courses of HAIC, CT revealed good deposition of lipiodol into residual tumor and PVTT, but two L/N metastases appeared behind pancreas newly and AFP re-increased, then irradiation with 30Gy/10fr was introduced. AFP remained still high (8,000 level), then Lenvatinib was administrated with 12 mg/day and AFP decreased to 3,000 level, but interrupted and reduced to 8mg/day due to thrombocytopenia, and interrupted again due to duodenal bleeding. CT revealed two L/N metastases reduced, but another metastasis appeared at para-aortic portion and AFP re-increased to 6,000 level. Instead, Sorafenib was administrated with the dosage of 800 mg/day, but interrupted due to high fever 10 days later. However, AFP decreased dramatically to normal range in two months and CT revealed L/N metastasis also reduced and disappeared finally. After that, she has been alive for five years.

Conclusion: Multidisciplinary treatment with combination of resection, HAIC, irradiation and systemic chemotherapy seemed to be effective in this advanced case with PV invasion and L/N metastasis.

Abstract Submission No. 101366
P-0780

A Serial Case Report: Successful Methylprednisolone Therapy for Biliary Atresia

Geo Fernanda1, 2, Rendy Aji Prihatiningtyas1, 2, Bagus Setyobudi1, 2
1Doktor Soetomo General Academic Hospital Surabaya Indonesia, 2Medical faculty Airlangga University Surabaya Indonesia

Introduction: Biliary atresia (BA) is the most common cause of obstructive cholestasis characterized by progressive intrahepatic and/or extrahepatic biliary fibrosis and destruction. In nearly 50% of patients, intrahepatic cholangiopathy remains unresolved after KPE. Based on the recent pathogenesis of BA, immune dysregulation plays an important role in fibrosis and biliary obstruction processes.

Case: First case, a 2-month-old girl with jaundice since birth, acholic stool, total bilirubin of 9.2 mg/dL and direct bilirubin of 6.4 mg/dL. Ultrasound revealed no visible gallbladder. Liver biopsy showed chronic hepatitis without fibrosis. Second case, a 3-month-old boy with jaundice since 2 weeks of age, urine-like tea, with a total bilirubin of 11.78 mg/dL and a direct bilirubin of 7.31 mg/dL. Ultrasound revealed a triangular cord sign, and liver biopsy showed extrahepatic cholestasis and mild fibrosis (F2). Third case, a 2-month-old boy with jaundice for 2 weeks, total bilirubin 10.7 mg/dL, direct bilirubin 7.5 mg/dL. Liver biopsy showed extrahepatic cholestasis and mild fibrosis (F1). All cases were treated with methylprednisolone 2 mg/kg/day. Clinical manifestation, bilirubin, liver function test, and abdominal ultrasonography improved following treatment. All patients had no jaundice, had pigmented stools, and yellow urine.

Results: This case series showed infants with BA who received oral methylprednisolone. In our three cases, all showed a good response to methylprednisolone treatment.

Conclusion: This case series provides evidence that steroids have potential effect on the suppression of bile duct inflammation and obliteration. Immunomodulatory treatment with steroids may stop the biliary inflammatory process.

Keyword: Biliary Atresia, Jaundice, Infant, Methylprednisolon

Abstract Submission No. 101427
P-0781

Gallstone ileus case report
An elderly patient presented with abdominal pain and vomiting for days

YU-FU CHEN1, Tsung-Chieh Yang1
1Taipei Veterans General Hospital Taipei Taiwan

A 81-year-old male had the underlying diseases poorly differentiated gastric adenocarcinoma status post wedge resection with recent recurrence at anastomosis. One 4.3 cm laminated gallstone had been documented on abdominal computed tomographic (CT) 5 months ago. This time, he presented to the Emergency Department with intermittent vomiting for 4 days and periumbilical pain for 1 day. Physical examination revealed soft but distended abdomen with periumbilical tenderness. The bowel sounds were decreased on abdominal auscultation. Lab testing revealed an elevated white blood cell count (19800/µL) and an elevated C-reactive protein (1.66 mg/dL). The abdominal CT revealed wall thickening of gallbladder with internal air density, and a gallstone impaction in the small bowel with proximal bowel loop dilation. Upper gastrointestinal endoscopy showed a small hole at duodenal bulb, suspected fistula formation. Under the impression of choledochoduodenal fistula related gallstone ileus, the patient underwent open enterolithotomy. A huge gallstone, locating at proximal jejunum was retrieved by enterolithotomy. He had an uneventful recovery thereafter.

Case of Hepatopulmonary Syndrome in Cirrhotic Patient with Primary Biliary Cholangitis

Minoru Kanazawa1, 3, Hideaki Takahashi2, 3, Kenjiro Nakaya2, 3, Yuki Mihara1, 3, Takuya Ehira0, Yoshiohito Yosida2, 3, Yuichiro Kawasaki Japan, 3St. Marianna University, School of Medicine, Internal Medicine, Division of Gastroenterology, Kawasaki, Japan

Definition of Hepatopulmonary Syndrome (HPS) is reduced arterial oxygen saturation due to dilated pulmonary vasculature in the presence of advanced liver disease or portal hypertension. Currently there is no medical establishment as an effective therapy and only possible cure is liver transplantation. Therefore Cirrhotic patients complicated by HPS have poor prognosis. We herein report a case of HPS in cirrhotic patient with primary biliary cholangitis (PBC).

A woman in her early 60s who had been diagnosed with liver cirrhosis due to PBC before fourteen years, had experienced episodes of respiratory discomfort before two years in daily life and moreover easy fatigability and dyspnea to and from hospital before eight months. The patient, 81-year-old male had the underlying diseases poorly differentiated gastric adenocarcinoma status post wedge resection with recent recurrence at anastomosis. One 4.3 cm laminated gallstone had been documented on abdominal computed tomographic (CT) 5 months ago. This time, he presented to the Emergency Department with intermittent vomiting for 4 days and periumbilical pain for 1 day. Physical examination revealed soft but distended abdomen with periumbilical tenderness. The bowel sounds were decreased on abdominal auscultation. Lab testing revealed an elevated white blood cell count (19800/µL) and an elevated C-reactive protein (1.66 mg/dL). The abdominal CT revealed wall thickening of gallbladder with internal air density, and a gallstone impaction in the small bowel with proximal bowel loop dilation. Upper gastrointestinal endoscopy showed a small hole at duodenal bulb, suspected fistula formation. Under the impression of choledochoduodenal fistula related gallstone ileus, the patient underwent open enterolithotomy. A huge gallstone, locating at proximal jejunum was retrieved by enterolithotomy. He had an uneventful recovery thereafter.

Abstract Submission No. 101440
P-0786

WAUGH’S SYNDROME: CASE OF ADULT COLO-COLONIC INTUSSUSCEPTION WITH MALROTATION IN A 61-YEAR-OLD MALE

Alexis Danica Drilon1, Vicente II Porciuncula1, 2, 3
1St. Luke’s Medical Center - Quezon City Quezon City Philippines, 2Providence Hospital, Inc. Quezon City Philippines, 3Nueva Ecija Medical Center Nueva Ecija Philippines

Significance: The coexistence of gut malrotation and acute-onset intussusception is termed as Waugh syndrome. It is extremely rare in adults as most commonly presents in infants. We discuss the case of a male patient born with deformities of the extremities, diagnosed with malrotation with colo-colonic intussusception at a late age, and an ascending colon mass as a lead point.

Clinical Presentation: This is the case of a 61-year-old male coming in due to a 1-week history of loose stools, cramping abdominal pain, and gradual abdominal enlargement which eventually led to difficulty passing of stool. Additional physical examination revealed...
macrodontia, long extremities with oligodactyly of the fingers and polydactyly of the foot suspicious for a syndromic presentation.

Management: Abdominal CT scan revealed a long segment intussusception from the level of the ano-rectal area, which also involved the sigmoid colon segment, left colon and parts of the transverse colonic segments. The rest of the evaluable colon was air distented. Hence, a total colectomy, reduction of colo-colonic intussusception, and ileostomy was done. Histopathology revealed a Mucoïdes adenocarcinoma of the transverse colon as the lead point.

Recommendation: The diagnosis of intussusception with malrotation requires a high index of suspicion. As malrotation itself can predispose to intussusception, an additional presence of intraluminal pathology would increase its risk. This necessitates appropriate surgical intervention because of the high incidence of underlying bowel malignancy. A good quality contrast-enhanced CT scan of abdomen can help to diagnose both these conditions and surgery remains the treatment of choice for managing these two conditions.

Abstract Submission No. 101531

P-0790

Primary biliary cholangitis masquerading as secondary hemochromatosis in a middle-aged male

MANISH KUMAR1, SIMI TAHILIANI2, KISHORE S3

1ABVIMS & Dr RML Hospital, New Delhi New Delhi India, 2ABVIMS &Dr RML Hospital New Delhi India, 3ABVIMS &Dr RML Hospital New Delhi India

Background: Primary biliary cholangitis (PBC) is characterised by biliary epithelial injury, causing apoptosis and ductopenia. Earlier thought to be exclusively a disease of middle-aged women, with a gender skew of 10:1; current data shows that it is not as uncommon in male (4:6:1).

Methods: We report a 63 years old Indian male smoker presenting with itching and darkening of skin for 3 years and yellow discolouration of eyes for 1 year. General examination revealed icterus, pruritic nodules over bilateral arms, thighs and back with darkening and lichenification. Systemic examination unremarkable. LFT revealed icterus, pruritus and jaundice. Hepatitis B, C serologies were negative. IgG > 1.1X upper limit. ANA (immunofluorescence) negative. Autoimmune hepatitis serology negative; AMA positive. Liver biopsy showed medium sized bile duct injury with periportal fibrosis, CK7 staining demonstrated loss of bile ducts; Nakamura stage 2. MRCP showed normal extrahepatic biliary tree.

Result: Based on raised Alkaline phosphatase, AMA positivity and liver biopsy, PBC was diagnosed and managed with UDCA. As pruritus did not improve, a trial of obeticholic acid and rifampicin was given, with good response.

Conclusion: Diagnosis of PBC should be considered in both sexes presenting with abnormal LFT, pruritus or fatigue in the susceptible age group. Early detection of PBC slows its progression to chronic liver disease.

Abstract Submission No. 101532

P-0790

A rare gastric tumor: mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)

Yu-Han Lu1, Guo-Wei Huang2, Hong-Jie Lan2, Chia-Sheng Chu2,3

1Department of Nursing, China Medical University Hospital Taichung City Taiwan, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei City Hospital Yang Ming Branch Taipei City Taiwan, 3Ph. D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan

Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) is a rare neoplasm representing about the third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN is composed of a neuroendocrine component, usually a PDNEC; and a non-neuroendocrine component, generally adenocarcinoma. Due to the lack of evidence, MiNENs are commonly treated according to the standard treatment for neuroendocrine carcinoma or adenocarcinoma from the same sites of origin. The prognosis is generally intermediate between the pure neuroendocrine and non-neuroendocrine carcinoma.

Here, we report accidently found gastric MiNEN. Since there are no specific symptoms or definite risk factors of MiNEN, the diagnosis of MiNEN is usually accidental and late. MiNEN is still a wicked tumor that warranted more studies and attentions.

Abstract Submission No. 101583

P-0791

Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma

TUNG-YEN LIN1, Tung-Hung Su1,2

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei City Taiwan, 3Ph. D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan

A rare gastric tumor: mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)

Yu-Han Lu1, Guo-Wei Huang2, Hong-Jie Lan2, Chia-Sheng Chu2,3

1Department of Nursing, China Medical University Hospital Taichung City Taiwan, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei City Hospital Yang Ming Branch Taipei City Taiwan, 3Ph. D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan

Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) is a rare neoplasm representing about the third of all poorly differentiated neuroendocrine carcinomas (PDNEC). MiNEN is composed of a neuroendocrine component, usually a PDNEC; and a non-neuroendocrine component, generally adenocarcinoma. Due to the lack of evidence, MiNENs are commonly treated according to the standard treatment for neuroendocrine carcinoma or adenocarcinoma from the same sites of origin. The prognosis is generally intermediate between the pure neuroendocrine and non-neuroendocrine carcinoma.

Here, we report accidently found gastric MiNEN. Since there are no specific symptoms or definite risk factors of MiNEN, the diagnosis of MiNEN is usually accidental and late. MiNEN is still a wicked tumor that warranted more studies and attentions.

Abstract Submission No. 101583

P-0791

Progression of portal hypertension after atezolizumab plus bevacizumab for hepatocellular carcinoma

TUNG-YEN LIN1, Tung-Hung Su1,2

1Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Taipei Taiwan, 2Hepatitis Research Center, National Taiwan University Hospital Taipei City Taiwan, 3Ph. D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan

Background: Immune checkpoint inhibitor becomes the first-line therapy for advanced hepatocellular carcinoma (HCC). Gastroesophageal varices should be monitored and managed due to the endothelial effect of bevacizumab. However, whether the progression of varices and portal hypertension during therapy is unclear.

Method: A case of portal hypertension progression (e.g., development of varices, ascites, and hepatic hydrothorax) during atezolizumab/bevacizumab therapy at National Taiwan University Hospital was reported, and the relevant literature from Pubmed were reviewed.

Results: We presented an 83-year-old male with resolved hepatitis B without cirrhosis. He had an 18cm HCC at BCLC stage C and received tri-weekly atezolizumab 1200mg/bevacizumab 500mg therapy for 34 cycles with sustained partial response. However, progressive ascites,
esophageal varices and left hepatic hydrothorax developed afterwards, even though his portal vein was patent and the tumor was under control. After the literature review, we found 3 case reports and one case series with 5 cases of HCC (BCLC B/C: n = 3/2). Among them, three had cirrhosis and all had small esophageal varices before treatment. One had a portal vein invasion. After 1–15 cycles of atezolizumab/bevacizumab therapy, progression of varices was found in 1 patient, and the other 4 patients developed variceal bleeding. None of these patients received beta blocker prophylaxis. The association between atezolizumab/bevacizumab and portal hypertension was possible and multifactorial, which might involve VEGF pathway and immune-related adverse events with hepatic fibrosis.

**Conclusion:** Atezolizumab/bevacizumab treatment might be associated with exacerbation of portal hypertension. Monitoring signs and prophylaxis management of portal hypertension should be considered during treatment.

Abstract Submission No. 101595
**P-0792**

**Case of PVT diagnosed and treated conservatively for hepatic mass with hepaticolitisis.**

Tomoya Takahashi1, Hitoshi Ohyama1, Miho Sakai1, Kazuki Watabe1, Syodai Toyama1, Yu Sekine1, Nana Yamada1, Chihie Sugihara1, Mayu Ouchi1, Motoyasu Kan2, Hiroki Nagashima1, Koji Takahashi2, Koichiro Okitsu2, Izumi Ohno2, Naoya Kato1

1Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan, 2) Department of Medical Oncology, Graduate School of Medicine, Chiba University Chiba Japan

We describe a case in which a postoperative patient with invasive intraductal papillary mucinous carcinoma (IPMC) developed a hepatic mass, which was diagnosed as portal vein thrombosis (PVT) and successfully treated conservatively by a combination of contrast-enhanced CT (cCT) and EOB-MRI. The patient was a 72-year-old man who had undergone pylorus preserving pancreatoduodenectomy for IPMC. He developed intrahepatic stone due to anastomotic stenosis and was treated endoscopically. He presented to one’s previous doctor with nausea and anorexia as his main complaints and intrahepatic stones were found on CT. He was referred to our department and admitted for treatment of intrahepatic stones. cCT showed a 40 mm-sized hypodense mass in S8 of the liver, which initially suggested the possibility of a neoplastic lesion, and we decided to perform a thorough examination of this lesion and treatment of intrahepatic stones. On admission, cCT was performed again and revealed a mass in S8 of the liver, which was thought to be an ischemic change in the liver secondary to obstruction of P8. Three months later, when the patient was hospitalized for stone removal, cCT was performed, confirming that the lesion had decreased in size and the thrombus had also improved. Intrahepatic stones were also removed. This patient had a hepatic mass after IPMC surgery, and we had difficulty differentiating it from a metastatic liver tumor. When a hepatic mass is found in a patient with intrahepatic stones, it is important to differentiate secondary changes due to PVT and to perform imaging diagnosis.

Abstract Submission No. 101597
**P-0793**

**A case of acute liver failure due to AIH complicated by APS type 3**

Naoto Abe1, Kazumichi Abe1, Tatsuro Sugaya1, Yosuke Takahata1, Masashi Fujita1, Manabu Hayashi1, Atsushi Takahashi1, Hiromasa Ohira1

1Fukushima Medical University Department of Gastroenterology Fukushima Japan

A 55-year-old woman, who had been diagnosed with type 1 diabetes mellitus, chronic thyroiditis, was transferred to our hospital because of severe acute hepatitis of unknown etiology. Blood tests revealed hepatic dysfunction with aminotransferase 503 U/L, total bilirubin 11.42 mg/dL, and abdominal ultrasound showed ascites and liver atrophy. She showed hypergamma globulinemia, positive antinuclear antibodies, and was diagnosed with autoimmune hepatitis (AIH) with a score of 19 on the International Autoimmune Hepatitis Group diagnostic criteria. Methylprednisolone 500 mg/day was administered for 3 days, and prednisolone 45 mg/day was started thereafter. On the 9th day, hepatic encephalopathy appeared, which led to the diagnosis of subacute type acute liver failure. Her consciousness and liver function gradually improved with medical treatment such as lactulose enema and defecation control, and she was discharged from the hospital on the 64th day. She was finally diagnosed with autoimmune polyglandular syndrome (APS) type 3, complicated with three different autoimmune diseases. APS is defined as multiple endocrine gland disorders. In the present case, the patient had acute liver failure due to acute-onset AIH. Since patients with type 3 APS may present many manifestations over a long period of time, they should be carefully monitored.

Abstract Submission No. 101599
**P-0794**

**Just Jelly Or Jelly Belly?: A case report on Pseudomyxoma Peritonei**

Jan Axel Yusi1, Ma. Cristina Africa1

1St. Luke's Medical Center Quezon City Quezon City Philippines

Pseudomyxoma peritonei is a rare disease characterized by intra-abdominal gelatinous ascites, commonly caused by a mucinous appendiceal neoplasm. Ten-year survival rate varies from 40-60% after CRS/HIPEC. This report can help highlight the features of this disease for early identification and treatment initiation as it can drastically affect patient’s survival. This is a 54 year old male, presenting with 7-months progressive abdominal enlargement accompanied by weight loss. Contrast abdominal CT scan showed: Massive ascites with scalloping of the hepatic, splenic, and pancreatic margins as well as nodular densities in the omentum and mesentery. The intestinal tract is unremarkable including the cecal/appendiceal area. Ascitic fluid analysis revealed: brownish mucoid fluid. Rare histiocytes with no malignant cells were seen on the cecal/appendiceal area. Ascitic fluid analysis revealed: brownish mucoid fluid. Rare histiocytes with no malignant cells were seen on the cecal/appendiceal area. The resected terminal ileum to upper rectum, peritoneum and omentum were sent for histopathology. The patient had a sudden cardiac arrest at the end of the surgery leading to his demise despite ACLS. The histopathology revealed: a mucinous adenocarcinoma, moderately-differentiated, diffusely invading the appendix and cecum with intraperitoneal metastasis involving ileum, all colonic segments, rectum, omentum, and perisplenic tissues. In patients found to have the following: mucoid ascites with histiocytes on cell block; scalloping on imaging, elevated CEA and CA 19-9 a diagnosis of Pseudomyxoma Peritonei can be strongly considered despite an unremarkable imaging of the appendix/cecum area
A case of hepatocellular carcinoma cured by drug therapy, microwave ablation, and c-TACE

Hiroshi Tobita1, Tomotaka Yazaki1, Masatoshi Kataoka1, Masaaki Masuhara2

1Department of Hepatology Shimane University Hospital Izumo Japan, 2Ohda City Hospital Ohda Japan

The case was an 84-year-old woman with liver cirrhosis due to HCV infection. She had a history of HBV infection and type 2 diabetes. Hepatocellular carcinoma first developed in 2013, and RFA and c-TACE were performed on the left lateral segment and S7 of the liver, respectively. She was cured of hepatitis C in 2014, but recurrence of hepatocellular carcinoma was observed in 2015 and 2018, and she underwent c-TACE and left hepatic lobectomy, respectively. When intermediate-stage hepatocellular carcinoma in which ABC-Conversion (Atezolizumab plus Bevacizumab Curative Conversion) was performed. In the IMbrave150 study, the response rate for intermediate-stage hepatocellular carcinoma recurred in 2020, she was treated with lenvatinib, but treatment was discontinued due to fatigue and loss of appetite. Subsequently, treatment with atezolizumab plus bevacizumab was performed 15 times, which resulted in a marked reduction of the lesion and normalization of PIVKA-II. In 2022, microwave ablation therapy was performed on the residual disease in S6 of the liver, but PIVKA-II rose again and a recurrent lesion was found so c-TACE was performed. We experienced a case of intermediate-stage hepatocellular carcinoma in which ABC-Conversion (Atezolizumab plus Bevacizumab Curative Conversion) was performed. In the IMbrave150 study, the response rate for intermediate-stage hepatocellular carcinoma in the atezolizumab plus bevacizumab group was 44%, indicating that the treatment has a strong tumor shrinkage effect, and it is necessary to perform treatment while timing conversion.

Hepatitis B virus infection and the risk of developing gastrointestinal cancer - case report

Elena G Toader1, 2, 3, Diana Dumitrescu1, 3, Corina Turcu1, Andreea Iacob1, 2, 3

1Gr.T.Popa University of Medicine and Pharmacy, Iasi, Romania Iasi Romania, 2Institute of Gastroenterology and Hepatology, Iasi, Romania Iasi Romania, 3“St. Spiridon” Emergency County Hospital, Iasi, Romania Iasi Romania

Hepatitis B virus (HBV), although considered a hepatotropic virus, can also exist in extrahepatic organs, playing a role in the development of gastrointestinal neoplasms through a mechanism similar to that involved in hepatocellular carcinoma (HCC) carcinogenesis. We present two cases associating chronic hepatitis B (CHB) with gastric cancer (GC) and colorectal cancer (CRC). Case 1: male, 65-year-old with family history of CHB and personal history of colon cancer operated and CHB under nucleoside analogue (NAs) treatment for the past 9 years. Clinically, he presented skin pallor, abdominal pain and intestinal transit disorders. Laboratory tests showed anemia and hematocrit. Imaging evaluation excluded HCC but identified changes suggestive of colon neoplasia, confirmed as adenocarcinoma on biopsies obtained during colonoscopy. Case 2: male, 73-year-old, diagnosed with CHB under NAs for 2 years, reported epigastric pain, vomiting, and weight loss persisting for 4 months. Laboratory tests indicated anemia. Endoscopic examination revealed malignant gastric alterations, T3N0Mx stage by CT scan. HCC was excluded by imaging. In both cases, the virological status indicates undetectable HBV DNA, Ag HBs positive, HBe negative. In conclusion, evidence regarding the mutagenic activity of HBV, demonstrated as an important factor in malignancy development, and the presence of HBV in the gastric and colonic mucosa, may support the risk of developing GC and CRC associated with HBV infection. This risk is highlighted even in patients with occult HBV infections and those receiving NAs. Regular screening for digestive cancers can be considered for these patient categories to prevent their development.

An autopsy case of hepatic EBV positive DLBCL

Hiroyuki Aoyagi1, Satomi Kishi1, Katsunori Kouyoun1, Takafuni Nakagawa1, Kouhei Yasu1, Hirokazu Hira1, Yoshihide Naito1, Keneki Hasatani1, Hajime Sunagozaka1, Yasuharu Kaizaki2

1The Department of Gastroenterology Fukui Prefectural Hospital Fukui Japan, 2The Department of Pathology Fukui Prefectural Hospital Fukui Japan

Introduction: Primary liver malignant lymphoma accounts for 0.41% of extranodal lymphoma, it is a rare disease that accounts for 0.07% of hepatic malignant tumors. Primary hepatic Epstein-Barr virus (EBV)
positive diffuse large B-cell lymphoma (DLBCL) is quite rare as primary liver malignant lymphoma.

Case: A 67 years old man was referred to our hospital for general malaise, and abdominal fullness. Computed tomography (CT) revealed multiple tumors in the liver and poor contrast effect with staining spreading from the margins to the center, and enlarged lymph nodes were observed around the aorta. We made the diagnosis of multiple metastatic liver tumor or cholangiocarcinoma. Blood examination showed that tumor marker was elevated only CEA. No abnormal finding was detected in the endoscopic examination of his stomach and large intestines. Aspects increased within a few days, and the patient and his family strongly desired treatment, so treatment for cholangiocarcinoma was started with UFT granules, but his general condition further deteriorated rapidly. The patient died 10 days after the decrease in oxygenation, and autopsy was performed.

Discussion: At autopsy, morphological change in the liver tumors were observed. Therefore, primary liver malignant lymphoma was suspected. His s-IL2R was measured in the remaining blood, it was found to be as high as 10,700U/ml. We finally diagnosed EBV positive DLBCL by immuno-histological examination.

Conclusion: In the case of liver tumors for which it is difficult to make a definitive diagnosis, diagnosis should be made by measuring s-IL2R or performing liver biopsy before treatment with malignant lymphoma in mind.

Abstract Submission No. 101725
P-0799

A case of rhabdomyolysis and acute renal failure due to atezolizumab plus bevacizumab therapy

Noriyuki Nakajima1, Yutaka Yata1,2, Yuma Inoue1, Sayuri Takada1, Hirota Ishizu1, Tsuneyuki Tanaka1, Yasuki Nakagawa1, Hayato Miyamoto1, Koichi Ikeo1, Junichi Miyazaki1
1Department of Gastroenterology, Hanwa memorial hospital Osaka Japan, 2Department of Hepatology, Osaka metropolitan university Osaka Japan

Combined immunotherapy for advanced hepatocellular carcinoma (HCC) has been widely implemented and effective. We experienced a case in which rhabdomyolysis due to atezolizumab plus bevacizumab therapy (Atez/Bev) and the patient died of acute renal failure. A man in his 50s. He developed HCC due to alcoholic cirrhosis. Before Atez/Bev, he had been treated with radiofrequency ablation (RFA), transcatheter chemoembolization (TACE) + RFA and Lenvatinib. Atez/Bev had started for multiple HCCs 4 years after initial diagnosis. Background liver function at the time of introduction was Child-Pugh grade B. A total of 11 courses of Atez/Bev were administered, and the tumor size and numbers decreased (PR on images) and tumor markers also decreased, evaluating effective. On the 7th day after completing the 11th course, the patient developed lower back pain and visited the emergency department. Influenza A infection and abnormally high levels of creatine phosphokinase (CPK) 65401 IU/L were observed, and severe rhabdomyolysis was diagnosed. Although the CPK decreased after hospitalization and treatment, the patient progressed to acute renal failure. Despite undergoing artificial dialysis, his general condition deteriorated, and also revealed infective endocarditis. The patient passed away 21 days after the onset of rhabdomyolysis. In the case of the 10th course as an outpatient without any problems except for poor background liver function, but after the 11th course, the disease rapidly worsened with the sudden onset of Influenza A infection and rhabdomyolysis. Atez/Bev for patients with poor liver function requires careful judgment, including the indications.

Abstract Submission No. 101749
P-0801

A bleeding perianal mass - varix or haemorroid

Hui Chuen Han1, Kim Wei Lim1
1MOHH Singapore Singapore

Despite the high prevalence of rectal varices, bleeding rates remain low and hence optimal treatment remains to be determined. In this report, we present a case of a middle aged man with an initial diagnostic dilemma of a bleeding varix versus haemorrhoid after presenting with hematochezia. He has a significant background of Child-Pugh B8 NASH cirrhosis complicated by gastro-oesophageal and rectal varices and untreated hepatocellular carcinoma (HCC).

Flexible sigmoidoscopy revealed external hemorrhoids and two columns of rectal varices. Towards the end of procedure, there was active spurting from the large mass protruding out of his rectum which was thought to be a haemorrhoid. Haemostasis was achieved with adrenaline packed gauze.

After discussion with the Colorectal surgeons, consensus was that the current degree of prolapse is unusual for a varix, however, it did not have typical features of haemorrhoids. MRI rectum suggested the bleeding perianal mass likely corresponded to varices. He eventually underwent successful percutaneous embolisation of varices. As he had an untreated HCC, he was not a candidate for transjugular intrahepatic
A 54-year-old renal transplant recipient was diagnosed persistent HEV-4 infection 15 weeks post-transplantation. She received a 12-week course of RBV (400mg daily for 4 weeks then 400mg twice daily for 8 weeks). Alanine aminotransferase (ALT) returned to normal after 4 weeks and HEV RNA became undetectable at the end of 8 weeks. Shortly after treatment completion, rebound viraemia occurred (Figure 1). She received a second course of RBV (800mg-1000mg daily). However, viraemia persisted and ALT rose to 124 U/L. After 8 months of RBV treatment, SOF/VPV 400/100mg daily was added for another 6 months. Although it had no effect on the viral load, ALT returned to normal (Figure 2). As hepatitis复发 after the treatment was stopped, we retreated her with the same regimen for indefinite period. Unexpectedly, viraemia was cleared at week 18 of treatment (Figure 3). After 18 months of treatment, the patient requested to cease treatment. Till now, SVR is still maintained 20 months off-treatment.

Conclusion: This is the first report of successful treatment of RBV-refractory HEV-4 infection by a prolonged course of SOF/VPV and RBV therapy in a renal transplant recipient.

Abstract Submission No. 101802
P-0804
Sympathy, intentional, acetaminophen overdose: a cautionary tale with a unique presentation

Sera Sato1, Linda Cummings1, Pierre M. Gholam1
1University Hospitals Cleveland Medical Center Cleveland United States

A 59-year-old female with a past medical history of polysubstance use disorder, major depression, gastric ulcer, and thoracic spinal stenosis, using daily naproxen, was admitted to the hospital after an overdose of acetaminophen 162,500mg. This event was in sympathy with her stepson’s own acetaminophen overdose which occurred on the same day. He had a history of poorly treated depression and schizophrenia. Both the patient and stepson were obtunded on presentation; therefore, they were intubated. Treatment included N-acetylcysteine, fomepizole, and hemodialysis. AST (U/L), ALT (U/L), INR and acetaminophen (ug/mL) peaked at 107/168/1.9/537 (her) and 249/1072/2.5/163.9 (him). Three days later, the patient had an episode of hematemesis with a hemoglobin drop concerning for upper gastrointestinal bleeding. Upper endoscopy showed large duodenal bulb ulcers with an adherent clot, and fistulization to the antrum, consistent with double pylorus. The area of the ulcer close to the greater curvature of the antrum was noted to be pulsatile in the face of active bleeding; therefore, the patient underwent gastroduodenal artery embolization. The patient was transferred to an inpatient psychiatry hospital upon discharge.

To our knowledge, this is the first reported case of sympathy, intentional, acetaminophen overdose complicated in one case by double pylorus and life-threatening NSAID-induced antral ulcer bleeding requiring GDA embolization. These cases highlight the psychosocial complexity associated with intentional drug overdose and the need to counsel households and family members at risk.

Abstract Submission No. 101806
P-0805
A case of imported infection with schistosomiasis japonica

Fumiya Suzuki1, Hiroaki Haga1, Keita Maki1, Tomohiro Katsumi1, Kyoko Hoshikawa1, Yoshiyuki Ueno1
1Department of Medicine and Geriatrics, Tuen Mun Hospital Tuen Mun Hong Kong

Hepatitis E virus (HEV) is known to cause chronic HEV infection in immunosuppressed patients. Though ribavirin (RBV) is the recommended treatment, non-responders is not uncommon. We report a genotype 4 HEV (HEV-4) infected patient who relapsed after RBV treatment, achieved sustained viral response (SVR) after retreatment with RBV and sofosbuvir/velpatasvir (SOF/VPV).

Abstract Submission No. 101779
P-0803
Successful treatment of genotype 4 chronic hepatitis E virus infection after ribavirin failure

Michael KK Li1, Tze Fai Cheng1, Tze Hoi Kwan1, Yiu Keung Ma1
1Department of Medicine and Geriatrics, Tuen Mun Hospital Tuen Mun Hong Kong

Successful treatment of genotype 4 chronic hepatitis E virus infection after ribavirin failure

Michael KK Li1, Tze Fai Cheng1, Tze Hoi Kwan1, Yiu Keung Ma1
1Department of Medicine and Geriatrics, Tuen Mun Hospital Tuen Mun Hong Kong

Hepatitis E virus (HEV) is known to cause chronic HEV infection in immunosuppressed patients. Though ribavirin (RBV) is the recommended treatment, non-responders is not uncommon. We report a genotype 4 HEV (HEV-4) infected patient who relapsed after RBV treatment, achieved sustained viral response (SVR) after retreatment with RBV and sofosbuvir/velpatasvir (SOF/VPV).

Abstract Submission No. 101779
P-0803
Successful treatment of genotype 4 chronic hepatitis E virus infection after ribavirin failure

Michael KK Li1, Tze Fai Cheng1, Tze Hoi Kwan1, Yiu Keung Ma1
1Department of Medicine and Geriatrics, Tuen Mun Hospital Tuen Mun Hong Kong

Hepatitis E virus (HEV) is known to cause chronic HEV infection in immunosuppressed patients. Though ribavirin (RBV) is the recommended treatment, non-responders is not uncommon. We report a genotype 4 HEV (HEV-4) infected patient who relapsed after RBV treatment, achieved sustained viral response (SVR) after retreatment with RBV and sofosbuvir/velpatasvir (SOF/VPV).
An uncommon cause of ascites: POEMS syndrome

Runjie Wei1, 2, Wei Zhang1, 2, Xiaoming Wang1, 2, Xinyan Zhao1, 2

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 2National Clinical Research Center for Digestive Diseases Beijing China

Introduction: Ascites can be a manifestation of many diseases and cirrhosis is the most common cause. Here we reported an uncommon cause of ascites: POEMS syndrome.

Case report: A 52-year-old man was referred to our department complaint of ascites and edema for 4 months. The SAAG of 12g/L was suggestive of portal hypertension. Abdominal CT showed splenomegaly and multiple enlarged abdominal lymph nodes. PET-CT scan was performed to determine the FDG uptake of lymph nodes, and a needle biopsy of the axillary lymph node was performed. During hospitalization, he complained about toes numbness and limbs weakness one day. Meanwhile, we observed some overlooked skin changes: clubbing fingers, white nails, and scattered hemangioma on his trunk. POEMS syndrome was suspected. As expected, electromyography showed peripheral nerve damage. Immunofixation electrophoresis demonstrated positivity of monoclonal IgA/λ lambda; light chain. Then lymph node biopsy reported Castleman disease. His VEGF level was 741 (range: 0-142) pg/ml. He also had papilledema, hypothyroidism, and pulmonary arterial hypertension. Finally, A POEMS syndrome was diagnosed since all the mandatory criteria were present (polyneuropathy, IgA/λ lambda; monoclonal component), together with two major criteria (elevated VEGF, Castleman disease) and five minor criteria (splenomegaly, extravascular fluid overload, skin changes, papilledema, endocrinopathy). Then the patient was treated with lenalidomide and dexamethasone. The VEGF level decreased to 133.27 pg/ml after the first course of therapy. The ascites and edema disappeared during the follow-up of 0.5 year.

Conclusion: Uncommon causes of ascites need to be considered for hepatologist, when the common causes including liver cirrhosis were excluded.
rheumatologic immune-related adverse events (irAEs) in cancer patients with immune checkpoint inhibitors (ICIs). We report a case of PMR-like syndrome that occurred following the combination therapy of durvalumab and tremelimumab for advanced hepatocellular carcinoma (HCC).

**Case Report:** A 74-year-old male was diagnosed with HCC 4 years ago and had been treated with RFA and TACE, but multiple intrahepatic metastases were found. He started on the combination therapy of durvalumab and tremelimumab for HCC. 6 weeks later, he visited our department due to a myalgia. He had difficulty in raising right upper extremity and proximal muscle weakness. Blood tests showed signs of inflammation, elevated CRP, erythrocyte sedimentation rate and matrix metalloproteinase-3 (MMP-3), while CPK was low. Neurological examination was no abnormal findings. We diagnosed PMR-like syndrome from irAEs with ICIs and initiated treatment with 15mg/day of oral steroid. His symptoms improved immediately after oral administration of steroids and he was discharged on the 10th day of hospitalization.

**Conclusion:** PMR-like syndrome from irAEs with the combination therapy of durvalumab and tremelimumab is rare, early recognition and treatment of PMR-like syndrome will be important in combination therapy for HCC.

**Abstract Submission No. 101919**

**P-0809**

A case of rapid deterioration of general condition after discontinuation of sequential treatment.

Shuntaro Obi,2, 1, Kentaro Takahashi1, Naoki Takamura1, Shinpei Sato1, Takahisa Sato1

1Department of Internal Medicine, Teikyo University Chiba Medical Center Chiba JAPAN, 2Department of Gastroenterology, Yamanashi Central Hospital Yamanashi JAPAN, 3Department of Gastroenterology and Hepatology, Kyounodo Hospital Sasaki Institute Tokyo JAPAN

**Background:** Treatment of advanced hepatocellular carcinoma has become more diverse with the addition of IO+IO. There is much discussion about the timing of switching from primary to secondary treatment and drug selection. We look back on the process of caring for an elderly patient with advanced hepatocellular carcinoma.

**Case:** 79-year-old male with type 2 diabetes mellitus and hypertension. Right costal pain since June 2022, weight loss of 3 kg/6 months. Initial visit to our hospital on 07/23/2022 revealed a 16 cm hyper vascular tumor centered in the right posterior lobe with invasion of hepatic vein and portal vein. Biopsy revealed a diagnosis of hepatocellular carcinoma. Atezolizumab + bevacizumab (ATZ+BEV) started 08/03/2022. After 4 courses with no adverse events on 11/10/2022, the patient was determined to be PD. On 11/24/2022, TACE performed, then after 3 courses of ATZ+BEV resumed. On 1/24/2023 PD determined again. Lenvatinib started, but discontinued on 03/10/2023 due to fatigue. Thereafter, he was treated symptomatically, and his HCC ruptured on 06/21/2023 and he died on 06/22/2023.

**Discussion:** A multicenter study was conducted on post-treatment of ATZ+BEV therapy, including our institution. Post-treatment was possible in 59% of the cases. Patients who were able to receive post-treatment were those with preserved liver function and PS.

**Conclusion:** Reflecting on the course of treatment for elderly patients with advanced HCC, we reaffirmed the importance of maintaining liver function and PS.

**Abstract Submission No. 101927**

**P-0811**

Cirrhotomimetic Hepatocellular Carcinoma - a mimic of sclerosing cholangitis

Wen Shern Lo1, Choon Hua Thng2, Miao Shan Lim1

1Department of Gastroenterology and Hepatology, Singapore General Hospital Singapore Singapore, 2Department of radiology, Singapore General Hospital Singapore Singapore

A 61-year-old Chinese man with Child-Pugh A5 liver cirrhosis secondary to chronic Hepatitis B was admitted for abdominal pain and scleral icterus. He was lost to followup for the past three years. On examination, he was jaundiced and cachectic. There was no ascites clinically. His liver function test showed raised total bilirubin (162 µmol/L) and transaminases. Magnetic Resonance Cholangiopancreatography (MRCP) revealed multiple areas of stenosis and dilatation of the biliary tree. This “beaded appearance” raised the suspicion for sclerosing cholangitis. The main portal vein (PV) and its branches was expanded and showed high T2 signal, raising the possibility of a thrombus. Given his cachexia and raised serum alpha-fetoprotein (10.1 ng/dl, normal was <7.1ng/dl), there were suspicions of malignancy even though...
hepatocellular carcinoma (HCC) was not reported on MRCP. He underwent ultrasound-guided fine needle aspiration cytology of the PV thrombus which showed HCC. He was diagnosed with diffuse/cirrhotomimetic HCC with tumour thrombus in PV. Diffuse/cirrhotomimetic HCC is a rare diagnosis and diagnosis is often challenging. It is frequently associated with PV tumour thrombus. While chronic PV thrombus may cause portal bilopathy changes (ie strictures in the biliary tree due to extrinsic compression of the bile ducts by cavernous collaterals), this is distinct from the true beaded biliary tree appearance classical of sclerosing cholangitis. The difficulty detecting diffuse/cirrhotomimetic HCC in a cirrhotic liver as well as imaging findings classical of sclerosing cholangitis resulted in delayed diagnosis. Greater awareness on diffuse/cirrhotomimetic HCC is needed so that prompt diagnosis and appropriate treatment can be achieved.

Abstract Submission No. 101963
P-0812

The elusive diagnosis of myelofibrosis presenting as noncirrhotic portal hypertension: a case report
Ryan Neo Yee Shien1,2, Sheru Sanbhnnani1,2, Miao Shan Lim2
1MOH Holdings Pte Ltd Singapore Singapore, 2Singapore General Hospital Singapore Singapore
Prehepatic causes of noncirrhotic portal hypertension (NCPH) are an infrequently encountered but important category of disorders to consider in patients presenting with esophageal variceal bleeding without objective evidence of liver synthetic dysfunction or cirrhosis. One key prehepatic cause to evaluate for is extrahepatic portal vein obstruction (EHPVO), which is commonly secondary to portal vein thrombosis (PVT). Once PVT is diagnosed, further evaluation should then be undertaken to identify underlying etiological factors. We present a rare case of a 37-year-old female with no past medical history who presented with esophageal variceal bleeding, and was found to have underlying NCPH secondary to chronic PVT, but with no apparent etiological factors identified for her PVT such as Protein S deficiency. She was not on any anticoagulation. In view of persistent remnant varices and progressively increasing splenomegaly, she subsequently underwent a splenectomy and splenorenal shunt. However, after the operation, a sharp rise in total white blood cell count from 9x10^9/L to 23x10^9/L was noted. Subsequently, JAK2 mutation studies were positive, and histology of the spleen was consistent with a myeloproliferative neoplasm (MPN), likely myelofibrosis (MF). Postoperatively, the patient developed mesenteric venous thrombosis complicated by small bowel ischemia with perforation and abscess formation, and underwent an open small bowel resection with terminal ileostomy and defunctioning cecostomy. She later developed short bowel syndrome. This case report highlights the importance of considering rare and sometimes elusive etiologies of NCPH such as MF, when a patient develops NCPH.

Abstract Submission No. 102021
P-0814

Gastric bronchogenic cyst mimicking pancreatic mucinous cyst
Osman F rat Duran1, Hale Gokcan2, Emin Bodakci2, Tugce Guvener2, Volkan Yilmaz2, Seda Yamak3, Sabite Kacar4, Erdal Birol Bostanci5, Meral Akdogan Kayhan6
1Ankara University Faculty of Medicine, Department of Internal Medicine Ankara Turkey, 2Ankara University Faculty of Medicine, Department of Gastroenterology Ankara Turkey, 3Ankara City Hospital, Medical Pathology Clinic Ankara Turkey, 4Ankara City Hospital, Health Sciences University, Department of Gastroenterology Ankara Turkey, 5Ankara City Hospital, Health Sciences University, Gastroenterology Surgery Department Ankara Turkey

Purpose: Bronchogenic cysts, benign congenital lesions resulting from abnormal foregut budding, are typically found in the posterior mediastinum but can occasionally be associated with cervical, thoracic, and abdominal structures. We present a case initially diagnosed as a pancreatic mucinous cyst on imaging but confirmed as a bronchogenic cyst after surgical resection.

Method: Retrospective, case-based case report

Results: A 59-year-old female presented to the gastroenterology clinic with abdominal pain. She had a normal physical exam, no systemic diseases, and used no regular medications. Laboratory results, including hemogram and biochemistry, were normal. An abdominal ultrasound revealed a pancreatic lesion, leading to dynamic pancreatic MRI, which identified a 47x44 mm cystic lesion in the pancreas tail and a 40x20 mm cyst nearby. Endoscopic ultrasonography, a dense echo measuring 37.5x30.1 mm was observed in the pancreatic tail localization, positioned in front of the spleen. Additionally, a cystic lesion with anechoic, homogeneous characteristics and a diameter of approximately 38x35 mm was noted in the distal part. Fine needle aspiration showed elevated CEA (30.6 ng/ml), CA19-9 (>700 U/ml), and amylase (766 U/L). Suspected mucinous cystic neoplasia led to cyst excision, but during the operation, cysts were found in the gastric mesentery, unrelated to the pancreas. The final pathology reported gastric bronchogenic cysts.

Abstract Submission No. 102021
P-0814

Gastric bronchogenic cyst mimicking pancreatic mucinous cyst
Osman F rat Duran1, Hale Gokcan2, Emin Bodakci2, Tugce Guvener2, Volkam Yilmaz2, Seda Yamak3, Sabite Kacar4, Erdal Birol Bostanci5, Meral Akdogan Kayhan6
1Ankara University Faculty of Medicine, Department of Internal Medicine Ankara Turkey, 2Ankara University Faculty of Medicine, Department of Gastroenterology Ankara Turkey, 3Ankara City Hospital, Medical Pathology Clinic Ankara Turkey, 4Ankara City Hospital, Health Sciences University, Department of Gastroenterology Ankara Turkey, 5Ankara City Hospital, Health Sciences University, Gastroenterology Surgery Department Ankara Turkey

Purpose: Bronchogenic cysts, benign congenital lesions resulting from abnormal foregut budding, are typically found in the posterior mediastinum but can occasionally be associated with cervical, thoracic, and abdominal structures. We present a case initially diagnosed as a pancreatic mucinous cyst on imaging but confirmed as a bronchogenic cyst after surgical resection.

Method: Retrospective, case-based case report

Results: A 59-year-old female presented to the gastroenterology clinic with abdominal pain. She had a normal physical exam, no systemic diseases, and used no regular medications. Laboratory results, including hemogram and biochemistry, were normal. An abdominal ultrasound revealed a pancreatic lesion, leading to dynamic pancreatic MRI, which identified a 47x44 mm cystic lesion in the pancreas tail and a 40x20 mm cyst nearby. Endoscopic ultrasonography, a dense echo measuring 37.5x30.1 mm was observed in the pancreatic tail localization, positioned in front of the spleen. Additionally, a cystic lesion with anechoic, homogeneous characteristics and a diameter of approximately 38x35 mm was noted in the distal part. Fine needle aspiration showed elevated CEA (30.6 ng/ml), CA19-9 (>700 U/ml), and amylase (766 U/L). Suspected mucinous cystic neoplasia led to cyst excision, but during the operation, cysts were found in the gastric mesentery, unrelated to the pancreas. The final pathology reported gastric bronchogenic cysts.
Conclusion: CT, MRI/MRCP, and EUS aid in differentiating pancreatic cysts, yet challenges may require surgical resection for diagnosis and treatment. Notably rare, as in our case, bronchogenic cysts can mimic mucinous cysts, underscoring the need for consideration in the differential diagnosis.

Abstract Submission No. 102057
P-0815
A case of hepatic Inflammatory pseudotumor with atypical image findings

Soo Ki Kim1, Soo Ryang kim1, Toyokazu Okuda2, Hisato Kobayashi1, Akira Asai1, Hiroki Nishikawa4
1Department of Gastroenterology, Kobe Asahi Hospital Kobe Japan,
2Department of Surgery, Kobe Asahi Hospital Kobe Japan,
3Department of Radiology, Kobe Asahi Hospital Kobe Japan,
4The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University Takatsuki Japan

A 70-year-old man with a history of HBV infection and slight liver dysfunction was admitted for further examination of a 3.8 cm tumor in segment 5: ultrasound (US) revealed a hypo-isodensity pattern and computed tomography (CT) revealed a low-isodensity density pattern (double-target-sign). While CE US revealed slight hypovascularity, early washout in the portal phase, and defect in the Kupffer phase, contrast-enhanced (CE) CT and ethoxybenzyl diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging (EOB MRI) revealed slight hypervascularity and slight hypointensity at the hepatobiliary phase. Echo planar imaging of MRI revealed remarkable hypointensity. The aforementioned imaging modalities raised suspicions of inflammatory pseudotumor (IPT), atypical hepatocellular carcinoma, cholangiocellular carcinoma, cholangiolocellular carcinoma, and metastatic liver cancer. US-guided biopsy, however, showed hepatic IPT, and histopathological analysis disclosed the proliferation of fibroblasts, lymphocytes, plasma cells, and macrophages with hemosiderin on a background of collagen fibers. Without receiving any kind of treatment, the tumor had shrunk from 3.8 to 2.6 cm three weeks after the diagnosis. IPT is generally defined as benign, non-malignant, non-metastasizing tumors featured by the presence of myofibroblastic spindle cells, heterogeneous populations of inflammatory cells, particularly plasma cells, lymphocytes and macrophages, as well as locations of fibrosis and necrosis without cellular anaplasia or atypical mitoses. Despite subsequent reports, hepatic IPT keeps difficult to diagnose, as it occasionally shows atypical image findings, compared with that of other various benign diseases and malignant hepatic tumors.

Abstract Submission No. 102065
P-0816
A case of unresectable HCC treated with durvalumab/tremelimumab followed by conversion surgery

Maho Egusa1, Issel Saeki1, Tsuyoshi Fujioka1, Natsuko Nishiyama1, Daiki Kawamoto2, Ryo Sasaki1, Tatsuro Nishimura1, Norikazu Tanabe1, Toshihiko Matsumoto1, Tsuyoshi Ishikawa1, Takahiro Yamasaki2, Taro Takami1
1Department of Gastroenterology & Hepatology, Yamaguchi University Graduate School of Medicine Yamaguchi Japan,
2Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine Yamaguchi Japan

Case Presentation: A 52-year-old man with chronic hepatitis C (post-SVR) who had not been followed after SVR. He was referred to our hospital due to multiple liver tumors. We diagnosed multiple huge HCCs occupying the right lobe and had slightly poor liver reserve function [ALBI score -1.47 (mALBI grade 2b)]. At the time of initial diagnosis, his general condition was poor due to cachexia (PS 2). We introduced durvalumab/tremelimumab (Durva/Treme) therapy. Two weeks after initiation, he developed skin eruption, and Durva/Treme could be continued. CT showed tumor necrosis (RECIST 1.1: PR) and the tumor shrank markedly, and tumor markers decreased (AFP:281900.0 to 14.1 ng/mL and PIVKA-II:34722.9 to 29.0 mAU/mL). After 4 treatment courses, hepatic reserve function improved to ALBI score -2.56. Durva/Treme showed a significant response, and his general condition improved with tumor shrinkage, therefore conversion surgery was performed. He had no recurrence in 2 months without post-operative chemotherapy. The resected specimen showed complete tumor necrosis and achieved TE4. A large number of lymphocytes infiltrated into the tumor and surrounding tissue, suggesting a favorable immune response. The patient’s general condition improved with the super-response of Durva/Treme, and conversion surgery was successfully performed. We believe this case is valuable for developing treatment strategies using Durva/Treme.

Abstract Submission No. 102070
P-0817
Acute Hepatitis due to Fenugreek

Vedat Goral1
1Istanbul Medipol University School of Medicine Istanbul Turkey

Fenugreek (Caksir) is a plant that belongs to the parsley family and has yellow flowers. It grows in Southeastern Anatolia, Eastern Anatolia and the Mediterranean region in our country. Gooseberry root; It is reported that it is used in the treatment of sexual problems such as impotence and infertility and increases sexual potency.

Case: A newly married patient (Male, 27 years old) came to us with nausea, vomiting, and darkening of the urine color after using chalk herb upon the advice of his friends. In the examinations carried out; ALT was 442 IU/ml, AST was 338 IU/ml, and bilirubin levels were slightly high. The liver and spleen appeared normal on USG. Acute hepatitis was considered in the patient. HBV, HCV, HAV, Alcohol and other viral markers were negative. He told the patient that whenever he used anything else, he used seaweed. After cutting this herb, a skin eruption and transaminase improved. After that PSL was tapered off, and Durva/Treme could be continued. CT showed tumor necrosis without cellular anaplasia or atypical mitoses. Despite subsequent reports, hepatic IPT keeps difficult to diagnose, as it occasionally shows atypical image findings, compared with that of other various benign diseases and malignant hepatic tumors.

Abstract Submission No. 102071
P-0818
Eosinophilic Ascites

Vedat Goral1, Ameenah Alkandari2, Isik Ikbal Baris3
1Istanbul Medipol University School of Medicine Istanbul Turkey,
2Istanbul Medipol University Department of Pathology Istanbul Turkey,
3Beaumont Hospital. Department of Gastroenterology Kuwait Kuwait
Eosinophilic gastrointestinal diseases are a group of rare diseases that present with signs and symptoms due to eosinophil infiltration in gastrointestinal tissues. In this case, a case with intestinal involvement and characterized by eosinophilic acid is presented.

Case: A 28-year-old Chinese patient applied to us with complaints of abdominal pain, bloating and diarrhea. His diarrhea was watery and soft and did not contain blood. Ascites puncture was performed, SAAG was found to be 1.27 and no TB bacilli were detected. Mild eosinophilia was detected in the blood count. At the endoscopy, Hp negative gastritis was found, Peritoneal fluid, cytological examination and cell block: Benign inflammatory smear consisting of eosinophil leukocytes was detected. Eosinophil leukocytes were observed in numbers greater than 100 in 1 high-power field, There was no growth in ascitic fluid culture. Abdominal USG revealed long segment wall thickening in the small bowel loops and minimal pleural effusion, without detecting hepatosplenomegaly. In MRI enteroclysis, diffuse minimal wall thickness increase and minimally increased contrast material retention in the small bowel segments, minimal dilatation in some small bowel segments, and intraabdominal free fluid were reported. No pathology was detected in the stool examination. After excluding other more common conditions such as inflammatory bowel disease, malignancy, vasculitis, infectious enteritis, celiac disease, and angioedema, eosinophilic gastroenteritis and eosinophilic acid were considered in the differential diagnosis. Corticosteroid treatment was planned for the patient.

Conclusion: This case is rare because the stomach, duodenum, and colon are spared from eosinophilic involvement.

Abstract Submission No. 200002
P-0819

Successful Treatment of Diffuse Postoperative Recurrences of HCC with Atezolizumab plus Bevacizumab

Shutaro Sumiyoshi1, Toshiya Ochiai2, Tomohito Nakajima2, Yuki Adachi2, Akihiro Taniguchi2, Kenichi Takenoto2, Junichi Hamada2, Kei Naito2
1Kumihama Hospital Kyoto Japan, 2North Medical Center Kyoto Prefectural University of Medicine Kyoto Japan

Atezolizumab plus bevacizumab (Atezo + Bev) is the first immuno-therapy for hepatocellular carcinoma (HCC), and in the current guidelines, it is positioned as the first-line chemotherapy for unresectable cases. Herein, we report a case of postoperative multiple diffuse recurrence of HCC by a complete response to Atezo + Bev. Herein, we define diffuse recurrence as uncountable HCCs recur within 3 months after treatment.

A 72-year-old man previously underwent trans arterial chemo embolization (TACE) and received hepatatectomies twice for metachronous solitary recurrent pStage II HCC, respectively. Three months after last surgery, multiple intrahepatic recurrences and marked elevation of tumor markers were observed. The patient was diagnosed with diffuse recurrences of HCC and received combination immunochemotherapy with Atezo (1,200 mg/body) + Bev (15 mg/kg). After the fourth administration of Atezo + Bev, serum levels of tumor markers decreased to the normal range. Contrast CT scan showed prominently reduced tumor size. After the ninth administration, the CT scan showed the disappearance of all the liver lesions, indicating a complete response (CR). At 36 months postoperatively, CR was maintained and tumor markers were in the normal range.

We report a case of multiple postoperative diffuse recurrences of HCC treated with Atezo + Bev. In our experience, average of postrecurrent survival of diffuse recurrent HCC cases before 2012 were 4.25±1.24 months. Immunochemotherapy with Atezo + Bev may be one of the effective treatments for diffusely recurrent HCC with poor prognosis.

Abstract Submission No. 200059
P-0820

Wilson’s Disease Masquerading as Steatotic Liver Disease: A Case Report

Chia-Sheng Chu1,2, Chia-Wen Huang2
1Ph.D. Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University Taipei City Taiwan, 2Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei City Hospital Yang Ming Branch Taipei Taiwan

Wilson’s disease is a rare metabolic disorder characterized by copper accumulation. It caused by mutations of the ATP7B gene on chromosome 13. Ceruloplasmin is a protein synthesized in the liver and low plasma level of ceruloplasmin is an indication for Wilson’s disease. A 16-year-old female visited for abnormal liver function for one year. The elevated aspartate aminotransferase and alanine aminotransferase were found accidently in health check and she received examinations in regularly endocrinologist visiting this year. Abdominal sonography found severe fatty liver and the metabolic dysfunction-associated steatohepatitis (MASH) was diagnosed. However, the liver function got worsen with alanine aminotransferase up to 200U/L despite weight loss. So, she was transferred to hepatologist for further survey. She mentioned that she ate lots of mushrooms for weight reduction. Due to the high copper level in mushrooms, we took Wilson’s disease into our consideration and checked plasma ceruloplasmin which revealed very low level (2.5mg/dL) later. The liver biopsy was done, and the pathology findings were compatible with steatotic liver disease with copper accumulation in liver. Nevertheless, under the strong suspicion of Wilson’s disease, we did the immunohistochemical stain for metallothionein and the stains showed strong positive at all.

Here, we report a case of Wilson’s disease who was diagnosed and treated as MASH at first. The hepatic histology was also compatible with steatotic liver disease. In this case, it warranted the importance of immunohistochemical staining for metallothionein, in patients with highly suspected Wilson’s disease, no matter whether copper accumulation in liver or not.

Abstract Submission No. 200080
P-0821

Silent pylephlebitis, as manifestations of Klebsiella pneumoniae invasive syndrome, a case report

Tanya Apichatvullop1
1Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen Hospital Khon Kaen Thailand

Introduction: Although Klebsiella pneumoniae invasive syndrome was a common disease entity in Asia, presenting with hepatosplenic microabscess and pylephlebitis was unusual. We aim to report a case of notable presentation of this organism.

Case presentation: A 66 -year- old Thai male patient with recently diagnosis of type 2 diabetes mellitus came to the hospital with a high grade fever and productive cough without abdominal pain for 2 weeks. Physical examination revealed left lower lung fine crepitation accompanied with hepatomegaly. Chest x-ray showed interstitial left lower lobe infiltration. After the patient had been admitted for 9 hr, the blood culture was identified as Klebsiella pneumoniae. Then he was treated with empirical antibiotics with Ceftriaxone. Due to hepatomegaly and
abnormal liver function test (isolated elevated ALP), an abdominal ultrasonography and abdominal computed tomography (CT) were obtained and revealed acute thrombosis within the right, left, and main portal vein downward to superior mesenteric vein and diffuse hepatomegaly with hepatosplenic microabscess size 6-8 mm (likely to be a pseudolesion more than abscess). The patient's fever subsided within the first week of intravenous antibiotics without anticoagulant. Ceftriaxone was continued for 2 weeks and the patient was discharged with oral amoxicillin-clavulanic acid.

**Discussion and conclusion:** Pylephlebitis (septic thrombophlebitis of portal vein) can occur as a complication of *Klebsiella pneumoniae* bacteremia with unclear pathogenesis, presumably triggered by inflammation during infection. It is also a challenge in diagnosis due to its silent symptom and should be a concern in case of patients with hepatomegaly and abnormal liver function test.

---

**Gastrointestinal Tuberculosis Appearing as A Colon Mass: A Case Report**

Franz Jeryl T. Liangco¹, Nicole Allyson A. Chu¹, Gina Y. Tecson¹, Kenji M. Sato¹

¹Cardinal Santos Medical Center Quezon City Philippines

Gastrointestinal tuberculosis presents with non-specific symptoms along with multiple various lesions on endoscopy. GI TB may be mistaken for malignancy in endoscopy which may lead to delay in diagnosis which can result in increase in morbidity or mortality. This is a case of an asymptomatic 53 year-old Filipino male, no known comorbidities, with a strong family history of colon cancer who underwent screening colonoscopy which revealed an ulcerating, friable, granular mass at the ascending colon approximately 1-1.5cm in widest diameter. Magnified chromoendoscopy suggests non-neoplastic features. Multiple biopsies taken and showed negative TBgeneXpert as well as absence of acid-fast bacilli but showed chronic granulomatous inflammation with multinucleated Langhans type giant cells as well as acute-on-chronic colitis with mucosal erosion and architectural distortion; positive for crypt abscess. Patient was then started on empiric anti-tuberculosis treatment and advised repeat colonoscopy after 6 months treatment of anti-tuberculosis therapy. Gastrointestinal tuberculosis may present differently in various cases and it may also mimic malignancy. High clinical suspicion, especially in endemic countries, along with combination of endoscopic findings should guide as in considering GI TB as part of our differential diagnosis in patients with non-specific GI symptoms with endoscopic findings resembling malignancy as this would reduce morbidity and mortality.

**Abstract Submission No. 200084**

*P-0822*

**PFIC -3 MASQUERADING AS WILSON DISEASE - FALLACY OF LEIPZIG SCORE**

Samriddhi Poylekar¹, Ravi Shah², Aabha Nagrale³

¹Jagjivanram Hospital Mumbai India, ²Jaslok Hospital and Research Centre Mumbai India

**Introduction:** Progressive Familial Intrahepatic Cholestasis -3 is a rare autosomal recessive disorder characterized by mutation in the ABCB4 gene clinically manifesting as progressive or recurrent cholestasis.

**Case:** A 23 year old female, first presented at 6 years of age with jaundice and ascites and was diagnosed as Wilson disease(WD) based on Leipzig score of 4 (24 hours urinary copper excretion - 162mcg/dl; liver copper - 1692mcg/gm of dry weight and a positive penicillamine challenge test). She maintained stable liver function for few years on treatment with D-penicillamine and zinc however, since the age of 17 years gradual worsening of her liver functions was seen with development of ascites at the age of 22 years. Autoimmune and viral etiology was negative. On revisiting her diagnosis, she had persistently elevated gamma glutamyl transpeptidase levels with history of intermittent mild itching. Her modified Leipzig score was 2 at time of diagnosis (>4 diagnostic). Whole exome sequencing revealed mutation in the ABCB4 gene.

**Discussion:** Chronic cholestasis is known to increase the hepatic copper content and may even result in false positive diagnostic tests for WD. Our case validates the modified leipzig score (Nagral A et al; J Clin Exp Hepatol 9 (2019) 74–98) which has excluded hepatic copper - 1692mcg/gm of dry weight and a positive penicillamine challenge test. She maintained stable liver function for few years on treatment with D-penicillamine and zinc however, since the age of 17 years gradual worsening of her liver functions was seen with development of ascites at the age of 22 years. Autoimmune and viral etiology was negative. On revisiting her diagnosis, she had persistently elevated gamma glutamyl transpeptidase levels with history of intermittent mild itching. Her modified Leipzig score was 2 at time of diagnosis (>4 diagnostic). Whole exome sequencing revealed mutation in the ABCB4 gene.

**Conclusion:** PFIC-3 is a clinical mimic of WD. Diagnostic tests for WD should be cautiously interpreted in presence of cholestasis. Failure of improvement of liver function with effective chelation should prompt evaluation for alternative diagnosis.

**Abstract Submission No. 200159**

*P-0825*

**WINDOW TO PORTAL VEIN VIA LUNGS (ABERNATHY MALFORMATION) - A MULTIDISCIPLINARY TEAM MANAGEMENT**

Samriddhi Poylekar¹, Shailesh Sable², Aabha Nagrale³, Rohan Chaodhary³, Ketul Shah², Prashant Bobhate¹, Darius Mirza²

¹Jagjivanram Hospital Mumbai India, ²Apollo Hospital NaVi Mumbai India, ³Kokilaben Dhirubhai Ambani Hospital Mumbai India

**Introduction:** Abernathy malformation (AM) is characterized by an abnormal congenital porto-systemic communication with resultant diversion of the portal inflow to systemic veins leading to numerous clinical manifestations including pulmonary hypertension (PH). The mainstay of treatment of PH includes endovascular or surgical closure of the shunt.
Case: A 23 year old female presented with hemoptysis and mild dyspnea secondary to moderate PH. Her workup did not reveal any cardiac, pulmonary and rheumatological etiology for PH. MR angiography of abdomen revealed a large venous sac of diameter 2.5cm draining the splanchic circulation into left renal vein. A portomesenteric venogram with balloon occlusion test revealed hypoplastic right PV with portal venous pressure of 23 mm Hg after shunt occlusion. She underwent surgical ligation as shorter length of the shunt precluded endovascular intervention. Propanolol was started a month prior to surgery to prevent acute rise in portal pressure after shunt occlusion. Intraoperatively, temporary clamping of shunt resulted in rapid reversal of flow in the hypoplastic right PV without any evidence of bowel ischemia. 24 hours post ligation, there was further improvement in the portal inflow. Six months postoperatively there is no worsening of PH.

Discussion: A single stage surgical closure of the shunt can be done if the portal pressures are < 30mmHg on shunt occlusion and does not result in acute portal hypertension if the main PV is visible (McLin VA et al; JHEP Reports. 2023 Oct).

Conclusion: Hypoplastic branch PV does not preclude successful AM closure in appropriately selected cases.

Abstract Submission No. 200170
P-0826

Extrahepatic Portal Vein Obstruction in a Filipino Male with VACTERL: A case report

Heidi Cruz1, Celina Celeste H. Adraneda1

1Jose R. Reyes Memorial Medical Center Manila Philippines

Introduction: The incidence of both extra hepatic portal vein obstruction (EHPVO) and VACTERL spectrum has not been reported yet in the literature. This case report illustrated a rare case of VACTERL (vertebral anomalies, imperforate anus or anal atresia, cardiac anomalies, tracheoesophageal fistula, renal and limb defect) spectrum associated with extra hepatic portal vein obstruction. Authors investigated if there was any interrelation between extra hepatic portal vein obstruction and VACTERL spectrum.

Case Presentation: A 19-year-old Filipino male presented with no any symptoms and admitted for follow-up surgery of his Imperforate Anus. Incidentally, Whole Abdominal CT scan showed a dilated portal vein with several tortuous enhancing vessels at the region of porta hepatitis with multiple tortuous vessels at the splenic vein, parametral vein and at the perigastric and lower paraesophageal region.

Conclusion: The authors proposed that the EHPVO found in the patient was caused by another anatomical aberration of patients with VACTERL association, resulting in portal hypertension. Considering there have been no research on the correlation of VACTERL spectrum and EHPVO yet, and this may be the first case reported, it would be challenging to draw any conclusions but future studies of VACTERL spectrum patients are worth considering. Hence further data is needed to support this unusual association.

Abstract Submission No. 200210
P-0827

PFIC - 2 RECURRENCE POST LIVER TRANSPLANT - LEARNING FROM MISTAKES

Aabha Nagral1,2, Samridhhi Poyekar3, GIRISH GUPTA4, Abhijit Bagde2, Rahul Verma2, DARIUS MIRZA2

1Jaslok Hospital and Research Centre Mumbai India, 2APOLLO HOSPITAL NAVI MUMBAI INDIA, 3JAGJIVAN RAM HOSPITAL MUMBAI INDIA, 4Queen Elizabeth Hospital Birmingham United Kingdom

Introduction: Progressive Familial Intrahepatic Cholestasis -2 is characterised by mutation in the ABCB11 gene encoding the BSEP resulting in end stage liver disease for which Liver transplantation (LT) is considered curative. Discerning the etiology of recurrent cholestasis post LT can be challenging.

Case: A 6 six year old boy with genetically proven PFIC-2 underwent living donor LT for decompensated cirrhosis. A year after LT, he developed cholestasis due to biliary stricture requiring percutaneous biliary drainage followed by hepaticojejunostomy with relief of symptoms. Cholestasis recurred a year later due to presumed hepaticojejunostomy stricture and was managed with balloon stricturoplasty. However, due to persistent itching and low GGTP, liver biopsy was done which revealed features of PFIC, portal fibrosis and no evidence of rejection. An internal biliary diversion was performed for recurrent PFIC-2 which reduced the itching for few months following which it recurred. Estimation of Anti BSEP antibody in his serum revealed a titre of 1:3200. He was treated with rituximab but died due to decompensated liver disease.

Discussion: PFIC - 2 recurrence post LT occurs due to development of antibodies against BSEP presenting as low GGTP cholestasis. Diagnosis is by immunoflourescence of liver biopsy specimen or serum testing for Anti BSEP antibodies. Treatment options include plasmapheresis, high dose human immunoglobulin and rituximab. Re-transplantation is done for intractable pruritus and decompensated cirrhosis but results in recurrent PFIC-2.

Conclusion: Low GGTP cholestasis post LT should prompt workup for recurrent PFIC -2 after exclusion of rejection and managed with measures for antibody reduction.

Abstract Submission No. 200214
P-0828

Liver transplantation in atypical Hemolytic uremic syndrome (aHUS - Complement Factor H mutation

KIRAN SATHE1, Samridhhi Poyekar2, Shailesh Sable3, Abhijit Bagde2, Rahul Verma2, Rohan Choudhary1, Ketul Shah1, Kalpana Tate1, Darius Mirza2, Aabha Nagral1

1H.N RELIANCE HOSPITAL MUMBAI India, 2JAGJIVANRAM HOSPITAL MUMBAI INDIA, 3APOLLO HOSPITAL NAVI MUMBAI INDIA

Introduction: We describe successful short term outcome of LT in a child with aHUS with CFH mutation.

Case description: 4-year old girl born of 3rd degree consanguineous marriage presented with aHUS & acute kidney injury at 3.5 months age. Genetic testing revealed homozygous missense CFH mutation on exon 22. Anti factor H antibody and ADAMTS 13 levels were normal. In the acute phase she was managed with peritoneal dialysis followed by plasma infusion for next 2 years. She then received fortnightly eculizumab due to development of anaphylaxis to plasma. Her renal function, growth and development remained normal. She underwent a successful living donor LT with her paternal grandfather being donor who was genetically negative for the mutation. Four weeks post LT and her last Eculizumab, CBC, serum LDH and renal function remain normal. She underwent a successful living donor LT with her paternal grandfather being donor who was genetically negative for the mutation. Four weeks post LT and her last Eculizumab, CBC, serum LDH and renal function remain normal.

Discussion: Genetic aHUS secondary to CFH mutation can be treated with plasma therapy, Eculizumab and LT. Difficult vascular access with intolerance to plasma therapy and high cost of eculizumab (~300 mg costs US $ 1900) precludes their longterm use. LT permanently cures the disease by providing CFH synthesized by the transplanted liver. Reported literature on LT in aHUS have described variable
perioperative morbidity due to complement activation which can be managed by pretransplant plasma exchange or eculizumab administration as was done in our case.

**Conclusion:** Liver Transplant is safe and effective treatment modality for aHUS and may prevent the need of simultaneous renal transplant if done before development of renal failure.

Abstract Submission No. 200254

**P-0829**


**Go Endo**¹, ², Yukiko Ito³, Koji Uchino¹, Hiroyoshi Taniguchi¹, Yousuke Nakai², Takuya Hashimoto¹, Hiroyuki Isayama³, Hideo Yoshida³

¹Japan Red Cross Medical Center Tokyo Japan, ²Graduate School of Medicine, The University of Tokyo Tokyo Japan, ³Graduate School of Medicine, Juntendo University Tokyo Japan

**Background:** Bile duct anastomotic stenosis and intrahepatic stones after liver transplantation are complications that can cause cholangitis and graft liver failure. Endoscopic stenting is the primary treatment, but managing these complications, particularly in living donor liver transplant (LDLT) cases, can be challenging and often requires long-term stenting or percutaneous approaches.

**Case presentation:** A 64-year-old woman underwent left LDLT for hepatocellular carcinoma due to type C cirrhosis in year X. Four months post-operation, she developed cholangitis from anastomotic stenosis. Despite balloon dilation via ERCP, recurrence led to placement of an inside stent (IS) in B3. Subsequent cholangitis in B2 necessitated another IS placement, but inflammation remained uncontrolled. Uncovered self-expandable metallic stents (UCSEMS) were placed in B2 and B3. Following immediate cholangitis, PTBD was performed in B4. She remained cholangitis free for over three years.

In year X+4, cholangitis recurred. ERCP showed stone-filled SEMSs in B2 and B3. Due to severe biliary angulation, PTBD was performed in B3. Percutaneous cholangioscopy with electronic hydraulic lithotripsy (EHL) was used to remove stones in B3.

In year X+5, recurrent stones in B3 were managed with percutaneous cholangioscopic stone removal. However, cholangitis due to stones in B2 occurred one month later, necessitating PTBD. Transpapillary stone removal using rendezvous technique was successful. The patient has not had the PTBD tube removed due to recurrent cholangitis but has avoided liver failure for 12 years post-surgery.

**Conclusion:** This case demonstrates the management of post LDLT complications over a decade using various approaches.

Abstract Submission No. 200257

**P-0831**

M.B., a complex case of unsuccessful TACE: a case report

**Luca Galbato Muscio**¹

¹Fondazione Policlinico Universitario Campus Bio-Medico di Roma Italy

This case report aims to focus on the concepts of TACE refractoriness and unsuitability, pointing out the need of a complete evaluation of all the patients affected by HCC, especially those who are candidate to TACE, as we currently cannot foresee how the patient will respond to the specific treatment. Further studies are needed in order to better understand this difference.

M.B. is a 84 years old caucasian male with many comorbidities. His most recent oncological history began in July 2020 when, after a traumatic event, the patient underwent a TC scan which showed a 7.7cm nodule in the right hepatic lobe and two smaller hepatic nodules. An hepatic US was performed, along with a fibroscan analysis, with no evidence of cirrhosis. A liver biopsy confirmed the radiological suspect of Hepatocellular cell carcinoma. The case was discussed in the multidisciplinary meeting, and a first TACE was performed. Two more TACEs were performed after incomplete responses, but the subsequent TC scan showed the appareance of at least 23 new hepatic nodules. A systemic treatment with Lenvatinib 8mg/die was then started (April 2021), after endoscopic and cardiological studies. A nutritional counseling was also needed as the patient lost about 5% of his weight during the first month. The first radiological evaluation during Lenvatinib showed an important partial response of the multiple hepatic nodules. The systemic treatment was continued for two years without major toxicities, and the TC scan performed at January 2023 showed a complete radiological response. The treatment was then stopped.

Abstract Submission No. 200273

**P-0832**

Endoscopic Ultrasound-guided RFA followed by Immunotherapy in A Patient with Cholangiocarcinoma

**Cosmas Rinaldi Adithya Lesmana**¹, ², ³, Laurentius A. Lesmana¹, ³

¹Fondazione Policlinico Universitario Campus Bio-Medico di Roma Italy

BCLC staging system is the most commonly used staging system of hepatocellular carcinoma. This prognostic classification coincides with the treatment algorithm. Since 2015, other proposals from Hong Kong, China, South Korea, also Italy have incorporated a stage hierarchy approach. A 72 -year-old Caucasian male started his oncologic story in April 2019 when an hepatocellular carcinoma at the segment V with patologic lymphadenopathy at the hilar and celiac tripod level was diagnosed, he had a mixed steatotic liver disease (diabetes; et-OH). For the lymph node metastasis involvement (Stage IV A BCLC C), in multidisciplinary meeting we decided to envolve the patient in a new clinical trial, a phase III LEAP-002 (First-line Lenvatinib Plus Pembrolizumab / Placebo in Advanced HCC). He started the chemotherapy at August 2019, he stopped Pembrolizumab/Placebo at May 2021 for suspected immunorelated pneumonia. In these years the disease was always in partial resonance or stability. He continued only Lenvatinib in reduced doses until May 2022, when the TC scan showed a progression epatic disease without patologic lymphadenopathy. In multidisciplinary meeting we discussed the possibility of RFA, but it was impossible for the shape and size of the HCC nodule. We agreed to stop Lenvatinib and to do surgery. In October 2022 he was subjected to atypical partial heparectomy embloc. The last follow-up was in November 2023 with TC scan which was complete response.

The therapeutic hierarchy strategy or the treatment migration are particularly important in intermediate and advanced stages of hepatocellular carcinoma, when initially curative therapies are usually excluded.
Cholangiocarcinoma is a rare hepatobiliary malignancy, and it is difficult to manage due to its aggressiveness and poor disease prognosis. Surgery is still the main treatment for curing the disease, however, most patients have come in the late stage of the disease. Endoscopic management is the main biliary drainage procedure, whereas chemotherapy is the standard treatment for prolonged survival. Recently, there has been innovation in endoscopic ultrasound (EUS) procedure for radiofrequency ablation (RFA) as an option for loco-regional therapy. Another new development in controlling the cancer cells through immunotherapy. Herewith, we presented a case of 80 years old female with past history of breast cancer and was referred due to liver mass which caused bile duct obstruction. No jaundice was found during clinical examination, and the bilirubin level was normal. The hepatitis virus markers were negative. Based on tumor markers evaluation, the AFP level was 2.66 ng/mL, and CA 19-9 was 125.60 U/mL. The patient has been suggested for liver biopsy, followed by bile duct stenting, and possible for EUS-guided RFA. The liver biopsy was done using 22G FNB needle. All the procedures were performed in the same session, and it was technically successful without any adverse events or complications, such as bleeding, infection, or perforation. One week after, the patient underwent the first single immunotherapy using Durvalumab. The patient’s condition is always stable with stable liver function test.

Abstract Submission No. 100647
P-0833

Barriers to patient adherence to longitudinal stool collection for microbiome research: pilot study

Joycelyn JX Lee1, Sharmaine Tan2, Matilda Boey3, Shi Qi Lim1, Umairah Binte Abdul Majeed1, Lin Liu2, Jonathan WJ Lee0
1Division of Medical Oncology, National Cancer Centre Singapore Singapore Singapore, 2Department of Internal Medicine, Dr. Cipto Mangunkusumo Hospital Jakarta Indonesia, 3Medistra Hospital Jakarta Indonesia

Background: To date, most microbiome studies in cancer patients involve patients from Western countries, China or Japan, and baseline samples. We performed a pilot study to assess the feasibility of longitudinal stool collection for microbiome research in cancer patients in Singapore.

Methods: 22 patients with hepatobiliary cancer planned for immunotherapy initiation were recruited. Stool samples were collected at baseline and 6-weekly till 1 year, patient refusal or disease progression. Patients could mail back samples or return them at their next appointment. Patients had to answer a Food Frequency Questionnaire (FFQ), baseline and 6 weekly till 1 year, patient refusal or disease progression. 22 patients with hepatobiliary cancer planned for immunotherapy initiation were recruited. Stool samples were collected at baseline and 6-weekly till 1 year, patient refusal or disease progression. Patients could mail back samples or return them at their next appointment. Patients had to answer a Food Frequency Questionnaire (FFQ), baseline and 6 weekly till 1 year, patient refusal or disease progression.

Results: 20 patients provided at least one sample. Only 38/83 (45.8%) of potential samples were collected. The commonest reason was patient refusal, citing inconvenience or discomfort with sample handling. 38/42 (90.5%) kits dispensed were returned. 37/38 (97.3%) returned kits passed quality control. Mean samples collected per patient was 1.53 (median 1, range 0 - 4).

Abstract Submission No. 100880
P-0835

Gut microbiota in patients with NAFLD without type 2 diabetes: Stratified by body mass index

Pisit Tangkijvanich1, Nonthaya Chuaypen1, Thananya Jinato1
Whether anti-TB drug-induced liver injury (ATDILI) affects the gut microbiota's signature in non-diabetic individuals with NAFLD is not well characterized. This study aimed to assess gut microbiota's signature in non-diabetic individuals with NAFLD stratified by BMI.

**Methods:** The 16S ribosomal RNA sequencing was performed for gut microbiota composition in 100 patients with NAFLD and 16 healthy individuals. Bioinformatic analysis was determined by the DADA2 pipeline in the R program. Significantly different genera from the top 50 relative abundance were applied to classify between subgroups of NAFLD by the Random Forest algorithm.

**Results:** The alpha diversity (Chao1, Shannon, and observed feature) and beta diversity of gut microbiota significantly differed between patients with NAFLD and healthy controls. However, significant differences in their diversities were not observed among subgroups of NAFLD. At the phylum level, there was no trend of elevated Firmicutes-to-Bacteroidetes ratio according to BMI. At the genus level, patients with lean NAFLD showed significant enrichments of Escherichia-Shigella, and the depletion of Lachnospira, and Subdoligranulum, compared to the non-lean subgroups. Combining these bacterial genera could discriminate lean from non-lean NAFLD with high diagnostic accuracy (AUC of 0.82).

**Conclusion:** Non-diabetic patients with lean NAFLD had a significant difference in bacterial composition compared with non-lean individuals. Our results might provide evidence regarding gut microbiota signatures associated with the pathogenesis of lean NAFLD.

Gut Dysbiosis in Chinese Patients with Antituberculosis Drug-induced Liver Injury

**Abstract Submission No. 200150**

**P-0836**

**Gut Dysbiosis in Chinese Patients with Antituberculosis Drug-induced Liver Injury**

shuting Wang, Kaijin Xu, Lanjuan Li

1Center of Excellence in Hepatitis and Liver Cancer, Department of Biochemistry, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

**Background:** The relationship between gut dysbiosis and body mass index (BMI) in non-diabetic patients with nonalcoholic fatty liver disease (NAFLD) is not well characterized. This study aimed to assess gut microbiota’s signature in non-diabetic individuals with NAFLD stratified by BMI.

**Methods:** The 16S ribosomal RNA sequencing was performed for gut microbiota composition in 100 patients with NAFLD and 16 healthy individuals. Bioinformatic analysis was determined by the DADA2 pipeline in the R program. Significantly different genera from the top 50 relative abundance were applied to classify between subgroups of NAFLD by the Random Forest algorithm.

**Results:** The alpha diversity (Chao1, Shannon, and observed feature) and beta diversity of gut microbiota significantly differed between patients with NAFLD and healthy controls. However, significant differences in their diversities were not observed among subgroups of NAFLD. At the phylum level, there was no trend of elevated Firmicutes-to-Bacteroidetes ratio according to BMI. At the genus level, patients with lean NAFLD showed significant enrichments of Escherichia-Shigella, and the depletion of Lachnospira, and Subdoligranulum, compared to the non-lean subgroups. Combining these bacterial genera could discriminate lean from non-lean NAFLD with high diagnostic accuracy (AUC of 0.82).

**Conclusion:** Non-diabetic patients with lean NAFLD had a significant difference in bacterial composition compared with non-lean individuals. Our results might provide evidence regarding gut microbiota signatures associated with the pathogenesis of lean NAFLD.

Abstract Submission No. 200089

**P-0837**

**Sarcopenia and Covert Hepatic Encephalopathy in the Latency Period of Abnormal Ammonia Metabolism**

Naruyasu Kakita, Kazuhiro Katayama, Hiroshi Tsumoro, Midori Jono, Shin Satake, Toshimitsu Yasui, Kenji Aoi, Hisashi Jo

1Kaizu City Hospital, Department of Gastroenterology and Hepatology, Kaizu City Japan

**Objective:** Early diagnosis is important for patients with Covert Hepatic Encephalopathy (CHE). We investigated the factors contributing to the development of sarcopenia and CHE in LAM.

**Subjects and Methods:** Subjects were 369 patients with clinically diagnosed cirrhosis between May 2022 and April 2023, who could undergo grip strength, abdominal CT, and neuropsychiatric tests at the same time, without a history of overt hepatic encephalopathy. 227 (62%) males, median age 69 (42-79) years, Child-pugh classification A/B/C: 209/133/27 cases, causative liver disease B/C/alcohol/NAFLD/Others: 46/55/156/76/36 cases. As previously reported, patients were divided into 4 groups: Stage 0 with normal liver disease, Stage 1a with only decreased BTR, Stage 1b with low Alb, and Stage 3 with high NH3 (161/28/93/87 patients). In addition, sarcopenia was diagnosed by grip strength and L3-PMI, and abnormalities in two or more of the NCT-A, B, Stroop-test, and Digit symbol test were defined as CHE using NP-test iPad ver. and factors related to CHE were examined by logistic regression analysis and ROC analysis. The factors associated with CHE were examined by logistic regression analysis and ROC analysis.

**Results:** CHE was observed in 42%, 28/29/53/59% in Stagl0/1a/1b/2, decreased grip strength in 33%, 23/18/46/43%, and sarcopenia in 15%, 6/7/26/23%, significantly increasing after Stage 1b (P=0.002, P<0.0001, P<0.0001).

When examining factors associated with the development of CHE during LAM (Stage1a+1b), sarcopenia-related factors was not significant factors, while NH3 (OR 0.40, 95%C.I. 1.010-1.060, P=0.009) and zinc (OR 0.956, 95%C.I. 0.934-0.979, P=0.0002) were extracted, and the cutoff values of ROC curves were NH3 47 (95%C.I:0.5639-0.7568, AUC: 0.6640) and zinc 71 (95%C.I: 0.6641-0.8447, AUC: 0.7544).

**Conclusion:** NH3 and zinc level were suggested to be possible predictors of CHE in LAM.

Abstract Submission No. 100058

**P-0818**

**Prevalence of Osteosarcopenia and Liver Frailty Index (LFI) in patients with Cirrhosis**

Shamim Nazir, Zaigham Abbas, Shaima Amjad

1POSTGRADUATE TRAINEE AT DR ZIAUDDIN HOSPITAL KARACHI, PAKISTAN KARACHI Pakistan, 2HEAD OF DEPARTMENT GASTROENTEROLOGY, DR ZIAUDDIN HOSPITAL KARACHI PAKISTAN KARACHI PAKISTAN, 3FAMILY MEDICINE TRAINEE AT DR ZIAUDDIN HOSPITAL KARACHI PAKISTAN KARACHI PAKISTAN

**Introduction:** Chronic Liver Disease (CLD) can have a significant impact on the nutritional status of patients. Malnutrition is an under-recognized condition in patients with cirrhosis. Malnutrition increases the incidence and severity of decompensation, increase the risk of infections, and increases mortality.

**Objectives:** The present study aimed to assess osteosarcopenia and frailty in patients with cirrhosis.
Methods: Total 141 patients have been enrolled during the months of November 2022 to June 2023 at Dr. Ziauddin Hospital Clifton Campus, Karachi. This prospective cross-sectional study included cases of cirrhosis, aged between 18 to 85 years. Anthropometric measurements were performed. Sarcopenia was assessed by hand-grip strength using a hand-held Dynamometer. Bone mineral density was measured with the help of an office-based DEXA scan (Osteosys). Liver Frailty Index (LFI) is assessed by performance-based tests.

Results: The total number of patients included in this study were 141, male 98 (69.5%) with mean age 51.8 ± 13.83. The prevalence of presarcopenia 66.7% and sarcopenia was 29.1%. The prevalence of osteopenia was 51.1 % and osteoporosis 14.9%. The patients who had osteopenia and osteoporosis were associated with high liver frailty index (p-value=0.001). Most of patients with Osteosarcopenia belonged to Child Pugh score C (p-value<0.001).

Conclusions: There is a high prevalence of pre-sarcopenia, sarcopenia, osteopenia, and osteoporosis, and high frailty in our patients with cirrhosis. Early detection and timely intervention of these conditions are important to reduce the associated consequences. All patients with cirrhosis should be assessed for Osteosarcopenia and frailty both at baseline and longitudinally.

Abstract Submission No. 100162
P-0839
A Diagnostic Marker for Portal Vein Thrombosis in Patients with Cirrhosis
Tadashi Namisaki1, Junya Suzuki1, Shohei Asada1, Akihiko Shibamoto1, Satoshi Iwai1, Kosuke Kaji1, Hitoshi Yoshiji1
1Nara medical university Kashihara Japan

Background and Aims: Portal vein thrombosis (PVT) is one of the most common hepatic vascular disorders associated significant morbidity and mortality. A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) specifically cleaves multimeric von Willebrand factor (VWF) thereby controls VWF-mediated platelet thrombus formation. An imbalance between ADAMTS13 and VWF is responsible for hypercoagulability, including spontaneous thrombus formation in blood vessels. We aimed to identify diagnostic markers for PVT in patients with cirrhosis.

Methods: 66 patients with cirrhosis were split into two group: PVT groups (n=33) and non PVT (NPVT) group (n=33). Plasma ADAMTS13 activity (ADAMTS13:AC) and VWF antigen (VWF:Ag) were measured using enzyme-linked immunosorbent assays at diagnosis of PVT in PVT group.

Results: Plasma ADAMTS13:AC was significantly higher in NPVT group than in PVT group, whereas no significant differences in plasma VWF:Ag were observed in patients with cirrhosis. ADAMTS13:AC was an independent risk factor for developing PVT on multivariate (Odds ratio [OR] = 0.00694, 95% confidence interval [95%CI]: 0.000786-0.0613, p < 0.001) as a risk factor of PVT. The Receiver operating characteristic analysis for PVT revealed a good classifying capability, with an AUC of 0.913. Patients having ADAMTS13:AC of greater than or equal to 20 had a higher incidence of PVT versus ADAMTS13:AC below 20.

Conclusion: Serum ADAMTS13:AC can serve as diagnostic maker for PVT in patients with cirrhosis

Abstract Submission No. 100185
P-0841
Predictive modelling of liver disease-related mortality in cirrhotic patients using LFI nomogram
Feng Guo1, Guzainuer Yiliyaer2, Jinhua Jing3, Hong Yu4, Yan Guo4, Lei Yang5, Zhaoxia Liu6, Huiing Du1, Xiaozhong Wang6, Binfang Zeng6
1Department of Hepatology, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University Urumqi China, 2School of Nursing, Xinjiang Medical University Urumqi China, 3The Fourth Clinical Medical College of Xinjiang Medical University Urumqi China, 4Traditional Chinese Medical College of Xinjiang Medical University Urumqi China

Objective: This study aimed to develop a predictive model for assessing the risk of mortality related to liver disease in patient with cirrhosis utilizing the Liver Frailty Index (LFI) nomogram.

Methods: Inpatients diagnosed with liver cirrhosis at the Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University from November 2021 to July 2022, were selected for predicting liver disease-related deaths based on the LFI.

Results: A total of 195 patients were ultimately included in the study, of which 28 (14.3%) experienced liver disease-related deaths. A multifactorial Cox proportional risk regression model was employed, revealing that LFI [HR=1.83, 95% CI (1.23, 2.72), P=0.003] and Child-Turcotte-Pugh (CTP) score [HR=1.26, 95% CI (1.03, 1.55), P=0.028] were independent risk factors for predicting liver disease-related deaths. The patients were randomly divided into a training set (136 patients) and a validation set (59 patients) in a 7:3 ratio. A nomogram
Abstract Submission No. 100315
P-0843

Risk Factors Leading to Hepatorenal Syndrome in Patients with Cirrhosis
Le Hien1, Le Quoc Tuan2
1Thai Nguyen University of Medicine and Pharmacy Thái Nguyên Vietnam, 203 Cam Khe Clinic Phú Thọ Việt Nam

Aims: Patients with hepatorenal syndrome (HRS) are usually poor prognosis. For better improving prognosis of patients, it requires a comprehensive analysis of the risk factors associated with HRS and clarify its predictive role for HRS.

Methods: 51 cases of inpatients from Central Hospital of Thai Nguyen were selected from January 2023 to July 2023. Their clinical data, including general information, clinical features, and blood biochemical indexes were analyzed as risk factors. They were furtherly divided into two groups: (1) control group: patients received intravenous sodium supplement and oral liver-protective drugs treatment. (2) treatment group: patients received a series of therapies including intravenous supplement of sodium, albumin and Terlipressin, oral administration of liver-protective drugs. We then compared the incidence of HRS development during the hospitalization between the two groups.

Results: we discovered that the factors including gastrointestinal hemorrhage, bacterial peritonitis, long-term use of diuretics and releasing ascites in large quantities, lower plasma sodium and albumin level were risk factors for prediction of HRS. Our results showed that the incidence rate of HRS was significantly lower in patients received therapies, which indicated a significantly better prognosis of patients with cirrhosis after reducing the risk.

Conclusion: The analysis of HRS associated risk factors benefits to predict HRS and cirrhosis patient’s prognosis.

Keywords: Risk Factors, Hepatorenal Syndrome, Cirrhosis

Abstract Submission No. 100315
P-0843

Acute gastrointestinal injury for the prediction of progression in acute decompensation of cirrhosis
Jia Lian1,3, Tao Han2, Qing Ye1
1Department of Gastroenterology and Hepatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Tianjin, China. No 83, Jintang road, Hedong district, Tianjin, C; 2Department of Hepatology and Gastroenterology, Tianjin Union Medical Center affiliated to Tianjin Medical University, 190 Jieyuan Road, Hongqiao District, Tianjin 300121, China Tianjin China; 3Department of Gastroenterology and Hepatology, The Third Central Clinical College of Tianjin Medical University, 83 Jintang Road, Hedong District, Tianjin, 300170, China Tianjin China

Background and Aims: This prospective, observational study evaluated the role of acute gastrointestinal injury (AGI) in the 28-day and 90-day prognosis of cirrhotic patients with acute decompensation (AD).

Methods: The baseline clinical characteristics of AD patients (N = 231) were recorded, and gastrointestinal function (GIF) was assessed. The patients were divided into three AGI groups based on their AGI grade (according to the European Society of Intensive Care Medicine guidelines), and they were followed for 90 days or until either death or liver transplantation.

Results: Follow up to 90 days, 63 patients (22.27%) died and 2 (0.87%) underwent liver transplantation. Cox regression analysis identified age, endotoxin, creatinine, international normalized (INR), and the occurrence of AGI as independent predictors of 28-day and 90-day death or transplantation. These five predictors were identified in the final Cox regression model, and 28-day (the AGIM28 model) and 90-day (the AGIM90 model) predictive models and their corresponding nomograms were constructed. Of five prognostic models, the AGIM models had the highest prediction efficiency. In the Kaplan-Meier survival curve analysis, the 90-day cumulative survival rate of the three AGI groups (no-AGI, AGI 1, and AGI 2) decreased gradually (P < 0.001). Multivariate logistic analysis showed that d-lactate, bilirubin, INR, and bowel sounds were independent predictors of AGI progression.

Conclusion: Our novel prediction models, the AGIM28 and AGIM90, can effectively predict the 28-day and 90-day death or transplantation risk of cirrhotic patients with AD. The presence of AGI plays an undeniable role in the poor prognosis of AD patients.

Abstract Submission No. 100388
P-0844

Endoscopic variceal ligation versus propranolol as prophylaxis of first variceal bleeding
Sung Hwan Yoo1, Hyun Woong Lee1, Jung Il Lee1
1Gangnam Severance Hospital Seoul South Korea

Introduction: Both endoscopic variceal ligation and propranolol are known to be effective methods for preventing variceal bleeding, but there are still few published data for comparing efficacy and safety. We analysed the efficacy and safety of endoscopic variceal ligation (EVL) and propranolol in terms of prophylaxis for the first bleeding rate.

Method: A retrospective cohort study was conducted in 1,052 cirrhotic patients with no history of previous esophageal bleeding with F2 or F3 esophageal varices from a university hospital between September 2008 and October 2022. 697 patients received EVL and 355 patients used propranolol. The primary end-point of the study was bleeding rate and secondary end-point was overall survival.

Results: Life-time table curves indicated that prophylactic EVL and propranolol were similarly effective for primary prophylaxis of variceal bleeding (147/697 [21%] vs 82/355 [23%], P=0.72) and overall mortality (279/697 [40%] vs 128/355 [36%], P=0.46). The 2-year cumulative mortality rate was 31%(217/697) in the EVL group and 27%(97/355) in the propranolol group. Comparison of Kaplan-Meier curves of the time to death of both groups showed no significant difference in mortality in both groups (P=0.78). Patients undergoing EVL died mainly of hepatic failure and propranolol group died mainly from infection.

Conclusion: Both prophylactic EVL and propranolol are effective and safe methods for reducing the incidence rate of first variceal bleeding and mortality.
Change in the Child-Pugh score after albumin infusion in decompensated cirrhosis

Apinya Leerapun1, Teerasak Uttama1, Kanjira Titsisaeng1, Satwat Thongsawat1

1Chiangmai university hospital chiangmai Thailand

Background and Aims: As albumin is quantitatively and qualitatively deficient in cirrhosis, it is hypothesized that albumin supplementation could prevent the decompensation of cirrhosis. This randomized unblinded pilot study compared the effect of albumin and the standard medical treatment on cirrhotic complications and survival in patients with decompensated cirrhosis.

Methods: Forty cirrhotic patients with Child-Pugh score 7-10 were randomized to receive the standard medical treatment (SMT) or SMT plus human albumin 40 grams at the initiation and 25 grams every two weeks for 12 weeks. Patients were followed up to 12 months.

Results: There were no significant differences between both groups in the one-year mortality (p = 0.78). However, patients treated with albumin showed a reduction in the progression of ascites and an improvement of liver function verified by Child-Pugh score (p = 0.019). No difference was found in the probability of developing complications of cirrhosis including spontaneous bacterial infections, hepatic encephalopathy, hepatorenal syndrome, and hyponatremia in the two patient groups.

Conclusion: In patients with decompensated cirrhosis, albumin infusion might act as a disease-modifying treatment and affect the improvement in liver function.

Hypozincemia and zinc supplementation in patients with chronic liver disease.

Takeharu Asano1, Shuhei Yoshikawa1, Hirokatsu Mashima1, Shinichi Asabe1

1Saitama Medical Center, Jichi Medical University Saitama Japan

Background: Hypozincemia has been reported to be a frequent complication in patients with cirrhosis. The purpose of this study was to clarify the relationship between serum zinc levels and the symptoms and disease progression of chronic liver disease.

Methods: 184 patients with chronic liver disease who visited our institution were subjected to measurement of fasting serum zinc levels in the morning. The presence of symptoms related to hypozincemia was confirmed by a questionnaire. 48 patients with zinc deficiency were treated with zinc replacement therapy with zinc acetate or polaprezinc.

Results: In 94 patients with cirrhosis, the median zinc level was 63 μg/dL (22-94), with <60 in 43% (39 patients). In 90 patients with chronic hepatitis, the median zinc level was 77 μg/dL (38-114), with <60 in 14.4% (13 patients). The most common symptoms associated with hypozincemia were dermatitis (23%), poor wound healing (18%), and aphthous stomatitis (14%). A significant increase in serum zinc (54.5→71 μg/dL) was observed 3 months after zinc replacement therapy in 48 cases. There was no significant difference in improvement rate between patients with and without cirrhosis. A significant decrease in ammonia level (44→39 μg/dL) was observed in patients with elevated zinc levels due to zinc supplementation.

Role of Endoscopic Ultrasound in diagnosis of unexplained distal Common Bile Duct stricture

Ahmed samir Atwa1, Mohammed Abbasy1, Talaat Zakaria1, Mahmoud Alham1, Reda Badr1, Hassan Zaghla1

1National Liver Institute, Shebin El-Koom, Menofia, Egypt Shebin El-Koom Egypt

Background: Determining the etiology of a distal biliary stricture without an identifiable mass on imaging is crucial to the provision of appropriate therapy.

Aim of the work: To assess the ability of Endoscopic Ultrasound (EUS) to diagnose distal biliary strictures for which cross-sectional imaging modalities such as Computed Tomography (CT) scan and Magnetic Resonance Imaging (MRI) could not detect a causative mass or bile duct thickening.

Patients and Methods: Prospective study on 80 patients with unexplained distal biliary stricture diagnosed by Magnetic Resonance Cholangiopancreatography (MRCP), Endoscopic Retrograde Cholangiopancreatography (ERCP), CT or MRI underwent EUS.

Results: 80 patients (50 male; mean age 57.9 ± 9.8 years) were studied. Based on EUS findings; 51 patients were diagnosed with malignant strictures 63.75% (21 distal cholangiocarcinoma, 17 pancreatic head mass, 11 ampullary mass lesion and 2 intraductal papillary mucinous neoplasm) and rest of patients were diagnosed with benign strictures 36.25%. Mean distal CBD wall thickness in benign strictures (2.87 ± 0.76 mm) while in malignant strictures (4.49 ± 1.4 mm) with very high statistical significant difference (P-value <0.001).ROC analysis between malignant and benign strictures for distal CBD wall thickness has shown a cutoff value >3.2 (Sensitivity 80.39%, Specificity 89.66%, Positive predictive value (PPV) 93.2, Negative predictive value (NPV) 72.2 and accuracy 85.7%).

Conclusion: EUS is a useful investigational modality for patients with unexplained distal CBD stricture.

Endoscopic ultrasound for ampullary cancer: a case report

Xinke Wang1, Li Yang2, Chaoming Pan3

1Nanfang Hospital of Southern Medical University Guangdong Province China, 2Guangdong Provincial Key Laboratory of Gastroenterology Guangdong Province China, 3Development of Gastroenterology Guangdong Province China

Primary ampullary carcinoma is a rare type of periampullary tumor, with an incidence of about 4-10/1 million, accounting for about 6% of periampullary lesions, and leading to 20% of tumor-associated bile duct obstruction. For jaundice patients with suspected malignant biliary obstruction, Endoscopic retrograde cholangiopancreatography (ERCP) is the preferred initial endoscopic examination Because of its flexibility and practicality though it cannot figure out the extent of
local invasion of ampulla carcinoma. While endoscopic ultrasonography (EUS) to small ampulla carcinoma is as sensitive as ERCP and it can find out the depth of tumor invasion and the degree of tumor expansion, which is conducive to preoperative staging. Some new endoscopic ultrasound techniques are used in the treatment. Here is a case: male, 73-year-old, chief complaint: skin and urine have been yellow for more than 20 days. In 2023.08, the patient was performed with EUS-BD-CDS, then jaundice relieved. Endoscopic ultrasonography played an important role in this case, indicating that endoscopic ultrasonography has certain value in the diagnosis and treatment of ampulla carcinoma.

Abstract Submission No. 100540
P-0849

Longitudinal analysis of repeated variceal ligation in acute EV bleeding: a 5-year perspective
Pakkapon Rattanachaist1, 2, Piyapan Prueksapanich3, Roongruedee Chaiteerakij3, Piyawat Komolmit3, Sombat Treenprasertsuk2

1Department of Physiology, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital Bangkok Thailand

Background: In acute esophageal variceal bleeding (EVB), initial treatment combines pharmacology and endoscopy, especially endoscopic variceal ligation (EVL). For rebleeding, transjugular intrahepatic portosystemic shunt (TIPS) is recommended, but in settings with limited TIPS access, repeated endoscopic therapy is common. This study assesses EVL outcomes on rebleeding and mortality in resource-limited contexts.

Methods: Patients experiencing acute EVB and undergoing EVL were monitored for up to five years or until their demise. These patients received treatment involving vasoactive drugs and EVL until variceal eradication was achieved. The primary endpoints were the effectiveness of bleeding control and the necessity for a second EVL session to manage EVB. Mortality rates at both 6 weeks and 5 years were analyzed. Logistic regression analysis was employed to identify risk factors associated with mortality.

Results: Among the 118 patients with acute EVB who underwent EVL, no treatment failures occurred within five days. 83% were successfully controlled with one EVL session, while 17% required at least two sessions for recurrent bleeding. There was no significant difference in 6-week mortality between rebleeding (15%) and non-rebleeding (18%) groups (p=0.72). Factors associated with 6-week mortality included age, hepatocellular carcinoma, post-bleeding beta-blocker use, creatinine, bilirubin, albumin, Child-Pugh class, and MELD score (Table). Over five years, rebleeding group had a higher mortality trend (90%) compared to non-rebleeding group (68.8%), although it wasn’t statistically significant (p=0.06).

Conclusion: In resource-limited settings, multiple attempts of EVL demonstrates success in controlling rebleeding. The long-term trends showed higher mortality in rebleeding cases, though not statistically significant.

Abstract Submission No. 101232
P-0851

NEW TUNNEL TECHNIQUE IN LAPAROSCOPIC-CHOLANGIOSCOPIC COOPERATIVE SURGERY FOR HEPATOLITHIATIS
Hieu LE TRUNG1, Thanh LE VAN2, Quang VU VAN2

1Human Organ and Tissue Transplantation Center, Military Central Hospital 108 Hanoi Vietnam, 2Dept of HBP Surgery, Military Central Hospital 108 Hanoi Vietnam

Introduction: Laparoscopic common bile duct (CBD) exploration using the cholangioscope has become a standardized technique within the last years. However, the using of the cholangioscope remove intrahepatic and bile stones often becomes a time-consuming and difficult part of the operation. Our newly design instrument, is a tube placed through the skin into CBD, the cholangioscope will be inserted through this tunnel to remove the stones.

Method: We describe the step-by-step technique using the new instrument under laparoscopic guidance, in patients with hepatolithiasis combined with choledocholithiasis. Main outcomes were complete stone clearance rate, single-session stone clearance rate, number of endoscopic sessions needed for stone clearance, and adverse events.

Abstract Submission No. 101203
P-0850

Self-expanding metal stent as therapy for refractory variceal bleeding: a single centre experience
Jonathan Koh1, Wei Lyn Yang1, Zhi Guang Ng1, Liang Raymond1, Christopher Chia1, Alyssa Sim1

1Tan Tock Seng Hospital Singapore Singapore

Refractory oesophageal variceal bleeding (OVB) is associated with high mortality rate. Balloon tamponade (BT) is a bridge to definitive therapy. Novel SEMS such as SX-ELLA Danis are alternatives to BT for refractory OVB. We report our centre’s experience of two such cases which necessitated deployment of SEMS focusing on technical success, immediate haemostasis control, stent-related complications and mortality.

Case 1: A 43-year old male with Child-Turcotte-Pugh score (CTP) B8 alcoholic liver cirrhosis, MELD 18 presented with haemorrhagic shock from refractory oesophageal VB despite standard of care (SOC) and endoscopic variceal ligation (EVL). Although immediate haemostasis was achieved with SEMS insertion, he demised from multiorgan failure (MOF) shortly after.

Case 2: A 49-year old female with CTP A6 alcoholic liver cirrhosis, MELD 20 presented with OVB. Despite SOC, she had rebleeding and haemorrhagic shock requiring stabilisation with BT. Despite this, refractory bleeding was seen on removal of BT and EVL was unsuccessful, requiring SEMS deployment, after which haemostasis was achieved. Transjugular intrahepatic portosystemic shunt (TIPS) was performed 24 hours after with SEMS removal done 1 week later. In both cases, technical success and immediate haemostasis were 100% after SEMS insertion. There were no stent-related complications. In conclusion, SEMS insertion is safe, has good technical success and effective in achieving temporary haemostasis in refractory oesophageal VB. Timely insertion of oesophageal SEMS before development of MOF may be a determining factor for clinical success. Larger studies are required to evaluate early timing of SEMS insertion and cost-effectiveness.
**Result:** Among 31 patients with hepatolithiasis and choledocholithiasis underwent laparoscopic CBD exploration to remove stones using cholangioscopy through the tube from June 2019 to June 2022. 32.2% of patients had a history of laparotomy, in which 22.5% had a history of CBD exploration. The complete stone clearance rate was 83.8%. Single-session stone clearance was achieved in 70.9%. Two cases of postoperative complication of minor bile leakage, no treatment were necessary. The average operative time and tube insertion time were 126 ± 36 minutes and 5 ± 2 minutes, respectively. Postoperative hospital stay was 8.5 ± 2.6 (days).

**Conclusion:** The combination of laparoscopic CBD exploration using the cholangioscope and the new instrument is an effective and safety technique, and may be considered as a standard approach of the treatment for hepatolithiasis combined with choledocholithiasis.

---

**Feasibility of EUS-BD in the initial drainage for unresectable malignant hilar biliary obstruction**

Saburo Matsubara1, Tomohiro Arai1, Kentaro Suda1, Takeshi Otsuka1, Masashi Oka1, Sumiko Nagoshi1

1Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University Kawagoe Japan

**Background:** The efficacy and safety of EUS-guided biliary drainage (EUS-BD) in the initial drainage for unresectable malignant hilar biliary obstruction (MHBO) have not been well evaluated.

**Methods:** We retrospectively analyzed 42 patients who underwent EUS-BD in the initial drainage for unresectable MHBO with Bismuth II or higher.

**Results:** Characteristics of the study patients were as follows: age, median 72 years (range: 42-86); sex, 50% male; Bismuth classification, II (9)/IIIa (13)/IIIb (1)/IV (19); primary cancer site, pancreas (9)/colorectal (8)/gallbladder (7)/bile duct (6)/ICC (5)/others (7); reason for MHBO, II (9)/IIIa (13)/IIIb (1)/IV (19); primary cancer site, pancreas (9)/colorectal (8)/gallbladder (7)/bile duct (6)/ICC (5)/others (7); reason for EUS-BD, severe stricture (16)/surgical altered anatomy (15)/duodenal invasion (5)/tumor characteristics (5)/failed cannulation (1). Drainage methods included EUS-BD alone in 28 and EUS-BD combined with ERC-BD in 14 cases. EUS-BD procedures included hepaticogastrostomy (HGS) in 25, HGS with bridging in 10, hepatocoduodenostomy (HDS) in 4, and HGS with HDS in 3 cases. Median procedural time, technical success rate, and functional success rate were 40.5 min (16-130), 100% (bridging success rate: 67%), and 86%, respectively. Early adverse events developed in 8 (19%), which included biliary peritonitis in 4, abdominal pain in 2, fever in 1, and cholangitis in 1 case. Recurrent biliary obstruction (RBO) developed in 8 (19%) with the median time to RBO of 126 days (95%CI: 75-NA). Median overall survival was 69 days (95%CI: 41-115).

**Conclusion:** Applying EUS-BD in the initial drainage for unresectable MHBO might be safe and feasible.

---

**Post Transjugular Intrahepatic Portosystemic Shunt Cardiac Failure in patients with cirrhosis**

shumei du1

1West China Hospital of Sichuan University sichuan china

**Background:** This study was designed to evaluate the incidence of post-TIPS cardiac failure and predisposing factors in patients with cirrhosis.

**Methods:** This was a retrospective study consisting of 737 patients who had undergone TIPS from January 2012 to December 2019. The baseline characteristics were collected. The univariate and multivariate cox regression analyses were used to identify the risk factors for hepatic encephalopathy after TIPS.

**Results:** Of the 737 patients included in this study, 545(74.3%) were male, the mean age was 49.5 ± 10.7 years, and the etiology was mostly hepatitis cirrhosis(85.7%). Before the surgery, the mean MELD and CP scores were 11.2 ± 3.5, 7.9 ± 2.6, the mean liver and spleen volume ± standard deviation respectively were 9.6 ±2.3 and 6.0±2.7 at baseline. After a median follow-up of 49 (31-79) months, 306(41.5%) patients occurred hepatic encephalopathy. In the multivariate cox regression analyses, liver volume (HR 0.98, 95% CI 0.94 -1.0, P = 0.21) and spleen volume (HR 0.99, 95% CI 0.96–1.0 P = 0.43) was not a significant predictor for HE post-TIPS.

**Conclusion:** The liver and spleen volume before the placement of stent were not associated with HE in Post-TIPS cirrhosis.
Yamazaki is effective in albumin retention, but if CART (Zinc re-concentrated Ascites Reinfusion Therapy) is necessary. CART is useful not only in albumin retention but also in zinc retention.

Background: Sleep disturbance (SD) is common in patients with cirrhosis and may lead to poor quality of life. Data regarding post-TIPS SD is scarce. The present study was designed to investigate the incidence and outcomes of post-TIPS SD.

Methods: From August 2018 to November 2019, 73 patients treated with TIPS were prospectively enrolled. The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality, and the presence of hepatic encephalopathy was evaluated using the West Haven criteria before and after TIPS. The primary outcome was the incidence of SD after TIPS.

Results: 19 patients (26%) were the new onset of SD after TIPS and the median time from TIPS creation to the occurrence was 67 (40-98) days. Minimal hepatic encephalopathy (MHE) after TIPS (OR =3.95% CI 1.87; P=0.046) was demonstrated as an independent risk factor for SD. Five of six (83%) patients with SD improved after treatment with eszopiclone. Ten of thirteen (77%) patients with SD improved spontaneously without treatment. The incidence of MHE in patients with SD was higher than in patients without SD (58% vs 31%, P=0.04).

Conclusions: The incidence of SD is not uncommon in patients who underwent TIPS. MHE is an independent risk factor associated with post-TIPS SD. Eszopiclone may be effective and safe for patients with SD after TIPS.

Abstract Submission No. 100616
P-0856

CART in patients with liver cirrhosis is useful not only albumin retention but also zinc retention

MASANORI KAWAGUCHI, YASUTO TABATA, HIROFUMI YAMAZAKI
1Saiseikai Wakayama Hospital Department of Gastroenterology Wakayama City Japan

Background: Liver cirrhosis causes zinc deficiency. If ascites cannot be controlled with diuretics, Ascites drainage alone or Cell-free and concentrated Ascites Reinfusion Therapy (CART) is necessary. CART is effective in albumin retention, but if CART is effective in Zinc retention or not.

Methods: We investigated zinc concentration of ascites who underwent CART (2018.4-2023.10). Asahikasei Medical’s AHF-MO/AHF-UP were used.

Results: 13 cases were registered. but 2 were excluded due to insufficient filtration. Age68±12y.o, M/F 8/3, ALD/NAFLD/HBV/HCV 3/3/3/2, HCC/CCC 7/1, Diuretics use 11, and 10 cases use zinc preparations. TB 1.5±2.0mg/dL, PT 62±36%, Alb 2.7±0.4 g/dL, Zinc 56±21μg/dL. Zinc of ascites was 12±7μg/dL. Zinc in the filtered and concentrated ascites was 99±81μg/dL. The amount of zinc in ascites was calculated by checking the scale value on the collection bag, 490 ±249 μg. The zinc recovery rate is calculated by assuming that the specific gravity of the ascites and the filtered concentrate are almost similar, and calculating Zinc of the filtered and concentrated (μg/dL) x the weight of the filtered and concentrate (kg) / Ascites zinc (μg/dL) x Ascites weight (kg), it was 84 ±22%.

Conclusion: The daily zinc intake of Japanese people is said to be 11 mg/average, but the absorption rate of zinc is about 20-40%, although it depends on comorbidities, concomitant medications, and status of zinc transporters at small intestinal epithelial cells. Zinc deficiency in patients with liver cirrhosis results from malabsorption, loss of zinc due to diuretics, etc. Simple ascites drainage causes zinc loss, on the other hand, CART is useful in zinc retention.

Abstract Submission No. 100637
P-0857

Frailty based on LFI as predictor of mortality in liver cirrhosis: A systematic review

Pitt Akbar, Juferdy Kurniawan, Aulia Rizkographic
1Hepatobiliary division, Cipto Mangunkusumo Hospital Jakarta Indonesia, Geriatric division, Cipto Mangunkusumo Hospital Jakarta Indonesia

Background: Frailty is a biological syndrome that can lead to susceptibility to poorer outcomes. Frailty assessment is currently developing in the population of patients with liver cirrhosis, one of which is Liver Frailty Index (LFI). The prevalence of liver cirrhosis patients who experience frail is high that will increase the risk of mortality.

Aims: To assess frailty based on the Liver Frailty Index as a predictor of mortality in patients with liver cirrhosis

Methods and Material: Literature search was conducted through online databases: PubMed/MEDLINE, EMBASE, ProQuest, and EBSCOhost using the keywords “cirrhosis of the liver” and “liver frailty index”. The studies included were prospective and retrospective cohort studies that included patients with liver cirrhosis and reported patient mortality based on frailty status.

Results: A total of 7 articles were included in this systematic review, 3 of which were included in a meta-analysis to assess the association with mortality and 2 studies assessed the association with the incidence of decompensation. There was a higher risk of mortality in cirrhotic patients with frailty (HR 1.68; 95% CI 1.36-2.08; P<0.0001). In addition, frailty was found to be associated with the incidence of ascites (OR 1.84 95% CI 1.41-2.40; P=0.0001). However, there was no association between frailty and the incidence of HE in patients with liver cirrhosis (OR 1.57 95% CI 0.65-3.80; P=0.31).

Conclusions: Frailty is a predictor of mortality in patients with liver cirrhosis. Frail liver cirrhosis patients have a greater risk of death than non-frail.

Abstract Submission No. 100668
P-0838

Contrast-induced Nephropathy in Patients with Cirrhosis: A Systematic Review and Meta-Analysis

Bea Regine Panganiban, Jayson C. Villavicencio, Eric Yasay
1Philippine General Hospital Manila Philippines

Background: Cirrhotic patients are frequently subjected to imaging procedures involving contrast agents, and may have additional risk factors that predispose them to contrast-induced nephropathy (CIN). The nephrotoxic potential of contrast agents among cirrhotic patients is still a debated issue due to limited and conflicting evidence.

Objective: To determine if the use of contrast agents for imaging procedures among cirrhotic patients is associated with the development of CIN

Methodology: A comprehensive search for databases of randomized controlled trials (RCTs) and observational studies comparing contrast-enhanced studies versus without contrast for occurrence of CIN among adult patients with cirrhosis was done. PubMed, EMBASE, Cochrane library, and ClinicalTrials.gov were searched using relevant terms including cirrhosis, CIN or contrast associated acute kidney injury (AKI)
until October 2023. Data extraction was performed using a standard- ized data form, and any discrepancies were resolved by consensus among the authors. Data were pooled using Review Manager Software version 5.4.

Results: A total of nine studies were included in the systematic review, with reported incidence of CIN ranging from 2.5-5%. Two prospective (n=385) and two retrospective (n=604) observational studies were included in the meta-analysis. The contrast group was associated with an increased risk for CIN, OR 2.52, 95%CI: 1.52-4.16. Risk factors predisposing cirrhotic patients to CIN include ascites and presence of infection (OR 2.796, 95%CI: 1.109–7.052; OR 22.18, 95%CI: 2.87-171.22, p=0.003 respectively).

Conclusion: Available evidence suggests that the risk of AKI among cirrhotic patients exposed to contrast agents is increased, and thus post-contrast renal function should be closely followed.

Abstract Submission No. 100672
P-0859

Multi-target drug discovery for TGFβ-mediated liver cirrhosis/HCC: in silico and in vitro approaches

Haytham M. M. Makki1,2, Junyang Jung1,2

1Department of Anatomy and Neurobiology, College of Medicine, Kyung Hee University Seoul South Korea, 2Department of Biomedical Science, Graduate School of Medicine, Kyung Hee University Seoul South Korea

Background: It is well known that decompensated liver cirrhosis (LC), regardless of etiology, eventually develops hepatocellular carcinoma (HCC). Transforming growth factor beta (TGF-β) activates multiple kinases in the pathogenesis of LC/HCC. Multi-target drug discovery is the preferred approach in chronic disease therapy. Therefore, we used this approach involving in silico and in vitro techniques.

Methods: We conducted virtual high-throughput screening (VHTS) of the Korea Chemical Bank (KCB) natural products library against TGF-β receptor type-1 (TGF-βR1), focal adhesion kinase (FAK), and phosphoinositide 3-kinase (PI3K) using AutoDock Vina software. We used VMD and NAMD software for dynamics simulation. We predicted the drug-likeness and pharmacokinetics profiles of the hit compounds using free webtools, SwissADME and ADMETTab 2.0. We examined the anticancer effects of diosmetin and luteolin on HepG2 cell lines using MTS and q-PCR techniques.

Results: Docking and dynamics simulation results revealed potential TGF-β inhibitors with better binding affinities (ranging from -11.2 to -10.4 kcal/mol) than galunisertib (-10.0 kcal/mol). Dihydrosanguinarine (DHS) and eriocitrin showed the best docking scores against the key targets of LC. Matrix metallopeptidase 2 (MMP2) and MMP13 were identified as potential targets related to alcoholic LC through bioinformatic approaches. Moreover, the drug-likeness and pharmacokinetic profiles demonstrated that DHS, trisindoline, and alpha-naphthoflavone could be acceptable oral drug candidates. Luteolin exhibited dose-dependent, multi-target inhibitory effects. However, diosmetin upregulated the gene expressions dose-dependently.

Conclusions: VHTS revealed promising multi-target hit compounds in comparison with reference inhibitors. However, validation of the anti-fibrotic effects in an in vivo LC model is needed.

Abstract Submission No. 100702
P-0860

Nutritional Status is Associated with Cognitive Function in Chronic Liver Disease

Kwang Il Seo1, Hyun Joon Park1, Byung Cheol Yun1, Sang Uk Lee1, Jung Wook Lee1

1Kosin University Gospel Hospital Busan South Korea

Background: Nutritional status and cognitive function are important factors to affect the morbidity and mortality in chronic liver disease patients. The aim of this study is to find out whether the nutritional status of chronic liver disease patient could affect patients’ cognitive function.

Methods: Among chronic liver disease patients admitted to the tertiary hospital, department of Hepatology from 2018 to 2021, who underwent a number connection test (NCT) before performing diagnostic endoscopy were retrospectively analyzed. Nutritional status was evaluated by the Psoas Muscle Index (PMI), which was calculated using psosas muscle area at the L3 level adjusted by height (cm²/m²).

Results: A total of 134 patients had NCT results. The mean age was 56.93(±9.598) years, and 99 (73.9%) were males. HBs Ag was positive in 43 patients (32.1%), and Anti-HCV was positive in 21 patients (15.7%). Hepatocellular carcinoma was diagnosed in 49 patients (26.6%) and liver cirrhosis in 85 patients (63.4%). The baseline NCT was 47.12 (±18.241), the MELD score was 7.74 (±6.579), and the PMI was 3.57 (±5.075). The NCT baseline was associated with age (r =-0.514, P <0.0001), MELD (r =0.519, P =0.010), and PMI (r =-0.272, P =0.002), respectively. PMI was statistically associated with NCT in both LC (r =-0.230, P=0.034) and HCC (r =-0.432, P<0.002) patients. As a result of multiple regression analysis, the regression coefficients were revealed as age: 0.964 (P<0.0001), MELD: 0.519 (P<0.010), and PMI: -2.780 (P<0.026), respectively.

Conclusion: The nutritional status of chronic liver disease was significantly associated with cognitive function.

Abstract Submission No. 100734
P-0861

The Comparison of PEG 3350 and Lactulose Use for Hepatic Encephalopathy Management: an EBCR

Iqbal Taufiqurrachman1,2, Czresna Heriawan Soejono2

1Pondok Indah Hospital, Jakarta, Indonesia Jakarta Indonesia, 2Geriatric Division, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital Jakarta Indonesia

A 68-year-old male patient with liver cirrhosis was admitted to the ER with altered consciousness and diagnosed with hepatic encephalopathy (HE). The lactulose was given. Hepatic encephalopathy is caused by the increase of ammonia levels and neurotransmitters. Inhibiting ammonia absorption with lactulose is the current management for hepatic encephalopathy. However, PEG (Polyethylene Glycol) 3350 is considered to have a role in HE management. The article search from five sources of articles was done with the keywords: “(((hepatic encephalopathy) AND polyethylene glycol 3350) OR PEG 3350) AND lactulose) AND hepatic encephalopathy scoring algorithm) OR HESA”. A study that compared the use of PEG 3350 and lactulose in HE management showed that the HESA (hepatic encephalopathy scoring algorithm) score improved more rapidly in the PEG 3350 group with a relative risk (RR) of 1.61, absolute relative risk (ARR) of 0.32, relative risk reduction (RRR) of 0.615, and number needed to treat (NNT) of 3.125. PEG 3350 can increase the fecal excretion of ammonia compared to lactulose. In addition, the mild metabolic acidosis effect of PEG 3350 can increase the level of NH₄ and lower the level of NH₃, a compound that can bypass the blood-brain barrier. However, because of the high amount of PEG that needed to be given (4 liters of PEG in 4 hours), lactulose use (only 20-30 grams or 30-45 mL) is more...
feasible. In conclusion, the use of PEG 3350 for improving HESA in HE patients is more potent than lactulose, but it lacks of practical feasibility.

Abstract Submission No. 100791
P-0862

A novel tool for the treatment of liver cirrhosis and hypertension: wearable technologies

Manvendra Singh1, Deepika Singh2
1HMFA-MIET Handia India, 2SHUATS Allahabad India

Introduction: A common and significant cause of death in India is liver cirrhosis, along with hypertension. Heart rate monitoring, cardiovascular identification and liver problems, and access to health-related data are all features of modern wearable smartwatches. The present study examines that patients would wear and keep wearable smart watches on a regular basis, as well as would effectively collect and transmit sensor data, we conducted a feasibility study in this study.

Method: About 135 individuals with liver cirrhosis and hypertension participated for the current study. Every patient was given a set of wearable technology, and information was collected via questionnaires, audio recordings, physical activity, acceleration, and heart rate. A variety of methods were employed to collect data on relevant adherence factors, including life questionnaires on quality health-related aspects, examinations of cardiovascular health, and the Scale Compliance on Hypertensive.

Result: Of the 135 patients with liver cirrhosis and hypertension, 110 underwent the research, used the wearable watches on a regular basis and successful. Reduced adherence to lifestyle changes and prescription regimens, and increased overall adherence are significant predictors of compliance, according to the binary logistic regression models. Direct data extraction from the devices yielded the heart rate and accelerometer values. An average day of 60.2, 61.3, and 58.2 was reported for secondary findings such as heart rate, physical activity, and questionnaire survey.

Conclusion: According to our hypothesis, people who have liver cirrhosis and hypertension wear and utilize the wearable device on a regular basis and provide this technology positive feedback.

Abstract Submission No. 100809
P-0863

Specialist nurse-led ‘stable cirrhosis’ clinics in a UK hospital – enabling service development

Fenella Marley1, Ankur Srivastava1, Katharine Caddick1, James Maurice1, Talal Valliani2
1Department of Gastroenterology and Hepatology, Southmead Hospital, North Bristol NHS Trust Bristol United Kingdom, 2Australian National Liver Transplant Unit, Royal Prince Alfred Hospital Sydney Australia

Background: In our unit, patients with stable cirrhosis are seen in a specialist nurse-led clinic if they have Child-Pugh A disease, no hospital admissions in the preceding year and have had a senior medical review.

Methods: This was a retrospective analysis of patients reviewed in the clinic from January 2017 to December 2017. Medical notes and blood tests were reviewed for the three-year period from the point of referral.

Results: Over 3 years, 56 patients were referred to the clinic. Alcohol-related liver disease (ARLD) (34%) and NAFLD (34%) were the most common aetiologies. Over the 3-year period, 37 patients (66%) remained in the clinic whilst 19 patients (34%) left. Reasons included death (11%), repeated non-attendance (37%) and decompensation of liver disease (32%). The mean time for departing from clinic was 17 months and median time was 21 months. Overall, 11% of patients referred to the clinic decompensated (requiring hospitalisation/consultant-led care). Rate of decompensation has previously been shown to be 11.8% per year in a UK cohort study (1).

Of non-attenders, 71% had ARLD, whilst 67% of decompensations had a background of ARLD. 50% of patients who decompensated required hospital admission. Mean time from referral to decompensation was 16 months.

Conclusions: This analysis demonstrates the effectiveness of a specialist nurse-led clinic in managing compensated cirrhosis patients. Patients can be seen in a timely fashion, and the clinic facilities increased capacity in medical-led clinics. The strategy is likely to be cost-effective. We also demonstrated a lower rate of decompensation than previously seen.

Abstract Submission No. 100888
P-0864

Simvastatin in Treatment and Reducing Events of Decompensation in Liver Cirrhosis: A Meta-Analysis

Miguel Jemuel Cabusas1, Nicole Ferrer1, Ian Homer Cua1
1St. Luke's Medical Center - Global City Taguig City Philippines

Background: Liver cirrhosis represents a late stage of progressive hepatic fibrosis with most deaths being secondary to decompensation and evolution of portal hypertension. Since disease progression reversal is hardly attainable, it is essential to intervene early with a therapeutic agent that could reduce disease evolution. There are studies coming out about statins being beneficial in patients with liver cirrhosis, in which they are showed to have modest direct effect in lowering portal vein blood pressure from vasodilatory properties. This will be explored in our study.

Methods: A systematic review and meta-analysis was done using randomized control trials who applied patients aged 18-75 years old with known liver cirrhosis with portal hypertension using Simvastatin as therapy. Decrease in levels of HVPG post treatment was used as marker for improvement.

Results: There was significant difference in HVPG levels and liver function among patients with liver cirrhosis who had adjunct use of simvastatin vs. standard treatment. Visual inspection of the forest plot appears to favor use of simvastatin in improving liver function in patients with liver cirrhosis. A moderate heterogeneity was also observed using the fixed effect model.

Conclusion: While earlier data depict statins to have harmful effects in the liver, evidence, as shown in this paper, suggest that there is positive impact in reducing events of decompensation and portal hypertension. Combining this knowledge with our long track-record of safety and tolerability of statins, we might soon rely on statins to achieve better outcomes in patients with liver cirrhosis without significant additional costs.

Abstract Submission No. 100953
P-0865

Impact of the growth hormone-insulin like growth factor on complications and prognosis in cirrhosis
PARMINDER KAUR1, Nipun Verma1, Aishani Wadhawan1, Pratibha Garg2, Swati M. Raval3, Naveen Kalra4, Abhimanyu Bali5, Sahaj Rathi1, Arka De1, Madhumita PremKumar1, Sunil Taneja1, Ajay Duseja1, Virendra Singh1

1Department of Hepatology, Postgraduate Institute of Medical Education and Research Chandigarh India, 2Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research Chandigarh India

Background: This study evaluated the impact of growth hormone–insulin-like growth factor (GH-IGF1) axis on sarcopenia, frailty, autonomic neuropathy, and the prognosis in decompensated cirrhosis patients.

Methods: Adult stable decompensated cirrhosis out-patients recruited at a tertiary care institute between 2021-2023 were subjected to the estimations of serum GH-IGF1, sarcopenia, frailty, autonomic dysfunction, clinical decompensations, and survival.

Results: 150 patients, 95% males with a mean age of 45.5±9.86 years, with ascites (grade-I: 30%, grade-II: 47.3%, grade-III: 19.3%), HE (grade-I: 5.4%, grade-II: 2%), MELD-Na of 15.4(IQR:11.9-18.6), and CTP of 8(7-9) (CTP A-11.3%, CTP B-64.7%, CTP C-24%) were recruited. Sarcopenia, frailty, and autonomic neuropathy were noted in 64.7%, 25%, and 29% patients.

IGF-1 levels were significantly reduced in patients with sarcopenia (OR:0.15; p=0.021), negatively associated with liver frailty index (β=-0.453), severity of autonomic neuropathy (β=-0.11), MELD (β=-4.74), and CTP (β=-1.92) (p<0.05, each). Three-month survival was significantly lower in patients with low IGF-1 levels (79%; with IGF-1<28.1ng/ml) than those with intermediate (93%; IGF-1 28.1-58.7ng/ml) and high (97%; IGF-1>58.7ng/ml) IGF-1 levels (p<0.001).

Both IGF-1 and MELD predicted 3-month mortality with an AUC of 0.732 (p<0.001). GH levels were not associated with sarcopenia, frailty, autonomic dysfunction, MELD and survival.

Conclusion: Reduced IGF-1 levels are associated with sarcopenia, frailty, autonomic dysfunction, increased severity, and mortality in stable decompensated cirrhosis. Modulation of GH-IGF1 axis is a potentially disease modifying target in cirrhosis.

Abstract Submission No. 100961
P-0866

Recurrence of portosystemic encephalopathy in cirrhotic patients and its risk factors

Zahabia Sohail1, Masood Karim2, Abdullah Khalid1

1The Aga Khan University Karachi Pakistan

Objectives: Recurrent episodes of Portal Systemic Encephalopathy (PSE), poses a significant burden of illness on the patients and healthcare system. The objective of this study was to assess the recurrence of PSE in cirrhotic patients after index episode of PSE and to identify various risk factors associated with it.

Methods: A retrospective, single-centre study was conducted at Aga Khan University Hospital over a span of one year. Patients who were admitted first time with PSE and admitted within three months of index PSE were enrolled in the study. Variables assessed were demographic data, associated comorbid conditions, aetiology of cirrhosis, Child-Turcotte-Pugh (CTP) score, Model of End-Stage Liver Disease (MELD) score, PSE grade, laboratory tests, ascites with spontaneous bacterial peritonitis (SBP), variceal bleeding. Statistical analysis was done and variables of those who developed recurrence were compared with those who did not.

Results: Fifty one patients were recruited. Thirty three (64.7%) were readmitted with PSE. On comparative analysis of both groups; infection, Meld score, low albumin, and raised total bilirubin showed significant P-value (<0.05)

Conclusion: Identification of risk factors during assessment can reduce the recurrence of PSE. We would recommend to validate result of our study on a large scale prospectively.

KEYWORDS: Portosystemic Encephalopathy, Risk Factors, Recurrence

Abstract Submission No. 101029
P-0868

Impaired endothelial integrity and density of mucosal vessels in the small intestine of cirrhotics

IOANNIS VLACHOGIANNAKOS1, Theodoros Voulgaris1, Dina Tiniakos2, Dimitrios Karagiannakis1, Despoina Karandrea2, Spiillos Manolakopoulos1, Giorgos Papatheodoridis1

1Academic Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens Athens Ελλάδα,2Dept. of Pathology, Aretaieion Hospital, Medical School, National
and Kapodistrian University of Athens Athens Greece. 2nd Academic Department of Internal Medicine, General Hospital of Athens “Hippokration”, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

**Background/Aim:** Disruption of endothelial integrity in small intestinal mucosal vessels is possibly correlated with the translocation of antigens to the portal circulation. Decreased ZO-1 expression may contribute to the impaired endothelial integrity.

**Methods:** We enrolled 63 cirrhotics (M/F:35/28, mean age±SD:62±13). Nine non-cirrhotics served as controls. Small intestine biopsy samples were taken during endoscopy and endothelial ZO-1 expression was assessed by indirect streptavidin biotin peroxidase method.

**Results:** Thirty-four (54%) had compensated and 29 (46%) decompensated cirrhosis. Child-Turcotte-Pugh (CTP) classification was A:46/B:14/C:3. Mean±SD MELD score was 10.5±3.7. CTP-A patients had increased number of mucosal vessels per x20 optical field compared to controls (3.8±1.1 vs 3.2±0.9, p=0.048) as also compared to CTP-B (3.8±1.1 vs 3.2±0.7, p=0.045). A negative correlation was observed between the number of mucosal vessels and CTP score (r: -0.428, p=0.016). Loss of endothelial ZO-1 staining in more than 50% of vessel perimeter or total loss of ZO-1 staining across vessel perimeter, in more than 50% of vessels was observed more frequently in cirrhotic samples (42/63, 66.6%) compared to controls (1/9, 11.1%, p=0.001).

**Discussion:** Increased loss of endothelial ZO-1 expression was found in the small intestine of cirrhotic patients. We also observed an increase of vessel numbers in patients with CTP-A compared to controls and to CTP-B patients. We believe that bacterial translocation mechanisms in cirrhosis are not confined to the intestinal lumen and merit further investigation.

Abstract Submission No. 101084

P-0869

**Carnitine deficiency and improvement of symptoms by administration of carnitine in patients with LC**

Naoki Hotta

1masuko memorial hospital JAPAN Japan

**Context:** In recent years, there are reports that L-carnitine is useful in improvement of hyperammonemia and cognitive function in patients with liver cirrhosis, and of muscle symptoms in dialysis patients. We measured carnitine levels in patients with liver cirrhosis including dialysis patients, and examined whether administration of L-carnitine improved muscle symptoms.

**Methods:** We measured carnitine levels in 19 patients with liver cirrhosis (Child-pugh classification A/B/C=10/5/4) who were receiving treatment in our hospital, and administered L-carnitine (600 mg - 1,800 mg) to patients having muscle cramps for approximately one month and examined the presence/absence of the symptom.

We measured carnitine concentration before and after the administration to 12 patients. In addition, we examined the presence/absence of symptom after the administration of L-carnitine in symptomatic patients.

**Results:** Patients, the total carnitine levels were significantly increased from 71.7μmol/L to 101.7μmol/L after the administration of L-carnitine (p<0.05). In a total of 19 patients, muscle cramps existed in 14 patients (74%). For symptomatic patients, significant improvement of muscle clamps was observed in the L-carnitine administrated group when compared with the non-administrated group (p=0.0002).

**Conclusions:** Administration of L-carnitine increased the total carnitine levels and improved the symptom. Based on these results, we conclude that L-carnitine is useful for carnitine deficiency in patients with liver cirrhosis.

Abstract Submission No. 101087

P-0871

**Carnitine before and after in patients with ascites and LC and improvement by intravenous**

Naoki Hotta

1masuko memorial hospital JAPAN Japan

**Context:** In recent years, there are reports that L-carnitine is useful in improvement of hyperammonemia and cognitive function in patients with liver cirrhosis, and of muscle symptoms in dialysis patients. We measured carnitine levels in patients with liver cirrhosis including dialysis patients, and examined whether administration of L-carnitine improved muscle symptoms.

**Methods:** We measured carnitine levels in 19 patients with liver cirrhosis (Child-pugh classification A/B/C=10/5/4) who were receiving treatment in our hospital, and administered L-carnitine (600 mg - 1,800 mg) to patients having muscle cramps for approximately one month and examined the presence/absence of the symptom.

We measured carnitine concentration before and after the administration to 12 patients. In addition, we examined the presence/absence of symptom after the administration of L-carnitine in symptomatic patients.

**Results:** Patients, the total carnitine levels were significantly increased from 71.7μmol/L to 101.7μmol/L after the administration of L-carnitine (p<0.05). In a total of 19 patients, muscle cramps existed in 14 patients (74%). For symptomatic patients, significant improvement of muscle clamps was observed in the L-carnitine administrated group when compared with the non-administrated group (p=0.0002).

**Conclusions:** Administration of L-carnitine increased the total carnitine levels and improved the symptom. Based on these results, we conclude that L-carnitine is useful for carnitine deficiency in patients with liver cirrhosis.

Abstract Submission No. 101087

P-0871
**Introduction:** Recently, carnitine has been reported to be useful for improving blood ammonia and cognitive function in cirrhotic patients with subclinical hepatic encephalopathy in Japan.

**Method:** Total carnitine concentration was measured in 5 cirrhotic patients undergoing ascites drainage during our hospital ambulatory, and after ascites drainage, intravenous administration of ercarnitine was conducted to examine whether or not the symptoms improved. drainage.

**Case presentation:** In a patient with liver cirrhosis, improvement of hepatic encephalopathy associated with decreased carnitine level and decreased ammonia were reported, and deterioration of muscle symptoms associated with carnitine deficiency in a dialysis patient was also reported. Therefore, Carnitine concentration and acylcarnitine/free carnitine ratio were measured in this patient, and administration of ercarnitine preparation was started. Carnitine concentration 1 month after administration of carnitine was increased in all cases, and the ratio of acylcarnitine/free carnitine was also decreased (0.388 to 0.253). one patient is currently hospitalized and discharged from the hospital after drainage of ascites. Ascites drainage was performed once or twice a week. Carnitine administration after ascites drainage increased the carnitine level without cramping or general malaise.

**Result:** The total carnitine concentration was within the normal range in the non-dialysis patients, and the concentration of carnitine decreased in the dialysis patients before and after dialysis.

**Conclusion:** The case in which the muscle cramp disappeared in the liver cirrhosis patient with the ercarnitine administration was experienced.

**Conclusions:** We obtained the hub genes of GBE in treating LC. And GBE might exert anti-LC effect by regulating the PI3-AKT and MAPK signaling pathways.

**Impact of endoplasmic reticulum stress on neutrophil extracellular traps in liver cirrhosis**

**Shide Lin**

1 Affiliated Hospital of Zunyi Medical University Zunyi China

**Backgrounds:** The present study aims to investigate the impact of endoplasmic reticulum stress (ERS) on the phagocytic activity and neutrophil extracellular traps (NETs) in patients with liver cirrhosis and acute-on-chronic liver failure (ACLF).

**Methods:** The correlation between ERS and NETs, phagocytic activity in patients with liver cirrhosis and ACLF were studied by in vivo and vitro study.

**Results:** The mRNA and protein of XBP1S, GRP78, ATF4, ATF6a, and CHOP in neutrophils of patients with liver cirrhosis and ACLF were significantly elevated compared to those in the normal control (NC). The level of double-stranded DNA (dsDNA) in neutrophils were significantly elevated in patients with liver cirrhosis and ACLF compared to those in NC ($P<0.05$). The levels of neutrophil elastase (NE) in neutrophils of ACLF were significantly increased compared to those in NC ($P<0.05$). The phagocytic activity in patients with liver cirrhosis and ACLF were significantly decreased compared to that in NC ($P<0.05$). In vitro studies demonstrated that 4-PBA significantly inhibited the expression of XBP1S, GRP78, ATF4, CHOP, and ATF6α in neutrophils of NC induced by TG ($P<0.05$). Moreover, 4-PBA significantly inhibited the expression of NE and CitH3 induced by TG ($P<0.05$) and increased the phagocytic activity of neutrophils ($P<0.05$).

**Conclusion:** In patients with liver cirrhosis and ACLF, neutrophils had significant ERS, reduced phagocytic function and increased NETs. The ERS is involved in increased release of NETs and decreased phagocytic function in neutrophils in patients with liver cirrhosis and ACLF.

**Network pharmacology analysis of Ginkgo biloba extract in treating liver cirrhosis**

**Tingyu Zhang**$^{1,2}$, **Xu Cao**$^{1,2}$, **Xin Sun**$^{1,2}$, **Xiaoke Li**$^{1,2}$, **Xiaobin Zao**$^3$

$^1$Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine Beijing China, $^2$Institute of Liver Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, $^3$Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China

**Background:** Liver cirrhosis (LC) has been a seriously threaten the public health. Ginkgo biloba extract (GBE), a long-standing and well-used medicine, has been widely used to treat cirrhosis diseases. Here, we aimed to explore the mechanism of GBE in the treating LC.

**Methods:** We first obtained target genes of GBE and LC from public databases. Then we constructed a protein-protein interaction network of the key targets and screened out the hub genes. The LC rat model was constructed by intraperitoneal injection of diethylnitrosamine. The hub genes’ expression was further verified in the LC rats’ liver tissues with RNA-sequencing approach. Finally, we performed the pathway enrichment analysis of the key targets and hub genes.

**Results:** After database mining, we obtained 368 overlapped genes between GBE’s targets and LC’s targets. These overlapped genes were further used to construct PPI network and screen the hub genes. With the rat LC model, we next detected the mRNA expression of the hub genes in the liver tissues. And the results showed that compared with the control, the expression of MAPK14, EGFR, and NR3C1 was significantly down regulated in LC; while the expression of AR, CASP3, and CCND1 was just the reverse. In the last, the KEGG pathway enrichment analysis results showed that the key targets and hub genes were significantly correlated to the PI3-AKT and MAPK signaling pathways.

**Abstract Submission No. 101103**

**P-0872**

**Network pharmacology analysis of Ginkgo biloba extract in treating liver cirrhosis**

**Abstract Submission No. 101138**

**P-0874**

**Association between gut microbiota and glucose metabolism disorders**

**Shide Lin**

1 Affiliated Hospital of Zunyi Medical University Zunyi China

**Background:** The purpose of this study was to explore the association between gut microbiota and glucose metabolism disorders in patients with liver cirrhosis (LC).

**Methods:** The gut microbiota were detected by 16s rRNA gene sequencing in 80 patients with LC. Oral glucose tolerance test (OGTT) was performed to evaluate glucose metabolism disorders. The association of gut microbiota with glucose metabolism disorders was analyzed.

**Results:** The richness of gut microbiota was significantly lower in patients with liver cirrhosis patient with the ercarnitine administration was experienced. The total carnitine concentration was measured in 5 cirrhotic patients undergoing ascites drainage during our hospital ambulatory, and after ascites drainage, intravenous administration of ercarnitine was conducted to examine whether or not the symptoms improved. drainage.

**Conclusions:** We obtained the hub genes of GBE in treating LC. And GBE might exert anti-LC effect by regulating the PI3-AKT and MAPK signaling pathways.

**Abstract Submission No. 101113**

**P-0873**

**Impact of endoplasmic reticulum stress on neutrophil extracellular traps in liver cirrhosis**

**Shide Lin**

1 Affiliated Hospital of Zunyi Medical University Zunyi China

**Backgrounds:** The present study aims to investigate the impact of endoplasmic reticulum stress (ERS) on the phagocytic activity and neutrophil extracellular traps (NETs) in patients with liver cirrhosis and acute-on-chronic liver failure (ACLF).

**Methods:** The correlation between ERS and NETs, phagocytic activity in patients with liver cirrhosis and ACLF were studied by in vivo and vitro study.

**Results:** The mRNA and protein of XBP1S, GRP78, ATF4, ATF6α, and CHOP in neutrophils of patients with liver cirrhosis and ACLF were significantly elevated compared to those in the normal control (NC). The level of double-stranded DNA (dsDNA) in neutrophils were significantly elevated in patients with liver cirrhosis and ACLF compared to those in NC ($P<0.05$). The levels of neutrophil elastase (NE) in neutrophils of ACLF were significantly increased compared to those in NC ($P<0.05$). The phagocytic activity in patients with liver cirrhosis and ACLF were significantly decreased compared to that in NC ($P<0.05$). In vitro studies demonstrated that 4-PBA significantly inhibited the expression of XBP1S, GRP78, ATF4, CHOP, and ATF6α in neutrophils of NC induced by TG ($P<0.05$). Moreover, 4-PBA significantly inhibited the expression of NE and CitH3 induced by TG ($P<0.05$) and increased the phagocytic activity of neutrophils ($P<0.05$).

**Conclusion:** In patients with liver cirrhosis and ACLF, neutrophils had significant ERS, reduced phagocytic function and increased NETs. The ERS is involved in increased release of NETs and decreased phagocytic function in neutrophils in patients with liver cirrhosis and ACLF.
Association of hepatogenous diabetes with minimal hepatic encephalopathy in liver cirrhosis

Shide Lin³

1Affiliated Hospital of Zunyi Medical University Zunyi China

Objective: Hepatogenous diabetes (HD) and minimal hepatic encephalopathy (MHE) are common complications in patients with liver cirrhosis. The purpose of this study is to study the association of HD with MHE in patients with liver cirrhosis.

Methods: 134 patients were prospectively included. Oral glucose tolerance test (OGTT) was used to diagnose HD. Traditional neuropsychological tests and new neuropsychological tests and animal naming tests were used to diagnose MHE.

Result: 1. Among 134 patients with liver cirrhosis, 36 (26.9%) patients had HD and 65 (48.5%) patients had MHE. Patients with HD had significantly higher levels of total bilirubin, MELD score, total bile acid, aspartate aminotransferase/alanine aminotransferase (AAR) ratio, liver fibrosis score 4 (FIB-4) index, and significantly lower level of hemoglobin (Hb) than those without HD (P<0.05); Patients with HD had significantly older age and higher levels of fasting insulin, aspartate aminotransferase/alanine aminotransferase (AAR) ratio, liver fibrosis score 4 (FIB-4) index, and significantly lower level of hemoglobin (Hb) than those without MHE (P<0.05); Among 36 patients with HD, 23 patients (63.9%) had MHE, which was significantly higher than that (42.9%) of 98 patients without HD (P<0.05). Multivariate logistic analysis showed that HD (OR=2.388, 95% CI: 1.021-5.856), AAR ratio (OR=2.09, 95% CI: 1.053-3.832), and Hb (OR=0.981, 95% CI: 0.966-0.996) were independent risk factors for MHE.

Conclusion: The incidence of HD and MHE in patients with liver cirrhosis increases with the severity of liver injury. HD, higher AAR ratio and lower Hb are independent risk factors for MHE in patients with liver cirrhosis.
Improving the Uptake of Advance Care Planning in Patients with Decompensated Liver Cirrhosis

Chung Yau Nah1, Kalaiyarasi Kaliyaperumal2

1Woodlands Health Singapore Singapore, 2Tan Tock Seng Hospital Singapore Singapore

Advance care planning (ACP) is essential in the care of patients with liver cirrhosis. However, its uptake remains low and variable. A Quality Improvement Project was performed, targeting patients with decompensated liver cirrhosis presenting for their regular abdominal paracentesis and/or intravenous albumin infusion. A two-step intervention was implemented. The first step involved administration of a brochure containing information on ACP to the patient at registration, with a brief explanation on what ACP is and instructions to read the brochure during therapy. The second step involved a Hepatology nurse educating the patient on cirrhosis with simple pictorial aids, while the patient was undergoing therapy. This was followed by the showcase of a short video depicting an interview of an actual ACP participant, and verbal counselling on its importance. The study was performed over three months. The “Plan-Do-Study-Act” methodology was used to refine the intervention.

In the preceding three months pre-intervention, 3 out of 18 patients had prior ACPs. After the intervention, 12 out of 19 patients agreed to participating in the ACP discussion, while 3 patients had prior ACPs. This increased the percentage of eligible patients with ACPs from 17% to 78% in 3 months. Patients interviewed after shared that the intervention was effective, and the order of the interventions was logical. As of August 2023, 26 out of 37 eligible patients have agreed to ACP discussion.

Our two-step intervention is effective in increasing ACP uptake amongst patients with decompensated cirrhosis, and may be considered for adoption on a larger scale.

Clinical Performance of Serum ELF levels on Predicting LC in Patients with CHB

Hyunjoon Park1, Kwang Il Seo1, Sang Uk Lee1, Byung Cheol Yun1, Jung Wook Lee1, Jun Yeb Nam1, Bang Ju Kim1

1Department of Internal Medicine, Kosin University College of Medicine Busan South Korea

Background/Aim: The Enhanced liver fibrosis (ELF) is known as a serological biomarker for predicting liver fibrosis. However, there was lack of data to evaluate the clinical performance of the serum ELF levels on predicting liver cirrhosis (LC) in Korean patients with chronic hepatitis B (CHB).

Methods: We reviewed medical records for 312 patients with CHB who were performed serum ELF levels in Kosin University Hospital from September 2020 to August 2022. Exclusion criteria were co-infection with chronic hepatitis C, significant alcohol intake, malignancy except hepatocellular carcinoma, and inadequate data. Multivariate logistic regression analysis was performed to identify independent predictors for diagnosing LC. The diagnostic accuracy of serum ELF levels for predicting LC was compared to that of other fibrosis markers, FIB-4 and APRI using ROC.

Results: The mean (±SD) of age of study patients was 62.1 (±10.9) years and the proportion of male was 73.4%. 209 (67.0%) patients were diagnosed with LC. The mean (±SD) of serum ELF levels showed significant differences between LC group (11.3±1.51) and non-LC group (10.2±1.63) (P<0.001). (Table 1) Adjusting for age, gender, platelet count, albumin, INR, and sodium, serum ELF levels was an independent predictor of LC [adjusted odds ratio (OR): 1.40, 95% confidence interval (CI) 1.17-1.68, P<0.001]. The area under the curve of serum ELF level for prediction of LC (0.700) was comparable to that of FIB-4 (0.763) and APRI (0.708), respectively. (P <0.001) (Fig. 1) The cut-off value of serum ELF that maximized the sum of sensitivity (73.2%) and specificity (62.1%) was 10.2.

Conclusion: Serum ELF levels would be a reliable non-invasive marker for diagnosing LC in Korean patients with CHB.
Serum C-Reactive Protein Predicts Early Mortality in Patients with Decompensated Cirrhosis

Md Islam1, kazi Hossain1
1Sheikh Russel National Gastroliver Institute Dhaka Bangladesh

Background: Serum C-reactive protein is a marker of systemic inflammation, which has been studied to predict mortality in cirrhosis

Objectives: To evaluate the role of serum C-reactive protein as a predictor of early mortality in patients with decompensated cirrhosis.

Materials and methods: This was a prospective observational study, carried out in the Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Patients were compared of CRP level, CTP score, MELD score and cirrhosis related complications. Receiver-operator characteristic curve was used to detect serum CRP level for prediction of mortality within 30 days.

Results: Total WBC count, serum CRP, serum sodium, bilirubin, CTP score & MELD score were statistically significant (p < 0.05) between the groups. In multivariate analysis, only serum CRP level (OR 1.075, 95% CI, 1.027-1.122%, p = 0.001) was found significantly associated with mortality within 30 days. Receiver-operator characteristic (ROC) was constructed, using serum CRP level, which gave a cut off value of 31mg/L, with 78% sensitivity and 90% specificity for prediction of mortality within 30 days.

Conclusion: Elevated serum CRP level is an independent predictor of early mortality in patients with decompensated cirrhosis of liver.

Abstract Submission No. 101297
P-0882

The long term efficacy of Rifaximin for overt and non-overt hepatic encephalopathy.

Katsunori Komyo1, Hajime Sunagoroka1, Satomi Kishi1, Takaumi Nakagawa1, Kohei Yashuda1, Hirokazu Hira1, Ryoei Ugaji1, Yoshihide Naito1, Kenkei Hasatani1, Jun Yoshikawa1, Hiroyuki Aoyagi1
1Fukui Prefectural Hospital Fukui Japan

Background: Rifaximin (RFX) improve on overt hepatic encephalopathy. However, the efficacy of long-term RFX administration for non-overt hepatic encephalopathy and have remain unclear. In this study, we compared the clinical outcomes of RFX for overt and non-overt hepatic encephalopathy.

Methods: We enrolled 72 patients with hepatic encephalopathy for whom RFX was newly introduced between January 2018 and December 2022. We retrospectively examined (1) patient backgrounds, (2) concomitant drugs, (3) opportunities for administration of RFX, and (4) early and long-term (4/12weeks) efficacy of RFX.

Results: Of the 72 patients, 60 patients who could take RFX for more than one month were included in this analysis. Background liver diseases were nutritional in 33, viral in 10, autoimmune in 7, and other in 10 cases. Regarding the opportunities for RFX administration, 37 cases had overt encephalopathy. On the other hand, the opportunities for administration in non-overt encephalopathy was hyperammonemia alone in 12, amnesia in 5, intolerance diarrhea due to disaccharides in 4, respectively. The number of taken tablets before/after administration of RFX were 15.5±5.2 / 21.1±5.2 tablets/day, and the patients were advanced polypharmacy states.

The ammonia levels were significantly reduced after 4 and 12 weeks (P<0.001). Comparing between overt and non-overt encephalopathy cases, after the administration of RFX, the period until readmission due to encephalopathy tended to be prolonged in the non-overt encephalopathy group (P=0.051).

Conclusion: RFX significantly reduced ammonia levels even with long-term administration. The early administration of RFX for non-overt hepatic encephalopathy could prolong the period until readmission.

Abstract Submission No. 101376
P-0883

Enhancing Bioavailability of Furosemide for the Management of Liver Cirrhosis

Pankajkumar Yadav1
1SHUATS Prayagraj India

Objective: The objective of this study was to enhance the bioavailability of furosemide (FURO), an antihypertensive loop diuretic used in the management of liver cirrhosis, by improving its water solubility, permeability, and absorption after oral administration. To achieve this aim, a novel drug delivery system, Self Nano Emulsifying Drug Delivery System (SNEDDS), was employed.

Methods: Various oils, surfactants, and co-surfactants were tested to determine their ability to improve the solubility of FURO. The self-emulsification region was identified using pseudoternary diagrams, and SNEDDS formulations were developed accordingly. The formulations were characterized using zeta potential determination, droplet size analysis, dilution test, viscosity determination, in vitro dissolution studies, and in vivo pharmacodynamic evaluation.

Results: Mean droplet size of the optimized formulation was found to be 26.8 nm. In vitro performance of the optimized preparation was satisfactory as observed by various analyses such as dilution test, emulsification time, and precipitation assessment. In vitro dissolution studies exhibited that the optimized SNEDDS formulation F3 exhibited a 1.7 fold increase in dissolution efficiency as compared to plain FURO and marketed formulations. In vivo studies showed enhanced bioavailability of F3 in terms of diuretic efficacy.

Conclusion: The study confirms the potential use of SNEDDS formulation as an alternative to traditional oral formulations of FURO to enhance its bioavailability in the management of liver cirrhosis.

Abstract Submission No. 101464
P-0884

The prognostic value of high-density lipoprotein cholesterol in patients with hepatic encephalopathy

Ke Shi1, Xianbo Wang1
1Beijing Ditan Hospital, Capital Medical University Beijing China

Background: Overt hepatic encephalopathy (OHE) is a serious complication of liver cirrhosis that impacts lipid and lipoprotein metabolism. We aimed to determine the relationship between high-density lipoprotein cholesterol (HDL-C) and transplant-free (TF) mortality in patients with OHE.

Methods: We identified 821 patients with OHE at Beijing Ditan Hospital between January 2010 and August 2016. A multivariate regression analysis was performed to indentify the independent risk factors associated with TF-mortality, and the area under the receiver operating characteristic curve (AUC) was used to assess the prognostic values of
these factors. One-year TF mortality was analyzed using the Kaplan-Meier method and compared using the log-rank test. All the results were confirmed in a prospective cohort (n=480).

**Results:** Patients with OHE who died were more likely to have lower HDL-C levels than those who survived. The prognostic value of HDL-C was good (AUC at 1 year: 0.745) and was similar to the Model for End-Stage Liver Disease (MELD) score (AUC at 1 year: 0.788). In the validation set, the HDL-C showed AUC values similar to those of MELD at 1 year (0.724 vs. 0.724). The optimal cutoff value of HDL-C and MELD were 0.5 mmol/L and 17, respectively. The 1-year TF mortality rates in the low-risk (HDL-C ≥ 0.5 mmol/L and MELD <17) and high-risk (HDL-C < 0.5 mmol/L and MELD ≥17) groups were 7.5 and 51.5% in the training set, and 10.1 and 48.2% in the validation set, respectively.

**Conclusions:** HDL-C is closely linked with 1-year TF mortality in patients with OHE. HDL-C < 0.5 mmol/L and MELD >17 can facilitate identification of high-risk patients and therefore provide timely treatment and care.

---

**Study of sleep patterns in patients with liver cirrhosis/chronic liver disease.**

**Hafsa Dayo**

1Dow University of Health Sciences, Karachi, Pakistan. Karachi Pakistan

**BACKGROUND:** Chronic liver disease is an important cause of morbidity and mortality in general population across our country. Sleep disturbances have been reported in patients with hepatic cirrhosis. Therefore this study aimed to investigate sleep patterns in these patients to help optimize their overall health outcomes.

**METHOD:** A descriptive cross sectional study was conducted in a tertiary health care hospital. A total of 50 patients diagnosed with CLD were included in the study and their sleep patterns were carefully analysed. Demographic profile was documented, structured questionnaire and Pittsburgh Sleep Quality Index Scale (PSQI) were used for sleep pattern and quality assessment.

**RESULTS:** Findings revealed distinct sleep disturbances among these patients, with varying prevalence rates. Among the participants 12% reported experiencing constant drowsiness indicating a significant level of day time sleepiness and fatigue. Moreover 26% of the patients exhibited sleep reversal, leading to sleep during day time hours and wakefulness at night. Furthermore, a substantial portion of participants, 42% reported experiencing insomnia.

**CONCLUSION:** According to the PSQI scale, 96% of the patients experienced poor sleep (score >5) and only 4% of the patients had good sleep (score <5). These results confirm that majority of patients with DCLD experience sleep disturbances. Insomnia being the dominant pattern of disturbed sleep. Further research is warranted to explore the underlying mechanisms of sleep disturbances in DCLD and to develop tailored approaches to address this significant aspect of patient care.

---

**VWF/ADAMTS13 ratio is a useful marker for ACLF onset and prognosis in patients with liver cirrhosis.**

**Tadashi Namisaki**1, Shohi Asada1, Akihiko Shibamoto1, Satoshi Iwai1, Junya Suzuki2, Kosuke Kaji2, Hiroaki Takaya1, Hitoshi Yoshiji1

1Nara medical university Kashiwara Japan

**Aim:** Acute-on-chronic liver failure (ACLF) is associated with a high risk of shortterm mortality after progression to multiple organ failure. A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF). An imbalance between ADAMTS13 enzyme and VWF substrate is associated with liver cirrhosis progression that induces ACLF. This study examined the relationship between ADAMTS13 and VWF and ACLF development to determine whether ADAMTS13 and VWF are useful predictive biomarkers for ACLF development and prognosis of patients with liver cirrhosis.

**Methods:** The study enrolled 67 patients with Child–Pugh class A and B liver cirrhosis. ADAMTS13 activity (ADAMTS13:AC) and VWF antigen (VWF:Ag) were measured using enzyme-linked immunoassorbent assays. The ratio of VWF:Ag to ADAMTS13:AC (VWF:Ag/ADAMTS13:AC) was used to divide patients into two groups according to the classification and regression tree based on Gray model survival analysis.

**Results:** Compared with patients with Child–Pugh class A liver cirrhosis, class B patients had a higher VWF:Ag/ADAMTS13:AC and a higher risk of ACLF development. Cumulative incidence of ACLF was significantly higher in patients with high (>7.9) versus low (≤7.9) VWF:Ag/ADAMTS13:AC (hazard ratio [HR], 6.50; 95% CI, 2.31–18.29; p < 0.001). Cumulative survival was significantly lower in cirrhotic patients with high versus low VWF:Ag/ADAMTS13:AC (HR 5.11; 95% CI, 1.85–14.14; p = 0.002).

---

**Validation of MELD scores in patients with acute decompensation in alcoholic liver cirrhosis.**

**Jung Hee Kim**1, Jihye Lim2

1Hallym university Dongtan sacred heart hospital Hwasung Si South Korea, 2Yeouido St. Mary’s Hospital Seoul South Korea

The Model for End-Stage Liver Disease (MELD) has long served as a dependable prognostic tool for short-term outcome prediction in patients with end-stage liver disease. Recently, MELD 3.0 was introduced to enhance the accuracy of its predecessors. This study sought to assess the performance of MELD 3.0 in comparison to MELD and MELD-Na in patients with alcoholic liver cirrhosis. This study utilized a multicenter prospective cohort comprising patients with alcoholic cirrhosis who were admitted due to acute deterioration of liver function in the Republic of Korea between 2015 and 2019. The study compared the predictive abilities of MELD, MELD-Na, and MELD 3.0 for 30- and 90-day outcomes, specifically death or liver transplantation. Additionally, the study explored the factors influencing these outcomes.

This study utilized a multicenter prospective cohort comprising patients with alcoholic cirrhosis who were admitted due to acute deterioration of liver function in the Republic of Korea between 2015 and 2019. The study compared the predictive abilities of MELD, MELD-Na, and MELD 3.0 for 30- and 90-day outcomes, specifically death or liver transplantation. Additionally, the study explored the factors influencing these outcomes. All MELD models exhibited strong predictive power for short-term outcomes in patients with alcoholic liver cirrhosis. While MELD 3.0
demonstrated improved performance compared to previous models, the differences were not statistically significant.

Abstract Submission No. 101514
P-0888

Causal role of immunophenotypes in non-autoimmune related cirrhosis: a Mendelian randomization study
Yangjie Li1, Lingna Lyu1, Huiguo Ding1, Qianxi Su2
1Department of Gastroenterology and Hepatology, Beijing You’an Hospital Affiliated to Capital Medical University Beijing China, 2Department of Clinical Laboratory, Seventh Medical Center of Chinese PLA General Hospital Beijing China

Abstract
Background: Complex immune-liver interactions is closely linked to liver disease development. While observational studies have reported positive associations between immune-mediated inflammatory and autoimmune liver disease, the genetic association between these immune cells and non-immune mediated cirrhosis is still divergent.

Methods: Summary Genome Wide Association Study (GWAS) data of non-autoimmune liver disease related cirrhosis and 731 immune cell signatures were obtained from the GWAS Cataloga. Bidirectional Mendelian randomization was performed to determine the causal relationship between immune cells and non-autoimmune liver disease related cirrhosis.

Results: According to inverse variance weighted method, a total of 29 immune cells (p<0.05) were associated with non-immune mediated cirrhosis. Among them, significantly protective causal associations were identified for CD38 on CD20-, BAFF-R on IgD+ CD38dim and BAFF-R on naïve-mature B cell, CM CD88r %T cell, CD28 on CD4+, CD28-CD25++, CD20- %B cell. Furthermore, the expression of CD38 on CD20-, Unsw Mem %lymphocyte, activated Treg %CD4 Treg, secreting Treg %CD4, and SSC-A on DC plasmacytoid were associated with an increased risk of non-immune mediated cirrhosis. In addition, genetically predicted non-immune mediated cirrhosis did not affect the expression of immunophenotypes.

Conclusions: Our findings do support a genetic association between immune cells and non-autoimmune liver disease induced cirrhosis. Immunosuppression and immune escape related immunophenotypes are associated with the liver cirrhosis development. However, larger-scale GWAS summary data and more genetic instruments are needed to confirm these findings.

Abstract Submission No. 101536
P-0890

Oral branched-chain amino acids as a cost-effective option for managing hepatic encephalopathy
Sang Hoon Ahn1, Hankil Lee2, Beom Kyung Kim3
1Yonsei University College of Medicine Seoul South Korea, 2Ajou University Suwon South Korea

Background: Oral branched-chain amino acids (BCAAs) may benefit patients with cirrhosis, especially those with hepatic encephalopathy (HE). We aimed to analyze the cost-effectiveness of BCAAs in improving the prognosis of patients with HE.

Methods: We compared the total costs and effectiveness of oral BCAA treatment (Scenario 1) versus no BCAA supplementation (Scenario 2) in a virtual cohort of 10,000 patients who had experienced HE over a 5-year period. A nested Markov model consisting of four health states (remission, recurrence, stabilization after recurrence, and death) for decompensated cirrhosis was used. Effectiveness was estimated as the cumulative number of HE recurrences and deaths. Additionally, the number of life-years and quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were analyzed. Deterministic and probabilistic sensitivity analyses were also performed.

Results: Oral BCAA treatment prevented 34% of HE recurrences and reduced the number of HE-related deaths by 18%. Although the patients in the BCAA-treated group had spent an additional 4,086 USD on average compared with their counterparts in the non-treated group ($27,088 vs. $23,003), they experienced 0.34 more QALYs (2.77 vs. 2.43) during the 5-year period. The ICER for BCAA treatment was 12,017 USD/QALY, indicating the high cost-effectiveness of the therapeutic option. Moreover, the sensitivity analyses showed that its economic feasibility was robust. With the willingness-to-pay threshold set at 1 GDP per capita, the probability of cost-effectiveness of BCAA treatment exceeded 80%.

Conclusions: Oral BCAAs for HE prevention may contribute positively to both the clinical status of the patient and the national healthcare budget.

Abstract Submission No. 101536
P-0890

Oral branched-chain amino acids as a cost-effective option for managing hepatic encephalopathy
Sang Hoon Ahn1, Hankil Lee2, Beom Kyung Kim3
1Yonsei University College of Medicine Seoul South Korea, 2Ajou University Suwon South Korea

Background: Oral branched-chain amino acids (BCAAs) may benefit patients with cirrhosis, especially those with hepatic encephalopathy (HE). We aimed to analyze the cost-effectiveness of BCAAs in improving the prognosis of patients with HE.

Methods: We compared the total costs and effectiveness of oral BCAA treatment (Scenario 1) versus no BCAA supplementation (Scenario 2) in a virtual cohort of 10,000 patients who had experienced HE over a 5-year period. A nested Markov model consisting of four health states (remission, recurrence, stabilization after recurrence, and death) for decompensated cirrhosis was used. Effectiveness was estimated as the cumulative number of HE recurrences and deaths. Additionally, the number of life-years and quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) were analyzed. Deterministic and probabilistic sensitivity analyses were also performed.

Results: Oral BCAA treatment prevented 34% of HE recurrences and reduced the number of HE-related deaths by 18%. Although the patients in the BCAA-treated group had spent an additional 4,086 USD on average compared with their counterparts in the non-treated group ($27,088 vs. $23,003), they experienced 0.34 more QALYs (2.77 vs. 2.43) during the 5-year period. The ICER for BCAA treatment was 12,017 USD/QALY, indicating the high cost-effectiveness of the therapeutic option. Moreover, the sensitivity analyses showed that its economic feasibility was robust. With the willingness-to-pay threshold set at 1 GDP per capita, the probability of cost-effectiveness of BCAA treatment exceeded 80%.

Conclusions: Oral BCAAs for HE prevention may contribute positively to both the clinical status of the patient and the national healthcare budget.
Impact of Vitamin K On International Normalized Ratio In Chronic Liver Disease

Tahreem Sajjad1, Prof Amanullah Abbasi1, Dr Sana Hussain1

1Dr Ruth KM Pfau Civil Hospital Karachi Karachi Pakistan

The use of vitamin K to correct deranged INR in cirrhotic patients is still questionable. This single-center observational cross-sectional study aimed to determine the effect of intravenous vitamin K on deranged INR in chronic liver disease (CLD). Hospitalized CLD patients ≥ 18yrs of age, baseline INR > 1.3 and received vitamin K were included. The primary and secondary outcomes were the change in INR after 1st and 3rd doses of vitamin K and comparing dosing frequency (single vs multiple doses) and Child–Pugh Classification (CTP) respectively. Eighty patients included with 58.8% males and 41.3% females of which CTP A, B and C was 5%, 15% and 80% respectively. The mean change in INR after 1st and 3rd doses was 0.078 ± 0.265; P = 0.01 and 0.1403 ± 0.382; P = 0.002 respectively. The mean change in INR between single vs three doses was -0.056 ± 0.33; P = 0.049. The mean change in INR after 1st and 3rd doses in CTP A was 0.195 ± 0.404; P=0.001 and 0.0250 ± 0.635; P= 0.005 respectively. The mean change in INR after 1st and 3rd doses in CTP B was 0.0825 ± 0.449; P = < 0.001 and 0.0717 ± 0.15; P= < 0.001 respectively. The mean change in INR after 1st and 3rd doses in CTP C was 0.077 ± 0.299; P= < 0.001 and 0.160 ± 0.420; P= < 0.001 respectively. Overall majority of CLD patients showed improvement in INR after three doses of vitamin K primarily CTP C.

Paracentesis in Cirrhotic Patients: Conventional Angiocatheter vs. New Anchoring Device (KARAHOC)

So hyun Jeon1, Hae won Yoo1, Ka young Hwang1, Meung chul Park1, Seo hyun Yang1, Jae yun Heo2, Yeon seok Seo3, Sang gyune Kim1

1Soonchunhyang University Bucheon Hospital Bucheon City South Korea, 2Inje University Haeundae Paik Hospital Busan City South Korea, 3Korea University Anam Hospital Seoul City South Korea

Background: In cirrhotic patients with intractable ascites, paracentesis is commonly performed using an 18G angiocatheter. However, catheter is unstable and frequently falls out during percutaneous drainage. KARAHOC (KH) is a new anchoring device designed to compensate for this instability. This study compares the success rates and complications of paracentesis using conventional angiocatheters and KARAHOC. (NCT05578573)

Methods: Eighty-seven cirrhotic patients with intractable ascites were randomized between January 2022 and Jan 2023. Regardless of the order, paracentesis using KARAHOC and conventional angiocatheter were performed once in all patients at intervals of 7 days or more. Successful paracentesis (≥3L ascites drainage) was assessed, along with patient satisfaction using a visual analogue scale.

Results: Thirteen out of 87 patients were excluded from the paired analysis because they did not receive the second paracentesis. The success rate of paracentesis was significantly better in KARAHOC (70/80, 87.5%) than angiocatheter (58/81, 71.6%) (odds ratio:2.78, p-value=0.024). There was also a significant difference in the time taken for paracentesis and total drainage time (p=0.024), but not different in the number of repeated punctures (p=0.997). The patient’s satisfaction score was also higher in KARAHOC group. 30 minutes after paracentesis, KARAHOC patients had lower systolic blood pressure and slightly higher pulse rates. Serious adverse events occurred in 3 cases, with no significant difference between groups.

Conclusion: KARAHOC is an effective and safe device for cirrhotic patients requiring frequent paracentesis.

Comparison of methods that evaluate the prognosis of liver cirrhosis

Galsan Ulzmaa1, Dorjgotov Badamsuren1, Oidov Baatarkhuu2,3,4

1Third State Central Hospital, Ulaanbaatar Ulaanbaatar Mongolia, 2Mongolian National University of Medical Sciences Ulaanbaatar Mongolia, 3Mongolian Academy of Medical Sciences Ulaanbaatar Mongolia, 4Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia

Objective: To compare the new method that evaluate prognosis of liver failure with the traditional method.

Materials and Methods: 322 patients with liver cirrhosis who had been in the Third State Central hospital were evaluated. Before treatment we took the sample of hematology, biochemistry and coagulation. Laboratory examination performed by Sysmex-KX 21, Biochemistry
by Humalizer 2000, for the coagulation we used Humaclot apparatus. All statistical analysis were conducted with the SPSS 21.0.

Results: Among all cases 39.3% of patients were in group A, 50.8% in group B, 9.8% in group C according to the Child Pugh classification. For the MELD score 10.9% of patients were in up to 10 score, 73.2% were in 10-19, 13.7% were in 20-29, 2.2% were in 30-39 score and there was no patients who had over 40 score. In the MELD classification total bilirubin or liver functional test indicate jaundice, INR point to coagulation, creatinine shows renal function thus it is more sensitive than the Child Pugh. Therefore we have some idea other researchers. PLT was 119.2±6.2 in A group according to the Child Pugh whereas PLT was 132.3±16.7±109/1 in 0-9 score group in the MELD, PLT% was 26.9±1.3 in A group and 26.7±2.3 in 0-9 score of MELD, prothrombin time was 17.3±0.4 in A group and 16.4±0.9 in 0-9 score of MELD. The splenic length was 12.1±0.2 in A group whereas 11.8±0.5 in 0-9 score of MELD.

Conclusion: The MELD score more sensitively than CTPscore. 13.7% of studied patients requires urgent liver transplantation.

Abstract Submission No. 101929

P-0895

Albumin in Decompensated Cirrhosis: A Cost-Effectiveness Breakthrough in Low-Resource Settings

Chyntia Olivia Maurine Jasirwan1, Irsan Hasan1, Ignatia Sinta Murti1, Putut Bapupurnama1, Kemal Fariz Kalista1, Christina Hill Zabal1, Dennis Kananda3, Elisabet Viayna6

1Hepatobiliary Division, Department of Internal Medicine, Cipto Mangunkusumo Hospital, Faculty of Medicine, Universitas Indonesia Jakarta Indonesia, 2Department of Internal Medicine, Abdul Wahab Sjahranie General Hospital Samarinda, East Kalimantan, Indonesia Samarinda Indonesia, 3Gastroenterology and Hepatology Division, Department of Internal Medicine, Dr. Sardjito General Hospital, Faculty of Medicine, Public Health and Nursing, University of Gadjah Mada, Yogyakarta. Yogyakarta Indonesia, 4Grifols Asia Pacific Pte Ltd Singapore Singapore, 5IQVIA Jakarta Indonesia, Jakarta Indonesia, 6Grifols SA, Av Generalitat, 152, 08174, Sant Cugat del Vallés, Spain Sant Cugat del Vallés Spain

Background: In the treatment of decompensated cirrhosis, Human Albumin (HA) is highly effective for managing complications like spontaneous bacterial peritonitis (SBP), hepatorenal syndrome (HRS), and large-volume paracentesis (LVP). However, its cost poses a significant barrier, particularly in low-resource settings.

Objective: This study aims to assess the cost-effectiveness of HA in treating SBP, HRS, and LVP in such environments, using Indonesia’s healthcare system as a model.

Methods: We constructed three decision-tree models to evaluate: 1) antibiotics with and without HA for SBP, 2) terlipressin with and without HA for HRS, and 3) LVP with HA vs. gelatins for ascites. The analysis integrated clinical, utility, and economic data over a three-month period, presenting outcomes as incremental cost-effectiveness ratios (ICER) in 2021 IDR per quality-adjusted life year (QALY).

Results: Our findings reveal that HA addition significantly enhances cost-effectiveness across all scenarios: ICER for SBP was 64,505,960 IDR/QALY (3,741 EUR/QALY), for HRS 15,665,600 IDR/QALY (908 EUR/QALY), and for LVP 16,374,871 IDR/QALY (949 EUR/QALY) - all well below the determined willingness-to-pay thresholds.

Conclusion: This groundbreaking study demonstrates HA’s cost-effectiveness in SBP, HRS, and LVP treatments in resource-limited settings, offering a viable, economical solution for healthcare systems like Indonesia’s. This approach could be revolutionary for similar settings globally, indicating a significant shift in managing decompensated cirrhosis cost-effectively.

Keywords: Human Albumin, Decompensated Cirrhosis, Cost-Effectiveness, Resource-Limited Settings, SBP, HRS, LVP, Indonesia

Abstract Submission No. 101950

P-0896

Outcome of PARTO(vascular plug assisted retrograde transvenous obliteration) for Gastric varix

Seok Hyun KIm1, Byung Seok Lee1, Hyuk Soo Eun1, Woo Sun Rou3, Hong Jae Jeon9

1Chungnam National University Hospital Daejeon City South Korea, 2Chungnam National University Seojong Hospital Seojong City South Korea, 3Chungnam National University Daejeon City South Korea

The purpose of this study was to determine the effectiveness of PARTO for gastro varices. A retrospective study was conducted on 49 patients who underwent PARTO for gastric varices from January 1, 2018, to January 2023. The PARTO procedure was performed on 26 patients who were hospitalized due to bleeding from gastric varices, and 23 patients who did not have gastric variceal bleeding but underwent the procedure prophylactically due to the high possibility of future bleeding. Of the 26 patients hospitalized with gastric variceal bleeding, PARTO succeeded in hemostasis in 21 (80.8%), hemostasis failed in 5 patients, 4 patients died from gastric variceal bleeding. One patient had rebleeding 2 days after the PARTO procedure, so an additional histoacryl injection was administered for gastric varices, which successfully achieved hemostasis, and the patient survived. Two patients died due to liver failure, not gastric variceal bleeding. All 23 patients who underwent PARTO prophylactically because they did not have gastric variceal bleeding but had a high risk of future bleeding had successful procedures, and there was no gastric variceal bleeding during follow-up. In 2 of the 23 patients, esophageal variceal bleeding occurred 73 and 537 days after the PARTO procedure, respectively. Hemostasis was successfully achieved with endoscopic variceal ligation. All 26 patients who underwent PARTO prophylactically were alive. In conclusion, this study showed that PARTO was relatively very safe and effective as a primary or secondary preventive treatment for gas- tric variceal bleeding.

Abstract Submission No. 101995

P-0897

EFFICACY OF HOME-BASED EXERCISE AND BRANCHED-CHAIN AMINO ACIDS FOR TREATMENT SARCOPENIA IN CIRRHOSIS

Napakul Siripan1, Soonthorn Chonprasertsuk1, Bubpha Pornthiars1, Ratha-korn Vilaichone1, 2, Patommatat Bhanthumkomol1, Pongjarat Nunanan1, Navapan Issariyakulkarn1, Natsuda Aumpan1, 2, Sith Siramolpiwat4

1Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Thammasat University Hospital Pathumthani Thailand, 2Chulabhorn International College of Medicine (CICM) at Thammasat University Pathumthani Thailand

Background and Aim: Sarcopenia is associated with an increase in morbidity and mortality in cirrhosis. This study aimed to evaluate the
efficacy of 12-week supervised home-based exercise and branched-chain amino acids (BCAAs) supplementation in cirrhotic patients with sarcopenia.

Methods: This prospective pilot study enrolled compensated cirrhotic patients with sarcopenia defined by gender specific L3 skeletal muscle index (SMI) cut-offs (<42 for men and <38 for women). All participants received a tailored 12-week home-based exercise program supervised by sport scientists included: (1) aerobic walking exercise (>5,000 steps/day monitored by personal activity tracker), and (2) progressive full-body resistance training (30 minutes/day, at least 5 sessions/week). After the first 1:1 face-to-face training session, participants were provided with training videos and monitored for compliance by mobile calls/applications at least 3 times/week throughout the study period. Individualized dietary counselling by nutritionists and once-daily BCAAs supplementation (210 kcal, protein 13.5 g, BCAA 2.03 g) were given to all patients. The primary outcome was changes in SMI and psoas muscle index (PMI) at L3 evaluated by CT. Secondary outcomes were aerobic fitness evaluated by six-minute walk test (6MWT), cardiopulmonary exercise test (CPET), and functional capacity evaluated by liver frailty index (LFI).

Results: 15 patients were enrolled and 12 patients who had >80% adherence rate to the study protocol were included for final analysis (age 63.3±4.2 years, female 58%, HCV/alcohol 33%/33%, BMI 30.7±20.3 kg/m², MELD 8.5±1.6, Child A 91.7%). At week 12, there was a significant increase in SMI at L3 level (37.6±2.2 vs. 44.5±3 cm²/m², P<0.001); PMI at L3 level (4.6±1.7 vs. 6.1±1.8 cm²/m², P=0.002). Notably, 11/12 (91.7%) of participants had sarcopenia resolution. In addition, there were a significant increase in 6MWT distance (372.5±58.2 vs. 442.5±78.7 m., P=0.002), LFI (4.16±0.4 vs. 3.71±0.4, P=0.001) and hand-grip strength (23.07 ± 8.1 vs. 26.23 ± 7.9 kg., P=0.047). No significant changes in CPET parameters, MELD and MELD-Na were observed. There was no major intervention-related adverse event was found.

Conclusion: A 12-week supervised home-based exercise program and BCAAs supplementation was effective for the treatment of sarcopenia in cirrhotic patients. This intervention also resulted in an improvement in functional capacity in these patients.

Abstract Submission No. 102004
P-0989

LIVER STIFFNESS ACROSS AGES: A STRATIFIED ANALYSIS OF VIRAL ETIOLOGIES USING ELASTOGRAPHY

Anar Bayanmunkh1, Zauza Matai1, Amarzaya Batchimeg1, Purevsod Lkhagvasuren1, Buren-Ochir Tsakhiiurtumur1, 2, Baatarkhuu Oidov1, 3, Amarzanaa Jazag0, Erdenebayar Gonchig1, 2, 3, Enkhtuya Damba0

1MASLD, Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia, 2Otoch Manramba University Ulaanbaatar Mongolia, 3Happy Veritas Hospital Ulaanbaatar Mongolia

INTRODUCTION: Chronic HBV and HCV infections account for 57% of cirrhosis cases worldwide. Given the tendency of viral hepatitis-induced cirrhosis to progress to liver cancer, understanding liver disease subtleties across demographic age groups is imperative for effective health strategies.

METHOD: This study involved the selection of 1,631 participants aged 30 to 90, diagnosed with cirrhosis, from the results of 11,696 individuals who underwent the elastography (FibroTouch) test at Happy Veritas Hospital between 2015 and 2023.

RESULT: Participants were stratified into three cohorts based on virus detection: those without, those with HBV alone, and those with combined HBV and HDV. Examining liver cirrhosis across age groups revealed a consistent lower prevalence in the group without viral hepatitis. However, in the HBV only group, notable peaks in liver cirrhosis were observed in the 30-35 years old cohort and the 41-45 years old group. Among participants with viral infections, a positive correlation was observed between viral presence and liver stiffness, indicating that increased number of viral presence was associated with increased liver stiffness, implying a potential synergistic effect in co-infection scenarios. The odds of liver cirrhosis were 2.71 times higher in participants with HBV and HCV co-infection. Delving into age-specific dynamics, the 41-60 age group exhibited a heightened prevalence of co-infection compared to single virus infection and non-viral groups.

Abstract Submission No. 200032
P-0899

Antibiotic prophylaxis: does it protect against recurrence of spontaneous bacterial peritonitis?

Fatima Zohra Benamor Seghir1, Fatima Zahra El Rhaoussi1, Mohamed Tahiri Joutei Hassani1, Fouad Haddad1, Wafaa Hliwa1, Ahmed Bellabah1, Wafaa Badre1

1UHC Ibn Rochd Casablanca Morocco

Background: Spontaneous bacterial peritonitis(SBP) is associated with significant short-term mortality. Antibiotic-prophylaxis is the main method of prevention. Our aim was to determine the prevalence of SBP recurrence in cirrhotic-patients receiving antibiotic-prophylaxis and to identify predictive factors.

Patients and methods: We conducted a retrospective and analytical study including all cirrhotic patients hospitalized for a recurrence of SBP who were undergoing fluoroquinolone-based antibiotic-prophylaxis.

Results: Of the 73 patients with SBP, only 8 patients had recurrent SBP, with a prevalence of 10.95%.

The mean age was 60±21 years and the sex-ratio(F/M) was 1.6. The etiology of cirrhosis was dominated by viral origin in 50% of cases. All patients had a C Child-Pugh-score and a mean MELD-score of 20. The mean time between the first and second episodes was 6 months. Antibiotic-prophylaxis had been in place for at least 8 months on average. The mean time between the last esophageal-variceal ligation session and the episode of SBP was 5 months. The mean value of biological data was: CRP 94.9mg/L, total-bilirubin 95.92mg/L, creatinemia 14.9mg/L, albumin 18g/L and ascites fluid protein level at 10.

The predictive factors for recurrence in the univariate study were: age>60 years(p=0.04), viral etiology of cirrhosis(p=0.05), C Child-Pugh-score(p=0.02), occurrence of digestive hemorrhage during hospitalization(p=0.042), and a history of esophageal-variceal ligation<5 months(p=0.029). No independent factors were found in the multivariate analysis.

Conclusion: In our study, recurrence of SBP in cirrhotic patients undergoing antibiotic-prophylaxis was noted in 10.95% of cases, which is a difficult infection to anticipate because there are few predictive factors.

Abstract Submission No. 200070
P-0990

Association between controlled attenuation parameters and clinical outcomes in cirrhotic patients
Utility of ultrasonography shear wave for esophageal varices in patient with chronic liver disease

Azusa Wada1, Yasunobu Yamashita1, Yudai Taniguchi1, Shiori Kaji1, Masaki Takao1, Fumiaki Kuwashima1, Jun Kinoshita1, Shinya Taki1, Shuya Maeshima1, Ryo Shimizu1, Yoshiyuki Ida1, Reiko Ashida1, Takao Maekita1, Mikitaka Iguchi1, Masayuki Kitano1

1Second Department of Internal Medicine, Wakayama Medical University, Wakayama Japan

Background and aim: Esophageal varices (EV) are one of the serious complications in liver cirrhosis. The guideline of cirrhosis/chronic disease does not specify a follow-up period or the need for esophagogastroduodenoscopy (EGD) in patients with chronic liver disease. On the other hand, follow-up with periodic abdominal ultrasonography (AUS) is recommended. If EV are assessed by AUS, minimally invasive and effective EGD can be performed for close examination. We investigated whether AUS shear wave elastography (Vs and F-index) could predict the presence and morphology of EV.

Methods: Between April 2018 and October 2022, we retrospectively collected data in 181 patients who underwent elastography and EGD for liver disease. Elastography was measured at liver segment 7 with intercostal manipulation. Endoscopic evaluation of EV was assessed with EV guideline. Vs and F-index were evaluated by presence and morphological of EV. The cut-off values of diagnosis and treatment indication for EV were investigated.

Results: Vs and F-index were significantly higher in patients with EV (n=109) than without EV (n=72) (p<0.0001), and positively correlated with the morphological grade of EV. The cut-off values of Vs and F-index were 1.63 and 1.86, with sensitivity (86.5%, 85.1%), specificity (45.8%, 49.2%) and AUC (0.70, 0.69), respectively, for the presence of EV, and 1.68 and 1.92, with sensitivity (91.4%, 88.6%), specificity (40.8%, 41.8%) and AUC (0.68, 0.65), respectively, for treatment indication.

Conclusions: AUS elastography may provide objective assessment and can thus be a non-invasive screening tool for diagnosis and treatment indication of EV.
**CHIBA score - novel model for predicting 3-month mortality in a cohort of Decompensated Liver Disease**

**SHANID A¹, Jijo Vargheese²**

¹MEDICAL COLLEGE, TRIVANDRUM TRIVANDRUM India, ²Medical college Trivandrum India

**Background:** Decompensated liver disease (DCLD) has high mortality, and is important to prognosticate and prioritize for liver transplantation. MELD, MELD variants, and CTP were tested for this with drawbacks. The aim of study is to propose new prognostic model for DCLD.

**Materials and methods:** Retrospective study with 321 DCLD patients were enrolled. Patient relatives were contacted regarding date of death, and mortality at 3 months was assessed. After Logistic regression, coefficients of beta of independent variables were found out, and new CHIBA score was proposed.

**Results:** CHIBA score has AUROC of 0.793 (at a cutoff of > 5.5, it has a sensitivity of 66% and specificity of 76%) compared to MELD-Na of 0.735 (cutoff > 25, sensitivity 65%, and specificity 72%); MELD of 0.727 (cutoff > 17 sensitivity of 80.37% and specificity of 55.14%); I-MELD of 0.72; MESO index of 0.72; and UKELD of 0.686. For validation, 214 patients were selected, and AUROC of CHIBA score in the validation cohort was 0.77. At a cutoff of > 5.5, it has a sensitivity of 60% and specificity of 77%.

**Conclusion:** CHIBA score is superior to MELD and variants in predicting 3 month mortality and is validated in external cohort. It can be calculated at bedside as it is simple score with no logarithmic variables.

Abstract Submission No. 200169
P-0905

**Self-Care of Japanese Patients with Decompensated Cirrhosis**

**Megumi Kawakubo¹,², Yasuko Shimizu³, Yuichiro Eguchi⁴**

¹Faculty of Medicine, Department of Lifelong Developmental Nursing, Saga University Saga Japan, ²Doctoral Program in Health Sciences, Osaka University Graduate School of Medicine Suita Japan, ³Area of Nursing Science, Division of Health Sciences, Osaka University Graduate School of Medicine Suita Japan, ⁴Loco Medical General Institute Ogi Japan

**Background:** Patients with decompensated cirrhosis (P-DC) have various physical symptoms and are repeatedly hospitalized and discharged before gradually transitioning to the end-of-life phase. The aim of this study was to identify the self-care experiences of P-DC in order to provide implications of the support needed by P-DC.

**Methods:** Semi-constructive interviews with six P-DC. Data were analyzed using qualitative integration methods (KJ method).

**Results:** Self-care of P-DC included “management they had done” in their own way and “management buried in life” due to being busy and other reasons. These were based on two aspects of their relationship with other people around them: “management supported by the connection with the people around them” or “management at a distance from the people around them.” Furthermore, as P-DC gradually realized the progression of their illnesses, they began “coming to terms with their declining bodies” while still being “anxious about the future.” Overall, these self-care experiences were influenced by an “elusive body” experience as P-DC were not well aware of the conditions of their own livers or the need for treatment.

**Conclusion:** This study showed that P-DC live with “anxiety about the future” and “elusive bodies.” Our results suggest the need for end-of-life care from early stages and from a long-term perspective, as this is a complex disease with various physical symptoms.

Abstract Submission No. 200217
P-0906

**FB-1603: a potential therapeutic agent for liver injury_ preclinical and ongoing clinical studies**

**Jyyuan Huang¹, Kai-Wen Huang², Yi-Hsiang Chen¹, Chuang-Chun Chiu³**

¹Febico Biomedical Corp. Taipei Taiwan, ²National Taiwan University Hospital Department of Surgery Taipei Taiwan

**Background:** In our previous study, given the *Arthrora* FEM-102 strain as a supplement to hepatocellular carcinoma patients undergoing liver resection or transarterial chemoembolization for 30 weeks was found to improve the total bilirubin (T-Bil), ALT, and AST post-surgery, and also albumin, liver stiffness relief significantly. Therefore, the active pharmaceutical ingredient, FB-1603, isolated from the FEM-102 was for further development.

**Methods:** The anti-oxidant efficacy of FB-1603 in-vitro is by co-culture with H2O: and then measured by OxirRed staining. We also treat the TGf-beta activated Hepatic Stellate cell (HSC) with FB-1603 to evaluate the anti-stiffness activity. Finally, DEN-induced liver cirrhosis rat model was administrated with FB-1603 in chaw diet, and were sacrificed in 12th week for liver tumor burden, hydroxyproline, AST, ALT, γ-glutamyl transpeptidase (γ-GT), T-bil, and oxidative stress.
Results: First, the FB-1603 showed the H_2O_2 scavenging activity in 400 μg/ml. We also found the specific cytotoxicity in TGF-beta activated HSC cell (EC_50= 22.6μg/ml). Given the FB-1603 to DEN treated liver cirrhosis rats displayed reduced hepatic hydroxyproline level upon administration of 0.4-2 g/kg/day of FB-1603 and also mitigated the AST, ALT, γ-GT, T-bil, and oxidative stress in liver tissue.

Discussion: The FB-1603, can decrease hepatic impairment, oxidative stress, and liver stiffness in DEN induced rat model, and also no toxicity in acute, sub-acute toxicity, or genetic mutation assay. A Phase I/II randomized, double-blind study of FB-1603 to evaluate the safety and efficacy in hepatocellular carcinoma patients receiving transarterial chemoembolization (FECHT trial) is excueting in Taiwan since Feb., 2024.

Abstract Submission No. 200243
P-0907

SII is used to evaluate the degree of fibrosis and the severity of liver cirrhosis

ming shao¹, Qiongfang Yu¹
¹Nachang University Nachang municipality China

Objective: To the role of SII in the assessment of fibrosis and disease severity in patients with liver cirrhosis.

Methods: A total of 185 patients with liver cirrhosis diagnosed in the Second Affiliated Hospital of Nanchang University from January 2019 to December 2021 were randomly selected. The transient elastography was used to detect the liver stiffness of the patients. According to the degree of fibrosis, the patients were divided into group A (E < 13.450, n=77) and group B (E > 13.450, n=108). The differences of se-rological indicators in different groups were compared. Multivariate logistic regression was used to analyze the independent risk factors of decompen-sated cirrhosis, and a prediction probability model was constructed. At the same time, the correlation between independent risk factors and the prediction probability model and the degree of liver fibrosis was analyzed.

Results: Univariate analysis showed that there were no significant differences in age, height, weight, BMI, admission temperature, heart rate, and mean arterial pressure between group A and group B (p>0.05). The RBC, HGB, PLT, PLR, Child-Pug score, CHO, CHE, NE, LYM, SII and ALB in group A were significantly higher than those in group B (p<0.05). The HA, LN, III, IV, TBA, MELD score, FIB-4, APRI, PT, ALP, AST and INR of group A were significantly lower than those of group B (p<0.05). Multivariate logistic regression analysis showed that ALB, SII, CHO and HA were independent risk factors for group B (p<0.001). According to the combination of SII and ALB, the prediction probability model was logit(P) = 8.714 - 0.181 × ALB - 0.003 × SII. SII and ALB were negatively correlated with Fibroscan-E(kPa) (r = -0.30, -0.54, p < 0.001, p < 0.001), and the prediction model was positively correlated with Fibroscan-E(kPa) (r = 0.554, p < 0.001).

Conclusions: SII is an independent risk factor for decompensation cirrhosis. The lower the SII, the higher the degree of liver fibrosis and the more severe the disease.

Key words: SII, liver stiffness, prediction model

Abstract Submission No. 200259
P-0908

Long-term CARTO results in a patient with cirrhosis of the liver. the experience of Kazakhstan.

Niyaz Malayev¹,², Samat Suparbeyev³, Nadiyar Musin³, Saule Kubekova³
¹National Scientific Medical Center Astana Kazakhstan, ²JSC West kazakhstan Medical academy Aqtobe Kazakhstan, ³JSC Astana Medical University Astana Kazakhstan

A 60-year-old patient with cirrhosis of the liver with portal hypertension, VRS 2-3 degrees. 2 SAE courses were conducted. Initially, PLT - 20.00 10E9/L; after 2 courses of SAE, the level of PLT - 41.00 10E9/L. Ultrasound - varicose veins of the esophagus and stomach, 3 cases of bleeding, computed tomography with contrast revealed a gastrointestinal shunt with a diameter from 15 to 18 mm. CARTO embolization was performed using 3 removable Azur CX 0.18 coils (Terumo Europe NV) and 2 removable PC400 coils (Penumbra) through the femoral vein (Fig.1,2).

After the coils were implanted through a 2.4 Fr coaxial microcatheter (Terumo Europe N.V.), an adhesive suspension with complete occlusion of the gastrointestinal shunt.

Control angiography showed complete occlusion of the gastrointestinal shunt.

A control CT scan 3 days after the CARTO procedure: the gastrointestinal shunt is still working, but the varicose veins are partially throm-bosed - since the shunt is so huge/large, a second CARTO procedure or a combination with another technique (BARTO) may be required in the future (Fig.6-8).

A control CT scan with contrast after 12 months.

A decrease in the volume and number of varicose-dilated shunts, the shunts disappeared, and the varicose veins of the esophagus decreased to 0-1 degrees.

Reduction of clinical signs of portal hypertension and encephalopathy. (Fig. 9-10).

Transvenous obliteration is currently a recognized minimally invasive endovascular method that is effective and durable in the treatment of varicose bleeding from the stomach caused by portal hypertension.

Abstract Submission No. 200270
P-0909

Development and validation of the Adult cirrhosiS Knowledge Questionnaire (ASK-Q)

Hak Keith Leung¹, Sanjiv Mahadeva¹, Ruveena Bahavani Rajaram², Pauline Siew Mei Lai²,³
¹Department of Medicine, Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia, ²Department of Primary Care, Faculty of Medicine, University of Malaya Kuala Lumpur Malaysia, ³School of Medical and Life Sciences, Sunway University Sunway City Malaysia

Background: Assessing a patient’s liver cirrhosis knowledge is important in improving patient outcomes. To date, no questionnaire has been developed to assess patients’ knowledge regarding multiple aspects of liver cirrhosis. This study aimed to develop and validate the Adult cirrhosiS Knowledge Questionnaire (ASK-Q).

Methods: The ASK-Q was developed based on literature review and input from an expert panel. Five English-speaking cirrhotic patients who participated in a pilot study commented that the font size was too small. Hence, the font was enlarged and the final version of the ASK-Q [which consists of 24 items with 4 domains: self-understanding (5 items), aetiology (5 items), complications (5 items), and management (9 items) of liver cirrhosis] was then administered to English-speaking cirrhotic patients, aged ≥18 years, with or without decompensation at a tertiary centre, from September 2020 to November 2021, at baseline and a fortnight later. Patients with hepatic encephalopathy were excluded.
Results: A total of 120/135 patients agreed to participate (response rate=88.9%). The overall median score was 59.1[45.6-68.2]. A total of 7/22(31.8%) items were “easy”, 14/22(63.6%) items were “moderately easy” and 1/22(4.5%) items were “difficult”. Exploratory factor analysis extracted nine factors and two items were omitted. The ASK-Q was able to discriminate the knowledge level of patients with and without tertiary education (59.1[50.0-72.7] vs 54.5 [36.4-63.6], p<0.05). The overall Kuder-Richardson(KR) coefficient was 0.760 indicating adequate internal consistency. At retest, 77/120 patients participated (response rate=64.2%) and 15/22 items were not statistically significant, indicating adequate reliability.

Conclusions: The ASK-Q was found to be a valid and reliable questionnaire for evaluating the knowledge of liver cirrhosis amongst English-speaking adult patients.

Abstract Submission No. 200282
P-0910

Clinical characteristics of patients with decompensated cirrhosis with sepsis

Peng ZHU1

1Suining First People Hospital Suining China

Objective: To investigate the clinical features and prognosis of patients with decompensated cirrhosis with sepsis.

Methods: A total of 120 patients with decompensated cirrhosis from October 2018 to October 2022 were enrolled and divided into sepsis group (n=56) and No-sepsis group (n=64) according to whether there was sepsis during hospitalization. There was no difference in age, gender and etiology between the two groups. The general condition and laboratory parameters of patients were collected. Patients with sepsis were treated with empirical antibiotic therapy to observe the short-term prognosis of patients.

Results: There were differences between the two groups in SBP, antibiotic exposure within 30 days, Child-Pugh grade, MELD score, gastrointestinal bleeding within 30 days, HGB and PCT. Logistic regression analysis showed that MELD score (OR=2.310, 95%CI: 1.586-5.145), Child-Pugh grade (OR=3.217, 95%CI: 1.236-7.159), gastrointestinal bleeding within 30 days (OR=5.596, 95%CI: 1.798-17.322), antibiotic exposure within 30 days (OR=3.358, 95%CI: 2.519-11.198) were independent risk factors for sepsis. In sepsis group, 23 (41.1%) patients were blood culture-positive, of which 18 (78.2%) were Gram-negative and 5 (21.8%) were Gram-positive. The main Gram-negative bacteria were Escherichia Coli (n=12, 66.7%), Pseudomonas Aeruginosa (n=4, 22.2%) and Klebsiella Pneumoniae (n=2, 11.1%). The main Gram-positive bacteria were Staphylococcus Aureus (n=3, 60.0%), Staphylococcus Epidermidis (n=1, 20.0%) and Streptococcus Viridis (n=1, 20.0%).

Conclusion: Recent gastrointestinal bleeding and antibiotic exposure may increase the susceptibility of patients. Gram-negative bacteria are still the most common cause of sepsis in patients with decompensated cirrhosis, which is helpful to guide the use of empirical antibiotics.

Abstract Submission No. 100079
P-0911

Mindin promotes macrophage-driven liver fibrosis resolution and tissue remodeling

Bayasi Guleng2, Yong-Dong Huang3

2Department of Gastroenterology, Zhongshan Hospital of Xiamen University; School of Medicine, Xiamen University Xiamen China

Background and Aims: Liver disease accounts for approximately 2 million deaths per year worldwide and the half was due to complications of cirrhosis. The secretary protein Mindin has been demonstrated to have important functional roles in the immune responses, but its role in maintaining liver homeostasis is largely unknown. This study aimed to investigate the role of Mindin in the regulation of liver fibrosis.

Methods and Results: Mindin was up-regulated in CCl4 and TAA-induced liver fibrosis mouse models. Expression of Mindin was mostly expressed in hepatocytes but not in nonparenchymal liver cells. By constructing global Mindin knockout mice, we found that Mindin protected against CCl4 and TAA-induced liver fibrosis. Further results revealed that Mindin fail to directly act hepatic stellate cells, but rather influenced the progression of liver fibrosis by orchestrating the immune status, particularly macrophages recruitment. Mindin recruited more macrophages to promote deposited extracellular matrix degradation by releasing matrix metalloproteinases, which in turn remodeled fibrosis. Meanwhile, liver fibrosis aggravated after macrophage clearance. Liver fibrosis was induced in parallel in Mindin and its acceptor CD11b-/- mice, Mindin-/-CD11b-/- mice, and their corresponding controls. Results revealed that either Mindin or CD11b-/- individually would increase liver fibrosis, and when both genes knocked out simultaneously, liver fibrosis exacerbated dramatically. The Mindin/CD11b axis promoted the phenotypic switch of restorative macrophages by promoting phagocytosis, which facilitated collagen degradation via up-regulation of MMP-9. In turn, liver fibrosis resolved.

Conclusions: Mindin promotes liver fibrosis resolution and may provide a rationale for therapeutic strategies in chronic liver disease.

Abstract Submission No. 100120
P-0912

KDM4C represses liver fibrosis regulating H3K9me3 methylation

of ALKBH5 and m6A of snail1 mRNA

jing ma1

1Department of Infectious Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China Changsha China

Object: Snail1 is involved in liver fibrosis by mediating epithelial-mesenchymal transition. This present study hence probed into the molecular mechanism of snail1 in liver fibrosis.

Methods: The mouse model of liver fibrosis was induced by CCl4. Serum levels of ALT and AST were determined, and liver pathological alterations were assessed utilizing hematoxylin-eosin and Masson stainings. Rat hepatic stellate cells (HSC-T6) were activated by TGF-β1, followed by assessment of cell viability and migration using MTT and scratch tests. Snail1, ALKBH5, and KDM4C levels were determined by means of immunohistochemistry, Western blot, or RT-qPCR.

The levels of α-SMA, Col1a1, vimentin, and E-cadherin were also measured. m6A modification of snail1 was detected by Me-RIP. PAR-CLIP and RNAstability analysis were performed to assess the relationship between ALKBH5 and snail1. ChiP was processed to determine the level of KDM4C-bound ALKBH5 promoter and enrichment of H3K9me3 at the ALKBH5 promoter.

Results: Snail1 was upregulated but ALKBH5 and KDM4C were downregulated in liver fibrosis mice. KDM4C overexpression reduced
serum ALT/AST levels, liver injury, and α-SMA/Col1a1/vimentin levels, and increased E-cadherin. However, the above trends were counteracted by simultaneous overexpression of snail1. In TGF-β1-activated HSC-T6 cells, ALKBH5 overexpression weakened cell viability and migration, downregulated α-SMA/Col1a1/vimentin, upregulated E-cadherin, and decreased m6Amodification of snail1 and its mRNA stability. KDM4C promoted ALKBH5 expression by reducing the level of H3K9me3. KDM4C inhibited HSC-T6 activation by regulating the ALKBH5/snail1 axis. **Conclusion:** KDM4C decreases H3K9me3 methylation to upregulate ALKBH5 and subsequently represses snail1, ultimately impeding liver fibrosis. **Keywords:** KDM4C; ALKBH5; Snail1; Hepatic stellate cell; Liver fibrosis; m6A

Abstract Submission No. 100135

P-0913

Preventive Effect of Angiotensin II Receptor and Neprilysin Inhibitor on hepatic fibrosis in mice

Kosuke Kaji1, Junya Suzuki1, Norihisa Nishimura1, Hitoshi Yoshii1

1Department of Gastroenterology Nara Medical University Kashiwara Japan

The renin–angiotensin–aldosterone system has gained attention due to its role as a mediator of liver fibrosis and hepatic stellate cell (HSC) activation. Meanwhile, the natriuretic peptide (NP) system, including atrial NP (ANP) and C-type NP (CNP), is a counter-regulatory hormone regulated by neprilysin. Although the combination of an angiotensin receptor and a neprilysin inhibitor (sacubitril/valsartan: SAC/VAL) has shown clinical efficacy in patients with heart failure, its potential effects on hepatic fibrosis have not been clarified. This study assessed the effects of SAC/VAL in carbon tetrachloride (CCL4)-induced murine liver fibrosis as well as the in vitro phenotypes of HSCs. Treatment with SAC and VAL markedly attenuated CCL4-induced liver fibrosis while reducing α-SMA-HSC expansion and decreasing hepatic hydroxyproline and mRNA levels of pro-fibrogenic markers. Treatment with SAC increased plasma ANP and CNP levels in CCL4-treated mice, and ANP effectively suppressed cell proliferation and TGF-β-stimulated MMP2 and TIMP2 expression in LX-2 cells by activating guanylate cyclase-A/cGMP/protein kinase G signaling. Meanwhile, CNI did not affect the pro-fibrogenic activity of LX-2 cells. Moreover, VAL directly inhibited angiotensin II (AT-II)-stimulated cell proliferation and the expression of TIMP1 and CTGF through the blockade of the AT-II type 1 receptor/protein kinase C pathway. Collectively, SAC/VAL may be a novel therapeutic treatment for liver fibrosis.

Abstract Submission No. 100141

P-0914

Liver fibrosis and association factors in blood-transfused thalassemia patients

Ratchanok Suppawat1, Chinnavat Suthiwana2, Chanuntha Hongthanakorn2

1The Digestive diseases center, Department of Internal Medicine Bhumibol Adulyadej Hospital Bangkok Thailand, 2The Digestive diseases center, Department of Internal Medicine Bhumibol Adulyadej Hospital Bangkok Thailand

**Background:** Iron accumulation in liver is an important cause of liver fibrosis in thalassemia patients. Therefore, early detection with a reliable and non-invasive approach is crucial. **Method:** A cross-sectional study of 74 blood-transfused intermediate thalassemia patients at Bhumibol-Adulyadej Hospital from October 2018 to 2019. We evaluated the correlation between significant liver fibrosis by using transient elastography (TE) and association factors (patient history, laboratory test). **Result:** Significant liver fibrosis was found in 26 (35.13%) patients, which 4 (15.4%) were TDT (Transfusion-Dependent-Thalassemia) and 22 (84.6%) were NTDT (Non-Transfusion-Dependent-Thalassemia). The mean value of TE was 13.65±5.71 kPa. Higher level of direct bilirubin (DB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), iron and ferritin were found in the significant liver fibrosis group compared to the nonsignificant liver fibrosis group as the following data; DB 0.68±0.28 mg/dL vs 0.51±0.16 mg/dL (p-value=0.008), AST 43.04±26.7 U/L vs 27.98±12.16 U/L (p-value=0.01), ALT 36.35±29.27 U/L vs 21.27±11.98 U/L (p-value=0.018), iron 190.42±102.14 µg/dL vs 145.02±55.02 µg/dL (p-value=0.043) and ferritin 2381.35±1937.92 ng/ml vs 1635.31±1624.98 ng/ml(p-value=0.082), but the chelating agents initiation rate was lower as 6/26 (23.07%) vs 25/48 (52.08%). The APRI and FIB-4 scores elevated in the significant liver fibrosis group 7/26 (26.9%) and 2/26 (7.7%) respectively. **Conclusion:** The ferritin level may not be an adequate indicator for iron-chelating therapy, but DB, AST, ALT and iron level should necessarily be considered. APRI and FIB-4 scores were not correlated to significant liver fibrosis by TE in thalassemia patients.

Abstract Submission No. 100218

P-0915

Fibroscan 402 in the Management of Chronic Viral Hepatitis in Armenia

Narek Pepanyan1, Inessa Nazaryan1, Tatevik Shahinyan1

1Diagnostic center Ecosense Yerevan Armenia

**Background:** Chronic viral hepatitis represents a significant public health challenge in Armenia. Early diagnosis and effective management of infections are crucial to reduce disease burden. Fibroscan402, a non-invasive elastography-based tool, has emerged as a valuable diagnostic and monitoring tool for assessing liver fibrosis in chronic liver diseases patients. **Material and methods:** 18months we conducted liver stiffness measurements(LSM) on 458 patients diagnosed with HBV(273 patients) and HCV(185 patients). Unfortunately in3 patients reliable LSM results were not attainable. The remaining 455 patients were included in study For hepatitis B treatment was indicated if LSM results showed significant fibrosis (>F2) along with a significant viral load (>2000IU/mL). In the case of hepatitis C genotypes 2 or 3 antiviral treatment was advised irrespective of LSM results. For genotypes 1 and 4 treatment was recommended if the fibrosis stage exceeded F2. Patients with fibrosis stage > F3 were advised to further observation for HCC. **Results:** Fibroscan402 LSM findings revealed that patients 240(52.7%) had F0-F1, 85 patients (18.5%) were at F2, 130 patients (28.8%) were at F3 and F4.102 patients underwent liver biopsies within one year of LSM. Notably, LSM results led to a change in clinical management for 32% of the patients (147 cases). Specifically, 215 patients were recommended antiviral treatment, 130 patients were advised to further
observation for HCC and 26 patients with successfully treated hepatitis C were able to be discharged from clinical follow-up due to the absence of severe fibrosis or cirrhosis.

**Conclusion:** Based on the experiences it is evident that the incorporation of liver stiffness measurement via Fibroscan402 represents a significant non-invasive enhancement to clinical care for individuals afflicted by chronic viral hepatitis B and C.

Abstract Submission No. 100426
P-0916

**Discordance between transient elastography and liver biopsy for assessing fibrosis in HBV and HCV**

Young Kul Jung1, Seong Hee Kang1, Sun Young Yim2, Young-Sun Lee3, Yeon Seok Seo1, Ji Hoon Kim1, Hyung Joon Yim1, Jong Eun Yeo1, Kwan Soo Byun3

1Korea Univ. Ansan Hospital Ansan South Korea, 2Korea Univ. Anam Hospital Seoul South Korea, 3Korea Univ. Guro Hospital Seoul South Korea

**Introduction:** The objective of this study was to determine the frequency of major discrepancies and identify the clinical variables associated with these differences.

**Methods:** The data of 391 patients with chronic HBV infection (CHB) and 453 patients with chronic HCV infection (CHC) who accepted VCTE, liver biopsy, clinical, and biological examination were collected retrospectively. Liver fibrosis was evaluated using the META-VIR scoring system.

**Results:** The optimal diagnostic values of liver stiffness measurement (LSM) for significant fibrosis (≥ F2), severe fibrosis (≥ F3), cirrhosis (F4) were 6.85, 8.85, 11.65 kPa in CHB cohort and 7.85, 9.40, 11.15 kPa in CHC cohort, respectively. Among the CHB patients, 240 (61.3%) exhibited discrepant results for the diagnosis of fibrosis. Of these, 111 patients (28.3%) had an overestimation, while 129 patients (32.9%) had an underestimation. Also, a total of 304 (67.1%) [overestimation, 105 (23.1 %); underestimation, 199 (43.9 %)] patients showed discrepant results in CHC cohort. We found that an association between host factors and measurement factors like BMI, gender, inter-quartile range/median LSM values with underestimation, while AST and ALT, reflecting inflammation, was associated with overestimation.

**Conclusions:** Our findings demonstrate that overestimation or underestimation of fibrosis by VCTE is common, particularly in patients with high levels of clinical inflammatory activity. While VCTE is highly sensitive in detecting liver fibrosis, its specificity is not as reliable.

Abstract Submission No. 100554
P-0917

**Diagnostic Accuracy of FIB-4 compared to Liver Elastography in Assessing Liver Fibrosis in Filipinos**

Rafael Emmanuel Mendoza1, Dyan Gabrelle H. De Guzman-David1, Arielle Nicole Y. Cheng1, Ian Homer Y. Cua1

1St. Luke's Medical Center Global City Taguig City, Metro Manila Philippines

**Background:** The Philippines has the third highest mortality growth worldwide from cirrhosis. The Fibrosis-4 (FIB-4) index is a non-invasive scoring uses age, platelet count, and liver transaminase levels generally used to estimate the degree of hepatic fibrosis. No previous study has looked into the applicability of this tool in Filipino patients.

**Objectives:** The aim of this study is to determine the diagnostic accuracy of the FIB-4 index compared to liver elastography for assessment of liver fibrosis in Filipinos.

**Methodology:** This cross-sectional study collected clinical data, laboratory results, and liver elastography findings. Data was analyzed using an area under the receiver operating characteristic (AUROC) curve.

**Results:** In 459 patients (57.1 percent male, mean age 53.1 years, mean BMI 28.79 kg/m2), the FIB-4 has an AUC of 0.698 (95% CI 0.633-0.739). Using the best cut-off score through Youden’s index 1.21, FIB-4 showed sensitivity of 63.3% (95% CI 56-70.2) and specificity of 73.1% (95% CI 67.4 to 78.3) in detecting the presence of fibrosis on liver elastography.

In the subset of non-obese Filipinos, FIB-4 has an AUC of 0.778 (95% CI 0.695-0.847). The best cut-off score through Youden’s index is 1.37, sensitivity of 69.8% (95% CI 53.9-82.8), and specificity of 82.9% (95% CI 73-90.3).

**Conclusion:** FIB-4 still has a low sensitivity and low to moderate specificity in predicting hepatic fibrosis in Filipinos. Thus, we recommend further research on other feasible and accessible non-invasive modalities to assess liver fibrosis.

Abstract Submission No. 100638
P-0918

**Corylin attenuated CCl4-induced liver fibrosis in mice by regulating the GAS6/AXL signaling pathway**

Tong-Hong Wang1, Chin-Chuan Chen2, Chi-Yuan Chen2, Chau-Ting Yeh4, Chuen Hsueh6

1Biobank, Chang Gung Memorial Hospital Taoyuan Taiwan, 2Graduate Institute of Natural Products, Chang Gung University Taoyuan Taiwan, 3Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology Taoyuan Taiwan, 4Liver Research Center, Chang Gung Memorial Hospital Taoyuan Taiwan, 5Department of Anatomic Pathology, Chang Gung Memorial Hospital Taoyuan Taiwan

Liver fibrosis can be reversed when treated in its early stages and the factors that cause liver inflammation are inhibited. No studies have investigated the therapeutic effects of corylin, a flavonoid extracted from Psoralea corylifolia L. (Fabaceae), on liver fibrosis. Therefore, we evaluated the anti-inflammatory activity of corylin and investigated its efficacy and mechanism of action in ameliorating liver fibrosis. Corylin significantly inhibited the activation of MAPK signaling pathways and expression of interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha in human THP-1 and mouse RAW264.7 macrophages, thereby inhibiting inflammatory responses. Furthermore, corylin inhibited the expression of growth arrest-specific gene 6 (GAS6) in human hepatic stellate cells (HSCs) and the activation of downstream phosphatidylinositol 3-kinase (PI3K)/Akt pathway, thereby inhibiting the activation of HSCs and the expression of extracellular matrix proteins, including α-smooth muscle actin and type I collagen. Additionally, corylin induced caspase 9 and caspase 3 activation, which promoted apoptosis in HSCs. Further, in vivo experiments confirmed the regulatory effects of corylin on these proteins, and corylin alleviated the symptoms of carbon tetrachloride-induced liver fibrosis in mice. These findings revealed that corylin has anti-inflammatory activity and inhibits HSC activation; thus, it represents a potential adjunct in the treatment of liver fibrosis.

Abstract Submission No. 100657
P-0919
Serum CHI3L1 combined with GP73 helps evaluate liver fibrosis in CHB patients

Xinyu Hu1, Qianqian Chen2,3,4, Li Zhu3, Chuanwu Zhu5, Chao Wu6, Jie Li7,2,3,4

1Department of Infectious Disease, Shandong Provincial Hospital, Shandong University Jinan China, 2Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing China, 3Department of Infectious Disease, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University Nanjing China, 4Institute of Viruses and Infectious Diseases, Nanjing University Nanjing China, 5Department of Hepatology, The Fifth People's Hospital of Suzhou Suzhou China

Background: Early identification of fibrosis in chronic hepatitis B(CHB) patients can reduce liver-related adverse events. Though numbers of predicting models have been reported, there is still a need of more effective, practicable non-invasive serological diagnosis modes. Previous studies indicated that both chitinase-3-like protein 1 (CHI3L1) and serum Golgi protein 73(GP73) were associated with liver fibrosis.

Methods: Our study enrolled 324 CHB patients with biopsy and 167 had completed liver stiffness measurement (LSM). Serum CHI3L1 and GP73 level, LSM, fibrosis-4(FIB4), and aspartate aminotransferase-to-platelet ratio index (APRI) were determined to analyze the correlation between these non-invasive tests and liver fibrosis by logistic regression analysis. The area under receiver operating characteristic (AUROC) was calculated to evaluate the diagnostic accuracy of each model.

Results: Multivariate logistic regression analysis indicated that CHI3L1 and GP73 were independent risk factors for significant fibrosis (S2-4) and advanced fibrosis (S3-4). We combined the two markers and developed our prediction model. The AUROC of our prediction model for identifying significant fibrosis was 0.757 (95 CI 0.685-0.828), significantly higher than the model with FIB-4(0.636, 95CI 0.553-0.719, p=0.022), comparable to LSM(0.743, 95CI 0.668-0.819, p=0.790) and APRI(0.717, 95CI 0.638-0.795, p=0.431) models. The AUROC of the prediction model for identifying advanced fibrosis was 0.735 (95CI 0.652-0.818), comparable to LSM (0.832, 95CI 0.766-0.898, p=0.051), FIB-4(0.653, 95CI 0.560-0.746, p=0.185) and APRI(0.724, 95CI 0.637-0.811, p=0.845) model.

Conclusion: CHI3L1 and GP73 were positively correlated with liver fibrosis. The diagnostic model constructed by CHI3L1 and GP73 can help identify the significant and advanced liver fibrosis in CHB patients.

Abstract Submission No. 100721
P-0921

Factors contributing to liver stiffness in the acute phase of acute hepatitis

NAOYUKI YOSHIMINE1, Noritaka Waku1, Hideki Nagumo1, Kunihide Mohri2, Kojiro Kobayashi3, Yu Ogino1, Takanori Mukozu1, Teppei Matsui1, Yasuko Daido1, Koichi Momiyama1, Hidenari Nagai1, Takahisa Matsuda1

1Toho University Omori Medical Center Tokyo Japan

Background: The factors involved in liver stiffness in acute hepatitis still need to be investigated. This study performed to clarify factors affected to liver stiffness in patients with acute phase of acute hepatitis.

Subjects and methods: Blood samples were collected, abdominal ultrasound examination and liver stiffness measurement were performed early in the morning the day after admission. Previous reports on chronic liver disease have defined a Vs value ≥1.63 as F4. Patients were divided into two groups according to liver stiffness, follow as normal stiffness (N group) and high stiffness (H group). Patients with a Vs value of 1.63 or higher were included in the H group.

Results: A total of 43 adult Japanese patients with acute hepatitis except for chronic liver diseases. Twenty-seven patients had virus related acute hepatitis and 16 patients had drug induced liver injury. Serum levels of total bilirubin (T-Bil) and direct Bil (D-Bil) in the H group were significantly higher than those of the N group. The average of length of hospital stay in the H group was significantly higher than those of the N group, also. In univariate analysis, collapsed gallbladder, T-Bil, and D-Bil were related to the liver stiffness. But serum levels of transaminase and hepatomegaly were not related to it.

Abstract Submission No. 100893
P-0922

Liver regeneration after resection: progressive versus regressive fibrosis of cirrhosis

Young Nyun Park1, Ha Young Woo2, Jin Ho Le3, Jeong Eun Yoo1, Seung Up Kim1, Jin-Sub Choi1

1Yonsei University College of Medicine Seoul South Korea, 2Chung-ang University College of Medicine Seoul South Korea, 3IlSan Hospital Ilsan South Korea

Background: Hepatocellular carcinoma (HCC) occurs in chronic hepatitis/cirrhosis. The aim of this study is to investigate pathological features of non-neoplastic liver, which are related to hepatic regeneration after HCC resection.
Loss of SREBP-1c Ameliorates Hepatic Steatosis and Liver injury in NASH through Lipocalin-2

Eun-Ho Lee1, Min-Hee Seo1, Dae-Kyu Song1, Jae-Hoon Bae1, Seung-Soon Im1
1Department of Physiology, Keimyung University School of Medicine Daegu South Korea

Roles of sterol regulatory element-binding proteins (SREBPs) have been established as lipid synthetic transcription factors especially for cholesterol and fatty acid synthesis. SREBP-1c isoform, which constitutes more than 90% of the in vivo SREBP-1, is a key regulator of early events in the liver’s response to insulin and is a major determinant of lipogenic gene transcription. In this study, we explored the role of SREBP-1c on NASH and LCN2 gene expression regulation. Wild-type and SREBP-1c knockout (KO) mice fed with a high-fat/high-sucrose diet, carbon tetrachloride (CCl4)-treated, and with lipocalin-2 (LCN2) overexpression. LCN2 gene expression and secretion increased in CCl4-induced liver fibrosis mice models, and SREBP-1c regulated LCN2 gene transcription. Moreover, treatment with holo-LCN2 stimulated intracellular iron accumulation and fibrosis gene expression in mouse HSCs, but this effect was not observed in SREBP-1cKO HSCs, indicating that SREBP-1c-induced LCN2 expression and secretion regulate HSCs' activation through iron accumulation. Further, LCN2 expression was strongly correlated with inflammation and fibrosis in patients with NASH. Our findings indicate that SREBP-1c regulates Lcn2 gene expression, contributing to diet-induced NASH. Reduced Lcn2 expression in SREBP-1cKO mice protects against NASH development. Therefore, the activation of Lcn2 by SREBP-1c establishes new connection between iron and lipid metabolism, affecting inflammation. These findings may lead to new therapeutic strategies for NASH.

This work was supported by the Technology development Program (RS-2022-00167190) funded by the Ministry of SMEs and Startups (MSS, Korea) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2021R1A6A3A01088315).

Abstract Submission No. 101114
P-0924

Predictive value of AIMS65 score and carvedilol in cirrhotic patients with acute variceal bleeding.

Myeong Jun Song1, Seok Hwan Kim1
1The Catholic University of Korea Seoul South Korea

Background: Acute variceal bleeding (AVB) remains a common and life-threatening complication in patients with liver cirrhosis. We evaluated the ability of various bleeding risk stratification scores including AIMS65 and compared with liver severity as predictors of mortality and rebleeding.

Methods: We retrospectively enrolled 122 patients with liver cirrhosis and AVB at the Daejeon St. Mary’s hospital from April 2014 to March 2021. Patients were risk stratified using AIMS65, ABC, Child-Pugh, Model for End-stage Liver Disease (MELD) scores. Primary outcomes were overall survival and rebleeding.

Results: Liver function showed child A, B, and C (32.7%, 40.9%, and 26.2% respectively). 1-month mortality showed 12.2%. Child class, MELD grade, AIMS65, and carvedilol showed significant stratification of 1Month-Mortality except ABC score (P=0.011, 0.015, <0.001, and 0.007 but P=0.353). The mean OS of AIMS65 grade 1, grade 2, and grade 3 patients were 72.9, 40.3, and 28.9 months, respectively (<0.001). The ABC, child class, and MELD also significantly showed survival difference (P=0.025, P=0.003, and P=0.000, respectively). However, AIMS65, ABC, child class, and MELD did not predict rebleeding risk (P=0.655, P=0.548, P=0.180, and P=0.160, respectively). On the other hand, treatment of carvedilol showed survival benefit and reduced rebleeding rates (P=0.001, 0.021, respectively). In a multivariate analysis, the AIMS65 and carvedilol treatment were significant predictive factors for OS (P=0.006, 0.000, respectively).

Conclusion: AIMS65 is superior to established AVB and liver disease severity risk stratification scores in predicting mortality of cirrhotic patients with AVB. In addition, carvedilol treatment reduced overall mortality and rebleeding. Therefore, application of AIMS65 score and treatment of carvedilol may show more favorable clinical outcome in patients with AVB.

Abstract Submission No. 101374
P-0925

Overexpression of MUDENG in liver enhances CCl4-induced liver fibrosis

Ju-Yeon Cho1, Jung Hee Park1, Ji Hye Han1, Seung Hyun Myung1, Tae Hyung Kim1
1Chosun University Gwang-Ju South Korea

A diagnostic ultrasound system (Aplio™, Toshiba Medical Systems Corporation, Tochigi, Japan) and convex probe was employed in this study.

5. Results
The SWE values were 1.5 m/s in the normal adult group 2.73 m/s in the chronic hepatitis group 2.71 m/s in the cirrhosis group and 9.43 m/s for patients with cirrhosis and ascites. In the ascites patients, we measured before and after ascites drainage.

7. Conclusion
The results of the present study suggest that noninvasive SWE may become the method of choice for assessing hepatic fibrosis in routine clinical practice.

Abstract Submission No. 101374
P-0925

Overexpression of MUDENG in liver enhances CCl4-induced liver fibrosis

Ju-Yeon Cho1, Jung Hee Park1, Ji Hye Han1, Seung Hyun Myung1, Tae Hyung Kim1
1Chosun University Gwang-Ju South Korea
**Background and Aims:** Transforming growth factor (TGF)-β plays an important role in the activation of hepatic stellate cells. AP5M1 is known to participate in cell death and has been reported to be involved in Golgi trafficking. In this study, we identified the physiological effects of AP5M1 in mouse liver with overexpression and suppression of IL11.

**Method:** Eight 8-weeks-old male human AP5M1 transgenic (hAP5M1-Tg) mice and eight C57BL/6N male mice were injected with carbon tetrachloride. Lenti-mIL11 and Lenti-mIL11 mutein viruses were injected intraperitoneally into 6-week-old mice and intranascally into the mice after a week. The difference in the percent collagen area was evaluated.

**Results:** The collagen proportionate area (CPA) in C57BL/6N mice infected with Lenti:mIL11 or Lenti:mIL11 11 mutein showed no difference in the absence of liver injury caused by CCl4. However, CCl4 injected Lenti:mIL11 mutein infected C57BL/6N mice demonstrated significantly reduced collagen accumulation in the liver tissue compared to Lenti:mIL11 infected C57BL/6N mice. In hAP5M1 transgenic mice, the infection of Lenti::mIL11 or Lenti::mIL 11 mutein showed no significant difference in the CPA. The expression levels of collagen, α-SMA, and TGF-β were higher in the liver of hAP5M1-Tg mice challenged with CC14 than in the liver of C57BL/6 mice.

**Conclusion:** Overexpression of hAP5M1 enhances liver fibrosis caused by intraperitoneal injection of CCl4. C57BL/6N mice infected with Lenti::mIL11 11 mutein showed significantly reduced collagen accumulation in the liver. The application of IL11 mutein may be considered as a potential treatment method for alleviating liver fibrosis.

Abstract Submission No. 101639

**NAFLD combined with HBV significantly worsens the clinical tests and degree of the liver fibrosis**

Gulzhan Seidakhmetova1, Ainura Amirkulova1, Rauza Bigarinaova1

1Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan Astana Kazakhstan

**Background:** Nonalcoholic fatty liver disease (NAFLD) and Hepatitis B virus infection (HBV) are increasingly prevalent with worldwide distribution and represent a growing challenge in terms of prevention and treatment. To determine whether body-mass index (BMI) is associated with liver-related enzyme elevation and liver tissue state among HBV carriers and other viral infections we prospectively reviewed to analyze the relationship between HBV infection and NAFLD.

**Patients and Methods:** Our study was performed on 51 patients who were treated in our hospital from May 2019 to June 2023, who were free of cancer and surgery. Main outcome measures included biochemical blood tests, Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDF), and imaging-based elastography.

**Results:** During the follow-up of four years, there was no case of hepatocellular carcinoma (HCC) or death. There is no association between gender or age with NAFLD. Excess BMI was significantly associated with the occurrence of liver steatosis (p<0.0001), detected by MRI-PDF as well as elevated ALT, AST, bilirubin, and triglycerides during follow-up (Table 1). Also, the association of BMI with liver fibrosis (p<0.009), detected by elastography (Figure 1), was strong and together with elevated alpha-fetoprotein (AFP) levels might be the accurate predictors for incident HCC and liver-related death. In addition, HBV infection cases elevated, but not significantly (p=0.0674) in NAFLD patients.

**Conclusion:** In conclusion, our study indicates that dysregulated fatty-acid metabolism and lipotoxicity in NAFLD seem to initiate liver-tissue inflammation, disrupt hepatocyte cell homeostasis, and promote the progression to fibrosis, and HCC. HBV-NAFLD co-existence may further have an additional impact on liver disease progression.

Abstract Submission No. 101895

**Enhancing Diagnostic Precision in Advanced Liver Disease Detection Utilizing M2BPGi**

Naphathorn Asavapuriyothin1, Swee Jin Tan1, Wattana Sukeepaisarnjaroen2

1Sysmex Thailand Bangkok Thailand, 2Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Khon Kaen University Khon Kaen Thailand

**Background:** Chronic liver disease is a major challenge in Thailand, requiring easily accessible biomarkers for identifying critical cases. Non-invasive testing, particularly using the novel serum marker Mac-2 binding protein glycosylation isomer (M2BPGi), is a promising method for remote support. The study aims to assess M2BPGi’s accuracy in complementing existing protocols for detecting severe fibrosis and cirrhosis across diverse causes.

**Methods:** The study, approved by the institutional review board, involved 132 patients with varied liver fibrosis, stemming from hepatitis B and C, and non-alcoholic fatty liver disease. Utilizing residual serum samples, the accuracy of the novel serum marker M2BPGi was assessed against classical biomarkers, including APRI, FIB-4, transient elastography, and liver biopsy. Additionally, a sequential assessment aimed to determine diagnostic accuracy in profiling advanced liver disease (F3/4 cases), crucial for specialist center care.

**Results:** Our study found positive correlations between M2BPGi and classical liver disease markers (APRI, FIB-4, TE, and liver biopsy) using Pearson correlations. M2BPGi showed superior diagnostic accuracy compared to other non-invasive markers (AAR, PLT, APRI, and FIB-4) based on AUROC curve analysis. Combining M2BPGi with TE for fibrosis staging in advanced liver disease resulted in an AUROC of 0.83. Using a sequential diagnostic algorithm with FIB-4 as the initial parameter and subsequent M2BPGi testing (cutoff of 1.0) improved the ability to distinguish advanced disease, increasing patient referral accuracy from 59% (using FIB-4 alone) to 79%.

**Conclusions:** In conclusion, non-invasive liver disease testing using novel serum marker M2BPGi emerges as a promising method, particularly in supporting remote testing.

Abstract Submission No. 102034

**Serum DANCE levels in MASLD and significance of elastic fibers in fibrosis development**

Hirotoshi Ebinuma1, Kazuaki Inoue1, Mina Komuta2

1Department of Gastroenterology & Hepatology, School of Medicine, International University of Health and Welfare Narita Japan, 2Department of Pathology, School of Medicine, International University of Health and Welfare Narita Japan

**Background and Purpose:** There are two types of fibers that construct liver fibrosis: collagen fibers and elastic fibers, but in recent years there have been few reports on the differences and significance of the two types of fibers. However, elastic fibers have some useful findings, such as the absence of newly developed elastic fibers in acute hepatitis and the fact that those in the portal region reflect the actual degree of hepatic fibrosis. In particular, the involvement of elastic
fibers in fatty liver diseases such as alcohol-associated liver disease and NASLD has been considered less significant than in viral liver diseases. Recently, DANCE (developmental arteries and neural crest EGF-like), an index of elastic fiber content, has become available as a simple serum assay. Therefore, we measured serum DANCE levels in patients with NASLD and investigated its usefulness.

**Methods:** We measured serum DANCE concentrations in 60 NAFLD patients and 20 healthy subjects undergoing treatment at our units, and compared them with existing fibrosis markers such as M2BPGi, type IV collagen 7S, and FIB-4, as well as liver histology in patients who underwent liver biopsy, in addition to general blood data.

**Results:** Serum DANCE levels were higher in NAFLD patients than in healthy controls, especially in MASH patients (healthy vs. non-MASH vs. MASH: 122 vs. 151 vs. 213 ng/mL, p=0.0001). This value correlated with the degree of fibrosis on liver biopsy histology (p<0.0001) and with existing fibrosis markers such as M2BPGi (p=0.0002), type IV collagen 7S (p<0.0001) and FIB-4 (p<0.0001). DANCE levels did not correlate with the degree of liver tissue inflammation or AST and ALT levels, suggesting that DANCE is a fibrosis marker independent of liver inflammation.

**Conclusion:** DANCE, also known as fibulin-5, is an essential protein for elastic fiber formation. In this study, DANCE levels increased with the progression of liver tissue regardless of the intensity of inflammation, suggesting that DANCE may be useful as a new fibrosis marker. On the other hand, elastic fibers are involved in the progression of NASLD, and their role in the progression of fibrosis should be investigated in the future.

Abstract Submission No. 200031

**P-0929**

**Role of Spleen Stiffness Measurements with 2D-SWE for esophageal varices in patients with cACLD**

ZENOVIA SEBASTIAN1, 2, 3, C Stanciu1, 2, 3, CM Muzica1, 2, 3, AM Singeap1, 2, 3, H Minea1, C Sfarti1, 2, 3, I Girleanu1, S Chiriac1, 2, 3, T Cuciureanu1, L Huihan1, R Nastasa1, R Stafe1, E Stratința1, A Rotaru1, 2, 3, A Trifan1, 2, 3

1St Spiridon Clinical Hospital, Iasi, University of medicine and Pharmacy Gr.T.Popa Iasi Iasi Romania, 2St Spiridon Clinical Hospital, Iasi, University of medicine and Pharmacy Gr.T.Popa Iasi Iasi Romania, 3St Spiridon Clinical Hospital, Iasi, University of medicine and Pharmacy Gr.T.Popa Iasi Iasi Romania

**Background:** Spleen stiffness measures (SSM) as a non-invasive diagnostic technique for esophageal varices (EV) have been studied, with the majority of the data collected by transient elastography (TE). Using 2D Shear-Wave Elastography(2D-SWE.PLUS) integrated into the Supersonic Imagine Axiplozer system.

**Aim:** We aimed to determine the diagnostic performance of SSM for the presence of EV in patients with compensated advanced chronic liver disease (cACLD).

**Methods:** We prospectively enrolled patients with cACLD (≥12.5 kPa by Transient Elastography) from January 2023 to November 2023 without history of liver decompensation. All patients included performed an esophago-gastro-duodenoscopy (EGD) for varices assessment and a complete abdominal multiparametric assessment of liver and spleen assessment using Axiplozer MACH 30 (Supersonic Imagine, Aix-en-Provence, France).

**Results:** There were 73 patients analyzed (78% were men, the mean age 60.3 ± 12.1, BMI 23.1± 5.12 kg/m2). Eighteen (24.7%) had alcoholic liver disease, 29 (39.7%) had non-alcoholic fatty liver disease, 11 (15.1%) had chronic viral hepatitis, and 15 (20.5%) had various etiologies. The mean SSM was 38.6 ± 12.8 kPa whereas the mean liver 2D-SWE.PLUS was 17.4 ± 8.61 kPa. EV was detected in 37 (50.7%) patients [grade I – 11 (29.7%); grade II – 10 (27%); grade III 16 (43.2%)]. High risk EV (grades II/III) were associated with higher spleen (p<0.001) and liver (p = 0.017) 2D-SWE.PLUS, increased spleen volume (p< 0.001), portal vein (p <0.001) and splenic vein diameter (p = 0.008). A cut-off of 31.3 kPa of SSM could predict any grades of EV (Ss 92%, Sp 54%, PPV 73.7%,NPV 90%, AUROC 0.807, p< 0.001), while a value of 44.3 kPa can predict EV grade 3 with red signs and white nipples of Sp of 92.1%, Sv of 73.1%, PPV of 37.3%, and NPV of 92.9%, AUC = 0.881, P = 0.001.

**Conclusion:** 2D-SWE SSM is a valid approach for ruling in or out EV in cACLD individuals. If bigger studies validate this results, up to 50% of endoscopies might be prevented in this patients.

Abstract Submission No. 200135

**P-0930**

**Rosa rugosa Thunb. extract attenuates hepatic fibrosis via inhibition of TGF/Smad signaling pathway**

Sang Mi Park1, 2, Sung Hui Byun1, Sang Chan Kim1, 2

1Daegu Haany University College of Korean Medicine Gyeongsangbuk-Do South Korea, 2Daegu Haany University Research Center for Herbal Convergence on Liver Disease Gyeongsangbuk-Do South Korea

*Rosa rugosa* Thunb. has been used to treat hematemesis, dysmenorrhea, diarrhea, and dysentery. The present study investigated anti-fibrogenic effects of *Rosa rugosa* Thub. extract (RRE) in vivo and in vitro. We evaluated the effects of RRE to inhibit transforming growth factor-β1 (TGF-β1)-induced LX-2 cells (a human hepatic stellate cell (HSC) line) using biochemical assays, reporter gene assays, and immunoblot analysis. Additionally, we conducted a model of carbon tetrachloride (CCl4)-mediated liver fibrosis to examine the effects of RRE using serum biochemistry, histopathological analysis, and immunohistochemistry. Up to 100 μg/ml RRE treatment showed no cytotoxicity on LX-2 cells. Treatment with RRE significantly blocked TGF-β1-inducible Smad binding element-driven luciferase activity, Smad2 and Smad3 phosphorylations, and plasminogen activator inhibitor-1 expression in HSCs. Also, increases of matrix metalloproteinases-2 and -9 genes, and α-smooth muscle actin (α-SMA) expression by TGF-β1 were diminished by RRE treatment. Moreover, administration of RRE significantly inhibited the alanine aminotransferase and aspartate aminotransferase activities mediated by CCl4. RRE administration also prevented liver fibrosis, as showed by decreases in hepatocellular degeneration, inflammatory cell infiltrations, collagen fiber accumulation, and α-SMA immunoreactivity in mice. Therefore, RRE may be a promising candidate to attenuate hepatic fibrosis through inhibition of TGF/Smad signaling pathway.

Abstract Submission No. 200137

**P-0931**

**A prospective validation study for the Baveno elastography criteria in shear wave elastography**

Teng-Yu Lee1, Chia-Chang Chen1, Jing-Tong Fu2, Shou-Wu Lee1, Hsin-Ju Tsai1, Sheng-Shun Yang1

1Division of Gastroenterology & Hepatology, Taichung Veterans General Hospital Taichung Taiwan, 2Department of Pathology and Laboratory Medicine, Taichung Veterans General Hospital Taichung Taiwan
Background: The Baveno criteria for assessing advanced liver fibrosis were mainly determined by transient elastography (TE), and its pathology-based validation studies in two-dimensional shear-wave elastography (2D-SWE) remain limited.

Aim: To validate the Baveno criteria through use of 2D-SWE.

Method: Consecutive patients who underwent liver biopsies for various benign liver diseases were prospectively recruited. Liver stiffness measurement (LSM) was simultaneously evaluated by TE and 2D-SWE. The optimal cut-off value to predict advanced liver fibrosis was determined by the Youden Index, and the diagnostic performance was estimated using area under the receiver operating characteristic (AUROC) analysis.

Results: A total of 101 patients were enrolled having a median age of 55.0 (IQR: 46.0-63.5) years, with 53 (52.48%) of them being male. Using <9 and >14 kPa as the optimal dual cut-offs, the AUROC values in TE and 2D-SWE were 0.92 (95% CI: 0.83-0.97) and 0.93 (95% CI: 0.84-0.98), respectively (P= 0.61). The sensitivity and specificity of LSM by TE/2D-SWE achieved rates of 94.44%/94.44% and 86.00%/88.00%, respectively. However, using the Baveno criteria, the AUROC values in TE and 2D-SWE could remain achieving 0.91 (95% CI: 0.82-0.97) and 0.93 (95% CI: 0.84-0.98), respectively (P= 0.36). The sensitivity and specificity in TE/2D-SWE were 88.24%/88.24% and 86.79%/90.57%, respectively.

Conclusion: This study establishes the compatibility of the Baveno dual cut-off criteria with 2D-SWE, positioning it as an easily used criteria in clinical practice and research.

Abstract Submission No. 100466
P-0934

Drug-related problems managed by pharmacists for cirrhotic patients in Singapore General Hospital

Carissa Jing Hui Fok1, Mei Ling Yee1
1Singapore General Hospital Singapore Singapore

Background: Pharmaceutical care service with the Liver Team was initiated in 2017 in Singapore General Hospital (SGH). The roles of the liver pharmacist include reviewing medications for patients admitted under the Liver team, identifying drug-related problems (DRP), discussing and optimising pharmacotherapy with hepatologists.

Aim: Describe types of DRP identified and managed by a Liver pharmacist for patients admitted under Liver team specialty in SGH.

Methods: DRP intervened by Liver pharmacists from 1 January to 31 December 2022 were retrospectively retrieved from SGH electronic medical records.

Results: A total of 484 patients were reviewed by Liver pharmacists. 261 DRP were identified and interventions made. The highest percentage of DRP was for inappropriate drug regimens (37.2%), followed by omission of drug therapy at 16.9%. 13.4% of DRP were to avoid adverse drug reactions, where recommendations include discontinuation of drug, dose reduction or switching to alternative drug choice. 11.5% of DRP were for drugs with no indication and thus discontinuation was recommended. Some commonly encountered DRP were renal dose adjustment of antibiotics, deprescribing proton-pump inhibitors and changing diluent of intravenous medications to reduce sodium load for ascitic patients. Vaccination in cirrhosis patients was initiated in July 2022. 17 patients (3.5%) had vaccinations prior to discharge.

Conclusion: The continual involvement of pharmacists in optimizing medication therapy has improved prescribing accuracy and safety, thereby improving patient quality of care. Moving forward, the analysis on DRP may guide designing of an effective education on pharmacotherapy in liver cirrhosis for our junior doctors, nurses and pharmacists.

Abstract Submission No. 100841
P-0945

Values of Nurse Practitioners in Managing Chronic Liver Disease Patients in an Acute Care Hospital

Colina Yim1, Elizabeth Lee1
1University Health Network Toronto Canada

Background: Literature has provided evidence the value of integrating nurse practitioners (NPs) into the health care system. NPs specialized in hepatology remain rare in Canada. This study aims to describe the clinical role and outcomes of the two hepatology NPs practicing in an acute care hospital in Toronto.

Abstract Submission No. 100188
P-0933


Zhi Boon Tan1, Yang Hee Seung1, Cheng Han Ng1, Wen Hui Lim1, Darren Jun Hao Tan1, Nicholas Syn1, Daniel Q. Huang1, Mark D. Muthiah1, Margaret Teng1
1National University Hospital (NUH) Singapore Singapore

Chronic liver disease (CLD) is an important cause of morbidity and mortality globally. Socioeconomic factors of CLD patients such as employment status can potentially affect their prognosis. This study thus investigates the influence of employment status on mortality in CLD patients using data from the National Health Interview Survey (NHIS) from 2005 to 2018.

NHIS is a cross-sectional health survey representing the non-institutionalized U.S. population. Individuals aged ≥18 years with available parameters for CLD evaluation and employment status were included in the study. Mortality analysis utilized NHIS data linked to National Death Index (NDI) death certificates. Cox proportional hazards and Fine-Gray subdistribution hazard ratio models were applied to assess associations, adjusting for various factors, including comorbidities, lifestyle behaviors, and sociodemographic characteristics.

18,108 CLD patients, with 7,856 employed and 10,252 unemployed individuals were included in the study. Employed CLD patients were younger, more likely to be male, and had fewer comorbidities. Univariate and multivariate analyses revealed that employment status was significantly associated with lower overall mortality (multivariate HR: 0.329, 95% CI: 0.194 to 0.557, p<0.001). Employed CLD patients also had lower rates of cardiovascular-related mortality (sHR: 0.297, 95% CI: 0.122 to 0.720, p=0.007) and cancer-related mortality (sHR: 0.228, 95% CI: 0.094 to 0.552, p<0.001).

Overall, employment status is a significant predictor of lower mortality in CLD patients, with employed individuals experiencing reduced overall, cardiovascular, and cancer-related mortality.

Abstract Submission No. 100188
P-0933
Methods: The Toronto Centre for Liver Disease has 2 full time NPs working collaboratively with hepatologists. Data presented were extracted from hospital EMR. Outcome measures include 90-days hospital readmission rate, safety of paracentesis performed, and size of HCC on detection.

Results: A total of 1,108 patients were under the direct care of the 2 NPs. Disease etiologies of their patients are largely hepatitis B and alcohol related liver disease. They performed 11 % of the total number of therapeutic paracenteses within a 6-month study period. No procedure complications were observed demonstrating NPs can perform the procedure as safely as their physicians counterparts.

The NP-led post discharge transitional care program is effective in reducing 90-day readmission risk for patients with advanced liver disease. This is the result of a retrospective cohort study (Jan 2018 to Dec 2019) (Manuscript in preparation).

In patients with chronic hepatitis B being followed by the NP for > 2 years, the size of hepatocellular carcinoma at presentation is smaller (< 2.9 cm) if detected.

Conclusions: This study demonstrates the extended clinical role and the values of hepatology NPs. The NPs' specific role and scope of practice can be tailored to organization and departmental needs.

Abstract Submission No. 100955
P-0936

Kidney transplantation and the regeneration: From the past to the future

Zulfa Saumia

1UNIVERSITAS JAMBI Jambi Indonesia

According to the World Health Organization, 5 to 10 individuals die globally each year due to a lack of access to kidney disease treatment. Kidney disease continues to be a significant contributor to mortality and morbidity worldwide. The available treatment options for managing kidney disease involve medical or surgical intervention.

How will technology and science impact kidney transplants and drug usage currently and in the future?

Kidney transplant is crucial in treating end-stage kidney disease and can enhance patients’ quality of life while extending their lifespan. Many issues can be prevented by correcting abnormalities found during preoperative evaluation. However, it’s essential to avoid technical errors during all stages of the transplant process (donor nephrectomy, bench work preparation, and implant) and to conduct attentive postoperative monitoring, including a comprehensive examination by attending physicians.

Obesity is a growing problem worldwide. It puts kidney transplant recipients at risk both before and after surgery. Experts do not agree on the impact of obesity before and after a transplant. Further research is needed to fully understand this issue.

Finally, there exist two potential pathways for kidney regeneration through the utilization of stem cells: the development of a completely new kidney using stem cells (known as de novo whole kidney fabrication) or the application of stem cell therapy

The progress of knowledge and technology has positively affected kidney transplantation, and it has also lessened the impact on patients after the procedure. However, experts still need to conduct more research to decrease post-surgery mortality.

Abstract Submission No. 101217
P-0937

Bibliometric analysis of publications in Post hepatectomy live failure based on Web of Science

Hezhao Wang1, Jitao Wang1, Congxi Xu1

1Hebei Medical University Shijiazhuang China

Abstract

Aims The article about Post hepatectomy live failure(PHLF) in the Web of Science database was visualized and analyzed by bibliometrics method, so as to provide reference for future research in this field.

Methods: The PHLF-related studies in the Web of Science Core Collection (WoSCC) database were retrospectively collected, and bibliometrics were used to analyze the number of literatures, countries, journals, authors, keywords, etc.

Results: A total of 2150 English literatures were included in the analysis, and the annual publication volume showed an overall increasing trend. The country with the highest number of articles was Japan (488); The journal with the largest number of articles is HPB; The author with the most publications is Timothy M. Bowlik from the United States (30 articles); The research focuses on the mechanism of liver regeneration and liver transplantation in PHLF in the early stage, clinical research and prognosis in the middle stage, and prediction in the near future.

Conclusion: Based on the analysis of articles in the PHLF field by Vosviewer and Citespace, the prediction of PHLF is expected to become a research hotspot in the future.

Abstract Submission No. 101403
P-0938

Effect of branched-chain amino acids in increasing survival among hepatic encephalopathy patients

Micaella Aliza Empleo1, Margarita Isabel Fernandez2, Aaron Lemuel Ong3

1Philippine General Hospital Manila Philippines, 2Philippine General Hospital Manila Philippines, 3Philippine General Hospital Manila Philippines

Hepatic encephalopathy (HE) is a serious complication of cirrhosis and is associated with decreased branched-chain amino acid (BCAAs) levels. Recent meta-analyses have shown that oral BCAAs can help prevent HE development. However, there is conflicting evidence regarding their mortality benefit. A 2017 Cochrane review by Gluud et al. on the efficacy and safety of oral and intravenous BCAAs included 16 studies from 1984 to 2011, with a comprehensive search for articles until May 2017. Their review showed no significant difference in mortality rates between patients given BCAA and control, but there was a beneficial effect on the signs and symptoms of HE among patients who were not treated with lactulose or neomycin. Here, we aim to provide an updated meta-analysis by incorporating the latest available randomized controlled trials (RCTs) to re-assess the treatment and mortality benefit of BCAAs in patients with HE. Databases and existing meta-analyses were thoroughly searched until October 26, 2023. A total of 146 articles were thoroughly screened, with 126 articles excluded and 18 RCTs included based on set inclusion criteria. A total of 996 participants (473 treatment, 521 control) were included. Preliminary findings suggest that BCAAs whether oral, intravenous, or given with active interventions do not have a significant effect on mortality (OR 0.84, 0.60 - 1.18 [95% CI]). Patients given BCAAs orally were shown to have HE improvement when compared against placebo (OR 0.24 (0.08-0.69 [95% CI]) but had no significant effect versus all combined control groups (BCAA OR 0.93, 0.69 - 1.25 [95% CI]).
Role of MR Enterography in assessment of small bowels diseases

Mohamed Soliman1, Enas Mohamed Korayem2, Mohamed Mohamed Houseni3, Manal Ebrahim Gomaa4

1Department of Radiology, National Liver Institute, Menofia University Shebin Elkom Egypt, 2Department of Radiology, National Liver Institute, Menofia University Shebin Elkom Egypt, 3Department of Radiology, National Liver Institute, Menofia University Shebin Elkom Egypt, 4Department of Radiology, National Liver Institute, Menofia University Shebin Elkom Egypt

MR Enterography is a valuable tool in diagnosis and follow up of small bowel diseases. As a non-invasive, radiation-free method for visualizing small bowel and provide information about morphology and function of small bowel, despite small bowel imaging challenges related to its long and tortuous anatomy, continuous peristaltic movement, complex histology.

MRE is done using surface coil and both oral and intra-venous contrast with bowel preparation and antispasmodylic agent, MRE has wide variety of sequences including; Echoplanar imaging, Rapid acquisition with bowel preparation and antispasmodylic agent, MRE has found to be helpful in detected of small bowel vasculitis.

The ShuGanAnWei formula inhibited NSAIDs induced gastrointestinal inflammation and injury

Xu Cao1, 2, Xin Sun1, Tingyu Zhang1, Xiaobin Zao1, 3, Hongbo Du1, Yong'an Ye1, 2, Xiaoke Li1

1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 2Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing Chia, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China

Background: This study aimed to observe the effect of ShuGanAnWei formula (SGAW) in the treatment of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) induced gastrointestinal inflammation and its potential mechanisms.

Methods: The 24 healthy male Sprague Dawley rats were categorized into control, model, SGAW, and rebamipide groups (6 rats/group). Over a 2-week period, the SGAW and rebamipide treatment groups received an clinical equivalent dose drug via gavage. To induce the rat model, 7.5mg/kg diclofenac sodium solution was administered twice a day for the final 5 days, except in the control group. We utilized BAT-MAN-TCM public databases, Cytoscape software and network pharmacology analysis methods to investigate the medicated mechanisms.

Results: Network pharmacology analysis results suggested the mainly related to pathways of SGAW on NSAIDs induced gastrointestinal inflammation were IL-17 signaling pathway. Compared to the model group, SGAW-treated and rebamipide-treated groups rat showed lighter gastrointestinal injury based on the gross photograph observation of the stomach, intestines, and intestinal wall. However, the model group rats exhibited gastrointestinal perforation phenomenon, and the liver surface of the perforated rats were contaminated.

Conclusions: Our study suggested that the preventive treatment of SGAW is beneficial in reducing the occurrence of NSAIDs induced gastrointestinal injury, with efficacy similar to that of rebamipide.
Efficacy of Zinc Acetate in Patients with Chronic Liver Disease

Cleo Christille Lynn G. Lom-oc1, Theresa Leona B. Prudencio1, Karl Paolo O. Diliera1

1Davao Medical School Foundation Hospital, Inc. Davao City Philippines

Background: Upper gastrointestinal bleeding (UGIB) is a common cause of hospitalizations in adult Filipinos. While guidelines recommend upper endoscopy within 24 hours, data on its optimal timing remains limited in the locality. Thus, this study investigated the clinical outcomes in relation to endoscopy timing.

Methods: A single-center retrospective analysis of adult patients diagnosed with UGIB who underwent endoscopy between 2019 and 2022. Patient demographics, clinical data, and endoscopy results were recorded. Patients were categorized based on the endoscopic timing from admission or diagnosis of UGIB: urgent (t≤6 hours), early (t>6-24 hours), late (t>24-48 hours), and very late (t>48 hours). Clinical outcomes compared were 30-day all-cause mortality, further bleeding, endoscopic treatment, average units of blood transfusion, intensive care unit (ICU) admission, and duration of hospitalization within 30 days.

Results: 142 patients were included with a mean age of 62 years, and 66.2% were male. The most common findings were non-variceal (53.7%), malignancy (8.45%), and varices (7.75%). The 30-day all-cause mortality (p=0.26), ICU admission (p=0.747), and number of blood transfusions (p=0.246) were not significantly different. Further bleeding occurred mostly from the late group (14.8%). Endoscopic treatment was performed in 18.3% of patients, with higher rates of intervention for variceal bleeding. A significant association in the duration of hospitalization was observed (p=0.032).

Conclusions: No differences in mortality and clinical outcomes were found in all four groups except for the duration of hospitalization. This study demonstrates endoscopy within 24 hours or until patient is stabilized can be safely performed in an acute setting.

Abstract Submission No. 101899
P-0943

Efficacy of Zinc Acetate in Patients with Chronic Liver Disease Complicated by Hypozincemia

Takashi Kawaguchi1, Yoshiyuki Ida2, Ryo Shimizu2, Shuya Maeshima1, Shiori Kaji2, Reiko Ashida1, Takao Maekita2, Mikitaka Iguchi2, Masayuki Kitano2

1Department of Internal Medicine, Wakayama Medical University Kihoku Hospital Wakayama Japan, 2Second Department of Internal Medicine, Wakayama Medical University School of Medicine Wakayama Japan

Background: Chronic liver disease is one of the known causes of hypozincemia and some studies suggest the effects of zinc acetate administration on liver function in patients with chronic liver disease complicated with hypozincemia. Methods: Among 55 patients with chronic liver disease complicated with hypozincemia who received zinc acetate at our hospital between April 2017 and December 2021 and blood ammonia level, serum albumin level, Child-Pugh score, ALBI score, and Fib-4 Index were con- firmed. The changes in the above laboratory parameters before and 3, 6, 9, and 12 months after zinc acetate administration were compared.

Results: Ammonia levels decreased significantly from 80.3±41.6 μg/dL before treatment to 65.9±41.2 μg/dL at 6 months (p=0.006) and 70.5±39.4 μg/dL at 9 months (p=0.045). Albumin levels increased significantly from 3.2±0.6 g/mL before treatment to 3.3±0.5 g/mL at 3 months (p=0.015) and 3.3±0.5 g/mL at 6 months (p=0.041). Child Pugh score was improved significantly from 7.4±1.8 before treatment to 7.0±1.7 at 6 months compared (p=0.047). The ALBI score was significantly improved from -1.8±0.6 before treatment to -1.9±0.6 at 3 months (p=0.004) and -1.9±0.5 at 6 months (p=0.018). Fib-4 Index was significantly improved from 7.0±4.8 before treatment to 5.8±3.0 at 3 months (p=0.042).

Conclusion: Significant improvement in liver function was observed at 3 and 6 months after administration of zinc acetate. However, the improvement in hepatic function at 9 and 12 months was less pronounced.

Abstract Submission No. 102058
P-0944

Efficacy of MR imaging in clinical management of hepatic encephalopathy and Alzheimer’s disease

Soo Ki Kim1, Soo Ryang Kim1, Toyokazu Okuda2, Hisato Kobayashi3, Akita Asai4, Hiroki Nishikawa4

1Department of Gastroenterology, Kobe Asahi Hospital Kobe Japan, 2Department of Surgery, Kobe asahi hospital Kobe Japan, 3Department of Radiology, Kobe Asahi Hospital Kobe Japan, 4The Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University Takatsuki Japan

In the current aging society, the number of patients with liver cirrhosis demonstrating encephalopathy and/or Alzheimer’s disease (AD) has been increasing; however, addressing the complex clinical diagnosis of hepatic encephalopathy and/or AD is challenging. Hepatic encephalopathy (HE) is defined as brain dysfunction caused by liver insufficiency and/or portosystemic shunting; it manifests as a wide spectrum of neurological or psychiatric abnormalities ranging from subclinical alterations to coma. AD is defined as progressively deteriorating dysfunction of various intellectual domains, memory, language, and executive function. Imaging findings through T1 weighted magnetic resonance imaging (MRI) have disclosed, bilateral symmetric high signal intensity at the globus pallidus, as described in the clinical diagnosis of HE. On the other hand, imaging findings of the Voxel-based specific regional analysis system (VSRAD) in the clinical diagnosis of AD have disclosed significant atrophy exceeding the threshold value of 2 and 1 on a scale of 5 in the target parahippocampal gyrus, revealing significant atrophy extending to the whole brain. The VSRAD system revealed that 12 of 32 (37.5%) elderly patients under treatment for hepatic encephalopathy displayed signs of brain atrophy. The presence or absence of brain atrophy under the VSRAD system has been closely associated with the degree of self-support ability in the activities of Daily Living (ADL) of the aged with HE. The VSRAD system could, thus, play an essential role in the management of the clinical course of patients with HE.

Abstract Submission No. 102067
P-0945

The predictors of the effect by lusutrombopag in patients with liver cirrhosis

Shuji Matsumura1, Koichi Takaguchi1, Akemi Tsutsui1, Tomonori Seno1, Takuya Nagano1

1Kagawa prefectural Central Hospital Takamatsu-shi Japan

Objective: We examined the factors that predict the increase in platelet count in patients with chronic liver disease treated with lusutrombopag. Methods: The subjects were 26 cases.
**Background:** Liver disease was 38/23/15/12 (%) for ALD/HCV/NASH/HBV/others, mean age 65.2 years, 20:6 for men and women, and 42/27/15/8/8 (%) for RFA/TACE/Liver biopsy/EIS/other invasive procedures. They were classified into three groups (< 40,000/40,000 \leq <50,000/50,000 \leq ) based on their platelet counts before administration.

**Methods:** We examined relationship between platelet increase and WBC/RBC/Hb/PT Activity/Alb/Total Bil/AST/ALT/NH3/ALBI Score/VCTE/CAP/Spleen Index (SI)/spleen volume/collateral path diameter.

**Results:** The pre-dose platelet count was \(<40,000\) in 10 patients, 5 patients with 4-50,000, and 11 patients with 50,000, and the mean /Max/Min/Med before administration was 4.8±1.6/8.0/2.6/4.7. On the day of treatment, the rate of platelet count of 50,000 \leq \% was 70% in the <40,000 group and 100% in the 4-50,000 group. The time to reach the highest values was 13±5.3 days and 12.0±5.4 days. The cut-off value of the platelet count required to increase the platelet count to 50,000 \leq \% on the ROC curve was 37.000 (P=0.037), and 100% (3/3) for 37,000 \leq <40,000 and 57.1% (4/7) for <37,000 increased to 50,000 \leq \%.

**Conclusion:** In lusutrombopag treatment, if the platelet count is 37,000 or more, it increases to 50,000 or more, but if it is less than 37,000, it is a strategy to select a treatment drug based on the ALBI score and SI value.

---

**Feasibility and Safety of Transjugular Liver Biopsy (TJLB) for Patients with Chronic Liver Diseases**

Toshihiko Oonishi1, Makoto Iijima1, Takahiro Arisaka1, Akira Yamamiya1, Yuichi Majima1, Keiichi Tominaga1, Kazuyuki Ishida1, Atsushi Irisawa1

1Dokkyo Medical University Hospital TochigiKenn Japan

**Background:** TJLB is recognized as an alternative liver biopsy method in cases where percutaneous liver biopsy (PLB) is not applicable or where bleeding is at risk. The aim of this study to investigate the usefulness of TJLB.

**Methods:** This study is a retrospective cohort study conducted in a single institution. The patient who was requiring liver biopsy between 2014 and 2021at our institution was enrolled. TJLB was performed on patients with accumulated ascites, coagulopathy, and bleeding tendency. The primary endpoint was the utility and safety of TJLB in patients who were not indicated for PLB. Secondary endpoints were technical success rate, the rate of appropriate sample collection for histology and adverse events.

**Results:** The detail of the 26 patients who underwent TJLB were as follows: 8 in acute immune hepatitis (AIH), 4 in drug-induced liver injury, 3 in alcoholic hepatopathy, and 2 in non-alcoholic steatohepatitis (NASH). Conversely, the 123 patients who underwent PLB as follows: AIH in 43, NASH in 13, drug-induced liver injury in 10, Primary biliary cholangitis in 9. Child Pugh score was 9.9 in the TJLB group and 6.4 in the PLB group (P=0.001). The technical success rate and the rate of appropriate sample collection for histology was 100% in both groups. No severe adverse events were recorded in either group.

**Conclusions:** TJLB can be performed safely even in patients for whom regular PLB is difficult, and can be an alternative to PLB.

---

**Mendelian randomization identifies 1400 metabolites that may be pathogenic candidates for NAFLD**

ziwei guo1, Wenliang Lv1

1Guang'anmen Hospital, China Academy of Traditional Chinese Medicine Beijing China

Mitochondria-related proteins (MRPs) and chronic liver diseases have been linked in various studies, although their causal relationship has not been elucidated. In this study, we investigated the causal associations between MRPs and non-alcoholic fatty liver disease (NAFLD), liver cirrhosis and hepatocellular carcinoma (HCC) by two-sample bi-directional Mendelian randomisation (MR) analysis. The random-effect inverse variance weighted (IVW) is the primary analysis for causality analysis while MR-Egger and Weighted Median (WM) as complementary analyses. Cochran Q test, MR-Egger intercept test, MR-PRESSO and leave-one-out analysis were used for sensitivity analyses. In addition, we performed bonferroni correction, multivariable MR analysis (MVMR), reverse causality detection and protein-protein interaction (PPI) network to enrich the results of this study. After rigorous genetic variant selection, IVW, sensitivity analysis, 3 genetically determined MRPs were significantly associated with NAFLD [MRPL33 (OR: 1.06, 95% CI: 1.00-1.11, p=0.0284), MRPL34 (OR: 0.88, 95% CI: 0.78-0.98, p=0.0294) and FARS2 (OR: 0.90, 95% CI: 0.84-0.97, p=0.0120)]. 2 MRPs were significantly associated with liver cirrhosis [MICU1 (OR: 1.11, 95% CI: 1.00-1.22, p=0.0337) and NUDT8 (OR: 1.16, 95% CI: 1.03-1.30, p=0.0096)]. 4 MRPs were significantly correlated with HCC [MRPL32 (OR: 0.62, 95% CI: 0.39-0.99, p=0.0492), MRPL33 (OR: 1.29, 95% CI: 1.07-1.55, p=0.0063), SCO1 (OR: 0.56, 95% CI: 0.38-0.83, p=0.0036) and SIRT5 (OR: 0.71, 95% CI: 0.53-0.96, p=0.0283)]. Our findings provide a new perspective on the exploration of the underlying mechanisms of chronic liver diseases. However, further studies are still needed to explore the mechanisms of possible potential causal associations between MRPs and chronic liver diseases.
0.006), bilirubin degradation product, C17H18N2O4 (2) levels (OR = 1.13, 95% CI = 1.06-1.21, P = 0.0001), bilirubin degradation product, C17H18N2O4 (3) levels (OR = 1.12, 95% CI = 1.05-1.18, P = 0.023). This study provides evidence support for the causal effect of seven metabolites on NAFLD, and provides new perspectives for combining genomics and metabolomics to explore the biological mechanisms of NAFLD.

Abstract Submission No. 200134
P-0949

Sihosogan-tang has diverse pharmacological effects on liver disease

Hyo Jeong Jin1, Sang Mi Park1, Ye Lim Kim1, Jong Seong Roh1, Sook Jahr Park2, Sang Chan Kim1
1Daegu Haany University College of Korean Medicine Gyeongsangbuk-Do South Korea, 2Daegu Haany University Department of Pharmaceutical Engineering Gyeongsangbuk-Do South Korea

Liver diseases, including hepatitis, fatty liver, liver fibrosis, liver cirrhosis and liver cancer, are occurred due to various causes such as damage of hepatocytes, activation of Kupffer cells and stellate cells. Therefore, we investigated diverse pharmacological effects of Sihosogan-tang (SST) on liver disease. To confirm the effects of SST, HepG2 cells were exposed to AA+iron to induce oxidative stress. RAW 264.7 cells were activated by LPS to induce inflammatory response. LX-2 cells were treated by TGF-β1 to induce fibrosis. Cell viability was measured through MTT assay and the expression level of proteins was confirmed by immunoblot analysis. ROS production, GSH level, mitochondrial membrane potential, NO production and pro-inflammatory cytokines were measured using DCFH-DA, GSH assay kit, FACS analysis, Greiss reagent and ELISA kits, respectively. As a result of study, SST suppressed AA+iron-induced cell death, in addition, SST inhibited the mitochondrial dysfunction and excessive ROS production and increased GSH level. Furthermore, SST increased the accumulation of Nrf2 in the nucleus and regulated Nrf2 target genes. In LX-2 cells, SST suppressed the expression of phospho-IkBα, NF-kB and phospho-MAPK. In LX-2 cells, SST decreased the expression of α-SMA, phospho-Smad 2/3 and PAI-1 induced by TGF-β1. On the whole, SST has diverse pharmacological effects such as hepatoprotective effect via Nrf2 pathway, anti-inflammatory effect through the NF-κB pathway and anti-fibrotic effect by way of TGF-β1/Smad signaling pathway.

Abstract Submission No. 200263
P-0950

Establishment of Ultrasonography Center for Effective Diagnostic Testing at Our Hospital

Hayate Ishizuka1, Kazuhiko Osawa2, Minoru Fukunaga3, Ai Fujiwara4, Miki Matsui5, Maki Tobari2, Hitoshi Maruyama2, Shuichiro Shiina2, Akio Saiura3, Ryohei Kuwatsuru4
1Department of Clinical Laboratory, Juntendo University Hospital Tokyo Japan, 2Department of Gastroenterology, Juntendo University Hospital Tokyo Japan, 3Department of Hepatobiliary-Pancreatic Surgery, Juntendo University Hospital Tokyo Japan, 4Department of Radiology, Juntendo University Hospital Tokyo Japan

Background: Our hospital’s Ultrasonography Center was established in November 2021. Prior to its opening, abdominal, pelvic, and superficial ultrasonography examinations were conducted separately by each medical department. The centralization of these examinations has enabled the efficient operation of staff and ultrasound diagnostic equipment. By increasing the number of examinations, we contribute to the early detection and treatment of diseases. Additionally, collaborative discussions among examination staff regarding ultrasound findings have led to an improvement in technical proficiency.

Overview of the Ultrasonography Center: The Ultrasonography Center consists of 9 examination rooms, each equipped with medical information terminals and high-definition monitors. Examinations are conducted with reference to electronic medical records and images. There is a separate space for creating reports, enhancing the overall efficiency of the examination booths. The average monthly imaging efficiency of the examination booths. The average monthly
The effectiveness of hepatitis A vaccine in liver transplanted children

Palitthya Sintusek1, Siriporn Kunhsri2, Preeyaporn Vichaiwattana3, Supranee Buranapraditkun2, Yong Poovorawan1

1Chulalongkorn University Bangkok Thailand, 2Thai Pediatric Gastroenterology, Hepatology and Immunology Research Unit Bangkok Thailand, 3Center of Excellence in Clinical Virology Bangkok Thailand

Objectives: The data in liver transplant (LT) children have been not established. The present study aims to evaluate the seroprevalence of HAV and the effectiveness of inactivated HAV vaccine in seronegative LT children.

Methods: Medical record, vaccination book and anti-HAV IgG were assessed. Seronegative LT children received inactivated HAV vaccine at 0 and 6 months. Blood sampling was collected for anti-HAV IgG at 0, 1, 6 and 7 months after the first dose (visit 1, 2, 3 and 4). Adverse effect was recorded within 3 days after immunization.

Results: Of 105 LT children, there were 85 (81%) children had vaccination record in which 6 (7.1%) and 14 (16.5%) of them received one dose and two doses of HAV vaccine. After LT, the prevalence of seropositive was 20.1% in which 9.5% of them was from immunization. The seropositive rate in 2-dose immunized children was 71.4%. Of 83 LT children (age 7.25 (4.40) years) who had seronegative and received 2-doses HAV vaccination. The seropositive rate was significantly increased from 68.1% to 95.7% at visit 2 comparing to visit 4 (P=0.035). The were significantly increase of the titer of anti-HAV IgG at visit 2 comparing with visit 4 (0.24 (1.24 (0.53, 2.6) vs 12.81 (9.61, 14.42), (P<0.001)). No serious adverse effect was recorded. Serum albumin tended to be an associated factor for antibody response after vaccination (277.93 (0.66, 117656.1), P=0.068).

Conclusions: The seroprevalence of HAV in LT children was low. Two-dose inactivated HAV vaccination in LT children were significantly effective and safe.

Abstract Submission No. 101961
P-0954

Psychosocial Programs for Pediatric Liver-Related Disease
Treatment Approach: LMICs Analysis

Vivi Usmayanti1, Helena Kartika Utami2

1Universitas Sriwijaya Palembang Indonesia, 2Bhayangkara Hospital Jambi Indonesia

Objectives: The crucial role of psychosocial programs (PP) has risen in children with liver disease. This study aims to analyze the field of study in which treatment can be delivered to children in emerging countries by discovering research that may be beneficial for adopting the best treatment for pediatric liver disease.

Methods: This study used the review procedures with modifications, including co-word analysis, themes mapping. The articles to be reviewed were identified by entering the search keywords “Pediatric” AND “Liver” AND “Psychosocial Program” AND “Emerging Countries” in the Scopus. After applying the criteria, 34 articles were used in the subsequent analysis in Asia.

Results: Psychosocial programs focus on the treatment of care planning and Quality of Life (QoL) in the long term. Initiating the treatment in psychosocial assessment such as reducing anxiety or depression, and improving family and social support are the main goals. Pediatric autoimmune liver disease that requires life-long psychosocial programs reports children tend to have lower health-related QoL. Therefore, the parents as informal caregivers of pediatric liver transplantation have high anxiety (51.5 ± 4.8) which results in a lower of the children’s QoL. Meanwhile, the satisfaction of both caregivers and
Clinicopathological Study of Intrahepatic IPNB Resection Cases at Our Hospital

SHOICHIRO ARAI1, Toru Hisaka1, Daiki Miyazaki1, Kazuaki Hasimoto1, Ryuta Midorikawa1, Syougo Fukutomi1, Masanori Akas1, Yuichi Goto1, Taro Isobe1, Naoki Mori1, Hisamune Sakai1, Nobuya Ishibashi1, Fumihiro Fujita1

1KURUME UNIVERSITY Kurume Japan

Abstract Submission No. 200003
P-0955

Background: Intraductal papillary neoplasm of the bile duct (IPNB) has been reported to be pathologically similar to intraductal papillary mucinous neoplasm of the pancreas (IPMN). However, to date, there have been few reports on the relationship between the two neoplasms, and many points remain poorly understood. In this study, we clarified the characteristics of IPNB using an autopsy case and investigated its relationship to IPMN.

Methods: We conducted a histopathological study of 14 cases of intrahepatic IPNB resected at our hospital between 2005 and 2021.

Results: The median patient age was 67.2 years. Cases could be classified into four subtypes according to the handling protocol. Mucus production was observed grossly in 7 cases and microscopically in all cases. Histologically, papillary growth of mild to highly atypical adenoma or invasive carcinoma was observed, and the advanced part of the tumor showed intraepithelial extension along the bile duct mucosa. Recurrence was observed in four patients, with a median recurrence period of 35.1 months, and all recurrences occurred in the common bile duct distal from the site.

Conclusions: A variety of atypia characteristic of adenoma to intraepithelial carcinoma and invasive carcinoma was observed in IPNB, which was shown to be clinicopathologically similar to IPMN in terms of intraepithelial extension and atypical recurrence. A comparatively more favorable prognosis is associated with IPNB compared with that of conventional cholangiocarcinoma, and in cases of recurrence, IPNB can be safely resected.

Abstract Submission No. 200212
P-0956

Correlation between monocytes and HBsAg clearance in children with chronic hepatitis B

Yanwei Zhong1, Xiuchang Zhang2, Min Zhang1, Yuxi Ning1, Ce Shi1

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing China, 2Hebei North University Zhangjiakou China

Abstract Submission No. 200222
P-0957

B cell transcriptional characteristics of children with chronic hepatitis B

Yanwei Zhong1, Min Zhang1, Xiuchang Zhang2, Qingchen Lv1, Ce Shi1

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing China, 2Hebei North University Zhangjiakou China

Abstract Submission No. 200230
P-0958

Correlation between monocytes and HBsAg clearance in children with chronic hepatitis B

Yanwei Zhong1, Xiuchang Zhang2, Min Zhang1, Yuxi Ning1, Ce Shi1

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing China, 2Hebei North University Zhangjiakou China

Abstract Submission No. 200222
P-0957

B cell transcriptional characteristics of children with chronic hepatitis B

Yanwei Zhong1, Min Zhang1, Xiuchang Zhang2, Qingchen Lv1, Ce Shi1

1the Fifth Medical Center of Chinese PLA General Hospital, Beijing China, 2Hebei North University Zhangjiakou China

Abstract Submission No. 200230
P-0958
Immune characteristics of CHB children with poor treatment outcomes

Yanwei Zhong¹, Min Zhang¹, Xiuchang Zhang¹, Ce Shi¹, Lingrui Ren¹
¹the Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, ²Hebei North University Zhangjiakou, China

Objective: To explore the immune characteristics of chronic hepatitis B children with poor treatment outcomes.

Methods: Establishing antiviral treatment cohort for children with chronic hepatitis B. The qualified peripheral blood cell samples were obtained for cell sorting, and the selected B cell samples were sequenced by single cell 5'ST terminal transcriptome and immune bank, and the transcriptome data and BCR immune bank data were obtained for single cell sequencing, cell clustering analysis and labeling annotation.

Results: Plasma cells, naive B cells, memory B cells, activated memory B cells and other cell clusters were identified, and the proportion of naive B cells in the HBsAg loss group was higher than those with poor treatment outcomes, while memory B cells showed a lower proportion of cells in poor treatment outcomes group.

Conclusion: Naive B cell and memory cell populations may be associated with children with poor treatment outcomes.

Abstract Submission No. 100047
P-0959

IMPACT OF TIME TO ENDOSCOPY ON OUTCOMES OF VARICEAL BLEEDING IN A TERTIARY CENTER IN THE PHILIPPINES

Alinda Mae C. Gordola¹, Eric B. Yasay¹
¹Philippine General Hospital Manila, Philippines

BACKGROUND: The evidence on the effects of performing endoscopy within 12 hours of presentation for variceal bleeding on outcomes is conflicting. Local data are also lacking.

AIM: This study aimed to determine if timing of endoscopy is associated with clinical outcomes.

METHODS: Adult cirrhotic patients admitted at a tertiary center for VB from January 2016 to September 2022 were retrospectively evaluated. The primary outcomes were in-hospital and 6-week mortality. Secondary outcomes included 5-day rebleeding, length of hospital stay (LOS) and blood transfusion requirements (BTR). The relationship between timing of endoscopy and outcomes was evaluated using regression analysis.

RESULTS: In 140 patients, 5.7% underwent urgent endoscopy (≤12 hours). The overall median door-to-endoscopy time was 39.4 hours (IQR 20.0–73.4). The overall in-hospital mortality, 6-week mortality, and 5-day rebleeding rates were 12.9%, 11.4%, and 8.6%, respectively, without significant variability at different time intervals to endoscopy (p >0.05). Longer LOS was evident when endoscopy was delayed to >12 hours from admission (3.5 [IQR 2.25–5.75] vs 6 days [IQR 4–9.75], p = 0.02). BTR was greater starting at endoscopies performed at >24 hours (1 [0–2] vs 2 units [1–3], p = 0.000). Delayed endoscopy was significantly correlated with LOS (Beta 0.316, SE 0.011, p = 0.000) and BTR (Beta 0.214, SE 0.469, p = 0.003), but not with mortality and early rebleeding.

CONCLUSION: Timing of endoscopy may be independent of mortality and early rebleeding. Timely endoscopy may shorten hospitalization and decrease need for blood transfusion. Other factors affecting clinical outcomes may be at play.

Abstract Submission No. 100018
P-0960

Association between pancreatic congestion and exocrine pancreatic function in patients with LC

Masahito Kokubu¹, Yoshihi Imamura¹, Mitsuho Koizumi², Kaori Marui¹, Shou Ishikawa¹, Yuusuke Okujima¹, Yuuki Numata¹, Teru Kumaki², Masashi Horioka¹, Youshi Hiasa¹
¹Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Ehime, Japan Toon Japan, ²Postgraduate Medical Education Center, Ehime University Hospital, Ehime Japan

AIM: In the liver cirrhosis (LC), pancreas exhibits congestion due to portal hypertension because pancreatic drainage blood flow drains to a portal system. We have clarified that portal hypertension induces pancreatic congestion and impaired insulin secretion in patients with liver cirrhosis (LC). However, it remains controversial whether pancreatic congestion results in exocrine pancreatic insufficiency (EPI). The present study focused on exocrine pancreatic function, as assessed by fecal elastase 1 (FE-1), and examined its association with portal hypertension.

Method: 82 patients were prospectively enrolled in the study. Relevant clinical data, shear wave elastography (SWE), shear wave dispersion (SWD) and FE-1 were examined and compared.

Result: 82 patients were divided into LC group (n=41) or control group (n=41). The baseline characteristics were similar between the LC and control group. FE-1 in the LC group was lower than in the control group (312±89 μg/g vs 442±100 μg/g, p <0.01). The number of patients with EPI was higher in the LC group than in the control group (6 cases vs 0 case, p=0.03). Pancreatic SWE values and pancreatic SWD values were significantly higher in the LC group (7.78±1.36 kPa vs 5.41±0.93 kPa, p <0.01, DS, 14.6±2.3 /m/s kHz vs 10.4±1.6 /m/s kHz, p <0.01, respectively). FE-1 was significantly correlated with pancreatic SWE values (R=0.62) and pancreatic SWD values (R=0.57).

Conclusion: FE-1 in the LC group was lower than in the control group and FE-1 was significantly correlated with pancreatic congestion. Thus, in LC patients, portal hypertension may result in EPI.

Abstract Submission No. 100113
P-0961

Abdominal Tuberculosis Lymphadenopathy presenting as Portal Hypertension: A Case Report

MA. LIEFE CHARMAINE VILLANUEVA¹, Roberto N De Guzman², Renelene A. Macabeo¹
¹Our Lady of Lourdes Hospital Manila, Philippines

Gastrointestinal tuberculosis makes up to 3% of tuberculoses. This case presents a patient having extra pulmonary tuberculosis manifesting as portal hypertension. Upper abdominal CT scan shows lymphadenopaths in faliform ligament and peritoneal wall. Biopsy of these lymphadenopaths shows granulomatous inflammation with caseous necrosis suggestive of tuberculosis. Portal hypertension usually rises from compromised vascular resistance and blood flow in the liver, often associated with liver cirrhosis. However, in rare occasions, portal hypertension can be caused by non-cirrhotic factors, accounting for 16–25% of cases. Common non-cirrhotic causes include extrahepatic portal venous obstruction, idiopathic portal hypertension, schistosomiasis, biliary cirrhosis, congenital hepatic fibrosis, veno-occlusive disease, nodular transformation, hepatoporal sclerosis, and peliosis hepatis. For patients presenting with non-cirrhotic portal hypertension, extra intestinal tuberculosis should be considered especially in our country where tuberculosis is endemic. This study aims to present a case of gastrointestinal tuberculosis presenting as portal hypertension. In the Philippines where case of TB was endemic, diagnosis of
gastrointestinal tuberculosis should be considered and managing such case, medical management will not suffice and surgical intervention should be considered in addressing the progression of portal hypertension and Gastrointestinal bleeding. Further, this case report highlights an uncommon incidence of abdominal tuberculosis lymphadenopathy causing portal hypertension which leads to compromised portal blood flow, underscoring the importance of recognizing and managing such unique clinical presentations in a clinical setting.

Abstract Submission No. 100169
P-0962

Duration of vasoconstrictors after endoscopic ligation in variceal bleeding: A network meta-analysis

Suprabhat Giri1, Ankita Singh2, Dibya Lochan Praharaj1, Kailash Kolhe3, Akash Roy4
1Kalinga Institute of Medical Sciences Bhubaneswar India, 2Seth GS Medical College and KEM Hospital Mumbai India, 3Narayana Hospital Nanded India, 4Apollo Multispecialty Hospital Kolkata India

Background: Guidelines recommending continuation of vasoconstrictors for at least 3-5 days after endotherapy for acute variceal bleeding (AVB) are based primarily on old studies in which sclerotherapy was used. Hence, the present network meta-analysis was conducted to compare the outcome of vasoconstrictors after Endoscopic variceal ligation (EVL) based on the duration of therapy.

Methods: A comprehensive literature search from inception to March 2023 was done for randomized trials, comparing the outcome of continuing vasoconstrictors after EVL in AVB based on the duration (Group 1: 5 days, Group 2: 2 to 3 days, Group 3: Less than 24 hours). Both pairwise and network meta-analyses were performed to analyze the risk of rebleeding and mortality.

Results: A total of 9 studies (n = 816) were included in the final analysis. There was no difference in the risk of rebleeding in Group 2 (Risk ratio [RR]: 1.34, 95% confidence interval [CI]: 0.42 – 4.13) and Group 3 (RR: 1.12, 95% CI: 0.42 – 2.49), compared to Group 1. Similarly, there was no difference in the mortality risk between Group 2 (RR: 3.80, 95% confidence interval [CI]: 0.46 – 39.1) and Group 3 (RR: 0.36, 95% CI: 0.04 – 1.54) compared to Group 1. There was neither significant inconsistency nor publication bias.

Conclusion: The present network meta-analysis did not show any benefit of continuing vasoconstrictors after EVL.

Abstract Submission No. 100602
P-0963

Tracheal Intubation And Long Hospital<br

Kalki Rajamanickam Chandrasekaran1, Adrienne YH Chew2, Bryan GJ Loh2, Garrett Kang1, Clarence KW Kwan1, Marianne A De Roza1
1Sengkang General Hospital, SingHealth, Singapore Singapore Singapore, 2Yong Loo Lin School of Medicine, National University of Singapore Singapore Singapore

Aim: Our aim was to determine endotracheal intubation practices for variceal bleeding and associated factors leading to worse outcomes.

Methods: All variceal bleeding events in cirrhotic patients between July 2018 and February 2023 at a tertiary hospital in Singapore were analyzed retrospectively. Patients were grouped into those that bled once and those that bled more than once within a six-month period.

Abstract Submission No. 100716
P-0965

The effect of B-RTO on hepatic functional reserve and its volume in cirrhotic patients

Yusuke Komeda1, Daisuke Kaya1, Shinshaku Nagamatsu1, Masakazu Uejima1, Hideki Matsu1, Kei Moriya1
1Department of gastroenterology, Nara prefecture general medical center Nara Japan

Aims: Balloon-occluded retrograde transvenous obliteration (B-RTO) has come to be reported to improve shunt encephalopathy. In this study, we aimed to analyze the changes in hepatic functional reserve (HFR) and its volume before and after B-RTO, with related clinical parameters.
Methods: Nineteen cirrhotic patients (12 males and 7 females, median age 72 years) who underwent B-RTO for gastric varices in our institution in the last decade were included. Their HFRs were evaluated before and 1/6/12 months after B-RTO. Hepatic and splenic volumes were calculated by SYNAPSE VINCENT® software.

Results: In the 13 patients with F2/F3 gastric varices, twelve successfully had down-staged varices of F0/F1 within a month after B-RTO treatments, and all of the six patients with overt encephalopathy got a drastic improvement in the same period. The median pre-treatment Child-Pugh score of 6.9 [5.0-8.0] was significantly improved into 6.4 [5.0-10.0] at 6 months after treatment (p<0.05). Total hepatic volume as well as splenic one were not significantly changed in the comparison between before and after B-RTO treatments (p<0.985 and p=0.127, respectively). An increase in postoperative hepatic volume of more than 10% and the presence of overt encephalopathy before intervention contributed to the improvement of HFRs (p<0.05 and p<0.01, respectively). A case of esophageal varices rupture was derived.

Conclusion: B-RTO is effective not only for the size reduction and rupture risk of gastric varices but for hepatic encephalopathy and may also improve HFRs. Future studies are desired to predict which population would increase their total hepatic volume after B-RTO.

Abstract Submission No. 100786
P-0966

Portal hypertension in a non-cirrhotic liver: modified Sugiura’s procedure and complications

Ronald Heredia, Wilmyr Hababag
1De Los Santos Medical Center Quezon Philippines, 2De Los Santos Medical Center Quezon Philippines

We report a 34-year-old male, managed as a case of recurrent esophageal variceal bleed secondary to portal hypertension despite five sessions of esophageal variceal ligations. He also underwent endoscopic retrograde pancreatography (ERCP) with biliary stenting for obstructive jaundice secondary to biliary compression by pericholedochal varices which was confirmed by endoscopic ultrasound (EUS). The patient was advised for modified Sugiura’s procedure instead of transjugular intrahepatic portal systemic shunt (TIPS), because of the high rate of hepatic encephalopathy nor of surgical shunts since the patient had portal cavernoma. Patient had a complicated course post operatively. This report highlights the choice of management for failed endoscopic therapy for bleeding esophageal varices, the choice of surgical management and associated complications. He underwent devascularization known as modified Sugiura’s procedure but developed dyspepsia post operatively. He was diagnosed with pneumothorax and was managed with chest tube thoracotomy. However, on feeding, he experienced abdominal pain and vomiting accompanied with bilious leak on his surgical drain placed adjacent to the transected esophagus. Jejunostomy tube was inserted and used for feeding until the healing of esophageal varices in cirrhotic patients with PV bleeding. Imaging techniques like bedside US Doppler and CT angiography aid in diagnosis. The role of NSBs is debatable in the management of ectopic varix hence addressing portal hypertension through procedures like transjugular intrahepatic portal systemic shunt is necessary. Embolization of the uterine varix and its shunt can be a useful interm therapeutic option to reduce the risk of rebleeding.

Abstract Submission No. 100826
P-0967

An Unusual Cause of Massive Per-Vaginal Bleeding

Samantha Koh1, Justin Leong1, Kevin Teh2, Wei Lun Liu3
1Singapore General Hospital Singapore Singapore, 2Singapore General Hospital Singapore Singapore, 3Singapore General Hospital Singapore Singapore

This clinical case report highlights an unusual cause of per-vaginal (PV) bleeding associated with ectopic uterine varix bleeding; an exceedingly rare manifestation of clinically significant portal hypertension secondary to liver cirrhosis.

A 60-year-old woman with previous history of caesarean section presented with massive PV bleed. Initial test revealed low haemoglobin (8g/dL), low platelet (71x10^9/L), prolonged prothrombin time of 23.8 seconds and partial thromboplastin time of 53.4 seconds, and deranged liver function tests (bilirubin of 25 µmol/L, albumin 15g/L, ALT 20 U/L, AST 52 U/L). CT angiography revealed incidental finding of liver cirrhosis, extensive portosystemic collaterals with shunting from splenic vein to the anterior uterine wall at the region of the caesarean scar. She was planned for early transjugular intrahepatic portosystemic shunt (TIPSS) procedure but this was held off due to presence of pulmonary hypertension during TIPSS workup. She eventually underwent angiographic embolization of the uterine varix and splenic vein shunt. She recovered well post-procedure and did not have a recurrence of PV bleeding in the following 6 months.

This case highlights the importance of considering ectopic uterine varices in cirrhotic patients with PV bleeding. Imaging techniques like bedside US Doppler and CT angiography aid in diagnosis. The role of NSBs is debatable in the management of ectopic varix hence addressing portal hypertension through procedures like transjugular intrahepatic portosystemic shunt is necessary. Embolization of the uterine varix and its shunt can be a useful interm therapeutic option to reduce the risk of rebleeding.

Abstract Submission No. 101181
P-0968

Clinical outcomes of acute variceal bleeding in a tertiary asian hospital

Guan Sen Kew1,2, Jia Hong Koh2, Margaret Li Peng Teng2
1Woodlands Health Singapore Singapore, 2National University Hospital Singapore Singapore

INTRODUCTION: Acute variceal bleeding (AVB) is a serious complication in patients with liver cirrhosis with significant morbidity and mortality. We aim to evaluate the clinical outcomes of patients who present with AVB in our cohort.

METHODS: A retrospective study of 199 patients who presented to National University Hospital between January 2015 to December 2021 with AVB was conducted. The main clinical outcomes assessed were ability to achieve haemostasis on endoscopy, rebleeding within 5 days as well as mortality within 6 weeks and 1 year.

RESULTS: The most common etiologies of cirrhosis were non-alcoholic fatty liver disease (24.1%), chronic hepatitis B (22.6%) and alcohol (12.6%). A fifth of the patients (20.6%) had hepatocellular carcinoma (HCC) and 17.6% had portal vein thrombosis (PVT). The patients who were child pugh A, B and C were 38.4%, 48.5% and 13.1% respectively. Most bleeding was from esophageal varices (84.4%) and 15.6% was from gastric varix. Endoscopic haemostasis was not achieved in 4.5% of the patients. The 5-day rebleeding rate was 8.5% and mortality rate at 6 week and 1 year was 8.5% and 29.6% respectively. A higher child pugh score (OR 7.21, p=0.007) and gastric varix (OR 7.21, p=0.007) were associated with a higher rebleeding rate at 5 days. A higher child pugh score (OR 12.1, p=0.003), PVT (OR 6.82,
Abstract Submission No. 101220

P-0969

The Role of Vasoactive Drugs in Acute Variceal bleeding in Child A Cirrhosis patients.

Mai Saeed1, Maha Elsabaawy1, Zahraa Salah1, Dalia Elsabaawy2, Mohamed Akl1, Ahmed Aboamer1

1Hepatology and gastroenterology department, National liver institute Menoufia University, ShebeenElkoom Egypt, 2Clinical pharmacy department national liver institute. Menoufia University, ShebeenElkoom Egypt

Background: According to Baveno VII recommendations, the role of vasoactive drugs in CHILD A cirrhosis patients with acute variceal bleeding (AVB) is yet an unmet need.

Aim: To evaluate the role of vasoactive drugs (VAD) in in Child A cirrhosis with AVB.

Method: A prospective study was conducted on 100 child cirrhotic patients with AVH who were double blindly randomized 1:1 to two groups. A group which was subjected to VAD (Occtrotide 50 mcg IV bolus followed by 25-50 mcg/hr up to 5 days) and a second non-VAD treated group. All patients were admitted to intensive care unit for resuscitation and management and upper endoscopy within 12 hours of hemodynamic stability.

Results: The 2 studied groups were predominantly males, (75%) in group I and (83%) in group II with mean age of (53.7 ± 10.5) years and (53.2 ± 7) years in group I and II, respectively. No significant difference between the studied groups as regards MELD score, type and size of varices and all laboratory results. VAD group had significantly (p<0.001) higher rate of control of AVB with significantly lower rate of early rebleeding (p=0.001), duration of hospitalization (p<0.001), and blood transfusion requirement (p<0.001) as well as significantly lower mortality rates (p=0.001). In multivariate analysis, age, total bilirubin, albumin, AST, and platelets count were the only risk factors for controlling AVB.

Conclusion: The role of vasoactive drugs in patients with Child A cirrhosis in controlling active variceal bleeding was substantially negated with recommended further larger size studies.

Abstract Submission No. 101706

P-0971

Changes in liver/spleen volume and HVPG after DAA treatment for decompensated HCV-related cirrhosis

Kohei Kotani1, Masaru Enomoto1, Ritsuou Kozuka1, Sawako Uchida-Kobayashi1, Hiroko Ikenaga1, Yoshimi Yukawa-Muto1, Naoshi Odagiri1, Hiroyuki Motoyama1, Etsushi Kawamura1, Hideki Fujii1, Ken Kageyama1, Akira Yamamoto2, Norifumi Kawada2

1Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, 2Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan

Background: The relationship between changes in liver and spleen volume and hepatic venous pressure gradient (HVPG) after direct-acting antiviral (DAA) treatment in patients with hepatitis C virus (HCV)-related cirrhosis remains unclear.

Methods: This observational, single-centered study included 21 patients with decompensated HCV-related cirrhosis treated with sofosbuvir/velpatasvir and 19 patients with compensated cirrhosis treated with glecaprevir/pibrentasvir. All patients underwent laboratory tests, computed tomography, and transient elastography, and HVPG was measured in patients with decompensated cirrhosis. Changes in parameters after achieving sustained virological response (SVR) at 24 weeks after DAA treatment were evaluated.

Results: The level of Mac-2 binding protein glycan isomer (p<0.001, p<0.001) and the FIB-4 index (p<0.001, p=0.012) decreased in the compensated and decompensated groups. Spleen volume decreased in the compensated (p=0.034), but not in the decompensated group (p=0.251). Liver stiffness decreased in the compensated (p=0.043), but not in the decompensated group (p=0.552). HVPG declined in 67% of the compensated group. Spleen volume before DAA treatment (p=0.006) and after SVR (p<0.003) were significantly smaller in patients with decreased HVPG than with increased HVPG. Spleen volume decreased in patients with decreased HVPG, while increased in those with increased HVPG (median, −21 vs. 43 mL; p=0.039).

Conclusions: Liver and spleen volumes changed after DAA treatment in patients with HCV-related cirrhosis. Spleen volume decreased in...
Abstract Submission No. 101723

P-0972

Analysis of the incidence of sarcopenia among cirrhotic patients with portal hypertension

Yuki Shirane¹, Eisuke Murakami¹, Kei Amioka¹, Kensuke Naruto¹, Kenji Yamaoka¹, Yasutomo Fujii¹, Shinsuke Uchikawa¹, Hatsue Fujino¹, Atsushi Ono¹, Takashi Nakahara¹, Tomokazu Kawoaka¹, Daiki Miki¹, Masataka Tsuge¹, Shiro Oka¹

¹Hiroshima University Hospital Hiroshima Japan

Background: Sarcopenia is a syndrome characterized by a decrease in skeletal muscle and strength, and has been reported to relate with the poor prognosis of patients with liver cirrhosis. 

Aim: The incidence of the sarcopenia was analyzed in 182 cirrhotic patients complicated with portal hypertension which required invasive treatments.

Methods: All patients undergone therapeutic interventions for portal hypertension such as gastro-esophageal varices and were measured their grip strength and skeletal muscle mass using bio-impedance analysis (BIA) at the same time. Clinical factors related to the sarcopenia were retrospectively analyzed.

Results: The subjects included a median age of 69 years, a male to female ratio of 126:56, and major cause of the liver disease were viral hepatitis (40.7%) and alcohol (27.5%), and the main treatment for portal hypertension were endoscopic (69.8%). The median skeletal muscle index (SMI) was 7.17 kg/m², and the median grip strength was 26.9 kg. Thirty-two cases (17.6%) were diagnosed as sarcopenia according to the standards of the Japan Society of Hepatology. Of the remaining cases, 31 cases (17.0%) had insufficient SMI diagnosed as pre-sarcopenia, 26 cases (14.3%) had a decrease in grip strength diagnosed as dynapenia. In multivariate analysis of factors contributing to sarcopenia, age (odds ratio 11.45), female (odds ratio 2.43), and non-obese (odds ratio 5.86) were significant independent factors (P<0.05).

Conclusion: In cirrhotic patients complicated with portal hypertension, the incidence of sarcopenia was thought to be relatively high in elderly woman without obesity, suggesting that muscle mass evaluation might be desirable.

Abstract Submission No. 101788

P-0973

Efficacy of partial splenic embolization on portal hypertensive gastropathy in cirrhotic patients

Hironao Okubo¹, Yuka Fukuo¹, Hiroo Fukada¹-², Kenichi Ikejima²

¹Juntendo University Nerima Hospital, Department of Gastroenterology Tokyo Japan, ²Department of Gastroenterology, Juntendo University School of Medicine Tokyo Japan

Background: There are few reports regarding endoscopic findings before and after partial splenic embolization (PSE) in cirrhotic patients and the application of PSE for treatment of portal hypertensive gastropathy (PHG). The purpose of this study was to investigate the therapeutic effect of PSE for PHG in relation to portal hemodynamics.

Methods: We retrospectively analyzed endoscopic findings and the portal venous system of 32 cirrhotic patients with PHG. The improved group was defined as amelioration of PHG findings using the Mc Cormack classification.

Results: PHG was improved in 19 of 32 (59%) patients (improved group). Child–Pugh scores of the improved group were significantly lower compared with those of the non-improved group (p = 0.011). The changes in the diameters of the portal trunk and those of the spleno-portal junction and spleen hilum in the splenic vein of the improved group were significantly larger than those of the non-improved group (p = 0.004, p = 0.018, and p = 0.004, respectively). The changes in the diameters of the portal vein and splenic hilum of the splenic vein showed significant correlations with Child–Pugh score (r = 0.45, p = 0.013; r = 0.465, p = 0.008). In multivariate analysis of baseline factors related to the improved group, Child–Pugh grade A was significantly associated with the improvement of PHG by PSE (odds ratio 7.56, p = 0.024).

Conclusion: PSE could be useful for PHG, especially in patients with Child–Pugh grade A.

Abstract Submission No. 200043

P-0974

VALIDATION OF THE AIMS65 SCORE IN VARICEAL UPPER GASTROINTESTINAL HEMORRHAGE

Nam Nguyen¹, Anh Tran Ngoc²

¹E Hospital Hanoi Vietnam, ²Hanoi Medical University Hospital Hanoi Vietnam

Objectives: Validation of the AIMS65 score to predict 30-day mortality and 30-day rebleeding in variceal upper gastrointestinal hemorrhage.

Study method: Descriptive and prospective study of 237 patients diagnosed with variceal upper gastrointestinal hemorrhage because of portal hypertension at Bach Mai Hospital and Hanoi Medical University hospital from 12/2018 to 6/2019. AIMS65 scores are evaluated to determine the predicted value. AIMS65 scores were calculated by allotting 1 point each for albumin (A) levels <30 g/L, INR (I) >1.5, alteration in mental status (M), systolic blood pressure (S) <90 mm Hg, and age >65 years.

Result: A total of 237 patients (mean age 52.86 ± 10.63 years), mostly diagnosed with alcoholic cirrhosis (180/75.9%), presented with variceal UGH. Rebleeding occurred in 33 (13.9%) patients and 30-day mortality was 16 (6.8%). Initial hemostasis was achieved with endoscopic variceal ligation (181/76.4%), and N-butyl cyanoacrylate (23/9.7%). Median hospital stay was 5.28 ± 2.79 days. The mean AIMS65 scores were 1.32 ± 1. The predictive accuracy of AIMS65 scores ≥2 was high for blood transfusion (AUROC, 0.73), fresh frozen plasma transfusion (AUROC, 0.784), and 30-day mortality (AUROC, 0.757). The overall mortality was 6.8% (n=16), and was 0%, 4.1%, 9.2%, 22.2% and 0% for AIMS65 scores of 0, 1, 2, 3, and 4, respectively; these values were significantly higher in those with scores ≥2 (12.4%) than in those with scores <2 (2.3%, p=0.02).

Abstract Submission No. 200047

P-0975

Mortality and risk factors for elderly cirrhotic patients with acute upper gastrointestinal bleeding

Qi Li¹, Qikun Zhang², Lingna Lv¹, Chunlei Fan¹, Huiguo Ding¹

¹Department of Gastroenterology and Hepatology, Beijing You'an Hospital Affiliated with Capital Medical University Beijing China,
Background: Acute upper gastrointestinal bleeding (AUGIB) is a life-threatening complication of liver cirrhosis. Elderly patients with this condition have increased with the aging of population. Clinical characteristics and risk factors associated with short term mortality in elderly cirrhotic patients with AUGIB remain little known.

Methods: We retrospectively included cirrhotic patients with AUGIB admitted in Department of Emergency from April 1st 2021 to Dec 31st 2022 in Beijing You’an hospital. Clinical characteristics of the elderly patients were compared with younger ones. Risk factors for short term mortality were analyzed with adjusted multivariate logistic regression models.

Results: A total of 628 patients aged ≥60 years constituted the elderly group. Compared with the younger patients < 60 years old, the elderly ones were more likely to present with lower level of DBP, pulse and shock index, lower PT, higher BUN and Cr level. The elderly patients had a higher incidence of hypertension, diabetes, coronary heart disease, chronic kidney disease, HCC and simultaneous PVT/Diabetes. All-cause mortality in hospital and at 6-week of the elderly was 16.7% and 24.0%, respectively. Age and male were independent risk factors for both in-hospital mortality and 6-week mortality. Esophageal sclerotherapy, melena, obvious encephalopathy, hyperlipidemia and Con PVT/Diabetes were independent risk factors for in-hospital mortality, whereas unknown source of AUGIB and HCC were independent risk factors for 6-week mortality.

Conclusion: Age and male increase in hospital mortality and 6-week mortality in elderly cirrhotic patients with AUGIB. Esophageal sclerotherapy, control of diabetes, treatment of encephalopathy and PVT help to reduce in-hospital mortality.

Abstract Submission No. 200083
P-0976

Omeprazole plus sucralfate Vs omeprazole alone for prevent post EVL ulcer in cirrhotic CTP A or B

Tanya Apichatvullop1, Kawin Tangvoraphonkchai2, Tanita Suttichaimongkol3, Kookwan Sawadpanich2, Pisah Maiwang1

1Division of Gastroenterology and Hepatology, Department of Medicine, Khon Kaen Hospital, Khon Kaen Thailand; 2Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen Thailand

Background: Post-endoscopic variceal ligation (EVL) ulcers represent a complication following EVL, with potential implications for mortality in cirrhotic patients. Prophylaxis against this complication typically involves either a proton pump inhibitor (PPI) or sucralfate. Limited studies have explored the combination of PPI with sucralfate suspension in the prevention of post-EVL ulcers. We aimed to assess the efficacy of the combination of omeprazole and sucralfate suspension in comparison to omeprazole alone for preventing post-EVL ulcers in cirrhotic patients.

Methods: From March 2019 to December 2022, a prospective, single-center, randomized controlled trial was conducted. We enrolled patients diagnosed liver cirrhosis CTP A or B with esophageal varices to receive either omeprazole plus sucralfate suspension or omeprazole alone and performed subsequent esophagogastroduodenoscopy at 2 weeks to evaluate EVL ulceration using Jamwal’s classification and complications.

Results: 84 cirrhotic patients were enrolled. There were no significant differences between the combination of omeprazole plus sucralfate suspension and omeprazole alone groups in terms of EVL ulcer type, EVL ulcer numbers, and percent decreasing of EVL ulcer numbers. No statistically significant variations in post-EVL complications were observed between the two treatment groups.

Conclusion: This study indicates no discernible differences in post-EVL ulcer type, EVL ulcer numbers, percentage reduction in EVL ulcer numbers, and complications between the combination of omeprazole plus sucralfate suspension and omeprazole alone. However, there is a trend towards reducing complications such as chest pain, dysphagia, nausea and vomiting, and diarrhea in the combination therapy group.

Abstract Submission No. 200249
P-0977

New ARFI-based ratio scores, identify cirrhotic patients with high-risk oesophageal varices.

Giovanni Galati1, Antonio Fabio Massimo Vainieri2, De Vincentis Antonio3, Elisa Brando3, Giulia Di Pasquale1, Valentina Flagiello1, Paolo Gallo1, Francesca Barone2, Evelyn Di Matteo2, Antonio Picardi1

1Internal Medicine and Hepatology, Fondazione Policlinico Campus Bio-Medico Rome Italy, 2Internal Medicine School, University Campus Bio-Medico Rome Italy, 3Internal Medicine, Azienda Ospedaliera San Giovanni Addolorata Rome Italy, 4Internal Medicine, University Campus Bio-Medico Rome Italy

Introduction: Portal hypertension is a complication of liver cirrhosis. Acoustic Radiation Force Impulse (ARFI) is an ultrasound integrated method, measuring tissues stiffness by point shear wave elastography.

Aims: To evaluate the diagnostic performance of liver and spleen ARFI, combined with spleen dimension and platelet count in new ratio scores, in predicting clinical events related to portal hypertension.

Materials and methods: Between May 2016 and November 2020, a prospective and cross-sectional study was conducted, enrolling for the first six months all consecutive cirrhotic patients in ultrasound surveillance for hepatocellular carcinoma. The following ratio scores with ARFI measurements were performed at the enrollment: ALSDP (ARFI Liver-Spleen Diameter-to-Platelets ratio score), ASSDP (ARFI Spleen-Spleen Diameter-to-Platelets ratio score), ASSAP (ARFI Spleen-Spleen Area-to-Platelets ratio score), ALSAP (ARFI Liver-Spleen Area-to-Platelets ratio score).

Results: 100 subjects were enrolled. Spleen ARFI, ASSDP, ASSAP, were significantly associated with high-risk varices (HRVs) in the prospective short- and long-term follow-up and in the cross-sectional study (p<0.05), while ALSDP and ALSAP were associated with HRVs only in the prospective long-term follow-up and cross-sectional study (p<0.05). ASSAP was the ARFI-ratio score best performing for HRVs at the long-term follow-up [value of area under curve (AUC) = 0.88], although all the ARFI-ratio scores performed better than liver and spleen ARFI alone [AUC > 0.7] in detecting HRVs. Moreover, liver ARFI at the long-term follow-up (p=0.039) and spleen ARFI, at the short-term follow-up (p=0.009), identified only patients at risk of ascites.

Conclusions: ARFI-ratio scores can predict, in cirrhotic patients, the risk of developing HVRs in short and long-term period.

Abstract Submission No. 200258
P-0978

The role of interventional radiology methods in the treatment of portal hypertension in Kazakhstan.
Niyaz Malayev1, 2, Saule Kubekova3, Samat Saparbayev4, Nadiyar Mussin2

1National Scientific Medical Center Astana Kazakhstan, 2JSC West Kazakhstan Medical academy Aqtobe Kazakhstan, 3JSC Astana Medical University Astana Kazakhstan

The aim of the study was to evaluate partial superselective spiral embolization of splenic artery branches in patients with splenomegaly. 146 cases of superselective spiral embolization in 71 patients from April 2021 to December 2022. The average age of the patients was 48±5.2 years, 51 (72%) women. The main causes of liver cirrhosis are hepatitis B - 33%, hepatitis C - 21%, hepatitis D - 14%, primary biliary cirrhosis and autoimmune hepatitis in 32% of patients. We used a microcatheter (Progreat, Terumo Corporation, Japan) and removable coils Azur CX (MicroVention, USA) and PC-400 (Penumbra, USA). Angiographically, the target artery, more often the branches of the inferior segmental artery, its diameter and the area of blood supply to the spleen were determined. The first course led to a decrease in blood flow by 10-20%, the second - by 20-30% and a further increase. The frequency of partial superselective spiral embolization averages 2.5±0.4 times. At the first observation from 6 to 12 months, the average volume of the spleen decreased by 23% according to computed tomography and ultrasound. The initial average platelet level ranged from 65±15x10^9/L, after 1-2 courses of embolization, the platelet level reached 93±21x10^9/L. Clinically, there was a decrease in the symptoms of portal hypertension.

Conclusions: step-by-step partial superselective spiral embolization of splenic artery branches in portal hypertension can be performed safely and gives positive results in the form of symptom relief and normalization of hematological parameters.

Abstract Submission No. 100081
P-0979

IMPLEMENTED RESPONSES OF VIRAL HEPATITIS ELIMINATION IN MONGOLIA

Badrai Davgasuren1

1National Center for Communicable Diseases Ulaanbaatar Mongolia

Mongolia has some of the highest rates of viral hepatitis prevalence in the world with 9.3% for hepatitis C virus and 7.8% for HBsAg infections as of 2021, and following, the high burden prevalence of liver cirrhosis and liver cancer which most of them diagnosed at a late stage. To address these public health threats, the Healthy liver program (HLP) was implemented between 2017-2021 years to combat viral hepatitis and embarked on ambitious criteria as global goals. The HLP have successfully implemented aims to control hepatitis B virus and eliminate hepatitis C virus as a public health threat. Otherwise it is population based given opportunity mass screening the whole population to identify prevalence of these infections. Therefore, the Ministry of Health has approved the HLP to continue with 34 different actions and 15 national criteria in four goals during 2022-2025 years. Additionally, Mongolia has piloted a pre-assessment for validation of viral hepatitis elimination in 2022 to understand experience and gaps, and it was crucial to address the way forward. For chronic surveillance, Mongolia has assessed the situation analysis on establishing hospital based sentinel surveillance of viral hepatitis sequelae including liver cirrhosis, cancer, and death and developing guidance on sequelae surveillance for liver cirrhosis and liver cancer caused by viral hepatitis.

Conclusion: Prevalence and incidence rate of viral hepatitis infection is decreasing year by year in Mongolia.

Abstract Submission No. 100145
P-0980

Prevalence of obesity among school-aged children in Vietnam: A systematic review and meta-analysis

Thi Quynh Chi Vu1

1School of Medicine and Pharmacy, The University of Danang Da Nang Vietnam

Aim: The global incidence of obesity is rising, posing a substantial public health threat. This meta-analysis aims to estimate the prevalence of obesity among school-aged children in Vietnam and to analyze the risk variables that have been linked to this problem.

Method: MEDLINE, PubMed, and Scopus were used to identify articles published up to May 2022. According to peer-reviewed literature, studies reported the proportion of obesity among Vietnamese school-aged children. The Scales of Newcastle-Ottawa Quality Assessment was used to evaluate the study quality for all qualifying research. The data was analyzed using R-Studio software, and the combined effects were estimated using a random-effects model.

Results: Eleven studies with 27,363 participants were suitable for inclusion in the final model after meeting the prerequisites. The proportion of obesity among Vietnamese school-aged children was 13.08% (95% CI, 7.04%–23.01%) with higher heterogeneity through the observed prevalence estimates (Q = 1.0339, p < 0.01, I^2 = 99%). A higher prevalence was observed in boys (17.5%) than in girls (8.07%). Male gender of the children: 2.42 (95% CI: 1.43–4.09), mothers have less education: 2.63 (95% CI 1.52–4.55) have shown a positive association with the development of obesity among children.

Conclusions: The recent pooled analysis of studies demonstrates that school-aged children in Vietnam have a high prevalence of obesity. The male gender and the low education status of the mother were found to be significantly associated with obesity. The findings provide evidence for prevention intervention strategies to reduce obesity in school-age children.

Abstract Submission No. 100152
P-0981

Mechanistic Underpinning And Weight Loss Effects Of Time-Restricted Eating Across Diverse Adult

Quang Duc Tran1, Thi Quynh Chi Vu2

1College of Health Sciences, VinUnivesity Hanoi Vietnam, 2School of Medicine and Pharmacy, The University of Danang Da Nang Vietnam

Time-restricted eating (TRE) is a promising and cost-effective dietary approach for weight management. This study aimed to evaluate the effects of TRE on weight loss in three adult populations using pre- and post-intervention analyses while also investigating its underlying mechanisms. A systematic search was conducted across four databases (PubMed, Web of Science, Scopus, and the Cochrane Library) up until April 20, 2023, specifically focusing on cohort studies that examined the efficacy of TRE in achieving weight loss. A random effects model was employed to conduct meta-analyses, while heterogeneity was assessed using the I^2 statistic. The study encompassed 36 selected studies involving 44 effect sizes and 914 participants. The effectiveness of the TRE diet was found to vary across health conditions, with modest weight loss observed in healthy individuals (pooled effect size -1.04 Kg, 95% CI: -1.42 to -0.65) and more significant weight reduction seen in participants with chronic diseases (pooled effect size -3.33 Kg, 95%
Prevalence of Vitamin C Deficiency and its Association with Stroke Risk in the U.S. Adult Population

Duc Tran Quang1, Khanh Nguyen Di2, Cu Dao Huy3, Chi Vu Thi Quynh3, Khuyen Tran Thi4, Huyen Nguyen Thi Hoa5

1Faculty of Health Sciences, Dong Nai Technology University, Bien Hoa City, Vietnam; 2Center for Community Health and Injury Prevention Hanoi Vietnam; 3School of Medicine and Pharmacy, The University of Danang Danang Vietnam; 4College of Health Sciences, VinUniversity Hanoi Vietnam

Background: Stroke is a major health concern, prompting the need for urgent public health measures. While Vitamin C shows potential against cardiovascular diseases, its role in stroke risk remains uncertain. This study aimed to assess Vitamin C deficiency prevalence in stroke patients and its correlation with stroke risk.

Methods: We examined data from 13,339 U.S. adults in the National Health and Nutrition Examination Survey between 2003-2018, excluding those with missing serum Vitamin C levels and self-reported stroke status. Using adjusted multivariate logistic regression models, we assessed the association between Vitamin C deficiency (<11.4 μmol/L) and stroke incidence, considering various factors.

Results: Stroke prevalence rates in the NHANES cycles 2003-2006 and 2017-2018 were 2.8% (95% CI: 2.3-3.4) and 3.3% (95% CI: 2.7-4.2), respectively. Vitamin C deficiency was more common in individuals with a history of stroke, with rates of 3.6% (95% CI: 2.2-5.8) and 5.3% (95% CI: 3.9-7.1) compared to 2.7% (95% CI: 2.3-3.3) and 3.2% (95% CI: 2.5-4.1) in the non-stroke cohorts. Nevertheless, vitamin C deficiency was distinctly prevalent across diverse demographic and health-related subgroups. Multivariate analyses invalidated any statistically significant correlation between Vitamin C deficiency and stroke risk across all employed analytical models within both time intervals.

Conclusions: Our study found no evidence linking Vitamin C deficiency to increased stroke risk in U.S. adults, despite higher deficiency rate among stroke patients. Further trials are needed to clarify its role in managing stroke-related oxidative stress, including optimal dosing and delivery methods. Healthcare providers should consider its prevalence in specific subgroups.

Impact of HCV on Health-Related Quality of Life and Work Productivity Loss in Pakistani Patients

Siwaporn Niyomsri1, Ambreen Arif2, Muhammad Asim1, Ajj Chaudhry4, Asad Chaudhry4, Naheed Chaudhry4, Graham Foster5, Saeed Sadiq Hamid6, Aliya Hasnain1, Aaron G. Lim1, Saad Niaz3, Noor Saba4, Huma Qureshi2, Peter Vickerman1, Josephine Walker4

1Bristol Medical School, Population Health Sciences, University of Bristol Bristol United Kingdom, 2Doctors Plaza Karachi Pakistan, 3Dow University of Health Sciences (DUHS) Karachi Pakistan, 4The Liver Clinic Gujranwala Pakistan, 5Queen Mary University of London London United Kingdom, 6Aga Khan University Karachi Pakistan

Background and aims: Pakistan has the highest hepatitis C virus burden. We examined health-related quality of life (HRQoL) and work productivity loss in screened individuals, emphasizing socio-demographic HRQoL influences.

Methods: A cross-sectional study with HRQoL assessment conducted mainly in Karachi and Gujranwala. Chronic hepatitis C (CHC) patients received 12- or 24-week treatments based on cirrhosis risk. HRQoL was assessed using the EuroQol-EQ-5D-3L, before revealing HCV antibody status. Work productivity loss was evaluated through the WPAI-GH questionnaires. EQ-5D-3L scores were converted to HRQoL weights from Pakistani general population values. Tobit regression identified associations between HCV or cirrhosis status and HRQoL, controlling for socio-demographics.

Results: Among 5,468 participants, median age 39 (IQR: 30, 50), 59.14% males, 1,263 were CHC positive. CHC patients experienced greater productivity loss in screened individuals, emphasizing socio-demographic HRQoL influences.
lower HRQoL (0.952, 95% CI: 0.947-0.956) compared to HCV Ab-negative participants [0.979, 95% CI: 0.977-0.981, p<0.001]. Tobit regression found significant associations. CHC was linked to lower HRQoL, as unemployed, and older age. Living in Karachi and being widowed related to significantly lower HRQoL, while residing in Karachi had a significantly positive effect. Cirrhosis and 24-week treatment duration didn’t significantly affect HRQoL. CHC was associated with increased absenteeism (29.14% vs. 13.56%, p=0.002) and an annual indirect cost of USD440.

Conclusions: HCV infection may be reducing HRQoL in Pakistan, incurring a significant cost to individuals and the economy. Further research is needed to understand whether treatment of HCV can reduce these detrimental effects.

Role of Reimbursement in Survival of Sorafenib-eligible Advanced Hepatocellular Carcinoma Patients

Sheng-Nan Lu1, Hiu-Ling Huang2,3, Lariza Marie Canseco4, Te-Sheng Chang2, Fan Wu1

1Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital Kaohsiung Taiwan, 2Chang Gung Memory Hospital, Chiayi Branch Chiayi Taiwan, 3Department of Management Information Systems, National Chung Cheng University Chiayi Taiwan, 4Section of Gastroenterology, Department of Internal Medicine, De Los Santos Medical Center, Metro Manila Philippines

In 2008, sorafenib became the first approved systemic therapeutic agent for advanced HCC. Although its pharmacological efficacy has been established, reimbursement for such new, high-cost drug as well as physicians’ awareness and prescription practice, Likewise contribute to its clinical effectiveness. We therefore conducted a retrospective study using 38 sorafenib-eligible advanced HCC patients when sorafenib was approved but not yet reimbursed, as control, and 216 patients during the reimbursed era. Study group showed longer survival at 8.2 months versus the control’s 4.9 months (p=0.0063 hazard ratio: 0.612 (0.431-0.868), p=0.0059). Among the 42 (19.4%) patients who survived more than 2 years, 50% with tumor rupture and all 32 patients with portal vein tumor thrombus and/or extrahepatic metastasis, received sorafenib (p=0.003). Furthermore, during their first 2 years of HCC management, sorafenib had been given in 29.1% of the treatment courses among survivors between 2 and 5 years, while it was prescribed in 55.8% among the more than 5 years survivor group (p<0.001). In conclusion, survival of sorafenib-eligible HCC patients significantly improved after reimbursement. Patients who underwent longer sorafenib treatment had a survival advantage, except for those with tumor rupture. Reimbursement and awareness of prescription for a newly introduced medication therefore improve clinical effectiveness.

Including mpMRI in liver resection pathways reduces healthcare costs in a Japanese Healthcare system

Marika French1, Tomoko Hyodo2, John Connell1

1Perspectum Ltd Oxford United Kingdom, 2Nihon University Itabashi Hospital Tokyo Japan

The reported societal cost of liver cancer in Japan is more than ¥600 billion and growing, therefore steps to reduce the economic burden are needed. Liver resection is a curative option however the per patient cost of liver cancer hepatectomy is up to ¥5 million including surgery, hospitalisation, complications and drugs. Up to 16% of patients experience post-operative complications including infection, bleeding and organ failure. Assessing liver tissue pre-surgery using non-invasive multiparametric MRI (proton density fat fraction (PDFF) and iron corrected T1 mapping (cT1)) may lead to changes in surgeon decision making, decreased complication rates, and better clinical outcomes. Using a hypothetical cohort of 100 post-surgery patients, costs associated with experiencing post-operative complications were compared between 2 scenarios: 1. Standard care, and 2. After introducing mpMRI. The incidence and cost of post-operative complications were taken from literature. Costs were reported per 100 patients and per patient. Where complication costs were unavailable for a Japanese health care system, published costs were converted to Japanese Yen. Microsoft Excel was used for analysis.

16 patients experienced major complications post-surgery in scenario 1 compared to four patients in scenario 2. The total cost of complications in scenarios 1 and 2 were ¥121,389,197 and ¥23,048,582 respectively. The difference in total costs (complication and no complication) between scenarios was ¥55,931,532 per 100 patients. Per patient difference was ¥55,932.

The introduction of mpMRI to those undergoing liver resection due to liver tumours may lead to cost savings benefiting both patients and society and improve clinical outcomes.
hepatitis-coordinators, the number of dentists became the largest in the number of hepatitis-coordinators by occupation in Aichi Prefecture.

**Conclusion:** The training courses by ADA serve to provide an opportunity to take a leading position on hepatitis for dentists. Because dentists play a major role in health management, improving their knowledge about viral hepatitis is important for infection control.

Abstract Submission No. 100671

**P-0988**

**Evaluation of the attributable fraction of liver diseases due to hepatitis B and C in Hong Kong**

Chin Man Poon1, Angel Sau Yin Ng1, Bonnie Chun Kwan Wong2, Ka Hing Wong2

1Viral Hepatitis Control Office, Department of Health Hong Kong China, 2Special Preventive Programme, Department of Health Hong Kong China

**Background:** A retrospective review of clinical and laboratory record of deaths from selected liver diseases was conducted to estimate their attributable fraction due to hepatitis B and C, and thus to measure the hepatitis-related mortality in Hong Kong.

**Methods:** All deceased Hong Kong residents registered in 2015 and 2020, whose ICD-10 code of their underlying cause of death was liver cancer (C22), cirrhosis (K74.3-K74.6) or other chronic liver diseases (CLD) (K72-K75, excluding K74.3-K74.6), were included. Those with history of hepatitis B and C diagnosis were identified by record tracing in the databases of local public hospitals, and evaluated by causes of death.

**Results:** A total of 1977 and 1915 persons died from the selected liver diseases in 2015 and 2020 respectively. Of hepatocellular carcinoma (HCC) deaths, 68.5% (2015) and 66.4% (2020) had HBV infection, and 13.4% (2015) and 11.1% (2020) had HCV infection. For deaths from non-HCC liver cancer, cirrhosis and other CLD, 31.9%-39.0% (2015) and 29.8%-36.8% (2020) had HBV infection, and 5.2%-12.6% (2015) and 4.4%-12.2% (2020) had HCV infection. In 2020, the estimated crude mortality due to hepatitis B and C was 12.7 and 2.2 per 100,000 population respectively. As compared with 2015, the relative reduction in mortality was 6.8% and 20.5% for hepatitis B and C respectively.

**Conclusions:** While elimination of HCV infection has been on track in Hong Kong, more actions are required to achieve the WHO goal of eliminating viral hepatitis as a public health threat by 2030, in particular to reduction of hepatitis B-related deaths.

Abstract Submission No. 100745

**P-0989**

**SAGA MODEL OF HEPATITIS COORDINATORS IN MONGOLIA TO ELIMINATE VIRAL HEPATITIS**

Munkhjargal Ayurzana1,2, Munkhnas Myagmarjav3, Meredith Potts4, Eguchi Yuichiro2

1Rotary Club of Ulaanbaatar Ulaanbaatar Mongolia, 2Mongolian Public Health Professional’s Association Ulaanbaatar Mongolia, 3Loco Medical General Institute Saga Japan, 4World NASH Council Washington United States

**BACKGROUND:** Mongolia is with the highest prevalence of viral hepatitis B, C and liver cancer in the world. Approximately, 53% and 35% are respectively, of estimated people chronically infected with HBV and HCV are diagnosed through government-funded screening program (Cumulative data for 2017-2020). Mainly, uninsured individuals, herders and mobile residents are not enrolled in the screening program. There is a greater challenge to reach out to those who live in the rural countryside, who do not know their liver disease status.

**METHODS:** “Hepatitis Coordinators” (HC) is a new model in Mongolia developed by Japanese all prefectures organized by the Ministry of health, including Saga prefecture and adopted be by “Hepatitis Free Mongolia” project funded by the Rotary Foundation.

In coordination with local government authorities and primary health care providers, we select health care workers, social workers, and community members to be trained as HCs.

**RESULTS:** Since 2017, 500 health care workers, social workers, and community members have been trained as HCs in three different provinces. HCs were helpful during the screening to reach out to community members to invite them to the screening and disseminate information about liver disease.

**CONCLUSIONS:** Social worker HCs will contact every community member in their assigned community who needs to be tested and communicate until they are tested. The health care worker HCs will follow each person who is positive for viral hepatitis B or C until they are treated. HCs will work within this long-standing social system of Mongolia to locate individuals.

Abstract Submission No. 100988

**P-0990**

**SAMe compared to UDCA for intrahepatic cholestasis treatment in China: a cost-utility analysis**

Kyoo Kim1, Hansoo Kim2, J Lyu2, R Royle2, Joshua Byrnes2

1Abbott Products Operations Ag Allschwil Switzerland, 2Centre for Applied Health Economics, School of Medicine, Griffith University Brisbane Australia

**Introduction:** Intrahepatic cholestasis (IHC) is a disorder of bile formation, secretion, or excretion such that bile flow is impeded from entering the duodenum and bloodstream. Two main treatments are available in China for the treatment of IHC, namely S-Adenosylmethionine (SAMe) and ursodeoxycholic acid (UDCA). The aim of this study is to assess the cost-utility of SAMe and UDCA.

**Methods:** A 3-state Markov model (mild IHC, severe/moderate IHC, dead) was developed to analyze the cost-utility of each drug. Quality-adjusted life years (QALYs) and incremental cost-utility ratio (ICUR) were chosen as the primary endpoints. Clinical trial input data was obtained from the literature, and local costs and clinical practice input were sought from key Chinese clinical experts.

**Results:** SAMe yielded additional 0.0349 QALYs at CNY2,634, resulting in an ICUR of CNY75,398 compared to placebo. The cost difference was driven by CNY3,438 in drug costs but offset with -CNY201 in health care costs. UDCA resulted in a gain of 0.0087 QALYs at an additional cost of CNY3,582 and an ICUR=CNY410,198.

**Conclusion:** This study shows SAMe leads to 0.0262 QALYs when compared to UDCA at -CNY948. While the drug costs were similar the SAMe health care costs were four (-CNY804/-CNY201=4) times lower than UDCA. In conclusion, SAMe is estimated to deliver improved health outcomes and savings for the treatment of IHC.

Abstract Submission No. 101210

**P-0991**
Nationale survey of clinical indicators to assess quality of liver disease care in Japan

Hiroko Setoyama1, 2, Noriko Oza1, Tetsuro Shimakami4, Junko Tanaka5, Yasuhito Tanaka1, Tatsuya Kanto1
1Department of Gastroenterology & Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan, 2The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine Ichikawa Japan, 3Saga-Ken Medical Center Koseikan Saga Japan, 4Kanazawa University Kanazawa Japan, 5Department of Epidemiology, Infectious Disease Control, and Prevention, Biomedical and Health Sciences, Hiroshima University Hiroshima Japan

Background: Since 2017, we have been developing clinical indicators for hepatitis and cirrhosis care at regional core centers for the management of liver disease in Japan. In this study, we have used these indicators to assess the changes in the quality of care for liver disease that is provided at the regional core centers across the country.

Methods: The survey regarding 29 clinical indicators (“hepatitis CIs”) was conducted with 72 regional core centers from 2018 to 2022 (except for 2019). The hepatitis CIs consisted of 5 categories (general hepatitis and cirrhosis, hepatitis C, hepatitis B, cirrhosis and subsidy systems). Based on the results of our survey over the past four years, we evaluated the trends of each indicator over time.

Results: In this survey, most of CIs in five categories showed the rate of achievement more than 80% of the relevant target values. However, six indicators, including resistance-associated substitutions testing for HCV DAA failure and routine upper GI endoscopy for cirrhosis patients, failed to meet their goals. In 2021, the CIs showed the lowest values for all categories, except for the subsidized systems, due to the negative impact of COVID-19 pandemic. Most categories showed recovery in 2022, except for the CIs regarding the management of liver cirrhosis.

Conclusion: The annual survey using CIs is useful for the trend assessment of the achievement of clinical practice for hepatitis patients. In Japan, highly standardized treatment and care has been provided nationwide to the patients in need.

Abstract Submission No. 101296
P-0992

Level of immunity against HBV in of pre-and post-HBV vaccinated populations of Mongolia

Enkhtuya Damba1, 2, Lkhaasuren Nemekhbaatar1, 2, Uuganbayar Gambaatar1, 2, Erdenebayar Gonchig1, 3, 4, Amarsanaa Jazag5
1MASLD, Mongolian Association for the Study of Liver Diseases Ulaanbaatar Mongolia, 2Otoch Manramba University Ulaanbaatar Mongolia, 3Happy Veritas Hospital Ulaanbaatar Mongolia, 4Research Institute of Mongolian Genomes Ulaanbaatar Mongolia

Background: Since 1991 newborns were partially or fully vaccinated with HBV vaccine. People who born before 1991 were not. We wanted to see the difference between those groups.

Methods: 492 patients have enrolled who were investigated with quantitative HBsAb (qHBsAb) using Sysmex HISCL-800 (full automated analyzer) at Happy Veritas hospital. The vaccination scheme consists of three doses. Vaccination is considered successful if the antibody-titer (qHBsAb) is higher than 10 mIU/L.

Results: In this study 492 patients have participated, 313 female (63%) and 179 male (37%), out of which 471 (96%) people born before 1991 and remaining 21 (4%) people born after 1991. Twelve people (57%) who were born after 1991 or vaccinated within 24 hours after birth had qHBsAb low titer (<10 mIU/L), remaining (43%) were qHBsAb titer (>10 mIU/L), while 297 people (64%) who born before 1991 were qHBsAb titer (<10 mIU/L), and remaining 109 people or 36% had higher than cut-off value. The 99 people who born before 1991 have enrolled in HBV catch up vaccination voluntarily, while 372 people were not vaccinated at all.

Conclusion: Persistent immunity against HBV is developed not only in people who were vaccinated but also in persons who have had HBV infections. It was observed people aged 50-60, had the highest HBV non-immune population in Mongolia. Catch-up vaccinations need be advocated and implemented aggressively.

Abstract Submission No. 101410
P-0993

Cost-utility of novel biomarker-based strategies for HCC surveillance in Thailand

Pisit Tangkijvanich1, David Wastlund2, Peng Lu2, Rebecca Sim Shu Yu2, Fabian Mueller1, Charles Qishi Zheng1, Ulises Garay5
1Center of Excellence in Hepatitis and Liver Cancer, Faculty of Medicine, Chulalongkorn University Bangkok Thailand, 2Vista Health Ltd Pte Singapore Singapore, 3Roche Diagnostics (Thailand) Ltd. Bangkok Thailand, 4Roche Diagnostics Asia Pacific Pte Ltd. Bangkok Thailand, 5Roche Diagnostics International AG Rotkreuz Switzerland

Background: Hepatocellular carcinoma (HCC) represents the fifth leading cause of death in Thailand. Even though alpha-fetoprotein (AFP)+Ultrasound (US) has been suggested for HCC surveillance, most patients still lack access. Novel biomarker-based strategies are suggested to help overcome the limitations of current surveillance methods. This study assessed the cost-utility of different routine HCC surveillance methods in Thailand from a public-payer perspective.

Methods: A health-economic model was developed to simulate lifetime outcomes from bi-annual HCC surveillance strategies in patients with chronic hepatitis B or compensated liver cirrhosis (CLC) aged 40-60. US+AFP and ‘no-surveillance’ were the main comparators in patients with CLC and chronic hepatitis B, respectively. Further routine surveillance strategies and scenarios were analyzed. The model was based upon the best available local data and utilized a Markov-style microsimulation framework for simulating disease progression, screening outcomes, and subsequent treatments.

Results: The model found GAAD2 to be the dominant strategy in CLC patients over US+AFP, mostly due to its better sensitivity and specificity which are associated with higher true positive and significantly lower false positive cases. This corresponds to better health (QALYs) and lower overall costs for the healthcare system. In HBV patients and compared to ‘no-surveillance’, GAAD is suggested to be cost-effective with an incremental cost-effectiveness ratio (ICER) of $168,115 per QALY.

Conclusions: This economic modeling analysis suggests that GAAD appears to be a cost-effective strategy for HCC surveillance in Thailand for both CLC and hepatitis B patients when compared to various surveillance strategies.

[1] Gender, Age, AFP, DCP (PIVKA-II)

Impact of the novel coronavirus disease 2019 on outpatient care of liver disease

Abstract Submission No. 101535
P-0994
February 2023—the study examined 509 referred cases. Defined in four periods—pre-COVID-19 (March 2019 to February 2020), early pandemic (March 2020 to February 2021), mid-pandemic (March 2021 to February 2022), and late pandemic (March 2022 to February 2023)—the study examined 509 referred cases. Results revealed a decline from 140 to 114 cases in the early pandemic, a mid-pandemic increase to 147 cases, and a subsequent late pandemic decrease to 108 cases. Post-pandemic, referred patients skewed younger. Significant variations were observed in referrals for primary liver cancer: 36 cases pre-pandemic, 24 cases early pandemic, 44 cases mid-pandemic, and 25 cases late pandemic. Hepatocellular carcinoma diagnosis stages shifted, with UICC stage III/IV cases increasing from 30% pre-pandemic to 42%, 42%, and 48% during subsequent pandemic periods. Over the three-year COVID-19 course, changes in hepatocellular carcinoma referral patterns aligned with societal responses to pandemic phases. Trends of younger referred patients and increased advanced hepatocellular carcinoma cases suggest reduced healthcare-seeking among the elderly and potential delays in cancer detection due to screening reductions. In conclusion, continuous screening of high-risk patients is crucial during pandemics to avert delays in hepatocellular carcinoma detection.

Abstract Submission No. 101581
P-0995

Does public health insurance in Indonesia help improve health? A Systematic Literature Review

Mega Dwi Septivani

1Politeknik Negeri Padang Padang Indonesia

In the majority of low- and middle-income countries (LMICs), universal health coverage (UHC) is a major health policy concern (World Health Organization 2014). National health insurance programs are gaining traction again as a result of UHC’s inclusion in the Sustainable Development Goals (SDGs) for health (United Nations 2018). In Indonesia itself, the Healthy Indonesia Card program called JKN-KIS (Jaminan Kesehatan Nasional -Kartu Indonesia sehat) has been implemented to provide socio-economic protection to people who are part of the responsibilities and obligations of the state. JKN-KIS one of the most single payer social health insurance programs in the world, provided coverage to around 186 million people in Indonesia by the middle of 2018 (Pinto et al. 2016; BPJS Kesehatan 2017). This study examined how the JKN program affected people’s ability to receive healthcare as indicated by how often they used it. Several previous studies reveal that the JKN program has raised the likelihood that people may seek both inpatient and outpatient care. The contributing group is more affected, and this is probably because they are a wealthier and better educated population (Erlangga, et al 2019). However, the effect on visit frequency is more susceptible to time-varying variables that are not observed, suggesting that estimated treatment effects may be overestimated in relation to the actual treatment effect on visit frequency. However, the impact of this increase is more susceptible to unobserved time-varying factors. In summary, this findings provided scant evidence in favor of the JKN program’s advantages for the subsidized group.

Abstract Submission No. 101819
P-0997

Dynamics of Liver Cancer Incidence and Mortality in Hong Kong: A Join Point Regression Analysis

Jing Chen1, Dong Ji2, Eliza Wong1, George Lau3

1JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong Hong Kong Hong Kong, 2Senior Department of Hepatology, Fifth Medical Center of Chinese PLA General Hospital Beijing China, 3Humanity and Health Clinical Trial Center, Humanity and Health Medical group Hong Kong SAR China

Background: Liver cancer is the fifth leading cancer in Hong Kong. We aimed to identify the temporal trends in liver cancer incidence and mortality in HK from 2001 to 2020.

Methods: Data grouped by sex and age were obtained from Surveillance of Viral Hepatitis in Hong Kong (2021 report). Joinpoint regression program (version 5.0), with annual percentage change (APC) and average annual percentage change (AAPC), was used to assess trends.
Results: Liver cancer incidence and mortality declined overall, with slower declines in older age groups. Mortality had no join points for men, but women aged 65+ experienced a faster post-2012 decline in mortality (APC=-4.3% [-8.1 to -2.6]). In terms of incidence, women aged 65+ showed four periods (jointed in 2003, 2014, 2018), with a notable increase (9.7%, 2.9 to 16.6) in 2001/2003 and a significant decrease (-7.9%, -12.3 to -5.2) in 2014/2018; men aged 20-44 and 45-64 had significant decrease in post-join points in 2018 and 2016 (-24.8% and -5.0% respectively). TDF introduction in 2008-9 and TAF in 2015-16 significantly decreased mortality in women aged 65+ but not in men, with a greater decrease post-2015/16 (-4.3%, vs. 0.8% in 2001-2008). Similar impact was observed on incidence in men of younger age groups.

Conclusion: Decrease in liver cancer incidence and mortality in HK was driven mainly by younger age groups. HBV treatment changes significantly accelerated this decline, particularly in women. Universal screening and timely HBV treatment are crucial for achieving HBV elimination in Hong Kong.

Abstract Submission No. 101859 P-0998

Assessing Pricing and Affordability of HBV Treatment in Asia-Pacific Region: Barrier to Elimination

Jing Chen1,2,3, Jidong Jia2,3, Ji Mo Yang1,2, Tawesak Tanwannde4,5, Diana Payawal6,7, Saeed Hamid6,7, SK Sarin6,7, Madao Omana8,9, George Lau1,2

1JC School of Public Health and Primary Care, Faculty of Medicine, Chinese University of Hong Kong Hong Kong, 2Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China, 3Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea Seoul South Korea, 4Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University Bangkok Thailand, 5Department of Medicine, Cardinal Santos Medical Center Mandaluyong Philippines, 6Aga Khan University Karachi Pakistan, 7Department of Hepatology, Institute of Liver and Biliary Sciences New Delhi India, 8Yamanashi Hospitals (Central and Kita) Organization, 1-1-1 Fujimi, Kofu-shi Yamanashi Japan, 9Humanity and Health Clinical Trial Center, Humanity and Health Development Center Ulaanbaatar Mongolia, 10On behalf of APASL Viral Elimination Task Force APASL APASL

Background: The Asia-Pacific (AP) region carries a substantial burden of HBV. Affordable HBV treatment is crucial to attain the WHO’s elimination goal. This study assesses the pricing and affordability of HBV treatment in AP.

Methods: A survey conducted among APASL members from Aug 2nd to Oct 30th, 2023, gathered data on antiviral HBV treatment costs, covering CHB, DC, CC, HCC, liver transplant, and monitoring expenses. Drug costs for TDF and ETV were compared to their production minimums (TDF: $23, ETV: $36), generating a minimum price ratio (MPR) where MPR < 1 indicated an acceptable local price. Affordability was evaluated by comparing yearly CHB treatment cost to the yearly minimum wage in each country/region, all converted to 2023 US$. A survey conducted among APASL members from Aug 2nd to Oct 30th, 2023, gathered data on antiviral HBV treatment costs, covering CHB, DC, CC, HCC, liver transplant, and monitoring expenses.

Results: TDF costs ranged from $42 in Pakistan to $2,640 in Malaysia, while ETV costs varied from $12.9 in mainland China to $2,446 in Hong Kong. All MPR exceeded 1, except for ETV in mainland China. Affordability of HBV treatment varied, with CHB patients in Australia paying 1.4% of the minimum yearly wage to get one-year CHB treatment, in contrast to Myanmar’s 118%. Affordability disparities were also evident for patients with CC, DC, HCC, and liver transplant needs, though monitoring costs were generally affordable.

Conclusions: Despite patent expiration and the availability of low-cost generics for TDF and ETV, HBV medication costs in the Asia-Pacific region remain high compared to production minimums. CHB treatment is generally unaffordable for patients, potentially posing a significant barrier to HBV elimination in this endemic region.

Abstract Submission No. 101965 P-0999

Rapid decline of acute and chronic HBV and HCV prevalence in Mongolia over the last decade

Rakhmyetdolla Savitai1,2, Gan-Erdene G3, Amarsanaa Jazag1,2, Baatarkhuu Oidov1,2, Erdenebayar Gonchig3

1MASLD Ulaanbaatar Mongolia, 2Otoch Manramba University Ulaanbaatar Mongolia, 3Happy Vertitas Hospital Ulaanbaatar Mongolia, 4Health Development Center Ulaanbaatar Mongolia

Introduction: We aimed to assess the prevalence of HBV and HCV among apparently healthy population of Mongolia over the last 10-15 years

Method: The research was carried out by combining the statistics and health indicators of the Center for Health Development of Mongolia, articles and WHO reports.

Results: According to our research, chronic C virus infection decreased from prevalence of 15.6% in 2008, to 11.1% in 2013, 9.4% in 2017, and 0.39% in 2022-2023. Acute HCV infection was 167 cases in 2012, 117 in 2013, 126 in 2014, 131 in 2015, 103 in 2016, 91 in 2017, 93 in 2018, 71 in 2019, 75 in 2020, and 39 in 2021 respectively, decreasing by 4.2 times from 2012.

HBsAg positivity was 8.2% in 2005, 10.6% in 2013, 4.3% in 2017-2018, and 0.23% in 2022-2023 decreasing by 35.6 times. While acute HBV incidence was 748 in 2009, 747 in 2010, 749 in 2011, 632 in 2012, 615 in 2013, 574 in 2014, 483 in 2015, 367 in 2016, 304 in 2017, 269 in 2018, 219 in 2019, 2020 143 and 60 cases in 2021 was recorded and it was 12.4 times lower than in 2009.

Conclusion: Prevalence and incidence B and C virus infections has decreased dramatically over the years 2009-2023, which may be due to the following factors: Vaccination against the B virus. Hospital disinfection has improved and more disposable equipment is used. C virus DAA treatment was introduced in 2016. Improved public health education. This trend might be global.

Abstract Submission No. 101982 P-1000

Empowering People Who Inject Drugs for Hepatitis C Screening through Peer-Led Education

Sahnaz Putri1, Andi Nursanti Andi ureng1, Maria Rosalia1

1Health Management Laboratory, International University Semen Indonesia Gresik Indonesia

Background/Aim: In response to the heightened risk of hepatitis C (HCV) transmission among people who inject drugs (PWID), this cluster randomized controlled trial aimed to evaluate the impact of peer-led educational workshops on HCV screening uptake. The study, conducted in communities with prevalent injection drug use, sought to assess whether a peer-led approach could effectively increase awareness, diminish stigma, and improve engagement with HCV screening services.
Methods: Clusters within high-risk communities were randomized to either receive peer-led educational workshops or standard care. Peers, individuals with lived experience in drug use, facilitated workshops covering HCV transmission, prevention, and the significance of screening. Screening uptake was monitored through healthcare records and self-reporting. Participant feedback on the peer-led approach was collected through surveys and qualitative interviews.

Results: The peer-led educational workshops yielded a remarkable 40% (95% CI: 35-45) increase in HCV screening uptake compared to the control group. Participants reported diminished stigma and heightened comfort in accessing screening services. Qualitative data underscored the unique value of peer-led education in fostering trust and understanding within the PWID community.

Conclusions: This research provides compelling evidence for the effectiveness of peer-led educational workshops in significantly enhancing HCV screening uptake among PWID. The findings emphasize the potential of community-driven interventions to address health disparities, reduce stigma, and promote active participation in essential healthcare services among high-risk populations.

Abstract Submission No. 102025
P-1001

Importance of implementation of reliable tests for HDV and HEV-infections diagnosis in Armenia

Narina Sargsyants¹

¹National Institute of Health Yerevan Armenia

Background: Of the five main forms of viral hepatitis, the most neglected are hepatitis caused by delta virus (HDV) and hepatitis E virus (HEV). It was estimated that globally approximately 5% of patients with chronic hepatitis B virus (HBV) infection co-infected with HDV leads to the most serious form of chronic viral hepatitis; on average, progression to cirrhosis occurs within 5 years and to hepatocellular carcinoma within 10 years. Autochthonous zoonotic HEV-infection caused by genotypes 3 and 4, is diagnosed in developed countries during last decades. HEV-infection can occur via transfusion of blood products and poorly cooked contaminated food, predominantly pork. The improvement of diagnostic techniques and increased awareness have influenced on increase EU cases since 2010.

Methods: All HBV-positive patients should be screening on HDV to improving diagnostic rates, subsequently outcomes disease and reduce the transmission of HDV. The screening of HEV RNA in blood products for transfusion and diagnosing high risk populations including pregnant women, patients with liver disease and immunocompromised patients especially in low income areas remains challenging.

Results: The prevalence of HDV-HBV-co-infection, especially in high-risk sexual behavior and intravenous drug users and HEV-infection, include HEV-associated extrahepatic manifestations remains unclear in Armenia. The problems with availability and accuracy of HDV and HEV testing contribute to underdiagnosis. The lack of international standards for serological and molecular detection result to misdiagnosing of two serious viral hepatitis.

Conclusion: It is necessary to introduce high accuracy and standardized serological and molecular assay to estimate the real burden of HDV and HEV-infections in Armenia.

Abstract Submission No. 102072
P-1002

The legal basis of treatment for Hepatitis C patients caused by stimulant use

Yuuske Shinozaki¹, Mizuki Shinozaki¹, Naoya Kato²

¹Department of Internal Medicine, Blue Bird Clinic Chiba Chiba Japan, ²Department of Gastroenterology, Graduate School of Medicine, Chiba University Chiba Japan

Background: In Japan, Hepatitis C was mostly infected through blood transfusions and the use of blood products. However, there are currently no cases of Hepatitis C virus infection associated with blood transfusions, and most cases are due to stimulant drug use.

Methods: We analyzed the reasons for infection in 51 Hepatitis C patients who received interferon-free therapy at our clinic from May 2018 to November 2023.

Results: The mean age was 60 years (±17 years), there were 49 men and 12 women. 34 (66.7%) were stimulant users. Among those born after 1960, 21 out of 25 (84%) were stimulant users.

Discussion: Since 1989, the Japanese Red Cross Society has been conducting HCV antibody testing. The number of people infected with Hepatitis C related to medical procedures is decreasing, and the proportion of stimulant users is expected to continue rising. In Japan, most of the medical costs for antiviral therapy are covered by public insurance and welfare. For this reason, some are skeptical that large amounts of medical costs will be spent on Hepatitis C patients infected through criminal activity. However, in Japan, Article 11 of the Constitution, which came into effect in 1947, enshrines “respect for fundamental human rights,” and Public Assistance Act (effect in 1950) also abolishes disqualification items (provisions that prohibit those with poor behavior from receiving protection). We should provide treatment based on political stances based on scientific insight and fairer social policies.

Abstract Submission No. 200173
P-1003

Analysis of Influencing Factors of anxiety and fatigue in patients with abnormal liver function

Yu Zhang¹, Renshan Liang¹, Hua Hu², Ailin Qin¹, Yunhai Yao¹, Zutao Chen¹, Zhi Li¹, Tingting Feng¹

¹The First Affiliated Hospital of Soochow University Suzhou China, ²The Second Affiliated Hospital of Soochow University Suzhou China

Abstract) Objective: To explore the related influencing factors of anxiety and fatigue in patients with abnormal liver function.

Methods: GAD-7 and FS-14 were used to investigate 175 patients and 40 healthy adults in the Department of Infectious Diseases of the First Affiliated Hospital of Soochow University. Two-sample rank sum test and Kruskal-Wallis test were used to explore the influencing factors of anxiety and fatigue.

Results: The score of GAD-7 in female patients was higher than that in male patients, and the difference was statistically significant (P < 0.05), but there was no significant difference in FS-14 score between them (P > 0.05). There was no significant difference in GAD-7 and FS-14 scores among all age groups (P > 0.05). There were statistically significant differences in the scores of GAD-7 among all etiological groups (P < 0.05), the scores of GAD-7 in cirrhosis group and other groups were significantly higher than those in healthy group. There were prominent differences in the scores of FS-14 among all etiological groups (P < 0.05), and the score of FS-14 in cirrhosis group was significantly higher than that in healthy group.

Conclusions: Female patients with abnormal liver function need psychological counseling more than male patients. Fatigue and anxiety are common symptoms in patients with abnormal liver function.
Abstract Submission No. 200211

**P-1004**

Gardeniae Fructus Attenuates Thioacetamide-Induced Liver Fibrosis via NF-κB and Nrf2 Signaling

Seong Soo Roh¹, Mi Rae Shin¹, Min Ju Kim¹, Hyeok Jae Choi², Ju Won Nam³, Yeon Ja Mun³

¹DaeguHaany University Gyeongsan South Korea, ²Yeonnam University Gyeongsan South Korea, ³Wonkwang University Iksan South Korea

Liver fibrosis, which means a sort of the excessive accumulation of extracellular matrices (ECMs) components through the liver tissue, is considered as tissue repair or wound-healing status. This pathological stage potentially leads to cirrhosis, if not controlled, it progressively results in hepatocellular carcinoma. Gardeniae Fructus (GF, the dried ripe fruits of *Gardenia jasminoides* Ellis) not only has been popularly applied to traditional medicine to treat hepatic disorders or to decrease various inflammation but also epidemiologically used as an excellent natural colorant. In the current study, as pursued to investigate the pharmacological properties of GF against TAA (i.p.) to induce liver fibrosis of mice model, and our data elucidated new knowledge about anti-hepatofibrotic effects of GF. GF attenuated liver fibrosis through both of AMPK/SIRT1 pathway and the Nrf2 signaling cascades. Therefore, GF could be considered a potential drug candidate for the treatment of liver fibrosis. However, further studies are needed to demonstrate its safety and toxicity for future clinical applications.

Abstract Submission No. 101198

**P-1005**

Enhancing Abdominal Ultrasound Training Through an Integrated Video and Testing Instruction System

Sawako Uchida-Kobayashi¹,², Hiroyuki Motoyama¹,², Hiroko Ikenaga², Yoshimi Muto², Naoshi Odarigi², Kohei Kotani², Riitsu Kozuka², Etsushi Kawamura², Atsushi Hagihara², Hideki Fuji², Masaru Enomoto², Norifumi Kawada²

¹Departments of Premier Preventive Medicine, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan, ²Departments of Hepatology, Graduate School of Medicine, Osaka Metropolitan University Osaka Japan

**Background:** Abdominal ultrasound (US) is noninvasive and highly versatile test, but it depends on the skill of the examiner and it is difficult to learn the technique. Normally, one-on-one instruction is provided, but there are problems such as it is time-consuming, puts a heavy burden on the instructor, and the instruction methods vary depending on the instructor. We have constructed a US instruction system using videos and tests with basic observation points.

**Methods:** In this system, one training session lasted for one hour, and one instructor taught five trainees. We conducted a trainee satisfaction survey and test to evaluate the learning effect. 1) We compared the learning effects before (n=119) and after (n=107) the introduction of the system. 2) We compared the differences in effectiveness due to differences in instructors.

**Results:** 1) The trainee satisfaction level (out of 10) at the end of the training was 7.1 before and 7.5 after the introduction of the system, with no significant difference (p=0.14). The test scores (out of 26) before and after the training using this system were 14 and 23 points, respectively, and the scores were significantly higher after the training (p<0.001). 2) The test scores of instructors A and B were 20 and 18 points, respectively, with no significant difference (p=0.05).

**Conclusions:** This system, which uses videos and test tools, allows one instructor to instruct multiple trainees at the same time in a short period of time, and even if the instructor changes, the same content and level can be maintained.

Abstract Submission No. 200085

**P-1006**

Use of Gel Immersion Technique in Colonic Diverticular Bleeding

Ronell Lee¹, Patricia S. Te¹, Willy S. Alba¹

¹Chinese General Hospital and Medical Center Manila Philippines

**OBJECTIVES:**

1. To demonstrate the consistency of the gel
2. To compare the visibility of water from the gel once mixed with fresh blood
3. Demonstrate the effectiveness of gel immersion technique in active colonic diverticular bleeding

**MATERIALS AND METHODS:**

**Materials:**
- Viscoclear gel #1, 50cc Syringe filled with fresh blood #1, Liter Glass bottles #2, Water

**Methods:**
- Two different 1.0 Liter glass bottles were filled with same amount of water in one bottle and viscoclear in another bottle. Fresh blood in a 50cc syringe was poured on both bottles consecutively. The mixtures were observed up to 1 hour.

**Clinical:**
- An 87 year old male with a Lower Gastrointestinal bleeding from an ascending colon diverticulosis underwent colonoscopy. Gel was flushed to the bleeding site.

**RESULTS:**
- Water immediately mixed with blood upon contact. Gel appeared to hold and prevent blood from scattering throughout the gel medium. After 1 hour, water appeared to mix thoroughly with blood while the blood in the gel did not scatter.

**Clinical:**
- The bleeding lesion was easily identified because the bleeding was slowly oozing from the site and did not scatter. A hemoclip was deployed on the bleeding site. Hemostasis was achieved afterwards.

**CONCLUSION:**
- 1. The gel immersion technique is an effective method of improving endoscopic visualization during active colonic diverticular bleeding

Abstract Submission No. 100353

**P-1007**

Efficacy and Safety of Terlipressin in the Treatment of ESLD Complicated with Intestinal Obstruction

Xia Wan¹, Shan Zhong¹, Huaidong Zhang¹, Zhi Zhou¹

¹THE SECOND AFFILATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY Chongqing China

**Background:** Dynamic intestinal obstruction (DIO) is a common complication of end-stage liver disease (ESLD). Traditional treatments typically offer limited relief, which affect a patient’s quality of life and overall prognosis.
**Objective:** To evaluate the efficacy and safety of low-dose terlipressin in treating ESLD complicated with DIO.

**Method:** The research was divided into the exploratory phase (January 2018 to December 2020) and the clinical study phase (January 2021 to September 2022). The DIO patients were randomly assigned to receive terlipressin or placebo. The placebo group received treatments including fasting, glycerin enema, gastrointestinal decompression, and the terlipressin group was administered terlipressin (1 mg mixed with 48 ml of 0.9% sodium chloride solution, adjusted based on patient tolerance, every 8-12 hours) in addition to the standard treatments. The differences in alleviation of DIO, time to symptom relief, and adverse reactions between the two groups were compared.

**Results:** From the exploratory study, 26 DIO patients treated with terlipressin, 46.2%(12/26) achieved complete relief, 42.3%(11/26) experienced partial relief. The median time for abdominal distension relief was 2.0 (1.0,3.0) days, and the median time to anal defecation and bowel movement was 1.0 (1.0,1.8) days. The results of the clinical study phase demonstrated that out of the total 1,120 patients admitted for ESLD, 131(11.7%) cases were complicated with DIO-33 were assigned to the terlipressin group and 98 to the placebo group. In the terlipressin group, the time to relief of abdominal pain and bloating, anal defecation and bowel movement was significantly shorter compared to the placebo group (2.0d vs 4.0d, 1.0d vs 3.0d, P <0.001), and the rate of relief of DIO was higher than the placebo group (93.9% vs 78.6%, P <0.05). Multivariate logistic regression analysis showed that enema, gastrointestinal decompression, and terlipressin use were the independent factors influencing the resolution of DIO. The incidence of adverse events was similar in both groups.

**Conclusion:** Terlipressin use combined with the conventional treatment notably accelerates symptomatic relief in those ESLD patients with concurrent DIO, improves both the relief rate and overall clinical prognosis, and no additional side effect.

---

**Abstract Submission No. 101166**

**P-1008**

**Minimal Hepatic Encephalopathy in patients with Budd Chiari syndrome (BCS)**

**KASHMIRA KAWLI**, **Akash Shukla**, **Sidharth Harindranath**, **Amrit Gopan**, **Aditya Kale**

1SETH GSMC AND KEM HOSPITAL MUMBAI India, 2SETH GSMC AND KEM HOSPITAL MUMBAI INDIA, 3SETH GSMC AND KEM HOSPITAL MUMBAI INDIA, 4SETH GSMC AND KEM HOSPITAL MUMBAI INDIA

**Introduction:** Prevalence of minimal hepatic encephalopathy (mHE) covert is largely unknown in BCS.

**Aims and Methods:** To study prevalence of mHE in BCS and its outcome following endovascular intervention. 127 newly diagnosed patients with BCS (18-65y) between July 2017 to January 2020 were included and subjected to a pencil-paper based Psychometric Hepatic Encephalopathy Test (PHET). At baseline and post intervention days 1, 7, 30, 90 and 12mo PHET scores were expressed as z scores (-3 to +1) and then analyzed as per baseline liver disease severity.

**Results:** Total 30 patients [27.5(22,32)y,17(56.7%) males] were included in the study. 15(50%) had mHE at baseline. Age(p=0.93), MELD score (p=0.30), CTP (p=0.27), MELD Na (p=0.25) and total bilirubin (p=0.44) were similar among those with (bmHE+) or without baseline mHE (bmHE-). In bmHE- group (n=15), new onset mHE was more common at 3 months (p=0.039) and 12 months (p=0.039) but not at 7day (p=0.53) and 30day (p=0.22), among those with MELD ≥15 as compared to MELD <15. In bmHE+ group, baseline scores were not associated with a new onset mHE. In bmHE+ group, those with improvement/normalization of total serum bilirubin at 30 days show a significantly lower 30-day mHE (p=0.039) with significant correlation between the two parameters (p=0.04, r =0.55). Age at >27.5years was associated with higher 30 days mHE.

**Conclusion:** mHE is common before and after intervention in BCS. Baseline disease severity, baseline mHE, age of intervention and trend of liver functions at 30 days influence presence of mHE in BCS after therapy.

---

**Abstract Submission No. 100232**

**P-1010**

**Influence of Stereotactic Body Radiotherapy on Hepatic Reserve Capacity in HCC patients.**

**Hideo Yoshida**, **Koji Uchino**, **Hiroyoshi Taniguchi**

1Japanese Red Cross Medical Center Tokyo Japan

**Aim:** Stereotactic body radiotherapy is effective in the treatment of hepatocellular carcinoma (HCC) for intrahepatic lesions. It is especially indicated when the lesion is untreated or unsuitable for percutaneous ablation (radiofrequency/microwave). In this study, we
investigated the effect of stereotactic radiotherapy on hepatic reserve capacity for intrahepatic lesions.

Methods: Patients underwent stereotactic radiotherapy (CyberKnife®) for intrahepatic lesions of HCC between April 2014 and December 2022 at our institution. Background data, tumor status, and treatment status of the treated cases were examined. The trend of hepatic reserve capacity was examined before, one month, three months, and one year after treatment.

Results: Ninety-four cases were treated during the above period. Child classification was A 82, B 9, and C 3. BCLC stage was early 3, intermediate 13, advanced 75, and terminal 3. Tumor diameter was median 28mm (range 11-56mm). The number of stereotactic radiotherapy sessions was 3-10 (5 median), and the radiation dose was 40 Gy median (range 25-75 Gy). The liver reserve markers before, 1 month, 3 months, and 6 months after treatment were 3.6±0.6, 3.6±0.5, 3.7±0.6, and 3.7±0.5 for albumin, 1.0±0.7, 1.0±0.4, 1.0±0.5, and 1.0±0.6 for total bilirubin, and 91±18, 92±20, 89±17, and 92±13 for PT% respectively. There were no characteristics in tumor diameter, irradiation dose, or tumor localization among the patients with decreased reserve. There were no cases of post-irradiation hepatitis exacerbation.

Conclusion: Stereotactic radiotherapy for intrahepatic lesions of HCC can be performed without reducing hepatic reserve.

Abstract Submission No. 100757
P-1011
Role of palliative radiotherapy in patients with chemo unfit gallbladder cancer - Time to rethink.

DIVYESH KUMAR1, Harish Bhujade1,2, Arun Oinam1
1Department of Radiotherapy and Oncology, Post Graduate Institute of Medical Education and Research Chandigarh India. 2Department of Radiodiagnosis, Post Graduate Institute of Medical Education and Research Chandigarh India

Background: Gallbladder carcinoma (GBC) usually carries a poor prognosis. Pain and jaundice (either alone or in combination) are the presenting complaints for these patients. Although palliative chemotherapy (CT) is the treatment of choice for patients who are fit to receive CT, the rest all the cases are generally kept on best supportive care only. We hypothesised that palliative radiotherapy (RT) might be a useful methodology for GBC patients who otherwise are unfit for CT. Moreover, the role of RT has scarcely been documented for this entity. The present prospective pilot clinical study thus aimed to evaluate the role of palliative RT in unresectable/chemo-unfit GBC patients.

Patients and Methods: Patients presenting with jaundice and/or pain were taken up for three-dimensional conformal radiation therapy (3DCRT) to a dose of 30 Gy/10#. The response was assessed after 6 weeks of RT using RECIST criteria version 1.1. Acute toxicities, if any were assessed on weekly check-ups. A visual analog scale (VAS) was used for the assessment of pain. Also, EORTC QLQ C30 was used for assessing the quality of life (QOL). Results were analysed statistically.

Results: N=15 patients (6 males and 9 females) with a median age of 49 years (range 42-63 years) were evaluated. 8/15 (53.33%) patients showed partial response (PR) and 5/15 (33.33%) showed stable disease (SD) after RT while 2/15 (13.33%) patients defaulted treatment in between and were lost to follow-up. Grade II skin and gastrointestinal acute toxicities were observed in 3/15 (20%) patients. A statistically significant (p<0.05) reduction in VAS scores and GBC mass was observed. QOL at 6 weeks also shows better scores post-RT.

Conclusion: Palliative RT seems a feasible option in GBC patients who are otherwise not fit for definitive management. We propose its routine use in such patients who otherwise are deemed unfit for definitive therapy. Studies with larger sample sizes are warranted.

Abstract Submission No. 101731
P-1012
Patients with PBC-specific antibodies and cholestasis may not be primary biliary cholangitis

Xin Zeng1, Ting-ting Lv1, Shu-xiang Li1, Sha Chen1, Bu-er Li2, Zhi-jiao Lu1, Yu Wang1, Xin-yan Zhao2, Hong You1, Wei-jia Duan1, Ji-dong Jia1
1Liver Research Center, Beijing Friendship Hospital Capital Medical University Beijing, China China

Background & Aims: Patients with positive primary biliary cholangitis (PBC)-specific antibodies and evidence of cholestasis fulfill the diagnostic criteria of PBC. However, PBC-specific antibodies can appear in various diseases, and abnormal liver biochemistry might have non-PBC origins. Do these patients have PBC? Our study focused on patients with PBC-specific antibodies and cholestatic index elevation attributable to non-PBC etiologies.

Methods: We enrolled patients with positive PBC-specific antibodies at Beijing Friendship Hospital, Capital Medical University, between February 2017 and May 2023. Changes in liver biochemistry after non-ursodeoxycholic acid (UDCA) etiological treatments were monitored via electronic medical records and/or telephone interviews.

Results: One hundred and fifty-five patients with positive PBC-specific antibodies and elevated ALP and/or GGT levels due to non-PBC diseases were enrolled. One hundred patients had non-PBC liver diseases including non-alcoholic fatty liver diseases (n=36), drug-induced liver injury (n=35), autoimmune hepatitis (n=9), and others (n=20). Fifty-five patients had non-liver diseases, predominately consisting of connective tissue diseases (CTDs) (n=28). The median follow-up was 15.9 (4.7-25.6) months, and patients taking UDCA were excluded. After treatment targeting primary diseases, 73 patients exhibited decreases in both ALP and GGT levels, eventually normalizing within normal ranges. Among patients with persistently elevated liver enzymes, 12 patients underwent liver biopsy, and no specific manifestations of PBC were observed. Additionally, 55 patients had elevated GGT levels but normal ALP levels.

Conclusion: Patients with PBC-specific antibodies and cholestasis may not be PBC. For patients with non-PBC liver diseases and CTDs, treatments of primary diseases can normalize cholestatic index instead of UDCA.

Abstract Submission No. 101739
P-1013
Shared genetic architecture between Primary sclerosing cholangitis and inflammatory bowel diseases

Xuan Dong1,2,3,4, Li-Li Gong5, Mei-Zhu Hong5, Jin-Shui Pan1,2,3,4
1Department of Hepatology, the First Affiliated Hospital of Fujian Medical University Fuzhou China, 2Hepatology Research Institute, Fujian Medical University Fuzhou China, 3Department of Hepatology, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University Fuzhou China, 4Fujian Clinical Research Center for Hepatology and Intestinal Diseases Fuzhou China, 5Department of General Practice, Zhongsan Hospital, Xiamen University Xiamen China, 6Department of Traditional Chinese Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University Fuzhou China
Background: Several studies have found that primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) are closely associated. However, the direction and causality of their interactions remain unclear. Thus, this study employs Mendelian Randomization to explore whether there are causal associations of genetically predicted PSC with IBD.

Methods: Genetic variants associated with the genome-wide association study (GWAS) of PSC were used as instrumental variables. The statistics for IBD, including ulcerative colitis (UC), and Crohn’s disease (CD) were derived from GWAS. Then, five methods were used to estimate the effects of genetically predicted PSC on IBD, including MR Egger, Weighted median (WM), Inverse variance weighted (IVW), Simple mode, and Weighted mode. Last, we also evaluated the pleiotropic effects, heterogeneity, and a leave-one-out sensitivity analysis that drives causal associations to confirm the validity of the analysis.

Results: Genetically predicted PSC was significantly associated with an increased risk of UC, according to the study (odds ratio [OR] IVW = 1.0014, P = 0.05). However, none of the MR methods found significant causal evidence of genetically predicted PSC in CD (All P > 0.05). The sensitivity analysis results showed that the causal effect estimations of genetically predicted PSC on IBD were robust, and there was no horizontal pleiotropy or statistical heterogeneity.

Conclusions: Our study corroborated a causal association between genetically predicted PSC and UC but did not between genetically predicted PSC and CD. Then, we identified a set of shared SNPs for PSC and UC, including rs3184504, rs9858213, rs725613, rs10909839, and rs4147359. More animal experiments and clinical observational studies are required to further clarify the underlying mechanisms of PSC and IBD.

Abstract Submission No. 101717
P-1014

Clinical features of immune-related liver injury caused by immune checkpoint inhibitors

Yoko Yoshimaru1, Katsuya Nagaoka1, Kentaro Tanaka1, Satoshi Narahara1, Hiroki Inada1, Sotaro Kurano1, Takayuki Tokunaga1, Etsuko Ito1, Takehisa Watanabe1, Hiroko Setoyama1, Yasuhito Tanaka1

1Department of Gastroenterology and Hepatology, Graduate School of Medical Sciences, Kumamoto University Kumamoto Japan

Background: Immune checkpoint inhibitors (ICIs) have been developed as promising treatments for many advanced malignancies. Despite their efficacy, ICIs occasionally induce liver injury. We revealed the clinical features of immune-related liver injury caused by ICIs (ILICI).

Methods: We evaluated the complication rates and the risk factor of ILICI in 1023 cases treated with ICIs between July 2014 and May 2022. Among those who developed ILICI, we revealed the clinical features of 40 patients whose follow-up could be observed.

Results: ILICI (≥ Grade 2) occurred in 45 (4.4%) patients during the follow-up period (median 11.6 months). Factor that was significantly associated with the incidence of ILICI was use of ipilimumab [hazard ratio 11.49, P < 0.001]. The liver-injuries patterns of 40 patients (Grade 2, n = 13: Grade 3, n = 23: Grade 4, n=4) were hepatocellular (n = 23), mixed (n = 10), or cholestatic (n = 7). The median period between the initial administration of ICIs and the incidence of ILICI was 62 days. Corticosteroids were administered to 29 (72.5%) patients and three with Grade 3 and one with Grade 4 needed secondary immunosuppression with mycophenolate mofetil (MMF). Furthermore, in one patient who did not improve with MMF, azathioprine was administered. Of the 39 patients in which liver injury improved, ICI was readministered in 23 patients, and ILICI relapsed in 2 (8.7%).

Conclusions: ILICI (≥ Grade 2) was observed in 4.4%. In particular, attention must be paid to the incidence of ILICI in cases of ipilimumab administration.

Abstract Submission No. 100484
P-1015

Overexpressed CYP7A1 inhibits HBV replication via activating NF-kappa B pathway

Guixin Li1, Hongsong Chen1, Fengmin Lu1,2
1Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China, 2Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Background: Cholesterol 7a-hydroxylase (CYP7A1) is a rate-limiting enzyme catalyzing cholesterol to synthesize bile acids, which can activate nuclear receptors to regulate hepatitis B virus (HBV) replication. However, due to the complexity of bile acid feedback regulation, the integral effects of CYP7A1 on HBV life cycle have not been fully revealed.

Methods: Different doses (0.5μg, 1.5μg, 2.5μg) of plasmid expressing CYP7A1 (pCYP7A1) were co-transfected with 1.3×HBV (pHBV1.3) into Huh7 cells. Cell viability, transcription and gene expression of HBV, intracellular cholesterol levels were quantified. Total and phosphorylated protein levels of P65 were detected. After ammonium pyrrolidine dithiocarbamate (PDTC, an inhibitor of NF-κB) treated, the indicators of HBV were reassessed.

Results: First of all, CYP7A1 overexpression at the experimental dosages didn’t significantly inhibit cell viability. Compared with controls, the intracellular cholesterol level gradually decreased and was significantly lower at 2.5μg of pCYP7A1. Meanwhile, the levels of HBsAg and HBV DNA were reduced in the supernatant of Huh7 cells transfected with high dose of pCYP7A1. The HBsAg level decreased at 2.5μg of pCYP7A1, while increased at 0.5μg. In addition, CYP7A1 overexpression decreased the levels of intracellular HBV 3.5kb mRNA and precore mRNA. Western blot analysis showed the phosphorylated P65 protein level was downregulated at low dose of pCYP7A1 and upregulated at 1.5μg and 2.5μg dosages. And the inhibitory effect of CYP7A1 overexpression on HBV replication was partially reversed by the administration of PDTC.

Conclusions: High level of ectopic CYP7A1 expression can inhibit HBV replication by activating the NF-kappa B pathway.

Abstract Submission No. 100507
P-1016

Effects and mechanism of KDM1B on transcriptional activity of HBV covalently closed circular DNA

Qianqian Jiang1, Fengmin Lu1,2
1Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China, 2Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

Background: Lysine demethylase 1B (KDM1B) is a member of KDM family. KDM1A has been reported to cooperate with the HBx and...
promote hepatitis B virus (HBV) replication. However, the effects of KDM1B on HBV have not been reported.

**Methods:** Plasmids prcccDNA/pCMV-Cre and pKDM1B/siKDM1B were co-transfected into HuH7 or HepG2 cells. Supernatant HBsAg/HBeAg or HBV DNA were quantified by chemiluminescence immunoassay or qPCR, respectively. Intracellular HBV RNAs and virus proteins were detected by qRT-PCR or Western Blot. Then KDM1B was knocked down in HepG2-NTCP cells, subsequently infected with HBV viral particles. Viral parameters were detected 4 days post infection. pKDM1B and pGL3-Enhancer I/BCP/Enhancer II=BCP-Luci were co-transfected into HepG2 cells. Luciferase assay was performed to determine the transcriptional activity of HBV promoter and enhancers.

**Results:** In human hepatoma cells, KDM1B overexpression significantly increased the levels of HBsAg, HBeAg, HBV RNAs and HBV DNA. Western blot analysis showed that KDM1B overexpression increased HBcAg/HBsAg but decreased p53 level. The results were reverse after knocking down KDM1B. Consistently, knockdown of the endogenous KDM1B also significantly decreased the levels of the superantigen HBeAg and intracellular HBV RNAs in HepG2-NTCP cells. Luciferase assay showed that KDM1B could significantly enhance the transcriptional activity of BCP, Enhancer I, Enhancer II=BCP. Mechanistically, Western Blot analysis suggested that KDM1B overexpression could significantly reduce the protein level of HBV transcriptional suppressor p53.

**Conclusions:** KDM1B can promote HBV replication by mitigating inhibitory effect of p53 on the transcriptional activity of promoter and enhancers on covalently closed circular DNA.

**Abstract Submission No. 100508**

**P-1017**

**Regulation and mechanism of AZI2 on HBV replication**

Qianqian Jiang¹, Fengmin Lu¹,²

¹Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis Beijing China, ²Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Beijing China

**Background:** The understanding of the interactions between hepatitis B virus (HBV) and host is still limited. It has been reported that 5-azacytidine induced 2 (AZI2) can induce the production of type I interferon. However, the role of AZI2 in HBV is elusive. In this study, we aim to clarify the effects and related mechanisms of AZI2 on HBV replication.

**Methods:** Plasmids prcccDNA/pCMV-Cre and pAZI2/siAZI2 were co-transfected into HepG2 cells. AZI2 was knocked down in HepAD38 cells using siRNA. The levels of superantigen HBsAg/HBeAg or HBV DNA were determined by chemiluminescence immunoassay or qPCR. Intracellular HBV RNAs and a serial of interferon stimulating genes were detected by qRT-PCR. Besides, levels of intracellular HBcAg were detected by Western Blot.

**Results:** In HepG2 cells, AZI2 overexpression significantly increased the level of HBsAg, HBeAg, HBV RNAs and HBV DNA. Western blot analysis showed that AZI2 overexpression could increase intracellular HBcAg. Agreed with results of AZI2 overexpression, knockdown of AZI2 decreased the levels of viral parameters in both supernatant and cell lysates. Furthermore, when AZI2 was knocked down, the mRNA level of IRF3 which can suppress HBV replication was decreased, while no significant change was observed in MX1, ISG20 and OAS2. In addition, knockdown of AZI2 also significantly decreased the levels of superantigen HBeAg/HBV DNA and intracellular HBV RNAs in HepAD38 cells, and no significant change in mRNA levels of MX1, ISG20 and OAS2 was observed.

**Conclusions:** AZI2 is likely to promote HBV replication by elevating HBV RNA levels without increasing type I interferon levels.

**Abstract Submission No. 101337**

**P-1018**

**Relationship between immune cells and chronic hepatitis B: A Mendelian randomization study**

Wei Wang¹, Ting Fang², Xu Cao¹, Wenyi Qian³, Yue Chen¹, Xiaoke Li¹, Xiaobin Zao¹, Yong'an Ye¹

¹Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, ²Guanganmen Hospital, China Academy of Chinese Medical Science Beijing China

**Background:** Chronic hepatitis B (CHB) is an immune related disease. Growing evidence has suggested that there is a close association between immune cells and the progression of CHB. However, establishing a causal relationship between immune cells and CHB remains a subject of investigation.

**Methods:** Based on publicly available genetic data, we conducted a two-sample, Mendelian randomization (MR) analysis to explore causal associations between 731 immune cells and CHB.

**Results:** We used the inverse variance weighted method as the primary analysis, and genetically predicted Sw mem %B cell (odds ratio [OR]=1.27, 95% confidence interval [CI]=1.04-1.56, P=0.022), IgD-CD38- %B cell (OR=1.34, 95% CI=1.09-1.65, P=0.006), CD39+ secreting Treg % (OR=1.10, 95% CI=1.05-1.32, P=0.007), EM DN (CD4-CD8+) %DN (OR=1.13, 95% CI=1.01-1.26, P=0.038), CD25 on CD24+CD27+ (OR=1.10, 95% CI=1.02-1.18, P=0.016) and CD40 on CD14+CD16- monocyte (OR=1.09, 95% CI=1.00-1.18, P=0.041) were associated with an increased risk of CHB. On the other hand, Plasmacytoid DC AC (OR=0.90, 95% CI=0.83-0.97, P=0.007), CD14+CD16- monocyte AC (OR=0.84, 95% CI=0.73-0.97, P=0.015), CD14+CD16+ monocyte %monocyte (OR=0.86, 95% CI=0.76-0.97, P=0.012), CD4 on EM CD4+ (OR=0.84, 95% CI=0.71-0.99, P=0.037) and HLA DR on CD33br HLA DR+ CD14dim (OR=0.85, 95% CI=0.73-0.98, P=0.029) exhibited a protective effect against CHB. The results of sensitivity analyses for these immune cells were consistent. The reverse MR analysis did not support the causal relationship between CHB and these 11 immune cells.

**Conclusions:** Our study has demonstrated the potential causal relationship between immune cells and CHB by genetic means, thus providing guidance for future clinical research.

**Abstract Submission No. 101606**

**P-1019**

**E-CFCC exerts potent antiviral activity against drug-resistant HBV with a high genetic barrier**

Sanae Hayashi¹, Nobuyo Higashi-Kuwata², Hiroaki Mitsuya²,³,⁴, Yasuhiro Tanaka¹

¹Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan, ²Department of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute Tokyo Japan, ³Department of Clinical Sciences, Kumamoto University Hospital Kumamoto Japan, ⁴Experimental Retrovirology Section, HIV and AIDS Malignancy
Aim: Our study aims to assess the efficacy and influencing factors of different conversion strategies for treating LLV patients.

Methods: We retrospectively collected data from 97 LLV patients. Patients were divided into three groups according to their continued antiviral treatment: NAs (n=34), NAs+IFNα-2b (n=16), NAs+IFNα-2b monotherapy, whole process combination therapy (NAs for 12-24 weeks followed by Peg-IFNα-2b add-on, and NAs+NAs treatment groups). The baseline HBsAg levels (<10, 10-100, 100-1000, >1000 IU/mL). The AUC of HBV DNA combined with HBsAg was 0.825 (95% CI: 0.731-0.918) with a cutoff value of 0.10 log10 IU/mL. The HBsAg decline in the NAs + IFNα-2b group was significantly higher than in the NAs group and NAs+IFNα-2b group (P<0.05). Three patients in the NAs+IFNα-2b group achieved HBsAg negative conversion.

Conclusion: Combining another NAs or IFN therapy effectively improves the 96-week CVR rate in LLV patients after NAs treatment. Furthermore, combined IFN therapy significantly enhances decline the HBsAg levels.

Abstract Submission No. 100505

P-1023

48 weeks of initial treatment with TMF versus TAF for patients with CHB: a retrospective study

Lu Junfeng1, Zhang Qing1, Liu Dan1, Wang Liun1, Ren Shan1, Hou Wei1, Zheng Sujuan1

1Capital Medical University, Beijing Youan Hospital Beijing China

Background: Tenofovir alafenamide (TMF) utilizes innovative ProTide technology and a methylWin strategy to add a methyl group to the amide bond group compared to tenofovir alafenamide (TAF), which improves lipid solubility and maintains higher stability in plasma. The Phase III clinical registration trial of TMF has shown that it has good antiviral efficacy. However, there is still limited clinical data on TMF in the real world.

Objective: To compare the antiviral efficacy and safety of TMF and TAF in the initial treatment of patients with high viral load chronic hepatitis B (CHB).

Methods: Clinical data of high viral load CHB patients who received initial antiviral treatment with TMF (n=58) or TAF (n=32) monotherapy in the outpatient department of Beijing You’an Hospital from March 2022 to June 2022 was collected retrospectively and the efficacy and safety of antiviral therapy for 48 weeks between two groups were compared.

Results: The baseline HBV DNA levels in the TMF group and TAF group were 7.85 IgIU/ml and 7.44 IgIU/ml, respectively (P=0.343). Compared with the baseline, the decrease in HBV DNA levels between the two groups after 4 weeks, 12 weeks, 24 weeks, and 48 weeks of antiviral treatment was 3.65 IgIU/ml vs 3.70 IgIU/ml (P=0.863), 4.63 IgIU/ml vs 4.84 IgIU/ml (P=0.329), 5.82 IgIU/ml vs 5.77 IgIU/ml (P=0.817) and 6.85 IgIU/ml vs 6.38 IgIU/ml (P=0.071) with no significant statistical difference. The HBV DNA clearance rates (<100 IU/ml) of the TMF and TAF treatment for 48 week were 41.5% (22/53) and 40.0% (12/30) respectively. The baseline median ALT levels in the TMF and TAF treatment groups were 102.0 U/L (56.0 U/L, 210 U/L) and 195.0 U/L (73.5 U/L, 371.0 U/L), respectively (P=0.071). The normalization rates of ALT at 12 weeks, 24 weeks and 48 weeks were 65.2%, 86.1%, 93.4%, vs 58.3%, 81.6%, and 92.7% respectively. Compared with baseline, there was no significant statistical difference in serum Cr, eGFR, and lipid levels between the two groups at 24 and 48 weeks (P<0.05).

Conclusion: Both TMF and TAF can achieve good antiviral efficacy and safety in newly treated CHB patients with high viral load.

Abstract Submission No. 100882

P-1024

The interim analysis of E-Cure study for inactive hepatitis B surface antigen carriers in China

Zhishuo Mo1, Qingfa Ruan2, Xiulan Xue2, Yawen Luo1, Xiaoping Wa3, Shuangshuo Dang4, Shumei Lin5, Haidong Zhao6, Xiaorong Mao7, Qihuan Xu1, Zhiliang Gao1

1The third affiliated hospital of Sun Yat-sen university Guangzhou China, 2Xiamen Hospital of Traditional Chinese Medicine Xiamen China, 3The First Affiliated Hospital of Xiamen University Xiamen China, 4Affiliated Hospital of Zunyi Medical University Zunyi China, 5The First Affiliated Hospital Of Nanchang University Nanchang China, 6The second affiliated hospital of Xi’an jiaotong university Xi’an China, 7The first affiliated hospital of Xi’an jiaotong university Xi’an China, 8Xiamen Changhai Hospital Co., Ltd. Xiamen China, 9The first hospital of Lanzhou university Lanzhou China

Objective: To investigate the efficacy of different Peg-IFNα based treatment strategies of inactive HBsAg carriers.

Methods: A multi-center real world study (E-Cure study) of 103 hospitals started in January 2022. The study enrolled inactive HBsAg carriers (IHCs) consistent with the definition of inactive CHB in the guideline of AASLD 2018. The patients received one of the following treatments: NAs monotherapy, Peg-IFNα monotherapy, Initial combination therapy (Peg-IFNα-2b with NAs for 12-24 weeks followed by Peg-IFNα-2b monotherapy), Whole process combination therapy (combination of Peg-IFNα-2b and NAs for the entire period) and Sequential combination therapy (NAs for 12-24 weeks followed by Peg-IFNα-2b add-on).

Results: By June 2023, 927 patients who completed 12 weeks of treatment and had completed clinical information were included in this analysis, of whom 671 completed 24 weeks of treatment. The HBsAg clearance rate at 12w and 24w were 11% and 22.1% (P=0.001), with on significant difference between five treatment groups (0%, 11.5%, 4.1%, 12.2%, 13% at 12w; 0%, 23.8%, 14.6%, 20.4%, 11.1% at 24w, respectively). Further stratified analysis was performed according to baseline HBsAg levels (<10, 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10, 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL). The HBsAg clearance rate were 35.9%, 10.5%, 1.9% and 0% at 12w (<10), 10-100, 100-1000, >1000 IU/mL).

Conclusions: Peg-IFNα based treatments result in a high HBsAg clearance rate, especially in patients with low HBsAg level. The in-depth antiviral study of IHCs is valuable.

Abstract Submission No. 100956

P-1025

Hepatitis B serological screening: A single centre experience

Janavi Sridhar1, Reethika Sankar1, Karthikeyan Mun1, Padma Srikant1, Jayanthi Venkataraman1

1Sri Ramachandra Institute of Higher Education and Research Chennai India
**Background:** Profiling of Hepatitis B virus infection (HBV) involves HBsAg, anti-HBc (total) and anti-HBs (titre) serological markers. Standard protocol involves routinely screening for HBsAg alone to identify HBV infection. This protocol can fail to provide information on occult Hepatitis B infection, past HBV infection and HBV vaccination status.

**Aim:** To determine the profile of chronic HBV infection using HBsAg, anti-HBs (titre) and anti-HBc (Total) serological markers.

**Method:** Patients registered in the Hepatology outpatient clinic between Jan 2018 and June 2022 were categorized as incidental HBV infection (HBsAg positive; anti-HBc (total) positive), past infection (anti-HBs (Total); anti-HBc positive), occult HBV infection (HBsAg; anti-HBs (titre) and anti-HBc (Total) serological markers. Infection status.

**Results:** Of the 931 patients registered, 637 were men (68.4%) and 294 were women (31.6%). 510 patients (54.9%) were incidental HBsAg positive, 55 (6%) had past infection, and 56 (6%) were anti-HBc (total) positivity (raised HBV DNA (100 IU/mL) in one). A significant number of patients between 41 to 59 years had present (p-value .00004) or an occult HBV infection (0.0029). 37 had serological protective anti-HBs titre; 22 (59.5%) were < 40 years old (p-value .0015).

**Conclusion:** Approximately 12% of patients had either a past (5.9%) or an occult HBV infection (6%). Do these subsets of patients require a protocol surveillance for hepatocellular carcinoma? Is there a likelihood of reactivation in an immunocompromised state or under treatment with potent biologicals? These questions remain unanswered.

Abstract Submission No. 101135

**P-1026**

**PegIFN alpha-2b in HBeAg negative CHB patients with normal ALT: A multicenter real-world study**

Chong Zhang1, Xiaoguang Dou1, Dawu Zeng2, Dachuan Cai3, Xuan Xue4, Lingyi Zhang5, Jia Shang6, Yan Huang7, Yufeng Gao8, Xiaofeng Wu9, Baojun Song10

1Shengjing Hospital of China Medical University Shenyang China, 2The First Affiliated Hospital of Fujian Medical University Fuzhou China, 3The Second Affiliated Hospital of Chongqing Medical University Chongqing China, 4The First Affiliated Hospital of Xiamen University Xiamen China, 5Lanzhou University Second Hospital Lanzhou China, 6Henan Provincial People’s Hospital Zhengzhou China, 7Xiangya Hospital Central South University Changsha China, 8The First Affiliated Hospital of Anhui Medical University Hefei China, 9The Sixth People’s Hospital of Shenyang Shenyang China, 10The Sixth People’s Hospital of Fushun Fushun China

**Background:** The purpose of this study was to analyze the efficacy of pegylated interferon alpha-2b (PegIFN alpha-2b) in HBeAg negative CHB patients with normal ALT, and to explore the predictive factors of virological and serological responses.

**Method:** This is a multi-center, prospective, non-interventional, real-world clinical study conducted in China, involving 20 hospitals in 12 provinces or municipalities, which enrolled CHB patients with age of 18-60 years, HBeAg positive for more than 6 months, HBeAg negative, HBV DNA > 20 IU/mL and normal ALT, without antivirus treatment history. PegIFN alpha-2b 180 μg/week was applied.

**Results:** 53 patients with complete data collection have been summarized for 24 weeks of treatment. The median baseline HBV DNA was 1.01 × 10^5 IU/mL (Figure 1a), the median baseline HBsAg was 657.22 IU/mL (Figure 1b). After 24 weeks of PegIFN alpha-2b treatment, the median HBV DNA was 0 IU/mL, and the rate of HBV DNA negative was 62.3% (Figure 1c), the median HBsAg was decreased to 106.45 IU/mL, and the HBsAg loss rate was 11.3% (Figure 1d). The patients with HBV DNA undetectable at treatment week 24 had much lower baseline HBsAg level (p = 0.032). The rate of HBV DNA negative at 24 weeks was 71.1% in patients with baseline HBsAg ≤ 1500 IU/mL (p = 0.036).

**Conclusion:** For HBeAg negative CHB patients with normal ALT, PegIFN alpha-2b treatment for 24 weeks can achieve a high rate of HBV DNA negative and significant HBsAg decrease, even HBsAg loss.

Abstract Submission No. 101241

**P-1027**

**Long-term outcomes of HBeAg-positive grey-zone patients**

Jung Hyun Kwon1, Dongwoo Cho1, Soon Kyu Lee1, Soon Woo Nam1, Jeong Won Jang2, Ji Won Kim3, Chang Young Chung3, Moon Sung Cho1, Hyung Jin Kim3

1The Catholic University of Korea Incheon South Korea, 2The Catholic University of Korea, Seoul St. Mary's Hospital Seoul South Korea, 3The Catholic University of Korea, Eunpyung St. Mary’s Hospital Seoul South Korea

**Background and aims:** HBeAg-positive patients consisted of immune tolerant (IT) and immune active (IA) groups. Recently, a more detailed classification beyond the original criteria of ALT levels or HBV DNA levels has placed these patients into a grey-zone (GZ). It remains unclear whether these patients will demonstrate different long-term outcomes from the conventional group.

**Methods:** Out of 256 HBeAg-positive IT and IA patients in a naive cohort from our hospital (published in year 2011) 201 without HCC were finally analyze. Currently, IT was strictly re-defined as HBV DNA >10^4 IU/mL and ALT<40 U/L, while IT-GZ was defined by HBV DNA >10^4 IU/mL and ALT=80 U/L, IA was defined as ALT >80 U/L regardless of HBV DNA levels, IA-GZ defined by HBV DNA >10^4 IU/mL and ALT=80 U/L. We evaluated the rate of de novo HCC development and cumulative rate of antiviral therapy (AVT) of IT versus IT-GZ, IA versus IA-GZ groups.

**Results:** Of the 59 original IT patients, 39 were in the strict IT group and 20 were in the IT-GZ group. Of the 142 original IA patients, 93 were in the IA group and 49 were in the IA-GZ group. Both GZ groups had significantly lower levels of HBsAg, HBeAg, HBV DNA levels and platelet levels than IT and IA patients (P<0.01). The IA-GZ group was older in the IA group.

During a long-term follow-up period (9.1 ± 4.4 year), 18 patients developed HCC (8 in IA, 10 in IA-GZ, and only 1 in IT-GZ). During follow-up compared to the starting AVT baseline, was a significant risk factor (HR 4.747, P=0.035) for HCC development but not in the IA-GZ group (P=0.099). For the predicting the HCC in IA/IA-GZ group, male gender, HBeAg titer <200 IU/mL, HBV DNA <10^5 IU/mL, and ALT <80 U/L were significant variables.

**Conclusions:** The present study showed the long-term outcomes of IT and IA phase of HBeAg-positive patients including those in the GZ. In the re-defined phases, there was only one case of HCC development in IT-GZ group. The IA-GZ group had slightly higher HCC development than the IA group.

Abstract Submission No. 101652
Genomic landscape of non-Hodgkin lymphoma patients with current or past hepatitis B virus infections
Moon Haeng Hur1, Jeayeon Park1, Youngsu Park1, Yunnic Ko1, Hyunjae Shin1, Yun Bin Lee1, Eun Ju Cho1, Jeong-Hoon Lee1, Yoon Jun Kim1, Jung-Hwan Yoon1, Su Jong Yu1

1Seoul National University College of Medicine Seoul South Korea

Background: As hepatitis B virus (HBV) infection is a risk factor for non-Hodgkin lymphoma (NHL), we aimed to assess the effect of current or past HBV infections on the development of NHL.

Methods: Patients who were diagnosed with NHL and underwent targeted next-generation sequencing (NGS) for NHL tissue at Seoul National University Hospital between 2019 and 2022 were consecutively enrolled. Targeted NGS was performed for 166 NHL-related genes to detect single nucleotide variant (SNV). Current and past HBV infections were defined by a positive HBV surface antigen (HBsAg) and a positive HBV core antibody (HBcAb) with a negative HBsAg, respectively. The incidence of SNV was compared among three groups.

Results: A total of 252 patients were included for analysis. The incidence of MYD88 (control vs. current HBV infection vs. past HBV infection: 14.0% vs. 34.8% vs. 30.0%; P=0.005), PIM1 (16.3% vs. 34.8% vs. 29.0%; P=0.03), and MHC (3.1% vs. 8.7% vs. 12.0%; P=0.03) gene mutation was significantly higher in the current or past HBV infection group compared to the control group. On the other hand, the current HBV infection group showed significantly higher incidence of ATM (4.7% vs. 13.0% vs. 0%; P=0.004), BCL10 (3.9% vs. 17.4% vs. 6.0%; P=0.046), and BIRC3 (0.8% vs. 13.0% vs. 0%; P=0.003) gene mutation than the other two groups.

Conclusion: Although current or past HBV infections share some of the gene mutations associated with the development of NHL, current HBV infection exhibited other distinct gene mutations.

Impact of antiviral therapy on HCV-infected patients with unresectable hepatocellular carcinoma
Shao Wu Lee1,2,3, Teng Yu Lee1,2, Sheng Shun Yang1,2,5, Yi Hsiang Huang1,5

1Division of Gastroenterology and Hepatology, Taichung Veterans General Hospital Taichung Taiwan, 2School of Medicine, Chung Shan Medical University Taichung Taiwan, 3Department of Post-Graduate Medicine, Chung Hsing University, Taichung Taiwan, 4Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital Taipei Taiwan, 5School of Medicine, Yang Ming Chiao Tung University Taipei Taiwan

Background: Direct-acting antiviral agents (DAAs) are the recommended treatment for HCV infection, with a benefit in reducing incident hepatocellular carcinoma (HCC) and patients’ mortality. The aim of this study was to evaluate the affecting factors of survival outcomes in the patients with BCLC stage B/C HCC and HCV underwent DAA therapy.

Methods: Data for subjects with BCLC stage B/C HCC and HCV receiving DAA therapy at Taichung Veterans General Hospital and Taipei Veterans General Hospital from January 2017 to April 2022 was collected respectively.

Results: Among the 197 enrolled patients, the SVR rate was 93.9%. Logistic analysis found non-significant association between clinical variables and fail to achieve SVR. The clinical presentations of Child-Pugh B (P=0.001), viable (p=0.003) or progressive HCC (P=0.009) and non-SVR (p=0.001) had significant poor impacts to survival outcomes. The median OS of the patients with SVR and those with non-SVR to DAA therapy were 4.36 years and 1.71 years respectively. The stratified analysis showed that achieving SVR had a significantly impact to decrease risk of death in most patients, but not in the group of Child-Pugh B, ALBI grade 2/3, FIB4<3.25, BCLC stage C, progressive HCC and AFP>400.

Conclusion: The SVR rate of patients with BCLC stage B/C HCC receiving DAA therapy was high. Achieving SVR to DAA therapy was associated with better survival outcomes in these patients, but this benefit was lost in the subjects with severe cirrhosis stage or progressive HCC.
challenging. We report one case of failed treatment of DAAs containing NS5A inhibitors, who received SVR after 12 weeks of treatment with Sofosbuvir/Velpatasvir and ribavirin. Case, a male, 50 years old, chronic hepatitis C cirrhotic patient, genotype 3b, took oral Sofosbuvir 400 mg/d, daclatasvir 60 mg, and ribavirin 1000mg/time, once a day for 24 weeks. The patients personally cut down the ribavirin dose after a few days to 400mg. RNA viral load less than 15 IU/ml at 4, 12, and 24 weeks of treatment. However, after 12 weeks of treatment, the viral load had increased to 6,76 * 102 IU/ml. Two mutations of L31M and A30K were found. 4 months later, initiation of salvage therapy with Sofosbuvir/Velpatasvir 1 tablet/d + ribavirin 1000 mg/d for 24 weeks. SVR12 was obtained.

The patient was infected with HCV genotype 3, which is currently one of the most difficult genotypes to treat in the field of DAA therapy and was co-infected with cirrhosis and drug-resistant variants. The patient self-reduced the dose of ribavirin during the treatment period, but the dose was insufficient, which caused the relapse. This suggests that in the treatment of hepatitis C, the dose and duration of ribavirin may be closely related to relapse and that an adequate dose and duration of ribavirin are essential.

Abstract Submission No. 100175

P-1032

HCV Reinfection in High-Risk Patients Following DAA Therapy – Real-World Data from a Medical Center

Pei-yuan Su1, Ya-Huei Zeng1, Ching-Chun Lin1, Fang-Chi Yang1, Hsu-Heng Yen1

1Changhua Christian Hospital Changhua city Taiwan

Background: HCV reinfection in high-risk patient groups, such as people living with HIV (PLWH), individuals engaging in injection drug use (PWID), and those undergoing hemodialysis (HD), remains a significant concern even after achieving sustained virologic response (SVR). This study presents real-world data from a medical center regarding reinfection rates in these specific populations.

Methods: This retrospective study focused on three high-risk groups of HCV patients who achieved SVR12 after DAA therapy between January 2018 and June 2022. HCV RNA levels were rechecked at least once after SVR12, and reinfection was defined as the recurrence of detectable viremia post SVR12.

Results: A total of 140 HCV patients were recruited, including PLWH from sexual transmission (n=22), PLWH combined with PWID (n=51), PWID (n=36), and individuals undergoing HD (n=31). The number of patients experiencing reinfection was 3 in PLWH from sexual transmission, 6 in PLWH combined with PWID, 6 in PWID, and 0 in HD, respectively. The incidence of reinfection was 6.1 per 100 person-years of follow-up (PYFU), 5.3 per 100 PYFU, 6.7 per 100 PYFU, and 0 per 100 PYFU in each group. The median time to reinfection was shorter in PWID (1.79 years) and PLWH combined with PWID (2.55 years) compared to PLWH from sexual transmission (3.17 years).

Conclusions: The reinfection rate remains notably high in PLWH and PWID groups. Effective HIV prevention programs and syringe services programs are still crucial in addressing the needs of these high-risk populations.

Abstract Submission No. 100257

P-1033

Lysyl oxidase-like 2 as a predictor of hepatocellular carcinoma after HCV eradication.

Abstract Submission No. 100271

P-1034

The epidemiological and clinical characteristics of hepatitis C virus infection in Dongguan City

Lihua Zhang1

1The 9th hospital of Dongguang Dongguan China

Background: Aims to provide evidence for the subsequent regional hepatitis C elimination and appropriate treatment for those affected.

Methods: We conducted a retrospective analysis of 617 HCV RNA positive patients in Dongguan from October 2020 to December 2022. Demographics, genotype and transmission route of hepatitis C were investigated.

Results: Of the 617 HCV RNA-positive patients, 69.2% were males, with a median age of 46 years. The proportion of 33-59 years old is the highest, accounting for 80.4%. Genotype 1,3 and 6 are the common genotypes, accounting for 37.4%, 18% and 28.2% respectively. The proportion of patients infected by unknown route was the highest (38.1%), while the proportion of patients infected by intravenous drug addiction, blood transfusion, sexual transmission and other invasive operations were 27.4%, 23.8%, 2.4% and 13.3%, respectively. Genotype 3 and 6 were more common among patients infected through
intravenous drug use (34.9% and 43.8%). Genotype 1 was more common in patients infected by blood transfusion (66.4%), while genotype 1, 3 and 6 were more common in patients infected by sexual transmission (35.7%, 17.9% and 32.1%), and the genotype 1 and 6 were more common in patients infected by other invasive procedure (43.4%, 25.3%), and the difference among the groups was statistically significant (P < 0.05).

Conclusion: Hepatitis C antibody screening in residents aged 33-59 years can significantly improve the screening efficiency of HCV.

The proportion of HCV infection with unknown transmission route can significantly improve the screening efficiency of HCV.

Conclusion: Hepatitis C antibody screening in residents aged 33-59 years can significantly improve the screening efficiency of HCV.

Treatment cascade of hepatitis C virus infection in patients undergoing surgery

Jae Seung Lee¹, Hye Won Lee¹, Mi Na Kim¹, Beom Kyung Kim¹, Jun Yong Park¹, Do Young Kim¹, Sang Hoon Ahn¹, Seung Up Kim¹

¹Yonsei University College of Medicine Seoul South Korea

Background: A lack of awareness compromises appropriate consideration of hepatitis C virus (HCV) infection in patients undergoing surgery. We evaluated the status of HCV screening, confirmation, and treatment in patients undergoing surgery.

Method: Patients who underwent surgery in a tertiary academic center between 2019 and 2021 were eligible for this retrospective study. The testing and positivity rates for anti-HCV antibodies and HCV RNA were analyzed.

Results: Among 96,894 patients (40,121 males, 41.4%) who underwent surgery under general anaesthesia, 83,920 (86.6%) were tested for anti-HCV antibodies before surgery. Of these patients, 576 (0.7%) went surgery under general anaesthesia, 83,920 (86.6%) were tested for anti-HCV antibodies before surgery. Of these patients, 576 (0.7%) were positive for anti-HCV antibodies and had significantly higher rates of diabetes mellitus (32.6% vs. 18.5%), hypertension (50.5% vs. 28.6%), liver cirrhosis (13.2% vs. 1.7%), and unfavourable laboratory test results compared with those who were negative (all P < 0.05).

The HCV RNA status was assessed in 215 (37.3%) of the anti-HCV antibody-positive patients, and the rate of HCV RNA positivity was 20.5% (n = 44 of 215). Of these 44 patients, 42 (95.5%) were referred for treatment, and all 29 treatable patients were successfully treated with direct-acting antiviral therapy. The HCV RNA positivity rate was significantly higher in the hepatobiliary and transplant surgery department (76.6%) than in other surgical departments (25.0–34.6%).

Conclusion: A significant number of preoperative anti-HCV antibody-positive patients did not receive appropriate HCV management. An automated alert system may be required.

Abstract Submission No. 100362
P-1035

Elimination of HCV in women of childbearing age at hospital in southern China

Li Guo¹, Wenbin Wu¹, Cailian Cai², Bihua Gao³

¹Beihai City People's Hospital Beihai City China, ²Guangxi Medical University Nanning City China

Background: The disease burden of HCV infection in women of childbearing age is high in low- and middle-income countries. Data on HCV elimination in this population is lacking.

Methods: We initiated the “Program for the Elimination of Hepatitis C Virus in Women of Childbearing Age”. This program provided primary healthcare practitioners with education related to HCV disease and treatment and distributes corresponding promotional materials. Also, we cooperated with the IT department to build data collation platform for this program. Patients who are HCV-Ab (+) are called back by phone to complete the HCV RNA test. HCV RNA positive patients are reminded by phone to return to the hospital for antiviral treatment. Meanwhile, HCV RNA positive patients within the hospital are automatically referred to liver disease specialists, and subsequent treatment plans are developed for them.

Results: From January 2017 to January 2023, there are 458 women of childbearing age are enrolled in this project, 267 women with positive HCV antibodies, 191 women with HCV RNA positive. From February 2023 to August 2023, 152 of the 458 childbearing aged women were successfully contacted by phone, and 14.5%(22/152) patients were successfully call back to the hospital. Out of the 14.5%(22/152) HCV RNA positive patients, 5.3%(8/152) have initiated antiviral treatments, and a further 23.7%(36/152) patients have agreed to come to the hospital for antiviral treatments in the near future.

Conclusion: Many women of childbearing age with HCV infection have not received effective treatment. A clear callback plan can effectively clear Hepatitis C in this population.

Abstract Submission No. 100783
P-1037

Analysis of the overuse of DAA therapy among patients with HCV infection

Jae Seung Lee¹, Hye Won Lee¹, Mi Na Kim¹, Beom Kyung Kim¹, Jun Yong Park¹, Do Young Kim¹, Sang Hoon Ahn¹, Seung Up Kim¹

¹Yonsei University College of Medicine Seoul South Korea

Background: This study aims to assess the risk of HBV reactivation and disease progression during direct-acting antiviral (DAA) therapy.

Methods: A retrospective analysis was conducted on the patients treated with DAA at the Guizhou Public Health Treatment Center between January 2018 and December 2022. HCV RNA, liver function, HBV markers, and HBV DNA, were assessed before and after DAA therapy.

Results: 1652 HCV patients were enrolled, 5.08% (84/1652) were HBsAg positive, and 44.79% (740/1652) had HBV exposure (HBsAg-negative/HBcAb-positive, HBV DNA < 20 IU/ml). Compared to mono-infection, HBsAg positive patients had a higher proportion of males, liver cirrhosis and HCC, and lower platelet counts (χ²=15.482, 46.101, F=7.292, all P < 0.05). The incidence of HBV reactivation was 16.67% (9/54) among HBsAg-positive patients and 0.1% (1/740) among those with a history of HBV infection. Baseline HBsAg levels were higher in patients who experienced HBV reactivation than in those who did not (Z=-4.291, P < 0.05). Moreover, patients with baseline HBsAg levels < 185 IU/ml have an extremely low risk of HBV reactivation. After HBV reactivation, there were no differences in liver function, platelet counts, or other parameters compared to baseline (P > 0.05), and no cases of liver failure were identified.

Conclusion: The prevalence of HBsAg positivity among HCV-infected individuals in Guizhou is higher than in other regions of China. There is a substantial proportion of individuals with a history of HBV infection. HCV/HBV coinfected patients treated with DAA therapy may experience HBV reactivation, but the disease progression risk is relatively low.

Abstract Submission No. 100752
P-1036

HBV Reactivation Among Patients with HCV During Direct Acting Antiviral Therapy in Guizhou, China

Mei Wang¹, Hugang Xiong², Zhigang Yang³, Yi Wang⁴

¹Guiyang Public Health Clinical Center Guiyang City China, ²Guiyang Public Health Clinical Center Guiyang City China, ³Guiyang Public Health Clinical Center Guiyang City China, ⁴Guiyang Public Health Clinical Center Guiyang City China

Background: In the treatment of the population of high-risk of HCV population, the proportion of HCV infection with unknown transmission route can significantly improve the screening efficiency of HCV.

Conclusion: Hepatitis C antibody screening in residents aged 33-59 years can significantly improve the screening efficiency of HCV.
Analysis of Hepatitis C Virus Infection in Women of Childbearing Age in Jilin Province, China

Jiaying Hou1, Yukun Chen1, Yanhang Gao1, Yan Huang1, Lina Yu1, Xing Wu1, Yi Liu1

1The First Hospital of Jilin University Changchun China

Background: With the encouragement of China’s birth policy, the second-child birth rate has gradually increased in recent years, which means more older women may choose to give birth again. Focusing on the prevalence of hepatitis C virus (HCV) infection in women of childbearing age can help further reduce the progression of liver disease in women of childbearing age and reduce the rate of mother-to-child transmission of HCV.

Methods: In this study, women of childbearing age (defined as 20-49 years old) who underwent anti-HCV testing in our hospital from January to September 2023 were included. Patients with positive anti-HCV antibodies were tested for serum anti-HCV RNA using fluorescence quantitative PCR.

Results: A total of 14,729 women of childbearing age underwent anti-HCV testing, and 355 were positive for anti-HCV. Among them, 239 patients underwent further HCV RNA testing, and 70 cases were positive for HCV RNA, with a positive detection rate of 29.29%. In the 20-29 years old group, 30-39 years old group, and 40-49 years old group, the positive rates were 15.79%, 27.59%, and 32.33%, respectively.

Conclusion: With increasing age, the positive detection rate of HCV RNA in women of childbearing age significantly increased. Strengthening attention to the prevalence of hepatitis C in women of childbearing age can help further reduce the progression of liver disease in women of childbearing age and the mother-to-child transmission of HCV, which is of extremely important practical significance.

Abstract Submission No. 101431

P-1038

An Innovative Management Mode of Integrated Prevention and Treatment of HCV in Jilin Province

Jiaying Hou1, Guoyue Lv1, Yukun Chen1, Junqi Niu1, Yan Huang1, Xiao Liu1, Yuanqing Zhang1

1The First Hospital of Jilin University Changchun China

Background: To further strengthen the prevention and treatment of hepatitis C, reduce the prevalence of hepatitis C and the incidence of liver cancer, we developed a research system for an innovative management mode of integrated prevention, detection, and treatment for hepatitis C public health hazards in the First Hospital of Jilin University. The aim of this study is to verify the effectiveness of this system.

Methods: The hospital has implemented various methods for integrated management, including improving relevant work systems for hepatitis C prevention and treatment, carrying out health education on hepatitis C testing, including hepatitis C screening rates in clinical departments and hospital performance assessment, and publicizing the results throughout the hospital. The detection rate of HCV RNA in inpatients with (data from January to September 2023) or without the new management model (data from January to September 2021) were compared.

Results: From January to September 2023 and January to September 2021, hepatitis C antibody testing was carried out in 114926 and 98259 inpatients, respectively, with 1920 (1.67%) and 1875 (1.82%) positive cases. Among them, HCV RNA testing was carried out in 1048 (54.58%) and 867 (48.57%) patients (P < 0.05), with 332 (31.68%) and 226 (26.07%) positive cases, respectively (P < 0.05).

Conclusion: Through the hospital's innovative management mode of integrated prevention, detection, and treatment for hepatitis C public health hazards, it can effectively improve the detection rate of HCV RNA in anti-HCV positive inpatients.

Abstract Submission No. 101697

P-1040

The Significance of DAA Therapies in Patients with Chronic HCV Infection Complicated by HCC

Yoshihito UCHIDA1, Nobuaki NAKAYAMA1, Suguru MIZUNO1, Satoshi MOCHIDA1

1Department of Gastroenterology & Hepatology, Saitama Medical University Moroyama-cho, Iruma-gun, Saitama Japan

Aim: Patients with previous HCC due to HCV infection remain at a high risk of HCC recurrence even after achieving SVR. Furthermore, there are no clear guidelines regarding antiviral therapy in patients with unresectable HCC. We evaluated the significance of DAA therapies in such patients.

Methods: A total of 1,196 patients that underwent DAA therapy after September 2014, with a follow-up observation of at least one year after SVR, were subjected. The subsequent clinical course was retrospectively analyzed.

Results: The cumulative rates of HCC development after SVR (1-, 3-, 5-year) were higher in patients with previous HCC (n=82) at 24%, 60%, 73%, compared to those without HCC (n=1,114) at 1%, 4%, 7% (P<0.0001). Among patients with previous HCC, 56 patients experienced HCC recurrence over median interval of 33 months. Recurrence was associated with initial HCC treatment involving TACE (HR 3.93, P=0.0019) and RFA (HR 2.62, P=0.0141). At the time of HCC recurrence, the frequency of mALBI-2b or higher at HCC recurrence decreased from 52% at DAA therapy to 14% (P<0.0001). With BCLC C (HR 53.70, P<0.0001) and mALBI-2b or higher (HR 2.64, P=0.0401) were associated with outcome. Two patients with unresectable HCC and complications of esophageal varices and refractory ascites, making treatment impossible, later achieved SVR with SOF/VEL, and they became eligible for combination immunotherapy and radiation.

Conclusion: Achieving SVR improves liver function, enabling HCC treatment upon recurrence. Thus, in patients where the disease stabilizes after HCC treatment, prompt implementation of DAA therapy is advisable.

Abstract Submission No. 101415

P-1041

Non-Invasive Approaches to Liver Function Management Study

Munkh-uyanga Boldbaatar1, Tunshinzhul Battogtokh1, Delgertsog Gantumur1, Elbegzayaa Erdene-ochir2, Altantuya Idkhuu3, Tolson Batjargal2

1Department of Radiology, Rehamed Hospital Ulaanbaatar Mongolia, 2Department of Gastroenterology, Mongolia Japan Hospital, 3Marketing Administration, Ayaluun Pharm Ulaanbaatar Mongolia

Aim: To further strengthen the prevention and treatment of hepatitis C, reduce the prevalence of hepatitis C and the incidence of liver cancer, we developed a research system for an innovative management mode of integrated prevention, detection, and treatment for hepatitis C public health hazards in the First Hospital of Jilin University. The aim of this study is to verify the effectiveness of this system.

Methods: The hospital has implemented various methods for integrated management, including improving relevant work systems for hepatitis C prevention and treatment, carrying out health education on hepatitis C testing, including hepatitis C screening rates in clinical departments and hospital performance assessment, and publicizing the results throughout the hospital. The detection rate of HCV RNA in inpatients with (data from January to September 2023) or without the new management model (data from January to September 2021) were compared.

Results: From January to September 2023 and January to September 2021, hepatitis C antibody testing was carried out in 114926 and 98259 inpatients, respectively, with 1920 (1.67%) and 1875 (1.82%) positive cases. Among them, HCV RNA testing was carried out in 1048 (54.58%) and 867 (48.57%) patients (P < 0.05), with 332 (31.68%) and 226 (26.07%) positive cases, respectively (P < 0.05).

Conclusion: Through the hospital's innovative management mode of integrated prevention, detection, and treatment for hepatitis C public health hazards, it can effectively improve the detection rate of HCV RNA in anti-HCV positive inpatients.
Background: While effective strategies exist for managing hepatitis B and C viruses in our country, Delta hepatitis remains a severe and complex viral liver disease. Promisingly, non-invasive tests exhibit potential for early liver disease detection without requiring a biopsy. Currently, the only treatment for HDV is Peg-Interferon administered for 48-72 weeks, which has little therapeutic effect.

Material and method: This cross-sectional study involved 28 outpatients with liver fibrosis at the Mongolia-Japan Hospital of the Mongolian National University of Medical Sciences from July to August 2023. Serum levels of platelet count, prothrombin time, bilirubin, AST, ALT, albumin, and cholesterol were analyzed. Additionally, we calculated the AST-to-platelet ratio index (APRI) and FIB-4. Descriptive analysis characterized the data using SPSS version 19.0.

Result: Patients with viral hepatitis comprised 2.6% of the 1056 outpatients in our hospital. The majority of the patients (78.6%) had hepatitis B and Delta (HBV and HDV) coinfection, while patients with hepatitis B and hepatitis C accounted for 14.8% and 17.9%, respectively. The age range of the patients was 24 to 52 years, with no significant difference in sex distribution. The mean BMI was 25.5±1.14. In patients with liver fibrosis, the mean values were as follows: prothrombin time (14.7±31.4), albumin level (33.6±20.3), AST-to-platelet ratio index (APRI) (1.3±2.1), and FIB-4 (3.99±1.4).

Conclusion: The high prevalence of B and D virus dual infection, with significant changes in noninvasive tests compared to other groups, suggests the need to consider introducing antiviral medication into our daily practice based on this study’s findings.

Abstract Submission No. 101690
P-1042
Dysfunction of ATP7B splicing variant caused by enhanced interaction with COMMD1 in Wilson Disease
Donghu Zhou1, Huaduan Zi1, Xiaoxi Yang1, Xiaojin Li1, Yanneng Li1, Anjian Xu1, Bei Zhang1, Wei Zhang1, Xiaojuan Ou1, Jidong Jia1, Jian Huang1, Hong You1
1Kyung Hee University Hospital at Gangdong Seoul South Korea

The association between Wilson disease and various mutations is well-established; however, the exact pathogenic mechanism of these variants, particularly the molecular mechanism underlying the functional consequence of the splicing mutations, remains unclear. This study focused on the ATP7B c.1543+1G>C variant, which caused aberrations in the splicing of exon 3. Two potential regulators, hnRNP C and SF3B1, were identified to be responsible for the abnormal splicing, resulting in the skipping of ATP7B exon 3 and the formation of a mutant ATP7B isoform with altered secondary and tertiary structure. The mutant ATP7B showed a loss of membrane localization and was degraded via the ubiquitin-proteasome pathway, facilitated by enhanced interactions with COMMD1. Protein docking analysis further indicated a universal regulatory effect of COMMD1. Consequently, an elevated intercellular copper concentration and reduced survival rate was observed in HuH-7 cells expressing mutant ATP7B. Genetically engineered Atpb7b−/− mice were created and fed with a copper-containing diet, and purified adenoviruses carrying both wild-type and mutant ATP7B cDNAs were administered through tail vein injection. The wild-type ATP7B led to a noticeable improvement in the clinical phenotype, whereas no such improvement was observed in mice treated with the mutant ATP7B. Our research investigated the pathogenicity and mechanism of the ATP7B c.1543+1G>C variant, with a particular focus on its enhanced interaction with COMMD1 as a potential universal mechanism contributing to the dysfunction of various ATP7B variants. These findings provide a foundation for the development of innovative therapeutic strategies that target abnormal splicing events in hereditary diseases, including Wilson disease.

Abstract Submission No. 100127
P-1043
IL-19 contributes to the development of nonalcoholic steatohepatitis by altering lipid metabolism
Yasu-Taka Azuma1
1Laboratory of Prophylactic Pharmacology, Osaka Metropolitan University Graduate School of Veterinary Science Izumisano Japan

Interleukin (IL)-19, a member of the IL-10 family, is an anti-inflammatory cytokine produced primarily by macrophages. Nonalcoholic steatohepatitis (NASH) is a disease that has progressed from nonalcoholic fatty liver disease (NAFLD) and is characterized by inflammation and fibrosis. We evaluated the functions of IL-19 in a NAFLD/NASH mouse model using a 60% high-fat diet with 0.1% methionine without choline with 2% cholesterol (CDAHFD). Wild-type (WT) and IL-19 gene-deficient (KO) mice were fed a CDAHFD or standard diet for 9 weeks. Liver injury, inflammation, and fibrosis induced by CDAHFD were significantly worse in IL-19 KO mice than in WT mice. IL-6, TNF-alpha, and TGF-beta were significantly higher in IL-19 KO mice than in WT mice. As a mechanism using an in vitro experiment, palmitate-induced triglyceride and cholesterol contents were decreased by the addition of IL-19 in HepG2 cells. Furthermore, addition of IL-19 decreased the expression of fatty acid synthesis-related enzymes and increased ATP content in HepG2 cells. The action of IL-19 in vitro suppressed lipid metabolism. In conclusion, IL-19 may play an important role in the development of steatosis and fibrosis by directly regulating liver metabolism and may be a potential target for the treatment of liver diseases.

Abstract Submission No. 100427
P-1044
Differential effects of PPARγ activation on TFEB and autophagy in hepatocytes and stellate cells
You-Cheol Hwang1
1Kyung Hee University Hospital at Gangdong Seoul South Korea

Background: Peroxisome proliferator-activated receptor γ (PPARγ) activation suppresses HSC activation and liver fibrosis. Moreover, autophagy is implicated in hepatic lipid metabolism. Here, we determined whether PPARγ activation ameliorates HSC activation by downregulating transcription factor EB (TFEB)-mediated autophagy.

Methods and results: Atg7 or Tfeb knockdown in human HSC line LX-2 cells downregulated the expression of fibrogenic markers including α smooth muscle actin, glial fibrillary acidic protein, and collagen type 1. Conversely, Atg7 or Tfeb overexpression upregulated fibrogenic marker expression. Rosiglitazone (RGlZ)-mediated PPARγ activation and/or overexpression in LX-2 cells and primary HSCs decreased autophagy, as indicated by LC3B conversion, total and nuclear-TFEB contents, mRFP-LC3 and BODIPY 493/503 colocalization, and GFP-LC3 and LysoTracker colocalization. RGlZ treatment decreased liver fat content, liver enzyme levels, and fibrogenic marker expression in high-fat high-cholesterol diet-fed mice. Electron microscopy showed that RGlZ treatment restored the high-fat high-cholesterol diet-mediated lipid droplet decrease and autophagic vesicle induction in primary HSCs and liver tissues. However, TFEB overexpression in LX-2 cells offset the aforementioned effects of RGlZ on autophagic flux, lipid droplets, and fibrogenic marker expression.
Conclusions: Activation of PPARγ with RGZ ameliorated liver fibrosis and downregulation of TFEB and autophagy in HSCs may be important for the antifibrotic effects of PPARγ activation.

Abstract Submission No. 101202  
P-1045

The Chinese herbal TGXZ alleviates the progression of MAFLD by regulating the gut microbiota

Wenying Qi1, Xu Cao1, Yue Chen1, Hening Chen1, Ningyi Zhang1, Ruijia Liu1, Wei Wang1, Xiaobin Zao1,2, Yong’an Ye6

1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 2Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 3Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing China

Ethnopharmacological relevance: As a traditional Chinese medicine, the TiaoGanXiaoZhi formula (TGXZ) has previously been found to delay the progression of metabolic-associated fatty liver disease (MAFLD) in the clinic. However, its mechanism requires further clarification.

Aim of the study: This study aimed to explore the effect and mechanism of TGXZ in treating MAFLD in mice models.

Methods: The mice MAFLD model was induced with a high-fat diet feedstuffs and 5% fructose water, and further treated with TGXZ. After treatment, the mice’s serum, liver tissues, and fecal were used to detect biochemical indices, perform pathological examinations, and perform microbiota sequencing and lipidomics analysis.

Results: Compared to the MAFLD mice, TGXZ treatment significantly downregulated the levels of ALT, AST, TBA, CHE, CHO, TG, HDL-C, LDL-C, IL-6, IL-1β, and TNF-α in serum and liver tissues, decreased the body weight growth rate, decreased the accumulation of abdominal fat, and improve the liver steatohepatitis pathology. Through the microbiota sequencing and lipidomics analysis of mice fecal, we further constructed the interaction network between gut microbiota and lipid metabolism that was regulated by TGXZ.

Discussion: Our study showed that TGXZ treatment could effectively inhibit the progression of MAFLD by regulating gut microbiota and lipid metabolism. And Coliesterbacter, Tuzzereilla, Rikenella, and norank_o_Clostridia_UCG-014 regulated by TGXZ might be the targets for the treatment of MAFLD.

Abstract Submission No. 101256  
P-1046

DDC promotes the formation of peridroplet mitochondria in the liver tissue of CDAAD diet-induced NASH

Tianhui Liu1, Xiangyun Sun1, Qinghong Yu1, Yifei Qi1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: Lipid droplets (LDs) can contact mitochondria to form peridroplet mitochondria (PDM), and PDM could support LD expansion by providing ATP for triglyceride synthesis and prevent cell injury from lipotoxicity. In this study, we investigated whether PDM could be regulated in vivo by diethyldithiocarbamate (DDC), which we previously demonstrated its protective effect on non-alcoholic steatohepatitis (NASH) in mice.

Methods: Male C57BL/6 mice received choline-deficient, L-amino acid-deficient (CDAAD) diet for 9 weeks to establish the model of NASH. The CDAAD group were treated with or without 4 mg/ml DDC via daily drinking water. The contact between LDs and mitochondria was observed by electron microscope and co-staining with LD and mitochondria. PDM were isolated from the liver tissue and was quantified.

Results: Electron microscopic images of liver tissue showed that lots of mitochondria were recruited to the surface of LDs (PDM) after DDC treatment when compared with the CDAAD diet-induced NASH group. The liver tissues were harvested and homogenized. After low-speed centrifugation, PDM in the upper fat layer were co-stained for mitochondria and LDs. Confocal microscopy revealed more large LDs and PDM in DDC-treated group. Accordingly, fluorescent staining show that the purified PDM extracted from fat layer were increased by DDC treatment. In addition, the content of PDM protein obtained from the same amount of liver tissue was significantly higher in DDC-treated mice.

Conclusions: DDC promotes the formation of PDM in the steatotic liver of NASH mice, which may be one of the reasons for its treatment of NASH.

Abstract Submission No. 101261  
P-1047

Gremlin1 regulates the expression of Tcfl12 in adipose tissue

Qinghong Yu1, Yifei Qi1, Tianhui Liu1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: Gremlin1 is a novel adipokine that has an effect on insulin sensitivity and might be a novel therapeutic target for non-alcoholic fatty liver disease (NAFLD). However, the mechanisms underlying the role of Gremlin1 in NAFLD remain unclear. In this study, we investigated the possible regulatory mechanism of Gremlin1 in adipose tissue.

Methods: A novel rAAV vector (AAV-Rec) with highly efficient and specific transduction of adipose tissue was used to achieve the knockdown of Gremlin1. AAV-Rec-GFAP-Sh-Gremlin1 was administrated to C57BL/6 mice by intraperitoneal injection. Different organs were harvested to evaluated the targeting effect of AAV-Rec-Sh-Gremlin1 on adipose tissue. PCR Array was used to detect the changes of adipogenesis related genes after Gremlin1 knockdown in adipose tissue. The differential genes identified were then investigated in 3T3-L1 cells in vitro.

Results: Frozen sections of tissues were observed under fluorescence microscope. Distinct green fluorescence can be observed in both white and brown adipose tissues, but rare in other tissues including brain, heart, liver, spleen, lung, kidney and Skeletal muscle. RT-PCR results showed that Gremlin1 was knockdown in both white and brown adipose tissues, indicating that AAV-Rec-GFAP-Sh-Gremlin1 specifically target on adipose tissue and knockdown Gremlin1 successfully. PCR array showed that Gremlin1 knockdown upregulates Tcf7l2, which is the key transcription factor of Wnt and closely associated with insulin resistance. In addition, the in vitro experiments in 3T3-L1 cells confirmed the regulation of Gremlin1 on Tcf7l2.

Conclusions: Gremlin1 regulates Tcf7l2 in adipose tissue, which might be one of the mechanisms of its role in NAFLD.

Abstract Submission No. 101262  
P-1048

DDC improves CDAAD diet-induced non-alcoholic steatohepatitis through INSR/Akt

Abstract Submission No. 101260  
P-1049

Abstract Submission No. 101261  
P-1047

Gremlin1 regulates the expression of Tcf7l2 in adipose tissue

Qinghong Yu1, Yifei Qi1, Tianhui Liu1

1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: Gremlin1 is a novel adipokine that has an effect on insulin sensitivity and might be a novel therapeutic target for non-alcoholic fatty liver disease (NAFLD). However, the mechanisms underlying the role of Gremlin1 in NAFLD remain unclear. In this study, we investigated the possible regulatory mechanism of Gremlin1 in adipose tissue.

Methods: A novel rAAV vector (AAV-Rec) with highly efficient and specific transduction of adipose tissue was used to achieve the knockdown of Gremlin1. AAV-Rec-GFAP-Sh-Gremlin1 was administrated to C57BL/6 mice by intraperitoneal injection. Different organs were harvested to evaluated the targeting effect of AAV-Rec-Sh-Gremlin1 on adipose tissue. PCR Array was used to detect the changes of adipogenesis related genes after Gremlin1 knockdown in adipose tissue. The differential genes identified were then investigated in 3T3-L1 cells in vitro.

Results: Frozen sections of tissues were observed under fluorescence microscope. Distinct green fluorescence can be observed in both white and brown adipose tissues, but rare in other tissues including brain, heart, liver, spleen, lung, kidney and Skeletal muscle. RT-PCR results showed that Gremlin1 was knockdown in both white and brown adipose tissues, indicating that AAV-Rec-GFAP-Sh-Gremlin1 specifically target on adipose tissue and knockdown Gremlin1 successfully. PCR array showed that Gremlin1 knockdown upregulates Tcf7l2, which is the key transcription factor of Wnt and closely associated with insulin resistance. In addition, the in vitro experiments in 3T3-L1 cells confirmed the regulation of Gremlin1 on Tcf7l2.

Conclusions: Gremlin1 regulates Tcf7l2 in adipose tissue, which might be one of the mechanisms of its role in NAFLD.

Abstract Submission No. 101262  
P-1048

DDC improves CDAAD diet-induced non-alcoholic steatohepatitis through INSR/Akt
Yifei Qi1, Qinghong Yu1, Tianhui Liu1
1Liver Research Center, Beijing Friendship Hospital, Capital Medical University Beijing China

Background: Impaired insulin receptor (INSR) activities lead to insulin resistance, the key factor in the pathology of metabolic disorders including non-alcoholic fatty liver disease (NAFLD). Diethylthiocarbamate (DDC) attenuates non-alcoholic steatohepatitis (NASH) in mice, but its underlying mechanisms remains unclear. In this study, we investigated whether INSR/Akt could be regulated by DDC.

Methods: Male C57BL/6 mice received choline-deficient, L-amino acid-defined (CDAA) diet for 12 weeks to establish the model of NASH. The CDAA group were administered with or without 600 mg/kg/day DDC via daily gavage. INSR expression and its downstream Akt signaling pathway were detected by Western Blotting and Real-time PCR.

Results: Compared with the control group, INSR mRNA in the liver tissue of CDAA group was significantly decreased. Compared with CDAA group, INSR mRNA was not changed in DDC treated group. In contrast, INSR protein in the liver tissue of CDAA group was significantly increased compared with the control group, while was significantly increased in the DDC treated group compared with CDAA group. These data indicate that DDC regulates the expression of INSR at the post-transcriptional level. Compared with the control group, the phosphorylation of Akt was inhibited in liver tissues of CDAA group. Compared with CDAA group, the phosphorylation of Akt was increased in DDC treated group. These data suggest that DDC upregulates INSR and then activates its downstream Akt.

Conclusions: DDC activates INSR/Akt pathway, which may contribute to its treatment of NASH.

Abstract Submission No. 101386
P-1049

Polyene phosphatidylcholine alleviates MAFLD by regulating intestinal flora and lipid metabolism

Wenying Qi1, Xu Cao1, Yue Chen1, Hening Chen1, Ningsi Zhang1, Ruijia Liu1, Wei Wang1, Yongan Ye1,2, Xiaobin Zao0
1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 2Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing China, 3Liver Diseases Academy of Traditional Chinese Medicine, Beijing University of Chinese Medicine Beijing China

Background: The global prevalence of metabolic-associated fatty liver disease (MAFLD) is as high as 25%~30%. Polyene Phosphatidylcholine Capsules (PCC) has a certain curative effect on MAFLD, but its mechanism is not clear. This study aimed to explore the effect and mechanism of PCC in treating MAFLD.

Methods: A mouse model of metabolic-related fatty liver disease was established, and the therapeutic effect was evaluated after treatment with Jigucao capsule aqueous solution, and the results of liver transcriptome were analyzed. Screening effective chemical components and target genes of Jigucao capsules by mass spectrometry. Search DisGeNET database and GeneCards database to obtain target genes related to metabolic steatohepatitis. Cytoscape3.7.2 was used to construct the network of Jigucao Capsule in the treatment of metabolic steatohepatitis, and the topological structure was analyzed. Protein interaction analysis was carried out on STRING platform, PPI network was constructed, and GO and KEGG enrichment analysis were carried out.

Results: Network pharmacology predicted 139 potential targets of JGC Capsule, and liver transcriptome analysis showed 97 differential genes in three groups of mice. Transcriptome analysis and PCR verification of mouse liver showed that the mechanism of JGC capsule in treating metabolic-related steatohepatitis is related to the down-regulation of PPARG gene.

Conclusions: JGC capsule can delay the progress of metabolism-related steatohepatitis, and its mechanism may be related to regulating the lipid metabolism pathway of liver.

Abstract Submission No. 101587
P-1051

Clinical implication of MAFLD and reflux esophagitis in primary care institution

Min Seong Kim1
1Millenium Seoul IM Clinic Incheon South Korea

Background: Nonalcoholic Fatty Liver Disease (NAFLD) has emerged as a significant health concern, paralleling the rise of metabolic syndrome in contemporary society. Recent studies suggest that NAFLD may exert adverse effects not only on the liver but also on...
other segments of the gastrointestinal tract. In this context, our study aimed to explore the association between NAFLD and Reflux Esophagitis (RE).

**Method:** We conducted a case-control study involving 50 individuals with NAFLD and 50 control subjects. Participants underwent expert evaluation and endoscopy to determine the presence of RE. Logistic regression analysis was employed to assess the independent association between NAFLD and RE, adjusting for various potential confounding factors. Additionally, clinical assessments and endoscopic findings were scrutinized to obtain a comprehensive understanding of the gastrointestinal status.

**Result:** The occurrence of RE was statistically significantly higher in the NAFLD group. Logistic regression analysis revealed NAFLD to be an independent predictor for the development of RE, even after accounting for diverse potential confounders. Endoscopic findings indicated that individuals with NAFLD and RE exhibited a more pronounced degree of esophageal mucosal damage.

**Conclusion:** Our study demonstrates a significant association between NAFLD and an increased risk of RE, providing novel insights into the interplay between these two conditions. These findings underscore the need for additional monitoring and preventive strategies for gastrointestinal health in individuals with NAFLD.

---

**Abstract Submission No. 101700**

**P-1052**

**Current status of metabolic dysfunction associated steatohepatitis (MASH) at our hospital**

Tsutomu Tamai¹, Seichi Mawatari², Masafumi Hashiguchi³, Sho Ijuin¹, Kaori Muromachi¹, Takeshi Hori¹, Hirohito Tsubouchi¹, Akio Ido²

¹Department of Gastroenterology, Kagoshima City Hospital
Kagoshima City Japan, ²Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences
Kagoshima City Japan, ³Department of Internal medicine, Machara General Medical Hospital Hioki City Japan

**Aim:** The purpose of this study was to confirm the current status of MASH patients visiting our hospital.

**Methods:** We retrospectively evaluated ninety-one MASH patients who consulted our department from April to September 2022. We assessed factors associated with the achievement ratio of weight loss. And we evaluated the rate of weight loss achievement and ALT improvement by generation. In addition, we were divided into two groups with a weight loss rate of >2% in Propensity Score Matching and evaluated for changes in BMI, ALT, γ-GTP, FIB-4 index, VCTE, and CAP.

**Results:** The median age was 59 years (range: 15-84), 44 patients were male. The achievement ratio of weight loss were -7%: -5%: -2% = 15.1%: -23%; 48.1%. Age and weight loss rates were not correlated. ALT and BMI loss rates were correlated. BMI decrease rates were poor among the middle-aged generation. ALT reduction rates were mild in the middle-aged generation and poor in the elderly. In BW-2% group, BMI, ALT, and γ-GTP were significantly improved. In not BW-2% group, FIB-4 index was improved, but VCTE and CAP were not.

**Conclusion:** Weight loss contributes to improved laboratory data, but does not improve liver fibrosis in the short term. Further investigation of factors that contribute to improve liver fibrosis is necessary in the future.

---

**Abstract Submission No. 101707**

**P-1053**

**The Effect of Pemafibrate on Non-Alcoholic Fatty Liver Disease Complicated with Hypertriglyceridemia**

Hidenao Noritake¹, Takeshi Chida¹, Kazuhito Kawata¹

¹Hamamatsu University School of Medicine Hamamatsu Japan

**Background:** To date, there is no approved treatment for non-alcoholic fatty liver disease (NAFLD). The practical guidelines recommend only lifestyle interventions for NAFLD, such as diet and exercise. However, some medications used for comorbid conditions with NAFLD have the potential to improve NAFLD as well as the associated diseases and NAFLD.

**Methods:** Patients with hypertriglyceridemia and NAFLD, who received pemafibrate for 30 days or more from June 2018 to September 2023, were included. In some cases, magnetic resonance imaging (MRI) scans were conducted before and after treatment to measure liver elasticity and proton density fat fraction (PDFF). Wilcoxon signed-rank tests with paired samples were used for the comparison of pre- and post-treatment values, with a significance level set at p = 0.05.

**Results:** The median age was 62, with 58% males and a median BMI of 26.8 kg/m². Median pre-treatment clinical test values were as follows; total bilirubin 0.80 mg/dL, AST 42 U/L, ALT 66 U/L, ALB 4.5 g/dL, platelet count 23.7 x 10⁴/μL, LDL cholesterol 142 mg/dL, Crl 0.78 mg/dL, triglyceride 229 mg/dL, HDL cholesterol 46 mg/dL, HbA1c 6.4%, type 4 collagen 7S 5.5 ng/mL, liver elasticity 3.0 kPa, PDFF 12.0%. After pemafibrate administration, significant reductions were observed in triglyceride, AST, ALT, GGT, and type 4 collagen 7S, while the platelet count increased significantly. There was also a trend toward improved liver elasticity. No significant changes were observed in PDFF, BMI, or HbA1c.

**Conclusion:** Pemafibrate shows potential for improving NAFLD.

---

**Abstract Submission No. 101844**

**P-1054**

**APRI/FIB-4/NFS in predicting liver fibrosis in MAFLD patients with/without viral hepatitis**

Chung-Feng Huang¹

¹Kaohsiung Medical University Hospital Kaohsiung Taiwan

**Background/Aims:** The accuracy of noninvasive seromarkers in predicting liver fibrosis in MAFLD patients with or without viral hepatitis is elusive.

**Methods:** The AST to platelet ratio index (APRI), fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) were assessed in 871 MAFLD patients who received elastography in a hepatitis B virus (HBV) and hepatitis C virus (HCV) endemic area.

**Results:** The area under the receiver operating characteristic (AUROC) curve increased substantially with increasing fibrotic stage across the 3 biomarkers. APRI (AUROC range 0.73-0.80) and FIB-4 (AUROC range 0.66-0.82) performed better than NFS (AUROC range 0.63-0.75). When patients were divided into viral and non-viral MAFLD groups, a better AUROC of APRI (range 0.76-0.80) and FIB-4 (range 0.68-0.78) than NFS (range 0.62-0.70) existed only in viral MAFLD but not in non-viral MAFLD. Regarding the NFS, the AUROC was higher in non-viral MAFLD (range 0.69-0.86) and outperformed viral MAFLD at all fibrotic stages. Overall, the AUROC was lowest using NFS (0.63-0.95% confidence intervals [CI]: 0.59-0.67) for predicting viral MAFLD patients with liver fibrosis (>7 kPa), whereas the AUROC was highest (0.92/CI: 0.84-0.99) using FIB-4 for predicting non-viral MAFLD patients with liver cirrhosis (>12 kPa). The accuracy of APRI and FIB-4 was similar between viral and non-viral
MALFD. Nevertheless, NFS exerted better accuracy in non-viral MAFLD patients than in viral MAFLD patients.

Conclusions: The APRI and FIB-4 performed better than the NFS in predicting liver fibrosis in MAFLD as a whole. The suboptimal performance and accuracy of the NFS existed only in viral MAFLD patients.

Abstract Submission No. 200075  
**P-1055**

Frequency and Clinical Characteristics of Dual-Etiology Fatty liver Diseases in Korean Patients

Kyoung-Jin Park1, Jong-Ho Park2, Young-Jae Kim3

1Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon South Korea, 2Samsung Medical Center Seoul South Korea, 3Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon South Korea

**Background:** A nomenclature of metabolic-associated fatty liver disease (MAFLD) has been proposed to describe the fatty liver condition associated with metabolic dysfunction. Little is known about dual-etiologic fatty liver disease associated with both hepatitis C virus (HCV) infection and MAFLD in Korean patients. We aimed to investigate the frequency and clinical characteristics of the Korean patients with concomitant MAFLD with HCV infection.

**Methods:** This cross-sectional study consisted of 96,667 consecutive subjects visiting comprehensive health promotion center from 2019 to 2022. Anthropometric and biochemical parameters were measured. The MAFLD was diagnosed based on hepatic steatosis by abdominal ultrasonography and the presence of overweight/obesity, type 2 diabetes, or the evidence of metabolic dysregulation.

**Results:** The frequencies of MAFLD in general population and HCV-infected patients were 26% and 28%, respectively. Triglyceride, apolipoprotein B, HbA1c, insulin, and high-sensitivity C-reactive protein levels were significantly higher in patients with concomitant MAFLD and HCV infection compared to those with HCV infection only. However, there is no statistical significance of the levels of total cholesterol, low density lipoprotein–cholesterol, apolipoprotein A and lipoprotein(a) between the groups. Advanced fibrosis by fibrosis-4 index (FIB-4) and NAFLD fibrosis score (NFS) was significantly increased in patients with concomitant MAFLD with HCV infection ($P < 0.0001$).

**Conclusions:** Frequency of MAFLD in HCV-infected Korean patients was higher than that of MAFLD in the general population. This study demonstrated that patients with dual-etiologic fatty liver disease associated with concomitant MAFLD with HCV infection had more advanced fibrosis than those with HCV infection alone.

Abstract Submission No. 200196  
**P-1056**

Therapeutic Efficacy of Radiofrequency Ablation with D-sorbitol in Animal Livers.

Ryosuke Imado1, Asahiho Morishita1, Kei Takuma1, Mai Nakahara1, Kyoko Oura1, Tomoko Tadokoro1, Koji Fujita1, Joji Tani1, Tsutomu Masaki1

1Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University Takamatsu Japan

**Aim:** Radiofrequency ablation (RFA) is an effective, minimally invasive treatment for hepatocellular carcinoma. On the other hand, inadequate ablation may result in local recurrence. In fact, the size of coagulation necrosis is limited due to increased impedance by tissue fragments. D-sorbitol, which is a dielectric fluid, is a perfusate in transurethral resection of the prostate and used as lavage for removing tissue fragments. Therefore, the aim of this study is to investigate if the use of D-sorbitol in RFA can increase the coagulation range and provide a better therapeutic effect using animal liver.

**Methods:** Using a pig liver and a live dog liver, RFA with or without D-sorbitol were performed in five different liver sites. After RFA needle insertion, up to 20 ml of 3% D-sorbitol was slowly injected into the lesion from the same puncture site during RFA procedure. RFA was terminated when the impedance threshold was exceeded.

**Results:** The RFA group with D-sorbitol had significantly a larger volume of coagulated necrotic areas and a greater total energy content than that without D-sorbitol. No significant complications such as hemorrhage or injury were observed in the RFA group with D-sorbitol in the living dog liver. In addition, RFA has been performed without serious complications.

**Conclusion:** RFA with D-sorbitol might be a safe and effective therapeutic method for the treatment of early stage of hepatocellular carcinoma.

Abstract Submission No. 102062  
**P-1057**

Effectiveness of DLR for Liver Tumor Delineation in the Hepatobiliary phase of Gd-EOB-MRI

Yukihisa Takayama1, Keisuke Sto1, Shinji Tanaka1, Ryo Murayama1, Ryoataro Jingui2, Yoichiro Ikushima1, Atsushi Nozaki1, Kengo Yoshimitsu1

1Department of Radiology, Faculty of Medicine, Fukuoka University Fukuoka Japan, 2Radiology Center, Fukuoka University Hospital Fukuoka Japan, 3GE Healthcare Tokyo Japan

**Purpose:** To evaluate the efficacy of deep Learning-based Reconstruction (DLR) for the improvement of image-quality and tumor detectability of the iso-voxel high-resolution breath-hold fat-suppressed T1-weighted imaging (HR-BH-T1WI) in hepatobiliary phase (HBP) of Gd-EOB-MRI

**Materials and Methods:** This was a retrospective study of a single institute. We evaluated 42 patients with 98 liver tumors, including hepatocellular carcinomas, hypovascular nodules, hemangiomas and metastatic tumors, who underwent Gd-EOB-MRI between March 2023 and May 2023. We evaluated three imaging techniques of HBP images: (1) iso-voxel HR-BH-T1WI that was reconstructed with DLR (BH-DLR+); and (2) that without DLR (BH-DLR−); and (3) HR-FS-T1WI was scanned with free-breathing technique using a navigator-echo-triggered technique and DLR (Navi-DLR+). Three imaging techniques were qualitatively and quantitatively compared. Tumor detectability was also compared among the three imaging techniques.

**Results:** BH-DLR+ (3.84, average score of two radiologists) showed significantly better qualitative scores for image noise than BH-DLR− (2.84) and Navi-DLR+ (3.37) ($P<0.05$), and Navi-DLR+ showed significantly better scores than BH-DLR− ($P<0.0167$). BH-DLR+ (3.77) and BH-DLR− (3.77) showed significantly better qualitative scores for respiratory motion artifact than Navi-DLR+ (2.75) ($P<0.05$), but there was no significant difference in scores between BH-DLR+ and BH-DLR− ($P=0.0167$). BH-DLR+ (0.32) and Navi-DLR+ (0.33) showed significantly higher lesion-to-nonlesion CR than BH-DLR− (0.29) ($P=0.0167$), but there was no significant difference in lesion-to-nonlesion CR between BH-DLR+ and Navi-DLR+ ($P=0.0167$). BH-DLR+ (89.8%) showed significantly better tumor detectability than BH-DLR− (76.0%) and Navi-DLR+ (77.6%) ($P<0.05$).
Conclusion: The use of DLR for the iso-voxel HR-BH-FS-T1WI was effective to improve image quality and tumor detectability in HBP of G-EOB-MRI.

Abstract Submission No. 102093
P-1058
Prevalence of arterial hypertension in liver cirrhosis and correlation with the severity

Nabila ElGazzar1, Lobna AbuAli1, Mohamed Rabea1, Asem Elfert1
1Faculty of medicine Tanta University Tanta Egypt

Background and aim: Metabolic diseases and hypertension have increased dramatically in recent years, so the prevalence of hypertension in patients with cirrhosis is expected to increase.

The aim of the study was to estimate the prevalence of hypertension in patients with liver cirrhosis and to determine its association with the severity of the liver disease.

Patients and methods: This was a descriptive, cross-sectional, analytical study conducted at the Tropical Medicine and Infectious Diseases Department, Tanta University Hospital, Egypt. A total of 2051 patients with liver cirrhosis of various etiology were screened for participation in this study. 2014 patients were enrolled. They underwent blood pressure evaluation, blood tests and abdominal ultrasonography. Patients were classified into hypertensive and non-hypertensive groups.

Results: The prevalence of arterial hypertension in patients with liver cirrhosis was 30.8%. As regards Child-Pugh class, hypertensive patients in class A were significantly increased (72.9 versus 48.7% respectively) while patients in class B and C were significantly decreased when compared with non-hypertensive patients (25.5,1.6 versus 33.29,17.93% respectively) (P <0.001).

Conclusions: The prevalence of arterial hypertension in Egyptian cirrhotic patients is 30.7%, lower than that of the general population. Arterial hypertension in patients with liver cirrhosis is expected to increase.

Abstract Submission No. 100527
P-1060
Chinese Medicine Modulates Gut Microbial and Lipid Metabolism to Suppress Hepatocellular Carcinoma

xiaobin li¹, Yu Ran², shiping Hu³
1Beijing university of Chinese medicine beijing China, 2Beijing university of Chinese medicine beijing China, 3Beijing university of Chinese medicine beijing China

Aim: To investigate the effects of Chai Qi Yi Gan Ke Li (CQYGKL) in the treatment of hepatocellular carcinoma (HCC) and the underlying mechanisms of systemic regulation of gut microbiota and metabolite profiles.

Methods: The inhibitory effects of CQYGKL on HCC were assessed using tumor weight measurements, HE staining, and TUNEL assays in HCC mice. 16S rRNA sequencing and metabolomics were performed to identify the mechanism of sorafenib combined with WAY-262611 in vitro and in vivo.

Results: Sorafenib combined with WAY-262611 decreased the expression levels of p110α, phospho-Akt (all P<0.05), active β-catenin (all P<0.05), and phospho-GSK3β (Ser9), whereas combined treatment increased the expression levels of phospho-GSK3β (Tyr216) compared to sorafenib alone in vitro and in vivo. Sorafenib combined with WAY-262611 significantly increased the expression levels of PI3K/Akt pathway inhibitory genes, whereas combined treatment significantly decreased the expression levels of Wnt/β-catenin pathway target genes (all P<0.05). In addition, simultaneous expression of HrasG12V, mirR53, and PI3Kαβγ significantly increased the expression levels of p110α (P<0.01), p-Akt, active β-catenin, cyclin D1 (P<0.01), and DKK1 (P<0.05) compared to simultaneous expression of HrasG12V and mirR53.

Conclusions: Sorafenib combined with DKK1 inhibitor significantly inhibited the PI3K/Akt and Wnt/β-catenin pathways and these pathways were regulated through GSK3β in HCC. Therefore, DKK1 inhibitor may be a promising therapeutic strategy in HCC.

Abstract Submission No. 100588
P-1059
Sorafenib combined with WAY-262611 inhibited Wnt/PI3K/Akt pathway in hepatocellular carcinoma

SeungUp Kim¹ ² ³, SangHyun Seo², KyungJoo Cho², HyeJung Park², HyeWon Lee², BoomKyung Kim¹ ² ³, JunYong Park², DoYoung Kim¹ ² ³, SangHoon Ahn⁴
1Yonsei University College of Medicine Seoul South Korea, 2Yonsei Liver Center, Severance Hospital Seoul South Korea, 3Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine Seoul South Korea

Background: Sorafenib extended overall survival in advanced hepatocellular carcinoma (HCC) patients. Elevated expression levels of Dickkopf-1 (DKK1) were found in HCC. In this study, we investigated synergistic effects and mechanism of sorafenib combined with DKK1 inhibitor on HCC in vitro and in vivo.

Methods: Huh7 and Hep3B cells were treated with IC₅₀ values of sorafenib and WAY-262611, which is a DKK1 inhibitor. Xenograft mouse was generated using Hep3B cells and transgenic mouse was developed using hydrodynamic tail vein injection. Mice were orally administered sorafenib (32 mg/kg) and WAY-262611 (16 mg/kg) for 10 days. Western blotting, immunostaining, and qRT-PCR were used to identify the mechanism of sorafenib combined with WAY-262611 in vitro and in vivo.

Results: Sorafenib combined with WAY-262611 decreased the expression levels of p110α, phospho-Akt (all P<0.05), active β-catenin (all P<0.05), and phospho-GSK3β (Ser9), whereas combined treatment increased the expression levels of phospho-GSK3β (Tyr216) compared to sorafenib alone in vitro and in vivo. Sorafenib combined with WAY-262611 significantly increased the expression levels of PI3K/Akt pathway inhibitory genes, whereas combined treatment significantly decreased the expression levels of Wnt/β-catenin pathway target genes (all P<0.05). In addition, simultaneous expression of HrasG12V, mirR53, and PI3Kαβγ significantly increased the expression levels of p110α (P<0.01), p-Akt, active β-catenin, cyclin D1 (P<0.01), and DKK1 (P<0.05) compared to simultaneous expression of HrasG12V and mirR53.

Conclusions: Sorafenib combined with DKK1 inhibitor significantly inhibited the PI3K/Akt and Wnt/β-catenin pathways and these pathways were regulated through GSK3β in HCC. Therefore, DKK1 inhibitor may be a promising therapeutic strategy in HCC.
Liver cancer remains a primary worldwide health concern, necessitating the development of innovative and effective treatment options. In this study, we present a biocompatible iron-based metal-organic framework (Fe-MOF) consisting of iron ligands connected by terephthalate linkers loaded with Safranal, a natural molecule extracted from stigmas (also known as Saffron) of Crocus Sativus flower, a therapeutic intervention with dual efficiency. This compound not only meets the demand for improved liver cancer therapies but also exhibits antibacterial properties against Escherichia coli and Lactobacillus. The synthesis stage of the study focuses on preparing MIL-88B(Fe) and loading Safranal into/onto its structure. The material’s composition and purity are validated through various characterization techniques, including XRD, FTIR, TGA, and N2-adsorption. Furthermore, the morphology and uniformity are assessed using the SEM-EDX approach, while the successful loading of Safranal is confirmed through the NMR technique. The potential of MIL-88B(Fe) and loaded-MIL-88B(Fe) as promising anticancer/antibacterial agents is highlighted by their substantial inhibitory impact on the growth of HepG2 cells and the examined bacterial strains. The present findings pave the way for developing innovative multifunctional agents with potential applications in biotechnology.

**Abstract Submission No. 101097**

*P-1062*

**KXYA formula reverses the lenvatinib resistance of hepatoma cells by<\/strong>**

_Xiaobin Zhao1,2,3, Xu Cao1,2, Ruijia Liu1,2, Yongan Ye1,2_1

1Dongzhimen hospital Beijing China, 2Institute of Liver Diseases, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China, 3Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing China

**Background:** Lenvatinib resistance (LR) is a major obstacle to improving the prognosis of hepatocellular carcinoma (HCC) patients at present. The traditional Chinese medicine KangXianYiAi formula (KXYA) has shown a good therapeutic effect in liver lesions. Here, we aimed to explore the effect and mechanism of KXYA in treating LR-HCC.

**Methods:** We first constructed the hepatoma Huh7 cell model of LR via sustained low-concentration lenvatinib stimulation. The cell viability was detected by CCK-8 assay. The Huh7-LR cells were treated with DMSO and KXYA for 48 hours, then performed RNA sequencing (RNA-seq) analysis. With RNA-seq data, the differently expressed genes (DEGs) between two groups were screened out and further used to perform enrichment analysis including Reactome, Gene Ontology, and Kyoto Encyclopedia of Genes and Genomes.

**Results:** The results showed that compared to the wide-type Huh7 cells, Huh7-LR cells had higher cell viability after lenvatinib treatment. And compared with lenvatinib treatment, KXYA combined lenvatinib treatment had an increased inhibition effect in both Huh7-WT and Huh7-LR cells. With RNA-seq analysis, we obtained 511 DEGs. Compared with the DMSO group, most genes of DEGs had lower expression in the KXYA group, while others were upregulated. The enrichment analysis results showed that these DEGs were mainly correlated to the NOTCH signaling pathway.

**Conclusions:** Our study showed that KXYA treatment could effectively inhibit the cell viability of Huh7-LR cells, and the mechanism was correlated to the regulation of the NOTCH pathway.

**Abstract Submission No. 101646**

*P-1063*

**Astragalus-Atractyloides herb pair treated HCC by regulating IL-6/STAT3 signaling pathway**

_Yuling Liang1, Yuqing Xie1, Xiaoli Liu1, Lihua Yu1, Huifen Yan1, Zimeng Shang1, Yuan Wu1, Xue Cai1, Wanxin Shi1, Juan Du2, Zhiyun Yang1_1

1Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China

**Abstract:** Astragalus(Astragalus: Chinese name: Huang Qi, HQ) and Atractyloides(Astragalus: Chinese name: Bai Zhu, BZ) herb pair has potential efficacy in the treatment of hepatocellular carcinoma (HCC). However, the main components and potential mechanisms of HQBZ therapy for HCC remain unclear. Through network pharmacology, molecular docking and experimental verification, this study found that the effective active ingredient of HQBZ in the treatment of HCC is biatractyloid, the key targets are EGFR, RELA and IL-6, and the key signaling pathway is IL-6/STAT3 signaling pathway. Combined with in vitro and in vivo experimental results, we verified that HQBZ can alleviate T cell exhaustion by regulating IL-6/STAT3 signaling pathway, increase tumor infiltration CD8+ T cells, and play a therapeutic role in HCC. Our findings provide a reliable basis for further exploration of the key active ingredients of traditional Chinese medicine in the treatment of HCC.

**Keyword:** Astragalus-Atractyloides herb pair; Hepatocellular carcinoma; Network pharmacology; Molecular docking; IL-6/STAT3 signaling pathway.

**Abstract Submission No. 101648**

*P-1064*

**Mechanism of Glehniae Radix-Ophiopogon japonicus herb pair in treating hepatocellular carcinoma**

_Yuqing Xie1, Fengna Yan1, Xinhu Wang1, Lihua Yu1, Huiwen Yan1, Qing Pu1, Yuan Wu1, Xue Cai1, Yaxian Kong2, Zhiyun Yang1_1

1Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Department of Chinese Medicine, National Center for Children's Health, Beijing Children's Hospital, Capital Medical University Beijing China

**Abstract:** The incidence and mortality of primary liver cancer remain high, which is the burden of cancer worldwide. Yangyni Fuzheng Jiudu Prescription(YFJP) has been used as a traditional Chinese...
Digoxigenin activates autophagy in HCC by regulating the PI3K/Akt/mTOR pathway

Mengqin Ma1, Xiaozhou Zhou1,2,3
1The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine Shenzhen China, 2Macau University of Science and Technology Macau China, 3Shenzhen Traditional Chinese Medicine Hospital Shenzhen China

As we all know, Hepatocellular carcinoma (HCC) is a highly malignant tumor. Targeted combination immunotherapy is the approved preliminary drug regimen to treat severe HCC; however, adverse side effects and a low response rate limit its efficacy during clinical treatment. Traditional Chinese medicine and its derived natural compounds exhibit anti-cancer effects, and have the benefit of being low-toxic and low cost. Therefore, in this study, we conducted high-throughput phenotypic screening in vitro to identify alternative drugs with significant anti-HCC effects. Digoxigenin (DIG) was observed to significantly impede the progression activity of HCC cells in a drug combinator assay. Subsequently, we verified the therapeutic effects of DIG using cell counting by CCK8, lactate dehydrogenase, and cloning assays. Transmission electron microscopy, Western blotting and immunofluorescence analysis showed that DIG inhibited the proliferation of HCC cells through autophagy. According to network pharmacology and molecular docking analysis, DIG may target the Notch-1 signaling pathway. Moreover, DIG showed that DIG stops the development of subcutaneous graft tumors. In summary, DIG appears to be safe, clinically effective and improve the prognosis in patients with advanced HCC as a second line therapy.

Regorafenib as a second line therapy for Egyptian patients with an advanced stage HCC

Eman Elkhatieeb1, Hosam el din Taha1, Mohamed Kohla1, Mohamed Houseni2, Mostafa Elhelbawy1, Eman Rewisha1
1Hepatology and Gastroenterology department, National liver institute, menofia Egypt Shebin elkom Egypt, 2Interventional Radiology department, National liver institute, menofia Egypt Shebin El-koom Egypt

Background: Regorafenib has been approved among the treatment options for patients with hepatocellular carcinoma (HCC). Aim: To assess the efficacy, safety and drug adverse effects of regorafenib in Egyptian patients with HCC who have progressed during sorafenib treatment. Methods: We conducted 57 patients with advanced HCC who were shifted to regorafenib after failure of sorafenib therapy. Data included patient demographics, performance status, duration of previous line of treatment, number of treatment cycles, side effects, best-tolerated dose, laboratory, and radiological results and treatment discontinuation due to intolerability. Results: A total of 57 patients received regorafenib as a 2nd-line treatment after sorafenib progression. Of these patients, 34 (59.6%) and 23 (40.4%) were diagnosed with Barcelona Clinic Liver Cancer (BCLC) stages B and C, respectively. 24 patients (42%) had progressive disease with mean disease progression free survival (PFS) of 11.44 [95% confidence interval (CI): 10.29-12.59] months, 10 patients (18.18%) died. The OS and PFS were better in the group who shifted to regorafenib after 3 months progression on sorafenib than who shifted after 6 months progression. The cumulative survival propablity was 80.7%. The mean survival time was 14.5 (95% CI, 13.13-14.91) months. The most common toxicity was diarrhea (52.6%) hand-foot skin reaction (38.5%), fatigue (29.8%) and hypertension (19.2%). The most common grade 3-4 toxicities were hypoalbuminemia (8.7%), anemia (7%) and mouth sores (3.5%). Conclusion: Regorafenib appears to be safe, clinically effective and improve the prognosis in patients with advanced HCC as a second line therapy.
muscles, and the area of the lumbar vertebral body on an axial CT scan, and the CT density of the muscle area was measured for the evaluation of myosteatosis.

Overall survival (OS) and independent prognostic factors were evaluated using the Cox proportional hazards model.

**Results:** Psoas muscle area, psoas muscle-vertebral ratio, muscle-spine ratio, and myosteatosis are independent predictors of overall survival in patients with HCC (p < 0.001). According to the corrected Akaike information criterion, the psoas muscle-to-spine ratio outperformed the performance of other predictors, and the receiver operating curve analysis showed that the optimal cut-off point of the psoas muscle-to-spine ratio for overall survival was 4.42 (AUC 0.641, 95% CI 0.607–0.675, sensitivity 0.641, specificity 0.566) between all participants.

**Conclusions:** The psoas muscle-to-spine ratio was an independent prognostic predictor for HCC patients and can be applied to the staging of patients with HCC.

Abstract Submission No. 100690

P-1068

**Impact of Sarcopenia on the Prognosis in Cirrhotic Patients Complicated with SBP**

Hye Jin Kang1, Chang Hun Lee1, In Hee Kim1

1Department of Internal Medicine, Research Institute of Clinical Medicine of Jeonbuk National University- Biomedical Research Institute of Jeonbuk National University Hospital, Jeonbuk National University Medical School Jeon-ju South Korea

**Backgrounds:** This study aimed to investigate the initial treatment response and mortality of spontaneous bacterial peritonitis (SBP) in cirrhotic patients according to the presence of the sarcopenia.

**Methods:** We retrospectively reviewed data from SBP patients admitted from January 2004 to December 2020 at Jeonbuk National University Hospital. We defined patients with sarcopenia by analyzing CT data using the Asan J morphometry program. Among them, both male and female patients with L3MI belonging to the 25th percentile were selected.

**Results:** A total of 126 patients was enrolled for the study. Of these, 32 (25.4%) were diagnosed with sarcopenia. Overall, the initial treatment response rate was not significantly different between non-sarcopenic group and sarcopenic group (68.1% vs. 78.1%, P=0.394). But, the hospitalization days was significantly longer in sarcopenic group compared with non-sarcopenic group (28.3±19.1 vs. 22.1±18.7, P=0.037). In patients with SBP, there was no significant difference in in-hospital mortality according to the sarcopenia (31.9% vs. 37.5%, P=0.717). The mortality was increased over time in the sarcopenic group (47.4% vs. 64.0% at 6-month, 56.5% vs. 76.2% at 12-month, P=0.225 and 0.173, respectively), but, it was not significantly different (P=0.330). In the multivariate analysis, sarcopenia showed no significant association with both initial treatment failure and 30-day mortality.

**Conclusion:** Sarcopenia did not show a significant difference in initial treatment response and short-term mortality in cirrhotic patients with SBP. However, sarcopenia is more likely to affect long-term prognosis when considering the long-term mortality.

Abstract Submission No. 101171

P-1070

**Prevalence of sarcopenia and its related factors among patients with HCC: A meta-analysis**

Zhang Wen1,2, Qiuju Ran1,2, Shuyue Tuo1,2, Jia Yuan1,2, Yong Li3, Chan Li1,2, Shijiao Dai4, Jinhai Wang1,2, Na Liu5, Xinxing Tantai6

1Department of Gastroenterology, the Second Affiliated Hospital of Xi’an Jiaotong University Xi’an China, 2Clinical Research Center for Gastrointestinal diseases of Shaanxi Province, the Second Affiliated Hospital of Xi’An Jiaotong University Xi’an China

**Background:** Sarcopenia is associated with poor outcomes in patients with hepatocellular carcinoma (HCC). However, prevalence characteristics and potential related factors of sarcopenia remain to be determined. This study aimed to depict the demographic, disease-specific, and inter-study distribution of sarcopenia prevalence, and explore study-level factors related to sarcopenia in HCC patients.

**Methods:** Electronic searches were performed from inception to December 12, 2022 to identify eligible studies that reported the prevalence data of sarcopenia in HCC patients. The random-effects model was used to pool the prevalence of sarcopenia in all HCC patients and subgroups. Study-level factors associated with sarcopenia prevalence were evaluated using meta-regression.

**Results:** A total of 77 studies involving 13,158 patients from 12 countries were included (Table 1). Among the included HCC patients, the median age was 64.3 years, 78.5% were male, 74.5% coexisted with cirrhosis, and 73.0% derived from viral hepatitis. The overall prevalence of sarcopenia was 41.3% (95% CI 36.8%-45.9%) in all HCC patients. The pooled prevalence of sarcopenia was higher in Europe
compared to Asia, and it was also higher in the late stage than in the early stage. The prevalence of sarcopenia was positively and linearly associated with 3rd lumbar vertebra (L3)-skeletal muscle index (SMI)/psoas muscle index cutoff values both in males and females. In the adjusted meta-regression model, only the L3-SMI cutoff value was significantly associated with sarcopenia prevalence (Table 2).

Conclusions: Sarcopenia is highly prevalent, and the prevalence of sarcopenia was linearly and independently related to the selected cutoffs for sarcopenia in HCC patients.

Abstract Submission No. 101543

P-1071

Serum FOLR1 is a prognostic marker for hepatocellular carcinoma

Takayuki Matsumae1, Yuto Shiode2, Takahiro Kodama1, Akira Doi1, Yuki Tahata1, Akira Nishio1, Kunimaro Furuta1, Hayato Hikita1, Tomohide Tatsumi1, Tetsuo Takehara1

1Osaka University Graduate School of Medicine Department of Gastroenterology and Hepatology Suita Japan, 2Laboratory of Human Carcinogenesis Center for Cancer Research, National Cancer Institute Bethesda USA

Background: Hepatocellular carcinoma (HCC) is a deadly cancer and desires novel biomarkers for ideal surveillance and treatment strategies. We focused on the folate receptor (FR) and investigated its clinical utility as a serum biomarker of HCC.

Method: The association between the expression levels of FOLR1 gene and patient prognosis was evaluated in 364 HCC patients of TCGA cohort. Total 206 consecutive HCC patients treated with either RFA or TACE in the Osaka University Hospital between 2014 and 2021 were retrospectively enrolled. Serum concentrations of FOLR1 were assessed by enzyme-linked immunosorbent assay (ELISA) and their association with disease status and patient prognosis were evaluated.

Results: In the TCGA cohort, HCC patients with high FOLR1 levels showed significantly shorter overall survival (OS) than those with low FOLR1 levels. In our cohort, HCC patients with high FOLR1 levels showed significantly lower levels of hemoglobin, creatinine, albumin, and platelet counts compared to those with low levels. Serum AFP and DCP levels, and tumor stages were not different between 2 groups. Serum FOLR1 levels were not clearly associated with any scoring system including GALAD, ALBI and FIB-4 index. HCC patients with high serum FOLR1 showed a significantly shorter OS than those with low serum FOLR1. Multivariate analysis indicated that FOLR1 and GALAD were independent predictors of poor OS. In the subgroup analysis, serum FOLR1 levels stratified OS irrespective of treatment methods (RFA/TACE) and in the early stage HCC patients (Stage 1 and 2).

Conclusion: Serum FOLR1 is a potential new prognostic biomarker of HCC.

Abstract Submission No. 101607

P-1073

A novel erythrocyte-related risk score for prognosis prediction in hepatocellular carcinoma

Huiwen Yan1, Shuyan Zhang2, Zhiyun Yang1, Xiaoli Liu1, Lihua Yu1, Xinhui Wang3, Fengna Yan2, Yuqin Xie1

1Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University Beijing China, 3Beijing Children's Hospital, Capital Medical University Beijing China

Objective: Accurate prognostic tools are essential for hepatocellular carcinoma (HCC) management. This study aimed to develop a novel risk score based on erythrocyte-related genes to predict HCC prognosis.

Methods: HCC datasets from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized. A gene set associated with erythrocyte development and differentiation was obtained from Molecular Signature Databases. The risk score was developed using the least absolute shrinkage and selection operator (LASSO) regression model, considering erythrocyte-related genes. Additionally, a user-friendly visualization model incorporating clinical parameters was established to evaluate the risk score’s calibration, accuracy, and clinical utility. The relationship between the erythrocyte-related risk score and molecular pathways, immune cells, and functions was explored. Furthermore, the predictive abilities of hub genes across various cancer prognoses were investigated.

Results: The developed erythrocyte-related risk score effectively differentiated the prognosis of HCC patients and exhibited associations with molecular and immune-related features. This provides valuable insights and potential strategies for personalized treatment.
Conclusion: The novel erythrocyte-related risk score has demonstrated promising potential for predicting HCC prognosis and offers a foundation for future personalized treatment approaches.

Abstract Submission No. 101612
P-1074

Initial experience with the RF Ablation System (Arfa) for hepatocellular carcinoma (HCC)

Tsutomu Tamai1, Seiichi Mawatari2, Masafumi Hashiguchi3, Sho Ijuin4, Kaori Muromachi5, Takeshi Hori5, Hirohito Tsubouchi5, Akio Ido7

1Department of Gastroenterology, Kagoshima City Hospital Kagoshima City Japan, 2Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima City Japan, 3Department of Internal medicine, Maehara General Medical Hospital Hiki City Japan

Objective: Recently, variable-tip needles of radiofrequency ablation (RFA) have become available for ablation therapy of HCC. We report on our initial experience with Arfa compared to VIVARF.

Method: 52 analyzable patients with 59 nodes who underwent RFA using Arfa and VIVARF. The background was male/ female: 35/ 17, median age 74 years. HBV/ HCV/ alcohol/ NASH/ NBNC: 6/ 18/ 14/ 3/ 17.

Study 1: Comparison of RFA voltage, roll-off time, ablation temperature, ablation size, and ablation range by RFA tip length.

Study 2: Safety during and after treatment was evaluated.

Result: 1. 15 mm tip: Arfa (n=4) / VIVARF (n=6) showed a significant difference of 52.5/ 40W (p=0.022) in the maximum voltage at RFA only. Tip 20 mm: Arfa (n=8) / VIVARF (n=25) showed significant differences in maximum voltage: 77.5/ 60.0 (p=0.004), initial roll-off time: 4 / 6 min (p=0.030), and total ablation time: 9 min 30 sec / 7 min (p=0.008). There was no difference between the two groups in the extent of cauterization, although both groups had a wider cauterization area than the length of each tip. There was no significant difference in complications between the two groups.

2 cases of bleeding were observed in the VIVARF group, and in one case, hemostasis was achieved with additional cauterization of the liver surface.

Conclusion: The experience of Arfa is still small, further accumulation of cases is needed in the future.

Abstract Submission No. 101650
P-1076

A platelet related prognostic model in Hepatocellular carcinoma with portal vein tumor thrombosis

Wanxin Shi1,2, Huiwen Yan1, Xiaoli Liu1, Lihua Yu1, Yuqing Xie1, Yuan Wu1, Yuling Liang1, Zhiyun Yang1

1Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University Beijing China, 2First Clinical Medical College, Beijing University of Chinese Medicine Beijing China

Background and Aim: Portal vein tumor thrombosis (PVTT) is one of the hallmarks of advanced Hepatocellular carcinoma (HCC). Platelet (PLT) function parameters and CD8+T cells (CD8+Ts) play an important role in HCC progression and metastasis. This study is committed to establishing an efficient prognosis prediction model and exploring the combined effect of PLT and CD8+Ts on PVTT prognosis.

Methods: This retrospective study collected 932 HCC patients with PVTT from 2007 to 2017, and randomly divided them into a training cohort (n=656) and a validation cohort(n=276). We performed multivariate cox and Elastic-net regression analysis, constructed a nomogram and used Kaplan-Meier survival curves to compare overall survival and progression-free survival rates in different substrata. Relationships between indicators involved were also analyzed.

Result: We found tumor number, size, treatment, PLT, γ-glutamyl transferase, alpha-fetoprotein, mean platelet volume, and CD8+Ts were related to the 5-year OS of patients with PVTT, and established a nomogram. The area under the receiver operating characteristic curve (AUCs) for predicting the 1-year OS rates were 0.767 and 0.794 in training and validation cohorts. The calibration curve and decision curve indicated its predictive consistency and strong clinical utility. We also found those with low PLT (<100*10^9/L) and high CD8+Ts (>320 cells/μL) had a better prognosis.

Conclusion: We established a well-performing prognostic model for PVTT based on platelet functional parameters and CD8+Ts, and found that PT-8 formed by PLT and CD8+Ts was an excellent predictor of the prognosis of PVTT.

Key words: Hepatocellular carcinoma, Portal vein tumor thrombus, Platelet, CD8+T cells counts, Prognostic modeling
Importance of CONUT Score in Continuation of Atezolizumab plus Bevacizumab.

Satoshi Narahara1, Takayuki Tokunaga1, Kentaro Tanaka1, Hiroki Inada1, Etsuko Iio1, Yoko Yoshimaru1, Takehisa Watanabe1, Katsuya Nagaoka1, Hiroko Setoyama1, Yasuhito Tanaka1

1Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University Kumamoto Japan

Background: Atezolizumab plus bevacizumab (Atezo+Bev) is commonly administered for advanced hepatocellular carcinoma. In this study, we investigated the nutritional assessment for achieving good disease control.

Methods: We included 106 patients treated with Atezo+Bev at our hospital from December 2018 to February 2023, divided into 74 patients in primary treatment and 32 patients in secondary treatment. We estimated the difference in platelet count, albumin level, total cholesterol level, and lymphocyte count, which reflects protein metabolism, lipid metabolism, and immunocompetence, a lower score at 3 weeks from the start contributed to prolonged OS (primary treatment: P = 0.037, secondary treatment and later: P = 0.05).

Results: The median OS for all patients treated with Atezo+Bev was 21.4 months and the median DFS was 5.5 months. There were no differences in age, gender, or liver background between the two groups, and there were significantly more Stage IVB cases after second-line treatment (P = 0.001). Response rates between the two groups were significantly higher for first-line treatment (first-line: 46.2%, second-line: 21.4 months and the median PFS was 5.5 months). There were no differences in age, gender, or liver background between the two groups, and there were significantly more Stage IVB cases after second-line treatment (P = 0.001). Response rates between the two groups were significantly higher for first-line treatment (first-line: 46.2%, second-line: 21.4 months and the median PFS was 5.5 months).

Conclusions: Long-term continuation of Atezo+Bev with a high response rate was important for prolonging OS, and nutritional assessment using the CONUTS score was useful.

Utility of ALBI grade for predicting prognoses in patients who underwent repeat hepatectomy

TATSUKI KUSUHARA1, Hitoshi Gon1, Kido Masahiro1, Shohei Komatsu1, Kenji Fukushima1, Takeshi Urade1, Shinichi So1, Toshikiko Yoshida1, Keisuke Arai1, Yoshitake Ianno2, Daishu Tsugawa1, Sadaki Asari2, Hiroaki Yanagimoto1, Hirochika Toyama1, Takumi Fukumoto1

1Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine Hyogo Japan

Background: The albumin-bilirubin grade as a prognostic indicator for patients with recurrent hepatocellular carcinoma who undergo repeat hepatectomy has not been sufficiently investigated. We evaluated the utility of the albumin-bilirubin grade for predicting the prognosis after repeat hepatectomy of patients with recurrent hepatocellular carcinoma.

Methods: Ninety patients with intrahepatic recurrent hepatocellular carcinoma who underwent repeat hepatectomy at our hospital between 2005 and 2019 were retrospectively analyzed. Independent preoperative prognostic factors, including the albumin-bilirubin grade, were evaluated using Cox proportional-hazards regression models. Prognosis differences between patients with albumin-bilirubin grades 1 and 2 were analyzed using the Kaplan-Meier method.

Results: Cox proportional-hazards regression analysis revealed that albumin-bilirubin grade 2 (hazard ratio, 2.18; 95% confidence interval, 1.30-3.65; P=0.003) and early recurrence within 1 year from the initial surgery (hazard ratio, 4.19; 95% confidence interval, 1.74-10.07; P=0.001) were independently associated with poor recurrence-free survival; albumin-bilirubin grade 2 (hazard ratio, 3.17; 95% confidence interval, 1.20-8.37; P=0.020) was independently associated with poor overall survival. The 5-year recurrence-free survival rates of 31% and 17% after repeat hepatectomy for patients with albumin-bilirubin grades 1 and 2, respectively, were significantly different between groups (P=0.003). The 5-year overall survival rates of 86% and 60% for patients with albumin-bilirubin grades 1 and 2, respectively, were significantly different between groups (P=0.003).

Conclusions: Patients with albumin-bilirubin grade 1 are better candidates for surgical treatment of recurrent hepatocellular carcinoma. The albumin-bilirubin grade is considered useful for preoperatively predicting favorable prognoses after repeat hepatectomy for patients with recurrent hepatocellular carcinoma.

Relationship between hepatocellular carcinoma and insomnia: A Mendelian randomization study

Wei Wang1, Ting Fang2, Xu Cao1, Xuqiang Xue1, Shihao Zheng1, Sizhe Li1, Xiaobin Zao1, Yong’an Ye1

1Dongzhimen Hospital, Beijing University of Chinese Medicine Beijing, China, 2Guanganmen Hospital, China Academy of Chinese Medical Science Beijing, China, 3Sunsimiao Hospital, Beijing University of Chinese Medicine Shaanxi China

Background: Hepatocellular carcinoma (HCC) is a commonly diagnosed cancer worldwide. In some patients, there appears to be a relationship between hepatocellular carcinoma and insomnia. It is noteworthy that previous conclusions are prone to be biased by confounding effects and reverse causation due to the nature of observational studies. However, Mendelian randomization (MR) analyses can potentially overcome some of the limitations inherent in conventional epidemiologic studies.

Methods: We obtained the genome-wide association study (GWAS) summary statistics for hepatocellular carcinoma from the GWAS Catalog (https://www.ebi.ac.uk/gwas/). And GWAS summary statistics of insomnia traits can be accessed via the IEU Open GWAS Project (http://gwas.mrcieu.ac.uk). Based on publicly available genetic data, we conducted a bidirectional, two-sample, MR analysis to explore causal associations between hepatocellular carcinoma and insomnia, and we used the inverse variance weighted method as the primary analysis. Additionally, we used sensitivity analysis and outlier detection to examine robustness and pleiotropy of effect estimates.

Results: We revealed no causal relationship between hepatocellular carcinoma and insomnia using 6 SNPs in forward-direction MR (odds ratio [OR]=1.0021, 95% confidence interval [CI]=1.0005-1.0037, P=0.0088). And we revealed no causal relationship between insomnia and hepatocellular carcinoma using 23 SNPs in reverse-direction MR analysis (OR=0.2754, 95% CI=0.0009-83.8180, P=0.6585).

Conclusions: Our bi-directional MR analysis affirms no causal effect of hepatocellular carcinoma on insomnia, or insomnia on hepatocellular carcinoma.
Differential expression of miRNA in PBMC of primary liver cancer with qi deficiency and blood stasis

Minling Lyu1,2, Xiaozhou Zhou1,2

1Department of Hepatology, Shenzhen Traditional Chinese Medicine Hospital Guangdong, Shenzhen China, 2The Fourth School of Clinical Medicine, Guangzhou University of Chinese Medicine Guangdong, Shenzhen China

Qi deficiency and blood stasis are the main traditional Chinese medicine (TCM) syndromes of primary liver cancer (PLC). We extracted peripheral blood mononuclear cells from patients with PLC of Qi deficiency and blood stasis, sequenced the high-throughput transcriptome, analyzed the differentially expressed miRNAs, predicted the possible target genes, analyzed their biological functions, and evaluated their correlation with the abundance of immune cells, in order to provide potential microscopic objective evidence for the dialectical treatment of patients with PLC of Qi deficiency and blood stasis. The results show that, compared with the non-Qi-deficiency and blood stasis group, there were three significantly differentially expressed miRNAs in the Qi-deficiency and blood stasis group, including hsa-miR-1299, hsa-miR-328-5p, and hsa-miR-3168. GO and KEGG analyses indicated that the biological functions and enrichment pathways of target genes from differential miRNAs were mainly related to autophagy, metabolism, and stemness. In the group of qi deficiency and blood stasis, hsa-miR-1299 may target MANSC1, PRND, ATP6V0C and KCNJ2, Hsa-miR-3168 may target IL-10. In the group of non-qi deficiency and blood stasis, hsa-miR-1299 may target BPGM and hsa-miR-3168 may target FCGR3B. By comparing the abundance of the possible target genes, we found that there were differences in the expression of miRNAs in peripheral blood immune cells of patients with PLC between the Qi deficiency and blood stasis group and the non-qi deficiency and blood stasis group. These differences might be potential biomarkers for TCM diagnosis.

SERUM AFP, AFP-L3 % & DCP RESPONSES FOR MONITORING TREATMENT OUTCOMES IN HCC PATIENTS TREATED BY TACE

Min Shan1, Aye M Soe2, Kyaw S Tun3, Khin M Win4

1Defence Services Liver Hospital Yangon Myanmar, 2Defence Services Medical Academy Yangon Myanmar, 3Defence Services Medical Academy Yangon Myanmar, 4Yangon Gl and Liver Center Yangon Myanmar

Background: Alpha-fetoprotein (AFP) responder alone without doing contrast enhanced computed tomography (CECT) couldn’t be applied as further treatment decision after transcatheter chemoembolization (TACE) therapy in hepatocellular carcinoma (HCC) patients.

Objective: To find out the association between tumor marker responder using AFP and newly US FDA approved serum biomarkers specific for HCC like Alpha-fetoprotein Lens culinaris agglutinin 3 (AFP-L3), Des-gamma carboxyprothrombin (DCP) and radiological responder with modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria at before and one month after TACE in HCC patients.

Methods: Serum AFP was measured by c 411 fully automated immunoassay analyzer and AFP-L3 and DCP were measured by sandwich-ELISAZ kit with semi-automatic immunology analyzer assay. An AFP, AFP-L3 % and DCP responder was defined as a reduction of more than 50% from the baseline level and radiological responder with mRECIST criteria was classified as complete response and partial response defined as more than 30% decrease in the sum of longest diameters of viable (arterially enhancing) target lesions compare with baseline) at one month after TACE.

Results: AFP, AFP-L3 % and DCP responders were determined in 41 (48.1%), 49 (57.6%) and 60 (70.6%) in HCC patients at one month after TACE. Single tumor marker responder (AFP-L3 % or DCP) was significantly associated with radiological responder (p=0.013 and p=0.001) while AFP responder was not associated. Combination of two tumor marker responder including DCP (DCP plus AFP, DCP plus AFP-L3 %) were also positively associated with radiological responder (p=0.004 and p<0.001) while AFP plus AFP-L3 % responder was not associated. The combination of all three tumor marker responder (DCP plus AFP plus AFP-L3 %) was also be associated with radiological responder (p=0.004).

Conclusion: DCP tumor marker measurement alone would be more informative for tumor burden and decisive for further treatment option after TACE in HCC patient.

Keywords: HCC, AFP, AFP-L3%, DCP, mRECIST

Long-term outcomes and evaluation of HCC recurrence and simple scoring system: AKLD Group Study

Shungo Kimura1, Tani Joji1, Tomonori Senoh2, Akio Moriyama1, Chikara Ogawa1, Akihiro Deguchi2, Teppei Sakamoto2, Kei Takuma1, Mai Nakahara1, Kyoko Oura1, Tomoko Tadokoro1, Koji Fujita1, Hideki Kobara1, Asahiro Morishita1, Itsumo Masaki2

1Department of Gastroenterology and Neurology, Faculty of Medicine Kagawa Japan, 2Department of Hepatology, Kagawa Prefectural Central Hospital Kagawa Japan, 3Department of Gastroenterology, Mitoyo General Hospital Kagawa Japan, 4Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital Kagawa Japan, 5Department of Gastroenterology, Kagawa Rosai Hospital Kagawa Japan, 6Department of Internal Medicine, Yashima General Hospital Kagawa Japan

Aims: Direct acting antivirals (DAA) has improved the cure rate of HCV patients. However, the occurrence rate of hepatocellular carcinoma (HCC) and the long-term outcomes in patients with HCC recurrence after DAA treatment remains unknown.

Methods: At first, we aimed to iden-tify predictors of HCC occurrence following DAA treatment. Among 1218 patients infected with HCV, 1,088 patients who achieved sustained virologic response and who had no history of HCC treatment were recruited between September 2014 and November 2018.

Results: The incidence of HCC was 0.61, 1.88, 2.82 and 3.71% at 6, 12, 18 and 24 months after treatment with DAA, respectively. The results of multivariate analysis identified age [hazard ratio (HR), 1.0729; P=0.0044] and α-fetoprotein (AFP) level after DAA treatment (HR, 1.0486; P=0.0486) as independent factors that may contribute to HCC occurrence following DAA treatment. By using these two factors, a novel scoring system (0-2 points) was established to predict HCC occurrence following HCV eradication by DAA treatment. The incidence
of HCC at 2 years was 0.3% in the 0 points group, 6.27% in the 1point group and 18.37% in the 2points group.

Conclusions: AFP level after DAA treatment and age at DAA administration were identified as independent predictors of HCC occurrence in patients that were treated with DAA. The scoring system that was established in the present study is simple and easy, and using pre-treatment factors may be a convenient tool to predict the risk of HCC occurrence in HCV-free patients following DAA treatment.

Abstract Submission No. 101173
P-1083

Head-to-head comparison among FAST, MAST and multiparametric MRI in diagnosing at-risk NASH

Kento Imajo¹, Shinya Nishida¹, Nobuyoshi Kawamura¹, Shigeyoshi Kokubu¹
¹Shin-yrugaoka General Hospital Kawasaki Japan

Background: The presence of at-risk non-alcoholic steatohepatitis (NASH) (Nonalcoholic fatty liver disease (NAFLD) activity score>2) and significant fibrosis (Fibrosis stage≥2) is associated with progression to cirrhosis. Therefore, noninvasive assessment of at-risk NASH is a critical need for pharmacologic therapy. We developed new scores to identify at-risk NASH using multiparametric magnetic resonance elastography (mpMRI).

Methods: A prospective study was conducted on 176 patients with suspected or diagnosed NAFLD paired with an MR scan, vibration controlled transient elastography (VCTE) and liver biopsy. Liver stiffness measurement (LSM) using magnetic resonance elastography (MRE), proton density fat fraction (PDFF), and mpMRI-based corrected T1 (cT1) were combined to develop a one-step strategy, named MPcT (MRE+PDF+cT1, combined score), and a two-step strategy—MRE-based LSM followed by PDFF with cT1 (M-PcT, paired score) for diagnosing at-risk NASH. Each model was categorized using rule-in and rule-out criteria (three categorized analysis).

Results: PDFF+cT1 (PcT) had the highest diagnostic performance for severe activity (hepatic inflammation plus ballooning grade≥3) and for NAS≥4 (active NASH). Areas under receiver operating characteristic curves (AUROCs) of M-PcT (0.832) for detecting at-risk NASH were significantly higher than those of Fibroscan-AST (FAST) (0.744, p=0.017), MRI-AST (MAST) (0.710, p=0.002) and MPcT (0.695, p=0.001) in three categorized analysis. Following the rule-in criteria, positive predictive values of M-PcT (84.5%) was higher than those of FAST (73.5%), MAST (70.0%) and MPcT (66.7%). Following the rule-out criteria, negative predictive values of M-PcT (88.7%) were higher than those of FAST (84.0%), MAST (73.9%) and MPcT (84.9%).

Conclusions: The two-step strategy, M-PcT (paired score), showed re-liability of rule-in/-out for at-risk NASH, with better predictive performance compared with FAST and MAST (combined score).

Abstract Submission No. 101791
P-1084

Usefulness of Medical Imaging Projection System for open liver resection

Tatsuya Yamazaki¹, Takeshi Aoki¹, Yoshihiko Tashiro¹, Kazuhiro Matsuda¹, Kusano Tomokazu¹, Kosuke Yamada¹, Akira Fujimori¹, Koji Nogaki¹, Yusuke Wada¹, Hideki Shibata¹, Kodai Tomioka¹, Takahito Hira³, Marie Uchida¹, Kazuhiko Saito¹, Masahiro Nagashi¹

¹General and Gastroenterological Surgery, Showa university Tokyo Japan

Background: Indocyanine green (ICG) fluorescence-guided surgery is a real-time navigation technology for tumor detection, securing surgical margins, segmentation mapping, and cholangiography in liver surgery. According to recent reports, the Medical Imaging Projection System (MIPS, Mitaka Kohki Co, Tokyo, Japan) may be a useful new real-time navigation technology for open anatomical liver resection. We report usefulness of MIPS-assisted liver resection for real-time navigation.

Methods: We conducted a retrospective review of surgical and clinical outcomes for patients who underwent hepatectomy using the MIPS a, between September 2021 and December 2023. 0.025 mg ICG is injected for positive staining and negative staining technique is intravenously injected with 2.5mg ICG after blood flow occlusion. For tumor detection and securing surgical margins, ICG of 0.5 mg/kg was administered 2-14 days before the surgery. 2.5 mg/body of ICG is administered 1 hour before surgery for ICG cholangiography.

Results: We included 12 patients who underwent open liver resection for hepatocellular carcinoma (n=5), liver metastasis (n=4), or intrahepatic cholangiocarcinoma (n=3). Eight patients underwent anatomical resection with positive (n=3) or negative staining (n=5) technique and four patients were non-anatomical resection. MIPS could visualize the demarcation line and clarify the boundaries of the liver segments with positive (n=3) or negative staining (n=5) techniques and could detect all tumors (n=4) within 10mm from liver surface. All patients were no positive margins and no complications.

Conclusion: MIPS could be useful for real-time navigation during open liver surgery.

Abstract Submission No. 102047
P-1085

B-mode shear wave elastography can be an alternative to vibration-controlled transient elastography

Shota Izumi¹, Masashi Hirooka¹, Ryo Yano¹, Makoto Morita¹, Yuki Okazaki¹, Yoshihiko Nakamura¹, Yusuke Ima², Yohe Koizumi¹, Takao Watanabe¹, Osamu Yoshida¹, Yoshio Tokutomo¹, Masanori Abe¹, Yoichi Hiasa¹
¹Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine Ehime Japan

Background: The aim of this study was to evaluate the comparability of vibration controlled transient elastography (VCTE) and shear wave elastography (SWE) by combination elastography, and to establish regression equations between VCTE and new point SWE.

Methods: A total of 829 patients with chronic liver disease participated, excluding those with a skin-liver capsule distance≥25 mm. Reproducibility for VCTE and SWE was verified by phantom and clinical studies. A similar analysis was performed for the Liver Fibrosis Index (LFI), a quantitative assessment of liver fibrosis using strain elastography image features. Regression equations between VCTE and SWE values were derived by linear regression analysis.

Results: Strong correlations between VCTE and SWE were observed in both phantom and clinical studies [r=0.995 (p<0.001) and r=0.747 (p<0.001), respectively]. The regression equation was determined as VCTE (kPa)=1.09×point SWE (kPa)-0.17. Bland-Altman plots showed no significant bias. Conversely, there was no correlation between VCTE and LFI (r=0.279), indicating a statistically significant bias in the Bland-Altman plots. Inter-operator reliability showed a favourable intraclass correlation coefficient of 0.760 (95% confidence interval: 0.720-0.779).

Conclusion: Liver stiffness measured using point SWE was comparable to that measured using VCTE.
A case of foreign body granuloma suspected of peritoneal dissemination of hepatocellular carcinoma

Shogo Nagahama1, Akira Kaneko1, Nobuyuki Tatsumi1, Satomi Asada1

1Department of Gastroenterological and General Surgery, Showa University School of Medicine Tokyo Japan

A woman in her 60s was referred to our hospital with suspicion of hepatocellular carcinoma in November 3 years ago. A contrast-enhanced CT scan revealed a 55mm-sized, early phase, ischemic mass in liver S5 with uneven enhancement only at the margins. S5 subsegmental resection was performed in January 2 years ago. Pathological results showed poorly differentiated hepatocellular carcinoma. In August last year, laparoscopic S8 partial resection was performed for recurrence of hepatocellular carcinoma in liver S8. Radiofrequency ablation (RFA) was performed for the recurrent lesion in liver S7 in April that year.

A CT scan after RFA revealed an 8mm-sized contrast-enhanced nodule just below the abdominal wall of the right upper quadrant, which had slightly increased in size since the CT scan 4 months earlier. EOB-MRI examination showed that the nodule was enhanced in the hepatobiliary phase. PET-CT examination revealed relatively clear FDG accumulation in the nodular lesion. Peritoneal dissemination of hepatocellular carcinoma was suspected, so laparoscopic tumor removal was performed for total-biopsy in August. The excised peritoneal tissue was covered with connective tissue. A large number of foreign body-type giant cells densely clustered in the tumor, and artifacts resembling sutures were observed between these cells. Based on these findings, a diagnosis of foreign body granuloma was made.

As in our case, a benign nodule may be suspected to be peritoneal dissemination by imaging, so histological diagnosis before treatment is important.
Comparison of resection, ablation and SBRT in treating solitary hepatocellular carcinoma ≤ 5 cm

Yizhen Fu1,3,4, Zhoutian Yang1,3,4, Shiliang Liu2,3,4, Minshan Chen1,3,4, Mian Xi9, Yaojun Zhang1,3,4
1Department of Liver Surgery, Sun Yat-sen University Cancer Center Guangzhou China, 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center Guangzhou China, 3State Key Laboratory of Oncology in South China Guangzhou China, 4Guangdong Provincial Clinical Research Center for Cancer Guangzhou China

Abstract Submission No. 100209
P-1092

Albumin-indocyanine green evaluation of future liver remnant as a surgical indicator for hepatectomy

Tomoyuki Nagaoka1, Kohei Ogawa1, Katsunori Sakamoto1, Taro Nakamura2, Yoshinori Imai2, Yusuke Nishi1, Masahiko Honjo1, Kei Tamura1, Naotake Funamizu1, Yasutsugu Takada1
1Ehime University Graduate School of Medicine Toon Japan, 2Uwajima City Hospital Uwajima Japan

Abstract Submission No. 100209
P-1092

Salvage hepatectomy for recurrent hepatocellular carcinoma after radiofrequency ablation

Jai Young Cho1, Yeshong Park1, Ho-Seong Han1, Hae Won Lee1, Boram Lee1, MeeYoung Kang1, Jinju Kim1
1Seoul National University Bundang Hospital Seongnam South Korea

Abstract Submission No. 100161
P-1091

Introduction: HAV IgG seroprevalence is different according to the age. Coinfection of hepatitis A can aggravate liver damage in chronic liver disease patient. We need to know HAV IgG seroprevalence among chronic liver disease patients

Method: We checked HAV IgG in 40 patients who have chronic liver disease from 2021 to 2022. Hepatitis B patients were 16, Hepatitis C patients were 4 and alcoholic liver disease patients were 20. Seroprevalence of HAV IgG was analyzed retrospectively.

Result: Seroprevalence of HAV IgG is 55%(22/40). According to age, 10-19years 25%(1/4), 20-29years 25%(2/8), 30-39years 33%(4/12), 40-49years 87%(7/8), 50-59years 100%(8/8) Seroprevalence of IgG is increasing as age becomes higher(p<0.05). Seroprevalence of patients below 40 years old is 29%(7/24) and above 40 years old is 93%(15/16). Seroprevalence is high in patient above 40years old (p=0.05). Seroprevalence of IgG among underlying disease( HBV, HCV, alcoholic liver disease) was not different(p>0.05)

Conclusion: Seroprevalence of HAV IgG was low in young generation because of recent good hygiene. HAV vaccination can be reasonable for chronic liver disease under 40 years old in South Korea.
The ALICE-FLR, ALICE scores, and indocyanine green clearance of FLR (ICGK-FLR) were evaluated for severe PHLF prediction. Results: Severe PHLF was observed in 40 patients (18.6%). The areas under the curve (AUCs) for the ALICE-FLR, ALICE scores, ICGK-FLR, and FLR were 0.76, 0.64, 0.73, and 0.69, respectively. The AUC of the ALICE-FLR score was significantly higher than that of the ALICE score. The ALICE-FLR score was identified as an independent predictor of severe PHLF (p = 0.004). Among patients with severe PHLF, the ALICE-FLR score was significantly higher in the grade C than in the grade B PHLF group.

Conclusion: The combination of liver function models, including indocyanine green, albumin, and FLR is considered compatible for predicting severe PHLF.

OUTCOME OF PATIENTS WITH ACLF UNDERGOING PLASMAPHERESIS – AN OBSERVATIONAL STUDY

Shivangi Negi1, Piyush Ranjan2, Mandhir Kumar1
1Sir Ganga Ram hospital Delhi India, 2Sir Ganga Ram hospital Delhi India

BACKGROUND: ACLF is associated with high mortality and few treatment options. This study aims to investigate the potential benefit of plasmapheresis in ACLF patients without transplant.

METHODS: Prospective study conducted at Sir Ganga Ram Hospital. 72 patients with ACLF (EASL CLIF criteria) enrolled. Patients with no improvement in ACLF grade or MELD score (after 72 hours), were evaluated for plasmapheresis (including alcohol hepatitis patients not eligible for steroid therapy or Lille score > 0.45 after 7 days) (Group A) and rest were continued on SMT (Group B). Low volume PLEX done on alternate days as per clinical response.

RESULTS: In PLEX (n=22) group 12 (54.5 %) patients were discharged compared to 17 (34.0%) in the SMT (n=50) group (p=0.257). 30 days survival in the PLEX group was (n=16/81.25%) compared to (n=29/68.9%) (p=.321) in SMT. 90 days survival was (n=16/81.25%) compared to (n=20/60%) (p=.321) in SMT. 90 days survival in the PLEX group was (n=16/81.25%) compared to (n=20/60%) (p=.321) in SMT group. In PLEX group (n=12/54.5 %) patients discharged had significant decrease in MELD Na (35.46 +/- 4.63) as compared to pre PLEX MELD (32.15 +/- 5.47) (p=.004). No PLEX related severe adverse effect seen.

CONCLUSIONS: In our study patients undergoing PLEX had increased hospital survival by 20 % and increase in 30 days survival by 10 % as compared to SMT group. However values were not statistically significant due to small sample size. Hence PLEX may be a viable therapy in patients awaiting transplant by increasing short term survival however further randomized control trials are needed.

A case of acute liver failure with HELLP syndrome treated with plasma exchange and steroid pulse

Hiroyoshi Taniguchi1, Rintaro Fukuda1, Ayane Matsuzaki1, Yasuki Niimura1, Keiko Nakamura1, Mika Kashiwagi1, Go Endo1, Ayako Nakata1, Hirobumi Suzuki1, Koji Uchino1, Shinzo Yamamoto1, Yukiho Itó1, Hideo Yoshida1
1Japanese Red Cross Medical Center, Department of Gastroenterology and Hepatology Tokyo Japan

Case: 30-year-old female
Complaint: General malaise.

She was admitted to the obstetrics and gynecology department of our hospital at 35 weeks 0 days after receiving ritodrine hydrochloride. On 36 weeks 5 days of pregnancy, increased AST and LDH were observed, and an emergency caesarean section was performed with a diagnosis of partial HELLP syndrome. On the second postoperative day, the patient was found to have worsening liver dysfunction and was referred to the Department of Gastroenterology and Hepatology. The patient was diagnosed as a severe acute liver failure, and plasma exchange started on the same day. Considering the possibility of liver transplantation, preparations for transplantation were also started. After 3 days of plasma exchange, the patient continued to deteriorate, and a steroid pulse therapy was administered. Although her liver enzymes peaked out, elevated blood pressure and seizures appeared on the sixth postoperative day, and postnatal PRES syndrome was suspected, and she was intubated. The patient was extubated on the 8th postoperative day after administration of anticonvulsants and antihypertensive drugs, and thereafter, her liver function improved, and a liver transplant was avoided.
HELLP syndrome generally improves after childbirth. However, the patient continued to deteriorate even after delivery, leading to acute liver failure. We consider this case is didactic in that the patient responded well to plasma exchange and steroid pulse therapy.

Abstract Submission No. 200269  
P-1096

A case of drug induced hypersensitivity syndrome with liver failure caused by acetaminophen

Hiroyoshi Taniguchi1, Yusuke Iwata1, Ayane Matsuzaki2, Yasuki Niimura1, Keiko Nakamura1, Mika Kiihatsu1, Go Endo1, Ayako Nakata1, Hirobumi Suzuki1, Koji Uchino1, Shinzou Yamamoto1, Yukiko Itu1, Hideo Yoshida1  

1Japanese Red Cross Medical Center, Department of Gastroenterology and Hepatology Tokyo Japan  

A 74-year-old man was administered acetaminophen at another hospital after fracturing a rib in May. In mid-June, erythema appeared all over the skin, liver enzymes were elevated, PT was prolonged, ascites and mediastinal lymphadenopathy were noted on CT, and the patient was admitted to another hospital with a diagnosis of acute liver failure. Prednisolone 500mg was administered for 3 days, but his PT was further prolonged, and he was transferred to our hospital. The administration of acetaminophen by chance caused further worsening of erythema and prolongation of PT from 43% to 19%. Plasma exchange (PE) and hemodialysis were started. The patient was diagnosed as drug-induced hypersensitivity syndrome (DIHS) by eosinophilia and skin rash, and HHV6 reactivation. Prednisolone 50 mg/day was started, and PE was performed 10 times, but his liver function did not recover, and he died in early August.  

Discussion: DIHS is a drug hypersensitivity reaction with skin rash, organ damage, eosinophilia, and lymphadenopathy. The rash appears 2 to 8 weeks after drug initiation and continues for at least 15 days after drug discontinuation. Eosinophilia, atypical lymphocytes, liver and kidney damage, etc. appear, and the disease resolves within a few weeks to a few months, but liver failure and multi-organ failure cause death in 5-10% of patients. Acetaminophen-induced DIHS is rarely reported, but in this case, all 7 diagnostic criteria were met. Steroids are recommended in cases of organ failure, but in this case, steroids could not save the patient’s life, and further case studies are needed.

Abstract Submission No. 200178  
P-1097

Endoscopic biliary drainage for unresectable malignant hilar biliary obstruction.

Naoki Fujita1, Hideki Kamada1, Masahiro Ono1, Ryota Nakabayashi1, Kono Toshiaki2, Hiroki Yamana1, Kiyoyuki Kobayashi1, Tsutomu Masaki1  

1Department of Gastroenterology & Neurology, Faculty of Medicine, Kagawa University Kitagun Japan  

Background: Endoscopic drainage of unresectable malignant hilar biliary obstruction (UMHBO) often requires either side-by-side (SBS) or stent-in-stent (SIS) techniques. In this study, we compared the short-term and long-term results of the SBS and SIS methods. Methods: This was a single-center retrospective review of 28 patients who underwent endoscopic biliary an uncovered self-expanding metal stenting for unresectable MHBO from October 2014 to April 2022. Patients underwent endoscopic retrograde cholangiopancreatography and stenting using either the SBS or SIS technique.  

Results: There were no significant differences between groups in technical and functional success (SBS vs. SIS, 95 vs. 86 %, respectively), mean procedure time (72 vs. 110 min), RBO rate (55 vs. 50 %), TRBO (143 vs. 136 days), early complications (24 vs. 14 %), late complications (10 vs. 14 %). There were no significant differences in reintervention success rates (98 vs. 86 %), but the mean procedure time for reintervention was significantly shorter for SBS than for SIS (31 vs. 58 min; p < 0.001).  

Conclusions: Our results showed no significant difference in clinical outcomes such as success rate or RBO between SBS and SIS technique for UMHBO. However, SBS technique may be superior to the SIS technique in terms of reintervention.

Abstract Submission No. 100090  
P-1098

Amiodarone induce acute hepatotoxicity in Pakistani population: two case reports

QURAT UL AIN HAFEEZ1, Amanullah Abbasi1  

1DR. RUTH K.M PFAU CIVIL HOSPITAL KARACHI KARACHI Pakistan  

Background: Although rare, intravenous amiodarone can cause substantial hepatotoxicity, leading to a rapid increase in transaminases, often exceeding 100 times the upper limit of normal (ULN). The effect tends to reverse upon discontinuation, allowing for oral therapy. This study presents two cases of acute hepatocellular injury due to amiodarone infusion, emphasizing its discontinuation and confounding factor removal on transaminase levels in Pakistani patients.

Method: Case 1, a 52-year-old male patient undergoing CABBG, received a 16-hour infusion of Amiodarone for postoperative atrial fibrillation. Concurrently, co-amoxiclav, esomeprazole, acetaminophen, and rosuvastatin were administered. SGPT was normal before amiodarone treatment but increased 60-fold after infusion. After switching to low-dose oral Amiodarone (400 mg per day), the SGPT returned to normal within 26 days.  

Case 2 is a 72-year-old woman with multiple conditions received amiodarone and ceftriaxone for atrial fibrillation. Within 24 hours, SGPT increased 100-fold. After discontinuation of amiodarone, SGPT returned to normal within 52 days of switching to digoxin and imipenem.

Conclusion: Case 1 responded well to oral amiodarone, possibly due to polysorbate 80 solubilizer in injection or higher intravenous dose. Acetaminophen, amoxicillin-clavulanate, and statins elevated SGPT, while omeprazole exhibited safer hepatic profiles than esomeprazole. Case 2 shifted to safer alternatives. Reversal of SGPT was seen in both cases up to several weeks after drug discontinuation. Amiodarone’s extended elimination time due to its large volume of distribution underscores the vigilant liver function tests monitoring to mitigate this rare yet harmful effect.

Abstract Submission No. 100115  
P-1099

Splenical Marginal Zone B-Cell Lymphoma with Hepatitis B virus infection during the Covid 19 Pandemic

Jeuz Geluz1, Jeanette Pascual1  

1James L Gordon Memorial Hospital Olongapo City Philippines
INTRODUCTION: An indolent B-cell lymphoma originating from the marginal zone namely splenic marginal zone lymphoma (SMZL) comprised only 1-2% of non-Hodgkin’s lymphoma (NHL) was known to be associated with hepatitis infection. In cases where splenectomy is contraindicated, a combination of a bone marrow biopsy results, and immunohistochemistry confirmed by a hematologist confirms the diagnosis of SMZL.

CASE REPORT: This is to report a case of SMZL in a 63-year-old male with chronic hepatitis B infection on Tenofovir medication who presented with unintentional weight loss and intermittent left upper quadrant discomfort. A bone marrow morphologic diagnosis revealed a markedly hypercellular bone marrow, with mature CD5 to be more than 95% and CD10 negative, B-cell lymphoproliferative disorder supported with an immunohistochemistry report showing CD20 positive, CD3 negative, CD5 negative, CD10 negative, KL6 positive, low 5-10 %, Cyclin D1 negative and presence of splenomegaly thereby, confirms the diagnosis of splenic marginal zone B cell lymphoma.

DISCUSSION: There are some reports where Hepatitis B is associated with SMZL and treatment of the viral infection showed resolution of the lymphoma, however the exact oncogenesis is still an area of exploration. This case highlights the pre-existence of Hepatitis B infection in SMZL and the response to a second line treatment drug, Ibrutinib due to infusion reaction to first line regimen – Rituximab in this time of Covid 19 pandemic.

Liver Injury and Cholecystitis due to Endoscopic Treatments for Duodenal Ulcer Bleeding

Anbang Chen1, Qian Li1, Guanchuang Wang1,2, Chunqing Zhang3, Yongjun Shi1, Zhen Li1, Guangjun Huang2

1Department of Gastroenterology, Shandong Provincial Hospital, Shandong University Jinan China, 2Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

A 67-year-old male with asymptomatic polycystic kidney and polycystic liver presented with recurrent hematemesis and hypotension shock. He was diagnosed with duodenal bulb ulcer 6 days ago and underwent endoscopic treatment using a through-the-scope clip. After resuscitation, we performed an emergency endoscopy and replaced the malfunctioning clip (Figure 1A) with an over-the-scope clip, but pulsatile bleeding persisted. Consequently, we injected N-butyl-2-cyanoacrylate (histoacryl) and lauromacrogol (hardener) at a sequence but pulsatile bleeding persisted. Consequently, we injected N-butyl-2-cyanoacrylate (histoacryl) and lauromacrogol (hardener) at a sequence

Abstract Submission No. 100180
P-1100

Functional Cure of a Chronic Hepatitis B Cirrhosis Child Treated by Peginterferon α: A Case Report

Hongfei Zhang1, Yu Gan2

1Jumei Doctor Group Medical (Shenzhen) Co., Ltd Shenzhen China, 2Pediatric Hepatology, Hepatobiliary Pancreatic Center, Beijing Tsinghua Changgung Hospital, Tsinghua University Beijing China

Background: Pediatric HBV-infected patients are susceptible to breaking through the immune tolerance and developing varying degrees of disease progression. However, current researches on antiviral therapy in children are relatively limited, particularly for those under 1 year of age.

Method: An 8-month-old infant with positive hepatitis B surface antigen (HBsAg) and abnormal liver function was diagnosed as chronic hepatitis B cirrhosis (G3S3-4) with active compensatory phase. The treatment regimen commenced with lamivudine (LAM) for the initial 8 weeks, followed by the addition of interferon α (IFNα) after 1 year of age. At 2 years old, LAM was substituted with entecavir (ETV), and at 3 years old, IFNα was replaced with peginterferon α (PEG IFNα).

Results: After 8 weeks of LAM monotherapy, the child experienced HBsAg loss. Subsequently, after 36 weeks of IFNα add-on therapy, HBV DNA became undetectable, and after 48 weeks of switching to PEG IFNα treatment, HBsAg loss was observed. During the 50-week follow-up period after drug discontinuation, the child remained functionally cured. Remarkably, the child did not experience any noticeable adverse reactions throughout the treatment course.

Conclusion: Chronic HBV-infected infants and young children can also significantly benefit or even achieve functional cure after PEG IFNα-based individualized therapy. This case serves as a valuable reference for the diagnosis and treatment of such patients.

Abstract Submission No. 100346
P-1102

TEMPI syndrome misdiagnosed as cirrhosis with ascites: A case report

Hua Liu1,2,3,4, Yan Yin5, Fushuang Ha1,2,3,4, Jing Liang1,2,3,4, Jiayu Lv5, Hongmin Lv1,2,3,4

1The Third Central Hospital of Tianjin Tianjin China, 2Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin China, 3Artificial Cell Engineering Technology Research Center Tianjin China, 4Tianjin Institute of Hepatobiliary Disease Tianjin China, 5Tianjin Chest Hospital Tianjin China

Background: TEMPI syndrome is an extremely rare monoclonal plasma cell disease that can easily be misdiagnosed or missed. Currently, the diagnosis of TEMPI syndrome requires presence of telangiectasia, elevated erythropoietin, erythrocytosis, monoclonal gammopathy, perinephric fluid collection, and intrapulmonary shunting.

Case Summary: The present case involved a 58-year-old man with a large amount of ascites as the first symptom and a history of alcohol consumption, telangiectasia during physical examination, an ascitic albumin pressure gradient >11, and coagulation disorders. Ascites due to cirrhosis should be considered during the initial diagnosis. However, a blood test revealed a hemoglobin level of 201 g/L, suggesting...
Cavernous Transformation of the Portal Vein with Pyogenic Liver Abscess: A Case Report

Ma. Althea Kathrine Elinzano1, Lovell Gatchalian1, Michael Gonzaga1, Patrick Michael Roslyn1
1East Avenue Medical Center Quezon City Philippines

In cavernous transformation of the portal vein (CTPV) (also known as portal cavernoma or chronic portal vein thrombosis), the obstructed portal vein is substituted by a network of portoportal collateral veins. Complete obstruction of the portal vein almost always leads to portal hypertension and the development of portosystemic collaterals, which may present with ruptured gastrointestinal varices. We report a case of a 21-year-old female who presented with six years history of upper gastrointestinal bleeding secondary to ruptured gastrointestinal varices. She underwent endoscopic band ligation. Portal doppler ultrasound revealed cavernous transformation of the portal vein, splenomegaly, and splenic varices. She had right upper quadrant pain and fever for two months. CT scan showed a 16.1x14.2x13.5cm segment IV abscess, splenomegaly, tortuous portal vein with dilated collateral vessels in the splenic hilum and left perinephric region. Ultrasound-guided percutaneous insertion of a pigtail catheter drained purulent fluid and culture demonstrated Pseudomonas luteola sensitive tocefazidime. Ascidic fluid analysis revealed a serum asci six albumin gradient of 1.2 g/dL. Variceal screening showed a small varix and portal hypertensive gastropathy. Hepatitis markers were non-reactive. Cefazidime was given for 14 days and shifted to Ciprofloxacin. Propranolol was continued. Resolution of the abscess was documented and the pigtail catheter was removed prior to discharge. Hematologic work-up demonstrated antibodies to beta-2 glycoprotein I, thus, antiphospholipid syndrome is the etiology of her hypercoagulable state. Aspirin was started. Antiphospholipid syndrome leads to a hypercoagulable state which causes CTPV. Although CTPV is a rare condition, this can predispose to abscess formation.

Liver Cirrhosis with Recurrent Ascites In Diabetic Heart Disease: A Case Report

Eduward Thendiono1
1Bunda hospital Gorontalo Gorontalo Indonesia

Background: Management of recurrent ascites in liver cirrhotic may be challenging. 

Case Report: A 60-year-old patient with liver cirrhosis, admitted due to fatigue and abdominal discomfort. Comorbidities are type2 diabetes, heart failure (ejection fraction 48%), and fatty liver. He underwent endoscopic band ligation and (two times) abdominal paracentesis followed up examinations. In July 2021, the patient was found to have an increased serum creatinine level (1.8 mg/dL) and significant ascites. The patient was placed on spironolactone 100mg/day, furosemide 40mg/day, and albumin supplement. Upon admission, he was comatose with blood pressure 90/60mmHg, heart rate 68 x/minute, normal temperature. There were palmar erythema, and palpated spleen. Noted hypoaalbuminemia (3.2 g/dL), hyperglycemia (265 mg/dL), hypokalemia (2.6 mEq/L), hypoproteinemia (133 mEq/L), cardiomegaly, minimal ascites and splenomegaly (schuffner II), thrombocytopenia (62,000/mm3), and eGFR 52 mL/min/1.73 m2. Potassium replacement and B1-aminofluid intravenous were administered. Maintenance was continued. Episodes of hypotension impede optimization of diuretics dose. Dapaglifozin 10mg/day was started. Paracentesis was scheduled should ascites worsened. Seven days later, re-evaluation showed normal electrolyte, resolution of ascites, blood glucose within target, eGFR 43 mL/min/1.73m2 with clinical improvement, and lead for outpatient. Latest routine follow-up showed no recurrences of ascites on ultrasound, A1c 7.2%, normal electrolytes, and eGFR 50 mL/min/1.73m2.

Discussion: Electrolyte disturbances and hypotension are the side effects of diuretic treatment in managing ascites. The study showed that sodium glucose co-transporter-2 inhibitor/SGLT2i has natriuresis effect, which may alleviate ascites. Despite its positive cardiometabolic effect, dapaglifozin provides a synergistic effect with diuretics in controlling ascites in this case.
Conclusion: SGLT2i may provide benefit over conventional therapy for liver cirrhosis patient with recurrent ascites.

Abstract Submission No. 101062
P-1106

Bilothorax after hepatocellular carcinoma rupture: a case report

Tonguk Teerasarntipan1,2, Nirada Limsoontarakul1, Lynlada Ruangsomvong1
1Thonburi Hospital Bangkok Thailand, 2Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University Bangkok Thailand

Case presentation: A 72-year-old man presented with acute abdominal pain. Computed tomography (CT) showed a 17.7x12.3x13.5 cm mass with arterial phase hyper-enhancement and washout in portovenous phase at right lobe of cirrhotic liver with left hepatic lobe and pulmonary metastases. Heterogeneous-enhancing fluid, size 11.5 x 3.6 cm, was detected at right subcapsular region, compatible with ruptured hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) and partial Gelfoam embolization was performed to successfully control bleeding. Two weeks later, the patient developed progressive dyspnea. Chest radiography showed moderate amount of right pleural effusion with right lower lung atelectasis. Thoracocentesis found olive-green colored fluid (figure 1) with WBC 413 cells/mm3 (mononuclear 75%). Pleural fluid/serum profiles were as followed; protein 5.5/8.5 g/dL, albumin 2.1/2.5 g/dL and bilirubin 3.7/2.1 mg/dL. No organism or malignancy cell was detected. Abdominal ultrasonography found stable-sized heterogeneous hypoechoic fluid at right perihpatic region and unchanged liver masses. The final diagnosis was bilothorax secondary from subdiaphragmatic biloma resulted from small bile duct injury, which might occur spontaneously during HCC rupture or after TACE procedure. Pleural and biloma drainage was not performed by three reasons; pleural fluid was sterile, the patient had no respiratory distress, and there was no evidence of ongoing bile leakage from liver that might further accumulate into pleural cavity. Therefore, we conservatively treated by giving oxygenation and breathing exercise. Pembrolizumab was prescribed for HCC treatment. Follow-up chest radiography at 6 weeks revealed complete resolution of bilothorax.

Conclusion: Bilothorax in patients with HCC rupture is extremely rare but could be treated conservatively.

Abstract Submission No. 101091
P-1107

Title: An Uncommon Instance of Liver Abscess Attributable to Dual Organisms.

Yumna Shahid1, Masood Karim1, Om Parkash1
1Aga Khan Hospital Karachi Karachi Pakistan

Introduction: Liver abscesses are primarily divided into amebic or pyogenic. Pyogenic liver abscesse(PLA) accounts for 2.3 cases per 100,000. Most common pathogens are E.coli, Klebsiella, Streptococcus. Pseudomonas aeruginosa liver abscess (PALA) is a rare occurrence. Tayal et al described in his study that Amebic Liver Abscess can be complicated by pyogenic organisms. We present a unique case of liver abscess instigated by the coexistence of Entamoeba and Pseudomonas.

Case: 59 years old female presented with high grade fever and abdominal pain. She was found to have cholangitis secondary to choledocholithiasis. ERCP revealed a CBD stone which was removed, followed by placement of plastic biliary stent. Post ERCP patient did not improve and stayed febrile. Clinical parameters kept worsening. CT Scan abdomen showed large abscesses in both lobes of liver. Largest abscess in right lobe measured 91x75x93mm. U/S guided drain was placed and aspirates were sent for culture which showed Pseudomonas Aeruginosa. Meanwhile Amobic IHA levels sent earlier also came positive. Patient was started on Meropenem, Daloxamide furoate and IV Meropenem.

Discussion: The incidence of PALA is around 2-6%. There have been few case reports in which Pseudomonas was isolated from liver abscesses post ERCP. In our case it could be a possibility that Pseudomonas was inoculated during ERCP, which caused super infection over already ongoing ALA. To the best of our knowledge co-infection of Pseudomonas and ALA has never been reported before. It is important to consider the possibility of rare organisms and sending cultures to start pertinent antibiotic. The crucial factor lies in timely diagnosis and management.

Abstract Submission No. 101163
P-1108

A case of HCC in which MWA was performed under ultrasound and laparoscopic guidance

YUKI TOKUDA1, NOBAYUKI TATSUMI1, SHOGO NAGAHAMA1, AKIRA KANEKO2
1Japan Community Health care Organization Osaka Hospital Osaka Japan

Ultrasound sonography (US)-guided microwave ablation (MWA) for hepatocellular carcinoma (HCC) near the gallbladder carries the risk of gallbladder perforation and may result in insufficient ablation. Here, we report a case in which local recurrence occurred after US-guided MWA, and laparoscopic MWA was performed at the surgery. The case is a man in his 70s. He is being treated for MAFLD (metabolic dysfunction associated fatty liver disease). The first HCC appeared in 2012. He underwent hepatic arterial chemoembolization (TACE) in 2012, 2014, and 2019. There was a recurrence near the TACE treatment site and near the gallbladder bed on S5/8 of 2019, and US-guided MWA was performed in April 2022. Additional US-guided MWA was performed due to insufficient catureization. Subsequently, EOB-MRI in August revealed a small residual lesion near the ablation site. Since the tumor was located near the gallbladder bed, further US-guided MWA was judged to be dangerous, and a surgical referral was made for laparoscopic S5 partial resection of the liver and removal of the gallbladder. Laparoscopic MWA was performed instead of partial resection because the patient had undergone surgery for gastric cancer, and the lesion site was unclear due to adhesion between the lower surface of the liver and the omentum, making it difficult to remove the tumor. There has been no recurrence after surgery. Although it is often difficult to select a treatment method for patients with multiple recurrences, we believe that if possible, a treatment method that leads to local radical cure should be selected.

Abstract Submission No. 101660
P-1109

A case of multiple HCC in which good control was obtained by Atezo/Bev and heavy ion radiotherapy

KEITA MAKI1, Fumiya Suzuki1, Tomohiro Katsumi1, Kyoko Hoshikawa1, Hiroaki Haga1, Yoshiyuki Ueno1
1Japan Community Health care Organization Osaka Hospital Osaka Japan
Cholecystitis as a Rare Extra-medullary Manifestation of Acute Myeloid Leukemia: A Case Report

Muhammad Bilal Saifulhaq1, Tohari Amin1, Syifa Mustika2, Shinta Oktya Wardhani3

1Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia, 2Gastroenterology and Hepatology Division of Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia, 3Hematology-Oncology Division of Internal Medicine Department, Saiful Anwar Regional Hospital, Brawijaya University Malang Indonesia

Background: Extra-medullary disease can be observed in patients with Acute Myeloid Leukemia (AML), including leukemic involvement of the gastrointestinal tract, although infiltration of the gallbladder is a rare occurrence. Recognizing the disease entity is essential for diagnostic workup and identifying the etiology.

Methods: We report a rare case of AML in the form of extramedullary infiltration of the gallbladder in a 56-year-old male patient.

Results: A 56-year-old male, presenting with worsening diarrhea, intermittent nausea and vomiting, fever, right upper quadrant pain, and decreased oral intake in last two weeks. Laboratory investigations revealed pancytopenia (hemoglobin 98 g/L [120–160 g/L], platelets 31 × 10^9/L [150–400 × 10^9/L], WBC 1.1 × 10^9/L [4.0–11.0 × 10^9/L] with 0% blasts) with elevated total bilirubin of 26.2 μmol/L [≤22 μmol/L]. Abdominal USG showed cholecystitis more likely caused by leukemic infiltration. He was diagnosed with AML-M5 from bone marrow biopsy (10–12% blasts) and peripheral blood smear (5–6% blasts). Empiric treatment with antibiotics showed unsuccessful and open cholecystectomy was then performed. Histopathological examination exhibited transmural infiltration by atypical mononuclear cells with dissimilar nuclei and cells immunohistochemically staining indicated AML-M5.

Conclusions: This case highlights the importance of maintaining a high index of suspicion of atypical manifestations of AML.
comprehensive treatment of variceal bleeding until resolved and stable condition, the patient showed clinical and laboratory improvement following steroid administration.

**Conclusion:** Only a few were known about the possibility of cirrhosis hepatitis causing MDS or vice versa. One of the possibilities is that the autoimmune condition directly causes MDS, and intrahepatic extra-medullary hematopoiesis, respectively which may be overlapping and difficult to determine.

**Abstract Submission No. 101936**

**P-1113**

**Role of serum autotaxin in the diagnosis of Intrahepatic Cholestasis of Pregnancy (ICP)**

Kumiko Fukami1, Tsuneco Kitamura1, Shingo Ogiwara1, Yusuke Nomoto1, Shinjiro Nishi1, Yoichi Nakatsu1, Hiroki Okawa1, Shintaro Yano1, Haruka Hagiwara1, Hirotaka Ishino1, Koyo Yoshida2, Shintaro Makino2, Taro Osada1, Yuka Hirasawa1

1Gastroenterology, Juntendo University Urayasu Hospital Urayasu Japan, 2Obstetrics and Gynecology, Juntendo University Urayasu Hospital Urayasu Japan

Intrahepatic Cholestasis of Pregnancy (ICP) is the hepatic disorder related to the second/third trimester of pregnancy, which is characterized by pruritus with elevation of serum bile acid concentrations and liver enzymes in the absence of other systemic hepatobiliary disorders. The etiology is multifactorial and may be linked to increasing estrogen levels in pregnancy as well as altered expression of hepatobiliary transport proteins. Incidence of ICP is different between ethnic groups depending on the geographical region: 0.4 – 1% of pregnancies in North America and Western Europe, but 1.5–4% of pregnancies in Asia, Africa and South America. Although ICP is a rare disease in Japan, recent studies suggest that serum ATX may be a reliable circulating biomarker to diagnose ICP. In this study, we report the patient who is a 39-year-old female in the 22nd week of gestation with pruritus, jaundice, and abnormal liver function tests. The patient presented with elevated serum concentrations of ATX (11.5 mg/L [< 1.27]) as well as total bile acids (268.5 μmol/L [< 10]), and ursodeoxycholic acid (UDCA) was effective in ameliorating symptoms and liver function tests. The elevated serum concentrations of ATX were normalized immediately after delivery. The measurement of serum ATX may thus help diagnose ICP in areas where the incidence of ICP is not prevalent.

**Abstract Submission No. 100322**

**P-1115**

**The effect of embolization of the portosystemic shunt on the long-term clinical course in cirrhosis**

Kentaro Fujimoto1, Takayuki Kondo1, Kisako Fujiwara1, Naoya Kato1, Kazufumi Kobayashi1, Soichiro Kiyono1, Masato Nakamura1, Naoya Kanogawa1, Sadahisa Ogasawara1, Shingo Nakamoto1, Jun Kato1, Hitomi Uozawa1, Keisuke Koroki1, Masanori Inoue1

1Chiba University Graduate School of Medicine Chiba Japan

**Background:** Evidence-based Clinical Practice Guidelines for Liver Cirrhosis weakly recommend Balloon-occluded Retrograde Venous Obliteration (BRTO) for the prevention of rebleeding of gastric varices or hepatic encephalopathy of portosystemic shunt, and the indications for treatment are not well defined. Therefore, we compared overall survival and incidence of adverse events in liver cirrhotic patients treated with or without BRTO.

**Methods:** In this study, 492 cirrhotic patients with a portosystemic shunt with a diameter of 6 mm or larger who underwent Doppler ultrasonic from 2007 to 2022 were included. The overall survival and the incidence of gastrointestinal bleeding, hepatic encephalopathy, portal vein thrombosis, infection, and ascites were compared between patients who treated with or without BRTO.

**Results:** A total of 428 patients who did not receive BRTO and 64 patients who received BRTO were included in the study. There was no difference in liver functional reserve. There was no difference in overall survival and the cumulative incidence of ascites, infection, portal vein thrombosis, gastrointestinal bleeding. However, the cumulative incidence of hepatic encephalopathy decreased after BRTO (BRTO treated group vs BRTO untreated group: 3.4% at 1 year vs. 13.1% at 1 year; p < 0.01).

**Conclusion:** BRTO may be effective in reducing hepatic encephalopathy. However, considering that embolization does not necessarily improve OS, further careful consideration is needed in the selection of patients who are candidates for BRTO.
Neutrophil/lymphocyte and MPV/platelets ratios can predict cirrhosis decompensations

Elio Mikhail1, Chadi Hage Chehade1, Rita Slim1, Celina Doueihy1, Lamis Amer1, Melissa Khanfour1, Santa El Helou1, Joseph Amara1, Eid Mahfouz1, Khalil Honein1, Cesar Yaghi1
1Saint-Joseph University of Beirut Beirut Lebanon

Background: In liver disease, inflammatory markers on a complete blood count (CBC) can predict liver fibrosis, but their role in predicting cirrhosis decompensation remains unclear. The aim of our study is to establish this association.

Methods: Our study population (n=206) was divided in three: 73 decompensated cirrhosis, 63 compensated cirrhosis, and 70 controls (no history of liver disease). Decompensations included variceal bleeding, ascites, hepatic encephalopathy, and spontaneous bacterial peritonitis. Mean values of CBC markers including red cell distribution width (RDW), mean platelet volume (MPV), and the MPV/platelet, lymphocyte/neutrophil ratios were compared among subgroups. For decompensated patients, mean values at cirrhosis and decompensation diagnoses were compared.

Results: The mean age was 72.0 ± 15.5 years old, with 112 (54.4%) male patients. Decompensated cirrhotics had higher mean RDW (p=0.002) and mean MPV/platelets (p=0.017), and neutrophils/lymphocytes (p=0.001) ratios compared to compensated cirrhotics and compared to controls (p=0.001 for these parameters). Compensated cirrhotics had a higher mean MPV/platelets ratio (p=0.001) than controls.

Table 1 shows a comparison between CBC markers at the time of cirrhosis and decompensation diagnoses. A neutrophil/lymphocyte ratio greater than 3 had an area under the curve (AUC) of 0.716 with an odds ratio (OR) for decomposition of 9.4 (95%CI 5.7-15.4) during a mean follow-up of 34.8 months. An MPV/platelets ratio greater than 0.5 had an AUC of 0.652, predicting decomposition with an OR of 9.4 (95%CI 5.7-15.4) during a mean follow-up.

Conclusion: Neutrophil/lymphocyte and MPV/platelets ratios can predict cirrhosis decompensations, suggesting their potential integration into a predictive decompensation score pending confirmation through prospective studies.

Fracture Risks Among Filipinos with Liver Cirrhosis Using Fracture Risk Assessment Tool Scoring.

Patrick Michael Roslyn1, Michael Chu1, Lovell Gatchalian1
1East Avenue Medical Center Quezon City Philippines

Background: Patients with liver cirrhosis are at risk for developing malnutrition-associated fractures. This study compared the major osteoporotic and hip fracture risks of cirrhotic patients to the general population using the Fracture Risk Assessment Tool (FRAX) without Bone Mineral Density testing.

Method: This is a prospective study that included 172 patients (86 patients with cirrhosis and 86 non-cirrhotic patients). Comparison of variables between groups was performed using independent t-test for continuous variables and Fisher’s Exact test for categorical variables. Kruskal-Wallis test was conducted to compare osteoporotic and hip fracture risks by severity and etiology of cirrhosis. Univariable and multivariable linear regression analysis were performed. P value < 0.05 was considered statistically significant.

Results: In this study, chronic hepatitis B (38%) was the leading etiology of cirrhosis. Majority were classified as CTP-C (53%) with median MELD score of 20.5. Patients with cirrhosis had significantly lower BMI, hemoglobin, platelet count, sodium, and albumin levels compared to the healthy population. Osteoporotic and hip fracture risk was significantly higher in the cirrhotic group (p value <0.00001 ). No significant difference in osteoporotic fracture risk by etiology and severity of liver cirrhosis (p value 0.240). Univariable analysis showed osteoporotic risk was 1.73 times higher among MAFLD compared to patients with alcoholic liver disease. For every unit increase in INR, osteoporotic risk decreased by 0.98.

Conclusion: Liver cirrhosis was associated with increased risk of osteoporotic and hip fractures. No significant difference seen in the risk of fracture with regards to severity and etiology of cirrhosis. Meanwhile, osteoporotic risk was higher among patients with MAFLD than ALD.

The Effectiveness of TIPS + E in Reducing Rebleeding and HE: A Real-World Data Validation Study

Qian Li1, Guangchuan Wang2, Jun Tie1, Hao Wu1, Yuzheng Zhuge3, Hui Xue4, Wei Wu2, Chunqing Zhang1, Lianhui Zhao5
1Department of Gastroenterology, Shandong Provincial Hospital, Shandong University Jinan China, 2Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China, 3National Clinical Research Centre for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University Xi’an China, 4West China Hospital, Sichuan University Chengdu China, 5Nanjing Medical University Drum Tower Clinical Medical School and Department of Gastroenterology, Affiliated Drum Tower Hospital of Nanjing University Medical School Nanjing China, 6First Affiliated Hospital of Xi’an Jiaotong University Xi’an China, 7First Affiliated Hospital of Wenzhou Medical University Wenzhou China, 8Department of Infectious Disease, Qilu Hospital, Cheeloo College of Medicine, Shandong University Jinan China

Objectives: The efficacy of transjugular intrahepatic portosystemic shunt (TIPS) plus extrahepatic collateral embolization (TIPS + E) in reducing rebleeding and post-TIPS hepatic encephalopathy (HE) was recently reported in a meta-analysis, but further validation is essential. This study aims to confirm the effectiveness of TIPS + E using real-world data.

Methods: The multicenter retrospective cohort included 2077 cirrhotic patients who underwent TIPS ± E (TIPS: 631, TIPS + E 1446) between January 2010 and December 2022. Regression and propensity-score methods (PSM) were used to adjust for baseline characteristics differences. After PSM, clinical outcomes, including rebleeding, HE, survival and further decompensation (FDC), were analyzed. Baseline data from all patients contributed to the construction of prognostic models.

Results: After PSM, 1136 matched patients (TIPS+E: TIPS = 568:568) were included. TIPS + E demonstrated a significant reduction in rebleeding (HR 0.77; 95%CI 0.59, 0.99; p = 0.04), HE (HR 0.82; 95%CI 0.68, 0.99; p = 0.04) and FDC (HR 0.85; 95%CI 0.73, 0.99; p = 0.036), comparing to TIPS. Notably, TIPS + E also significantly reduced rebleeding, HE and FDC in subgroup of using 8mm- diameter stents and embolizing of gastric varices + spontaneous portosystemic shunts (GV + SPSS). However, there were no differences in overall or subgroup survival analysis. Additionally, the random forest models showed moderate predictive value in prognostic models with accuracy of 0.80-0.85 and AUROC of 0.71-0.89. Controlling post-TIPS portal pressure
gradient (pPPG) within 7mmHg<pPPG<8.5mmHg improved prognosis, especially in TIPS+E group.
Conclusion: Our real-world data validation confirms the high efficacy of TIPS + E in reducing rebleeding and HE, particularly when using 8mm diameter stents, embolizing GV + SPSS, and maintaining an optimal pPPG.

Abstract Submission No. 101698
P-1119

The Therapeutic Strategy for Patients Developing Covert Hepatic Encephalopathy Based on Zinc Levels
Yoshimoto UCHIDA1, Naoto SOMA1, Nobuaki NAKAYAMA1, Suguru MIZUNO2, Satoshi MOCHIDA1
1Department of Gastroenterology & Hepatology, Saitama Medical University Moroyama-cho, Iruma-gun, Saitama Japan

Aim: We previously reported that patients with liver cirrhosis showing zinc deficiency were recommended to maintain a serum zinc level of ≥50 μg/dl through zinc supplementation to prevent overt hepatic encephalopathy (OHE) development. In this study, the significance of serum zinc levels in diagnosing and treating covert hepatic encephalopathy (CHE) were evaluated.

Methods: A total of 99 cirrhotic patients without a history of OHE were enrolled. CHE was defined as scoring above the age-based cutoff value in the Stroop test (NP-test iPad version 3.1). Sarcopenia (JSH, second edition) was evaluated through grip strength and muscle mass measurements (InBody S10).

Results: CHE was observed in 44 patients (44%) and sarcopenia occurred in 23 patients (23%). The multiple logistic regression analysis identified serum zinc levels (per-1 μg/dl, OR 0.95, P=0.0004) as the only risk factor associating with CHE, with a cutoff value of 58 μg/dl. (AUC 0.86, P=0.0001). Blood ammonia levels and sarcopenia were not involved in presence of CHE. During a median observation period of 212 days, OHE developed in 10 patients (10%). The Cox proportional hazard model identified presence of CHE at a factor associated with OHE development (OR 5.46, P=0.0322).

Conclusion: Cirrhotic patients without a history of OHE exhibit a high risk of developing CHE if serum zinc levels are below 58 μg/dl regardless of blood ammonia levels. These patients are at a high risk of developing OHE in the short term, and early zinc supplementation are recommended for prevention of OHE development.

Abstract Submission No. 102019
P-1121

Comparison of Prognostic Models for post-TIPS Outcomes: Machine Learning VS Traditional methods
Qian Li1, Anbang Chen1, Chunqing Zhang1,2, Lianhui Zhao2, Guangchuan Wang3
1Department of Gastroenterology, Shandong Provincial Hospital, Shandong University Jinan China, 2Department of Infectious Disease, Qilu Hospital, Cheeloo College of Medicine, Shandong University Jinan China, 3Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

Objectives: Following Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures, a prolonged asymptomatic phase approaching recompensation is commonly observed. This study aims to define “pseudo” recompensation as the absence of liver cirrhosis-related complications within 1-year post-TIPS and presents a comparative analysis of prognostic models for TIPS outcomes, employing both machine learning and traditional statistical approaches.

Methods: A total of 234 cirrhotic patients underwent TIPS between January 2014 and June 2022, with a median follow-up time of 39.8 (24.6, 65.2) months. Prognostic models using Random Forests (RF), Support Vector Machines (SVM), Artificial Neural Networks (ANN), and Logistic Regression (LR) were constructed to predict outcomes, including recompensation, rebleeding, hepatic encephalopathy, ascites, and overall survival.

Results: The RF models exhibited significantly higher predictive value across all outcomes, with accuracy ranging from 0.73 to 0.85, precision from 0.73 to 0.87, recall from 0.74 to 0.84, F1 score from 0.74 to 0.84, and AUC from 0.75 to 0.82. Top 10 variables in the RF model, ranked by feature importance, included international normalized ratio, albumin, creatinine, extent of prothrombin time, portal pressure gradient (PPG), decline proportion of PPG, bilirubin, age, sodium, and hemoglobin. Subgroup analysis identified patients with ePT > 3 + MELD score ≥20(calculated by INR, Cr, and TBIL), accounting for 88.2% of post-TIPS secondary recompensation.

Abstract Submission No. 102015
P-1120

TIPS in Decompensated Cirrhosis: Unraveling the Dynamics of Post-TIPS Stable State and Recompensation
Qian Li1, Anbang Chen1, Lianhui Zhao2, Chunqing Zhang1,2, Yifu Xia1, Guangchuan Wang3, Guangjun Huang3, Zhen Li3
1Department of Gastroenterology, Shandong Provincial Hospital, Shandong University Jinan China, 2Department of Infectious Disease, Qilu Hospital, Cheeloo College of Medicine, Shandong University Jinan China, 3Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan China

Background: To investigate the survival benefits in decompensated cirrhotic patients undergoing Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures who met the Baveno VII criteria for recompensation.

Methods: 91 patients receiving etiological treatment (antiviral/alcohol cessation) and TIPS procedures were retrospectively analyzed with a median follow-up time of 32.5 (18.1, 42.1) months, from December 2016 to July 2022. Recompensation and further recompensation were defined based on Baveno VII criteria combined with liver function criteria from a validation study (PMID: 36038017), while post-TIPS stable state was defined as no clinical manifestations within 1 year after TIPS.

Results: Out of 91 patients, 65 (71.4%) achieved stable, 35 (38.5%) achieved recompensation, and 26 suffered further decompensation. Patients with further decompensation had significantly higher mortality compared to those in stable (P=0.002; HR 4.71, 95% CI 1.46 to 15.19) or recompensated groups (P=0.004; HR 6.79, 95% CI 2.03 to 22.70). While no significant survival differences were observed between stable and recompensated patients, the recompensated group showed a trend towards liver function improvement (valued by Child-Turcotte-Pugh score decrease ≥2 or grades decreased).

Conclusion: In our study, TIPS procedures might bring about stable states or recompensation in over 70% of patients with decompensated liver cirrhosis. However, the survival benefits observed in patients achieving stable or recompensation within 1 year post-TIPS may not necessarily originating from improved liver function. Risk factors of survival of patients in stable or recompensated after TIPS require further exploration.
Conclusion: This study highlights the superior predictive capabilities of RF in modeling TIPS outcomes, contributing to the advancement of precision medicine in portal hypertension interventions.

Abstract Submission No. 102029
P-1122

Impact of sex on 10-year survival of cirrhosis patients: a cohort study of 15,876 U.S. patients

Ashley Fong1, Joanne K. Liu1, Vy H. Nguyen1,2, Isaac Le3, Annie Fung2, Kee Seok Lee3, Surya T. Gudapati3, Sally Tran3, Angela Chau4, Leslie Kamb5, Xinrong Zhang1, Jung Eun Park2, Catherine Hand2, Ramsey Cheung4, Mindie H. Nguyen4
1Division of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, CA, USA Palo Alto United States, 2Harvard Medical School Boston United States of America, 3Long School of Medicine San Antonio United States of America, 4Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System Palo Alto United States of America, 5Department of Epidemiology and Population Health, Stanford University School of Medicine Palo Alto United States of America

Background: Data on the impact of sex on long-term survival rates of patients with cirrhosis are limited. We aimed to fill this gap.

Methods: This retrospective cohort study included 15,876 consecutive patients with cirrhosis (2000-2022) at a U.S. center. Cirrhosis was defined by the presence of cirrhosis morphology on imaging or histology or noninvasive test showing stage 4 fibrosis, coupled with the presence of a chronic underlying liver disease.

Results: This cohort included 59.1% males (N=9379) and 40.9% females (N=6497). Females were slightly older than males (59.2±13.7 vs. 58.0±12.8, p<0.0001). No significant differences found between racial/ethnic distribution between the sexes. Female patients were more likely to have non-viral etiology compared to males (68.9% vs. 56.3%, p<0.001). Males were twice as likely to present with HCC (39.6% vs. 22.9%, p<0.001). Overall, survival rates were significantly lower for male compared to female patients with 5- and 10-year cumulative survival rates (61.79% vs. 67.89% and 43.49% vs. 50.26%, respectively). The disparities were consistent across age, race and ethnicity, liver disease etiology and subgroups (Figure 1A/B). On multivariable Cox regression analysis adjusted for sex, age, race and ethnicity, cirrhosis diagnosis year, and liver disease etiology (Table 1), the disparities were consistent across age, race and ethnicity, liver disease etiology and time period, male patients with cirrhosis had poorer 10-year survival rates compared to females. Male sex was independently associated with 20% higher risk overall.

Conclusion: Male sex was independently associated with 20% higher risk overall.

Abstract Submission No. 200024
P-1124

Transient Elastography for the prediction of Esophageal Varices in Egyptian Cirrhotic Patients

Rania Elkafoury1, Abdelrahman Abdelraouf Kobtan1, Hanan Hamed Soliman1, Raafat Abdelkader Salah1
1Tropical medicine and infectious diseases department, Faculty of medicine, Tanta University Tanta Egypt

Background: Esophageal varices (EVs) are atypically dilated submucosal veins, which occurs consequently to portal hypertension. Liver stiffness measurement (LSM), obtained by transient elastography (Fibroscan), strongly correlates with portal hypertension.

Aim: To predict the presence and grading of esophageal varices in Egyptian patients with liver cirrhosis using Fibroscan and other non-invasive tests.

Methods: A 101 cirrhotic patients indicated for upper endoscopy were enrolled consecutively and subdivided according to endoscopic findings into: Group I (70 patients with EVs) and Group II (31 patients without EVs). Upper endoscopy, ultrasonography, routine lab. and Fibroscan assessment were done to all patients.

Results: LSM correlated directly and significantly with the presence (p<0.001), and grading of EVs (p=0.001). A LSM cut off value of 18.55 kPa had an AUC of 0.726, sensitivity of 74.3%, specificity of 54.8%, PPV of 78.79%, and a NPV of 48.57% for predicting the presence of EVs. Platelet count/spleen diameter ratio (PSR) inversely correlated with the EVs presence (p=0.002), and grading (p<0.001). PSR had a cut off value of 54.8%, sensitivity of 71% and a specificity of 58.6% (PPV of 82%, NPV of 43.14%) for EVs presence. Right lobe diameter/Albumin ratio (RLAR) correlated directly with EVs presence (p=0.001), and grading (p=0.012). RLAR cut off value of 3.62 had AUC, sensitivity, specificity, PPV, and NPV...
of 0.7, 64.3%, 67.7%, 81.8%, and 45.7%, respectively, for the prediction of EVs presence.

Conclusion: LSM, PSR, RLAR as noninvasive methods for predicting the presence and grading of EVs are of moderate accuracy.

Abstract Submission No. 200038
P-1125

Validation of the EncephalApp Stroop test for minimal hepatic encephalopathy in cirrhotics

Irina Girleanu1, Laura Huiban1, Cristina Muzica1, Ana Maria Singeap1, Camelia Cojocaru1, Catalin Sfarti1, Sebastian Zenovia1, Remus Stafie1, Adrian Rotaru1, Ermina Stratina1, Robert Nastasa1, Oana Petrea1, Anca Trifan1, Carol Stanciu1
1Grigore T Popa University of Medicine and Pharmacy Iasi Romania

Background and Aims: The diagnostic of minimal hepatic encephalopathy (MHE) is still under debate, and point-of-care tests are needed. Until now Stroop EncephalApp test has been validated for MHE diagnosis in United States, China and Korea. The aim of the study was to validate EncephalApp Stroop test for MHE diagnosis in a Romanian cirrhotic population.

Methods: In this study we included cirrhotic patients without prior hepatic encephalopathy (HE) and controls without liver cirrhosis. All of them EncephalApp Stroop test and psychometric hepatic encephalopathy score (PHES). The normative data of PHES in the Romanian population were used for MHE diagnosis.

Results: A total of 78 cirrhotics (mean age 56.3±10.4 years, mean MELD score 12.4±3.4) and 78 controls (mean age 51.54±2.4 years) were included in the study. The prevalence of MHE based on PHES was 23.1%, and it was in direct correlation with the severity of liver cirrhosis (LC). The Onset Time Stroop test had the highest sensitivity (77.7%) and specificity (80%) for MHE diagnosis in cirrhotic patients, with an AUC of 0.789 and a cutoff of 148 seconds (P<0.001, confidence interval 0.629-0.903).

Conclusions: The EncephalApp Stroop test has a good validity for the diagnosis of MHE, and can be easily used in daily clinical practice for Romanian cirrhotic population MHE evaluation.

Abstract Submission No. 200205
P-1126

Impact of Sarcopenia on the Presence High-Risk Variceal Esophagus in Cirrhotic Patients

Iwandhenny Sepmeitu1, Juferdy Kurniawan1, Hasan Maulahela2, Ikhwan Rinaldi3, C. Rinaldi A. Lesmana1, Rudy Hadaya1, Purwita Wijaya Laksmi3, Hamzah Shatri3
1Hepatobiliary Division, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia DKI Jakarta Indonesia; 2Division of Gastroenterology, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia DKI Jakarta Indonesia; 3Hamatology and Medical Oncology Division, Internal Medicine Department, Cipto Mangunkusumo National General Hospital, Faculty of Medicine, Universitas Indonesia DKI Jakarta Indonesia

Background: The high prevalence of sarcopenia in chronic liver disease has a negative impact on the quality of life and the susceptibility to various complications of cirrhosis, including esophageal varices. The aim of this study was to determine the prevalence of sarcopenia in cirrhotic patients and explore its association with high-risk esophageal varices stratified by Child-Pugh.

Methods: An observational cross-sectional study included patients with liver cirrhosis in Cipto Mangunkusumo Hospital between January to September 2023. Sarcopenia is defined by a reduction in muscle mass combined with decreased grip strength or walking speed, in accordance with the AWGS 2019 criteria (Asian Working Group for Sarcopenia). Multivariate logistic regression was conducted to evaluate the association of sarcopenia and high-risk esophageal varices.

Results: A total of 155 liver cirrhosis patients were included in this study. In this study, 74.2% of liver cirrhosis patients were male, with an average age of 53.3 ± 9.7 years. Hepatitis B was the most prevalent etiology (77.4%). Most patients had Child-Pugh A classification (80.6%), followed by Child-Pugh B (16.8%) and Child-Pugh C (2.6%). Sarcopenia was found in 89 patients (57.4%). In multivariate analysis showed that the presence of sarcopenia in liver cirrhosis patients has significant statistical implications in increasing the risk of high-risk esophageal varices, particularly in those classified as Child-Pugh B and C (AOR = 7.50 (CI 95%: 1.48 – 37.91, p=0.030)). However, no association was found between sarcopenia and high-risk esophageal varices in the sub group Child-Pugh A (AOR = 1.46 (CI 95%: 0.65 – 3.29, p=0.477)).

Conclusion: Sarcopenia significantly increase the risk of high-risk esophageal varices in liver cirrhosis, especially in those with Child-Pugh B and C classification.

Keyword: Sarcopenia, variceal esophageal, liver cirrhosis

Abstract Submission No. 100069
P-1127

Extracellular vesicles derived from injured hepatocyte cooperate with macrophage to promote fibrosis

jie sun1, Xiaoli Fan1, Yi Shen1, Li Yang1
1West China Hospital, Sichuan University Chengdu China

Background: Massive deposition of extracellular matrix such as collagen is the main mechanism of liver fibrosis, in which activated hepatic stellate cells are key cells for the generation of fibrous tissue. Some reports have suggested that extracellular vesicles play an important role in intercellular communication. Therefore, this study aims to investigate the role of extracellular vesicles derived from carbon tetrachloride-treated hepatocytes in liver fibrosis.

Methods: In vivo: Inhibition the production of extracellular vesicles. Carbon tetrachloride (ccl4) was dissolved in olive oil and intraperitoneally injected for 1ml/kg with 3W to induce hepatic fibrosis in mice. The same volume of olive oil was used as the control. EVs inhibitor GW4869 was intraperitoneally injected after carbon tetrachloride injection. In vitro: Extracellular vesicles(EVs) from normal hepatocytes and ccl4-treated hepatocytes (AML12) were extracted. Hepatic stellate cells were treated with EVs or EVs-macrophage (RAW264.7) conditioned medium (Con).

Results: 1. In vivo injection of GW4869 inhibited ccl4-induced liver fibrosis. (Figure1)
2. EVs released by control hepatocytes (ctrl-EVs) and ccl4-treated hepatocytes (ccl4-EVs) failed to promote the activation of hepatic stellate cells. (Figure 2)
3. EVs released by ccl4-treated hepatocytes enhanced the expression of fibrotic factors and inflammatory factors in macrophages. (Figure 3)
4. EVs released by ccl4-treated hepatocytes cooperated with macrophages to promote the activation of hepatic stellate cells. (Figure 4)

Conclusion: Extracellular vesicles released by ccl4-treated hepatocytes cooperate with macrophages to promote the activation of hepatic stellate cells.

Abstract Submission No. 100238
P-1128

The effect and mechanism of empagliflozin on CCL4-induced hepatic fibrosis

Fushuang Ha1, Tao Han1, 2, Junqing Yan1, Junjun Cai3
1 The Third Central Clinical College of Tianjin Medical University Tianjin China, 2 Tianjin Union Medical Center, Naikai University Affiliated Hospital Tianjin China

Objective: To observe the effect of empagliflozin on hepatic fibrosis model mice induced by carbon tetrachloride (CCL4).

Methods: The mice were divided into normal control group, CCL4 group and empagliflozin group. The liver function, abdominal insulin tolerance test, serum cytokine levels, activity of oxidative stress enzymes of each group was analyzed.

Results: There was no significant difference in the ratio of average liver weight to body weight among 3 groups. After CCL4-induced hepatic fibrosis model, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were significantly increased, but there was no significant difference between empagliflozin group and CCL4 group. In the insulin tolerance test, it was shown that the blood sugar of mice in the empagliflozin group was almost stable among the three groups. Empagliflozin group showed lower diffuse necrosis of liver cells by HE staining and alleviative fibrosis by quantitative analysis of Sirius red staining. The liver tissue activity of superoxide dismutase, malondialdehyde, catalase and glutathione peroxidase in the empagliflozin group were lower than in the normoglycemic group. Compared with hepatic fibrosis group, the number of Keap1-positive cells in empagliflozin group was further reduced.

Conclusion: Empagliflozin did not cause liver function deterioration and hypoglycemia in CCL4-induced hepatic fibrosis mouse model. Empagliflozin can reduce the degree of diffuse necrosis and liver fibrosis in CCL4-induced liver fibrosis mice, and the mechanism may be related to the reduction of oxidative stress in liver tissue by empagliflozin through Keap1-NF2 signaling pathway.

Abstract Submission No. 100927
P-1129

Dysregulation of the PUM1 aggravates liver fibrosis in nonalcoholic steatohepatitis

Zhiping Wan1, 2, Xiaquan Liu1, 2, Xiaoman Chen1, 2, Xiaolan Yang1, 2, Hong Deng3
1 Department of Infectious Diseases, the Third Affiliated Hospital, Sun Yat-sen University Guangzhou China, 2 Guangdong Provincial Key Laboratory of Liver Disease Research, the Third Affiliated Hospital, Sun Yat-sen University Guangzhou China

Background: Liver fibrosis is a worrisome feature of nonalcoholic steatohepatitis (NASH). However, the mechanism of liver fibrosis in NASH remains unclear. We explored the role of PUMILIO proteins in NASH-related liver fibrosis.

Methods: Two isoforms of PUMILIO proteins (PUM1, PUM2) expression were analyzed in NASH patients and models. A choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) and a western diet combined with intraperitoneal carbon tetrachloride (WD+CCL4) were used to induce NASH-related liver fibrosis in mice. Adeno-associated virus type 8 carrying Pum1 shRNA were injected into the tail vein to downregulate PUM1. RNA sequencing was used to analyze gene expression profiles after downregulation of PUM1. Hepatic stellate cells (HSCs) were transfected with plasmids or siRNA to upregulate or downregulate the expression of PUM1 and its target genes.

Results: We found that the level of PUM1, not PUM2, was reduced in both NASH patients and models. The level of PUM1 was significantly negatively correlated with liver weight, liver index, and degree of liver fibrosis. Downregulation of PUM1 in the liver aggravated liver damage and fibrosis in two models of NASH-related liver fibrosis mice. We further found that the expression of PUM1, but not PUM2, was reduced in activated HSCs. Downregulating the expression of PUM1 in HSCs promoted the activation of HSCs. RNA sequencing analysis and various experiments demonstrated that tropomyosin 4 gene (Tpm4) was a target gene of PUM1. Importantly, PUM1 regulated HSCs activation via regulating Tpm4 expression.

Conclusions: PUM1 is dysregulated in NASH progression, leading to HSCs activation and aggravating liver fibrosis.

Abstract Submission No. 101659
P-1130

Constructing an in vitro model of liver fibrosis using tissue engineering liver

Long Huang1, Min Cong2, Xu Fan3
1 18561390078 Beijing Friendship Hospital, Capital Medical University China, 2 Beijing Friendship Hospital, Capital Medical University Beijing China, 3 Beijing Friendship Hospital, Capital Medical University Beijing China

Objective: To generate an in vitro 3D liver fibrosis model incorporating cells representing key players in fibrotic liver using a decellularized scaffold and to assess its response to fibrogenic compounds.

Methods: HepG2, SK-hep1 and LX-2 were co-cultured on a decellularized rat liver scaffold, which was treated with fibrogenic compounds (TGF-β1 or CC4) for up to 9 days. The validity of the in vitro liver fibrosis model was evaluated by measuring biochemical indicators in the supernatant (AST, ALT, LDH), assessing the deposition and secretion of extracellular matrix proteins and examining the induction of gene expression of fibrosis biomarkers (α-SMA, TIMP-1). Oxidative stress-related indicators (ROS, Nrf2) were also evaluated in this model.

Results: After stimulation with TGF-β1, the 3D liver fibrosis model based on the co-culture system demonstrated superior responsiveness to pro-fibrotic stimuli compared to 2D single culture. We observed increased collagen expression and deposition in the 3D model, along with elevated fibrosis indicators: the HSC activation marker α-SMA and tissue metallopeptase inhibitor TIMP-1. After stimulation with CC4, not only were liver fibrosis markers elevated, but indicators of hepatocellular damage were also increased in the culture supernatant. Additionally, a stronger involvement of oxidative stress-related molecules upon stimulation with CCL4 in the 3D model was observed.

Conclusion: The newly constructed 3D in vitro liver fibrosis model successfully mimics the characteristics of liver fibrosis and can be used...
as a tool to study the mechanisms of liver fibrosis and screen for antifibrotic drugs.

**Keywords:** Liver fibrosis; Tissue engineering liver; Collagen deposition; oxidative stress

---

**Abstract Submission No. 200078**

**P-1131**

**Liver Fibrosis Score Could Predict Carotid Plaque in an Asymptomatic Korean Population**

Kyoung-Jin Park1, Jong-Ho Park2, Duk-Kyung Kim3

1Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon South Korea, 2Samsung Medical Center Seoul South Korea, 3Samsung Changwon Hospital, Sungkyunkwan University School of Medicine Changwon South Korea

**Background:** Early identification of carotid atherosclerosis (CAS) is critical for preventing cardiovascular events at the asymptomatic stage. To date, little study has been performed to predict asymptomatic CAS using liver fibrosis scores in the general Korean population. The aim of this study was to evaluate the performance of the liver fibrosis algorithms to screen CAS in the Korean population.

**Methods:** This study consisted of 19,367 asymptomatic Korean adults who underwent carotid ultrasonography and biochemical testing at a comprehensive health promotion center. The CAS was defined as having carotid plaque, carotid stenosis, and/or increased carotid intima-media thickness (CIMT ≥ 1.0 mm). Hepatic fibrosis indices such as the NAFLD fibrosis score (NFS), Fibrosis-4 (FIB-4), aspartateaminotransferase-to-platelet ratio index (APRI), and BARD score were evaluated.

**Results:** The frequency of individuals with increased carotid intima-media thickness (CIMT), plaque, and stenosis was 2.1% (6,217/19,367), 2.7% (527/19,367), and 0.3% (67/19,367). The FIB-4 showed the highest area under the receiver operating characteristic curve (AUROC: 0.777, 95% CI, 0.735 - 0.745) for carotid plaque, followed by the NFS (0.756), and APRI (0.638), and BARD (0.576). When FIB-4 was used as an indicator for carotid ultrasonography, advanced atherosclerosis was diagnosed in 5% (527/9,272) of the asymptomatic individuals without carotid ultrasonography.

**Conclusions:** This study demonstrated that FIB-4 and NFS can be useful for screening carotid plaque in an asymptomatic Korean population. Liver fibrosis markers such as FIB-4 and NFS could be used indication for carotid ultrasonography in primary clinical or health check-up settings in a cost-effective fashion.

---

**Abstract Submission No. 101267**

**P-1132**

**Metabolomic analysis of bile in liver regeneration after partial hepatectomy in rats**

Hiroaki Haga1, Shinpei Sugahara1, Kyoko Hoshikawa1, Tomohiro Katsumi1, Keita Maki1, Fumiya Suzuki1, Yoshiyuki Ueno1

1Department of Gastroenterology, Yamagata University Faculty of Medicine Yamagata Japan

**Background:** Although liver regeneration has been extensively studied, the relationship between bile and liver regeneration has rarely been examined. In this study, bile from a 70% partial hepatectomy (PH) model was collected over time using a bile duct cannulation rat and metabolomic analysis was performed.

---

**Abstract Submission No. 101470**

**P-1133**

**RAJENDRA BOLLUPALLE1, Jayanthi venkatraman2**

1Global Hospital Chennai India, 2Global hospital Chennai India

**Abstract**

Derangement of liver enzymes as a measure of liver injury is not uncommon in ICU

**Aim:** To determine the incidence of deranged liver enzymes (AST/ALT/ALP/GGT) in a non-liver ICU at admission and to predict 30-day mortality.

**Methods:** Patients admitted in MICU, NeuroICU and CCU, between Jan 2022 to Dec 2022 were included. All patients had liver biochemistry at admission. R factor (RF-C) and COVID criteria (COV-C Type 1 or 2) for liver injury were used to stratify the patients into hepatocellular, cholestatic, and mixed types. Support systems during admission were noted. Patients were followed up until discharge/death.

**Statistical Analysis:** SPSS v26 (IBM Corp.). For descriptive statistics averages and standard deviations for continuous variables, frequencies and percentages for categorical variables. Fisher’s Exact test, if the expected frequency in the contingency tables was < 5 for more than 25% of the cells, p < 0.05 was considered significant.

**Results:** 108 of 246 patients enrolled had abnormal liver tests (43.9%). AST, ALT, ALP and GGT were marginally elevated (<2 times ULN) across all ICUs. 92 (85.2%) patients had a hepatocellular type and 44 (40.7%) had a cholestatic injury. Between the 2 criteria, RF-C was the better of the two. RF-C predicted the need for support in HC-I (p<0.001) and served as a significant predictor of survival (p=0.023).

**Conclusions:** Liver enzymes were < 2 times ULN abnormal in non-liver ICU. RF-C is the best to stratify pattern of liver injury and predicts supportive system and survival.

---

**Abstract Submission No. 100580**

**P-1134**

**Living-donor Liver Transplantation (LDLT) for Lysosomal acid lipase( LAL) Deficiency: A case series**

Keerthivasan Seetharaman1, Mohan B Kasala1, Karanam Perumal1, Mettu Srinivas Reddy1, Joy Varghese1, Nirmala Dheivamani2, Somashekara HR1, Jayanthi Venkataraman1

**Abstract**

Living-donor Liver Transplantation (LDLT) for Lysosomal acid lipase (LAL) Deficiency: A case series
Background and Aim: Late-onset LAL deficiency, also known as Cholesteryl ester storage disease (CESD) is a genetic lysosomal storage disorder, caused by deficiency of LAL due to mutations in the LIPA gene. It is a systemic disease leading to accumulation of cholesteryl ester in the liver, premature atherosclerosis and gastrointestinal disease. Most of the patients require liver transplantation due to decompensated chronic liver disease(DCLD). Previous case series report disease progression and high rates of recurrence following LT.

Methods: We describe 3 children (16 years,10 years, 2 years) with LAL deficiency presenting with DCLD, who underwent living-donor liver transplant (LDLT) successfully and discuss ethical dilemmas in considering LDLT for CESD.

Results: All children presented with abdominal distension since early childhood and had features of DCLD. Liver biopsy showed microvascular steatosis. Work up revealed low levels of LAL (ranging from 2% to 5% of normal activity) suggesting CESD, confirmed by genetic analysis. After detailed discussion with the family regarding risk of recurrence, need of Sebelipase Alpha if recurrence occurs, all three children underwent successful LDLT. At a mean follow up of 25 months (range: 9 to 48), all are well with normal graft function and lipid profile.

Conclusion: Disease recurrence in the allograft and disease progression has been reported after LT for LAL deficiency. However, there are isolated case reports of successful long-term outcomes of LT as seen in our patients. It is likely that our patients had milder phenotype. This is the first case series of LDLT for LAL deficiency.

Abstract Submission No. 102082
P-1135

Transient Elastography for Predicting Portal Hypertensive Gastropathy in Egyptian Cirrhotic Patients

Rania Elkafoury1, Abdelrahman Abdelaouf Kobotan1, Hanan Hamed Soliman1, Raafat Abdelkader Salah1

1Tropical medicine and Infectious diseases department, Faculty of Medicine, Tanta University Tanta Egypt

Background: Portal hypertensive gastropathy (PHG) is a state of mucosal ectasia affecting stomach in portal hypertension. Transient elastography (Fibroscan) measures liver stiffness (LSM) which had a strong correlation with portal hypertension and the prediction of esophageal varices (EVs). Our aim is to evaluate the diagnostic accuracy of Fibroscan and other non-invasive parameters in predicting PHG presence and severity in Egyptian cirrhotic patients.

Methods: 101 cirrhotic patients categorized into Group 1 (36 patients with PHG and EVs), Group 2 (34 patients with EVs), Group 3 (15 patients with PHG), and Group 4 (16 patients with neither PHG nor EVs as control). All patients underwent upper endoscopy, ultrasonography, routine lab. and Fibroscan evaluation.

Results: LSM median was significantly (P<0.001) increased in groups 1, 2, and 3 than in group 4. LSM directly correlated with PHG severity represented by the PHG score (P = 0.016). Platelet count/spleen diameter ratio (PSR) correlated inversely with PHG presence (P = 0.012) and severity (P = 0.007). PSR cut off value of 705.54 predicted PHG presence with AUC = 0.644, sensitivity 66%, specificity 58.8%, PPV 63.83%, and NPV 61.1%. Right lobe diameter/Albumin ratio (RLAR) correlated directly with the presence (P = 0.002) and severity (P = 0.004) of PHG. RLAR cut off value of > 3.62 had AUC, sensitivity, specificity, PPV, and NPV of 0.656, 62.7%, 54%, 58.18%, and 58.7% for the prediction of PHG, respectively.

Conclusion: Fibroscan LSM, PSR, and RLAR are easy, non-invasive, inexpensive modalities predicting the existence and severity of PHG in cirrhotic patients.
Background: Epidemiological studies have found a correlation between gut microbiome and pancreatic tumors. However, it is still being determined whether there is a causal relationship between the two due to the limited sample size and confounding factors. We aimed to analyze the causal relationship between the gut microbiome and the development of pancreatic neoplasms by Mendelian randomization (MR).

Methods: We extracted gut microbiota GWAS data from the MiBioGen database and pancreatic neoplasms data from the IEU database. The causal relationship between gut microbiota and pancreatic tumors by performing a two-sample MR analysis using the IVW method. Sensitivity analysis was performed to assess the robustness of the MR results.

Results: The results of this study showed that seven gut microbiotas were protective against benign pancreatic tumors: Family Desulfovibrionaceae (p=0.032), Family Rikenellaceae (p=0.017), Family Verrucomicrobiaceae (p=0.030), Genus Akkermansia (p=0.013), Genus Romboutsia (p=0.008), Order Desulfovibrionales (p=0.028), Phylum Verrucomicrobia (p=0.007). The corresponding heterogeneity tests and sensitivity analyses did not reveal abnormal results (p > 0.05). Three gut microbiotas were positively associated with the risk of pancreatic cancer in the MR analysis of the disease: Family Veillonellaceae (p=0.020), Genus Coprococcus1 (p=0.043), and Genus Sutterella (p=0.047); two gut microbiotas were positively associated with a reduction in risk causally: Genus Blautia (p=0.043), and Genus Parasutterella (p=0.015). No horizontal pleiotropy or heterogeneity was found in the sensitivity analysis (p > 0.05). Conclusions: This is the first MR study to investigate the causal association between specific gut microbiota and pancreatic neoplasms. The direction and theoretical underpinnings for future pancreatic neoplasm prevention and therapy are provided by this work.